FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU White, MJ
   Tacconelli, A
   Chen, JS
   Wejse, C
   Hill, PC
   Gomes, VF
   Velez-Edwards, DR
   Ostergaard, LJ
   Hu, T
   Moore, JH
   Novelli, G
   Scott, WK
   Williams, SM
   Sirugo, G
AF White, M. J.
   Tacconelli, A.
   Chen, J. S.
   Wejse, C.
   Hill, P. C.
   Gomes, V. F.
   Velez-Edwards, D. R.
   Ostergaard, L. J.
   Hu, T.
   Moore, J. H.
   Novelli, G.
   Scott, W. K.
   Williams, S. M.
   Sirugo, G.
TI Epiregulin (EREG) and human V-ATPase (TCIRG1): genetic variation,
   ethnicity and pulmonary tuberculosis susceptibility in Guinea-Bissau and
   The Gambia
SO GENES AND IMMUNITY
LA English
DT Article
ID STATISTICAL EPISTASIS NETWORKS; PROTON PUMP SUBUNIT; MEMBRANE-PROTEIN;
   H+-ATPASE; ASSOCIATION; VISUALIZATION; ACIDIFICATION; ACTIVATION; TIRC7;
   HOST
AB We analyzed two West African samples (Guinea-Bissau: n = 289 cases and 322 controls; The Gambia: n=240 cases and 248 controls) to evaluate single-nucleotide polymorphisms (SNPs) in Epiregulin (EREG) and V-ATPase (T-cell immune regulator 1 (TCIRG1)) using single and multilocus analyses to determine whether previously described associations with pulmonary tuberculosis (PTB) in Vietnamese and Italians would replicate in African populations. We did not detect any significant single locus or haplotype associations in either sample. We also performed exploratory pairwise interaction analyses using Visualization of Statistical Epistatis Networks (ViSEN), a novel method to detect only interactions among multiple variables, to elucidate possible interaction effects between SNPs and demographic factors. Although we found no strong evidence of marginal effects, there were several significant pairwise interactions that were identified in either the Guinea-Bissau or the Gambian samples, two of which replicated across populations. Our results indicate that the effects of EREG and TCIRG1 variants on PTB susceptibility, to the extent that they exist, are dependent on gene gene interactions in West African populations as detected with ViSEN. In addition, epistatic effects are likely to be influenced by inter- and intra-population differences in genetic or environmental context and/or the mycobacterial lineages causing disease.
C1 [White, M. J.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37235 USA.
   [White, M. J.; Chen, J. S.; Hu, T.; Moore, J. H.; Williams, S. M.] Dartmouth Coll, Dept Genet, Hanover, NH 03755 USA.
   [White, M. J.; Chen, J. S.; Hu, T.; Moore, J. H.; Williams, S. M.] Dartmouth Coll, Inst Quantitat Biomed Sci, Hanover, NH 03755 USA.
   [Tacconelli, A.; Novelli, G.; Sirugo, G.] Osped San Pietro Fatebenefratelli, Ctr Ric, Rome, Italy.
   [Wejse, C.; Gomes, V. F.] Danish Epidemiol Sci Ctr, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Wejse, C.; Gomes, V. F.] Statens Serum Inst, Bissau, Guinea Bissau.
   [Wejse, C.; Ostergaard, L. J.] Aarhus Univ Hosp, Dept Infect Dis, Skejby, Denmark.
   [Wejse, C.] Aarhus Univ, Sch Publ Hlth, Ctr Global Hlth, Skejby, Denmark.
   [Hill, P. C.] Univ Otago, Sch Med, Ctr Int Hlth, Dunedin, New Zealand.
   [Hill, P. C.] MRC Labs, Fajara, Gambia.
   [Velez-Edwards, D. R.] Vanderbilt Univ, Vanderbilt Epidemiol Ctr, Nashville, TN 37235 USA.
   [Velez-Edwards, D. R.] Vanderbilt Univ, Inst Med & Publ Hlth, Nashville, TN 37235 USA.
   [Velez-Edwards, D. R.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37235 USA.
   [Velez-Edwards, D. R.] Vanderbilt Univ, Dept Obstet & Gynecol, Nashville, TN USA.
   [Novelli, G.] Univ Roma Tor Vergata, Sez Genet, Dipartimento Biomed & Prevenz, Rome, Italy.
   [Scott, W. K.] Univ Miami, Miller Sch Med, Dept Human Genet, Dr John T Macdonald Fdn, Miami, FL 33136 USA.
   [Scott, W. K.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
RP Williams, SM (reprint author), Dartmouth Coll, Geisel Sch Med, Dept Genet, 78 Colleg ST,NB 6044, Hanover, NH 03755 USA.
EM Scott.Williams@dartmouth.edu; sirugo.giorgio@fbfrm.it
RI Wejse, Christian/C-8468-2014
OI Wejse, Christian/0000-0002-2534-2942; Novelli,
   Giuseppe/0000-0002-7781-602X; Moore, Jason/0000-0002-5015-1099
FU Medical Research Council (MRC UK) [G0000690]; Danish Medical Research
   Council; Danish Society of Respiratory Medicine; Danish Council of
   Development Research; NIH [P20 GM103534]
FX This work was supported by the Medical Research Council (MRC UK) award
   G0000690 to GS and by grants from the Danish Medical Research Council,
   the Danish Society of Respiratory Medicine and the Danish Council of
   Development Research to CW and LJO. MJW and SMW were partially supported
   by NIH Grant P20 GM103534.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Capparelli R, 2009, GENES IMMUN, V10, P641, DOI 10.1038/gene.2009.48
   Caws M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000034
   Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324
   Coussens AK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003468
   Del Fattore A, 2008, BONE, V42, P19, DOI 10.1016/j.bone.2007.08.029
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4
   Grady Benjamin J, 2010, Pac Symp Biocomput, P315
   Greene CS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005639
   Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026
   Heinemann T, 1999, GENOMICS, V57, P398, DOI 10.1006/geno.1999.5751
   Hinton A, 2009, PFLUG ARCH EUR J PHY, V457, P589, DOI 10.1007/s00424-007-0382-4
   Hu T, 2013, GENET EPIDEMIOL, V37, P283, DOI 10.1002/gepi.21718
   Hu T, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-364
   Kolonko M, 2013, CELL MICROBIOL, V16, P232
   Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145
   Morris GAJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016656
   Nalbandian A, 2009, ONCOGENE, V28, P1928, DOI 10.1038/onc.2009.32
   Olesen R, 2007, GENES IMMUN, V8, P456, DOI 10.1038/sj.gene.6364410
   Pareek M, 2013, THORAX, V68, P221, DOI 10.1136/thoraxjnl-2012-201824
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   R Core Team, 2013, R LANG ENV STAT COMP
   Ryckman KK, 2008, GENET EPIDEMIOL, V32, P600, DOI 10.1002/gepi.20342
   Salle M, 2013, J INFECT DIS, V209, P216
   Scott BB, 1998, EUR J PHARMACOL, V346, pR3, DOI 10.1016/S0014-2999(98)00163-0
   Singh CR, 2006, J IMMUNOL, V177, P3250
   Sirugo G, 2008, HUM GENET, V123, P557, DOI 10.1007/s00439-008-0511-y
   StataCorp, 2009, STAT STAT SOFTW REL
   Stein CM, 2010, MAMM GENOME, V22, P91
   STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277
   Thuong NTT, 2012, GENES IMMUN, V13, P275, DOI 10.1038/gene.2011.83
   Thuong N. T. T., 2008, PLOS PATHOG, V4
   Thye T, 2012, EUR RESPIR MONOGR, P38, DOI 10.1183/1025448x.10024812
   Thye T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020908
   Toei M, 2010, BIOCHEMISTRY-US, V49, P4715, DOI 10.1021/bi100397s
   TOYODA H, 1995, J BIOL CHEM, V270, P7495
   Utku N, 1998, IMMUNITY, V9, P509, DOI 10.1016/S1074-7613(00)80634-2
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Wong D, 2011, P NATL ACAD SCI USA, V108, P19371, DOI 10.1073/pnas.1109201108
   Zamar D, 2007, J STAT SOFTW, V21, P21
NR 40
TC 4
Z9 4
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
EI 1476-5470
J9 GENES IMMUN
JI Genes Immun.
PD SEP
PY 2014
VL 15
IS 6
BP 370
EP 377
DI 10.1038/gene.2014.28
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA AO3KK
UT WOS:000341227900004
PM 24898387
OA No
DA 2017-08-15
ER

PT J
AU Ndiath, MO
   Cailleau, A
   Diedhiou, SM
   Gaye, A
   Boudin, C
   Richard, V
   Trape, JF
AF Ndiath, Mamadou Ousmane
   Cailleau, Aurelie
   Diedhiou, Seynabou Mocote
   Gaye, Abdoulaye
   Boudin, Christian
   Richard, Vincent
   Trape, Jean-Francois
TI Effects of the kdr resistance mutation on the susceptibility of wild
   Anopheles gambiae populations to Plasmodium falciparum: a hindrance for
   vector control
SO MALARIA JOURNAL
LA English
DT Article
DE Anopheles; Susceptibility; Infection; kdr resistance; Dielmo; Senegal
ID MOLECULAR-FORMS M; MALARIA VECTOR; GENETIC DIFFERENTIATION; CHROMOSOMAL
   FORMS; BURKINA-FASO; S.S.; IDENTIFICATION; ARABIENSIS; MOSQUITOS;
   COMPLEX
AB Background: In the context of generalization of insecticide resistance, the hypothesis that insecticide resistance has a positive impact on the capacity of mosquitoes to transmit malaria constitutes a hindrance for malaria elimination. The aim of this study was to investigated populations of Anopheles coluzzii and Anopheles gambiae S molecular form to assess whether different genotypes at the kdr locus are responsible for different susceptibility to Plasmodium falciparum infection.
   Methods: F3 progeny of An. gambiae s.l. collected in Dielmo were infected by direct membrane feeding with P. falciparum gametocyte-containing blood sampled from volunteer patients. The presence of oocysts was determined by light microscopy after seven days, and the presence of sporozoites by ELISA after 14 days. Mosquito species and molecular forms were identified by PCR. Generalized linear models were performed using the R software to test the effect of explanatory variables including the genotype at the kdr locus on infection rate and density.
   Results: The odds of being infected with oocysts and sporozoites were greater in RS and RR groups than in SS groups (X-2 = 42.8, df = 1, P(>X-2) = 6.1e-11). The density of infection was also dependent on genotype, with RR and RS genotypes showing denser infection than SS genotypes. Pairwise comparisons of oocyst number and absorbance indicated sometime a small betwen species (i.e. between An. gambiae S form, and An. coluzzii), but the effect of genotype was much more important.
   Conclusion: The presence of the resistance allele at the kdr locus increases susceptibility to Plasmodium not only at the oocyst stage but also at the sporozoite stage in non-genetically modified wild mosquitoes. These results have significant implications and should be taken into account in the development of strategies for malaria control.
C1 [Ndiath, Mamadou Ousmane] Inst Pasteur, Inst Pasteur Int Network, Grp G4, Bangui, Cent Afr Republ.
   [Cailleau, Aurelie] Afrique One, Ctr Suisse Rech Sci, Abidjan 01, Cote Ivoire.
   [Diedhiou, Seynabou Mocote] Cheikh Anta Diop Univ, Dept Anim Biol, Dakar, Senegal.
   [Gaye, Abdoulaye] The Gambia, Med Res Concil Unit, Banjul, Gambia.
   [Boudin, Christian; Trape, Jean-Francois] Lab Paludol & Zool Med, Dakar, Senegal.
   [Richard, Vincent] Inst Pasteur, Unite Epidemiol, Dakar, Senegal.
RP Ndiath, MO (reprint author), Inst Pasteur, Inst Pasteur Int Network, Grp G4, Bangui BP 923, Bangui, Cent Afr Republ.
EM ousmane.ndiath@gmail.com
FU NGO Malaria Dino Alliance Italian; French Research Institute for
   Development (IRD); Afrique One - Wellcome Trust; G4 Pasteur Bangui (CAR)
   Fellowship by Institut Pasteur International Network
FX We thank the villagers of Anene for their continuous support to the
   project. We acknowledge Moussa Gueye the supervisor of the burg of
   Anene, Ndeye Maimouna Diedhiou and Dino Masutti for they logistical
   assistance. Many thanks to Dr Mirdad Kazanji for her support. Dr
   Catherine Bourgouin provided very useful comments on an earlier draft of
   the paper. This work was supported by the NGO Malaria Dino Alliance
   Italian, the French Research Institute for Development (IRD) and Afrique
   One funded by the Wellcome Trust. The funders had no role in study
   design, data collocation and analysis, decision to publish, or
   preparation of the manuscript. MON was supported by a G4 Pasteur Bangui
   (CAR) Fellowship provided by Institut Pasteur International Network.
CR Alout H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063849
   BEIER JC, 1991, J MED ENTOMOL, V28, P533
   Beier JC, 1998, ANNU REV ENTOMOL, V43, P519, DOI 10.1146/annurev.ento.43.1.519
   Bonnet S, 2000, T ROY SOC TROP MED H, V94, P103, DOI 10.1016/S0035-9203(00)90456-5
   Chandre F, 1999, J AM MOSQUITO CONTR, V15, P53
   Coetzee M, 2013, ZOOTAXA, V3619, P246, DOI 10.11646/zootaxa.3619.3.2
   Cohuet A, 2010, TRENDS PARASITOL, V26, P130, DOI 10.1016/j.pt.2009.12.001
   Coluzzi M, 2002, SCIENCE, V298, P1415, DOI 10.1126/science.1077769
   COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1
   Corbel V, 2012, LANCET INFECT DIS, V12, P617, DOI 10.1016/S1473-3099(12)70081-6
   CURTIS CF, 1994, MED VET ENTOMOL, V8, P107, DOI 10.1111/j.1365-2915.1994.tb00147.x
   della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x
   della Torre A, 2005, INSECT BIOCHEM MOLEC, V35, P755, DOI 10.1016/j.ibmb.2005.02.006
   Diabate A, 2002, AM J TROP MED HYG, V67, P617
   Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Favia G, 1997, INSECT MOL BIOL, V6, P377, DOI 10.1046/j.1365-2583.1997.00189.x
   FAVIA G, 1994, P NATL ACAD SCI USA, V91, P10315, DOI 10.1073/pnas.91.22.10315
   Feachem R, 2008, LANCET, V371, P1633, DOI [10.1016/S0140-6736(08)60424-9, 10.1016/S1473-3099(08)70045-8]
   Felix RC, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-312
   Gething PW, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-378
   Gneme A, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-204
   Greenwood Brian, 2008, Travel Med Infect Dis, V6, P173, DOI 10.1016/j.tmaid.2007.11.003
   Greenwood Brian, 2009, Trans R Soc Trop Med Hyg, V103 Suppl 1, pS2, DOI 10.1016/j.trstmh.2008.10.027
   Martinez-Torres D, 1998, INSECT MOL BIOL, V7, P179, DOI 10.1046/j.1365-2583.1998.72062.x
   Mulder B, 1999, EXP PARASITOL, V92, P81, DOI 10.1006/expr.1999.4398
   Ndiath MO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031943
   Ndiath MO, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-269
   Ndiath MO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-136
   Norris DE, 2001, J MED ENTOMOL, V38, P336, DOI 10.1603/0022-2585-38.2.336
   Ranson H, 2000, INSECT MOL BIOL, V9, P491, DOI 10.1046/j.1365-2583.2000.00209.x
   Reidenbach KR, 2012, GENOME BIOL EVOL, V4, P1202, DOI 10.1093/gbe/evs095
   Rivero A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001000
   Slotman MA, 2007, MOL ECOL, V16, P639, DOI 10.1111/j.1365-294X.2006.03172.x
   Sokhna C, 2013, CLIN MICROBIOL INFEC, V19, P902, DOI 10.1111/1469-0691.12314
   Sougoufara S, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-125
   Takken W, 2009, TRENDS PARASITOL, V25, P101, DOI 10.1016/j.pt.2008.12.002
   Toure Y. T., 1998, Parassitologia (Rome), V40, P477
   Trape JF, 2011, LANCET INFECT DIS, V11, P925, DOI 10.1016/S1473-3099(11)70194-3
   VAUGHAN JA, 1994, J PARASITOL, V80, P674, DOI 10.2307/3283245
   Villalon JM, 2003, J INSECT PHYSIOL, V49, P891, DOI 10.1016/S0022-1910(03)00135-5
   Vizioli J, 2000, INSECT MOL BIOL, V9, P75, DOI 10.1046/j.1365-2583.2000.00164.x
   Vontas J, 2005, INSECT MOL BIOL, V14, P509, DOI 10.1111/j.1365-2583.2005.00582.x
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   Wondji C, 2002, INSECT MOL BIOL, V11, P11, DOI 10.1046/j.0962-1075.2001.00306.x
   Yawson AE, 2007, GENETICS, V175, P751, DOI 10.1534/genetics.106.065888
NR 46
TC 11
Z9 11
U1 1
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 30
PY 2014
VL 13
AR 340
DI 10.1186/1475-2875-13-340
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AO3GC
UT WOS:000341216200001
PM 25176292
OA gold
DA 2017-08-15
ER

PT J
AU Scott, S
   Mens, PF
   Tinto, H
   Nahum, A
   Ruizendaal, E
   Pagnoni, F
   Grietens, KP
   Kendall, L
   Bojang, K
   Schallig, H
   D'Alessandro, U
AF Scott, Susana
   Mens, Petra F.
   Tinto, Halidou
   Nahum, Alain
   Ruizendaal, Esmee
   Pagnoni, Franco
   Grietens, Koen Peeters
   Kendall, Lindsay
   Bojang, Kalifa
   Schallig, Henk
   D'Alessandro, Umberto
TI Community-based scheduled screening and treatment of malaria in
   pregnancy for improved maternal and infant health in The Gambia, Burkina
   Faso and Benin: study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE Malaria; Pregnancy; Community based treatment; Rapid diagnostic tests;
   Sulfadoxine-pyrimethamine; Sub-Saharan Africa; Artemether-lumefantrine
ID INTERMITTENT PREVENTIVE TREATMENT; PLASMODIUM-FALCIPARUM MALARIA;
   SULFADOXINE-PYRIMETHAMINE; PLACENTAL MALARIA; RESISTANCE; EFFICACY;
   WOMEN; INFECTION; AFRICA; BURDEN
AB Background: In sub-Saharan Africa, malaria continues to cause over 10,000 maternal deaths and 75,000 to 200,000 infant deaths. Successful control of malaria in pregnancy could save lives of mothers and babies and is an essential part of antenatal care in endemic areas. The primary objective is to determine the protective efficacy of community-scheduled screening and treatment (CSST) using community health workers (CHW) against the primary outcome of prevalence of placental malaria. The secondary objectives are to determine the protective efficacy of CSST on maternal anaemia, maternal peripheral infection, low birth weight, selection of sulfadoxine-pyrimethamine (SP) resistance markers, and on antenatal clinic (ANC) attendance and coverage of intermittent preventive treatment during pregnancy (IPTp-SP).
   Methods/design: This is a multi-centre cluster-randomised controlled trial involving three countries with varying malaria endemicity; low (The Gambia) versus high transmission (Burkina Faso and Benin), and varying degrees of SP resistance (high in Benin and moderate in Gambia and Burkina Faso). CHW and their related catchment population who are randomised into the intervention arm will receive specific training on community-based case management of malaria in pregnancy. All women in both study arms will be enrolled at their first ANC visits in their second trimester where they will receive their first dose of IPTp-SP. Thereafter, CHW in the intervention arm will perform scheduled monthly screening and treatment in the womens homes. At time of delivery, a placental biopsy will be collected from all women to determine placental malaria. At each contact point, filter paper and blood slides will be collected for detection of malaria infection and SP resistance markers.
   Discussion: To reach successful global malaria control, there is an urgent need to access those at greatest risk of malaria infection. The project is designed to develop a low-cost intervention in pregnant women which will have an immediate impact on the malaria burden in resource-limited countries. This will be done by adding to the standard IPTp-SP delivered through the health facilities: an "extension" strategy to the communities in rural areas thus bringing health services closer to where women live.
C1 [Scott, Susana; Kendall, Lindsay; Bojang, Kalifa; D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Scott, Susana] London Sch Hyg & Trop Med, Infect Dis Epidemiol Dept, London WC1, England.
   [Mens, Petra F.; Ruizendaal, Esmee; Schallig, Henk] Royal Trop Inst, Parasitol Unit, NL-1105 AZ Amsterdam, Netherlands.
   [Tinto, Halidou] URCN CMA, Ctr Muraz, Clin Res Unit Nanoro, Ouagadougou, Burkina Faso.
   [Nahum, Alain] Ctr Rech Entomol Cotonou, Cotonou, Benin.
   [Pagnoni, Franco] WHO, Special Programme Res & Training Trop Dis TDR, CH-1211 Geneva, Switzerland.
   [Grietens, Koen Peeters] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Grietens, Koen Peeters] Nagasaki Univ, Sch Int Hlth Dev, Nagasaki 852, Japan.
RP Scott, S (reprint author), MRC Unit, Fajara, Gambia.
EM sscott@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Bojang,
   Kalifa/0000-0001-7506-0938
FU Disease Control and Elimination Theme, Medical Research Council Unit,
   The Gambia; Royal Tropical Institute/Koninklijk Instituut voor de
   Tropen, Parasitology Unit, Amsterdam, The Netherlands; Clinical Research
   Unit of Nanoro, URCN/CMA, Centre Muraz, Burkina Faso; Centre de
   Recherches Entomologiques de Cotonou, Benin; Special Programme for
   Research and Training in Tropical Diseases (TDR), World Health
   Organization, Switzerland; Institute of Tropical Medicine, Antwerp,
   Belgium; European Union [305662-COSMIC]
FX The study is supported by the Disease Control and Elimination Theme,
   Medical Research Council Unit, The Gambia; Royal Tropical
   Institute/Koninklijk Instituut voor de Tropen, Parasitology Unit,
   Amsterdam, The Netherlands; Clinical Research Unit of Nanoro, URCN/CMA,
   Centre Muraz, Burkina Faso; Centre de Recherches Entomologiques de
   Cotonou, Benin; Special Programme for Research and Training in Tropical
   Diseases (TDR), World Health Organization, Switzerland; Institute of
   Tropical Medicine, Antwerp, Belgium. For Figure 2 we used symbols from
   thenounproject.com collection: 'baby' symbol (1), 'baby' symbol (2) by
   Edward Boatman, 'house' symbol by Marco Olgio, 'medicine' symbol by
   Emmanual Mangatia, 'medicine' symbol by Paulo Volkova, 'doctor' symbol
   by Paulo Volkova, 'pointer' symbol by Evan MacDonald and 'drop' symbol
   by Eric Bergholz.; The research is funded by the European Union Seventh
   Framework Programme (FP7/2002-2016) under grant agreement no
   305662-COSMIC.
CR Achadi E, 2007, TROP MED INT HEALTH, V12, P1490, DOI 10.1111/j.1365-3156.2007.01957.x
   BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6
   Bertin G, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-196
   BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x
   Dellicour S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000221
   Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X
   Greenwood B, 2011, TRENDS PARASITOL, V27, P477, DOI 10.1016/j.pt.2011.06.005
   Grietens KP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012013
   Harrington WE, 2009, P NATL ACAD SCI USA, V106, P9027, DOI 10.1073/pnas.0901415106
   Harrington WE, 2011, CLIN INFECT DIS, V53, P224, DOI 10.1093/cid/cir376
   Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319
   Hill J, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001488
   Hounton S, 2008, TROP MED INT HEALTH, V13, P44, DOI 10.1111/j.1365-3156.2008.02086.x
   Malhotra I, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000116
   Manyando C, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-141
   Menendez C, 2007, LANCET INFECT DIS, V7, P126, DOI 10.1016/S1473-3099(07)70024-5
   Mens PF, 2010, EUR J OBSTET GYN R B, V152, P126, DOI 10.1016/j.ejogrb.2010.05.013
   Ministry of Health BF, 2012, DIR NAT PRIS CHARG P
   Ministere de la sante Benin PNdLclP, 2011, DIR NAT PRIS CHARG C
   Mount AM, 2004, LANCET, V363, P1860, DOI 10.1016/S0140-6736(04)16354-X
   Mutabingwa TK, 2005, PLOS MED, V2, P1260, DOI 10.1371/journal.pmed.0020407
   National Malaria Control Program MoHaSW, 2010, GAMB GUID MAN MAL
   Schwarz NG, 2008, CLIN INFECT DIS, V47, P1017, DOI 10.1086/591968
   Sexton AR, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-157
   Tagbor H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014425
   ter Kuile FO, 2007, JAMA-J AM MED ASSOC, V297, P2603, DOI 10.1001/jama.297.23.2603
   THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7
   Tinto H, 2007, AM J TROP MED HYG, V76, P608
   van Eijk AM, 2013, LANCET INFECT DIS, V13, P1029, DOI 10.1016/S1473-3099(13)70199-3
   WHO, 2013, WORLD MALARIA REPORT 2013, P1
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   World Health Organization, 2012, INT PREV TREATM MAL
   World Health Organization, 2010, GUID TREATM MAL
   Wort UU, 2007, INT J GYNECOL OBSTET, V96, P171, DOI 10.1016/j.ijgo.2006.11.023
NR 34
TC 2
Z9 2
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD AUG 28
PY 2014
VL 15
AR 340
DI 10.1186/1745-6215-15-340
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AO3FT
UT WOS:000341215300001
PM 25169073
OA gold
DA 2017-08-15
ER

PT J
AU Williams, CML
   Cheah, ESG
   Malkin, J
   Patel, H
   Otu, J
   Mlaga, K
   Sutherland, JS
   Antonio, M
   Perera, N
   Woltmann, G
   Haldar, P
   Garton, NJ
   Barer, MR
AF Williams, Caroline M. L.
   Cheah, Eddy S. G.
   Malkin, Joanne
   Patel, Hemu
   Otu, Jacob
   Mlaga, Kodjovi
   Sutherland, Jayne S.
   Antonio, Martin
   Perera, Nelun
   Woltmann, Gerrit
   Haldar, Pranabashis
   Garton, Natalie J.
   Barer, Michael R.
TI Face Mask Sampling for the Detection of Mycobacterium tuberculosis in
   Expelled Aerosols
SO PLOS ONE
LA English
DT Article
ID AIRBORNE TRANSMISSION; PULMONARY TUBERCULOSIS; INFECTION; VARIABILITY;
   RESISTANCE; BACILLI
AB Background: Although tuberculosis is transmitted by the airborne route, direct information on the natural output of bacilli into air by source cases is very limited. We sought to address this through sampling of expelled aerosols in face masks that were subsequently analyzed for mycobacterial contamination.
   Methods: In series 1, 17 smear microscopy positive patients wore standard surgical face masks once or twice for periods between 10 minutes and 5 hours; mycobacterial contamination was detected using a bacteriophage assay. In series 2, 19 patients with suspected tuberculosis were studied in Leicester UK and 10 patients with at least one positive smear were studied in The Gambia. These subjects wore one FFP30 mask modified to contain a gelatin filter for one hour; this was subsequently analyzed by the Xpert MTB/RIF system.
   Results: In series 1, the bacteriophage assay detected live mycobacteria in 11/17 patients with wearing times between 10 and 120 minutes. Variation was seen in mask positivity and the level of contamination detected in multiple samples from the same patient. Two patients had non-tuberculous mycobacterial infections. In series 2, 13/20 patients with pulmonary tuberculosis produced positive masks and 0/9 patients with extrapulmonary or non-tuberculous diagnoses were mask positive. Overall, 65% of patients with confirmed pulmonary mycobacterial infection gave positive masks and this included 3/6 patients who received diagnostic bronchoalveolar lavages.
   Conclusion: Mask sampling provides a simple means of assessing mycobacterial output in non-sputum expectorant. The approach shows potential for application to the study of airborne transmission and to diagnosis.
C1 [Williams, Caroline M. L.; Cheah, Eddy S. G.; Malkin, Joanne; Haldar, Pranabashis; Garton, Natalie J.; Barer, Michael R.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England.
   [Malkin, Joanne; Patel, Hemu; Perera, Nelun; Barer, Michael R.] Univ Hosp Leicester NHS Trust, Dept Clin Microbiol, Leicester, Leics, England.
   [Otu, Jacob; Mlaga, Kodjovi; Sutherland, Jayne S.; Antonio, Martin] MRC Unit, Banjul, Gambia.
   [Woltmann, Gerrit; Haldar, Pranabashis] Glenfield Hosp, Dept Resp Med, Leicester, Leics, England.
   [Haldar, Pranabashis] Glenfield Hosp, Resp Biomed Res Unit, Natl Inst Hlth Res, Leicester, Leics, England.
RP Barer, MR (reprint author), Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England.
EM mrb19@le.ac.uk
OI Sutherland, Jayne/0000-0002-7083-4997
FU Henry Smith Charity; Edith Murphy Foundation
FX MRB and ESGC received funding from the Henry Smith Charity
   (www.henrysmithcharity.org.uk) and the Edith Murphy Foundation
   (www.edithmurphy.co.uk). CMLW held a UK National Institute for Health
   Research Academic Clinical Fellowship (www.nihr.ac.uk) during this
   study. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Akkerman OW, 2013, J CLIN MICROBIOL, V51, P3505, DOI 10.1128/JCM.00843-13
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0
   Boston LN, 1901, J AMER MED ASSOC, V37, P685
   Bridges CB, 2003, CLIN INFECT DIS, V37, P1094, DOI 10.1086/378292
   Cheah ESG, 2010, J MOL DIAGN, V12, P250, DOI 10.2353/jmoldx.2010.090030
   Dharmadhikari AS, 2011, TUBERCULOSIS, V91, P329, DOI 10.1016/j.tube.2011.03.002
   Escombe AR, 2007, CLIN INFECT DIS, V44, P1349, DOI 10.1086/515397
   FEIGIN RD, 1982, NEW ENGL J MED, V307, P1255, DOI 10.1056/NEJM198211113072007
   Fennelly KP, 2007, CLIN INFECT DIS, V44, P1358, DOI 10.1086/516617
   Fennelly KP, 2012, AM J RESP CRIT CARE, V186, P450, DOI 10.1164/rccm.201203-0444OC
   Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC
   Friedrich SO, 2013, LANCET RESP MED, V1, P462, DOI 10.1016/S2213-2600(13)70119-X
   Garton NJ, 2008, PLOS MED, V5, P634, DOI 10.1371/journal.pmed.0050075
   Helb D, 2010, J CLIN MICROBIOL, V48, P229, DOI 10.1128/JCM.01463-09
   Hernandez-Garduno E, 2004, THORAX, V59, P286, DOI 10.1136/thx.2003.011759
   Huynh KN, 2008, CLIN INFECT DIS, V46, P93, DOI 10.1086/523000
   Jones-Lopez EC, 2013, AM J RESP CRIT CARE, V187, P1007, DOI 10.1164/rccm.201208-1422OC
   Mole R, 2007, J MED MICROBIOL, V56, P1334, DOI 10.1099/jmm.0.46936-0
   Mukamolova GV, 2010, AM J RESP CRIT CARE, V181, P174, DOI 10.1164/rccm.200905-0661OC
   Parsons LM, 2011, CLIN MICROBIOL REV, V24, P314, DOI 10.1128/CMR.00059-10
   RILEY RL, 1959, AM J HYG, V70, P185
   Roy CJ, 2004, NEW ENGL J MED, V350, P1710, DOI 10.1056/NEJMp048051
   Sepkowitz KA, 1996, CLIN INFECT DIS, V23, P954
   STEINBERG P, 1969, AM J EPIDEMIOL, V89, P62
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Wurie Fatima, 2013, F1000Res, V2, P14, DOI 10.12688/f1000research.2-14.v1
NR 26
TC 2
Z9 2
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2014
VL 9
IS 8
AR e104921
DI 10.1371/journal.pone.0104921
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO0QT
UT WOS:000341017000075
PM 25122163
OA gold
DA 2017-08-15
ER

PT J
AU de Vries, J
   Williams, TN
   Bojang, K
   Kwiatkowski, DP
   Fitzpatrick, R
   Parker, M
AF de Vries, Jantina
   Williams, Thomas N.
   Bojang, Kalifa
   Kwiatkowski, Dominic P.
   Fitzpatrick, Raymond
   Parker, Michael
TI Knowing who to trust: exploring the role of 'ethical metadata' in
   mediating risk of harm in collaborative genomics research in Africa
SO BMC MEDICAL ETHICS
LA English
DT Article
DE Data sharing; Genomics; Africa; MalariaGEN; Ethnic stigmatisation;
   Secondary use; Ethics; Ethnic groups
ID BIOMEDICAL-RESEARCH; WIDE ASSOCIATION; CHALLENGES; CONSENT; SCIENCE;
   RACE
AB Background: The practice of making datasets publicly available for use by the wider scientific community has become firmly integrated in genomic science. One significant gap in literature around data sharing concerns how it impacts on scientists' ability to preserve values and ethical standards that form an essential component of scientific collaborations. We conducted a qualitative sociological study examining the potential for harm to ethnic groups, and implications of such ethical concerns for data sharing. We focused our empirical work on the MalariaGEN Consortium, one of the first international collaborative genomics research projects in Africa.
   Methods: We conducted a study in three MalariaGEN project sites in Kenya, the Gambia, and the United Kingdom. The study entailed analysis of project documents and 49 semi-structured interviews with fieldworkers, researchers and ethics committee members.
   Results: Concerns about how best to address the potential for harm to ethnic groups in MalariaGEN crystallised in discussions about the development of a data sharing policy. Particularly concerning for researchers was how best to manage the sharing of genomic data outside of the original collaboration. Within MalariaGEN, genomic data is accompanied by information about the locations of sample collection, the limitations of consent and ethics approval, and the values and relations that accompanied sample collection. For interviewees, this information and context were of important ethical value in safeguarding against harmful uses of data, but is not customarily shared with secondary data users. This challenged the ability of primary researchers to protect against harmful uses of 'their' data.
   Conclusion: We identified three protective mechanisms - trust, the existence of a shared morality, and detailed contextual understanding - which together might play an important role in preventing the use of genomic data in ways that could harm the ethnic groups included in the study. We suggest that the current practice of sharing of datasets as isolated objects rather than as embedded within a particular scientific culture, without regard for the normative context within which samples were collected, may cause ethical tensions to emerge that could have been prevented or addressed had the 'ethical metadata' that accompanies genomic data also been shared.
C1 [de Vries, Jantina] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa.
   [Williams, Thomas N.] Kilifi Dist Hosp, Ctr Geog Med Res, Kenya Med Res Inst KEMRI Wellcome Trust Programme, Kilifi 80108, Kenya.
   [Bojang, Kalifa] MRC Unit, Banjul, Gambia.
   [Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Hinxton, England.
   [Fitzpatrick, Raymond] Univ Oxford, Nuffield Dept Populat Hlth, Oxford OX3 7LF, England.
   [Parker, Michael] Univ Oxford, Nuffield Dept Populat Hlth, Ethox Ctr, Oxford OX3 7LF, England.
RP de Vries, J (reprint author), Univ Cape Town, Dept Med, Anzio Rd Observ, ZA-7925 Cape Town, South Africa.
EM Jantina.devries@uct.ac.za
RI De Vries, Jantina/I-2752-2014
OI De Vries, Jantina/0000-0001-7192-2633; Kwiatkowski,
   Dominic/0000-0002-5023-0176
FU Wellcome Trust [WT083326, WT076934/Z/05/Z, WT087285, WT096527,
   WT077383/Z/05/Z, 090770/Z/09/Z]; MRC UK; European Union Network 7
   EVIMalR Consortium; UK Medical Research Council [G19/9]; Foundation for
   the National Institutes of Health as part of the Bill & Melinda Gates'
   Grand Challenges in Global Health Initiative [566]; Medical Research
   Council [G0600718]
FX JdV gratefully acknowledges the support of a Wellcome Trust Research
   Studentship for this research (WT083326). KB receives support from the
   MRC UK. TNW is funded by the Wellcome Trust (WT076934/Z/05/Z) and by the
   European Union Network 7 EVIMalR Consortium. This paper is published
   with permission from the director of KEMRI. DPK receives support from
   the UK Medical Research Council (G19/9). MP is supported by a Wellcome
   Trust Biomedical Ethics Enhancement Award (WT087285) and Strategic Award
   (WT096527). The MalariaGEN Project is supported by the Wellcome Trust
   (WT077383/Z/05/Z) and by the Foundation for the National Institutes of
   Health (566) as part of the Bill & Melinda Gates' Grand Challenges in
   Global Health Initiative. The Resource Centre for Genomic Epidemiology
   of Malaria is supported by the Wellcome Trust (090770/Z/09/Z). This
   research was supported by the Medical Research Council (G0600718).
CR Anderson JA, 2013, NAT METHODS, V10, P843, DOI 10.1038/nmeth.2564
   Anderson B., 2007, J COMPUT-MEDIAT COMM, V12, P635, DOI DOI 10.1111/J.1083-6101.2007.00342.X
   Clark J, 2003, PEER REV HLTH SCI, V2, P219
   de Vries J, 2012, SOC SCI MED, V75, P1400, DOI 10.1016/j.socscimed.2012.05.020
   De Vries J, 2011, BMC MED ETH, V12
   Edwards PN, 2011, SOC STUD SCI, V41, P667, DOI 10.1177/0306312711413314
   Evans JA, 2011, SCIENCE, V331, P721, DOI 10.1126/science.1201765
   Faniel I., 2011, J LIB MET, V11, P155
   Foster MW, 2007, NAT REV GENET, V8, P633, DOI 10.1038/nrg2124
   Foster MW, 2006, J LAW MED ETHICS, V34, P508, DOI 10.1111/j.1748-720X.2006.00063.x
   Fujimura JH, 2011, SOC STUD SCI, V41, P5, DOI 10.1177/0306312710379170
   Grubb AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023420
   Harding A, 2012, ENVIRON HEALTH PERSP, V120, P6, DOI 10.1289/ehp.1103904
   Harmon A, 2006, DNA GATHERERS HIT SN
   Heeney C, 2010, PUBLIC HEALTH GENOM, V14, P17
   Kaye J, 2012, ANNU REV GENOM HUM G, V13, P415, DOI 10.1146/annurev-genom-082410-101454
   Kaye J, 2009, NAT REV GENET, V10, P331, DOI 10.1038/nrg2573
   Lowrance WW, 2007, SCIENCE, V317, P600, DOI 10.1126/science.1147699
   Mason M, 2010, FORUM, V11, P3
   McGregor J, 2010, AM J BIOETHICS, V10, P23, DOI 10.1080/15265161.2010.492888
   Molyneux CS, 2004, SOC SCI MED, V59, P2547, DOI 10.1016/j.socscimed.2004.03.037
   Ndebele P, 2007, GATEWAY BIOMEDICAL R, P9
   Nyika A, 2009, J MED ETHICS, V35, P189, DOI 10.1136/jme.2008.025189
   QSR, 2009, NVIVO 8
   Parker M, 2012, CAMB BIOETH LAW, P1, DOI 10.1017/CBO9781139107792
   Parker M, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000143
   Pisani E, 2010, B WORLD HEALTH ORGAN, V88, P462, DOI 10.2471/BLT.09.074393
   Piwowar HA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018657
   Quinn-Patton M, 2002, QUALITATIVE RES EVAL
   Ramsay M, 2011, HUM MOL GENET, V20, pR214, DOI 10.1093/hmg/ddr401
   Rosenberg NA, 2010, NAT REV GENET, V11, P356, DOI 10.1038/nrg2760
   Tang H, 2005, AM J HUM GENET, V76, P268, DOI 10.1086/427888
   Teo YY, 2010, NAT REV GENET, V11, P149, DOI 10.1038/nrg2731
   Tindana P, 2012, BMC MED ETHICS, V13, DOI 10.1186/1472-6939-13-15
   Walport M, 2011, LANCET, V377, P538
   World Health Organization, 2002, GEN WORLD HLTH
   Zimmerman Ann, 2007, International Journal on Digital Libraries, V7, P5, DOI 10.1007/s00799-007-0015-8
NR 37
TC 3
Z9 3
U1 1
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6939
J9 BMC MED ETHICS
JI BMC Med. Ethics
PD AUG 13
PY 2014
VL 15
AR 62
DI 10.1186/1472-6939-15-62
PG 10
WC Ethics; Medical Ethics; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Biomedical Social
   Sciences
GA AN9GJ
UT WOS:000340914100001
PM 25124199
OA gold
DA 2017-08-15
ER

PT J
AU Okebe, J
   Mwesigwa, J
   Kama, EL
   Ceesay, SJ
   Njie, F
   Correa, S
   Bojang, K
AF Okebe, Joseph
   Mwesigwa, Julia
   Kama, Eugene L.
   Ceesay, Serign J.
   Njie, Fanta
   Correa, Simon
   Bojang, Kalifa
TI A comparative case control study of the determinants of clinical malaria
   in The Gambia
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Risk; Socio-economic
ID ENVIRONMENTAL RISK-FACTORS; PERIURBAN AREA; CHILDREN; EPIDEMIOLOGY;
   TRANSMISSION; HOUSEHOLD; AFRICA
AB Background: The massive deployment of life saving malaria interventions has not only resulted in a decline in disease burden but a change in the risk of infection and disease. The study reassesses the importance of known risk factors and reviews demographic and socio-economic determinants of malaria risk in the population.
   Methods: This was a case-control study involving 150 children with test-confirmed malaria infection recruited from the outpatient clinics of three health facilities (cases) in the Greater Banjul area, The Gambia. One hundred and fifty controls, negative for malaria were matched on age, residence. Information was collected from respondents on the use of long lasting insecticidal nets, occupation, housing structure, knowledge of malaria and socio-demographic factors.
   Results: The mean age of study participants was 6.8 (SD 3.3) years with 147 (49%) being males. Significant determinants of malaria risk were parent's occupation: mother as trader (OR 0.18, 95% CI 0.04 - 0.73, p = 0.017), father as trader (OR 0.02, 95% CI 0.002- 0.193, p = 0.001), civil servants (OR 0.04, 95% CI 0.008- 0.257, p = 0.001) or handyman (OR 0.03, 95% CI 0.005- 0.182, p < 0.001). Children sleeping in rooms with windowpanes had a 76% reduction in their odds of malaria (OR 0.24, 95% CI 0.07- 0.82, p = 0.022.
   Conclusion: Household socio-economic status plays an important role in management of illnesses. The ability of mothers to engage in an occupation increases household resources to access healthcare and on time. The balance between the type of mother's occupation and her time available to supervise the child is an interesting emerging issue that needs further investigation.
C1 [Okebe, Joseph; Mwesigwa, Julia; Ceesay, Serign J.; Njie, Fanta; Correa, Simon; Bojang, Kalifa] MRC Unit, Fajara, Gambia.
   [Kama, Eugene L.] Natl Inst Publ Hlth, Conakry, Guinea.
RP Okebe, J (reprint author), MRC Unit, Fajara, Gambia.
EM jokebe@mrc.gm
OI Bojang, Kalifa/0000-0001-7506-0938
FU MRC; Wellcome Trust
FX This study was supported by the MRC and Wellcome Trust grant to Malaria
   Capacity Development Consortium.
CR Al-Taiar A, 2009, T ROY SOC TROP MED H, V103, P72, DOI 10.1016/j.trstmh.2008.09.010
   Biritwum RB, 2000, ANN TROP MED PARASIT, V94, P771, DOI 10.1080/00034980020013037
   Breman JG, 2004, AM J TROP MED HYG, V71, P1
   Bruno MP, 2011, MALARIA J, V10, P145
   CATTANI JA, 1986, AM J TROP MED HYG, V35, P3
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Coleman M, 2010, T ROY SOC TROP MED H, V104, P143, DOI 10.1016/j.trstmh.2009.07.010
   Ghebreyesus TA, 2000, T ROY SOC TROP MED H, V94, P17, DOI 10.1016/S0035-9203(00)90424-3
   Graves PM, 2009, T ROY SOC TROP MED H, V103, P1211, DOI 10.1016/j.trstmh.2008.11.016
   Greenwood B.M., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P25, DOI 10.1016/0035-9203(89)90599-3
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   Guthmann JP, 2001, T ROY SOC TROP MED H, V95, P577, DOI 10.1016/S0035-9203(01)90084-7
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P146, DOI 10.1016/0035-9203(95)90471-9
   Lindblade KA, 2013, EXPERT REV ANTI-INFE, V11, P623, DOI [10.1586/eri.13.45, 10.1586/ERI.13.45]
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   Robert V, 2003, AM J TROP MED HYG, V68, P169
   Rutherford ME, 2009, B WORLD HEALTH ORGAN, V87, P216, DOI 10.2471/BLT.08.052175
   Safeukui-Noubissi I, 2004, MICROBES INFECT, V6, P572, DOI 10.1016/j.micinf.2004.02.007
   West P, 2013, PLOS ONE, V8, P6
NR 19
TC 3
Z9 3
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 8
PY 2014
VL 13
AR 306
DI 10.1186/1475-2875-13-306
PG 5
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AN5OI
UT WOS:000340640600001
PM 25106080
OA gold
DA 2017-08-15
ER

PT J
AU Idoko, OT
   Roberts, E
   Cox, M
   Jafali, J
   Njie-Jobe, J
   Mackenzie, G
   Ota, MO
   Kampmann, B
AF Idoko, O. T.
   Roberts, E.
   Cox, M.
   Jafali, J.
   Njie-Jobe, J.
   Mackenzie, G.
   Ota, M. O.
   Kampmann, B.
TI Antibodies against Haemophilus influenzae type b in The Gambia:
   Investigating the extent of protection across age groups
SO VACCINE
LA English
DT Article
DE Hib vaccine; Antibody; Protection; Gambia
ID CONJUGATE VACCINE; HIB DISEASE; IMMUNIZATION; INFANTS; IMMUNOGENICITY;
   POLYSACCHARIDE; EPIDEMIOLOGY; ELIMINATION; MENINGITIS; PREVENTION
AB Following a landmark clinical trial, the vaccine against Haemophilus influenzae type b (Hib) was introduced in The Gambia in 1997. Whilst the immunogenicity of this vaccine is well established subsequent to the doses administered under the EPI schedule, little data exists assessing longevity of protection, using serology. Such data are needed however to predict the susceptibility to Hib at the population level.
   To determine antibody persistence in 5-6 year old fully vaccinated Gambian children compared with older children, adolescents and young adults, 427 serum samples from healthy 5-37 year old participants were tested for Hib antibodies using VaccZyme Human Anti-Hib ELISA kits.
   86% of the children who had received 3 doses of Hib vaccine in infancy had Hib antibody concentrations >= 0.15 mg/l at the age of 5-6 years. This proportion was 76% for adolescents who had also largely been vaccinated and 90% for adults who had never received Hib vaccine.
   Although most participants had anti-Hib antibody above concentrations putatively defined as protective, significantly fewer had concentrations thought to confer long-term protection. This suggests a population with insufficient or waning antibody that may be susceptible to breakthrough disease and transmission. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Idoko, O. T.; Roberts, E.; Cox, M.; Jafali, J.; Njie-Jobe, J.; Mackenzie, G.; Kampmann, B.] MRC Unit, Banjul, Gambia.
   [Mackenzie, G.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Ota, M. O.] WHO, Reg Off Africa, Brazzaville, Congo.
   [Kampmann, B.] Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, London W2 1NY, England.
RP Idoko, OT (reprint author), MRC Unit, Banjul, Gambia.
EM oidoko@mrc.gm
FU Medical Research Council (MRC) United Kingdom [MR/K007602/1]
FX The authors acknowledge the Meningitis Vaccine Project (MVP) and Serum
   Institute of India (SIIL) for providing the framework within which data
   was collected for this manuscript. We specifically acknowledge MVP
   director Dr. Marie-Pierre Preziosi for her contributions and for
   reviewing the manuscript. We also thank all field and lab staff and the
   study communities. We are grateful to Medical Research Council (MRC)
   United Kingdom for funding, grant number MR/K007602/1.
CR Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103
   Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X
   AGBARAKWE AE, 1995, J CLIN PATHOL, V48, P206, DOI 10.1136/jcp.48.3.206
   Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   Arvas A, 2008, PEDIATR INT, V50, P469, DOI 10.1111/j.1442-200X.2008.02591.x
   Bamberger EE, 2014, PEDIAT INFECT DIS J
   Choisy M, 2012, P ROY SOC B-BIOL SCI, V279, P4574, DOI 10.1098/rspb.2012.1761
   Donovan Helen, 2013, Nurs Child Young People, V25, P16, DOI 10.7748/ncyp2013.11.25.9.16.e466
   Fernandez J, 2000, J INFECT DIS, V182, P1553, DOI 10.1086/315870
   Howie SRC, 2007, VACCINE, V25, P6305, DOI 10.1016/j.vaccine.2007.06.023
   Howie SRC, 2013, CLIN INFECT DIS, V57, P1527, DOI 10.1093/cid/cit598
   Hutter J, 2012, AM J TROP MED HYG, V86, P1026, DOI 10.4269/ajtmh.2012.11-0807
   Jones C, 2013, BMJ OPEN, V3
   Jones CE, 2011, JAMA-J AM MED ASSOC, V305, P576, DOI 10.1001/jama.2011.100
   KAYHTY H, 1983, J INFECT DIS, V147, P1100
   Li J, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-986
   MULHOLLAND EK, 1994, ANN TROP PAEDIATR, V14, P183
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   Oluwalana C, 2013, J PEDIATR-US, V163, pS4, DOI 10.1016/j.jpeds.2013.03.023
   Schmitt HJ, 2001, PEDIATR INFECT DIS J, V20, P767, DOI 10.1097/00006454-200108000-00010
   Sow SO, 2011, NEW ENGL J MED, V364, P2293, DOI 10.1056/NEJMoa1003812
   Wenger J, 1997, Afr Health, V20, P15
   Xion Y, 2014, HUM VACCINES IMMUNOT, V10
   [Anonymous], 2013, WKLY EPIDEMIOL REC, V81, P445
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 6
PY 2014
VL 32
IS 36
BP 4620
EP 4624
DI 10.1016/j.vaccine.2014.06.078
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AN1EX
UT WOS:000340326600004
PM 24975810
OA No
DA 2017-08-15
ER

PT J
AU Roy, A
   Eisenhut, M
   Harris, RJ
   Rodrigues, LC
   Sridhar, S
   Habermann, S
   Snell, L
   Mangtani, P
   Adetifa, I
   Lalvani, A
   Abubakar, I
AF Roy, A.
   Eisenhut, M.
   Harris, R. J.
   Rodrigues, L. C.
   Sridhar, S.
   Habermann, S.
   Snell, L.
   Mangtani, P.
   Adetifa, I.
   Lalvani, A.
   Abubakar, I.
TI Effect of BCG vaccination against Mycobacterium tuberculosis infection
   in children: systematic review and meta-analysis
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID GAMMA RELEASE ASSAY; SKIN-TEST; DIAGNOSIS; RISK; PROTECTION; OUTBREAK;
   TESTS; TIME
AB Objectives To determine whether BCG vaccination protects against Mycobacterium tuberculosis infection as assessed by interferon. release assays (IGRA) in children.
   Design Systematic review and meta-analysis. Searches of electronic databases 1950 to November 2013, checking of reference lists, hand searching of journals, and contact with experts.
   Setting Community congregate settings and households.
   Inclusion criteria Vaccinated and unvaccinated children aged under 16 with known recent exposure to patients with pulmonary tuberculosis. Children were screened for infection with M tuberculosis with interferon. release assays.
   Data extraction Study results relating to diagnostic accuracy were extracted and risk estimates were combined with random effects meta-analysis.
   Results The primary analysis included 14 studies and 3855 participants. The estimated overall risk ratio was 0.81 (95% confidence interval 0.71 to 0.92), indicating a protective efficacy of 19% against infection among vaccinated children after exposure compared with unvaccinated children. The observed protection was similar when estimated with the two types of interferon. release assays (ELISpot or QuantiFERON). Restriction of the analysis to the six studies (n = 1745) with information on progression to active tuberculosis at the time of screening showed protection against infection of 27% (risk ratio 0.73, 0.61 to 0.87) compared with 71% (0.29, 0.15 to 0.58) against active tuberculosis. Among those infected, protection against progression to disease was 58% (0.42, 0.23 to 0.77).
   Conclusions BCG protects against M tuberculosis infection as well as progression from infection to disease.
C1 [Roy, A.; Harris, R. J.; Abubakar, I.] Publ Hlth England, Ctr Infect Dis Surveillance & Control, London NW9 5EQ, England.
   [Eisenhut, M.; Habermann, S.; Snell, L.] NHS Fdn Trust, Luton & Dunstable Univ Hosp, Luton, Beds, England.
   [Rodrigues, L. C.; Mangtani, P.] London Sch Hyg & Trop Med, London WC1, England.
   [Sridhar, S.; Lalvani, A.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, TB Res Ctr, Resp Infect Sect, London, England.
   [Adetifa, I.] MRC, Fajara, Gambia.
   [Abubakar, I.] UCL, Ctr Infect Dis Epidemiol, London, England.
   [Abubakar, I.] UCL, MRC Clin Trials Unit, London, England.
RP Abubakar, I (reprint author), Publ Hlth England, Ctr Infect Dis Surveillance & Control, London NW9 5EQ, England.
EM i.abubakar@ucl.ac.uk
OI Rodrigues, Laura Cunha/0000-0001-9008-660X; Sridhar,
   Saranya/0000-0002-4267-3102; Abubakar, Ibrahim/0000-0002-0370-1430
FU UK National Institute for Health Research; UK MRC
FX This research received no specific grant from any funding agency in the
   public, commercial, or not-for-profit sectors. IA is supported by the UK
   National Institute for Health Research and the UK MRC.
CR Abu-Raddad LJ, 2009, P NATL ACAD SCI USA, V106, P13980, DOI 10.1073/pnas.0901720106
   Abubakar I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17370
   Adetifa IMO, 2010, PEDIATR INFECT DIS J, V29, P439, DOI 10.1097/INF.0b013e3181cb45da
   Altet-Gomez N, 2011, EUR RESPIR J, V37, P1166, DOI 10.1183/09031936.00022710
   Bianchi L, 2009, PEDIATR INFECT DIS J, V28, P510, DOI 10.1097/INF.0b013e31819abf6b
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Dominguez J, 2008, CLIN VACCINE IMMUNOL, V15, P168, DOI 10.1128/CVI.00364-07
   Dosanjh DPS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028754
   Eisenhut M, 2009, VACCINE, V27, P6116, DOI 10.1016/j.vaccine.2009.08.031
   Eriksen J, 2010, THORAX, V65, P1067, DOI 10.1136/thx.2010.140186
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   FINE PEM, 1988, BRIT MED BULL, V44, P691
   Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Higgins Jpt GS, 2011, COCHRANE HDB SYSTEMA
   Hill PC, 2006, PEDIATRICS, V117, P1542, DOI 10.1542/peds.2005-2095
   Lalvani A, 2007, CURR OPIN INFECT DIS, V20, P264, DOI 10.1097/QCO.0b013e32813e3fd8
   Lalvani A, 2010, THORAX, V65, P1036, DOI 10.1136/thx.2010.140996
   Lienhardt C, 2005, LANCET, V366, P1414, DOI 10.1016/S0140-6736(05)67535-6
   Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790
   Narayanan P R, 2006, Indian J Med Res, V123, P119
   Neira-Munoz Edmundo, 2008, Pediatr Infect Dis J, V27, P835, DOI 10.1097/INF.0b013e31816ff7c5
   Okada K, 2008, EPIDEMIOL INFECT, V136, P1179, DOI 10.1017/S0950268807009831
   Rodrigues LC, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5974
   Rutherford ME, 2012, INT J TUBERC LUNG D, V16, P496, DOI 10.5588/ijtld.11.0491
   Soysal A, 2005, LANCET, V366, P1443, DOI 10.1016/S0140-6736(05)67534-4
   Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761
   Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
   Tsiouris SJ, 2006, INT J TUBERC LUNG D, V10, P939
   Tsolia MN, 2010, PEDIATR INFECT DIS J, V29, P1137, DOI 10.1097/INF.0b013e3181ebfe8a
   Wells GA, NEWCASTLE OTTAWA SCA
   Zodpey Sanjay P, 2007, Indian J Public Health, V51, P205
NR 33
TC 85
Z9 85
U1 4
U2 24
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD AUG 5
PY 2014
VL 349
AR g4643
DI 10.1136/bmj.g4643
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AM9MP
UT WOS:000340206000002
PM 25097193
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Ideh, RC
   Pollock, L
   Sanneh, A
   Garba, D
   Anderson, STB
   Corrah, T
AF Ideh, R. C.
   Pollock, L.
   Sanneh, A.
   Garba, D.
   Anderson, S. T. B.
   Corrah, T.
TI Management of persistent purulent pericarditis using streptokinase for
   intrapericardial fibrinolysis
SO PAEDIATRICS AND INTERNATIONAL CHILD HEALTH
LA English
DT Article
DE Persistent purulent pericarditis; Intrapericardial fibrinolysis;
   Streptokinase; Child
AB Purulent pericarditis (PP) is a very serious condition with almost 100% mortality if untreated. Intrapericardial fibrinolysis is a preferred alternative to pericardectomy in the treatment of persistent PP, but there are no consensus guidelines on the standard protocol for this procedure in children. A 9-year-old boy was referred to the Medical Research Council Unit in The Gambia (MRC). He had been unwell for 18 days with a high continuous fever, cough, fast breathing, and dyspnoea on exertion. Prior to referral he had been treated for malaria and pneumonia with no improvement. At the MRC, he was diagnosed with purulent pericarditis caused by Staphylococcus aureus and after admission he was managed for 4 weeks with intravenous antibiotics, pericardial aspirations followed by saline lavage of the pericardium and intrapericardial antibiotic instillation. Despite these measures, massive re-accumulation of the purulent pericardial effusion continued. Once daily intrapericardial instillation of streptokinase at a dose of 18,000 i.u/kg diluted in 50 ml of normal saline, and saline washout of the pericardium after 2 hours was commenced on the 29th day of admission, in addition to the antibiotics. This technique of fibrinolysis employed for 2 days was effective in managing the persistent purulent pericarditis when pericardial aspiration and intravenous and intrapericardial antibiotics failed.
C1 [Ideh, R. C.; Pollock, L.; Sanneh, A.; Garba, D.; Anderson, S. T. B.; Corrah, T.] MRC, Banjul, Gambia.
RP Ideh, RC (reprint author), MRC, Banjul, Gambia.
EM idehreadon@yahoo.com
CR Augustin P, 2011, CRIT CARE, V15, DOI 10.1186/cc10022
   BOYLE JD, 1961, MEDICINE, V40, P119
   Cakir O, 2002, J PEDIATR SURG, V37, P1404, DOI 10.1053/jpsu.2002.35401
   Defouilloy C, 1997, INTENS CARE MED, V23, P117, DOI 10.1007/s001340050301
   Ekim H, 2004, SURG TODAY, V34, P569, DOI 10.1007/s00595-004-2773-x
   Juneja R, 1999, ARCH DIS CHILD, V80, P275
   MannSegal DDM, 1996, J THORAC CARDIOV SUR, V111, P487, DOI 10.1016/S0022-5223(96)70462-2
   Onyeama CO, 2007, INT J CARDIOL, V119, P392, DOI 10.1016/j.ijcard.2006.07.176
   Pankuweit Sabine, 2005, Am J Cardiovasc Drugs, V5, P103, DOI 10.2165/00129784-200505020-00004
   Tomkowski W Z, 2003, Monaldi Arch Chest Dis, V59, P308
   Ustunsoy H, 2002, EUR J CARDIO-THORAC, V22, P373, DOI 10.1016/S1010-7940(02)00258-0
NR 11
TC 0
Z9 0
U1 1
U2 2
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 2046-9047
EI 2046-9055
J9 PAEDIATR INT CHILD H
JI Paediatr. Int. Child Health
PD AUG
PY 2014
VL 34
IS 3
BP 220
EP 223
DI 10.1179/2046905513Y.0000000109
PG 4
WC Pediatrics
SC Pediatrics
GA AU0QH
UT WOS:000345328100014
PM 24621239
OA No
DA 2017-08-15
ER

PT J
AU Edwards, T
   Allen, E
   Harding-Esch, EM
   Hart, J
   Burr, SE
   Holland, MJ
   Sillah, A
   West, SK
   Mabey, D
   Bailey, R
AF Edwards, Tansy
   Allen, Elizabeth
   Harding-Esch, Emma M.
   Hart, John
   Burr, Sarah E.
   Holland, Martin J.
   Sillah, Ansumana
   West, Sheila K.
   Mabey, David
   Bailey, Robin
TI Non-Participation during Azithromycin Mass Treatment for Trachoma in The
   Gambia: Heterogeneity and Risk Factors
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID OCULAR CHLAMYDIA-TRACHOMATIS; CLUSTER RANDOMIZED-TRIALS; ACTIVE
   TRACHOMA; COMMUNITY; INFECTION; ELIMINATION; HOUSEHOLDS; CHILDREN;
   TANZANIA; ETHIOPIA
AB Background: There is concern that untreated individuals in mass drug administration (MDA) programs for neglected tropical diseases can reduce the impact of elimination efforts by maintaining a source of transmission and re-infection.
   Methodology/Principal Findings: Treatment receipt was recorded against the community census during three MDAs with azithromycin for trachoma in The Gambia, a hypo-endemic setting. Predictors of non-participation were investigated in 1-9 year olds using random effects logistic regression of cross-sectional data for each MDA. Two types of non-participators were identified: present during MDA but not treated (PNT) and eligible for treatment but absent during MDA (EBA). PNT and EBA children were compared to treated children separately. Multivariable models were developed using baseline data and validated using year one and two data, with a priori adjustment for previous treatment status. Analyses included approximately 10000 children at baseline and 5000 children subsequently. There was strong evidence of spatial heterogeneity, and persistent non-participation within households and individuals. By year two, non-participation increased significantly to 10.4% overall from 6.2% at baseline, with more, smaller geographical clusters of non-participating households. Multivariable models suggested household level predictors of non-participation (increased time to water and household head non-participation for both PNT and EBA; increased household size for PNT status only; non-inclusion in a previous trachoma examination survey and younger age for EBA only). Enhanced coverage efforts did not decrease non-participation. Few infected children were detected at year three and only one infected child was EBA previously. Infected children were in communities close to untreated endemic areas with higher rates of EBA non-participation during MDA.
   Conclusions/Significance: In hypo-endemic settings, with good coverage and no association between non-participation and infection, efforts to improve participation during MDA may not be required. Further research could investigate spatial hotspots of infection and non-participation in other low and medium prevalence settings before allocating resources to increase participation.
C1 [Edwards, Tansy] Univ London London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1E 7HT, England.
   [Allen, Elizabeth] Univ London London Sch Hyg & Trop Med, Dept Med Stat, London WC1E 7HT, England.
   [Harding-Esch, Emma M.; Hart, John; Burr, Sarah E.; Holland, Martin J.; Mabey, David; Bailey, Robin] Univ London London Sch Hyg & Trop Med, Dept Clin Res, London WC1E 7HT, England.
   [Burr, Sarah E.; Holland, Martin J.] Med Res Council Unit MRC, Banjul, Gambia.
   [Sillah, Ansumana] Minist Hlth & Social Welf, Natl Eye Hlth Programme, Kanifing, Gambia.
   [West, Sheila K.] Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
RP Edwards, T (reprint author), Univ London London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, Keppel St, London WC1E 7HT, England.
EM tansy.edwards@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276
FU Bill and Melinda Gates Foundation [48027]; Wellcome Trust
   [079246/Z/06/Z]; MRC; DFID [MR/K012126/1]
FX The original PRET trial (www.clinicaltrials.gov: NCT00792922) was funded
   by the Bill and Melinda Gates Foundation (grant number 48027). MJH
   receives salary funding from the Wellcome Trust (grant number
   079246/Z/06/Z). TE receives salary support from MRC and DFID (grant
   MR/K012126/1).
CR Anderson R, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0435
   Blake IM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000401
   Broman AT, 2006, INVEST OPHTH VIS SCI, V47, P99, DOI 10.1167/iovs.05-0326
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Cromwell EA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001995
   Cromwell EA, 2009, INT HEALTH, V1, P182, DOI 10.1016/j.inhe.2009.09.002
   Edwards T, 2008, TROP MED INT HEALTH, V13, P556, DOI 10.1111/j.1365-3156.2008.02034.x
   Edwards T, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001585
   Hagi M, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000583
   Harding-Esch EM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002115
   Harding-Esch EM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000861
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Jo B, 2008, STAT MED, V27, P5565, DOI 10.1002/sim.3370
   Jo B, 2008, PSYCHOL METHODS, V13, P1, DOI 10.1037/1082-989X.13.1.1
   Keenan JD, 2011, CLIN INFECT DIS, V52, P883, DOI 10.1093/cid/cir069
   Kulldorff M, 2010, SATSCAN USER GUIDE V
   Liu FC, 2014, EPIDEMICS-NETH, V6, P10, DOI 10.1016/j.epidem.2013.12.001
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   Montgomery MA, 2011, SOC SCI MED, V73, P1, DOI 10.1016/j.socscimed.2011.05.003
   Munoz B, 2003, INVEST OPHTH VIS SCI, V44, P1464, DOI 10.1167/iovs.02-0234
   Njomo D. W., 2012, Annals of Tropical Medicine and Public Health, V5, P103, DOI 10.4103/1755-6783.95962
   Nuwaha F, 2005, TROP MED INT HEALTH, V10, P659, DOI 10.1111/j.1365-3156.2005.01436.x
   Pullan RL, 2012, PARASITOLOGY, V139, P1870, DOI 10.1017/S0031182012000698
   QGIS Development Team, 2013, QGIS GEOGR INF SYST
   Shah NA, 2010, OPHTHAL EPIDEMIOL, V17, P113, DOI 10.3109/09286581003624921
   Solomon AW, 2006, TRACHOMA CONTROL GUI
   SOMMER A, 1991, STAT MED, V10, P45, DOI 10.1002/sim.4780100110
   Ssemanda Elizabeth N, 2015, Clin Epidemiol Glob Health, V3, P37
   Ssemanda EN, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001576
   Ssemanda EN, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000838
   Stare D, 2011, OPHTHAL EPIDEMIOL, V18, P20, DOI 10.3109/09286586.2010.545500
   StataCorp, 2013, STAT STAT SOFTW REL
   Uniting to Combat NTDs, 2012, LOND DECL NEGL TROP
   World Health Organization, 2012, ACC WORK OV GLOB IMP
   World Health Organization, 2011, 15 M WHO ALL EL BLIN
   World Health Organization, 2013, WHO VACC PREV DIS MO
   Yirga D, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-48
NR 37
TC 2
Z9 2
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2014
VL 8
IS 8
AR e3098
DI 10.1371/journal.pntd.0003098
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AO8AN
UT WOS:000341574700059
PM 25165994
OA gold
DA 2017-08-15
ER

PT J
AU Smith, CL
   Dickinson, P
   Forster, T
   Craigon, M
   Ross, A
   Khondoker, MR
   France, R
   Ivens, A
   Lynn, DJ
   Orme, J
   Jackson, A
   Lacaze, P
   Flanagan, KL
   Stenson, BJ
   Ghazal, P
AF Smith, Claire L.
   Dickinson, Paul
   Forster, Thorsten
   Craigon, Marie
   Ross, Alan
   Khondoker, Mizanur R.
   France, Rebecca
   Ivens, Alasdair
   Lynn, David J.
   Orme, Judith
   Jackson, Allan
   Lacaze, Paul
   Flanagan, Katie L.
   Stenson, Benjamin J.
   Ghazal, Peter
TI Identification of a human neonatal immune-metabolic network associated
   with bacterial infection
SO NATURE COMMUNICATIONS
LA English
DT Article
ID PEDIATRIC SEPTIC SHOCK; BIRTH-WEIGHT INFANTS; GENE-EXPRESSION; SEPSIS;
   INNATE; CELLS; LIPOCALIN-2; HOMEOSTASIS; RECEPTORS; DISEASE
AB Understanding how human neonates respond to infection remains incomplete. Here, a system-level investigation of neonatal systemic responses to infection shows a surprisingly strong but unbalanced homeostatic immune response; developing an elevated set-point of myeloid regulatory signalling and sugar-lipid metabolism with concomitant inhibition of lymphoid responses. Innate immune-negative feedback opposes innate immune activation while suppression of T-cell co-stimulation is coincident with selective upregulation of CD85 co-inhibitory pathways. By deriving modules of co-expressed RNAs, we identify a limited set of networks associated with bacterial infection that exhibit high levels of inter-patient variability. Whereas, by integrating immune and metabolic pathways, we infer a patient-invariant 52-gene-classifier that predicts bacterial infection with high accuracy using a new independent patient population. This is further shown to have predictive value in identifying infection in suspected cases with blood culture-negative tests. Our results lay the foundation for future translation of host pathways in advancing diagnostic, prognostic and therapeutic strategies for neonatal sepsis.
C1 [Smith, Claire L.; Orme, Judith; Jackson, Allan; Stenson, Benjamin J.] Royal Infirm Edinburgh NHS Trust, Ctr Reprod Hlth, Neonatal Unit, Edinburgh EH16 4SA, Midlothian, Scotland.
   [Smith, Claire L.; Dickinson, Paul; Forster, Thorsten; Craigon, Marie; Ross, Alan; Khondoker, Mizanur R.; France, Rebecca; Lacaze, Paul; Ghazal, Peter] Univ Edinburgh, Div Pathway Med, Edinburgh Infect Dis, Edinburgh EH16 4SB, Midlothian, Scotland.
   [Dickinson, Paul; Forster, Thorsten; Ghazal, Peter] Univ Edinburgh, SynthSys Synthet & Syst Biol, Edinburgh EH9 3JD, Midlothian, Scotland.
   [Ivens, Alasdair] Fios Genom Ltd, ETTC, Edinburgh EH9 3JL, Midlothian, Scotland.
   [Lynn, David J.] TEAGASC, AGRIC, Anim Biosci Res Dept, Dunsany, Meath, Ireland.
   [Flanagan, Katie L.] MRC, Res Labs, Fajara, Gambia.
RP Ghazal, P (reprint author), Univ Edinburgh, Div Pathway Med, Edinburgh Infect Dis, Edinburgh EH16 4SB, Midlothian, Scotland.
EM p.ghazal@ed.ac.uk
RI Khondoker, Mizanur/A-9860-2011; Forster, Thorsten/F-4483-2017
OI Forster, Thorsten/0000-0002-4483-3069
FU Wellcome Trust [WT066784]; EU; Chief Scientists Office [ETM202]; BBSRC
   [BB/D019621/1]; Centre for Synthetic and Systems Biology at Edinburgh
   (SynthSys); BBSRC; EPSRC [BB/D019621/1]; MRC [G0701291]; Teagasc
   [RMIS6018]
FX We thank the infants and their parents for their participation in the
   study. We thank Jurgen Schwarze and Harry Campbell for helpful comments
   on our manuscript. This work was supported by the Wellcome Trust
   (WT066784) programme grant, EU FP7 IAPP project ClouDx-i, Chief
   Scientists Office (ETM202) and BBSRC (BB/D019621/1) the Centre for
   Synthetic and Systems Biology at Edinburgh (SynthSys) supported by the
   BBSRC and EPSRC (BB/D019621/1) to P. G. and P. D.; MRC (G0701291) to K.
   L. F., P. D. and P. G. Teagasc (RMIS6018) funded D.J.L.'s participation
   in this study. There was no involvement in study design, analysis or
   interpretation of results from any funding source.
CR Abbas AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006098
   Akelma AZ, 2012, J PEDIATR ENDOCR MET, V25, P525, DOI 10.1515/jpem-2011-0477
   Anderson KJ, 2009, IMMUNOLOGY, V127, P8, DOI 10.1111/j.1365-2567.2009.03097.x
   Ardura MI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005446
   Barsky A, 2007, BIOINFORMATICS, V23, P1040, DOI 10.1093/bioinformatics/btm057
   Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103
   Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247
   Birle Alexandra, 2003, J Perinatol, V23, P294, DOI 10.1038/sj.jp.7210906
   Brown D, 2004, TISSUE ANTIGENS, V64, P215, DOI 10.1111/j.1399-0039.2004.00290.x
   Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760
   Cotton CM, 2010, ARCH DIS CHILDHOOD-E, V95, P94, DOI 10.1136/adc.2010.187732
   Decker T, 2005, NAT REV IMMUNOL, V5, P675, DOI 10.1038/nri1684
   Elahi S, 2013, NATURE, V504, P158, DOI 10.1038/nature12675
   Fjaerli HO, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-175
   Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104
   Ghazal P, 2013, CURR OPIN INFECT DIS, V26, P213, DOI 10.1097/QCO.0b013e32835fb8bf
   Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6
   Hodge G, 2004, CLIN EXP IMMUNOL, V135, P125, DOI 10.1046/j.1365-2249.2004.02346.x
   Horbar JD, 2012, PEDIATRICS, V129, P1019, DOI 10.1542/peds.2011-3028
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang Y, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-11
   Hyatt G, 2006, NAT IMMUNOL, V7, P686, DOI 10.1038/ni0706-686
   Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233
   Jiang Hong, 2004, Journal of Immunology, V172, P5870
   Johnson SB, 2007, ANN SURG, V245, P611, DOI 10.1097/01.sla.0000251619.10648.32
   Kamada N, 2013, NAT REV IMMUNOL, V13, P321, DOI 10.1038/nri3430
   Kauffmann A, 2009, BIOINFORMATICS, V25, P2092, DOI 10.1093/bioinformatics/btp354
   Khondoker Mizanur R., 2010, Journal of Bioinformatics and Computational Biology, V8, P945, DOI 10.1142/S0219720010005063
   Labib A. Z. M., 2013, INT J, V4, P77
   Lauss M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-532
   Lavoie PM, 2010, J INFECT DIS, V202, P1754, DOI 10.1086/657143
   Layseca-Espinosa E, 2002, PEDIATR ALLERGY IMMU, V13, P319, DOI 10.1034/j.1399-3038.2002.01064.x
   Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075
   Liew CC, 2006, J LAB CLIN MED, V147, P126, DOI 10.1016/j.lab.2005.10.005
   Lin CY, 2008, NUCLEIC ACIDS RES, V36, pW438, DOI 10.1093/nar/gkn257
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   Lynn DJ, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.55
   Madsen-Bouterse SA, 2010, AM J REPROD IMMUNOL, V63, P73, DOI 10.1111/j.1600-0897.2009.00791.x
   Manger ID, 2000, CURR OPIN IMMUNOL, V12, P215, DOI 10.1016/S0952-7915(99)00077-1
   Ng PC, 2006, CURR OPIN PEDIATR, V18, P125, DOI 10.1097/01.mop.0000193293.87022.4c
   Ng PC, 1997, ARCH DIS CHILD, V77, pF221
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   R Core Team, 2013, R LANG ENV STAT COMP
   Ramilo O, 2007, BLOOD, V109, P2066, DOI 10.1182/blood-2006-02-002477
   Shanley TP, 2007, MOL MED, V13, P495, DOI 10.2119/2007-00065.Shanley
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sharma AA, 2012, CLIN IMMUNOL, V145, P61, DOI 10.1016/j.clim.2012.08.006
   Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100
   Smith CL, 2007, ANALYST, V132, P1200, DOI 10.1039/b707122c
   Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165
   Smyth G. K., 2005, BIOINFORMATICS COMPU
   Srinivasan G, 2012, J IMMUNOL, V189, P1911, DOI 10.4049/jimmunol.1200892
   Stoll BJ, 2004, JAMA-J AM MED ASSOC, V292, P2357, DOI 10.1001/jama.292.19.2357
   Tang BMP, 2007, AM J RESP CRIT CARE, V176, P676, DOI 10.1164/rccm.200612-1819OC
   Theocharidis A, 2009, NAT PROTOC, V4, P1535, DOI 10.1038/nprot.2009.177
   Wong HR, 2007, PHYSIOL GENOMICS, V30, P146, DOI 10.1152/physiolgenomics.00024.2007
NR 56
TC 22
Z9 22
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG
PY 2014
VL 5
AR 4649
DI 10.1038/ncomms5649
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO1FJ
UT WOS:000341057500003
PM 25120092
OA gold
DA 2017-08-15
ER

PT J
AU Adegbola, RA
   DeAntonio, R
   Hill, PC
   Roca, A
   Usuf, E
   Hoet, B
   Greenwood, BM
AF Adegbola, Richard A.
   DeAntonio, Rodrigo
   Hill, Philip C.
   Roca, Anna
   Usuf, Effua
   Hoet, Bernard
   Greenwood, Brian M.
TI Carriage of Streptococcus pneumoniae and Other Respiratory Bacterial
   Pathogens in Low and Lower-Middle Income Countries: A Systematic Review
   and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID PNEUMOCOCCAL CONJUGATE VACCINE; INFLUENZAE TYPE-B; VITAMIN-A
   SUPPLEMENTATION; HIV-INFECTED CHILDREN; NASOPHARYNGEAL CARRIAGE;
   HAEMOPHILUS-INFLUENZAE; MENINGOCOCCAL CARRIAGE; STAPHYLOCOCCUS-AUREUS;
   ANTIBIOTIC-RESISTANCE; SEROTYPE DISTRIBUTION
AB Background: Infection with Streptococcus pneumoniae is a major cause of childhood morbidity and mortality worldwide, especially in low income countries where pneumococcal conjugate vaccines (PCVs) are still underused. In countries where PCVs have been introduced, much of their efficacy has resulted from their impact on nasopharyngeal carriage in vaccinated children. Understanding the epidemiology of carriage for S. pneumoniae and other common respiratory bacteria in developing countries is crucial for implementing appropriate vaccination strategies and evaluating their impact.
   Methods and Findings: We have systematically reviewed published studies reporting nasopharyngeal or oropharyngeal carriage of S. pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Neisseria meningitidis in children and adults in low and lower-middle income countries. Studies reporting pneumococcal carriage for healthy children <5 years of age were selected for a meta-analysis. The prevalences of carriage for S. pneumoniae, H. influenzae, and M. catarrhalis were generally higher in low income than in lower-middle income countries and were higher in young children than in adults. The prevalence of S. aureus was high in neonates. Meta-analysis of data from young children before the introduction of PCVs showed a pooled prevalence estimate of 64.8% (95% confidence interval, 49.8%-76.1%) in low income countries and 47.8% (95% confidence interval, 44.7%-50.8%) in lower-middle income countries. The most frequent serotypes were 6A, 6B, 19A, 19F, and 23F.
   Conclusions: In low and lower-middle income countries, pneumococcal carriage is frequent, especially in children, and the spectrum of serotypes is wide. However, because data are limited, additional studies are needed to adequately assess the impact of PCV introduction on carriage of respiratory bacteria in these countries.
C1 [Adegbola, Richard A.; DeAntonio, Rodrigo; Hoet, Bernard] GlaxoSmithKline Vaccines, Wavre, Belgium.
   [Hill, Philip C.; Roca, Anna; Usuf, Effua] MRC Unit, Banjul, Gambia.
   [Hill, Philip C.] Univ Otago, Sch Med, Ctr Int Hlth, Dunedin, New Zealand.
   [Greenwood, Brian M.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England.
RP Adegbola, RA (reprint author), GlaxoSmithKline Vaccines, Wavre, Belgium.
EM richard.a.adegbola@gsk.com
FU GSK Biologicals SA
FX GSK Biologicals SA paid for all costs associated with the development
   and the publishing of the present manuscript. The sponsor contributed to
   all stages of the study, including study design, data analyses, data
   interpretation, and the writing of this report.
CR Abdullahi O, 2008, PEDIATR INFECT DIS J, V27, P59, DOI 10.1097/INF.0b013e31814da70c
   Abdullahi O, 2012, J INFECT DIS, V206, P1020, DOI 10.1093/infdis/jis447
   Abdullahi O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030787
   Adegbola RA, 1998, J INFECT DIS, V177, P1758, DOI 10.1086/517440
   Adetifa IMO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030548
   Agrawal A, 2011, J CLIN MICROBIOL, V49, P3728, DOI 10.1128/JCM.05476-11
   Akinsola AK, 2012, PLOS ONE, V7
   AMIR M, 1995, EUR J CLIN MICROBIOL, V14, P34, DOI 10.1007/BF02112615
   Anthony L, 2012, INT J INFECT DIS, V16, pE753, DOI 10.1016/j.ijid.2012.05.1037
   Anwar Muhammad Saeed, 2004, J Coll Physicians Surg Pak, V14, P661
   Blossom DB, 2006, INT J INFECT DIS, V10, P458, DOI 10.1016/j.ijid.2006.05.010
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Bogaert D, 2004, LANCET, V363, P1871, DOI 10.1016/S0140-6736(04)16357-5
   Bogaert D, 2002, J CLIN MICROBIOL, V40, P3903, DOI 10.1128/JCM.40.11.3903-3908.2002
   Bogaert D, 2001, J CLIN MICROBIOL, V39, P3316, DOI 10.1128/JCM.39.9.3316-3320.2001
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   Casey JR, 2010, PEDIATR INFECT DIS J, V29, P304, DOI 10.1097/INF.0b013e3181c1bc48
   Caulfield LE, 2004, AM J CLIN NUTR, V80, P193
   CHEESBROUGH JS, 1995, EPIDEMIOL INFECT, V114, P75
   Cheung YB, 2009, PEDIATR INFECT DIS J, V28, P990, DOI 10.1097/INF.0b013e3181a78185
   Choi YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026190
   Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6
   Coles CL, 2008, J NUTR, V138, P2462, DOI 10.3945/jn.108.095422
   Coles CL, 2011, J NUTR, V141, P1907, DOI 10.3945/jn.111.141622
   Coles CL, 2001, J NUTR, V131, P255
   Dagan R, 2000, CLIN INFECT DIS, V30, P319, DOI 10.1086/313645
   Das B. K., 2002, Indian Journal of Pediatrics, V69, P775, DOI 10.1007/BF02723690
   Das Bhattacharya S, 2012, INDIAN J PEDIATR, V79, P1447, DOI 10.1007/s12098-012-0762-4
   Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005
   De Wals P, 2012, VACCINE, V30, P6416, DOI 10.1016/j.vaccine.2012.08.017
   Denno Donna M, 2002, West Afr J Med, V21, P233
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Devi U, 2012, INDIAN J MED RES, V136, P495
   Donkor ES, 2010, SCAND J INFECT DIS, V42, P254, DOI 10.3109/00365540903490000
   Dunne EM, 2013, VACCINE, V31, P2333, DOI 10.1016/j.vaccine.2013.03.024
   Egere U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049143
   Fedson DS, 1999, VACCINE, V17, pS11, DOI 10.1016/S0264-410X(99)00122-X
   Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517
   Feikin DR, 2004, LANCET INFECT DIS, V4, P445, DOI 10.1016/S1473-3099(04)01060-6
   Fervers B, 2008, TUMORI, V94, P154
   Flasche S, 2011, EUROSURVEILLANCE, V16, P13
   Gessner BD, 1998, PEDIATR INFECT DIS J, V17, pS179, DOI 10.1097/00006454-199809001-00018
   Gilks CF, 1997, T ROY SOC TROP MED H, V91, P627, DOI 10.1016/S0035-9203(97)90498-3
   Gill CJ, 2008, J INFECT DIS, V197, P1000, DOI 10.1086/528806
   Gill CJ, 2008, B WORLD HEALTH ORGAN, V86, P929, DOI 10.2471/BLT.07.049668
   Goldblatt D, 2013, VACCINE, V32, P146, DOI 10.1016/j.vaccine.2013.06.040
   Granat SM, 2007, PEDIATR INFECT DIS J, V26, P319, DOI 10.1097/01.inf.0000257425.24492.11
   Greenberg D, 2004, J CLIN MICROBIOL, V42, P4604, DOI 10.1128/JCM.42.10.4604-4609.2004
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Hill PC, 2010, CLIN INFECT DIS, V50, P1468, DOI 10.1086/652443
   Huang SS, 2005, PEDIATRICS, V116, pE408, DOI 10.1542/peds.2004-2338
   ICHHPUJANI R L, 1990, Journal of Communicable Diseases, V22, P264
   Isaacman DJ, 2010, INT J INFECT DIS, V14, pE197, DOI 10.1016/j.ijid.2009.05.010
   Jacoby P, 2011, PEDIATR INFECT DIS J, V30, P480, DOI 10.1097/INF.0b013e318217dc6e
   Johnson H.L., 2010, PLOS MED, V7
   Kateete David P, 2012, BMC Res Notes, V5, P28, DOI 10.1186/1756-0500-5-28
   Kellner JD, 2009, CLIN INFECT DIS, V49, P205, DOI 10.1086/599827
   Kristiansen PA, 2013, CLIN INFECT DIS, V56, P354, DOI 10.1093/cid/cis892
   Kristiansen PA, 2011, CLIN VACCINE IMMUNOL, V18, P435, DOI 10.1128/CVI.00479-10
   Kwambana BA, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-175
   LANKINEN KS, 1994, J CLIN MICROBIOL, V32, P2948
   Leimkugel J, 2007, PLOS MED, V4, P535, DOI 10.1371/journal.pmed.0040101
   Lijek RS, 2012, CURR OPIN IMMUNOL, V24, P417, DOI 10.1016/j.coi.2012.05.005
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Lupisan SP, 2000, AM J TROP MED HYG, V62, P341
   Mackenzie GA, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001161
   Martinelli D, 2013, HUM VACCIN IMMUNOTHE, V10
   MASTRO TD, 1993, PEDIATR INFECT DIS J, V12, P824, DOI 10.1097/00006454-199310000-00006
   Millar EV, 2008, CLIN INFECT DIS, V47, P989, DOI 10.1086/591966
   Millar EV, 2009, PEDIATR INFECT DIS J, V28, P711, DOI 10.1097/INF.0b013e3181a06303
   Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moyo SJ, 2012, J MED MICROBIOL, V61, P952, DOI 10.1099/jmm.0.042598-0
   Mueller JE, 2007, EMERG INFECT DIS, V13, P847
   Mueller JE, 2008, TROP MED INT HEALTH, V13, P1543, DOI 10.1111/j.1365-3156.2008.02165.x
   Murphy TF, 2007, J INFECT DIS, V195, P81, DOI 10.1086/509824
   Mwenya DM, 2010, ANTIMICROB AGENTS CH, V54, P3756, DOI 10.1128/AAC.01409-09
   Nicolas P, 2007, VACCINE, V25, pA53, DOI 10.1016/j.vaccine.2007.04.041
   O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833
   O'Brien KL, 2014, PEDIATR INFECT DIS J, V33, pS107, DOI 10.1097/INF.0000000000000075
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   ODUGBEMI T, 1992, ETHIOPIAN MED J, V30, P33
   Odutola A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075558
   Ota MO, 2011, VACCINE, V29, P2999, DOI 10.1016/j.vaccine.2011.01.098
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494
   Pradeepa R, 2012, DIABETES TECHNOL THE, V14, pS59, DOI 10.1089/dia.2012.0065
   Raymond J, 2000, J INFECT DIS, V181, P1983, DOI 10.1086/315505
   Regev-Yochay G, 2004, JAMA-J AM MED ASSOC, V292, P716, DOI 10.1001/jama.292.6.716
   Regev-Yochay G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035061
   Roca A, 2012, CLIN INFECT DIS, V55, P816, DOI 10.1093/cid/cis554
   Roca A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072198
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Rupa V, 2012, INT J PEDIATR OTORHI, V76, P1835, DOI 10.1016/j.ijporl.2012.09.013
   Rusen ID, 1997, PEDIATR INFECT DIS J, V16, P656, DOI 10.1097/00006454-199707000-00007
   Russell FM, 2006, ANN TROP PAEDIATR, V26, P187, DOI 10.1179/146532806X120273
   Saha SK, 2003, J CLIN MICROBIOL, V41, P5582, DOI 10.1128/JCM.41.12.5582-5587.2003
   Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062
   SEHGAL SC, 1994, INFECTION, V22, P193, DOI 10.1007/BF01716701
   Sekhar S, 2009, EPIDEMIOL INFECT, V137, P156, DOI 10.1017/S095026880800071X
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/ERV.12.53, 10.1586/erv.12.53]
   Soewignjo S, 2001, CLIN INFECT DIS, V32, P1039, DOI 10.1086/319605
   Steens A, 2013, VACCINE
   Tigoi CC, 2012, CLIN INFECT DIS, V55, P180, DOI 10.1093/cid/cis371
   Trotter CL, 2007, LANCET INFECT DIS, V7, P797, DOI 10.1016/S1473-3099(07)70288-8
   Usuf E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085001
   Utsunomiya Y, 1998, J TROP PEDIATRICS, V44, P338, DOI 10.1093/tropej/44.6.338
   Valles X, 2006, TROP MED INT HEALTH, V11, P358, DOI 10.1111/j.1365-3156.2006.01565.x
   Verduin CM, 2002, CLIN MICROBIOL REV, V15, P125, DOI 10.1128/CMR.15.1.125-144.2002
   Vives M, 1997, PEDIATR INFECT DIS J, V16, P852, DOI 10.1097/00006454-199709000-00007
   Vu Huong Thi Thu, 2011, Pediatr Infect Dis J, V30, P11, DOI 10.1097/INF.0b013e3181f111a2
   Wang SA, 2013, MMWR-MORBID MORTAL W, V62, P308
   Wattal C, 2007, INDIAN J PEDIATR, V74, P905, DOI 10.1007/s12098-007-0166-z
   Weinberger DM, 2013, AM J EPIDEMIOL
   Wenger JD, 2010, PEDIATR INFECT DIS J, V29, P251, DOI 10.1097/INF.0b013e3181bdbed5
   Wertheim HFL, 2005, LANCET INFECT DIS, V5, P751, DOI 10.1016/S1473-3099(05)70295-4
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2
   World Health Organization, 2008, WKLY EPIDEMIOL REC, V83, P373
   World Health Organization, 2008, EST HIB PNEUM DEATHS
   Wiertsema SP, 2011, VACCINE, V29, P5163, DOI 10.1016/j.vaccine.2011.05.035
   Williams EJ, 2011, J CLIN MICROBIOL, V49, P1323, DOI 10.1128/JCM.02200-10
   World Bank, 2012, COUNTR LEND GROUPS
NR 124
TC 27
Z9 29
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 1
PY 2014
VL 9
IS 8
AR e103293
DI 10.1371/journal.pone.0103293
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM4JL
UT WOS:000339819800026
PM 25084351
OA gold
DA 2017-08-15
ER

PT J
AU Grietens, KP
   Ribera, JM
   Erhart, A
   Hoibak, S
   Ravinetto, RM
   Gryseels, C
   Dierickx, S
   O'Neill, S
   Muela, SH
   D'Alessandro, U
AF Grietens, Koen Peeters
   Ribera, Joan Muela
   Erhart, Annette
   Hoibak, Sarah
   Ravinetto, Raffaella M.
   Gryseels, Charlotte
   Dierickx, Susan
   O'Neill, Sarah
   Muela, Susanna Hausmann
   D'Alessandro, Umberto
TI Doctors and Vampires in Sub-Saharan Africa: Ethical Challenges in
   Clinical Trial Research
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID MEDICAL-RESEARCH; BLOOD; GAMBIA
AB Collecting blood samples from individuals recruited into clinical research projects in sub-Saharan Africa can be challenging. Strikingly, one of the reasons for participant reticence is the occurrence of local rumors surrounding "blood stealing" or "blood selling." Such fears can potentially have dire effects on the success of research projects for example, high dropout rates that would invalidate the trial's results and have ethical implications related to cultural sensitivity and informed consent. Though commonly considered as a manifestation of the local population's ignorance, these rumors represent a social diagnosis and a logical attempt to make sense of sickness and health. Born from historical antecedents, they reflect implicit contemporary structural inequalities and the social distance between communities and public health institutions. We aim at illustrating the underlying logic governing patients' fear and argue that the management of these beliefs should become an intrinsic component of clinical research.
C1 [Grietens, Koen Peeters; Gryseels, Charlotte; Dierickx, Susan; O'Neill, Sarah] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.
   Nagasaki Univ, Sch Int Hlth Dev, Nagasaki, Japan.
   Partners Appl Social Sci PASS Int, Tessenderlo, Belgium.
   Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium.
   [Hoibak, Sarah] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland.
   [Ravinetto, Raffaella M.] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.
   Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Louvain, Belgium.
   MRC, Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   [Ribera, Joan Muela; Muela, Susanna Hausmann] PASS Int, Tessenderlo, Belgium.
   [Erhart, Annette] Inst Trop Med, Antwerp, Inciralt, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
RP Grietens, KP (reprint author), Nationalestr 155, B-2000 Antwerp, Belgium.
EM kpeeters@itg.be; joan.muela@yahoo.com; aerhart@itg.be;
   Hoibak@theglobalfund.org; rravinetto@itg.be; cgryseels@itg.be;
   sdierickx@itg.be; soneill@itg.be; Susanna.hausmann_muela@yahoo.es;
   udalessandro@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
CR Barnard A, 2002, ENCY SOCIAL CULTURAL, P562
   Bastian M., 2001, MAGICAL INTERPRETATI, P71
   Bildhauer B., 2013, JRAI SPECIAL ISSU SS, V19
   Carsten J, 2013, JRAI SPECIAL ISSU SS, V19
   Chapman RR, 2006, MED ANTHROPOL Q, V20, P487, DOI 10.1525/maq.2006.20.4.487
   [Anonymous], 2002, INT ETH GUID BIOM RE
   Comaroff Jean, 1993, MODERNITY ITS MALCON
   Dugger CW, 2006, RUMOR FEAR FATIGUE H
   Erwin K, 2006, MED ANTHROPOL Q, V20, P139, DOI 10.1525/maq.2006.20.2.139
   Fairhead J, 2006, SOC SCI MED, V63, P1109, DOI 10.1016/j.socscimed.2006.02.018
   Feldman-Savelsberg P, 2000, MED ANTHROPOL Q, V14, P159, DOI 10.1525/maq.2000.14.2.159
   Feldman-Savelsberg Pamela, 1999, PLUNDERED KITCHENS E
   Gardinier DE, 2000, J CONT AFRICAN STUDI, V18, P225, DOI 10.1080/713675627
   Geissler PW, 2006, TROP MED INT HEALTH, V11, P975, DOI 10.1111/j.1365-3156.2006.01682.x
   Geissler PW, 2008, SOC SCI MED, V67, P696, DOI [10.1016/j.socscimed.2008.02.004, 10.1016/.j.socscimed.2008.02.004]
   Geissler PW, 2005, AFRICA, V75, P173
   Geschiere Peter, 1997, MODERNITY WITCHCRAFT
   Geschiere P, 1988, CRITIQUE ANTHR, V8, P35, DOI 10.1177/0308275X8800800104
   Grietens KP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036954
   Hardon A., 2004, ENCY MED ANTHR, P262, DOI 10.1007/0-387-29905-X_31
   Kaler A, 2004, STUD FAMILY PLANN, V35, P105, DOI 10.1111/j.1728-4465.2004.00012.x
   Kaler A, 2009, SOC SCI MED, V68, P1711, DOI 10.1016/j.socscimed.2009.01.038
   Kessel M, 2013, SCIENTIST
   Kuriyama Shigehisa, 1999, EXPRESSIVENESS BODY
   Mayblin M., 2013, JRAI SPECIAL ISSU SS, V19
   Moore Henrietta, 2002, MAGICAL INTERPRETATI
   Ngolet F., 2000, AFR STUD REV, V43, P55, DOI 10.2307/524984
   Niehaus I, 2005, J ROY ANTHROPOL INST, V11, P191, DOI 10.1111/j.1467-9655.2005.00232.x
   Nuffield Council on Bioethics, 2002, ETH RES REL HEALTHC
   Nyamnjoh Francis, 2001, MAGICAL INTERPRETATI, P28
   Report B, 1979, ETHICAL PRINCIPLES G
   Sanders T., 2001, MAGICAL INTERPRETATI, P160
   Scheper-Hughes N, 1996, ANTHR TODAY, V12, P3, DOI 10.2307/2783143
   Shaw R, 2001, MAGICAL INTERPRETATI, P50
   Soiron M, 2006, CAHIERS ETUDES AFRIC
   TDR-Special Programme for Research and Training in Tropical Diseases/World Health Organization, 2007, TDRSDRSEBST072
   Tonda J, 2006, CAHIERS GABONAIS DAR, V17, P1982
   Tonda J, 2011, SOC COMPASS, V58, P42, DOI 10.1177/0037768610392731
   Weiss B., 1998, BODIES PERSONS COMP, P172, DOI 10.1017/CBO9780511802782.008
   White L, 1995, AM HIST REV, V100, P1379, DOI 10.2307/2169863
   White L, 1993, REPRESENTATIONS, V43, P27, DOI 10.1525/rep.1993.43.1.99p0179v
   White L., 2000, SPEAKING VAMPIRES RU
   White Owen, 2005, FRENCH HIST, V19, P91, DOI 10.1093/fh/cri002
NR 43
TC 7
Z9 7
U1 1
U2 8
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD AUG
PY 2014
VL 91
IS 2
BP 213
EP 215
DI 10.4269/ajtmh.13-0630
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AM4ZD
UT WOS:000339863800002
PM 24821846
OA No
DA 2017-08-15
ER

PT J
AU Olaniyan, SA
   Amodu, OK
   Yindom, LM
   Conway, DJ
   Aka, P
   Bakare, AA
   Omotade, OO
AF Olaniyan, Subulade A.
   Amodu, Olukemi K.
   Yindom, Louis-Marie
   Conway, David J.
   Aka, Peter
   Bakare, Adekunle A.
   Omotade, Olayemi O.
TI Killer-cell immunoglobulin-like receptors and falciparum malaria in
   southwest Nigeria
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE KIR genes; Severe malaria; Genotyping; Disease association study; West
   Africa
ID HUMAN NK CELLS; HLA CLASS-I; PLASMODIUM-FALCIPARUM; HETEROZYGOTE
   ADVANTAGE; INFECTED ERYTHROCYTES; ASSOCIATION ANALYSIS; WEST-AFRICA;
   KIR; SELECTION; DISEASE
AB Killer-cell immunoglobulin-like receptors (KIRs) are a group of natural killer cell receptors (NKRs) that regulate NK-cell-mediated production of interferon gamma (IFN-gamma) in response to infection. These receptors have recently been suggested to influence the severity of clinical Plasmodium falciparum malaria infection. We examined the KIR locus in relation to malaria in children from southwest Nigeria. Sequence specific priming (SSP)-PCR was used to detect the KIR genes. The presence or absence of fifteen different KIR genes was determined in each individual and the proportions compared across 3 clinical groups: asymptomatic malaria, uncomplicated clinical malaria and severe clinical malaria. The genes KIR2DL5, KIR2DS3 and KIR2DS5 were present in a significantly higher proportion of individuals in the asymptomatic control group than in the malaria cases. Furthermore, KIR2DS3 and KIR2DS5 were present in a higher proportion of uncomplicated malaria cases than severe malaria cases. Carriage c-AB2 genotype (which comprises all centromeric KIR genes including KIR2DL5, KIR2DS3 and KIR2DS5) decreases with severity of the disease suggesting that the KIR AB profile might be associated with protection from severe malaria infection in this population in Nigeria. (C) 2014 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
C1 [Olaniyan, Subulade A.; Amodu, Olukemi K.; Omotade, Olayemi O.] Univ Ibadan, Inst Child Hlth, Coll Med, Ibadan, Nigeria.
   [Yindom, Louis-Marie; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Conway, David J.] London Sch Hyg & Trop Med, London WC1, England.
   [Aka, Peter] NIH, Bethesda, MD 20892 USA.
   [Yindom, Louis-Marie] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Bakare, Adekunle A.] Univ Ibadan, Dept Zool, Ibadan, Nigeria.
RP Amodu, OK (reprint author), Univ Ibadan, Inst Child Hlth, Coll Med, Ibadan, Nigeria.
EM subulade.olaniyan@yahoo.com; amkemi@hotmail.com;
   louis-marie.yindom@ndm.ox.ac.uk; David.Conway@lshtm.ac.uk;
   peter.aka@nih.gov; adebakar19@yahoo.com; edjohnade@gmail.com
OI Amodu, Olukemi/0000-0003-1477-4229; Conway, David/0000-0002-8711-3037
FU European Community [LSHP-CT-2004-503578]; Seventh Framework Programme
   [242095]
FX We are grateful to all study participants and their parents/guardians.
   We appreciate all the field and laboratory staff of the malaria
   pathogenesis unit, Institute Child Health, University of lbadan. We
   acknowledge Omar janha and Fanta Conteh for their assistance with KIR
   typing. The research leading to these results has received funding from
   the European Community under grant agreement LSHP-CT-2004-503578 and
   Seventh Framework Programme (FP7/2007-2013) under grant agreement No.
   242095.
CR Artavanis-Tsakonas K, 2003, J IMMUNOL, V171, P5396
   Artavanis-Tsakonas K, 2002, J IMMUNOL, V169, P2956
   Ashouri E, 2012, HUM IMMUNOL, V73, P1017, DOI 10.1016/j.humimm.2012.07.325
   Biassoni R, 2012, IMMUNOLOGY MICROBIOL
   Boulet S, 2008, AIDS, V22, P595, DOI [10.1097/QAD.0b013e3282f56b23, 10.1097/QAD.0b013e3282ffde7e]
   Boyton RJ, 2007, CLIN EXP IMMUNOL, V149, P1, DOI 10.1111/j.1365-2249.2007.03424.x
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Cooley S, 2010, BLOOD, V116, P2411, DOI 10.1182/blood-2010-05-283051
   Denis L, 2005, TISSUE ANTIGENS, V66, P267, DOI 10.1111/j.1399-0039.2005.00473.x
   Driss A, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-271
   Giebel S, 2008, LEUKEMIA, V22, P2129, DOI 10.1038/leu.2008.108
   Giebel S, 2008, LEUKEMIA, V22, P2130
   Guinan KJ, 2010, GENES IMMUN, V11, P467, DOI 10.1038/gene.2010.9
   Hirayasu K, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002565
   Hsu KC, 2002, IMMUNOL REV, V190, P40, DOI 10.1034/j.1600-065X.2002.19004.x
   Jallow M, 2009, NAT GENET, V41, P657, DOI 10.1038/ng.388
   Korbel DS, 2009, J IMMUNOL, V182, P6426, DOI 10.4049/jimmunol.0804224
   Lodoen MB, 2006, CURR OPIN IMMUNOL, V18, P391, DOI 10.1016/j.coi.2006.05.002
   Lourembam SD, 2011, INFECT GENET EVOL, V11, P1921, DOI 10.1016/j.meegid.2011.08.017
   Martin Maureen P., 2008, V415, P49, DOI 10.1007/978-1-59745-570-1_3
   Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934
   Maxwell LD, 2004, HUM IMMUNOL, V65, P613, DOI 10.1016/j.humimm.2004.02.028
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   Nelson GW, 2004, J IMMUNOL, V173, P4273
   Norman PJ, 2007, NAT GENET, V39, P1092, DOI 10.1038/ng2111
   Norman PJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003938
   Norman PJ, 2002, GENES IMMUN, V3, P86, DOI 10.1038/sj/gene/6363836
   Pydi SS, 2013, HUM IMMUNOL, V74, P85, DOI 10.1016/j.humimm.2012.10.006
   Pyo CW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015115
   Single RM, 2007, NAT GENET, V39, P1114, DOI 10.1038/ng2077
   Taniguchi M, 2009, IMMUNOGENETICS, V61, P717, DOI 10.1007/s00251-009-0401-z
   Trowsdale J, 2001, IMMUNOL REV, V181, P20, DOI 10.1034/j.1600-065X.2001.1810102.x
   Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942
   WHO, 2012, WORLD MALARIA REPORT 2012, P1
   Yawata M, 2006, J EXP MED, V203, P633, DOI 10.1084/jem.20051884
   Yindom LM, 2012, TISSUE ANTIGENS, V79, P104, DOI 10.1111/j.1399-0039.2011.01818.x
   Yindom LM, 2010, J VIROL, V84, P8202, DOI 10.1128/JVI.00116-10
   Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055
NR 38
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
EI 1879-1166
J9 HUM IMMUNOL
JI Hum. Immunol.
PD AUG
PY 2014
VL 75
IS 8
BP 816
EP 821
DI 10.1016/j.humimm.2014.06.002
PG 6
WC Immunology
SC Immunology
GA AM7CN
UT WOS:000340022400017
PM 24929143
OA No
DA 2017-08-15
ER

PT J
AU Thomas, E
   Jallow, BJ
   Carayol, I
   Ideh, RC
   Anderson, ST
AF Thomas, Elizabeth
   Jallow, Bintou J.
   Carayol, Ilene
   Ideh, Readon C.
   Anderson, Suzanne T.
TI Rabies post-exposure prophylaxis at a clinic in Fajara, The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE Dog bite; Gambia; Post-exposure prophylaxis; Rabies
AB The Gambia is a popular holiday destination that is classified as a high-risk area for rabies exposure by the WHO.
   This was a retrospective study of 49 subjects with rabies exposure attending The Medical Research Council Clinical Service, The Gambia, for treatment. Their demographics, details of exposure and treatment delivery were evaluated.
   An estimated 16% (8/49) of all exposures were likely to be from rabid animals. Moreover, 24% (12/49) of patients were tourists, none of whom had received pre-exposure prophylaxis.
   Rabies exposure is a serious risk for Gambians and visitors. Tourists should be advised about pre-exposure prophylaxis and risk reduction of rabies exposure.
C1 [Thomas, Elizabeth] Wolfson Med Sch, Glasgow G12 8QQ, Lanark, Scotland.
   [Thomas, Elizabeth; Jallow, Bintou J.; Carayol, Ilene; Ideh, Readon C.; Anderson, Suzanne T.] Med Res Council Unit Gambia, Banjul, Gambia.
RP Anderson, ST (reprint author), Med Res Council Unit Gambia, Atlantic Rd,POB 273, Banjul, Gambia.
EM sanderson@mrc.gm
CR Aghahowa SE, 2010, VACCINE, V28, P4847, DOI 10.1016/j.vaccine.2010.04.004
   Diop SA, 2007, MED MALADIES INFECT, V37, P787, DOI 10.1016/j.medmal.2007.01.010
   Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360
   Public Health England, 2013, RAB GREEN BOOK
   World Health Organization, 2014, RAB GUID POST PROPH
   WHO Publication, 2010, VACCINE, V28, P7140
NR 6
TC 0
Z9 0
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0035-9203
EI 1878-3503
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD AUG
PY 2014
VL 108
IS 8
BP 513
EP 515
DI 10.1093/trstmh/tru069
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AM6EA
UT WOS:000339954100010
PM 24849125
OA No
DA 2017-08-15
ER

PT J
AU Liu, J
   Kabir, F
   Manneh, J
   Lertsethtakarm, P
   Begum, S
   Gratz, J
   Becker, SM
   Operario, DJ
   Taniuchi, M
   Janaki, L
   Platts-Mills, JA
   Haverstick, DM
   Kabir, M
   Sobuz, SU
   Nakjarung, K
   Sakpaisal, P
   Silapong, S
   Bodhidatta, L
   Qureshi, S
   Kalam, A
   Saidi, Q
   Swai, N
   Mujaga, B
   Maro, A
   Kwambana, B
   Dione, M
   Antonio, M
   Kibiki, G
   Mason, CJ
   Haque, R
   Iqbal, N
   Zaidi, AKM
   Houpt, ER
AF Liu, Jie
   Kabir, Furqan
   Manneh, Jainaba
   Lertsethtakarm, Paphavee
   Begum, Sharmin
   Gratz, Jean
   Becker, Steve M.
   Operario, Darwin J.
   Taniuchi, Mami
   Janaki, Lalitha
   Platts-Mills, James A.
   Haverstick, Doris M.
   Kabir, Mamun
   Sobuz, Shihab U.
   Nakjarung, Kaewkanya
   Sakpaisal, Pimmada
   Silapong, Sasikom
   Bodhidatta, Ladaporn
   Qureshi, Shahida
   Kalam, Adil
   Saidi, Queen
   Swai, Ndealilia
   Mujaga, Buliga
   Maro, Athanasia
   Kwambana, Brenda
   Dione, Michel
   Antonio, Martin
   Kibiki, Gibson
   Mason, Carl J.
   Haque, Rashidul
   Iqbal, Najeeha
   Zaidi, Anita K. M.
   Houpt, Eric R.
TI Development and assessment of molecular diagnostic tests for 15
   enteropathogens causing childhood diarrhoea: a multicentre study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID GLOBAL ENTERIC MULTICENTER; DEVELOPING-COUNTRIES; QUANTITATIVE PCR;
   INFECTIOUS-DISEASES; YOUNG-CHILDREN; VIRAL LOAD; INFANTS; ROTAVIRUS;
   CASE/CONTROL; ETIOLOGY
AB Background Childhood diarrhoea can be caused by many pathogens that are difficult to assay in the laboratory. Molecular diagnostic techniques provide a uniform method to detect and quantify candidate enteropathogens. We aimed to develop and assess molecular tests for identification of enteropathogens and their association with disease.
   Methods We developed and assessed molecular diagnostic tests for 15 enteropathogens across three platforms-PCR-Luminex, multiplex real-time PCR, and TaqMan array card-at five laboratories worldwide. We judged the analytical and clinical performance of these molecular techniques against comparator methods (bacterial culture, ELISA, and PCR) using 867 diarrhoeal and 619 non-diarrhoeal stool specimens. We also measured molecular quantities of pathogens to predict the association with diarrhoea, by univariate logistic regression analysis.
   Findings The molecular tests showed very good analytical and clinical performance at all five laboratories. Comparator methods had limited sensitivity compared with the molecular techniques (20-85% depending on the target) but good specificity (median 97-3%, IQR 96.5-98.9; mean 95.2%, SD 9.1). Positive samples by comparator methods usually had higher molecular quantities of pathogens than did negative samples, across almost all platforms and for most pathogens (p<0.05). The odds ratio for diarrhoea at a given quantity (measured by quantification cyde, Cq) showed that for most pathogens associated with diarrhoea-including Campylobacter jejuni and Campylobacter coli, Cryptosporidium spp, enteropathogenic Escherichia coli, heat-stable enterotoxigenic E coli, rotavirus, Shigella spp and enteroinvasive E coli, and Vibrio cholerae-the strength of association with diarrhoea increased at higher pathogen loads. For example, Shigella spp at a Cq range of 15-20 had an odds ratio of 8.0 (p<0.0001), but at a Cq range of 25-30 the odds ratio fell to 1.7 (p=0.043).
   Interpretation Molecular diagnostic tests can be implemented successfully and with fidelity across laboratories around the world. In the case of diarrhoea, these techniques can detect pathogens with high sensitivity and ascribe diarrhoeal associations based on quantification, including in mixed infections, providing rich and unprecedented measurements of infectious causes.
C1 [Liu, Jie; Gratz, Jean; Becker, Steve M.; Operario, Darwin J.; Taniuchi, Mami; Janaki, Lalitha; Platts-Mills, James A.; Houpt, Eric R.] Univ Virginia, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA.
   [Haverstick, Doris M.] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA.
   [Kabir, Furqan; Qureshi, Shahida; Kalam, Adil; Iqbal, Najeeha; Zaidi, Anita K. M.] Aga Khan Univ, Dept Pediat & Child Hlth, Karachi, Pakistan.
   [Manneh, Jainaba; Kwambana, Brenda; Dione, Michel; Antonio, Martin] MRC Unit, Banjul, Gambia.
   [Lertsethtakarm, Paphavee; Nakjarung, Kaewkanya; Sakpaisal, Pimmada; Silapong, Sasikom; Bodhidatta, Ladaporn; Mason, Carl J.] AFRIMS, Dept Enter Dis, Bangkok, Thailand.
   [Begum, Sharmin; Kabir, Mamun; Sobuz, Shihab U.; Haque, Rashidul] ICDDR B, Dhaka, Bangladesh.
   [Gratz, Jean; Saidi, Queen; Swai, Ndealilia; Maro, Athanasia; Kibiki, Gibson] Kilimanjaro Clin Res Inst, Moshi, Tanzania.
   [Mujaga, Buliga] Haydom Lutheran Hosp, Haydom, Tanzania.
RP Houpt, ER (reprint author), Univ Virginia, Dept Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA.
EM erh6k@virginia.edu
FU Bill & Melinda Gates Foundation Next Generation Molecular Diagnostics
   Project
FX Bill & Melinda Gates Foundation Next Generation Molecular Diagnostics
   Project.
CR Burd EM, 2010, CLIN MICROBIOL REV, V23, P550, DOI 10.1128/CMR.00074-09
   Caliendo AM, 2013, CLIN INFECT DIS, V57, pS139, DOI 10.1093/cid/cit578
   Elfving K, 2014, J CLIN MICROBIOL, V52, P916, DOI 10.1128/JCM.02697-13
   Feuerman M, 2008, J EVAL CLIN PRACT, V14, P930, DOI 10.1111/j.1365-2753.2008.00984.x
   Fournier PE, 2013, NAT REV MICROBIOL, V11, P574, DOI 10.1038/nrmicro3068
   Hague R, 2009, CLIN INFECT DIS, V48, P1191
   Houpt E, CLIN INFECT IN PRESS
   Houpt ER, 2008, LANCET, V372, P873, DOI 10.1016/S0140-6736(08)61377-X
   Kahlau P, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-106
   Kang G, 2004, J MED VIROL, V73, P118, DOI 10.1002/jmv.20053
   Kosek M, 2013, AM J TROP MED HYG, V88, P390, DOI 10.4269/ajtmh.2012.12-0549
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Kotloff KL, 2012, CLIN INFECT DIS, V55, pS232, DOI 10.1093/cid/cis753
   Lindsay B, 2013, J CLIN MICROBIOL, V51, P1740, DOI 10.1128/JCM.02713-12
   Lindsay BR, 2014, FEMS MICROBIOL LETT, V352, P25, DOI 10.1111/1574-6968.12362
   Liu J, 2013, J CLIN MICROBIOL, V51, P472, DOI 10.1128/JCM.02658-12
   Mukhopadhya I, 2013, J MED VIROL, V85, P1661, DOI 10.1002/jmv.23641
   Navidad JF, 2013, J CLIN MICROBIOL, V51, P3018, DOI 10.1128/JCM.00896-13
   Panchalingam S, 2012, CLIN INFECT DIS, V55, pS294, DOI 10.1093/cid/cis754
   Phillips G, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-63
   Platts-Mills JA, 2014, J CLIN MICROBIOL, V52, P1074, DOI 10.1128/JCM.02935-13
   Platts-Mills JA, 2014, AM J TROP MED HYG, V90, P133, DOI 10.4269/ajtmh.13-0439
   Ramani S, 2010, J MED VIROL, V82, P1803, DOI 10.1002/jmv.21872
   Taniuchi M, 2013, J INFECT DIS, V208, P1794, DOI 10.1093/infdis/jit507
   Urdea Mickey, 2006, Nature, V444 Suppl 1, P73, DOI 10.1038/nature05448
   Walker CLF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029151
NR 26
TC 61
Z9 62
U1 4
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD AUG
PY 2014
VL 14
IS 8
BP 716
EP 724
DI 10.1016/S1473-3099(14)70808-4
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA AL9LD
UT WOS:000339461700030
PM 25022434
OA No
DA 2017-08-15
ER

PT J
AU Idoko, OT
   Okolo, SN
   Plikaytis, B
   Akinsola, A
   Viviani, S
   Borrow, R
   Carlone, G
   Findlow, H
   Elie, C
   Kulkarni, PS
   Preziosi, MP
   Ota, M
   Kampmann, B
AF Idoko, Olubukola T.
   Okolo, Seline N.
   Plikaytis, Brian
   Akinsola, Adebayo
   Viviani, Simonetta
   Borrow, Ray
   Carlone, George
   Findlow, Helen
   Elie, Cheryl
   Kulkarni, Prasad S.
   Preziosi, Marie-Pierre
   Ota, Martin
   Kampmann, Beate
TI The impact of pre-existing antibody on subsequent immune responses to
   meningococcal A-containing vaccines
SO VACCINE
LA English
DT Article
DE Meningococcal A; Antibody; Pre-existing; Immune response; Conjugate
   vaccine
ID MENINGITIDIS SEROGROUP-A; CONJUGATE VACCINE; NEISSERIA-MENINGITIDIS;
   CAPSULAR POLYSACCHARIDE; EPIDEMIC MENINGITIS; BURKINA-FASO; AFRICA;
   DISEASE; PERSISTENCE; SAFETY
AB Major epidemics of serogroup A meningococcal meningitis continue to affect the African meningitis belt. The development of an affordable conjugate vaccine against the disease became a priority for World Health Organization (WHO) in the late 1990s. Licensing of meningococcal vaccines has been based on serological correlates of protection alone, but such correlates might differ in different geographical regions. If high pre-vaccination antibody concentrations/titers impacts on the response to vaccination and possibly vaccine efficacy, is not clearly understood. We set out to define the pre-vaccination Meningococcal group A (Men A) antibody concentrations/titers in The Gambia and study their impact on the immunogenicity of Men A containing vaccines.
   Data from subjects originally enrolled in studies to test the safety and immunogenicity of the MenA vaccine recently developed for Africa meningococcal A polysaccharide conjugated to tetanus toxoid, MenAfriVac (R) (PsA-TT) were analyzed. Participants had been randomized to receive either the study vaccine PsA-TT or the reference quadrivalent plain polysaccharide vaccine containing meningococcal groups A, C, W, and Y, Mencevax (R) ACWY, GlaxoSmithKline (PsACWY) in a 2:1 ratio. Venous blood samples were collected before and 28 days after vaccination. Antibodies were assayed by enzyme-linked immunosorbent assay (ELISA) for geometric mean concentrations and serum bactericidal antibody (SBA) for functional antibody. The inter age group differences were compared using ANOVA and the pre and post-vaccination differences by t test.
   Over 80% of the >= 19 year olds had pre-vaccination antibody concentrations above putatively protective concentrations as compared to only 10% of 1-2 year olds. Ninety-five percent of those who received the study vaccine had >= 4-fold antibody responses if they had low pre-vaccination concentrations compared to 76% of those with high pre-vaccination concentrations. All subjects with low pre-vaccination titers attained >= 4-fold responses as compared to 76% with high titers where study vaccine was received.
   Our data confirm the presence of high pre-vaccination Men A antibody concentrations/titers within the African meningitis belt, with significantly higher concentrations in older individuals. Although all participants had significant increase in antibody levels following vaccination, the four-fold or greater response in antibody titers were significantly higher in individuals with lower pre-existing antibody titers, especially after receiving PsA-TT. This finding may have some implications for vaccination strategies adopted in the future. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Idoko, Olubukola T.; Akinsola, Adebayo; Ota, Martin; Kampmann, Beate] MRC Unit, Serrekunda, Gambia.
   [Okolo, Seline N.] Univ Jos, Teaching Hosp, Jos, Nigeria.
   [Plikaytis, Brian; Carlone, George; Elie, Cheryl] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
   [Viviani, Simonetta] PATH Europe, Meningitis Vaccine Project, F-01210 Ferney Voltaire, France.
   [Borrow, Ray; Findlow, Helen] Manchester Royal Infirm, Vaccine Evaluat Unit, Publ Hlth England, Manchester M13 9WL, Lancs, England.
   [Kulkarni, Prasad S.] Serum Inst India Ltd, Pune 411028, Maharashtra, India.
   [Preziosi, Marie-Pierre] WHO, MVP, CH-1211 Geneva, Switzerland.
   [Ota, Martin] WHO Reg Off Africa, Brazzaville, Congo.
   [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, London W2 1NY, England.
RP Idoko, OT (reprint author), MRC Unit, POB 273, Serrekunda, Gambia.
EM oidoko@mrc.gm
FU Medical Research Council [MC_UP_A900_1122, MC_UP_A900_1115]; World
   Health Organization [001]
CR Akpede G O, 1995, West Afr J Med, V14, P217
   Ali O, 2013, TROP MED INT HEALTH, V18, P968, DOI 10.1111/tmi.12125
   ARMAND J, 1982, J BIOL STAND, V10, P335, DOI 10.1016/S0092-1157(82)80010-3
   Borrow R, 2005, VACCINE, V23, P2222, DOI 10.1016/j.vaccine.2005.01.051
   Borrow R, 2002, J INFECT DIS, V186, P1353, DOI 10.1086/344324
   Chandramohan D, 2007, VACCINE, V25, pA58, DOI 10.1016/j.vaccine.2007.04.042
   Daugla DM, 2014, LANCET, V383, P30
   Djingarey MH, 2012, VACCINE, V30, pB40, DOI 10.1016/j.vaccine.2011.12.073
   GHEESLING LL, 1994, J CLIN MICROBIOL, V32, P1475
   Girard MP, 2006, VACCINE, V24, P4692, DOI 10.1016/j.vaccine.2006.03.034
   Greenwood B, 1999, T ROY SOC TROP MED H, V93, P341, DOI 10.1016/S0035-9203(99)90106-2
   Greenwood B, 2006, TROP MED INT HEALTH, V11, P773, DOI 10.1111/j.1365-3156.2006.01639.x
   GUIRGUIS N, 1985, J EXP MED, V162, P1837, DOI 10.1084/jem.162.6.1837
   Hodgson A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002159
   Holmlund E, 2011, VACCINE, V29, P4565, DOI 10.1016/j.vaccine.2011.04.068
   Jodar L, 2003, LANCET, V361, P1902, DOI 10.1016/S0140-6736(03)13494-0
   KAYHTY H, 1981, J INFECT DIS, V143, P32
   Kieny MP, 2007, VACCINE, V25, pA108, DOI 10.1016/j.vaccine.2007.05.001
   Kim SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029116
   Kristiansen PA, 2013, CLIN INFECT DIS, V56, P354, DOI 10.1093/cid/cis892
   Kshirsagar N, 2007, VACCINE, V25, pA101, DOI 10.1016/j.vaccine.2007.04.050
   LaForce FM, 2007, VACCINE, V25, pA97, DOI 10.1016/j.vaccine.2007.04.049
   LAPEYSSONNIE L, 1961, Med Trop (Mars), V21, P129
   Lennon D, 2009, CLIN INFECT DIS, V49, P597, DOI 10.1086/603552
   Luo N, 1998, J INFECTION, V36, P141, DOI 10.1016/S0163-4453(98)80002-9
   Maslanka SE, 1997, CLIN DIAGN LAB IMMUN, V4, P156
   Molesworth AM, 2002, T ROY SOC TROP MED H, V96, P242, DOI 10.1016/S0035-9203(02)90089-1
   Norheim G, 2007, CLIN VACCINE IMMUNOL, V14, P451, DOI 10.1128/CVI.00008-07
   Novak RT, 2012, LANCET INFECT DIS, V12, P757, DOI 10.1016/S1473-3099(12)70168-8
   Okoko BJ, 2009, VACCINE, V27, P2023, DOI 10.1016/j.vaccine.2008.11.092
   Ouandaogo CR, 2012, VACCINE, V30, pB46, DOI 10.1016/j.vaccine.2011.12.112
   PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302
   Pichichero ME, 2006, POSTGRAD MED, V119, P47
   PINNER RW, 1992, J INFECT DIS, V166, P359
   ROBBINS JB, 1972, INFECT IMMUN, V6, P651
   Robbins JB, 2003, B WORLD HEALTH ORGAN, V81, P745
   Safadi Marco Aurelio Palazzi, 2006, J Pediatr (Rio J), V82, pS35, DOI 10.1590/S0021-75572006000400005
   SANGPETCHSONG V, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P117
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   Soriano-Gabarro M, 2004, J HEALTH POPUL NUTR, V22, P275
   Sow SO, 2011, NEW ENGL J MED, V364, P2293, DOI 10.1056/NEJMoa1003812
   Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2
   Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1
   VANN WF, 1976, INFECT IMMUN, V13, P1654
   Immunization Vaccines and Biologicals, IMM VACC BIOL REV ME
   Woodard JL, 2006, FETAL PEDIATR PATHOL, V25, P311, DOI 10.1080/15513810701209538
NR 46
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 16
PY 2014
VL 32
IS 33
BP 4220
EP 4227
DI 10.1016/j.vaccine.2014.04.052
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AM1JO
UT WOS:000339602400016
PM 24863486
OA No
DA 2017-08-15
ER

PT J
AU White, MT
   Bejon, P
   Olotu, A
   Griffin, JT
   Bojang, K
   Lusingu, J
   Salim, N
   Abdulla, S
   Otsyula, N
   Agnandji, ST
   Lell, B
   Asante, KP
   Owusu-Agyei, S
   Mahama, E
   Agbenyega, T
   Ansong, D
   Sacarlal, J
   Aponte, JJ
   Ghani, AC
AF White, Michael T.
   Bejon, Philip
   Olotu, Ally
   Griffin, Jamie T.
   Bojang, Kalifa
   Lusingu, John
   Salim, Nahya
   Abdulla, Salim
   Otsyula, Nekoye
   Agnandji, Selidji T.
   Lell, Bertrand
   Asante, Kwaku Poku
   Owusu-Agyei, Seth
   Mahama, Emmanuel
   Agbenyega, Tsiri
   Ansong, Daniel
   Sacarlal, Jahit
   Aponte, John J.
   Ghani, Azra C.
TI A combined analysis of immunogenicity, antibody kinetics and vaccine
   efficacy from phase 2 trials of the RTS,S malaria vaccine
SO BMC MEDICINE
LA English
DT Article
DE Malaria; Vaccine; Circumsporozoite protein; Antibody; RTS,S; Phase 2
   clinical trials; Mathematical model; Clinical immunity
ID PLASMODIUM-FALCIPARUM INFECTION; RANDOMIZED-TRIAL; CONJUGATE VACCINE;
   AFRICAN CHILDREN; DOUBLE-BLIND; SAFETY; PROTECTION; INFANTS;
   RTS,S/AS02A; IMMUNIZATION
AB The RTS,S malaria vaccine is currently undergoing phase 3 trials. High vaccine-induced antibody titres to the circumsporozoite protein (CSP) antigen have been associated with protection from infection and episodes of clinical malaria.
   Methods: Using data from 5,144 participants in nine phase 2 trials, we explore predictors of vaccine immunogenicity (anti-CSP antibody titres), decay in antibody titres, and the association between antibody titres and clinical outcomes. We use empirically-observed relationships between these factors to predict vaccine efficacy in a range of scenarios.
   Results: Vaccine-induced anti-CSP antibody titres were significantly associated with age (P = 0.04), adjuvant (P < 0.001), pre-vaccination anti-hepatitis B surface antigen titres (P = 0.005) and pre-vaccination anti-CSP titres (P < 0.001). Co-administration with other vaccines reduced anti-CSP antibody titres although not significantly (P = 0.095). Antibody titres showed a bi-phasic decay over time with an initial rapid decay in the first three months and a second slower decay over the next three to four years. Antibody titres were significantly associated with protection, with a titre of 51 (95% Credible Interval (CrI): 29 to 85) ELISA units/ml (EU/mL) predicted to prevent 50% of infections in children. Vaccine efficacy was predicted to decline to zero over four years in a setting with entomological inoculation rate (EIR) = 20 infectious bites per year (ibpy). Over a five-year follow-up period at an EIR = 20 ibpy, we predict RTS, S will avert 1,782 cases per 1,000 vaccinated children, 1,452 cases per 1,000 vaccinated infants, and 887 cases per 1,000 infants when co-administered with expanded programme on immunisation (EPI) vaccines. Our main study limitations include an absence of vaccine-induced cellular immune responses and short duration of follow-up in some individuals.
   Conclusions: Vaccine-induced anti-CSP antibody titres and transmission intensity can explain variations in observed vaccine efficacy.
C1 [White, Michael T.; Griffin, Jamie T.; Ghani, Azra C.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, MRC Ctr Outbreak Anal & Modelling, London W2 1PG, England.
   [Bejon, Philip; Olotu, Ally] Kenya Govt Med Res Ctr, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Bejon, Philip] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Bojang, Kalifa] MRC Unit, Fajara, Gambia.
   [Lusingu, John] Natl Inst Med Res, Tanga Ctr, Tanga, Tanzania.
   [Salim, Nahya; Abdulla, Salim] Ifakara Hlth Inst, Bagamoyo, Tanzania.
   [Otsyula, Nekoye] Kenya Govt Med Res Ctr, Nairobi, Kenya.
   [Otsyula, Nekoye] US Army Med Res Unit Kenya, Nairobi, Kenya.
   [Agnandji, Selidji T.; Lell, Bertrand] Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon.
   [Agnandji, Selidji T.; Lell, Bertrand] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Asante, Kwaku Poku; Owusu-Agyei, Seth; Mahama, Emmanuel] Kintampo Hlth Res Ctr, Kintampo, Ghana.
   [Agbenyega, Tsiri; Ansong, Daniel] Sch Med Sci, Kumasi, Ghana.
   [Sacarlal, Jahit; Aponte, John J.] Ctr Invest Saude Manhica, Manhica, Mozambique.
   [Sacarlal, Jahit] Univ Eduardo Mondlane, Fac Med, Maputo, Mozambique.
   [Aponte, John J.] Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain.
RP White, MT (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, MRC Ctr Outbreak Anal & Modelling, London W2 1PG, England.
EM m.white08@imperial.ac.uk
RI Ghani, Azra/B-8560-2009
OI ANSONG, Daniel/0000-0003-1328-9117
FU Bill & Melinda Gates Foundation; MRC Fellowship [G1002624]; Wellcome
   Trust Strategic Award; UK Medical Research Council
FX MTW was supported by a grant from The Bill & Melinda Gates Foundation.
   PB is funded by an MRC Fellowship (G1002624). AO is funded by a Wellcome
   Trust Strategic Award. ACG acknowledges support from the UK Medical
   Research Council. No funding bodies had any role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. GSK Vaccines did not fund the investigators to undertake the
   analysis. GSK funded transport expenses for the investigators to attend
   meetings to review the progress and the final outcomes of the modelling
   project.
CR Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773
   Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6
   Asante KP, 2011, LANCET INFECT DIS, V11, P741, DOI 10.1016/S1473-3099(11)70100-1
   Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381
   Bejon P, 2013, LANCET INFECT DIS, V13, P319, DOI 10.1016/S1473-3099(13)70005-7
   Bijker EM, 2013, P NATL ACAD SCI USA, V110, P7862, DOI 10.1073/pnas.1220360110
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Dalby T, 2010, J MED MICROBIOL, V59, P1029, DOI 10.1099/jmm.0.020826-0
   Duah NO, 2010, PARASITE IMMUNOL, V32, P125, DOI 10.1111/j.1365-3024.2009.01165.x
   Eskola J, 1996, LANCET, V348, P1688, DOI 10.1016/S0140-6736(96)04356-5
   Foquet L, 2014, J CLIN INVEST, V124, P140, DOI 10.1172/JCI70349
   Gething PW, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-378
   Griffin JT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4136
   Hu YL, 2008, VACCINE, V26, P6064, DOI 10.1016/j.vaccine.2008.09.014
   Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120
   Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205
   Lell B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007611
   Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394
   Moorthy VS, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-312
   Olotu A, 2013, NEW ENGL J MED, V368, P1111, DOI 10.1056/NEJMoa1207564
   Olotu A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025786
   Olotu A, 2011, LANCET INFECT DIS, V11, P102, DOI [10.1016/S1473-3099(10)70262-0, 10.1016/51473-3099(10)70262-0]
   Demoitie MA, 2009, PLOS ONE, V4, P7302
   Polhemus ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006465
   PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407
   Qin L, 2007, J INFECT DIS, V196, P1304, DOI 10.1086/522428
   Riley EM, 2013, NAT MED, V19, P168, DOI 10.1038/nm.3083
   Sacarlal J, 2009, J INFECT DIS, V200, P329, DOI 10.1086/600119
   Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800
   Sharp BL, 2007, AM J TROP MED HYG, V76, P42
   Shinefield HR, 1999, PEDIATR INFECT DIS J, V18, P757, DOI 10.1097/00006454-199909000-00004
   Smith T, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001157
   Stanisic DI, 2009, INFECT IMMUN, V77, P1165, DOI 10.1128/IAI.01129-08
   Swysen C, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-223
   Warimwe GM, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-184
   White M, J INFECT DI IN PRESS
   White MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061395
   White MT, 2011, P ROY SOC B-BIOL SCI, V278, P1298, DOI 10.1098/rspb.2010.1697
NR 40
TC 28
Z9 28
U1 1
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD JUL 10
PY 2014
VL 12
AR 117
DI 10.1186/s12916-014-0117-2
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AM2KK
UT WOS:000339679200001
PM 25012228
OA gold
DA 2017-08-15
ER

PT J
AU Clark, MA
   Goheen, MM
   Fulford, A
   Prentice, AM
   Elnagheeb, MA
   Patel, J
   Fisher, N
   Taylor, SM
   Kasthuri, RS
   Cerami, C
AF Clark, Martha A.
   Goheen, Morgan M.
   Fulford, Anthony
   Prentice, Andrew M.
   Elnagheeb, Marwa A.
   Patel, Jaymin
   Fisher, Nancy
   Taylor, Steve M.
   Kasthuri, Raj S.
   Cerami, Carla
TI Host iron status and iron supplementation mediate susceptibility to
   erythrocytic stage Plasmodium falciparum
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RED-BLOOD-CELLS; MALARIA INFECTION; YOUNG-CHILDREN; DEFICIENCY;
   INVASION; PARASITE; ANEMIA; ASSAY; DEFORMABILITY; COINFECTION
AB Iron deficiency and malaria have similar global distributions, and frequently co-exist in pregnant women and young children. Where both conditions are prevalent, iron supplementation is complicated by observations that iron deficiency anaemia protects against falciparum malaria, and that iron supplements increase susceptibility to clinically significant malaria, but the mechanisms remain obscure. Here, using an in vitro parasite culture system with erythrocytes from iron-deficient and replete human donors, we demonstrate that Plasmodium falciparum infects iron-deficient erythrocytes less efficiently. In addition, owing to merozoite preference for young erythrocytes, iron supplementation of iron-deficient individuals reverses the protective effects of iron deficiency. Our results provide experimental validation of field observations reporting protective effects of iron deficiency and harmful effects of iron administration on human malaria susceptibility. Because recovery from anaemia requires transient reticulocytosis, our findings imply that in malarious regions iron supplementation should be accompanied by effective measures to prevent falciparum malaria.
C1 [Clark, Martha A.; Goheen, Morgan M.; Fisher, Nancy] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Fulford, Anthony; Prentice, Andrew M.] London Sch Hyg & Trop Med, Int Nutr Grp, MRC, London WC1E 7HT, England.
   [Fulford, Anthony; Prentice, Andrew M.] MRC, Keneba, Gambia.
   [Elnagheeb, Marwa A.; Patel, Jaymin; Cerami, Carla] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
   [Taylor, Steve M.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC 27710 USA.
   [Kasthuri, Raj S.] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA.
RP Cerami, C (reprint author), Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
EM ccerami@unc.edu
OI Cerami, Carla/0000-0002-7634-0955
FU National Institute of Child Health and Human Development [U01HD061235];
   NCI Center Core Grant [P30CA06086]; National Institute of Allergy and
   Infectious Diseases [K08AI100924]
FX We gratefully acknowledge the individual donors who participated in the
   study. We also thank Michael Nicholson of Precision Biosciences for the
   use of the Beckman Quanta Flow cytometer and Steven R. Meshnick for
   critically reading the manuscript. The work was supported by the
   National Institute of Child Health and Human Development under award
   number U01HD061235 (to C.C.). The UNC Flow Cytometry Core Facility is
   supported in part by an NCI Center Core Grant number P30CA06086. S.M.T.
   is supported by the National Institute of Allergy and Infectious
   Diseases under award number K08AI100924.
CR Bei AK, 2010, AM J HEMATOL, V85, P234, DOI 10.1002/ajh.21642
   Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299
   BOSCH FH, 1992, BLOOD, V79, P254
   Brandao MM, 2009, CLIN HEMORHEOL MICRO, V43, P217, DOI 10.3233/CH-2009-1211
   Bratosin D, 2005, CYTOM PART A, V66A, P78, DOI 10.1002/cyto.a.20152
   Bronzan RN, 2007, J INFECT DIS, V195, P895, DOI 10.1086/511437
   BUNYARATVEJ A, 1992, BLOOD, V79, P2460
   Chotivanich K, 2000, J INFECT DIS, V181, P1206, DOI 10.1086/315353
   Church J, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-31
   Clark M, 2013, BRIT J HAEMATOL, V161, P262, DOI 10.1111/bjh.12234
   Cromer D, 2009, J THEOR BIOL, V257, P533, DOI 10.1016/j.jtbi.2008.12.019
   Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577
   Esposito A, 2010, BIOPHYS J, V99, P953, DOI 10.1016/j.bpj.2010.04.065
   Goma J, 1996, PARASITOLOGY, V112, P165
   Gwamaka M, 2012, CLIN INFECT DIS, V54, P1137, DOI 10.1093/cid/cis010
   Jonker FAM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042670
   Kabyemela ER, 2008, J INFECT DIS, V198, P163, DOI 10.1086/589512
   Koka S, 2007, BIOCHEM BIOPH RES CO, V357, P608, DOI 10.1016/j.bbrc.2007.03.175
   lark M. A., 2014, PLOS ONE, V9
   Lim C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2612
   Matsuzaki-Moriya C, 2011, EUR J IMMUNOL, V41, P1365, DOI 10.1002/eji.201040942
   McQueen PG, 2004, P NATL ACAD SCI USA, V101, P9161, DOI 10.1073/pnas.0308256101
   Nweneka CV, 2010, T ROY SOC TROP MED H, V104, P175, DOI 10.1016/j.trstmh.2009.08.007
   Nyakeriga AM, 2004, J INFECT DIS, V190, P439, DOI 10.1086/422331
   PASVOL G, 1980, BRIT J HAEMATOL, V45, P285, DOI 10.1111/j.1365-2141.1980.tb07148.x
   Portugal S, 2011, NAT MED, V17, P732, DOI 10.1038/nm.2368
   Price RN, 2001, AM J TROP MED HYG, V65, P614
   Sangare L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087743
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Schumann K, 2012, ANN NUTR METAB, V60, P98, DOI 10.1159/000336177
   Senga EL, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-47
   Simpson JA, 1999, T ROY SOC TROP MED H, V93, P165, DOI 10.1016/S0035-9203(99)90295-X
   Skaar EP, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000949
   Soofi S, 2013, LANCET, V382, P29, DOI 10.1016/S0140-6736(13)60437-7
   Sriprawat K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-115
   Theron M, 2010, CYTOM PART A, V77A, P1067, DOI 10.1002/cyto.a.20972
   Tian LP, 1998, ACTA OBSTET GYN SCAN, V77, P717, DOI 10.1034/j.1600-0412.1998.770704.x
   Tiffert T, 2005, BLOOD, V105, P4853, DOI 10.1182/blood-2004-12-4948
   Veenemans J, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001125
   Yermiahu T, 1999, ANN HEMATOL, V78, P468, DOI 10.1007/s002770050600
   YIP R, 1983, BLOOD, V62, P99
   Zhao H, 2012, CELL HOST MICROBE, V12, P705, DOI 10.1016/j.chom.2012.10.010
NR 42
TC 31
Z9 32
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL
PY 2014
VL 5
AR 4446
DI 10.1038/ncomms5446
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AN5IB
UT WOS:000340622900038
PM 25059846
OA gold
DA 2017-08-15
ER

PT J
AU Burr, SE
   Milne, S
   Jafali, J
   Bojang, E
   Rajasekhar, M
   Hart, J
   Harding-Esch, EM
   Holland, MJ
   Mabey, DCW
   Sillah, A
   Bailey, RL
   Roca, A
AF Burr, Sarah E.
   Milne, Sally
   Jafali, James
   Bojang, Ebrima
   Rajasekhar, Megha
   Hart, John
   Harding-Esch, Emma M.
   Holland, Martin J.
   Mabey, David C. W.
   Sillah, Ansumana
   Bailey, Robin L.
   Roca, Anna
TI Mass administration of azithromycin and Streptococcus pneumoniae
   carriage: cross-Sectional surveys in the Gambia
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; SINGLE-DOSE AZITHROMYCIN;
   CHLAMYDIA-TRACHOMATIS; NASOPHARYNGEAL CARRIAGE; RESISTANCE;
   DISTRIBUTIONS; COMMUNITY; MORTALITY; BLINDNESS; TANZANIA
AB Objective To evaluate the effect of repeated mass drug administration (MDA) of azithromycin in the Gambia on the nasopharyngeal carriage of Streptococcus pneumoniae and on the emergence of antibiotic-resistant strains.
   Methods This study involved villages that participated in a cluster randomized trial comparing the effect of one versus three azithromycin MDA rounds on the prevalence of trachoma. Only villages in which most children received 7-valent pneumococcal conjugate vaccine were included. Three cross-sectional surveys were performed in two villages that received three annual MDA rounds: the first immediately before the third MDA round and the second and third, 1 and 6 months, respectively, after the third MDA round. The third survey also covered six villages that had received one MDA round 30 months previously. Pneumococcal carriage was assessed using nasopharyngeal swabs and azithromycin resistance was detected using the Etest.
   Findings The prevalence of pneumococca I carriage decreased from 43.4% to 19.2% between the first and second surveys (P < 0.001) but rebounded by the third survey (45.8%; P = 0.591). Being a carrier at the first survey was a risk factor for being a carrier at the second (odds ratio: 3.71; P < 0.001). At the third survey, the. prevalence of carriage was similar after one and three MDA rounds (50.3% versus 45.8%, respectively; P = 0.170), as was the prevalence of azithromycin resistance (0.3% versus 0.9%, respectively; P = 0.340).
   Conclusion Three azithromycin MDA rounds did not increase the prevalence of nasopharyngeal carriage of azithromycin-resistant S. pneumoniae strains compared with one round.
C1 [Burr, Sarah E.; Rajasekhar, Megha; Hart, John; Holland, Martin J.; Mabey, David C. W.; Bailey, Robin L.] Univ London London Sch Hyg & Trop Med, Dept Clin Res, London WC1E 7HT, England.
   [Milne, Sally] Univ Manchester, Fac Life Sci, Manchester, Lancs, England.
   [Jafali, James; Bojang, Ebrima; Roca, Anna] MRC Unit, Banjul, Gambia.
   [Harding-Esch, Emma M.] Publ Hlth England, London, England.
   [Sillah, Ansumana] Minist Hlth & Social Welf, Natl Eye Hlth Programme, Kanifing, Gambia.
RP Burr, SE (reprint author), Univ London London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London WC1E 7HT, England.
EM Sarah.Burr@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276
FU Bill & Melinda Gates Foundation; Medical Research Council, United
   Kingdom of Great Britain and Northern Ireland
FX This study was funded by the Bill & Melinda Gates Foundation and the
   Medical Research Council, United Kingdom of Great Britain and Northern
   Ireland.
CR BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9
   Batt SL, 2003, ANTIMICROB AGENTS CH, V47, P2765, DOI 10.1128/AAC.47.9.2765-2769.2003
   Brito DA, 2003, J CLIN MICROBIOL, V41, P2378, DOI 10.1128/JCM.41.6.2378-2384.2003
   Burton MJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000835
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Carvalho MD, 2010, J CLIN MICROBIOL, V48, P1611, DOI 10.1128/JCM.02243-09
   Coles CL, 2013, CLIN INFECT DIS, V56, P1519, DOI 10.1093/cid/cit137
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   Fry AM, 2002, CLIN INFECT DIS, V35, P395, DOI 10.1086/341414
   Harding-Esch EM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002115
   Harding-Esch EM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000861
   Haug S, 2010, CLIN INFECT DIS, V51, P571, DOI 10.1086/655697
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Hong KC, 2009, EMERG INFECT DIS, V15, P1088, DOI 10.3201/eid1507.081563
   Keenan JD, 2011, CLIN INFECT DIS, V52, P883, DOI 10.1093/cid/cir069
   Leach AJ, 1997, CLIN INFECT DIS, V24, P356
   Morona JK, 1999, J BACTERIOL, V181, P3599
   Porco TC, 2009, JAMA-J AM MED ASSOC, V302, P962, DOI 10.1001/jama.2009.1266
   Roca A, 2012, CLIN INFECT DIS, V55, P816, DOI 10.1093/cid/cis554
   Roca A, 2011, PLOS MED, V8
   Skalet AH, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000377
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Stare D, 2011, OPHTHAL EPIDEMIOL, V18, P20, DOI 10.3109/09286586.2010.545500
   World Health Organization, 1998, 3 M WHO ALL GLOB EL
   World Health Organization, 2007, WKLY EPIDEMIOL REC, V82, P93
   [Anonymous], 1997, 1 WHO ALL GLOB EL TR
   [Anonymous], 2010, 14 M WHO ALL GLOB EL
   [Anonymous], 2006, MAK PROGR GLOB EL BL
NR 29
TC 6
Z9 7
U1 1
U2 3
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
EI 1564-0604
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD JUL
PY 2014
VL 92
IS 7
BP 490
EP 498
DI 10.2471/BLT.13.133462
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AM3TT
UT WOS:000339776400012
PM 25110374
OA No
DA 2017-08-15
ER

PT J
AU Clark, MA
   Goheen, MM
   Spidale, NA
   Kasthuri, RS
   Fulford, A
   Cerami, C
AF Clark, Martha A.
   Goheen, Morgan M.
   Spidale, Nicholas A.
   Kasthuri, Raj S.
   Fulford, Anthony
   Cerami, Carla
TI RBC Barcoding Allows for the Study of Erythrocyte Population Dynamics
   and P-falciparum Merozoite Invasion
SO PLOS ONE
LA English
DT Article
ID RED-BLOOD-CELLS; MALARIA PARASITE INVASION; FLOW-CYTOMETRY; INSIGHTS;
   LIGAND; ASSAY; MATURATION; INFECTION; BIOTIN; ANEMIA
AB Plasmodium falciparum invasion of host erythrocytes is essential for the propagation of the blood stage of malaria infection. Additionally, the brief extracellular merozoite stage of P. falciparum represents one of the rare windows during which the parasite is directly exposed to the host immune response. Therefore, efficient invasion of the host erythrocyte is necessary not only for productive host erythrocyte infection, but also for evasion of the immune response. Host traits, such as hemoglobinopathies and differential expression of erythrocyte invasion ligands, can protect individuals from malaria by impeding parasite erythrocyte invasion. Here we combine RBC barcoding with flow cytometry to study P. falciparum invasion. This novel high-throughput method allows for the (i) direct comparison of P. falciparum invasion into different erythrocyte populations and (ii) assessment of the impact of changing erythrocyte population dynamics on P. falciparum invasion.
C1 [Clark, Martha A.; Goheen, Morgan M.; Spidale, Nicholas A.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA.
   [Kasthuri, Raj S.] Univ N Carolina, Div Hematol, Chapel Hill, NC USA.
   [Fulford, Anthony] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   [Cerami, Carla] London Sch Hyg & Trop Med, Med Res Council Int Nutr Grp, London WC1, England.
   [Cerami, Carla] Med Res Council Keneba, Serrekunda, Gambia.
RP Cerami, C (reprint author), London Sch Hyg & Trop Med, Med Res Council Int Nutr Grp, London WC1, England.
EM ccerami@unc.edu
OI Cerami, Carla/0000-0002-7634-0955
FU National Institute of Child Health and Human Development [U01HD061235];
   NCI Center [P30CA06086]; NCI [CA16086-36]; Lineberger Comprehensive
   Cancer Center; UNC Department of Pathology & Laboratory Medicine
FX The work was supported by the National Institute of Child Health and
   Human Development under award number U01HD061235 (to CC). The UNC Flow
   Cytometry Core Facility is supported in part by an NCI Center Core Grant
   number P30CA06086. The UNC Microscopy Core facility is supported by NCI
   grant CA16086-36 and the Lineberger Comprehensive Cancer Center Core
   Grant and the UNC Department of Pathology & Laboratory Medicine. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Badiane AS, 2013, CLIN VACCINE IMMUNOL, V20, P1238, DOI 10.1128/CVI.00135-13
   Baum J, 2003, INFECT IMMUN, V71, P1856, DOI 10.1128/IAI.71.4.1856-1863.2003
   Bei AK, 2012, INT J PARASITOL, V42, P575, DOI 10.1016/j.ijpara.2012.03.006
   Bei AK, 2010, AM J HEMATOL, V85, P234, DOI 10.1002/ajh.21642
   Boyle MJ, 2013, INT J PARASITOL, V43, P1, DOI 10.1016/j.ijpara.2012.11.002
   Brandao MM, 2009, CLIN HEMORHEOL MICRO, V43, P217, DOI 10.3233/CH-2009-1211
   BREUER WV, 1983, BIOCHIM BIOPHYS ACTA, V755, P263, DOI 10.1016/0304-4165(83)90213-1
   Clark M, 2013, BRIT J HAEMATOL, V161, P262, DOI 10.1111/bjh.12234
   Cordero JF, 2004, CELL BIOL INT, V28, P423, DOI 10.1016/j.cellbi.2004.03.002
   Cowman AF, 2012, J CELL BIOL, V198, P961, DOI 10.1083/jcb.201206112
   Cromer D, 2009, J THEOR BIOL, V257, P533, DOI 10.1016/j.jtbi.2008.12.019
   Franco RS, 2013, AM J HEMATOL, V88, P44, DOI 10.1002/ajh.23344
   Gifford SC, 2006, BRIT J HAEMATOL, V135, P395, DOI 10.1111/j.1365-2141.2006.06279.x
   Krutzik PO, 2006, NAT METHODS, V3, P361, DOI 10.1038/NMETH872
   Lantos PM, 2009, PARASITOLOGY, V136, P1, DOI 10.1017/S0031182008005167
   Lobo CA, 2006, MOL BIOCHEM PARASIT, V149, P246, DOI 10.1016/j.molbiopara.2006.05.011
   Lopez-Perez M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047913
   Nagababu E, 2008, FREE RADICAL RES, V42, P824, DOI 10.1080/10715760802459879
   Pattanapanyasat K, 1996, CYTOMETRY, V25, P287, DOI 10.1002/(SICI)1097-0320(19961101)25:3<287::AID-CYTO10>3.0.CO;2-S
   Pattanapanyasat K, 1999, BLOOD, V93, P3116
   Ribaut C, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-45
   ROTH EF, 1983, P NATL ACAD SCI-BIOL, V80, P298, DOI 10.1073/pnas.80.1.298
   Rowe JA, 2009, CURR OPIN HEMATOL, V16, P480, DOI 10.1097/MOH.0b013e3283313de0
   SANSONE G, 1963, Pathologica, V55, P371
   Shapiro HM, 2013, CURR PROTOC CYTOM ED
   Taylor SM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003327
   Tham WH, 2010, P NATL ACAD SCI USA, V107, P17327, DOI 10.1073/pnas.1008151107
   Theron M, 2010, CYTOM PART A, V77A, P1067, DOI 10.1002/cyto.a.20972
   Walker P S, 2010, Immunohematology, V26, P60
   World Health Organization, WORLD MAL REP 2011
   Wright GJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003943
NR 31
TC 5
Z9 5
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 1
PY 2014
VL 9
IS 7
AR e101041
DI 10.1371/journal.pone.0101041
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM1UX
UT WOS:000339635000051
PM 24984000
OA gold
DA 2017-08-15
ER

PT J
AU Lange, C
   Abubakar, I
   Alffenaar, JWC
   Bothamley, G
   Caminero, JA
   Carvalho, ACC
   Chang, KC
   Codecasa, L
   Correia, A
   Crudu, V
   Davies, P
   Dedicoat, M
   Drobniewski, F
   Duarte, R
   Ehlers, C
   Erkens, C
   Goletti, D
   Gunther, G
   Ibraim, E
   Kampmann, B
   Kuksa, L
   de Lange, W
   van Leth, F
   van Lunzen, J
   Matteelli, A
   Menzies, D
   Monedero, I
   Richter, E
   Rusch-Gerdes, S
   Sandgren, A
   Scardigli, A
   Skrahina, A
   Tortoli, E
   Volchenkov, G
   Wagner, D
   van der Werf, MJ
   Williams, B
   Yew, WW
   Zellweger, JP
   Cirillo, DM
AF Lange, Christoph
   Abubakar, Ibrahim
   Alffenaar, Jan-Willem C.
   Bothamley, Graham
   Caminero, Jose A.
   Carvalho, Anna Cristina C.
   Chang, Kwok-Chiu
   Codecasa, Luigi
   Correia, Ana
   Crudu, Valeriu
   Davies, Peter
   Dedicoat, Martin
   Drobniewski, Francis
   Duarte, Raquel
   Ehlers, Cordula
   Erkens, Connie
   Goletti, Delia
   Guenther, Gunar
   Ibraim, Elmira
   Kampmann, Beate
   Kuksa, Liga
   de lange, Wiel
   van Leth, Frank
   van Lunzen, Jan
   Matteelli, Alberto
   Menzies, Dick
   Monedero, Ignacio
   Richter, Elvira
   Ruesch-Gerdes, Sabine
   Sandgren, Andreas
   Scardigli, Anna
   Skrahina, Alena
   Tortoli, Enrico
   Volchenkov, Grigory
   Wagner, Dirk
   van der Werf, Marieke J.
   Williams, Bhanu
   Yew, Wing-Wai
   Zellweger, Jean-Pierre
   Cirillo, Daniela Maria
TI Management of patients with multidrug-resistant/extensively
   drug-resistant tuberculosis in Europe: a TBNET consensus statement
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
ID EARLY BACTERICIDAL ACTIVITY; MULTICENTER LABORATORY VALIDATION; POSITIVE
   PULMONARY TUBERCULOSIS; FILTERING-FACEPIECE RESPIRATORS; RANDOMIZED
   CONTROLLED-TRIAL; COMMUNITY-BASED THERAPY; OF-THE-ART;
   MYCOBACTERIUM-TUBERCULOSIS; RISK-FACTORS; POPULATION PHARMACOKINETICS
AB The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence.
   This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.
C1 [Lange, Christoph] Res Ctr Borstel, Med Clin, German Ctr Infect Res DZIF, Div Clin Infect Dis, D-23845 Borstel, Germany.
   [Abubakar, Ibrahim] Univ Namibia, Sch Med, Dept Med, Windhoek, Namibia.
   [Alffenaar, Jan-Willem C.] UCL, Res Dept Infect & Populat Hlth, London, England.
   [Alffenaar, Jan-Willem C.] UCL, MRC Clin Trials Unit, London, England.
   [Bothamley, Graham] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.
   [Caminero, Jose A.] Homerton Univ Hosp, London, England.
   [Carvalho, Anna Cristina C.] Univ Hosp Gran Canaria Dr Negrin, Dept Pneumol, Las Palmas Gran Canaria, Spain.
   [Carvalho, Anna Cristina C.] Int Union TB & Lung Dis Union, Multidrug Resistant TB Unit, Paris, France.
   [Carvalho, Anna Cristina C.] Int Union TB & Lung Dis Union, TB & HIV Dept, Paris, France.
   [Chang, Kwok-Chiu] Univ Brescia, Clin Infect & Trop Dis, WHO, Collaborating Ctr TB HIV Coinfect, Brescia, Italy.
   [Chang, Kwok-Chiu] Inst Oswaldo Cruz, Lab Innovat Therapies Educ & Bioprod, BR-20001 Rio De Janeiro, Brazil.
   [Codecasa, Luigi] TB & Chest Serv, Dept Hlth, Hong Kong, Hong Kong, Peoples R China.
   [Correia, Ana] Osped Niguarda Ca Granda, Reg TB Reference Ctr, Villa Marelli Inst, Milan, Italy.
   [Crudu, Valeriu] Portuguese Northern Hlth Adm, Dept Publ Hlth, Oporto, Portugal.
   [Davies, Peter] Phthisiopneumol Inst, Kishinev, Moldova.
   [Dedicoat, Martin] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England.
   [Drobniewski, Francis] Heart England Fdn Trust, Birmingham, W Midlands, England.
   [Drobniewski, Francis] Univ Warwick, Coventry CV4 7AL, W Midlands, England.
   [Duarte, Raquel] Publ Hlth England Natl Mycobacterial Reference La, London, England.
   [Duarte, Raquel] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Ehlers, Cordula] Univ Porto, Ctr Hosp Vila Nova de Gaia Espinho, Portuguese Reference Ctr M XDR TB, P-4100 Oporto, Portugal.
   [Ehlers, Cordula] Univ Porto, Inst Publ Hlth, Dept Clin Epidemiol Predict Med & Publ Hlth, P-4100 Oporto, Portugal.
   [Erkens, Connie] Take That TB, Hamburg, Germany.
   [Goletti, Delia] KNCV TB Fdn, The Hague, Netherlands.
   [Guenther, Gunar] L Spallanzani Natl Inst Infect Dis INMI, Translat Res Unit, Dept Epidemiol & Preclin Res, Rome, Italy.
   [Ibraim, Elmira] German Ctr Infect Res, Med Clin, Res Ctr Borstel, Div Clin Infect Dis, Borstel, Germany.
   [Ibraim, Elmira] Univ Namibia, Sch Med, Dept Med, Windhoek, Namibia.
   [Kampmann, Beate] Marius Nasta Inst Pulmonology, Bucharest, Romania.
   [Kuksa, Liga] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London, England.
   [Kuksa, Liga] MRC Unit, Serrekunda, Gambia.
   [de lange, Wiel] Riga East Univ Hosp, TB & Lunge Dis Ctr, Riga, Latvia.
   [van Leth, Frank] Univ Groningen, Univ Med Ctr Groningen, TB Ctr Beatrixoord, NL-9713 AV Groningen, Netherlands.
   [van Lunzen, Jan] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, NL-1105 AZ Amsterdam, Netherlands.
   [van Lunzen, Jan] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands.
   [Matteelli, Alberto] Univ Med Ctr Hamburg, Infect Dis Unit, Hamburg, Germany.
   [Menzies, Dick] Univ Brescia, Clin Infect & Trop Dis, WHO Collaborating Ctr TB HIV Coinfect, Brescia, Italy.
   [Monedero, Ignacio] McGill Univ, Montreal Chest Inst, Montreal, PQ, Canada.
   [Richter, Elvira; Skrahina, Alena] Multidrug Resistant TB Unit, TB & HIV Dept, Paris, France.
   [Richter, Elvira] Hosp Serveis Clin, Barcelona, Spain.
   [Ruesch-Gerdes, Sabine; Sandgren, Andreas] Res Ctr Borstel, Natl Reference Ctr Mycobacteria, D-23845 Borstel, Germany.
   [Scardigli, Anna] European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden.
   [Tortoli, Enrico] Republican Res & Pract Ctr Pulmonol & TB, Minsk, Byelarus.
   [Volchenkov, Grigory] Ist Sci San Raffaele, Emerging Bacterial Pathogens Unit, I-20132 Milan, Italy.
   [Wagner, Dirk] Vladimir Reg TB Dispensary, Ctr Excellence TB Infect Control, Vladimir, Russia.
   [van der Werf, Marieke J.] Univ Med Ctr Freiburg, Ctr Infect Dis, Freiburg, Germany.
   [van der Werf, Marieke J.] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany.
   [Williams, Bhanu] ECDC, Stockholm, Sweden.
   [Yew, Wing-Wai] North West London Hosp NHS Trust, Dept Paediat, London, England.
   [Zellweger, Jean-Pierre] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Cirillo, Daniela Maria] Swiss Lung Assoc, Bern, Switzerland.
   Ist Sci San Raffaele, Emerging Bacterial Pathogens Unit, I-20132 Milan, Italy.
RP Lange, C (reprint author), Res Ctr Borstel, Med Clin, German Ctr Infect Res DZIF, Div Clin Infect Dis,Clin TB Ctr, Parkallee 35, D-23845 Borstel, Germany.
EM clange@fz-borstel.de
RI Matteelli, Alberto/M-8784-2015; Wagner, Dirk/D-9778-2016; TORTOLI,
   ENRICO/K-4749-2016
OI Matteelli, Alberto/0000-0001-5109-9248; Wagner,
   Dirk/0000-0002-3271-5815; TORTOLI, ENRICO/0000-0001-5512-704X; van der
   Werf, Marieke J./0000-0001-8021-1358; Abubakar,
   Ibrahim/0000-0002-0370-1430; Duarte, Raquel/0000-0003-2257-3099;
   Kampmann, Beate/0000-0002-6546-4709; Goletti, Delia/0000-0001-8360-4376;
   van Leth, Frank/0000-0002-5490-8968
FU EU FP7 project TBPANNET; German Center for Infection Research (DZIF);
   German Federal Ministry of Education and Research; UK Medical Research
   Council; National Institute for Medical Research; National Institute of
   Health Research (UK)
FX This work was supported by the EU FP7 project TBPANNET (D.M. Cirillo and
   C. Lange), the German Center for Infection Research (DZIF) (C. Lange),
   the German Federal Ministry of Education and Research (D. Wagner), the
   UK Medical Research Council (I. Abubakar and B. Kampmann) and National
   Institute for Medical Research (I. Abubakar), and the National Institute
   of Health Research (UK) (B. Kampmann).
CR Abubakar I, 2013, LANCET INFECT DIS, V13, P529, DOI 10.1016/S1473-3099(13)70030-6
   Ahuja SD, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001300
   Al-Dabbagh M, 2011, PEDIATR INFECT DIS J, V30, P501, DOI 10.1097/INF.0b013e31820b583d
   Alffenaar JWC, 2010, CLIN PHARMACOKINET, V49, P559, DOI 10.2165/11532080-000000000-00000
   Da Silva PEA, 2011, J ANTIMICROB CHEMOTH, V66, P1417, DOI 10.1093/jac/dkr173
   Alvirez-Freites EJ, 2002, ANTIMICROB AGENTS CH, V46, P1022, DOI 10.1128/AAC.46.4.1022-1025.2002
   Aubry A, 2004, ANTIMICROB AGENTS CH, V48, P1281, DOI 10.1128/AAC.48.4.1281-1288.2004
   Balabanova Y, 2012, EUR RESPIR J, V39, P1266, DOI 10.1183/09031936.00133911
   Balabanova Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020531
   Balabanova Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007129
   Bate R, 2013, INT J TUBERC LUNG D, V17, P308, DOI 10.5588/ijtld.12.0355
   Becerra MC, 2011, LANCET, V377, P147, DOI 10.1016/S0140-6736(10)61972-1
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0
   Behr MA, 1998, AM J RESP CRIT CARE, V158, P465
   Bekker LG, 2010, INT J TUBERC LUNG D, V14, P379
   Blasi F, 2013, EUR RESPIR J, V41, P491, DOI 10.1183/09031936.00196712
   Bloss E, 2010, INT J TUBERC LUNG D, V14, P275
   Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661
   Boehme CC, 2011, LANCET, V377, P1495, DOI 10.1016/S0140-6736(11)60438-8
   Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847
   Bottger EC, 2011, CLIN MICROBIOL INFEC, V17, P1128, DOI 10.1111/j.1469-0691.2011.03551.x
   Bonacci RA, 2013, J INFECTION, V66, P303, DOI [10.1016/j.jinf.2012.09.005, 10.1016/j.jinf.2012.09.0051]
   Borrell S, 2009, INT J TUBERC LUNG D, V13, P1456
   Brannan J W, 1904, Trans Am Climatol Assoc, V20, P149
   Brewer TF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025861
   Brown J, 2011, DRUG RESISTANT TUBER
   Brust JCM, 2012, INT J TUBERC LUNG D, V16, P998, DOI 10.5588/ijtld.11.0713
   Caminero JA, 2006, INT J TUBERC LUNG D, V10, P829
   Caminero JA, 2005, EUR RESPIR J, V25, P928, DOI 10.1183/09031936.05.00103004
   Caminero JA, 2004, TUBERCULOSIS GUIDE S
   Caminero JA, 2013, EUR RESPIR J, V42, P5, DOI 10.1183/09031936.00206712
   Caminero JA, 2012, EUR RESPIR MONOGR, P154, DOI 10.1183/1025448x.10023511
   Caminero JA, 2010, LANCET INFECT DIS, V10, P621, DOI 10.1016/S1473-3099(10)70139-0
   Cayla JA, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-127
   Centers for Disease Control and Prevention (CDC), 2005, MMWR-MORBID MORTAL W, V54, P1
   Centers for Disease Control and Prevention, 2009, ENV CONTR TUB BASIC
   Chang KC, 2013, ANTIMICROB AGENTS CH, V57, P4097, DOI 10.1128/AAC.00120-13
   Chang KC, 2013, ANTIMICROB AGENTS CH, V57, P3445, DOI 10.1128/AAC.00388-13
   Cholo MC, 2012, J ANTIMICROB CHEMOTH, V67, P290, DOI 10.1093/jac/dkr444
   Coffey CC, 2004, J OCCUP ENVIRON HYG, V1, P262, DOI 10.1080/15459620490433799
   Connor S, 2012, INT J TUBERC LUNG D, V16, P712, DOI 10.5588/ijtld.12.0267
   Cox H, 2011, LANCET, V377, P103, DOI 10.1016/S0140-6736(10)61390-6
   Crudu V, 2012, J CLIN MICROBIOL, V50, P1264, DOI 10.1128/JCM.05903-11
   Cynamon MH, 1999, ANTIMICROB AGENTS CH, V43, P2922
   Dalton T, 2012, LANCET, V380, P1406, DOI 10.1016/S0140-6736(12)60734-X
   de Jager P, 2002, INT J TUBERC LUNG D, V6, P622
   De Lorenzo S, 2013, EUR RESPIR J, V41, P1386, DOI 10.1183/09031936.00124312
   Denholm JT, 2012, INT J TUBERC LUNG D, V16, P1320, DOI 10.5588/ijtld.12.0092
   US Department of Labor, 2004, OCC HLTH SAF STAND
   Dey T, 2013, J ANTIMICROB CHEMOTH, V68, P284, DOI 10.1093/jac/dks389
   Dharmadhikari AS, 2012, AM J RESP CRIT CARE, V185, P1104, DOI 10.1164/rccm.201107-1190OC
   Dheda K, 2010, LANCET, V375, P1798, DOI 10.1016/S0140-6736(10)60492-8
   Diacon AH, 2011, INT J TUBERC LUNG D, V15, P949, DOI 10.5588/ijtld.10.0616
   Diacon AH, 2010, EUR J CLIN MICROBIOL, V29, P1561, DOI 10.1007/s10096-010-1043-7
   Diacon AH, 2012, LANCET, V380, P986, DOI 10.1016/S0140-6736(12)61080-0
   Diacon AH, 2009, NEW ENGL J MED, V360, P2397, DOI 10.1056/NEJMoa0808427
   Diel R, 2012, EUR RESPIR J, V40, P143, DOI 10.1183/09031936.00204611
   Dominguez J, 2009, DIAGN MICR INFEC DIS, V63, P43, DOI 10.1016/j.diagmicrobio.2008.09.010
   Donald PR, 2012, TUBERCULOSIS, V92, P1, DOI 10.1016/j.tube.2011.05.006
   DONALD PR, 1991, CENT AFR J MED, V37, P268
   Donald PR, 2001, SCAND J INFECT DIS, V33, P466
   Donald PR, 2001, INT J TUBERC LUNG D, V5, P533
   DONOMAE I, 1966, ANN NY ACAD SCI, V135, P1011, DOI 10.1111/j.1749-6632.1966.tb45543.x
   Dorman SE, 2009, AM J RESP CRIT CARE, V180, P273, DOI 10.1164/rccm.200901-0078OC
   Drobac PC, 2006, PEDIATRICS, V117, P2022, DOI 10.1542/peds.2005-2235
   Drobniewski F, 2005, JAMA-J AM MED ASSOC, V293, P2726, DOI 10.1001/jama.293.22.2726
   East African/British Medical Research Council, 1977, AM REV RESPIR DIS, V116, P3
   ECHEVARRIA AM, 2007, AN PEDIATR, V67, P206
   Eker B, 2008, EMERG INFECT DIS, V14, P1700, DOI 10.3201/eid1411.080729
   Erkens CGM, 2010, EUR RESPIR J, V36, P925, DOI 10.1183/09031936.00201609
   Escombe AR, 2008, PLOS MED, V5, P1387, DOI 10.1371/journal.pmed.0050188
   Estlin Katherine Anne Talbert, 2010, International Ophthalmology, V30, P63, DOI 10.1007/s10792-009-9293-z
   Ettehad D, 2012, LANCET INFECT DIS, V12, P449, DOI 10.1016/S1473-3099(12)70033-6
   European Centre for Disease Prevention and Control WHO Regional Office for Europe., 2013, RUB SURV MON EUR
   European Centre for Disease Prevention and Control, 2012, MAN CONT MDR TB XDR
   European Medicines Agency, EUR MED AG REC 2 NEW
   Fairlie L, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-28
   Falzon D, 2011, EUR RESPIR J, V38, P516, DOI 10.1183/09031936.00073611
   Falzon D, 2013, LANCET INFECT DIS, V13, P690, DOI 10.1016/S1473-3099(13)70130-0
   Falzon D, 2013, EUR RESPIR J, V42, P156, DOI 10.1183/09031936.00134712
   Faustini A, 2006, THORAX, V61, P158, DOI 10.1136/thx.2005.045963
   Feja K, 2008, PEDIATR INFECT DIS J, V27, P907, DOI 10.1097/INF.0b013e3181783aca
   Fennelly KP, 2012, AM J RESP CRIT CARE, V186, P450, DOI 10.1164/rccm.201203-0444OC
   Fitzpatrick C, 2012, PHARMACOECONOMICS, V30, P63, DOI 10.2165/11595340-000000000-00000
   Fitzwater SP, 2010, CLIN INFECT DIS, V51, P371, DOI 10.1086/655127
   Fortun J, 2011, ENFERM INFEC MICR CL, V29, P654, DOI 10.1016/j.eimc.2011.04.002
   Fox GJ, 2011, COCHRANE DB SYST REV, V9
   FOX W, 1979, TUBERCLE, V60, P177, DOI 10.1016/0041-3879(79)90021-7
   Fox W, 1999, INT J TUBERC LUNG D, V3, pS231
   Fraser A, 2009, COCHRANE DB SYST REV, V2
   Gandhi Neel R, 2006, Lancet, V368, P1575
   Gandhi NR, 2010, LANCET, V375, P1830, DOI 10.1016/S0140-6736(10)60410-2
   Gandhi NR, 2010, AM J RESP CRIT CARE, V181, P80, DOI 10.1164/rccm.200907-0989OC
   Gelmanova IY, 2007, B WORLD HEALTH ORGAN, V85, P703, DOI 10.2471/BLT.06.038331
   Gelmanova IY, 2011, INT J TUBERC LUNG D, V15, P1373, DOI 10.5588/ijtld.10.0531
   Georghiou SB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033275
   Getahun H, 2012, J INFECT DIS, V205, pS216, DOI 10.1093/infdis/jis009
   Gler MT, 2012, NEW ENGL J MED, V366, P2151, DOI 10.1056/NEJMoa1112433
   Goemaere E, 2007, PLOS MED, V4, P771, DOI 10.1371/journal.pmed.0040162
   GOOD JT, 1981, AM J OBSTET GYNECOL, V140, P492
   Gopal M, 2013, INT J TUBERC LUNG D, V17, P1001, DOI 10.5588/ijtld.12.0144
   Granich RM, 2005, JAMA-J AM MED ASSOC, V293, P2732, DOI 10.1001/jama.293.22.2732
   Greco S, 2006, THORAX, V61, P783, DOI 10.1136/thx.2005.054908
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Gumbo T, 2004, J INFECT DIS, V190, P1642, DOI 10.1086/424849
   Gumbo T, 2009, ANTIMICROB AGENTS CH, V53, P3197, DOI 10.1128/AAC.01681-08
   Hales Craig M, 2013, Ann Am Thorac Soc, V10, P18, DOI 10.1513/AnnalsATS.201207-038OC
   Harding R, 2012, LANCET INFECT DIS, V12, P643, DOI 10.1016/S1473-3099(12)70084-1
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Heller T, 2010, INT J TUBERC LUNG D, V14, P420
   Hospice Palliative Care Association, GUID PROV PALL CAR P
   Hu Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019548
   International Union Against Tuberculosis and Lung Disease, 2013, GUID CLIN OP MAN DRU
   Isaakidis P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028066
   ISEMAN MD, 1990, AM REV RESPIR DIS, V141, P623
   Jensen Paul A., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Johnson JL, 2006, INT J TUBERC LUNG D, V10, P605
   Jonsson S, 2011, ANTIMICROB AGENTS CH, V55, P4230, DOI 10.1128/AAC.00274-11
   Jordan TS, 2012, INT J TUBERC LUNG D, V16, P950, DOI 10.5588/ijtld.11.0411
   Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181
   Kass JS, 2010, CNS DRUGS, V24, P655, DOI 10.2165/11534340-000000000-00000
   Katiyar SK, 2008, INT J TUBERC LUNG D, V12, P139
   Kempker RR, 2012, LANCET INFECT DIS, V12, P157, DOI 10.1016/S1473-3099(11)70244-4
   Kim SJ, 2005, EUR RESPIR J, V25, P564, DOI 10.1183/09031936.05.00111304
   Kim SJ, 2004, INT J TUBERC LUNG D, V8, P1157
   Koh WJ, 2009, J ANTIMICROB CHEMOTH, V64, P388, DOI 10.1093/jac/dkp171
   Kritski AL, 1996, AM J RESP CRIT CARE, V153, P331
   Kruuner A, 2006, J CLIN MICROBIOL, V44, P811, DOI 10.1128/JCM.44.3.811-818.2006
   Kurbatova EV, 2012, TUBERCULOSIS, V92, P397, DOI 10.1016/j.tube.2012.06.003
   Lan NTN, 2003, EMERG INFECT DIS, V9, P1633
   Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x
   LASSEN O, 1950, Acta Tuberc Scand Suppl, V26, P169
   Laurenzo D, 2011, ACTA TROP, V119, P5, DOI 10.1016/j.actatropica.2011.04.008
   Lawn SD, 2012, CLIN INFECT DIS, V54, P1071, DOI 10.1093/cid/cir1039
   Lee HW, 2009, INT J TUBERC LUNG D, V13, P1161
   Lee K, 2004, J OCCUP ENVIRON HYG, V1, P22, DOI 10.1080/15459620490250026
   Lehloenya RJ, 2012, EXPERT REV ANTI-INFE, V10, P475, DOI [10.1586/eri.12.13, 10.1586/ERI.12.13]
   Leimane V, 2010, EUR RESPIR J, V36, P584, DOI 10.1183/09031936.00003710
   Lessnau KDKL, 2003, CHEST, V123, P953, DOI 10.1378/chest.123.3.953
   Leung ECC, 2011, EUR RESPIR J, V38, P227, DOI 10.1183/09031936.00186310
   Liang LB, 2012, THORAX, V67, P632, DOI 10.1136/thoraxjnl-2011-200018
   Lienhardt C, 2012, J INFECT DIS, V205, pS241, DOI 10.1093/infdis/jis034
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   Loddenkemper R, 2012, EUR RESPIR J, V40, P9, DOI 10.1183/09031936.00027612
   Loebstein R, 1998, ANTIMICROB AGENTS CH, V42, P1336
   Lutge EE, 2012, COCHRANE DB SYST REV, V1
   Ma ZK, 2010, LANCET, V375, P2100, DOI 10.1016/S0140-6736(10)60359-9
   Malla P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008313
   Marais BJ, 2006, CLIN INFECT DIS, V42, pE69, DOI 10.1086/502652
   Martineau AR, 2011, LANCET, V377, P242, DOI 10.1016/S0140-6736(10)61889-2
   Matteelli Alberto, 2009, Expert Rev Respir Med, V3, P245, DOI 10.1586/ers.09.15
   McDonnell ME, 2005, NEW ENGL J MED, V352, P2757, DOI 10.1056/NEJM200506303522621
   McGee B, 2009, ANTIMICROB AGENTS CH, V53, P3981, DOI 10.1128/AAC.01378-08
   Menzies D, 1997, INFECT CONT HOSP EP, V18, P582
   Migliori GB, 2012, EUR RESPIR J, V39, P807, DOI 10.1183/09031936.00203811
   Minion J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053466
   Miotto P, 2012, EUR RESPIR J, V40, P690, DOI 10.1183/09031936.00164111
   Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928
   Nunn A, EVALUATION STANDARDI
   O'Donnell MR, 2013, EMERG INFECT DIS, V19, P416, DOI 10.3201/eid1903.120998
   Orenstein EW, 2009, LANCET INFECT DIS, V9, P153, DOI 10.1016/S1473-3099(09)70041-6
   Otero L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026276
   Pai M, 2008, SEMIN RESP CRIT CARE, V29, P560, DOI 10.1055/s-0028-1085707
   Palacios E, 2009, CLIN INFECT DIS, V48, P1413, DOI 10.1086/598191
   Pasipanodya J, 2011, ANTIMICROB AGENTS CH, V55, P24, DOI 10.1128/AAC.00749-10
   Pasipanodya JG, 2013, J INFECT DIS, V208, P1464, DOI 10.1093/infdis/jit352
   Pedrazzoli D, 2012, TUBERCULOSIS UK 2012
   Peloquin CA, 2004, CLIN INFECT DIS, V38, P1538, DOI 10.1086/420742
   Peloquin CA, 2008, ANTIMICROB AGENTS CH, V52, P852, DOI 10.1128/AAC.01036-07
   Perez-Guzman C, 2005, CHEST, V127, P643, DOI 10.1378/chest.127.2.643
   Pfyffer GE, 1999, J CLIN MICROBIOL, V37, P3179
   Plinke C, 2006, ANTIMICROB AGENTS CH, V50, P1900, DOI 10.1128/AAC.50.5.1900-1902.2006
   POULSEN A, 1950, Acta Tuberc Scand, V24, P311
   Pranger AD, 2011, EUR RESPIR J, V38, P888, DOI 10.1183/09031936.00176610
   Rachow A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020458
   Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002
   Rieder HL, 2002, INTERVENTIONS TUBERC, P1
   RILEY RL, 1995, AM J EPIDEMIOL, V142, P3
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511
   Rodrigues C, 2008, INT J TUBERC LUNG D, V12, P1449
   Rodriguez JC, 2004, J ANTIMICROB CHEMOTH, V53, P441, DOI 10.1093/jac/dkh119
   ROUILLON A, 1976, TUBERCLE, V57, P275
   Royce S, 2013, INT J TUBERC LUNG D, V17, P511, DOI 10.5588/ijtld.12.0286
   Rusch-Gerdes S, 2006, J CLIN MICROBIOL, V44, P688, DOI 10.1128/JCM.44.3.688-692.2006
   Rustomjee R, 2008, INT J TUBERC LUNG D, V12, P128
   Schaaf HS, 2011, PAEDIATR RESPIR REV, V12, P31, DOI 10.1016/j.prrv.2010.09.010
   Schaaf HS, 2002, PEDIATRICS, V109, P765, DOI 10.1542/peds.109.5.765
   Seddon JA, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-392
   Seddon JA, 2012, AM J RESP CRIT CARE, V186, P953, DOI 10.1164/rccm.201206-1001CI
   Seddon JA, 2012, CLIN INFECT DIS, V54, P157, DOI 10.1093/cid/cir772
   Sepkowitz KA, 1996, CLIN INFECT DIS, V23, P954
   Shandil RK, 2007, ANTIMICROB AGENTS CH, V51, P576, DOI 10.1128/AAC.00414-06
   Shen X, 2009, INT J TUBERC LUNG D, V13, P253
   Shin S, 2003, CLIN INFECT DIS, V36, P996, DOI 10.1086/374225
   Shin SS, 2010, AM J RESP CRIT CARE, V182, P426, DOI 10.1164/rccm.200911-1768OC
   Singla R, 2012, EUR RESPIR J, V39, P956, DOI 10.1183/09031936.00076811
   Skrahina A, 2013, B WORLD HEALTH ORGAN, V91, P36, DOI 10.2471/BLT.12.104588
   Skrahina A, 2012, EUR RESPIR J, V39, P1425, DOI 10.1183/09031936.00145411
   Skripconoka V, 2013, EUR RESPIR J, V41, P1393, DOI 10.1183/09031936.00125812
   Soldatou Alexandra, 2003, Paediatr Respir Rev, V4, P193, DOI 10.1016/S1526-0542(03)00061-7
   Somasundaram S, 2006, CHEMOTHERAPY, V52, P190, DOI 10.1159/000093486
   Sotgiu G, 2012, EUR RESPIR J, V40, P1430, DOI 10.1183/09031936.00022912
   Starke JR, 2003, TUBERCULOSIS, V83, P208, DOI 10.1016/S1472-9792(02)00088-4
   Steingart KR, 2013, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD009593.PUB2.0N
   Streifel Andrew J., 1999, P1211
   Stuckler D, 2008, P NATL ACAD SCI USA, V105, P13280, DOI 10.1073/pnas.0801200105
   Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X
   Sulochana S, 1999, INDIAN J MED RES, V110, P186
   Tabarsi P, 2011, INT J TUBERC LUNG D, V15, P547, DOI 10.5588/ijtld.10.0140
   Teixeira L, 2001, INT J TUBERC LUNG D, V5, P321
   Toczek A, 2013, INT J TUBERC LUNG D, V17, P299, DOI 10.5588/ijtld.12.0537
   Toman K, 1979, TUBERCULOSIS CASE FI
   Tortoli E, 2012, EUR RESPIR J, V40, P442, DOI 10.1183/09031936.00176311
   Traore H, 2000, INT J TUBERC LUNG D, V4, P481
   Tuberculosis Coalition for Technical Assistance, 2009, INT STAND TUB CAR
   Tupasi TE, 2006, PLOS MED, V3, P1587, DOI 10.1371/journal.pmed.0030352
   Udwadia ZF, 2012, CLIN INFECT DIS, V54, P579, DOI 10.1093/cid/cir889
   UNAIDS, GLOB HIV AIDS RESP E
   van der Watt JJ, 2011, INT J TUBERC LUNG D, V15, P722, DOI 10.5588/ijtld.10.0284
   van der Werf MJ, 2012, INT J TUBERC LUNG D, V16, P288, DOI 10.5588/ijtld.11.0437
   van der Werf MJ, 2012, EUR RESPIR J, V39, P1511, DOI 10.1183/09031936.00125711
   van der Werf MJ, 2012, INT J TUBERC LUNG D, V16, P426, DOI 10.5588/ijtld.11.0605
   Van Deun A, 2010, INT J TUBERC LUNG D, V14, P131
   Van Deun A, 2013, J CLIN MICROBIOL, V51, P2633, DOI 10.1128/JCM.00553-13
   Van Deun A, 2010, AM J RESP CRIT CARE, V182, P684, DOI 10.1164/rccm.201001-0077OC
   VEEN J, 1992, TUBERCLE LUNG DIS, V73, P73, DOI 10.1016/0962-8479(92)90058-R
   Velayati AA, 2009, CHEST, V136, P420, DOI 10.1378/chest.08-2427
   Via LE, 2010, J CLIN MICROBIOL, V48, P402, DOI 10.1128/JCM.01476-09
   Von Groll A, 2009, ANTIMICROB AGENTS CH, V53, P4498, DOI 10.1128/AAC.00287-09
   Vynnycky E, 2000, AM J EPIDEMIOL, V152, P247, DOI 10.1093/aje/152.3.247
   Wallis RS, 2011, ANTIMICROB AGENTS CH, V55, P567, DOI 10.1128/AAC.01179-10
   Wejse C, 2008, SCAND J INFECT DIS, V40, P111, DOI 10.1080/00365540701558698
   Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665
   Wells WA, 2013, LANCET INFECT DIS, V13, P449, DOI 10.1016/S1473-3099(13)70025-2
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   World Health Organization, 2007, US LIQ CULT DRUG SUS
   World Health Organisation, UN ACC DIAGN TREATM
   World Health Organization, 2011, GLOB TUB CONTR 2011
   World Health Organization (WHO), WHO POL TB INF CONTR
   World Health Organization, MAN MDR TB FIELD GUI
   World Health Organization, 2008, GUID PROGR MAN DRUG
   World Health Organization, STOP TB DEP WHO TECH
   World Health Organization, WHO DEF PALL CAR
   World Health Organization, 2013, DEF REP FRAM TUB 201
   World Health Organization (WHO), GUID PROGR MAN DRUG
   World Health Organization, 2010, MULT EXT DRUG RES TB
   World Health Organization, 2012, M 3 GLOB GLC M 17 19
   WHO, 2011, POL STAT AUT REAL TI
   World Health Organization, ROADM PREV COMB DRUG
   World Health Organization, XPERT MTB RIF INCR T
   Atkinson J., 2009, NAT VENT INF CONTR H
   Xu HB, 2012, INT J TUBERC LUNG D, V16, P358, DOI 10.5588/ijtld.11.0493
   Xu P, 2005, ENVIRON SCI TECHNOL, V39, P9656, DOI 10.1021/es0504892
   Yew WW, 2011, EUR RESPIR J, V37, P441, DOI 10.1183/09031936.00033010
   Yew WW, 2006, RESPIROLOGY, V11, P699, DOI 10.1111/j.1400-1843.2006.00941.x
   Zar HJ, 2010, EXPERT REV ANTI-INFE, V8, P277, DOI [10.1586/eri.10.9, 10.1586/ERI.10.9]
   Zhang Y, 2009, INT J TUBERC LUNG D, V13, P1320
   ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0
   Zhao YL, 2012, NEW ENGL J MED, V366, P2161, DOI 10.1056/NEJMoa1108789
   Zhu M, 2002, TUBERCULOSIS, V82, P91, DOI 10.1054/tube.330
   Zignol M, 2012, B WORLD HEALTH ORGAN, V90, P111, DOI 10.2471/BLT.11.092585
   Zumla A, 2013, NAT REV DRUG DISCOV, V12, P388, DOI 10.1038/nrd4001
   [Anonymous], 2009, MMWR MORB MORTAL WKL, V58, P253
   [Anonymous], 2000, AM J RESP CRIT CARE, V161, pS221
NR 264
TC 87
Z9 89
U1 7
U2 38
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD JUL
PY 2014
VL 44
IS 1
BP 23
EP 63
DI 10.1183/09031936.00188313
PG 41
WC Respiratory System
SC Respiratory System
GA AL1SP
UT WOS:000338906700008
PM 24659544
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Ota, MOC
   Mendy, JF
   Donkor, S
   Togun, T
   Daramy, M
   Gomez, MP
   Chegou, NN
   Sillah, AK
   Owolabi, O
   Kampmann, B
   Walzl, G
   Sutherland, JS
AF Ota, Martin O. C.
   Mendy, Joseph F.
   Donkor, Simon
   Togun, Toyin
   Daramy, Mohammed
   Gomez, Marie P.
   Chegou, Novel N.
   Sillah, Abdou K.
   Owolabi, Olumuyiwa
   Kampmann, Beate
   Walzl, Gerhard
   Sutherland, Jayne S.
TI Rapid diagnosis of tuberculosis using ex vivo host biomarkers in sputum
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Letter
ID MYCOBACTERIUM-TUBERCULOSIS; INFECTION
C1 [Ota, Martin O. C.; Mendy, Joseph F.; Donkor, Simon; Togun, Toyin; Daramy, Mohammed; Gomez, Marie P.; Sillah, Abdou K.; Owolabi, Olumuyiwa; Kampmann, Beate; Sutherland, Jayne S.] MRC Unit, Fajara, Gambia.
   [Chegou, Novel N.; Walzl, Gerhard] Univ Stellenbosch, Fac Med & Hlth Sci, DST NRF Ctr Excellence Biomed TB Res, Div Mol Biol & Human Genet,Dept Biomed Sci, ZA-7505 Tygerberg, South Africa.
   [Chegou, Novel N.; Walzl, Gerhard] Univ Stellenbosch, Fac Med & Hlth Sci, Ctr Mol & Cellular Biol, Div Mol Biol & Human Genet,Dept Biomed Sci,MRC, ZA-7505 Tygerberg, South Africa.
RP Sutherland, JS (reprint author), MRC Unit, Atlantic Blvd, Banjul, Gambia.
EM jsutherland@mrc.gm
OI Kampmann, Beate/0000-0002-6546-4709; Walzl, Gerhard/0000-0003-2487-125X;
   Sutherland, Jayne/0000-0002-7083-4997
FU Medical Research Council [MC_EX_MR/K011944/1, MC_U190071468,
   MC_UP_A900_1122]
CR Albanna AS, 2013, EUR RESPIR J, V42, P547, DOI 10.1183/09031936.00064713
   Batz HG, LAB FREE TUBERCULOSI
   Chegou NN, 2014, EUR RESPIR J, V43, P1472, DOI 10.1183/09031936.00151413
   Cormican LJ, 2004, EUR RESPIR J, V23, P649, DOI 10.1183/09031936.04.00053804
   Diel R, 2013, EUR RESPIR J, V42, P785, DOI 10.1183/09031936.00205512
   Mariotti S, 2013, HUM IMMUNOL, V74, P722, DOI 10.1016/j.humimm.2013.02.005
   Minion J, 2011, EUR RESPIR J, V38, P1398, DOI 10.1183/09031936.00025711
   Ribeiro-Rodrigues R, 2002, CLIN DIAGN LAB IMMUN, V9, P818, DOI 10.1128/CDLI.9.4.818-823.2002
   Sutherland JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030324
   Weyer K, 2013, EUR RESPIR J, V42, P252, DOI 10.1183/09031936.00157212
   World Health Organization, WHO GLOB TUB REP 201
   Yang CT, 2012, CELL HOST MICROBE, V12, P301, DOI 10.1016/j.chom.2012.07.009
NR 12
TC 6
Z9 6
U1 0
U2 2
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD JUL
PY 2014
VL 44
IS 1
BP 254
EP 257
DI 10.1183/09031936.00209913
PG 4
WC Respiratory System
SC Respiratory System
GA AL1SP
UT WOS:000338906700030
PM 24627540
OA No
DA 2017-08-15
ER

PT J
AU Hong, NV
   Amambua-Ngwa, A
   Tuan, NQ
   Cuong, DD
   Giang, NTH
   Dung, NV
   Tinh, TT
   Tien, NV
   Phuc, BQ
   Duong, TT
   Rosanas-Urgell, A
   D'Alessandro, U
   Van Geertruyden, JP
   Erhart, A
AF Nguyen Van Hong
   Amambua-Ngwa, Alfred
   Nguyen Quang Tuan
   Do Duy Cuong
   Nguyen Thi Huong Giang
   Nguyen Van Dung
   Ta Thi Tinh
   Nguyen Van Tien
   Bui Quang Phuc
   Tran Thanh Duong
   Rosanas-Urgell, Anna
   D'Alessandro, Umberto
   Van Geertruyden, Jean-Pierre
   Erhart, Annette
TI Severe Malaria Not Responsive to Artemisinin Derivatives in Man
   Returning from Angola to Vietnam
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
AB Resistance to artemisinin derivatives, the most potent antimalarial drugs currently used, has emerged in Southeast Asia and threatens to spread to Africa. We report a case of malaria in a man who returned to Vietnam after 3 years in Angola that did not respond to intravenous artesunate and clindamycin or an oral artemisinin-based combination.
C1 [Nguyen Van Hong; Ta Thi Tinh; Bui Quang Phuc; Tran Thanh Duong] Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam.
   [Nguyen Van Hong; Rosanas-Urgell, Anna; Erhart, Annette] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Nguyen Van Hong; Van Geertruyden, Jean-Pierre] Univ Antwerp, B-2020 Antwerp, Belgium.
   [Amambua-Ngwa, Alfred; D'Alessandro, Umberto] Med Res Unit, Fajara, Gambia.
   [Nguyen Quang Tuan; Do Duy Cuong; Nguyen Thi Huong Giang; Nguyen Van Dung; Nguyen Van Tien] Bach Mai Hosp, Hanoi, Vietnam.
RP Erhart, A (reprint author), Inst Trop Med, Natl Straat155, B-2000 Antwerp, Belgium.
EM aerhart@mrc.gm
RI Van geertruyden, Jean-pierre/K-6425-2014; D'Alessandro,
   Umberto/D-3457-2015
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364; D'Alessandro,
   Umberto/0000-0001-6341-5009
FU Belgium Cooperation within the Framework Agreement 3 Program
FX This study was supported by the Belgium Cooperation within the Framework
   Agreement 3 Program.
CR Demographic and Health Surveys, ANG MAL IND SURV 201
   Health and Life, 2013, IMP MAL WARN
   Institute of Malariology Parasitology and Entomology Quy Nhon Vietnam, 2013, PAR ENT QUY NHON VIE
   Liljander A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-78
   Rubio J M, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS199, DOI 10.1016/S0035-9203(02)90077-5
   Tri Dan, 2013, DAN TRI
   US Agency for International Development. President's Malaria Initiative. (PMI), 2013, PRES MAL IN PMI COUN
   World Health Organization, 2011, JOINT ASS RESP ART R
   [Anonymous], 2013, ED MAGAZINE
NR 9
TC 1
Z9 1
U1 0
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUL
PY 2014
VL 20
IS 7
BP 1199
EP 1202
DI 10.3201/eid2007.140155
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AK4JB
UT WOS:000338389900015
OA gold
DA 2017-08-15
ER

PT J
AU Huang, HL
   Ideh, RC
   Gitau, E
   Thezenas, ML
   Jallow, M
   Ebruke, B
   Chimah, O
   Oluwalana, C
   Karanja, H
   Mackenzie, G
   Adegbola, RA
   Kwiatkowski, D
   Kessler, BM
   Berkley, JA
   Howie, SRC
   Casals-Pascual, C
AF Huang, Honglei
   Ideh, Readon C.
   Gitau, Evelyn
   Thezenas, Marie L.
   Jallow, Muminatou
   Ebruke, Bernard
   Chimah, Osaretin
   Oluwalana, Claire
   Karanja, Henri
   Mackenzie, Grant
   Adegbola, Richard A.
   Kwiatkowski, Dominic
   Kessler, Benedikt M.
   Berkley, James A.
   Howie, Stephen R. C.
   Casals-Pascual, Climent
TI Discovery and Validation of Biomarkers to Guide Clinical Management of
   Pneumonia in African Children
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE pneumonia; malaria; lipocalin-2; NGAL; respiratory infection; biomarkers
ID ACUTE RESPIRATORY-INFECTIONS; PLACEBO-CONTROLLED-TRIAL; AGED 2-59
   MONTHS; ORAL AMOXICILLIN; FALCIPARUM-MALARIA; LOBAR PNEUMONIA;
   DOUBLE-BLIND; CHILDHOOD; MORTALITY; BACTERIAL
AB Background. Pneumonia is the leading cause of death in children globally. Clinical algorithms remain suboptimal for distinguishing severe pneumonia from other causes of respiratory distress such as malaria or distinguishing bacterial pneumonia and pneumonia from others causes, such as viruses. Molecular tools could improve diagnosis and management.
   Methods.aEuro integral We conducted a mass spectrometry-based proteomic study to identify and validate markers of severity in 390 Gambian children with pneumonia (n = 204) and age-, sex-, and neighborhood-matched controls (n = 186). Independent validation was conducted in 293 Kenyan children with respiratory distress (238 with pneumonia, 41 with Plasmodium falciparum malaria, and 14 with both). Predictive value was estimated by the area under the receiver operating characteristic curve (AUC).
   Results.aEuro integral Lipocalin 2 (Lpc-2) was the best protein biomarker of severe pneumonia (AUC, 0.71 [95% confidence interval, .64-.79]) and highly predictive of bacteremia (78% [64%-92%]), pneumococcal bacteremia (84% [71%-98%]), and "probable bacterial etiology" (91% [84%-98%]). These results were validated in Kenyan children with severe malaria and respiratory distress who also met the World Health Organization definition of pneumonia. The combination of Lpc-2 and haptoglobin distinguished bacterial versus malaria origin of respiratory distress with high sensitivity and specificity in Gambian children (AUC, 99% [95% confidence interval, 99%-100%]) and Kenyan children (82% [74%-91%]).
   Conclusions.aEuro integral Lpc-2 and haptoglobin can help discriminate the etiology of clinically defined pneumonia and could be used to improve clinical management. These biomarkers should be further evaluated in prospective clinical studies.
C1 [Huang, Honglei; Thezenas, Marie L.; Kwiatkowski, Dominic; Kessler, Benedikt M.; Casals-Pascual, Climent] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
   [Berkley, James A.] Univ Oxford, Nuffield Dept Med, Ctr Clin Vaccinol & Trop Med, Oxford OX1 2JD, England.
   [Gitau, Evelyn] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England.
   [Ideh, Readon C.; Jallow, Muminatou; Ebruke, Bernard; Chimah, Osaretin; Oluwalana, Claire; Mackenzie, Grant; Adegbola, Richard A.; Howie, Stephen R. C.] MRC Unit, Banjul, Gambia.
   [Gitau, Evelyn; Karanja, Henri; Berkley, James A.] Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya.
RP Casals-Pascual, C (reprint author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM ccasals@well.ox.ac.uk
OI Gitau, Evelyn /0000-0002-5270-7492; Berkley, James/0000-0002-1236-849X;
   Kwiatkowski, Dominic/0000-0002-5023-0176; Casals-Pascual,
   Climent/0000-0002-0867-8954; Kessler, Benedikt/0000-0002-8160-2446
FU Medical Research Council UK [G0600718]; Wellcome Trust [077383/Z/05/Z,
   090532/Z09/Z, 075491/Z/04]; Bill & Melinda Gates Foundation, through the
   Foundation for the National Institutes of Health as part of the Grand
   Challenges in Global Health initiative; Medical Research Council UK;
   Wellcome Trust; MRC; Bill and Melinda Gates Foundation; MRC UK
   [G0701885]
FX Financial support. This work was supported by the Medical Research
   Council UK (grant G0600718), the Wellcome Trust (grants 077383/Z/05/Z,
   090532/Z09/Z, and 075491/Z/04) and the Bill & Melinda Gates Foundation,
   through the Foundation for the National Institutes of Health as part of
   the Grand Challenges in Global Health initiative. H. H., R. I., M. L.
   T., M. J., B. E., O. C., C. O., G. M., D. K., and S. H. are supported by
   the Medical Research Council UK. E. G., H. K., and J. B. are supported
   by the Wellcome Trust. D. K. is supported by the MRC, Wellcome Trust,
   and the Bill and Melinda Gates Foundation. C. C. P. is supported by the
   MRC UK (Clinician Scientist Fellowship G0701885).
CR Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511
   Agarwal Girdhar, 2004, BMJ, V328, P791
   Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200
   Awasthi S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001991
   Bachman MA, 2009, PLOS PATHOG, V5
   Banya WAS, 1996, PEDIATR INFECT DIS J, V15, P292, DOI 10.1097/00006454-199604000-00003
   Bari A, 2011, LANCET, V378, P1796, DOI 10.1016/S0140-6736(11)61140-9
   Berkley J, 1999, T ROY SOC TROP MED H, V93, P283, DOI 10.1016/S0035-9203(99)90024-X
   Berkley JA, 2005, BRIT MED J, V330, P995, DOI 10.1136/bmj.38408.471991.8F
   Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8
   Diez-Padrisa N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013226
   Drain PK, 2014, LANCET INFECT DIS, V14, P239, DOI 10.1016/S1473-3099(13)70250-0
   English M, 1996, T ROY SOC TROP MED H, V90, P658, DOI 10.1016/S0035-9203(96)90423-X
   Falade AG, 2001, ANN TROP PAEDIATR, V21, P293, DOI 10.1080/07430170120093472
   Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104
   Greenberg D, 2014, PEDIATR INFECT DIS J, V33, P136, DOI 10.1097/INF.0000000000000023
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   Hazir T, 2011, CLIN INFECT DIS, V52, P293, DOI 10.1093/cid/ciq142
   Howie SRC, 2006, LANCET, V368, P1646, DOI 10.1016/S0140-6736(06)69687-6
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Lamikanra AA, 2007, BLOOD, V110, P18, DOI 10.1182/blood-2006-09-018069
   Lin Chao-Jen, 2006, Journal of Microbiology Immunology and Infection, V39, P489
   Madhi SA, 2008, B WORLD HEALTH ORGAN, V86, P365, DOI 10.2471/BLT.07.044503
   Mathers C, 2002, 50 WHO
   Mohammed AO, 2003, ACTA TROP, V87, P279, DOI 10.1016/S0001-706X(03)00116-5
   Moreno L, 2006, PEDIATR PULM, V41, P331, DOI 10.1002/ppul.20364
   Mulholland K, 2003, PEDIATR PULM, V36, P469, DOI 10.1002/ppul.10344
   Mwaniki MK, 2009, B WORLD HEALTH ORGAN, V87, P263, DOI 10.2471/BLT.07.049148
   NAGEL RL, 1971, J BIOL CHEM, V246, P69
   Nelson AL, 2005, CELL MICROBIOL, V7, P1404, DOI 10.1111/j.1462-5822.2005.00566.x
   Nesvizhskii AI, 2005, MOL CELL PROTEOMICS, V4, P1419, DOI 10.1074/mcp.R500012-MCP200
   Niessen L, 2009, B WORLD HEALTH ORGAN, V87, P472, DOI 10.2471/BLT.08.050872
   Reinhart K, 2012, CLIN MICROBIOL REV, V25, P609, DOI 10.1128/CMR.00016-12
   Reyes H, 1997, HEALTH POLICY PLANN, V12, P214, DOI 10.1093/heapol/12.3.214
   Scott JAG, 2008, B WORLD HEALTH ORGAN, V86, P494, DOI 10.2471/BLT.08.052753
   Scott JAG, 2011, LANCET, V378, P1316, DOI 10.1016/S0140-6736(11)60888-X
   United Nations, 2001, 56 SESS UN GEN ASS
   World Health Organization, 2013, 2013 GUID MAN COMM C
   Zimmermann O, 2005, NEW ENGL J MED, V352, P1379
NR 39
TC 17
Z9 18
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2014
VL 58
IS 12
BP 1707
EP 1715
DI 10.1093/cid/ciu202
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AI7AO
UT WOS:000337031700011
PM 24696240
OA No
DA 2017-08-15
ER

PT J
AU Tebruegge, M
   Ritz, N
   Koetz, K
   Noguera-Julian, A
   Seddon, JA
   Welch, SB
   Tsolia, M
   Kampmann, B
AF Tebruegge, Marc
   Ritz, Nicole
   Koetz, Karsten
   Noguera-Julian, Antoni
   Seddon, James A.
   Welch, Steven B.
   Tsolia, Maria
   Kampmann, Beate
CA Paediat TB Network European
TI Availability and Use of Molecular Microbiological and Immunological
   Tests for the Diagnosis of Tuberculosis in Europe
SO PLOS ONE
LA English
DT Article
ID GAMMA RELEASE ASSAYS; LINE-PROBE ASSAY; XPERT MTB/RIF; RESPIRATORY
   SPECIMENS; PULMONARY TUBERCULOSIS; RESISTANT TUBERCULOSIS; RIFAMPIN
   RESISTANCE; RAPID DIAGNOSIS; COMPLEX; INFECTION
AB Introduction: Currently only limited data exist regarding the availability and clinical use of molecular and immunological tests for tuberculosis (TB) in the European setting.
   Methods: Web-based survey of Paediatric-Tuberculosis-Network-European-Trialsgroup (ptbnet) and Tuberculosis-Network-European-Trialsgroup (TBnet) members conducted June to December 2013. Both networks comprise clinicians, microbiologists, epidemiologists and researchers predominately based in Europe.
   Results: 191 healthcare professionals from 31 European countries participated. Overall, 26.8% of respondents did not have access to the Xpert MTB/RIF assay; only 44.6% had access to the assay in-house. However, a substantial proportion had access to other commercial and/or non-commercial PCR-based assays for TB (68.8% and 31.8%, respectively). Only 6.4% did not have access to any PCR-based assays for TB. A large proportion of participants with access to the Xpert MTB/RIF assay had used it for the analysis of non-respiratory samples [pleural fluid: 36.5%, gastric aspirates: 34.7%, cerebrospinal fluid: 34.7%, stool samples: 4.3%, blood/serum: 2.6%, 'other samples' (which included biopsy/tissue samples, lymph node aspirates, joint aspirates and urine samples): 16.5%]. Regarding interferon-gamma release assays, a greater proportion of respondents had access to the QuantiFERON-TB Gold assay (84.7%) than to the T-SPOT.TB assay (52.2%).
   Conclusions: Both immunological and molecular TB tests are widely available across Europe. The QuantiFERON-TB Gold assay is more widely used than the T-SPOT.TB assay, which may reflect the difficulties of integrating an ELISPOT assay into the routine laboratory setting. Although Xpert MTB/RIF assays are optimised and solely licensed for the analysis of sputum samples, in clinical practice they are commonly used for non-respiratory samples. Further research is needed to establish how current molecular TB tests impact on patient care and outcome in the routine clinical setting.
C1 [Tebruegge, Marc] Univ Southampton, Fac Med, Acad Unit Clin & Expt Sci, Southampton SO9 5NH, Hants, England.
   [Tebruegge, Marc] Univ Hosp Southampton NHS Fdn Trust, Dept Paediat Infect Dis & Immunol, Southampton, Hants, England.
   [Tebruegge, Marc] Univ Southampton, Inst Life Sci, Southampton, Hants, England.
   [Tebruegge, Marc; Ritz, Nicole] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.
   [Ritz, Nicole] Univ Childrens Hosp Basel, Infect Dis Unit, Basel, Switzerland.
   [Koetz, Karsten] Sahlgrens Univ Hosp, Dept Paediat, Gothenburg, Sweden.
   [Noguera-Julian, Antoni] Univ Barcelona, Hosp St Joan de Deu, Dept Paediat, Barcelona, Spain.
   [Seddon, James A.; Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Fac Med, Acad Dept Paediat, London, England.
   [Welch, Steven B.] Heart England NHS Fdn Trust, Birmingham Chest Clin, Southampton, Hants, England.
   [Tsolia, Maria] Univ Athens, Sch Med, P&A Kyriakou Childrens Hosp, Univ Dept Pediat 2, Athens 11528, Greece.
   [Kampmann, Beate] Med Res Council MRC Unit Gambia, Banjul, Gambia.
RP Tebruegge, M (reprint author), Univ Southampton, Fac Med, Acad Unit Clin & Expt Sci, Southampton SO9 5NH, Hants, England.
EM m.tebruegge@soton.ac.uk
RI Ritz, Nicole/G-2924-2015
OI Ritz, Nicole/0000-0002-1498-1685; Seddon, James/0000-0002-2296-2302
FU UK National Institute for Health Research (NIHR); NIHR Southampton
   Respiratory Biomedical Research Unit; UK Technology Strategy Board
   (TSB); University of Basel; NIHR Senior Research Fellowship; MRC Program
   grant; Rozalia Foundation
FX No funding specifically related to this study was received. MT is
   supported by a Clinical Lectureship provided by the UK National
   Institute for Health Research (NIHR), the NIHR Southampton Respiratory
   Biomedical Research Unit, and a research grant provided by the UK
   Technology Strategy Board (TSB). NR is supported by a career advancement
   grant from the University of Basel and a grant from the Rozalia
   Foundation. BK is supported by an NIHR Senior Research Fellowship and an
   MRC Program grant. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ablanedo-Terrazas Y, 2013, LARYNGOSCOP IN PRESS, DOI [10.1002/lary.24478, DOI 10.1002/LARY.24478]
   Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2
   Barnard M, 2012, AM J RESP CRIT CARE, V186, P1298, DOI 10.1164/rccm.201205-0960OC
   Boehme CC, 2011, LANCET, V377, P1495, DOI 10.1016/S0140-6736(11)60438-8
   Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847
   DAMATO RF, 1995, J CLIN MICROBIOL, V33, P1832
   Dheda K, 2009, CURR OPIN PULM MED, V15, P188, DOI 10.1097/MCP.0b013e32832a0adc
   European Centre for Disease Prevention and Control/WHO Regional Office for Europe, 2013, TUB SURV MON EUR 201
   Heifets L, 2000, J CLIN MICROBIOL, V38, P1227
   Herrera V, 2011, CLIN INFECT DIS, V52, P1031, DOI 10.1093/cid/cir068
   Hillemann D, 2011, J CLIN MICROBIOL, V49, P1202, DOI 10.1128/JCM.02268-10
   Lacoma A, 2008, J CLIN MICROBIOL, V46, P3660, DOI 10.1128/JCM.00618-08
   Lawn SD, 2013, LANCET INFECT DIS, V13, P349, DOI 10.1016/S1473-3099(13)70008-2
   Lawn SD, 2012, INT J TUBERC LUNG D, V16, P701, DOI 10.5588/ijtld.12.0131
   Lawn SD, 2011, FUTURE MICROBIOL, V6, P1067, DOI [10.2217/fmb.11.84, 10.2217/FMB.11.84]
   Ligthelm LJ, 2011, J CLIN MICROBIOL, V49, P3967, DOI 10.1128/JCM.01310-11
   Moure R, 2012, J CLIN MICROBIOL, V50, P513, DOI 10.1128/JCM.06467-11
   Nhu NTQ, 2014, J CLIN MICROBIOL, V52, P226, DOI 10.1128/JCM.01834-13
   Nicol MP, 2013, CLIN INFECT DIS, V57, pE18, DOI 10.1093/cid/cit230
   Nulty DD, 2008, ASSESS EVAL HIGH EDU, V33, P301, DOI 10.1080/02602930701293231
   Pai M, 2007, LANCET INFECT DIS, V7, P428, DOI 10.1016/S1473-3099(07)70086-5
   Patel VB, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001536
   Pfyffer GE, 1999, J CLIN MICROBIOL, V37, P137
   Porcel JM, 2013, INT J TUBERC LUNG D, V17, P1217, DOI 10.5588/ijtld.13.0178
   Tebruegge M, 2010, EUR RESPIR J, V36, P214, DOI 10.1183/09031936.00025510
   Tebruegge M, 2013, THORAX, V68, P588, DOI 10.1136/thoraxjnl-2012-202824
   Tebruegge M, 2012, NEW ENGL J MED, V367, P1568, DOI 10.1056/NEJMc1210173#SA2
   Theron G, 2014, LANCET, V383, P424, DOI 10.1016/S0140-6736(13)62073-5
   Tortoli E, 2012, EUR RESPIR J, V40, P442, DOI 10.1183/09031936.00176311
   U.S. Food and Drug Administration, 2013, XPERT MTB RIF ASS DE
   U.S. Food and Drug Administration, 2001, DEV APPR CLEAR QUANT
   Viveiros M, 2005, J CLIN MICROBIOL, V43, P4880, DOI 10.1128/JCM.43.9.4880-4884.2005
   VUORINEN P, 1995, J CLIN MICROBIOL, V33, P1856
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   World Health Organization, 2014, WHO MON XPERT MTB RI
   WHO, 2013, XPERT MTB RIF SYST D
NR 36
TC 11
Z9 11
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2014
VL 9
IS 6
AR e99129
DI 10.1371/journal.pone.0099129
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK8TP
UT WOS:000338701300035
PM 24922084
OA gold
DA 2017-08-15
ER

PT J
AU Nambozi, M
   Malunga, P
   Mulenga, M
   Van Geertruyden, JP
   D'Alessandro, U
AF Nambozi, Michael
   Malunga, Phidelis
   Mulenga, Modest
   Van Geertruyden, Jean-Pierre
   D'Alessandro, Umberto
TI Defining the malaria burden in Nchelenge District, northern Zambia using
   the World Health Organization malaria indicators survey
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria indicator survey; Zambia; Children; Endemicity
ID PLASMODIUM-FALCIPARUM INFECTION; SEVERE ANEMIA; GAMETOCYTES; CHILDREN;
   AFRICA; IMPACT; EPIDEMIOLOGY; MOZAMBIQUE; MODERATE
AB Background: Malaria is considered as one of the major public health problems and among the diseases of poverty. In areas of stable and relatively high transmission, pregnant women and their newborn babies are among the higher risk groups. A multicentre trial on the safety and efficacy of several formulations of artemisinin-based combination therapy (ACT) during pregnancy is currently on-going in four African countries, including Zambia, whose study site is in Nchelenge district. As the study outcomes may be influenced by the local malaria endemicity, this needs to be characterized. A cross-sectional survey to determine the prevalence and intensity of infection among <10 years old was carried out in March-April 2012 in Nchelenge district.
   Methods: The sampling unit was the household where all children < 10 years of age were included in the survey using simple random household selection on a GPS coded list. A blood sample for determining haemoglobin concentration and identifying malaria infection was collected from each recruited child.
   Results: Six hundred thirty households were selected and 782 children tested for malaria and anaemia. Prevalence of malaria infection was 30.2% (236/782), the large majority (97.9%, 231/236) being Plasmodium falciparum and the remaining ones (2.1%, 5/236) Plasmodium malariae. Anaemia, defined as haemoglobin concentration <11 g/dl, was detected in 51.2% (398/782) children.
   Conclusion: In Zambia, despite the reported decline in malaria burden, pockets of high malaria endemicity, such as Nchelenge district, still remain. This is a border area and significant progress can be achieved only by concerted efforts aimed at increasing coverage of current control interventions across the border.
C1 [Nambozi, Michael; Malunga, Phidelis; Mulenga, Modest] Trop Dis Res Ctr, Dept Clin Sci, Ndola, Zambia.
   [Nambozi, Michael; Van Geertruyden, Jean-Pierre] Univ Antwerp, Unit Int Hlth, B-2020 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Serrekunda, Gambia.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
RP Nambozi, M (reprint author), Trop Dis Res Ctr, Dept Clin Sci, POB 71769, Ndola, Zambia.
EM michaelnambozi@yahoo.com
RI Van geertruyden, Jean-pierre/K-6425-2014; D'Alessandro,
   Umberto/D-3457-2015
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364; D'Alessandro,
   Umberto/0000-0001-6341-5009
FU EDCTP through Institute of Tropical Medicine, Antwerp, Belgium
FX We acknowledge the data research assistants in Nchelenge, the DMO, Chief
   Kambwali for allowing us carry the study in their area. The study team
   also acknowledge the children and their parentsguardians of Nchelenge
   district for participating in the study. TDRC staff Samson Mwale who did
   the quality control, Bridget Musonda and Lucy Phiri who did the data
   entry. We acknowledge David Mwakazanga and Dr Webster Kasongo for
   helping in data analysis. Sources of funding: EDCTP through Institute of
   Tropical Medicine, Antwerp, Belgium.
CR Abilio AP, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-110
   Babiker HA, 2008, TRENDS PARASITOL, V24, P525, DOI 10.1016/j.pt.2008.08.001
   Bejon P, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-104
   Bousema T, 2011, CLIN MICROBIOL REV, V24, P377, DOI 10.1128/CMR.00051-10
   Bouyou-Akotet MK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-166
   Chizema-Kawesha E, 2010, AM J TROP MED HYG, V83, P480, DOI 10.4269/ajtmh.2010.10-0035
   Eisele TP, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001386
   Karl S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-98
   Korenromp EL, 2004, TROP MED INT HEALTH, V9, P1050, DOI 10.1111/j.1365-3156.2004.01317.x
   Lozoff B, 2011, J NUTR, V1, p740S
   Lusingu JP, 2004, MALARIA J, V28, P26
   Mharakurwa S, 2012, ACTA TROP, V121, P202, DOI 10.1016/j.actatropica.2011.06.012
   Ministry of Health, 2004, REP FOLL RBM SURV 10
   Ministry of Health National Malaria Control Centre, 2010, NAT MAL STRAT PLAN 2
   Ministry of Health, 2013, GUID DIAGN TREATM MA
   National Malaria Control Center [Zambia] Ministry of Health, 2012, DROP
   National Malaria Control Center [Zambia], 2010, MIN HLTH CENTR STAT
   National Malaria Control Center [Zambia], 2008, MIN HLTH CENTR STAT
   Ong'echa JM, 2006, AM J TROP MED HYG, V74, P376
   Ouedraogo AL, 2009, PLOS ONE, V22, pe8410, DOI DOI 10.1371/J0URNAL.P0NE.0008410
   Ouedraogo HZ, 2008, J TROP PEDIATRICS, V54, P395, DOI 10.1093/tropej/fmn049
   Raosoft Sample Size Calculation: Raosoft. Inc, 2004, RAOS SAMPL SIZ CALC
   RBM MEASURE Evaluation WHO UNICEF, 2005, MAL IND SURV
   RBM: Roll Back Malaria MEASURE Evaluation World Health Organization UNICEF, 2006, GUID COR POP COV IND
   Schneider P, 2007, AM J TROP MED HYG, V76, P470
   Sharmanov A, 2000, ANEMIA TESTING MANUA
   Sharp BL, 2007, AM J TROP MED HYG, V76, P42
   Warhurst DC, 1996, J CLIN PATHOL, V49, P533, DOI 10.1136/jcp.49.7.533
   WHO, 2003, MIN MERG AN TASK FOR
NR 29
TC 5
Z9 5
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUN 5
PY 2014
VL 13
AR 220
DI 10.1186/1475-2875-13-220
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AL1PU
UT WOS:000338898300003
PM 24902708
OA gold
DA 2017-08-15
ER

PT J
AU Preston, MD
   Campino, S
   Assefa, SA
   Echeverry, DF
   Ocholla, H
   Amambua-Ngwa, A
   Stewart, LB
   Conway, DJ
   Borrmann, S
   Michon, P
   Zongo, I
   Ouedraogo, JB
   Djimde, AA
   Doumbo, OK
   Nosten, F
   Pain, A
   Bousema, T
   Drakeley, CJ
   Fairhurst, RM
   Sutherland, CJ
   Roper, C
   Clark, TG
AF Preston, Mark D.
   Campino, Susana
   Assefa, Samuel A.
   Echeverry, Diego F.
   Ocholla, Harold
   Amambua-Ngwa, Alfred
   Stewart, Lindsay B.
   Conway, David J.
   Borrmann, Steffen
   Michon, Pascal
   Zongo, Issaka
   Ouedraogo, Jean-Bosco
   Djimde, Abdoulaye A.
   Doumbo, Ogobara K.
   Nosten, Francois
   Pain, Arnab
   Bousema, Teun
   Drakeley, Chris J.
   Fairhurst, Rick M.
   Sutherland, Colin J.
   Roper, Cally
   Clark, Taane G.
TI A barcode of organellar genome polymorphisms identifies the geographic
   origin of Plasmodium falciparum strains
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MITOCHONDRIAL-DNA; MALARIA PARASITE; LINKAGE DISEQUILIBRIUM; COPY
   NUMBER; APICOPLAST; EVOLUTION; ARTEMISININ; GAMETOCYTOGENESIS;
   SUSCEPTIBILITY; REPLICATION
AB Malaria is a major public health problem that is actively being addressed in a global eradication campaign. Increased population mobility through international air travel has elevated the risk of re-introducing parasites to elimination areas and dispersing drug-resistant parasites to new regions. A simple genetic marker that quickly and accurately identifies the geographic origin of infections would be a valuable public health tool for locating the source of imported outbreaks. Here we analyse the mitochondrion and apicoplast genomes of 711 Plasmodium falciparum isolates from 14 countries, and find evidence that they are non-recombining and co-inherited. The high degree of linkage produces a panel of relatively few single-nucleotide polymorphisms (SNPs) that is geographically informative. We design a 23-SNP barcode that is highly predictive (similar to 92%) and easily adapted to aid case management in the field and survey parasite migration worldwide.
C1 [Preston, Mark D.; Assefa, Samuel A.; Stewart, Lindsay B.; Conway, David J.; Bousema, Teun; Drakeley, Chris J.; Sutherland, Colin J.; Roper, Cally; Clark, Taane G.] London Sch Hyg & Trop Med, Immunol & Infect Dept, London WC1E 7HT, England.
   [Campino, Susana; Djimde, Abdoulaye A.] Wellcome Trust Sanger Inst, Malaria Programme, Hinxton CB10 1SA, England.
   [Echeverry, Diego F.] Purdue Univ, Dept Entomol, W Lafayette, IN 47907 USA.
   [Echeverry, Diego F.] Int Ctr Med Res & Training, Cali, Colombia.
   [Ocholla, Harold] Univ Malawi, Coll Med, Blantyre 3, Malawi.
   [Ocholla, Harold] Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre 30096 BT3, Malawi.
   [Ocholla, Harold] Univ Liverpool Liverpool Sch Trop Med, Malaria Capac Dev Consortium, Liverpool L3 5QA, Merseyside, England.
   [Amambua-Ngwa, Alfred; Conway, David J.] Med Res Council Labs UK, Fajara, Gambia.
   [Borrmann, Steffen] KEMRI Wellcome Trust Res Programme, Kilifi 80108, Kenya.
   [Borrmann, Steffen] Univ Tubingen, Dept Parasitol, Inst Trop Med, D-72074 Tubingen, Germany.
   [Michon, Pascal] Divine Word Univ, Fac Hlth Sci, Dept Rural Hlth, Madang, Papua N Guinea.
   [Zongo, Issaka; Ouedraogo, Jean-Bosco] Inst Rech Sci Sant, Bobo Dioulasso, Burkina Faso.
   [Djimde, Abdoulaye A.; Doumbo, Ogobara K.] Univ Bamako, Fac Med Pharm & Dent, Malaria Res & Training Ctr, Bamako BP1805, Mali.
   [Nosten, Francois] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford OX3 9DS, England.
   [Nosten, Francois] Mahidol Univ, Fac Trop Med, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Mae Sot 63110, Thailand.
   [Pain, Arnab] King Abdullah Univ Sci & Technol, Pathogen Genom Lab, Thuwal 239556900, Saudi Arabia.
   [Fairhurst, Rick M.] NIAID, Malaria Pathogenesis & Human Immun Unit, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
RP Clark, TG (reprint author), London Sch Hyg & Trop Med, Immunol & Infect Dept, London WC1E 7HT, England.
EM cally.roper@lshtm.ac.uk; taane.clark@lshtm.ac.uk
RI Pain, Arnab/L-5766-2015; Roper, Cally/K-2989-2013; Bousema,
   Teun/N-3574-2014; Preston, Mark/P-1429-2015
OI Pain, Arnab/0000-0002-1755-2819; Roper, Cally/0000-0002-6545-309X;
   Preston, Mark/0000-0002-6506-3104; Borrmann,
   Steffen/0000-0001-9189-4393; Nosten, Francois/0000-0002-7951-0745;
   Conway, David/0000-0002-8711-3037
FU UK Medical Research Council; Malaria Capacity Development Consortium;
   Wellcome Trust [WT084289MA]; Public Health England; Intramural Research
   Program of the NIH, NIAID
FX M. D. P. and T. G. C. received funding from the UK Medical Research
   Council. H.O. is supported by the Malaria Capacity Development
   Consortium, which is funded by The Wellcome Trust (WT084289MA). C.J.S.
   is supported by Public Health England. We wish to thank Scott Jackson,
   Catherine Hill, Tim Anderson and the malaria research team at CIDEIM for
   providing Colombian parasite samples, and the investigators who placed
   their sequencing data into the public domain. We wish to thank the
   Malaria Programs at the Wellcome Trust Sanger and Broad Institutes for
   putting raw sequence data into the public domain. This work was
   supported in part by the Intramural Research Program of the NIH, NIAID.
CR Amambua-Ngwa A, 2012, MOL BIOL EVOL, V29, P3249, DOI 10.1093/molbev/mss151
   Ariey F, 2014, NATURE, V505, P50, DOI 10.1038/nature12876
   Arisue N, 2012, MOL BIOL EVOL, V29, P2095, DOI 10.1093/molbev/mss082
   Auburn S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032891
   Baker DA, 2010, MOL BIOCHEM PARASIT, V172, P57, DOI 10.1016/j.molbiopara.2010.03.019
   Bender A, 2003, MOL BIOCHEM PARASIT, V132, P59, DOI 10.1016/j.molbiopara.2003.07.001
   Bispo NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059288
   Borrmann S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03318
   Breiman L., 1984, CLASSIFICATION REGRE
   CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0
   Conway DJ, 2000, MOL BIOCHEM PARASIT, V111, P163, DOI 10.1016/S0166-6851(00)00313-3
   CREASEY A, 1994, MOL BIOCHEM PARASIT, V65, P95, DOI 10.1016/0166-6851(94)90118-X
   Dahl EL, 2008, TRENDS PARASITOL, V24, P279, DOI 10.1016/j.pt.2008.03.007
   Daniels R, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-223
   Echeverri-Garcia D. F., 2013, POPULATION GENETICS
   Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132
   Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599
   Friesen J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001058
   Hershberg R, 2008, PLOS BIOL, V6, P2658, DOI 10.1371/journal.pbio.0060311
   Holsinger KE, 2009, NAT REV GENET, V10, P639, DOI 10.1038/nrg2611
   Hurst LD, 2002, TRENDS GENET, V18, P486, DOI 10.1016/S0168-9525(02)02722-1
   Imazio S, 2006, GENET RESOUR CROP EV, V53, P1003, DOI 10.1007/s10722-004-6896-0
   Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449
   Liaw A, 2002, R NEWS, V2002, P18, DOI DOI 10.1016/J.MEMSCI.2010.02.036
   Lim L, 2010, PHILOS T R SOC B, V365, P749, DOI 10.1098/rstb.2009.0273
   Luo HM, 2013, NEW ENGL J MED, V369, P1981, DOI 10.1056/NEJMoa1303368
   Miotto O, 2013, NAT GENET, V45, P648, DOI 10.1038/ng.2624
   Mobegi VA, 2014, MOL BIOL EVOL
   Mueller JC, 2004, BRIEF BIOINFORM, V5, P355, DOI 10.1093/bib/5.4.355
   Musset L, 2007, MOL BIOL EVOL, V24, P1582, DOI 10.1093/molbev/msm087
   Okamoto N, 2009, EUKARYOT CELL, V8, P128, DOI 10.1128/EC.00267-08
   Olson MS, 2000, P ROY SOC B-BIOL SCI, V267, P1801, DOI 10.1098/rspb.2000.1213
   Pecnikar F. Z., 2014, J APPL GENET, V55, P43
   Park DJ, 2012, P NATL ACAD SCI USA, V109, P13052, DOI 10.1073/pnas.1210585109
   Phyo AP, 2012, LANCET, V379, P1960, DOI 10.1016/S0140-6736(12)60484-X
   Preston MD, 2014, J INFECT DIS, V209, P1808, DOI 10.1093/infdis/jit812
   Preston M. D., 2013, BIOINFORMATICS, V28, P2983
   Ralph SA, 2001, DRUG RESIST UPDATE, V4, P145, DOI 10.1054/drup.2001.0205
   Robinson T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023204
   Seow F, 2005, MOL BIOCHEM PARASIT, V141, P145, DOI 10.1016/j.molbiopara.2005.02.002
   Sepulveda N, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-128
   Sidhu ABS, 2006, J INFECT DIS, V194, P528, DOI 10.1086/507115
   TAJIMA F, 1989, GENETICS, V123, P585
   Thyssen G, 2012, PLANT J, V72, P84, DOI 10.1111/j.1365-313X.2012.05057.x
   Waller Ross F., 2005, Current Issues in Molecular Biology, V7, P57
   Wang J, 2010, PLOS ONE, V5, pA158, DOI 10.1371/journal.pone.0009582
   WHO, 2012, WORLD MALARIA REPORT 2012, P1
   Williamson DH, 2002, MOL MICROBIOL, V45, P533, DOI 10.1046/j.1365-2958.2002.03033.x
   Wilson RJM, 1996, J MOL BIOL, V261, P155
   Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813
NR 50
TC 27
Z9 27
U1 2
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN
PY 2014
VL 5
AR 4052
DI 10.1038/ncomms5052
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL0SR
UT WOS:000338837600014
PM 24923250
OA gold
DA 2017-08-15
ER

PT J
AU Last, AR
   Burr, SE
   Weiss, HA
   Harding-Esch, EM
   Cassama, E
   Nabicassa, M
   Mabey, DC
   Holland, MJ
   Bailey, RL
AF Last, Anna R.
   Burr, Sarah E.
   Weiss, Helen A.
   Harding-Esch, Emma M.
   Cassama, Eunice
   Nabicassa, Meno
   Mabey, David C.
   Holland, Martin J.
   Bailey, Robin L.
TI Risk Factors for Active Trachoma and Ocular Chlamydia trachomatis
   Infection in Treatment-Naive Trachoma-Hyperendemic Communities of the
   Bijagos Archipelago, Guinea Bissau
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; ABORIGINAL COMMUNITIES; CENTRAL ETHIOPIA;
   GAMBIAN VILLAGE; MASS TREATMENT; SAFE STRATEGY; MUSCA-SORBENS;
   PREVALENCE; TANZANIA; AZITHROMYCIN
AB Background: Trachoma, caused by ocular infection with Chlamydia trachomatis, is hyperendemic on the Bijagos Archipelago of Guinea Bissau. An understanding of the risk factors associated with active trachoma and infection on these remote and isolated islands, which are atypical of trachoma-endemic environments described elsewhere, is crucial to the implementation of trachoma elimination strategies.
   Methodology/Principal Findings: A cross-sectional population-based trachoma prevalence survey was conducted on four islands. We conducted a questionnaire-based risk factor survey, examined participants for trachoma using the World Health Organization (WHO) simplified grading system and collected conjunctival swab samples for 1507 participants from 293 randomly selected households. DNA extracted from conjunctival swabs was tested using the Roche Amplicor CT/NG PCR assay. The prevalence of active (follicular and/or inflammatory) trachoma was 11% (167/1508) overall and 22% (136/618) in 1-9 year olds. The prevalence of C. trachomatis infection was 18% overall and 25% in 1-9 year olds. There were strong independent associations of active trachoma with ocular and nasal discharge, C. trachomatis infection, young age, male gender and type of household water source. C. trachomatis infection was independently associated with young age, ocular discharge, type of household water source and the presence of flies around a latrine.
   Conclusions/Significance: In this remote island environment, household-level risk factors relating to fly populations, hygiene behaviours and water usage are likely to be important in the transmission of ocular C. trachomatis infection and the prevalence of active trachoma. This may be important in the implementation of environmental measures in trachoma control.
C1 [Last, Anna R.; Harding-Esch, Emma M.; Mabey, David C.; Holland, Martin J.; Bailey, Robin L.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England.
   [Burr, Sarah E.] MRC Unit, Fajara, Gambia.
   [Weiss, Helen A.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, MRC Trop Epidemiol Grp, London WC1, England.
   [Cassama, Eunice; Nabicassa, Meno] Minist Saude Publ, Programa Nacl Saude Visao, Bisssau, Guinea Bissau.
RP Last, AR (reprint author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England.
EM anna.last@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276
FU Wellcome Trust [097330/Z/11/Z]
FX This work was supported by the Wellcome Trust [grant number
   097330/Z/11/Z]. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abdou A, 2007, BRIT J OPHTHALMOL, V91, P13, DOI 10.1136/bjo.2006.099507
   Alemayehu W, 2005, T ROY SOC TROP MED H, V99, P840, DOI 10.1016/j.trstmh.2005.06.013
   Baggaley RF, 2006, TROP MED INT HEALTH, V11, P220, DOI 10.1111/j.1365-3156.2005.01553.x
   Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY R, 1991, T ROY SOC TROP MED H, V85, P824, DOI 10.1016/0035-9203(91)90470-J
   Bejiga A, 2001, Ophthalmic Epidemiol, V8, P119, DOI 10.1076/opep.8.2.119.4168
   BENNETT S, 1991, World Health Statistics Quarterly, V44, P98
   BRECHNER RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P687
   Burr SE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002347
   Burton MJ, 2011, INVEST OPHTH VIS SCI, V52, P6012, DOI 10.1167/iovs.11-7326
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Cumberland P, 2005, T ROY SOC TROP MED H, V99, P120, DOI 10.1016/j.trstmh.2004.03.011
   da Cruz L, 2002, CLIN EXP OPHTHALMOL, V30, P80, DOI 10.1046/j.1442-6404.2002.00491.x
   Edwards T, 2008, TROP MED INT HEALTH, V13, P556, DOI 10.1111/j.1365-3156.2008.02034.x
   Emerson PM, 2005, TROP MED INT HEALTH, V10, P706, DOI 10.1111/j.1365-3156.2005.01432.x
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x
   Emerson PM, 2000, TROP MED INT HEALTH, V5, P515, DOI 10.1046/j.1365-3156.2000.00603.x
   Gambhir M, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000462
   Golovaty I, 2009, ETHIOPIA, V4, pe6702, DOI DOI 10.1371/J0URNAL.P0NE.0006702
   Hagi M, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000583
   Harding-Esch EM, 2008, T ROY SOC TROP MED H, V102, P1255, DOI 10.1016/j.trstmh.2008.04.022
   Harding-Esch EM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000861
   Holland MJ, 2010, INVEST OPHTH VIS SCI, V51, P3893, DOI 10.1167/iovs.09-5054
   [Anonymous], 2010, NAT POP CENS BOL BIJ
   Keenan JD, 2010, AM J TROP MED HYG, V82, P482, DOI 10.4269/ajtmh.2010.09-0315
   Kuper H, 2003, LANCET INFECT DIS, V3, P372, DOI 10.1016/S1473-3099(03)00659-5
   Leslie David E, 2003, Commun Dis Intell Q Rep, V27, P373
   Mesfin MM, 2006, OPHTHAL EPIDEMIOL, V13, P173, DOI 10.1080/09286580600611427
   Michel CEC, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000986
   Miller K, 2004, BRIT J OPHTHALMOL, V88, P750, DOI 10.1136/bjo.2003.038661
   Ngondi J, 2009, B WORLD HEALTH ORGAN, V87, P143, DOI 10.2471/BLT.07.046326
   O'Loughlin R, 2006, TROP MED INT HEALTH, V11, P1406, DOI 10.1111/j.1365-3156.2006.01689.x
   Polack S, 2006, T ROY SOC TROP MED H, V100, P1075, DOI 10.1016/j.trstmh.2005.12.002
   Ramesh A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002513
   Schemann JF, 2002, INT J EPIDEMIOL, V31, P194, DOI 10.1093/ije/31.1.194
   Solomon AW, 2004, CLIN MICROBIOL REV, V17, P982, DOI 10.1128/CMR.17.4.982-1011.2004
   Stare D, 2011, OPHTHAL EPIDEMIOL, V18, P20, DOI 10.3109/09286586.2010.545500
   Steyerberg EW, 1999, J CLIN EPIDEMIOL, V52, P935, DOI 10.1016/S0895-4356(99)00103-1
   Taye A, 2007, ANN TROP MED PARASIT, V101, P441, DOI 10.1179/136485907X176544
   TAYLOR HR, 1985, B WORLD HEALTH ORGAN, V63, P559
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088
   WEST SK, 1991, J INFECT DIS, V163, P752
   World Health Organization, 2004, 8 M WHO ALL GLOB EL
   WHO, 2012, PREV BLINDN VIS IMP
   World Bank, 2013, CLIM CHANG KNOWL POR
   Wright HR, 2005, BRIT J OPHTHALMOL, V89, P526, DOI 10.1136/bjo.2005.066183
NR 50
TC 17
Z9 17
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2014
VL 8
IS 6
AR e2900
DI 10.1371/journal.pntd.0002900
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AL0VW
UT WOS:000338846100023
PM 24967629
OA gold
DA 2017-08-15
ER

PT J
AU Taylor, SM
   Mayor, A
   Mombo-Ngoma, G
   Kenguele, HM
   Ouedraogo, S
   Ndam, NT
   Mkali, H
   Mwangoka, G
   Valecha, N
   Singh, JPN
   Clark, MA
   Verweij, JJ
   Adegnika, AA
   Severini, C
   Menegon, M
   Macete, E
   Menendez, C
   Cistero, P
   Njie, F
   Affara, M
   Otieno, K
   Kariuki, S
   ter Kuile, FO
   Meshnick, SR
AF Taylor, Steve M.
   Mayor, Alfredo
   Mombo-Ngoma, Ghyslain
   Kenguele, Hilaire M.
   Ouedraogo, Smaila
   Ndam, Nicaise Tuikue
   Mkali, Happy
   Mwangoka, Grace
   Valecha, Neena
   Singh, Jai Prakash Narayan
   Clark, Martha A.
   Verweij, Jaco J.
   Adegnika, Ayola Akim
   Severini, Carlo
   Menegon, Michela
   Macete, Eusebio
   Menendez, Clara
   Cistero, Pau
   Njie, Fanta
   Affara, Muna
   Otieno, Kephas
   Kariuki, Simon
   ter Kuile, Feiko O.
   Meshnick, Steven R.
TI A Quality Control Program within a Clinical Trial Consortium for PCR
   Protocols To Detect Plasmodium Species
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; MIXED INFECTIONS; MALARIA;
   SENSITIVITY; MICROSCOPY; DIAGNOSIS
AB Malaria parasite infections that are only detectable by molecular methods are highly prevalent and represent a potential transmission reservoir. The methods used to detect these infections are not standardized, and their operating characteristics are often unknown. We designed a proficiency panel of Plasmodium spp. in order to compare the accuracy of parasite detection of molecular protocols used by labs in a clinical trial consortium. Ten dried blood spots (DBSs) were assembled that contained P. falciparum, P. vivax, P. malariae, and P. ovale; DBSs contained either a single species or a species mixed with P. falciparum. DBS panels were tested in 9 participating laboratories in a masked fashion. Of 90 tests, 68 (75.6%) were correct; there were 20 false-negative results and 2 false positives. The detection rate was 77.8% (49/63) for P. falciparum, 91.7% (11/12) for P. vivax, 83.3% (10/12) for P. malariae, and 70% (7/10) for P. ovale. Most false-negative P. falciparum results were from samples with an estimated <= 5 parasites per mu l of blood. Between labs, accuracy ranged from 100% to 50%. In one lab, the inability to detect species in mixed-species infections prompted a redesign and improvement of the assay. Most PCR-based protocols were able to detect P. falciparum and P. vivax at higher densities, but these assays may not reliably detect parasites in samples with low P. falciparum densities. Accordingly, formal quality assurance for PCR should be employed whenever this method is used for diagnosis or surveillance. Such efforts will be important if PCR is to be widely employed to assist malaria elimination efforts.
C1 [Taylor, Steve M.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC USA.
   [Taylor, Steve M.; Meshnick, Steven R.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27514 USA.
   [Mayor, Alfredo; Menendez, Clara; Cistero, Pau] Barcelona Ctr Int Hlth Res, Barcelona, Catalonia, Spain.
   [Mayor, Alfredo; Macete, Eusebio; Menendez, Clara] Ctr Invest Saude Manhica, Maputo, Mozambique.
   [Mombo-Ngoma, Ghyslain; Kenguele, Hilaire M.; Adegnika, Ayola Akim] Ctr Rech Med Lambarene, Lambarene, Gabon.
   [Mombo-Ngoma, Ghyslain] Univ Sci Sante, Dept Parasitol, Libreville, Gabon.
   [Mombo-Ngoma, Ghyslain] Ngounie Med Res Ctr, Fougamou, Gabon.
   [Mombo-Ngoma, Ghyslain; Adegnika, Ayola Akim] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Kenguele, Hilaire M.] Univ Sci & Tech Masuku, Dept Biol, Franceville, Gabon.
   [Ouedraogo, Smaila] Fac Sci Sante, Parasitol Lab, Cotonou, Benin.
   [Ouedraogo, Smaila] Ctr Hosp Univ Yalgado Ouedraogo, Ouagadougou, Burkina Faso.
   [Ouedraogo, Smaila] Univ Ouagadougou, Unite Format & Rech Sci Sante, Dept Sante Publ, Ouagadougou, Burkina Faso.
   [Ndam, Nicaise Tuikue] Fac Sci Biol & Pharmaceut, Inst Rech Dev, Paris, France.
   [Ndam, Nicaise Tuikue] Univ Abomey Calavi, Fac Sci Sante, Ctr Etud & Rech Paludisme Associe Grossesse & Enf, Cotonou, Benin.
   [Mkali, Happy; Mwangoka, Grace] Ifakara Hlth Inst, Bagamoyo, Tanzania.
   [Valecha, Neena; Singh, Jai Prakash Narayan] Natl Inst Malaria Res, New Delhi, India.
   [Clark, Martha A.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA.
   [Verweij, Jaco J.] Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands.
   [Severini, Carlo; Menegon, Michela] Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, I-00161 Rome, Italy.
   [Njie, Fanta; Affara, Muna] MRC Labs, Banjul, Gambia.
   [Otieno, Kephas; Kariuki, Simon] Ctr Dis Control & Prevent, Kenya Med Res Inst, Kisumu, Kenya.
   [ter Kuile, Feiko O.] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Malaria Epidemiol Unit, Liverpool L3 5QA, Merseyside, England.
RP Meshnick, SR (reprint author), Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27514 USA.
EM steve.taylor@duke.edu
RI SEVERINI, CARLO/C-4977-2016; Cistero, Pau/H-2468-2017; Mayor,
   Alfredo/H-7488-2017
OI Cistero, Pau/0000-0001-7225-4331; Mayor, Alfredo/0000-0003-3890-2897;
   Tuikue Ndam, Nicaise/0000-0003-2646-2513; ter Kuile,
   Feiko/0000-0003-3663-5617
FU Malaria in Pregnancy Consortium through a grant from the Bill & Melinda
   Gates Foundation to the Liverpool School of Tropical Medicine; European
   & Developing Countries Clinical Trials Partnership; European Union
   Seventh Framework Programme (FP7) [201588]
FX This work was supported by the Malaria in Pregnancy Consortium, which is
   funded through a grant from the Bill & Melinda Gates Foundation to the
   Liverpool School of Tropical Medicine and the European & Developing
   Countries Clinical Trials Partnership. Tests at Istituto Superiore di
   Sanita in Rome were performed in the framework of the PregVax
   Consortium; the PregVax project received funding from the European Union
   Seventh Framework Programme (FP7/2007-2013) under grant agreement
   201588.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Alemayehu S, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-277
   Andrews L, 2005, AM J TROP MED HYG, V73, P191
   Beshir KB, 2013, J INFECT DIS, V208, P2017, DOI 10.1093/infdis/jit431
   Bialasiewicz S, 2007, J CLIN MICROBIOL, V45, P1621, DOI 10.1128/JCM.02145-06
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Hermsen CC, 2001, MOL BIOCHEM PARASIT, V118, P247, DOI 10.1016/S0166-6851(01)00379-6
   Johnston SP, 2006, J CLIN MICROBIOL, V44, P1087, DOI 10.1128/JCM.44.3.1087-1089.2006
   Karl S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020805
   Mayor A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-9
   Mosha JF, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-221
   Muller-Stover Irmela, 2008, Parasitol Res, V102, P547, DOI 10.1007/s00436-007-0804-4
   O'Meara WP, 2005, AM J TROP MED HYG, V73, P593
   Okell LC, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2241
   Okell LC, 2009, J INFECT DIS, V200, P1509, DOI 10.1086/644781
   Padley DJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-139
   Parkin N, 2012, CLIN INFECT DIS, V54, pS266, DOI 10.1093/cid/cir992
   Rantala AM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-269
   Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004
   Saunders N, 2013, J CLIN VIROL, V56, P260, DOI 10.1016/j.jcv.2012.11.013
   Shokoples SE, 2009, J CLIN MICROBIOL, V47, P975, DOI 10.1128/JCM.01858-08
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8
   Sutcliffe CG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031396
   Sutherland CJ, 2010, J INFECT DIS, V201, P1544, DOI 10.1086/652240
   Taylor SM, 2010, J CLIN MICROBIOL, V48, P512, DOI 10.1128/JCM.01800-09
   Veron V, 2009, EXP PARASITOL, V121, P346, DOI 10.1016/j.exppara.2008.12.012
   WHO-TDR-FIND, 2010, METH MAN LAB QUAL CO
   World Health Organization, 2009, MAL MICR QUAL ASS MA
   [Anonymous], 2012, WHO EXT QUAL ASS PRO
   Wiria AE, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-77
NR 30
TC 8
Z9 8
U1 1
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2014
VL 52
IS 6
BP 2144
EP 2149
DI 10.1128/JCM.00565-14
PG 6
WC Microbiology
SC Microbiology
GA AJ7YZ
UT WOS:000337919500046
PM 24740073
OA No
DA 2017-08-15
ER

PT J
AU Ekwochi, U
   Chinawa, JM
   Osuorah, CDI
   Odetunde, OI
   Obu, HA
   Agwu, S
AF Ekwochi, Uchenna
   Chinawa, Josephat M.
   Osuorah, Chidi D. I.
   Odetunde, Odutola I.
   Obu, Herbert A.
   Agwu, Samuel
TI The Use of Unprescribed Antibiotics in Management of Upper Respiratory
   Tract Infection in Children in Enugu, South East Nigeria
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
DE unprescribed antibiotics; children aged < 5 years; URTI
ID PRESCRIPTION; EXPERIENCES; DECISION; ADULTS
AB Background: It is a documented fact that upper respiratory tract infection (URTI) is more of a viral illness.
   Objectives: This study aims at documenting the prevalence of the use of unprescribed antibiotics in children aged < 5 years with upper respiratory symptomatology.
   Methods: Four hundred twenty-three mother-child pairs were enrolled for this study. Chi-square and logistic regression analysis were used to find association between use of unprescribed antibiotics and variables of interest.
   Results: The prevalence of unprescribed antibiotics in children aged < 5 years in the management of URTI is 75.9%. The antibiotics abuse was commoner in older children with URTI (45.9% in children aged 12-24 months) and among mothers with higher educational attainment.
   Conclusion: Antibiotics abuse among mothers is high. Government, through its responsible agencies, should enforce stricter control or outrightly stop sale of antibiotics over-the-counter to prevent the dreaded antibiotics resistance.
C1 [Ekwochi, Uchenna] Enugu State Univ Sci & Technol, Coll Med, Dept Paediat, Enugu, Enugu State, Nigeria.
   [Chinawa, Josephat M.; Odetunde, Odutola I.; Obu, Herbert A.] Univ Nigeria, Teaching Hosp, Dept Paediat, Nsukka, Enugu State, Nigeria.
   [Osuorah, Chidi D. I.] MRC, Dept Child Survival Unit, Serrekunda, Gambia.
   [Agwu, Samuel] Enugu State Univ, Teaching Hosp, Dept Paediat, Enugu, Enugu State, Nigeria.
RP Chinawa, JM (reprint author), UNTH, Dept Paediat, PMB 01129, Enugu 400001, Enugu State, Nigeria.
EM josephat.chinawa@unn.edu.ng
CR Bi P, 2000, SOC SCI MED, V50, P1445, DOI 10.1016/S0277-9536(99)00304-4
   Braun BL, 2000, ARCH FAM MED, V9, P589, DOI 10.1001/archfami.9.7.589
   Britten N, 1997, BRIT MED J, V315, P1506
   Butler CC, 2001, J ANTIMICROB CHEMOTH, V48, P435, DOI 10.1093/jac/48.3.435
   Carey B, 2003, Ir Med J, V96, P43
   Carey B, 2003, IRAN MED J, V96, P46
   Johnson AW, 2007, PAEDIAT CHILD HLTH, P396
   KAFLE KK, 1992, SOC SCI MED, V35, P1015, DOI 10.1016/0277-9536(92)90241-H
   Kozyrskyj AL, 2004, CAN MED ASSOC J, V171, P139, DOI 10.1503/cmaj.1031629
   LANSANG MA, 1990, J CLIN EPIDEMIOL, V43, P61, DOI 10.1016/0895-4356(90)90057-V
   Macfarlane J, 1997, RESP MED, V91, P427, DOI 10.1016/S0954-6111(97)90258-4
   Przemyslaw K, 2005, INT J MICROB, V10, P1
   Vanden Eng Jodi, 2003, Emerging Infectious Diseases, V9, P1128
   [Anonymous], 2003, ASS PHARM SECT AUSTR
   Wutzke SE, 2007, HEALTH PROMOT INT, V22, P53, DOI 10.1093/heapro/dal034
NR 15
TC 3
Z9 4
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
EI 1465-3664
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD JUN
PY 2014
VL 60
IS 3
BP 249
EP 252
DI 10.1093/tropej/fmt111
PG 4
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA AI7MM
UT WOS:000337075700012
PM 24436341
OA No
DA 2017-08-15
ER

PT J
AU Mobegi, VA
   Duffy, CW
   Amambua-Ngwa, A
   Loua, KM
   Laman, E
   Nwakanma, DC
   MacInnis, B
   Aspeling-Jones, H
   Murray, L
   Clark, TG
   Kwiatkowski, DP
   Conway, DJ
AF Mobegi, Victor A.
   Duffy, Craig W.
   Amambua-Ngwa, Alfred
   Loua, Kovana M.
   Laman, Eugene
   Nwakanma, Davis C.
   MacInnis, Bronwyn
   Aspeling-Jones, Harvey
   Murray, Lee
   Clark, Taane G.
   Kwiatkowski, Dominic P.
   Conway, David J.
TI Genome-Wide Analysis of Selection on the Malaria Parasite Plasmodium
   falciparum in West African Populations of Differing Infection Endemicity
SO MOLECULAR BIOLOGY AND EVOLUTION
LA English
DT Article
DE pathogen; balancing selection; directional selection; population
   genomics; immunity; transmission
ID NATURAL-SELECTION; DRUG-RESISTANCE; POLYMORPHISM; GENES; RECOMBINATION;
   ADAPTATION; DIVERGENCE; ANTIGENS; REGION; PFS47
AB Locally varying selection on pathogens may be due to differences in drug pressure, host immunity, transmission opportunities between hosts, or the intensity of between-genotype competition within hosts. Highly recombining populations of the human malaria parasite Plasmodium falciparum throughout West Africa are closely related, as gene flow is relatively unrestricted in this endemic region, but markedly varying ecology and transmission intensity should cause distinct local selective pressures. Genome-wide analysis of sequence variation was undertaken on a sample of 100 P. falciparum clinical isolates from a highly endemic region of the Republic of Guinea where transmission occurs for most of each year and compared with data from 52 clinical isolates from a previously sampled population from The Gambia, where there is relatively limited seasonal malaria transmission. Paired-end short-read sequences were mapped against the 3D7 P. falciparum reference genome sequence, and data on 136,144 single nucleotide polymorphisms (SNPs) were obtained. Within-population analyses identifying loci showing evidence of recent positive directional selection and balancing selection confirm that antimalarial drugs and host immunity have been major selective agents. Many of the signatures of recent directional selection reflected by standardized integrated haplotype scores were population specific, including differences at drug resistance loci due to historically different antimalarial use between the countries. In contrast, both populations showed a similar set of loci likely to be under balancing selection as indicated by very high Tajima's D values, including a significant overrepresentation of genes expressed at the merozoite stage that invades erythrocytes and several previously validated targets of acquired immunity. Between-population F-ST analysis identified exceptional differentiation of allele frequencies at a small number of loci, most markedly for five SNPs covering a 15-kb region within and flanking the gdv1 gene that regulates the early stages of gametocyte development, which is likely related to the extreme differences in mosquito vector abundance and seasonality that determine the transmission opportunities for the sexual stage of the parasite.
C1 [Mobegi, Victor A.; Duffy, Craig W.; Aspeling-Jones, Harvey; Murray, Lee; Clark, Taane G.; Conway, David J.] London Sch Hyg & Trop Med, Pathogen Mol Biol Dept, London WC1, England.
   [Mobegi, Victor A.; Amambua-Ngwa, Alfred; Nwakanma, Davis C.; Conway, David J.] MRC Unit, Banjul, Gambia.
   [Loua, Kovana M.; Laman, Eugene] Natl Inst Publ Hlth, Conakry, Guinea.
   [MacInnis, Bronwyn; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Cambridge, England.
   [Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
RP Conway, DJ (reprint author), London Sch Hyg & Trop Med, Pathogen Mol Biol Dept, London WC1, England.
EM david.conway@lshtm.ac.uk
OI Duffy, Craig/0000-0001-9359-4888; Kwiatkowski,
   Dominic/0000-0002-5023-0176; Conway, David/0000-0002-8711-3037
FU UK Medical Research Council [G1100123, G0600718]; Wellcome Trust
   [090770/Z/09/Z]; European Research Council [AdG-2011-294428]
FX The authors are grateful to the malaria patients who contributed samples
   to this study and to staff of the local health facilities, the National
   Institute for Public Health in Guinea, and the Medical Research Council
   in The Gambia for support in sample collection. The authors thank
   colleagues at the London School of Hygiene and Tropical Medicine and the
   Wellcome Trust Sanger Institute who gave advice and technical support,
   particularly Magnus Manske, Eleanor Drury, Daniel Alcock, and Lindsay
   Stewart. This research was supported by funding from the UK Medical
   Research Council (G1100123 and G0600718), the Wellcome Trust
   (090770/Z/09/Z), and the European Research Council (AdG-2011-294428).
CR Alexa A, 2006, BIOINFORMATICS, V22, P1600, DOI 10.1093/bioinformatics/btl140
   Amambua-Ngwa A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002992
   Amambua-Ngwa A, 2012, MOL BIOL EVOL, V29, P3249, DOI 10.1093/molbev/mss151
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   Anthony TG, 2007, MOL BIOCHEM PARASIT, V156, P117, DOI 10.1016/j.moibiopara.2007.07.008
   Auburn S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032891
   Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814
   Baker DA, 2010, MOL BIOCHEM PARASIT, V172, P57, DOI 10.1016/j.molbiopara.2010.03.019
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Chang HH, 2012, MOL BIOL EVOL, V29, P3427, DOI 10.1093/molbev/mss161
   Cheeseman IH, 2012, SCIENCE, V336, P79, DOI 10.1126/science.1215966
   Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272
   CONWAY DJ, 1992, INFECT IMMUN, V60, P1122
   Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6
   Eksi S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002964
   Fu WQ, 2013, ANNU REV GENOM HUM G, V14, P467, DOI 10.1146/annurev-genom-091212-153509
   Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048
   Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449
   Kublin JG, 2003, J INFECT DIS, V187, P1870, DOI 10.1086/375419
   Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025
   Mackinnon MJ, 2004, PHILOS T R SOC B, V359, P965, DOI 10.1098/rstb.2003.1414
   Manske M, 2012, NATURE, V487, P375, DOI 10.1038/nature11174
   McVean G, 2002, GENETICS, V160, P1231
   Miotto O, 2013, NAT GENET, V45, P648, DOI 10.1038/ng.2624
   Mobegi VA, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-223
   Molina-Cruz A, 2013, SCIENCE, V340, P984, DOI 10.1126/science.1235264
   Nash D, 2005, P ROY SOC B-BIOL SCI, V272, P1153, DOI 10.1098/rspb.2004.3026
   Neafsey DE, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r171
   Nwakanma DC, 2014, J INFECT DIS, V209, P1126, DOI 10.1093/infdis/jit618
   Ochola LI, 2010, MOL BIOL EVOL, V27, P2344, DOI 10.1093/molbev/msq119
   Olson-Manning CF, 2012, NAT REV GENET, V13, P867, DOI 10.1038/nrg3322
   Park DJ, 2012, P NATL ACAD SCI USA, V109, P13052, DOI 10.1073/pnas.1210585109
   Preston MD, 2014, J INFECT DIS, V209, P1808, DOI 10.1093/infdis/jit812
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Scheinfeldt LB, 2013, NAT REV GENET, V14, P692, DOI 10.1038/nrg3604
   TAJIMA F, 1989, GENETICS, V123, P585
   Takala-Harrison S, 2013, P NATL ACAD SCI USA, V110, P240, DOI 10.1073/pnas.1211205110
   Tanabe K, 2007, GENE, V397, P153, DOI 10.1016/j.gene.2007.04.033
   Venkatesan M, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-41
   Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072
   Weedall GD, 2010, TRENDS PARASITOL, V26, P363, DOI 10.1016/j.pt.2010.04.002
   WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x
NR 42
TC 23
Z9 23
U1 1
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0737-4038
EI 1537-1719
J9 MOL BIOL EVOL
JI Mol. Biol. Evol.
PD JUN
PY 2014
VL 31
IS 6
BP 1490
EP 1499
DI 10.1093/molbev/msu106
PG 10
WC Biochemistry & Molecular Biology; Evolutionary Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Evolutionary Biology; Genetics &
   Heredity
GA AI7KD
UT WOS:000337067400016
PM 24644299
OA No
DA 2017-08-15
ER

PT J
AU Afolabi, MO
   Okebe, JU
   McGrath, N
   Larson, HJ
   Bojang, K
   Chandramohan, D
AF Afolabi, Muhammed O.
   Okebe, Joseph U.
   McGrath, Nuala
   Larson, Heidi J.
   Bojang, Kalifa
   Chandramohan, Daniel
TI Informed consent comprehension in African research settings
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Review
DE informed consent; understanding; Africa; vulnerable population;
   systematic review; consentement eclaire; comprehension; Afrique;
   population vulnerable; revue systematique; Consentimiento informado;
   comprension; africa; poblacion vulnerable; revision sistematica
ID MICROBICIDE TRIAL; WEST-AFRICA; HEALTH RESEARCH; VACCINE TRIAL; QUALITY;
   HIV; PARTICIPATION; VOLUNTARY; GAMBIA; PERSPECTIVES
AB ObjectivePrevious reviews on participants' comprehension of informed consent information have focused on developed countries. Experience has shown that ethical standards developed on Western values may not be appropriate for African settings where research concepts are unfamiliar. We undertook this review to describe how informed consent comprehension is defined and measured in African research settings.
   MethodsWe conducted a comprehensive search involving five electronic databases: Medline, Embase, Global Health, EthxWeb and Bioethics Literature Database (BELIT). We also examined African Index Medicus and Google Scholar for relevant publications on informed consent comprehension in clinical studies conducted in sub-Saharan Africa. 29 studies satisfied the inclusion criteria; meta-analysis was possible in 21 studies. We further conducted a direct comparison of participants' comprehension on domains of informed consent in all eligible studies.
   ResultsComprehension of key concepts of informed consent varies considerably from country to country and depends on the nature and complexity of the study. Meta-analysis showed that 47% of a total of 1633 participants across four studies demonstrated comprehension about randomisation (95% CI 13.9-80.9%). Similarly, 48% of 3946 participants in six studies had understanding about placebo (95% CI 19.0-77.5%), while only 30% of 753 participants in five studies understood the concept of therapeutic misconception (95% CI 4.6-66.7%). Measurement tools for informed consent comprehension were developed with little or no validation. Assessment of comprehension was carried out at variable times after disclosure of study information. No uniform definition of informed consent comprehension exists to form the basis for development of an appropriate tool to measure comprehension in African participants.
   ConclusionsComprehension of key concepts of informed consent is poor among study participants across Africa. There is a vital need to develop a uniform definition for informed consent comprehension in low literacy research settings in Africa. This will be an essential step towards developing appropriate tools that can adequately measure informed consent comprehension. This may consequently suggest adequate measures to improve the informed consent procedure.
   ObjectifLes normes ethiques elaborees selon les valeurs occidentales ne sont peut-etre pas appropriees au contexte africain oU les concepts de recherche ne sont pas familiers. Cette revue decrit comment la comprehension du consentement eclaire est definie et mesuree dans les cadres de recherche africains.
   MethodesDes recherches ont ete effectuees sur Medline, Embase, Global Health, EthxWeb, base de donnees de la Bioethique Litterature, Index Medicus African et Google Scholar pour des publications pertinentes sur la comprehension du consentement eclaire dans les etudes cliniques menees en Afrique sub-saharienne. 29 etudes repondaient aux criteres d'inclusion; une meta-analyse a ete possible pour 21 etudes. La comprehension des participants sur les domaines du consentement eclaire dans toutes les etudes admissibles a ete comparee directement.
   ResultatsLa comprehension des concepts cles du consentement eclaire varie considerablement selon les pays et depend de la nature et de la complexite de l'etude. La meta-analyse a montre que 47% des participants ont compris la randomisation (IC95%: 13,9 - 80,9%), 48% ont compris le placebo (IC95%: 19,0 - 77,5%), 30% ont compris le concept de meprise therapeutique (IC95%: 4,6 - 66,7%). Les outils de mesure de la comprehension du consentement eclaire etaient developpes avec peu ou pas de validation.
   ConclusionsLa comprehension des concepts cles du consentement eclaire est faible en Afrique. Il y a une necessite vitale d'elaborer une definition uniforme pour la comprehension du consentement eclaire dans les cadres de recherche avec un faible niveau d'alphabetisation en Afrique.
   ObjetivoLos estandares eticos desarrollados basandose en valores occidentales podrian no ser apropiados para emplazamientos Africanos en donde los conceptos de investigacion no son familiares. En esta revision se describe como la comprension del consentimiento informado se define y mide en un centro de investigacion Africano.
   MetodosSe buscaron publicaciones relevantes sobre la comprension del consentimiento informado en estudios clinicos en africa subsahariana en Medline, Embase, Global Health, EthxWeb, Bioethics Literature Database, African Index Medicus y Google Scholar. 29 estudios satisfacian los criterios de inclusion y el metaanalisis era posible para 21. La comprension del consentimiento informado por parte de los participantes se comparo directamente en todos los estudios elegibles.
   ResultadosLa comprension de conceptos claves del consentimiento informado vario de forma considerable entre paises, y dependia de la naturaleza y de la complejidad del estudio. El meta-analisis mostro que un 47% entendia la aleatorizacion (IC 95% 13.9-80.9%); un 48% entendia el placebo (IC 95% 19.0-77.5%); y un 30% entendio el concepto terapeutico errado (IC 95% 4.6-66.7%). Las herramientas para medir la comprension del consentimiento informado se desarrollaron con poca o ninguna validacion.
   ConclusionesEn africa, la comprension de conceptos claves del consentimiento informado es pobre. Existe una necesidad vital de desarrollar una definicion uniforme para la comprension del consentimiento informado en lugares con bajos niveles de alfabetizacion en africa.
C1 [Afolabi, Muhammed O.; Okebe, Joseph U.; Bojang, Kalifa] MRC Unit, Fajara, Gambia.
   [Afolabi, Muhammed O.; Larson, Heidi J.; Chandramohan, Daniel] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [McGrath, Nuala] Univ Southampton, Southampton, Hants, England.
RP Afolabi, MO (reprint author), MRC Unit, POB 273, Banjul, Gambia.
EM mafolabi@mrc.gm
OI Bojang, Kalifa/0000-0001-7506-0938
FU European and Developing Countries Clinical Trial Partnership
FX The authors are grateful to the European and Developing Countries
   Clinical Trial Partnership for supporting this work with a capacity
   building grant. We acknowledge the inputs on the manuscript by Raffaella
   Ravinetto, Head of Clinical Trials Unit, Institute of Tropical Medicine,
   Anterwerp, Belgium.
CR Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209
   Annas GJ, 2009, NEW ENGL J MED, V360, P2050, DOI 10.1056/NEJMp0901474
   APPELBAUM PS, 1982, INT J LAW PSYCHIAT, V5, P319, DOI 10.1016/0160-2527(82)90026-7
   Chaisson LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022696
   Ciampa PJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039391
   [Anonymous], 2002, INT ETH GUID BIOM RE
   Collins F, 2013, LANCET GLOB HEALTH, V1, pE64, DOI 10.1016/S2214-109X(13)70012-3
   Coulibaly-Traore D, 2003, PRESSE MED, V32, P343
   Ekouevi KD, 2004, AIDS, V18, P1486, DOI 10.1097/01.aids.0000131349.22032.63
   Ellis RD, 2010, AM J TROP MED HYG, V83, P868, DOI 10.4269/ajtmh.2010.10-0062
   Fairhead J, 2006, J BIOSOC SCI, V38, P103, DOI 10.1017/S0021932005000945
   Fairhead J, 2006, SOC SCI MED, V63, P1109, DOI 10.1016/j.socscimed.2006.02.018
   Falagas ME, 2009, AM J SURG, V198, P420, DOI 10.1016/j.amjsurg.2009.02.010
   Friedland B, 2011, 3 POP COUNC RES EV M
   Friedland B, 2011, EVALUATION INFORM CO
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hill Z, 2008, J MED ETHICS, V34, P48, DOI 10.1136/jme.2006.019059
   Hussein I, 2011, ETHIOP J HEALTH DEV, V25, P126
   Hyder AA, 2006, DEV WORLD BIOETH, V6, P33, DOI 10.1111/j.1471-8847.2006.00134.x
   IJSSELMUIDEN CB, 1992, NEW ENGL J MED, V326, P830, DOI 10.1056/NEJM199203193261212
   Jefford M, 2008, LANCET ONCOL, V9, P485, DOI 10.1016/S1470-2045(08)70128-1
   Joffe S, 2001, J NATL CANCER I, V93, P139, DOI 10.1093/jnci/93.2.139
   Joubert G, 2003, AM J PUBLIC HEALTH, V93, P582, DOI 10.2105/AJPH.93.4.582
   Karim QA, 1998, AM J PUBLIC HEALTH, V88, P637
   Kiguba R, 2012, BMC MED ETHICS, V13, DOI 10.1186/1472-6939-13-21
   Krosin MT, 2006, CLIN TRIALS, V3, P306, DOI 10.1191/1740774506cn150oa
   Leach A, 1999, SOC SCI MED, V48, P139, DOI 10.1016/S0277-9536(98)00317-7
   Manafa Ogenna, 2007, Indian J Med Ethics, V4, P26
   Mandava A, 2012, J MED ETHICS, V38, P356, DOI 10.1136/medethics-2011-100178
   Marshall PA, 2006, J EMPIR RES HUM RES, V1, P25, DOI 10.1525/jer.2006.1.1.25
   Marshall PA, 2006, AM J PUBLIC HEALTH, V96, P1989, DOI 10.2105/AJPH.2005.076232
   Minnies Deon, 2008, BMC Med Ethics, V9, P15, DOI 10.1186/1472-6939-9-15
   Molyneux CS, 2004, SOC SCI MED, V59, P2547, DOI 10.1016/j.socscimed.2004.03.037
   Moodley K, 2005, J MED ETHICS, V31, P727, DOI 10.1136/jme.2004.009910
   NBAC. National Bioethics Advisory Commission, 2001, ETH POL ISS INT RES
   Ndebele PM, 2012, BMC MED ETHICS, V13, DOI 10.1186/1472-6939-13-29
   Oduro Abraham R, 2008, BMC Med Ethics, V9, P12, DOI 10.1186/1472-6939-9-12
   Oria PA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-391
   Pace C, 2005, AM J PUBLIC HEALTH, V95, P1184, DOI 10.2105/AJPH.2004.053082
   Preziosi MP, 1997, NEW ENGL J MED, V336, P370, DOI 10.1056/NEJM199701303360511
   PRIESTLEY KA, 1992, BRIT MED J, V305, P1263
   Ravinetto R, 2010, ITALIAN J TROPICAL M, V15, P15
   Saidu Y., 2013, Journal of Clinical Research and Bioethics, V4, P1000141
   Sand K., 2010, AJOB PRIMARY RESEARC, V1, P4
   Spreitzer GM, 2004, AM BEHAV SCI, V47, P828, DOI 10.1177/0002764203260212
   Sreenivasan G, 2003, LANCET, V362, P2016, DOI 10.1016/S0140-6736(03)15025-8
   Taiwo OO, 2009, BMC MED ETHICS, V10, DOI 10.1186/1472-6939-10-11
   Tekola F, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000482
   Onvomaha Tindana P, 2006, IRB, V28, P1
   Vallely A, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-133
   Vallely A, 2010, BMC MED ETHICS, V11, DOI 10.1186/1472-6939-11-10
   Vreeman R, 2012, BMC MED ETHICS, V13, DOI 10.1186/1472-6939-13-23
   Woodsong C, 2005, AM J PUBLIC HEALTH, V95, P412, DOI 10.2105/AJPH.2004.041624
NR 53
TC 8
Z9 8
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2014
VL 19
IS 6
BP 625
EP 642
DI 10.1111/tmi.12288
PG 18
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AG2GJ
UT WOS:000335234000002
PM 24636078
OA No
DA 2017-08-15
ER

PT J
AU Tinto, H
   Bonkian, LN
   Nana, LA
   Yerbanga, I
   Lingani, M
   Kazienga, A
   Valea, I
   Sorgho, H
   Kpoda, H
   Guiguemde, TR
   Ouedraogo, JB
   Mens, PF
   Schallig, H
   D'Alessandro, U
AF Tinto, Halidou
   Bonkian, Lea N.
   Nana, Louis A.
   Yerbanga, Isidore
   Lingani, Moussa
   Kazienga, Adama
   Valea, Innocent
   Sorgho, Hermann
   Kpoda, Herve
   Guiguemde, Tinga Robert
   Ouedraogo, Jean Bosco
   Mens, Petronella F.
   Schallig, Henk
   D'Alessandro, Umberto
TI Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum
   field isolates from Burkina Faso five years after the national policy
   change
SO MALARIA JOURNAL
LA English
DT Article
ID PLUS SULFADOXINE-PYRIMETHAMINE; IN-VITRO SUSCEPTIBILITY; COMBINATION
   THERAPY; ARTEMETHER-LUMEFANTRINE; MOLECULAR EPIDEMIOLOGY; UNCOMPLICATED
   MALARIA; RESISTANT MALARIA; RANDOMIZED-TRIAL; CENTRAL-AFRICA;
   AMODIAQUINE
AB Background: The recent reports on the decreasing susceptibility of Plasmodium falciparum to artemisinin derivatives along the Thailand and Myanmar border are worrying. Indeed it may spread to India and then Africa, repeating the same pattern observed for chloroquine resistance. Therefore, it is essential to start monitoring P. falciparum sensitivity to artemisinin derivatives and its partner drugs in Africa. Efficacy of AL and ASAQ were tested by carrying out an in vivo drug efficacy test, with an ex vivo study against six anti-malarial drugs nested into it. Results of the latter are reported here.
   Methods: Plasmodium falciparum ex-vivo susceptibility to chloroquine (CQ), quinine (Q), lumefantrine (Lum), monodesethylamodiaquine (MDA), piperaquine (PPQ) and dihydroartemisinin (DHA) was investigated in children (6 months - 15 years) with a parasitaemia of at least >= 4,000/mu l. The modified isotopic microtest technique was used. The results of cellular proliferation were analysed using ICEstimator software to determine the 50% inhibitory concentration (IC50) values.
   Results: DHA was the most potent among the 6 drugs tested, with IC50 values ranging from 0.8 nM to 0.9 nM (Geometric mean IC50 = 0.8 nM; 95% CI [0.8 - 0.9]). High IC50 values ranged between 0.8 nM to 166.1 nM were reported for lumefantrine (Geometric mean IC50 = 25.1 nM; 95% CI [22.4 - 28.2]). MDA and Q IC50s were significantly higher in CQ-resistant than in CQ-sensitive isolates (P = 0.0001). However, the opposite occurred for Lum and DHA (P < 0.001). No difference was observed for PPQ.
   Conclusion: Artemisinin derivatives are still very efficacious in Burkina Faso and DHA-PPQ seems a valuable alternative ACT. The high lumefantrine IC50 found in this study is worrying as it may indicate a decreasing efficacy of one of the first-line treatments. This should be further investigated and monitored over time with large in vivo and ex vivo studies that will include also plasma drug measurements.
C1 [Tinto, Halidou; Bonkian, Lea N.; Valea, Innocent; Kpoda, Herve; Guiguemde, Tinga Robert; Ouedraogo, Jean Bosco] Ctr Muraz, Unite Rech Paludisme & Malad Trop Negligees, Bobo Dioulasso, Burkina Faso.
   [Tinto, Halidou; Sorgho, Hermann; Ouedraogo, Jean Bosco] IRSS DRO, Bobo Dioulasso, Burkina Faso.
   [Tinto, Halidou; Nana, Louis A.; Yerbanga, Isidore; Lingani, Moussa; Kazienga, Adama; Valea, Innocent; Sorgho, Hermann; Guiguemde, Tinga Robert] Clin Res Unit Nanoro IRSS CRUN, Nanoro, Burkina Faso.
   [Guiguemde, Tinga Robert] Inst Super Sci Sante INSSA, Bobo Dioulasso, Burkina Faso.
   [Mens, Petronella F.; Schallig, Henk] KIT, Royal Trop Inst, Amsterdam, Netherlands.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [D'Alessandro, Umberto] Prince Leopold Inst Trop Med, Antwerp, Belgium.
RP Sorgho, H (reprint author), IRSS DRO, Bobo Dioulasso, Burkina Faso.
EM hsorgho@hotmail.com
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU European Union Framework Program 7 (FP7)
FX This study was funded by the European Union Framework Program 7 (FP7)
   through the grant attributed to the MALACTRES Project
   (www.malactres.eu).
CR Anderson T, 2009, PLOS MED, V6, P2
   Aubouy A, 2004, AM J TROP MED HYG, V71, P294
   Barennes H, 2004, TROP MED INT HEALTH, V9, P438, DOI 10.1111/j.1365-3156.2004.01224.x
   Basco LK, 2007, AM J TROP MED HYG, V76, P20
   Basco LK, 2003, ANTIMICROB AGENTS CH, V47, P1391, DOI 10.1128/AAC.47.4.1391-1394.2003
   Basco LK, 2002, AM J TROP MED HYG, V66, P117
   Borrmann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026005
   Brasseur P, 1999, T ROY SOC TROP MED H, V93, P645, DOI 10.1016/S0035-9203(99)90083-4
   DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Fall B, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-107
   Fall B, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-310
   Four T, 2011, PLOS MED, V8
   Fule Ritesh, 2013, Journal of Pharmaceutical Investigation, V43, P305, DOI 10.1007/s40005-013-0078-z
   Gansane A, 2009, Bull Soc Pathol Exot, V102, P31, DOI 10.3185/pathexo3235
   Gharbi M, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-35
   Gorissen E, 2000, TROP MED INT HEALTH, V5, P459, DOI 10.1046/j.1365-3156.2000.00570.x
   Kublin JG, 2003, J INFECT DIS, V187, P1870, DOI 10.1086/375419
   Lim P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-11
   Maude RJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-31
   Mwai L, 2009, ANTIMICROB AGENTS CH, V53, P5069, DOI 10.1128/AAC.00638-09
   Na-Bangchang K, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-273
   Noedl H, 2010, CLIN INFECT DIS, V51, P82
   Nsobya SL, 2010, ANTIMICROB AGENTS CH, V54, P1200, DOI 10.1128/AAC.01412-09
   Ouedraogo JB, 2003, TROP MED INT HEALTH, V3, P159
   Pascual A, 2012, MALARIA J, V11, P9
   Pettinelli FO, 2004, AM J TROP MED HYG, V70, P635
   Pradines B, 1998, J ANTIMICROB CHEMOTH, V42, P333, DOI 10.1093/jac/42.3.333
   Pradines B, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-268
   Ringwald P, 1999, J CLIN MICROBIOL, V37, P700
   Rogers WO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-10
   Shretta R, 2000, TROP MED INT HEALTH, V5, P755, DOI 10.1046/j.1365-3156.2000.00643.x
   Sibley CH, 2010, TRENDS PARASITOL, V26, P221, DOI 10.1016/j.pt.2010.02.008
   Siribie M, 2012, Bull Soc Pathol Exot, V105, P202, DOI 10.1007/s13149-012-0209-6
   Staedke SG, 2001, LANCET, V358, P368, DOI 10.1016/S0140-6736(01)05557-X
   Tinto H, 2006, T ROY SOC TROP MED H, V100, P509, DOI 10.1016/j.trstmh.2005.09.018
   Tinto H, 2002, TROP MED INT HEALTH, V7, P925, DOI 10.1046/j.1365-3156.2002.00952.x
   White NJ, 1998, ANN TROP MED PARASIT, V92, P449
   World Health Organization, 2011, WHO TECHNICAL REPORT, P193
   World Health Organization, 2010, GUID TREATM MAL, P166
   World Health Organization, 2007, GLOB TUB CONTR SURV, P23
   Witkowski B, 2013, LANCET INFECT DIS, V13, P1043, DOI 10.1016/S1473-3099(13)70252-4
   Woitsch B, 2007, WIEN KLIN WOCHENSCHR, V122, P76
   Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6
   Zongo I, 2007, CLIN INFECT DIS, V45, P1453, DOI 10.1086/522985
   Zongo I, 2007, LANCET, V369, P491, DOI 10.1016/S0140-6736(07)60160-3
   Zwang J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-203
NR 47
TC 7
Z9 7
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAY 31
PY 2014
VL 13
AR 207
DI 10.1186/1475-2875-13-207
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AL1OZ
UT WOS:000338896100001
PM 24885950
OA gold
DA 2017-08-15
ER

PT J
AU Shimakawa, Y
   Bottomley, C
   Njie, R
   Mendy, M
AF Shimakawa, Yusuke
   Bottomley, Christian
   Njie, Ramou
   Mendy, Maimuna
TI The association between maternal hepatitis B e antigen status, as a
   proxy for perinatal transmission, and the risk of hepatitis B e
   antigenaemia in Gambian children
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Hepatitis B; Hepatitis B e antigens; Infectious disease transmission;
   Vertical; Age factors; Africa
ID HEPATOCELLULAR-CARCINOMA; VIRUS-INFECTION; WEST-AFRICA; HBEAG
   SEROCONVERSION; CHRONIC CARRIERS; HBV; VACCINATION; AGE; IMMUNIZATION;
   MUTATIONS
AB Background: Early age at infection with hepatitis B virus (HBV) increases the risk of chronic HBV infection. In addition early age at infection may further increase the risk of persistent viral replication beyond its effect on chronicity. The effects of perinatal and early postnatal transmission on the risk of prolonged hepatitis B e antigenaemia in children with chronic HBV infection are not well documented in Africa. We examine these associations using maternal HBV sero-status and the number of HBV-positive older siblings as proxy measures for perinatal and early postnatal transmission, respectively.
   Methods: Hepatitis B e antigen (HBeAg)-positive mothers were identified in six population-based HBV sero-surveys conducted in The Gambia between 1986 and 1990. For every HBeAg-positive mother, a hepatitis B surface antigen (HBsAg)-positive HBeAg-negative mother and HBsAg-negative mother were randomly selected from the population surveyed. These mothers and their family members were tested for HBV sero-markers in a subsequent survey conducted between 1991 and 1993.
   Results: Thirty-eight HBeAg positive mothers and the same number of HBsAg-positive HBeAg-negative mothers and HBsAg-negative mothers participated in the study. Sixty-nine percent of their children also participated. There was a non-significant positive association between HBeAg prevalence in children and the number of HBeAg-positive older siblings (64.1%, 69.2% and 83.3% in children with 0, 1 and >= 2 HBeAg-positive older siblings, respectively). After adjusting for confounders, having an HBeAg-positive mother was a risk factor for HBeAg positivity in children carrying HBsAg (adjusted OR 4.5, 95% CI: 1.0-19.5, p = 0.04), whilst the number of HBeAg-positive older siblings was not.
   Conclusions: Maternal HBeAg was associated with positive HBeAg in children with chronic HBV infection. This suggests that interrupting mother-to-infant transmission in sub-Saharan Africa might help reduce the burden of liver disease. A timely dose of HBV vaccine within 24 hours of birth, as recommended by WHO, should be implemented in sub-Saharan Africa.
C1 [Shimakawa, Yusuke; Njie, Ramou] Med Res Council MRC Unit, Banjul, Gambia.
   [Shimakawa, Yusuke; Bottomley, Christian] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England.
   [Njie, Ramou] MRC Unit, IARC, Gambia Hepatitis Intervent Study, Banjul, West Africa, Gambia.
   [Mendy, Maimuna] Int Agcy Res Canc, F-69372 Lyon 08, France.
RP Shimakawa, Y (reprint author), Med Res Council MRC Unit, Atlantic Blvd,POB 273, Banjul, Gambia.
EM yshimakawa@mrc.gm
FU Gambia Government; WHO/IARC; MRC
FX The authors would thank the Gambia Government, WHO/IARC and MRC which
   supported the study. We also thank Prof Andrew Hall, Prof Hilton Whittle
   and Dr Abdoulie Jack who initiated the study. Finally, we acknowledge
   all the study participants in this study.
CR Barin F, 1981, Prog Med Virol, V27, P148
   BEASLEY RP, 1982, HEPATOLOGY, V2, pS21
   BOTHA JF, 1984, LANCET, V1, P1210
   CHANG MH, 1989, J PEDIATR-US, V115, P385, DOI 10.1016/S0022-3476(89)80836-4
   Chen DS, 2009, J HEPATOL, V50, P805, DOI 10.1016/j.jhep.2009.01.002
   Chen HL, 2012, GASTROENTEROLOGY, V142, P773, DOI 10.1053/j.gastro.2011.12.035
   Chu CJ, 2002, GASTROENTEROLOGY, V122, P1756, DOI 10.1053/gast.2002.33588
   Cui FQ, 2013, VACCINE, V31, pJ36, DOI 10.1016/j.vaccine.2012.11.061
   Dumpis U, 2001, J MED VIROL, V65, P664, DOI 10.1002/jmv.2088
   Edmunds WJ, 1996, EPIDEMIOL INFECT, V117, P313
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197
   Gambia Hepatitis Study Group, 1987, CANCER RES, V47, P5782
   Gouas DA, 2012, CARCINOGENESIS, V33, P1219, DOI [10.1093/carcin/bgs068, 10.1093/carcin/bgs135]
   Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008
   Hadziyannis SJ, 2011, J HEPATOL, V55, P183, DOI 10.1016/j.jhep.2010.12.030
   HALL AJ, 1989, LANCET, V1, P1057
   Hopkirk N, 2000, NEW ZEAL MED J, V113, P114
   HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1115
   IARC, 2011, IARC MONOGR EVAL C B, V100B, P1
   Kojima M, 1985, ACTA HEPATOL JPN, V26, P1139
   Kramvis A, 2007, HEPATOL RES, V37, pS9, DOI 10.1111/j.1872-034X.2007.00098.x
   Kramvis A, 2010, VACCINE, V28, P6408, DOI 10.1016/j.vaccine.2010.07.042
   LAROUZE B, 1976, LANCET, V2, P534
   MAYANS MV, 1990, LANCET, V336, P1107
   Mendy M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058029
   Mendy ME, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-49
   Ni YH, 2012, J HEPATOL, V57, P730, DOI [10.1016/j.jhep.2012.05.021, 10.1016/j.jhep.2012.06.032]
   Olinger CM, 2006, J GEN VIROL, V87, P1163, DOI 10.1099/vir.0.81614-0
   RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122
   Shimakawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069430
   Soderstrom A, 2002, J PEDIATR GASTR NUTR, V35, P487, DOI 10.1097/00005176-200210000-00006
   Tseng YR, 2011, LIVER INT, V31, P1373, DOI 10.1111/j.1478-3231.2011.02574.x
   Villar S, 2011, ENVIRON HEALTH PERSP, V119, P1635, DOI 10.1289/ehp.1103539
   WHEELEY SM, 1989, J HEPATOL, V8, P226, DOI 10.1016/0168-8278(89)90011-1
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WHITTLE HC, 1983, LANCET, V1, P1203
   WHO, 2013, WKLY EPIDEMIOL REC, V88, P482
   WHO, 2009, WKLY EPIDEMIOL REC, V84, P405
   Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215
NR 40
TC 9
Z9 9
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD MAY 30
PY 2014
VL 14
AR 532
DI 10.1186/1471-2458-14-532
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AL2ME
UT WOS:000338958900001
PM 24885392
OA gold
DA 2017-08-15
ER

PT J
AU Le Doare, K
   Kampmann, B
AF Le Doare, Kirsty
   Kampmann, Beate
TI Breast milk and Group B streptococcal infection: Vector of transmission
   or vehicle for protection?
SO VACCINE
LA English
DT Review
DE Group-B streptococcus; Breast milk; Immunity; Antibody; Vaccination
ID MOTHERS OWN MILK; ESCHERICHIA-COLI; MATERNAL IMMUNIZATION; FED INFANTS;
   LATE-ONSET; HAEMOPHILUS-INFLUENZAE; MONOCLONAL-ANTIBODIES;
   IMMUNE-RESPONSES; VIBRIO-CHOLERAE; HUMAN COLOSTRUM
AB Invasive Group-B streptococcal (GBS) disease is a leading cause of infant mortality and morbidity worldwide. GBS colonises the maternal rectum and vagina and transmission of bacteria from a colonized mother to her infant at birth is an important risk factor for GBS disease. GBS disease has also been associated with case reports of transmission via infected breast milk raising questions about mode of acquisition and transmission of this enteric pathogen and the development of neonatal disease. However, most breastfed infants remain unaffected by GBS in breast milk. Mechanisms associated with transmission of GBS in breast milk and potential factors that may protect the infant from transmission remain poorly understood. Understanding factors involved in protection or transmission of GBS infection via breast milk is important both for premature infants who are a high-risk group and for infants in the developing world where breastfeeding is the only sustainable infant feeding option. In this review we discuss the proposed mechanisms for GBS colonization in breast milk on one hand and its immune factors that may protect from transmission of GBS from mother to infant on the other. Innate and adaptive immune factors, including serotype-specific antibody and their significance in the prevention of infant disease are presented. We further report on the role of human oligosaccharides in protection from invasive GBS disease. Advances in our knowledge about breast milk and immunity in GBS disease are needed to fully appreciate what might mitigate transmission from mother to infant and protect neonates from this devastating disease and to contribute to the development of novel prevention strategies, including maternal immunization to prevent infant disease. (C) 2014 The Authors. Published by Elsevier Ltd.
C1 [Le Doare, Kirsty; Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, St Marys Hosp, London W2 1NY, England.
   [Le Doare, Kirsty] Wellcome Trust Ctr Global Hlth Res, London, England.
   [Le Doare, Kirsty; Kampmann, Beate] Vaccinol Theme, MRC Unit, Fajara, Gambia.
RP Le Doare, K (reprint author), Wellcome Trust Ctr Global Hlth Res, Norfolk Pl, London, England.
EM kirstyledoare@gmail.com; b.kampmann@imperial.ac.uk
OI le doare, kirsty/0000-0002-5104-085X
FU Imperial College Biomedical Research Centre (BRC)
FX We acknowledge the support of the Imperial College Biomedical Research
   Centre (BRC) for our work.
CR Albesharat R, 2011, SYST APPL MICROBIOL, V34, P148, DOI 10.1016/j.syapm.2010.12.001
   ANDERSSON B, 1986, J INFECT DIS, V153, P232
   ANIANSSON G, 1990, MICROB PATHOGENESIS, V8, P315, DOI 10.1016/0882-4010(90)90090-D
   BAKER CJ, 1973, J PEDIATR-US, V82, P724, DOI 10.1016/S0022-3476(73)80606-7
   Bedford H, 2001, BRIT MED J, V323, P533, DOI 10.1136/bmj.323.7312.533
   Berardi A, 2013, J PEDIATR-US, V163, P1099, DOI 10.1016/j.jpeds.2013.05.064
   Bergeron MG, 2000, NEW ENGL J MED, V343, P175, DOI 10.1056/NEJM200007203430303
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Brandtzaeg P, 2007, VACCINE, V25, P5467, DOI 10.1016/j.vaccine.2006.12.001
   Burianova I, 2013, J HUM LACT, V29, P586, DOI 10.1177/0890334413479448
   BUTTER MNW, 1967, A VAN LEEUW J MICROB, V33, P439, DOI 10.1007/BF02045596
   Christen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085867
   Cossey V, 2013, NEONATOLOGY, V103, P170, DOI 10.1159/000345419
   CRAVIOTO A, 1991, J INFECT DIS, V163, P1247
   CRUZ JR, 1988, ACTA PAEDIATR SCAND, V77, P658, DOI 10.1111/j.1651-2227.1988.tb10726.x
   Dagnew AF, 2012, CLIN INFECT DIS, V55, P91, DOI 10.1093/cid/cis395
   Darmstadt GL, 2009, J INFECT DIS, V200, P906, DOI 10.1086/605473
   Davanzo R, 2013, J HUM LACT, V29, P452, DOI 10.1177/0890334413480427
   Dickinson EC, 1998, SURGERY, V124, P284, DOI 10.1016/S0039-6060(98)70132-1
   Eden C S, 1979, Lancet, V2, P1235
   Edmond K, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000213
   Edwards MS, 2004, PEDIATR INFECT DIS J, V23, P961, DOI 10.1097/01.inf.0000142333.72511.8c
   EVANS TJ, 1978, ARCH DIS CHILD, V53, P239
   Ewaschuk JB, 2011, J PERINATOL, V31, P593, DOI 10.1038/jp.2010.209
   Filleron A, 2013, ARCH DIS CHILD FETAL, V99
   Fluegge K, 2006, PEDIATRICS, V117, pE1139, DOI 10.1542/peds.2005-2481
   Fry RM, 1938, LANCET, V1, P199
   Gagneur A, 2009, EUR J PEDIATR, V168, P1155, DOI 10.1007/s00431-008-0903-y
   Goldman A, 2002, FETAL NEONATAL PHYSL, V2, P2022
   Goldman AS, 2000, J NUTR, V130, P426
   GRAY BM, 1988, PEDIATR RES, V24, P68, DOI 10.1203/00006450-198807000-00017
   Gray KJ, 2007, EMERG INFECT DIS, V13, P223
   HAHNZORIC M, 1993, PEDIATR RES, V33, P475, DOI 10.1203/00006450-199305000-00011
   Hanson Lars A, 2002, Semin Neonatol, V7, P275, DOI 10.1016/S1084-2756(02)90124-7
   Heath PGT, 2004, LANCET, V363, P292, DOI 10.1016/S0140-6736(03)15389-5
   HEIMAN HS, 1989, PEDIATR RES, V26, P629, DOI 10.1203/00006450-198912000-00023
   HOLMGREN J, 1981, INFECT IMMUN, V33, P136
   HOOD M, 1961, AM J OBSTET GYNECOL, V82, P809
   ISAACS CE, 1995, J NUTR BIOCHEM, V6, P362, DOI 10.1016/0955-2863(95)00048-5
   JATSYK GV, 1985, ACTA PAEDIATR SCAND, V74, P246, DOI 10.1111/j.1651-2227.1985.tb10958.x
   Jeurink PV, 2013, BENEF MICROBES, V4, P17, DOI 10.3920/BM2012.0040
   Jones CA, 2001, J PAEDIATR CHILD H, V37, P576, DOI 10.1046/j.1440-1754.2001.00743.x
   Jones N, 2006, J CLIN PATHOL, V59, P363, DOI 10.1136/jcp.2005.029058
   Kalliola S, 1999, PEDIATR INFECT DIS J, V18, P806, DOI 10.1097/00006454-199909000-00012
   Kobata A, 2010, P JPN ACAD B-PHYS, V86, P731, DOI 10.2183/pjab.86.731
   Kotiw M, 2003, PEDIATR DEVEL PATHOL, V6, P251, DOI 10.1007/s10024-001-0276-y
   KRAKAUER R, 1975, AM J GASTROENTEROL, V64, P319
   KUBIN V, 1987, ZBL BAKT-INT J MED M, V265, P210
   Kuruvilla KA, 1999, ACTA PAEDIATR, V88, P1031, DOI 10.1080/08035259950168577
   Kvist LJ, 2008, INT BREASTFEED J, V3, DOI 10.1186/1746-4358-3-6
   Labbok MH, 2004, NAT REV IMMUNOL, V4, P565, DOI 10.1038/nri1393
   LAGERGARD T, 1992, EUR J PEDIATR, V151, P98, DOI 10.1007/BF01958951
   Lancefield RC, 1935, J EXP MED, V61, P335, DOI 10.1084/jem.61.3.335
   Lawrence RM, 2004, CLIN PERINATOL, V31, P501, DOI 10.1016/j.clp.2004.03.019
   LeBouder E, 2006, J IMMUNOL, V176, P3742
   Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075
   Lim N L, 1995, Med J Malaysia, V50, P59
   Morrow AL, 2004, ADV EXP MED BIOL, V554, P443
   Munoz FM, 2001, VACCINE, V20, P826, DOI 10.1016/S0264-410X(01)00397-8
   Neto MT, 2008, ARCH DIS CHILD-FETAL, V93, pF90, DOI 10.1136/adc.2007.127464
   Newburg DS, 2007, PEDIATR RES, V61, P2, DOI 10.1203/01.pdr.0000250274.68571.18
   Nocard N, 1887, ANN I PASTEUR, V1, P109
   Olver WJ, 2000, ARCH DIS CHILD, V83, pF48, DOI 10.1136/fn.83.1.F48
   OTNAESS ABK, 1983, INFECT IMMUN, V40, P563
   Perez PF, 2007, PEDIATRICS, V119, pE724, DOI 10.1542/peds.2006-1649
   Phares CR, 2008, JAMA-J AM MED ASSOC, V299, P2056, DOI 10.1001/jama.299.17.2056
   Prevention CfDCa, 2012, ACT BACT COR SURV RE, V2012
   PRITCHARD DG, 1992, INFECT IMMUN, V60, P1598
   RUIZPALACIOS GM, 1990, J PEDIATR-US, V116, P707, DOI 10.1016/S0022-3476(05)82652-6
   Schanler RJ, 2005, PEDIATRICS, V116, P400, DOI 10.1542/peds.2004-1974
   Serafini AB, 2003, REV SAUDE PUBL, V37, P775, DOI 10.1590/S0034-89102003000600013
   Shahid NS, 2002, VACCINE, V20, P2404, DOI 10.1016/S0264-410X(02)00061-0
   Sigauque B, 2009, PEDIATR INFECT DIS J, V28, P108, DOI 10.1097/INF.0b013e318187a87d
   STEPHENS S, 1984, ACTA PAEDIATR SCAND, V73, P426, DOI 10.1111/j.1651-2227.1984.tb09950.x
   Van de Perre P, 2003, VACCINE, V21, P3374, DOI 10.1016/S0264-410X(03)00336-0
   Vassilev TL, 1996, SCAND J IMMUNOL, V44, P535, DOI 10.1046/j.1365-3083.1996.d01-333.x
   Verani JR, 2010, MMWR RECOMM REP, V19, P1
   WALTERSPIEL JN, 1994, PEDIATRICS, V93, P28
   Weaver LTWN, 1991, PEDIAT ALLERGY IMMUN, V2, P2
   Weisman L E, 1991, Adv Exp Med Biol, V310, P345
   Weisner AM, 2004, CLIN INFECT DIS, V38, P1203, DOI 10.1086/382881
   WILKINSON HW, 1975, INFECT IMMUN, V11, P845
   Zangwill Kenneth M., 1992, Morbidity and Mortality Weekly Report, V41, P25
NR 83
TC 12
Z9 13
U1 2
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 30
PY 2014
VL 32
IS 26
BP 3128
EP 3132
DI 10.1016/j.vaccine.2014.04.020
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI4YL
UT WOS:000336872500003
PM 24736004
OA No
DA 2017-08-15
ER

PT J
AU Atkinson, SH
   Armitage, AE
   Khandwala, S
   Mwangi, TW
   Uyoga, S
   Bejon, PA
   Williams, TN
   Prentice, AM
   Drakesmith, H
AF Atkinson, Sarah H.
   Armitage, Andrew E.
   Khandwala, Shivani
   Mwangi, Tabitha W.
   Uyoga, Sophie
   Bejon, Philip A.
   Williams, Thomas N.
   Prentice, Andrew M.
   Drakesmith, Hal
TI Combinatorial effects of malaria season, iron deficiency, and
   inflammation determine
SO BLOOD
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; TRANSFERRIN RECEPTOR LEVELS; SERUM
   HEPCIDIN; AFRICAN CHILDREN; CHRONIC DISEASE; WEST-AFRICA; ANEMIA;
   TRANSMISSION; INFECTION; KENYA
AB Hepcidin is the master regulatory hormone that governs iron homeostasis and has a role in innate immunity. Although hepcidin has been studied extensively in model systems, there is less information on hepcidin regulation in global health contexts where iron deficiency (ID), anemia, and high infectious burdens (including malaria) all coexist but fluctuate over time. We evaluated iron status, hepcidin levels, and determinants of hepcidin in 2 populations of rural children aged <= 8 years, in the Gambia and Kenya (total n = 848), at the start and end of a malaria season. Regression analyses and structural equation modeling demonstrated, for both populations, similar combinatorial effects of upregulating stimuli (iron stores and to a lesser extent inflammation) and downregulating stimuli (erythropoietic drive) on hepcidin levels. However, malaria season was also a significant factor and was associated with an altered balance of these opposing factors. Consistent with these changes, hepcidin levels were reduced whereas the prevalence of ID was increased at the end of the malaria season. More prevalent ID and lower hepcidin likely reflect an enhanced requirement for iron and an ability to efficiently absorb it at the end of the malaria season. These results, therefore, have implications for ID and malaria control programs.
C1 [Atkinson, Sarah H.] Univ Oxford, Oxford Univ Hosp, Dept Paediat, Oxford, England.
   [Atkinson, Sarah H.] Univ Oxford, Clin Acad Grad Sch, Oxford, England.
   [Atkinson, Sarah H.; Khandwala, Shivani; Mwangi, Tabitha W.; Uyoga, Sophie; Bejon, Philip A.; Williams, Thomas N.] Kilifi Dist Hosp, Ctr Geog Med Res Coast, Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya.
   [Armitage, Andrew E.; Khandwala, Shivani; Drakesmith, Hal] Univ Oxford, Oxford Univ Hosp, MRC, Human Immunol Unit,Weatherall Inst Mol med, Oxford OX1 2JD, England.
   [Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England.
   [Prentice, Andrew M.] Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Prentice, Andrew M.] Med Res Council Keneba, Keneba, Gambia.
RP Atkinson, SH (reprint author), Kilifi Dist Hosp, Ctr Geog Med Res Coast, Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya.
EM satkinson@kemri-wellcome.org; alexander.drakesmith@ndm.ox.ac.uk
FU Career Support Award from Oxford University Clinical Academic Graduate
   School; Academy of Medical Sciences; Wellcome Trust; British Heart
   Foundation; Arthritis Research UK; UK MRC [MC-A760-5QX00]; UK Department
   for International Development (DFID) under the MRC/DFID Concordat
   agreement; Bill and Melinda Gates Foundation Global Health Grant
   (Hepcidin and Iron in Global Health, HIGH Partnership) [OPP1055865];
   Beit Memorial Fellowship for Medical Research; MRC New Investigator
   award; NIHR Oxford Biomedical Research Centre; Wellcome Trust [091758];
   European Union FP7 EVIMalR Consortium
FX This work was supported by a Career Support Award from Oxford University
   Clinical Academic Graduate School and by funding from the Academy of
   Medical Sciences, the Wellcome Trust, the British Heart Foundation, and
   Arthritis Research UK. The research was jointly funded by the UK MRC
   (grant MC-A760-5QX00) and the UK Department for International
   Development (DFID) under the MRC/DFID Concordat agreement, and by a Bill
   and Melinda Gates Foundation Global Health Grant (Hepcidin and Iron in
   Global Health, HIGH Partnership, OPP1055865). During this work, H.D. was
   funded by a Beit Memorial Fellowship for Medical Research, an MRC New
   Investigator award, and NIHR Oxford Biomedical Research Centre. T.N.W.
   is funded by a fellowship from the Wellcome Trust (091758) and by funds
   from the European Union FP7 EVIMalR Consortium.
CR Armitage AE, 2009, BRIT J HAEMATOL, V147, P769, DOI 10.1111/j.1365-2141.2009.07880.x
   Armitage P, 2001, STAT METHODS MED RES, P378
   Atkinson SH, 2008, BLOOD, V112, P4276, DOI 10.1182/blood-2008-06-162008
   Atkinson SH, 2006, PLOS MED, V3, P652, DOI 10.1371/journal.pmed.0030172
   Ayoya M A, 2009, Bull Soc Pathol Exot, V102, P219
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Burte F, 2013, BLOOD, V121, P3016, DOI 10.1182/blood-2012-10-461418
   Casals-Pascual C, 2012, HAEMATOL-HEMATOL J, V97, P1695, DOI 10.3324/haematol.2012.065854
   Cercamondi CI, 2010, AM J CLIN NUTR, V92, P1385, DOI 10.3945/ajcn.2010.30051
   Cherian S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004030
   Choi Hyoung Soo, 2012, Korean J Hematol, V47, P286, DOI 10.5045/kjh.2012.47.4.286
   Darshan D, 2010, HAEMATOL-HEMATOL J, V95, P1660, DOI 10.3324/haematol.2010.022426
   de Mast Q, 2010, HAEMATOL-HEMATOL J, V95, P1068, DOI 10.3324/haematol.2009.019331
   de Mast Q, 2009, BRIT J HAEMATOL, V145, P657, DOI 10.1111/j.1365-2141.2009.07664.x
   de Mast Q, 2009, J INFECT DIS, V199, P253, DOI 10.1086/595790
   Doherty CP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002133
   Finberg KE, 2008, NAT GENET, V40, P569, DOI 10.1038/ng.130
   Galesloot TE, 2011, BLOOD, V117, pE218, DOI 10.1182/blood-2011-02-337907
   Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467
   Grantham-McGregor S, 2001, J NUTR, V131, p649S
   Hay SI, 1998, T ROY SOC TROP MED H, V92, P12, DOI 10.1016/S0035-9203(98)90936-1
   Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3
   Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000290
   Howard CT, 2007, AM J TROP MED HYG, V77, P623
   Huang H, 2009, BLOOD, V113, P3593, DOI 10.1182/blood-2008-08-173641
   Kemna EHJM, 2008, BLOOD CELL MOL DIS, V40, P339, DOI 10.1016/j.bcmd.2007.10.002
   MBOGO CNM, 1995, AM J TROP MED HYG, V52, P201
   McCrae JE, 1996, FOODS RURAL GAMBIA
   Menendez C, 2001, AM J TROP MED HYG, V65, P138
   Mockenhaupt FP, 1999, HAEMATOLOGICA, V84, P869
   Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Nyakeriga AM, 2004, J INFECT DIS, V190, P439, DOI 10.1086/422331
   Prentice AM, 2013, JAMA-J AM MED ASSOC, V310, P914, DOI 10.1001/jama.2013.6771
   Prentice AM, 2012, BLOOD, V119, P1922, DOI 10.1182/blood-2011-11-391219
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Soofi S, 2013, LANCET, V382, P29, DOI 10.1016/S0140-6736(13)60437-7
   Spottiswoode N, 2012, ADV NUTR, V3, P570, DOI 10.3945/an.111.001156
   Theurl I, 2009, BLOOD, V113, P5277, DOI 10.1182/blood-2008-12-195651
   Thurnham D, 2012, INFLUENCE INFECT INF
   Traglia M, 2011, J MED GENET, V48, P629, DOI 10.1136/jmedgenet-2011-100061
   United Nations Children's Fund United Nations University World Health Organization (WHO), 2001, IR DEF AN ASS PREV C
   Veenemans J, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001125
   Verhoef H, 2001, AM J CLIN NUTR, V74, P767
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2
   Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260
   WHO, 2011, HAEM CONC DIAGN AN A
   World Health Organisation, 2004, ASS IR STAT POP INCL
   Yadav D, 2011, INDIAN J PEDIATR, V78, P65, DOI 10.1007/s12098-010-0129-7
NR 49
TC 19
Z9 20
U1 1
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 22
PY 2014
VL 123
IS 21
BP 3221
EP 3229
DI 10.1182/blood-2013-10-533000
PG 9
WC Hematology
SC Hematology
GA AQ2LA
UT WOS:000342616300007
PM 24596418
OA No
DA 2017-08-15
ER

PT J
AU Manyando, C
   Njunju, EM
   Mwakazanga, D
   Chongwe, G
   Mkandawire, R
   Champo, D
   Mulenga, M
   De Crop, M
   Claeys, Y
   Ravinetto, RM
   van Overmeir, C
   D' Alessandro, U
   Van Geertruyden, JP
AF Manyando, Christine
   Njunju, Eric M.
   Mwakazanga, David
   Chongwe, Gershom
   Mkandawire, Rhoda
   Champo, Davies
   Mulenga, Modest
   De Crop, Maaike
   Claeys, Yves
   Ravinetto, Raffaella M.
   van Overmeir, Chantal
   D' Alessandro, Umberto
   Van Geertruyden, Jean-Pierre
TI Safety of Daily Co-Trimoxazole in Pregnancy in an Area of Changing
   Malaria Epidemiology: A Phase 3b Randomized Controlled Clinical Trial
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; HIV-INFECTION;
   TRIMETHOPRIM-SULFAMETHOXAZOLE; SULFADOXINE-PYRIMETHAMINE; PLACENTAL
   MALARIA; PRETERM DELIVERY; WESTERN KENYA; RURAL MALAWI; BIRTH-WEIGHT
AB Introduction: Antibiotic therapy during pregnancy may be beneficial and impacts positively on the reduction of adverse pregnancy outcomes. No studies have been done so far on the effects of daily Co-trimoxazole (CTX) prophylaxis on birth outcomes. A phase 3b randomized trial was conducted to establish that daily (TX in pregnancy is not inferior to SP intermittent preventive treatment (PT) in reducing placental malaria; preventing peripheral parasitaemia; preventing perinatal mortality and also improving birth weight. To establish its safety on the offspring by measuring the gestational age and birth weight at delivery, and compare the safety and efficacy profile of CTX to that of SP
   Methods: Pregnant women (HIV infected and uninfected) attending antenatal clinic were randomized to receive either daily CTX or sulfadoxine-pyrimethamine as per routine IPT. Safety was assessed using standard and pregnancy specific measurements. Women were followed up monthly until delivery and then with their offspring up to six weeks after delivery.
   Results: Data from 346 pregnant women (CTX = 190; SP = 156) and 311 newborns (CTX = 166 and SP = 145) showed that preterm deliveries (CTX 3.6%; SP 3.0%); still births (CTX 3.0%; SP 2.1%), neonatal deaths (CTX 0%; SP 1.4%), and spontaneous abortions (CTX 0.6%; SP 0%) were similar between study arms. The low birth weight rates were 9% for CTX and 13% for SP. There were no birth defects reported. Both drug exposure groups had full term deliveries with similar birth weights (mean of 3.1 Kg). The incidence and severity of AEs in the two groups were comparable.
   Conclusion: Exposure to daily CTX in pregnancy may not be associated with particular safety risks in terms of birth outcomes such as preterm deliveries, still births, neonatal deaths and spontaneous abortions compared to SP. However, more data are required on CTX use in pregnant women both among HIV infected and un-infected individuals.
C1 [Manyando, Christine; Njunju, Eric M.; Mwakazanga, David; Chongwe, Gershom; Champo, Davies; Mulenga, Modest] Trop Dis Res Ctr, Ndola, Zambia.
   [Mkandawire, Rhoda] Choma Dist Hlth Management Team, Choma, Zambia.
   [De Crop, Maaike; Claeys, Yves; Ravinetto, Raffaella M.; van Overmeir, Chantal; D' Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
   [D' Alessandro, Umberto] MRC, Fajara, Gambia.
   [Manyando, Christine; Njunju, Eric M.; Van Geertruyden, Jean-Pierre] Univ Antwerp, Int Hlth Unit, B-2020 Antwerp, Belgium.
   [Ravinetto, Raffaella M.] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium.
RP Manyando, C (reprint author), Trop Dis Res Ctr, Ndola, Zambia.
EM cmanyando@yahoo.com
RI Van geertruyden, Jean-pierre/K-6425-2014; D'Alessandro,
   Umberto/D-3457-2015
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364; D'Alessandro,
   Umberto/0000-0001-6341-5009
FU Belgian Development Cooperation
FX The study was funded under a program for institutional capacity
   strengthening, funded by the Belgian Development Cooperation and
   coordinated by the Institute of Tropical Medicine in Antwerp. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR ALLEN S, 1991, J INFECT DIS, V164, P67
   ALTMAN DG, 1995, BRIT MED J, V311, P485
   Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1
   Ayisi JG, 2003, AIDS, V17, P585, DOI 10.1097/01.aids.0000042977.95433.37
   BLOLAND PB, 1995, AIDS, V9, P721, DOI 10.1097/00002030-199507000-00009
   Brentlinger PE, 2006, LANCET INFECT DIS, V6, P100, DOI 10.1016/S1473-3099(06)70383-8
   Chizema-Kawesha E, 2010, AM J TROP MED HYG, V83, P480, DOI 10.4269/ajtmh.2010.10-0035
   Cot M, 2003, BRIT MED BULL, V67, P137, DOI 10.1093/bmb/ldg003
   Czeizel AE, 2001, REPROD TOXICOL, V15, P637, DOI 10.1016/S0890-6238(01)00178-2
   Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603
   Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204
   Juarez-Vazquez J, 2002, BJOG-INT J OBSTET GY, V109, P1009, DOI 10.1016/S1470-0328(02)01378-2
   Manyando C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056916
   Manyando C, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-249
   Marti-Carvajal V, 2004, ARCH LATINOAMNUTRI, V54, P45
   Masaninga F, 2012, MALAR J, V11
   Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5
   Meshnick SR, 2006, J INFECT DIS, V194, P273, DOI 10.1086/505087
   Nosten F, 1999, LANCET, V354, P546, DOI 10.1016/S0140-6736(98)09247-2
   Omar SA, 2001, T ROY SOC TROP MED H, V95, P657, DOI 10.1016/S0035-9203(01)90107-5
   Parise ME, 1998, AM J TROP MED HYG, V59, P813
   Peters PJ, 2007, DRUG SAFETY, V30, P481, DOI 10.2165/00002018-200730060-00003
   Shulman CE, 2003, T ROY SOC TROP MED H, V97, P30, DOI 10.1016/S0035-9203(03)90012-5
   Siega-Riz AM, 2004, AM J OBSTET GYNECOL, V191, P1851, DOI 10.1016/j.ajog.2004.07.076
   Steketee RW, 1996, AM J TROP MED HYG, V55, P33
   Steketee RW, 1996, AM J TROP MED HYG, V55, P42
   Ter Kuile FO, 2004, AM J TROP MED HYG, V71, P41
   Thera MA, 2005, J INFECT DIS, V192, P1823, DOI 10.1086/498249
   Ticconi C, 2003, JAIDS-J ACQ IMM DEF, V34, P289, DOI 10.1097/00126334-200311010-00005
   van Eijk AM, 2002, T ROY SOC TROP MED H, V96, P586, DOI 10.1016/S0035-9203(02)90319-6
   Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35
   Verhoeff FH, 1999, TROP MED INT HEALTH, V4, P5, DOI 10.1046/j.1365-3156.1999.00349.x
   Verhoeff FH, 1998, ANN TROP MED PARASIT, V92, P141
   Walter J, 2006, J INFECT DIS, V194, P1510, DOI 10.1086/508996
   Whitty CJM, 2005, BJOG-INT J OBSTET GY, V112, P1189, DOI 10.1111/j.1471-0528.2005.00714.x
   WHO, 2012, WORLD MALARIA REPORT 2012, P1
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   World Health Organization (WHO), 2006, GUID COTR PROPH HIV
   World Health Organization, 2007, ASS SAF ART COMP PRE
   Roll Back Malaria Partnership, 2006, ROLL BACK MAL PARTN
   World Health Organization, 2012, INT PREV TREATM MAL
   World Health Organization, ASS SAF ART COMP PRE
NR 44
TC 5
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2014
VL 9
IS 5
AR e96017
DI 10.1371/journal.pone.0096017
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI3UI
UT WOS:000336789500012
PM 24830749
OA gold
DA 2017-08-15
ER

PT J
AU Pasricha, SR
   Atkinson, SH
   Armitage, AE
   Khandwala, S
   Veenemans, J
   Cox, SE
   Eddowes, LA
   Hayes, T
   Doherty, CP
   Demir, AY
   Tijhaar, E
   Verhoef, H
   Prentice, AM
   Drakesmith, H
AF Pasricha, Sant-Rayn
   Atkinson, Sarah H.
   Armitage, Andrew E.
   Khandwala, Shivani
   Veenemans, Jacobien
   Cox, Sharon E.
   Eddowes, Lucy A.
   Hayes, Theodore
   Doherty, Conor P.
   Demir, Ayse Y.
   Tijhaar, Edwin
   Verhoef, Hans
   Prentice, Andrew M.
   Drakesmith, Hal
TI Expression of the Iron Hormone Hepcidin Distinguishes Different Types of
   Anemia in African Children
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; DEFICIENCY ANEMIA; CHRONIC DISEASE; SERUM
   HEPCIDIN; ROUND-ROBIN; FERRITIN; MALARIA; SUPPLEMENTATION; HOMEOSTASIS;
   HEMOGLOBIN
AB Childhood anemia is a major global health problem resulting from multiple causes. Iron supplementation addresses iron deficiency anemia but is undesirable for other types of anemia and may exacerbate infections. The peptide hormone hepcidin governs iron absorption; hepcidin transcription is mediated by iron, inflammation, and erythropoietic signals. However, the behavior of hepcidin in populations where anemia is prevalent is not well established. We show that hepcidin measurements in 1313 African children from The Gambia and Tanzania (samples taken in 2001 and 2008, respectively) could be used to identify iron deficiency anemia. A retrospective secondary analysis of published data from 25 Gambian children with either postmalarial or nonmalarial anemia demonstrated that hepcidin measurements identified individuals who incorporated >20% oral iron into their erythrocytes. Modeling showed that this sensitivity of hepcidin expression at the population level could potentially enable simple groupings of individuals with anemia into iron-responsive and non-iron-responsive subtypes and hence could guide iron supplementation for those who would most benefit.
C1 [Pasricha, Sant-Rayn; Armitage, Andrew E.; Khandwala, Shivani; Eddowes, Lucy A.; Hayes, Theodore; Drakesmith, Hal] Univ Oxford, MRC, John Radcliffe Hosp, Weatherall Inst Mol Med,Human Immunol Unit, Oxford OX3 9DS, England.
   [Atkinson, Sarah H.] Univ Oxford, Oxford Univ Hosp, Dept Paediat, Oxford OXS 9DU, England.
   [Atkinson, Sarah H.] Oxford Univ Clin Acad Grad Sch, Oxford OX3 9DU, England.
   [Atkinson, Sarah H.] Ctr Geog Med Res Coast, Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi 23080108, Kenya.
   [Veenemans, Jacobien; Tijhaar, Edwin; Verhoef, Hans] Wageningen Univ, Cell Biol & Immunol Grp, NL-6700 AH Wageningen, Netherlands.
   [Cox, Sharon E.; Verhoef, Hans; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Cox, Sharon E.; Verhoef, Hans; Prentice, Andrew M.] MRC Keneba, Keneba, Gambia.
   [Doherty, Conor P.] Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland.
   [Demir, Ayse Y.] Meander Med Ctr, Lab Clin Chem & Haematol, NL-3800 BM Amersfoort, Netherlands.
RP Prentice, AM (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
EM andrew.prentice@lshtm.ac.uk; hdrakes@hammer.imm.ox.ac.uk
RI ; Verhoef, Hans/L-3024-2015
OI Cox, Sharon/0000-0002-9908-2936; Verhoef, Hans/0000-0002-9346-9689;
   Pasricha, Sant-Rayn/0000-0002-5502-0434
FU National Health and Medical Research Council Early Career Fellowship
   (Australia); Haematology Society of Australia; New Zealand New
   Investigator Award; MRC/Oxford University Clinical Academic Graduate
   School/Academy of Medical Sciences; Wellcome Trust; INSTAPA project;
   European Union's Seventh Framework Programme [211484]; MRC UK;
   Netherlands Organisation for Scientific Research/WOTRO [W93-413,
   WAO93-441]; United Nations International Children's Emergency Fund;
   Cornelis Visser Foundation; Wageningen University (Interdisciplinary
   Research and Education Fund); Wellcome Trust [094780]; MRC UK
   [MC-A760-5QX00]; NIHR Oxford Biomedical Research Centre; Bill and
   Melinda Gates Foundation ("Hepcidin and Iron in Global Health")
   [OPP1055865]
FX Supported by a National Health and Medical Research Council Early Career
   Fellowship (Australia) and the Haematology Society of Australia and New
   Zealand New Investigator Award (S.-R.P.), MRC/Oxford University Clinical
   Academic Graduate School/Academy of Medical Sciences (S. H. A.), The
   Wellcome Trust (S. E. C.), INSTAPA project and European Union's Seventh
   Framework Programme (FP7/2007-2013, no. 211484) (H. V.), the MRC UK (A.
   E. A., A. M. P., and H. D.), and The Netherlands Organisation for
   Scientific Research/WOTRO (grants W93-413 and WAO93-441), United Nations
   International Children's Emergency Fund, Cornelis Visser Foundation and
   Wageningen University (Interdisciplinary Research and Education Fund),
   The Wellcome Trust (094780), MRC UK (MC-A760-5QX00), NIHR Oxford
   Biomedical Research Centre, and the Bill and Melinda Gates Foundation
   ("Hepcidin and Iron in Global Health", OPP1055865).
CR Atkinson SH, 2008, BLOOD, V112, P4276, DOI 10.1182/blood-2008-06-162008
   Atkinson SH, 2006, PLOS MED, V3, P652, DOI 10.1371/journal.pmed.0030172
   Black MM, 2011, NUTR REV, V69, pS64, DOI 10.1111/j.1753-4887.2011.00435.x
   Bregman DB, 2013, AM J HEMATOL, V88, P97, DOI 10.1002/ajh.23354
   Choi Hyoung Soo, 2012, Korean J Hematol, V47, P286, DOI 10.5045/kjh.2012.47.4.286
   Doherty CP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002133
   Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577
   Du X, 2008, SCIENCE, V320, P1088, DOI 10.1126/science.1157121
   Finberg KE, 2008, NAT GENET, V40, P569, DOI 10.1038/ng.130
   Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135
   Food and Drug Administration, 2008, 10 K SUBST EQ DET DE, V2013
   Ganz T, 2013, PHYSIOL REV, V93, P1721, DOI 10.1152/physrev.00008.2013
   Ganz T, 2009, SEMIN HEMATOL, V46, P387, DOI 10.1053/j.seminhematol.2009.06.001
   HASTKA J, 1993, BLOOD, V81, P1200
   HERBERT V, 1987, AM J CLIN NUTR, V45, P679
   Huang H, 2009, BLOOD, V113, P3593, DOI 10.1182/blood-2008-08-173641
   Kroot JJC, 2012, AM J HEMATOL, V87, P977, DOI 10.1002/ajh.23289
   Kroot JJC, 2009, HAEMATOL-HEMATOL J, V94, P1748, DOI 10.3324/haematol.2009.010322
   Low M, 2013, CAN MED ASSOC J, V185, pE791, DOI 10.1503/cmaj.130628
   Mei ZG, 2005, J NUTR, V135, P1974
   Miller JL, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011866
   Pasricha SR, 2011, HAEMATOL-HEMATOL J, V96, P1099, DOI 10.3324/haematol.2010.037960
   Prentice AM, 2012, BLOOD, V119, P1922, DOI 10.1182/blood-2011-11-391219
   Punnonen K, 1997, BLOOD, V89, P1052
   Roe MA, 2009, AM J CLIN NUTR, V89, P1088, DOI 10.3945/ajcn.2008.27297
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Soofi S, 2013, LANCET, V382, P29, DOI 10.1016/S0140-6736(13)60437-7
   Theurl I, 2009, BLOOD, V113, P5277, DOI 10.1182/blood-2008-12-195651
   Thomas C, 2011, INT J LAB HEMATOL, V33, P187, DOI 10.1111/j.1751-553X.2010.01265.x
   Thurnham D. I., 2012, PRIORITIES ASSESSMEN
   van Santen S, 2011, ARTHRITIS RHEUM-US, V63, P3672, DOI 10.1002/art.30623
   Veenemans J, 2008, J INFECT DIS, V198, P401, DOI 10.1086/589884
   Veenemans J, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001125
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   World Health Organisation, 2004, ASS IR STAT POP INCL
   [Anonymous], 2001, IR DEF AN ASS PREV C
   Young MF, 2009, AM J CLIN NUTR, V89, P533, DOI 10.3945/ajcn.2008.26589
   Zimmermann MB, 2010, AM J CLIN NUTR, V92, P1406, DOI 10.3945/ajcn.110.004564
   Zimmermann MB, 2009, AM J CLIN NUTR, V90, P1280, DOI 10.3945/ajcn.2009.28129
NR 39
TC 27
Z9 27
U1 0
U2 4
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 7
PY 2014
VL 6
IS 235
AR 235re3
DI 10.1126/scitranslmed.3008249
PG 7
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA AG6GE
UT WOS:000335516300005
PM 24807559
OA No
DA 2017-08-15
ER

PT J
AU Bash, MC
   Lynn, F
   Mocca, B
   Borrow, R
   Findlow, H
   Hassan-King, M
   Preziosi, MP
   Idoko, O
   Sow, S
   Kulkarni, P
   LaForcec, FM
AF Bash, Margaret C.
   Lynn, Freyja
   Mocca, Brian
   Borrow, Ray
   Findlow, Helen
   Hassan-King, Musa
   Preziosi, Marie-Pierre
   Idoko, Olubukola
   Sow, Samba
   Kulkarni, Prasad
   LaForcec, F. Marc
TI Development and Use of a Serum Bactericidal Assay Using Pooled Human
   Complement To Assess Responses to a Meningococcal Group A Conjugate
   Vaccine in African Toddlers
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID MENINGITIDIS GROUP-A; NEISSERIA-MENINGITIDIS; CAPSULAR POLYSACCHARIDE;
   HUMAN IMMUNITY; SEROGROUP-A; W-135; IMMUNOGENICITY; PERSISTENCE;
   ANTIBODY; SAFETY
AB A meningococcal group A polysaccharide (PS) conjugate vaccine (PsA-TT) has been developed for African countries affected by epidemic meningitis caused by Neisseria meningitidis. Complement-mediated serum bactericidal antibody (SBA) assays are used to assess protective immune responses to meningococcal vaccination. Human complement (hC') was used in early studies demonstrating antibody-mediated protection against disease, but it is difficult to obtain and standardize. We developed and evaluated a method for sourcing hC' and then used the SBA assay with hC' (hSBA) to measure bactericidal responses to PsA-TT vaccination in 12- to 23-month-old African children. Sera with active complement from 100 unvaccinated blood donors were tested for intrinsic bactericidal activity, SBA titer using rabbit complement (rSBA), and anti-group A PS antibody concentration. Performance criteria and pooling strategies were examined and then verified by comparisons of three independently prepared hC' lots in two laboratories. hSBA titers of clinical trial sera were then determined using this complement sourcing method. Two different functional antibody tests were necessary for screening hC'. hSBA titers determined using three independent lots of pooled hC' were within expected assay variation among lots and between laboratories. In African toddlers, PsA-TT elicited higher hSBA titers than meningococcal polysaccharide or Hib vaccines. PsA-TT immunization or PS challenge of PsA-TT-primed subjects resulted in vigorous hSBA memory responses, and titers persisted in boosted groups for over a year. Quantifying SBA using pooled hC' is feasible and showed that PsA-TT was highly immunogenic in African toddlers.
C1 [Bash, Margaret C.; Lynn, Freyja; Mocca, Brian] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.
   [Borrow, Ray; Findlow, Helen] Manchester Royal Infirm, Vaccine Evaluat Unit, Publ Hlth England, Manchester M13 9WL, Lancs, England.
   [Hassan-King, Musa; Preziosi, Marie-Pierre; LaForcec, F. Marc] PATH, Meningitis Vaccine Project, Ferney Voltaire, France.
   [Preziosi, Marie-Pierre] WHO, Meningitis Vaccine Project, Initiat Vaccine Res, CH-1211 Geneva, Switzerland.
   [Idoko, Olubukola] MRC, Basse, Gambia.
   [Sow, Samba] Ctr Dev Vaccins, Bamako, Mali.
   [Kulkarni, Prasad] Serum Inst India, Pune, Maharashtra, India.
RP Bash, MC (reprint author), US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.
EM margaret.bash@fda.hhs.gov
FU PATH; World Health Organization; Bill & Melinda Gates Foundation;
   Pfizer; Novartis Vaccines; Baxter Bioscience; GlaxoSmithKline; Sanofi
   Pasteur; Merck
FX This study was funded in part by the Meningitis Vaccine Project, a
   partnership between PATH and the World Health Organization (http:
   //www.meningvax.org/) supported by a grant from the Bill & Melinda Gates
   Foundation.; Helen Findlow has received assistance to attend scientific
   meetings from Baxter Bioscience. Ray Borrow and Helen Findlow have
   performed contract research on behalf of Public Health England (funded
   by Pfizer, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi
   Pasteur, and Merck). Prasad Kulkarni is employed by Serum Institute of
   India Ltd., the manufacturer of the study vaccine. F. Marc LaForce has
   received honoraria and research support from Merck for earlier work on
   pneumococcal polysaccharide vaccine. The remaining authors have no
   conflicts to declare.
CR Borja-Tabora C, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-116
   CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154
   Elie CM, 2002, CLIN DIAGN LAB IMMUN, V9, P725, DOI 10.1128/CDLI.9.3.725-726.2002
   Findlow H, 2009, CLIN VACCINE IMMUNOL, V16, P969, DOI 10.1128/CVI.00068-09
   Findlow H, 2013, ADV THER, V30, P431, DOI 10.1007/s12325-013-0032-5
   Gill CJ, 2011, VACCINE, V30, P29, DOI 10.1016/j.vaccine.2011.10.068
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327
   Granoff D., 2012, VACCINES, P388
   GUIRGUIS N, 1985, J EXP MED, V162, P1837, DOI 10.1084/jem.162.6.1837
   Khatami A, 2012, VACCINE, V30, P2831, DOI 10.1016/j.vaccine.2012.02.046
   Klein NP, 2013, PEDIATR INFECT DIS J, V32, P760, DOI 10.1097/INF.0b013e31828693c5
   Kshirsagar N, 2007, VACCINE, V25, pA101, DOI 10.1016/j.vaccine.2007.04.050
   Lee CH, 2009, VACCINE, V27, P726, DOI 10.1016/j.vaccine.2008.11.065
   Maslanka SE, 1997, CLIN DIAGN LAB IMMUN, V4, P156
   Miller E, 2001, VACCINE, V20, pS58, DOI 10.1016/S0264-410X(01)00299-7
   MYEROWITZ RL, 1973, INFECT IMMUN, V8, P896
   Ostergaard L, 2013, INT J INFECT DIS, V17, pE173, DOI 10.1016/j.ijid.2012.10.001
   Patel M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001093.pub2
   PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302
   Santos GF, 2001, CLIN DIAGN LAB IMMUN, V8, P616, DOI 10.1128/CDLI.8.3.616-623.2001
   Sow SO, 2011, NEW ENGL J MED, V364, P2293, DOI 10.1056/NEJMoa1003812
   Welsch JA, 2008, VACCINE, V26, pI40, DOI 10.1016/j.vaccine.2008.11.060
NR 23
TC 5
Z9 5
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD MAY
PY 2014
VL 21
IS 5
BP 755
EP 761
DI 10.1128/CVI.00812-13
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AJ0NU
UT WOS:000337352300020
PM 24671551
OA No
DA 2017-08-15
ER

PT J
AU Okebe, J
   Bojang, K
   D'Alessandro, U
AF Okebe, Joseph
   Bojang, Kalifa
   D'Alessandro, Umberto
TI Use of Artemisinin and Its Derivatives for the Treatment of Malaria in
   Children
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Editorial Material
ID RANDOMIZED-TRIAL; AFRICAN CHILDREN; ARTESUNATE; DRUG; COMBINATION;
   QUININE
C1 [Okebe, Joseph; Bojang, Kalifa; D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
RP D'Alessandro, U (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.
EM udalessandro@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Bojang,
   Kalifa/0000-0001-7506-0938
FU Medical Research Council [MC_UP_A900_1118, MC_UP_A900_1119]
CR Achan J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-144
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   Kurth F, 2010, LANCET INFECT DIS, V10, P125, DOI 10.1016/S1473-3099(09)70327-5
   The malERA Consultative Group on Drugs, 2011, PLOS MED, V8
   Novartis Pharma AG, RAND INV BLIND MULT
   Shekalaghe SA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-247
   Sinclair D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007483.pub2
   Stepniewska K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-200
   von Seidlein L, 2003, T ROY SOC TROP MED H, V97, P217
   White NJ, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-418
   World Health Organization, 2010, GUID TREATM MAL, P194
   [Anonymous], 2011, GLOB PLAN ART RES CO
   World Health Organization, WORLD MAL REP 2012
NR 13
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAY
PY 2014
VL 33
IS 5
BP 522
EP 524
DI 10.1097/INF.0000000000000306
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AG9PC
UT WOS:000335750600021
PM 24736442
OA No
DA 2017-08-15
ER

PT J
AU Sirugo, G
   Predazzi, IM
   Bartlett, J
   Tacconelli, A
   Walther, M
   Williams, SM
AF Sirugo, Giorgio
   Predazzi, Irene M.
   Bartlett, Jacquelaine
   Tacconelli, Alessandra
   Walther, Michael
   Williams, Scott M.
TI Short Report: G6PD A- Deficiency and Severe Malaria in The Gambia:
   Heterozygote Advantage and Possible Homozygote Disadvantage
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID GLUCOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY; NATURAL-SELECTION;
   RESISTANCE; HETEROGENEITY; AFRICA; HEMIZYGOTES; POPULATION
AB Glucose-6-phosphate dehydrogenase (G6PD) deficiency is frequent in Africa, because it confers resistance to Plasmodium falciparum malaria; however, the nature of the protection and the genotypes associated with it have been controversial. In 1972, Bienzle and others described protection from malaria in West African females heterozygous for G6PD A-. They determined that G6PD A- heterozygotes had lower parasite counts than A- homozygotes, hemizygous males, and normal individuals. However, other studies have reached different conclusions about the protective genotypes. DNA samples from 135 children with severe malaria and 146 children with mild malaria from The Gambia were genotyped for the G6PD A- mutation that is most frequent among Gambians (G6PD 968 T->C); there was a marked deficiency of heterozygotes and an excess of homozygotes with severe malaria, producing a strong deviation from Hardy Weinberg equilibrium. Our results support the protective effect in G6PD A- heterozygous females and suggest that homozygotes might be more susceptible to severe malaria attacks.
C1 [Sirugo, Giorgio; Tacconelli, Alessandra] Osped San Pietro Fatebenefratelli, Ctr Ric, I-00189 Rome, Italy.
   [Predazzi, Irene M.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
   [Bartlett, Jacquelaine; Williams, Scott M.] Dartmouth Coll, Geisel Sch Med, Dept Genet, Hanover, NH 03755 USA.
   [Walther, Michael] NIAID, NIH, Lab Malaria Immunol & Vaccinol, Rockville, MD USA.
   MRC Labs, Banjul, Gambia.
RP Sirugo, G (reprint author), Osped San Pietro Fatebenefratelli, Ctr Ric, Via Cassia 600, I-00189 Rome, Italy.
EM sirugo.giorgio@fbfrm.it; irene.m.predazzi@vanderbilt.edu;
   Jacquelaine.Bartlett@dartmouth.edu; alessandra.tacconelli@gmail.com;
   michael.walther@nih.gov; Scott.Williams@dartmouth.edu
FU NIH [GM103534]
FX SMW was partially supported by NIH grant GM103534.
CR Ademowo O G, 2002, East Afr Med J, V79, P42
   BATTISTUZZI G, 1977, AM J HUM GENET, V29, P31
   BEUTLER E, 1989, BLOOD, V74, P2550
   BIENZLE U, 1972, LANCET, V1, P107
   Clark TG, 2009, EUR J HUM GENET, V17, P1080, DOI 10.1038/ejhg.2009.8
   De Araujo C, 2006, HAEMATOL-HEMATOL J, V91, P262
   Guindo A, 2007, PLOS MED, V4, P516, DOI 10.1371/journal.pmed.0040066
   Hirono A, 2002, BLOOD, V99, P1498, DOI 10.1182/blood.V99.4.1498
   Howes RE, 2012, PLOS MED, V9
   Luzzatto L, 2012, HEREDITY, V108, P456, DOI 10.1038/hdy.2011.90
   May J, 2000, TROP MED INT HEALTH, V5, P119, DOI 10.1046/j.1365-3156.2000.00529.x
   Rodrigues MO, 2002, BLOOD CELL MOL DIS, V28, P249, DOI 10.1006/bcmd.2002.0505
   RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0
   Sirugo G, 2013, AM J HEMATOL, V88, P436, DOI 10.1002/ajh.23424
   Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573
   Walther M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002579
NR 16
TC 8
Z9 8
U1 0
U2 7
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 2014
VL 90
IS 5
BP 856
EP 859
DI 10.4269/ajtmh.13-0622
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AG8ZN
UT WOS:000335707600017
PM 24615128
OA No
DA 2017-08-15
ER

PT J
AU Afolabi, MO
   Adetifa, JU
   Imoukhuede, EB
   Viebig, NK
   Kampmann, B
   Bojang, K
AF Afolabi, Muhammed O.
   Adetifa, Jane U.
   Imoukhuede, Egeruan B.
   Viebig, Nicola K.
   Kampmann, Beate
   Bojang, Kalifa
TI Early Phase Clinical Trials with Human Immunodeficiency Virus-1 and
   Malaria Vectored Vaccines in The Gambia: Frontline Challenges in Study
   Design and Implementation
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID ENDEMIC COUNTRIES; SOUTH-AFRICA; T-CELLS; HIV; UGANDA; IMMUNIZATION;
   EXPERIENCE; INDUCTION; RESPONSES; LESSONS
AB Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and malaria are among the most important infectious diseases in developing countries. Existing control strategies are unlikely to curtail these diseases in the absence of efficacious vaccines. Testing of HIV and malaria vaccines candidates start with early phase trials that are increasingly being conducted in developing countries where the burden of the diseases is high. Unique challenges, which affect planning and implementation of vaccine trials according to internationally accepted standards have thus been identified. In this review, we highlight specific challenges encountered during two early phase trials of novel HIV-1 and malaria vectored vaccine candidates conducted in The Gambia and how some of these issues were pragmatically addressed. We hope our experience will be useful for key study personnel involved in day-to-day running of similar clinical trials. It may also guide future design and implementation of vaccine trials in resource-constrained settings.
C1 [Afolabi, Muhammed O.; Adetifa, Jane U.; Kampmann, Beate; Bojang, Kalifa] MRC Unit, Fajara, Gambia.
   [Imoukhuede, Egeruan B.] Univ Oxford, Jenner Inst, Oxford OX1 2JD, England.
   [Viebig, Nicola K.] European Vaccine Initiat, Heidelberg, Germany.
RP Afolabi, MO (reprint author), MRC Unit, Atlantic Rd,POB 273, Banjul, Gambia.
EM mafolabi@mrc.gm; jadetifa@mrc.gm; egeruan.imoukhuede@ndm.ox.ac.uk;
   nicola.viebig@euvaccine.eu; bkampmann@mrc.gm; kbojang@mrc.gm
OI Imoukhuede, Egeruan Babatunde/0000-0001-6679-0904; Afolabi,
   Muhammed/0000-0002-9967-6419; Bojang, Kalifa/0000-0001-7506-0938
FU EDCTP [IP.2008.31100.001, CT.2006.33111.002]
FX We thank European and Developing Countries Clinical Trials Partnership
   for funding the two trials: (EDCTP grant nos. IP.2008.31100.001 and
   CT.2006.33111.002).
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Bejon P, 2007, J IMMUNOL, V179, P4193
   Bekker Linda-Gail, 2005, J Int Assoc Physicians AIDS Care (Chic), V4, P93, DOI 10.1177/1545109705284836
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Chapman R, 2010, CURR HIV RES, V8, P282
   Chilengi R, 2009, HUM VACCINES, V5, P627
   Dhingra B, 2011, ANN TROP PAEDIATR, V31, P339, DOI 10.1179/1465328111Y.0000000039
   Essack Z, 2010, DEV WORLD BIOETH, V10, P11, DOI 10.1111/j.1471-8847.2009.00254.x
   Fawzi WW, 1999, CONTROL CLIN TRIALS, V20, P75, DOI 10.1016/S0197-2456(98)00045-2
   Ghouth Abdulla Salim Bin, 2012, Trop Parasitol, V2, P35, DOI 10.4103/2229-5070.97237
   Girard MP, 2007, VACCINE, V25, P1567, DOI 10.1016/j.vaccine.2006.09.074
   Goonetilleke N, 2006, J VIROL, V80, P4717, DOI 10.1128/JVI.80.10.4717-4728.2006
   Grady C, 2007, ETHICAL ISSUES INT B, P225
   Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000290
   Ibango HB, 2006, LANCET INFECT DIS, V6, P522, DOI 10.1016/S1473-3099(06)70552-7
   Idoko OT, 2013, AM J TROP MED HYG, V88, P414, DOI 10.4269/ajtmh.12-0576
   Jackson LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020102
   Jaffar S, 2008, TROP MED INT HEALTH, V13, P795, DOI 10.1111/j.1365-3156.2008.02068.x
   Kampmann B, 2006, LANCET, V368, P282, DOI 10.1016/S0140-6736(06)69064-8
   Kilama WL, 2007, AM J TROP MED HYG, V77, P282
   Kumar P, 2013, J IMMUNE BASED THER, V2, P9
   Kumwenda NI, 2012, PAEDIATR INT CHILD H, V32, P213, DOI 10.1179/2046905512Y.0000000034
   Kwong PD, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007278
   Lang TA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000619
   Leach M, 2011, BERGHAHN SERIES, P77
   Matsuo K, 2011, TUBERC RES TREAT, V2011, DOI [10.1155/2011/574591, DOI 10.1155/2011/574591]
   Moodley K, 2002, J MED PHILOS, V27, P197, DOI 10.1076/jmep.27.2.197.2986
   Moorthy Vasee, 2007, Vaccine, V25, P5115, DOI 10.1016/j.vaccine.2007.01.085
   Mugyenyi PN, 2002, VACCINE, V20, P1905, DOI 10.1016/S0264-410X(02)00064-6
   Mwangoka G, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-86
   Nyika A, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-86
   Ota MOC, 2013, VACCINE, V31, P2483, DOI 10.1016/j.vaccine.2012.06.018
   Otti PO, 2003, SOCIOCULTURAL STUDY
   Quinto L, 2006, TROP MED INT HEALTH, V11, P1741, DOI 10.1111/j.1365-3156.2006.01764.x
   Rose MA, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-98
   Saidu Y., 2013, Journal of Clinical Research and Bioethics, V4, P1000141
   Sepulveda RL, 1997, INT J TUBERC LUNG D, V1, P122
   Shields B, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e5931
   Sista Nirupama Deshmane, 2011, Clin Investig (Lond), V1, P1609
   Sullivan M, 2009, IMMUNOL CELL BIOL, V87, P366, DOI 10.1038/icb.2009.30
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   White GP, 2002, J IMMUNOL, V168, P2820
   World Health Organization-WHO, 2012, GLOB HLTH OBS HIV AI
   World Health Organization (WHO), 2010, DEL HIV TEST RES MES
   World Health Organization, 2010, WHO REC DIAGN HIV IN
NR 46
TC 3
Z9 3
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 2014
VL 90
IS 5
BP 908
EP 914
DI 10.4269/ajtmh.13-0615
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AG8ZN
UT WOS:000335707600025
PM 24615122
OA No
DA 2017-08-15
ER

PT J
AU Tientcheu, LD
   Sutherland, JS
   de Jong, BC
   Kampmann, B
   Jafali, J
   Adetifa, IM
   Antonio, M
   Dockrell, HM
   Ota, MO
AF Tientcheu, Leopold D.
   Sutherland, Jayne S.
   de Jong, Bouke C.
   Kampmann, Beate
   Jafali, James
   Adetifa, Ifedayo M.
   Antonio, Martin
   Dockrell, Hazel M.
   Ota, Martin O.
TI Differences in T- cell responses between Mycobacterium tuberculosis and
   Mycobacterium africanum- infected patients
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Cytokines; Mycobacterium africanum; Mycobacterium tuberculosis; T cells;
   Tuberculosis
ID LATENT INFECTION; ACTIVE DISEASE; COMPLEX; LYMPHOCYTES; GENOME;
   PROGRESSION; EXPRESSION; LINEAGE; GAMBIA; COMMON
AB In The Gambia, Mycobacterium tuberculosis (Mtb) and Mycobacterium africanum (Maf) are major causes of tuberculosis (TB). Maf is more likely to cause TB in immune suppressed individuals, implying differences in virulence. Despite this, few studies have assessed the underlying immunity to the two pathogens in human. In this study, we analyzed T-cell responses from 19 Maf- and 29 Mtb-infected HIV-negative patients before and after TB chemotherapy following overnight stimulation of whole blood with TB-specific antigens. Before treatment, percentages of early secreted antigenic target-6(ESAT-6)/culture filtrate protein-10(CFP-10) and purified protein derivative-specific single-TNF--producing CD4(+) and CD8(+) T cells were significantly higher while single-IL-2-producing T cells were significantly lower in Maf- compared with Mtb-infected patients. Purified protein derivative-specific polyfunctional CD4(+) T cells frequencies were significantly higher before than after treatment, but there was no difference between the groups at both time points. Furthermore, the proportion of CD3(+)CD11b(+) T cells was similar in both groups pretreatment, but was significantly lower with higher TNF-, IL-2, and IFN- production in Mtb- compared with that of Maf-infected patients posttreatment. Our data provide evidence of differences in T-cell responses to two mycobacterial strains with differing virulence, providing some insight into TB pathogenesis with different Mtb strains that could be prospectively explored as biomarkers for TB protection or susceptibility.
C1 [Tientcheu, Leopold D.; Sutherland, Jayne S.; Kampmann, Beate; Jafali, James; Adetifa, Ifedayo M.; Antonio, Martin; Ota, Martin O.] MRC Unit, Banjul, Gambia.
   [Tientcheu, Leopold D.; Dockrell, Hazel M.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1, England.
   [de Jong, Bouke C.] Inst Trop Med, B-2000 Antwerp, Belgium.
RP Tientcheu, LD (reprint author), MRC Unit, POB 273, Banjul, Gambia.
EM ltientcheu@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; Dockrell, Hazel/0000-0003-1869-9107;
   Kampmann, Beate/0000-0002-6546-4709; Sutherland,
   Jayne/0000-0002-7083-4997
FU MRC Unit, The Gambia
FX We would like to thank all study participants, field workers for sample
   collection, MRC TB clinic staff, the TB Immunology and TB diagnostic
   laboratory staff and the Gambian National Tuberculosis and Leprosy
   Control programme for continuing collaboration. This work was funded by
   the MRC Unit, The Gambia as a PhD fellowship awarded to L.D.T.
CR Aldous WK, 2005, J CLIN MICROBIOL, V43, P2471, DOI 10.1128/JCM.43.5.2471-2473.2005
   Bekker LG, 2000, INFECT IMMUN, V68, P6954, DOI 10.1128/IAI.68.12.6954-6961.2000
   Bentley SD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001552
   Bold TD, 2012, J INFECT DIS, V205, P984, DOI 10.1093/infdis/jir883
   Caccamo N, 2010, EUR J IMMUNOL, V40, P2211, DOI 10.1002/eji.201040455
   Christensen JE, 2001, INT IMMUNOL, V13, P593, DOI 10.1093/intimm/13.4.593
   Day CL, 2008, J INFECT DIS, V197, P990, DOI 10.1086/529048
   Day CL, 2011, J IMMUNOL, V187, P2222, DOI 10.4049/jimmunol.1101122
   de Jong BC, 2007, INT J TUBERC LUNG D, V11, P450
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   de Jong BC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000744
   de Jong BC, 2010, FEMS IMMUNOL MED MIC, V58, P102, DOI 10.1111/j.1574-695X.2009.00628.x
   de Jong BC, 2009, J CLIN MICROBIOL, V47, P994, DOI 10.1128/JCM.01216-08
   Ernst JD, 2012, NAT REV IMMUNOL, V12, P581, DOI 10.1038/nri3259
   Gagneux S, 2012, PHILOS T R SOC B, V367, P850, DOI 10.1098/rstb.2011.0316
   GROSSET J, 1971, Revue de Tuberculose et de Pneumologie, V35, P430
   Harari A, 2011, NAT MED, V17, P372, DOI 10.1038/nm.2299
   Keane J, 2005, RHEUMATOLOGY, V44, P714, DOI 10.1093/rheumatology/keh567
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110
   Koser CU, 2013, NEW ENGL J MED, V369, P290, DOI 10.1056/NEJMc1215305
   Kotsougiani D, 2010, INT J INFLAMM, V2010
   Lewinsohn DA, 2003, AM J RESP CRIT CARE, V168, P1346, DOI 10.1164/rccm.200306-837OC
   Lewinsohn DM, 2001, J IMMUNOL, V166, P439
   NIELSEN HV, 1994, J IMMUNOL, V153, P2021
   Pollock KM, 2013, J INFECT DIS, V208, P952, DOI 10.1093/infdis/jit265
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Rozot V, 2013, EUR J IMMUNOL, V43, P1568, DOI 10.1002/eji.201243262
   Singh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030947
   Skerry C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039680
   Streitz M, 2012, CYTOM PART B-CLIN CY, V82B, P360, DOI [10.1002/cyto.b.21041, 10.1002/cyto.b.21040]
   Sutherland JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012365
   Sutherland JS, 2009, EUR J IMMUNOL, V39, P723, DOI 10.1002/eji.200838693
   Torok ME, 2013, J CLIN MICROBIOL, V51, P611, DOI 10.1128/JCM.02279-12
   Via LE, 2013, INFECT IMMUN, V81, P2909, DOI 10.1128/IAI.00632-13
   Wagner C, 2001, EUR J IMMUNOL, V31, P1173, DOI 10.1002/1521-4141(200104)31:4<1173::AID-IMMU1173>3.0.CO;2-9
   Wagner C, 2008, IMMUNOLOGY, V125, P503, DOI 10.1111/j.1365-2567.2008.02863.x
   WHO, 2010, TREATMENT OF TUBERCULOSIS: GUIDELINES, FOURTH EDITION, P1
   Young JM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011237
NR 39
TC 10
Z9 10
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD MAY
PY 2014
VL 44
IS 5
BP 1387
EP 1398
DI 10.1002/eji.201343956
PG 12
WC Immunology
SC Immunology
GA AF8YZ
UT WOS:000335003200015
PM 24481948
OA No
DA 2017-08-15
ER

PT J
AU Ma, DZ
   Jasinska, AJ
   Feyertag, F
   Wijewardana, V
   Kristoff, J
   He, TY
   Raehtz, K
   Schmitt, CA
   Jung, Y
   Cramer, JD
   Dione, M
   Antonio, M
   Tracy, R
   Turner, T
   Robertson, DL
   Pandrea, I
   Freimer, N
   Apetrei, C
AF Ma, Dongzhu
   Jasinska, Anna J.
   Feyertag, Felix
   Wijewardana, Viskam
   Kristoff, Jan
   He, Tianyu
   Raehtz, Kevin
   Schmitt, Christopher A.
   Jung, Yoon
   Cramer, Jennifer Danzy
   Dione, Michel
   Antonio, Martin
   Tracy, Russell
   Turner, Trudy
   Robertson, David L.
   Pandrea, Ivona
   Freimer, Nelson
   Apetrei, Cristian
CA Int Vervet Res Consortium
TI Factors Associated with Siman Immunodeficiency Virus Transmission in a
   Natural African Nonhuman Primate Host in the Wild
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CD4(+) T-CELLS; MONKEYS CERCOPITHECUS-AETHIOPS; MANDRILLS
   MANDRILLUS-SPHINX; CROSS-SPECIES TRANSMISSION; PRIMARY SIV INFECTION;
   CHRONIC HIV-INFECTION; STLV TYPE-I; GREEN MONKEYS; SOOTY MANGABEYS;
   LENTIVIRAL INFECTIONS
AB African green monkeys (AGMs) are naturally infected with simian immunodeficiency virus (SIV) at high prevalence levels and do not progress to AIDS. Sexual transmission is the main transmission route in AGM, while mother-to-infant transmission (MTIT) is negligible. We investigated SIV transmission in wild AGMs to assess whether or not high SIV prevalence is due to differences in mucosal permissivity to SIV (i.e., whether the genetic bottleneck of viral transmission reported in humans and macaques is also observed in AGMs in the wild). We tested 121 sabaeus AGMs (Chlorocebus sabaeus) from the Gambia and found that 53 were SIV infected (44%). By combining serology and viral load quantitation, we identified 4 acutely infected AGMs, in which we assessed the diversity of the quasispecies by single-genome amplification (SGA) and documented that a single virus variant established the infections. We thus show that natural SIV transmission in the wild is associated with a genetic bottleneck similar to that described for mucosal human immunodeficiency virus (HIV) transmission in humans. Flow cytometry assessment of the immune cell populations did not identify major differences between infected and uninfected AGM. The expression of the SIV coreceptor CCR5 on CD4(+) T cells dramatically increased in adults, being higher in infected than in uninfected infant and juvenile AGMs. Thus, the limited SIV MTIT in natural hosts appears to be due to low target cell availability in newborns and infants, which supports HIV MTIT prevention strategies aimed at limiting the target cells at mucosal sites. Combined, (i) the extremely high prevalence in sexually active AGMs, (ii) the very efficient SIV transmission in the wild, and (iii) the existence of a fraction of multiparous females that remain uninfected in spite of massive exposure to SIV identify wild AGMs as an acceptable model of exposed, uninfected individuals.
C1 [Ma, Dongzhu; Wijewardana, Viskam; Kristoff, Jan; He, Tianyu; Raehtz, Kevin; Pandrea, Ivona; Apetrei, Cristian] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Jasinska, Anna J.; Schmitt, Christopher A.; Jung, Yoon; Freimer, Nelson] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Ctr Neurobehav Genet, Los Angeles, CA USA.
   [Feyertag, Felix; Robertson, David L.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England.
   [Cramer, Jennifer Danzy] Amer Mil Univ, Dept Sociol Anthropol & Womens Studies, Charles Town, WV USA.
   [Cramer, Jennifer Danzy] Amer Publ Univ, Charles Town, WV USA.
   [Dione, Michel; Antonio, Martin] MRC, Fajara, Gambia.
   [Tracy, Russell] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA.
   [Tracy, Russell] Univ Vermont, Dept Biochem, Burlington, VT 05405 USA.
   [Turner, Trudy] Univ Wisconsin, Dept Anthropol, Milwaukee, WI 53201 USA.
   [Pandrea, Ivona] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
   [Apetrei, Cristian] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
RP Apetrei, C (reprint author), Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
EM apetreic@pitt.edu
RI Schmitt, Christopher/F-7251-2013
OI Schmitt, Christopher/0000-0003-2143-9226; Wijewardana,
   Viskam/0000-0002-5787-8792
FU NIH [R01RR016300, R01OD010980]; NIH/NIAID/NCRR/NIDCR [R01 RR025781, P01
   AI088564, R56 DE023508]; BBSRC studentship
FX We thank Beatrice Hahn, Vanessa Hirsch, Brandon Keele, and Preston Marx
   for helpful discussions. Samples used in this study were collected as a
   part of the Systems Biology Sample Repository. Sample collection was
   performed through the UCLA Systems Biology Sample Repository funded by
   NIH grants R01RR016300 and R01OD010980 to N.F. We thank the Department
   of Parks & Wildlife Management, Ministry of Forestry & the Environment,
   and Medical Research Council (MRC) The Gambia Unit for enabling our
   sample collection from free-ranging monkeys. We thank MRC The Gambia
   Unit for making laboratory, equipment, and cold-storage space available
   for our project and all the staff of the MRC that helped with organizing
   field sample collection and providing administrative support and
   transportation, in particular, Sanneh Mamkumba for administrative help,
   Ousman Secka for help with supplies and sample storage and shipment, and
   drivers Ousman Bah and Lamin Gibba. We gratefully acknowledge the
   expertise and assistance of Oliver (Pess) Morton, Ebou Jarjou, and
   Katherine Camfield during the field work as well as Ben Kigbu and Toye
   Adegboye for veterinary care.; Virology investigations were funded
   through NIH/NIAID/NCRR/NIDCR grants R01 RR025781 (C.A. and I.P.), P01
   AI088564 (C.A.), and R56 DE023508 (C.A.). Coagulation and inflammation
   markers were tested through RO1 HL117715 (I.P.). F.F. is funded by a
   BBSRC studentship to D.L.R.
CR Abrahams MR, 2009, J VIROL, V83, P3556, DOI 10.1128/JVI.02132-08
   ALLAN JS, 1991, J VIROL, V65, P2816
   Apetrei C, 2004, J VIROL, V78, P11506, DOI 10.1128/JVI.78.21.11506-11518.2004
   Apetrei C, 2007, J VIROL, V81, P7913, DOI 10.1128/JVI.00281-07
   Apetrei C, 2011, J VIROL, V85, P13077, DOI 10.1128/JVI.05693-11
   Apetrei C, 2010, J INFECT DIS, V202, pS371, DOI 10.1086/655970
   Bailes E, 2003, SCIENCE, V300, P1713, DOI 10.1126/science.1080657
   Beaumier CM, 2009, NAT MED, V15, P879, DOI 10.1038/nm.1970
   Beer B, 1998, J ACQ IMMUN DEF SYND, V18, P210
   Bibollet-Ruche F, 2004, J VIROL, V78, P7748, DOI 10.1128/JVI.78.14.7748-7762.2004
   Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brenchley JM, 2011, BLOOD, V118, P847, DOI 10.1182/blood-2010-12-325936
   Brenchley JM, 2010, IMMUNITY, V32, P737, DOI 10.1016/j.immuni.2010.06.004
   Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316
   Broussard SR, 2001, J VIROL, V75, P2262, DOI 10.1128/JVI.75.5.2262-2275.2001
   Chahroudi A, 2011, J VIROL, V85, P5757, DOI 10.1128/JVI.02690-10
   Chakrabarti LA, 2000, J MED PRIMATOL, V29, P158, DOI 10.1034/j.1600-0684.2000.290309.x
   Chakrabarti LA, 2000, J VIROL, V74, P1209, DOI 10.1128/JVI.74.3.1209-1223.2000
   Ciaranello AL, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001156
   Cohen HJ, 2003, AM J MED, V114, P180, DOI 10.1016/S0002-9343(02)01484-5
   Courgnaud V, 2003, J VIROL, V77, P12523, DOI 10.1128/JVI.77.23.12523-12534.2003
   Courgnaud V, 2002, J VIROL, V76, P8298, DOI 10.1128/JVI.76.16.8298-8309.2002
   Courgnaud V, 2001, J VIROL, V75, P857, DOI 10.1128/JVI.75.2.857-866.2001
   Cumont MC, 2008, J VIROL, V82, P1175, DOI 10.1128/JVI.00450-07
   Damond F, 2004, AIDS RES HUM RETROV, V20, P666, DOI 10.1089/0889222041217392
   Deeks SG, 2013, IMMUNITY, V39, P633, DOI 10.1016/j.immuni.2013.10.001
   Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549
   DURAND JP, 1995, AIDS RES HUM RETROV, V11, P985, DOI 10.1089/aid.1995.11.985
   ESTAQUIER J, 1994, P NATL ACAD SCI USA, V91, P9431, DOI 10.1073/pnas.91.20.9431
   Favre D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000295
   Fennessey CM, 2013, CURR OPIN HIV AIDS, V8, P280, DOI 10.1097/COH.0b013e328361cfff
   Fenton-May AE, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-146
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/01.aids.0000076308.76477.b8
   FULTZ PN, 1990, AIDS, V4, P619, DOI 10.1097/00002030-199007000-00002
   GAO F, 1994, J VIROL, V68, P7433
   Gaufin T, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-42
   Gaufin T, 2009, J VIROL, V83, P10347, DOI 10.1128/JVI.00880-09
   Gautam R, 2009, J VIROL, V83, P7894, DOI 10.1128/JVI.00444-09
   Gicheru MM, 1999, J MED PRIMATOL, V28, P97
   Gnanadurai CW, 2010, J VIROL, V84, P12245, DOI 10.1128/JVI.01603-10
   Goldstein S, 2000, J VIROL, V74, P11744, DOI 10.1128/JVI.74.24.11744-11753.2000
   Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365
   Grobler P, 2010, S AFR J WILDLIFE RES, V40, P163
   Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607
   HIRSCH VM, 1994, VIRUS RES, V32, P183, DOI 10.1016/0168-1702(94)90041-8
   Hirsch VM, 2004, AIDS REV, V6, P40
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Jasinska AJ, 2013, ILAR J, V54, P122, DOI 10.1093/ilar/ilt049
   JIN MJ, 1994, EMBO J, V13, P2935
   JIN MJ, 1994, J VIROL, V68, P8454
   Jolly CJ, 1996, J MED PRIMATOL, V25, P78
   Karim QA, 2010, CLIN INFECT DIS, V50, pS122, DOI 10.1086/651483
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Keele BF, 2011, BLOOD, V118, P839, DOI 10.1182/blood-2010-12-325860
   Keele BF, 2009, CURR OPIN HIV AIDS, V4, P352, DOI 10.1097/COH.0b013e32832d9fef
   Keele BF, 2009, J EXP MED, V206, P1117, DOI 10.1084/jem.20082831
   Kornfeld C, 2005, J CLIN INVEST, V115, P1082, DOI 10.1172/JCI200523006
   Pond SLK, 2006, MOL BIOL EVOL, V23, P1891, DOI 10.1093/molbev/msl051
   Kuhmann SE, 2001, J VIROL, V75, P8449, DOI 10.1128/JVI.75.18.8449-8460.2001
   Kuller L. H., 2008, PLoS Medicine, V5, pe203, DOI 10.1371/journal.pmed.0050203
   Ling BH, 2004, J VIROL, V78, P8902, DOI 10.1128/JVI.78.16.8902-8908.2004
   Liu JY, 2010, J VIROL, V84, P10406, DOI 10.1128/JVI.01155-10
   Locatelli S, 2012, AIDS, V26, P659, DOI 10.1097/QAD.0b013e328350fb68
   Ma DZ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003011
   Maydt J, 2006, BIOINFORMATICS, V22, P1064, DOI 10.1093/bioinformatics/btl057
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Mellors JW, 1997, ANN INTERN MED, V126, P946
   MULLER MC, 1993, J VIROL, V67, P1227
   Nerrienet E, 1998, AIDS RES HUM RETROV, V14, P785, DOI 10.1089/aid.1998.14.785
   Onanga R, 2002, J VIROL, V76, P10256, DOI 10.1128/JVI.76.20.10256-10263.2002
   Onanga R, 2006, J VIROL, V80, P3303
   OTSYULA MG, 1995, ANN TROP MED PARASIT, V89, P573
   Paiardini M, 2011, NAT MED, V17, P830, DOI 10.1038/nm.2395
   Pandrea I, 2006, J VIROL, V80, P4858, DOI 10.1128/JVI.80.10.4858-4867.2006
   Pandrea I, 2005, J VIROL, V79, P6249, DOI 10.1128/JVI.79.10.6249-6259.2005
   Pandrea I, 2003, VIROLOGY, V317, P119, DOI 10.1016/j.virol.2003.08.015
   Pandrea I, 2001, AIDS, V15, P2461, DOI 10.1097/00002030-200112070-00019
   Pandrea I, 2008, TRENDS IMMUNOL, V29, P419, DOI DOI 10.1016/J.IT.2008.05.004)
   Pandrea I, 2008, J IMMUNOL, V181, P6687
   Pandrea I, 2008, J VIROL, V82, P5501, DOI 10.1128/JVI.02555-07
   Pandrea I, 2008, J VIROL, V82, P3713, DOI 10.1128/JVI.02402-07
   Pandrea I, 2007, BLOOD, V109, P1069, DOI 10.1182/blood-2006-05-024364
   Pandrea I, 2006, J MED PRIMATOL, V35, P194, DOI 10.1111/j.1600-0684.2006.00168.x
   Pandrea I, 2012, BLOOD, V120, P1357, DOI 10.1182/blood-2012-03-414706
   Pandrea I, 2012, J VIROL, V86, P4158, DOI 10.1128/JVI.07141-11
   Pandrea I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002170
   Pandrea Ivona, 2010, Curr HIV/AIDS Rep, V7, P28, DOI 10.1007/s11904-009-0034-8
   Pandrea I, 2009, CURR HIV RES, V7, P57
   Pandrea IV, 2007, J IMMUNOL, V179, P3035
   Parrish NF, 2013, P NATL ACAD SCI USA, V110, P6626, DOI 10.1073/pnas.1304288110
   PHILLIPSCONROY JE, 1994, J MED PRIMATOL, V23, P1
   Plantier JC, 2009, NAT MED, V15, P871, DOI 10.1038/nm.2016
   Rey-Cuille MA, 1998, J VIROL, V72, P3872
   Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295
   Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378
   Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118
   Schmitz JE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000691
   Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8
   Silvestri G, 2007, J CLIN INVEST, V117, P3148, DOI 10.1172/JCI33034
   Simon F, 2001, AIDS RES HUM RETROV, V17, P937, DOI 10.1089/088922201750290050
   Sodora DL, 2008, AIDS, V22, P439, DOI 10.1097/QAD.0b013e3282f2dbe7
   Sodora DL, 2009, NAT MED, V15, P861, DOI 10.1038/nm.2013
   Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446
   Sumpter B, 2007, J IMMUNOL, V178, P1680
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   TRAINADORGE V, 1992, AIDS RES HUM RETROV, V8, P97, DOI 10.1089/aid.1992.8.97
   Turner TR, 1997, AM J PHYS ANTHROPOL, V103, P19, DOI 10.1002/(SICI)1096-8644(199705)103:1<19::AID-AJPA3>3.0.CO;2-8
   VandeWoude S, 2006, CLIN MICROBIOL REV, V19, P728, DOI 10.1128/CMR.00009-06
   Veazey RS, 2004, J EXP MED, V200, P697, DOI 10.1084/jem.20041464
   Vinton C, 2011, J VIROL, V85, P8702, DOI 10.1128/JVI.00332-11
   Walston J, 2002, ARCH INTERN MED, V162, P2333, DOI 10.1001/archinte.162.20.2333
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Zahn RC, 2010, BLOOD, V115, P3070, DOI 10.1182/blood-2009-10-245225
   Zahn RC, 2008, J VIROL, V82, P11577, DOI 10.1128/JVI.01779-08
NR 115
TC 17
Z9 17
U1 2
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2014
VL 88
IS 10
BP 5687
EP 5705
DI 10.1128/JVI.03606-13
PG 19
WC Virology
SC Virology
GA AG5GB
UT WOS:000335446400043
PM 24623416
OA No
DA 2017-08-15
ER

PT J
AU Kajungu, DK
   Erhart, A
   Talisuna, AO
   Bassat, Q
   Karema, C
   Nabasumba, C
   Nambozi, M
   Tinto, H
   Kremsner, P
   Meremikwu, M
   D'Alessandro, U
   Speybroeck, N
AF Kajungu, Dan K.
   Erhart, Annette
   Talisuna, Ambrose Otau
   Bassat, Quique
   Karema, Corine
   Nabasumba, Carolyn
   Nambozi, Michael
   Tinto, Halidou
   Kremsner, Peter
   Meremikwu, Martin
   D'Alessandro, Umberto
   Speybroeck, Niko
TI Paediatric Pharmacovigilance: Use of Pharmacovigilance Data Mining
   Algorithms for Signal Detection in a Safety Dataset of a Paediatric
   Clinical Study Conducted in Seven African Countries
SO PLOS ONE
LA English
DT Article
ID EVENT REPORTING SYSTEM; ADVERSE; GENERATION
AB Background: Pharmacovigilance programmes monitor and help ensuring the safe use of medicines which is critical to the success of public health programmes. The commonest method used for discovering previously unknown safety risks is spontaneous notifications. In this study we examine the use of data mining algorithms to identify signals from adverse events reported in a phase IIIb/IV clinical trial evaluating the efficacy and safety of several Artemisinin-based combination therapies (ACTs) for treatment of uncomplicated malaria in African children.
   Methods: We used paediatric safety data from a multi-site, multi-country clinical study conducted in seven African countries (Burkina Faso, Gabon, Nigeria, Rwanda, Uganda, Zambia, and Mozambique). Each site compared three out of four ACTs, namely amodiaquine-artesunate (ASAQ), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL) or chlorproguanil/dapsone and artesunate (CD+A). We examine two pharmacovigilance signal detection methods, namely proportional reporting ratio and Bayesian Confidence Propagation Neural Network on the clinical safety dataset.
   Results: Among the 4,116 children (6-59 months old) enrolled and followed up for 28 days post treatment, a total of 6,238 adverse events were reported resulting into 346 drug-event combinations. Nine signals were generated both by proportional reporting ratio and Bayesian Confidence Propagation Neural Network. A review of the manufacturer package leaflets, an online Multi-Drug Symptom/Interaction Checker (DoubleCheckMD) and further by therapeutic area experts reduced the number of signals to five. The ranking of some drug-adverse reaction pairs on the basis of their signal index differed between the two methods.
   Conclusions: Our two data mining methods were equally able to generate suspected signals using the pooled safety data from a phase IIIb/IV clinical trial. This analysis demonstrated the possibility of utilising clinical studies safety data for key pharmacovigilance activities like signal detection and evaluation. This approach can be applied to complement the spontaneous reporting systems which are limited by under reporting.
C1 [Kajungu, Dan K.; Speybroeck, Niko] Catholic Univ Louvain, Res Inst Hlth & Soc IRSS, B-1200 Brussels, Belgium.
   [Erhart, Annette; D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Talisuna, Ambrose Otau] Univ Oxford, KEMRI Wellcome Trust Programme, Malaria Publ Hlth Dept, Nairobi, Kenya.
   [Talisuna, Ambrose Otau] Infect Dis Res Collaborat, Uganda Malaria Surveillance Project, Kampala, Uganda.
   [Bassat, Quique] Ctr Invest Saude Manhica, Maputo, Mozambique.
   [Bassat, Quique] Univ Barcelona, Hosp Clin Barcelona, Barcelona Ctr Int Hlth Res, CRESIB, Barcelona, Spain.
   [Karema, Corine] Minist Hlth, Natl Malaria Control Program TRAC Plus, Kigali, Rwanda.
   [Nabasumba, Carolyn] Epicentre, Paris, France.
   [Nabasumba, Carolyn] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda.
   [Nambozi, Michael] Trop Dis Res Ctr, Ndola, Zambia.
   [Tinto, Halidou] Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso.
   [Tinto, Halidou] Ctr Muraz, Bobo Dioulasso, Burkina Faso.
   [Meremikwu, Martin] Univ Calabar, Dept Paediat, Calabar, Nigeria.
   [Meremikwu, Martin] Inst Trop Dis Res & Prevent, Calabar, Nigeria.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Kajungu, Dan K.] Sante Stat & Analyt Res Inst, Kampala, Uganda.
   [Kremsner, Peter] Univ Tubingen, Inst Tropenmed, Tubingen, Germany.
   [Kremsner, Peter] Ctr Rech Med Lambarene, Lambarene, Gabon.
RP Kajungu, DK (reprint author), Catholic Univ Louvain, Res Inst Hlth & Soc IRSS, B-1200 Brussels, Belgium.
EM kajungu_dan@yahoo.co.uk
RI D'Alessandro, Umberto/D-3457-2015; Bassat, Quique/P-2341-2016
OI D'Alessandro, Umberto/0000-0001-6341-5009; Bassat,
   Quique/0000-0003-0875-7596
FU EDCTP
FX The main study was funded by EDCTP (www.edctp.org). This is an analysis
   of secondary data. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Four Artemisinin-Based Combinations (4ABC) Study Group, 2011, PLOS MED, V8, DOI DOI 10.1371/J0URNAL.PMED.1001119
   *AGD HTG, MED DICT REG ACT MED
   Almenoff J, 2005, DRUG SAFETY, V28, P981, DOI 10.2165/00002018-200528110-00002
   Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466
   BEGAUD B, 1994, BRIT J CLIN PHARMACO, V38, P401
   Calabrese L, 2000, AM J MED, V108, P487, DOI 10.1016/S0002-9343(99)00408-8
   Castro-Pastrana Lucila I, 2011, J Popul Ther Clin Pharmacol, V18, pe76
   CERRITO DP, 2001, CARDIOVASC TOXICOL, V1, P177
   Council for International Organizations of Medical Sciences, 2010, PRACT ASP SIGN DET P
   DuMouchel W, 1999, AM STAT, V53, P177, DOI 10.2307/2686093
   Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483, DOI 10.1002/pds.677
   Harpaz R, 2013, CLIN PHARMACOL THER, V93, P539, DOI 10.1038/clpt.2013.24
   HARPAZ R, 2010, BMC BIOINFORM S9, pS7
   HAUBEN DM, 2009, DRUG SAFETY, V32, P99
   Hauben Manfred, 2005, Expert Opin Drug Saf, V4, P929, DOI 10.1517/14740338.4.5.929
   ISAH AO, 2011, THER ADV DRUG SAF
   ISMAIL A, 2013, PHVID R PACKAGE PHAR
   Niu MT, 2001, VACCINE, V19, P4627, DOI 10.1016/S0264-410X(01)00237-7
   Pirmohamed M, 1998, BRIT MED J, V316, P1295
   R Development Core Team, 2013, R LANG ENV STAT COMP
   SACHS RM, 1986, AM J MED, V81, P49
   Waller PC, 2003, PHARMACOEPIDEM DR S, V12, P17, DOI 10.1002/pds.773
   *WHO, 2013, IMP PHARM SAF MON ME
   WHO, 2006, SAF MED PUBL HLTH PR
NR 24
TC 0
Z9 0
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2014
VL 9
IS 5
AR e96388
DI 10.1371/journal.pone.0096388
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG6EE
UT WOS:000335510600096
PM 24787710
OA gold
DA 2017-08-15
ER

PT J
AU Mackenzie, GA
   Bottomley, C
   van Hoek, AJ
   Jeffries, D
   Ota, M
   Zaman, SMA
   Greenwood, B
   Cutts, F
AF Mackenzie, Grant A.
   Bottomley, Christian
   van Hoek, Albert J.
   Jeffries, David
   Ota, Martin
   Zaman, Syed M. A.
   Greenwood, Brian
   Cutts, Felicity
TI Efficacy of different pneumococcal conjugate vaccine schedules against
   pneumonia, hospitalisation, and mortality: Re-analysis of a randomised
   trial in The Gambia
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Vaccine; Schedule; Pneumonia; Mortality
ID STREPTOCOCCUS-PNEUMONIAE; IMMUNOGENICITY; DISEASE; CHILDREN; SAFETY;
   BOOSTER
AB Background: Pneumococcal conjugate vaccines (PCV) reduce disease due to Streptococcus pneumoniae. We aimed to determine the efficacy of different PCV schedules in Gambian children.
   Methods: We reanalysed data from a randomised placebo-controlled trial. Infants aged 6-51 weeks were allocated to three doses of nine-valent PCV (n=8718) or placebo (n=8719) and followed until age 30 months. We categorised participants to compare: (a) a first dose at age 6 or 10 weeks, (b) intervals of 1 or 2 months between doses, and (c) different intervals between second and third doses. The primary endpoint was first episode of radiologic pneumonia; other endpoints were hospitalisation and mortality. Using the placebo group as the reference population, Poisson regression models were used with follow-up after the first dose to estimate the efficacy of each schedule and from age 6 weeks to estimate the incidence rate difference between schedules.
   Results: Predicted efficacy in the groups aged 6 weeks (n=2467, 154 events) or 10 weeks (n =2420, 106 events) at first dose against radiologic pneumonia were 32% (95% Cl 19-43%) and 33% (95% Cl 21-44%), against hospitalisation 14% (95% CI 3-23%) and 17% (95% CI 7-26%), and against mortality 17% (95% Cl -3 to 33%) and 16% (95% CI -3 to 32%) respectively. Predicted efficacy in the groups with intervals of 1 month (n=2701, 133 events) or 2 months (n=1351, 58 events) between doses against radiologic pneumonia were 33% (95% CI 20-44%) and 36% (95% Cl 24-46%), against hospitalisation 15% (95% CI 5-24%) and 18% (95% CI 8-27%), and against mortality 17% (95% Cl -2 to 33%) and 13% (95% CI -8 to 29%) respectively. Efficacy did not differ by interval between second and third doses, nor did the incidence rate difference between schedules.
   Conclusions: We found no evidence that efficacy or effectiveness of PCV9 differed when doses were given with modest variability around the scheduled ages or intervals between doses. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Mackenzie, Grant A.; Jeffries, David; Ota, Martin] Med Res Council UK, Gambia Unit, Banjul, Gambia.
   [Bottomley, Christian] London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1E 7HT, England.
   [van Hoek, Albert J.; Zaman, Syed M. A.] Publ Hlth England, London NW9 5EQ, England.
   [Greenwood, Brian; Cutts, Felicity] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England.
RP Mackenzie, GA (reprint author), MRC Basse Field Stn, POB 273, Banjul, Gambia.
EM gmackenzie@mrc.gm; Christian.bottomley@lshtm.ac.uk;
   albertjan.vanhoek@hpa.org.uk; djeffries@mrc.gm; otama@afro.who.int;
   azaman@mrc.gm; Brian.Greenwood@lshtm.ac.uk; Felicity.Cutts@lshtm.ac.uk
FU National Institute of Allergy and Infectious Diseases at the USA
   National Institutes of Health [N01-AI-25477]; WHO [V23/181/127];
   Children's Vaccine Programme at PATH; US Agency for International
   Development
FX The original trial was supported by grants from the National Institute
   of Allergy and Infectious Diseases at the USA National Institutes of
   Health (N01-AI-25477); WHO (V23/181/127); the Children's Vaccine
   Programme at PATH; and US Agency for International Development. Wyeth
   Vaccines donated study vaccine and placebo, Tetramune for all children
   in the Upper and Central River Divisions, and PCV7 for children who
   received placebo, after the trial results were reviewed. No additional
   funding was required for this analysis. No funding body had a role in
   the conception of this reanalysis, the interpretation, writing of the
   report, or the decision to submit for publication. The corresponding
   author had full access to all the data and had final responsibility for
   the decision to submit for publication.
CR Andrews N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028435
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Conklin L, 2011, 10 AVITAC
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Esposito S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-12
   Givon-Lavi N, 2010, PEDIATR INFECT DIS J, V29, P756, DOI 10.1097/INF.0b013e3181d99345
   Klugman KP, 2011, VACCINE, V29, P3372, DOI 10.1016/j.vaccine.2011.02.089
   Klugman KP, 2008, PNEUMOCOCCAL VACCINES: THE IMPACT OF CONJUGATE VACCINE, P317
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Mackenzie GA, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001161
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   Ota MO, 2011, VACCINE, V29, P2999, DOI 10.1016/j.vaccine.2011.01.098
   Palmu AA, 2013, LANCET, V381, P214, DOI 10.1016/S0140-6736(12)61854-6
   Rothman KJ, 2008, MODERN EPIDEMIOLOGY, P128
   Ruckinger S, 2010, VACCINE, V28, P5012, DOI 10.1016/j.vaccine.2010.05.021
   Russell FM, 2010, CLIN VACCINE IMMUNOL, V17, P1970, DOI 10.1128/CVI.00117-10
   Russell FM, 2009, VACCINE, V27, P5685, DOI 10.1016/j.vaccine.2009.06.098
   Scott P, 2011, PNEUMOCOCCAL CONJUGA
   Scott P, 2011, VACCINE, V29, P9711, DOI 10.1016/j.vaccine.2011.07.042
   Sigurdardottir ST, 2008, VACCINE, V26, P4178, DOI 10.1016/j.vaccine.2008.05.072
   Silfverdal Sven Arne, 2009, Pediatr Infect Dis J, V28, pe276, DOI 10.1097/INF.0b013e3181b48ca3
   Spijkerman J, 2013, JAMA-J AM MED ASSOC, V310, P930, DOI 10.1001/jama.2013.228052
   Trotter CL, 2008, VACCINE, V26, P4434, DOI 10.1016/j.vaccine.2008.05.073
   World Health Organization, 2012, WKLY EPIDEMIOL REC, V87, P129
   World Health Organization Pneumonia Vaccine Trial Investigators' Group, STAND INT CHEST RAD
NR 26
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2014
VL 32
IS 21
BP 2493
EP 2500
DI 10.1016/j.vaccine.2014.02.081
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AG7RJ
UT WOS:000335615200018
PM 24631086
OA No
DA 2017-08-15
ER

PT J
AU Reiches, MW
   Moore, SE
   Prentice, AM
   Ellison, PT
AF Reiches, Meredith W.
   Moore, Sophie E.
   Prentice, Andrew M.
   Ellison, Peter T.
TI Endocrine Responses, Weight Change, and Energy Sparing Mechanisms During
   Ramadan Among Gambian Adolescent Women
SO AMERICAN JOURNAL OF HUMAN BIOLOGY
LA English
DT Article
ID BODY-COMPOSITION; LEPTIN SECRETION; INSULIN; PATTERNS; EXPOSURE;
   BALANCE; MILK
AB ObjectivesRamadan fasting imposes a diurnal rather than a chronic energetic challenge. When Ramadan occurs during the agricultural season in subsistence populations, diurnal and chronic effects combine. The impact of layered energetic challenges on adolescent activity, metabolism, and body composition have not been quantified. This study compares the effects of a Ramadan (30 July-3 October 2009) and subsequent non-Ramadan (14 July-12 August 2010) agricultural season in 67 Gambian subsistence agriculturalist women between 14 and 20 years old.
   MethodsResearchers collected body composition, anthropometric, metabolic, and activity data. Metabolic hormones were measured in weekly urine (C-peptide of insulin) and serum (leptin). Energy expenditure was estimated from heart rate calibrated for oxygen consumption.
   ResultsParticipants lost more weight (Wald Chi-square 8.7, P<0.01) and lean mass (Wald Chi-square 4.7, P<0.05) in Ramadan than in the non-Ramadan agricultural season. Energy expenditure was lower (Wald Chi-square 11.2, P=0.001) and there was a negative correlation between resting metabolic rate and energy expenditure in activity (R-2=0.097, F=5.366, P=0.025) during Ramadan. Leptin and C-peptide were higher during Ramadan (Wald Chi-square 53.7, P<0.001 and Wald Chi-square 15.0, P<0.001).
   ConclusionsEven using energy sparing behaviors, adolescent women enter negative energy balance when Ramadan and the agricultural season co-occur. Metabolic physiology shows a transient response to high glycemic index foods consumed at night. Older and larger individuals sustain greater losses during Ramadan. Am. J. Hum. Biol. 26:395-400, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Reiches, Meredith W.] Univ Massachusetts, Dept Anthropol, Boston, MA 02125 USA.
   [Moore, Sophie E.; Prentice, Andrew M.] MRC Keneba, MRC Unit, Banjul, Gambia.
   [Moore, Sophie E.; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
   [Ellison, Peter T.] Harvard Univ, Dept Human Evolutionary Biol, Cambridge, MA 02138 USA.
RP Reiches, MW (reprint author), Univ Massachusetts, Dept Anthropol, 100 Morrissey Blvd, Boston, MA 02125 USA.
EM meredith.reiches@umb.edu
FU Doctoral Dissertation Improvement Grant [BCS-0925768]; Senior Research
   Grant from the National Science Foundation of the United States
   [BCS-0921237]; UK Medical Research Council [MC-A760-5QX00, U105960371,
   U123261351]
FX Contract grant sponsor: Doctoral Dissertation Improvement Grant;
   Contract grant number: BCS-0925768; Contract grant sponsor: Senior
   Research Grant from the National Science Foundation of the United
   States; Contract grant number: BCS-0921237; Contract grant sponsor: UK
   Medical Research Council; Contract grant number: MC-A760-5QX00,
   U105960371, and U123261351.
CR Al-Hourani H. M., 2007, SMJ Singapore Medical Journal, V48, P906
   Alwasel SH, 2013, AM J HUM BIOL, V25, P341, DOI 10.1002/ajhb.22374
   Alwasel SH, 2011, AM J HUM BIOL, V23, P651, DOI 10.1002/ajhb.21193
   Alwasel SH, 2010, PLACENTA, V31, P607, DOI 10.1016/j.placenta.2010.04.010
   Bogdan A, 2005, BRIT J NUTR, V93, P515, DOI 10.1079/BJN20041380
   Cammisotto PG, 2005, AM J PHYSIOL-ENDOC M, V289, pE166, DOI 10.1152/ajpendo.00602.2004
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Charnov Eric L., 1993, Evolutionary Anthropology, V1, P191, DOI 10.1002/evan.1360010604
   Dominguez-Salas P, 2013, AM J CLIN NUTR, V97, P1217, DOI 10.3945/ajcn.112.048462
   Ellison PT, 2012, ANN HUM BIOL, V39, P352, DOI 10.3109/03014460.2012.693199
   GADGIL M, 1970, American Naturalist, V104, P1, DOI 10.1086/282637
   HAKKOU F, 1994, CHRONOBIOL INT, V11, P340, DOI 10.3109/07420529409057250
   Hawkesworth S, 2008, J NUTR, V138, P2468, DOI 10.3945/jn.108.098665
   Kassab S, 2004, ANN SAUDI MED, V24, P345
   Khoshdel A, 2007, IRAN J PEDIATR, V17, P345
   Lamri-Senhadji MY, 2009, SINGAP MED J, V50, P288
   Lee MJ, 2009, AM J PHYSIOL-ENDOC M, V296, pE1230, DOI 10.1152/ajpendo.90927.2008
   Levy JR, 2001, ENDOCRINOLOGY, V142, P3558, DOI 10.1210/en.142.8.3558
   Ndiaye GM, 2007, ANN HUM BIOL, V34, P454, DOI 10.1080/03014460701383774
   Nieman David C, 2006, Res Sports Med, V14, P89, DOI 10.1080/15438620600651512
   Norouzy A, 2013, J HUM NUTR DIET, V26, P97, DOI 10.1111/jhn.12042
   Poh B, 1996, Malays J Nutr, V2, P1
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   PRENTICE AM, 1984, CLIN SCI, V66, P291
   Prins M, 2008, EUR J CLIN NUTR, V62, P1065, DOI 10.1038/sj.ejcn.1602830
   Rahman M, 2004, East Mediterr Health J, V10, P131
   Rakicioglu N, 2006, PEDIATR INT, V48, P278, DOI 10.1111/j.1442-200X.2006.02204.x
   Reiches Meredith W, 2013, Evol Med Public Health, V2013, P75, DOI 10.1093/emph/eot005
   Saleh SA, 2005, MAL J NUTR, V11, P143
   Shruthi B, 2013, INT J RECENT TRENDS, V8, P31
   TAUSSKY HH, 1954, J BIOL CHEM, V208, P853
   Thompson ME, 2008, HORM BEHAV, V53, P526, DOI 10.1016/j.yhbeh.2007.12.005
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1
   Yamauchi F, 2011, PRENATAL SEASONALITY
   Ziaee V., 2006, SMJ Singapore Medical Journal, V47, P409
NR 35
TC 1
Z9 1
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1042-0533
EI 1520-6300
J9 AM J HUM BIOL
JI Am. J. Hum. Biol.
PD MAY
PY 2014
VL 26
IS 3
BP 395
EP 400
DI 10.1002/ajhb.22531
PG 6
WC Anthropology; Biology
SC Anthropology; Life Sciences & Biomedicine - Other Topics
GA AF7WG
UT WOS:000334925200013
PM 24590590
OA No
DA 2017-08-15
ER

PT J
AU Redmond, J
   Jarjou, LMA
   Zhou, B
   Prentice, A
   Schoenmakers, I
AF Redmond, J.
   Jarjou, L. M. A.
   Zhou, B.
   Prentice, A.
   Schoenmakers, I.
TI Ethnic differences in calcium, phosphate and bone metabolism
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article; Proceedings Paper
CT Annual Summer Meeting of the Nutrition-Society / Conference on Nutrition
   and Healthy Ageing
CY JUL 15-18, 2013
CL Newcastle Univ, Newcastle upon Tyne, ENGLAND
SP Nutr Soc
HO Newcastle Univ
DE Diurnal rhythm; Bone; Dietary intake; Calcium; Phosphate; Parathyroid
   hormone
ID RURAL GAMBIAN WOMEN; POSTMENOPAUSAL CHINESE WOMEN; NUTRITION EXAMINATION
   SURVEY; INTACT PARATHYROID-HORMONE; HIP FRACTURE INCIDENCE; CHRONIC
   KIDNEY-DISEASE; VITAMIN-D DEFICIENCY; BODY-MASS INDEX; CIRCADIAN-RHYTHM;
   RACIAL-DIFFERENCES
AB The prevalence of osteoporosis and the incidence of age-related fragility fracture vary by ethnicity. There is greater than 10-fold variation in fracture probabilities between countries across the world. Mineral and bone metabolism are intimately interlinked, and both are known to exhibit patterns of daily variation, known as the diurnal rhythm (DR). Ethnic differences are described for Ca and P metabolism. The importance of these differences is described in detail between select ethnic groups, within the USA between African-Americans and White-Americans, between the Gambia and the UK and between China and the UK. Dietary Ca intake is higher in White-Americans compared with African-Americans, and is higher in White-British compared with Gambian and Chinese adults. Differences are observed also for plasma 25-hydroxy vitamin D, related to lifestyle differences, skin pigmentation and skin exposure to UVB-containing sunshine. Higher plasma 1,25-dihydroxy vitamin D and parathyroid hormone are observed in African-American compared with White-American adults. Plasma parathyroid hormone is also higher in Gambian adults and, in winter, in Chinese compared with White-British adults. There may be ethnic differences in the bone resorptive effects of parathyroid hormone, with a relative skeletal resistance to parathyroid hormone observed in some, but not all ethnic groups. Renal mineral excretion is also influenced by ethnicity; urinary Ca (uCa) and urinary P (uP) excretions are lower in African-Americans compared with White-Americans, and in Gambians compared with their White-British counterparts. Little is known about ethnic differences in the DR of Ca and P metabolism, but differences may be expected due to known differences in lifestyle factors, such as dietary intake and sleep/wake pattern. The ethnic-specific DR of Ca and P metabolism may influence the net balance of Ca and P conservation and bone remodelling. These ethnic differences in Ca, P and the bone metabolism may be important factors in the variation in skeletal health.
C1 [Redmond, J.; Prentice, A.; Schoenmakers, I.] Med Res Council Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Jarjou, L. M. A.; Prentice, A.] Med Res Council Keneba, Serrekunda, Gambia.
   [Zhou, B.] Shenyang Med Coll, Dept Publ Hlth, Shenyang 110034, Peoples R China.
RP Redmond, J (reprint author), Med Res Council Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
EM jean.redmond@mrc-hnr.cam.ac.uk
FU Medical Research Council [U123261351, MC_U105960371, U105960371]
CR ABRAMS SA, 1995, J BONE MINER RES, V10, P829
   ADEBAJO AO, 1991, AGE AGEING, V20, P435, DOI 10.1093/ageing/20.6.435
   Aerssens J, 1999, CALCIFIED TISSUE INT, V65, P34, DOI 10.1007/s002239900654
   Ahmad AM, 2003, BONE, V32, P170, DOI 10.1016/S8756-3282(02)00952-3
   Alaimo K, 1994, ADV DATA VITAL HLTH, V258, P1
   Aloia JF, 1998, J LAB CLIN MED, V132, P383, DOI 10.1016/S0022-2143(98)90109-3
   Angbratt M, 2007, PUBLIC HEALTH NURS, V24, P511, DOI 10.1111/j.1525-1446.2007.00663.x
   Arunabh S, 2003, J CLIN ENDOCR METAB, V88, P157, DOI 10.1210/jc.2002-020978
   Aspray TJ, 1996, J BONE MINER RES, V11, P1019
   Aspray TJ, 2005, BONE, V36, P710, DOI 10.1016/j.bone.2005.01.002
   Barrett JA, 1999, J CLIN EPIDEMIOL, V52, P243, DOI 10.1016/S0895-4356(98)00167-X
   Bates B, 2014, NATL DIET NUTR SURVE
   Bell NH, 1997, TRENDS ENDOCRIN MET, V8, P240, DOI 10.1016/S1043-2760(97)00065-9
   BELL NH, 1993, J BONE MINER RES, V8, P1111
   BELL NH, 1985, J CLIN INVEST, V76, P470, DOI 10.1172/JCI111995
   Bell NH, 2001, OSTEOPOROSIS INT, V12, P43, DOI 10.1007/s001980170156
   BLUMSOHN A, 1994, J CLIN ENDOCR METAB, V79, P730, DOI 10.1210/jc.79.3.730
   Braun M, 2007, AM J CLIN NUTR, V85, P1657
   BRAZEROL WF, 1988, J AM COLL NUTR, V7, P111
   CALVO MS, 1991, J CLIN ENDOCR METAB, V72, P69
   Carpenter TO, 2010, J CLIN ENDOCR METAB, V95, P352
   Cheserek Maureen J., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P86, DOI 10.1080/21551197.2012.647562
   CLEMENS TL, 1982, LANCET, V1, P74
   Clowes JA, 2002, BONE, V30, P886, DOI 10.1016/S8756-3282(02)00728-7
   Coney P, 2012, INT J GYNECOL OBSTET, V119, P21, DOI 10.1016/j.ijgo.2012.05.024
   Cosman F, 1997, J BONE MINER RES, V12, P958, DOI 10.1359/jbmr.1997.12.6.958
   Dawson-Hughes B, 2004, AM J CLIN NUTR, V80, p1763S
   DAWSONHUGHES B, 1995, J CLIN ENDOCR METAB, V80, P3068, DOI 10.1210/jc.80.10.3068
   Department of Health, 1998, NUTR BON HLTH PART R
   EASTELL R, 1992, J CLIN ENDOCR METAB, V74, P487, DOI 10.1210/jc.74.3.487
   Engelsen O., 2005, DURATION VITAMIN D S
   Favus MJ, 2008, PRIMER METABOLIC BON, P104
   Finkelstein JS, 2002, J CLIN ENDOCR METAB, V87, P3051, DOI 10.1210/jc.87.7.3051
   Fraser WD, 2004, CURR OPIN NEPHROL HY, V13, P437, DOI 10.1097/01.mnh.0000133985.29880.34
   Fraser WD, 1998, OSTEOPOROSIS INT, V8, P121, DOI 10.1007/BF02672507
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756-3282(03)00202-3
   FULEIHAN GE, 1997, J CLIN ENDOCR METAB, V82, P281, DOI DOI 10.1210/JC.82.1.281
   Fulgoni V, 2007, J AM DIET ASSOC, V107, P256, DOI 10.1016/j.jada.2006.11.007
   Greenspan SL, 1997, CALCIFIED TISSUE INT, V60, P419
   GUNDBERG CM, 1985, J CLIN ENDOCR METAB, V60, P736
   Gutierrez OM, 2011, OSTEOPOROSIS INT, V22, P1745, DOI 10.1007/s00198-010-1383-2
   Gutierrez OM, 2010, NEPHROL DIAL TRANSPL, V25, P3970, DOI 10.1093/ndt/gfq316
   Hu J, 1993, AM J CLIN NUTR, V58, P217
   Jarjou LMA, 2010, AM J CLIN NUTR, V92, P450, DOI 10.3945/ajcn.2010.29217
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   Jiang L, 2012, ACTA PAEDIATR, V101, pE192, DOI 10.1111/j.1651-2227.2011.02557.x
   Joseph F, 2008, J BONE MINER RES, V23, P721, DOI 10.1359/JBMR.071117
   JUBIZ W, 1972, J CLIN INVEST, V51, P2040, DOI 10.1172/JCI107010
   Kamycheva E, 2004, EUR J ENDOCRINOL, V151, P167, DOI 10.1530/eje.0.1510167
   Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198-012-1964-3
   KELLIE SE, 1990, AM J PUBLIC HEALTH, V80, P326, DOI 10.2105/AJPH.80.3.326
   KLEEREKOPER M, 1994, J BONE MINER RES, V9, P1745
   Knochel J, 2006, MODERN NUTR HLTH DIS
   Koizumi M, 2013, CONTRIB NEPHROL, V180, P110, DOI 10.1159/000346791
   Kruger MC, 2012, EUR J CLIN NUTR, V66, P856, DOI 10.1038/ejcn.2012.54
   Lambers TT, 2006, KIDNEY INT, V69, P650, DOI 10.1038/sj.ki.5000169
   LAU E, 1988, BRIT MED J, V297, P1441
   Lau EMC, 2001, J BONE MINER RES, V16, P1704, DOI 10.1359/jbmr.2001.16.9.1704
   Lauderdale DS, 1997, AM J EPIDEMIOL, V146, P502
   LEDGER GA, 1995, J CLIN ENDOCR METAB, V80, P3304, DOI 10.1210/jc.80.11.3304
   Lewiecki EM, 2013, J CLIN DENSITOM, V16, P28, DOI 10.1016/j.jocd.2012.11.013
   National Osteoporosis Guideline Group, 2010, GUID DIAGN MAN OST
   Nelson M., 2007, LOW INCOME DIET NUTR
   Oxford English Dictionary, 2002, OXFORD ENGLISH DICT
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   PRENTICE A, 1991, BONE MINER, V12, P201, DOI 10.1016/0169-6009(91)90033-V
   Prentice A, 2008, NUTR REV, V66, pS153, DOI 10.1111/j.1753-4887.2008.00100.x
   Prentice A, 2007, P NUTR SOC, V66, P512, DOI 10.1017/S0029665107005836
   Redmond J, 2013, NUTR SOC SUMM M NEWC
   Refinetti R., 2006, CIRCADIAN PHYSL
   Rejnmark L, 2002, EUR J ENDOCRINOL, V146, P635, DOI 10.1530/eje.0.1460635
   Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899
   Schlemmer A, 1999, EUR J ENDOCRINOL, V140, P332, DOI 10.1530/eje.0.1400332
   SCHLEMMER A, 1994, J BONE MINER RES, V9, P1883
   SCHNITZLER CM, 1993, CALCIFIED TISSUE INT, V53, pS27, DOI 10.1007/BF01673398
   Schoenmakers I, 2013, OSTEOPOROSIS INT, V24, P2301, DOI 10.1007/s00198-013-2280-2
   Schoenmakers I, 2010, J STEROID BIOCHEM, V121, P217, DOI 10.1016/j.jsbmb.2010.03.012
   Schoenmakers I, 2008, BRIT J NUTR, V99, P1171, DOI 10.1017/S0007114508898662
   Scopacasa F, 2002, HORM METAB RES, V34, P44, DOI 10.1055/s-2002-19967
   Signorello LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028623
   SILVERMAN SL, 1988, AM J PUBLIC HEALTH, V78, P1482, DOI 10.2105/AJPH.78.11.1482
   SPENCER H, 1978, J NUTR, V108, P447
   Tam CY, 2011, NUTR CANCER, V63, P687, DOI 10.1080/01635581.2011.563026
   Taylor EN, 2007, J AM SOC NEPHROL, V18, P654, DOI 10.1681/ASN.2006080854
   U. S. Department of Health and Human Services, 2004, BON HLTH OST
   Walsh JS, 2010, ARCH BIOCHEM BIOPHYS, V503, P11, DOI 10.1016/j.abb.2010.06.020
   WEINSTEIN RS, 1988, NEW ENGL J MED, V319, P1698, DOI 10.1056/NEJM198812293192603
   White K. E., 2008, PRIMER METABOLIC BON, P112, DOI 10.1002/9780470623992.ch23
   Wichers M, 1999, CLIN CHEM, V45, P1858
   Woo J, 1994, J GERONTOL, V49, P189
   Yan L, 1999, BONE, V24, P151, DOI 10.1016/S8756-3282(98)00168-9
   Yan L, 2003, BONE, V33, P620, DOI 10.1016/S8756-3282(03)00216-3
   Yan LY, 2009, BONE, V45, P238, DOI 10.1016/j.bone.2009.04.237
   YANO K, 1985, AM J CLIN NUTR, V42, P877
   Zhang Ji, 2012, Zhonghua Liu Xing Bing Xue Za Zhi, V33, P1119
   Zhang W, 2013, NUTRITION
NR 97
TC 10
Z9 10
U1 1
U2 15
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0029-6651
EI 1475-2719
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD MAY
PY 2014
VL 73
IS 2
BP 340
EP 351
DI 10.1017/S0029665114000068
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AE6LF
UT WOS:000334103400020
PM 24621477
OA No
DA 2017-08-15
ER

PT J
AU Mendy, A
   Aderonke, A
   Sutherlan, J
   Ota, M
   Mendy, A
AF Mendy, Awa
   Aderonke, Adutola
   Sutherlan, Jayne
   Ota, Matrin
   Mendy, Awa
TI Kinetics of antibodies against major pneumococcal proteins in mother and
   child
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Mendy, Awa; Aderonke, Adutola; Sutherlan, Jayne; Ota, Matrin; Mendy, Awa] MRC, Vaccinoloyg, Banjul, Gambia.
   [Ota, Matrin] World Hlth Org, Brazzaville, Congo.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA HUM8P.348
PG 1
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765002042
OA No
DA 2017-08-15
ER

PT J
AU Lloyd-Fox, S
   Papademetriou, M
   Darboe, MK
   Everdell, NL
   Wegmuller, R
   Prentice, AM
   Moore, SE
   Elwell, CE
AF Lloyd-Fox, Sarah
   Papademetriou, M.
   Darboe, M. K.
   Everdell, N. L.
   Wegmuller, R.
   Prentice, A. M.
   Moore, S. E.
   Elwell, C. E.
TI Functional near infrared spectroscopy (fNIRS) to assess cognitive
   function in infants in rural Africa.
SO SCIENTIFIC REPORTS
LA English
DT Article
ID 1ST 2 YEARS; SPEECH-PERCEPTION; DEVELOPING BRAIN; EYE GAZE; GROWTH;
   AUTISM; VOICE; LIFE; FACE; SUPPLEMENTATION
AB Cortical mapping of cognitive function during infancy is poorly understood in low-income countries due to the lack of transportable neuroimaging methods. We have successfully piloted functional near infrared spectroscopy (fNIRS) as a neuroimaging tool in rural Gambia. Four-to-eight month old infants watched videos of Gambian adults perform social movements, while haemodynamic responses were recorded using fNIRS. We found distinct regions of the posterior superior temporal and inferior frontal cortex that evidenced either visual-social activation or vocally selective activation (vocal. non-vocal). The patterns of selective cortical activation in Gambian infants replicated those observed within similar aged infants in the UK. These are the first reported data on the measurement of localized functional brain activity in young infants in Africa and demonstrate the potential that fNIRS offers for field-based neuroimaging research of cognitive function in resource-poor rural communities.
C1 [Lloyd-Fox, Sarah] Birkbeck Univ London, Ctr Brain & Cognit Dev, London, England.
   [Papademetriou, M.; Everdell, N. L.; Elwell, C. E.] UCL, Dept Med Phys & Bioengn, London, England.
   [Darboe, M. K.; Wegmuller, R.; Prentice, A. M.; Moore, S. E.] MRC, Int Nutr Grp, MRC Keneba, MRC Unit, Keneba, Gambia.
   [Prentice, A. M.; Moore, S. E.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
RP Lloyd-Fox, S (reprint author), Birkbeck Univ London, Ctr Brain & Cognit Dev, London, England.
EM s.fox@bbk.ac.uk
FU Bill & Melinda Gates Foundation Phase One Grand Challenges Exploration
   Grant [OPP1061089, MC-A760-5QX00]; Medical Research Council UK; UK
   Department for International Development (DfID) under the MRC/DfID
   COncordant agreement; UK Medical Research Council [G0701484]
FX We would like to thank the parents and infants who took part in this
   study as well as the field workers at the MRC Keneba Field Station
   without whom this work would not have been possible. This study was
   supported by a Bill & Melinda Gates Foundation Phase One Grand
   Challenges Exploration Grant OPP1061089, core funding MC-A760-5QX00 to
   the International Nutrition Group by the Medical Research Council UK and
   the UK Department for International Development (DfID) under the
   MRC/DfID COncordant agreement, and a UK Medical Research Council
   (G0701484) grant.
CR Aslin RN, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1854672
   Beard JL, 2003, ANNU REV NUTR, V23, P41, DOI 10.1146/annurev.nutr.23.020102.075739
   Belin P, 2000, NATURE, V403, P309, DOI 10.1038/35002078
   Belin P, 2008, BEHAV RES METHODS, V40, P531, DOI 10.3758/BRM.40.2.531
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Blasi A, 2011, CURR BIOL, V21, P1220, DOI 10.1016/j.cub.2011.06.009
   Coutts LV, 2012, CEPHALALGIA, V32, P621, DOI 10.1177/0333102412444474
   Cristia A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058906
   Currie J., 2011, HDB LABOR EC, V4, P1315, DOI DOI 10.1016/S0169-7218(11)02413-0
   Cusick SE, 2012, ARCH PEDIAT ADOL MED, V166, P481, DOI 10.1001/archpediatrics.2012.199
   Dehaene-Lambertz G, 2002, SCIENCE, V298, P2013, DOI 10.1126/science.1077066
   Elsabbagh M, 2012, CURR BIOL, V22, P338, DOI 10.1016/j.cub.2011.12.056
   Elsabbagh M, 2009, BIOL PSYCHIAT, V65, P31, DOI 10.1016/j.biopsych.2008.09.034
   Everdell NL, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.2038567
   Fox S. E., 2013, FRONT HUM NEUROSCI, V7, P1
   Fukui Y, 2003, APPL OPTICS, V42, P2881, DOI 10.1364/AO.42.002881
   Georgieff MK, 2007, AM J CLIN NUTR, V85, p614S
   Gervain J, 2011, DEV COGN NEUROS-NETH, V1, P22, DOI 10.1016/j.dcn.2010.07.004
   Grossmann T, 2008, P ROY SOC B-BIOL SCI, V275, P2803, DOI 10.1098/rspb.2008.0986
   Grossmann T, 2010, NEURON, V65, P852, DOI 10.1016/j.neuron.2010.03.001
   Guiraud JA, 2011, NEUROREPORT, V22, P845, DOI 10.1097/WNR.0b013e32834c0bec
   Huotilainen M, 2003, NEUROREPORT, V14, P1871, DOI 10.1097/01.wnr.0000090589.35425.10
   Imada T, 2006, NEUROREPORT, V17, P957, DOI 10.1097/01.wnr.0000223387.51704.89
   Isaacs E. B., 2013, FRONT HUM NEUROSCI, V7, P1
   Jackson P. A., 2013, FRONT HUM NEUROSCI, V7
   Kolyva C, 2013, ADV EXP MED BIOL, V765, P101, DOI 10.1007/978-1-4614-4989-8_15
   Kretchmer Norman, 1996, American Journal of Clinical Nutrition, V63, p997S
   Lee KH, 1999, PEDIATR RES, V45, P331, DOI 10.1203/00006450-199903000-00007
   Lloyd-Fox S, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.3026
   Lloyd-Fox S, 2012, SOC NEUROSCI-UK, V7, P317, DOI 10.1080/17470919.2011.614696
   Lloyd-Fox S, 2010, NEUROSCI BIOBEHAV R, V34, P269, DOI 10.1016/j.neubiorev.2009.07.008
   Lloyd-Fox S, 2015, CEREB CORTEX, V25, P289, DOI 10.1093/cercor/bht207
   Lloyd-Fox S, 2011, J COGNITIVE NEUROSCI, V23, P2521, DOI 10.1162/jocn.2010.21598
   Lloyd-Fox S, 2009, CHILD DEV, V80, P986, DOI 10.1111/j.1467-8624.2009.01312.x
   Lunn PG, 2000, P NUTR SOC, V59, P147, DOI 10.1017/S0029665100000173
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   Luyster RJ, 2011, BRAIN TOPOGR, V24, P220, DOI 10.1007/s10548-011-0176-z
   Martorell R, 2010, J NUTR, V140, P348, DOI 10.3945/jn.109.112300
   McCleery JP, 2009, BIOL PSYCHIAT, V66, P950, DOI 10.1016/j.biopsych.2009.07.031
   Mendez MA, 1999, J NUTR, V129, P1555
   Minagawa-Kawai Y, 2011, CEREB CORTEX, V21, P254, DOI 10.1093/cercor/bhq082
   Minagawa-Kawai Y, 2009, NEUROREPORT, V20, P1219, DOI 10.1097/WNR.0b013e32832fa65f
   Minagawa-Kawai Y, 2009, CEREB CORTEX, V19, P284, DOI 10.1093/cercor/bhn081
   Obrig H, 2003, J CEREBR BLOOD F MET, V23, P1, DOI 10.1097/01.WCB.0000043472.45775.29
   Otsuka Y, 2007, NEUROIMAGE, V34, P399, DOI 10.1016/j.neuroimage.2006.08.013
   POWELL CA, 1995, ACTA PAEDIATR, V84, P22, DOI 10.1111/j.1651-2227.1995.tb13479.x
   Salamon G., 1990, MAGNETIC RESONANCE I
   Sato H, 2013, NEUROIMAGE, V83, P158, DOI 10.1016/j.neuroimage.2013.06.043
   Shimada S, 2006, NEUROIMAGE, V32, P930, DOI 10.1016/j.neuroimage.2006.03.044
   Steinbrink J, 2006, MAGN RESON IMAGING, V24, P495, DOI 10.1016/j.mri.2005.12.034
   Tomalski P, 2013, DEVELOPMENTAL SCI, V16, P676, DOI 10.1111/desc.12079
   Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P454, DOI 10.1006/nimg.2001.0979
   United Nations Children's Fund (UNICEF), 2013, IMPR CHILD NUTR ACH
   van der Merwe LF, 2013, AM J CLIN NUTR, V97, P45, DOI 10.3945/ajcn.112.042267
   Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4
   Victora CG, 2010, PEDIATRICS, V125, pE473, DOI 10.1542/peds.2009-1519
   Watanabe H, 2008, NEUROIMAGE, V43, P346, DOI 10.1016/j.neuroimage.2008.07.014
   Wilcox T., 2005, J BIOMED OPT, V10
   Wilcox T, 2014, NEUROIMAGE, V85, P302, DOI 10.1016/j.neuroimage.2013.08.045
   Wolff J. J., 2012, AM J PSYCHIAT, V169, P580
NR 60
TC 13
Z9 13
U1 3
U2 26
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 22
PY 2014
VL 4
AR 4740
DI 10.1038/srep04740
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AF4FO
UT WOS:000334667300001
PM 24751935
OA gold
DA 2017-08-15
ER

PT J
AU Okebe, J
   Amambua-Ngwa, A
   Parr, J
   Nishimura, S
   Daswani, M
   Takem, EN
   Affara, M
   Ceesay, SJ
   Nwakanma, D
   D'Alessandro, U
AF Okebe, Joseph
   Amambua-Ngwa, Alfred
   Parr, Jason
   Nishimura, Sei
   Daswani, Melissa
   Takem, Ebako N.
   Affara, Muna
   Ceesay, Serign J.
   Nwakanma, Davis
   D'Alessandro, Umberto
TI The prevalence of glucose-6-phosphate dehydrogenase deficiency in
   Gambian school children
SO MALARIA JOURNAL
LA English
DT Article
DE Glucose-6-phosphate dehydrogenase deficiency; Malaria; Genotype;
   Phenotype; Prevalence
ID G6PD DEFICIENCY; SEVERE MALARIA; GAMETOCYTOCIDAL DRUG; WEST-AFRICA;
   SENEGAL; ASSOCIATION; TANZANIA; SUSCEPTIBILITY; POLYMORPHISMS;
   TRANSMISSION
AB Background: Primaquine, the only available drug effective against Plasmodium falciparum sexual stages, induces also a dose-dependent haemolysis, especially in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals. Therefore, it is important to determine the prevalence of this deficiency in areas that would potentially benefit from its use. The prevalence of G6PD deficiency by genotype and enzyme activity was determined in healthy school children in The Gambia.
   Methods: Blood samples from primary school children collected during a dry season malaria survey were screened for G6PDd and malaria infection. Genotypes for allele mutations reported in the country; 376, 202A-, 968A- and 542 were analysed while enzyme activity (phenotype) was assayed using a semi-quantitative commercial test kit. Enzyme activity values were fitted in a finite mixture model to determine the distribution and calculate a cut-off for deficiency. The association between genotype and phenotype for boys and girls as well as the association between mutant genotype and deficient phenotype was analysed.
   Results: Samples from 1,437 children; 51% boys were analysed. The prevalence of P. falciparum malaria infection was 14%. The prevalence of the 202A-, 968 and 542 mutations was 1.8%, 2.1% and 1.0%, respectively, and higher in boys than in girls. The prevalence of G6PDd phenotype was 6.4% (92/1,437), 7.8% (57/728) in boys and 4.9% (35/709) in girls with significantly higher odds in the former (OR 1.64, 95% CI 1.05, 2.53, p = 0.026). The deficient phenotype was associated with reduced odds of malaria infection (OR 0.77, 95% CI 0.36, 1.62, p = 0.49).
   Conclusions: There is a weak association between genotype and phenotype estimates of G6PDd prevalence. The phenotype expression of deficiency represents combinations of mutant alleles rather than specific mutations. Genotype studies in individuals with a deficient phenotype would help identify alleles responsible for haemolysis.
C1 [Okebe, Joseph; Amambua-Ngwa, Alfred; Nishimura, Sei; Daswani, Melissa; Takem, Ebako N.; Affara, Muna; Ceesay, Serign J.; Nwakanma, Davis; D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Parr, Jason] Univ Manchester, Manchester, Lancs, England.
   [D'Alessandro, Umberto] London Sch Hyg & Trop Med, London WC1, England.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
RP Okebe, J (reprint author), MRC Unit, Atlantic Blvd, Fajara, Gambia.
EM jokebe@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Medical Research Council UK
FX The study was funded by the Medical Research Council UK. The funders did
   not play any role in the study design, data collection and analysis or
   in drafting the manuscript. The authors acknowledge the support of the
   Teachers, parents and the staff of the Ministry of Basic and Secondary
   Education, The Gambia on this project.
CR ALLISON AC, 1961, NATURE, V190, P1198, DOI 10.1038/1901198a0
   Baird JK, 2011, TRENDS PARASITOL, V27, P11, DOI 10.1016/j.pt.2010.08.005
   Cappellini MD, 2008, LANCET, V371, P64, DOI 10.1016/S0140-6736(08)60073-2
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Clark TG, 2009, EUR J HUM GENET, V17, P1080, DOI 10.1038/ejhg.2009.8
   CLYDE DF, 1981, B WORLD HEALTH ORGAN, V59, P391
   De Araujo C, 2006, HAEMATOL-HEMATOL J, V91, P262
   Dunyo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017371
   Guindo A, 2007, PLOS MED, V4, P516, DOI 10.1371/journal.pmed.0040066
   Johnson MK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007246
   Lin ZL, 2005, MOL GENET METAB, V86, P212, DOI 10.1016/j.ymgme.2005.05.009
   Luzzatto L, 2009, NATHAN OSKIS HEMATOL, P884
   malERA Consultative Group on Drugs, 2011, PLOS MED, V8
   Mason PJ, 2007, BLOOD REV, V21, P267, DOI 10.1016/j.blre.2007.05.002
   Migot-Nabias F, 2006, MICROBES INFECT, V8, P2352, DOI 10.1016/j.micinf.2006.03.021
   Minucci A, 2009, IUBMB LIFE, V61, P27, DOI 10.1002/iub.137
   Mtove G, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-320
   Ngomane L, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-19
   Nkhoma ET, 2009, BLOOD CELL MOL DIS, V42, P267, DOI 10.1016/j.bcmd.2008.12.005
   Orimadegun AE, 2011, J INFECT DEV COUNTR, V5, P792, DOI 10.3855/jidc.1837
   Peters AL, 2009, J HISTOCHEM CYTOCHEM, V57, P1003, DOI 10.1369/jhc.2009.953828
   Ruwende C, 1998, J MOL MED-JMM, V76, P581, DOI 10.1007/s001090050253
   RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0
   Shah SS, 2012, SCI REP-UK, V2, DOI 10.1038/srep00299
   Shekalaghe SA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-247
   Shekalaghe SA, 2010, ANTIMICROB AGENTS CH, V54, P1762, DOI 10.1128/AAC.01135-09
   Takem EN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067108
   Tine Roger C K, 2012, BMC Res Notes, V5, P565, DOI 10.1186/1756-0500-5-565
   Vafa M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-17
   Van Malderen C, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-139
   World Health Organization (WHO), 2006, GUID TREATM MAL
   WHO Working Group, 1989, B WORLD HEALTH ORGAN, V67, P601
NR 32
TC 3
Z9 3
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD APR 17
PY 2014
VL 13
AR 148
DI 10.1186/1475-2875-13-148
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AL8AD
UT WOS:000339358000001
PM 24742291
OA gold
DA 2017-08-15
ER

PT J
AU Usuf, E
   Mackenzie, G
   Lowe-Jallow, Y
   Boye, B
   Atherly, D
   Suraratdecha, C
   Griffiths, UK
AF Usuf, E.
   Mackenzie, G.
   Lowe-Jallow, Y.
   Boye, B.
   Atherly, D.
   Suraratdecha, C.
   Griffiths, U. K.
TI Costs of vaccine delivery in the Gambia before and after, pentavalent
   and pneumococcal conjugate vaccine introductions
SO VACCINE
LA English
DT Article
DE Pneumococcal conjugate vaccine; Vaccine; Costs; Gambia; Immunisation
ID IMMUNIZATION SERVICES
AB Background: The Gambia introduced seven-valent pneumococcal conjugate vaccine (PCV) in August 2009 and switched to 13-valent PCV in April 2011. In April 2009 monovalent hepatitis B and combined Diphtheria-Tetanus-Pertussis and Haemophilus influenzae type b vaccines were transitioned to a combined pentavalent vaccine. The current schedule offers three doses of PCV and pentavalent, and continues to give children monovalent hepatitis B vaccine at birth. We estimated the overall costs of the Gambian immunisation programme and the incremental costs of introducing pentavalent and the seven-valent PCV.
   Methods: Twenty health facilities out of a total of 56 were surveyed. Data collected included number of vaccine doses delivered, staff time spent on vaccine delivery, distance travelled to collect vaccines, and cold chain expansion due to new vaccine introduction. National level data were collected from key informant interviews. Annualised costs were calculated in 2009 US$.
   Results: With a PCV price of US$7 per dose, the incremental costs of introducing PCV was US$1.6 million, equivalent to US$25 per fully immunised child, with systems costs accounting for US$1.90. The switch to pentavalent vaccine resulted in cost savings of US$0.45 per fully immunised child. Total annual costs increased by 45% after the introduction of the new vaccines, amounting to US$ 3.0 million, or US$45 per fully immunised child.
   Conclusion: Vaccine prices were the most important determinant of total incremental costs and cold chain expansion the biggest cost component of systems costs. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Usuf, E.; Mackenzie, G.] Gambia Unit, MRC, Banjul, Gambia.
   [Usuf, E.; Lowe-Jallow, Y.; Boye, B.] Gambia Govt, Banjul, Gambia.
   [Usuf, E.; Griffiths, U. K.] London Sch Hyg & Trop Med, London, England.
   [Atherly, D.] PATH, San Francisco, CA USA.
   [Suraratdecha, C.] USAID, Washington, DC USA.
RP Usuf, E (reprint author), Gambia Unit, Pneumococcal Surveillance Project, MRC, POB 273, Banjul, Gambia.
EM effuau@gmail.com
FU Program for Appropriate Technology in Health (PATH); Global Alliance for
   Vaccines and Immunisation (GAVI)
FX Support for this project was provided by Program for Appropriate
   Technology in Health (PATH) through funding from the Global Alliance for
   Vaccines and Immunisation (GAVI). The views expressed by the authors do
   not necessarily reflect the views of GAVI and/or PATH.
CR [Anonymous], 2010, ANN REPORT
   [Anonymous], 2009, GAMB ANN INFL RAT PO
   [Anonymous], 2009, INT RAT
   GAVI, 2008, ALL APPL FORM COUNTR
   Griffiths UK, 2009, VACCINE, V27, P1426, DOI 10.1016/j.vaccine.2008.12.037
   HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253
   Khleghian P, 2001, 40 ABT ASS INC PARTN
   Kou U, 2002, GUIDELINES ESTIMATIN
   The Republic of The Gambia, INTR NEW VACC 2009 2
   Nguyen A, 2012, GAVI ALL BOARD 12 13
   Ojo LR, 2010, VACCINE, V28, P7117, DOI 10.1016/j.vaccine.2010.07.074
   Parmar D, 2010, HUM VACCINE, P2010
   [Anonymous], 2009, PURA ANN REP 2009
   Rammohan S, 2010, RIDERS HLTH FLEET LE
   ROBERTSON RL, 1992, HEALTH POLICY PLANN, V7, P111, DOI 10.1093/heapol/7.2.111
   ROBERTSON RL, 1985, J TROP MED HYG, V88, P343
   UNICEF, 2009, VACC PROJ QUANT PRIC
   UNICEF, 2009, PROD MEN VACC SUPPL
   Usher AD, 2009, LANCET, V374, P1879
   Walker D, 2004, B WORLD HEALTH ORGAN, V82, P676
   WHO, 2000, WHO UNICEF PROD INF
   WHO, PROJ VACC WAST
   WHO, 2009, VACC VOL CALC
   [Anonymous], 2011, GLOB IMM DAT
   Wolfson LJ, 2008, B WORLD HEALTH ORGAN, V86, P27, DOI 10.2471/BLT.07.045096
NR 25
TC 8
Z9 8
U1 1
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 7
PY 2014
VL 32
IS 17
BP 1975
EP 1981
DI 10.1016/j.vaccine.2014.01.045
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AH3IK
UT WOS:000336016700009
PM 24503271
OA No
DA 2017-08-15
ER

PT J
AU Hur, YG
   Gorak-Stolinska, P
   Lalor, MK
   Mvula, H
   Floyd, S
   Raynes, J
   Ben-Smith, A
   Fitchett, JR
   Flanagan, KL
   Burl, S
   Ota, MO
   Crampin, AC
   Smith, SG
   Dockrell, HM
AF Hur, Yun-Gyoung
   Gorak-Stolinska, Patricia
   Lalor, Maeve K.
   Mvula, Hazzie
   Floyd, Sian
   Raynes, John
   Ben-Smith, Anne
   Fitchett, Joseph R.
   Flanagan, Katie L.
   Burl, Sarah
   Ota, Martin O.
   Crampin, Amelia C.
   Smith, Steven G.
   Dockrell, Hazel M.
TI Factors affecting immunogenicity of BCG in infants, a study in Malawi,
   The Gambia and the UK
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE BCG vaccination; CRP; Cytokine; Infant immune response; M. tuberculosis
   PPD; Zinc
ID C-REACTIVE PROTEIN; CALMETTE-GUERIN VACCINATION; IMMUNE-RESPONSES;
   IMMUNOLOGICAL BIOMARKERS; MYCOBACTERIAL ANTIGENS; ZINC; TUBERCULOSIS;
   CHILDREN; EFFICACY; DISEASE
AB Background: BCG immunogenicity in infants differs between populations and these differences have been attributed to various factors. In this study, the influence of geographical location, season of birth, timing of vaccination, micronutrient status (zinc) and inflammatory status (C-reactive protein, CRP) were assessed.
   Methods: Immunogenicity was assessed by cytokine signature in culture supernatants from diluted whole blood samples stimulated with M. tuberculosis PPD, using a multiplex bead assay.
   Results were correlated with the plasma zinc and CRP concentrations at the time of sampling, and with interview and household data. BCG vaccinated infants were recruited in Malawi, The Gambia and the UK. Results: In Malawi, infants vaccinated within the first week after birth showed lower production of most cytokines measured than those vaccinated later. The number of cytokines showing significant differences between Malawian and Gambian infants decreased after adjusting for season of birth. In Malawi, a proportion of infants had zinc deficiency and elevated plasma CRP (>10 mg/L), but neither zinc deficiency nor high CRP was associated with production of any of the cytokines measured.
   Conclusions: The cytokine/chemokine signatures observed in response to M. tuberculosis PPD in infants at 3 months post BCG vaccination were affected by geographical location, season of birth, and timing of vaccination but not associated with the concentration of plasma zinc or inflammatory status. These factors should be considered in future trials of new TB vaccines.
C1 [Hur, Yun-Gyoung; Gorak-Stolinska, Patricia; Lalor, Maeve K.; Raynes, John; Ben-Smith, Anne; Fitchett, Joseph R.; Smith, Steven G.; Dockrell, Hazel M.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1E 7HT, England.
   [Mvula, Hazzie; Ben-Smith, Anne; Crampin, Amelia C.] Karonga Prevent Study, Chilumba, Karonga Distric, Malawi.
   [Floyd, Sian; Crampin, Amelia C.] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, London WC1E 7HT, England.
   [Flanagan, Katie L.; Burl, Sarah; Ota, Martin O.] MRC Unit, Fajara, Gambia.
   [Hur, Yun-Gyoung] Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea.
   [Hur, Yun-Gyoung] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul 120752, South Korea.
RP Hur, YG (reprint author), Yonsei Univ, Coll Med, Seoul 120752, South Korea.
EM hur1225@gmail.com
RI Raynes, John/G-7932-2011
OI Raynes, John/0000-0002-8536-1328; Dockrell, Hazel/0000-0003-1869-9107
FU Gordon Smith Travelling Scholarship; University of London Central
   Research Fund; Bill and Melinda Gates Foundation Grand Challenges in
   Global Health [37772]; EU [241745]; Wellcome Trust
FX This work was supported by a Gordon Smith Travelling Scholarship and in
   part by the University of London Central Research Fund. Additional
   support for the collection and testing of the samples was provided
   through the GC6-74 consortium funded by the Bill and Melinda Gates
   Foundation Grand Challenges in Global Health 37772 and the EU FP7 funded
   NEWTBVAC Consortium 241745. The Karonga Prevention Study was supported
   by funding from the Wellcome Trust.
CR Anderson EJ, 2012, VACCINE, V30, P2083, DOI 10.1016/j.vaccine.2012.01.053
   Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713
   Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Black GF, 2001, J INFECT DIS, V184, P322, DOI 10.1086/322042
   Clyne B, 1999, J EMERG MED, V17, P1019, DOI 10.1016/S0736-4679(99)00135-3
   Dardenne M, 2002, EUR J CLIN NUTR, V56, pS20, DOI 10.1038/sj.ejcn.1601479
   Dewey Kathryn G., 2003, Food and Nutrition Bulletin, V24, P5
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Fitchett JR, 2010, THESIS U LONDON LOND
   Hur YG, 2014, CLIN VACCINE IMMUNOL, V21, P133, DOI 10.1128/CVI.00620-13
   IZiNCG: International Zinc Nutrition Consultative Group, 2012, IZINCG TECHN BRIEF A
   Kagina BMN, 2009, VACCINE, V27, P5488, DOI 10.1016/j.vaccine.2009.06.103
   Lalor MK, 2011, J INFECT DIS, V204, P1075, DOI 10.1093/infdis/jir515
   Lalor MK, 2009, J INFECT DIS, V199, P795, DOI 10.1086/597069
   Lalor MK, 2009, THESIS U LONDON LOND
   Lutwama F, 2014, J INFECT DIS, V209, P887, DOI 10.1093/infdis/jit570
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Pourcyrous M, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e3
   Pulliam PN, 2001, PEDIATRICS, V108, P1275, DOI 10.1542/peds.108.6.1275
   Ritz N, 2012, AM J RESP CRIT CARE, V185, P213, DOI 10.1164/rccm.201104-0714OC
   Ritz N, 2009, TUBERCULOSIS, V89, P248, DOI 10.1016/j.tube.2009.03.002
   SANDSTROM B, 1992, J TRACE ELEM ELECT H, V6, P99
   Walker CLF, 2009, EUR J CLIN NUTR, V63, P591, DOI 10.1038/ejcn.2008.9
   Walker CF, 2004, ANNU REV NUTR, V24, P255, DOI 10.1146/annurev.nutr.23.011702.073054
   Walzl G, 2011, NAT REV IMMUNOL, V11, P343, DOI 10.1038/nri2960
   WILSON ME, 1995, CLIN INFECT DIS, V20, P982
   [Anonymous], 2013, GLOB TUB REP
NR 28
TC 7
Z9 8
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD APR 5
PY 2014
VL 14
AR 184
DI 10.1186/1471-2334-14-184
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA AG5PW
UT WOS:000335472000001
PM 24708690
OA gold
DA 2017-08-15
ER

PT J
AU McDonald, SLR
   Savy, M
   Fulford, AJC
   Kendall, L
   Flanagan, KL
   Prentice, AM
AF McDonald, Suzanna L. R.
   Savy, Mathilde
   Fulford, Anthony J. C.
   Kendall, Lindsay
   Flanagan, Katie L.
   Prentice, Andrew M.
TI A double blind randomized controlled trial in neonates to determine the
   effect of vitamin A supplementation on immune responses: The Gambia
   protocol
SO BMC PEDIATRICS
LA English
DT Article
DE Neonatal; Vitamin A supplementation; Immune responses; Africa; Double
   blind randomised control trial
ID RETINOIC ACID; INFANT-MORTALITY; T-CELLS; DENDRITIC CELLS;
   GUINEA-BISSAU; DIFFERENTIATION; METAANALYSIS; EXPRESSION; MORBIDITY;
   INFECTION
AB Background: Vitamin A supplementation significantly reduces all-cause mortality when given between 6-59 months of age, but has a null or detrimental effect when given between 1-5 months. Studies of neonatal vitamin A supplementation conducted across Africa and South Asia have produced conflicting findings. These age-pattern variations might result from immunological interactions between vitamin A supplementation and vaccines. Knowledge on the potential immunological sequelae of human neonatal vitamin A supplementation is so scarce that the foremost aim of this study is to seek indicative data on aspects of immunity likely to be affected by neonatal vitamin A supplementation. The objective of this trial is to test whether human neonatal vitamin A supplementation modulates immune function including improved thymic maturation in infancy and improved systemic immune responses to routine immunization.
   Methods/design: In an area of moderate vitamin A deficiency in a peri-urban area of The Gambia, 200 mother-infant pairs were enrolled in a double-blind randomised controlled trial. Within 48 hours of birth, neonates were randomised with stratification by birth weight and sex to receive either an oral dose of 50,000 IU vitamin A or placebo. Expanded Programme of Immunisation birth vaccinations were administered after supplementation, with subsequent vaccinations administered at 8, 12 and 16 weeks of age. A range of immunological outcomes were examined up to 17 weeks of age, with additional morbidity and anthropometry follow-up carried out throughout the first year of life. The primary endpoint of this trial is the frequency of circulating T regulatory (T-reg) cells expressing gut homing receptors in infants at 17 week post-supplementation, with secondary outcomes including thymus maturation and B cell immune responses.
   Discussion: Indicative immunological data from this trial (and its Bangladeshi counterpart), will complement the larger randomised controlled trials (conducted in India, Tanzania and Ghana), on the effectiveness and safety of neonatal vitamin A supplementation in improving infant survival. Combined these trials, in addition to the existing trials, will inform policy.
C1 [McDonald, Suzanna L. R.; Savy, Mathilde; Fulford, Anthony J. C.; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Kendall, Lindsay] MRC Keneba, London, Gambia.
   [Flanagan, Katie L.] MRC Gambia Unit, Banjul, Gambia.
   [Flanagan, Katie L.] Monash Univ, Dept Immunol, Melbourne, Vic 3181, Australia.
RP McDonald, SLR (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM Suzanna.McDonald@lshtm.ac.uk
FU World HealthOrganization via Bill and Melinda Gates Foundation
   [2010/98441-0]; Medical Research Council (UK) through MRC International
   Nutrition Group [MC-A760-5QX00]; London School of Hygiene and Tropical
   Medicine
FX This trial is supported by the World HealthOrganization via Bill and
   Melinda Gates Foundation funding (2010/98441-0) and the Medical Research
   Council (UK), through core funding to the MRC International Nutrition
   Group (MC-A760-5QX00). This trial was sponsored by the London School of
   Hygiene and Tropical Medicine. Thanks to Dr Lisa Rogers and Dr Jaun
   Pablo Pena-Rosas, (Department of Nutrition for Health and Development,
   WHO) for technical support and coordination for the trials. Thanks to
   the Infant Immunology Laboratory (led by Dr Ed Clarke) and Vaccinology
   Theme (led by Prof Beate Kampmann), MRC Unit The Gambia, for operational
   support. We thank all trial staff, the staff based at MRC Sukuta field
   site and Sukuta Health Centre. We also acknowledge the support of the
   mothers and infants without whom this trial could not have taken place.
CR Bah A, 2001, NATL SURVEY PREVALEN, P1
   Bahl R, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-22
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719
   Burl S, 2010, J IMMUNOL, V185, P2620, DOI 10.4049/jimmunol.1000552
   Darboe MK, 2007, LANCET, V369, P2088, DOI 10.1016/S0140-6736(07)60981-7
   DePaolo RW, 2011, NATURE, V471, P220, DOI 10.1038/nature09849
   Diness BR, 2007, AM J CLIN NUTR, V86, P1152
   Diness BR, 2010, J INFECT DIS, V202, pS243, DOI 10.1086/653569
   Diness BR, 2011, BR J NUTR, V1, P4
   Elias KM, 2008, BLOOD, V111, P1013, DOI 10.1182/blood-2007-06-096438
   Engedal N, 2011, VITAM HORM, V86, P153, DOI 10.1016/B978-0-12-386960-9.00007-1
   FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898
   Gogia S, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b919
   Hall JA, 2011, IMMUNITY, V35, P13, DOI 10.1016/j.immuni.2011.07.002
   Hasselbalch H, 1996, EUR RADIOL, V6, P700
   Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1
   Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011
   Kang SG, 2007, J IMMUNOL, V179, P3724
   Klemm RDW, 2008, PEDIATRICS, V122, pE242, DOI 10.1542/peds.2007-3448
   Malaba LC, 2005, AM J CLIN NUTR, V81, P454
   Manicassamya S, 2009, SEMIN IMMUNOL, V21, P22, DOI 10.1016/j.smim.2008.07.007
   Martines J, 1998, LANCET, V352, P1257
   Mayo-Wilson E, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5094
   Mielke LA, 2013, J EXP MED, V210, P1117, DOI 10.1084/jem.20121588
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742
   Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697
   Pino-Lagos K, 2011, J EXP MED, V208, P1767, DOI 10.1084/jem.20102358
   Pino-Lagos K, 2010, BIOFACTORS, V36, P430, DOI 10.1002/biof.117
   Rahmathullah L, 2003, BRIT MED J, V327, P254, DOI 10.1136/bmj.327.7409.254
   Ribeiro RM, 2007, IMMUNOL REV, V216, P21
   Ross AC, 2012, AM J CLIN NUTR, V96, p1166S, DOI 10.3945/ajcn.112.034637
   Ross AC, 2011, VITAM HORM, V86, P103, DOI 10.1016/B978-0-12-386960-9.00005-8
   Stephensen CB, 2002, J IMMUNOL, V168, P4495
   Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167
   Tanumihardjo SA, 1996, AM J CLIN NUTR, V64, P966
   Thurnham DI, 2000, J INFECT DIS, V182, pS23, DOI 10.1086/315912
   United Nations, 2014, UN DAT COUNTR PROF G
   UNICEF, 2013, GLANC GAMB STAT
   WEST KP, 1995, AM J CLIN NUTR, V62, P143
   WHO, 2009, GLOB PREV VIT A DEF
NR 42
TC 7
Z9 7
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD APR 4
PY 2014
VL 14
AR 92
DI 10.1186/1471-2431-14-92
PG 8
WC Pediatrics
SC Pediatrics
GA AH5NM
UT WOS:000336177000001
PM 24708735
OA gold
DA 2017-08-15
ER

PT J
AU Nkum, BC
   Micah, FB
   Ankrah, TC
   Nyan, O
AF Nkum, Bernard Cudjoe
   Micah, Frank Botsi
   Ankrah, Theophilus C.
   Nyan, Ousman
TI Left Ventricular Hypertrophy and Insulin Resistance in Adults from an
   Urban Community in the Gambia: Cross-Sectional Study
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-I; HYPERTENSIVE PATIENTS; METABOLIC SYNDROME; CARDIAC
   STRUCTURE; MASS INDEX; SENSITIVITY; ASSOCIATION; RAT; HYPERINSULINEMIA;
   TRIGLYCERIDE
AB Objective: To determine the association between left ventricular hypertrophy and insulin resistance in Gambians.
   Design: Cross-sectional study.
   Setting: Outpatient clinics of Royal Victoria Teaching Hospital and Medical Research Council Laboratories in Banjul.
   Participants: Three hundred and sixteen consecutive patients were enrolled from outpatient clinics. The data of 275 participants (89 males) were included in the analysis with a mean (+/- standard deviation) age of 53.7 (+/- 11.9) years.
   Interventions: A questionnaire was filled and anthropometric measurements were taken. 2-D guided M-mode echocardiography, standard 12-1ead electrocardiogram, fasting insulin and the oral glucose tolerance test were performed.
   Main Outcome Measures: The Penn formula was used to determine the left ventricular mass index, 125 g/m(2) in males and 110 g/m2 in females as the cut-off for left ventricular hypertrophy. Using the fasting insulin and fasting glucose levels, the insulin resistance was estimated by the homeostatic model assessment formula. Logistic regression analysis was used to determine the association between left ventricular hypertrophy and insulin resistance.
   Results: The mean Penn left ventricular mass index was 119.5 (+/- 54.3) and the prevalence of Penn left ventricular mass index left ventricular hypertrophy was 41%. The mean fasting glucose was 5.6 (+/- 2.5) mmol/l, fasting insulin was 6.39 (+/- 5.49) mu U/ml and insulin resistance was 1.58 (+/- 1.45). There was no association between Penn left ventricular mass index left ventricular hypertrophy and log of insulin resistance in univariate (OR = 0.98, 95% CI = 0.80 - 1.19, p = 0.819) and multivariate logistic regression (OR = 0.93, 95% CI = 0.76-1.15, p = 0.516) analysis.
   Conclusion: No association was found in this study between left ventricular hypertrophy and insulin resistance in Gambians and this does not support the suggestion that insulin is an independent determinant of left ventricular hypertrophy in hypertensives.
C1 [Nkum, Bernard Cudjoe; Micah, Frank Botsi; Ankrah, Theophilus C.] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Med, Kumasi, Ghana.
   [Nyan, Ousman] Royal Victoria Teaching Hosp, Dept Med, Banjul, Gambia.
RP Nkum, BC (reprint author), Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Med, Kumasi, Ghana.
EM bcnkum@yahoo.co.uk
FU Medical Research Council (MRC), UK
FX This study was funded by the Medical Research Council (MRC), UK. The
   funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agabiti-Rosei E, 2006, J AM SOC NEPHROL, V17, pS104, DOI 10.1681/ASN.2005121336
   Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
   ATTAH EB, 1977, AM HEART J, V94, P189, DOI 10.1016/S0002-8703(77)80279-2
   Barud Wojciech, 2004, Ann Univ Mariae Curie Sklodowska Med, V59, P232
   COSTA CHRM, 1995, HYPERTENSION, V26, P1085
   DAEMEN MJAP, 1991, CIRC RES, V68, P450
   Ebinc H, 2006, ACTA CARDIOL, V61, P398, DOI 10.2143/AC.61.4.2017299
   *EXP COMM ART HYP, 1962, WHO TECHN REP SER, V231, P28
   FERRANNINI E, 1991, DIABETOLOGIA, V34, P416, DOI 10.1007/BF00403180
   Galvan AQ, 2000, CIRCULATION, V102, P2233
   Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2
   HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639
   Homcy CJ, 1998, CIRCULATION, V97, P1890
   Hsueh WA, 1999, AM J CARDIOL, V84, p21J
   Ilercil A, 2002, DIABETES, V51, P1543, DOI 10.2337/diabetes.51.5.1543
   ITO H, 1993, CIRCULATION, V87, P1715
   Kahan T, 1998, J HYPERTENS, V16, pS23
   LIND L, 1995, J HYPERTENS, V13, P433
   Malmqvist K, 2001, J HYPERTENS, V19, P311, DOI 10.1097/00004872-200102000-00019
   MAYET J, 1994, BMJ-BRIT MED J, V308, P1011
   Nickenig G, 1998, CIRCULATION, V98, P2453
   NKUM BC, 2009, J SCI TECHNOL, V29, P130
   Okada K, 2004, HYPERTENS RES, V27, P293, DOI 10.1291/hypres.27.293
   Poornima IG, 2006, CIRC RES, V98, P596, DOI 10.1161/01.RES.0000207406.94146.c2
   Rheeder P, 1999, AM J CARDIOL, V84, P233, DOI 10.1016/S0002-9149(99)00243-X
   ROCCHINI AP, 1989, HYPERTENSION, V14, P367
   Ruilope LM, 2008, AM J HYPERTENS, V21, P500, DOI 10.1038/ajh.2008.16
   Rutter MK, 2003, CIRCULATION, V107, P448, DOI 10.1161/01.CIR.0000045671.62860.98
   Ryden L, 2007, EUR HEART J, V28, P88, DOI [10.1093/eurheartj/ehl260, 10.1093/eurheartj/ehm124]
   SASSON Z, 1993, CIRCULATION, V88, P1431
   Scherrer U, 1997, CIRCULATION, V96, P4104
   SHARP SD, 1992, CARDIOLOGY, V81, P207, DOI 10.1159/000175806
   Sherif K, 2000, AM J MED SCI, V320, P13, DOI 10.1097/00000441-200007000-00003
   Top C, 2007, J INT MED RES, V35, P909
   Urbina EM, 1999, AM HEART J, V138, P122, DOI 10.1016/S0002-8703(99)70256-5
   Verdecchia P, 1999, CIRCULATION, V100, P1802
   Whaley-Connell A, 2007, AM J PHYSIOL-ENDOC M, V293, pE355, DOI 10.1152/ajpendo.00632.2006
NR 37
TC 1
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2014
VL 9
IS 4
AR e93606
DI 10.1371/journal.pone.0093606
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE6MJ
UT WOS:000334107500048
PM 24705608
OA gold
DA 2017-08-15
ER

PT J
AU Halliday, D
   Lloyd-Fox, S
   Begus, K
   Maris, H
   Papademetriou, M
   Everdell, N
   Darboe, M
   Prentice, A
   Moore, S
   Elwell, C
AF Halliday, Drew
   Lloyd-Fox, Sarah
   Begus, Katarina
   Maris, Helen
   Papademetriou, Maria
   Everdell, Nick
   Darboe, Momodou
   Prentice, Andrew
   Moore, Sophie
   Elwell, Clare
TI Brain imaging of nutrition related cognitive development in rural
   Gambia: studies from birth to 24 months of age
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting
CY APR 26-30, 2014
CL San Diego, CA
SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 [Lloyd-Fox, Sarah; Begus, Katarina; Maris, Helen] Univ London, Ctr Brain & Cognit Dev Birkbeck, London, England.
   [Prentice, Andrew; Moore, Sophie] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   [Darboe, Momodou] MRC, Int Nutr Grp, Keneba, Gambia.
   [Halliday, Drew; Papademetriou, Maria; Everdell, Nick; Elwell, Clare] UCL, Dept Med Phys & Bioengn, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 7
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2014
VL 28
IS 1
SU S
MA 619.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA AX0MP
UT WOS:000346646702201
OA No
DA 2017-08-15
ER

PT J
AU Lloyd-Fox, S
   Halliday, D
   Maris, H
   Begus, K
   Darboe, M
   Prentice, A
   Moore, S
   Elwell, C
AF Lloyd-Fox, Sarah
   Halliday, Drew
   Maris, Helen
   Begus, Katarina
   Darboe, Momodou
   Prentice, Andrew
   Moore, Sophie
   Elwell, Clare
TI Behavioural measures of nutrition related cognitive development in rural
   Gambia: studies from birth to 24 months of age
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting
CY APR 26-30, 2014
CL San Diego, CA
SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 [Lloyd-Fox, Sarah; Maris, Helen; Begus, Katarina] Univ London, Ctr Brain & Cognit Dev Birkbeck, London, England.
   [Prentice, Andrew; Moore, Sophie] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
   [Darboe, Momodou] MRC Int Nutr Grp, Keneba, Gambia.
   [Elwell, Clare] UCL, London, England.
   [Halliday, Drew] UCL, Dept Med Phys & Bioengn, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2014
VL 28
IS 1
SU S
MA 389.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA AX0MP
UT WOS:000346646701085
OA No
DA 2017-08-15
ER

PT J
AU Minchella, P
   Donkor, S
   Sutherland, J
   McDermid, J
AF Minchella, Peter
   Donkor, Simon
   Sutherland, Jayne
   McDermid, Joann
TI Tuberculosis treatment modifies iron status without iron intervention
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting
CY APR 26-30, 2014
CL San Diego, CA
SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 [Minchella, Peter; McDermid, Joann] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.
   [Donkor, Simon; Sutherland, Jayne] Med Res Council Unit UK, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2014
VL 28
IS 1
SU S
MA 389.8
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA AX0MP
UT WOS:000346646701092
OA No
DA 2017-08-15
ER

PT J
AU Owen, J
   Silver, M
   Corbin, K
   Dominguez-Salas, P
   Moore, S
   Hennig, B
   Zeisel, S
AF Owen, Jennifer
   Silver, Matt
   Corbin, Karen
   Dominguez-Salas, Paula
   Moore, Sophie
   Hennig, Branwen
   Zeisel, Steven
TI Distribution of functional 1-carbon metabolism single nucleotide
   polymorphisms in Gambian versus European populations
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting
CY APR 26-30, 2014
CL San Diego, CA
SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 [Silver, Matt; Dominguez-Salas, Paula; Moore, Sophie; Hennig, Branwen] MRC Int Nutr Grp, Keneba, Gambia.
   [Silver, Matt; Dominguez-Salas, Paula; Moore, Sophie; Hennig, Branwen] LSHTM, MRC Int Nutr Grp, London, England.
   [Corbin, Karen; Zeisel, Steven] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC USA.
   [Owen, Jennifer; Corbin, Karen; Zeisel, Steven] Univ N Carolina, Inst Nutr Res, Kannapolis, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2014
VL 28
IS 1
SU S
MA 827.4
PG 2
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA AX0MP
UT WOS:000346646705014
OA No
DA 2017-08-15
ER

PT J
AU Janha, RE
   Worwui, A
   Linton, KJ
   Shaheen, SO
   Sisay-Joof, F
   Walton, RT
AF Janha, Ramatoulie E.
   Worwui, Archibald
   Linton, Kenneth J.
   Shaheen, Seif O.
   Sisay-Joof, Fatoumatta
   Walton, Robert T.
TI Inactive alleles of cytochrome P450 2C19 may be positively selected in
   human evolution
SO BMC EVOLUTIONARY BIOLOGY
LA English
DT Article
DE Positive selection; Cytochrome P450 2C19; Xenobiotics; Drug metabolism;
   Extended haplotype homozygosity; Bifurcation plots
ID HUMAN LIVER-MICROSOMES; DRUG-METABOLIZING-ENZYMES; N-DEMETHYLATION;
   S-MEPHENYTOIN; IN-VITRO; NATURAL-SELECTION; GENETIC-VARIATION;
   POLYMORPHISM; CYP2C19; HYDROXYLATION
AB Background: Cytochrome P450 CYP2C19 metabolizes a wide range of pharmacologically active substances and a relatively small number of naturally occurring environmental toxins. Poor activity alleles of CYP2C19 are very frequent worldwide, particularly in Asia, raising the possibility that reduced metabolism could be advantageous in some circumstances. The evolutionary selective forces acting on this gene have not previously been investigated. We analyzed CYP2C19 genetic markers from 127 Gambians and on 120 chromosomes from Yoruba, Europeans and Asians (Japanese + Han Chinese) in the Hapmap database. Haplotype breakdown was explored using bifurcation plots and relative extended haplotype homozygosity (REHH). Allele frequency differentiation across populations was estimated using the fixation index (F-ST) and haplotype diversity with coalescent models.
   Results: Bifurcation plots suggested conservation of alleles conferring slow metabolism (CYP2C19*2 and *3). REHH was high around CYP2C19*2 in Yoruba (REHH 8.3, at 133.3 kb from the core) and to a lesser extent in Europeans (3.5, at 37.7 kb) and Asians (2.8, at -29.7 kb). F-ST at the CYP2C19 locus was low overall (0.098). CYP2C19*3 was an F-ST outlier in Asians (0.293), CYP2C19 haplotype diversity < = 0.037, p < 0.001.
   Conclusions: We found some evidence that the slow metabolizing allele CYP2C19*2 is subject to positive selective forces worldwide. Similar evidence was also found for CYP2C19*3 which is frequent only in Asia. F-ST is low at the CYP2C19 locus, suggesting balancing selection overall. The biological factors responsible for these selective pressures are currently unknown. One possible explanation is that early humans were exposed to a ubiquitous novel toxin activated by CYP2C19. The genetic adaptation took place within the last 10,000 years which coincides with the development of systematic agricultural practices.
C1 [Janha, Ramatoulie E.; Worwui, Archibald; Sisay-Joof, Fatoumatta] Med Res Council Unit Gambia, Serrekunda, Gambia.
   [Shaheen, Seif O.; Walton, Robert T.] Queen Mary Univ, Barts & London Sch Med & Dent, Ctr Publ Hlth & Primary Care, London, England.
   [Linton, Kenneth J.] Queen Mary Univ, Barts & London Sch Med & Dent, Blizard Inst, Ctr Cutaneous Res, London, England.
RP Janha, RE (reprint author), Med Res Council Unit Gambia, Serrekunda, Gambia.
EM touliej@yahoo.co.uk
FU Medical Research Council Unit The Gambia; European and Developing
   Countries Clinical Trials Partnership [CG_ta_05_40204_018]
FX This work was supported by the Medical Research Council Unit The Gambia
   and the European and Developing Countries Clinical Trials Partnership
   [grant number CG_ta_05_40204_018].
CR Akey JM, 2002, GENOME RES, V12, P1805, DOI 10.1101/gr.631202
   ANDERSSON T, 1990, CLIN PHARMACOL THER, V47, P79
   Antao T, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-323
   BIRKETT DJ, 1994, BRIT J CLIN PHARMACO, V37, P413
   Botchkarev VA, 2005, J INVEST DERM SYMP P, V10, P247, DOI 10.1111/j.1087-0024.2005.10129.x
   DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
   DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
   Dunyo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017371
   Faeste CK, 2011, DRUG METAB DISPOS, V39, P1768, DOI 10.1124/dmd.111.039529
   Goldstein JA, 1997, PHARMACOGENETICS, V7, P59, DOI 10.1097/00008571-199702000-00008
   Gomes LG, 2009, J CLIN ENDOCR METAB, V94, P89, DOI 10.1210/jc.2008-1174
   Graf J, 2005, HUM MUTAT, V25, P278, DOI 10.1002/humu.20143
   Hanchard NA, 2006, AM J HUM GENET, V78, P153, DOI 10.1086/499252
   He XY, 2006, INT J CANCER, V118, P2665, DOI 10.1002/ijc.21665
   Ingelman-Sundberg M, 1999, TRENDS PHARMACOL SCI, V20, P342, DOI 10.1016/S0165-6147(99)01363-2
   Janha RE, 2009, PHARMACOGENOMICS, V10, P1423, DOI [10.2217/pgs.09.72, 10.2217/PGS.09.72]
   Kaneko A, 1997, LANCET, V349, P921, DOI 10.1016/S0140-6736(05)62696-7
   Koyama E, 1997, J PHARMACOL EXP THER, V281, P1199
   Kunz S, 2005, J VIROL, V79, P14282, DOI 10.1128/JVI.79.22.14282-14296.2005
   KUPFER A, 1984, EUR J CLIN PHARMACOL, V26, P753, DOI 10.1007/BF00541938
   Lamason RL, 2005, SCIENCE, V310, P1782, DOI 10.1126/science.1116238
   Librado P, 2009, BIOINFORMATICS, V25, P1451, DOI 10.1093/bioinformatics/btp187
   Librado P, 2009, BIOINFORMATICS, V25, P1367
   Matimba Alice, 2009, Human Genomics, V3, P169
   Musumba CO, 2013, CLIN PHARMACOL THER, V93, P195, DOI 10.1038/clpt.2012.215
   NAKAMURA K, 1985, CLIN PHARMACOL THER, V38, P402
   Nebert DW, 2000, PHARMACOLOGY, V61, P124, DOI 10.1159/000028393
   Nebert DW, 1997, AM J HUM GENET, V60, P265
   Nelson DR, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0474
   Nesbitt M, 1996, OXFORD COMPANION ARC
   Park JY, 2003, ANTIMICROB AGENTS CH, V47, P3464, DOI 10.1128/AAC.47.11.3464-3469.2003
   Pimenoff VN, 2012, PHARMACOGENET GENOM, V22, P846, DOI 10.1097/FPC.0b013e32835a3a6d
   Richardson A, 2001, GENES IMMUN, V2, P343, DOI 10.1038/sj.gene.6363789
   Ruwende C, 1998, J MOL MED-JMM, V76, P581, DOI 10.1007/s001090050253
   Sabeti P, 2002, GENES IMMUN, V3, P286, DOI 10.1038/sj.gene.636877
   Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309
   Sabeti PC, 2007, NATURE, V449, P913, DOI 10.1038/nature06250
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Scheet P, 2006, AM J HUM GENET, V78, P629, DOI 10.1086/502802
   Sim SC, 2006, CLIN PHARMACOL THER, V79, P103, DOI 10.1016/j.clpt.2005.10.002
   Stathopoulou MG, 2013, INT J CARDIOL, V168, P3057, DOI 10.1016/j.ijcard.2013.04.097
   Stout SM, 2014, DRUG METAB REV, V46, P86, DOI 10.3109/03602532.2013.849268
   van Waterschoot RAB, 2011, PHARMACOL REV, V63, P390, DOI 10.1124/pr.110.002584
   Venkatakrishnan K, 1998, J CLIN PHARMACOL, V38, P112
   Vormfelde SV, 2007, PHARMACOGENOMICS J, V7, P200, DOI 10.1038/sj.tpj.6500410
   Walsh EC, 2006, HUM GENET, V119, P92, DOI 10.1007/s00439-005-0090-0
   Walton R, 2005, NAT GENET, V37, P915, DOI 10.1038/ng0905-915
   WEDLUND PJ, 1984, CLIN PHARMACOL THER, V36, P773
   Wojnowski L, 2004, PHARMACOGENETICS, V14, P691, DOI 10.1097/00008571-200410000-00007
   Yamazaki H, 1999, XENOBIOTICA, V29, P231, DOI 10.1080/004982599238632
   Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V346, P161, DOI 10.1006/abbi.1997.0302
   Yamazaki Y, 2004, MUTAT RES-GEN TOX EN, V562, P151, DOI 10.1016/j.mrgentox.2004.06.003
   Yang YN, 2010, CLIN APPL THROMB-HEM, V16, P579, DOI 10.1177/1076029610364522
   YASUMORI T, 1993, PHARMACOGENETICS, V3, P291, DOI 10.1097/00008571-199312000-00003
NR 54
TC 5
Z9 5
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2148
J9 BMC EVOL BIOL
JI BMC Evol. Biol.
PD APR 1
PY 2014
VL 14
AR 71
DI 10.1186/1471-2148-14-71
PG 10
WC Evolutionary Biology; Genetics & Heredity
SC Evolutionary Biology; Genetics & Heredity
GA AI3MP
UT WOS:000336766000001
PM 24690327
OA gold
DA 2017-08-15
ER

PT J
AU Roberts, CH
   Last, A
   Burr, SE
   Bailey, RL
   Mabey, DC
   Holland, MJ
AF Roberts, Chrissy H.
   Last, Anna
   Burr, Sarah E.
   Bailey, Robin L.
   Mabey, David C.
   Holland, Martin J.
TI Will droplet digital PCR become the test of choice for detecting and
   quantifying ocular Chlamydia trachomatis infection? Maybe Response
SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
LA English
DT Letter
ID POLYMERASE-CHAIN-REACTION; SAMPLES; ASSAYS; BLOOD; DNA
C1 [Roberts, Chrissy H.; Last, Anna; Burr, Sarah E.; Bailey, Robin L.; Mabey, David C.; Holland, Martin J.] Univ London London Sch Hyg & Trop Med, Dept Clin Res, London WC1E 7HT, England.
   [Burr, Sarah E.] MRC Unit, Fajara, Gambia.
RP Roberts, CH (reprint author), Univ London London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London WC1E 7HT, England.
EM chrissy.roberts@lshtm.ac.uk
OI Roberts, Chrissy h./0000-0003-1064-5980
FU Wellcome Trust [100714]
CR Alexander NDE, 2005, T ROY SOC TROP MED H, V99, P175, DOI 10.1016/j.trstmh.2004.05.003
   Baker M, 2012, NAT METHODS, V9, P541, DOI 10.1038/nmeth.2027
   Benesova L, 2013, ANAL BIOCHEM, V433, P227, DOI 10.1016/j.ab.2012.06.018
   Chen GR, 2007, CLIN CHEM, V53, P1962, DOI 10.1373/clinchem.2007.089854
   Chen WW, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.28
   Dean D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051685
   Dize L, 2013, J CLIN MICROBIOL, V51, P1611, DOI 10.1128/JCM.00519-13
   Feasey NA, 2013, J CLIN MICROBIOL, V51, P2311, DOI 10.1128/JCM.00330-13
   Hadgu A, 1999, J CLIN EPIDEMIOL, V52, P1231, DOI 10.1016/S0895-4356(99)00101-8
   Henrich TJ, 2012, J VIROL METHODS, V186, P68, DOI 10.1016/j.jviromet.2012.08.019
   Hindson CM, 2013, NAT METHODS, V10, P1003, DOI 10.1038/nmeth.2633
   Huggett JF, 2013, CLIN CHEM, V59, P892, DOI 10.1373/clinchem.2013.206375
   Kell M, 2007, STRENGTHENING SUPPOR
   Last AR, 2013, J CLIN MICROBIOL, V52, P324
   Lawn SD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001067
   Roberts CH, 2013, J CLIN MICROBIOL, V51, P2195, DOI 10.1128/JCM.00622-13
   Ross DM, 2011, LEUKEMIA LYMPHOMA, V52, P1161, DOI 10.3109/10428194.2011.580481
   Schachter J, 2006, J CLIN MICROBIOL, V44, P2512, DOI 10.1128/JCM.02620-05
   Schachter J, 2013, EXPERT REV MOL DIAGN, V13, P789, DOI 10.1586/14737159.2013.847792
   Sedlak RH, 2013, DIAGN MICR INFEC DIS, V75, P1, DOI 10.1016/j.diagmicrobio.2012.10.009
   Strain MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055943
   Strain MC, 2013, CURR OPIN HIV AIDS, V8, P106, DOI 10.1097/COH.0b013e32835d811b
NR 22
TC 3
Z9 3
U1 0
U2 5
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1473-7159
EI 1744-8352
J9 EXPERT REV MOL DIAGN
JI Expert Rev. Mol. Diagn.
PD APR
PY 2014
VL 14
IS 3
BP 253
EP 256
DI 10.1586/14737159.2014.897609
PG 4
WC Pathology
SC Pathology
GA AG3UP
UT WOS:000335345600003
PM 24649815
OA No
DA 2017-08-15
ER

PT J
AU Lim, ES
   Cao, S
   Holtz, LR
   Antonio, M
   Stine, OC
   Wang, D
AF Lim, Efrem S.
   Cao, Song
   Holtz, Lori R.
   Antonio, Martin
   Stine, O. Colin
   Wang, David
TI Discovery of rosavirus 2, a novel variant of a rodent-associated
   picornavirus, in children from The Gambia
SO VIROLOGY
LA English
DT Article
DE Picornavirus; Virus discovery; Emerging viruses; Developing country
ID RNA STRUCTURE; ENTRY SITE; VIRUS; REPLICATION; DIVERSITY; SEQUENCE;
   DIARRHEA; DISEASE; PROTEIN; IRES
AB We describe the identification of a novel picornavirus recovered from the fecal specimen of a Child in The Gambia, provisionally named rosavirus 2. Comparison of the rosavirus 2 complete genome demonstrated 71.9% nucleotide identity to its closest relative rosavirus M-7, an unclassified picornavirus identified from rodent fecal material. A unique RNA structure was predicted in the 3' UTR of rosavirus 2 that was conserved with rosavirus M-7 and cadiciviruses. We detected rosavirus 2 in four pediatric fecal specimens (0.55% prevalence) in a Gambian diarrheal case-control cohort, but we did not detect it in a panel of 634 pediatric diarrhea! stool specimens from the USA. There was no statistical evidence that rosavirus 2 was associated with diarrhea! cases. This study broadens our understanding of unknown viruses present in children in developing country settings. (c) 2014 Elsevier Inc. All rights reserved.
C1 [Lim, Efrem S.; Cao, Song; Wang, David] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Lim, Efrem S.; Cao, Song; Wang, David] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Holtz, Lori R.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
   [Antonio, Martin] MRC Unit, Banjul, Gambia.
   [Stine, O. Colin] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
RP Wang, D (reprint author), Washington Univ, Sch Med, Campus Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.
EM davewang@borcim.wustl.edu
OI Stine, O. Colin/0000-0003-3974-3752; Holtz, Lori/0000-0002-5591-7794
FU NIH grant [U54 AI057160]; National Institutes of Health/National Center
   for Research Resources Washington University-ICTS [KL2 RR024994];
   Children's Discovery Institute [MD-FR-2013-292]; Bill & Melinda Gates
   Foundation [OPP1016839]; Burroughs Wellcome Fund; Eli & Edythe Broad
   Fellow of the Life Sciences Research Foundation
FX This work was supported in part by the NIH grant U54 AI057160 to the
   Midwest Regional Center of Excellence for Biodefense and Emerging
   Infectious Disease Research, the National Institutes of Health/National
   Center for Research Resources Washington University-ICTS (KL2 RR024994),
   Children's Discovery Institute (MD-FR-2013-292), and the Bill & Melinda
   Gates Foundation (OPP1016839). DW holds an investigator in the
   pathogenesis of infectious disease award from the Burroughs Wellcome
   Fund. ESL is an Eli & Edythe Broad Fellow of the Life Sciences Research
   Foundation.
CR Adams MJ, 2013, ARCH VIROL, V158, P2023, DOI 10.1007/s00705-013-1688-5
   Ambert-Balay K, 2008, J CLIN MICROBIOL, V46, P1252, DOI 10.1128/JCM.02140-07
   Boros A, 2012, J GEN VIROL, V93, P2171, DOI 10.1099/vir.0.043224-0
   Bradley RK, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000392
   Chikhi-Brachet R, 2002, J CLIN MICROBIOL, V40, P4266, DOI 10.1128/JCM.40.11.4266-4272.2002
   Correll CC, 2003, RNA, V9, P355, DOI 10.1261/rna.2147803
   Denno Donna M., 2007, Animal Health Research Reviews, V8, P69, DOI 10.1017/S1466252307001302
   Drummond AJ., 2009, TRACER V 1 5
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Fauquet C. M., 2005, VIRUS TAXONOMY
   Fernandez-Miragall O, 2006, RNA, V12, P223, DOI 10.1261/rna.2153206
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2
   Hird TR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002599
   Holtz LR, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-86
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   KAPIKIAN AZ, 1993, JAMA-J AM MED ASSOC, V269, P627, DOI 10.1001/jama.269.5.627
   Kapoor A, 2008, P NATL ACAD SCI USA, V105, P20482, DOI 10.1073/pnas.0807979105
   Knowles NJ, 2012, VIRUS TAXONOMY CLASS, P855
   Koonin EV, 2008, NAT REV MICROBIOL, V6, P925, DOI 10.1038/nrmicro2030
   Kotloff KL, 2012, CLIN INFECT DIS, V55, pS232, DOI 10.1093/cid/cis753
   Le Gall O, 2008, ARCH VIROL, V153, P715, DOI 10.1007/s00705-008-0041-x
   Li LL, 2009, J VIROL, V83, P12002, DOI 10.1128/JVI.01241-09
   Lim ES, 2013, VIROLOGY, V436, P295, DOI 10.1016/j.virol.2012.12.005
   Lole KS, 1999, J VIROL, V73, P152
   Martinez-Salas E, 2008, TRENDS MICROBIOL, V16, P230, DOI 10.1016/j.tim.2008.01.013
   Nylander JAA, 2008, BIOINFORMATICS, V24, P581, DOI 10.1093/bioinformatics/btm388
   Pham NTK, 2007, J CLIN MICROBIOL, V45, P2287, DOI 10.1128/JCM.00525-07
   Phan T. G., 2013, VIRUS GENES
   Phan TG, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002218
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Ren LL, 2009, EMERG INFECT DIS, V15, P1509, DOI 10.3201/eid1509.081531
   Sanfacon H, 2009, ARCH VIROL, V154, P899, DOI 10.1007/s00705-009-0367-z
   Serrano P, 2007, RNA, V13, P849, DOI 10.1261/rna.506607
   Shan TL, 2010, EMERG INFECT DIS, V16, P1303, DOI 10.3201/eid1608.100087
   Toyoda H, 2007, J VIROL, V81, P10017, DOI 10.1128/JVI.00516-07
   Walker CLF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029151
   Woo PCY, 2012, J VIROL, V86, P2797, DOI 10.1128/JVI.05481-11
   Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078470
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 40
TC 7
Z9 7
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD APR
PY 2014
VL 454
BP 25
EP 33
DI 10.1016/j.virol.2014.01.018
PG 9
WC Virology
SC Virology
GA AF4AY
UT WOS:000334655000003
PM 24725928
OA No
DA 2017-08-15
ER

PT J
AU Sutherland, JS
   Loxton, AG
   Haks, MC
   Kassa, D
   Ambrose, L
   Lee, JS
   Ran, L
   van Baarle, D
   Maertzdorf, J
   Howe, R
   Mayanja-Kizza, H
   Boom, WH
   Thiel, BA
   Crampin, AC
   Hanekom, W
   Ota, MOC
   Dockrell, H
   Walzl, G
   Kaufmann, SHE
   Ottenhoff, THM
AF Sutherland, J. S.
   Loxton, A. G.
   Haks, M. C.
   Kassa, D.
   Ambrose, L.
   Lee, J. -S.
   Ran, L.
   van Baarle, D.
   Maertzdorf, J.
   Howe, R.
   Mayanja-Kizza, H.
   Boom, W. H.
   Thiel, B. A.
   Crampin, A. C.
   Hanekom, W.
   Ota, M. O. C.
   Dockrell, H.
   Walzl, G.
   Kaufmann, S. H. E.
   Ottenhoff, T. H. M.
CA GCGH Biomarkers TB Consortium
TI Differential gene expression of activating Fc gamma receptor classifies
   active tuberculosis regardless of human immunodeficiency virus status or
   ethnicity
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Article
DE Biosignature; gene expression; RT-MLPA; tuberculosis
ID T-CELLS CORRELATE; MYCOBACTERIUM-TUBERCULOSIS; INFECTION; DISEASE;
   BIOMARKERS; IDENTIFICATION; RESISTANCE; PATTERN; ASSAY
AB New diagnostics and vaccines for tuberculosis (TB) are urgently needed, but require an understanding of the requirements for protection from/susceptibility to TB. Previous studies have used unbiased approaches to determine gene signatures in single-site populations. The present study utilized a targeted approach, reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA), to validate these genes in a multisite study. We analysed exvivo whole blood RNA from a total of 523 participants across four sub-Saharan countries (Ethiopia, Malawi, South Africa, and The Gambia) with differences in TB and human immunodeficiency virus (HIV) status. We found a number of genes that were expressed at significantly lower levels in participants with active disease than in those with latent TB infection (LTBI), with restoration following successful TB treatment. The most consistent classifier of active disease was FCGR1A (high-affinity IgG Fc receptor1 (CD64)), which was the only marker expressed at significantly higher levels in participants with active TB than in those with LTBI before treatment regardless of HIV status or genetic background. This is the first study to identify a biomarker for TB that is not affected by HIV status or geo-genetic differences. These data provide valuable clues for understanding TB pathogenesis, and also provide a proof-of-concept for the use of RT-MLPA in rapid and inexpensive validation of unbiased gene expression findings.
C1 [Sutherland, J. S.; Ota, M. O. C.] MRC Unit, Fajara, Gambia.
   [Loxton, A. G.; Walzl, G.] Univ Stellenbosch, Cape Town, South Africa.
   [Haks, M. C.; Ottenhoff, T. H. M.] Leiden Univ, Med Ctr, Leiden, Netherlands.
   [Kassa, D.] Ethiopian Hlth & Nutr Res Inst, Addis Ababa, Ethiopia.
   [Ambrose, L.; Crampin, A. C.] Karonga Prevent Study, Chilumba, Malawi.
   [Lee, J. -S.; Dockrell, H.] London Sch Hyg & Trop Med, London WC1, England.
   [Ran, L.; van Baarle, D.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
   [Maertzdorf, J.; Kaufmann, S. H. E.] Max Planck Inst Infect Biol, Berlin, Germany.
   [Howe, R.] Armauer Hansen Res Inst, Addis Ababa, Ethiopia.
   [Mayanja-Kizza, H.] Makerere Univ, Kampala, Uganda.
   [Boom, W. H.; Thiel, B. A.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Hanekom, W.] Univ Cape Town, ZA-7925 Cape Town, South Africa.
RP Sutherland, JS (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM jsutherland@mrc.gm
RI Joosten, Simone/E-4731-2011; Joosten, Simone/F-1357-2011; Kaufmann,
   Stefan HE/I-5454-2014
OI Kaufmann, Stefan HE/0000-0001-9866-8268; Mayanja-Kizza,
   Harriet/0000-0002-9297-6208; Joloba, Moses/0000-0002-0334-9983;
   Sutherland, Jayne/0000-0002-7083-4997
FU Bill & Melinda Gates Foundation
FX We gratefully acknowledge the support of the Bill & Melinda Gates
   Foundation. We are indebted to all of the study participants at the
   African field sites for their contributions. The Principal Investigator
   of the GCGH Biomarkers for TB Consortium is S. H. E. Kaufmann, and the
   Project Coordinator is R. Golinski, both at the Max Planck Institute for
   Infection Biology (MPIIB), Berlin, Germany. The consortium consists of
   15 partner institutions, including seven from Africa, five from Europe,
   and three from the USA, represented by the following members, past and
   present: G. Walzl, N. Beyers, P. van Helden, B. Thompson, A. Loxton, N.
   Chegou, G. Black, D. Kriel, K. Stanley, H. Golakai, N. Du Plessis and G.
   van der Spuy of Stellenbosch University, Tygerberg, South Africa; M.
   Ota, J. Sutherland, I. Adetifa, T. Togun, S. Donkor, M. Antonio, P. Hill
   and R. Adegbola of the Medical Research Council Unit, The Gambia; W.
   Henry Boom, K. Chervenak, B. Thiel and E. Heaphy of Case Western Reserve
   University, OH, USA; H. Mayanja-Kizza, M. Joloba, S. Zalwango, M.
   Nsereko, B. Okwera Hussein Kisingo, J. Baseke, H. Buteme and S.
   Nalukwango of Makerere University, Kampala, Uganda; M. Crampin, N.
   French, B. Ngwira, A. Ben Smith, K. Watkins, L. Ambrose, F. Simukonda,
   H. Mvula, F. Chilongo, J. Saul and K. Branson of the Karonga Prevention
   Study, Chilumba, Malawi; H. Dockrell, M. Lalor, S. Smith, P.
   Gorak-Stolinska, Y.-G. Hur and R. Blitz of the London School of Hygiene
   and Tropical Medicine, London, UK; T. Ottenhoff, M. Haks, K. Franken, S.
   Joosten, A. Friggen, K. van Meijgaarden, A. Geluk and M. Klein of Leiden
   University Medical Centre, Leiden, The Netherlands; R. Howe, L. Yamuah,
   A. Mihret, A. Asseffa, M. Aytenew, Y. Assefa, S. Girma, R. Iwnetu and M.
   Tafesse of the Armauer Hansen Research Institute, Addis Ababa, Ethiopia;
   F. Miedema, L. Ran, R. Jacobi and D. van Baarle of the University
   Medical Centre, Utrecht, The Netherlands; D. Kassa, A. Abebe, G.
   Gebremichael, T. Mesele, B. Tegbaru and Y. Alemayehu of the Ethiopian
   Health & Nutrition Research Institute, Addis Ababa, Ethiopia; P.
   Andersen, M. Doherty, I. Rosenkrands and K. Weldingh of Statens Serum
   Institute, Copenhagen, Denmark; W. Hanekom, T. Scriba, J. Hughes, H.
   Mohamed, B. Abel, M. Bowmaker, B. Kagina, W. Kwong Chung, H. Mulenga, A.
   Keyser, M. Erasmus and G. Hussey of the University of Cape Town, Cape
   Town, South Africa; J. Sadoff, D. Sizemore, L. Barker, M. Brennan, F.
   Weichold, A. Malone, J. Zhou, S. Mueller and L. Geiter of AERAS,
   Bethesda, MD, USA; G. Schoolnik, G. Dolganov and T. Van of Stanford
   University, Stanford, CA, USA; and S. H. E. Kaufmann, R. Golinski, S.
   Parida, M. Jacobsen, J. Weiner, R. Lauhkonen and J. Maertzdorf of MPIIB,
   Berlin, Germany.
CR ARMSTRON.JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713
   Balboa L, 2013, EUR J IMMUNOL, V43, P335, DOI 10.1002/eji.201242557
   Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247
   Caccamo N, 2010, EUR J IMMUNOL, V40, P2211, DOI 10.1002/eji.201040455
   Caccamo N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005528
   Chegou Novel N, 2009, BMC Pulm Med, V9, P21, DOI 10.1186/1471-2466-9-21
   Cliff JM, 2013, J INFECT DIS, V207, P18, DOI 10.1093/infdis/jis499
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   Eldering E, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng153
   Gagneux S, 2007, LANCET INFECT DIS, V7, P328, DOI 10.1016/S1473-3099(07)70108-1
   Goletti D, 2006, J INFECT DIS, V194, P984, DOI 10.1086/507427
   Hwang SA, 2011, TUBERC RES TREAT, DOI [10.1155/2011/835410, DOI 10.1155/2011/835410]
   Jacobsen M, 2007, J MOL MED-JMM, V85, P613, DOI 10.1007/s00109-007-0157-6
   Joosten SA, 2012, GENES IMMUN, V13, P71, DOI 10.1038/gene.2011.64
   Kaufmann SHE, 2008, CELL HOST MICROBE, V4, P219, DOI 10.1016/j.chom.2008.08.002
   Lewinsohn DA, 2003, AM J RESP CRIT CARE, V168, P1346, DOI 10.1164/rccm.200306-837OC
   Maertzdorf J., 2011, PLoS ONE, pe26938, DOI 10.1371/journal.pone.0026938
   Maertzdorf J, 2011, GENES IMMUN, V12, P15, DOI 10.1038/gene.2010.51
   Martineau AR, 2007, J CLIN INVEST, V117, P1988, DOI 10.1172/JCI31097
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704
   Ottenhoff THM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045839
   Ottenhoff THM, 2012, TUBERCULOSIS, V92, pS17, DOI 10.1016/S1472-9792(12)70007-0
   Ratledge C, 2004, TUBERCULOSIS, V84, P110, DOI 10.1016/j.tube.2003.08.012
   Rodrigues DSS, 2002, CLIN EXP IMMUNOL, V128, P149, DOI 10.1046/j.1365-2249.2002.01809.x
   Sutherland JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012365
   Sutherland JS, 2009, EUR J IMMUNOL, V39, P723, DOI 10.1002/eji.200838693
   White SJ, 2004, HUM MUTAT, V24, P86, DOI 10.1002/humu.20054
   World Health Organization, 2012, WHO GLOB TUB REP 201
NR 28
TC 22
Z9 22
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1198-743X
EI 1469-0691
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD APR
PY 2014
VL 20
IS 4
BP O230
EP O238
DI 10.1111/1469-0691.12383
PG 9
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA AC7CR
UT WOS:000332685100004
PM 24205913
OA No
DA 2017-08-15
ER

PT J
AU van Leth, F
   Kampmann, B
AF van Leth, Frank
   Kampmann, Beate
TI Embracing the challenges of HIV-TB co-infection in children
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Editorial Material
ID PULMONARY TUBERCULOSIS; DIAGNOSIS
C1 [van Leth, Frank] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, Amsterdam Inst Global Hlth & Dev, NL-1105 AZ Amsterdam, Netherlands.
   [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England.
   [Kampmann, Beate] Vaccinol Theme, MRC Unit, Banjul, Gambia.
RP van Leth, F (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, Amsterdam Inst Global Hlth & Dev, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM f.vanleth@aighd.org
OI Kampmann, Beate/0000-0002-6546-4709; van Leth, Frank/0000-0002-5490-8968
FU Department of Health [SRF-2009-02-07]; Medical Research Council
   [MC_EX_MR/K011944/1, MC_UP_A900_1122]
CR Auld AF, 2014, INT J TUBERC LUNG D, V18, P381, DOI 10.5588/ijtld.13.0395
   Blok N, 2014, INT J TUBERC LUNG D, V18, P205, DOI 10.5588/ijtld.13.0526
   Hermans SM, 2012, HIV MED, V13, P337, DOI 10.1111/j.1468-1293.2011.00980.x
   Marais BJ, 2006, PEDIATRICS, V118, pE1350, DOI 10.1542/peds.2006-0519
   Newton SM, 2008, LANCET INFECT DIS, V8, P498, DOI 10.1016/S1473-3099(08)70182-8
   Zar HJ, 2012, CLIN INFECT DIS, V55, P1088, DOI 10.1093/cid/cis598
NR 6
TC 3
Z9 3
U1 0
U2 3
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
EI 1815-7920
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD APR
PY 2014
VL 18
IS 4
BP 379
EP 379
DI 10.5588/ijtld.14.0171
PG 1
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA AE7AV
UT WOS:000334150000001
PM 24670688
OA No
DA 2017-08-15
ER

PT J
AU Hegedus, A
   Nyamweya, S
   Zhang, Y
   Govind, S
   Aspinall, R
   Mashanova, A
   Jansen, V
   Whittle, H
   Jaye, A
   Flanagan, K
   Macallan, D
AF Hegedus, A.
   Nyamweya, S.
   Zhang, Y.
   Govind, S.
   Aspinall, R.
   Mashanova, A.
   Jansen, V.
   Whittle, H.
   Jaye, A.
   Flanagan, K.
   Macallan, D.
TI Protection versus pathology in aviremic and high viral load HIV-2
   infection - the pivotal role of immune activation and T-cell kinetics
SO HIV MEDICINE
LA English
DT Meeting Abstract
C1 [Hegedus, A.; Zhang, Y.; Macallan, D.] Univ London, London WC1E 7HU, England.
   [Nyamweya, S.; Whittle, H.; Jaye, A.; Flanagan, K.] Med Res Labs, Fajara, Gambia.
   [Govind, S.; Aspinall, R.] Cranfield Univ, Cranfield MK43 0AL, Beds, England.
   [Mashanova, A.; Jansen, V.] Royal Holloway Univ London, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD APR
PY 2014
VL 15
SU 3
SI SI
BP 4
EP 5
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA AE0KB
UT WOS:000333652300013
OA No
DA 2017-08-15
ER

PT J
AU Nwakanma, DC
   Duffy, CW
   Amambua-Ngwa, A
   Oriero, EC
   Bojang, KA
   Pinder, M
   Drakeley, CJ
   Sutherland, CJ
   Milligan, PJ
   MacInnis, B
   Kwiatkowski, DP
   Clark, TG
   Greenwood, BM
   Conway, DJ
AF Nwakanma, Davis C.
   Duffy, Craig W.
   Amambua-Ngwa, Alfred
   Oriero, Eniyou C.
   Bojang, Kalifa A.
   Pinder, Margaret
   Drakeley, Chris J.
   Sutherland, Colin J.
   Milligan, Paul J.
   MacInnis, Bronwyn
   Kwiatkowski, Dominic P.
   Clark, Taane G.
   Greenwood, Brian M.
   Conway, David J.
TI Changes in Malaria Parasite Drug Resistance in an Endemic Population
   Over a 25-Year Period With Resulting Genomic Evidence of Selection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE resistance monitoring; population genetics; genomic surveillance;
   archival analysis; policy and practice
ID PLASMODIUM-FALCIPARUM MALARIA; CHLOROQUINE RESISTANCE; POSITIVE
   SELECTION; GAMBIAN CHILDREN; PYRIMETHAMINE; ARTESUNATE; SPREAD;
   SULFADOXINE; EVOLUTION; HAPLOTYPE
AB Background. Analysis of genome-wide polymorphism in many organisms has potential to identify genes under recent selection. However, data on historical allele frequency changes are rarely available for direct confirmation.
   Methods. We genotyped single nucleotide polymorphisms (SNPs) in 4 Plasmodium falciparum drug resistance genes in 668 archived parasite-positive blood samples of a Gambian population between 1984 and 2008. This covered a period before antimalarial resistance was detected locally, through subsequent failure of multiple drugs until introduction of artemisinin combination therapy. We separately performed genome-wide sequence analysis of 52 clinical isolates from 2008 to prospect for loci under recent directional selection.
   Results. Resistance alleles increased from very low frequencies, peaking in 2000 for chloroquine resistance-associated crt and mdr1 genes and at the end of the survey period for dhfr and dhps genes respectively associated with pyrimethamine and sulfadoxine resistance. Temporal changes fit a model incorporating likely selection coefficients over the period. Three of the drug resistance loci were in the top 4 regions under strong selection implicated by the genome-wide analysis.
   Conclusions. Genome-wide polymorphism analysis of an endemic population sample robustly identifies loci with detailed documentation of recent selection, demonstrating power to prospectively detect emerging drug resistance genes.
C1 [Nwakanma, Davis C.; Amambua-Ngwa, Alfred; Oriero, Eniyou C.; Bojang, Kalifa A.; Pinder, Margaret; Conway, David J.] MRC Unit, Fajara, Gambia.
   [Duffy, Craig W.; Drakeley, Chris J.; Sutherland, Colin J.; Milligan, Paul J.; Clark, Taane G.; Greenwood, Brian M.; Conway, David J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [MacInnis, Bronwyn; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Cambridge, England.
   [Kwiatkowski, Dominic P.] Univ Oxford, Med Res Council Ctr Genom & Global Hlth, Oxford OX1 2JD, England.
   [Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
RP Conway, DJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, Keppel St, London WC1E 7HT, England.
EM david.conway@lshtm.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Sutherland,
   Colin/0000-0003-1592-6407; Duffy, Craig/0000-0001-9359-4888;
   Kwiatkowski, Dominic/0000-0002-5023-0176; Conway,
   David/0000-0002-8711-3037
FU UK Medical Research Council [G1100123, G0600718]; Wellcome Trust
   [074695/Z/04/B, 098051, 090770/Z/09/Z]; European Research Council
   [294428]
FX This work was supported by the UK Medical Research Council (funding to
   the MRC Gambia Unit; grants G1100123 and G0600718); the Wellcome Trust
   (grants 074695/Z/04/B, 098051, and 090770/Z/09/Z); and the European
   Research Council (grant 294428). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amambua-Ngwa A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002992
   Amambua-Ngwa A, 2012, MOL BIOL EVOL, V29, P3249, DOI 10.1093/molbev/mss151
   Antao T, 2011, P ROY SOC B-BIOL SCI, V278, P1705, DOI 10.1098/rspb.2010.1907
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Chang HH, 2012, MOL BIOL EVOL, V29, P3427, DOI 10.1093/molbev/mss161
   Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403
   Drakeley CJ, 2000, T ROY SOC TROP MED H, V94, P472, DOI 10.1016/S0035-9203(00)90056-7
   Dunyo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017371
   Duraisingh MT, 1998, EXP PARASITOL, V89, P1, DOI 10.1006/expr.1998.4274
   Duraisingh MT, 2000, PARASITOLOGY, V121, P1, DOI 10.1017/S0031182099006022
   Frank M, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-304
   Grossman SR, 2010, SCIENCE, V327, P883, DOI 10.1126/science.1183863
   Kublin JG, 2003, J INFECT DIS, V187, P1870, DOI 10.1086/375419
   Laufer MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042284
   Laufer MK, 2010, J INFECT DIS, V202, P801, DOI 10.1086/655659
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Malisa AL, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-317
   Manske M, 2012, NATURE, V487, P375, DOI 10.1038/nature11174
   MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1
   McCollum AM, 2008, ANTIMICROB AGENTS CH, V52, P4089, DOI 10.1128/AAC.00623-08
   McCollum AM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-77
   McVean G, 2002, GENETICS, V160, P1231
   MENON A, 1990, T ROY SOC TROP MED H, V84, P638, DOI 10.1016/0035-9203(90)90130-7
   Mita T, 2011, J INFECT DIS, V204, P1980, DOI 10.1093/infdis/jir664
   Mixson-Hayden T, 2010, ANTIMICROB AGENTS CH, V54, P997, DOI 10.1128/AAC.00846-09
   Mwai L, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-106
   Nair S, 2003, MOL BIOL EVOL, V20, P1526, DOI 10.1093/molbev/msg162
   Nair S, 2007, MOL BIOL EVOL, V24, P562, DOI 10.1093/molbev/msl185
   Nash D, 2005, P ROY SOC B-BIOL SCI, V272, P1153, DOI 10.1098/rspb.2004.3026
   Nsanzabana C, 2010, J INFECT DIS, V201, P435, DOI 10.1086/649784
   Ord R, 2007, J INFECT DIS, V196, P1613, DOI 10.1086/522154
   PANTON LJ, 1985, T ROY SOC TROP MED H, V79, P484, DOI 10.1016/0035-9203(85)90072-0
   Park DJ, 2012, P NATL ACAD SCI USA, V109, P13052, DOI 10.1073/pnas.1210585109
   Pearce RJ, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000055
   Raman J, 2010, AM J TROP MED HYG, V82, P788, DOI 10.4269/ajtmh.2010.09-0401
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Sutherland CJ, 2002, AM J TROP MED HYG, V66, P700
   Taylor SM, 2012, INFECT GENET EVOL, V12, P282, DOI 10.1016/j.meegid.2011.11.006
   Tshefu AK, 2010, LANCET, V375, P1457, DOI 10.1016/S0140-6736(10)60322-4
   Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072
   von Seidlein L, 2001, TROP MED INT HEALTH, V6, P92, DOI 10.1046/j.1365-3156.2001.00683.x
   vonSeidlein L, 1997, T ROY SOC TROP MED H, V91, P450, DOI 10.1016/S0035-9203(97)90281-9
   Witkowski B, 2010, ANTIMICROB AGENTS CH, V54, P3049, DOI 10.1128/AAC.00209-10
   Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813
NR 47
TC 20
Z9 20
U1 1
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD APR 1
PY 2014
VL 209
IS 7
BP 1126
EP 1135
DI 10.1093/infdis/jit618
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AD2TI
UT WOS:000333087900020
PM 24265439
OA No
DA 2017-08-15
ER

PT J
AU Njai, HF
   Ceesay, A
   Bayzid, N
   Ndow, G
   Lemoine, M
   Shimakawa, Y
   Dalessandro, U
   Thursz, M
   Mendy, M
   Chemin, I
   Njie, R
AF Njai, H. F.
   Ceesay, A.
   Bayzid, N.
   Ndow, G.
   Lemoine, M.
   Shimakawa, Y.
   Dalessandro, U.
   Thursz, M.
   Mendy, M.
   Chemin, I.
   Njie, R.
TI Virological profiles of hepatitis B virus (HBV)-infected African
   patients treated with tenofovir
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Njai, H. F.; Ceesay, A.; Bayzid, N.; Ndow, G.; Lemoine, M.; Shimakawa, Y.; Dalessandro, U.] MRC, Gambia Unit, Fajara, Gambia.
   [Thursz, M.] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Mendy, M.; Njie, R.] IARC, Lyon, France.
   [Chemin, I.] Ctr Rech Canc, UMR INSERM, Lyon, France.
RI Chemin, Isabelle/I-3032-2016
OI Ndow, Gibril/0000-0001-5837-5110
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD APR
PY 2014
VL 21
SU 1
MA Pre.015
BP 8
EP 8
DI 10.1016/j.ijid.2014.03.422
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA V43TP
UT WOS:000209704000016
OA gold
DA 2017-08-15
ER

PT J
AU Noho-Konteh, F
   Adetifa, J
   Cox, M
   Forster, T
   Drammeh, A
   Njie-Jobe, J
   Jeffries, D
   Plebanski, M
   Ghazal, P
   Dickinson, P
   Whittle, H
   Rowland-Jones, S
   Sutherland, J
   Flanagan, K
AF Noho-Konteh, F.
   Adetifa, J.
   Cox, M.
   Forster, T.
   Drammeh, A.
   Njie-Jobe, J.
   Jeffries, D.
   Plebanski, M.
   Ghazal, P.
   Dickinson, P.
   Whittle, H.
   Rowland-Jones, S.
   Sutherland, J.
   Flanagan, K.
TI Sex differences in immune responses to vaccines
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Noho-Konteh, F.; Adetifa, J.; Cox, M.; Drammeh, A.; Njie-Jobe, J.; Jeffries, D.; Whittle, H.; Sutherland, J.] MRC Labs, Banjul, Gambia.
   [Forster, T.; Ghazal, P.; Dickinson, P.] Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland.
   [Plebanski, M.] Monash Univ, Melbourne, Vic 3004, Australia.
   [Rowland-Jones, S.] Univ Oxford, Oxford, England.
   [Flanagan, K.] Monash Univ, Melbourne, Tas, Australia.
RI Forster, Thorsten/F-4483-2017
OI Forster, Thorsten/0000-0002-4483-3069
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD APR
PY 2014
VL 21
SU 1
MA 31.001
BP 65
EP 65
DI 10.1016/j.ijid.2014.03.556
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA V43TP
UT WOS:000209704000143
OA gold
DA 2017-08-15
ER

PT J
AU Ndow, G
   Manga, NM
   Ba, IO
   Ka, D
   Cisse-Diallo, V
   Diop, SA
   Dia-Badiane, NM
   Deguenovo, LF
   Ndour, CT
   Seydi, M
AF Ndow, G.
   Manga, N. M.
   Ba, I. O.
   Ka, D.
   Cisse-Diallo, V.
   Diop, S. A.
   Dia-Badiane, N. M.
   Deguenovo, L. Fortes
   Ndour, C. T.
   Seydi, M.
TI Role of Neisseria meningitidis W135 in the cerebrospinal meningitis
   outbreak in Senegal in 2012: Epidemiological and biological
   characteristics
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Ndow, G.] Med Res Council MRC, Gambia Unit, Fajara, Gambia.
   [Manga, N. M.; Ka, D.; Cisse-Diallo, V.; Diop, S. A.; Dia-Badiane, N. M.; Deguenovo, L. Fortes; Ndour, C. T.; Seydi, M.] Univ Cheik Anta Diop, Dakar, Senegal.
   [Ba, I. O.] Direct Prevent Med, Dakar, Senegal.
OI Ndow, Gibril/0000-0001-5837-5110
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD APR
PY 2014
VL 21
SU 1
MA 43.026
BP 148
EP 148
DI 10.1016/j.ijid.2014.03.733
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA V43TP
UT WOS:000209704000318
OA gold
DA 2017-08-15
ER

PT J
AU Okoi, CB
AF Okoi, C. B.
TI The prevalence of non-tuberculous mycobacteria (NTM) in The Gambia
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Okoi, C. B.] Med Resarch Council Unit, Gambia MRC, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD APR
PY 2014
VL 21
SU 1
MA 51.011
BP 220
EP 220
DI 10.1016/j.ijid.2014.03.879
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA V43TP
UT WOS:000209704000463
OA gold
DA 2017-08-15
ER

PT J
AU Njai, HF
   Shimakawa, Y
   Ferguson, L
   Sanneh, B
   Dalessandro, U
   Mendy, M
   Thursz, M
   Njie, R
   Lemoine, M
AF Njai, H. F.
   Shimakawa, Y.
   Ferguson, L.
   Sanneh, B.
   Dalessandro, U.
   Mendy, M.
   Thursz, M.
   Njie, R.
   Lemoine, M.
TI Validation of hepatitis B surface antigen (HBsAg) rapid test to screen
   HBV infection in rural Gambia
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Njai, H. F.; Shimakawa, Y.; Ferguson, L.; Dalessandro, U.; Lemoine, M.] MRC, Gambia Unit, Fajara, Gambia.
   [Sanneh, B.] NPHL, Kotu, Gambia.
   [Mendy, M.; Njie, R.] IARC, Lyon, France.
   [Thursz, M.] Univ London Imperial Coll Sci Technol & Med, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD APR
PY 2014
VL 21
SU 1
MA 53.025
BP 271
EP 271
DI 10.1016/j.ijid.2014.03.984
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA V43TP
UT WOS:000209704000568
OA gold
DA 2017-08-15
ER

PT J
AU James, A
   Darboe, S
   Ceesay, B
   Jallow, M
AF James, A.
   Darboe, S.
   Ceesay, B.
   Jallow, M.
TI A new perspective to invasive bacterial infections in The Gambia:
   Surveillance of etiological agents responsible for admission of patients
   in the clinic
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [James, A.; Darboe, S.; Ceesay, B.; Jallow, M.] MRC Unit, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD APR
PY 2014
VL 21
SU 1
MA 53.041
BP 279
EP 279
DI 10.1016/j.ijid.2014.03.1000
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA V43TP
UT WOS:000209704000584
OA gold
DA 2017-08-15
ER

PT J
AU Oriero, EC
   Van Geertruyden, JP
   Jacobs, J
   D'Alessandro, U
   Nwakanma, DC
AF Oriero, E. C.
   Van Geertruyden, J. -P.
   Jacobs, J.
   D'Alessandro, U.
   Nwakanma, D. C.
TI Comparison of two isothermal amplification methods: Thermophilic
   helicase dependent amplification (tHDA) and loop mediated isothermal
   amplification (LAMP) for detection of Plasmodium falciparum
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Oriero, E. C.; D'Alessandro, U.; Nwakanma, D. C.] MRC Unit, Banjul, Gambia.
   [Van Geertruyden, J. -P.] Univ Antwerp, B-2020 Antwerp, Belgium.
   [Jacobs, J.] Inst Trop Med, B-2000 Antwerp, Belgium.
RI Van geertruyden, Jean-pierre/K-6425-2014
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD APR
PY 2014
VL 21
SU 1
MA 59.044
BP 381
EP 381
DI 10.1016/j.ijid.2014.03.1206
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA V43TP
UT WOS:000209704000789
OA gold
DA 2017-08-15
ER

PT J
AU Ladep, NG
   Lewis, M
   Gomez-Romero, M
   Lemoine, M
   Okeke, E
   Njie, R
   Banwat, E
   Fye, H
   Khan, SA
   Garside, D
   Crossey, M
   Fiyaktu, Y
   Mary, D
   Thursz, M
   Holmes, E
   Taylor-Robinson, SD
AF Ladep, N. G.
   Lewis, M.
   Gomez-Romero, M.
   Lemoine, M.
   Okeke, E.
   Njie, R.
   Banwat, E.
   Fye, H.
   Khan, S. A.
   Garside, D.
   Crossey, M.
   Fiyaktu, Y.
   Mary, D.
   Thursz, M.
   Holmes, E.
   Taylor-Robinson, S. D.
TI BIOMARKER DISCOVERY USING ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY
   QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY IDENTIFIES DIAGNOSTIC
   URINARY METABOLIC PANELS FOR HCC IN AFRICANS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Lewis, M.; Gomez-Romero, M.; Holmes, E.] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Lemoine, M.; Njie, R.; Fye, H.] MRC, Fajara, Gambia.
   [Okeke, E.; Banwat, E.; Fiyaktu, Y.; Mary, D.] Univ Jos, Teaching Hosp, Jos, Nigeria.
EM n.ladep@imperial.ac.uk
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA P561
BP S256
EP S256
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CS3HB
UT WOS:000361961700722
OA No
DA 2017-08-15
ER

PT J
AU Lemoine, M
   Shimakawa, Y
   Goldin, R
   Khalil, M
   Lloyd, J
   Suso, P
   Nayagam, S
   Njai, HF
   Taal, M
   Ndow, G
   D'Alessandro, U
   Njie, R
   Thursz, M
AF Lemoine, M.
   Shimakawa, Y.
   Goldin, R.
   Khalil, M.
   Lloyd, J.
   Suso, P.
   Nayagam, S.
   Njai, H. Freeya
   Taal, M.
   Ndow, G.
   D'Alessandro, U.
   Njie, R.
   Thursz, M.
TI VALIDATION AND COMPARISON OF NON-INVASIVE MARKERS OF LIVER FIBROSIS IN
   WEST-AFRICAN PATIENTS WITH CHRONIC HEPATITIS B LIVING IN THE GAMBIA
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Lemoine, M.; Nayagam, S.; Thursz, M.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp,London, Liver Ctr, London, England.
   [Lemoine, M.; Shimakawa, Y.; Njai, H. Freeya; Ndow, G.; D'Alessandro, U.; Njie, R.] MRC, Gambia Unit, Dis Control & Eliminat Theme, Fajara, Gambia.
   [Shimakawa, Y.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Goldin, R.; Lloyd, J.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Ctr Pathol, London, England.
   [Khalil, M.; Suso, P.] Edward Francis Small Teaching Hosp, Dept Histopathol, Banjul, Gambia.
   [Taal, M.] Minist Hlth, Fajara, Gambia.
EM mlemoine@mrc.gm
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA P1019
BP S414
EP S415
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5DT
UT WOS:000362828600435
OA No
DA 2017-08-15
ER

PT J
AU Nayagam, S
   Shimakawa, Y
   Lemoine, M
   Njie, R
   Tamba, S
   D'Alessandro, U
   Hallett, T
   Conteh, L
   Thursz, M
AF Nayagam, S.
   Shimakawa, Y.
   Lemoine, M.
   Njie, R.
   Tamba, S.
   D'Alessandro, U.
   Hallett, T.
   Conteh, L.
   Thursz, M.
TI FEASIBILITY AND COST ANALYSIS OF COMMUNITY BASED HEPATITIS B SCREENING
   PROGRAMME IN SUB-SAHARAN AFRICA
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Nayagam, S.; Lemoine, M.; Thursz, M.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Hepatol, London, England.
   [Shimakawa, Y.; Lemoine, M.; Njie, R.; Tamba, S.; D'Alessandro, U.] MRC Unit, Banjul, Gambia.
   [Shimakawa, Y.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England.
   [Hallett, T.; Conteh, L.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England.
   [Conteh, L.] Univ London Imperial Coll Sci Technol & Med, Ctr Hlth Policy, London, England.
EM s.nayagam01@imperial.ac.uk
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA O87
BP S36
EP S36
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CS3HB
UT WOS:000361961700088
OA No
DA 2017-08-15
ER

PT J
AU Njai, HF
   Ceesay, A
   Bazyid, N
   Ndow, G
   Shimakawa, Y
   Taal, M
   Corrah, T
   Dalessandro, U
   Lemoine, M
   Mendy, M
   Thursz, M
   Chemin, I
   Njie, R
AF Njai, H. F.
   Ceesay, A.
   Bazyid, N.
   Ndow, G.
   Shimakawa, Y.
   Taal, M.
   Corrah, T.
   Dalessandro, U.
   Lemoine, M.
   Mendy, M.
   Thursz, M.
   Chemin, I.
   Njie, R.
TI VIROLOGICAL PROFILES OF HEPATITIS B VIRUS (HBV)-INFECTED AFRICAN
   PATIENTS TREATED WITH TENOFOVIR
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Njai, H. F.; Ceesay, A.; Bazyid, N.; Ndow, G.; Shimakawa, Y.; Corrah, T.; Dalessandro, U.; Lemoine, M.; Njie, R.] MRC, Gambia Unit, Fajara, Gambia.
   [Taal, M.] NPHL, Kotu, Gambia.
   [Mendy, M.; Njie, R.] Int Agcy Res Canc, F-69372 Lyon, France.
   [Thursz, M.] Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Hepatol, London, England.
   [Chemin, I.] Ctr Rech Cancerol UMR INSERM, CNRS 5286 1052, Lyon, France.
EM harrnjai@gmail.com
RI Chemin, Isabelle/I-3032-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA P1090
BP S441
EP S441
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5DT
UT WOS:000362828600506
OA No
DA 2017-08-15
ER

PT J
AU Njai, HF
   Shimakawa, Y
   Ferguson, L
   Sanneh, B
   Dalessandro, U
   Njie, R
   Thursz, M
   Lemoine, M
AF Njai, H. F.
   Shimakawa, Y.
   Ferguson, L.
   Sanneh, B.
   Dalessandro, U.
   Njie, R.
   Thursz, M.
   Lemoine, M.
TI PERFORMANCE OF TWO RAPID TESTS OF HEPATITIS B SURFACE ANTIGEN FOR
   SCREENING HEPATITIS B VIRUS (HBV) INFECTION IN THE RURAL COMMUNITIES OF
   THE GAMBIA
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 09-13, 2014
CL London, ENGLAND
SP European Assoc Study Liver
C1 [Njai, H. F.; Shimakawa, Y.; Ferguson, L.; Dalessandro, U.; Njie, R.; Lemoine, M.] MRC, Gambia Unit, Fajara, Gambia.
   [Sanneh, B.] NPHL, Kotu, Gambia.
   [Njie, R.] IARC, Lyon, France.
   [Thursz, M.; Lemoine, M.] Univ London Imperial Coll Sci Technol & Med, London, England.
EM harrnjai@gmail.com
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2014
VL 60
IS 1
SU S
MA P1298
BP S522
EP S522
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5DT
UT WOS:000362828600713
OA No
DA 2017-08-15
ER

PT J
AU Zwang, J
   Dorsey, G
   Martensson, A
   d'Alessandro, U
   Ndiaye, JL
   Karema, C
   Djimde, A
   Brasseur, P
   Sirima, SB
   Olliaro, P
AF Zwang, Julien
   Dorsey, Grant
   Martensson, Andreas
   d'Alessandro, Umberto
   Ndiaye, Jean-Louis
   Karema, Corine
   Djimde, Abdoulaye
   Brasseur, Philippe
   Sirima, Sodiomon B.
   Olliaro, Piero
TI Plasmodium falciparum clearance in clinical studies of
   artesunate-amodiaquine and comparator treatments in sub-Saharan Africa,
   1999-2009
SO MALARIA JOURNAL
LA English
DT Article
ID ARTEMISININ COMBINATION THERAPIES; PLUS SULFADOXINE-PYRIMETHAMINE;
   FIXED-DOSE COMBINATIONS; UNCOMPLICATED MALARIA; PARASITE CLEARANCE;
   ARTEMETHER-LUMEFANTRINE; MOLECULAR MARKERS; WESTERN CAMBODIA; CENTRAL
   ANGOLA; NIMBA COUNTY
AB Background: Artemisinin-based combination therapy (ACT) is the recommended first-line therapy for uncomplicated Plasmodium falciparum malaria worldwide but decreased artemisinin susceptibility, phenotypically characterized as slow parasite clearance time (PCT), has now been reported in Southeast Asia. This makes it all too important to measure the dynamics of parasite clearance in African patients treated with ACT over time, to understand trends and detect changes early enough to intervene
   Methods: Individual patient data from 27 clinical trials of artesunate-amodiaquine (ASAQ) vs comparators conducted between 1999 and 2009 were analysed for parasite clearance on modified intent-to-treat (ITT) basis.
   Results: Overall 15,017 patients treated for uncomplicated P. falciparum malaria at 44 sites in 20 sub-Saharan African countries were included in the analysis; 51% (n=7,660) vs 49% (n=7,357) were treated with ASAQ and comparator treatments, respectively. Seventy-seven per cent (77%) were children under six years of age. The proportion of the patients treated with ASAQ with persistent parasitaemia on Day 2 was 8.6%, and 1.5% on Day 3. Risk factor for not clearing parasites on Day 2 and Day 3 calculated by multivariate logistic regression with random effect on site and controlling for treatment were: high parasitaemia before treatment was (adjusted risk ratios (AOR) 2.12, 95% CI 1.91-2.35, AOR 2.43, 95% CI 1.98-3.00, respectively); non-ACT treatment (p=0.001, for all comparisons). Anaemia (p=0.001) was an additional factor for Day 2 and young age (p=0.005) for Day 3. In patients treated with ASAQ in studies who had complete parasitaemia data every 24 hours up to Day 3 and additionally Day 7, the parasite reduction ratio was 93.9% by Day 1 and 99.9% by Day 2. Using the median parasitaemia before treatment (p0=27,125 mu L) and a fitted model, the predicted PCT (pPCT =3.614*ln (p0) - 6.135, r(2) = 0.94) in ASAQ recipients was 31 hours.
   Conclusion: Within the period covered by these studies, rapid Plasmodium falciparum clearance continues to be achieved in Sub-Saharan African patients treated with ACT, and in particular with ASAQ. The prediction formula for parasite clearance time could be a pragmatic tool for studies with binary outcomes and once-daily sampling, both for research and monitoring purposes.
C1 [Zwang, Julien] Drugs Neglected Dis Initiat DNDi, Geneva, Switzerland.
   [Dorsey, Grant] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Martensson, Andreas] Karolinska Inst, Dept Publ Hlth Sci, Div Global Hlth IHCAR, Stockholm, Sweden.
   [d'Alessandro, Umberto] MRC Unit, Banjul, Gambia.
   [Ndiaye, Jean-Louis] Cheikh Anta Diop Univ, Fac Med, Dept Parasitol, Dakar, Senegal.
   [Karema, Corine] Minist Hlth, Malaria & Other Parasit Dis Div RBC, Rugenge, Kigali, Rwanda.
   [Djimde, Abdoulaye] Univ Sci Tech & Technol Bamako, Fac Med & Pharm, Dept Epidemiol Parasit Dis, Malaria Res & Training Ctr, Bamako, Mali.
   [Brasseur, Philippe] Inst Rech Dev, Unite Mixte Rech 198, Dakar, Senegal.
   [Sirima, Sodiomon B.] Minist Sante, Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso.
   [Olliaro, Piero] UNICEF UNDP WB WHO Special Programme Res & Traini, Geneva, Switzerland.
   [Olliaro, Piero] Univ Oxford, Churchill Hosp, Nuffield Dept Med, Ctr Trop Med & Vaccinol, Oxford OX3 7LJ, England.
RP Olliaro, P (reprint author), UNICEF UNDP WB WHO Special Programme Res & Traini, Geneva, Switzerland.
EM olliarop@who.int
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU DNDi (Drugs for Neglected Diseases initiative); European and Developing
   Countries Clinical Trial Partnership (EDCTP) fellowship [2004.2.C.f1];
   Sanofi Aventis [ARTEN-L-00848]
FX We would like to thank all the patients and staff at all trial sites who
   participated in these trials. We would like to thank Epicentre, Paris,
   France, for sharing the datasets [23,29-32,34-36] and all the principal
   investigators of the other studies. JZ received a grant from DNDi (Drugs
   for Neglected Diseases initiative) to do this analysis. DNDi sponsored
   four of the trials [19-22] but had no role in the design and conduct of
   the analysis, interpretation of results of the manuscript. The Mali
   study was supported by European and Developing Countries Clinical Trial
   Partnership (EDCTP) fellowship (Grant to AAD # 2004.2.C.f1) and by
   Sanofi Aventis (ARTEN-L-00848) who provided the monitoring services, the
   study insurance, the study drugs, and the biological parameters
   assessment machines.
CR Four Artemisinin-Based Combinations (4ABC) Study Group, 2011, PLOS MED, V8, DOI DOI 10.1371/J0URNAL.PMED.1001119
   Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4
   Agnamey P, 2005, TROP MED INT HEALTH, V10, P926, DOI 10.1111/j.1365-3156.2005.01482.x
   Amaratunga C, 2012, LANCET INFECT DIS, V12, P851, DOI 10.1016/S1473-3099(12)70181-0
   Ariey F, 2014, NATURE, V505, P50, DOI 10.1038/nature12876
   Bonnet M, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-54
   Brasseur P, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-150
   Bukirwa H, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010007
   Carrara VI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004551
   Das D, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-125
   Djimde AA, 2008, AM J TROP MED HYG, V78, P455
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Dorsey G, 2007, JAMA-J AM MED ASSOC, V297, P2210, DOI 10.1001/jama.297.20.2210
   Flegg JA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-339
   Grandesso F, 2006, TROP MED INT HEALTH, V11, P1017, DOI 10.1111/j.1365-3156.2006.01655.x
   Guthmann JP, 2006, AM J TROP MED HYG, V75, P143
   Guthmann JP, 2005, T ROY SOC TROP MED H, V99, P485, DOI 10.1016/j.trstmh.2004.11.010
   Hamour S, 2005, T ROY SOC TROP MED H, V99, P548, DOI 10.1016/j.trstmh.2004.10.003
   Juni B, 2001, BMJ-BRIT MED J, V323, P42
   Karema C, 2006, T ROY SOC TROP MED H, V100, P1105, DOI 10.1016/j.trstmh.2006.01.001
   Maiga AW, 2012, AM J TROP MED HYG, V87, P23, DOI 10.4269/ajtmh.2012.12-0058
   Martensson A, 2005, CLIN INFECT DIS, V41, P1079, DOI 10.1086/444460
   Ndiaye JL, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-125
   Rwagacondo CE, 2004, TROP MED INT HEALTH, V9, P1091, DOI 10.1111/j.1365-3156.2004.01316.x
   Schramm B, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-250
   Schramm B, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-251
   Sinclair D, 2009, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD007483.PUB2
   Sirima SB, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-48
   Staedke SG, 2004, LANCET, V364, P1950, DOI 10.1016/S0140-6736(04)17478-3
   Stepniewska K, 2010, J INFECT DIS, V201, P570, DOI 10.1086/650301
   Swarthout TD, 2006, TROP MED INT HEALTH, V11, P1503, DOI 10.1111/j.1365-3156.2006.01710.x
   Takala-Harrison S, 2013, P NATL ACAD SCI USA, V110, P240, DOI 10.1073/pnas.1211205110
   van den Broek I, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-14
   van den Broek I, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-113
   White NJ, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-278
   World Health Organization, 2010, GUID TREATM MAL
   WHO African Region, COUNTR ANT DRUG POL
   Witkowski B, 2013, LANCET INFECT DIS, V13, P1043, DOI 10.1016/S1473-3099(13)70252-4
   Witkowski B, 2013, ANTIMICROB AGENTS CH, V57, P914, DOI 10.1128/AAC.01868-12
   Yeka Adoke, 2005, PLoS Med, V2, pe190
   Zwang J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-203
NR 41
TC 11
Z9 11
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAR 25
PY 2014
VL 13
AR 114
DI 10.1186/1475-2875-13-114
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AF6EH
UT WOS:000334806700001
PM 24666562
OA gold
DA 2017-08-15
ER

PT J
AU Almaguer-Mederos, LE
   Abascal, JV
   Cabrera, AR
   Quilez, FG
   Alvarez, PB
   Rosales, FM
   Ramirez, AF
   Khalil, MIA
   Lopez, LD
   Volpini, V
   Nyan, O
AF Almaguer-Mederos, Luis E.
   Abascal, Jorge Vega
   Cabrera, Asmell Ramos
   Quilez, Fatima Garcia
   Alvarez, Pablo Betancourt
   Rosales, Filiberto Miranda
   Ramirez, Ania Ferriol
   Khalil, M. I. A.
   de Jorge Lopez, Laura
   Volpini, Victor
   Nyan, Ousman
TI First case with Huntington's disease in The Gambia
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Letter
ID WEIGHT-LOSS
C1 [Almaguer-Mederos, Luis E.; Abascal, Jorge Vega; Cabrera, Asmell Ramos; Quilez, Fatima Garcia; Alvarez, Pablo Betancourt; Rosales, Filiberto Miranda; Ramirez, Ania Ferriol; Nyan, Ousman] Univ Gambia, Sch Med & Allied Hlth Sci, Sere Kunda, Gambia.
   [Abascal, Jorge Vega; Cabrera, Asmell Ramos; Quilez, Fatima Garcia; Rosales, Filiberto Miranda; Khalil, M. I. A.; Nyan, Ousman] EFSTH, Banjul, Gambia.
   [de Jorge Lopez, Laura; Volpini, Victor] Inst Invest Biomed Bellvitge Idibell Hosp Duran &, Barcelona, Spain.
RP Almaguer-Mederos, LE (reprint author), Univ Gambia, Sch Med & Allied Hlth Sci, Sere Kunda, Gambia.
EM almaguerluis76@yahoo.com
CR Andrich JE, 2009, J NEURAL TRANSM, V116, P1607, DOI 10.1007/s00702-009-0310-1
   Aziz NA, 2008, NEUROLOGY, V71, P1506, DOI 10.1212/01.wnl.0000334276.09729.0e
   Aziz NA, 2010, EUR J NEUROL, V17, P1068, DOI 10.1111/j.1468-1331.2010.02973.x
   Baine FK, 2013, EUR J HUM GENET, V21, P1120, DOI 10.1038/ejhg.2013.2
   Coulibaly T, 2012, MOVEMENT DISORD, V27, pS52
   Kabore J, 2000, REV NEUROL-FRANCE, V156, P1157
   Magazi DS, 2008, SAMJ S AFR MED J, V98, P200
   Ross R. A., 2010, ORPH J RARE DIS, V5, P40
   Silber E, 1998, MOVEMENT DISORD, V13, P726, DOI 10.1002/mds.870130420
   Stephany F, 1984, Dakar Med, V29, P75
   Sturrock A, 2010, J GERIATR PSYCH NEUR, V23, P243, DOI 10.1177/0891988710383573
   van der Burg JMM, 2011, NEUROBIOL DIS, V44, P1, DOI 10.1016/j.nbd.2011.05.006
   WHO Expert Committee, 1995, WHO TECHN REP SER
NR 13
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAR 15
PY 2014
VL 338
IS 1-2
BP 238
EP 240
DI 10.1016/j.jns.2013.12.045
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AE3NO
UT WOS:000333883400048
PM 24439197
OA No
DA 2017-08-15
ER

PT J
AU Nunez-de La Mora, A
   Lawson, DW
   Cooper, G
   Moore, S
   Fulford, T
   Sear, R
AF Nunez-de la Mora, A.
   Lawson, D. W.
   Cooper, G.
   Moore, S.
   Fulford, T.
   Sear, R.
TI The impact of Ramadan fasting on measurements of salivary testosterone
   among Gambian men
SO AMERICAN JOURNAL OF HUMAN BIOLOGY
LA English
DT Meeting Abstract
C1 [Nunez-de la Mora, A.; Cooper, G.] Univ Durham, Dept Anthropol, Durham DH1 3HP, England.
   [Lawson, D. W.] UCL, Dept Anthropol, London WC1E 6BT, England.
   [Moore, S.] MRC Keneba, Banjul, Gambia.
   [Fulford, T.; Sear, R.] London Sch Hyg & Trop Med, Dept Populat Hlth, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1042-0533
EI 1520-6300
J9 AM J HUM BIOL
JI Am. J. Hum. Biol.
PD MAR 4
PY 2014
VL 26
IS 2
BP 275
EP 275
PG 1
WC Anthropology; Biology
SC Anthropology; Life Sciences & Biomedicine - Other Topics
GA AB0DH
UT WOS:000331461500074
OA No
DA 2017-08-15
ER

PT J
AU Reiches, MW
   Moore, SE
   Prentice, AM
   Ellison, PT
AF Reiches, M. W.
   Moore, S. E.
   Prentice, A. M.
   Ellison, P. T.
TI Endocrine responses and behavioral energy sparing mechanisms during
   Ramadan among Gambian adolescent women.
SO AMERICAN JOURNAL OF HUMAN BIOLOGY
LA English
DT Meeting Abstract
C1 [Reiches, M. W.] Univ Massachusetts, Dept Anthropol, Boston, MA 02125 USA.
   [Moore, S. E.; Prentice, A. M.] MRC Keneba, MRC Unit, Banjul, Gambia.
   [Moore, S. E.; Prentice, A. M.] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
   [Ellison, P. T.] Harvard Univ, Dept Human Evolutionary Biol, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1042-0533
EI 1520-6300
J9 AM J HUM BIOL
JI Am. J. Hum. Biol.
PD MAR 4
PY 2014
VL 26
IS 2
BP 279
EP 279
PG 1
WC Anthropology; Biology
SC Anthropology; Life Sciences & Biomedicine - Other Topics
GA AB0DH
UT WOS:000331461500086
OA No
DA 2017-08-15
ER

PT J
AU Lerberg, PM
   Sundby, J
   Jammeh, A
   Fretheim, A
AF Lerberg, Priya Miriam
   Sundby, Johanne
   Jammeh, Abdou
   Fretheim, Atle
TI Barriers to Skilled Birth Attendance: A Survey among Mothers in Rural
   Gambia
SO African Journal of Reproductive Health
LA English
DT Article
DE Childbirth; maternal health services; access; barriers; birth
   preparedness; complication readiness
ID MATERNAL MORTALITY; DISTRICT; HEALTH; WALK
AB The objectives of this cross-sectional survey were to identify the most important barriers for use of skilled attendance during childbirth by women in rural Gambia. We also assessed information received during antenatal care, preparations made prior to childbirth, and experiences and perceptions that may influence the use of skilled birth attendance in rural Gambia. The most frequently stated barriers for giving birth in a health facility were not having enough time to go (75%), and lack of transport (29%). The majority of the women (83%) stated that they preferred having a health worker attending their childbirth. More than seventy percent of the participants gave birth attended by a traditional birth attendant, but only 27% had intended to give birth at home. Sixty-four percent had made advance arrangements for the childbirth. Only 22% were informed about expected time of birth during antenatal care. Our findings suggest that the participants hold the knowledge and motivation that is necessary if practices are to be changed. Interventions aiming at ensuring timely transport of women to health facilities seem key to increased use of skilled birth attendants.
C1 [Lerberg, Priya Miriam; Sundby, Johanne; Jammeh, Abdou; Fretheim, Atle] Univ Oslo, Inst Hlth & Soc, Oslo, Norway.
   [Jammeh, Abdou] Minist Hlth & Social Welf, Banjul, Gambia.
   [Fretheim, Atle] Norwegian Knowledge Ctr Hlth Serv, N-0130 Oslo, Norway.
RP Lerberg, PM (reprint author), Univ Oslo, Inst Hlth & Soc, POB 1130, Oslo, Norway.
EM priler@gmail.com
CR Adegoke AA, 2009, BJOG-INT J OBSTET GY, V116, P33, DOI 10.1111/j.1471-0528.2009.02336.x
   Amooti-Kaguna B, 2000, SOC SCI MED, V50, P203, DOI 10.1016/S0277-9536(99)00275-0
   Anya SE, 2008, BMC PREGNANCY CHILDB, V8
   bij de Vaate Annelies, 2002, Midwifery, V18, P3
   Bazzano AN, 2008, INT J GYNECOL OBSTET, V102, P91
   Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1
   Cham M, 2005, REPROD HLTH, V2, P3, DOI DOI 10.1186/1742-4755-2-3
   Department of State for Health, 2006, HLTH IS WEALTH
   Filippi V, 2009, BEST PRACT RES CL OB, V23, P389, DOI 10.1016/j.bpobgyn.2008.12.006
   Gabrysch S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-34
   Jammeh A, 2011, ISRN OBSTET GYNECOL
   JHPIEGO, 2004, MON BIRTH PREP COMPL
   Kunst AE, 2001, SAFE MOTHERHOOD STRA, P297
   Matsuoka S, 2010, HEALTH POLICY, V95, P255, DOI 10.1016/j.healthpol.2009.12.011
   Mills S, 2005, STUD FAMILY PLANN, V36, P45, DOI 10.1111/j.1728-4465.2005.00040.x
   Moran AC, 2006, J HEALTH POPUL NUTR, V24, P489
   Nyanzi S., 2008, GOVERNING HLTH SYSTE, P225
   Otis KE, 2008, REV PANAM SALUD PUBL, V24, P46, DOI 10.1590/S1020-49892008000700006
   Seljeskog Line, 2006, Afr J Reprod Health, V10, P66
   Telfer Michelle L, 2002, Afr J Reprod Health, V6, P74, DOI 10.2307/3583148
   THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7
   United Nations, 2008, OFF UN SIT MILL DEV
   United Nations Development Programme, 2010, HUM DEV REP 2010 20
   WHO, 1999, RED MAT MORT JOINT W
   The World Health Organization, 2009, WHO COUNTR COOP STRA
   World Health Organization, 2010, TRENDS MAT MORT 1990
   The World Bank, 2005, HLTH POV GAMB
NR 27
TC 4
Z9 4
U1 1
U2 5
PU WOMENS HEALTH & ACTION RESEARCH CENTRE
PI BENIN CITY
PA IGUE-IHEYA VILLAGE, BENIN-LAGOS EXPRESS RD, PO BOX 10231, UGBOWO, BENIN
   CITY, EDO STATE 00000, NIGERIA
SN 1118-4841
EI 2141-3606
J9 AFR J REPROD HEALTH
JI Afr. J. Reprod. Health
PD MAR
PY 2014
VL 18
IS 1
BP 35
EP 43
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CA5KN
UT WOS:000348947400004
PM 24796167
OA No
DA 2017-08-15
ER

PT J
AU Roberts, CH
   Molina, S
   Makalo, P
   Joof, H
   Harding-Esch, EM
   Burr, SE
   Mabey, DCW
   Bailey, RL
   Burton, MJ
   Holland, MJ
AF Roberts, Chrissy H.
   Molina, Sandra
   Makalo, Pateh
   Joof, Hassan
   Harding-Esch, Emma M.
   Burr, Sarah E.
   Mabey, David C. W.
   Bailey, Robin L.
   Burton, Matthew J.
   Holland, Martin J.
TI Conjunctival Scarring in Trachoma Is Associated with the HLA-C Ligand of
   KIR and Is Exacerbated by Heterozygosity at KIR2DL2/KIR2DL3
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID NATURAL-KILLER-CELLS; CLASS-I MOLECULES; IMMUNOGLOBULIN-LIKE RECEPTORS;
   CHLAMYDIA-TRACHOMATIS; NK CELLS; IMMUNE-RESPONSES; INHIBITORY RECEPTORS;
   INTERFERON-GAMMA; GENE-CONTENT; PERIPHERAL-BLOOD
AB Background: Chlamydia trachomatis is globally the predominant infectious cause of blindness and one of the most common bacterial causes of sexually transmitted infection. Infections of the conjunctiva cause the blinding disease trachoma, an immuno-pathological disease that is characterised by chronic conjunctival inflammation and fibrosis. The polymorphic Killer-cell Immunoglobulin-like Receptors (KIR) are found on Natural Killer cells and have co-evolved with the Human Leucocyte Antigen (HLA) class I system. Certain genetic constellations of KIR and HLA class I polymorphisms are associated with a number of diseases in which modulation of the innate responses to viral and intracellular bacterial pathogens is central.
   Methodology: A sample of 134 Gambian pedigrees selected to contain at least one individual with conjunctival scarring in the F-1 generation was used. Individuals (n = 830) were genotyped for HLA class I and KIR gene families. Family Based Association Tests and Case Pseudo-control tests were used to extend tests for transmission disequilibrium to take full advantage of the family design, genetic model and phenotype.
   Principle findings: We found that the odds of trachomatous scarring increased with the number of genome copies of HLA-C2 (C1/C2 OR = 2.29 P-BH-value = 0.006; C2/C2 OR = 3.97 P-BH-value = 0.0004) and further increased when both KIR2DL2 and KIR2DL3 (C2/C2 OR = 5.95 P-BH-value = 0.006) were present.
   Conclusions: To explain the observations in the context of chlamydial infection and trachoma we propose a two-stage model of response and disease that balances the cytolytic response of KIR expressing NK cells with the ability to secrete interferon gamma, a combination that may cause pathology. The data presented indicate that HLA-C genotypes are important determinants of conjunctival scarring in trachoma and that KIR2DL2/KIR2DL3 heterozygosity further increases risk of conjunctival scarring in individuals carrying HLA-C2.
C1 [Roberts, Chrissy H.; Molina, Sandra; Harding-Esch, Emma M.; Burr, Sarah E.; Mabey, David C. W.; Bailey, Robin L.; Holland, Martin J.] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England.
   [Makalo, Pateh; Joof, Hassan; Burr, Sarah E.; Holland, Martin J.] MRC Unit, Fajara, Gambia.
   [Burton, Matthew J.] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1, England.
RP Roberts, CH (reprint author), London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England.
EM chrissy.roberts@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169;
   Roberts, Chrissy h./0000-0003-1064-5980
FU Wellcome Trust [079246/Z/06/Z, GR079246MA]
FX This study was funded by grants from the Wellcome Trust (079246/Z/06/Z
   and GR079246MA). The funders had no part in the study design; in the
   collection, analysis, and interpretation of data; in the writing of the
   report; and in the decision to submit the paper for publication.
CR AbdelRahman YM, 2005, FEMS MICROBIOL REV, V29, P949, DOI 10.1016/j.femsre.2005.03.002
   Ahlenstiel G, 2008, J CLIN INVEST, V118, P1017, DOI 10.1172/JCI32400
   Bari R, 2009, BLOOD, V114, P5182, DOI 10.1182/blood-2009-07-231977
   Besson C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000406
   Cano P, 2007, HUM IMMUNOL, V68, P392, DOI 10.1016/j.humimm.2007.01.014
   CATES W, 1985, LANCET, V2, P596
   Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537
   Chen AL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002842
   CICCONE E, 1994, EUR J IMMUNOL, V24, P1003, DOI 10.1002/eji.1830240434
   COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543
   COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000
   COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555
   Cordell HJ, 2004, GENET EPIDEMIOL, V26, P167, DOI 10.1002/gepi.10307
   Derrick T, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002117
   Dohring C, 1996, EUR J IMMUNOL, V26, P365, DOI 10.1002/eji.1830260215
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198
   Gall A, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00010
   Gendzekhadze K, 2006, IMMUNOGENETICS, V58, P474, DOI 10.1007/s00251-006-0108-3
   Gendzekhadze K, 2009, P NATL ACAD SCI USA, V106, P18692, DOI 10.1073/pnas.0906051106
   GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133
   GURUJEYALAKSHMI G, 1995, EXP LUNG RES, V21, P791, DOI 10.3109/01902149509050842
   Hall LJ, 2010, J IMMUNOL, V184, P4327, DOI 10.4049/jimmunol.0903357
   Harding-Esch EM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000861
   Hirayasu K, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002565
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   Hollenbach JA, 2012, IMMUNOGENETICS, V64, P719, DOI 10.1007/s00251-012-0629-x
   Hollenbach JA, 2009, IMMUNOGENETICS, V61, P663, DOI 10.1007/s00251-009-0396-5
   HOROWITZ A, 2013, SCI TRANSL MED, V5, DOI DOI 10.1126/SCITRANSLMED.3006702
   Horowitz A, 2012, J IMMUNOL, V188, P5054, DOI 10.4049/jimmunol.1102710
   Horowitz A, 2010, J IMMUNOL, V185, P2808, DOI 10.4049/jimmunol.1000844
   Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625
   Hsu KC, 2002, IMMUNOL REV, V190, P40, DOI 10.1034/j.1600-065X.2002.19004.x
   Hu VH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002020
   Hu VH, 2012, INFECT IMMUN, V80, P121, DOI 10.1128/IAI.05965-11
   Ibana JA, 2011, INFECT DIS OBSTET GY, V2011, DOI [10.1155/2011/420905, DOI 10.1155/2011, DOI 10.1155/2011/420905]
   Ibana JA, 2012, FEMS IMMUNOL MED MIC, V65, P32, DOI 10.1111/j.1574-695X.2012.00930.x
   Kagebein D, 2014, INFECT IMMUN, V82, P993, DOI 10.1128/IAI.01473-13
   Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670
   Korbel DS, 2009, J IMMUNOL, V182, P6426, DOI 10.4049/jimmunol.0804224
   Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.0.CO;2-M
   Leavy O, 2013, NAT REV IMMUNOL, V13, DOI 10.1038/nri3566
   Lu C, 2012, GENET MOL RES, V11, P1370, DOI 10.4238/2012.May.15.7
   Lu ZM, 2008, CELL MOL IMMUNOL, V5, P457, DOI 10.1038/cmi.2008.57
   Mahfouz R, 2011, INT J TUBERC LUNG D, V15, P1688, DOI 10.5588/ijtld.11.0138
   Maiers M, 2007, HUM IMMUNOL, V68, P779, DOI 10.1016/j.humimm.2007.04.005
   Malik S, 2005, P NATL ACAD SCI USA, V102, P12183, DOI 10.1073/pnas.0503368102
   Martin MP, 2008, IMMUNOGENETICS, V60, P767, DOI 10.1007/s00251-008-0334-y
   Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035
   Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934
   Mendez A, 2006, TISSUE ANTIGENS, V68, P386, DOI 10.1111/j.1399-0039.2006.00685.x
   Middleton D, 2007, IMMUNOGENETICS, V59, P145, DOI 10.1007/s00251-006-0181-7
   Moesta AK, 2008, J IMMUNOL, V180, P3969
   MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597
   MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875
   Nagarajan UM, 2011, INFECT IMMUN, V79, P486, DOI 10.1128/IAI.00843-10
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   Natividad A, 2008, HUM MOL GENET, V17, P323, DOI 10.1093/hmg/ddm310
   Natividad A, 2010, INFECT IMMUN, V78, P4895, DOI 10.1128/IAI.00844-10
   Norman PJ, 2007, NAT GENET, V39, P1092, DOI 10.1038/ng2111
   Norman PJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003938
   Norman PJ, 2002, GENES IMMUN, V3, P86, DOI 10.1038/sj/gene/6363836
   Parham P, 2013, NAT REV IMMUNOL, V13, P133, DOI 10.1038/nri3370
   Parham P, 2012, PHILOS T R SOC B, V367, P800, DOI 10.1098/rstb.2011.0266
   Pende D, 1996, J EXP MED, V184, P505, DOI 10.1084/jem.184.2.505
   Pydi SS, 2013, HUM IMMUNOL, V74, P85, DOI 10.1016/j.humimm.2012.10.006
   Qutob N, 2012, IMMUNOGENETICS, V64, P165, DOI 10.1007/s00251-011-0576-y
   Resnikoff S, 2004, POLICY PRACTICE GLOB
   Rolle A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003548
   Rowley J, 2008, GLOBAL INCIDENCE PRE
   Saftlas AF, 2004, AM J EPIDEMIOL, V160, P77, DOI 10.1093/aje/kwh171
   Sanchez-Mazas A, 2000, TISSUE ANTIGENS, V56, P303, DOI 10.1034/j.1399-0039.2000.560402.x
   SCHAPIRO JM, 1990, J MED VIROL, V30, P196, DOI 10.1002/jmv.1890300310
   Single RM, 2007, NAT GENET, V39, P1114, DOI 10.1038/ng2077
   Stare D, 2011, OPHTHAL EPIDEMIOL, V18, P20, DOI 10.3109/09286586.2010.545500
   Stewart CA, 2005, P NATL ACAD SCI USA, V102, P13224, DOI 10.1073/pnas.0503594102
   Tseng CTK, 1998, INFECT IMMUN, V66, P5867
   Uhrberg M, 2002, IMMUNOGENETICS, V54, P221, DOI 10.1007/s00251-002-0463-7
   Uhrberg M, 1997, IMMUNITY, V7, P753, DOI 10.1016/S1074-7613(00)80394-5
   Valiante NM, 1997, IMMUNITY, V7, P739, DOI 10.1016/S1074-7613(00)80393-3
   Van Steen Kristel, 2005, Hum Genomics, V2, P67
   Vilches C, 2007, TISSUE ANTIGENS, V70, P415, DOI 10.1111/j.1399-0039.2007.00923.x
   Wilson MJ, 2000, P NATL ACAD SCI USA, V97, P4778, DOI 10.1073/pnas.080588597
   Winter CC, 1998, J IMMUNOL, V161, P571
   Woo CY, 2006, EXPERT REV VACCINES, V5, P55, DOI 10.1586/14760584.5.1.55
   Yindom LM, 2012, TISSUE ANTIGENS, V79, P104, DOI 10.1111/j.1399-0039.2011.01818.x
   Zhong GM, 2001, J EXP MED, V193, P935, DOI 10.1084/jem.193.8.935
   Zhong GM, 2000, J EXP MED, V191, P1525, DOI 10.1084/jem.191.9.1525
NR 89
TC 8
Z9 8
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAR
PY 2014
VL 8
IS 3
AR e2744
DI 10.1371/journal.pntd.0002744
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AJ0MU
UT WOS:000337348800028
PM 24651768
OA gold
DA 2017-08-15
ER

PT J
AU Peitzmeier, S
   Mason, K
   Ceesay, N
   Diouf, D
   Drame, F
   Loum, J
   Baral, S
AF Peitzmeier, Sarah
   Mason, Krystal
   Ceesay, Nuha
   Diouf, Daouda
   Drame, Fatou
   Loum, Jaegan
   Baral, Stefan
TI A cross-sectional evaluation of the prevalence and associations of HIV
   among female sex workers in the Gambia
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE epidemiology; Treponema pallidum; sexually transmitted infections; HIV;
   sexual risk behaviour; syphilis; Gambia; HIV risk; female sex worker;
   HIV prevalence; condom use; AIDS
ID POLYMERASE-CHAIN-REACTION; CONDOM USE; PREEXPOSURE PROPHYLAXIS; REGULAR
   PARTNERS; HIGH-RISK; INFECTION; PREVENTION; CLIENTS; PROSTITUTES; INDIA
AB To determine HIV prevalence among female sex workers in the Gambia and HIV risk factors, we accrued participants (n = 251) through peer-referral and venue-based recruitment. Blood samples were screened for HIV and participants were administered a questionnaire. Bivariate and multivariate logistic regression identified factors associated with HIV status. Forty respondents (15.9%) were HIV-positive: 20 (8.0%) were infected with HIV-1 only, 10 (4.0%) with HIV-2 only, and 10 (4.0%) with both HIV-1 and HIV-2; 12.5% (n = 5/40) knew their status. Condom usage at last sex was 97.1% (n = 170/175) with new clients and 44.2% (n = 53/120) with non-paying partners. Having a non-paying partner, living with relatives or friends, having felt scared to walk in public, selling sex in multiple locations, and recent depressive symptoms were positively associated with HIV under multivariate regression. Female sex workers have a higher prevalence of HIV compared to the general Gambian population. Interventions should be rights-based, promote safer sex practices and regular testing for female sex workers and linkage to HIV treatment and care with adherence support for those living with HIV. In addition, service providers should consider non-paying partners of female sex workers, improve knowledge and availability of condoms and lubricant, and address safety and mental health needs.
C1 [Peitzmeier, Sarah; Mason, Krystal; Baral, Stefan] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Baltimore, MD 21205 USA.
   [Ceesay, Nuha] UNAIDS, Cape Point, Gambia.
   [Diouf, Daouda; Drame, Fatou] Enda Sante, Dakar, Senegal.
   [Loum, Jaegan] Network AIDS Serv Org, Banjul, Gambia.
RP Baral, S (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, 615 N Wolfe St,Suite E7146, Baltimore, MD 21205 USA.
EM sbaral@jhsph.edu
FU National AIDS Secretariat and Action Aid - The Gambia; UNAIDS; Enda
   Sante of Senegal; Johns Hopkins Bloomberg School of Public Health
FX This research was funded by the National AIDS Secretariat and Action Aid
   - The Gambia, UNAIDS, Enda Sante of Senegal and the Johns Hopkins
   Bloomberg School of Public Health.
CR Arnott J, 2009, RIGHTS NOT RESCUE RE
   Baral S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-482
   Baral S, 2012, LANCET INFECT DIS, V12, P538, DOI 10.1016/S1473-3099(12)70066-X
   Campbell-Yesufu OT, 2011, CLIN INFECT DIS, V52, P780, DOI 10.1093/cid/ciq248
   Central Intelligence Agency, 2013, WORLD FACTB GAMB
   Cockram A, 1999, AUST NZ J PSYCHIAT, V33, P344, DOI 10.1046/j.1440-1614.1999.00579.x
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cote AM, 2004, AIDS, V18, P917, DOI 10.1097/01.aids.0000111475.61782.98
   Dandona L, 2011, BMC PUBLIC HLTH S6, V11, pI1
   Dandona R, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-87
   Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068
   Deering KN, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S6-S11
   Diallo BL, 2010, REV EPIDEMIOL SANTE, V58, P245, DOI 10.1016/j.respe.2010.03.003
   Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243
   Gupta R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014252
   HAWKES S, 1995, GENITOURIN MED, V71, P224
   Jallow C., 2011, GAMBIA 2010 BEHAV SU
   Kane CT, 2009, INT J STD AIDS, V20, P793, DOI 10.1258/ijsa.2008.008414
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kerrigan D, 2006, AM J PUBLIC HEALTH, V96, P120, DOI 10.2105/AJPH.2004.042200
   Lowndes CM, 2000, AIDS, V14, P2523, DOI 10.1097/00002030-200011100-00015
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   Mosoko JJ, 2009, AIDS BEHAV, V13, P277, DOI 10.1007/s10461-007-9294-8
   Murray L, 2007, AIDS BEHAV, V11, P463, DOI 10.1007/s10461-006-9184-5
   National AIDS Secretariat, 2012, COUNTR PROGR REP GAM
   Nhurod P, 2010, SE ASIAN J TROP MED, V41, P153
   Panchanadeswaran S, 2008, INT J DRUG POLICY, V19, P106, DOI 10.1016/j.drugpo.2007.11.013
   Pardasani MP, 2005, INT J SOC WELF, V14, P116, DOI 10.1111/j.1369-6866.2005.00348.x
   PEPIN J, 1991, AIDS, V5, P69
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   PICKERING H, 1993, AIDS, V7, P1093, DOI 10.1097/00002030-199308000-00011
   PICKERING H, 1992, SOC SCI MED, V34, P75, DOI 10.1016/0277-9536(92)90069-3
   Rekart ML, 2005, LANCET, V366, P2123, DOI 10.1016/S0140-6736(05)67732-X
   Sobela F, 2009, JAIDS-J ACQ IMM DEF, V51, P216, DOI 10.1097/QAI.0b013e31819c170f
   Sule WF, 2010, AFR J BIOTECHNOL, V8, P941
   UNAIDS, 2009, UNAIDS GUID NOT HIV
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   van der Straten A, 2012, AIDS, V26, pF13, DOI 10.1097/QAD.0b013e3283522272
   Van Blerk DL, 2007, AIDS CARE, V19, P79
   Voeten HACM, 2007, TROP MED INT HEALTH, V12, P174, DOI 10.1111/j.1365-3156.2006.01776.x
   Walther-Jallow L, 1999, AIDS RES HUM RETROV, V15, P957, DOI 10.1089/088922299310467
   Wang C, 2007, SEX TRANSM INFECT, V83, P534, DOI 10.1136/sti.2007.027151
   World Health Organization, 2005, INF B SER, V3, P1
   Wolitski Richard J, 2007, AIDS Behav, V11, P167, DOI 10.1007/s10461-007-9277-9
   Yam EA, 2013, SEX TRANSM DIS, V40, P406, DOI 10.1097/OLQ.0b013e318283c16d
NR 46
TC 6
Z9 6
U1 2
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD MAR
PY 2014
VL 25
IS 4
BP 244
EP 252
DI 10.1177/0956462413498858
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AC0WB
UT WOS:000332215100002
PM 23970652
OA No
DA 2017-08-15
ER

PT J
AU Sanneh, ES
   Hu, AH
   Njai, M
   Ceesay, OM
   Manjang, B
AF Sanneh, Edward Saja
   Hu, Allen H.
   Njai, Modou
   Ceesay, Omar Malleh
   Manjang, Buba
TI Making Basic Health Care Accessible to Rural Communities: A Case Study
   of Kiang West District in Rural Gambia
SO PUBLIC HEALTH NURSING
LA English
DT Article
DE bottom of the pyramid; partnership; poverty penalty; multi-stakeholder;
   access
ID MORTALITY; CHILDREN; TRENDS
AB This study focuses on lack of access to basic health care, which is one of the hindrances to the development of the poor, and subjects them to the poverty penalty. It also focuses on contributing to the Bottom of the Pyramid in a general sense, in addition to meeting the health needs of communities where people live on less than $1 a day. Strengthened multistakeholder responses and better-targeted, low-cost prevention, and care strategies within health systems are suggested to address the health burdens of poverty-stricken communities. In this study, a multistakeholder model which includes the government, World Health Organization, United Nations Children Emergency Fund, and the Medical Research Council was created to highlight the collaborative approach in rural Gambia. The result shows infant immunization and antenatal care coverage were greatly improved which contributes to the reduction in mortality. This case study also finds that strategies addressing health problems in rural communities are required to achieve 'Millennium Development Goals'. In particular, actual community visits to satellite villages within a district (area of study) are extremely vital to making health care accessible.
C1 [Sanneh, Edward Saja; Hu, Allen H.] Natl Taipei Univ Technol, Inst Environm Engn Technol, Taipei 10643, Taiwan.
   [Njai, Modou] Minist Hlth & Social Welf, Integrated Management Childhood Illness, Banjul, Gambia.
   [Ceesay, Omar Malleh] Kanifing Municipal Council, Hlth Promot & Dev Org HePDO, Serekunda, Gambia.
   [Manjang, Buba] Reg Hlth Management Team, Farafenni, Gambia.
RP Hu, AH (reprint author), Natl Taipei Univ Technol, Inst Environm Engn Technol, 1,Sec 3,Chung Hsiao East Rd, Taipei 10643, Taiwan.
EM allenhu@ntut.edu.com
CR Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8
   Chan M, 2008, LANCET, V372, P865, DOI 10.1016/S0140-6736(08)61372-0
   Cole-Ceesay R, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-21
   Reproductive and Child Health Department of State for health (DoSH) The Gambia & Center for Innovation Against Malaria, 2007, ANN REP STUD COND CI
   The Gambia Bureau of Statistics (GBOS), 2011, GAMB MULT IND CLUST
   Guindo G, 2004, HEALTH POLICY PLANN, V19, pI87, DOI 10.1093/heapol/czh049
   Haines A, 2007, LANCET, V369, P2121, DOI 10.1016/S0140-6736(07)60325-0
   Hammond A.L., 2007, INNOVATIONS, V2, P147, DOI DOI 10.1162/ITGG.2007.2.1-2.147
   Joseph AE, 2002, SOC SCI MED, V55, P2193, DOI 10.1016/S0277-9536(01)00364-1
   Marter-Kenyon J., 2005, GREENER MANAGEMENT I, V51, P53
   Ministry of Health (MOH), 1998, DEP STAT HLTH SOC WE
   Murray CJL, 2007, LANCET, V370, P1040, DOI 10.1016/S0140-6736(07)61478-0
   The Gambia National Nutrition Agency (NaNA), 2009, NANA WORK COMM BETT
   Narayan Deepa, 2000, VOICES POOR CAN ANYO
   Navaneetham K, 2002, SOC SCI MED, V55, P1849, DOI 10.1016/S0277-9536(01)00313-6
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   Rutherford ME, 2009, B WORLD HEALTH ORGAN, V87, P216, DOI 10.2471/BLT.08.052175
   Van den Waeyenberg S., 2006, WHICH BUSINESS STRAT
   WHO: World Health Organization United Nations Children's Fund United Nations Population Fund and The World Bank, 2011, TRENDS MAT MORT 1990
   World Health Organization, 2011, P WORLD C SOC DET HL
   World Bank, 2005, AFR REG HUM DEV WORK
   Zere E, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-252
NR 22
TC 0
Z9 0
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0737-1209
EI 1525-1446
J9 PUBLIC HEALTH NURS
JI Public Health Nurs.
PD MAR
PY 2014
VL 31
IS 2
BP 126
EP 133
DI 10.1111/phn.12057
PG 8
WC Public, Environmental & Occupational Health; Nursing
SC Public, Environmental & Occupational Health; Nursing
GA AB8YR
UT WOS:000332076600005
PM 24588131
OA No
DA 2017-08-15
ER

PT J
AU Payne, S
   Townend, J
   Jasseh, M
   Jallow, YL
   Kampmann, B
AF Payne, Sarah
   Townend, John
   Jasseh, Momodou
   Jallow, Yamundow Lowe
   Kampmann, Beate
TI Achieving comprehensive childhood immunization: an analysis of obstacles
   and opportunities in The Gambia
SO HEALTH POLICY AND PLANNING
LA English
DT Article
DE The Gambia; immunization; socio-demographic; determinants; child
ID COVERAGE; VACCINATION; CHILDREN; BANGLADESH; MORTALITY
AB Introduction Immunization is a vital component in the drive to decrease global childhood mortality, yet challenges remain in ensuring wide coverage of immunization and full immunization, particularly in low- and middle-income countries. This study assessed immunization coverage and the determinants of immunization in a semi-rural area in The Gambia.
   Methods Data were drawn from the Farafenni Health and Demographic Surveillance System. Children born within the surveillance area between January 2000 and December 2010 were included. Main outcomes assessed included measles, BCG and DTP vaccination status and full immunization by 12 months of age as reported on child healthcards. Predictor variables were evaluated based on a literature review and included gender, ethnicity, area of residence, household wealth and mother's age.
   Results Of the 7363 children included in the study, immunization coverage was 73% (CI 72-74) for measles, 86% (CI 86-87) for BCG, 79% (CI 78-80) for three doses of DTP and 52% (CI 51-53) for full immunization. Coverage was significantly associated with area of residence and ethnicity, with children in urban areas and of Mandinka ethnicity being least likely to be fully immunized.
   Conclusions Despite high levels of coverage of many individual vaccines, delivery of vaccinations later in the schedule and achieving high coverage of full immunization remain challenges, even in a country with a committed childhood immunization programme, such as The Gambia. Our data indicate areas for targeted interventions by the national Expanded Programme of Immunization.
C1 [Payne, Sarah] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London W2 1PG, England.
   [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London W2 1PG, England.
   [Townend, John; Jasseh, Momodou; Kampmann, Beate] MRC Unit, Fajara, Gambia.
   [Jallow, Yamundow Lowe] Minist Hlth & Social Welf Govt Gambia, The Quadrangle Banjul, Gambia.
RP Payne, S (reprint author), Univ Oxford, Dept Publ Hlth, Room 106,Rosemary Rue Bldg,Old Rd Campus, Oxford OX3 7LG, England.
EM sarah.payne@oxsph.org
FU UK Medical Research Council (MRC); Imperial College London
FX This work was supported by the UK Medical Research Council (MRC) (B.K.,
   J.T. and M.J.) and Imperial College London (travel grant to S.P.). We
   acknowledge the assistance provided by the FHDSS Data and Field Teams
   led by Pierre Gomez in enabling access to data and the INDEPTH Network.
   We also acknowledge the assistance of The Government of The Gambia EPI
   Team. We extend our thanks to the current and former residents of the
   Farafenni Demographic Surveillance Area for participating in the DSS
   activities.
CR BHUIYA A, 1995, HEALTH POLICY PLANN, V10, P304, DOI 10.1093/heapol/10.3.304
   Bosu WK, 2003, J INFECT DIS, V187, pS44, DOI 10.1086/368056
   Burton A, 2009, B WORLD HEALTH ORGAN, V87, P535, DOI 10.2471/BLT.08.053819
   Canavati S, 2011, B WORLD HEALTH ORGAN, V89, P528, DOI 10.2471/BLT.10.084244
   Cassell JA, 2006, HEALTH POLICY PLANN, V21, P373, DOI 10.1093/heapol/czl020
   Cutts FT, 1993, IMMUNOLOGICAL BASIS
   Durrheim DN, 2010, CLIN THER, V32, P1496, DOI 10.1016/j.clinthera.2010.04.019
   Government of The Gambia UNICEF, 2002, GAMB MULT IND CLUST
   Government of The Gambia, 2007, GAMB MULT IND CLUST
   Gwatkin D, 2000, SOCIOECONOMIC DIFFER
   HANLON P, 1988, J TROP MED HYG, V91, P29
   Hilber AM, 2010, GENDER IMMUNISATION
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   Hosmer D. W., 2000, APPL LOGISTIC REGRES
   Jamil K, 1999, HEALTH POLICY PLANN, V14, P49, DOI 10.1093/heapol/14.1.49
   Jasseh M, 2011, TROP MED INT HEALTH, V16, P1314, DOI 10.1111/j.1365-3156.2011.02809.x
   Jones CE, 2011, JAMA-J AM MED ASSOC, V305, P576, DOI 10.1001/jama.2011.100
   Medical Research Council, 2004, PROF FAR DSS GAMB
   Mutua MK, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-6
   Odusanya OO, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-381
   Oyo-Ita A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub2
   Pande RP, 2003, SOC SCI MED, V57, P2075, DOI 10.1016/S0277-9536(03)00085-6
   PATH, 2002, ATT IMM CAMB QUAL ST
   Rutherford ME, 2009, TROP MED INT HEALTH, V14, P149, DOI 10.1111/j.1365-3156.2008.02204.x
   StataCorp, 2007, STAT STAT SOFTW REL
   Sullivan MC, 2010, J COMMUN HEALTH, V35, P53, DOI 10.1007/s10900-009-9192-2
   Szilagyi P, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003941
   Tadesse H, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-150
   Uddin MJ, 2010, VACCINE, V28, P1221, DOI 10.1016/j.vaccine.2009.11.028
   Waters HR, 2004, B WORLD HEALTH ORGAN, V82, P668
   WHO, 2011, GAMB HLTH PROF
   World Health Organization, 2010, WORLD HLTH STAT 2010
   [United Nations Childrens Fund (UNICEF) India WHO], 2011, WHO UNICEF EST IMM C
   World Health Organization, 2009, STAT WORLDS VACC IMM
   WHO, 2010, WHO VACC PREV DIS 2
   World Health Organization & United Nations Children's Fund, 2005, GIVS GLOB IMM VIS ST
   World Bank, 1994, BETT HLTH AFR EXP LE
   World Bank, 1993, WORLD DEV REP 1993 I
NR 38
TC 9
Z9 9
U1 1
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1080
EI 1460-2237
J9 HEALTH POLICY PLANN
JI Health Policy Plan.
PD MAR
PY 2014
VL 29
IS 2
BP 193
EP 203
DI 10.1093/heapol/czt004
PG 11
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AC7WJ
UT WOS:000332743400005
PM 23426974
OA No
DA 2017-08-15
ER

PT J
AU Jasinska, AJ
   Schmitt, CA
   Ma, DZ
   Huang, Y
   Svardal, H
   Wassercheid, J
   Grobler, P
   Jorensen, M
   Muller-Trutwin, M
   Antonio, M
   Dewar, K
   Warren, W
   Weinstock, G
   Pandrea, I
   Apetrei, C
   Nordborg, M
   Woods, R
   Jentsch, D
   Turner, T
   Freimer, N
AF Jasinska, Anna J.
   Schmitt, Christopher A.
   Ma, Dongzhu
   Huang, Yu
   Svardal, Hannes
   Wassercheid, Jessica
   Grobler, Paul
   Jorensen, Mathew
   Muller-Trutwin, Michaela
   Antonio, Martin
   Dewar, Ken
   Warren, Wesley
   Weinstock, George
   Pandrea, Ivona
   Apetrei, Cristian
   Nordborg, Magnus
   Woods, Roger
   Jentsch, David
   Turner, Trudy
   Freimer, Nelson
TI Biological resources for genomic investigation in vervet monkey
   (Chlorocebus)
SO AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY
LA English
DT Meeting Abstract
CT 83rd Annual Meeting of the
   American-Association-of-Physical-Anthropologists
CY APR 08-12, 2014
CL Calgary, CANADA
SP Amer Assoc Phys Anthropologists
C1 [Jasinska, Anna J.; Schmitt, Christopher A.; Huang, Yu; Freimer, Nelson] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
   [Ma, Dongzhu; Pandrea, Ivona; Apetrei, Cristian] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Svardal, Hannes; Nordborg, Magnus] Austrian Acad Sci, Gregor Mendel Inst, A-1010 Vienna, Austria.
   [Wassercheid, Jessica; Dewar, Ken] McGill Univ, Montreal, PQ, Canada.
   [Wassercheid, Jessica; Dewar, Ken] Genome Quebec Innovat Ctr, Montreal, PQ, Canada.
   [Grobler, Paul; Turner, Trudy] Univ Orange Free State, Dept Genet, Bloemfontein, South Africa.
   [Jorensen, Mathew] Wake Forest Sch Med, Comparat Med Sect, Dept Pathol, Winston Salem, NC USA.
   [Muller-Trutwin, Michaela] Inst Pasteur, Virol Dept, Paris, France.
   [Antonio, Martin] MRC, Fajara, Gambia.
   [Warren, Wesley; Weinstock, George] St Louis Univ, Genome Inst Washington, St Louis, MO 63103 USA.
   [Woods, Roger] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
   [Jentsch, David] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
   [Turner, Trudy] Univ Wisconsin, Dept Anthropol, Milwaukee, WI 53201 USA.
RI Schmitt, Christopher/F-7251-2013
OI Schmitt, Christopher/0000-0003-2143-9226
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-9483
EI 1096-8644
J9 AM J PHYS ANTHROPOL
JI Am. J. Phys. Anthropol.
PD MAR
PY 2014
VL 153
SU 58
SI SI
BP 151
EP 152
PG 2
WC Anthropology; Evolutionary Biology
SC Anthropology; Evolutionary Biology
GA AA6RH
UT WOS:000331225100391
OA No
DA 2017-08-15
ER

PT J
AU Svardal, H
   Huang, YS
   Schmitt, CA
   Jasinska, AJ
   Jung, Y
   Wasserscheid, J
   Jureticx, N
   Muller-Trutwin, M
   Jacquelin, B
   Antonio, M
   Dione, M
   Grobler, P
   Wilson, RK
   Dewar, K
   Warren, W
   Weinstock, G
   Turner, T
   Nordborg, M
   Freimer, NB
AF Svardal, Hannes
   Huang, Yu S.
   Schmitt, Christopher A.
   Jasinska, Anna J.
   Jung, Yoon
   Wasserscheid, Jessica
   Jureticx, Nikoleta
   Muller-Trutwin, Michaela
   Jacquelin, Beatrice
   Antonio, Martin
   Dione, Michel
   Grobler, Paul
   Wilson, Richard K.
   Dewar, Ken
   Warren, Wesley
   Weinstock, George
   Turner, Trudy
   Nordborg, Magnus
   Freimer, Nelson B.
TI The evolutionary history of the genus Chlorocebus inferred from whole
   genome sequencing
SO AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY
LA English
DT Meeting Abstract
CT 83rd Annual Meeting of the
   American-Association-of-Physical-Anthropologists
CY APR 08-12, 2014
CL Calgary, CANADA
SP Amer Assoc Phys Anthropologists
C1 [Svardal, Hannes; Nordborg, Magnus] Austrian Acad Sci, Gregor Mendel Inst, A-1010 Vienna, Austria.
   [Huang, Yu S.; Schmitt, Christopher A.; Jasinska, Anna J.; Jung, Yoon; Freimer, Nelson B.] Univ Calif Los Angeles, Ctr Neurobehav Genet, Los Angeles, CA 90024 USA.
   [Wasserscheid, Jessica; Jureticx, Nikoleta; Dewar, Ken] McGill Univ, Montreal, PQ H3A 2T5, Canada.
   [Wasserscheid, Jessica; Jureticx, Nikoleta; Dewar, Ken] Genome Quebec Innovat Ctr, Quebec City, PQ, Canada.
   [Muller-Trutwin, Michaela; Jacquelin, Beatrice] Inst Pasteur, Virol Dept, Paris, France.
   [Antonio, Martin; Dione, Michel] MRC, Serrekunda, Gambia.
   [Grobler, Paul; Turner, Trudy] Univ Free State, Dept Genet, Bloemfontein, South Africa.
   [Wilson, Richard K.; Warren, Wesley; Weinstock, George] Washington Univ, Genome Inst, St Louis, MO 63130 USA.
   [Turner, Trudy] Univ Wisconsin Milwaukee, Dept Anthropol, Milwaukee, WI USA.
RI Schmitt, Christopher/F-7251-2013
OI Schmitt, Christopher/0000-0003-2143-9226
NR 0
TC 1
Z9 1
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-9483
EI 1096-8644
J9 AM J PHYS ANTHROPOL
JI Am. J. Phys. Anthropol.
PD MAR
PY 2014
VL 153
SU 58
SI SI
BP 250
EP 250
PG 1
WC Anthropology; Evolutionary Biology
SC Anthropology; Evolutionary Biology
GA AA6RH
UT WOS:000331225100826
OA No
DA 2017-08-15
ER

PT J
AU Lemoine, M
   Shimakawa, Y
   Nayagam, S
   Njie, R
   Thursz, M
AF Lemoine, M.
   Shimakawa, Y.
   Nayagam, S.
   Njie, R.
   Thursz, M.
TI Commentary: how long does one need to fast before a Fibroscan
   examination? Authors' reply
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Editorial Material
ID HEPATITIS-C VIRUS; LIVER STIFFNESS
C1 [Lemoine, M.; Shimakawa, Y.; Njie, R.] MRC, Gambia Unit, Liver Unit, Fajara, Gambia.
   [Lemoine, M.; Nayagam, S.; Thursz, M.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Hepatol, London, England.
   [Shimakawa, Y.] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.
RP Lemoine, M (reprint author), MRC, Gambia Unit, Liver Unit, Fajara, Gambia.
EM mlemoine@mrc.gm
OI Nayagam, Amanda Shevanthi/0000-0002-8030-3380
FU Medical Research Council [MR/L002086/1, MC_UP_A900_1120]
CR Arena U, 2013, HEPATOLOGY, V58, P65, DOI 10.1002/hep.26343
   Berzigotti A, 2013, PLOS ONE, V8
   Lam KLY, 2014, ALIMENT PHARM THER, V39, P540, DOI 10.1111/apt.12598
   Lemoine M, 2014, ALIMENT PHARM THER, V39, P188, DOI 10.1111/apt.12561
   Mederacke I, 2009, LIVER INT, V29, P1500, DOI 10.1111/j.1478-3231.2009.02100.x
NR 5
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD MAR
PY 2014
VL 39
IS 5
BP 541
EP 542
DI 10.1111/apt.12623
PG 2
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 301XF
UT WOS:000330564900010
PM 24494840
OA No
DA 2017-08-15
ER

PT J
AU Odutola, AA
   Afolabi, MO
   Jafali, J
   Baldeh, I
   Owolabi, OA
   Owiafe, P
   Bah, G
   Jaiteh, B
   Mohammed, NI
   Donkor, SA
   Ndure, J
   Adetifa, J
   Flanagan, KL
   Ota, MOC
AF Odutola, Aderonke A.
   Afolabi, Muhammed O.
   Jafali, James
   Baldeh, Ignatius
   Owolabi, Olumuyiwa A.
   Owiafe, Patrick
   Bah, Gibril
   Jaiteh, Boto
   Mohammed, Nuredin I.
   Donkor, Simon A.
   Ndure, Jorjoh
   Adetifa, Jane
   Flanagan, Katie L.
   Ota, Martin O. C.
TI Haematological and biochemical reference values of Gambian infants
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE reference values; haematological; biochemical; Gambian infants
ID IMMUNOLOGICAL REFERENCE VALUES; REFERENCE INTERVALS; REFERENCE RANGES;
   AFRICAN CHILDREN; INDEXES; POPULATION; PARAMETERS; GROWTH; SYSTEM; ZINC
AB Objective To establish haematological and biological reference values for Gambian infants.
   Methods Basic haematological and biochemical indices were analysed in blood samples obtained from healthy infants from Sukuta in the Western Division of The Gambia. The 2.5 and the 97.5 centiles for these indices were estimated.
   Results Reference ranges for haematological and biochemical indices were determined. Haemoglobin, total white cell count (WBC) and platelet levels decreased with age (P<0.001), whereas most of the white cell count subsets except monocytes did not vary with age. Potassium and alkaline phosphatase fell significantly with increasing age (P<0.001; P<0.001), whereas urea and creatinine rose with increasing age (P=0.002; P<0.001, respectively).
   Conclusion Our set of haematological and biochemical reference values for healthy infants in The Gambia differs from values in other settings, thus underscoring the importance of establishing region-specific paediatric reference ranges to ensure optimal patient management and evaluate the impact of interventions in clinical research.
C1 [Odutola, Aderonke A.; Afolabi, Muhammed O.; Owolabi, Olumuyiwa A.; Owiafe, Patrick; Ndure, Jorjoh; Adetifa, Jane; Flanagan, Katie L.; Ota, Martin O. C.] MRC Unit, Fajara, Gambia.
   [Jafali, James; Mohammed, Nuredin I.; Donkor, Simon A.] MRC Unit, Stat & Data Management Dept, Fajara, Gambia.
   [Baldeh, Ignatius; Bah, Gibril; Jaiteh, Boto] MRC Unit, Clin Labs, Fajara, Gambia.
RP Odutola, AA (reprint author), MRC Unit, POB 273, Banjul, Gambia.
EM aaodutola@mrc.gm
OI Afolabi, Muhammed/0000-0002-9967-6419; Kwasi Owiafe,
   Patrick/0000-0002-4287-3577
CR Adetifa IMO, 2009, INT J LAB HEMATOL, V31, P615, DOI 10.1111/j.1751-553X.2008.01087.x
   Andersson AM, 1998, J CLIN ENDOCR METAB, V83, P675, DOI 10.1210/jc.83.2.675
   Bain BJ, 1996, J CLIN PATHOL, V49, P664, DOI 10.1136/jcp.49.8.664
   Bain BJ, 2006, HAEMOGLOBINOPATHY DIAGNOSIS, 2ND EDITION, P1, DOI 10.1002/9780470988787
   Buchanan AM, 2010, TROP MED INT HEALTH, V15, P1011, DOI 10.1111/j.1365-3156.2010.02585.x
   Bugeac N, 2007, ARCH DIS CHILD, V92, P1109, DOI 10.1136/adc.2007.121194
   Buseri FI, 2010, PATHOLOGY LAB MED IN, V2, P65
   Centres for Diseases Control and Prevention (CDC) A GA USA. EPI INFO, EPI INFO VERS 3 4 NU
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Central Statistics Department TG, 2008, ATL GAMB PROV FIG 20
   Dal Colletto G M, 1993, Acta Genet Med Gemellol (Roma), V42, P245
   El-Hazmi MAF, 2001, ANN SAUDI MED, V21, P165
   Erasmus R. T., 1997, Papua New Guinea Medical Journal, V40, P89
   Evans D M, 1999, Twin Res, V2, P250, DOI 10.1375/136905299320565735
   FACER CA, 1979, T ROY SOC TROP MED H, V73, P309, DOI 10.1016/0035-9203(79)90090-7
   Glader B, 2004, NELSON TXB PEDIAT, P1383
   Karita E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004401
   Kibaya RS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003327
   Kliegman RBR, 2004, LAB MED
   Lewis S. M., 2006, DACIE LEWIS PRACTICA, P11, DOI 10.1016/B0-44-306660-4/50006-4
   Lugada ES, 2004, CLIN DIAGN LAB IMMUN, V11, P29, DOI 10.1128/CDLI.11.1.29-34.2004
   McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401
   Miller DR, 1995, BLOOD DIS INFANCY CH, P30
   MOCCHEGIANI E, 1989, DIABETES, V38, P932, DOI 10.2337/diabetes.38.7.932
   Odunukwe Nkiru N, 2004, Turk J Haematol, V21, P71
   ONWUKEME KE, 1991, TROP GEOGR MED, V43, P171
   Pan HQ, 1998, STAT MED, V17, P2755, DOI 10.1002/(SICI)1097-0258(19981215)17:23<2755::AID-SIM41>3.0.CO;2-E
   Quinto L, 2006, TROP MED INT HEALTH, V11, P1741, DOI 10.1111/j.1365-3156.2006.01764.x
   Rink L, 2000, P NUTR SOC, V59, P541, DOI 10.1017/S0029665100000781
   ROYSTON P, 1995, STAT MED, V14, P1417, DOI 10.1002/sim.4780141303
   SAXENA S, 1990, ARCH PATHOL LAB MED, V114, P715
   StataCorp, 2011, STAT 12 BAS REF MAN, P548
   Taylor MRH, 1997, CLIN LAB HAEMATOL, V19, P1, DOI 10.1046/j.1365-2257.1997.00204.x
   TUGUME SB, 1995, CLIN DIAGN LAB IMMUN, V2, P233
   UNAIDS, 2008, UNGASS COUNTR PROGR
   WHO, 1995, PHYS STAT US INT ANT
NR 36
TC 5
Z9 5
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAR
PY 2014
VL 19
IS 3
BP 275
EP 283
DI 10.1111/tmi.12245
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 304IJ
UT WOS:000330740000004
PM 24393095
OA No
DA 2017-08-15
ER

PT J
AU Castelino, JM
   Dominguez-Salas, P
   Routledge, MN
   Prentice, AM
   Moore, SE
   Hennig, BJ
   Wild, CP
   Gong, YY
AF Castelino, Jovita M.
   Dominguez-Salas, Paula
   Routledge, Michael N.
   Prentice, Andrew M.
   Moore, Sophie E.
   Hennig, Branwen J.
   Wild, Christopher P.
   Gong, Yun Yun
TI Seasonal and gestation stage associated differences in aflatoxin
   exposure in pregnant Gambian women
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE aflatoxin; in utero exposure; seasonality
ID HEPATITIS-B INFECTION; WEST-AFRICA; ALBUMIN ADDUCTS;
   DEVELOPING-COUNTRIES; DIETARY AFLATOXIN; PLASMA-VOLUME; IN-UTERO;
   CHILDREN; HEALTH; GROWTH
AB Objective Aflatoxin is known to cross the placental barrier and exposures in utero could influence genomic programming, foetal growth and development, resulting in long-term health effects. We aimed to determine aflatoxin exposure in Gambian women at two stages of pregnancy and during the rainy and dry seasons.
   Methods We examined aflatoxin exposure in pregnant Gambian women at early (<16weeks) and later (16weeks onward) stages of pregnancy and at different times of the year, during the rainy (June to October 2009) or dry (November to May 2010) season, using aflatoxin-albumin adducts (AF-alb).
   Results Mean AF-alb was higher during the dry season than in the rainy season, in both early and later pregnancy although the difference was strongest in later pregnancy. There was a modest increase in AF-alb in later than early pregnancy (geometric mean 41.8 vs. 34.5pg/mg, P<0.05), but this was restricted to the dry season when exposures were generally higher.
   Conclusions The study confirmed that Gambian pregnant women were exposed to aflatoxin throughout the pregnancy, with higher levels in the dry season. There was some evidence in the dry season that women in later pregnancy had higher AF-alb levels than those in earlier pregnancy. Further research on the effects of exposure to this potent mutagen and carcinogen throughout pregnancy, including the epigenetic modification of foetal gene expression and impact on pre- and post-natal growth and development, are merited.
C1 [Castelino, Jovita M.; Routledge, Michael N.; Gong, Yun Yun] Univ Leeds, Sch Med, Div Epidemiol, Leeds LS2 9JT, W Yorkshire, England.
   [Dominguez-Salas, Paula; Prentice, Andrew M.; Moore, Sophie E.; Hennig, Branwen J.] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
   [Dominguez-Salas, Paula] MRC Keneba, Kiang West, Gambia.
   [Wild, Christopher P.] Int Agcy Res Canc, F-69372 Lyon, France.
   [Gong, Yun Yun] Queens Univ Belfast, Inst Global Food Secur, Belfast BT9 5AG, Antrim, North Ireland.
RP Gong, YY (reprint author), Queens Univ Belfast, Inst Global Food Secur, Sch Biol Sci, Belfast BT9 5AG, Antrim, North Ireland.
EM y.gong@qub.ac.uk
RI Hennig, Branwen/M-6444-2014; Gong, Yun/L-7094-2016
OI Gong, Yun/0000-0003-4927-5526
FU National Institute of Environmental Health Sciences, USA; IARC; UK
   Medical Research Council; Wellome Trust
FX We thank all the study participants as well as the field, laboratory and
   data office staff at MRC Keneba. YY Gong and CP Wild are supported by
   the National Institute of Environmental Health Sciences, USA. We would
   also like to acknowledge the finance contribution from IARC towards JM
   Castelino's PhD study. MRC Keneba is supported by the UK Medical
   Research Council, and the study within which this analysis was embedded
   was funded by the Wellome Trust.
CR Abdulrazzaq YM, 2002, ANN TROP PAEDIATR, V22, P3, DOI 10.1170/9027249302125000094
   ALLEN SJ, 1992, T ROY SOC TROP MED H, V86, P426, DOI 10.1016/0035-9203(92)90253-9
   Azziz-Baumgartner E, 2005, ENVIRON HEALTH PERSP, V113, P1779, DOI 10.1289/ehp.8384
   Bacq Y, 1996, HEPATOLOGY, V23, P1030
   BUTLER WH, 1966, BRIT J EXP PATHOL, V47, P242
   Chapot B., 1991, TECHNIQUES DIAGNOSTI, P135
   Cotty PJ, 2007, INT J FOOD MICROBIOL, V119, P109, DOI 10.1016/j.ijfoodmicro.2007.07.060
   GALLERY EDM, 1979, Q J MED, V48, P593
   Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473
   Gong YY, 2004, ENVIRON HEALTH PERSP, V112, P1334, DOI 10.1289/ehp.6954
   Gong YY, 2002, BRIT MED J, V325, P20, DOI 10.1136/bmj.325.7354.20
   Guengerich FP, 1998, MUTAT RES-FUND MOL M, V402, P121, DOI 10.1016/S0027-5107(97)00289-3
   Hell K, 2000, J STORED PROD RES, V36, P365, DOI 10.1016/S0022-474X(99)00056-9
   Hudson Geoffrey J., 1992, Natural Toxins, V1, P100, DOI 10.1002/nt.2620010208
   The International Agency for Research on Cancer (IARC), 2002, IARC MONOGR EVAL CAR, V82, P1
   Jiang Y, 2005, INT IMMUNOL, V17, P807, DOI 10.1093/intimm/dxh262
   LAWRENCE M, 1984, LANCET, V2, P363
   Li Y, 1997, CANCER RES, V57, P641
   Marin DE, 2002, J ANIM SCI, V80, P1250
   Moore SE, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-107
   Partanen HA, 2010, TOXICOL SCI, V113, P216, DOI 10.1093/toxsci/kfp257
   PAUL AA, 1979, T ROY SOC TROP MED H, V73, P686, DOI 10.1016/0035-9203(79)90022-1
   PIRANI BBK, 1973, J OBSTET GYN BR COMM, V80, P884
   POPPITT SD, 1993, AM J CLIN NUTR, V57, P353
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   Qureshi MA, 1998, POULTRY SCI, V77, P812
   ROBERTS SB, 1982, T ROY SOC TROP MED H, V76, P668, DOI 10.1016/0035-9203(82)90239-5
   Strosnider H, 2006, ENVIRON HEALTH PERSP, V114, P1898, DOI 10.1289/ehp.9302
   Thomson A M, 1966, J Obstet Gynaecol Br Commonw, V73, P724
   Tracy TS, 2005, AM J OBSTET GYNECOL, V192, P633, DOI 10.1016/j.ajog.2004.08.030
   Turner PC, 2007, INT J EPIDEMIOL, V36, P1119, DOI 10.1093/ije/dym122
   Turner PC, 2003, ENVIRON HEALTH PERSP, V111, P217, DOI 10.1289/ehp.5753
   Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x
   Villar S, 2011, ENVIRON HEALTH PERSP, V119, P1635, DOI 10.1289/ehp.1103539
   Walker MC, 1999, AM J OBSTET GYNECOL, V180, P660, DOI 10.1016/S0002-9378(99)70269-3
   Wild CP, 2010, CARCINOGENESIS, V31, P71, DOI 10.1093/carcin/bgp264
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   Williams JH, 2004, AM J CLIN NUTR, V80, P1106
   Wojnowski L, 2004, PHARMACOGENETICS, V14, P691, DOI 10.1097/00008571-200410000-00007
NR 41
TC 6
Z9 6
U1 2
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAR
PY 2014
VL 19
IS 3
BP 348
EP 354
DI 10.1111/tmi.12250
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 304IJ
UT WOS:000330740000013
PM 24372685
OA No
DA 2017-08-15
ER

PT J
AU Braithwaite, V
   Jones, KS
   Assar, S
   Schoenmakers, I
   Prentice, A
AF Braithwaite, Vickie
   Jones, Kerry S.
   Assar, Shima
   Schoenmakers, Inez
   Prentice, Ann
TI Predictors of intact and C-terminal fibroblast growth factor 23 in
   Gambian children
SO ENDOCRINE CONNECTIONS
LA English
DT Article
DE FGF23; vitamin D half-life; rickets; iron status; children
AB Elevated C-terminal fibroblast growth factor 23 (C-FGF23) concentrations have been reported in Gambian children with and without putative Ca-deficiency rickets. The aims of this study were to investigate whether i) elevated C-FGF23 concentrations in Gambian children persist long term; ii) they are associated with higher intact FGF23 concentrations (I-FGF23), poor iron status and shorter 25-hydroxyvitamin D half-life (25OHD-t(1/2)); and iii) the persistence and predictors of elevated FGF23 concentrations differ between children with and without a history of rickets. Children (8-16 years, n=64) with a history of rickets and a C-FGF23 concentration >125 RU/ml (bone deformity (BD), n=20) and local community children with a previously measured elevated C-FGF23 concentration (LC+, n=20) or a previously measured C-FGF23 concentration within the normal range (LC-, n=24) participated. BD children had no remaining signs of bone deformities. C-FGF23 concentration had normalised in BD children, but remained elevated in LC+ children. All the children had I-FGF23 concentration within the normal range, but I-FGF23 concentration was higher and iron status poorer in LC+ children. 1,25-dihydroxyvitamin D was the strongest negative predictor of I-FGF23 concentration (R-2=18%; P=0.0006) and soluble transferrin receptor was the strongest positive predictor of C-FGF23 concentration (R-2=33%; P <= 0.0001). C-FGF23 and I-FGF23 concentrations were poorly correlated with each other (R-2=5.3%; P=0.07). 25OHD-t(1/2) was shorter in BD children than in LC- children (mean (S.D.): 24.5 (6.1) and 31.5 (11.5) days respectively; P=0.05). This study demonstrated that elevated C-FGF23 concentrations normalised over time in Gambian children with a history of rickets but not in local children, suggesting a different aetiology; that children with resolved rickets had a shorter 25OHD-t(1/2), suggesting a long-standing increased expenditure of 25OHD, and that iron deficiency is a predictor of elevated C-FGF23 concentrations in both groups of Gambian children.
C1 [Braithwaite, Vickie; Jones, Kerry S.; Assar, Shima; Schoenmakers, Inez; Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Labs, Fulbourn Rd, Cambridge CB1 9NL, England.
   [Jones, Kerry S.; Prentice, Ann] MRC Keneba, Keneba, West Kiang, Gambia.
RP Braithwaite, V (reprint author), MRC Human Nutr Res, Elsie Widdowson Labs, Fulbourn Rd, Cambridge CB1 9NL, England.
EM Vickie.braithwaite@mrc-hnr.cam.ac.uk
OI Braithwaite, Vickie/0000-0002-3366-2903; Jones,
   Kerry/0000-0002-7380-9797
FU Medical Research Council, UK programme [U105960371, U123261351]; MRC;
   Department for International Development (DFID) under the MRC/DFID
   Concordat agreement
FX This work was funded by the Medical Research Council, UK programme
   numbers U105960371 and U123261351. This research was jointly funded by
   the MRC and the Department for International Development (DFID) under
   the MRC/DFID Concordat agreement.
CR Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   Berndt TJ, 2007, PFLUG ARCH EUR J PHY, V454, P615, DOI 10.1007/s00424-007-0231-5
   Braithwaite Vickie, 2012, Int J Pediatr Endocrinol, V2012, P27, DOI 10.1186/1687-9856-2012-27
   Braithwaite V, 2012, BONE, V50, P1351, DOI 10.1016/j.bone.2012.03.010
   Braithwaite V, 2012, BONE, V50, P218, DOI 10.1016/j.bone.2011.10.009
   Burnett-Bowie SAM, 2012, CLIN J AM SOC NEPHRO, V7, P624, DOI 10.2215/CJN.10030911
   CLEMENTS MR, 1987, NATURE, V325, P62, DOI 10.1038/325062a0
   Clinkenbeard EL, 2014, J BONE MINER RES, V29, P361, DOI 10.1002/jbmr.2049
   Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F
   Committee on Medical Aspects of Food Policy, 1991, REP HLTH SOC SUBJ, pxxiv
   Durham BH, 2007, ANN CLIN BIOCHEM, V44, P463, DOI 10.1258/000456307781646102
   Farrow EG, 2011, P NATL ACAD SCI USA, V108, pE1146, DOI 10.1073/pnas.1110905108
   Gattineni J, 2009, AM J PHYSIOL-RENAL, V297, pF282, DOI 10.1152/ajprenal.90742.2008
   Goetz R, 2010, P NATL ACAD SCI USA, V107, P407, DOI 10.1073/pnas.0902006107
   Spiegel HE, 2001, ADV CLIN CHEM, P72, DOI 10.1016/S0065-2423(01)35015-1
   Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Heijboer AC, 2009, ANN CLIN BIOCHEM, V46, P338, DOI 10.1258/acb.2009.009066
   Igaki JM, 2011, ENDOCR J, V58, P647
   Imel EA, 2011, J CLIN ENDOCR METAB, V96, P3541, DOI 10.1210/jc.2011-1239
   Jones KS, 2012, BRIT J NUTR, V107, P1128, DOI 10.1017/S0007114511004132
   Larsson T, 2004, ENDOCRINOLOGY, V145, P3087, DOI 10.1210/en.2003-1768
   Lord R. S., 2008, LAB EVALUATIONS INTE
   Lu Yongbo, 2011, Curr Osteoporos Rep, V9, P103, DOI 10.1007/s11914-011-0053-4
   LUNN PG, 1989, CLIN CHIM ACTA, V183, P163, DOI 10.1016/0009-8981(89)90332-X
   NorthropClewes CA, 1997, J PEDIATR GASTR NUTR, V24, P257, DOI 10.1097/00005176-199703000-00005
   Passaro DJ, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.5.e87
   Payne RB, 1998, ANN CLIN BIOCHEM, V35, P201
   Prentice A, 2008, AM J CLIN NUTR, V88, p500S
   Prentice A, 2008, BONE, V42, P788, DOI 10.1016/j.bone.2007.11.014
   Paul AA, 2007, FOOD COMPOSITION TAB
   Savy M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011075
   Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198
   Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179
   Smith ER, 2011, CLIN CHIM ACTA, V412, P1008, DOI 10.1016/j.cca.2011.02.009
   Thomas JE, 1999, PEDIATR RES, V46, P147, DOI 10.1203/00006450-199908000-00003
   Thomas JE, 1999, PEDIATR RES, V45, P218, DOI 10.1203/00006450-199902000-00010
   Uzum AK, 2010, EUR J ENDOCRINOL, V163, P825, DOI 10.1530/EJE-10-0591
NR 37
TC 6
Z9 6
U1 0
U2 0
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
EI 2049-3614
J9 ENDOCR CONNECT
JI Endocr. Connect.
PD MAR 1
PY 2014
VL 3
IS 1
BP 1
EP 10
DI 10.1530/EC-13-0070
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V44UL
UT WOS:000209773800004
PM 24258305
OA gold
DA 2017-08-15
ER

PT J
AU Bradley, BD
   Howie, SRC
   Chan, TCY
   Cheng, YL
AF Bradley, Beverly D.
   Howie, Stephen R. C.
   Chan, Timothy C. Y.
   Cheng, Yu-Ling
TI Estimating Oxygen Needs for Childhood Pneumonia in Developing Country
   Health Systems: A New Model for Expecting the Unexpected
SO PLOS ONE
LA English
DT Article
ID RESOURCE-LIMITED SETTINGS; DISCRETE-EVENT SIMULATION; PAPUA-NEW-GUINEA;
   ACUTE RESPIRATORY-INFECTIONS; NASAL PRONGS; SEASONAL INFLUENZA;
   WEST-AFRICA; CHILDREN; HYPOXEMIA; DELIVERY
AB Background: Planning for the reliable and cost-effective supply of a health service commodity such as medical oxygen requires an understanding of the dynamic need or 'demand' for the commodity over time. In developing country health systems, however, collecting longitudinal clinical data for forecasting purposes is very difficult. Furthermore, approaches to estimating demand for supplies based on annual averages can underestimate demand some of the time by missing temporal variability.
   Methods: A discrete event simulation model was developed to estimate variable demand for a health service commodity using the important example of medical oxygen for childhood pneumonia. The model is based on five key factors affecting oxygen demand: annual pneumonia admission rate, hypoxaemia prevalence, degree of seasonality, treatment duration, and oxygen flow rate. These parameters were varied over a wide range of values to generate simulation results for different settings. Total oxygen volume, peak patient load, and hours spent above average-based demand estimates were computed for both low and high seasons.
   Findings: Oxygen demand estimates based on annual average values of demand factors can often severely underestimate actual demand. For scenarios with high hypoxaemia prevalence and degree of seasonality, demand can exceed average levels up to 68% of the time. Even for typical scenarios, demand may exceed three times the average level for several hours per day. Peak patient load is sensitive to hypoxaemia prevalence, whereas time spent at such peak loads is strongly influenced by degree of seasonality.
   Conclusion: A theoretical study is presented whereby a simulation approach to estimating oxygen demand is used to better capture temporal variability compared to standard average-based approaches. This approach provides better grounds for health service planning, including decision-making around technologies for oxygen delivery. Beyond oxygen, this approach is widely applicable to other areas of resource and technology planning in developing country health systems.
C1 [Bradley, Beverly D.; Chan, Timothy C. Y.; Cheng, Yu-Ling] Univ Toronto, Ctr Global Engn, Toronto, ON, Canada.
   [Bradley, Beverly D.; Cheng, Yu-Ling] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON, Canada.
   [Howie, Stephen R. C.] MRC Unit, Banjul, Gambia.
   [Chan, Timothy C. Y.] Univ Toronto, Dept Mech & Ind Engn, Toronto, ON, Canada.
RP Bradley, BD (reprint author), Univ Toronto, Ctr Global Engn, Toronto, ON, Canada.
EM bev.bradley@mail.utoronto.ca
FU Natural Sciences and Engineering Research Council (NSERC) of Canada
FX B. Bradley is supported by a graduate scholarship from the Natural
   Sciences and Engineering Research Council (NSERC) of Canada. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Ahmed JA, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-7
   Alexopoulos C, 2008, OMEGA-INT J MANAGE S, V36, P33, DOI 10.1016/j.omega.2005.07.013
   Assi TM, 2013, VACCINE, V31, P2828, DOI 10.1016/j.vaccine.2013.04.011
   Assi TM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-425
   Belle J, 2010, J INFECT DEV COUNTR, V4, P419
   Bishai D, 2007, AIDS, V21, P1333, DOI 10.1097/QAD.0b013e328137709e
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Blumenfeld S, 1985, OPERATIONS RES METHO
   Chew FT, 1998, EPIDEMIOL INFECT, V121, P121, DOI 10.1017/S0950268898008905
   Deo S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035479
   Dosseh A, 2000, AM J TROP MED HYG, V62, P639
   Duke T, 2010, INT J TUBERC LUNG D, V14, P1362
   Duke T, 2001, INT J TUBERC LUNG D, V5, P511
   Duke T, 2002, ARCH DIS CHILD, V86, P108, DOI 10.1136/adc.86.2.108
   Duke T, 2008, LANCET, V372, P1328, DOI 10.1016/S0140-6736(08)61164-2
   Tudur Evans H, 2012, PNEUMONIA, V1, P3
   Fone D, 2003, J PUBLIC HEALTH MED, V25, P325, DOI 10.1093/pubmed/fdg075
   Gessner BD, 2011, LANCET INFECT DIS, V11, P223, DOI 10.1016/S1473-3099(11)70008-1
   Ginsburg AS, 2012, J TROP PEDIATRICS, V58, P389, DOI 10.1093/tropej/fmr103
   Hill SE, 2009, INT J TUBERC LUNG D, V13, P587
   Hoffmann J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043666
   Howie SRC, 2009, B WORLD HEALTH ORGAN, V87, P763, DOI 10.2471/BLT.08.058370
   Jacobson SH, 2006, INT SER OPER RES MAN, V91, P211, DOI 10.1007/978-0-387-33636-7_8
   Jun JB, 1999, J OPER RES SOC, V50, P109, DOI 10.2307/3010560
   Junge S, 2006, TROP MED INT HEALTH, V11, P367, DOI 10.1111/j.1365-3156.2006.01570.x
   Khor CS, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-32
   Kwofie TB, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-78
   La Vincente SF, 2011, INT J TUBERC LUNG D, V15, P693, DOI 10.5588/ijtld.10.0544
   Langley I, 2012, HEALTH CARE MANAG SC, V15, P239, DOI 10.1007/s10729-012-9201-3
   Lozano JM, 2001, INT J TUBERC LUNG D, V5, P496
   Marazzi A, 1998, MED CARE, V36, P915, DOI 10.1097/00005650-199806000-00014
   Matai S, 2008, ANN TROP PAEDIATR, V28, P71, DOI 10.1179/146532808X270716
   Muhe L, 1998, J TROP PEDIATRICS, V44, P365, DOI 10.1093/tropej/44.6.365
   Muhe L, 1997, ANN TROP PAEDIATR, V17, P273
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Rauner MS, 2005, J OPER RES SOC, V56, P222, DOI 10.1057/palgrave.jors.2601884
   Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895
   RUFFIEUX C, 1993, SOZ PRAVENTIV MED, V38, P77, DOI 10.1007/BF01318464
   Shek Lynette Pei-Chi, 2003, Paediatr Respir Rev, V4, P105, DOI 10.1016/S1526-0542(03)00024-1
   Subhi R, 2009, LANCET INFECT DIS, V9, P219, DOI 10.1016/S1473-3099(09)70071-4
   Swartzman G, 1970, Health Serv Res, V5, P320
   Tchidjou HK, 2010, J TROP PEDIATRICS, V56, P317, DOI 10.1093/tropej/fmp127
   Turner C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050100
   WEBER MW, 1995, J PEDIATR-US, V127, P378, DOI 10.1016/S0022-3476(95)70067-6
   Weber MW, 2002, B WORLD HEALTH ORGAN, V80, P562
   Weber MW, 1998, PEDIATR INFECT DIS J, V17, P224, DOI 10.1097/00006454-199803000-00010
   Duke T, 2009, CLIN USE OXYGEN HOSP
   WHO, 2012, CHILDR RED MORT
   WHO, 2013, POCK BOOK HOSP CAR C
   Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0
   Williams P, 2009, ANN OPER RES, V178, P263, DOI 10.1007/s10479-009-0580-x.
NR 52
TC 3
Z9 3
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2014
VL 9
IS 2
AR e89872
DI 10.1371/journal.pone.0089872
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AB3UC
UT WOS:000331714700135
PM 24587089
OA gold
DA 2017-08-15
ER

PT J
AU Jones, C
   Pollock, L
   Barnett, SM
   Battersby, A
   Kampmann, B
AF Jones, Christine
   Pollock, Louisa
   Barnett, Sara M.
   Battersby, Anna
   Kampmann, Beate
TI The relationship between concentration of specific antibody at birth and
   subsequent response to primary immunization
SO VACCINE
LA English
DT Article
DE Vaccine; Infant; Immune response
ID INFLUENZAE TYPE-B; BORDETELLA-PERTUSSIS; MATERNAL ANTIBODIES; VACCINE
   IMMUNOGENICITY; HOUSEHOLD EXPOSURE; CONJUGATE VACCINE; IGG ANTIBODIES;
   INFANTS; TETANUS; MEASLES
AB Background and aims: Trans-placentally acquired antibodies can protect infants from infection in the first months of life. However, high concentrations of antibody at birth may impact the infant's own immune response to primary immunization. We examine the relationship between concentration of specific antibody to Bordetella pertussis, Haemophilus influenzae type b (Hib), tetanus toxoid and pneumococcal antigens at birth and following primary immunization.
   Methods: Healthy mother-infant pairs were recruited from a UK maternity unit Peripheral blood samples were obtained at birth and 4 weeks after primary immunization. Specific antibody concentrations were determined using enzyme-linked immunosorbent assays. Pertussis antibody concentrations >50 IU/ml, Tetanus antibody levels >0.1 IU/ml and Hib antibody levels >0.15 mg/l were regarded as protective.
   Results: Following primary immunization, 35/36 (97%) infants had specific antibody concentrations associated with protection against Hib, 32/36 (89%) against pertussis and 36/36 (100%) against tetanus. Concentrations of all specific antibodies were significantly higher than at birth (p < 0.0001), except anti-tetanus toxoid,p = 0.41. However, there was an inverse correlation between infant antibody concentration at birth and fold-increase in antibody concentration post-immunization for tetanus: r(s) -0.86 (95%CI -0.93 to -0.74),p < 0.0001; pneumococcus: r(s) -0.82 (95% CI -0.91 to -0.67),p < 0.0001; pertussis: r(s) -0.77 (95% CI -0.89 to -0.58),p < 0.0001 and Hib: r(s) -0.66 (95%CI -0.82 to -0.42),p < 0.0001. The highest concentrations of specific IgG at birth were associated with lower concentrations post-immunization for tetanus (p = 0.009) and pneumococcus (p = 0.03). This association was not observed for Hib (p = 0.88) or pertussis (p = 0.14).
   Conclusion: Higher antibody concentration at birth appeared to inhibit the response to infant immunization for tetanus and pneumococcus; the effect was less marked for Hib and pertussis. However, the majority of infants achieved high antibody levels post-immunization. This supports maternal immunization, as high levels of maternally derived antibody at birth may not inhibit infants' immunization responses in a clinically relevant manner. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Jones, Christine; Barnett, Sara M.; Battersby, Anna; Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, London W2 1PG, England.
   [Pollock, Louisa; Battersby, Anna; Kampmann, Beate] Med Res Council Unit Gambia, Banjul, Gambia.
RP Kampmann, B (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Paediat, 2nd Floor Wright Fleming Bldg,Norfolk Pl, London W2 1PG, England.
EM cjones@sgul.ac.uk; l.pollock@imperial.ac.uk; s.barnett@imperial.ac.uk;
   a.battersby@imperial.ac.uk; b.kampmann@imperial.ac.uk
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Imperial College Healthcare NHS Trust; National Institute for
   Health Research (NIHR) Biomedical Research Centre based at Imperial
   College London; MRC; Wellcome Trust Clinical PhD Fellowship
FX The research was funded by the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Imperial College Healthcare
   NHS Trust and Imperial College London. The views expressed are those of
   the author( s) and not necessarily those of the NHS, the NIHR or the
   Department of Health. The funding body had no role in study design; in
   the collection, analysis or interpretation of data; in the writing of
   the report or in the decision to submit the article for publication.;
   BK, LP are additionally supported by MRC funding. LP is now supported by
   a Wellcome Trust Clinical PhD Fellowship.
CR Abel J, 2013, P OBSTET GYNAECOLOGY, V3
   AGBARAKWE AE, 1995, J CLIN PATHOL, V48, P206, DOI 10.1136/jcp.48.3.206
   ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4
   AMINO N, 1978, OBSTET GYNECOL, V52, P415
   Belloni C, 2003, PEDIATRICS, V111, P1042, DOI 10.1542/peds.111.5.1042
   Beyer WEP, 2004, VIRUS RES, V103, P125, DOI 10.1016/j.virusres.2004.02.024
   Blanchard-Rohner G, 2012, VACCINE, V30, P4153, DOI 10.1016/j.vaccine.2012.04.063
   BOOY R, 1992, LANCET, V339, P507, DOI 10.1016/0140-6736(92)90336-2
   BURSTYN DG, 1983, INFECT IMMUN, V41, P1150
   Campbell H, 2012, EMERG INFECT DIS, V18, P38, DOI 10.3201/eid1801.110784
   Cherry JD, 1998, VACCINE, V16, P1901, DOI 10.1016/S0264-410X(98)00226-6
   CIRNE MD, 1995, J INFECT DIS, V171, P1097
   ENGLUND JA, 1995, PEDIATRICS, V96, P580
   Englund JA, 2003, VACCINE, V21, P3455, DOI 10.1016/S0264-410X(03)00350-5
   Gall SA, 2011, AM J OBSTET GYNECOLO, V204
   Gans H, 2001, J INFECT DIS, V184, P817, DOI 10.1086/323346
   Guiso N, 2011, EUR J CLIN MICROBIOL, V30, P307, DOI 10.1007/s10096-010-1104-y
   Joint Committee on Vaccination and Immunisation, 2012, TEL PERT
   Jones C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002473
   Jones CE, 2011, JAMA-J AM MED ASSOC, V305, P576, DOI 10.1001/jama.2011.100
   KAYHTY H, 1983, J INFECT DIS, V147, P1100
   Kim D, 2011, BLOOD, V117, P6143, DOI 10.1182/blood-2010-11-320317
   Klinge J, 2000, VACCINE, V18, P3134, DOI 10.1016/S0264-410X(00)00096-7
   Kuehn BM, 2012, JAMA-J AM MED ASSOC, V308, P1960, DOI 10.1001/jama.2012.54092
   Leuridan E, 2007, VACCINE, V25, P6296, DOI 10.1016/j.vaccine.2007.06.020
   Nohynek H, 1999, PEDIATR INFECT DIS J, V18, P25, DOI 10.1097/00006454-199901000-00008
   O'Brien KL, 2007, J INFECT DIS, V196, P104, DOI 10.1083/518438
   Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646
   Plikaytis BD, 2005, VACCINE, V23, P1606, DOI 10.1016/j.vaccine.2004.06.047
   PRITCHARD JA, 1965, AM J OBSTET GYNECOL, V91, P621
   SARVAS H, 1992, J INFECT DIS, V165, P977
   Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6
   Siegrist CA, 1998, VACCINE, V16, P1409, DOI 10.1016/S0264-410X(98)00100-5
   Storsaeter J, 2003, VACCINE, V21, P3542, DOI 10.1016/S0264-410X(03)00407-9
   Storsaeter J, 1998, VACCINE, V16, P1907, DOI 10.1016/S0264-410X(98)00227-8
   Taranger J, 2000, J INFECT DIS, V181, P1010, DOI 10.1086/315318
   VANSAVAGE J, 1990, J INFECT DIS, V161, P487
   Wang ZQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025130
   [Anonymous], 2006, WEEKLY EPIDEMIOLOGIC, V81, P197
NR 39
TC 24
Z9 24
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 12
PY 2014
VL 32
IS 8
BP 996
EP 1002
DI 10.1016/j.vaccine.2013.11.104
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AB0VM
UT WOS:000331510200017
PM 24342250
OA No
DA 2017-08-15
ER

PT J
AU Dial, NJ
   Ceesay, SJ
   Gosling, RD
   D'Alessandro, U
   Baltzell, KA
AF Dial, Natalie J.
   Ceesay, Serign J.
   Gosling, Roly D.
   D'Alessandro, Umberto
   Baltzell, Kimberly A.
TI A qualitative study to assess community barriers to malaria mass drug
   administration trials in the Gambia
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Mass drug administration; Compliance; Adherence; Qualitative
   interviewing
ID ARTEMETHER-LUMEFANTRINE; PLASMODIUM-FALCIPARUM; LYMPHATIC FILARIASIS;
   ELIMINATION; TRANSMISSION; PERCEPTIONS; COMBINATION; CHALLENGES;
   EDUCATION; PROGRESS
AB Background: Mass drug administration (MDA) is a strategy widely used in the control of human parasitic diseases but has been rarely attempted with malaria, the most common and dangerous parasitic disease in humans. MDA is an intervention strategy that involves simultaneously dispensing treatment to an entire population in a given geographic area. With some areas in sub-Saharan Africa documenting a decline in malaria transmission, the feasibility of MDA to further reduce malaria transmission is being considered. Understanding community perceptions of such an activity is vitally important for the design of the study and gaining the support of participants in order to maximize compliance and adherence.
   Methods: A qualitative study to assess factors likely to influence community acceptance of MDA in the seasonal and low malaria transmission setting of The Gambia was conducted. Using in-depth interviews, the perceptions, knowledge and attitudes of medical personnel and community members who have undergone MDA trials in The Gambia were investigated.
   Results: Several major themes emerged, namely: 1) the importance of timing of rounds of MDA doses for maximum participation; 2) the need to educate the target population with accurate information on the procedures, drug regimen, and possible side effects to enhance adherence; 3) the need for continuous sensitization meetings to maintain and increase uptake of MDA; and, 4) the importance for defining roles in the delivery and assessment of MDA, including existing healthcare structures.
   Discussion: To increase the likelihood of participation in MDA trials in this setting, activities should be undertaken just before and during the rainy season when community members are less mobile. Importantly, fears regarding blood sampling and side effects of the drug regimen need to be addressed prior to the start of the trial and repeated throughout the study period. Accurate and frequent communication is essential, and village leaders should consistently be included in sensitization meetings to enhance community participation. Additionally, village healthcare workers should be included in training and implementation, with supervision by a fieldworker permanently posted in every few villages during the trial. Future collaboration with Senegal may prove important for enhanced elimination efforts in The Gambia.
C1 [Dial, Natalie J.; Gosling, Roly D.] Univ Calif San Francisco, Dept Global Hlth Sci, San Francisco, CA 94105 USA.
   [Ceesay, Serign J.; D'Alessandro, Umberto] MRC Unit, Banjul, Gambia.
   [Baltzell, Kimberly A.] Univ Calif San Francisco, Dept Global Hlth Sci, San Francisco, CA 94143 USA.
   [Baltzell, Kimberly A.] Univ Calif San Francisco, Dept Family Hlth Care Nursing, San Francisco, CA 94143 USA.
RP Dial, NJ (reprint author), Univ Calif San Francisco, Dept Global Hlth Sci, 50 Beale St Ste 1200, San Francisco, CA 94105 USA.
EM njdial@gmail.com
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Bill and Melinda Gates Foundation
FX This study was supported by a grant from the Bill and Melinda Gates
   Foundation to the Malaria Elimination Initiative at UCSF Global Health
   Group and UCSF Global Health Sciences. We would like to thank our field
   team, especially Samba Baldeh, Musa Badjie, Kutubo Secka, and the entire
   driving staff at the MRC Gambia.
CR Audet CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070326
   Babiker HA, 2013, DRUG RESIST UPDATE, V16, P1, DOI 10.1016/j.drup.2013.02.001
   Bhullar N, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-70
   Bojang KA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000409
   Cantey PT, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000728
   Cotter C, 2013, LANCET, V382, P900, DOI 10.1016/S0140-6736(13)60310-4
   De Martin S, 2001, TROP MED INT HEALTH, V6, P442, DOI 10.1046/j.1365-3156.2001.00723.x
   Eberhard M, 2013, MMWR-MORBID MORTAL W, V62, P405
   Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6
   Febir LG, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-156
   GARFIELD RM, 1986, SOC SCI MED, V22, P869, DOI 10.1016/0277-9536(86)90241-8
   Ghosh S, 2013, TROP PARASITOL, V3, P3167
   Harper ME, 2004, INT J TUBERC LUNG D, V8, P1266
   Hill A, 2000, TROP MED INT HEALTH, V2, P107
   Hodges MH, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-16
   Kaneko A, 2000, LANCET, V356, P1560, DOI 10.1016/S0140-6736(00)03127-5
   Kaneko A, 2010, ACTA TROP, V3, P177
   Kern SE, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-210
   Lemma H, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-349
   Maude RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037166
   Okell LC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020179
   Roy RN, 2013, J HEALTH POPUL NUTR, V2, P171
   Shekalaghe SA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-247
   Song JP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-57
   Sturrock HJW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001467
   von Seidlein L, 2003, T ROY SOC TROP MED H, V97, P217
   WHO, 2013, WORLD MALARIA REPORT 2013, P1
   WHO, 2011, CONS MASS DRUG ADM C
   WHO, 2013, WORLD FACTSH LYMPH F
NR 29
TC 14
Z9 14
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD FEB 4
PY 2014
VL 13
AR 47
DI 10.1186/1475-2875-13-47
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AA9IE
UT WOS:000331406200002
PM 24495715
OA gold
DA 2017-08-15
ER

PT J
AU Wegmuller, R
   Tay, F
   Zeder, C
   Brnic, M
   Hurrell, RF
AF Wegmueller, Rita
   Tay, Fabian
   Zeder, Christophe
   Brnic, Marica
   Hurrell, Richard F.
TI Zinc Absorption by Young Adults from Supplemental Zinc Citrate Is
   Comparable with That from Zinc Gluconate and Higher than from Zinc Oxide
SO JOURNAL OF NUTRITION
LA English
DT Article
ID HELICOBACTER-PYLORI INFECTION; IRON-ABSORPTION; HEALTHY-MEN; ORAL ZINC;
   CHILDREN; BIOAVAILABILITY; SULFATE; HUMANS; ADOLESCENTS; EDTA
AB The water-soluble zinc salts gluconate, sulfate, and acetate are commonly used as supplements in tablet or syrup form to prevent zinc deficiency and to treat diarrhea in children in combination with oral rehydration. Zinc citrate is an alternative compound with high zinc content, slightly soluble in water, which has better sensory properties in syrups but no absorption data in humans. We used the double-isotope tracer method with Zn-67 and Zn-70 to measure zinc absorption from zinc citrate given as supplements containing 10 mg of zinc to 15 healthy adults without food and compared absorption with that from zinc gluconate and zinc oxide (insoluble in water) using a randomized, double-masked, 3-way crossover design. Median (IQR) fractional absorption of zinc from zinc citrate was 61.3% (56.6-71.0) and was not different from that from zinc gluconate with 60.9% (50.6-71.7). Absorption from zinc oxide at 49.9% (40.9-57.7) was significantly lower than from both other supplements (P < 0.01). Three participants had little or no absorption from zinc oxide. We conclude that zinc citrate, given as a supplement without food, is as well absorbed by healthy adults as zinc gluconate and may thus be a useful alternative for preventing zinc deficiency and treating diarrhea. The more insoluble zinc oxide is less well absorbed when given as a supplement without food and may be minimally absorbed by some individuals. This trial was registered at clinicaltrials.gov as NCT01576627.
C1 [Wegmueller, Rita; Zeder, Christophe; Brnic, Marica; Hurrell, Richard F.] Swiss Fed Inst Technol, Inst Food Nutr & Hlth, Human Nutr Lab, Zurich, Switzerland.
   [Tay, Fabian] Univ Zurich Hosp, Clin Res Ctr, Clin Trials Ctr, CH-8091 Zurich, Switzerland.
RP Wegmuller, R (reprint author), MRC Unit Gambia, MRC Keneba, MRC Int Nutr Grp, Banjul, Gambia.
EM rwegmuller@mrc.gm
OI Zeder, Christophe/0000-0001-6675-3708
FU Jungbunzlauer International, Basel, Switzerland
FX Supported by Jungbunzlauer International, Basel, Switzerland. This is a
   free access article, distributed under terms
   (http://www.nutrition.org/publications/guidelines-and-policies/license/)
   that permit unrestricted noncommercial use, distribution, and
   reproduction in any medium, provided the original work is properly
   cited.
CR Bertinato J, 2012, J TRACE ELEM MED BIO, V26, P227, DOI 10.1016/j.jtemb.2012.04.008
   Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516
   Biasucci LM, 2004, CIRCULATION, V110, pE560, DOI 10.1161/01.CIR.0000148983.88334.80
   Brown K.H., 2004, FOOD NUTR BULL, V25, pS99
   de Romana DL, 2005, AM J CLIN NUTR, V81, P637
   FRIEL JK, 1992, AM J CLIN NUTR, V55, P473
   Gibson RS, 2008, BRIT J NUTR, V99, pS14, DOI 10.1017/S0007114508006818
   Guillem A, 2000, BIOL TRACE ELEM RES, V75, P11, DOI 10.1385/BTER:75:1-3:11
   Haider BA, 2009, FOOD NUTR BULL, V30, pS41
   HENDERSON LM, 1995, JPEN-PARENTER ENTER, V19, P393, DOI 10.1177/0148607195019005393
   Herman S, 2002, AM J CLIN NUTR, V76, P813
   Heuberger F, 2003, EUR J GASTROEN HEPAT, V15, P179, DOI 10.1097/00042737-200302000-00012
   Hotz C, 2005, J NUTR, V135, P1102
   Lowe NM, 2000, AM J CLIN NUTR, V71, P523
   Mishaan AMA, 2004, J PEDIATR-US, V145, P26, DOI 10.1016/j.jpeds.2004.02.031
   Morihara M, 2001, BIOL PHARM BULL, V24, P313, DOI 10.1248/bpb.24.313
   Pinna K, 2001, J NUTR, V131, P2288
   Sarker SA, 2004, AM J CLIN NUTR, V80, P149
   SERFATYLACROSNIERE C, 1995, J AM COLL NUTR, V14, P364
   Shames DM, 2001, J NUTR, V131, P1854
   Siepmann M, 2005, INT J CLIN PHARM TH, V43, P562
   Sparacino G, 2002, AM J PHYSIOL-ENDOC M, V282, pE679
   Tran CD, 2004, AM J CLIN NUTR, V80, P1570
   Vitale G, 2011, Minerva Gastroenterol Dietol, V57, P369
   WHO, 2005, DIARRH TREATM GUID C
   WHO, 2002, WORLD HLTH REP 2002
   World Health Organization, 2006, IMPL NEW REC CLIN MA
   WOLFE SA, 1994, J AM COLL NUTR, V13, P154
   Yang LC, 2005, J TRACE ELEM MED BIO, V19, P159, DOI 10.1016/j.jtemb.2005.09.001
NR 29
TC 12
Z9 12
U1 1
U2 17
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD FEB
PY 2014
VL 144
IS 2
BP 132
EP 136
DI 10.3945/jn.113.181487
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 294XF
UT WOS:000330080500004
PM 24259556
OA No
DA 2017-08-15
ER

PT J
AU Hart, JD
   Edwards, T
   Burr, SE
   Harding-Esch, EM
   Takaoka, K
   Holland, MJ
   Sillah, A
   Mabey, DCW
   Bailey, RL
AF Hart, John D.
   Edwards, Tansy
   Burr, Sarah E.
   Harding-Esch, Emma M.
   Takaoka, Kensuke
   Holland, Martin J.
   Sillah, Ansumana
   Mabey, David C. W.
   Bailey, Robin L.
TI Effect of azithromycin mass drug administration for trachoma on spleen
   rates in Gambian children
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE malaria; spleen; splenomegaly; azithromycin; mortality
ID RANDOMIZED-TRIAL; MALARIA; INDEXES; PRET
AB ObjectiveTo assess the effect of azithromycin mass drug administration regimens on spleen rates in children aged 0-5years.
   MethodsClinical assessment of spleen size was carried out during a cluster-randomised trial of azithromycin mass treatment for trachoma elimination in The Gambia. Twenty-four communities received three annual mass treatments with azithromycin, and 24 communities received treatment at baseline only.
   ResultsAt the 30-month follow-up, 3646 children aged 0-5years had spleen examination and measurement. Palpable splenomegaly was significantly lower in annually treated vs. baseline-only treatment communities and in treated vs. untreated children at 24months in the annual treatment arm.
   ConclusionThe results suggest an effect of azithromycin on spleen rates at the individual level and are most plausibly due to the antimalarial effects of azithromycin.
   ObjectifEvaluer l'effet de l'administration en masse d'azithromycine sur les parametres de la rate chez les enfants ages de 0 a 5 ans.
   MethodesL'evaluation clinique de la taille de la rate a ete realisee au cours d'un essai randomise par grappes de traitement de masse de l'azithromycine pour l'elimination du trachome en Gambie. Vingt-quatre collectivites ont recu trois traitements de masse annuels a l'azithromycine et 24 collectivites ont recu un traitement a la base uniquement.
   ResultatsA 30 mois de suivi, 3646 enfants ages de 0 a 5 ans ont recu un examen et une mesure de la rate. Une splenomegalie palpable etait significativement moins courante dans les collectivites traitees annuellement que dans celles traitees au depart seulement et chez les enfants traites par rapport a ceux non traites a 24 mois dans le groupe traite annuellement.
   ConclusionLes resultats suggerent un effet de l'azithromycine sur les parametres de la rate a l'echelle individuelle et est plus plausiblement du aux effets antipaludiques de l'azithromycine.
   ObjetivoEvaluar el efecto de la administracion masiva de azitromicina sobre la tasa de esplenomegalia en ninos con edades entre 0-5 anos.
   MetodosSe realizo la evaluacion clinica del tamano del bazo durante un ensayo aleatorizado en conglomerados sobre el tratamiento masivo con azitromicina para la eliminacion del tracoma en Gambia. Veinticuatro comunidades recibieron tres tratamientos anuales masivos con azitromicina y 24 comunidades recibieron solamente tratamiento al inicio del estudio.
   ResultadosDurante el seguimiento a los 30 meses, a 3646 ninos con edades entre los 0-5 anos se les habia realizado el examen y se tenia la medida de su bazo. Una esplenomegalia palpable era significativamente menor en comunidades tratadas anualmente vs. las comunidades tratadas solo al comienzo del estudio, y en ninos tratados vs. ninos sin tratar a los 24 meses, dentro del brazo de tratamiento anual.
   ConclusionEstos resultados sugieren un efecto de la azitromicina sobre las tasas de incidencia de la esplenomegalia a nivel individual y son ademas plausibles debido al efecto antimalarico de la azitromicina.
C1 [Hart, John D.; Burr, Sarah E.; Harding-Esch, Emma M.; Takaoka, Kensuke; Holland, Martin J.; Mabey, David C. W.; Bailey, Robin L.] Univ London London Sch Hyg & Trop Med, Dept Clin Res, London WC1E 7HT, England.
   [Edwards, Tansy] Univ London London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1E 7HT, England.
   [Burr, Sarah E.] MRC Unit, Fajara, Gambia.
   [Harding-Esch, Emma M.] Publ Hlth England, HIV STI Dept, London, England.
   [Sillah, Ansumana] Minist Hlth & Social Welf, Natl Eye Hlth Programme, Kanifing, Gambia.
RP Hart, JD (reprint author), Univ London London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London WC1E 7HT, England.
EM john.hart@doctors.org.uk
OI Mabey, David/0000-0002-0031-8276
FU Bill and Melinda Gates Foundation [NCT00792922]
FX We are grateful to the community leaders and villagers for their
   participation in the study. We also thank Pateh Makalo, Hassan Joof,
   Josephine Hough, Mass Laye, Sarjo Dibba, Muhamed Jallow, Ousman Jallow,
   Omar Manneh and Omar Camara for their work in the field. The PRET trial,
   used as the framework for this study, is registered at
   www.clinicaltrials.gov with identifier NCT00792922 and was supported by
   the Bill and Melinda Gates Foundation.
CR Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Dahl EL, 2007, ANTIMICROB AGENTS CH, V51, P3485, DOI 10.1128/AAC.00527-07
   Hackett LW, 1944, J NAT MAL SOC, V3, P11
   Harding-Esch EM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002115
   Oduro AR, 2011, PLOS ONE, V6
   Porco TC, 2009, JAMA-J AM MED ASSOC, V302, P962, DOI 10.1001/jama.2009.1266
   SADIQ ST, 1995, LANCET, V346, P881, DOI 10.1016/S0140-6736(95)92712-3
   Shimizu S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-73
   Stare D, 2011, OPHTHAL EPIDEMIOL, V18, P20, DOI 10.3109/09286586.2010.545500
   Taylor WRJ, 1999, CLIN INFECT DIS, V28, P74, DOI 10.1086/515071
   Thriemer K, 2010, J INFECT DIS, V202, P392, DOI 10.1086/653710
   Terlouw D. J., 2011, COCHRANE DATABASE SY
   Whitty CJM, 1999, PEDIATR INFECT DIS J, V18, P955, DOI 10.1097/00006454-199911000-00003
   World Health Organisation, 1951, WHO TECHN REP SER, V38, P45
NR 14
TC 0
Z9 0
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD FEB
PY 2014
VL 19
IS 2
BP 207
EP 211
DI 10.1111/tmi.12234
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 291IM
UT WOS:000329822400011
PM 24433194
OA No
DA 2017-08-15
ER

PT J
AU Zhou, Z
   Dionisio, KL
   Verissimo, TG
   Kerr, AS
   Coull, B
   Howie, S
   Arku, RE
   Koutrakis, P
   Spengler, JD
   Fornace, K
   Hughes, AF
   Vallarino, J
   Agyei-Mensah, S
   Ezzati, M
AF Zhou, Zheng
   Dionisio, Kathie L.
   Verissimo, Thiago G.
   Kerr, Americo S.
   Coull, Brent
   Howie, Stephen
   Arku, Raphael E.
   Koutrakis, Petros
   Spengler, John D.
   Fornace, Kimberly
   Hughes, Allison F.
   Vallarino, Jose
   Agyei-Mensah, Samuel
   Ezzati, Majid
TI Chemical Characterization and Source Apportionment of Household Fine
   Particulate Matter in Rural, Peri-urban, and Urban West Africa
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article
ID INDOOR AIR-POLLUTION; POSITIVE MATRIX FACTORIZATION; BIOMASS FUELS;
   PARTICLES; EXPOSURE; ACCRA; CHILDREN; INFANTS; QUALITY; GAMBIA
AB Household air pollution in sub-Saharan Africa and other developing regions is an important cause of disease burden. Little is known about the chemical composition and sources of household air pollution in sub-Saharan Africa, and how they differ between rural and urban homes. We analyzed the chemical composition and sources of fine particles (PM2.5) in household cooking areas of multiple neighborhoods in Accra, Ghana, and in pen-urban (Banjul) and rural (Basse) areas in The Gambia. In Accra, biomass burning accounted for 39-62% of total PM2.5 mass in the cooking area in different neighborhoods; the absolute contributions were 10-45 mu g/m(3). Road dust and vehicle emissions comprised 12-33% of PM2.5 mass. Solid waste burning was also a significant contributor to household PM2.5 in a low-income neighborhood but not for those living in better-off areas. In Banjul and Basse, biomass burning was the single dominant source of cooking-area PM2.5, accounting for 74-87% of its total mass; the relative and absolute contributions of biomass smoke to PM2.5 mass were larger in households that used firewood than in those using charcoal, reaching as high as 463 mu g/m(3) in Basse homes that used firewood for cooking. Our findings demonstrate the need for policies that enhance access to cleaner fuels in both rural and urban areas, and for controlling traffic emissions in cities in sub-Saharan Africa.
C1 [Zhou, Zheng; Dionisio, Kathie L.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
   [Zhou, Zheng; Dionisio, Kathie L.; Coull, Brent; Arku, Raphael E.; Koutrakis, Petros; Spengler, John D.; Vallarino, Jose] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
   [Verissimo, Thiago G.; Kerr, Americo S.] Univ Sao Paulo, Inst Phys, Sao Paulo, Brazil.
   [Coull, Brent] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Howie, Stephen; Fornace, Kimberly] MRC Unit, Fajara, Gambia.
   [Fornace, Kimberly] Royal Vet Coll, Vet Epidemiol & Publ Hlth Grp, London, England.
   [Hughes, Allison F.] Univ Ghana, Dept Phys, Legon, Ghana.
   [Agyei-Mensah, Samuel] Univ Ghana, Dept Geog & Resource Dev, Legon, Ghana.
   [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, Med Res Council,Publ Hlth England Ctr Environm &, London, England.
RP Ezzati, M (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, Med Res Council,Publ Hlth England Ctr Environm &, London, England.
EM majid.ezzati@imperial.ac.uk
RI Institute of Physics, USP/H-5191-2017
OI Fornace, Kimberly/0000-0002-5484-241X
FU National Science Foundation [0527536]; National Institute of
   Environmental Health Sciences [1R21ES017855-01]; UK MRC
FX This work was supported by grants from the National Science Foundation
   (0527536) and the National Institute of Environmental Health Sciences
   (1R21ES017855-01). We thank the households who participated in the study
   for their help and hospitality, our field workers and field supervisors
   for valuable assistance in data collection, the Legal Resources Center
   and the Department of Geography and Resource Development at the
   University of Ghana for valuable help with logistical arrangements, and
   the Biomedical Engineering Department at the MRC Laboratories for
   technical assistance. Majid Ezzati is supported by a UK MRC Strategic
   Award. This research was approved by the Institutional Review Boards of
   the Harvard School of Public Health, Noguchi Memorial Institute for
   Medical Research at the University of Ghana, and The Gambia
   Government-MRC Joint Ethics Committee.
CR Adonis M, 2001, INDOOR BUILT ENVIRON, V10, P138, DOI 10.1159/000049228
   Amato F, 2009, ATMOS ENVIRON, V43, P1650, DOI 10.1016/j.atmosenv.2008.12.009
   Bailis R, 2005, SCIENCE, V308, P98, DOI 10.1126/science.1106881
   Begum BA, 2009, BUILD ENVIRON, V44, P898, DOI 10.1016/j.buildenv.2008.06.005
   Bell ML, 2009, AM J RESP CRIT CARE, V179, P1115, DOI 10.1164/rccm.200808-1240OC
   Bell M. L., 2012, RES REP HLTH EFF I, V161, P5
   Bonjour S, 2013, ENVIRON HEALTH PERSP, V121, P784, DOI 10.1289/ehp.1205987
   Dasgupta S, 2006, INDOOR AIR, V16, P426, DOI 10.1111/j.1600-0668.2006.00436.x
   Dionisio KL, 2008, INDOOR AIR, V18, P317, DOI 10.1111/j.1600-0668.2008.00533.x
   Dionisio KL, 2012, ENVIRON SCI TECHNOL, V46, P3519, DOI 10.1021/es203047e
   Dionisio KL, 2012, J EXPO SCI ENV EPID, V22, P173, DOI 10.1038/jes.2011.47
   Dionisio KL, 2010, ENVIRON SCI TECHNOL, V44, P2270, DOI 10.1021/es903276s
   Duda RB, 2007, INT J CARDIOL, V117, P115, DOI 10.1016/j.ijcard.2006.05.004
   Echeverry J. C., 2005, ECONOMIA, V5, P151, DOI 10.1353/eco.2005.0014
   Ghana Statistical Service (GSS), 2012, 2010 POP HOUS CENS S
   Gunawardana C, 2012, CHEMOSPHERE, V87, P163, DOI 10.1016/j.chemosphere.2011.12.012
   Heltberg R., 2003, HOUSEHOLD FUEL ENERG
   Johansen JM, 2011, ENERG FUEL, V25, P4961, DOI 10.1021/ef201098n
   Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052
   Larson T, 2004, J AIR WASTE MANAGE, V54, P1175
   Li J, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002310
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   MARPLE VA, 1976, ATMOS ENVIRON, V10, P891, DOI 10.1016/0004-6981(76)90144-X
   MARPLE VA, 1987, JAPCA J AIR WASTE MA, V37, P1303
   Massey D, 2009, BUILD ENVIRON, V44, P2037, DOI 10.1016/j.buildenv.2009.02.010
   MCINNES LM, 1994, J GEOPHYS RES-ATMOS, V99, P8257, DOI 10.1029/93JD03453
   MIGUEL AH, 1995, ENVIRON SCI TECHNOL, V29, P338, DOI 10.1021/es00002a009
   PAATERO P, 1994, ENVIRONMETRICS, V5, P111, DOI 10.1002/env.3170050203
   Pervez S, 2012, AEROSOL AIR QUAL RES, V12, P49, DOI 10.4209/aaqr.2011.08.0124
   Reid JS, 2005, ATMOS CHEM PHYS, V5, P799
   Saksena S, 2003, J EXPO ANAL ENV EPID, V13, P219, DOI 10.1038/sj.jea.7500273
   SCHOONOVER RM, 1981, ANAL CHEM, V53, P900, DOI 10.1021/ac00229a036
   Taneja A, 2008, ANN NY ACAD SCI, V1140, P228, DOI 10.1196/annals.1454.033
   Turn SQ, 1997, J GEOPHYS RES-ATMOS, V102, P3683, DOI 10.1029/96JD02979
   Vehlow J, 2003, ENVIRON SCI POLLUT R, V10, P329, DOI 10.1065/espr2003.02.147
   World Health Organization (WHO), 2011, WHOPEP923A
   Yli-Tuomi T, 2008, ENVIRON SCI TECHNOL, V42, P4440, DOI 10.1021/es0716655
   Zanobetti A, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-58
   Zhou Z, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/4/044025
   Zhou Z, 2011, P NATL ACAD SCI USA, V108, P11028, DOI 10.1073/pnas.1019183108
NR 40
TC 11
Z9 11
U1 4
U2 63
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
EI 1520-5851
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD JAN 21
PY 2014
VL 48
IS 2
BP 1343
EP 1351
DI 10.1021/es404185m
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 296SF
UT WOS:000330205000061
PM 24351083
OA No
DA 2017-08-15
ER

PT J
AU Usuf, E
   Bottomley, C
   Adegbola, RA
   Hall, A
AF Usuf, Effua
   Bottomley, Christian
   Adegbola, Richard A.
   Hall, Andrew
TI Pneumococcal Carriage in Sub-Saharan Africa-A Systematic Review
SO PLOS ONE
LA English
DT Review
ID 1ST 24 MONTHS; STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE;
   CONJUGATE VACCINE; HAEMOPHILUS-INFLUENZAE; CHANGING EPIDEMIOLOGY;
   SEROTYPE DISTRIBUTION; INVASIVE-DISEASE; GAMBIAN INFANTS; UNITED-STATES
AB Background: Pneumococcal epidemiology varies geographically and few data are available from the African continent. We assess pneumococcal carriage from studies conducted in sub-Saharan Africa (sSA) before and after the pneumococcal conjugate vaccine (PCV) era.
   Methods: A search for pneumococcal carriage studies published before 2012 was conducted to describe carriage in sSA. The review also describes pneumococcal serotypes and assesses the impact of vaccination on carriage in this region.
   Results: Fifty-seven studies were included in this review with the majority (40.3%) from South Africa. There was considerable variability in the prevalence of carriage between studies (I-squared statistic = 99%). Carriage was higher in children and decreased with increasing age, 63.2% (95% CI: 55.6-70.8) in children less than 5 years, 42.6% (95% CI: 29.9-55.4) in children 5-15 years and 28.0% (95% CI: 19.0-37.0) in adults older than 15 years. There was no difference in the prevalence of carriage between males and females in 9/11 studies. Serotypes 19F, 6B, 6A, 14 and 23F were the five most common isolates. A meta-analysis of four randomized trials of PCV vaccination in children aged 9-24 months showed that carriage of vaccine type (VT) serotypes decreased with PCV vaccination; however, overall carriage remained the same because of a concomitant increase in non-vaccine type (NVT) serotypes.
   Conclusion: Pneumococcal carriage is generally high in the African continent, particularly in young children. The five most common serotypes in sSA are among the top seven serotypes that cause invasive pneumococcal disease in children globally. These serotypes are covered by the two PCVs recommended for routine childhood immunization by the WHO. The distribution of serotypes found in the nasopharynx is altered by PCV vaccination.
C1 [Usuf, Effua] MRC, Gambia Unit, Fajara, Gambia.
   [Bottomley, Christian] Univ London London Sch Hyg & Trop Med, Trop Epidemiol Grp, London WC1E 7HT, England.
   [Adegbola, Richard A.] GlaxoSmithKline Vaccines, Wavre, Belgium.
   [Hall, Andrew] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Publ Hlth, London WC1E 7HT, England.
RP Usuf, E (reprint author), MRC, Gambia Unit, Fajara, Gambia.
EM effuau@gmail.com
FU Medical Research Council
FX This work was supported by a Medical Research Council PhD studentship
   awarded to EU. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abdullahi O, 2007, VALIDATION NASOPHARY
   Abdullahi O, 2008, PEDIATR INFECT DIS J, V27, P59, DOI 10.1097/INF.0b013e31814da70c
   Adegbola RA, 2001, EVALUATION BINAX NOW
   Antonio M, 2008, BMC MICROBIOLOGY, V8
   Batt SL, 2003, IMPACT AZITHROMYCIN
   Bere Leonard C, 2009, Pak J Biol Sci, V12, P1282, DOI 10.3923/pjbs.2009.1282.1286
   Blossom DB, 2006, OROPHARYNGEAL COLONI
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   CAPEDING MRZ, 1995, J CLIN MICROBIOL, V33, P3077
   Cheung YB, 2009, PEDIAT INFECT DIS J
   Cotton MF, 2008, HIGH INCIDENCE ANTIM
   Dagan R, 2000, CLIN INFECT DIS, V30, P319, DOI 10.1086/313645
   Darboe MK, 2007, EFFECTIVENESS EARLY
   Darboe MK, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-195
   Denno DM, 2002, NASOPHARYNGEAL CARRI
   Donkor ES, 2010, SCAND J INFECT DIS, V42, P254, DOI 10.3109/00365540903490000
   Faden H, 1997, J INFECT DIS, V175, P1440
   Feikin DR, 2003, ANTIBIOTIC RESISTANC
   Feikin DR, 2000, INCREASED CARRIAGE T
   Fenoll A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-239
   Frederiksen B, 1988, THROAT CARRIAGE STRE
   Gordon SB, 2003, POOR POTENTIAL COVER
   GRAY BM, 1980, J INFECT DIS, V142, P923
   GRAY BM, 1982, AM J EPIDEMIOL, V116, P692
   Guevara M, 2009, CLIN MICROBIOL INFEC, V15, P1013, DOI 10.1111/j.1469-0691.2009.02904.x
   Hansman D, 1978, LANCET, V1102
   Haug S, 2010, CLIN INFECT DIS, V51, P571, DOI 10.1086/655697
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Hill PC, 2010, CLIN INFECT DIS, V50, P1468, DOI 10.1086/652443
   Ho PL, 2011, VACCINE, V29, P3270, DOI 10.1016/j.vaccine.2011.02.025
   Huang SS, 2004, AM J EPIDEMIOL, V159, P645, DOI 10.1093/aje/kwh088
   Huebner RE, 2000, S AFR MED J, V90, P1116
   Huebner RE, 1998, NASOPHARYNGEAL CARRI
   Jacobs MR, 1978, EMERGENCE MULTIPLY R
   Johnson H.L., 2010, PLOS MED, V7
   Joloba ML, 2001, HIGH PREVALENCE CARR
   Kacou-N'douba A, 2010, INDIAN J MED MICROBI, V28, P80, DOI 10.4103/0255-0857.58742
   Kacou-N'Douba A, 2001, ANTIMICROBIAL RESIST
   Kandakai-Olukemi Y T, 2009, Ann Afr Med, V8, P10
   Kaplan SL, 2004, PEDIATRICS, V113, P443, DOI 10.1542/peds.113.3.443
   Kellner JD, 2009, CLIN INFECT DIS, V49, P205, DOI 10.1086/599827
   Klugman KP, 1998, AM J DIS CHILD, V140, P1186
   Levy C, 2011, PEDIATR INFECT DIS J, V30, P168, DOI 10.1097/INF.0b013e3181f4cf69
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Mackenzie GA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-304
   Marcus L, 1996, S AFR MED J, V86, P1132
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   McNally LM, 2006, J INFECT DIS, V194, P385, DOI 10.1086/505076
   Millar EV, 2009, PEDIATR INFECT DIS J, V28, P711, DOI 10.1097/INF.0b013e3181a06303
   Mthwalo M, 1998, ANTIBIOTIC RESISTANC
   Mureithi MW, 2009, J INFECT DIS, V200, P783, DOI 10.1086/605023
   Mwenya DM, 2010, ANTIMICROB AGENTS CH, V54, P3756, DOI 10.1128/AAC.01409-09
   Ndip RN, 2008, ANTIMICROBIAL RESIST
   Nwachukwu NOA, 2008, MERA AFRICAN J RESP, V16
   Nyandiko WM, 2007, NASOPHARYNGEAL STREP
   O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833
   O'Brien Katherine L, 2003, Pediatr Infect Dis J, V22, pe1, DOI 10.1097/01.inf.0000049347.42983.77
   Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   Oppenheim B, 1986, ANTIBIOTIC RESISTANT
   Ota MO, 2011, VACCINE, V29, P2999, DOI 10.1016/j.vaccine.2011.01.098
   Pemba L, 2008, IMPACT COTRIMOXAZOLE
   Publication WHO, 2012, VACCINE, V30, P4717
   Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632
   Ringertz S, 1993, PREVALENCE POTENTIAL
   Rinta-Kokko H, 2009, VACCINE, V27, P3831, DOI 10.1016/j.vaccine.2009.04.009
   Robins-Browne RM, 1984, ANTIBIOTIC RESISTANT
   Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Roche PW, 2008, COMMUN DIS INTELL, V32, P18
   Rowe AK, 2000, ANTIMICROBIAL RESIST
   Rusen ID, 1997, NASOPHARYNGEAL PNEUM
   Scott JAG, 2011, CLIN INFECT DIS, V53, P663, DOI 10.1093/cid/cir444
   Scott JAG, 1998, CLIN INFECT DIS, V27, P1442, DOI 10.1086/515013
   Scott JR, 2012, J INFECT DIS, V205, P280, DOI 10.1093/infdis/jir730
   Skalet AH, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000377
   Smith-Vaughan H, 2009, CLIN VACCINE IMMUNOL, V16, P218, DOI 10.1128/CVI.00283-08
   Syrjanen RK, 2001, J INFECT DIS, V184, P451, DOI 10.1086/322048
   Trotter CL, 2010, J INFECTION, V60, P200, DOI 10.1016/j.jinf.2009.12.008
   Valles X, 2006, TROP MED INT HEALTH, V11, P358, DOI 10.1111/j.1365-3156.2006.01565.x
   Varon E, 2000, CLIN INFECT DIS, V31, P477, DOI 10.1086/313981
   von Gottberg A, 2008, EMERGENCE LEVOFLOXAC
   Vu Huong Thi Thu, 2011, Pediatr Infect Dis J, V30, P11, DOI 10.1097/INF.0b013e3181f111a2
   Williams SR, 2011, MED J AUSTRALIA, V194, P116
   Woolfson A, 1997, NASOPHARYNGEAL CARRI
   Yang S, 2005, J CLIN MICROBIOL, V43, P3221, DOI 10.1128/JCM.43.7.3221-3226.2005
   Yomo A, 1997, CARRIAGE PENICILLIN
NR 89
TC 12
Z9 12
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 20
PY 2014
VL 9
IS 1
AR e85001
DI 10.1371/journal.pone.0085001
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 297FH
UT WOS:000330240500028
PM 24465464
OA gold
DA 2017-08-15
ER

PT J
AU Klaasen, M
   Roest, HJ
   van der Hoek, W
   Goossens, B
   Secka, A
   Stegeman, A
AF Klaasen, Marieke
   Roest, Hendrik-Jan
   van der Hoek, Wim
   Goossens, Bart
   Secka, Arss
   Stegeman, Arjan
TI Coxiella burnetii Seroprevalence in Small Ruminants in The Gambia
SO PLOS ONE
LA English
DT Article
ID HOSPITALIZED FEBRILE PATIENTS; Q-FEVER; DOMESTIC RUMINANTS; NORTHERN
   TANZANIA; GOATS; NETHERLANDS; PREVALENCE; ANTIBODIES; DIAGNOSIS;
   CHILDREN
AB Background: Q fever is a zoonosis caused by Coxiella burnetii, a Gram negative bacterium present worldwide. Small ruminants are considered the main reservoirs for infection of humans. This study aimed to estimate the extent of C. burnetii infection among sheep and goats in part of The Gambia.
   Methodology/Principal Findings: This survey was carried out from March to May 2012 at two areas in The Gambia. The first area comprised a cluster of seven rural villages situated 5-15 km west of Farafenni as well as the local abattoir. A second sampling was done at the central abattoir in Abuko (30 km from the capital, Banjul) in the Western Region. Serum samples were obtained from 490 goats and 398 sheep. In addition, 67 milk samples were obtained from lactating dams. Sera were tested with a Q fever ELISA kit. C. burnetii DNA was extracted from milk samples and then detected using a specific quantitative multiplex PCR assay, targeting the IS1111a element. A multivariable mixed logistic regression model was used to examine the relationship between seropositivity and explanatory variables. An overall seroprevalence of 21.6% was found. Goats had a significantly higher seroprevalence than sheep, respectively 24.2% and 18.5%. Seropositive animals were significantly older than seronegative animals. Animals from the villages had a significantly lower seroprevalence than animals from the central abattoir (15.1% versus 29.1%). C. burnetii DNA was detected in 2 out of 67 milk samples, whereas 8 samples gave a doubtful result.
   Conclusion/Significance: A substantial C. burnetii seroprevalence in sheep and goats in The Gambia was demonstrated. People living in close proximity to small ruminants are exposed to C. burnetii. Q fever should be considered as a possible cause of acute febrile illness in humans in The Gambia. Future studies should include a simultaneous assessment of veterinary and human serology, and include aetiology of febrile illness in local clinics.
C1 [Klaasen, Marieke; Stegeman, Arjan] Univ Utrecht, Fac Vet Med, Dept Farm Anim Hlth, Utrecht, Netherlands.
   [Roest, Hendrik-Jan] Cent Vet Inst, Dept Bacteriol & TSEs, Lelystad, Netherlands.
   [van der Hoek, Wim] Natl Inst Publ Hlth & Environm, Epidemiol & Surveillance Unit, NL-3720 BA Bilthoven, Netherlands.
   [Goossens, Bart] SOS Childrens Villages Int, Bakau, Gambia.
   [Secka, Arss] Int Trypanotolerance Ctr, Banjul, Gambia.
RP Stegeman, A (reprint author), Univ Utrecht, Fac Vet Med, Dept Farm Anim Hlth, Utrecht, Netherlands.
EM J.A.Stegeman@uu.nl
FU Dutch Ministry of Economic Affairs
FX This project was funded by a grant of the Dutch Ministry of Economic
   Affairs. The funder had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR AITKEN ID, 1987, INFECTION, V15, P323, DOI 10.1007/BF01647731
   Bates D., 2011, LME4 LINEAR MIXED EF
   Biggs HM, 2011, AM J TROP MED HYG, V85, P275, DOI 10.4269/ajtmh.2011.11-0176
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Devendra C., 2005, Livestock and wealth creation: improving the husbandry of animals kept by resource-poor people in developing countries, P29
   Dohoo I, 2009, VET EPIDEMIOLOGIC RE, P580
   DUPONT HT, 1995, CLIN INFECT DIS, V21, P1126, DOI 10.1093/clinids/21.5.1126
   Geerts S, 2008, TRENDS PARASITOL, V25, P132
   Georgiev M, 2013, EURO SURVEILL, V18
   Gething PW, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000301
   Goossens B, 1998, VET REC, V142, P277
   Guatteo R, 2011, VET MICROBIOL, V149, P1, DOI 10.1016/j.vetmic.2010.10.007
   Horigan MW, 2011, J VET DIAGN INVEST, V23, P924, DOI 10.1177/1040638711416971
   Kampschreur LM, 2012, EMERG INFECT DIS, V18, P563, DOI 10.3201/eid1804.111478
   KELLY PJ, 1993, S AFR MED J, V83, P21
   Kobbe R, 2008, EMERG INFECT DIS, V14, P344, DOI 10.3201/eid1402.070971
   Maichomo M W, 2000, Afr J Health Sci, V7, P114
   Maurin M, 1999, CLIN MICROBIOL REV, V12, P518
   McQuiston JH, 2002, J AM VET MED ASSOC, V221, P796, DOI 10.2460/javma.2002.221.796
   Mediannikov O, 2010, PLOS NEGLECT TROP D, V4, P654, DOI DOI 10.1371/J0URNAL.PNTD.0000654
   Ndip LM, 2004, EMERG INFECT DIS, V10, P432
   Osaer S, 1999, VET PARASITOL, V82, P101, DOI 10.1016/S0304-4017(99)00011-4
   Osaer S, 1999, THESIS UTRECHT U UTR, P300
   Prabhu M, 2011, CLIN INFECT DIS, V53, pe8, DOI 10.1093/cid/cir411
   R Development Core Team, 2011, R LANG ENV STAT COMP
   Raoult D, 2005, LANCET INFECT DIS, V5, P219, DOI 10.1016/S1473-3099(05)70052-9
   Reyburn H, 2007, BRIT MED J, V334, P403, DOI 10.1136/bmj.39073.496829.AE
   Rodrigues A, 2008, TROP MED INT HEALTH, V13, P410, DOI 10.1111/j.1365-3156.2008.02016.x
   Roest HIJ, 2011, EMERG INFECT DIS, V17, P668, DOI 10.3201/eid1704.101562
   Roest HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048949
   Ruiz-Fons F, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-3
   Ryan E, 2011, VET REC, V169, p280B, DOI 10.1136/vr.d5208
   Schelling E, 2003, PREV VET MED, V61, P279, DOI 10.1016/j.prevetmed.2003.08.004
   Thrusfield M, 2001, VET REC, V148, P567
   Vaidya VM, 2010, COMP IMMUNOL MICROB, V33, P307, DOI 10.1016/j.cimid.2008.10.006
   van der Hoek W, 2013, TROP MED INT HEALTH, V18, P850, DOI 10.1111/tmi.12116
   van der Hoek W, 2011, INT J ENVIRON HEAL R, V21, P441, DOI 10.1080/09603123.2011.574270
NR 37
TC 11
Z9 11
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 15
PY 2014
VL 9
IS 1
AR e85424
DI 10.1371/journal.pone.0085424
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 297DH
UT WOS:000330235100082
PM 24454863
OA gold
DA 2017-08-15
ER

PT J
AU Carpenter, D
   Taype, C
   Goulding, J
   Levin, M
   Eley, B
   Anderson, S
   Shaw, MA
   Armour, JAL
AF Carpenter, Danielle
   Taype, Carmen
   Goulding, Jon
   Levin, Mike
   Eley, Brian
   Anderson, Suzanne
   Shaw, Marie-Anne
   Armour, John A. L.
TI CCL3L1 copy number, CCR5 genotype and susceptibility to tuberculosis
SO BMC MEDICAL GENETICS
LA English
DT Article
DE CCL3L1; Mycobacterium tuberculosis; Association; CCR5; MIP-1 alpha
ID MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; DIFFERENT CLINICAL FORMS; HUMAN
   BLOOD MONOCYTES; RECEPTOR 5 GENE; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY
   TUBERCULOSIS; T-CELLS; IMMUNODEFICIENCY-VIRUS; ALVEOLAR MACROPHAGES;
   PERUVIAN POPULATION
AB Background: Tuberculosis is a major infectious disease and functional studies have provided evidence that both the chemokine MIP-1 alpha and its receptor CCR5 play a role in susceptibility to TB. Thus by measuring copy number variation of CCL3L1, one of the genes that encode MIP-1 alpha, and genotyping a functional promoter polymorphism -2459A > G in CCR5 (rs1799987) we investigate the influence of MIP-1 alpha and CCR5, independently and combined, in susceptibility to clinically active TB in three populations, a Peruvian population (n = 1132), a !Xhosa population (n = 605) and a South African Coloured population (n = 221). The three populations include patients with clinically diagnosed pulmonary TB, as well as other, less prevalent forms of extrapulmonary TB.
   Methods and results: Copy number of CCL3L1 was measured using the paralogue ratio test and exhibited ranges between 0-6 copies per diploid genome (pdg) in Peru, between 0-12 pdg in !Xhosa samples and between 0-10 pdg in South African Coloured samples. The CCR5 promoter polymorphism was observed to differ significantly in allele frequency between populations (*A; Peru f = 0.67, !Xhosa f = 0.38, Coloured f = 0.48).
   Conclusions: The case-control association studies performed however find, surprisingly, no evidence for an influence of variation in genes coding for MIP-1 alpha or CCR5 individually or together in susceptibility to clinically active TB in these populations.
C1 [Carpenter, Danielle; Goulding, Jon; Armour, John A. L.] Univ Nottingham, Sch Life Sci, Nottingham NG7 2UH, England.
   [Taype, Carmen; Shaw, Marie-Anne] Univ Leeds, Inst Integrat & Comparat Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England.
   [Levin, Mike; Anderson, Suzanne] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2AZ, England.
   [Eley, Brian] Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, ZA-7925 Cape Town, South Africa.
   [Anderson, Suzanne] MRC Unit, Banjul, Fajara, Gambia.
RP Carpenter, D (reprint author), Univ Nottingham, Sch Life Sci, Nottingham NG7 2UH, England.
EM danielle.carpenter@nottingham.ac.uk
FU Wellcome Trust [083929]; Burroughs Wellcome Grant; Beit Fellowship
FX This work was supported by a Wellcome Trust grant awarded to JALA
   (number 083929) a Burroughs Wellcome Grant awarded to ML and a Beit
   Fellowship awarded to STA.
CR Algood HMS, 2004, J IMMUNOL, V173, P3287
   Algood HMS, 2003, CYTOKINE GROWTH F R, V14, P467, DOI 10.1016/S1359-6101(03)00054-6
   Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Armour JAL, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1089
   BARNES PF, 1993, INFECT IMMUN, V61, P3482
   BERKMAN N, 1995, J IMMUNOL, V155, P4412
   Bhattacharyya S, 2002, J INFECT DIS, V185, P1704, DOI 10.1086/340820
   Blanpain C, 2000, BLOOD, V96, P1638
   Carpenter D, 2012, GENES IMMUN, V13, P374, DOI 10.1038/gene.2012.5
   Carpenter D, 2012, INFECT GENET EVOL, V12, P1147, DOI 10.1016/j.meegid.2012.03.021
   Carpenter D, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-418
   Carrington M, 1997, AM J HUM GENET, V61, P1261, DOI 10.1086/301645
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   Cook DN, 1999, J IMMUNOL, V162, P5423
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Dissanayeke SR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006698
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Gale LM, 1999, BIOESSAYS, V21, P17, DOI 10.1002/(SICI)1521-1878(199901)21:1<17::AID-BIES3>3.0.CO;2-4
   Juffermans NP, 2000, BLOOD, V96, P2649
   Kaufmann SHE, 2002, ANN RHEUM DIS, V61, P54
   Kostrikis LG, 1999, J VIROL, V73, P10264
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Mamtani M, 2011, J INFECT DIS, V203, P1590, DOI 10.1093/infdis/jir145
   Mayanja-Kizza H, 2001, J INFECT DIS, V183, P1805, DOI 10.1086/320725
   McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0
   Menten P, 1999, J CLIN INVEST, V104, pR1, DOI 10.1172/JCI7318
   Mummidi S, 2000, J BIOL CHEM, V275, P18946, DOI 10.1074/jbc.M000169200
   Pokkali S, 2009, HUM IMMUNOL, V70, P110, DOI 10.1016/j.humimm.2008.11.003
   Qiu LY, 2008, J INFECT DIS, V198, P1514, DOI 10.1086/592448
   Quillent C, 1998, LANCET, V351, P14, DOI 10.1016/S0140-6736(97)09185-X
   Rao KR, 2005, J CLIN MICROBIOL, V43, P5978, DOI 10.1128/JCM.43.12.5978-5982.2005
   RHOADES ER, 1995, INFECT IMMUN, V63, P3871
   Sadek MI, 1998, AM J RESP CELL MOL, V19, P513
   Sato N, 1999, J IMMUNOL, V163, P5519
   Saukkonen JJ, 2002, INFECT IMMUN, V70, P1684, DOI 10.1128/IAI.70.4.1684-1693.2002
   Schluger NW, 1997, CURR OPIN IMMUNOL, V9, P504, DOI 10.1016/S0952-7915(97)80102-1
   STANDIFORD TJ, 1993, AM J RESP CELL MOL, V9, P192
   Taype CA, 2006, INFECT GENET EVOL, V6, P361, DOI 10.1016/j.meegid.2006.01.002
   Taype CA, 2010, INFECT GENET EVOL, V10, P495, DOI 10.1016/j.meegid.2010.02.011
   Townson JR, 2002, EUR J IMMUNOL, V32, P3016, DOI 10.1002/1521-4141(2002010)32:10<3016::AID-IMMU3016>3.0.CO;2-D
   Vesosky B, 2010, J LEUKOCYTE BIOL, V87, P1153, DOI 10.1189/jlb.1109742
   Walker S, 2009, GENOMICS, V93, P98, DOI 10.1016/j.ygeno.2008.09.004
   Zhu XW, 2006, CLIN IMMUNOL, V120, P10, DOI 10.1016/j.clim.2006.01.009
NR 43
TC 5
Z9 6
U1 3
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD JAN 9
PY 2014
VL 15
AR 5
DI 10.1186/1471-2350-15-5
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 294TE
UT WOS:000330069200001
PM 24405814
OA gold
DA 2017-08-15
ER

PT J
AU Peto, TJ
   Mendy, ME
   Lowe, Y
   Webb, EL
   Whittle, HC
   Hall, AJ
AF Peto, Thomas J.
   Mendy, Maimuma E.
   Lowe, Yamundow
   Webb, Emily L.
   Whittle, Hilton C.
   Hall, Andrew J.
TI Efficacy and effectiveness of infant vaccination against chronic
   hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in
   the nationwide immunisation program
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; EXPANDED PROGRAM; VIRUS-INFECTION;
   LIVER-CANCER; PROTECTION; CARRIAGE; LONG; ANTIBODIES; AFRICANS; CHILDREN
AB Background: Gambian infants were not routinely vaccinated against hepatitis B virus (HBV) before 1986. During 1986-90 the Gambia Hepatitis Intervention Study (GHIS) allocated 125,000 infants, by area, to vaccination or not and thereafter all infants were offered the vaccine through the nationwide immunisation programme. We report HBV serology from samples of GHIS vaccinees and unvaccinated controls, and from children born later.
   Methods: During 2007-08, 2670 young adults born during the GHIS (1986-90) were recruited from 80 randomly selected villages and four townships. Only 28% (753/2670) could be definitively linked to their infant HBV vaccination records (255 fully vaccinated, 23 partially vaccinated [1-2 doses], 475 not vaccinated). All were tested for current HBV infection (HBV surface antigen [HBsAg]) and, if HBsAg-negative, evidence of past infection (HBV coreprotein antibody [anti-HBc]). HBsAg-positive samples (each with two age-and sex-matched HBsAg-negative samples) underwent liver function tests. In addition, 4613 children born since nationwide vaccination (in 1990-2007) were tested for HBsAg. Statistical analyses ignore clustering.
   Results: Comparing fully vaccinated vs unvaccinated GHIS participants, current HBV infection was 0.8% (2/255) vs 12.4% (59/475), p < 0.0001, suggesting 94% (95% CI 77-99%) vaccine efficacy. Among unvaccinated individuals, the prevalence was higher in males (p = 0.015) and in rural areas (p = 0.009), but adjustment for this did not affect estimated vaccine efficacy. Comparing fully vaccinated vs unvaccinated participants, anti-HBc was 27.4% (70/255) vs 56.0% (267/475), p < 0.00001. Chronic active hepatitis was not common: the proportion of HBsAg-positive subjects with abnormal liver function tests (ALT > 2 ULN) was 4.1%, compared with 0.2% in those HBsAg-negative. The prevalence of antibodies to hepatitis C virus was low (0.5%, 13/2592). In children born after the end of GHIS, HBsAg prevalence has remained low; 1.4% (15/1103) in those born between 1990-97, and 0.3% (9/35150) in those born between 1998-2007.
   Conclusions: Infant HBV vaccination achieves substantial protection against chronic carriage in early adulthood, even though approximately a quarter of vaccinated young adults have been infected. This protection persists past the potential onset of sexual activity, reinforcing previous GHIS findings of protection during childhood and suggesting no need for a booster dose. Nationwide infant HBV vaccination is controlling chronic infection remarkably effectively.
C1 [Peto, Thomas J.; Mendy, Maimuma E.; Whittle, Hilton C.] MRC Labs, Fajara, Gambia.
   [Peto, Thomas J.; Webb, Emily L.; Whittle, Hilton C.; Hall, Andrew J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Peto, Thomas J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok 10400, Thailand.
   [Mendy, Maimuma E.; Hall, Andrew J.] Int Agcy Res Canc, F-69372 Lyon, France.
   [Lowe, Yamundow] Minist Hlth & Social Welf, Banjul, Gambia.
RP Peto, TJ (reprint author), MRC Labs, Fajara, Gambia.
EM tom@tropmedres.ac
OI Webb, Emily/0000-0002-4019-7456
FU UK MRC; IARC
FX UK MRC and IARC sponsored this study.
CR CHOTARD J, 1992, J INFECT DIS, V166, P764
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   HALL A J, 1987, Cancer Research, V47, P5782
   HALL AJ, 1989, LANCET, V1, P1057
   HALL AJ, 1993, BRIT MED J, V307, P276
   International Agency for Research on Cancer, 2012, IARC MON EV CARC R B, V100B, P93
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Lai CL, 2007, J VIRAL HEPATITIS, V14, P6, DOI 10.1046/j.1365-2893.2003.00453.x-i1
   Liaw YF, 2009, LANCET, V373, P582, DOI 10.1016/S0140-6736(09)60207-5
   Madhava V, 2002, LANCET INFECT DIS, V2, P293, DOI 10.1016/S1473-3099(02)00264-5
   Mboto CI, 2005, BRIT J BIOMED SCI, V62, P89
   Merrill RM, 2011, INT J INFECT DIS, V15, pE78, DOI 10.1016/j.ijid.2010.09.005
   Parkin DM, 2008, LANCET ONCOL, V9, P683, DOI 10.1016/S1470-2045(08)70175-X
   Poorolajal J, 2010, VACCINE, V28, P623, DOI 10.1016/j.vaccine.2009.10.068
   Romano L, 2011, DIGEST LIVER DIS, V43, pS2, DOI 10.1016/S1590-8658(10)60685-8
   Sylla BS, 2012, INT J CANCER, V130, P245, DOI 10.1002/ijc.26333
   van der Sande MAB, 2007, VACCINE, V25, P1509, DOI 10.1016/j.vaccine.2006.10.023
   van der Sande MAB, 2006, J INFECT DIS, V193, P1528
   van der Sande MAB, 2007, PLOS ONE, V2, pe753
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Viviani S, 2008, CANCER EPIDEM BIOMAR, V17, P3216, DOI 10.1158/1055-9965.EPI-08-0303
   Wenzel JJ, 2010, LANCET INFECT DIS, V10, P738, DOI 10.1016/S1473-3099(10)70217-6
   Whittle H, 2002, BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   World Health Organization, 2009, WKLY EPIDEMIOL REC, V84, P405
   Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2
   Zanetti AR, 2008, VACCINE, V26, P6266, DOI 10.1016/j.vaccine.2008.09.056
NR 30
TC 27
Z9 29
U1 2
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JAN 7
PY 2014
VL 14
AR 7
DI 10.1186/1471-2334-14-7
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 294NC
UT WOS:000330052400001
PM 24397793
OA gold
DA 2017-08-15
ER

PT J
AU Delgado-Ratto, C
   Soto-Calle, VE
   Van den Eede, P
   Gamboa, D
   Rosas, A
   Abatih, EN
   Ferrucci, HR
   Llanos-Cuentas, A
   Van Geertruyden, JP
   Erhart, A
   D'Alessandro, U
AF Delgado-Ratto, Christopher
   Soto-Calle, Veronica E.
   Van den Eede, Peter
   Gamboa, Dionicia
   Rosas, Angel
   Abatih, Emmanuel N.
   Rodriguez Ferrucci, Hugo
   Llanos-Cuentas, Alejandro
   Van Geertruyden, Jean-Pierre
   Erhart, Annette
   D'Alessandro, Umberto
TI Population structure and spatio-temporal transmission dynamics of
   Plasmodium vivax after radical cure treatment in a rural village of the
   Peruvian Amazon
SO MALARIA JOURNAL
LA English
DT Article
DE Plasmodium vivax; Malaria; Genotyping; Microsatellites; Population
   genetics; Spatio-temporal analysis; Peruvian amazon
ID MICROSATELLITE MARKERS; MALARIA CONTROL; FALCIPARUM; INFECTION;
   ELIMINATION; RESISTANCE; REGION; POLYMORPHISM; CHLOROQUINE; COMPLEXITY
AB Background: Despite the large burden of Plasmodium vivax, little is known about its transmission dynamics. This study explored the population structure and spatio-temporal dynamics of P. vivax recurrent infections after radical cure in a two-year cohort study carried out in a rural community of the Peruvian Amazon.
   Methods: A total of 37 P. vivax participants recruited in San Carlos community (Peru) between April and December 2008 were treated radically with chloroquine and primaquine and followed up monthly for two years with systematic blood sampling. All samples were screened for malaria parasites and subsequently all P. vivax infections genotyped using 15 microsatellites. Parasite population structure and dynamics were determined by computing different genetic indices and using spatio-temporal statistics.
   Results: After radical cure, 76% of the study participants experienced one or more recurrent P. vivax infections, most of them sub-patent and asymptomatic. The parasite population displayed limited genetic diversity (He = 0.49) and clonal structure, with most infections (84%) being monoclonal. Spatio-temporal clusters of specific haplotypes were found throughout the study and persistence of highly frequent haplotypes were observed over several months within the same participants/households.
   Conclusions: In San Carlos community, P. vivax recurrences were commonly observed after radical treatment, and characterized by asymptomatic, sub-patent and clustered infections (within and between individuals from a few neighbouring households). Moreover low genetic diversity as well as parasite inbreeding are likely to define a clonal parasite population which has important implications on the malaria epidemiology of the study area.
C1 [Delgado-Ratto, Christopher; Van Geertruyden, Jean-Pierre] Univ Antwerp, Fac Med, ESOC Dept, Unit Int Hlth, B-2610 Antwerp, Belgium.
   [Delgado-Ratto, Christopher; Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Inst Trop Med Alexander von Humboldt IMTAvH, Unit Mol Epidemiol, Lab Malaria, Lima, Peru.
   [Soto-Calle, Veronica E.; Rosas, Angel; Llanos-Cuentas, Alejandro] Univ Peruana Cayetano Heredia, ITMAvH, GELM, Lima 31, Peru.
   [Van den Eede, Peter; Erhart, Annette] Inst Trop Med, Dept Biomed Sci, Malariol Unit, B-2000 Antwerp, Belgium.
   [Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Dept Ciencias Celulares & Mol, Lima, Peru.
   [Abatih, Emmanuel N.] Inst Trop Med, Unit Vet Biostat & Epidemiol, B-2000 Antwerp, Belgium.
   [Rodriguez Ferrucci, Hugo] Minist Hlth, Loreto, Peru.
   [D'Alessandro, Umberto] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Banjul, Gambia.
RP Delgado-Ratto, C (reprint author), Univ Antwerp, Fac Med, ESOC Dept, Unit Int Hlth, Univ Pl 1, B-2610 Antwerp, Belgium.
EM richardchristopher.delgadoratto@uantwerpen.be
RI Mashamba-Thompson, Tivani /B-6087-2014; Van geertruyden,
   Jean-pierre/K-6425-2014; D'Alessandro, Umberto/D-3457-2015; Rosas
   Aguirre, Angel/A-5054-2016
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364; D'Alessandro,
   Umberto/0000-0001-6341-5009; Rosas Aguirre, Angel/0000-0002-3271-7028;
   Delgado-Ratto, Christopher/0000-0003-2300-5181
FU Belgian Agency Cooperation for Development; Institute of Tropical
   Medicine "Alexander von Humboldt" - Universidad Peruana Cayetano
   Heredia, Lima; Institute of Tropical Medicine in Antwerp, Belgium
   [95503]
FX We thank the San Carlos community and the field workers who participated
   in this study. The work was supported by the Belgian Agency Cooperation
   for Development, within the third framework agreement of the
   Institutional collaboration between the Institute of Tropical Medicine
   "Alexander von Humboldt" - Universidad Peruana Cayetano Heredia, Lima
   and the Institute of Tropical Medicine in Antwerp, Belgium (Project
   95503). CD was supported by a VLIR-UOS (Vlaamse Interuniversitaire Road
   - University Development Cooperation, Belgium) for the data analysis and
   paper writing. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abeles SR, 2013, AM J TROP MED HYG, V88, P1130, DOI 10.4269/ajtmh.12-0752
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   Anderson TJC, 1999, PARASITOLOGY, V119, P113, DOI 10.1017/S0031182099004552
   Arnaud-Haond S, 2007, MOL ECOL NOTES, V7, P3
   Arnott A, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-14
   Baird JK, 2009, CLIN MICROBIOL REV, V22, P508, DOI 10.1128/CMR.00008-09
   Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37
   Branch O, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-27
   Branch OH, 2001, INFECT IMMUN, V69, P7783, DOI 10.1128/IAI.69.12.7783-7792.2001
   Bruce MC, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-38
   Chenet SM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-412
   Chuquiyauri R, 2013, AM J TROP MED HYG, V89, P326, DOI 10.4269/ajtmh.13-0060
   Chuquiyauri R, 2012, ACTA TROP, V121, P292, DOI 10.1016/j.actatropica.2011.11.003
   Clark EH, 2012, INFECT IMMUN, V80, P1583, DOI 10.1128/IAI.05961-11
   da Silva-Nunes M, 2011, ACTA TROP, V121, P281
   Evanno G, 2005, MOL ECOL, V14, P2611, DOI 10.1111/j.1365-294X.2005.02553.x
   Feil EJ, 2004, J BACTERIOL, V186, P1518, DOI 10.1128/JB.186.5.1518-1530.2004
   Ferreira MU, 2007, J INFECT DIS, V195, P1218, DOI 10.1086/512685
   Goudet J, 1995, J HERED, V86, P485
   Grietens KP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050294
   Grietens KP, 2010, AM J TROP MED HYG, V82, P1017, DOI 10.4269/ajtmh.2010.09-0521
   Gunawardena S, 2010, AM J TROP MED HYG, V82, P235, DOI 10.4269/ajtmh.2010.09-0588
   Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437
   Gutierrez S, 2003, MANUAL PROCEDIMIENTO
   Hastings IM, 2000, PARASITOL TODAY, V16, P340, DOI 10.1016/S0169-4758(00)01707-5
   Haubold B, 2000, BIOINFORMATICS, V16, P847, DOI 10.1093/bioinformatics/16.9.847
   Imwong M, 2007, INT J PARASITOL, V37, P1013, DOI 10.1016/j.ijpara.2007.02.010
   Imwong M, 2007, J INFECT DIS, V195, P927, DOI 10.1086/512241
   Karunaweera ND, 2007, MOL ECOL NOTES, V7, P172, DOI 10.1111/j.1471-8286.2006.01534.x
   Karunaweera ND, 2008, GENE, V410, P105, DOI 10.1016/j.gene.2007.11.022
   Kosek M, 2012, AM J TROP MED HYG, V86, P580, DOI 10.4269/ajtmh.2012.11-0627
   Kulldorff M., 1997, COMMUN STAT-THEOR M, V26, P16
   Kulldorff M, 2011, SATSCANTM SOFTWARE S
   Lee G, 2012, INT J EPIDEMIOL, V41, P531, DOI 10.1093/ije/dyr190
   LEVINSON G, 1987, MOL BIOL EVOL, V4, P203
   Markus MB, 2012, TRENDS PARASITOL, V28, P39, DOI 10.1016/j.pt.2011.10.005
   ORAS-CONHU, SIT MAL PER 2009
   Orjuela-Sanchez P, 2009, AM J TROP MED HYG, V81, P961, DOI 10.4269/ajtmh.2009.09-0337
   PLOWE CV, 1995, AM J TROP MED HYG, V52, P565
   Price RN, 2007, AM J TROP MED HYG, V77, P79
   Raymond M, 1995, EVOLUTION, V49, P4
   Restrepo E, 2011, ACTA TROP, V119, P23, DOI 10.1016/j.actatropica.2011.03.012
   Rezende AM, 2009, AM J TROP MED HYG, V80, P729
   Roper MH, 2000, AM J TROP MED HYG, V62, P247
   Roshanravan B, 2003, AM J TROP MED HYG, V69, P45
   Rousset F, 2008, MOL ECOL RESOUR, V8, P103, DOI 10.1111/j.1471-8286.2007.01931.x
   Rubio J M, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS199, DOI 10.1016/S0035-9203(02)90077-5
   Ruebush TK, 2003, AM J TROP MED HYG, V69, P548
   Sutton PL, 2009, AM J TROP MED HYG, V81, P950, DOI 10.4269/ajtmh.2009.09-0132
   Van den Eede P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016257
   Van den Eede P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-151
   Van den Eede P, 2010, AM J TROP MED HYG, V82, P223, DOI 10.4269/ajtmh.2010.09-0458
   Villalobos-Salcedo JM, 2000, ANN TROP MED PARASIT, V94, P749, DOI 10.1080/00034980020027960
   Wykes MN, 2011, P NATL ACAD SCI USA, V108, P11205, DOI 10.1073/pnas.1108579108
NR 54
TC 12
Z9 12
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JAN 6
PY 2014
VL 13
AR 8
DI 10.1186/1475-2875-13-8
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 285IW
UT WOS:000329388400001
PM 24393454
OA gold
DA 2017-08-15
ER

PT J
AU Kwambana, BA
   Ikumapayi, UN
   Sallah, N
   Dione, M
   Jarju, S
   Panchalingham, S
   Jafali, J
   Lamin, M
   Betts, M
   Adeyemi, M
   Akinsola, A
   Bittaye, O
   Jasseh, M
   Kotloff, KL
   Levine, MM
   Nataro, JP
   Corrah, T
   Hossain, J
   Saha, D
   Antonio, M
AF Kwambana, Brenda A.
   Ikumapayi, Usman N.
   Sallah, Neneh
   Dione, Michel
   Jarju, Sheikh
   Panchalingham, Sandra
   Jafali, James
   Lamin, Modou
   Betts, Modupeh
   Adeyemi, Mitchell
   Akinsola, Adebayo
   Bittaye, Ousman
   Jasseh, Momodou
   Kotloff, Karen L.
   Levine, Myron M.
   Nataro, James P.
   Corrah, Tumani
   Hossain, Jahangir
   Saha, Debasish
   Antonio, Martin
TI High Genotypic Diversity among Rotavirus Strains Infecting Gambian
   Children
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
ID GLOBAL ENTERIC MULTICENTER; POLYMERASE-CHAIN-REACTION; VACCINATION
   PROGRAMS; DEVELOPING-COUNTRIES; DIARRHEAL DISEASE; GHANAIAN CHILDREN;
   KENYAN CHILDREN; YOUNG-CHILDREN; AFRICA; BURDEN
AB Background: Rotavirus is the leading cause of diarrhea in children <5 years of age. In light of the implementation of rotavirus vaccines of limited valency, it is important to characterize the genotypic diversity of circulating rotavirus in sub-Saharan Africa.
   Methods: We collected stool samples from children 0-59 months of age who presented at the health centres as cases with moderate-to-severe diarrhea in the Upper River Region of The Gambia. Stool samples were also collected from age, sex and area-matched healthy controls. All stool samples were assayed for rotavirus antigens by enzyme-linked immunosorbent assay and genotyping was done using reverse transcriptase polymerase chain reaction.
   Results: We enrolled 1029 cases and 1569 controls during the 3-year study period (2008-2010). The detection rate of rotavirus among the cases was 20% (204/1029) and 3% (42/1569) among controls. At least 18 genotypes were found and the predominant genotypes were G2P[6] (28%), G1P[8] (26%) and G1P[10] (10%). The rare identified genotypes (<1%) were G2P[14], G8P[6], G9P[6] and G4P[10]. There was also a strong positive association between rotavirus infection and the dry season (odds ratio: 9.83, 95% confidence interval: 6.18-15.63, P < 0.001). A significant increase in the odds of rotavirus and G1P[8] detection with the use of untreated water and the presence of cats, rodents and cows in the child's residence was also found.
   Conclusion: This study provides important baseline data for the genotypes circulating before vaccine implementation. The wide diversity of genotypes circulating in The Gambia implies the need for vigilant effectiveness surveillance following the implementation of RotaTeq in August 2013.
C1 [Kwambana, Brenda A.; Ikumapayi, Usman N.; Sallah, Neneh; Dione, Michel; Jarju, Sheikh; Jafali, James; Lamin, Modou; Betts, Modupeh; Adeyemi, Mitchell; Akinsola, Adebayo; Bittaye, Ousman; Jasseh, Momodou; Corrah, Tumani; Hossain, Jahangir; Saha, Debasish; Antonio, Martin] MRC Unit, Fajara, Gambia.
   [Panchalingham, Sandra; Kotloff, Karen L.; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Nataro, James P.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA.
RP Antonio, M (reprint author), MRC Unit, Vaccinol Theme, Atlantic Rd,POB 273, Banjul, Gambia.
EM mantonio@mrc.gm
FU Bill and Melinda Gates Foundation
FX Many thanks go to the Bill and Melinda Gates Foundation for sponsoring
   the GEMS projects and the Medical Research Council Unit, The Gambia for
   facilitating the study. We acknowledge the immense contributions of
   World Health Organization Regional Office for Africa and the GEMS Core
   team. We would also like to appreciate the field, clinical and
   laboratory teams that worked hard on this project. Finally, we would
   like to thank the study participants and Beate Kampmann for critical
   reading of the manuscript.
CR Akran V, 2010, J INFECT DIS, V202, pS220, DOI 10.1086/653567
   Amarilla A, 2007, MED SCI MONITOR, V13, pCR333
   Aminu M, 2010, J INFECT DIS, V202, pS198, DOI 10.1086/653570
   Armah GE, 2001, J MED VIROL, V63, P67, DOI 10.1002/1096-9071(200101)63:1<67::AID-JMV1010>3.0.CO;2-T
   Armah GE, 2010, J INFECT DIS, V202, pS231, DOI 10.1086/653572
   Armah GE, 2010, J INFECT DIS, V202, pS64, DOI 10.1086/653571
   Audu R, 2002, J HEALTH POPUL NUTR, V20, P59
   Banyai K, 2012, VACCINE, V30, pA122, DOI 10.1016/j.vaccine.2011.09.111
   Binka E, 2011, PEDIATR INFECT DIS J, V30, P716, DOI 10.1097/INF.0b013e318223bd85
   Biswas K, 2012, CLIN INFECT DIS, V55, pS254, DOI 10.1093/cid/cis755
   Carvalho-Costa FA, 2009, EMERG INFECT DIS, V15, P95, DOI 10.3201/eid1501.071136
   Correia JB, 2010, J INFECT DIS, V201, P363, DOI 10.1086/649843
   Cunliffe NA, 1998, B WORLD HEALTH ORGAN, V76, P525
   Cunliffe NA, 1999, J MED VIROL, V57, P308, DOI 10.1002/(SICI)1096-9071(199903)57:3<308::AID-JMV15>3.0.CO;2-B
   Cunliffe NA, 2002, J CLIN MICROBIOL, V40, P1534, DOI 10.1128/JCM.40.4.1534-1537.2002
   Dione MM, 2011, J INFECT DEV COUNTR, V5, P765
   Dulgheroff ACB, 2012, J CLIN VIROL, V55, P67, DOI 10.1016/j.jcv.2012.06.003
   Esona MD, 2010, J INFECT DIS, V202, pS205, DOI 10.1086/653575
   Farag TH, 2012, CLIN INFECT DIS, V55, pS225, DOI 10.1093/cid/cis787
   FLORES J, 1986, J VIROL, V60, P972
   Gentsch JR, 2005, J INFECT DIS, V192, pS146, DOI 10.1086/431499
   GENTSCH JR, 1992, J CLIN MICROBIOL, V30, P1365
   Glass RI, 2006, LANCET, V368, P323, DOI 10.1016/S0140-6736(06)68815-6
   GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276
   Gurgel RQ, 2008, LANCET, V371, P301, DOI 10.1016/S0140-6736(08)60164-6
   Iturriza-Gomara M, 1999, J VIROL METHODS, V78, P93, DOI 10.1016/S0166-0934(98)00168-2
   Kapikian A. Z., 2001, FIELDS VIROLOGY, V2, P1787
   Kirkwood CD, 2010, J INFECT DIS, V202, pS43, DOI 10.1086/653548
   Kiulia NM, 2008, J TROP PEDIATRICS, V54, P401, DOI 10.1093/tropej/fmn052
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Kotloff KL, 2012, CLIN INFECT DIS, V55, pS232, DOI 10.1093/cid/cis753
   Lindsay B, 2013, J CLIN MICROBIOLOGY
   Lindsay B, 2013, J CLIN MICROBIOL, V51, P1740, DOI 10.1128/JCM.02713-12
   Mwenda JM, 2010, J INFECT DIS, V202, pS5, DOI 10.1086/653557
   Nokes DJ, 2010, J INFECT DIS, V202, pS180, DOI 10.1086/653566
   Panchalingam S, 2012, CLIN INFECT DIS, V55, pS294, DOI 10.1093/cid/cis754
   Parashar UD, 2009, J INFECT DIS, V200, pS9, DOI 10.1086/605025
   Patel MM, 2011, PEDIATR INFECT DIS J, V30, pS1, DOI 10.1097/INF.0b013e3181fefa1f
   Potgieter N, 2010, J INFECT DIS, V202, pS148, DOI 10.1086/653561
   Rahman M, 2007, EMERG INFECT DIS, V13, P18
   Sanchez-Padilla E, 2009, LANCET INFECT DIS, V9, P567, DOI 10.1016/S1473-3099(09)70179-3
   Santos N, 2005, REV MED VIROL, V15, P29, DOI 10.1002/rmv.448
   Steele AD, 2003, VACCINE, V21, P361, DOI 10.1016/S0264-410X(02)00616-3
   Tate JE, 2012, LANCET INFECT DIS, V12, P136, DOI 10.1016/S1473-3099(11)70253-5
   Todd S, 2010, J INFECT DIS, V202, pS34, DOI 10.1086/653555
   van Doorn LJ, 2009, J CLIN MICROBIOL, V47, P2704, DOI 10.1128/JCM.00378-09
   World Health Organization, 2007, WKLY EPIDEMIOL REC, V82, P285
NR 47
TC 6
Z9 6
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JAN
PY 2014
VL 33
SU 1
BP S69
EP S75
DI 10.1097/INF.0000000000000087
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA CI2UI
UT WOS:000354602300014
PM 24343618
OA No
DA 2017-08-15
ER

PT S
AU Papademetriou, MD
   Lloyd-Fox, S
   Everdell, NL
   Darboe, MK
   Moore, SE
   Prentice, AM
   Elwell, CE
AF Papademetriou, Marie D.
   Lloyd-Fox, S.
   Everdell, N. L.
   Darboe, M. K.
   Moore, S. E.
   Prentice, A. M.
   Elwell, C. E.
BE Swartz, HM
   Harrison, DK
   Bruley, DF
TI Optical Imaging of Brain Activation in Gambian Infants
SO OXYGEN TRANSPORT TO TISSUE XXXVI
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Proceedings Paper
CT 41st Annual Meeting of the
   International-Society-on-Oxygen-Transport-to-Tissue (ISOTT)
CY JUN 22-26, 2013
CL Dartmouth Coll, Hanover, NH
SP Int Soc Oxygen Transport Tissue, Bruker, Clin EPR LLC, Oxford Univ Press, Dartmouth Hitchcock Norris Cotton Canc Ctr, Dartmouth Hitchcock Dept Med, Radiol & Radiat Oncol, Springer
HO Dartmouth Coll
DE Brain development; Infant undernutrition; Functional near infrared
   spectroscopy
ID CEREBRAL HEMODYNAMICS; SPECIALIZATION; TOPOGRAPHY; VOICE
AB We used optical topography (OT) to investigate cognitive function in infants in rural Gambia. Images of changes in oxyhaemoglobin and deoxyhaemoglobin concentrations were reconstructed using a multispectral algorithm which uses the finite element method (FEM) to model the propagation of light through scattering tissue using the diffusion equation. High quality OT data enabled us to reconstruct images with robust representation of haemodynamic changes. OT is a feasible neuroimage technology for this resource-poor setting.
C1 [Papademetriou, Marie D.; Everdell, N. L.; Elwell, C. E.] UCL, Dept Med Phys & Bioengn, London WC1E 6BT, England.
   [Lloyd-Fox, S.] Univ London, Ctr Brain & Cognit Dev, London, England.
   [Darboe, M. K.; Moore, S. E.; Prentice, A. M.] MRC Keneba, MRC Int Nutr Grp, Keneba, Gambia.
   [Moore, S. E.; Prentice, A. M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
RP Papademetriou, MD (reprint author), UCL, Dept Med Phys & Bioengn, Malet Pl Engn Bldg, London WC1E 6BT, England.
EM m.papademetriou@ucl.ac.uk
FU Grand Challenges Exploration Phase 1 grant from the Bill and Melinda
   Gates Foundation
FX This work is supported by a Grand Challenges Exploration Phase 1 grant
   from the Bill and Melinda Gates Foundation, and hosted by MRC Keneba
   (MC-A760-5QX00). We are grateful to the field workers at MRC Keneba,
   Lamin Sanyang, Saikou Drammeh and Ousman Kambi, for their help with data
   collection.
CR Arridge SR, 2000, INT J IMAG SYST TECH, V11, P2
   Blasi A, 2007, PHYS MED BIOL, V52, P6849, DOI 10.1088/0031-9155/52/23/005
   Blasi A, 2011, CURR BIOL, V21, P1220, DOI 10.1016/j.cub.2011.06.009
   Correia T, 2012, PHYS MED BIOL, V57, P1135, DOI 10.1088/0031-9155/57/5/1135
   Elwell CE, 2011, PHILOS T R SOC A, V369, P4358, DOI 10.1098/rsta.2011.0302
   Everdell NL, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.2038567
   Fang QQ, 2009, 2009 IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: FROM NANO TO MACRO, VOLS 1 AND 2, P1142, DOI 10.1109/ISBI.2009.5193259
   Geoghegan T, 2012, NUTR 1 1000 DAYS STA
   Kolyva C, 2013, ADV EXP MED BIOL, V765, P101, DOI 10.1007/978-1-4614-4989-8_15
   Lloyd-Fox S, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.3026
   Lloyd-Fox S, 2012, SOC NEUROSCI-UK, V7, P317, DOI 10.1080/17470919.2011.614696
   Lloyd-Fox S, 2015, CEREB CORTEX, V25, P289, DOI 10.1093/cercor/bht207
   Papademetriou MD, 2013, ADV EXP MED BIOL, V789, P455, DOI 10.1007/978-1-4614-7411-1_61
NR 13
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
SN 0065-2598
BN 978-1-4939-0620-8; 978-1-4939-0583-6
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2014
VL 812
BP 263
EP 269
DI 10.1007/978-1-4939-0620-8_35
PG 7
WC Medicine, Research & Experimental; Physiology; Respiratory System
SC Research & Experimental Medicine; Physiology; Respiratory System
GA BB6YB
UT WOS:000345121200036
PM 24729242
OA No
DA 2017-08-15
ER

PT J
AU Jammeh, SSS
   Liu, CY
   Cheng, SF
   Lee-Hsieh, J
AF Jammeh, Sulayman S. S.
   Liu, Chieh-Yu
   Cheng, Su-Fen
   Lee-Hsieh, Jane
TI Community based study on married couples' family planning knowledge,
   attitude and practice in rural and urban Gambia
SO AFRICAN HEALTH SCIENCES
LA English
DT Article
DE Family planning; knowledge; attitude; practice; married couples; The
   Gambia
AB Background
   Family planning services have been free of charge and available in all the health facilities in the Gambia since 1975 yet contraceptive prevalence is only 17.5% and even 6% in some areas. Since the last census in 2003, there existed no available data on married couples' contraception status.
   Objectives
   To explore married couples' family planning knowledge, attitudes, and practices in rural and urban Gambia and to analyze what factors may affect such knowledge, attitudes and practices.
   Methods
   Quantitative cross-sectional study design was used. Through convenience sampling, 176 men and 235 women representing a total of 176 couples participated. A structured questionnaire was used for data collection.
   Results
   The mean scores of the married couples family planning knowledge, attitudes, and practices were 19.00 +/- 6.11(ranging from 0 to 64), 6.90 +/- 3.08 (0 to 14) and 4.69 +/- 3.3 (0 to 19) respectively. Urban residents had higher scores on family planning practice than rural residents (p<.05). Attitude is the strongest predictor of practice (accounted for 34.6% of variance).
   Conclusions
   These findings offer a descriptive answer to "what are married couples' family planning knowledge, attitude and practice in Gambia", as well as suggesting broader health intervention programs in health education and promotion.
C1 [Jammeh, Sulayman S. S.] Minist Hlth, Reprod & Child Hlth Program, Banjul, Gambia.
   [Jammeh, Sulayman S. S.; Liu, Chieh-Yu; Cheng, Su-Fen; Lee-Hsieh, Jane] Natl Taipei Univ Nursing & Hlth Sci, Coll Nursing, Taipei, Taiwan.
RP Lee-Hsieh, J (reprint author), 365 Ming Te Rd, Taipei 11219, Taiwan.
EM hsiehjane@ntunhs.edu.tw
CR Beekle AT, 2006, INT NURS REV, V53, P269, DOI 10.1111/j.1466-7657.2006.00492.x
   Cham M, 2009, THESIS U OSLO OSLO
   Cohen J., 1988, STAT POWER ANAL BEHA
   Dieudonne MN, 2009, INT PERSPECTIVES SEX, V35, P122
   Duze Mustapha C, 2006, Afr J Reprod Health, V10, P53
   Gambia Bureau of Statistics (GBOS), 2009, AUTH POP HOUS CENS 2
   Guzman JM, 2009, POPULATION DYNAMICS
   Kabbash I. A., 2007, Eastern Mediterranean Health Journal, V13, P1405
   Kaggwa EB, 2008, INT FAM PLAN PERSPEC, V34, P79, DOI 10.1363/ifpp.34.079.08
   Kimuna SR, 2001, J BIOSOC SCI, V33, P13, DOI 10.1017/S002193200100013X
   Museveni YK, 2009, HIS EXCELLENCY
   Nashid K., 2000, HLTH POLICY PLANNING, V15, P43
   Pranitha M, 2005, WOMEN HLTH, V41, P31
   Ria R, 2009, CONTRACEPTIVE USE PA
   Steve C, 2004, AFRICAN J REPROD HLT, V8, P124
   Wasileh PN, 2002, HEALTH CARE WOMEN IN, V23, P516
   [Anonymous], 2010, GAMBIA MATERNAL NEWB
   [Anonymous], 2010, REPOSITIONING FAMILY
NR 18
TC 3
Z9 3
U1 1
U2 2
PU MAKERERE UNIV, FAC MED
PI KAMPALA
PA PO BOX 7072, KAMPALA, 00000, UGANDA
SN 1680-6905
EI 1729-0503
J9 AFR HEALTH SCI
JI Afr. Health Sci.
PY 2014
VL 14
IS 2
BP 273
EP U21
DI 10.4314/ahs.v14i2.1
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA AS5HL
UT WOS:000344302300002
PM 25320575
OA No
DA 2017-08-15
ER

PT J
AU Sanneh, AFNS
   Al-Shareef, AM
AF Sanneh, A. F. N. S.
   Al-Shareef, A. M.
TI Effectiveness and costeffectiveness of screening immigrants schemes for
   tuberculosis (TB) on arrival from high TB endemic countries to low TB
   prevalent countries
SO AFRICAN HEALTH SCIENCES
LA English
DT Article
ID COST-EFFECTIVENESS; UNITED-STATES; REFUGEES; CANADA
AB Background:
   Immigrants to developed countries are a major source of TB. Therefore amongst strategies adopted for TB control in developed countries include; 1) Screening immigrants at ports of entry referred to as "Port of Arrival Screening" (PoA) and 2) Passive screening (PS) for TB which means screening immigrants through general practices, hospitals, chest-clinics and emergency departments. Evidence of the effectiveness and cost effectiveness of these strategies is not consistent.
   Objective:
   Evaluate efficiency of active PoA TB screening for immigrants from TB endemic-regions compared with Passive Screening of immigrant-populations from TB endemic-regions.
   Methods:
   Major electronic-databases and reference lists of relevant studies were searched. Experts of immigrants' TB screening were contacted for additional studies published or unpublished. Systematic search of major databases identified only retrospective cohort-studies. Their qualities were assessed using Scottish Intercollegiate Guidelines Network (SIGN) methodological checklist for comparative cohort-studies.
   Results:
   Systematic electronic searches identified 1443 citations. Of these 74 studies were retrieved for evaluation against the review's inclusion/exclusion criteria (see study inclusion/exclusion criteria). Four studies met the inclusion criteria (figure 2) which were low in the evidence hierarchy of primary effectiveness studies and had heterogeneities between them. Thus descriptive data-synthesis was performed. Proportionately PoA screening had the lowest percentage of receipt of tuberculin skin test (TST) and the highest percentage of non-attendance for TST reading (table 2). Active PoA screening reduced infectiousness by 34% compared to 30% by passive screening and new entrants screened at PoA were 80% less likely to be hospitalised Odds ratio (OR) = 0.2 (95% confidence interval (CI) 0.1-0.2).
   Economic analysis:
   One cost effectiveness analysis was found that compared the costs of; active PoA screening, general practice screening and homeless screening groups. The cost of detecting a case of TB were; 1.26 pound, 13.17and pound 96.36 pound for PS, homeless screening and active PoA screening respectively. The cost of preventing a case of TB were; 6.32 pound, 23.00 pound and 10.00 pound for PS, homeless screening and PoA screening respectively, showing there is little difference between the different strategies.
   Conclussion:
   Active PoA screening is worth doing with significant benefits including early identification of risk groups with possible timely treatment/chemoprophylaxis intervention, prevention of transmission by significantly reducing infectiousness with subsequent avoidance of hospitalisation in active PoA screening group.
C1 [Sanneh, A. F. N. S.; Al-Shareef, A. M.] Univ Birmingham, Fac Publ Hlth Biostat & Epidemiol, Birmingham B15 2TT, W Midlands, England.
RP Sanneh, AFNS (reprint author), Kombo Cent Western Div, POB 5242, Banjul, Gambia.
CR Barnett DE, 2004, TRAVEL MED, V39, P833
   Binkin NJ, 1996, CLIN INFECT DIS, V23, P1226
   BONVIN L, 1992, TUBERCLE LUNG DIS, V73, P322, DOI 10.1016/0962-8479(92)90034-H
   Bothamley GH, 2002, THORAX, V57, P45, DOI 10.1136/thorax.57.1.45
   California department of health services, 2004, TUB CONTR BRANCH REP
   Callister MEJ, 2002, THORAX, V57, P152, DOI 10.1136/thorax.57.2.152
   Catchpole M., 1995, BMJ-BRIT MED J, V311, P197
   Coker R, 2001, Lancet Infect Dis, V1, P270, DOI 10.1016/S1473-3099(01)00122-0
   Dahle UR, 2003, J CLIN MICROBIOL, V41, P2968, DOI 10.1128/JCM.41.7.2968-2973.2003
   Dasgupta K, 2000, AM J RESP CRIT CARE, V162, P2079
   Dasgupta K, 2005, EUR RESPIR J, V25, P1107, DOI 10.1183/09031936.05.00074004
   DAVIES PDO, 1995, J ROY COLL PHYS LOND, V29, P113
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   ENARSON D, 1979, AM REV RESPIR DIS, V119, P11
   Thomas RE., 1995, CANADIAN J INFECT DI, V6, p246 
   Lavender M, 1997, J PUBLIC HEALTH MED, V19, P320
   MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606
   Menzies D, 2003, CAN MED ASSOC J, V169, P1035
   Menzies D, 2000, INT J TUBERC LUNG D, V4, pS153
   Ormerod LP, 1998, THORAX, V53, P176
   Reider H., 1994, EUR RESPIR J, V7, P1545
   Veen J, 1998, EUR RESPIR J, V12, P505, DOI 10.1183/09031936.98.12020505
   World health organisation, 2005, GLOB TUB FACT SHEET
   [Anonymous], 2000, THORAX, V55, P887
NR 24
TC 1
Z9 1
U1 0
U2 1
PU MAKERERE UNIV, FAC MED
PI KAMPALA
PA PO BOX 7072, KAMPALA, 00000, UGANDA
SN 1680-6905
EI 1729-0503
J9 AFR HEALTH SCI
JI Afr. Health Sci.
PY 2014
VL 14
IS 3
BP 663
EP 671
DI 10.4314/ahs.v14i3.23
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA AS5HM
UT WOS:000344302400024
PM 25352886
OA No
DA 2017-08-15
ER

PT J
AU Pop, M
   Walker, AW
   Paulson, J
   Lindsay, B
   Antonio, M
   Hossain, MA
   Oundo, J
   Tamboura, B
   Mai, V
   Astrovskaya, I
   Bravo, HC
   Rance, R
   Stares, M
   Levine, MM
   Panchalingam, S
   Kotloff, K
   Ikumapayi, UN
   Ebruke, C
   Adeyemi, M
   Ahmed, D
   Ahmed, F
   Alam, MT
   Amin, R
   Siddiqui, S
   Ochieng, JB
   Ouma, E
   Juma, J
   Mailu, E
   Omore, R
   Morris, JG
   Breiman, RF
   Saha, D
   Parkhill, J
   Nataro, JP
   Stine, OC
AF Pop, Mihai
   Walker, Alan W.
   Paulson, Joseph
   Lindsay, Brianna
   Antonio, Martin
   Hossain, M. Anowar
   Oundo, Joseph
   Tamboura, Boubou
   Mai, Volker
   Astrovskaya, Irina
   Bravo, Hector Corrada
   Rance, Richard
   Stares, Mark
   Levine, Myron M.
   Panchalingam, Sandra
   Kotloff, Karen
   Ikumapayi, Usman N.
   Ebruke, Chinelo
   Adeyemi, Mitchell
   Ahmed, Dilruba
   Ahmed, Firoz
   Alam, Meer Taifur
   Amin, Ruhul
   Siddiqui, Sabbir
   Ochieng, John B.
   Ouma, Emmanuel
   Juma, Jane
   Mailu, Euince
   Omore, Richard
   Morris, J. Glenn
   Breiman, Robert F.
   Saha, Debasish
   Parkhill, Julian
   Nataro, James P.
   Stine, O. Colin
TI Diarrhea in young children from low-income countries leads to
   large-scale alterations in intestinal microbiota composition
SO GENOME BIOLOGY
LA English
DT Article
ID GLOBAL ENTERIC MULTICENTER; HUMAN GUT MICROBIOME; CLOSTRIDIUM-DIFFICILE;
   SYSTEMATIC ANALYSIS; DISEASE; DIVERSITY; INFANTS; COMMUNITIES; ETIOLOGY;
   BURDEN
AB Background: Diarrheal diseases continue to contribute significantly to morbidity and mortality in infants and young children in developing countries. There is an urgent need to better understand the contributions of novel, potentially uncultured, diarrheal pathogens to severe diarrheal disease, as well as distortions in normal gut microbiota composition that might facilitate severe disease.
   Results: We use high throughput 16S rRNA gene sequencing to compare fecal microbiota composition in children under five years of age who have been diagnosed with moderate to severe diarrhea (MSD) with the microbiota from diarrhea-free controls. Our study includes 992 children from four low-income countries in West and East Africa, and Southeast Asia. Known pathogens, as well as bacteria currently not considered as important diarrhea-causing pathogens, are positively associated with MSD, and these include Escherichia/Shigella, and Granulicatella species, and Streptococcus mitis/pneumoniae groups. In both cases and controls, there tend to be distinct negative correlations between facultative anaerobic lineages and obligate anaerobic lineages. Overall genus-level microbiota composition exhibit a shift in controls from low to high levels of Prevotella and in MSD cases from high to low levels of Escherichia/Shigella in younger versus older children; however, there was significant variation among many genera by both site and age.
   Conclusions: Our findings expand the current understanding of microbiota-associated diarrhea pathogenicity in young children from developing countries. Our findings are necessarily based on correlative analyses and must be further validated through epidemiological and molecular techniques.
C1 [Pop, Mihai; Paulson, Joseph; Astrovskaya, Irina; Bravo, Hector Corrada] Univ Maryland, College Pk, MD 20742 USA.
   [Walker, Alan W.; Rance, Richard; Stares, Mark; Parkhill, Julian] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
   [Lindsay, Brianna; Levine, Myron M.; Panchalingam, Sandra; Kotloff, Karen; Stine, O. Colin] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Antonio, Martin; Ikumapayi, Usman N.; Ebruke, Chinelo; Adeyemi, Mitchell; Saha, Debasish] MRC Unit, Serrekunda, Gambia.
   [Hossain, M. Anowar; Ahmed, Dilruba; Ahmed, Firoz; Alam, Meer Taifur; Amin, Ruhul; Siddiqui, Sabbir] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Oundo, Joseph; Ochieng, John B.; Ouma, Emmanuel; Juma, Jane; Mailu, Euince; Omore, Richard] Kenya Med Res Inst KEMRI, US Ctr Dis Control & Prevent Res Collaborat, Kisumu, Kenya.
   [Tamboura, Boubou] Ctr Vaccine Dev, Bamako, Mali.
   [Morris, J. Glenn] Univ Florida, Gainesville, FL USA.
   [Breiman, Robert F.] Emory Univ, Atlanta, GA 30322 USA.
   [Nataro, James P.] Univ Virginia, Charlottesville, VA USA.
RP Stine, OC (reprint author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
EM ostin001@umaryland.edu
RI Pop, Mihai/A-7987-2013
OI Pop, Mihai/0000-0001-9617-5304; Walker, Alan/0000-0001-5099-8495
FU William and Melinda Gates Foundation [42917]; US National Institutes of
   Health [5R01HG005220, 5R01HG004885]; US National Science Foundation
   [DGE0750616]; Wellcome Trust [WT098051]
FX This work was funded in part by the William and Melinda Gates
   Foundation, award 42917 to JPN and OCS; US National Institutes of Health
   grants 5R01HG005220 to HCB, 5R01HG004885 to MP; US National Science
   Foundation Graduate Research Fellowship award DGE0750616 to JNP; AWW and
   JP are funded by The Wellcome Trust (Grant No. WT098051).
CR Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Cebra JJ, 1999, AM J CLIN NUTR, V69, P10465
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Cole JR, 2005, NUCLEIC ACIDS RES, V33, pD294, DOI 10.1093/nar/gki038
   De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107
   DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05
   Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
   Frank JA, 2008, APPL ENVIRON MICROB, V74, P2461, DOI 10.1128/AEM.02272-07
   Friedman J, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002687
   Ghodsi M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-271
   Girvan MS, 2005, ENVIRON MICROBIOL, V7, P301, DOI 10.1111/j.1462-2920.2005.00695.x
   Huse SM, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r143
   Jangi S, 2010, J PEDIATR GASTR NUTR, V51, P2, DOI 10.1097/MPG.0b013e3181d29767
   Jin D, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-141
   Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Kotloff KL, 2012, CLIN INFECT DIS, V55, pS232, DOI 10.1093/cid/cis753
   Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676
   Lawley TD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002995
   Lay C, 2005, APPL ENVIRON MICROB, V71, P4153, DOI 10.1128/AEM.71.7.4153-4155.2005
   Levine MM, 2012, CLIN INFECT DIS, V55, pS215, DOI 10.1093/cid/cis761
   Lin A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053838
   Lindsay B, 2013, J CLIN MICROBIOL, V51, P3263, DOI 10.1128/JCM.01342-13
   Lindsay B, 2013, J CLIN MICROBIOL, V51, P1740, DOI 10.1128/JCM.02713-12
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Mackie R I, 1999, Am J Clin Nutr, V69, p1035S
   Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008
   McCann KS, 2000, NATURE, V405, P228, DOI 10.1038/35012234
   McDonald D, 2012, GIGASCIENCE, V1, DOI 10.1186/2047-217X-1-7
   Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209
   Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177
   Panchalingam S, 2012, CLIN INFECT DIS, V55, pS294, DOI 10.1093/cid/cis754
   Parks DH, 2010, BIOINFORMATICS, V26, P715, DOI 10.1093/bioinformatics/btq041
   Paulson JN, 2013, NAT METHODS, V10, P1200, DOI [10.1038/nmeth.2658, 10.1038/NMETH.2658]
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Rajilic-Stojanovic M, 2007, ENVIRON MICROBIOL, V9, P2125, DOI 10.1111/j.1462-2920.2007.01369.x
   Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107
   Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09
   SEARS CL, 1995, CLIN INFECT DIS, V20, pS142
   Senior K, 2013, LANCET INFECT DIS, V13, P200, DOI 10.1016/S1473-3099(13)70052-5
   Shields TM, 2012, INFECT DIS CLIN PRAC, V20, P357
   Sim K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032543
   Sjogren YM, 2009, CLIN EXP ALLERGY, V39, P1842, DOI 10.1111/j.1365-2222.2009.03326.x
   Taniuchi M, 2013, J INFECT DIS, V208, P1794, DOI 10.1093/infdis/jit507
   Taweechotipatr M, 2009, FEMS MICROBIOL LETT, V293, P65, DOI 10.1111/j.1574-6968.2009.01506.x
   Ubeda C, 2013, INFECT IMMUN, V81, P965, DOI 10.1128/IAI.01197-12
   Walker AW, 2013, PHARMACOL RES, V69, P75, DOI 10.1016/j.phrs.2012.09.008
   Walker CLF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029151
   White JR, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-152
   Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344
   Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053
NR 54
TC 40
Z9 42
U1 4
U2 36
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-6906
EI 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PY 2014
VL 15
IS 6
AR R76
DI 10.1186/gb-2014-15-6-r76
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA AO3WZ
UT WOS:000341269300002
PM 24995464
OA gold
DA 2017-08-15
ER

PT J
AU Afolabi, MO
   Bojang, K
   D'Alessandro, U
   Ota, MOC
   Imoukhuede, EB
   Ravinetto, R
   Larson, HJ
   McGrath, N
   Chandramohan, D
AF Afolabi, Muhammed O.
   Bojang, Kalifa
   D'Alessandro, Umberto
   Ota, Martin O. C.
   Imoukhuede, Egeruan B.
   Ravinetto, Raffaella
   Larson, Heidi J.
   McGrath, Nuala
   Chandramohan, Daniel
TI Digitised audio questionnaire for assessment of informed consent
   comprehension in a low-literacy African research population: development
   and psychometric evaluation
SO BMJ OPEN
LA English
DT Article
ID CLINICAL-TRIALS; VACCINE TRIAL; QUALITY; EXPERIENCES; INTERVENTIONS;
   CHALLENGES; COUNTRIES; VALIDITY
AB Objective: To develop and psychometrically evaluate an audio digitised tool for assessment of comprehension of informed consent among low-literacy Gambian research participants.
   Setting: We conducted this study in the Gambia where a high illiteracy rate and absence of standardised writing formats of local languages pose major challenges for research participants to comprehend consent information. We developed a 34-item questionnaire to assess participants' comprehension of key elements of informed consent. The questionnaire was face validated and content validated by experienced researchers. To bypass the challenge of a lack of standardised writing formats, we audiorecorded the questionnaire in three major Gambian languages: Mandinka, Wolof and Fula. The questionnaire was further developed into an audio computer-assisted interview format.
   Participants: The digitised questionnaire was administered to 250 participants enrolled in two clinical trials in the urban and rural areas of the Gambia. One week after first administration, the questionnaire was readministered to half of the participants who were randomly selected. Participants were eligible if enrolled in the parent trials and could speak any of the three major Gambian languages.
   Outcome measure: The primary outcome measure was reliability and validity of the questionnaire.
   Results: Item reduction by factor analysis showed that 21 of the question items have strong factor loadings. These were retained along with five other items which were fundamental components of informed consent. The 26-item questionnaire has high internal consistency with a Cronbach's a of 0.73-0.79 and an intraclass correlation coefficient of 0.94 (95% CI 0.923 to 0.954). Hypotheses testing also showed that the questionnaire has a positive correlation with a similar questionnaire and discriminates between participants with and without education.
   Conclusions: We have developed a reliable and valid measure of comprehension of informed consent information for the Gambian context, which might be easily adapted to similar settings. This is a major step towards engendering comprehension of informed consent information among low-literacy participants.
C1 [Afolabi, Muhammed O.; Bojang, Kalifa; D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Afolabi, Muhammed O.; D'Alessandro, Umberto; Chandramohan, Daniel] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England.
   [Ota, Martin O. C.] World Hlth Org Reg Off Africa, Res Serv, Brazzaville, Congo.
   [Ota, Martin O. C.] World Hlth Org Reg Off Africa, Publicat Serv, Brazzaville, Congo.
   [Ota, Martin O. C.] World Hlth Org Reg Off Africa, Lib Serv, Brazzaville, Congo.
   [Imoukhuede, Egeruan B.] Univ Oxford, Jenner Inst, Oxford, England.
   [Ravinetto, Raffaella] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.
   [Ravinetto, Raffaella] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium.
   [Larson, Heidi J.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England.
   [McGrath, Nuala] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England.
RP Afolabi, MO (reprint author), MRC Unit, Fajara, Gambia.
EM mafolabi@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Imoukhuede, Egeruan
   Babatunde/0000-0001-6679-0904; Bojang, Kalifa/0000-0001-7506-0938
FU European and Developing Countries Clinical Trials Partnership
   [IP.2008.31100.001]
FX This study is supported by a capacity building grant (IP.2008.31100.001)
   from the European and Developing Countries Clinical Trials Partnership.
CR Afolabi MO, 2014, AM J TROP MED HYG, V90, P908, DOI 10.4269/ajtmh.13-0615
   Afolabi Muhammed Olanrewaju, 2014, J Clin Res Bioeth, V5, P178
   Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209
   Annas GJ, 2009, NEW ENGL J MED, V360, P2050, DOI 10.1056/NEJMp0901474
   Bryman A, 2005, QUANTITATIVE DATA AN, P327
   Buccini L, 2011, NEW MEASURE INFORM 1
   Buccini LD, 2009, RES ETHICS REV, V5, P3
   [Anonymous], 2002, INT ETH GUID BIOM RE
   Department of Central Statistics The Gambia, PROV FIG 2013 POP HO
   DeVellis RF, 1991, APPL SOCIAL SCI METH
   DeVon HA, 2007, J NURS SCHOLARSHIP, V39, P155, DOI 10.1111/j.1547-5069.2007.00161.x
   Fitzgerald DW, 2002, LANCET, V360, P1301, DOI 10.1016/S0140-6736(02)11338-9
   Flory J, 2004, JAMA-J AM MED ASSOC, V292, P1593, DOI 10.1001/jama.292.13.1593
   [Anonymous], 2000, GUID SCI GAMB GOV ME
   Guarino P, 2006, J CLIN EPIDEMIOL, V59, P608, DOI 10.1016/j.jclinepi.2005.11.009
   Joffe S, 2001, J NATL CANCER I, V93, P139, DOI 10.1093/jnci/93.2.139
   Kane MT, 2001, J EDUC MEAS, V38, P319, DOI 10.1111/j.1745-3984.2001.tb01130.x
   Kline P., 2000, HDB PSYCHOL TESTING
   Lindegger G, 2006, JAIDS-J ACQ IMM DEF, V43, P560
   Mandava A, 2012, J MED ETHICS, V38, P356, DOI 10.1136/medethics-2011-100178
   Marsh VM, 2010, BMC MED ETHICS, V11, DOI 10.1186/1472-6939-11-13
   Marshall PA, 2007, SPECIAL TOPICS SOCIA, V5
   Miller CK, 1996, PHARMACOTHERAPY, V16, P872
   Minnies Deon, 2008, BMC Med Ethics, V9, P15, DOI 10.1186/1472-6939-9-15
   Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006
   Molyneux CS, 2004, SOC SCI MED, V59, P2547, DOI 10.1016/j.socscimed.2004.03.037
   Mystakidou K, 2009, SAHARA J-J SOC ASP H, V6, P46
   Nishimura A, 2013, BMC MED ETHICS, V14, DOI 10.1186/1472-6939-14-28
   Nunnally J. C., 1994, PSYCHOMETRIC THEORY
   Penn C, 2010, PATIENT EDUC COUNS, V80, P191, DOI 10.1016/j.pec.2009.10.019
   Preziosi MP, 1997, NEW ENGL J MED, V336, P370, DOI 10.1056/NEJM199701303360511
   Ravinetto R., 2010, Giornale Italiano di Medicina Tropicale, V15, P15
   Ravinetto RM, 2013, BMJ-BRIT MED J, V346, pf2837
   Saidu Y, 2013, J CLIN RES BIOETH, V141, DOI [10.4172/2155-9627.1000141, DOI 10.4172/2155-9627.1000141]
   Sand K., 2010, AJOB PRIMARY RESEARC, V1, P4
   Stevens J. P., 2002, APPL MULTIVARIATE ST
   Sugarman J, 2005, CLIN TRIALS, V2, P34, DOI 10.1191/1740774505cn066oa
   Tabachnick B. G., 2008, USING MULTIVARIATE S
   Tangwa Godfrey B, 2009, Acta Trop, V112 Suppl 1, pS16, DOI 10.1016/j.actatropica.2009.08.021
   Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012
   Onvomaha Tindana P, 2006, IRB, V28, P1
   U. S. Department of Health and Human Services, 1979, BELM REP ETH PRINC G
   WMA, 2013, WORLD ASS DECL HELS
   Woodsong C, 2005, AM J PUBLIC HEALTH, V95, P412, DOI 10.2105/AJPH.2004.041624
NR 44
TC 3
Z9 3
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2014
VL 4
IS 6
AR e004817
DI 10.1136/bmjopen-2014-004817
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AM2YH
UT WOS:000339717100040
PM 24961716
OA gold
DA 2017-08-15
ER

PT J
AU Okebe, J
   Eisenhut, M
AF Okebe, Joseph
   Eisenhut, Michael
TI Pre-referral rectal artesunate for severe malaria
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID SEVERE FALCIPARUM-MALARIA; PAPUA-NEW-GUINEA; AFRICAN CHILDREN;
   RANDOMIZED-TRIAL; FLAWED TRIAL; EFFICACY; QUININE; SUPPOSITORIES;
   DIHYDROARTEMISININ; PHARMACOKINETICS
AB Background
   Severe or complicated malaria is a medical emergency and people die as a result of delays in starting treatment. Most patients need parenteral treatment, and in primary healthcare facilities, where intravenous therapy is not available but intramuscular injections can be given, intramuscular quinine, artesunate, and artemether have been used before transporting patients to hospital.
   However, in rural settings with limited access to health care, intramuscular injections may also be unavailable. In these situations, rectal artesunate given prior to transfer to hospital by volunteers with little medical training, may be a feasible option.
   Objectives
   To evaluate the effects of pre-referral treatment with rectal artesunate on mortality and morbidity in people with severe malaria.
   Search methods
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) published in The Cochrane Library; MEDLINE; EMBASE and LILACS up to 21 May 2014. We also searched the WHO clinical trial registry platform and the metaRegister of Controlled Trials (mRCT) for ongoing trials.
   Selection criteria
   Individual or cluster-randomized controlled trials comparing pre-referral rectal artesunate with placebo or injectable antimalarials in children and children with severe malaria.
   Data collection and analysis
   Two authors independently screened titles and abstracts for potentially eligible trials, and extracted data from the included trials. Dichotomous outcomes were summarized using risk ratios (RR) and presented with 95% confidence intervals (95% CI). Where data allowed, we conducted subgroup analyses by age, trial region and whether participants were included in the trial analysis. We assessed the quality of evidence for the most important outcomes using the GRADE approach.
   Main results
   One trial met the inclusion criteria; a placebo-controlled trial of 17,826 children and adults living in rural villages in Ghana and Tanzania (Africa) and Bangladesh (Asia). Villagers with no previous medical training were trained to recognize the symptoms of severe malaria, administer rectal artesunate and refer patients to hospital. The trained villagers were supervised during the trial period.
   In the African sites only children aged 6 to 72 months were enrolled, whereas in Bangladesh, older children and adults were also enrolled. In young children (aged 6 to 72 months) there were fewer deaths following rectal artesunate than with placebo (RR 0.74; 95% CI 0.59 to 0.93; one trial; 8050 participants; moderate quality evidence), while in older children and adults there were more deaths in those given rectal artesunate (RR 2.21; 95% CI 1.18 to 4.15; one trial; 4018 participants; low quality evidence).
   In Africa, only 56% of participants reached a secondary healthcare facility within six hours compared to over 90% in Asia. There were no differences between the intervention and control groups in the proportion of participants reaching a healthcare facility within six hours (RR 0.99; 95% CI 0.98 to 1.01; 12,068 participants), or in the proportion with parasitaemia (RR 1.00; 95% CI 0.98 to 1.02; 17,826 participants), or with coma or convulsions on arrival (RR 1.01; 95% CI 0.90 to 1.14; 12,068 participants).
   There are no existing trials that compare rectal versus intramuscular artesunate.
   Authors' conclusions
   In rural areas without access to injectable antimalarials rectal artesunate provided before transfer to a referral facility probably reduces mortality in severely ill young children compared to referral without treatment. However, the unexpected finding of possible higher mortality in older children and adults has to be taken into account in forming any national or local policies about pre-referral rectal artesunate.
C1 [Okebe, Joseph] MRC Unit, Banjul, Gambia.
   [Eisenhut, Michael] Luton Dunstable Univ Hosp NHS Fdn Trust, Dept Paediat, Luton, Beds, England.
RP Okebe, J (reprint author), MRC Unit, POB 273, Banjul, Gambia.
EM jokebe@mrc.gm
FU UK Department for International Development
FX We thank the Cochrane Infectious Diseases Group for their support of
   this project. The editorial base for the Cochrane Infectious Diseases
   Group is funded by the UK Department for International Development for
   the benefit of developing countries.
CR Aceng JR, 2005, BRIT MED J, V330, P334, DOI 10.1136/bmj.330.7487.334
   Awad MI, 2003, AM J TROP MED HYG, V68, P153
   Aweeka FT, 2008, CLIN PHARMACOKINET, V47, P91, DOI 10.2165/00003088-200847020-00002
   Barnes KI, 2004, LANCET, V363, P1598, DOI 10.1016/S0140-6736(04)16203-X
   Bello SO, 2009, LANCET, V373, P1762, DOI 10.1016/S0140-6736(09)60980-6
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   Faiz MA, 2005, LANCET, V366, P717
   Gomes MF, 2010, DRUG DEVELOP RES, V71, P92, DOI 10.1002/ddr.20352
   Gomes MF, 2009, LANCET, V373, P557, DOI 10.1016/S0140-6736(08)61734-1
   Gomes M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-39
   Gomes MF, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-189
   Higgins Jpt GS, 2011, COCHRANE HDB SYSTEMA
   Hirji KF, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-188
   Inthavilay S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-342
   Kaatano G M, 2009, Tanzan J Health Res, V11, P210
   Kamugisha M L, 2007, Tanzan Health Res Bull, V9, P32
   Karunajeewa HA, 2006, ANTIMICROB AGENTS CH, V50, P968, DOI 10.1128/AAC.50.3.968-974.2006
   Karunajeewa HA, 2004, ANTIMICROB AGENTS CH, V48, P2966, DOI 10.1128/AAC.48.8.2966-2972.2004
   Karunajeewa HA, 2007, JAMA-J AM MED ASSOC, V297, P2381, DOI 10.1001/jama.297.21.2381
   Kitua A, 2010, J MED ETHICS, V36, P116, DOI 10.1136/jme.2009.030874
   Krishna S, 2001, ANTIMICROB AGENTS CH, V45, P509, DOI 10.1128/AAC.45.2.509-516.2001
   Lefebvre C, 2011, COCHRANE HDB SYSTEMA
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Morris CA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-263
   Mudenda SS, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-40
   The Nordic Cochrane Centre The Cochrane Collaboration, 2012, REV MAN REVMAN 5 2
   Sinclair D, 2012, COCHRANE DB SYST REV, V6
   Stepniewska K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-200
   Tozan Y, 2010, LANCET, V376, P1910, DOI 10.1016/S0140-6736(10)61460-2
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
   World Health Organization, 2010, GUID TREATM MAL
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
   Wilairatana P, 1997, ANN TROP MED PARASIT, V91, P891
   [Anonymous], 2004, EVIDENCE BASED HEALT, V8, P375
NR 35
TC 3
Z9 3
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2014
IS 5
AR CD009964
DI 10.1002/14651858.CD009964.pub2
PG 29
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI2AD
UT WOS:000336657000027
PM 24869943
OA No
DA 2017-08-15
ER

PT J
AU Ameh, D
   Uchendu, UO
   Adeyemi, OA
   Ideh, RC
   Ebruke, BE
   Mackenzie, G
   Howie, S
   Corrah, T
AF Ameh, David
   Uchendu, Uchendu O.
   Adeyemi, Oyedeji A.
   Ideh, Readon C.
   Ebruke, Bernard E.
   Mackenzie, Grant
   Howie, Stephen
   Corrah, Tumani
TI Is the absolute requirement for informed consent before HIV testing a
   barrier to public health? A case report and management challenges
SO AJAR-AFRICAN JOURNAL OF AIDS RESEARCH
LA English
DT Article
DE diagnosis; HIV/AIDS; provider-initiated testing and counselling;
   'opt-out'; stigmatisation; sub-Saharan Africa; virological testing;
   voluntary testing and counselling
ID SOUTH-AFRICA; OPT-OUT; ACCEPTABILITY; ETHICS; EXCEPTIONALISM; FRAMEWORK;
   ATTITUDES; ZIMBABWE; TRIAL; WOMEN
AB Clinicians in sub-Saharan Africa are faced with a major challenge of parental refusal to test their children for HIV. We present a case of a nine-month-old child with a clinical presentation suggestive of HIV infection whose mother persistently declined HIV testing of the child or herself. The case illustrates the difficulties faced by the clinicians caring for the child in an isolated location in West Africa. While not eliminating these difficulties, an opt-out approach to paediatric HIV testing in sub-Saharan Africa may increase the proportion of children who access treatment when they need it, particularly when this is backed by the development of more effective national and regional clinical and legislative frameworks for HIV testing in children.
C1 [Ameh, David] Fajara Stn, Med Res Council Unit, Caio, Gambia.
   Basse Stn, Med Res Council Unit, Caio, Gambia.
RP Ameh, D (reprint author), Fajara Stn, Med Res Council Unit, Caio, Gambia.
EM dave_ameh@yahoo.com
CR Amitabh BS, 2013, PLOS MED, V10
   April MD, 2010, B WORLD HEALTH ORGAN, V88, P703, DOI 10.2471/BLT.09.073049
   Bayer R, 2006, NEW ENGL J MED, V355, P647, DOI 10.1056/NEJMp068153
   Booth J, 1993, BLOOD TRANSFUSION, V2, P757
   Centers for Disease Control and Prevention, 2004, MMWR-MORBID MORTAL W, V53, P523
   Corbett EL, 2006, PLOS MED, V3, P1005, DOI 10.1371/journal.pmed.0030238
   Duke C, 1996, LANCET, V348, P247, DOI 10.1016/S0140-6736(96)00428-X
   Etiebet MA, 2004, AIDS CARE, V16, P37, DOI 10.1080/09540120310001633958
   Etzel MA, 2003, NAT HIV PREV C JUL 2
   Ferrand R, 2010, B WORLD HEALTH ORGAN, V88, P428, DOI 10.2471/BLT.09.066126
   GMC (General Medical Council), 1995, DUT DOCT HIV AIDS ET
   Government of the Republic of The Gambia, 2006, NAT AIDS COUNC REV N
   ICN (International Council of Nurses), 2008, PROV IN HIV TEST COU
   Jurgens R, 2006, ROUTINIZING HIV TEST
   Kalichman SC, 2003, SEX TRANSM INFECT, V79, P442, DOI 10.1136/sti.79.6.442
   Kass NE, 2001, AM J PUBLIC HEALTH, V91, P1776, DOI 10.2105/AJPH.91.11.1776
   Meiberg Annemarie E, 2008, East Afr J Public Health, V5, P49
   Mgosha PC, 2009, BMC PUBLIC HEALTH, V9, P128
   Miller A, 2006, PEPFAR IMPL M DURB S
   Ministry of Health, 2000, HIV TREATM MAN
   National AIDS and STD Control Programme, 2004, GUID HIV TEST CLIN S
   Nieburg P, 2005, EXPANDED HIV TESTING
   Nuwaha F, 2002, East Afr Med J, V79, P626
   O'Neill O, 2003, J MED ETHICS, V29, P4, DOI 10.1136/jme.29.1.4
   Pearshouse R, 2007, HIV AIDS POLICY LAW
   Perez F, 2006, JAIDS-J ACQ IMM DEF, V41, P514, DOI 10.1097/01.qai.0000191285.70331.a0
   Rennie S, 2006, B WORLD HEALTH ORGAN, V84, P52
   Shankar AV, 2003, AIDS CARE, V15, P871, DOI 10.1080/09540120310001618702
   Simpson WM, 1998, BRIT MED J, V316, P262
   Strode A, 2010, SAMJ S AFR MED J, V100, P247
   Turoldo F, 2009, AM J PUBLIC HEALTH, V99, P1197, DOI 10.2105/AJPH.2007.127514
   UNAIDS (Joint United Nations Programme on HIV/ AIDS), 2000, VOL TEST COUNS UNAID
   UNAIDS, 2013, REP GLOB AIDS EP 201
   Weiser SD, 2006, PLOS MED, V3, P1013, DOI 10.1371/journal.pmed.0030261
   Wheeler R, 2011, CLIN ETHICS, V6, P203
   WHO/UNAIDS, 2007, NEW GUID HIV TEST CO
   [Anonymous], 2004, UNAIDS WHO POL STAT
   World Health Organization, 2010, POL REQ HIV TEST COU
   World Health Organization, 2003, INCR ACC HIV TEST CO
   World Health Organization, 2007, GUID PROV IN HIV TES
   WHO, 2007, WHO CAS DEF HIV SURV
   Zimba C, 2006, 16 INT AIDS C TOR CA
NR 42
TC 0
Z9 0
U1 0
U2 1
PU NATL INQUIRY SERVICES CENTRE PTY LTD
PI GRAHAMSTOWN
PA 19 WORCESTER STREET, PO BOX 377, GRAHAMSTOWN 6140, SOUTH AFRICA
SN 1608-5906
EI 1727-9445
J9 AJAR-AFR J AIDS RES
JI AJAR-Afr. J. Aids Res.
PY 2014
VL 13
IS 1
BP 93
EP 98
DI 10.2989/16085906.2014.901978
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG4NI
UT WOS:000335396400011
PM 25174520
OA No
DA 2017-08-15
ER

PT J
AU Sankoh, O
   Sharrow, D
   Herbst, K
   Kabudula, CW
   Alam, N
   Kant, S
   Ravn, H
   Bhuiya, A
   Vui, LT
   Darikwa, T
   Gyapong, M
   Jasseh, M
   Kim, NCT
   Abdullah, S
   Crampin, A
   Ojal, J
   Owusu-Agyei, S
   Odhiambo, F
   Urassa, M
   Streatfield, K
   Shimada, M
   Sacoor, C
   Beguy, D
   Derra, K
   Wak, G
   Delaunay, V
   Sie, A
   Soura, A
   Diallo, D
   Wilopo, S
   Masanja, H
   Bonfoh, B
   Phuanukoonnon, S
   Clark, SJ
AF Sankoh, Osman
   Sharrow, David
   Herbst, Kobus
   Kabudula, Chodziwadziwa Whiteson
   Alam, Nurul
   Kant, Shashi
   Ravn, Henrik
   Bhuiya, Abbas
   Le Thi Vui
   Darikwa, Timotheus
   Gyapong, Margaret
   Jasseh, Momodou
   Nguyen Chuc Thi Kim
   Abdullah, Salim
   Crampin, Amelia
   Ojal, John
   Owusu-Agyei, Seth
   Odhiambo, Frank
   Urassa, Mark
   Streatfield, Kim
   Shimada, Masaaki
   Sacoor, Charfudin
   Beguy, Donatien
   Derra, Karim
   Wak, George
   Delaunay, Valerie
   Sie, Ali
   Soura, Abdramane
   Diallo, Diadier
   Wilopo, Siswanto
   Masanja, Honorati
   Bonfoh, Bassirou
   Phuanukoonnon, Suparat
   Clark, Samuel J.
TI The INDEPTH standard population for low- and middle-income countries,
   2013
SO GLOBAL HEALTH ACTION
LA English
DT Article
DE crude death rate; age-specific mortality rate; age-standardized crude
   death rate; demography; standardized age structure; low- and
   middle-income countries
AB Crude rates such as the crude death rate are functions of both the age-specific rates and the age composition of a population. However, differences in the age structure between two populations or two time periods can result in specious differences in the corresponding crude rates making direct comparisons between populations or across time inappropriate. Therefore, when comparing crude rates between populations, it is desirable to eliminate or minimize the influence of age composition. This task is accomplished by using a standard age structure yielding an age-standardized rate. This paper proposes an updated International Network for the Demographic Evaluation of Populations and Their Health (INDEPTH) standard for use in low-and middle-income countries (LMICs) based on newly available data from the health and demographic surveillance system site members of the INDEPTH network located throughout Africa and southern Asia. The updated INDEPTH standard should better reflect the age structure of LMICs and result in more accurate health indicators and demographic rates. We demonstrate use of the new INDEPTH standard along with several existing 'world' standards and show how resulting age-standardized crude deaths rates differ when using the various standard age compositions.
C1 [Sankoh, Osman; Clark, Samuel J.] INDEPTH Network, Kanda, Accra, Ghana.
   [Sankoh, Osman; Clark, Samuel J.] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa.
   [Sankoh, Osman] Hanoi Med Univ, Fac Publ Hlth, Hanoi, Vietnam.
   [Sharrow, David; Clark, Samuel J.] Univ Washington, Seattle, WA 98195 USA.
   [Herbst, Kobus] Africa Ctr, Kwa Zulu Natal, South Africa.
   [Kabudula, Chodziwadziwa Whiteson; Clark, Samuel J.] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, MRC,Wits Rural Publ Hlth & Hlth Transit Res Unit, Johannesburg, South Africa.
   [Alam, Nurul] AMK HDSS, Dhaka, Bangladesh.
   [Kant, Shashi] Ballabgarh HDSS, Ballabgarh, India.
   [Ravn, Henrik] Bandim HDSS, Bissau, Guinea.
   [Bhuiya, Abbas] Chakaria HDSS, Dhaka, Bangladesh.
   [Le Thi Vui] Chililab HDSS, Chililab, Vietnam.
   [Darikwa, Timotheus] Dikgale HDSS, Polokwane, South Africa.
   [Gyapong, Margaret] Dodowa HDSS, Accra, Ghana.
   [Jasseh, Momodou] Farafanni HDSS, Farafanni, Gambia.
   [Nguyen Chuc Thi Kim] Filabavi HDS, Filabavi, Vietnam.
   [Abdullah, Salim] Ifakara HDSS, Dar Es Salaam, Tanzania.
   [Crampin, Amelia] Karonga HDSS, Karonga, Malawi.
   [Ojal, John] Kilifi HDSS, Kilifi, Kenya.
   [Owusu-Agyei, Seth] Kintampo HDSS, Kintampo, Ghana.
   [Odhiambo, Frank] Kisumu HDSS, Kisumu, Kenya.
   [Urassa, Mark] Magu HDSS, Magu, Tanzania.
   [Streatfield, Kim] Matlab HDSS, Dhaka, Bangladesh.
   [Shimada, Masaaki] Mbita HDSS, Mbita, Kenya.
   [Sacoor, Charfudin] Manhica HDSS, Manhica, Mozambique.
   [Beguy, Donatien] Nairobi HDSS, Nairobi, Kenya.
   [Derra, Karim] Nanoro HDSS, Nanoro, Burkina Faso.
   [Wak, George] Navrongo HDSS, Navrongo, Ghana.
   [Delaunay, Valerie] Niakhar HDSS, Niakhar, Senegal.
   [Delaunay, Valerie] Aix Marseille Univ, IRD, LPED, Aix Marseille, France.
   [Sie, Ali] Nouna HDSS, Nouna, Burkina Faso.
   [Soura, Abdramane] Ouagadougou HDSS, Ouagadougou, Burkina Faso.
   [Diallo, Diadier] Oubritenga HDSS, Oubritenga, Burkina Faso.
   [Wilopo, Siswanto] Purworejo HDSS, Purworejo, Indonesia.
   [Masanja, Honorati] Rufiji HDSS, Rufiji, Tanzania.
   [Bonfoh, Bassirou] Taabo HDSS, Taabo, Cote Ivoire.
   [Phuanukoonnon, Suparat] Wosera HDSS, Wosera, Papua N Guinea.
   [Clark, Samuel J.] ALPHA Network, London, England.
RP Sankoh, O (reprint author), INDEPTH Network, POB KD 213, Kanda, Accra, Ghana.
EM osman.sankoh@indepth-network.org
OI SIE, Ali/0000-0002-3959-2520; Wilopo, Siswanto/0000-0003-1284-7228
CR Ahmad OP, 2001, GPE DISCUSSION PAPER, V31
   Collinson M, 2009, DYNAMICS OF MIGRATION, HEALTH AND LIVELIHOODS: INDEPTH NETWORK PERSPECTIVES, pXXVII
   INDEPTH Network, 2002, POP HLTH DEV COUNTR, V1
   Preston S. H., 2001, DEMOGRAPHY MEASURING
   Sankoh OA, 2006, DIS MORTALITY SUBSAH
   Segi M., 1960, CANC MORTALITY SELEC
NR 6
TC 15
Z9 15
U1 0
U2 0
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PY 2014
VL 7
AR 23286
DI 10.3402/gha.v7.23286
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AE0WT
UT WOS:000333687700001
PM 24679543
OA gold
DA 2017-08-15
ER

PT J
AU Copin, R
   Coscolla, M
   Seiffert, SN
   Bothamley, G
   Sutherland, J
   Mbayo, G
   Gagneux, S
   Ernst, JD
AF Copin, Richard
   Coscolla, Mireia
   Seiffert, Salome N.
   Bothamley, Graham
   Sutherland, Jayne
   Mbayo, Georgetta
   Gagneux, Sebastien
   Ernst, Joel D.
TI Sequence Diversity in the pe_pgrs Genes of Mycobacterium tuberculosis Is
   Independent of Human T Cell Recognition
SO MBIO
LA English
DT Article
ID ANTIGENIC VARIATION; CLASS-I; INFECTION; EVOLUTION; IMMUNITY;
   POLYMORPHISM; PREDICTION; BACTERIAL; PE-PGRS33; RESPONSES
AB The Mycobacterium tuberculosis genome includes the large family of pe_pgrs genes, whose functions are unknown. Because of precedents in other pathogens in which gene families showing high sequence variation are involved in antigenic variation, a similar role has been proposed for the pe_pgrs genes. However, the impact of immune selection on pe_pgrs genes has not been examined. Here, we sequenced 27 pe_pgrs genes in 94 clinical strains from five phylogenetic lineages of the M. tuberculosis complex (MTBC). We found that pe_pgrs genes were overall more diverse than the remainder of the MTBC genome, but individual members of the family varied widely in their nucleotide diversity and insertion/deletion (indel) content: some were more, and others were much less, diverse than the genome average. Individual pe_pgrs genes also differed in the ratio of nonsynonymous to synonymous mutations, suggesting that different selection pressures act on individual pe_pgrs genes. Using bioinformatic methods, we tested whether sequence diversity in pe_pgrs genes might be selected by human T cell recognition, the major mechanism of adaptive immunity to MTBC. We found that the large majority of predicted human T cell epitopes were confined to the conserved PE domain and experimentally confirmed the antigenicity of this domain in tuberculosis patients. In contrast, despite being genetically diverse, the PGRS domains harbored few predicted T cell epitopes. These results indicate that human T cell recognition is not a significant force driving sequence diversity in pe_pgrs genes, which is consistent with the previously reported conservation of human T cell epitopes in the MTBC.
   IMPORTANCE Recognition of Mycobacterium tuberculosis antigens by T lymphocytes is known to be important for immune protection against tuberculosis, but it is unclear whether human T cell recognition drives antigenic variation in M. tuberculosis. We previously discovered that the known human T cell epitopes in the M. tuberculosis complex are highly conserved, but we hypothesized that undiscovered epitopes with naturally occurring sequence variants might exist. To test this hypothesis, we examined the pe_pgrs genes, a large family of genes that has been proposed to function in immune evasion by M. tuberculosis. We found that the pe_pgrs genes exhibit considerable sequence variation, but the regions containing T cell epitopes and the regions of variation are distinct. These findings confirm that the majority of human T cell epitopes of M. tuberculosis are highly conserved and indicate that selection forces other than T cell recognition drive sequence variation in the pe_pgrs genes.
C1 [Copin, Richard; Ernst, Joel D.] NYU, Sch Med, Dept Med, Div Infect Dis, New York, NY 10012 USA.
   [Coscolla, Mireia; Seiffert, Salome N.; Gagneux, Sebastien] Swiss Trop & Publ Hlth Inst, Dept Med Parasitol & Infect Biol, Basel, Switzerland.
   [Coscolla, Mireia; Seiffert, Salome N.; Gagneux, Sebastien] Univ Basel, Basel, Switzerland.
   [Coscolla, Mireia] Ctr Super Invest Salud Publ, Valencia, Spain.
   [Bothamley, Graham] Homerton Univ Hosp, NHS Fdn Trust, London, England.
   [Sutherland, Jayne; Mbayo, Georgetta] MRC Unit, TB Immunol Lab, Fajara, Gambia.
   [Ernst, Joel D.] NYU, Sch Med, Dept Pathol & Microbiol, New York, NY USA.
RP Ernst, JD (reprint author), NYU, Sch Med, Dept Med, Div Infect Dis, New York, NY 10012 USA.
EM Sebastien.Gagneux@unibas.ch; joel.ernst@med.nyu.edu
RI Coscolla, Mireia/L-5893-2017
OI Coscolla, Mireia/0000-0003-0752-0538; Ernst, Joel/0000-0001-9951-6207;
   Sutherland, Jayne/0000-0002-7083-4997
FU National Institutes of Health [R01 AI090928, HHSN266200700022C]; Swiss
   National Science Foundation [PP0033-119205]; Potts Memorial Foundation;
   Belgian American Educational Foundation; Programa VALi+d
FX This work was supported by the National Institutes of Health (R01
   AI090928 and HHSN266200700022C) and the Swiss National Science
   Foundation (PP0033-119205). R. C. was supported by the Potts Memorial
   Foundation and the Belgian American Educational Foundation. M. C. was
   supported by the Programa VALi+d.
CR Achkar JM, 2013, CELL HOST MICROBE, V13, P250, DOI 10.1016/j.chom.2013.02.009
   Achtman M, 2008, ANNU REV MICROBIOL, V62, P53, DOI 10.1146/annurev.micro.62.081307.162832
   Banu S, 2002, MOL MICROBIOL, V44, P9, DOI 10.1046/j.1365-2958.2002.02813.x
   Basu S, 2007, J BIOL CHEM, V282, P1039, DOI 10.1074/jbc.M604379200
   Black GF, 2001, INT J TUBERC LUNG D, V5, P664
   Black GF, 2009, CLIN VACCINE IMMUNOL, V16, P1203, DOI 10.1128/CVI.00111-09
   Bold TD, 2011, PLOS PATHOG, V7, DOI DOI 10.1371/J0URNAL.PPAT.1002063
   Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416
   Cadieux N, 2011, MICROBIOL-SGM, V157, P793, DOI 10.1099/mic.0.041996-0
   Chaves FA, 2012, J IMMUNOL, V188, P4235, DOI 10.4049/jimmunol.1103640
   Chen CY, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000392
   Cole ST, 1998, NATURE, V393, P537
   Comas I, 2013, NAT GENET, V45, P1176, DOI 10.1038/ng.2744
   Comas I, 2010, NAT GENET, V42, P498, DOI 10.1038/ng.590
   Comas I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007815
   Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703
   Coscolla M, 2010, TODAY DIS MECH, V7, pe43, DOI DOI 10.1016/J.DDM0D.2010.10.001
   Croucher NJ, 2011, SCIENCE, V331, P430, DOI 10.1126/science.1198545
   Deitsch KW, 2009, NAT REV MICROBIOL, V7, P493, DOI 10.1038/nrmicro2145
   Delogu G, 2001, INFECT IMMUN, V69, P5606, DOI 10.1128/IAI.69.9.5606-5611.2001
   Delogu G, 2008, HDB TUBERCULOSIS, V1, P131
   Ernst JD, 2012, NAT REV IMMUNOL, V12, P581, DOI 10.1038/nri3259
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47
   Firdessa R, 2013, EMERG INFECT DIS, V19, P460, DOI 10.3201/eid1903.120256
   Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037
   Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103
   Gagneux S, 2010, ART & SCIENCE OF TUBERCULOSIS VACCINE DEVELOPMENT, P131
   Gey van Pittius NC, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-95
   Hershberg R, 2008, PLOS BIOL, V6, P2658, DOI 10.1371/journal.pbio.0060311
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Hirsh AE, 2004, P NATL ACAD SCI USA, V101, P4871, DOI 10.1073/pnas.0305627101
   Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z
   HOWARD JC, 1991, NATURE, V352, P565, DOI 10.1038/352565a0
   Karboul A, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-107
   Katoh K, 2005, NUCLEIC ACIDS RES, V33, P511, DOI 10.1093/nar/gki198
   Kawashima Y, 2009, NATURE, V458, P641, DOI 10.1038/nature07746
   Kwan CK, 2011, CLIN MICROBIOL REV, V24, P351, DOI 10.1128/CMR.00042-10
   Lancioni C, 2012, AM J RESP CRIT CARE, V185, P206, DOI 10.1164/rccm.201107-1355OC
   Lin PL, 2009, INFECT IMMUN, V77, P4631, DOI 10.1128/IAI.00592-09
   McEvoy CRE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030593
   Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   NEI M, 1986, MOL BIOL EVOL, V3, P418
   Nei M., 1987, MOL EVOLUTIONARY GEN
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Nielsen Morten, 2010, Immunome Res, V6, P9, DOI 10.1186/1745-7580-6-9
   North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635
   Peters B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-132
   Podlaha O, 2003, P NATL ACAD SCI USA, V100, P12241, DOI 10.1073/pnas.2033555100
   Reed MB, 2009, J CLIN MICROBIOL, V47, P1119, DOI 10.1128/JCM.02142-08
   RIPLEY LS, 1990, ANNU REV GENET, V24, P189
   Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359
   Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236
   Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361
   Strong M, 2006, P NATL ACAD SCI USA, V103, P8060, DOI 10.1073/pnas.0602606103
   Stucki D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041253
   Talarico S, 2005, J CLIN MICROBIOL, V43, P4954, DOI 10.1128/JCM.43.10.4954-4960.2005
   Talarico S, 2008, TUBERCULOSIS, V88, P283, DOI 10.1016/j.tube.2008.01.001
   Talarico S, 2007, TUBERCULOSIS, V87, P338, DOI 10.1016/j.tube.2007.03.003
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tufariello JM, 2003, LANCET INFECT DIS, V3, P578, DOI 10.1016/S1473-3099(03)00741-2
   Virji M, 2009, NAT REV MICROBIOL, V7, P274, DOI 10.1038/nrmicro2097
   Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048
   World Health Organization, 2011, GLOB TUB CONTR
   Winslow GM, 2008, IMMUNOL REV, V225, P284, DOI 10.1111/j.1600-065X.2008.00693.x
   Wirth T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000160
   Woodworth JS, 2011, J IMMUNOL, V186, P1627, DOI 10.4049/jimmunol.1002911
   Young D, 2002, NAT IMMUNOL, V3, P1026, DOI 10.1038/ni1102-1026
NR 69
TC 29
Z9 29
U1 1
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD JAN-FEB
PY 2014
VL 5
IS 1
AR e00960-13
DI 10.1128/mBio.00960-13
PG 11
WC Microbiology
SC Microbiology
GA AC4YF
UT WOS:000332526500014
PM 24425732
OA gold
DA 2017-08-15
ER

PT J
AU Jobarteh, ML
   Moore, SE
   Kennedy, C
   Gambling, L
   McArdle, HJ
AF Jobarteh, M. L.
   Moore, S. E.
   Kennedy, C.
   Gambling, L.
   McArdle, H. J.
TI The effect of delay in collection and processing on RNA integrity in
   human placenta: Experiences from rural Africa
SO PLACENTA
LA English
DT Article
DE RNA integrity number (RIN); Ribonucleic acid (RNA); Placenta transferrin
   receptor; Placental genes; Iron metabolism
AB This paper examines the relationship between time to processing and RNA quality in placentas collected from women in a field setting in rural Gambia. Placental samples were collected from the villages and transferred to the laboratory. RNA was extracted using Trizol and integrity assessed using the RNA integrity number (RIN). Values were inversely correlated with delay in processing. Expression levels of candidate genes increased with decreasing RIN. Normalising to a housekeeper gene removed this artefact. We propose a cut-off point of 90 min from delivery, after which samples cannot be used for gene expression analysis. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
C1 [Jobarteh, M. L.; Moore, S. E.] MRC Keneba, Med Res Council Unit Gambia, Banjul, Gambia.
   [Jobarteh, M. L.; Kennedy, C.; Gambling, L.; McArdle, H. J.] Univ Aberdeen, Rowett Inst Nutr & Hlth, Aberdeen AB21 9SB, Scotland.
   [Moore, S. E.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
RP McArdle, HJ (reprint author), Univ Aberdeen, Rowett Inst Nutr & Hlth, Greenburn Rd, Aberdeen AB21 9SB, Scotland.
EM h.mcardle@abdn.ac.uk
OI Jobarteh, Modou Lamin/0000-0002-7350-6980
FU UK Medical Research Council [MC-A760-5QX00]; Scottish Government (Rural
   and Environmental Sciences and Analytical Services)
FX The ENID Trial is funded by the UK Medical Research Council (core
   funding to the MRC International Nutrition Group; MC-A760-5QX00). This
   study was further supported by the Scottish Government (Rural and
   Environmental Sciences and Analytical Services). The authors are
   grateful to Dr Helen Hayes for technical assistance and are especially
   grateful to the mothers and the ENID Trial staff who made this study
   possible.
CR Carter AM, 2013, PHYSIOL REV, V92, P1543
   Cleal JK, 2009, PLACENTA, V30, P1002, DOI 10.1016/j.placenta.2009.09.002
   Fajardy I, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-21
   Lanoix D, 2010, MOL BIOTECHNOL, V52, P234
   Moore S, 2010, BMC PREGNANCY CHILDB, V12, P107
   Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3
NR 6
TC 3
Z9 3
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0143-4004
EI 1532-3102
J9 PLACENTA
JI Placenta
PD JAN
PY 2014
VL 35
IS 1
BP 72
EP 74
DI 10.1016/j.placenta.2013.08.016
PG 3
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA AA2HU
UT WOS:000330916500011
PM 24125806
OA No
DA 2017-08-15
ER

PT J
AU Alderman, H
   Hawkesworth, S
   Lundberg, M
   Tasneem, A
   Mark, H
   Moore, SE
AF Alderman, Harold
   Hawkesworth, Sophie
   Lundberg, Mattias
   Tasneem, Afia
   Mark, Henry
   Moore, Sophie E.
TI Supplemental feeding during pregnancy compared with maternal
   supplementation during lactation does not affect schooling and cognitive
   development through late adolescence
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID NUTRITIONAL SUPPLEMENTATION; EARLY-CHILDHOOD; PSYCHOSOCIAL STIMULATION;
   DIETARY SUPPLEMENTATION; MENTAL-DEVELOPMENT; GUATEMALAN ADULTS; GAMBIAN
   WOMEN; BIRTH-WEIGHT; EDUCATION; JAMAICAN
AB Background: The long-term impact of early malnutrition on human capital outcomes remains unclear, and existing evidence has come largely from observational studies.
   Objective: We compared the impact of a nutritional supplement given during pregnancy or lactation in rural Gambia on educational performance and cognitive ability in offspring at their maturity.
   Design: This study was a follow-up of a randomized trial of prenatal high protein and energy supplementation conducted between 1989 and 1994. Subjects were 16-22 y of age at follow-up, and information was collected on schooling achievement and cognitive ability by using the Raven's progressive matrices test, Mill Hill vocabulary test, and forward and backward digit-span tests.
   Results: A total of 1459 individuals were traced and interviewed and represented 71% of the original cohort and 81% of the surviving cohort. There was no difference in cognitive ability or educational attainment between treatment groups by using any of the methods of assessment.
   Conclusion: We have shown little evidence to support a long-term effect of prenatal protein-energy supplementation compared with supplementation during lactation on cognitive development in rural Gambians.
C1 [Alderman, Harold; Lundberg, Mattias; Tasneem, Afia] World Bank, Human Dev Network, Washington, DC 20433 USA.
   [Alderman, Harold] Int Food Policy Res Inst, Washington, DC 20036 USA.
   [Hawkesworth, Sophie; Mark, Henry; Moore, Sophie E.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Hawkesworth, Sophie; Mark, Henry; Moore, Sophie E.] MRC Keneba, MRC Unit, Fajara, Gambia.
RP Moore, SE (reprint author), London Sch Hyg & Trop Med, Dept Populat Hlth, Int Nutr Grp, MRC, Keppel St, London WC1E 7HT, England.
EM sophie.moore@lshtm.ac.uk
OI Hawkesworth, Sophie/0000-0002-3554-242X
FU World Bank's Strategic Impact Evaluation Fund and Research Committee;
   Medical Research Council (MRC) UK core funding [MC-A760-5QX00]
FX Supported by Research Grants from the World Bank's Strategic Impact
   Evaluation Fund and Research Committee and by the Medical Research
   Council (MRC) UK core funding to the MRC International Nutrition Group
   (MC-A760-5QX00).
CR ADAIR LS, 1985, AM J CLIN NUTR, V41, P948
   Alderman H, 2010, J DEV ORIG HLTH DIS, V1, P19, DOI 10.1017/S2040174409990158
   Alderman H., 2001, DEMOGR RES, V5, P78
   Behrman J., 2004, GLOBAL CRISES GLOBAL
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Fischer K, 1994, HUMAN BEHAV DEV BRAI
   Fitzgerald J, 1998, J HUM RESOUR, V33, P251, DOI 10.2307/146433
   Flax VL, 2012, J NUTR, V142, P1350, DOI 10.3945/jn.111.155598
   GRANTHAMMCGREGOR SM, 1991, LANCET, V338, P1, DOI 10.1016/0140-6736(91)90001-6
   Hawkesworth S, 2011, AM J CLIN NUTR, V94, p1853S
   Hawkesworth S, 2009, INT J EPIDEMIOL, V38, P119, DOI 10.1093/ije/dyn156
   Hawkesworth S, 2008, J NUTR, V138, P2468, DOI 10.3945/jn.108.098665
   Hoddinott J, 2008, LANCET, V371, P411, DOI 10.1016/S0140-6736(08)60205-6
   Huttenlocher P., 2002, NEURAL PLASTICITY EF
   Huybregts L, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001313
   Kramer MS, 2008, ARCH GEN PSYCHIAT, V65, P578, DOI 10.1001/archpsyc.65.5.578
   Leung BMY, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-12
   Lundberg M., 2012, CHILDREN YOUTH CRISI
   Maluccio JA, 2009, ECON J, V119, P734, DOI 10.1111/j.1468-0297.2009.02220.x
   MARTORELL R, 1995, J NUTR, V125, pS1027
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P53
   WABER DP, 1981, AM J CLIN NUTR, V34, P807
   Walker SP, 2011, LANCET, V378, P1325, DOI 10.1016/S0140-6736(11)60555-2
   Walker SP, 2010, DEV MED CHILD NEUROL, V52, pe148, DOI 10.1111/j.1469-8749.2010.03637.x
NR 24
TC 7
Z9 7
U1 1
U2 5
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JAN
PY 2014
VL 99
IS 1
BP 122
EP 129
DI 10.3945/ajcn.113.063404
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 281DN
UT WOS:000329080200016
PM 24132979
OA No
DA 2017-08-15
ER

PT J
AU Last, AR
   Roberts, CH
   Cassama, E
   Nabicassa, M
   Molina-Gonzalez, S
   Burr, SE
   Mabey, DCW
   Bailey, RL
   Holland, MJ
AF Last, Anna R.
   Roberts, Chrissy H.
   Cassama, Eunice
   Nabicassa, Meno
   Molina-Gonzalez, Sandra
   Burr, Sarah E.
   Mabey, David C. W.
   Bailey, Robin L.
   Holland, Martin J.
TI Plasmid Copy Number and Disease Severity in Naturally Occurring Ocular
   Chlamydia trachomatis Infection
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID TRANSCRIPTIONAL REGULATOR; NONHUMAN-PRIMATES; DIGITAL PCR; VIRULENCE;
   DIVERSITY; STRAINS; GENES
AB The Chlamydia trachomatis plasmid is a virulence factor. Plasmid copy number, C. trachomatis load and disease severity were assessed in a treatment-naive population where trachoma is hyperendemic. By using droplet digital PCR, plasmid copy number was found to be stable (median, 5.34 [range, 1 to 18]) and there were no associations with C. trachomatis load or disease severity.
C1 [Last, Anna R.; Roberts, Chrissy H.; Molina-Gonzalez, Sandra; Burr, Sarah E.; Mabey, David C. W.; Bailey, Robin L.; Holland, Martin J.] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England.
   [Cassama, Eunice; Nabicassa, Meno] Minist Saude Publ, Programa Nacl Saude Visao, Bissau, Guinea Bissau.
   [Burr, Sarah E.] Med Res Council Unit Gambia, Fajara, Gambia.
RP Last, AR (reprint author), London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England.
EM anna.last@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276
FU Wellcome Trust [097330/Z/11/Z]
FX This work was supported by the Wellcome Trust (grant 097330/Z/11/Z).
CR AN Q, 1992, J CLIN MICROBIOL, V30, P2814
   Carlson JH, 2008, INFECT IMMUN, V76, P2273, DOI 10.1128/IAI.00102-08
   COMANDUCCI M, 1994, INFECT IMMUN, V62, P5491
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Ferreira R, 2013, MICROBIOL RES, V168, P333, DOI 10.1016/j.micres.2013.02.001
   Frazer LC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030747
   Hindson CM, 2013, NAT METHODS, V10, P1003, DOI 10.1038/nmeth.2633
   Kari L, 2008, J INFECT DIS, V197, P449, DOI 10.1086/525285
   Kari L, 2011, J EXP MED, V208, P2217, DOI 10.1084/jem.20111266
   Keenan JD, 2010, AM J TROP MED HYG, V82, P482, DOI 10.4269/ajtmh.2010.09-0315
   Miyairi I, 2011, J INFECT DIS, V204, P654, DOI 10.1093/infdis/jir333
   Nunes A, 2013, INFECT GENET EVOL, V16, P392, DOI 10.1016/j.meegid.2013.03.018
   O'Connell CM, 2007, J IMMUNOL, V179, P4027
   O'Connell CM, 2011, INFECT IMMUN, V79, P1044, DOI 10.1128/IAI.01118-10
   PALMER L, 1986, PLASMID, V16, P52, DOI 10.1016/0147-619X(86)90079-X
   PETERSON EM, 1990, PLASMID, V23, P144, DOI 10.1016/0147-619X(90)90033-9
   Pickett MA, 2005, MICROBIOL-SGM, V151, P893, DOI 10.1099/mic.0.27625-0
   Roberts CH, 2013, J CLIN MICROBIOL, V51, P2195, DOI 10.1128/JCM.00622-13
   Russell M, 2011, INFECT IMMUN, V79, P98, DOI 10.1128/IAI.01105-10
   Seth-Smith HMB, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-239
   Song LH, 2013, INFECT IMMUN, V81, P636, DOI 10.1128/IAI.01305-12
   Stare D, 2011, OPHTHAL EPIDEMIOL, V18, P20, DOI 10.3109/09286586.2010.545500
   TAM JE, 1992, PLASMID, V27, P231, DOI 10.1016/0147-619X(92)90025-6
   Thomas NS, 1997, MICROBIOL-SGM, V143, P1847
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0
NR 26
TC 12
Z9 12
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JAN
PY 2014
VL 52
IS 1
BP 324
EP 327
DI 10.1128/JCM.02618-13
PG 4
WC Microbiology
SC Microbiology
GA 283CM
UT WOS:000329222400051
PM 24197878
OA No
DA 2017-08-15
ER

PT J
AU Lemoine, M
   Shimakawa, Y
   Njie, R
   Njai, HF
   Nayagam, S
   Khalil, M
   Goldin, R
   Ingiliz, P
   Taal, M
   Nyan, O
   Corrah, T
   D'Alessandro, U
   Thursz, M
AF Lemoine, M.
   Shimakawa, Y.
   Njie, R.
   Njai, H. F.
   Nayagam, S.
   Khalil, M.
   Goldin, R.
   Ingiliz, P.
   Taal, M.
   Nyan, O.
   Corrah, T.
   D'Alessandro, U.
   Thursz, M.
TI Food intake increases liver stiffness measurements and hampers reliable
   values in patients with chronic hepatitis B and healthy controls: the
   PROLIFICA experience in The Gambia
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID TRANSIENT ELASTOGRAPHY; NONINVASIVE ASSESSMENT; PORTAL-HYPERTENSION; C
   VIRUS; FIBROSIS; CIRRHOSIS; HEMODYNAMICS; DOPPLER; PERFORMANCE; MEAL
AB BackgroundBy increasing the hepatic blood circulation, food intake has been suggested to increase liver stiffness measurement (LSM) values in HCV-infected patients.
   AimTo investigate prospectively the effects of food intake on LSM in hepatitis B virus (HBV)-infected patients and healthy controls.
   MethodsIn The Gambia, patients included in the PROLIFICA project are screened for HBV at the community level and then invited for fasting assessment including LSM. Between April 2012 and October 2012, each day, the first five participants were invited to participate in this study. After the initial examination, a standardised 850Kcal breakfast was provided. Effect of food intake was assessed by examining mean difference of LSM, IQR and IQR/LSM at T0 (fasting LSM1), T30min (LSM2) and T120min (LSM3) respectively.
   ResultsA total of 209 subjects were enrolled in this study (133 were HBV positive, 76 healthy controls). Unreliable measurements occurred more frequently after food intake (5%, 24% and 18% at T0, T30min and T120min respectively). In both groups, median LSM2 was significantly higher than LSM1 [6.2 (IQR: 5.4, 7.9)] vs. 4.9 (4.2, 6.2), P<0.0001. LSM3 was still higher than the baseline, but lower than LSM2. In multivariable analysis, no factor modified the effect of breakfast on LSM. In a subgroup of patients having liver biopsies, we confirmed that food intake can overestimate liver fibrosis.
   ConclusionsFood intake significantly increases liver stiffness measurement and its IQR values in patients with chronic hepatitis B as well as healthy individuals; and also the number of unreliable liver stiffness measurement values.
C1 [Lemoine, M.; Shimakawa, Y.; Njie, R.; Njai, H. F.; Corrah, T.; D'Alessandro, U.] Liver Unit, Dis Control & Eliminat Theme, Gambia Unit, Med Res Council, Fajara, Gambia.
   [Lemoine, M.; Nayagam, S.; Thursz, M.] Univ London Imperial Coll Sci Technol & Med, Dept Hepatol, London, England.
   [Shimakawa, Y.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England.
   [Khalil, M.] Royal Victoria Teaching Hosp, Dept Histopathol, Banjul, Gambia.
   [Goldin, R.] Univ London Imperial Coll Sci Technol & Med, Ctr Pathol, London, England.
   [Ingiliz, P.] Med Ctr Infect Dis, Berlin, Germany.
   [Taal, M.] Minist Hlth & Social Welf, Banjul, Gambia.
   [Nyan, O.] Edward Francis Small Teaching Hosp, Sch Med, Banjul, Senegal.
RP Lemoine, M (reprint author), Gambia Unit, Med Res Council Labs, Fajara, Gambia.
EM mlemoine@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Nayagam, Amanda
   Shevanthi/0000-0002-8030-3380
FU European Union (FP7)
FX This study is part of the PROLIFICA programme funded by the European
   Union (FP7) coordinated by Prof. Mark Thursz.
CR Arena U, 2008, HEPATOLOGY, V47, P380, DOI 10.1002/hep.22007
   Arena U, 2013, HEPATOLOGY, V58, P65, DOI 10.1002/hep.26343
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   BENDTSEN F, 1992, GASTROENTEROLOGY, V102, P1017
   Berzigotti A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058742
   Cardoso AC, 2012, LIVER INT, V32, P612, DOI 10.1111/j.1478-3231.2011.02660.x
   Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018
   Castera L, 2008, J HEPATOL, V48, P835, DOI 10.1016/j.jhep.2008.02.008
   Castera L, 2012, GASTROENTEROLOGY, V142, P1293, DOI 10.1053/j.gastro.2012.02.017
   Castera L, 2010, HEPATOLOGY, V51, P828, DOI 10.1002/hep.23425
   Coco B, 2007, J VIRAL HEPATITIS, V14, P360, DOI 10.1111/j.1365-2893.2006.00811.x
   Colli A, 2010, RADIOLOGY, V257, P872, DOI 10.1148/radiol.10100013
   DAUZAT M, 1994, EUR J APPL PHYSIOL, V68, P373, DOI 10.1007/BF00843732
   DAUZAT M, 1994, J ULTRAS MED, V13, P129
   Friedrich-Rust M, 2008, GASTROENTEROLOGY, V134, P960, DOI 10.1053/j.gastro.2008.01.034
   Iwao T, 1996, RADIOLOGY, V201, P711
   Lemoine M, 2008, ALIMENT PHARM THER, V28, P1102, DOI 10.1111/j.1365-2036.2008.03825.x
   Marcellin P, 2009, LIVER INT, V29, P242, DOI 10.1111/j.1478-3231.2008.01802.x
   Mederacke I, 2009, LIVER INT, V29, P1500, DOI 10.1111/j.1478-3231.2009.02100.x
   Millonig G, 2008, HEPATOLOGY, V48, P1718, DOI 10.1002/hep.22577
   OBRIEN S, 1992, GUT, V33, P364, DOI 10.1136/gut.33.3.364
   Popescu A, 2013, ULTRASOUND MED BIOL, V39, P579, DOI 10.1016/j.ultrasmedbio.2012.11.013
   Salvatore V, 2012, DIGEST LIVER DIS, V44, P154, DOI 10.1016/j.dld.2011.08.021
   Sandrin L, 2003, ULTRASOUND MED BIOL, V29, P1705, DOI 10.1016/j.ultrasmedbio.2003.07.001
   Vizzutti F, 2007, HEPATOLOGY, V45, P1290, DOI 10.1002/hep.21665
   Ziol M, 2005, HEPATOLOGY, V41, P48, DOI 10.1002/hep.20506
NR 26
TC 15
Z9 17
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD JAN
PY 2014
VL 39
IS 2
BP 188
EP 196
DI 10.1111/apt.12561
PG 9
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 269ZK
UT WOS:000328283900007
PM 24308698
OA No
DA 2017-08-15
ER

PT J
AU Lemoine, M
   Thursz, M
   Njie, R
   Dusheiko, G
AF Lemoine, Maud
   Thursz, Mark
   Njie, Ramou
   Dusheiko, Geoffrey
TI Forgotten, not neglected: viral hepatitis in resource-limited settings,
   recall for action
SO LIVER INTERNATIONAL
LA English
DT Article
DE access to treatment; global health policy; hepatocellular carcinoma;
   HIV; AIDS-resource-limited countries; viral hepatitis
ID TO-INFANT TRANSMISSION; LIVER-DISEASE; B-VIRUS; TIME; INFECTION;
   HIV/AIDS; THERAPY
AB In 2010, the World Health Assembly adopted a resolution calling for interventions for the prevention and control of chronic viral hepatitis. These infectious diseases mostly affect resource-limited countries accounting for 80% of the world's population and facing numerous obstacles to contain the epidemic. At a time when morbidity and mortality of chronic liver disease have been considerably improved in wealthy countries by new innovative strategies and new potent antiviral drugs, it is now urgent to recall for concrete actions from stakeholders of global health policy to reduce the burden in resource-limited countries.
C1 [Lemoine, Maud; Njie, Ramou] Gambia Unit, Med Res Council Labs, Fajara, Gambia.
   [Thursz, Mark] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Hepatol & Gastroenterol, London, England.
   [Dusheiko, Geoffrey] Royal Free Hosp, UCL Inst Liver & Digest Hlth, London NW3 2QG, England.
   [Dusheiko, Geoffrey] UCL Med Sch, London, England.
RP Lemoine, M (reprint author), MRC, Liver Unit, Gambia Unit, Atlantic Rd,Fajara POB 273, Fajara, Gambia.
EM mlemoine@mrc.gm
FU Medical Research Council [MC_UP_A900_1120]
CR Chen HL, 2012, GASTROENTEROLOGY, V142, P773, DOI 10.1053/j.gastro.2011.12.035
   Dusheiko G, 2012, LANCET, V379, P2019, DOI 10.1016/S0140-6736(11)61182-3
   Easterbrook P, 2012, SEMIN LIVER DIS, V32, P147, DOI 10.1055/s-0032-1316476
   Ford N, 2012, B WORLD HEALTH ORGAN, V90, P540, DOI 10.2471/BLT.11.097147
   Ford N, 2012, CLIN INFECT DIS, V54, P1465, DOI 10.1093/cid/cis227
   Ford N, 2010, CURR OPIN HIV AIDS, V5, P38, DOI 10.1097/COH.0b013e3283339b41
   Jemal A, 2012, CANCER-AM CANCER SOC, V118, P4372, DOI 10.1002/cncr.27410
   Joshi D, 2011, LANCET, V377, P1198, DOI 10.1016/S0140-6736(10)62001-6
   Kuhn R, 2012, NAT MED, V18, P1168, DOI 10.1038/nm0812-1168
   Lemoine M, 2013, J HEPATOL, V58, pS402
   Lemoine M, 2012, J PUBLIC HEALTH POL, V33, P430, DOI 10.1057/jphp.2012.29
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013
   Piot P., 2012, NO TIME LOSE LIFE PU
   Piot P, 2013, NEW ENGL J MED, V368, P2210, DOI 10.1056/NEJMra1201533
   Stiglitz J., 2002, GLOBALIZATION ITS DI
   Thursz M, 2012, NAT REV GASTRO HEPAT, V9, P492, DOI 10.1038/nrgastro.2012.155
   Thursz M, 2010, TROP MED INT HEALTH, V15, P2, DOI 10.1111/j.1365-3156.2009.02410.x
   WHO, 2012, 2012 REP EST 3 DOS H
   WHO, 2009, UN ACC
   World Health Assembly, 2010, WHA6318 WHO
NR 21
TC 8
Z9 8
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1478-3223
EI 1478-3231
J9 LIVER INT
JI Liver Int.
PD JAN
PY 2014
VL 34
IS 1
BP 12
EP 15
DI 10.1111/liv.12283
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 265UP
UT WOS:000327977700004
PM 23998284
OA No
DA 2017-08-15
ER

PT J
AU Jasseh, M
   Howie, SRC
   Gomez, P
   Scott, S
   Roca, A
   Cham, M
   Greenwood, B
   Corrah, T
   D'Alessandro, U
AF Jasseh, Momodou
   Howie, Stephen R. C.
   Gomez, Pierre
   Scott, Susana
   Roca, Anna
   Cham, Mamady
   Greenwood, Brian
   Corrah, Tumani
   D'Alessandro, Umberto
TI Disease-specific mortality burdens in a rural Gambian population using
   verbal autopsy, 1998-2007
SO GLOBAL HEALTH ACTION
LA English
DT Article
DE verbal autopsy; cause of death; mortality; disease-specific mortality;
   communicable disease; non-communicable disease; Farafenni; The Gambia
AB Objective: To estimate and evaluate the cause-of-death structure and disease-specific mortality rates in a rural area of The Gambia as determined using the InterVA-4 model.
   Design: Deaths and person-years of observation were determined by age group for the population of the Farafenni Health and Demographic Surveillance area from January 1998 to December 2007. Causes of death were determined by verbal autopsy (VA) using the InterVA-4 model and ICD-10 disease classification. Assigned causes of death were classified into six broad groups: infectious and parasitic diseases; cancers; other non-communicable diseases; neonatal; maternal; and external causes. Poisson regression was used to estimate age and disease-specific mortality rates, and likelihood ratio tests were used to determine statistical significance.
   Results: A total of 3,203 deaths were recorded and VA administered for 2,275 (71%). All-age mortality declined from 15 per 1,000 person-years in 1998-2001 to 8 per 1,000 person-years in 2005-2007. Children aged 1-4 years registered the most marked (74%) decline from 27 to 7 per 1,000 person-years. Communicable diseases accounted for half (49.9%) of the deaths in all age groups, dominated by acute respiratory infections (ARI) (13.7%), malaria (12.9%) and pulmonary tuberculosis (10.2%). The leading causes of death among infants were ARI (5.59 per 1,000 person-years [95% CI: 4.38-7.15]) and malaria (4.11 per 1,000 person-years [95% CI: 3.09-5.47]). Mortality rates in children aged 1-4 years were 3.06 per 1,000 person-years (95% CI: 2.58-3.63) for malaria, and 1.05 per 1,000 person-years (95% CI: 0.79-1.41) for ARI. The HIV-related mortality rate in this age group was 1.17 per 1,000 person-years (95% CI: 0.89-1.54). Pulmonary tuberculosis and communicable diseases other than malaria, HIV/AIDS and ARI were the main killers of adults aged 15 years and over. Stroke-related mortality increased to become the leading cause of death among the elderly aged 60 years or more in 2005-2007.
   Conclusions: Mortality in the Farafenni HDSS area was dominated by communicable diseases. Malaria and ARI were the leading causes of death in the general population. In addition to these, diarrhoeal disease was a particularly important cause of death among children under 5 years of age, as was pulmonary tuberculosis among adults aged 15 years and above.
C1 [Jasseh, Momodou; Howie, Stephen R. C.; Gomez, Pierre; Scott, Susana; Roca, Anna; Corrah, Tumani; D'Alessandro, Umberto] MRC, Gambia Unit, Atlantic Blvd,POB 273, Fajara, Banjul, Gambia.
   [Jasseh, Momodou] INDEPTH Network, Accra, Ghana.
   [Scott, Susana; Greenwood, Brian] London Sch Hyg & Trop Med, London WC1, England.
   [Cham, Mamady] AFPRC Gen Hosp, Farafenni, Gambia.
RP Jasseh, M (reprint author), MRC, Gambia Unit, Atlantic Blvd,POB 273, Fajara, Banjul, Gambia.
EM mjasseh@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU INDEPTH Secretariat from Sida (Research Cooperation); Wellcome Trust;
   William & Flora Hewlett Foundation
FX We are grateful to the residents of the Farafenni HDSS and all the
   respondents who agreed to participate in the verbal autopsy interviews.
   We also express sincere gratitude to the following fieldworkers for
   conducting the VA interviews: Louie Loppy, Lamin M.D. Sanneh, Rohey
   John, Bakary Jallow, Saikou Sawo, Lamin Makalo, Ebrima Janneh, Malick
   Njie, Tumani Trawally, Foday Conteh, Yerro Bah, Ebou Touray, Yamundow
   Jallow and Yusupha Dampha. Thanks also to Dr. Ifedayo Adetifa for useful
   comments on an earlier version of the manuscript. We are grateful to the
   INDEPTH Secretariat for organising and funding a series of data analysis
   and scientific writing workshops in Ghana, Thailand, Belgium and UK
   through core support grants from Sida (Research Cooperation), the
   Wellcome Trust and the William & Flora Hewlett Foundation.
CR Baiden F, 2007, B WORLD HEALTH ORGAN, V85, P570, DOI 10.2471/BLT.07.043745
   Bauni E, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-49
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Byass P, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.19281
   Byass P, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-46
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Etard JF, 2004, INT J EPIDEMIOL, V33, P1286, DOI 10.1093/ije/dyh259
   Fottrell E, 2010, EPIDEMIOL REV, V32, P38, DOI 10.1093/epirev/mxq003
   Gambia Bureau of Statistics, 2007, GAMB MULT IND CLUST
   Gambia Government, 2012, NAT HLTH POL 2012 20, P52
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   Herbst AJ, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-47
   INDEPTH Network, 2014, INDEPTH NETW CAUS SP, DOI [10.7796/INDEPTH.GH003.COD2014.v1, DOI 10.7796/INDEPTH.GH003.C0D2014.V1]
   INDEPTH Network, 2002, POP HLTH DEV COUNTR, V1
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Jasseh M, 2011, TROP MED INT HEALTH, V16, P1314, DOI 10.1111/j.1365-3156.2011.02809.x
   Kumar R, 2012, J EPIDEMIOL COMMUN H, V66, P890, DOI 10.1136/jech-2011-200336
   Leitao J, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.21518
   Masanja H, 2008, LANCET, V371, P1276, DOI 10.1016/S0140-6736(08)60562-0
   Mathers CD, 2009, BRIT MED BULL, V92, P7, DOI 10.1093/bmb/ldp028
   Murray CJL, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-18
   Nakamura H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017774
   Oti SO, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-21
   Payne S, 2014, HEALTH POLICY PLANN, V29, P193, DOI 10.1093/heapol/czt004
   Ramroth H, 2012, TROP MED INT HEALTH, V17, P904, DOI 10.1111/j.1365-3156.2012.02998.x
   Rutherford ME, 2009, TROP MED INT HEALTH, V14, P149, DOI 10.1111/j.1365-3156.2008.02204.x
   Setel PW, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-20
   Soleman N, 2006, B WORLD HEALTH ORGAN, V84, P239, DOI 10.2471/BLT.05.027003
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   van der Sande MAB, 2001, B WORLD HEALTH ORGAN, V79, P133
   van der Sande MAB, 2000, J HUM HYPERTENS, V14, P489, DOI 10.1038/sj.jhh.1001050
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
NR 33
TC 5
Z9 5
U1 0
U2 1
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PY 2014
VL 7
BP 1
EP 12
AR 25598
DI 10.3402/gha.v7.25598
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V44GE
UT WOS:000209736700001
PM 25377344
OA gold
DA 2017-08-15
ER

PT J
AU Streatfield, PK
   Alam, N
   Compaore, Y
   Rossier, C
   Soura, AB
   Bonfoh, B
   Jaeger, F
   Ngoran, EK
   Utzinger, J
   Gomez, P
   Jasseh, M
   Ansah, A
   Debpuur, C
   Oduro, A
   Williams, J
   Addei, S
   Gyapong, M
   Kukula, VA
   Bauni, E
   Mochamah, G
   Ndila, C
   Williams, TN
   Desai, M
   Moige, H
   Odhiambo, FO
   Ogwang, S
   Beguy, D
   Ezeh, A
   Oti, S
   Chihana, M
   Crampin, A
   Price, A
   Delaunay, V
   Diallo, A
   Douillot, L
   Sokhna, C
   Collinson, MA
   Kahn, K
   Tollman, SM
   Herbst, K
   Mossong, J
   Emina, JBO
   Sankoh, OA
   Byass, P
AF Streatfield, P. Kim
   Alam, Nurul
   Compaore, Yacouba
   Rossier, Clementine
   Soura, Abdramane B.
   Bonfoh, Bassirou
   Jaeger, Fabienne
   Ngoran, Eliezer K.
   Utzinger, Juerg
   Gomez, Pierre
   Jasseh, Momodou
   Ansah, Akosua
   Debpuur, Cornelius
   Oduro, Abraham
   Williams, John
   Addei, Sheila
   Gyapong, Margaret
   Kukula, Vida A.
   Bauni, Evasius
   Mochamah, George
   Ndila, Carolyne
   Williams, Thomas N.
   Desai, Meghna
   Moige, Hellen
   Odhiambo, Frank O.
   Ogwang, Sheila
   Beguy, Donatien
   Ezeh, Alex
   Oti, Samuel
   Chihana, Menard
   Crampin, Amelia
   Price, Alison
   Delaunay, Valerie
   Diallo, Aldiouma
   Douillot, Laetitia
   Sokhna, Cheikh
   Collinson, Mark A.
   Kahn, Kathleen
   Tollman, Stephen M.
   Herbst, Kobus
   Mossong, Joel
   Emina, Jacques B. O.
   Sankoh, Osman A.
   Byass, Peter
TI Pregnancy-related mortality in Africa and Asia: evidence from INDEPTH
   Health and Demographic Surveillance System sites
SO GLOBAL HEALTH ACTION
LA English
DT Article
DE maternal mortality; cause of death; Africa; Asia; verbal autopsy;
   INDEPTH Network
AB Background: Women continue to die in unacceptably large numbers around the world as a result of pregnancy, particularly in sub-Saharan Africa and Asia. Part of the problem is a lack of accurate, population-based information characterising the issues and informing solutions. Population surveillance sites, such as those operated within the INDEPTH Network, have the potential to contribute to bridging the information gaps.
   Objective: To describe patterns of pregnancy-related mortality at INDEPTH Network Health and Demographic Surveillance System sites in sub-Saharan Africa and southeast Asia in terms of maternal mortality ratio (MMR) and cause-specific mortality rates. Design: Data on individual deaths among women of reproductive age (WRA) (15-49) resident in INDEPTH sites were collated into a standardised database using the INDEPTH 2013 population standard, the WHO 2012 verbal autopsy (VA) standard, and the InterVA model for assigning cause of death.
   Results: These analyses are based on reports from 14 INDEPTH sites, covering 14,198 deaths among WRA over 2,595,605 person-years observed. MMRs varied between 128 and 461 per 100,000 live births, while maternal mortality rates ranged from 0.11 to 0.74 per 1,000 person-years. Detailed rates per cause are tabulated, including analyses of direct maternal, indirect maternal, and incidental pregnancy-related deaths across the 14 sites.
   Conclusions: As expected, these findings confirmed unacceptably high continuing levels of maternal mortality. However, they also demonstrate the effectiveness of INDEPTH sites and of the VA methods applied to arrive at measurements of maternal mortality that are essential for planning effective solutions and monitoring programmatic impacts.
C1 [Streatfield, P. Kim] Matlab HDSS, Chandpur Dist, Bangladesh.
   [Streatfield, P. Kim; Ezeh, Alex] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Streatfield, P. Kim; Alam, Nurul; Compaore, Yacouba; Rossier, Clementine; Soura, Abdramane B.; Bonfoh, Bassirou; Jaeger, Fabienne; Ngoran, Eliezer K.; Utzinger, Juerg; Gomez, Pierre; Jasseh, Momodou; Ansah, Akosua; Debpuur, Cornelius; Oduro, Abraham; Williams, John; Addei, Sheila; Gyapong, Margaret; Kukula, Vida A.; Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.; Desai, Meghna; Moige, Hellen; Odhiambo, Frank O.; Ogwang, Sheila; Beguy, Donatien; Oti, Samuel; Chihana, Menard; Crampin, Amelia; Price, Alison; Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh; Collinson, Mark A.; Kahn, Kathleen; Tollman, Stephen M.; Herbst, Kobus; Mossong, Joel; Emina, Jacques B. O.; Sankoh, Osman A.; Byass, Peter] INDEPTH Network, POB KD213, Kanda, Accra, Ghana.
   [Alam, Nurul] AMK HDSS, Dhaka, Bangladesh.
   [Alam, Nurul] Int Ctr Diarrhoeal Dis Res, Ctr Populat Urbanisat & Climate Change, Dhaka 1000, Bangladesh.
   [Compaore, Yacouba; Rossier, Clementine; Soura, Abdramane B.] Ouagadougou HDSS, Ouagadougou, Burkina Faso.
   [Compaore, Yacouba; Rossier, Clementine; Soura, Abdramane B.] Univ Ouagadougou, Inst Super Sci Populat, Ouagadougou, Burkina Faso.
   [Rossier, Clementine] Univ Geneva, Inst Etud Demog & Parcours Vie, Geneva, Switzerland.
   [Bonfoh, Bassirou; Jaeger, Fabienne; Ngoran, Eliezer K.; Utzinger, Juerg] Taabo HDSS, Taabo, Cote Ivoire.
   [Bonfoh, Bassirou; Jaeger, Fabienne; Ngoran, Eliezer K.; Utzinger, Juerg] Ctr Suisse Rech Sci Cote Iviore, Abidjan, Cote Ivoire.
   [Jaeger, Fabienne; Utzinger, Juerg] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Ngoran, Eliezer K.] Univ Felix Houphoet Boigny, Abidjan, Cote Ivoire.
   [Gomez, Pierre; Jasseh, Momodou] Farafenni HDSS, Farafenni, Gambia.
   [Gomez, Pierre; Jasseh, Momodou] MRC, Gambia Unit, Fajara, Gambia.
   [Ansah, Akosua; Debpuur, Cornelius; Oduro, Abraham; Williams, John] Navrongo HDSS, Navrongo, Ghana.
   [Ansah, Akosua; Debpuur, Cornelius; Oduro, Abraham; Williams, John] Navrongo Hlth Res Ctr, Navrongo, Ghana.
   [Addei, Sheila; Gyapong, Margaret; Kukula, Vida A.] Dodowa HDSS, Dodowa, Ghana.
   [Addei, Sheila; Gyapong, Margaret; Kukula, Vida A.] Dodowa Hlth Res Ctr, Dodowa, Ghana.
   [Kukula, Vida A.] Univ Ghana, Sch Publ Hlth, Legon, Ghana.
   [Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.] Kilifi HDSS, Kilifi, Kenya.
   [Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Med, London, England.
   [Desai, Meghna; Moige, Hellen; Odhiambo, Frank O.; Ogwang, Sheila] Kisumu HDSS, Kisumu, Kenya.
   [Desai, Meghna; Moige, Hellen; Odhiambo, Frank O.; Ogwang, Sheila] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya.
   [Desai, Meghna; Moige, Hellen; Odhiambo, Frank O.; Ogwang, Sheila] KEMRI Ctr Global Hlth Res, Kisumu, Kenya.
   [Beguy, Donatien; Ezeh, Alex; Oti, Samuel] African Populat & Hlth Res Ctr, Nairobi, Kenya.
   [Chihana, Menard; Crampin, Amelia; Price, Alison] Karonga HDSS, Karonga, Malawi.
   [Chihana, Menard; Crampin, Amelia; Price, Alison] Karonga Prevent Study, Chilumba, Malawi.
   [Crampin, Amelia; Price, Alison] London Sch Hyg & Trop Med, London WC1, England.
   [Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh] Niakhar HDSS, Niakhar, Senegal.
   [Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh] IRD, Dakar, Senegal.
   [Collinson, Mark A.; Kahn, Kathleen; Tollman, Stephen M.] Agincourt HDSS, Johannesburg, South Africa.
   [Collinson, Mark A.; Kahn, Kathleen; Tollman, Stephen M.; Byass, Peter] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Johannesburg, South Africa.
   [Collinson, Mark A.; Kahn, Kathleen; Tollman, Stephen M.] Umea Univ, Umea Ctr Global Hlth Res, Umea, Sweden.
   [Herbst, Kobus; Mossong, Joel] Africa Ctr HDSS, Johannesburg, South Africa.
   [Herbst, Kobus; Mossong, Joel] Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Somkhele, Kwazulu Natal, South Africa.
   [Mossong, Joel] Natl Hlth Lab, Surveillance & Epidemiol Infect Dis, Dudelange, Luxembourg.
   [Sankoh, Osman A.] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa.
   [Sankoh, Osman A.] Hanoi Med Univ, Hanoi 100803, Vietnam.
   [Byass, Peter] Umea Univ, Umea Ctr Global Hlth Res, WHO Collaborating Ctr Verbal Autopsy, Umea, Sweden.
RP Sankoh, OA (reprint author), INDEPTH Network, POB KD213, Kanda, Accra, Ghana.
EM osman.sankoh@indepth-network.org
RI Mossong, Joel/D-4998-2009
OI Mossong, Joel/0000-0003-0717-9835; Ezeh, Alex/0000-0002-1309-4697;
   Price, Alison/0000-0002-3891-3337; Byass, Peter/0000-0001-5474-4361
FU Sida; Wellcome Trust; William & Flora Hewlett Foundation; Forte, the
   Swedish Research Council for Health, Working Life and Welfare
   [2006-1512]; European Community [295168]; Government of Australia;
   Government of Bangladesh; Government of Canada; Government of Sweden;
   Government of UK; Wellcome Trust [WT081993MA, 091758, 084538]; UK
   Medical Research Council; Rockefeller Foundation (USA); Wellcome Trust
   (UK); William and Flora Hewlett Foundation (USA); Comic Relief (UK);
   Swedish International Development Cooperation Agency (SIDA); Bill and
   Melinda Gates Foundation (USA); Wellcome Trust, UK [058893/Z/99/A,
   069683/Z/02/Z, 085477/Z/08/Z]; National Institute on Aging (NIA) of the
   NIH; William and Flora Hewlett Foundation; Andrew W Mellon Foundation,
   USA
FX We are grateful to all the residents of INDEPTH HDSS sites who have
   contributed personal information to this mortality dataset, to the field
   staff who undertook so many VA interviews, and the data management staff
   who handled the data at every participating site. INDEPTH thanks all the
   site scientists who have participated in bringing this work together,
   and who variously participated in analysis workshops in Ghana, Belgium,
   Thailand, and the United Kingdom. The INDEPTH Network is grateful for
   core funding from Sida, the Wellcome Trust, and the William & Flora
   Hewlett Foundation. The Umea Centre for Global Health Research is core
   funded by Forte, the Swedish Research Council for Health, Working Life
   and Welfare (grant 2006-1512). PB's residency at the University of the
   Witwatersrand Rural Knowledge Hub to analyse and draft these results was
   supported by the European Community Marie Curie Actions IPHTRE project
   (no. 295168). icddr,b is thankful to the Governments of Australia,
   Bangladesh, Canada, Sweden and the UK for providing core/unrestricted
   support. The Ouagadougou site is thankful to the Wellcome Trust for its
   financial support to the Ouagadougou HDSS (grant number WT081993MA). The
   Farafenni site is supported by the UK Medical Research Council. The
   Kilifi HDSS is supported through core support to the KEMRI-Wellcome
   Trust Major Overseas Programme from the Wellcome Trust. TNW is supported
   by a Senior Fellowship (091758) and CN through a Strategic Award
   (084538) from the Wellcome Trust. This paper is published with
   permission from the Director of KEMRI. The Kisumu site wishes to
   acknowledge the contribution of the late Dr. Kubaje Adazu to the
   development of KEMRI/CDC HDSS, which was implemented and continues to be
   supported through a cooperative agreement between KEMRI and CDC. The
   Nairobi Urban Health and Demographic Surveillance System (NUHDSS),
   Kenya, since its inception has received support from the Rockefeller
   Foundation (USA), the Wellcome Trust (UK), the William and Flora Hewlett
   Foundation (USA), Comic Relief (UK), the Swedish International
   Development Cooperation Agency (SIDA) and the Bill and Melinda Gates
   Foundation (USA). The Agincourt site notes that the School of Public
   Health and Faculty of Health Sciences, University of the Witwatersrand,
   and the Medical Research Council, South Africa, have provided vital
   support since inception of the Agincourt HDSS. Core funding has been
   provided by The Wellcome Trust, UK (Grants 058893/Z/99/A; 069683/Z/02/Z;
   085477/Z/08/Z) with contributions from the National Institute on Aging
   (NIA) of the NIH, William and Flora Hewlett Foundation, and Andrew W
   Mellon Foundation, USA.
CR Byass P, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.22448
   Byass P, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.19281
   Byass P, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000155
   Crampin AC, 2012, INT J EPIDEMIOL, V41, P676, DOI 10.1093/ije/dys088
   Delaunay V, 2013, INT J EPIDEMIOL, V42, P1002, DOI 10.1093/ije/dyt100
   Garenne M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064414
   Gyapong M, 2013, INT J EPIDEMIOL, V42, P1686, DOI 10.1093/ije/dyt197
   Herbst AJ, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-47
   INDEPIH Network, 2014, INDEPTH NETW CAUS SP, DOI [10.7796/INDEPTH.GH003.COD2014.vl, DOI 10.7796/INDEPTH.GH003.COD2014.V1]
   Jasseh M, 2011, TROP MED INT HEALTH, V16, P1314, DOI 10.1111/j.1365-3156.2011.02809.x
   Kahn K, 2012, INT J EPIDEMIOL, V41, P988, DOI 10.1093/ije/dys115
   Kassebaum NJ, 2014, LANCET, V384, P980, DOI 10.1016/S0140-6736(14)60696-6
   Kouadio M'bra Kd, 2013, BMC Hematol, V13, P5, DOI 10.1186/2052-1839-13-5
   Leitao J, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.21518
   Lindeboom W, 2011, HLTH DEMOGRAPHIC SUR
   [ICF International Measure DHS], 2013, DEM HLTH SURV METH
   Merdad L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059834
   Odhiambo FO, 2012, INT J EPIDEMIOL, V41, P977, DOI 10.1093/ije/dys108
   Oduro AR, 2012, INT J EPIDEMIOL, V41, P968, DOI 10.1093/ije/dys111
   Oti SO, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-588
   Razzaque A, 2010, GLOBAL HEALTH ACTION, V3, P70, DOI 10.3402/gha.v3i0.4618
   Rossier C, 2012, INT J EPIDEMIOL, V41, P658, DOI 10.1093/ije/dys090
   Sankoh O, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.23286
   Sankoh O, 2012, INT J EPIDEMIOL, V41, P579, DOI 10.1093/ije/dys081
   Scott JAG, 2012, INT J EPIDEMIOL, V41, P650, DOI 10.1093/ije/dys062
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25370
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25369
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25362
   World Health Organization, 2012, TRENDS MAT MORT 1990
   WHO, 2012, VERB AUT STAND 2012
   World Health Organization, 2014, TRENDS MAT MORT 1990
   Zaba B, 2013, LANCET, V381, P1763, DOI 10.1016/S0140-6736(13)60803-X
NR 32
TC 9
Z9 9
U1 1
U2 2
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PY 2014
VL 7
AR 25368
DI 10.3402/gha.v7.25368
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V44FO
UT WOS:000209735100001
PM 25377328
OA gold
DA 2017-08-15
ER

PT J
AU Streatfield, PK
   Khan, WA
   Bhuiya, A
   Hanifi, SMA
   Alam, N
   Diboulo, E
   Niamba, L
   Sie, A
   Lankoande, B
   Millogo, R
   Soura, AB
   Bonfoh, B
   Kone, S
   Ngoran, EK
   Utzinger, J
   Ashebir, Y
   Melaku, YA
   Weldearegawi, B
   Gomez, P
   Jasseh, M
   Azongo, D
   Oduro, A
   Wak, G
   Wontuo, P
   Attaa-Pomaa, M
   Gyapong, M
   Manyeh, AK
   Kant, S
   Misra, P
   Rai, SK
   Juvekar, S
   Patil, R
   Wahab, A
   Wilopo, S
   Bauni, E
   Mochamah, G
   Ndila, C
   Williams, TN
   Khaggayi, C
   Nyaguara, A
   Obor, D
   Odhiambo, FO
   Ezeh, A
   Oti, S
   Wamukoya, M
   Chihana, M
   Crampin, A
   Collinson, MA
   Kabudula, CW
   Wagner, R
   Herbst, K
   Mossong, JL
   Emina, JBO
   Sankoh, OA
   Byass, P
AF Streatfield, P. Kim
   Khan, Wasif A.
   Bhuiya, Abbas
   Hanifi, Syed M. A.
   Alam, Nurul
   Diboulo, Eric
   Niamba, Louis
   Sie, Ali
   Lankoande, Bruno
   Millogo, Roch
   Soura, Abdramane B.
   Bonfoh, Bassirou
   Kone, Siaka
   Ngoran, Eliezer K.
   Utzinger, Juerg
   Ashebir, Yemane
   Melaku, Yohannes A.
   Weldearegawi, Berhe
   Gomez, Pierre
   Jasseh, Momodou
   Azongo, Daniel
   Oduro, Abraham
   Wak, George
   Wontuo, Peter
   Attaa-Pomaa, Mary
   Gyapong, Margaret
   Manyeh, Alfred K.
   Kant, Shashi
   Misra, Puneet
   Rai, Sanjay K.
   Juvekar, Sanjay
   Patil, Rutuja
   Wahab, Abdul
   Wilopo, Siswanto
   Bauni, Evasius
   Mochamah, George
   Ndila, Carolyne
   Williams, Thomas N.
   Khaggayi, Christine
   Nyaguara, Amek
   Obor, David
   Odhiambo, Frank O.
   Ezeh, Alex
   Oti, Samuel
   Wamukoya, Marylene
   Chihana, Menard
   Crampin, Amelia
   Collinson, Mark A.
   Kabudula, Chodziwadziwa W.
   Wagner, Ryan
   Herbst, Kobus
   Mossong, Joe L.
   Emina, Jacques B. O.
   Sankoh, Osman A.
   Byass, Peter
TI Mortality from external causes in Africa and Asia: evidence from INDEPTH
   Health and Demographic Surveillance System Sites
SO GLOBAL HEALTH ACTION
LA English
DT Article
DE external causes; accidents; suicide; assault; transport; drowning;
   Africa; Asia; mortality; INDEPTH Network; verbal autopsy; InterVA
AB Background: Mortality from external causes, of all kinds, is an important component of overall mortality on a global basis. However, these deaths, like others in Africa and Asia, are often not counted or documented on an individual basis. Overviews of the state of external cause mortality in Africa and Asia are therefore based on uncertain information. The INDEPTH Network maintains longitudinal surveillance, including cause of death, at population sites across Africa and Asia, which offers important opportunities to document external cause mortality at the population level across a range of settings.
   Objective: To describe patterns of mortality from external causes at INDEPTH Network sites across Africa and Asia, according to the WHO 2012 verbal autopsy (VA) cause categories.
   Design: All deaths at INDEPTH sites are routinely registered and followed up with VA interviews. For this study, VA archives were transformed into the WHO 2012 VA standard format and processed using the InterVA-4 model to assign cause of death. Routine surveillance data also provide person-time denominators for mortality rates.
   Results: A total of 5,884 deaths due to external causes were documented over 11,828,253 person-years. Approximately one-quarter of those deaths were to children younger than 15 years. Causes of death were dominated by childhood drowning in Bangladesh, and by transport-related deaths and intentional injuries elsewhere. Detailed mortality rates are presented by cause of death, age group, and sex.
   Conclusions: The patterns of external cause mortality found here generally corresponded with expectations and other sources of information, but they fill some important gaps in population-based mortality data. They provide an important source of information to inform potentially preventive intervention designs.
C1 [Streatfield, P. Kim] Matlab HDSS, Chandpur Dist, Bangladesh.
   [Streatfield, P. Kim; Khan, Wasif A.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Streatfield, P. Kim; Khan, Wasif A.; Bhuiya, Abbas; Hanifi, Syed M. A.; Alam, Nurul; Diboulo, Eric; Niamba, Louis; Sie, Ali; Lankoande, Bruno; Millogo, Roch; Soura, Abdramane B.; Bonfoh, Bassirou; Kone, Siaka; Ngoran, Eliezer K.; Utzinger, Juerg; Ashebir, Yemane; Melaku, Yohannes A.; Weldearegawi, Berhe; Gomez, Pierre; Jasseh, Momodou; Azongo, Daniel; Oduro, Abraham; Wak, George; Wontuo, Peter; Attaa-Pomaa, Mary; Gyapong, Margaret; Manyeh, Alfred K.; Kant, Shashi; Misra, Puneet; Rai, Sanjay K.; Juvekar, Sanjay; Patil, Rutuja; Wahab, Abdul; Wilopo, Siswanto; Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.; Khaggayi, Christine; Nyaguara, Amek; Obor, David; Odhiambo, Frank O.; Ezeh, Alex; Oti, Samuel; Wamukoya, Marylene; Chihana, Menard; Crampin, Amelia; Collinson, Mark A.; Kabudula, Chodziwadziwa W.; Wagner, Ryan; Herbst, Kobus; Mossong, Joe L.; Emina, Jacques B. O.; Sankoh, Osman A.; Byass, Peter] INDEPTH Network, POB KD213, Kanda, Accra, Ghana.
   [Khan, Wasif A.] Bandarban HDSS, Bandarban, Bangladesh.
   [Bhuiya, Abbas; Hanifi, Syed M. A.] Chakaria HDSS, Chakaria, Bangladesh.
   [Bhuiya, Abbas; Hanifi, Syed M. A.] Int Ctr Diarrhoeal Dis Res, Ctr Equity & Hlth Syst, Dhaka 1000, Bangladesh.
   [Alam, Nurul] AMK HDSS, Dhaka, Bangladesh.
   [Alam, Nurul] Int Ctr Diarrhoeal Dis Res, Ctr Populat Urbanisat & Climate Change, Dhaka 1000, Bangladesh.
   [Diboulo, Eric; Niamba, Louis; Sie, Ali] Nouna HDSS, Nouna, Burkina Faso.
   [Diboulo, Eric; Niamba, Louis; Sie, Ali] Nouna Hlth Res Ctr, Nouna, Burkina Faso.
   [Lankoande, Bruno; Millogo, Roch; Soura, Abdramane B.] Ouagadougou HDSS, Ouagadougou, Burkina Faso.
   [Lankoande, Bruno; Millogo, Roch; Soura, Abdramane B.] Univ Ouagadougou, Inst Super Sci Populat, Ouagadougou, Burkina Faso.
   [Bonfoh, Bassirou; Kone, Siaka; Ngoran, Eliezer K.; Utzinger, Juerg] Taabo HDSS, Taabo, Cote Ivoire.
   [Bonfoh, Bassirou; Kone, Siaka] Ctr Suisse Rech Sci Cote Ivoire, Abidjan, Cote Ivoire.
   [Ngoran, Eliezer K.] Univ Felix Houphoet Boigny, Abidjan, Cote Ivoire.
   [Utzinger, Juerg] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Ashebir, Yemane; Melaku, Yohannes A.; Weldearegawi, Berhe] Kilite Awlaelo HDSS, Kilite Awlaelo, Ethiopia.
   [Ashebir, Yemane; Melaku, Yohannes A.; Weldearegawi, Berhe] Mekelle Univ, Coll Hlth Sci, Dept Publ Hlth, Mekelle, Ethiopia.
   [Gomez, Pierre; Jasseh, Momodou] Farafenni HDSS, Farafenni, Gambia.
   [Gomez, Pierre; Jasseh, Momodou] MRC, Gambia Unit, Fajara, Gambia.
   [Azongo, Daniel; Oduro, Abraham; Wak, George; Wontuo, Peter] Navrongo HDSS, Navrongo, Ghana.
   [Azongo, Daniel; Oduro, Abraham; Wak, George; Wontuo, Peter] Navrongo Hlth Res Ctr, Navrongo, Ghana.
   [Attaa-Pomaa, Mary; Gyapong, Margaret; Manyeh, Alfred K.] Dodowa HDSS, Dodowa, Ghana.
   [Attaa-Pomaa, Mary; Gyapong, Margaret; Manyeh, Alfred K.] Dodowa Hlth Res Ctr, Dodowa, Ghana.
   [Kant, Shashi; Misra, Puneet; Rai, Sanjay K.] Ballabgarh HDSS, Ballabgarh, India.
   [Kant, Shashi; Misra, Puneet; Rai, Sanjay K.] All India Inst Med Sci, New Delhi, India.
   [Juvekar, Sanjay; Patil, Rutuja] Vadu HDSS, Vadu, India.
   [Juvekar, Sanjay; Patil, Rutuja] KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India.
   [Wahab, Abdul; Wilopo, Siswanto] Purworejo HDSS, Purworejo, Indonesia.
   [Wahab, Abdul; Wilopo, Siswanto] Univ Gadjah Mada, Dept Publ Hlth, Yogyakarta, Indonesia.
   [Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.] Kilifi HDSS, Kilifi, Kenya.
   [Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Med, London, England.
   [Khaggayi, Christine; Nyaguara, Amek; Obor, David; Odhiambo, Frank O.] Kisumu HDSS, Kisumu, Kenya.
   [Khaggayi, Christine; Nyaguara, Amek; Obor, David; Odhiambo, Frank O.] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya.
   [Khaggayi, Christine; Nyaguara, Amek; Obor, David; Odhiambo, Frank O.] KEMRI Ctr Global Hlth Res, Kisumu, Kenya.
   [Ezeh, Alex; Oti, Samuel; Wamukoya, Marylene] Nairobi HDSS, Nairobi, Kenya.
   [Ezeh, Alex; Oti, Samuel; Wamukoya, Marylene] African Populat & Hlth Res Ctr, Nairobi, Kenya.
   [Chihana, Menard; Crampin, Amelia] Karonga HDSS, Karonga, Malawi.
   [Chihana, Menard; Crampin, Amelia] Karonga Prevent Study, Chilumba, Malawi.
   [Crampin, Amelia] London Sch Hyg & Trop Med, London WC1, England.
   [Collinson, Mark A.; Kabudula, Chodziwadziwa W.; Wagner, Ryan] Agincourt HDSS, Johannesburg, South Africa.
   [Collinson, Mark A.; Kabudula, Chodziwadziwa W.; Wagner, Ryan; Byass, Peter] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Johannesburg, South Africa.
   [Collinson, Mark A.; Herbst, Kobus; Mossong, Joe L.] Umea Univ, Umea Ctr Global Hlth Res, Umea, Sweden.
   [Herbst, Kobus; Mossong, Joe L.] Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Somkhele, KwaZulu Natal, South Africa.
   [Mossong, Joe L.] Natl Hlth Lab, Surveillance & Epidemiol Infect Dis, Dudelange, Luxembourg.
   [Sankoh, Osman A.] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa.
   [Sankoh, Osman A.] Hanoi Med Univ, Hanoi 100803, Vietnam.
   [Byass, Peter] Umea Ctr Global Hlth Res, WHO Collaborating Ctr Verbal Autopsy, Umea, Sweden.
RP Sankoh, OA (reprint author), INDEPTH Network, POB KD213, Kanda, Accra, Ghana.
EM osman.sankoh@indepth-network.org
RI ; Mossong, Joel/D-4998-2009
OI SIE, Ali/0000-0002-3959-2520; Mossong, Joel/0000-0003-0717-9835; Ezeh,
   Alex/0000-0002-1309-4697; Wilopo, Siswanto/0000-0003-1284-7228; Byass,
   Peter/0000-0001-5474-4361
FU Sida; Wellcome Trust; William & Flora Hewlett Foundation; Forte; Swedish
   Research Council for Health, Working Life and Welfare [2006-1512];
   European Community Marie Curie Actions IPHTRE project [295168]; Wellcome
   Trust [WT081993MA, 091758, 084538]; US Centers for Disease Control and
   Prevention (CDC); Ethiopian Public Health Association (EPHA); EPHA-CDC
   Cooperative Agreement [5U22/PS022179_10]; Mekelle University; KEM
   Hospital Research Centre; KEMRI; CDC; Rockefeller Foundation (USA);
   Wellcome Trust (UK); William and Flora Hewlett Foundation (USA); Comic
   Relief (UK); Swedish International Development Cooperation Agency
   (SIDA); Bill and Melinda Gates Foundation (USA); Wellcome Trust, UK
   [058893/Z/99/A, 069683/Z/02/Z, 085477/Z/08/Z]; William and Flora Hewlett
   Foundation; Andrew W. Mellon Foundation, USA
FX We are grateful to all the residents of INDEPTH HDSS sites who have
   contributed personal information to this mortality data set, and to the
   field staff who undertook so many verbal autopsy interviews and data
   management staff who handled the data at every participating site.
   INDEPTH acknowledges all the site scientists who have participated in
   bringing this work together, and who variously participated in analysis
   workshops in Ghana, Belgium, Thailand, and the United Kingdom. The
   INDEPTH Network is grateful for core funding from Sida, the Wellcome
   Trust, and the William & Flora Hewlett Foundation. The Umea Centre for
   Global Health Research is core funded by Forte, the Swedish Research
   Council for Health, Working Life and Welfare (grant no. 2006-1512). PB's
   residency at the University of the Witwatersrand Rural Knowledge Hub to
   analyse and draft these results was supported by the European Community
   Marie Curie Actions IPHTRE project (no. 295168). icddr,b is thankful to
   the Governments of Australia, Bangladesh, Canada, Sweden and the UK for
   providing core/unrestricted support. The Ouagadougou site acknowledges
   the Wellcome Trust for its financial support to the Ouagadougou HDSS
   (grant no. WT081993MA). The Kilite Awlaelo HDSS is supported by the US
   Centers for Disease Control and Prevention (CDC) and the Ethiopian
   Public Health Association (EPHA), in accordance with the EPHA-CDC
   Cooperative Agreement No. 5U22/PS022179_10 and Mekelle University,
   though these findings do not necessarily represent the funders' official
   views. The Farafenni site is supported by the UK Medical Research
   Council. The Vadu site acknowledges core continued funding support from
   the KEM Hospital Research Centre since 2004. The Kilifi HDSS is
   supported through core support to the KEMRI-Wellcome Trust Major
   Overseas Programme from the Wellcome Trust. TNW is supported by a Senior
   Fellowship (no. 091758) and CN through a Strategic Award (no. 084538)
   from the Wellcome Trust. This article is published with permission from
   the Director of KEMRI. The Kisumu site wishes to acknowledge the
   contribution of the late Dr Kubaje Adazu to the development of the
   KEMRI/CDC HDSS, which was implemented and continues to be supported
   through a cooperative agreement between KEMRI and CDC. The Nairobi Urban
   Health and Demographic Surveillance System (NUHDSS), Kenya, since its
   inception has received support from the Rockefeller Foundation (USA),
   the Wellcome Trust (UK), the William and Flora Hewlett Foundation (USA),
   Comic Relief (UK), the Swedish International Development Cooperation
   Agency (SIDA) and the Bill and Melinda Gates Foundation (USA). The
   Agincourt site acknowledges that the School of Public Health and Faculty
   of Health Sciences, University of the Witwatersrand, and the Medical
   Research Council, South Africa, have provided vital support since the
   inception of the Agincourt HDSS. Core funding has been provided by the
   Wellcome Trust, UK (Grants 058893/Z/99/A, 069683/Z/02/Z, and
   085477/Z/08/Z), with contributions from the National Institute on Aging
   (NIA) of the NIH, the William and Flora Hewlett Foundation, and the
   Andrew W. Mellon Foundation, USA.
CR Byass P, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.19281
   Crampin AC, 2012, INT J EPIDEMIOL, V41, P676, DOI 10.1093/ije/dys088
   Delaunay V, 2013, INT J EPIDEMIOL, V42, P1002, DOI 10.1093/ije/dyt100
   Gyapong M, 2013, INT J EPIDEMIOL, V42, P1686, DOI 10.1093/ije/dyt197
   Hanifi MA, 2012, INT J EPIDEMIOL, V41, P667, DOI 10.1093/ije/dys089
   Herbst AJ, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-47
   Hirve S, 2012, INT J EPIDEMIOL, V41, P1719, DOI 10.1093/ije/dys163
   Huong Dao Lan, 2006, Popul Health Metr, V4, P9, DOI 10.1186/1478-7954-4-9
   INDEPTH Network, BAND HDSS
   INDEPTH Network, 2014, INDEPTH NETW CAUS SP, DOI [10.7796/INDEPTH.GH003.COD2014.vl, DOI 10.7796/INDEPTH.GH003.COD2014.V1]
   Jasseh M, 2011, TROP MED INT HEALTH, V16, P1314, DOI 10.1111/j.1365-3156.2011.02809.x
   Kahn K, 2012, INT J EPIDEMIOL, V41, P988, DOI 10.1093/ije/dys115
   Kant S, 2013, INT J EPIDEMIOL, V42, P37
   Kapusta ND, 2011, ARCH GEN PSYCHIAT, V68, P1050, DOI 10.1001/archgenpsychiatry.2011.66
   Kouadio M'bra Kd, 2013, BMC Hematol, V13, P5, DOI 10.1186/2052-1839-13-5
   Leitao J, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.21518
   Lindeboom W, 2011, HLTH DEMOGRAPHIC SUR
   Mars B, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-606
   Ng N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035308
   Odhiambo FO, 2012, INT J EPIDEMIOL, V41, P977, DOI 10.1093/ije/dys108
   Oduro AR, 2012, INT J EPIDEMIOL, V41, P968, DOI 10.1093/ije/dys111
   Oti SO, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-588
   Razzaque A, 2010, GLOBAL HEALTH ACTION, V3, P70, DOI 10.3402/gha.v3i0.4618
   Rossier C, 2012, INT J EPIDEMIOL, V41, P658, DOI 10.1093/ije/dys090
   Sankoh O, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.23286
   Sankoh O, 2012, INT J EPIDEMIOL, V41, P579, DOI 10.1093/ije/dys081
   Scott JAG, 2012, INT J EPIDEMIOL, V41, P650, DOI 10.1093/ije/dys062
   Sie A, 2010, GLOBAL HEALTH ACTION, V3, DOI 10.3402/gha.v3i0.5284
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25362
   Varnik P, 2012, INT J ENV RES PUB HE, V9, P760, DOI 10.3390/ijerph9030760
   Weldearegawi B, 2013, HEALTH POLICY PLANN, V28, P891, DOI 10.1093/heapol/czs135
   WHO, 2012, VERB AUT STAND 2012
   WHO, 2013, GLOB STAT REP ROAD S
   World Health Organization, 2008, WORLD REPORT CHILD I
NR 34
TC 8
Z9 8
U1 0
U2 1
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PY 2014
VL 7
AR 25366
DI 10.3402/gha.v7.25366
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V44FN
UT WOS:000209735000001
PM 25377327
OA gold
DA 2017-08-15
ER

PT J
AU Streatfield, PK
   Khan, WA
   Bhuiya, A
   Hanifi, SMA
   Alam, N
   Millogo, O
   Sie, A
   Zabre, P
   Rossier, C
   Soura, AB
   Bonfoh, B
   Kone, S
   Ngoran, EK
   Utzinger, J
   Abera, SF
   Melaku, YA
   Weldearegawi, B
   Gomez, P
   Jasseh, M
   Ansah, P
   Azongo, D
   Kondayire, F
   Oduro, A
   Amu, A
   Gyapong, M
   Kwarteng, O
   Kant, S
   Pandav, CS
   Rai, SK
   Juvekar, S
   Muralidharan, V
   Wahab, A
   Wilopo, S
   Bauni, E
   Mochamah, G
   Ndila, C
   Williams, TN
   Khagayi, S
   Laserson, KF
   Nyaguara, A
   Van Eijk, AM
   Ezeh, A
   Kyobutungi, C
   Wamukoya, M
   Chihana, M
   Crampin, A
   Price, A
   Delaunay, V
   Diallo, A
   Douillot, L
   Sokhna, C
   Gomez-Olive, FX
   Mee, P
   Tollman, SM
   Herbst, K
   Mossong, J
   Chuc, NTK
   Arthur, SS
   Sankoh, OA
   Byass, P
AF Streatfield, P. Kim
   Khan, Wasif A.
   Bhuiya, Abbas
   Hanifi, Syed M. A.
   Alam, Nurul
   Millogo, Ourohire
   Sie, Ali
   Zabre, Pascal
   Rossier, Clementine
   Soura, Abdramane B.
   Bonfoh, Bassirou
   Kone, Siaka
   Ngoran, Eliezer K.
   Utzinger, Juerg
   Abera, Semaw F.
   Melaku, Yohannes A.
   Weldearegawi, Berhe
   Gomez, Pierre
   Jasseh, Momodou
   Ansah, Patrick
   Azongo, Daniel
   Kondayire, Felix
   Oduro, Abraham
   Amu, Alberta
   Gyapong, Margaret
   Kwarteng, Odette
   Kant, Shashi
   Pandav, Chandrakant S.
   Rai, Sanjay K.
   Juvekar, Sanjay
   Muralidharan, Veena
   Wahab, Abdul
   Wilopo, Siswanto
   Bauni, Evasius
   Mochamah, George
   Ndila, Carolyne
   Williams, Thomas N.
   Khagayi, Sammy
   Laserson, Kayla F.
   Nyaguara, Amek
   Van Eijk, Anna M.
   Ezeh, Alex
   Kyobutungi, Catherine
   Wamukoya, Marylene
   Chihana, Menard
   Crampin, Amelia
   Price, Alison
   Delaunay, Valerie
   Diallo, Aldiouma
   Douillot, Laetitia
   Sokhna, Cheikh
   Gomez-Olive, F. Xavier
   Mee, Paul
   Tollman, Stephen M.
   Herbst, Kobus
   Mossong, Joel
   Chuc, Nguyen T. K.
   Arthur, Samuelina S.
   Sankoh, Osman A.
   Byass, Peter
TI HIV/AIDS-related mortality in Africa and Asia: evidence from INDEPTH
   health and demographic surveillance system sites
SO GLOBAL HEALTH ACTION
LA English
DT Article
DE HIV/AIDS; tuberculosis; Africa; Asia; Mortality; INDEPTH Network; Verbal
   Autopsy; InterVA
AB Background: As the HIV/AIDS pandemic has evolved over recent decades, Africa has been the most affected region, even though a large proportion of HIV/AIDS deaths have not been documented at the individual level. Systematic application of verbal autopsy (VA) methods in defined populations provides an opportunity to assess the mortality burden of the pandemic from individual data.
   Objective: To present standardised comparisons of HIV/AIDS-related mortality at sites across Africa and Asia, including closely related causes of death such as pulmonary tuberculosis (PTB) and pneumonia.
   Design: Deaths related to HIV/AIDS were extracted from individual demographic and VA data from 22 INDEPTH sites across Africa and Asia. VA data were standardised to WHO 2012 standard causes of death assigned using the InterVA-4 model. Between-site comparisons of mortality rates were standardised using the INDEPTH 2013 standard population.
   Results: The dataset covered a total of 10,773 deaths attributed to HIV/AIDS, observed over 12,204,043 person-years. HIV/AIDS-related mortality fractions and mortality rates varied widely across Africa and Asia, with highest burdens in eastern and southern Africa, and lowest burdens in Asia. There was evidence of rapidly declining rates at the sites with the heaviest burdens. HIV/AIDS mortality was also strongly related to PTB mortality. On a country basis, there were strong similarities between HIV/AIDS mortality rates at INDEPTH sites and those derived from modelled estimates.
   Conclusions: Measuring HIV/AIDS-related mortality continues to be a challenging issue, all the more so as anti-retroviral treatment programmes alleviate mortality risks. The congruence between these results and other estimates adds plausibility to both approaches. These data, covering some of the highest mortality observed during the pandemic, will be an important baseline for understanding the future decline of HIV/AIDS.
C1 [Streatfield, P. Kim] Matlab HDSS, Dhaka, Bangladesh.
   [Streatfield, P. Kim; Khan, Wasif A.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Streatfield, P. Kim; Khan, Wasif A.; Bhuiya, Abbas; Hanifi, Syed M. A.; Alam, Nurul; Millogo, Ourohire; Sie, Ali; Zabre, Pascal; Rossier, Clementine; Soura, Abdramane B.; Bonfoh, Bassirou; Kone, Siaka; Ngoran, Eliezer K.; Utzinger, Juerg; Abera, Semaw F.; Melaku, Yohannes A.; Weldearegawi, Berhe; Gomez, Pierre; Jasseh, Momodou; Ansah, Patrick; Azongo, Daniel; Kondayire, Felix; Oduro, Abraham; Amu, Alberta; Gyapong, Margaret; Kwarteng, Odette; Kant, Shashi; Pandav, Chandrakant S.; Rai, Sanjay K.; Juvekar, Sanjay; Muralidharan, Veena; Wahab, Abdul; Wilopo, Siswanto; Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.; Khagayi, Sammy; Laserson, Kayla F.; Nyaguara, Amek; Van Eijk, Anna M.; Ezeh, Alex; Kyobutungi, Catherine; Wamukoya, Marylene; Chihana, Menard; Crampin, Amelia; Price, Alison; Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh; Gomez-Olive, F. Xavier; Mee, Paul; Tollman, Stephen M.; Herbst, Kobus; Mossong, Joel; Chuc, Nguyen T. K.; Arthur, Samuelina S.; Sankoh, Osman A.] INDEPTH Network, POB KD213, Kanda, Accra, Ghana.
   [Khan, Wasif A.] Bandarban HDSS, Bandarban, Bangladesh.
   [Bhuiya, Abbas; Hanifi, Syed M. A.] Chakaria HDSS, Chakaria, Bangladesh.
   [Bhuiya, Abbas; Hanifi, Syed M. A.] Int Ctr Diarrhoeal Dis Res, Ctr Equ & Hlth Syst, Dhaka 1000, Bangladesh.
   [Alam, Nurul] AMK HDSS, Dhaka, Bangladesh.
   [Alam, Nurul] Int Ctr Diarrhoeal Dis Res, Ctr Populat Urbanisat & Climate Change, Dhaka 1000, Bangladesh.
   [Millogo, Ourohire; Sie, Ali; Zabre, Pascal] Nouna HDSS, Nouna, Burkina Faso.
   [Millogo, Ourohire; Sie, Ali; Zabre, Pascal] Nouna Hlth Res Ctr, Nouna, Burkina Faso.
   [Rossier, Clementine; Soura, Abdramane B.] Ouagadougou HDSS, Ouagadougou, Burkina Faso.
   [Rossier, Clementine; Soura, Abdramane B.] Univ Ouagadougou, Inst Super Sci Populat, Ouagadougou, Burkina Faso.
   [Rossier, Clementine] Univ Geneva, Inst Etud Demograph & Parcours Vie, Geneva, Switzerland.
   [Bonfoh, Bassirou; Kone, Siaka; Ngoran, Eliezer K.; Utzinger, Juerg] Taabo HDSS, Taabo, Cote Ivoire.
   [Bonfoh, Bassirou; Kone, Siaka] Ctr Suisse Rech Sci Cote Div, Abidjan, Cote Ivoire.
   [Ngoran, Eliezer K.] Univ Felix Houphoet Boigny, Abidjan, Cote Ivoire.
   [Utzinger, Juerg] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Abera, Semaw F.; Melaku, Yohannes A.; Weldearegawi, Berhe] Kilite Awlaelo HDSS, Kilite Awlaelo, Ethiopia.
   [Abera, Semaw F.; Melaku, Yohannes A.; Weldearegawi, Berhe] Mekelle Univ, Dept Publ Hlth, Coll Hlth Sci, Mekelle, Ethiopia.
   [Gomez, Pierre; Jasseh, Momodou] Farafenni HDSS, Farafenni, Gambia.
   [Gomez, Pierre; Jasseh, Momodou] MRC, Gambia Unit, Fajara, Gambia.
   [Ansah, Patrick; Azongo, Daniel; Kondayire, Felix; Oduro, Abraham] Navrongo HDSS, Navrongo, Ghana.
   [Ansah, Patrick; Azongo, Daniel; Kondayire, Felix; Oduro, Abraham] Navrongo Hlth Res Ctr, Navrongo, Ghana.
   [Amu, Alberta; Gyapong, Margaret; Kwarteng, Odette] Dodowa HDSS, Dodowa, Ghana.
   [Amu, Alberta; Gyapong, Margaret; Kwarteng, Odette] Dodowa Hlth Res Ctr, Dodowa, Ghana.
   [Kant, Shashi; Pandav, Chandrakant S.; Rai, Sanjay K.] Ballabgarh HDSS, Faridabad, Haryana, India.
   [Kant, Shashi; Pandav, Chandrakant S.; Rai, Sanjay K.] All India Inst Med Sci, New Delhi, India.
   [Juvekar, Sanjay; Muralidharan, Veena] Vadu HDSS, Vadhu Budruk, Maharashtra, India.
   [Juvekar, Sanjay; Muralidharan, Veena] KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India.
   [Wahab, Abdul; Wilopo, Siswanto] Purworejo HDSS, Purworejo, Indonesia.
   [Wahab, Abdul; Wilopo, Siswanto] Univ Gadjah Mada, Dept Publ Hlth, Yogyakarta, Indonesia.
   [Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.] Kilifi HDSS, Kilifi, Kenya.
   [Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Med, London, England.
   [Khagayi, Sammy; Laserson, Kayla F.; Nyaguara, Amek; Van Eijk, Anna M.] Kisumu HDSS, Kisumu, Kenya.
   [Khagayi, Sammy; Laserson, Kayla F.; Nyaguara, Amek; Van Eijk, Anna M.] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya.
   [Khagayi, Sammy; Laserson, Kayla F.; Nyaguara, Amek; Van Eijk, Anna M.] KEMRI Ctr Global Hlth Res, Kisumu, Kenya.
   [Ezeh, Alex; Kyobutungi, Catherine; Wamukoya, Marylene] Nairobi HDSS, Nairobi, Kenya.
   [Ezeh, Alex; Kyobutungi, Catherine; Wamukoya, Marylene; Chihana, Menard] African Populat & Hlth Res Ctr, Nairobi, Kenya.
   [Chihana, Menard; Crampin, Amelia; Price, Alison] Karonga HDSS, Karonga, Malawi.
   [Crampin, Amelia; Price, Alison] Karonga Prevent Study, Chilumba, Malawi.
   [Crampin, Amelia; Price, Alison] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh] Niakhar HDSS, Niakhar, Senegal.
   [Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh; Tollman, Stephen M.] IRD, Dakar, Senegal.
   [Gomez-Olive, F. Xavier; Mee, Paul; Tollman, Stephen M.] Agincourt HDSS, Mozambique, South Africa.
   [Gomez-Olive, F. Xavier; Mee, Paul; Byass, Peter] Univ Witwatersrand, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa.
   [Tollman, Stephen M.] Umea Univ, Umea Ctr Global Hlth Res, Umea, Sweden.
   [Herbst, Kobus; Mossong, Joel] Africa Ctr HDSS, Maputo City, South Africa.
   [Herbst, Kobus; Mossong, Joel] Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Somkhele, Kwazulu Natal, South Africa.
   [Mossong, Joel] Natl Hlth Lab, Surveillance & Epidemiol Infect Dis, Dudelange, Luxembourg.
   [Chuc, Nguyen T. K.] FilaBavi HDSS, Hanoi, Vietnam.
   [Chuc, Nguyen T. K.] Hanoi Med Univ, Hlth Syst Res, Hanoi 100803, Vietnam.
   [Sankoh, Osman A.] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa.
   [Sankoh, Osman A.] Hanoi Med Univ, Hanoi 100803, Vietnam.
   [Byass, Peter] Umea Univ, Umea Ctr Global Hlth Res, WHO Collaborating Ctr Verbal Autopsy, Umea, Sweden.
RP Sankoh, OA (reprint author), INDEPTH Network, POB KD213, Kanda, Accra, Ghana.
EM osman.sankoh@indepth-network.org
RI ; Mossong, Joel/D-4998-2009
OI SIE, Ali/0000-0002-3959-2520; Wilopo, Siswanto/0000-0003-1284-7228;
   Mossong, Joel/0000-0003-0717-9835; Ezeh, Alex/0000-0002-1309-4697;
   Price, Alison/0000-0002-3891-3337; Byass, Peter/0000-0001-5474-4361
FU Sida; Wellcome Trust; William & Flora Hewlett Foundation; Forte, the
   Swedish Research Council for Health, Working Life and Welfare
   [2006-1512]; European Community Marie Curie Actions IPHTRE project
   [295168]; Wellcome Trust [WT081993MA, 084538, 091758]; US Centers for
   Disease Control and Prevention (CDC); Ethiopian Public Health
   Association (EPHA); EPHA-CDC [5U22/PS022179_10]; Mekelle University; UK
   Medical Research Council; KEMRI; CDC; Rockefeller Foundation (USA);
   William and Flora Hewlett Foundation (USA); Comic Relief (UK); Swedish
   International Development Cooperation Agency (SIDA); Bill and Melinda
   Gates Foundation (USA); Wellcome Trust, UK [058893/Z/99/A,
   069683/Z/02/Z, 085477/Z/08/Z]
FX We are grateful to all the residents of INDEPTH HDSS sites who have
   contributed personal information to this mortality dataset, to the field
   staff who undertook so many VA interviews, and the data management staff
   who handled the data at every participating site. INDEPTH acknowledges
   all the site scientists who have participated in bringing this work
   together, and who participated in analysis workshops in Ghana, Belgium,
   Thailand, and the United Kingdom. The INDEPTH Network is grateful for
   core funding from Sida, the Wellcome Trust, and the William & Flora
   Hewlett Foundation. The Umea Centre for Global Health Research is core
   funded by Forte, the Swedish Research Council for Health, Working Life
   and Welfare (grant 2006-1512). PB's residency at the University of the
   Witwatersrand Rural Knowledge Hub to analyse and draft these results was
   supported by the European Community Marie Curie Actions IPHTRE project
   (no. 295168). icddr,b is thankful to the Governments of Australia,
   Bangladesh, Canada, Sweden and the UK for providing core/unrestricted
   support. The Ouagadougou site acknowledges the Wellcome Trust for its
   financial support to the Ouagadougou HDSS (grant number WT081993MA). The
   Kilite Awlaelo HDSS is supported by the US Centers for Disease Control
   and Prevention (CDC) and the Ethiopian Public Health Association (EPHA),
   in accordance with the EPHA-CDC Cooperative Agreement No.
   5U22/PS022179_10 and Mekelle University, though these findings do not
   necessarily represent the funders' official views. The Farafenni HDSS is
   supported by the UK Medical Research Council. The Kilifi HDSS is
   supported through core support to the KEMRI-Wellcome Trust Major
   Overseas Programme from the Wellcome Trust. TNW is supported by a Senior
   Fellowship (091758) and CN through a Strategic Award (084538) from the
   Wellcome Trust. This paper is published with permission from the
   Director of KEMRI. The Kisumu site wishes to acknowledge the
   contribution of the late Dr. Kubaje Adazu to the development of
   KEMRI/CDC HDSS, which was implemented and continues to be supported
   through a cooperative agreement between KEMRI and CDC. The Nairobi Urban
   Health and Demographic Surveillance System (NUHDSS), Kenya, since its
   inception has received support from the Rockefeller Foundation (USA),
   the Wellcome Trust (UK), the William and Flora Hewlett Foundation (USA),
   Comic Relief (UK), the Swedish International Development Cooperation
   Agency (SIDA) and the Bill and Melinda Gates Foundation (USA). The
   Agincourt site acknowledges that the School of Public Health and Faculty
   of Health Sciences, University of the Witwatersrand, and the Medical
   Research Council, South Africa, have provided vital support since
   inception of the Agincourt HDSS. Core funding has been provided by The
   Wellcome Trust, UK (Grants 058893/Z/99/A; 069683/Z/02/Z; 085477/Z/08/Z)
   with contributions from the National Institute on Aging of the NIH,
   William and Flora Hewlett Foundation, and Andrew W Mellon Foundation,
   USA.
CR Byass P, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.22448
   Byass P, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.19281
   Byass P, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1001006
   Crampin AC, 2012, INT J EPIDEMIOL, V41, P676, DOI 10.1093/ije/dys088
   De Cock M, 2011, EMERG INFECT DIS, V17, P1044
   Delaunay V, 2013, INT J EPIDEMIOL, V42, P1002, DOI 10.1093/ije/dyt100
   Floyd S, 2012, TROP MED INT HEALTH, V17, pe84, DOI 10.1111/j.1365-3156.2012.03032.x
   Fottrell E, 2010, EPIDEMIOL REV, V32, P38, DOI 10.1093/epirev/mxq003
   Global Burden of Disease Study 2010, 2012, GLOB BURD DIS STUD 2
   Gyapong M, 2013, INT J EPIDEMIOL, V42, P1686, DOI 10.1093/ije/dyt197
   Hanifi MA, 2012, INT J EPIDEMIOL, V41, P667, DOI 10.1093/ije/dys089
   Herbst AJ, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-47
   Hirve S, 2012, INT J EPIDEMIOL, V41, P1719, DOI 10.1093/ije/dys163
   Huong Dao Lan, 2006, Popul Health Metr, V4, P9, DOI 10.1186/1478-7954-4-9
   INDEPIH Network, 2014, INDEPTH NETW CAUS SP, DOI [10.7796/INDEPTH.GH003.COD2014.vl, DOI 10.7796/INDEPTH.GH003.COD2014.V1]
   INDEPTH Network, BAND HDSS
   Jasseh M, 2011, TROP MED INT HEALTH, V16, P1314, DOI 10.1111/j.1365-3156.2011.02809.x
   Kahn K, 2012, INT J EPIDEMIOL, V41, P988, DOI 10.1093/ije/dys115
   Kant S, 2013, INT J EPIDEMIOL, V42, P37
   Kouadio M'bra Kd, 2013, BMC Hematol, V13, P5, DOI 10.1186/2052-1839-13-5
   Leitao J, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.21518
   Lindeboom W, 2011, HLTH DEMOGRAPHIC SUR
   Ng N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035308
   Odhiambo FO, 2012, INT J EPIDEMIOL, V41, P977, DOI 10.1093/ije/dys108
   Oduro AR, 2012, INT J EPIDEMIOL, V41, P968, DOI 10.1093/ije/dys111
   Oti SO, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-588
   Razzaque A, 2010, GLOBAL HEALTH ACTION, V3, P70, DOI 10.3402/gha.v3i0.4618
   Rossier C, 2012, INT J EPIDEMIOL, V41, P658, DOI 10.1093/ije/dys090
   Sankoh O, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.23286
   Sankoh O, 2012, INT J EPIDEMIOL, V41, P579, DOI 10.1093/ije/dys081
   Scott JAG, 2012, INT J EPIDEMIOL, V41, P650, DOI 10.1093/ije/dys062
   Sie A, 2010, GLOBAL HEALTH ACTION, V3, DOI 10.3402/gha.v3i0.5284
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25368
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25362
   UNAIDS, SPECTR MOD
   Weldearegawi B, 2013, HEALTH POLICY PLANN, V28, P891, DOI 10.1093/heapol/czs135
   World Health Organization International Statistical Classification of Diseases and Related Health Problems, 2011, INSTR MAN, V2
   WHO, 2012, VERB AUT STAND 2012
   Zaba B, 2013, LANCET, V381, P1763, DOI 10.1016/S0140-6736(13)60803-X
NR 39
TC 12
Z9 12
U1 0
U2 3
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PY 2014
VL 7
AR 25370
DI 10.3402/gha.v7.25370
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V44FQ
UT WOS:000209735300001
OA gold
DA 2017-08-15
ER

PT J
AU Streatfield, PK
   Khan, WA
   Bhuiya, A
   Hanifi, SMA
   Alam, N
   Diboulo, E
   Sie, A
   Ye, M
   Compaore, Y
   Soura, AB
   Bonfoh, B
   Jaeger, F
   Ngoran, EK
   Utzinger, J
   Melaku, YA
   Mulugeta, A
   Weldearegawi, B
   Gomez, P
   Jasseh, M
   Hodgson, A
   Oduro, A
   Welaga, P
   Williams, J
   Awini, E
   Binka, FN
   Gyapong, M
   Kant, S
   Misra, P
   Srivastava, R
   Chaudhary, B
   Juvekar, S
   Wahab, A
   Wilopo, S
   Bauni, E
   Mochamah, G
   Ndila, C
   Williams, TN
   Hamel, MJ
   Lindblade, KA
   Odhiambo, FO
   Slutsker, L
   Ezeh, A
   Kyobutungi, C
   Wamukoya, M
   Delaunay, V
   Diallo, A
   Douillot, L
   Sokhna, C
   Gomez-Olive, FX
   Kabudula, CW
   Mee, P
   Herbst, K
   Mossong, J
   Chuc, NTK
   Arthur, SS
   Sankoh, OA
   Tanner, M
   Byass, P
AF Streatfield, P. Kim
   Khan, Wasif A.
   Bhuiya, Abbas
   Hanifi, Syed M. A.
   Alam, Nurul
   Diboulo, Eric
   Sie, Ali
   Ye, Maurice
   Compaore, Yacouba
   Soura, Abdramane B.
   Bonfoh, Bassirou
   Jaeger, Fabienne
   Ngoran, Eliezer K.
   Utzinger, Juerg
   Melaku, Yohannes A.
   Mulugeta, Afework
   Weldearegawi, Berhe
   Gomez, Pierre
   Jasseh, Momodou
   Hodgson, Abraham
   Oduro, Abraham
   Welaga, Paul
   Williams, John
   Awini, Elizabeth
   Binka, Fred N.
   Gyapong, Margaret
   Kant, Shashi
   Misra, Puneet
   Srivastava, Rahul
   Chaudhary, Bharat
   Juvekar, Sanjay
   Wahab, Abdul
   Wilopo, Siswanto
   Bauni, Evasius
   Mochamah, George
   Ndila, Carolyne
   Williams, Thomas N.
   Hamel, Mary J.
   Lindblade, Kim A.
   Odhiambo, Frank O.
   Slutsker, Laurence
   Ezeh, Alex
   Kyobutungi, Catherine
   Wamukoya, Marylene
   Delaunay, Valerie
   Diallo, Aldiouma
   Douillot, Laetitia
   Sokhna, Cheikh
   Gomez-Olive, F. Xavier
   Kabudula, Chodziwadziwa W.
   Mee, Paul
   Herbst, Kobus
   Mossong, Joel
   Chuc, Nguyen T. K.
   Arthur, Samuelina S.
   Sankoh, Osman A.
   Tanner, Marcel
   Byass, Peter
TI Malaria mortality in Africa and Asia: evidence from INDEPTH health and
   demographic surveillance system sites
SO GLOBAL HEALTH ACTION
LA English
DT Article
DE malaria; Africa; Asia; mortality; INDEPTH Network; verbal autopsy;
   InterVA
AB Background: Malaria continues to be a major cause of infectious disease mortality in tropical regions. However, deaths from malaria are most often not individually documented, and as a result overall understanding of malaria epidemiology is inadequate. INDEPTH Network members maintain population surveillance in Health and Demographic Surveillance System sites across Africa and Asia, in which individual deaths are followed up with verbal autopsies.
   Objective: To present patterns of malaria mortality determined by verbal autopsy from INDEPTH sites across Africa and Asia, comparing these findings with other relevant information on malaria in the same regions.
   Design: From a database covering 111,910 deaths over 12,204,043 person-years in 22 sites, in which verbal autopsy data were handled according to the WHO 2012 standard and processed using the InterVA-4 model, over 6,000 deaths were attributed to malaria. The overall period covered was 1992-2012, but two-thirds of the observations related to 2006-2012. These deaths were analysed by site, time period, age group and sex to investigate epidemiological differences in malaria mortality.
   Results: Rates of malaria mortality varied by 1: 10,000 across the sites, with generally low rates in Asia (one site recording no malaria deaths over 0.5 million person-years) and some of the highest rates in West Africa (Nouna, Burkina Faso: 2.47 per 1,000 person-years). Childhood malaria mortality rates were strongly correlated with Malaria Atlas Project estimates of Plasmodium falciparum parasite rates for the same locations. Adult malaria mortality rates, while lower than corresponding childhood rates, were strongly correlated with childhood rates at the site level.
   Conclusions: The wide variations observed in malaria mortality, which were nevertheless consistent with various other estimates, suggest that population-based registration of deaths using verbal autopsy is a useful approach to understanding the details of malaria epidemiology.
C1 [Streatfield, P. Kim] Matlab HDSS, Dhaka, Bangladesh.
   [Streatfield, P. Kim; Khan, Wasif A.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Streatfield, P. Kim; Khan, Wasif A.; Bhuiya, Abbas; Hanifi, Syed M. A.; Alam, Nurul; Diboulo, Eric; Sie, Ali; Ye, Maurice; Compaore, Yacouba; Soura, Abdramane B.; Bonfoh, Bassirou; Jaeger, Fabienne; Ngoran, Eliezer K.; Utzinger, Juerg; Melaku, Yohannes A.; Mulugeta, Afework; Weldearegawi, Berhe; Gomez, Pierre; Jasseh, Momodou; Hodgson, Abraham; Oduro, Abraham; Welaga, Paul; Williams, John; Awini, Elizabeth; Binka, Fred N.; Gyapong, Margaret; Kant, Shashi; Misra, Puneet; Srivastava, Rahul; Chaudhary, Bharat; Juvekar, Sanjay; Wahab, Abdul; Wilopo, Siswanto; Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.; Hamel, Mary J.; Lindblade, Kim A.; Odhiambo, Frank O.; Slutsker, Laurence; Ezeh, Alex; Kyobutungi, Catherine; Wamukoya, Marylene; Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh; Gomez-Olive, F. Xavier; Kabudula, Chodziwadziwa W.; Mee, Paul; Herbst, Kobus; Mossong, Joel; Chuc, Nguyen T. K.; Arthur, Samuelina S.; Sankoh, Osman A.] INDEPTH Network, POB KD213, Kanda, Accra, Ghana.
   [Khan, Wasif A.] Bandarban HDSS, Dhaka, Bangladesh.
   [Bhuiya, Abbas; Hanifi, Syed M. A.] Chakaria HDSS, Dhaka, Bangladesh.
   [Bhuiya, Abbas; Hanifi, Syed M. A.] Int Ctr Diarrhoeal Dis Res, Ctr Equ & Hlth Syst, Dhaka 1000, Bangladesh.
   [Alam, Nurul] AMK HDSS, Dhaka, Bangladesh.
   [Alam, Nurul] Int Ctr Diarrhoeal Dis Res, Ctr Populat Urbanisat & Climate Change, Dhaka 1000, Bangladesh.
   [Diboulo, Eric; Sie, Ali; Ye, Maurice] Nouna HDSS, Nouna, Burkina Faso.
   [Diboulo, Eric; Sie, Ali; Ye, Maurice] Nouna Hlth Res Ctr, Nouna, Burkina Faso.
   [Compaore, Yacouba; Soura, Abdramane B.] Ouagadougou HDSS, Ouagadougou, Burkina Faso.
   [Compaore, Yacouba; Soura, Abdramane B.] Univ Ouagadougou, Inst Super Sci Populat, Ouagadougou, Burkina Faso.
   [Bonfoh, Bassirou; Jaeger, Fabienne; Ngoran, Eliezer K.; Utzinger, Juerg] Taabo HDSS, Abidjan, Cote Ivoire.
   [Bonfoh, Bassirou] Ctr Suisse Rech Sci Cote Ivoire, Abidjan, Cote Ivoire.
   [Jaeger, Fabienne; Utzinger, Juerg] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Ngoran, Eliezer K.] Univ Felix Houphoet Boigny, Abidjan, Cote Ivoire.
   [Melaku, Yohannes A.; Mulugeta, Afework; Weldearegawi, Berhe] Kilite Awlaelo HDSS, Kilite Awlaelo, Ethiopia.
   [Melaku, Yohannes A.; Mulugeta, Afework; Weldearegawi, Berhe] Mekelle Univ, Dept Publ Hlth, Coll Hlth Sci, Mekelle, Ethiopia.
   [Gomez, Pierre; Jasseh, Momodou] Farafenni HDSS, Fajara, Gambia.
   [Gomez, Pierre; Jasseh, Momodou] MRC, Gambia Unit, Fajara, Gambia.
   [Hodgson, Abraham; Oduro, Abraham; Welaga, Paul; Williams, John] Navrongo HDSS, Accra, Ghana.
   [Hodgson, Abraham; Oduro, Abraham; Welaga, Paul; Williams, John] Navrongo Hlth Res Ctr, Navrongo, Ghana.
   [Awini, Elizabeth; Binka, Fred N.; Gyapong, Margaret] Dodowa HDSS, Dodowa, Ghana.
   [Awini, Elizabeth] Dodowa Hlth Res Ctr, Dodowa, Ghana.
   [Awini, Elizabeth; Binka, Fred N.; Gyapong, Margaret] Univ Ghana, Sch Publ Hlth, Legon, Ghana.
   [Kant, Shashi; Misra, Puneet; Srivastava, Rahul] Ballabgarh HDSS, Faridabad, Haryana, India.
   [Kant, Shashi; Misra, Puneet; Srivastava, Rahul] All India Inst Med Sci, New Delhi, India.
   [Chaudhary, Bharat; Juvekar, Sanjay] Vadu HDSS, Vadhu Budruk, Maharashtra, India.
   [Chaudhary, Bharat; Juvekar, Sanjay] KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India.
   [Wahab, Abdul; Wilopo, Siswanto] Purworejo HDSS, Purworejo, Indonesia.
   [Wahab, Abdul; Wilopo, Siswanto] Univ Gadjah Mada, Dept Publ Hlth, Yogyakarta, Indonesia.
   [Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.] Kilifi HDSS, Kilifi, Kenya.
   [Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, Dept Med, St Marys Hosp, London, England.
   [Hamel, Mary J.; Lindblade, Kim A.; Slutsker, Laurence] Kisumu HDSS, Kisumu, Kenya.
   [Hamel, Mary J.; Lindblade, Kim A.; Slutsker, Laurence] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya.
   [Hamel, Mary J.; Lindblade, Kim A.; Slutsker, Laurence] KEMRI Ctr Global Hlth Res, Kisumu, Kenya.
   [Odhiambo, Frank O.; Ezeh, Alex; Kyobutungi, Catherine; Wamukoya, Marylene] Nairobi HDSS, Nairobi, Kenya.
   [Odhiambo, Frank O.; Ezeh, Alex; Kyobutungi, Catherine; Wamukoya, Marylene] African Populat & Hlth Res Ctr, Nairobi, Kenya.
   [Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh] Niakhar HDSS, Niakhar, Senegal.
   [Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh] IRD, Dakar, Senegal.
   [Gomez-Olive, F. Xavier; Kabudula, Chodziwadziwa W.; Mee, Paul] Agincourt HDSS, Mozambique, South Africa.
   [Gomez-Olive, F. Xavier; Kabudula, Chodziwadziwa W.; Mee, Paul; Byass, Peter] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Johannesburg, South Africa.
   [Herbst, Kobus; Mossong, Joel] Africa Ctr HDSS, Mozambique, South Africa.
   [Herbst, Kobus; Mossong, Joel] Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Somkhele, Kwazulu Natal, South Africa.
   [Mossong, Joel] Natl Hlth Lab, Surveillance Epidemiol Infect Dis, Dudelange, Luxembourg.
   [Chuc, Nguyen T. K.] FilaBavi HDSS, Hanoi, Vietnam.
   [Chuc, Nguyen T. K.] Hanoi Med Univ, Hlth Syst Res, Hanoi 100803, Vietnam.
   [Sankoh, Osman A.] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa.
   [Sankoh, Osman A.] Hanoi Med Univ, Hanoi 100803, Vietnam.
   [Tanner, Marcel] Umea Univ, Umeaa Ctr Global Hlth Res, WHO Collaborating Ctr Verbal Autopsy, Umea, Sweden.
RP Sankoh, OA (reprint author), INDEPTH Network, POB KD213, Kanda, Accra, Ghana.
EM osman.sankoh@indepth-network.org
RI ; Mossong, Joel/D-4998-2009
OI SIE, Ali/0000-0002-3959-2520; Wilopo, Siswanto/0000-0003-1284-7228;
   Mossong, Joel/0000-0003-0717-9835; Ezeh, Alex/0000-0002-1309-4697;
   Byass, Peter/0000-0001-5474-4361
FU Sida; Wellcome Trust; William & Flora Hewlett Foundation; Forte; Swedish
   Research Council for Health, Working Life and Welfare [2006-1512];
   European Community Marie Curie Actions IPHTRE project [295168];
   Government of Australia; Government of Bangladesh; Government of Canada;
   Government of Sweden; Government of UK; Wellcome Trust [WT081993MA,
   084538]; US Centers for Disease Control and Prevention (CDC); Ethiopian
   Public Health Association (EPHA); EPHA-CDC [5U22/PS022179_10]; UK
   Medical Research Council; Senior Fellowship [091758]; Wellcome Trust, UK
   [058893/Z/99/A, 069683/Z/02/Z, 085477/Z/08/Z]
FX We are grateful to all the residents of INDEPTH HDSS sites who have
   contributed personal information to this mortality dataset, and to the
   field staff who undertook so many verbal autopsy interviews and data
   management staff who handled the data at every participating site.
   INDEPTH acknowledges all the site scientists who have participated in
   bringing this work together, and who participated in analysis workshops
   in Ghana, Belgium, Thailand and the United Kingdom. The INDEPTH Network
   is grateful for core funding from Sida, the Wellcome Trust, and the
   William & Flora Hewlett Foundation. The Umea Centre for Global Health
   Research is core funded by Forte, the Swedish Research Council for
   Health, Working Life and Welfare (grant 2006-1512). PB's residency at
   the University of the Witwatersrand Rural Knowledge Hub to analyse and
   draft these results was supported by the European Community Marie Curie
   Actions IPHTRE project (no. 295168). icddr,b is thankful to the
   Governments of Australia, Bangladesh, Canada, Sweden and the UK for
   providing core/unrestricted support. The Ouagadougou site acknowledges
   the Wellcome Trust for its financial support to the Ouagadougou HDSS
   (grant number WT081993MA). The Kilite Awlaelo HDSS is supported by the
   US Centers for Disease Control and Prevention (CDC) and the Ethiopian
   Public Health Association (EPHA), in accordance with the EPHA-CDC
   Cooperative Agreement No. 5U22/PS022179_10 and Mekelle University,
   though these findings do not necessarily represent the funders' official
   views. The Farafenni HDSS is supported by the UK Medical Research
   Council. The Kilifi HDSS is supported through core support to the
   KEMRIWellcome Trust Major Overseas Programme from the Wellcome Trust.
   TNW is supported by a Senior Fellowship (091758) and CN through a
   Strategic Award (084538) from the Wellcome Trust. This paper is
   published with permission from the Director of KEMRI. The Kisumu site
   wishes to acknowledge the contribution of the late Dr. Kubaje Adazu to
   the development of KEMRI/CDC HDSS, which was implemented and continues
   to be supported through a cooperative agreement between KEMRI and CDC.
   The Nairobi Urban Health and Demographic Surveillance System (NUHDSS),
   Kenya, since its inception has received support from the Rockefeller
   Foundation (USA), the Welcome Trust (UK), the William and Flora Hewlett
   Foundation (USA), Comic Relief (UK), the Swedish International
   Development Cooperation Agency (SIDA) and the Bill and Melinda Gates
   Foundation (USA). The Agincourt site acknowledges that the School of
   Public Health and Faculty of Health Sciences, University of the
   Witwatersrand, and the Medical Research Council, South Africa, have
   provided vital support since inception of the Agincourt HDSS. Core
   funding has been provided by the Wellcome Trust, UK (Grants
   058893/Z/99/A; 069683/Z/02/Z; 085477/Z/08/Z) with contributions from the
   National Institute on Aging of the NIH, William and Flora Hewlett
   Foundation, and Andrew W Mellon Foundation, USA.
CR Amegah AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069181
   BYASS P, 1991, J TROP MED HYG, V94, P22
   Byass P, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-23
   Byass P, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.19281
   Byass P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022897
   Child Epidemiology Reference Group, 2010, EST NUMB DEATHS CAUS
   Delaunay V, 2013, INT J EPIDEMIOL, V42, P1002, DOI 10.1093/ije/dyt100
   Desai M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106197
   Fink G, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-12
   Gething PW, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-378
   Griffin JT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4136
   Gyapong M, 2013, INT J EPIDEMIOL, V42, P1686, DOI 10.1093/ije/dyt197
   Hanifi MA, 2012, INT J EPIDEMIOL, V41, P667, DOI 10.1093/ije/dys089
   Herbst AJ, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-47
   Hirve S, 2012, INT J EPIDEMIOL, V41, P1719, DOI 10.1093/ije/dys163
   Huong Dao Lan, 2006, Popul Health Metr, V4, P9, DOI 10.1186/1478-7954-4-9
   INDEPIH Network, 2014, INDEPTH NETW CAUS SP, DOI [10.7796/INDEPTH.GH003.COD2014.vl, DOI 10.7796/INDEPTH.GH003.COD2014.V1]
   INDEPTH Network, BAND HDSS
   Jasseh M, 2011, TROP MED INT HEALTH, V16, P1314, DOI 10.1111/j.1365-3156.2011.02809.x
   Kahn K, 2012, INT J EPIDEMIOL, V41, P988, DOI 10.1093/ije/dys115
   Kant S, 2013, INT J EPIDEMIOL, V42, P37
   Kouadio M'bra Kd, 2013, BMC Hematol, V13, P5, DOI 10.1186/2052-1839-13-5
   Leitao J, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-22
   Leitao J, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.21518
   Lemma H, 2010, TROP MED INT HEALTH, V15, P241, DOI 10.1111/j.1365-3156.2009.02447.x
   Lindeboom W, HLTH DEMOGRAPHIC SUR
   Mudenda V, 2012, J INFECT DIS, V205, pS340, DOI 10.1093/infdis/jir859
   Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8
   Murray CJL, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-27
   Ng N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035308
   Noor AM, 2014, LANCET, V383, P1739, DOI 10.1016/S0140-6736(13)62566-0
   Odhiambo FO, 2012, INT J EPIDEMIOL, V41, P977, DOI 10.1093/ije/dys108
   Oduro AR, 2012, INT J EPIDEMIOL, V41, P968, DOI 10.1093/ije/dys111
   Okiro EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062214
   Oti SO, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-588
   Population Health Metrics Research Consortium, PHMRC GOLD STAND VER
   Razzaque A, 2010, GLOBAL HEALTH ACTION, V3, P70, DOI 10.3402/gha.v3i0.4618
   Reyburn H, 2005, JAMA-J AM MED ASSOC, V293, P1461, DOI 10.1001/jama.293.12.1461
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   Ross A, 2006, AM J TROP MED HYG, V75, P63
   Rossier C, 2012, INT J EPIDEMIOL, V41, P658, DOI 10.1093/ije/dys090
   Sankoh OA, 2003, J PUBLIC HEALTH MED, V25, P372, DOI 10.1093/pubmed/fdg080
   Sankoh O, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.23286
   Sankoh O, 2012, INT J EPIDEMIOL, V41, P579, DOI 10.1093/ije/dys081
   Scott JAG, 2012, INT J EPIDEMIOL, V41, P650, DOI 10.1093/ije/dys062
   Sie A, 2010, GLOBAL HEALTH ACTION, V3, DOI 10.3402/gha.v3i0.5284
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25362
   Weldearegawi B, 2013, HEALTH POLICY PLANN, V28, P891, DOI 10.1093/heapol/czs135
   WHO, 2013, WORLD MALARIA REPORT 2013, P1
   WHO, 2012, VERB AUT STAND 2012
   World Health Organization, 2013, MAL COUNTR PROF BANG
   World Health Organization, 2013, MAL COUNTR PROF KEN
   World Health Organization, 2013, MAL COUNTR PROF S AF
   World Health Organization, GLOB HLTH OBS NUMB M
NR 54
TC 13
Z9 14
U1 1
U2 2
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PY 2014
VL 7
AR 25369
DI 10.3402/gha.v7.25369
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V44FP
UT WOS:000209735200001
PM 25377329
OA gold
DA 2017-08-15
ER

PT J
AU Streatfield, PK
   Khan, WA
   Bhuiya, A
   Hanifi, SMA
   Alam, N
   Bagagnan, CH
   Sie, A
   Zabre, P
   Lankoande, B
   Rossier, C
   Soura, AB
   Bonfoh, B
   Kone, S
   Ngoran, EK
   Utzinger, J
   Haile, F
   Melaku, YA
   Weldearegawi, B
   Gomez, P
   Jasseh, M
   Ansah, P
   Debpuur, C
   Oduro, A
   Wak, G
   Adjei, A
   Gyapong, M
   Sarpong, D
   Kant, S
   Misra, P
   Rai, SK
   Juvekar, S
   Lele, P
   Bauni, E
   Mochamah, G
   Ndila, C
   Williams, TN
   Laserson, KF
   Nyaguara, A
   Odhiambo, FO
   Phillips-Howard, P
   Ezeh, A
   Kyobutungi, C
   Oti, S
   Crampin, A
   Nyirenda, M
   Price, A
   Delaunay, V
   Diallo, A
   Douillot, L
   Sokhna, C
   Gomez-Olive, FX
   Kahn, K
   Tollman, SM
   Herbst, K
   Mossong, J
   Chuc, NTK
   Bangha, M
   Sankoh, OA
   Byass, P
AF Streatfield, P. Kim
   Khan, Wasif A.
   Bhuiya, Abbas
   Hanifi, Syed M. A.
   Alam, Nurul
   Bagagnan, Cheik H.
   Sie, Ali
   Zabre, Pascal
   Lankoande, Bruno
   Rossier, Clementine
   Soura, Abdramane B.
   Bonfoh, Bassirou
   Kone, Siaka
   Ngoran, Eliezer K.
   Utzinger, Juerg
   Haile, Fisaha
   Melaku, Yohannes A.
   Weldearegawi, Berhe
   Gomez, Pierre
   Jasseh, Momodou
   Ansah, Patrick
   Debpuur, Cornelius
   Oduro, Abraham
   Wak, George
   Adjei, Alexander
   Gyapong, Margaret
   Sarpong, Doris
   Kant, Shashi
   Misra, Puneet
   Rai, Sanjay K.
   Juvekar, Sanjay
   Lele, Pallavi
   Bauni, Evasius
   Mochamah, George
   Ndila, Carolyne
   Williams, Thomas N.
   Laserson, Kayla F.
   Nyaguara, Amek
   Odhiambo, Frank O.
   Phillips-Howard, Penelope
   Ezeh, Alex
   Kyobutungi, Catherine
   Oti, Samuel
   Crampin, Amelia
   Nyirenda, Moffat
   Price, Alison
   Delaunay, Valerie
   Diallo, Aldiouma
   Douillot, Laetitia
   Sokhna, Cheikh
   Gomez-Olive, F. Xavier
   Kahn, Kathleen
   Tollman, Stephen M.
   Herbst, Kobus
   Mossong, Joel
   Chuc, Nguyen T. K.
   Bangha, Martin
   Sankoh, Osman A.
   Byass, Peter
TI Adult non-communicable disease mortality in Africa and Asia: evidence
   from INDEPTH Health and Demographic Surveillance System sites
SO GLOBAL HEALTH ACTION
LA English
DT Article
DE adults; non-communicable disease; Africa; Asia; mortality; INDEPTH
   Network; verbal autopsy; InterVA
AB Background: Mortality from non-communicable diseases (NCDs) is a major global issue, as other categories of mortality have diminished and life expectancy has increased. The World Health Organization's Member States have called for a 25% reduction in premature NCD mortality by 2025, which can only be achieved by substantial reductions in risk factors and improvements in the management of chronic conditions. A high burden of NCD mortality among much older people, who have survived other hazards, is inevitable. The INDEPTH Network collects detailed individual data within defined Health and Demographic Surveillance sites. By registering deaths and carrying out verbal autopsies to determine cause of death across many such sites, using standardised methods, the Network seeks to generate population-based mortality statistics that are not otherwise available.
   Objective: To describe patterns of adult NCD mortality from INDEPTH Network sites across Africa and Asia, according to the WHO 2012 verbal autopsy (VA) cause categories, with separate consideration of premature (15 - 64 years) and older (65+ years) NCD mortality.
   Design: All adult deaths at INDEPTH sites are routinely registered and followed up with VA interviews. For this study, VA archives were transformed into the WHO 2012 VA standard format and processed using the InterVA-4 model to assign cause of death. Routine surveillance data also provide person-time denominators for mortality rates.
   Results: A total of 80,726 adult (over 15 years) deaths were documented over 7,423,497 person-years of observation. NCDs were attributed as the cause for 35.6% of these deaths. Slightly less than half of adult NCD deaths occurred in the 15 - 64 age group. Detailed results are presented by age and sex for leading causes of NCD mortality. Per-site rates of NCD mortality were significantly correlated with rates of HIV/AIDS-related mortality.
   Conclusions: These findings present important evidence on the distribution of NCD mortality across a wide range of African and Asian settings. This comes against a background of global concern about the burden of NCD mortality, especially among adults aged under 70, and provides an important baseline for future work.
C1 [Streatfield, P. Kim] Matlab HDSS, Dhaka, Bangladesh.
   [Streatfield, P. Kim; Khan, Wasif A.] Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh.
   [Streatfield, P. Kim; Khan, Wasif A.; Bhuiya, Abbas; Hanifi, Syed M. A.; Alam, Nurul; Bagagnan, Cheik H.; Sie, Ali; Zabre, Pascal; Lankoande, Bruno; Rossier, Clementine; Soura, Abdramane B.; Bonfoh, Bassirou; Kone, Siaka; Ngoran, Eliezer K.; Utzinger, Juerg; Haile, Fisaha; Melaku, Yohannes A.; Weldearegawi, Berhe; Gomez, Pierre; Jasseh, Momodou; Ansah, Patrick; Debpuur, Cornelius; Oduro, Abraham; Wak, George; Adjei, Alexander; Gyapong, Margaret; Sarpong, Doris; Kant, Shashi; Misra, Puneet; Rai, Sanjay K.; Juvekar, Sanjay; Lele, Pallavi; Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.; Laserson, Kayla F.; Nyaguara, Amek; Odhiambo, Frank O.; Phillips-Howard, Penelope; Ezeh, Alex; Kyobutungi, Catherine; Oti, Samuel; Crampin, Amelia; Nyirenda, Moffat; Price, Alison; Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh; Gomez-Olive, F. Xavier; Kahn, Kathleen; Tollman, Stephen M.; Herbst, Kobus; Mossong, Joel; Chuc, Nguyen T. K.; Bangha, Martin; Sankoh, Osman A.; Byass, Peter] INDEPTH Network, Accra, Ghana.
   [Khan, Wasif A.] Bandarban HDSS, Dhaka, Bangladesh.
   [Bhuiya, Abbas; Hanifi, Syed M. A.] Chakaria HDSS, Dhaka, Bangladesh.
   [Bhuiya, Abbas; Hanifi, Syed M. A.] Int Ctr Diarrhoeal Dis Res, Ctr Equ & Hlth Syst, Dhaka, Bangladesh.
   [Alam, Nurul] AMK HDSS, Dhaka, Bangladesh.
   [Alam, Nurul] Int Ctr Diarrhoeal Dis Res, Ctr Populat Urbanisat & Climate Change, Dhaka, Bangladesh.
   [Bagagnan, Cheik H.; Sie, Ali; Zabre, Pascal] Nouna HDSS, Ouagadougou, Burkina Faso.
   [Bagagnan, Cheik H.; Sie, Ali; Zabre, Pascal] Nouna Hlth Res Ctr, Nouna, Burkina Faso.
   [Lankoande, Bruno; Rossier, Clementine; Soura, Abdramane B.] Ouagadougou HDSS, Ouagadougou, Burkina Faso.
   [Lankoande, Bruno; Rossier, Clementine; Soura, Abdramane B.] Univ Ouagadougou, Inst Super Sci Populat, Ouagadougou, Burkina Faso.
   [Lankoande, Bruno; Rossier, Clementine; Soura, Abdramane B.] Univ Geneva, Inst Etud Demog & Parcours Vie, Geneva, Switzerland.
   [Bonfoh, Bassirou; Kone, Siaka; Ngoran, Eliezer K.; Utzinger, Juerg] Taabo HDSS, Yamoussoukro, Cote Ivoire.
   [Bonfoh, Bassirou; Kone, Siaka] Ctr Suisse Rech Sci Cote Ivoire, Abidjan, Cote Ivoire.
   [Ngoran, Eliezer K.] Univ Felix Houphoet Boigny, Abidjan, Cote Ivoire.
   [Utzinger, Juerg] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Haile, Fisaha; Melaku, Yohannes A.; Weldearegawi, Berhe] Kilite Awlaelo HDSS, Addis Ababa, Ethiopia.
   [Haile, Fisaha; Melaku, Yohannes A.; Weldearegawi, Berhe] Mekelle Univ, Dept Publ Hlth, Coll Hlth Sci, Mekelle, Ethiopia.
   [Gomez, Pierre; Jasseh, Momodou] Farafenni HDSS, Banjul, Gambia.
   [Gomez, Pierre; Jasseh, Momodou] MRC, Gambia Unit, Fajara, Gambia.
   [Ansah, Patrick; Debpuur, Cornelius; Oduro, Abraham; Wak, George] Navrongo HDSS, Accra, Ghana.
   [Ansah, Patrick; Debpuur, Cornelius; Oduro, Abraham; Wak, George] Navrongo Hlth Res Ctr, Navrongo, Ghana.
   [Adjei, Alexander; Gyapong, Margaret; Sarpong, Doris] Dodowa HDSS, Accra, Ghana.
   [Adjei, Alexander] Dodowa Hlth Res Ctr, Dodowa, Ghana.
   [Gyapong, Margaret; Sarpong, Doris; Kant, Shashi; Misra, Puneet; Rai, Sanjay K.] Ballabgarh HDSS, Ballabgarh, India.
   [Kant, Shashi; Misra, Puneet; Rai, Sanjay K.] All India Inst Med Sci, New Delhi, India.
   [Juvekar, Sanjay; Lele, Pallavi] Vadu HDSS, Pune, Maharashtra, India.
   [Juvekar, Sanjay; Lele, Pallavi] KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India.
   [Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.] Kilifi HDSS, Nairobi, Kenya.
   [Bauni, Evasius; Mochamah, George; Ndila, Carolyne; Williams, Thomas N.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, Dept Med, St Marys Hosp, London, England.
   [Laserson, Kayla F.; Nyaguara, Amek; Odhiambo, Frank O.; Phillips-Howard, Penelope] Kisumu HDSS, Nairobi, Kenya.
   [Laserson, Kayla F.; Nyaguara, Amek; Odhiambo, Frank O.; Phillips-Howard, Penelope] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya.
   [Laserson, Kayla F.; Nyaguara, Amek; Odhiambo, Frank O.; Phillips-Howard, Penelope] KEMRI Ctr Global Hlth Res, Kisumu, Kenya.
   [Ezeh, Alex; Kyobutungi, Catherine; Oti, Samuel] Nairobi HDSS, Nairobi, Kenya.
   [Ezeh, Alex; Kyobutungi, Catherine; Oti, Samuel] African Populat & Hlth Res Ctr, Nairobi, Kenya.
   [Crampin, Amelia; Nyirenda, Moffat; Price, Alison] Karonga HDSS, Lilongwe, Malawi.
   [Crampin, Amelia; Nyirenda, Moffat; Price, Alison] Karonga Prevent Study, Chilumba, Malawi.
   [Crampin, Amelia; Price, Alison] London Sch Hyg & Trop Med, London WC1, England.
   [Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh] Niakhar HDSS, Dakar, Senegal.
   [Delaunay, Valerie; Diallo, Aldiouma; Douillot, Laetitia; Sokhna, Cheikh] IRD, Dakar, Senegal.
   [Gomez-Olive, F. Xavier; Kahn, Kathleen; Tollman, Stephen M.] Agincourt HDSS, Durban, South Africa.
   [Gomez-Olive, F. Xavier; Kahn, Kathleen; Tollman, Stephen M.; Byass, Peter] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Johannesburg, South Africa.
   [Kahn, Kathleen; Tollman, Stephen M.] Umea Univ, Umea Ctr Global Hlth Res, Umea, Sweden.
   [Herbst, Kobus; Mossong, Joel] Africa Ctr HDSS, Durban, South Africa.
   [Herbst, Kobus] Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Somkhele, Kwazulu Natal, South Africa.
   [Mossong, Joel] Natl Hlth Lab, Surveillance & Epidemiol Infect Dis, Dudelange, Luxembourg.
   [Chuc, Nguyen T. K.] Matlab HDSS, Dhaka, Bangladesh.
   [Chuc, Nguyen T. K.] Hanoi Med Univ, Hlth Syst Res, Hanoi 100803, Vietnam.
   [Sankoh, Osman A.] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa.
   [Sankoh, Osman A.] Hanoi Med Univ, Hanoi 100803, Vietnam.
   [Byass, Peter] Umea Univ, WHO Collaborating Ctr Verbal Autopsy, Umea Ctr Global Hlth Res, Umea, Sweden.
RP Sankoh, OA (reprint author), INDEPTH Network, POB KD213, Kanda, Accra, Ghana.
EM osman.sankoh@indepth-network.org
RI Mossong, Joel/D-4998-2009
OI Mossong, Joel/0000-0003-0717-9835; Phillips-Howard, Penelope
   A/0000-0003-1018-116X; Ezeh, Alex/0000-0002-1309-4697; Price,
   Alison/0000-0002-3891-3337; Byass, Peter/0000-0001-5474-4361; SIE,
   Ali/0000-0002-3959-2520
FU Sida; Wellcome Trust [WT081993MA, 091758, 084538]; William & Flora
   Hewlett Foundation; Forte, the Swedish Research Council for Health,
   Working Life and Welfare [2006-1512]; European Community Marie Curie
   Actions IPHTRE project [295168]; US Centers for Disease Control and
   Prevention (CDC); Ethiopian Public Health Association (EPHA)
   [5U22/PS022179_10]; Mekelle University; UK Medical Research Council; KEM
   Hospital Research Centre; KEMRI-Wellcome Trust Major Overseas Programme
   from the Wellcome Trust; KEMRI; CDC; Rockefeller Foundation (USA);
   Wellcome Trust (UK); William and Flora Hewlett Foundation (USA); Comic
   Relief (UK); Swedish International Development Cooperation Agency
   (SIDA); Bill and Melinda Gates Foundation (USA); School of Public Health
   and Faculty of Health Sciences, University of the Witwatersrand; Medical
   Research Council, South Africa; Wellcome Trust, UK [058893/Z/99/A,
   069683/Z/02/Z, 085477/Z/08/Z]; National Institute on Aging (NIA) of the
   NIH; William and Flora Hewlett Foundation; Andrew W Mellon Foundation,
   USA
FX We are grateful to all the residents of INDEPTH HDSS sites who have
   contributed personal information to this mortality dataset, to the field
   staff who undertook so many verbal autopsy interviews, and the data
   management staff who handled the data at every participating site.
   INDEPTH thanks all the site scientists who participated in bringing this
   work together, and who variously participated in analysis workshops in
   Ghana, Belgium, Thailand, and the United Kingdom. The INDEPTH Network is
   grateful for core funding from Sida, the Wellcome Trust, and the William
   & Flora Hewlett Foundation. The Umea Centre for Global Health Research
   is core funded by Forte, the Swedish Research Council for Health,
   Working Life and Welfare (grant 2006-1512). PB's residency at the
   University of the Witwatersrand Rural Knowledge Hub to analyse and draft
   these results was supported by the European Community Marie Curie
   Actions IPHTRE project (no. 295168). icddr,b is thankful to the
   Governments of Australia, Bangladesh, Canada, Sweden and the UK for
   providing core/unrestricted support. The Ouagadougou site thanks the
   Wellcome Trust for its financial support to the Ouagadougou HDSS (grant
   number WT081993MA). The Kilite Awlaelo HDSS is supported by the US
   Centers for Disease Control and Prevention (CDC) and the Ethiopian
   Public Health Association (EPHA), in accordance with the EPHA-CDC
   Cooperative Agreement No. 5U22/PS022179_10 and Mekelle University,
   though these findings do not necessarily represent the funders' official
   views. The Farafenni site is supported by the UK Medical Research
   Council. The Vadu site is thankful for the core continued funding
   support from KEM Hospital Research Centre since 2004. The Kilifi site is
   supported through core support to the KEMRI-Wellcome Trust Major
   Overseas Programme from the Wellcome Trust. TNW is supported by a Senior
   Fellowship (091758) and CN through a Strategic Award (084538) from the
   Wellcome Trust. This paper is published with permission from the
   Director of KEMRI. The Kisumu site wishes to convey its gratitude for
   the contribution of the late Dr. Kubaje Adazu to the development of
   KEMRI/CDC HDSS, which was implemented and continues to be supported
   through a cooperative agreement between KEMRI and CDC. The Nairobi Urban
   Health and Demographic Surveillance System (NUHDSS), Kenya, since its
   inception has received support from the Rockefeller Foundation (USA),
   the Wellcome Trust (UK), the William and Flora Hewlett Foundation (USA),
   Comic Relief (UK), the Swedish International Development Cooperation
   Agency (SIDA) and the Bill and Melinda Gates Foundation (USA). The
   Agincourt site thanks the School of Public Health and Faculty of Health
   Sciences, University of the Witwatersrand, and the Medical Research
   Council, South Africa, for having provided vital support since inception
   of the Agincourt HDSS. Core funding has been provided by the Wellcome
   Trust, UK (Grants 058893/Z/99/A; 069683/Z/02/Z; 085477/Z/08/Z) with
   contributions from the National Institute on Aging (NIA) of the NIH,
   William and Flora Hewlett Foundation, and Andrew W Mellon Foundation,
   USA.
CR Alleyne G, 2013, LANCET, V381, P566, DOI 10.1016/S0140-6736(12)61806-6
   Bah E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075775
   Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0
   Byass P, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.22448
   Byass P, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.19281
   Crampin AC, 2012, INT J EPIDEMIOL, V41, P676, DOI 10.1093/ije/dys088
   Dalal S, 2011, INT J EPIDEMIOL, V40, P885, DOI 10.1093/ije/dyr050
   Delaunay V, 2013, INT J EPIDEMIOL, V42, P1002, DOI 10.1093/ije/dyt100
   Gyapong M, 2013, INT J EPIDEMIOL, V42, P1686, DOI 10.1093/ije/dyt197
   Hanifi MA, 2012, INT J EPIDEMIOL, V41, P667, DOI 10.1093/ije/dys089
   Herbst AJ, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-47
   Hirve S, 2012, INT J EPIDEMIOL, V41, P1719, DOI 10.1093/ije/dys163
   Huong Dao Lan, 2006, Popul Health Metr, V4, P9, DOI 10.1186/1478-7954-4-9
   [Anonymous], 2011, SURV REP 2009 ABH MI
   INDEPIH Network, 2014, INDEPTH NETW CAUS SP, DOI [10.7796/INDEPTH.GH003.COD2014.vl, DOI 10.7796/INDEPTH.GH003.COD2014.V1]
   INDEPTH Network, BAND HDSS
   Jasseh M, 2011, TROP MED INT HEALTH, V16, P1314, DOI 10.1111/j.1365-3156.2011.02809.x
   Kahn K, 2012, INT J EPIDEMIOL, V41, P988, DOI 10.1093/ije/dys115
   Kant S, 2013, INT J EPIDEMIOL, V42, P758, DOI 10.1093/ije/dyt055
   Kontis V, 2014, LANCET, V384, P427, DOI 10.1016/S0140-6736(14)60616-4
   Kouadio M'bra Kd, 2013, BMC Hematol, V13, P5, DOI 10.1186/2052-1839-13-5
   Leitao J, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.21518
   Lindeboom W, HLTH DEMOGRAPHIC SUR
   Ng N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035308
   Odhiambo FO, 2012, INT J EPIDEMIOL, V41, P977, DOI 10.1093/ije/dys108
   Oduro AR, 2012, INT J EPIDEMIOL, V41, P968, DOI 10.1093/ije/dys111
   Oti SO, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-588
   Razzaque A, 2010, GLOBAL HEALTH ACTION, V3, P70, DOI 10.3402/gha.v3i0.4618
   Rossier C, 2012, INT J EPIDEMIOL, V41, P658, DOI 10.1093/ije/dys090
   Sankoh O, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.23286
   Sankoh O, 2012, INT J EPIDEMIOL, V41, P579, DOI 10.1093/ije/dys081
   Santosa A, 2014, GLOB HLTH ACTION, V7, P25374, DOI DOI 10.3402/GHA.V7.25374
   Scott JAG, 2012, INT J EPIDEMIOL, V41, P650, DOI 10.1093/ije/dys062
   Sie A, 2010, GLOBAL HEALTH ACTION, V3, DOI 10.3402/gha.v3i0.5284
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25370
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25362
   United Nations, 2013, WORLD POP PROSP 2012
   Weldearegawi B, 2013, HEALTH POLICY PLANN, V28, P891, DOI 10.1093/heapol/czs135
   WHO, 2012, VERB AUT STAND 2012
   World Health Organization, 2011, INT STAT CLASS DIS R, V2
   World Health Organization, 2011, GLOB STAT NONC DIS 2
NR 41
TC 18
Z9 18
U1 5
U2 8
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PY 2014
VL 7
AR 25365
DI 10.3402/gha.v7.25365
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V44FM
UT WOS:000209734900001
PM 25377326
OA gold
DA 2017-08-15
ER

PT J
AU Streatfield, PK
   Khan, WA
   Bhuiya, A
   Alam, N
   Sie, A
   Soura, AB
   Bonfoh, B
   Ngoran, EK
   Weldearegawi, B
   Jasseh, M
   Oduro, A
   Gyapong, M
   Kant, S
   Juvekar, S
   Wilopo, S
   Williams, TN
   Odhiambo, FO
   Beguy, D
   Ezeh, A
   Kyobutungi, C
   Crampin, A
   Delaunay, V
   Tollman, SM
   Herbst, K
   Chuc, NTK
   Sankoh, OA
   Tanner, M
   Byass, P
AF Streatfield, P. Kim
   Khan, Wasif A.
   Bhuiya, Abbas
   Alam, Nurul
   Sie, Ali
   Soura, Abdramane B.
   Bonfoh, Bassirou
   Ngoran, Eliezer K.
   Weldearegawi, Berhe
   Jasseh, Momodou
   Oduro, Abraham
   Gyapong, Margaret
   Kant, Shashi
   Juvekar, Sanjay
   Wilopo, Siswanto
   Williams, Thomas N.
   Odhiambo, Frank O.
   Beguy, Donatien
   Ezeh, Alex
   Kyobutungi, Catherine
   Crampin, Amelia
   Delaunay, Valerie
   Tollman, Stephen M.
   Herbst, Kobus
   Chuc, Nguyen T. K.
   Sankoh, Osman A.
   Tanner, Marcel
   Byass, Peter
TI Cause-specific mortality in Africa and Asia: evidence from INDEPTH
   health and demographic surveillance system sites
SO GLOBAL HEALTH ACTION
LA English
DT Article
DE mortality; cause of death; Africa; Asia; verbal autopsy; INDEPTH Network
AB Background: Because most deaths in Africa and Asia are not well documented, estimates of mortality are often made using scanty data. The INDEPTH Network works to alleviate this problem by collating detailed individual data from defined Health and Demographic Surveillance sites. By registering all deaths over time and carrying out verbal autopsies to determine cause of death across many such sites, using standardised methods, the Network seeks to generate population-based mortality statistics that are not otherwise available.
   Objective: To build a large standardised mortality database from African and Asian sites, detailing the relevant methods, and use it to describe cause-specific mortality patterns.
   Design: Individual demographic and verbal autopsy (VA) data from 22 INDEPTH sites were collated into a standardised database. The INDEPTH 2013 population was used for standardisation. The WHO 2012 VA standard and the InterVA-4 model were used for assigning cause of death.
   Results: A total of 111,910 deaths occurring over 12,204,043 person-years (accumulated between 1992 and 2012) were registered across the 22 sites, and for 98,429 of these deaths (88.0%) verbal autopsies were successfully completed. There was considerable variation in all-cause mortality between sites, with most of the differences being accounted for by variations in infectious causes as a proportion of all deaths.
   Conclusions: This dataset documents individual deaths across Africa and Asia in a standardised way, and on an unprecedented scale. While INDEPTH sites are not constructed to constitute a representative sample, and VA may not be the ideal method of determining cause of death, nevertheless these findings represent detailed mortality patterns for parts of the world that are severely under-served in terms of measuring mortality. Further papers explore details of mortality patterns among children and specifically for NCDs, external causes, pregnancy-related mortality, malaria, and HIV/ AIDS. Comparisons will also be made where possible with other findings on mortality in the same regions. Findings presented here and in accompanying papers support the need for continued work towards much wider implementation of universal civil registration of deaths by cause on a worldwide basis.
C1 [Streatfield, P. Kim] Matlab HDSS, Dhaka, Bangladesh.
   [Streatfield, P. Kim; Khan, Wasif A.] Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh.
   [Streatfield, P. Kim; Khan, Wasif A.; Bhuiya, Abbas; Alam, Nurul; Sie, Ali; Soura, Abdramane B.; Bonfoh, Bassirou; Ngoran, Eliezer K.; Weldearegawi, Berhe; Jasseh, Momodou; Oduro, Abraham; Gyapong, Margaret; Kant, Shashi; Juvekar, Sanjay; Wilopo, Siswanto; Williams, Thomas N.; Odhiambo, Frank O.; Beguy, Donatien; Ezeh, Alex; Kyobutungi, Catherine; Crampin, Amelia; Delaunay, Valerie; Tollman, Stephen M.; Herbst, Kobus; Chuc, Nguyen T. K.; Sankoh, Osman A.] INDEPTH Network, POB KD 213, Kanda, Accra, Ghana.
   [Khan, Wasif A.] Bandarban HDSS, Bandarban Dist, Bangladesh.
   [Bhuiya, Abbas] Chakaria HDSS, South Eastern Coast, Bangladesh.
   [Bhuiya, Abbas] Int Ctr Diarrhoeal Dis Res, Ctr Equ & Hlth Syst, GPO Box 128, Dhaka 1000, Bangladesh.
   [Alam, Nurul] AMK HDSS, Khulna Div, Bangladesh.
   [Alam, Nurul] Int Ctr Diarrhoeal Dis Res, Ctr Populat Urbanisat & Climate Change, GPO Box 128, Dhaka 1000, Bangladesh.
   [Sie, Ali] Nouna HDSS, Nouna, Burkina Faso.
   [Sie, Ali] Nouna Hlth Res Ctr, Nouna, Burkina Faso.
   [Soura, Abdramane B.] Ouagadougou HDSS, Ouagadougou, Burkina Faso.
   [Soura, Abdramane B.] Univ Ouagadougou, Inst Super Sci Populat, Ouagadougou, Burkina Faso.
   [Bonfoh, Bassirou; Ngoran, Eliezer K.] Taabo HDSS, Taabo, Cote Ivoire.
   [Bonfoh, Bassirou] Ctr Suisse Rech Sci Cote Ivoire, Abidjan, Cote Ivoire.
   [Ngoran, Eliezer K.] Univ Felix Houphoet Boigny, Abidjan, Cote Ivoire.
   [Weldearegawi, Berhe] Kilite Awlaelo HDSS, Kilite Awlaelo, Ethiopia.
   [Weldearegawi, Berhe] Mekelle Univ, Dept Publ Hlth, Coll Hlth Sci, Mekelle, Ethiopia.
   [Jasseh, Momodou] Farafenni HDSS, Farafenni, Gambia.
   [Jasseh, Momodou] MRC, Gambia Unit, Fajara, Gambia.
   [Oduro, Abraham] Navrongo HDSS, Navrongo, Ghana.
   [Oduro, Abraham] Navrongo Hlth Res Ctr, Navrongo, Ghana.
   [Gyapong, Margaret] Dodowa HDSS, Dodowa, Ghana.
   [Gyapong, Margaret] Dodowa Hlth Res Ctr, Dodowa, Ghana.
   [Kant, Shashi] Ballabgarh HDSS, Ballabgarh, India.
   [Kant, Shashi] All India Inst Med Sci, New Delhi, India.
   [Juvekar, Sanjay] Vadu HDSS, Vadu, India.
   [Juvekar, Sanjay] KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India.
   [Wilopo, Siswanto] Purworejo HDSS, Purworejo, Indonesia.
   [Wilopo, Siswanto] Univ Gadjah Mada, Dept Publ Hlth, Yogyakarta, Indonesia.
   [Williams, Thomas N.] Kilifi HDSS, Kilifi, Kenya.
   [Williams, Thomas N.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, Dept Med, St Marys Hosp, London, England.
   [Odhiambo, Frank O.] Kisumu HDSS, Kisumu, Kenya.
   [Odhiambo, Frank O.] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya.
   [Odhiambo, Frank O.] KEMRI Ctr Global Hlth Res, Kisumu, Kenya.
   [Beguy, Donatien; Ezeh, Alex; Kyobutungi, Catherine] Nairobi HDSS, Nairobi, Kenya.
   [Beguy, Donatien; Ezeh, Alex; Kyobutungi, Catherine] African Populat & Hlth Res Ctr, Nairobi, Kenya.
   [Crampin, Amelia] Karonga HDSS, Karonga, Malawi.
   [Crampin, Amelia] Karonga Prevent Study, Chilumba, Malawi.
   [Crampin, Amelia] London Sch Hyg & Trop Med, London WC1, England.
   [Delaunay, Valerie] Niakhar HDSS, Niakhar, Senegal.
   [Delaunay, Valerie] IRD, Dakar, Senegal.
   [Tollman, Stephen M.] Agincourt HDSS, Acornhoek, South Africa.
   [Tollman, Stephen M.; Byass, Peter] Univ Witwatersrand, Sch Publ Hlth, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Fac Hlth Sci, Johannesburg 2050, South Africa.
   [Tollman, Stephen M.] Umea Univ, Umea Ctr Global Hlth Res, Umea, Sweden.
   [Herbst, Kobus] Africa Ctr HDSS, Kwa Zulu, South Africa.
   [Herbst, Kobus] Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Somkhele, Kwazulu Natal, South Africa.
   [Chuc, Nguyen T. K.] FilaBavi HDSS, Filabavi, Vietnam.
   [Chuc, Nguyen T. K.] Hanoi Med Univ, Hlth Syst Res, Hanoi 100803, Vietnam.
   [Sankoh, Osman A.] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa.
   [Sankoh, Osman A.] Hanoi Med Univ, Hanoi 100803, Vietnam.
   [Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Byass, Peter] Umea Univ, WHO Collaborating Ctr Verbal Autopsy, Umea Ctr Global Hlth Res, Umea, Sweden.
RP Sankoh, OA (reprint author), INDEPTH Network, POB KD 213, Kanda, Accra, Ghana.
EM osman.sankoh@indepth-network.org
OI Ezeh, Alex/0000-0002-1309-4697; Byass, Peter/0000-0001-5474-4361; SIE,
   Ali/0000-0002-3959-2520; Wilopo, Siswanto/0000-0003-1284-7228
FU Sida; Wellcome Trust; William & Flora Hewlett Foundation; Forte, the
   Swedish Research Council for Health, Working Life and Welfare
   [2006-1512]; European Community [295168]; Government of Australia;
   Government of Bangladesh; Government of Canada; Government of Sweden;
   Government of UK; Wellcome Trust [WT081993MA, 091758]; US Centers for
   Disease Control and Prevention (CDC); Ethiopian Public Health
   Association (EPHA); EPHA-CDC [5U22/PS022179_10]; Mekelle University; UK
   Medical Research Council; KEM Hospital Research Centre; Rockefeller
   Foundation (USA); Wellcome Trust (UK); William and Flora Hewlett
   Foundation (USA); Comic Relief (UK); Swedish International Development
   Cooperation Agency (SIDA); Bill and Melinda Gates Foundation (USA);
   Wellcome Trust, UK [058893/Z/99/A, 069683/Z/02/Z, 085477/Z/08/Z];
   National Institute on Aging (NIA) of the NIH; William and Flora Hewlett
   Foundation; Andrew W Mellon Foundation, USA
FX We are grateful to all the residents of INDEPTH HDSS sites who have
   contributed personal information to this mortality dataset, and to the
   field staff who undertook so many VA interviews, and data management
   staff who handled the data at every participating site. INDEPTH thanks
   all the site scientists who have participated in bringing this work
   together, and who variously participated in analysis workshops in Ghana,
   Belgium, Thailand, and the United Kingdom. The INDEPTH Network is
   grateful for core funding from Sida, the Wellcome Trust, and the William
   & Flora Hewlett Foundation. The Umea Centre for Global Health Research
   is core funded by Forte, the Swedish Research Council for Health,
   Working Life and Welfare (grant 2006-1512). PB's residency at the
   University of the Witwatersrand Rural Knowledge Hub to analyse and draft
   these results was supported by the European Community Marie Curie
   Actions IPHTRE project (no. 295168). icddr,b is thankful to the
   Governments of Australia, Bangladesh, Canada, Sweden and the UK for
   providing core/unrestricted support. The Ouagadougou site acknowledges
   the Wellcome Trust for its financial support to the Ouagadougou HDSS
   (grant number WT081993MA). The Kilite Awlaelo HDSS is supported by the
   US Centers for Disease Control and Prevention (CDC) and the Ethiopian
   Public Health Association (EPHA), in accordance with the EPHA-CDC
   Cooperative Agreement No.5U22/PS022179_10 and Mekelle University, though
   these findings do not necessarily represent the funders' official views.
   The Farafenni site is supported by the UK Medical Research Council. The
   Vadu site notes core continued funding support from KEM Hospital
   Research Centre since 2004. The Kilifi site is supported through core
   support to the KEMRI-Wellcome Trust Major Overseas Programme from the
   Wellcome Trust. TNW is supported by a Senior Fellowship (091758) from
   the Wellcome Trust. This paper is published with permission from the
   Director of KEMRI. The Kisumu site wishes to acknowledge the
   contribution of the late Dr. Kubaje Adazu to the development of
   KEMRI/CDC HDSS, which was implemented and continues to be supported
   through a cooperative agreement between KEMRI and CDC. The Nairobi Urban
   Health and Demographic Surveillance System (NUHDSS), Kenya, since its
   inception has received support from the Rockefeller Foundation (USA),
   the Wellcome Trust (UK), the William and Flora Hewlett Foundation (USA),
   Comic Relief (UK), the Swedish International Development Cooperation
   Agency (SIDA) and the Bill and Melinda Gates Foundation (USA). The
   Agincourt site acknowledges that the School of Public Health and Faculty
   of Health Sciences, University of the Witwatersrand, and the Medical
   Research Council, South Africa, have provided vital support since
   inception of the Agincourt HDSS. Core funding has been provided by the
   Wellcome Trust, UK (Grants 058893/Z/99/A; 069683/Z/02/Z; 085477/Z/08/Z)
   with contributions from the National Institute on Aging (NIA) of the
   NIH, William and Flora Hewlett Foundation, and Andrew W Mellon
   Foundation, USA.
CR Aggarwal AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054865
   Alam N, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25510
   Alam N, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25511
   Amek NO, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25581
   Awini E, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25543
   Byass P, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-23
   Byass P, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.22448
   Byass P, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001477
   Byass P, 2012, LANCET, V380, P1643, DOI 10.1016/S0140-6736(12)61940-0
   Byass P, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.19281
   Byass P, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-46
   Byass P, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-23
   Crampin AC, 2012, INT J EPIDEMIOL, V41, P676, DOI 10.1093/ije/dys088
   Delaunay V, 2013, INT J EPIDEMIOL, V42, P1002, DOI 10.1093/ije/dyt100
   Gulsvik AK, 2011, EUR J EPIDEMIOL, V26, P221, DOI 10.1007/s10654-010-9535-4
   Gyapong M, 2013, INT J EPIDEMIOL, V42, P1686, DOI 10.1093/ije/dyt197
   Hanifi MA, 2012, INT J EPIDEMIOL, V41, P667, DOI 10.1093/ije/dys089
   Hanifi SMA, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25473
   Herbst AJ, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-47
   Herrett E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2350
   Hirve S, 2012, INT J EPIDEMIOL, V41, P1719, DOI 10.1093/ije/dys163
   Huong Dao Lan, 2006, Popul Health Metr, V4, P9, DOI 10.1186/1478-7954-4-9
   INDEPIH Network, 2014, INDEPTH NETW CAUS SP, DOI [10.7796/INDEPTH.GH003.COD2014.vl, DOI 10.7796/INDEPTH.GH003.COD2014.V1]
   INDEPTH Network, BAND HDSS
   Jasseh M, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.25598
   Jasseh M, 2011, TROP MED INT HEALTH, V16, P1314, DOI 10.1111/j.1365-3156.2011.02809.x
   Kabudula CW, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25596
   Kahn K, 2000, TROP MED INT HEALTH, V5, P824, DOI 10.1046/j.1365-3156.2000.00638.x
   Kahn K, 2012, INT J EPIDEMIOL, V41, P988, DOI 10.1093/ije/dys115
   Kant S, 2013, INT J EPIDEMIOL, V42, P758, DOI 10.1093/ije/dyt055
   Kouadio M'bra Kd, 2013, BMC Hematol, V13, P5, DOI 10.1186/2052-1839-13-5
   Leitao J, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-22
   Leitao J, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.21518
   Lindeboom W, 2011, HLTH DEMOGRAPHIC SUR
   Misganaw A, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-130
   Mossong J, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25496
   Murray CJL, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-5
   Ndila C, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25593
   Ndila C, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-65
   Ng N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035308
   Odhiambo FO, 2012, INT J EPIDEMIOL, V41, P977, DOI 10.1093/ije/dys108
   Oduro AR, 2012, INT J EPIDEMIOL, V41, P968, DOI 10.1093/ije/dys111
   Ordi J, 2009, PLOS MED, V6, P174, DOI 10.1371/journal.pmed.1000036
   Oti SO, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-588
   Oti SO, 2003, GLOB HLTH ACTION, V7, P25533, DOI DOI 10.3402/GHA.V7.25533.ECOLLECTION@2014.:25533
   Rai SK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25573
   Razzaque A, 2010, GLOBAL HEALTH ACTION, V3, P70, DOI 10.3402/gha.v3i0.4618
   Rossier C, 2012, INT J EPIDEMIOL, V41, P658, DOI 10.1093/ije/dys090
   Sankoh O, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25590
   Sankoh O, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.23286
   Sankoh O, 2013, LANCET GLOB HEALTH, V1, pE69, DOI 10.1016/S2214-109X(13)70034-2
   Sankoh O, 2012, INT J EPIDEMIOL, V41, P579, DOI 10.1093/ije/dys081
   Scott JAG, 2012, INT J EPIDEMIOL, V41, P650, DOI 10.1093/ije/dys062
   Sie A, 2010, GLOBAL HEALTH ACTION, V3, DOI 10.3402/gha.v3i0.5284
   Soura AB, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25523
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25368
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25366
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25370
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25369
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25365
   Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25363
   Swaro A, 2010, J R Coll Physicians Edinb, V40, P205, DOI 10.4997/JRCPE.2010.304
   Weldearegawi B, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25550
   Weldearegawi B, 2013, HEALTH POLICY PLANN, V28, P891, DOI 10.1093/heapol/czs135
   WHO, 2012, VERB AUT STAND 2012
   World Health Organization, CIV REG COV CAUS DEA
   World Health Organization, 2011, INT STAT CLASS DIS R, V2
NR 67
TC 20
Z9 20
U1 2
U2 5
PU CO-ACTION PUBLISHING
PI JARFALLA
PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN
SN 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PY 2014
VL 7
AR 25362
DI 10.3402/gha.v7.25362
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V44FK
UT WOS:000209734700001
PM 25377324
OA gold
DA 2017-08-15
ER

PT J
AU Tahita, MC
   Tinto, H
   Menten, J
   Ouedraogo, JB
   Guiguemde, RT
   van Geertruyden, JP
   Erhart, A
   D'Alessandro, U
AF Tahita, Marc C.
   Tinto, Halidou
   Menten, Joris
   Ouedraogo, Jean-Bosco
   Guiguemde, Robert T.
   van Geertruyden, Jean Pierre
   Erhart, Annette
   D'Alessandro, Umberto
TI Clinical signs and symptoms cannot reliably predict Plasmodium
   falciparum malaria infection in pregnant women living in an area of high
   seasonal transmission
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Pregnancy; Signs and symptoms
ID INFANT-MORTALITY; ANEMIA
AB Background: Malaria in pregnancy is a major public health problem in endemic countries. Though the signs and symptoms of malaria among pregnant women have been already described, clinical presentation may vary according to intensity of transmission and local perceptions. Therefore, determining common signs and symptoms among pregnant women with a malaria infection may be extremely useful to identify those in need of further investigation by rapid diagnostic test or microscopy.
   Methods: Six hundred pregnant women attending the maternity clinic of Nanoro District Hospital, Burkina Faso were recruited, 200 with suspected clinical malaria and 400 as controls. Cases were matched with controls by gestational age and parity. Signs and symptoms were collected and a blood sample taken for rapid diagnostic test, microscopy and haemoglobin measurement. A multivariate model was used to assess the predictive value of signs and symptoms for malaria infection.
   Results: The overall prevalence of malaria was 42.6% (256/600) while anaemia was found in 60.8% (365/600) of the women. Nearly half (49%) of the cases and 39.5% of the controls had a malaria infection (p = 0.03). The most common signs and symptoms among the cases were fever (36%, 72/200), history of fever (29%, 58/200) and headache (52%, 104/200). The positive predictive value for fever was 53% (95% CI: 41-64), history of fever 58% (95% CI: 37-63) and headache 51% (95% CI: 41-61).
   Conclusion: Signs and symptoms suggestive of malaria are frequent among pregnant women living in areas of intense transmission. Common malaria symptoms are not strong predictors of infection. For a better management of malaria in pregnancy, active screening to detect and treat malaria infection early should be performed on all pregnant women attending a health facility.
C1 [Tahita, Marc C.; Tinto, Halidou; Ouedraogo, Jean-Bosco] Inst Rech Sci Sante, Direct Reg Ouest, Bobo Dioulasso, Burkina Faso.
   [Tahita, Marc C.; Tinto, Halidou; Ouedraogo, Jean-Bosco; Guiguemde, Robert T.] Ctr Muraz, Lab Parasitol & Entomol, Bobo Dioulasso, Burkina Faso.
   [Menten, Joris; Erhart, Annette; D'Alessandro, Umberto] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.
   [van Geertruyden, Jean Pierre] Univ Antwerp, Int Hlth Unit, B-2020 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
RP D'Alessandro, U (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.
EM udalessandro@mrc.gm
RI Van geertruyden, Jean-pierre/K-6425-2014; D'Alessandro,
   Umberto/D-3457-2015
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364; D'Alessandro,
   Umberto/0000-0001-6341-5009
CR Bardaji A, 2011, J INFECT DIS, V203, P691, DOI 10.1093/infdis/jiq049
   Bardaji A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-27
   Huynh BT, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-72
   BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005
   Chima AO, 2012, MALARIA J, V11, P82
   Dellicour S, 2010, PLOS MED, V7, P1
   Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X
   Diagne N, 2000, NEW ENGL J MED, V343, P598, DOI 10.1056/NEJM200008313430901
   Dicko A, 2003, ACTA TROP, V89, P17, DOI 10.1016/j.actatropica.2003.07.001
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Koen P, 2010, PLOS ONE, V5, P8
   Kyabayinze DJ, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-306
   Luxemburger C, 2001, AM J EPIDEMIOL, V154, P459, DOI 10.1093/aje/154.5.459
   McGready R, 2012, PLOS ONE, V7, P7
   Ministere de la Sante (Burkina Faso), 1994, STAT SAN
   Nosten F, 2004, TRENDS PARASITOL, V20, P425, DOI 10.1016/j.pt.2004.06.007
   Rodriguez-Morales AJ, 2006, AM J TROP MED HYG, V74, P755
   Rogerson SJ, 2000, AM J TROP MED HYG, V62, P335
   Singh N, 2001, ANN TROP MED PARASIT, V95, P15
   Tagbor H, 2008, TROP MED INT HEALTH, V13, P1016, DOI 10.1111/j.1365-3156.2008.02111.x
   WHO/AFRO, 2004, AFRMAL0401 WHOAFRO
   World Health Organization Malaria Policy Advisory Committee and Secretariat, 2012, MALARIA J, V11, P424, DOI DOI 10.1186/1475-2875-11-424
NR 22
TC 4
Z9 4
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD DEC 27
PY 2013
VL 12
AR 464
DI 10.1186/1475-2875-12-464
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 285IS
UT WOS:000329388000001
PM 24373481
OA gold
DA 2017-08-15
ER

PT J
AU Satzke, C
   Turner, P
   Virolainen-Julkunen, A
   Adrian, PV
   Antonio, M
   Hare, KM
   Henao-Restrepo, AM
   Leach, AJ
   Klugman, KP
   Porter, BD
   Sa-Leao, R
   Scott, JA
   Nohynek, H
   O'Brien, KL
AF Satzke, Catherine
   Turner, Paul
   Virolainen-Julkunen, Anni
   Adrian, Peter V.
   Antonio, Martin
   Hare, Kim M.
   Henao-Restrepo, Ana Maria
   Leach, Amanda J.
   Klugman, Keith P.
   Porter, Barbara D.
   Sa-Leao, Raquel
   Scott, J. Anthony
   Nohynek, Hanna
   O'Brien, Katherine L.
CA WHO Pneumococcal Carriage
TI Standard method for detecting upper respiratory carriage of
   Streptococcus pneumoniae: Updated recommendations from the World Health
   Organization Pneumococcal Carriage Working Group
SO VACCINE
LA English
DT Article
DE Nasopharynx; Carriage; Colonization; Pneumococcus
ID VIRIDANS GROUP STREPTOCOCCI; 7-VALENT CONJUGATE VACCINE;
   POLYMERASE-CHAIN-REACTION; BLOT HYBRIDIZATION ASSAY; IN-VITRO GROWTH;
   MULTIPLEX PCR; NASOPHARYNGEAL CARRIAGE; HAEMOPHILUS-INFLUENZAE;
   STAPHYLOCOCCUS-AUREUS; INVASIVE DISEASE
AB In 2003 the World Health Organization (WHO) convened a working group and published a set of standard methods for studies measuring nasopharyngeal carriage of Streptococcus pneumoniae (the pneumococcus). The working group recently reconvened under the auspices of the WHO and updated the consensus standard methods. These methods describe the collection, transport and storage of nasopharyngeal samples, as well as provide recommendations for the identification and serotyping of pneumococci using culture and non-culture based approaches. We outline the consensus position of the working group, the evidence supporting this position, areas worthy of future research, and the epidemiological role of carriage studies. Adherence to these methods will reduce variability in the conduct of pneumococcal carriage studies undertaken in the context of pneumococcal vaccine trials, implementation studies, and epidemiology studies more generally so variability in methodology does not confound the interpretation of study findings. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Satzke, Catherine; Porter, Barbara D.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.
   [Satzke, Catherine] Royal Childrens Hosp, Murdoch Childrens Res Inst, Ctr Int Child Hlth, Parkville, Vic 3052, Australia.
   [Satzke, Catherine] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia.
   [Turner, Paul] Angkor Hosp Children, Dept Microbiol, Siem Reap, Cambodia.
   [Turner, Paul] Univ Oxford, Ctr Trop Med, Oxford, England.
   [Virolainen-Julkunen, Anni] Natl Inst Hlth & Welf, Dept Infect Dis Surveillance & Control, Helsinki, Finland.
   [Adrian, Peter V.] Univ Witwatersrand, MRC Wits Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
   [Antonio, Martin] MRC Unit, Banjul, Gambia.
   [Hare, Kim M.; Leach, Amanda J.] Charles Darwin Univ, Menzies Sch Hlth Res, Child Hlth Div, Darwin, NT 0909, Australia.
   [Henao-Restrepo, Ana Maria] WHO, Initiat Vaccine Res, CH-1211 Geneva, Switzerland.
   [Klugman, Keith P.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Klugman, Keith P.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
   [Sa-Leao, Raquel] Univ Nova Lisboa, Inst Tecnol Quim & Biol, Lab Mol Microbiol Human Pathogens, Oeiras, Portugal.
   [Scott, J. Anthony] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Scott, J. Anthony] London Sch Hyg & Trop Med, London WC1, England.
   [Nohynek, Hanna] Natl Inst Hlth & Welf, Vaccine Programme Unit, Helsinki, Finland.
   [O'Brien, Katherine L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
RP Satzke, C (reprint author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.
EM catherine.satzke@mcri.edu.au
RI Hare, Kim/N-2300-2013; Goldblatt, David/C-5972-2008; Sa-Leao,
   Raquel/A-9341-2011; Satzke, Catherine/D-6501-2013
OI Goldblatt, David/0000-0002-0769-5242; Sa-Leao,
   Raquel/0000-0001-9804-827X; Satzke, Catherine/0000-0003-3164-8849;
   Turner, Paul/0000-0002-1013-7815
FU Bill and Melinda Gates Foundation
FX The 2012 WHO working group meeting was funded by the Bill and Melinda
   Gates Foundation. Thanks to Neddy Mafunga and Alina Ximena Laurie for
   assistance with organization of the meeting, and to Susan Morpeth and
   the reviewers for critical reading of the manuscript.
CR Abdullahi O, 2007, J CLIN MICROBIOL, V45, P3408, DOI 10.1128/JCM.01393-07
   Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Albrich WC, 2012, CLIN INFECT DIS, V54, P601, DOI 10.1093/cid/cir859
   Arbique JC, 2004, J CLIN MICROBIOL, V42, P4686, DOI 10.1128/JCM.42.10.4686-4696.2004
   Auranen K, 2013, VACCINE
   AUSTRIAN R, 1976, MT SINAI J MED, V43, P699
   Azzari C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009282
   Battig P, 2006, MICROBES INFECT, V8, P2612, DOI 10.1016/j.micinf.2006.07.013
   Bentley SD, 2006, PLOS GENET, V2, P262, DOI 10.1371/journal.pgen.0020031
   Bishop CJ, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-3
   Bogaert D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017035
   Bronsdon MA, 2004, J CLIN MICROBIOL, V42, P1596, DOI 10.1128/JCM.42.4.1596-1600.2004
   Brugger SD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011638
   Brugger SD, 2009, J CLIN MICROBIOL, V47, P1750, DOI 10.1128/JCM.01877-08
   Carvalho MD, 2012, J CLIN MICROBIOL, V50, P3146, DOI 10.1128/JCM.01505-12
   Carvalho MD, 2010, J CLIN MICROBIOL, V48, P1611, DOI 10.1128/JCM.02243-09
   Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06
   Carville KS, 2007, J CLIN MICROBIOL, V45, P244, DOI 10.1128/JCM.01131-06
   Castillo D, 2011, LAB METHODS DIAGNOSI, P265
   Ceyhan M, 2010, EUR J CLIN MICROBIOL, V29, P289, DOI 10.1007/s10096-009-0853-y
   Charalambous BM, 2003, J CLIN MICROBIOL, V41, P5551, DOI 10.1128/JCM.41.12.5551-5551-2003
   Cloud JL, 2002, J CLIN MICROBIOL, V40, P3838, DOI 10.1128/JCM.40.10.3838-3840-2002
   Cohen R, 2006, PEDIATR INFECT DIS J, V25, P1001, DOI 10.1097/01.inf.0000243163.85163.a8
   De Silva S, 2010, J CLIN MICROBIOL, V48, P2963, DOI 10.1128/JCM.01617-09
   DeByle C, 2012, J VIROL METHODS, V185, P89, DOI 10.1016/j.jviromet.2012.06.009
   Diagnostica: SSI, 2011, PNEUM ANT IN VITR DI
   DILWORTH JA, 1975, J CLIN MICROBIOL, V2, P453
   Donkor ES, 2011, MBIO, V2, DOI 10.1128/mBio.00040-11
   Dowson C G, 1997, Soc Appl Bacteriol Symp Ser, V26, p42S
   Dube FS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068097
   El Aila NA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-104
   Elberse KEM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020390
   Fenoll A, 1997, J CLIN MICROBIOL, V35, P764
   Findlow H, 2009, CLIN VACCINE IMMUNOL, V16, P222, DOI 10.1128/CVI.00292-08
   Flasche S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001017
   Gherna RL, 1981, MANUAL METHODS GEN B, P208
   GIBSON LF, 1986, LETT APPL MICROBIOL, V3, P127, DOI 10.1111/j.1472-765X.1986.tb01565.x
   Gladstone RA, 2012, VACCINE, V30, P6738, DOI 10.1016/j.vaccine.2012.08.080
   Gould KA, 2010, 7 INT S PNEUM PNEUM
   Granat SM, 2007, PEDIATR INFECT DIS J, V26, P319, DOI 10.1097/01.inf.0000257425.24492.11
   GRATTEN M, 1994, J CLIN MICROBIOL, V32, P2871
   Gratten M, 1989, J TROP MED PUBLIC HL, V20, P501
   Greenberg D, 2011, PEDIATR INFECT DIS J, V30, P227, DOI 10.1097/INF.0b013e3181f87802
   Gritzfeld Jenna F, 2011, BMC Res Notes, V4, P122, DOI 10.1186/1756-0500-4-122
   Habib M, 2013, J VIS EXP IN PRESS
   Hanage WP, 2010, EPIDEMICS-NETH, V2, P80, DOI 10.1016/j.epidem.2010.03.005
   Hanage WP, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-6
   Hare KM, 2011, J MICROBIOL METH, V86, P364, DOI 10.1016/j.mimet.2011.06.016
   Hare KM, 2009, J CLIN MICROBIOL, V47, P1981, DOI 10.1128/JCM.00046-09
   Hare KM, 2008, PEDIATR INFECT DIS J, V27, P178, DOI 10.1097/INF.0b013e31815bb6c5
   Hathaway LJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002574
   HENDLEY JO, 1975, J INFECT DIS, V132, P55
   Hernes SS, 2011, EUR J CLIN MICROBIOL, V30, P159, DOI 10.1007/s10096-010-1064-2
   Hinds J, 2010, 7 INT S PNEUM PNEUM
   Hinds J, 2008, 6 INT S PNEUM PNEUM
   Hoshino T, 2005, J CLIN MICROBIOL, V43, P6073, DOI 10.1128/JCM.43.12.6073-6085.2005
   Huang SS, 2005, PEDIATRICS, V116, pE408, DOI 10.1542/peds.2004-2338
   Huebner RE, 2000, PEDIATR INFECT DIS J, V19, P1017, DOI 10.1097/00006454-200010000-00019
   Ikryannikova LN, 2011, INFECT GENET EVOL, V11, P1709, DOI 10.1016/j.meegid.2011.07.010
   Jado I, 2001, CLIN DIAGN LAB IMMUN, V8, P895, DOI 10.1128/CDLI.8.5.895-898.2001
   Jang D, 2012, SEX TRANSM INFECT, V88, P160, DOI 10.1136/sextrans-2011-050084
   Jin P, 2009, J INFECT DIS, V200, P1375, DOI 10.1086/606118
   Johnson HL, 2010, PLOS MED, P7
   Johnston C, 2010, J CLIN MICROBIOL, V48, P2762, DOI 10.1128/JCM.01746-09
   Kaijalainen T, 2004, J CLIN MICROBIOL, V42, P412, DOI 10.1128/JCM.42.1.412-414.2004
   Kaltoft MS, 2008, J MICROBIOL METH, V75, P540, DOI 10.1016/j.mimet.2008.08.010
   Kilian M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002683
   Kong FR, 2006, J CLIN MICROBIOL, V44, P1887, DOI 10.1128/JCM.44.5.1887-1891.2006
   Konradsen HB, 2005, VACCINE, V23, P1368, DOI 10.1016/j.vaccine.2004.09.01
   Kwambana BA, 2011, BMC CLIN PATHOL, V11, DOI 10.1186/1472-6890-11-2
   Lal G, 2005, J IMMUNOL METHODS, V296, P135, DOI 10.1016/j.jim.2004.11.006
   Leach AJ, 2008, J CLIN MICROBIOL, V46, P2081, DOI 10.1128/JCM.00048-08
   Leung MH, 2012, J CLIN MICROBIOL, V50, P2419, DOI 10.1128/JCM.06384-11
   Lieberman D, 2006, J CLIN MICROBIOL, V44, P525, DOI 10.1128/JCM.44.2.525-528.2006
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Llull D, 2006, J CLIN MICROBIOL, V44, P1250, DOI 10.1128/JCM.44.4.1250-1256.2006
   LUND E, 1960, Bull World Health Organ, V23, P5
   Madhi SA, 2005, CLIN INFECT DIS, V40, P1511, DOI 10.1086/429828
   Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077
   Marsh R, 2010, J CLIN MICROBIOL, V48, P831, DOI 10.1128/JCM.01701-09
   Mason CK, 2010, BRIT J BIOMED SCI, V67, P1
   Massire C, 2012, J CLIN MICROBIOL, V50, P2018, DOI 10.1128/JCM.06735-11
   Messmer TO, 2004, DIAGN MICR INFEC DIS, V49, P249, DOI 10.1016/j.diagmicrobio.2004.04.013
   Miernyk K, 2011, J CLIN MICROBIOL, V49, P3209, DOI 10.1128/JCM.00610-11
   Moore MR, 2004, J INFECT DIS, V190, P2031, DOI 10.1086/425422
   Morrison KE, 2000, J CLIN MICROBIOL, V38, P434
   Mthwalo M, 1998, B WORLD HEALTH ORGAN, V76, P641
   Mulholland K, 2012, LANCET, V379, P1387, DOI 10.1016/S0140-6736(12)60588-1
   Mundy LS, 1998, AM J CLIN PATHOL, V109, P55
   NICHOLS T, 1980, J CLIN PATHOL, V33, P770, DOI 10.1136/jcp.33.8.770
   Nunes MC, 2011, AIDS, V25, P453, DOI 10.1097/QAD.0b013e328341b7f1
   O'Brien KL, 2011, PEDIATR INFECT DIS J, V30, P185, DOI 10.1097/01.inf.0000393761.39939.a5
   O'Brien KL, 2001, J CLIN MICROBIOL, V39, P1021, DOI 10.1128/JCM.39.3.1021-1024.2001
   Ortika Belinda D, 2013, BMC Res Notes, V6, P49, DOI 10.1186/1756-0500-6-49
   Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006
   Park HK, 2010, FEMS MICROBIOL LETT, V305, P58, DOI 10.1111/j.1574-6968.2010.01913.x
   Park IH, 2007, J CLIN MICROBIOL, V45, P1225, DOI 10.1128/JCM.02199-06
   Park MK, 2000, CLIN DIAGN LAB IMMUN, V7, P486, DOI 10.1128/CDLI.7.3.486-489.2000
   Park SY, 2008, PEDIATR INFECT DIS J, V27, P335, DOI 10.1097/INF.0b013e318161434d
   Pell CL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072353
   PETTS DN, 1984, J CLIN MICROBIOL, V19, P4
   Picard FJ, 2004, J CLIN MICROBIOL, V42, P3686, DOI 10.1128/jcm.42.8.3686-3695.2004
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Pimenta FC, 2012, J CLIN MICROBIOL
   Prere MF, 2011, DIAGN MICR INFEC DIS, V70, P45, DOI 10.1016/j.diagmicrobio.2011.02.005
   Rapola S, 1997, J CLIN MICROBIOL, V35, P1077
   Reasonover A, 2011, J CLIN MICROBIOL, V49, P138, DOI 10.1128/JCM.01238-10
   Reed C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027793
   Rivera-Olivero IA, 2009, J MED MICROBIOL, V58, P584, DOI 10.1099/jmm.0.006726-0
   ROBINSBROWNE RM, 1982, J CLIN MICROBIOL, V16, P1
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Rolo D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057047
   Rubin LG, 2008, J CLIN MICROBIOL, V46, P2635, DOI 10.1128/JCM.01903-07
   Russell FM, 2006, J CLIN MICROBIOL, V44, P3346, DOI 10.1128/JCM.02631-05
   Saha SK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003576
   Scholz CFP, 2012, J CLIN MICROBIOL, V50, P1968, DOI 10.1128/JCM.00365-12
   Scott JR, 2012, J INFECT DIS, V205, P280, DOI 10.1093/infdis/jir730
   Selva L, 2012, J CLIN MICROBIOL, V50, P3451, DOI 10.1128/JCM.01368-12
   Sharma D, 2013, PEDIATR INFECT DIS J, V32, pE45, DOI 10.1097/INF.0b013e3182788fdd
   Sheppard CL, 2011, J MED MICROBIOL, V60, P49, DOI 10.1099/jmm.0.023150-0
   Simoes AS, 2011, DIAGN MICR INFEC DIS, V71, P208, DOI 10.1016/j.diagmicrobio.2011.07.009
   Simoes AS, 2010, J CLIN MICROBIOL, V48, P238, DOI 10.1128/JCM.01313-09
   Simonsen L, 2011, MBIO, V2, P1
   Slotved Hans-Christian, 2013, BMC Res Notes, V6, P208, DOI 10.1186/1756-0500-6-208
   Stubbs E, 2005, PEDIATR INFECT DIS J, V24, P423, DOI 10.1097/01.inf.0000160945.87356.ca
   Sullivan CB, 2005, MOL BIOTECHNOL, V29, P245, DOI 10.1385/MB:29:3:245
   Suzuki N, 2006, J MED MICROBIOL, V55, P709, DOI 10.1099/jmm.0.46296-0
   Syrjanen RK, 2001, J INFECT DIS, V184, P451, DOI 10.1086/322048
   Toikka P, 1999, J CLIN MICROBIOL, V37, P633
   Tomita Y, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/352736
   Turner P, 2011, J CLIN MICROBIOL, V49, P1784, DOI 10.1128/JCM.00157-11
   Valente C, 2012, PLOS ONE
   Valente C, 2013, PEDIATR INFECT DIS J, V32, P703, DOI 10.1097/INF.0b013e31828692be
   van den Bergh MR, 2012, J CLIN MICROBIOL, V50, P4134, DOI 10.1128/JCM.02376-12
   Verhoeven P, 2010, J CLIN MICROBIOL, V48, P4242, DOI 10.1128/JCM.01425-10
   Vu Huong Thi Thu, 2011, Pediatr Infect Dis J, V30, P11, DOI 10.1097/INF.0b013e3181f111a2
   Wang QA, 2007, J MICROBIOL METH, V68, P128, DOI 10.1016/j.mimet.2006.07.001
   Weinberger DM, 2013, AM J EPIDEMIOL
   Wessels E, 2012, J CLIN MICROBIOL, V50, P1171, DOI 10.1128/JCM.06609-11
   Whalan RH, 2006, J BACTERIOL, V188, P1031, DOI 10.1128/JB.188.3.1031-1038.2006
   Whatmore AM, 2000, INFECT IMMUN, V68, P1374, DOI 10.1128/IAI.68.3.1374-1382.2000
   Wright AKA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002622
   Yu J, 2008, J MED MICROBIOL, V57, P171, DOI 10.1099/jmm.0.47549-0
   Yu JG, 2011, CLIN VACCINE IMMUNOL, V18, P1900, DOI 10.1128/CVI.05312-11
   Zbinden A, 2011, J CLIN MICROBIOL, V49, P523, DOI 10.1128/JCM.01450-10
   Zhang Q, 2010, MICROBIOL IMMUNOL, V54, P313, DOI 10.1111/j.1348-0421.2010.00216.x
   Zhou F, 2007, J CLIN MICROBIOL, V45, P3411, DOI 10.1128/JCM.01076-07
NR 147
TC 78
Z9 78
U1 4
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 17
PY 2013
VL 32
IS 1
BP 165
EP 179
DI 10.1016/j.vaccine.2013.08.062
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 289LT
UT WOS:000329684700027
PM 24331112
OA No
DA 2017-08-15
ER

PT J
AU Clarke, ET
   Williams, NA
   Findlow, J
   Borrow, R
   Heyderman, RS
   Finn, A
AF Clarke, Edward T.
   Williams, Neil A.
   Findlow, Jamie
   Borrow, Ray
   Heyderman, Robert S.
   Finn, Adam
TI Polysaccharide-Specific Memory B Cells Generated by Conjugate Vaccines
   in Humans Conform to the CD27(+)IgG(+) Isotype-Switched Memory B Cell
   Phenotype and Require Contact-Dependent Signals from Bystander T Cells
   Activated by Bacterial Proteins To Differentiate into Plasma Cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HAEMOPHILUS-INFLUENZAE; NEISSERIA-MENINGITIDIS; IN-VIVO;
   STREPTOCOCCUS-PNEUMONIAE; IMMUNE-RESPONSE; CPG OLIGODEOXYNUCLEOTIDES;
   CAPSULAR POLYSACCHARIDE; MUCOSAL IMMUNITY; HEALTHY-ADULTS; CD40 LIGAND
AB The polysaccharides (PS) surrounding encapsulated bacteria are generally unable to activate T cells and hence do not induce B cell memory (B-MEM). PS conjugate vaccines recruit CD4(+) T cells via a carrier protein, such as tetanus toxoid (TT), resulting in the induction of PS-specific B-MEM. However, the requirement for T cells in the subsequent activation of the B-MEM at the time of bacterial encounter is poorly understood, despite having critical implications for protection. We demonstrate that the PS-specific B-MEM induced in humans by a meningococcal serogroup C PS (Men C)-TT conjugate vaccine conform to the isotype-switched (IgG(+) CD27(+)) rather than the IgM memory (IgM(+) CD27(+)) phenotype. Both Men C and TT-specific B-MEM require CD4(+) T cells to differentiate into plasma cells. However, noncognate bystander T cells provide such signals to PS-specific B-MEM with comparable effect to the cognate T cells available to TT-specific B-MEM. The interaction between the two populations is contact-dependent and is mediated in part through CD40. Meningococci drive the differentiation of the Men C-specific B-MEM through the activation of bystander T cells by bacterial proteins, although these signals are enhanced by T cell-independent innate signals. An effect of the TT-specific T cells activated by the vaccine on unrelated B-MEM in vivo is also demonstrated. These data highlight that any protection conferred by PS-specific B-MEM at the time of bacterial encounter will depend on the effectiveness with which bacterial proteins are able to activate bystander T cells. Priming for T cell memory against bacterial proteins through their inclusion in vaccine preparations must continue to be pursued.
C1 [Clarke, Edward T.; Williams, Neil A.; Heyderman, Robert S.; Finn, Adam] Univ Bristol, Sch Cellular & Mol Med, Bristol BS8 1TD, Avon, England.
   [Clarke, Edward T.] Gambia, Med Res Council Unit, Banjul, Gambia.
   [Findlow, Jamie; Borrow, Ray] Manchester Royal Infirm, Vaccine Evaluat Unit, Hlth Protect Agcy, Publ Hlth Lab, Manchester M13 9WZ, Lancs, England.
   [Heyderman, Robert S.] Malawi Liverpool Wellcome Trust Clin Res Program, Blantyre 3, Malawi.
RP Clarke, ET (reprint author), Gambia, Med Res Council Unit, Atlantic Rd,Box 273, Banjul, Gambia.
EM eclarke@mrc.gm; adam.finn@bristol.ac.uk
FU David Baum Trust
FX This work was supported by the David Baum Trust.
CR Agematsu K, 2000, IMMUNOL TODAY, V21, P204, DOI 10.1016/S0167-5699(00)01605-4
   Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092
   Arjunaraja S, 2012, J IMMUNOL, V188, P569, DOI 10.4049/jimmunol.1101446
   Auckland C, 2006, J INFECT DIS, V194, P1745, DOI 10.1086/509619
   Barocchi MA, 2007, VACCINE, V25, P2963, DOI 10.1016/j.vaccine.2007.01.065
   Benson MJ, 2009, J EXP MED, V206, P2013, DOI 10.1084/jem.20090667
   Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579
   Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071
   Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569
   Bohnhorst JO, 2001, J IMMUNOL, V167, P3610
   Borrow R, 2009, EXPERT REV VACCINES, V8, P265, DOI 10.1586/14760584.8.3.265
   Bourke E, 2003, BLOOD, V102, P956, DOI 10.1182/blood-2002-11-3355
   Brams P, 2001, INT IMMUNOPHARMACOL, V1, P277, DOI 10.1016/S1567-5769(00)00020-5
   BRIAN AA, 1988, P NATL ACAD SCI USA, V85, P564, DOI 10.1073/pnas.85.2.564
   Chu RS, 2000, INFECT IMMUN, V68, P1450, DOI 10.1128/IAI.68.3.1450-1456.2000
   Clarke ET, 2013, MUCOSAL IMMUNOL, V6, P288, DOI 10.1038/mi.2012.70
   Constant SL, 1999, J IMMUNOL, V162, P5695
   CROFT M, 1992, J IMMUNOL, V149, P3157
   Crotty S, 2004, J IMMUNOL METHODS, V286, P111, DOI 10.1016/j.jim.2003.12.015
   Davenport V, 2003, J IMMUNOL, V171, P4263
   Davenport V, 2008, J INFECT DIS, V198, P731, DOI 10.1086/590669
   DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671
   Dogan I, 2009, NAT IMMUNOL, V10, P1292, DOI 10.1038/ni.1814
   Duffy D, 2006, IMMUNOLOGY, V119, P376, DOI 10.1111/j.1365-2567.2006.02446.x
   Ganley-Leal LM, 2006, CLIN IMMUNOL, V120, P272, DOI 10.1016/j.clim.2006.04.571
   Geeraedts F, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000138
   Goldblatt D, 1999, J INFECT DIS, V180, P538, DOI 10.1086/314901
   Gonzalez-Garcia I, 2006, J IMMUNOL, V176, P4042
   Guthrie T, 2004, J INFECT DIS, V190, P1927, DOI 10.1086/425517
   Hebeis BJ, 2004, J EXP MED, V199, P593, DOI 10.1084/jem.20030091
   Hornung V, 2002, J IMMUNOL, V168, P4531
   Humphries HE, 2005, CELL MICROBIOL, V7, P415, DOI 10.1111/j.1462-5822.2004.00471.x
   JANEWAY CA, 1987, J IMMUNOL, V138, P1051
   Kamboj KK, 2003, J INFECT DIS, V187, P1629, DOI 10.1086/374785
   Kamboj KK, 2001, J INFECT DIS, V184, P931, DOI 10.1086/323342
   Kelly DF, 2006, BLOOD, V108, P2642, DOI 10.1182/blood-2006-01-009282
   Khaskhely N, 2012, J IMMUNOL, V188, P2455, DOI 10.4049/jimmunol.1102809
   Lal G, 2005, J IMMUNOL METHODS, V296, P135, DOI 10.1016/j.jim.2004.11.006
   LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209
   Lanzavecchia A, 1985, Behring Inst Mitt, P82
   LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0
   Latz E, 2004, J IMMUNOL, V172, P2431
   Levitz SM, 2012, CELL, V148, P1284, DOI 10.1016/j.cell.2012.02.012
   MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117
   Magnusson M, 2007, J IMMUNOL, V179, P31
   Manz RA, 1998, INT IMMUNOL, V10, P1703, DOI 10.1093/intimm/10.11.1703
   MAURER D, 1992, J IMMUNOL, V148, P3700
   McHeyzer-Williams M, 2012, NAT REV IMMUNOL, V12, P24, DOI 10.1038/nri3128
   McVernon J, 2004, LANCET INFECT DIS, V4, P40, DOI 10.1016/S1473-3099(03)00859-4
   Mogensen TH, 2006, J LEUKOCYTE BIOL, V80, P267, DOI 10.1189/jlb.1105626
   MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.immunol.13.1.655
   Ochsenbein AF, 2000, P NATL ACAD SCI USA, V97, P13263, DOI 10.1073/pnas.230417497
   Odendahl M, 2005, BLOOD, V105, P1614, DOI 10.1182/blood-2004-07-2507
   Pape KA, 2011, SCIENCE, V331, P1203, DOI 10.1126/science.1201730
   Parra D, 2012, J LEUKOCYTE BIOL, V91, P525, DOI 10.1189/jlb.0711372
   Pollard AJ, 2001, VACCINE, V19, P1327, DOI 10.1016/S0264-410X(00)00333-9
   Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494
   Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886
   Richmond P, 1999, J INFECT DIS, V179, P1569, DOI 10.1086/314753
   Sen G, 2005, J IMMUNOL, V175, P3084
   Singleton TE, 2005, J IMMUNOL, V174, P3545
   Sjolinder H, 2008, INFECT IMMUN, V76, P5421, DOI 10.1128/IAI.00615-08
   Snapper CM, 2012, ANN NY ACAD SCI, V1253, P92, DOI 10.1111/j.1749-6632.2011.06329.x
   Snapper CM, 1997, INFECT IMMUN, V65, P3203
   Tangye SG, 2007, J IMMUNOL, V179, P13
   Tarlinton D, 2008, J EXP MED, V205, P1251, DOI 10.1084/jem.20081057
   Taylor JJ, 2012, J EXP MED, V209, P597, DOI 10.1084/jem.20111696
   Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1
   van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964
   VIEIRA P, 1990, INT IMMUNOL, V2, P487, DOI 10.1093/intimm/2.6.487
   Wagner M, 2004, J IMMUNOL, V172, P954
   Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346
   Zhong GM, 1997, J EXP MED, V186, P673, DOI 10.1084/jem.186.5.673
   ZUBLER RH, 1987, IMMUNOL REV, V99, P281, DOI 10.1111/j.1600-065X.1987.tb01181.x
NR 74
TC 11
Z9 11
U1 5
U2 9
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2013
VL 191
IS 12
BP 6071
EP 6083
DI 10.4049/jimmunol.1203254
PG 13
WC Immunology
SC Immunology
GA 272TM
UT WOS:000328483900034
PM 24227777
OA No
DA 2017-08-15
ER

PT J
AU Bottomley, C
   Roca, A
   Hill, PC
   Greenwood, B
   Isham, V
AF Bottomley, Christian
   Roca, Anna
   Hill, Philip C.
   Greenwood, Brian
   Isham, Valerie
TI A mathematical model of serotype replacement in pneumococcal carriage
   following vaccination
SO JOURNAL OF THE ROYAL SOCIETY INTERFACE
LA English
DT Article
DE serotype replacement; bacterial carriage; mathematical model;
   pneumococcal vaccine
ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; EPIDEMIOLOGIC
   EVIDENCE; ACQUIRED-IMMUNITY; CONJUGATE VACCINE; INVASIVE DISEASE;
   CHILDREN; MECHANISM; EVOLUTION; IMPACT
AB A number of childhood vaccination programmes have recently introduced vaccination against Streptococcus pneumoniae, the pneumococcus, a major cause of pneumonia and meningitis. The pneumococcal conjugate vaccines (PCVs) that are currently in use only protect against some serotypes of the bacterium, and there is now strong evidence that those serotypes not included in the vaccine increase in prevalence among most vaccinated populations. We present a mathematical model for the dynamics of nasopharyngeal carriage of S. pneumoniae that allows for carriage with multiple serotypes. The model is used to predict the prevalence of vaccine type (VT) and non-VT (NVT) serotypes following the introduction of PCV. Parameter estimates for the model are obtained by maximum likelihood using prevaccination data from The Gambia. The model predicts that low (1, 6A and 9V) and medium (4, 5, 7F, 14, 18C, 19A and 19F) prevalence serotypes can be eliminated through vaccination, but that the overall prevalence of carriage will be reduced only slightly because of an increase in the prevalence of NVT serotypes. Serotype replacement will be sequential, with high and medium prevalence NVT serotypes dominating initially, followed by an increase of serotypes of low prevalence. We examine the impact of a hypothetical vaccine that provides partial protection against all serotypes, and find that this reduces overall carriage, but is unable to eliminate low or medium prevalence serotypes.
C1 [Bottomley, Christian] LSHTM, MRC Trop Epidemiol Grp, London WC1E 7HT, England.
   [Greenwood, Brian] LSHTM, Fac Infect & Trop Dis, London WC1E 7HT, England.
   [Roca, Anna] MRC Unit, Banjul, Gambia.
   [Hill, Philip C.] Univ Ontago, Sch Med, Ctr Int Hlth, Dunedin 9054, New Zealand.
   [Isham, Valerie] UCL, Dept Stat Sci, London WC1E 6BT, England.
RP Bottomley, C (reprint author), LSHTM, MRC Trop Epidemiol Grp, Keppel St, London WC1E 7HT, England.
EM christian.bottomley@lshtm.ac.uk
FU Medical Research Council [G0700837]
FX This work was supported by funding from the Medical Research Council
   (grant code no. G0700837).
CR Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Auranen K, 2010, AM J EPIDEMIOL, V171, P169, DOI 10.1093/aje/kwp351
   Baltimore RS, 1998, BACTERIAL INFECT HUM, P559
   Brueggemann AB, 2004, J INFECT DIS, V190, P1203, DOI 10.1086/423820
   Cheung YB, 2009, PEDIATR INFECT DIS J, V28, P990, DOI 10.1097/INF.0b013e3181a78185
   Choi YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026190
   Cobey S, 2012, SCIENCE, V335, P1376, DOI 10.1126/science.1215947
   Cox D. R., 1965, THEORY STOCHASTIC PR
   Egere U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049143
   Flasche S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001017
   Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2010, CLIN INFECT DIS, V50, P1468, DOI 10.1086/652443
   Lipsitch M, 1997, P NATL ACAD SCI USA, V94, P6571, DOI 10.1073/pnas.94.12.6571
   Lipsitch M, 2005, PLOS MED, V2, P62, DOI 10.1371/journal.pmed.0020015
   Lipsitch M, 2012, EPIDEMIOLOGY, V23, P510, DOI 10.1097/EDE.0b013e31824f2f32
   Melegaro A, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-90
   NOWAK MA, 1994, P ROY SOC B-BIOL SCI, V255, P81, DOI 10.1098/rspb.1994.0012
   Nurhonen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056079
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   Pletz MW, 2008, INT J ANTIMICROB AG, V32, P199, DOI 10.1016/j.ijantimicag.2008.01.021
   Regev-Yochay G, 2004, JAMA-J AM MED ASSOC, V292, P716, DOI 10.1001/jama.292.6.716
   Rinta-Kokko H, 2009, VACCINE, V27, P3831, DOI 10.1016/j.vaccine.2009.04.009
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/ERV.12.53, 10.1586/erv.12.53]
   Tanaka MM, 1999, J THEOR BIOL, V198, P145, DOI 10.1006/jtbi.1999.0906
   Usuf EA, 2013, THESIS U LONDON LOND
   Weinberger DM, 2008, J INFECT DIS, V197, P1511, DOI 10.1086/587941
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
   Whitney CG, 2008, PNEUMOCOCCAL VACCINES: THE IMPACT OF CONJUGATE VACCINE, P353
NR 30
TC 12
Z9 12
U1 0
U2 5
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1742-5689
EI 1742-5662
J9 J R SOC INTERFACE
JI J. R. Soc. Interface
PD DEC 6
PY 2013
VL 10
IS 89
AR 20130786
DI 10.1098/rsif.2013.0786
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 298CU
UT WOS:000330302400013
PM 24132203
OA No
DA 2017-08-15
ER

PT J
AU Foma, MA
   Saidu, Y
   Omoleke, SA
   Jafali, J
AF Foma, Mafomekong Ayuk
   Saidu, Yauba
   Omoleke, Semeeh Akinwale
   Jafali, James
TI Awareness of diabetes mellitus among diabetic patients in the Gambia: a
   strong case for health education and promotion
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Diabetes mellitus; Awareness; The Gambia; Causes; Prevention and
   management; Health education and promotion
ID SUB-SAHARAN AFRICA; PREVALENCE
AB Background: Awareness of various aspects of Diabetes Mellitus (DM) is essential for the prevention, management and control of the disease. However, several studies have consistently shown that awareness of DM in the general population is low. None of these studies, however, was conducted in The Gambia, even though the condition constitutes a major public health problem in the country. In this paper, we assessed the awareness of DM among diabetic patients attending the Medical Out-Patient Department (MOPD) of Royal Victoria Teaching Hospital (RVTH), Banjul.
   Methods: We interviewed 200 patients attending the MOPD of RVTH. We used a tool containing questions on patient's demographic characteristics and awareness of various aspects of DM including general knowledge on DM, causes, complications, management and prevention.
   Results: Of the 199 patients who were aware of their condition, only 47% said they knew what DM is. Similarly, 53% of the study participants had no knowledge of the causes of DM and about 50% were not aware of the methods of prevention. 67% knew that DM can result to loss of sight while 46.5% knew that DM can cause poor wound healing. Few respondents knew that DM can lead to kidney failure (13.5%), skin sepsis (12.0%), heart failure (5.5%) and stroke (4.5%). Close to 50% of the respondent did not know how DM can be prevented. Level of education, duration of illness and knowledge of a family member with diabetes were important predictors of knowledge in our study.
   Conclusion: Our study shows that the majority of patients attending the MOPD have poor knowledge on several aspects of DM. Hence, there is need for conscious efforts towards improving the level of awareness through health education and promotion, not limited to the hospital but also within the general population, as part of strategies to prevent, manage and control DM.
C1 [Foma, Mafomekong Ayuk] Univ Gambia, Sch Med & Allied Hlth Sci, Banjul, Gambia.
   [Saidu, Yauba; Omoleke, Semeeh Akinwale; Jafali, James] MRC, Gambia Unit, Fajara, Gambia.
RP Saidu, Y (reprint author), MRC, Gambia Unit, Fajara, Gambia.
EM yaubasaidu@yahoo.com
CR Al Shafaee MA, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-249
   Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Avi B, 2012, PREVALENCE TREATMENT
   Azevedo M, 2008, INT J DIABETES DEV C, V28, P101, DOI 10.4103/0973-3930.45268
   Danquah I, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-210
   Faeh D, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-163
   Gill G, 2009, DIABETOLOGIA, V52, P8, DOI 10.1007/s00125-008-1167-9
   Guariguata L, 2011, DIABETES RES CLIN PR, V94, P322, DOI 10.1016/j.diabres.2011.10.040
   Hall V, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-564
   Hashmi NR, 2008, PROFESSIONAL MED J, V15, P96
   Jane K, 2011, NATL DIABETES ED PRO
   Maina WK, 2010, PAN AFR MED J, V7, P15
   Mbanya JCN, 2010, LANCET, V375, P2254, DOI 10.1016/S0140-6736(10)60550-8
   Mohieldein A, 2011, J DIAB ENDOCRINOL, V2, P14
   Muninarayana C, 2010, INT J DIABETES DEV C, V30, P18, DOI 10.4103/0973-3930.60005
   Mwangi MW, 2011, INT J HUMANIT SOC SC, V1, P140
   Omoleke SA, 2013, PAN AFR MED J, V14
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Tan A. S. L., 1997, SMJ, V38, P156
   Ulvi Osman Saleem, 2009, JPMA Journal of the Pakistan Medical Association, V59, P798
   Unadike BC, 2009, AFRICAN J DIABETES M, V3, P12
   Vandenheede H, 2012, J PUBLIC HEALTH-UK, V34, P100, DOI 10.1093/pubmed/fdr045
   World Health Organisation, 2012, DIAB PROGR COUNTR RE
   Zhang P, 2010, DIABETES RES CLIN PR, V87, P293, DOI 10.1016/j.diabres.2010.01.026
NR 24
TC 1
Z9 1
U1 1
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD DEC 5
PY 2013
VL 13
AR 1124
DI 10.1186/1471-2458-13-1124
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AC1SM
UT WOS:000332276500001
PM 24304618
OA gold
DA 2017-08-15
ER

PT J
AU Jawara, M
AF Jawara, Musa
TI ALTERNATIVES TO DDT FOR INDOOR RESIDUAL SPRAYING (IRS) FOR MALARIA
   VECTOR CONTROL IN THE GAMBIA
SO PATHOGENS AND GLOBAL HEALTH
LA English
DT Meeting Abstract
C1 [Jawara, Musa] Med Res Council Unit Gambia, Serrekunda, Gambia.
NR 0
TC 0
Z9 0
U1 2
U2 7
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 2047-7724
EI 2047-7732
J9 PATHOG GLOB HEALTH
JI Pathog. Glob. Health
PD DEC
PY 2013
VL 107
IS 8
BP 438
EP 438
PG 1
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA AF9SZ
UT WOS:000335056200104
OA No
DA 2017-08-15
ER

PT J
AU Dillon, DG
   Gurdasani, D
   Riha, J
   Ekoru, K
   Asiki, G
   Mayanja, BN
   Levitt, NS
   Crowther, NJ
   Nyirenda, M
   Njelekela, M
   Ramaiya, K
   Nyan, O
   Adewole, OO
   Anastos, K
   Azzoni, L
   Boom, WH
   Compostella, C
   Dave, JA
   Dawood, H
   Erikstrup, C
   Fourie, CM
   Friis, H
   Kruger, A
   Idoko, JA
   Longenecker, CT
   Mbondi, S
   Mukaya, JE
   Mutimura, E
   Ndhlovu, CE
   Praygod, G
   Yone, EWP
   Pujades-Rodriguez, M
   Range, N
   Sani, MU
   Schutte, AE
   Sliwa, K
   Tien, PC
   Vorster, EH
   Walsh, C
   Zinyama, R
   Mashili, F
   Sobngwi, E
   Adebamowo, C
   Kamali, A
   Seeley, J
   Young, EH
   Smeeth, L
   Motala, AA
   Kaleebu, P
   Sandhu, MS
AF Dillon, David G.
   Gurdasani, Deepti
   Riha, Johanna
   Ekoru, Kenneth
   Asiki, Gershim
   Mayanja, Billy N.
   Levitt, Naomi S.
   Crowther, Nigel J.
   Nyirenda, Moffat
   Njelekela, Marina
   Ramaiya, Kaushik
   Nyan, Ousman
   Adewole, Olanisun O.
   Anastos, Kathryn
   Azzoni, Livio
   Boom, W. Henry
   Compostella, Caterina
   Dave, Joel A.
   Dawood, Halima
   Erikstrup, Christian
   Fourie, Carla M.
   Friis, Henrik
   Kruger, Annamarie
   Idoko, John A.
   Longenecker, Chris T.
   Mbondi, Suzanne
   Mukaya, Japheth E.
   Mutimura, Eugene
   Ndhlovu, Chiratidzo E.
   Praygod, George
   Yone, Eric W. Pefura
   Pujades-Rodriguez, Mar
   Range, Nyagosya
   Sani, Mahmoud U.
   Schutte, Aletta E.
   Sliwa, Karen
   Tien, Phyllis C.
   Vorster, Este H.
   Walsh, Corinna
   Zinyama, Rutendo
   Mashili, Fredirick
   Sobngwi, Eugene
   Adebamowo, Clement
   Kamali, Anatoli
   Seeley, Janet
   Young, Elizabeth H.
   Smeeth, Liam
   Motala, Ayesha A.
   Kaleebu, Pontiano
   Sandhu, Manjinder S.
CA APCDR
TI Association of HIV and ART with cardiometabolic traits in sub-Saharan
   Africa: a systematic review and meta-analysis
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Review
DE HIV; ART; cardiometabolic disease; sub-Saharan Africa
ID ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS-INFECTION;
   REGIONAL ADIPOSE-TISSUE; CORONARY HEART-DISEASE; BLACK SOUTH-AFRICANS;
   LOW-INCOME COUNTRIES; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   BODY-COMPOSITION; PULMONARY TUBERCULOSIS
AB Background Sub-Saharan Africa (SSA) has the highest burden of HIV in the world and a rising prevalence of cardiometabolic disease; however, the interrelationship between HIV, antiretroviral therapy (ART) and cardiometabolic traits is not well described in SSA populations.
   Methods We conducted a systematic review and meta-analysis through MEDLINE and EMBASE (up to January 2012), as well as direct author contact. Eligible studies provided summary or individual-level data on one or more of the following traits in HIV+ and HIV-, or ART+ and ART- subgroups in SSA: body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TGs) and fasting blood glucose (FBG) or glycated hemoglobin (HbA1c). Information was synthesized under a random-effects model and the primary outcomes were the standardized mean differences (SMD) of the specified traits between subgroups of participants.
   Results Data were obtained from 49 published and 3 unpublished studies which reported on 29 755 individuals. HIV infection was associated with higher TGs [SMD, 0.26; 95% confidence interval (CI), 0.08 to 0.44] and lower HDL (SMD, -0.59; 95% CI, -0.86 to -0.31), BMI (SMD, -0.32; 95% CI, -0.45 to -0.18), SBP (SMD, -0.40; 95% CI, -0.55 to -0.25) and DBP (SMD, -0.34; 95% CI, -0.51 to -0.17). Among HIV+ individuals, ART use was associated with higher LDL (SMD, 0.43; 95% CI, 0.14 to 0.72) and HDL (SMD, 0.39; 95% CI, 0.11 to 0.66), and lower HbA1c (SMD, -0.34; 95% CI, -0.62 to -0.06). Fully adjusted estimates from analyses of individual participant data were consistent with meta-analysis of summary estimates for most traits.
   Conclusions Broadly consistent with results from populations of European descent, these results suggest differences in cardiometabolic traits between HIV-infected and uninfected individuals in SSA, which might be modified by ART use. In a region with the highest burden of HIV, it will be important to clarify these findings to reliably assess the need for monitoring and managing cardiometabolic risk in HIV-infected populations in SSA.
C1 [Dillon, David G.; Gurdasani, Deepti; Riha, Johanna; Ekoru, Kenneth; Young, Elizabeth H.; Sandhu, Manjinder S.] Univ Cambridge, Dept Publ Hlth & Primary Care, Inst Publ Hlth, Cambridge, England.
   [Dillon, David G.; Gurdasani, Deepti; Riha, Johanna; Ekoru, Kenneth; Young, Elizabeth H.; Sandhu, Manjinder S.] Wellcome Trust Sanger Inst, Genet Epidemiol Grp, Cambridge, England.
   [Ekoru, Kenneth; Asiki, Gershim; Mayanja, Billy N.; Kamali, Anatoli; Seeley, Janet; Kaleebu, Pontiano] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda.
   [Levitt, Naomi S.] Univ Cape Town, Dept Med, Div Diabet Med & Endocrinol, ZA-7925 Cape Town, South Africa.
   [Crowther, Nigel J.] Univ Witwatersrand, Sch Med, Dept Chem Pathol, Natl Hlth Lab Serv, Johannesburg, South Africa.
   [Nyirenda, Moffat] Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.
   [Njelekela, Marina; Mashili, Fredirick] Muhimbili Univ Hlth & Allied Sci, Dept Physiol, Dar Es Salaam, Tanzania.
   [Ramaiya, Kaushik] Muhimbili Univ Hlth & Allied Sci, Dept Med, Dar Es Salaam, Tanzania.
   [Nyan, Ousman] Univ Gambia, Sch Med, Royal Victoria Teaching Hosp, Banjul, Gambia.
   [Adewole, Olanisun O.] Obafemi Awolowo Univ, Dept Med, Ife, Nigeria.
   [Anastos, Kathryn; Mutimura, Eugene] Womens Equ Access Care & Treatment, Kigali, Rwanda.
   [Azzoni, Livio] Wistar Inst Anat & Biol, HIV Immunopathogenesis Lab 1, Philadelphia, PA 19104 USA.
   [Boom, W. Henry] Case Western Reserve Univ, Dept Med, TB Res Unit, Cleveland, OH 44106 USA.
   [Compostella, Caterina] Univ Padua, Dept Med & Surg Sci, Padua, Italy.
   [Dave, Joel A.] Univ Cape Town, Dept Med, Div Diabet Med & Endocrinol, ZA-7925 Cape Town, South Africa.
   [Dawood, Halima] Greys Hosp, Dept Med, Infect Dis Unit, Pietermaritzburg, South Africa.
   [Erikstrup, Christian] Aarhus Univ Hosp, Dept Clin Immunol, DK-8000 Aarhus, Denmark.
   [Fourie, Carla M.; Schutte, Aletta E.] North West Univ, HART, Potchefstroom, South Africa.
   [Friis, Henrik] Univ Copenhagen, Fac Sci, Dept Nutr Exercise & Sports, Copenhagen, Denmark.
   [Kruger, Annamarie] North West Univ, Africa Unit Transdisciplinary Hlth Res AUTHeR, Potchefstroom, South Africa.
   [Idoko, John A.] Jos Univ Teaching Hosp, Dept Med, Jos, Nigeria.
   [Longenecker, Chris T.] Univ Hosp Case Med Ctr, Cleveland, OH USA.
   [Mbondi, Suzanne] German Dev Cooperat GTZ, Yaounde, Cameroon.
   [Mukaya, Japheth E.] Makerere Univ, Dept Med, Kampala, Uganda.
   [Ndhlovu, Chiratidzo E.] Univ Zimbabwe, Coll Hlth Sci, Clin Epidemiol Resource Training Ctr, Harare, Zimbabwe.
   [Praygod, George; Range, Nyagosya] Natl Inst Med Res, Dar Es Salaam, Tanzania.
   [Yone, Eric W. Pefura] Jamot Hosp, Chest Unit, Yaounde, Cameroon.
   [Pujades-Rodriguez, Mar] Medecins Sans Frontieres, Epictr, Paris, France.
   [Pujades-Rodriguez, Mar] UCL, Dept Epidemiol & Publ Hlth, Clin Epidemiol Grp, London, England.
   [Sani, Mahmoud U.] Aminu Kano Teaching Hosp, Dept Med, Cardiol Unit, Kano, Nigeria.
   [Sliwa, Karen] Univ Witwatersrand, Chris Hani Baragwanath Hosp, Soweto Cardiovasc Res Unit, Johannesburg, South Africa.
   [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Vorster, Este H.] North West Univ, Fac Hlth Sci, Potchefstroom, South Africa.
   [Walsh, Corinna] Univ Free State, Dept Nutr & Dietet, Bloemfontein, South Africa.
   [Zinyama, Rutendo] Univ Zimbabwe, Dept Med Lab Sci, Med Res Council Zimbabwe, Harare, Zimbabwe.
   [Sobngwi, Eugene] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon.
   [Sobngwi, Eugene] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Adebamowo, Clement] Inst Human Virol, Abuja, Nigeria.
   [Adebamowo, Clement] Univ Maryland, Sch Med, Inst Human Virol, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
   [Adebamowo, Clement] Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
   [Smeeth, Liam] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England.
   [Motala, Ayesha A.] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Endocrinol & Diabet, Durban, South Africa.
RP Sandhu, MS (reprint author), Univ Cambridge, Dept Publ Hlth & Primary Care, Int Hlth Res Grp, Cambridge, England.
EM ms23@sanger.ac.uk
RI Pujades-Rodriguez, Mar/G-4388-2014; Friis, Henrik/N-2047-2014
OI Pujades-Rodriguez, Mar/0000-0002-7778-3520; Friis,
   Henrik/0000-0002-2848-2940; Smeeth, Liam/0000-0002-9168-6022; Seeley,
   Janet/0000-0002-0583-5272; Pujades Rodriguez, Mar/0000-0002-1375-1028;
   Schutte, Aletta/0000-0001-9217-4937; Adebamowo,
   Clement/0000-0002-6571-2880
FU African Partnership for Chronic Disease Research strategic award from
   the UK Medical Research Council
FX This work was supported by the African Partnership for Chronic Disease
   Research strategic award from the UK Medical Research Council. The
   funders had no role in study design, data collection or analysis,
   decision to publish or preparation of the manuscript.
CR Addo AA, 2011, MATERN CHILD NUTR, V7, P80, DOI 10.1111/j.1740-8709.2009.00229.x
   Adewole OO, 2010, AFR HEALTH SCI, V10, P144
   Agaba E I, 2003, Niger J Med, V12, P120
   Ahoua L, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-2
   Anastos L, 2007, J ACQ IMMUN DEF SYND, V45, P34
   Asiki G, 2013, INT J EPIDEMIOL
   Awotedu K, 2010, DIABETES METAB SYNDR, V4, P210, DOI [10.1016/j.dsx.2010.09.002, DOI 10.1016/J.DSX.2010.09.002]
   Barth RE, 2010, LANCET INFECT DIS, V10, P155, DOI 10.1016/S1473-3099(09)70328-7
   Beaglehole R, 2003, LANCET, V362, P903, DOI 10.1016/S0140-6736(03)14335-8
   Beaglehole R, 2008, LANCET, V372, P940, DOI 10.1016/S0140-6736(08)61404-X
   Becker AC, 2011, CLIN APPL THROMB-HEM, V17, P264, DOI 10.1177/1076029609358883
   Bergersen BM, 2003, EUR J CLIN MICROBIOL, V22, P731, DOI 10.1007/s10096-003-1034-z
   Bloomfield G, 2011, PLOS ONE, V6, pe7
   Brar I, 2007, JAIDS-J ACQ IMM DEF, V45, P66, DOI 10.1097/QAI.0b013e318031d7e3
   Brown TT, 2005, ARCH INTERN MED, V165, P1179, DOI 10.1001/archinte.165.10.1179
   Buchacz K, 2008, JAIDS-J ACQ IMM DEF, V47, P304
   Butt AA, 2004, HEPATOLOGY, V40, P115, DOI 10.1002/hep.20289
   Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1
   Ceffa S, 2007, Ann Ig, V19, P519
   Cohen J., 1988, STAT ANAL BEHAV SCI
   Compostella C, 2008, Minerva Cardioangiol, V56, P417
   Currier J, 2008, JAIDS-J ACQ IMM DEF, V48, P35, DOI 10.1097/QAI.0b013e318164227f
   Dave JA, 2011, JAIDS-J ACQ IMM DEF, V57, P284, DOI 10.1097/QAI.0b013e318221863f
   De Maria N, 2002, HEPATO-GASTROENTEROL, V49, P788
   De Wit S, 2008, DIABETES CARE, V31, P1224, DOI 10.2337/dc07-2013
   de-Graft Aikins Ama, 2010, Global Health, V6, P6, DOI 10.1186/1744-8603-6-6
   Dube MP, 2003, CLIN INFECT DIS, V37, P613, DOI 10.1086/378131
   Erikstrup C, 2007, JAIDS-J ACQ IMM DEF, V44, P478, DOI 10.1097/QAI.0b013e318032bbcd
   Ezechi OC, 2010, J OBSTET GYNAECOL RE, V36, P1053, DOI 10.1111/j.1447-0756.2010.01253.x
   Fontas E, 2004, J INFECT DIS, V189, P1056, DOI 10.1086/381783
   Fourie CMT, 2010, LIPIDS, V45, P73, DOI 10.1007/s11745-009-3369-4
   Friis H, 2002, J NUTR, V132, P3747
   Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Gazzaruso C, 2003, J HYPERTENS, V21, P1377, DOI 10.1097/01.hjh.0000059071.43904.dc
   Goedecke JH, 2010, METABOLISM, V59, P1341, DOI 10.1016/j.metabol.2009.12.018
   Grinspoon S, 2005, NEW ENGL J MED, V352, P48, DOI 10.1056/NEJMra041811
   GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045
   Grunfeld C, 2007, JAIDS-J ACQ IMM DEF, V46, P283
   Grunfeld C, 2010, AIDS, V24, P1717, DOI 10.1097/QAD.0b013e32833ac7a2
   Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541
   Hattingh Z., 2009, SAJCN - South African Journal of Clinical Nutrition, V22, P23
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hill A, 2009, HIV CLIN TRIALS, V10, P1, DOI [10.1310/hct1001-001, 10.1310/hct1001-1]
   Isezuo SA, 2009, NIGER J CLIN PRACT, V12, P375
   Islam FM, 2012, HIV MED, V13, P453, DOI 10.1111/j.1468-1293.2012.00996.x
   Jerico C, 2005, AM J HYPERTENS, V18, P1396, DOI 10.1016/j.amjhyper.2005.05.016
   Kaplan FJL, 2000, QJM-MON J ASSOC PHYS, V93, P603, DOI 10.1093/qjmed/93.9.603
   Kawai K, 2011, INT J TUBERC LUNG D, V15, P1380, DOI 10.5588/ijtld.10.0784
   Kelly P, 2002, ACTA TROP, V83, P151, DOI 10.1016/S0001-706X(02)00095-5
   KengeyaKayondo JF, 1996, INT J EPIDEMIOL, V25, P1077, DOI 10.1093/ije/25.5.1077
   Kim PS, 2009, DIABETES CARE, V32, P1591, DOI 10.2337/dc09-0177
   Klein D, 2002, J ACQ IMMUN DEF SYND, V30, P471, DOI 10.1097/01.QAI.0000021391.89256.97
   Lazar JM, 2009, AIDS RES HUM RETROV, V25, P877, DOI 10.1089/aid.2008.0269
   Lohse N, 2007, ANN INTERN MED, V146, P87
   Longenecker CT, 2011, INT J CARDIOL, V147, P300, DOI 10.1016/j.ijcard.2010.12.047
   Lundgren JD, 2008, HIV MED, V9, P72, DOI 10.1111/j.1468-1293.2007.00534.x
   Maas JJ, 1998, J ACQ IMMUN DEF SYND, V19, P254
   Maher D, 2011, INT J EPIDEMIOL, V40, P160, DOI 10.1093/ije/dyq156
   Masaisa F, 2011, AM J TROP MED HYG, V84, P456, DOI [10.4269/ajtmh.2011.10-0519, 10.4269/ajtmh.2011.10.0519]
   Mbanya JC, 2006, LANCET, V368, P1628, DOI 10.1016/S0140-6736(06)69673-6
   Mekonen Mekdem, 2010, Ethiop Med J, V48, P203
   Mercier S, 2009, JAIDS-J ACQ IMM DEF, V51, P224, DOI 10.1097/QAI.0b013e31819c16f4
   MOORE PS, 1993, J ACQ IMMUN DEF SYND, V6, P611
   Mukaya JE, 2009, SAMJ S AFR MED J, V99, P881
   Mutimura Eugene, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P173, DOI 10.1177/1545109710366472
   Negin Joel, 2012, AIDS, V26 Suppl 1, pS1
   Ngondi J, 2007, J MED SCI, V7, P670
   Ngondi J, 2007, J MED SCI, V7, P609
   Nguemaim N, 2010, HIV MED, V11, P353, DOI 10.1111/j.1468-1293.2009.00784.x
   Niyongabo T, 1999, NUTRITION, V15, P289, DOI 10.1016/S0899-9007(99)00003-9
   Njamnshi AK, 2009, J NEUROL SCI, V285, P149, DOI 10.1016/j.jns.2009.06.043
   Noeske J, 2006, East Afr Med J, V83, P25
   Noeske J, 2011, INT J TUBERC LUNG D, V15, P223
   Nzou C, 2010, SAMJ S AFR MED J, V100, P602
   Ogundahunsi O, 2008, AFR J BIOMED RES, P27
   Okeahialam B N, 2006, Afr J Med Med Sci, V35 Suppl, P99
   Omech B, 2012, ISRN AIDS, V2012, P6
   Papathakis PC, 2005, AM J CLIN NUTR, V82, P538
   Papathakis PC, 2006, JAIDS-J ACQ IMM DEF, V43, P467, DOI 10.1097/01.qai.0000243094.42276.92
   Peeters M, 2001, TRANSFUS CLIN BIOL, V8, P222, DOI 10.1016/S1246-7820(01)00131-8
   Perret JL, 2000, CLIN CHEM LAB MED, V38, P673, DOI 10.1515/CCLM.2000.097
   PrayGod G, 2011, T ROY SOC TROP MED H, V105, P140, DOI 10.1016/j.trstmh.2010.11.009
   Range NS, 2010, ANN TROP MED PARASIT, V104, P81, DOI 10.1179/136485910X12607012373830
   Riddler SA, 2007, HIV MED, V8, P280, DOI 10.1111/j.1468-1293.2007.00470.x
   Riddler SA, 2003, JAMA-J AM MED ASSOC, V289, P2978, DOI 10.1001/jama.289.22.2978
   Sackoff JE, 2006, ANN INTERN MED, V145, P397
   Sani Mahmoud U, 2005, J Natl Med Assoc, V97, P1657
   Scarcella P, 2011, Ig Sanita Pubbl, V67, P41
   Schuster Dara P, 2007, J Cardiometab Syndr, V2, P260, DOI 10.1111/j.1559-4564.2007.07484.x
   Schutte AE, 2012, INT J EPIDEMIOL, V41, P1114, DOI 10.1093/ije/dys106
   Schutte AE, 2010, J CLIN ENDOCR METAB, V95, P2503, DOI 10.1210/jc.2009-2329
   Sharrett AR, 2001, CIRCULATION, V104, P1108, DOI 10.1161/hc3501.095214
   Sliwa K, 2011, INT J CARDIOL, V147, P202, DOI 10.1016/j.ijcard.2009.08.022
   Thompson V, 2011, AIDS RES HUM RETROV, V27, P785, DOI [10.1089/AID.2010.0272, 10.1089/aid.2010.0272]
   Tien PC, 2012, JAIDS-J ACQ IMM DEF, V61, P334, DOI 10.1097/QAI.0b013e31826bfc32
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   Tsiodras S, 2000, ARCH INTERN MED, V160, P2050, DOI 10.1001/archinte.160.13.2050
   UNAIDS, 2010, UNAIDS REP GLOB AIDS
   Vorster HH, 2004, PUBLIC HEALTH NUTR, V7, P1055, DOI 10.1079/PHN2004643
   Wallis RS, 2004, AIDS, V18, P257, DOI 10.1097/01.aids.0000104367.21567.d8
   World Health Organization, 2011, PROGR REP 2011 GLOB
   WHO, 2010, MOR DEV COUNTR SHOW
   Yone EWP, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-33
   Young J, 2005, ANTIVIR THER, V10, P585
   Yusuf S, 2011, LANCET, V378, P1231, DOI 10.1016/S0140-6736(11)61215-4
NR 106
TC 48
Z9 48
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD DEC
PY 2013
VL 42
IS 6
BP 1754
EP 1771
DI 10.1093/ije/dyt198
PG 18
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 291ZC
UT WOS:000329870400037
PM 24415610
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Goodier, MR
   White, MJ
   Darboe, A
   Moore, S
   Jones, K
   Hall, A
   Riley, EM
AF Goodier, M. R.
   White, M. J.
   Darboe, A.
   Moore, S.
   Jones, K.
   Hall, A.
   Riley, E. M.
TI Impact of age on the function of CD57 defined NK cell subsets
SO IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Congress of the British-Society-for-Immunology
CY DEC 02-05, 2013
CL Liverpool, ENGLAND
SP British Soc Immunol
C1 [Goodier, M. R.; White, M. J.; Darboe, A.; Riley, E. M.] London Sch Hyg & Trop Med, London WC1, England.
   [Darboe, A.; Moore, S.; Jones, K.] MRC Keneba, Human Nutr Grp, Keneba, Gambia.
   [Moore, S.] London Sch Hyg & Trop Med, Nutr Grp, London WC1, England.
   [Hall, A.] London Sch Hyg & Trop Med, London WC1, England.
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
EI 1365-2567
J9 IMMUNOLOGY
JI Immunology
PD DEC
PY 2013
VL 140
SU 1
SI SI
BP 173
EP 173
PG 1
WC Immunology
SC Immunology
GA 258VV
UT WOS:000327487700454
OA No
DA 2017-08-15
ER

PT J
AU Mason, K
   Ketende, S
   Peitzmeier, S
   Ceesay, N
   Diouf, D
   Loum, J
   Deen, D
   Drame, F
   Baral, S
AF Mason, Krystal
   Ketende, Sosthenes
   Peitzmeier, Sarah
   Ceesay, Nuha
   Diouf, Daouda
   Loum, Jaegan
   Deen, Donald
   Drame, Fatou
   Baral, Stefan
TI A Cross-Sectional Analysis of Population Demographics, HIV Knowledge and
   Risk Behaviors, and Prevalence and Associations of HIV Among Men Who
   Have Sex with Men in the Gambia
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID SEXUALLY-TRANSMITTED INFECTIONS; ANTIRETROVIRAL THERAPY; HUMAN-RIGHTS;
   PREVENTION; AFRICA; COUNTRIES; EPIDEMIC; HIDDEN
AB HIV epidemics in West Africa appear far more concentrated among key populations including men who have sex with men (MSM) and female sex workers (FSW) as compared to the more generalized epidemics of Southern and Eastern Africa. Since there has been no prior quantitative assessment of HIV risk among MSM in the Gambia, this study aims to describe the burden of HIV and associations of HIV infections. A total of 207 study participants reporting anal sex with another man in the previous 12 months were accrued using snowball sampling for this cross-sectional study and were administered an anonymous structured questionnaire. Bivariate and multivariate logistic regression models were used to identify factors associated with prevalent HIV infections. HIV prevalence was 9.8% (20/205) and the highest HIV prevalence age group was among the participants who were older than 25 years with 22.9% (8/35) living with HIV. Less than 10% of participants reported always using condoms with male partners (19/201) while 33.8% (69/204) of men reported no access to condoms and 82.5% (146/177) reported no access to latex condom-compatible lubricants (CCL). Knowledge of HIV risks was low with 3.5% (7/200) knowing that receptive anal intercourse was the highest risk sexual practice and CCL were the safest to use. This study highlighted that, similar to other West Africa countries, MSM are a high risk and underserved population for HIV prevention, treatment, and care services in the Gambia. Multilateral efforts including government, service providers, and community are needed to achieve reductions in HIV incidence and eventually prevalence among MSM in the Gambia.
C1 [Mason, Krystal; Ketende, Sosthenes; Peitzmeier, Sarah; Baral, Stefan] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Baltimore, MD 21205 USA.
   [Ceesay, Nuha] UNAIDS, Country Off, Banjul, Gambia.
   [Diouf, Daouda] Enda Sante, Dakar, Senegal.
   [Loum, Jaegan; Deen, Donald] Network AIDS Serv Org, Banjul, Gambia.
   [Drame, Fatou] Univ Gaston Berger, St Louis, Senegal.
RP Mason, K (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, 615 North Wolfe St, Baltimore, MD 21205 USA.
EM kmason@jhsph.edu
FU Action Aid International; UNAIDS; Network of AIDS Service
   Organizations-The Gambia; Jobot Laboratories; Global Fund; Enda Sante;
   National AIDS Secretariat and Action Aid-The Gambia; Enda Sante of
   Senegal; Johns Hopkins Bloomberg School of Public Health
FX The Center for Public Health and Human Rights at the Johns Hopkins
   School of Public Health provided support for the effort of the
   investigators and students. We also want to thank Action Aid
   International, UNAIDS, Network of AIDS Service Organizations-The Gambia,
   Jobot Laboratories, The Global Fund, and Enda Sante for their financial
   and technical support in conducting this study. The authors acknowledge
   Alieu Jammeh and Bai Cham from the National AIDS Secretariat as well as
   Makie Taal for technical support in the development and implementation
   of this project. Finally, we like to thank the study participants and
   MSM community in the Gambia, without whom this work would not have been
   possible.; This research was funded by the National AIDS Secretariat and
   Action Aid-The Gambia, UNAIDS, Enda Sante of Senegal, and the Johns
   Hopkins Bloomberg School of Public Health.
CR Baral S, 2013, AIDS BEHAV S1, V17, pS60
   Baral S, 2013, UNPUB
   Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339
   Baral S, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-36
   Baral S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004997
   Beyrer C, 2011, DIR DEV, P1, DOI 10.1596/978-0-8213-8726-9
   Beyrer C, 2008, SEX TRANSM INFECT, V84, P410, DOI 10.1136/sti.2008.033290
   Beyrer C, 2012, LANCET, V380, P424, DOI 10.1016/S0140-6736(12)61022-8
   Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6
   Beyrer C, 2010, CLIN INFECT DIS, V50, pS108, DOI 10.1086/651481
   Burrell E, 2010, SEX HEALTH, V7, P149, DOI 10.1071/SH09090
   CDC, 1981, PNEUM PNEUM
   [Anonymous], 1981, KAP SARC PNEUM PNEUM
   CIA, 2012, WORLD FACTB GAMB
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Dahoma M, 2011, AIDS BEHAV, V15, P186, DOI 10.1007/s10461-009-9646-7
   Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243
   Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI 10.1525/sp.1997.44.2.03x0221m
   Hladik W, 2012, PLOS ONE, V7
   International Gay and Lesbian Human Rights Commission (IGLHRC), 2007, MAP HIV AIDS PROGR I
   Jallow C, 2011, GAMB 2010 BEH SURV S
   Mah Timothy L, 2008, HIV AIDS GAMBIA QUAL
   NAS, 2009, NAT HIV AIDS STRAT F
   Peterson I, 2011, AIDS, V25, P2167, DOI 10.1097/QAD.0b013e32834c4adb
   Poteat T, 2011, PLOS ONE, V6
   Sanders EJ, 2007, AIDS, V21, P2513
   Semugoma P, 2012, LANCET, V380, P312, DOI 10.1016/S0140-6736(12)60901-5
   Smith AD, 2009, LANCET, V374, P416, DOI 10.1016/S0140-6736(09)61118-1
   Sullivan PS, 2012, LANCET, V380, P388, DOI 10.1016/S0140-6736(12)60955-6
   Sullivan PS, 2009, ANN EPIDEMIOL, V19, P423, DOI 10.1016/j.annepidem.2009.03.004
   Trapence G, 2012, LANCET, V380, P400, DOI 10.1016/S0140-6736(12)60834-4
   van Griensven F, 2009, CURR OPIN HIV AIDS, V4, P300, DOI 10.1097/COH.0b013e32832c3bb3
   Wade AS, 2005, AIDS, V19, P2133, DOI 10.1097/01.aids.0000194128.97640.07
   [Anonymous], 2012, RESP PROT FULF BEST
NR 34
TC 12
Z9 13
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC 1
PY 2013
VL 29
IS 12
BP 1547
EP 1552
DI 10.1089/aid.2013.0092
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 255CX
UT WOS:000327218000003
PM 23875674
OA No
DA 2017-08-15
ER

PT J
AU Howie, SRC
   Oluwalana, C
   Secka, O
   Scott, S
   Ideh, RC
   Ebruke, BE
   Balloch, A
   Sambou, S
   Erskine, J
   Lowe, Y
   Corrah, T
   Adegbola, RA
AF Howie, Stephen R. C.
   Oluwalana, Claire
   Secka, Ousman
   Scott, Susana
   Ideh, Readon C.
   Ebruke, Bernard E.
   Balloch, Anne
   Sambou, Sana
   Erskine, James
   Lowe, Yamundow
   Corrah, Tumani
   Adegbola, Richard A.
TI The Effectiveness of Conjugate Haemophilus influenzae Type B Vaccine in
   The Gambia 14 Years After Introduction
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Hib vaccination; Hib disease; surveillance; Gambia; Africa
ID HIB VACCINE; ROUTINE IMMUNIZATION; UNITED-KINGDOM; SOUTH-AFRICA;
   DISEASE; MENINGITIS; POLYSACCHARIDE; BOOSTER; IMPACT; IMMUNOGENICITY
AB Background. The Gambia was the first country in Africa to introduce conjugate Haemophilus influenzae type b (Hib) vaccine, which, as in other developing countries but unlike industrialized countries, is delivered as a 3-dose primary series with no booster. This study assessed its effectiveness 14 years after introduction.
   Methods. Using methods standardized during >20 years in the study site, clinical and microbiological surveillance for invasive Hib disease (primarily meningitis) in the Western Region of The Gambia from 2007 to 2010 was complemented with studies of Hib carriage in children aged 1 to <2 years, Hib antibody levels in children aged <5 years, and Hib vaccine coverage and timing in children aged 1 to <2 years.
   Results. The incidence of Hib meningitis remained low (averaging 1.3 per 100 000 children aged <5 years annually), as did the Hib oropharyngeal carriage rate (0.9%). Hib antibody levels were protective in >99% of those surveyed, albeit with lower titers in older children; and coverage of conjugate Hib vaccination was high (91% having 3 doses at 1-2 years of age) using a schedule that was delivered at median ages of 2.6 months, 4.3 months, and 6 months for the first, second, and third doses, respectively.
   Conclusions. Conjugate Hib vaccine was delivered on time in a 3-dose primary series without booster to a high proportion of eligible children and this was associated with effective disease control up to 14 years after introduction. It is important that surveillance continues in this first African country to introduce the vaccine to determine if effective control persists or if a booster dose becomes necessary as has been the case in industrialized countries.
C1 [Howie, Stephen R. C.; Oluwalana, Claire; Scott, Susana; Ideh, Readon C.; Ebruke, Bernard E.] MRC Unit, Fajara, Gambia.
   [Secka, Ousman] MRC Unit, Lab Serv, Fajara, Gambia.
   [Scott, Susana] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Balloch, Anne] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
   [Sambou, Sana] Minist Hlth & Social Welf, Banjul, Gambia.
   [Erskine, James] WEC Miss Hosp, Sibanor, Gambia.
   [Lowe, Yamundow; Adegbola, Richard A.] MRC Unit, Bacterial Dis Programme, Fajara, Gambia.
   [Adegbola, Richard A.] GlaxoSmithKline Vaccines, Wavre, Belgium.
RP Howie, SRC (reprint author), MRC, POB 273, Banjul, Gambia.
EM showie@mrc.gm
FU Global Alliance for Vaccines and Immunization's Hib Initiative
   [90022369, 2000217173]; Medical Research Council, UK; Medical Research
   Council; Government of the Republic of The Gambia; WEC Mission
   International; GlaxoSmithKline
FX This work was supported by The Global Alliance for Vaccines and
   Immunization's Hib Initiative (grant numbers 90022369 and 2000217173)
   and the Medical Research Council, UK (core unit funding). S. R. C. H.,
   C. O., O. S., R. C. I., B. E. E., S. Sc., and T. C. are funded by the
   Medical Research Council; S. Sa. and Y. L. are funded by the Government
   of the Republic of The Gambia; J. E. is funded by WEC Mission
   International; R. A. A. was funded at the time of the study by the
   Medical Research Council, and is currently funded by GlaxoSmithKline.
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Akumu AO, 2007, B WORLD HEALTH ORGAN, V85, P511, DOI 10.2471/BLT.06.034686
   Booy R, 1997, LANCET, V349, P1197, DOI 10.1016/S0140-6736(96)06392-1
   CEPA LLP, GAVI 2 EV REP 2010
   CLEMENTS DA, 1993, PEDIATR INFECT DIS J, V12, P362, DOI 10.1097/00006454-199305000-00002
   Fitzgerald M, 2005, EUROSURVEILLANCE, V10
   Gambian National AIDS Secretariat, 2012, COUNTR PROGR REP GAM
   Garcia S, 2012, VACCINE, V30, P486, DOI 10.1016/j.vaccine.2011.10.101
   Gupta SK, 2012, INDIAN PEDIATR, V49, P707, DOI 10.1007/s13312-012-0151-0
   Hajjeh RA, 2010, VACCINE, V28, P7123, DOI 10.1016/j.vaccine.2010.07.028
   Heath PT, 2002, ARCH DIS CHILD, V86, P396, DOI 10.1136/adc.86.6.396
   International Vaccine Access Centre, 2012, VIMS REP GLOB VACC I
   KAYHTY H, 1983, J INFECT DIS, V147, P1100
   Ladhani S, 2008, ARCH DIS CHILD, V93, P665, DOI 10.1136/adc.2007.126888
   Madore DV, 1996, CLIN DIAGN LAB IMMUN, V3, P84
   McCormick DW, 2011, EMERG INFECT DIS, V17, P688, DOI 10.3201/eid1704.101045
   McVernon J, 2004, EPIDEMIOL INFECT, V132, P765, DOI 10.1017/S0950268804002122
   McVernon J, 2003, LANCET, V361, P1521, DOI 10.1016/S0140-6736(03)13171-6
   Muanya C, 2012, GUARDIAN
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   Nair Harish, 2011, J Glob Health, V1, P32
   Ojo LR, 2010, VACCINE, V28, P7117, DOI 10.1016/j.vaccine.2010.07.074
   Oluwalana C, 2013, J PEDIAT IN PRESS
   Peltola H, 2000, CLIN MICROBIOL REV, V13, P302, DOI 10.1128/CMR.13.2.302-317.2000
   PHIPPS DC, 1990, J IMMUNOL METHODS, V135, P121, DOI 10.1016/0022-1759(90)90264-V
   Pietrzyk JJ, 2008, VACCINE, V26, P5296, DOI 10.1016/j.vaccine.2008.07.033
   Ribeiro GS, 2007, VACCINE, V25, P4420, DOI 10.1016/j.vaccine.2007.03.024
   Southern J, 2007, CLIN VACCINE IMMUNOL, V14, P1328, DOI 10.1128/CVI.00191-07
   von Gottberg A, 2006, B WORLD HEALTH ORGAN, V84, P811, DOI 10.2471/BLT.06.030361
   von Gottberg A, 2012, VACCINE, V30, P565, DOI 10.1016/j.vaccine.2011.11.066
   Watt J, 2012, HAEMOPHILUS INFLUENZ
   World Health Organization, COUNTR HAV INTR HIB
   World Health Organization Department of Immunization Vaccines and Biologicals, 2005, WHOIVB0423
   World Health Organization, 2012, NUMB COUNTR HAV INTR
   World Health Organization, 2011, NEW UND UT VACC IMPL
   World Health Organization, 2011, IMM SURV ASS MON HAE
   Zanella RC, 2011, VACCINE, V29, P8937, DOI 10.1016/j.vaccine.2011.09.053
NR 37
TC 10
Z9 12
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 1
PY 2013
VL 57
IS 11
BP 1527
EP 1534
DI 10.1093/cid/cit598
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 247XK
UT WOS:000326657000008
PM 24046305
OA No
DA 2017-08-15
ER

PT J
AU Ezenwosu, OU
   Emodi, IJ
   Ikefuna, AN
   Chukwu, BF
   Osuorah, CD
AF Ezenwosu, Osita U.
   Emodi, Ifeoma J.
   Ikefuna, Anthony N.
   Chukwu, Barth F.
   Osuorah, Chidiebere D.
TI Determinants of academic performance in children with sickle cell
   anaemia
SO BMC PEDIATRICS
LA English
DT Article
DE Sickle; Determinants; Academic; Children
ID SILENT CEREBRAL INFARCTS; SCHOOL-CHILDREN; DISEASE; SCHOOLCHILDREN;
   ABNORMALITIES; ACHIEVEMENT; DYSFUNCTION; DISORDERS; CHILDHOOD; ABSENCE
AB Background: Some factors are known to influence the academic performance of children with Sickle Cell Anaemia (SCA). Information on their effects in these children is limited in Nigeria. The factors which influence academic performance of children with SCA in Enugu, Nigeria are determined in this study.
   Methods: Consecutive children with SCA aged 5-11 years were recruited at the weekly sickle cell clinic of the University of Nigeria Teaching Hospital (UNTH) Enugu, Nigeria. Their age-and sex-matched normal classmates were recruited as controls. The total number of days of school absence for 2009/2010 academic session was obtained for each pair of pupils from the class attendance register. Academic performance was assessed using the average of the overall scores in the three term examinations of same session. Intelligence ability was determined with Draw-A-Person Quotient (DAPQ) using the Draw-A-Person Test while socio-economic status was determined using the occupational status and educational attainment of each parent.
   Results: Academic performance of children with SCA showed statistically significant association with their socio-economic status (X-2 = 9.626, p = 0.047), and significant correlation with DAPQ (r = 0.394, p = 0.000) and age (r = -0.412, p = 0.000). However, no significant relationship existed between academic performance and school absence in children with SCA (r = -0.080, p = 0.453).
   Conclusions: Academic performance of children with SCA is influenced by their intelligence ability, age and socio-economic status but not negatively affected by their increased school absenteeism.
C1 [Ezenwosu, Osita U.; Emodi, Ifeoma J.; Ikefuna, Anthony N.; Chukwu, Barth F.] Univ Nigeria, Teaching Hosp, Dept Paediat, Enugu, Nigeria.
   [Osuorah, Chidiebere D.] Med Res Council UK, Child Survival Unit, Gambia Unit, Serrekunda, Gambia.
RP Ezenwosu, OU (reprint author), Univ Nigeria, Teaching Hosp, Dept Paediat, Enugu, Nigeria.
EM docsita31@yahoo.com
CR Akpan MU, 2010, AFR HEALTH SCI, V10, P154
   Alikor EAD, 2007, PAEDITRICS CHILD HLT, P70
   Anie KA, 2010, GLOBALIZATION HEALTH, V6, DOI 10.1186/1744-8603-6-2
   Ansari D, 2010, LEARN INDIVID DIFFER, V20, P123, DOI 10.1016/j.lindif.2009.06.001
   Araoye MO., 2003, RES METHODOLOGY STAT
   Buckhalt JA, 2007, CHILD DEV, V78, P213, DOI 10.1111/j.1467-8624.2007.00993.x
   Day Sara, 2006, J Sch Nurs, V22, P330
   Dowling MM, 2010, PEDIATR BLOOD CANCER, V54, P461, DOI 10.1002/pbc.22242
   Eaton M L, 1995, Issues Compr Pediatr Nurs, V18, P1, DOI 10.3109/01460869509080953
   Ebigbo PO, 1981, DRAW PERSON TEST STA
   Hawasawi ZM, 1998, ANN SAUDI MED, V18, P293
   Hogan AM, 2006, DEVELOPMENTAL SCI, V9, P379, DOI 10.1111/j.1467-7687.2006.00503.x
   Ibekwe R. C., 2008, Journal of College of Medicine, V13, P18
   Ibekwe RC, 2008, TROP DOCT, V38, P258, DOI 10.1258/td.2007.070305
   Ikefuna A N, 2007, Niger J Clin Pract, V10, P216
   Karande Sunil, 2005, Indian Journal of Pediatrics, V72, P961, DOI 10.1007/BF02731673
   Kinney TR, 1999, PEDIATRICS, V103, P640, DOI 10.1542/peds.103.3.640
   KNIGHT S, 1995, ARCH DIS CHILD, V73, P316
   Kral MC, 2006, J CHILD NEUROL, V21, P37, DOI 10.2310/7010.2006.00008
   Kral MC, 2004, J PEDIATR PSYCHOL, V29, P185, DOI 10.1093/jpepsy/jsh020
   Kwiatkowski JL, 2009, BRIT J HAEMATOL, V146, P300, DOI 10.1111/j.1365-2141.2009.07753.x
   Moonie S, 2008, J SCHOOL HEALTH, V78, P140, DOI 10.1111/j.1746-1561.2007.00276.x
   Moser FG, 1996, AM J NEURORADIOL, V17, P965
   Noll RB, 2001, J PEDIATR PSYCHOL, V26, P69, DOI 10.1093/jpepsy/26.2.69
   Ogala WN, 2007, PAEIDTRICS CHILD HLT, P596
   Ogunfowora OB, 2005, J NATL MED ASSOC, V97, P405
   Ong LC, 2010, SINGAP MED J, V51, P247
   Ozmert EN, 2005, J TROP PEDIATRICS, V51, P25, DOI 10.1093/tropej/fmh070
   Pegelow CH, 2002, BLOOD, V99, P3014, DOI 10.1182/blood.V99.8.3014
   Pickett JL, 1999, AM J KIDNEY DIS, V33, P1122, DOI 10.1016/S0272-6386(99)70150-2
   Richard HW, 1997, PSYCHOL REP, V81, P27
   Roby D. E., 2004, ED RES Q, V28, P3
   Schatz J, 2004, J PEDIATR PSYCHOL, V29, P627, DOI 10.1093/jpepsy/jsh065
   Schatz J, 2001, NEUROLOGY, V56, P1109
   Schwartz LA, 2009, PEDIATR BLOOD CANCER, V52, P92, DOI 10.1002/pbc.21819
   Steen G, 2003, AM J NEURORADIOL, V24, P382
   Steenari MR, 2003, J AM ACAD CHILD PSY, V42, P85, DOI 10.1097/01.CHI.0000024911.60748.D3
   Taras H, 2005, J SCHOOL HEALTH, V75, P255, DOI 10.1111/j.1746-1561.2005.00034.x
   Van-Dunem J C Carlos, 2007, West Afr J Med, V26, P269
   Vichinsky EP, 2010, JAMA-J AM MED ASSOC, V303, P1823, DOI 10.1001/jama.2010.562
   Wang W, 2001, J PEDIATR-US, V139, P391, DOI 10.1067/mpd.2001.116935
   Weiskopf RB, 2000, ANESTHESIOLOGY, V92, P1646, DOI 10.1097/00000542-200006000-00023
   WHO, 2005, EX BOARD 117 SESS SI, V4, P8
   WHO, 2006, 59 WORLD HLTH ASS SI, V11, P4
NR 44
TC 2
Z9 2
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD NOV 19
PY 2013
VL 13
AR 189
DI 10.1186/1471-2431-13-189
PG 8
WC Pediatrics
SC Pediatrics
GA 259AB
UT WOS:000327498700001
PM 24246094
OA gold
DA 2017-08-15
ER

PT J
AU Martins, C
   Garly, ML
   Bale, C
   Rodrigues, A
   Benn, CS
   Whittle, H
   Aaby, P
AF Martins, Cesario
   Garly, May-Lill
   Bale, Carlitos
   Rodrigues, Amabelia
   Benn, Christine S.
   Whittle, Hilton
   Aaby, Peter
TI Measles antibody levels after vaccination with Edmonston-Zagreb and
   Schwarz measles vaccine at 9 months or at 9 and 18 months of age: A
   serological study within a randomised trial of different measles
   vaccines
SO VACCINE
LA English
DT Article
DE Antibody response; Edmonston-Zagreb measles vaccine; Non-specific
   effects of vaccines; Schwarz measles vaccine; Two-dose measles
   vaccination
ID GUINEA-BISSAU; MORTALITY; CHILDREN; AFRICA
AB Standard-titre Schwarz (SW) and Edmonston-Zagreb (EZ) measles vaccines (MV) are both used in the routine immunisation programme. Within a trial of different strains of MV, we examined antibody responses in both one-dose and two-dose schedules when the first dose was administered at 9 months.
   Setting and Methods: The trial was conducted in an urban area in Guinea-Bissau where we have had a health and demographic surveillance system and studied strategies to prevent measles infection since 1978. In the present study, children were randomised to SW or EZ as the first MV and furthermore randomised to a second dose of the same MV or no vaccine at 18 months of age. We obtained blood samples from 996 children at baseline; post-vaccination blood samples were collected at 18 and 24 months of age to assess measles antibody levels after one or two doses of MV.
   Results: At age 18 months all had responded to the first dose and only 1% (8/699) of the children had non-protective antibody levels irrespective of vaccine type. SW was associated with significantly higher levels of measles antibodies (geometric mean titre (GMT) = 2114 mIU/mL (95%CI 1153-2412)) than EZ (GMT = 807 mIU/mL (722-908)) (p = 0.001). Antibody concentration was significantly higher in girls than in boys after EZ but not after SW. Antibody levels were higher in the rainy than the dry season. There was no clear indication that a booster dose at 18 months increased the antibody level at 24 months of age.
   Conclusions: Maternal antibody levels have declined significantly in recent years and 99% had protective levels of measles antibody following primary MV at 9 months of age. It is unlikely that measles prevention and child health will be improved by increasing the age of MV as currently recommended. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
C1 [Martins, Cesario; Garly, May-Lill; Bale, Carlitos; Rodrigues, Amabelia; Benn, Christine S.; Aaby, Peter] Bandim Hlth Project, Indepth Network, Bissau, Guinea Bissau.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Aaby, P (reprint author), Bandim Hlth Project, Apartado 861, Bissau, Guinea Bissau.
EM c.martins@bandim.org
FU Danish Council for Development Research; EU FP7 programme (OPTIMUNIZE);
   ERC Starting Grant [ERC-2009-StG-243149]; Novo Nordisk Foundation;
   Danish National Research Foundation
FX The study received financial support from the Danish Council for
   Development Research. CM is supported by an EU FP7 programme
   (OPTIMUNIZE). CSB is supported by an ERC Starting Grant
   (ERC-2009-StG-243149). PA holds a professorship grant from Novo Nordisk
   Foundation. The Research Centre for Vitamins and Vaccines (CVIVA) is
   funded by the Danish National Research Foundation.
CR AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2003, PEDIATR INFECT DIS J, V22, P798, DOI 10.1097/01.inf.0000083821.33187.b5
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   Aaby P, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000761
   Aaby P, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6495
   Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5
   Cisse B, 2001, THESIS LONDON SCH HY
   de Quadros CA, 2004, J INFECT DIS, V189, pS227, DOI 10.1086/377741
   Expanded Programme on Immunization, 1992, WKLY EPIDEMIOL REC, V67, P357
   Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347
   Garly M-L, 1919, VACCINE, V2001, P51
   George K, 1998, TROP MED INT HEALTH, V3, P751, DOI 10.1046/j.1365-3156.1998.00295.x
   HUBER SA, 1994, J VIROL, V68, P5126
   Martins C, 2009, VACCINE, V27, P5220, DOI 10.1016/j.vaccine.2009.06.076
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   Martins CL, 2002, THESIS BRAZIL
   NORRBY E, 1962, P SOC EXP BIOL MED, V111, P814
   ROSENTHAL SR, 1993, B WORLD HEALTH ORGAN, V71, P421
   TAYLOR WR, 1988, AM J EPIDEMIOL, V127, P788
   WHITTLE HC, 1990, LANCET, V336, P1046, DOI 10.1016/0140-6736(90)92501-8
   Whittle HC, 1999, PEDIATR INFECT DIS J, V149, P295
   [Anonymous], 2007, WKLY EPIDMIOL REC, V82, P1
   [Anonymous], 2002, WKLY EPIDMIOL REC, V77, P50
NR 23
TC 7
Z9 7
U1 4
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 19
PY 2013
VL 31
IS 48
BP 5766
EP 5771
DI 10.1016/j.vaccine.2013.08.044
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 260FL
UT WOS:000327580300021
PM 23994379
OA No
DA 2017-08-15
ER

PT J
AU Bhaskaran, K
   Ebonyi, AO
   Walther, B
   Walther, M
AF Bhaskaran, Krishnan
   Ebonyi, Augustine O.
   Walther, Brigitte
   Walther, Michael
TI Predictors of hyperlactataemia among children presenting with malaria in
   a low transmission area in The Gambia
SO MALARIA JOURNAL
LA English
DT Article
DE Hyperlactataemia; Lactate; Malaria; Children
ID SEVERE FALCIPARUM-MALARIA; AFRICAN CHILDREN; ACIDOSIS; INTENSITY;
   FEATURES; CARE; AGE
AB Background: Hyperlactataemia and metabolic acidosis are important risk factors for malaria death, but measuring lactate at the point of care is not financially viable in many resource-poor settings. This study aimed to identify combinations of routinely available parameters that could identify children at high risk of hyperlactataemia.
   Methods: Using data from a study of Gambian children aged six months to 16 years with severe or uncomplicated malaria, logistic regression modelling with a forward stepwise model selection process was used to develop a predictive model for hyperlactataemia from routinely available demographic, clinical and laboratory parameters. Potential predictors of hyperlactataemia considered for the modelling process were patient characteristics (age, sex, prior use of anti-malarials, and weight percentile for age), respiratory symptoms (deep breathing, irregular respiration, use of accessory muscles of respiration, lung crepitations, grunting respiration, cough, and age-specific respiratory rate), other clinical parameters recorded at presentation (duration of symptoms, Blantyre coma score, number of convulsions prior to admission, axillary temperature, dehydration, severe prostration, splenomegaly) and laboratory measures from blood tests (percentage parasitaemia, white cell count, lymphocyte count, neutrophil count, monocyte count, platelet count, haemoglobin level, blood glucose level).
   Results: 495 children were included, and 68 (14%) had laboratory-confirmed hyperlactataemia (lactate > 7 mmol/L). Four features were independently associated with increased hyperlactataemia risk in a multivariable age- and sex-adjusted model: lower Blantyre score (odds ratio (OR) compared to score 5 = 2.68 (95% CI, 1.03-6.96) for score 3-4 and 6.18 (95% CI, 2.24-17.07) for score 0-2, p = 0.001), higher percentage parasitaemia (OR = 1.07 (1.03-1.11) per 0031% increase, p < 0.001), high respiratory rate for age (OR = 3.09 (1.50-6.38) per unit increase, p = 0.002), and deep breathing (OR = 2.81 (1.20-6.60), p = 0.02). Cross-validated predictions from the final model achieved area under the receiver operating characteristic curve of 0.83.
   Conclusions: This study identified predictors of hyperlactataemia requiring only simple bedside clinical examination and blood film examination that can be carried out in resource-limited settings to quickly identify children at risk of dangerously raised lactate. A simple spreadsheet tool implementing the final model is supplied as supplementary material.
C1 [Bhaskaran, Krishnan] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1, England.
   [Ebonyi, Augustine O.; Walther, Brigitte; Walther, Michael] MRC Labs UK, Gambia Unit, Fajara, Gambia.
   [Walther, Michael] NIAID, NIH, Div Intramural Res, Lab Malaria Immunol & Vaccinol, Rockville, MD USA.
RP Bhaskaran, K (reprint author), London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1, England.
EM krishnan.bhaskaran@lshtm.ac.uk
FU Medical Research Council Laboratories (UK); National Institute for
   Health Research postdoctoral fellowship
FX The original study on which this analysis is based was funded by Medical
   Research Council Laboratories (UK), The Gambia. KB is funded by a
   National Institute for Health Research postdoctoral fellowship. The MRC
   and National Institute for Health Research had no role in the design,
   analysis, writing up, or decision to publish.
CR Arlot S, 2010, STAT SURV, V4, P40, DOI DOI 10.1214/09-SS054
   Bejon P, 2007, PLOS MED, V4, P1333, DOI 10.1371/journal.pmed.0040251
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Crawley J, 1998, T ROY SOC TROP MED H, V92, P305, DOI 10.1016/S0035-9203(98)91023-9
   Dzeing-Ella A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-1
   Edwards MD, 2012, MOL CELL PROBE, V26, P151, DOI 10.1016/j.mcp.2012.04.003
   English M, 1997, QJM-INT J MED, V90, P263, DOI 10.1093/qjmed/90.4.263
   English M, 1996, AM J TROP MED HYG, V55, P521
   Fleming S, 2011, LANCET, V377, P1011, DOI 10.1016/S0140-6736(10)62226-X
   Idro R, 2006, TROP MED INT HEALTH, V11, P115, DOI 10.1111/j.1365-3156.2005.01518.x
   Jallow M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045645
   KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5
   Maitland K, 2005, TRENDS PARASITOL, V21, P11, DOI 10.1016/j.pt.2004.10.010
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Mockenhaupt FP, 2004, AM J TROP MED HYG, V71, P167
   Mtove G, 2011, CLIN INFECT DIS, V53, P548, DOI 10.1093/cid/cir471
   Newton CRJC, 2005, CLIN INFECT DIS, V41, P948, DOI 10.1086/432941
   Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363
   Reyburn H, 2005, JAMA-J AM MED ASSOC, V293, P1461, DOI 10.1001/jama.293.12.1461
   US Centers for Disease Control and Prevention, CLIN GROWTH CHARTS
   von Seidlein L, 2012, CLIN INFECT DIS, V54, P1080, DOI 10.1093/cid/cis034
   WALLER D, 1995, CLIN INFECT DIS, V21, P577
   Walther M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002579
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   World Health Organization, 2000, T R SOC TROP MED HYG, V94
   WHO, GUID TREATM MAL
   World Health Organization, WORLD MAL REP 2012
NR 27
TC 1
Z9 1
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD NOV 15
PY 2013
VL 12
AR 423
DI 10.1186/1475-2875-12-423
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 281MI
UT WOS:000329105300006
PM 24237749
OA gold
DA 2017-08-15
ER

PT J
AU Toe, LP
   Ravinetto, RM
   Dierickx, S
   Gryseels, C
   Tinto, H
   Rouamba, N
   Diallo, I
   Cissao, Y
   Bayala, K
   Hausmann, S
   Muela, J
   D'Alessandro, U
   Grietens, KP
AF Toe, Lea Pare
   Ravinetto, Raffaella M.
   Dierickx, Susan
   Gryseels, Charlotte
   Tinto, Halidou
   Rouamba, Noel
   Diallo, Ibrahim
   Cissao, Yacouba
   Bayala, Korotimi
   Hausmann, Susanna
   Muela, Joan
   D'Alessandro, Umberto
   Grietens, Koen Peeters
TI Could the Decision of Trial Participation Precede the Informed Consent
   Process? Evidence From Burkina Faso
SO PLOS ONE
LA English
DT Article
ID EMERGENCY RESEARCH; CAPACITY; COUNTRY; ASSENT
AB Background: Over the last years, the number of clinical trials carried out in low-income countries with poor medical infrastructure and limited access to health care has increased. In these settings, the decision of participating in a clinical study may be influenced by factors related to participants' vulnerability that limit the efficacy of the informed consent.
   Methods: A mixed methods social science study, based on the triangulation of qualitative and quantitative data, was carried out in a socio-economically disadvantaged and semi-urban area of Bobo Dioulasso, Burkina Faso. The study aimed at assessing the relevance of the informed consent procedure on the decision-making process of the parents and/or guardians of potential participants in a pediatric malaria trial.
   Results: For most parents (70.4%), the decision of participating had already been taken before undergoing the informed consent process and was based on the information conveyed through the community. Access to free and good quality health care often inspired this decision. In addition, the parents' willingness to have their child included in the trial made them develop active strategies to achieve this purpose.
   Discussion: In a context of socio-economic vulnerability and poor access to free health care, the process of informed consent does not always accomplish its goal of informing people and enabling them to make a free and informed decision. This information role is somehow anticipated by the community and trial participation becomes a strategic action to secure otherwise unavailable health resources leading community members to decide on participation even prior to the informed consent process.
C1 [Toe, Lea Pare; Tinto, Halidou; Rouamba, Noel; Diallo, Ibrahim; Cissao, Yacouba; Bayala, Korotimi] IRSS, Ctr Muraz, Bobo Dioulasso, Burkina Faso.
   [Ravinetto, Raffaella M.] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.
   [Ravinetto, Raffaella M.] Catholic Univ KU, Dept Pharmaceut & Pharmacol Sci, B-3000 Louvain, Belgium.
   [Dierickx, Susan; Gryseels, Charlotte; D'Alessandro, Umberto; Grietens, Koen Peeters] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.
   [Hausmann, Susanna; Muela, Joan; Grietens, Koen Peeters] Partners Appl Social Sci PASS Int, Tessenderlo, Belgium.
   [D'Alessandro, Umberto] MRC, Fajara, Gambia.
RP Ravinetto, RM (reprint author), Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.
EM rravinetto@itg.be
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Belgian Development Cooperation; European Commission
FX The social science research was funded under a programme for
   institutional capacity strengthening, funded by the Belgian Development
   Cooperation and coordinated by the Institute of Tropical Medicine in
   Antwerp (http://www.itg.be/itg/GeneralSite/Default.aspx?WPID=139&L=E).
   The Malactres trial was funded by the European Commission's Seventh
   Framework Programme (http://cordis.europa.eu/fp7/home_en.html). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR American Anthropological Association, 2004, STAT ETHN I REV BOAR
   Baines P, 2011, ARCH DIS CHILD, V96, P960, DOI 10.1136/adc.2011.211342
   Behrendt C, 2011, J MED ETHICS, V37, P74, DOI 10.1136/jme.2010.035485
   Bosk CL, 2002, MED CARE, V40, P64, DOI 10.1097/01.MLR.0000023957.23565.E9
   Brierley J, 2011, J MED ETHICS, V37, P429, DOI 10.1136/jme.2010.040667
   Chaisson LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022696
   [Anonymous], 2002, INT ETH GUID BIOM RE
   Council Nuffieldof Bioethics, 2002, ETH RES REL HEALTHC
   Dixon-Woods M, 2009, J MED ETHICS, V35, P377, DOI 10.1136/jme.2008.027094
   Dolgin E, 2010, NAT MED, V16, P8, DOI 10.1038/nm0110-8a
   European Medicines Agency, 2012, REFL PAP ETH GCP ASP
   Fitzgerald DW, 2002, LANCET, V360, P1301, DOI 10.1016/S0140-6736(02)11338-9
   Gainotti S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011150
   Kuehn BM, 2011, JAMA-J AM MED ASSOC, V305, P1186, DOI 10.1001/jama.2011.317
   Levinson DR, 2010, OEI010800510 OFF INS
   Lidz CW, 2002, MED CARE, V40, P55, DOI 10.1097/01.MLR.0000023956.25813.18
   Ministry of Healthof Burkina Faso, 2007, PLAN STRAT LUTT PAL
   Mitka M, 2007, JAMA-J AM MED ASSOC, V298, P2608, DOI 10.1001/jama.298.22.2608
   Nabulsi M, 2011, J MED ETHICS, V37, P420, DOI 10.1136/jme.2010.035899
   Nakkash R, 2009, J MED ETHICS, V35, P638, DOI 10.1136/jme.2008.028936
   National Commission, 1979, BELM REP ETH PRINC G
   Paradis C, 2010, J MED ETHICS, V36, P580, DOI 10.1136/jme.2009.032904
   Sibley A, 2012, J MED ETHICS, V38, P3, DOI 10.1136/medethics-2011-100317
   Unguru Y, 2010, PEDIATRICS, V125, P876, DOI [10.1542/peds.2009-2317, DOI 10.1542/PEDS.2009-2317.PUBMED:20385637]
   Wetta C, 2011, PROJET RECHERCHE PAU
   Wilkinson D, 2012, J MED ETHICS, V38, P2, DOI 10.1136/medethics-2011-100242
   [Anonymous], 1947, JAMA, V276, P1691
NR 27
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 15
PY 2013
VL 8
IS 11
AR e80800
DI 10.1371/journal.pone.0080800
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 255RX
UT WOS:000327258600087
OA gold
DA 2017-08-15
ER

PT J
AU Gryseels, C
   Uk, S
   Erhart, A
   Gerrets, R
   Sluydts, V
   Durnez, L
   Ribera, JM
   Muela, SH
   Menard, D
   Heng, S
   Sochantha, T
   D'Alessandro, U
   Coosemans, M
   Grietens, KP
AF Gryseels, Charlotte
   Uk, Sambunny
   Erhart, Annette
   Gerrets, Rene
   Sluydts, Vincent
   Durnez, Lies
   Ribera, Joan Muela
   Muela, Susanna Hausmann
   Menard, Didier
   Heng, Somony
   Sochantha, Tho
   D'Alessandro, Umberto
   Coosemans, Marc
   Grietens, Koen Peeters
TI Injections, Cocktails and Diviners: Therapeutic Flexibility in the
   Context of Malaria Elimination and Drug Resistance in Northeast Cambodia
SO PLOS ONE
LA English
DT Article
ID FALCIPARUM-MALARIA; CENTRAL VIETNAM; ANTIMALARIAL-DRUGS; SOUTHEAST-ASIA;
   VECTOR CONTROL; COUNTERFEIT; AGE
AB Background: Adherence to effective malaria medication is extremely important in the context of Cambodia's elimination targets and drug resistance containment. Although the public sector health facilities are accessible to the local ethnic minorities of Ratanakiri province (Northeast Cambodia), their illness itineraries often lead them to private pharmacies selling "cocktails" and artemether injections, or to local diviners prescribing animal sacrifices to appease the spirits.
   Methods: The research design consisted of a mixed methods study, combining qualitative (in-depth interviews and participant observation) and quantitative methods (household and cross-sectional survey).
   Results: Three broad options for malaria treatment were identified: i) the public sector; ii) the private sector; iii) traditional treatment based on divination and ceremonial sacrifice. Treatment choice was influenced by the availability of treatment and provider, perceived side effects and efficacy of treatments, perceived etiology of symptoms, and patient-health provider encounters. Moreover, treatment paths proved to be highly flexible, changing mostly in relation to the perceived efficacy of a chosen treatment.
   Conclusions: Despite good availability of anti-malarial treatment in the public health sector, attendance remained low due to both structural and human behavioral factors. The common use and under-dosage of anti-malaria monotherapy in the private sector (single-dose injections, single-day drug cocktails) represents a threat not only for individual case management, but also for the regional plan of drug resistance containment and malaria elimination.
C1 [Gryseels, Charlotte; Erhart, Annette; Sluydts, Vincent; Durnez, Lies; Coosemans, Marc; Grietens, Koen Peeters] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Uk, Sambunny; Heng, Somony; Sochantha, Tho] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia.
   [Gerrets, Rene] Univ Amsterdam, Amsterdam Inst Social Sci Res, Amsterdam, Netherlands.
   [Ribera, Joan Muela; Muela, Susanna Hausmann; Grietens, Koen Peeters] Partners Appl Social Sci PASS Int, Tessenderlo, Belgium.
   [Menard, Didier] Inst Pasteur Cambodge, Phnom Penh, Cambodia.
   [D'Alessandro, Umberto] MRC, Fajara, Gambia.
   [Coosemans, Marc] Univ Antwerp, B-2020 Antwerp, Belgium.
RP Gryseels, C (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.
EM cgryseels@itg.be
RI Menard, Didier/O-3294-2013; D'Alessandro, Umberto/D-3457-2015
OI Menard, Didier/0000-0003-1357-4495; D'Alessandro,
   Umberto/0000-0001-6341-5009
FU Institute of Tropical Medicine (ITM), Antwerp, Belgium; National Center
   for Parasitology, Entomology and Malaria Control (CNM), Phnom Penh,
   Cambodia; Bill and Melinda Gates Foundation
FX The qualitative study and the household survey received financial
   support from the Belgian Cooperation within the Framework Agreement III
   consisting of a bilateral cooperation between the Institute of Tropical
   Medicine (ITM), Antwerp, Belgium and the National Center for
   Parasitology, Entomology and Malaria Control (CNM), Phnom Penh,
   Cambodia. The cross-sectional survey was financially supported by the
   Bill and Melinda Gates Foundation within the framework of the project
   'Repellents as an added control measure to LLINs in Southeast Asia'. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Asian Development Bank, 2002, IND PEOPL ETHN MIN P
   Bourdier Frederic, 2006, MOUNTAIN PRECIOUS ST
   Bourdier F., 2009, DEV DOMINION INDIGEN
   Coosemans M, 2006, INT C HUBS HARB DELT, P551
   Dondorp AM, 2010, NAT REV MICROBIOL, V8, P272, DOI 10.1038/nrmicro2331
   Good C. M., 1987, ETHNOMEDICAL SYSTEMS
   Hausmann Muela S., 2002, Social Science & Medicine, V55, P403, DOI 10.1016/S0277-9536(01)00179-4
   Hausmann-Muela S, 2012, MALAR REP, V2, P17
   Nguyen HV, 2012, AM J TROP MED HYG, V87, P989, DOI 10.4269/ajtmh.2012.12-0047
   Lon CT, 2006, T ROY SOC TROP MED H, V100, P1019, DOI 10.1016/j.trstmh.2006.01.003
   Meessen B, 2011, HEALTH POLICY PLANN, V26, pi30, DOI 10.1093/heapol/czr026
   Kingdom of Cambodia Ministry of Health Cambodia, 2011, TRAT PLAN EL MAL CAM
   Montagu D., 2010, LARGE SCALE MALARIA
   National Center for Parasitology Entomology and Malaria Control Kingdom of Cambodia Ministry of Health Cambodia, 2012, MIS NAT MAL PROGR
   National Center for Parasitology Entomology and Malaria Control, 2009, VILL MAL WORK PROJ S
   National Institute of Statistics, 2008, GEN POP CENS CAMB 20
   Newton PN, 2003, LANCET, V362, P169, DOI 10.1016/S0140-6736(03)13872-X
   Noedl H, 2008, NEW ENGL J MED, V359, P2619, DOI 10.1056/NEJMc0805011
   O'Connell KA, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-335
   Ovesen J, 2004, CIVILIZING THE MARGINS: SOUTHEAST ASIAN GOVERNMENT POLICIES FOR THE DEVELOPMENT OF MINORITIES, P241
   Packard R., 2007, MAKING TROPICAL DIS
   Price R, 1999, AM J TROP MED HYG, V60, P547
   Shanks GD, 2006, J POSTGRAD MED, V52, P277
   Steenkeste N, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-108
   Thriemer K, 2013, TROP MED INT HEALTH, V18, P66
   Tran HT, 2012, MALARIA J, V11, P355, DOI [10.1186/1475-2875-11-355, DOI 10.1186/1475-2875-11-355.PUBMED:23101492]
   Trankell I, 2007, MED IDENTITIES HEALI, P36
   Trung HD, 2005, TROP MED INT HEALTH, V10, P251, DOI 10.1111/j.1365-3156.2004.01378.x
   Van Bortel W, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-373
   White NJ, 2004, J CLIN INVEST, V113, P1084, DOI 10.1172/JCI200421682
   World Health Organization, 2013, EM RESP ART RES GREA
   Yasuoka J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-109
   Yeung S, 2005, TROP MED INT HEALTH, V10, P121, DOI 10.1111/j.1365-3156.2004.01364.x
   Yeung S, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-96
NR 34
TC 14
Z9 14
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 11
PY 2013
VL 8
IS 11
AR e80343
DI 10.1371/journal.pone.0080343
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 255EG
UT WOS:000327221600204
PM 24244678
OA gold
DA 2017-08-15
ER

PT J
AU Quicke, E
   Sillah, A
   Harding-Esch, EM
   Last, A
   Joof, H
   Makalo, P
   Bailey, RL
   Burr, SE
AF Quicke, E.
   Sillah, A.
   Harding-Esch, E. M.
   Last, A.
   Joof, H.
   Makalo, P.
   Bailey, R. L.
   Burr, S. E.
TI Follicular trachoma and trichiasis prevalence in an urban community in
   The Gambia, West Africa: is there a need to include urban areas in
   national trachoma surveillance?
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE trachoma; urban; prevalence; The Gambia; trichiasis
ID ACTIVE TRACHOMA; RISK-FACTORS; INFECTION; VILLAGE; EPIDEMIOLOGY;
   ELIMINATION; ACCEPTANCE; TANZANIA; BARRIERS; SURGERY
AB ObjectivesUrban areas are traditionally excluded from trachoma surveillance activities, but due to rapid expansion and population growth, the urban area of Brikama in The Gambia may be developing social problems that are known risk factors for trachoma. It is also a destination for many migrants who may be introducing active trachoma into the area. This study aimed to determine the prevalence and risk factors for follicular trachoma and trichiasis in Brikama.
   MethodsA community-based cross-sectional prevalence survey including 27 randomly selected households in 12 randomly selected enumeration areas (EAs) of Brikama. Selected households were offered eye examinations, and the severity of trachoma was graded according to WHO's simplified grading system. Risk factor data were collected from each household via a questionnaire.
   ResultsThe overall prevalence of trachomatous inflammation-follicular (TF) in children aged 1-9years was 3.8% (95% CI 2.5-5.6), and the overall prevalence of trichiasis in adults aged 15years was 0.46% (95% CI 0.17-1.14). EA prevalence of TF varied from 0% to 8.4%. The major risk factors for TF were dirty faces (P<0.01, OR=9.23, 95% CI 1.97-43.23), nasal discharge (P=0.039, OR=5.11, 95% CI 1.08-24.10) and residency in Brikama for <1year (P=0.047, OR=7.78, 95% CI 1.03-59.03).
   ConclusionsFollicular trachoma can be considered to have been eliminated as a public health problem in Brikama according to WHO criteria. However, as the prevalence in some EAs is >5%, it may be prudent to include Brikama in surveillance programmes. Trichiasis remains a public health problem (>0.1%), and active case finding needs to be undertaken.
C1 [Quicke, E.] Univ Birmingham, Sch Med, Birmingham B15 2TT, W Midlands, England.
   [Sillah, A.] Minist Hlth, Natl Eye Hlth Programme, Banjul, Gambia.
   [Harding-Esch, E. M.] Hlth Protect Agcy, HIV STI Dept, London, England.
   [Harding-Esch, E. M.; Last, A.; Bailey, R. L.; Burr, S. E.] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England.
   [Joof, H.; Makalo, P.; Burr, S. E.] MRC, Fajara, Gambia.
RP Quicke, E (reprint author), Univ Birmingham, Sch Med, Birmingham B15 2TT, W Midlands, England.
EM exq890@bham.ac.uk
FU Wellcome Trust [097330, 100714]
CR Ajewole J F, 2001, Ophthalmic Epidemiol, V8, P163, DOI 10.1076/opep.8.2.163.4161
   BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY RL, 1994, BRIT J OPHTHALMOL, V78, P813, DOI 10.1136/bjo.78.11.813
   Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   Bowman RJC, 2002, INVEST OPHTH VIS SCI, V43, P936
   Burton MJ, 2011, INVEST OPHTH VIS SCI, V52, P6012, DOI 10.1167/iovs.11-7326
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Emerson Paul, 2006, IMPLEMENTING SAFE ST
   Harding-Esch EM, 2008, T ROY SOC TROP MED H, V102, P1255, DOI 10.1016/j.trstmh.2008.04.022
   Harding-Esch EM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000861
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Hu VH, 2010, TROP MED INT HEALTH, V15, P673, DOI 10.1111/j.1365-3156.2010.02521.x
   Kuper H, 2003, LANCET INFECT DIS, V3, P372, DOI 10.1016/S1473-3099(03)00659-5
   MABEY DCW, 1992, EPIDEMIOL INFECT, V108, P343
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   Moalic E, 2000, PEDIATR INFECT DIS J, V19, P979, DOI 10.1097/00006454-200010000-00008
   Nagpal G, 2006, OPHTHAL EPIDEMIOL, V13, P53, DOI 10.1080/09286580500428518
   Ngondi J, 2008, PLOS NEGLECT TROP D, V2, pe299
   Ngondi J, 2009, B WORLD HEALTH ORGAN, V87, P143, DOI 10.2471/BLT.07.046326
   Rajak SN, 2010, INVEST OPHTH VIS SCI, V51, P4996, DOI 10.1167/iovs.10-5169
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schemann JF, 2002, INT J EPIDEMIOL, V31, P194, DOI 10.1093/ije/31.1.194
   Shah NA, 2010, OPHTHAL EPIDEMIOL, V17, P113, DOI 10.3109/09286581003624921
   Solomon AW, 2006, TRACHOMA CONTROL GUI
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   [Anonymous], 2007, 11 M WHO ALL GLOB EL
   [Anonymous], 2012, 16 M WHO ALL EL BLIN
NR 29
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD NOV
PY 2013
VL 18
IS 11
BP 1344
EP 1352
DI 10.1111/tmi.12182
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 270PP
UT WOS:000328331200004
PM 24033501
OA No
DA 2017-08-15
ER

PT J
AU Sawo, Y
   Jarjou, LMA
   Goldberg, GR
   Laskey, MA
   Prentice, A
AF Sawo, Y.
   Jarjou, L. M. A.
   Goldberg, G. R.
   Laskey, M. A.
   Prentice, A.
TI Bone mineral changes after lactation in Gambian women accustomed to a
   low calcium intake
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE lactation; bone; calcium; DXA; The Gambia
ID HUMAN-PREGNANCY; BREAST-MILK; SUPPLEMENTATION; DENSITY; WEIGHT; SIZE;
   LIFE
AB BACKGROUND/OBJECTIVES: Previous studies in Gambian women with a low calcium intake have described decreases in whole-body and regional bone mineral content (BMC) and areal bone mineral density (aBMD) during the first year of lactation. The aim of this study was to examine whether these effects are reversed after lactation.
   SUBJECTS/METHODS: Thirty-three Gambian women who had a previous dual-energy X-ray absorptiometry (DXA) scan at 52 weeks lactation (L52) were invited to participate in a follow-up study when neither pregnant nor lactating (NPNL) for >= 3 months and/or when 52 weeks postpartum in a subsequent lactation (F52). Whole body, lumbar spine and hip bone mineral were measured by DXA. Anthropometry and dietary assessments were also conducted. Repeated-measures analysis of covariance was used to determine differences from L52 at NPNL and F52.
   RESULTS: Twenty-eight women were scanned at NPNL and 20 at F52. The mean +/- s.d. calcium intake of the 33 women at NPNL and F52 was 360 168 mg/day. BMC, aBMD and size-adjusted BMC (SA-BMC) at all sites were higher at NPNL than L52. Percent increases in SA-BMC (mean +/- s.e.m.) were significant (P<0.0001): whole body= 2.7 +/- 0.4%; lumbar spine =4.9 +/- 1.0%; total hip = 3.7 +/- 1.0%. There were no significant differences in any measurements between the two lactation time points (L52 and F52).
   CONCLUSIONS: This study of Gambian women with low calcium intakes demonstrates that bone mineral mobilised during lactation is recovered after lactation. Successive periods of long lactation are not associated with progressive skeletal depletion.
C1 [Sawo, Y.; Jarjou, L. M. A.; Goldberg, G. R.; Prentice, A.] MRC Keneba, West Kiang, Gambia.
   [Goldberg, G. R.; Laskey, M. A.; Prentice, A.] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
RP Prentice, A (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
FU UK Medical Research Council [U105960371, U123261351]
FX This work was funded by the UK Medical Research Council (Unit Programme
   numbers U105960371 and U123261351). We thank the women who participated
   in this study and the staff of MRC Keneba, The Gambia, particularly
   Michael Mendy, Mustapha Ceesay, Mariama Jammeh, Fatou Manneh, Buba
   Ceesay, Morikebba Sanyang and Lamin Jammeh. We also are grateful for the
   contributions of staff at MRC Human Nutrition Research, Cambridge,
   especially Sheila Levitt, Celia Prynne and Jenny Thompson.
CR Abrams SA, 2001, P NUTR SOC, V60, P283
   Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F
   CROSS NA, 1995, J BONE MINER RES, V10, P1312
   Department of Health, 1998, NUTR BON HLTH PART R
   Holmberg-Marttila D, 2000, OSTEOPOROSIS INT, V11, P570, DOI 10.1007/s001980070077
   Institute of Medicine Food and Nutrition Board, 2011, DIETARY REFERENCE IN
   Jarjou LMA, 2012, EUR J CLIN NUTR, V66, P673, DOI 10.1038/ejcn.2012.7
   Jarjou LMA, 2010, AM J CLIN NUTR, V92, P450, DOI 10.3945/ajcn.2010.29217
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   Kalkwarf HJ, 1997, NEW ENGL J MED, V337, P523, DOI 10.1056/NEJM199708213370803
   KALKWARF HJ, 1995, OBSTET GYNECOL, V86, P26, DOI 10.1016/0029-7844(95)00083-4
   Kolthoff N, 1998, CLIN SCI, V94, P405
   Kovacs CS, 2011, ENDOCRIN METAB CLIN, V40, P795, DOI 10.1016/j.ecl.2011.08.002
   Laskey MA, 2004, J CLIN DENSITOM, V7, P341, DOI 10.1385/JCD:7:3:341
   Laskey MA, 1999, OBSTET GYNECOL, V94, P608, DOI 10.1016/S0029-7844(99)00369-5
   Miller SC, 2007, ANAT REC, V290, P65, DOI 10.1002/ar.a.20403
   Olausson H, 2008, AM J CLIN NUTR, V88, P1032
   Olausson H, 2012, NUTR RES REV, V25, P40, DOI 10.1017/S0954422411000187
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   Prentice A, 2003, J NUTR, V133, p1693S
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   Prynne C, 2011, FOOD COMPOSITION TAB
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   Ritchie LD, 1998, AM J CLIN NUTR, V67, P693
   World Health Organization/Food and Agriculture Organization, 2004, VIT MIN REQ HUM NUTR
NR 25
TC 3
Z9 3
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD NOV
PY 2013
VL 67
IS 11
BP 1142
EP 1146
DI 10.1038/ejcn.2013.162
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 248AO
UT WOS:000326666300006
PM 24084511
OA No
DA 2017-08-15
ER

PT J
AU Fletcher, HA
   Tanner, R
   Wallis, RS
   Meyer, J
   Manjaly, ZR
   Harris, S
   Satti, I
   Silver, RF
   Hoft, D
   Kampmann, B
   Walker, KB
   Dockrell, HM
   Fruth, U
   Barker, L
   Brennan, MJ
   McShane, H
AF Fletcher, Helen A.
   Tanner, Rachel
   Wallis, Robert S.
   Meyer, Joel
   Manjaly, Zita-Rose
   Harris, Stephanie
   Satti, Iman
   Silver, Richard F.
   Hoft, Dan
   Kampmann, Beate
   Walker, K. Barry
   Dockrell, Hazel M.
   Fruth, Uli
   Barker, Lew
   Brennan, Michael J.
   McShane, Helen
TI Inhibition of Mycobacterial Growth In Vitro following Primary but Not
   Secondary Vaccination with Mycobacterium bovis BCG
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID CLUSTER-RANDOMIZED-TRIAL; SCHOOL-AGED CHILDREN; ANTIMYCOBACTERIAL
   IMMUNITY; CALMETTE-GUERIN; WHOLE-BLOOD; T-CELLS; TUBERCULOSIS;
   REVACCINATION; EFFICACY; VACCINES
AB Despite the widespread use of the Mycobacterium bovis BCG vaccine, there are more than 9 million new cases of tuberculosis (TB) every year, and there is an urgent need for better TB vaccines. TB vaccine candidates are selected for evaluation based in part on the detection of an antigen-specific gamma interferon (IFN-gamma) response. The measurement of mycobacterial growth in blood specimens obtained from subjects immunized with investigational TB vaccines may be a better in vitro correlate of in vivo vaccine efficacy. We performed a clinical study with 30 United Kingdom adults who were followed for 6 months to evaluate the abilities of both a whole-blood- and a novel peripheral blood mononuclear cell (PBMC)-based mycobacterial growth inhibition assay to measure a response to primary vaccination and revaccination with BCG. Using cryopreserved PBMCs, we observed a significant improvement in mycobacterial growth inhibition following primary vaccination but no improvement in growth inhibition following revaccination with BCG (P<0.05). Mycobacterial growth inhibition following primary BCG vaccination was not correlated with purified protein derivative (PPD) antigen-specific IFN-gamma enzyme-linked immunospot (ELISPOT) responses. We demonstrate that a mycobacterial growth inhibition assay can detect improved capacity to control growth following primary immunization, but not revaccination, with BCG. This is the first study to demonstrate that an in vitro growth inhibition assay can identify a difference in vaccine responses by comparing both primary and secondary BCG vaccinations, suggesting that in vitro growth inhibition assays may serve as better surrogates of clinical efficacy than the assays currently used for the assessment of candidate TB vaccines.
C1 [Fletcher, Helen A.; Tanner, Rachel; Meyer, Joel; Manjaly, Zita-Rose; Harris, Stephanie; Satti, Iman; McShane, Helen] Univ Oxford, Jenner Inst, Oxford, England.
   [Wallis, Robert S.] Pfizer Inc, Groton, CT 06340 USA.
   [Silver, Richard F.] Case Western Reserve Univ, Sch Med, Div Pulm Crit Care & Sleep Med, Cleveland, OH USA.
   [Hoft, Dan] St Louis Univ, Dept Internal Med, St Louis, MO 63103 USA.
   [Hoft, Dan] St Louis Univ, Dept Mol Microbiol, St Louis, MO 63103 USA.
   [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England.
   [Kampmann, Beate] MRC Unit, Banjul, Gambia.
   [Walker, K. Barry; Barker, Lew; Brennan, Michael J.] Aeras, Rockville, MD USA.
   [Dockrell, Hazel M.] London Sch Hyg & Trop Med, Dept Immunol & Infect, London WC1, England.
   [Fruth, Uli] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland.
RP Brennan, MJ (reprint author), Aeras, Rockville, MD USA.
EM mbrennan@aeras.org
OI Dockrell, Hazel/0000-0003-1869-9107; Kampmann,
   Beate/0000-0002-6546-4709; Fletcher, Helen/0000-0002-0435-1006
FU U.S. Food and Drug Administration; Aeras
FX H.A.F. is an Oxford Martin Fellow, and H. M. is a Wellcome Trust Senior
   Clinical Fellow. This work was supported in part by grants from the U.S.
   Food and Drug Administration and from Aeras.
CR Barreto ML, 2011, VACCINE, V29, P4875, DOI 10.1016/j.vaccine.2011.05.023
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Brennan MJ, 2012, TUBERCULOSIS, V92, pS6, DOI 10.1016/S1472-9792(12)70005-7
   Cheon SH, 2002, CLIN DIAGN LAB IMMUN, V9, P901, DOI 10.1128/CDLI.9.4.901-907.2002
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Cunha SS, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000167
   Fine PEM, 1996, LANCET, V348, P17
   Fourth report to the Medical Research Council by its Tuberculosis Vaccines Clinical Trials Committee, 1972, B WHO, V46, P371
   Hanekom WA, 2008, PLOS MED, V5, P1033, DOI 10.1371/journal.pmed.0050145
   Hoft DF, 2002, J INFECT DIS, V186, P1448, DOI 10.1086/344359
   Kagina BMN, 2010, AM J RESP CRIT CARE, V182, P1073, DOI [10.1164/rccm.201003-0334OC, 10.1164/rrcm.201003-0334OC]
   Kampmann B, 2004, INFECT IMMUN, V72, P6401, DOI 10.1128/IAI.72.11.6401.6407.2004
   Kampmann B, 2000, J INFECT DIS, V182, P895, DOI 10.1086/315766
   Leung CC, 2001, INT J TUBERC LUNG D, V5, P717
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   Parra M, 2009, CLIN VACCINE IMMUNOL, V16, P1025, DOI 10.1128/CVI.00067-09
   Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0
   SEPULVEDA RL, 1992, TUBERCLE LUNG DIS, V73, P372, DOI 10.1016/0962-8479(92)90043-J
   Silver RF, 1998, J IMMUNOL, V160, P2408
   Tala-Heikkila M, 1991, Bull Int Union Tuberc Lung Dis, V66, P57
   Tuomela M, 2005, GENE THER, V12, pS131, DOI 10.1038/sj.gt.3302627
   Wallis RS, 2001, J INFECT DIS, V183, P1300, DOI 10.1086/319679
   Whelan KT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005934
   Worku S, 2000, CLIN INFECT DIS, V30, pS257, DOI 10.1086/313887
NR 25
TC 26
Z9 26
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD NOV
PY 2013
VL 20
IS 11
BP 1683
EP 1689
DI 10.1128/CVI.00427-13
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 241KI
UT WOS:000326165300004
PM 23986316
OA No
DA 2017-08-15
ER

PT J
AU Sillah, F
   Ho, HJ
   Chao, JCJ
AF Sillah, Famara
   Ho, Hsin-Jung
   Chao, Jane C-J
TI The use of oral rehydration salt in managing children under 5 y old with
   diarrhea in the Gambia: Knowledge, attitude, and practice
SO NUTRITION
LA English
DT Article
DE Childhood diarrhea; Oral rehydration solution; Knowledge; Attitude;
   Practice; Mothers
ID CHILDHOOD DIARRHEA; HOME MANAGEMENT; DISEASE; COMMUNITY
AB Objective: Diarrhea is a leading cause of mortality in children under the age of 5 y in developing countries. To our knowledge, no other studies have investigated the management of diarrhea in the Gambia. The aim of this study was to assess maternal knowledge, attitude, and practice in the causes, prevention, and management of diarrhea in children under the age of 5 y in the Gambia.
   Methods: Four hundred mothers with children who have diarrhea and are under the age of 5 y were randomly recruited. Data were collected using structured questionnaires, including demographic information, knowledge about diarrhea, attitude toward the management of diarrhea, and practice for the prevention and management of diarrhea. chi(2) and Student's t tests were used for the descriptive and quantitative analysis, respectively. Simple and multiple linear regressions were used to determine the association between the variables. A P-value < 0.05 was considered statistically significant.
   Results: The mean of maternal knowledge (K), attitude (A), practice (P), and knowledge-attitude-practice sum (KAP) scores were 14.4, 6.3, 13.2, and 33.9, respectively. The mean of knowledge scores were significantly higher in mothers who responded positively for germs (13.4 versus 12.6) and dirty hands (13.7 versus 13.0) as causes of diarrhea. Mothers with education had significantly higher knowledge (14.7 versus 14.2) and attitude scores (6.6 versus 6.1) in management of diarrhea. However, the study found a low use rate (4%) of oral rehydration solution in practice. Multiple linear regression analysis revealed that maternal age was positively associated with practice (beta = 0.061) and KAP scores (beta = 0.102). The number of children in the family was positively correlated with attitude scores (beta = 0.408). Socioeconomic status was positively associated. with attitude (beta = 0.549), practice (beta = 0.841), and KAP scores (beta = 1.887).
   Conclusions: The mothers have high knowledge scores in the management of diarrhea; however, use of oral rehydration solution is low among children with diarrhea under the age of 5 y in the Gambia. Higher maternal age and socioeconomic status are correlated with higher practice and ICAP scores. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Sillah, Famara; Ho, Hsin-Jung; Chao, Jane C-J] Taipei Med Univ, Coll Publ Hlth & Nutr, Sch Nutr & Hlth Sci, Taipei, Taiwan.
   [Sillah, Famara] Minist Hlth & Social Welf, Banjul, Gambia.
   [Chao, Jane C-J] Taipei Med Univ, Coll Publ Hlth & Nutr, Master Program Global Hlth & Dev, Taipei, Taiwan.
   [Chao, Jane C-J] Taipei Med Univ Hosp, Nutr Res Ctr, Taipei, Taiwan.
RP Chao, JCJ (reprint author), Taipei Med Univ, Coll Publ Hlth & Nutr, Sch Nutr & Hlth Sci, Taipei, Taiwan.
EM chenjui@tmu.edu.tw
CR Adimora GN, 2011, NIGER J CLIN PRACT, V14, P237, DOI 10.4103/1119-3077.84028
   All M, 2000, J HEALTH POPUL NUTR, V18, P103
   Anidi I, 2002, AMBUL PEDIATR, V2, P201, DOI 10.1367/1539-4409(2002)002<0201:KAMODA>2.0.CO;2
   Bachrach Lela Rose, 2002, Rev Panam Salud Publica, V12, P37, DOI 10.1590/S1020-49892002000700006
   Cezard JP, 2007, ARCH PEDIATRIE, V14, pS169, DOI 10.1016/S0929-693X(07)80023-6
   Datta Vikram, 2001, Indian Journal of Pediatrics, V68, P1035, DOI 10.1007/BF02722350
   Delgado Mario Francisco, 2006, Colomb. Med., V37, P293
   Duggan C, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.3.e29
   Duggan C, 1992, MMWR Recomm Rep, V41, P1
   Ellis AA, 2007, SOC SCI MED, V64, P701, DOI 10.1016/j.socscimed.2006.10.011
   Greenbau LA, 2003, NELSON TXB PEDIAT, P249
   Kaltenthaler EC, 1996, J DIARRHOEAL DIS RES, V14, P75
   Keusch GT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P371
   KOHLI KL, 1983, J BIOSOC SCI, V15, P339
   MacDonald SE, 2007, ASIA-PAC J PUBLIC HE, V19, P34, DOI 10.1177/10105395070190010701
   Maqbool A, 1999, PAK PAED J, V23, P5
   MCDIVITT JA, 1994, SOC SCI MED, V38, P1221, DOI 10.1016/0277-9536(94)90187-2
   Mustapha MG, 2008, NIGERIAN MED J, V49, P5
   Ogunrinde OG, 2012, J TROP PEDIATRICS, V58, P143, DOI 10.1093/tropej/fmr048
   Olusanya O, 1985, W AFR J MED, V4, P205
   PICKERING H, 1987, T ROY SOC TROP MED H, V81, P853, DOI 10.1016/0035-9203(87)90052-6
   Rashid J, 2005, ANN KING EDWARD MED, V11, P10
   RATNAIKE RN, 1988, EUR J EPIDEMIOL, V4, P451, DOI 10.1007/BF00146397
   ROWLAND MGM, 1988, AM J CLIN NUTR, V47, P134
   Seyal T, 2009, ANN KING EDWARD MED, V15, P38
   Shah M. S., 2011, Biology and Medicine, V3, P76
   Sultana A, 2010, J RAWALPINDI MED COL, V14, P109
   The United Nations Children's Fund (UNICEF)/World Health Organization (WHO), 2009, DIARRH WHY CHILDR AR, P4
   Victora CG, 2000, B WORLD HEALTH ORGAN, V78, P1246
   Fischer Walker CL, 2012, BMC PUBLIC HEALTH, V12, P220, DOI [10.1186/1471-2458-12-220, DOI 10.1186/1471-2458-12-220]
   WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804
   Webb AL, 2010, MATERN CHILD HLTH J, V14, P799, DOI 10.1007/s10995-009-0510-1
   Yilgwan Christopher S, 2012, Ann Afr Med, V11, P217, DOI 10.4103/1596-3519.102852
NR 33
TC 7
Z9 7
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD NOV-DEC
PY 2013
VL 29
IS 11-12
BP 1368
EP 1373
DI 10.1016/j.nut.2013.05.014
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 241BW
UT WOS:000326142400016
PM 24103515
OA No
DA 2017-08-15
ER

PT J
AU Afolabi, MO
   Ndure, J
   Drammeh, A
   Darboe, F
   Mehedi, SR
   Rowland-Jones, SL
   Borthwick, N
   Black, A
   Ambler, G
   John-Stewart, GC
   Reilly, M
   Hanke, T
   Flanagan, KL
AF Afolabi, Muhammed O.
   Ndure, Jorjoh
   Drammeh, Abdoulie
   Darboe, Fatoumatta
   Mehedi, Shams-Rony
   Rowland-Jones, Sarah L.
   Borthwick, Nicola
   Black, Antony
   Ambler, Gwen
   John-Stewart, Grace C.
   Reilly, Marie
   Hanke, Tomas
   Flanagan, Katie L.
TI A Phase I Randomized Clinical Trial of Candidate Human Immunodeficiency
   Virus type 1 Vaccine MVA.HIVA Administered to Gambian Infants
SO PLOS ONE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; TO-CHILD TRANSMISSION; EXPRESSING HIV-1
   GAG; PRIME-BOOST REGIMEN; CLADE-A VACCINE; HIV-1-INFECTED WOMEN; ANKARA
   MVA; AFRICAN CHILDREN; RECOMBINANT BCG; CELL RESPONSES
AB Background: A vaccine to decrease transmission of human immunodeficiency virus type 1 (HIV-1) during breast-feeding would complement efforts to eliminate infant HIV-1 infection by antiretroviral therapy. Relative to adults, infants have distinct immune development, potentially high-risk of transmission when exposed to HIV-1 and rapid progression to AIDS when infected. To date, there have been only three published HIV-1 vaccine trials in infants.
   Trial Design: We conducted a randomized phase I clinical trial PedVacc 001 assessing the feasibility, safety and immunogenicity of a single dose of candidate vaccine MVA.HIVA administered intramuscularly to 20-week-old infants born to HIV-1-negative mothers in The Gambia.
   Methods: Infants were followed to 9 months of age with assessment of safety, immunogenicity and interference with Expanded Program on Immunization (EPI) vaccines. The trial is the first stage of developing more complex prime-boost vaccination strategies against breast milk transmission of HIV-1.
   Results: From March to October 2010, 48 infants (24 vaccine and 24 no-treatment) were enrolled with 100% retention. The MVA.HIVA vaccine was safe with no difference in adverse events between vaccinees and untreated infants. Two vaccine recipients (9%) and no controls had positive ex vivo interferon-gamma ELISPOT assay responses. Antibody levels elicited to the EPI vaccines, which included diphtheria, tetanus, whole-cell pertussis, hepatitis B virus, Haemophilus influenzae type b and oral poliovirus, reached protective levels for the vast majority and were similar between the two arms.
   Conclusions: A single low-dose of MVA.HIVA administered to 20-week-old infants in The Gambia was found to be safe and without interference with the induction of protective antibody levels by EPI vaccines, but did not alone induce sufficient HIV-1-specific responses. These data support the use of MVA carrying other transgenes as a boosting vector within more complex prime-boost vaccine strategies against transmission of HIV-1 and/or other infections in this age group.
   Trial Registration: ClinicalTrials.gov NCT00982579 The Pan African Clinical Trials Registry PACTR2008120000904116
C1 [Afolabi, Muhammed O.; Ndure, Jorjoh; Drammeh, Abdoulie; Darboe, Fatoumatta; Flanagan, Katie L.] MRC Unit, Fajara, Gambia.
   [Mehedi, Shams-Rony] MRC Unit, Stat & Data Management Dept, Fajara, Gambia.
   [Rowland-Jones, Sarah L.] Univ Oxford, Jenner Inst, Oxford, England.
   [Borthwick, Nicola; Black, Antony; Ambler, Gwen; John-Stewart, Grace C.; Hanke, Tomas] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Borthwick, Nicola; Black, Antony; Ambler, Gwen; John-Stewart, Grace C.; Hanke, Tomas] Univ Washington, Dept Med, Seattle, WA USA.
   [Borthwick, Nicola; Black, Antony; Ambler, Gwen; John-Stewart, Grace C.; Hanke, Tomas] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Reilly, Marie] Dept Med Epidemiol & Biostat, Stockholm, Sweden.
RP Hanke, T (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
EM tomas.hanke@ndm.ox.ac.uk
OI Afolabi, Muhammed/0000-0002-9967-6419
FU European and Developing Countries Clinical Trials Partnership (EDCTP)
   [CT.2006.33111.002]; MRC UK; SIDA (Swedish International Development
   Cooperation Agency)
FX This work was supported by the European and Developing Countries
   Clinical Trials Partnership (EDCTP; CT.2006.33111.002) with co-funding
   from MRC UK and SIDA (Swedish International Development Cooperation
   Agency). The MRC Unit in The Gambia provided the infrastructure to
   perform the study, which was sponsored by MRC UK. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Adetifa IMO, 2009, INT J LAB HEMATOL, V31, P615, DOI 10.1111/j.1751-553X.2008.01087.x
   Bejon P, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010029
   Borkowsky W, 2000, J INFECT DIS, V181, P890, DOI 10.1086/315298
   Borthwick N, 2012, IMMUNOGENICITY UNIVE
   Buchanan AM, 2010, TROP MED INT HEALTH, V15, P1011, DOI 10.1111/j.1365-3156.2010.02585.x
   Cebere I, 2006, VACCINE, V24, P417, DOI 10.1016/j.vaccine.2005.08.041
   Chapman R, 2010, CURR HIV RES, V8, P282
   Coutsoudis A, 2004, J INFECT DIS, V189, P2154
   Cunningham CK, 2001, CLIN INFECT DIS, V32, P801, DOI 10.1086/319215
   Dorrell L, 2006, J VIROL, V80, P4705, DOI 10.1128/JVI.80.10.4705-4716.2006
   Dorrell L, 2005, AIDS, V19, P1321, DOI 10.1097/01.aids.0000180104.65640.16
   Dorrell L, 2007, VACCINE, V25, P3277, DOI 10.1016/j.vaccine.2007.01.005
   Eggers M, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-347
   Goonetilleke N, 2006, J VIROL, V80, P4717, DOI 10.1128/JVI.80.10.4717-4728.2006
   Hanke T, 2000, NAT MED, V6, P951, DOI 10.1038/79626
   Hanke T, 2003, J GEN VIROL, V84, P361, DOI 10.1099/vir.0.18738-0
   Hanke T, 2007, J GEN VIROL, V88, P1, DOI 10.1099/vir.0.82493-0
   Hanke T, 2011, EUR J IMMUNOL, V41, P3390, DOI 10.1002/eji.201190072
   Hicar MD, 2013, CURR HIV RES, V11, P137, DOI 10.2174/1570162X11311020006
   Hopkins R, 2011, EUR J IMMUNOL, V41, P3542, DOI 10.1002/eji.201141962
   Hopkins R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020067
   Im EJ, 2007, J VIROL, V81, P9408, DOI 10.1128/JVI.00707-07
   Im Eung-Jun, 2004, Expert Rev Vaccines, V3, pS89, DOI 10.1586/14760584.3.4.S89
   JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0
   Jaoko W, 2008, VACCINE, V26, P2788, DOI 10.1016/j.vaccine.2008.02.071
   Johnson DC, 2005, J INFECT DIS, V192, P2129, DOI 10.1086/498163
   Joseph J, 2006, EXPERT REV VACCINES, V5, P827, DOI 10.1586/14760584.5.6.827
   Kintu K, 2013, JAIDS-J ACQ IMM DEF, V63, P1, DOI 10.1097/QAI.0b013e31827f1c2d
   Kourtis AP, 2007, AM J OBSTET GYNECOL, V197, pS113, DOI 10.1016/j.ajog.2007.03.003
   Letourneau S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000984
   Luzuriaga Katherine, 2002, AIDS Reviews, V4, P21
   MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375
   Mbori-Ngacha D, 2001, JAMA-J AM MED ASSOC, V286, P2413, DOI 10.1001/jama.286.19.2413
   McFarland EJ, 2001, J INFECT DIS, V184, P1331, DOI 10.1086/323994
   McFarland EJ, 2006, AIDS, V20, P1481, DOI 10.1097/01.aids.0000237363.33994.45
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   Miles DJC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002905
   Mo HM, 1998, AIDS RES HUM RETROV, V14, P607, DOI 10.1089/aid.1998.14.607
   Mwau M, 2004, J GEN VIROL, V85, P911, DOI 10.1099/vir.0.19701-0
   Ondondo BO, 2006, EUR J IMMUNOL, V36, P2585, DOI 10.1002/eji.200636508
   ONWUKEME KE, 1991, TROP GEOGR MED, V43, P171
   Ota M. O. C., 2011, SCI TRANSL MED, V3
   Peters BS, 2007, VACCINE, V25, P2120, DOI 10.1016/j.vaccine.2006.11.016
   Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
   Quinto L, 2006, TROP MED INT HEALTH, V11, P1741, DOI 10.1111/j.1365-3156.2006.01764.x
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Richardson BA, 2003, J VIROL, V77, P7120, DOI 10.1128/JVI.77.12.7120-7123.2003
   Rosario M, 2010, J VIROL, V84, P7815, DOI 10.1128/JVI.00726-10
   Rosario M, 2010, J VIROL, V84, P5898, DOI 10.1128/JVI.02607-09
   Rousseau CM, 2003, J INFECT DIS, V187, P741, DOI 10.1086/374273
   Saubi N, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/516219
   UNAIDS, 2012, REP GLOB AIDS EP 201
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2012, GLOB REP UNAIDS REP
   van Gageldonk PGM, 2008, J IMMUNOL METHODS, V335, P79, DOI 10.1016/j.jim.2008.02.018
   Winstone N, 2009, EUR J IMMUNOL, V39, P975, DOI 10.1002/eji.200839167
   Yang HB, 2007, J IMMUNOL, V179, P597
   Young SL, 2011, ADV NUTR, V2, P225, DOI 10.3945/an.110.000224
NR 58
TC 9
Z9 10
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2013
VL 8
IS 10
AR e78289
DI 10.1371/journal.pone.0078289
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 241FR
UT WOS:000326152300047
PM 24205185
OA gold
DA 2017-08-15
ER

PT J
AU Gehre, F
   Antonio, M
   Faihun, F
   Odoun, M
   Uwizeye, C
   de Rijk, P
   de Jong, BC
   Affolabi, D
AF Gehre, Florian
   Antonio, Martin
   Faihun, Frank
   Odoun, Mathieu
   Uwizeye, Cecile
   de Rijk, Pim
   de Jong, Bouke C.
   Affolabi, Dissou
TI The First Phylogeographic Population Structure and Analysis of
   Transmission Dynamics of M. africanum West African 1-Combining Molecular
   Data from Benin, Nigeria and Sierra Leone
SO PLOS ONE
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS COMPLEX; GENETIC DIVERSITY; MIRU-VNTRPLUS;
   STRAINS; IDENTIFICATION; EPIDEMIOLOGY; BACTERIA; CAMEROON; LINEAGE;
   BACILLI
AB Mycobacterium africanum is an important cause of tuberculosis (TB) in West Africa. So far, two lineages called M. africanum West African 1 (MAF1) and M. africanum West African 2 (MAF2) have been defined. Although several molecular studies on MAF2 have been conducted to date, little is known about MAF1. As MAF1 is mainly present in countries around the Gulf of Guinea we aimed to estimate its prevalence in Cotonou, the biggest city in Benin. Between 2005-06 we collected strains in Cotonou/Benin and genotyped them using spoligo- and 12-loci-MIRU-VNTR-typing. Analyzing 194 isolates, we found that 31% and 6% were MAF1 and MAF2, respectively. Therefore Benin is one of the countries with the highest prevalence (37%) of M. africanum in general and MAF1 in particular. Moreover, we combined our data from Benin with publicly available genotyping information from Nigeria and Sierra Leone, and determined the phylogeographic population structure and genotypic clustering of MAF1. Within the MAF1 lineage, we identified an unexpected great genetic variability with the presence of at least 10 sub-lineages. Interestingly, 8 out of 10 of the discovered sub-lineages not only clustered genetically but also geographically. Besides showing a remarkable local restriction to certain regions in Benin and Nigeria, the sub-lineages differed dramatically in their capacity to transmit within the human host population. While identifying Benin as one of the countries with the highest overall prevalence of M. africanum, this study also contains the first detailed description of the transmission dynamics and phylogenetic composition of the MAF1 lineage.
C1 [Gehre, Florian; Antonio, Martin; de Jong, Bouke C.] MRC Unit, Fajara, Gambia.
   [Gehre, Florian; Uwizeye, Cecile; de Rijk, Pim; de Jong, Bouke C.] Inst Trop Med, B-2000 Antwerp, Belgium.
   [de Jong, Bouke C.] NYU, New York, NY USA.
   [Faihun, Frank; Odoun, Mathieu; Affolabi, Dissou] Lab Reference Mycobacteries, Cotonou, Benin.
RP Gehre, F (reprint author), MRC Unit, Fajara, Gambia.
EM fgehre@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU Belgian Directorate-Generale for Development Co-orporation (DGDC) as
   part of the "Strategic Network TB 3.14"; project "Study on M. africanum
   population structure in Benin and The Gambia"; European Developing
   Countries Clinical Trials Partnership (EDCTP)
FX The study was supported by a grant from the Belgian Directorate-Generale
   for Development Co-orporation (DGDC) as part of the "Strategic Network
   TB 3.14" and the project "Study on M. africanum population structure in
   Benin and The Gambia" as well as by the European Developing Countries
   Clinical Trials Partnership (EDCTP) - funded "West African Node of
   Excellence for Tuberculosis and Malaria" (WANETAM-plus). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Affolabi D, 2009, INT J TUBERC LUNG D, V13, P317
   Allix-Beguec C, 2008, J CLIN MICROBIOL, V46, P2692, DOI 10.1128/JCM.00540-08
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299
   Comas I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007815
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   de Jong BC, 2005, AIDS, V19, P1714, DOI 10.1097/01.aids.0000185991.54595.41
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   de Jong BC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000744
   Glynn JR, 1999, AM J EPIDEMIOL, V149, P366
   Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x
   Groenheit R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018601
   Hill V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041991
   Homolka S, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-103
   HUET M, 1971, Revue de Tuberculose et de Pneumologie, V35, P413
   Koro FK, 2013, J CLIN MICROBIOL, V51, P299, DOI 10.1128/JCM.01196-12
   Lawson L, 2012, PLOS ONE, V7
   Niobe-Eyangoh SN, 2003, J CLIN MICROBIOL, V41, P2547, DOI 10.1128/JCM.41.6.2547-2553.2003
   Ouassa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045363
   Shabbeer A, 2012, INFECT GENET EVOL, V12, P789, DOI 10.1016/j.meegid.2012.02.010
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402
   Thumamo BP, 2012, INFECT GENET EVOL, V12, P671, DOI 10.1016/j.meegid.2011.08.011
   Weniger T, 2010, NUCLEIC ACIDS RES, V38, pW326, DOI 10.1093/nar/gkq351
   Yeboah-Manu D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021906
NR 23
TC 8
Z9 8
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2013
VL 8
IS 10
AR e77000
DI 10.1371/journal.pone.0077000
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 237TP
UT WOS:000325894100033
PM 24143198
OA gold
DA 2017-08-15
ER

PT J
AU Gehre, F
   Antonio, M
   Otu, JK
   Sallah, N
   Secka, O
   Faal, T
   Owiafe, P
   Sutherland, JS
   Adetifa, IM
   Ota, MO
   Kampmann, B
   Corrah, T
   de Jong, BC
AF Gehre, Florian
   Antonio, Martin
   Otu, Jacob K.
   Sallah, Neneh
   Secka, Oumie
   Faal, Tutty
   Owiafe, Patrick
   Sutherland, Jayne S.
   Adetifa, Ifedayo M.
   Ota, Martin O.
   Kampmann, Beate
   Corrah, Tumani
   de Jong, Bouke C.
TI Immunogenic Mycobacterium africanum Strains Associated with Ongoing
   Transmission in The Gambia
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID TUBERCULOSIS COMPLEX; EPIDEMIOLOGY; DIFFERENTIATION; CLASSIFICATION;
   SPOLIGOTYPES; DIAGNOSIS; ASSAY
AB In West Africa, Mycobacterium tuberculosis strains co-circulate with M. africanum, and both pathogens cause pulmonary tuberculosis in humans. Given recent findings that M. tuberculosis T-cell epitopes are hyperconserved, we hypothesized that more immunogenic strains have increased capacity to spread within the human host population. We investigated the relationship between the composition of the mycobacterial population in The Gambia, as measured by spoligotype analysis, and the immunogenicity of these strains as measured by purified protein derivative-induced interferon-gamma release in ELISPOT assays of peripheral blood mononuclear cells. We found a positive correlation between strains with superior spreading capacity and their relative immunogenicity. Although our observation is true for M. tuberculosis and M. africanum strains, the association was especially pronounced in 1 M. africanum sublineage, characterized by spoligotype shared international type 181, which is responsible for 20% of all tuberculosis cases in the region and therefore poses a major public health threat in The Gambia.
C1 [Gehre, Florian; Antonio, Martin; Otu, Jacob K.; Sallah, Neneh; Secka, Oumie; Faal, Tutty; Owiafe, Patrick; Sutherland, Jayne S.; Adetifa, Ifedayo M.; Ota, Martin O.; Kampmann, Beate; Corrah, Tumani; de Jong, Bouke C.] MRC Unit, Fajara, Gambia.
   [Gehre, Florian; de Jong, Bouke C.] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, London, England.
   [de Jong, Bouke C.] NYU, New York, NY USA.
RP Gehre, F (reprint author), Inst Trop Med, Mycobacteria Unit, Natl Str 155, B-2000 Antwerp, Belgium.
EM fgehre@itg.be
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; Kampmann, Beate/0000-0002-6546-4709;
   Kwasi Owiafe, Patrick/0000-0002-4287-3577; Sutherland,
   Jayne/0000-0002-7083-4997
FU Flemish Science Foundation
FX F.G. was supported by a "Travel Grant for a long stay abroad," awarded
   by the Flemish Science Foundation.
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23
   Castets M, 1968, Rev Tuberc Pneumol (Paris), V32, P179
   Comas I, 2010, NAT GENET, V42, P498, DOI 10.1038/ng.590
   Comas I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007815
   de Jong BC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000744
   de Jong BC, 2009, J CLIN MICROBIOL, V47, P994, DOI 10.1128/JCM.01216-08
   Groenheit R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018601
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   Kulldorff M, 1997, COMMUN STAT-THEOR M, V26, P1481, DOI 10.1080/03610929708831995
   Reyes JF, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-496
   Shabbeer A, 2012, INFECT GENET EVOL, V12, P789, DOI 10.1016/j.meegid.2012.02.010
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402
   Tanaka MM, 2006, P NATL ACAD SCI USA, V103, P15266, DOI 10.1073/pnas.0603130103
   Tang C, 2008, BIOINFORMATICS, V24, P2414, DOI 10.1093/bioinformatics/btn434
   Uplekar S, 2011, INFECT IMMUN, V79, P4042, DOI 10.1128/IAI.05344-11
   VANSOOLINGEN D, 1993, J CLIN MICROBIOL, V31, P1987
   World Health Organization, 2011, GLOB TUB CONTR 2011
NR 20
TC 8
Z9 8
U1 0
U2 2
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD OCT
PY 2013
VL 19
IS 10
BP 1598
EP 1604
DI 10.3201/eid1910.121023
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 268MC
UT WOS:000328173900006
PM 24050158
OA gold
DA 2017-08-15
ER

PT J
AU Hong, NV
   van den Eede, P
   Van Overmeir, C
   Vythilingham, I
   Rosanas-Urgell, A
   Thanh, PV
   Thang, ND
   Hung, NM
   Hung, LX
   D'Alessandro, U
   Erhart, A
AF Nguyen Van Hong
   van den Eede, Peter
   Van Overmeir, Chantal
   Vythilingham, Indra
   Rosanas-Urgell, Anna
   Pham Vinh Thanh
   Ngo Duc Thang
   Nguyen Manh Hung
   Le Xuan Hung
   D'Alessandro, Umberto
   Erhart, Annette
TI Short Report: A Modified Semi-Nested Multiplex Malaria PCR (SnM-PCR) for
   the Identification of the Five Human Plasmodium Species Occurring in
   Southeast Asia
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID KNOWLESI INFECTIONS; PARASITE
AB We have modified an existing semi-nested multiplex polymerase chain reaction (PCR) by adding one Plasmodium knowlesi-specific nested PCR, and validated the latter against laboratory and clinical samples. This new method has the advantage of being relatively affordable in low resource settings while identifying the five human Plasmodium species with a three-step PCR.
C1 [Nguyen Van Hong] Natl Inst Malariol Parasitol & Entomol, Dept Clin Res, Hanoi, Vietnam.
   [Erhart, Annette] Inst Trop Med, Malariol Unit, B-2000 Antwerp, Belgium.
   [Vythilingham, Indra] Univ Malaya, Fac Med, Dept Parasitol, Kuala Lumpur, Malaysia.
   IMR, Infect Dis Res Ctr, Parasitol Unit, Kuala Lumpur, Malaysia.
   Med Res Unit, Fajara, Gambia.
   [Pham Vinh Thanh; Ngo Duc Thang; Nguyen Manh Hung; Le Xuan Hung] Natl Inst Malariol Parasitol & Entomol, Dept Epidemiol, Hanoi, Vietnam.
RP Erhart, A (reprint author), Inst Trop Med, Malariol Unit, Natl Str 155, B-2000 Antwerp, Belgium.
EM nvhong1982@yahoo.com; petervandeneede@gmail.com; cvoverm@itg.be;
   Indra.vythilingham@gmail.com; arosanas@itg.be; phamvinht@gmail.com;
   thangnimpevn@yahoo.com; drmanhhung@gmail.com; xuanhungvsr@yahoo.com;
   udalessandro@mrc.gm; aerhart@itg.be
RI D'Alessandro, Umberto/D-3457-2015; Vythilingam, Indra/Q-5019-2016
OI D'Alessandro, Umberto/0000-0001-6341-5009; 
FU UBS Optimus Foundation; Belgian Cooperation within the Framework
   Agreement III
FX This study was financed by the UBS Optimus Foundation and the Belgian
   Cooperation within the Framework Agreement III.
CR Babady NE, 2009, AM J TROP MED HYG, V81, P516
   Chew CH, 2012, J CLIN MICROBIOL, V50, P4012, DOI 10.1128/JCM.06454-11
   Cox-Singh J, 2008, TRENDS PARASITOL, V24, P406, DOI 10.1016/j.pt.2008.06.001
   Cox-Singh J, 2008, CLIN INFECT DIS, V46, P165, DOI 10.1086/524888
   Divis PCS, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-344
   Imwong M, 2009, J CLIN MICROBIOL, V47, P4173, DOI 10.1128/JCM.00811-09
   Iseki H, 2010, J CLIN MICROBIOL, V48, P2509, DOI 10.1128/JCM.00331-10
   Lucchi NW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031848
   Ministry of Health, 2012, INTERNAL REPORT
   Hong Nguyen V, 2012, AM J TROP MED HYG, V87, P989
   Rubio J M, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS199, DOI 10.1016/S0035-9203(02)90077-5
   Singh B, 2004, LANCET, V363, P1017, DOI 10.1016/S0140-6736(04)15836-4
   Van den Eede P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-249
   Vythilingam I, 2008, PARASITE VECTOR, V1, DOI 10.1186/1756-3305-1-26
   White NJ, 2008, CLIN INFECT DIS, V46, P172, DOI 10.1086/524889
NR 15
TC 0
Z9 1
U1 0
U2 8
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2013
VL 89
IS 4
BP 721
EP 723
DI 10.4269/ajtmh.13-0027
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 240UB
UT WOS:000326122100017
OA No
DA 2017-08-15
ER

PT J
AU Goldberg, GR
   Jarjou, LMA
   Cole, TJ
   Prentice, A
AF Goldberg, Gail R.
   Jarjou, Landing M. A.
   Cole, Tim J.
   Prentice, Ann
TI Randomized, placebo-controlled, calcium supplementation trial in
   pregnant Gambian women accustomed to a low calcium intake: effects on
   maternal blood pressure and infant growth
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID ENERGY-EXPENDITURE; BIRTH-WEIGHT; BREAST-MILK; RISK; PREECLAMPSIA;
   HYPERTENSION; PREVALENCE; LACTATION; MORTALITY; METABOLISM
AB Background: Dietary calcium intake in rural Gambian women is very low (similar to 350 mg/d) compared with international recommendations. Studies have suggested that calcium supplementation of women receiving low-calcium diets significantly reduces risk of pregnancy hypertension.
   Objective: We tested the effects on blood pressure (BP) of calcium carbonate supplementation (1500 mg Ca/d) in pregnant, rural Gambian women.
   Design: The study was a randomized, double-blind, parallel, placebo-controlled supplementation trial from 20 wk of gestation (P20) until delivery (calcium: n = 330; placebo; n = 332). BP and anthropometric measures were taken at P20 and then 4 weekly until 36 wk of gestation (P36), and infant anthropometric measures were taken at 2, 13, and 52 wk postdelivery.
   Results: A total of 525 (calcium: n = 260; placebo: n = 265) women had BP measured at P36 and subsequently delivered a healthy term singleton infant. Mean compliance was 97%, and urinary calcium measures confirmed the group allocation. At P20, the mean (+/- SD) systolic blood pressure (SBP) was 101.2 +/- 9.0 and 102.1 +/- 9.3 mm Hg, and diastolic blood pressure (DBP) was 54.5 +/- 7.3 and 55.8 +/- 7.8 mm Hg, in the calcium and placebo groups, respectively. The intention-to-treat analysis that was adjusted for confounders showed no significant effect of calcium supplementation on the change between P20 and P36 (calcium compared with placebo; mean 6 SEM) in SBP (-0.64 +/- 0.65%; P = 0.3) or DBP (-0.22 +/- 1.15%; P = 0.8). There was no significant effect of supplementation on BP, pregnancy weight gain, weight postpartum, or infant weight, length, and other measures of growth. However, the comparability of the original randomly assigned groups may have been compromised by the exclusion of 20.7% of women from the final analysis.
   Conclusions: Calcium supplementation did not affect BP in pregnancy. This result may have been because the Gambian women were adapted to a low dietary calcium intake, and/or obesity, high gestational weight gain, high underlying BP, tobacco use, alcohol consumption, and sedentary lifestyles were rare. This trial was registered at the International Standard Randomized Controlled Trial Register (www.controlled-trials.com/mrct/) as ISRCTN96502494.
C1 [Goldberg, Gail R.; Prentice, Ann] Med Res Council Human Nutr Res, Cambridge CB1 9NL, England.
   [Goldberg, Gail R.; Jarjou, Landing M. A.] MRC, Keneba, Gambia.
   [Cole, Tim J.] UCL, Inst Child Hlth, Ctr Epidemiol Child Hlth, Med Res Council, London, England.
RP Goldberg, GR (reprint author), Med Res Council Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM gail.goldberg@mrc-hnr.cam.ac.uk
RI Cole, Tim/B-7883-2008
OI Cole, Tim/0000-0001-5711-8200
FU UK Medical Research Council (MRC) [U105960371, U123261351,
   MR/J004839/1]; MRC; Department for International Development (DFID)
FX Supported by the UK Medical Research Council (MRC) under programs
   U105960371, U123261351, and MR/J004839/1. This research is jointly
   funded by the MRC and the Department for International Development
   (DFID) under the MRC/DFID Concordat agreement. Shire Pharmaceuticals and
   Nycomed Pharma donated calcium and placebo tablets. This is an open
   access article distributed under the CC-BY license
   (http://creativecommons.org/licenses/by/3.0/).
CR BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002
   BELIZAN JM, 1983, AM J OBSTET GYNECOL, V146, P175
   Buppasiri P, 2011, COCHRANE DB SYST REV, V10
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F
   Darwish AM, 2009, J OBSTET GYNAECOL RE, V35, P106, DOI 10.1111/j.1447-0756.2008.00879.x
   Department of Health, 1998, NUTR BON HLTH PART R
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Finch S, 1998, NATL DIET NUTR SURVE
   Foord F., 1993, WHO GAMBIA DNU MRC S
   Friedman B, 1997, LANCET, V350, P217, DOI 10.1016/S0140-6736(05)62383-5
   Hoestermann CFL, 1996, TROP MED INT HEALTH, V1, P710
   Hofmeyr GJ, 2010, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD001059.PUB3
   IOM (Institute of Medicine), 2011, DIETARY REFERENCE IN
   Jarjou LMA, 2012, EUR J CLIN NUTR, V66, P673, DOI 10.1038/ejcn.2012.7
   Jarjou LMA, 2010, AM J CLIN NUTR, V92, P450, DOI 10.3945/ajcn.2010.29217
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   KNIGHT KB, 1992, AM J CLIN NUTR, V55, P891
   Koo Winston, 2012, Evid Based Med, V17, P186, DOI 10.1136/ebmed-2012-100778
   Kumar A, 2009, INT J GYNECOL OBSTET, V104, P32, DOI 10.1016/j.ijgo.2008.08.027
   LAWRENCE M, 1988, EUR J CLIN NUTR, V42, P145
   Li DK, 2000, AM J EPIDEMIOL, V151, P57
   LOPEZJARAMILLO P, 1989, BRIT J OBSTET GYNAEC, V96, P648, DOI 10.1111/j.1471-0528.1989.tb03278.x
   LopezJaramillo P, 1997, OBSTET GYNECOL, V90, P162, DOI 10.1016/S0029-7844(97)00254-8
   LOPEZJARAMILLO P, 1990, LANCET, V335, P293, DOI 10.1016/0140-6736(90)90112-I
   Luo ZC, 2007, PAEDIATR PERINAT EP, V21, P36, DOI 10.1111/j.1365-3016.2007.00836.x
   MARCOUX S, 1991, AM J EPIDEMIOL, V133, P1266
   MARGETTS BM, 1991, INT J EPIDEMIOL, V20, P938, DOI 10.1093/ije/20.4.938
   Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3
   OBrien E, 1997, LANCET, V349, P1026, DOI 10.1016/S0140-6736(05)62926-1
   Oelman B, 1993, MATERNAL MORTALITY G
   POPPITT SD, 1994, AM J OBSTET GYNECOL, V171, P118
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   Prentice A, 1998, J CLIN ENDOCR METAB, V83, P1059, DOI 10.1210/jc.83.4.1059
   PRENTICE A, 1987, HUM NUTR-CLIN NUTR, V41C, P319
   Prentice AM, 1996, EUR J CLIN NUTR, V50, pS82
   Prentice A, 2006, AM J CLIN NUTR, V84, P944
   Purwar M, 1996, J Obstet Gynaecol Res, V22, P425
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   REPKE JT, 1989, AM J OBSTET GYNECOL, V160, P684
   Roberts JM, 2003, HYPERTENSION, V41, P437, DOI 10.1161/01.HYP.0000054981.03589.E9
   SINGH J, 1989, BRIT J NUTR, V62, P315, DOI 10.1079/BJN19890033
   Tubbergen P, 1999, J REPROD IMMUNOL, V45, P81, DOI 10.1016/S0165-0378(99)00040-6
   van der Sande MAB, 2001, J HUM HYPERTENS, V15, P733, DOI 10.1038/sj.jhh.1001259
   van der Sande MAB, 2000, J HUM HYPERTENS, V14, P489, DOI 10.1038/sj.jhh.1001050
   vanderSande MAB, 1997, TROP MED INT HEALTH, V2, P1039, DOI 10.1046/j.1365-3156.1997.d01-184.x
   Villar J, 2006, AM J OBSTET GYNECOL, V194, P639, DOI 10.1016/j.ajog.2006.01.068
   VILLAR J, 1987, OBSTET GYNECOL, V70, P317
   VILLAR J, 1983, INT J GYNECOL OBSTET, V21, P271, DOI 10.1016/0020-7292(83)90016-4
   Villar J, 2003, PREECLAMPSIA, P57
   World Health Organization, 2012, WORLD HLTHS TAT 2012
   Wosje KS, 2004, AM J CLIN NUTR, V80, P423
   Xu HR, 2009, NUTR REV, V67, P639, DOI 10.1111/j.1753-4887.2009.00249.x
   Yan LY, 2009, BONE, V45, P238, DOI 10.1016/j.bone.2009.04.237
NR 55
TC 8
Z9 9
U1 1
U2 21
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT
PY 2013
VL 98
IS 4
BP 972
EP 982
DI 10.3945/ajcn.113.059923
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 221YF
UT WOS:000324696100015
PM 24004887
OA No
DA 2017-08-15
ER

PT J
AU Sighoko, D
   Kamate, B
   Traore, C
   Malle, B
   Coulibaly, B
   Karidiatou, A
   Diallo, C
   Bah, E
   McCormack, V
   Muwonge, R
   Bourgeois, D
   Gormally, E
   Curado, MP
   Bayo, S
   Hainaut, P
AF Sighoko, Dominique
   Kamate, Bakarou
   Traore, Cheick
   Malle, Brahima
   Coulibaly, Bourama
   Karidiatou, Agnes
   Diallo, Coulibaly
   Bah, Ebrima
   McCormack, Valerie
   Muwonge, Richard
   Bourgeois, Denis
   Gormally, Emmanuelle
   Curado, Maria Paula
   Bayo, Sine
   Hainaut, Pierre
TI Breast cancer in pre-menopausal women in West Africa: Analysis of
   temporal trends and evaluation of risk factors associated with
   reproductive life
SO BREAST
LA English
DT Article
DE Breast cancer; Trends; Africa; Risk factors; Menopausal status;
   Population-based cancer registry
ID BRITISH BLACK-WOMEN; HORMONE-RECEPTOR; DEVELOPING-COUNTRIES;
   EARLY-ONSET; SUBTYPES; NIGERIA; FEMALE; EXPRESSION; ESTROGEN; GAMBIA
AB Background: In West Africa, trends and risk factors for breast cancer (BC) have been rarely studied.
   Methods: Here we have analyzed trends of BC over two periods in two population-based cancer registries, in Mali-Bamako (1987-1997; 1998-2009) and in The Gambia (1988-1997; 1998-2006). We have conducted a case-control study (n = 253 cases, 249 controls) on risk factors associated with reproductive life stratified by menopausal status in Bamako.
   Results: Between the two periods, BC incidence rates increased by 20% (incidence rate ratio (IRR) 1.20 (95% CI [1.07-1.35])) in Bamako, with an annual percentage change of 2% (95% CI [0.4-3.6]). The increase was of 30% in women under 55 years (IRR 1.30 (95% CI [1.14-1.60])). A similar pattern was observed in The Gambia for women under 50 years (IRR 1.47 (95% CI [1.07-2.01])). Overall, pre-menopausal breast cancer was predominant in both countries. In contrary to what is well established, case-control study showed that late age at menarche (>14 years) increased the risk of BC among pre-menopausal women (OR: 2.02 (95% CI [1.08-3.78])) while it tended to be protective in post-menopausal women (OR: 0.61 (95% CI [0.29-1.29])). Later age at a first pregnancy (>20 years) was associated with a reduction of risk in pre-menopausal women (OR: 0.41 (95% CI [0.18-0.89])).
   Conclusion: These results indicate that the burden of pre-menopausal BC is increasing in West African countries. These cancers appear to be associated with distinct reproductive risk factors, highlighting the need for better understanding the biological bases of early BC in African populations. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Sighoko, Dominique; Bah, Ebrima; McCormack, Valerie; Muwonge, Richard; Hainaut, Pierre] Int Agcy Res Canc, F-69372 Lyon 08, France.
   [Kamate, Bakarou; Traore, Cheick; Malle, Brahima; Coulibaly, Bourama; Karidiatou, Agnes; Diallo, Coulibaly; Bayo, Sine] Univ Hosp Point G, Dept Pathol Anat & Cytol, Bamako, Mali.
   [Bah, Ebrima] Gambia Hepatitis Intervent Study, Banjul, Gambia.
   [Sighoko, Dominique; Bourgeois, Denis] Univ Lyon 1, Lab Sci Complex Decis & Hlth Policy, F-69365 Lyon, France.
   [Gormally, Emmanuelle] Catholic Univ Lyon, Fac Sci, Lyon, France.
RP Hainaut, P (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
EM pierre.hainaut@i-pri.org
RI Hainaut, Pierre /B-6018-2012; Muwonge, Richard/P-6375-2015; Curado,
   Maria Paula/M-6200-2013
OI Hainaut, Pierre /0000-0002-1303-1610; Curado, Maria
   Paula/0000-0001-8172-2483
FU International Agency for Research on Cancer
FX This work was supported by the International Agency for Research on
   Cancer.
CR Adebamowo CA, 2008, BREAST CANCER RES TR, V110, P183, DOI 10.1007/s10549-007-9694-5
   Akinola R, 2011, DIAGN INTERV RADIOL, V17, P125, DOI 10.4261/1305-3825.DIR.3078-09.2
   Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BAYO S, 1990, INT J CANCER, V45, P679, DOI 10.1002/ijc.2910450418
   Bharat A, 2009, J SURG ONCOL, V100, P248, DOI 10.1002/jso.21268
   Bird PA, 2008, ANN SURG ONCOL, V15, P1983, DOI 10.1245/s10434-008-9900-7
   Bowen RL, 2008, BRIT J CANCER, V98, P277, DOI 10.1038/sj.bjc.6604174
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Clavel-Chapelon F, 2002, BRIT J CANCER, V86, P723, DOI 10.1038/sj/bjc/6600124
   Corbex M, 2012, BREAST, V21, P428, DOI 10.1016/j.breast.2012.01.002
   Dindyal S, 2008, BRIT J CANCER, V98, P1482, DOI 10.1038/sj.bjc.6604336
   Ekanem Victor J, 2006, Afr J Reprod Health, V10, P71
   El Saghir NS, 2012, BREAST, V21, P423, DOI 10.1016/j.breast.2012.06.007
   Elsie Kiguli-Malwadde, 2010, Pan Afr Med J, V5, P9
   Ferlay J, 2010, INT J CANC
   Huo D, 2008, BRIT J CANCER, V98, P992, DOI 10.1038/sj.bjc.6604275
   Ihemelandu CU, 2007, ANN SURG ONCOL, V14, P2994, DOI 10.1245/s10434-007-9477-6
   Jedy-Agba E, 2012, CANC EPIDEMIOL
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   KELSEY JL, 1993, EPIDEMIOL REV, V15, P36
   Ly M, 2002, B CANCER, V89, P323
   Ma H, 2006, BREAST CANCER RES, V8, pR43, DOI DOI 10.1186/BCR1525
   Ma HY, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1514
   Maly RC, 2003, CANCER, V97, P1517, DOI 10.1002/cncr.11211
   Mbonde MP, 2000, ONCOL REP, V7, P277
   Miron L, 2008, Rev Med Chir Soc Med Nat Iasi, V112, P51
   Mittra I, 2011, PREV MED, V53, P121, DOI 10.1016/j.ypmed.2011.06.010
   Nggada HA, 2008, BREAST J, V14, P284, DOI 10.1111/j.1524-4741.2008.00576.x
   Opoku Samuel Yaw, 2012, Pan Afr Med J, V11, P28
   Panieri E, 2012, BEST PRACT RES CL OB, V26, P283, DOI 10.1016/j.bpobgyn.2011.11.007
   Sighoko D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018415
   Sighoko D, 2010, INT J CANCER, V127, P2248, DOI 10.1002/ijc.25244
   Ursin G, 2005, BRIT J CANCER, V93, P364, DOI 10.1038/sj.bjc.6602712
   Yang XR, 2011, J NATL CANCER I, V103, P250, DOI 10.1093/jnci/djq526
   [Anonymous], 2006, CANC EPIDEMIOLOGY PR
NR 36
TC 12
Z9 12
U1 2
U2 9
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD OCT
PY 2013
VL 22
IS 5
BP 828
EP 835
DI 10.1016/j.breast.2013.02.011
PG 8
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 219OO
UT WOS:000324516800042
PM 23489760
OA No
DA 2017-08-15
ER

PT J
AU Lindsay, B
   Pop, M
   Antonio, M
   Walker, AW
   Mai, V
   Ahmed, D
   Oundo, J
   Tamboura, B
   Panchalingam, S
   Levine, MM
   Kotloff, K
   Li, S
   Magder, LS
   Paulson, JN
   Liu, B
   Ikumapayi, U
   Ebruke, C
   Dione, M
   Adeyemi, M
   Rance, R
   Stares, MD
   Ukhanova, M
   Barnes, B
   Lewis, I
   Ahmed, F
   Alam, MT
   Amin, R
   Siddiqui, S
   Ochieng, JB
   Ouma, E
   Juma, J
   Mailu, E
   Omore, R
   O'Reilly, CE
   Hannis, J
   Manalili, S
   DeLeon, J
   Yasuda, I
   Blyn, L
   Ranken, R
   Li, F
   Housley, R
   Ecker, DJ
   Hossain, MA
   Breiman, RF
   Morris, JG
   McDaniel, TK
   Parkhill, J
   Saha, D
   Sampath, R
   Stine, OC
   Nataro, JP
AF Lindsay, Brianna
   Pop, Mihai
   Antonio, Martin
   Walker, Alan W.
   Mai, Volker
   Ahmed, Dilruba
   Oundo, Joseph
   Tamboura, Boubou
   Panchalingam, Sandra
   Levine, Myron M.
   Kotloff, Karen
   Li, Shan
   Magder, Laurence S.
   Paulson, Joseph N.
   Liu, Bo
   Ikumapayi, Usman
   Ebruke, Chinelo
   Dione, Michel
   Adeyemi, Mitchell
   Rance, Richard
   Stares, Mark D.
   Ukhanova, Maria
   Barnes, Bret
   Lewis, Ian
   Ahmed, Firoz
   Alam, Meer Taifur
   Amin, Ruhul
   Siddiqui, Sabbir
   Ochieng, John B.
   Ouma, Emmanuel
   Juma, Jane
   Mailu, Eunice
   Omore, Richard
   O'Reilly, Ciara E.
   Hannis, James
   Manalili, Sheri
   DeLeon, Jonna
   Yasuda, Irene
   Blyn, Lawrence
   Ranken, Raymond
   Li, Feng
   Housley, Roberta
   Ecker, David J.
   Hossain, M. Anowar
   Breiman, Robert F.
   Morris, J. Glenn
   McDaniel, Timothy K.
   Parkhill, Julian
   Saha, Debasish
   Sampath, Rangarajan
   Stine, O. Colin
   Nataro, James P.
TI Survey of Culture, GoldenGate Assay, Universal Biosensor Assay, and 16S
   rRNA Gene Sequencing as Alternative Methods of Bacterial Pathogen
   Detection
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID DIARRHEA; CASE/CONTROL; AGREEMENT; COUNTRIES; CHILDREN
AB Cultivation-based assays combined with PCR or enzyme-linked immunosorbent assay (ELISA)-based methods for finding virulence factors are standard methods for detecting bacterial pathogens in stools; however, with emerging molecular technologies, new methods have become available. The aim of this study was to compare four distinct detection technologies for the identification of pathogens in stools from children under 5 years of age in The Gambia, Mali, Kenya, and Bangladesh. The children were identified, using currently accepted clinical protocols, as either controls or cases with moderate to severe diarrhea. A total of 3,610 stool samples were tested by established clinical culture techniques: 3,179 DNA samples by the Universal Biosensor assay (Ibis Biosciences, Inc.), 1,466 DNA samples by the GoldenGate assay (Illumina), and 1,006 DNA samples by sequencing of 16S rRNA genes. Each method detected different proportions of samples testing positive for each of seven enteric pathogens, entero-aggregative Escherichia coli (EAEC), enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), Shigella spp., Campylobacter jejuni, Salmonella enterica, and Aeromonas spp. The comparisons among detection methods included the frequency of positive stool samples and kappa values for making pairwise comparisons. Overall, the standard culture methods detected Shigella spp., EPEC, ETEC, and EAEC in smaller proportions of the samples than either of the methods based on detection of the virulence genes from DNA in whole stools. The GoldenGate method revealed the greatest agreement with the other methods. The agreement among methods was higher in cases than in controls. The new molecular technologies have a high potential for highly sensitive identification of bacterial diarrheal pathogens.
C1 [Lindsay, Brianna; Panchalingam, Sandra; Levine, Myron M.; Kotloff, Karen; Li, Shan; Magder, Laurence S.; Stine, O. Colin] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Pop, Mihai; Paulson, Joseph N.; Liu, Bo] Univ Maryland, College Pk, MD 20742 USA.
   [Antonio, Martin; Ikumapayi, Usman; Ebruke, Chinelo; Dione, Michel; Adeyemi, Mitchell; Saha, Debasish] MRC Unit, Serrekunda, Gambia.
   [Walker, Alan W.; Rance, Richard; Stares, Mark D.; Parkhill, Julian] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
   [Mai, Volker; Ukhanova, Maria; Morris, J. Glenn] Univ Florida, Gainesville, FL USA.
   [Ahmed, Dilruba; Ahmed, Firoz; Alam, Meer Taifur; Amin, Ruhul; Siddiqui, Sabbir; Hossain, M. Anowar] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Oundo, Joseph; Ochieng, John B.; Ouma, Emmanuel; Juma, Jane; Mailu, Eunice; Omore, Richard; Breiman, Robert F.] CDC, Kenya Med Res Inst, Res Stn, Kisumu, Kenya.
   [Tamboura, Boubou] Ctr Vaccine Dev, Bamako, Mali.
   [Barnes, Bret; Lewis, Ian; O'Reilly, Ciara E.; McDaniel, Timothy K.] Illumina, San Diego, CA USA.
   [Hannis, James; Manalili, Sheri; DeLeon, Jonna; Yasuda, Irene; Blyn, Lawrence; Ranken, Raymond; Li, Feng; Housley, Roberta; Ecker, David J.; Sampath, Rangarajan] Ibis, San Diego, CA USA.
   [Nataro, James P.] Univ Virginia, Charlottesville, VA USA.
   [Barnes, Bret; Lewis, Ian; O'Reilly, Ciara E.; McDaniel, Timothy K.] US Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
RP Lindsay, B (reprint author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
EM blind002@umaryland.edu
RI Parkhill, Julian/G-4703-2011; Pop, Mihai/A-7987-2013
OI Parkhill, Julian/0000-0002-7069-5958; Pop, Mihai/0000-0001-9617-5304;
   Walker, Alan/0000-0001-5099-8495
FU Bill and Melinda Gates Foundation [42917]; Illumina
FX This work was supported by the Bill and Melinda Gates Foundation (grant
   42917).; T.K.M., B.B., and I.L. are employees and shareholders of
   Illumina, the manufacturer of GoldenGate technology, one of the
   platforms evaluated in this study. J.H., S.M., J.D., I.Y., L.B., R.R.,
   F.L., R.H., D.J.E., and R.S. are employees of Ibis Biosciences, the
   manufacturer of Universal Biosensor technology. J.P. has received
   funding for conference travel and accommodation from Illumina.
CR Benson AK, 2010, P NATL ACAD SCI USA, V107, P18933, DOI 10.1073/pnas.1007028107
   Ecker DJ, 2008, NAT REV MICROBIOL, V6, P553, DOI 10.1038/nrmicro1918
   Feuerman M, 2008, J EVAL CLIN PRACT, V14, P930, DOI 10.1111/j.1365-2753.2008.00984.x
   Ghodsi M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-271
   Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234
   Guerrant RL, 2001, CLIN INFECT DIS, V32, P331, DOI 10.1086/318514
   Huse SM, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r143
   Iijima Y, 2007, DIAGN MICR INFEC DIS, V58, P303, DOI 10.1016/j.diagmicrobio.2007.02.007
   Illumina, VERACODE GOLDENGATE
   Illumina, 2013, GOLDENGATE ASS WORKF
   Kotloff KL, 2012, CLIN INFECT DIS, V55, pS232, DOI 10.1093/cid/cis753
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lindsay B, 2013, J CLIN MICROBIOL, V51, P1740, DOI 10.1128/JCM.02713-12
   Lindsay B, 2011, EMERG INFECT DIS, V17, P606, DOI [10.3201/eid1704.100939, 10.3201/eid1704100939]
   Liu J, 2013, J CLIN MICROBIOL, V51, P472, DOI 10.1128/JCM.02658-12
   Nair GB, 2010, GUT PATHOG, V2, DOI 10.1186/1757-4749-2-4
   Operario DJ, 2011, CURR OPIN INFECT DIS, V24, P464, DOI 10.1097/QCO.0b013e32834aa13a
   Panchalingam S, 2012, CLIN INFECT DIS, V55, pS294, DOI 10.1093/cid/cis754
   Zaidi AKM, 1999, PEDIATRICS, V103, P1189, DOI 10.1542/peds.103.6.1189
NR 19
TC 8
Z9 8
U1 1
U2 21
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD OCT
PY 2013
VL 51
IS 10
BP 3263
EP 3269
DI 10.1128/JCM.01342-13
PG 7
WC Microbiology
SC Microbiology
GA 220YU
UT WOS:000324624300016
PM 23884998
OA No
DA 2017-08-15
ER

PT J
AU Jasinska, AJ
   Huang, Y
   Schmitt, C
   Jung, Y
   Svardal, H
   Wasserscheid, J
   Juretic, N
   Dewar, K
   Grobler, P
   Jacquelin, B
   Muller-Trutwin, M
   Dione, M
   Antonio, M
   Wilson, R
   Warren, W
   Weinstock, G
   Turner, T
   Nordborg, M
   Freimer, N
AF Jasinska, A. J.
   Huang, Y.
   Schmitt, C.
   Jung, Y.
   Svardal, H.
   Wasserscheid, J.
   Juretic, N.
   Dewar, K.
   Grobler, P.
   Jacquelin, B.
   Muller-Trutwin, M.
   Dione, M.
   Antonio, M.
   Wilson, R.
   Warren, W.
   Weinstock, G.
   Turner, T.
   Nordborg, M.
   Freimer, N.
TI SNP DISCOVERY IN AFRICAN GREEN MONKEY (CHLOROCEBUS AETHIOPS) THROUGH
   WHOLE GENOME SEQUENCING
SO AMERICAN JOURNAL OF PRIMATOLOGY
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the American-Society-of-Primatologists
CY JUN 19-22, 2013
CL San Juan, PR
SP Amer Soc Primatologists
C1 [Jasinska, A. J.; Huang, Y.; Schmitt, C.; Jung, Y.; Freimer, N.] Semel Inst Neurosci & Human Behav, Ctr Behav Genet, Los Angeles, CA 90095 USA.
   [Svardal, H.; Nordborg, M.] Austrian Acad Sci, Gregor Mendel Inst, A-1010 Vienna, Austria.
   [Wasserscheid, J.; Juretic, N.; Dewar, K.] McGill Univ, Montreal, PQ, Canada.
   [Wasserscheid, J.; Juretic, N.; Dewar, K.] Genome Quebec Innovat Ctr, Montreal, PQ, Canada.
   [Grobler, P.] Univ Free State, Dept Genet, Bloemfontein, South Africa.
   [Jacquelin, B.; Muller-Trutwin, M.] Inst Pasteur, Dept Virol, Paris, France.
   [Dione, M.; Antonio, M.] MRC, Fajara, Gambia.
   [Wilson, R.; Warren, W.; Weinstock, G.] Washington Univ, Genome Inst, St Louis, MO 63130 USA.
   [Turner, T.] Univ Wisconsin, Dept Anthropol, Milwaukee, WI 53201 USA.
   [Jasinska, A. J.] Polish Acad Sci, Inst Bioorgan Chem, Poznan, Poland.
NR 0
TC 0
Z9 0
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-2565
J9 AM J PRIMATOL
JI Am. J. Primatol.
PD OCT
PY 2013
VL 75
SU 1
MA 121
BP 68
EP 68
PG 1
WC Zoology
SC Zoology
GA 205BF
UT WOS:000323414700120
OA No
DA 2017-08-15
ER

PT J
AU de Silva, T
   Peng, YC
   Leligdowicz, A
   Zaidi, I
   Li, L
   Griffin, H
   Blais, ME
   Vincent, T
   Saraiva, M
   Yindom, LM
   van Tienen, C
   Jaye, A
   Whittle, H
   Dong, T
   Rowland-Jones, S
AF de Silva, Thushan
   Peng, Yanchun
   Leligdowicz, Aleksandra
   Zaidi, Irfan
   Li, Lucy
   Griffin, Harry
   Blais, Marie-Eve
   Vincent, Tim
   Saraiva, Mavinga
   Yindom, Louis-Marie
   van Tienen, Carla
   Jaye, Assan
   Whittle, Hilton
   Dong, Tao
   Rowland-Jones, Sarah
TI THE ROLE OF CD8+T-CELL RESPONSES IN THE PATHOGENESIS OF HIV-2, A
   NATURALLY CONTAINED HUMAN RETROVIRAL INFECTION
SO JOURNAL OF INFECTION
LA English
DT Meeting Abstract
C1 [de Silva, Thushan; Leligdowicz, Aleksandra; Zaidi, Irfan; Li, Lucy; Vincent, Tim; Saraiva, Mavinga; Yindom, Louis-Marie; van Tienen, Carla; Jaye, Assan; Whittle, Hilton] MRC Labs, Fajara, Gambia.
   [Peng, Yanchun; Leligdowicz, Aleksandra; Griffin, Harry; Blais, Marie-Eve; Yindom, Louis-Marie; Dong, Tao; Rowland-Jones, Sarah] Weatherall Inst Mol Med, Oxford, England.
   [de Silva, Thushan] Univ Sheffield, Sheffield, S Yorkshire, England.
   [Whittle, Hilton] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RI van Tienen, Carla/A-1119-2012
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
NR 0
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
J9 J INFECTION
JI J. Infect.
PD OCT
PY 2013
VL 67
IS 4
BP 344
EP 344
DI 10.1016/j.jinf.2013.07.006
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 207KY
UT WOS:000323598900016
OA No
DA 2017-08-15
ER

PT J
AU Bah, E
   Carrieri, MP
   Hainaut, P
   Bah, Y
   Nyan, O
   Taal, M
AF Bah, Ebrima
   Carrieri, Maria Patrizia
   Hainaut, Pierre
   Bah, Yusupha
   Nyan, Ousman
   Taal, Makie
TI 20-Years of Population-Based Cancer Registration in Hepatitis B and
   Liver Cancer Prevention in The Gambia, West Africa
SO PLOS ONE
LA English
DT Article
ID PROSTATE-CANCER; BREAST-CANCER; INFECTION; ZIMBABWE; AIDS; UGANDA;
   TRENDS; HARARE; EPIDEMIOLOGY; WOMEN
AB Background: The Gambia Hepatitis Intervention Study (GHIS) was designed as a randomised control trial of infant hepatitis B vaccination applied to public health policy, with the main goal of preventing primary liver cancer later in adult life in The Gambia. To that effect, the National Cancer Registry of The Gambia (NCR), a population-based cancer registry (PBCR), was established in 1986 to actively collect data on all cancer diagnosis nation-wide. We extracted 20-years (1990-2009) of data to assess for the first time, the evolution of the most common cancers, also describe and demonstrate the role of the PBCR in a hepatitis B and liver cancer prevention programme in this population.
   Methods and Findings: We estimated Age-Standardised Incidence Rates (ASR (W)) of the most common cancers registered during the period by gender. The registration period was divided into four 5-year intervals and incidence rates were estimated for each interval. The most common cancers in males were liver, prostate, lung plus bronchus, non-Hodgkin lymphoma (NHL) and stomach, accounting for 60%, 5%, 4%, 5% and 3%, respectively. Similarly, cancers of the cervix uteri, liver, breast and NHL, were the most common in females, accounting for 33%, 24%, 11% and 4% of the female cancers, respectively.
   Conclusions: Cancer incidence has remained relatively stable over time, but as shown elsewhere in sub-Saharan Africa the disease is a threat in The Gambia. The infection related cancers which are mostly preventable (HBV in men and HPV/HIV in women) were the most common. At the moment the data is not enough to detect an effect of hepatitis B vaccination on liver cancer incidence in The Gambia. However, we observed that monitoring case occurrence through PBCR is a key public health pre-requisite for rational planning and implementation of targeted interventions for improving the health of the population.
C1 [Bah, Ebrima; Taal, Makie] Minist Hlth & Social Welf, Banjul, Gambia.
   [Carrieri, Maria Patrizia] INSERM, U379, F-13258 Marseille, France.
   [Hainaut, Pierre] IPRI, Lyon, France.
   [Bah, Ebrima; Bah, Yusupha] Natl Canc Registry, Fajara, Gambia.
   [Nyan, Ousman] Univ Gambia, Brikama, Senegal.
   [Bah, Ebrima] Univ Tampere, FIN-33101 Tampere, Finland.
   [Bah, Ebrima; Bah, Yusupha] Gambia Hepatitis Intervent Study GHIS Project, Fajara, Gambia.
RP Bah, E (reprint author), Minist Hlth & Social Welf, Banjul, Gambia.
EM eb71608@yahoo.co.uk
RI Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
FU Gambian Government (GG); International Agency for Research on Cancer
   (IARC); Medical Research Council of the United Kingdom; Gambia Unit
   (MRC) via The Gambia Hepatitis Intervention Study (GHIS) project;
   Direzione Generale per la Cooperazione allo Sviluppo of the Ministry of
   Foreign Affairs of Italy; Regione Autonoma Valle d'Aosta, Italy; Swedish
   Medical Research Council
FX The work was supported through a collaborative initiative between the
   Gambian Government (GG), International Agency for Research on Cancer
   (IARC) and the Medical Research Council of the United Kingdom, The
   Gambia Unit (MRC) via The Gambia Hepatitis Intervention Study (GHIS)
   project. The GHIS project was a joint venture between the above three
   institutions with financial support from the Direzione Generale per la
   Cooperazione allo Sviluppo of the Ministry of Foreign Affairs of Italy,
   the Regione Autonoma Valle d'Aosta, Italy and the Swedish Medical
   Research Council. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ARMSTRONG BK, 1992, CANCER CAUSE CONTROL, V3, P569, DOI 10.1007/BF00052754
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347
   BASSETT MT, 1995, INT J CANCER, V63, P29, DOI 10.1002/ijc.2910630107
   BAYO S, 1990, INT J CANCER, V45, P679, DOI 10.1002/ijc.2910450418
   Bowen RL, 2008, BRIT J CANCER, V98, P277, DOI 10.1038/sj.bjc.6604174
   Boyle P, 1991, IARC SCI PUBL, V95, P126
   Brawley OW, 2012, WORLD J UROL, V30, P195, DOI 10.1007/s00345-012-0824-2
   Central Statistics Department, 1996, NAT MIGR AN, P1
   Chokunonga E, 1999, AIDS, V13, P2583, DOI 10.1097/00002030-199912240-00012
   Chokunonga E, 2000, INT J CANCER, V85, P54, DOI 10.1002/(SICI)1097-0215(20000101)85:1<54::AID-IJC10>3.3.CO;2-4
   Cooke A, 1998, 9803 IARC
   Echimane AK, 2000, CANCER, V89, P653, DOI 10.1002/1097-0142(20000801)89:3<653::AID-CNCR22>3.0.CO;2-Z
   Esteve J, 1994, IARC SCI PUBL, V4, P1
   Fritz A., 2000, INT CLASSIFICATION D
   HALL A J, 1987, Cancer Research, V47, P5782
   Hennis AJ, 2009, INT J CANCER, V124, P429, DOI 10.1002/ijc.23889
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Koulibaly M, 1997, INT J CANCER, V70, P39, DOI 10.1002/(SICI)1097-0215(19970106)70:1<39::AID-IJC6>3.0.CO;2-7
   Muir C S, 1977, Natl Cancer Inst Monogr, V47, P3
   Muir C S, 1985, IARC Sci Publ, P13
   MUIR CS, 1984, ARCH GESCHWULSTFORSC, V54, P491
   Ogunbiyi JO, 1999, J NATL MED ASSOC, V91, P159
   Parkin D M, 1992, IARC Sci Publ, P45
   Parkin DM, 2008, LANCET ONCOL, V9, P683, DOI 10.1016/S1470-2045(08)70175-X
   Parkin DM, 1999, AIDS, V13, P2563, DOI 10.1097/00002030-199912240-00010
   Parkin DM, 2003, CANC AFRICA EPIDEMIO
   Parkin DM, 2006, NAT REV CANCER, V6, P603, DOI 10.1038/nrc1948
   Plesko I, 1993, Cent Eur J Public Health, V1, P19
   RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122
   Serraino D, 1999, AIDS, V13, P2589, DOI 10.1097/00002030-199912240-00013
   Shimakawa Y, 2013, INT J CANCER, V132, P658, DOI 10.1002/ijc.27646
   Sighoko D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018415
   Sighoko D, 2010, INT J CANCER, V127, P2248, DOI 10.1002/ijc.25244
   Szymanska K, 2003, ACTA BIOCHIM POL, V50, P231
   TORTEY E, 1985, LANCET, V1, P514
   Valsecchi MG, 2008, LANCET ONCOL, V9, P159, DOI 10.1016/S1470-2045(08)70028-7
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Viviani S, 2008, CANCER EPIDEM BIOMAR, V17, P3216, DOI 10.1158/1055-9965.EPI-08-0303
   WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106
   Wabinga HR, 2000, BRIT J CANCER, V82, P1585
   Wall SR, 2005, BRIT J CANCER, V93, P1068, DOI 10.1038/sj.bjc.6602736
   Waterhouse J, 1982, CANC INCIDENCE 5 CON, VIV, P1
   WILKINS A, 1991, AIDS, V5, P1127, DOI 10.1097/00002030-199109000-00012
NR 44
TC 6
Z9 6
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2013
VL 8
IS 9
AR e75775
DI 10.1371/journal.pone.0075775
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 231NL
UT WOS:000325423500095
PM 24098724
OA gold
DA 2017-08-15
ER

PT J
AU Roca, A
   Dione, MM
   Bojang, A
   Townend, J
   Egere, U
   Darboe, O
   Howie, SRC
   Hill, PC
   Adegbola, RA
   Greenwood, BM
   Antonio, M
AF Roca, Anna
   Dione, Michel M.
   Bojang, Abdoulie
   Townend, John
   Egere, Uzochukwu
   Darboe, Ousainou
   Howie, Stephen R. C.
   Hill, Philip C.
   Adegbola, Richard A.
   Greenwood, Brian M.
   Antonio, Martin
TI Nasopharyngeal Carriage of Pneumococci Four Years after Community-Wide
   Vaccination with PCV-7 in The Gambia: Long-Term Evaluation of a Cluster
   Randomized Trial
SO PLOS ONE
LA English
DT Article
ID DETERMINING CAPSULAR SEROTYPES; SEQUENTIAL MULTIPLEX PCR; CONJUGATE
   VACCINE; STREPTOCOCCUS-PNEUMONIAE; DISEASE; CHILDREN; AZITHROMYCIN;
   TRACHOMA; STRAINS; YOUNGER
AB Background: A village-randomized trial of a seven-valent pneumococcal-conjugate-vaccine (PCV-7) conducted in rural Gambia showed a decrease of vaccine-type (VT) and a non-significant increase in non-vaccine-type (NVT) nasopharyngeal carriage of pneumococci two years after vaccination. Here, we report findings four years after vaccination.
   Methods: PCV-7 was given to all children below 30 months of age enrolled in the trial and to those born during its course in all study villages. Villages were randomized (older children and adults) to receive PCV-7 (wholly vaccinated villages) or serogroup-C-meningococcal-conjugate-vaccine (partly vaccinated villages). Cross-sectional surveys (CSS) to collect nasopharyngeal swabs were conducted before and at various intervals after vaccination. Sixteen of these randomized villages (8 wholly vaccinated and 8 partly vaccinated) participated in a CSS conducted four years after vaccination started.
   Results: Four years after vaccination, the prevalence of VT pneumococcal carriage was slightly higher in partly than in wholly vaccinated villages [6.4% versus 3.9% (p = 0.120)] compared to 24.4% in the pre-vaccination CSS (p<0.001). Prevalence of NVT four years after vaccination was similar between study groups [32.7% versus 29.8% (p = 0.392), respectively] compared to 51.1% in the pre-vaccination CSS (p<0.001). Four years after vaccination started, lower prevalence of serotype 6A was detected in wholly vaccinated than in partly vaccinated villages (1.6% versus 3.5%, p = 0.093) whilst the prevalence of serotype 19A was similar between groups (2.9% versus 2.5%, p = 0.779). The most prevalent serotype 19A clone was ST 847. The most prevalent serotype 6A clone before vaccination was ST3324 whilst after vaccination ST913 and ST1737 predominated. Fourteen out of 26 STs detected among the serotype 6A isolates were new while no new 19A serotype ST was found.
   Conclusions: The decline in prevalence of VT pneumococci seen shortly after PCV-7 vaccination was sustained four years later with only a small difference between study arms. No significant serotype replacement was detected.
C1 [Roca, Anna; Dione, Michel M.; Bojang, Abdoulie; Townend, John; Egere, Uzochukwu; Darboe, Ousainou; Howie, Stephen R. C.; Hill, Philip C.; Adegbola, Richard A.; Antonio, Martin] MRC Unit, Banjul, Gambia.
   [Hill, Philip C.] Univ Otago, Sch Med, Ctr Int Hlth, Dunedin, New Zealand.
   [Adegbola, Richard A.] GlaxoSmithKline Vaccines, Wavre, Belgium.
   [Greenwood, Brian M.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
RP Roca, A (reprint author), MRC Unit, Banjul, Gambia.
EM aroca@mrc.gm
FU United Kingdom Medical Research Council
FX The study was funded by the United Kingdom Medical Research Council.
   Study vaccines were donated by Wyeth Lederle Vaccines (Pfizer). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akinsola AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031050
   Antonio M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-81
   Brueggemann AB, 2007, PLOS PATHOG, V3, P1628, DOI 10.1371/journal.ppat.0030168
   Cheung YB, 2009, PEDIATR INFECT DIS J, V28, P990, DOI 10.1097/INF.0b013e3181a78185
   Cooper D, 2011, VACCINE, V29, P7207, DOI 10.1016/j.vaccine.2011.06.056
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525
   Dias CA, 2007, J MED MICROBIOL, V56, P1185, DOI 10.1099/jmm.0.47347-0
   Fry AM, 2002, CLIN INFECT DIS, V35, P395, DOI 10.1086/341414
   Hanage WP, 2010, EPIDEMICS-NETH, V2, P80, DOI 10.1016/j.epidem.2010.03.005
   Hanquet G, 2010, EMERG INFECT DIS, V16, P1428, DOI 10.3201/eid1609.100102
   Hicks LA, 2007, J INFECT DIS, V196, P1346, DOI 10.1086/521626
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Hill PC, 2010, CLIN INFECT DIS, V50, P1468, DOI 10.1086/652443
   Hsieh YC, 2009, VACCINE, V27, P5513, DOI 10.1016/j.vaccine.2009.06.091
   Leach AJ, 1997, CLIN INFECT DIS, V24, P356
   Lexau CA, 2005, JAMA-J AM MED ASSOC, V294, P2043, DOI 10.1001/jama.294.16.2043
   O'Brien Katherine L, 2003, Pediatr Infect Dis J, V22, pe1, DOI 10.1097/01.inf.0000049347.42983.77
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Saeland E, 2001, J INFECT DIS, V183, P253, DOI 10.1086/317934
   Scott JR, 2012, J INFECT DIS, V205, P280, DOI 10.1093/infdis/jir730
   van Gils EJM, 2010, JAMA-J AM MED ASSOC, V304, P1099, DOI 10.1001/jama.2010.1290
   Vestrheim DF, 2012, CLIN VACCINE IMMUNOL, V19, P443, DOI 10.1128/CVI.05563-11
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2
NR 28
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 27
PY 2013
VL 8
IS 9
AR UNSP e72198
DI 10.1371/journal.pone.0072198
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 228WY
UT WOS:000325223900007
PM 24086259
OA gold
DA 2017-08-15
ER

PT J
AU Odutola, A
   Antonio, M
   Owolabi, O
   Bojang, A
   Foster-Nyarko, E
   Donkor, S
   Adetifa, I
   Taylor, S
   Bottomley, C
   Greenwood, B
   Ota, M
AF Odutola, Aderonke
   Antonio, Martin
   Owolabi, Olumuyiwa
   Bojang, Abdoulie
   Foster-Nyarko, Ebenezer
   Donkor, Simon
   Adetifa, Ifedayo
   Taylor, Sylvia
   Bottomley, Christian
   Greenwood, Brian
   Ota, Martin
TI Comparison of the Prevalence of Common Bacterial Pathogens in the
   Oropharynx and Nasopharynx of Gambian Infants
SO PLOS ONE
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; UPPER RESPIRATORY-TRACT;
   STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; STAPHYLOCOCCUS-AUREUS;
   SYSTEMATIC ANALYSIS; CARRIAGE; CHILDREN; DISEASE; COLONIZATION
AB Background: CRM-based pneumococcal conjugate vaccines generally have little impact on the overall prevalence of pneumococcal carriage because of serotype replacement. In contrast, protein vaccines could substantially reduce the overall prevalence of pneumococcal carriage with potential microbiological and clinical consequences. Therefore, trials of pneumococcal protein vaccines need to evaluate their impact on carriage of other potentially pathogenic bacteria in addition to the pneumococcus.
   Methods: As a prelude to a trial of an investigational pneumococcal vaccine containing pneumococcal polysaccharide conjugates and pneumococcal proteins, the prevalence of carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella species and Staphylococcus aureus in the nasopharynx of 1030 Gambian infants (median age 35 weeks) was determined. An oropharyngeal swab was obtained at the same time from the first 371 infants enrolled. Standard microbiological techniques were used to evaluate the bacterial flora of the pharynx and to compare that found in the oropharynx and in the nasopharynx.
   Results: The overall pneumococcal carriage rate was high. Isolation rates of S. pneumoniae and Moraxella species were significantly higher using nasopharyngeal rather than oropharyngeal swabs (76.1% [95% CI 73.4%, 78.7%] vs. 21.3% [95% CI 17.2%, 25.8%] and 48.9% [95% CI 45.8%, 52.0%] vs. 20.5% % [95% CI 16.5%, 25.0%] respectively). In contrast, S. aureus and H. influenzae were isolated more frequently from oropharyngeal than from nasopharyngeal swabs (65.0% [95% CI 59.9%, 69.8%] vs. 33.6% [95% CI 30.7%, 36.5%] and 31.8% [95% CI 16.5%, 25.0%] vs. 22.4% [95% CI 19.9%, 25.1%] respectively). No group A beta haemolytic streptococci were isolated.
   Conclusion: Collection of an oropharyngeal swab in addition to a nasopharyngeal swab will provide little additional information on the impact of a novel pneumococcal vaccine on pneumococcal carriage but it might provide additional, valuable information on the impact of the vaccine on the overall microbiota of the pharynx.
C1 [Odutola, Aderonke; Antonio, Martin; Owolabi, Olumuyiwa; Bojang, Abdoulie; Foster-Nyarko, Ebenezer; Donkor, Simon; Adetifa, Ifedayo; Ota, Martin] MRC Unit, Banjul, Gambia.
   [Taylor, Sylvia] GlaxoSmithKline Vaccines, Global Epidemiol, Wavre, Belgium.
   [Bottomley, Christian; Greenwood, Brian] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
   [Ota, Martin] WHO, Reg Off Africa, Brazzaville, Congo.
RP Odutola, A (reprint author), MRC Unit, Banjul, Gambia.
EM aaodutola@mrc.gm
FU MRC UK; PATH, Seattle
FX The study was supported by MRC UK and by a grant from PATH, Seattle. A
   steering committee which included staff employed by PATH or GSK in
   addition to representative of the partner academic organisations
   provided overall advice on the conduct of the trial but played no direct
   role in the analysis of data, its interpretation or in the writing of
   the paper.
CR Altman DG, 1991, PRACTICAL STAT MED R
   Bogaert D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017035
   CAPEDING MRZ, 1995, J CLIN MICROBIOL, V33, P3077
   Cheung YB, 2009, PEDIATR INFECT DIS J, V28, P990, DOI 10.1097/INF.0b013e3181a78185
   GRAY BM, 1980, J INFECT DIS, V142, P923
   Greenberg D, 2004, J CLIN MICROBIOL, V42, P4604, DOI 10.1128/JCM.42.10.4604-4609.2004
   Hare KM, 2011, J MICROBIOL METH, V86, P364, DOI 10.1016/j.mimet.2011.06.016
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Kwambana BA, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-175
   Kwambana BA, 2011, BMC CLIN PATHOL, V11, DOI 10.1186/1472-6890-11-2
   Lieberman D, 2006, J CLIN MICROBIOL, V44, P525, DOI 10.1128/JCM.44.2.525-528.2006
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Madhi SA, 2007, J INFECT DIS, V196, P1662, DOI 10.1086/522164
   MASTERS PL, 1958, BRIT MED J, V1, P1200
   Morais L, 2007, J MED MICROBIOL, V56, P1181, DOI 10.1099/jmm.0.47346-0
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Prymula R, 2012, SAFETY IMMUNOGENICIT
   Rapola S, 1997, J CLIN MICROBIOL, V35, P1077
   Regev-Yochay G, 2004, JAMA-J AM MED ASSOC, V292, P716, DOI 10.1001/jama.292.6.716
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Spijkerman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039730
   van der Veen EL, 2006, ARCH OTOLARYNGOL, V132, P752, DOI 10.1001/archotol.132.7.752
   van Gils EJM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020229
   Watt JP, 2004, J CLIN MICROBIOL, V42, P4974, DOI 10.1128/JCM.42.11.4974-4976.2004
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
NR 28
TC 10
Z9 11
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 23
PY 2013
VL 8
IS 9
AR e75558
DI 10.1371/journal.pone.0075558
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 246EK
UT WOS:000326520200112
PM 24086570
OA gold
DA 2017-08-15
ER

PT J
AU Mavoko, HM
   Nabasumba, C
   Tinto, H
   D'Alessandro, U
   Grobusch, MP
   Lutumba, P
   Van Geertruyden, JP
AF Mavoko, Hypolite Muhindo
   Nabasumba, Carolyn
   Tinto, Halidou
   D'Alessandro, Umberto
   Grobusch, Martin Peter
   Lutumba, Pascal
   Van Geertruyden, Jean-Pierre
TI Impact of retreatment with an artemisinin-based combination on malaria
   incidence and its potential selection of resistant strains: study
   protocol for a randomized controlled clinical trial
SO TRIALS
LA English
DT Article
DE Malaria; Artemisinin-based combination treatment;
   Artesunate-amodiaquine; Artemether-lumefantrine; Quinine; Clindamycin;
   Randomized trial; Democratic Republic of Congo; Uganda
ID UNCOMPLICATED FALCIPARUM-MALARIA; PLUS SULFADOXINE-PYRIMETHAMINE;
   ARTEMETHER-LUMEFANTRINE; ARTESUNATE-AMODIAQUINE; PLASMODIUM-FALCIPARUM;
   AFRICAN CHILDREN; EFFICACY; QUININE; THERAPY; SAFETY
AB Background: Artemisinin-based combination therapy is currently recommended by the World Health Organization as first-line treatment of uncomplicated malaria. Recommendations were adapted in 2010 regarding rescue treatment in case of treatment failure. Instead of quinine monotherapy, it should be combined with an antibiotic with antimalarial properties; alternatively, another artemisinin-based combination therapy may be used. However, for informing these policy changes, no clear evidence is yet available. The need to provide the policy makers with hard data on the appropriate rescue therapy is obvious. We hypothesize that the efficacy of the same artemisinin-based combination therapy used as rescue treatment is as efficacious as quinine + clindamycin or an alternative artemisinin-based combination therapy, without the risk of selecting drug resistant strains.
   Design: We embed a randomized, open label, three-arm clinical trial in a longitudinal cohort design following up children with uncomplicated malaria until they are malaria parasite free for 4 weeks. The study is conducted in both the Democratic Republic of Congo and Uganda and performed in three steps. In the first step, the pre-randomized controlled trial (RCT) phase, children aged 12 to 59 months with uncomplicated malaria are treated with the recommended first-line drug and constitute a cohort that is passively followed up for 42 days. If the patients experience an uncomplicated malaria episode between days 14 and 42 of follow-up, they are randomized either to quinine + clindamycin, or an alternative artemisinin-based combination therapy, or the same first-line artemisinin-based combination therapy to be followed up for 28 additional days. If between days 14 and 28 the patients experience a recurrent parasitemia, they are retreated with the recommended first-line regimen and actively followed up for another 28 additional days (step three; post-RCT phase). The same methodology is followed for each subsequent failure. In any case, all patients without an infection at day 28 are classified as treatment successes and reach a study endpoint. The RCT phase allows the comparison of the safety and efficacy of three rescue treatments. The prolonged follow-up of all children until they are 28 days parasite-free allows us to assess epidemiological-, host- and parasite-related predictors for repeated malaria infection.
C1 [Mavoko, Hypolite Muhindo; Lutumba, Pascal] Univ Kinshasa, Fac Med, Dept Trop Med, Kinshasa, Zaire.
   [Nabasumba, Carolyn] Epictr Mbarara Res Base, Mbarara, Uganda.
   [Tinto, Halidou] Inst Rech Sci Sante, Ctr Muraz, Bobo Dioulasso, Burkina Faso.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC, Gambia Unit, Banjul, Gambia.
   [Grobusch, Martin Peter] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [Van Geertruyden, Jean-Pierre] Univ Antwerp, Int Hlth Unit, B-2610 Antwerp, Belgium.
RP Mavoko, HM (reprint author), Univ Kinshasa, Fac Med, Dept Trop Med, BP 747 Kin 11, Kinshasa, Zaire.
EM mavoko@yahoo.com
RI Van geertruyden, Jean-pierre/K-6425-2014; D'Alessandro,
   Umberto/D-3457-2015
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364; D'Alessandro,
   Umberto/0000-0001-6341-5009
FU EDCTP [MS.2010.10800.004]; FWO [G.078.11]; VLIR-UOS [ZRDC2012MP076,
   ZEIN2013PR401]; Belgian Technical Cooperation in DRC [FEE/06/12]
FX The authors thank all co-funders of this study: EDCTP (Grant reference
   MS.2010.10800.004), FWO (Grant reference G.078.11), VLIR-UOS (Grant
   reference ZRDC2012MP076 and ZEIN2013PR401) and the Belgian Technical
   Cooperation in DRC (Grant reference FEE/06/12). We acknowledge the
   contribution of Raffaella Ravinetto to the conception of the idea. We
   would like to thank the monitoring team: Elske Straatsma, Joachim Doua,
   Caroline Bako and Sophie Nabasirye. We acknowledge the reliability of
   the study staff in both sites. Many thanks to the participants and their
   parents, as well as the managing boards of health facilities where the
   study is conducted.
CR Achan J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2763
   Bassat Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007871
   Bloland PB, 2001, DRUG RESISTANCE MALA
   Bonnet M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-192
   Byakika-Kibwika P, 2010, THER CLIN RISK MANAG, V6, P11
   de Vries PJ, 2000, ANTIMICROB AGENTS CH, V44, P1302, DOI 10.1128/AAC.44.5.1302-1308.2000
   [Anonymous], 2002, CPMPICH13595 EMEA
   Fungladda W, 1998, Bull World Health Organ, V76 Suppl 1, P59
   Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6
   McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074
   Ndiaye JL, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-125
   Obonyo CO, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-2
   Sirima SB, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-48
   Swarthout TD, 2006, TROP MED INT HEALTH, V11, P1503, DOI 10.1111/j.1365-3156.2006.01710.x
   White N J, 1998, Med Trop (Mars), V58, P54
   WHO, 2003, ASS MON ANT DRUG EFF
   World Health Organization, 2010, GUID TREATM MAL
   WHO, 2000, T R SOC TROP MED S1, V94, P1
   Yeka A, 2009, LANCET INFECT DIS, V9, P448, DOI 10.1016/S1473-3099(09)70109-4
   Zwang J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-203
NR 20
TC 2
Z9 2
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD SEP 23
PY 2013
VL 14
AR 307
DI 10.1186/1745-6215-14-307
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 228BB
UT WOS:000325158800001
OA gold
DA 2017-08-15
ER

PT J
AU Rosas-Aguirre, A
   Llanos-Cuentas, A
   Speybroeck, N
   Cook, J
   Contreras-Mancilla, J
   Soto, V
   Gamboa, D
   Pozo, E
   Ponce, OJ
   Pereira, MO
   Soares, IS
   Theisen, M
   D'Alessandro, U
   Erhart, A
AF Rosas-Aguirre, Angel
   Llanos-Cuentas, Alejandro
   Speybroeck, Niko
   Cook, Jackie
   Contreras-Mancilla, Juan
   Soto, Veronica
   Gamboa, Dionicia
   Pozo, Edwar
   Ponce, Oscar J.
   Pereira, Mayne O.
   Soares, Irene S.
   Theisen, Michael
   D'Alessandro, Umberto
   Erhart, Annette
TI Assessing malaria transmission in a low endemicity area of north-western
   Peru
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria transmission intensity; Low endemicity; Elimination; Polymerase
   chain reaction; Serology; Peru
ID ENTOMOLOGICAL INOCULATION RATE; PLASMODIUM-FALCIPARUM MALARIA;
   GLUTAMATE-RICH PROTEIN; SUB-SAHARAN AFRICA; CONTROL STRATEGIES; RAPID
   ASSESSMENT; SOUTH-AMERICA; AMAZON; ELIMINATION; PYRIMETHAMINE
AB Background: Where malaria endemicity is low, control programmes need increasingly sensitive tools for monitoring malaria transmission intensity (MTI) and to better define health priorities. A cross-sectional survey was conducted in a low endemicity area of the Peruvian north-western coast to assess the MTI using both molecular and serological tools.
   Methods: Epidemiological, parasitological and serological data were collected from 2,667 individuals in three settlements of Bellavista district, in May 2010. Parasite infection was detected using microscopy and polymerase chain reaction (PCR). Antibodies to Plasmodium vivax merozoite surface protein-1(19) (PvMSP1(19)) and to Plasmodium falciparum glutamate-rich protein (PfGLURP) were detected by ELISA. Risk factors for exposure to malaria (seropositivity) were assessed by multivariate survey logistic regression models. Age-specific antibody prevalence of both P. falciparum and P. vivax were analysed using a previously published catalytic conversion model based on maximum likelihood for generating seroconversion rates (SCR).
   Results: The overall parasite prevalence by microscopy and PCR were extremely low: 0.3 and 0.9%, respectively for P. vivax, and 0 and 0.04%, respectively for P. falciparum, while seroprevalence was much higher, 13.6% for P. vivax and 9.8% for P. falciparum. Settlement, age and occupation as moto-taxi driver during previous year were significantly associated with P. falciparum exposure, while age and distance to the water drain were associated with P. vivax exposure. Likelihood ratio tests supported age seroprevalence curves with two SCR for both P. vivax and P. falciparum indicating significant changes in the MTI over time. The SCR for PfGLURP was 19-fold lower after 2002 as compared to before (lambda 1 = 0.022 versus lambda 2 = 0.431), and the SCR for PvMSP119 was four-fold higher after 2006 as compared to before (lambda 1 = 0.024 versus lambda 2 = 0.006).
   Conclusion: Combining molecular and serological tools considerably enhanced the capacity of detecting current and past exposure to malaria infections and related risks factors in this very low endemicity area. This allowed for an improved characterization of the current human reservoir of infections, largely hidden and heterogeneous, as well as providing insights into recent changes in species specific MTIs. This approach will be of key importance for evaluating and monitoring future malaria elimination strategies.
C1 [Rosas-Aguirre, Angel; Llanos-Cuentas, Alejandro; Contreras-Mancilla, Juan; Soto, Veronica; Gamboa, Dionicia; Ponce, Oscar J.] Univ Peruana Cayetano Heredia, Inst Trop Med, Lima, Peru.
   [Speybroeck, Niko] Catholic Univ Louvain, Res Inst Hlth & Soc IRSS, B-1200 Brussels, Belgium.
   [Cook, Jackie] Karolinska Inst, Dept Med Solna, Malaria Res Unit, Stockholm, Sweden.
   [Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Dept Ciencias Celulares & Mol, Lima, Peru.
   [Pozo, Edwar] Subreg Salud Luciano Castillo Coloma, Sullana, Peru.
   [Pereira, Mayne O.; Soares, Irene S.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil.
   [Theisen, Michael] Statens Serum Inst, Dept Clin Biochem & Immunol, DK-2300 Copenhagen, Denmark.
   [Theisen, Michael] Copenhagen Univ Hosp, Dept Infect Dis, Copenhagen, Denmark.
   [Theisen, Michael] Univ Copenhagen, Rigshosp, Dept Int Hlth Immunol & Microbiol, Ctr Med Parasitol, DK-2100 Copenhagen, Denmark.
   [Theisen, Michael; D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Rosas-Aguirre, Angel; D'Alessandro, Umberto; Erhart, Annette] Inst Trop Med, B-2000 Antwerp, Belgium.
RP Rosas-Aguirre, A (reprint author), Univ Peruana Cayetano Heredia, Inst Trop Med, Lima, Peru.
EM angelrosasa@gmail.com
RI Soares, Irene/C-5974-2012; D'Alessandro, Umberto/D-3457-2015; Rosas
   Aguirre, Angel/A-5054-2016
OI D'Alessandro, Umberto/0000-0001-6341-5009; Rosas Aguirre,
   Angel/0000-0002-3271-7028; Contreras Mancilla, Juan
   Jose/0000-0003-0447-0926
CR Aguas R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001767
   Aramburu Guarda J, 1999, Emerg Infect Dis, V5, P209
   Bellina C, 1999, B SOC PERU MED INTER, V12, P163
   Bousema T, 2010, J INFECT DIS, V201, P1764, DOI 10.1086/652456
   Bousema T, 2010, EMERG INFECT DIS, V16, P392, DOI 10.3201/eid1603.090732
   Branch O, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-27
   Byass P, 2008, LANCET, V372, P1523, DOI 10.1016/S0140-6736(08)61631-1
   CAMPBELL CC, 1980, AM J TROP MED HYG, V29, P151
   Chuquiyauri R, 2012, ACTA TROP, V121, P292, DOI 10.1016/j.actatropica.2011.11.003
   Cook J, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-86
   Cook J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025137
   Cook J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-169
   Corran P, 2007, TRENDS PARASITOL, V23, P575, DOI 10.1016/j.pt.2007.08.023
   Corran PH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-195
   Coura JR, 2006, MEM I OSWALDO CRUZ, V101, P229, DOI 10.1590/S0074-02762006000300001
   Culleton R, 2009, J INFECT DIS, V200, P1465, DOI 10.1086/644510
   da Silva-Nunes M, 2012, ACTA TROP, V121, P281, DOI 10.1016/j.actatropica.2011.10.001
   de Stricker K, 2000, MOL BIOCHEM PARASIT, V111, P123
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Elissa N, 2003, ACTA TROP, V85, P355, DOI 10.1016/S0001-706X(02)00266-8
   Flores W, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-379
   Gagnon AS, 2002, INT J BIOMETEOROL, V46, P81, DOI 10.1007/s00484-001-0119-6
   Greenwood BM, 2008, TRENDS PARASITOL, V24, P449, DOI 10.1016/j.pt.2008.07.002
   Guthmann JP, 2002, TROP MED INT HEALTH, V7, P518, DOI 10.1046/j.1365-3156.2002.00883.x
   Guthmann JP, 2001, T ROY SOC TROP MED H, V95, P577, DOI 10.1016/S0035-9203(01)90084-7
   Hay SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0
   Johnston SP, 2006, J CLIN MICROBIOL, V44, P1087, DOI 10.1128/JCM.44.3.1087-1089.2006
   Kelly-Hope LA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-19
   Marquino W, 2003, AM J TROP MED HYG, V68, P608
   Marquino W, 2003, AM J TROP MED HYG, V68, P120
   Ministerio de Salud del Peru - Direccion General de Epidemiologia, 2011, B EPIDEMIOL, V20, P1108
   Ministerio de Salud del Peru, 2003, SER NORM TECN, V39
   Ministerio de Salud del Peru - Direccion General de Epidemiologia, 2010, AN SIT SAL PER ASIS
   Mutapi F, 2007, MEM I OSWALDO CRUZ, V102, P405, DOI 10.1590/S0074-02762007005000046
   PLOWE CV, 1995, AM J TROP MED HYG, V52, P565
   Roberts DR, 1997, EMERG INFECT DIS, V3, P295
   Rodrigues MHC, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-39
   Rosas-Aguirre Angel, 2011, Rev Peru Med Exp Salud Publica, V28, P228, DOI 10.1590/s1726-46342011000200009
   Rubio J M, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS199, DOI 10.1016/S0035-9203(02)90077-5
   Speybroeck N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016705
   Steenkeste N, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-108
   Stewart L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006083
   Taylor SM, 2010, J CLIN MICROBIOL, V48, P512, DOI 10.1128/JCM.01800-09
   THEISEN M, 1995, CLIN DIAGN LAB IMMUN, V2, P30
   Vinetz JM, 2002, AM J TROP MED HYG, V66, P639
   Vittor AY, 2006, AM J TROP MED HYG, V74, P3
   WHO Global Malaria Programme, 2011, WORLD MAL REP 2011
   Williams GS, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-168
   Williams HA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-85
   [Anonymous], 2011, PIUR COMP EST 2011
   [Anonymous], 2001, AN SIT SAL AN 2000
NR 51
TC 12
Z9 12
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD SEP 22
PY 2013
VL 12
AR 339
DI 10.1186/1475-2875-12-339
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 227JJ
UT WOS:000325108500001
PM 24053144
OA gold
DA 2017-08-15
ER

PT J
AU Pettengill, M
   Robson, S
   Tresenriter, M
   Millan, JL
   Usheva, A
   Bingham, T
   Belderbos, M
   Bergelson, I
   Burl, S
   Kampmann, B
   Gelinas, L
   Kollmann, T
   Bont, L
   Levy, O
AF Pettengill, Matthew
   Robson, Simon
   Tresenriter, Megan
   Millan, Jose Luis
   Usheva, Anny
   Bingham, Taiese
   Belderbos, Mirjam
   Bergelson, Ilana
   Burl, Sarah
   Kampmann, Beate
   Gelinas, Laura
   Kollmann, Tobias
   Bont, Louis
   Levy, Ofer
TI Soluble Ecto-5 '-nucleotidase (5 '-NT), Alkaline Phosphatase, and
   Adenosine Deaminase (ADA1) Activities in Neonatal Blood Favor Elevated
   Extracellular Adenosine
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SUPEROXIDE ANION GENERATION; HUMAN-NEUTROPHILS; INNATE IMMUNITY; HUMAN
   NEWBORN; BASIC MECHANISMS; CELL-DEVELOPMENT; A2 ADENOSINE; IN-VIVO; ATP;
   ACTIVATION
AB Extracellular adenosine, a key regulator of physiology and immune cell function that is found at elevated levels in neonatal blood, is generated by phosphohydrolysis of adenine nucleotides released from cells and catabolized by deamination to inosine. Generation of adenosine monophosphate (AMP) in blood is driven by cell-associated enzymes, whereas conversion of AMP to adenosine is largely mediated by soluble enzymes. The identities of the enzymes responsible for these activities in whole blood of neonates have been defined in this study and contrasted to adult blood. We demonstrate that soluble 5 '-nucleotidase (5 '-NT) and alkaline phosphatase (AP) mediate conversion of AMP to adenosine, whereas soluble adenosine deaminase (ADA) catabolizes adenosine to inosine. Newborn blood plasma demonstrates substantially higher adenosine-generating 5 '-NT and AP activity and lower adenosine-metabolizing ADA activity than adult plasma. In addition to a role in soluble purine metabolism, abundant AP expressed on the surface of circulating neonatal neutrophils is the dominant AMPase on these cells. Plasma samples from infant observational cohorts reveal a relative plasma ADA deficiency at birth, followed by a gradual maturation of plasma ADA through infancy. The robust adenosine-generating capacity of neonates appears functionally relevant because supplementation with AMP inhibited whereas selective pharmacologic inhibition of 5 '-NT enhanced Toll-like receptor-mediated TNF-alpha production in neonatal whole blood. Overall, we have characterized previously unrecognized age-dependent expression patterns of plasma purine-metabolizing enzymes that result in elevated plasma concentrations of anti-inflammatory adenosine in new-borns. Targeted manipulation of purine-metabolizing enzymes may benefit this vulnerable population.
C1 [Pettengill, Matthew; Tresenriter, Megan; Bingham, Taiese; Bergelson, Ilana; Levy, Ofer] Boston Childrens Hosp, Div Infect Dis, Dept Med, Boston, MA 02115 USA.
   [Robson, Simon; Usheva, Anny] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
   [Pettengill, Matthew; Robson, Simon; Usheva, Anny; Bingham, Taiese; Levy, Ofer] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Millan, Jose Luis] Sanford Childrens Hlth Res Ctr, Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA.
   [Belderbos, Mirjam; Bont, Louis] Univ Med Ctr Utrecht, Dept Pediat, NL-3584 CX Utrecht, Netherlands.
   [Burl, Sarah; Kampmann, Beate] MRC Unit, Vaccinol Theme Grp, Fajara, Gambia.
   [Burl, Sarah; Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Pediat, London W2 1PG, England.
   [Gelinas, Laura] Univ British Columbia, Dept Med, Expt Med Program, Vancouver, BC V6T 1Z4, Canada.
   [Kollmann, Tobias] Univ British Columbia, Dept Pediat, Div Infect & Immunol Dis, Vancouver, BC V6T 1Z4, Canada.
RP Levy, O (reprint author), Boston Childrens Hosp, Div Infect Dis, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.
EM ofer.levy@childrens.harvard.edu
OI Gelinas, Laura/0000-0003-3713-4275
FU National Institutes of Health (NIH) [1R01AI100135-01]; NIH [T32
   HD055148, R01 HL094400, R21 CA164970, P01 HL087203]; NIH, NIDCR [R01
   DE012889]; NIH, NIAMS [R01 AR053102]; NIH, NIAID [N01 AI50023]; European
   Society for Pediatric Infectious Diseases; Medical Research Council,
   United Kingdom; Canadian Institutes of Health Research; Burroughs
   Wellcome Career Award in the Biomedical Sciences, a Michael Smith
   Foundation for Health Research Career Investigator Award; AllerGen NCE
   [07-A1A, 07-B2B]; Bill and Melinda Gates Foundation Global Health Award
   [OPPGH5284]; Grand Challenges Explorations Award [OPP1035192]
FX This work was supported, in whole or in part, by National Institutes of
   Health (NIH) Grant 1R01AI100135-01 (to O.L.); NIH Training Grant T32
   HD055148 (to M.P.); NIH Grants R01 HL094400, R21 CA164970, and P01
   HL087203 (to S.R.); NIH, NIDCR, Grant R01 DE012889 and NIH, NIAMS, Grant
   R01 AR053102 (to J.L.M.); and NIH, NIAID, Grant N01 AI50023 (to
   T.R.K.).; Supported by a European Society for Pediatric Infectious
   Diseases travel grant.; Supported by the Medical Research Council,
   United Kingdom.; Recipient of a Frederick Banting and Charles Best
   Canada Graduate Scholarship from the Canadian Institutes of Health
   Research.; Supported in part by a Burroughs Wellcome Career Award in the
   Biomedical Sciences, a Michael Smith Foundation for Health Research
   Career Investigator Award, and the AllerGen NCE Grants 07-A1A and
   07-B2B.; The laboratory of this author is supported in part by Bill and
   Melinda Gates Foundation Global Health Award OPPGH5284 and Grand
   Challenges Explorations Award OPP1035192. To whom correspondence should
   be addressed: Dept. of Medicine, Division of Infectious Diseases, Boston
   Children's Hospital, 300 Longwood Ave., Boston, MA 02115. Tel.:
   617-919-2904; Fax: 617-730-0254; E-mail:
   ofer.levy@childrens.harvard.edu.
CR Angelone DF, 2006, PEDIATR RES, V60, P205, DOI 10.1203/01.pdr.0000228319.10481.ea
   BALAZOVICH KJ, 1990, J IMMUNOL, V144, P631
   Banz Y, 2008, BRIT J HAEMATOL, V142, P627, DOI 10.1111/j.1365-2141.2008.07230.x
   Baricordi OR, 1996, BLOOD, V87, P682
   Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206
   Belderbos ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033419
   BORN GVR, 1984, J PHYSIOL-LONDON, V354, P419
   Bouma MG, 1997, J IMMUNOL, V158, P5400
   Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013
   Burl S, 2011, PLOS ONE, V6
   Chen Y, 2004, J LEUKOCYTE BIOL, V76, P245, DOI 10.1189/jlb.0204066
   COADE SB, 1989, CIRC RES, V65, P531
   COCKCROFT S, 1989, FEBS LETT, V245, P25, DOI 10.1016/0014-5793(89)80184-X
   Coombs MRP, 2011, EXPERT REV ANTI-INFE, V9, P261, DOI [10.1586/ERI.10.158, 10.1586/eri.10.158]
   Corbett NP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015041
   Coutinho-Silva R, 2009, PURINERG SIGNAL, V5, P197, DOI 10.1007/s11302-009-9130-x
   CROFTON PM, 1987, CLIN CHEM, V33, P1778
   CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/jem.158.4.1160
   CRONSTEIN BN, 1985, J IMMUNOL, V135, P1366
   CRONSTEIN BN, 1986, J CLIN INVEST, V78, P760, DOI 10.1172/JCI112638
   Csoka B, 2008, FASEB J, V22, P3491, DOI 10.1096/fj.08-107458
   Dahl R, 2009, J MED CHEM, V52, P6919, DOI 10.1021/jm900383s
   Deaglio S, 2011, ADV PHARMACOL, V61, P301, DOI 10.1016/B978-0-12-385526-8.00010-2
   DEMEESTER I, 1994, EUR J IMMUNOL, V24, P566, DOI 10.1002/eji.1830240311
   Eltzschig HK, 2004, BLOOD, V104, P3986, DOI 10.1182/blood-2004-06-2066
   FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8267, DOI 10.1073/pnas.87.21.8267
   Gao Zhan-Guo, 2008, BMC Pharmacology, V8, P20, DOI 10.1186/1471-2210-8-20
   HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x
   Herrera C, 2001, MOL PHARMACOL, V59, P127
   HIRSCHHORN R, 1973, LANCET, V2, P1217
   Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638
   Junger WG, 2011, NAT REV IMMUNOL, V11, P201, DOI 10.1038/nri2938
   Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481
   Lehto Marty T., 1998, Biochemical Journal, V332, P101
   Levy O, 2004, J IMMUNOL, V173, P4627
   Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075
   Levy O, 2006, J IMMUNOL, V177, P1956
   LOCKITCH G, 1988, CLIN CHEM, V34, P1622
   LOW MG, 1987, BIOCHEM J, V244, P1
   Mack D, 1996, J BACTERIOL, V178, P175
   Millan JL, 2006, MAMMALIAN ALKALINE P
   Molina-Arcas M, 2009, CURR VASC PHARMACOL, V7, P426
   Nauseef William M., 2007, V412, P15, DOI 10.1007/978-1-59745-467-4_2
   Nguyen M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010407
   Pedata F, 2001, ANN NY ACAD SCI, V939, P74
   Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599
   Philbin VJ, 2012, J ALLERGY CLIN IMMUN, V130, P195, DOI 10.1016/j.jaci.2012.02.042
   Proytcheva MA, 2011, DIAGNOSTIC PEDIAT HE, P5
   Remington J. S., 2011, INFECT DIS FETUS NEW, P80
   Robson Simon C, 2006, Purinergic Signal, V2, P409, DOI 10.1007/s11302-006-9003-5
   ROSALKI SB, 1984, CLIN CHEM, V30, P1182
   SCHELONKA RL, 1994, J PEDIATR-US, V125, P603, DOI 10.1016/S0022-3476(94)70018-4
   Schenk U, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1160583
   Schon MP, 2007, BRIT J DERMATOL, V157, P8, DOI 10.1111/j.1365-2133.2007.08265.x
   Schon MP, 2006, J INVEST DERMATOL, V126, P1338, DOI 10.1038/sj.jid.5700286
   Sergienko E, 2009, J BIOMOL SCREEN, V14, P824, DOI 10.1177/1087057109338517
   Sitkovsky MV, 2005, TRENDS IMMUNOL, V26, P299, DOI 10.1016/j.it.2005.04.004
   Solter PF, 1999, AM J VET RES, V60, P1010
   Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447
   Strunk T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010111
   Sud'ina G F, 1998, FEBS Lett, V423, P243, DOI 10.1016/S0014-5793(98)00102-1
   SUSSMAN HH, 1968, NATURE, V218, P359, DOI 10.1038/218359a0
   Thammavongsa V, 2009, J EXP MED, V206, P2417, DOI 10.1084/jem.20090097
   THOMPSON LF, 1986, J IMMUNOL, V137, P2496
   Trautmann A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.256pe6
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Weetman AP, 1999, THYROID, V9, P643, DOI 10.1089/thy.1999.9.643
   Willems F, 2009, EUR J IMMUNOL, V39, P26, DOI 10.1002/eji.200838391
   Wynn JL, 2008, BLOOD, V112, P1750, DOI 10.1182/blood-2008-01-130500
   Yegutkin GG, 2008, BBA-MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024
   Yegutkin GG, 2012, FASEB J, V26, P3875, DOI 10.1096/fj.12-205658
   Yoneyama Y., 2003, Archives of Gynecology and Obstetrics, V267, P205
   Yoneyama Y, 2000, AM J OBSTET GYNECOL, V182, P1200, DOI 10.1067/mob.2000.104832
   Zavialov AV, 2010, J BIOL CHEM, V285, P12367, DOI 10.1074/jbc.M109.083527
   Zavialov AV, 2005, BIOCHEM J, V391, P51, DOI 10.1042/BJ.20050683
NR 75
TC 32
Z9 33
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 20
PY 2013
VL 288
IS 38
BP 27315
EP 27326
DI 10.1074/jbc.M113.484212
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 302IG
UT WOS:000330597300028
PM 23897810
OA No
DA 2017-08-15
ER

PT J
AU Renner, LA
   Dicko, F
   Koueta, F
   Malateste, K
   Gueye, RD
   Aka, E
   Eboua, TK
   Azondekon, A
   Okomo, U
   Toure, P
   Ekouevi, D
   Leroy, V
AF Renner, Lorna A.
   Dicko, Fatoumata
   Koueta, Fla
   Malateste, Karen
   Gueye, Ramatoulaye D.
   Aka, Edmond
   Eboua, Tanoh K.
   Azondekon, Alain
   Okomo, Uduok
   Toure, Pety
   Ekouevi, Didier
   Leroy, Valeriane
CA Iedea West Africa Paediat Collabor
TI Anaemia and zidovudine-containing antiretroviral therapy in paediatric
   antiretroviral programmes in the IeDEA Paediatric West African Database
   to evaluate AIDS
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE antiretroviral therapy; children; cohort studies; HIV infection; adverse
   reactions; West Africa
ID HIV-INFECTED CHILDREN; RESOURCE-LIMITED SETTINGS; HIV-1-INFECTED
   CHILDREN; RISK-FACTORS; RETROSPECTIVE ANALYSIS; SOUTHERN AFRICA;
   FOLLOW-UP; MORTALITY; PREVALENCE; OUTCOMES
AB Introduction: There is a risk of anaemia among HIV-infected children on antiretroviral therapy (ART) containing zidovudine (ZDV) recommended in first-line regimens in the WHO guidelines. We estimated the risk of severe anaemia after initiation of a ZDV-containing regimen in HIV-infected children included in the IeDEA West African database.
   Methods: Standardized collection of data from HIV-infected children (positive PCRB < 18 months or positive serology >= 18 months) followed up in HIV programmes was included in the regional IeDEA West Africa collaboration. Ten clinical centres from seven countries contributed (Benin, Burkina Faso, Cote d'Ivoire, Gambia, Ghana, Mali and Senegal) to this collection. Inclusion criteria were age < 16 years and starting ART. We explored the data quality of haemoglobin documentation over time and the incidence and predictors of severe anaemia (Hb < 7g/dL) per 100 child-years of follow-up over the duration of first-line antiretroviral therapy.
   Results: As of December 2009, among the 2933 children included in the collaboration, 45% were girls, median age was five years; median CD4 cell percentage was 13%; median weight-for-age z-score was -2.7; and 1772 (60.4%) had a first-line ZDV-containing regimen. At baseline, 70% of the children with a first-line ZDV-containing regimen had a haemoglobin measure available versus 76% in those not on ZDV (p <= 0.01): the prevalence of severe anaemia was 3.0% (n = 38) in the ZDV group versus 10.2% (n = 89) in those without (p < 0. 01). Over the first-line follow-up, 58.9% of the children had >= 1 measure of haemoglobin available in those exposed to ZDV versus 60.4% of those not (p <= 0.45). Severe anaemia occurred in 92 children with an incidence of 2.47 per 100 child-years of follow-up in those on a ZDV-containing regimen versus 4.25 in those not (p <= 0.01). Adjusted for age at ART initiation and first-line regimen, a weight-for-age z-score <=- 3 was a strong predictor associated with a 5.59 times risk of severe anaemia (p < 0.01).
   Conclusions: Severe anaemia is frequent at baseline and guides the first-line ART prescription, but its incidence seems rare among children on ART. Severe malnutrition at baseline is a strong predictor for development of severe anaemia, and interventions to address this should form an integral component of clinical care.
C1 [Renner, Lorna A.] Univ Ghana, Sch Med, Dept Child Hlth, Korle Bu Teaching Hosp, Accra, Ghana.
   [Dicko, Fatoumata] Hop Gabriel Toure, Bamako, Mali.
   [Koueta, Fla] CHU Charles de Gaulle, Ouagadougou, Burkina Faso.
   [Malateste, Karen; Leroy, Valeriane] Univ Bordeaux Segalen, Inst Sante Publ Epidemiol & Dev, INSERM, U897, Bordeaux, France.
   [Gueye, Ramatoulaye D.] Hop Enfants Albert Royer, Dakar, Senegal.
   [Aka, Edmond] Ctr Prise Charge Rech & Format CePReF, Abidjan, Cote Ivoire.
   [Eboua, Tanoh K.] CHU Yopougon, Pediat Ward, Abidjan, Cote Ivoire.
   [Azondekon, Alain] Hop Instruct Armees, UPEIV, Cotonou, Benin.
   [Okomo, Uduok] MRC Unit, Fajara, Gambia.
   [Toure, Pety] MTCT Plus Network, Abidjan, Cote Ivoire.
   [Ekouevi, Didier] IeDEA Reg Ctr, Programme PACCI, Abidjan, Cote Ivoire.
RP Renner, LA (reprint author), Univ Ghana, Sch Med, Dept Child Hlth, POB 4236, Accra, Ghana.
EM lornarenner@gmail.com
RI Wejse, Christian/C-8468-2014; EKOUEVI, Didier/E-7960-2014; Leroy,
   Valeriane/F-8129-2013
OI Wejse, Christian/0000-0002-2534-2942; Leroy,
   Valeriane/0000-0003-3542-8616
FU National Cancer Institute (NCI); Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD); National
   Institute of Allergy and Infectious Diseases (NIAID); U.S. National
   Institutes of Health (NIH)
FX Funding from the National Cancer Institute (NCI), the Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   and the National Institute of Allergy and Infectious Diseases (NIAID) of
   the U.S. National Institutes of Health (NIH), as part of the
   International Epidemiologic Databases to Evaluate AIDS (IeDEA) under
   Award Number U01AI069919. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   NIH.
CR Agarwal D, 2010, INDIAN J MED RES, V132, P386
   Anwikar S R, 2011, Int J Risk Saf Med, V23, P163, DOI 10.3233/JRS-2011-0532
   ARROW Trial team, 2013, LANCET, P381
   Aurpibul L, 2008, HIV MED, V9, P317, DOI 10.1111/j.1468-1293.2008.00560.x
   Bolton-Moore C, 2007, JAMA-J AM MED ASSOC, V298, P1888, DOI 10.1001/jama.298.16.1888
   Brabin BJ, 2001, J NUTR, V131, p636S
   Calis JCJ, 2008, AIDS, V22, P1099, DOI 10.1097/QAD.0b013e3282fa759f
   Clark TD, 2002, ANN TROP PAEDIATR, V22, P11, DOI 10.1170/027249302125000102
   Cornet M, 1998, AM J TROP MED HYG, V58, P606
   Davies MA, 2009, SAMJ S AFR MED J, V99, P730
   Eley BS, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-3
   Fassinou P, 2004, AIDS, V18, P1905, DOI 10.1097/00002030-200409240-00006
   Fenner L, 2010, JAIDS-J ACQ IMM DEF, V54, P524, DOI 10.1097/QAI.0b013e3181e0c4cf
   Forna Fatu, 2009, J Int Assoc Physicians AIDS Care (Chic), V8, P128, DOI 10.1177/1545109709333081
   Gibb DM, 2008, AIDS, V22, P97
   Greenwell F, 2006, CHILDRENS ANEMIA LEV
   Heckman J, 2010, S AFR MED J, V100, P7
   Huffam SE, 2007, HIV MED, V8, P465, DOI 10.1111/j.1468-1293.2007.00498.x
   IeDEA Pediatric Working Group, 2013, J INT AIDS SOC, V16, P17998
   Kiragga AN, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-42
   Laufer MK, 2006, PEDIATR INFECT DIS J, V25, P623, DOI 10.1097/01.inf.0000220264.45692.a0
   Meyers T, 2007, J INFECT DIS, V196, pS474, DOI 10.1086/521116
   Midvan D, 2007, CURR MED RES OPIN, V23, P343
   Okechukwu A A, 2010, Niger J Med, V19, P50
   Owiredu WKBA, 2011, AFR HEALTH SCI, V11, P2
   Rajesh Radhakrishnan, 2011, Int J Risk Saf Med, V23, P171, DOI 10.3233/JRS-2011-0531
   Shet A, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-37
   Ssali F, 2006, ANTIVIR THER, V11, P741
   Sullivan PS, 2008, JAIDS-J ACQ IMM DEF, V48, P163, DOI 10.1097/QAI.0b013e3181685714
   Volberding Paul A, 2004, Clin Infect Dis, V38, P1454, DOI 10.1086/383031
   Vreeman RC, 2008, JAIDS-J ACQ IMM DEF, V49, P163, DOI 10.1097/QAI.0b013e318183a996
   Wamalwa DC, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-33
   Weigel R, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-31
   Whitescarter J, 2008, J ACQ IMMUN DEF SYND, V49, P523
   World Health Organization, 2006, ANT THER HIV INF INF
   WHO, 2011, WHONMHNHDMNM111
   World Health Organization, WORLD WID PREV AN 19
NR 37
TC 4
Z9 4
U1 0
U2 6
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD SEP 17
PY 2013
VL 16
AR 18024
DI 10.7448/IAS.16.1.18024
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 223LT
UT WOS:000324807400001
PM 24047928
OA gold
DA 2017-08-15
ER

PT J
AU Kaplan, A
   Hechavarria, S
   Bernal, M
   Bonhoure, I
AF Kaplan, Adriana
   Hechavarria, Suiberto
   Bernal, Mariola
   Bonhoure, Isabelle
TI Knowledge, attitudes and practices of female genital mutilation/cutting
   among health care professionals in The Gambia: a multiethnic study
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Female genital mutilation/cutting; The Gambia; Health care
   professionals; Knowledge; Attitudes and practices (KAP); Sexual and
   reproductive health; Africa
ID WOMEN; CONSEQUENCES; EXPERIENCE; MIDWIVES; SYSTEM
AB Background: Female genital mutilation/cutting (FGM/C) is a harmful traditional practice with severe consequences for the health and well-being of girls and women. Health care professionals (HCPs) are therefore expected to be aware of how to identify and manage these consequences in order to ensure that those affected by the practice receive quality health care. Moreover, their integration and legitimacy within the communities allow them to play a key role in the prevention of the practice. Nevertheless, the perception of HCPs on FGM/C has been barely explored in African contexts. This study seeks to contribute to this field of knowledge by examining the knowledge, attitudes, and practices regarding FGM/C among HCPs working in rural settings in The Gambia.
   Methods: A cross-sectional descriptive study was designed through a quantitative methodology, following a multiethnic approach. A pre-tested questionnaire with open and closed-ended questions was created. Forty medical students from the Community-based Medical Programme were trained to administer the questionnaire, face to face, at village health facilities in rural areas of The Gambia. A final sample of 468 HCPs included all nurse cadres and midwives.
   Results: A significant proportion of Gambian HCPs working in rural areas embraced the continuation of FGM/C (42.5%), intended to subject their own daughters to it (47.2%), and reported having already performed it during their medical practice (7.6%). However, their knowledge, attitudes, and practices were shaped by sex and ethnic identity. Women showed less approval for continuation of FGM/C and higher endorsement of the proposed strategies to prevent it than men. However, it was among ethnic groups that differences were more substantial. HCPs belonging to traditionally practicing groups were more favourable to the perpetuation and medicalisation of FGM/C, suggesting that ethnicity prevails over professional identity.
   Conclusions: These findings demonstrate an urgent need to build HCP's capacities for FGM/C-related complications, through strategies adapted to their specific characteristics in terms of sex and ethnicity. A culturally and gender sensitive training programme might contribute to social change, promoting the abandonment of FGM/C, avoiding medicalisation, and ensuring accurate management of its health consequences.
C1 [Kaplan, Adriana] Univ Autonoma Barcelona, Dept Social & Cultural Anthropol, Chair Social Knowledge Transfer, E-08193 Barcelona, Spain.
   [Kaplan, Adriana; Bernal, Mariola; Bonhoure, Isabelle] Univ Autonoma Barcelona, Interdisciplinary Grp Prevent & Study Harmful Tra, Dept Social & Cultural Anthropol, E-08193 Barcelona, Spain.
   [Kaplan, Adriana] NGO Wassu Gambia Kafo, Fajara Sect F, Banjul, Gambia.
   [Hechavarria, Suiberto] Cuban Med Mission Gambia, Banjul, Gambia.
   [Hechavarria, Suiberto] Minist Hlth & Social Welf, Community Based Med Programme, Banjul, Gambia.
   [Hechavarria, Suiberto] Univ Med La Habana, Fac Ciencias Med Manuel Fajardo, Havana, Cuba.
RP Kaplan, A (reprint author), Univ Autonoma Barcelona, Dept Social & Cultural Anthropol, Chair Social Knowledge Transfer, Parc Recerca UAB Santander, E-08193 Barcelona, Spain.
EM adriana.kaplan@uab.cat
RI Hechavarria Toledo, Suiberto/G-8706-2016
OI Hechavarria Toledo, Suiberto/0000-0002-3470-8352; Bonhoure,
   Isabelle/0000-0002-2971-3069
FU Cuban Medical Mission in The Gambia; Regional Health Teams;
   Community-based Medical students; Fundacio "La Caixa"; Diputacion Foral
   de Alava; Agencia Espanola de Cooperacion Internacional para el
   Desarrollo (AECID)
FX This study was made possible by close collaboration with the Cuban
   Medical Mission in The Gambia, Regional Health Teams, and
   Community-based Medical students. We thank those involved for their
   interest, support and commitment. We especially thank the HCPs who
   agreed to participate in this study, whose time and collaboration
   allowed this research to become a reality. A final acknowledgement is
   dedicated to Elise Johansen, Sandra Blanco, and Ana Seixas for their
   collaboration in reviewing the manuscript. This study was funded by the
   Fundacio "La Caixa", Diputacion Foral de Alava and Agencia Espanola de
   Cooperacion Internacional para el Desarrollo (AECID).
CR Red Activas, 2012, EF AYUD MEJ SAL DER
   Afifi M, 2009, ARCH IRAN MED, V12, P154
   Ahmadu F., 2000, FEMALE CIRCUMCISION
   Ali AAA, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-23
   Alsibiani SA, 2010, FERTIL STERIL, V93, P722, DOI 10.1016/j.fertnstert.2008.10.035
   Banks E, 2006, LANCET, V367, P1835
   Behrendt A, 2005, AM J PSYCHIAT, V162, P1000, DOI 10.1176/appi.ajp.162.5.1000
   Cham M, 2005, REPROD HLTH, V2, P3, DOI DOI 10.1186/1742-4755-2-3
   Cham Mamady, 2009, Reprod Health, V6, P5, DOI 10.1186/1742-4755-6-5
   Chibber R, 2011, J MATERN-FETAL NEO M, V24, P833, DOI 10.3109/14767058.2010.531318
   Cole-Ceesay R, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-21
   Dare F. O., 2004, INT J GYNECOL OBSTET, V24, P281
   Gage AJ, 2006, INT J GYNECOL OBSTET, V92, P92, DOI 10.1016/j.ijgo.2005.09.019
   Gambia Bureau of Statistics (GBoS), 2011, GAMB MULT IND DUST S
   Gambia Bureau of Statistics (GBoS), 2006, GAMB MULT IND CLUST
   Gambia Bureau of Statistics (GBoS), 2006, GAMB ATL 2003 POP HO
   Hernlund Y, 2000, FEMALE CIRCUMCISION
   Hess RF, 2010, J MIDWIFERY WOM HEAL, V55, P46, DOI 10.1016/j.jmwh.2009.01.005
   Kaplan A, 1998, SENEGAMBIA CATALONIA
   Kaplan A, 1999, LEARNING MOTHERHOOD
   Kaplan A, 2013, MTL J WOMENS HEALTH, V5, P323
   Kaplan A, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-26
   Kaplan-Marcusan A, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-11
   Leye E, 2008, EUR J CONTRACEP REPR, V13, P182, DOI 10.1080/13625180701780957
   Mathews B, 2011, MED J AUSTRALIA, V194, P139
   Morison L, 2001, TROP MED INT HEALTH, V6, P643, DOI 10.1046/j.1365-3156.2001.00749.x
   Mostafa S. R. A., 2006, Eastern Mediterranean Health Journal, V12, pS78
   Onuh SO, 2006, J NATL MED ASSOC, V98, P409
   Ragheb S S, 1978, Bull High Inst Public Health, V8, P293
   Reveyrand O, 1982, THESIS U BORDEAUX
   Shell-Duncan B, 2011, SOC SCI MED, V73, P1275, DOI 10.1016/j.socscimed.2011.07.022
   Simister JG, 2010, J FAM VIOLENCE, V25, P247, DOI 10.1007/s10896-009-9288-6
   Simpson J, 2012, BMJ-BRIT MED J, V14, P344
   Tamaddon Leila, 2006, Health Care Women Int, V27, P709, DOI 10.1080/07399330600817741
   Thierfelder C, 2005, EUR J PUBLIC HEALTH, V15, P86, DOI 10.1093/eurpub/cki120
   United Nations Children's Fund, 2010, DYN SOC CHANG AB FEM
   World Health Organization, 2008, EL FEM GEN MUT INT S
   WHO, 2010, GLOB STRAT STOP HLTH
   Zaidi N, 2007, J OBSTET GYNAECOL, V27, P161, DOI 10.1080/01443610601124257
NR 39
TC 10
Z9 10
U1 1
U2 34
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD SEP 16
PY 2013
VL 13
AR 851
DI 10.1186/1471-2458-13-851
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 220XD
UT WOS:000324619700001
PM 24040762
OA gold
DA 2017-08-15
ER

PT J
AU Tangena, JAA
   Adiamoh, M
   D'Alessandro, U
   Jarju, L
   Jawara, M
   Jeffries, D
   Malik, N
   Nwakanma, D
   Kaur, H
   Takken, W
   Lindsay, SW
   Pinder, M
AF Tangena, Julie-Anne A.
   Adiamoh, Majidah
   D'Alessandro, Umberto
   Jarju, Lamin
   Jawara, Musa
   Jeffries, David
   Malik, Naiela
   Nwakanma, Davis
   Kaur, Harparkash
   Takken, Willem
   Lindsay, Steve W.
   Pinder, Margaret
TI Alternative Treatments for Indoor Residual Spraying for Malaria Control
   in a Village with Pyrethroid- and DDT-Resistant Vectors in The Gambia
SO PLOS ONE
LA English
DT Article
ID INSECTICIDE-TREATED NETS; ANOPHELES-GAMBIAE; PIRIMIPHOS-METHYL;
   MOLECULAR-FORMS; AREA; SUSCEPTIBILITY; PROTECTION; MOZAMBIQUE;
   BENDIOCARB; MUTATIONS
AB Background: Malaria vector control is threatened by resistance to pyrethroids, the only class of insecticides used for treating bed nets. The second major vector control method is indoor residual spraying with pyrethroids or the organochloride DDT. However, resistance to pyrethroids frequently confers resistance to DDT. Therefore, alternative insecticides are urgently needed.
   Methodology/Principal Findings: Insecticide resistance and the efficacy of indoor residual spraying with different insecticides was determined in a Gambian village. Resistance of local vectors to pyrethroids and DDT was high (31% and 46% mortality, respectively) while resistance to bendiocarb and pirimiphos methyl was low (88% and 100% mortality, respectively). The vectors were predominantly Anopheles gambiae s.s. with 94% of them having the putative resistant genotype kdr 1014F. Four groups of eight residential compounds were each sprayed with either (1) bendiocarb, a carbamate, (2) DDT, an organochlorine, (3) microencapsulated pirimiphos methyl, an organophosphate, or (4) left unsprayed. All insecticides tested showed high residual activity up to five months after application. Mosquito house entry, estimated by light traps, was similar in all houses with metal roofs, but was significantly less in IRS houses with thatched roofs (p=0.02). Residents participating in focus group discussions indicated that IRS was considered a necessary nuisance and also may decrease the use of long-lasting insecticidal nets.
   Conclusion/Significance: Bendiocarb and microencapsulated pirimiphos methyl are viable alternatives for indoor residual spraying where resistance to pyrethroids and DDT is high and may assist in the management of pyrethroid resistance.
C1 [Tangena, Julie-Anne A.; Takken, Willem] Univ Wageningen & Res Ctr, Entomol Lab, Eh Wageningen, Netherlands.
   [Tangena, Julie-Anne A.] Inst Pasteur Laos, Viangchan, Laos.
   [Adiamoh, Majidah; D'Alessandro, Umberto; Jawara, Musa; Jeffries, David; Nwakanma, Davis; Pinder, Margaret] MRC Unit, Banjul, Gambia.
   [D'Alessandro, Umberto] Inst Trop Med, Unit Malariol, B-2000 Antwerp, Belgium.
   [Jarju, Lamin] Natl Malaria Control Programme, Kanifing, Gambia.
   [Malik, Naiela; Kaur, Harparkash; Lindsay, Steve W.; Pinder, Margaret] London Sch Hyg & Trop Med, London WC1, England.
   [Tangena, Julie-Anne A.; Lindsay, Steve W.; Pinder, Margaret] Univ Durham, Sch Biol & Biomed Sci, Durham, England.
RP Pinder, M (reprint author), MRC Unit, Banjul, Gambia.
EM mpinder@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU MRC, United Kingdom [MRC GO900220]; Research and Policy for Infectious
   Disease Dynamics (RAPIDD) Program of the Science and Technology
   Directory, Department of Homeland Security; Fogarty International
   Center, National Institutes of Health, Medical Research Council, UK
FX The study was financed by the MRC, United Kingdom (www.mrc.ac.uk Grant
   Reference Number: MRC GO900220) to SWL. SWL received support from the
   Research and Policy for Infectious Disease Dynamics (RAPIDD) Program of
   the Science and Technology Directory, Department of Homeland Security,
   and Fogarty International Center, National Institutes of Health, Medical
   Research Council, UK. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akogbeto M, 2011, AM J TROP MED HYG, V85, P586, DOI 10.4269/ajtmh.2011.10-0668
   Alou LPA, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-167
   ANTHONY N, 1995, FEBS LETT, V368, P461, DOI 10.1016/0014-5793(95)00711-H
   Asidi A, 2012, EMERG INFECT DIS, V18, P1101, DOI 10.3201/eid1807.120218
   Bass C, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-111
   Betson M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-187
   Bradley J, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-242
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Clarke S, 2001, THESIS COPENHAGEN, P162
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   Conteh L, 2004, TROP MED INT HEALTH, V9, P125, DOI 10.1046/j.1365-3156.2003.01150.x
   Dabire KR, 2012, INSECTICIDES PEST EN
   DAS M, 1987, MED VET ENTOMOL, V1, P289, DOI 10.1111/j.1365-2915.1987.tb00357.x
   Dawson S., 1993, MANUAL USE FOCUS GRO
   Djogbenou L, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-70
   ELISSA N, 1993, ANN SOC BELG MED TR, V73, P291
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Fuseini G, 2011, J MED ENTOMOL, V48, P437, DOI 10.1603/ME09286
   Gillies M. T., 1968, S A Inst med Res Johannesburg Publ, VNo. 54, P1
   Gillies MT, 1987, PUBL S AFR I MED RES, V55, P1
   Graham K, 2005, MED VET ENTOMOL, V19, P72, DOI 10.1111/j.0269-283X.2005.00543.x
   HEMINGWAY J, 1995, B ENTOMOL RES, V85, P229
   Kirby MJ, 2010, AM J TROP MED HYG, V83, P965, DOI [10.4269/ajtmh.2010.10-0311, 10.4269/ajtmh.2010.10.0311]
   Kirby MJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-2
   KRUSE C. W., 1950, INDIAN JOUR MALARIOL, V4, P267
   Maharaj R, 2004, J MED ENTOMOL, V41, P130, DOI 10.1603/0022-2585-41.1.130
   Ndiath MO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031943
   Ranson H, 2011, TRENDS PARASITOL, V27, P91, DOI 10.1016/j.pt.2010.08.004
   Reimer L, 2008, J MED ENTOMOL, V45, P260, DOI 10.1603/0022-2585(2008)45[260:RBKMAR]2.0.CO;2
   Santolamazza F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-74
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   WHO, 2006, PEST THEIR APPL CONT
   World Health Organization, 2006, GUID TEST MOSQ AD IN
   [Anonymous], 2012, WHO GLOB MAL PROGR G
   World Health Organization Global Alert and Response, 2012, WHO GLOB MAL PROGR, p[30, 70]
NR 35
TC 16
Z9 16
U1 0
U2 29
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2013
VL 8
IS 9
AR e74351
DI 10.1371/journal.pone.0074351
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 218BU
UT WOS:000324408400066
PM 24058551
OA gold
DA 2017-08-15
ER

PT J
AU Sutherland, JS
   Lalor, MK
   Black, GF
   Ambrose, LR
   Loxton, AG
   Chegou, NN
   Kassa, D
   Mihret, A
   Howe, R
   Mayanja-Kizza, H
   Gomez, MP
   Donkor, S
   Franken, K
   Hanekom, W
   Klein, MR
   Parida, SK
   Boom, WH
   Thiel, BA
   Crampin, AC
   Ota, M
   Walzl, G
   Ottenhoff, THM
   Dockrell, HM
   Kaufmann, SHE
AF Sutherland, Jayne S.
   Lalor, Maeve K.
   Black, Gillian F.
   Ambrose, Lyn R.
   Loxton, Andre G.
   Chegou, Novel N.
   Kassa, Desta
   Mihret, Adane
   Howe, Rawleigh
   Mayanja-Kizza, Harriet
   Gomez, Marie P.
   Donkor, Simon
   Franken, Kees
   Hanekom, Willem
   Klein, Michel R.
   Parida, Shreemanta K.
   Boom, W. Henry
   Thiel, Bonnie A.
   Crampin, Amelia C.
   Ota, Martin
   Walzl, Gerhard
   Ottenhoff, Tom H. M.
   Dockrell, Hazel M.
   Kaufmann, Stefan H. E.
CA GCGH Biomarkers TB Consortium
TI Analysis of Host Responses to Mycobacterium tuberculosis Antigens in a
   Multi-Site Study of Subjects with Different TB and HIV Infection States
   in Sub-Saharan Africa
SO PLOS ONE
LA English
DT Article
ID INTERFERON-GAMMA; REGULON; CELLS; VACCINATION; DORMANCY; DISEASE
AB Background: Tuberculosis (TB) remains a global health threat with 9 million new cases and 1.4 million deaths per year. In order to develop a protective vaccine, we need to define the antigens expressed by Mycobacterium tuberculosis (Mtb), which are relevant to protective immunity in high-endemic areas.
   Methods: We analysed responses to 23 Mtb antigens in a total of 1247 subjects with different HIV and TB status across 5 geographically diverse sites in Africa (South Africa, The Gambia, Ethiopia, Malawi and Uganda). We used a 7-day whole blood assay followed by IFN-gamma ELISA on the supernatants. Antigens included PPD, ESAT-6 and Ag85B (dominant antigens) together with novel resuscitation-promoting factors (rpf), reactivation proteins, latency (Mtb DosR regulon-encoded) antigens, starvation-induced antigens and secreted antigens.
   Results: There was variation between sites in responses to the antigens, presumably due to underlying genetic and environmental differences. When results from all sites were combined, HIV- subjects with active TB showed significantly lower responses compared to both TST- and TST+ contacts to latency antigens (Rv0569, Rv1733, Rv1735, Rv1737) and the rpf Rv0867; whilst responses to ESAT-6/CFP-10 fusion protein (EC), PPD, Rv2029, TB10.3, and TB10.4 were significantly higher in TST+ contacts (LTBI) compared to TB and TST- contacts fewer differences were seen in subjects with HIV co-infection, with responses to the mitogen PHA significantly lower in subjects with active TB compared to those with LTBI and no difference with any antigen.
   Conclusions: Our multi-site study design for testing novel Mtb antigens revealed promising antigens for future vaccine development. The IFN-gamma ELISA is a cheap and useful tool for screening potential antigenicity in subjects with different ethnic backgrounds and across a spectrum of TB and HIV infection states. Analysis of cytokines other than IFN-gamma is currently on-going to determine correlates of protection, which may be useful for vaccine efficacy trials.
C1 [Sutherland, Jayne S.; Gomez, Marie P.; Donkor, Simon; Ota, Martin] MRC Unit, Fajara, Gambia.
   [Lalor, Maeve K.; Crampin, Amelia C.; Dockrell, Hazel M.] London Sch Hyg & Trop Med, Dept Immunol & Infect, London WC1, England.
   [Black, Gillian F.; Loxton, Andre G.; Chegou, Novel N.; Walzl, Gerhard] Univ Stellenbosch, Fac Med & Hlth Sci, Dept Biomed Sci, ZA-7505 Tygerberg, South Africa.
   [Ambrose, Lyn R.; Crampin, Amelia C.] Karonga Prevent Study, Chilumba, Malawi.
   [Kassa, Desta] Ethiopian Hlth & Nutr Res Inst, Infect & Noninfect Dis Res Directorate, Addis Ababa, Ethiopia.
   [Mihret, Adane; Howe, Rawleigh] Armauer Hansen Res Inst, Immunol Unit, Addis Ababa, Ethiopia.
   [Mayanja-Kizza, Harriet] Makerere Univ, Dept Med, Kampala, Uganda.
   [Franken, Kees; Klein, Michel R.] Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands.
   [Hanekom, Willem] Univ Cape Town, ZA-7925 Cape Town, South Africa.
   [Parida, Shreemanta K.; Kaufmann, Stefan H. E.] Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany.
   [Boom, W. Henry; Thiel, Bonnie A.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Sutherland, JS (reprint author), MRC Unit, Fajara, Gambia.
EM jsutherland@mrc.gm
RI Joosten, Simone/E-4731-2011; Joosten, Simone/F-1357-2011; Kaufmann,
   Stefan HE/I-5454-2014
OI Walzl, Gerhard/0000-0003-2487-125X; van der Spuy,
   Gian/0000-0002-9067-5903; Sutherland, Jayne/0000-0002-7083-4997;
   Kaufmann, Stefan HE/0000-0001-9866-8268; Mayanja-Kizza,
   Harriet/0000-0002-9297-6208; Joloba, Moses/0000-0002-0334-9983; Parida,
   Shreemanta K/0000-0003-2129-6691; Dockrell, Hazel/0000-0003-1869-9107
FU Bill and Melinda Gates Foundation: Grand Challenges in Global Health
   [37772]
FX This work was funded through the Bill and Melinda Gates Foundation:
   Grand Challenges in Global Health grant no. 37772. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. BMGF website:
   http://www.gatesfoundation.org. GCGH website:
   http://www.biomarkers-for-tb.net
CR Arlehamn CSL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003130
   Black GF, 2001, INT J TUBERC LUNG D, V5, P664
   Black GF, 2009, CLIN VACCINE IMMUNOL, V16, P1203, DOI 10.1128/CVI.00111-09
   Caccamo N, 2010, EUR J IMMUNOL, V40, P2211, DOI 10.1002/eji.201040455
   Chegou NN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038501
   Comas I, 2010, NAT GENET, V42, P498, DOI 10.1038/ng.590
   Commandeur S, 2013, J IMMUNOL, V190, P1659, DOI 10.4049/jimmunol.1201593
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   Ernst JD, 2012, NAT REV IMMUNOL, V12, P581, DOI 10.1038/nri3259
   Goldsack L, 2007, TUBERCULOSIS, V87, P465, DOI 10.1016/j.tube.2007.07.001
   Inokuchi N, 2003, DIAGN MICR INFEC DIS, V46, P109, DOI 10.1016/S0732-8893(03)00018-X
   Leistikow RL, 2010, J BACTERIOL, V192, P1662, DOI 10.1128/JB.00926-09
   Leyten EMS, 2006, MICROBES INFECT, V8, P2052, DOI 10.1016/j.micinf.2006.03.018
   Macdonald SHF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038488
   Odutola AA, 2012, VACCINE, V30, P5591, DOI 10.1016/j.vaccine.2012.06.054
   Ottenhoff THM, 2012, TRENDS MICROBIOL, V20, P419, DOI 10.1016/j.tim.2012.06.002
   Ottenhoff THM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002607
   Ottenhoff THM, 2012, TUBERCULOSIS, V92, pS17, DOI 10.1016/S1472-9792(12)70007-0
   Phong WY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056037
   Santema W, 2013, INFECT IMMUN, V81, P1990, DOI 10.1128/IAI.01121-12
   Sutherland JS, 2009, EUR J IMMUNOL, V39, P723, DOI 10.1002/eji.200838693
   Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
NR 23
TC 20
Z9 20
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 10
PY 2013
VL 8
IS 9
AR e74080
DI 10.1371/journal.pone.0074080
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 259PK
UT WOS:000327538600068
PM 24040170
OA gold
DA 2017-08-15
ER

PT J
AU Prentice, AM
   Verhoef, H
   Cerami, C
AF Prentice, Andrew M.
   Verhoef, Hans
   Cerami, Carla
TI Iron Fortification and Malaria Risk in Children
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID PLASMODIUM-FALCIPARUM; CONTROLLED-TRIAL; YOUNG-CHILDREN
C1 [Prentice, Andrew M.; Verhoef, Hans] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   [Prentice, Andrew M.; Verhoef, Hans] MRC Keneba, Keneba, Gambia.
   [Verhoef, Hans] Wageningen Univ, Cell Biol & Immunol Grp, NL-6700 AP Wageningen, Netherlands.
   [Cerami, Carla] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Hlth, Chapel Hill, NC USA.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM andrew.prentice@lshtm.ac.uk
RI Verhoef, Hans/L-3024-2015
OI Verhoef, Hans/0000-0002-9346-9689; Cerami, Carla/0000-0002-7634-0955
FU Medical Research Council [MC_U123292701, MC_U123292699]; NICHD NIH HHS
   [U01 HD061235]
CR Clark MA, 2013, 5 C INT BIOLR SOC BI
   Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577
   Gwamaka M, 2012, CLIN INFECT DIS, V54, P1137, DOI 10.1093/cid/cis010
   Kerlin DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057434
   MURRAY MJ, 1978, BRIT MED J, V2, P1113
   Muthayya S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067860
   PASVOL G, 1980, BRIT J HAEMATOL, V45, P285, DOI 10.1111/j.1365-2141.1980.tb07148.x
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Senga EL, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-47
   Soofi S, 2013, LANCET, V382, P29, DOI 10.1016/S0140-6736(13)60437-7
   Veenemans J, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001125
   WHO, 2007, FOOD NUTR BULL, V28, pS621
   Zimmermann MB, 2010, AM J CLIN NUTR, V92, P1406, DOI 10.3945/ajcn.110.004564
   Zlotkin S, 2013, JAMA-J AM MED ASSOC, V310
NR 14
TC 11
Z9 11
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD SEP 4
PY 2013
VL 310
IS 9
BP 914
EP 915
DI 10.1001/jama.2013.6771
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 211DT
UT WOS:000323885700020
PM 24002276
OA No
DA 2017-08-15
ER

PT J
AU Hossain, MJ
   Roca, A
   Mackenzie, GA
   Jasseh, M
   Hossain, MI
   Muhammad, S
   Ahmed, M
   Chidiebere, OD
   Malick, N
   Bilquees, SM
   Ikumapayi, UN
   Jeng, B
   Njie, B
   Cham, M
   Kampmann, B
   Corrah, T
   Howie, S
   D'Alessandro, U
AF Hossain, M. Jahangir
   Roca, Anna
   Mackenzie, Grant A.
   Jasseh, Momodou
   Hossain, Mohammad Ilias
   Muhammad, Shah
   Ahmed, Manjang
   Chidiebere, Osuorah Donatus
   Malick, Ndiaye
   Bilquees, S. M.
   Ikumapayi, Usman N.
   Jeng, Baba
   Njie, Baba
   Cham, Mamady
   Kampmann, Beate
   Corrah, Tumani
   Howie, Stephen
   D'Alessandro, Umberto
TI Serogroup W135 Meningococcal Disease, The Gambia, 2012
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID WEST-AFRICA; NEISSERIA-MENINGITIDIS; BURKINA-FASO; VACCINATION;
   CARRIAGE; EPIDEMIC; IMPACT
AB In 2012, an outbreak of Neisseria meningitidis serogroup W135 occurred in The Gambia. The attack rate was highest among young children. The associated risk factors were male sex, contact with meningitis patients, and difficult breathing. Enhanced surveillance facilitates early epidemic detection, and multiserogroup conjugate vaccine could reduce meningococcal epidemics in The Gambia.
C1 [Hossain, M. Jahangir; Roca, Anna; Mackenzie, Grant A.; Jasseh, Momodou; Hossain, Mohammad Ilias; Muhammad, Shah; Ahmed, Manjang; Chidiebere, Osuorah Donatus; Malick, Ndiaye; Bilquees, S. M.; Ikumapayi, Usman N.; Kampmann, Beate; Corrah, Tumani; Howie, Stephen; D'Alessandro, Umberto] MRC Unit, Banjul, Gambia.
   [Jeng, Baba; Njie, Baba; Cham, Mamady] Minist Hlth, Banjul, Gambia.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
RP Hossain, MJ (reprint author), MRC Unit, POB 273, Banjul, Gambia.
EM jhossain@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Medical Research Council; Bill & Melinda Gates Foundation
FX The study. was supported by the Medical Research Council. The Bill &
   Melinda Gates Foundation funded the prospective bacterial disease
   surveillance.
CR Collard JM, 2010, EMERG INFECT DIS, V16, P1496, DOI 10.3201/eid1609.100510
   Greenwood B, 1999, T ROY SOC TROP MED H, V93, P341, DOI 10.1016/S0035-9203(99)90106-2
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P536, DOI 10.1016/0035-9203(87)90397-X
   GREENWOOD BM, 1987, J INFECTION, V14, P167, DOI 10.1016/S0163-4453(87)92052-4
   Greenwood B, 2013, VACCINE, V31, P1453, DOI 10.1016/j.vaccine.2012.12.035
   Hodgson A, 2001, T ROY SOC TROP MED H, V95, P477, DOI 10.1016/S0035-9203(01)90007-0
   Kristiansen PA, 2013, CLIN INFECT DIS, V56, P354, DOI 10.1093/cid/cis892
   Kwara A, 1998, TROP MED INT HEALTH, V3, P742
   Mackenzie GA, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001161
   Nathan N, 2007, EMERG INFECT DIS, V13, P920
   Novak RT, 2012, LANCET INFECT DIS, V12, P757, DOI 10.1016/S1473-3099(12)70168-8
   World Health Organisation regional office for Africa, 2009, STAND OP PROC ENH ME
   Wilder-Smith A, 2002, BRIT MED J, V325, P365, DOI 10.1136/bmj.325.7360.365
   [Anonymous], 2013, WKLY EPIDEMIOL REC, V88, P129
   [Anonymous], 2005, WKLY EPIDEMIOL REC, V80, P313
NR 15
TC 12
Z9 12
U1 0
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2013
VL 19
IS 9
BP 1507
EP 1510
DI 10.3204/eid1909.130077
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 268MB
UT WOS:000328173800023
PM 23965435
OA gold
DA 2017-08-15
ER

PT J
AU Tokarz, R
   Haq, S
   Sameroff, S
   Howie, SRC
   Lipkin, WI
AF Tokarz, Rafal
   Haq, Saddef
   Sameroff, Stephen
   Howie, Stephen R. C.
   Lipkin, W. Ian
TI Genomic analysis of coxsackieviruses A1, A19, A22, enteroviruses 113 and
   104: viruses representing two clades with distinct tropism within
   enterovirus C
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; HUMAN RHINOVIRUS; SPECIES-C; RESPIRATORY
   ENTEROVIRUS; RECOMBINATION; PICORNAVIRUS; SEQUENCE; SEROTYPES;
   EVOLUTION; MEMBERS
AB Coxsackieviruses (CV) A1, CV-A19 and CV-A22 have historically comprised a distinct phylogenetic clade within Enterovirus (EV) C. Several novel serotypes that are genetically similar to these three viruses have been recently discovered and characterized. Here, we report the coding sequence analysis of two genotypes of a previously uncharacterized serotype EV-C113 from Bangladesh and demonstrate that it is most similar to CV-A22 and EV-C116 within the capsid region. We sequenced novel genotypes of CV-A1, CV-A19 and CV-A22 from Bangladesh and observed a high rate of recombination within this group. We also report genomic analysis of the rarely reported EV-C104 circulating in the Gambia in 2009. All available EV-C104 sequences displayed a high degree of similarity within the structural genes but formed two clusters within the non-structural genes. One cluster included the recently reported EV-C117, suggesting an ancestral recombination between these two serotypes. Phylogenetic analysis of all available complete genome sequences indicated the existence of two subgroups within this distinct Enterovirus C clade: one has been exclusively recovered from gastrointestinal samples, while the other cluster has been implicated in respiratory disease.
C1 [Tokarz, Rafal; Haq, Saddef; Sameroff, Stephen; Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10027 USA.
   [Howie, Stephen R. C.] Child Survival Theme, Med Res Council Unit, Banjul, Fajara, Gambia.
RP Tokarz, R (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10027 USA.
EM rt2249@columbia.edu
FU National Institutes of Health [AI057158]; Defense Threat Reduction
   Agency
FX This work was supported by grants from the National Institutes of Health
   AI057158 (North-east Biodefence Center-Lipkin) and the Defense Threat
   Reduction Agency.
CR Begier EM, 2008, CLIN INFECT DIS, V47, P616, DOI 10.1086/590562
   Benschop K, 2010, DIAGN MICR INFEC DIS, V68, P166, DOI 10.1016/j.diagmicrobio.2010.05.016
   Bessaud M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024823
   Briese T, 2005, EMERG INFECT DIS, V11, P310
   Brown B, 2003, J VIROL, V77, P8973, DOI 10.1128/JVI.77.16.8973-8984.2003
   Brown BA, 2009, J GEN VIROL, V90, P1713, DOI 10.1099/vir.0.008540-0
   Combelas N, 2011, VIRUSES-BASEL, V3, P1460, DOI 10.3390/v3081460
   Daleno C, 2013, J CLIN VIROL, V56, P159, DOI 10.1016/j.jcv.2012.10.013
   Daleno C, 2012, J VIROL, V86, P10888, DOI 10.1128/JVI.01721-12
   GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0
   Harvala H, 2012, J MED VIROL, V84, P536, DOI 10.1002/jmv.23203
   Kaida A, 2012, EMERG INFECT DIS, V18, P882, DOI 10.3201/eid1805.111890
   Kapusinszky B, 2010, VIRUS GENES, V40, P163, DOI 10.1007/s11262-009-0440-4
   Khetsuriani Nino, 2006, MMWR Surveill Summ, V55, P1
   Knowles NJ, 2012, VIRUS TAXONOMY CLASS
   LIPSON SM, 1988, J CLIN MICROBIOL, V26, P1298
   Lukashev AN, 2012, J GEN VIROL, V93, P2357, DOI 10.1099/vir.0.043216-0
   Lukashev AN, 2005, REV MED VIROL, V15, P157, DOI 10.1002/rmv.457
   MIRKOVIC RR, 1973, B WORLD HEALTH ORGAN, V49, P341
   Oberste MS, 2013, J VIROL, V87, P558, DOI 10.1128/JVI.00837-12
   Oberste MS, 2004, J GEN VIROL, V85, P1597, DOI 10.1099/vir.0.79789-0
   Oberste MS, 2004, J VIROL, V78, P855, DOI 10.1128/JVI.78.2.855-867.2004
   Oberste MS, 1999, J CLIN MICROBIOL, V37, P1288
   Oberste MS, 1999, J VIROL, V73, P1941
   Piralla A, 2012, DIAGN MICR INFEC DIS, V73, P162, DOI 10.1016/j.diagmicrobio.2012.02.019
   SCHIEBLE JH, 1967, AM J EPIDEMIOL, V85, P297
   SCHMIDT NJ, 1975, J CLIN MICROBIOL, V2, P183
   Simmonds P, 2006, J VIROL, V80, P483, DOI 10.1128/JVI.80.1.483-493.2006
   Smura T, 2007, J GEN VIROL, V88, P2520, DOI 10.1099/vir.0.82866-0
   Sun Q, 2012, J VIROL, V86, P10228, DOI 10.1128/JVI.01567-12
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tapparel C, 2013, INFECT GENET EVOL, V14, P282, DOI 10.1016/j.meegid.2012.10.016
   Tapparel C, 2009, EMERG INFECT DIS, V15, P719, DOI 10.3201/eid1505.081286
   Tokarz R, 2013, J GEN VIROL, V94, P120, DOI 10.1099/vir.0.046250-0
   Tokarz R, 2012, J GEN VIROL, V93, P1952, DOI 10.1099/vir.0.043935-0
   Tokarz R, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-288
   Witso E, 2006, J CLIN MICROBIOL, V44, P4095, DOI 10.1128/JCM.00653-06
   Xiang ZC, 2012, EMERG INFECT DIS, V18, P821, DOI 10.3201/eid1805.111376
   Xiao C, 2001, J VIROL, V75, P2444, DOI 10.1128/JVI.75.5.2444-2451.2001
   Yip CCY, 2011, J VIROL, V85, P12098, DOI 10.1128/JVI.05944-11
   Yozwiak NL, 2010, J VIROL, V84, P9047, DOI 10.1128/JVI.00698-10
NR 41
TC 12
Z9 12
U1 0
U2 3
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD SEP
PY 2013
VL 94
BP 1995
EP 2004
DI 10.1099/vir.0.053462-0
PN 9
PG 10
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 243GJ
UT WOS:000326304600007
PM 23761409
OA No
DA 2017-08-15
ER

PT J
AU Njai, H
   Ceesay, A
   Johnson, L
   Njie, R
   Corrah, T
   Dalessandro, U
   Thurz, M
   Mendy, M
   Chemin, I
AF Njai, H.
   Ceesay, A.
   Johnson, L.
   Njie, R.
   Corrah, T.
   Dalessandro, U.
   Thurz, M.
   Mendy, M.
   Chemin, I.
TI Implementation of a reliable, low cost, in-house quantitative-PCR method
   to measure hepatitis B virus viral load in sub-Saharan Africa
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT Viral Hepatitis Congress
CY SEP 26-28, 2013
CL Frankfurt, GERMANY
C1 [Njai, H.; Ceesay, A.; Johnson, L.; Njie, R.; Corrah, T.; Dalessandro, U.] MRC Gambia Unit, Fajara, Gambia.
   [Thurz, M.] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Mendy, M.] Int Agcy Res Canc, F-69372 Lyon, France.
   [Chemin, I.] Ctr Rech Cancerol, Lyon, France.
RI Chemin, Isabelle/I-3032-2016
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD SEP
PY 2013
VL 20
SU 3
SI SI
BP 32
EP 32
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA 225XI
UT WOS:000324998100057
OA No
DA 2017-08-15
ER

PT J
AU Thriemer, K
   Van Nguyen, H
   Phuc, BQ
   Ha, DM
   Duong, TT
   Rosanas-Urgell, A
   d'Alessandro, U
   Erhart, A
AF Thriemer, K.
   Van Nguyen, H.
   Phuc, B. Q.
   Ha, D. M.
   Duong, T. T.
   Rosanas-Urgell, A.
   d'Alessandro, U.
   Erhart, A.
TI Delayed parasite clearance after treatment with
   dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients
   in Central Vietnam
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Thriemer, K.; Rosanas-Urgell, A.; d'Alessandro, U.; Erhart, A.] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Van Nguyen, H.; Phuc, B. Q.; Ha, D. M.; Duong, T. T.] Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam.
   [d'Alessandro, U.] MRC Unit Fajara, Dis Control & Eliminat Theme, Fajara, Gambia.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2013
VL 18
SU 1
SI SI
BP 66
EP 66
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 213BS
UT WOS:000324029000169
OA No
DA 2017-08-15
ER

PT J
AU Manyando, C
   Njunju, E
   Alessandro, UD
   Van Geertruyden, JP
AF Manyando, C.
   Njunju, E.
   Alessandro, U. D.
   Van Geertruyden, J-P
TI Safety and efficacy of Co-trimoxazole for treatment and prevention of
   Plasmodium falciparum malaria: a systematic review
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Manyando, C.; Njunju, E.] Trop Dis Res Ctr, Ndola, Zambia.
   [Alessandro, U. D.] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Alessandro, U. D.] MRC Unit, Fajara, Gambia.
   [Van Geertruyden, J-P] Univ Antwerp, Antwerp, Belgium.
RI Van geertruyden, Jean-pierre/K-6425-2014
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2013
VL 18
SU 1
SI SI
BP 143
EP 143
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 213BS
UT WOS:000324029000385
OA No
DA 2017-08-15
ER

PT J
AU Manyando, C
   Njunju, E
   Mwakazanga, D
   Chongwe, G
   Mkandawire, R
   Alessandro, UD
   Van Geertruyden, JP
AF Manyando, C.
   Njunju, E.
   Mwakazanga, D.
   Chongwe, G.
   Mkandawire, R.
   Alessandro, U. D.
   Van Geertruyden, J-P
TI The effect of daily Co-trimoxazole in pregnancy in an area of change in
   malaria epidemiology
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Manyando, C.; Njunju, E.; Mwakazanga, D.; Chongwe, G.] Trop Dis Res Ctr, Ndola, Zambia.
   [Mkandawire, R.] Dist Hlth Off, Choma, Zambia.
   [Alessandro, U. D.] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Alessandro, U. D.] Malaria Res Council Unit, Fajara, Gambia.
   [Van Geertruyden, J-P] Univ Antwerp, Antwerp, Belgium.
RI Van geertruyden, Jean-pierre/K-6425-2014
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2013
VL 18
SU 1
SI SI
BP 146
EP 147
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 213BS
UT WOS:000324029000397
OA No
DA 2017-08-15
ER

PT J
AU Samadoulougou, S
   Valea, I
   Tinto, H
   Kirakoya-Samadoulougou, F
   D'Alessandro, U
   Robert, A
AF Samadoulougou, S.
   Valea, I.
   Tinto, H.
   Kirakoya-Samadoulougou, F.
   D'Alessandro, U.
   Robert, A.
TI Incidence of malaria infection and related risk factors among pregnant
   women in rural Burkina Faso
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Samadoulougou, S.; Kirakoya-Samadoulougou, F.; Robert, A.] Catholic Univ Louvain, FSP, IREC, B-1200 Brussels, Belgium.
   [Valea, I.; Tinto, H.] Ctr Muraz, Lab Parasitol & Entomol, Bobo Dioulasso, Burkina Faso.
   [Tinto, H.] Direct Reg Ouest, Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso.
   [D'Alessandro, U.] Inst Trop Med, Unit Malariol, B-2000 Antwerp, Belgium.
   [D'Alessandro, U.] MRC Unit, Fajara, Gambia.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2013
VL 18
SU 1
SI SI
BP 150
EP 150
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 213BS
UT WOS:000324029000407
OA No
DA 2017-08-15
ER

PT J
AU Gryseels, C
   Uk, S
   Erhart, A
   Sochantha, T
   D'Allessandro, U
   Coosemans, M
   Peeters, K
AF Gryseels, C.
   Uk, S.
   Erhart, A.
   Sochantha, T.
   D'Allessandro, U.
   Coosemans, M.
   Peeters, K.
TI Injections, cocktails and diviners: therapeutic flexibility in the
   context of malaria elimination and drug resistance in Northeast Cambodia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Gryseels, C.; Erhart, A.; D'Allessandro, U.; Coosemans, M.; Peeters, K.] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Uk, S.; Sochantha, T.] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia.
   Malaria Res Council Unit, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2013
VL 18
SU 1
SI SI
BP 152
EP 153
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 213BS
UT WOS:000324029000414
OA No
DA 2017-08-15
ER

PT J
AU Takem, E
   Affara, M
   Ngwa, A
   Okebe, J
   Ceesay, S
   Jawara, M
   Oriero, E
   Nwakanma, D
   Pinder, M
   Clifford, C
   Taal, M
   Sowe, M
   Suso, P
   Mendy, A
   Mbaye, A
   Drakeley, C
   D'Alessandro, U
AF Takem, E.
   Affara, M.
   Ngwa, A.
   Okebe, J.
   Ceesay, S.
   Jawara, M.
   Oriero, E.
   Nwakanma, D.
   Pinder, M.
   Clifford, C.
   Taal, M.
   Sowe, M.
   Suso, P.
   Mendy, A.
   Mbaye, A.
   Drakeley, C.
   D'Alessandro, U.
TI Detecting foci of malaria transmission with school surveys: a pilot
   study in the Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Takem, E.; Affara, M.; Ngwa, A.; Okebe, J.; Ceesay, S.; Jawara, M.; Oriero, E.; Nwakanma, D.; Pinder, M.; D'Alessandro, U.] MRC Unit, Fajara, Gambia.
   [Clifford, C.] Univ Manchester, Manchester M13 9PL, Lancs, England.
   [Taal, M.; Sowe, M.; Suso, P.; Mendy, A.] Natl Publ Hlth Lab, Kotu, Gambia.
   [Mbaye, A.] Minist Basic & Secondary Educ, Banjul, Gambia.
   [Drakeley, C.] London Sch Hyg & Trop Med, London WC1, England.
   [D'Alessandro, U.] Inst Trop Med, B-2000 Antwerp, Belgium.
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2013
VL 18
SU 1
SI SI
BP 153
EP 153
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 213BS
UT WOS:000324029000416
OA No
DA 2017-08-15
ER

PT J
AU Jarjou, LMA
   Sawo, Y
   Goldberg, GR
   Laskey, MA
   Cole, TJ
   Prentice, A
AF Jarjou, Landing M. A.
   Sawo, Yankuba
   Goldberg, Gail R.
   Laskey, M. Ann
   Cole, Tim J.
   Prentice, Ann
TI Unexpected long-term effects of calcium supplementation in pregnancy on
   maternal bone outcomes in women with a low calcium intake: a follow-up
   study
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID MINERAL CHANGES; GAMBIAN WOMEN; LACTATION; WEIGHT; SIZE
AB Background: Calcium supplementation of pregnant Gambian women with a low calcium intake results in lower maternal bone mineral content in the subsequent lactation.
   Objective: The objective was to investigate whether the lower bone mineral content persists long term.
   Design: All women in the calcium supplementation trial (International Trial Registry ISRCTN96502494) who had been scanned with dual-energy X-ray absorptiometry at 52 wk of lactation (L52; n = 79) were invited for follow-up when neither pregnant nor lactating for >= 3 mo (NPNL) or at 52 wk postpartum in a future lactation (F52). Bone scans and anthropometric and dietary assessments were conducted.
   Results: Sixty-eight women participated (35 at both NPNL and F52 and 33 at only one time point): n = 59 NPNL (n = 31 calcium, a = 28 placebo) and n = 44 F52 = 24 calcium, a = 20 placebo). The mean (+/- SD) time from L52 was 4.9 +/- 1.9 y for NPNL and 5.0 +/- 1.3 y for F52. Size-adjusted bone mineral content (SA-BMC) was greater at NPNL than at L52 in the placebo group (P <= 0.001) but not in the calcium group (P for time-by-group interaction: lumbar spine, 0.002; total hip, 0.03; whole body, 0.03). No significant changes in SA-BMC from L52 to F52 were observed in either group. Consequently, the lower SA-BMC in the calcium group at L52 persisted at NPNL and F52 (P 0.001): NPNL (lumbar spine, -7.5 +/- 0.7%; total hip, -10.5 +/- 1.0%; whole body, -3.6 +/- 0.5%) and F52 (lumbar spine, -6.2 +/- 0.9%; total hip, -10.3 +/- 1.4%; whole body, -3.2 +/- 0.6%).
   Conclusion: In rural Gambian women with a low-calcium diet, a calcium supplement of 1500 mg/d during pregnancy resulted in lower maternal bone mineral content in the subsequent lactation that persisted long term. This trial was registered at www/controlled-trials.com/mrct/ as ISRCTN96502494.
C1 [Jarjou, Landing M. A.; Sawo, Yankuba; Goldberg, Gail R.; Prentice, Ann] Med Res Council Keneba, Keneba, Gambia.
   [Goldberg, Gail R.; Laskey, M. Ann; Prentice, Ann] Med Res Council Human Nutr Res, Cambridge, England.
   [Cole, Tim J.] UCL, Inst Child Hlth, Ctr Epidemiol Child Hlth, MRC, London, England.
RP Prentice, A (reprint author), Med Res Council Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
RI Cole, Tim/B-7883-2008
OI Cole, Tim/0000-0001-5711-8200
FU UK Medical Research Council [U105960371, U123261351, MR/J004839/1]
FX Supported by the UK Medical Research Council under program numbers
   U105960371, U123261351, and MR/J004839/1. Shire Pharmaceuticals and
   Nycomed Pharma donated the calcium and placebo tablets. This is a free
   access article, distributed under terms
   (http://www.nutrition.org/publications/guidelines-and-policies/license/)
   that permit unrestricted noncommercial use, distribution, and
   reproduction in any medium, provided the original work is properly
   cited.
CR Akesson A, 2004, ACTA OBSTET GYN SCAN, V83, P1049, DOI 10.1111/j.0001-6349.2004.00428.x
   Atkins GJ, 2012, OSTEOPOROSIS INT, V23, P2067, DOI 10.1007/s00198-012-1915-z
   Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F
   Goldberg GR, AM J CLIN N IN PRESS
   Holmberg-Marttila D, 2000, OSTEOPOROSIS INT, V11, P570, DOI 10.1007/s001980070077
   Jarjou LMA, 2010, AM J CLIN NUTR, V92, P450, DOI 10.3945/ajcn.2010.29217
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   Kolthoff N, 1998, CLIN SCI, V94, P405
   Kovacs CS, 2011, ENDOCRIN METAB CLIN, V40, P795, DOI 10.1016/j.ecl.2011.08.002
   Laskey MA, 1999, OBSTET GYNECOL, V94, P608, DOI 10.1016/S0029-7844(99)00369-5
   Olausson H, 2008, AM J CLIN NUTR, V88, P1032
   Olausson H, 2012, NUTR RES REV, V25, P40, DOI 10.1017/S0954422411000187
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   Prentice A, 2003, J NUTR, V133, p1693S
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   Prentice A, 1997, NEW ENGL J MED, V337, P558, DOI 10.1056/NEJM199708213370809
   Prentice A, 2012, AM J CLIN NUTR, V96, P1042, DOI 10.3945/ajcn.112.037481
   Prynne C, 2011, FOOD COMPOSITION TAB
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   Sawo Y, EUR J CLIN IN PRESS
   SKERRY TM, 1988, J ORTHOPAED RES, V6, P547, DOI 10.1002/jor.1100060411
   Teti A, 2009, BONE, V44, P11, DOI 10.1016/j.bone.2008.09.017
   WALKER ARP, 1972, AM J CLIN NUTR, V25, P518
NR 24
TC 13
Z9 14
U1 0
U2 9
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD SEP
PY 2013
VL 98
IS 3
BP 723
EP 730
DI 10.3945/ajcn.113.061630
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 206OT
UT WOS:000323532700014
PM 23902782
OA No
DA 2017-08-15
ER

PT J
AU Jobarteh, ML
   Moore, S
   Kennedy, C
   Gambling, L
   McArdle, HJ
AF Jobarteh, Modou Lamin
   Moore, Sophie
   Kennedy, Christine
   Gambling, Lorraine
   McArdle, Harry J.
TI THE EFFECT OF NUTRITIONAL SUPPLEMENTATION DURING PREGNANCY ON PLACENTAL
   TRANSPORTER EXPRESSION IN PLACENTAS FROM GAMBIAN WOMEN
SO PLACENTA
LA English
DT Meeting Abstract
CT Meeting of the International-Federation-of-Placenta-Associations (IFPA)
CY SEP 11-14, 2013
CL Whistler, CANADA
SP Int Federat Placenta Assoc (IFPA)
C1 [Jobarteh, Modou Lamin; Kennedy, Christine; Gambling, Lorraine; McArdle, Harry J.] Univ Aberdeen, Rowett Inst Nutr & Hlth, Aberdeen, Scotland.
   [Jobarteh, Modou Lamin; Moore, Sophie] MRC Unit Gambia, MRC Keneba, MRC Int Nutr Grp, Banjul, Gambia.
NR 0
TC 2
Z9 2
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0143-4004
J9 PLACENTA
JI Placenta
PD SEP
PY 2013
VL 34
IS 9
BP A81
EP A82
DI 10.1016/j.placenta.2013.06.241
PG 2
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA 207GW
UT WOS:000323587900249
OA No
DA 2017-08-15
ER

PT J
AU Cunnington, AJ
   Bretscher, MT
   Nogaro, SI
   Riley, EM
   Walther, M
AF Cunnington, Aubrey J.
   Bretscher, Michael T.
   Nogaro, Sarah I.
   Riley, Eleanor M.
   Walther, Michael
TI Comparison of parasite sequestration in uncomplicated and severe
   childhood Plasmodium falciparum malaria
SO JOURNAL OF INFECTION
LA English
DT Article
DE Cerebral malaria; Microcirculation; Lactic acid; Sequestration; HRP2;
   Anaemia; Parasite Biomass
ID CEREBRAL MALARIA; AFRICAN CHILDREN; RANDOMIZED-TRIAL; ADJUNCTIVE
   THERAPY; MALAWIAN CHILDREN; PATHOGENESIS; MANAGEMENT; MORTALITY; AGE;
   PATHOPHYSIOLOGY
AB Objectives: To determine whether sequestration of parasitized red blood cells differs between children with uncomplicated and severe Plasmodium falciparum malaria.
   Methods: We quantified circulating-, total-and sequestered-parasite biomass, using a mathematical model based on plasma concentration of P. falciparum histidine rich protein 2, in Gambian children with severe (n = 127) and uncomplicated (n = 169) malaria.
   Results: Circulating-and total-, but not sequestered-, parasite biomass estimates were significantly greater in children with severe malaria than in those with uncomplicated malaria. Sequestered biomass estimates in children with hyperlactataemia or prostration were similar to those in uncomplicated malaria, whereas sequestered biomass was higher in patients with severe anaemia, and showed a trend to higher values in cerebral malaria and fatal cases. Blood lactate concentration correlated with circulating-and total-, but not sequestered parasite biomass. These findings were robust after controlling for age, prior antimalarial treatment and clonality of infection, and over a realistic range of variation in model parameters.
   Conclusion: Extensive sequestration is not a uniform requirement for severe paediatric malaria. The pathophysiology of hyperlactataemia and prostration appears to be unrelated to sequestered parasite biomass. Different mechanisms may underlie different severe malaria syndromes, and different therapeutic strategies may be required to improve survival. Published by Elsevier Ltd on behalf of The British Infection Association.
C1 [Cunnington, Aubrey J.; Bretscher, Michael T.; Nogaro, Sarah I.; Riley, Eleanor M.] Univ London London Sch Hyg & Trop Med, Dept Immunol & Infect, Fac Infect & Trop Dis, London WC1E 7HT, England.
   [Cunnington, Aubrey J.; Nogaro, Sarah I.; Walther, Michael] Med Res Council UK Labs, Banjul, Gambia.
   [Cunnington, Aubrey J.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Paediat Sect, London W2 1PG, England.
   [Walther, Michael] NIAID, Immune Regulat Sect, Lab Malaria Immunol & Vaccinol, Div Intramural Res,NIH, Rockville, MD 20852 USA.
RP Walther, M (reprint author), NIAID, Immune Regulat Sect, Lab Malaria Immunol & Vaccinol, Div Intramural Res,NIH, Twinbrook 2 Rm 239 A,12441 Parklawn Dr, Rockville, MD 20852 USA.
EM Michael.Walther@nih.gov
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570; Cunnington,
   Aubrey/0000-0002-1305-3529
FU Medical Research Council, UK [G0701427]
FX This work was supported by core funding from the Medical Research
   Council, UK to the malaria research programme, and a Medical Research
   Council, UK, clinical research training fellowship [G0701427 to A.J.C.].
CR Anstey NM, 2012, ADV PARASIT, V80, P151, DOI 10.1016/B978-0-12-397900-1.00003-7
   Bejon P, 2007, PLOS MED, V4, P1333, DOI 10.1371/journal.pmed.0040251
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299
   Bronzan RN, 2007, J INFECT DIS, V195, P895, DOI 10.1086/511437
   Buffet PA, 2011, BLOOD, V117, P381, DOI 10.1182/blood-2010-04-202911
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Clark IA, 2009, TRENDS PARASITOL, V25, P314, DOI 10.1016/j.pt.2009.04.003
   Craig AG, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002401
   Cromer D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055961
   Cunnington AJ, 2013, J INFECT DIS, V207, P369, DOI 10.1093/infdis/jis681
   Cunnington AJ, 2012, J IMMUNOL, V189, P5336, DOI 10.4049/jimmunol.1201028
   Cunnington Aubrey J, 2011, Nat Med, V18, P120, DOI 10.1038/nm.2601
   Dondorp AM, 2005, PLOS MED, V2, P788, DOI 10.1371/journal.pmed.0020204
   Dondorp AM, 2004, ACTA TROP, V89, P309, DOI 10.1016/j.actatropica.2003.10.004
   Dondorp AM, 2008, CLIN INFECT DIS, V47, P151, DOI 10.1086/589287
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   Edwards MD, 2012, MOL CELL PROBE, V26, P151, DOI 10.1016/j.mcp.2012.04.003
   English M, 1997, QJM-INT J MED, V90, P263, DOI 10.1093/qjmed/90.4.263
   Faiz MA, 2005, LANCET, V366, P717
   Genton B, 2008, PLOS MED, V5, P881, DOI 10.1371/journal.pmed.0050127
   Grau GER, 2012, FUTURE MICROBIOL, V7, P291, DOI [10.2217/fmb.11.155, 10.2217/FMB.11.155]
   Gravenor MB, 1998, P NATL ACAD SCI USA, V95, P7620, DOI 10.1073/pnas.95.13.7620
   GRAVENOR MB, 1995, PARASITOLOGY, V110, P115
   Hanson J, 2012, J INFECT DIS
   Hanson J, 2010, CLIN INFECT DIS, V50, P679, DOI 10.1086/649928
   Hendriksen ICE, 2013, J INFECT DIS, V207, P351, DOI 10.1093/infdis/jis675
   Hendriksen ICE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001297
   Higgins SJ, 2011, EXPERT REV ANTI-INFE, V9, P803, DOI [10.1586/eri.11.96, 10.1586/ERI.11.96]
   Jallow M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045645
   John CC, 2010, EXPERT REV ANTI-INFE, V8, P997, DOI [10.1586/eri.10.90, 10.1586/ERI.10.90]
   Kim H, 2011, CURR OPIN HEMATOL, V18, P177, DOI 10.1097/MOH.0b013e328345a4cf
   Krishna S, 2012, CURR OPIN INFECT DIS, V25, P484, DOI 10.1097/QCO.0b013e3283567b20
   Maitland K, 2006, TRENDS PARASITOL, V22, P457, DOI 10.1016/j.pt.2006.07.006
   Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549
   Miller LH, 2013, NAT MED, V19, P156, DOI 10.1038/nm.3073
   Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8
   Newton CRJC, 2005, CLIN INFECT DIS, V41, P948, DOI 10.1086/432941
   Planche T, 2003, CLIN INFECT DIS, V37, P890, DOI 10.1086/377536
   Planche T, 2005, CURR OPIN INFECT DIS, V18, P369, DOI 10.1097/01.qco.0000180161.38530.81
   Raes Ann, 2006, BMC Pediatr, V6, P3, DOI 10.1186/1471-2431-6-3
   Reyburn H, 2005, JAMA-J AM MED ASSOC, V293, P1461, DOI 10.1001/jama.293.12.1461
   Rowe JA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001082
   Rubach MP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035985
   Schoeps A, 2011, AM J EPIDEMIOL, V173, P492, DOI 10.1093/aje/kwq386
   Seydel KB, 2012, J INFECT DIS, V206, P309, DOI 10.1093/infdis/jis371
   Seydel K.B., 2006, J INFECT DIS, V194, P205
   Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X
   Smith T, 2004, PARASITOLOGY, V129, P289, DOI 10.1017/S003118200400575X
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986
   von Seidlein L, 2012, CLIN INFECT DIS, V54, P1080, DOI 10.1093/cid/cis034
   WALLER D, 1995, CLIN INFECT DIS, V21, P577
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Warimwe GM, 2012, SCI TRANSL MED, V4, P129, DOI DOI 10.1126/SCITRANSLMED.3003247
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
   Yeo TW, 2013, J INFECT DIS, V207, P528, DOI 10.1093/infdis/jis692
NR 57
TC 13
Z9 13
U1 0
U2 13
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
J9 J INFECTION
JI J. Infect.
PD SEP
PY 2013
VL 67
IS 3
BP 220
EP 230
DI 10.1016/j.jinf.2013.04.013
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 195XO
UT WOS:000322737300007
PM 23623771
OA No
DA 2017-08-15
ER

PT J
AU Cooke, GS
   Lemoine, M
   Thursz, M
   Gore, C
   Swan, T
   Kamarulzaman, A
   DuCros, P
   Ford, N
AF Cooke, G. S.
   Lemoine, M.
   Thursz, M.
   Gore, C.
   Swan, T.
   Kamarulzaman, A.
   DuCros, P.
   Ford, N.
TI Viral hepatitis and the Global Burden of Disease: a need to regroup
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
ID SYSTEMATIC ANALYSIS; MORTALITY
C1 [Cooke, G. S.] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Lemoine, M.] MRC Gambia, Fajara, Gambia.
   [Thursz, M.] EASL, Secretary Generals Off, Geneva, Switzerland.
   [Gore, C.] World Hepatitis Alliance, Brighton, E Sussex, England.
   [Swan, T.] Treatment Act Grp, New York, NY USA.
   [Kamarulzaman, A.] Univ Malaysia, Fac Med, Kuala Lumpur, Malaysia.
   [DuCros, P.] MSF, Lister Unit, London, England.
   [Ford, N.] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa.
RP Cooke, GS (reprint author), Univ London Imperial Coll Sci Technol & Med, London, England.
EM g.cooke@imperial.ac.uk
FU BRC of Imperial College NHS Trust
FX We would like to thank Mohsen Naghavi and Stefan Wiktor for their
   helpful comments. This work was supported in part by the BRC of Imperial
   College NHS Trust.
CR Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4
   Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6
   Rajaratnam JK, 2010, LANCET, V375, P1704, DOI 10.1016/S0140-6736(10)60517-X
   Seaberg EC, 2002, LANCET, V9349, P1921
NR 5
TC 31
Z9 31
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD SEP
PY 2013
VL 20
IS 9
BP 600
EP 601
DI 10.1111/jvh.12123
PG 2
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA 195ND
UT WOS:000322708700002
PM 23910643
OA No
DA 2017-08-15
ER

PT J
AU Lopez-Garcia, J
   Bilek, F
   Lehocky, M
   Junkar, I
   Mozetic, M
   Sowe, M
AF Lopez-Garcia, Jorge
   Bilek, Frantisek
   Lehocky, Marian
   Junkar, Ita
   Mozetic, Miran
   Sowe, Musa
TI Enhanced printability of polyethylene through air plasma treatment
SO VACUUM
LA English
DT Article
DE Polyethylene; Plasma treatment; Surface modification; Printability
ID MEDICAL-GRADE PVC; SURFACE MODIFICATION; PHYSICOCHEMICAL APPROACH;
   BACTERIAL ADHESION; ARGON PLASMA; THIN-FILMS;
   POLY(ETHYLENE-TEREPHTHALATE); ATTACHMENT; PARTICLES; COATINGS
AB Low-density polyethylene (LOPE) foils were surface-modified by using non-thermal non-equilibrium oxidative air 40 kHz frequency, radiofrequency (RF) and microwave (MW) discharge plasma treatment. The pristine and treated specimens were morphologically and chemically characterised by Scanning Electron Microscopy (SEM) imaging, X-ray Photoelectron Spectroscopy (XPS) and contact angle measurement with surface energy evaluation. In addition, printability and ink adhesion tests were carried out on the samples, and quantitatively appraised by UV-VIS transmission spectroscopy. The overall outcome indicated chemical and physical changes after each treatment, and the improvement of printability. The present approach could serve as a viable and promising method to improve printability of polyethylene. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Lopez-Garcia, Jorge; Bilek, Frantisek; Lehocky, Marian; Sowe, Musa] Tomas Bata Univ Zlin, Ctr Polymer Syst, Zlin 76001, Czech Republic.
   [Junkar, Ita; Mozetic, Miran] Jozef Stefan Inst, Plasma Lab, Dept Surface Engn, SI-1000 Ljubljana, Slovenia.
   [Sowe, Musa] Univ Gambia, Sere Kunda, Gambia.
RP Lehocky, M (reprint author), Tomas Bata Univ Zlin, Ctr Polymer Syst, Nam TG Masaryka 5555, Zlin 76001, Czech Republic.
EM lehocky@post.cz
RI Lehocky, Marian/H-1981-2012; Lopez Garcia, Jorge/H-6581-2012; Mozetic,
   Miran/K-8784-2014
OI Lehocky, Marian/0000-0002-5368-5029
FU Ministry of Education, Youth and Sport of the Czech Republic
   [CZ.1.05/2.1.00/03.0111]; Slovenia Ministry of Higher Education,
   Science, and Technology [P2-0082-2]; Ad Futura [L7-4009]
FX The authors would like to express their gratitude to the Ministry of
   Education, Youth and Sport of the Czech Republic
   (CZ.1.05/2.1.00/03.0111). The Slovenia Ministry of Higher Education,
   Science, and Technology (Program P2-0082-2) and Ad Futura L7-4009 are
   also gratefully acknowledged for financial support of this research.
CR Almazan-Almazan MC, 2006, J COLLOID INTERF SCI, V293, P353, DOI 10.1016/j.jcis.2005.06.073
   Asadinezhad A, 2010, PLASMA PROCESS POLYM, V7, P504, DOI 10.1002/ppap.200900132
   Asadinezhad A, 2010, COLLOID SURFACE B, V77, P246, DOI 10.1016/j.colsurfb.2010.02.006
   Asadinezhad A, 2010, MOLECULES, V15, P1007, DOI 10.3390/molecules15021007
   Bag DS, 1999, J APPL POLYM SCI, V71, P1041, DOI 10.1002/(SICI)1097-4628(19990214)71:7<1041::AID-APP1>3.0.CO;2-R
   Bilek F, 2011, COLLOID SURFACE B, V88, P440, DOI 10.1016/j.colsurfb.2011.07.027
   Bursikova V, 2004, SURFACE ENERGY EVALU
   [Anonymous], 2012, MARK STUD POL HDPE
   Chan CM, 1994, POLYM SURFACE MODIFI, P285
   Coutinho Fernanda M. B., 2003, Polímeros, V13, P01, DOI 10.1590/S0104-14282003000100005
   Cvelbar U, 2005, IEEE T PLASMA SCI, V33, P236, DOI 10.1109/TPS.2005.845345
   Desai SM, 2004, ADV POLYM SCI, V169, P231, DOI 10.1007/b13524
   Desmet T, 2009, BIOMACROMOLECULES, V10, P2351, DOI 10.1021/bm900186s
   Duske K, 2012, J CLIN PERIODONTOL, V39, P400, DOI 10.1111/j.1600-051X.2012.01853.x
   France RM, 1997, J CHEM SOC FARADAY T, V93, P3173, DOI 10.1039/a702311a
   Garcia JL, 2011, PROG COLL POL SCI S, V138, P89, DOI 10.1007/978-3-642-19038-4_16
   Garcia JL, 2010, MOLECULES, V15, P2845, DOI 10.3390/molecules15042845
   Jana T, 2001, J APPL POLYM SCI, V79, P1273, DOI 10.1002/1097-4628(20010214)79:7<1273::AID-APP150>3.0.CO;2-L
   Junkar I., 2010, VACUUM, V84, P83
   Junkar I, 2011, MATER TEHNOL, V45, P221
   Kamgang JO, 2009, PLASMA SCI TECHNOL, V11, P187, DOI 10.1088/1009-0630/11/2/11
   Kasirajan S, 2012, AGRON SUSTAIN DEV, V32, P501, DOI 10.1007/s13593-011-0068-3
   Lehocky M, 2008, SURF ENG, V24, P23, DOI 10.1179/174329408X271444
   Lehocky M, 2004, CZECH J PHYS, V54, pC533
   Lehocky M, 2003, COLLOID SURFACE A, V222, P125, DOI 10.1016/S0927-7757(03)00242-5
   Lehocky M, 2003, MATER SCI FORUM, V426-4, P2533
   Lehocky M, 2009, J MATER PROCESS TECH, V209, P2871, DOI 10.1016/j.jmatprotec.2008.06.042
   Lide D. P., 2007, CRC HDB CHEM PHYS, P2640
   MCGARRY FJ, 1994, ANNU REV MATER SCI, V24, P63
   Morent R, 2008, SURF COAT TECH, V202, P3427, DOI 10.1016/j.surfcoat.2007.12.027
   Polaskova M, 2010, POLYM COMPOSITE, V31, P1427, DOI 10.1002/pc.20928
   Popelka A, 2012, MOLECULES, V17, P762, DOI 10.3390/molecules17010762
   Sedlacik M, 2011, COLLOID SURFACE A, V387, P99, DOI 10.1016/j.colsurfa.2011.07.035
   Sowe M, 2009, INT J POLYM ANAL CH, V14, P641, DOI 10.1080/10236660903225494
   Vasile C, 2008, PRACTICAL GUIDE POLY, P184
   Vesel A., 2012, VACUUM, V86, P632
   Vesel A, 2008, SURF INTERFACE ANAL, V40, P1444, DOI 10.1002/sia.2923
   Zahedi AR, 2006, J PLAST FILM SHEET, V22, P163, DOI 10.1177/8756087906066753
NR 38
TC 9
Z9 9
U1 3
U2 59
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-207X
J9 VACUUM
JI Vacuum
PD SEP
PY 2013
VL 95
BP 43
EP 49
DI 10.1016/j.vacuum.2013.02.008
PG 7
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 137VP
UT WOS:000318466600008
OA No
DA 2017-08-15
ER

PT J
AU Wilson, H
   de Jong, BC
   Peterson, K
   Jaye, A
   Kampmann, B
   Ota, MOC
   Sutherland, JS
AF Wilson, Harry
   de Jong, Bouke C.
   Peterson, Kevin
   Jaye, Assan
   Kampmann, Beate
   Ota, Martin O. C.
   Sutherland, Jayne S.
TI Skewing of the CD4(+) T-Cell Pool Toward Monofunctional Antigen-Specific
   Responses in Patients With Immune Reconstitution Inflammatory Syndrome
   in The Gambia
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV; immune reconstitution inflammatory syndrome; tuberculosis;
   polyfunctional T cells; West Africa
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-1-INFECTED PATIENTS; TUBERCULOSIS;
   RISK
AB Background. A common complication of starting antiretroviral therapy (ART) for human immunodeficiency virus (HIV) is the development of immune reconstitution inflammatory syndrome (IRIS) in approximately 25% of patients. Despite similarities with paradoxical reactions to tuberculosis and reversal reactions in leprosy, the exact mechanisms, and therefore potential determinants, of IRIS are still unknown.
   Methods. In this longitudinal cohort study, we analyzed 20 patients who developed IRIS following initiation of ART and 16 patients who did not, matched for ART time point. Peripheral blood mononuclear cells were stimulated overnight with a positive control antigen and 2 tuberculosis-specific antigens (purified protein derivative [PPD] and ESAT-6/CFP10), followed by polychromatic flow cytometry for analysis of cytokine production from CD4(+) and CD8(+) T cells.
   Results. Responses to PPD were significantly higher in IRIS patients compared to controls during the IRIS time point, but CD4(+) and CD8(+) T-cell responses to the positive control stimulation were significantly lower in IRIS patients at all time points. Furthermore, whereas control patients had rejuvenated polyfunctional T-cell responses by 3 months after ART, IRIS patients were strikingly monofunctional (generally interferon gamma alone), even up to 6 months of ART in response to all stimulations. Conclusions. Our findings suggest that the peripheral T-cell responses to the underlying pathogen are exaggerated in IRIS patients but that the overall quality of the peripheral T-cell pool is significantly reduced compared to non-IRIS patients. Furthermore, these effects are apparent at least up to 3 months after cessation of IRIS.
C1 [Wilson, Harry; de Jong, Bouke C.; Peterson, Kevin; Jaye, Assan; Kampmann, Beate; Ota, Martin O. C.; Sutherland, Jayne S.] MRC Unit, Fajara, Gambia.
RP Sutherland, JS (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM jsutherland@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; Kampmann, Beate/0000-0002-6546-4709;
   Sutherland, Jayne/0000-0002-7083-4997
FU Medical Research Council
FX This work was funded by the Medical Research Council.
CR Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3
   Beveridge NER, 2007, EUR J IMMUNOL, V37, P3089, DOI 10.1002/eji.2007375041
   Bourgarit A, 2009, J IMMUNOL, V183, P3915, DOI 10.4049/jimmunol.0804020
   Chen CY, 2012, J IMMUNOL, V188, P4278, DOI 10.4049/jimmunol.1101291
   Ferrando-Martinez S, 2012, J VIROL, V86, P3667, DOI 10.1128/JVI.07034-11
   Girardi E, 2000, AIDS, V14, P1985, DOI 10.1097/00002030-200009080-00015
   Grant PM, 2012, J INFECT DIS, V206, P1715, DOI 10.1093/infdis/jis604
   Haddow LJ, 2009, CLIN INFECT DIS, V49, P1424, DOI 10.1086/630208
   Haddow LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040623
   Mahnke YD, 2012, BLOOD, V119, P3105, DOI 10.1182/blood-2011-09-380840
   Marais S, 2013, CLIN INFECT DIS, V56, P450, DOI 10.1093/cid/cis899
   Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1
   Murdoch David M, 2007, AIDS Res Ther, V4, P9, DOI 10.1186/1742-6405-4-9
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Shelburne SA, 2005, AIDS, V19, P399, DOI 10.1097/01.aids.0000161769.06158.8a
   Sutherland JS, 2010, J IMMUNOL, V184, P6537, DOI 10.4049/jimmunol.1000399
   Tadokera R, 2011, EUR RESPIR J, V37, P1248, DOI 10.1183/09031936.00091010
   Tieu Hong Van, 2009, AIDS Res Hum Retroviruses, V25, P1083, DOI 10.1089/aid.2009.0055
   World Health Organization, 2012, STRAT US ANT HELP EN
   Worsley CM, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-36
   Zaidi I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039213
NR 21
TC 1
Z9 1
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2013
VL 57
IS 4
BP 594
EP 603
DI 10.1093/cid/cit285
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 190LV
UT WOS:000322342500025
PM 23645847
OA No
DA 2017-08-15
ER

PT J
AU Blunden, J
   Arndt, DS
   Achberger, C
   Ackerman, SA
   Albanil, A
   Alexander, P
   Alfaro, EJ
   Allan, R
   Alves, LM
   Amador, JA
   Ambenje, P
   Andrianjafinirina, S
   Antonov, J
   Aravequia, JA
   Arendt, A
   Arevalo, J
   Ashik, I
   Atheru, Z
   Banzon, V
   Baringer, MO
   Barreira, S
   Barriopedro, DE
   Beard, G
   Becker, A
   Behrenfeld, MJ
   Bell, GD
   Benedetti, A
   Bernhard, G
   Berrisford, P
   Berry, DI
   Bhatt, U
   Bidegain, M
   Bindoff, N
   Bissolli, P
   Blake, ES
   Booneeady, R
   Bosilovich, M
   Box, JE
   Boyer, T
   Braathen, GO
   Bromwich, DH
   Brown, R
   Brown, L
   Bruhwiler, L
   Bulygina, ON
   Burgess, D
   Burrows, J
   Calderon, B
   Camargo, SJ
   Campbell, J
   Cao, Y
   Cappelen, J
   Carrasco, G
   Chambers, DP
   Chang'a, L
   Chappell, P
   Chehade, W
   Cheliah, M
   Christiansen, HH
   Christy, JR
   Ciais, P
   Coelho, CAS
   Cogley, JG
   Colwell, S
   Cross, JN
   Crouch, J
   Cunningham, SA
   Dacic, M
   De Jeu, RAM
   Dekaa, FS
   Demircan, M
   Derksen, C
   Diamond, HJ
   Dlugokencky, EJ
   Dohan, K
   Dolman, AJ
   Domingues, CM
   Dong, SF
   Dorigo, WA
   Drozdov, DS
   Duguay, CR
   Dunn, RJH
   Duran-Quesada, AM
   Dutton, GS
   Ehmann, C
   Elkins, JW
   Euscategui, C
   Famiglietti, JS
   Fang, F
   Fauchereau, N
   Feely, RA
   Fekete, BM
   Fenimore, C
   Fioletov, VE
   Fogarty, CT
   Fogt, RL
   Folland, CK
   Foster, MJ
   Frajka-Williams, E
   Franz, BA
   Frith, SH
   Frolov, I
   Ganter, C
   Garzoli, S
   Geai, ML
   Gerland, S
   Gitau, W
   Gleason, KL
   Gobron, N
   Goldenberg, SB
   Goni, G
   Good, SA
   Gottschalck, J
   Gregg, MC
   Griffiths, G
   Grooss, JU
   Guard, C
   Gupta, SK
   Hall, BD
   Halpert, MS
   Harada, Y
   Hauri, C
   Heidinger, AK
   Heikkila, A
   Heim, RR
   Heimbach, P
   Hidalgo, HG
   Hilburn, K
   Ho, SP
   Hobbs, WR
   Holgate
   Hovsepyan, A
   Hu, ZZ
   Hughes, P
   Hurst, DF
   Ingvaldsen, R
   Inness, A
   Jaimes, E
   Jakobsson, M
   James, AI
   Jeffries, MO
   Johns, WE
   Johnsen, B
   Johnson, GC
   Johnson, B
   Jones, LT
   Jumaux, G
   Kabidi, K
   Kaiser, JW
   Kamga, A
   Kang, KK
   Kanzow, TO
   Kao, HY
   Keller, LM
   Kennedy, JJ
   Key, J
   Khatiwala, S
   Pour, HK
   Kholodov, AL
   Khoshkam, M
   Kijazi, A
   Kikuchi, T
   Kim, BM
   Kim, SJ
   Kimberlain, TB
   Knaff, JA
   Korshunova, NN
   Koskela, T
   Kousky, VE
   Kramarova, N
   Kratz, DP
   Krishfield, R
   Kruger, A
   Kruk, MC
   Kumar, A
   Lagerloef, GSE
   Lakkala, K
   Lander, MA
   Landsea, CW
   Lankhorst, M
   Laurila, T
   Lazzara, MA
   Lee, C
   Leuliette, E
   Levitus, S
   L'Heureux, M
   Lieser, J
   Lin, II
   Liu, YY
   Liu, Y
   Liu, HX
   Liu, YJ
   Lobato-Sanchez, R
   Locarnini, R
   Loeb, NG
   Loeng, H
   Long, CS
   Lorrey, AM
   Luhunga, P
   Lumpkin, R
   Luo, JJ
   Lyman, JM
   Macdonald, AM
   Maddux, BC
   Malekela, C
   Manney, G
   Marchenko, SS
   Marengo, JA
   Marotzke, J
   Marra, JJ
   Martinez-Guingla, R
   Massom, RA
   Mathis, JT
   McBride, C
   McCarthy, G
   McVicar, TR
   Mears, C
   Meier, W
   Meinen, CS
   Menendez, M
   Merrifield, MA
   Mitchard, E
   Mitchum, GT
   Montzka, SA
   Morcrette, JJ
   Mote, T
   Muhle, J
   Muhr, B
   Mullan, AB
   Muller, R
   Nash, ER
   Nerem, RS
   Newlin, ML
   Newman, PA
   Ng'ongolo, H
   Nieto, JJ
   Nishino, S
   Nitsche, H
   Noetzli, J
   Oberman, NG
   Obregon, A
   Ogallo, LA
   Oludhe, CS
   Omar, MI
   Overland, J
   Oyunjargal, L
   Parinussa, RM
   Park, GH
   Park, EH
   Parker, D
   Pasch, RJ
   Pascual-Ramirez, R
   Pelto, MS
   Penalba, O
   Peng, L
   Perovich, DK
   Pezza, AB
   Phillips, D
   Pickart, R
   Pinty, B
   Pitts, MC
   Purkey, SG
   Quegan, S
   Quintana, J
   Rabe, B
   Rahimzadeh, F
   Raholijao, N
   Raiva, I
   Rajeevan, M
   Ramiandrisoa, V
   Ramos, A
   Ranivoarissoa, S
   Rayner, NA
   Rayner, D
   Razuveav, VN
   Reagan, J
   Reid, P
   Renwick, J
   Revedekar, J
   Richter-Menge, J
   Rivera, IL
   Robinson, DA
   Rodell, M
   Romanovsky, VE
   Ronchail, J
   Rosenlof, KH
   Sabine, CL
   Salvador, MA
   Sanchez-Lugo, A
   Santee, ML
   Sasgen, I
   Sawaengphokhai, P
   Sayouri, A
   Scambos, TA
   Schauer, U
   Schemm, J
   Schlosser, P
   Schmid, C
   Schreck, C
   Semiletov, I
   Send, U
   Sensoy, S
   Setzer, A
   Severinghaus, J
   Shakhova, N
   Sharp, M
   Shiklomanov, NI
   Siegel, DA
   Silva, VBS
   Silva, FDS
   Sima, F
   Simeonov, P
   Simmonds, I
   Simmons, A
   Skansi, M
   Smeed, DA
   Smethie, WM
   Smith, AB
   Smith, C
   Smith, SL
   Smith, TM
   Sokolov, V
   Srivastava, AK
   Stackhouse PW Jr
   Stammerjohn, S
   Steele, M
   Steffen, K
   Steinbrecht, W
   Stephenson, T
   Su, J
   Svendby, T
   Sweet, W
   Takahashi, T
   Tanabe, RM
   Taylor, MA
   Tedesco, M
   Teng, WL
   Thepaut, JN
   Thiaw, WM
   Thoman, R
   Thompson, P
   Thorne, PW
   Timmermans, ML
   Tobin, S
   Toole, J
   Trewin, BC
   Trigo, RM
   Trotman, A
   Tschudi, M
   van de Wal, RSW
   Van der Werf, GR
   Vautard, R
   Vazquez, JL
   Vieira, G
   Vincent, L
   Vose, RS
   Wagner, WW
   Wahr, J
   Walsh, J
   Wang, JH
   Wang, CZ
   Wang, M
   Wang, SH
   Wang, L
   Wanninkhof, R
   Weaver, S
   Weber, M
   Werdell, PJ
   Whitewood, R
   Wijffels, S
   Wilber, AC
   Wild, JD
   Willett, KM
   Williams, W
   Willis, JK
   Wolken, G
   Wong, T
   Woodgate, R
   Worthy, D
   Wouters, B
   Wovrosh, AJ
   Xue, Y
   Yamada, R
   Yin, ZG
   Yu, LS
   Zhang, LY
   Zhang, PQ
   Zhao, L
   Zhao, J
   Zhong, W
   Ziemke, J
   Zimmermann, S
AF Blunden, Jessica
   Arndt, Derek S.
   Achberger, Christine
   Ackerman, Stephen A.
   Albanil, Adelina
   Alexander, P.
   Alfaro, Eric J.
   Allan, Rob
   Alves, Lincoln M.
   Amador, Jorge A.
   Ambenje, Peter
   Andrianjafinirina, Solonomenjanahary
   Antonov, John
   Aravequia, Jose A.
   Arendt, A.
   Arevalo, Juan
   Ashik, I.
   Atheru, Zachary
   Banzon, Viva
   Baringer, Molly O.
   Barreira, Sandra
   Barriopedro, David E.
   Beard, Grant
   Becker, Andreas
   Behrenfeld, Michael J.
   Bell, Gerald D.
   Benedetti, Angela
   Bernhard, Germar
   Berrisford, Paul
   Berry, David I.
   Bhatt, U.
   Bidegain, Mario
   Bindoff, Nathan
   Bissolli, Peter
   Blake, Eric S.
   Booneeady, Raj
   Bosilovich, Michael
   Box, J. E.
   Boyer, Tim
   Braathen, Geir O.
   Bromwich, David H.
   Brown, R.
   Brown, L.
   Bruhwiler, Lori
   Bulygina, Olga N.
   Burgess, D.
   Burrows, John
   Calderon, Blanca
   Camargo, Suzana J.
   Campbell, Jayaka
   Cao, Y.
   Cappelen, J.
   Carrasco, Gualberto
   Chambers, Don P.
   Chang'a, L.
   Chappell, Petra
   Chehade, Wissam
   Cheliah, Muthuvel
   Christiansen, Hanne H.
   Christy, John R.
   Ciais, Phillipe
   Coelho, Caio A. S.
   Cogley, J. G.
   Colwell, Steve
   Cross, J. N.
   Crouch, Jake
   Cunningham, Stuart A.
   Dacic, Milan
   De Jeu, Richard A. M.
   Dekaa, Francis S.
   Demircan, Mesut
   Derksen, C.
   Diamond, Howard J.
   Dlugokencky, Ed J.
   Dohan, Kathleen
   Dolman, A. Johannes
   Domingues, Catia M.
   Dong Shenfu
   Dorigo, Wouter A.
   Drozdov, D. S.
   Duguay, Claude R.
   Dunn, Robert J. H.
   Duran-Quesada, Ana M.
   Dutton, Geoff S.
   Ehmann, Christian
   Elkins, James W.
   Euscategui, Christian
   Famiglietti, James S.
   Fang Fan
   Fauchereau, Nicolas
   Feely, Richard A.
   Fekete, Balazs M.
   Fenimore, Chris
   Fioletov, Vitali E.
   Fogarty, Chris T.
   Fogt, Ryan L.
   Folland, Chris K.
   Foster, Michael J.
   Frajka-Williams, Eleanor
   Franz, Bryan A.
   Frith, Stacey H.
   Frolov, I.
   Ganter, Catherine
   Garzoli, Silvia
   Geai, M.-L.
   Gerland, S.
   Gitau, Wilson
   Gleason, Karin L.
   Gobron, Nadine
   Goldenberg, Stanley B.
   Goni, Gustavo
   Good, Simon A.
   Gottschalck, Jonathan
   Gregg, Margarita C.
   Griffiths, Georgina
   Grooss, Jens-Uwe
   Guard, Charles 'Chip'
   Gupta, Shashi K.
   Hall, Bradley D.
   Halpert, Michael S.
   Harada, Yayoi
   Hauri, C.
   Heidinger, Andrew K.
   Heikkila, Anu
   Heim, Richard R., Jr.
   Heimbach, Patrick
   Hidalgo, Hugo G.
   Hilburn, Kyle
   Ho, Shu-peng (Ben)
   Hobbs, Will R.
   Holgate, Simon
   Hovsepyan, Anahit
   Hu Zeng-Zhen
   Hughes, P.
   Hurst, Dale F.
   Ingvaldsen, R.
   Inness, Antje
   Jaimes, Ena
   Jakobsson, Martin
   James, Adamu I.
   Jeffries, Martin O.
   Johns, William E.
   Johnsen, Bjorn
   Johnson, Gregory C.
   Johnson, Bryan
   Jones, Luke T.
   Jumaux, Guillaume
   Kabidi, Khadija
   Kaiser, Johannes W.
   Kamga, Andre
   Kang, Kyun-Kuk
   Kanzow, Torsten O.
   Kao, Hsun-Ying
   Keller, Linda M.
   Kennedy, John J.
   Key, J.
   Khatiwala, Samar
   Pour, H. Kheyrollah
   Kholodov, A. L.
   Khoshkam, Mahbobeh
   Kijazi, Agnes
   Kikuchi, T.
   Kim, B.-M.
   Kim, S.-J.
   Kimberlain, Todd B.
   Knaff, John A.
   Korshunova, Natalia N.
   Koskela, T.
   Kousky, Vernon E.
   Kramarova, Natalya
   Kratz, David P.
   Krishfield, R.
   Kruger, Andries
   Kruk, Michael C.
   Kumar, Arun
   Lagerloef, Gary S. E.
   Lakkala, K.
   Lander, Mark A.
   Landsea, Chris W.
   Lankhorst, Matthias
   Laurila, T.
   Lazzara, Matthew A.
   Lee, Craig
   Leuliette, Eric
   Levitus, Sydney
   L'Heureux, Michelle
   Lieser, Jan
   Lin, I-I
   Liu, Y. Y.
   Liu, Y.
   Liu Hongxing
   Liu Yanju
   Lobato-Sanchez, Rene
   Locarnini, Ricardo
   Loeb, Norman G.
   Loeng, H.
   Long, Craig S.
   Lorrey, Andrew M.
   Luhunga, P.
   Lumpkin, Rick
   Luo Jing-Jia
   Lyman, John M.
   Macdonald, Alison M.
   Maddux, Brent C.
   Malekela, C.
   Manney, Gloria
   Marchenko, S. S.
   Marengo, Jose A.
   Marotzke, Jochem
   Marra, John J.
   Martinez-Gueingla, Rodney
   Massom, Robert A.
   Mathis, Jeremy T.
   McBride, Charlotte
   McCarthy, Gerard
   McVicar, Tim R.
   Mears, Carl
   Meier, W.
   Meinen, Christopher S.
   Menendez, Melisa
   Merrifield, Mark A.
   Mitchard, Edward
   Mitchum, Gary T.
   Montzka, Stephen A.
   Morcrette, Jean-Jacques
   Mote, Thomas
   Muehle, Jens
   Muehr, Bernhard
   Mullan, A. Brett
   Mueller, Rolf
   Nash, Eric R.
   Nerem, R. Steven
   Newlin, Michele L.
   Newman, Paul A.
   Ng'ongolo, H.
   Nieto, Juan Jose
   Nishino, S.
   Nitsche, Helga
   Noetzli, Jeannette
   Oberman, N. G.
   Obregon, Andre'
   Ogallo, Laban A.
   Oludhe, Christopher S.
   Omar, Mohamed I
   Overland, James
   Oyunjargal, Lamjav
   Parinussa, Robert M.
   Park, Geun-Ha
   Park, E-Hyung
   Parker, David
   Pasch, Richard J.
   Pascual-Ramirez, Reynaldo
   Pelto, Mauri S.
   Penalba, Olga
   Peng, L.
   Perovich, Don K.
   Pezza, Alexandre B.
   Phillips, David
   Pickart, R.
   Pinty, Bernard
   Pitts, Michael C.
   Purkey, Sarah G.
   Quegan, Shaun
   Quintana, Juan
   Rabe, B.
   Rahimzadeh, Fatemeh
   Raholijao, Nirivololona
   Raiva, I.
   Rajeevan, Madhavan
   Ramiandrisoa, Voahanginirina
   Ramos, Alexandre
   Ranivoarissoa, Sahondra
   Rayner, Nick A.
   Rayner, Darren
   Razuveav, Vyacheslav N.
   Reagan, James
   Reid, Phillip
   Renwick, James
   Revedekar, Jayashree
   Richter-Menge, Jacqueline
   Rivera, Ingrid L.
   Robinson, David A.
   Rodell, Matthew
   Romanovsky, Vladimir E.
   Ronchail, Josyane
   Rosenlof, Karen H.
   Sabine, Christopher L.
   Salvador, Mozar A.
   Sanchez-Lugo, Ahira
   Santee, Michelle L.
   Sasgen, I.
   Sawaengphokhai, P.
   Sayouri, Amal
   Scambos, Ted A.
   Schauer, U.
   Schemm, Jae
   Schlosser, P.
   Schmid, Claudia
   Schreck, Carl
   Semiletov, Igor
   Send, Uwe
   Sensoy, Serhat
   Setzer, Alberto
   Severinghaus, Jeffrey
   Shakhova, Natalia
   Sharp, M.
   Shiklomanov, Nicolai I.
   Siegel, David A.
   Silva, Viviane B. S.
   Silva, Frabricio D. S.
   Sima, Fatou
   Simeonov, Petio
   Simmonds, I.
   Simmons, Adrian
   Skansi, Maria
   Smeed, David A.
   Smethie, W. M.
   Smith, Adam B.
   Smith, Cathy
   Smith, Sharon L.
   Smith, Thomas M.
   Sokolov, V.
   Srivastava, A. K.
   Stackhouse, Paul W., Jr.
   Stammerjohn, Sharon
   Steele, M.
   Steffen, Konrad
   Steinbrecht, Wolfgang
   Stephenson, Tannecia
   Su, J.
   Svendby, T.
   Sweet, William
   Takahashi, Taro
   Tanabe, Raymond M.
   Taylor, Michael A.
   Tedesco, Marco
   Teng, William L.
   Thepaut, Jean-Noel
   Thiaw, Wassila M.
   Thoman, R.
   Thompson, Philip
   Thorne, Peter W.
   Timmermans, M.-L.
   Tobin, Skie
   Toole, J.
   Trewin, Blair C.
   Trigo, Ricardo M.
   Trotman, Adrian
   Tschudi, M.
   van de Wal, Roderik S. W.
   Van der Werf, Guido R.
   Vautard, Robert
   Vazquez, J. L.
   Vieira, Goncalo
   Vincent, Lucie
   Vose, Russ S.
   Wagner, Wolfgang W.
   Wahr, John
   Walsh, J.
   Wang Junhong
   Wang Chunzai
   Wang, M.
   Wang Sheng-Hung
   Wang Lei
   Wanninkhof, Rik
   Weaver, Scott
   Weber, Mark
   Werdell, P. Jeremy
   Whitewood, Robert
   Wijffels, Susan
   Wilber, Anne C.
   Wild, J. D.
   Willett, Kate M.
   Williams, W.
   Willis, Joshua K.
   Wolken, G.
   Wong, Takmeng
   Woodgate, R.
   Worthy, D.
   Wouters, B.
   Wovrosh, Alex J.
   Xue Yan
   Yamada, Ryuji
   Yin Zungang
   Yu Lisan
   Zhang Liangying
   Zhang Peiqun
   Zhao Lin
   Zhao, J.
   Zhong, W.
   Ziemke, Jerry
   Zimmermann, S.
TI State of the Climate in 2012
SO BULLETIN OF THE AMERICAN METEOROLOGICAL SOCIETY
LA English
DT Article
ID SEA-SURFACE-TEMPERATURE; MADDEN-JULIAN OSCILLATION; WESTERN NORTH
   PACIFIC; INTERNATIONAL POLAR YEAR; COUPLED KELVIN WAVES; MERIDIONAL
   OVERTURNING CIRCULATION; OUTGOING LONGWAVE RADIATION; CALIFORNIA CURRENT
   SYSTEM; OCEAN THERMAL STRUCTURE; GLOBAL WATER CYCLE
AB For the first time in serveral years, the El Nino-Southern Oscillation did not dominate regional climate conditions around the globe. A weak La Ni a dissipated to ENSOneutral conditions by spring, and while El Nino appeared to be emerging during summer, this phase never fully developed as sea surface temperatures in the eastern conditions. Nevertheless, other large-scale climate patterns and extreme weather events impacted various regions during the year. A negative phase of the Arctic Oscillation from mid-January to early February contributed to frigid conditions in parts of northern Africa, eastern Europe, and western Asia. A lack of rain during the 2012 wet season led to the worst drought in at least the past three decades for northeastern Brazil. Central North America also experienced one of its most severe droughts on record. The Caribbean observed a very wet dry season and it was the Sahel's wettest rainy season in 50 years.
   Overall, the 2012 average temperature across global land and ocean surfaces ranked among the 10 warmest years on record. The global land surface temperature alone was also among the 10 warmest on record. In the upper atmosphere, the average stratospheric temperature was record or near-record cold, depending on the dataset. After a 30-year warming trend from 1970 to 1999 for global sea surface temperatures, the period 2000-12 had little further trend. This may be linked to the prevalence of La Ni a-like conditions during the 21st century. Heat content in the upper 700 m of the ocean remained near record high levels in 2012. Net increases from 2011 to 2012 were observed at 700-m to 2000-m depth and even in the abyssal ocean below. Following sharp decreases in to the effects of La Ni a, sea levels rebounded to reach records highs in 2012. The increased hydrological cycle seen in recent years continued, with more evaporation in drier locations and more precipitation in rainy areas. In a pattern that has held since 2004, salty areas of the ocean surfaces and subsurfaces were anomalously salty on average, while fresher areas were anomalously fresh.
   Global tropical cyclone activity during 2012 was near average, with a total of 84 storms compared with the 1981-2010 average of 89. Similar to 2010 and 2011, the North Atlantic was the only hurricane basin that experienced above-normal activity. In this basin, Sandy brought devastation to Cuba and parts of the eastern North American seaboard. All other basins experienced either near-or below-normal tropical cyclone activity. Only three tropical cyclones reached Category 5 intensity-all in Bopha became the only storm in the historical record to produce winds greater than 130 kt south of 7 N. It was also the costliest storm to affect the Philippines and killed more than 1000 residents.
   Minimum Arctic sea ice extent in September and Northern Hemisphere snow cover extent in June both reached new record lows. June snow cover extent is now declining at a faster rate (-17.6% per decade) than September sea ice extent (-13.0% per decade). Permafrost temperatures reached record high values in northernmost Alaska. A new melt extent record occurred on 11-12 July on the Greenland ice sheet; 97% of the ice sheet showed some form of melt, four times greater than the average melt for this time of year.
   The climate in Antarctica was relatively stable overall. The largest maximum sea ice extent since records begain in 1978 was observed in September 2012. In the stratosphere, warm air led to the second smallest ozone hole in the past two decades. Even so, the springtime ozone layer above Antarctica likely will not return to its early 1980s state until about 2060.
   Following a slight decline associated with the global 2 emissions from fossil fuel combustion and cement production reached a record 9.5 +/- 0.5 Pg C in 2011 and a new record of 9.7 +/- 0.5 Pg C is estimated for 2012. Atmospheric CO2 concentrations increased by 2.1 ppm in 2012, to 392.6 ppm. In spring 2012, 2 concentration exceeded 400 ppm at 7 of the 13 Arctic observation sites. Globally, other greenhouse gases including methane and nitrous oxide also continued to rise in concentration and the combined effect now represents a 32% increase in radiative forcing over a 1990 baseline. Concentrations of most ozone depleting substances continued to fall.
C1 [Achberger, Christine] Univ Gothenburg, Dept Earth Sci, Gothenburg, Sweden.
   [Ackerman, Stephen A.; Foster, Michael J.; Heidinger, Andrew K.; Liu, Y.; Pascual-Ramirez, Reynaldo] Univ Wisconsin, Cooperat Inst Meteorol Satellite Studies, Madison, WI USA.
   [Albanil, Adelina; Lobato-Sanchez, Rene; Vazquez, J. L.] Natl Meteorol Serv Mexico, Mexico City, DF, Mexico.
   [Alexander, P.; Tedesco, Marco] CUNY City Coll, Dept Earth & Atmospher Sci, New York, NY USA.
   [Alfaro, Eric J.; Amador, Jorge A.; Calderon, Blanca; Duran-Quesada, Ana M.; Hidalgo, Hugo G.; Rivera, Ingrid L.] Univ Costa Rica, Ctr Geophys Res, San Jose, Costa Rica.
   [Alfaro, Eric J.; Amador, Jorge A.; Duran-Quesada, Ana M.; Hidalgo, Hugo G.; Parker, David] Univ Costa Rica, Sch Phys, San Jose, Costa Rica.
   [Allan, Rob; Dunn, Robert J. H.; Folland, Chris K.; Good, Simon A.; Kennedy, John J.; Rayner, Nick A.; Willett, Kate M.] Met Off Hadley Ctr, Exeter, Devon, England.
   [Alves, Lincoln M.] INPE, CCST, Sao Paulo, Brazil.
   [Ambenje, Peter] KMD, Nairobi, Kenya.
   [Andrianjafinirina, Solonomenjanahary; Newlin, Michele L.; Raholijao, Nirivololona; Ramiandrisoa, Voahanginirina; Ranivoarissoa, Sahondra] Direct Meteorol Natl Madagascar, Antananarivo, Madagascar.
   [Antonov, John; Boyer, Tim; Gregg, Margarita C.; Levitus, Sydney; Locarnini, Ricardo] NOAA NESDIS Natl Oceanog Data Ctr, Silver Spring, MD USA.
   [Antonov, John] Univ Corp Atmospher Res, Boulder, CO USA.
   [Aravequia, Jose A.; Marchenko, S. S.] INPE, Ctr Previsao Tempo & Estudos Climat, Sao Paulo, Brazil.
   [Arendt, A.; Bhatt, U.; Jeffries, Martin O.; Kholodov, A. L.; Romanovsky, Vladimir E.] Univ Alaska Fairbanks, Geophys Inst, Fairbanks, AK USA.
   [Arevalo, Juan] Inst Nacl Meteorol & Hidrol Venezuela INAMEH, Caracas, Venezuela.
   [Arndt, Derek S.; Banzon, Viva; Crouch, Jake; Fenimore, Chris; Gleason, Karin L.; Heim, Richard R., Jr.; Hughes, P.; Reagan, James; Sanchez-Lugo, Ahira; Smith, Adam B.; Vose, Russ S.] NOAA NESDIS Natl Climat Data Ctr, Asheville, NC USA.
   [Ashik, I.; Frolov, I.; Sokolov, V.] Arctic & Antarctic Res Inst, St Petersburg, Russia.
   [Atheru, Zachary; Meinen, Christopher S.; Park, Geun-Ha] IGAD Climate Predict & Applicat Ctr ICPAC, Nairobi, Kenya.
   [Baringer, Molly O.; Dong Shenfu; Garzoli, Silvia; Goldenberg, Stanley B.; Goni, Gustavo; Lumpkin, Rick; Schmid, Claudia; Wang Chunzai; Wanninkhof, Rik] NOAA OAR Atlantic Oceanog & Meteorol Lab, Miami, FL USA.
   [Barreira, Sandra] Argentine Naval Hydrog Serv, Buenos Aires, DF, Argentina.
   [Barriopedro, David E.] UCM, Madrid, Spain.
   [Beard, Grant; Ganter, Catherine; Obregon, Andre'] Bur Meteorol, Melbourne, Vic, Australia.
   [Becker, Andreas] Deutsch Wetterdienst DWD, Offenbach, Germany.
   [Behrenfeld, Michael J.] Oregon State Univ, Portland, OR USA.
   [Bell, Gerald D.; Gottschalck, Jonathan; Halpert, Michael S.; Hu Zeng-Zhen; Kousky, Vernon E.; Kumar, Arun; L'Heureux, Michelle; Morcrette, Jean-Jacques; Schemm, Jae; Thiaw, Wassila M.; Weaver, Scott; Wild, J. D.; Xue Yan] NOAA NWS Climate Predict Ctr, College Pk, MD USA.
   [Benedetti, Angela; Inness, Antje; Jones, Luke T.; Kaiser, Johannes W.; Simmons, Adrian; Thepaut, Jean-Noel] European Ctr Medium Range Weather Forecasts, Reading, Berks, England.
   [Bernhard, Germar] Biospher Instruments, San Diego, CA USA.
   [Berrisford, Paul; McCarthy, Gerard] European Ctr Medium Range Weather Forecasts, NCAS Climate, Reading, Berks, England.
   [Berry, David I.; Rayner, Darren; Smeed, David A.] Natl Oceanog Ctr, Southampton, Hants, England.
   [Bidegain, Mario] Direcc Nacl Meteorol, Div Climatol, Montevideo, Uruguay.
   [Bindoff, Nathan] Antarctic Climate & Ecosyst Cooperat Res Ctr, Hobart, Tas, Australia.
   [Bindoff, Nathan; Wijffels, Susan] CSIRO Marine & Atmospher Labs, Hobart, Tas, Australia.
   [Bissolli, Peter; Pasch, Richard J.] Deutsch Wetterdienst, Offenbach, Germany.
   [Blake, Eric S.; Kimberlain, Todd B.; Landsea, Chris W.] NOAA NWS Natl Hurricane Ctr, Miami, FL USA.
   [Blunden, Jessica; Kruk, Michael C.; Yin Zungang] NOAA NESDIS Natl Climat Data Ctr, ERT Inc, Asheville, NC USA.
   [Booneeady, Raj] Mauritius Meteorol Serv, Vacoas, Mauritius.
   [Bosilovich, Michael; Cheliah, Muthuvel] NASA GSFC, Global Modeling & Assimilat Off, Greenbelt, MD USA.
   [Box, J. E.] Geol Survey Denmark & Greenland, Copenhagen, Denmark.
   [Box, J. E.; Bromwich, David H.; Wang Sheng-Hung] Ohio State Univ, Byrd Polar Res Ctr, Columbus, OH USA.
   [Braathen, Geir O.] WMO Atmospher Environm Res Div, Geneva, Switzerland.
   [Brown, R.] Environm Canada, Climate Res Div, Montreal, PQ, Canada.
   [Brown, L.; Montzka, Stephen A.] Environm Canada, Climate Res Div, Downsview, ON, Canada.
   [Bruhwiler, Lori; Dlugokencky, Ed J.; Elkins, James W.; Hall, Bradley D.; Rosenlof, Karen H.] NOAA OAR Earth Syst Res Lab, Boulder, CO USA.
   [Bulygina, Olga N.; Razuveav, Vyacheslav N.] Russian Inst Hydrometeorol Informat, Obninsk, Russia.
   [Burgess, D.; Smith, Sharon L.] Nat Resources Canada, Geol Survey Canada, Ottawa, ON, Canada.
   [Burrows, John; Takahashi, Taro] Univ Bremen, Bremen, Germany.
   [Camargo, Suzana J.; Khatiwala, Samar; Schlosser, P.; Smethie, W. M.] Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY USA.
   [Campbell, Jayaka; Stephenson, Tannecia; Taylor, Michael A.] Univ West Indies, Dept Phys, Kingston, Jamaica.
   [Cao, Y.; Su, J.; Zhao, J.; Zhong, W.] Ocean Univ China, Qingdao, Peoples R China.
   [Cappelen, J.] Danish Meteorol Inst, Copenhagen, Denmark.
   [Carrasco, Gualberto] Serv Nacl Meteorol & Hidrol Bolivia SENAMHI, La Paz, Bolivia.
   [Chambers, Don P.; Malekela, C.; Ng'ongolo, H.] Univ S Florida, Coll Marine Sci, St Petersburg, FL USA.
   [Chang'a, L.; Kijazi, Agnes; Luhunga, P.] Tanzania Meteorol Agcy, Dar Es Salaam, Tanzania.
   [Chappell, Petra; Griffiths, Georgina; Lorrey, Andrew M.; Weber, Mark] Natl Inst Water & Atmosphere Res Ltd, Auckland, New Zealand.
   [Chehade, Wissam] Univ Bremen FBI, Bremen, Germany.
   [Christiansen, Hanne H.] Univ Ctr Svalbard, Dept Geol, UNIS, Svalbard, Norway.
   [Christiansen, Hanne H.] Univ Oslo, Dept Geosci, Oslo, Norway.
   [Christy, John R.; Vautard, Robert] Univ Alabama, Huntsville, AL USA.
   [Ciais, Phillipe] CEA CNR UVSQ, LSCE, Gif Sur Yvette, France.
   [Coelho, Caio A. S.] CPTEC INPE Ctr Weather Forecasts & Climate Studies, Cachoeira Paulista, Brazil.
   [Cogley, J. G.] Trent Univ, Dept Geog, Peterborough, ON, Canada.
   [Colwell, Steve] British Antarctic Survey, Cambridge, England.
   [Cross, J. N.; Hauri, C.] Univ Alaska Fairbanks, Sch Fisheries & Ocean Sci, Fairbanks, AK USA.
   [Cunningham, Stuart A.] Scottish Marine Inst Oban, Argyll, Scotland.
   [Dacic, Milan; Parinussa, Robert M.] Republ Hydrometeorol Serv Serbia, Belgrade, Serbia.
   [De Jeu, Richard A. M.; Dolman, A. Johannes; Van der Werf, Guido R.] Vrije Univ Amsterdam, Dept Earth Sci, Fac Earth & Life Sci, Amsterdam, Netherlands.
   [Dekaa, Francis S.; James, Adamu I.; Sensoy, Serhat] Nigerian Meteorol Agency, Abuja, Nigeria.
   [Demircan, Mesut] Turkish State Meteorol Serv, Ankara, Turkey.
   [Derksen, C.; Worthy, D.] Environm Canada, Climate Res Div, Toronto, ON, Canada.
   [Diamond, Howard J.] NOAA NESDIS Natl Climat Data Ctr, Silver Spring, MD USA.
   [Dohan, Kathleen; Lagerloef, Gary S. E.] Earth & Space Res, Seattle, WA USA.
   [Domingues, Catia M.] Antarctic Climate & Ecosyst Cooperat Res Ctr, Hobart, Tas, Australia.
   [Dong Shenfu; Garzoli, Silvia] Cooperat Inst Marine & Atmospher Sci, Miami, FL USA.
   [Dorigo, Wouter A.; Wagner, Wolfgang W.] Vienna Univ Technol, Dept Geodesy & Geoinformat, Vienna, Austria.
   [Drozdov, D. S.] Earth Cryosphere Inst, Tumen, Russia.
   [Duguay, Claude R.; Kang, Kyun-Kuk; Pour, H. Kheyrollah] Univ Waterloo, Interdisciplinary Ctr Climate Change, Waterloo, ON, Canada.
   [Duguay, Claude R.; Kang, Kyun-Kuk; Pour, H. Kheyrollah] Univ Waterloo, Dept Geog & Environm Management, Waterloo, ON, Canada.
   [Dutton, Geoff S.; Hurst, Dale F.; Wahr, John] Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO USA.
   [Ehmann, Christian] KIT, Inst Meteorol & Climate Res IMK, Karlsruhe, Germany.
   [Euscategui, Christian] Inst Hidrol Meteorol & Estudios Ambientales, Bogota, Colombia.
   [Famiglietti, James S.] Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA USA.
   [Fang Fan] NASA, Goddard Earth Sci Data & Informat Serv Ctr, Greenbelt, MD USA.
   [Fauchereau, Nicolas] Natl Inst Water & Atmospher Res Ltd, Auckland, New Zealand.
   [Fauchereau, Nicolas; Overland, James] Univ Cape Town, Dept Oceanog, Rondebosch, South Africa.
   [Feely, Richard A.; Johnson, Gregory C.; Purkey, Sarah G.; Sabine, Christopher L.] NOAA OAR Pacific Marine Environ Lab, Seattle, WA USA.
   [Fekete, Balazs M.] CUNY City Coll, CUNY Environm CrossRd Initiat, New York, NY USA.
   [Fioletov, Vitali E.] Environm Canada, Measurements & Anal Res Sect, Toronto, ON, Canada.
   [Fogarty, Chris T.] Environm Canada, Canadian Hurricane Ctr, Dartmouth, NS, Canada.
   [Fogt, Ryan L.; Wovrosh, Alex J.] Ohio Univ, Dept Geog, Athens, OH USA.
   [Frajka-Williams, Eleanor] Natl Oceanog Ctr, Southampton, Hants, England.
   [Franz, Bryan A.; Frith, Stacey H.; Werdell, P. Jeremy; Ziemke, Jerry] NASA Goddard Space Flight Ctr, Greenbelt, MD USA.
   [Geai, M.-L.; Sharp, M.] Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB, Canada.
   [Gerland, S.] Norwegian Polar Res Inst, Fram Ctr, Tromso, Norway.
   [Gitau, Wilson; Oludhe, Christopher S.; Pinty, Bernard] Univ Nairobi, Dept Meteorol, Nairobi, Kenya.
   [Gobron, Nadine] European Commiss, Joint Res Ctr, Inst Environm & Sustainabil, I-21027 Ispra, Italy.
   Cooperat Inst Marine & Atmospher Sci, Miami, FL 33149 USA.
   Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2M7, Canada.
   Fram Ctr, Norwegian Polar Inst, N-9296 Tromso, Norway.
   [Gupta, Shashi K.; Sawaengphokhai, P.; Wilber, Anne C.] Sci Syst & Applicat Inc, Hampton, VA 23666 USA.
   [Harada, Yayoi] Japan Meteorol Agency, Climate Predict Div, Tokyo, Japan.
   [Heikkila, Anu; Koskela, T.; Laurila, T.] Finnish Meteorol Inst, Helsinki, Finland.
   [Heimbach, Patrick; Mears, Carl] MIT, Boston, MA USA.
   [Hilburn, Kyle] Remote Sensing Syst, Santa Rosa, CA 95401 USA.
   [Ho, Shu-peng (Ben); Muehle, Jens; Peng, L.] UCAR COSMIC, Boulder, CO USA.
   [Hobbs, Will R.; Lankhorst, Matthias; Send, Uwe; Severinghaus, Jeffrey] Univ Calif San Diego, Scripps Inst Oceanography, La Jolla, CA 92093 USA.
   [Hovsepyan, Anahit] Climate Res Div, Armstatehydromet, Armenia.
   [Ingvaldsen, R.; Loeng, H.] Inst Marine Res, Bergen, Norway.
   [Jakobsson, Martin] Stockholm Univ, Dept Geol Sci, Stockholm, Sweden.
   [Johns, William E.] Rosenstiel Sch Marine & Atmospher Sci, Miami, FL USA.
   [Johnsen, Bjorn] Norwegian Radiat Protect Author, Osteras, Norway.
   [Johnson, Bryan] NOAA OAR Earth Syst Res Lab, Global Monitoring Div, Boulder, CO USA.
   [Johnson, Bryan; Tschudi, M.; Wahr, John] Univ Colorado, Boulder, CO 80309 USA.
   [Jumaux, Guillaume] Meteo France, St Denis, Reunion.
   [Kabidi, Khadija; Sayouri, Amal] Direct Meteorol Natl Maroc, Rabat, Morocco.
   [Kaiser, Johannes W.] Kings Coll London, London WC2R 2LS, England.
   [Kaiser, Johannes W.] Max Planck Inst, Mainz, Germany.
   [Kamga, Andre; Raiva, I.] African Ctr Meteorol Applicat Dev, Niamey, Niger.
   [Kanzow, Torsten O.] Helmholtz Ctr Ocean Res Kiel GEOMAR, Kiel, Germany.
   [Kao, Hsun-Ying] Earth & Space Res, Seattle, WA USA.
   [Keller, Linda M.] Univ Wisconsin Madison, Dept Atmospher & Ocean Sci, Madison, WI USA.
   [Key, J.; Smith, Thomas M.] NOAA NESDIS Ctr Satellite Applicat & Res, Madison, WI USA.
   Univ Alaska Fairbanks, Geophys Inst, Fairbanks, AK USA.
   [Khoshkam, Mahbobeh; Nishino, S.] IRIMO, Tehran, Iran.
   [Kikuchi, T.] Japan Agcy Marine Earth Sci & Technol, Tokyo, Japan.
   [Kim, B.-M.; Kim, S.-J.] Korea Polar Res Inst, Inchon, South Korea.
   [Knaff, John A.] NOAA, NESDIS Ctr Satellite Applicat & Res, Ft Collins, CO USA.
   [Korshunova, Natalia N.; Nash, Eric R.] World Data Ctr, All Russian Res Inst Hydrometeorol Informat, Obninsk, Russia.
   [Kramarova, Natalya] NASA, Goddard Space Flight Ctr, Sci Syst & Applicat Inc, Greenbelt, MD USA.
   [Kratz, David P.; Loeb, Norman G.; Pitts, Michael C.; Stackhouse, Paul W., Jr.; Wong, Takmeng] NASA, Langley Res Ctr, Hampton, VA USA.
   [Krishfield, R.; Macdonald, Alison M.; McBride, Charlotte; Pickart, R.; Toole, J.; Yu Lisan] Woods Hole Oceanog Inst, Woods Hole, MA USA.
   [Kruger, Andries] South African Weather Serv, Pretoria, South Africa.
   [Lakkala, K.] Arctic Res Ctr, Finnish Meteorol Inst, Sodankyla, Finland.
   [Lander, Mark A.] Univ Guam, Mangilao, GU USA.
   Finnish Meteorol Inst, Helsinki, Finland.
   [Lazzara, Matthew A.] Univ Wisconsin, Space Sci & Engn Ctr, Madison, WI USA.
   [Lee, Craig; Woodgate, R.] Univ Washington, Appl Phys Lab, Seattle, WA USA.
   [Leuliette, Eric; Massom, Robert A.] NOAA, NESDIS Lab Satellite Altimetry, Silver Spring, MD USA.
   [Lieser, Jan] Univ Tasmania, ACE CRC, Hobart, Tas, Australia.
   [Lin, I-I] Natl Taiwan Univ, Taipei, Taiwan.
   [Liu, Y. Y.] Univ New S Wales, Sch Civil & Environm Engn, Sydney, NSW, Australia.
   [Liu Hongxing] Univ Cincinnati, Dept Geog, Cincinnati, OH USA.
   [Liu Yanju] China Meteorol Adm, Natl Climate Ctr, Beijing, Peoples R China.
   NASA, Langley Res Ctr, Hampton, VA USA.
   [Long, Craig S.] NOAA, NWS Natl Ctr Environm Predict, College Pk, MD USA.
   [Luo Jing-Jia; Mathis, Jeremy T.] Ctr Australian Weather & Climate Res, Melbourne, Vic, Australia.
   [Lyman, John M.; Merrifield, Mark A.] NOAA, OAR Pacific Marine Environm Lab, Seattle, WA USA.
   [Lyman, John M.; Maddux, Brent C.; Thompson, Philip] Univ Hawaii, Joint Inst Marine & Atmospher Res, Honolulu, HI USA.
   [Maddux, Brent C.] Univ Wisconsin, AOS CIMSS, Madison, WI USA.
   [Manney, Gloria] KNMI Royal Netherlands Meteorol Inst, De Bilt, Netherlands.
   [Manney, Gloria] NW Res Associates Inc, Socorro, NM USA.
   [Marengo, Jose A.] New Mexico Inst Min & Technol, Socorro, NM USA.
   [Marotzke, Jochem] CCST, INPE, Sao Paulo, Brazil.
   [Marra, John J.] Max Planck Inst Meteorol, Hamburg, Germany.
   [Martinez-Gueingla, Rodney; Nieto, Juan Jose] NOAA, NESDIS Natl Climat Data Ctr, Honolulu, HI USA.
   CIIFEN, Guayaquil, Ecuador.
   [McVicar, Tim R.] Univ Tasmania, Australian Antarctic Div, Hobart, Tas, Australia.
   [Meier, W.] CSIRO Land & Water, Canberra, ACT, Australia.
   [Menendez, Melisa] Univ Colorado, Natl Snow & Ice Data Ctr, Cooperat Inst Res Environm Sci, Boulder, CO USA.
   [Mitchard, Edward] Univ Cantabria, Environm Hydraul Inst, Santander, Spain.
   [Mitchum, Gary T.] Univ Edinburgh, Sch Geosci, Edinburgh, Midlothian, Scotland.
   Univ S Florida, Coll Marine Sci, St Petersburg, FL USA.
   [Mote, Thomas] NOAA, OAR Earth Syst Res Lab, Boulder, CO USA.
   [Muehr, Bernhard] Univ Georgia, Dept Geog, Athens, GA USA.
   [Mullan, A. Brett] Lacunosa Weather Serv, Karlsruhe, Germany.
   [Mueller, Rolf] Natl Inst Water & Atmospher Res Ltd, Wellington, New Zealand.
   [Grooss, Jens-Uwe; Nerem, R. Steven] Forschungszentrum Julich, Julich, Germany.
   [Newman, Paul A.] Univ Colorado, Dept Aerosp Engn Sci, Boulder, CO USA.
   [Nitsche, Helga] NASA, Atmospheres Lab, Goddard Space Flight Ctr, Greenbelt, MD USA.
   [Noetzli, Jeannette] Deutscher Wetterdienst DWD, Climate Monitoring Satellite Applicat Facil, Offenbach, Germany.
   [Oberman, N. G.] Univ Zurich, Dept Geog, Zurich, Switzerland.
   [Obregon, Andre'] MIREKO, Syktyvkar, Russia.
   [Ogallo, Laban A.] WMO RA VI Reg Climate Ctr Climate Monitoring, Offenbach, Germany.
   IGAD Climate Predict & Applicat Ctr ICPAC, Nairobi, Kenya.
   [Omar, Mohamed I] Egyptian Meteorol Author, Cairo, Egypt.
   [Oyunjargal, Lamjav] Natl Agcy Meteorol Hydrol & Environm Monitoring, Inst Meteorol & Hydrol, Ulaanbaatar, Mongol Peo Rep.
   [Park, E-Hyung] Korea Meteorol Adm, Seoul, South Korea.
   [Pelto, Mauri S.] Nichols Coll, Dudley, MA USA.
   [Penalba, Olga] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Ciencias Atmosfera & Oceanos, Buenos Aires, DF, Argentina.
   [Perovich, Don K.; Richter-Menge, Jacqueline] USACE, ERDC, Cold Reg Res & Engn Lab, Hanover, NH USA.
   [Perovich, Don K.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH USA.
   [Pezza, Alexandre B.] Univ Melbourne, Melbourne, Vic, Australia.
   [Phillips, David; Vincent, Lucie] Environm Canada, Toronto, ON, Canada.
   [Purkey, Sarah G.; Whitewood, Robert] Univ Washington, Sch Oceanog, Seattle, WA USA.
   [Quegan, Shaun] Univ Sheffield, Ctr Terr Climate Dynam, Sheffield, S Yorkshire, England.
   [Quintana, Juan] Direcc Meteorol Chile, Santiago, Chile.
   [Rabe, B.; Schauer, U.] Alfred Wegener Inst, Bremerhaven, Germany.
   [Rahimzadeh, Fatemeh] ASMERC, Tehran, Iran.
   [Rajeevan, Madhavan] Natl Atmospher Res Lab, Gadanki, India.
   [Ramos, Alexandre; Trigo, Ricardo M.] Univ Lisboa Campo Grande, Inst Dom Luiz, Lisbon, Portugal.
   [Reid, Phillip] Australian Bur Meteorol, Hobart, Tas, Australia.
   [Reid, Phillip] Ctr Australian Weather & Climate Res, Hobart, Tas, Australia.
   [Renwick, James] Victoria Univ Wellington, Wellington, New Zealand.
   [Revedekar, Jayashree] Indian Inst Trop Meteorol, Pune, Maharashtra, India.
   [Robinson, David A.] Rutgers State Univ, Piscataway, NJ USA.
   [Rodell, Matthew] NASA, Hydrol Sci Lab, Goddard Space Flight Ctr, Greenbelt, MD USA.
   [Ronchail, Josyane] Univ Paris, Paris, France.
   [Salvador, Mozar A.; Silva, Frabricio D. S.] INMET, Inst Nacl Meteorol, Brasilia, DF, Brazil.
   [Santee, Michelle L.] NASA, Jet Propuls Lab, Pasadena, CA USA.
   [Sasgen, I.] GFZ German Res Ctr Geosci, Potsdam, Germany.
   [Scambos, Ted A.] Univ Colorado, Natl Snow & Ice Data Ctr, Boulder, CO USA.
   [Schreck, Carl; Thorne, Peter W.] NC State Univ, Cooperat Inst Climate & Satellites, Asheville, NC USA.
   [Semiletov, Igor; Shakhova, Natalia; Walsh, J.] Univ Alaska Fairbanks, Int Arctic Res Ctr, Fairbanks, AK USA.
   [Setzer, Alberto] Natl Inst Space Res, Sao Jose Dos Campos, Brazil.
   [Shiklomanov, Nicolai I.] George Washington Univ, Dept Geog, Washington, DC USA.
   [Siegel, David A.] Univ Calif Santa Barbara, Santa Barbara, CA USA.
   [Silva, Viviane B. S.] NOAA, NWS Off Climate Water & Weather Serv, Silver Spring, MD USA.
   [Sima, Fatou] Dept Water Resources, Div Meteorol, Banjul, Gambia.
   [Simeonov, Petio] BAS, Natl Inst Meteorol & Hydrol, Sofia, Bulgaria.
   [Simmonds, I.] Univ Melbourne, Sch Earth Sci, Melbourne, Vic, Australia.
   [Skansi, Maria] Serv Meteorol Nacl, Buenos Aires, DF, Argentina.
   [Smith, Cathy] NOAA, OAR, Earth Syst Res Lab, Phys Sci Div, Boulder, CO USA.
   [Smith, Cathy] Climate Diagnost Ctr, Cooperat Inst Res Environm Sci, Boulder, CO USA.
   NOAA, NESDIS, Ctr Satellite Applicat & Res, College Pk, MD USA.
   [Smith, Thomas M.] Univ Maryland, Cooperat Inst Climate & Satellites, College Pk, MD USA.
   [Srivastava, A. K.] Indian Meteorol Dept, Pune, Maharashtra, India.
   [Stammerjohn, Sharon] Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO USA.
   [Steele, M.] Univ Washington, Appl Phys Lab, Seattle, WA USA.
   [Steffen, Konrad] Swiss Fed Res Inst WSL, Birmensdorf, Switzerland.
   [Steinbrecht, Wolfgang] DWD German Weather Serv, Hohenpeissenberg, Germany.
   [Svendby, T.] Norwegian Inst Air Res, Kjeller, Norway.
   [Sweet, William] NOAA, NOS, Ctr Operat Oceanog Prod & Serv, Honolulu, HI USA.
   [Tanabe, Raymond M.] NOAA, NWS, Cent Pacific Hurricane Ctr, Honolulu, HI USA.
   [Teng, William L.] NASA, Goddard Earth Sci Data & Informat Serv Ctr ADNET, Greenbelt, MD USA.
   [Thoman, R.] NOAA, NWS Weather Forecast Off, Fairbanks, AK USA.
   [Timmermans, M.-L.] Yale Univ, New Haven, CT USA.
   [Tobin, Skie; Trewin, Blair C.] Australian Bur Meteorol, Melbourne, Vic, Australia.
   [Trotman, Adrian] Caribbean Inst Meteorol & Hydrol, Bridgetown, Barbados.
   [van de Wal, Roderik S. W.] Univ Utrecht, Inst Marine & Atmospher Res Utrecht, Utrecht, Netherlands.
   [Vieira, Goncalo] Univ Lisbon, Dept Geog, Lisbon, Portugal.
   [Wouters, B.] Univ Colorado, Dept Phys, Boulder, CO USA.
   [Wang Junhong; Zhang Liangying] NCAR, Earth Observing Lab, Boulder, CO USA.
   [Wang Junhong] SUNY Albany, Dept Atmospher & Environm Sci, Albany, NY USA.
   [Wang, M.] Univ Washington, Joint Inst Study Atmosphere & Ocean, Seattle, WA USA.
   [Wang Lei] LA State Univ, Dept Geog & Anthropol, Baton Rouge, LA USA.
   [Williams, W.; Zimmermann, S.] Fisheries & Oceans Canada, Inst Ocean Sci, Sidney, BC, Canada.
   [Willis, Joshua K.] CALTECH, Jet Propuls Lab, Pasadena, CA USA.
   [Wolken, G.] Alaska Div Geol & Geophys Surveys, Fairbanks, AK USA.
   [Wouters, B.] Univ Bristol, Sch Geog Sci, Bristol, Avon, England.
   [Yamada, Ryuji] Japan Meteorol Agcy, Tokyo Climate Ctr, Climate Predict Div, Tokyo, Japan.
   [Zhang Peiqun] Beijing Climate Ctr, Beijing, Peoples R China.
   [Zhao Lin] Cold & Arid Reg Environm & Engn Res Inst, Lanzhou, Peoples R China.
RP Achberger, C (reprint author), Univ Gothenburg, Dept Earth Sci, Gothenburg, Sweden.
RI Garzoli, Silvia/A-3556-2010; Baringer, Molly/D-2277-2012; Luo,
   Jing-Jia/B-2481-2008; Steffen, Konrad/C-6027-2013; Wang,
   Menghua/F-5631-2010; Wang, Muyin/K-4006-2014; Menendez,
   Melisa/L-4600-2014; Heimbach, Patrick/K-3530-2013; Steinbrecht,
   Wolfgang/G-6113-2010; Schlosser, Peter/C-6416-2012; Frajka-Williams,
   Eleanor/H-2415-2011; Blunden, Jessica/G-1309-2012; Banzon,
   Viva/D-5499-2014; Coelho, Caio/G-4275-2012; Dong, Shenfu/I-4435-2013;
   Ackerman, Steven/G-1640-2011; Rodell, Matthew/E-4946-2012; Lin,
   I-I/J-4695-2013; Thorne, Peter/F-2225-2014; Vieira, Goncalo/G-5958-2010;
   Bromwich, David/C-9225-2016; Hurst, Dale/D-1554-2016; Cooper,
   Owen/H-4875-2013; wilber, anne/F-6270-2011; Bindoff,
   Nathaniel/C-8050-2011; Hobbs, Will/G-5116-2014; Leuliette,
   Eric/D-1527-2010; Lumpkin, Rick/C-9615-2009; Hu, Zeng-Zhen/B-4373-2011;
   Meinen, Christopher/G-1902-2012; Camargo, Suzana/C-6106-2009; Knaff,
   John /F-5599-2010; van de wal, roderik/D-1705-2011; Trigo,
   Ricardo/B-7044-2008; Johnson, Gregory/I-6559-2012; Purkey,
   Sarah/K-1983-2012; Muller, Rolf/A-6669-2013; GrooSS,
   Jens-Uwe/A-7315-2013; Timmermans, Mary-Louise/N-5983-2014; Kramarova,
   Natalya/D-2270-2014; Domingues, Catia  /A-2901-2015; Key,
   Jeffrey/F-5597-2010; Smith, Thomas M./F-5626-2010; Heidinger,
   Andrew/F-5591-2010; Kim, Baek-Min/A-4634-2015; Rosenlof,
   Karen/B-5652-2008; Berry, David/C-1268-2011; Franz, Bryan/D-6284-2012;
   Tedesco, Marco/F-7986-2015; Schmid, Claudia/D-5875-2013; Barriopedro,
   David/C-1421-2008; Bulygina, Olga/H-1251-2016; Arndt, Derek/J-3022-2013;
   Box, Jason/H-5770-2013; Dunn, Robert/O-5910-2016; Schreck,
   Carl/B-8711-2011; Goni, Gustavo/D-2017-2012; Goldenberg,
   Stanley/C-5965-2014; Manager, CSD Publications/B-2789-2015; Burrows,
   John/B-6199-2014; McVicar, Tim/D-8614-2011; Heikkila, Anu/F-1261-2017;
   Famiglietti, James/G-7383-2017; Newman, Paul/D-6208-2012; Heim  (Jr.),
   Richard/H-9667-2017; Ramos, Alexandre/A-1998-2009; Shakhova,
   Natalia/H-6691-2016; Lieser, Jan/J-7157-2014; Semiletov,
   Igor/B-3616-2013; Kaiser, Johannes/A-7057-2012
OI Garzoli, Silvia/0000-0003-3553-2253; Baringer,
   Molly/0000-0002-8503-5194; Luo, Jing-Jia/0000-0003-2181-0638; Steffen,
   Konrad/0000-0001-8658-1026; Wang, Menghua/0000-0001-7019-3125; Heimbach,
   Patrick/0000-0003-3925-6161; Steinbrecht, Wolfgang/0000-0003-0680-6729;
   Schlosser, Peter/0000-0002-6514-4203; Frajka-Williams,
   Eleanor/0000-0001-8773-7838; Dong, Shenfu/0000-0001-8247-8072; Ackerman,
   Steven/0000-0002-4476-0269; Rodell, Matthew/0000-0003-0106-7437; Lin,
   I-I/0000-0002-8364-8106; Thorne, Peter/0000-0003-0485-9798; Vieira,
   Goncalo/0000-0001-7611-3464; Hurst, Dale/0000-0002-6315-2322; Bindoff,
   Nathaniel/0000-0001-5662-9519; Hobbs, Will/0000-0002-2061-0899;
   Leuliette, Eric/0000-0002-3425-4039; Lumpkin, Rick/0000-0002-6690-1704;
   Hu, Zeng-Zhen/0000-0002-8485-3400; Meinen,
   Christopher/0000-0002-8846-6002; Camargo, Suzana/0000-0002-0802-5160;
   Knaff, John /0000-0003-0427-1409; Trigo, Ricardo/0000-0002-4183-9852;
   Johnson, Gregory/0000-0002-8023-4020; Muller, Rolf/0000-0002-5024-9977;
   GrooSS, Jens-Uwe/0000-0002-9485-866X; Kramarova,
   Natalya/0000-0002-6083-8548; Domingues, Catia  /0000-0001-5100-4595;
   Key, Jeffrey/0000-0001-6109-3050; Smith, Thomas M./0000-0001-7469-7849;
   Heidinger, Andrew/0000-0001-7631-109X; Rosenlof,
   Karen/0000-0002-0903-8270; Franz, Bryan/0000-0003-0293-2082; Schmid,
   Claudia/0000-0003-2132-4736; Barriopedro, David/0000-0001-6476-944X;
   Arndt, Derek/0000-0001-7698-6740; Dunn, Robert/0000-0003-2469-5989;
   Schreck, Carl/0000-0001-9331-5754; Goni, Gustavo/0000-0001-7093-3170;
   Goldenberg, Stanley/0000-0001-6730-5819; Burrows,
   John/0000-0002-6821-5580; Heikkila, Anu/0000-0002-1050-5673;
   Famiglietti, James/0000-0002-6053-5379; Newman,
   Paul/0000-0003-1139-2508; Heim  (Jr.), Richard/0000-0003-1701-6861;
   Ramos, Alexandre/0000-0003-3129-7233; Lieser, Jan/0000-0001-6870-1311;
   Kaiser, Johannes/0000-0003-3696-9123; Dorigo,
   Wouter/0000-0001-8054-7572; Alfaro, Eric/0000-0001-9278-5017; Fioletov,
   Vitali/0000-0002-2731-5956; Simmonds, Ian/0000-0002-4479-3255; Chambers,
   Don/0000-0002-5439-0257; Mitchard, Edward/0000-0002-5690-4055; Cross,
   Jessica/0000-0002-6650-9905; Smeed, David/0000-0003-1740-1778; Hidalgo,
   Hugo/0000-0003-4638-0742; Montzka, Stephen/0000-0002-9396-0400; Dolman,
   A.J./0000-0003-0099-0457; RAJEEVAN, Madhavan/0000-0002-3000-2459;
   Wouters, Bert/0000-0002-1086-2435; Wagner, Wolfgang/0000-0001-7704-6857;
   Rabe, Benjamin/0000-0001-5794-9856; Renwick, James/0000-0002-9141-2486;
   Meier, Walter/0000-0003-2857-0550
CR Ackerman SA, 2008, J ATMOS OCEAN TECH, V25, P1073, DOI 10.1175/2007JTECHA1053.1
   Adler RF, 2003, J HYDROMETEOROL, V4, P1147, DOI 10.1175/1525-7541(2003)004<1147:TVGPCP>2.0.CO;2
   Aiyyer A, 2008, J ATMOS SCI, V65, P2691, DOI 10.1175/2007JAS2348.1
   Akerman HJ, 2008, PERMAFROST PERIGLAC, V19, P279, DOI 10.1002/ppp.626
   Allan R., 2012, B AM METEOROL SOC, V93, pS35
   Allan R., 1996, EL NINO SO OSCILLATI
   Allan RJ, 2003, DEEP-SEA RES PT II, V50, P2331, DOI 10.1016/S0967-0645(03)00059-6
   Allan R, 2006, J CLIMATE, V19, P5816, DOI 10.1175/JCLI3937.1
   Alley WM, 2002, SCIENCE, V296, P1985, DOI 10.1126/science.1067123
   Alvarez M, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2010JC006475
   Amador J. A., 2011, B AM METEOROL SOC, V92, pS182
   Amador JA, 2006, PROG OCEANOGR, V69, P101, DOI 10.1016/j.pocean.2006.03.007
   Andersson A., 2010, EARTH SYST SCI DATA, V2, P215, DOI DOI 10.5194/ESSD-2-215-2010
   Antonov J. I., 2010, WORLD OCEAN ATLAS, V2
   AOSB, 2005, INT ARCT OC OBS SYST
   Argo Science Team, 1999, 21 CLIVAR ICPO ARG S
   Armstrong R. L., DMSP SSM 1 SSMIS PAT
   Arrigo KR, 2011, J GEOPHYS RES-OCEANS, V116, DOI DOI 10.1029/2011JC007151
   Asplin MG, 2012, J GEOPHYS RES-OCEANS, V117, DOI 10.1029/2011JC007221
   Atkinson DE, 2006, ATMOS OCEAN, V44, P347, DOI 10.3137/ao.440403
   Atkinson G. D., 1971, 240 US AIR FORC
   Baccini A, 2012, NAT CLIM CHANGE, V2, P182, DOI [10.1038/NCLIMATE1354, 10.1038/nclimate1354]
   Bakker AMR, 2013, WIND ENERGY, V16, P927, DOI 10.1002/we.1534
   Ballantyne AP, 2012, NATURE, V488, P70, DOI 10.1038/nature11299
   Baringer MO, 2001, GEOPHYS RES LETT, V28, P3179, DOI 10.1029/2001GL013246
   Baringer M. O., 2011, B AM METEOROL SOC, V92, pS95
   Baringer M. O., 2012, B AM METEOROL SOC, V93, pS78
   Barrett BE, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036369
   Bates NR, 2009, BIOGEOSCIENCES, V6, P2433
   Bates NR, 2007, J GEOPHYS RES-OCEANS, V112, DOI 10.1029/2006JC003759
   Bates NR, 2009, J GEOPHYS RES-OCEANS, V114, DOI 10.1029/2008JC004862
   Becker A, 2013, EARTH SYST SCI DATA, V5, P71, DOI 10.5194/essd-5-71-2013
   Behrenfeld MJ, 2006, NATURE, V444, P752, DOI 10.1038/nature05317
   Behringer DW, 1998, MON WEATHER REV, V126, P1013, DOI 10.1175/1520-0493(1998)126<1013:AICMFE>2.0.CO;2
   Bekryaev RV, 2010, J CLIMATE, V23, P3888, DOI 10.1175/2010JCLI3297.1
   Bell GD, 2006, J CLIMATE, V19, P590, DOI 10.1175/JCLI3659.1
   Bell GD, 2000, B AM METEOROL SOC, V81, pS1, DOI 10.1175/1520-0477(2000)81[s1:CAF]2.0.CO;2
   Bell G. D., 2011, B AM METEOROL SOC, V92, pS115
   Bell GD, 2012, B AM METEOROL SOC, V93, pS99
   Bell G. D., 2007, B AM METEOROL SOC, V88, pS48
   Bentamy A, 2003, J CLIMATE, V16, P637, DOI 10.1175/1520-0442(2003)016<0637:SEOWSA>2.0.CO;2
   Berry DI, 2011, INT J CLIMATOL, V31, P987, DOI 10.1002/joc.2059
   Berry DI, 2009, B AM METEOROL SOC, V90, P645, DOI 10.1175/2008BAMS2639.1
   Bichet A, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051685
   Blake E., 2009, TROPICAL CYCLONES E, V6-5
   Blake E.S., 2011, NHC6 NOAA NWS
   Bockheim J, 2013, GLOBAL PLANET CHANGE, V100, P215, DOI 10.1016/j.gloplacha.2012.10.018
   Boning CW, 2008, NAT GEOSCI, V1, P864, DOI 10.1038/ngeo362
   Boening C, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL053055
   BOJKOV RD, 1986, J CLIM APPL METEOROL, V25, P343, DOI 10.1175/1520-0450(1986)025<0343:SODTSH>2.0.CO;2
   Bojkov RD, 2001, ANN GEOPHYS, V19, P797
   Bolch T, 2012, SCIENCE, V336, P310, DOI 10.1126/science.1215828
   Bond TC, 2013, J GEOPHYS RES-ATMOS, V118, P5380, DOI 10.1002/jgrd.50171
   Bonsal BR, 2006, J HYDROL, V330, P340, DOI 10.1016/j.jhydrol.2006.03.022
   Boon JD, 2012, J COASTAL RES, V28, P1437, DOI 10.2112/JCOASTRES-D-12-00102.1
   Bowman KW, 2006, IEEE T GEOSCI REMOTE, V44, P1297, DOI [10.1109/TGRS.2006.871234, 10.1109/TGRS.2006871234]
   Box JE, 2012, CRYOSPHERE, V6, P821, DOI 10.5194/tc-6-821-2012
   Box JE, 2011, ANN GLACIOL, V52, P91, DOI 10.3189/172756411799096312
   Box J. E., 2012, NOAA REP, P146
   Boyer T, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030126
   Boyer TP, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021791
   Boyer T. P., 2012, B AM METEOROL SOC, V93, pS72
   Boyer T. P., 2009, NOAA ATLAS NESDIS, V66, P18
   Bradley RS, 2006, NATURE, V442, P627, DOI 10.1038/442627b
   Brasnett B, 1999, J APPL METEOROL, V38, P726, DOI 10.1175/1520-0450(1999)038<0726:AGAOSD>2.0.CO;2
   Broecker W., 2001, GEOCHEM GEOPHY GEOSY, V2, P1065, DOI [10.1029/2001GC000185, DOI 10.1029/2001GC000185]
   Bromwich DH, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007859
   Bromwich DH, 2013, NAT GEOSCI, V6, P139, DOI [10.1038/ngeo1671, 10.1038/NGEO1671]
   Bromwich DH, 2011, J CLIMATE, V24, P4189, DOI 10.1175/2011JCLI4074.1
   Bromwich DH, 2000, J CLIMATE, V13, P1406, DOI 10.1175/1520-0442(2000)013<1406:EAARDO>2.0.CO;2
   Bromwich DH, 2004, J CLIMATE, V17, P109, DOI 10.1175/1520-0442(2004)017<0109:MTEMOA>2.0.CO;2
   Brown J., 2001, CIRCUM ARCTIC MAP PE
   Brown LC, 2010, PROG PHYS GEOG, V34, P671, DOI 10.1177/0309133310375653
   Brown RD, 2011, CRYOSPHERE, V5, P219, DOI 10.5194/tc-5-219-2011
   Brown RD, 2003, ATMOS OCEAN, V41, P1, DOI 10.3137/ao.410101
   Burn CR, 2009, PERMAFROST PERIGLAC, V20, P83, DOI 10.1002/ppp.655
   BUTCHART N, 1986, J ATMOS SCI, V43, P1319, DOI 10.1175/1520-0469(1986)043<1319:TAOTSP>2.0.CO;2
   Butler J. H., 2012, NOAA ANN GREENHOUSE
   Cai WJ, 2010, SCIENCE, V329, P556, DOI 10.1126/science.1189338
   Cai WJ, 2011, J CLIMATE, V24, P3910, DOI 10.1175/2011JCLI4129.1
   Caldeira K, 2003, NATURE, V425, P365, DOI 10.1038/425365a
   Caldeira K, 2005, J GEOPHYS RES-OCEANS, DOI [10.1029/2004jc002671, DOI 10.1029/2004JC002671]
   Calder J., 2009, P OCEANOBS 09 SUST O, VWPP-306
   Callaghan TV, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2009GL042064
   Camargo SJ, 2007, J CLIMATE, V20, P4819, DOI 10.1175/JCLI4282.1
   CAMPBELL JW, 1995, J GEOPHYS RES-OCEANS, V100, P13237, DOI 10.1029/95JC00458
   Espinoza JC, 2013, J HYDROMETEOROL, V14, P1000, DOI 10.1175/JHM-D-12-0100.1
   Carton JA, 2008, MON WEATHER REV, V136, P2999, DOI 10.1175/2007MWR1978.1
   Cartus O, 2012, REMOTE SENS-BASEL, V4, P3320, DOI 10.3390/rs4113320
   Cassou C, 2008, NATURE, V455, P523, DOI 10.1038/nature07286
   Cavallo SM, 2012, MON WEATHER REV, V140, P1683, DOI 10.1175/MWR-D-11-00182.1
   Chambers DP, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2010JB007530
   Chen L, 2013, INT J CLIMATOL, V33, P2579, DOI 10.1002/joc.3613
   Chen L, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2012JD017533
   Chen MY, 2002, J HYDROMETEOROL, V3, P249, DOI 10.1175/1525-7541(2002)003<0249:GLPAYM>2.0.CO;2
   Christiansen HH, 2010, PERMAFROST PERIGLAC, V21, P156, DOI 10.1002/ppp.687
   Christiansen H H, 2012, B AM METEOROL SOC, V93, pS19
   Christy JR, 2011, INT J REMOTE SENS, V32, P671, DOI 10.1080/01431161.2010.517803
   Church JA, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL048794
   Colwell S., 2012, B AM METEOROL SOC, V93, pS151
   Comiso J., 2008, BOOTSTRAP SEA ICE CO
   Comiso J C, 2010, SEA ICE, P205, DOI DOI 10.1002/9781444317145.CH6
   Compo GP, 2011, Q J ROY METEOR SOC, V137, P1, DOI 10.1002/qj.776
   Cooper OR, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2012JD018261
   Cullather RI, 1996, J GEOPHYS RES-ATMOS, V101, P19109, DOI 10.1029/96JD01769
   Cunningham SA, 2007, SCIENCE, V317, P935, DOI 10.1126/science.1141304
   Curry RG, 2001, J PHYS OCEANOGR, V31, P3374, DOI 10.1175/1520-0485(2001)031<3374:OGCCAW>2.0.CO;2
   Dai A, 2006, J CLIMATE, V19, P3589, DOI 10.1175/JCLI3816.1
   Dai AG, 2011, J CLIMATE, V24, P965, DOI 10.1175/2010JCLI3816.1
   Daniel J. S., 2011, SCI ASSESSMENT OZONE
   Dare RA, 2011, MON WEATHER REV, V139, P3798, DOI 10.1175/MWR-D-10-05019.1
   Davidson EA, 2009, NAT GEOSCI, V2, P659, DOI 10.1038/NGEO608
   Dee DP, 2011, Q J ROY METEOR SOC, V137, P553, DOI 10.1002/qj.828
   De Jeu R., 2012, B AM METEOROL SOC, V93, pS30
   De Jeu RAM., 2012, B AM METEOROL SOC, V93, pS32
   Delworth TL, 2000, CLIM DYNAM, V16, P661, DOI 10.1007/s003820000075
   Dentener F., 2011, HEMISPHERIC TRANSPOR, V17
   Derksen C, 2012, CLIMATIC CHANGE, V115, P59, DOI 10.1007/s10584-012-0470-0
   Derksen C, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL053387
   DESER C, 1993, J CLIMATE, V6, P1743, DOI 10.1175/1520-0442(1993)006<1743:SCVOTN>2.0.CO;2
   Deser C, 2010, ANNU REV MAR SCI, V2, P115, DOI 10.1146/annurev-marine-120408-151453
   Dhomse S, 2006, ATMOS CHEM PHYS, V6, P1165
   Diamond HJ, 2012, INT J CLIMATOL, V32, P2240, DOI 10.1002/joc.2412
   Diamond H. J., 2011, B AM METEOROL SOC, V92, pS109
   Diamond H. J., 2012, B AM METEOROL SOC, V93, pS93
   Di Girolamo L., 2010, JPL PUBL
   Ding AJ, 2008, ATMOS CHEM PHYS, V8, P1
   Dlugokencky EJ, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039780
   Dlugokencky EJ, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018126
   Dlugokencky EJ, 1998, NATURE, V393, P447, DOI 10.1038/30934
   Doherty RM, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006849
   Domingues CM, 2008, NATURE, V453, P1090, DOI 10.1038/nature07080
   Dong SF, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039356
   Dore JE, 2009, P NATL ACAD SCI USA, V106, P12235, DOI 10.1073/pnas.0906044106
   Dorigo W, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL052988
   Drozdov D S, 2012, P 10 INT C PERM SACK, V2, P65
   Duguay CR, 2006, HYDROL PROCESS, V20, P781, DOI 10.1002/hyp.6131
   Dunn RJH, 2012, CLIM PAST, V8, P1649, DOI 10.5194/cp-8-1649-2012
   Durack PJ, 2012, SCIENCE, V336, P455, DOI 10.1126/science.1212222
   Durack PJ, 2010, J CLIMATE, V23, P4342, DOI 10.1175/2010JCLI3377.1
   ECMWF, 2012, ECMWF NEWS      0713
   Elvehoy H., 2012, GLACIER LENGTH CHANG
   Emanuel K, 2001, J GEOPHYS RES-ATMOS, V106, P14771, DOI 10.1029/2000JD900641
   Emanuel K., 2004, P 26 C HURR TROP MET, V10A.2, P240
   Enfield D. B., 1999, J CLIMATE, V12, P2719
   England MH, 2005, J CLIMATE, V18, P1435, DOI 10.1175/JCLI3322.1
   Environment Canada, SEL OZ MAPS
   Esaias WE, 1998, IEEE T GEOSCI REMOTE, V36, P1250, DOI 10.1109/36.701076
   Ezer T, 2013, J GEOPHYS RES-OCEANS, V118, P685, DOI 10.1002/jgrc.20091
   Ezer T, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL053435
   Fabry VJ, 2009, OCEANOGRAPHY, V22, P160
   Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329
   Feely RA, 2009, OCEANOGRAPHY, V22, P36, DOI 10.5670/oceanog.2009.95
   Fekete BM, 2012, J HYDROMETEOROL, V13, P1977, DOI 10.1175/JHM-D-11-0126.1
   Fekete B. M., 2011, B AM METEOROL SOC, V92, pS46
   Fekete B. M., 2012, B AM METEOROL SOC, V93, pS28
   Fekete B. M., 2010, B AM METEOROL SOC, V91, pS35
   Feldpausch TR, 2012, BIOGEOSCIENCES, V9, P3381, DOI 10.5194/bg-9-3381-2012
   field D. B., 2001, GEOPHYS RES LETT, V28, P2077
   Fioletov VE, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2008JD009809
   Fioletov VE, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001350
   Fischer A., 2012, GLETSCHERBERICHT 201, V66
   Fofonoff N. P., 1979, J OCEANOGR SOC JAPAN, V35, P63, DOI [10.1007/BF02108283, DOI 10.1007/BF02108283]
   Fogt RL, 2006, J CLIMATE, V19, P979, DOI 10.1175/JCLI3671.1
   Fogt RL, 2011, CLIM DYNAM, V36, P1555, DOI 10.1007/s00382-010-0905-0
   Folland CK, 2009, J CLIMATE, V22, P1082, DOI 10.1175/2008JCLI2459.1
   Forster P, 2007, CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P129
   Frajka-Williams E, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2011JC007168
   Francis JA, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051000
   Free M, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2005JD006169
   Freeland H., 2010, ESA PUBLICATION, VWPP-306, DOI [10.5270/OceanObs09.cwp.32, DOI 10.5270/OCEAN0BS09.CWP.32]
   FUNG I, 1991, J GEOPHYS RES-ATMOS, V96, P13033, DOI 10.1029/91JD01247
   Gardner AS, 2007, J CLIMATE, V20, P4586, DOI 10.1175/JCLI4268.1
   Gardner AS, 2011, NATURE, V473, P357, DOI 10.1038/nature10089
   Garzoli SL, 2007, DEEP-SEA RES PT I, V54, P1402, DOI 10.1016/j.dsr.2007.04.013
   Garzoli SL, 2013, DEEP-SEA RES PT I, V71, P21, DOI 10.1016/j.dsr.2012.09.003
   GCOS, 2010, GCOS138 WORLD MET OR
   GCOS, 2003, GCOS82 WORLD MET ORG
   Giglio L, 2010, BIOGEOSCIENCES, V7, P1171
   Gobron N, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL043870
   Goldenberg SB, 1996, J CLIMATE, V9, P1169, DOI 10.1175/1520-0442(1996)009<1169:PMFTAO>2.0.CO;2
   Goldenberg SB, 2001, SCIENCE, V293, P474, DOI 10.1126/science.1060040
   Goni G, 1996, J GEOPHYS RES-OCEANS, V101, P16273, DOI 10.1029/96JC01146
   Goni GJ, 2001, J GEOPHYS RES-OCEANS, V106, P31117, DOI 10.1029/2000JC000396
   Goni G., 2003, EOS T AM GEOPHYS UN, V84, P573, DOI DOI 10.1029/2003EO510001
   Goni G, 2009, OCEANOGRAPHY, V22, P190
   Goni GJ, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2011JC007198
   Gonzalez-Davila M, 2010, BIOGEOSCIENCES, V7, P3067, DOI 10.5194/bg-7-3067-2010
   Gouretski V, 2010, DEEP-SEA RES PT I, V57, P812, DOI 10.1016/j.dsr.2010.03.011
   Gouretski V. V., 2004, WOCE GLOB HYDR CLIM, V35
   Granier C, 2011, CLIMATIC CHANGE, V109, P163, DOI [10.1007/s10584-011-0154-1, 10.1007/S10584-011-0154-1]
   Grebmeier J., 2012, ARCTIC REPORT CARD 2, P68
   Gruber N, 1998, GLOBAL BIOGEOCHEM CY, V12, P165, DOI 10.1029/97GB03658
   Gruber N, 2012, SCIENCE, V337, P220, DOI 10.1126/science.1216773
   Guard C. P., 2012, B AM METEOROL SOC, V93, pS215
   Haeberli W, 2000, ANN GLACIOL, V31, P241, DOI 10.3189/172756400781820192
   Haeberli W, 2010, J GLACIOL, V56, P1043
   Hakkinen S, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2010JC006275
   Haimberger L, 2012, J CLIMATE, V25, P8108, DOI 10.1175/JCLI-D-11-00668.1
   Hanley D, 2001, MON WEATHER REV, V129, P2570, DOI 10.1175/1520-0493(2001)129<2570:ACSOTI>2.0.CO;2
   Hansen J, 2010, REV GEOPHYS, V48, DOI 10.1029/2010RG000345
   Harden JW, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051958
   Harris NL, 2012, SCIENCE, V336, P1573, DOI 10.1126/science.1217962
   Hart RE, 2003, MON WEATHER REV, V131, P585, DOI 10.1175/1520-0493(2003)131<0585:ACPSDF>2.0.CO;2
   Hart RE, 2001, J CLIMATE, V14, P546, DOI 10.1175/1520-0442(2001)014<0546:ACOTET>2.0.CO;2
   Hart RE, 2007, MON WEATHER REV, V135, P3990, DOI 10.1175/2007MWR2038.1
   Hauri C, 2013, BIOGEOSCIENCES, V10, P193, DOI 10.5194/bg-10-193-2013
   Hauri C, 2009, OCEANOGRAPHY, V22, P60, DOI 10.5670/oceanog.2009.97
   Haywood JM, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005232
   Held IM, 2006, J CLIMATE, V19, P5686, DOI 10.1175/JCLI3990.1
   Helfrich SR, 2007, HYDROL PROCESS, V21, P1576, DOI 10.1002/hyp.6720
   Helm KP, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL044222
   Helmig D, 2007, ATMOS ENVIRON, V41, P5138, DOI 10.1016/j.atmosenv.2006.09.053
   Hendon HH, 1999, J CLIMATE, V12, P2538, DOI 10.1175/1520-0442(1999)012<2538:IVOTMJ>2.0.CO;2
   Hilburn KA, 2008, J APPL METEOROL CLIM, V47, P778, DOI 10.1175/2007JAMC1635.1
   Ho SP, 2010, REMOTE SENS-BASEL, V2, P1320, DOI 10.3390/rs2051320
   Ho S.-P., 2010, B AM METEOROL SOC, V91, pS36, DOI [10.1175/BAMS-91-7-StateoftheClimate, DOI 10.1175/BAMS-91-7-STATEOFTHECLIMATE]
   Hobbs WR, 2012, J GEOPHYS RES-OCEANS, V117, DOI 10.1029/2011JC007039
   Hofmann DJ, 2006, TELLUS B, V58, P614, DOI 10.1111/j.1600-0889.2006.00201.x
   Hofmann D. J., 2009, EOS T AM GEOPHYS UN, V90, P1, DOI [10.1029/2009EO010001, DOI 10.1029/2009E0010001]
   Holt E, 2012, J APPL METEOROL CLIM, V51, P2188, DOI 10.1175/JAMC-D-11-0205.1
   Hood LL, 2001, J GEOPHYS RES-ATMOS, V106, P20925, DOI 10.1029/2001JD900093
   Hosoda S, 2009, J OCEANOGR, V65, P579
   Houghton J, 1990, CLIMATE CHANGE IPCC
   Hu ZZ, 2011, J CLIMATE, V24, P5812, DOI 10.1175/2011JCLI4213.1
   Huffman GJ, 2007, J HYDROMETEOROL, V8, P38, DOI 10.1175/JHM560.1
   Hurst D., 2012, B AM METEOROL SOC, V93, pS48
   Hurst DF, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD015065
   IARPC, 2007, ARCT OBS NETW US CON, V21
   Ingleby B, 2007, J MARINE SYST, V65, P158, DOI 10.1016/j.jmarsys.2005.11.019
   INPE, 2012, DIV EST TAX DESM COR
   Isaksen K, 2007, J GEOPHYS RES-EARTH, V112, DOI 10.1029/2006JF000522
   Isaksen K, 2011, PERMAFROST PERIGLAC, V22, P361, DOI 10.1002/ppp.728
   Ishihara K., 2006, SOKKO JIHO, V73, pS19
   Ishii M, 2009, J OCEANOGR, V65, P287, DOI 10.1007/s10872-009-0027-7
   Jacob DJ, 1999, GEOPHYS RES LETT, V26, P2175, DOI 10.1029/1999GL900450
   Jacob T, 2012, NATURE, V482, P514, DOI 10.1038/nature10847
   Jacobson MZ, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027838
   James PM, 1998, INT J CLIMATOL, V18, P1287, DOI 10.1002/(SICI)1097-0088(1998100)18:12<1287::AID-JOC315>3.0.CO;2-4
   Jeffries M. O., 2012, US GEOLOGICAL SURVEY, pA381
   Jin FF, 1997, J ATMOS SCI, V54, P811, DOI 10.1175/1520-0469(1997)054<0811:AEORPF>2.0.CO;2
   Johns WE, 2008, J PHYS OCEANOGR, V38, P605, DOI 10.1175/2007JPO3791.1
   Johnson F, 2010, J HYDROMETEOROL, V11, P105, DOI 10.1175/2009JHM1158.1
   Johnson G. C., 2012, B AM METEOROL SOC, V93, pS72
   JOHNSON GC, 2012, B AM METEOROL SOC, V93, pS68
   JOHNSON GC, 2012, B AM METEOROL SOC, V93, pS62, DOI DOI 10.1175/2012BAMSSTATEOFTHECLIMATE.1
   Johnson GC, 2007, PROG OCEANOGR, V73, P277, DOI 10.1016/j.pocean.2006.03.022
   Johnson GC, 2012, J GEOPHYS RES-OCEANS, V117, DOI 10.1029/2011JC007651
   Johnson GC, 2011, OCEANOGRAPHY, V24, P112, DOI 10.5670/oceanog.2011.31
   Johnson GC, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035619
   Johnson GC, 2008, J GEOPHYS RES-OCEANS, V113, DOI 10.1029/2007JC004477
   Jones PD, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2011JD017139
   Josey SA, 1999, J CLIMATE, V12, P2856, DOI 10.1175/1520-0442(1999)012<2856:NIITOH>2.0.CO;2
   Kaiser JW, 2012, BIOGEOSCIENCES, V9, P527, DOI 10.5194/bg-9-527-2012
   Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2
   Kang NY, 2012, J CLIMATE, V25, P7564, DOI 10.1175/JCLI-D-11-00735.1
   Kanzow T, 2010, J CLIMATE, V23, P5678, DOI 10.1175/2010JCLI3389.1
   Kanzow T, 2008, DEEP-SEA RES PT I, V55, P1601, DOI 10.1016/j.dsr.2008.07.011
   Kanzow T, 2008, J OPER OCEANOGR, V1, P19
   Kaplan A., 2011, B AM METEOROL SOC, V92, pS20
   Kaplan J, 2003, WEATHER FORECAST, V18, P1093, DOI 10.1175/1520-0434(2003)018<1093:LCORIT>2.0.CO;2
   Karl TR, 2010, PROCEDIA ENVIRON SCI, V1, P192, DOI 10.1016/j.proenv.2010.09.013
   Kaverin D, 2012, P 10 INT C PERM SAL, V2, P145
   Kayano MT, 1999, TELLUS A, V51, P373, DOI 10.1034/j.1600-0870.1999.t01-3-00003.x
   Kellndorfer J., 2012, NACP ABOVEGROUND BIO
   Kennedy JJ, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD015218
   Kennedy JJ, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD015220
   Kennedy J. J., 2010, B AM METEOROL SOC, V91, pS26
   Kent EC, 2007, J ATMOS OCEAN TECH, V24, P214, DOI 10.1175/JTECH1949.1
   Kew SF, 2010, MON WEATHER REV, V138, P1234, DOI 10.1175/2009MWR3193.1
   Khatiwala S, 2013, BIOGEOSCIENCES, V10, P2169, DOI 10.5194/bg-10-2169-2013
   Khatiwala S, 2009, NATURE, V462, P346, DOI 10.1038/nature08526
   Kiladis GN, 2009, REV GEOPHYS, V47, DOI 10.1029/2008RG000266
   KILADIS GN, 1992, MON WEATHER REV, V120, P1900, DOI 10.1175/1520-0493(1992)120<1900:CAAWTC>2.0.CO;2
   Kiladis GN, 2005, J ATMOS SCI, V62, P2790, DOI 10.1175/JAS3520.1
   Kimball SK, 2004, J CLIMATE, V17, P3555, DOI 10.1175/1520-0442(2004)017<3555:AYCONA>2.0.CO;2
   Kistler R, 2001, B AM METEOROL SOC, V82, P247, DOI 10.1175/1520-0477(2001)082<0247:TNNYRM>2.3.CO;2
   Klotzbach P. J., 2012, SUMMARY 2012 ATLANTI
   Knaff J. A., 2012, WEA FORECASTING, V18, P204
   Knaff JA, 2013, J CLIMATE, V26, P2631, DOI 10.1175/JCLI-D-12-00038.1
   Knapp KR, 2010, B AM METEOROL SOC, V91, P363, DOI 10.1175/2009BAMS2755.1
   Knight JR, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026242
   KNUTSON TR, 1987, MON WEATHER REV, V115, P1407, DOI 10.1175/1520-0493(1987)115<1407:DAOCLC>2.0.CO;2
   Knutti R, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032904
   Kobayashi S, 2009, Q J ROY METEOR SOC, V135, P2086, DOI 10.1002/qj.514
   Kopp G, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL045777
   Kossin JP, 2007, B AM METEOROL SOC, V88, P1767, DOI 10.1175/BAMS-88-11-1767
   Kouketsu S, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2010JC006464
   Kouketsu S, 2009, J GEOPHYS RES-OCEANS, V114, DOI 10.1029/2008JC004778
   KOUSKY VE, 1994, J CLIMATE, V7, P1131, DOI 10.1175/1520-0442(1994)007<1131:PMOOLR>2.0.CO;2
   Kratz DP, 2010, J APPL METEOROL CLIM, V49, P164, DOI 10.1175/2009JAMC2246.1
   Kuhlbrodt T, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL052952
   L'Heureux ML, 2006, J CLIMATE, V19, P276, DOI 10.1175/JCLI3617.1
   Lagerloef G, 2010, OCEANOGRAPHY, V23, P82
   Landsea CW, 1998, MON WEATHER REV, V126, P1174, DOI 10.1175/1520-0493(1998)126<1174:TEAAHS>2.0.CO;2
   Lassey KR, 2007, ATMOS CHEM PHYS, V7, P2141
   Latifovic R, 2007, REMOTE SENS ENVIRON, V106, P492, DOI 10.1016/j.rse.2006.09.015
   Lee K, 1998, NATURE, V396, P155, DOI 10.1038/24139
   Lefohn AS, 2010, ATMOS ENVIRON, V44, P5199, DOI 10.1016/j.atmosenv.2010.08.049
   Lefsky MA, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL043622
   Lelieveld J, 2004, SCIENCE, V304, P1483, DOI 10.1126/science.1096777
   Lenaerts JTM, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2010JD015419
   Levitus S, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051106
   Li HC, 2010, ATMOS ENVIRON, V44, P3605, DOI 10.1016/j.atmosenv.2010.04.011
   Liebmann B, 1996, B AM METEOROL SOC, V77, P1275
   Lin H, 2009, J CLIMATE, V22, P364, DOI 10.1175/2008JCLI2515.1
   Lin II, 2008, MON WEATHER REV, V136, P3288, DOI 10.1175/2008MWR2277.1
   Lin II, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL035815
   Lin II, 2009, MON WEATHER REV, V137, P3744, DOI 10.1175/2009MWR2713.1
   Lin YK, 2010, ENVIRON MONIT ASSESS, V169, P143, DOI 10.1007/s10661-009-1158-4
   Liu HX, 2006, J GEOPHYS RES-EARTH, V111, DOI 10.1029/2005JF000318
   Liu HX, 2005, INT J REMOTE SENS, V26, P4639, DOI 10.1080/01431160500213342
   Liu JP, 2012, P NATL ACAD SCI USA, V109, P4074, DOI 10.1073/pnas.1114910109
   Liu Y, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030042
   Liu YH, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051251
   Llovel W, 2011, GLOBAL PLANET CHANGE, V75, P76, DOI 10.1016/j.gloplacha.2010.10.008
   Llovel W, 2010, OCEAN DYNAM, V60, P1193, DOI 10.1007/s10236-010-0324-0
   Loeb NG, 2012, SURV GEOPHYS, V33, P359, DOI 10.1007/s10712-012-9175-1
   Loeb NG, 2009, J CLIMATE, V22, P748, DOI 10.1175/2008JCLI2637.1
   Logan JA, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2011JD016952
   Long C., 2012, B AM METEOROL SOC, V93, pS16
   Los SO, 2012, GEOSCI MODEL DEV, V5, P413, DOI 10.5194/gmd-5-413-2012
   Lozier MS, 2012, ANNU REV MAR SCI, V4, P291, DOI 10.1146/annurev-marine-120710-100740
   Lumpkin R, 2007, J PHYS OCEANOGR, V37, P2550, DOI 10.1175/JPO3130.1
   Lumpkin R, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2010JC006285
   Luo JJ, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032793
   Luo JJ, 2007, J CLIMATE, V20, P2178, DOI 10.1175/JCLI4132.1
   Luo JJ, 2012, P NATL ACAD SCI USA, V109, P18701, DOI 10.1073/pnas.1210239109
   Luo JJ, 2010, J CLIMATE, V23, P726, DOI 10.1175/2009JCLI3104.1
   Lyman JM, 2008, J CLIMATE, V21, P5629, DOI 10.1175/2008JCLI2259.1
   Lyman JM, 2012, SURV GEOPHYS, V33, P387, DOI 10.1007/s10712-011-9167-6
   Lyman JM, 2010, NATURE, V465, P334, DOI 10.1038/nature09043
   MADDEN RA, 1971, J ATMOS SCI, V28, P702, DOI 10.1175/1520-0469(1971)028<0702:DOADOI>2.0.CO;2
   MADDEN RA, 1972, J ATMOS SCI, V29, P1109, DOI 10.1175/1520-0469(1972)029<1109:DOGSCC>2.0.CO;2
   MADDEN RA, 1994, MON WEATHER REV, V122, P814, DOI 10.1175/1520-0493(1994)122<0814:OOTDTO>2.0.CO;2
   Mader JA, 2010, ATMOS CHEM PHYS, V10, P12161, DOI 10.5194/acp-10-12161-2010
   Mainelli M, 2008, WEATHER FORECAST, V23, P3, DOI 10.1175/2007WAF2006111.1
   Maloney ED, 2001, J ATMOS SCI, V58, P2545, DOI 10.1175/1520-0469(2001)058<2545:TMJOBD>2.0.CO;2
   Manney GL, 2011, NATURE, V478, P469, DOI 10.1038/nature10556
   Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2
   MARENCO A, 1994, J GEOPHYS RES-ATMOS, V99, P16617, DOI 10.1029/94JD00021
   Marlon JR, 2012, P NATL ACAD SCI USA, V109, pE535, DOI 10.1073/pnas.1112839109
   Marshall GJ, 2003, J CLIMATE, V16, P4134, DOI 10.1175/1520-0442(2003)016<4134:TITSAM>2.0.CO;2
   Maslanik JA, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL032043
   Maslanik J. A., 1999, NEAR REAL TIME DMSP
   Maslanik J, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047735
   Massom RA, 2001, ANN GLACIOL, V33, P391, DOI 10.3189/172756401781818518
   Massom R. A., 2012, B AM METEOROL SOC, V93, pS157
   Masunaga H, 2010, J CLIMATE, V23, P1189, DOI 10.1175/2009JCLI3124.1
   Mathis JT, 2007, LIMNOL OCEANOGR, V52, P1789, DOI 10.4319/lo.2007.52.5.1789
   Mathis JT, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051574
   Mathis JT, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2010JC006453
   McCarthy G, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL052933
   McClain CR, 2009, ANNU REV MAR SCI, V1, P19, DOI 10.1146/annurev.marine.010908.163650
   McGrath D., 2012, B AM METEOROL SOC, V93, pS154
   McGuire AD, 2012, BIOGEOSCIENCES, V9, P3185, DOI 10.5194/bg-9-3185-2012
   McInnes KL, 2011, ATMOS SCI LETT, V12, P325, DOI 10.1002/asl.341
   McKinlay A. F., 1987, CIE J, V6, P17
   McVicar TR, 2012, ECOHYDROLOGY, V5, P381, DOI 10.1002/eco.1298
   McVicar TR, 2012, J HYDROL, V416, P182, DOI 10.1016/j.jhydrol.2011.10.024
   McVicar TR, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035627
   Mears CA, 2009, J ATMOS OCEAN TECH, V26, P1493, DOI 10.1175/2009JTECHA1237.1
   Meehl GA, 2011, NAT CLIM CHANGE, V1, P360, DOI 10.1038/NCLIMATE1229
   Meier MF, 2007, SCIENCE, V317, P1064, DOI 10.1126/science.1143906
   Meijers AJS, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2010JC006832
   Meinen CS, 2010, DEEP-SEA RES PT I, V57, P835, DOI 10.1016/j.dsr.2010.04.001
   Meister G, 2012, IEEE T GEOSCI REMOTE, V50, P310, DOI 10.1109/TGRS.2011.2160552
   Mekonnen A, 2008, J CLIMATE, V21, P6649, DOI 10.1175/2008JCLI2008.1
   Menemenlis D, 2005, MON WEATHER REV, V133, P1224, DOI 10.1175/MWR2912.1
   Merrifield MA, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL052032
   Merrifield MA, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL049576
   Merrifield MA, 2011, J CLIMATE, V24, P4126, DOI 10.1175/2011JCLI3932.1
   Miller BR, 2010, ATMOS CHEM PHYS, V10, P7875, DOI 10.5194/acp-10-7875-2010
   Mishra U., 2012, RES TRAINING EXPEDIT
   Mitchard ETA, 2012, BIOGEOSCIENCES, V9, P179, DOI 10.5194/bg-9-179-2012
   Mo KC, 2000, MON WEATHER REV, V128, P4097, DOI 10.1175/1520-0493(2000)129<4097:TABIOA>2.0.CO;2
   MO KC, 1993, J GEOPHYS RES-ATMOS, V98, P5103, DOI 10.1029/92JD02952
   Monks PS, 2009, ATMOS ENVIRON, V43, P5268, DOI 10.1016/j.atmosenv.2009.08.021
   Montzka S., 2011, GLOBAL OZONE RES MON
   Morcrette J. J., 2011, 659 ECMWF
   Morice CP, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2011JD017187
   Morison J, 2012, NATURE, V481, P66, DOI 10.1038/nature10705
   MOTE TL, 1995, J GLACIOL, V41, P51
   Mounier F, 2007, J CLIMATE, V20, P1487, DOI 10.1175/JCLI4059.1
   Msadek R, 2013, J CLIMATE, V26, P4335, DOI 10.1175/JCLI-D-12-00081.1
   Muhle J, 2010, ATMOS CHEM PHYS, V10, P5145, DOI 10.5194/acp-10-5145-2010
   Muller R, 2008, ATMOS CHEM PHYS, V8, P251
   Munnich M, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023900
   Murata A, 2010, J GEOPHYS RES-OCEANS, V115, DOI 10.1029/2010JC006250
   Murata A, 2007, J GEOPHYS RES-OCEANS, V112, DOI 10.1029/2005JC003405
   Murray M. S., 2009, INT STUDY ARCTIC CHA
   Muto A, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL048086
   Nakazawa T, 2009, SOLA, V5, P33, DOI 10.2151/sola.2009-009
   National Academy of Sciences, 2003, UND CLIM CHANG FEEDB, P21
   National Ice Center, 2008, UPD DAIL IMS DAIL NO
   National Research Council, 2011, ASS REQ SUST OC COL
   National Research Council, 1991, RETH OZ PROBL URB RE
   Nerem RS, 2010, MAR GEOD, V33, P435, DOI 10.1080/01490419.2010.491031
   New M, 1999, J CLIMATE, V12, P829, DOI 10.1175/1520-0442(1999)012<0829:RTCSTC>2.0.CO;2
   New M, 2000, J CLIMATE, V13, P2217, DOI 10.1175/1520-0442(2000)013<2217:RTCSTC>2.0.CO;2
   Newman PA, 2007, ATMOS CHEM PHYS, V7, P4537
   Nghiem SV, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL053611
   Nicolas JP, 2011, SURV GEOPHYS, V32, P475, DOI 10.1007/s10712-011-9114-6
   NIWA, 2012, UND NZ MOUNT CLIM NA
   Nobre P, 1996, J CLIMATE, V9, P2464, DOI 10.1175/1520-0442(1996)009<2464:VOSSTW>2.0.CO;2
   OBPG, 2013, OC COL DAT REPR
   Oltmans SJ, 2013, ATMOS ENVIRON, V67, P331, DOI 10.1016/j.atmosenv.2012.10.057
   Thompson D. W. J., 2012, NATURE, V491, P692, DOI [10.1038/nature11579, DOI 10.1038/NATURE11579]
   Onogi K, 2007, J METEOROL SOC JPN, V85, P369, DOI 10.2151/jmsj.85.369
   Thorne P. W., 2005, J GEOPHYS RES, V110, DOI [10.1029/2004JD005753, DOI 10.1029/2004JD005753]
   ORNL DAAC, 2010, MOD SUBS LAND PROD C
   Orr JC, 2005, NATURE, V437, P681, DOI 10.1038/nature04095
   Orr J.C., 2011, OCEAN ACIDIFICATION, P41
   Orsi AH, 1999, PROG OCEANOGR, V43, P55, DOI 10.1016/S0079-6611(99)00004-X
   Orsi AJ, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051260
   Overeem I, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL048681
   OVERLAND J., 2012, ARCTIC REPORT CARD 2
   Overland J., 2010, NOAA REP
   Overland J., 2011, NOAA REP
   Overland JE, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL053268
   Overland JE, 2011, POLAR RES, V30, DOI 10.3402/polar.v30i0.15787
   Owens WB, 2009, DEEP-SEA RES PT I, V56, P450, DOI 10.1016/j.dsr.2008.09.008
   Palmer MD, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031712
   Palmer MD, 2011, INT J CLIMATOL, V31, P980, DOI 10.1002/joc.2224
   Park GH, 2006, J GEOPHYS RES-OCEANS, V111, DOI 10.1029/2005JC003090
   Park GH, 2010, TELLUS B, V62, P352, DOI 10.1111/j.1600-0889.2010.00498.x
   Park G.-H., 2010, 98OARAOML NOAA
   Parkinson CL, 2013, GEOPHYS RES LETT, V40, DOI 10.1002/grl.50349
   Parrish DD, 2012, ATMOS CHEM PHYS, V12, P11485, DOI 10.5194/acp-12-11485-2012
   Pavelin EG, 1999, ATMOS ENVIRON, V33, P919, DOI 10.1016/S1352-2310(98)00257-X
   Pelto MS, 2010, CRYOSPHERE, V4, P67
   Pelto M., N AM GLAC MASS BAL
   Pelto M., 2012, B AM METEOROL SOC, V93, pS22
   Pena M, 2002, MON WEATHER REV, V130, P3054, DOI 10.1175/1520-0493(2002)130<3054:COWADS>2.0.CO;2
   Pereira HM, 2013, SCIENCE, V339, P277, DOI 10.1126/science.1229931
   Perez FF, 2010, BIOGEOSCIENCES, V7, P1789, DOI 10.5194/bg-7-1789-2010
   PERMOS, 2010, PERM SWITZ 2006 2007
   Peters GP, 2013, NAT CLIM CHANGE, V3, P4
   Peters GP, 2012, NAT CLIM CHANGE, V2, P2
   Peterson TC, 1997, B AM METEOROL SOC, V78, P2837, DOI 10.1175/1520-0477(1997)078<2837:AOOTGH>2.0.CO;2
   Peterson T. C., 2011, B AM METEOROL SOC, V92, pS57
   Peuch V.-H., 2012, ECMWF NEWSLETTER, P20
   Phillips M, 2009, PERMAFROST PERIGLAC, V20, P1, DOI 10.1002/ppp.638
   Pickart RS, 2013, DEEP-SEA RES PT I, V76, P35, DOI 10.1016/j.dsr.2013.01.007
   Pinty B, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD015373
   Pinty B., 2012, B AM METEOROL SOC, V93, pS52
   Pitts MC, 2009, ATMOS CHEM PHYS, V9, P7577
   Polar Research Board, 2006, INT ARCT OBS NETW
   Pour HK, 2012, TELLUS A, V64, DOI 10.3402/tellusa.v64i0.17614
   Prather MJ, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051440
   Proshutinsky A., 2012, B AM METEOROL SOC, V93, pS57
   Proshutinsky A, 2009, J GEOPHYS RES-OCEANS, V114, DOI 10.1029/2008JC005104
   Prowse T, 2011, AMBIO, V40, P53, DOI 10.1007/s13280-011-0216-7
   Pryor SC, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD011416
   Pun IF, 2007, IEEE T GEOSCI REMOTE, V45, P1616, DOI 10.1109/TGRS.2007.895950
   Pun IF, 2013, GEOPHYS RES LETT, V40, P4680, DOI 10.1002/grl.50548
   Purkey SG, 2012, J CLIMATE, V25, P5830, DOI 10.1175/JCLI-D-11-00612.1
   Purkey SG, 2010, J CLIMATE, V23, P6336, DOI 10.1175/2010JCLI3682.1
   Rayner D, 2011, DEEP-SEA RES PT II, V58, P1744, DOI 10.1016/j.dsr2.2010.10.056
   Rayner NA, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002670
   REED RJ, 1977, MON WEATHER REV, V105, P317, DOI 10.1175/1520-0493(1977)105<0317:TSAPOA>2.0.CO;2
   Ren L, 2010, DEEP-SEA RES PT II, V57, P1161, DOI 10.1016/j.dsr2.2009.12.005
   Reynolds RW, 2007, J CLIMATE, V20, P5473, DOI 10.1175/2007JCLI1824.1
   Reynolds RW, 2002, J CLIMATE, V15, P1609, DOI 10.1175/1520-0442(2002)015<1609:AIISAS>2.0.CO;2
   Riddle EE, 2013, CLIM DYNAM, V40, P1749, DOI 10.1007/s00382-012-1493-y
   Rienecker MM, 2011, J CLIMATE, V24, P3624, DOI 10.1175/JCLI-D-11-00015.1
   Rintoul SR, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028550
   ROACH AT, 1995, J GEOPHYS RES-OCEANS, V100, P18443, DOI 10.1029/95JC01673
   Rodell M, 2001, WATER RESOUR RES, V37, P1327, DOI 10.1029/2000WR900306
   Rodell M, 2009, NATURE, V460, P999, DOI 10.1038/nature08238
   Roemmich D, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047992
   Roemmich D, 2009, OCEANOGRAPHY, V22, P46
   Roemmich D, 2009, PROG OCEANOGR, V82, P81, DOI 10.1016/j.pocean.2009.03.004
   Roemmich D, 2009, OCEANOGRAPHY, V22, P34, DOI 10.5670/oceanog.2009.36
   Romanovsky VE, 2010, PERMAFROST PERIGLAC, V21, P136, DOI 10.1002/ppp.683
   Romanovsky V. E., 2012, ARCTIC REPORT CARD 2, P159
   Romanovsky V. E., 2012, B AM METEOROL SOC, V93, pS137
   Romanovsky VE, 2010, PERMAFROST PERIGLAC, V21, P106, DOI 10.1002/ppp.689
   Ropelewski CF, 1989, J CLIMATE, V2, P268, DOI 10.1175/1520-0442(1989)002<0268:PPAWTH>2.0.CO;2
   Rossow WB, 1999, B AM METEOROL SOC, V80, P2261, DOI 10.1175/1520-0477(1999)080<2261:AIUCFI>2.0.CO;2
   The Royal Society, 2008, 1808 ROYAL SOC
   Rykaczewski RR, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL045019
   Saatchi SS, 2011, P NATL ACAD SCI USA, V108, P9899, DOI 10.1073/pnas.1019576108
   Sabine CL, 2008, J GEOPHYS RES-OCEANS, V113, DOI 10.1029/2007JC004577
   Sabine CL, 2007, GREENHOUSE GAS SINKS, P31, DOI 10.1079/9781845931896.0031
   Sabine CL, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001639
   Sabine CL, 2004, SCIENCE, V305, P367, DOI 10.1126/science.1097403
   Saha S, 2010, B AM METEOROL SOC, V91, P1015, DOI 10.1175/2010BAMS3001.1
   Saji NH, 1999, NATURE, V401, P360, DOI 10.1038/43855
   Sallenger AH, 2012, NAT CLIM CHANGE, V2, P884, DOI [10.1038/nclimate1597, 10.1038/NCLIMATE1597]
   Santoro M, 2011, REMOTE SENS ENVIRON, V115, P490, DOI 10.1016/j.rse.2010.09.018
   Sasgen I, 2012, J GEODYN, V59-60, P49, DOI 10.1016/j.jog.2012.03.004
   Schaefer K, 2011, TELLUS B, V63, P165, DOI 10.1111/j.1600-0889.2011.00527.x
   Schaner N, 2012, ENVIRON RES LETT, V7, DOI 10.1088/1748-9326/7/3/034029
   SEARCH (Study of Environmental Arctic Change), 2005, STUD ENV ARCT CHANG
   WGMS, 2012, PREL GLAC MASS BAL D
   WGMS, 2011, GLAC MASS BAL B
   WHO, 2002, GLOB SOL UV IND PRAC
   WMO, 2013, 1108 WMO
   *WORLD GLAC MON SE, PREL GLAC MASS BAL D
   Schanze JJ, 2010, J MAR RES, V68, P569, DOI 10.1357/002224010794657164
   Schauffler SM, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2001JD002040
   Schmitt RW, 2008, OCEANOGRAPHY, V21, P12
   Schnadt Poberaj C., 2009, ATMOS CHEM PHYS, V9, P5343
   Schneider U, 2011, GPCC MONITORING PROD
   Schneider U., 2011, GLOBAL PRECIPITATION
   Schott FA, 2001, PROG OCEANOGR, V51, P1, DOI 10.1016/S0079-6611(01)00083-0
   Schreck CJ, 2011, MON WEATHER REV, V139, P2723, DOI 10.1175/MWR-D-10-05060.1
   Schreck C. J., 2012, 30 C HURR TROP MET P, p1B4
   Schrier G., 2013, J GEOPHYS R IN PRESS, DOI [10.1029/JGRD.504444, DOI 10.1029/JGRD.504444]
   Schulz J, 2009, ATMOS CHEM PHYS, V9, P1687
   Schweiger AJ, 2008, J CLIMATE, V21, P4799, DOI 10.1175/200SJCLI2156.1
   Screen JA, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2011JD015847
   Seidel DJ, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL053850
   Send U, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL049801
   Seneviratne SI, 2010, EARTH-SCI REV, V99, P125, DOI 10.1016/j.earscirev.2010.02.004
   Shakhova N, 2010, SCIENCE, V327, P1246, DOI 10.1126/science.1182221
   Sharp M, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047381
   Shay LK, 2000, MON WEATHER REV, V128, P1366, DOI 10.1175/1520-0493(2000)128<1366:EOAWOF>2.0.CO;2
   Shiklomanov N. I., 2012, P 10 INT C PERM SAL, V1, P377
   Shiklomanov NI, 2010, J GEOPHYS RES-BIOGEO, V115, DOI 10.1029/2009JG001248
   Siegel DA, 2013, REMOTE SENS ENVIRON, V135, P77, DOI 10.1016/j.rse.2013.03.025
   Siegel D. A., 2012, B AM METEOROL SOC, V93, pS107
   Siegel DA, 2010, NATURE, V466, P569, DOI 10.1038/466569a
   Simard M, 2011, J GEOPHYS RES-BIOGEO, V116, DOI 10.1029/2011JG001708
   Simmonds I, 2002, METEOROL ATMOS PHYS, V80, P1, DOI 10.1007/s007030200009
   Simmonds I, 2008, J CLIMATE, V21, P5777, DOI 10.1175/2008JCLI2366.1
   Simmonds I, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL054259
   Simmons AJ, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2009JD012442
   Simpson IJ, 2012, NATURE, V488, P490, DOI 10.1038/nature11342
   Sinclair MR, 2002, MON WEATHER REV, V130, P590, DOI 10.1175/1520-0493(2002)130<0590:ETOSPT>2.0.CO;2
   Singh OP, 2000, METEOROL ATMOS PHYS, V75, P11, DOI 10.1007/s007030070011
   Slade SA, 2013, MON WEATHER REV, V141, P1925, DOI 10.1175/MWR-D-12-00268.1
   Smith AB, 2013, NAT HAZARDS, V67, P387, DOI 10.1007/s11069-013-0566-5
   Smith SL, 2010, PERMAFROST PERIGLAC, V21, P117, DOI 10.1002/ppp.690
   Smith SL, 2012, CAN J EARTH SCI, V49, P914, DOI 10.1139/E2012-019
   Smith SL, 2009, PERMAFROST PERIGLAC, V20, P201, DOI 10.1002/ppp.651
   Smith TM, 2008, J CLIMATE, V21, P2283, DOI 10.1175/2007JCLI2100.1
   Smith TM, 2005, J CLIMATE, V18, P2021, DOI 10.1175/JCLI3362.1
   Smith TM, 1998, J CLIMATE, V11, P3320, DOI 10.1175/1520-0442(1998)011<3320:AHRGSS>2.0.CO;2
   Sobel AH, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL053380
   Song JJ, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2009JD013058
   Srokosz M, 2012, B AM METEOROL SOC, V93, P1663, DOI 10.1175/BAMS-D-11-00151.1
   Stackhouse Jr P. W., 2006, P 12 C ATM RAD MAD W
   Stammerjohn SE, 2008, J GEOPHYS RES-OCEANS, V113, DOI 10.1029/2007JC004269
   Stammerjohn S, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL050874
   Steig EJ, 2013, NAT GEOSCI, V6, P87, DOI 10.1038/ngeo1717
   Steig EJ, 2009, NATURE, V457, P459, DOI 10.1038/nature07669
   Steinbrecht W, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL046634
   Stevenson DS, 2013, ATMOS CHEM PHYS, V13, P3063, DOI 10.5194/acp-13-3063-2013
   Stohl A, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002490
   Stolarski RS, 2006, ATMOS CHEM PHYS, V6, P4057
   Straub KH, 2006, DYNAM ATMOS OCEANS, V42, P216, DOI 10.1016/j.dynatmoce.2006.02.005
   STRELETSKIY D. A., 2008, P 9 INT C PERM FAIRB, V2, P1727
   Stroeve JC, 2012, CLIMATIC CHANGE, V110, P1005, DOI 10.1007/s10584-011-0101-1
   Sutton RT, 2012, NAT GEOSCI, V5, P788, DOI [10.1038/ngeo1595, 10.1038/NGEO1595]
   Sweet W., 2009, 051 NOAA NOS COOOPS
   Swift JH, 2012, OCEANOGRAPHY, V25, P54
   Takahashi T, 2009, DEEP-SEA RES PT II, V56, P554, DOI 10.1016/j.dsr2.2008.12.009
   Takala M, 2011, REMOTE SENS ENVIRON, V115, P3517, DOI 10.1016/j.rse.2011.08.014
   Takaya K, 2005, J ATMOS SCI, V62, P4441, DOI 10.1175/JAS3628.1
   Takaya K, 2005, J ATMOS SCI, V62, P4423, DOI 10.1175/JAS3629.1
   Tapley BD, 2004, SCIENCE, V305, P503, DOI 10.1126/science.1099192
   Tarasova OA, 2009, ATMOS CHEM PHYS, V9, P4157
   Tarnocai C, 2009, GLOBAL BIOGEOCHEM CY, V23, DOI 10.1029/2008GB003327
   Taylor CM, 2012, NATURE, V489, P423, DOI 10.1038/nature11377
   Tedesco M, 2009, REMOTE SENS ENVIRON, V113, P979, DOI 10.1016/j.rse.2009.01.009
   Tedesco M, 2012, CRYOSPHERE DISCUSS, V6, P4939, DOI DOI 10.5194/TCD-6-4939-2012
   Tedesco M, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028466
   Tedesco M, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039186
   Timmermans M.-L., 2012, ARCTIC REPORT CARD 2
   Timokhov L., 1997, ARCTIC CLIMATOLOGY P
   Tiwari VM, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039401
   Tokinaga H, 2011, J CLIMATE, V24, P267, DOI 10.1175/2010JCLI3789.1
   Torinesi O, 2003, J CLIMATE, V16, P1047, DOI 10.1175/1520-0442(2003)016<1047:VATOTS>2.0.CO;2
   Trofimov A., 2012, IMR PINRO JOINT REPO, P7
   Tschudi M, 2010, IEEE J-STARS, V3, P536, DOI 10.1109/JSTARS.2010.2048305
   Turpie K. R., 2012, SPIE P, V8510
   van de Wal RSW, 2005, ANN GLACIOL, V42, P311, DOI 10.3189/172756405781812529
   van de Wal RSW, 2012, EARTH SYST SCI DATA, V4, P31, DOI 10.5194/essd-4-31-2012
   van der Werf GR, 2013, CLIM PAST, V9, P289, DOI 10.5194/cp-9-289-2013
   van der Werf GR, 2010, ATMOS CHEM PHYS, V10, P11707, DOI 10.5194/acp-10-11707-2010
   Vautard R., 2012, B AM METEOROL SOC, V93, pS36
   Vautard R, 2010, NAT GEOSCI, V3, P756, DOI [10.1038/ngeo979, 10.1038/NGEO979]
   Vecchi GA, 2008, SCIENCE, V322, P687, DOI 10.1126/science.1164396
   Velicogna I, 2006, NATURE, V443, P329, DOI 10.1038/nature05168
   Venegas SA, 1997, J CLIMATE, V10, P2904, DOI 10.1175/1520-0442(1997)010<2904:AOCVIT>2.0.CO;2
   Ventrice MJ, 2012, MON WEATHER REV, V140, P2198, DOI 10.1175/MWR-D-11-00305.1
   Ventrice MJ, 2012, MON WEATHER REV, V140, P1108, DOI 10.1175/MWR-D-11-00122.1
   Vieira G, 2010, PERMAFROST PERIGLAC, V21, P182, DOI 10.1002/ppp.685
   Vomel H, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007224
   VOLZ A, 1988, NATURE, V332, P240, DOI 10.1038/332240a0
   Vorosmarty CJ, 2000, J HYDROL, V237, P17, DOI 10.1016/S0022-1694(00)00282-1
   Vorosmarty CJ, 1998, J HYDROL, V207, P147, DOI 10.1016/S0022-1694(98)00109-7
   Voss KA, 2013, WATER RESOUR RES, V49, P904, DOI 10.1002/wrcr.20078
   Wagner W., 2012, ISPRS ANN PHOTOGRAMM, VI-7, P315, DOI DOI 10.5194/ISPRSANNALS-I-7-315-2012
   WALISER DE, 1993, J CLIMATE, V6, P2162, DOI 10.1175/1520-0442(1993)006<2162:ASDCOT>2.0.CO;2
   Wallcraft AJ, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD011696
   Walter A. K., 2012, NAT GEOSCI, V5, P419, DOI [10.1038/NGEO1480, DOI 10.1038/NGE01480]
   Wang CZ, 2008, J CLIMATE, V21, P2437, DOI 10.1175/2007JCLI2029.1
   Wang CZ, 2006, J CLIMATE, V19, P3011, DOI 10.1175/JCLI3770.1
   Wang CZ, 2013, J CLIMATE, V26, P1322, DOI 10.1175/JCLI-D-12-00107.1
   Wang CZ, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL049265
   Wang CZ, 2010, CLIM DYNAM, V34, P953, DOI 10.1007/s00382-009-0560-5
   Wang CZ, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2007GC001809
   Wang CZ, 2003, J CLIMATE, V16, P1476, DOI 10.1175/1520-0442-16.10.1476
   Wang CZ, 2001, GEOPHYS RES LETT, V28, P1635, DOI 10.1029/2000GL011763
   Wang H, 2007, J CLIMATE, V20, P1188, DOI 10.1175/JCLI4061.1
   Wang JH, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007529
   Wang L., 2012, B AM METEOROL SOC, V93, pS156
   Wang L., 2011, B AM METEOROL SOC, V92, pS167
   Wang T, 2009, ATMOS CHEM PHYS, V9, P6217
   Wanninkhof R, 2010, J GEOPHYS RES-OCEANS, V115, DOI 10.1029/2010JC006251
   Waugh DW, 2006, TELLUS B, V58, P376, DOI 10.1111/j.1600-0889.2006.00222.x
   Weber M, 2011, ATMOS CHEM PHYS, V11, P11221, DOI 10.5194/acp-11-11221-2011
   Weber M., 2007, ESA SP, V636
   Wentz FJ, 1997, J GEOPHYS RES-OCEANS, V102, P8703, DOI 10.1029/96JC01751
   Wentz FJ, 2007, SCIENCE, V317, P233, DOI 10.1126/science.1140746
   Werdell PJ, 2009, REMOTE SENS ENVIRON, V113, P1319, DOI 10.1016/j.rse.2009.02.012
   Wever N, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2011JD017118
   Wheeler M, 1999, J ATMOS SCI, V56, P374, DOI 10.1175/1520-0469(1999)056<0374:CCEWAO>2.0.CO;2
   Wheeler M, 2001, MON WEATHER REV, V129, P2677, DOI 10.1175/1520-0493(2001)129<2677:RTMAPO>2.0.CO;2
   Wielicki BA, 1998, IEEE T GEOSCI REMOTE, V36, P1127, DOI 10.1109/36.701020
   Willett KM, 2013, CLIM PAST, V9, P657, DOI 10.5194/cp-9-657-2013
   Willett KM, 2008, J CLIMATE, V21, P5364, DOI 10.1175/2008JCLI2274.1
   Willis JK, 2004, J GEOPHYS RES-OCEANS, V109, DOI 10.1029/2003JC002260
   Willis JK, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL042372
   Willis JK, 2008, J GEOPHYS RES-OCEANS, V113, DOI 10.1029/2007JC004690
   Winker DM, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030135
   Wisser D, 2010, HYDROL EARTH SYST SC, V14, P1
   Wisser D, 2010, J HYDROL, V384, P264, DOI [10.1016/j.jhydro1.2009.07.032, 10.1016/j.jhydrol.2009.07.032]
   Wolter K., 1998, WEATHER, V53, P315, DOI DOI 10.1002/J.1477-8696.1998.TB06408.X
   Wong APS, 2003, J ATMOS OCEAN TECH, V20, P308, DOI 10.1175/1520-0426(2003)020<0308:DMCOAC>2.0.CO;2
   Woodgate RA, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL054092
   Woodruff SD, 2011, INT J CLIMATOL, V31, P951, DOI 10.1002/joc.2103
   Wouters B, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL032098
   Wu M.-C., 2006, EOS T AGU, V87, P537, DOI [10.1029/2006EO480001, DOI 10.1029/2006E0480001]
   Wunsch C, 2013, J CLIMATE, V26, P7167, DOI 10.1175/JCLI-D-12-00478.1
   Wylie D, 2005, J CLIMATE, V18, P3021, DOI 10.1175/JCLI3461.1
   WYRTKI K, 1981, J PHYS OCEANOGR, V11, P1205, DOI 10.1175/1520-0485(1981)011<1205:AEOEUI>2.0.CO;2
   Xie PP, 1997, B AM METEOROL SOC, V78, P2539, DOI 10.1175/1520-0477(1997)078<2539:GPAYMA>2.0.CO;2
   Xue Y., 2011, B AM METEOROL SOC, V92, pS78
   Yamamoto-Kawai M, 2009, SCIENCE, V326, P1098, DOI 10.1126/science.1174190
   Ying M, 2011, SCI CHINA EARTH SCI, V54, P1226, DOI 10.1007/s11430-011-4213-2
   Young PJ, 2013, ATMOS CHEM PHYS, V13, P2063, DOI 10.5194/acp-13-2063-2013
   Yu H, 2012, J TROP METEOROL, V18, P119, DOI 10.3969/j.issn.1006-8775.2012.02.002
   Yu L., 2008, OC200801 OFLUX PROJ
   Yu LS, 2007, B AM METEOROL SOC, V88, P527, DOI 10.1175/BAMS-88-4-527
   Yu LS, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2010JC006937
   Zagorodnov V, 2012, CRYOSPHERE, V6, P675, DOI 10.5194/tc-6-675-2012
   Zarin DJ, 2012, SCIENCE, V336, P1518, DOI 10.1126/science.1223251
   Zenklusen-Mutter E., 2010, J GEOPHYS RES, V115, DOI DOI 10.1029/2009JF001648
   Zhang CD, 2005, REV GEOPHYS, V43, DOI 10.1029/2004RG000158
   Zhang CD, 2002, J CLIMATE, V15, P2429, DOI 10.1175/1520-0442(2002)015<2429:SAOEAT>2.0.CO;2
   Zhang JL, 2013, GEOPHYS RES LETT, V40, P720, DOI 10.1002/grl.50190
   Zhang XB, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL053240
   Zhao L, 2010, PERMAFROST PERIGLAC, V21, P198, DOI 10.1002/ppp.688
   Ziemke JR, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2006JD007089
   Ziemke JR, 2011, ATMOS CHEM PHYS, V11, P9237, DOI 10.5194/acp-11-9237-2011
   Zou CZ, 2010, J ATMOS OCEAN TECH, V27, P1960, DOI 10.1175/2009JTECHA1333.1
   ZWALLY HJ, 1994, J GLACIOL, V40, P463
NR 661
TC 37
Z9 39
U1 18
U2 217
PU AMER METEOROLOGICAL SOC
PI BOSTON
PA 45 BEACON ST, BOSTON, MA 02108-3693 USA
SN 0003-0007
EI 1520-0477
J9 B AM METEOROL SOC
JI Bull. Amer. Meteorol. Soc.
PD AUG
PY 2013
VL 94
IS 8
BP S1
EP S258
DI 10.1175/2013BAMSStateoftheClimate.1
PG 258
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA 304EZ
UT WOS:000330731200001
OA No
DA 2017-08-15
ER

PT J
AU Williams, B
   Ramroop, S
   Shah, P
   Anderson, L
   Das, S
   Riddell, A
   Liebeschuetz, S
   Bernatoniene, J
   Shingadia, D
   Kampmann, B
AF Williams, Bhanu
   Ramroop, Shiva
   Shah, Pooja
   Anderson, Laura
   Das, Sreena
   Riddell, Anna
   Liebeschuetz, Susan
   Bernatoniene, Jolanta
   Shingadia, Delane
   Kampmann, Beate
TI Management of Pediatric Contacts of Multidrug Resistant Tuberculosis in
   the United Kingdom
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
ID PULMONARY TUBERCULOSIS; CHILDREN
C1 [Williams, Bhanu] North West London Hosp NHS Trust, Harrow, Middx, England.
   [Ramroop, Shiva; Shingadia, Delane] Great Ormond St Hosp Sick Children, London WC1N 3JH, England.
   [Shah, Pooja] Imperial NHS Trust, London, England.
   [Anderson, Laura] Hlth Protect Agcy, London, England.
   [Das, Sreena; Riddell, Anna; Liebeschuetz, Susan] Barts Hlth NHS Trust, London, England.
   [Bernatoniene, Jolanta] Bristol Royal Hosp Children, Bristol, Avon, England.
   [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Kampmann, Beate] MRC Unit, Serrekunda, Gambia.
RP Williams, B (reprint author), North West London Hosp NHS Trust, Harrow, Middx, England.
OI Kampmann, Beate/0000-0002-6546-4709
FU Department of Health [SRF-2009-02-07]; Medical Research Council
   [MC_UP_A900_1122]
CR Beyers N, 1997, INT J TUBERC LUNG D, V1, P38
   Schaaf HS, 2002, PEDIATRICS, V109, P765, DOI 10.1542/peds.109.5.765
   van der Werf MJ, 2012, INT J TUBERC LUNG D, V16, P288, DOI 10.5588/ijtld.11.0437
   World Health Organization (WHO), 2006, GUID NAT TUB PROGR M
   Williams B, 2013, EUR R J
NR 5
TC 6
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD AUG
PY 2013
VL 32
IS 8
BP 926
EP 927
DI 10.1097/INF.0b013e31829157e9
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 301HT
UT WOS:000330524100029
PM 23856715
OA No
DA 2017-08-15
ER

PT J
AU Hawkesworth, S
   Moore, SE
   Fulford, AJC
   Barclay, GR
   Darboe, AA
   Mark, H
   Nyan, OA
   Prentice, AM
AF Hawkesworth, S.
   Moore, S. E.
   Fulford, A. J. C.
   Barclay, G. R.
   Darboe, A. A.
   Mark, H.
   Nyan, O. A.
   Prentice, A. M.
TI Evidence for metabolic endotoxemia in obese and diabetic Gambian women
SO NUTRITION & DIABETES
LA English
DT Article
DE type 2 diabetes; bacteria; metabolic endotoxemia; The Gambia
ID INNATE IMMUNE-SYSTEM; DIET-INDUCED OBESITY; INSULIN-RESISTANCE; GUT
   MICROBIOTA; ADIPOSE-TISSUE; HEALTHY-MEN; INFLAMMATION;
   LIPOPOLYSACCHARIDE; INTERLEUKIN-6; MECHANISMS
AB OBJECTIVE: Emerging evidence from animal models suggests that translocation of bacterial debris across a leaky gut may trigger low-grade inflammation, which in turn drives insulin resistance. The current study set out to investigate this phenomenon, termed 'metabolic endotoxemia', in Gambian women.
   METHODS: In a cross-sectional study, we recruited 93 age-matched middle-aged urban Gambian women into three groups: lean (body mass index (BMI): 18.5-22.9 kg m(-2)), obese non-diabetic (BMI: >= 30.0 kg m(-2)) and obese diabetic (BMI: >= 30.0 kg m(-2) and attending a diabetic clinic). We measured serum bacterial lipopolysaccharide (LPS) and endotoxin-core IgM and IgG antibodies (EndoCAb) as measures of endotoxin exposure and interleukin-6 (IL-6) as a marker of inflammation.
   RESULTS: Inflammation (IL-6) was independently and positively associated with both obesity and diabetes (F = 12.7, P < 0.001). LPS levels were highest in the obese-diabetic group compared with the other two groups (F = 4.4, P < 0.02). IgM EndoCAb (but not total IgM) was highly significantly reduced in the obese (55% of lean value) and obese diabetic women (30% of lean; F = 21.7, P < 0.0001 for trend) compared with lean women.
   CONCLUSION: These data support the hypothesis that gut-derived inflammatory products are associated with obesity and diabetes. Confirmation of these findings and elucidation of the role of the microbiota, gut damage and the pathways for translocation of bacterial debris, could open new avenues for prevention and treatment of type 2 diabetes.
C1 [Hawkesworth, S.; Moore, S. E.; Fulford, A. J. C.; Prentice, A. M.] Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Moore, S. E.; Fulford, A. J. C.; Darboe, A. A.; Mark, H.; Prentice, A. M.] MRC, Int Nutr Grp, Mrc Keneba, Gambia.
   [Barclay, G. R.] Univ Edinburgh, SNBTS Cell Therapy Res Grp, Ctr Regenerat Med, Edinburgh EH8 9YL, Midlothian, Scotland.
   [Nyan, O. A.] Univ Gambia, Sch Med & Allied Hlth Sci, Banjul, Gambia.
RP Hawkesworth, S (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM sophie.hawkesworth@lshtm.ac.uk
OI Hawkesworth, Sophie/0000-0002-3554-242X; Darboe,
   Alansana/0000-0002-1152-8156
FU UK Medical Research Council [MC-A760-5QX00]
FX This work was supported by UK Medical Research Council core funding to
   the International Nutrition Group (MC-A760-5QX00). We thank Ebou Touray
   for his assistance in the field and Kerry Jones, Ebrima Danso and Bakary
   Darboe for their work in the laboratories in MRC Keneba and MRC Fajara,
   The Gambia.
CR Al-Attas OS, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-20
   Amar J, 2008, AM J CLIN NUTR, V87, P1219
   Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816
   Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104
   BARCLAY GR, 1989, CIRC SHOCK, V29, P93
   BARCLAY GR, 1995, BACTERIAL ENDOTOXINS
   Bellido C, 2004, AM J CLIN NUTR, V80, P1487
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491
   Cani PD, 2009, CURR PHARM DESIGN, V15, P1546, DOI 10.2174/138161209788168164
   Creely SJ, 2007, AM J PHYSIOL-ENDOC M, V292, pE740, DOI 10.1152/ajpendo.00302.2006
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   Delzenne NM, 2011, ANNU REV NUTR, V31, P15, DOI 10.1146/annurev-nutr-072610-145146
   Deopurkar R, 2010, DIABETES CARE, V33, P991, DOI 10.2337/dc09-1630
   Erridge C, 2007, AM J CLIN NUTR, V86, P1286
   Ghanim H, 2009, DIABETES CARE, V32, P2281, DOI 10.2337/dc09-0979
   Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665
   Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402
   Kelly P, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-72
   Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745
   Laugerette F, 2011, BIOCHIMIE, V93, P39, DOI 10.1016/j.biochi.2010.04.016
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/nature4441022a
   Lunn PG, 2000, P NUTR SOC, V59, P147, DOI 10.1017/S0029665100000173
   Magne J, 2010, J NUTR BIOCHEM, V21, P550, DOI 10.1016/j.jnutbio.2009.03.004
   Musso G, 2010, DIABETES CARE, V33, P2277, DOI 10.2337/dc10-0556
   PIROFSKY B, 1982, J CLIN IMMUNOL, V2, pS7, DOI 10.1007/BF00918361
   Poullis A, 2002, ALIMENT PHARM THERAP, V16, P675, DOI 10.1046/j.1365-2036.2002.01196.x
   POXTON IR, 1995, J IMMUNOL METHODS, V186, P1, DOI 10.1016/0022-1759(95)00123-R
   Rubino F, 2010, ANNU REV MED, V61, P393, DOI 10.1146/annurev.med.051308.105148
   Sandoval D, 2011, INT J OBESITY, V35, pS45, DOI 10.1038/ijo.2011.148
   Shoelson SE, 2007, GASTROENTEROLOGY, V132, P2169, DOI 10.1053/j.gastro.2007.03.059
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Stephens RCM, 2006, INTENS CARE MED, V32, P286, DOI 10.1007/s00134-005-0019-z
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1
   Venables MC, 2009, DIABETES-METAB RES, V25, pS18, DOI 10.1002/dmrr.983
   Vozarova B, 2001, OBES RES, V9, P414, DOI 10.1038/oby.2001.54
   WHO/IDF, 2006, DEF DIAGN DIAB MELL
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Zhang HS, 2009, P NATL ACAD SCI USA, V106, P2365, DOI 10.1073/pnas.0812600106
NR 40
TC 17
Z9 18
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-4052
J9 NUTR DIABETES
JI Nutr. Diabetes
PD AUG
PY 2013
VL 3
AR UNSP e83
DI 10.1038/nutd.2013.24
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 219XH
UT WOS:000324544500002
PM 23978817
OA gold
DA 2017-08-15
ER

PT J
AU Burl, S
   Holder, BS
   Lo, BKM
   Kampmann, B
AF Burl, S.
   Holder, B. S.
   Lo, B. K. M.
   Kampmann, B.
TI Optimisation of a functional mycobacterial growth-inhibition assay to
   improve its suitability for infant TB vaccine studies
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE BCG-lux; Mycobacterium tuberculosis; Paediatric tuberculosis; Vaccine
   immunogenicity
ID INTRACELLULAR GROWTH; CALMETTE-GUERIN; IMMUNITY; TUBERCULOSIS;
   EXPRESSION; INFECTION
AB The development of vaccines against tuberculosis continues to be hindered by the lack of correlates of protection. Immunity to Mycobacterium tuberculosis (M.tb) infection relies predominantly on cell mediated response, which is routinely measured using a read-out of host cytokine profiles. However, to date none of the cytokine profiles have been found to predict protection. A number of functional in vitro approaches that measure growth of mycobacteria pre- and post-vaccination as a potential functional surrogate marker for vaccine take have been developed. The use of a reporter-gene tagged BCG-lux assay measuring the viability of mycobacteria in whole blood samples has previously been described by our group to assess vaccine immunogenicity. Since only very small blood samples are usually available in paediatric studies, we now report a modification of the BCG-lux assay to reduce the volume required and make it more field-friendly. Our results show that a 2-fold reduction in blood volume made no significant difference to bacterial growth ratios, used as the main read-out. These results confirm the suitability of the BCG-lux assay for functional studies of vaccine immunogenicity and immunopathogenesis in young children and could play a role in late-phase TB vaccine trials of novel candidates. (C) 2013 The Authors. Published by Elsevier B.V. All rights reserved.
C1 [Burl, S.; Holder, B. S.; Lo, B. K. M.; Kampmann, B.] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London W2 1PG, England.
   [Kampmann, B.] Gambia, MRC Unit, Fajara, Gambia.
RP Burl, S (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Paediat, St Marys Campus,Norfolk Pl, London W2 1PG, England.
EM s.burl@imperial.ac.uk; b.kampmann@imperial.ac.uk
OI Lo, Belinda/0000-0002-1080-9837
FU Medical Research Council (UK)
FX The study was supported by the funding from the Medical Research Council
   (UK) to BK and SB. Funders did not participate in the study design,
   collection, analysis and interpretation of data; in the writing of the
   report; and in the decision to submit the article for publication.
CR FINE PEM, 1994, LANCET, V344, P1245, DOI 10.1016/S0140-6736(94)90748-X
   Kagina BMN, 2010, AM J RESP CRIT CARE, V182, P1073, DOI [10.1164/rccm.201003-0334OC, 10.1164/rrcm.201003-0334OC]
   Kampmann B, 2006, AIDS, V20, P1011, DOI 10.1097/01.aids.0000222073.45372.ce
   Kampmann B, 2004, INFECT IMMUN, V72, P6401, DOI 10.1128/IAI.72.11.6401.6407.2004
   Kampmann B, 2000, J INFECT DIS, V182, P895, DOI 10.1086/315766
   Martineau AR, 2007, J IMMUNOL, V178, P7190
   Pai M, 2008, ANN INTERN MED, V149, P177
   Silver RF, 1998, INFECT IMMUN, V66, P1190
   Snewin VA, 1999, INFECT IMMUN, V67, P4586
   Tameris M. D., 2013, LANCET IN PRESS
   Worku S, 2000, CLIN INFECT DIS, V30, pS257, DOI 10.1086/313887
NR 11
TC 5
Z9 5
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD AUG
PY 2013
VL 394
IS 1-2
BP 121
EP 124
DI 10.1016/j.jim.2013.05.006
PG 4
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 197NE
UT WOS:000322857100015
PM 23707325
OA No
DA 2017-08-15
ER

PT J
AU Njie, B
   Asimiran, S
   Basri, R
AF Njie, Baboucarr
   Asimiran, Soaib
   Basri, Ramli
TI An Exploratory Study of the Free Riding Debacle in a Malaysian
   University: Students' Perspectives
SO ASIA-PACIFIC EDUCATION RESEARCHER
LA English
DT Article
DE Free riding; University; Malaysia; Group work
ID COMMONS; WORK
AB The inherent benefits of group works continue to project it as a prominent means of learning in an era when theory is as important as the practical skills that students develop to cope with the demands of the recruiters. The benefits are, however, shadowed by the downsides of free riding complicated by the social settings, rather innocuous relationships which exist between students and the responsibilities of cooperation of students and lecturers. An exploration of the phenomenon was the thrust of this study with views of six postgraduate students in a Malaysian University sought through interviews. The analysis revealed that strong policies exist which encourage group activities concretized by the adherence on the side of the lecturers on the ground. However, such strong will has not been transformed into a strict workable formula to curtail free riding due to the looseness of forming groups, lack of supervision of group activities, the special bond of group members, and the student workloads. The paper finally advices on the need for more stringent supervisory means in group projects, group formation modalities, and a re-look into the academic workload of students especially those working full time.
C1 [Njie, Baboucarr; Asimiran, Soaib; Basri, Ramli] Univ Putra Malaysia, Fac Educ Studies, Serdang 43400, Selangor Darul, Malaysia.
   [Njie, Baboucarr] Univ Gambia, Sere Kunda, Gambia.
RP Njie, B (reprint author), Univ Putra Malaysia, Fac Educ Studies, Serdang 43400, Selangor Darul, Malaysia.
EM babukarr75@yahoo.co.uk; soaib@putra.upm.edu.my; ramlibasri@upm.edu.my
CR Abernethy A. M., 2005, MARKETING ED REV, V15, P47, DOI DOI 10.1080/10528008.2005.11488891
   Aggarwal P, 2008, J MARKET EDUC, V30, P255, DOI 10.1177/0273475308322283
   Ashraf M., 2004, J ED BUSINESS, V79, P213, DOI 10.3200/JOEB.79.4.213-216
   Wright L, 2006, J MANAGEMENT ED, V30, P557, DOI DOI 10.1177/1052562905284872
   Clark G. L., 1989, J MARKETING ED, V11, P41, DOI DOI 10.1177/027347538901100308
   Cohen SG, 1997, J MANAGE, V23, P239, DOI 10.1177/014920639702300303
   Creswell J., 2007, QUALITATIVE INQUIRY
   Dawes R. M., 1975, HUMAN JUDGMENT DECIS, P88
   Deeter-Schmelz D. R., 1998, J MARKETING ED, V20, P86
   Dommeyer CJ, 2007, J MARKET EDUC, V29, P175, DOI 10.1177/0273475307302019
   EDNEY JJ, 1980, AM PSYCHOL, V35, P131
   Green S., 2006, J MANAGEMENT ED, V30, P788, DOI DOI 10.1177/1052562906287968
   Garow A., 2009, NURS EDUC TODAY, V29, P580
   HARDIN G, 1968, SCIENCE, V162, P1243
   Johnson D.W., 1996, JOINING TOGETHER GRO
   King P. E., 2005, COLL TEACHING, V53, P57, DOI 10.3200/CTCH.53.2.57-61
   Leedy P., 1997, PRACTICAL RES PLANNI
   Liden RC, 2004, J MANAGE, V30, P285, DOI 10.1016/j.jm.2003.02.002
   Maiden B, 2011, ASSESS EVAL HIGH EDU, V36, P451, DOI 10.1080/02602930903429302
   Materu P, 2007, 124 WORLD BANK
   Myers D. G., 1990, SOCIAL PSYCHOL
   OLSON Mancur, 1965, LOGIC COLLECTIVE ACT
   Orbell J. M., 1981, PROGR APPLIED SOCIAL, V1, P37
   PLATT J, 1973, AM PSYCHOL, V28, P641, DOI 10.1037/h0035723
NR 24
TC 1
Z9 1
U1 1
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0119-5646
J9 ASIA-PAC EDUC RES
JI Asia-Pac. Educ. Res.
PD AUG
PY 2013
VL 22
IS 3
BP 257
EP 262
DI 10.1007/s40299-012-0029-x
PG 6
WC Education & Educational Research
SC Education & Educational Research
GA 186HS
UT WOS:000322033800005
OA No
DA 2017-08-15
ER

PT J
AU Schoenmakers, I
   Jarjou, LMA
   Goldberg, GR
   Tsoi, K
   Harnpanich, D
   Prentice, A
AF Schoenmakers, I.
   Jarjou, L. M. A.
   Goldberg, G. R.
   Tsoi, K.
   Harnpanich, D.
   Prentice, A.
TI Acute response to oral calcium loading in pregnant and lactating women
   with a low calcium intake: a pilot study
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Calcium; Calciumexcretion; Lactation; Parathyroid hormone; Phosphate;
   Pregnancy
ID SERUM TOTAL CALCIUM; PARATHYROID-HORMONE; BREAST-MILK; GAMBIAN MOTHERS;
   BONE TURNOVER; SUPPLEMENTATION; HOMEOSTASIS; ADJUSTMENT; METABOLISM; AGE
AB This pilot study in women from The Gambia with low habitual calcium intakes showed differences in calciotropic hormones between pregnant, lactating and non-pregnant, non-lactating women similar to those in Western women. The response to oral calcium loading indicates a high degree of calcium conservation independent of reproductive status.
   In pregnancy and early lactation, parathyroid hormone (PTH) concentrations may be suppressed. Uncertainty exists about how calcium metabolism is regulated, particularly when calcium intake is low.
   We investigated fasting markers of calcium metabolism and the acute calcemic and calciuric responses after an oral calcium load in 30 pregnant, lactating or non-pregnant, non-lactating (NPNL) Gambian women with low habitual calcium intakes. Women received 1 g elemental calcium (CaCO3) at 0 min. Blood was collected at -30 and 180 min. Urine was collected from -60 to 0, 0-120 and 120-240 min. Samples were analysed (blood: ionized calcium (iCa); plasma (p): total calcium (tCa), phosphate (P), creatinine (Cr), PTH, 1,25-dihydroxyvitamin D (1,25(OH)(2)D), osteocalcin (OC), beta C-terminal cross-linked telopeptide of type 1 collagen (beta CTX), cyclic adenosine monophosphate (cAMP); urine (u): Ca, P, Cr, cAMP).
   Pre-loading, groups did not differ significantly in iCa, pP, uCa/Cr and uP/Cr. pOC concentrations were significantly lower and NcAMP and p1,25(OH)(2)D higher in pregnant women; pPTH and p beta CTX in lactating women were higher than in NPNL women. Post-loading, iCa, ptCa and uCa/Cr concentrations increased; pPTH, NcAMP, beta CTX and uP/Cr decreased in all groups, but the magnitude of change did not differ significantly between groups.
   Differences between pregnant, lactating and NPNL Gambian women in pPTH, NcAMP and p1,25(OH)(2)D and bone markers were similar to Western women. However, the response to calcium loading indicates that there may be no differences in renal and intestinal calcium economy associated with reproductive status, potentially due to a high degree of calcium conservation associated with low intakes.
C1 [Schoenmakers, I.; Goldberg, G. R.; Tsoi, K.; Harnpanich, D.; Prentice, A.] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Jarjou, L. M. A.; Goldberg, G. R.; Prentice, A.] MRC Labs, MRC Keneba, Banjul, Gambia.
RP Schoenmakers, I (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM inez.schoenmakers@mrc-hnr.cam.ac.uk
FU UK Medical Research Council [U105960371, U123261351]; Nestle Foundation
FX This study was supported by the UK Medical Research Council under
   Programmes U105960371 and U123261351. Ms Tsoi was in receipt of a travel
   award from The Nestle Foundation. We thank the staff of MRC Keneba, The
   Gambia for their help with this study. Specifically, we would like to
   thank Fabakary Bajo and Lamin Jammeh for performing the fieldwork,
   Sophie Moore, Head of Station, for accommodating the project and
   providing local support, Kerry Jones for advice on sample processing and
   ionized calcium measurements and Janet Bennett, Ann Laidlaw and Shailja
   Nigdikar, MRC Human Nutrition Research, for the laboratory analyses.
   This work was supported by the UK Medical Research Council (Programme
   numbers U105960371 and U123261351). The Nestle Foundation awarded a
   student travel grant for Ms Tsoi.
CR Aspray TJ, 2005, BONE, V36, P710, DOI 10.1016/j.bone.2005.01.002
   Barth JH, 1996, ANN CLIN BIOCHEM, V33, P55
   BLAND JM, 1986, LANCET, V1, P307
   Brannon PM, 2011, ANNU REV NUTR, V31, P89, DOI 10.1146/annurev.nutr.012809.104807
   Broadus A E, 1981, Recent Prog Horm Res, V37, P667
   FAIRWEATHERTAIT S, 1995, AM J CLIN NUTR, V62, P1188
   GERTNER JM, 1986, AM J MED, V81, P451, DOI 10.1016/0002-9343(86)90298-6
   Jarjou LMA, 2012, EUR J CLIN NUTR, V66, P673, DOI 10.1038/ejcn.2012.7
   Jarjou LMA, 2010, AM J CLIN NUTR, V92, P450, DOI 10.3945/ajcn.2010.29217
   Kalkwarf HJ, 1999, J CLIN ENDOCR METAB, V84, P464, DOI 10.1210/jc.84.2.464
   KENT GN, 1991, MINER ELECTROL METAB, V17, P1
   Kovacs CS, 2011, ENDOCRIN METAB CLIN, V40, P795, DOI 10.1016/j.ecl.2011.08.002
   Kovacs Christopher S, 2011, Curr Osteoporos Rep, V9, P274, DOI 10.1007/s11914-011-0073-0
   LASKEY MA, 1990, ACTA PAEDIATR SCAND, V79, P507, DOI 10.1111/j.1651-2227.1990.tb11504.x
   Olausson H, 2008, AM J CLIN NUTR, V88, P1032
   Olausson H, 2012, NUTR RES REV, V25, P40, DOI 10.1017/S0954422411000187
   Payne RB, 1998, ANN CLIN BIOCHEM, V35, P201
   Payne RB, 1996, ANN CLIN BIOCHEM, V33, P59
   PRENTICE A, 1995, AM J CLIN NUTR, V62, P58
   Simmonds CS, 2010, CRIT REV EUKAR GENE, V20, P235
   Tietz NW., 1990, CLIN GUIDE LAB TESTS
   Yan LY, 2009, BONE, V45, P238, DOI 10.1016/j.bone.2009.04.237
NR 22
TC 6
Z9 6
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD AUG
PY 2013
VL 24
IS 8
BP 2301
EP 2308
DI 10.1007/s00198-013-2280-2
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 181GH
UT WOS:000321655500018
PM 23417353
OA No
DA 2017-08-15
ER

PT J
AU O'Callaghan-Gordo, C
   Bassat, Q
   Diez-Padrisa, N
   Morais, L
   Machevo, S
   Nhampossa, T
   Quinto, L
   Alonso, PL
   Roca, A
AF O'Callaghan-Gordo, Cristina
   Bassat, Quique
   Diez-Padrisa, Nuria
   Morais, Luis
   Machevo, Sonia
   Nhampossa, Tacilta
   Quinto, Llorenc
   Alonso, Pedro L.
   Roca, Anna
TI Lower Respiratory Tract Infections Associated with Rhinovirus during
   Infancy and Increased Risk of Wheezing during Childhood. A Cohort Study
SO PLOS ONE
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; SYNCYTIAL-VIRUS BRONCHIOLITIS;
   HOSPITALIZED CHILDREN; RURAL MOZAMBIQUE; VIRAL-INFECTIONS;
   HIGH-PREVALENCE; ASTHMA; EPIDEMIOLOGY; ETIOLOGY; LIFE
AB Background and Objectives: Although association between respiratory syncytial virus infection and later asthma development has been established, little is known about the role of other respiratory viruses. Rhinovirus was considered a mild pathogen of the upper respiratory tract but current evidence suggests that rhinovirus is highly prevalent among children with lower respiratory tract infections (LRTI). The aim of the study was to evaluate whether LRTI hospitalization associated with rhinovirus during infancy was associated with an increased risk of wheezing - a proxy measure of asthma - during childhood.
   Methods: During a 12 months period, all infants <1 year admitted to Manhica District Hospital with symptoms of LRTI who survived the LRTI episode, were enrolled in the study cohort. Nasopharyngeal aspirates were collected on admission for viral determination and study infants were classified according to presence or not of rhinovirus. The study cohort was passively followed-up at the Manhica District Hospital for up to 4 years and 9 months to evaluate the association between LRTI associated with rhinovirus in infancy and wheezing during childhood. Findings and
   Conclusions: A total of 220 infants entered the cohort; 25% of them had rhinovirus detected during the LRTI episode as opposed to 75% who tested negative for rhinovirus. After adjusting for sex and age and HIV infection at recruitment, infants hospitalized with LRTI associated with rhinovirus had higher incidence of subsequent visits with wheezing within the year following hospitalization [Rate ratio=1.68, (95% confidence interval=1.02-2.75); Wald test p-value = 0.039]. No evidence of increased incidence rate of visits with wheezing was observed for the remaining follow-up period. Our data suggest a short term increased risk of wheezing after an initial episode of LRTI with RV.
C1 [O'Callaghan-Gordo, Cristina; Bassat, Quique; Diez-Padrisa, Nuria; Quinto, Llorenc; Alonso, Pedro L.; Roca, Anna] Univ Barcelona, Hosp Clin, CRESIB, Barcelona Ctr Int Hlth Res, Barcelona, Spain.
   [O'Callaghan-Gordo, Cristina; Bassat, Quique; Morais, Luis; Machevo, Sonia; Nhampossa, Tacilta; Alonso, Pedro L.; Roca, Anna] Ctr Invest Saude Manhica, Manhica, Maputo, Mozambique.
   [Roca, Anna] MRC Unit, Banjul, Gambia.
RP O'Callaghan-Gordo, C (reprint author), Univ Barcelona, Hosp Clin, CRESIB, Barcelona Ctr Int Hlth Res, Barcelona, Spain.
EM cristina.ocallaghan@cresib.cat
RI Bassat, Quique/P-2341-2016
OI Bassat, Quique/0000-0003-0875-7596; O'Callaghan-Gordo,
   Cristina/0000-0002-4229-2991
FU Health Research Found of the Spanish Ministry of Science and Innovation
   [FIS: PS09/01843]; Spanish Agency of International Cooperation; Spanish
   Ministry of Science and Innovation [FIS: CM05/00134, RYC-2008-02777]
FX The study was supported by a grant from the Health Research Found of the
   Spanish Ministry of Science and Innovation (FIS: PS09/01843). The Centro
   de Investigacao em Sa de da Manhica receives major core funding from the
   Spanish Agency of International Cooperation
   (http://www.micinn.es/portal/site/MICINN/). QB and AR were supported
   during the time of the study implementation by grants from the Spanish
   Ministry of Science and Innovation (FIS: CM05/00134 and Ramon y Cajal:
   RYC-2008-02777, respectively; http://www.micinn.es/portal/site/MICINN/).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alonso PL, 2002, MANHICA DEMOGRAPHIC, P189
   Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0
   Asher MI, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-8
   Bassat Q, 2011, AM J TROP MED HYG, V85, P626, DOI 10.4269/ajtmh.2011.11-0223
   Bassat Q, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-37
   Cevey-Macherel M, 2009, EUR J PEDIATR, V168, P1429, DOI 10.1007/s00431-009-0943-y
   Cilla G, 2008, J MED VIROL, V80, P1843, DOI 10.1002/jmv.21271
   Cookson W, 2011, J ALLERGY CLIN IMMUN, V128, P266, DOI 10.1016/j.jaci.2011.06.026
   Dharmage SC, 2009, EUR RESPIR J, V33, P237, DOI 10.1183/09031936.00062907
   Gern JE, 2010, J VIROL, V84, P7418, DOI 10.1128/JVI.02290-09
   Gern JE, 2000, J ALLERGY CLIN IMMUN, V105, pS497
   Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P532, DOI 10.1016/j.jaci.2011.06.037
   HAZLETT DTG, 1988, AM J TROP MED HYG, V39, P632
   Hyvarinen MK, 2005, PEDIATR PULM, V40, P316, DOI 10.1002/ppul.20273
   Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293
   Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33
   Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669
   Lehtinen P, 2007, J ALLERGY CLIN IMMUN, V119, P570, DOI 10.1016/j.jaci.2006.11.003
   Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024
   Loscertales MP, 2002, PEDIATR INFECT DIS J, V21, P148, DOI 10.1097/00006454-200202000-00013
   MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301
   Menendez C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001934
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   O'Callaghan-Gordo C, 2011, TROP MED INT HEALTH, V16, P1054, DOI 10.1111/j.1365-3156.2011.02811.x
   O'Callaghan-Gordo C, 2011, PEDIATR INFECT DIS J, V30, P39, DOI 10.1097/INF.0b013e3181f232fe
   Onyango CO, 2012, J MED VIROL, V84, P823, DOI 10.1002/jmv.23251
   Papadopoulos Nikolaos G, 2004, Paediatr Respir Rev, V5 Suppl A, pS191, DOI 10.1016/S1526-0542(04)90036-X
   Perez-Yarza EG, 2007, PEDIATR INFECT DIS J, V26, P733, DOI 10.1097/INF.0b013e3180618c42
   Puig C, 2010, ARCH BRONCONEUMOL, V46, P514, DOI 10.1016/j.arbres.2010.07.001
   Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC
   Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501
   Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582
   Smuts HE, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-65
   Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162
   Tsolia MN, 2004, CLIN INFECT DIS, V39, P681, DOI 10.1086/422996
   Venter M, 2011, J MED VIROL, V83, P1458, DOI 10.1002/jmv.22120
   The WHO Young Infants Study Group, 1999, PEDIATR INFECT DIS J, V18, pS23
NR 38
TC 11
Z9 12
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 31
PY 2013
VL 8
IS 7
AR e69370
DI 10.1371/journal.pone.0069370
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 194LB
UT WOS:000322633700026
PM 23935997
OA gold
DA 2017-08-15
ER

PT J
AU Lin, GM
   Li, YH
   Jaiteh, LES
   Han, CL
AF Lin, Gen-Min
   Li, Yi-Hwei
   Jaiteh, Lamin E. S.
   Han, Chih-Lu
TI The obesity paradox of mortality in patients with coronary artery
   disease undergoing percutaneous coronary intervention
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE The obesity paradox; Coronary artery disease; Percutaneous coronary
   intervention
C1 [Lin, Gen-Min] Hualien Armed Forces Gen Hosp, Dept Med, Hualien 97144, Hualien County, Taiwan.
   [Li, Yi-Hwei] Tzu Chi Univ, Dept Publ Hlth, Hualien, Taiwan.
   [Jaiteh, Lamin E. S.] Royal Victoria Teaching Hosp, Dept Med, Banjul, Gambia.
   [Han, Chih-Lu] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.
RP Lin, GM (reprint author), Hualien Armed Forces Gen Hosp, 163 Jiali Rd, Hualien 97144, Hualien County, Taiwan.
EM farmer507@yahoo.com.tw
CR Bucholz EM, 2012, AM J MED, V125, P796, DOI 10.1016/j.amjmed.2012.01.018
   Carnethon MR, 2012, JAMA-J AM MED ASSOC, V308, P581, DOI 10.1001/jama.2012.9282
   Florez H, 2012, JAMA-J AM MED ASSOC, V308, P619, DOI 10.1001/jama.2012.9776
   Lin GM, 2011, INT J CARDIOL, V146, P422, DOI 10.1016/j.ijcard.2010.10.094
   Sung SH, 2011, HEART, V97, P648, DOI 10.1136/hrt.2010.211110
   Tsukinoki R, 2012, STROKE, V43, P1478, DOI 10.1161/STROKEAHA.112.650317
   Younge JO, 2013, INT J CARDIOL, V167, P1154, DOI 10.1016/j.ijcard.2012.03.105
NR 7
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD JUL 31
PY 2013
VL 167
IS 2
BP 597
EP 597
DI 10.1016/j.ijcard.2012.09.216
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 169GU
UT WOS:000320768800063
PM 23103136
OA No
DA 2017-08-15
ER

PT J
AU Fye, HKS
   Wright-Drakesmith, C
   Kramer, HB
   Camey, S
   da Costa, AN
   Jeng, A
   Bah, A
   Kirk, GD
   Sharif, MIF
   Ladep, NG
   Okeke, E
   Hainaut, P
   Taylor-Robinson, SD
   Kessler, BM
   Mendy, ME
AF Fye, Haddy K. S.
   Wright-Drakesmith, Cynthia
   Kramer, Holger B.
   Camey, Suzi
   da Costa, Andre Nogueira
   Jeng, Adam
   Bah, Alasana
   Kirk, Gregory D.
   Sharif, Mohamed I. F.
   Ladep, Nimzing G.
   Okeke, Edith
   Hainaut, Pierre
   Taylor-Robinson, Simon D.
   Kessler, Benedikt M.
   Mendy, Maimuna E.
TI Protein Profiling in Hepatocellular Carcinoma by Label-Free Quantitative
   Proteomics in Two West African Populations
SO PLOS ONE
LA English
DT Article
ID CHRONIC HEPATITIS-B; GLOBAL CANCER STATISTICS; HUMAN LIVER-CANCER;
   ALPHA-FETOPROTEIN; VIRUS-DNA; DIETARY AFLATOXINS; SERUM MARKERS; C
   VIRUS; BIOMARKERS; CIRRHOSIS
AB Background: Hepatocellular Carcinoma is the third most common cause of cancer related death worldwide, often diagnosed by measuring serum AFP; a poor performance stand-alone biomarker. With the aim of improving on this, our study focuses on plasma proteins identified by Mass Spectrometry in order to investigate and validate differences seen in the respective proteomes of controls and subjects with LC and HCC.
   Methods: Mass Spectrometry analysis using liquid chromatography electro spray ionization quadrupole time-of-flight was conducted on 339 subjects using a pooled expression profiling approach. ELISA assays were performed on four significantly differentially expressed proteins to validate their expression profiles in subjects from the Gambia and a pilot group from Nigeria. Results from this were collated for statistical multiplexing using logistic regression analysis.
   Results: Twenty-six proteins were identified as differentially expressed between the three subject groups. Direct measurements of four; hemopexin, alpha-1-antitrypsin, apolipoprotein A1 and complement component 3 confirmed their change in abundance in LC and HCC versus control patients. These trends were independently replicated in the pilot validation subjects from Nigeria. The statistical multiplexing of these proteins demonstrated performance comparable to or greater than ALT in identifying liver cirrhosis or carcinogenesis. This exercise also proposed preliminary cut offs with achievable sensitivity, specificity and AUC statistics greater than reported AFP averages.
   Conclusions: The validated changes of expression in these proteins have the potential for development into high-performance tests usable in the diagnosis and or monitoring of HCC and LC patients. The identification of sustained expression trends strengthens the suggestion of these four proteins as worthy candidates for further investigation in the context of liver disease. The statistical combinations also provide a novel inroad of analyses able to propose definitive cutoffs and combinations for evaluation of performance.
C1 [Fye, Haddy K. S.; Wright-Drakesmith, Cynthia; Kramer, Holger B.; Kessler, Benedikt M.] Univ Oxford, Nuffield Dept Med, Oxford, Oxfordshire, England.
   [Camey, Suzi; da Costa, Andre Nogueira; Hainaut, Pierre; Mendy, Maimuna E.] Int Agcy Res Canc, Lab Serv, F-69372 Lyon, France.
   [Camey, Suzi; da Costa, Andre Nogueira; Hainaut, Pierre; Mendy, Maimuna E.] Int Agcy Res Canc, Biobank Grp, F-69372 Lyon, France.
   [Fye, Haddy K. S.; Jeng, Adam; Bah, Alasana; Mendy, Maimuna E.] Gambia Labs, MRC Unit UK, Dept Dis Control & Eliminat, Banjul, Gambia.
   [Kirk, Gregory D.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Camey, Suzi] Univ Fed Rio Grande do Sul, Dept Estatist, Inst Matemat, BR-90046900 Rio Grande, Brazil.
   [Sharif, Mohamed I. F.; Ladep, Nimzing G.; Taylor-Robinson, Simon D.] Imperial Coll London, Dept Med, Liver Unit, Div Diabet Endocrinol & Metab, London, England.
   [Hainaut, Pierre] Int Prevent Res Inst, Lyon, France.
   [Okeke, Edith] Univ Jos, Teaching Hosp, Jos, Plateau State, Nigeria.
RP Kessler, BM (reprint author), Univ Oxford, Nuffield Dept Med, Henry Wellcome Bldg Mol Physiol, Oxford, Oxfordshire, England.
EM bmk@ccmp.ox.ac.uk
RI Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610; Kessler,
   Benedikt/0000-0002-8160-2446; Kramer, Holger/0000-0002-6400-0945; Camey,
   Suzi/0000-0002-5564-081X
FU Medical Research Council (The Gambia); EU [Health-F2-2011-265994,
   265994]; National Cancer Institute, National Institutes of Health,
   Department of Health and Human Services [N02CP40521]; American Cancer
   Society [MRSG-07-284-01-CCE]; Biomedical Research Centre (NIHR) Oxford,
   UK
FX HKSF was supported by the Medical Research Council (The Gambia) and the
   EU Collaborative Project Prolifica 7th Framework Programme
   FP7-AFRICA-2010, Health-F2-2011-265994 (Grant Nr. 265994). The GLCS
   study was supported in part by the National Cancer Institute, National
   Institutes of Health, Department of Health and Human Services (Contract
   # N02CP40521). GDK was supported in part by the American Cancer Society
   (MRSG-07-284-01-CCE). BMK was supported by the Biomedical Research
   Centre (NIHR) Oxford, UK. SDT, MIFS and NGL acknowledge the NIHR
   Biomedical Facility at Imperial College London for infrastructure
   support. The authors are grateful to Drs Fumi Lesi and PH for their
   contribution to testing single Nucleotide Polymorphisms (SNPs) in the
   p53 gene. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x
   Bartosch B, 2009, J HEPATOL, V51, P810, DOI 10.1016/j.jhep.2009.05.008
   Behne T, 2012, INT J HEPATOL, V2012, DOI [10.1155/2012/859076, DOI 10.1155/2012/859076]
   BRECHOT C, 1980, NATURE, V286, P533, DOI 10.1038/286533a0
   CHANG WY, 1988, CANCER, V62, P227, DOI 10.1002/1097-0142(19880715)62:2<227::AID-CNCR2820620202>3.0.CO;2-D
   Chen CF, 2011, GASTROENTEROLOGY, V141, P1240, DOI 10.1053/j.gastro.2011.06.036
   Comunale MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012419
   Comunale MA, 2009, J PROTEOME RES, V8, P595, DOI 10.1021/pr800752c
   Constantin Cristin Vere, 2010, Maedica (Buchar), V5, P265
   Daniele B, 2004, GASTROENTEROLOGY, V127, pS108, DOI 10.1053/j.gastro.2004.09.023
   Fu Q, 2005, PROTEOMICS, V5, P2656, DOI 10.1002/pmic.200402048
   Giannini EG, 2012, HEPATOLOGY
   GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4
   Goldman R, 2007, CARCINOGENESIS, V28, P2149, DOI 10.1093/carcin/bgm177
   Gupta S, 2003, ANN INTERN MED, V139, P46
   He QY, 2003, PROTEOMICS, V3, P666, DOI 10.1002/pmic.200300394
   HINO O, 1984, HEPATOLOGY, V4, P90, DOI 10.1002/hep.1840040116
   HJELM H, 1972, FEBS LETT, V28, P73, DOI 10.1016/0014-5793(72)80680-X
   Hsieh SY, 2011, J PROTEOME RES, V10, P4715, DOI 10.1021/pr200519q
   Hung CH, 2003, J GASTROENTEROL, V38, P153, DOI 10.1007/s005350300025
   Hutin Y, 2004, J CLIN PHARMACOL, V44, P20, DOI 10.1177/0091270003258669
   Kanamori H, 2011, ONCOLOGY-BASEL, V80, P406, DOI 10.1159/000330734
   Kang XN, 2010, J CANCER RES CLIN, V136, P1151, DOI 10.1007/s00432-010-0762-6
   Kanmura S, 2010, J GASTROENTEROL, V45, P459, DOI 10.1007/s00535-009-0160-5
   Kim WR, 2008, HEPATOLOGY, V47, P1363, DOI 10.1002/hep.22109
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   Kobayashi S, 2012, HEPATOL RES
   Kolarich D, 2006, PROTEOMICS, V6, P3369, DOI 10.1002/pmic.200500751
   Lee IN, 2006, PROTEOMICS, V6, P2865, DOI 10.1002/pmic.200500488
   Lee YY, 2011, J PROTEOME RES, V10, P5070, DOI 10.1021/pr2005204
   Li Chang-yu, 2011, Front Biosci (Elite Ed), V3, P212, DOI 10.2741/e235
   LIN DY, 1993, J CLIN ULTRASOUND, V21, P303, DOI 10.1002/jcu.1870210502
   Masuzaki R, 2012, SEMIN ONCOL, V39, P434, DOI 10.1053/j.seminoncol.2012.05.009
   MATSUBARA K, 1990, MOL BIOL MED, V7, P243
   Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645
   Morota K, 2011, CLIN CHEM LAB MED, V49, P711, DOI 10.1515/CCLM.2011.097
   Motulsky H, 2004, FITTING MODELS BIOL
   NAMIENO T, 1995, ANN SURG, V221, P308, DOI 10.1097/00000658-199503000-00014
   OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E
   OKUDA K, 1982, CANCER, V49, P450, DOI 10.1002/1097-0142(19820201)49:3<450::AID-CNCR2820490310>3.0.CO;2-4
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Parkin DM, 2002, CANC INCIDENCE 5 CON, VVIII, P1
   PEERS FG, 1976, INT J CANCER, V17, P167, DOI 10.1002/ijc.2910170204
   Pollicino T, 2004, GASTROENTEROLOGY, V126, P102, DOI 10.1053/j.gastro.2003.10.048
   QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3
   Qiu JG, 2008, J CANCER RES CLIN, V134, P299, DOI 10.1007/s00432-007-0236-7
   ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G
   Schmucker DL, 2005, EXP GERONTOL, V40, P650, DOI 10.1016/j.exger.2005.06.009
   Shang S, 2011, HEPATOLOGY
   SHANK RC, 1972, FOOD COSMET TOXICOL, V10, P171, DOI 10.1016/S0015-6264(72)80195-0
   Shariff MIF, 2010, J PROTEOME RES, V9, P1096, DOI 10.1021/pr901058t
   Steel LF, 2003, PROTEOMICS, V3, P601, DOI 10.1002/pmic.200300399
   Stuver SO, 1998, SEMIN CANCER BIOL, V8, P299, DOI 10.1006/scbi.1998.0079
   Wang MJ, 2009, CANCER EPIDEM BIOMAR, V18, P1914, DOI 10.1158/1055-9965.EPI-08-0980
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6
   Wright CA, 2011, MOL CELL PROTEOMICS, V10, pM110
   Xu DM, 2008, MOL CELL PROTEOMICS, V7, P2215, DOI 10.1074/mcp.M800095-MCP200
   Yuen MF, 2005, GUT, V54, P1610, DOI 10.1136/gut.2005.065136
   Yuen MF, 2003, GUT, V52, P416, DOI 10.1136/gut.52.3.416
NR 61
TC 6
Z9 6
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 30
PY 2013
VL 8
IS 7
AR e68381
DI 10.1371/journal.pone.0068381
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 201AX
UT WOS:000323114200006
PM 23935864
OA gold
DA 2017-08-15
ER

PT J
AU Harrington, H
   Asugeni, J
   Jimuru, C
   Gwalaa, J
   Ribeyro, E
   Bradbury, R
   Joseph, H
   Melrose, W
   MacLaren, D
   Speare, R
AF Harrington, Humpress
   Asugeni, James
   Jimuru, Christopher
   Gwalaa, John
   Ribeyro, Elmer
   Bradbury, Richard
   Joseph, Hayley
   Melrose, Wayne
   MacLaren, David
   Speare, Rick
TI A practical strategy for responding to a case of lymphatic filariasis
   post-elimination in Pacific Islands
SO PARASITES & VECTORS
LA English
DT Article
DE Lymphatic filariasis; Elimination; Solomon Islands; Atoifi; Wuchereria
   bancrofti; Surveillance response; Research capacity building
ID CONTINUING TRANSMISSION; SOLOMON-ISLANDS; ANTIGENS; PROGRAM
AB Background: Lymphatic filariasis (LF) due to Wuchereria bancrofti is being eliminated from Oceania under the Pacific Elimination of Lymphatic Filariasis Programme. LF was endemic in Solomon Islands but in the 2010-2020 Strategic Plan of the Global Programme to Eliminate LF, Solomon Islands was listed as non-endemic for LF. In countries now declared free of LF an important question is what monitoring strategy should be used to detect any residual foci of LF?
   This paper describes how a new case of elephantiasis in a post-elimination setting may be used as a trigger to initiate a local survey for LF.
   Methods: The index case, a 44 year old male, presented to Atoifi Adventist Hospital, Malaita, Solomon Islands in April 2011 with elephantiasis of the lower leg. Persistent swelling had commenced 16 months previously. He was negative for antigen by TropBio Og4C3 ELISA and for microfilaria. A week later a survey of 197 people aged from 1 year to 68 years was conducted at Alasi, the index case's village, by a research team from Atoifi Adventist Hospital and Atoifi College of Nursing. This represented 66.3% of the village population. Blood was collected between 22:00 and 03:00 by finger-prick and made into thick smears to detect microfilaria and collected onto filter paper for W. bancrofti antigen tests. A second group of 110 specimens was similarly collected from residents of the Hospital campus and inpatients. W. bancrofti antigen was tested for using the Trop-Bio Og4C3 test.
   Results: One sample (1/307) from an 18 year old male from Alsai was positive for W. bancrofti antigen. No samples were positive for microfilaria. Although antigen-positivity indicated a live worm, the case was regarded as having been acquired some years previously.
   Conclusions: We propose that when LF has been eliminated from a country, a case of elephantiasis should be a trigger to conduct a survey of the case's community using a decision pathway. W. bancrofti antigen should be tested for with screening for microfilariae in antigen positive cases. The field survey was designed and conducted by local researchers, highlighting the value of local research capacity in remote areas.
C1 [Harrington, Humpress; Asugeni, James; Jimuru, Christopher; Gwalaa, John; Ribeyro, Elmer] Atoifi Adventist Hosp, Malaita, Solomon Islands.
   [Bradbury, Richard] MRC, Int Nutr Grp, Keneba, Gambia.
   [Joseph, Hayley; Melrose, Wayne; Speare, Rick] James Cook Univ, Sch Publ Hlth Trop Med & Rehabil Sci, WHO Collaborating Ctr Control Lymphat Filariasis, Townsville, Qld 4811, Australia.
   [MacLaren, David] James Cook Univ, Sch Med & Dent, Cairns, Australia.
   [Speare, Rick] Trop Hlth Solut Pty Ltd, Townsville, Qld, Australia.
RP Speare, R (reprint author), James Cook Univ, Sch Publ Hlth Trop Med & Rehabil Sci, WHO Collaborating Ctr Control Lymphat Filariasis, Townsville, Qld 4811, Australia.
EM rickspeare@gmail.com
RI Bradbury, Richard/N-3273-2013
OI Bradbury, Richard/0000-0002-5524-506X; Harrington,
   Humpress/0000-0002-9543-3719; Speare, Rick/0000-0002-9993-1213
FU Atoifi Adventist Hospital, JCU through JCU WHO Collaborating Centre for
   Control of Lymphatic Filariasis and Soil Transmitted Helminths; Tropical
   Health Solutions
FX Thanks to Rowan Shee for transporting filter papers from Australia to
   Solomon Islands, to Esau Kekeubata for organizing transport of filter
   papers from Honiara to Atoifi, to nursing students of Atoifi College of
   Nursing and nurses of Atoifi Adventist Hospital for assisting with the
   nocturnal surveys and to the people of Alasi and Atoifi for their
   enthusiastic participation. Thanks to Robert Strachan of Yungaburra for
   production of Figures. Funding for the survey was provided by Atoifi
   Adventist Hospital, JCU through a Research Infrastructure Block Grant
   for the capacity building workshop and for laboratory tests by the JCU
   WHO Collaborating Centre for Control of Lymphatic Filariasis and Soil
   Transmitted Helminths. Tropical Health Solutions provided funds for
   preparation of figures.
CR Burkot T, 2002, TRENDS PARASITOL, V18, P109, DOI 10.1016/S1471-4922(01)02221-8
   Dreyer G, 2002, BASIC LYMPHOEDEMA MA
   Durrheim David N, 2003, Pac Health Dialog, V10, P149
   El-Moamly AAR, 2012, PARASITOL RES, V111, P1379, DOI 10.1007/s00436-012-2870-5
   Gass K, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001479
   Hoti SL, 2002, NATL MED J INDIA, V15, P263
   Ichimori K, 2005, TRENDS PARASITOL, V21, P441, DOI 10.1016/j.pt.2005.08.010
   Joseph H, 2011, ANN TROP MED PARASIT, V105, P567, DOI 10.1179/2047773211Y.0000000008
   Joseph H, 2011, ACTA TROP, V120, pS39, DOI 10.1016/j.actatropica.2010.12.004
   Massey PD, 2012, RURAL REMOTE HEALTH, V12
   Ottesen EA, 2000, TROP MED INT HEALTH, V5, P591, DOI 10.1046/j.1365-3156.2000.00620.x
   Redman-MacLaren M, 2012, INT J EQUITY HEALTH, V11, DOI 10.1186/1475-9276-11-79
   SCHLOSSER RJ, 1945, AM J TROP MED, V25, P493
   Webber R, 1979, T R SOC TROP MED HYG, V76, P722
   WEBBER RH, 1977, T ROY SOC TROP MED H, V71, P396, DOI 10.1016/0035-9203(77)90037-2
   WEBBER RH, 1981, T ROY SOC TROP MED H, V75, P499, DOI 10.1016/0035-9203(81)90185-1
   World Health Organization, 2005, GLOB PROGR EL LYMPH
   World Health Organization, 2007, T R SOC TROP MED HYG
   WHO, 2010, GLOB PROGR EL LYMPH
   World Health Organization, 2011, LYMPH FIL MAN NAT EL
   [Anonymous], 2011, WER, V86, P377
NR 21
TC 3
Z9 3
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD JUL 26
PY 2013
VL 6
AR 218
DI 10.1186/1756-3305-6-218
PG 7
WC Parasitology
SC Parasitology
GA 191GG
UT WOS:000322400500001
PM 23890320
OA gold
DA 2017-08-15
ER

PT J
AU Kotloff, KL
   Nataro, JP
   Blackwelder, WC
   Nasrin, D
   Farag, TH
   Panchalingam, S
   Wu, Y
   Sow, SO
   Sur, D
   Breiman, RF
   Faruque, ASG
   Zaidi, AKM
   Saha, D
   Alonso, PL
   Tamboura, B
   Sanogo, D
   Onwuchekwa, U
   Manna, B
   Ramamurthy, T
   Kanungo, S
   Ochieng, JB
   Omore, R
   Oundo, JO
   Hossain, A
   Das, SK
   Ahmed, S
   Qureshi, S
   Quadri, F
   Adegbola, RA
   Antonio, M
   Hossain, MJ
   Akinsola, A
   Mandomando, I
   Nhampossa, T
   Acacio, S
   Biswas, K
   O'Reilly, CE
   Mintz, ED
   Berkeley, LY
   Muhsen, K
   Sommerfelt, H
   Robins-Browne, RM
   Levine, MM
AF Kotloff, Karen L.
   Nataro, James P.
   Blackwelder, William C.
   Nasrin, Dilruba
   Farag, Tamer H.
   Panchalingam, Sandra
   Wu, Yukun
   Sow, Samba O.
   Sur, Dipika
   Breiman, Robert F.
   Faruque, Abu S. G.
   Zaidi, Anita K. M.
   Saha, Debasish
   Alonso, Pedro L.
   Tamboura, Boubou
   Sanogo, Doh
   Onwuchekwa, Uma
   Manna, Byomkesh
   Ramamurthy, Thandavarayan
   Kanungo, Suman
   Ochieng, John B.
   Omore, Richard
   Oundo, Joseph O.
   Hossain, Anowar
   Das, Sumon K.
   Ahmed, Shahnawaz
   Qureshi, Shahida
   Quadri, Farheen
   Adegbola, Richard A.
   Antonio, Martin
   Hossain, M. Jahangir
   Akinsola, Adebayo
   Mandomando, Inacio
   Nhampossa, Tacilta
   Acacio, Sozinho
   Biswas, Kousick
   O'Reilly, Ciara E.
   Mintz, Eric D.
   Berkeley, Lynette Y.
   Muhsen, Khitam
   Sommerfelt, Halvor
   Robins-Browne, Roy M.
   Levine, Myron M.
TI Burden and aetiology of diarrhoeal disease in infants and young children
   in developing countries (the Global Enteric Multicenter Study, GEMS): a
   prospective, case-control study
SO LANCET
LA English
DT Article
ID ENTEROPATHOGENIC ESCHERICHIA-COLI; SUB-SAHARAN AFRICA; ROTAVIRUS
   VACCINATION; CHILDHOOD MORTALITY; ATTRIBUTABLE RISK; EPIDEMIOLOGY;
   CASE/CONTROL; CRYPTOSPORIDIOSIS; PERFORMANCE; POPULATION
AB Background Diarrhoeal diseases cause illness and death among children younger than 5 years in low-income countries. We designed the Global Enteric Multicenter Study (GEMS) to identify the aetiology and population-based burden of paediatric diarrhoeal disease in sub-Saharan Africa and south Asia.
   Methods The GEMS is a 3-year, prospective, age-stratified, matched case-control study of moderate-to-severe diarrhoea in children aged 0-59 months residing in censused populations at four sites in Africa and three in Asia. We recruited children with moderate-to-severe diarrhoea seeking care at health centres along with one to three randomly selected matched community control children without diarrhoea. From patients with moderate-to-severe diarrhoea and controls, we obtained clinical and epidemiological data, anthropometric measure ments, and a faecal sample to identify enteropathogens at enrolment; one follow-up home visit was made about 60 days later to ascertain vital status, clinical outcome, and interval growth.
   Findings We enrolled 9439 children with moderate-to-severe diarrhoea and 13 129 control children without diarrhoea. By analysing adjusted population attributable fractions, most attributable cases of moderate-to-severe diarrhoea were due to four pathogens: rotavirus, Cryptosporidium, enterotoxigenic Escherichia coli producing heat-stable toxin (ST-ETEC; with or without co-expression of heat-labile enterotoxin), and Shigella. Other pathogens were important in selected sites (eg, Aeromonas, Vibrio cholerae O1, Campylobacter jejuni). Odds of dying during follow-up were 8.5-fold higher in patients with moderate-to-severe diarrhoea than in controls (odd ratio 8.5, 95% CI 5.8-12.5, p<0.0001); most deaths (167 [87.9%]) occurred during the first 2 years of life. Pathogens associated with increased risk of case death were ST-ETEC (hazard ratio [HR] 1.9; 0.99-3.5) and typical enteropathogenic E coli (HR 2.6; 1.6-4.1) in infants aged 0-11 months, and Cryptosporidium (HR 2.3; 1.3-4.3) in toddlers aged 12-23 months.
   Interpretation Interventions targeting five pathogens (rotavirus, Shigella, ST-ETEC, Cryptosporidium, typical enteropathogenic E coli) can substantially reduce the burden of moderate-to-severe diarrhoea. New methods and accelerated implementation of existing interventions (rotavirus vaccine and zinc) are needed to prevent disease and improve outcomes.
C1 [Kotloff, Karen L.; Nataro, James P.; Blackwelder, William C.; Nasrin, Dilruba; Farag, Tamer H.; Panchalingam, Sandra; Wu, Yukun; Berkeley, Lynette Y.; Muhsen, Khitam; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Kotloff, Karen L.; Nataro, James P.; Levine, Myron M.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA.
   [Kotloff, Karen L.; Nataro, James P.; Blackwelder, William C.; Nasrin, Dilruba; Farag, Tamer H.; Panchalingam, Sandra; Wu, Yukun; Muhsen, Khitam; Levine, Myron M.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
   [Nataro, James P.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA.
   [Sow, Samba O.; Tamboura, Boubou; Sanogo, Doh; Onwuchekwa, Uma] Ctr Dev Vaccins, Bamako, Mali.
   [Sur, Dipika; Manna, Byomkesh; Ramamurthy, Thandavarayan; Kanungo, Suman] Natl Inst Cholera & Enter Dis, Kolkata, India.
   [Breiman, Robert F.] US Ctr Dis Control & Prevent, Kenya Off, Global Dis Detect Div, Nairobi, Kenya.
   [Faruque, Abu S. G.; Hossain, Anowar; Das, Sumon K.; Ahmed, Shahnawaz] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Zaidi, Anita K. M.; Qureshi, Shahida; Quadri, Farheen] Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan.
   [Saha, Debasish; Adegbola, Richard A.; Antonio, Martin; Hossain, M. Jahangir; Akinsola, Adebayo] Med Res Council UK Unit, Fajara, Gambia.
   [Alonso, Pedro L.; Mandomando, Inacio; Nhampossa, Tacilta; Acacio, Sozinho] Ctr Invest Saude Manhica, Maputo, Mozambique.
   [Alonso, Pedro L.] Hosp Clin Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain.
   [Ochieng, John B.; Omore, Richard; Oundo, Joseph O.] Ctr Dis Control & Prevent KEMRI CDC, Kenya Med Res Inst, Kisumu, Kenya.
   [Adegbola, Richard A.] GlaxoSmithKline Biol, Global Med Affairs, Wavre, Belgium.
   [Akinsola, Adebayo] Daffodils Pediat & Family Med, Tucker, GA USA.
   [Mandomando, Inacio; Nhampossa, Tacilta; Acacio, Sozinho] Minist Saude, Inst Nacl Saude, Maputo, Mozambique.
   [Biswas, Kousick] US Dept Vet Affairs, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA.
   [O'Reilly, Ciara E.; Mintz, Eric D.] US Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
   [Berkeley, Lynette Y.] Ctr Drug Evaluat & Res, Off Antimicrobial Prod, Div Antiinfect Prod, Silver Spring, MD USA.
   [Sommerfelt, Halvor] Univ Bergen, Ctr Int Hlth, Bergen, Norway.
   [Sommerfelt, Halvor] Norwegian Inst Publ Hlth, Div Infect Dis Control, Oslo, Norway.
   [Robins-Browne, Roy M.] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia.
RP Kotloff, KL (reprint author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
EM kkotloff@medicine.umaryland.edu
OI Robins-Browne, Roy/0000-0001-9179-7884
FU Bill & Melinda Gates Foundation
FX The Bill & Melinda Gates Foundation.
CR Amadi B, 2005, J TROP PEDIATRICS, V51, P5, DOI 10.1093/tropej/fmh064
   Arifeen SE, 2009, LANCET, V374, P393, DOI 10.1016/S0140-6736(09)60828-X
   Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Atherly DE, 2012, VACCINE, V30, pA7, DOI 10.1016/j.vaccine.2011.12.096
   BAQUI AH, 1991, INT J EPIDEMIOL, V20, P1057, DOI 10.1093/ije/20.4.1057
   Biswas K, 2012, CLIN INFECT DIS, V55, pS254, DOI 10.1093/cid/cis755
   Blackwelder WC, 2012, CLIN INFECT DIS, V55, pS246, DOI 10.1093/cid/cis788
   Breslow NE, 1980, IARC SCI PUBL, V32, P5
   BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904
   Farag TH, 2012, CLIN INFECT DIS, V55, pS225, DOI 10.1093/cid/cis787
   Figueras MI, 2007, J MED MICROBIOL, V56, P996, DOI 10.1099/jmm.0.47062-0
   Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292
   FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.1093/biomet/80.1.27
   GART JJ, 1990, BIOMETRICS, V46, P637, DOI 10.2307/2532084
   Gladstone BP, 2011, NEW ENGL J MED, V365, P337, DOI 10.1056/NEJMoa1006261
   Jiang V, 2010, HUM VACCINES, V6, P532
   Kotloff KL, 2012, CLIN INFECT DIS, V55, pS232, DOI 10.1093/cid/cis753
   LEVINE MM, 1984, EPIDEMIOL REV, V6, P31
   LEVINE MM, 1978, LANCET, V1, P1119
   Levine MM, 2012, CLIN INFECT DIS, V55, pS215, DOI 10.1093/cid/cis761
   Levine MM, 2012, CLIN INFECT DIS, V55, pS303, DOI 10.1093/cid/cis789
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   Lopman BA, 2011, J INFECT DIS, V204, P980, DOI 10.1093/infdis/jir492
   MOLBAK K, 1993, BRIT MED J, V307, P417
   Mor SM, 2008, CLIN INFECT DIS, V47, P915, DOI 10.1086/591539
   Nasrin D, 2013, AM J TROP MED HYG, V89, P3, DOI 10.4269/ajtmh.12-0749
   Okeke IN, 2009, J INFECT DEV COUNTR, V3, P817
   Panchalingam S, 2012, CLIN INFECT DIS, V55, pS294, DOI 10.1093/cid/cis754
   Robins-Browne RM, 2012, CLIN INFECT DIS, V55, pS312, DOI 10.1093/cid/cis756
   SANTOSHAM M, 1985, J INFECT DIS, V152, P778
   Trabulsi LR, 2002, EMERG INFECT DIS, V8, P508
   Valentiner-Branth P, 2003, J CLIN MICROBIOL, V41, P4238, DOI 10.1128/JCM.41.9.4238-4245.2003
   Walker CLF, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-220
   WHO-World Health Organization, 2009, WHO ANTHR PERS COMP
   WHO Multicentre Growth Reference Study Group, WHO CHILD GROWTH STA
   You D, 2010, LANCET, V375, P100, DOI 10.1016/S0140-6736(09)61601-9
NR 36
TC 680
Z9 697
U1 12
U2 143
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUL 20
PY 2013
VL 382
IS 9888
BP 209
EP 222
DI 10.1016/S0140-6736(13)60844-2
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 193FL
UT WOS:000322543700031
PM 23680352
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Burr, SE
   Hart, JD
   Edwards, T
   Baldeh, I
   Bojang, E
   Harding-Esch, EM
   Holland, MJ
   Lietman, TM
   West, SK
   Mabey, DCW
   Sillah, A
   Bailey, RL
AF Burr, Sarah E.
   Hart, John D.
   Edwards, Tansy
   Baldeh, Ignatius
   Bojang, Ebrima
   Harding-Esch, Emma M.
   Holland, Martin J.
   Lietman, Thomas M.
   West, Sheila K.
   Mabey, David C. W.
   Sillah, Ansumana
   Bailey, Robin L.
TI Association between Ocular Bacterial Carriage and Follicular Trachoma
   Following Mass Azithromycin Distribution in The Gambia
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; STREPTOCOCCUS-PNEUMONIAE;
   HAEMOPHILUS-INFLUENZAE; LOW-PREVALENCE; NASOPHARYNGEAL CARRIAGE;
   CHLAMYDIA-TRACHOMATIS; CLINICAL-DIAGNOSIS; CONJUGATE VACCINE; ACTIVE
   TRACHOMA; RESISTANCE
AB Background: Trachoma, caused by ocular Chlamydia trachomatis infection, is the leading infectious cause of blindess, but its prevalence is now falling in many countries. As the prevalence falls, an increasing proportion of individuals with clinical signs of follicular trachoma (TF) is not infected with C. trachomatis. A recent study in Tanzania suggested that other bacteria may play a role in the persistence of these clinical signs.
   Methodology/Principal Findings: We examined associations between clinical signs of TF and ocular colonization with four pathogens commonly found in the nasopharnyx, three years after the initiation of mass azithromycin distribution. Children aged 0 to 5 years were randomly selected from 16 Gambian communitites. Both eyes of each child were examined and graded for trachoma according to the World Health Organization (WHO) simplified system. Two swabs were taken from the right eye: one swab was processed for polymerase chain reaction (PCR) using the Amplicor test for detection of C. trachomatis DNA and the second swab was processed by routine bacteriology to assay for the presence of viable Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus and Moraxella catarrhalis. Prevalence of TF was 6.2% (96/1538) while prevalence of ocular C. trachomatis infection was 1.0% (16/1538). After adjustment, increased odds of TF were observed in the presence of C. trachomatis (OR = 10.4, 95% CI 1.32-81.2, p = 0.03), S. pneumoniae (OR = 2.14, 95% CI 1.03-4.44, p = 0.04) and H. influenzae (OR = 4.72, 95% CI 1.53-14.5, p = 0.01).
   Conclusions/Significance: Clinical signs of TF can persist in communities even when ocular C. trachomatis infection has been controlled through mass azithromycin distribution. In these settings, TF may be associated with ocular colonization with bacteria commonly carried in the nasopharnyx. This may affect the interpretation of impact surveys and the determinations of thresholds for discontinuing mass drug administration.
C1 [Burr, Sarah E.; Hart, John D.; Harding-Esch, Emma M.; Holland, Martin J.; Mabey, David C. W.; Bailey, Robin L.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England.
   [Burr, Sarah E.; Baldeh, Ignatius; Bojang, Ebrima] MRC Unit, Banjul, Gambia.
   [Edwards, Tansy] London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1, England.
   [Lietman, Thomas M.] Univ Calif San Francisco, Francis I Proctor Fdn Res Ophthalmol, San Francisco, CA 94143 USA.
   [West, Sheila K.] Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
   [Sillah, Ansumana] Minist Hlth & Social Welf, Natl Eye Hlth Programe, Kanifing, Gambia.
RP Burr, SE (reprint author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England.
EM sburr@mrc.gm
OI Mabey, David/0000-0002-0031-8276
FU Bill and Melinda Gates Foundation [48027]
FX This study was supported by the Bill and Melinda Gates Foundation
   (http://www.gatesfoundation.org/), grant number 48027. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   ADEGBOLA RA, 1995, PEDIATR INFECT DIS J, V14, P335, DOI 10.1097/00006454-199504000-00024
   Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   Batt SL, 2003, ANTIMICROB AGENTS CH, V47, P2765, DOI 10.1128/AAC.47.9.2765-2769.2003
   Biebesheimer JB, 2009, OPHTHALMOLOGY, V116, P2047, DOI 10.1016/j.ophtha.2009.04.041
   Burton MJ, 2007, INVEST OPHTH VIS SCI, V48, P4440, DOI 10.1167/iovs.07-0315
   Burton MJ, 2011, INVEST OPHTH VIS SCI, V52, P6012, DOI 10.1167/iovs.11-7326
   Burton MJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000835
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P1282, DOI 10.1136/bjo.2004.062489
   Cheung YB, 2009, PEDIATR INFECT DIS J, V28, P990, DOI 10.1097/INF.0b013e3181a78185
   Cumberland P, 2008, INT J EPIDEMIOL, V37, P549, DOI 10.1093/ije/dyn045
   Dabernat H, 2003, J CLIN MICROBIOL, V41, P1664, DOI 10.1128/JCM.41.4.1664-1672.2003
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Egere U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049143
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Faal H, 2000, BRIT J OPHTHALMOL, V84, P948, DOI 10.1136/bjo.84.9.948
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   Fry AM, 2002, CLIN INFECT DIS, V35, P395, DOI 10.1086/341414
   Gaynor BD, 2005, BRIT J OPHTHALMOL, V89, P1097, DOI 10.1136/bjo.2005.068981
   GIBSON LF, 1986, LETT APPL MICROBIOL, V3, P127, DOI 10.1111/j.1472-765X.1986.tb01565.x
   Harding-Esch EM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002115
   Harding-Esch EM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000861
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Haug S, 2010, CLIN INFECT DIS, V51, P571, DOI 10.1086/655697
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Kaijalainen T, 2004, J CLIN MICROBIOL, V42, P412, DOI 10.1128/JCM.42.1.412-414.2004
   Krachmer JH, 1997, CORNEA CORNEA EXTERN, V2
   Kwambana BA, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-175
   Leach AJ, 1997, CLIN INFECT DIS, V24, P356
   Leung MHY, 2011, INFECT GENET EVOL, V11, P1989, DOI 10.1016/j.meegid.2011.09.002
   Miller K, 2004, BRIT J OPHTHALMOL, V88, P750, DOI 10.1136/bjo.2003.038661
   Moyo SJ, 2012, J MED MICROBIOL, V61, P952, DOI 10.1099/jmm.0.042598-0
   Murphy TF, 2009, PEDIATR INFECT DIS J, V28, P43, DOI 10.1097/INF.0b013e318184dba2
   O'Brien KL, 2001, J CLIN MICROBIOL, V39, P1021, DOI 10.1128/JCM.39.3.1021-1024.2001
   Organization WH, 2011, 15 M WHO ALL EL BLIN
   Solomon AW, 2008, NEW ENGL J MED, V358, P1870, DOI 10.1056/NEJMc0706263
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Stare D, 2011, OPHTHAL EPIDEMIOL, V18, P20, DOI 10.3109/09286586.2010.545500
   Thein J, 2002, OPHTHALMIC EPIDEMIOL, V9, P263, DOI 10.1076/opep.9.4.263.1508
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   World Health Organization, 2012, 16 M WHO ALL EL BLIN, P14
   World Health Organization, 2003, 2 GLOB SCI M TRACH
   World Health Organization, 2012, VACC PREV DIS VACC M
NR 43
TC 12
Z9 12
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2013
VL 7
IS 7
AR e2347
DI 10.1371/journal.pntd.0002347
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 190EJ
UT WOS:000322321500048
PM 23936573
OA gold
DA 2017-08-15
ER

PT J
AU Fan, SKS
   Chang, YJ
   Aidara, N
AF Fan, Shu-Kai S.
   Chang, Yuan-Jung
   Aidara, Nafy
TI Nonlinear Profile Monitoring of Reflow Process Data Based on the Sum of
   Sine Functions
SO QUALITY AND RELIABILITY ENGINEERING INTERNATIONAL
LA English
DT Article
DE statistical process control (SPC); nonlinear profiles; sum of sine
   functions; polynomial regression; average run length (ARL); Hotelling's;
   (2) statistics; metrics
ID MULTIVARIATE CONTROL CHARTS; INDIVIDUAL OBSERVATIONS
AB In most statistical process control (SPC) applications, it is often assumed that the quality of a process or product can be adequately represented by the distribution of a univariate quality characteristic. However, in some particular situations, the quality-related response of interest is not a single variable but a function of some independent variables. Such a functional relationship is called a profile. Recently, profile monitoring has drawn considerable attention in the statistical process control literature. This article proposes a new approach for the reflow process data, which applies the sum of sine functions to model the nonlinear profiles and then the vector of parameter estimates is monitored using the Hotelling T-2 and metric control charts. Through an actual data set of the reflow process, the proposed approach is compared with the polynomial regression approach in phase I and phase II analyses. The experimental results show that the proposed approach demonstrates good abilities to detect outlying profiles in phase I and provides better out-of-control average run length performances than the polynomial regression approach in phase II. Copyright (C) 2012 John Wiley & Sons, Ltd.
C1 [Fan, Shu-Kai S.] Natl Taipei Univ Technol, Dept Ind Engn & Management, Taipei 106, Taiwan.
   [Chang, Yuan-Jung] Yuan Ze Univ, Dept Ind Engn & Management, Taoyuan Cty, Taiwan.
   [Aidara, Nafy] Univ Gambia, Serrekunda, Gambia.
RP Fan, SKS (reprint author), Natl Taipei Univ Technol, Dept Ind Engn & Management, Taipei 106, Taiwan.
EM morrisfan@ntut.edu.tw
FU National Science Council [NSC 100-2221-E-027-115-MY3]
FX The authors are grateful to the Chief Editor, Dr D. C. Montgomery, and
   an anonymous referee for their comments and suggestions that greatly
   improved an earlier draft of the article. Dr Fan is financially
   supported by the National Science Council (grant no. NSC
   100-2221-E-027-115-MY3).
CR Amiri A, 2010, QUAL RELIAB ENG INT, V26, P509, DOI 10.1002/qre.1071
   Boeing Commercial Airplane Group, 1998, ADV QUALITY SYSTEM
   Brill RV, 2001, PRESENTATION 45 ANN
   Chen SH, 2011, QUAL RELIAB ENG INT, V27, P451, DOI 10.1002/qre.1140
   Ding Y, 2006, J QUAL TECHNOL, V38, P199
   Fan SKS, 2011, J PROCESS CONTR, V21, P1217, DOI 10.1016/j.jprocont.2011.06.005
   Gardner M. M., 1997, IEEE Transactions on Components, Packaging & Manufacturing Technology, Part C (Manufacturing), V20, P295, DOI 10.1109/3476.650961
   Hawkins DM, 1974, MATH GEOL, V6, P263
   Holmes DS, 1993, QUAL ENG, V5, P619, DOI DOI 10.1080/08982119308919004
   Jensen AJ, 2009, J QUALITY, V41, P18
   Jensen WA, 2006, J QUAL TECHNOL, V38, P349
   Jin J, 1999, FEATURE PRESERVING D, V41, P327
   Kang L, 2000, J QUAL TECHNOL, V32, P418
   LOWRY CA, 1995, IIE TRANS, V27, P800, DOI 10.1080/07408179508936797
   Mahmoud MA, 2004, PHASE 1 ANAL LINEAR, V46, P377
   MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431
   Mason R. L., 2002, MULTIVARIATE STAT PR
   Moguerza JM, 2007, LECT NOTES COMPUT SC, V4756, P574
   Qiu PH, 2010, TECHNOMETRICS, V52, P265, DOI 10.1198/TECH.2010.08188
   Ryan, 1989, STAT METHODS QUALITY
   Sullivan JH, 1996, J QUAL TECHNOL, V28, P398
   TRACY ND, 1992, J QUAL TECHNOL, V24, P88
   Vargas NJA, 2003, J QUAL TECHNOL, V35, P367
   Walker E, 2002, J QUAL TECHNOL, V34, P118
   Williams JD, 2006, J QUAL TECHNOL, V38, P217
   Williams JM, 2007, OPT PHOTONICS NEWS, V18, P8
   Winistorfer PM, 1996, WOOD FIBER SCI, V28, P133
   Woodall WH, 2004, J QUAL TECHNOL, V36, P309
   Zou C F, 2007, MONITORING PROFILES, V49, P395
NR 29
TC 8
Z9 8
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0748-8017
EI 1099-1638
J9 QUAL RELIAB ENG INT
JI Qual. Reliab. Eng. Int.
PD JUL
PY 2013
VL 29
IS 5
BP 743
EP 758
DI 10.1002/qre.1425
PG 16
WC Engineering, Multidisciplinary; Engineering, Industrial; Operations
   Research & Management Science
SC Engineering; Operations Research & Management Science
GA 188VB
UT WOS:000322222600013
OA No
DA 2017-08-15
ER

PT J
AU Nasrin, D
   Wu, YK
   Blackwelder, WC
   Farag, TH
   Saha, D
   Sow, SO
   Alonso, PL
   Breiman, RF
   Sur, D
   Faruque, ASG
   Zaidi, AKM
   Biswas, K
   Van Eijk, AM
   Walker, DG
   Levine, MM
   Kotloff, KL
AF Nasrin, Dilruba
   Wu, Yukun
   Blackwelder, William C.
   Farag, Tamer H.
   Saha, Debasish
   Sow, Samba O.
   Alonso, Pedro L.
   Breiman, Robert F.
   Sur, Dipika
   Faruque, Abu S. G.
   Zaidi, Anita K. M.
   Biswas, Kousick
   Van Eijk, Anna Maria
   Walker, Damian G.
   Levine, Myron M.
   Kotloff, Karen L.
TI Health care seeking for Childhood Diarrhea in Developing Countries:
   Evidence from Seven Sites in Africa and Asia
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID RURAL WESTERN KENYA; ILLNESSES; DISEASE; MANAGEMENT; INTERVENTIONS;
   DETERMINANTS; BANGLADESH; COMMUNITY; SETTINGS; CHILDREN
AB We performed serial Health Care Utilization and Attitudes Surveys (HUASs) among caretakers of children ages 0-59 months randomly selected from demographically defined populations participating in the Global Enteric Multicenter Study (GEMS), a case-control study of moderate-to-severe diarrhea (MSD) in seven developing countries. The surveys aimed to estimate the proportion of children with MSD who would present to sentinel health centers (SHCs) where GEMS case recruitment would occur and provide a basis for adjusting disease incidence rates to include cases not seen at the SHCs. The proportion of children at each site reported to have had an incident episode of MSD during the 7 days preceding the survey ranged from 0.7% to 4.4% for infants (0-11 months of age), from 0.4% to 4.7% for toddlers (12-23 months of age), and from 0.3% to 2.4% for preschoolers (24-59 months of age). The proportion of MSD episodes at each site taken to an SHC within 7 days of diarrhea onset was 15-56%, 17-64%, and 7-33% in the three age strata, respectively. High cost of care and insufficient knowledge about danger signs were associated with lack of any care-seeking outside the home. Most children were not offered recommended fluids and continuing feeds at home. We have shown the utility of serial HUASs as a tool for optimizing operational and methodological issues related to the performance of a large case-control study and deriving population-based incidence rates of MSD. Moreover, the surveys suggest key targets for educational interventions that might improve the outcome of diarrheal diseases in low-resource settings.
C1 Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Pediat & Med, Baltimore, MD 21201 USA.
   MRC, Basse, Gambia.
   [Sow, Samba O.] Ctr Dev Vaccins Mali CVD Mali, Ctr Natl Appui Lutte Malad CNAM, Ex Inst Marchoux, Bamako, Mali.
   [Alonso, Pedro L.] CISM, Manhica, Mozambique.
   US Ctr Dis Control & Prevent, Kenya Off, Global Dis Detect Div, Nairobi, Kenya.
   [Sur, Dipika] NICED, Kolkata, India.
   [Faruque, Abu S. G.] Int Ctr Diarrheal Dis Res ICDDR B, Mirzapur, Bangladesh.
   [Zaidi, Anita K. M.] Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan.
   [Biswas, Kousick] Cooperat Studies Program Coordinating Ctr, Dept Vet Affairs, Perry Point, MD USA.
   [Van Eijk, Anna Maria] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Nasrin, D (reprint author), Univ Maryland, Sch Med, Ctr Vaccine Dev, HSF-1 Room 480,685 West Baltimore St, Baltimore, MD 21201 USA.
EM dnasrin@medicine.umaryland.edu; wu@medicine.umaryland.edu;
   wblackwe@medicine.umaryland.edu; tfarag@medicine.umaryland.edu;
   debu_saha@hotmail.com; ssow@medicine.umaryland.edu;
   pedro.alonso@isglobal.es; rfbreiman@emory.edu; dipikasur@hotmail.com;
   gfaruque@icddrb.org; anita.zaidi@aku.edu; Kousick.Biswas@va.gov;
   amvaneijk@gmail.com; damian.walker@gatesfoundation.org;
   mlevine@medicine.umaryland.edu; kkotloff@medicine.umaryland.edu
FU Bill and Melinda Gates Foundation [38874]
FX This work was supported by Bill and Melinda Gates Foundation Grant 38874
   (M.M.L., Principal Investigator).
CR ALAM N, 1989, INT J EPIDEMIOL, V18, P697, DOI 10.1093/ije/18.3.697
   Bigogo G, 2010, INT J INFECT DIS, V14, pE967, DOI 10.1016/j.ijid.2010.05.016
   Biswas K, 2012, CLIN INFECT DIS, V55, pS254, DOI 10.1093/cid/cis755
   Boschi-Pinto C, 2009, J HEALTH POPUL NUTR, V27, P755
   Breiman RF, 2011, J HEALTH POPUL NUTR, V29, P123
   Burgert CR, 2011, TROP MED INT HEALTH, V16, P711, DOI 10.1111/j.1365-3156.2011.02752.x
   Burton DC, 2011, J HEALTH POPUL NUTR, V29, P61
   El Arifeen S, 2008, J HEALTH POPUL NUTR, V26, P22
   Ellis AA, 2007, SOC SCI MED, V64, P701, DOI 10.1016/j.socscimed.2006.10.011
   Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292
   Goodall RM, 2012, DIARRHEA DEHYDRATION
   Hill Z, 2003, TROP MED INT HEALTH, V8, P668, DOI 10.1046/j.1365-3156.2003.01058.x
   Jordan HT, 2009, INT J INFECT DIS, V13, P355, DOI 10.1016/j.ijid.2008.07.014
   Kotloff KL, 2012, CLIN INFECT DIS, V55, pS232, DOI 10.1093/cid/cis753
   Manesh AO, 2008, INT J EPIDEMIOL, V37, P194, DOI 10.1093/ije/dym202
   Nyamongo IK, 2002, SOC SCI MED, V54, P377, DOI 10.1016/S0277-9536(01)00036-3
   Ramakrishnan R, 1999, Indian J Public Health, V43, P136
   Rheingans R, 2012, CLIN INFECT DIS, V55, pS317, DOI 10.1093/cid/cis763
   Rheingans R, 2012, CLIN INFECT DIS, V55, pS327, DOI 10.1093/cid/cis764
   ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203
   Searle SR, 1971, LINEAR MODELS, P57
   Shapiro RL, 2001, J INFECT DIS, V183, P1701, DOI 10.1086/320710
   Taffa N, 2005, TROP MED INT HEALTH, V10, P240, DOI 10.1111/j.1365-3156.2004.01381.x
   UNDP, 2012, HUM DEV REP
   UNICEF, 2012, STAT WORLDS CHILDR 2
   Viera AJ, 2005, FAM MED, V37, P360
   Walker CLF, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-220
   WHO, 2005, HDB IMCI INT MAN CHI
   World Health Organization, 2002, GEN PROT I HOSP BAS
   WHO MDG 6, 2012, HIV AIDS MAL OTH DIS
   Winch PJ, 2008, J HEALTH POPUL NUTR, V26, P151
NR 31
TC 29
Z9 30
U1 0
U2 10
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 2013
VL 89
IS 1
SU S
BP 3
EP 12
DI 10.4269/ajtmh.12-0749
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 185BH
UT WOS:000321939700002
PM 23629939
OA No
DA 2017-08-15
ER

PT J
AU Prentice, A
AF Prentice, Ann
TI Nutritional rickets around the world
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper
CT 15th Vitamin D Workshop
CY JUN 20-22, 2012
CL Houston, TX
DE Calcium; FGF23; Iron; Phosphate; Rickets; Vitamin D
ID VITAMIN-D-DEFICIENCY; FIBROBLAST GROWTH FACTOR-23; NIGERIAN CHILDREN;
   GAMBIAN CHILDREN; BONE; FGF23; PREVALENCE; PHOSPHATE; CALCIUM; HEALTH
AB Nutritional rickets is a major public health problem in many countries of the world. The disease is characterized by deformities of the long bones, enlargement of the wrists and costochondral junctions, hypotonia and, in infants, craniotabes and delayed fontanelle closure. Predominantly caused by severe vitamin D deficiency, rickets can also be associated with hypocalcemic seizures and cardiac failure. First presentation is typically at 6-24 months of age, although hypocalcemia may be evident in younger infants. In many affluent industrialized countries, the prevalence of rickets in the general population diminished after the introduction of clean-air legislation and dietary supplementation. However, in such countries, vitamin-D deficiency rickets has re-emerged in recent years, particularly among groups with limited exposure to UVB-containing sunshine. Infants at risk of rickets tend to be those whose mothers had poor vitamin D status during pregnancy and those exclusively breast-fed for a prolonged period with little skin exposure to UVB. In other countries of the world, the prevalence of rickets can be high, even in regions with abundant year-round UVB-containing sunshine. In general, this is also due to vitamin D deficiency related to limited sun exposure. However, reports from Africa and Asia suggest that there may be other etiological factors involved. Studies in South Africa, Nigeria, The Gambia and Bangladesh have identified rickets in children, typically 3-5 years old at first presentation, in whom plasma 25-hydroxyvitamin D concentrations are higher than those characteristic of primary vitamin D deficiency. Calcium deficiency has been implicated, and in some, but not all, disturbances of phosphate metabolism, renal compromise and iron deficiency may also be involved. Continuing studies of the etiology of nutritional rickets will provide evidence to underpin guidelines for the prevention and treatment of rickets world-wide.
   This article is part of a Special Issue entitled 'Vitamin D Workshop'. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Prentice, Ann] MRC Human Nutr Res, Cambridge CB1 9NL, England.
   [Prentice, Ann] MRC Keneba, Keneba, Gambia.
RP Prentice, A (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulboum Rd, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
FU UK Medical Research Council [U105960371, U123261351]
FX Funded by the UK Medical Research Council, programmes U105960371 and
   U123261351.
CR Ahmed SF, 2011, ARCH DIS CHILD, V96, P694, DOI 10.1136/adc.2009.173195
   Al-Atawi M S, 2009, Saudi J Kidney Dis Transpl, V20, P260
   Ashraf S, 2002, ARCH DIS CHILD, V87, P263, DOI 10.1136/adc.87.3.263-a
   Baroncelli GI, 2008, J CLIN ENDOCR METAB, V93, P1743, DOI 10.1210/jc.2007-1413
   Beck-Nielsen SS, 2009, EUR J ENDOCRINOL, V160, P491, DOI 10.1530/EJE-08-0818
   Bener A, 2010, INT J PEDIAT ENDOCRI, V2010
   BESER E, 1994, E AFR MED J, V71, P358
   Braithwaite V., 2012, OSTEOPOROSIS INT, DOI DOI 10.1007/S00198-00012-02029-00192
   Braithwaite Vickie, 2012, Int J Pediatr Endocrinol, V2012, P27, DOI 10.1186/1687-9856-2012-27
   Braithwaite V, 2012, BONE, V50, P1351, DOI 10.1016/j.bone.2012.03.010
   Braithwaite V, 2012, BONE, V50, P218, DOI 10.1016/j.bone.2011.10.009
   Carpenter KJ, 2008, J NUTR, V138, P827
   DeLucia MC, 2003, J CLIN ENDOCR METAB, V88, P3539, DOI 10.1210/jc.2002-021935
   Durham BH, 2007, ANN CLIN BIOCHEM, V44, P463, DOI 10.1258/000456307781646102
   Fischer PR, 2000, J BONE MINER RES, V15, P2206, DOI 10.1359/jbmr.2000.15.11.2206
   Fischer PR, 1999, J TROP PEDIATRICS, V45, P291, DOI 10.1093/tropej/45.5.291
   Fraser DR, 2004, J STEROID BIOCHEM, V89-90, P491, DOI 10.1016/j.jsbmb.2004.03.057
   Harris NS, 2001, NEW ENGL J MED, V344, P341, DOI 10.1056/NEJM200102013440504
   ICDDRB, 2009, HLTH SCI B, V7, P7
   Jones HL, 2009, BONE, V45, pS83, DOI 10.1016/j.bone.2009.04.114
   Khadilkar A, 2009, ARCH DIS CHILD, V94, P932, DOI 10.1136/adc.2008.149674
   Kolek OI, 2005, AM J PHYSIOL-GASTR L, V289, pG1036, DOI 10.1152/ajpgi.00243.2005
   Martin A, 2012, ADV EXP MED BIOL, V728, P65, DOI 10.1007/978-1-4614-0887-1_4
   Matsuo K, 2009, PEDIATR INT, V51, P559, DOI 10.1111/j.1442-200X.2009.02834.x
   Mughal M Zulf, 2011, Curr Osteoporos Rep, V9, P291, DOI 10.1007/s11914-011-0081-0
   Muhe L, 1997, LANCET, V349, P1801, DOI 10.1016/S0140-6736(96)12098-5
   Odeka E, 2005, ARCH DIS CHILD, V90, P1203
   Oginni LM, 1996, J PEDIATR-US, V128, P692, DOI 10.1016/S0022-3476(96)80137-5
   Pettifor J.M., 2012, PEDIAT BONE BIOL DIS
   Pettifor JM, 2011, BEST PRACT RES CL EN, V25, P573, DOI 10.1016/j.beem.2011.06.010
   Pfitzner MA, 1998, J PEDIATR-US, V133, P740, DOI 10.1016/S0022-3476(98)70143-X
   PORTALE AA, 1989, J CLIN INVEST, V83, P1494, DOI 10.1172/JCI114043
   Prentice A., 2011, J CLIN ENDOCRINOLOGY, V96, DOI DOI 10.1210/JC.2011-1239
   Prentice A., 2007, INT C SERIES, V1297, P15, DOI 10.1016/j.ics.2006.08.011
   Prentice A, 2008, NUTR REV, V66, pS153, DOI 10.1111/j.1753-4887.2008.00100.x
   Prentice A, 2008, BONE, V42, P788, DOI 10.1016/j.bone.2007.11.014
   Prentice A, 2006, P NUTR SOC, V65, P348, DOI 10.1079/PNS2006519
   SALIMPOUR R, 1975, ARCH DIS CHILD, V50, P63
   Scientific Advisory Committee on Nutrition, 2007, UPD VIT D
   Shaw NJ, 2002, ARCH DIS CHILD, V86, P147, DOI 10.1136/adc.86.3.147
   Thacher TD, 2006, ANN TROP PAEDIATR, V26, P1, DOI 10.1179/146532806X90556
   Thacher TD, 2000, J TROP PEDIATRICS, V46, P132, DOI 10.1093/tropej/46.3.132
   Thacher TD, 1999, NEW ENGL J MED, V341, P563, DOI 10.1056/NEJM199908193410803
   Thacher TD, 2000, J PEDIATR-US, V137, P367, DOI 10.1067/mpd.2000.107527
   Tserendolgor U., 1998, J CLIN NUTR, V7, P325
   UNDERWOOD P, 1987, SOC SCI MED, V24, P37, DOI 10.1016/0277-9536(87)90136-5
   ZHOU HK, 1991, NESTLE NUTR WORKS SE, V21, P253
NR 47
TC 29
Z9 31
U1 3
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD JUL
PY 2013
VL 136
SI SI
BP 201
EP 206
DI 10.1016/j.jsbmb.2012.11.018
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 177WJ
UT WOS:000321405800041
PM 23220549
OA No
DA 2017-08-15
ER

PT J
AU Roberts, CH
   Last, A
   Molina-Gonzalez, S
   Cassama, E
   Butcher, R
   Nabicassa, M
   McCarthy, E
   Burr, SE
   Mabey, DC
   Bailey, RL
   Holland, MJ
AF Roberts, Chrissy H.
   Last, Anna
   Molina-Gonzalez, Sandra
   Cassama, Eunice
   Butcher, Robert
   Nabicassa, Meno
   McCarthy, Elizabeth
   Burr, Sarah E.
   Mabey, David C.
   Bailey, Robin L.
   Holland, Martin J.
TI Development and Evaluation of a Next-Generation Digital PCR Diagnostic
   Assay for Ocular Chlamydia trachomatis Infections
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID REAL-TIME PCR; CHAIN-REACTION ASSAY; DNA COPY NUMBER; MASS TREATMENT;
   ACTIVE TRACHOMA; HYPERENDEMIC COMMUNITY; NEISSERIA-GONORRHOEAE; ABSOLUTE
   QUANTITATION; DISCREPANT ANALYSIS; AZITHROMYCIN
AB Droplet digital PCR (ddPCR) is an emulsion PCR process that performs absolute quantitation of nucleic acids. We developed a ddPCR assay for Chlamydia trachomatis infections and found it to be accurate and precise. Using PCR mixtures containing plasmids engineered to include the PCR target sequences, we were able to quantify with a dynamic range between 0.07 and 3,160 targets/mu l (r(2) = 0.9927) with >95% confidence. Using 1,509 clinical conjunctival swab samples from a population in which trachoma is endemic in Guinea Bissau, we evaluated the specificity and sensitivity of the quantitative ddPCR assay in diagnosing ocular C. trachomatis infections by comparing the performances of ddPCR and the Roche Amplicor CT/NG test. We defined ddPCR tests as positive when we had >= 95% confidence in a nonzero estimate of target load. The sensitivity of ddPCR against Amplicor was 73.3% (95% confidence interval [CI], 67.9 to 78.7%), and specificity was 99.1% (95% CI, 98.6 to 99.6%). Negative and positive predictive values were 94.6% (95% CI, 93.4 to 95.8%) and 94.5% (95% CI, 91.3 to 97.7%), respectively. Based on Amplicor CT/NG testing, the estimated population prevalence of C. trachomatis ocular infection was similar to 17.5%. Receiver-operator curve analysis was used to select critical cutoff values for use in clinical settings in which a balance between higher sensitivity and specificity is required. We concluded that ddPCR is an effective diagnostic technology suitable for both research and clinical use in diagnosing ocular C. trachomatis infections.
C1 [Roberts, Chrissy H.; Last, Anna; Molina-Gonzalez, Sandra; Butcher, Robert; Burr, Sarah E.; Mabey, David C.; Bailey, Robin L.; Holland, Martin J.] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England.
   [McCarthy, Elizabeth] London Sch Hyg & Trop Med, Dept Immunol, London WC1, England.
   [Burr, Sarah E.] MRC Unit, Banjul, Gambia.
   [Cassama, Eunice; Nabicassa, Meno] Minist Saude Publ, Programa Nacl Saude Visao, Bissau, Guinea Bissau.
RP Roberts, CH (reprint author), London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England.
EM chrissy.roberts@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276
FU Wellcome Trust [GR079246MA]
FX The Wellcome Trust provided financial support (grant number GR079246MA).
CR Andreasen AA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000306
   BANOO S, 2006, NAT REV MICROBIOL S, V4, pS20, DOI DOI 10.1038/NRMICRO1570
   BASS CA, 1993, J CLIN MICROBIOL, V31, P2648
   Bassiri M, 1997, J CLIN MICROBIOL, V35, P2556
   BENNETT S, 1991, World Health Statistics Quarterly, V44, P98
   Burton MJ, 2011, INFECT IMMUN, V79, P4977, DOI 10.1128/IAI.05718-11
   Burton MJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000835
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Cheng A, 2011, J CLIN MICROBIOL, V49, P1294, DOI 10.1128/JCM.02595-10
   Chidambaram JD, 2006, JAMA-J AM MED ASSOC, V295, P1142, DOI 10.1001/jama.295.10.1142
   Dube S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002876
   Green TA, 2001, J CLIN EPIDEMIOL, V54, P210, DOI 10.1016/S0895-4356(00)00288-2
   Hadgu A, 1999, J CLIN EPIDEMIOL, V52, P1231, DOI 10.1016/S0895-4356(99)00101-8
   Harding-Esch EM, 2008, T ROY SOC TROP MED H, V102, P1255, DOI 10.1016/j.trstmh.2008.04.022
   Harding-Esch EM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001234
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Hayden RT, 2013, J CLIN MICROBIOL, V51, P540, DOI 10.1128/JCM.02620-12
   Henrich TJ, 2012, J VIROL METHODS, V186, P68, DOI 10.1016/j.jviromet.2012.08.019
   Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g
   JASCHEK G, 1993, J CLIN MICROBIOL, V31, P1209
   Kalinina O, 1997, NUCLEIC ACIDS RES, V25, P1999, DOI 10.1093/nar/25.10.1999
   Keenan JD, 2012, INVEST OPHTH VIS SCI, V53, P235, DOI 10.1167/iovs.11-8493
   Leng XF, 2010, LAB CHIP, V10, P2841, DOI [10.1039/c0lc00145g, 10.1039/c01c00145g]
   Luo W, 2005, J CLIN MICROBIOL, V43, P1851, DOI 10.1128/JCM.43.4.1851-1857.2005
   McGowin CL, 2009, DIAGN MICR INFEC DIS, V64, P117, DOI 10.1016/j.diagmicrobio.2009.01.032
   MIYASHITA N, 1994, MICROBIOL IMMUNOL, V38, P81
   Nakano M, 2003, J BIOTECHNOL, V102, P117, DOI 10.1016/S0168-1656(03)00023-3
   Pickett MA, 2005, MICROBIOL-SGM, V151, P893, DOI 10.1099/mic.0.27625-0
   Pinheiro LB, 2012, ANAL CHEM, V84, P1003, DOI 10.1021/ac202578x
   RUMPIANESI F, 1993, MICROBIOLOGICA, V16, P293
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Skalet AH, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000377
   Solomon AW, 2008, NEW ENGL J MED, V358, P1870, DOI 10.1056/NEJMc0706263
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   Solomon AW, 2006, TRACHOMA CONTROL GUI
   Stare D, 2011, OPHTHAL EPIDEMIOL, V18, P20, DOI 10.3109/09286586.2010.545500
   Stevens MP, 2010, J CLIN MICROBIOL, V48, P2060, DOI 10.1128/JCM.02308-09
   Tan YC, 2006, SENSOR ACTUAT B-CHEM, V114, P350, DOI 10.1016/j.snb.2005.06.008
   Van der Pol B, 2001, J CLIN MICROBIOL, V39, P3092, DOI 10.1128/JCM.39.9.3092-3098.2001
   Vihinen M, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S4-S2
   Vincelette J, 1999, J CLIN MICROBIOL, V37, P74
   Vincent ME, 2010, CHEM SOC REV, V39, P974, DOI 10.1039/b917851a
   Vogelstein B, 1999, P NATL ACAD SCI USA, V96, P9236, DOI 10.1073/pnas.96.16.9236
   Wang YB, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002258
   Wei HB, 2012, CLIN BIOCHEM, V45, P663, DOI 10.1016/j.clinbiochem.2012.03.010
   West ES, 2005, INVEST OPHTH VIS SCI, V46, P83, DOI 10.1167/iovs.04-0327
   West SK, 2005, LANCET, V366, P1296, DOI 10.1016/S0140-6736(05)67529-0
   White RA, 2012, J VIROL METHODS, V179, P45, DOI 10.1016/j.jviromet.2011.09.017
   World Health Organization, 2012, WKLY EPIDEMIOL REC, V87, P161
   Yang JL, 2007, BRIT J OPHTHALMOL, V91, P293, DOI 10.1136/bjo.2006.099150
NR 51
TC 31
Z9 31
U1 4
U2 17
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUL
PY 2013
VL 51
IS 7
BP 2195
EP 2203
DI 10.1128/JCM.00622-13
PG 9
WC Microbiology
SC Microbiology
GA 166YB
UT WOS:000320595800026
PM 23637300
OA No
DA 2017-08-15
ER

PT J
AU Oduro, AR
   Conway, DJ
   Schellenberg, D
   Satoguina, J
   Greenwood, BM
   Bojang, KA
AF Oduro, Abraham R.
   Conway, David J.
   Schellenberg, David
   Satoguina, Judith
   Greenwood, Brian M.
   Bojang, Kalifa A.
TI Seroepidemiological and parasitological evaluation of the heterogeneity
   of malaria infection in the Gambia
SO MALARIA JOURNAL
LA English
DT Article
DE Evaluation; Microheterogeneity; Plasmodium falciparum; Parasite
   prevalence; Serology; The Gambia
ID TREATED BED NETS; WEST-AFRICA; TARGETED CHEMOPROPHYLAXIS; TRANSMISSION
   INTENSITY; RURAL AREA; EPIDEMIOLOGY
AB Background: As countries make progress in malaria control, transmission may be reduced to such an extent that few cases occur, and identification of the remaining foci of transmission may require a combination of surveillance tools. The study explored the usefulness of parasite prevalence, seroprevalence and model-estimated seroconversion rates for detecting local differences in malaria transmission in a West African country.
   Methods: Age-stratified cross-sectional surveys were conducted during the wet season in 2008 and the following dry season in 2009 in The Gambia. In each season, 20 village communities were sampled from six diverse areas throughout the country. A total of 7,586 participants were surveyed, 51% (3,870) during the wet season. Parasites were detected by thick film slide microscopy, and anti-MSP1-(19) antibodies were detected by ELISA using eluted dried blood from filter papers.
   Results: Overall parasite prevalence was 12.4% in the wet season and 2.2% in the dry season, with village-specific parasite prevalence ranging from 1.4 to 45.9% in the wet season and from 0.0 to 13.2% in the dry season. Prevalence was highest in the eastern part of the country. Serological indices also varied between villages, indicating local heterogeneity in transmission, and there was a high correlation between wet and dry season estimates across the villages. The overall prevalence of anti-MSP1(19) antibodies was similar in the wet (19.5%) and in the dry (19.6%) seasons.
   Conclusion: The study illustrates the utility of measuring both parasite prevalence and serological indices for monitoring local variation in malaria transmission, which are more informative than single measures as control intensifies and malaria declines. Measurements of seropositivity have the logistical advantage of being relative stable seasonally so that sampling at any time of year may be conducted.
C1 [Oduro, Abraham R.; Conway, David J.; Satoguina, Judith; Bojang, Kalifa A.] MRC Unit, Fajara, Gambia.
   [Conway, David J.; Schellenberg, David; Greenwood, Brian M.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Oduro, Abraham R.] Navrongo Hlth Res Ctr, Navrongo, Ghana.
RP Oduro, AR (reprint author), MRC Unit, Atlantic Rd, Fajara, Gambia.
EM aroduro@yahoo.com
OI Bojang, Kalifa/0000-0001-7506-0938; Conway, David/0000-0002-8711-3037
FU Medical Research Council (UK) PhD studentship; Malaria Programme at the
   Medical Research Council Laboratories in The Gambia
FX We thank all participants, communities and field workers who
   participated in the study. We are grateful to the heads and staff of the
   six health centres that supported and participated in this study. We
   acknowledge the advice of colleagues at the Medical Research Council
   Laboratories in The Gambia, and Dr Chris Drakeley at the London School
   of Hygiene and Tropical Medicine. This work was sponsored by a Medical
   Research Council (UK) PhD studentship for ARO, and supported by core
   funding to the Malaria Programme at the Medical Research Council
   Laboratories in The Gambia. The funders had no direct role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akachi Y, 2002, PLOS ONE, V6
   Bousema T, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001165
   Caputo B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-182
   Carneiro I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008988
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Cook J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025137
   Corran P, 2007, TRENDS PARASITOL, V23, P575, DOI 10.1016/j.pt.2007.08.023
   Corran PH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-195
   Dolgin E, 2010, NAT MED, V16, P1055, DOI 10.1038/nm1010-1055
   Drakeley C, 2003, TROP MED INT HEALTH, V8, P767, DOI 10.1046/j.1365-3156.2003.01100.x
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   Hay SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0
   Koram KA, 2003, TROP MED INT HEALTH, V8, P793, DOI 10.1046/j.1365-3156.2003.01092.x
   Lindsay SW, 1998, P ROY SOC B-BIOL SCI, V265, P847
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L
   Mbogo CM, 2003, AM J TROP MED HYG, V68, P734
   O'Meara WP, 2010, LANCET INFECT DIS, V10, P545, DOI 10.1016/S1473-3099(10)70096-7
   Oduro AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026305
   Smith DL, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-131
   Smith DM, 2005, J INFECT DIS, V192, P438, DOI 10.1086/431682
   Stewart L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006083
   Thomson M, 1996, SOC SCI MED, V43, P101, DOI 10.1016/0277-9536(95)00346-0
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   Woolhouse MEJ, 1997, P NATL ACAD SCI USA, V94, P338, DOI 10.1073/pnas.94.1.338
   Ye Y, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-46
NR 26
TC 12
Z9 12
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUL 1
PY 2013
VL 12
AR 222
DI 10.1186/1475-2875-12-222
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 176OE
UT WOS:000321313200002
PM 23815826
OA gold
DA 2017-08-15
ER

PT J
AU Nyamweya, S
   Hegedus, A
   Jaye, A
   Rowland-Jones, S
   Flanagan, KL
   Macallan, DC
AF Nyamweya, Samuel
   Hegedus, Andrea
   Jaye, Assan
   Rowland-Jones, Sarah
   Flanagan, Katie L.
   Macallan, Derek C.
TI Comparing HIV-1 and HIV-2 infection: Lessons for viral
   immunopathogenesis
SO REVIEWS IN MEDICAL VIROLOGY
LA English
DT Review
ID IMMUNODEFICIENCY-VIRUS TYPE-2; NEUTRALIZING ANTIBODY-RESPONSES; T-CELL
   RESPONSES; RURAL GUINEA-BISSAU; HIV-2-INFECTED INDIVIDUALS; SIMIAN
   IMMUNODEFICIENCY; GAMBIAN PATIENTS; PROVIRAL LOAD; ACTIVATION SIGNALS;
   IMMUNE ACTIVATION
AB <title content-type="main">SUMMARY
   HIV-1 and HIV-2 share many similarities including their basic gene arrangement, modes of transmission, intracellular replication pathways and clinical consequences: both result in AIDS. However, HIV-2 is characterised by lower transmissibility and reduced likelihood of progression to AIDS. The underlying mechanistic differences between these two infections illuminate broader issues of retroviral pathogenesis, which remain incompletely understood. Comparisons between these two infections from epidemiological, clinical, virologic and immunologic viewpoints provide a basis for hypothesis generation and testing in this natural experiment' in viral pathogenesis. In terms of epidemiology, HIV-2 remains largely confined to West Africa, whereas HIV-1 extends worldwide. Clinically, HIV-2 infected individuals seem to dichotomise, most remaining long-term non-progressors, whereas most HIV-1 infected individuals progress. When clinical progression occurs, both diseases demonstrate very similar pathological processes, although progression in HIV-2 occurs at higher CD4 counts. Plasma viral loads are consistently lower in HIV-2, as are average levels of immune activation. Significant differences exist between the two infections in all components of the immune system. For example, cellular responses to HIV-2 tend to be more polyfunctional and produce more IL-2; humoral responses appear broader with lower magnitude intratype neutralisation responses; innate responses appear more robust, possibly through differential effects of tripartite motif protein isoform 5 alpha. Overall, the immune response to HIV-2 appears more protective against disease progression suggesting that pivotal immune factors limit viral pathology. If such immune responses could be replicated or induced in HIV-1 infected patients, they might extend survival and reduce requirements for antiretroviral therapy. Copyright (c) 2013 John Wiley & Sons, Ltd.
C1 [Nyamweya, Samuel; Hegedus, Andrea; Jaye, Assan; Flanagan, Katie L.] MRC Labs, Fajara, Gambia.
   [Hegedus, Andrea; Macallan, Derek C.] Univ London, Infect & Immun Res Ctr, Div Clin Sci, London SW17 0RE, England.
   [Rowland-Jones, Sarah] Univ Oxford, Nuffield Dept Med, Oxford, England.
RP Macallan, DC (reprint author), Univ London, Infect & Immun Res Ctr, Div Clin Sci, Cranmer Terrace, London SW17 0RE, England.
EM macallan@sgul.ac.uk
OI Macallan, Derek/0000-0002-3014-7148
FU HIV Research Trust Fund; South-West London Academic Network
FX SN received funding from the HIV Research Trust Fund. AH received
   funding from the South-West London Academic Network as part of a PhD
   studentship.
CR Ahn J, 2012, J BIOL CHEM, V287, P12550, DOI 10.1074/jbc.M112.340711
   Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002
   ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303
   Arien KK, 2005, J VIROL, V79, P8979, DOI 10.1128/JVI.79.14.8979-8990.2005
   Ariyoshi K, 1998, J Hum Virol, V1, P193
   Arvidson N, 2004, AIDS RES HUM RETROV, V20, P711, DOI 10.1089/0889222041524625
   Barroso Helena, 2005, Infection Genetics and Evolution, V5, P239, DOI 10.1016/j.meegid.2004.07.008
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Blaak H, 2006, VIROLOGY, V353, P144, DOI 10.1016/j.virol.2006.05.029
   Campbell-Yesufu OT, 2011, CLIN INFECT DIS, V52, P780, DOI 10.1093/cid/ciq248
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   Carotenuto P, 1998, AIDS, V12, P1591, DOI 10.1097/00002030-199813000-00005
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   Cooper M, 2010, TROP DOCT, V40, P181, DOI 10.1258/td.2010.090460
   da Silva ZJ, 2008, AIDS, V22, P1195, DOI 10.1097/QAD.0b013e328300a33d
   de Silva TI, 2012, J VIROL, V86, P930, DOI 10.1128/JVI.06126-11
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   Duvall MG, 2007, J VIROL, V81, P13486, DOI 10.1128/JVI.00976-07
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x
   Esbjornsson J, 2012, NEW ENGL J MED, V367, P224, DOI 10.1056/NEJMoa1113244
   Feldmann J, 2009, J VIROL, V83, P12968, DOI 10.1128/JVI.01252-09
   Foxall RB, 2008, J VIROL, V82, P9795, DOI 10.1128/JVI.01217-08
   Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837
   Gautier D, 2007, J VIROL, V81, P12685, DOI 10.1128/JVI.01131-07
   Gillespie GMA, 2005, EUR J IMMUNOL, V35, P1445, DOI 10.1002/eji.200526007
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Gottlieb GS, 2006, AIDS, V20, P895, DOI 10.1097/01.aids.0000218554.59531.80
   Gottlieb GS, 2002, J INFECT DIS, V185, P905, DOI 10.1086/339295
   Grassly NC, 1998, J VIROL, V72, P7895
   Gueudin M, 2008, AIDS, V22, P211
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Hamel DJ, 2007, AIDS RES HUM RETROV, V23, P1189, DOI 10.1089/aid.2007.0037
   HANNIBAL MC, 1993, J VIROL, V67, P5035
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Hanson A, 2005, AIDS RES HUM RETROV, V21, P791, DOI 10.1089/aid.2005.21.791
   Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772
   Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195
   Jaffar S, 2005, AIDS RES HUM RETROV, V21, P560, DOI 10.1089/aid.2005.21.560
   JALECO AC, 1994, CLIN EXP IMMUNOL, V98, P185
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   Jia B, 2009, PLOS PATHOGENS, V5
   Jobe O, 1999, CLIN EXP IMMUNOL, V116, P474
   Khalid M, 2012, J VIROL, V86, P4906, DOI 10.1128/JVI.06856-11
   Kong R, 2012, J VIROL, V86, P947, DOI 10.1128/JVI.06155-11
   Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117
   Le Tortorec A, 2009, J VIROL, V83, P11966, DOI 10.1128/JVI.01515-09
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Leligdowicz A, 2010, EUR J IMMUNOL, V40, P1963, DOI 10.1002/eji.200940295
   Leligdowicz A, 2010, J INFECT DIS, V201, P114, DOI 10.1086/648733
   Lopes AR, 2003, J IMMUNOL, V171, P307
   LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005
   Machuca A, 2004, AIDS RES HUM RETROV, V20, P507, DOI 10.1089/088922204323087750
   Manel N, 2010, NATURE, V467, P214, DOI 10.1038/nature09337
   Marchant D, 2006, J GEN VIROL, V87, P411, DOI 10.1099/vir.0.81391-0
   Martinez-Steele E, 2007, AIDS, V21, P317, DOI 10.1097/QAD.0b013e328011d7ab
   Michel P, 2000, J INFECT DIS, V181, P64, DOI 10.1086/315170
   Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277
   Montefiori DC, 1996, J IMMUNOL, V157, P5528
   Morner A, 2003, AIDS, V17, P1451, DOI 10.1097/01.aids.0000076269.76134.c7
   Moulignier A, 2006, CLIN INFECT DIS, V42, pE89, DOI 10.1086/503909
   Nakayama EE, 2005, J VIROL, V79, P8870, DOI 10.1128/JVI.79.14.8870-8877.2005
   Ndour M, 2000, TROP MED INT HEALTH, V5, P687, DOI 10.1046/j.1365-3156.2000.00627.x
   Nowroozalizadeh S, 2010, J INFECT DIS, V201, P1150, DOI 10.1086/651430
   Nowroozalizadeh S, 2009, CYTOKINE, V46, P325, DOI 10.1016/j.cyto.2009.03.003
   Nuvor SV, 2006, J VIROL, V80, P2529, DOI 10.1128/JVI.80.5.2529-2538.2006
   Nuvor SV WH, 2012, WORLD J AIDS, V2, P103
   Nyamweya S., 2012, PLOS ONE, V7
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Ondondo BO, 2008, EUR J IMMUNOL, V38, P3549, DOI 10.1002/eji.200838759
   Onyango CO, 2010, VACCINE, V28, pB60, DOI 10.1016/j.vaccine.2009.08.060
   Padua E, 2009, HIV MED, V10, P182, DOI 10.1111/j.1468-1293.2008.00669.x
   Peterson I, 2011, AIDS, V25, P2167, DOI 10.1097/QAD.0b013e32834c4adb
   Peterson K, 2011, AIDS RES TREATMENT, V2011, P463
   Peterson K, 2012, ANTIVIR THER, V17, P435, DOI 10.3851/IMP2031
   Pilgrim AK, 1997, J INFECT DIS, V176, P924
   Popper SJ, 2000, J VIROL, V74, P1554, DOI 10.1128/JVI.74.3.1554-1557.2000
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407
   Rodriguez SK, 2007, J VIROL, V81, P5331, DOI 10.1128/JVI.02789-06
   Sahin GO, 2012, J VIROL, V86, P961, DOI 10.1128/JVI.06315-11
   Schaller T, 2012, SCIENCE, V335, P1313, DOI 10.1126/science.1221057
   Schramm B, 2000, J VIROL, V74, P9594, DOI 10.1128/JVI.74.20.9594-9600.2000
   Sharp PM, 2011, COLD SPRING HARBOR P, V1
   Shea A, 2004, AIDS RES HUM RETROV, V20, P630, DOI 10.1089/0889222041217383
   Shi Y, 2005, J GEN VIROL, V86, P3385, DOI 10.1099/vir.0.81259-0
   Skar H, 2010, J VIROL, V84, P7412, DOI 10.1128/JVI.02548-09
   Soares RS, 2011, J VIROL, V85, P2429, DOI 10.1128/JVI.01921-10
   Soriano V, 2000, J MED VIROL, V61, P111, DOI 10.1002/(SICI)1096-9071(200005)61:1<111::AID-JMV18>3.0.CO;2-W
   Sousa AE, 2001, J INFECT DIS, V184, P552, DOI 10.1086/322804
   Tendeiro R, 2012, AIDS, V26, P1065, DOI 10.1097/QAD.0b013e32835374db
   Tienen Carla van, 2010, J Acquir Immune Defic Syndr, V53, P640, DOI 10.1097/QAI.0b013e3181bf1a25
   TONGSTARKSEN SE, 1990, J IMMUNOL, V145, P4348
   UNAIDS, 2011, UNAIDS REP GLOB AIDS
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   van der Loeff MFS, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-46
   van der Loeff MFS, 2003, AIDS, V17, P2389, DOI 10.1097/01.aids.0000076344.42412.05
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   van der Loeff MFS, 2002, AIDS, V16, P1775
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   Willey SJ, 2003, J VIROL, V77, P6138, DOI 10.1128/JVI.77.11.6138-6152.2003
   Wood BR, 2012, AIDS PATIENT CARE ST, V26, P383, DOI 10.1089/apc.2012.0048
   Ylinen LMJ, 2005, J VIROL, V79, P11580, DOI 10.1128/JVI.79.18.11580-11587.2005
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 107
TC 34
Z9 34
U1 4
U2 52
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1052-9276
J9 REV MED VIROL
JI Rev. Med. Virol.
PD JUL
PY 2013
VL 23
IS 4
BP 221
EP 240
DI 10.1002/rmv.1739
PG 20
WC Virology
SC Virology
GA 175AV
UT WOS:000321202500003
PM 23444290
OA No
DA 2017-08-15
ER

PT J
AU Oluwalana, C
   Howie, SRC
   Secka, O
   Ideh, RC
   Ebruke, B
   Sambou, S
   Erskine, J
   Lowe, Y
   Corrah, T
   Adegbola, RA
AF Oluwalana, Claire
   Howie, Stephen R. C.
   Secka, Ousman
   Ideh, Readon C.
   Ebruke, Bernard
   Sambou, Sana
   Erskine, James
   Lowe, Yamundow
   Corrah, Tumani
   Adegbola, Richard A.
TI Incidence of Haemophilus influenzae Type b Disease in The Gambia 14
   Years after Introduction of Routine Haemophilus influenzae Type b
   Conjugate Vaccine Immunization
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID HIB DISEASE; ELIMINATION
AB Objective Haemophilus influenzae type b (Hib) conjugate vaccine was first introduced in Africa in The Gambia in 1997 as a primary 3-dose course in infancy with no booster, and was followed by the disappearance of invasive Hib disease by 2002. A cluster of cases detected non-systematically in post-infant children in 2005-2006 raised the question of the need for a booster dose. The objective of this study was to determine the incidence of invasive Hib disease in Gambian children 14 years after the introduction of Hib conjugate vaccine.
   Study design This hospital-based clinical and microbiological Hib disease surveillance in 3 hospitals in the western region of The Gambia was undertaken between October 2007 and December 2010 applying the same methods used in a previous Hib vaccine effectiveness study in 1997-2002.
   Results The annual incidences of Hib meningitis and all invasive Hib disease in children aged <5 years remained below 5 cases per 100 000 children during 2008-2010. The median age of patients with any invasive Hib disease was 5 months.
   Conclusion Hib conjugate vaccination as a primary 3-dose course in The Gambia remains highly effective in controlling invasive Hib disease, and current data do not support the introduction of a booster dose.
C1 [Oluwalana, Claire; Howie, Stephen R. C.; Secka, Ousman; Ideh, Readon C.; Ebruke, Bernard; Corrah, Tumani; Adegbola, Richard A.] MRC Unit, Banjul, Gambia.
   [Sambou, Sana; Lowe, Yamundow] Minist Hlth & Social Welf, Banjul, Gambia.
   [Erskine, James] Worldwide Evangelisat Christ Int WEC Hosp, Sibanor, Gambia.
   [Adegbola, Richard A.] GlaxoSmithKline Vaccines, Wavre, Belgium.
RP Howie, SRC (reprint author), MRC Unit, POB 273, Banjul, Gambia.
EM showie@mrc.gm
FU GAVI Hib Initiative and Medical Research Council UK; Medical Research
   Council Unit, The Gambia
FX R.A. is an employee of GlaxoSmithKline Vaccines (Belgium) and has
   received grants for studies of bacterial diseases while working as an
   employee of the Medical Research Council Unit, The Gambia. The authors
   declare no conflicts of interest, real or perceived.; Funded by the GAVI
   Hib Initiative and Medical Research Council UK.
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Fitzwater SP, 2010, HUM VACCINES, V6, P810, DOI 10.4161/hv.6.10.13017
   Hajjeh RA, 2010, VACCINE, V28, P7123, DOI 10.1016/j.vaccine.2010.07.028
   Howie SRC, 2007, VACCINE, V25, P6305, DOI 10.1016/j.vaccine.2007.06.023
   Ojo LR, 2010, VACCINE, V28, P7117, DOI 10.1016/j.vaccine.2010.07.074
   Peltola H, 2000, CLIN MICROBIOL REV, V13, P302, DOI 10.1128/CMR.13.2.302-317.2000
   Ramsay ME, 2003, J INFECT DIS, V188, P481, DOI 10.1086/376997
   Rijkers GT, 2003, LANCET, V361, P1563, DOI 10.1016/S0140-6736(03)13201-1
   Swingler G, 2003, COCHRANE DB SYST REV
   Trotter C L, 2003, Commun Dis Public Health, V6, P55
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   World Health Organization, 2006, WKLY EPIDEMIOL REC, V81, P445
NR 12
TC 6
Z9 6
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD JUL
PY 2013
VL 163
IS 1
SU S
BP S4
EP S7
DI 10.1016/j.jpeds.2013.03.023
PG 4
WC Pediatrics
SC Pediatrics
GA 167RW
UT WOS:000320652700002
PM 23773593
OA No
DA 2017-08-15
ER

PT J
AU Richards, AA
   Fulford, AJ
   Prentice, AM
   Moore, SE
AF Richards, Anna A.
   Fulford, Anthony J.
   Prentice, Andrew M.
   Moore, Sophie E.
TI Birth weight, season of birth and postnatal growth do not predict levels
   of systemic inflammation in gambian adults
SO AMERICAN JOURNAL OF HUMAN BIOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS;
   LOW-GRADE INFLAMMATION; FACTOR-VII CONCENTRATIONS; BODY-MASS INDEX;
   CATCH-UP GROWTH; BLOOD-PRESSURE; GESTATIONAL-AGE; YOUNG ADULTHOOD
AB Objectives Studies testing whether systemic inflammation might lie on the causal pathway between aberrant fetal and post-natal growth patterns and later cardiovascular disease have been inconclusive, possibly due to the use of single markers of unknown predictive value. We used repeated measures of a comprehensive set of inflammatory markers to investigate the relationship between early life measures and systemic inflammation in an African population. Methods Individuals born in three rural villages in The Gambia, and for whom early life measurements were recorded, were traced (n=320). Fasting levels of eight inflammatory markers (C-reactive protein, serum amyloid A, orosomucoid, fibrinogen, 1-antichymotrypsin, sialic acid, interleukin-6 and neopterin) were measured, and potential confounding factors recorded. The association between early life measurements and systemic inflammation was assessed using regression analysis. Results Levels of most markers were unrelated to early growth patterns. In analyses adjusted for age and sex, more rapid growth between birth and 3 months of age was associated with higher levels of fibrinogen, orosomucoid, and sialic acid. These relationships persisted after further adjustment for body mass index but after full adjustment only the association with fibrinogen remained. Conclusions This study provides little evidence that size at birth or growth in early infancy determine levels of inflammatory markers in young Gambian adults. Am. J. Hum. Biol. 25:457-464, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Richards, Anna A.; Fulford, Anthony J.; Prentice, Andrew M.; Moore, Sophie E.] Univ London London Sch Hyg & Trop Med, Dept Populat Hlth, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Fulford, Anthony J.; Prentice, Andrew M.; Moore, Sophie E.] MRC Unit Gambia, MRC Keneba, Banjul, Gambia.
RP Moore, SE (reprint author), Univ London London Sch Hyg & Trop Med, Dept Populat Hlth, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM sophie.moore@lshtm.ac.uk
FU MRC Research Grant [G0500048]; MRC core funding to the International
   Nutrition Group [MC-A760-5QX00]
FX Contract grant sponsor: MRC Research Grant; Contract grant number:
   G0500048; Contract grant sponsor: MRC core funding to the International
   Nutrition Group; Contract grant number: MC-A760-5QX00.
CR Adair LS, 2007, AM J HUM BIOL, V19, P327, DOI 10.1002/ajhb.20587
   Baird J, 2005, BRIT MED J, V331, P929, DOI 10.1136/bmj.38586.411273.E0
   BARKER DJP, 1992, BRIT MED J, V304, P148
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Browning LM, 2004, METABOLISM, V53, P899, DOI 10.1016/j.metabol.2004.01.013
   Canoy D, 2009, J CLIN ENDOCR METAB, V94, P1916, DOI 10.1210/jc.2008-2545
   Chalmers J, 1999, J HYPERTENS, V17, P151
   Cook DG, 1999, AM J EPIDEMIOL, V150, P727
   Cook DG, 2000, ATHEROSCLEROSIS, V149, P139, DOI 10.1016/S0021-9150(99)00312-3
   Danesh J, 2000, BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199
   Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477
   Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804
   Dobbelsteyn CJ, 2001, INT J OBESITY, V25, P652, DOI 10.1038/sj.ijo.0801582
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   FALL CHD, 1995, BRIT MED J, V310, P428
   Forsen T, 1997, BRIT MED J, V315, P837
   Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7
   Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Genuth S, 2003, DIABETES CARE, V26, P3160
   Gillman MW, 2002, INT J EPIDEMIOL, V31, P294, DOI 10.1093/ije/31.2.294
   Gillum RF, 2003, J NATL MED ASSOC, V95, P545
   Gurven M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006590
   Hemachandra AH, 2007, PEDIATRICS, V119, pE1264, DOI 10.1542/peds.2005-2486
   Horta BL, 2003, J EPIDEMIOL COMMUN H, V57, P226, DOI 10.1136/jech.57.3.226
   Jarvelin MR, 2004, HYPERTENSION, V44, P838, DOI 10.1161/01.HYP.0000148304.33869.ee
   Kuh D., 1997, LIFE COURSE APPROACH
   Leger J, 1997, BRIT MED J, V315, P341
   Leon DA, 1998, BRIT MED J, V317, P241
   LINDBERG G, 1993, ATHEROSCLEROSIS, V103, P123, DOI 10.1016/0021-9150(93)90255-S
   Lucas A, 1999, BRIT MED J, V319, P245
   Macy EM, 1997, CLIN CHEM, V43, P52
   MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142
   McDade TW, 2012, AM J HUM BIOL, V24, P675, DOI 10.1002/ajhb.22296
   McDade TW, 2010, P ROY SOC B-BIOL SCI, V277, P1129, DOI 10.1098/rspb.2009.1795
   Min JW, 2007, J HUM HYPERTENS, V21, P868, DOI 10.1038/sj.jhh.1002215
   Monteiro POA, 2005, OBES REV, V6, P143, DOI 10.1111/j.1467-789X.2005.00183.x
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Nazmi A, 2009, AM J HUM BIOL, V21, P192, DOI 10.1002/ajhb.20852
   Ockene IS, 2001, CLIN CHEM, V47, P444
   Oldroyd JC, 2009, ATHEROSCLEROSIS, V207, P227, DOI 10.1016/j.atherosclerosis.2009.03.045
   Ong KK, 2006, ACTA PAEDIATR, V95, P904, DOI 10.1080/08035250600719754
   Raqib R, 2007, AM J CLIN NUTR, V85, P845
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   RichEdwards JW, 1997, BRIT MED J, V315, P396
   Roseboom TJ, 2000, BRIT J HAEMATOL, V111, P112, DOI 10.1046/j.1365-2141.2000.02268.x
   Sattar N, 2004, ARTERIOSCL THROM VAS, V24, P583, DOI 10.1161/01.ATV.0000118277.41584.63
   Soto N, 2003, J CLIN ENDOCR METAB, V88, P3645, DOI 10.1210/jc.2002-030031
   Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3
   Tzoulaki I, 2008, EUR HEART J, V29, P1049, DOI 10.1093/eurheartj/ehn105
   Whincup PH, 1996, BRIT MED J, V313, P79
   World Health Organization, 2000, 894 WHO
NR 52
TC 3
Z9 3
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1042-0533
J9 AM J HUM BIOL
JI Am. J. Hum. Biol.
PD JUL-AUG
PY 2013
VL 25
IS 4
BP 457
EP 464
DI 10.1002/ajhb.22413
PG 8
WC Anthropology; Biology
SC Anthropology; Life Sciences & Biomedicine - Other Topics
GA 167WE
UT WOS:000320665300002
PM 23754612
OA No
DA 2017-08-15
ER

PT J
AU Risk, R
   Naismith, H
   Burnett, A
   Moore, SE
   Cham, M
   Unger, S
AF Risk, Rachel
   Naismith, Hamish
   Burnett, Alexander
   Moore, Sophie E.
   Cham, Mamady
   Unger, Stefan
TI Rational prescribing in paediatrics in a resource-limited setting
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID DRUG-USE PRACTICES; OUTPATIENT CHILDREN; CARE PHYSICIANS; KHARTOUM
   STATE; HEALTH; SUDAN; FACILITIES; HOSPITALS; DISTRICT; TRENDS
AB Introduction There is evidence of inappropriate medication use, causing unnecessary costs for health systems, particularly those with limited resources. Overprescription is commonly reported and can lead to antibiotic resistance. Prescribing patterns differ between countries; little is known about paediatric prescribing practices in Africa.
   Objectives To investigate prescribing practices in children in The Gambia, West Africa.
   Method A retrospective survey of prescribing practices in children under 5 years of age based on WHO protocol DAP/93.1 was conducted. Twenty government-run health centres across all six regions in The Gambia were assessed. The first 10 encounters each month in 2010 were recorded. For each encounter, patient demographics, diagnoses and medications were recorded as per protocol.
   Results Two thousand and four hundred patient encounters were included. The mean number of medications per encounter was 2.2 (median 2.0, IQR 2.0-3.0). Across different geographical regions within The Gambia antibiotics were prescribed in 63.4% (IQR 62.8-65.8%) and micronutrients in 21.7% (IQR 15.3-27.1%) of patient encounters. There was evidence of high antibiotic prescription in children with cough and coryzal symptoms (54.5%; IQR 35.8-59.0%) and simple diarrhoea without dehydration (44.8%; IQR 36.7-61.3%). 74.8% (IQR 71.8-76.1%) of medications were prescribed generically.
   Conclusions The study showed an overprescription of antibiotics and substantial usage of micronutrients despite a lack of international evidence-based guidelines. Cost-effective interventions to improve prescribing practices are called for and more studies with a focus on rational prescribing in paediatrics in low-income settings are urgently required to fill the gap in current knowledge.
C1 [Risk, Rachel; Naismith, Hamish; Burnett, Alexander] Univ Edinburgh, Edinburgh Med Sch, Edinburgh, Midlothian, Scotland.
   [Moore, Sophie E.; Unger, Stefan] MRC, Int Nutr Grp, Gambia Unit, Keneba, Gambia.
   [Cham, Mamady] Minist Hlth & Social Welf, Banjul, Gambia.
RP Unger, S (reprint author), MRC, MRC Unit Gambia, Int Nutr Grp, POB 273, Banjul, Gambia.
EM sunger@doctors.net.uk
FU Medical Research Council (MRC) UK [MC-A760-5QX00]
FX This work was supported by the Medical Research Council (MRC) UK core
   funding to the MRC International Nutrition Group (MC-A760-5QX00). The
   source of funding did not influence study methods or interpretation of
   the results.
CR Ahmed AM, 2010, ANN PHARMACOTHER, V44, P1986, DOI 10.1345/aph.1P423
   Awad A, 2010, EUR J CLIN PHARMACOL, V66, P1247, DOI 10.1007/s00228-010-0872-8
   Awad AI, 2006, EUR J CLIN PHARMACOL, V62, P1087, DOI 10.1007/s00228-006-0216-x
   Basu S, 2008, NIGER J CLIN PRACT, V11, P52
   Cheraghali AM, 2009, PHARM WORLD SCI, V31, P209, DOI 10.1007/s11096-009-9282-3
   Clavenna A, 2009, EUR J PEDIATR, V168, P173, DOI 10.1007/s00431-008-0725-y
   Clavenna A, 2009, EUR J CLIN PHARMACOL, V65, P749, DOI 10.1007/s00228-009-0679-7
   Das N., 2001, JPMA (Journal of the Pakistan Medical Association), V51, P74
   Department of State for Health and Social Welfare, 2001, STAND DRUG TREATM GU
   HOGERZEIL HV, 1993, LANCET, V342, P1408, DOI 10.1016/0140-6736(93)92760-Q
   Hulscher MEJL, 2010, INT J MED MICROBIOL, V300, P351, DOI 10.1016/j.ijmm.2010.04.003
   Imdad A, 2011, CURR OPIN CLIN NUTR, V14, P276, DOI 10.1097/MCO.0b013e328345364a
   Jasseh M, 2011, TROP MED INT HEALTH, V16, P1314, DOI 10.1111/j.1365-3156.2011.02809.x
   Kaushal R, 2004, AMBUL PEDIATR, V4, P73, DOI 10.1367/1539-4409(2004)004<0073:PMEWDW>2.0.CO;2
   Keohavong B, 2006, PHARMACOEPIDEM DR S, V15, P344, DOI 10.1002/pds.1169
   Lamichhane D C, 2006, Mcgill J Med, V9, P126
   Massele A Y, 2001, East Afr Med J, V78, P510
   McCaig LF, 2002, JAMA-J AM MED ASSOC, V287, P3096, DOI 10.1001/jama.287.23.3096
   Nsimba SED, 2007, TROP DOCT, V37, P197, DOI 10.1258/004947507782333099
   Nsimba Stephen Elias Damson, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P206
   Nwolisa CE, 2006, J TROP PEDIATRICS, V52, P197, DOI 10.1093/tropej/fmi095
   Pandey Anuja A, 2010, Indian J Community Med, V35, P70, DOI 10.4103/0970-0218.62564
   Pavin M, 2003, TROP MED INT HEALTH, V8, P182, DOI 10.1046/j.1365-3156.2003.00992.x
   Ramakrishnan U, 2011, J NUTR, V141, P2066, DOI 10.3945/jn.111.146845
   Roumie CL, 2005, J GEN INTERN MED, V20, P697, DOI 10.1111/j.1525-1497.2005.0148.x
   Sanz E, 2004, EUR J CLIN PHARMACOL, V60, P127, DOI 10.1007/s00228-004-0739-y
   Siddiqi S, 2002, INT J HEALTH PLAN M, V17, P23, DOI 10.1002/hpm.650
   World Health Organization, 2000, WHO REP INF DIS 2000
   WHO, 1993, INV DRUG US HLTH FAC
   World Health Organization, 2001, WHO GLOB STRAT CONT
   WHO, 2010, MED RAT US MED
   World Health Organization, 2010, GAMB FACTSH HLTH STA
   World Health Organization, 2010, INT STAT CLASS DIS R
   World Health Organization, 2006, INJ SAF
   The World Bank, WE CLASS COUNTR
NR 35
TC 14
Z9 15
U1 0
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD JUL
PY 2013
VL 98
IS 7
BP 503
EP 509
DI 10.1136/archdischild-2012-302987
PG 7
WC Pediatrics
SC Pediatrics
GA 161BZ
UT WOS:000320167400007
PM 23661572
OA No
DA 2017-08-15
ER

PT J
AU van der Hoek, W
   Sarge-Njie, R
   Herremans, T
   Chisnall, T
   Okebe, J
   Oriero, E
   Versteeg, B
   Goossens, B
   van der Sande, M
   Kampmann, B
   Nwakanma, D
AF van der Hoek, Wim
   Sarge-Njie, Ramu
   Herremans, Tineke
   Chisnall, Thomas
   Okebe, Joseph
   Oriero, Eniyou
   Versteeg, Bart
   Goossens, Bart
   van der Sande, Marianne
   Kampmann, Beate
   Nwakanma, Davis
TI Short Communication: Prevalence of antibodies against Coxiella burnetii
   (Q fever) in children in The Gambia, West Africa
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Q fever; Coxiella burnetii; seroprevalence; fever; Gambia
ID SPOTTED-FEVER; SEROPREVALENCE; NETHERLANDS; POPULATION; INFECTION;
   TANZANIA; TYPHUS
AB Objective To estimate the prevalence of antibodies against Coxiella burnetii (Q fever) among children in eight villages in The Gambia, West Africa. Methods Sera of 796 children aged 1-15years were tested for presence of antibodies against phase II of C.burnetii by ELISA. Results IgG and/or IgM phase II antibodies against C.burnetii were detectable in 8.3% (66/796) of all serum samples analysed with significant differences in seroprevalence between villages. Highest prevalence was found in the age group 1-4years. Conclusions Exposure to C.burnetii is considerable in the early years of life in The Gambia, and further studies are warranted to estimate the role of Q fever in acute febrile illness in The Gambia and elsewhere in Africa.
C1 [van der Hoek, Wim; Herremans, Tineke; Versteeg, Bart; van der Sande, Marianne] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
   [Sarge-Njie, Ramu; Okebe, Joseph; Oriero, Eniyou; Kampmann, Beate; Nwakanma, Davis] MRC Unit, Banjul, Gambia.
   [Chisnall, Thomas] Univ Manchester, Manchester, Lancs, England.
   [Goossens, Bart] SOS Childrens Villages Int, Bakau, Gambia.
   [van der Sande, Marianne] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
RP van der Hoek, W (reprint author), Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, POB 1, NL-3720 BA Bilthoven, Netherlands.
EM wim.van.der.hoek@rivm.nl
OI Kampmann, Beate/0000-0002-6546-4709
FU Medical Research Council [MC_UP_A900_1122, MC_EX_MR/K011944/1,
   MC_UP_A900_1117]
CR Blaauw GJ, 2012, EPIDEMIOL INFECT, V140, P36, DOI 10.1017/S0950268811000021
   Cardenosa N, 2006, AM J TROP MED HYG, V75, P33
   Ceesay SJ, 2010, PLOS ONE, V5
   Dijkstra F, 2012, FEMS IMMUNOL MED MIC, V64, P3, DOI 10.1111/j.1574-695X.2011.00876.x
   ECDC, 2010, RISK ASS Q FEV
   Gething PW, 2010, PLOS MED, V7
   Kobbe R, 2008, EMERG INFECT DIS, V14, P344, DOI 10.3201/eid1402.070971
   Maltezou HC, 2002, LANCET INFECT DIS, V2, P686, DOI 10.1016/S1473-3099(02)00440-1
   Okabayashi T, 1999, AM J TROP MED HYG, V61, P70
   Parker N, 2010, AUST NZ J PUBL HEAL, V34, P79, DOI 10.1111/j.1753-6405.2010.00478.x
   Prabhu M, 2011, CLIN INFECT DIS, V53, pe8, DOI 10.1093/cid/cir411
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   RICHARDUS JH, 1987, EPIDEMIOL INFECT, V98, P211
   Schimmer B, 2012, EPIDEMIOL INFECT, V140, P27, DOI 10.1017/S0950268811000136
   Steinmann P, 2005, TROP MED INT HEALTH, V10, P612, DOI 10.1111/j.1365-3156.2005.01420.x
   Teunis PFM, 2013, EPIDEMIOL INFECT, V141, P62, DOI 10.1017/S0950268812000404
NR 16
TC 6
Z9 6
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUL
PY 2013
VL 18
IS 7
BP 850
EP 853
DI 10.1111/tmi.12116
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 163KR
UT WOS:000320335400008
PM 23600611
OA No
DA 2017-08-15
ER

PT J
AU Takem, EN
   Affara, M
   Amambua-Ngwa, A
   Okebe, J
   Ceesay, SJ
   Jawara, M
   Oriero, E
   Nwakanma, D
   Pinder, M
   Clifford, C
   Taal, M
   Sowe, M
   Suso, P
   Mendy, A
   Mbaye, A
   Drakeley, C
   D'Alessandro, U
AF Takem, Ebako N.
   Affara, Muna
   Amambua-Ngwa, Alfred
   Okebe, Joseph
   Ceesay, Serign J.
   Jawara, Musa
   Oriero, Eniyou
   Nwakanma, Davis
   Pinder, Margaret
   Clifford, Caitlin
   Taal, Makie
   Sowe, Momodou
   Suso, Penda
   Mendy, Alphonse
   Mbaye, Amicoleh
   Drakeley, Chris
   D'Alessandro, Umberto
TI Detecting Foci of Malaria Transmission with School Surveys: A Pilot
   Study in the Gambia
SO PLOS ONE
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; PLASMODIUM-FALCIPARUM; PRESCHOOL-CHILDREN;
   NUTRITIONAL-STATUS; CLINICAL MALARIA; WESTERN KENYA; AFRICA; AREA;
   SCHOOLCHILDREN; SURVEILLANCE
AB Background: In areas of declining malaria transmission such as in The Gambia, the identification of malaria infected individuals becomes increasingly harder. School surveys may be used to identify foci of malaria transmission in the community.
   Methods: The survey was carried out in May-June 2011, before the beginning of the malaria transmission season. Thirty two schools in the Upper River Region of The Gambia were selected with probability proportional to size; in each school approximately 100 children were randomly chosen for inclusion in the study. Each child had a finger prick blood sample collected for the determination of antimalarial antibodies by ELISA, malaria infection by microscopy and PCR, and for haemoglobin measurement. In addition, a simple questionnaire on socio-demographic variables and the use of insecticide-treated bed nets was completed. The cut-off for positivity for antimalarial antibodies was obtained using finite mixture models. The clustered nature of the data was taken into account in the analyses.
   Results: A total of 3,277 children were included in the survey. The mean age was 10 years (SD = 2.7) [range 4-21], with males and females evenly distributed. The prevalence of malaria infection as determined by PCR was 13.6% (426/3124) [95% CI = 12.2-16.3] with marked variation between schools (range 3-25%, p < 0.001), while the seroprevalence was 7.8% (234/2994) [95% CI = 6.4-9.8] for MSP1(19), 11.6% (364/2997) [95% CI = 9.4-14.5] for MSP2, and 20.0% (593/2973) [95% CI = 16.5-23.2) for AMA1. The prevalence of all the three antimalarial antibodies positive was 2.7% (79/2920).
   Conclusions: This survey shows that malaria prevalence and seroprevalence before the transmission season were highly heterogeneous.
C1 [Takem, Ebako N.; Affara, Muna; Amambua-Ngwa, Alfred; Okebe, Joseph; Ceesay, Serign J.; Jawara, Musa; Oriero, Eniyou; Nwakanma, Davis; Pinder, Margaret; D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Clifford, Caitlin] Univ Manchester, Manchester, Lancs, England.
   [Taal, Makie; Sowe, Momodou; Suso, Penda; Mendy, Alphonse] Natl Publ Hlth Lab, Kotu, Gambia.
   [Mbaye, Amicoleh] Minist Basic & Secondary Educ, Banjul, Gambia.
   [Drakeley, Chris] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
RP Takem, EN (reprint author), MRC Unit, Fajara, Gambia.
EM etakem@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Medical Research Council Unit, The Gambia
FX The study was funded by Medical Research Council Unit, The Gambia (core
   funding). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ashton RA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-25
   Ayi I, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-98
   Bejon P, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000304
   Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309
   Bojang K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011225
   Bousema T, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001165
   Brooker S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-231
   CAMPBELL H, 1987, LANCET, V1, P859
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Clarke SE, 2004, AM J TROP MED HYG, V71, P732
   Corran PH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-195
   Corran PH, 2004, INFECT IMMUN, V72, P6185, DOI 10.1128/IAI.72.10.6185-6189.2004
   Crookston BT, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-39
   Custodio E, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-225
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497
   Deribew A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010775
   Dodoo D, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-108
   Egan AF, 1996, J INFECT DIS, V173, P765
   Fillol F, 2009, AM J TROP MED HYG, V80, P202
   Friedman JF, 2005, AM J TROP MED HYG, V73, P698
   Gitonga CW, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-306
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hay SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0
   Kazadi W, 2004, AM J TROP MED HYG, V71, P97
   Kirby MJ, 2009, LANCET, V374, P998, DOI 10.1016/S0140-6736(09)60871-0
   Kirby MJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-2
   Koukounari A, 2008, INT J PARASITOL, V38, P1663, DOI 10.1016/j.ijpara.2008.05.013
   Lee PW, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-26
   Magnussen P, 2001, TROP MED INT HEALTH, V6, P273, DOI 10.1046/j.1365-3156.2001.00720.x
   Metzger WG, 2003, PARASITE IMMUNOL, V25, P307, DOI 10.1046/j.1365-3024.2003.00636.x
   Midzi N, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-169
   Moore SE, 2003, ACTA PAEDIATR, V92, P170
   Ndyomugyenyi R, 2007, TROP MED INT HEALTH, V12, P230, DOI 10.1111/j.1365-3165.2006.01767.x
   Nebie I, 2008, INFECT IMMUN, V76, P759, DOI 10.1128/IAI.01147-07
   Oduro AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026305
   Okello G, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-185
   Ong'echa JM, 2006, AM J TROP MED HYG, V74, P376
   Otten M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-14
   Poskitt EME, 1999, ARCH DIS CHILD, V80, P115
   RILEY EM, 1993, PARASITE IMMUNOL, V15, P513, DOI 10.1111/j.1365-3024.1993.tb00639.x
   Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004
   Satoguina J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-274
   Sesay S, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-2
   Smith DL, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-131
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8
   Teklehaimanot HD, 2009, AM J TROP MED HYG, V80, P133
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   Tongren JE, 2006, INFECT IMMUN, V74, P257, DOI 10.1128/IAI.74.1.257-264.2006
   Wang SJ, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-40
   WHO, 2012, WORLD MALARIA REPORT 2012, P1
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   World Health Organization:, 2007, MAL EL FIELD MAN LOW
   WHO, 1995, PHYS STAT US INT ANT
NR 56
TC 8
Z9 8
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 27
PY 2013
VL 8
IS 6
AR e67108
DI 10.1371/journal.pone.0067108
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 174IX
UT WOS:000321150000028
PM 23826205
OA gold
DA 2017-08-15
ER

PT J
AU Yang, HM
   Duvall, S
   Ratcliffe, A
   Jeffries, D
   Stevens, W
AF Yang, Hongmei
   Duvall, Susan
   Ratcliffe, Amy
   Jeffries, David
   Stevens, Warren
TI Modeling health impact of global health programs implemented by
   Population Services International
SO BMC PUBLIC HEALTH
LA English
DT Article
ID HIV-1 TRANSMISSION; MALE CIRCUMCISION; COITAL ACT; INFECTION; UGANDA;
   RAKAI; PROBABILITY; PREVENTION; THERAPY; TRIAL
AB Background: Global health implementing organizations benefit most from health impact estimation models that isolate the individual effects of distributed products and services - a feature not typically found in intervention impact models, but which allow comparisons across interventions and intervention settings. Population Services International (PSI), a social marketing organization, has developed a set of impact models covering seven health program areas, which translate product/service distribution data into impact estimates. Each model's primary output is the number of disability-adjusted life-years (DALYs) averted by an intervention within a specific country and population context. This paper aims to describe the structure and inputs for two types of DALYs averted models, considering the benefits and limitations of this methodology.
   Methods: PSI employs two modeling approaches for estimating health impact: a macro approach for most interventions and a micro approach for HIV, tuberculosis (TB), and behavior change communication (BCC) interventions. Within each intervention country context, the macro approach determines the coverage that one product/service unit provides a population in person-years, whereas the micro approach estimates an individual's risk of infection with and without the product/service unit. The models use these estimations to generate per unit DALYs averted coefficients for each intervention. When multiplied by program output data, these coefficients predict the total number of DALYs averted by an intervention in a country.
   Results: Model outputs are presented by country for two examples: Water Chlorination DALYs Averted Model, a macro model, and the HIV Condom DALYs Averted Model for heterosexual transmission, a micro model. Health impact estimates measured in DALYs averted for PSI interventions on a global level are also presented.
   Conclusions: The DALYs averted models offer implementing organizations practical measurement solutions for understanding an intervention's contribution to improving health. These models calculate health impact estimates that reflect the scale and diversity of program operations and intervention settings, and that enable comparisons across health areas and countries. Challenges remain in accounting for intervention synergies, attributing impact to a single organization, and sourcing and updating model inputs. Nevertheless, these models demonstrate how DALYs averted can be viably used by the global health community as a metric for predicting intervention impact using standard program output data.
C1 [Yang, Hongmei; Ratcliffe, Amy] Populat Serv Int, Washington, DC USA.
   [Duvall, Susan] Independent Global Hlth Consultant, Seattle, WA USA.
   [Jeffries, David] Independent Consultant, Fajara, Gambia.
   [Stevens, Warren] Independent Hlth Econ Consultant, Boston, MA USA.
RP Yang, HM (reprint author), Populat Serv Int, Washington, DC USA.
EM hyang@psi.org
FU Population Services International; technical departments at PSI
FX We would like to thank all of those who provided input into the
   development of PSI's DALYs averted models. In particular, we would like
   to thank our PSI colleagues for providing the data to feed into the
   models. We also wish to acknowledge the support we enjoyed from
   technical departments at PSI, especially their help with understanding
   each program. We are grateful to Peter Vickerman (London School of
   Hygiene and Tropical Medicine), Simon Gregson (Imperial College, London)
   and Steven Forsythe (Futures Institute) for their review of the HIV
   condom model and their constructive comments. We would also like to
   thank Lek Ngamkitpaiboon at PSI for generating model outputs from which
   we produced our results. Our sincere thanks also to Kim Longfield, Julie
   Archer, and other colleagues at Population Services International for
   reviewing this paper and organizing this series. Finally, we appreciate
   the funding support that Population Services International provided for
   the development of this paper.; This article is part of the supplement
   of BMC Public Health Volume 13, Supplement 2, 2013: Use of health impact
   metrics for programmatic decision making in global health. Population
   Services International, a registered non-profit organization, provided
   the funding for the publication of this supplement. The full contents of
   the supplement are available online at
   http://www.biomedcentral.com/bmcpublichealth/supplements/13/S2.
CR Auvert B, 2005, PLOS MED, V11, P1111
   Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0
   Clasen T., 2006, COCHRANE LIB, P3
   Cole BL, 2007, ANNU REV PUBL HEALTH, V28, P393, DOI 10.1146/annurev.publhealth.28.083006.131942
   CORREA H, 1971, AM J PUBLIC HEALTH N, V61, P138, DOI 10.2105/AJPH.61.1.138
   Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2
   Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4
   Jayakumar B, 2011, WORLD VISION INT 201
   Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4
   Meekers D, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-5
   MOLINEAUX L, 1978, B WORLD HEALTH ORGAN, V56, P565
   Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6
   MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P481
   Myer L, 2001, AFR J REPROD HLTH, V5, P66, DOI 10.2307/3583199
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333
   Pinkerton SD, 1997, SOC SCI MED, V44, P1303, DOI 10.1016/S0277-9536(96)00258-4
   PSI Research & Metrics, 2007, EX US VOL COUNS TEST
   PSI Research & Metrics, 2008, EV KNOWL HIV STAT ME
   Rottingen JA, 2001, SEX TRANSM DIS, V28, P579
   SATTEN GA, 1994, STAT MED, V13, P2097, DOI 10.1002/sim.4780131918
   Thompson T, 2003, INT J ENVIRON HEAL R, V13, pS29, DOI [10.1080/09603120020019629, 10.1080/0960312031000102787]
   Todd J, 2007, AIDS, V21, pS55, DOI 10.1097/01.aids.0000299411.75269.e8
   Tumwine JK, 2002, TROP MED INT HEALTH, V7, P750, DOI 10.1046/j.1365-3156.2002.00927.x
   United Nations Population Division, 2011, GLOB HLTH OBS DAT RE
   UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention, 2009, PLOS MED, V6
   UNAIDS, 2010, GLOB REP UNAIDS REP
   Walker N, 2010, INT J EPIDEMIOL, V39, P21, DOI 10.1093/ije/dyq036
   Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411
   WHO, 2009, MORT BURD DIS EST WH
   Williams BG, 2006, PLOS MED, V3, P1032, DOI 10.1371/journal.pmed.0030262
   Winfrey W, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S32
   [Anonymous], 2011, PEPFAR GUID INT PREV
NR 35
TC 8
Z9 4
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD JUN 17
PY 2013
VL 13
SU 2
AR S3
DI 10.1186/1471-2458-13-S2-S3
PG 18
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 184OG
UT WOS:000321900300003
PM 23902668
OA gold
DA 2017-08-15
ER

PT J
AU Dixey, R
   Njai, M
AF Dixey, Rachael
   Njai, Modou
TI The call to action: health promotion in The Gambia - closing the
   implementation gap?
SO GLOBAL HEALTH PROMOTION
LA English
DT Article
DE capacity building; development; health promotion; Sub-Saharan Africa;
   The Gambia
ID AFRICA
AB This paper discusses the difficulties facing the development of health promotion in The Gambia, and in closing the implementation gap' noted by the WHO 7(th) Global Conference on Health Promotion (2009, Nairobi). The Gambia has achieved a great deal so far, but health promotion as a discipline has not really informed the development of its approach to health. There is not a central concern with determinants of health and tackling health inequalities and there is no well-developed health promotion infrastructure. The difficulties facing sub-Saharan Africa generally can be extrapolated from the paper, with the conclusion that sub-Saharan Africa faces many disease and health challenges not experienced by richer countries and thus not only does the discourse of health promotion need to take this into account, but also the basic needs of Africa need to be placed at the forefront.
C1 [Dixey, Rachael] Leeds Metropolitan Univ, Inst Hlth & Wellbeing, Leeds LS2 8NU, W Yorkshire, England.
   [Njai, Modou] Minist Hlth & Social Welf, Banjul, Gambia.
RP Dixey, R (reprint author), Leeds Metropolitan Univ, Inst Hlth & Wellbeing, Queen Sq House,80 Woodhouse Lane, Leeds LS2 8NU, W Yorkshire, England.
EM r.dixey@leedsmet.ac.uk
CR Abubakari AR, 2009, PUBLIC HEALTH, V123, P602, DOI 10.1016/j.puhe.2009.07.009
   Amunyunzu-Nyamongo M, 2009, EVIDENCE HLTH PROMOT
   Amunyunzu-Nyamongo M, 2009, EVIDENCE HLTH PROMOT, P179
   Asante FA, 2009, NATL SPENDING ASSESS
   Attwood M., 2003, LEADING CHANGE GUIDE
   Bah A, 2009, FOOD VULNERABILITY U
   Bartram J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000367
   Cassidy R, 2009, AFR AFFAIRS, V108, P559, DOI 10.1093/afraf/adp057
   Catford J, 2010, HEALTH PROMOT INT, V25, P1, DOI 10.1093/heapro/daq018
   Chopra M, 2005, CRITICAL PUBLIC HLTH, V15, P19, DOI 10.1080/09581590500048218
   Culp Kennith, 2007, Clin Nurs Res, V16, P170, DOI 10.1177/1054773807302399
   Department of State for Health and Social Welfare The Gambia, 2007, HLTH IS WEALTH HLTH
   Dixey R., 2009, INT J ENV CULTURAL E, V5, P301
   Dovlo D., 2003, REG TRAIN C IMPR TER
   Dovlo Delanyo, 2005, Hum Resour Health, V3, P6, DOI 10.1186/1478-4491-3-6
   Gambia Government, 2007, NAT DIS MAN POL
   Huddard J, 2003, HLTH SECTOR HUMAN RE
   Kebaabetswe PM, 2007, AIDS CARE, V19, P355, DOI 10.1080/09540120600942407
   Kuye Rex A, 2007, J Agromedicine, V12, P57
   Lamour Y., 2009, SITUATIONAL ANAL SAN
   Lave J., 1998, SITUATED LEARNING LE
   Mooney C, 2000, SOC SCI MED, V50, P1743, DOI 10.1016/S0277-9536(99)00414-1
   Nyamwaya D, 2003, HEALTH PROMOT INT, V18, P85, DOI 10.1093/heapro/18.2.85
   Nyamwaya D, 2009, EVIDENCE HLTH PROMOT, P13
   Onya Hans E, 2009, Glob Health Promot, V16, P47, DOI 10.1177/1757975909104104
   Peltzer Karl, 2007, Afr J Reprod Health, V11, P57
   Sanders D., 2008, Critical Public Health, V18, P509, DOI 10.1080/09581590802503076
   UNICEF, 2011, GLANC GAMB
   UNICEF TGo TGa, 2006, MULT IND CLUST SURV
   World Health Organization, 2008, PRIMARY HLTH CARE
   Woodall J, 2010, EMPOWERMENT HLTH WEL
NR 31
TC 4
Z9 4
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1757-9759
J9 GLOB HEALTH PROMOT
JI Glob. Health Promot.
PD JUN
PY 2013
VL 20
IS 2
BP 5
EP 12
DI 10.1177/1757975913486682
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 169FL
UT WOS:000320764100002
PM 23797935
OA No
DA 2017-08-15
ER

PT J
AU Harding-Esch, EM
   Sillah, A
   Edwards, T
   Burr, SE
   Hart, JD
   Joof, H
   Laye, M
   Makalo, P
   Manjang, A
   Molina, S
   Sarr-Sissoho, I
   Quinn, TC
   Lietman, T
   Holland, MJ
   Mabey, D
   West, SK
   Bailey, R
AF Harding-Esch, Emma M.
   Sillah, Ansumana
   Edwards, Tansy
   Burr, Sarah E.
   Hart, John D.
   Joof, Hassan
   Laye, Mass
   Makalo, Pateh
   Manjang, Ahmed
   Molina, Sandra
   Sarr-Sissoho, Isatou
   Quinn, Thomas C.
   Lietman, Tom
   Holland, Martin J.
   Mabey, David
   West, Sheila K.
   Bailey, Robin
CA Partnership Rapid Elimination Trac
TI Mass Treatment with Azithromycin for Trachoma: When Is One Round Enough?
   Results from the PRET Trial in The Gambia
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID OCULAR CHLAMYDIA-TRACHOMATIS; ACTIVE TRACHOMA; ANTIBIOTIC-TREATMENT;
   INFECTIOUS TRACHOMA; RISK-FACTORS; COMMUNITY; PREVALENCE; TANZANIA;
   ELIMINATION; STRATEGIES
AB Background: The World Health Organization has recommended three rounds of mass drug administration (MDA) with antibiotics in districts where the prevalence of follicular trachoma (TF) is >= 10% in children aged 1-9 years, with treatment coverage of at least 80%. For districts at 5-10% TF prevalence it was recommended that TF be assessed in 1-9 year olds in each community within the district, with three rounds of MDA provided to any community where TF >= 10%. Worldwide, over 40 million people live in districts whose TF prevalence is estimated to be between 5 and 10%. The best way to treat these districts, and the optimum role of testing for infection in deciding whether to initiate or discontinue MDA, are unknown.
   Methods: In a community randomized trial with a factorial design, we randomly assigned 48 communities in four Gambian districts, in which the prevalence of trachoma was known or suspected to be above 10%, to receive annual mass treatment with expected coverage of 80-89% ("Standard"), or to receive an additional visit in an attempt to achieve coverage of 90% or more ("Enhanced"). The same 48 communities were randomised to receive mass treatment annually for three years ("3x"), or to have treatment discontinued if Chlamydia trachomatis (Ct) infection was not detected in a sample of children in the community after mass treatment (stopping rule("SR")). Primary outcomes were the prevalence of TF and of Ct infection in 0-5 year olds at 36 months.
   Results: The baseline prevalence of TF and of Ct infection in the target communities was 6.5% and 0.8% respectively. At 36 months the prevalence of TF was 2.8%, and that of Ct infection was 0.5%. No differences were found between the arms in TF or Ct infection prevalence either at baseline (Standard-3x: TF 5.6%, Ct 0.7%; Standard-SR: TF 6.1%, Ct 0.2%; Enhanced-3x: TF 7.4%, Ct 0.9%; and Enhanced-SR: TF 6.2%, Ct 1.2%); or at 36 months (Standard-3x: TF 2.3%, Ct 1.0%; Standard-SR TF 2.5%, Ct 0.2%; Enhanced-3x TF 3.0%, Ct 0.2%; and Enhanced-SR TF 3.2%, Ct 0.7%). The implementation of the stopping rule led to treatment stopping after one round of MDA in all communities in both SR arms. Mean treatment coverage of children aged 0-9 in communities randomised to standard treatment was 87.7% at baseline and 84.8% and 88.8% at one and two years, respectively. Mean coverage of children in communities randomized to enhanced treatment was 90.0% at baseline and 94.2% and 93.8% at one and two years, respectively. There was no evidence of any difference in TF or Ct prevalence at 36 months resulting from enhanced coverage or from one round of MDA compared to three.
   Conclusions: The Gambia is close to the elimination target for active trachoma. In districts prioritised for three MDA rounds, one round of MDA reduced active trachoma to low levels and Ct infection was not detectable in any community. There was no additional benefit to giving two further rounds of MDA. Programmes could save scarce resources by determining when to initiate or to discontinue MDA based on testing for Ct infection, and one round of MDA may be all that is necessary in some settings to reduce TF below the elimination threshold.
C1 [Harding-Esch, Emma M.; Edwards, Tansy; Burr, Sarah E.; Hart, John D.; Molina, Sandra; Holland, Martin J.; Mabey, David; Bailey, Robin] London Sch Hyg & Trop Med, London WC1, England.
   [Sillah, Ansumana; Laye, Mass] Natl Eye Hlth Programme Gambia, Kanifing, Gambia.
   [Burr, Sarah E.; Hart, John D.; Joof, Hassan; Makalo, Pateh; Manjang, Ahmed; Sarr-Sissoho, Isatou; Holland, Martin J.] MRC Unit, Fajara, Gambia.
   [Quinn, Thomas C.] NIAID, Bethesda, MD 20892 USA.
   [Lietman, Tom] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [West, Sheila K.] Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA.
RP Harding-Esch, EM (reprint author), London Sch Hyg & Trop Med, London WC1, England.
EM Robin.Bailey@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276
FU Bill and Melinda Gates Foundation
FX This study was funded by a grant from the Bill and Melinda Gates
   Foundation. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Antal GM, 2002, MICROBES INFECT, V4, P83, DOI 10.1016/S1286-4579(01)01513-1
   Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   Burton MJ, 2011, INVEST OPHTH VIS SCI, V52, P6012, DOI 10.1167/iovs.11-7326
   Burton MJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000835
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Ekwaru JP, 2001, GEOGR ANAL, V33, P19
   Harding-Esch EM, 2008, T ROY SOC TROP MED H, V102, P1255, DOI 10.1016/j.trstmh.2008.04.022
   Harding-Esch EM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001234
   Harding-Esch EM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000861
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Holm SO, 2001, B WORLD HEALTH ORGAN, V79, P194
   Hsiang MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029550
   ITI, 2012, ITI FIGHT BLIND TRAC
   Lakew T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000507
   Michel CEC, 2006, LANCET, V367, P1585, DOI 10.1016/S0140-6736(06)68695-9
   Miller K, 2004, OPHTHAL EPIDEMIOL, V11, P255, DOI 10.1080/09286580490514577
   MORAN PAP, 1950, BIOMETRIKA, V37, P17, DOI 10.2307/2332142
   Ngondi J, 2009, T ROY SOC TROP MED H, V103, P1001, DOI 10.1016/j.trstmh.2008.11.023
   Pascolini D, 2011, BR J OPHTHALMOL, V65, P614
   Sillah A, 2006, GAMBIAN NATL PLAN TR
   Smith JL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000973
   Solomon AW, 2008, NEW ENGL J MED, V358, P1870, DOI 10.1056/NEJMc0706263
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   Ssemanda EN, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000838
   Stare D, 2011, OPHTHAL EPIDEMIOL, V18, P20, DOI 10.3109/09286586.2010.545500
   The Trachoma Atlas, TRACHOMA ATLAS
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   West S., COMMUNICATION
   West SK, 2005, LANCET, V366, P1296, DOI 10.1016/S0140-6736(05)67529-0
   World Health Organization, 2012, WKLY EPIDEMIOL REC, V87, P161
   WHO, 1998, WORLD HLTH ASS RES 5
   WHO, 2006, TRACH CONTR GUID PRO
   Zhaoxia Z, COMMUNICATION
NR 36
TC 18
Z9 18
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2013
VL 7
IS 6
AR e2115
DI 10.1371/journal.pntd.0002115
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 175AL
UT WOS:000321201300003
PM 23785525
OA gold
DA 2017-08-15
ER

PT J
AU Koehler, AV
   Bradbury, RS
   Stevens, MA
   Haydon, SR
   Jex, AR
   Gasser, RB
AF Koehler, Anson V.
   Bradbury, Richard S.
   Stevens, Melita A.
   Haydon, Shane R.
   Jex, Aaron R.
   Gasser, Robin B.
TI Genetic characterization of selected parasites from people with
   histories of gastrointestinal disorders using a mutation
   scanning-coupled approach
SO ELECTROPHORESIS
LA English
DT Article
DE Cryptosporidium; Giardia; Hookworm; Pathogen; Single-strand conformation
   polymorphism (SSCP) analysis
ID NEGLECTED TROPICAL DISEASES; HUMAN HOOKWORM INFECTION;
   CRYPTOSPORIDIUM-PARVUM; GIARDIA-DUODENALIS; MOLECULAR EPIDEMIOLOGY;
   ANCYLOSTOMA-CEYLANICUM; ZOONOTIC TRANSMISSION; INTESTINAL PARASITES;
   HELMINTH INFECTIONS; ISOMERASE GENE
AB A SSCP analysis and targeted sequencing approach was used for the genetic characterization of some major pathogens from a cohort of 227 people with histories of gastrointestinal disorders. Genomic DNAs from fecal samples were subjected to PCR-amplification of regions in the glycoprotein (gp60) or triose phosphate isomerase (tpi) gene, or the second internal transcribed spacer of nuclear ribosomal DNA (ITS-2). Cryptosporidium, Giardia, and strongylid nematodes were detected in 94, 132 and 12 samples. Cryptosporidium hominis subgenotypes IbA10G2, IdA15G1, IgA17, IgA18, and IfA13G1 were identified in 74.6, 16.9, 5.6, 1.4, and 1.4% of 71 samples, respectively. For Cryptosporidium parvum, subgenotypes IIaA17G2R1 (47.6%) and IIaA18G3R1 (23.8%) were identified in 23 samples. Giardia duodenalis assemblage B (78%) was more common than assemblage A (22%). In addition, DNA of the nematodes Ancylostoma ceylanicum (n= 2), Ancylostoma duodenale (4), Necator americanus (5), and Haemonchus contortus (1) was specifically detected. This is the first report of A. ceylanicum in two persons in Australia and, we provide molecular evidence of H. contortus in a child. This SSCP-based approach should provide a useful diagnostic and analytical tool for a wide range of pathogens.
C1 [Koehler, Anson V.; Jex, Aaron R.; Gasser, Robin B.] Univ Melbourne, Fac Vet Sci, Parkville, Vic 3010, Australia.
   [Bradbury, Richard S.] MRC, Int Nutr Grp, Keneba, Gambia.
   [Bradbury, Richard S.] Univ Tasmania, Sch Med, Hobart, Tas, Australia.
   [Stevens, Melita A.; Haydon, Shane R.] Melbourne Water Corp, Melbourne, Vic, Australia.
RP Koehler, AV (reprint author), Univ Melbourne, Fac Vet Sci, Corner Pk Dr,Flemington Rd, Parkville, Vic 3010, Australia.
EM anson.koehler@unimelb.edu.au; robinbg@unimelb.edu.au
RI Bradbury, Richard/N-3273-2013; Koehler, Anson/P-3658-2015
OI Bradbury, Richard/0000-0002-5524-506X; Koehler,
   Anson/0000-0001-8330-6416
FU Australian Research Council (ARC); National Health and Medical Research
   Council (NHMRC); Melbourne Water Corporation; Victorian Life Sciences
   Computation Initiative (VLSCI) [VR0007]; Alexander von Humboldt
   Foundation (RBG); IBM Research Collaboratory for Life Sciences-Melbourne
FX This project was funded by the Australian Research Council (ARC), the
   National Health and Medical Research Council (NHMRC), and Melbourne
   Water Corporation. This project was also supported by a Victorian Life
   Sciences Computation Initiative (VLSCI) grant number VR0007 on its Peak
   Computing Facility at The University of Melbourne, an initiative of the
   Victorian Government. Other support from the Alexander von Humboldt
   Foundation (RBG) and the IBM Research Collaboratory for Life
   Sciences-Melbourne is gratefully acknowledged. We thank the Path West
   Enteric Reference Laboratory and Western Diagnostic Pathology for
   providing samples.
CR Abeywardena H, 2012, INFECT GENET EVOL, V12, P1984, DOI 10.1016/j.meegid.2012.08.004
   Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4
   Caccio Simone M, 2006, Expert Rev Anti Infect Ther, V4, P429, DOI 10.1586/14787210.4.3.429
   CARROLL SM, 1986, T ROY SOC TROP MED H, V80, P406, DOI 10.1016/0035-9203(86)90326-3
   Chalmers RM, 2009, GIARDIA AND CRYPTOSPORIDIUM: FROM MOLECULES TO DISEASE, P147, DOI 10.1079/9781845933913.0147
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Davidson RK, 2012, TRENDS PARASITOL, V28, P239, DOI 10.1016/j.pt.2012.03.004
   Eckert J, 2004, CLIN MICROBIOL REV, V17, P107, DOI 10.1128/CMR.17.1.107-135.2004
   El-Osta YGA, 2003, MOL CELL PROBE, V17, P127, DOI 10.1016/S0890-8508(03)00030-6
   Feng YY, 2011, CLIN MICROBIOL REV, V24, P110, DOI 10.1128/CMR.00033-10
   Fletcher SM, 2012, CLIN MICROBIOL REV, V25, P420, DOI 10.1128/CMR.05038-11
   Furst T, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4093
   Furst T, 2011, LANCET INFECT DIS, V12, P210
   Garcia L. S., 1983, CLIN MICROBIOL NEWSL, V5, P60, DOI 10.1016/S0196-4399(83)80080-4
   Garcia L.S., 2009, PRACTICAL GUIDE DIAG
   Gasser RB, 1999, VET PARASITOL, V84, P229, DOI 10.1016/S0304-4017(99)00036-9
   Gasser RB, 2004, MOL CELL PROBE, V18, P329, DOI [10.1016/j.mcp.2004.05.002, 10.1016/j.mep.2004.05.002]
   GASSER RB, 1993, NUCLEIC ACIDS RES, V21, P2525, DOI 10.1093/nar/21.10.2525
   Gasser RB, 2003, APPL ENVIRON MICROB, V69, P2719, DOI 10.1128/AEM.69.5.2719-2730.2003
   Gasser RB, 2006, VET PARASITOL, V136, P69, DOI 10.1016/j.vetpar.2005.12.002
   Gasser RB, 2006, NAT PROTOC, V1, P3121, DOI 10.1038/nprot.2006.485
   Gasser RB, 2013, VET PARASITOL, V193, P353, DOI 10.1016/j.vetpar.2012.12.031
   GHADIRIAN E, 1973, J PARASITOL, V59, P1144, DOI 10.2307/3278661
   Hildreth M., 2012, MOL DETECTION HUMAN, P571
   Holt DC, 2010, INT J PARASITOL, V40, P1119, DOI 10.1016/j.ijpara.2010.04.002
   Hotez PJ, 2008, J CLIN INVEST, V118, P1311, DOI 10.1172/JCI34261
   Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142
   Hotez PJ, 2006, TRENDS PARASITOL, V22, P327, DOI 10.1016/j.pt.2006.05.004
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Jex AR, 2008, BIOTECHNOL ADV, V26, P304, DOI 10.1016/j.biotechadv.2008.02.003
   Jex AR, 2008, J CLIN MICROBIOL, V46, P2252, DOI 10.1128/JCM.00116-08
   Jex AR, 2007, ELECTROPHORESIS, V28, P3875, DOI 10.1002/elps.200700279
   Jex AR, 2007, ELECTROPHORESIS, V28, P2818, DOI 10.1002/elps.200600772
   Jex AR, 2010, BIOTECHNOL ADV, V28, P17, DOI 10.1016/j.biotechadv.2009.08.003
   Jex A.R., 2011, OXFORD TXB ZOONOSES, P536
   Johnston SP, 2003, J CLIN MICROBIOL, V41, P623, DOI 10.1128/JCM.41.2.623-626.2003
   Kohli A, 2008, T ROY SOC TROP MED H, V102, P718, DOI 10.1016/j.trstmh.2008.03.002
   Koroma JB, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000891
   Kosch TA, 2013, MOL ECOL RESOUR, V13, P230, DOI 10.1111/1755-0998.12041
   Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lebbad M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001262
   LIU Q, 1995, BIOTECHNIQUES, V18, P470
   Maddison W. P., 2011, MESQUITE MODULAR SYS, P75
   Mallon M, 2003, J MOL EVOL, V56, P407, DOI 10.1007/s00239-002-2412-3
   Ndao M., 2009, INTERDISCIP PERSPECT, V2009
   Ng J, 2010, EXP PARASITOL, V125, P348, DOI 10.1016/j.exppara.2010.02.017
   Ngui R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001522
   Nolan MJ, 2013, WATER RES, V47, P1726, DOI 10.1016/j.watres.2012.12.027
   Nolan MJ, 2011, ELECTROPHORESIS, V32, P2075, DOI 10.1002/elps.201100283
   Nolan MJ, 2010, ELECTROPHORESIS, V31, P287, DOI 10.1002/elps.200900480
   Nolan MJ, 2009, ELECTROPHORESIS, V30, P2640, DOI 10.1002/elps.200900071
   Palmer CS, 2007, VET PARASITOL, V145, P304, DOI 10.1016/j.vetpar.2006.12.018
   Pangasa A, 2009, MOL CELL PROBE, V23, P10, DOI 10.1016/j.mcp.2008.10.003
   Pontiroli A, 2011, PLOS ONE, V6
   PROCIV P, 1995, MED J AUSTRALIA, V162, P150
   Pullan R, 2008, PARASITOLOGY, V135, P783, DOI 10.1017/S0031182008000346
   Read C, 2002, INT J PARASITOL, V32, P229, DOI 10.1016/S0020-7519(01)00340-X
   Robinson R. A., 2001, DOGS ZOONOSES PUBLIC, P273
   SAUCH JF, 1985, APPL ENVIRON MICROB, V50, P1434
   Savioli L, 2006, TRENDS PARASITOL, V22, P203, DOI 10.1016/j.pt.2006.02.015
   Stark D, 2011, J CLIN MICROBIOL, V49, P257, DOI 10.1128/JCM.01796-10
   Stensvold CR, 2012, J CLIN MICROBIOL, V50, P540, DOI 10.1128/JCM.06012-11
   Strong WB, 2000, INFECT IMMUN, V68, P4117, DOI 10.1128/IAI.68.7.4117-4134.2000
   Sturrock HJW, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000537
   Sulaiman IM, 2003, EMERG INFECT DIS, V9, P1444
   ten Hove RJ, 2009, EUR J CLIN MICROBIOL, V28, P1045, DOI 10.1007/s10096-009-0745-1
   van Lieshout L, 2010, CURR OPIN INFECT DIS, V23, P488, DOI 10.1097/QCO.0b013e32833de0eb
   Waldron LS, 2011, APPL ENVIRON MICROB, V77, P7766, DOI 10.1128/AEM.00616-11
   Waldron LS, 2011, APPL ENVIRON MICROB, V77, P7757, DOI 10.1128/AEM.00615-11
   Weitzel T, 2006, CLIN MICROBIOL INFEC, V12, P656, DOI 10.1111/j.1469-0691.2006.01457.x
   Wu ZL, 2003, APPL ENVIRON MICROB, V69, P4720, DOI 10.1128/AEM.69.8.4720-4726.2003
   Xiao LH, 2008, FEMS IMMUNOL MED MIC, V52, P309, DOI 10.1111/j.1574-695X.2008.00377.x
   Xiao LH, 2010, EXP PARASITOL, V124, P80, DOI 10.1016/j.exppara.2009.03.018
   Yang RC, 2010, INT J PARASITOL, V40, P293, DOI 10.1016/j.ijpara.2009.08.003
   YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852
NR 76
TC 14
Z9 15
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0173-0835
J9 ELECTROPHORESIS
JI Electrophoresis
PD JUN
PY 2013
VL 34
IS 12
SI SI
BP 1720
EP 1728
DI 10.1002/elps.201300100
PG 9
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 164CC
UT WOS:000320385400002
PM 23592267
OA No
DA 2017-08-15
ER

PT J
AU Noulin, F
   Borlon, C
   Van Den Abbeele, J
   D'Alessandro, U
   Erhart, A
AF Noulin, Florian
   Borlon, Celine
   Van Den Abbeele, Jan
   D'Alessandro, Umberto
   Erhart, Annette
TI 1912-2012: a century of research on Plasmodium vivax in vitro culture
SO TRENDS IN PARASITOLOGY
LA English
DT Review
DE malaria; Plasmodium vivax; in vitro culture; reticulocyte
ID RED-BLOOD-CELLS; EMBRYONIC STEM-CELLS; SHORT-TERM CULTURE; MALARIA
   PARASITES; INVITRO CULTIVATION; CORD BLOOD; DEFINED CONDITIONS; HUMAN
   ERYTHROCYTES; FALCIPARUM; SUSCEPTIBILITY
AB The development of a continuous Plasmodium vivax blood cycle in vitro was first attempted 100 years ago. Since then, and despite the use of different methods, only short-term cultures have been achieved so far. The available literature has been reviewed in order to provide a critical overview of the currently available knowledge on P. vivax blood cycle culture systems and identify some unexplored ways forward. Results show that data accumulated over the past century remain fragmented and often contradictory, making it difficult to draw conclusions. There is the need for an international consortium on P. vivax culture able to collect, update, and share new evidence, including negative results, and thus better coordinate current efforts towards the establishment of a continuous P. vivax culture.
C1 [Noulin, Florian; Borlon, Celine; D'Alessandro, Umberto; Erhart, Annette] Inst Trop Med, Unit Malariol, B-2000 Antwerp, Belgium.
   [Noulin, Florian] Stem Cell Inst, B-3000 Louvain, Belgium.
   [Van Den Abbeele, Jan] Inst Trop Med, Unit Vet Protozool, B-2000 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Fajara 273, Gambia.
RP Noulin, F (reprint author), Inst Trop Med, Unit Malariol, B-2000 Antwerp, Belgium.
EM fuoulin@itg.be
RI chen, zhu/K-5923-2013; D'Alessandro, Umberto/D-3457-2015; noulin,
   florian/J-3809-2013
OI D'Alessandro, Umberto/0000-0001-6341-5009; noulin,
   florian/0000-0001-7430-8073
FU Secondary Research Funding (SOFT-B) project of the Institute of Tropical
   Medicine (ITM), Antwerp, Belgium
FX We would like to thank Dr Aurelien Mercier for providing some of the
   publications that were difficult to access. We thank Dr Yemiao Chen for
   his translation of the Chinese publications and Esra Kutmen for her
   translation of the Turkish publication. We are grateful to Dr Margaret
   Pinder for assisting with the English. We would like to thank Professor
   Anna Rosanas for her useful comments during manuscript revisions. F.N.
   is funded, (fellowship) by the Secondary Research Funding (SOFT-B)
   project of the Institute of Tropical Medicine (ITM), Antwerp, Belgium.
CR Alonso PL, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000406
   Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011
   BARNWELL JW, 1989, J EXP MED, V169, P1795, DOI 10.1084/jem.169.5.1795
   BASCO LK, 1994, PARASITOL RES, V80, P262, DOI 10.1007/BF00932686
   Bass CC, 1912, J EXP MED, V16, P567, DOI 10.1084/jem.16.4.567
   Bei AK, 2010, J INFECT DIS, V202, P1722, DOI 10.1086/657157
   Borlon C, 2012, INT J PARASITOL, V42, P155, DOI 10.1016/j.ijpara.2011.10.011
   Bouhassira EE, 2012, STEM CELL TRANSL MED, V1, P927, DOI 10.5966/sctm.2012-0097
   Bozdech Z, 2008, P NATL ACAD SCI USA, V105, P16290, DOI 10.1073/pnas.0807404105
   BROCKELMAN CR, 1987, PARASITOL RES, V73, P107, DOI 10.1007/BF00536465
   BROCKELMAN CR, 1985, J PROTOZOOL, V32, P76, DOI 10.1111/j.1550-7408.1985.tb03016.x
   Burrows JN, 2011, CURR TOP MED CHEM, V11, P1226
   Butcher G A, 1979, Bull World Health Organ, V57 Suppl 1, P17
   CHIN W, 1979, AM J TROP MED HYG, V28, P591
   Chotivanich K, 2001, T ROY SOC TROP MED H, V95, P677, DOI 10.1016/S0035-9203(01)90113-0
   Collins WE, 2009, AM J TROP MED HYG, V80, P152
   Giarratana MC, 2005, NAT BIOTECHNOL, V23, P69, DOI 10.1038/nbt1047
   Golenda CF, 1997, P NATL ACAD SCI USA, V94, P6786, DOI 10.1073/pnas.94.13.6786
   Grimberg BT, 2007, PLOS MED, V4, P1940, DOI 10.1371/journal.pmed.0040337
   Grimberg BT, 2012, EXP PARASITOL, V132, P304, DOI 10.1016/j.exppara.2012.07.006
   GUO SC, 1983, AM J TROP MED HYG, V32, P473
   KITCHEN S. F., 1938, AMER JOUR TROP MED, V18, P347
   Kocken CHM, 1996, EXP PARASITOL, V84, P439, DOI 10.1006/expr.1996.0132
   LANNERS HN, 1992, PARASITOL RES, V78, P699, DOI 10.1007/BF00931524
   Lapillonne H, 2010, HAEMATOL-HEMATOL J, V95, P1651, DOI 10.3324/haematol.2010.023556
   LARROUY G, 1981, CR ACAD SCI III-VIE, V292, P929
   Lu Feng, 2010, Chinese Journal of Schistosomiasis Control, V22, P56
   *MAIERA, PLOS MED, V8
   McClean CM, 2010, AM J TROP MED HYG, V83, P1183, DOI 10.4269/ajtmh.2010.10-0195
   MONS B, 1988, EXP PARASITOL, V66, P183, DOI 10.1016/0014-4894(88)90089-6
   MONS B, 1983, INT J PARASITOL, V13, P213, DOI 10.1016/0020-7519(83)90015-2
   Moon RW, 2013, P NATL ACAD SCI USA, V110, P531, DOI 10.1073/pnas.1216457110
   Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X
   NGUYENDINH P, 1980, SCIENCE, V209, P1249, DOI 10.1126/science.6773146
   NGUYENDINH P, 1981, SCIENCE, V212, P1146, DOI 10.1126/science.7233207
   NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776
   Noulin F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040798
   Panichakul Tasanee, 2007, Int J Parasitol, V37, P1551, DOI 10.1016/j.ijpara.2007.05.009
   PASVOL G, 1977, NATURE, V270, P171, DOI 10.1038/270171a0
   Pazarbasi A., 1995, Turkiye Parazitoloji Dergisi, V19, P449
   Price RN, 2009, CURR OPIN INFECT DIS, V22, P430, DOI 10.1097/QCO.0b013e32832f14c1
   RENAPURKAR DM, 1983, IRCS MED SCI-BIOCHEM, V11, P7
   ROSSAN RN, 1985, AM J TROP MED HYG, V34, P207
   Russell B, 2008, ANTIMICROB AGENTS CH, V52, P1040, DOI 10.1128/AAC.01334-07
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   Sattabongkot J, 2006, AM J TROP MED HYG, V74, P708
   Schwartz RE, 2005, STEM CELLS DEV, V14, P643, DOI 10.1089/scd.2005.14.643
   SIDDIQUI A, 1979, PRACTICAL TISSUE CUL, P279
   Spadafora C, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-96
   Sriprawat K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-115
   SUTAR NK, 1991, INDIAN J EXP BIOL, V29, P286
   Tamez PA, 2009, BLOOD, V114, P3652, DOI 10.1182/blood-2009-07-231894
   Touboul T, 2010, HEPATOLOGY, V51, P1754, DOI 10.1002/hep.23506
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   TRAGER W, 1971, J PROTOZOOL, V18, P239, DOI 10.1111/j.1550-7408.1971.tb03314.x
   Udomsangpetch R, 2007, PARASITOL INT, V56, P65, DOI 10.1016/j.parint.2006.12.005
   Usha Devi C., 2000, Journal of Parasitic Diseases, V24, P61
   WARD RA, 1969, NATURE, V224, P1126, DOI 10.1038/2241126a0
   White NJ, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-297
   Zhou W Z, 1991, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V9, P258
NR 60
TC 33
Z9 33
U1 0
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4922
J9 TRENDS PARASITOL
JI Trends Parasitol.
PD JUN
PY 2013
VL 29
IS 6
BP 286
EP 294
DI 10.1016/j.pt.2013.03.012
PG 9
WC Parasitology
SC Parasitology
GA 165IR
UT WOS:000320477600005
PM 23623759
OA No
DA 2017-08-15
ER

PT J
AU Williams, B
   Ramroop, S
   Shah, P
   Anderson, L
   Das, S
   Riddell, A
   Liebeschuetz, S
   Roy, RB
   O'Callaghan, M
   Sloper, K
   Bematoniene, J
   Shingadia, D
   Kampmann, B
AF Williams, Bhanu
   Ramroop, Shiva
   Shah, Pooja
   Anderson, Laura
   Das, Sreena
   Riddell, Anna
   Liebeschuetz, Sue
   Roy, Robin Basu
   O'Callaghan, Maria
   Sloper, Katherine
   Bematoniene, Jolanta
   Shingadia, Delane
   Kampmann, Beate
TI Multidrug-resistant tuberculosis in UK children: presentation,
   management and outcome
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Letter
C1 [Williams, Bhanu] North West London Hosp NHS Trust, London, England.
   [Ramroop, Shiva; Shingadia, Delane] Great Ormond St Hosp Sick Children, London, England.
   [Shah, Pooja] Imperial Healthcare NHS Trust, London, England.
   [Anderson, Laura] Hlth Protect Agcy, London, England.
   [Das, Sreena; Riddell, Anna; Liebeschuetz, Sue; O'Callaghan, Maria] Barts Hlth NHS Trust, London, England.
   [Roy, Robin Basu; Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Sloper, Katherine] Ealing NHS Trust, London, England.
   [Bematoniene, Jolanta] Bristol Royal Hosp Children, Bristol, Avon, England.
   [Kampmann, Beate] MRC Unit, Fajara, Gambia.
RP Williams, B (reprint author), NWLH NHS Trust, Northwick Pk Hosp, Watford Rd, Harrow HA1 3UJ, Middx, England.
EM bhanu.williams@nhs.net
RI Basu Roy, Robin/L-2979-2016
OI Basu Roy, Robin/0000-0001-5648-3628; Kampmann, Beate/0000-0002-6546-4709
FU Department of Health [SRF-2009-02-07]; Medical Research Council
   [MC_UP_A900_1122]
CR Al-Dabbagh M, 2011, PEDIATR INFECT DIS J, V30, P501, DOI 10.1097/INF.0b013e31820b583d
   Drobniewski FA, 2003, LANCET INFECT DIS, V3, P141, DOI 10.1016/S1473-3099(03)00544-9
   Ettehad D, 2012, LANCET INFECT DIS, V12, P449, DOI 10.1016/S1473-3099(12)70033-6
   Falzon D, 2011, EUR RESPIR J, V38, P516, DOI 10.1183/09031936.00073611
   Gandhi NR, 2010, LANCET, V375, P1830, DOI 10.1016/S0140-6736(10)60410-2
   Marais BJ, 2006, CLIN INFECT DIS, V42, pE69, DOI 10.1086/502652
   National Institute for Health and Clinical Excellence, CG117 TUB CLIN DIAGN
   Pedrazzoli D, 2011, TUBERCULOSIS UK 2011
   Sandgren A, 2012, EUR RESPIR J, V40, P294, DOI 10.1183/09031936.00187711
   Seddon JA, 2012, CLIN INFECT DIS, V54, P157, DOI 10.1093/cid/cir772
NR 10
TC 5
Z9 5
U1 0
U2 6
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
J9 EUR RESPIR J
JI Eur. Resp. J.
PD JUN
PY 2013
VL 41
IS 6
BP 1456
EP 1458
DI 10.1183/09031936.00179712
PG 3
WC Respiratory System
SC Respiratory System
GA 161RT
UT WOS:000320211700031
PM 23728407
OA No
DA 2017-08-15
ER

PT J
AU Braithwaite, V
   Bruggraber, SFA
   Prentice, A
AF Braithwaite, V.
   Bruggraber, S. F. A.
   Prentice, A.
TI Intact fibroblast growth factor-23 in plasma from Gambian children:
   response to the letter from Smith et al.
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Letter
C1 [Braithwaite, V.; Bruggraber, S. F. A.; Prentice, A.] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Prentice, A.] MRC Keneba, West Kiang, Gambia.
RP Braithwaite, V (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
EM vickie.braithwaite@mrc-hnr.cam.ac.uk
OI Braithwaite, Vickie/0000-0002-3366-2903
FU Medical Research Council [MC_U105960399, MC_U105960371, MC_U123292701]
CR Braithwaite V, 2013, OSTEOPOROSIS INT, V24, P1121, DOI 10.1007/s00198-012-2029-3
   Weber TJ, 2003, J BONE MINER RES, V18, P1227, DOI 10.1359/jbmr.2003.18.7.1227
NR 2
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUN
PY 2013
VL 24
IS 6
BP 1935
EP 1936
DI 10.1007/s00198-012-2251-z
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 155TA
UT WOS:000319769900022
PM 23288027
OA No
DA 2017-08-15
ER

PT J
AU Dominguez-Salas, P
   Moore, SE
   Cole, D
   da Costa, KA
   Cox, SE
   Dyer, RA
   Fulford, AJC
   Innis, SM
   Waterland, RA
   Zeisel, SH
   Prentice, AM
   Hennig, BJ
AF Dominguez-Salas, Paula
   Moore, Sophie E.
   Cole, Darren
   da Costa, Kerry-Ann
   Cox, Sharon E.
   Dyer, Roger A.
   Fulford, Anthony J. C.
   Innis, Sheila M.
   Waterland, Robert A.
   Zeisel, Steven H.
   Prentice, Andrew M.
   Hennig, Branwen J.
TI DNA methylation potential: dietary intake and blood concentrations of
   one-carbon metabolites and cofactors in rural African women
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID S-ADENOSYLHOMOCYSTEINE; GAMBIAN WOMEN; MICRONUTRIENT SUPPLEMENTATION;
   MASS-SPECTROMETRY; RIBOFLAVIN STATUS; CYSTIC-FIBROSIS; HOMOCYSTEINE;
   CHOLINE; FOLATE; METHIONINE
AB Background: Animal models show that periconceptional supplementation with folic acid, vitamin B-12, choline, and betaine can induce differences in offspring phenotype mediated by epigenetic changes in DNA. In humans, altered DNA methylation patterns have been observed in offspring whose mothers were exposed to famine or who conceived in the Gambian rainy season.
   Objective: The objective was to understand the seasonality of DNA methylation patterns in rural Gambian women. We studied natural variations in dietary intake of nutrients involved in methyl-donor pathways and their effect on the respective metabolic biomarkers.
   Design: In 30 women of reproductive age (18-45 y), we monitored diets monthly for 1 y by using 48-h weighed records to measure intakes of choline, betaine, folate, methionine, riboflavin, and vitamins B-6 and B-12. Blood biomarkers of these nutrients, S-adenosylhomocysteine (SAH), S-adenosylmethionine (SAM), homocysteine, cysteine, and dimethylglycine were also assessed monthly.
   Results: Dietary intakes of riboflavin, folate, choline, and betaine varied significantly by season; the most dramatic variation was seen for betaine. All metabolic biomarkers showed significant seasonality, and vitamin B-6 and folate had the highest fluctuations. Correlations between dietary intakes and blood biomarkers were found for riboflavin, vitamin B-6, active vitamin B-12 (holotranscobalamin), and betaine. We observed a seasonal switch between the betaine and folate pathways and a probable limiting role of riboflavin in these processes and a higher SAM/SAH ratio during the rainy season.
   Conclusions: Naturally occurring seasonal variations in food-consumption patterns have a profound effect on methyl-donor biomarker status. The direction of these changes was consistent with previously reported differences in methylation of metastable epi-alleles.
C1 [Dominguez-Salas, Paula; Moore, Sophie E.; Cox, Sharon E.; Fulford, Anthony J. C.; Prentice, Andrew M.; Hennig, Branwen J.] Univ London London Sch Hyg & Trop Med, Int Nutr Grp, MRC, London WC1E 7HT, England.
   [Dominguez-Salas, Paula; Moore, Sophie E.; Fulford, Anthony J. C.; Prentice, Andrew M.] MRC Unit, MRC Keneba, Keneba, Gambia.
   [Cole, Darren] Elsie Widdowson Lab, MRC Human Nutr Res, Cambridge, England.
   [da Costa, Kerry-Ann; Zeisel, Steven H.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC USA.
   [da Costa, Kerry-Ann; Zeisel, Steven H.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
   [Dyer, Roger A.; Innis, Sheila M.] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada.
   [Waterland, Robert A.] Baylor Coll Med, Childrens Nutr Res Ctr, USDA ARS, Dept Pediat, Houston, TX 77030 USA.
   [Waterland, Robert A.] Baylor Coll Med, Childrens Nutr Res Ctr, USDA ARS, Dept Mol & Human Genet, Houston, TX 77030 USA.
RP Dominguez-Salas, P (reprint author), Univ London London Sch Hyg & Trop Med, Int Nutr Grp, MRC, Keppel St, London WC1E 7HT, England.
EM paula.dominguez-salas@lshtm.ac.uk
RI Hennig, Branwen/M-6444-2014
OI Cox, Sharon/0000-0002-9908-2936
FU Wellcome Trust grant [WT086369MA]; MRC core funding [MC-A760-5QX00];
   Bill and Melinda Gates Foundation; NIH [P30DK056350]; NIH/National
   Institute of Diabetes and Digestive and Kidney Diseases [1R01DK081557];
   USDA [CRIS 6250-51000-055]
FX Supported by Wellcome Trust grant WT086369MA (to BJH) and MRC core
   funding MC-A760-5QX00 (to the International Nutrition Group). SHZ and
   K-AdC were supported in part by a grant from the Bill and Melinda Gates
   Foundation and from the NIH (P30DK056350) to the University of North
   Carolina-CH Nutrition Obesity Research Center. RAW was supported by
   grants from NIH/National Institute of Diabetes and Digestive and Kidney
   Diseases (1R01DK081557) and the USDA (CRIS 6250-51000-055).
CR Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235
   BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   BLOCK G, 1989, AM J CLIN NUTR, V50, P1133
   Block G, 1989, AM J CLIN NUTR, V50, P231
   Brosnan JT, 2006, J NUTR, V136, p1636S
   Caudill MA, 2001, J NUTR, V131, P2811
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cooper WN, 2012, FASEB J, V26, P1782, DOI 10.1096/fj.11-192708
   Dhonukshe-Rutten RAM, 2009, EUR J CLIN NUTR, V63, P18, DOI 10.1038/sj.ejcn.1602897
   Dominguez-Salas P, 2012, P NUTR SOC, V71, P154, DOI 10.1017/S0029665111003338
   Fischer LM, 2010, AM J CLIN NUTR, V92, P1113, DOI [10.3945/ajcn.2010.30064, 10.3945/ajen.2010.30064]
   Fulford AJC, 2006, PAEDIATR PERINAT EP, V20, P251, DOI 10.1111/j.1365-3016.2006.00714.x
   Gibson R., 2005, PRINCIPLES NUTR ASSE
   Green R, 2011, AM J CLIN NUTR, V94, p666S, DOI 10.3945/ajcn.110.009613
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Hill MHE, 2009, BRIT J NUTR, V102, P273, DOI 10.1017/S0007114508162997
   HUDSON GJ, 1995, BRIT J NUTR, V73, P551, DOI 10.1079/BJN19950058
   Innis SM, 2007, AM J CLIN NUTR, V85, P702
   Innis SM, 2006, J NUTR, V136, P2226
   Institute of Medicine National Academy of Sciences, 1998, DIET REF INT FOL THI
   Jacob RA, 1999, J NUTR, V129, P712
   James SJ, 2002, J NUTR, V132, p2361S
   Kalhan SC, 2012, REV ENDOCR METAB DIS, V13, P109, DOI 10.1007/s11154-012-9215-7
   Khulan B, 2012, HUM MOL GENET, V21, P2086, DOI 10.1093/hmg/dds026
   Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x
   Loikas S, 2003, CLIN CHEM, V49, P455, DOI 10.1373/49.3.455
   McCrae JE, 1996, FOODS RURAL GAMBIA
   Midttun O, 2005, CLIN CHEM, V51, P1206, DOI 10.1373/clinchem.2005.051169
   Moat SJ, 2003, CLIN CHEM, V49, P295, DOI 10.1373/49.2.295
   MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2
   Niculescu MD, 2002, J NUTR, V132, p2333S
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Refsum H, 2004, CLIN CHEM, V50, P3, DOI 10.1373/clinchem.2003.021634
   ROBERTS SB, 1982, T ROY SOC TROP MED H, V76, P668, DOI 10.1016/0035-9203(82)90239-5
   Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104
   Stead LM, 2006, AM J CLIN NUTR, V83, P5
   VUILLEUMIER JP, 1990, INT J VITAM NUTR RES, V60, P126
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
   Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252
   WHO/FAO (World Health Organization/Food and Agriculture Organization of the United Nations), 2004, VIT MIN REQ HUM NUTR
   Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200
NR 43
TC 47
Z9 47
U1 0
U2 22
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUN
PY 2013
VL 97
IS 6
BP 1217
EP 1227
DI 10.3945/ajcn.112.048462
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 150DX
UT WOS:000319371500010
PM 23576045
OA No
DA 2017-08-15
ER

PT J
AU Lindsay, B
   Ochieng, JB
   Ikumapayi, UN
   Toure, A
   Ahmed, D
   Li, S
   Panchalingam, S
   Levine, MM
   Kotloff, K
   Rasko, DA
   Morris, CR
   Juma, J
   Fields, BS
   Dione, M
   Malle, D
   Becker, SM
   Houpt, ER
   Nataro, JP
   Sommerfelt, H
   Pop, M
   Oundo, J
   Antonio, M
   Hossain, A
   Tamboura, B
   Stine, OC
AF Lindsay, Brianna
   Ochieng, John B.
   Ikumapayi, Usman N.
   Toure, Aliou
   Ahmed, Dilruba
   Li, Shan
   Panchalingam, Sandra
   Levine, Myron M.
   Kotloff, Karen
   Rasko, David A.
   Morris, Carolyn R.
   Juma, Jane
   Fields, Barry S.
   Dione, Michel
   Malle, Dramane
   Becker, Stephen M.
   Houpt, Eric R.
   Nataro, James P.
   Sommerfelt, Halvor
   Pop, Mihai
   Oundo, Joe
   Antonio, Martin
   Hossain, Anowar
   Tamboura, Boubou
   Stine, O. Colin
TI Quantitative PCR for Detection of Shigella Improves Ascertainment of
   Shigella Burden in Children with Moderate-to-Severe Diarrhea in
   Low-Income Countries
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; ESCHERICHIA-COLI; CASE/CONTROL; MULTICENTER;
   VOLUNTEER; DISEASE; VACCINE; TESTS
AB Estimates of the prevalence of Shigella spp. are limited by the suboptimal sensitivity of current diagnostic and surveillance methods. We used a quantitative PCR (qPCR) assay to detect Shigella in the stool samples of 3,533 children aged <59 months from the Gambia, Mali, Kenya, and Bangladesh, with or without moderate-to-severe diarrhea (MSD). We compared the results from conventional culture to those from qPCR for the Shigella ipaH gene. Using MSD as the reference standard, we determined the optimal cutpoint to be 2.9 x 10(4) ipaH copies per 100 ng of stool DNA for set 1 (n = 877). One hundred fifty-eight (18%) specimens yielded >2.9 x 10(4) ipaH copies. Ninety (10%) specimens were positive by traditional culture for Shigella. Individuals with >= 2.9 x 10(4) ipaH copies have 5.6-times-higher odds of having diarrhea than those with <2.9 x 10(4) ipaH copies (95% confidence interval, 3.7 to 8.5; P<0.0001). Nearly identical results were found using an independent set of samples. qPCR detected 155 additional MSD cases with high copy numbers of ipaH, a 90% increase from the 172 cases detected by culture in both samples. Among a subset (n = 2,874) comprising MSD cases and their age-, gender-, and location-matched controls, the fraction of MSD cases that were attributable to Shigella infection increased from 9.6% (n = 129) for culture to 17.6% (n = 262) for qPCR when employing our cutpoint. We suggest that qPCR with a cutpoint of approximately 1.4 x 10(4) ipaH copies be the new reference standard for the detection and diagnosis of shigellosis in children in low-income countries. The acceptance of this new standard would substantially increase the fraction of MSD cases that are attributable to Shigella.
C1 [Lindsay, Brianna; Li, Shan; Panchalingam, Sandra; Levine, Myron M.; Kotloff, Karen; Rasko, David A.; Morris, Carolyn R.; Stine, O. Colin] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Ochieng, John B.; Juma, Jane; Fields, Barry S.; Oundo, Joe] CDC Kenya Med Res Inst KEMRI, Res Stn, Kisumu, Kenya.
   [Ikumapayi, Usman N.; Dione, Michel; Antonio, Martin] MRC, Basse, Gambia.
   [Toure, Aliou; Malle, Dramane; Tamboura, Boubou] Ctr Dev Vaccins Mali, Bamako, Mali.
   [Ahmed, Dilruba; Hossain, Anowar] Icddr B, Dhaka, Bangladesh.
   [Becker, Stephen M.; Houpt, Eric R.; Nataro, James P.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
   [Sommerfelt, Halvor] Univ Bergen, Bergen, Norway.
   [Pop, Mihai] Univ Maryland, College Pk, MD 20742 USA.
RP Lindsay, B (reprint author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
EM blind002@umaryland.edu
RI kotloff, karen/E-7768-2012; Pop, Mihai/A-7987-2013
OI kotloff, karen/0000-0003-1808-6431; Pop, Mihai/0000-0001-9617-5304;
   David, Rasko/0000-0002-7337-7154
FU Bill & Melinda Gates Foundation
FX This work was supported by the Bill & Melinda Gates Foundation.
CR Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x
   Barletta F, 2011, CLIN INFECT DIS, V53, P1223, DOI 10.1093/cid/cir730
   BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904
   Gaudio PA, 1997, J INFECT DIS, V176, P1013
   Giocoli G, 2009, ANN I SUPER SANITA, V45, P168
   Hadgu A, 2005, EPIDEMIOLOGY, V16, P604, DOI 10.1097/01.ede.0000173042.07579.17
   Kotloff KL, 2012, CLIN INFECT DIS, V55, pS232, DOI 10.1093/cid/cis753
   KOTLOFF KL, 1995, VACCINE, V13, P1488, DOI 10.1016/0264-410X(95)00102-7
   Levine MM, 2012, CLIN INFECT DIS, V55, pS303, DOI 10.1093/cid/cis789
   Panchalingam S, 2012, CLIN INFECT DIS, V55, pS294, DOI 10.1093/cid/cis754
   Phantouamath B, 2005, JPN J INFECT DIS, V58, P232
   Phillips G, 2009, BMC INFECT DIS, V9, P1
   Rasko DA, 2011, NEW ENGL J MED, V365, P709, DOI 10.1056/NEJMoa1106920
   Sahl JW, 2011, INFECT IMMUN, V79, P950, DOI 10.1128/IAI.00932-10
   Samosornsuk S, 2007, THAMMASAT INT J SCI, V12, P52
   Tacket CO, 1997, AM J TROP MED HYG, V56, P533
   Taniuchi M, 2012, DIAGN MICR INFEC DIS, V73, P121, DOI 10.1016/j.diagmicrobio.2012.03.008
   Taylor DN, 1997, INFECT IMMUN, V65, P3852
   von Seidlein L, 2006, PLOS MED, V3, P1556, DOI 10.1371/journal.pmed.0030353
   Vu Dinh Thiem, 2004, J Clin Microbiol, V42, P2031, DOI 10.1128/JCM.42.5.2031-2035.2004
NR 20
TC 32
Z9 33
U1 1
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2013
VL 51
IS 6
BP 1740
EP 1746
DI 10.1128/JCM.02713-12
PG 7
WC Microbiology
SC Microbiology
GA 147VV
UT WOS:000319197800014
PM 23536399
OA No
DA 2017-08-15
ER

PT J
AU Abubakar, I
   Zignol, M
   Falzon, D
   Raviglione, M
   Ditiu, L
   Masham, S
   Adetifa, L
   Ford, N
   Cox, H
   Lawn, SD
   Marais, B
   McHugh, TD
   Mwaba, P
   Bates, M
   Lipman, M
   Zijenah, L
   Logan, S
   McNerney, R
   Zumla, A
   Sarda, K
   Nahid, P
   Hoelscher, M
   Pletschette, M
   Memish, ZA
   Kim, P
   Hafner, R
   Cole, S
   Migliori, GB
   Maeurer, M
   Schito, M
   Zumla, A
AF Abubakar, Ibrahim
   Zignol, Matteo
   Falzon, Dennis
   Raviglione, Mario
   Ditiu, Lucica
   Masham, Susan
   Adetifa, Lfedayo
   Ford, Nathan
   Cox, Helen
   Lawn, Stephen D.
   Marais, Ben J.
   McHugh, Timothy D.
   Mwaba, Peter
   Bates, Matthew
   Lipman, Marc
   Zijenah, Lynn
   Logan, Simon
   McNerney, Ruth
   Zumla, Adam
   Sarda, Krishna
   Nahid, Payam
   Hoelscher, Michael
   Pletschette, Michel
   Memish, Ziad A.
   Kim, Peter
   Hafner, Richard
   Cole, Stewart
   Migliori, Giovanni Battista
   Maeurer, Markus
   Schito, Marco
   Zumla, Alimuddin
TI Tuberculosis 2013:5 Drug-resistant tuberculosis: time for visionary
   political leadership
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; MULTIDRUG-RESISTANCE;
   TREATMENT OUTCOMES; MDR-TB; PULMONARY TUBERCULOSIS; INFECTION-CONTROL;
   EUROPEAN REGION; UNITED-STATES; RISK-FACTORS
AB Two decades ago, WHO declared tuberculosis a global emergency, and invested in the highly cost-effective directly observed treatment short-course programme to control the epidemic. At that time, most strains of Mycobacterium tuberculosis were susceptible to first-line tuberculosis drugs, and drug resistance was not a major issue. However, in 2013, tuberculosis remains a major public health concern worldwide, with prevalence of multidrug-resistant (MDR) tuberculosis rising. WHO estimates roughly 630 000 cases of MDR tuberculosis worldwide, with great variation in the frequency of MDR tuberculosis between countries. In the past 8 years, extensively drug-resistant (XDR) tuberculosis has emerged, and has been reported in 84 countries, heralding the possibility of virtually untreatable tuberculosis. Increased population movement, the continuing HIV pandemic, and the rise in MDR tuberculosis pose formidable challenges to the global control of tuberculosis. We provide an overview of the global burden of drug-resistant disease; discuss the social, health service, management, and control issues that fuel and sustain the epidemic; and suggest specific recommendations for important next steps. Visionary political leadership is needed to curb the rise of MDR and XDR tuberculosis worldwide, through sustained funding and the implementation of global and regional action plans.
C1 [Abubakar, Ibrahim] UCL, Dept Infect & Populat Hlth, Ctr Infect Dis Epidemiol, London NW3 2PF, England.
   [Abubakar, Ibrahim] Hlth Protect Agcy, London, England.
   [Zignol, Matteo; Falzon, Dennis; Raviglione, Mario] WHO, Stop TB Dept, CH-1211 Geneva, Switzerland.
   [Ditiu, Lucica] STOP TB Partnership, Geneva, Switzerland.
   [Masham, Susan; Logan, Simon] All Party Parliamentary Grp Global TB, London, England.
   [Masham, Susan] House Lords, London, England.
   [Adetifa, Lfedayo] MRC, Banjul, Gambia.
   [Ford, Nathan; Cox, Helen] Med Sans Frontieres, Cape Town, South Africa.
   [Ford, Nathan; Cox, Helen] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa.
   [Lawn, Stephen D.; McNerney, Ruth] Univ London London Sch Hyg & Trop Med, Fac Infect andTrop Dis, London, England.
   [Marais, Ben J.] Univ Sydney, Sydney Emerging Infect & Biosecur Inst, Sydney, NSW 2006, Australia.
   [McHugh, Timothy D.; Bates, Matthew; Zumla, Alimuddin] UCL, Ctr Clin Microbiol, Div Infect & Immun, London NW3 2PF, England.
   [Mwaba, Peter; Bates, Matthew; Zumla, Adam] Univ Zambia Univ Coll London Med Sch UNZA UCLMS, Res andTraining Project, Univ Teaching Hosp, Lusaka, Zambia.
   [Mwaba, Peter] Minist Hlth, Lusaka, Zambia.
   [Lipman, Marc] UCL, Royal Free Hosp NHS Fdn Trust, Dept Resp Med, London NW3 2PF, England.
   [Zijenah, Lynn] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe.
   [Zumla, Adam] Univ London, Sch Pharm, London WC1N 1AX, England.
   [Sarda, Krishna] India 800 Fdn, New Delhi, India.
   [Nahid, Payam] Univ Calif San Francisco, Div Pulm & Crit Care, San Francisco, CA 94143 USA.
   [Hoelscher, Michael] Klinikum Univ Munich, Dept Infect Dis & Trop Med, Munich, Germany.
   [Pletschette, Michel] Univ Zurich, Inst Med Microbiol, Zurich, Switzerland.
   [Migliori, Giovanni Battista] WHO Collaborating Ctr forTB & Lung Dis, Fdn S Maugeri, Care & Res Inst, Tradate, Italy.
   [Memish, Ziad A.] Minist Hlth, Riyadh, Saudi Arabia.
   [Memish, Ziad A.] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia.
   [Cole, Stewart] Ecole Polytech Fed Lausanne, Global Hlth Inst, Lausanne, Switzerland.
   [Maeurer, Markus] Karolinska Inst, Dept Microbiol, Stockholm, Sweden.
   [Schito, Marco] NIAID, Henry M Jackson Fdn Div AIDS, NIH, Bethesda, MD 20892 USA.
   [Kim, Peter; Hafner, Richard] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA.
RP Zumla, A (reprint author), UCL, Royal Free Hosp, Dept Infect, Ctr Clin Microbiol, Royal Free Campus, London NW3 2PF, England.
EM a.zumla@ucl.ac.uk
RI Hoelscher, Michael/D-3436-2012
OI Abubakar, Ibrahim/0000-0002-0370-1430; Cox, Helen/0000-0002-6538-7192;
   Zumla, Alimuddin/0000-0002-5111-5735; Migliori, Giovanni
   Battista/0000-0002-2597-574X
FU European and Developing Countries Clinical Trials Partnership,
   Netherlands; UK Medical Research Council (MRC); UBS Optimus Foundation,
   Switzerland; University College London Hospitals (UCLH) Comprehensive
   Biomedical Research Centre, UK; UCLH National Health Service Foundation
   Trust, UK; UK National Institute for Health Research; Wellcome Trust, UK
FX Al Z, PM, MB, and MH are supported by the European and Developing
   Countries Clinical Trials Partnership (grants REM OX, PANACEA, and
   TB-NEAT), Netherlands. AZ receives support from the UK Medical Research
   Council (MRC); UBS Optimus Foundation, Switzerland; University College
   London Hospitals (UCLH) Comprehensive Biomedical Research Centre, UK;
   and the UCLH National Health Service Foundation Trust, UK. IA is
   supported by the UK National Institute for Health Research and the UK
   MRC. SDL is supported by the Wellcome Trust, UK. The opinions expressed
   herein are those of the authors and should not be construed as
   representing the official views or policies of the US Department of
   Health and Human Services or the authors' national governments. Nor does
   mention of trade names, commercial practices, or organisations imply
   endorsement by the US Government or the authors' national governments.
   DF, MR, and MZ are staff members of WHO. The authors alone are
   responsible for the views expressed in this publication and they do not
   necessarily represent the decisions or policies of WHO.
CR Abubakar I, 2009, THORAX, V64, P512, DOI 10.1136/thx.2008.108712
   Abubakar I, 2012, LANCET, V379, P21
   Abubakar I, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4281
   Ahuja SD, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001300
   Alsaad N, 2013, EUR RESPIR J, V42, P504, DOI 10.1183/09031936.00114812
   Amaral L, 2012, INT J TUBERC LUNG D, V16, P1706, DOI 10.5588/ijtld.12.0616
   Balaji V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009527
   Barry PM, 2012, EMERG INFECT DIS, V18, P113, DOI 10.3201/eid1801.110671
   Bhatter P, 2012, INTERDISCIP PERSPECT, V2012
   Blondal K, 2011, INT J TUBERC LUNG D, V15, P892, DOI 10.5588/ijtld.10.0601
   Bloss E, 2010, INT J TUBERC LUNG D, V14, P275
   Blumberg HM, 2010, LANCET, V375, P2127, DOI 10.1016/S0140-6736(10)60574-0
   CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535
   Caws M, 2006, J CLIN MICROBIOL, V44, P3934, DOI 10.1128/JCM.01181-06
   Centers for disease control, 1991, MMWR-MORBID MORTAL W, V40, P585
   Centers for Disease Control and Prevention, 2012, MMWR-MORBID MORTAL W, V61, P181
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301
   Cohen T, 2012, CLIN MICROBIOL REV, V25, P708, DOI 10.1128/CMR.00021-12
   Cohen T, 2011, EMERG INFECT DIS, V17, P969, DOI [10.3201/eid/1706.101471, 10.3201/eid1706.101471]
   Cooke GS, 2011, EMERG INFECT DIS, V17, P2035, DOI 10.3201/eid1711.110291
   Dara M, 2012, EUR RESPIR J, V40, P1081, DOI 10.1183/09031936.00053012
   De Lorenzo S, 2013, EUR RESPIR J, V41, P1386, DOI 10.1183/09031936.00124312
   Dheda K, 2012, LANCET, V379, P773, DOI 10.1016/S0140-6736(11)61062-3
   Diacon AH, 2012, LANCET, V380, P986, DOI 10.1016/S0140-6736(12)61080-0
   Diacon AH, 2009, NEW ENGL J MED, V360, P2397, DOI 10.1056/NEJMoa0808427
   Dobbins Claire, 2012, Morbidity and Mortality Weekly Report, V61, P186
   Ettehad D, 2012, LANCET INFECT DIS, V12, P449, DOI 10.1016/S1473-3099(12)70033-6
   European Centre for Disease Prevention and Control WHO Regional Office for Europe, 2012, WHO REG OFF EUR
   Falzon D, 2011, EUR RESPIR J, V38, P516, DOI 10.1183/09031936.00073611
   Falzon D, 2013, EUR RESPIR J, V42, P156, DOI 10.1183/09031936.00134712
   Farley JE, 2012, INT J TUBERC LUNG D, V16, P82, DOI 10.5588/ijtld.10.0791
   French CE, 2009, EPIDEMIOL INFECT, V137, P591, DOI 10.1017/S0950268808001118
   FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406
   Gandhi Neel R, 2006, Lancet, V368, P1575
   Gavin P, 2012, INFECT GENET EVOL, V12, P701, DOI 10.1016/j.meegid.2011.05.016
   Gler MT, 2012, NEW ENGL J MED, V366, P2151, DOI 10.1056/NEJMoa1112433
   Government of India, 2012, TB IND 2012 REV NAT
   Hinman AR, 1992, MMWR RECOMM REP, V41, P5
   Hu Y, 2011, EPIDEMIOL INFECT, V139, P130, DOI 10.1017/S0950268810000890
   Jenkins HE, EUR RESP J IN PRESS
   Johnston JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006914
   Keshavjee S, 2008, ANN NY ACAD SCI, V1136, P1, DOI 10.1196/annals.1425.009
   Keshavjee S, 2012, NEW ENGL J MED, V367, P931, DOI 10.1056/NEJMra1205429
   Keshavjee S, 2010, NEW ENGL J MED, V363, P1781, DOI 10.1056/NEJMp1010023
   Kruijshaar ME, 2008, BRIT MED J, V336, P1231, DOI 10.1136/bmj.39546.573067.25
   Lowenthal P, 2011, INT J TUBERC LUNG D, V15, P761, DOI 10.5588/ijtld.10.0370
   Marais BJ, 2010, LANCET, V375, P2179, DOI 10.1016/S0140-6736(10)60554-5
   Migliori GB, 2012, CLIN INFECT DIS, V54, P1379, DOI 10.1093/cid/cis128
   Migliori GB, 2013, EUR RESPIR J, V42, P169, DOI 10.1183/09031936.00136312
   Migliori GB, 2012, EUR RESPIR J, V40, P814, DOI 10.1183/09031936.00036812
   Mitnick CD, 2007, PLOS MED, V4, P1730, DOI 10.1371/journal.pmed.0040292
   Mitruka K, 2011, EMERG INFECT DIS, V17, P425, DOI 10.3201/eid1703.101550
   Nathanson E, 2006, EMERG INFECT DIS, V12, P1389
   Nathanson E, 2010, NEW ENGL J MED, V363, P1050, DOI 10.1056/NEJMra0908076
   Nodieva A, 2010, INT J TUBERC LUNG D, V14, P427
   Nunn A, 2010, INT J TUBERC LUNG D, V14, P380
   Olson S, 2011, NEW PROFILE DRUG RES
   Olson S, 2012, FACING REALITY DRUG
   Orenstein EW, 2009, LANCET INFECT DIS, V9, P153, DOI 10.1016/S1473-3099(09)70041-6
   Paolo WF, 2004, LANCET INFECT DIS, V4, P287, DOI 10.1016/S1473-3099(04)01004-7
   Pedrazzoli D, 2012, RUBERCULOSIS UK 2012
   Peloquin CA, 2004, CLIN INFECT DIS, V38, P1538, DOI 10.1086/420742
   Raviglione MC, 2011, EUR RESPIR J, V37, P978, DOI 10.1183/09031936.00003111
   Raviglione M, 2012, LANCET, V379, P1902, DOI 10.1016/S0140-6736(12)60727-2
   Ruddy MC, 2004, THORAX, V59, P279, DOI 10.1136/thx.2003.010405
   Schaaf HS, 2011, PAEDIATR RESPIR REV, V12, P31, DOI 10.1016/j.prrv.2010.09.010
   Seddon JA, 2012, CLIN INFECT DIS, V56, P167
   Seddon JA, 2013, J INFECTION, V66, P320, DOI 10.1016/j.jinf.2012.09.002
   Skrahina A, 2012, EUR RESPIR J, V39, P1425, DOI 10.1183/09031936.00145411
   Skripconoka V, 2013, EUR RESPIR J, V41, P1393, DOI 10.1183/09031936.00125812
   Sotgiu G, 2011, EUR RESPIR J, V38, P1221, DOI 10.1183/09031936.00029311
   Sotgiu G, 2012, EUR RESPIR J, V40, P1430, DOI 10.1183/09031936.00022912
   Spigelman M, 2010, INT J TUBERC LUNG D, V14, P663
   The Lancet, 2010, LANCET, V376, P1274
   Tocsek A, 2013, INT J TUBERC LUNG D, V17, P299
   Torun T, 2005, INT J TUBERC LUNG D, V9, P1373
   Udwadia ZF, 2012, CLIN INFECT DIS, V54, P579, DOI 10.1093/cid/cir889
   van der Werf MJ, 2012, EUR RESPIR J, V39, P1511, DOI 10.1183/09031936.00125711
   Van Deun A, 2010, AM J RESP CRIT CARE, V182, P684, DOI 10.1164/rccm.201001-0077OC
   Veen J, 2011, EUR RESPIR J, V37, P950, DOI 10.1183/09031936.00019410
   Velayati AA, 2009, CHEST, V136, P420, DOI 10.1378/chest.08-2427
   Voelker R, 2013, JAMA-J AM MED ASSOC, V309, P430, DOI 10.1001/jama.2013.94
   Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665
   Weyer K, 2013, EUR RESPIR J, V42, P252, DOI 10.1183/09031936.00157212
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   World Health Organization, 2011, GUID PROGR MAN DRUG
   World Health Organization, TUB MDR TB XDR TB 20
   WHO, 2011, ROADM PREV COMB DRUG
   World Health Organization (WHO), 2012, TOT DRUG RES TUB WHO
   World Health Organization, 2006, WKLY EPIDEMIOL REC, V81, P430
   WHO, 2011, UN ACC DIAGN TREATM
   Zhao P, 2012, J INT MED RES, V40, P436
   Zhao YL, 2012, NEW ENGL J MED, V366, P2161, DOI 10.1056/NEJMoa1108789
   Zignol M, 2013, EUR RESPIR J, V42, P701, DOI 10.1183/09031936.00175812
   Zignol M, 2012, B WORLD HEALTH ORGAN, V90, P111, DOI 10.2471/BLT.11.092585
NR 95
TC 121
Z9 122
U1 1
U2 40
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUN
PY 2013
VL 13
IS 6
BP 529
EP 539
DI 10.1016/S1473-3099(13)70030-6
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 152NZ
UT WOS:000319539700027
PM 23531391
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Miotto, O
   Almagro-Garcia, J
   Manske, M
   MacInnis, B
   Campino, S
   Rockett, KA
   Amaratunga, C
   Lim, P
   Suon, S
   Sreng, S
   Anderson, JM
   Duong, S
   Nguon, C
   Chuor, CM
   Saunders, D
   Se, Y
   Lon, C
   Fukuda, MM
   Amenga-Etego, L
   Hodgson, AVO
   Asoala, V
   Imwong, M
   Takala-Harrison, S
   Nosten, F
   Su, XZ
   Ringwald, P
   Ariey, F
   Dolecek, C
   Hien, TT
   Boni, MF
   Thai, CQ
   Amambua-Ngwa, A
   Conway, DJ
   Djimde, AA
   Doumbo, OK
   Zongo, I
   Ouedraogo, JB
   Alcock, D
   Drury, E
   Auburn, S
   Koch, O
   Sanders, M
   Hubbart, C
   Maslen, G
   Ruano-Rubio, V
   Jyothi, D
   Miles, A
   O'Brien, J
   Gamble, C
   Oyola, SO
   Rayner, JC
   Newbold, CI
   Berriman, M
   Spencer, CCA
   McVean, G
   Day, NP
   White, NJ
   Bethell, D
   Dondorp, AM
   Plowe, CV
   Fairhurst, RM
   Kwiatkowski, DP
AF Miotto, Olivo
   Almagro-Garcia, Jacob
   Manske, Magnus
   MacInnis, Bronwyn
   Campino, Susana
   Rockett, Kirk A.
   Amaratunga, Chanaki
   Lim, Pharath
   Suon, Seila
   Sreng, Sokunthea
   Anderson, Jennifer M.
   Duong, Socheat
   Nguon, Chea
   Chuor, Char Meng
   Saunders, David
   Se, Youry
   Lon, Chantap
   Fukuda, Mark M.
   Amenga-Etego, Lucas
   Hodgson, Abraham V. O.
   Asoala, Victor
   Imwong, Mallika
   Takala-Harrison, Shannon
   Nosten, Francois
   Su, Xin-zhuan
   Ringwald, Pascal
   Ariey, Frederic
   Dolecek, Christiane
   Tran Tinh Hien
   Boni, Maciej F.
   Cao Quang Thai
   Amambua-Ngwa, Alfred
   Conway, David J.
   Djimde, Abdoulaye A.
   Doumbo, Ogobara K.
   Zongo, Issaka
   Ouedraogo, Jean-Bosco
   Alcock, Daniel
   Drury, Eleanor
   Auburn, Sarah
   Koch, Oliver
   Sanders, Mandy
   Hubbart, Christina
   Maslen, Gareth
   Ruano-Rubio, Valentin
   Jyothi, Dushyanth
   Miles, Alistair
   O'Brien, John
   Gamble, Chris
   Oyola, Samuel O.
   Rayner, Julian C.
   Newbold, Chris I.
   Berriman, Matthew
   Spencer, Chris C. A.
   McVean, Gilean
   Day, Nicholas P.
   White, Nicholas J.
   Bethell, Delia
   Dondorp, Arjen M.
   Plowe, Christopher V.
   Fairhurst, Rick M.
   Kwiatkowski, Dominic P.
TI Multiple populations of artemisinin-resistant Plasmodium falciparum in
   Cambodia
SO NATURE GENETICS
LA English
DT Article
ID PARASITE CLEARANCE RATE; CHLOROQUINE RESISTANCE; WESTERN CAMBODIA;
   DRUG-RESISTANCE; DIHYDROPTEROATE SYNTHASE; DIHYDROFOLATE-REDUCTASE;
   MALARIA PARASITES; SPREAD; PYRIMETHAMINE; GENOME
AB We describe an analysis of genome variation in 825 P. falciparum samples from Asia and Africa that identifies an unusual pattern of parasite population structure at the epicenter of artemisinin resistance in western Cambodia. Within this relatively small geographic area, we have discovered several distinct but apparently sympatric parasite subpopulations with extremely high levels of genetic differentiation. Of particular interest are three subpopulations, all associated with clinical resistance to artemisinin, which have skewed allele frequency spectra and high levels of haplotype homozygosity, indicative of founder effects and recent population expansion. We provide a catalog of SNPs that show high levels of differentiation in the artemisinin-resistant subpopulations, including codon variants in transporter proteins and DNA mismatch repair proteins. These data provide a population-level genetic framework for investigating the biological origins of artemisinin resistance and for defining molecular markers to assist in its elimination.
C1 [Miotto, Olivo; Almagro-Garcia, Jacob; Rockett, Kirk A.; Amenga-Etego, Lucas; Koch, Oliver; Miles, Alistair; Newbold, Chris I.; Spencer, Chris C. A.; Kwiatkowski, Dominic P.] Univ Oxford, MRC, Ctr Genom & Global Hlth, Oxford, England.
   [Miotto, Olivo; Imwong, Mallika; Nosten, Francois; Day, Nicholas P.; White, Nicholas J.; Dondorp, Arjen M.] Mahidol Univ, Mahidol Oxford Trop Med Res Unit, Bangkok 10700, Thailand.
   [Miotto, Olivo; Almagro-Garcia, Jacob; Manske, Magnus; MacInnis, Bronwyn; Campino, Susana; Rockett, Kirk A.; Alcock, Daniel; Drury, Eleanor; Sanders, Mandy; Maslen, Gareth; Ruano-Rubio, Valentin; Jyothi, Dushyanth; Oyola, Samuel O.; Rayner, Julian C.; Newbold, Chris I.; Berriman, Matthew; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Cambridge, England.
   [Almagro-Garcia, Jacob; Rockett, Kirk A.; Hubbart, Christina; Ruano-Rubio, Valentin; Miles, Alistair; O'Brien, John; Spencer, Chris C. A.; McVean, Gilean; Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Amaratunga, Chanaki; Lim, Pharath; Anderson, Jennifer M.; Su, Xin-zhuan; Fairhurst, Rick M.] NIAID, US Natl Inst Hlth, Bethesda, MD 20892 USA.
   [Lim, Pharath; Suon, Seila; Sreng, Sokunthea; Duong, Socheat; Nguon, Chea; Chuor, Char Meng] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia.
   [Saunders, David; Fukuda, Mark M.; Bethell, Delia] US Army Med Component, Armed Forces Res Inst Med Sci USAMC AFRIMS, Dept Immunol & Med, Bangkok, Thailand.
   [Se, Youry; Lon, Chantap] USAMC AFRIMS, Phnom Penh, Cambodia.
   [Fukuda, Mark M.] Armed Forces Hlth Surveillance Ctr, Silver Spring, MD USA.
   [Amenga-Etego, Lucas; Hodgson, Abraham V. O.; Asoala, Victor] Navrongo Hlth Res Ctr, Navrongo, Ghana.
   [Imwong, Mallika] Mahidol Univ, Fac Trop Med, Dept Mol Trop Med & Genet, Bangkok, Thailand.
   [Takala-Harrison, Shannon; Plowe, Christopher V.] Univ Maryland, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21201 USA.
   [Nosten, Francois] Shoklo Malaria Res Unit, Mae Sot, Tak, Thailand.
   [Nosten, Francois; Dolecek, Christiane; Tran Tinh Hien; Boni, Maciej F.; Day, Nicholas P.; White, Nicholas J.; Dondorp, Arjen M.] Univ Oxford, Ctr Trop Med, Oxford, England.
   [Ringwald, Pascal] WHO, Global Malaria Programme, CH-1211 Geneva, Switzerland.
   [Ariey, Frederic] Inst Pasteur, Unite Immunol Mol Parasites, Paris, France.
   [Dolecek, Christiane; Tran Tinh Hien; Boni, Maciej F.; Cao Quang Thai] Oxford Univ Clin Res Unit, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam.
   [Amambua-Ngwa, Alfred; Conway, David J.] MRC Labs, Fajara, Gambia.
   [Conway, David J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Djimde, Abdoulaye A.; Doumbo, Ogobara K.] Univ Sci Tech & Technol Bamako, Fac Pharm, Malaria Res & Training Ctr, Bamako, Mali.
   [Zongo, Issaka; Ouedraogo, Jean-Bosco] Direct Reg Ouest, Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso.
   [Auburn, Sarah] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia.
   [Gamble, Chris] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   [Newbold, Chris I.] Univ Oxford, Weatherall Inst Mol Med, Oxford, England.
RP Kwiatkowski, DP (reprint author), Univ Oxford, MRC, Ctr Genom & Global Hlth, Oxford, England.
EM dominic@sanger.ac.uk
RI ; Valle, Ruben/A-7512-2013; Koch, Oliver/A-9480-2016; Jyothi,
   Dushyanth/H-9517-2014
OI Nosten, Francois/0000-0002-7951-0745; Jyothi,
   Dushyanth/0000-0002-0448-5303; McVean, Gil/0000-0002-5012-4162; Newbold,
   Chris/0000-0002-9274-3789; Miotto, Olivo/0000-0001-8060-6771; Oyola,
   Samuel O./0000-0002-6425-7345; Rayner, Julian/0000-0002-9835-1014; Su,
   Xinzhuan/0000-0003-3246-3248; Kwiatkowski, Dominic/0000-0002-5023-0176;
   Mead, Daniel/0000-0001-7717-4330; Manske, Magnus/0000-0001-5916-0947;
   Auburn, Sarah/0000-0002-4638-536X; Conway, David/0000-0002-8711-3037
FU Wellcome Trust through core funding of the Wellcome Trust Sanger
   Institute [098051]; Wellcome Trust through core funding of the Wellcome
   Trust Centre for Human Genetics [090532/Z/09/Z]; Wellcome Trust through
   a Strategic Award [090770/Z/09/Z]; MRC through the MRC Centre for
   Genomics and Global Health [G0600718]; MRC through an MRC Professorship
   [G19/9]; Wellcome Trust; MRC; Division of Intramural Research, National
   Institute of Allergy and Infectious Diseases, US National Institutes of
   Health; Howard Hughes Medical Institute International Scholarship
   [55005502]
FX We would like to thank V. Cornelius and R. Giacomantonio for their
   support in producing and reviewing this manuscript; S. Uk and E.S.
   Phelps for their contributions in the Cambodian studies; and T. Anderson
   for helpful review comments. The sequencing, genotyping and analysis
   components of this study were supported by the Wellcome Trust through
   core funding of the Wellcome Trust Sanger Institute (098051), core
   funding of the Wellcome Trust Centre for Human Genetics (090532/Z/09/Z)
   and a Strategic Award (090770/Z/09/Z) and the MRC through the MRC Centre
   for Genomics and Global Health (G0600718) and an MRC Professorship to
   D.P.K. (G19/9). Other parts of this study were partly supported by the
   Wellcome Trust; the MRC; the Division of Intramural Research, National
   Institute of Allergy and Infectious Diseases, US National Institutes of
   Health; and a Howard Hughes Medical Institute International Scholarship
   (55005502) to A.A.D. P.R. is a staff member of the World Health
   Organization; he alone is responsible for the views expressed in this
   publication, and they do not necessarily represent the decisions, policy
   or views of the World Health Organization.
CR Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109
   Amaratunga C, 2012, LANCET INFECT DIS, V12, P851, DOI 10.1016/S1473-3099(12)70181-0
   Anderson TJC, 2010, J INFECT DIS, V201, P1326, DOI 10.1086/651562
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   Anderson TJC, 2005, ANTIMICROB AGENTS CH, V49, P2180, DOI 10.1128/AAC.49.6.2180-2188.2005
   Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814
   Bethell D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019283
   Cheeseman IH, 2012, SCIENCE, V336, P79, DOI 10.1126/science.1215966
   Dondorp AM, 2011, NEW ENGL J MED, V365, P1073, DOI 10.1056/NEJMp1108322
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Dye C, 1997, P ROY SOC B-BIOL SCI, V264, P61
   Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(00)00084-8
   Flegg JA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-339
   FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0
   Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535
   Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048
   Isozumi R, 2010, J CLIN MICROBIOL, V48, P70, DOI 10.1128/JCM.01449-09
   Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427
   Kublin JG, 1998, LANCET, V351, P1629, DOI 10.1016/S0140-6736(98)24022-0
   Lawson DJ, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002453
   Lim P, 2003, ANTIMICROB AGENTS CH, V47, P87, DOI 10.1128/AAC.47.1.87-94.2002
   Manske M, 2012, NATURE, V487, P375, DOI 10.1038/nature11174
   Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200
   Mita T, 2011, J INFECT DIS, V204, P1980, DOI 10.1093/infdis/jir664
   Mu JB, 2003, MOL MICROBIOL, V49, P977, DOI 10.1046/j.1365-2958.2003.03627.x
   Mu JB, 2010, NAT GENET, V42, P268, DOI 10.1038/ng.528
   Noedl H, 2008, NEW ENGL J MED, V359, P2619, DOI 10.1056/NEJMc0805011
   PAYNE D, 1987, PARASITOL TODAY, V3, P241, DOI 10.1016/0169-4758(87)90147-5
   PAYNE D, 1988, PARASITOL TODAY, V4, P112, DOI 10.1016/0169-4758(88)90042-7
   PEEL SA, 1994, AM J TROP MED HYG, V51, P648
   PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114
   Phyo AP, 2012, LANCET, V379, P1960, DOI 10.1016/S0140-6736(12)60484-X
   Plowe Christopher V, 2009, Trans R Soc Trop Med Hyg, V103 Suppl 1, pS11, DOI 10.1016/j.trstmh.2008.11.002
   Plowe CV, 1997, J INFECT DIS, V176, P1590
   Preechapornkul P, 2009, ANTIMICROB AGENTS CH, V53, P1509, DOI 10.1128/AAC.00241-08
   Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389
   Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876
   Shankar J, 2008, GENE, V410, P223, DOI 10.1016/j.gene.2007.12.015
   Sinka ME, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-89
   Tran TH, 2012, MALARIA J, V11, P355, DOI DOI 10.1186/1475-2875-11-355
   Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807
   VERDRAGER J, 1986, J TROP MED HYG, V89, P277
   Vinayak S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000830
   White NJ, 2010, LANCET, V376, P2051, DOI 10.1016/S0140-6736(10)61963-0
   World Health Organization (WHO), 2011, GLOB PLAN ART RES CO
NR 45
TC 196
Z9 199
U1 1
U2 66
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2013
VL 45
IS 6
BP 648
EP +
DI 10.1038/ng.2624
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 152XA
UT WOS:000319563900012
PM 23624527
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Pollock, L
   Roy, RB
   Kampmann, B
AF Pollock, Louisa
   Roy, Robindra Basu
   Kampmann, Beate
TI How to use: interferon gamma release assays for tuberculosis
SO ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION
LA English
DT Article
ID ACTIVE TUBERCULOSIS; SKIN-TEST; MYCOBACTERIUM-TUBERCULOSIS; LATENT
   TUBERCULOSIS; SOUTH-AFRICA; CHILDREN; INFECTION; DIAGNOSIS;
   METAANALYSIS; DISEASE
AB Diagnosis and treatment of latent tuberculosis infection (LTBI) is important to reduce risk of progression to active tuberculosis (TB) disease. For the past century the tuberculin skin test (TST) has been used as a measure of exposure to Mycobacterium tuberculosis (MTB), but this test has limitations in test performance, sensitivity and specificity. Interferon. release assays (IGRA), like TST, measure host immune response to MTB. IGRA are designed to be more specific for the diagnosis of LTBI than TST in patients with previous BCG or exposure to non-tuberculous mycobacteria, detecting interferon. generated by T cells in response to antigens more specific to MTB. Although developed as an alternative to TST, recent data, particularly in children, suggest IGRA have their own limitations. Superiority to TST as a diagnostic test in children has not been demonstrated. Neither test discriminates between current or past MTB infection, or between latent infection and active disease. This article reviews the current literature on sensitivity and specificity of IGRA in the diagnosis of LTBI, and summarises current NICE recommendations for the use of IGRA in combination with TST. Although not developed for this purpose, in clinical practice IGRA have also been used as a diagnostic test for active TB. The gold standard for diagnosis of active TB disease is microbiological confirmation by culture of MTB. This article discusses the utility of IGRA as an adjunct to diagnosis of active TB disease, but emphasises that IGRA do not have sufficient sensitivity or specificity to exclude or confirm active TB disease.
C1 [Pollock, Louisa; Roy, Robindra Basu; Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Med, Acad Dept Paediat, London W2 1PG, England.
   [Kampmann, Beate] MRC Unit, Fajara, Gambia.
RP Kampmann, B (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Med, Acad Dept Paediat, St Marys Campus,Norfolk Pl, London W2 1PG, England.
EM b.kampmann@imperial.ac.uk
RI Basu Roy, Robin/L-2979-2016
OI Basu Roy, Robin/0000-0001-5648-3628
FU NIHR [SRF-2009-02-07]; BRC at Imperial College; Medical Research Council
   [MR/K011944/1]
FX We would like to acknowledge our research funding from NIHR grant number
   SRF-2009-02-07 (BK, RBR), the BRC at Imperial College (BK, LP) and the
   Medical Research Council grant number MR/K011944/1 (BK, LP).
CR Bamford ARJ, 2010, ARCH DIS CHILD, V95, P180, DOI 10.1136/adc.2009.169805
   Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247
   Denkinger CM, 2011, CLIN MICROBIOL INFEC, V17, P806, DOI 10.1111/j.1469-0691.2011.03555.x
   Diel R, 2011, EUR RESPIR J, V37, P88, DOI 10.1183/09031936.00115110
   Diel R, 2008, AM J RESP CRIT CARE, V177, P1164, DOI 10.1164/rccm.200711-1613OC
   GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90
   Higuchi K, 2009, J INFECTION, V58, P352, DOI 10.1016/j.jinf.2009.02.019
   [Anonymous], 2012, TUB UK ANN REP TUB S
   Kampmann B, 2009, EUR RESPIR J, V33, P1374, DOI 10.1183/09031936.00153408
   Machingaidze S, 2011, PEDIATR INFECT DIS J, V30, P694, DOI 10.1097/INF.0b013e318214b915
   Mandalakas AM, 2011, INT J TUBERC LUNG D, V15, P1018, DOI 10.5588/ijtld.10.0631
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P392
   Moyo S, 2011, INT J TUBERC LUNG D, V15, P1176, DOI 10.5588/ijtld.10.0770
   Moyo S, 2011, INT J TUBERC LUNG D, V15, pi
   National Institute for Health and Clinical Excellence, 2011, NICE GUID CG117 TUB
   Nicol MP, 2011, LANCET INFECT DIS, V11, P819, DOI 10.1016/S1473-3099(11)70167-0
   Roy RB, 2012, AM J RESP CRIT CARE, V186, P378, DOI 10.1164/rccm.201201-0026OC
   Smieja MJ, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001363
   Vynnycky E, 2000, AM J EPIDEMIOL, V152, P247, DOI 10.1093/aje/152.3.247
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
NR 20
TC 16
Z9 17
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1743-0585
EI 1743-0593
J9 ARCH DIS CHILDHOOD-E
JI Arch. Dis. Childhood-Educ. Pract. Ed.
PD JUN
PY 2013
VL 98
IS 3
BP 99
EP 105
DI 10.1136/archdischild-2013-303641
PG 7
WC Pediatrics
SC Pediatrics
GA 143ZC
UT WOS:000318907200006
PM 23580543
OA No
DA 2017-08-15
ER

PT J
AU Fulford, AJC
   Moore, SE
   Arifeen, SE
   Persson, LA
   Neufeld, LM
   Wagatsuma, Y
   Prentice, AM
AF Fulford, A. J. C.
   Moore, S. E.
   Arifeen, S. E.
   Persson, L. A. .
   Neufeld, L. M.
   Wagatsuma, Y.
   Prentice, A. M.
TI Disproportionate early fetal growth predicts postnatal thymic size in
   humans
SO JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE
LA English
DT Article
DE Bangladesh; fetal growth; thymus size; ultrasound
ID BREAST-FED INFANTS; CROWN-RUMP LENGTH; LOW-BIRTH-WEIGHT; RURAL
   BANGLADESH; CHARTS; MORTALITY; DETERMINANTS; DEFINITIONS; CHILDREN;
   DELIVERY
AB Prenatal events can affect neonatal thymus size and adult immune function. The causal insults are unknown, although fetal nutrient restriction is suspected. We used ultrasound at three time points during pregnancy (14, 19 and 30 weeks) to measure the growth of six fetal dimensions in rural Bangladeshi women participating in the Maternal and Infant Nutrition Interventions, Matlab study. Postnatal ultrasound was used to calculate thymic index (TI) at birth, 2, 6 and 12 m. Of the 3267 women recruited, 2861 participated by providing data at least at one fetal biometry and one TI time point. Patterns of fetal growth were summarized using principal components calculated from fetal dimension z-scores. Random effects regression, controlling for infant size and season of measurement were used to relate these patterns to TI. We found that smaller leg length relative to head circumference, characteristic of head-sparing growth restriction, was predictive of lower TI. This association was significant at all time points but strongest in earlier pregnancy. Each standard deviation increase in leg-head proportion was associated with an increase in TI of similar to 5%. We conclude that growth patterns typical of poor fetal nutrition are associated with poor thymic development. The greater strength of this association in the first trimester is consistent with a period of vulnerability during the early ontogeny of the thymus and suggests that preventative intervention would need to be given in early pregnancy.
C1 [Fulford, A. J. C.; Moore, S. E.; Prentice, A. M.] MRC Unit, MRC Keneba, Banjul, Gambia.
   [Fulford, A. J. C.; Prentice, A. M.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, Dept Populat Hlth, London WC1E 7HT, England.
   [Arifeen, S. E.] ICDDR B, Dhaka, Bangladesh.
   [Persson, L. A. .] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden.
   [Neufeld, L. M.] Micronutrient Initiat, Ottawa, ON, Canada.
   [Wagatsuma, Y.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Epidemiol, Tsukuba, Ibaraki, Japan.
RP Fulford, AJC (reprint author), Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, Dept Populat Hlth, Keppel St, London WC1E 7HT, England.
EM tony.fulford@lshtm.ac.uk
FU UNICEF; Department for International Development (DFID); Swedish
   International Development Cooperation Agency (SIDA); United States
   Agency for International Development (USAID); Child Health and Nutrition
   Research Initiative (CHNRI); Japanese Society for Promotion of Science
   (JSPS); UK Medical Research Council; MRC
FX L.A.P. and S. E. A. conceived and oversaw the original MINIMat trial.
   L.M.N. and Y.W. designed and implemented the fetal ultrasound component
   of the MINIMat study. S. E. M., Y.W. and A. M. P. designed and
   implemented the thymus ultrasound component of the study. A.J.C.F.
   conceived the current analysis, performed all statistical analysis and
   wrote the manuscript. All authors read and approved the final
   manuscript. The authors acknowledge the contribution of the families in
   Matlab participating in the MINIMat project. The authors are grateful to
   all the staff from the MINIMat study. The MINIMat project has been
   financially supported by UNICEF, the Department for International
   Development (DFID), Swedish International Development Cooperation Agency
   (SIDA), the United States Agency for International Development (USAID)
   and the Child Health and Nutrition Research Initiative (CHNRI). The
   Japanese Society for Promotion of Science (JSPS) provided funding for
   the ultrasound component; the thymic ultrasound sub-study also received
   support from the UK Medical Research Council.; Financial support was
   received from UNICEF, DFID, SIDA, USAID, CHNRI, JSPS and MRC.
CR Aaby P, 2002, ACTA PAEDIATR, V91, P698, DOI 10.1080/080352502760069142
   ALTMAN DG, 1994, BRIT J OBSTET GYNAEC, V101, P29, DOI 10.1111/j.1471-0528.1994.tb13006.x
   Bakketeig LS, 1998, EUR J CLIN NUTR, V52, pS1
   Bakketeig LS, 1998, EUR J CLIN NUTR, V52, pS94
   Barker DJ, 1993, BRIT MED J, V311, P171
   Barker DJP, 2004, J AM COLL NUTR, V23, p588S
   CHITTY LS, 1994, BRIT J OBSTET GYNAEC, V101, P125, DOI 10.1111/j.1471-0528.1994.tb13077.x
   CHITTY LS, 1994, BRIT J OBSTET GYNAEC, V101, P132, DOI 10.1111/j.1471-0528.1994.tb13078.x
   Chitty LS, 2002, BJOG-INT J OBSTET GY, V109, P919, DOI 10.1016/S1470-0328(02)01922-5
   CHITTY LS, 1994, BRIT J OBSTET GYNAEC, V101, P35, DOI 10.1111/j.1471-0528.1994.tb13007.x
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   Fulford AJC, 2006, PAEDIATR PERINAT EP, V20, P251, DOI 10.1111/j.1365-3016.2006.00714.x
   Hasselbalch H, 1996, EUR RADIOL, V6, P700
   Hasselbalch H, 1996, ACTA PAEDIATR, V85, P1029, DOI 10.1111/j.1651-2227.1996.tb14211.x
   Hasselbalch H, 1999, EUR J PEDIATR, V158, P964, DOI 10.1007/s004310051258
   Joshi BR, 2009, IRAN J RADIOL, V6, P167
   Kramer M. S., 2001, Nutrition and health in developing countries, P57
   KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   McDade TW, 2001, J NUTR, V131, P1225
   Moore SE, 2009, ACTA PAEDIATR, V98, P1168, DOI 10.1111/j.1651-2227.2009.01292.x
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Moore SE, 2008, VACCINE, V26, P158, DOI 10.1016/j.vaccine.2007.11.007
   Neufeld LM, 2009, ULTRASOUND OBST GYN, V34, P387, DOI 10.1002/uog.6385
   Neufeld LM, 2004, INT J GYNECOL OBSTET, V84, P220, DOI 10.1016/S0020-7292(03)00335-7
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   Palmer AC, 2011, ADV NUTR, V2, P377, DOI 10.3945/an.111.000570
   Palmer PES, 1995, MAN DIAGN ULTR
   Persson LA, 2012, JAMA-J AM MED ASSOC, V307, P2050, DOI 10.1001/jama.2012.4061
   Pexsters A, 2010, ULTRASOUND OBST GYN, V35, P650, DOI 10.1002/uog.7654
   Prentice AM, 1999, BRIT J NUTR, V81, P345
   ROWLANDS S, 1993, BRIT J GEN PRACT, V43, P322
   Saha KK, 2008, AM J CLIN NUTR, V87, P1852
   Wilson JG, 1973, ENV SCI SERIES
NR 35
TC 3
Z9 3
U1 0
U2 5
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 2040-1744
J9 J DEV ORIG HLTH DIS
JI J. Dev. Orig. Health Dis.
PD JUN
PY 2013
VL 4
IS 3
BP 223
EP 231
DI 10.1017/S2040174413000044
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 137KQ
UT WOS:000318435100003
PM 25054841
OA No
DA 2017-08-15
ER

PT J
AU de Silva, TI
   Peng, YC
   Leligdowicz, A
   Zaidi, I
   Li, L
   Griffin, H
   Blais, ME
   Vincent, T
   Saraiva, M
   Yindom, LM
   van Tienen, C
   Easterbrook, P
   Jaye, A
   Whittle, H
   Dong, T
   Rowland-Jones, SL
AF de Silva, Thushan I.
   Peng, Yanchun
   Leligdowicz, Aleksandra
   Zaidi, Irfan
   Li, Lucy
   Griffin, Harry
   Blais, Marie-Eve
   Vincent, Tim
   Saraiva, Mavinga
   Yindom, Louis-Marie
   van Tienen, Carla
   Easterbrook, Philippa
   Jaye, Assan
   Whittle, Hilton
   Dong, Tao
   Rowland-Jones, Sarah L.
TI Correlates of T-cell-mediated viral control and phenotype of CD8(+) T
   cells in HIV-2, a naturally contained human retroviral infection
SO BLOOD
LA English
DT Article
ID HLA CLASS-I; DISEASE PROGRESSION; GUINEA-BISSAU; RESPONSES; VIRUS; AIDS;
   EXPRESSION; SURVIVAL; WOMEN; LOAD
AB While a significant proportion of HIV-2-infected individuals are asymptomatic and maintain undetectable viral loads (controllers), 15% to 20% progress to AIDS and are predicted by detectable viremia. Identifying immune correlates that distinguish these 2 groups should provide insights into how a potentially pathogenic retrovirus can be naturally controlled. We performed a detailed study of HIV-2-specific cellular responses in a unique community cohort in Guinea-Bissau followed for over 2 decades. T-cell responses were compared between controllers (n = 33) and viremic subjects (n = 27) using overlapping peptides, major histocompatibility complex class I tetramers, and multiparameter flow cytometry. HIV-2 viral control was significantly associated with a high-magnitude, polyfunctional Gag-specific CD8(+) T-cell response but not with greater perforin upregulation. This potentially protective HIV-2-specific response is surprisingly narrow. HIV-2 Gag-specific CD8(+) T cells are at an earlier stage of differentiation than cytomegalovirus-specific CD8(+) T-cells, do not contain high levels of cytolytic markers, and exhibit low levels of activation and proliferation, representing distinct properties from CD8(+) T cells associated with HIV-1 control. These data reveal the potential T-cell correlates of HIV-2 control and the detailed phenotype of virus-specific CD8(+) T cells in a naturally contained retroviral infection.
C1 [de Silva, Thushan I.; Leligdowicz, Aleksandra; Zaidi, Irfan; Li, Lucy; Vincent, Tim; Saraiva, Mavinga; van Tienen, Carla; Jaye, Assan; Whittle, Hilton] Med Res Council United Kingdom Labs Gambia, Fajara, Gambia.
   [de Silva, Thushan I.; Leligdowicz, Aleksandra; Griffin, Harry; Blais, Marie-Eve; Yindom, Louis-Marie; Rowland-Jones, Sarah L.] John Radcliffe Hosp, Nuffield Dept Med, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [de Silva, Thushan I.] Univ Sheffield, Sch Med, Acad Unit Immunol & Infect Dis, Dept Infect & Immun, Sheffield, S Yorkshire, England.
   [Peng, Yanchun; Dong, Tao] John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [Vincent, Tim; Saraiva, Mavinga] Projecto Saude Bandim Indepth Network, Bissau, Guinea Bissau.
   [Easterbrook, Philippa] Univ KwaZulu, Nelson Mandela Sch Med, Dept Infect Dis, Berea, South Africa.
   [Whittle, Hilton] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
RP de Silva, TI (reprint author), Univ Sheffield, Sch Med, Acad Dept Immunol & Infect Dis, Dept Infect & Immun, Sheffield, S Yorkshire, England.
EM thushandesilva@hotmail.com
RI van Tienen, Carla/A-1119-2012
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
FU UK MRC [G0701313]
FX This work was supported by a UK MRC clinical research training
   fellowship (G0701313) (T.I.d.S.).
CR Addo MM, 2007, PLOS ONE, V2, pe321
   Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Berry N, 1998, J Hum Virol, V1, P457
   Bertoletti A, 1998, J VIROL, V72, P2439
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Brinkhof MWG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000066
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Burgers WA, 2009, J IMMUNOL, V182, P4751, DOI 10.4049/jimmunol.0803801
   Chevalier MF, 2011, J VIROL, V85, P733, DOI 10.1128/JVI.02030-10
   Chun TW, 2004, P NATL ACAD SCI USA, V101, P2464, DOI 10.1073/pnas.0307328101
   de Silva TI, 2012, J VIROL, V86, P930, DOI 10.1128/JVI.06126-11
   de Silva TI, 2008, TRENDS MICROBIOL, V16, P588, DOI 10.1016/j.tim.2008.09.003
   Dong T, 2004, J EXP MED, V200, P1547, DOI 10.1084/jem.20032044
   Duraiswamy J, 2011, J IMMUNOL, V186, P4200, DOI 10.4049/jimmunol.1001783
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   Esbjiornsson J, 2012, NEW ENGL J MED, V367, P224
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Hersperger AR, 2011, BLOOD, V117, P3799, DOI 10.1182/blood-2010-12-322727
   Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917
   Holmgren B, 1999, SCAND J INFECT DIS, V31, P459
   Jaffar S, 2005, AIDS RES HUM RETROV, V21, P560, DOI 10.1089/aid.2005.21.560
   Julg B, 2010, J VIROL, V84, P5540, DOI 10.1128/JVI.02031-09
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505
   Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Leligdowicz A, 2010, EUR J IMMUNOL, V40, P1963, DOI 10.1002/eji.200940295
   Leligdowicz A, 2010, J INFECT DIS, V201, P114, DOI 10.1086/648733
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83
   Martinez-Steele E, 2007, AIDS, V21, P317, DOI 10.1097/QAD.0b013e328011d7ab
   Matthews PC, 2012, J VIROL, V86, P12643, DOI 10.1128/JVI.01381-12
   Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010
   Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020
   Papagno L, 2002, CLIN EXP IMMUNOL, V130, P509, DOI 10.1046/j.1365-2249.2002.02005.x
   Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Sauce D, 2007, AIDS, V21, P2005
   Tussey LG, 2003, J INFECT DIS, V187, P364, DOI 10.1086/367707
   van der Loeff MFS, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-46
   van Tienen C, 2010, JAIDS-J ACQ IMM DEF, V53, P640, DOI 10.1097/QAI.0b013e3181bf1a25
   Yamamoto T, 2011, BLOOD, V117, P4805, DOI 10.1182/blood-2010-11-317297
   Yindom LM, 2010, J VIROL, V84, P8202, DOI 10.1128/JVI.00116-10
   Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006
NR 48
TC 16
Z9 16
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 23
PY 2013
VL 121
IS 21
BP 4330
EP 4339
DI 10.1182/blood-2012-12-472787
PG 10
WC Hematology
SC Hematology
GA 184FS
UT WOS:000321873900016
PM 23558015
OA No
DA 2017-08-15
ER

PT J
AU Courtiol, A
   Rickard, IJ
   Lummaa, V
   Prentice, AM
   Fulford, AJC
   Stearns, SC
AF Courtiol, Alexandre
   Rickard, Ian J.
   Lummaa, Virpi
   Prentice, Andrew M.
   Fulford, Anthony J. C.
   Stearns, Stephen C.
TI The Demographic Transition Influences Variance in Fitness and Selection
   on Height and BMI in Rural Gambia
SO CURRENT BIOLOGY
LA English
DT Article
ID CONTEMPORARY HUMAN-POPULATION; NATURAL-SELECTION; SEXUAL SELECTION;
   SECULAR TREND; OPPORTUNITY; MORTALITY; VILLAGES; GENETICS; GROWTH; WILD
AB Recent human history is marked by demographic transitions characterized by declines in mortality and fertility [1]. By influencing the variance in those fitness components, demographic transitions can affect selection on other traits [2]. Parallel to changes in selection triggered by demography per se, relationships between fitness and anthropometric traits are also expected to change due to modification of the environment. Here we explore for the first time these two main evolutionary consequences of demographic transitions using a unique data set containing survival, fertility, and anthropometric data for thousands of women in rural Gambia from 1956-2010 [3]. We show how the demographic transition influenced directional selection on height and body mass index (BMI). We observed a change in selection for both traits mediated by variation in fertility: selection initially favored short females with high BMI values but shifted across the demographic transition to favor tall females with low BMI values. We demonstrate that these differences resulted both from changes in fitness variance that shape the strength of selection and from shifts in selective pressures triggered by environmental changes. These results suggest that demographic and environmental trends encountered by current human populations worldwide are likely to modify, but not stop, natural selection in humans.
C1 [Courtiol, Alexandre] Leibniz Inst Zoo & Wildlife Res, Dept Evolutionary Genet, D-10315 Berlin, Germany.
   [Courtiol, Alexandre; Rickard, Ian J.; Lummaa, Virpi; Stearns, Stephen C.] Wissensch Kolleg Berlin, D-14193 Berlin, Germany.
   [Rickard, Ian J.; Lummaa, Virpi] Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.
   [Rickard, Ian J.] Univ Durham, Dept Anthropol, Thornaby TS17 6BH, Stockton On Tee, England.
   [Prentice, Andrew M.; Fulford, Anthony J. C.] MRC Keneba, Keneba, Gambia.
   [Prentice, Andrew M.; Fulford, Anthony J. C.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   [Stearns, Stephen C.] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA.
RP Rickard, IJ (reprint author), Univ Durham, Dept Anthropol, Queens Campus Stockton,Univ Blvd, Thornaby TS17 6BH, Stockton On Tee, England.
EM ian.rickard@durham.ac.uk
OI Stearns, Stephen/0000-0002-6621-4373; Courtiol,
   Alexandre/0000-0003-0637-2959
FU UK MRC [MC-A760-5QX00]; Wellcome Trust; European Research Council;
   Wissenschaftskolleg zu Berlin; European Institutes for Advanced Study
   (EURIAS) Fellowship.Program; Leibniz Institute for Zoo; Wildlife
   Research (IZW); ERC
FX The longitudinal data collection has been continuously funded by the UK
   MRC since 1948, currently via award MC-A760-5QX00. I.J.R. was funded by
   the Wellcome Trust, European Research Council, and Wissenschaftskolleg
   zu Berlin; A.C. by the European Institutes for Advanced Study (EURIAS)
   Fellowship.Program and the Leibniz Institute for Zoo and Wildlife
   Research (IZW); V.L. by the ERC, Wissenschaftskolleg zu Berlin, and the
   Royal Society of London; and S.C.S. by Wissenschaftskolleg zu Berlin. We
   thank Jake Moorad, Michael Morrissey, and the reviewers for helpful
   discussions.
CR Alfonso-Sanchez MA, 2004, HUM BIOL, V76, P361, DOI 10.1353/hub.2004.0041
   ARNOLD SJ, 1984, EVOLUTION, V38, P709, DOI 10.1111/j.1558-5646.1984.tb00344.x
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   Brommer JE, 2007, AM NAT, V170, P643, DOI 10.1086/521241
   Byars SG, 2010, P NATL ACAD SCI USA, V107, P1787, DOI 10.1073/pnas.0906199106
   CALDWELL JC, 1976, POPUL DEV REV, V2, P321, DOI 10.2307/1971615
   Courtiol A, 2012, P NATL ACAD SCI USA, V109, P8044, DOI 10.1073/pnas.1118174109
   CROW JAMES F., 1958, HUMAN BIOL, V30, P1
   Das Farida Ahmed, 2010, Indian J Hum Genet, V16, P61, DOI 10.4103/0971-6866.69328
   Davis K, 1945, ANN AM ACAD POLIT SS, V237, P1, DOI 10.1177/000271624523700102
   Foerster K, 2007, NATURE, V447, P1107, DOI 10.1038/nature05912
   Galor O, 2000, AM ECON REV, V90, P806, DOI 10.1257/aer.90.4.806
   Gautam RK, 2009, J BIOSOC SCI, V41, P705, DOI 10.1017/S0021932009990095
   Grafen A, 1987, SEXUAL SELECTION TES, P221
   HED HME, 1987, HUM BIOL, V59, P785
   Jennions MD, 2012, J EVOLUTION BIOL, V25, P591, DOI 10.1111/j.1420-9101.2011.02451.x
   Kelley JL, 2008, ANNU REV GENOM HUM G, V9, P143, DOI 10.1146/annurev.genom.9.081307.164411
   Klug H, 2010, J EVOLUTION BIOL, V23, P447, DOI 10.1111/j.1420-9101.2009.01921.x
   Korpelainen H, 2003, AM J PHYS ANTHROPOL, V120, P384, DOI 10.1002/ajpa.10191
   Krakauer AH, 2011, J EVOLUTION BIOL, V24, P2064, DOI 10.1111/j.1420-9101.2011.02317.x
   LANDE R, 1983, EVOLUTION, V37, P1210, DOI 10.1111/j.1558-5646.1983.tb00236.x
   Lee R, 2003, J ECON PERSPECT, V17, P167, DOI 10.1257/089533003772034943
   Milot E, 2011, P NATL ACAD SCI USA, V108, P17040, DOI 10.1073/pnas.1104210108
   Moorad J. A., 2013, EVOLUTION, DOI DOI 10.1111/EV0.12023
   Moorad JA, 2013, AM NAT, V181, P291, DOI 10.1086/669158
   Moorad JA, 2011, EVOL HUM BEHAV, V32, P147, DOI 10.1016/j.evolhumbehav.2010.10.004
   Morrissey MB, 2012, EVOLUTION, V66, P435, DOI 10.1111/j.1558-5646.2011.01444.x
   Mulder MB, 1998, TRENDS ECOL EVOL, V13, P266, DOI 10.1016/S0169-5347(98)01357-3
   PRICE GR, 1970, NATURE, V227, P520, DOI 10.1038/227520a0
   Qvarnstrom A, 2006, NATURE, V441, P84, DOI 10.1038/nature04564
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   Rook GAW, 2012, CLIN REV ALLERG IMMU, V42, P5, DOI 10.1007/s12016-011-8285-8
   Sear R, 2004, RES ECON ANTHROPOL, V23, P203, DOI 10.1016/S0190-1281(04)23008-6
   SEAR R, 2006, BIODEMOGRAPHY SOCIAL, V53, P172
   Robertson A, 1966, ANIM PROD, V8, P95
   Spuhler J. N., 1976, DEMOGRAPHIC ANTHR QU, P185
   Stearns SC, 2010, NAT REV GENET, V11, P611, DOI 10.1038/nrg2831
   TERRENATO L, 1979, ANN HUM GENET, V42, P391, DOI 10.1111/j.1469-1809.1979.tb00671.x
   Tishkoff SA, 2007, NAT GENET, V39, P31, DOI 10.1038/ng1946
   Naciones Unidas (UN), 2011, WORLD POP PROSP 2010, VI
NR 41
TC 16
Z9 16
U1 1
U2 23
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
J9 CURR BIOL
JI Curr. Biol.
PD MAY 20
PY 2013
VL 23
IS 10
BP 884
EP 889
DI 10.1016/j.cub.2013.04.006
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 151TK
UT WOS:000319482900023
PM 23623548
OA No
DA 2017-08-15
ER

PT J
AU Ota, MOC
   Idoko, OT
   Ogundare, EO
   Afolabi, MO
AF Ota, M. O. C.
   Idoko, O. T.
   Ogundare, E. O.
   Afolabi, M. O.
TI Human immune responses to vaccines in the first year of life:
   Biological, socio-economic and ethical issues - A viewpoint
SO VACCINE
LA English
DT Review
DE Vaccines; Immune responses; Human; Infancy; Biological factors;
   Socioeconomic factors
ID BACILLUS-CALMETTE-GUERIN; TITER MEASLES-VACCINES; INFECTIOUS-DISEASES;
   HEALTH INFORMATION; BCG VACCINATION; VERBAL AUTOPSY; INFANTS BORN;
   MORTALITY; IMMUNIZATION; ENVIRONMENT
AB Human newborns are vulnerable to infectious diseases that account for majority of the morbidity and mortality, particularly in first year of life. Vaccines have become the most effective public health intervention strategy to curtail the prevalence of these infectious diseases. Although vaccines against a number of diseases exist, there are no vaccines against many other diseases that commonly affect children. The adequate assessment of immune responses to vaccines is an important step in the development of vaccines. However, a number of biological and "non-medical" socio-economic and ethical factors could influence either the administration and/or evaluation of vaccines in infants. Recognition and understanding of these determinants are crucial in planning interventions and for logical interpretations of results. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Ota, M. O. C.; Idoko, O. T.; Ogundare, E. O.; Afolabi, M. O.] Med Res Council MRC Unit, Banjul, Gambia.
RP Ota, MOC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM mota@mrc.gm
OI Afolabi, Muhammed/0000-0002-9967-6419
FU Medical Research Council [MC_UP_A900_1122, MC_U190071468]
CR AABY P, 1993, AM J EPIDEMIOL, V138, P746
   Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x
   Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773
   Abramczuk BM, 2011, CLIN VACCINE IMMUNOL, V18, P1406, DOI 10.1128/CVI.05065-11
   Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   BURSTYN DG, 1983, INFECT IMMUN, V41, P1150
   Chougnet C, 2000, J INFECT DIS, V181, P1590, DOI 10.1086/315458
   Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247
   Coughlin SS, 2006, EMERG THEMES EPIDEMI, V3, DOI 10.1186/1742-7622-3-16
   Dauby N, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000571
   DeStefano Frank, 2004, Expert Rev Vaccines, V3, P19, DOI 10.1586/14760584.3.1.19
   Duclos P, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S2
   Dugas M, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S9
   Fadnes LT, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-404
   Fairhead J, 2006, J BIOSOC SCI, V38, P103, DOI 10.1017/S0021932005000945
   Fillol F, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-116
   Fillol F, 2009, AM J TROP MED HYG, V80, P202
   Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
   Flanagan KL, 2010, EUR J IMMUNOL, V40, P1062, DOI 10.1002/eji.200939638
   Franca E, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-39
   Furuhjelm C, 2011, PEDIATR RES, V69, P259, DOI 10.1203/PDR.0b013e3182072229
   Gostin LO, 2001, HEALTH CARE ANAL, V9, P321, DOI 10.1023/A:1012905932744
   HALSEY NA, 1993, PEDIATR INFECT DIS J, V12, P462, DOI 10.1097/00006454-199306000-00002
   Hinman A, 1999, ANNU REV PUBL HEALTH, V20, P211, DOI 10.1146/annurev.publhealth.20.1.211
   Hou F, 2005, SOC SCI MED, V60, P1557, DOI 10.1016/j.socscimed.2004.08.033
   Howie SRC, 2011, B WORLD HEALTH ORGAN, V89, P46, DOI 10.2471/BLT.10.080010
   Ismaili J, 2003, CLIN EXP IMMUNOL, V133, P414, DOI 10.1046/j.1365-2249.2003.02243.x
   Kaufmann JR, 2009, HEALTH AFFAIR, V28, P1091, DOI 10.1377/hlthaff.28.4.1091
   Lalor MK, 2011, J INFECT DIS, V204, P1075, DOI 10.1093/infdis/jir515
   Lalor MK, 2009, J INFECT DIS, V199, P795, DOI 10.1086/597069
   Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8
   LEACH M, EVIDENCE ETHOS EXPT, P77
   Malhotra I, 1999, J IMMUNOL, V162, P6843
   Marchant A, 2000, CURR OPIN INFECT DIS, V13, P241
   Mayanja BN, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-36
   Miller CMD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005692
   Mostert S, 2008, PEDIATR BLOOD CANCER, V50, P1001, DOI 10.1002/pbc.21324
   Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051
   Ota MOC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002461
   Ota MO, 2005, J NEUROVIROL, V11, P447, DOI 10.1080/13550280591002441
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Ota MOC, 1999, AIDS, V13, P996, DOI 10.1097/00002030-199905280-00020
   Pabst HF, 1997, ACTA PAEDIATR, V86, P1291, DOI 10.1111/j.1651-2227.1997.tb14900.x
   PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207
   Schempf A, 2009, SOC SCI MED, V68, P100, DOI 10.1016/j.socscimed.2008.10.006
   Schwarz NG, 2009, VACCINE, V27, P5371, DOI 10.1016/j.vaccine.2009.06.100
   SHEA B, 2009, BMC INT HEALTH HUM R, V9, P5
   Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77
   Supali T, 2010, INT J PARASITOL, V40, P1171, DOI 10.1016/j.ijpara.2010.05.003
   Van Rie A, 2006, CLIN VACCINE IMMUNOL, V13, P246, DOI 10.1128/CVI.13.2.246-252.2006
   von Hertzen L, 1999, J ALLERGY CLIN IMMUN, V104, P1211
   Webb EL, 2011, LANCET, V377, P52, DOI 10.1016/S0140-6736(10)61457-2
   Woodsong C, 2005, AM J PUBLIC HEALTH, V95, P412, DOI 10.2105/AJPH.2004.041624
   Yen IH, 1999, ANNU REV PUBL HEALTH, V20, P287, DOI 10.1146/annurev.publhealth.20.1.287
   Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173
NR 56
TC 3
Z9 3
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAY 17
PY 2013
VL 31
IS 21
SI SI
BP 2483
EP 2488
DI 10.1016/j.vaccine.2012.06.018
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 160TK
UT WOS:000320143200002
PM 22728219
OA No
DA 2017-08-15
ER

PT J
AU Lim, ES
   Reyes, A
   Antonio, M
   Saha, D
   Ikumapayi, UN
   Adeyemi, M
   Stine, OC
   Skelton, R
   Brennan, DC
   Mkakosya, RS
   Manary, MJ
   Gordon, JI
   Wang, D
AF Lim, Efrem S.
   Reyes, Alejandro
   Antonio, Martin
   Saha, Debasish
   Ikumapayi, Usman N.
   Adeyemi, Mitchell
   Stine, O. Colin
   Skelton, Rebecca
   Brennan, Daniel C.
   Mkakosya, Rajhab S.
   Manary, Mark J.
   Gordon, Jeffrey I.
   Wang, David
TI "Discovery of STL polyomavirus, a polyomavirus of ancestral recombinant
   origin that encodes a unique T antigen by alternative splicing" (vol
   436, pg 295, 2013)
SO VIROLOGY
LA English
DT Correction
C1 [Lim, Efrem S.; Wang, David] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Lim, Efrem S.; Wang, David] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Reyes, Alejandro; Gordon, Jeffrey I.] Washington Univ, Sch Med, Ctr Genome Sci & Syst Biol, St Louis, MO 63110 USA.
   [Skelton, Rebecca; Brennan, Daniel C.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.
   [Manary, Mark J.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
   [Antonio, Martin; Saha, Debasish; Ikumapayi, Usman N.; Adeyemi, Mitchell] MRC Unit, Banjul, Gambia.
   [Stine, O. Colin] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
   [Mkakosya, Rajhab S.] Univ Malawi, Coll Med, Dept Pathol, Blantyre 3, Malawi.
   [Manary, Mark J.] Univ Malawi, Coll Med, Dept Community Hlth, Blantyre 3, Malawi.
RP Wang, D (reprint author), Washington Univ, Sch Med, Dept Mol Microbiol, Campus Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.
EM davewang@borcim.wustl.edu
CR Lim ES, 2013, VIROLOGY, V436, P295, DOI 10.1016/j.virol.2012.12.005
NR 1
TC 3
Z9 3
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAY 10
PY 2013
VL 439
IS 2
BP 163
EP 164
DI 10.1016/j.virol.2013.01.016
PG 2
WC Virology
SC Virology
GA 168EC
UT WOS:000320687500012
OA No
DA 2017-08-15
ER

PT J
AU Flanagan, KL
   Noho-Konteh, F
   Ghazal, P
   Dickinson, P
AF Flanagan, K. L.
   Noho-Konteh, F.
   Ghazal, P.
   Dickinson, P.
TI Transcriptional profiling technology for studying vaccine responses: An
   untapped goldmine
SO METHODS
LA English
DT Article
DE RNA; Microarray; Transcriptome; Pathway; Vaccines; Immunogenicity
ID GENE-EXPRESSION PATTERNS; IMMUNE-RESPONSES; SYSTEMS BIOLOGY; MICROARRAY
   DATA; DNA MICROARRAY; INFLUENZA; BLOOD; CHILDREN; HUMANS; IMMUNOGENICITY
AB There is much that we do not understand about the immune mechanisms whereby vaccines exert their specific and non-specific effects. Most studies take the reductionist approach of examining vaccine responses at the humoral or cellular level. Whole human transcriptional profiling is becoming more accessible, and provides a picture of the entire immune response to vaccination in a single 'snapshot'. The potential uses of such information are enormous, and the data mining tools are becoming more sophisticated to handle the complex data generated. We now face the exciting prospect of gaining in depth knowledge as to exactly what vaccines do to the immune system as a whole, and identifying molecular signatures and biomarkers that can predict immediate and long term outcomes of vaccination. The challenge now is to carry out the studies and generate the much needed data. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Flanagan, K. L.; Noho-Konteh, F.] MRC Labs, Fajara, Gambia.
   [Flanagan, K. L.] Monash Univ, Dept Immunol, Prahran, Vic 3181, Australia.
   [Flanagan, K. L.] Statens Serum Inst, Res Ctr Vitamins & Vaccines, DK-2300 Copenhagen S, Denmark.
   [Ghazal, P.; Dickinson, P.] Univ Edinburgh, Sch Med, Div Pathway Med, Edinburgh EH16 4SB, Midlothian, Scotland.
RP Flanagan, KL (reprint author), Monash Univ, Dept Immunol, Commercial Rd, Prahran, Vic 3181, Australia.
EM katie.flanagan@dhhs.tas.gov.au; fatounohokonteh@gmail.com;
   p.ghazal@ed.ac.uk; Paul.Dickinson@ed.ac.uk
RI Dickinson, Paul/B-7598-2014
FU CVIVA; MRC UK [G0701291, G0701289]; Chief Scientist Office [ETM/202];
   Wellcome Trust
FX KF receives financial support from CVIVA; FNK is funded by MRC UK Grant
   No. G0701291; PG and PD receive funding from MRC UK Grant Nos. G0701291
   and G0701289 and Chief Scientist Office Grant No. ETM/202 and a Wellcome
   Trust Programme Grant (to PG).
CR Aaby P, 2012, BMJ OPEN, V2
   Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   Abbas AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006098
   Aranday-Cortes E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030626
   Aranday-Cortes E., 2010, PLOS ONE, V5
   Ashburner M, 2000, NAT GENET, V25, P25
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Bonferroni C., 1936, PUBBLICAZIONI R I SU, V8, P3
   Bryant PA, 2004, LANCET INFECT DIS, V4, P100, DOI 10.1016/S1473-3099(04)00930-2
   Bryant PA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004427
   Bucasas KL, 2011, J INFECT DIS, V203, P921, DOI 10.1093/infdis/jiq156
   Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd.961
   Chaussabel D, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-84
   Consortium M., 2010, NAT BIOTECHNOL, V28, P827
   Consortium M, 2006, NAT BIOTECHNOL, V24, P1151, DOI DOI 10.1038/NBT1239
   Delaloye J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000480
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dhiman N, 2009, EXPERT REV VACCINES, V8, P963, DOI [10.1586/erv.09.67, 10.1586/ERV.09.67]
   Draghici S, 2003, GENOMICS, V81, P98, DOI 10.1016/S0888-7543(02)00021-6
   Gomez CE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035485
   Flanagan KL, 2011, VACCINE, V29, P2349, DOI 10.1016/j.vaccine.2011.01.071
   Fletcher HA, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-10
   Guerra S, 2007, J VIROL, V81, P8707, DOI 10.1128/JVI.00444-07
   Gupta B, 2012, J IMMUNOTHER, V35, P488, DOI 10.1097/CJI.0b013e31826183a7
   Haralambieva I.H., 2012, J INFECT DIS
   Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Kaveh DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038926
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Kwissa M, 2012, BLOOD, V119, P2044, DOI 10.1182/blood-2011-10-388579
   Ma C, 2011, NAT MED, V17, P738, DOI 10.1038/nm.2375
   MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1679, DOI 10.1093/nar/20.7.1679
   Mizukami T, 2008, VACCINE, V26, P2270, DOI 10.1016/j.vaccine.2008.02.031
   Nakaya HI, 2011, NAT IMMUNOL, V12, P786, DOI 10.1038/ni.2067
   Pulendran B, 2010, IMMUNITY, V33, P516, DOI 10.1016/j.immuni.2010.10.006
   Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688
   Reif DM, 2008, J INFECT DIS, V198, P16, DOI 10.1086/588670
   SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467
   Shann F, 2010, ARCH DIS CHILD, V95, P662, DOI 10.1136/adc.2009.157537
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Smith CL, 2007, ANALYST, V132, P1200, DOI 10.1039/b707122c
   Vahey MT, 2010, J INFECT DIS, V201, P580, DOI 10.1086/650310
   VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484
   White OJ, 2012, VACCINE, V30, P1865, DOI 10.1016/j.vaccine.2011.12.118
   Whitney AR, 2003, P NATL ACAD SCI USA, V100, P1896, DOI 10.1073/pnas.252784499
   Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683
   Zhu W, 2010, VACCINE, V28, P2865, DOI 10.1016/j.vaccine.2010.01.060
NR 48
TC 2
Z9 2
U1 1
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
J9 METHODS
JI Methods
PD MAY 1
PY 2013
VL 60
IS 3
BP 269
EP 274
DI 10.1016/j.ymeth.2013.03.032
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 173QE
UT WOS:000321093200008
PM 23578546
OA No
DA 2017-08-15
ER

PT J
AU Band, G
   Le, QS
   Jostins, L
   Pirinen, M
   Kivinen, K
   Jallow, M
   Sisay-Joof, F
   Bojang, K
   Pinder, M
   Sirugo, G
   Conway, DJ
   Nyirongo, V
   Kachala, D
   Molyneux, M
   Taylor, T
   Ndila, C
   Peshu, N
   Marsh, K
   Williams, TN
   Alcock, D
   Andrews, R
   Edkins, S
   Gray, E
   Hubbart, C
   Jeffreys, A
   Rowlands, K
   Schuldt, K
   Clark, TG
   Small, KS
   Teo, YY
   Kwiatkowski, DP
   Rockett, KA
   Barrett, JC
   Spencer, CCA
AF Band, Gavin
   Le, Quang Si
   Jostins, Luke
   Pirinen, Matti
   Kivinen, Katja
   Jallow, Muminatou
   Sisay-Joof, Fatoumatta
   Bojang, Kalifa
   Pinder, Margaret
   Sirugo, Giorgio
   Conway, David J.
   Nyirongo, Vysaul
   Kachala, David
   Molyneux, Malcolm
   Taylor, Terrie
   Ndila, Carolyne
   Peshu, Norbert
   Marsh, Kevin
   Williams, Thomas N.
   Alcock, Daniel
   Andrews, Robert
   Edkins, Sarah
   Gray, Emma
   Hubbart, Christina
   Jeffreys, Anna
   Rowlands, Kate
   Schuldt, Kathrin
   Clark, Taane G.
   Small, Kerrin S.
   Teo, Yik Ying
   Kwiatkowski, Dominic P.
   Rockett, Kirk A.
   Barrett, Jeffrey C.
   Spencer, Chris C. A.
CA Malaria Genomic Epidemiological Ne
TI Imputation-Based Meta-Analysis of Severe Malaria in Three African
   Populations
SO PLOS GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GENOTYPE-IMPUTATION; GENE; COMMON; CONSORTIUM;
   MORTALITY; VARIANTS
AB Combining data from genome-wide association studies (GWAS) conducted at different locations, using genotype imputation and fixed-effects meta-analysis, has been a powerful approach for dissecting complex disease genetics in populations of European ancestry. Here we investigate the feasibility of applying the same approach in Africa, where genetic diversity, both within and between populations, is far more extensive. We analyse genome-wide data from approximately 5,000 individuals with severe malaria and 7,000 population controls from three different locations in Africa. Our results show that the standard approach is well powered to detect known malaria susceptibility loci when sample sizes are large, and that modern methods for association analysis can control the potential confounding effects of population structure. We show that pattern of association around the haemoglobin S allele differs substantially across populations due to differences in haplotype structure. Motivated by these observations we consider new approaches to association analysis that might prove valuable for multicentre GWAS in Africa: we relax the assumptions of SNP-based fixed effect analysis; we apply Bayesian approaches to allow for heterogeneity in the effect of an allele on risk across studies; and we introduce a region-based test to allow for heterogeneity in the location of causal alleles.
C1 [Band, Gavin; Le, Quang Si; Pirinen, Matti; Hubbart, Christina; Jeffreys, Anna; Rowlands, Kate; Schuldt, Kathrin; Clark, Taane G.; Small, Kerrin S.; Teo, Yik Ying; Kwiatkowski, Dominic P.; Rockett, Kirk A.; Spencer, Chris C. A.] Wellcome Trust Ctr Human Genet, Oxford, England.
   [Jostins, Luke; Kivinen, Katja; Alcock, Daniel; Andrews, Robert; Edkins, Sarah; Gray, Emma; Clark, Taane G.; Kwiatkowski, Dominic P.; Rockett, Kirk A.; Barrett, Jeffrey C.] Wellcome Trust Sanger Inst, Cambridge, England.
   [Jallow, Muminatou; Sisay-Joof, Fatoumatta; Bojang, Kalifa; Pinder, Margaret; Sirugo, Giorgio; Conway, David J.] MRC Unit, Fajara, Gambia.
   [Jallow, Muminatou] Royal Victoria Teaching Hosp, Banjul, Gambia.
   [Conway, David J.; Clark, Taane G.] London Sch Hyg & Trop Med, London WC1, England.
   [Nyirongo, Vysaul; Kachala, David; Molyneux, Malcolm] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.
   [Molyneux, Malcolm] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Taylor, Terrie] Univ Malawi, Coll Med, Blantyre Malaria Project, Blantyre, Malawi.
   [Ndila, Carolyne; Peshu, Norbert; Marsh, Kevin; Williams, Thomas N.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Schuldt, Kathrin] Bernhard Nocht Inst Trop Med, Dept Mol Med, D-20359 Hamburg, Germany.
   [Small, Kerrin S.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England.
   [Teo, Yik Ying] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
RP Band, G (reprint author), Wellcome Trust Ctr Human Genet, Oxford, England.
EM chris.spencer@well.ox.ac.uk
RI Le, Quang/A-4861-2012
OI Le, Quang/0000-0002-3715-210X; Barrett, Jeffrey/0000-0002-1152-370X;
   Small, Kerrin/0000-0003-4566-0005; Kwiatkowski,
   Dominic/0000-0002-5023-0176; Mead, Daniel/0000-0001-7717-4330; Pirinen,
   Matti/0000-0002-1664-1350; Conway, David/0000-0002-8711-3037
FU Medical Research Council [MC_UP_A900_1118, G0600230, G0600718, G19/9];
   Wellcome Trust [075491/Z/04, 077012/Z/05/Z, 087285, 090532,
   090532/Z/09/Z, 090770, 090770/Z/09/Z, 091758, 091758/Z/10/Z, 092654,
   096527, 097364/Z/11/Z, WT077383/Z/05/Z, WT098051]
CR Aidoo M, 2002, LANCET, V359, P1311, DOI 10.1016/S0140-6736(02)08273-9
   Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298
   Astle W, 2009, STAT SCI, V24, P451, DOI 10.1214/09-STS307
   BELLENGUEZ C, 2012, NAT GENET
   Chokshi DA, 2007, PLOS MED, V4, P636, DOI 10.1371/journal.pmed.0040095
   Chung CM, 2011, DIABETES, V60, P2417, DOI 10.2337/db10-1321
   Cortes A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3204
   Dastani Z, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002607
   de Bakker PIW, 2008, HUM MOL GENET, V17, pR122, DOI 10.1093/hmg/ddn288
   de Vries J, 2011, BMC MED ETHICS, V12, DOI 10.1186/1472-6939-12-5
   Dubois PCA, 2010, NAT GENET, V42, P295, DOI 10.1038/ng.543
   Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873
   Fisher RA, 1925, STAT METHODS RES WOR
   Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963
   Ganesh SK, 2009, NAT GENET, V41, P1191, DOI 10.1038/ng.466
   Gieger C, 2011, NATURE, V480, P201, DOI 10.1038/nature10659
   Han B, 2011, AM J HUM GENET, V88, P586, DOI 10.1016/j.ajhg.2011.04.014
   Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Huang L, 2009, AM J HUM GENET, V84, P235, DOI 10.1016/j.ajhg.2009.01.013
   Jallow M, 2009, NAT GENET, V41, P657, DOI 10.1038/ng.388
   Jostins L, 2011, EUR J HUM GENET, V19, P662, DOI 10.1038/ejhg.2011.10
   McVean G, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000686
   Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8
   Nalls MA, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002113
   PAGNIER J, 1984, P NATL ACAD SCI-BIOL, V81, P1771, DOI 10.1073/pnas.81.6.1771
   Parker M, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000143
   Pirinen M, 2012, ANN APPL ST IN PRESS
   Price AL, 2010, NAT REV GENET, V11, P459, DOI 10.1038/nrg2813
   R Development Core Team, 2011, R LANG ENV STAT COMP
   Raychaudhuri S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000534
   Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251
   Soranzo N, 2009, NAT GENET, V41, P1182, DOI 10.1038/ng.467
   Spencer C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001337
   Spencer CCA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000477
   Su Z, 2011, BIOINFORMATICS, V27, P2304, DOI 10.1093/bioinformatics/btr341
   Teo YY, 2010, NAT REV GENET, V11, P149, DOI 10.1038/nrg2731
   TIMMANN C, 2012, NATURE
   Wakefield J, 2007, AM J HUM GENET, V81, P208, DOI 10.1086/519024
   Wang X, 2012, EUR J HUM GENET, V20, P469, DOI 10.1038/ejhg.2011.219
   World Health Organization, 2010, GUID TREATM MAL
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Zhu MH, 2005, J IMMUNOL, V174, P5612
   [Anonymous], 2007, NATURE, V447, P661
NR 45
TC 31
Z9 31
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAY
PY 2013
VL 9
IS 5
AR UNSP e1003509
DI 10.1371/journal.pgen.1003509
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA 159FH
UT WOS:000320030000030
PM 23717212
OA gold
DA 2017-08-15
ER

PT J
AU Gehre, F
   Otu, J
   DeRiemer, K
   de Sessions, PF
   Hibberd, ML
   Mulders, W
   Corrah, T
   de Jong, BC
   Antonio, M
AF Gehre, Florian
   Otu, Jacob
   DeRiemer, Kathryn
   de Sessions, Paola Florez
   Hibberd, Martin L.
   Mulders, Wim
   Corrah, Tumani
   de Jong, Bouke C.
   Antonio, Martin
TI Deciphering the Growth Behaviour of Mycobacterium africanum
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID TUBERCULOSIS COMPLEX; GENOME; ACQUISITION; VIRULENCE; SEQUENCE;
   IDENTIFICATION; TRANSPORTER; METABOLISM; RESISTANCE; SECRETION
AB Background: Human tuberculosis (TB) in West Africa is not only caused by M. tuberculosis but also by bacteria of the two lineages of M. africanum. For instance, in The Gambia, 40% of TB is due to infections with M. africanum West African 2. This bacterial lineage is associated with HIV infection, reduced ESAT-6 immunogenicity and slower progression to active disease. Although these characteristics suggest an attenuated phenotype of M. africanum, no underlying mechanism has been described. From the first descriptions of M. africanum in the literature in 1969, the time to a positive culture of M. africanum on solid medium was known to be longer than the time to a positive culture of M. tuberculosis. However, the delayed growth of M. africanum, which may correlate with the less virulent phenotype in the human host, has not previously been studied in detail.
   Methodology/Principal Findings: We compared the growth rates of M. tuberculosis and M. africanum isolates from The Gambia in two liquid culture systems. M. africanum grows significantly slower than M. tuberculosis, not only when grown directly from sputa, but also in growth experiments under defined laboratory conditions. We also sequenced four M. africanum isolates and compared their whole genomes with the published M. tuberculosis H37Rv genome. M. africanum strains have several non-synonymous SNPs or frameshift mutations in genes that were previously associated with growth-attenuation. M. africanum strains also have a higher mutation frequency in genes crucial for transport of sulphur, ions and lipids/fatty acids across the cell membrane into the bacterial cell. Surprisingly, 5 of 7 operons, recently described as essential for intracellular survival of H37Rv in the host macrophage, showed at least one non-synonymously mutated gene in M. africanum.
   Conclusions/Significance: The altered growth behaviour of M. africanum might indicate a different survival strategy within host cells.
C1 [Gehre, Florian; Mulders, Wim; de Jong, Bouke C.] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Gehre, Florian; Otu, Jacob; Corrah, Tumani; de Jong, Bouke C.; Antonio, Martin] MRC Unit, Fajara, Gambia.
   [DeRiemer, Kathryn] Univ Calif Davis, Davis, CA 95616 USA.
   [de Sessions, Paola Florez; Hibberd, Martin L.] Genome Inst Singapore, Singapore, Singapore.
   [de Jong, Bouke C.] NYU, New York, NY USA.
RP Gehre, F (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.
EM fgehre@itg.be
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; DeRiemer,
   Kathryn/0000-0002-8375-7505; Hibberd, Martin/0000-0001-8587-1849
FU UK's Medical Research Council; Flemish Science Foundation (FWO)
FX The study was funded by the UK's Medical Research Council. Florian Gehre
   was supported by a "Travel Grant for a long stay abroad", awarded by the
   Flemish Science Foundation (FWO). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agranoff D, 2004, FRONT BIOSCI, V9, P2996, DOI 10.2741/1454
   Amon J, 2009, J MOL MICROB BIOTECH, V17, P20, DOI 10.1159/000159195
   Bentley SD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001552
   Bhave Devayani P., 2007, Infectious Disorders - Drug Targets, V7, P140
   Bold TD, 2012, J INFECT DIS, V205, P984, DOI 10.1093/infdis/jir883
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299
   Buchmeier N, 2000, MOL MICROBIOL, V35, P1375, DOI 10.1046/j.1365-2958.2000.01797.x
   Carlsson F, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000285
   Castets M, 1968, Rev Tuberc Pneumol (Paris), V32, P179
   Castets M, 1979, Med Trop (Mars), V39, P145
   Champion PAD, 2006, SCIENCE, V313, P1632, DOI 10.1126/science.1131167
   Cole ST, 1998, NATURE, V393, P537
   Cook GM, 2009, ADV MICROB PHYSL, V55, P318
   Cook GM, 2009, ADV MICROB PHYSIOL, V55, P81, DOI 10.1016/S0065-2911(09)05502-7
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   de Jong BC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000744
   de Jong BC, 2009, J CLIN MICROBIOL, V47, P994, DOI 10.1128/JCM.01216-08
   Domenech P, 2005, INFECT IMMUN, V73, P3492, DOI 10.1128/IAI.73.6.3492-3501.2005
   Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103
   Hatzios SK, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002036
   Kallenius G, 1999, J CLIN MICROBIOL, V37, P3872
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601
   Niederweis M, 2008, MICROBIOL-SGM, V154, P679, DOI 10.1099/mic.0.2007/012872-0
   Rengarajan J, 2005, P NATL ACAD SCI USA, V102, P8327, DOI 10.1073/pnas.0503272102
   Rodriguez GM, 2006, J BACTERIOL, V188, P424, DOI 10.1128/JB.188.2.424-430.2006
   Rowland JL, 2012, TUBERCULOSIS, V92, P202, DOI 10.1016/j.tube.2011.12.006
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x
   Sharma AK, 2011, J BIOL CHEM, V286, P8534, DOI 10.1074/jbc.M110.165449
   Stephan J, 2005, MOL MICROBIOL, V58, P714, DOI 10.1111/j.1365-2958.2005.04878.x
   Stewart GR, 2005, PLOS PATHOG, V1, P269, DOI 10.1371/journal.ppat.0010033
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406
   Wooff E, 2002, MOL MICROBIOL, V43, P653, DOI 10.1046/j.1365-2958.2002.02771.x
   Zeng JM, 2012, J PROTEOME RES, V11, P4682, DOI 10.1021/pr3006233
NR 35
TC 13
Z9 13
U1 2
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2013
VL 7
IS 5
AR e2220
DI 10.1371/journal.pntd.0002220
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 158SW
UT WOS:000319994400025
PM 23696911
OA gold
DA 2017-08-15
ER

PT J
AU Saidu, Y
   De Angelis, D
   Aiolli, S
   Stefano, G
   Georges, AM
AF Saidu, Yauba
   De Angelis, Dario
   Aiolli, Silvia
   Stefano, Gonnelli
   Georges, Anne Marie
TI Product Registration in Developing Countries: A Proposal for an
   Integrated Regional Licensing System Among Countries in Regional
   Economic Blocs
SO THERAPEUTIC INNOVATION & REGULATORY SCIENCE
LA English
DT Article
DE product registration; regulatory cooperation; regulatory model;
   regulatory review; regional harmonization initiatives; developing
   countries
AB The product pipeline for diseases that disproportionately affect the developing world has considerably expanded over the last decade. Indeed, there are about 134 products for these diseases in the pipeline, including vaccines, drugs, diagnostics, microbicides, and vector control tools, and dozens of these products are currently being evaluated in human trials in developing countries where the disease of interest exists. While these efforts are underway, the need to identify regulatory pathways for licensing these new products is becoming obvious to many manufacturers. In many developing countries, where the need of these products is greatest, the national regulatory authorities often lack the resources and regulatory capacity to review the registration dossiers to approve the use of new products. Given this challenge, new regulatory models are urgently needed to offset product registration. In this paper, we propose how regional regulatory frameworks established by regional harmonization initiatives can be used to set up an integrated regional licensing system, a system that will provide for a single product dossier application and a single review, leading to a single approval that will grant access to all the markets in the region. The proposed model aims at complementing the ongoing regional regulatory harmonization efforts by pooling the activities of different national expertise groups so as to make the best use of the available skills at a reduced cost. By sharing the various regulatory tasks in an integrated manner, the total process will be accelerated and will facilitate product registration in the region.
C1 [Saidu, Yauba] MRC, Vaccinol Unit, Fajara, Gambia.
   [De Angelis, Dario; Aiolli, Silvia] Novartis Vaccines & Diagnost, Siena, Italy.
   [Stefano, Gonnelli] Univ Siena, Fac Med & Surg, I-53100 Siena, Italy.
   [Georges, Anne Marie] AmQuidPharma, Brussels, Belgium.
RP Saidu, Y (reprint author), MRC, Vaccinol Unit, 20 Atlantic Rd,POB 273, Banjul, Gambia.
EM yaubasaidu@yahoo.com
FU Novartis Vaccines and Diagnostics srl (Siena, Italy)
FX The author(s) received the following financial support for the research,
   authorship, and/or publication of this article: This research was
   supported by an educational grant from Novartis Vaccines and Diagnostics
   srl (Siena, Italy) in the form of a fellowship that was awarded to Dr
   Saidu to undertake a 2-year master's program in vaccinology and
   pharmaceutical clinical development at the University of Siena.
CR Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   Association of Southeast Asian Nations, 2009, ASEAN COMM TECHN REQ
   Bollyky JT., 2010, BRIDGING GAP IMPROVI
   Brennan MJ, 2007, PLOS MED, V4, P1299, DOI 10.1371/journal.pmed.0040252
   Brennan MJ, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000095
   Fakudze F, 2012, ICH GCG C NOV 13 SAN
   Food and Drug Administration, 2008, GUID IND GEN PRINC D
   Hashan H, 2004, KINGDOM SAUDI ARABIA
   Hills S, 2004, EMERGING CHALLENGES
   Hlangwane FF, 2008, ICH GCG C MAY 7 BRUS
   Health Canada, 2012, MUT REC AGR CAN EUR
   Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2011, OP PROC PROC ASEAN
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2011, OP PROC PROC GCC
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2011, TOP HARM GCC
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2010, OP PROC PROC SADC
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2012, FORM ICH PROC
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2010, OP PROC PROC PANDRH
   Kaufmann SHE, 2010, LANCET, V375, P2110, DOI 10.1016/S0140-6736(10)60393-5
   Mahlangu GN, 2005, 1 AFR MED REG AUTH C
   Maiga D, 2009, VACCINE, V28, P571, DOI 10.1016/j.vaccine.2009.09.117
   Moran M, 2010, NEGLECTED DIS RES DE
   Pan American Health Organization (PANDRH), 2011, HARM REQ LIC VACC AM
   Payal S, 2009, PHARM TIMES, V41, P69
   Program for Appropriate Technology in Health, 2009, DEV NEW VACC DIARRH
   Therapeutic Goods Administration, 2012, INT REG CONS
   Tufts Center for the Study of Drug Development, 2009, 11 TUFTS CTR STUD DR
   World Health Organization, 2004, WORLD MED SIT
NR 28
TC 0
Z9 0
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2168-4790
J9 THER INNOV REGUL SCI
JI Ther. Innov. Regul. Sci.
PD MAY
PY 2013
VL 47
IS 3
BP 327
EP 335
DI 10.1177/2168479013478952
PG 9
WC Medical Informatics; Pharmacology & Pharmacy
SC Medical Informatics; Pharmacology & Pharmacy
GA 136ED
UT WOS:000318343400008
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
   Ward, KA
   Goldberg, GR
   Jarjou, LM
   Moore, SE
   Fulford, AJ
   Prentice, A
AF Prentice, Andrew M.
   Ward, Kate A.
   Goldberg, Gail R.
   Jarjou, Landing M.
   Moore, Sophie E.
   Fulford, Anthony J.
   Prentice, Ann
TI Critical windows for nutritional interventions against stunting
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID CATCH-UP GROWTH; CALCIUM SUPPLEMENTATION; DEVELOPING-COUNTRIES; INCOME
   COUNTRIES; EARLY-CHILDHOOD; BIRTH-WEIGHT; CHILDREN; AGE; PREGNANCY;
   HEIGHT
AB An analysis of early growth patterns in children from 54 resource-poor countries in Africa and Southeast Asia shows a rapid falloff in the height-for-age z score during the first 2 y of life and no recovery until >= 5 y of age. This finding has focused attention on the period -9 to 24 mo as a window of opportunity for interventions against stunting and has garnered considerable political backing for investment targeted at the first 1000 d. These important initiatives should not be undermined, but the objective of this study was to counteract the growing impression that interventions outside of this period cannot be effective. We illustrate our arguments using longitudinal data from the Consortium of Health Oriented Research in Transitioning collaboration (Brazil, Guatemala, India, Philippines, and South Africa) and our own cross-sectional and longitudinal growth data from rural Gambia. We show that substantial height catch-up occurs between 24 mo and midchildhood and again between midchildhood and adulthood, even in the absence of any interventions. Longitudinal growth data from rural Gambia also illustrate that an extended pubertal growth phase allows very considerable height recovery, especially in girls during adolescence. In light of the critical importance of maternal stature to her children's health, our arguments are a reminder of the importance of the more comprehensive UNICEF/Sub-Committee on Nutrition Through the Life-Cycle approach. In particular, we argue that adolescence represents an additional window of opportunity during which substantial life cycle and intergenerational effects can be accrued. The regulation of such growth is complex and may be affected by nutritional interventions imposed many years previously. Am J Clin Nutr 2013;97:911-8.
C1 [Prentice, Andrew M.; Moore, Sophie E.; Fulford, Anthony J.] Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Ward, Kate A.; Goldberg, Gail R.; Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
   [Prentice, Andrew M.; Goldberg, Gail R.; Jarjou, Landing M.; Fulford, Anthony J.; Prentice, Ann] MRC, Keneba, Gambia.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM andrew.prentice@lshtm.ac.uk
FU UK Medical Research Council [MC-A760-5QX00, U105960371, U123261351,
   G0700961]
FX Supported by the UK Medical Research Council (MC-A760-5QX00, U105960371,
   U123261351, and G0700961).
CR Coordination UNACO, 2000, 4 REP WORLD NUTR SIT
   Behrman JR, 2009, AM J CLIN NUTR, V90, P1372, DOI 10.3945/ajcn.2009.27524
   Cameron N, 2005, AM J HUM BIOL, V17, P412, DOI 10.1002/ajhb.20408
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Crookston BT, 2010, J NUTR, V140, P1996, DOI 10.3945/jn.109.118927
   Dahlgren J, 2005, PEDIATR RES, V57, P216, DOI 10.1203/01.PDR.0000148716.71231.81
   Darnton-Hill I, 2004, PUBLIC HEALTH NUTR, V7, P101, DOI 10.1079/PHN2003584
   DELUCA F, 1988, EUR J PEDIATR, V147, P188
   Dewey KG, 2008, MATERN CHILD NUTR, V4, P24, DOI 10.1111/j.1740-8709.2007.00124.x
   Dibba B, 2000, AM J CLIN NUTR, V71, P544
   Fall CHD, 2009, FOOD NUTR BULL, V30, pS533
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   Gandhi M, 2011, ACTA PAEDIATR, V100, P1113, DOI 10.1111/j.1651-2227.2011.02254.x
   Gebreselassie SG, 2011, J HEALTH POPUL NUTR, V29, P134
   GOLDEN MHN, 1994, EUR J CLIN NUTR, V48, pS58
   GRAHAM GG, 1982, AM J DIS CHILD, V136, P348
   Ho DH, 2010, J EXP BIOL, V213, P3, DOI 10.1242/jeb.019752
   Humphrey JH, 2009, LANCET, V374, P1032, DOI 10.1016/S0140-6736(09)60950-8
   Jarjou LMA, 2010, AM J CLIN NUTR, V92, P450, DOI 10.3945/ajcn.2010.29217
   Karlberg J, 1989, Acta Paediatr Scand Suppl, V350, P70
   Kinra S, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a605
   KRAMER MS, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000032
   KULIN HE, 1982, AM J CLIN NUTR, V36, P527
   Lwambo NJS, 2000, EUR J CLIN NUTR, V54, P36, DOI 10.1038/sj.ejcn.1600890
   MARTORELL R, 1994, EUR J CLIN NUTR, V48, pS45
   Martorell R, 2012, PAEDIATR PERINAT EP, V26, P302, DOI 10.1111/j.1365-3016.2012.01298.x
   Parent AS, 2003, ENDOCR REV, V24, P668, DOI 10.1210/er.2002-0019
   Paulino AC, 2010, SEMIN RADIAT ONCOL, V20, P12, DOI 10.1016/j.semradonc.2009.08.003
   Pena-Rosas JP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004736.pub3
   Prentice A. M., 1983, J GERONTOL B-PSYCHOL, V321, P489, DOI DOI 10.1016/S0140-6736(83)92188-8
   Prentice A, 2012, AM J CLIN NUTR, V96, P1042, DOI 10.3945/ajcn.112.037481
   Proos L A, 1991, Indian J Pediatr, V58, P105, DOI 10.1007/BF02810420
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   Read M.S., 1993, FOOD NUTR BULL, V14, P169
   Richter LM, 2012, INT J EPIDEMIOL, V41, P621, DOI 10.1093/ije/dyq251
   Shrimpton R, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.5.e75
   Stein AD, 2010, AM J HUM BIOL, V22, P353, DOI 10.1002/ajhb.20998
   Victora CG, 2010, PEDIATRICS, V125, pE473, DOI 10.1542/peds.2009-1519
   WALD N, 1991, LANCET, V338, P131
   World Health Organisation, 2006, ACTA PAEDIATR, V450, P76
   *WHO, 1995, B WHO S, V73, P1
   Yajnik CS, 2003, INT J OBESITY, V27, P173, DOI 10.1038/sj.ijo.802219
   Yajnik CS, 2004, J NUTR, V134, P205
NR 43
TC 102
Z9 103
U1 2
U2 42
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD MAY
PY 2013
VL 97
IS 5
BP 911
EP 918
DI 10.3945/ajcn.112.052332
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 131NP
UT WOS:000318000700003
PM 23553163
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Jobarteh, ML
   Moore, SE
   Kennedy, C
   Gambling, L
   McArdle, HJ
AF Jobarteh, M. L.
   Moore, S. E.
   Kennedy, C.
   Gambling, L.
   McArdle, H. J.
TI THE EFFECT OF MATERNAL BODY MASS INDEX ON EXPRESSION OF GENES OF IRON
   METABOLISM IN THE HUMAN PLACENTA
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Jobarteh, M. L.; Kennedy, C.; Gambling, L.; McArdle, H. J.] Univ Aberdeen, Rowett Res Inst Nutr & Hlth, Aberdeen AB21 9SN, Scotland.
   [Jobarteh, M. L.; Moore, S. E.] Med Res Council Unit Gambia, MRC Keneba, Banjul, Gambia.
   [Moore, S. E.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
CR Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672
   Moore S., BMC PREGNANCY CHILDB, V12, P107
NR 2
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAY
PY 2013
VL 88
IS 5
BP E192
EP E192
PG 1
WC Hematology
SC Hematology
GA 132BT
UT WOS:000318043500323
OA No
DA 2017-08-15
ER

PT J
AU Bowdish, DME
   Sakamoto, K
   Lack, NA
   Hill, PC
   Sirugo, G
   Newport, MJ
   Gordon, S
   Hill, AVS
   Vannberg, FO
AF Bowdish, Dawn M. E.
   Sakamoto, Kaori
   Lack, Nathan A.
   Hill, Philip C.
   Sirugo, Giorgio
   Newport, Melanie J.
   Gordon, Siamon
   Hill, Adrian V. S.
   Vannberg, Fredrick O.
TI Genetic variants of MARCO are associated with susceptibility to
   pulmonary tuberculosis in a Gambian population
SO BMC MEDICAL GENETICS
LA English
DT Article
DE Scavenger receptors; Mycobacterium tuberculosis; Single nucleotide
   polymorphisms; Case control study; MARCO
ID SCAVENGER RECEPTOR MARCO; MYCOBACTERIUM-TUBERCULOSIS; GENOME-WIDE;
   COMPLEMENT RECEPTORS; DENDRITIC CELLS; HOST-DEFENSE; LUNG DEFENSE;
   RISK-FACTORS; SR-AI/II; IN-VIVO
AB Background: The two major class A scavenger receptors are scavenger receptor A (SRA), which is constitutively expressed on most macrophage populations, and macrophage receptor with collagenous structure (MARCO), which is constitutively expressed on a more restricted subset of macrophages, (e.g. alveolar macrophages) but whose expression increases on most macrophages during the course of infection. Although the primary role of SRA appears to be clearance of modified host proteins and lipids, mice defective in expression of either MARCO or SRA are immunocompromised in multiple models of infection and in vitro assays, the scavenger receptors have been demonstrated to bind bacteria and to enhance pro-inflammatory signalling to many bacterial lung pathogens; however their importance in Mycobacterium tuberculosis infection, is less clear.
   Methods: To determine whether polymorphisms in either SRA or MARCO were associated with tuberculosis, a case-control study of was performed. DNA samples from newly-detected, smear-positive, pulmonary tuberculosis cases were collected from The Gambia. Controls for this study consisted of DNA from cord bloods obtained from routine births at local Gambian health clinics. Informed written consent was obtained from patients or their parents or guardians. Ethical approval was provided by the joint The Gambian Government/MRC Joint Ethics Committee.
   Results: We studied the frequencies of 25 polymorphisms of MSR1 (SRA) and 22 in MARCO in individuals with tuberculosis (n=1284) and matched controls (n=1349). No SNPs within the gene encoding or within 1 kb of the promoter sequence of MSR1 were associated with either susceptibility or resistance to tuberculosis. Three SNPs in MARCO (rs4491733, Mantel-Haenszel 2x2 chi 2 = 6.5, p = 0.001, rs12998782, Mantel-Haenszel 2x2 chi 2 = 6.59, p = 0.001, rs13389814 Mantel-Haenszel 2x2 chi 2 = 6.9, p = 0.0009) were associated with susceptibility to tuberculosis and one (rs7559955, Mantel-Haenszel 2x2 chi 2 = 6.9, p = 0.0009) was associated with resistance to tuberculosis.
   Conclusions: These findings identify MARCO as a potentially important receptor in the host response to tuberculosis.
C1 [Bowdish, Dawn M. E.] McMaster Univ, McMaster Immunol Res Ctr, Hamilton, ON L8S 4K1, Canada.
   [Sakamoto, Kaori] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30605 USA.
   [Lack, Nathan A.] Koc Univ, Sch Med, TR-34450 Istanbul, Turkey.
   [Hill, Philip C.; Sirugo, Giorgio] MRC Labs, Fajara, Gambia.
   [Hill, Philip C.] Univ Otago, Sch Med, Dept Prevent & Social Med, Ctr Int Hlth, Dunedin, New Zealand.
   [Sirugo, Giorgio] Osped San Pietro Fatebenefratelli, Rome, Italy.
   [Newport, Melanie J.] Brighton & Sussex Med Sch, Brighton BN1 9PS, E Sussex, England.
   [Gordon, Siamon] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
   [Hill, Adrian V. S.] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Vannberg, Fredrick O.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA.
RP Bowdish, DME (reprint author), McMaster Univ, McMaster Immunol Res Ctr, Hamilton, ON L8S 4K1, Canada.
EM bowdish@mcmaster.ca
FU Wellcome Trust; NIH [1 R15 AI094436-01A1]; McMaster Immunology Research
   Centre; M. G. DeGroote Institute for Infectious Disease Research
FX This work was funded by the Wellcome Trust. A.V.S.H. was supported by a
   Wellcome Trust Principal Fellowship. This work was funded in part by NIH
   Grant Number 1 R15 AI094436-01A1 to KS. DMEB would like to thank Dr.
   Chris Verschoor for critical reading of the manuscript. Work in the
   Bowdish laboratory is supported in part by the McMaster Immunology
   Research Centre and the M. G. DeGroote Institute for Infectious Disease
   Research.
CR Apt A, 2009, TUBERCULOSIS, V89, P195, DOI 10.1016/j.tube.2009.02.002
   Arredouani M, 2004, J EXP MED, V200, P267, DOI 10.1084/jem.20040731
   Arredouani MS, 2006, AM J RESP CELL MOL, V35, P474, DOI 10.1165/rcmb.0128OC
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074
   Bermudez LE, 1997, INFECT IMMUN, V65, P1916
   Bowdish DME, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000474
   Bowdish DME, 2009, IMMUNOL REV, V227, P19, DOI 10.1111/j.1600-065X.2008.00728.x
   Bowdish DME, 2008, UNPUB
   Court N, 2010, J IMMUNOL, V184, P7057, DOI 10.4049/jimmunol.1000164
   Dorrington MG, 2013, J IMMUNOL, V190, P250, DOI 10.4049/jimmunol.1202113
   Drage MG, 2009, CELL IMMUNOL, V258, P29, DOI 10.1016/j.cellimm.2009.03.008
   Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Ghosh S, 2011, AM J RESP CELL MOL, V45, P1036, DOI 10.1165/rcmb.2010-0349OC
   Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431
   Ito S, 1999, ARCH HISTOL CYTOL, V62, P83, DOI 10.1679/aohc.62.83
   Jallow M, 2009, NAT GENET, V41, P657, DOI 10.1038/ng.388
   Jozefowski S, 2005, J IMMUNOL, V175, P8032
   Jozefowski S, 2011, MICROB PATHOGENESIS, V50, P350, DOI 10.1016/j.micpath.2011.03.001
   Jurinke Christian, 2002, Methods Mol Biol, V187, P179
   Jurinke Christian, 2002, Adv Biochem Eng Biotechnol, V77, P57
   King DC, 2005, GENOME RES, V15, P1051, DOI 10.1101/gr.3642605
   Kolbe D, 2004, GENOME RES, V14, P700, DOI 10.1101/gr.1976004
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Ma MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024069
   Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200
   Montoya D, 2009, CELL HOST MICROBE, V6, P343, DOI 10.1016/j.chom.2009.09.002
   Neyrolles O, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000043
   Palecanda Aiyappa, 2001, Current Molecular Medicine (Hilversum), V1, P589, DOI 10.2174/1566524013363384
   Pedroza-Gonzalez A, 2004, INT J EXP PATHOL, V85, P135, DOI 10.1111/j.0959-9673.2004.00381.x
   Rothfuchs AG, 2007, J IMMUNOL, V179, P3463
   SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920
   SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771
   Schoenen H, 2010, J IMMUNOL, V184, P2756, DOI 10.4049/jimmunol.0904013
   Schug J., 2008, CURR PROTOC BIOINFOR, DOI DOI 10.1002/0471250953.BI0206S21
   Sever-Chroneos Z, 2011, TUBERCULOSIS, V91, pS69, DOI 10.1016/j.tube.2011.10.014
   Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0
   Taylor J, 2006, GENOME RES, V16, P1596, DOI 10.1101/gr.4537706
   Thomsen M, RESPIRATION
   Thye T, 2010, NAT GENET, V42, P739, DOI 10.1038/ng.639
   van der Laan LJW, 1999, J IMMUNOL, V162, P939
   vanderLaan LJW, 1997, IMMUNOL LETT, V57, P203, DOI 10.1016/S0165-2478(97)00077-1
   Wang M, 2006, GENE, V366, P219, DOI 10.1016/j.gene.2005.07.015
   World Health Organization (WHO), 2011, GLOB TUB CONTR WHO R
   Zimmerli S, 1996, AM J RESP CELL MOL, V15, P760
NR 46
TC 12
Z9 12
U1 2
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD APR 23
PY 2013
VL 14
AR 47
DI 10.1186/1471-2350-14-47
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 143IY
UT WOS:000318862300001
PM 23617307
OA gold
DA 2017-08-15
ER

PT J
AU Pollock, L
   Anderson, STB
   Kampmann, B
AF Pollock, Louisa
   Anderson, Suzanne T. B.
   Kampmann, Beate
TI Paediatric emergency care in resource-limited settings
SO LANCET
LA English
DT Letter
ID SUPPORT; TRIAGE
C1 [Pollock, Louisa; Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, London W2 1PG, England.
   [Pollock, Louisa; Kampmann, Beate] MRC Unit, Vaccinol Theme Serv, Fajara, Gambia.
   [Anderson, Suzanne T. B.] MRC Unit, Clin Serv, Fajara, Gambia.
RP Pollock, L (reprint author), Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, London W2 1PG, England.
EM l.pollock@imperial.ac.uk
FU Medical Research Council [MC_EX_MR/K011944/1, MC_UP_A900_1122]
CR Brierley J, 2009, CRIT CARE MED, V37, P666, DOI 10.1097/CCM.0b013e31819323c6
   Duke T, 2006, B WORLD HEALTH ORGAN, V84, P922, DOI 10.2471/BLT.06.037515
   Gove S, 1999, ARCH DIS CHILD, V81, P473
   Molyneux E, 2006, B WORLD HEALTH ORGAN, V84, P314, DOI 10.2471/BLT.04.019505
   Ralston ME, 2013, LANCET, V381, P256, DOI 10.1016/S0140-6736(12)61191-X
NR 5
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 20
PY 2013
VL 381
IS 9875
BP 1357
EP 1357
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 130EF
UT WOS:000317894800023
PM 23601944
OA No
DA 2017-08-15
ER

PT J
AU Nair, H
   Simoes, EAF
   Rudan, I
   Gessner, BD
   Azziz-Baumgartner, E
   Zhang, JSF
   Feikin, DR
   Mackenzie, GA
   Moisi, JC
   Roca, A
   Baggett, HC
   Zaman, SMA
   Singleton, RJ
   Lucero, MG
   Chandran, A
   Gentile, A
   Cohen, C
   Krishnan, A
   Bhutta, ZA
   Arguedas, A
   Clara, AW
   Andrade, AL
   Ope, M
   Ruvinsky, RO
   Hortal, M
   McCracken, JP
   Madhi, SA
   Bruce, N
   Qazi, SA
   Morris, SS
   El Arifeen, S
   Weber, MW
   Scott, JAG
   Brooks, WA
   Breiman, RF
   Campbell, H
AF Nair, Harish
   Simoes, Eric A. F.
   Rudan, Igor
   Gessner, Bradford D.
   Azziz-Baumgartner, Eduardo
   Zhang, Jian Shayne F.
   Feikin, Daniel R.
   Mackenzie, Grant A.
   Moisi, Jennifer C.
   Roca, Anna
   Baggett, Henry C.
   Zaman, Syed M. A.
   Singleton, Rosalyn J.
   Lucero, Marilla G.
   Chandran, Aruna
   Gentile, Angela
   Cohen, Cheryl
   Krishnan, Anand
   Bhutta, Zulfiqar A.
   Arguedas, Adriano
   Clara, Alexey Wilfrido
   Andrade, Ana Lucia
   Ope, Maurice
   Ruvinsky, Raul Oscar
   Hortal, Maria
   McCracken, John P.
   Madhi, Shabir A.
   Bruce, Nigel
   Qazi, Shamim A.
   Morris, Saul S.
   El Arifeen, Shams
   Weber, Martin W.
   Scott, J. Anthony G.
   Brooks, W. Abdullah
   Breiman, Robert F.
   Campbell, Harry
CA Severe Acute Lower Resp Infections
TI Global and regional burden of hospital admissions for severe acute lower
   respiratory infections in young children in 2010: a systematic analysis
SO LANCET
LA English
DT Article
ID INVASIVE PNEUMOCOCCAL DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; RANDOMIZED
   CONTROLLED-TRIAL; ALASKA NATIVE CHILDREN; AGED 2-59 MONTHS; TRACT
   INFECTIONS; CONJUGATE VACCINE; ORAL AMOXICILLIN; RURAL BANGLADESH;
   SYNCYTIAL VIRUS
AB Background The annual number of hospital admissions and in-hospital deaths due to severe acute lower respiratory infections (ALRI) in young children worldwide is unknown. We aimed to estimate the incidence of admissions and deaths for such infections in children younger than 5 years in 2010.
   Methods We estimated the incidence of admissions for severe and very severe ALRI in children younger than 5 years, stratified by age and region, with data from a systematic review of studies published between Jan 1, 1990, and March 31, 2012, and from 28 unpublished population-based studies. We applied these incidence estimates to population estimates for 2010, to calculate the global and regional burden in children admitted with severe ALRI in that year. We estimated in-hospital mortality due to severe and very severe ALRI by combining incidence estimates with case fatality ratios from hospital-based studies.
   Findings We identified 89 eligible studies and estimated that in 2010, 11.9 million (95% CI 10.3-13.9 million) episodes of severe and 3.0 million (2.1-4.2 million) episodes of very severe ALRI resulted in hospital admissions in young children worldwide. Incidence was higher in boys than in girls, the sex disparity being greatest in South Asian studies. On the basis of data from 37 hospital studies reporting case fatality ratios for severe ALRI, we estimated that roughly 265 000 (95% CI 160 000-450 000) in-hospital deaths took place in young children, with 99% of these deaths in developing countries. Therefore, the data suggest that although 62% of children with severe ALRI are treated in hospitals, 81% of deaths happen outside hospitals.
   Interpretation Severe ALRI is a substantial burden on health services worldwide and a major cause of hospital referral and admission in young children. Improved hospital access and reduced inequities, such as those related to sex and rural status, could substantially decrease mortality related to such infection. Community-based management of severe disease could be an important complementary strategy to reduce pneumonia mortality and health inequities.
C1 [Nair, Harish; Rudan, Igor; Campbell, Harry] Univ Edinburgh, Global Hlth Acad, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.
   [Nair, Harish] Publ Hlth Fdn India, New Delhi, India.
   [Simoes, Eric A. F.] Univ Colorado Denver, Denver, CO USA.
   [Simoes, Eric A. F.] Childrens Hosp, Denver, CO 80218 USA.
   [Simoes, Eric A. F.] Padjadjaran State Univ, Bandung, Indonesia.
   [Gessner, Bradford D.] Agence Med Prevent, Paris, France.
   [Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Zhang, Jian Shayne F.] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic 3010, Australia.
   [Feikin, Daniel R.; Breiman, Robert F.] Ctr Dis Control & Prevent, Nairobi, Kenya.
   [Feikin, Daniel R.; Chandran, Aruna] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Mackenzie, Grant A.; Zaman, Syed M. A.] Gambia Unit, MRC, Banjul, Gambia.
   [Moisi, Jennifer C.; Scott, J. Anthony G.] Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya.
   [Roca, Anna] Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain.
   [Roca, Anna] Minist Saude, Ctr Invest Saude Manhica, Maputo, Mozambique.
   [Baggett, Henry C.] Thailand MOPH US CDC Collaborat, Global Dis Detect Reg Ctr, Int Emerging Infect Program, Nonthaburi, Thailand.
   [Zaman, Syed M. A.] Hlth Protect Agcy, Hlth Protect Serv Colindale, London, England.
   [Singleton, Rosalyn J.] CDC, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA.
   [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA.
   [Lucero, Marilla G.] Res Inst Trop Med, Dept Hlth, Alabang, Muntinlupa, Philippines.
   [Gentile, Angela] Ricardo Gutierrez Childrens Hosp, Buenos Aires, DF, Argentina.
   [Cohen, Cheryl; Madhi, Shabir A.] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa.
   [Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa.
   [Krishnan, Anand] All India Inst Med Sci, Ctr Community Med, New Delhi, India.
   [Bhutta, Zulfiqar A.] Aga Khan Univ, Div Women & Child Hlth, Karachi, Pakistan.
   [Arguedas, Adriano] Univ Ciencias Med Ctr Amer, Inst Atenc Pediat, San Jose, Costa Rica.
   [Clara, Alexey Wilfrido] CDC Cent Amer Reg, Guatemala City, Guatemala.
   [Andrade, Ana Lucia] Univ Fed Goias, Goiania, Go, Brazil.
   [Ope, Maurice] East African Community Secretariat, Arusha, Tanzania.
   [Ruvinsky, Raul Oscar] Natl Univ Buenos Aires, Buenos Aires, DF, Argentina.
   [Hortal, Maria] Natl Univ PNUD, Program Basic Sci Dev, Montevideo, Uruguay.
   [McCracken, John P.] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala.
   [Bruce, Nigel] Univ Liverpool, Liverpool L69 3BX, Merseyside, England.
   [Qazi, Shamim A.] WHO, Dept Maternal Neonatal & Child & Adolescent Hlth, CH-1211 Geneva, Switzerland.
   [Morris, Saul S.] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [El Arifeen, Shams; Brooks, W. Abdullah] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Weber, Martin W.] WHO, Indonesia Country Off, Jakarta, Indonesia.
RP Nair, H (reprint author), Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.
EM harish.nair@ed.ac.uk
RI Theodoratou, Evropi/C-3430-2014; Nair, Harish/E-7431-2010; Andrade, Ana
   Lucia/L-5751-2013; Rudan, Igor/I-1467-2012
OI Theodoratou, Evropi/0000-0001-5887-9132; Nair,
   Harish/0000-0002-9432-9100; Rudan, Igor/0000-0001-6993-6884; Gupta,
   Vivek/0000-0002-6157-3705; Krishnan, Anand/0000-0002-9173-7811;
   McAllister, David/0000-0003-3550-1764; Hanlon, Peter/0000-0002-5828-3934
FU WHO Global Influenza Program [HQGIP1002906]; GlaxoSmithKline (GSK);
   Wyeth; Pfizer; Sanofi Pasteur; Crucell; Merck; Novartis; Bill & Melinda
   Gates Foundation
FX AA has received research grants, honoraria for participation in advisory
   boards, and travel grants from GlaxoSmithKline (GSK), Wyeth, and Pfizer.
   BDG works for Agence de Medecine Preventive, which receives unrestricted
   funding from Sanofi Pasteur, and has received grant support from
   Crucell, GSK, Merck, Pfizer, and Sanofi Pasteur. JAGS has received
   research funding from GSK and a travel grant from Merck. SAM has been a
   clinical trialist in studies of vaccines against pneumonia-causing
   pathogens from GSK, Pfizer, Sanofi-Aventis, Novartis, and Medimmune; his
   institution has received research grants from GSK, Pfizer, and Novartis;
   and he has been on the speaker's bureau of GSK, Pfizer, and
   Sanofi-Aventis, has received travel support and honoraria, and has acted
   on advisory boards of GSK, Pfizer, and Novartis. HNo is part of ARIVAC
   consortium that includes Sanofi Pasteur, undertook a phase 3 trial of an
   11-valent pneumococcal conjugate vaccine (Sanofi Pasteur, Lyon, France)
   in the Philippines in 2002-04, and has received research funding from
   GSK. ALA has received research grant from GSK, financial support from
   Pfizer and GSK to attend meetings, and has served as an adviser to
   Pfizer. WAB has received funding from the Bill & Melinda Gates
   Foundation for vaccine-related work related to childhood pneumonia;
   donation of vaccine from Sanofi Pasteur for a vaccine trial against
   early childhood pneumonia; project funding from Sanofi Pasteur for
   pneumococcal vaccine trials and a study in pneumococcal pneumonia
   disease burden in young children; and has been on the speakers bureau
   for Sanofi Pasteur. SSM is an employee of the Bill & Melinda Gates
   Foundation. SAQ, AWM, and MWW are WHO staff members. All other authors
   declare that they have no conflicts of interest.; Financial support for
   this work was provided by WHO Global Influenza Program (Grant number
   HQGIP1002906). The findings and conclusions in this report are those of
   the authors and do not necessarily represent the policies of the United
   States Centers for Disease Control and Prevention or WHO. This work was
   done as part of the wider programme of the Child Health Epidemiology
   Working Group (CHERG) and Global Health Epidemiology Reference Group
   (GHERG) to establish the major causes of global childhood disease
   burden. Endang Sedyaningsih sadly died suddenly and unexpectedly while
   this paper was being prepared for publication. We would like to
   acknowledge her important contribution to this study and her role as a
   promoter of child health in Indonesia. We thank Johannes Forster
   (Department of Paediatrics, St Josefskrankenhaus Freiburg and University
   of Freiburg, Freiburg, Germany); Gabriele Ihorst (Clinical Trials
   Center, University Medical Center Freiburg, Freiburg, Germany); and
   Carlos G Grijalva (Vanderbilt University, US) for providing additional
   data from their published papers. We are grateful to Felicity Cutts
   (London School of Hygiene and Tropical Medicine, London, UK); Fatema
   Khatun, Peter Kim Streatfield, Sajal Kumar Saha, Kamrun Nahar, Amina
   Tahia Sharmeen, Anjali Bilkis Ara, Sultana Yeasmin (International Centre
   for Diarrhoeal Disease Research, Bangladesh); Leilani T Nillos (Research
   Institute for Tropical Medicine, Philippines); Elias Jimenez, Ana Laura
   Jimenez, Carolina Soley (Instituto de Atencion Pediatrica, Costa Rica);
   Ron Dagan, Nurith Porat (Pediatric Infectious Disease Unit, Soroka
   University Medical Center and the Faculty of Health Sciences, Ben-Guiron
   University of the Negav, Beer-Sheva, Israel); Gail Rodgers, Sharon Gray,
   Darmendra Ramcharran (Pfizer Inc. Collegeville, PA, USA); Uchendu
   Uchendu, David Ameh, Bolanle Akinsola, Readon Ideh, Bernard Ebruke,
   Debasish Saha, Momodou Jasseh (MRC Unit, The Gambia); Pedro L Alonso,
   Llorenc Quinto (Barcelona Centre for International Health Research
   (CRESIB, Hospital Clinic-Universitat de Barcelona) and Centro de
   Investigacao em Saude de Manhica, Mozambique); Maria Aparecida da Silva
   Vieira (Pontifical Catholic University of Goias, Goiania, Brazil);
   Renato Mauricio Oliveira (Federal University of Goias, Goiania, Brazil);
   Vicente Porfirio Pessoa-Jr (Secretariat of Health of Municipality of
   Goiania, Brazil); Simonne Nouer (UTHSC-Department of Preventive
   Medicine, Memphis, TN, USA); Licia Kamilla Assis Melo Thorn (Karolinska
   Institutet, Stockholm); Luiza Helena Ribeiro (Samaritano Hospital,
   Goiania, Brazil); Jose Cassio de Moraes (Santa Casa School of Medical
   Sciences, Sao Paulo, Brazil); David Rodriguez (Ministry of Health of El
   Salvador); Celina de Lozano (National Influenza Center of El Salvador);
   Kim A Lindblade, Jennifer Verani (US Centers for Disease Control and
   Prevention Regional Office for Central America and Panama, International
   Emerging Infections Program, Guatemala); Somsak Thamthitiwat, Sununta
   Henchaichon, Prabda Prapasiri, Sathapana Naorat (International Emerging
   Infections Program, Global Disease Detection Regional Center, Thailand
   Ministry of Public Health - U. S. Centers for Disease Control and
   Prevention Collaboration, Nonthaburi, Thailand); Peera Areerat (Nakhon
   Phanom Provincial Health Office, Nakhon Phanom, Thailand); Asadang
   Ruayajin (Sa Kaeo Provincial Health Office, Sa Kaeo, Thailand) for their
   assistance.; The Indian Council for Medical Research (ICMR) led a
   multisite study with funding provided by the Hib Initiative; we thank
   the investigators at ICMR and the study sites of Christian Medical
   College, Vellore; Post Graduate Institute of Medical Education and
   Research, Chandigarh; and the National Institute of Cholera and Enteric
   Diseases, Kolkata. Costa Rica's LEAP study team thank all the physicians
   within the study area, in private practice, and from the Caja
   Costarricense de Seguro Social for referring their patients to
   participate in the active epidemiological surveillance. We thank the
   South African Severe Acute Respiratory Infections Surveillance Group,
   Wyeth-Pfizer, CNPq-Brazilian Council for Scientific Development and
   Technology, MRC Gambia Pneumococcal Surveillance Project and Severe
   Pneumonia Studies teams, MRC Gambia Basse Health and Demographic
   Surveillance System, Gambia Government, Basse Health Centre staff, the
   MRC Gambia Pneumococcal Vaccine Trial team for their assistance; Ana
   Ceballos, (CEDEPAP, Cordoba, Argentina), Jane Crawley (University of
   Oxford), and Olaf Muller (Ruprecht-Karls-University Heidelberg, Germany)
   for participating in the Working Group Meeting and providing valuable
   inputs; and Arti Nair (University of Edinburgh) for assistance with
   extracting data from the DHS and MICS databases.
CR Alam N, 2009, MATERN CHILD HLTH J, V13, P119, DOI 10.1007/s10995-008-0320-x
   Anh DD, 2009, CLIN INFECT DIS, V48, pS57, DOI 10.1086/596483
   Ansaldi F, 2008, J INT MED RES, V36, P1255
   Banajeh SM, 1998, J TROP PEDIATRICS, V44, P343, DOI 10.1093/tropej/44.6.343
   Baqui AH, 2007, J HEALTH POPUL NUTR, V25, P179
   Bari A, 2011, LANCET, V378, P1796, DOI 10.1016/S0140-6736(11)61140-9
   Brooks WA, 2005, LANCET, V366, P999, DOI 10.1016/S0140-6736(05)67109-7
   BYASS P, 1991, J TROP MED HYG, V94, P22
   Campbell James D, 2004, J Trop Pediatr, V50, P158, DOI 10.1093/tropej/50.3.158
   Carroll KN, 2008, PEDIATRICS, V122, P58, DOI 10.1542/peds.2007-2087
   CASTELLANO AMC, 2005, AN MED INTERN, V22, P118
   Chandyo RK, 2010, J NUTR, V140, P1677, DOI 10.3945/jn.109.117978
   Che D, 2010, EPIDEMIOL INFECT, V138, P573, DOI 10.1017/S0950268809990951
   Cheng P, 1996, JIANGSU J PREV MED, V2, P48
   Chen W, 1997, CHINESE J RURAL MED, V25, P25
   Chi XX, 1996, STRAIT J PREV MED, V2, P1
   Chowdhury EK, 2008, LANCET, V372, P822, DOI 10.1016/S0140-6736(08)61166-6
   Cilla G, 2009, EPIDEMIOL INFECT, V137, P66, DOI 10.1017/S0950268808000666
   [Anonymous], 2005, HDB IMCI INT MAN CHI
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Forster J, 2004, EUR J PEDIATR, V163, P709, DOI 10.1007/s00431-004-1523-9
   Gao JY, 2004, CHINESE J MATERNAL C, V19, P13
   Garces-Sanchez MD, 2005, AN PEDIAT BARC, V63, P125
   Gil A, 2002, J INFECTION, V44, P84, DOI 10.1053/jinf.2002.0966
   Grant CC, 1998, J PAEDIATR CHILD H, V34, P355, DOI 10.1046/j.1440-1754.1998.00237.x
   Grijalva CG, 2010, CLIN INFECT DIS, V50, P805, DOI 10.1086/650573
   Henrickson KJ, 2004, PEDIATR INFECT DIS J, V23, pS11, DOI 10.1097/01.inf.0000108188.37237.48
   Ho PL, 2007, VACCINE, V25, P6837, DOI 10.1016/j.vaccine.2007.07.039
   Hoo AF, 2002, AM J RESP CRIT CARE, V165, P1084, DOI 10.1164/rccm.2103035
   Hu YC, 1996, SHANGHAI J PREV MED, V8, P94
   Huang WH, 1999, STRAIT J PREV MED, V5, P21
   JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977
   Lee GE, 2010, PEDIATRICS, V126, P204, DOI 10.1542/peds.2009-3109
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   Liu Q, 1994, ACTA ACAD MED QINGDA, V30, P232
   Lou LY, 1995, CHINESE J PRIMARY HL, V9, P39
   Lowther SA, 2000, PEDIATR INFECT DIS J, V19, P11, DOI 10.1097/00006454-200001000-00004
   Madhi SA, 2005, CLIN INFECT DIS, V40, P1511, DOI 10.1086/429828
   Magree HC, 2005, B WORLD HEALTH ORGAN, V83, P427
   Mo JZ, 1998, CHINESE J PRIMARY HL, V12, P26
   Monge V, 2001, INFECTION, V29, P3, DOI 10.1007/s15010-001-0024-2
   Moore HC, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-757
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Nizami Shaikh Qamaruddin, 2006, JPMA Journal of the Pakistan Medical Association, V56, P163
   Owais A, 2010, TROP MED INT HEALTH, V15, P1029, DOI 10.1111/j.1365-3156.2010.02591.x
   Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540
   Pandey A, 2002, J HEALTH POPUL NUTR, V20, P306
   Peck AJ, 2005, PEDIATR INFECT DIS J, V24, P342, DOI 10.1097/01.inf.0000157250.95880.91
   Qu JS, 2009, QILU J MED, V24, P37
   Robertson SE, 2004, B WORLD HEALTH ORGAN, V82, P914
   Roxburgh CSD, 2008, ARCH DIS CHILD, V93, P316, DOI 10.1136/adc.2007.126540
   Rudan I, 2005, LANCET, V365, P2031, DOI 10.1016/S0140-6736(05)66697-4
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Russell FM, 2009, ANN TROP PAEDIATR, V29, P111, DOI 10.1179/146532809X440725
   Shah AS, 2009, CLIN INFECT DIS, V48, pS123, DOI 10.1086/596490
   Shah Aparna S, 2009, Indian J Med Sci, V63, P498, DOI 10.4103/0019-5359.58879
   Soofi S, 2012, LANCET, V379, P729, DOI 10.1016/S0140-6736(11)61714-5
   Subhi R, 2009, LANCET INFECT DIS, V9, P219, DOI 10.1016/S1473-3099(09)70071-4
   Sun YF, 1992, CHINESE MATERNAL CHI, V7, P42
   Sutanto A, 2002, AM J TROP MED HYG, V66, P175
   Tornheim JA, 2007, INT J INFECT DIS, V11, P536, DOI 10.1016/j.ijid.2007.03.006
   TUPASI TE, 1990, REV INFECT DIS, V12, pS940
   van Gageldonk-Lafeber AB, 2009, EPIDEMIOL INFECT, V137, P1472, DOI 10.1017/S0950268809002258
   Vicente D, 2003, EPIDEMIOL INFECT, V131, P867, DOI 10.1017/S0950268803008926
   Wang L, 1997, CHINESE J PRIMARY HL, V11, P28
   Weber MW, 2002, B WORLD HEALTH ORGAN, V80, P562
   Weigl JAI, 2005, KLIN PADIATR, V217, P211, DOI 10.1055/s-2004-822699
   Weinberg GA, 2009, J PEDIATR-US, V154, P694, DOI 10.1016/j.jpeds.2008.11.034
   WHO, 2012, REC MAN COMM CHILDH
   Williams EJ, 2009, CLIN INFECT DIS, V48, pS114, DOI 10.1086/596488
   Williams P, 1997, INT J EPIDEMIOL, V26, P797, DOI 10.1093/ije/26.4.797
   Wu PS, 2009, PEDIATR PULM, V44, P162, DOI 10.1002/ppul.20969
   Xie SM, 1993, CHONGQING MED J, V22, P375
   Xu GL, 2000, MATERN CHILD HLTH J, V14, P36
   Yorita KL, 2008, PEDIATRICS, V121, P244, DOI 10.1542/peds.2007-1392
   Yoshida LM, 2010, PEDIATR INFECT DIS J, V29, P75, DOI 10.1097/INF.0b013e3181af61e9
   Zaman K, 1997, J TROP PEDIATRICS, V43, P133, DOI 10.1093/tropej/43.3.133
NR 79
TC 152
Z9 158
U1 4
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 20
PY 2013
VL 381
IS 9875
BP 1380
EP 1390
DI 10.1016/S0140-6736(12)61901-1
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 130EF
UT WOS:000317894800035
PM 23369797
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Andersen, A
   Roth, A
   Jensen, KJ
   Erikstrup, C
   Lisse, IM
   Whittle, H
   Sartono, E
   Yazdanbakhsh, M
   Aaby, P
   Benn, CS
AF Andersen, Andreas
   Roth, Adam
   Jensen, Kristoffer Jarlov
   Erikstrup, Christian
   Lisse, Ida Marie
   Whittle, Hilton
   Sartono, Erliyani
   Yazdanbakhsh, Maria
   Aaby, Peter
   Benn, Christine Stabell
TI The immunological effect of revaccination with Bacille Calmette-Guerin
   vaccine at 19 months of age
SO VACCINE
LA English
DT Article
DE BCG; Immunology; Non-specific effects; DTP-booster; Micronutrients
ID DIPHTHERIA-TETANUS-PERTUSSIS; VITAMIN-A SUPPLEMENTATION; FEMALE-MALE
   MORTALITY; BCG VACCINATION; GUINEA-BISSAU; RANDOMIZED-TRIAL;
   IMMUNE-RESPONSE; IN-VITRO; IL-10 PRODUCTION; CHILDREN
AB Background: Bacille Calmette-Guerin (BCG) vaccination has important non-specific immune effects. In a randomized trial in Guinea-Bissau, BCG revaccination was associated with significantly increased survival in children who received diphtheria-tetanus-pertussis (DTP)-booster vaccine before enrolment and in children who did not receive micronutrient supplementation (MN). Within the trial we assessed the immunological effects of BCG revaccination.
   Methods: Children were randomized to BCG or nothing. Blood was sampled 6-11 weeks after randomization (early sample group) or 5-9 months later (late sample group). In vitro cytokine responses (interferon (IFN)-gamma, interleukin (IL)-13, tumor-necrosis-factor (TNF)-alpha, and IL-10) were assessed in whole blood cultures stimulated with lipopolysaccharide (LPS), purified protein derivative (PPD) or phytohaemagglutinin (PHA). Effect-modification by sex, DTP-booster vaccination and MN was studied.
   Results: Cytokines were measured in 345 infants. BCG was associated with significantly increased IFN-gamma (geometric mean ratio (GMR) = 4.54 (95% confidence interval: 3.13-6.58)) and IL-13 (GMR = 1.43 (1.00-2.05)) PPD responses, the effect being strongest in the early sample group. Across all three conditions BCG tended to increase IL-10 (LPS, PHA, PPD: GMR = 1.20, 1.12, 1.20), most pronounced in the late sample group. BCG reduced the TNF-alpha/IL-10 ratio in boys with DTP-booster at bleeding and increased it in those without (interaction test: p = 0.03). In children without MN, BCG was associated with reduced TNF-alpha response in the early sample group (p = 0.006), and increased IL-10 in the late sample group (p = 0.03).
   Conclusion: BCG revaccination resulted in a strong IFN-gamma response to PPD, which waned slightly over time. BCG also affected the pro-/anti-inflammatory balance, with reduced TNF-alpha and increased IL-10 responses to LPS, PHA and PPD. This effect depended on sex, DTP-booster vaccination and micronutrient supplementation, being most pronounced in children who had received DTP-booster before enrolment and children who had not received MN, i.e. the group of children which also had lower mortality after BCG revaccination. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Andersen, Andreas; Jensen, Kristoffer Jarlov; Aaby, Peter; Benn, Christine Stabell] Statens Serum Inst, Bandim Hlth Project, Res Ctr Vitamins & Vaccines CVIVA, DK-2300 Copenhagen S, Denmark.
   [Andersen, Andreas; Roth, Adam; Jensen, Kristoffer Jarlov; Aaby, Peter; Benn, Christine Stabell] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Roth, Adam] Lund Univ, Dept Med Microbiol, S-20502 Malmo, Sweden.
   [Erikstrup, Christian] Aarhus Univ Hosp, Dept Clin Immunol, DK-8000 Aarhus, Denmark.
   [Lisse, Ida Marie] Herlev Univ Hosp, Dept Pathol, DK-2730 Herlev, Denmark.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
   [Sartono, Erliyani; Yazdanbakhsh, Maria] Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands.
RP Andersen, A (reprint author), Statens Serum Inst, Bandim Hlth Project, CVIVA, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM a.andersen@bandim.org
OI Jensen, Kristoffer Jarlov/0000-0001-9687-5706
FU EU [ICA4-CT-2002-10053]; Danish National Research Foundation; DANIDA;
   Novo Nordisk Foundation; ERC [ERC-2009-StG-243149]; Danish Council for
   Independent Research; Danish National Research Foundation [DNRF108]
FX The REVAC trial was funded by the EU (ICA4-CT-2002-10053) and the Danish
   National Research Foundation. The Bandim Health Project received support
   from DANIDA. PA holds a research professorship grant from the Novo
   Nordisk Foundation. CSB is funded by an ERC Starting Grant
   (ERC-2009-StG-243149). AA and KJJ are funded through a Female Research
   Leader grant from the Danish Council for Independent Research to CSB.
   CVIVA is funded by the Danish National Research Foundation (DNRF108).
   The funding agencies had no role in the study design, data collection,
   data analysis, data interpretation, or the writing of the report.
CR Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2012, BMJ OPEN, P2
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   Akkoc T, 2010, PEDIAT ALLERG IMM-UK, V21, P1059, DOI 10.1111/j.1399-3038.2010.01051.x
   Andersen A, 2012, STAT MED
   Anderson EJ, 2012, VACCINE, V30, P2083, DOI 10.1016/j.vaccine.2012.01.053
   Barbosa T, 2003, VACCINE, V21, P2152, DOI 10.1016/S0264-410X(02)00721-1
   Benn CS, 2009, INT J EPIDEMIOL, V38, P304, DOI 10.1093/ije/dyn195
   Biering-Sorensen S, 2012, PEDIATR INFECT DIS J, V31, P306, DOI 10.1097/INF.0b013e3182458289
   Burl S, 2010, J IMMUNOL, V185, P2620, DOI 10.4049/jimmunol.1000552
   Diness BR, 2007, AM J CLIN NUTR, V86, P1152
   Djuardi Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014066
   Elliott AM, 2010, VACCINE, V29, P247, DOI 10.1016/j.vaccine.2010.10.047
   Hanekom WA, 2005, ANN NY ACAD SCI, V1062, P69, DOI 10.1196/annals.1358.010
   Jason J, 2002, INFECT IMMUN, V70, P6188, DOI 10.1128/IAI.70.11.6188-6195.2002
   Kleinnijenhuis J, 2012, P NATL ACAD SCI US
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Lalor MK, 2011, J INFECT DIS, V204, P1075, DOI 10.1093/infdis/jir515
   Lalor MK, 2009, J INFECT DIS, V199, P795, DOI 10.1086/597069
   Larsen JM, 2007, IMMUNOLOGY, V121, P276, DOI 10.1111/j.1365-2567.2007.02575.x
   Malhotra I, 1999, J IMMUNOL, V162, P6843
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   Mendez-Samperio P, 2008, CELL IMMUNOL, V251, P37, DOI 10.1016/j.cellimm.2008.03.002
   Nadler R, 2003, CLIN EXP IMMUNOL, V131, P206, DOI 10.1046/j.1365-2249.2003.02071.x
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Ozera A, 2003, IMMUNOL LETT, V86, P29, DOI 10.1016/S0165-2478(02)00261-4
   Rasmussen J, 2012, EUR J CLIN NUTR, V66, P998, DOI 10.1038/ejcn.2012.95
   Ritz N, 2012, AM J RESP CRIT CARE, V185, P213, DOI 10.1164/rccm.201104-0714OC
   Rodrigues A, 2007, TROP MED INT HEALTH, V12, P224, DOI 10.1111/j.1365-3165.2006.01766.x
   Roth A, 2005, VACCINE, V23, P3991, DOI 10.1016/j.vaccine.2004.10.022
   Roth A, 2006, EXPERT REV VACCINES, V5, P277, DOI 10.1586/14760584-5.2.277
   Roth AE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c671
   Shann F, 2010, ARCH DIS CHILD, V95, P662, DOI 10.1136/adc.2009.157537
   Smith SG, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-35
   Stensballe LG, 2005, VACCINE, V23, P1251, DOI 10.1016/j.vaccine.2004.09.006
   TOBIN J, 1958, ECONOMETRICA, V26, P24, DOI 10.2307/1907382
NR 39
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 19
PY 2013
VL 31
IS 17
BP 2137
EP 2144
DI 10.1016/j.vaccine.2013.02.050
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 135ZO
UT WOS:000318329400006
PM 23474315
OA No
DA 2017-08-15
ER

PT J
AU Anderson, LJ
   Dormitzer, PR
   Nokes, DJ
   Rappuoli, R
   Roca, A
   Graham, BS
AF Anderson, L. J.
   Dormitzer, P. R.
   Nokes, D. J.
   Rappuoli, R.
   Roca, A.
   Graham, B. S.
TI Strategic priorities for respiratory syncytial virus (RSV) vaccine
   development
SO VACCINE
LA English
DT Review
DE Respiratory syncytial virus; Vaccines; Global health priorities
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FORMALIN-INACTIVATED RSV; HIGH-RISK
   INFANTS; YOUNG-CHILDREN; MONOCLONAL-ANTIBODY; MATERNAL ANTIBODY; BALB/C
   MICE; FIELD TRIAL; INFECTION; LIVE
AB Although RSV has been a high priority for vaccine development, efforts to develop a safe and effective vaccine have yet to lead to a licensed product. Clinical and epidemiologic features of RSV disease suggest there are at least 4 distinct target populations for vaccines, the RSV naive young infant, the RSV naive child >= 6 months of age, pregnant women (to provide passive protection to newborns), and the elderly. These target populations raise different safety and efficacy concerns and may require different vaccination strategies. The highest priority target population is the RSV naive child. The occurrence of serious adverse events associated with the first vaccine candidate for young children, formalin inactivated RSV (FI-RSV), has focused vaccine development for the young RSV naive child on live virus vaccines. Enhanced disease is not a concern for persons previously primed by a live virus infection. A variety of live-attenuated viruses have been developed with none yet achieving licensure. New live-attenuated RSV vaccines are being developed and evaluated that maybe sufficiently safe and efficacious to move to licensure. A variety of subunit vaccines are being developed and evaluated primarily for adults in whom enhanced disease is not a concern. An attenuated parainfluenza virus 3 vector expressing the RSV F protein was evaluated in RSV naive children. Most of these candidate vaccines have used the RSV F protein in various vaccine platforms including virus-like particles, nanoparticles, formulated with adjuvants, and expressed by DNA or virus vectors. The other surface glycoprotein, the G protein, has also been used in candidate vaccines.
   We now have tools to make and evaluate a wide range of promising vaccines. Costly clinical trials in the target population are needed to evaluate and select candidate vaccines for advancement to efficacy trials. Better data on RSV-associated mortality in developing countries, better estimates of the risk of long term sequelae such as wheezing after infection, better measures of protection in target populations, and data on the costs and benefits of vaccines for target populations are needed to support and justify funding this process. Addressing these challenges and needs should improve the efficiency and speed of achieving a safe and effective, licensed RSV vaccine. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Anderson, L. J.] Emory Univ, Div Pediat Infect Dis, Sch Med, Atlanta, GA 30322 USA.
   [Dormitzer, P. R.] Novartis Vaccines & Diagnost, Cambridge, MA 02139 USA.
   [Nokes, D. J.] KEMRI Wellcome Trust Res Programme, Ctr Geog Med Res Coast, Kilifi 80108, Kenya.
   [Nokes, D. J.] Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England.
   [Rappuoli, R.] Novartis Vaccines & Diagnost Srl, I-53100 Siena, Italy.
   [Roca, A.] The Gambia, MRC Unit, Banjul, Gambia.
   [Graham, B. S.] NIAID, NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA.
RP Anderson, LJ (reprint author), Emory Univ, Div Pediat Infect Dis, Sch Med, 2015 Uppergate Dr, Atlanta, GA 30322 USA.
EM larry.anderson@emory.edu
FU MedImmune, Inc.; Novartis Vaccines and Diagnostics; Trellis, Inc.
FX Dr. Anderson has done paid consultancies on RSV vaccines and
   therapeutics for MedImmune, Inc. and Novartis Vaccines and Diagnostics;
   is a co-inventor on patents related to RSV anti-G protein antibody
   treatment and vaccines; and is doing animal studies on RSV anti-G
   protein treatment of RSV infection funded in part by Trellis, Inc.
CR Acedo L, 2010, EPIDEMIOL INFECT, V138, P853, DOI 10.1017/S0950268809991373
   Anderson R, 2010, FUTURE MICROBIOL, V5, P585, DOI [10.2217/fmb.10.22, 10.2217/FMB.10.22]
   BELSHE RB, 1982, J INFECT DIS, V145, P311
   Belshe RB, 2004, J INFECT DIS, V190, P2096, DOI 10.1086/425981
   Bernstein DI, 2012, PEDIATR INFECT DIS J, V31, P109, DOI 10.1097/INF.0b013e31823386f1
   Chang J, 2011, BMB REP, V44, P232, DOI 10.5483/BMBRep.2011.44.4.232
   CHIN J, 1969, AM J EPIDEMIOL, V89, P449
   Collins PL, 2011, VIRUS RES, V162, P80, DOI 10.1016/j.virusres.2011.09.020
   Cox MJ, 1998, J MED VIROL, V55, P234, DOI 10.1002/(SICI)1096-9071(199807)55:3<234::AID-JMV9>3.0.CO;2-2
   Crowe James E Jr, 2003, Paediatr Respir Rev, V4, P112, DOI 10.1016/S1526-0542(03)00033-2
   Falsey AR, 2008, J INFECT DIS, V198, P1317, DOI 10.1086/592168
   Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
   Feltes TF, 2011, PEDIATR RES, V70, P186, DOI 10.1203/PDR.0b013e318220a553
   FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543
   GLEZEN WP, 1981, J PEDIATR-US, V98, P708
   Graham BS, 2011, IMMUNOL REV, V239, P149, DOI 10.1111/j.1600-065X.2010.00972.x
   GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102
   Groothuis JR, 1998, J INFECT DIS, V177, P467
   Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877
   HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004
   Hurwitz JL, 2011, EXPERT REV VACCINES, V10, P1415, DOI [10.1586/erv.11.120, 10.1586/ERV.11.120]
   KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405
   Karron RA, 2005, J INFECT DIS, V191, P1093, DOI 10.1086/427813
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422
   LAMPRECHT CL, 1976, J INFECT DIS, V134, P211
   Luongo C, 2009, VACCINE, V27, P5667, DOI 10.1016/j.vaccine.2009.07.022
   Madhi SA, 2000, J PEDIATR-US, V137, P78, DOI 10.1067/mpd.2000.105350
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Nokes DJ, 2008, CLIN INFECT DIS, V46, P50, DOI 10.1086/524019
   Null D, 1998, PEDIATRICS, V102, P531
   O'Callaghan-Gordo C, 2011, PEDIATR INFECT DIS J, V30, P39, DOI 10.1097/INF.0b013e3181f232fe
   Radu GU, 2010, J VIROL, V84, P9632, DOI 10.1128/JVI.00451-10
   Robertson SE, 2004, B WORLD HEALTH ORGAN, V82, P914
   Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440
   Sommer Constanze, 2011, Open Microbiol J, V5, P144, DOI 10.2174/1874285801105010144
   Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P398, DOI 10.1016/j.jaci.2008.10.043
   Stockman LJ, 2012, PEDIATR INFECT DIS J, V31, P5, DOI 10.1097/INF.0b013e31822e68e6
   van Bleek Grada M, 2011, Vaccine, V29, P7285, DOI 10.1016/j.vaccine.2011.07.114
   Waris ME, 1997, J VIROL, V71, P6935
   Weber MW, 1999, INT J EPIDEMIOL, V28, P157, DOI 10.1093/ije/28.1.157
   Wu PS, 2011, EXPERT REV ANTI-INFE, V9, P731, DOI [10.1586/eri.11.92, 10.1586/ERI.11.92]
NR 42
TC 72
Z9 72
U1 4
U2 40
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 18
PY 2013
VL 31
SU 2
BP B209
EP B215
DI 10.1016/j.vaccine.2012.11.106
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 137TV
UT WOS:000318462000025
PM 23598484
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
   Nabwera, H
   Kwambana, B
   Antonio, M
   Moore, SE
AF Prentice, Andrew M.
   Nabwera, Helen
   Kwambana, Brenda
   Antonio, Martin
   Moore, Sophie E.
TI Microbes and the Malnourished Child
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Editorial Material
ID SEVERE ACUTE MALNUTRITION; PART
AB New research implicates a dysfunctional gut microbiome in the etiology of severe childhood malnutrition and confirms a role for antibiotics in its treatment.
C1 [Prentice, Andrew M.; Nabwera, Helen; Moore, Sophie E.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Prentice, Andrew M.; Nabwera, Helen; Moore, Sophie E.] MRC Keneba, Keneba, Gambia.
   [Kwambana, Brenda; Antonio, Martin] MRC Unit Gambia, Banjul, Gambia.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM andrew.prentice@lshtm.ac.uk
FU Medical Research Council [MC_U123292701]
CR Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0
   Minot S, 2011, GENOME RES, V21, P1616, DOI 10.1101/gr.122705.111
   Reyes A, 2010, NATURE, V466, P334, DOI 10.1038/nature09199
   Smith MI, 2013, SCIENCE, V339, P548, DOI 10.1126/science.1229000
   Trehan I, 2013, NEW ENGL J MED, V368, P425, DOI 10.1056/NEJMoa1202851
   Trehan I, 2010, TROP MED INT HEALTH, V15, P1022, DOI 10.1111/j.1365-3156.2010.02580.x
   World Health Organization, 2007, COMM BAS MAN SEV AC
   Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053
NR 8
TC 2
Z9 3
U1 0
U2 21
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD APR 10
PY 2013
VL 5
IS 180
AR 180fs11
DI 10.1126/scitranslmed.3006212
PG 3
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 124NI
UT WOS:000317471000001
PM 23576812
OA No
DA 2017-08-15
ER

PT J
AU Lin, GM
   Li, YH
   Jaiteh, LES
   Han, CL
AF Lin, Gen-Min
   Li, Yi-Hwei
   Jaiteh, Lamin E. S.
   Han, Chih-Lu
TI Warfarin may reduce risk of ischemic stroke by preventing atrial
   fibrillation for patients with heart failure and sinus rhythm
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE Warfarin; Aspirin; Atrial fibrillation; Heart failure
ID RANDOMIZED-TRIAL; ANTIPLATELET THERAPY; WATCH TRIAL; ASPIRIN;
   CLOPIDOGREL
C1 [Lin, Gen-Min] Hualien Armed Forces Gen Hosp, Dept Med, Hualien 97144, Hualien County, Taiwan.
   [Li, Yi-Hwei] Tzu Chi Univ, Dept Publ Hlth, Hualien, Taiwan.
   [Jaiteh, Lamin E. S.] Dept Royal Victoria Teaching Hosp, Banjul, Gambia.
   [Han, Chih-Lu] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.
RP Lin, GM (reprint author), Hualien Armed Forces Gen Hosp, 163 Jiali Rd, Hualien 97144, Hualien County, Taiwan.
EM farmer507@yahoo.com.tw
CR Cleland JGF, 2004, AM HEART J, V148, P157, DOI 10.1016/j.ahj.2004.03.010
   Cokkinos DV, 2006, EUR J HEART FAIL, V8, P428, DOI 10.1016/j.ejheart.2006.02.012
   Eikelboom JW, 2012, NEW ENGL J MED, V366, P1936, DOI 10.1056/NEJMe1202504
   Freudenberger RS, 2010, THROMB HAEMOSTASIS, V103, P489, DOI 10.1160/TH09-04-0247
   Homma S, 2012, NEW ENGL J MED, V366, P1859, DOI 10.1056/NEJMoa1202299
   Kan LP, 2009, CIRCULATION, V120, pE164, DOI 10.1161/CIRCULATIONAHA.109.882308
   Kater AP, 2002, CLIN DIAGN LAB IMMUN, V9, P1396, DOI 10.1128/CDLI.9.6.1396-1397.2002
   Marcus GM, 2008, AM HEART J, V155, P303, DOI 10.1016/j.ahj.2007.09.006
   Massie BM, 2009, CIRCULATION, V119, P1616, DOI 10.1161/CIRCULATIONAHA.108.801753
NR 9
TC 1
Z9 1
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD APR 5
PY 2013
VL 164
IS 2
BP 245
EP 246
DI 10.1016/j.ijcard.2012.06.080
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 112NO
UT WOS:000316599200022
PM 22795713
OA No
DA 2017-08-15
ER

PT J
AU Van Waerebeek, K
   Djiba, A
   Krakstad, JO
   Bilal, ASQ
   Bamy, IL
   Almeida, A
   Mbye, EM
AF Van Waerebeek, Koen
   Djiba, Abdoulaye
   Krakstad, Jens-Otto
   Bilal, Abdellahi Samba Quid
   Bamy, Idrissa L.
   Almeida, Amadeu
   Mbye, Ebou Mass
TI New evidence for a South Atlantic stock of humpback whales wintering on
   the Northwest African continental shelf
SO AFRICAN ZOOLOGY
LA English
DT Editorial Material
DE humpback whale; wintering grounds; shelf; Senegal; The Gambia;
   Guinea-Bissau; Guinea
ID CAPE-VERDE ISLANDS; MEGAPTERA-NOVAEANGLIAE; CETACEANS; ABUNDANCE; WATERS
AB Seventeen confirmed and four probable sightings of humpback whales, Megaptera novaeangliae, were documented from platform-of-opportunity Research Vessel (R/V) Dr. Fridtjof Nansen in a passing-mode visual survey of continental shelf waters between Conakry and Cap Vert Peninsula (Dakar), 21 October-5 November 2011. None were encountered in the northern stratum Dakar-Agadir, 6 November-15 December 2011. Total visual survey effort was 468 h, 01 min, covering 5335 km. Depending on the exclusion or inclusion of probable records, the sum of group sizes totalled 33 or 43 individuals, respectively. Humpback whale encounter rates between Conakry and Dakar then amounted to 1.74 or 2.27 whales/100 km, respectively. Group sizes ranged from 1-6 individuals (mean = 1.94, S.D. = 1.20, n = 17; median = 2). Minimally five of 17 groups (29.4%) consisted of adult-calf pairs, with a minimum crude birth rate ranging from 0.060-0.152. All sightings occurred in shallow water, 22-60 m (mean = 35.0 m, S.D. = 10.13, n = 17) but survey effort in deeper, offshore water was negligible. Sea-surface temperature at sighting locations ranged from 25.5-29.0 degrees C (mean = 27.34, S.D. = 0.96, n = 17). No humpback whales were sighted during a second survey covering Conakry-Tangier-Las Palmas, from 9 May to 22 July 2012 (519h, 13 min; 6278 km). The Cape Verde Islands comprised, to date, the only known wintering ground located in the North-East Atlantic. This study showed that Senegal, The Gambia, Guinea-Bissau and Guinea are normal range states for M. novaeangliae. A temporal signature, six to seven months out-of-phase with mid-season in the Cape Verde Islands, and neonate presence strongly suggest that the wide Conakry-Dakar continental shelf serves as both wintering and nursery grounds for a South Atlantic stock, in agreement with Bamy et al. (2010). This stock may comprise the northwesternmost component of the large humpback whale assemblage migrating in and out of the northern Gulf of Guinea in austral winter/spring. Further research is required to consolidate insights linking temporal and spatial distribution off western Africa with hemispheric stock identity and migration paths.
C1 [Van Waerebeek, Koen; Djiba, Abdoulaye] IFAN CHAD, COREWAM Senegal, Musee Mer, Ille De Goree, Senegal.
   [Van Waerebeek, Koen] Museo Delfines, Peruvian Ctr Cetacean Res CEPEC, Lima 20, Peru.
   [Djiba, Abdoulaye] Univ Cheikh Anta Diop Dakar UCAD, Musee Mer Goree, Inst Fondamental Afrique Noire Cheikh Anta Diop I, Dakar, Senegal.
   [Krakstad, Jens-Otto] Marine Res Inst, N-5817 Bergen, Norway.
   [Bilal, Abdellahi Samba Quid] Inst Mauritanien Rech Oceanog & Peches, Nouadhibou, Mauritania.
   [Bamy, Idrissa L.] Ctr Natl Sci Halieut Boussoura, Boussoura, Conakry, Guinea.
   [Almeida, Amadeu] Ctr Invest Pesqueira Aplicada, Bissau, Guinea Bissau.
   [Mbye, Ebou Mass] Dept Fisheries, Banjul, Gambia.
RP Van Waerebeek, K (reprint author), IFAN CHAD, COREWAM Senegal, Musee Mer, Ille De Goree, Senegal.
EM corewam@gmail.com
CR Aloncle H., 1964, Bulletin de l'Institut des Peches Maritimes du Maroc, V12, P21
   Aloncle H., 1967, Bulletin de l'Institut des Peches Maritimes du Maroc, V15, P33
   BAMY I. L., 2010, MARINE DIVERSITY REC, V3, P1, DOI 10.1017/51755267210000436
   BAMY I.L., 2011, INVENTAIRE CET UNPUB
   BAYED A, 1987, MAMMALIA, V51, P437, DOI 10.1515/mamm.1987.51.3.437
   Cadenat J., 1955, Notes Africaines, VNo. 67, P91
   Cadenat J., 1957, Bull Inst franY Afr N, V19A, P1358
   CAMPHUYSEN K., 2012, SHIP BASED SEA UNPUB
   DIALLO S.T., 2002, CAMPAGNE OBSER UNPUB
   DIALLO S.T., 2004, CAMPAGNE OBSER UNPUB
   Notarbartolo di Sciara G, 1998, REPORTS INT WHALING, V48, P547
   Duguy R., 1976, REV TRAV I PECHES, V39, P321
   DUPUY A R, 1983, Bulletin de l'Institut Fondamental d'Afrique Noire Serie A Sciences Naturelles, V45, P380
   Felix Fernando, 2001, Revista de Biologia Marina y Oceanografia, V36, P61
   FLOREZ-GONZALEZ L, 1991, Memoirs of the Queensland Museum, V30, P291
   Gordon J. C. D., 2003, MARINE TECHNOLOGY SO, V37, P14
   Hazevoet CJ, 2000, CONTRIB ZOOL, V69, P197
   Hazevoet Cornelis J., 2011, Zoologia Caboverdiana, V2, P25
   IMR, 2012, CRUIS REP F NANS CCL
   JALLOW A.O., 2005, P 1 BIOD RES S GAMB, P37
   KRAKSTAD J-O., 2012, CCLME N W AFRICA ECO
   KRAKSTAD J-O., 2012, EAFN201110 CCLME I M
   LAGENDIJK P., 1984, SC36PS16 INT WHAL CO
   Laptikhovskii VV, 2001, ZOOL ZH, V80, P358
   MAIGRET J., 1981, B CTR NATL RECHERCHE, V9, P130
   MURPHY P.F., 1997, SC49SM11 IWC
   Northridge S, 1984, 251 FAO
   Papastavrou V., 1998, REPORTS INT WHALING, V47, P945
   Picanco C, 2009, J MAR BIOL ASSOC UK, V89, P1071, DOI 10.1017/S0025315409002379
   Punt Andre E., 2006, Journal of Cetacean Research and Management, V8, P145
   REEVES RR, 1990, AM NEPTUNE, V50, P119
   Reiner F, 1996, MAR MAMMAL SCI, V12, P434, DOI 10.1111/j.1748-7692.1996.tb00595.x
   Robineau D, 1998, REV ECOL-TERRE VIE, V53, P123
   Rosenbaum Howard, 2006, Bulletin of the Biological Society of Washington, V12, P425
   Rosenbaum HC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007318
   Segniagbeto G., 2010, SC62SM11 IWC
   Slijper EJ, 1964, BIJDR DIERKD, V34, P3
   Tomilin A. G., 1967, MAMMALS USSR ADJACEN, V9
   TOWNSEND CHARLES HASKINS, 1935, ZOOLOGICA [NEW YORK], V19, P1
   TULP I., 2004, MAXINE MAMMALS UNPUB
   VAN WAEREBEEK K., 2001, SC53IA21 IVVC
   Van Waerebeek K., 2009, W AFRICAN J APPL ECO, V15, P61
   Van Waerebeek K., 2000, SURVEY CONSERVATION
   VAN WAEREBEEK K., 2012, MARINE MAMMAL UNPUB
   VAN WAEREBEEK K., 2003, WAFCET2 UNEPCMS
   Weir CR, 2011, AFR J MAR SCI, V33, P1, DOI 10.2989/1814232X.2011.572333
   Wenzel Frederick W., 2009, Aquatic Mammals, V35, P502, DOI 10.1578/AM.35.4.2009.502
   WENZEL F.W., 1995, SONAR, V13, P22
NR 48
TC 3
Z9 4
U1 0
U2 12
PU ZOOLOGICAL SOC SOUTHERN AFRICA
PI SCOTTSVILLE
PA AFRICAN ZOOLOGY CIRCULATION OFFICE, UNIV KWAZULU-NATAL, SCHOOL BIOL &
   CONSERVATION SCI, P B X01, SCOTTSVILLE 3209, SOUTH AFRICA
SN 1562-7020
EI 2224-073X
J9 AFR ZOOL
JI Afr. Zool.
PD APR
PY 2013
VL 48
IS 1
BP 177
EP 186
PG 10
WC Zoology
SC Zoology
GA 296QT
UT WOS:000330201200018
OA No
DA 2017-08-15
ER

PT J
AU Ladep, NG
   Dona, A
   McPhail, MJW
   Shariff, MI
   Crossey, MM
   Wijeyesekera, A
   Okeke, EN
   Banwat, E
   Lemoine, M
   Njie, R
   Garside, D
   Khan, SA
   Thillainayagam, AV
   Thursz, M
   Holmes, EC
   Taylor-Robinson, SD
AF Ladep, N. G.
   Dona, A.
   McPhail, M. J. W.
   Shariff, M. I.
   Crossey, M. M.
   Wijeyesekera, A.
   Okeke, E. N.
   Banwat, E.
   Lemoine, M.
   Njie, R.
   Garside, D.
   Khan, S. A.
   Thillainayagam, A. V.
   Thursz, M.
   Holmes, E. C.
   Taylor-Robinson, S. D.
CA PROLIFICA
TI URINARY METABOLIC PROFILE DISCRIMINATES HEPATOCELLULAR CARCINOMA BETTER
   THAN SERUM ALPHA FETOPROTEIN IN WEST AFRICANS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Ladep, N. G.; Dona, A.; McPhail, M. J. W.; Shariff, M. I.; Crossey, M. M.; Wijeyesekera, A.; Garside, D.; Khan, S. A.; Thursz, M.; Holmes, E. C.; Taylor-Robinson, S. D.] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Okeke, E. N.; Banwat, E.] Univ Jos, Univ Teaching Hosp, Jos, Nigeria.
   [Lemoine, M.; Njie, R.] MRC, Gambia Hepatitis Intervent Study, Fajara, Gambia.
   [Thillainayagam, A. V.] Imperial Coll Healthcare, London, England.
EM n.ladep@imperial.ac.uk
RI Dona, Anthony/E-5968-2016
OI Dona, Anthony/0000-0001-6403-6721
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 110
BP S49
EP S49
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000111
OA No
DA 2017-08-15
ER

PT J
AU Lemoine, M
   Njai, H
   Shimakawa, Y
   Taal, M
   Corrah, T
   D'Alessandro, U
   Njie, R
   Thursz, M
AF Lemoine, M.
   Njai, H.
   Shimakawa, Y.
   Taal, M.
   Corrah, T.
   D'Alessandro, U.
   Njie, R.
   Thursz, M.
TI RURAL AND URBAN COMMUNITY-BASED HEPATITIS B SCREENING IN THE GAMBIA:
   ASSESSMENT OF LIVER DISEASE REVEALS A SIGNIFICANT PROPORTION OF ELIGIBLE
   PATIENTS FOR ANTIVIRAL THERAPY
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Lemoine, M.; Njai, H.; Shimakawa, Y.; Corrah, T.; D'Alessandro, U.; Njie, R.] MRC, Liver Unit, Fajara, Gambia.
   [Taal, M.] Minist Hlth, Fajara, Gambia.
   [Thursz, M.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, London, England.
EM mlemoine@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 976
BP S402
EP S403
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983001237
OA No
DA 2017-08-15
ER

PT J
AU Lemoine, M
   Shimakawa, Y
   Njai, H
   Tamba, S
   Corrah, T
   D'Alessandro, U
   Njie, R
   Thursz, M
AF Lemoine, M.
   Shimakawa, Y.
   Njai, H.
   Tamba, S.
   Corrah, T.
   D'Alessandro, U.
   Njie, R.
   Thursz, M.
TI FOOD INTAKE DRAMATICALLY INCREASES LIVER STIFFNESS MEASUREMENTS AND
   HAMPERS RELIABLE VALUES: RESULTS FROM A LARGE COHORT OF HBV INFECTED AND
   NON INFECTED AFRICAN SUBJECTS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Lemoine, M.; Shimakawa, Y.; Njai, H.; Tamba, S.; Corrah, T.; D'Alessandro, U.; Njie, R.] MRC, Liver Unit, Fajara, Gambia.
   [Thursz, M.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, London, England.
EM mlemoine@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 725
BP S294
EP S294
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000726
OA No
DA 2017-08-15
ER

PT J
AU Shimakawa, Y
   Lemoine, M
   Njai, HF
   Jatta, A
   Sanneh, B
   Taal, M
   Corrah, T
   D'Alessandro, U
   Njie, R
   Thursz, M
AF Shimakawa, Y.
   Lemoine, M.
   Njai, H. F.
   Jatta, A.
   Sanneh, B.
   Taal, M.
   Corrah, T.
   D'Alessandro, U.
   Njie, R.
   Thursz, M.
TI COMMUNITY-BASED SCREENING FOR HEPATITIS B VIRUS INFECTION IN THE GAMBIA,
   WEST AFRICA: PREVALENCE OF INFECTION AND FACTORS AFFECTING THE SCREENING
   ATTENDANCE
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Shimakawa, Y.] Univ London London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England.
   [Taal, M.] Minist Hlth, Banjul, Gambia.
   [Thursz, M.] Univ London Imperial Coll Sci Technol & Med, London, England.
EM yshimakawa@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
NR 0
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 48
BP S21
EP S21
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000049
OA No
DA 2017-08-15
ER

PT J
AU Bejon, P
   White, MT
   Olotu, A
   Bojang, K
   Lusingu, JPA
   Salim, N
   Otsyula, NN
   Agnandji, ST
   Asante, KP
   Owusu-Agyei, S
   Abdulla, S
   Ghani, AC
AF Bejon, Philip
   White, Michael T.
   Olotu, Ally
   Bojang, Kalif
   Lusingu, John P. A.
   Salim, Nahya
   Otsyula, Nekoye N.
   Agnandji, Selidji T.
   Asante, Kwaku Poku
   Owusu-Agyei, Seth
   Abdulla, Salim
   Ghani, Azra C.
TI Efficacy of RTS,S malaria vaccines: individual-participant pooled
   analysis of phase 2 data
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM INFECTION; RANDOMIZED CONTROLLED-TRIAL; MOZAMBICAN
   CHILDREN; AFRICAN CHILDREN; DOUBLE-BLIND; FOLLOW-UP; RTS,S/AS02A;
   SAFETY; PROTECTION; TRANSMISSION
AB Background The efficacy of RTS,S/AS01 as a vaccine for malaria is being tested in a phase 3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria and severe malaria. To ascertain variations in vaccine efficacy according to covariates such as transmission intensity, choice of adjuvant, age at vaccination, and bednet use, we did an individual-participant pooled analysis of phase 2 clinical data.
   Methods We analysed data from 11 different sites in Africa, including 4453 participants. We measured heterogeneity in vaccine efficacy by estimating the interactions between covariates and vaccination in pooled multivariable Cox regression and Poisson regression analyses. Endpoints for measurement of vaccine efficacy were infection, clinical malaria, severe malaria, and death. We defined transmission intensity levels according to the estimated local parasite prevalence in children aged 2-10 years (PrP2-10), ranging from 5% to 80%. Choice of adjuvant was either AS01 or AS02.
   Findings Vaccine efficacy against all episodes of clinical malaria varied by transmission intensity (p=0.001). At low transmission (PrP2-10 10%) vaccine efficacy was 60% (95% CI 54 to 67), at moderate transmission (PrP2-10 20%) it was 41% (21 to 57), and at high transmission (PrP2-10 70%) the efficacy was 4% (-10 to 22). Vaccine efficacy also varied by adjuvant choice (p<0.0001)-eg, at low transmission (PrP2-10 10%), efficacy varied from 60% (95% CI 54 to 67) for AS01 to 47% (14 to 75) for AS02. Variations in efficacy by age at vaccination were of borderline significance (p=0.038), and bednet use and sex were not significant covariates. Vaccine efficacy (pooled across adjuvant choice and transmission intensity) varied significantly (p<0.0001) according to time since vaccination, from 36% efficacy (95% Cl 24 to 45) at time of vaccination to 0% (-38 to 38) after 3 years.
   Interpretation Vaccine efficacy against clinical disease was of limited duration and was not detectable 3 years after vaccination. Furthermore, efficacy fell with increasing transmission intensity. Outcomes after vaccination cannot be gauged accurately on the basis of one pooled efficacy figure. However, predictions of public-health outcomes of vaccination will need to take account of variations in efficacy by transmission intensity and by time since vaccination.
C1 [Bejon, Philip; Olotu, Ally] Kenya Govt Med Res Ctr, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Bejon, Philip] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford OX1 2JD, England.
   [White, Michael T.; Ghani, Azra C.] Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modelling, London, England.
   [Bojang, Kalif] MRC Labs, Fajara, Gambia.
   [Lusingu, John P. A.] Tanga Ctr, Natl Inst Med Res, Tanga, Tanzania.
   [Salim, Nahya] Ifakara Hlth Inst, Bagamoyo, Tanzania.
   [Otsyula, Nekoye N.] Kenya Govt Med Res Ctr, Nairobi, Kenya.
   [Otsyula, Nekoye N.] US Army Med Res Unit Kenya, Nairobi, Kenya.
   [Agnandji, Selidji T.] Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon.
   [Owusu-Agyei, Seth] Kintampo Hlth Res Ctr, Kintampo, Ghana.
RP Bejon, P (reprint author), Kenya Govt Med Res Ctr, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
EM pbejon@kilifi.kemri-wellcome.org
RI Ghani, Azra/B-8560-2009
OI Bojang, Kalifa/0000-0001-7506-0938
FU Medical Research Council (UK); Bill & Melinda Gates Foundation Vaccine
   Modelling Initiative; Wellcome Trust; MRC Centre
FX Funding Medical Research Council (UK); Bill & Melinda Gates Foundation
   Vaccine Modelling Initiative; Wellcome Trust.; ACG acknowledges support
   from the Bill & Melinda Gates Foundation Vaccine Modelling Initiative
   and MRC Centre funding. GSK Biologicals did not sponsor the
   investigators to do the analysis, but did fund transport expenses for
   investigators to attend a meeting to discuss their progress.
CR Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773
   Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976
   Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6
   Asante KP, 2011, LANCET INFECT DIS, V11, P741, DOI 10.1016/S1473-3099(11)70100-1
   Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381
   Bejon P, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000304
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Guinovart C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005165
   HALLORAN ME, 1992, AM J EPIDEMIOL, V136, P328
   Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048
   Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120
   Mabunda S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-74
   Maire N, 2006, AM J TROP MED HYG, V75, P104
   Moorthy VS, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-312
   O'Meara WP, 2008, LANCET, V372, P1555, DOI 10.1016/S0140-6736(08)61655-4
   Olotu A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015569
   Olotu A, 2011, LANCET INFECT DIS, V11, P102, DOI [10.1016/S1473-3099(10)70262-0, 10.1016/51473-3099(10)70262-0]
   Polhemus ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006465
   Royston P, 2006, BRIT J CANCER, V94, P1785, DOI 10.1038/sj.bjc.6603192
   Sacarlal J, 2009, J INFECT DIS, V200, P329, DOI 10.1086/600119
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   White MT, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-82
   WHO, 2004, MANAGEMENT OF SEVERE
NR 27
TC 41
Z9 41
U1 0
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD APR
PY 2013
VL 13
IS 4
BP 319
EP 327
DI 10.1016/S1473-3099(13)70005-7
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 136TL
UT WOS:000318386200030
PM 23454164
OA No
DA 2017-08-15
ER

PT J
AU Lemoine, M
   Nayagam, S
   Thursz, M
AF Lemoine, Maud
   Nayagam, Shevanthi
   Thursz, Mark
TI Viral hepatitis in resource-limited countries and access to antiviral
   therapies: current and future challenges
SO FUTURE VIROLOGY
LA English
DT Review
DE DAA; global health; HBV; HCC; HCV; HIV/AIDS; resource-limited countries;
   social justice; treatment
ID B-VIRUS-INFECTION; TO-INFANT TRANSMISSION; HEALTH-CARE WORKERS;
   SUB-SAHARAN AFRICA; HEPATOCELLULAR-CARCINOMA; C VIRUS; LIVER-DISEASE;
   GLOBAL EPIDEMIOLOGY; RISK-FACTORS; HIV
AB Chronic viral hepatitis is a major public health issue worldwide and mostly affects resource-limited countries. These regions combine a considerable set of barriers to containing the epidemic, including shortage of healthcare workers, poor medical infrastructures, insufficient screening and poor access to care and treatment. At a time when morbidity and mortality of chronic liver disease has been widely improved in wealthy countries by new innovative strategies and potent antiviral drugs, it is now urgent to face the challenges of better management of chronic hepatitis in resource-poor countries from the perspectives of global health and social justice.
C1 [Lemoine, Maud] MRC, Gambia Unit, Dis Control & Eliminat theme Liver Unit, Banjul, Gambia.
   [Nayagam, Shevanthi; Thursz, Mark] Univ London Imperial Coll Sci Technol & Med, Dept Gastroenterol & Hepatol, London W2 1NY, England.
RP Lemoine, M (reprint author), MRC, Gambia Unit, Dis Control & Eliminat theme Liver Unit, Atlantic Rd,POB 273, Banjul, Gambia.
EM mlemoine@mrc.gm
OI Nayagam, Amanda Shevanthi/0000-0002-8030-3380
FU Wellcome Trust [097816/Z/11/Z]
FX S Nayagam is a Wellcome Trust/Imperial College London clinical research
   fellow. Her work is funded by the Wellcome Trust (grant 097816/Z/11/Z).
   The authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abdelwahab S, 2012, T ROY SOC TROP MED H, V106, P98, DOI 10.1016/j.trstmh.2011.10.003
   Adebamowo C A, 1997, West Afr J Med, V16, P93
   Alazawi W, 2010, ALIMENT PHARM THER, V32, P344, DOI 10.1111/j.1365-2036.2010.04370.x
   Allain JP, 2003, BLOOD, V101, P2419, DOI 10.1181/blood-2002-04-1084
   Bruno S, 2007, HEPATOLOGY, V45, P579, DOI 10.1002/hep.21492
   Chen HL, 2012, GASTROENTEROLOGY, V142, P773, DOI 10.1053/j.gastro.2011.12.035
   de Martel Catherine, 2012, Lancet Oncol, V13, P607, DOI 10.1016/S1470-2045(12)70137-7
   Durier N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034548
   Dusheiko G, 2012, LANCET, V379, P2019, DOI 10.1016/S0140-6736(11)61182-3
   Easterbrook P, 2012, SEMIN LIVER DIS, V32, P147, DOI 10.1055/s-0032-1316476
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
   Ferlay J, 2010, INT J CANC
   Ford N, 2012, B WORLD HEALTH ORGAN, V90, P540, DOI 10.2471/BLT.11.097147
   Ford N, 2010, CURR OPIN HIV AIDS, V5, P38, DOI 10.1097/COH.0b013e3283339b41
   Goldstein ST, 2005, INT J EPIDEMIOL, V34, P1329, DOI 10.1093/ije/dyi206
   Hoen E, 2011, J INT AIDS SOC, V14, P15, DOI DOI 10.1186/1758-2652-14-15
   Hoffmann CJ, 2007, LANCET INFECT DIS, V7, P402, DOI 10.1016/S1473-3099(07)70135-4
   International Agency for Research on Cancer, GLOBOCAN FACTSH 2008
   Jemal A, 2012, CANCER-AM CANCER SOC, V118, P4372, DOI 10.1002/cncr.27410
   Jimenez AP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007193
   Joshi D, 2011, LANCET, V377, P1198, DOI 10.1016/S0140-6736(10)62001-6
   Kaplan W, 2004, ESSENTIAL MED EUROPE
   Kim HN, 2011, J VIRAL HEPATITIS, V18, pE447, DOI 10.1111/j.1365-2893.2011.01466.x
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kondili LA, 2007, INFECTION, V35, P94, DOI 10.1007/s15010-007-6076-1
   Lacombe K, 2010, J ANTIMICROB CHEMOTH, V65, P10, DOI 10.1093/jac/dkp414
   Lacombe K, 2012, GUT, V61, P47, DOI 10.1136/gutjnl-2012-302062
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Lemoine M, 2012, J PUBLIC HEALTH POL, V33, P430, DOI 10.1057/jphp.2012.29
   Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364
   Lin XM, 2005, J GASTROEN HEPATOL, V20, P833, DOI 10.1111/j.1400-1746.2005.03813.x
   Logie DE, 2008, LANCET, V372, P256, DOI 10.1016/S0140-6736(08)60962-9
   Marcellin P, 2012, LANCET, V381, P468
   Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6
   Nelson PK, 2011, LANCET, V378, P571, DOI 10.1016/S0140-6736(11)61097-0
   Ocama P, 2011, CURR OPIN HIV AIDS, V6, P539, DOI 10.1097/COH.0b013e32834bd23f
   Olokoba AB, 2011, NIGER J CLIN PRACT, V14, P10, DOI 10.4103/1119-3077.79232
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Papatheodoridis G, 2012, J HEPATOL, V57, P167
   Piot P., 2012, NO TIME LOSE LIFE PU
   Rawls John, 1971, THEORY JUSTICE
   Salmon-Ceron D, 2009, J HEPATOL, V50, P736, DOI 10.1016/j.jhep.2008.11.018
   Sampat BN, 2009, AM J PUBLIC HEALTH, V99, P9, DOI 10.2105/AJPH.2007.128769
   Sen A., 1999, DEV FREEDOM
   STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503
   Stewart Balint, 2011, BMC Res Notes, V4, P561, DOI 10.1186/1756-0500-4-561
   Sukriti, 2008, J GASTROEN HEPATOL, V23, P1710, DOI 10.1111/j.1440-1746.2008.05483.x
   Thursz M, 2012, NAT REV GASTRO HEPAT, V9, P492, DOI 10.1038/nrgastro.2012.155
   TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501
   Tuaillon E, 2010, HEPATOLOGY, V51, P752, DOI 10.1002/hep.23407
   Welsch C, 2012, GUT, V61, P36, DOI 10.1136/gutjnl-2012-302144
   WHITTLE HC, 1983, LANCET, V1, P1203
   World Health Organization, 2010, 63 WORLD HLTH ASS
   WHO, UN ACC
   World Health Organisation, PREV CONTR VIR HEP I
   World Health Organization, HEP B
   Wurie I M, 2005, West Afr J Med, V24, P18
   Yang HI, 2008, J NATL CANCER I, V100, P1134, DOI 10.1093/jnci/djn243
   Zanetti AR, 2008, VACCINE, V26, P6266, DOI 10.1016/j.vaccine.2008.09.056
   Zoulim F, 2009, GASTROENTEROLOGY, V137, P1593, DOI 10.1053/j.gastro.2009.08.063
NR 62
TC 26
Z9 29
U1 0
U2 9
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
J9 FUTURE VIROL
JI Future Virol.
PD APR
PY 2013
VL 8
IS 4
BP 371
EP 380
DI 10.2217/FVL.13.11
PG 10
WC Virology
SC Virology
GA 122UQ
UT WOS:000317344000010
PM 23662157
OA No
DA 2017-08-15
ER

PT J
AU Tinto, H
   Noor, RA
   Wanga, CL
   Valea, I
   Mbaye, MN
   D'Alessandro, U
   Ravinetto, RM
AF Tinto, Halidou
   Noor, Ramadhani A.
   Wanga, Charles L.
   Valea, Innocent
   Mbaye, Maimouna Ndour
   D'Alessandro, Umberto
   Ravinetto, Raffaella M.
TI Perspective Piece: Good Clinical Practice in Resource-Limited Settings:
   Translating Theory into Practice
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PARTNERSHIP; WORLD
AB A Good Clinical Practices (GCPs) course, based on the combination of theoretical modules with a practical training in real-life conditions, was held in 2010 in Burkina Faso. It was attended by 15 trainees from nine African, Asian, and Latin American countries. There were some discrepancies between the average good results at the end of the theoretical phase and the GCP application during the first days of the practical phase, underlying the difficulties of translating theoretical knowledge into good practices. Most of the findings were not unexpected and reflected the challenges commonly faced by clinical investigators in resource-poor contexts (i.e., the high workload at peripheral health facilities, the need to conciliate routine clinical activities with clinical research, and the risk of creating a double standard among patients attending the same health facility [free care for recruited patients versus user fees for non-recruited patients with the same medical condition]). Even if limited in number and time, these observations suggest that a theoretical training alone may not be sufficient to prepare trainees for the challenges of medical research in real-life settings. Conversely, when a practical phase immediately follows a theoretical one, trainees can immediately experience what the research methodology implicates in terms of work organization and relationship with recruited and non-recruited patients. This initial experience shows the complexity of translating GCP into practice and suggests the need to rethink the current conception of GCP training.
C1 [Tinto, Halidou; Valea, Innocent] Inst Rech Sci Sante Direct Rege Ouest IRSS Ctr Mu, Clin Res Unit Nanoro, Bobo Dioulasso, Burkina Faso.
   QGates Clin Res Org, Darjeeling, India.
   [Mbaye, Maimouna Ndour] Hop Abass Ndao, Serv Med Interne, Dakar, Senegal.
   [D'Alessandro, Umberto] Inst Trop Med, Malariol Unit, B-2000 Antwerp, Belgium.
   Inst Trop Med, Clin Trials Unit, Dept Clin Sci, B-2000 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Banjul, Gambia.
   [Ravinetto, Raffaella M.] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Louvain, Belgium.
RP Ravinetto, RM (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.
EM tintohalidou@yahoo.fr; ramanoor@gmail.com; charles.wanga@gmail.com;
   innocentvalea@yahoo.fr; mbayester@gmail.com; udalessandro@mrc.gm;
   rravinetto@itg.be
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Belgian Directorate-General for Development Cooperation (DGD) [3 (FA3)];
   Institute of Tropical Medicine, Antwerp (Belgium); Department of
   Economy, Science and Innovation of the Flemish Government
FX This course was funded by the Belgian Directorate-General for
   Development Cooperation (DGD) under the Framework Agreement 3 (FA3) with
   the Institute of Tropical Medicine, Antwerp (Belgium). The Clinical
   Trials Unit of the Institute of Tropical Medicine (ITM) is supported by
   the Department of Economy, Science and Innovation of the Flemish
   Government.
CR Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209
   Chilengi R, 2010, WEBMEDCENTRAL CLIN T, V1
   Claeys Y, 2011, TROPICAL MED INT S1, V16
   Dolgin E, 2010, NAT MED, V16, P8, DOI 10.1038/nm0110-8a
   Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709
   [New Technologies to the European Commission European Group on Ethics in Science], 2003, OP ETH ASP CLIN RES
   European Medicine Agency, 2012, EMA1213402011
   Frenk J, 2010, LANCET, V376, P1923, DOI 10.1016/S0140-6736(10)61854-5
   Glickman SW, 2009, NEW ENGL J MED, V360, P816, DOI 10.1056/NEJMsb0803929
   Heimburger DC, 2011, AM J TROP MED HYG, V85, P971, DOI 10.4269/ajtmh.2011.11-0141
   [Anonymous], 1996, TRIP GUID GOOD CLIN
   Lancet, 2007, LANCET, V369, P1233
   Lang T, 2011, LANCET, V377, P1553, DOI 10.1016/S0140-6736(10)62052-1
   Levinson DR, 2010, OEI010800510 US DEP
   Mgone CS, 2009, TROP MED INT HEALTH, V14, P1327, DOI 10.1111/j.1365-3156.2009.02391.x
   The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979, BELM REP ETH PRINC G
   Nuffield Council on Bioethics, 1999, ETH CLIN RES DEV COU
   Nuffield Council on Bioethics, 2002, ETH RES REL HEALTHC
   Ravinetto R, 2010, ITALIAN J TROPICAL M, V15, P15
   Ravinetto R, 2011, TROP MED INT HEALTH, V16, P527, DOI 10.1111/j.1365-3156.2011.02732.x
   Pare Toe L, 2011, COMMUNICATION
   van Loen H, 2011, COMMUNICATION
   World Health Organization, 2002, WHO HDB GOOD CLIN RE
   WHO, 1995, WHO TECHN REP SER
   World Health Organization, 2008, B WORLD HEALTH ORGAN, V86, P58
   World Health Organization, 2002, INT ETH GUID BIOM RE
   World Medical Association Declaration of Helsinki, 2011, 18 WMA GEN ASS HELS
   [Anonymous], 1996, JAMA, V276, P1691
NR 28
TC 8
Z9 8
U1 0
U2 8
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD APR
PY 2013
VL 88
IS 4
BP 608
EP 613
DI 10.4269/ajtmh.12-0330
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 118KP
UT WOS:000317024700002
PM 23553224
OA No
DA 2017-08-15
ER

PT J
AU Nwakanma, DC
   Neafsey, DE
   Jawara, M
   Adiamoh, M
   Lund, E
   Rodrigues, A
   Loua, KM
   Konate, L
   Sy, N
   Dia, I
   Awolola, TS
   Muskavitch, MAT
   Conway, DJ
AF Nwakanma, Davis C.
   Neafsey, Daniel E.
   Jawara, Musa
   Adiamoh, Majidah
   Lund, Emily
   Rodrigues, Amabelia
   Loua, Kovana M.
   Konate, Lassana
   Sy, Ngayo
   Dia, Ibrahima
   Awolola, T. Samson
   Muskavitch, Marc A. T.
   Conway, David J.
TI Breakdown in the Process of Incipient Speciation in Anopheles gambiae
SO GENETICS
LA English
DT Article
ID S MOLECULAR-FORMS; MALARIA VECTOR; WEST-AFRICA; GENETIC DIFFERENTIATION;
   REPRODUCTIVE ISOLATION; PLASMODIUM-FALCIPARUM; BURKINA-FASO; DIVERGENCE;
   COMPLEX; IDENTIFICATION
AB Understanding genetic causes and effects of speciation in sympatric populations of sexually reproducing eukaryotes is challenging, controversial, and of practical importance for controlling rapidly evolving pests and pathogens. The major African malaria vector mosquito Anopheles gambiae sensu stricto (s.s.) is considered to contain two incipient species with strong reproductive isolation, hybrids between the M and S molecular forms being very rare. Following recent observations of higher proportions of hybrid forms at a few sites in West Africa, we conducted new surveys of 12 sites in four contiguous countries (The Gambia, Senegal, Guinea-Bissau, and Republic of Guinea). Identification and genotyping of 3499 A. gambiae s.s. revealed high frequencies of M/S hybrid forms at each site, ranging from 5 to 42%, and a large spectrum of inbreeding coefficient values from 0.11 to 0.76, spanning most of the range expected between the alternative extremes of panmixia and assortative mating. Year-round sampling over 2 years at one of the sites in The Gambia showed that M/S hybrid forms had similar relative frequencies throughout periods of marked seasonal variation in mosquito breeding and abundance. Genome-wide scans with an Affymetrix high-density single-nucleotide polymorphism (SNP) micro-array enabled replicate comparisons of pools of different molecular forms, in three separate populations. These showed strong differentiation between M and S forms only in the pericentromeric region of the X chromosome that contains the molecular form-specific marker locus, with only a few other loci showing minor differences. In the X chromosome, the M/S hybrid forms were more differentiated from M than from S forms, supporting a hypothesis of asymmetric introgression and backcrossing.
C1 [Nwakanma, Davis C.; Jawara, Musa; Adiamoh, Majidah; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Neafsey, Daniel E.; Muskavitch, Marc A. T.] Broad Inst, Cambridge, MA 02467 USA.
   [Lund, Emily; Muskavitch, Marc A. T.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Rodrigues, Amabelia] Bandim Hlth Project, Bissau, Guinea Bissau.
   [Loua, Kovana M.] Natl Inst Publ Hlth, Conakry, Guinea.
   [Konate, Lassana] Univ Cheikh Anta Diop, Dakar, Senegal.
   [Sy, Ngayo] Serv Lutte Antiparasitaire, Thies, Senegal.
   [Dia, Ibrahima] Inst Pasteur, Dakar, Senegal.
   [Awolola, T. Samson] Nigerian Inst Med Res, Lagos, Nigeria.
   [Muskavitch, Marc A. T.] Boston Coll, Chestnut Hill, MA 02467 USA.
   [Conway, David J.] London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Conway, DJ (reprint author), London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, Keppel St, London WC1E 7HT, England.
EM david.conway@lshtm.ac.uk
OI Conway, David/0000-0002-8711-3037
FU Burroughs Wellcome Fund Request [1008238]; Broad Institute Director's
   Fund; Harvard School of Public Health Department of Immunology and
   Infectious Diseases; Wellcome Trust Programme [077229/Z/05/Z]; United
   Kingdom Medical Research Council (MRC); Foundation for the National
   Institutes of Health (FNIH)/Gates Grand Challenges in Global Health to
   the MRC Unit in The Gambia
FX We thank the staff of our institutes who were involved in entomological
   field collections, particularly Sainey Kanteh, Lamin Camara, Alhadji
   Kaba Sylla, Tolno Gnouma Benoit, and Aboubacarr Conteh, and those who
   assisted in the laboratory, transport, or administration. We appreciate
   the encouragement and strong support from institute and departmental
   heads including Tumani Corrah and Moussa Dieng Sarr. We acknowledge the
   expert efforts of members of the Biological Samples Platform and Genetic
   Analysis Platform of the Broad Institute. The genome-wide SNP array was
   supported by joint funding from several sources, including Burroughs
   Wellcome Fund Request 1008238, the Broad Institute Director's Fund,
   Harvard School of Public Health Department of Immunology and Infectious
   Diseases under direction of D. F. Wirth, Wellcome Trust Programme grant
   077229/Z/05/Z to F. C. Kafatos and G. K. Christophides, and the DeLuca
   Professorship from Boston College to M. A. T. M. This work was enabled
   by funding from the United Kingdom Medical Research Council (MRC) and
   Foundation for the National Institutes of Health (FNIH)/Gates Grand
   Challenges in Global Health to the MRC Unit in The Gambia.
CR Aboagye-Antwi F, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-243
   Aguilar R, 2010, INSECT MOL BIOL, V19, P695, DOI 10.1111/j.1365-2583.2010.01031.x
   Black WC, 2001, INSECT MOL BIOL, V10, P3, DOI 10.1046/j.1365-2583.2001.00234.x
   Caputo B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-182
   Caputo B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016415
   Carnevale P, 2010, T ROY SOC TROP MED H, V104, P484, DOI 10.1016/j.trstmh.2010.02.002
   Cassone BJ, 2008, MOL ECOL, V17, P2491, DOI 10.1111/j.1365-294X.2008.03774.x
   Cheng CD, 2012, GENETICS, V190, P1417, DOI 10.1534/genetics.111.137794
   Coluzzi M, 2002, SCIENCE, V298, P1415, DOI 10.1126/science.1077769
   Dabire KR, 2009, TROP MED INT HEALTH, V14, P396, DOI 10.1111/j.1365-3156.2009.02243.x
   della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x
   della Torre A, 2005, INSECT BIOCHEM MOLEC, V35, P755, DOI 10.1016/j.ibmb.2005.02.006
   Dia I, 2008, ACTA TROP, V105, P145, DOI 10.1016/j.actatropica.2007.10.010
   Diabate A, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-5
   Diabate A, 2006, J MED ENTOMOL, V43, P480, DOI 10.1603/0022-2585(2006)43[480:MSOTMM]2.0.CO;2
   Diabate Abdoulaye, 2003, Journal of Medical Entomology, V40, P195
   Diabate A, 2009, P R SOC B, V276, P4215, DOI 10.1098/rspb.2009.1167
   Djogbenou L, 2010, MED VET ENTOMOL, V25, P256, DOI [10.1111/j.1365-2915.2010.00925.x, DOI 10.1111/J.1365-2915.2010.00925.X]
   Djogbenou L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002172
   Esnault C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001968
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Gimonneau G, 2011, MED VET ENTOMOL, V26, P9
   Lawniczak MKN, 2010, SCIENCE, V330, P512, DOI 10.1126/science.1195755
   Lehmann T, 2003, J HERED, V94, P133, DOI 10.1093/jhered/esg024
   Lynd A, 2010, MOL BIOL EVOL, V27, P1117, DOI 10.1093/molbev/msq002
   Marsden CD, 2011, MOL ECOL, V20, P4983, DOI 10.1111/j.1365-294X.2011.05339.x
   Ndiath MO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-136
   Neafsey DE, 2010, SCIENCE, V330, P514, DOI 10.1126/science.1193036
   Oliveira E, 2008, J MED ENTOMOL, V45, P1057, DOI 10.1603/0022-2585(2008)45[1057:HLOHBM]2.0.CO;2
   Pennetier C, 2010, CURR BIOL, V20, P131, DOI 10.1016/j.cub.2009.11.040
   Speed T. P., 2007, BRLMM P GENOTYPE CAL
   Reidenbach KR, 2012, GENOME BIOL EVOL, V4, P1202, DOI 10.1093/gbe/evs095
   Riehle MM, 2011, SCIENCE, V331, P596, DOI 10.1126/science.1196759
   Rottschaefer SM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000600
   Sanford MR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027920
   Santolamazza F, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-215
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Slotman MA, 2007, MOL ECOL, V16, P639, DOI 10.1111/j.1365-294X.2006.03172.x
   Turner TL, 2005, PLOS BIOL, V3, P1572, DOI 10.1371/journal.pbio.0030285
   Vezenegho SB, 2009, MED VET ENTOMOL, V23, P326, DOI 10.1111/j.1365-2915.2009.00840.x
   Wallace AR, 1889, DARWINISM EXPOSITION
   Weetman D, 2012, MOL BIOL EVOL, V29, P279, DOI 10.1093/molbev/msr199
   Weill M, 2000, INSECT MOL BIOL, V9, P451, DOI 10.1046/j.1365-2583.2000.00206.x
   White BJ, 2011, P NATL ACAD SCI USA, V108, P244, DOI 10.1073/pnas.1013648108
   White BJ, 2009, GENETICS, V183, P275, DOI 10.1534/genetics.109.105817
   White BJ, 2007, PLOS GENET, V3, P2404, DOI 10.1371/journal.pgen.0030217
NR 46
TC 18
Z9 18
U1 0
U2 21
PU GENETICS SOC AM
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 1943-2631
J9 GENETICS
JI Genetics
PD APR
PY 2013
VL 193
IS 4
BP 1221
EP +
DI 10.1534/genetics.112.148718
PG 17
WC Genetics & Heredity
SC Genetics & Heredity
GA 117EY
UT WOS:000316937300016
PM 23335339
OA No
DA 2017-08-15
ER

PT J
AU Mendy, M
   Peterson, I
   Hossin, S
   Peto, T
   Jobarteh, ML
   Jeng-Barry, A
   Sidibeh, M
   Jatta, A
   Moore, SE
   Hall, AJ
   Whittle, H
AF Mendy, Maimuna
   Peterson, Ingrid
   Hossin, Safayet
   Peto, Tom
   Jobarteh, Momodou L.
   Jeng-Barry, Adam
   Sidibeh, Mamadi
   Jatta, Abdoulie
   Moore, Sophie E.
   Hall, Andrew J.
   Whittle, Hilton
TI Observational Study of Vaccine Efficacy 24 Years after the Start of
   Hepatitis B Vaccination in Two Gambian Villages: No Need for a Booster
   Dose
SO PLOS ONE
LA English
DT Article
ID VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; SURFACE-ANTIGEN; CHILDREN
   BORN; HBV; ANTIBODY; TRIAL; IMMUNIZATION; PREVALENCE; PROTECTION
AB Objectives: To determine the duration of protection from hepatitis B vaccine given in infancy and early childhood and asses risk factors for HBV infection and chronic infection.
   Methods: In 1984 infant HBV vaccination was started in two Gambian villages. Cross sectional serological surveys have been undertaken every 4 years to determine vaccine efficacy. In the current survey 84.6% of 1508 eligible participants aged 128 years were tested. A spouse study was conducted in females (aged 14 years and above) and their male partners.
   Results: Vaccine efficacy against chronic infection with hepatitis B virus was 95.1% (95% confidence interval 91.5% to 97.1%), which did not vary significantly between age groups or village. Efficacy against infection was 85.4% (82.7% to 87.7%), falling significantly with age. Concentrations of hepatitis B antibody fell exponentially with age varying according to peak response: 20 years after vaccination only 17.8% (95% Cl 10.1-25.6) of persons with a low peak response (10-99 mIU/ml) had detectable HBs antibody compared to 27% (21.9% to 32.2%) of those with a high peak response (>999 mIU/ml). Time since vaccination and a low peak response were the strongest risk factors for HBV infections; males were more susceptible, marriage was not a significant risk for females. Hepatitis B DNA was not detected after infection, which tested soley core antibody positive. An undetectable peak antibody response of <10 mIU/ml and a mother who was hepatitis B e antigen positive were powerful risk factors for chronic infection.
   Conclusions: Adolescents and young adults vaccinated in infancy are at increased risk of hepatitis B infection, but not chronic infection. Married women were not at increased risk. There is no compelling evidence for the use of a booster dose of HBV vaccine in The Gambia.
C1 [Mendy, Maimuna; Peterson, Ingrid; Hossin, Safayet; Peto, Tom; Jobarteh, Momodou L.; Jeng-Barry, Adam; Sidibeh, Mamadi; Jatta, Abdoulie; Whittle, Hilton] MRC Labs, Banjul, Gambia.
   [Moore, Sophie E.] MRC Keneba, MRC Unit, Banjul, Gambia.
   [Hall, Andrew J.; Whittle, Hilton] London Sch Hyg & Trop Med, London WC1, England.
RP Mendy, M (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.
EM mendym@iarc.fr
OI Jobarteh, Modou Lamin/0000-0002-7350-6980
FU MRC (UK)
FX MRC (UK) funded this study with funds allocated to the Viral Disease
   Program (Scientific Co-ordinating Committee 1134). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   ALTER MJ, 1990, MED CLIN N AM, V74, P1529
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Beasley RP, 2009, ANN EPIDEMIOL, V19, P231, DOI 10.1016/j.annepidem.2009.01.017
   BEASLEY RP, 1983, HEPATOLOGY, V3, P135
   Bulkow LR, 1998, CLIN INFECT DIS, V26, P933, DOI 10.1086/513939
   Chang MH, 2000, JAMA-J AM MED ASSOC, V284, P3040, DOI 10.1001/jama.284.23.3040
   Chang MH, 2006, J CLIN VIROL, V36, pS45, DOI 10.1016/S1386-6532(06)80008-9
   Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602
   Dienstag JL, 2008, NEW ENGL J MED, V359, P1486, DOI 10.1056/NEJMra0801644
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   Hennig BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001898
   Huang LM, 1999, HEPATOLOGY, V29, P954, DOI 10.1002/hep.510290349
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   LEVINE OS, 1994, EPIDEMIOL REV, V16, P418
   Liang XF, 2009, J INFECT DIS, V200, P39, DOI 10.1086/599332
   Liaw YF, 2010, ANTIVIR THER, V15, P25, DOI 10.3851/IMP1621
   Lin YC, 2003, J INFECT DIS, V187, P134, DOI 10.1086/345871
   McMahon BJ, 2011, HEPATOLOGY, V54, P801, DOI 10.1002/hep.24442
   McMahon BJ, 2009, J INFECT DIS, V200, P1390, DOI 10.1086/606119
   Mendy M, 2008, J MED VIROL, V80, P1537, DOI 10.1002/jmv.21221
   Mendy ME, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-23
   Milich DR, 2003, AUTOIMMUN REV, V2, P248, DOI 10.1016/S1568-9972(03)00031-4
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Poovorawan Y, 2010, VACCINE, V28, P730, DOI 10.1016/j.vaccine.2009.10.074
   Poovorawan Y, 2009, J INFECT DIS, V200, P33, DOI 10.1086/599331
   Ratcliffe AA, 2000, B WORLD HEALTH ORGAN, V78, P570
   Ryckman KK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012273
   Shaw M, 2001, SEX TRANSM INFECT, V77, P358, DOI 10.1136/sti.77.5.358
   Shen LP, 2012, VACCINE, V30, P6623, DOI 10.1016/j.vaccine.2012.08.067
   Tharmaphornpilas P, 2009, VACCINE, V27, P6110, DOI 10.1016/j.vaccine.2009.08.034
   Thursz M, 2001, ANTIVIR RES, V52, P113, DOI 10.1016/S0166-3542(01)00175-9
   van der Sande MAB, 2007, VACCINE, V25, P1509, DOI 10.1016/j.vaccine.2006.10.023
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000753
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Whittle H, 2002, BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6
   WHITTLE HC, 1983, LANCET, V1, P1203
   [Anonymous], 2012, HEPATITIS B FACT SHE
NR 43
TC 33
Z9 34
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 22
PY 2013
VL 8
IS 3
AR e58029
DI 10.1371/journal.pone.0058029
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 111VQ
UT WOS:000316549400015
PM 23533578
OA gold
DA 2017-08-15
ER

PT J
AU Lin, GM
   Li, YH
   Jaiteh, LES
   Han, CL
AF Lin, Gen-Min
   Li, Yi-Hwei
   Jaiteh, Lamin E. S.
   Han, Chih-Lu
TI The risk of cardiovascular death associated with macrolide antibiotic
   use for acute lung injury
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE Macrolide antibiotics; Acute lung injury; Cardiac toxicity
ID AZITHROMYCIN
C1 [Lin, Gen-Min] Hualien Armed Forces Gen Hosp, Dept Med, Hualien 97144, Hualien County, Taiwan.
   [Li, Yi-Hwei] Tzu Chi Univ, Dept Publ Hlth, Hualien, Taiwan.
   [Jaiteh, Lamin E. S.] Royal Victoria Teaching Hosp, Dept Med, Banjul, Gambia.
   [Han, Chih-Lu] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.
RP Lin, GM (reprint author), Hualien Armed Forces Gen Hospital, 163 Jiali Rd, Hualien 97144, Hualien County, Taiwan.
EM farmer507@yahoo.com.tw
CR Altenburg J, 2011, RESPIRATION, V81, P67, DOI 10.1159/000320319
   Lopez-Boado YS, 2008, CURR OPIN PHARMACOL, V8, P286, DOI 10.1016/j.coph.2008.01.010
   Parchure N, 2002, CIRCULATION, V105, P1298, DOI 10.1161/hc1102.105649
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Walkey AJ, 2012, CHEST, V141, P1153, DOI 10.1378/chest.11-1908
NR 5
TC 0
Z9 0
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD MAR 20
PY 2013
VL 164
IS 1
BP 126
EP 126
DI 10.1016/j.ijcard.2012.06.079
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 098DE
UT WOS:000315525400024
PM 22795706
OA No
DA 2017-08-15
ER

PT J
AU Ogwang, C
   Afolabi, M
   Kimani, D
   Jagne, YJ
   Sheehy, SH
   Bliss, CM
   Duncan, CJA
   Collins, KA
   Knight, MAG
   Kimani, E
   Anagnostou, NA
   Berrie, E
   Moyle, S
   Gilbert, SC
   Spencer, AJ
   Soipei, P
   Mueller, J
   Okebe, J
   Colloca, S
   Cortese, R
   Viebig, NK
   Roberts, R
   Gantlett, K
   Lawrie, AM
   Nicosia, A
   Imoukhuede, EB
   Bejon, P
   Urban, BC
   Flanagan, KL
   Ewer, KJ
   Chilengi, R
   Hill, AVS
   Bojang, K
AF Ogwang, Caroline
   Afolabi, Muhammed
   Kimani, Domtila
   Jagne, Ya Jankey
   Sheehy, Susanne H.
   Bliss, Carly M.
   Duncan, Christopher J. A.
   Collins, Katharine A.
   Knight, Miguel A. Garcia
   Kimani, Eva
   Anagnostou, Nicholas A.
   Berrie, Eleanor
   Moyle, Sarah
   Gilbert, Sarah C.
   Spencer, Alexandra J.
   Soipei, Peninah
   Mueller, Jenny
   Okebe, Joseph
   Colloca, Stefano
   Cortese, Riccardo
   Viebig, Nicola K.
   Roberts, Rachel
   Gantlett, Katherine
   Lawrie, Alison M.
   Nicosia, Alfredo
   Imoukhuede, Egeruan B.
   Bejon, Philip
   Urban, Britta C.
   Flanagan, Katie L.
   Ewer, Katie J.
   Chilengi, Roma
   Hill, Adrian V. S.
   Bojang, Kalifa
TI Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with
   Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA
   ME-TRAP, in Healthy Gambian and Kenyan Adults
SO PLOS ONE
LA English
DT Article
ID VIRUS ANKARA VACCINES; FOWLPOX STRAIN FP9; T-CELLS RECOGNIZE;
   CIRCUMSPOROZOITE PROTEIN; NONIMMUNE VOLUNTEERS; IMMUNE-RESPONSES;
   RANDOMIZED-TRIAL; VIRAL VECTORS; PHASE-3 TRIAL; ENDEMIC AREA
AB Background: Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine candidate, capable of inducing sterile protection in malaria naive adults following controlled human malaria infection (CHMI).
   Methodology: We conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission patterns.
   Results: ChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median >1300 SFU/million PBMC).
   Conclusions: ChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field are now warranted.
C1 [Ogwang, Caroline; Kimani, Domtila; Knight, Miguel A. Garcia; Kimani, Eva; Soipei, Peninah; Bejon, Philip; Urban, Britta C.; Chilengi, Roma] Ctr Geog Med Res Coast, Kenya Med Res Inst, Kilifi, Kenya.
   [Afolabi, Muhammed; Jagne, Ya Jankey; Mueller, Jenny; Okebe, Joseph; Flanagan, Katie L.; Bojang, Kalifa] MRC Unit, Fajara, Gambia.
   [Sheehy, Susanne H.; Duncan, Christopher J. A.; Anagnostou, Nicholas A.; Roberts, Rachel; Gantlett, Katherine; Lawrie, Alison M.; Hill, Adrian V. S.] Churchill Hosp, Jenner Inst, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England.
   [Bliss, Carly M.; Collins, Katharine A.; Gilbert, Sarah C.; Spencer, Alexandra J.; Ewer, Katie J.; Hill, Adrian V. S.] Univ Oxford, Jenner Inst Labs, Oxford, England.
   [Berrie, Eleanor; Moyle, Sarah] Univ Oxford, Churchill Hosp, Clin Biomfg Facil, Oxford, England.
   [Colloca, Stefano; Cortese, Riccardo; Nicosia, Alfredo] Okairos AG, Rome, Italy.
   [Nicosia, Alfredo] CEINGE, Naples, Italy.
   [Viebig, Nicola K.; Imoukhuede, Egeruan B.] European Vaccine Initiat, Heidelberg, Germany.
   [Nicosia, Alfredo] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy.
   [Urban, Britta C.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
RP Sheehy, SH (reprint author), Churchill Hosp, Jenner Inst, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England.
EM Susanne.sheehy@ndm.ox.ac.uk
RI ; Ewer, Katie/B-4328-2011
OI Gilbert, Sarah/0000-0002-6823-9750; Collins,
   Katharine/0000-0002-7080-2215; Spencer, Alexandra/0000-0001-7958-6961;
   Ewer, Katie/0000-0001-9827-9836; OGWANG, CAROLINE/0000-0003-2689-9459;
   Imoukhuede, Egeruan Babatunde/0000-0001-6679-0904; Afolabi,
   Muhammed/0000-0002-9967-6419; Urban, Britta/0000-0002-4197-8393; Garcia
   Knight, Miguel Antonio/0000-0001-9556-3719
FU European and Developing Countries Clinical Trials Partnership (EDCTP);
   UK National Institute of Health Research through the Oxford Biomedical
   Research Centre [A91301 Adult Vaccine]; Wellcome Trust [084113/Z/07/Z];
   Medical Research Council
FX This work was performed by the Malaria Vectored Vaccines Consortium
   (MVVC), a four year integrated project funded by the European and
   Developing Countries Clinical Trials Partnership (EDCTP). The work was
   also supported by the UK National Institute of Health Research through
   the Oxford Biomedical Research Centre (http://www.oxfordbrc.org/)
   [A91301 Adult Vaccine], the Wellcome Trust (http://www.wellcome.ac.uk/)
   [084113/Z/07/Z] and the Medical Research Council. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6
   Barnes E, 2012, SCI TRANSL MED, V4, DOI DOI 10.1126/SCITRANSLMED.3003155
   Bejon P, 2006, CLIN INFECT DIS, V42, P1102, DOI 10.1086/501459
   Bejon P, 2006, VACCINE, V24, P4709, DOI 10.1016/j.vaccine.2006.03.029
   Bejon P, 2007, PLOS ONE, V2, pe707
   Bejon P, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010029
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Cohen J, 2010, HUM VACCINES, V6, P90
   Das P, 2010, LANCET, V376, P1515, DOI 10.1016/S0140-6736(10)61551-6
   Douglas AD, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1615
   Draper SJ, 2010, J IMMUNOL, V185, P7583, DOI 10.4049/jimmunol.1001760
   Dudareva M, 2009, VACCINE, V27, P3501, DOI 10.1016/j.vaccine.2009.03.080
   Duerr A, 2012, J INFECT DIS, V206, P258, DOI 10.1093/infdis/jis342
   Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   Greenwood B, 2011, LANCET INFECT DIS, V11, P75, DOI 10.1016/S1473-3099(11)70001-9
   Hill AVS, 2011, PHILOS T R SOC B, V366, P2806, DOI 10.1098/rstb.2011.0091
   Hill AVS, 2010, HUM VACCINES, V6, P78
   Hill AV, 2012, NEW ENGL J MED, P765
   Hill AV, 2012, NEW ENGL J MED, P366
   HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877
   Imoukhuede EB, 2006, VACCINE, V24, P6526, DOI 10.1016/j.vaccine.2006.06.022
   KHUSMITH S, 1994, INFECT IMMUN, V62, P2979
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515
   Moorthy VS, 2003, VACCINE, V21, P1995, DOI 10.1016/S0264-410X(02)00771-5
   Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8
   Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006
   O'Hara GA, 2012, J INFECT DIS, V205, P772, DOI 10.1093/infdis/jir850
   Okiro EA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-151
   Prieur E, 2004, P NATL ACAD SCI USA, V101, P290, DOI 10.1073/pnas.0307158101
   ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   Schwenk RJ, 2011, TRENDS PARASITOL
   Elias SC, 2012, MOL THER
   Sheehy SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031208
   Sheehy SH, 2011, MOL THER, V19, P2269, DOI 10.1038/mt.2011.176
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657
   Vuola JM, 2005, J IMMUNOL, V174, P449
   Webster DP, 2006, VACCINE, V24, P3026, DOI 10.1016/j.vaccine.2005.10.058
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
   WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   World Health Organization, 2000, BENCH AIDS DIAGN MAL
NR 49
TC 31
Z9 33
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 19
PY 2013
VL 8
IS 3
AR e57726
DI 10.1371/journal.pone.0057726
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 125SR
UT WOS:000317562100016
PM 23526949
OA gold
DA 2017-08-15
ER

PT J
AU Kendjo, E
   Agbenyega, T
   Bojang, K
   Newton, CRJC
   Bouyou-Akotet, M
   Pedross, F
   Kombila, M
   Helbok, R
   Kremsner, PG
AF Kendjo, Eric
   Agbenyega, Tsiri
   Bojang, Kalifa
   Newton, Charles R. J. C.
   Bouyou-Akotet, Marielle
   Pedross, Florian
   Kombila, Maryvonne
   Helbok, Raimund
   Kremsner, Peter Gottfried
TI Mortality Patterns and Site Heterogeneity of Severe Malaria in African
   Children
SO PLOS ONE
LA English
DT Article
ID SUB-SAHARAN AFRICA; TRANSMISSION INTENSITY; MALAWIAN CHILDREN;
   PROGNOSTIC INDICATORS; FALCIPARUM-MALARIA; CLINICAL-FEATURES;
   AGE-PATTERNS; SEASONALITY; MANAGEMENT; INFECTION
AB Background: In this study we aimed to assess site heterogeneity of early, intermediate, and late mortality prediction in children with severe Plasmodium falciparum malaria in sub-Saharan Africa.
   Methods: Medical records of 26,036 children admitted with severe Plasmodium falciparum malaria in six hospital research centers between December 2000 to May 2005 were analyzed. Demographic, clinical and laboratory data of children who died within 24 hours (early), between 24 and 47 hours (intermediate) and thereafter (48 hours or later, late mortality) were compared between groups and survivors.
   Results: Overall mortality was 4.3% (N = 1,129). Median time to death varied across sites (P<0.001), ranging from 8h (3h-2h) in Lambarene to 40h (10h-100h) in Kilifi. Fifty-eight percent of deaths occurred within 24 hours and intermediate and late mortality rate were 19% and 23%, respectively. Combining all sites, deep breathing, prostration and hypoglycemia were independent predictors for early, intermediate and late mortality (P<0.01). Site specific independent predictors for early death included prostration, coma and deep breathing at all sites (P<0.001). Site specific independent predictors for intermediate and late death largely varied between sites (P<0.001) and included between 1 and 7 different clinical and laboratory variables.
   Conclusion: Site heterogeneity for mortality prediction is evident in African children with severe malaria. Prediction for early mortality has the highest consistency between sites.
C1 [Kendjo, Eric; Helbok, Raimund; Kremsner, Peter Gottfried] Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon.
   [Kendjo, Eric; Kremsner, Peter Gottfried] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Kendjo, Eric; Bouyou-Akotet, Marielle; Kombila, Maryvonne] Univ Hlth Sci, Fac Med, Dept Parasitol Mycol & Trop Med, Libreville, Gabon.
   [Kendjo, Eric] Univ Paris 06, CNR Paludisme, Paris, France.
   [Agbenyega, Tsiri] Univ Sci & Technol Kumasi, Sch Med Sci, Kumasi, Ghana.
   [Bojang, Kalifa] MRC Labs, Banjul, Gambia.
   [Newton, Charles R. J. C.] KEMRI Ctr Geog Med Res Coast, Kilifi, Kenya.
   [Newton, Charles R. J. C.] UCL, Inst Child Hlth, London, England.
   [Pedross, Florian] Med Univ Innsbruck, Dept Med Stat Informat & Hlth Econ, A-6020 Innsbruck, Austria.
   [Helbok, Raimund] Med Univ Innsbruck, Dept Clin Neurol, A-6020 Innsbruck, Austria.
RP Helbok, R (reprint author), Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon.
EM raimund.helbok@uki.at
RI Newton, 21/B-7578-2014
OI Newton, 21/0000-0002-6999-5507; Bojang, Kalifa/0000-0001-7506-0938
FU US National Institutes of Health, Institute of Allergy and Infectious
   Diseases [AI45955]
FX The study was funded by a grant from the US National Institutes of
   Health, Institute of Allergy and Infectious Diseases, AI45955. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agbenyega T, 2000, J CLIN ENDOCR METAB, V85, P1569, DOI 10.1210/jc.85.4.1569
   Berkley JA, 2003, BRIT MED J, V326, P361, DOI 10.1136/bmj.326.7385.361
   Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299
   Biai S, 2007, BRIT MED J, V335, P862, DOI 10.1136/bmj.39345.467813.80
   Branca F, 2002, ANN NUTR METAB, V46, P8, DOI 10.1159/000066397
   Bronzan RN, 2007, J INFECT DIS, V195, P895, DOI 10.1086/511437
   Carneiro I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008988
   ENGLISH M, 1995, ARCH DIS CHILD, V72, P334
   Fernando D, 2003, T ROY SOC TROP MED H, V97, P161, DOI 10.1016/S0035-9203(03)90107-6
   Helbok R, 2009, J INFECT DIS, V200, P1834, DOI 10.1086/648409
   Idro R, 2006, TROP MED INT HEALTH, V11, P115, DOI 10.1111/j.1365-3156.2005.01518.x
   Kazembe LN, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-93
   Kremsner PG, 2009, J INFECT DIS, V199, P142, DOI 10.1086/595295
   KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5
   LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O
   Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Muller O, 2003, TROP MED INT HEALTH, V8, P290, DOI 10.1046/j.1365-3156.2003.01030.x
   Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4
   Nyakeriga AM, 2004, AM J CLIN NUTR, V80, P1604
   Reyburn H, 2005, JAMA-J AM MED ASSOC, V293, P1461, DOI 10.1001/jama.293.12.1461
   Reyburn H, 2008, B WORLD HEALTH ORGAN, V86, P132, DOI 10.2471/BLT.07.041723
   Roca-Feltrer A, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-282
   Rowe AK, 2009, AM J PUBLIC HEALTH, V99, P837, DOI 10.2105/AJPH.2008.134411
   Taylor T, 2006, T ROY SOC TROP MED H, V100, P615, DOI 10.1016/j.trstmh.2005.09.021
   WALLER D, 1995, CLIN INFECT DIS, V21, P577
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
NR 28
TC 9
Z9 10
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2013
VL 8
IS 3
AR e58686
DI 10.1371/journal.pone.0058686
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136BN
UT WOS:000318334500113
PM 23505549
OA gold
DA 2017-08-15
ER

PT J
AU Saidu, Y
   De Angelis, D
   Aiolli, S
   Gonnelli, S
   Georges, AM
AF Saidu, Yauba
   De Angelis, Dario
   Aiolli, Silvia
   Gonnelli, Stefano
   Georges, Anne Marie
TI A Review of Regulatory Mechanisms Used by the WHO, EU, and US to
   Facilitate Access to Quality Medicinal Products in Developing Countries
   With Constrained Regulatory Capacities
SO THERAPEUTIC INNOVATION & REGULATORY SCIENCE
LA English
DT Review
DE product registration; developing nations; medicine regulation; National
   Regulatory Authority
ID DISEASES; PEPFAR; DRUG
AB Adequate medicine regulation requires nations to establish robust regulatory agencies that will subject all pharmaceutical products to pre- and postmarketing evaluation. These agencies are essential for any country wishing to ensure that the medicinal products it authorizes for use in its territory meet internationally agreed standards of safety, quality, and efficacy. Many developing nations, however, lack regulatory systems that can guarantee this set of requirements. As a result, almost all of these nations tend to rely on regulatory decisions made by well-resourced institutions, particularly the US Food and Drug Administration, the European Medicines Agency, and the World Health Organization. In this paper, the authors review the objectives, strengths, and weaknesses of some key regulatory initiatives instituted by these bodies to facilitate product registration in developing countries with constrained regulatory capacities.
C1 [Saidu, Yauba] MRC, Vaccinol Unit, Gambia Unit, Banjul, Gambia.
   [De Angelis, Dario; Aiolli, Silvia] Novartis Vaccines & Diagnost, Siena, Italy.
   [Gonnelli, Stefano] Univ Siena, Fac Med & Surg, I-53100 Siena, Italy.
   [Georges, Anne Marie] AmQuidPharma, Brussels, Belgium.
RP Saidu, Y (reprint author), MRC, 20 Atlantic Rd,POB 273, Banjul, Gambia.
EM yaubasaidu@yahoo.com
FU Novartis Vaccines and Diagnostics, srl, Siena, Italy
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   research was supported by an educational grant from Novartis Vaccines
   and Diagnostics, srl, Siena, Italy, in the form of a fellowship that was
   awarded to Saidu Yauba to undertake a 2-year Master's in Vaccinology and
   Pharmaceutical Clinical Development at the University of Siena, Italy.
CR Anderson T, 2009, LANCET, V373, P1414
   Bio Ventures for Global Health, 2012, DEV NEW DRUGS VACC N
   Bioventure for Global Health, 2012, PRIOR REV VOUCH
   Bollyky JT., 2010, BRIDGING GAP IMPROVI
   Boyd MA, 2010, CURR OPIN HIV AIDS, V5, P83, DOI 10.1097/COH.0b013e328333b8c0
   Brennan MJ, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000095
   Cohen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010610
   El-Sadr WM, 2012, JAIDS-J ACQ IMM DEF, V60, pS96, DOI 10.1097/QAI.0b013e31825eb27b
   European Medicines Agency, 2011, OP MED US OUTS EUR U
   European Medicines Agency, 2007, WITHDR ASS REP GLOB
   European Medicines Agency, 2005, GUID PROC ASP REG CH
   European Medicines Agency, 2004, ART 58 APPL REG PROC
   European Medicines Agency, 2004, ART 58 Q A
   European Medicines Agency, 2005, Q A SUNS CLAUS MON
   [Anonymous], FED REG
   Food and Drug Administration, 2011, GUID IND NEGL TROP D
   Food and Drug Administration, 2008, GUID IND GEN PRINC D
   Food and Drug Administration, 2012, GUID IND TROP DIS VO
   Goosby E, 2012, JAIDS-J ACQ IMM DEF, V60, pS51, DOI 10.1097/QAI.0b013e31825ca721
   Hills S, 2004, EMERGING CHALLENGES
   Holmes CB, 2010, JAMA-J AM MED ASSOC, V304, P313, DOI 10.1001/jama.2010.993
   McAuslane N, 2005, R D BRIEFING CROSS R
   Milstien J, 2005, HEALTH AFFAIR, V24, P718, DOI 10.1377/hlthaff.24.3.718
   Moran M, 2010, REGISTERING NEW DRUG
   Regnstrom J, 2010, EUR J CLIN PHARMACOL, V66, P39, DOI 10.1007/s00228-009-0756-y
   Ridley DB, 2010, LANCET, V376, P922, DOI 10.1016/S0140-6736(10)60669-1
   Ridley DB, 2006, HEALTH AFFAIR, V25, P313, DOI 10.1377/hlthaff.25.2.313
   Robertson AS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001750
   Rosenbaum L, 2011, NEW ENGL J MED, V365, P2345, DOI 10.1056/NEJMp1112235
   US Food and Drug Administration, 2004, PRES EM PLAN AIDS RE
   Villa S, 2009, INT J HEALTH PLAN M, V24, P27, DOI 10.1002/hpm.930
   World Health Organization (WHO), 1999, EFF DRUG REG WHAT CA
   WHO (World Health Organization), 2012, WHO LIST PREQ MED PR
   World Health Organization, 2012, SYST PREQ VACC UN SU
   WHO, 2012, WHO DRUG INF, V26, P248
   WHO, 2011, WHO DRUG INF, V25, P231
   World Health Organization, 2012, PREQ MED WHO
   World Health Organization, 2010, PREQ MED WHO
   World Health Organization, 2012, WHO PREQ INF GUID DO
   WHO, 2006, SAF MED PUBL HLTH PR
   World Health Organization, 2012, PROC ASS ACC PRINC V
   World Health Organization, 2012, WHO PREQ VACC
   WHO, 2011, WHO DRUG INF, V25, P101
   World Health Organization, 2003, WHO POL PERSP MED EF
   World Health Organization, 2004, WORLD MED SIT
   World Health Organization, 2010, REV PROC WHO PREQ VA
   [Anonymous], 2012, PHARM LETT MORE 150
   [Anonymous], 2008, US PRESIDENTS PLAN A
NR 48
TC 2
Z9 2
U1 1
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2168-4790
J9 THER INNOV REGUL SCI
JI Ther. Innov. Regul. Sci.
PD MAR
PY 2013
VL 47
IS 2
BP 268
EP 276
DI 10.1177/2168479012474281
PG 9
WC Medical Informatics; Pharmacology & Pharmacy
SC Medical Informatics; Pharmacology & Pharmacy
GA 136DZ
UT WOS:000318342900019
OA No
DA 2017-08-15
ER

PT J
AU Derrick, T
   Roberts, CH
   Rajasekhar, M
   Burr, SE
   Joof, H
   Makalo, P
   Bailey, RL
   Mabey, DCW
   Burton, MJ
   Holland, MJ
AF Derrick, Tamsyn
   Roberts, Chrissy H.
   Rajasekhar, Megha
   Burr, Sarah E.
   Joof, Hassan
   Makalo, Pateh
   Bailey, Robin L.
   Mabey, David C. W.
   Burton, Matthew J.
   Holland, Martin J.
TI Conjunctival MicroRNA Expression in Inflammatory Trachomatous Scarring
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID REAL-TIME PCR; EPITHELIAL-MESENCHYMAL TRANSITION; QUANTITATIVE PCR;
   MICROARRAY; INFECTION; TRANSCRIPTOME; FIBROSIS; TARGETS; CANCER; GENES
AB Purpose: Trachoma is a fibrotic disease of the conjunctiva initiated by Chlamydia trachomatis infection. This blinding disease affects over 40 million people worldwide yet the mechanisms underlying its pathogenesis remain poorly understood. We have investigated host microRNA (miR) expression in health (N) and disease (conjunctival scarring with (TSI) and without (TS) inflammation) to determine if these epigenetic differences are associated with pathology.
   Methods: We collected two independent samples of human conjunctival swab specimens from individuals living in The Gambia (n = 63 & 194). miR was extracted, and we investigated the expression of 754 miR in the first sample of 63 specimens (23 N, 17 TS, 23 TSI) using Taqman qPCR array human miRNA genecards. Network and pathway analysis was performed on this dataset. Seven miR that were significantly differentially expressed between different phenotypic groups were then selected for validation by qPCR in the second sample of 194 specimens (93 N, 74 TS, 22 TSI).
   Results: Array screening revealed differential expression of 82 miR between N, TS and TSI phenotypes (fold change >3, p<0.05). Predicted mRNA targets of these miR were enriched in pathways involved in fibrosis and epithelial cell differentiation. Two miR were confirmed as being differentially expressed upon validation by qPCR. miR-147b is significantly up-regulated in TSI versus N (fold change = 2.3, p = 0.03) and miR-1285 is up-regulated in TSI versus TS (fold change = 4.6, p = 0.005), which was consistent with the results of the qPCR array.
   Conclusions: miR-147b and miR-1285 are up-regulated in inflammatory trachomatous scarring. Further investigation of the function of these miR will aid our understanding of the pathogenesis of trachoma.
C1 [Derrick, Tamsyn; Roberts, Chrissy H.; Rajasekhar, Megha; Burr, Sarah E.; Bailey, Robin L.; Mabey, David C. W.; Holland, Martin J.] London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect Trop Dis, London WC1, England.
   [Burr, Sarah E.; Joof, Hassan; Makalo, Pateh] MRC Unit, Banjul, Gambia.
   [Burton, Matthew J.] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Dept Clin Res, Fac Infect Trop Dis, London WC1, England.
RP Derrick, T (reprint author), London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect Trop Dis, London WC1, England.
EM tamsyn.derrick@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169;
   Roberts, Chrissy h./0000-0003-1064-5980
FU Wellcome Trust [079246/Z/06/Z, GR079246MA]; Fight for Sight
FX This study was funded by grants from the Wellcome Trust (079246/Z/06/Z
   and GR079246MA) with additional support from Fight for Sight for TD in
   the form of a graduate studentship (http://www.wellcome.ac.uk;
   http://www.fightforsight.org.uk). The funders had no part in the study
   design; in the collection, analysis, and interpretation of data; in the
   writing of the report; and in the decision to submit the paper for
   publication.
CR Ach RA, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-69
   Bavan L, 2011, BIODRUGS, V25, P27, DOI 10.2165/11585010-000000000-00000
   Bertero T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044919
   Burton MJ, 2011, INFECT IMMUN, V79, P4977, DOI 10.1128/IAI.05718-11
   Burton MJ, 2011, INFECT IMMUN, V79, P499, DOI 10.1128/IAI.00888-10
   Bustin SA, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-74
   Canales RD, 2006, NAT BIOTECHNOL, V24, P1115, DOI 10.1038/nbt1236
   Cole C, 2009, RNA, V15, P2147, DOI 10.1261/rna.1738409
   Cushing L, 2011, AM J RESP CELL MOL, V45, P287, DOI 10.1165/rcmb.2010-0323OC
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Deo A, 2011, J BIOINFORM COMPUT B, V9, P795, DOI 10.1142/S0219720011005793
   Duisters RF, 2009, CIRC RES, V104, P170, DOI 10.1161/CIRCRESAHA.108.182535
   Dvinge H, 2009, BIOINFORMATICS, V25, P3325, DOI 10.1093/bioinformatics/btp578
   Gaedcke J, 2012, CLIN CANCER RES, V18, P4919, DOI 10.1158/1078-0432.CCR-12-0016
   Git A, 2010, RNA, V16, P991, DOI 10.1261/rna.1947110
   Goldovsky Leon, 2005, Appl Bioinformatics, V4, P71, DOI 10.2165/00822942-200504010-00009
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Hidaka H, 2012, ONCOTARGET, V3, P44
   Izar B, 2012, INT J MOL SCI, V13, P1173, DOI 10.3390/ijms13011173
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kessler M, 2012, AM J PATHOL, V180, P186, DOI 10.1016/j.ajpath.2011.09.015
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Liu G, 2009, P NATL ACAD SCI USA, V106, P15819, DOI 10.1073/pnas.0901216106
   Lu TX, 2011, J IMMUNOL, V187, P3362, DOI 10.4049/jimmunol.1101235
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X
   Natividad A, 2010, INFECT IMMUN, V78, P4895, DOI 10.1128/IAI.00844-10
   Oertli M, 2011, J IMMUNOL, V187, P3578, DOI 10.4049/jimmunol.1101772
   Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299
   Rogler CE, 2009, HEPATOLOGY, V50, P575, DOI 10.1002/hep.22982
   Rothman KJ, 1986, MODERN EPIDEMIOLOGY
   Schopman NCT, 2010, RNA BIOL, V7, P573, DOI 10.4161/rna.7.4.13141
   Shao MH, 2009, CANCER RES, V69, P9192, DOI 10.1158/0008-5472.CAN-09-1257
   Thomas ME, 2009, RNA, V15, P493, DOI DOI 10.1261/RNA.1295509.CONTRAST
   Tian S, 2010, BIOCHEM BIOPH RES CO, V396, P435, DOI 10.1016/j.bbrc.2010.04.112
   VanGuilder HD, 2008, BIOTECHNIQUES, V44, P619, DOI 10.2144/000112776
   Vejnar CE, 2012, NUCLEIC ACIDS RES, V40, P11673, DOI 10.1093/nar/gks901
   Zhou HJ, 2012, ONCOL REP, V27, P807, DOI 10.3892/or.2011.1574
   Zhu S, 2012, NAT MED, V18, P1077, DOI 10.1038/nm.2815
   Zhu YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035147
NR 41
TC 18
Z9 18
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAR
PY 2013
VL 7
IS 3
AR e2117
DI 10.1371/journal.pntd.0002117
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 117HI
UT WOS:000316943800034
PM 23516655
OA gold
DA 2017-08-15
ER

PT J
AU Idoko, OT
   Kochhar, S
   Agbenyega, TE
   Ogutu, B
   Ota, MOC
AF Idoko, Olubukola T.
   Kochhar, Sonali
   Agbenyega, Tsiri E.
   Ogutu, Bernhards
   Ota, Martin O. C.
TI Review: Impact, Challenges, and Future Projections of Vaccine Trials in
   Africa
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Review
ID INFORMED-CONSENT; CLINICAL-TRIALS; DEVELOPING-COUNTRIES; CONJUGATE
   VACCINE; GAMBIA; HEALTH
AB Immunization remains the most cost effective method for the control of infectious diseases. Therefore, there is a global effort to deploy new vaccines for disease control and eradication. These new vaccines must be tested in the settings in which they will be used. This necessity has required the conduct of many vaccine trials in Africa, where several infectious diseases with significant public health impact are prevalent. However, these areas have peculiarities and are just beginning to gain expertise in the conduct of such trials. The vaccine developers and sponsors of these trials may also not be conversant with some issues unique to the trial site. The understanding gap from both partners can result in challenges if not addressed during the planning phase of the trial. This review seeks to highlight the issues surrounding the conduct of clinical trials in resource-constrained settings and suggests some ways of circumventing them.
C1 [Idoko, Olubukola T.; Ota, Martin O. C.] MRC Unit, Dept Vaccinol, Fajara, Gambia.
   [Kochhar, Sonali] PATH, New Delhi, India.
   [Agbenyega, Tsiri E.] Kwame Nkurma Univ Sci & Technol, Dept Physiol, Kumasi, Ghana.
   [Ogutu, Bernhards] Kenya Govt Med Res Ctr, Dept Clin Trials, Kisumu, Kenya.
RP Idoko, OT (reprint author), MRC, 6 Atlantic Rd,POB 273, Fajara, Gambia.
EM oidoko@mrc.gm; skochhar@path.com; tsiri@ghana.com; ogutu6@gmail.com;
   mota@mrc.gm
CR Arenas-Lopez S, 2011, PEDIATR DRUGS, V13, P257, DOI 10.2165/11590350-000000000-00000
   Beurret M, 2012, VACCINE, V30, P4897, DOI 10.1016/j.vaccine.2012.05.058
   Birn AE, 2011, CIENC SAUDE COLETIVA, V16, P591
   Craddock S, 2012, HEALTH PLACE, V18, P481, DOI 10.1016/j.healthplace.2011.05.004
   Cressey D, 2012, NATURE, V482, P16, DOI 10.1038/482016a
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Duclos P, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S2
   Englev Ebbe, 2003, Ugeskr Laeger, V165, P1659
   Erulkar AS, 2009, INT PERSPECT SEX R H, V35, P6, DOI 10.1363/ifpp.35.006.09
   Fairhead J, 2006, J BIOSOC SCI, V38, P103, DOI 10.1017/S0021932005000945
   Howie SRC, 2011, B WORLD HEALTH ORGAN, V89, P46, DOI 10.2471/BLT.10.080010
   Kaufmann JR, 2009, HEALTH AFFAIR, V28, P1091, DOI 10.1377/hlthaff.28.4.1091
   Kremer Michael, 2000, INNOVATION POLICY EC, V1, P35
   Lang T, 2011, AM J TROP MED HYG, V85, P967, DOI 10.4269/ajtmh.2011.11-0151
   Louisa Melva, 2012, Acta Med Indones, V44, P71
   Nunez-Wallace KR, 2010, INTELLECT DEV DISAB, V48, P175, DOI 10.1352/1944-7558-48.3.175
   Ota MO, 2012, VACCINE
   Preziosi MP, 1997, NEW ENGL J MED, V336, P370, DOI 10.1056/NEJM199701303360511
   Rehnquist J., 2001, GLOBALIZATION CLIN T
   Shapiro HT, 2001, NEW ENGL J MED, V345, P138
   Sow SO, 2011, NEW ENGL J MED, V364, P2293, DOI 10.1056/NEJMoa1003812
   Steketee RW, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-299
   UNESCO, 2010, ED ALL GLOB MON REP
   [UNICEF WHO], 2011, IMM SUMM
   [Anonymous], 1998, LANCET, V351, P286
NR 25
TC 10
Z9 10
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAR
PY 2013
VL 88
IS 3
BP 414
EP 419
DI 10.4269/ajtmh.12-0576
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 106QC
UT WOS:000316158800004
PM 23468356
OA No
DA 2017-08-15
ER

PT J
AU Thezenas, ML
   Huang, HL
   Njie, M
   Ramaprasad, A
   Nwakanma, DC
   Fischer, R
   Digleria, K
   Walther, M
   Conway, DJ
   Kessler, BM
   Casals-Pascual, C
AF Thezenas, Marie L.
   Huang, Honglei
   Njie, Madi
   Ramaprasad, Abhinay
   Nwakanma, Davis C.
   Fischer, Roman
   Digleria, Katalin
   Walther, Michael
   Conway, David J.
   Kessler, Benedikt M.
   Casals-Pascual, Climent
TI PfHPRT: A New Biomarker Candidate of Acute Plasmodium falciparum
   Infection
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE Plasmodium falciparum; malaria; biomarker; hypoxanthine
   phosphoribosyltransferase; pHPRT; shotgun proteomics; SRM
ID MASS-SPECTROMETRY; MALARIA; ENRICHMENT; PROTEOME; SEQUENCE
AB Plasmodium falciparum is a protozoan parasite that causes human malaria. This parasitic infection accounts for approximately 655 000 deaths each year worldwide. Most deaths could be prevented by diagnosing and treating malaria promptly. To date, few parasite proteins have been developed into rapid diagnostic tools. We have combined a shotgun and a targeted proteomic strategy to characterize the plasma proteome of Gambian children with severe malaria (SM), mild malaria, and convalescent controls in search of new candidate biomarkers. Here we report four P. falciparum proteins with a high level of confidence in SM patients, namely, PF10_0121 (hypoxanthine phosphoribosyltransferase, pHPRT), PF11_0208 (phosphoglycerate mutase, pPGM), PF13_0141 (lactate dehydrogenase, pLDH), and PF14_0425 (fructose bisphosphate aldolase, pFBPA). We have optimized selected reaction monitoring (SRM) assays to quantify these proteins in individual patients. All P. falciparum proteins were higher in SM compared with mild cases or control subjects. SRM-based measurements correlated markedly with clinical anemia (low blood hemoglobin concentration), and pLDH and pFBPA were significantly correlated with higher P. falciparum parasitemia. These findings suggest that pHPRT is a promising biomarker to diagnose P. falciparum malaria infection. The diagnostic performance of this marker should be validated prospectively.
C1 [Thezenas, Marie L.; Huang, Honglei; Ramaprasad, Abhinay; Fischer, Roman; Kessler, Benedikt M.; Casals-Pascual, Climent] Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet & Henry Wellcome B, Oxford OX3 7BN, England.
   [Njie, Madi; Nwakanma, Davis C.] MRC Unit, Malaria Programme, Banjul, Gambia.
   [Ramaprasad, Abhinay] King Abdulla Univ Sci & Technol, Jeddah, Saudi Arabia.
   [Digleria, Katalin] Univ Oxford, Nuffield Dept Med, Weatherall Inst Mol Med, Oxford OX3 7BN, England.
   [Walther, Michael] NIAID, NIH, Rockville, MD USA.
   [Conway, David J.] London Sch Hyg & Trop Med, London WC1, England.
RP Casals-Pascual, C (reprint author), Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet & Henry Wellcome B, Oxford OX3 7BN, England.
EM ccasals@well.ox.ac.uk
RI Ramaprasad, Abhinay/D-1181-2013
OI Ramaprasad, Abhinay/0000-0001-9372-5526; Fischer,
   Roman/0000-0002-9715-5951; Casals-Pascual, Climent/0000-0002-0867-8954;
   Kessler, Benedikt/0000-0002-8160-2446; Conway, David/0000-0002-8711-3037
FU Wellcome Trust [075491/Z/04]; Medical Research Council U.K. [G0701885]
FX The MRC Unit (The Gambia), field workers, nurses, laboratory staff, data
   staff, drivers and administrative staff, the staff at the MRC Hospital
   Fajara, and the government health staff at Royal Victoria Teaching
   Hospital (RVTH) are acknowledged. This work was supported by the
   Wellcome Trust [Grant No. 075491/Z/04]. C.C.-P. is supported by the
   Medical Research Council U.K. (Clinician Scientist Fellowship:
   G0701885).
CR Abba K., 2008, COCHRANE DB SYST REV
   Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1
   Anderson NL, 2009, MOL CELL PROTEOMICS, V8, P995, DOI 10.1074/mcp.M800446-MCP200
   Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200
   BELL D, 2006, NAT REV MICROBIOL S, V4, pS7, DOI DOI 10.1038/NRMICO1525
   BELL D, 2006, NAT REV MICROBIOL, V4, pS34, DOI DOI 10.1038/NRMICO1524
   Chang C. Y., 2012, MOL CELL PROTEOMICS, V11, DOI DOI 10.1074/mcp.M111.014662
   Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107
   Fusaro VA, 2009, NAT BIOTECHNOL, V27, P190, DOI 10.1038/nbt.1524
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Huang HL, 2005, ELECTROPHORESIS, V26, P2843, DOI 10.1002/elps.200500167
   Kiyonami R., 2010, MOL CELL PROTEOMICS, V10
   Koita OA, 2012, AM J TROP MED HYG, V86, P194, DOI 10.4269/ajtmh.2012.10-0665
   Lamikanra AA, 2007, BLOOD, V110, P18, DOI 10.1182/blood-2006-09-018069
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111
   MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
   Manning L, 2011, CLIN INFECT DIS, V52, P440, DOI 10.1093/cid/ciq105
   Ochola LB, 2005, PARASITOLOGY, V131, P449, DOI 10.1017/S0031182005008085
   Ossola R, 2011, METHODS MOL BIOL, V728, P179, DOI 10.1007/978-1-61779-068-3_11
   Picotti P., 2009, NAT METHODS, V7, P43
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Trudgian DC, 2010, BIOINFORMATICS, V26, P1131, DOI 10.1093/bioinformatics/btq081
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   White NJ, 2004, J CLIN INVEST, V113, P1084, DOI 10.1172/JCI200421682
   [Anonymous], 2010, WORLD MAL REP 2010, P205
   World Health Organization, 2003, MAL RAP DIAGN MAK IT
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
   Wongsrichanalai C, 2007, AM J TROP MED HYG, V77, P119
NR 29
TC 7
Z9 7
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAR
PY 2013
VL 12
IS 3
BP 1211
EP 1222
DI 10.1021/pr300858g
PG 12
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 100NN
UT WOS:000315708000014
PM 23339668
OA No
DA 2017-08-15
ER

PT J
AU Lin, GM
   Chen, YJ
   Kuo, DJ
   Jaiteh, LES
   Wu, YC
   Lo, TS
   Li, YH
AF Lin, Gen-Min
   Chen, Yu-Jung
   Kuo, De-Jhen
   Jaiteh, Lamin E. S.
   Wu, Yi-Chung
   Lo, Tzu-Shun
   Li, Yi-Hwei
TI Cancer Incidence in Patients With Schizophrenia or Bipolar Disorder: A
   Nationwide Population-Based Study in Taiwan, 1997-2009
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE schizophrenia; bipolar disorder; cancer; standardized incidence ratio
ID FIBROBLAST-GROWTH-FACTOR; NASOPHARYNGEAL CARCINOMA; NEUROLEPTIC
   MEDICATION; ONSET SCHIZOPHRENIA; COLORECTAL-CANCER; PROSTATE-CANCER;
   RISK; RECEPTOR; SUSCEPTIBILITY; HOSPITALS
AB Background: Both genetic and environmental factors have been reasoned for cancer development in schizophrenia patients. However, the influence of age of onset and duration of schizophrenia on cancer incidence has rarely been emphasized. Besides, bipolar disorder tends to resemble schizophrenia from the perspective of multiple rare mutations. Comparing pattern and risk of cancers between schizophrenia and bipolar patients is illuminating. Methods: This study used the Taiwan National Health Insurance Database. A total of 71 317 schizophrenia and 20 567 bipolar disorder patients from 1997 to 2009 were enrolled. Both cohorts were followed up for cancer during the same period by record linkage with the cancer certification in Taiwan. Age and gender standardized incidence ratios (SIRs) of overall and site-specific cancers were calculated. Results: The SIR for all cancers was 1.17 for the schizophrenia cohort. Increased cancer risk (SIR: 1.31, 95% CI: 1.17-1.48) was observed in females but not males. For the bipolar disorder cohort, the SIR for all cancers was 1.29, but the excess risk was found in males (SIR: 1.42, 95% CI: 1.14-1.77) and not females. Cancer risk decreases as the duration and age of onset of schizophrenia increases. If schizophrenia is diagnosed before 50, the SIRs for colorectal, breast, cervical, and uterine cancers increase but if diagnosed after 50, the SIRs for all cancers decrease except for breast cancer. In bipolar disorder, the SIRs for all site-specific cancers were insignificant. Conclusions: Among schizophrenia patients, overall cancer risk varies inversely with age at diagnosis and disease duration. Besides, gender-specific cancer risks differ between schizophrenia and bipolar disorder.
C1 [Lin, Gen-Min; Wu, Yi-Chung; Lo, Tzu-Shun; Li, Yi-Hwei] Tzu Chi Univ, Dept Publ Hlth, Hualien 97004, Taiwan.
   [Lin, Gen-Min; Chen, Yu-Jung; Wu, Yi-Chung] Hualien Armed Forces Gen Hosp, Dept Med, Hualien, Taiwan.
   [Chen, Yu-Jung] Tzu Chi Univ, Inst Med Sci, Hualien 97004, Taiwan.
   [Kuo, De-Jhen] Tzu Chi Coll Technol, Dept Hlth Adm, Hualien, Taiwan.
   [Jaiteh, Lamin E. S.] Royal Victoria Teaching Hosp, Dept Med, Banjul, Gambia.
RP Li, YH (reprint author), Tzu Chi Univ, Dept Publ Hlth, 701 Chung Yang Rd,Sect 3, Hualien 97004, Taiwan.
EM yihwei@mail.tcu.edu.tw
CR Barak Y, 2005, CANCER, V104, P2817, DOI 10.1002/cncr.21574
   BarChana M, 2008, J AFFECT DISORDERS, V108, P43, DOI 10.1016/j.jad.2007.09.003
   BREIER A, 1992, BRIT J PSYCHIAT, V161, P38
   Carrington M, 2005, J EXP MED, V201, P1069, DOI 10.1081/jem.20042158
   Catts VS, 2008, ACTA PSYCHIAT SCAND, V117, P323, DOI 10.1111/j.1600-0447.2008.01163.x
   Catts VS, 2000, SCHIZOPHR RES, V41, P405, DOI 10.1016/S0920-9964(99)00077-8
   CHANG TT, 1993, J MED VIROL, V40, P170, DOI 10.1002/jmv.1890400216
   Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610
   Chou FHC, 2011, SCHIZOPHR RES, V129, P97, DOI 10.1016/j.schres.2011.02.018
   Commissioners in Lunacy for England and Wales, 1909, ANN REPORT
   Cui DH, 2005, MOL PSYCHIATR, V10, P669, DOI 10.1038/sj.mp.4001653
   Dalton SO, 2006, BRIT J CANCER, V95, P934, DOI 10.1038/sj.bjc.6603259
   Dalton SO, 2005, SCHIZOPHR RES, V75, P315, DOI 10.1016/j.schres.2004.11.009
   Demirhan O, 2003, SCHIZOPHR RES, V65, P1, DOI 10.1016/S0920-9964(02)00504-2
   Duramad P, 2007, TOXICOL LETT, V172, P48, DOI 10.1016/j.toxlet.2007.05.017
   Grinshpoon A, 2005, SCHIZOPHR RES, V73, P333, DOI 10.1016/j.schres.2004.06.016
   Gulbinat W, 1992, BR J PSYCHIAT S, V18, P75
   Guo Jeff J, 2008, Evid Based Ment Health, V11, P93, DOI 10.1136/ebmh.11.3.93
   Hanson DR, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-7
   Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8
   Hashimoto K, 2003, PSYCHIAT RES, V120, P211, DOI 10.1016/S0165-1781(03)00186-0
   Hildesheim A, 2002, J NATL CANCER I, V94, P1780
   Hippisley-Cox J, 2007, ARCH GEN PSYCHIAT, V64, P1368, DOI 10.1001/archpsyc.64.12.1368
   Howard LM, 2010, LANCET ONCOL, V11, P797, DOI 10.1016/S1470-2045(10)70085-1
   Jeste DV, 1997, AM J GERIAT PSYCHIAT, V5, P302
   Joffe H, 2006, BIOL PSYCHIAT, V59, P1078, DOI 10.1016/j.biopsych.2005.10.017
   KATZ J, 1967, CANCER, V20, P2194, DOI 10.1002/1097-0142(196712)20:12<2194::AID-CNCR2820201220>3.0.CO;2-M
   Liao DL, 2002, NEUROPSYCHOBIOLOGY, V45, P172, DOI 10.1159/000063666
   Lichtermann D, 2001, ARCH GEN PSYCHIAT, V58, P573, DOI 10.1001/archpsyc.58.6.573
   Malzberg B, 1952, MENT HYG, V36, P104
   Massard C, 2011, CLIN CANCER RES, V17, P3876, DOI 10.1158/1078-0432.CCR-10-2815
   MORTENSEN PB, 1992, ACTA PSYCHIAT SCAND, V85, P390, DOI 10.1111/j.1600-0447.1992.tb10325.x
   MORTENSEN PB, 1989, J EPIDEMIOL COMMUN H, V43, P43, DOI 10.1136/jech.43.1.43
   PERT CB, 1988, SCHIZOPHRENIA BULL, V14, P243
   Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185
   Sonvilla G, 2010, BRIT J CANCER, V102, P1145, DOI 10.1038/sj.bjc.6605596
   Steiner J, 2008, J PSYCHIATR RES, V42, P151, DOI 10.1016/j.jpsychires.2006.10.013
   Tran-Johnson T K, 1992, Clin Geriatr Med, V8, P401
   Tworoger SS, 2006, CANCER LETT, V243, P160, DOI 10.1016/j.canlet.2006.01.032
   van Berckel BN, 2008, BIOL PSYCHIAT, V64, P820, DOI 10.1016/j.biopsych.2008.04.025
NR 40
TC 24
Z9 25
U1 2
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAR
PY 2013
VL 39
IS 2
BP 407
EP 416
DI 10.1093/schbul/sbr162
PG 10
WC Psychiatry
SC Psychiatry
GA 098NV
UT WOS:000315556900025
PM 22045828
OA No
DA 2017-08-15
ER

PT J
AU Secka, O
   Berg, DE
   Antonio, M
   Corrah, T
   Tapgun, M
   Walton, R
   Thomas, V
   Galano, JJ
   Sancho, J
   Adegbola, RA
   Thomas, JE
AF Secka, Ousman
   Berg, Douglas E.
   Antonio, Martin
   Corrah, Tumani
   Tapgun, Mary
   Walton, Robert
   Thomas, Vivat
   Galano, Juan J.
   Sancho, Javier
   Adegbola, Richard A.
   Thomas, Julian E.
TI Antimicrobial Susceptibility and Resistance Patterns among Helicobacter
   pylori Strains from The Gambia, West Africa
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID PENICILLIN-BINDING PROTEIN-1; 23S RIBOSOMAL-RNA; METRONIDAZOLE
   RESISTANCE; AMOXICILLIN RESISTANCE; CLARITHROMYCIN RESISTANCE;
   ANTIBIOTIC-RESISTANCE; BIOPSY SPECIMENS; MUTATIONS; RDXA; DNA
AB Helicobacter pylori is a globally important and genetically diverse gastric pathogen that infects most people in developing countries. Eradication efforts are complicated by antibiotic resistance, which varies in frequency geographically. There are very few data on resistance in African strains. Sixty-four Gambian H. pylori strains were tested for antibiotic susceptibility. The role of rdxA in metronidazole (Mtz) susceptibility was tested by DNA transformation and sequencing; RdxA protein variants were interpreted in terms of RdxA structure. Forty-four strains (69%) were resistant to at least 8 mu g of Mtz/ml. All six strains from infants, but only 24% of strains from adults, were sensitive (P = 0.0031). Representative Mtz-resistant (Mtz(r)) strains were rendered Mtz susceptible (Mtz(s)) by transformation with a functional rdxA gene; conversely, Mtz(s) strains were rendered Mtz(r) by rdxA inactivation. Many mutations were found by Gambian H. pylori rdxA sequencing; mutations that probably inactivated rdxA in Mtz(r) strains were identified and explained using RdxA protein's structure. All of the strains were sensitive to clarithromycin and erythromycin. Amoxicillin and tetracycline resistance was rare. Sequence analysis indicated that most tetracycline resistance, when found, was not due to 16S rRNA gene mutations. These data suggest caution in the use of Mtz-based therapies in The Gambia. The increasing use of macrolides against respiratory infections in The Gambia calls for continued antibiotic susceptibility monitoring. The rich variety of rdxA mutations that we found will be useful in further structure-function studies of RdxA, the enzyme responsible for Mtz susceptibility in this important pathogen.
C1 [Secka, Ousman; Antonio, Martin; Corrah, Tumani; Tapgun, Mary; Walton, Robert; Thomas, Vivat; Adegbola, Richard A.] MRC Unit, Fajara, Gambia.
   [Berg, Douglas E.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Galano, Juan J.; Sancho, Javier] Univ Zaragoza, Dept Biochem & Mol & Cellular Biol, Zaragoza, Spain.
   [Galano, Juan J.; Sancho, Javier] Univ Zaragoza, Biocomputat & Complex Syst Phys Inst BIFI, Joint Unit BIFI IQFR CSIC, Zaragoza, Spain.
   [Thomas, Julian E.] Newcastle Univ, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
RP Secka, O (reprint author), MRC Unit, Fajara, Gambia.
EM osecka@mrc.gm
OI Walton, Robert/0000-0001-7700-1907
FU Medical Research Council Unit (Fajara, The Gambia); U.S. National
   Institutes of Health [RO3-AI061308, R21-AI078237, R21-AI088337];
   Ministerio de Ciencia e Innovacion, Spain [BFU2010-16297]; Grupo Protein
   Target B89 (Diputacion General de Aragon, Spain); Banco Santander
   Central Hispano; Fundacion Carolina; Universidad de Zaragoza
FX This study was supported by funds from the Medical Research Council Unit
   (Fajara, The Gambia) and U.S. National Institutes of Health grants
   RO3-AI061308, R21-AI078237, and R21-AI088337, as well as by fund
   BFU2010-16297 (Ministerio de Ciencia e Innovacion, Spain) and Grupo
   Protein Target B89 (Diputacion General de Aragon, Spain). J.J.G. was
   funded by the Banco Santander Central Hispano, the Fundacion Carolina,
   and the Universidad de Zaragoza.
CR AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137
   Albert TJ, 2005, NAT METHODS, V2, P951, DOI 10.1038/NMETH805
   Atherton JC, 2006, ANNU REV PATHOL-MECH, V1, P63, DOI 10.1146/annurev.pathol.1.110304.100125
   Ben Mansour K, 2010, ANN CLIN MICROB ANTI, V9, DOI 10.1186/1476-0711-9-22
   Bruce MG, 2006, HELICOBACTER, V11, P581, DOI 10.1111/j.1523-5378.2006.00462.x
   Chisholm SA, 2003, J ANTIMICROB CHEMOTH, V51, P995, DOI 10.1093/jac/dkg192
   Choi SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018236
   Crowe SE, 2005, CURR OPIN GASTROEN, V21, P32
   Dailidiene D, 2002, ANTIMICROB AGENTS CH, V46, P3940, DOI 10.1128/AAC.46.12.3940-3946.2002
   de Boer WA, 2000, BRIT MED J, V320, P31, DOI 10.1136/bmj.320.7226.31
   Debets-Ossenkopp YJ, 1999, J ANTIMICROB CHEMOTH, V43, P511, DOI 10.1093/jac/43.4.511
   Dore MP, 1999, HELICOBACTER, V4, P154, DOI 10.1046/j.1523-5378.1999.99310.x
   Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720
   Eisig Jaime Natan, 2011, Arquivos de Gastroenterologia, V48, P261, DOI 10.1590/S0004-28032011000400008
   Estrada J, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-104
   Frenck RW, 2003, MICROBES INFECT, V5, P705, DOI 10.1016/S1286-4579(03)00112-6
   Gerrits MM, 2002, ANTIMICROB AGENTS CH, V46, P2229, DOI 10.1128/AAC.46.7.2229-2233.2002
   Goodwin A, 1998, MOL MICROBIOL, V28, P383, DOI 10.1046/j.1365-2958.1998.00806.x
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Herrera PM, 2008, J CLIN MICROBIOL, V46, P3912, DOI 10.1128/JCM.01453-08
   Jeong JY, 2000, J BACTERIOL, V182, P5082, DOI 10.1128/JB.182.18.5082-5090.2000
   Jeong JY, 2001, J BACTERIOL, V183, P5155, DOI 10.1128/JB.183.17.5155-5162.2001
   Kwon DH, 2001, ANTIMICROB AGENTS CH, V45, P2609, DOI 10.1128/AAC.45.9.2609-2615.2001
   Lin EA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000337
   Linz B, 2007, NATURE, V445, P915, DOI 10.1038/nature05562
   Martinez-Julvez M, 2012, FEBS J, V279, P4306, DOI 10.1111/febs.12020
   Megraud F, 2004, GUT, V53, P1374, DOI 10.1136/gut.2003.022111
   Mukhopadhyay AK, 2000, J BACTERIOL, V182, P3219, DOI 10.1128/JB.182.11.3219-3227.2000
   Nahar S, 2004, J CLIN MICROBIOL, V42, P4856, DOI 10.1128/JCM.42.10.4856-4858.2004
   Ndip RN, 2008, TROP MED INT HEALTH, V13, P848, DOI 10.1111/j.1365-3156.2008.02062.x
   Osato MS, 2001, ARCH INTERN MED, V161, P1217, DOI 10.1001/archinte.161.9.1217
   Passaro DJ, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.5.e87
   Paul R, 2001, ANTIMICROB AGENTS CH, V45, P962, DOI 10.1128/AAC.45.3.962-965.2001
   Qureshi NN, 2011, ANTIMICROB AGENTS CH, V55, P101, DOI 10.1128/AAC.00545-10
   Raymond J, 2004, EMERG INFECT DIS, V10, P1816
   Raymond J, 2007, HELICOBACTER, V12, P157, DOI 10.1111/j.1523-5378.2007.00486.x
   Rimbara E, 2008, J ANTIMICROB CHEMOTH, V61, P995, DOI 10.1093/jac/dkn051
   Rimbara E, 2011, NAT REV GASTRO HEPAT, V8, P79, DOI 10.1038/nrgastro.2010.210
   Schwarz S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000180
   Seck A, 2009, J INFECT DEV COUNTR, V3, P137
   Secka O, 2011, GUT PATHOG, V3, DOI 10.1186/1757-4749-3-5
   Sezgin O, 2008, TURK J GASTROENTEROL, V19, P163
   Sherif M, 2004, J CLIN MICROBIOL, V42, P4832, DOI 10.1028/JCM.42.10.4832-4834.2004
   Sisson G, 2000, J BACTERIOL, V182, P5091, DOI 10.1128/JB.182.18.5091-5096.2000
   Smith SI, 2001, J GASTROENTEROL, V36, P67, DOI 10.1007/s005350170158
   Tagliabue C, 2011, J ANTIMICROB CHEMOTH, V66, P2323, DOI 10.1093/jac/dkr306
   Tanih NF, 2010, ACTA TROP, V116, P68, DOI 10.1016/j.actatropica.2010.05.011
   Thomas JE, 2004, ARCH DIS CHILD, V89, P1149, DOI 10.1136/adc.2002.015313
   Thomas JE, 1999, PEDIATR RES, V45, P218, DOI 10.1203/00006450-199902000-00010
   Trieber CA, 2002, J BACTERIOL, V184, P2131, DOI 10.1128/JB.184.8.2131-2140.2002
   Versalovic J, 1996, ANTIMICROB AGENTS CH, V40, P477
   Windle HJ, 2007, PEDIATRICS, V119, pE754, DOI 10.1542/peds.2006-2196
   Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10
NR 53
TC 10
Z9 10
U1 1
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2013
VL 57
IS 3
BP 1231
EP 1237
DI 10.1128/AAC.00517-12
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 090GU
UT WOS:000314968100017
PM 23263004
OA No
DA 2017-08-15
ER

PT J
AU Tokarz, R
   Briese, T
   Morris, G
   Ideh, R
   Chimah, O
   Ebruke, B
   Desai, A
   Haq, S
   Sameroff, S
   Howie, SRC
   Lipkin, WI
AF Tokarz, Rafal
   Briese, Thomas
   Morris, Gerard
   Ideh, Readon
   Chimah, Osaretin
   Ebruke, Bernard
   Desai, Aaloki
   Haq, Saddef
   Sameroff, Stephen
   Howie, Stephen R. C.
   Lipkin, W. Ian
TI Serotype Analysis of Streptococcus pneumoniae in Lung and Nasopharyngeal
   Aspirates from Children in the Gambia by MassTag PCR
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; CONJUGATE VACCINE; INVASIVE DISEASE;
   MULTIPLEX PCR; DIAGNOSIS; PATHOGENS
AB Streptococcus pneumoniae strains comprise >90 serotypes. Here we describe establishment of a MassTag PCR assay designed to serotype S. pneumoniae and demonstrate its utility in tests using 31 paired lung aspirate and nasopharyngeal aspirate samples from children with pneumonia in the Gambia. Serotypes 1, 5, and 14 in were implicated in 90% of lung infections. With 5 exceptions, serotypes found in lung aspirates were also found in nasopharyngeal aspirates.
C1 [Tokarz, Rafal; Briese, Thomas; Desai, Aaloki; Haq, Saddef; Sameroff, Stephen; Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10027 USA.
   [Morris, Gerard; Ideh, Readon; Chimah, Osaretin; Ebruke, Bernard; Howie, Stephen R. C.] Child Survival Theme, Med Res Council Unit, Banjul, Gambia.
RP Tokarz, R (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10027 USA.
EM rt2249@columbia.edu
FU National Institutes of Health [AI057158]; Bill and Melinda Gates
   Foundation; Defense Threat Reduction Agency
FX This work was supported by grants from the National Institutes of Health
   AI057158 (Northeast Biodefense Center [W. I. Lipkin, PI]), the Bill and
   Melinda Gates Foundation, and the Defense Threat Reduction Agency.
CR Azzari C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009282
   Briese T, 2005, EMERG INFECT DIS, V11, P310
   Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Ideh RC, 2011, INT J TUBERC LUNG D, V15, P729, DOI 10.5588/ijtld.10.0468
   Johnson HL, 2010, PLOS MED, V10, P7, DOI DOI 10.1371/JOURNAL.PMED.1000348
   Marsh R, 2010, J CLIN MICROBIOL, V48, P831, DOI 10.1128/JCM.01701-09
   Mehr S, 2012, PAEDIATR RESPIR REV, V13, P258, DOI 10.1016/j.prrv.2011.12.001
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006
   Palacios G, 2006, EMERG INFECT DIS, V12, P692
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Tokarz R, 2009, VECTOR-BORNE ZOONOT, V9, P147, DOI 10.1089/vbz.2008.0088
   Turner P, 2011, J CLIN MICROBIOL, V49, P1784, DOI 10.1128/JCM.00157-11
   Weinberger DM, 2010, CLIN INFECT DIS, V51, P692, DOI 10.1086/655828
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
NR 16
TC 5
Z9 5
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAR
PY 2013
VL 51
IS 3
BP 995
EP 997
DI 10.1128/JCM.02974-12
PG 3
WC Microbiology
SC Microbiology
GA 092LA
UT WOS:000315121700042
PM 23254132
OA No
DA 2017-08-15
ER

PT J
AU Braithwaite, V
   Bruggraber, SFA
   Prentice, A
AF Braithwaite, V.
   Bruggraber, S. F. A.
   Prentice, A.
TI Intact fibroblast growth factor 23 and fragments in plasma from Gambian
   children
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE FGF23; Gambian rickets; Western blotting
ID FGF23; RICKETS; PHOSPHATE; FGF-23
AB Fibroblast growth factor 23 (FGF23) is grossly elevated in Gambian children with rickets and, at a lower prevalence, in those without bone deformities. We used western blotting to mimic the detection capabilities of the C-terminal FGF23 enzyme-linked immunosorbent assay (ELISA). Only intact FGF23 hormone was present in Gambian plasma samples from children with and without rickets.
   Elevated circulating FGF23 concentrations have been detected in plasma samples from Gambian children using the C-terminal Immutopics ELISA. The Immutopics ELISA detects both the intact FGF23 hormone and the C-terminal fragment. The aim of this study was to determine whether the elevated FGF23 concentrations as detected by the ELISA were predominantly due to a high proportion of intact FGF23 hormone and/or C-terminal FGF23 fragments.
   Stored, frozen plasma samples from previous studies of Gambian children with known concentrations of FGF23 as determined by C-terminal Immutopics ELISA assay, were selected for western blotting analysis: from children with rickets-like bone deformities (n = 4) and local controls (n = 4), with elevated > 900 RU/ml (n = 2) and normal < 30 RU/ml (n = 2; from each group). The anti-FGF23 polyclonal antibody that recognizes the C-terminal of FGF23 (as used in the Immutopics kit) was used as the primary antibody and the anti-IgG polyclonal antibody conjugated to horseradish peroxidase (HRP) was used as the secondary antibody.
   Firstly, C-terminal FGF23 fragments, although detectable in standards from the Immutopics ELISA kit, were not in the Gambian plasma samples. Secondly, there was no difference in the size of FGF23 molecules present in plasma from children with rickets-like bone deformities and children from the local community.
   Western blotting has provided evidence that elevated FGF23 concentrations, as determined by the C-terminal Immutopics ELISA, measured in Gambian children with and without rickets-like bone deformities was not caused by an increased proportion of circulating inactive C-terminal fragments.
C1 [Braithwaite, V.; Bruggraber, S. F. A.; Prentice, A.] Elsie Widdowson Lab, MRC Human Nutr Res, Cambridge CB1 9NL, England.
   [Prentice, A.] MRC Keneba, Keneba, West Kiang, Gambia.
RP Braithwaite, V (reprint author), Elsie Widdowson Lab, MRC Human Nutr Res, Cambridge CB1 9NL, England.
EM vickie.braithwaite@mrc-hnr.cam.ac.uk
OI Braithwaite, Vickie/0000-0002-3366-2903
FU UK Medical Research Council [U105960371, U105960399, U123261351]
FX The work was performed at MRC Human Nutrition Research, Cambridge, UK on
   samples collected at MRC Keneba, The Gambia and supported by the UK
   Medical Research Council [Unit Program numbers U105960371, U105960399
   and U123261351]. We would like to thank Immutopics for their antibody
   donation.
CR Beret-Pages A, 2004, BONE, V35, P455, DOI 10.1016/j.bone.2004.04.002
   Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   Braithwaite V, 2012, BONE, V50, P1351, DOI 10.1016/j.bone.2012.03.010
   Braithwaite V, 2012, BONE, V50, P218, DOI 10.1016/j.bone.2011.10.009
   Burnett SAM, 2006, J BONE MINER RES, V21, P1187, DOI 10.1359/JBMR.060507
   Liu SG, 2006, AM J PHYSIOL-ENDOC M, V291, pE38, DOI 10.1152/ajpendo.00008.2006
   Nishi H, 2005, NEPHRON CLIN PRACT, V101, pC94, DOI 10.1159/000086347
   Prentice A, 2008, BONE, V42, P788, DOI 10.1016/j.bone.2007.11.014
   Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179
NR 9
TC 3
Z9 3
U1 0
U2 3
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
EI 1433-2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2013
VL 24
IS 3
BP 1121
EP 1124
DI 10.1007/s00198-012-2029-3
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 089DH
UT WOS:000314889100042
PM 22648001
OA No
DA 2017-08-15
ER

PT J
AU Braithwaite, V
   Pettifor, JM
   Prentice, A
AF Braithwaite, Vickie
   Pettifor, John M.
   Prentice, Ann
TI Novel SLC34A3 mutation causing hereditary hypophosphataemic rickets with
   hypercalciuria in a Gambian family
SO BONE
LA English
DT Article
DE HHRH; Rickets; SLC34A3; Gene mutation; Africa
ID FGF23
AB Three siblings, aged 12,4 and 2 years, presented at a Gambian clinic with bone deformities. Radiographs of knees and wrists confirmed the presence of florid rickets. The family (including 2 unaffected siblings and the mother) were investigated for hereditary rickets.
   The three affected siblings had biochemical features of hereditary hypophosphataemic rickets with hypercalciuria (HHRH) with normal plasma calcium and 25-hydroxyvitamin D concentrations, elevated 1,25-dihydroxyvitamin D, hypophosphataemia, hyperphosphaturia and hypercalciuria. At presentation, two of the three affected siblings had an elevated fibroblast growth factor-23 (FGF23) concentration. The mother and clinically unaffected siblings had largely normal biochemistry.
   Genetic analysis of the SLC34A3 gene, encoding the type IIc sodium-phosphate cotransporter, in DNA samples from the siblings and their mother was conducted. Three single nucleotide polymorphisms (SNPs) S168F, E513V and L599L were identified. E513V and L599L had been previously identified as benign polymorphisms. S168F however, is a previously unreported variant. In silico mutation evaluation predicted that the S168F mutation causes changes in the protein product which are damaging to its function. In addition, the three clinically affected siblings were homozygous in the S168F variant whereas the unaffected family members were carriers. This study describes a biochemical profile and complementary gene data consistent with a rare genetic hypophosphataemic rickets disease in a family from rural Gambia. To our knowledge, this study reports the first cases of HHRH in Africa and describes a novel causal mutation within the SLC34A3 gene. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Braithwaite, Vickie; Prentice, Ann] Elsie Widdowson Lab, MRC Human Nutr Res, Cambridge CB1 9NL, England.
   [Pettifor, John M.] Univ Witwatersrand, Fac Hlth Sci, MRC Wits Dev Pathways Hlth Res Unit, Johannesburg, South Africa.
   [Prentice, Ann] MRC Keneba, Keneba, West Kiang, Gambia.
RP Braithwaite, V (reprint author), Elsie Widdowson Lab, MRC Human Nutr Res, Cambridge CB1 9NL, England.
EM vickie.braithwaite@mrc-hnr.cam.ac.uk
RI Pettifor, John/D-5943-2012
OI Pettifor, John/0000-0003-1155-0334; Braithwaite,
   Vickie/0000-0002-3366-2903
FU Medical Research Council, UK [U105960371, U123261351]
FX Funding sources: Medical Research Council, UK Programme numbers:
   U105960371 & U123261351.
CR Adzhubei IA, 2012, NAT METHODS, V7, P248
   Bergwitz C, 2006, AM J HUM GENET, V78, P179, DOI 10.1086/499409
   Braithwaite V, 2011, BONE, V50, P218
   Farrow EG, 2011, P NATL ACAD SCI USA, V108, pE1146, DOI 10.1073/pnas.1110905108
   Lorenz-Depiereux B, 2006, AM J HUM GENET, V78, P193, DOI 10.1086/499410
   Negri AL, 2007, NEPHROLOGY, V12, P317, DOI 10.1111/j.1440-1797.2007.00824.x
   Payne RB, 1998, ANN CLIN BIOCHEM, V35, P201
   Prentice A, 2008, BONE, V42, P788, DOI 10.1016/j.bone.2007.11.014
   Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575
   Thacher TD, 2000, J TROP PEDIATRICS, V46, P132, DOI 10.1093/tropej/46.3.132
NR 10
TC 2
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD MAR
PY 2013
VL 53
IS 1
BP 216
EP 220
DI 10.1016/j.bone.2012.12.003
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 080QB
UT WOS:000314257100029
PM 23246670
OA No
DA 2017-08-15
ER

PT J
AU Manyando, C
   Njunju, EM
   D'Alessandro, U
   Van Geertruyden, JP
AF Manyando, Christine
   Njunju, Eric M.
   D'Alessandro, Umberto
   Van Geertruyden, Jean-Pierre
TI Safety and Efficacy of Co-Trimoxazole for Treatment and Prevention of
   Plasmodium falciparum Malaria: A Systematic Review
SO PLOS ONE
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS;
   SUB-SAHARAN AFRICA; INSECTICIDE-TREATED BEDNETS; INFECTED UGANDAN
   CHILDREN; FOLIC-ACID ANTAGONISTS; SULFADOXINE-PYRIMETHAMINE;
   PREGNANT-WOMEN; PLACENTAL MALARIA; WESTERN KENYA
AB Introduction: Cotrimoxazole (CTX) has been used for half a century. It is inexpensive hence the reason for its almost universal availability and wide clinical spectrum of use. In the last decade, CTX was used for prophylaxis of opportunistic infections in HIV infected people. It also had an impact on the malaria risk in this specific group.
   Objective: We performed a systematic review to explore the efficacy and safety of CTX used for P. falciparum malaria treatment and prophylaxis.
   Result: CTX is safe and efficacious against malaria. Up to 75% of the safety concerns relate to skin reactions and this increases in HIV/AIDs patients. In different study areas, in HIV negative individuals, CTX used as malaria treatment cleared 56%-97% of the malaria infections, reduced fever and improved anaemia. CTX prophylaxis reduces the incidence of clinical malaria in HIV-1 infected individuals from 46%-97%. In HIV negative non pregnant participants, CTX prophylaxis had 39.5%-99.5% protective efficacy against clinical malaria. The lowest figures were observed in zones of high sulfadoxine-pyrimethamine resistance. There were no data reported on CTX prophylaxis in HIV negative pregnant women.
   Conclusion: CTX is safe and still efficacious for the treatment of P.falciparum malaria in non-pregnant adults and children irrespective of HIV status and antifolate resistance profiles. There is need to explore its effect in pregnant women, irrespective of HIV status. CTX prophylaxis in HIV infected individuals protects against malaria and CTX may have a role for malaria prophylaxis in specific HIV negative target groups.
C1 [Manyando, Christine] Trop Dis Res Ctr, Dept Publ Hlth, Ndola, Zambia.
   [D'Alessandro, Umberto] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Van Geertruyden, Jean-Pierre] Univ Antwerp, Antwerp, Belgium.
   [Njunju, Eric M.] Trop Dis Res Ctr, Dept Biomed Sci, Ndola, Zambia.
RP Manyando, C (reprint author), Trop Dis Res Ctr, Dept Publ Hlth, Ndola, Zambia.
EM cmanyando@yahoo.com
RI Van geertruyden, Jean-pierre/K-6425-2014; D'Alessandro,
   Umberto/D-3457-2015
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364; D'Alessandro,
   Umberto/0000-0001-6341-5009
FU Belgian Development Co-operation
FX Belgian Development Co-operation funded the process through an
   institutional collaboration between the Tropical Disease Research
   Center, Ndola, Zambia, and the Institute of Tropical Medicine, Antwerp,
   Belgium. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Akim NIJ, 2000, AM J TROP MED HYG, V63, P199
   Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1
   Anglaret X, 2010, LANCET, V375, P1231, DOI 10.1016/S0140-6736(10)60200-0
   Ayisi JG, 2003, AIDS, V17, P585, DOI 10.1097/01.aids.0000042977.95433.37
   Badri M, 1999, LANCET, V354, P334, DOI 10.1016/S0140-6736(05)75237-5
   Badri M, 2001, AIDS, V15, P1143, DOI 10.1097/00002030-200106150-00009
   Brahmbhatt H, 2006, JAIDS-J ACQ IMM DEF, V41, P504, DOI 10.1097/01.qai.0000188122.15493.0a
   Briand V, 2009, ANN TROP PAEDIATR, V29, P71, DOI 10.1179/146532809X440699
   BUSHBY SRM, 1968, BRIT J PHARMACOL, V33, P72
   Byakika-Kibwika Pauline, 2007, Afr Health Sci, V7, P86
   Corbett EL, 2002, CLIN INFECT DIS, V34, P1251, DOI 10.1086/339540
   Crampin AC, 2003, AIDS, V17, P389, DOI 10.1097/01.aids.0000042939.55529.a8
   Czeizel AE, 2001, REPROD TOXICOL, V15, P637, DOI 10.1016/S0890-6238(01)00178-2
   DARAMOLA OO, 1991, T ROY SOC TROP MED H, V85, P345, DOI 10.1016/0035-9203(91)90285-7
   DARRELL JH, 1968, J CLIN PATHOL, V21, P202, DOI 10.1136/jcp.21.2.202
   Dorsey G, 2004, AM J TROP MED HYG, V71, P758
   Farrell J, 2003, J PHARMACOL EXP THER, V306, P229, DOI 10.1124/jpet.103.050112
   FASAN PO, 1971, ANN TROP MED PARASIT, V65, P117
   Fehintola F A, 2010, Afr J Med Med Sci, V39, P63
   Feikin DR, 2000, J INFECT DIS, V181, P1501, DOI 10.1086/315382
   Filler SJ, 2006, J INFECT DIS, V194, P286, DOI 10.1086/505080
   Flateau C, 2011, LANCET INFECT DIS, V11, P541, DOI 10.1016/S1473-3099(11)70031-7
   Forna F, 2006, AIDS REV, V8, P24
   Gallagher M, 2005, AIDS, V19, P1849, DOI 10.1097/01.aids.0000189846.90946.5d
   Gasasira AF, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-177
   Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8
   Gill CJ, 2004, B WORLD HEALTH ORGAN, V82, P290
   Hamel MJ, 2008, AM J TROP MED HYG, V79, P320
   Hamel MJ, 2005, AM J TROP MED HYG, V73, P609
   HANSFORD CF, 1982, S AFR MED J, V61, P512
   Heimpel H, 1987, Infection, V15 Suppl 5, pS248, DOI 10.1007/BF01643198
   Hernandez-Diaz S, 2001, AM J EPIDEMIOL, V153, P961, DOI 10.1093/aje/153.10.961
   Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204
   HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305
   Ho JMW, 2011, CAN MED ASSOC J, V183, P1851, DOI 10.1503/cmaj.111152
   Inion I, 2003, J INFECT DIS, V188, P1675, DOI 10.1086/379737
   Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8
   JOOS B, 1995, ANTIMICROB AGENTS CH, V39, P2661
   Kamya MR, 2007, AIDS, V21, P2059
   Kapito-Tembo A, 2011, J INFECT DIS, V203, P464, DOI 10.1093/infdis/jiq072
   Kilian AHD, 1998, T ROY SOC TROP MED H, V92, P197, DOI 10.1016/S0035-9203(98)90748-9
   Kone A, 2010, INT J PARASITOL, V40, P1221, DOI 10.1016/j.ijpara.2010.05.004
   Korenromp EL, 2005, EMERG INFECT DIS, V11, P1410
   Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566
   Kuhn L, 2005, CLIN INFECT DIS, V41, P1654, DOI 10.1086/498029
   Kyabayinze D, 2003, AM J TROP MED HYG, V69, P247
   Ladner J, 2003, AIDS, V17, P275, DOI 10.1097/01.aids.0000050793.28043.8b
   Lynen L, 2007, T ROY SOC TROP MED H, V101, P1059, DOI 10.1016/j.trstmh.2007.07.001
   Malamba S, 2010, AM J TROP MED HYG, V82, P766, DOI 10.4269/ajtmh.2010.08-0408
   Malamba SS, 2006, AM J TROP MED HYG, V75, P375
   Mendez F, 2002, AM J EPIDEMIOL, V156, P230, DOI 10.1093/aje/kwf030
   Mermin J, 2006, LANCET, V367, P1256, DOI 10.1016/S0140-6736(06)68541-3
   Mermin J, 2006, JAIDS-J ACQ IMM DEF, V41, P129, DOI 10.1097/01.qai.0000179427.11789.a7
   Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5
   Mermin J, 2005, AIDS, V19, P1035, DOI 10.1097/01.aids.0000174449.32756.c7
   Molloy AM, 2008, FOOD NUTR BULL, V29, pS101
   Mutabingwa TK, 1996, T R SOC TROP MED HYG, V90, P476
   Mutabingwa TK, 2009, PLOS ONE, V4, P5138
   Nakanjako D, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-66
   Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7
   Newman PM, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-254
   Njama-Meya D, 2004, TROP MED INT HEALTH, V9, P862, DOI 10.1111/j.1365-3156.2004.01277.x
   Omar SA, 2001, T ROY SOC TROP MED H, V95, P657, DOI 10.1016/S0035-9203(01)90107-5
   Parise ME, 1998, AM J TROP MED HYG, V59, P813
   Peters PJ, 2007, DRUG SAFETY, V30, P481, DOI 10.2165/00002018-200730060-00003
   PETERSEN E, 1987, T ROY SOC TROP MED H, V81, P238, DOI 10.1016/0035-9203(87)90226-4
   Petri WA, 2012, GILMAN GOODMANS PHAR
   REEVES DS, 1969, BRIT MED J, V1, P541
   Robert V, 2000, AM J TROP MED HYG, V62, P210
   Sandison TG, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d1617
   Santos F, 2011, BJOG-INT J OBSTET GY, V118, P1374, DOI 10.1111/j.1471-0528.2011.03041.x
   Schellenberg D, 2002, AM J TROP MED HYG, V67, P17
   Siega-Riz AM, 2004, AM J OBSTET GYNECOL, V191, P1851, DOI 10.1016/j.ajog.2004.07.076
   Sowunmi A, 2006, ANN TROP MED PARASIT, V100, P205, DOI 10.1179/136485906X91503
   Sowunmi A, 2005, MEM I OSWALDO CRUZ, V100, P451, DOI 10.1590/S0074-02762005000400019
   Steketee RW, 2001, AM J TROP MED HYG, V64, P28
   ter Kuile FO, 2007, JAMA-J AM MED ASSOC, V297, P2603, DOI 10.1001/jama.297.23.2603
   Ter Kuile FO, 2004, AM J TROP MED HYG, V71, P41
   ter Kuile FO, 2003, AM J TROP MED HYG, V68, P100
   ter Kuile FO, 2003, AM J TROP MED HYG, V68, P68
   Thera MA, 2005, J INFECT DIS, V192, P1823, DOI 10.1086/498249
   Ticconi C, 2003, JAIDS-J ACQ IMM DEF, V34, P289, DOI 10.1097/00126334-200311010-00005
   Tomasulo Patricia, 2007, Medical Reference Services Quarterly, V26, P51, DOI 10.1300/J115v26n01_05
   Triglia T, 1997, P NATL ACAD SCI USA, V94, P13944, DOI 10.1073/pnas.94.25.13944
   Uneke Chigozie J, 2007, Yale J Biol Med, V80, P95
   van Eijk AM, 2003, AIDS, V17, P595, DOI 10.1097/01.aids.0000042975.95433.a5
   Van Eijk AM, 2001, AM J TROP MED HYG, V65, P623
   Van Geertruyden JP, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-134
   Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35
   von SL, 2001, TROP MED INT HEALTH, V6, P92
   Walker AS, 2010, LANCET, V375, P1278, DOI 10.1016/S0140-6736(10)60057-8
   Walter J, 2006, J INFECT DIS, V194, P1510, DOI 10.1086/508996
   Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6
   WHO, 2012, WORLD MALARIA REPORT 2012, P1
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   World Health Organization (WHO), 2006, GUID COTR PROPH HIV
   World Health Organization, 2012, INT PREV TREATM MAL
   WHO, 2010, WHO POL REC IPTI
   World Health Organization, 2010, GUID TREATM MAL
   WHO, 2008, FOOD NUTR BULL, V29, pS3
   Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0
   WILKINSON RN, 1973, T ROY SOC TROP MED H, V67, P148, DOI 10.1016/0035-9203(73)90340-4
   Yoshimine H, 2001, AM J TROP MED HYG, V64, P172
   Zachariah R, 2003, AIDS, V17, P1053, DOI 10.1097/01.aids.0000060355.78202.b7
NR 104
TC 27
Z9 27
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 22
PY 2013
VL 8
IS 2
AR e56916
DI 10.1371/journal.pone.0056916
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 113IC
UT WOS:000316658800048
PM 23451110
OA gold
DA 2017-08-15
ER

PT J
AU Lim, ES
   Reyes, A
   Antonio, M
   Saha, D
   Ikumapayi, UN
   Adeyemi, M
   Stine, OC
   Skelton, R
   Brennan, DC
   Mkakosya, RS
   Manary, MJ
   Gordon, JI
   Wang, D
AF Lim, Efrem S.
   Reyes, Alejandro
   Antonio, Martin
   Saha, Debasish
   Ikumapayi, Usman N.
   Adeyemi, Mitchell
   Stine, O. Colin
   Skelton, Rebecca
   Brennan, Daniel C.
   Mkakosya, Rajhab S.
   Manary, Mark J.
   Gordon, Jeffrey I.
   Wang, David
TI Discovery of STL polyomavirus, a polyomavirus of ancestral recombinant
   origin that encodes a unique T antigen by alternative splicing
SO VIROLOGY
LA English
DT Article
DE Polyomavirus; Virus discovery; Tumor antigen; Alternative splicing;
   Recombination
ID MERKEL CELL POLYOMAVIRUS; SIMIAN-VIRUS-40 LARGE T; EARLY MESSENGER-RNA;
   IDENTIFICATION; EVOLUTION; PROTEINS; FAMILY; DOMAIN; JC; TRANSFORMATION
AB The family Polyomaviridae is comprised of circular double-stranded DNA viruses, several of which are associated with diseases, including cancer, in immunocompromised patients. Here we describe a novel polyomavirus recovered from the fecal microbiota of a child in Malawi, provisionally named STL polyomavirus (STLPyV). We detected STLPyV in clinical stool specimens from USA and The Gambia at up to 1% frequency. Complete genome comparisons of two STLPyV strains demonstrated 5.2% nucleotide divergence. Alternative splicing of the STLPyV early region yielded a unique form of T antigen, which we named 229T, in addition to the expected large and small T antigens. STLPyV has a mosaic genome and shares an ancestral recombinant origin with MWPyV. The discovery of STLPyV highlights a novel alternative splicing strategy and advances our understanding of the complex evolutionary history of polyomaviruses. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Lim, Efrem S.; Wang, David] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Lim, Efrem S.; Wang, David] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Reyes, Alejandro; Gordon, Jeffrey I.] Washington Univ, Sch Med, Ctr Genome Sci & Syst Biol, St Louis, MO 63110 USA.
   [Skelton, Rebecca; Brennan, Daniel C.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.
   [Manary, Mark J.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
   [Antonio, Martin; Saha, Debasish; Ikumapayi, Usman N.; Adeyemi, Mitchell] MRC Unit, Banjul, Gambia.
   [Stine, O. Colin] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
   [Mkakosya, Rajhab S.] Univ Malawi, Coll Med, Dept Pathol, Blantyre 3, Malawi.
   [Manary, Mark J.] Univ Malawi, Coll Med, Dept Community Hlth, Blantyre 3, Malawi.
RP Wang, D (reprint author), Washington Univ, Sch Med, Dept Mol Microbiol, Campus Box 8230,660S Euclid Ave, St Louis, MO 63110 USA.
EM davewang@borcim.wustl.edu
OI Reyes, Alejandro/0000-0003-2907-3265
FU NIH [U54 AI057160, K24 DK002886, DK079333]; Roche Organ Transplantation
   Foundation; Medical Research Council (UK); Bill & Melinda Gates
   Foundation [OPP1016839]
FX This work was supported in part by the NIH Grant U54 AI057160 to the
   Midwest Regional Center of Excellence for Biodefense and Emerging
   Infectious Disease Research, NIH Grant K24 DK002886 and NIH DK079333
   (DCB), a Grant from the Roche Organ Transplantation Foundation, The
   Medical Research Council (UK) and the Bill & Melinda Gates Foundation
   (OPP1016839). DW holds an investigator in the pathogenesis of infectious
   disease award from the Burroughs Wellcome Fund. We thank Irma Bauer for
   performing the JCPyV screening.
CR Abend JR, 2009, J GEN VIROL, V90, P1238, DOI 10.1099/vir.0.009159-0
   Allander T, 2007, J VIROL, V81, P4130, DOI 10.1128/JVI.00028-07
   Babakir-Mina M, 2011, NEW MICROBIOL, V34, P1
   Bhattacharjee S, 2010, INDIAN J BIOTECHNOL, V9, P252
   Bialasiewicz S, 2010, J VIROL, V84, P6229, DOI 10.1128/JVI.02658-09
   Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451
   Boyapati A, 2003, VIROLOGY, V315, P148, DOI 10.1016/S0042-6822(03)00524-5
   Bradley RK, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000392
   Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098
   Cantalupo P, 2005, J VIROL, V79, P13094, DOI 10.1128/JVI.79.20.13094-13104.2005
   Chen YP, 2004, J GEN VIROL, V85, P2651, DOI 10.1099/vir.0.79920-0
   Crandall KA, 2006, ADV EXP MED BIOL, V577, P46
   Daniels R, 2007, PLOS PATHOG, V3, P928, DOI 10.1371/journal.ppat.0030098
   Drummond A, 2011, GENEIOUS V5 4
   Drummond AJ, 2009, TRACER V1 5
   Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586
   Gaynor AM, 2007, PLOS PATHOG, V3, P595, DOI 10.1371/journal.ppat.0030064
   Gottlieb KA, 2001, MICROBIOL MOL BIOL R, V65, P288, DOI 10.1128/MMBR.65.2.288-318.2001
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hatwell JN, 2000, J GEN VIROL, V81, P1191
   Huang YQ, 2009, FRONT BIOSCI, V14, P4968, DOI 10.2741/3581
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Johne R, 2007, J VIROL, V81, P11554, DOI 10.1128/JVI.01178-07
   Johne R, 2011, ARCH VIROL, V156, P1627, DOI 10.1007/s00705-011-1008-x
   Kotloff KL, 2012, CLIN INFECT DIS, V55, pS232, DOI 10.1093/cid/cis753
   Krumbholz A, 2009, INFECT GENET EVOL, V9, P784, DOI 10.1016/j.meegid.2009.04.008
   Lole KS, 1999, J VIROL, V73, P152
   Perez-Losada M, 2006, J VIROL, V80, P5663, DOI 10.1128/JVI.00056-06
   RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0
   Reyes A, 2010, NATURE, V466, P334, DOI 10.1038/nature09199
   Sauvage V, 2011, EMERG INFECT DIS, V17, P1364, DOI 10.3201/eid1708.110278
   Schowalter RM, 2010, CELL HOST MICROBE, V7, P509, DOI 10.1016/j.chom.2010.05.006
   Scuda N, 2011, J VIROL, V85, P4586, DOI 10.1128/JVI.02602-10
   Sharp PM, 2011, CURR OPIN VIROL, V1, P436, DOI 10.1016/j.coviro.2011.10.018
   Shuda M, 2008, P NATL ACAD SCI USA, V105, P16272, DOI 10.1073/pnas.0806526105
   Siebrasse EA, 2012, EMERG INFECT DIS, V18, P1676, DOI 10.3201/eid1810.120359
   Siebrasse EA, 2012, J VIROL, V86, P10321, DOI 10.1128/JVI.01210-12
   Srinivasan A, 1997, MOL CELL BIOL, V17, P4761
   Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000
   TREISMAN R, 1981, Journal of Molecular and Applied Genetics, V1, P83
   TROWBRIDGE PW, 1995, J NEUROVIROL, V1, P195, DOI 10.3109/13550289509113966
   van der Meijden E, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001024
   Van Ghelue M., 2012, REV MED VIROL, V6, P354
   Woolford L, 2007, J VIROL, V81, P13280, DOI 10.1128/JVI.01662-07
   Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053
   ZERRAHN J, 1993, EMBO J, V12, P4739
NR 48
TC 71
Z9 72
U1 1
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD FEB 20
PY 2013
VL 436
IS 2
BP 295
EP 303
DI 10.1016/j.virol.2012.12.005
PG 9
WC Virology
SC Virology
GA 083EX
UT WOS:000314446600006
PM 23276405
OA No
DA 2017-08-15
ER

PT J
AU Adetifa, IM
   Ota, MOC
   Jeffries, DJ
   Lugos, MD
   Hammond, AS
   Battersby, NJ
   Owiafe, PK
   Donkor, SD
   Antonio, M
   Ibanga, HB
   Brookes, RH
   Aka, P
   Walton, R
   Adegbola, RA
   Hill, PC
AF Adetifa, Ifedayo M.
   Ota, Martin O. C.
   Jeffries, David J.
   Lugos, Moses D.
   Hammond, Abdulrahman S.
   Battersby, Nicholas J.
   Owiafe, Patrick K.
   Donkor, Simon D.
   Antonio, Martin
   Ibanga, Hannah B.
   Brookes, Roger H.
   Aka, Peter
   Walton, Robert
   Adegbola, Richard A.
   Hill, Philip C.
TI Interferon-gamma ELISPOT as a Biomarker of Treatment Efficacy in Latent
   Tuberculosis Infection A Clinical Trial
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE latent tuberculosis infection; isoniazid; IFN-gamma release assays;
   clinical trial; ELISPOT reversion
ID LINKED IMMUNOSPOT ASSAY; T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS;
   RELEASE ASSAYS; SKIN-TEST; ARKANSAS METHOD; DIAGNOSIS; GAMBIA; ANTIGENS;
   RELEVANCE
AB Rationale: Biomarkers that can be used to evaluate new interventions against latent tuberculosis infection (LTBI) and predict reactivation TB disease are urgently required.
   Objectives: To evaluate ESAT-6 and CFP-10 (EC) IFN-gamma ELISPOT as a biomarker for treatment efficacy in LTBI.
   Methods: This was a randomized, blinded, and placebo-controlled trial of INH in EC ELISPOT and Mantoux test positive participants.
   Measurements and Main Results: Participants received a 6-month course of 900 mg INH twice weekly or a matching placebo. INH acetylator genotypes were determined and urine tested for INH metabolites to confirm adherence. The proportion of positive responders for CFP-10 and ESAT-6 between treatment arms was compared using mixed effects logistic regression models. A Tweedie (compound Poisson) model was fitted to allow for zero inflation and overdispersion of quantitative response. The proportions of EC ELISPOT-positive subjects reduced over time (P < 0.001) but did not differ by study arm (P = 0.36). Median spot-forming units for ESAT-6 and CFP-10 also declined significantly with time (P < 0.001) but did not differ by study arm (P = 0.74 and 0.71, respectively). There was no evidence of an interaction between acetylator status and INH treatment with respect to ELISPOT results over time.
   Conclusions: In contacts with LTBI, INH therapy plays no role in observed decreases in Mycobacterium tuberculosis antigen specific T-cell responses over time. IFN-gamma ELISPOT is probably not a useful biomarker of treatment efficacy in LTBI.
   Clinical trial registered with www.clinicaltrials.gov (NCT 00130325).
C1 [Adetifa, Ifedayo M.; Ota, Martin O. C.; Jeffries, David J.; Lugos, Moses D.; Hammond, Abdulrahman S.; Battersby, Nicholas J.; Owiafe, Patrick K.; Donkor, Simon D.; Antonio, Martin; Ibanga, Hannah B.; Brookes, Roger H.; Aka, Peter; Walton, Robert; Adegbola, Richard A.] MRC Unit, Fajara, Gambia.
   [Hill, Philip C.] Univ Otago, Sch Med, Dept Prevent & Social Med, Ctr Int Hlth, Dunedin, New Zealand.
RP Adetifa, IM (reprint author), MRC Unit, POB 273, Banjul, Gambia.
EM iadetifa@mrc.gm
FU Medical Research Council (UK); European and Developing Countries
   Clinical Trials Partnership Career Development Fellowship
   [CG_ta_2005_40203_001]
FX Supported by the Medical Research Council (UK) and the European and
   Developing Countries Clinical Trials Partnership Career Development
   Fellowship (grant number CG_ta_2005_40203_001 to I.M.A.).
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Adetifa IMO, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-122
   Adetifa IMO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012502
   Adetifa IMO, 2010, PEDIATR INFECT DIS J, V29, P439, DOI 10.1097/INF.0b013e3181cb45da
   Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66
   American Thoracic Society/CDC, 2000, MMWR RECOMM REP, V49, P1
   Barry CE, 2009, NAT REV MICROBIOL, V7, P845, DOI 10.1038/nrmicro2236
   Chee CBE, 2010, EUR RESPIR J, V36, P355, DOI 10.1183/09031936.00151309
   Chee CBE, 2007, AM J RESP CRIT CARE, V175, P282, DOI 10.1164/rccm.200608-1109OC
   De Gruttola VG, 2001, CONTROL CLIN TRIALS, V22, P485, DOI 10.1016/S0197-2456(01)00153-2
   Ewer K, 2006, AM J RESP CRIT CARE, V174, P831, DOI 10.1164/rccm.200511-1783OC
   Fielding KL, 2011, CONTEMP CLIN TRIALS, V32, P382, DOI 10.1016/j.cct.2010.12.008
   Guerra RL, 2010, RESP MED, V104, P754, DOI 10.1016/j.rmed.2010.02.001
   Hanifa Y, 2007, INT J TUBERC LUNG D, V11, P1232
   Hill PC, 2006, PEDIATRICS, V117, P1542, DOI 10.1542/peds.2005-2095
   Hill PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001379
   Hill PC, 2007, PLOS MED, V4, P1061, DOI 10.1371/journal.pmed.0040192
   Hill PC, 2010, LANCET INFECT DIS, V10, P723, DOI 10.1016/S1473-3099(10)70164-X
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   Kaech SM, 2001, NAT IMMUNOL, V2, P415
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189
   Lee SH, 2010, RESP MED, V104, P448, DOI 10.1016/j.rmed.2009.10.006
   Menzies D, 2007, ANN INTERN MED, V146, P340
   Mori T, 2007, INT J TUBERC LUNG D, V11, P1021
   Newport MJ, 2003, SCAND J IMMUNOL, V58, P383, DOI 10.1046/j.1365-3083.2003.01328.x
   Nicol MP, 2005, CLIN INFECT DIS, V40, P1301, DOI 10.1086/429245
   Patin E, 2006, HUM MUTAT, V27, P720, DOI 10.1002/humu.9438
   Sauzullo I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005187
   Sharma SK, 2012, CHEST, V142, P761, DOI 10.1378/chest.12-0142
   Theron G, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0037436, 10.1371/journal.pone.0037436d]
   van Zyl-Smit RN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008517
   Walzl G, 2011, NAT REV IMMUNOL, V11, P343, DOI 10.1038/nri2960
   World Health Organization, GAMB TUB PROF
   World Health Organization, 2008, JOINT TDR EC EXP CON
   World Health Organization, 2011, WHOHTMTB201118
   WHO, GLOB TUB CONTR
   World Health Organization (WHO), GUID NAT TUB PROGR M
   Wilkinson KA, 2006, J INFECT DIS, V193, P354, DOI 10.1086/499311
NR 40
TC 19
Z9 23
U1 1
U2 15
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 15
PY 2013
VL 187
IS 4
BP 439
EP 445
DI 10.1164/rccm.201208-1352OC
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 091UR
UT WOS:000315075800016
PM 23220919
OA No
DA 2017-08-15
ER

PT J
AU Grossman, SR
   Andersen, KG
   Shlyakhter, I
   Tabrizi, S
   Winnicki, S
   Yen, A
   Park, DJ
   Griesemer, D
   Karlsson, EK
   Wong, SH
   Cabili, M
   Adegbola, RA
   Bamezai, RNK
   Hill, AVS
   Vannberg, FO
   Rinn, JL
   Lander, ES
   Schaffner, SF
   Sabeti, PC
AF Grossman, Sharon R.
   Andersen, Kristian G.
   Shlyakhter, Ilya
   Tabrizi, Shervin
   Winnicki, Sarah
   Yen, Angela
   Park, Daniel J.
   Griesemer, Dustin
   Karlsson, Elinor K.
   Wong, Sunny H.
   Cabili, Moran
   Adegbola, Richard A.
   Bamezai, Rameshwar N. K.
   Hill, Adrian V. S.
   Vannberg, Fredrik O.
   Rinn, John L.
   Lander, Eric S.
   Schaffner, Stephen F.
   Sabeti, Pardis C.
CA 1000 Genomes Project
TI Identifying Recent Adaptations in Large-Scale Genomic Data
SO CELL
LA English
DT Article
ID RECENT POSITIVE SELECTION; HUMAN GENE-EXPRESSION; LARGE NONCODING RNAS;
   CHRONIC HEPATITIS-B; WIDE ASSOCIATION; POSTTRANSLATIONAL MODIFICATION;
   POPULATION GENOMICS; NATURAL-SELECTION; SUSCEPTIBILITY; VARIANTS
AB Although several hundred regions of the human genome harbor signals of positive natural selection, few of the relevant adaptive traits and variants have been elucidated. Using full-genome sequence variation from the 1000 Genomes (1000G) Project and the composite of multiple signals (CMS) test, we investigated 412 candidate signals and leveraged functional annotation, protein structure modeling, epigenetics, and association studies to identify and extensively annotate candidate causal variants. The resulting catalog provides a tractable list for experimental follow-up; it includes 35 high-scoring nonsynonymous variants, 59 variants associated with expression levels of a nearby coding gene or lincRNA, and numerous variants associated with susceptibility to infectious disease and other phenotypes. We experimentally characterized one candidate nonsynonymous variant in Toll-like receptor 5 (TLR5) and show that it leads to altered NF-kappa B signaling in response to bacterial flagellin.
C1 [Grossman, Sharon R.; Andersen, Kristian G.; Shlyakhter, Ilya; Tabrizi, Shervin; Winnicki, Sarah; Yen, Angela; Park, Daniel J.; Karlsson, Elinor K.; Cabili, Moran; Rinn, John L.; Lander, Eric S.; Schaffner, Stephen F.; Sabeti, Pardis C.] Broad Inst & Harvard, Cambridge, MA 02142 USA.
   [Grossman, Sharon R.; Lander, Eric S.] MIT, Dept Biol, Cambridge, MA 02139 USA.
   [Yen, Angela] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
   [Grossman, Sharon R.; Griesemer, Dustin] Harvard Univ, Sch Med, Div Hlth Sci & Technol, Boston, MA 02115 USA.
   [Cabili, Moran; Lander, Eric S.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
   [Andersen, Kristian G.; Shlyakhter, Ilya; Tabrizi, Shervin; Winnicki, Sarah; Park, Daniel J.; Griesemer, Dustin; Karlsson, Elinor K.; Sabeti, Pardis C.] Harvard Univ, Dept Organism & Evolutionary Biol, Ctr Syst Biol, Cambridge, MA 02138 USA.
   [Wong, Sunny H.; Hill, Adrian V. S.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Adegbola, Richard A.] MRC Labs, Fajara, Gambia.
   [Bamezai, Rameshwar N. K.] Jawaharlal Nehru Univ, Sch Life Sci, Natl Ctr Appl Human Genet, New Delhi 110067, India.
   [Vannberg, Fredrik O.] Georgia Inst Technol, Ctr Integrat Genom, Sch Biol, Atlanta, GA 30332 USA.
   [Rinn, John L.] Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Sabeti, Pardis C.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Cambridge, MA 02115 USA.
RP Grossman, SR (reprint author), Broad Inst & Harvard, Cambridge, MA 02142 USA.
EM grossman@broadinstitute.org; psabeti@oeb.harvard.edu
RI Andersen, Kristian/D-5006-2009; Schaffner, Stephen/D-1189-2011; Wong,
   Sunny/N-3754-2015
OI Andersen, Kristian/0000-0001-6431-5982; Wong, Sunny/0000-0002-3354-9310;
   Karlsson, Elinor/0000-0002-4343-3776
FU Burroughs Wellcome Fund Career Award; Packard Foundation Fellowship in
   Science and Engineering; Broad Institute SPARC award; NIH Innovator
   Award [1DP2OD006514-01, BAA-NIAID-DAIT-NIHAI2009061]; NIGMS
   [T32GM007753]; Carlsberg Foundation fellowship; NSF; American Cancer
   Society Fellowship; Wellcome Trust; UK Medical Research Council; UK
   National Institute for Health Research; European Commission
FX P.C.S. and her lab are supported by a Burroughs Wellcome Fund Career
   Award, a Packard Foundation Fellowship in Science and Engineering, a
   Broad Institute SPARC award, an NIH Innovator Award 1DP2OD006514-01, and
   BAA-NIAID-DAIT-NIHAI2009061. S.R.G. is supported by NIGMS T32GM007753,
   K.G.A. by a Carlsberg Foundation fellowship, D.J.P. by NSF, and E.K.K.
   by an American Cancer Society Fellowship. The mycobacterial disease
   studies analyzed were supported by funding from the Wellcome Trust, the
   UK Medical Research Council, the UK National Institute for Health
   Research, and the European Commission; we thank the many collaborators
   who contributed to generating these data sets. We would like to thank S.
   Hart for help with figures, C. Edwards for reviews of the text, and L.
   Ward and C. O'Dushlaine for technical guidance.
CR Abu-Maziad A, 2010, PEDIATR RES, V68, P323, DOI [10.1203/00006450-201011001-00632, 10.1203/PDR.0b013e3181e6a068]
   Akey JM, 2002, GENOME RES, V12, P1805, DOI 10.1101/gr.631202
   Akey JM, 2009, GENOME RES, V19, P711, DOI 10.1101/gr.086652.108
   Barreiro LB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000562
   Bersaglieri T, 2004, AM J HUM GENET, V74, P1111, DOI 10.1086/421051
   Bustamante CD, 2005, NATURE, V437, P1153, DOI 10.1038/nature04240
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405
   Currat M, 2002, AM J HUM GENET, V70, P207, DOI 10.1086/338304
   Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640
   Edelmann MJ, 2010, FEBS J, V277, P2515, DOI 10.1111/j.1742-4658.2010.07665.x
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
   Abecasis GR, 2010, NATURE, V467, P1061, DOI DOI 10.1038/NATURE09534
   Grossman SR, 2010, SCIENCE, V327, P883, DOI 10.1126/science.1183863
   Gusev A, 2012, MOL BIOL EVOL, V29, P473, DOI 10.1093/molbev/msr133
   Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220
   Hernandez RD, 2011, SCIENCE, V331, P920, DOI 10.1126/science.1198878
   Jallow M, 2009, NAT GENET, V41, P657, DOI 10.1038/ng.388
   Kamatani Y, 2009, NAT GENET, V41, P591, DOI 10.1038/ng.348
   Kamberov YG, 2013, CELL, V152, P691, DOI 10.1016/j.cell.2013.01.016
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Koedel U, 2000, J INFECT DIS, V182, P1437, DOI 10.1086/315877
   Kunz S, 2005, J VIROL, V79, P14282, DOI 10.1128/JVI.79.22.14282-14296.2005
   Lamason RL, 2005, SCIENCE, V310, P1782, DOI 10.1126/science.1116238
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lindblad-Toh K, 2011, NATURE, V478, P476, DOI 10.1038/nature10530
   Liu W, 2004, INT J TUBERC LUNG D, V8, P428
   Loizou L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018670
   Mbarek H, 2011, HUM MOL GENET, V20, P3884, DOI 10.1093/hmg/ddr301
   Montgomery SB, 2010, NATURE, V464, P773, DOI 10.1038/nature08903
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Ohashi J, 2004, AM J HUM GENET, V74, P1198, DOI 10.1086/421330
   Okugawa S, 2006, CELL MICROBIOL, V8, P1571, DOI 10.1111/j.1462-5822.2006.00731.x
   Pickrell JK, 2010, NATURE, V464, P768, DOI 10.1038/nature08872
   Pickrell JK, 2009, GENOME RES, V19, P826, DOI 10.1101/gr.087577.108
   Png E, 2011, HUM MOL GENET, V20, P3893, DOI 10.1093/hmg/ddr302
   Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309
   Sabeti PC, 2007, NATURE, V449, P913, DOI 10.1038/nature06250
   Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142
   Thye T, 2010, NAT GENET, V42, P739, DOI 10.1038/ng.639
   Uematsu S, 2006, NAT IMMUNOL, V7, P868, DOI 10.1038/ni1362
   Vernot B, 2012, GENOME RES, V22, P1689, DOI 10.1101/gr.134890.111
   Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072
   WANG YX, 1995, HUM MOL GENET, V4, P657, DOI 10.1093/hmg/4.4.657
   Williamson SH, 2007, PLOS GENET, V3, P901, DOI 10.1371/journal.pgen.0030090
   Wong SH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000979
   Yi X, 2010, SCIENCE, V329, P75, DOI 10.1126/science.1190371
   Zhang FR, 2009, NEW ENGL J MED, V361, P2609, DOI 10.1056/NEJMoa0903753
NR 54
TC 138
Z9 140
U1 6
U2 138
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD FEB 14
PY 2013
VL 152
IS 4
BP 703
EP 713
DI 10.1016/j.cell.2013.01.035
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 089YJ
UT WOS:000314945600007
PM 23415221
OA No
DA 2017-08-15
ER

PT J
AU Lindsay, TC
   Jawara, M
   D'Alessandro, U
   Pinder, M
   Lindsay, SW
AF Lindsay, T. C.
   Jawara, M.
   D'Alessandro, U.
   Pinder, M.
   Lindsay, S. W.
TI Preliminary studies developing methods for the control of Chrysomya
   putoria, the African latrine fly, in pit latrines in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Chrysomya putoria; African latrine fly; sanitation; fly control; pit
   latrines; diarrhoeal diseases
ID POLYSTYRENE BEADS; LARVAL HABITATS; MALARIA VECTORS; PYRIPROXYFEN;
   DIPTERA; MUSCIDAE
AB Objective To explore ways of controlling Chrysomya putoria, the African latrine fly, in pit latrines. As pit latrines are a major source of these flies, eliminating these important breeding sites is likely to reduce village fly populations, and may reduce the spread of diarrhoeal pathogens. Methods We treated 24 latrines in a Gambian village: six each with (i) pyriproxyfen, an insect juvenile hormone mimic formulated as Sumilarv (R) 0.5G, a 0.5% pyriproxyfen granule, (ii) expanded polystyrene beads (EPB), (iii) local soap or (iv) no treatment as controls. Flies were collected using exit traps placed over the drop holes, weekly for five weeks. In a separate study, we tested whether latrines also function as efficient flytraps using the faecal odours as attractants. We constructed six pit latrines each with a built-in flytrap and tested their catching efficiency compared to six fish-baited box traps positioned 10 m from the latrine. Focus group discussions conducted afterwards assessed the acceptability of the flytrap latrines. Results Numbers of emerging C. putoria were reduced by 96.0% (95% CIs: 94.597.2%) 45 weeks after treatment with pyriproxyfen; by 64.2% (95% CIs: 51.873.5%) after treatment with local soap; by 41.3% (95% CIs = 24.054.7%) after treatment with EPB 35 weeks after treatment. Flytraps placed on latrines collected C. putoria and were deemed acceptable to local communities. Conclusions Sumilarv 0.5G shows promise as a chemical control agent, whilst odour-baited latrine traps may prove a useful method of non-chemical fly control. Both methods warrant further development to reduce fly production from pit latrines. A combination of interventions may prove effective for the control of latrine flies and the diseases they transmit.
C1 [Lindsay, T. C.; Pinder, M.; Lindsay, S. W.] London Sch Hyg & Trop Med, London WC1, England.
   [Jawara, M.; D'Alessandro, U.; Pinder, M.] MRC Unit, Fajara, Gambia.
   [D'Alessandro, U.] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Lindsay, S. W.] Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3HP, England.
RP Lindsay, SW (reprint author), Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3HP, England.
EM S.W.Lindsay@durham.ac.uk
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Bill and Melinda Gates Foundation; Research and Policy for Infectious
   Disease Dynamics (RAPIDD) Program of the Science and Technology
   Directory; Department of Homeland Security; Fogarty International
   Center, National Institutes of Health
FX We are grateful to those in the study villages who participated in this
   study. We also acknowledge the assistance of Omar Jallow and Alhaji
   Sidibeh with the fieldwork and Abdoulie Jallow in the laboratory. We
   thank Sumitomo Chemical for donating the pyriproxyfen. The work was
   supported by the Bill and Melinda Gates Foundation. SWL is supported by
   the Research and Policy for Infectious Disease Dynamics (RAPIDD) Program
   of the Science and Technology Directory, Department of Homeland
   Security, and Fogarty International Center, National Institutes of
   Health.
CR BULL DL, 1994, J ECON ENTOMOL, V87, P1407
   Curtis C, 2005, TRENDS PARASITOL, V21, P504, DOI 10.1016/j.pt.2005.08.025
   CURTIS C F, 1985, Parasitology Today, V1, P36, DOI 10.1016/0169-4758(85)90106-1
   Curtis CF, 1984, T ROY SOC TROP MED H, V76, P99
   Dawson S., 1993, MANUAL USE FOCUS GRO
   Devine GJ, 2009, P NATL ACAD SCI USA, V106, P11530, DOI 10.1073/pnas.0901369106
   Dumpert J, 2009, WATERLINES, V28, P250
   Emerson PM, 2005, TROP MED INT HEALTH, V10, P706, DOI 10.1111/j.1365-3156.2005.01432.x
   Geden CJ, 2012, J MED ENTOMOL, V49, P606, DOI 10.1603/ME11226
   Hatakoshi M., 1987, Japanese Journal of Sanitary Zoology, V38, P271
   Invest J. F., 2008, P 6 INT C URB PESTS
   Kawada H, 1987, JAPANESE J SANITARY, V38, P317
   LAURENCE BR, 1988, MED VET ENTOMOL, V2, P285, DOI 10.1111/j.1365-2915.1988.tb00197.x
   Lindsay SW, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001895
   Lindsay TC, PLOS ONE IN PRESS
   Londershausen M, 1996, ARCH INSECT BIOCHEM, V32, P651, DOI 10.1002/(SICI)1520-6327(1996)32:3/4<651::AID-ARCH36>3.0.CO;2-9
   Morgan P R, 1977, Cent Afr J Med, V23, P1
   Reiter P., 1985, J AM MOSQUITO CONTR, V4, P519
   Rozendaal JA, 1997, VECTOR CONTROL METHO
   Service M.W., 1976, MOSQUITO ECOLOGY FIE
   Sihuincha M, 2005, J MED ENTOMOL, V42, P620, DOI 10.1603/0022-2585(2005)042[0620:PUOPFC]2.0.CO;2
   Simms VM, 2005, T ROY SOC TROP MED H, V99, P631, DOI 10.1016/j.trstmh.2004.10.004
   THOMSON RCM, 1948, B ENTOMOL RES, V38, P527
   UNICEF WHO, 2012, PROGR DRINK WAT SAN, P66
   WHO, 2006, PEST THEIR APPL CONT
   Yapabandara AMGM, 2002, ACTA TROP, V81, P211, DOI 10.1016/S0001-706X(01)00208-X
NR 26
TC 3
Z9 3
U1 3
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD FEB
PY 2013
VL 18
IS 2
BP 159
EP 165
DI 10.1111/tmi.12033
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 075NR
UT WOS:000313894300005
PM 23198767
OA No
DA 2017-08-15
ER

PT J
AU Ward, K
   Cole, TJ
   Sawo, Y
   Laskey, A
   Prentice, A
AF Ward, Kate
   Cole, Tim J.
   Sawo, Yankuba
   Laskey, Ann
   Prentice, Ann
TI Prepubertal calcium supplementation alters the timing of adolescent
   skeletal growth and mineral accretion in boys
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-for-Bone-and-Mineral-Research
CY OCT 04-07, 2013
CL Baltimore, MD
SP Amer Soc Bone & Mineral Res
C1 [Ward, Kate; Laskey, Ann; Prentice, Ann] MRC Human Nutr Res, Cambridge, England.
   [Cole, Tim J.] MRC Ctr Epidemol Child Hlth, London, England.
   [Sawo, Yankuba] MRC Keneba, Banjul, Gambia.
RI Cole, Tim/B-7883-2008
OI Cole, Tim/0000-0001-5711-8200
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2013
VL 28
SU 1
MA LB-SU02
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AB8JI
UT WOS:000332035801007
OA No
DA 2017-08-15
ER

PT J
AU Shimakawa, Y
   Bah, E
   Wild, CP
   Hall, AJ
AF Shimakawa, Yusuke
   Bah, Ebrima
   Wild, Christopher P.
   Hall, Andrew J.
TI Evaluation of data quality at the Gambia national cancer registry
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE cancer registry; quality control; validity; completeness; Africa
ID CAPTURE-RECAPTURE METHODS; COMPLETENESS
AB The Gambia National Cancer Registry (GNCR) is one of the few nationwide population-based cancer registries in sub-Saharan Africa. Most registries in sub-Saharan Africa are limited to cities; therefore, the GNCR is important in providing estimates of cancer incidence in rural Africa. Our study assesses the quality of its data. The methods proposed by Bray and Parkin, and Parkin and Bray (Eur J Cancer 2009;45:74764) were applied to the registry data from 1990 to 2009 to assess comparability, validity and completeness. The system used for classification and coding of neoplasms followed international standards. The percentage of cases morphologically verified was 18.1% for men and 33.1% for women, and that of death certificate only cases was 6.6 and 3.6%, respectively. Incidence rates in rural regions were lower than in the urban part of the country, except amongst young male adults. Comparison with other West African registries showed that the incidences of liver and uterine cervical cancer were comparable, but those of prostate and breast in The Gambia were relatively low. The overall completeness was estimated at 50.3% using the capturerecapture method. The GNCR applies international standard practices to data collection and handling, providing valuable data on cancer incidence in sub-Saharan Africa. However, the data are incomplete in the rural and elderly populations probably because of health care access and use.
C1 [Shimakawa, Yusuke; Hall, Andrew J.] Univ London London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HU, England.
   [Bah, Ebrima] MRC Labs, Gambia Hepatitis Intervent Study, IARC, Banjul, Gambia.
   [Wild, Christopher P.] Int Agcy Res Canc, F-69372 Lyon 08, France.
RP Shimakawa, Y (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HU, England.
EM yusuke.shimakawa@lshtm.ac.uk
FU Gambian Government; Medical Research Council (MRC); IARC
FX The authors are grateful to colleagues at the Gambia National Cancer
   Registry (GNCR) for help with this study: Yusupha Bah, Lamin Giana,
   Ebrima Bojang, Mariato Rahman and Yusupha Colley. They also thank
   Elizabeth Turner for technical advice on the capture-recapture methods,
   and Louise Pealing and Freddie Bray for improving the manuscript. They
   acknowledge the Gambian Government, Medical Research Council (MRC) and
   IARC for funding the GNCR.
CR Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347
   Bray F, 2009, EUR J CANCER, V45, P747, DOI 10.1016/j.ejca.2008.11.032
   BRENNER H, 1995, J EPIDEMIOL COMMUN H, V49, P426, DOI 10.1136/jech.49.4.426
   Coleman MP, 1991, IARC SCI PUBL, V95, P267
   Crocetti E, 2001, EUR J CANCER PREV, V10, P417, DOI 10.1097/00008469-200110000-00005
   Curado MP, 2007, IARC SCI PUBLICATION, V160
   Doll R, 1966, CANC INCIDENCE 5 CON, V1
   Ferlay J, 2005, 42 IARCIACR
   Fritz A., 2000, INT CLASSIFICATION D
   Gambia Hepatitis Study Group, 1987, CANCER RES, V47, P5782
   Hook EB, 1995, EPIDEMIOL REV, V17, P243
   International Association of Cancer Registries. International rules for multiple primary cancers, 2005, ASIAN PAC J CANCER P, V6, P104
   Jensen OM, 1991, IARC SCI PUBLICATION, V95
   Maree JE, 2010, EUR J ONCOL NURS, V14, P190, DOI 10.1016/j.ejon.2009.10.009
   Parkin DM, 2009, EUR J CANCER, V45, P756, DOI 10.1016/j.ejca.2008.11.033
   Parkin DM, 2001, CANCER CAUSE CONTROL, V12, P147, DOI 10.1023/A:1008966225984
   Parkin DM, 2003, IARC SCI PUBLICATION, V153
   Parkin DM, 2002, IARC SCI PUBLICATION, VVIII
   Sighoko D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018415
   Sighoko D, 2010, INT J CANCER, V127, P2248, DOI 10.1002/ijc.25244
   Sitas F, 2006, DISEASE AND MORTALITY IN SUB-SAHARAN AFRICA, 2ND EDITION, P289
   Swaminathan R, 2010, CANCER EPIDEMIOL, V34, P107, DOI 10.1016/j.canep.2009.11.006
   Tilling K, 2001, INT J EPIDEMIOL, V30, P12, DOI 10.1093/ije/30.1.12
NR 24
TC 16
Z9 16
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD FEB 1
PY 2013
VL 132
IS 3
BP 658
EP 665
DI 10.1002/ijc.27646
PG 8
WC Oncology
SC Oncology
GA 044LG
UT WOS:000311620100023
PM 22618962
OA No
DA 2017-08-15
ER

PT J
AU McDermid, JM
   Hennig, BJ
   van der Sande, M
   Hill, AVS
   Whittle, HC
   Jaye, A
   Prentice, AM
AF McDermid, Joann M.
   Hennig, Branwen J.
   van der Sande, Marianne
   Hill, Adrian V. S.
   Whittle, Hilton C.
   Jaye, Assan
   Prentice, Andrew M.
TI Host iron redistribution as a risk factor for incident tuberculosis in
   HIV infection: an 11-year retrospective cohort study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; HAPTOGLOBIN;
   SUSCEPTIBILITY; MORTALITY; SLC11A1; ANEMIA; POLYMORPHISMS; ACQUISITION;
   POPULATION
AB Background: Identifying people at higher risk of developing tuberculosis with human immunodeficiency virus (HIV) infection may improve clinical management of co-infections. Iron influences tuberculosis (TB) pathogenesis, but understanding the exact mechanisms of how and timing of when iron is involved remains challenging since biological samples are rarely available from the disease susceptibility period due to the difficulty in predicting in who and when, if ever, TB will develop. The objective of this research was to determine how host iron status measured at HIV diagnosis and genotypes related to host iron metabolism were associated with incident TB.
   Methods: Archived clinical data, plasma and DNA were analyzed from 1139 adult participants in a large HIV-1, HIV-2 and dual seroprevalent cohort based at the Medical Research Council Laboratories in The Gambia. Incident pulmonary and/or extrapulmonary TB diagnoses a minimum of 28 days after HIV diagnosis were independently re-confirmed using available evidence (n=152). Multiple host iron status biomarkers, Haptoglobin and solute carrier family 11, member 1 (SLC11A1) genotypes were modeled to characterize how indicators of host iron metabolism were associated with TB susceptibility.
   Results: Hemoglobin (incidence rate ratio, IRR=0.88, 95% CI=0.79-0.98), plasma transferrin (IRR=0.53, 0.33-0.84) and ferritin (IRR=1.26, 1.05-1.51) were significantly associated with TB after adjusting for TB susceptibility factors. While genotype associations were not statistically significant, SLC11A1 associations replicated similar directions as reported in HIV-seronegative meta-analyses.
   Conclusions: Evidence of host iron red istribution at HIV diagnosis was associated with incident TB, and genetic influences on iron homeostasis may be involved. Low hemoglobin was associated with subsequent diagnosis of TB, but when considered in combination with additional iron status biomarkers, the collective findings point to a mechanism whereby anemia and iron redistribution are likely due to viral and/or bacteria-driven processes and the host immune response to infection. As a result, iron supplementation may not be efficacious or safe under these circumstances. Clinical and nutritional management of HIV and Mycobacterium tuberculosis co-infected individuals, especially in regions where food insecurity and malnutrition co-exist, may be further improved when the iron-related TB risk factors identified here are better understood and managed to favor host rather than pathogen outcomes.
C1 [McDermid, Joann M.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.
   [Hennig, Branwen J.; Prentice, Andrew M.] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Hennig, Branwen J.; Prentice, Andrew M.] MRC, Keneba, Gambia.
   [van der Sande, Marianne] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Epidemiol & Surveillance Unit, NL-3720 BA Bilthoven, Netherlands.
   [van der Sande, Marianne] Univ Med Ctr Utrecht, Julius Ctr, Utrecht, Netherlands.
   [Hill, Adrian V. S.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Whittle, Hilton C.; Jaye, Assan] MRC Labs, Fajara, Gambia.
RP McDermid, JM (reprint author), Cornell Univ, Div Nutr Sci, 310 Savage Hall, Ithaca, NY 14853 USA.
EM jmm585@cornell.edu
RI Hennig, Branwen/M-6444-2014
FU Bristol Myers Squibb Mead Johnson Unrestricted Grant Programme; Canadian
   Institutes of Health Research; Medical Research Council (United
   Kingdom); Wellcome Trust; Medical Research Council
FX The project was funded in part by the Bristol Myers Squibb Mead Johnson
   Unrestricted Grant Programme (AMP), the Canadian Institutes of Health
   Research (JMM), the Medical Research Council (United Kingdom) (AMP, BHJ,
   AJ, HCW) and the Wellcome Trust (AVSH). The funding bodies were not
   involved in the design, data collection, analysis, interpretation,
   manuscript writing or decision to submit the manuscript for
   publication.; The authors declare they have no conflicts of interest.
   The project was funded in part by the Bristol Myers Squibb Mead Johnson
   Unrestricted Grant Programme, the Canadian Institutes of Health
   Research, the Medical Research Council and the Wellcome Trust.
CR Banerjee S, 2011, INFECT GENET EVOL, V11, P825, DOI 10.1016/j.meegid.2011.02.016
   Cronje L, 2005, FEMS IMMUNOL MED MIC, V45, P103, DOI 10.1016/j.femsim.2005.02.007
   de Wit E, 2011, MAMM GENOME, V22, P100, DOI 10.1007/s00335-010-9280-8
   Fitness J, 2004, AM J TROP MED HYG, V71, P341
   Fritsche G, 2008, IMMUNOBIOLOGY, V212, P751, DOI 10.1016/j.imbio.2007.09.014
   Galesloot TE, 2011, BLOOD, V117, pE218, DOI 10.1182/blood-2011-02-337907
   Getahun Haileyesus, 2012, Morbidity and Mortality Weekly Report, V61, P484
   Gkouvatsos K., 2011, BIOCHIM BIOPHYS ACTA, V1820, P188
   Hoal EG, 2004, INT J TUBERC LUNG D, V8, P1464
   Johnson EE, 2012, MICROBES INFECT, V14, P207, DOI 10.1016/j.micinf.2011.10.001
   Johnson EE, 2010, FEMS IMMUNOL MED MIC, V58, P138, DOI 10.1111/j.1574-695X.2009.00622.x
   Jones CM, 2011, J BACTERIOL, V193, P1767, DOI 10.1128/JB.01312-10
   Karyadi E, 2007, ASIA PAC J CLIN NUTR, V16, P218
   Kasvosve I, 2000, INT J TUBERC LUNG D, V4, P771
   Lee SW, 2006, J KOREAN MED SCI, V21, P1028
   Li XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015831
   Lounis N, 2003, INT J TUBERC LUNG D, V7, P575
   LOUNIS N, 1999, CLIN MICROBIOL INFEC, V5, P687, DOI DOI 10.1111/J.1469-0691.1999.TB00514.X
   McDermid JM, 2006, CLIN SCI, V110, P503, DOI 10.1042/CS20050273
   McDermid JM, 2009, AM J CLIN NUTR, V90, P225, DOI 10.3945/ajcn.2009.27709
   Mugusi FM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-409
   RAGHU B, 1993, BIOCHEM MOL BIOL INT, V31, P341
   Ramey G, 2010, HAEMATOL-HEMATOL J, V95, P501, DOI 10.3324/haematol.2009.014399
   Saathoff E, 2011, INT J TUBERC LUNG D, V15, P925, DOI 10.5588/ijtld.10.0477
   Sahiratmadja E, 2007, BRIT J NUTR, V98, P684, DOI 10.1017/S0007114507742691
   Schaible UE, 2002, J EXP MED, V196, P1507, DOI 10.1084/jem.20020897
   Spagnuolo MS, 2011, BIOL CHEM, V392, P371, DOI 10.1515/BC.2011.033
   Tullius MV, 2011, P NATL ACAD SCI USA, V108, P5051, DOI 10.1073/pnas.1009516108
   van der Sande MAB, 2004, AIDS, V18, P1933, DOI 10.1097/00002030-200409240-00009
   Velez DR, 2009, INT J TUBERC LUNG D, V13, P1068
   Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825
   Weiss G, 2009, BBA-GEN SUBJECTS, V1790, P682, DOI 10.1016/j.bbagen.2008.08.006
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Yano A, 1998, ACTA MED OKAYAMA, V52, P173
NR 34
TC 21
Z9 22
U1 1
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JAN 29
PY 2013
VL 13
AR 48
DI 10.1186/1471-2334-13-48
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 086UZ
UT WOS:000314714800002
PM 23360117
OA gold
DA 2017-08-15
ER

PT J
AU Affara, M
   Sanders, D
   Araki, H
   Tamada, Y
   Dunmore, BJ
   Humphreys, S
   Imoto, S
   Savoie, C
   Miyano, S
   Kuhara, S
   Jeffries, D
   Print, C
   Charnock-Jones, DS
AF Affara, Muna
   Sanders, Debbie
   Araki, Hiromitsu
   Tamada, Yoshinori
   Dunmore, Benjamin J.
   Humphreys, Sally
   Imoto, Seiya
   Savoie, Christopher
   Miyano, Satoru
   Kuhara, Satoru
   Jeffries, David
   Print, Cristin
   Charnock-Jones, D. Stephen
TI Vasohibin-1 is identified as a master-regulator of endothelial cell
   apoptosis using gene network analysis
SO BMC GENOMICS
LA English
DT Article
DE Vasohibin; HUVEC; Bayesian; Gene regulatory network
ID SYSTEMS BIOLOGY; HUMAN GENOME; ANGIOGENESIS; EXPRESSION; DISEASE;
   TRANSCRIPTOME; MICROARRAY; INHIBITOR; CANCER; PROLIFERATION
AB Background: Apoptosis is a critical process in endothelial cell (EC) biology and pathology, which has been extensively studied at protein level. Numerous gene expression studies of EC apoptosis have also been performed, however few attempts have been made to use gene expression data to identify the molecular relationships and master regulators that underlie EC apoptosis. Therefore, we sought to understand these relationships by generating a Bayesian gene regulatory network (GRN) model.
   Results: ECs were induced to undergo apoptosis using serum withdrawal and followed over a time course in triplicate, using microarrays. When generating the GRN, this EC time course data was supplemented by a library of microarray data from EC treated with siRNAs targeting over 350 signalling molecules.
   The GRN model proposed Vasohibin-1 (VASH1) as one of the candidate master-regulators of EC apoptosis with numerous downstream mRNAs. To evaluate the role played by VASH1 in EC, we used siRNA to reduce the expression of VASH1. Of 10 mRNAs downstream of VASH1 in the GRN that were examined, 7 were significantly up- or down-regulated in the direction predicted by the GRN. Further supporting an important biological role of VASH1 in EC, targeted reduction of VASH1 mRNA abundance conferred resistance to serum withdrawal-induced EC death.
   Conclusion: We have utilised Bayesian GRN modelling to identify a novel candidate master regulator of EC apoptosis. This study demonstrates how GRN technology can complement traditional methods to hypothesise the regulatory relationships that underlie important biological processes.
C1 [Affara, Muna; Sanders, Debbie; Dunmore, Benjamin J.; Humphreys, Sally; Charnock-Jones, D. Stephen] Univ Cambridge, Rosie Hosp, Dept Obstet & Gynaecol, Cambridge CB2 0SW, England.
   [Araki, Hiromitsu; Savoie, Christopher] GNI Ltd, Syst Pharmacol Res Inst, Fukuoka, Japan.
   [Tamada, Yoshinori; Imoto, Seiya; Miyano, Satoru] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan.
   [Kuhara, Satoru] Kyushu Univ, Grad Sch Genet Resources Technol, Fukuoka 812, Japan.
   [Jeffries, David] MRC, Gambia Unit, Fajara, Gambia.
   [Print, Cristin] Univ Auckland, Sch Med Sci, Dept Mol Med & Pathol, Auckland 1, New Zealand.
   [Print, Cristin] Univ Auckland, Bioinformat Inst, Auckland 1, New Zealand.
   [Charnock-Jones, D. Stephen] Cambridge Comprehens Biomed Ctr, Natl Inst Hlth Res, Cambridge, England.
RP Charnock-Jones, DS (reprint author), Univ Cambridge, Rosie Hosp, Dept Obstet & Gynaecol, Robinson Way, Cambridge CB2 0SW, England.
EM c.print@auckland.ac.nz; dscj1@cam.ac.uk
RI Charnock-Jones, D. Stephen/B-3743-2009
OI Charnock-Jones, D. Stephen/0000-0002-2936-4890; Tamada,
   Yoshinori/0000-0003-3483-9712; Print, Cristin/0000-0001-8345-7812
FU company GNI Ltd.; Biotechnology and Biological Sciences Research Council
   (BBSRC); Health Research Council of New Zealand's International
   Investment Opportunities Fund
FX A subset of the laboratory work described in this manuscript was funded
   by the company GNI Ltd. The Biotechnology and Biological Sciences
   Research Council (BBSRC) also supported aspects of this research. Part
   of CP's contribution was funded by the Health Research Council of New
   Zealand's International Investment Opportunities Fund. The
   supercomputing resource for the estimation of GRN was provided by Human
   Genome Center, Institute of Medical Science, University of Tokyo
   (http://sc.hgc.jp/shirokane.html).
CR Aderem A, 2005, CELL, V121, P511, DOI 10.1016/j.cell.2005.04.020
   Affara M, 2007, PHILOS T R SOC B, V362, P1469, DOI 10.1098/rstb.2007.2129
   Akutsu T, 1998, GENOME INFORMATICS, V9, P151
   Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455
   Araki H, 2012, FEBS OPEN BIO, V2, P76, DOI 10.1016/j.fob.2012.04.003
   Babu MM, 2004, CURR OPIN STRUC BIOL, V14, P283, DOI 10.1016/j.sbi.2004.05.004
   Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532
   Brazhnik P, 2002, TRENDS BIOTECHNOL, V20, P467, DOI 10.1016/S0167-7799(02)02053-X
   Butte A J, 2000, Pac Symp Biocomput, P418
   Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757
   CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407
   Cloonan N, 2008, NAT METHODS, V5, P613, DOI 10.1038/nmeth.1223
   Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001
   Duval Helene, 2003, Angiogenesis, V6, P171, DOI 10.1023/B:AGEN.0000021390.09275.bc
   Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758
   Fabregat I, 2009, WORLD J GASTROENTERO, V15, P513, DOI 10.3748/wjg.15.513
   Friedman N, 2000, J COMPUT BIOL, V7, P601, DOI 10.1089/106652700750050961
   Guo RB, 2007, NUCLEIC ACIDS RES, V35, P6297, DOI 10.1093/nar/gkm536
   Hacker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193
   Hartemink A J, 2001, Pac Symp Biocomput, P422
   Hosaka T, 2009, AM J PATHOL, V175, P430, DOI 10.2353/ajpath.2009.080788
   Hurley D, 2011, NUCLEIC ACIDS RES, V40, P2377
   Hurley D, 2012, NUCLEIC ACIDS RES, V40, P2377, DOI 10.1093/nar/gkr902
   Imoto S, 2006, PAC S BIOC, V11, P559
   Imoto Seiya, 2004, J Bioinform Comput Biol, V2, P77, DOI 10.1142/S021972000400048X
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   Johnson NA, 2004, FASEB J, V18, P188, DOI 10.1096/fj.03-0097fje
   Kerbel RS, 2004, J CLIN INVEST, V114, P884, DOI 10.1172/JC1200423153
   Kermani P, 2005, J CLIN INVEST, V115, P653, DOI 10.1172/JCI200522655
   Kermani P, 2007, TRENDS CARDIOVAS MED, V17, P140, DOI 10.1016/j.tcm.2007.03.002
   Kern J, 2008, ARTERIOSCL THROM VAS, V28, P478, DOI 10.1161/ATVBAHA.107.160432
   Kern J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-284
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kimura H, 2009, BLOOD, V113, P4810, DOI 10.1182/blood-2008-07-170316
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lan YS, 2008, INT J CANCER, V123, P543, DOI 10.1002/ijc.23548
   Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016
   Lunt SJ:ChaudaryN, 2008, CLIN EXP METASTASIS
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Palmero EI, 2011, GENET MOL BIOL, V34, P363, DOI 10.1590/S1415-47572011000300001
   Pearse RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood-2004-08-3096
   Pezzino S, 2011, CURR PHARM DESIGN, V17, P190
   Reed JC, 1999, J CLIN ONCOL, V17, P2941
   Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3
   Sato Y, 2011, J BIOCHEM, V149, P229, DOI 10.1093/jb/mvq152
   Savoie CJ, 2003, DNA RES, V10, P19, DOI 10.1093/dnares/10.1.19
   SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467
   Schoenfeld Jonathan, 2004, Angiogenesis, V7, P143, DOI 10.1007/s10456-004-1677-0
   Shimizu K, 2005, BIOCHEM BIOPH RES CO, V327, P700, DOI 10.1016/j.bbrc.2004.12.073
   Slavov N, 2009, P NATL ACAD SCI USA, V106, P4079, DOI 10.1073/pnas.0810803106
   Stefanec T, 2000, CHEST, V117, P841, DOI 10.1378/chest.117.3.841
   Tai YC, 2006, ANN STAT, V34, P2387, DOI 10.1214/009053606000000759
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Wang L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034247
   WANG XZ, 2009, STUD FUZZINESS SOFT, V245, P1
   Wang Y, 2009, BIOCHEM BIOPH RES CO, V384, P341, DOI 10.1016/j.bbrc.2009.04.119
   Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152
   Xia L, 2011, HUM CELL, V24, P127, DOI 10.1007/s13577-011-0031-2
   Zhang WG, 2004, AM J PHYSIOL-HEART C, V286, pH354, DOI 10.1152/ajpheart.00579.2003
NR 59
TC 2
Z9 6
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD JAN 16
PY 2013
VL 14
AR 23
DI 10.1186/1471-2164-14-23
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 088CU
UT WOS:000314812200001
PM 23324451
OA gold
DA 2017-08-15
ER

PT J
AU Donkor, ES
   Adegbola, RA
   Wren, BW
   Antonio, M
AF Donkor, Eric S.
   Adegbola, Richard A.
   Wren, Brendan W.
   Antonio, Martin
TI Population Biology of Streptococcus pneumoniae in West Africa:
   Multilocus Sequence Typing of Serotypes That Exhibit Different
   Predisposition to Invasive Disease and Carriage
SO PLOS ONE
LA English
DT Article
ID DAY-CARE-CENTERS; PNEUMOCOCCAL DISEASE; RESISTANCE PATTERNS; GENETIC
   RELATEDNESS; CONJUGATE VACCINE; CHILDREN; ERA; MENINGITIS; CLONES;
   IDENTIFICATION
AB Background: Little is known about the population biology of Streptococcus pneumoniae in developing countries, although the majority of pneumococcal infections occur in this setting. The aim of the study was to apply MLST to investigate the population biology of S. pneumoniae in West Africa.
   Methods: Seventy three invasive and carriage S. pneumoniae isolates from three West African countries including The Gambia, Nigeria and Ghana were investigated. The isolates covered seven serotypes (1, 3, 5, 6A, 11, 14, 23F) and were subjected to multilocus sequence typing and antibiotic susceptibility testing.
   Results: Overall, 50 different sequence types (STs) were identified, of which 38% (29) were novel. The most common ST was a novel clone-ST 4012 (6.5%), and some clones including STs 913, 925, 1737, 2160 and 3310 appeared to be specific to the study region. Two STs including ST 63 and ST 4012 were associated with multiple serotypes indicating a history of serotype switching. ST 63 was associated with serotypes 3 and 23F, while ST 4012 was associated with serotypes 6A and 23. eBURST analyses using the stringent 6/7 identical loci definition grouped the 50 STs into 5 clonal complexes and 65 singletons, expressing a high level of genetic diversity among the isolates. Compared to the other serotypes, serotypes 1 and 5 isolates appeared to be more clonal. Internationally recognized antibiotic resistant clones of S. pneumoniae were generally absent in the population investigated and the only multidrug resistant isolate identified (1/66) belong to the Pneumocococcal Epidemiology Network clone ST 63.
   Conclusions: The pneumococcal population in West Africa is quite divergent, and serotypes that are common in invasive disease (such as serotypes 1 and 5) are more likely to be clonal than serotypes that are common in carriage.
C1 [Donkor, Eric S.; Wren, Brendan W.] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London WC1, England.
   [Antonio, Martin] MRC, Fajara, Gambia.
   [Adegbola, Richard A.] GlaxoSmithKline Vaccines, Wavre, Belgium.
   [Donkor, Eric S.] Univ Ghana, Sch Med, Dept Microbiol, Accra, Ghana.
RP Antonio, M (reprint author), MRC, Fajara, Gambia.
EM mantonio@mrc.gm
FU Medical Research Council
FX This study was supported by the Medical Research Council. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Adetifa IMO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030548
   Antonio M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-81
   Antonio M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-198
   Blossom DB, 2007, MICROB DRUG RESIST, V13, P21, DOI 10.1089/mdr.2006.9993
   BOWERS EF, 1955, J CLIN PATHOL, V8, P58, DOI 10.1136/jcp.8.1.58
   Brueggemann AB, 2003, J CLIN MICROBIOL, V41, P4966, DOI 10.1128/JCM.41.11.4966-4970.2003
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   CADOZ M, 1981, B WORLD HEALTH ORGAN, V59, P575
   Croucher NJ, 2011, SCIENCE, V331, P430, DOI 10.1126/science.1198545
   Donkor ES, 2011, MBIO, V2, DOI 10.1128/mBio.00040-11
   Donkor ES, 2001, SCAND J INFECT DIS, V42, P254
   Enright MC, 1998, MICROBIOL-UK, V144, P3049
   Falade AG, 2009, CLIN INFECT DIS, V48, P190
   Feil EJ, 2000, GENETICS, V154, P1439
   Fraser D, 2001, CLIN INFECT DIS, V33, P421, DOI 10.1086/321874
   Hall LMC, 1996, J CLIN MICROBIOL, V34, P853
   Hausdorff WP, 2007, VACCINE, V25, P2406, DOI 10.1016/j.vaccine.2006.09.009
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P122, DOI 10.1086/313609
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Holliman RE, 2007, T ROY SOC TROP MED H, V101, P405, DOI 10.1016/j.trstmh.2006.08.014
   Johnson HL, 2010, PLOS MED, V10, P7, DOI DOI 10.1371/JOURNAL.PMED.1000348
   Leimkugel J, 2005, J INFECT DIS, V192, P192, DOI 10.1086/431151
   Louie M, 1999, J INFECT DIS, V179, P892, DOI 10.1086/314664
   Maiden M. C., 1988, P NATL ACAD SCI USA, V95, P3140
   Marsh R, 2010, J CLIN MICROBIOL, V48, P831, DOI 10.1128/JCM.01701-09
   Marsh RL, 2007, VACCINE, V25, P2434, DOI 10.1016/j.vaccine.2006.09.016
   Martin DR, 1996, NEW ZEAL MED J, V109, P288
   MUFSON MA, 1974, ARCH INTERN MED, V134, P505, DOI 10.1001/archinte.134.3.505
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Obaro S, 2001, LANCET, V357, P1800, DOI 10.1016/S0140-6736(00)04915-1
   Overweg K, 2000, J CLIN MICROBIOL, V38, P4548
   Porat N, 2001, J CLIN MICROBIOL, V39, P1827, DOI 10.1128/JCM.39.5.1827-1832.2001
   Rivera-Olivero IA, 2009, CLIN INFECT DIS, V45, P1427
   Sa-Leao R, 2000, J INFECT DIS, V182, P1153, DOI 10.1086/315813
   Slotved HC, 2004, J CLIN MICROBIOL, V42, P2518, DOI 10.1128/JCM.42.6.2518-2522.2004
   Smith-Vaughan H, 2009, CLIN VACCINE IMMUNOL, V16, P218, DOI 10.1128/CVI.00283-08
   Spratt BG, 1999, CURR OPIN MICROBIOL, V2, P312, DOI 10.1016/S1369-5274(99)80054-X
   Spratt BG, 2004, THE PNEUMOCOCCUS, P119
   Syrogiannopoulos GA, 1997, CLIN INFECT DIS, V25, P188, DOI 10.1086/514526
   Vialle-Valentin CE, 2012, TROP MED INT HEALTH, V17, P211, DOI 10.1111/j.1365-3156.2011.02895.x
   Yaro S, 2006, CLIN INFECT DIS, V43, P693, DOI 10.1086/506940
NR 42
TC 8
Z9 8
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 16
PY 2013
VL 8
IS 1
AR e53925
DI 10.1371/journal.pone.0053925
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 072OV
UT WOS:000313682700065
PM 23342041
OA gold
DA 2017-08-15
ER

PT J
AU Grietens, KP
   Ribera, JM
   Soto, V
   Tenorio, A
   Hoibak, S
   Aguirre, AR
   Toomer, E
   Rodriguez, H
   Cuentas, AL
   D'Alessandro, U
   Gamboa, D
   Erhart, A
AF Grietens, Koen Peeters
   Muela Ribera, Joan
   Soto, Veronica
   Tenorio, Alex
   Hoibak, Sarah
   Rosas Aguirre, Angel
   Toomer, Elizabeth
   Rodriguez, Hugo
   Llanos Cuentas, Alejandro
   D'Alessandro, Umberto
   Gamboa, Dionicia
   Erhart, Annette
TI Traditional Nets Interfere with the Uptake of Long-Lasting Insecticidal
   Nets in the Peruvian Amazon: The Relevance of Net Preference for
   Achieving High Coverage and Use
SO PLOS ONE
LA English
DT Article
ID BED-NETS; MALARIA ELIMINATION; ANOPHELES-DARLINGI; PLASMODIUM-VIVAX;
   WESTERN KENYA; MOSQUITO NETS; TREATED NETS; AREA; ACCEPTABILITY;
   OWNERSHIP
AB Background: While coverage of long-lasting insecticide-treated nets (LLIN) has steadily increased, a growing number of studies report gaps between net ownership and use. We conducted a mixed-methods social science study assessing the importance of net preference and use after Olyset (R) LLINs were distributed through a mass campaign in rural communities surrounding Iquitos, the capital city of the Amazonian region of Peru.
   Methods: The study was conducted in the catchment area of the Paujil and Cahuide Health Centres (San Juan district) between July 2007 and November 2008. During a first qualitative phase, participant observation and in-depth interviews collected information on key determinants for net preference and use. In a second quantitative phase, a survey among recently confirmed malaria patients evaluated the acceptability and use of both LLINs and traditional nets, and a case control study assessed the association between net preference/use and housing structure (open vs. closed houses).
   Results: A total of 10 communities were selected for the anthropological fieldwork and 228 households participated in the quantitative studies. In the study area, bed nets are considered part of the housing structure and are therefore required to fulfil specific architectural and social functions, such as providing privacy and shelter, which the newly distributed Olyset (R) LLINs ultimately did not. The LLINs' failure to meet these criteria could mainly be attributed to their large mesh size, transparency and perceived ineffectiveness to protect against mosquitoes and other insects, resulting in 63.3% of households not using any of the distributed LLINs. Notably, LLIN usage was significantly lower in houses with no interior or exterior walls (35.2%) than in those with walls (73.8%) (OR = 5.2, 95CI [2.2; 12.3], p<0.001).
   Conclusion: Net preference can interfere with optimal LLIN use. In order to improve the number of effective days of LLIN protection per dollar spent, appropriate quantitative and qualitative methods for collecting information on net preference should be developed before any LLIN procurement decision is made.
C1 [Grietens, Koen Peeters; D'Alessandro, Umberto; Erhart, Annette] Prince Leopold Inst Trop Med, Antwerp, Belgium.
   [Grietens, Koen Peeters; Muela Ribera, Joan; Toomer, Elizabeth] PASS Int, Partners Appl Social Sci, Tessenderlo, Belgium.
   [Soto, Veronica; Rosas Aguirre, Angel; Llanos Cuentas, Alejandro; Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Tenorio, Alex; Rosas Aguirre, Angel; Rodriguez, Hugo] Proyecto PAMAFRO, Organismo Andino Salud Convenio Hipolito Unanue, Lima, Peru.
   [Hoibak, Sarah] MENTOR Initiat, Crawley, England.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Dept Ciencias Celulares & Mol, Lima, Peru.
RP Grietens, KP (reprint author), Prince Leopold Inst Trop Med, Antwerp, Belgium.
EM kpeeters@itg.be
RI D'Alessandro, Umberto/D-3457-2015; Rosas Aguirre, Angel/A-5054-2016
OI D'Alessandro, Umberto/0000-0001-6341-5009; Rosas Aguirre,
   Angel/0000-0002-3271-7028
FU Belgian Cooperation [95502]; National Institute of Health [U19 SI089681]
FX The study received financial support from the Belgian Cooperation within
   the Framework Agreement III consisting of a bilateral cooperation
   between the Institute of Tropical Medicine (ITM), Antwerp- Belgium, and
   the ITM Alexander von Humboldt (ITM-AvH), Universidad Peruana Cayetano
   Heredia in Lima, Peru, Project 95502. DG is also supported by a National
   Institute of Health grant (U19 SI089681). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agypeong I, 1999, J BIOSOC SCI, V31, P79
   AIKINS MK, 1994, J TROP MED HYG, V97, P81
   Alliance for Malaria Prevention Toolkit 2.0, 2011, ALL MAL PREV TOOLK 2
   American Anthropological Association, 2004, AM ANTHR ASS STAT ET
   American Anthropological Association, 1998, COD ETH AM ANTHR ASS
   Atkinson JA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-298
   Atkinson JA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-119
   Baume CA, 2007, AM J TROP MED HYG, V77, P963
   Bean J, 2001, INSECTICIDE TR UNPUB
   Brieger W, 1994, HLTH ED RES, V11, P133
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   Fernando SD, 2008, T R SOC TROP MED HYG, V22, P222
   Gamble CL, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001031.pub2, 10.1002/14651858.CD003755.pub2]
   Githinji S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-250
   [Anonymous], QUICK FACTS PROC LON
   Global Fund to Fight Aids Tuberculosis and Malaria, 2011, COUNTR COORD MECH
   Grietens KP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029991
   Grietens KP, 2010, AM J TROP MED HYG, V82, P1017, DOI 10.4269/ajtmh.2010.09-0521
   Grietens KP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-23
   Guarda JA, 1999, EMERG INFECT DIS, V5, P209
   Gunasekaran K, 2009, ACTA TROP, V112, P149, DOI 10.1016/j.actatropica.2009.07.013
   Harvey SA, 2000, INSECTICIDE IM UNPUB
   Harvey SA, 2008, AM J TROP MED HYG, V79, P834
   Helman C.G., 2007, CULTURE HLTH ILLNESS
   Iwashita H, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-176
   Koenker H, 2011, PUBLIC HLTH BAYER CR
   LENGELER C, 2004, COCHRANE DATABASE SY, DOI 10.1002/14651858.CD000363
   Llanos-Zavalaga Fernando, 2005, Rev Med Hered, V16, P97
   Mendis K, 2001, AM J TROP MED HYG, V64, P97
   Oficina General de Epidemiologia DIRESA Loreto, 2008, AN SIT SAL REG LOR A
   OGEP, 2006, WEEKL EP B
   Organismo Andino de Salud-Convenio Hipolito Unanue, PROYECT PAMA FRO
   PAMAFRO, 2011, REP RES
   Pulford J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-83
   R4D, 2012, EXP ACC LLIN GLOB MA
   RBM, 2001, FIN REP INS TREAT BE
   Roll Back Malaria, 2011, REF UPD GMAP OBJ TAR
   Roper MH, 2000, AM J TROP MED HYG, V62, P247
   Rosas-Aguirre Angel, 2011, Rev Peru Med Exp Salud Publica, V28, P228, DOI 10.1590/s1726-46342011000200009
   Schoeler GB, 2003, J AM MOSQUITO CONTR, V19, P286
   SEXTON JD, 1990, AM J TROP MED HYG, V43, P11
   Teddlie C., 2008, FDN MIXED METHODS RE
   Thwing J, 2008, TROP MED INT HEALTH, V13, P827, DOI 10.1111/j.1365-3156.2008.02070.x
   Toe LP, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-175
   Van den Eede P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016257
   Vittor AY, 2006, AM J TROP MED HYG, V74, P3
   WHO, 2008, 12 WHOPES WORK GROUP
   WHO, 2011, VECT CONTR
   WHO, 2011, SYST IMPR VAL MON LL
   WHO, 2011, GUID MON DUR LONG LA
   WHO, 2011, INC M PIL STUD PROJ
   WHOPES, 2011, LONG LAST INS MOSQ N
   WINCH PJ, 1994, SOC SCI MED, V39, P63, DOI 10.1016/0277-9536(94)90166-X
NR 53
TC 13
Z9 13
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 2
PY 2013
VL 8
IS 1
AR e50294
DI 10.1371/journal.pone.0050294
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 067UP
UT WOS:000313320900003
PM 23300943
OA gold
DA 2017-08-15
ER

PT J
AU de Silva, TI
   van Tienen, C
   Onyango, C
   Jabang, A
   Vincent, T
   van der Loeff, MFS
   Coutinho, RA
   Jaye, A
   Rowland-Jones, S
   Whittle, H
   Cotten, M
   Hue, S
AF de Silva, Thushan I.
   van Tienen, Carla
   Onyango, Clayton
   Jabang, Abdoulie
   Vincent, Tim
   van der Loeff, Maarten F. Schim
   Coutinho, Roel A.
   Jaye, Assan
   Rowland-Jones, Sarah
   Whittle, Hilton
   Cotten, Matthew
   Hue, Stephane
TI Population dynamics of HIV-2 in rural West Africa: comparison with HIV-1
   and ongoing transmission at the heart of the epidemic
SO AIDS
LA English
DT Article
DE Guinea-Bissau; HIV-1; HIV-2; phylodynamics; phylogenetics; population
   dynamics; transmission
ID IMMUNODEFICIENCY-VIRUS TYPE-2; TO-CHILD TRANSMISSION; GUINEA-BISSAU;
   VIRAL LOAD; COMPETITIVE-EXCLUSION; NORMAL SURVIVAL; INFECTION; HISTORY;
   PREVALENCE; COMMUNITY
AB Objectives: To compare the population dynamics of HIV-2 and HIV-1, and to characterize ongoing HIV-2 transmission in rural Guinea-Bissau.
   Design: Phylogenetic and phylodynamic analyses using HIV-2 gag and env, and HIV-1 env sequences, combined with epidemiological data from a community cohort.
   Methods: Samples were obtained from surveys in 1989-1991, 1996-1997, 2003 and 2006-2007. Phylogenies were reconstructed using sequences from 103 HIV-2-infected and 56 HIV-1-infected patients using Bayesian Evolutionary Analysis by Sampling Trees (BEAST), a relaxed molecular clock and a Bayesian skyline coalescent model.
   Results: Bayesian skyline plots showed a strong increase in the 1990s of the HIV-1 effective population size (N-c) in the same period that the N-c of HIV-2 came into a plateau phase. The population dynamics of both viruses were remarkably similar following initial introduction. Incident infections were found more often in HIV-2 transmission clusters, with 55-58% of all individuals contributing to ongoing transmission. Some phylogenetically linked sexual partners had discordant viral loads (undetectable vs. detectable), suggesting host factors dictate the risk of disease progression in HIV-2. Multiple HIV-2 introductions into the cohort are evident, but ongoing transmission has occurred predominantly within the community.
   Conclusion: Comparison of HIV-1 and HIV-2 phylodynamics in the same community suggests both viruses followed similar growth patterns following introduction, and is consistent with the hypothesis that HIV-1 may have played a role in the decline of HIV-2 via competitive exclusion. The source of ongoing HIV-2 transmission in the cohort appears to be new HIV-2 cases, rather than the pool of older infections established during the early growth of HIV-2. (C) 2012 Wolters Kluwer Health I Lippincott Williams & Wilkins AIDS 2013, 27:125-134
C1 [de Silva, Thushan I.] Royal Hallamshire Hosp, Dept Infect & Trop Med, Sheffield S10 2JF, S Yorkshire, England.
   [de Silva, Thushan I.; van Tienen, Carla; Jabang, Abdoulie; Vincent, Tim; Jaye, Assan; Whittle, Hilton; Cotten, Matthew] Med Res Council UK Labs, Fajara, Gambia.
   [de Silva, Thushan I.; Hue, Stephane] UCL, Div Infect & Immun, MRC UCL Ctr Med Mol Virol, London WC1E 6BT, England.
   [van Tienen, Carla] Erasmus MC, Rotterdam, Netherlands.
   [Onyango, Clayton] KEMRI Wellcome Trust Programme, Kilifi, Kenya.
   [Rowland-Jones, Sarah] John Radcliffe Hosp, Weatherall Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DU, England.
   [Vincent, Tim] INDEPTH Network, Projecto Saude Bandim, Bissau Codex, Guinea Bissau.
   [van der Loeff, Maarten F. Schim] Hlth Serv Amsterdam GGD, Amsterdam, Netherlands.
   [van der Loeff, Maarten F. Schim] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [Coutinho, Roel A.] Bilthoven & Univ Med Ctr Utrecht, Ctr Infect Dis Control, Natl Inst Publ Hlth & Environm, Utrecht, Netherlands.
   [Whittle, Hilton] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
   [Cotten, Matthew] Wellcome Trust Sanger Inst, Hinxton, England.
RP de Silva, TI (reprint author), Royal Hallamshire Hosp, Dept Infect & Trop Med, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.
EM thushandesilva@hotmail.com
RI van Tienen, Carla/A-1119-2012
OI Hue, Stephane/0000-0002-8580-6905
FU UK Medical Research Council [G0701313]
FX This work was undertaken via a UK Medical Research Council Clinical
   Research Training Fellowship (G0701313) awarded to Td.S.
CR Anderson RM, 1996, AIDS, V10, P1663
   ANDREASSON PA, 1993, AIDS, V7, P989
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Barroso H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014548
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Brenner BG, 2007, J INFECT DIS, V195, P951, DOI 10.1086/512088
   Brown AJL, 2011, J INFECT DIS, V204, P1463, DOI 10.1093/infdis/jir550
   Bruhn CAW, 2011, LANCET INFECT DIS, V11, P260, DOI 10.1016/S1473-3099(11)70037-8
   Buckner M, 1999, VIVRE PENSER SIDA AF, P389
   Burgard M, 2010, CLIN INFECT DIS, V51, P833, DOI 10.1086/656284
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   da Silva ZJ, 2008, AIDS, V22, P1195, DOI 10.1097/QAD.0b013e328300a33d
   de Silva TI, 2012, J VIROL, V86, P930, DOI 10.1128/JVI.06126-11
   de Silva TI, 2008, TRENDS MICROBIOL, V16, P588, DOI 10.1016/j.tim.2008.09.003
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Dunkle KL, 2008, LANCET, V371, P2183, DOI 10.1016/S0140-6736(08)60953-8
   Esbjornsson J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017025
   Esbjornsson J, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-23
   Faria NR, 2012, J GEN VIROL, V93, P889, DOI 10.1099/vir.0.038638-0
   Faria NR, 2012, INFECT GENET EVOL, V12, P453, DOI 10.1016/j.meegid.2011.04.028
   Fisher M, 2010, AIDS, V24, P1739, DOI [10.1097/QAD.0b013e32833ac9e6, 10.1097/QAD.0b013e32833ac9c6]
   Gottlieb GS, 2006, AIDS, V20, P895, DOI 10.1097/01.aids.0000218554.59531.80
   Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9
   Grassly NC, 1998, J VIROL, V72, P7895
   Gray RR, 2009, AIDS, V23, pF9, DOI 10.1097/QAD.0b013e32832faf61
   Hawes SE, 2008, AIDS, V22, P2517, DOI 10.1097/QAD.0b013e328315cdbc
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Hughes GJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000590
   Jensen ML, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000101
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   Lemey P, 2006, AIDS REV, V8, P125
   Lewis F, 2008, PLOS MED, V5, P392, DOI 10.1371/journal.pmed.0050050
   Lowndes C, 2008, GLOBAL AIDS MONITORI
   Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Onyango CO, 2010, VACCINE, V28, pB60, DOI 10.1016/j.vaccine.2009.08.060
   Pao D, 2005, AIDS, V19, P85, DOI 10.1097/00002030-200501030-00010
   Pepin J, 2006, AIDS, V20, P1303
   Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333
   Popper SJ, 2000, J VIROL, V74, P1554, DOI 10.1128/JVI.74.3.1554-1557.2000
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   POULSEN AG, 1989, LANCET, V1, P827
   Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Schmidt WP, 2008, EPIDEMIOL INFECT, V136, P551, DOI 10.1017/S0950268807008758
   SLATKIN M, 1989, GENETICS, V123, P603
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   van der Loeff MFS, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-46
   van der Loeff MFS, 1999, AIDS, V13, pS69
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   van Tienen C, 2010, JAIDS-J ACQ IMM DEF, V53, P640, DOI 10.1097/QAI.0b013e3181bf1a25
   Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   Xiang Z, 1997, AIDS RES HUM RETROV, V13, P501, DOI 10.1089/aid.1997.13.501
NR 56
TC 14
Z9 14
U1 0
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JAN 2
PY 2013
VL 27
IS 1
BP 125
EP 134
DI 10.1097/QAD.0b013e32835ab12c
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 054QJ
UT WOS:000312358000015
PM 23032414
OA No
DA 2017-08-15
ER

PT J
AU Bashorun, A
   Worwui, A
   Parker, D
AF Bashorun, Adetokunbo
   Worwui, Archbald
   Parker, David
GP IEEE
TI Information Security: To determine its Level of Awareness in an
   Organization
SO 2013 7TH INTERNATIONAL CONFERENCE ON APPLICATION OF INFORMATION AND
   COMMUNICATION TECHNOLOGIES (AICT)
LA English
DT Proceedings Paper
CT 7th International Conference on Application of Information and
   Communication Technologies (AICT)
CY OCT 23-25, 2013
CL Baku, AZERBAIJAN
SP Minist Educ Azerbaijan, Minist Commun & Informat Technologies, Qafqaz Univ, Baku State Univ, Lomonosov Moscow State Univ, Baku branch, Azerbaijan Tech Univ, ANAS, Inst Informat Technol, SOCAR, IT & Commun Dept, Informat Technol Internationalizat Res Ctr, Inst Elect & Elect Engineers, IEEE Comp Soc Azerbaijan Chapter, State Oil Co Azerbaijan Republ, Azercell Telecom LLC, MiKRO Bilgi Kayit Dagitim A S, Turkish Cooperat & Coordinat Agcy
DE Information security awareness; organization; weakest link; knowledge;
   IT user
AB Information security awareness has become the focal point of businesses around the world. IT (information Technology) services are less effective due to the fact that IT users the key factor are the weakest security link which renders technology and its solutions less sufficient in providing a well secured environment. Thus, it is important for an organization to determine the level of information security awareness among users so as to gain valuable knowledge on how to encourage strong commitment and support. Also to put in place policies and procedures, provide security awareness and education, and stimulate future IT security plans.
C1 [Bashorun, Adetokunbo] MRC Unit Gambia, IT Dept, Banjul, Gambia.
   [Worwui, Archbald; Parker, David] MRC Unit Gambia, Banjul, Gambia.
RP Bashorun, A (reprint author), MRC Unit Gambia, IT Dept, Banjul, Gambia.
EM bashorunia@yahoo.com; warchibald@mrc.gm; dtparker71@yahoo.com
CR Choi N., 2008, INFORM MANAGEMENT CO, V16, P484, DOI 10.1108/09685220810920558
   Forte D., 2008, NETWORK SECURITY, V2008, P253
   Gerber M, 2008, COMPUT SECUR, V27, P124, DOI 10.1016/j.cose.2008.07.009
   Guenther M., 2001, SECURITY AWARENESS Q
   Rezgui Y, 2008, COMPUT SECUR, V27, P241, DOI 10.1016/j.cose.2008.07.008
   Shaw R., 2008, COMPUT EDUC, V52, P92
   Thomson K.L., 2006, CULTIVATING ORG INFO
NR 7
TC 0
Z9 0
U1 0
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-4673-6419-5
PY 2013
BP 176
EP 179
PG 4
WC Engineering, Electrical & Electronic; Telecommunications
SC Engineering; Telecommunications
GA BB7OG
UT WOS:000345830600030
OA No
DA 2017-08-15
ER

PT J
AU Redmond, J
   Jarjou, LMA
   Palla, L
   Prentice, A
   Schoenmakers, I
AF Redmond, J.
   Jarjou, L. M. A.
   Palla, L.
   Prentice, A.
   Schoenmakers, I.
TI Renal conservation of calcium in Gambian compared to British older
   adults
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Meeting Abstract
C1 [Redmond, J.; Palla, L.; Prentice, A.; Schoenmakers, I.] Med Res Council Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Jarjou, L. M. A.; Prentice, A.] Med Res Council Keneba, Serrekunda, Gambia.
RI Palla, Luigi/Q-4950-2016
OI Palla, Luigi/0000-0001-6944-1750
CR Cole, 2000, STAT MED, V19, P3109
   KENT GN, 1987, CLIN CHIM ACTA, V166, P155, DOI 10.1016/0009-8981(87)90417-7
   Yan LY, 2009, BONE, V45, P238, DOI 10.1016/j.bone.2009.04.237
NR 3
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0029-6651
EI 1475-2719
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PY 2013
VL 72
IS OCE4
BP E184
EP E184
DI 10.1017/S0029665113002097
PG 1
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 298VW
UT WOS:000330353600006
OA No
DA 2017-08-15
ER

PT J
AU Cox, SE
   Nweneka, CV
   Doherty, CP
   Fulford, AJ
   Moore, SE
   Prentice, AM
AF Cox, Sharon E.
   Nweneka, Chidi V.
   Doherty, Conor P.
   Fulford, Anthony J.
   Moore, Sophie E.
   Prentice, Andrew M.
TI Randomised controlled trial of weekly chloroquine to re-establish normal
   erythron iron flux and haemoglobin recovery in postmalarial anaemia
SO BMJ OPEN
LA English
DT Article
DE TROPICAL MEDICINE
ID SEVERE MALARIAL ANEMIA; FALCIPARUM-MALARIA; AFRICAN CHILDREN;
   PLASMODIUM-FALCIPARUM; GAMBIAN CHILDREN; DEFICIENCY ANEMIA; URINARY
   NEOPTERIN; WEST-AFRICA; HEPCIDIN; MANIFESTATIONS
AB Objective To determine if low-dose weekly chloroquine (CQ) therapy improves recovery from malaria-associated anaemia.
   Design Proof of concept randomised clinical trial.
   Setting West Kiang District, Lower River Region, The Gambia.
   Participants Children resident in participating communities, aged 12-72months, with uncomplicated malaria identified using active case detection over two consecutive malaria transmission seasons.
   Interventions In 2007, eligible children were randomised to chloroquine-sulfadoxine/pyrimethamine (CQ-SP) or co-artemether (ACT) antimalarial therapy, and after parasite clearance on day 3 were subsequently re-randomised (double-blind) to weekly low-dose CQ (5mg/kg) or placebo. In 2008, all eligible children were treated with ACT and subsequently randomised to CQ or placebo.
   Outcome measures The primary outcome was a change in haemoglobin from baseline (day 3 of antimalarial treatment) to day 90 in the CQ and placebo treatment arms. Secondary outcomes were changes in urinary neopterin as a marker of macrophage activation, markers of erythropoietic response and prevalence of submicroscopic parasitaemia. Change in haemoglobin in the placebo arm by initial antimalarial treatment was also assessed.
   Results In 2007, 101 children with uncomplicated malaria were randomised to antimalarial treatment with CQ-SP or ACT and 65 were subsequently randomised to weekly CQ or placebo. In 2008, all children received ACT antimalarial treatment and 31 were subsequently randomised to receive weekly CQ or placebo. Follow-up to day 90 was 96%. There was no effect of weekly CQ vs placebo on change in haemoglobin at day 90 (CQ+10.04g/L (95% CI 6.66 to 13.42) vs placebo +7.61g/L (95% CI 2.88 to 12.35)). There was no effect on the secondary outcomes assessed, or effect of initial antimalarial therapy on haemoglobin recovery. Higher day 90 haemoglobin correlated independently with older age, not being stunted, higher haemoglobin at day 0 and adequate iron status at day 3.
   Conclusions Weekly low-dose CQ after effective antimalarial treatment is not effective in improving recovery from postmalarial anaemia.
   Trial registration The clinical trial registration number is NCT00473837 (ClinicalTrials.gov).
C1 [Cox, Sharon E.; Nweneka, Chidi V.; Fulford, Anthony J.; Moore, Sophie E.; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   [Cox, Sharon E.] Muhimbili Univ Hlth & Allied Sci, Muhimbili Wellcome Programme, Dar Es Salaam, Tanzania.
   [Nweneka, Chidi V.; Fulford, Anthony J.; Moore, Sophie E.; Prentice, Andrew M.] MRC Keneba, Keneba, Gambia.
   [Doherty, Conor P.] Royal Hosp Sick Children, Dept Pediat, Glasgow G3 8SJ, Lanark, Scotland.
RP Prentice, AM (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
EM Andrew.Prentice@lshtm.ac.uk
OI Cox, Sharon/0000-0002-9908-2936
FU UK Medical Research Council [MC-A760-5QX00]
FX This study was supported by the UK Medical Research Council
   (MC-A760-5QX00).
CR ABDALLA SH, 1990, ANN TROP PAEDIATR, V10, P265
   Atkinson SH, 2008, BLOOD, V112, P4276, DOI 10.1182/blood-2008-06-162008
   Atkinson SH, 2006, PLOS MED, V3, P652, DOI 10.1371/journal.pmed.0030172
   Biemba G, 1998, TROP MED INT HEALTH, V3, P60, DOI 10.1046/j.1365-3156.1998.00168.x
   Bojang KA, 1997, T ROY SOC TROP MED H, V91, P557, DOI 10.1016/S0035-9203(97)90025-0
   Bojang KA, 1997, ANN TROP PAEDIATR, V17, P355
   Brabin BJ, 2001, J NUTR, V131, p636S
   Brabin BJ, 2001, J NUTR, V131, p46S
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   BROWN AE, 1992, T ROY SOC TROP MED H, V86, P134, DOI 10.1016/0035-9203(92)90539-O
   Cooper RG, 2008, INDIAN J MED RES, V127, P305
   Doherty CP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002133
   Dondorp AM, 2002, T ROY SOC TROP MED H, V96, P282, DOI 10.1016/S0035-9203(02)90100-8
   DRENOU B, 1995, NEW ENGL J MED, V332, P614, DOI 10.1056/NEJM199503023320920
   Evans KJ, 2006, BLOOD, V107, P1192
   FUCHS D, 1988, IMMUNOL TODAY, V9, P150, DOI 10.1016/0167-5699(88)91203-0
   Ganz T, 2006, PEDIATR BLOOD CANCER, V46, P554, DOI 10.1002/pbc.20656
   Ganz T, 2006, HEMATOL-AM SOC HEMAT, V29-35, P507
   Ghigo D, 1998, J CLIN INVEST, V102, P595, DOI 10.1172/JCI1052
   HERSHKO C, 1981, AM J CLIN NUTR, V34, P1600
   Lackritz EM, 1998, PLOS ONE, V12, pS81
   Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102
   Legssyer R, 1999, BIOCHEM PHARMACOL, V57, P907, DOI 10.1016/S0006-2952(98)00368-2
   Mulenga M, 2006, TROP MED INT HEALTH, V11, P1643, DOI 10.1111/j.1365-3156.2006.01726.x
   Murphy SC, 2001, AM J TROP MED HYG, V64, P57
   NaNA, 2001, NAT SURV PREV VIT A
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Nwakanma DC, 2009, J INFECT DIS, V199, P1567, DOI 10.1086/598856
   Nweneka CV, 2010, T ROY SOC TROP MED H, V104, P175, DOI 10.1016/j.trstmh.2009.08.007
   Ojukwu JU, 2009, COCHRANE DATABASE SY
   Phiri KS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002903
   Prentice AM, 2012, BLOOD, V119, P1922, DOI 10.1182/blood-2011-11-391219
   Price RN, 2001, AM J TROP MED HYG, V65, P614
   REIBNEGGER G, 1984, T ROY SOC TROP MED H, V78, P545, DOI 10.1016/0035-9203(84)90080-4
   Reyburn H, 2005, JAMA-J AM MED ASSOC, V293, P1461, DOI 10.1001/jama.293.12.1461
   vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7
   Verhoef H, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.4.e48
   Wallace DJ, 1996, LUPUS, V5, pS59
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
   Worwood M, 1997, CLIN CHIM ACTA, V259, P3, DOI 10.1016/S0009-8981(96)06488-1
NR 40
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2013
VL 3
IS 7
AR e002666
DI 10.1136/bmjopen-2013-002666
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 291CO
UT WOS:000329805500024
OA gold
DA 2017-08-15
ER

PT J
AU Jones, C
   Pollock, L
   Barnett, SM
   Battersby, A
   Kampmann, B
AF Jones, Christine
   Pollock, Louisa
   Barnett, Sara M.
   Battersby, Anna
   Kampmann, Beate
TI Specific antibodies against vaccine-preventable infections: a
   mother-infant cohort study
SO BMJ OPEN
LA English
DT Article
DE pertussis
ID INFLUENZAE TYPE-B; PNEUMOCOCCAL POLYSACCHARIDE VACCINE;
   HUMAN-IMMUNODEFICIENCY-VIRUS; LINKED IMMUNOSORBENT ASSAYS; MENINGITIDIS
   SEROGROUP C; MATERNAL HIV-INFECTION; BORDETELLA-PERTUSSIS;
   PLACENTAL-TRANSFER; IGG ANTIBODIES; CAPSULAR POLYSACCHARIDE
AB Objectives To determine maternal and neonatal specific antibody levels to selected vaccine-preventable infections (pertussis, Haemophilus influenzae type b (Hib), tetanus and pneumococcus).
   Design Prospective cohort study.
   Setting A UK secondary care maternity unit (March 2011-January 2012).
   Participants Mothers and infants within 72h of delivery were eligible. Unwell individuals, mothers less than 18years of age, and infants born at less than 36weeks gestation, or weighing less than 2500g, were excluded. HIV-infected mothers were included. 112 mother-infant pairs were recruited. Samples from 111 mothers and 109 infants (108 pairs) were available for analysis.
   Outcome measures Specific antibody levels were determined using standard commercial ELISAs. Specific antibody to pertussis antigens (PT and FHA) of >50IU/ml, defined as positive' by the test manufacturer, were interpreted as protective. Antitetanus antibody titres >0.1IU/ml and anti-Hib antibody titres >1mg/l were regarded as protective.
   Results Only 17% (19/111) of women exhibited a protective antibody response against pertussis. 50% (56/111) of women had levels of antibody protective against Hib and 79% (88/111) against tetanus. There was a strong positive correlation between maternal-specific and infant-specific antibodies' responses against pertussis (r(s)=0.71, p<0.001), Hib (r(s)=0.80, p<0.001), tetanus (r(s)=0.90, p<0.001) and pneumococcal capsular polysaccharide (r(s)=0.85, p<0.001). Only 30% (33/109) and 42% (46/109) of infants showed a protective antibody response to pertussis and Hib, respectively. Placental transfer (infant:mother ratio) of specific IgG to pertussis, Hib, pneumococcus and tetanus was significantly reduced from HIV-infected mothers to their HIV-exposed, uninfected infants (n=12 pairs) compared with HIV-uninfected mothers with HIV-unexposed infants (n=96 pairs) by 58% (<0.001), 61% (<0.001), 28% (p=0.034) and 32% (p=0.035), respectively.
   Conclusions Low baseline antibody levels against pertussis in this cohort suggest the recently implemented UK maternal pertussis immunisation programme has potential to be effective.
C1 [Jones, Christine; Pollock, Louisa; Barnett, Sara M.; Battersby, Anna; Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, London, England.
   [Jones, Christine] Univ London, Paediat Infect Dis Res Grp, London, England.
   [Kampmann, Beate] Med Res Council Unit Gambia, Fajara, Gambia.
RP Kampmann, B (reprint author), Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, London, England.
EM b.kampmann@imperial.ac.uk
OI Pollock, Louisa/0000-0002-4240-325X
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Imperial College Healthcare NHS Trust; Imperial College London
   [P31436]
FX This study was funded by the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Imperial College Healthcare
   NHS Trust and Imperial College London (grant number P31436). The views
   expressed are those of the author(s) and not necessarily those of the
   NHS, the NIHR or the Department of Health. The funding body had no role
   in the study design; in the collection, analysis or interpretation of
   data; in the writing of the report or in the decision to submit the
   article for publication.
CR AGBARAKWE AE, 1995, J CLIN PATHOL, V48, P206, DOI 10.1136/jcp.48.3.206
   Belloni C, 2003, PEDIATRICS, V111, P1042, DOI 10.1542/peds.111.5.1042
   Blencowe H, 2010, INT J EPIDEMIOL, V39, P102, DOI 10.1093/ije/dyq027
   Cattaneo LA, 1996, J INFECT DIS, V173, P1256
   Chaithongwongwatthana S, 2012, COCHRANE DATABASE SY, V7
   Cherry JD, 1998, VACCINE, V16, P1901, DOI 10.1016/S0264-410X(98)00226-6
   Cumberland P, 2007, J INFECT DIS, V196, P550, DOI 10.1086/519845
   de Voer RM, 2009, CLIN INFECT DIS, V49, P58, DOI 10.1086/599347
   deMoraesPinto MI, 1996, J INFECT DIS, V173, P1077
   DEMORAESPINTO MI, 1993, ACTA PAEDIATR, V82, P1034
   Department of Health, 2013, PERT VACC UPT PREGN
   Department of Health, 2012, SEAS INFL VACC UPT G
   ENGLUND JA, 1995, PEDIATRICS, V96, P580
   Esposito S, 2012, CLIN MICROBIOL INFEC, V18, P85, DOI 10.1111/j.1469-0691.2012.03936.x
   Flasche S, 2011, PLOS MED, V8
   Sa Gall, 2011, AM J OBSTET GYNECOL, V204
   Guiso N, 2011, EUR J CLIN MICROBIOL, V30, P307, DOI 10.1007/s10096-010-1104-y
   Healy CM, 2006, CLIN INFECT DIS, V42, P1439, DOI 10.1086/503567
   Healy CM, 2004, J INFECT DIS, V190, P335, DOI 10.1086/421033
   Health Protection Agency, 2012, CUMM WEEKL NUMB REP
   Holmlund E, 2011, VACCINE, V29, P4565, DOI 10.1016/j.vaccine.2011.04.068
   Joint Committee on Vaccination and Immunisation, 2012, MIN TEL PERT 30 AUG
   Jones CE, 2011, JAMA-J AM MED ASSOC, V305, P576, DOI 10.1001/jama.2011.100
   KAYHTY H, 1983, J INFECT DIS, V147, P1100
   Kosters K, 2000, CLIN DIAGN LAB IMMUN, V7, P422, DOI 10.1128/CDLI.7.3.422-426.2000
   Ladhani S, 2009, J INFECTION, V58, P3, DOI 10.1016/j.jinf.2008.10.007
   Ladhani SN, 2011, PEDIATR INFECT DIS J, V30, P893, DOI 10.1097/INF.0b013e31822ef670
   Lehmann D, 2003, VACCINE, V21, P3446, DOI 10.1016/S0264-410X(03)00348-7
   Leino T, 2000, EPIDEMIOL INFECT, V125, P583, DOI 10.1017/S0950268800004799
   Lindsey B, 2012, PATHOG GLOB HEALTH, V106, P137, DOI 10.1179/204777312X13462106637684
   McNally LM, 2007, LANCET, V369, P1440, DOI 10.1016/S0140-6736(07)60670-9
   Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1
   Munoz FM, 2001, VACCINE, V20, P826, DOI 10.1016/S0264-410X(01)00397-8
   National Records of Scotland, 2011, STAT VIT EV
   Office for National Statistics, 2011, LIV BIRTHS ENGL WAL
   Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646
   Quiambao BP, 2007, VACCINE, V25, P4470, DOI 10.1016/j.vaccine.2007.03.021
   Riffelmann M, 2010, J CLIN MICROBIOL, V48, P4459, DOI 10.1128/JCM.01371-10
   Roper MH, 2007, LANCET, V370, P1947, DOI 10.1016/S0140-6736(07)61261-6
   Schauer U, 2003, CLIN DIAGN LAB IMMUN, V10, P202, DOI 10.1128/CDLI.10.2.202-207.2003
   Scott S, 2005, J INFECT DIS, V191, P1854, DOI 10.1086/429963
   SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2
   Shakib JH, 2010, J PERINATOL, V30, P93, DOI 10.1038/jp.2009.138
   Storsaeter J, 2003, VACCINE, V21, P3542, DOI 10.1016/S0264-410X(03)00407-9
   Storsaeter J, 1998, VACCINE, V16, P1907, DOI 10.1016/S0264-410X(98)00227-8
   Taranger J, 2000, J INFECT DIS, V181, P1010, DOI 10.1086/315318
   van den Berg JP, 2010, PEDIATR INFECT DIS J, V29, P801, DOI 10.1097/INF.0b013e3181dc4f77
   VANSAVAGE J, 1990, J INFECT DIS, V161, P487
   Wendelboe Aaron M, 2005, Pediatr Infect Dis J, V24, pS58, DOI 10.1097/01.inf.0000160914.59160.41
   World Health Organization, 2006, WKLY EPIDEMIOL REC, V81, P198
NR 50
TC 12
Z9 12
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2013
VL 3
IS 4
AR e002473
DI 10.1136/bmjopen-2012-002473
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 291DZ
UT WOS:000329809200083
OA gold
DA 2017-08-15
ER

PT J
AU Zhou, YJ
   Gao, HY
   Mihindukulasuriya, KA
   La Rosa, PS
   Wylie, KM
   Vishnivetskaya, T
   Podar, M
   Warner, B
   Tarr, PI
   Nelson, DE
   Fortenberry, JD
   Holland, MJ
   Burr, SE
   Shannon, WD
   Sodergren, E
   Weinstock, GM
AF Zhou, Yanjiao
   Gao, Hongyu
   Mihindukulasuriya, Kathie A.
   La Rosa, Patricio S.
   Wylie, Kristine M.
   Vishnivetskaya, Tatiana
   Podar, Mircea
   Warner, Barb
   Tarr, Phillip I.
   Nelson, David E.
   Fortenberry, J. Dennis
   Holland, Martin J.
   Burr, Sarah E.
   Shannon, William D.
   Sodergren, Erica
   Weinstock, George M.
TI Biogeography of the ecosystems of the healthy human body
SO GENOME BIOLOGY
LA English
DT Article
DE Biogeography; Human microbiome; Biodiversity; Temporal stability
ID HUMAN ORAL MICROBIOME; RARE BIOSPHERE; RIBOSOMAL-RNA; DIVERSITY; GUT;
   BACTERIA; COMMUNITIES; DISEASE; CHILDREN; PROJECT
AB Background: Characterizing the biogeography of the microbiome of healthy humans is essential for understanding microbial associated diseases. Previous studies mainly focused on a single body habitat from a limited set of subjects. Here, we analyzed one of the largest microbiome datasets to date and generated a biogeographical map that annotates the biodiversity, spatial relationships, and temporal stability of 22 habitats from 279 healthy humans.
   Results: We identified 929 genera from more than 24 million 16S rRNA gene sequences of 22 habitats, and we provide a baseline of inter-subject variation for healthy adults. The oral habitat has the most stable microbiota with the highest alpha diversity, while the skin and vaginal microbiota are less stable and show lower alpha diversity. The level of biodiversity in one habitat is independent of the biodiversity of other habitats in the same individual. The abundances of a given genus at a body site in which it dominates do not correlate with the abundances at body sites where it is not dominant. Additionally, we observed the human microbiota exhibit both cosmopolitan and endemic features. Finally, comparing datasets of different projects revealed a project-based clustering pattern, emphasizing the significance of standardization of metagenomic studies.
   Conclusions: The data presented here extend the definition of the human microbiome by providing a more complete and accurate picture of human microbiome biogeography, addressing questions best answered by a large dataset of subjects and body sites that are deeply sampled by sequencing.
C1 [Zhou, Yanjiao; Gao, Hongyu; Mihindukulasuriya, Kathie A.; Wylie, Kristine M.; Sodergren, Erica; Weinstock, George M.] Washington Univ, Sch Med, Genome Inst, St Louis, MO 63108 USA.
   [La Rosa, Patricio S.; Shannon, William D.] Washington Univ, Sch Med, Div Gen Med Sci, Dept Med, St Louis, MO 63110 USA.
   [Vishnivetskaya, Tatiana] Univ Tennessee, Knoxville, TN 37916 USA.
   [Nelson, David E.; Fortenberry, J. Dennis] Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA.
   [Warner, Barb] Washington Univ, Sch Med, Div Newborn Med, Dept Pediat, St Louis, MO 63110 USA.
   [Tarr, Phillip I.] Washington Univ, Sch Med, Div Pediat Gastroenterol, Dept Pediat, St Louis, MO 63110 USA.
   [Nelson, David E.] Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.
   [Fortenberry, J. Dennis] Indiana Univ Sch Med, Dept Pediat, Sect Adolescent Med, Indianapolis, IN 46202 USA.
   [Holland, Martin J.; Burr, Sarah E.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Burr, Sarah E.] MRC Unit, Gambia 1000, Fajara, Gambia.
RP Weinstock, GM (reprint author), Washington Univ, Sch Med, Genome Inst, St Louis, MO 63108 USA.
EM gweinsto@genome.wustl.edu
OI Vishnivetskaya, Tatiana/0000-0002-0660-023X; Podar,
   Mircea/0000-0003-2776-0205; Mihindukulasuriya,
   Kathie/0000-0001-9372-3758
FU National Institutes of Health [U54HG004968]; NIH-NHGRI [1R01HG004857];
   Oak Ridge National Laboratory; Wellcome Trust [079246/Z/06/Z]; NIH [UH3
   AI083265, 5P30 DK052574, UH3 AI094641]
FX The authors are grateful to the NIH Common Fund Human Microbiome Project
   Consortium for generating and making available many of the datasets used
   in this study. The research leading to these results received funding
   from the National Institutes of Health, grant U54HG004968 to George
   Weinstock, The Genome Institute at Washington University. Tatiana
   Vishnivetskaya and Mircea Podar were supported by NIH-NHGRI grant
   1R01HG004857 and by the Oak Ridge National Laboratory (managed by
   UT-Battelle, LLC, for the U.S. Department of Energy). Martin J. Holland
   was supported by the Wellcome Trust Grant 079246/Z/06/Z. Phillip I. Tarr
   was supported by NIH grants UH3 AI083265 and 5P30 DK052574 (Biobank) for
   the Digestive Diseases Research Core Center. J. Dennis Fortenberry was
   supported by NIH grant UH3 AI094641.
CR Baas Becking LGM, 1934, GEOBIOLOGIE INLEIDIN
   Castellarin M, 2011, GENOME RES, V22, P299, DOI DOI 10.1101/GR.126516.111
   Chen T., 2010, DATABASE OXFORD
   Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879
   Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486
   Dewhirst FE, 2010, J BACTERIOL, V192, P5002, DOI 10.1128/JB.00542-10
   Donders GGG, 2000, AM J OBSTET GYNECOL, V182, P872, DOI 10.1016/S0002-9378(00)70338-3
   Faust K, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002606
   Fava F, 2006, CURR MED CHEM, V13, P3005, DOI 10.2174/092986706778521814
   Fava F, 2011, WORLD J GASTROENTERO, V17, P557, DOI 10.3748/wjg.v17.i5.557
   Fierer N, 2008, MICROBIAL BIOGEOGRAP
   Fierer N, 2008, P NATL ACAD SCI USA, V105, P17994, DOI 10.1073/pnas.0807920105
   Frank DN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010598
   Fredricks DN, 2005, NEW ENGL J MED, V353, P1899, DOI 10.1056/NEJMoa043802
   Friedman J, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002687
   Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700
   Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110
   Hamady M, 2009, GENOME RES, V19, P1141, DOI 10.1101/gr.085464.108
   Hendley JO, 2005, APMIS, V113, P213, DOI 10.1111/j.1600-0463.2005.apm1130310.x
   Holmes I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030126
   Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709
   Huse SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034242
   Huse SM, 2010, ENVIRON MICROBIOL, V12, P1889, DOI 10.1111/j.1462-2920.2010.02193.x
   Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234
   Janssen PH, 2006, APPL ENVIRON MICROB, V72, P1719, DOI 10.1128/AEM.72.3.1719-1728.2006
   Jumpstart Consortium Human Microbiome Project Data Generation Working Group, 2012, PLOS ONE, V7, DOI [DOI 10.1371/JOURNAL.PONE.0039315, 10.1371/journal.pone.0039315]
   Kostic A. D., 2011, GENOME RES, V22, P292, DOI DOI 10.1101/GR.126573.111
   La Rosa PS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052078
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/nature4441022a
   Li K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032118
   Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209
   Nelson DE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014116
   Oksanen J., 2011, VEGAN COMMUNITY ECOL
   Pace NR, 2009, MICROBIOL MOL BIOL R, V73, P565, DOI 10.1128/MMBR.00033-09
   Parracho HMRT, 2005, J MED MICROBIOL, V54, P987, DOI 10.1099/jmm.0.46101-0
   Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109
   Pozhitkov AE, 2011, PERIODONTOL 2000, V55, P70, DOI 10.1111/j.1600-0757.2010.00380.x
   Quince C, 2009, NAT METHODS, V6, P639, DOI [10.1038/nmeth.1361, 10.1038/NMETH.1361]
   Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107
   Reeder J, 2009, NAT METHODS, V6, P636, DOI 10.1038/nmeth0909-636
   Schauer R, 2010, ISME J, V4, P159, DOI 10.1038/ismej.2009.106
   Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/nmeth.2066, 10.1038/NMETH.2066]
   Smith B, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-73
   Smith T, 1905, J MED RES, V14, P193
   Spencer MD, 2011, GASTROENTEROLOGY, V140, P976, DOI 10.1053/j.gastro.2010.11.049
   Tarr PI, 2010, NATURE PRECEDINGS, DOI DOI 10.1038/NPRE.2010.5285.1]
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Wertz J., 2008, INTERDISCIP PERSPECT, V2008, DOI DOI 10.1155/2008/181253
   Wos-Oxley ML, 2010, ISME J, V4, P839, DOI 10.1038/ismej.2010.15
   Wu GD, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-206
   Yang F, 2012, ISME J, V6, P1, DOI 10.1038/ismej.2011.71
   Zarco MF, 2012, ORAL DIS, V18, P109, DOI 10.1111/j.1601-0825.2011.01851.x
   Zaura E, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-259
NR 53
TC 43
Z9 45
U1 0
U2 54
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-6906
J9 GENOME BIOL
JI Genome Biol.
PY 2013
VL 14
IS 1
AR R1
DI 10.1186/gb-2013-14-1-r1
PG 18
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 160YA
UT WOS:000320155200001
PM 23316946
OA gold
DA 2017-08-15
ER

PT J
AU Lin, GM
   Li, YH
   Zheng, NC
   Lai, CP
   Lin, CL
   Wang, JH
   Jaiteh, LES
   Han, CL
AF Lin, Gen-Min
   Li, Yi-Hwei
   Zheng, Nan-Cheng
   Lai, Cha-Po
   Lin, Chin-Lon
   Wang, Ji-Hung
   Jaiteh, Lamin E. S.
   Han, Chih-Lu
TI Serum uric acid as an independent predictor of mortality in high-risk
   patients with obstructive coronary artery disease A prospective
   observational cohort study from the ET-CHD registry, 1997-2003
SO JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Serum uric acid; Angiography; Coronary artery disease; Cardiac
   mortality; All-cause mortality
ID ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; ALL-CAUSE; HYPERURICEMIA;
   ASSOCIATION; INSULIN; INTERVENTION; HYPERTENSION; RESISTANCE
AB Background: Serum uric acid (SUA) has been observed to be highly associated with the development of cardiovascular disease for more than 50 years. Several studies have reported elevated SUA as an independent predictor of mortality in patients with coronary artery disease (CAD) after adjustment for classic risk factors but some studies did not find similar results.
   Methods: Between January 1997 and December 2003, a prospective cohort study was performed in 1054 patients with angiographically defined CAD, and their classic risk factors and SUA levels were determined at enrollment. The study cohort was followed for an average of 3.2 years, with a median of 3.1 years. The main outcome measure was death from cardiac disease and any cause.
   Results: Of all study patients, 789 (74.9%) were men and 265 (25.1%) were women. The mean age of the male and female patients was 64.8 and 66.9 years, respectively. The mean SUA level of all patients was 410.4 mu mol/L. There were grading effects of SUA quartiles on cardiac and all-cause mortality in univariate and multivariate Cox regression analyses. After adjustment, the multivariate analyses revealed that patients in the highest SUA quartile (>487 mu mol/L) had 2.08 (95% CI = 1.19-3.62, p = 0.01) fold increased risk of cardiac death, and 1.68 (95% CI = 1.10-2.57, p = 0.017) fold increase risk of overall mortality compared with the lowest quartile (<315 mu mol/L).
   Conclusions: SUA may be a significant predictor of cardiac and overall mortality, independent of classic risk factors in high-risk patients with obstructive CAD. (C) 2012 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
C1 [Lin, Gen-Min; Li, Yi-Hwei; Zheng, Nan-Cheng] Tzu Chi Univ, Dept Publ Hlth, Hualien 97004, Taiwan.
   [Lin, Gen-Min] Hualien Armed Forces Gen Hosp, Dept Med, Hualien, Taiwan.
   [Lai, Cha-Po; Lin, Chin-Lon; Wang, Ji-Hung] Buddhist Tzu Chi Gen Hosp, Div Cardiol, Hualien, Taiwan.
   [Jaiteh, Lamin E. S.] Royal Victoria Teaching Hosp, Dept Med, Banjul, Gambia.
   [Han, Chih-Lu] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.
RP Lin, GM (reprint author), Tzu Chi Univ, Dept Publ Hlth, 701 Zhongyang Rd,Sec 3, Hualien 97004, Taiwan.
EM farmer507@yahoo.com.tw; yihwei@mail.tcu.edu.tw
CR Aengevaeren WR, 1999, ATHEROSCLEROSIS, V147, pS11, DOI 10.1016/S0021-9150(99)00250-6
   Alderman MH, 1998, AM J HYPERTENS, V11, P16
   Alderman MH, 1998, J HYPERTENS, V16, P5
   Bickel C, 2002, AM J CARDIOL, V89, P12, DOI 10.1016/S0002-9149(01)02155-5
   CAPPUCCIO FP, 1993, JAMA-J AM MED ASSOC, V270, P354, DOI 10.1001/jama.270.3.354
   Chuang SY, 2012, INT J CARDIOL, V154, P316, DOI 10.1016/j.ijcard.2011.06.055
   Culleton BF, 1999, ANN INTERN MED, V131, P7
   FACCHINI F, 1991, JAMA-J AM MED ASSOC, V266, P3008, DOI 10.1001/jama.266.21.3008
   Fang J, 2000, JAMA-J AM MED ASSOC, V283, P2404, DOI 10.1001/jama.283.18.2404
   FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P637
   GALVAN AQ, 1995, AM J PHYSIOL-ENDOC M, V268, pE1
   Hillis GS, 2009, J THORAC CARDIOV SUR, V138, P200, DOI 10.1016/j.jtcvs.2008.12.052
   Iribarren C, 1996, ANN EPIDEMIOL, V6, P331, DOI 10.1016/S1047-2797(96)00052-X
   KANELLIS J, 2004, J SEMIN NEPHROL, V25, P39
   Kaya MG, 2012, AM J CARDIOL, V109, P486, DOI 10.1016/j.amjcard.2011.09.042
   LEVINE W, 1989, J CLIN EPIDEMIOL, V42, P257, DOI 10.1016/0895-4356(89)90061-9
   Liese AD, 1998, CIRCULATION, V97, P822
   MAPLES KR, 1988, J BIOL CHEM, V263, P1709
   MESSERLI FH, 1980, ANN INTERN MED, V93, P817
   Niskanen LK, 2004, ARCH INTERN MED, V164, P1546, DOI 10.1001/archinte.164.14.1546
   PERSKY VW, 1979, CIRCULATION, V59, P969
   Puddu P, 2012, J CARDIOL, V59, P235, DOI 10.1016/j.jjcc.2012.01.013
   RAO GN, 1991, J BIOL CHEM, V266, P8604
   Rathmann W, 1998, ANN EPIDEMIOL, V8, P250
   Rosengren A, 2004, EUR HEART J, V25, P663, DOI 10.1016/j.ehj.2004.02.023
   Santos CXC, 1999, ARCH BIOCHEM BIOPHYS, V372, P285, DOI 10.1006/abbi.1999.1491
   Sato Y, 2012, J CARDIOL, V59, P1, DOI 10.1016/j.jjcc.2011.11.001
   Sianos Georgios, 2005, EuroIntervention, V1, P219
   Spoon DB, 2010, J INTERV CARDIOL, V23, P277, DOI 10.1111/j.1540-8183.2010.00555.x
   Tomiyama H, 2011, AM J HYPERTENS, V24, P770, DOI 10.1038/ajh.2011.55
   Tsai Tzu-Hsien, 2009, Chang Gung Med J, V32, P605
   Wannamethee SG, 2005, CURR PHARM DESIGN, V11, P4125, DOI 10.2174/138161205774913200
   Ward HJ, 1998, LANCET, V352, P670, DOI 10.1016/S0140-6736(05)60816-1
NR 33
TC 22
Z9 24
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0914-5087
J9 J CARDIOL
JI J. Cardiol.
PD JAN-FEB
PY 2013
VL 61
IS 1-2
BP 122
EP 127
DI 10.1016/j.jjcc.2012.09.004
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 115RD
UT WOS:000316828700022
PM 23088935
OA No
DA 2017-08-15
ER

PT S
AU Prentice, AM
   Moore, SE
   Fulford, AJ
AF Prentice, Andrew M.
   Moore, Sophie E.
   Fulford, Anthony J.
BE Shamir, R
   Turck, D
   Phillip, M
TI Growth Faltering in Low-Income Countries
SO NUTRITION AND GROWTH
SE World Review of Nutrition and Dietetics
LA English
DT Article; Proceedings Paper
CT 1st International Conference on Nutrition and Growth
CY MAR 01-03, 2012
CL Paris, FRANCE
ID RANDOMIZED CONTROLLED-TRIAL; MICRONUTRIENT SUPPLEMENTATION;
   INTERVENTIONS; ASSOCIATION; ENTEROPATHY; CHILDREN; VILLAGES; GAMBIA;
   BIRTH
AB Meta-analysis of growth data from over 50 low and low-middle income countries shows a consistent pattern of stunting and poor weight gain from about 3 months of age and persisting until at least 5 years. Children tend not to be wasted because their short stature offsets their underweight, leading to a rather adequately proportioned appearance. This frequently conceals the true levels of malnutrition in communities. At the macro-environmental level such growth faltering is due to the combined effects of poverty, food insecurity, low-dietary diversity, a highly infectious environment, poor washing facilities and poor understanding of the principles of nutrition and hygiene. These tend to be ameliorated as communities pass through the demographic transition with improved incomes and education. Because such changes will take generations to achieve, the global health community continues to search for effective interim solutions. Disappointingly, apart from intensive feeding programmes aimed at rehabilitating severely malnourished children, there are few examples of very successful nutrition interventions. This emphasizes the need for a better understanding of the etiology of growth failure. This paper uses anthropometric data collected over 6 decades in subsistence-farming communities from rural Gambia to illustrate the typical key features of growth faltering. Arising from this analysis, and from gaps in the published literature, the following issues are highlighted as still requiring a better resolution: (1) the pre-natal and inter-generational influences on growth failure; (2) the ontogeny of the infant immune system; (3) the exact nature of the precipitating insults that initiate gastroenteropathy; (4) the effects of both enteric and systemic infections on the hormonal regulation of growth; (5) interactions between macro- and micro-nutrient deficiencies and infections in causing growth failure, and (6) the role of the microbiome in modulating dietary influences on health and growth. Copyright (C) 2013 S. Karger AG, Basel
C1 [Prentice, Andrew M.; Moore, Sophie E.; Fulford, Anthony J.] Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   MRC Keneba, Keneba, Gambia.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM Andrew.prentice@lshtm.ac.uk
FU UK Medical Research Council [MC-A760-5QX00]
FX The work of the MRC International Nutrition Group is supported by the UK
   Medical Research Council (MC-A760-5QX00). We thank the residents of West
   Kiang for their exceptional contributions to global health research over
   many years.
CR Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   Aaby P, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6495
   Bourc'his D, 2008, MOL CELL ENDOCRINOL, V282, P87, DOI 10.1016/j.mce.2007.11.025
   Campbell DI, 2004, J PEDIATR GASTR NUTR, V39, P153, DOI 10.1097/00005176-200408000-00005
   Collinson A, 2005, AM J CLIN NUTR, V81, P488
   Cooper WN, 2012, FASEB J, V26, P1782, DOI 10.1096/fj.11-192708
   Czerkinsky C, 2009, MUCOSAL IMMUNOL, V2, P284, DOI 10.1038/mi.2009.22
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   Humphrey JH, 2009, LANCET, V374, P1032, DOI 10.1016/S0140-6736(09)60950-8
   Husseini M, 2009, THESIS LONDON SCH HY
   Jackson AA, 1997, BRIT J NUTR, V77, P183, DOI 10.1079/BJN19970023
   Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213
   Khulan B, 2012, HUM MOL GENET, V21, P2086, DOI 10.1093/hmg/dds026
   Poskitt EME, 1999, ARCH DIS CHILD, V80, P115
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   Selling KE, 2006, BJOG-INT J OBSTET GY, V113, P430, DOI 10.1111/j.1471-0528.2006.00872.x
   Shrimpton R, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.5.e75
   Thomas JE, 2004, ARCH DIS CHILD, V89, P1149, DOI 10.1136/adc.2002.015313
   Victora CG, 2010, PEDIATRICS, V125, pE473, DOI 10.1542/peds.2009-1519
   Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252
   WHO Multicentre Growth Reference Study Group, 2006, ACTA PAEDIATR, V450, P76, DOI DOI 10.1080/08035320500495548
   Zeisel S H, 1997, Adv Pediatr, V44, P263
NR 22
TC 7
Z9 7
U1 4
U2 31
PU KARGER
PI BASEL
PA POSTFACH, CH-4009 BASEL, SWITZERLAND
SN 0084-2230
BN 978-3-318-02265-0
J9 WORLD REV NUTR DIET
JI World Rev.Nutr.Diet.
PY 2013
VL 106
BP 90
EP 99
DI 10.1159/000342563
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA BEH97
UT WOS:000316645700014
PM 23428686
OA No
DA 2017-08-15
ER

PT J
AU van der Merwe, LF
   Moore, SE
   Fulford, AJ
   Halliday, KE
   Drammeh, S
   Young, S
   Prentice, AM
AF van der Merwe, Liandre F.
   Moore, Sophie E.
   Fulford, Anthony J.
   Halliday, Katherine E.
   Drammeh, Saikou
   Young, Stephen
   Prentice, Andrew M.
TI Long-chain PUFA supplementation in rural African infants: a randomized
   controlled trial of effects on gut integrity, growth, and cognitive
   development
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; INTESTINAL PERMEABILITY PROBES;
   INFLAMMATORY BOWEL DISEASES; AUTOMATED ENZYMATIC ASSAYS; DOCOSAHEXAENOIC
   ACID; TERM INFANTS; GAMBIAN INFANTS; HUMAN-MILK;
   ENVIRONMENTAL-ENTEROPATHY; TROPICAL ENTEROPATHY
AB Background: Intestinal damage and malabsorption caused by chronic environmental enteropathy are associated with growth faltering seen in infants in less-developed countries. Evidence has suggested that supplementary omega-3 (n-3) long-chain PUFAs (LC-PUFAs) might ameliorate this damage by reducing gastrointestinal inflammation. LC-PUFA supplementation may also benefit cognitive development.
   Objective: We tested whether early n-3 LC-PUFA supplementation improves infant intestinal integrity, growth, and cognitive function.
   Design: A randomized, double-blind, controlled trial [200 mg DHA and 300 mg EPA or 2 mL olive oil/d for 6 mo] was conducted in a population of 172 rural Gambian infants aged 3-9 mo. The primary endpoints were anthropometric measures and gut integrity [assessed by using urinary lactulose:mannitol ratios (LMRs)]. Plasma fatty acid status, intestinal mucosal inflammation (fecal calprotectin), daily morbidity, and cognitive development (2-step means-end test and an attention assessment) were secondary endpoints.
   Results: PUFA supplementation resulted in a significant increase in plasma n-3 LC-PUFA concentrations (P < 0.001 for both DHA and EPA) and midupper arm circumference (MUAC) (effect size: 0.31 z scores; 95% CI: 0.06, 0.56; P = 0.017) at 9 mo of age. At 12 mo, MUAC remained greater in the intervention group, and we observed significant increases in skinfold thicknesses (P <= 0.022 for all). No other significant differences between treatment groups were detected for growth or LMRs at 9 mo or for secondary outcomes.
   Conclusions: Fish-oil supplementation successfully increased plasma n-3 fatty acid status. However, in young; breastfed Gambian infants, the intervention failed to improve linear growth, intestinal integrity, morbidity, or selected measures of cognitive development. The trial was registered at www.isrctn.org as ISRCTN66645725. Am J Clin Nutr 2013;97:45-57.
C1 [van der Merwe, Liandre F.; Moore, Sophie E.; Fulford, Anthony J.; Prentice, Andrew M.] Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Halliday, Katherine E.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England.
   [van der Merwe, Liandre F.; Moore, Sophie E.; Fulford, Anthony J.; Drammeh, Saikou; Prentice, Andrew M.] MRC Keneba, Keneba, Gambia.
   [Young, Stephen] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM andrew.prentice@lshtm.ac.uk
FU UK Medical Research Council [MC-A760-5QX00]; Overseas Research Students
   Awards Scheme; Ernest Oppenheimer Memorial Trust
FX Supported by the UK Medical Research Council (MC-A760-5QX00), the
   Overseas Research Students Awards Scheme, and the Ernest Oppenheimer
   Memorial Trust. Nordic Naturals kindly donated all supplement and
   control oils.
CR Beaton G H, 1982, Am J Clin Nutr, V35, P863
   BEHRENS RH, 1984, CLIN CHIM ACTA, V137, P361, DOI 10.1016/0009-8981(84)90125-6
   BEHRENS RH, 1987, AM J CLIN NUTR, V45, P1433
   Belluzzi A, 2000, AM J CLIN NUTR, V71, p339S
   Belluzzi A, 2002, P NUTR SOC, V61, P391, DOI 10.1079/PNS2002171
   Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311
   Birch EE, 1998, PEDIATR RES, V44, P201, DOI 10.1203/00006450-199808000-00011
   Brenna JT, 2007, AM J CLIN NUTR, V85, P1457
   Brown JL, 1996, SCI AM, V274, P38
   Calder PC, 2002, P NUTR SOC, V61, P345, DOI 10.1079/PNS2002166
   Calder PC, 2008, MOL NUTR FOOD RES, V52, P885, DOI 10.1002/mnfr.200700289
   Calder PC, 2006, PROSTAG LEUKOTR ESS, V75, P197, DOI 10.1016/j.plefa.2006.05.012
   Carlson SE, 1996, LIPIDS, V31, P85, DOI 10.1007/BF02522416
   Clements KA, 2003, DEV PSYCHOBIOL, V43, P57, DOI 10.1002/dev.10121
   Colombo J, 2004, CHILD DEV, V75, P1254, DOI 10.1111/j.1467-8624.2004.00737.x
   Darboe MK, 2007, LANCET, V369, P2088, DOI 10.1016/S0140-6736(07)60981-7
   Dewey KG, 2008, MATERN CHILD NUTR, V4, P24, DOI 10.1111/j.1740-8709.2007.00124.x
   FAGUNDESNETO U, 1984, J TROP PEDIATRICS, V30, P204
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   FORD RPK, 1985, J PEDIATR GASTR NUTR, V4, P568, DOI 10.1097/00005176-198508000-00012
   Forsyth JS, 1998, BIOCHEM SOC T, V26, P252
   Gamoh S, 1999, NEUROSCIENCE, V93, P237, DOI 10.1016/S0306-4522(99)00107-4
   Gamoh S, 2001, CLIN EXP PHARMACOL P, V28, P266, DOI 10.1046/j.1440-1681.2001.03437.x
   Gardner JM, 2003, J PEDIATR-US, V143, P634, DOI 10.1067/S0022-3476(03)00455-4
   Goto K, 1999, J PEDIATR GASTR NUTR, V28, P282, DOI 10.1097/00005176-199903000-00013
   Goto R, 2002, BRIT J NUTR, V88, P141, DOI 10.1079/BJN2002599
   Grantham-McGregor S. M., 2000, Food and Nutrition Bulletin, V21, P76
   Haghighi P, 1997, CRIT REV CL LAB SCI, V34, P313, DOI 10.3109/10408369708998096
   Helland IB, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.1.e39
   Helland IB, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.5.e82
   Hoare S, 1996, BRIT J NUTR, V76, P479, DOI 10.1079/BJN19960057
   Innis SM, 2001, J PEDIATR-US, V139, P532, DOI 10.1067/mpd.2001.118429
   Judge MP, 2007, AM J CLIN NUTR, V85, P1572
   Koletzko B, 2008, J PERINAT MED, V36, P5, DOI 10.1515/JPM.2008.001
   KUPFERMANN I, 1975, ANNU REV PSYCHOL, V26, P367, DOI 10.1146/annurev.ps.26.020175.002055
   Labenthal E, 1986, CHRONIC DIARRHEA CHI, P5
   Lapillonne A, 2000, EUR J PEDIATR, V159, P49, DOI 10.1007/s004310050009
   Lapillonne A, 2001, LIPIDS, V36, P901, DOI 10.1007/s11745-001-0800-y
   Lapillonne A, 2004, CURR OPIN CLIN NUTR, V7, P151, DOI 10.1097/00075197-200403000-00008
   Lauritzen L, 2005, REPROD NUTR DEV, V45, P535, DOI 10.1051/rnd:2005044
   LUNN PG, 1989, CLIN CHIM ACTA, V183, P163, DOI 10.1016/0009-8981(89)90332-X
   LUNN PG, 1992, CLIN CHIM ACTA, V205, P151, DOI 10.1016/S0009-8981(05)80011-7
   Lunn PG, 2000, P NUTR SOC, V59, P147, DOI 10.1017/S0029665100000173
   LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   Makrides M, 1996, LIPIDS, V31, P115, DOI 10.1007/BF02522420
   Makrides M, 2011, MATERN CHILD NUTR, V7, P80, DOI 10.1111/j.1740-8709.2011.00304.x
   McKay S, 2010, INT HEALTH, V2, P172, DOI 10.1016/j.inhe.2010.07.006
   Mendez MA, 1999, J NUTR, V129, P1555
   Menzies IS, 1999, GUT, V44, P483
   Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x
   Moriguchi T, 2003, J NEUROCHEM, V87, P297, DOI 10.1046/j.1471-4159.2003.01966.x
   NEUMANN C, 1991, PEDIATRICS, V88, P934
   Noetzel M, 2001, J MOL NEUROSCI, V16, P317
   NORTHROP CA, 1990, CLIN CHIM ACTA, V187, P79, DOI 10.1016/0009-8981(90)90333-N
   NorthropClewes CA, 1997, J PEDIATR GASTR NUTR, V24, P257, DOI 10.1097/00005176-199703000-00005
   PEARSON ADJ, 1982, BRIT MED J, V285, P20
   POWELL CA, 1995, ACTA PAEDIATR, V84, P22, DOI 10.1111/j.1651-2227.1995.tb13479.x
   Prentice AM, 2000, AM J CLIN NUTR S, V72, P1253
   Reisbick S, 1997, DEV PSYCHOL, V33, P387
   Rugtveit J, 2002, J PEDIATR GASTR NUTR, V34, P323, DOI 10.1097/00005176-200203000-00022
   Rugtveit J, 2002, J PEDIAT GASTROENTER, V34, P324
   Salem N, 2001, J MOL NEUROSCI, V16, P299, DOI 10.1385/JMN:16:2-3:299
   SCHROEDER DG, 1994, B WORLD HEALTH ORGAN, V72, P569
   Simmer K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000376.pub2
   Simmer K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000375.pub3
   Simmer K., 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858
   SULLIVAN PB, 1991, ACTA PAEDIATR SCAND, V80, P1025
   SULLIVAN PB, 1992, J PEDIATR GASTR NUTR, V14, P208, DOI 10.1097/00005176-199202000-00016
   Teitelbaum JE, 2001, J NUTR BIOCHEM, V12, P21, DOI 10.1016/S0955-2863(00)00141-8
   THOMAS G, 1976, GUT, V17, P888, DOI 10.1136/gut.17.11.888
   Tofail F, 2008, AM J CLIN NUTR, V87, P704
   Whaley SE, 1998, J DEV BEHAV PEDIATR, V19, P169, DOI 10.1097/00004703-199806000-00004
   WHO Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA
   WHO Multicentre Growth Reference Study Group, 2006, ACTA PAEDIATR, V95, P5
   Wiggins R C, 1982, Brain Res, V257, P151
   Willatts P, 1999, DEV PSYCHOL, V35, P651
   Willatts P, 1998, LIPIDS, V33, P973, DOI 10.1007/s11745-998-0294-7
   Willatts P, 1998, LANCET, V352, P688, DOI 10.1016/S0140-6736(97)11374-5
   Willatts P, 1989, INFANT DEV, P143
   Willatts P., 1997, INFANT DEV RECENT AD, P109
   Williams EA, 2007, AM J CLIN NUTR, V86, P421
   Yuhas R, 2006, LIPIDS, V41, P851, DOI 10.1007/s11745-006-5040-7
NR 83
TC 29
Z9 29
U1 5
U2 34
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JAN
PY 2013
VL 97
IS 1
BP 45
EP 57
DI 10.3945/ajcn.112.042267
PG 13
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 065GD
UT WOS:000313135600008
PM 23221579
OA No
DA 2017-08-15
ER

PT J
AU Horikoshi, M
   Yaghootkar, H
   Mook-Kanamori, DO
   Sovio, U
   Taal, HR
   Hennig, BJ
   Bradfield, JP
   St Pourcain, B
   Evans, DM
   Charoen, P
   Kaakinen, M
   Cousminer, DL
   Lehtimaki, T
   Kreiner-Moller, E
   Warrington, NM
   Bustamante, M
   Feenstra, B
   Berry, DJ
   Thiering, E
   Pfab, T
   Barton, SJ
   Shields, BM
   Kerkhof, M
   van Leeuwen, EM
   Fulford, AJ
   Kutalik, Z
   Zhao, JH
   den Hoed, M
   Mahajan, A
   Lindi, V
   Goh, LK
   Hottenga, JJ
   Wu, Y
   Raitakari, OT
   Harder, MN
   Meirhaeghe, A
   Ntalla, I
   Salem, RM
   Jameson, KA
   Zhou, KX
   Monies, DM
   Lagou, V
   Kirin, M
   Heikkinen, J
   Adair, LS
   Alkuraya, FS
   Al-Odaib, A
   Amouyel, P
   Andersson, EA
   Bennett, AJ
   Blakemore, AIF
   Buxton, JL
   Dallongeville, J
   Das, S
   de Geus, EJC
   Estivill, X
   Flexeder, C
   Froguel, P
   Geller, F
   Godfrey, KM
   Gottrand, F
   Groves, CJ
   Hansen, T
   Hirschhorn, JN
   Hofman, A
   Hollegaard, MV
   Hougaard, DM
   Hypponen, E
   Inskip, HM
   Isaacs, A
   Jorgensen, T
   Kanaka-Gantenbein, C
   Kemp, JP
   Kiess, W
   Kilpelainen, TO
   Klopp, N
   Knight, BA
   Kuzawa, CW
   McMahon, G
   Newnham, JP
   Niinikoski, H
   Oostra, BA
   Pedersen, L
   Postma, DS
   Ring, SM
   Rivadeneira, F
   Robertson, NR
   Sebert, S
   Simell, O
   Slowinski, T
   Tiesler, CMT
   Tonjes, A
   Vaag, A
   Viikari, JS
   Vink, JM
   Vissing, NH
   Wareham, NJ
   Willemsen, G
   Witte, DR
   Zhang, HT
   Zhao, JH
   Wilson, JF
   Stumvoll, M
   Prentice, AM
   Meyer, BF
   Pearson, ER
   Boreham, CAG
   Cooper, C
   Gillman, MW
   Dedoussis, GV
   Moreno, LA
   Pedersen, O
   Saarinen, M
   Mohlke, KL
   Boomsma, DI
   Saw, SM
   Lakka, TA
   Korner, A
   Loos, RJF
   Ong, KK
   Vollenweider, P
   van Duijn, CM
   Koppelman, GH
   Hattersley, AT
   Holloway, JW
   Hocher, B
   Heinrich, J
   Power, C
   Melbye, M
   Guxens, M
   Pennell, CE
   Bonnelykke, K
   Bisgaard, H
   Eriksson, JG
   Widen, E
   Hakonarson, H
   Uitterlinden, AG
   Pouta, A
   Lawlor, DA
   Smith, GD
   Frayling, TM
   McCarthy, MI
   Grant, SFA
   Jaddoe, VWV
   Jarvelin, MR
   Timpson, NJ
   Prokopenko, I
   Freathy, RM
AF Horikoshi, Momoko
   Yaghootkar, Hanieh
   Mook-Kanamori, Dennis O.
   Sovio, Ulla
   Taal, H. Rob
   Hennig, Branwen J.
   Bradfield, Jonathan P.
   St Pourcain, Beate
   Evans, David M.
   Charoen, Pimphen
   Kaakinen, Marika
   Cousminer, Diana L.
   Lehtimaki, Terho
   Kreiner-Moller, Eskil
   Warrington, Nicole M.
   Bustamante, Mariona
   Feenstra, Bjarke
   Berry, Diane J.
   Thiering, Elisabeth
   Pfab, Thiemo
   Barton, Sheila J.
   Shields, Beverley M.
   Kerkhof, Marjan
   van Leeuwen, Elisabeth M.
   Fulford, Anthony J.
   Kutalik, Zoltan
   Zhao, Jing Hua
   den Hoed, Marcel
   Mahajan, Anubha
   Lindi, Virpi
   Goh, Liang-Kee
   Hottenga, Jouke-Jan
   Wu, Ying
   Raitakari, Olli T.
   Harder, Marie N.
   Meirhaeghe, Aline
   Ntalla, Ioanna
   Salem, Rany M.
   Jameson, Karen A.
   Zhou, Kaixin
   Monies, Dorota M.
   Lagou, Vasiliki
   Kirin, Mirna
   Heikkinen, Jani
   Adair, Linda S.
   Alkuraya, Fowzan S.
   Al-Odaib, Ali
   Amouyel, Philippe
   Andersson, Ehm Astrid
   Bennett, Amanda J.
   Blakemore, Alexandra I. F.
   Buxton, Jessica L.
   Dallongeville, Jean
   Das, Shikta
   de Geus, Eco J. C.
   Estivill, Xavier
   Flexeder, Claudia
   Froguel, Philippe
   Geller, Frank
   Godfrey, Keith M.
   Gottrand, Frederic
   Groves, Christopher J.
   Hansen, Torben
   Hirschhorn, Joel N.
   Hofman, Albert
   Hollegaard, Mads V.
   Hougaard, David M.
   Hyppoenen, Elina
   Inskip, Hazel M.
   Isaacs, Aaron
   Jorgensen, Torben
   Kanaka-Gantenbein, Christina
   Kemp, John P.
   Kiess, Wieland
   Kilpelainen, Tuomas O.
   Klopp, Norman
   Knight, Bridget A.
   Kuzawa, Christopher W.
   McMahon, George
   Newnham, John P.
   Niinikoski, Harri
   Oostra, Ben A.
   Pedersen, Louise
   Postma, Dirkje S.
   Ring, Susan M.
   Rivadeneira, Fernando
   Robertson, Neil R.
   Sebert, Sylvain
   Simell, Olli
   Slowinski, Torsten
   Tiesler, Carla M. T.
   Toenjes, Anke
   Vaag, Allan
   Viikari, Jorma S.
   Vink, Jacqueline M.
   Vissing, Nadja Hawwa
   Wareham, Nicholas J.
   Willemsen, Gonneke
   Witte, Daniel R.
   Zhang, Haitao
   Zhao, Jianhua
   Wilson, James F.
   Stumvoll, Michael
   Prentice, Andrew M.
   Meyer, Brian F.
   Pearson, Ewan R.
   Boreham, Colin A. G.
   Cooper, Cyrus
   Gillman, Matthew W.
   Dedoussis, George V.
   Moreno, Luis A.
   Pedersen, Oluf
   Saarinen, Maiju
   Mohlke, Karen L.
   Boomsma, Dorret I.
   Saw, Seang-Mei
   Lakka, Timo A.
   Koerner, Antje
   Loos, Ruth J. F.
   Ong, Ken K.
   Vollenweider, Peter
   van Duijn, Cornelia M.
   Koppelman, Gerard H.
   Hattersley, Andrew T.
   Holloway, John W.
   Hocher, Berthold
   Heinrich, Joachim
   Power, Chris
   Melbye, Mads
   Guxens, Monica
   Pennell, Craig E.
   Bonnelykke, Klaus
   Bisgaard, Hans
   Eriksson, Johan G.
   Widen, Elisabeth
   Hakonarson, Hakon
   Uitterlinden, Andre G.
   Pouta, Anneli
   Lawlor, Debbie A.
   Smith, George Davey
   Frayling, Timothy M.
   McCarthy, Mark I.
   Grant, Struan F. A.
   Jaddoe, Vincent W. V.
   Jarvelin, Marjo-Riitta
   Timpson, Nicholas J.
   Prokopenko, Inga
   Freathy, Rachel M.
CA MAGIC
   Early Growth Genetics EGG
TI New loci associated with birth weight identify genetic links between
   intrauterine growth and adult height and metabolism
SO NATURE GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; TYPE-2 DIABETES RISK; SUSCEPTIBILITY LOCI;
   COMMON VARIANTS; BLOOD-PRESSURE; FASTING GLUCOSE; HEAD CIRCUMFERENCE;
   GLUCOKINASE GENE; METAANALYSIS; INDIVIDUALS
AB Birth weight within the normal range is associated with a variety of adult-onset diseases, but the mechanisms behind these associations are poorly understood(1). Previous genome-wide association studies of birth weight identified a variant in the ADCY5 gene associated both with birth weight and type 2 diabetes and a second variant, near CCNL1, with no obvious link to adult traits(2). In an expanded genome-wide association metaanalysis and follow-up study of birth weight (of up to 69,308 individuals of European descent from 43 studies), we have now extended the number of loci associated at genome-wide significance to 7, accounting for a similar proportion of variance as maternal smoking. Five of the loci are known to be associated with other phenotypes: ADCY5 and CDKAL1 with type 2 diabetes, ADRB1 with adult blood pressure and HMGA2 and LCORL with adult height. Our findings highlight genetic links between fetal growth and postnatal growth and metabolism.
C1 [Horikoshi, Momoko; Lagou, Vasiliki; Bennett, Amanda J.; Groves, Christopher J.; McCarthy, Mark I.; Prokopenko, Inga] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
   [Horikoshi, Momoko; Mahajan, Anubha; Lagou, Vasiliki; Robertson, Neil R.; McCarthy, Mark I.; Prokopenko, Inga] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Yaghootkar, Hanieh; Frayling, Timothy M.; Freathy, Rachel M.] Univ Exeter, Peninsula Coll Med & Dent, Exeter, Devon, England.
   [Mook-Kanamori, Dennis O.; Taal, H. Rob; Hofman, Albert; Jaddoe, Vincent W. V.] Erasmus MC, Generat Study Grp R, Rotterdam, Netherlands.
   [Mook-Kanamori, Dennis O.; Taal, H. Rob; Hofman, Albert; Rivadeneira, Fernando; Uitterlinden, Andre G.; Jaddoe, Vincent W. V.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Mook-Kanamori, Dennis O.; Taal, H. Rob; Jaddoe, Vincent W. V.] Erasmus MC, Dept Paediat, Rotterdam, Netherlands.
   [Mook-Kanamori, Dennis O.] Weill Cornell Med Coll Qatar, Dept Physiol & Biophys, Doha, Qatar.
   [Sovio, Ulla; Charoen, Pimphen; Das, Shikta; Sebert, Sylvain; Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England.
   [Sovio, Ulla] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Med Stat, London WC1, England.
   [Hennig, Branwen J.; Fulford, Anthony J.; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   [Hennig, Branwen J.; Fulford, Anthony J.; Prentice, Andrew M.] MRC Keneba, Med Res Council Labs, Banjul, Gambia.
   [Bradfield, Jonathan P.; Zhang, Haitao; Hakonarson, Hakon; Grant, Struan F. A.] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA.
   [St Pourcain, Beate; Evans, David M.; Kemp, John P.; McMahon, George; Lawlor, Debbie A.; Smith, George Davey; Timpson, Nicholas J.; Freathy, Rachel M.] Univ Bristol, Sch Social & Community Med, MRC Ctr Causal Anal Translat Epidemiol CAiTE, Bristol, Avon, England.
   [Charoen, Pimphen] Mahidol Univ, Fac Trop Med, Dept Trop Hyg, Bangkok, Thailand.
   [Kaakinen, Marika; Sebert, Sylvain; Jarvelin, Marjo-Riitta] Univ Oulu, Inst Hlth Sci, Oulu, Finland.
   [Kaakinen, Marika; Jarvelin, Marjo-Riitta] Univ Oulu, Bioctr Oulu, Oulu, Finland.
   [Cousminer, Diana L.; Heikkinen, Jani; Widen, Elisabeth] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland.
   [Lehtimaki, Terho] Univ Tampere, Dept Clin Chem, FIN-33101 Tampere, Finland.
   [Lehtimaki, Terho] Tampere Univ Hosp, Dept Clin Chem, Fimlab Labs, FIN-33521 Tampere, Finland.
   [Kreiner-Moller, Eskil; Pedersen, Louise; Vissing, Nadja Hawwa; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Fac Hlth Sci, Copenhagen Prospect Studies Asthma Childhood COPS, Copenhagen, Denmark.
   [Kreiner-Moller, Eskil; Pedersen, Louise; Vissing, Nadja Hawwa; Bonnelykke, Klaus; Bisgaard, Hans] Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Copenhagen, Denmark.
   [Warrington, Nicole M.; Newnham, John P.; Pennell, Craig E.] Univ Western Australia, Sch Womens & Infants Hlth, Perth, WA 6009, Australia.
   [Bustamante, Mariona; Guxens, Monica] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.
   [Bustamante, Mariona; Guxens, Monica] Hosp del Mar Res Inst IMIM, Barcelona, Spain.
   [Bustamante, Mariona; Estivill, Xavier; Guxens, Monica] Ctr Invest Biomed Red Epidemiol & Salud Publ CIBE, Barcelona, Spain.
   [Bustamante, Mariona; Estivill, Xavier] Pompeu Fabra Univ, Barcelona, Spain.
   [Bustamante, Mariona; Estivill, Xavier] CRG, Genes & Dis Program, Barcelona, Spain.
   [Feenstra, Bjarke; Geller, Frank; Melbye, Mads] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.
   [Berry, Diane J.; Hyppoenen, Elina; Power, Chris] UCL, Ctr Paediat Epidemiol & Biostat, MRC Ctr Epidemiol Child Hlth, Inst Child Hlth, London, England.
   [Thiering, Elisabeth; Flexeder, Claudia; Tiesler, Carla M. T.; Heinrich, Joachim] German Res Ctr Environm Hlth, Helmholtz Zentrum Muenchen, Inst Epidemiol 1, Munich, Germany.
   [Pfab, Thiemo] Charite, Med Klin Nephrol, D-13353 Berlin, Germany.
   [Pfab, Thiemo; Hocher, Berthold] Univ Potsdam, Inst Nutr Sci, Potsdam, Germany.
   [Barton, Sheila J.; Jameson, Karen A.; Godfrey, Keith M.; Inskip, Hazel M.; Cooper, Cyrus] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
   [Shields, Beverley M.; Knight, Bridget A.; Hattersley, Andrew T.] Royal Devon & Exeter Natl Hlth Serv NHS Fdn Trust, Exeter, Devon, England.
   [Shields, Beverley M.; Knight, Bridget A.; Hattersley, Andrew T.] Univ Exeter, Peninsula Natl Inst Hlth Res NIHR Clin Res Facil, Peninsula Coll Med & Dent, Exeter, Devon, England.
   [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.
   [van Leeuwen, Elisabeth M.; Isaacs, Aaron; van Duijn, Cornelia M.] Erasmus Univ, Med Ctr, Genet Epidemiol Unit, Dept Epidemiol, Rotterdam, Netherlands.
   [Kutalik, Zoltan] Univ Lausanne, Dept Med Genet, Lausanne, Switzerland.
   [Kutalik, Zoltan] Swiss Inst Bioinformat, Geneva, Switzerland.
   [Kutalik, Zoltan] Swiss Inst Bioinformat, Lausanne, Switzerland.
   [Kutalik, Zoltan] Swiss Inst Bioinformat, Basel, Switzerland.
   [Kutalik, Zoltan] Swiss Inst Bioinformat, Bern, Switzerland.
   [Kutalik, Zoltan] Swiss Inst Bioinformat, Zurich, Switzerland.
   [Zhao, Jing Hua; den Hoed, Marcel; Kilpelainen, Tuomas O.; Wareham, Nicholas J.; Loos, Ruth J. F.; Ong, Ken K.] Addenbrookes Hosp, MRC Epidemiol Unit, Inst Metab Sci, Cambridge, England.
   [Lindi, Virpi; Kilpelainen, Tuomas O.; Lakka, Timo A.] Univ Eastern Finland, Dept Physiol, Inst Biomed, Kuopio, Finland.
   [Goh, Liang-Kee; Saw, Seang-Mei] Duke Natl Univ Singapore NUS, Grad Sch Med, Singapore, Singapore.
   [Goh, Liang-Kee; Saw, Seang-Mei] NUS, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Hottenga, Jouke-Jan; de Geus, Eco J. C.; Vink, Jacqueline M.; Willemsen, Gonneke; Boomsma, Dorret I.] Vrije Univ VU Amsterdam, Dept Biol Psychol, Amsterdam, Netherlands.
   [Wu, Ying; Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
   [Raitakari, Olli T.; Simell, Olli; Saarinen, Maiju] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland.
   [Raitakari, Olli T.; Niinikoski, Harri; Simell, Olli; Viikari, Jorma S.] Turku Univ Hosp, FIN-20520 Turku, Finland.
   [Raitakari, Olli T.] Univ Turku, Dept Clin Physiol & Nucl Med, Turku, Finland.
   [Harder, Marie N.; Andersson, Ehm Astrid; Hansen, Torben; Kilpelainen, Tuomas O.; Pedersen, Oluf] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Fac Hlth Sci, Copenhagen, Denmark.
   [Meirhaeghe, Aline; Amouyel, Philippe; Dallongeville, Jean] INSERM, U744, F-59045 Lille, France.
   [Meirhaeghe, Aline; Amouyel, Philippe; Dallongeville, Jean; Froguel, Philippe] Inst Pasteur, F-59019 Lille, France.
   [Meirhaeghe, Aline; Amouyel, Philippe; Dallongeville, Jean; Froguel, Philippe] Univ Lille Nord France, Lille, France.
   [Meirhaeghe, Aline; Amouyel, Philippe; Dallongeville, Jean] Univ Lille 2, Lille, France.
   [Ntalla, Ioanna; Dedoussis, George V.] Harokopio Univ Athens, Dept Dietet Nutr, Athens, Greece.
   [Salem, Rany M.; Hirschhorn, Joel N.] Childrens Hosp, Div Genet, Boston, MA 02115 USA.
   [Salem, Rany M.; Hirschhorn, Joel N.] Broad Inst, Metab Program, Cambridge, MA USA.
   [Salem, Rany M.; Hirschhorn, Joel N.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Salem, Rany M.; Hirschhorn, Joel N.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
   [Salem, Rany M.; Hirschhorn, Joel N.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
   [Salem, Rany M.; Hirschhorn, Joel N.] Childrens Hosp, Program Genom, Boston, MA 02115 USA.
   [Zhou, Kaixin; Pearson, Ewan R.] Univ Dundee, Med Res Inst, Dundee, Scotland.
   [Monies, Dorota M.; Alkuraya, Fowzan S.; Al-Odaib, Ali; Meyer, Brian F.] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh 11211, Saudi Arabia.
   [Kirin, Mirna; Wilson, James F.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland.
   [Adair, Linda S.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA.
   [Alkuraya, Fowzan S.] King Khalid Eye Specialist Hosp, Dept Pediat, Riyadh, Saudi Arabia.
   [Alkuraya, Fowzan S.] Alfaisal Univ, Coll Med, Dept Anat & Cell Biol, Riyadh, Saudi Arabia.
   [Blakemore, Alexandra I. F.; Buxton, Jessica L.] Univ London Imperial Coll Sci Technol & Med, Sect Invest Med, Div Diabet Endocrinol & Metab, London, England.
   [Estivill, Xavier] UPF, Dept Expt & Hlth Sci, Barcelona, Spain.
   [Froguel, Philippe] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Hammersmith Hosp, London, England.
   [Godfrey, Keith M.] Univ Southampton, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England.
   [Godfrey, Keith M.] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England.
   [Gottrand, Frederic] Univ Lille 2, Fac Med, INSERM U995, Lille, France.
   [Hansen, Torben] Univ So Denmark, Fac Hlth Sci, Odense, Denmark.
   [Hollegaard, Mads V.; Hougaard, David M.] Statens Serum Inst, Dept Clin Biochem & Immunol, DK-2300 Copenhagen, Denmark.
   [Isaacs, Aaron] Ctr Med Syst Biol, Leiden, Netherlands.
   [Jorgensen, Torben] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark.
   [Jorgensen, Torben] Univ Copenhagen, Fac Hlth Sci, Dept Publ Hlth, Copenhagen, Denmark.
   [Kanaka-Gantenbein, Christina] Univ Athens, Sch Med, Div Endocrinol Diabetol & Metab, Aghia Sophia Childrens Hosp,Dept Pediat 1, GR-11527 Athens, Greece.
   [Kiess, Wieland; Koerner, Antje] Univ Leipzig, Dept Womens & Child Hlth, Pediat Res Ctr, Leipzig, Germany.
   [Klopp, Norman] German Res Ctr Environm Hlth, Helmholtz Zentrum Muenchen, Res Unit Mol Epidemiol, Munich, Germany.
   [Klopp, Norman] Hannover Med Sch, Hannover Unified Biobank, D-3000 Hannover, Germany.
   [Kuzawa, Christopher W.] Northwestern Univ, Dept Anthropol, Evanston, IL 60208 USA.
   [Kuzawa, Christopher W.] Northwestern Univ, Cells Soc Ctr Social Dispar & Hlth 2, Inst Policy Res, Evanston, IL USA.
   [Niinikoski, Harri; Simell, Olli] Univ Turku, Dept Pediat, Turku, Finland.
   [Oostra, Ben A.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
   [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, GRIAC,Res Inst, Groningen, Netherlands.
   [Ring, Susan M.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
   [Rivadeneira, Fernando; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Slowinski, Torsten] Charite, Med Klin Schwerpunkt Nephrol, D-13353 Berlin, Germany.
   [Tiesler, Carla M. T.] Univ Munich, Div Metab Dis & Nutr Med, Dr von Hauner Childrens Hosp, Munich, Germany.
   [Toenjes, Anke; Stumvoll, Michael] Univ Leipzig, Dept Med, Leipzig, Germany.
   [Toenjes, Anke; Stumvoll, Michael; Koerner, Antje] Univ Leipzig, Integrierte Forsch & Behandlungszentren IFB Adipo, Leipzig, Germany.
   [Vaag, Allan] Rigshosp, Dept Endocrinol, DK-2100 Copenhagen, Denmark.
   [Vaag, Allan; Witte, Daniel R.] Steno Diabet Ctr, Gentofte, Denmark.
   [Viikari, Jorma S.] Univ Turku, Dept Med, Turku, Finland.
   [Zhao, Jianhua; Hakonarson, Hakon; Grant, Struan F. A.] Childrens Hosp Philadelphia, Dept Human Genet, Philadelphia, PA 19104 USA.
   [Wilson, James F.] Univ Edinburgh, Western Gen Hosp, MRC Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland.
   [Boreham, Colin A. G.] Univ Coll Dublin, Inst Sport & Hlth, Dublin 2, Ireland.
   [Gillman, Matthew W.] Harvard Univ, Sch Med, Obes Prevent Program, Dept Populat Med,Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
   [Moreno, Luis A.] Univ Zaragoza, Escuela Univ Ciencias Salud, Growth Exercise Nutr & Dev GENUD Res Grp, Zaragoza, Spain.
   [Pedersen, Oluf] Univ Copenhagen, Inst Biomed Sci, Fac Hlth Sci, Copenhagen, Denmark.
   [Pedersen, Oluf] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark.
   [Pedersen, Oluf] Hagedorn Res Inst, Gentofte, Denmark.
   [Saw, Seang-Mei] Singapore Eye Res Inst, Singapore, Singapore.
   [Lakka, Timo A.] Kuopio Res Inst Exercise Med, Kuopio, Finland.
   [Vollenweider, Peter] CHU Vaudois, Dept Med, Lausanne, Switzerland.
   [Vollenweider, Peter] Fac Biol & Med, Lausanne, Switzerland.
   [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Groningen, Netherlands.
   [Holloway, John W.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England.
   [Hocher, Berthold] Charite, Inst Pharmacol, Cardiovasc Res Ctr, Berlin, Germany.
   [Eriksson, Johan G.] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland.
   [Eriksson, Johan G.] Univ Helsinki, Cent Hosp, Unit Gen Practice, Helsinki, Finland.
   [Eriksson, Johan G.] Folkhalsan Res Ctr, Helsinki, Finland.
   [Eriksson, Johan G.] Vaasa Cent Hosp, Vaasa, Finland.
   [Eriksson, Johan G.; Jarvelin, Marjo-Riitta] Natl Inst Hlth & Welf, Dept Hlth Promot & Chron Dis Prevent, Helsinki, Finland.
   [Hakonarson, Hakon; Grant, Struan F. A.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
   [Pouta, Anneli] Natl Inst Hlth & Welf, Dept Lifecourse & Serv, Oulu, Finland.
   [Pouta, Anneli] Univ Oulu, Inst Clin Med Obstet & Gynaecol, Oulu, Finland.
   [McCarthy, Mark I.] Churchill Hosp, Oxford NIHR Biomed Res Ctr, Oxford OX3 7LJ, England.
   [Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Hlth Protect Agcy HPA MRC Ctr, Sch Publ Hlth, London, England.
RP McCarthy, MI (reprint author), Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
EM mark.mccarthy@drl.ox.ac.uk; grants@chop.edu; v.jaddoe@erasmusmc.nl;
   m.jarvelin@imperial.ac.uk; n.j.timpson@bristol.ac.uk;
   ingap@well.ox.ac.uk; rachel.freathy@pms.ac.uk
RI Wilson, James F/A-5704-2009; Witte, Daniel/C-1722-2008; Warrington,
   Nicole/P-4868-2014; Meirhaeghe, Aline/E-4663-2015; gottrand,
   frederic/G-7370-2015; Bustamante, Mariona/M-7277-2015; de Geus,
   Eco/M-9318-2015; Rivadeneira, Fernando/O-5385-2015; Prokopenko,
   Inga/H-3241-2014; Fox, Laura /C-6249-2016; Davey Smith,
   George/A-7407-2013; van Leeuwen, Elisabeth/G-3382-2017; Bisgaard,
   Hans/N-4761-2016; den Hoed, Marcel/I-7138-2017; Korner,
   Antje/B-3988-2015; Thiering, Elisabeth/B-3342-2013; Holloway,
   John/B-5424-2009; Kronow, Joern/B-1054-2011; Evans, David/H-6325-2013;
   Colaus, PsyColaus/K-6607-2013; Lagou, Vasiliki/N-8451-2013; Hypponen,
   Elina/B-2596-2014; Buxton, Jessica/I-4033-2014; Wu, Ying/B-7283-2009;
   Estivill, Xavier/A-3125-2013; Hennig, Branwen/M-6444-2014
OI Wilson, James F/0000-0001-5751-9178; Freathy,
   Rachel/0000-0003-4152-2238; Thiering, Elisabeth/0000-0002-5429-9584;
   Barton, Sheila/0000-0003-4963-4242; Kaakinen,
   Marika/0000-0002-9228-0462; Meyer, Brian/0000-0002-0388-9568; Monsalve,
   Beatriz Elena/0000-0002-5994-866X; Hollegaard, Mads
   Vilhelm/0000-0003-1061-0091; Kreiner, Eskil/0000-0003-1204-2438;
   Jorgensen, Torben/0000-0001-9453-2830; Witte,
   Daniel/0000-0002-0769-2922; Warrington, Nicole/0000-0003-4195-775X;
   gottrand, frederic/0000-0002-5290-0436; Bustamante,
   Mariona/0000-0003-0127-2860; de Geus, Eco/0000-0001-6022-2666;
   Rivadeneira, Fernando/0000-0001-9435-9441; Prokopenko,
   Inga/0000-0003-1624-7457; Davey Smith, George/0000-0002-1407-8314;
   Bisgaard, Hans/0000-0003-4131-7592; den Hoed,
   Marcel/0000-0001-8081-428X; Korner, Antje/0000-0001-6001-0356; Holloway,
   John/0000-0001-9998-0464; Hypponen, Elina/0000-0003-3670-9399; Buxton,
   Jessica/0000-0002-0918-9335; Estivill, Xavier/0000-0002-0723-2256;
   Evans, David/0000-0003-0663-4621; St Pourcain,
   Beate/0000-0002-4680-3517; Lakka, Timo/0000-0002-9199-2871; Godfrey,
   Keith/0000-0002-4643-0618; Hattersley, Andrew/0000-0001-5620-473X;
   Newnham, John/0000-0001-9983-7457; Lindi, Virpi/0000-0001-6257-7209;
   Inskip, Hazel/0000-0001-8897-1749; Lawlor, Debbie A/0000-0002-6793-2262;
   Timpson, Nicholas/0000-0002-7141-9189; Saarinen,
   Maiju/0000-0003-3346-3688; Eriksson, Johan/0000-0002-2516-2060; Kemp,
   John/0000-0002-9105-2249; Kilpelainen, Tuomas/0000-0002-8349-3028;
   Moreno Aznar, Luis A./0000-0003-0454-653X; Jarvelin,
   Marjo-Riitta/0000-0002-2149-0630
FU Academy of Finland [126925, 121584, 124282, 129378, 117787, 41071,
   209072, 129255, 104781, 120315, 129269, 1114194, 206374, 251360,
   139900/24300796]; Biocentrum Helsinki; Arthritis Research UK; Augustinus
   Foundation; Biobanking and Biomolecular Resources Research
   Infrastructure (BBMRI-NL); Biomedical Research Council, Singapore [BMRC
   06/1/21/19/466]; BIF: Boehringer Ingelheim Fonds; British Heart
   Foundation; C.G. Sundell Foundation; Canadian Institutes of Health
   Research [MOP-82893]; Cancer Research UK; Chief Scientist Office of the
   Scottish Government; Children's Hospital of Philadelphia (Institute
   Development Award); Conselleria de Sanitat Generalitat Valenciana;
   Copenhagen Graduate School of Health Sciences; Cotswold Foundation
   (Research Development Award); Curtin University and Women and Infants
   Research Foundation; Danish Health Insurance Societies (Health Fund);
   Danish Medical Research Council; Danish National Research Foundation;
   Danish Pediatric Asthma Centre; Danish Pharmacists' Fund; Danish
   Strategic Research Council; Darlington Trust; Department of Health and
   Social Services in Northern Ireland; Deutsche Forschungsgemeinschaft
   (DFG); Diabetes Hilfs-und Forschungsfonds Deutschland (DHFD); Diabetes
   UK [RD08/0003704, RD08/0003692]; Dunhill Medical Trust; Dutch Asthma
   Foundation [3.4.01.26, 3.2.06.022, 3.4.09.081, 3.2.10.085CO]; Dutch
   Ministry of the Environment (EFRE); Europaische Fonds fur Regionale
   Entwicklung (LIFE Child Obesity); Egmont Foundation; Else
   Kroner-Fresenius Foundation; Emil Aaltonen Foundation; ENGAGE project
   [HEALTH-F4-2007-201413]; Erasmus Medical Center; Erasmus University,
   Rotterdam; European Commission [QLG1-CT-2000-01643, 018996,
   LSHG-CT-2006-018947, FOOD-CT-2005-007034]; European Research Council
   (ERC Advanced) [230374]; European Science Foundation (ESF)
   [EU/QLRT-2001-01254]; Exeter NHS Research and Development; Faculty of
   Biology and Medicine of Lausanne; Finnish Foundation of Cardiovascular
   Research; Finnish Cultural Foundation; Finnish Innovation Fund Sitra;
   Finnish Ministry of Education and Culture; Finnish Ministry of Social
   Affairs and Health; Finnish Social Insurance Institution; Foundation for
   Paediatric Research; Fundacio La Marato de TV3; Fundacion Roger Torne;
   Generalitat de Catalunya-Interminesterial Council for Research and
   Technological Innovation (CIRIT) [(1999SGR) 00241]; German Diabetes
   Association; German Bundesministerium fuer Forschung und Technology [01
   AK 803 A-H, 01 IG 07015 G]; German Research Foundation for the Clinical
   Research Group Atherobesity [KO3512/1]; GlaxoSmithKline; Hagedorn
   Research Institute; Instituto de Salud Carlos III [CB06/02/0041, FIS
   PI041436, PI081151, PI041705, PS09/00432, FISFEDER 03/1615, 04/1509,
   04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 07/0314, 09/02647];
   Interdisciplinary Centre for Clinical Research at the University of
   Leipzig [B27]; Integrated Research and Treatment Centre (IFB) Adiposity
   Diseases; Jackstadt-Foundation; Juho Vainio Foundation; Juvenile
   Diabetes Research Foundation International (JDRF); Kuopio, Tampere and
   Turku University Hospital Medical Funds [5031343, 9M048]; Lundbeck
   Foundation; Lundbeck Foundation Centre of Applied Medical Genomics for
   Personalized Disease Prediction, Prevention and Care (LuCAMP); March of
   Dimes Birth Defects Foundation [6-FY09-507]; MRC, UK [74882, G0000934,
   G0601653, G0500539, G0600705, G0601261, G0600331, PrevMetSyn/SALVE
   PS0476, MC-A760-5QX00]; Munich Center of Health Sciences (MC Health);
   National Health and Medical Research Council of Australia [403981,
   003209]; US National Human Genome Research Institute; US National
   Institute of Allergy and Infectious Diseases; US National Institute of
   Child Health and Human Development; US National Institute of Diabetes
   and Digestive and Kidney Diseases (NIDDK); US National Institutes of
   Health [U01DK062418, U01HG004423, U01HG004446, U01HG004438, R01DK075787,
   1R01HD056465-01A, R01D0042157-01A, DK078150, TW05596, HL085144,
   HD054501, RR20649, ES10126, DK56350]; Netherlands Bioinformatics Centre
   (NBIC) BioAssist [RK/2008.024]; National Heart, Lung, and Blood
   Institute (NHLBI) [5R01HL087679-02]; National Heart, Lung, and Blood
   Institute (NHLBI) through the STAMPEED program [1RL1MH083268-01]; NIH
   Genetic Association Information Network (GAIN); NIH/National Institute
   of Mental Health (NIMH) [5R01MH63706: 02, MH081802]; Rutgers University
   Cell and DNA Repository cooperative agreement [NIMH U24 MH068457-06];
   Novo Nordisk Foundation Center for Basic Metabolic Research; Center for
   Medical Systems Biology (CMSB; NWO Genomics); Netherlands Organization
   for Scientific Research (NWO: Social Sciences (MaGW); Netherlands
   Organization for Health Research and Development (ZonMw)
   [Middelgroot-911-09-032, Spinozapremie 56-464-14192, 904-61-090,
   904-61-193, 480-04-004, 400-05-717, Addiction-31160008, 985-10-002,
   40-005698- 9032, 912-03-031]; Paavo Nurmi Foundation; Peninsula NIHR
   Clinical Research Facility; Pharmacy Foundation of 1991; PhD School of
   Molecular Metabolism University of Southern Denmark; Raine Medical
   Research Foundation; Royal Society; Sigrid Juselius Foundation; South
   West NHS Research and Development; Spanish Ministry of Science and
   Innovation [SAF2008-00357]; Turku University Hospital; Swiss National
   Science Foundation [33CSCO-122661]; Tampere Tuberculosis Foundation;
   Telethon Institute for Child Health Research; Turku University
   Foundation; US Centers for Disease Control and Prevention; University
   Hospital Oulu, Biocenter, the University of Oulu [75617]; University of
   Bristol; University of Potsdam; University of Southampton; University of
   Western Australia (UWA); VU Institute for Health and Care Research
   (EMGO+); Neuroscience Campus Amsterdam (NCA); Wellcome Trust [GR069224,
   WT088806, 068545/Z/02, 076467, 085301, 090532, 083270, 083948,
   085541/Z/08/Z, WT089549, WT083431MA]; Yrjo Jahnsson Foundation; Academy
   of Finland (Center of Excellence in Complex Disease Genetics); Academy
   of Finland (SALVE)
FX A complete list of acknowledgments is given in the Supplementary Note.
   Major funding for the research in this paper is provided by the Academy
   of Finland (project grants 126925, 121584, 124282, 129378 (Salve),
   117787 (Gendi), 41071 (Skidi), 209072, 129255, 104781, 120315, 129269,
   1114194, 206374, 251360, 139900/24300796, Center of Excellence in
   Complex Disease Genetics and SALVE) and Biocentrum Helsinki; Arthritis
   Research UK; the Augustinus Foundation; the Biobanking and Biomolecular
   Resources Research Infrastructure (BBMRI-NL); the Biomedical Research
   Council, Singapore (BMRC 06/1/21/19/466); BIF: Boehringer Ingelheim
   Fonds (travel grant to A. T.); the British Heart Foundation; the C.G.
   Sundell Foundation; the Canadian Institutes of Health Research (grant
   MOP-82893); Cancer Research UK; the Chief Scientist Office of the
   Scottish Government; the Children's Hospital of Philadelphia (Institute
   Development Award); Conselleria de Sanitat Generalitat Valenciana; the
   Copenhagen Graduate School of Health Sciences; the Cotswold Foundation
   (Research Development Award); the Curtin University and Women and
   Infants Research Foundation; the Danish Health Insurance Societies
   (Health Fund); the Danish Medical Research Council; the Danish National
   Research Foundation; the Danish Pediatric Asthma Centre; the Danish
   Pharmacists' Fund; the Danish Strategic Research Council; the Darlington
   Trust; the Department of Health and Social Services in Northern Ireland;
   Deutsche Forschungsgemeinschaft (DFG); Diabetes Hilfs-und
   Forschungsfonds Deutschland (DHFD; travel grant to M. Stumvoll);
   Diabetes UK (grants RD08/0003704 and RD08/0003692); the Dunhill Medical
   Trust; the Dutch Asthma Foundation (grants 3.4.01.26, 3.2.06.022,
   3.4.09.081 and 3.2.10.085CO); the Dutch Ministry of the Environment
   (EFRE): Europaische Fonds fur Regionale Entwicklung (LIFE Child
   Obesity); the Egmont Foundation; the Else Kroner-Fresenius Foundation;
   the Emil Aaltonen Foundation (T. L.); the ENGAGE project and grant
   agreement HEALTH-F4-2007-201413; the Erasmus Medical Center; Erasmus
   University, Rotterdam; the European Commission (EURO-BLCS, Beta-JUDO,
   Framework 5 award QLG1-CT-2000-01643, GABRIEL (Integrated Program
   LSH-2004-1.2.5-1 contract 018996), framework programme 6 EUROSPAN
   project (contract LSHG-CT-2006-018947), Sixth Research, Technological
   Development (RTD) Framework Programme (Contract FOOD-CT-2005-007034) and
   Seventh Framework Programme (FP7/2007-2013)); the European Research
   Council (ERC Advanced; 230374); the European Science Foundation (ESF;
   EU/QLRT-2001-01254); the Exeter NHS Research and Development; Faculty of
   Biology and Medicine of Lausanne; the Finnish Foundation of
   Cardiovascular Research; the Finnish Cultural Foundation; the Finnish
   Innovation Fund Sitra; the Finnish Ministry of Education and Culture;
   the Finnish Ministry of Social Affairs and Health; the Finnish Social
   Insurance Institution; the Foundation for Paediatric Research; Fundacio
   La Marato de TV3; Fundacion Roger Torne; Generalitat de
   Catalunya-Interminesterial Council for Research and Technological
   Innovation (CIRIT; 1999SGR) 00241; the German Diabetes Association (A.
   T.); the German Bundesministerium fuer Forschung und Technology (grants
   01 AK 803 A-H and 01 IG 07015 G); the German Research Foundation for the
   Clinical Research Group Atherobesity KFO 152 (KO3512/1 to A. K.; );
   GlaxoSmithKline; the Hagedorn Research Institute; Instituto de Salud
   Carlos III (CB06/02/0041, FIS PI041436, PI081151, PI041705 and
   PS09/00432 and FISFEDER 03/1615, 04/1509, 04/1112, 04/1931, 05/1079,
   05/1052, 06/1213, 07/0314 and 09/02647); the Interdisciplinary Centre
   for Clinical Research at the University of Leipzig (B27 to A. T. and M.
   Stumvoll); the Integrated Research and Treatment Centre (IFB) Adiposity
   Diseases; the Jackstadt-Foundation; the Juho Vainio Foundation; the
   Juvenile Diabetes Research Foundation International (JDRF); Kuopio,
   Tampere and Turku University Hospital Medical Funds (grant 5031343 to T.
   A. Lakka and grant 9M048 to T. L.); The Lundbeck Foundation; the
   Lundbeck Foundation Centre of Applied Medical Genomics for Personalized
   Disease Prediction, Prevention and Care (LuCAMP); the March of Dimes
   Birth Defects Foundation (6-FY09-507); the MRC, UK (grants 74882,
   G0000934, G0601653, G0500539, G0600705, G0601261, G0600331,
   PrevMetSyn/SALVE PS0476 and MC-A760-5QX00); the Munich Center of Health
   Sciences (MC Health); the National Health and Medical Research Council
   of Australia (grants 403981 and 003209); the US National Human Genome
   Research Institute; the US National Institute of Allergy and Infectious
   Diseases; the US National Institute of Child Health and Human
   Development; the US National Institute of Diabetes and Digestive and
   Kidney Diseases (NIDDK); the US National Institutes of Health (grants
   U01DK062418, U01HG004423, U01HG004446, U01HG004438, R01DK075787,
   1R01HD056465-01A, R01D0042157-01A, DK078150, TW05596, HL085144,
   HD054501, RR20649, ES10126, DK56350 and Biomedical Research Centers
   funding); the Netherlands Bioinformatics Centre (NBIC) BioAssist
   (RK/2008.; 024); a National Heart, Lung, and Blood Institute (NHLBI)
   grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01);
   the NIH Genetic Association Information Network (GAIN); the NIH/National
   Institute of Mental Health (NIMH) (5R01MH63706: 02 and MH081802); the
   Rutgers University Cell and DNA Repository cooperative agreement (NIMH
   U24 MH068457-06); the Novo Nordisk Foundation Center for Basic Metabolic
   Research; the Center for Medical Systems Biology (CMSB; NWO Genomics);
   the Netherlands Organization for Scientific Research (NWO: Social
   Sciences (MaGW) and the Netherlands Organization for Health Research and
   Development (ZonMw) (Middelgroot-911-09-032, Spinozapremie 56-464-14192,
   904-61-090, 904-61-193, 480-04-004, 400-05-717, Addiction-31160008,
   985-10-002, 40-005698- 9032 and 912-03-031); the Paavo Nurmi Foundation;
   the Peninsula NIHR Clinical Research Facility; the Pharmacy Foundation
   of 1991; the PhD School of Molecular Metabolism University of Southern
   Denmark; the Raine Medical Research Foundation; the Royal Society; the
   Sigrid Juselius Foundation; South West NHS Research and Development; the
   Spanish Ministry of Science and Innovation (SAF2008-00357), Turku
   University Hospital; the Swiss National Science Foundation
   (33CSCO-122661); the Tampere Tuberculosis Foundation; the Telethon
   Institute for Child Health Research; the Turku University Foundation;
   the US Centers for Disease Control and Prevention; University Hospital
   Oulu, Biocenter, the University of Oulu (75617); the University of
   Bristol; the University of Potsdam; the University of Southampton; the
   University of Western Australia (UWA); the VU Institute for Health and
   Care Research (EMGO+) and the Neuroscience Campus Amsterdam (NCA); the
   Wellcome Trust (grants GR069224, WT088806, 068545/Z/02, 076467, 085301,
   090532, 083270, 083948, 085541/Z/08/Z, WT089549 and WT083431MA); and the
   Yrjo Jahnsson Foundation.
CR Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410
   Altshuler D, 2000, NAT GENET, V26, P76
   Andersson EA, 2010, DIABETOLOGIA, V53, P1908, DOI 10.1007/s00125-010-1790-0
   Aulchenko YS, 2007, BIOINFORMATICS, V23, P1294, DOI 10.1093/bioinformatics/btm108
   Aulchenko YS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-134
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520
   Ehret GB, 2011, NATURE, V478, P103, DOI 10.1038/nature10405
   Freathy RM, 2007, AM J HUM GENET, V80, P1150, DOI 10.1086/518517
   Freathy RM, 2010, DIABETES, V59, P2682, DOI 10.2337/db10-0177
   Freathy RM, 2010, NAT GENET, V42, P430, DOI 10.1038/ng.567
   Freathy RM, 2009, DIABETES, V58, P1428, DOI 10.2337/db08-1739
   Gamborg M, 2007, AM J EPIDEMIOL, V166, P634, DOI 10.1093/aje/kwm042
   Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S
   Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732
   Gudmundsson J, 2007, NAT GENET, V39, P977, DOI 10.1038/ng2062
   Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953
   Hattersley AT, 1999, LANCET, V353, P1789, DOI 10.1016/S0140-6736(98)07546-1
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ikram MA, 2012, NAT GENET, V44, P539, DOI 10.1038/ng.2245
   Johnson AD, 2011, HYPERTENSION, V57, P903, DOI 10.1161/HYPERTENSIONAHA.110.158667
   Kong A, 2009, NATURE, V462, P868, DOI 10.1038/nature08625
   Kooner JS, 2011, NAT GENET, V43, P984, DOI 10.1038/ng.921
   Krestyaninova M, 2009, BIOINFORMATICS, V25, P2768, DOI 10.1093/bioinformatics/btp420
   Lenfant C, 2008, METABOLISM, V57, pS32, DOI 10.1016/j.metabol.2008.07.013
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Magi R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-288
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   Metzger BE, 2008, NEW ENGL J MED, V358, P1991, DOI 10.1056/NEJMoa0707943
   NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x
   Prokopenko I, 2009, NAT GENET, V41, P77, DOI 10.1038/ng.290
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rung J, 2009, NAT GENET, V41, P1110, DOI 10.1038/ng.443
   Sandhu MS, 2007, NAT GENET, V39, P951, DOI 10.1038/ng2067
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Saxena R, 2010, NAT GENET, V42, P142, DOI 10.1038/ng.521
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Sovio U, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000409
   Speliotes EK, 2010, NAT GENET, V42, P937, DOI 10.1038/ng.686
   Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043
   Strawbridge RJ, 2011, DIABETES, V60, P2624, DOI 10.2337/db11-0415
   Taal HR, 2012, NAT GENET, V44, P532, DOI 10.1038/ng.2238
   Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270
   Voight BF, 2010, NAT GENET, V42, P579, DOI 10.1038/ng.609
   Weedon MN, 2008, NAT GENET, V40, P575, DOI 10.1038/ng.121
   Weedon MN, 2005, DIABETES, V54, P576
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Yamauchi T, 2010, NAT GENET, V42, P864, DOI 10.1038/ng.660
   Yang J, 2011, EUR J HUM GENET, V19, P807, DOI 10.1038/ejhg.2011.39
   Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120
   Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364
   Zhao JH, 2009, DIABETES, V58, P2414, DOI 10.2337/db09-0506
NR 53
TC 110
Z9 110
U1 3
U2 42
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD JAN
PY 2013
VL 45
IS 1
BP 76
EP U115
DI 10.1038/ng.2477
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 061HJ
UT WOS:000312838800016
PM 23202124
OA No
DA 2017-08-15
ER

PT J
AU Lin, GM
   Li, YH
   Jaiteh, LES
   Han, CL
AF Lin, Gen-Min
   Li, Yi-Hwei
   Jaiteh, Lamin E. S.
   Han, Chih-Lu
TI B-type natriuretic peptide level and postdischarge thrombotic events in
   older patients hospitalized with heart failure: Insights from the acute
   decompensated heart failure national registry
SO AMERICAN HEART JOURNAL
LA English
DT Letter
ID WARFARIN; ASPIRIN
C1 [Lin, Gen-Min] Hualien Armed Forces Gen Hosp, Dept Med, Hualien, Taiwan.
   [Li, Yi-Hwei] Tzu Chi Univ, Dept Publ Hlth, Hualien, Taiwan.
   [Jaiteh, Lamin E. S.] Dept Royal Victoria Teaching Hosp, Banjul, Gambia.
   [Han, Chih-Lu] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.
RP Lin, GM (reprint author), Hualien Armed Forces Gen Hosp, Dept Med, Hualien, Taiwan.
EM farmer507@yahoo.com.tw
CR Eikelboom JW, 2012, NEW ENGL J MED, V366, P1936, DOI 10.1056/NEJMe1202504
   Homma S, 2012, NEW ENGL J MED, V366, P1859, DOI 10.1056/NEJMoa1202299
   Kociol RD, 2012, AM HEART J, V163, P994, DOI 10.1016/j.ahj.2012.03.009
   Massie BM, 2009, CIRCULATION, V119, P1616, DOI 10.1161/CIRCULATIONAHA.108.801753
NR 4
TC 1
Z9 1
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD JAN
PY 2013
VL 165
IS 1
BP E1
EP E1
DI 10.1016/j.ahj.2012.09.015
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 053LL
UT WOS:000312272900001
PM 23237141
OA No
DA 2017-08-15
ER

PT J
AU Adewole, OO
   Ota, M
   Owiafe, P
   Erhabor, G
AF Adewole, O. O.
   Ota, M.
   Owiafe, P.
   Erhabor, G.
TI Interferon Gamma Response And Treatment Kinetics In Patients With
   Pulmonary Tuberculosis In Ile Ife, Nigeria
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Adewole, O. O.; Erhabor, G.] Obafemi Awolowo Univ, Ife, Nigeria.
   [Ota, M.; Owiafe, P.] MRC, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2013
VL 187
MA A2475
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TO
UT WOS:000209839101646
OA No
DA 2017-08-15
ER

PT J
AU Lin, GM
   Chen, YJ
   Li, YH
   Jaiteh, LES
   Han, CL
AF Lin, Gen-Min
   Chen, Yu-Jung
   Li, Yi-Hwei
   Jaiteh, Lamin E. S.
   Han, Chih-Lu
TI The Effect of Hypoxia-Hypercapnia on Neuropsychological Function in
   Adult Respiratory Distress Syndrome
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Letter
ID END-EXPIRATORY PRESSURE
C1 [Lin, Gen-Min; Chen, Yu-Jung] Hualien Armed Forces Gen Hosp, Hualien, Taiwan.
   [Li, Yi-Hwei] Tzu Chi Univ, Hualien, Taiwan.
   [Jaiteh, Lamin E. S.] Royal Victoria Teaching Hosp, Banjul, Gambia.
   [Han, Chih-Lu] Taipei Vet Gen Hosp, Taipei, Taiwan.
RP Lin, GM (reprint author), Hualien Armed Forces Gen Hosp, Hualien, Taiwan.
CR de Durante G, 2002, AM J RESP CRIT CARE, V165, P1271, DOI 10.1164/rccm.2105050
   Hung WW, 2009, AM J RESP CRIT CARE, V180, P134, DOI 10.1164/rccm.200902-0276OC
   Koutsoukou A, 2002, CRIT CARE MED, V30, P1941, DOI 10.1097/01.CCM.0000027847.00759.14
   Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
NR 5
TC 1
Z9 1
U1 0
U2 1
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD DEC 15
PY 2012
VL 186
IS 12
BP 1307
EP 1307
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 057OZ
UT WOS:000312574200020
PM 23250501
OA No
DA 2017-08-15
ER

PT J
AU Kotloff, KL
   Blackwelder, WC
   Nasrin, D
   Nataro, JP
   Farag, TH
   van Eijk, A
   Adegbola, RA
   Alonso, PL
   Breiman, RF
   Faruque, ASG
   Saha, D
   Sow, SO
   Sur, D
   Zaidi, AKM
   Biswas, K
   Panchalingam, S
   Clemens, JD
   Cohen, D
   Glass, RI
   Mintz, ED
   Sommerfelt, H
   Levine, MM
AF Kotloff, Karen L.
   Blackwelder, William C.
   Nasrin, Dilruba
   Nataro, James P.
   Farag, Tamer H.
   van Eijk, Annemieke
   Adegbola, Richard A.
   Alonso, Pedro L.
   Breiman, Robert F.
   Faruque, Abu Syed Golam
   Saha, Debasish
   Sow, Samba O.
   Sur, Dipika
   Zaidi, Anita K. M.
   Biswas, Kousick
   Panchalingam, Sandra
   Clemens, John D.
   Cohen, Dani
   Glass, Roger I.
   Mintz, Eric D.
   Sommerfelt, Halvor
   Levine, Myron M.
TI The Global Enteric Multicenter Study (GEMS) of Diarrheal Disease in
   Infants and Young Children in Developing Countries: Epidemiologic and
   Clinical Methods of the Case/Control Study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID SUB-SAHARAN AFRICA; ROTAVIRUS DIARRHEA; RURAL BANGLADESH; EPISODES;
   VACCINE; DEATHS; POPULATION; INFECTIONS; MORTALITY; COMMUNITY
AB Background. Diarrhea is a leading cause of illness and death among children aged <5 years in developing countries. This paper describes the clinical and epidemiological methods used to conduct the Global Enteric Multicenter Study (GEMS), a 3-year, prospective, age-stratified, case/control study to estimate the population-based burden, microbiologic etiology, and adverse clinical consequences of acute moderate-to-severe diarrhea (MSD) among a censused population of children aged 0-59 months seeking care at health centers in sub-Saharan Africa and South Asia.
   Methods. GEMS was conducted at 7 field sites, each serving a population whose demography and healthcare utilization practices for childhood diarrhea were documented. We aimed to enroll 220 MSD cases per year from selected health centers serving each site in each of 3 age strata (0-11, 12-23, and 24-59 months), along with 1-3 matched community controls. Cases and controls supplied clinical, epidemiologic, and anthropometric data at enrollment and again approximately 60 days later, and provided enrollment stool specimens for identification and characterization of potential diarrheal pathogens. Verbal autopsy was performed if a child died. Analytic strategies will calculate the fraction of MSD attributable to each pathogen and the incidence, financial costs, nutritional consequences, and case fatality overall and by pathogen.
   Conclusions. When completed, GEMS will provide estimates of the incidence, etiology, and outcomes of MSD among infants and young children in sub-Saharan Africa and South Asia. This information can guide development and implementation of public health interventions to diminish morbidity and mortality from diarrheal diseases.
C1 [Kotloff, Karen L.; Nataro, James P.; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Pediat, Baltimore, MD 21201 USA.
   [Kotloff, Karen L.; Blackwelder, William C.; Nasrin, Dilruba; Nataro, James P.; Farag, Tamer H.; Panchalingam, Sandra; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Med, Baltimore, MD 21201 USA.
   [van Eijk, Annemieke] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L69 3BX, Merseyside, England.
   [Adegbola, Richard A.; Saha, Debasish] Med Res Council United Kingdom Unit, Fajara, Gambia.
   [Alonso, Pedro L.] Univ Barcelona, Hosp Clin, Ctr Recerca Salut Int Barcelona, E-08007 Barcelona, Spain.
   [Breiman, Robert F.] US Ctr Dis Control & Prevent, Kenya Off, Global Dis Detect Div, Nairobi, Kenya.
   [Faruque, Abu Syed Golam] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Sow, Samba O.] Ctr Dev Vaccins, Bamako, Mali.
   [Sur, Dipika] Natl Inst Cholera & Enter Dis, Kolkata, India.
   [Zaidi, Anita K. M.] Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan.
   [Biswas, Kousick] Cooperat Studies Program Coordinating Ctr, Dept Vet Affairs, Perry Point, MD USA.
   [Clemens, John D.] Int Vaccine Inst, Seoul, South Korea.
   [Cohen, Dani] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Ramat Aviv, Israel.
   [Glass, Roger I.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
   [Mintz, Eric D.] US Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
   [Sommerfelt, Halvor] Univ Bergen, Ctr Int Hlth, Oslo, Norway.
   [Sommerfelt, Halvor] Norwegian Inst Publ Hlth, Div Infect Dis Control, Oslo, Norway.
RP Kotloff, KL (reprint author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Pediat, 685 W Baltimore St,HSF 480, Baltimore, MD 21201 USA.
EM kkotloff@medicine.umaryland.edu
RI kotloff, karen/E-7768-2012
OI kotloff, karen/0000-0003-1808-6431
FU Bill & Melinda Gates Foundation [38874]
FX This work was supported by the Bill & Melinda Gates Foundation (grant
   number 38874).
CR Ahmed F, 2001, PEDIATR INFECT DIS J, V20, P525, DOI 10.1097/00006454-200105000-00011
   Anker M, 1997, INT J EPIDEMIOL, V26, P1090, DOI 10.1093/ije/26.5.1090
   Anker M, WHOCDSCSRISR994
   BAQUI AH, 1991, INT J EPIDEMIOL, V20, P1057, DOI 10.1093/ije/20.4.1057
   BENNISH ML, 1991, REV INFECT DIS, V13, pS245
   BLACK RE, 1982, AM J EPIDEMIOL, V115, P315
   BLACK RE, 1984, PEDIATRICS, V73, P799
   BUTLER T, 1987, B WORLD HEALTH ORGAN, V65, P317
   CARY SG, 1964, J BACTERIOL, V88, P96
   CLARK HF, 1988, J INFECT DIS, V158, P570
   Cogill B., ANTHROPOMETRIC INDIC
   Cooper RS, 1998, LANCET, V351, P208, DOI 10.1016/S0140-6736(97)06512-4
   Dutta P, 1995, Indian Pediatr, V32, P313
   FERRECCIO C, 1991, AM J EPIDEMIOL, V134, P614
   Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292
   FLORES J, 1987, LANCET, V1, P882
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   Lawn JE, 2006, INT J EPIDEMIOL, V35, P706, DOI 10.1093/ije/dy1043
   LEVINE MM, 1993, AM J EPIDEMIOL, V138, P849
   Lozano R, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-32
   Madhi SA, 2010, NEW ENGL J MED, V362, P289, DOI 10.1056/NEJMoa0904797
   Morris SS, 2003, INT J EPIDEMIOL, V32, P1041, DOI 10.1093/ije/dyg241
   RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046
   Schmidt WP, 2011, INT J EPIDEMIOL, V40, P1678, DOI 10.1093/ije/dyr152
   STANTON B, 1986, TROP GEOGR MED, V38, P113
   THEA DM, 1993, NEW ENGL J MED, V329, P1696, DOI 10.1056/NEJM199312023292304
   UN Interagency Group for Child Mortality Estimation, LEV TRENDS CHILD MOR
   The United Nations Children's Fund (UNICEF), STAT WORLDS CHILDR 2
   UNICEF/ World Health Organization, DIARRH WHY CHILDR AR
   Walker CLF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029151
   Wang XY, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-17
   WELLS JG, 1981, J CLIN MICROBIOL, V13, P789
   WHO, VERB AUT STAND ASC A
   WHO, WHO WORLD MAL REP 20
   WHO, HDB IMCI INT MAN CHI
   WHO-World Health Organization, 2009, WHO ANTHR PERS COMP
   World Health Organization United Nations Children's Fund US Agency for International Development and Johns Hopkins Bloomberg School of Public Health, IMPL NEW REC CLIN MA
   World Health Organization, 2002, HDB GOOD CLIN RES PR
   WHO Multicentre Growth Reference Study Group, WHO CHILD GROWTH STA
   WHO, 2006, ACTA PAEDIATR, V95, P38
   WHO/UNICEF, WHO UNICEF JOINT MON
   Wright JA, 2006, J HEALTH POPUL NUTR, V24, P8
   You D, 2010, LANCET, V375, P100, DOI 10.1016/S0140-6736(09)61601-9
NR 43
TC 73
Z9 73
U1 3
U2 16
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 15
PY 2012
VL 55
SU 4
BP S232
EP S245
DI 10.1093/cid/cis753
PG 14
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 044QP
UT WOS:000311637600003
PM 23169936
OA No
DA 2017-08-15
ER

PT J
AU Panchalingam, S
   Antonio, M
   Hossain, A
   Mandomando, I
   Ochieng, B
   Oundo, J
   Ramamurthy, T
   Tamboura, B
   Zaidi, AKM
   Petri, W
   Houpt, E
   Murray, P
   Prado, V
   Vidal, R
   Steele, D
   Strockbine, N
   Sansonetti, P
   Glass, RI
   Robins-Browne, RM
   Tauschek, M
   Svennerholm, AM
   Kotloff, K
   Levine, MM
   Nataro, JP
AF Panchalingam, Sandra
   Antonio, Martin
   Hossain, Anowar
   Mandomando, Inacio
   Ochieng, Ben
   Oundo, Joseph
   Ramamurthy, T.
   Tamboura, Boubou
   Zaidi, Anita K. M.
   Petri, William
   Houpt, Eric
   Murray, Patrick
   Prado, Valeria
   Vidal, Roberto
   Steele, Duncan
   Strockbine, Nancy
   Sansonetti, Philippe
   Glass, Roger I.
   Robins-Browne, Roy M.
   Tauschek, Marija
   Svennerholm, Ann-Marie
   Kotloff, Karen
   Levine, Myron M.
   Nataro, James P.
TI Diagnostic Microbiologic Methods in the GEMS-1 Case/Control Study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID DIARRHEAGENIC ESCHERICHIA-COLI; FECAL SPECIMENS; PCR; CHILDREN; ANTIGEN;
   SAMPLES
AB To understand the etiology of moderate-to-severe diarrhea among children in high mortality areas of sub-Saharan Africa and South Asia, we performed a comprehensive case/control study of children aged < 5 years at 7 sites. Each site employed an identical case/control study design and each utilized a uniform comprehensive set of microbiological assays to identify the likely bacterial, viral and protozoal etiologies. The selected assays effected a balanced consideration of cost, robustness and performance, and all assays were performed at the study sites. Identification of bacterial pathogens employed streamlined conventional bacteriologic biochemical and serological algorithms. Diarrheagenic Escherichia coli were identified by application of a multiplex polymerase chain reaction assay for enterotoxigenic, enteroaggregative, and enteropathogenic E. coli. Rotavirus, adenovirus, Entamoeba histolytica, Giardia enterica, and Cryptosporidium species were detected by commercially available enzyme immunoassays on stool samples. Samples positive for adenovirus were further evaluated for adenovirus serotypes 40 and 41. We developed a novel multiplex assay to detect norovirus (types 1 and 2), astrovirus, and sapovirus. The portfolio of diagnostic assays used in the GEMS study can be broadly applied in developing countries seeking robust cost-effective methods for enteric pathogen detection.
C1 [Nataro, James P.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA.
   [Panchalingam, Sandra; Kotloff, Karen; Levine, Myron M.; Nataro, James P.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Antonio, Martin] MRC, Fajara, Gambia.
   [Hossain, Anowar] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Mandomando, Inacio] Ctr Invest Saude, Manhica, Maputo, Mozambique.
   [Ochieng, Ben; Oundo, Joseph] Kenya Med Res Inst CDC, Kisumu, Kenya.
   [Ramamurthy, T.] Natl Inst Cholera & Enter Dis, Kolkata, India.
   [Tamboura, Boubou] Ctr Vaccine Dev Mali, Bamako, Mali.
   [Zaidi, Anita K. M.] Aga Khan Univ, Karachi, Pakistan.
   [Petri, William; Houpt, Eric] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA.
   [Murray, Patrick; Strockbine, Nancy; Glass, Roger I.] US Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Prado, Valeria; Vidal, Roberto] Univ Chile, Santiago, Chile.
   [Steele, Duncan] World Hlth Org, Geneva, Switzerland.
   [Sansonetti, Philippe] Inst Pasteur, Paris, France.
   [Robins-Browne, Roy M.; Tauschek, Marija] Univ Melbourne, Melbourne, Vic 3010, Australia.
   [Svennerholm, Ann-Marie] Univ Gothenburg, Gothenburg, Sweden.
RP Nataro, JP (reprint author), Univ Virginia, Sch Med, Dept Pediat, 3601 W Clin,Hosp Dr, Charlottesville, VA 22908 USA.
EM jpn2r@virginia.edu
RI kotloff, karen/E-7768-2012
OI kotloff, karen/0000-0003-1808-6431; Robins-Browne,
   Roy/0000-0001-9179-7884
FU Bill & Melinda Gates Foundation [38874]
FX This work was supported by the Bill & Melinda Gates Foundation (grant
   number 38874).
CR BERNAGOZZI M, 1994, ZBL HYG UMWELTMED, V195, P121
   Bialek R, 2002, DIAGN MICR INFEC DIS, V43, P283, DOI 10.1016/S0732-8893(02)00408-X
   BLASER MJ, 1979, ANN INTERN MED, V91, P179
   Blessmann J, 2003, J CLIN MICROBIOL, V41, P4745, DOI 10.1128/JCM.41.10.4745-4750.2003
   Boisen N, 2012, J INFECT DIS, V205, P431, DOI 10.1093/infdis/jir757
   Boone JH, 1999, J CLIN MICROBIOL, V37, P611
   CARY SG, 1964, J BACTERIOL, V88, P96
   Gaafar MR, 2011, INT J INFECT DIS, V15, pE541, DOI 10.1016/j.ijid.2011.04.004
   Haque R, 1998, J CLIN MICROBIOL, V36, P449
   Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818
   KHAITOVICH AB, 1987, ANTIBIOT MED BIOTEK, V32, P446
   Murray P. R., 2003, MANUAL CLIN MICROBIO
   Nataro JP, 1998, CLIN MICROBIOL REV, V11, P142
   Nguyen TV, 2005, J CLIN MICROBIOL, V43, P755, DOI 10.1128/JCM.43.2.755-760.2005
   Srijan Apichai, 2005, Southeast Asian J Trop Med Public Health, V36 Suppl 4, P26
   WELLS JG, 1981, J CLIN MICROBIOL, V13, P789
   Yan HN, 2003, J VIROL METHODS, V114, P37, DOI 10.1016/j.jviromet.2003.08.009
   Youn S, 2009, J CLIN MICROBIOL, V47, P451, DOI 10.1128/JCM.01736-08
NR 18
TC 57
Z9 57
U1 0
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 15
PY 2012
VL 55
SU 4
BP S294
EP S302
DI 10.1093/cid/cis754
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 044QP
UT WOS:000311637600008
PM 23169941
OA No
DA 2017-08-15
ER

PT J
AU D'Alessandro, U
   Ubben, D
   Hamed, K
   Ceesay, SJ
   Okebe, J
   Taal, M
   Lama, EK
   Keita, M
   Koivogui, L
   Nahum, A
   Bojang, K
   Sonko, AAJ
   Lalya, HF
   Brabin, B
AF D'Alessandro, Umberto
   Ubben, David
   Hamed, Kamal
   Ceesay, Serign Jawo
   Okebe, Joseph
   Taal, Makie
   Lama, Eugene Kaman
   Keita, Moussa
   Koivogui, Lamine
   Nahum, Alain
   Bojang, Kalifa
   Sonko, Aja Adam Jagne
   Lalya, Honorat Francis
   Brabin, Bernard
TI Malaria in infants aged less than six months - is it an area of unmet
   medical need?
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Neonate; Congenital; Prevalence; Parasitaemia;
   Artemisinin-based combination therapy
ID PLASMODIUM-FALCIPARUM MALARIA; SUB-SAHARAN AFRICA; CONGENITAL MALARIA;
   HYPERENDEMIC AREA; NEONATAL MALARIA; CHILDREN; NIGERIA; MORTALITY;
   INFECTION; DISTRICT
AB Despite the protection provided by several factors, including maternal antibodies, the burden of malaria in young infants may be higher than previously thought. Infants with congenital or neonatal malaria may have a different clinical presentation than older children, and diagnosis may be confused with other neonatal diseases due to an overlap of clinical manifestations. In addition, there is little information on the use of artemisinin-based combination therapy in young infants. There is the need for a more accurate estimate of the parasite prevalence and the incidence of clinical malaria in infants under 6 months old, as well as a better characterization of risk factors, pharmacokinetic profiles, safety and efficacy of currently available anti-malarial treatments, in order to develop evidence-based treatment guidelines for this population.
C1 [D'Alessandro, Umberto; Ceesay, Serign Jawo; Okebe, Joseph; Bojang, Kalifa] MRC Unit, Banjul, Gambia.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Ubben, David] MMV, CH-1215 Geneva 15, Switzerland.
   [Hamed, Kamal] Novartis Pharmaceut, E Hanover, NJ 07936 USA.
   [Taal, Makie; Sonko, Aja Adam Jagne] Minist Hlth & Social Welf, Banjul, Gambia.
   [Lama, Eugene Kaman; Keita, Moussa; Koivogui, Lamine] Minist Hlth, Conakry, Guinea.
   [Nahum, Alain] Ctr Rech Entomol Cotonou, Cotonou, Benin.
   [Lalya, Honorat Francis] Ctr Natl Hosp Univ Hubert K Maga, Cotonou, Benin.
   [Brabin, Bernard] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England.
RP D'Alessandro, U (reprint author), MRC Unit, POB 273, Banjul, Gambia.
EM udalessandro@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Bojang,
   Kalifa/0000-0001-7506-0938; Hamed, Kamal/0000-0003-1896-9736
FU Sigma Tau; MMV
FX UD has been invited as speaker at symposia organized by Sigma Tau and
   Novartis Pharma, and has received a research grant from Sigma Tau. KH is
   an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ,
   USA. This declaration is made in the interest of full disclosure and not
   because the author considers this to be a competing interest. The other
   authors have no competing interest to declare.; Editorial assistance was
   provided by Caroline Sharp (PreScript Communications), with funding from
   MMV.
CR Abdullah S, 2007, AM J TROP MED HYG, V77, P99
   Adja E Akaffou, 2009, Mali Med, V24, P36
   Afolabi BM, 2001, AM J TROP MED HYG, V65, P822
   Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   AKINDELE JA, 1993, ANN TROP PAEDIATR, V13, P273
   Amaratunga C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014798
   Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7
   Bardaji A, 2011, J INFECT DIS, V203, P691, DOI 10.1093/infdis/jiq049
   BIGGAR RJ, 1980, AM J TROP MED HYG, V29, P720
   Brabin B., 1990, TROP DIS B, V87, P1
   Carneiro I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008988
   CORKILL JA, 1989, ARCH DIS CHILD, V64, P541
   Daily JP, 2012, NEW ENGL J MED, V367, P2349, DOI 10.1056/NEJMe1213392
   Dicko-Traore F., 2011, J PEDIAT PUERIC, V24, P57, DOI 10.1016/j.jpp.2011.01.002
   Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08
   Ekanem AD, 2008, TROP DOCT, V38, P73, DOI 10.1258/td.2007.005274
   Falade C, 2007, TROP MED INT HEALTH, V12, P1279, DOI 10.1111/j.1365-3156.2007.01931.x
   Fischer PR, 1997, CLIN PEDIATR, V36, P411, DOI 10.1177/000992289703600706
   Fischer PR, 2003, J TROP PEDIATRICS, V49, P132, DOI 10.1093/tropej/49.3.132
   FISCHER PR, 1995, WESTERN J MED, V163, P395
   FOLL CV, 1968, B WORLD HEALTH ORGAN, V38, P255
   Geerligs PDP, 2003, B WORLD HEALTH ORGAN, V81, P205
   Gitau GM, 2005, OBSTET GYNECOL, V7, P5, DOI 10.1576/toag.7.1.005.27036
   Gosling RD, 2011, CLIN MICROBIOL INFEC, V17, P1617, DOI 10.1111/j.1469-0691.2011.03660.x
   Guinovart C, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-36
   Gwamaka M, 2012, CLIN INFECT DIS, V54, P1137, DOI 10.1093/cid/cis010
   Hailegiorgis B, 2010, TROP MED INT HEALTH, V15, P1449, DOI 10.1111/j.1365-3156.2010.02646.x
   Hashemzadeh A, 2005, ARCH IRAN MED, V8, P226
   Ibhanesebhor SE, 1995, J TROP PEDIATRICS, V41, P330
   Ishengoma DRS, 2010, ANN TROP MED PARASIT, V104, P123, DOI 10.1179/136485910X12607012373993
   Kamwendo DD, 2002, T ROY SOC TROP MED H, V96, P145, DOI 10.1016/S0035-9203(02)90284-1
   Kassim OO, 2000, J TROP PEDIATRICS, V46, P92, DOI 10.1093/tropej/46.2.92
   Kearns GL, 2003, NEW ENGL J MED, V349, P1157
   Klouwenberg PMCK, 2005, ACTA TROP, V95, P81, DOI 10.1016/j.actatropica.2005.05.003
   LARKIN GL, 1991, AM J TROP MED HYG, V45, P587
   Larru B, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-310
   Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5
   Lesi FEA, 2010, NIGER J CLIN PRACT, V13, P134
   Macdonald G., 1950, Tropical Diseases Bulletin, V47, P915
   Malhotra I, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000116
   MCGREGOR IA, 1956, BRIT MED J, V2, P686
   Menendez C, 2007, SEMIN FETAL NEONAT M, V12, P207, DOI 10.1016/j.siny.2007.01.018
   MILSAP RL, 1994, ENVIRON HEALTH PERSP, V102, P107
   Mosha TC, 2010, TANZANIA J HLTH RES, V12, P1
   Mukhtar M, 2007, Niger J Med, V16, P25
   Mukhtar MY, 2006, J TROP PEDIATRICS, V52, P19, DOI 10.1093/tropej/fmi044
   Mwangoka GW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-117
   Mwaniki MK, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-313
   Nankabirwa V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021862
   Obiajunwa PO, 2005, J TROP PEDIATRICS, V51, P219, DOI 10.1093/tropej/fmi003
   Oduwole OA, 2011, AM J TROP MED HYG, V84, P386, DOI 10.4269/ajtmh.2011.10-0253
   Ojukwu JU, 2004, NIG J PAEDIAT, V31, P48
   Okafor U H, 2006, J Obstet Gynaecol, V26, P612, DOI 10.1080/09638280600902893
   Okechukwu AA, 2011, NIGERIAN J PAEDIAT, V38, P82
   Omalu IC, 2012, J TROP MED, V201
   Orogade A. A., 2008, Journal of Pediatric Infectious Diseases, V3, P181
   Pedro R, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-307
   Pineros-Jimenez JG, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-239
   Riley EM, 2000, INFECT IMMUN, V68, P5856, DOI 10.1128/IAI.68.10.5856-5863.2000
   Riley EM, 2001, PARASITE IMMUNOL, V23, P51, DOI 10.1046/j.1365-3024.2001.00364.x
   The RTS S Clinical Trials Partnership, 2012, NEW ENGL J MED, DOI [10.1056/NEJMoa1208394, DOI 10.1056/NEJMOA1208394]
   Runsewe-Abiodun Iyabo T, 2006, BMC Pediatr, V6, P19, DOI 10.1186/1471-2431-6-19
   Sacarlal J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-67
   Schwarz NG, 2008, CLIN INFECT DIS, V47, P1017, DOI 10.1086/591968
   Sehgal V M, 1989, Trans R Soc Trop Med Hyg, V83 Suppl, P105, DOI 10.1016/0035-9203(89)90616-0
   Sule-Odu A O, 2002, J Obstet Gynaecol, V22, P25, DOI 10.1080/01443610120101664
   Thomson J G, 1935, Proc R Soc Med, V28, P391
   Uneke CJ, 2007, PARASITOL RES, V101, P835, DOI 10.1007/s00436-007-0577-9
   van Eijk AM, 2007, J INFECT DIS, V196, P30, DOI 10.1086/518441
   Wagner G, 1998, AM J TROP MED HYG, V59, P115
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   World Health Organization, 2010, GUID TREATM MAL
   WHO Global Malaria Programme, 2012, WHO POL REC SEAS MAL
NR 73
TC 15
Z9 16
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD DEC 2
PY 2012
VL 11
AR 400
DI 10.1186/1475-2875-11-400
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 058SZ
UT WOS:000312655600001
PM 23198986
OA gold
DA 2017-08-15
ER

PT J
AU Lin, GM
   Li, YH
   Jaiteh, LES
   Han, CL
AF Lin, Gen-Min
   Li, Yi-Hwei
   Jaiteh, Lamin E. S.
   Han, Chih-Lu
TI Pexelizumab fails to inhibit assembly of the terminal complement complex
   in patients with ST-elevation myocardial infarction undergoing primary
   percutaneous coronary intervention. Insight from a substudy of the
   Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI)
   trial
SO AMERICAN HEART JOURNAL
LA English
DT Letter
ID ANTIBODY
C1 [Lin, Gen-Min] Hualien Armed Forces Gen Hosp, Dept Med, Hualien, Taiwan.
   [Li, Yi-Hwei] Tzu Chi Univ, Dept Publ Hlth, Hualien, Taiwan.
   [Jaiteh, Lamin E. S.] Royal Victoria Teaching Hosp, Dept Med, Banjul, Gambia.
   [Han, Chih-Lu] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.
RP Lin, GM (reprint author), Hualien Armed Forces Gen Hosp, Dept Med, Hualien, Taiwan.
EM farmer507@yahoo.com.tw
CR Fitch JCK, 1999, CIRCULATION, V100, P2499
   Lin Gen-Min, 2011, Cardiovascular & Hematological Disorders - Drug Targets, V11, P97
   Lin GM, 2011, INT J CARDIOL, V147, P340, DOI 10.1016/j.ijcard.2010.12.100
   Lin GM, 2010, INT J CARDIOL, V146, P280
   Martel C, 2012, AM HEART J, V164, P43, DOI 10.1016/j.ahj.2012.04.007
   RINDER CS, 1995, J CLIN INVEST, V96, P1564, DOI 10.1172/JCI118195
   ROGER M, 1995, PLATELETS, V6, P160, DOI 10.3109/09537109509013269
   Sawa Y, 1998, J THORAC CARDIOV SUR, V116, P511, DOI 10.1016/S0022-5223(98)70018-2
NR 8
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD DEC
PY 2012
VL 164
IS 6
BP E19
EP E19
DI 10.1016/j.ahj.2012.09.012
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 044PU
UT WOS:000311634500001
PM 23194495
OA No
DA 2017-08-15
ER

PT J
AU Cunnington, AJ
   Njie, M
   Correa, S
   Takem, EN
   Riley, EM
   Walther, M
AF Cunnington, Aubrey J.
   Njie, Madi
   Correa, Simon
   Takem, Ebako N.
   Riley, Eleanor M.
   Walther, Michael
TI Prolonged Neutrophil Dysfunction after Plasmodium falciparum Malaria Is
   Related to Hemolysis and Heme Oxygenase-1 Induction
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CHRONIC GRANULOMATOUS-DISEASE; SALMONELLA INFECTION; OXIDATIVE BURST;
   KENYAN CHILDREN; NONTYPHOIDAL SALMONELLA; HUMAN MONOCYTES;
   FLOW-CYTOMETRY; NADPH OXIDASE; WHOLE-BLOOD; SUSCEPTIBILITY
AB It is not known why people are more susceptible to bacterial infections such as nontyphoid Salmonella during and after a malaria infection, but in mice, malarial hemolysis impairs resistance to nontyphoid Salmonella by impairing the neutrophil oxidative burst. This acquired neutrophil dysfunction is a consequence of induction of the cytoprotective, heme-degrading enzyme heme oxygenase-1 (HO-1) in neutrophil progenitors in bone marrow. In this study, we assessed whether neutrophil dysfunction occurs in humans with malaria and how this relates to hemolysis. We evaluated neutrophil function in 58 Gambian children with Plasmodium falciparum malaria [55 (95%) with uncomplicated disease] and examined associations with erythrocyte count, haptoglobin, hemopexin, plasma heme, expression of receptors for heme uptake, and HO-1 induction. Malaria caused the appearance of a dominant population of neutrophils with reduced oxidative burst activity, which gradually normalized over 8 wk of follow-up. The degree of neutrophil impairment correlated significantly with markers of hemolysis and HO-1 induction. HO-1 expression was increased in blood during acute malaria, but at a cellular level HO-1 expression was modulated by changes in surface expression of the haptoglobin receptor (CD163). These findings demonstrate that neutrophil dysfunction occurs in P. falciparum malaria and support the relevance of the mechanistic studies in mice. Furthermore, they suggest the presence of a regulatory pathway to limit HO-1 induction by hemolysis in the context of infection and indicate new targets for therapeutic intervention to abrogate the susceptibility to bacterial infection in the context of hemolysis in humans. The Journal of Immunology, 2012, 189: 5336-5346.
C1 [Cunnington, Aubrey J.; Riley, Eleanor M.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1E 7HT, England.
   [Cunnington, Aubrey J.; Njie, Madi; Correa, Simon; Takem, Ebako N.; Walther, Michael] MRC Labs, Banjul, Gambia.
   [Walther, Michael] NIAID, Immune Regulat Sect, Lab Malaria Immunol & Vaccinol, Div Intramural Res,NIH, Rockville, MD USA.
RP Cunnington, AJ (reprint author), Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, Keppel St, London WC1E 7HT, England.
EM aubrey.cunnington@lshtm.ac.uk
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570; Cunnington,
   Aubrey/0000-0002-1305-3529
FU Medical Research Council (U.K.) [G0701427]; Medical Research Council
FX This work was supported by a clinical research training fellowship from
   the Medical Research Council (U.K.) (G0701427 to A.J.C.) and by Medical
   Research Council Institute funding to the Medical Research Council
   Laboratories, Gambia.
CR Adetifa IMO, 2009, INT J LAB HEMATOL, V31, P615, DOI 10.1111/j.1751-553X.2008.01087.x
   Avendano A, 2008, J IMMUNOL METHODS, V339, P124, DOI 10.1016/j.jim.2008.09.003
   Belyaev NN, 2010, NAT IMMUNOL, V11, P477, DOI 10.1038/ni.1869
   BENNETT IL, 1959, ANNU REV MED, V10, P1, DOI 10.1146/annurev.me.10.020159.000245
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299
   Brent AJ, 2006, PEDIATR INFECT DIS J, V25, P230, DOI 10.1097/01.inf.0000202066.02212.ff
   Bronzan RN, 2007, J INFECT DIS, V195, P895, DOI 10.1086/511437
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Cunnington AJ, 2004, AM J TROP MED HYG, V71, P43
   Cunnington AJ, 2012, NAT MED, V18, P120, DOI 10.1038/nm.2601
   DEHAAS M, 1994, BLOOD, V84, P3885
   Delanghe JR, 2001, CLIN CHIM ACTA, V312, P13, DOI 10.1016/S0009-8981(01)00586-1
   Dondorp AM, 2005, PLOS MED, V2, P788, DOI 10.1371/journal.pmed.0020204
   Eckerle I, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-167
   Fendel R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010038
   Ferreira A, 2008, J MOL MED, V86, P1097, DOI 10.1007/s00109-008-0368-5
   Giglioli G, 1929, Proc R Soc Med, V23, P165
   Gondwe EN, 2010, P NATL ACAD SCI USA, V107, P3070, DOI 10.1073/pnas.0910497107
   Hanscheid T, 2007, LANCET INFECT DIS, V7, P675, DOI 10.1016/S1473-3099(07)70238-4
   Hayasaka C., 1933, TOHOKU J EXP MED, V21, P466, DOI 10.1620/tjem.21.466
   Hirai H, 2003, BLOOD, V102, P1619, DOI 10.1182/blood-2002-12-3733
   Hocqueloux L, 2000, CLIN INFECT DIS, V30, P940, DOI 10.1086/313814
   Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185
   KAPPAS A, 1988, PEDIATRICS, V81, P485
   KAYE D, 1963, J IMMUNOL, V91, P65
   KAYE D, 1965, P SOC EXP BIOL MED, V120, P810
   KAYE D, 1963, J IMMUNOL, V91, P518
   Kowanko IC, 1996, INFECT IMMUN, V64, P3435
   Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097
   Kusi KA, 2008, CLIN VACCINE IMMUNOL, V15, P1456, DOI 10.1128/CVI.00506-07
   Lun A, 2000, CLIN CHEM, V46, P1836
   MABEY DCW, 1987, J INFECT DIS, V155, P1319
   Mackenzie G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010568
   Mackintosh CL, 2004, TRENDS PARASITOL, V20, P597, DOI 10.1016/j.pt.2004.09.006
   Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237
   Morpeth SC, 2009, CLIN INFECT DIS, V49, P606, DOI 10.1086/603553
   MULLEREBERHARD U, 1968, BLOOD, V32, P811
   Nadjm B, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1350
   Nielsen MJ, 2009, BLOOD, V114, P764, DOI 10.1182/blood-2009-01-198309
   O'Donnell A, 2009, T ROY SOC TROP MED H, V103, P679, DOI 10.1016/j.trstmh.2009.03.023
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Raes Ann, 2006, BMC Pediatr, V6, P3, DOI 10.1186/1471-2431-6-3
   REPINE JE, 1975, J PEDIATR-US, V87, P901, DOI 10.1016/S0022-3476(75)80902-4
   Richardson MP, 1998, J IMMUNOL METHODS, V219, P187, DOI 10.1016/S0022-1759(98)00136-7
   Roux CM, 2010, INFECT IMMUN, V78, P1520, DOI 10.1128/IAI.00887-09
   Rushworth SA, 2008, J IMMUNOL, V181, P6730
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033
   Schwarzer E, 1999, MOL BIOCHEM PARASIT, V100, P61, DOI 10.1016/S0166-6851(99)00031-6
   Scott JAG, 2011, LANCET, V378, P1316, DOI 10.1016/S0140-6736(11)60888-X
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Sheppard FR, 2005, J LEUKOCYTE BIOL, V78, P1025, DOI 10.1189/jlb.0804442
   Snow RW, 2004, AM J TROP MED HYG, V71, P16
   SOESAN M, 1993, T ROY SOC TROP MED H, V87, P288, DOI 10.1016/0035-9203(93)90131-9
   Soldin SJ, 2007, PEDIAT REFERENCE INT
   Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006
   Urban BC, 2002, CURR OPIN IMMUNOL, V14, P458, DOI 10.1016/S0952-7915(02)00368-0
   van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234
   Van Gorp H, 2010, MOL IMMUNOL, V47, P1650, DOI 10.1016/j.molimm.2010.02.008
   Walther M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002579
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Wenisch C, 1997, J ANTIMICROB CHEMOTH, V39, P99, DOI 10.1093/jac/39.1.99
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   WHO, 2000, T R SOC TROP MED HYG, V94, pS1/1
   Wolach B, 2005, BLOOD, V105, P61, DOI 10.1182/blood-2004-02-0675
   Wright J, 1997, J PEDIATR-US, V130, P394, DOI 10.1016/S0022-3476(97)70201-4
NR 67
TC 43
Z9 43
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 2012
VL 189
IS 11
BP 5336
EP 5346
DI 10.4049/jimmunol.1201028
PG 11
WC Immunology
SC Immunology
GA 039ZJ
UT WOS:000311287600030
PM 23100518
OA No
DA 2017-08-15
ER

PT J
AU Lindsay, TC
   Jawara, M
   D'Alessandro, U
   Pinder, M
   Lindsay, SW
AF Lindsay, Thomas C.
   Jawara, Musa
   D'Alessandro, Umberto
   Pinder, Margaret
   Lindsay, Steven W.
TI Development of Odour-Baited Flytraps for Sampling the African Latrine
   Fly, Chrysomya putoria, a Putative Vector of Enteric Diseases
SO PLOS ONE
LA English
DT Article
ID MUSCA-SORBENS; FLIES DIPTERA; TRAPS; GLOSSINIDAE; TRACHOMA
AB African pit latrines produce prodigious numbers of the latrine fly, Chrysomya putoria, a putative vector of diarrhoeal pathogens. We set out to develop a simple, low-cost odour-baited trap for collecting C. putoria in the field. A series of field experiments was carried out in The Gambia to assess the catching-efficiency of different trap designs. The basic trap was a transparent 3L polypropylene box baited with 50 g of fish, with a white opaque lid with circular entrance holes. We tested variations of the number, diameter, position and shape of the entrance holes, the height of the trap above ground, degree of transparency of the box, its shape, volume, colour, and the attractiveness of gridded surfaces on or under the trap. Traps were rotated between positions on different sampling occasions using a Latin Square design. The optimal trapping features were incorporated into a final trap that was tested against commercially available traps. Features of the trap that increased the number of flies caught included: larger entrance holes (compared with smaller ones, p<0.001), using conical collars inside the holes (compared with without collars, p = 0.01), entrance holes on the top of the trap (compared with the side or bottom, p<0.001), traps placed on the ground (compared with above ground, p<0.001), the box having transparent sides (compared with being opaque, p<0.001), and with no wire grids nearby (compared with those with grids, p = 0.03). This trap collected similar numbers of C. putoria to other common traps for blow flies. The optimum trap design was a transparent box, with a white plastic lid on top, perforated with 10 conical entrance holes, placed on the ground. Our simple trap provides a cheap, low-maintenance and effective method of sampling C. putoria in the field.
C1 [Lindsay, Thomas C.; Pinder, Margaret; Lindsay, Steven W.] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England.
   [Jawara, Musa; D'Alessandro, Umberto; Pinder, Margaret] MRC Unit, Fajara, Gambia.
   [D'Alessandro, Umberto] Inst Trop Med, Unit Malariol, B-2000 Antwerp, Belgium.
   [Lindsay, Steven W.] Univ Durham, Sch Biol & Biomed Sci, Durham, England.
RP Lindsay, SW (reprint author), London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England.
EM S.W.Lindsay@durham.ac.uk
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Bill and Melinda Gates Foundation [OPP1034747]; Research and Policy for
   Infectious Disease Dynamics (RAPIDD) Program of the Science and
   Technology Directory; Department of Homeland Security; Fogarty
   International Center, National Institutes of Health; Medical Research
   Council, UK
FX The work was supported by the Bill and Melinda Gates Foundation(#
   OPP1034747; Grand Challenges Explorations Phase I, Round 6 Project
   Grant). SWL received support from the Research and Policy for Infectious
   Disease Dynamics (RAPIDD) Program of the Science and Technology
   Directory, Department of Homeland Security, and Fogarty International
   Center, National Institutes of Health, Medical Research Council, UK. The
   sponsors of the study did not have a role in the design of the study,
   data collection, analysis, interpretation and writing of this
   manuscript. SWL had full access to the data and had the final
   responsibility for submitting the manuscript for publication.
CR CURTIS CF, 1982, T ROY SOC TROP MED H, V76, P99, DOI 10.1016/0035-9203(82)90031-1
   Emerson PM, 2005, TROP MED INT HEALTH, V10, P706, DOI 10.1111/j.1365-3156.2005.01432.x
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   Gilles J, 2007, MED VET ENTOMOL, V21, P65, DOI 10.1111/j.1365-2915.2006.00658.x
   Greenberg B, 1971, FLIES AND DISEASE EC
   Greenberg B, 1973, FLIES AND DISEASE BI
   Woodhill Gurney W, 1926, AGRIC DEPT NEW SOUTH, V27, P4
   HECHT O, 1970, Bulletin of the Entomological Society of America, V16, P94
   Kobayashi M, 1999, AM J TROP MED HYG, V61, P625
   LAURENCE BR, 1988, MED VET ENTOMOL, V2, P285, DOI 10.1111/j.1365-2915.1988.tb00197.x
   LINDSAY DR, 1956, ANNU REV ENTOMOL, V1, P323, DOI 10.1146/annurev.en.01.010156.001543
   Lindsay SW, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001895
   Pickens L. G., 1995, IPM Practitioner, V17, P1
   PICKENS LG, 1994, J MED ENTOMOL, V31, P828
   SCUDDER HI, 1947, PUBLIC HEALTH REP, V62, P681, DOI 10.2307/4586121
   UNICEF/WHO, 2009, DIARRHOEA WHY CHILDR
   VALE GA, 1982, B ENTOMOL RES, V72, P71
   VALE GA, 1982, B ENTOMOL RES, V72, P95
   VOGT W G, 1974, Journal of the Australian Entomological Society, V13, P249
NR 20
TC 2
Z9 2
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 30
PY 2012
VL 7
IS 11
AR e50505
DI 10.1371/journal.pone.0050505
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 054WM
UT WOS:000312376100108
PM 23226296
OA gold
DA 2017-08-15
ER

PT J
AU Egere, U
   Townend, J
   Roca, A
   Akinsanya, A
   Bojang, A
   Nsekpong, D
   Greenwood, B
   Adegbola, RA
   Hill, PC
AF Egere, Uzochukwu
   Townend, John
   Roca, Anna
   Akinsanya, Abiodun
   Bojang, Abdoulie
   Nsekpong, David
   Greenwood, Brian
   Adegbola, Richard A.
   Hill, Philip C.
TI Indirect Effect of 7-Valent Pneumococcal Conjugate Vaccine on
   Pneumococcal Carriage in Newborns in Rural Gambia: A Randomised
   Controlled Trial
SO PLOS ONE
LA English
DT Article
ID DAY-CARE-CENTERS; STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE;
   POLYSACCHARIDE VACCINE; MATERNAL IMMUNIZATION; INVASIVE DISEASE;
   BREAST-MILK; CHILDREN; INFANTS; COLONIZATION
AB Background: Gambian infants frequently acquire Streptococcus pneumoniae soon after birth. We investigated the indirect effect of 7-valent pneumococcal conjugate vaccine (PCV-7) on pneumococcal acquisition in newborn Gambian babies.
   Methods: Twenty-one villages were randomised to receive PCV-7 to all subjects (11 vaccinated villages) or to infants aged 2-30 months (10 control villages). Other control villagers received Meningococcal C conjugate vaccine. From 328 babies born during the trial, nasopharyngeal swabs were collected after birth, then weekly until 8 weeks of age when they received their first dose of PCV-7. Pneumococcal carriage and acquisition rates were compared between the study arms and with a baseline study.
   Results: 57.4% of 2245 swabs were positive for S. pneumoniae. Overall carriage was similar in both arms. In vaccinated villages fewer infants carried pneumococci of vaccine serotypes (VT) (16.9% [31/184] vs. 37.5% [54/144], p < 0.001) and more carried pneumococci of non-vaccine serotypes (NVT) (80.9% [149/184] vs. 75.7% [109/144], p = 0.246). Infants from vaccinated villages had a significantly lower acquisition rate of VT (HR 0.39 [0.26-0.58], p < 0.001) and increased acquisition of NVT (HR 1.16 [0.87-1.56], p = 0.312). VT carriage (51.6% vs. 37.5%, p = 031 in control and 46.1% vs. 16.8%, p < 0.001 in vaccinated villages) and acquisition rates (HR 0.68 [0.50-0.92], p = 0.013 in control villages and HR 0.31 [0.19-0.50], p < .001 in vaccinated villages) were significantly lower in both study arms than in the baseline study. NVT carriage (63.2% vs. 75.7%, p = 0.037 in control and 67.2% vs. 75.3%, p = 0.005 in vaccinated villages) and acquisition rates (HR 1.48 [1.06-2.06], p = 0.022) and (HR 1.52 [1.11-2.10], p = 0.010 respectively) were significantly higher.
   Conclusion: PCV-7 significantly reduced carriage of VT pneumococci in unvaccinated infants. This indirect effect likely originated from both the child and adult vaccinated populations. Increased carriage of NVT pneumococci needs ongoing monitoring.
C1 [Egere, Uzochukwu; Townend, John; Roca, Anna; Akinsanya, Abiodun; Bojang, Abdoulie; Nsekpong, David; Hill, Philip C.] MRC Unit, Banjul, Gambia.
   [Roca, Anna] Barcelona Ctr Int Hlth Res, Barcelona, Spain.
   [Greenwood, Brian] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
   [Adegbola, Richard A.] GlaxoSmithKline Biol, Wavre, Belgium.
   [Hill, Philip C.] Univ Otago, Ctr Int Hlth, Sch Med, Dunedin, New Zealand.
RP Egere, U (reprint author), MRC Unit, Banjul, Gambia.
EM uegere@mrc.gm; Philip.hill@otago.ac.nz
FU Medical Research Council, United Kingdom
FX The study was funded by the Medical Research Council, United Kingdom
   (www.mrc.ac.uk). The funders had no role in study design, data
   collection and analysis, decision to publ ish or preparation of the
   manuscript.
CR Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Almagro C, 2008, CLIN INFECT DIS, V46, P174
   Black S, 2004, PEDIATR INFECT DIS J, V23, P485, DOI 10.1097/01.inf.0000129685.04847.94
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Centers for Disease Control and Prevention (CDC), 2005, MMWR-MORBID MORTAL W, V54, P893
   Cheung YB, 2009, PEDIAT INFECT DIS J
   CORTESE MM, 1992, ARCH INTERN MED, V152, P2277, DOI 10.1001/archinte.152.11.2277
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525
   Dunais B, 2008, PEDIATR INFECT DIS J, V27, P1033, DOI 10.1097/INF.0b013e31817bb8cf
   Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602
   Frazao N, 2005, PEDIATR INFECT DIS J, V24, P243, DOI 10.1097/01.inf.0000154326.77617.3c
   Ghaffar F, 2004, CLIN INFECT DIS, V39, P930, DOI 10.1086/423379
   Hill PC, CLIN INFECT DIS, V50, P1468
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Huang SS, 2005, PEDIATRICS, V116, pE408, DOI 10.1542/peds.2004-2338
   Huang SS, 2009, PEDIATRICS, V124, pE1, DOI 10.1542/peds.2008-3099
   Hussain M, 2005, EPIDEMIOL INFECT, V133, P891, DOI 10.1016/S0950268805004012
   Isaacman DJ, 2007, VACCINE, V25, P2420, DOI 10.1016/j.vaccine.2006.09.011
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Lehmann D, 2003, VACCINE, V21, P3446, DOI 10.1016/S0264-410X(03)00348-7
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   Millar EV, 2008, CLIN INFECT DIS, V47, P989, DOI 10.1086/591966
   Millar EV, 2006, CLIN INFECT DIS, V43, P8, DOI 10.1086/504802
   Munoz FM, 2001, VACCINE, V20, P826, DOI 10.1016/S0264-410X(01)00397-8
   O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833
   O'Brien Katherine L, 2003, Pediatr Infect Dis J, V22, pe1, DOI 10.1097/01.inf.0000049347.42983.77
   Obaro SK, 2004, PEDIATR INFECT DIS J, V23, P1023, DOI 10.1097/01.inf.0000143651.54880.09
   Pelton SI, 2007, PEDIATR INFECT DIS J, V26, P468, DOI 10.1097/TNF.0b013e31803df9ca
   Poehling KA, 2006, JAMA-J AM MED ASSOC, V295, P1668, DOI 10.1001/jama.295.14.1668
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2
   [Anonymous], 1999, PEDIAT INFECT DIS J, V18, pS1
NR 36
TC 10
Z9 10
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 21
PY 2012
VL 7
IS 11
AR e49143
DI 10.1371/journal.pone.0049143
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 047ER
UT WOS:000311821000030
PM 23185303
OA gold
DA 2017-08-15
ER

PT J
AU Vannberg, FO
   McDermid, JM
   Jaye, A
AF Vannberg, Fredrik O.
   McDermid, Joann M.
   Jaye, Assan
CA MRC Gambia HIV Clinical Cohort
TI Effect of HIV-2 Infection on HIV-1 Disease Progression
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID PLASMA VIRAL LOAD; SURVIVAL
C1 [Vannberg, Fredrik O.] Georgia Inst Technol, Atlanta, GA 30332 USA.
   [McDermid, Joann M.] Cornell Univ, Ithaca, NY USA.
   [Jaye, Assan] MRC Gambia, Fajara, Gambia.
RP Vannberg, FO (reprint author), Georgia Inst Technol, Atlanta, GA 30332 USA.
EM fredrik.vannberg@biology.gatech.edu
FU Medical Research Council [MC_UP_A900_1125]
CR Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Andersson S, 2000, ARCH INTERN MED, V160, P3286, DOI 10.1001/archinte.160.21.3286
   Nkengasong JN, 2000, AIDS RES HUM RETROV, V16, P1371, DOI 10.1089/08892220050140919
   van der Loeff MFS, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-46
NR 4
TC 0
Z9 0
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 15
PY 2012
VL 367
IS 20
BP 1962
EP 1962
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 036MB
UT WOS:000311029300025
PM 23150975
OA No
DA 2017-08-15
ER

PT J
AU Amambua-Ngwa, A
   Tetteh, KKA
   Manske, M
   Gomez-Escobar, N
   Stewart, LB
   Deerhake, ME
   Cheeseman, IH
   Newbold, CI
   Holder, AA
   Knuepfer, E
   Janha, O
   Jallow, M
   Campino, S
   Maclnnis, B
   Kwiatkowski, DP
   Conway, DJ
AF Amambua-Ngwa, Alfred
   Tetteh, Kevin K. A.
   Manske, Magnus
   Gomez-Escobar, Natalia
   Stewart, Lindsay B.
   Deerhake, M. Elizabeth
   Cheeseman, Ian H.
   Newbold, Christopher I.
   Holder, Anthony A.
   Knuepfer, Ellen
   Janha, Omar
   Jallow, Muminatou
   Campino, Susana
   Maclnnis, Bronwyn
   Kwiatkowski, Dominic P.
   Conway, David J.
TI Population Genomic Scan for Candidate Signatures of Balancing Selection
   to Guide Antigen Characterization in Malaria Parasites
SO PLOS GENETICS
LA English
DT Article
ID APICAL MEMBRANE ANTIGEN-1; PLASMODIUM-FALCIPARUM MALARIA; DNA
   POLYMORPHISM ANALYSES; NATURAL-SELECTION; ERYTHROCYTE INVASION; POSITIVE
   SELECTION; TRANSCRIPTOME ANALYSIS; ANTIBODY-RESPONSES; MULTIGENE FAMILY;
   GENE-EXPRESSION
AB Acquired immunity in vertebrates maintains polymorphisms in endemic pathogens, leading to identifiable signatures of balancing selection. To comprehensively survey for genes under such selection in the human malaria parasite Plasmodium falciparum, we generated paired-end short-read sequences of parasites in clinical isolates from an endemic Gambian population, which were mapped to the 3D7 strain reference genome to yield high-quality genome-wide coding sequence data for 65 isolates. A minority of genes did not map reliably, including the hypervariable var, rifin, and stevor families, but 5,056 genes (90.9% of all in the genome) had >70% sequence coverage with minimum read depth of 5 for at least 50 isolates, of which 2,853 genes contained 3 or more single nucleotide polymorphisms (SNPs) for analysis of polymorphic site frequency spectra. Against an overall background of negatively skewed frequencies, as expected from historical population expansion combined with purifying selection, the outlying minority of genes with signatures indicating exceptionally intermediate frequencies were identified. Comparing genes with different stage-specificity, such signatures were most common in those with peak expression at the merozoite stage that invades erythrocytes. Members of clag, PfMC-2TM, surfin, and msp3-like gene families were highly represented, the strongest signature being in the msp3-like gene PF10_0355. Analysis of msp3-like transcripts in 45 clinical and 11 laboratory adapted isolates grown to merozoite-containing schizont stages revealed surprisingly low expression of PF10_0355. In diverse clonal parasite lines the protein product was expressed in a minority of mature schizonts (<1% in most lines and similar to 10% in clone HB3), and eight sub-clones of HB3 cultured separately had an intermediate spectrum of positive frequencies (0.9 to 7.5%), indicating phase variable expression of this polymorphic antigen. This and other identified targets of balancing selection are now prioritized for functional study.
C1 [Amambua-Ngwa, Alfred; Gomez-Escobar, Natalia; Cheeseman, Ian H.; Janha, Omar; Jallow, Muminatou; Conway, David J.] MRC Unit, Banjul, Gambia.
   [Tetteh, Kevin K. A.; Stewart, Lindsay B.; Deerhake, M. Elizabeth; Cheeseman, Ian H.; Conway, David J.] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London WC1, England.
   [Manske, Magnus; Campino, Susana; Maclnnis, Bronwyn; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Hinxton, England.
   [Newbold, Christopher I.] Univ Oxford, Weatherall Inst Mol Med, Oxford, England.
   [Holder, Anthony A.; Knuepfer, Ellen] Natl Inst Med Res, MRC, Div Parasitol, London NW7 1AA, England.
   [Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
RP Amambua-Ngwa, A (reprint author), MRC Unit, Banjul, Gambia.
EM david.conway@lshtm.ac.uk
RI Holder, Anthony/A-7554-2013
OI Holder, Anthony/0000-0002-8490-6058; cheeseman, ian/0000-0003-4426-4027;
   Newbold, Chris/0000-0002-9274-3789; Kwiatkowski,
   Dominic/0000-0002-5023-0176; Manske, Magnus/0000-0001-5916-0947; Conway,
   David/0000-0002-8711-3037
FU Wellcome Trust [074695/Z/04/B, 098051, 090770/Z/09/Z]; UK Medical
   Research Council [U117532067, G0600718]; European Union Network of
   Excellence EviMalaR [Health-2009-2.3.2-1-242095]
FX This research was supported by the Wellcome Trust (www.wellcome.ac.uk:
   grants 074695/Z/04/B, 098051, and 090770/Z/09/Z), the UK Medical
   Research Council (www.mrc.ac.uk: core funding for the MRC Gambia Unit,
   grant U117532067, and grant G0600718 for the Centre for Genomics and
   Global Health), and the European Union Network of Excellence EviMalaR
   (www.evimalar.org: grant Health-2009-2.3.2-1-242095). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Akey JM, 2009, GENOME RES, V19, P711, DOI 10.1101/gr.086652.108
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Anderson Tim J. C., 2004, Current Drug Targets - Infectious Disorders, V4, P65, DOI 10.2174/1568005043480943
   Anderson TJC, 2010, P ROY SOC B-BIOL SCI, V277, P2531, DOI 10.1098/rspb.2010.0196
   Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814
   Bozdech Z, 2003, PLOS BIOL, V1, pE5, DOI DOI 10.1371/J0URNAL.PBI0.0000005
   Charlesworth D, 2006, PLOS GENET, V2, P379, DOI 10.1371/journal.pgen.0020064
   Comeaux CA, 2011, MOL MICROBIOL, V80, P378, DOI 10.1111/j.1365-2958.2011.07572.x
   Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272
   CONWAY DJ, 1991, PARASITOLOGY, V103, P1
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   Cortes A, 2005, INFECT IMMUN, V73, P422, DOI 10.1128/IAI.73.1.422-430.2005
   Cortes A, 2003, INFECT IMMUN, V71, P1416, DOI 10.1128/IAI.71.3.1416-1426.2003
   Cortes A, 2007, PLOS PATHOG, V3, P1023, DOI 10.1371/journal.ppat.0030107
   Crowley VM, 2011, MOL MICROBIOL, V80, P391, DOI 10.1111/j.1365-2958.2011.07574.x
   Escalante AA, 1998, GENETICS, V149, P189
   Fowkes FJI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000218
   FU YX, 1993, GENETICS, V133, P693
   Fumagalli M, 2009, GENOME RES, V19, P199, DOI 10.1101/gr.082768.108
   Galamo CD, 2009, J INFECT DIS, V199, P1151, DOI 10.1086/597426
   Gomez-Escobar N, 2010, J INFECT DIS, V201, P444, DOI 10.1086/649902
   Grossman SR, 2010, SCIENCE, V327, P883, DOI 10.1126/science.1183863
   Healer J, 2004, MOL MICROBIOL, V52, P159, DOI 10.1111/j.1365-2958.2003.03974.x
   HUGHES MK, 1995, MOL BIOCHEM PARASIT, V71, P99, DOI 10.1016/0166-6851(95)00037-2
   Hutter S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-409
   Iriko H, 2008, MOL BIOCHEM PARASIT, V158, P11, DOI 10.1016/j.molbiopara.2007.11.004
   Jeffares DC, 2007, NAT GENET, V39, P120, DOI 10.1038/ng1931
   Jiang HY, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r33
   Jiang LB, 2010, P NATL ACAD SCI USA, V107, P2224, DOI 10.1073/pnas.0913396107
   Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449
   Kaewthamasorn M, 2011, PARASITOL INT, V61, P317
   Kaneko O, 2005, MOL BIOCHEM PARASIT, V143, P20, DOI 10.1016/j.molbiopara.2005.05.003
   Ko WY, 2011, AM J HUM GENET, V88, P741, DOI 10.1016/j.ajhg.2011.05.005
   Kusi KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015391
   Lavazec C, 2007, MOL MICROBIOL, V64, P1621, DOI 10.1111/j.1365-2958.2007.05767.x
   Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025
   Llinas M, 2006, NUCLEIC ACIDS RES, V34, P1166, DOI 10.1093/nar/gkj517
   Lopez-Rubio JJ, 2009, CELL HOST MICROBE, V5, P179, DOI 10.1016/j.chom.2008.12.012
   Mackinnon MJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000644
   Manske HM, 2009, GENOME RES, V19, P2125, DOI 10.1101/gr.093443.109
   Manske HM, 2009, BIOINFORMATICS, V25, P2434, DOI 10.1093/bioinformatics/btp403
   Manske M, 2012, NATURE, V487, P375, DOI 10.1038/nature11174
   Mu JB, 2007, NAT GENET, V39, P126, DOI 10.1038/ng1924
   Mu JB, 2010, NAT GENET, V42, P268, DOI 10.1038/ng.528
   Ndam NT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001855
   Neafsey DE, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r171
   Nery S, 2006, MOL BIOCHEM PARASIT, V149, P208, DOI 10.1016/j.molbiopara.2006.05.014
   Nkhoma SC, 2012, P ROY SOC B-BIOL SCI, V279, P2589, DOI 10.1098/rspb.2012.0113
   Nygaard S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001099
   Ochola LI, 2010, MOL BIOL EVOL, V27, P2344, DOI 10.1093/molbev/msq119
   Oleksyk TK, 2010, PHILOS T R SOC B, V365, P185, DOI 10.1098/rstb.2009.0219
   Osier FHA, 2010, INFECT IMMUN, V78, P4625, DOI 10.1128/IAI.00576-10
   Otto TD, 2010, MOL MICROBIOL, V76, P12, DOI 10.1111/j.1365-2958.2009.07026.x
   Park DJ, 2012, P NATL ACAD SCI US
   Pearce JA, 2005, MOL BIOCHEM PARASIT, V139, P141, DOI 10.1016/j.molbiopara.2004.09.012
   Polley SD, 2003, GENETICS, V165, P555
   Polley SD, 2003, INFECT IMMUN, V71, P1833, DOI 10.1128/IAI.71.4.1833-1842.2003
   Polley SD, 2001, GENETICS, V158, P1505
   Polley SD, 2007, J INFECT DIS, V195, P279, DOI 10.1086/509806
   Pollitt LC, 2011, AM NAT, V177, P358, DOI 10.1086/658175
   Reeder JC, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-126
   Rovira-Graells N, 2012, GENOME RES, V22, P925, DOI 10.1101/gr.129692.111
   Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359
   Sargeant TJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-r12
   Scherf A, 2008, ANNU REV MICROBIOL, V62, P445, DOI 10.1146/annurev.micro.61.080706.093134
   Singh S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005410
   Snounou G, 1999, T ROY SOC TROP MED H, V93, P369, DOI 10.1016/S0035-9203(99)90120-7
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351
   TAJIMA F, 1989, GENETICS, V123, P597
   TAJIMA F, 1989, GENETICS, V123, P585
   Tetteh KKA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005568
   Thera MA, 2011, NEW ENGL J MED, V365, P1004, DOI 10.1056/NEJMoa1008115
   Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009
   Van Tyne D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001383
   Verra F, 2006, MOL BIOCHEM PARASIT, V149, P182, DOI 10.1016/j.molbiopara.2006.05.010
   Volkman SK, 2007, NAT GENET, V39, P113, DOI 10.1038/ng1930
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Weedall GD, 2010, TRENDS PARASITOL, V26, P363, DOI 10.1016/j.pt.2010.04.002
   Wilson DJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002395
   Winter G, 2005, J EXP MED, V201, P1853, DOI 10.1084/jem.20041392
   Zhai WW, 2009, MOL BIOL EVOL, V26, P273, DOI 10.1093/molbev/msn231
NR 82
TC 49
Z9 49
U1 4
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD NOV
PY 2012
VL 8
IS 11
AR e1002992
DI 10.1371/journal.pgen.1002992
PG 14
WC Genetics & Heredity
SC Genetics & Heredity
GA 048DY
UT WOS:000311891600004
PM 23133397
OA gold
DA 2017-08-15
ER

PT J
AU Lindsay, SW
   Lindsay, TC
   Duprez, J
   Hall, MJR
   Kwambana, BA
   Jawara, M
   Nurudeen, IU
   Sallah, N
   Wyatt, N
   D'Alessandro, U
   Pinder, M
   Antonio, M
AF Lindsay, Steven W.
   Lindsay, Thomas C.
   Duprez, Jessica
   Hall, Martin J. R.
   Kwambana, Brenda A.
   Jawara, Musa
   Nurudeen, Ikumapayi U.
   Sallah, Neneh
   Wyatt, Nigel
   D'Alessandro, Umberto
   Pinder, Margaret
   Antonio, Martin
TI Chrysomya putoria, a Putative Vector of Diarrheal Diseases
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID ESCHERICHIA-COLI; DIPTERA CALLIPHORIDAE; MUSCA-DOMESTICA; FLY CONTROL;
   GAMBIA; FLIES; TRANSMISSION; SALMONELLA; HOUSEFLIES; SANITATION
AB Background: Chrysomya spp are common blowflies in Africa, Asia and parts of South America and some species can reproduce in prodigious numbers in pit latrines. Because of their strong association with human feces and their synanthropic nature, we examined whether these flies are likely to be vectors of diarrheal pathogens.
   Methodology/Principal Findings: Flies were sampled using exit traps placed over the drop holes of latrines in Gambian villages. Odor-baited fly traps were used to determine the relative attractiveness of different breeding and feeding media. The presence of bacteria on flies was confirmed by culture and bacterial DNA identified using PCR. A median of 7.00 flies/latrine/day (IQR = 0.0-25.25) was collected, of which 95% were Chrysomya spp, and of these nearly all were Chrysomya putoria (99%). More flies were collected from traps with feces from young children (median = 3.0, IQR = 1.75-10.75) and dogs (median = 1.50, IQR = 0.0-13.25) than from herbivores (median = 0.0, IQR = 0.0-0.0; goat, horse, cow and calf; p<0.001). Flies were strongly attracted to raw meat (median = 44.5, IQR = 26.25-143.00) compared with fish (median = 0.0, IQR = 0.0-19.75, ns), cooked and uncooked rice, and mangoes (median = 0.0, IQR = 0.0-0.0; p<0.001). Escherichia coli were cultured from the surface of 21% (15/72 agar plates) of Chrysomya spp and 10% of these were enterotoxigenic. Enteroaggregative E. coli were identified by PCR in 2% of homogenized Chrysomya spp, Shigella spp in 1.4% and Salmonella spp in 0.6% of samples.
   Conclusions/Significance: The large numbers of C. putoria that can emerge from pit latrines, the presence of enteric pathogens on flies, and their strong attraction to raw meat and fish suggests these flies may be common vectors of diarrheal diseases in Africa.
C1 [Lindsay, Steven W.; Pinder, Margaret] Univ Durham, Sch Biol & Biomed Sci, Durham, England.
   [Lindsay, Steven W.; Lindsay, Thomas C.; Duprez, Jessica; Pinder, Margaret] London Sch Hyg & Trop Med, London WC1, England.
   [Hall, Martin J. R.; Wyatt, Nigel] Nat Hist Museum, London SW7 5BD, England.
   [Kwambana, Brenda A.; Jawara, Musa; Nurudeen, Ikumapayi U.; Sallah, Neneh; D'Alessandro, Umberto; Antonio, Martin] MRC Unit, Fajara, Gambia.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
RP Lindsay, SW (reprint author), Univ Durham, Sch Biol & Biomed Sci, Durham, England.
EM S.W.Lindsay@durham.ac.uk
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Hall,
   Martin/0000-0002-8917-9646
FU Bill and Melinda Gates Foundation [OPP1034747]; Research and Policy for
   Infectious Disease Dynamics (RAPIDD) Program of the Science and
   Technology Directory; Department of Homeland Security; Fogarty
   International Center, National Institutes of Health, Medical Research
   Council, UK
FX The work was supported by the Bill and Melinda Gates Foundation
   (#OPP1034747; Grand Challenges Explorations Phase I, Round 6 Project
   Grant). SLW received support from the Research and Policy for Infectious
   Disease Dynamics (RAPIDD) Program of the Science and Technology
   Directory, Department of Homeland Security, and Fogarty International
   Center, National Institutes of Health, Medical Research Council, UK. The
   sponsors of the study did not have a role in the design of the study,
   data collection, analysis, interpretation and writing of this
   manuscript.
CR Bang YH, 1973, WHOVBC73451
   BERTRAM D. S., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P217, DOI 10.1016/0035-9203(58)90079-8
   Bervoets W, 1958, MEM ACAD ROY SCI COL, V7, P1
   Biggerstaff B. J., 2009, POOLEDINFRATE VERSIO
   BRYGOO E. R., 1962, BULL SOC PATHOL EXOT, V55, P866
   Cairncross S, 2010, INT J EPIDEMIOL, V39, P193, DOI 10.1093/ije/dyq035
   Cerigatto W, 2009, J ANIM VET ADV, V8, P534
   Chavasse DC, 1999, LANCET, V353, P22, DOI 10.1016/S0140-6736(98)03366-2
   Clermont O, 2000, APPL ENVIRON MICROB, V66, P4555, DOI 10.1128/AEM.66.10.4555-4558.2000
   COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N
   Cunningham SA, 2010, J CLIN MICROBIOL, V48, P2929, DOI 10.1128/JCM.00339-10
   CURTIS CF, 1982, T ROY SOC TROP MED H, V76, P99, DOI 10.1016/0035-9203(82)90031-1
   Dione MM, 2011, J INFECT DEV COUNTR, V5, P765
   Emerson PM, 2005, TROP MED INT HEALTH, V10, P706, DOI 10.1111/j.1365-3156.2005.01432.x
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   Feachem R.G., 1983, SANITATION DIS HLTH
   GREENBERG B, 1965, SCI AM, V213, P92
   Greenberg B, 1966, BACTERIAL INTERACTIO, P371
   Greenberg B., 1971, FLIES DIS ECOLOGY CL
   Greenberg B., 1973, FLIES DIS BIOL DIS T
   Woodhill Gurney W, 1926, AGRIC DEPT NEW SOUTH, V27, P4
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Kobayashi M, 1999, AM J TROP MED HYG, V61, P625
   Lane RP, 1993, MED INSECTS ARACHNID
   LAURENCE BR, 1988, MED VET ENTOMOL, V2, P285, DOI 10.1111/j.1365-2915.1988.tb00197.x
   LEWIS D. J., 1955, BULL SOC ENT EGYPTE, V39, P275
   MARA D, 1984, DESIGN VENTILATED IM
   Mendonca PM, 2012, MICROSC RES TECHNIQ, V75, P206, DOI 10.1002/jemt.21044
   Morgan P R, 1977, Cent Afr J Med, V23, P1
   Nguyen TV, 2005, J CLIN MICROBIOL, V43, P755, DOI 10.1128/JCM.43.2.755-760.2005
   NORRIS KR, 1965, ANNU REV ENTOMOL, V10, P47, DOI 10.1146/annurev.en.10.010165.000403
   Prins A.J., 1982, Annals of the South African Museum, V90, P201
   Rozendaal JA, 1997, VECTOR CONTROL METHO
   Service M.W., 1976, MOSQUITO ECOLOGY FIE
   Simms VM, 2005, T ROY SOC TROP MED H, V99, P631, DOI 10.1016/j.trstmh.2004.10.004
   Smith K. G. V, 1973, INSECTS OTHER ARTHRO
   Smith KGV, 1986, MANUAL FORENSIC ENTO
   Thyssen PJ, 2010, CURRENT CONCEPTS IN FORENSIC ENTOMOLOGY, P25, DOI 10.1007/978-1-4020-9684-6_2
   United Nations, 2011, MILL DEV GOALS REP 2
   unicef and world health organization, 2012, PROGR DRINK WAT SAN
   UNICEF/ WHO, 2009, DIARRH WHY CHILDR ST
   WATT J, 1948, PUBLIC HEALTH REP, V63, P1319, DOI 10.2307/4586723
   Woolhouse MEJ, 1997, P NATL ACAD SCI USA, V94, P338, DOI 10.1073/pnas.94.1.338
   Zumpt F, 1965, MYIASIS MAN ANIMALS
NR 45
TC 10
Z9 10
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD NOV
PY 2012
VL 6
IS 11
AR e1895
DI 10.1371/journal.pntd.0001895
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 048CX
UT WOS:000311888900023
PM 23133694
OA gold
DA 2017-08-15
ER

PT J
AU Talisuna, A
   Karema, C
   Ogutu, B
   Juma, E
   Logedi, J
   Nyandigisi, A
   Mulenga, M
   Mbacham, WF
   Roper, C
   Guerin, PJ
   D'Alessandro, U
   Snow, RW
AF Talisuna, Ambrose
   Karema, Corine
   Ogutu, Bernhards
   Juma, Elizabeth
   Logedi, John
   Nyandigisi, Andrew
   Mulenga, Modest
   Mbacham, Wilfred F.
   Roper, Cally
   Guerin, Philippe J.
   D'Alessandro, Umberto
   Snow, Robert W.
TI Mitigating the threat of artemisinin resistance in Africa: improvement
   of drug-resistance surveillance and response systems
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; SUB-SAHARAN AFRICA;
   ARTEMETHER-LUMEFANTRINE; TREATMENT POLICY; SULFADOXINE-PYRIMETHAMINE;
   DIHYDROFOLATE-REDUCTASE; CHLOROQUINE RESISTANCE; EAST-AFRICA; GLOBAL
   FUND; EFFICACY
AB Artemisinin-resistant Plasmodium falciparum malaria has emerged in western Cambodia and has been detected in western Thailand. The situation is ominously reminiscent of the emergence of resistance to chloroquine and to sulfadoxine pyrimethamine several decades ago. Artemisinin resistance is a major threat to global public health, with the most severe potential effects in sub-Saharan Africa, where the disease burden is highest and systems for monitoring and containment of resistance are inadequate. The mechanisms that underlie artemisinin resistance are not fully understood. The main phenotypic trait associated with resistance is a substantial delay in parasite clearance, so far reported in southeast Asia but not in Africa. One of the pillars of the WHO global plan for artemisinin resistance containment is to increase monitoring and surveillance. In this Personal View, we propose strategies that should be adopted by malaria-endemic countries in Africa: resource mobilisation to reactivate regional surveillance networks, establishment of baseline parasite clearance profiles to serve as benchmarks to track emerging artemisinin resistance, improved data sharing to allow pooled analyses to identify rare events, modelling of risk factors for drug resistance, and development and validation of new approaches to monitor resistance.
C1 [Talisuna, Ambrose] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 7LJ, England.
   [Talisuna, Ambrose; Snow, Robert W.] Univ Oxford & KEMRI Wellcome Trust Res Programme, Nairobi, Kenya.
   [Talisuna, Ambrose; Guerin, Philippe J.] Worldwide Antimalarial Resistance Network, Oxford, England.
   [Karema, Corine] Minist Hlth, Rwanda Biomed Ctr, Malaria & Other Parasit Dis Div, Kigali, Rwanda.
   [Ogutu, Bernhards] Kenya Govt Med Res Ctr, Walter Reed Project, Kisumu, Kenya.
   [Juma, Elizabeth] Kenya Govt Med Res Ctr, Nairobi, Kenya.
   [Logedi, John; Nyandigisi, Andrew] Minist Hlth, Div Malaria Control, Nairobi, Kenya.
   [Mulenga, Modest] Dis Res Ctr, Ndola, Zambia.
   [Mbacham, Wilfred F.] Univ Yaounde I, Ctr Biotechnol, Yaounde, Cameroon.
   [Roper, Cally] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
RP Talisuna, A (reprint author), Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, S Parks Rd, Oxford OX3 7LJ, England.
EM ambrose.talisuna@wwarn.org
RI D'Alessandro, Umberto/D-3457-2015; Roper, Cally/K-2989-2013
OI D'Alessandro, Umberto/0000-0001-6341-5009; Roper,
   Cally/0000-0002-6545-309X; Mbacham, Wilfred/0000-0002-3934-3233
FU Sanofi; Pfizer; Novartis; Sigma Tau; Worldwide Antimalarial Resistance
   Network through Bill & Melinda Gates Foundation [48807.01]; Wellcome
   Trust [079080, 092654/Z/10/A]
FX AOT and RWS have been invited speakers at scientific symposia organised
   by Novartis, Pfizer, Sigma Tau, and Sanofi. AOT has received a research
   grant from Sanofi and RWS has received research grants from Pfizer and
   Novartis. RWS and AOT have been co-chairpersons of best-practice
   workshops in regional and national malaria control programmes sponsored
   by Novartis, for which they received honoraria. UD'A has been an invited
   speaker at symposia organised by Sigma Tau and Novartis, and has
   received a research grant from Sigma Tau. BO has been an invited speaker
   at scientific symposia organised by Novartis, Sanofi, and Pfizer and has
   received research grants from the same companies. All the other authors
   declare that they have no conflicts of interest.; AOT is supported by
   the Worldwide Antimalarial Resistance Network through a grant from the
   Bill & Melinda Gates Foundation (grant number 48807.01). RWS is
   supported by the Wellcome Trust as Principal Research Fellow (grant
   number 079080). AOT and RWS acknowledge support from the Wellcome Trust
   core grant number 092654/Z/10/A.
CR Amin AA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-72
   Attaran A, 2004, LANCET, V363, P237, DOI 10.1016/S0140-6736(03)15330-5
   BLOLAND PB, 1993, J INFECT DIS, V167, P932
   Bruce-Chwatt LJ., 1986, WHO MONOGRAPH SERIES
   CAMPBELL CC, 1979, LANCET, V2, P1151
   Chan M, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000223
   Cheeseman IH, 2012, SCIENCE, V336, P79, DOI 10.1126/science.1215966
   Clyde D. F., 1966, East African Medical Journal, V43, P405
   Cox J, 2007, EMERG INFECT DIS, V13, P779
   Denis MB, 2006, TROP MED INT HEALTH, V11, P1800, DOI 10.1111/j.1365-3156.2006.01739.x
   Djimde A, 2001, LANCET, V358, P890, DOI 10.1016/S0140-6736(01)06040-8
   Dondorp AM, 2004, TROP MED INT HEALTH, V9, P1241, DOI 10.1111/j.1365-3156.2004.01342.x
   Dondorp AM, 2010, NAT REV MICROBIOL, V8, P272, DOI 10.1038/nrmicro2331
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Dorsey G, 2001, J INFECT DIS, V183, P1417, DOI 10.1086/319865
   Flegg JA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-339
   Frosch AEP, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-116
   Gardella F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-124
   HARINASU.T, 1965, LANCET, V2, P657
   Hastings IM, 2000, PARASITOL TODAY, V16, P340, DOI 10.1016/S0169-4758(00)01707-5
   Hastings IM, 2002, PHILOS T ROY SOC B, V357, P505, DOI 10.1098/rstb.2001.1036
   Hodel EM, 2010, J INFECT DIS, V202, P1088, DOI 10.1086/655779
   Imwong M, 2010, ANTIMICROB AGENTS CH, V54, P2886, DOI 10.1128/AAC.00032-10
   Kublin JG, 2003, J INFECT DIS, V187, P1870, DOI 10.1086/375419
   Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566
   Laufer MK, 2010, J INFECT DIS, V202, P801, DOI 10.1086/655659
   LEMESHOW S, 1991, World Health Statistics Quarterly, V44, P115
   Lynch C, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001040
   Malik EM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-65
   Malisa AL, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-190
   Mharakurwa S, 2004, INT J PARASITOL, V34, P1483, DOI 10.1016/j.ijpara.2004.10.011
   Mulligan JA, 2006, TROP MED INT HEALTH, V11, P452, DOI 10.1111/j.1365-3156.2006.01590.x
   Mutabingwa TK, 2001, TROP MED INT HEALTH, V6, P891
   Naidoo I, 2010, TRENDS PARASITOL, V26, P447, DOI 10.1016/j.pt.2010.05.001
   Najera J. A., 1999, Parassitologia (Rome), V41, P339
   Newton PN, 2006, PLOS MED, V3, P752, DOI 10.1371/journal.pmed.0030197
   Nsubuga P, 2009, GLOB PUBLIC HEALTH, V13, P1
   Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520
   Nzila AM, 2000, ANTIMICROB AGENTS CH, V44, P991, DOI 10.1128/AAC.44.4.991-996.2000
   PAYNE D, 1988, PARASITOL TODAY, V4, P112, DOI 10.1016/0169-4758(88)90042-7
   Pearce RJ, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000055
   Phyo AP, 2012, LANCET, V379, P1960, DOI 10.1016/S0140-6736(12)60484-X
   Plowe CV, 1996, AM J TROP MED HYG, V55, P467
   Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860
   Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876
   Sipilanyambe N, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-25
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Stepniewska K, 2010, J INFECT DIS, V201, P570, DOI 10.1086/650301
   Talisuna AO, 2007, AM J TROP MED HYG, V77, P170
   Talisuna AO, 2003, T ROY SOC TROP MED H, V97, P338, DOI 10.1016/S0035-9203(03)90163-5
   Talisuna AO, 2004, CLIN MICROBIOL REV, V17, P235, DOI 10.1128/CMR.17.1.235-254.2004
   Tatem AJ, 2010, P NATL ACAD SCI USA, V107, P12222, DOI 10.1073/pnas.1002971107
   Teklehaimanot HD, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-44
   Thomson MC, 2006, NATURE, V439, P576, DOI 10.1038/nature04503
   Tren R, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-305
   Van Geertruyden JP, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-134
   Watkins WM, 1997, PARASITOL TODAY, V13, P459, DOI 10.1016/S0169-4758(97)01124-1
   WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0
   WERNSDORFER WH, 1994, ACTA TROP, V56, P143, DOI 10.1016/0001-706X(94)90060-4
   White NJ, 2003, P ROY SOC B-BIOL SCI, V270, P545, DOI 10.1098/rspb.2002.2241
   White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   WHO, 2003, ASS MON ANT DRUG EFF
   World Health Organization (WHO), 2011, GLOB PLAN ART RES CO
   *WHO, 2001, ANT DRUG COMB THER R
   World Health Organization, 2010, GUID TREATM MAL
   World Health Organization, 2005, INT HLTH REG 2005
   WHO, 1996, ASS THER EFF ANT DRU
   WHO, 1965, WHO TECHN REP SER
   WHO Regional Office for Africa, 1999, INT DIS SURV STRAT R
   Williams HA, 2004, HEALTH POLICY PLANN, V19, P356, DOI 10.1093/heapol/czh051
   Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813
   Yeung S, 2004, AM J TROP MED HYG, V71, P179
   Zurovac D, 2005, BRIT MED J, V331, P734, DOI 10.1136/bmj.331.7519.734
   Zurovac D, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001176
   Zurovac D, 2011, LANCET, V378, P795, DOI 10.1016/S0140-6736(11)60783-6
   Zurovac D, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-181
NR 77
TC 33
Z9 34
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD NOV
PY 2012
VL 12
IS 11
BP 888
EP 896
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 029JT
UT WOS:000310492300028
PM 23099083
OA No
DA 2017-08-15
ER

PT J
AU Lemoine, M
   Girard, PM
   Thursz, M
   Raguin, G
AF Lemoine, Maud
   Girard, Pierre-Marie
   Thursz, Mark
   Raguin, Gilles
TI In the shadow of HIV/AIDS: Forgotten diseases in sub-Saharan Africa:
   Global health issues and funding agency responsibilities
SO JOURNAL OF PUBLIC HEALTH POLICY
LA English
DT Editorial Material
DE HIV/AIDS; resource limited settings; Africa; viral hepatitis;
   non-communicable diseases; public health policy
ID NONCOMMUNICABLE DISEASES; BURDEN; PREVENTION; COUNTRIES; SYSTEMS; VIRUS
AB The HIV/AIDS pandemic has generated international solidarity, particularly with sub-Saharan Africa. The mainly vertical approach to this challenge has, however, mobilized so much attention and so many resources that other crucial public health problems, such as chronic viral hepatitis and non-communicable diseases (NCDs), have been left in the shadows. One year after the first official World Hepatitis Day launched by WHO and the first UN meeting on NCDs, the world needs a vigorous debate on a more comprehensive approach to public health challenges in developing countries. Journal of Public Health Policy (2012) 33, 430-438. doi:10.1057/jphp.2012.29; published online 16 August 2012
C1 [Lemoine, Maud; Thursz, Mark] MRC, Gambia Unit, Div Hepatol, Fajara, Gambia.
   [Thursz, Mark] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Med, Hepatol Unit, London, England.
   [Girard, Pierre-Marie; Raguin, Gilles] Hop St Antoine, Serv Malad Infect & Trop, F-75571 Paris, France.
   [Girard, Pierre-Marie] INSERM, Dept Epidemiol, UMRS 707, Paris, France.
   [Raguin, Gilles] ESTHER, French Natl Aid Agcy HIV AIDS, Paris, France.
RP Lemoine, M (reprint author), MRC, Gambia Unit, Div Hepatol, Atlantic Rd,POB 273, Fajara, Gambia.
EM mlemoine@mrc.gm
CR Beaglehole R, 2011, LANCET, V378, P449, DOI 10.1016/S0140-6736(11)60879-9
   Burket BA, 2006, ETHNIC DIS, V16, P292
   Cerqueira MT, 2011, BMJ-BRIT MED J, V342, pd3823
   DFID, 2011, HLTH IS GLOB OUTC FR
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Garrett L, 2012, NATURE, V482, P7, DOI 10.1038/482007a
   The Global Fund, 2011, GLOB FUNDS APPR HLTH
   Goldstein ST, 2005, INT J EPIDEMIOL, V34, P1329, DOI 10.1093/ije/dyi206
   International Diabetes Foundation, 2007, DIABETES ATLAS
   Koffigan E.A., 2011, HLTH BATTLING HEPATI
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Lim SS, 2007, LANCET, V370, P2054, DOI 10.1016/S0140-6736(07)61699-7
   Logie DE, 2008, LANCET, V372, P256, DOI 10.1016/S0140-6736(08)60962-9
   Ministry of Health RoR, 2006, USAID NAT HLTH ACC R
   Narayan KMV, 2011, NEW ENGL J MED, V365, P876, DOI 10.1056/NEJMp1107189
   Ooms G, 2008, GLOBALIZATION HEALTH, V4, DOI 10.1186/1744-8603-4-6
   Parkin DM, 2008, LANCET ONCOL, V9, P683, DOI 10.1016/S1470-2045(08)70175-X
   Pratt B, 2012, B WORLD HEALTH ORGAN, V90, P55, DOI 10.2471/BLT.11.092007
   Puoti M, 2011, CURR OPIN HIV AIDS, V6, P534, DOI 10.1097/COH.0b013e32834bd2b7
   Sambo L.G., 2011, CANC CAN BE PREVENTE
   Shiffman J, 2008, HEALTH POLICY PLANN, V23, P95, DOI 10.1093/heapol/czm045
   Thursz M, 2010, TROP MED INT HEALTH, V15, P2, DOI 10.1111/j.1365-3156.2009.02410.x
   United Nations Programme on HIV/AIDS (UNAIDS), 2010, REP GLOB AIDS EP
   WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804
   Ward JW, 2011, LANCET, V378, P552, DOI 10.1016/S0140-6736(11)60839-8
   World Health Organization (WHO), 2000, HLTH SYST IMPR PERF
   World Health Organization, 2001, AB DECL
   World Health Organization, 2011, GLOB BURD DIS 2004 U
   WHO, 2011, PROJ MORT GLOB BURD
   Wiersma Steven T, 2011, Liver Int, V31, P755, DOI 10.1111/j.1478-3231.2010.02373.x
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   World Bank, 2009, WORLD BANK GROUP GUARANTEE INSTRUMENTS, 1990-2007: AN INDEPENDENT EVALUATION, P1, DOI 10.1596/978-0-8213-7679-9
   [Anonymous], 2008, PRIMARY HLTH CARE NO
NR 33
TC 7
Z9 7
U1 0
U2 16
PU PALGRAVE MACMILLAN LTD
PI BASINGSTOKE
PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND
SN 0197-5897
J9 J PUBLIC HEALTH POL
JI J. Public Health Policy
PD NOV
PY 2012
VL 33
IS 4
BP 430
EP 438
DI 10.1057/jphp.2012.29
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 033GL
UT WOS:000310782100006
PM 22895470
OA No
DA 2017-08-15
ER

PT J
AU Sirugo, G
   Edwards, DRV
   Ryckman, KK
   Bisseye, C
   White, MJ
   Kebbeh, B
   Morris, GAJ
   Adegbola, RA
   Tacconelli, A
   Predazzi, IM
   Novelli, G
   Vannberg, FO
   Odunsi, K
   Page, GP
   Williams, SM
AF Sirugo, Giorgio
   Edwards, Digna R. Velez
   Ryckman, Kelli K.
   Bisseye, Cyrille
   White, Marquitta J.
   Kebbeh, Bunja
   Morris, Gerard A. J.
   Adegbola, Richard A.
   Tacconelli, Alessandra
   Predazzi, Irene M.
   Novelli, Giuseppe
   Vannberg, Fredrik O.
   Odunsi, Kunle
   Page, Grier P.
   Williams, Scott M.
TI PTX3 Genetic Variation and Dizygotic Twinning in The Gambia: Could
   Pleiotropy with Innate Immunity Explain Common Dizygotic Twinning in
   Africa?
SO ANNALS OF HUMAN GENETICS
LA English
DT Article
DE Dizygotic twinning; fertility; innate immunity; Pentraxin 3; The Gambia;
   Africa
ID LONG PENTRAXIN PTX3; GROWTH-DIFFERENTIATION FACTOR-9;
   EXTRACELLULAR-MATRIX; RURAL GAMBIA; ASSOCIATION; TWINS; TUBERCULOSIS;
   FERTILITY; MORTALITY; SELECTION
AB Dizygotic (DZ) twinning has a genetic component and is common among sub-Saharan Africans; in The Gambia its frequency is up to 3% of live births. Variation in PTX3, encoding Pentraxin 3, a soluble pattern recognition receptor that plays an important role both in innate immunity and in female fertility, has been associated with resistance to Mycobacterium tuberculosis pulmonary disease and to Pseudomonas aeruginosa infection in cystic fibrosis patients. We tested whether PTX3 variants in Gambian women associate with DZ twinning, by genotyping five PTX3 single nucleotide polymorphisms (SNPs) in 130 sister pairs (96 full sibs and 34 half sibs) who had DZ twins. Two, three and five SNP haplotypes differed in frequency between twinning mothers and those without a history of twinning (from P= 0.006 to 3.03e-06 for two SNP and three SNP haplotypes, respectively). Twinning mothers and West African tuberculosis-controls from a previous study shared several frequent haplotypes. Most importantly, our data are consistent with an independently reported association of PTX3 and female fertility in a sample from Ghana. Taken together, these results indicate that selective pressure on PTX3 variants that affect the innate immune response to infectious agents, could also produce the observed high incidence of DZ twinning in Gambians.
C1 [Sirugo, Giorgio; Bisseye, Cyrille; Kebbeh, Bunja; Morris, Gerard A. J.; Adegbola, Richard A.] MRC Labs, Fajara, Gambia.
   [Sirugo, Giorgio; Tacconelli, Alessandra; Novelli, Giuseppe] Osped San Pietro FBF, Ctr Ric, Rome, Italy.
   [Edwards, Digna R. Velez; Ryckman, Kelli K.; White, Marquitta J.; Predazzi, Irene M.; Williams, Scott M.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA.
   [Ryckman, Kelli K.] Univ Iowa, Iowa City, IA USA.
   [Adegbola, Richard A.] GlaxoSmithKline Biol, Rixensart, Belgium.
   [Novelli, Giuseppe] Univ Roma Tor Vergata, Sch Med, Rome, Italy.
   [Vannberg, Fredrik O.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
   [Odunsi, Kunle] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
   [Page, Grier P.] RTI Int, Atlanta, GA USA.
RP Sirugo, G (reprint author), Osped San Pietro Fatebenefratelli, Ctr Ric, Via Cassia 600, I-00189 Rome, Italy.
EM sirugo.giorgio@fbfrm.it; Scott.williams@dartmouth.edu
RI Williams, Scott/B-9491-2012
OI Novelli, Giuseppe/0000-0002-7781-602X
FU NIH [2T32HL007751-16A2]; Medical Research Council (UK) [G0000690]
FX We gratefully acknowledge the participation of the many Gambian families
   who made this study possible. We would like to thank Dr Luca Lavra at
   Ospedale San Pietro FBF (Rome, Italy) for his helpful assistance during
   editing. Grant support: IP was supported by NIH grant 2T32HL007751-16A2;
   the twinning study in The Gambia was supported by the Medical Research
   Council (UK) award G0000690 to GS.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bottazzi B, 2009, IMMUNOL REV, V227, P9, DOI 10.1111/j.1600-065X.2008.00719.x
   Bowman J.E., 1990, GENETIC VARIATION DI
   Browning SR, 2005, GENET EPIDEMIOL, V28, P110, DOI 10.1002/gepi.20051
   Chiarini M, 2010, GENES IMMUN, V11, P665, DOI 10.1038/gene.2010.41
   Darwin Charles, 1871, DESCENT MAN SELECTIO, V1
   DEVLIN B, 1995, GENOMICS, V29, P311
   Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756
   Hancock DB, 2007, GENET EPIDEMIOL, V31, P883, DOI 10.1002/gepi.20249
   Helle S, 2004, EVOLUTION, V58, P430, DOI 10.1111/j.0014-3820.2004.tb01658.x
   Hoekstra C, 2008, HUM REPROD UPDATE, V14, P37, DOI 10.1093/humupd/dmm036
   Hoj L, 2002, BJOG-INT J OBSTET GY, V109, P792, DOI 10.1016/S1470-0328(02)01259-4
   Jaffar S, 1998, ANN TROP PAEDIATR, V18, P231
   Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282
   Lummaa V, 1998, NATURE, V394, P533, DOI 10.1038/28977
   Mantovani A, 2008, J CLIN IMMUNOL, V28, P1, DOI 10.1007/s10875-007-9126-7
   May L, 2010, BIOL REPROD, V82, P299, DOI 10.1095/biolreprod.109.079111
   Moalli F, 2011, J BIOMED BIOTECHNOL, P1, DOI 10.1155/2011/830421
   Montgomery GW, 2004, TWIN RES, V7, P548, DOI 10.1375/1369052042663823
   Newman R.B., 2000, MULTIFETAL PREGANCY
   Nylander P P, 1978, Prog Clin Biol Res, V24 Pt B, P35
   NYLANDER PP, 1971, J BIOSOC SCI, V3, P151
   NYLANDER PP, 1969, ANN HUM GENET, V33, P41, DOI 10.1111/j.1469-1809.1969.tb01627.x
   Olesen R, 2007, GENES IMMUN, V8, P456, DOI 10.1038/sj.gene.6364410
   Palmer JS, 2006, J CLIN ENDOCR METAB, V91, P4713, DOI 10.1210/jc.2006-0970
   PARISI P, 1983, NATURE, V304, P626, DOI 10.1038/304626a0
   Pate JL, 2001, REPRODUCTION, V122, P665, DOI 10.1530/rep.0.1220665
   Pison Gilles, 1992, MORTALITY SOC SUBSAH
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rovere P, 2000, BLOOD, V96, P4300
   Russell DL, 2006, SEMIN REPROD MED, V24, P217, DOI 10.1055/s-2006-948551
   Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056
   SCHMIDT HD, 1983, ANN HUM BIOL, V10, P371, DOI 10.1080/03014468300006541
   Sear R, 2000, P ROY SOC B-BIOL SCI, V267, P1641, DOI 10.1098/rspb.2000.1190
   Sear R, 2001, J EVOLUTION BIOL, V14, P433, DOI 10.1046/j.1420-9101.2001.00287.x
   Sedgwick W., 1863, BRIT FOREIGN MEDICOC, P170
   Smits J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025239
   Spanel-Borowski K, 2011, MOL CELL ENDOCRINOL, V333, P1, DOI 10.1016/j.mce.2010.12.008
   Thye T, 2010, NAT GENET, V42, P739, DOI 10.1038/ng.639
   van Rossum AP, 2004, ARTHRITIS RHEUM, V50, P2667, DOI 10.1002/art.20370
   Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154
   Vogel P., 1997, HDB HUMAN GENETICS
NR 43
TC 2
Z9 2
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-4800
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD NOV
PY 2012
VL 76
BP 454
EP 463
DI 10.1111/j.1469-1809.2012.00723.x
PN 6
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 021XF
UT WOS:000309918100003
PM 22834944
OA No
DA 2017-08-15
ER

PT J
AU Kong, R
   Li, H
   Georgiev, I
   Changela, A
   Bibollet-Ruche, F
   Decker, JM
   Rowland-Jones, SL
   Jaye, A
   Guan, YJ
   Lewis, GK
   Langedijk, JPM
   Hahn, BH
   Kwong, PD
   Robinson, JE
   Shaw, GM
AF Kong, Rui
   Li, Hui
   Georgiev, Ivelin
   Changela, Anita
   Bibollet-Ruche, Frederic
   Decker, Julie M.
   Rowland-Jones, Sarah L.
   Jaye, Assan
   Guan, Yongjun
   Lewis, George K.
   Langedijk, Johannes P. M.
   Hahn, Beatrice H.
   Kwong, Peter D.
   Robinson, James E.
   Shaw, George M.
TI Epitope Mapping of Broadly Neutralizing HIV-2 Human Monoclonal
   Antibodies
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; GP120 ENVELOPE GLYCOPROTEIN; PROXIMAL
   EXTERNAL REGION; MEMORY B-CELLS; MEDIATED NEUTRALIZATION; V3-SPECIFIC
   ANTIBODIES; POTENT NEUTRALIZATION; ANTIGENIC STRUCTURE; CORECEPTOR
   USAGE; CONSERVED REGION
AB Recent studies have shown that natural infection by HIV-2 leads to the elicitation of high titers of broadly neutralizing antibodies (NAbs) against primary HIV-2 strains (T. I. de Silva, et al., J. Virol. 86: 930-946, 2012; R. Kong, et al., J. Virol. 86:947-960, 2012; G. Ozkaya Sahin, et al., J. Virol. 86:961-971, 2012). Here, we describe the envelope (Env) binding and neutralization properties of 15 anti-HIV-2 human monoclonal antibodies (MAbs), 14 of which were newly generated from 9 chronically infected subjects. All 15 MAbs bound specifically to HIV-2 gp120 monomers and neutralized heterologous primary virus strains HIV-2(7312A) and HIV-2(ST). Ten of 15 MAbs neutralized a third heterologous primary virus strain, HIV-2(UC1). The median 50% inhibitory concentrations (IC(50)s) for these MAbs were surprisingly low, ranging from 0.007 to 0.028 mu g/ml. Competitive Env binding studies revealed three MAb competition groups: CG-I, CG-II, and CG-III. Using peptide scanning, site-directed mutagenesis, chimeric Env constructions, and single-cycle virus neutralization assays, we mapped the epitope of CG-I antibodies to a linear region in variable loop 3 (V3), the epitope of CG-II antibodies to a conformational region centered on the carboxy terminus of V4, and the epitope(s) of CG-III antibodies to conformational regions associated with CD4- and coreceptor-binding sites. HIV-2 Env is thus highly immunogenic in vivo and elicits antibodies having diverse epitope specificities, high potency, and wide breadth. In contrast to the HIV-1 Env trimer, which is generally well shielded from antibody binding and neutralization, HIV-2 is surprisingly vulnerable to broadly reactive NAbs. The availability of 15 human MAbs targeting diverse HIV-2 Env epitopes can facilitate comparative studies of HIV/SIV Env structure, function, antigenicity, and immunogenicity.
C1 [Kong, Rui; Li, Hui; Bibollet-Ruche, Frederic; Hahn, Beatrice H.; Shaw, George M.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kong, Rui; Decker, Julie M.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
   [Kong, Rui; Decker, Julie M.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Georgiev, Ivelin; Changela, Anita; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD USA.
   [Rowland-Jones, Sarah L.] John Radcliffe Hosp, Med Res Council, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [Jaye, Assan] Med Res Council United Kingdom Labs, Fajara, Gambia.
   [Guan, Yongjun; Lewis, George K.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.
   [Langedijk, Johannes P. M.] Pepscan Therapeut, Lelystad, Netherlands.
   [Robinson, James E.] Tulane Univ, Med Ctr, Dept Pediat, New Orleans, LA 70118 USA.
RP Shaw, GM (reprint author), Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM shawg@upenn.edu
FU NIH [AI67854, AI88564, AI87383]; Bill and Melinda Gates Foundation
FX This work was supported by intramural funding to the Vaccine Research
   Center, NIAID, and by grants from the NIH (AI67854, AI88564, AI87383),
   and grants from the Bill and Melinda Gates Foundation.
CR Bell CH, 2008, J MOL BIOL, V375, P969, DOI 10.1016/j.jmb.2007.11.013
   Binley JM, 2008, J VIROL, V82, P11651, DOI 10.1128/JVI.01762-08
   Binley JM, 1996, AIDS RES HUM RETROV, V12, P911, DOI 10.1089/aid.1996.12.911
   Bohne-Lang A, 2005, NUCLEIC ACIDS RES, V33, pW214, DOI 10.1093/nar/gki385
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Chen L, 2009, SCIENCE, V326, P1123, DOI 10.1126/science.1175868
   Cole KS, 2001, VIROLOGY, V290, P59
   Davis KL, 2009, VIROLOGY, V387, P414, DOI 10.1016/j.virol.2009.02.022
   Davis KL, 2009, J VIROL, V83, P1240, DOI 10.1128/JVI.01743-08
   de Silva TI, 2012, J VIROL, V86, P930, DOI 10.1128/JVI.06126-11
   Decker JM, 2005, J EXP MED, V201, P1407, DOI 10.1084/jem.20042510
   Dhillon AK, 2007, J VIROL, V81, P6548, DOI 10.1128/JVI.02749-06
   Doria-Rose NA, 2009, J VIROL, V83, P188, DOI 10.1128/JVI.01583-08
   Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130
   Gnanakaran S, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000955
   Gray ES, 2009, J VIROL, V83, P11265, DOI 10.1128/JVI.01359-09
   Gray ES, 2009, J VIROL, V83, P8925, DOI 10.1128/JVI.00758-09
   Guan YJ, 2009, P NATL ACAD SCI USA, V106, P3952, DOI 10.1073/pnas.0813392106
   Guillon C, 1998, J VIROL, V72, P6260
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607
   Hu GQ, 2011, J VIROL, V85, P2741, DOI 10.1128/JVI.01612-10
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   JAVAHERIAN K, 1994, J VIROL, V68, P2624
   Jiang XQ, 2010, NAT STRUCT MOL BIOL, V17, P955, DOI 10.1038/nsmb.1861
   KARWOWSKA S, 1992, AIDS RES HUM RETROV, V8, P1099, DOI 10.1089/aid.1992.8.1099
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Kong R, 2012, J VIROL, V86, P947, DOI 10.1128/JVI.06155-11
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   KWONG PD, 2011, CSH PERSPECT BIOL, V3, DOI DOI 10.1101/CSHPERSPECT.A007278
   Kwong PD, 2009, NAT IMMUNOL, V10, P573, DOI 10.1038/ni.1746
   Langedijk JPM, 1997, J VIROL, V71, P4055
   Letvin NL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002351
   Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   MCCLURE MO, 1987, NATURE, V330, P487, DOI 10.1038/330487a0
   Moore JP, 1996, J VIROL, V70, P1863
   Morner A, 1999, J VIROL, V73, P2343
   Musiani M, 2007, NAT PROTOC, V2, P2511, DOI 10.1038/nprot.2007.312
   MUSTER T, 1993, J VIROL, V67, P6642
   PALKER TJ, 1987, P NATL ACAD SCI USA, V84, P2479, DOI 10.1073/pnas.84.8.2479
   Pancera M, 2010, P NATL ACAD SCI USA, V107, P1166, DOI 10.1073/pnas.0911004107
   Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557
   Pinter A, 2007, CURR HIV RES, V5, P542, DOI 10.2174/157016207782418470
   Reeves JD, 2002, J GEN VIROL, V83, P1253, DOI 10.1099/vir.O.18253-O
   Ren XP, 2005, J VIROL, V79, P5616, DOI 10.1128/JVI.79.9.5616-5624.2005
   ROBEN P, 1994, J VIROL, V68, P4821
   Robinson JE, 1998, AIDS RES HUM RETROV, V14, P1253, DOI 10.1089/aid.1998.14.1253
   ROBINSON JE, 1990, AIDS RES HUM RETROV, V6, P567, DOI 10.1089/aid.1990.6.567
   Sahin GO, 2012, J VIROL, V86, P961, DOI 10.1128/JVI.06315-11
   Sather DN, 2009, J VIROL, V83, P757, DOI 10.1128/JVI.02036-08
   Sato S, 2008, J VIROL, V82, P9739, DOI 10.1128/JVI.00871-08
   Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227
   Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930
   Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09
   Sharp PM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006841
   Sol N, 1997, J VIROL, V71, P8237
   Stamatatos L, 2009, NAT MED, V15, P866, DOI 10.1038/nm.1949
   Stanfield RL, 2006, J VIROL, V80, P6093, DOI 10.1128/JVI.00205-06
   Stanfield RL, 2004, STRUCTURE, V12, P193, DOI 10.1016/j.str.2004.01.003
   THALI M, 1993, J VIROL, V67, P3978
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Timmerman P, 2005, CHEMBIOCHEM, V6, P821, DOI 10.1002/cbic.200400374
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   WEISS RA, 1988, AIDS, V2, P95, DOI 10.1097/00002030-198804000-00004
   White TA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001249
   Wu F, 2012, J VIROL, V86, P8835, DOI 10.1128/JVI.00923-12
   Wu SR, 2010, P NATL ACAD SCI USA, V107, P18844, DOI 10.1073/pnas.1007227107
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Yeh WW, 2010, J VIROL, V84, P6018, DOI 10.1128/JVI.02741-09
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
   Zolla-Pazner Susan, 2005, Human Antibodies, V14, P69
   Zwick MB, 2005, J VIROL, V79, P1252, DOI 10.1128/JVI.79.2.1252-1261.2005
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 85
TC 17
Z9 17
U1 0
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 2012
VL 86
IS 22
BP 12115
EP 12128
DI 10.1128/JVI.01632-12
PG 14
WC Virology
SC Virology
GA 027MK
UT WOS:000310356400014
PM 22933274
OA No
DA 2017-08-15
ER

PT J
AU Amambua-Ngwa, A
   Park, DJ
   Volkman, SK
   Barnes, KG
   Bei, AK
   Lukens, AK
   Sene, P
   Van Tyne, D
   Ndiaye, D
   Wirth, DF
   Conway, DJ
   Neafsey, DE
   Schaffner, SF
AF Amambua-Ngwa, Alfred
   Park, Daniel J.
   Volkman, Sarah K.
   Barnes, Kayla G.
   Bei, Amy K.
   Lukens, Amanda K.
   Sene, Papa
   Van Tyne, Daria
   Ndiaye, Daouda
   Wirth, Dyann F.
   Conway, David J.
   Neafsey, Daniel E.
   Schaffner, Stephen F.
TI SNP Genotyping Identifies New Signatures of Selection in a Deep Sample
   of West African Plasmodium falciparum Malaria Parasites
SO MOLECULAR BIOLOGY AND EVOLUTION
LA English
DT Article
DE Plasmodium falciparum; natural selection; SNP; genome; West Africa
ID CHLOROQUINE RESISTANCE; POSITIVE SELECTION; GENOME; POPULATION;
   RECOMBINATION; MUTATIONS; DIVERSITY; CELLS; GENE
AB We used a high-density single-nucleotide polymorphism array to genotype 75 Plasmodium falciparum isolates recently collected from Senegal and The Gambia to search for signals of selection in this malaria endemic region. We found little geographic or temporal stratification of the genetic diversity among the sampled parasites. Through application of the iHS and REHH haplotype-based tests for positive selection, we found evidence of recent selective sweeps at a known drug resistance locus, at several known antigenic loci, and at several genomic regions not previously identified as sites of recent selection. We discuss the value of deep population-specific genomic analyses for identifying selection signals within sampled endemic populations of parasites, which may correspond to local selection pressures such as distinctive therapeutic regimes or mosquito vectors.
C1 [Park, Daniel J.; Volkman, Sarah K.; Wirth, Dyann F.; Neafsey, Daniel E.; Schaffner, Stephen F.] Broad Inst, Cambridge, MA USA.
   [Amambua-Ngwa, Alfred] MRC Unit, Banjul, Gambia.
   [Volkman, Sarah K.; Barnes, Kayla G.; Bei, Amy K.; Lukens, Amanda K.; Van Tyne, Daria; Wirth, Dyann F.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.
   [Volkman, Sarah K.] Simmons Coll, Boston, MA USA.
   [Sene, Papa; Ndiaye, Daouda] Cheikh Anta Diop Univ, Dakar, Senegal.
   [Conway, David J.] London Sch Hyg & Trop Med, London WC1, England.
RP Schaffner, SF (reprint author), Broad Inst, Cambridge, MA USA.
EM sfs@broadinstitute.org
RI Schaffner, Stephen/D-1189-2011
OI Conway, David/0000-0002-8711-3037
FU Bill and Melinda Gates Foundation; Ellison Medical Foundation;
   ExxonMobil Foundation; NIH Fogarty; Broad Institute; NIAID; UK Medical
   Research Council; NSF
FX The authors thank colleagues at the MRC Unit in The Gambia including
   Michael Walther and Omar Janha for support in sample collection and
   processing. They thank colleagues at the Universite Cheikh Anta Diop and
   L'hopital Aristide le Dantec for support in sample collection and
   processing. This study was supported by the Bill and Melinda Gates
   Foundation, the Ellison Medical Foundation, the ExxonMobil Foundation,
   NIH Fogarty, the Broad Institute, and NIAID. A.A.-N. and D.J.C. were
   supported by funding from the UK Medical Research Council. D.J.P. was
   supported by an NSF Graduate Research Fellowship.
CR Cortes A, 2003, INFECT IMMUN, V71, P1416, DOI 10.1128/IAI.71.3.1416-1426.2003
   Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(00)00084-8
   Ghosh AK, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000265
   Gunasekera AM, 2007, MOL BIOL EVOL, V24, P939, DOI 10.1093/molbev/msm013
   Jiang HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002484
   McVean G, 2002, GENETICS, V160, P1231
   Mu JB, 2007, NAT GENET, V39, P126, DOI 10.1038/ng1924
   Mu JB, 2010, NAT GENET, V42, P268, DOI 10.1038/ng.528
   MULLER HM, 1993, EMBO J, V12, P2881
   Nguitragool W, 2011, CELL, V145, P665, DOI 10.1016/j.cell.2011.05.002
   Patel JJ, 2010, MOL MICROBIOL, V78, P770, DOI 10.1111/j.1365-2958.2010.07366.x
   Polley SD, 2003, GENETICS, V165, P555
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Stephens M, 2005, AM J HUM GENET, V76, P449, DOI 10.1086/428594
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Van Tyne D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001383
   VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85
   Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072
   Wang XH, 2005, AM J TROP MED HYG, V72, P410
   Weedall GD, 2007, INT J PARASITOL, V37, P77, DOI 10.1016/j.ijpara.2006.09.001
   WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
NR 22
TC 14
Z9 14
U1 1
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0737-4038
J9 MOL BIOL EVOL
JI Mol. Biol. Evol.
PD NOV
PY 2012
VL 29
IS 11
BP 3249
EP 3253
DI 10.1093/molbev/mss151
PG 5
WC Biochemistry & Molecular Biology; Evolutionary Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Evolutionary Biology; Genetics &
   Heredity
GA 025EG
UT WOS:000310167700001
PM 22688945
OA No
DA 2017-08-15
ER

PT J
AU Oura, CAL
   Batten, CA
   Ivens, PAS
   Balcha, M
   Alhassan, A
   Gizaw, D
   Elharrak, M
   Jallow, DB
   Sahle, M
   Maan, N
   Mertens, PC
   Maan, S
AF Oura, C. A. L.
   Batten, C. A.
   Ivens, P. A. S.
   Balcha, M.
   Alhassan, A.
   Gizaw, D.
   Elharrak, M.
   Jallow, D. B.
   Sahle, M.
   Maan, N.
   Mertens, P. C.
   Maan, S.
TI Equine encephalosis virus: evidence for circulation beyond southern
   Africa
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Equine disease; infectious disease epidemiology; reoviruses; veterinary
   epidemiology; veterinary virology
ID ANTIBODY; PREVALENCE; ISRAEL
AB Prior to the recent outbreak of equine encephalosis in Israel in 2009, equine encephalosis virus (EEV) had only been isolated from equids in South Africa. In this study we show the first evidence for the circulation of EEV beyond South Africa in Ethiopia, Ghana and The Gambia, indicating that EEV is likely to be freely circulating and endemic in East and West Africa. Sequence analysis revealed that the EEV isolate circulating in The Gambia was closely related to an EEV isolate that was isolated from a horse from Israel during the EEV outbreak in 2009, indicating that the two viruses have a common ancestry. Interestingly horses in Morocco tested negative for EEV antibodies indicating that the Sahara desert may be acting as a geographical barrier to the spread to the virus to North African countries. This evidence for EEV circulation in countries in East and West Africa sheds light on how the virus may have reached Israel to cause the recent outbreak in 2009.
C1 [Oura, C. A. L.; Batten, C. A.; Maan, N.; Mertens, P. C.; Maan, S.] Inst Anim Hlth, Woking, Surrey, England.
   [Ivens, P. A. S.] Buckingham Equine Med Referrals, Overton Fields, Buckingham, Bucks, England.
   [Balcha, M.; Gizaw, D.; Sahle, M.] NAHDIC, Sebeta, Ethiopia.
   [Alhassan, A.] Accra Vet Lab, Accra, Ghana.
   [Elharrak, M.] Biopharma, Rabat, Morocco.
   [Jallow, D. B.] Gambia Livestock Mkt Agcy, Abuko, Gambia.
RP Oura, CAL (reprint author), Univ W Indies, Sch Vet Med, Fac Med Sci, St Augustine, Trinid & Tobago.
EM chris.oura@sta.uwi.edu
RI Institute, Pirbright/K-4476-2014
OI Mertens, Peter/0000-0002-3438-3738
FU BEVA Trust; Defra; BBSRC
FX We thank the Department of Veterinary Services, The Gambia, and in
   particular Mr Borrie Jabang, Laboratory Technician at the Central
   Veterinary Laboratory, Abuko. We thank the entire local staff of The
   Gambia Horse and Donkey Trust, Sambel Kunda, and animal owners for
   providing their animals for sampling. We also thank the BEVA Trust for
   funding the field work in The Gambia. We also thank The Polo Club in
   Accra, Ghana for allowing their horses to be sampled and both Abid
   BinTarif and Kyriaki Nomikou for helping to process the samples at IAH,
   Pirbright. We also acknowledge financial support from Defra and BBSRC.
CR Aharonson-Raz K, 2011, EMERG INFECT DIS, V17, P1883, DOI 10.3201/eid1710.110350
   Crafford JE, 2011, J VIROL METHODS, V174, P60, DOI 10.1016/j.jviromet.2011.03.024
   Erasmus BJ, 1978, P 4 INT C EQ INF DIS, P447
   Hincheliff K. W., 2007, EQUINE INFECT DIS, P233, DOI 10.1016/B978-1-4160-2406-4.50030-2
   Howell PG, 2008, ONDERSTEPOORT J VET, V75, P153
   Howell P. G., 2004, Infectious diseases of livestock. Volume Two, P1247
   Howell PG, 2002, ONDERSTEPOORT J VET, V69, P79
   Maan S, 2007, J VIROL METHODS, V143, P132, DOI 10.1016/j.jviromet.2007.02.016
   Mildenberg Z, 2009, TRANSBOUND EMERG DIS, V56, P291, DOI 10.1111/j.1865-1682.2009.01087_1.x
   Potgieter AC, 2009, J GEN VIROL, V90, P1423, DOI 10.1099/vir.0.009381-0
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   WILLIAMS R, 1993, J VET DIAGN INVEST, V5, P3
NR 12
TC 8
Z9 8
U1 0
U2 17
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD NOV
PY 2012
VL 140
IS 11
BP 1982
EP 1986
DI 10.1017/S0950268811002688
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 019GC
UT WOS:000309724500008
PM 22166372
OA No
DA 2017-08-15
ER

PT J
AU Gouas, DA
   Villar, S
   Ortiz-Cuaran, S
   Legros, P
   Ferro, G
   Kirk, GD
   Lesi, OA
   Mendy, M
   Bah, E
   Friesen, MD
   Groopman, J
   Chemin, I
   Hainaut, P
AF Gouas, Doriane A.
   Villar, Stephanie
   Ortiz-Cuaran, Sandra
   Legros, Penelope
   Ferro, Gilles
   Kirk, Gregory D.
   Lesi, Olufunmilayo A.
   Mendy, Maimuna
   Bah, Ebrima
   Friesen, Marlin D.
   Groopman, John
   Chemin, Isabelle
   Hainaut, Pierre
TI TP53 R249S mutation, genetic variations in HBX and risk of
   hepatocellular carcinoma in The Gambia
SO CARCINOGENESIS
LA English
DT Article
ID HEPATITIS-B-VIRUS; X-PROTEIN; WEST-AFRICA; LIVER-CANCER; 1762(T)/1764(A)
   MUTATIONS; AFLATOXIN EXPOSURE; TP53 MUTATION; PLASMA DNA; P53 GENE;
   GENOTYPES
AB In regions with high prevalence of chronic hepatitis B virus (HBV) infection and dietary aflatoxin B-1 (AFB(1)) exposure, hepatocellular carcinomas (HCCs) often contain TP53 mutation at codon 249 (R249S). Furthermore, a C-terminal truncated HBx protein expressed from hepatocyte integrated HBV is associated with HCC development. This study evaluates the association between R249S and HBX status in relation to HCC in West African population. HBX (complete or 3' -truncated) and HBS genes were assessed by PCR in cell-free DNA (CFDN,A) from plasma of subjects recruited in a hospital-based case-control study (325 controls, 78 cirrhotic patients and 198 HCC cases) conducted in The Gambia. These samples had been previously analyzed for R249S and HBV serological status. Complete HBX sequence was frequently detected in CFDNA of HCC-R249S positive (77%, 43156) compared with HCC-R249S-negative cases (44%, 22/50). Conversely, the proportion of 3' -truncated HBX gene was significantly higher in HCC-R249S negative than positive cases (34%, 17/50, compared with 12%, 7/56) (chi(2) = 12.12; P = 0.002; distribution of R249S negative and positive according to HBX status). Occult HBV infection (detected by PCR) was present in 24% of HCC previously considered as negative by HBV serology. Moreover, HBV mutation analysis revealed that double mutation at nucleotides 1762(T)/1764(A) was associated with diagnosis of cirrhosis or HCC {cirrhosis: odds ratio (OR): 9.50 [95% confidence interval (Cl) 1.50-60.11]; HCC: OR: 11.29 [95% Cl 2.07-61.471]}. These findings suggest that in HCC from The Gambia, complete HBX sequences are often associated with the presence of TP53 R249S mutation.
C1 [Gouas, Doriane A.; Villar, Stephanie; Ortiz-Cuaran, Sandra; Legros, Penelope; Ferro, Gilles; Mendy, Maimuna; Bah, Ebrima; Hainaut, Pierre] Int Agcy Res Canc, Mol Carcinogenesis Grp, F-69372 Lyon 08, France.
   [Kirk, Gregory D.; Lesi, Olufunmilayo A.; Bah, Ebrima] Labs Fajara, Gambia Hepatitis Intervent Study, Banjul, Gambia.
   [Kirk, Gregory D.; Lesi, Olufunmilayo A.; Bah, Ebrima] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Lesi, Olufunmilayo A.] Univ Lagos, Teaching Hosp, Dept Med, Lagos, Nigeria.
   [Chemin, Isabelle] Ctr Rech Cancerol Lyon, INSERM, U1052, Lyon, France.
RP Hainaut, P (reprint author), Int Prevent Res Inst, 96 Cours Franklin Roosevelt, F-69006 Lyon, France.
EM pierre.hainaut@i-pri.org
RI Hainaut, Pierre /B-6018-2012; Chemin, Isabelle/I-3032-2016
OI Hainaut, Pierre /0000-0002-1303-1610; 
FU National Institutes of Health (NIH) [P01 ES006052]; National Cancer
   Institute, NIH, Department of Health and Human Services [N02 CP40521];
   Association pour la Recherche stir le Cancer [ARC-5044]; American Cancer
   Society [MRSG-07-284-01-CCE]
FX This research was supported in part by National Institutes of Health
   (NIH) grant (P01 ES006052), in part by the National Cancer Institute,
   NIH, Department of Health and Human Services grant (N02 CP40521), in
   part by Association pour la Recherche stir le Cancer (ARC-5044) and in
   part by the American Cancer Society (MRSG-07-284-01-CCE to G.D.K.).
CR Abedi-Ardekani B, 2011, HEPAT RES TREAT
   Ahn SH, 2003, GASTROENTEROLOGY, V125, P1370, DOI 10.1053/S0016-5085(03)01363-5
   Badvie S, 2000, POSTGRAD MED J, V76, P4, DOI 10.1136/pmj.76.891.4
   Benhenda S, 2009, ADV CANCER RES, V103, P75, DOI 10.1016/S0065-230X(09)03004-8
   BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0
   Chan HLY, 2011, J GASTROEN HEPATOL, V26, P8, DOI 10.1111/j.1440-1746.2010.06514.x
   Chang Mei-Hwei, 2006, Indian Journal of Pediatrics, V73, P803, DOI 10.1007/BF02790390
   Fang ZL, 2008, AM J GASTROENTEROL, V103, P2254, DOI 10.1111/j.1572-0241.2008.01974.x
   Feitelson MA, 2007, CANCER LETT, V252, P157, DOI 10.1016/j.canlet.2006.11.010
   Ferlay J., 2008, IARC CANCERBASE
   Forbi JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011615
   Gormally E, 2007, MUTAT RES-REV MUTAT, V635, P105, DOI 10.1016/j.mrrev.2006.11.002
   Gouas D, 2009, CANCER LETT, V286, P29, DOI 10.1016/j.canlet.2009.02.057
   Gouas DA, 2010, CARCINOGENESIS, V31, P1475, DOI 10.1093/carcin/bgq118
   HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0
   Iyer S, 2011, MOL CARCINOGEN, V50, P972, DOI 10.1002/mc.20767
   Jiang WD, 2010, INT J CANCER, V127, P1011, DOI 10.1002/ijc.25118
   Kew MC, 2010, PATHOL BIOL, V58, P273, DOI 10.1016/j.patbio.2010.01.005
   Kew MC, 2011, J GASTROEN HEPATOL, V26, P144, DOI 10.1111/j.1440-1746.2010.06546.x
   Kidd-Ljunggren K, 2002, J GEN VIROL, V83, P1267, DOI 10.1099/vir.O.18197-O
   Kimbi GC, 2004, J GEN VIROL, V85, P1211, DOI 10.1016/vir.0.19749-0
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2006, CARCINOGENESIS, V27, P2070, DOI 10.1093/carcin/bgl060
   Kramvis A, 2005, J VIRAL HEPATITIS, V12, P456, DOI 10.1111/j.1365-2893.2005.00624.x
   Kramvis A, 2005, VACCINE, V23, P2409, DOI 10.1016/j.vaccine.2004.10.045
   Kuang SY, 2005, CANCER EPIDEM BIOMAR, V14, P380, DOI 10.1158/1055-9965.EPI-04-0380
   Kuniholm MH, 2008, ENVIRON HEALTH PERSP, V116, P1553, DOI 10.1289/ehp.11661
   Liu CJ, 2005, LIVER INT, V25, P1097, DOI 10.1111/j.1478-3231.2005.01177.x
   Lleonart ME, 2005, CANCER EPIDEM BIOMAR, V14, P2956, DOI 10.1158/1055-9965.EPI-05-0612
   Ma NF, 2008, CLIN CANCER RES, V14, P5061, DOI 10.1158/1078-0432.CCR-07-5082
   Mendy ME, 2008, J CLIN MICROBIOL, V46, P2723, DOI 10.1128/JCM.01622-07
   Miyakawa Y, 2003, INTERVIROLOGY, V46, P329, DOI 10.1159/000074988
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1016/0270-9139(95)90086-1
   Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6
   Shi Y., 2011, LIVER INT, V32, P231
   Sighoko D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018415
   Sugauchi F, 2004, J GEN VIROL, V85, P811, DOI 10.1099/vir.0.79811-0
   Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Tu H, 2001, CANCER RES, V61, P7803
   Villar S, 2011, ENVIRON HEALTH PERSP, V119, P1635, DOI 10.1289/ehp.1103539
   Viviani S, 2008, CANCER EPIDEM BIOMAR, V17, P3216, DOI 10.1158/1055-9965.EPI-08-0303
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   Yuan JM, 2009, CANCER EPIDEM BIOMAR, V18, P590, DOI 10.1158/1055-9965.EPI-08-0966
NR 46
TC 11
Z9 13
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD NOV
PY 2012
VL 33
IS 6
BP 1219
EP 1224
DI 10.1093/carcin/bgs135
PG 6
WC Oncology
SC Oncology
GA 970MW
UT WOS:000306135800013
PM 22759751
OA No
DA 2017-08-15
ER

PT J
AU Rickard, IJ
   Courtiol, A
   Prentice, AM
   Fulford, AJC
   Clutton-Brock, TH
   Lummaa, V
AF Rickard, Ian J.
   Courtiol, Alexandre
   Prentice, Andrew M.
   Fulford, Anthony J. C.
   Clutton-Brock, Tim H.
   Lummaa, Virpi
TI Intergenerational effects of maternal birth season on offspring size in
   rural Gambia
SO PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article
DE intergenerational effects; maternal effects; birth season; epigenetics;
   maternal constraint; humans
ID PRENATAL DIETARY SUPPLEMENTATION; INTRAUTERINE GROWTH RESTRICTION;
   IN-UTERO EXPOSURE; LACTATING WOMEN; DUTCH FAMINE; REPRODUCTIVE SUCCESS;
   INSULIN-RESISTANCE; SEX-DIFFERENCES; AFRICAN WOMEN; WEIGHT
AB Environmental conditions experienced in early life can influence an individual's growth and long-term health, and potentially also that of their offspring. However, such developmental effects on intergenerational outcomes have rarely been studied. Here we investigate intergenerational effects of early environment in humans using survey- and clinic-based data from rural Gambia, a population experiencing substantial seasonal stress that influences foetal growth and has long-term effects on first-generation survival. Using Fourier regression to model seasonality, we test whether (i) parental birth season has intergenerational consequences for offspring in utero growth (1982 neonates, born 1976-2009) and (ii) whether such effects have been reduced by improvements to population health in recent decades. Contrary to our predictions, we show effects of maternal birth season on offspring birth weight and head circumference only in recent maternal cohorts born after 1975. Offspring birth weight varied according to maternal birth season from 2.85 to 3.03 kg among women born during 1975-1984 and from 2.84 to 3.41 kg among those born after 1984, but the seasonality effect reversed between these cohorts. These results were not mediated by differences in maternal age or parity. Equivalent patterns were observed for offspring head circumference (statistically significant) and length (not significant), but not for ponderal index. No relationships were found between paternal birth season and offspring neonatal anthropometrics. Our results indicate that even in rural populations living under conditions of relative affluence, brief variation in environmental conditions during maternal early life may exert long-term intergenerational effects on offspring.
C1 [Rickard, Ian J.; Courtiol, Alexandre; Lummaa, Virpi] Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.
   [Rickard, Ian J.; Courtiol, Alexandre; Lummaa, Virpi] Wissensch Kolleg Berlin, Berlin, Germany.
   [Courtiol, Alexandre] Leibniz Inst Zoo & Wildlife Res, Dept Evolutionary Genet, Berlin, Germany.
   [Prentice, Andrew M.; Fulford, Anthony J. C.] MRC Labs, MRC Keneba, Banjul, Gambia.
   [Prentice, Andrew M.; Fulford, Anthony J. C.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   [Clutton-Brock, Tim H.] Univ Cambridge, Dept Zool, Large Anim Res Grp, Cambridge CB2 3EJ, England.
RP Rickard, IJ (reprint author), Univ Durham, Dept Anthropol, Queens Campus Stockon,Univ Blvd, Thornaby TS17 6BH, Stockton On Tee, England.
EM ianjr81@gmail.com; andrew.prentice@lshtm.ac.uk
OI Courtiol, Alexandre/0000-0003-0637-2959
FU UK Medical Research Council; NERC; Wellcome Trust; Kone Foundation; MRC;
   Royal Society; ERC
FX Collection of the data used in this study was made possible by the
   efforts of many doctors, nurses, midwives and fieldworkers and funded by
   the UK Medical Research Council. Individual funding is by NERC (I.J.R.),
   the Wellcome Trust (I.J.R.), Kone Foundation (A.C.), MRC (A.M.P. and
   A.J.C.F.), the Royal Society (V.L.) and ERC (V.L. and I.J.R.). Data are
   from individual health records and thus for ethical and legal reasons
   cannot be made freely available. Requests for data access should be
   addressed to Prof. Andrew M. Prentice, Chair, Keneba Database Steering
   Group (KDSG) via email at andrew.prentice@lshtm.ac.uk. Further
   descriptions of the work in Keneba can be found at www.ing.mrc.ac.uk.
CR Alwasel SH, 2011, AM J HUM BIOL, V23, P651, DOI 10.1002/ajhb.21193
   Astone NM, 2007, PAEDIATR PERINAT EP, V21, P310, DOI 10.1111/j.1365-3016.2007.00821.x
   Barker DJP, 2007, HYPERTENSION, V50, P565, DOI 10.1161/HYPERTENSIONAHA.107.091512
   Barker DJP, 2000, J HYPERTENS, V18, P843, DOI 10.1097/00004872-200018070-00004
   BATES CJ, 1983, INT J VITAM NUTR RES, V53, P68
   BATES CJ, 1983, HUM NUTR-CLIN NUTR, V37, P427
   Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725
   Buchbinder A, 2002, AM J OBSTET GYNECOL, V186, P66, DOI 10.1067/mob.2002.120080
   Burns SP, 1997, J CLIN INVEST, V100, P1768, DOI 10.1172/JCI119703
   Bygren LO, 2001, ACTA BIOTHEOR, V49, P53, DOI 10.1023/A:1010241825519
   Catalano PM, 2003, J NUTR, V133, p1674S
   Cerda M, 2008, SOC SCI MED, V66, P2048, DOI 10.1016/j.socscimed.2008.01.027
   Collins JW, 2009, AM J EPIDEMIOL, V169, P712, DOI 10.1093/aje/kwn402
   Collinson AC, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-18
   Courtiol A, 2010, AM J PHYS ANTHROPOL, V142, P22, DOI 10.1002/ajpa.21187
   Cox NJ, 2006, STATA J, V6, P561
   Currie J, 2007, J LABOR ECON, V25, P231, DOI 10.1086/511377
   De Stavola BL, 2011, AM J EPIDEMIOL, V174, P52, DOI 10.1093/aje/kwr032
   Drake AJ, 2005, AM J PHYSIOL-REG I, V288, pR34, DOI 10.1152/ajpregu.00106.2004
   Drake AJ, 2004, J ENDOCRINOL, V180, P1, DOI 10.1677/joe.0.1800001
   Drake AJ, 2010, TRENDS ENDOCRIN MET, V21, P206, DOI 10.1016/j.tem.2009.11.006
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A
   Fulford AJC, 2006, PAEDIATR PERINAT EP, V20, P251, DOI 10.1111/j.1365-3016.2006.00714.x
   Fung W., 2010, RISK SHOCKS HUMAN DE, P222
   Gavin AR, 2012, PREV SCI, V13, P162, DOI 10.1007/s11121-011-0253-2
   Gisselmann MD, 2006, SOC SCI MED, V63, P1023, DOI 10.1016/j.socscimed.2006.03.015
   Gluckman PD, 2009, NAT REV ENDOCRINOL, V5, P401, DOI 10.1038/nrendo.2009.102
   Harville EW, 2010, ARCH PEDIAT ADOL MED, V164, P533, DOI 10.1001/archpediatrics.2010.61
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   LangleyEvans SC, 1996, J NUTR, V126, P1578
   LANGLEYEVANS SC, 1994, CLIN NUTR, V13, P319, DOI 10.1016/0261-5614(94)90056-6
   LUMEY LH, 1995, EUR J OBSTET GYN R B, V61, P23, DOI 10.1016/0028-2243(95)02149-M
   Lumey LH, 1995, EUR J OBSTET GYN R B, V63, P197, DOI 10.1016/0301-2115(95)02240-6
   Lumey LH, 1997, AM J EPIDEMIOL, V146, P810
   Lummaa V, 2002, TRENDS ECOL EVOL, V17, P141, DOI 10.1016/S0169-5347(01)02414-4
   Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2
   MCGREGOR IA, 1961, BRIT MED J, V2, P1661
   Moore SE, 2001, DIABETIC MED, V18, P646, DOI 10.1046/j.1464-5491.2001.00565.x
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Nyirenda MJ, 1998, J CLIN INVEST, V101, P2174, DOI 10.1172/JCI1567
   Ofordile O N, 2005, J Immunotoxicol, V2, P33, DOI 10.1080/15476910590949452
   OUNSTED M, 1966, NATURE, V212, P995, DOI 10.1038/212995a0
   Painter RC, 2008, BJOG-INT J OBSTET GY, V115, P1243, DOI 10.1111/j.1471-0528.2008.01822.x
   Painter RC, 2009, HUM REPROD, V24, P491, DOI 10.1093/humrep/den395
   Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5204538
   PINTO ML, 1995, BRIT J NUTR, V73, P645, DOI 10.1079/BJN19950070
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   PRENTICE AM, 1980, LANCET, V2, P886
   PRENTICE AM, 1983, LANCET, V1, P489
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P283
   R Development Core Team, 2011, R LANG ENV STAT COMP
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   Rickard IJ, 2010, ECOLOGY, V91, P3515, DOI 10.1890/10-0019.1
   Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338
   Sandman CA, 1997, ANN NY ACAD SCI, V814, P266, DOI 10.1111/j.1749-6632.1997.tb46162.x
   Sear R, 2001, J EVOLUTION BIOL, V14, P433, DOI 10.1046/j.1420-9101.2001.00287.x
   Stein AD, 2000, HUM BIOL, V72, P641
   Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353
   Veena SR, 2007, DIABETOLOGIA, V50, P43, DOI 10.1007/s00125-006-0516-9
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
   Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252
   Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y
   Zambrano E, 2005, J PHYSIOL-LONDON, V566, P225, DOI 10.1113/jphysiol.2005.086462
   Zhang YJ, 2006, INT J CANCER, V119, P985, DOI 10.1002/ijc.21699
NR 68
TC 7
Z9 7
U1 3
U2 32
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8452
J9 P ROY SOC B-BIOL SCI
JI Proc. R. Soc. B-Biol. Sci.
PD OCT 22
PY 2012
VL 279
IS 1745
BP 4253
EP 4262
DI 10.1098/rspb.2012.1363
PG 10
WC Biology; Ecology; Evolutionary Biology
SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences &
   Ecology; Evolutionary Biology
GA 005JZ
UT WOS:000308748000021
PM 22896641
OA No
DA 2017-08-15
ER

PT J
AU Williams, TM
   Loman, NJ
   Ebruke, C
   Musher, DM
   Adegbola, RA
   Pallen, MJ
   Weinstock, GM
   Antonio, M
AF Williams, Tiffany M.
   Loman, Nicholas J.
   Ebruke, Chinelo
   Musher, Daniel M.
   Adegbola, Richard A.
   Pallen, Mark J.
   Weinstock, George M.
   Antonio, Martin
TI Genome Analysis of a Highly Virulent Serotype 1 Strain of Streptococcus
   pneumoniae from West Africa
SO PLOS ONE
LA English
DT Article
ID INVASIVE PNEUMOCOCCAL DISEASE; MULTIPLE SEQUENCE ALIGNMENT; NONHEMOLYTIC
   PNEUMOLYSIN; MOLECULAR EPIDEMIOLOGY; MOSAIC CHROMOSOMES; CONJUGATE
   VACCINE; BINDING-PROTEINS; UNITED-STATES; RNA GENES; IDENTIFICATION
AB Streptococcus pneumoniae is a leading cause of pneumonia, meningitis, and bacteremia, estimated to cause 2 million deaths annually. The majority of pneumococcal mortality occurs in developing countries, with serotype 1 a leading cause in these areas. To begin to better understand the larger impact that serotype 1 strains have in developing countries, we characterized virulence and genetic content of PNI0373, a serotype 1 strain from a diseased patient in The Gambia. PNI0373 and another African serotype 1 strain showed high virulence in a mouse intraperitoneal challenge model, with 20% survival at a dose of 1 cfu. The PNI0373 genome sequence was similar in structure to other pneumococci, with the exception of a 100 kb inversion. PNI0373 showed only15 lineage specific CDS when compared to the pan-genome of pneumococcus. However analysis of non-core orthologs of pneumococcal genomes, showed serotype 1 strains to be closely related. Three regions were found to be serotype 1 associated and likely products of horizontal gene transfer. A detailed inventory of known virulence factors showed that some functions associated with colonization were absent, consistent with the observation that carriage of this highly virulent serotype is unusual. The African serotype 1 strains thus appear to be closely related to each other and different from other pneumococci despite similar genetic content.
C1 [Williams, Tiffany M.; Weinstock, George M.] Washington Univ, Genome Inst, St Louis, MO 63130 USA.
   [Loman, Nicholas J.; Pallen, Mark J.] Univ Birmingham, Ctr Syst Biol, Birmingham, W Midlands, England.
   [Ebruke, Chinelo; Adegbola, Richard A.; Antonio, Martin] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Musher, Daniel M.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA.
RP Weinstock, GM (reprint author), Washington Univ, Genome Inst, St Louis, MO 63130 USA.
EM gweinsto@genome.wustl.edu
RI Weinstock, George/C-6314-2013
OI Weinstock, George/0000-0002-2997-4592; Pallen, Mark/0000-0003-1807-3657;
   Williamson, Jane/0000-0003-3627-4508; Loman,
   Nicholas/0000-0002-9843-8988
FU NIH-NHGRI [U54HG003079, U54HG004968]; Medical Research Council, UK
FX Research was supported by grants from NIH-NHGRI U54HG003079 and
   U54HG004968. We also thank The Medical Research Council, UK for funding
   in The Gambia. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Aguiar SI, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-41
   Antonio M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-81
   Antonio M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-198
   Ashburner M, 2000, NAT GENET, V25, P25
   Bagnoli F, 2008, J BACTERIOL, V190, P5480, DOI 10.1128/JB.00384-08
   Bentley SD, 2006, PLOS GENET, V2, P262, DOI 10.1371/journal.pgen.0020031
   Blomberg C, 2009, J INFECT DIS, V199, P1032, DOI 10.1086/597205
   Bogaert D, 2004, VACCINE, V22, P2209, DOI 10.1016/j.vaccine.2003.11.038
   BORODOVSKY M, 1993, BIOSYSTEMS, V30, P161, DOI 10.1016/0303-2647(93)90068-N
   Bridy-Pappas AE, 2005, PHARMACOTHERAPY, V25, P1193, DOI 10.1592/phco.2005.25.9.1193
   Bruckner R, 2004, INT J MED MICROBIOL, V294, P157, DOI 10.1016/j.ijmm.2004.06.019
   Brueggemann AB, 2003, J CLIN MICROBIOL, V41, P4966, DOI 10.1128/JCM.41.11.4966-4970.2003
   Chiavolini D, 2008, CLIN MICROBIOL REV, V21, P666, DOI 10.1128/CMR.00012-08
   Chiou A. C., 2008, Journal of Medical Microbiology, V57, P839, DOI 10.1099/jmm.0.47612-0
   Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Fedson DS, 1999, VACCINE, V17, pS11, DOI 10.1016/S0264-410X(99)00122-X
   Felsenstein J., 2005, PHYLIP PHYLOGENY INF
   Garcia-Suarez MDM, 2006, ENFERM INFEC MICR CL, V24, P512
   Gardy JL, 2005, BIOINFORMATICS, V21, P617, DOI 10.1093/bioinformatics/bti057
   Gascuel O, 1997, MOL BIOL EVOL, V14, P685
   Gessner BD, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-22
   Glover DT, 2008, INFECT IMMUN, V76, P2767, DOI 10.1128/IAI.01126-07
   Gonzalez BE, 2004, J CLIN MICROBIOL, V42, P2810, DOI 10.1128/JCM.42.6.2810-2812.2004
   Gosink KK, 2000, INFECT IMMUN, V68, P5690, DOI 10.1128/IAI.68.10.5690-5695.2000
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Hakenbeck R, 2001, INFECT IMMUN, V69, P2477, DOI 10.1128/IAI.69.4.2477-2486.2001
   Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Hava D, 2002, MOL MICROBIOL, V45, P1389, DOI 10.1046/j.1365-2958.2002.03106.x
   Holliman RE, 2007, T ROY SOC TROP MED H, V101, P405, DOI 10.1016/j.trstmh.2006.08.014
   Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001
   Hsieh Yu-Chia, 2008, Chang Gung Med J, V31, P117
   Jefferies JMC, 2007, J INFECT DIS, V196, P936, DOI 10.1086/520091
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kaplan V, 2002, AM J RESP CRIT CARE, V165, P766, DOI 10.1164/rccm.2103038
   Kirkham LAS, 2006, J CLIN MICROBIOL, V44, P151, DOI 10.1128/JCM.44.1.151-159.2006
   Klugman KP, 2008, PNEUMOCOCCAL VACCINES: THE IMPACT OF CONJUGATE VACCINE, P317
   KLUGMAN KP, 1988, J INFECT DIS, V158, P956
   KOSTYUKOVA NN, 1995, FEMS IMMUNOL MED MIC, V10, P133
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Kurtz S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r12
   Lagesen K, 2007, NUCLEIC ACIDS RES, V35, P3100, DOI 10.1093/nar/gkm160
   Langille MGI, 2009, BIOINFORMATICS, V25, P664, DOI 10.1093/bioinformatics/btp030
   Lanie JA, 2007, J BACTERIOL, V189, P38, DOI 10.1128/JB.01148-06
   Lau GW, 2001, MOL MICROBIOL, V40, P555, DOI 10.1046/j.1365-2958.2001.02335.x
   Lefebure T, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r71
   Leimkugel J, 2005, J INFECT DIS, V192, P192, DOI 10.1086/431151
   Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503
   Lopez R, 2004, INT MICROBIOL, V7, P163
   Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955
   Mehiri-Zghal E, 2010, DIAGN MICR INFEC DIS, V66, P225, DOI 10.1016/j.diagmicrobio.2009.05.008
   Mitchell J, 2007, MOL MICROBIOL, V64, P844, DOI 10.1111/j.1365-2958.2007.05703.x
   Molina R, 2009, EMBO REP, V10, P246, DOI 10.1038/embor.2008.245
   Mulholland K, 1999, VACCINE, V17, pS79, DOI 10.1016/S0264-410X(99)00112-7
   Nawrocki EP, 2009, BIOINFORMATICS, V25, P1335, DOI 10.1093/bioinformatics/btp157
   Ng MP, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-192
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Obert C, 2006, INFECT IMMUN, V74, P4766, DOI 10.1128/IAI.00316-06
   Organization WH, 1999, PNEUM VACC, P177
   Polissi A, 1998, INFECT IMMUN, V66, P5620
   Ramdani-Bouguessa N, 2003, ANTIMICROB AGENTS CH, V47, P824, DOI 10.1128/AAC.47.2.824-826.2003
   Romero P, 2009, J BACTERIOL, V191, P4854, DOI 10.1128/JB.01272-08
   Sandgren A, 2005, J INFECT DIS, V192, P791, DOI 10.1086/432513
   Silva NA, 2006, INFECT IMMUN, V74, P3513, DOI 10.1128/IAI.00079-06
   Sjostrom K, 2006, CLIN INFECT DIS, V42, P451, DOI 10.1086/499242
   Sleeman KL, 2006, J INFECT DIS, V194, P682, DOI 10.1086/505710
   Tai SS, 2006, CRIT REV MICROBIOL, V32, P139, DOI 10.1080/10408410600822942
   Trooskens G, 2005, BIOINFORMATICS, V21, P3801, DOI 10.1093/bioinformatics/bti590
   Vernikos GS, 2006, BIOINFORMATICS, V22, P2196, DOI 10.1093/bioinformatics/btl369
   Yaro S, 2006, CLIN INFECT DIS, V43, P693, DOI 10.1086/506940
   YOTHER J, 1982, INFECT IMMUN, V36, P184
   Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847
NR 75
TC 7
Z9 10
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2012
VL 7
IS 10
AR e26742
DI 10.1371/journal.pone.0026742
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AF
UT WOS:000311146900001
PM 23082106
OA gold
DA 2017-08-15
ER

PT J
AU Moore, SE
   Fulford, AJC
   Darboe, MK
   Jobarteh, ML
   Jarjou, LM
   Prentice, AM
AF Moore, Sophie E.
   Fulford, Anthony J. C.
   Darboe, Momodou K.
   Jobarteh, Modou Lamin
   Jarjou, Landing M.
   Prentice, Andrew M.
TI A randomized trial to investigate the effects of pre-natal and infant
   nutritional supplementation on infant immune development in rural
   Gambia: the ENID trial: Early Nutrition and Immune Development
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
ID BIRTH-WEIGHT; ENVIRONMENTAL-INFLUENCES; ADULTS BORN; BREAST-MILK;
   MORTALITY; GROWTH; SEASON; VACCINATION; BANGLADESH; DISEASE
AB Background: Recent observational research indicates that immune development may be programmed by nutritional exposures early in life. Such findings require replication from trials specifically designed to assess the impact of nutritional intervention during pregnancy on infant immune development. The current trial seeks to establish: (a) which combination of protein-energy (PE) and multiple-micronutrient (MMN) supplements would be most effective; and (b) the most critical periods for intervention in pregnancy and infancy, for optimal immune development in infancy.
   Methods/Design: The ENID Trial is a 2 x 2 x 2 factorial randomized, partially blind trial to assess whether nutritional supplementation to pregnant women (from < 20 weeks gestation to term) and their infants (from 6 to 12 months of age) can enhance infant immune development. Eligible pregnant women from the West Kiang region of The Gambia (pregnancy dated by ultrasound examination) are randomized on entry to 4 intervention groups (Iron-folate (FeFol = standard care), multiple micronutrients (MMN), protein-energy (PE), PE + MMN). Women are visited at home weekly for supplement administration and morbidity assessment and seen at MRC Keneba at 20 and 30 weeks gestation for a detailed antenatal examination, including ultrasound. At delivery, cord blood and placental samples are collected, with detailed infant anthropometry collected within 72 hours. Infants are visited weekly thereafter for a morbidity questionnaire. From 6 to 12 months of age, infants are further randomized to a lipid-based nutritional supplement, with or without additional MMN. The primary outcome measures of this study are thymic development during infancy, and antibody response to vaccination. Measures of cellular markers of immunity will be made in a selected sub-cohort. Subsidiary studies to the main trial will additionally assess the impact of supplementation on infant growth and development to 24 months of age.
   Discussion: The proposed trial is designed to test whether nutritional repletion can enhance early immune development and, if so, to help determine the most efficacious form of nutritional support. Where there is evidence of benefit from a specific intervention/combination of interventions, future research should focus on refining the supplements to achieve the optimal, most cost-effective balance of interventions for improved health outcomes.
   Trial registration: ISRCTN49285450
C1 [Moore, Sophie E.; Fulford, Anthony J. C.; Darboe, Momodou K.; Jobarteh, Modou Lamin; Jarjou, Landing M.; Prentice, Andrew M.] MRC Keneba, MRC Unit Gambia, Banjul, Gambia.
   [Moore, Sophie E.; Fulford, Anthony J. C.; Prentice, Andrew M.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
RP Moore, SE (reprint author), MRC Keneba, MRC Unit Gambia, POB 273, Banjul, Gambia.
EM smoore@mrc.gm
OI Jobarteh, Modou Lamin/0000-0002-7350-6980
FU Medical Research Council (UK) [MC-A760-5QX00]
FX This trial is supported through by the Medical Research Council (UK),
   through core funding to the MRC International Nutrition Group
   (MC-A760-5QX00).
CR Adu-Afarwuah S, 2007, AM J CLIN NUTR, V86, P412
   Albernaz E, 2003, J NUTR, V133, P205
   Barker DJP, 1994, MOTHERS BABIES DIS L
   Briend Andre, 2003, Food and Nutrition Bulletin, V24, pS34
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   Collinson AC, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-18
   Dubowitz L M, 1980, Brain Dev, V2, P3
   Fawzi WW, 2004, NEW ENGL J MED, V351, P23, DOI 10.1056/NEJMoa040541
   Haider B.A., 2006, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858
   Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7
   Hasselbalch H, 1996, EUR RADIOL, V6, P700
   Kaestel P, 2005, EUR J CLIN NUTR, V59, P1081, DOI 10.1038/sj.ejcn.1602215
   Kramer MS, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD000032
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   Moore SE, 2009, ACTA PAEDIATR, V98, P1168, DOI 10.1111/j.1651-2227.2009.01292.x
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Moore SE, 2008, VACCINE, V26, P158, DOI 10.1016/j.vaccine.2007.11.007
   Moore SE, 2006, P NUTR SOC, V65, P311, DOI 10.1079/PNS2006503
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Rayco-Solon P, 2005, AM J OBSTET GYNECOL, V192, P1133, DOI 10.1016/j.ajog.2004.10.636
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
NR 24
TC 20
Z9 20
U1 1
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD OCT 11
PY 2012
VL 12
AR 107
DI 10.1186/1471-2393-12-107
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 064SC
UT WOS:000313094700001
PM 23057665
OA gold
DA 2017-08-15
ER

PT J
AU Okomo, U
   Togun, T
   Oko, F
   Peterson, K
   Jaye, A
AF Okomo, Uduak
   Togun, Toyin
   Oko, Francis
   Peterson, Kevin
   Jaye, Assan
TI Mortality and loss to programme before antiretroviral therapy among
   HIV-infected children eligible for treatment in The Gambia, West Africa
SO AIDS RESEARCH AND THERAPY
LA English
DT Article
DE Paediatrics; HIV; Pre-antiretroviral therapy; Loss to follow-up;
   Mortality; Retention; Sub-Saharan Africa
ID RESOURCE-LIMITED SETTINGS; SUB-SAHARAN AFRICA; RURAL ZAMBIA;
   SOUTH-AFRICA; FOLLOW-UP; CARE; ADHERENCE; DISCLOSURE; INITIATION;
   BARRIERS
AB Background: HIV infection among children, particularly those under 24 months of age, is often rapidly progressive; as a result guidelines recommend earlier access to combination antiretroviral therapy (cART) for HIV infected children. Losses to follow-up (LTFU) and death in the interval between diagnosis and initiation of ART profoundly limit this strategy. This study explores correlates of LTFU and death prior to ART initiation among children.
   Methods: The study is based on 337 HIV-infected children enrolled into care at an urban centre in The Gambia, including those alive and in care when antiretroviral therapy became available and those who enrolled later. Children were followed until they started ART, died, transferred to another facility, or were LTFU. Cox proportional hazards regression models were used to determine the hazard of death or LTFU according to the baseline characteristics of the children.
   Results: Overall, 223 children were assessed as eligible for ART based on their clinical and/or immunological status among whom 73 (32.7%) started treatment, 15 (6.7%) requested transfer to another health facility, 105 (47.1%) and 30 (13.5%) were lost to follow-up and died respectively without starting ART. The median survival following eligibility for children who died without starting treatment was 2.8 months (IQR: 0.9 - 5.8) with over half (60%) of all deaths occurring at home. ART-eligible children less than 2 years of age and those in WHO stage 3 or 4 were significantly more likely to be LTFU when compared with their respective comparison groups. The overall pre-treatment mortality rate was 25.7 per 100 child-years of follow-up (95% CI 19.9 - 36.8) and the loss to programme rate was 115.7 per 100 child-years of follow-up (95% CI 98.8 - 137). In the multivariable Cox proportional hazard model, significant independent predictors of loss to programme were being less than 2 years of age and WHO stage 3 or 4. The Adjusted Hazard Ratio (AHR) for loss to programme was 2.06 (95% CI 1.12 - 3.83) for being aged less than 2 years relative to being 5 years of age or older and 1.92 (95% CI 1.05 - 3.53) for being in WHO stage 3 or 4 relative to WHO stage 1 or 2.
   Conclusions: Earlier enrolment into HIV care is key to achieving better outcomes for HIV infected children in developing countries. Developing strategies to ensure early diagnosis, elimination of obstacles to prompt initiation of therapy and instituting measures to reduce losses to follow-up, will improve the overall outcomes of HIV-infected children.
C1 [Okomo, Uduak; Togun, Toyin; Oko, Francis; Jaye, Assan] Med Res Council UK Labs, Banjul, Gambia.
   [Peterson, Kevin] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Jaye, Assan] Univ Cheikh Anta Diop, WAPHIR Network, Lab Bacteriol Virol, Hop A le Dantec, Dakar, Senegal.
RP Okomo, U (reprint author), Med Res Council UK Labs, Atlantic Rd,POB 273, Banjul, Gambia.
EM uokomo@mrc.gm
FU Elizabeth Glaser Pediatric AIDS Foundation [01-15]
FX The authors thank the physicians, field workers and nurses of the MRC
   HIV Clinic, with special thanks to Mr. Saydiba Tamba. We also
   acknowledge and appreciate the efforts of Gilleh Thomas and Mehedi
   Shams-Rony in acquisition of the data; Ramu Sarge-Njie, Samuel Nyamweya
   and Sheikh Jarju for their assistance with HIV diagnostics and CD4
   measurements. UO work was supported by the Elizabeth Glaser Pediatric
   AIDS Foundation [grant number: ILA # 01-15 awarded to A.J]. Support for
   antiretroviral drugs and MRC HIV Clinic Staff was provided by the Global
   Fund for AIDS, TB and Malaria (GFATM).
CR Anaky MF, 2010, B WORLD HEALTH ORGAN, V88, P490, DOI 10.2471/BLT.09.068015
   Arrive E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033690
   Brouwer CNM, 2000, AIDS CARE, V12, P535, DOI 10.1080/095401200750003725
   Brown BJ, 2011, AIDS CARE, V23, P1053, DOI 10.1080/09540121.2011.554523
   Ciaranello AL, 2009, CLIN INFECT DIS, V49, P1915, DOI 10.1086/648079
   Department of State for Health, 2004, GAMB ANT THER MAN HL
   Fetzer BC, 2011, AIDS PATIENT CARE ST, V25, P611, DOI 10.1089/apc.2011.0083
   Feucht UD, 2007, J TROP PEDIATRICS, V53, P398, DOI 10.1093/tropej/fmm060
   Fox MP, 2012, TROP MED INT HEALTH, V17, P1235, DOI 10.1111/j.1365-3156.2012.03055.x
   Haberer Jessica, 2009, Curr HIV/AIDS Rep, V6, P194
   KIDS ART LINC, 2008, J ACQ IMMUN DEF SYND, V49, P523, DOI DOI 10.1097/QAI.0B013E31818AADCE
   Kimani-Murage EW, 2010, HEALTH SOC CARE COMM, V18, P264, DOI 10.1111/j.1365-2524.2009.00891.x
   Krabbendam AA, 1998, AIDS CARE, V10, pS25
   Little K, 2007, INT J EPIDEMIOL, V36, P679, DOI 10.1093/ije/dym019
   Little K, 2007, CURR HIV RES, V5, P139, DOI 10.2174/157016207780077002
   Meursing K, 2000, HEALTH POLICY PLANN, V15, P17, DOI 10.1093/heapol/15.1.17
   Moodley K, 2006, S Afr Med J, V96, P201
   National Sentinel Surveillance Working Group, 2008, NAT SENT SURV B 2008
   Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7
   Ntanda H, 2009, PEDIATR INFECT DIS J, V28, P153, DOI 10.1097/INF.0b013e318184eeeb
   Raguenaud ME, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-54
   Reddi Anand, 2007, BMC Pediatr, V7, P13, DOI 10.1186/1471-2431-7-13
   Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298
   Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056
   Sauvageot D, 2010, PEDIATRICS, V125, pE1039, DOI 10.1542/peds.2009-1062
   Sutcliffe CG, 2008, LANCET INFECT DIS, V8, P477, DOI 10.1016/S1473-3099(08)70180-4
   Sutcliffe CG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029294
   Sutcliffe CG, 2010, PEDIATR INFECT DIS J, V29, P849, DOI 10.1097/INF.0b013e3181e753a8
   Togun T, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-24
   UNAIDS, 2000, PROV WHO UNAIDS SECR
   UNICEF, 2009, UN CHILDR UN AIDS CH
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van Dijk JH, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-169
   [Anonymous], HAEM CONC DIAGN AN A
   Vreeman RC, 2008, JAIDS-J ACQ IMM DEF, V49, P163, DOI 10.1097/QAI.0b013e318183a996
   Vreeman RC, 2010, AIDS PATIENT CARE ST, V24, P639, DOI 10.1089/apc.2010.0079
   World Health Organization, 2006, ANT THER HIV INF INF
   World Health Organization (WHO), 2006, GUID COTR PROPH HIV
   World Health Organisation, 2004, SCAL ANT THER RES LT
   Alvarez-Uria G., 2012, ANT THER HIV INF INF, V1, pe14
   Yeap AD, 2010, AIDS CARE, V22, P1101, DOI 10.1080/09540121003602218
NR 41
TC 16
Z9 16
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-6405
J9 AIDS RES THER
JI Aids Res. Ther.
PD OCT 2
PY 2012
VL 9
AR 28
DI 10.1186/1742-6405-9-28
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 072WK
UT WOS:000313704000001
PM 23031736
OA gold
DA 2017-08-15
ER

PT J
AU Lemoine, M
   Ingiliz, P
AF Lemoine, Maud
   Ingiliz, Patrick
TI Liver injury in HIV monoinfected patients: Should we turn a blind eye to
   it?
SO CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NONALCOHOLIC FATTY LIVER; HEPATITIS-E
   VIRUS; NODULAR REGENERATIVE HYPERPLASIA; INFECTED PATIENTS;
   RISK-FACTORS; INSULIN-RESISTANCE; HEPATOCELLULAR-CARCINOMA;
   ANTIRETROVIRAL THERAPY; ALCOHOL-CONSUMPTION
AB With the advent of combined antiretroviral therapies, liver diseases have emerged as a key issue in the management of HIV infection. In addition to hepatitis co-infection, a large spectrum of liver diseases can affect the prognosis of HIV infection. Acute or progressive hepatic injuries require an accurate diagnosis for a better clinical management. Here, we provide an overview of the main liver diseases associated with HIV infection, which are not covered by the widely documented field of viral hepatitis co-infection. (c) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Lemoine, Maud] Imperial Coll London, Med Res Council, Hepatitis Dept, Fajara, Gambia.
   [Ingiliz, Patrick] Med Ctr Infect Dis, D-13353 Berlin, Germany.
RP Lemoine, M (reprint author), Imperial Coll London, Med Res Council, Hepatitis Dept, Atlantic Rd, Fajara, Gambia.
EM mlemoine@mrc.gm; ingiliz@mvz-mib.de
CR Bertholet N, 2010, DRUG ALCOHOL DEPEN, V112, P160, DOI 10.1016/j.drugalcdep.2010.05.009
   Blanco F, 2011, J VIRAL HEPATITIS, V18, P11, DOI 10.1111/j.1365-2893.2009.01261.x
   Bourcier V, 2012, CLIN RES HEPATOL GAS, V36, P214, DOI 10.1016/j.clinre.2011.11.002
   Brau N, 2007, J HEPATOL, V47, P527, DOI 10.1016/j.jhep.2007.06.010
   BUCKLEY JA, 1995, MODERN PATHOL, V8, P398
   Bugianesi E, 2005, HEPATOLOGY, V42, P987, DOI 10.1002/hep.20920
   Caron-Debarle M, 2010, TRENDS MOL MED, V16, P218, DOI 10.1016/j.molmed.2010.03.002
   Castaneda-Sceppa C, 2008, J VIRAL HEPATITIS, V15, P878, DOI 10.1111/j.1365-2893.2008.01021.x
   Chaudhry AA, 2009, HIV MED, V10, P133, DOI 10.1111/j.1468-1293.2008.00662.x
   Clifford GM, 2008, AIDS, V22, P2135, DOI 10.1097/QAD.0b013e32831103ad
   Colson P, 2011, J VIRAL HEPATITIS, V18, P227, DOI 10.1111/j.1365-2893.2010.01311.x
   Crum-Cianflone N, 2009, CLIN GASTROENTEROL H, V8, P183
   DallaPiazza M, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-116
   Dalton HR, 2009, NEW ENGL J MED, V361, P1025, DOI 10.1056/NEJMc0903778
   De Lazzari E, 2008, HIV MED, V9, P221, DOI 10.1111/j.1468-1293.2008.00552.x
   EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905
   Fainboim H, 2010, HEPATOLOGY, V52, p1119A
   Galvan FH, 2002, J STUD ALCOHOL, V63, P179
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Grunfeld C, 2007, JAIDS-J ACQ IMM DEF, V46, P283
   Guaraldi G, 2008, CLIN INFECT DIS, V47, P250, DOI 10.1086/589294
   Hadigan C, 2007, JAIDS-J ACQ IMM DEF, V46, P312
   Ingiliz P, 2009, HEPATOLOGY, V49, P436, DOI 10.1002/hep.22665
   Joshi D, 2011, LANCET, V377, P1198, DOI 10.1016/S0140-6736(10)62001-6
   Kaba M, 2011, J MED VIROL, V83, P1704, DOI 10.1002/jmv.22177
   Keane FE, 2012, HIV MED, V13, P83, DOI 10.1111/j.1468-1293.2011.00942.x
   Kovari H, 2010, CLIN INFECT DIS, V50, P502, DOI 10.1086/649922
   Kovari H, 2009, CLIN INFECT DIS, V49, P626, DOI 10.1086/603559
   Lacombe K, 2010, J ANTIMICROB CHEMOTH, V65, P10, DOI 10.1093/jac/dkp414
   Lemoine M, 2006, AIDS, V20, P387, DOI 10.1097/01.aids.0000206503.01536.11
   Lemoine M, 2012, CURR OPIN INFECT DIS, V25, P10, DOI 10.1097/QCO.0b013e32834ef599
   Lemoine M, 2009, PPAR RES, DOI 10.1155/2009/906167
   Li JCB, 2011, AIDS, V25, P15, DOI 10.1097/QAD.0b013e328340fd61
   Liu HY, 2009, J BIOL CHEM, V284, P31484, DOI 10.1074/jbc.M109.033936
   Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135
   Mallet V, 2007, AIDS, V21, P187, DOI 10.1097/QAD.0b013e3280119e47
   Mallet VO, 2009, AIDS, V23, P1511, DOI 10.1097/QAD.0b013e32832bfa51
   Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844
   Mason AL, 1998, LANCET, V351, P1620, DOI 10.1016/S0140-6736(97)10290-2
   Maylin S, 2012, J CLIN VIROL, V53, P346, DOI 10.1016/j.jcv.2012.01.001
   Molina JM, 2011, LANCET, V378, P238, DOI 10.1016/S0140-6736(11)60936-7
   Monforte AD, 2008, AIDS, V22, P2143, DOI 10.1097/QAD.0b013e3283112b77
   Nunez M, 2010, HEPATOLOGY, V52, P1143, DOI 10.1002/hep.23716
   Palacios R, 2006, ANTIVIR THER, V11, P529
   Parker RA, 2005, MOL PHARMACOL, V67, P1909, DOI 10.1124/mol.104.010165
   Puius YA, 2008, J CLIN GASTROENTEROL, V42, P425, DOI 10.1097/01.mcg.0000225591.08825.3e
   Puoti M, 2004, AIDS, V18, P2285, DOI 10.1097/00002030-200411190-00009
   Ratziu V, 2010, J HEPATOL, V53, P372, DOI 10.1016/j.jhep.2010.04.008
   Rockstroh JK, 2012, HIV MED, V13, P127, DOI 10.1111/j.1468-1293.2011.00933.x
   Rosenthal E, 2007, J VIRAL HEPATITIS, V14, P183, DOI 10.1111/j.1365-2893.2006.00791.x
   Salmon D, 2012, J HEPATOL, V56, P862, DOI 10.1016/j.jhep.2011.11.009
   Salmon-Ceron D, 2005, J HEPATOL, V42, P799, DOI 10.1016/j.jhep.2005.01.022
   Salmon-Ceron D, 2009, J HEPATOL, V50, P736, DOI 10.1016/j.jhep.2008.11.018
   Samet JH, 2004, ALCOHOL CLIN EXP RES, V28, P572, DOI 10.1097/01.ALC.0000122103.74491.78
   Shaib YH, 2005, GASTROENTEROLOGY, V128, P620, DOI 10.1053/j.gastro.2004.12.048
   Shuper PA, 2009, AIDS BEHAV, V13, P1021, DOI 10.1007/s10461-009-9589-z
   Sterling RK, 2008, DIGEST DIS SCI, V53, P1375, DOI 10.1007/s10620-007-9999-6
   Sulkowski MS, 2006, 13 C RETR OPP INF US
   Vallet-Pichard A, 2011, J HEPATOL, V55, P474, DOI 10.1016/j.jhep.2011.01.003
   Weber R, 2006, ARCH INTERN MED, V166, P1632
   Worm SW, 2010, AIDS, V24, P427, DOI 10.1097/QAD.0b013e328334344e
   Zatonski WA, 2010, EUR ADDICT RES, V16, P193, DOI 10.1159/000317248
NR 62
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 2210-7401
J9 CLIN RES HEPATOL GAS
JI Clin. Res. Hepatol. Gastroenterol.
PD OCT
PY 2012
VL 36
IS 5
BP 441
EP 447
DI 10.1016/j.clinre.2012.06.002
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 057UP
UT WOS:000312589800017
PM 23079114
OA No
DA 2017-08-15
ER

PT J
AU Peterson, K
   Togun, T
   Klis, S
   Menten, J
   Colebunders, R
AF Peterson, Kevin
   Togun, Toyin
   Klis, Sandor
   Menten, Joris
   Colebunders, Robert
TI Depression and Posttraumatic Stress Disorder Among HIV-Infected Gambians
   on Antiretroviral Therapy
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; MIDDLE-INCOME COUNTRIES; ANXIETY DISORDERS;
   MAJOR DEPRESSION; MENTAL-DISORDERS; POSITIVE ADULTS; SOUTH-AFRICA;
   SYMPTOMS; ADHERENCE; HAART
AB Mood disorders are more frequent among people with HIV infection than among non-HIV-infected individuals of the same age, socioeconomic status, and HIV risks. They have been associated with worse adherence and clinical outcomes, yet remain underdiagnosed and undertreated in sub-Saharan Africa. We explored the relationship between mood disorders using the 10-item depression scale of the Centers for Epidemiological Studies (CES-D10) and the 22-item Impact of Events Scale-Revised (IES-R) for posttraumatic stress disorder, and a range of demographic and HIV-related variables among 252 consecutive subjects on antiretroviral therapy (ART). The study was conducted in the Genito-Urinary Medicine Clinic of the Medical Research Council's Gambia Unit. These screening tests were positive in 7% and 30%, respectively, of the patients, with higher scores (more depression or more post-traumatic stress) associated with female gender, more advanced WHO clinical stage, and lower Karnofsky Perfomance Scale rating. Higher CES-D10 scores were also seen among those on their second ART regimen. No relationship was seen with age, time on ART, viral load, or CD4 cell count. Compared to an earlier study at the same site in subjects prior to starting ART, the prevalence of depression in those stabilized on ART was dramatically reduced (by 34%, from 41%) while that of PTSD dropped less (by 13%, from 43%). Integrating the CES-D10 or a similar instrument into patient preparation for ART is recommended in order to identify those who may benefit from further mental health investigations, specific therapy, or closer follow-up during early ART.
C1 [Peterson, Kevin; Menten, Joris; Colebunders, Robert] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.
   [Togun, Toyin] Med Res Council UK, Gambia Unit, Banjul, Gambia.
   [Klis, Sandor] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands.
   [Colebunders, Robert] Univ Antwerp, Dept Epidemiol & Social Med, Antwerp, Belgium.
RP Peterson, K (reprint author), Inst Trop Med, Dept Clin Sci, Natl Str 155, B-2000 Antwerp, Belgium.
EM kpeterson@itg.be
FU Global Fund for AIDS, TB, and Malaria
FX Tumani Corrah, Assan Jaye, Francoise Lequarre, Francis Oko, and Uduak
   Okomo provided helpful feedback and support for the study. Kristien
   Velding and Yori Gidron were involved in the earlier study that helped
   validate these tools for use in this population and demonstrate the
   scope of the mood disorders problem. Abraham Alabi, Matt Cotten, and
   others were crucial to the delivery of high-quality, affordable VL
   results. Gilleh Thomas and others provided data management. Olivier
   Koole supported the data analysis. Famara Bojang, Tijan Janneh, Lilian
   Colley, and the rest of the GUM staff, and of course the patients who
   participated, were crucial to the success of this study. Support from
   the Global Fund for AIDS, TB, and Malaria made the provision of ART care
   in The Gambia possible, for which all involved, both patients and MRC
   staff, were grateful.
CR Aromeh E, 2011, 6 IAS C HIV PATH TRE
   Arroll B, 2010, ANN FAM MED, V8, P348, DOI 10.1370/afm.1139
   Beckerman NL, 2010, SOC WORK HEALTH CARE, V49, P687, DOI 10.1080/00981389.2010.485089
   Bisson J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub3
   Boarts JM, 2006, AIDS BEHAV, V10, P253, DOI 10.1007/s10461-006-9069-7
   BRESLAU N, 1985, PSYCHIAT RES, V15, P219, DOI 10.1016/0165-1781(85)90079-4
   BURACK JH, 1993, JAMA-J AM MED ASSOC, V270, P2568, DOI 10.1001/jama.270.21.2568
   Celano Christopher M, 2011, Dialogues Clin Neurosci, V13, P109
   Cohen MH, 2009, J WOMENS HEALTH, V18, P1783, DOI 10.1089/jwh.2009.1367
   Cruess DG, 2003, BIOL PSYCHIAT, V54, P307, DOI 10.1016/S0006-3223(03)00318-4
   Cuijpers P, 2009, PSYCHIAT RES, V168, P250, DOI 10.1016/j.psychres.2008.05.012
   Ertl V, 2011, JAMA-J AM MED ASSOC, V306, P503, DOI 10.1001/jama.2011.1060
   Fincham D, 2008, AIDS CARE, V20, P1279, DOI 10.1080/09540120801927025
   Gibson K, 2011, AIDS PATIENT CARE ST, V25, P371, DOI 10.1089/apc.2010.0165
   Gonzalez A, 2012, AIDS PATIENT CARE ST, V26, P156, DOI 10.1089/apc.2011.0309
   Hartzell JD, 2008, J ANTIMICROB CHEMOTH, V62, P246, DOI 10.1093/jac/dkn193
   Igie T, 2011, 6 IAS C HIV PATH TRE
   Judd FK, 2000, AUST NZ J PSYCHIAT, V34, P1015, DOI 10.1046/j.1440-1614.2000.00837.x
   Kacanek D, 2010, JAIDS-J ACQ IMM DEF, V53, P266, DOI 10.1097/QAI.0b013e3181b720e7
   Kagee A, 2005, ETHNIC HEALTH, V10, P169, DOI 10.1080/13557850500071244
   Kaharuza FM, 2006, AIDS BEHAV, V10, pS105, DOI 10.1007/s10461-006-9142-2
   Kapetanovic S, 2011, AIDS PATIENT CARE ST, V25, P493, DOI 10.1089/apc.2011.0107
   Kekwaletswe C, 2011, 6 IAS C HIV PATH TRE
   Klis S, 2011, AIDS CARE, V23, P426, DOI 10.1080/09540121.2010.507756
   Kumar V, 2009, PSYCHIAT QUART, V80, P131, DOI 10.1007/s11126-009-9100-z
   Leserman J, 2008, PSYCHOSOM MED, V70, P539, DOI 10.1097/PSY.0b013e3181777a5f
   Leserman J, 2007, AM J PSYCHIAT, V164, P1707, DOI 10.1176/appi.ajp.2007.06111775
   Lima VD, 2007, AIDS, V21, P1175, DOI 10.1097/QAD.0b013e32811ebf57
   Lyketsos CG, 1996, AM J PSYCHIAT, V153, P1430
   Martin L, 2011, AIDS BEHAV, V15, P125, DOI 10.1007/s10461-008-9498-6
   Monahan PO, 2009, J GEN INTERN MED, V24, P189, DOI 10.1007/s11606-008-0846-z
   Myer L, 2008, AIDS PATIENT CARE ST, V22, P147, DOI 10.1089/apc.2007.0102
   Nakimuli-Mpungu E, 2011, J AFFECT DISORDERS, V135, P160, DOI 10.1016/j.jad.2011.07.009
   Olley BO, 2006, AIDS CARE, V18, P1025, DOI 10.1080/09540120600568756
   Olley BO, 2006, J PSYCHOSOM RES, V61, P479, DOI 10.1016/j.jpsychores.2006.03.010
   Patel V, 2007, LANCET, V370, P991, DOI 10.1016/S01406736(07)61240-9
   Penzak SR, 2000, AM J HEALTH-SYST PH, V57, P376
   Penzak SR, 2000, AM J HEALTH-SYST PH, V57, P387
   Peterson I, AIDS IN PRESS
   Schaal S, 2009, PSYCHOTHER PSYCHOSOM, V78, P298, DOI 10.1159/000229768
   Schneider G, 2004, ANTIRETROVIRAL THERA
   Sheriff RJS, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-69
   Sherr L, 2011, PSYCHOL HEALTH MED, V16, P612, DOI 10.1080/13548506.2011.579991
   Sledjeski EM, 2005, AIDS PATIENT CARE ST, V19, P728, DOI 10.1089/apc.2005.19.728
   Thoresen S, 2010, SOC PSYCH PSYCH EPID, V45, P405, DOI 10.1007/s00127-009-0073-x
   Vranceanu AM, 2008, AIDS PATIENT CARE ST, V22, P313, DOI 10.1089/apc.2007.0069
   Walkup J, 2008, PSYCHIAT QUART, V79, P43, DOI 10.1007/s11126-007-9055-x
   Wanke C, 2004, JAIDS-J ACQ IMM DEF, V37, pS277, DOI 10.1097/01.qai.0000144382.47468.34
   Yamazaki S., 2005, HEALTH QUAL LIFE OUT, V3, P48, DOI DOI 10.1186/1477-7525-3-48
NR 49
TC 7
Z9 7
U1 4
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD OCT
PY 2012
VL 26
IS 10
BP 589
EP 596
DI 10.1089/apc.2012.0089
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 015XF
UT WOS:000309479000004
PM 22989270
OA No
DA 2017-08-15
ER

PT J
AU de Vries, J
   Jallow, M
   Williams, TN
   Kwiatkowski, D
   Parker, M
   Fitzpatrick, R
AF de Vries, Jantina
   Jallow, Muminatou
   Williams, Thomas N.
   Kwiatkowski, Dominic
   Parker, Michael
   Fitzpatrick, Raymond
TI Investigating the potential for ethnic group harm in collaborative
   genomics research in Africa: Is ethnic stigmatisation likely?
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE Africa; Kenya; The Gambia; Ethnicity; Stigma; Genomics; MalariaGEN
ID WIDE ASSOCIATION; GENETIC RESEARCH; BIOMEDICAL-RESEARCH; WEST-AFRICA;
   STIGMA; RACE; HEALTH; POPULATIONS; INFORMATION; CHALLENGES
AB A common assumption in genomics research is that the use of ethnic categories has the potential to lead to ethnic stigmatisation - particularly when the research is done on minority populations. Yet few empirical studies have sought to investigate the relation between genomics and stigma, and fewer still with a focus on Africa. In this paper, we investigate the potential for genomics research to lead to harms to ethnic groups. We carried out 49 semi-structured, open-ended interviews with stakeholders in a current medical genomics research project in Africa, MalariaGEN. Interviews were conducted with MalariaGEN researchers, field-workers, members of three ethics committees who reviewed MalariaGEN project proposals, and with members of the two funding bodies providing support to the MalariaGEN project. Interviews were conducted in Kenya, The Gambia and the UK between June 2008 and October 2009. They covered a range of aspects relating to the use of ethnicity in the genomics project, including views on adverse effects of the inclusion of ethnicity in such research. Drawing on the empirical data, we argue that the risk of harm to ethnic groups is likely to be more acute in specific types of genomics research. We develop a typology of research questions and projects that carry a greater risk of harm to the populations included in genomics research. We conclude that the potential of generating harm to ethnic groups in genomics research is present if research includes populations that are already stigmatised or discriminated against, or where the research investigates questions with particular normative implications. We identify a clear need for genomics researchers to take account of the social context of the work they are proposing to do, including understanding the local realities and relations between ethnic groups, and whether diseases are already stigmatised. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [de Vries, Jantina; Parker, Michael] Univ Oxford, Ethox Ctr, Dept Publ Hlth, Oxford OX1 2JD, England.
   [Jallow, Muminatou] MRC Labs, Banjul, Gambia.
   [Williams, Thomas N.] Kenya Med Res Inst KEMRI, Wellcome Trust Programme, Ctr Geog Med Res, Nairobi, Kenya.
   [Kwiatkowski, Dominic] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
   [de Vries, Jantina] Univ Cape Town, Div Human Genet, Fac Hlth Sci, ZA-7700 Rondebosch, South Africa.
RP de Vries, J (reprint author), Univ Oxford, Ethox Ctr, Dept Publ Hlth, Oxford OX1 2JD, England.
EM Jantina.devries@uct.ac.za; muminatou@yahoo.com;
   twilliams@kilifi.kemri-wellcome.org; dominic@well.ox.ac.uk;
   michael.parker@ethox.ox.ac.uk; raymond.fitzpatrick@nuffield.ox.ac.uk
RI De Vries, Jantina/I-2752-2014
OI De Vries, Jantina/0000-0001-7192-2633; Kwiatkowski,
   Dominic/0000-0002-5023-0176
FU Wellcome Trust [WT083326, 075491/Z/04, WT076934, WT087285, WT096527,
   WT077383/Z/05/Z, 077012/Z/05/Z]; UK Medical Research Council [G19/9];
   European Union Network 7 EVIMaIR Consortium; Bill and Melinda Gates
   Foundation through the Foundations of the National Institutes of Health,
   Grand Challenges in Global Health Initiative [566]; Medical Research
   Council [G0600230]
FX JdV gratefully acknowledges the support of a Wellcome Trust Research
   Studentship for this research (WT083326). DPK receives support from the
   UK Medical Research Council (G19/9). The Wellcome Trust also provides
   core awards to Wellcome Trust Centre for Human Genetics (075491/Z/04)
   and the Wellcome Trust Sanger Institute (077012/Z/05/Z). TNW is funded
   by the Wellcome Trust (WT076934) and by the European Union Network 7
   EVIMaIR Consortium. MP is supported by a Wellcome Trust Biomedical
   Ethics Enhancement Award (WT087285) and Strategic Award (WT096527). The
   MalariaGEN Project was supported by the Wellcome Trust (WT077383/Z/05/Z)
   and the Bill and Melinda Gates Foundation through the Foundations of the
   National Institutes of Health (566) as part of the Grand Challenges in
   Global Health Initiative. The Medical Research Council (G0600230)
   provided additional support for genotyping, bioinformatics and analysis.
CR Aultman J. M., 2006, GENOMICS SOC POLICY, V2, P28
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Caulfield T, 2008, PLOS BIOL, V6, P430, DOI 10.1371/journal.pbio.0060073
   Coloma J, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000142
   De Vries J, 2011, BMC MED ETHICS, V12
   Fairhead J, 2006, SOC SCI MED, V63, P1109, DOI 10.1016/j.socscimed.2006.02.018
   Foster MW, 2006, HUM MOL GENET, V15, pR45, DOI 10.1093/hmg/ddl049
   Frank R, 2007, SOC SCI MED, V64, P1977, DOI 10.1016/j.socscimed.2007.01.010
   Fujimura JH, 2011, SOC STUD SCI, V41, P5, DOI 10.1177/0306312710379170
   Fullwiley D, 2010, AM ETHNOL, V37, P638, DOI 10.1111/j.1548-1425.2010.01276.x
   Goodman KW, 1996, COMPUT BIOL MED, V26, P223, DOI 10.1016/0010-4825(95)00059-3
   Greely HT, 2010, AM J BIOETHICS, V10, P1, DOI 10.1080/15265161.2010.494229
   Harmon A, 2010, NY TIMES        1121
   Hunt LM, 2008, SOC SCI MED, V66, P349, DOI 10.1016/j.socscimed.2007.08.034
   Jallow M, 2009, NAT GENET, V41, P657, DOI 10.1038/ng.388
   Kaye J, 2010, EUROPEAN J HUMAN GEN, V18
   Koenig Barbara A., 2008, REVISITING RACE GENO
   Kwiatkowski D, 2008, NATURE, V456, P732, DOI 10.1038/nature07632
   Lee C, 2009, SOC SCI MED, V68, P1183, DOI 10.1016/j.socscimed.2008.12.036
   Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363
   Lock M., 2010, ANTHR BIOMEDICINE
   Marsh V., 2008, SOCIAL SCI MED
   Ashcroft Richard, 2007, REVIVING RACIAL MED
   Mason M., 2010, FORUM QUALITATIVE SO, V11
   McGregor J, 2010, AM J BIOETHICS, V10, P23, DOI 10.1080/15265161.2010.492888
   Meiser B, 2005, SOC SCI MED, V60, P109, DOI 10.1016/j.socscimed.2004.04.016
   Milmo C., 2007, INDEPENDENT     0611
   Need AC, 2009, TRENDS GENET, V25, P489, DOI 10.1016/j.tig.2009.09.012
   Newport MJ, 2009, PUBLIC HEALTH GENOMI, V12, P251, DOI 10.1159/000197973
   Parfitt Tudor, 2005, GENETICS MASS MEDIA
   Parker R, 2003, SOC SCI MED, V57, P13, DOI 10.1016/S0277-9536(02)00304-0
   Phelan JC, 2005, J HEALTH SOC BEHAV, V46, P307
   QSR, 2009, NVIVO 8
   Quinn-Patton M., 2002, QUALITATIVE RES NURS
   Reardon J, 2005, IN-FORMATION, P1
   Rose N., 2006, BIOSOCIETIES, V1, P307, DOI 10.1017/S174585520600305X
   Rosenberg NA, 2010, NAT REV GENET, V11, P356, DOI 10.1038/nrg2760
   Sankar P, 2006, GENET MED, V8, P33, DOI 10.1097/01.gim.0000195894.67756.8b
   Shanawani H, 2006, J MED ETHICS, V32, P724, DOI 10.1136/jme.2005.014456
   Simpson B., 2000, ANTHR TODAY, V16, P3, DOI DOI 10.1111/1467-8322.00023
   Tekola F, 2009, BMC MED ETHICS, V10, DOI 10.1186/1472-6939-10-13
   Teo YY, 2010, NAT REV GENET, V11, P149, DOI 10.1038/nrg2731
   Tindana PO, 2007, PLOS MED, V4, P1451, DOI 10.1371/journal.pmed.0040273
   Wensley D, 2008, J MED ETHICS, V34, P507, DOI 10.1136/jme.2006.019596
   World Health Organisation, 2002, REP ADV COMM HLTH RE
   Yang LH, 2007, SOC SCI MED, V64, P1524, DOI 10.1016/j.socscimed.2006.11.013
NR 46
TC 12
Z9 12
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD OCT
PY 2012
VL 75
IS 8
BP 1400
EP 1407
DI 10.1016/j.socscimed.2012.05.020
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 007QC
UT WOS:000308902200009
PM 22749442
OA No
DA 2017-08-15
ER

PT J
AU Lin, GM
   Jaiteh, LES
   Han, CL
AF Lin, Gen-Min
   Jaiteh, Lamin E. S.
   Han, Chih-Lu
TI Letter by Lin et al Regarding Article, "Does Body Mass Index Impact on
   the Relationship Between Systolic Blood Pressure and Cardiovascular
   Disease? Meta-Analysis of 419 488 Individuals From the Asia Pacific
   Cohort Studies Collaboration"
SO STROKE
LA English
DT Letter
C1 [Lin, Gen-Min] Gen Hosp, Hualien Armed Forces, Dept Med, Hualien, Taiwan.
   [Jaiteh, Lamin E. S.] Royal Victoria Teaching Hosp, Dept Med, Banjul, Gambia.
   [Han, Chih-Lu] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.
RP Lin, GM (reprint author), Gen Hosp, Hualien Armed Forces, Dept Med, Hualien, Taiwan.
CR Beddhu S, 2005, AM J CLIN NUTR, V82, P909
   Beddhu S, 2005, AM J CLIN NUTR, V82, P910
   Kalantar-Zadeh K, 2004, J AM COLL CARDIOL, V43, P1439, DOI 10.1016/j.jacc.2003.11.039
   Lin GM, 2011, INT J CARDIOL, V146, P422, DOI 10.1016/j.ijcard.2010.10.094
   Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646
   Tsukinoki R, 2012, STROKE, V43, P1478, DOI 10.1161/STROKEAHA.112.650317
NR 6
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD OCT
PY 2012
VL 43
IS 10
BP E105
EP E105
DI 10.1161/STROKEAHA.112.668830
PG 1
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 012TG
UT WOS:000309258900003
PM 22933586
OA No
DA 2017-08-15
ER

PT J
AU Ahmed, S
   Bin Ahsan, K
   Kippler, M
   Mily, A
   Wagatsuma, Y
   Hoque, AMW
   Ngom, PT
   El Arifeen, S
   Raqib, R
   Vahter, M
AF Ahmed, Sultan
   Bin Ahsan, Khalid
   Kippler, Maria
   Mily, Akhirunnesa
   Wagatsuma, Yukiko
   Hoque, A. M. Waheedul
   Ngom, Pa Tamba
   El Arifeen, Shams
   Raqib, Rubhana
   Vahter, Marie
TI In Utero Arsenic Exposure Is Associated With Impaired Thymic Function in
   Newborns Possibly Via Oxidative Stress and Apoptosis
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE sjTREC; thymus; oxidative stress; apoptosis; arsenic; cord blood
ID RURAL BANGLADESH; INFANT-MORTALITY; RANDOMIZED-TRIAL; BIRTH-WEIGHT;
   CHILDREN; DISEASE; LIFE; PREGNANCY; MATLAB; COHORT
AB Prenatal arsenic exposure is associated with increased infant morbidity and reduced thymus size, indicating arsenic-related developmental immunotoxicity. We aimed to evaluate effects of prenatal arsenic exposure on thymic function at birth and related mechanisms of action. In a Bangladeshi cohort, arsenic was measured in urine (U-As, gestational week (GW) 8 and 30) and blood (B-As, GW14) in 130 women. Child thymic index was measured by sonography at birth and thymic function by signal-joint T-cell receptor-rearrangement excision circles (sjTRECs) in cord blood mononuclear cells (CBMC). In a subsample (n = 44), sjTRECs content in isolated CD4(+) and CD8(+) T cells, expression of oxidative-stress defense and apoptosis-related genes in CBMC, arsenic concentrations (urine, placenta, and cord blood), and oxidative stress markers in placenta and cord blood were measured. In multivariable-adjusted regression, In U-As (GW8) was inversely associated with In sjTRECs in CBMC (B = -0.25; 95% confidence interval [CI] -0.48 to -0.01). Using multivariable-adjusted spline regression, In U-As (GW30) and In B-As (GW14) were inversely associated with In sjTRECs in CBMC (B = -0.53; 95% CI -0.93 to -0.13 and B = -1.27; 95% CI -1.89 to -0.66, respectively) below spline knots at U-As 150 mu g/l and B-As 6 mu g/kg. Similar inverse associations were observed in separated CD4(+) and CD8(+) T cells. Arsenic was positively associated with 8-hydroxy-2'-deoxyguanosine in cord blood (B = 0.097; 95% CI 0.05 to 0.13), which was inversely associated with sjTRECs in CD4(+) and CI8(+). T cells. In conclusion, prenatal arsenic exposure was associated with reduced thymic function, possibly via induction of oxidative stress and apoptosis, suggesting subsequent immunosuppression in childhood.
C1 [Raqib, Rubhana] Int Ctr Diarrhoeal Dis Res, Div Sci Lab, Nutr Biochem Lab, Bangladesh ICDDR B, Dhaka 1212, Bangladesh.
   [Ahmed, Sultan; Kippler, Maria; Vahter, Marie] Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden.
   [Wagatsuma, Yukiko] Univ Tsukuba, Fac Med, Dept Clin Epidemiol, Tsukuba, Ibaraki 3058577, Japan.
   [Ngom, Pa Tamba] MRC Labs, Nutr Programme, Banjul, Gambia.
RP Raqib, R (reprint author), Int Ctr Diarrhoeal Dis Res, Div Sci Lab, Nutr Biochem Lab, Bangladesh ICDDR B, Dhaka 1212, Bangladesh.
EM rubhana@icddrb.org
OI Raqib, Rubhana/0000-0002-8116-4511
FU Swedish International Development Cooperation Agency (Sida) [75000431,
   75000512, 82030018]; European Commission (PHIME project)
   [FOOD-CT-2006-016253]; University of Tsukuba (JSPS) [18256005];
   Karolinska Institutet; International Centre for Diarrhoeal Disease
   Research, Bangladesh (ICDDR,B)'s core donors; ICDDR,B; UNICEF; Sida;
   U.K. Medical Research Council; Swedish Research Council; DFID, Japan
   Society for the Promotion of Science (JSPS); Child Health and Nutrition
   Research Initiative (CHNRI); Uppsala University; U.S. Agency for
   International Development (USAID)
FX Swedish International Development Cooperation Agency (Sida: contribution
   no. 75000431, 75000512, 82030018); the European Commission (PHIME
   project no. FOOD-CT-2006-016253); University of Tsukuba (JSPS no.
   18256005); the Karolinska Institutet, and International Centre for
   Diarrhoeal Disease Research, Bangladesh (ICDDR,B)'s core donors. The
   MINIMat supplementation trial was funded by ICDDR,B, UNICEF, Sida, U.K.
   Medical Research Council, Swedish Research Council, DFID, Japan Society
   for the Promotion of Science (JSPS), Child Health and Nutrition Research
   Initiative (CHNRI), Uppsala University, and U.S. Agency for
   International Development (USAID).
CR Aaby P, 2002, ACTA PAEDIATR, V91, P698, DOI 10.1080/080352502760069142
   Ahmed S., 2010, ENV HLTH PERSPECT, V119, P258, DOI 10.1289/ehp.1102086
   DeWitt JC, 2012, TOXICOL PATHOL, V40, P230, DOI 10.1177/0192623311427709
   Dietert RR, 2008, BIRTH DEFECTS RES B, V83, P547, DOI 10.1002/bdrb.20170
   Douek DC, 1998, NATURE, V396, P690
   Engstrom KS, 2010, FREE RADICAL BIO MED, V48, P1211, DOI 10.1016/j.freeradbiomed.2010.02.004
   Ferrario D, 2009, TOXICOLOGY, V260, P132, DOI 10.1016/j.tox.2009.03.019
   Flora SJS, 2011, FREE RADICAL BIO MED, V51, P257, DOI 10.1016/j.freeradbiomed.2011.04.008
   Fry RC, 2007, PLOS GENET, V3, P2180, DOI 10.1371/journal.pgen.0030207
   Gardner R, 2011, AM J PUBLIC HEALTH, V101, pS333, DOI 10.2105/AJPH.2010.300025
   Halnon NJ, 2005, PEDIATR RES, V57, P42, DOI 10.1203/01.PDR.0000147735.19342.DE
   Hasselbalch H, 1996, EUR RADIOL, V6, P700
   Hernandez-Castro B, 2009, J CLIN IMMUNOL, V29, P461, DOI 10.1007/s10875-009-9280-1
   Hough RL, 2010, INT ARCH OCC ENV HEA, V83, P471, DOI 10.1007/s00420-010-0519-1
   Jomova K, 2011, J APPL TOXICOL, V31, P95, DOI 10.1002/jat.1649
   Kippler M, 2010, TOXICOL LETT, V192, P162, DOI 10.1016/j.toxlet.2009.10.018
   Lindberg AL, 2010, ENVIRON HEALTH PERSP, V118, P533, DOI 10.1289/ehp.0900728
   Moore SE, 2009, ACTA PAEDIATR, V98, P1168, DOI 10.1111/j.1651-2227.2009.01292.x
   Moore SE, 2006, P NUTR SOC, V65, P311, DOI 10.1079/PNS2006503
   Nermell B, 2008, ENVIRON RES, V106, P212, DOI 10.1016/j.envres.2007.08.005
   Persson LA, 2012, JAMA-J AM MED ASSOC, V307, P2050, DOI 10.1001/jama.2012.4061
   Prentice AM, 1999, BRIT J NUTR, V81, P345
   Puck JM, 2011, ANN NY ACAD SCI, V1246, P108, DOI 10.1111/j.1749-6632.2011.06346.x
   Rahman A, 2010, ENV HLTH PERSPECT, V119, P719, DOI DOI 10.1289/EHP.1002265
   Rahman A, 2007, AM J EPIDEMIOL, V165, P1389, DOI 10.1093/aje/kwm025
   Rahman A, 2009, AM J EPIDEMIOL, V169, P304, DOI 10.1093/aje/kwn332
   Rahman M, 2006, J EPIDEMIOL COMMUN H, V60, P242, DOI 10.1136/jech.2005.040212
   Raqib R, 2007, AM J CLIN NUTR, V85, P845
   Raqib R, 2009, TOXICOL LETT, V185, P197, DOI 10.1016/j.toxlet.2009.01.001
   Rocha-Amador DO, 2011, ENVIRON TOXICOL PHAR, V32, P399, DOI 10.1016/j.etap.2011.08.004
   Saha KK, 2008, AM J CLIN NUTR, V87, P1852
   Selgrade MK, 2007, TOXICOL SCI, V100, P328, DOI 10.1093/toxsci/kfm244
   Smith AH, 2011, AM J EPIDEMIOL, V173, P414, DOI 10.1093/aje/kwq383
   Soto-Pena GA, 2006, FASEB J, V20, P779, DOI 10.1096/fj.05-4860fje
   Straif K, 2009, LANCET ONCOL, V10, P453
   Tofail F, 2008, AM J CLIN NUTR, V87, P704
   Vahter ME, 2006, J HEALTH POPUL NUTR, V24, P236
   Ye P, 2002, J IMMUNOL, V168, P4968
NR 38
TC 42
Z9 44
U1 2
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
J9 TOXICOL SCI
JI Toxicol. Sci.
PD OCT
PY 2012
VL 129
IS 2
BP 305
EP 314
DI 10.1093/toxsci/kfs202
PG 10
WC Toxicology
SC Toxicology
GA 009PM
UT WOS:000309037700007
PM 22713597
OA No
DA 2017-08-15
ER

PT J
AU Jallow, M
   Casals-Pascual, C
   Ackerman, H
   Walther, B
   Walther, M
   Pinder, M
   Sisay-Joof, F
   Usen, S
   Jallow, M
   Abubakar, I
   Olaosebikan, R
   Jobarteh, A
   Conway, DJ
   Bojang, K
   Kwiatkowski, D
AF Jallow, Muminatou
   Casals-Pascual, Climent
   Ackerman, Hans
   Walther, Brigitte
   Walther, Michael
   Pinder, Margaret
   Sisay-Joof, Fatou
   Usen, Stanley
   Jallow, Mariatou
   Abubakar, Ismaela
   Olaosebikan, Rasaq
   Jobarteh, Aminata
   Conway, David J.
   Bojang, Kalifa
   Kwiatkowski, Dominic
TI Clinical Features of Severe Malaria Associated with Death: A 13-Year
   Observational Study in The Gambia
SO PLOS ONE
LA English
DT Article
ID SEVERE FALCIPARUM-MALARIA; AFRICAN CHILDREN; CEREBRAL MALARIA;
   RANDOMIZED-TRIAL; TRANSMISSION; INDICATORS; MORBIDITY
AB Background: Severe malaria (SM) is a major cause of death in sub-Saharan Africa. Identification of both specific and sensitive clinical features to predict death is needed to improve clinical management.
   Methods: A 13-year observational study was conducted from 1997 through 2009 of 2,901 children with SM enrolled at the Royal Victoria Teaching Hospital in The Gambia to identify sensitive and specific predictors of poor outcome in Gambian children with severe malaria between the ages 4 months to 14 years. We have measured the sensitivity and specificity of clinical features that predict death or development of neurological sequelae.
   Findings: Impaired consciousness (odds ratio {OR} 4.4 [95% confidence interval {CI}, 2.7-7.3]), respiratory distress (OR 2.4 [95% CI, 1.7-3.2]), hypoglycemia (OR 1.7 [95%CI, 1.2-2.3]), jaundice (OR 1.9 [95%CI, 1.2-2.9]) and renal failure (OR 11.1 [95%CI, 3.3-36.5]) were independently associated with death in children with SM. The clinical features that showed the highest sensitivity and specificity to predict death were respiratory distress (area under the curve 0.63 [95% CI, 0.60-0.65]) and impaired consciousness (AUC 0.61[95% CI, 0.59-0.63]), which were comparable to the ability of hyperlactatemia (blood lactate>5 mM) to predict death (AUC 0.64 [95% CI, 0.55-0.72]). A Blantyre coma score (BCS) of 2 or less had a sensitivity of 74% and specificity of 67% to predict death (AUC 0.70 [95% C.I. 0.68-0.72]), and sensitivity and specificity of 74% and 69%, respectively to predict development of neurological sequelae (AUC 0.72 [95% CI, 0.67-0.76]). The specificity of this BCS threshold to identify children at risk of dying improved in children less than 3 years of age (AUC 0.74, [95% C.I 0.71-0.76]).
   Conclusion: The BCS is a quantitative predictor of death. A BCS of 2 or less is the most sensitive and specific clinical feature to predict death or development of neurological sequelae in children with SM.
C1 [Casals-Pascual, Climent; Kwiatkowski, Dominic] Wellcome Trust Ctr Human Genet, Oxford, England.
   [Jallow, Muminatou; Walther, Brigitte; Pinder, Margaret; Sisay-Joof, Fatou; Usen, Stanley; Abubakar, Ismaela; Olaosebikan, Rasaq; Jobarteh, Aminata; Bojang, Kalifa] MRC Labs, Malaria Programme, Banjul, Gambia.
   [Ackerman, Hans; Walther, Michael] NIAID, Lab Malaria & Vector Res, Rockville, MD USA.
   [Conway, David J.] London Sch Hyg & Trop Med, London WC1, England.
   [Jallow, Muminatou; Jallow, Mariatou] Royal Victoria Teaching Hosp, Banjul, Gambia.
RP Casals-Pascual, C (reprint author), Wellcome Trust Ctr Human Genet, Oxford, England.
EM ccasals@well.ox.ac.uk
OI Kwiatkowski, Dominic/0000-0002-5023-0176; Casals-Pascual,
   Climent/0000-0002-0867-8954; Conway, David/0000-0002-8711-3037
FU Wellcome Trust [077383/Z/05/Z, 075491/Z/04]; Bill & Melinda Gates
   Foundation through the Foundation for the National Institutes of Health
   as part of the Grand Challenges in Global Health initiative [566];
   Medical Research Council [G0701885]; Division of Intramural Research,
   National Institutes of Allergy and Infectious Diseases
FX This work was supported by the Wellcome Trust [grant number
   077383/Z/05/Z] [grant number 075491/Z/04] and by the Bill & Melinda
   Gates Foundation, through the Foundation for the National Institutes of
   Health (grant number 566) as part of the Grand Challenges in Global
   Health initiative. CC-P is supported by the Medical Research Council
   (Clinician Scientist Fellowship: G0701885). HA is supported by the
   Division of Intramural Research, National Institutes of Allergy and
   Infectious Diseases. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bejon P, 2007, PLOS MED, V4, P1333, DOI 10.1371/journal.pmed.0040251
   Berkley JA, 1999, QJM-MON J ASSOC PHYS, V92, P151, DOI 10.1093/qjmed/92.3.151
   Berkley JA, 2005, BRIT MED J, V330, P995, DOI 10.1136/bmj.38408.471991.8F
   Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   Gwer S, 2007, AM J TROP MED HYG, V77, P6
   Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7
   Idro R, 2007, JAMA-J AM MED ASSOC, V297, P2232, DOI 10.1001/jama.297.20.2232
   KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Newton CRJC, 2005, CLIN INFECT DIS, V41, P948, DOI 10.1086/432941
   Reyburn H, 2005, JAMA-J AM MED ASSOC, V293, P1461, DOI 10.1001/jama.293.12.1461
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Taylor T, 2006, T ROY SOC TROP MED H, V100, P615, DOI 10.1016/j.trstmh.2005.09.021
   von Seidlein L, 2012, CLIN INFECT DIS, V54, P1080, DOI 10.1093/cid/cis034
   WALLER D, 1995, CLIN INFECT DIS, V21, P577
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   WHO, 2006, WHO CHILD GROWTH STA
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
NR 22
TC 15
Z9 15
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 28
PY 2012
VL 7
IS 9
AR e45645
DI 10.1371/journal.pone.0045645
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 022PZ
UT WOS:000309973900049
PM 23029157
OA gold
DA 2017-08-15
ER

PT J
AU Roca, A
   Bottomley, C
   Hill, PC
   Bojang, A
   Egere, U
   Antonio, M
   Darboe, O
   Greenwood, BM
   Adegbola, RA
AF Roca, A.
   Bottomley, C.
   Hill, P. C.
   Bojang, A.
   Egere, U.
   Antonio, M.
   Darboe, O.
   Greenwood, B. M.
   Adegbola, R. A.
TI Effect of Age and Vaccination With a Pneumococcal Conjugate Vaccine on
   the Density of Pneumococcal Nasopharyngeal Carriage
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID STREPTOCOCCUS-PNEUMONIAE; LONGITUDINAL HOUSEHOLD; ANTIBODY-RESPONSES;
   CHILDREN; DISEASE; COLONIZATION; ADULTS; TRIAL; EPIDEMIOLOGY; SEROTYPES
AB Background. This study evaluated the impact of age and pneumococcal vaccination on the density of pneumococcal nasopharyngeal carriage.
   Methods. A cluster-randomized trial was conducted in rural Gambia. In 11 villages (the vaccine group), all residents received 7-valent pneumococcal conjugate vaccine (PCV-7), while in another 10 villages (the control group), only children <30 months old or born during the study period received PCV-7. Cross-sectional surveys (CSSs) were conducted to collect nasopharyngeal swabs before vaccination (baseline CSS) and 4, 12, and 22 months after vaccination. Pneumococcal density was defined using a semiquantitative classification (range, 1-4) among colonized individuals. An age-trend analysis of density was conducted using data from the baseline CSS. Mean pneumococcal density was compared in CSSs conducted before and after vaccination.
   Results. Mean bacterial density among colonized individuals in the baseline CSS was 2.57 for vaccine-type (VT) and non-vaccine-type (NVT) pneumococci; it decreased with age (P < .001 for VT and NVT). There was a decrease in the density of VT carriage following vaccination in individuals older than 5 years (from 2.44 to 1.88; P = .001) and in younger individuals (from 2.57 to 2.11; P = .070) in the vaccinated villages. Similar decreases in density were observed with NVT within vaccinated and control villages. No significant differences were found between vaccinated and control villages in the postvaccination comparisons for either VT or NVT.
   Conclusions. A high density of carriage among young subjects might partly explain why children are more efficient than adults in pneumococcal transmission. PCV-7 vaccination lowered the density of VT and of NVT pneumococcal carriage in the before-after vaccination analysis.
C1 [Roca, A.; Bojang, A.; Egere, U.; Antonio, M.; Darboe, O.; Adegbola, R. A.] MRC, Banjul, Gambia.
   [Bottomley, C.] Univ London London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1E 7HT, England.
   [Greenwood, B. M.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England.
   [Hill, P. C.] Univ Otago, Ctr Int Hlth, Dunedin, New Zealand.
   [Adegbola, R. A.] Global Med Affairs, GlaxoSmithKline Biol, Wavre, Belgium.
RP Roca, A (reprint author), MRC, POB 273, Banjul, Gambia.
EM aroca@mrc.gm
FU United Kingdom Medical Research Council
FX This work was supported by the United Kingdom Medical Research Council.
   Study vaccines were donated by Wyeth Lederle Vaccines (Pfizer).
CR Abdullahi O, 2008, PEDIATR INFECT DIS J, V27, P59, DOI 10.1097/INF.0b013e31814da70c
   Albrich WC, 2012, CLIN INFECT DIS, V54, P601, DOI 10.1093/cid/cir859
   Brueggemann AB, 2007, PLOS PATHOG, V3, P1628, DOI 10.1371/journal.ppat.0030168
   Cheung YB, 2009, PEDIATR INFECT DIS J, V28, P990, DOI 10.1097/INF.0b013e3181a78185
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525
   Feikin DR, 2005, CLIN INFECT DIS, V41, P481, DOI 10.1086/432015
   Flasche S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001017
   Frazao N, 2010, VACCINE, V28, P3445, DOI 10.1016/j.vaccine.2010.02.070
   Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524
   Hayes RJ, 2009, INTERD STAT, P3
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Hill PC, 2010, CLIN INFECT DIS, V50, P1468, DOI 10.1086/652443
   Hussain M, 2005, EPIDEMIOL INFECT, V133, P891, DOI 10.1016/S0950268805004012
   Kadioglu A, 2004, INFECT IMMUN, V72, P2689, DOI 10.1128/IAI.72.5.2689-2697.2004
   Klugman KP, 2011, PHILOS T R SOC B, V366, P2790, DOI 10.1098/rstb.2011.0032
   Lipsitch M, 2001, AM J EPIDEMIOL, V154, P85
   Lu YJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000159
   Mackenzie GA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-304
   McCool TL, 2004, INFECT IMMUN, V72, P5807, DOI 10.1128/IAI.72.10.5807-5813.2004
   Millar EV, 2008, CLIN INFECT DIS, V47, P989, DOI 10.1086/591966
   O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833
   O'Brien Katherine L, 2003, Pediatr Infect Dis J, V22, pe1, DOI 10.1097/01.inf.0000049347.42983.77
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Turner Paul, 2011, BMC Infect Dis, V11, P108, DOI 10.1186/1471-2334-11-108
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Vu Huong Thi Thu, 2011, Pediatr Infect Dis J, V30, P11, DOI 10.1097/INF.0b013e3181f111a2
   Walter ND, 2009, NEW ENGL J MED, V361, P2584, DOI 10.1056/NEJMc0904844
   Weinberger DM, 2008, J INFECT DIS, V197, P1511, DOI 10.1086/587941
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
   Zhang QB, 2006, EUR J IMMUNOL, V36, P46, DOI 10.1002/eji.200535101
NR 33
TC 21
Z9 21
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 15
PY 2012
VL 55
IS 6
BP 816
EP 824
DI 10.1093/cid/cis554
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 995LF
UT WOS:000308008900012
PM 22700830
OA No
DA 2017-08-15
ER

PT J
AU Nyamweya, S
   Townend, J
   Zaman, A
   Steele, SJ
   Jeffries, D
   Rowland-Jones, S
   Whittle, H
   Flanagan, KL
   Jaye, A
AF Nyamweya, Samuel
   Townend, John
   Zaman, Akram
   Steele, Sarah Jane
   Jeffries, David
   Rowland-Jones, Sarah
   Whittle, Hilton
   Flanagan, Katie L.
   Jaye, Assan
TI Are Plasma Biomarkers of Immune Activation Predictive of HIV
   Progression: A Longitudinal Comparison and Analyses in HIV-1 and HIV-2
   Infections?
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS-INFECTION; VIRAL LOAD PREDICTS;
   T-CELL-ACTIVATION; ANTIRETROVIRAL THERAPY; MICROBIAL TRANSLOCATION;
   SURVIVAL; MARKERS; INDIVIDUALS; RECEPTOR; LEVEL
AB Background: Chronic immune activation is a hallmark of HIV infection and has been associated with disease progression. Assessment of soluble biomarkers indicating immune activation provide clues into pathogenesis and hold promise for the development of point-of-care monitoring of HIV in resource-poor-settings. Their evaluation in cohort resources is therefore needed to further their development and use in HIV research.
   Methodology/Principal Findings: Longitudinal evaluation of beta-2 microglobulin (beta-2 m), neopterin and suPAR soluble urokinase-type plasminogen activator receptor (suPAR) was performed with archived plasma samples to predict disease progression and provided the first direct comparison of levels in HIV-1 and HIV-2 infections. At least 2095 samples from 137 HIV-1 and 198 HIV-2 subjects with starting CD4% of >= 28 and median follow up of 4 years were analysed. All biomarkers were correlated negatively to CD4% and positively to viral load and to each other. Analyses in subjects living for >= 5 years revealed increases in median beta-2 m and neopterin and decreases in CD4% over this period and the odds of death within 5 years were positively associated with baseline levels of beta-2 m and neopterin. ROC analyses strengthened the evidence of elevation of biomarkers in patients approaching death in both HIV-1 and HIV-2 infections. Regression models showed that rates of biomarker fold change accelerated from 6-8 years before death with no significant differences between biomarker levels in HIV-1 and HIV-2 at equal time points prior to death. An 'immune activation index' analysis indicative of biomarker levels at equivalent viral loads also showed no differences between the two infections.
   Conclusions/Significance: Our results suggest that beta-2 m and neopterin are useful tools for disease monitoring in both HIV-1 and HIV-2 infections, whereas sUPAR performed less well. Levels of immune activation per amount of virus were comparable in HIV-1 and HIV-2 infected subjects.
C1 [Nyamweya, Samuel; Townend, John; Zaman, Akram; Jeffries, David; Whittle, Hilton; Flanagan, Katie L.; Jaye, Assan] Med Res Council UK, Banjul, Gambia.
   [Steele, Sarah Jane] Univ Toronto, Toronto, ON, Canada.
   [Rowland-Jones, Sarah] Weatherall Inst Mol Med, Oxford, England.
   [Zaman, Akram] Hlth Protect Agcy, Ctr Infect, London, England.
RP Nyamweya, S (reprint author), Med Res Council UK, Banjul, Gambia.
EM ajaye@mrc.gm
FU UK Medical Research Council
FX This work was supported by The UK Medical Research Council. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Amirayan-Chevillard N, 2000, CLIN DIAGN LAB IMMUN, V7, P832, DOI 10.1128/CDLI.7.5.832-834.2000
   ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Berry N, 1998, J Hum Virol, V1, P457
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Chaudhary Monica, 2008, J Int Assoc Physicians AIDS Care (Chic), V7, P259, DOI 10.1177/1545109708322302
   Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549
   French MA, 2009, J INFECT DIS, V200, P1212, DOI 10.1086/605890
   Giorgi JV, 1999, IMMUNOL LETT, V66, P105, DOI 10.1016/S0165-2478(98)00170-9
   Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346
   Halota Waldemar, 2002, Pol Merkur Lekarski, V13, P126
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Hanson A, 2005, AIDS RES HUM RETROV, V21, P791, DOI 10.1089/aid.2005.21.791
   Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/01.aids.0000076311.76477.6e
   Hightower Maia, 2003, Braz J Infect Dis, V7, P7, DOI 10.1590/S1413-86702003000100002
   Hodges-Mameletzis I, 2011, EXPERT REV ANTI-INFE, V9, P195, DOI [10.1586/eri.10.176, 10.1586/ERI.10.176]
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Jaffar S, 2005, AIDS RES HUM RETROV, V21, P560, DOI 10.1089/aid.2005.21.560
   Kiepiela P, 2005, BEST PRACT RES CL OB, V19, P243, DOI 10.1016/j.bpobgyn.2004.11.002
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Leligdowicz A, 2010, J INFECT DIS, V201, P114, DOI 10.1086/648733
   Manasa J, 2007, CLIN VACCINE IMMUNOL, V14, P293, DOI 10.1128/CVI.00416-06
   Mandy Francis F, 2003, MMWR Recomm Rep, V52, P1
   Michel P, 2000, J INFECT DIS, V181, P64, DOI 10.1086/315170
   Mildvan D, 2005, CLIN INFECT DIS, V40, P853, DOI 10.1086/427877
   Nowroozalizadeh S, 2010, J INFECT DIS, V201, P1150, DOI 10.1086/651430
   Ostrowski SR, 2005, JAIDS-J ACQ IMM DEF, V39, P23, DOI 10.1097/01.qai.0000157950.02076.a6
   Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020
   PIWOWAR EM, 1995, CLIN DIAGN LAB IMMUN, V2, P236
   Plesner T, 1997, STEM CELLS, V15, P398
   Sidenius N, 2000, BLOOD, V96, P4091
   Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8
   Sousa AE, 2002, J IMMUNOL, V169, P3400
   van der Loeff MFS, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-46
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   Yilmaz A, 2008, JAIDS-J ACQ IMM DEF, V47, P168
   Zolopa AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005575
NR 37
TC 6
Z9 8
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 10
PY 2012
VL 7
IS 9
AR e44411
DI 10.1371/journal.pone.0044411
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 005KD
UT WOS:000308748400016
PM 22970212
OA gold
DA 2017-08-15
ER

PT J
AU Kajungu, DK
   Selemani, M
   Masanja, I
   Baraka, A
   Njozi, M
   Khatib, R
   Dodoo, AN
   Binka, F
   Macq, J
   D'Alessandro, U
   Speybroeck, N
AF Kajungu, Dan K.
   Selemani, Majige
   Masanja, Irene
   Baraka, Amuri
   Njozi, Mustafa
   Khatib, Rashid
   Dodoo, Alexander N.
   Binka, Fred
   Macq, Jean
   D'Alessandro, Umberto
   Speybroeck, Niko
TI Using classification tree modelling to investigate drug prescription
   practices at health facilities in rural Tanzania
SO MALARIA JOURNAL
LA English
DT Article
DE Polypharmacy; Co-prescription; Anti-malarials; Classification trees;
   Data mining; Tanzania
ID INAPPROPRIATE MEDICATION USE; UNCOMPLICATED MALARIA; RISK-FACTORS;
   MANAGEMENT; KENYA
AB Background: Drug prescription practices depend on several factors related to the patient, health worker and health facilities. A better understanding of the factors influencing prescription patterns is essential to develop strategies to mitigate the negative consequences associated with poor practices in both the public and private sectors.
   Methods: A cross-sectional study was conducted in rural Tanzania among patients attending health facilities, and health workers. Patients, health workers and health facilities-related factors with the potential to influence drug prescription patterns were used to build a model of key predictors. Standard data mining methodology of classification tree analysis was used to define the importance of the different factors on prescription patterns.
   Results: This analysis included 1,470 patients and 71 health workers practicing in 30 health facilities. Patients were mostly treated in dispensaries. Twenty two variables were used to construct two classification tree models: one for polypharmacy (prescription of >= 3 drugs) on a single clinic visit and one for co-prescription of artemether-lumefantrine (AL) with antibiotics. The most important predictor of polypharmacy was the diagnosis of several illnesses. Polypharmacy was also associated with little or no supervision of the health workers, administration of AL and private facilities. Co-prescription of AL with antibiotics was more frequent in children under five years of age and the other important predictors were transmission season, mode of diagnosis and the location of the health facility.
   Conclusion: Standard data mining methodology is an easy-to-implement analytical approach that can be useful for decision-making. Polypharmacy is mainly due to the diagnosis of multiple illnesses.
C1 [Kajungu, Dan K.; Dodoo, Alexander N.; Binka, Fred] INDEPTH Network, Accra, Ghana.
   [Kajungu, Dan K.; Macq, Jean; Speybroeck, Niko] Catholic Univ Louvain, Louvain, Belgium.
   [Selemani, Majige; Masanja, Irene; Baraka, Amuri; Njozi, Mustafa; Khatib, Rashid] Ifakara Hlth Inst, Dar Es Salaam, Tanzania.
   [Dodoo, Alexander N.] Univ Ghana, Ctr Trop Clin Pharmacol & Therapeut, Sch Med, Accra, Ghana.
   [D'Alessandro, Umberto] MRC Unit, Serrekunda, Gambia.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
RP Kajungu, DK (reprint author), INDEPTH Network, POB KD 213 Kanda, Accra, Ghana.
EM kajungu_dan@yahoo.co.uk
RI D'Alessandro, Umberto/D-3457-2015; AMURI, Mbaraka/C-5386-2011
OI D'Alessandro, Umberto/0000-0001-6341-5009; AMURI,
   Mbaraka/0000-0002-8583-9555
FU Bill and Melinda Gates Foundation
FX The authors wish to thank the many investigators, data collectors and
   field supervisors who contributed to the collection and analyses of
   these data. In addition, we wish to acknowledge the community members
   who participated in or otherwise contributed to these studies. This work
   was conducted as part of the INESS platform, a multicountry consortium
   funded by the Bill and Melinda Gates Foundation.
CR Breiman L., 1984, CLASSIFICATION REGRE
   Brugha R, 1999, TROP MED INT HEALTH, V4, P402, DOI 10.1046/j.1365-3156.1999.00411.x
   Chrischilles EA, 2009, J AM GERIATR SOC, V57, P1000, DOI 10.1111/j.1532-5415.2009.02269.x
   Dodoo ANO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-2
   Frischer M, 2001, J PUBLIC HEALTH MED, V23, P69, DOI 10.1093/pubmed/23.1.69
   Fu AZ, 2004, J AM GERIATR SOC, V52, P1934, DOI 10.1111/j.1532-5415.2004.52522.x
   HDSS Ifakara, TANZ
   Laroche ML, 2007, BRIT J CLIN PHARMACO, V63, P177, DOI 10.1111/j.1365-2125.2006.02831.x
   Lauritsen J, 2003, EPIDATA VERSION 3 CO
   McCarthy FD, 2000, GROWTH COSTS MALARIA
   McManus P, 1997, MED J AUSTRALIA, V167, P124
   Ministry of Health and Social Welfare URoT, 2006, NAT GUID DIAGN TREAT
   Mino-Leon D, 2011, REV INVEST CLIN, V63, P170
   Protopopoff N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008022
   Rennie W, 2009, WILLINGNESS USE PAY
   Rufiji DSS, TANZANIA ESSENTIAL C
   Saegerman C, 2004, J CLIN MICROBIOL, V42, P172, DOI 10.1128/JCM.42.1.172-178.2004
   Skarbinski J, 2009, AM J TROP MED HYG, V80, P919
   Speybroeck N, 2004, AGR SYST, V80, P133, DOI 10.1016/j.agsy.2003.06.006
   Speybroeck N, 2012, INT J PUBLIC HEALTH, V57, P243, DOI 10.1007/s00038-011-0315-z
   SPSS Inc, 2007, SPSS WIND VERS 16
   StataCorp LP, 2012, STATA VERS 11 2012
   Thang ND, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-28
   Trostle J, 1996, SOC SCI MED, V42, P1117, DOI 10.1016/0277-9536(95)00384-3
   vanEngelsdorp D, 2010, J ECON ENTOMOL, V103, P1517, DOI 10.1603/EC09429
   World Health Organization, 1987, RAT US DRUGS, P25
   World Health Organization, 2006, WHOHTMMAL2006
   World Health Organization, 2003, INTR DRUG UT RES
   World Health Organization, 2009, MED US PRIM CAR DEV
   WHO/UNICEF, 1999, WHOCHSCAH98
   Zhang H, 1999, REC PART HLTH SCI
   Zurovac D, 2004, INT J EPIDEMIOL, V33, P1080, DOI 10.1093/ije/dyh253
   [Anonymous], 2012, AFFORDABLE MED FACIL
NR 33
TC 6
Z9 6
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD SEP 5
PY 2012
VL 11
AR 311
DI 10.1186/1475-2875-11-311
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 043WC
UT WOS:000311580300001
PM 22950486
OA gold
DA 2017-08-15
ER

PT J
AU Reiches, MW
   Prentice, AM
   Moore, SE
   Prentice, A
   Sawo, Y
   Ellison, PT
AF Reiches, Meredith W.
   Prentice, Andrew M.
   Moore, Sophie E.
   Prentice, Ann
   Sawo, Yankuba
   Ellison, Peter T.
TI Maternal post-partum weight predicts adolescent daughters' size, body
   composition, and ratio of leptin to fat mass to a greater extent than
   does prenatal supplement status in a West African subsistence
   agriculturalist population
SO ANNALS OF HUMAN BIOLOGY
LA English
DT Meeting Abstract
C1 [Reiches, Meredith W.; Ellison, Peter T.] Harvard Univ, Dept Human Evolutionary Biol, Cambridge, MA 02138 USA.
   [Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
   [Prentice, Andrew M.; Moore, Sophie E.; Prentice, Ann; Sawo, Yankuba] MRC Keneba, MRC Labs, Fajara, Gambia.
   [Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0301-4460
J9 ANN HUM BIOL
JI Ann. Hum. Biol.
PD SEP-OCT
PY 2012
VL 39
IS 5
BP 451
EP 451
PG 1
WC Anthropology; Biology; Public, Environmental & Occupational Health
SC Anthropology; Life Sciences & Biomedicine - Other Topics; Public,
   Environmental & Occupational Health
GA 022CS
UT WOS:000309933300022
OA No
DA 2017-08-15
ER

PT J
AU Tokarz, R
   Firth, C
   Madhi, SA
   Howie, SRC
   Wu, W
   Sall, AA
   Haq, S
   Briese, T
   Lipkin, WI
AF Tokarz, Rafal
   Firth, Cadhla
   Madhi, Shabir A.
   Howie, Stephen R. C.
   Wu, Winfred
   Sall, Amadou Alpha
   Haq, Saddef
   Briese, Thomas
   Lipkin, W. Ian
TI Worldwide emergence of multiple clades of enterovirus 68
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID RESPIRATORY-TRACT INFECTIONS; INFLUENZA-LIKE ILLNESS; CHILDREN;
   PATHOGENS; JAPAN; VP1; PCR
AB Human enterovirus 68 (EV-D68) is a historically rarely reported virus linked with respiratory disease. In the past 3 years, a large increase in respiratory disease associated with EV-D68 has been reported, with documented outbreaks in North America, Europe and Asia. In several outbreaks, genetic differences were identified among the circulating strains, indicating the presence of multiple clades. In this report, we analyse archived and novel EV-D68 strains from Africa and the USA, obtained from patients with respiratory illness. Phylogenetic analysis of all EV-D68 sequences indicates that, over the past two decades, multiple clades of the virus have emerged and spread rapidly worldwide. All clades appear to be currently circulating and contributing to respiratory disease.
C1 [Tokarz, Rafal; Firth, Cadhla; Sall, Amadou Alpha; Haq, Saddef; Briese, Thomas; Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA.
   [Madhi, Shabir A.] Natl Inst Communicable Dis, Div Natl Hlth Lab Serv, ZA-2131 Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg 2050, South Africa.
   [Howie, Stephen R. C.] Child Survival Theme, Med Res Council Unit, Banjul, Gambia.
   [Wu, Winfred] New York City Dept Hlth & Mental Hyg, Gotham Ctr, New York, NY 11101 USA.
RP Tokarz, R (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, 722 W 168th St,Room 1701, New York, NY 10032 USA.
EM rt2249@columbia.edu
FU National Institutes of Health [Al57158]; US Department of Defense
   [W911SR-11-C-0077]
FX We thank Niranjan Bhat and Eric Jaffe for their assistance. This work
   was supported by National Institutes of Health grant Al57158 (Northeast
   Biodefense Center-Lipkin), and US Department of Defense grant
   W911SR-11-C-0077.
CR Briese T, 2005, EMERG INFECT DIS, V11, P310
   Coiras MT, 2004, J MED VIROL, V72, P484, DOI 10.1002/jmv.20008
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Gromeier M, 1996, P NATL ACAD SCI USA, V93, P2370, DOI 10.1073/pnas.93.6.2370
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hasegawa S, 2011, ALLERGY, V66, P1618, DOI 10.1111/j.1398-9995.2011.02725.x
   Ikeda T, 2012, MICROBIOL IMMUNOL, V56, P139, DOI 10.1111/j.1348-0421.2012.00411.x
   Imamura Tadatsugu, 2011, Morbidity and Mortality Weekly Report, V60, P1301
   Imamura T, 2011, EMERG INFECT DIS, V17, P1430, DOI 10.3201/eid1708.101328
   Jacobson LM, 2012, PEDIATR INFECT DIS J, V31, P309, DOI 10.1097/INF.0b013e3182443eaf
   Kaida A, 2011, EMERG INFECT DIS, V17, P1494, DOI 10.3201/eid1708.110028
   Khetsuriani Nino, 2006, MMWR Surveill Summ, V55, P1
   Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551
   Li RQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026237
   Meijer A, 2012, VIROLOGY, V423, P49, DOI 10.1016/j.virol.2011.11.021
   Oberste MS, 2004, J GEN VIROL, V85, P2577, DOI 10.1099/vir.0.79925-0
   Oberste MS, 1999, J CLIN MICROBIOL, V37, P1288
   Oberste MS, 1999, J VIROL, V73, P1941
   Petitjean-Lecherbonnier J, 2011, PATHOL BIOL, V59, P113, DOI 10.1016/j.patbio.2010.07.010
   Piralla A, 2011, J CLIN MICROBIOL, V49, P373, DOI 10.1128/JCM.01814-10
   Rahamat-Langendoen J, 2011, J CLIN VIROL, V52, P103, DOI 10.1016/j.jcv.2011.06.019
   SCHIEBLE JH, 1967, AM J EPIDEMIOL, V85, P297
   Tokarz R, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-288
   Wang Z, 2010, MICROB ECOL, V59, P623, DOI 10.1007/s00248-010-9636-3
NR 24
TC 94
Z9 98
U1 2
U2 25
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD SEP
PY 2012
VL 93
BP 1952
EP 1958
DI 10.1099/vir.0.043935-0
PN 9
PG 7
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 009OM
UT WOS:000309035100013
PM 22694903
OA No
DA 2017-08-15
ER

PT J
AU Hegedus, A
   Nyamweya, S
   Govind, S
   Aspinall, R
   Jaye, A
   Mashanova, A
   Jansen, V
   Macallan, DC
   Flanagan, KL
AF Hegedus, A.
   Nyamweya, S.
   Govind, S.
   Aspinall, R.
   Jaye, A.
   Mashanova, A.
   Jansen, V.
   Macallan, D. C.
   Flanagan, K. L.
TI Predictors of T lymphocyte turnover in HIV-2 infection
SO IMMUNOLOGY
LA English
DT Meeting Abstract
CT European Congress of Immunology
CY SEP 05-08, 2012
CL Glasgow, SCOTLAND
C1 [Hegedus, A.; Macallan, D. C.] St Georges Univ London, London, England.
   [Nyamweya, S.; Jaye, A.; Flanagan, K. L.] Viral Dis Programme, MRC Unit Gambia, Fajara, Gambia.
   [Govind, S.; Aspinall, R.] Cranfield Univ, Cranfield MK43 0AL, Beds, England.
   [Mashanova, A.; Jansen, V.] Royal Holloway Univ London, Egham, Surrey, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD SEP
PY 2012
VL 137
SU 1
SI SI
BP 113
EP 113
PG 1
WC Immunology
SC Immunology
GA 011TW
UT WOS:000309189100266
OA No
DA 2017-08-15
ER

PT J
AU Deitz, KC
   Athrey, G
   Reddy, MR
   Overgaard, HJ
   Matias, A
   Jawara, M
   Della Torre, A
   Petrarca, V
   Pinto, J
   Kiszewski, EA
   Kengne, P
   Costantini, C
   Caccone, A
   Slotman, MA
AF Deitz, Kevin C.
   Athrey, Giri
   Reddy, Michael R.
   Overgaard, Hans J.
   Matias, Abrahan
   Jawara, Musa
   Della Torre, Alessandra
   Petrarca, Vincenzo
   Pinto, Joao
   Kiszewski, Anthony E.
   Kengne, Pierre
   Costantini, Carlo
   Caccone, Adalgisa
   Slotman, Michel A.
TI Genetic isolation within the malaria mosquito Anopheles melas
SO MOLECULAR ECOLOGY
LA English
DT Article
DE Anopheles gambiae; Anopheles melas; malaria; microsatellites; migration;
   population structure
ID APPROXIMATE BAYESIAN COMPUTATION; GAMBIAE COMPLEX; POPULATION-STRUCTURE;
   EQUATORIAL-GUINEA; WEST-AFRICA; MAXIMUM-LIKELIHOOD; MOLECULAR-FORMS;
   INCIPIENT SPECIATION; MICROSATELLITE DATA; VECTOR CONTROL
AB Anopheles melas is a brackish waterbreeding member of the Anopheles gambiae complex that is distributed along the coast of West Africa and is a major malaria vector within its range. Because little is known about the population structure of this species, we analysed 15 microsatellite markers and 1161 bp of mtDNA in 11 A. melas populations collected throughout its range. Compared with its sibling species A. gambiae, A. melas populations have a high level of genetic differentiation between them, representing its patchy distribution due to its fragmented larval habitat that is associated with mangroves and salt marsh grass. Populations clustered into three distinct groups representing Western Africa, Southern Africa and Bioko Island populations that appear to be mostly isolated. Fixed differences in the mtDNA are present between all three clusters, and a Bayesian clustering analysis of the microsatellite data found no evidence for migration from mainland to Bioko Island populations, and little migration was evident between the Southern to the Western cluster. Surprisingly, mtDNA divergence between the three A. melas clusters is on par with levels of divergence between other species of the A. gambiae complex, and no support for monophyly was observed in a maximum-likelihood phylogenetic analysis. Finally, an approximate Bayesian analysis of microsatellite data indicates that Bioko Island A. melas populations were connected to the mainland populations in the past, but became isolated, presumably when sea levels rose after the last glaciation period (=10 00011 000 bp). This study has exposed species-level genetic divergence within A. melas and also has implications for control of this malaria vector.
C1 [Deitz, Kevin C.; Athrey, Giri; Slotman, Michel A.] Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA.
   [Reddy, Michael R.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA.
   [Overgaard, Hans J.] Norwegian Univ Life Sci, Dept Mat Sci & Technol, As, Norway.
   [Matias, Abrahan] Med Care Dev Int, Silver Spring, MD USA.
   [Jawara, Musa] MRC Labs, Fajara, Gambia.
   [Della Torre, Alessandra; Petrarca, Vincenzo] Univ Roma La Sapienza, Dipartimento Sanita Pubbl & Malattie Infett, Ist Pasteur Fdn Cenci Bolognetti, Rome, Italy.
   [Pinto, Joao] Univ Nova Lisboa, Inst Higene & Med, Ctr Malaria & Outras Doencas Tropicais, UEI Parasitol Med, P-1200 Lisbon, Portugal.
   [Kiszewski, Anthony E.] Bentley Univ, Dept Nat & Appl Sci, Waltham, MA USA.
   [Kengne, Pierre; Costantini, Carlo] UMR MIVEGEC, Inst Rech Dev, UM1, UM2,CNRS 5290,IRD 224, Montpellier, France.
   [Kengne, Pierre; Costantini, Carlo] OCEAC, Lab Rech Paludisme, Yaounde, Cameroon.
   [Caccone, Adalgisa] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT USA.
RP Slotman, MA (reprint author), Texas A&M Univ, Dept Entomol, 2475 TAMU, College Stn, TX 77843 USA.
EM maslotman@tamu.edu
RI Athrey, Giridhar/H-4077-2011; Pinto, Joao/C-2208-2012
OI Athrey, Giridhar/0000-0002-5295-9884; Pinto, Joao/0000-0001-8572-7708;
   Costantini, Carlo/0000-0003-1016-129X
FU Bioko Island Malaria Control Project; Marathon Oil Corporation (Houston,
   TX); Government of Equatorial Guinea
FX This work was supported by an operational research grant to MAS by the
   Bioko Island Malaria Control Project. The BIMCP is funded by a
   consortium led by Marathon Oil Corporation (Houston, TX) and the
   Government of Equatorial Guinea. Our thanks go to Dr. Chris Schwabe, Dr.
   Luis Segura and Ed Aldrich from Medical Care Development International,
   Dr. Gloria Nseng and Simon Abaga from the National Malaria Control
   Program and Jaime Kuklinski from One World Development Group for
   operations support in Equatorial Guinea. Vamsi Reddy and Vani Kulkarni
   provided technical support at Texas A&M University. We are thankful to
   Dr. Gregory Lanzaro for providing A. melas samples from Guinea Bissau
   and to Mr. Gian Carlo Carrara and representatives of the Angolan
   Ministry of Health for helping in the Angolan collections. Finally, we
   are also thankful to Dr Spencer Johnston, Dr. Raul Medina, Dr. Kostya V
   Krutovsky and Dr. Chris Schwabe for providing advise and/or comments on
   the manuscript.
CR Akogbeto M, 1999, B SOC PATHOL EXOT, V92, P3
   Akogbeto Martin, 1995, Journal of African Zoology, V109, P443
   BAFORT JM, 1983, ANN SOC BELG MED TR, V63, P167
   Beard C.B., 1993, Insect Molecular Biology, V2, P103, DOI 10.1111/j.1365-2583.1993.tb00131.x
   Beaumont MA, 2002, GENETICS, V162, P2025
   BESANSKY NJ, 1994, P NATL ACAD SCI USA, V91, P6885, DOI 10.1073/pnas.91.15.6885
   Besansky NJ, 1997, GENETICS, V147, P1817
   Bogh C, 2007, AM J TROP MED HYG, V76, P875
   Bryan J.H., 1987, Parassitologia (Rome), V29, P221
   BRYAN JH, 1983, ANN TROP MED PARASIT, V77, P1
   Burke K, 2001, J GEOL, V109, P349, DOI 10.1086/319977
   Calzetta M, 2008, AM J TROP MED HYG, V78, P169
   Caputo B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-182
   COLUZZI M, 1985, B ZOOL, V52, P45
   Coluzzi M, 2002, SCIENCE, V298, P1415, DOI 10.1126/science.1077769
   COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1
   Cornuet JM, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-401
   Cornuet JM, 2008, BIOINFORMATICS, V24, P2713, DOI 10.1093/bioinformatics/btn514
   DAVIDSON G, 1962, NATURE, V196, P907, DOI 10.1038/196907a0
   De Queiroz K, 2007, SYST BIOL, V56, P879, DOI 10.1080/10635150701701083
   Deitz KC, 2012, J HERED, V103, P585, DOI 10.1093/jhered/ess025
   della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x
   della Torre A, 2005, INSECT BIOCHEM MOLEC, V35, P755, DOI 10.1016/j.ibmb.2005.02.006
   Donnelly MJ, 2000, INSECT MOL BIOL, V9, P357, DOI 10.1046/j.1365-2583.2000.00197.x
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Earl DA., 2011, STRUCTURE HARVESTER
   Eisentraut M, 1965, ZOOL ANZ, V174, P37
   Evanno G, 2005, MOL ECOL, V14, P2611, DOI 10.1111/j.1365-294X.2005.02553.x
   EXCOFFIER L, 1992, GENETICS, V131, P479
   Excoffier L, 2010, MOL ECOL RESOUR, V10, P564, DOI 10.1111/j.1755-0998.2010.02847.x
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Favia G, 1997, INSECT MOL BIOL, V6, P377, DOI 10.1046/j.1365-2583.1997.00189.x
   GARRETTJONES C, 1980, B ENTOMOL RES, V70, P165
   Gaunt MW, 2002, MOL BIOL EVOL, V19, P748
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Howe K, 2002, BIOINFORMATICS, V18, P1546, DOI 10.1093/bioinformatics/18.11.1546
   Hunt RH, 1998, T ROY SOC TROP MED H, V92, P231, DOI 10.1016/S0035-9203(98)90761-1
   JONES PJ, 1994, BIODIVERS CONSERV, V3, P772, DOI 10.1007/BF00129657
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kleinschmidt I, 2009, AM J TROP MED HYG, V80, P882
   Kruskal J.B., 1956, P AM MATH SOC, V7, P48, DOI [DOI 10.1090/S0002-9939-1956-0078686-7, 10.1090/S0002-9939-1956-0078686-7]
   Lanfear R, 2010, TRENDS ECOL EVOL, V25, P495, DOI 10.1016/j.tree.2010.06.007
   Lehmann T, 2003, J HERED, V94, P133, DOI 10.1093/jhered/esg024
   Librado P, 2009, BIOINFORMATICS, V25, P1451, DOI 10.1093/bioinformatics/btp187
   Lis J T, 1980, Methods Enzymol, V65, P347
   Meirmans PG, 2011, MOL ECOL RESOUR, V11, P5, DOI 10.1111/j.1755-0998.2010.02927.x
   Meirmans PG, 2004, MOL ECOL NOTES, V4, P792, DOI 10.1111/j.1471-8286.2004.00770.x
   Moreau R. E., 1966, BIRD FAUNAS AFRICA I
   Moreno M, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-137
   Nei M, 2000, MOL EVOLUTION PHYLOG
   Overgaard HJ, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-56
   PETRARCA V, 1987, MED VET ENTOMOL, V1, P303, DOI 10.1111/j.1365-2915.1987.tb00359.x
   PETRARCA V, 1983, Parassitologia (Rome), V25, P29
   Posada D, 2004, SYST BIOL, V53, P793, DOI 10.1080/10635150490522304
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   PRIM RC, 1957, AT&T TECH J, V36, P1389
   Pritchard J, 2003, DOCUMENTATION FOR ST
   Pritchard JK, 2000, GENETICS, V155, P945
   Rambaut A, 2007, TREEANNOTATOR VER 1
   Rambaut A, 2009, FIGTREE TREE FIGURE
   Rambaut A, 2007, LOGCOMBINER VER 1 4
   Rambaut A, 2007, TRACER VER 1 4
   Reddy MR, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-184
   Sharp BL, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-52
   Silvestro D, 2012, ORG DIVERS EVOL, V12, P335, DOI 10.1007/s13127-011-0056-0
   Sinka ME, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-117
   Slotman MA, 2007, MOL ECOL, V16, P639, DOI 10.1111/j.1365-294X.2006.03172.x
   Slotman MA, 2006, GENETICS, V174, P2081, DOI 10.1534/genetics.106.059949
   Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446
   Stump AD, 2005, P NATL ACAD SCI USA, V102, P15930, DOI 10.1073/pnas.0508161102
   Szpiech ZA, 2008, BIOINFORMATICS, V24, P2498, DOI 10.1093/bioinformatics/btn478
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Teacher AGF, 2011, MOL ECOL RESOUR, V11, P151, DOI 10.1111/j.1755-0998.2010.02890.x
   Toure YT, 1983, PARASSITOLOGIA, V25, P367
   Tuno N, 2010, J MED ENTOMOL, V47, P28, DOI 10.1603/033.047.0104
   Turner TL, 2005, PLOS BIOL, V3, P1572, DOI 10.1371/journal.pbio.0030285
   Van Oosterhout C, 2004, MOL ECOL NOTES, V4, P535, DOI 10.1111/j.1471-8286.2004.00684.x
   Walker K, 2007, MED VET ENTOMOL, V21, P2, DOI 10.1111/j.1365-2915.2007.00674.x
   Warnock RCM, 2012, BIOL LETTERS, V8, P156, DOI 10.1098/rsbl.2011.0710
   White BJ, 2010, MOL ECOL, V19, P925, DOI 10.1111/j.1365-294X.2010.04531.x
   WHITE GB, 1974, T ROY SOC TROP MED H, V68, P278, DOI 10.1016/0035-9203(74)90035-2
   WHITE GB, 1980, T ROY SOC TROP MED H, V74, P683
NR 82
TC 9
Z9 9
U1 1
U2 37
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1083
EI 1365-294X
J9 MOL ECOL
JI Mol. Ecol.
PD SEP
PY 2012
VL 21
IS 18
BP 4498
EP 4513
DI 10.1111/j.1365-294X.2012.05724.x
PG 16
WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology;
   Evolutionary Biology
GA 003TN
UT WOS:000308634300009
PM 22882458
OA No
DA 2017-08-15
ER

PT J
AU Thursz, M
   Njie, R
   Lemoine, M
AF Thursz, Mark
   Njie, Ramatoulie
   Lemoine, Maud
TI HEPATITIS Global eradication of hepatitis B - feasible or fallacy?
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Editorial Material
ID IMMUNIZATION; ENDEMICITY; MODEL; HBV
C1 [Thursz, Mark] Univ London Imperial Coll Sci Technol & Med, London W2 1NY, England.
   [Njie, Ramatoulie; Lemoine, Maud] MRC Labs, Fajara, Gambia.
RP Thursz, M (reprint author), Univ London Imperial Coll Sci Technol & Med, Norfolk Pl, London W2 1NY, England.
EM m.thursz@imperial.ac.uk
FU Medical Research Council [MC_UP_A900_1120]
CR Aggarwal R, 2003, J HEPATOL, V38, P215, DOI 10.1016/S0168-8278(02)00382-3
   Chen HL, 2012, GASTROENTEROLOGY, V142, P773, DOI 10.1053/j.gastro.2011.12.035
   Edmunds WJ, 1996, EPIDEMIOL INFECT, V117, P313
   Goldstein ST, 2005, INT J EPIDEMIOL, V34, P1329, DOI 10.1093/ije/dyi206
   NI, J HEPATOLOGY
   Ni Y. H., J HEPATOL
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Thursz M, 2010, TROP MED INT HEALTH, V15, P2, DOI 10.1111/j.1365-3156.2009.02410.x
   van der Sande MAB, 2007, PLOS ONE, V2, pe753
   WHO, 2010, SMALLP ER PROGR
NR 10
TC 13
Z9 13
U1 0
U2 18
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD SEP
PY 2012
VL 9
IS 9
BP 492
EP 494
DI 10.1038/nrgastro.2012.155
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 002BB
UT WOS:000308503900002
PM 22868658
OA No
DA 2017-08-15
ER

PT J
AU Lin, GM
   Li, YH
   Jaiteh, LES
   Han, CL
AF Lin, Gen-Min
   Li, Yi-Hwei
   Jaiteh, Lamin E. S.
   Han, Chih-Lu
TI Role of Yin and Yang in Diurnal Blood Pressure Variation for
   Cardiovascular Disease
SO HYPERTENSION
LA English
DT Letter
ID MORNING SURGE; RISK
C1 [Lin, Gen-Min] Hualien Armed Forces Gen Hosp, Dept Med, Hualien, Taiwan.
   [Li, Yi-Hwei] Tzu Chi Univ, Dept Publ Hlth, Hualien, Taiwan.
   [Jaiteh, Lamin E. S.] Royal Victoria Teaching Hosp, Dept Med, Banjul, Gambia.
   [Han, Chih-Lu] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.
RP Lin, GM (reprint author), Hualien Armed Forces Gen Hosp, Dept Med, Hualien, Taiwan.
CR Grossman E, 2012, HYPERTENSION, V60, pE1, DOI 10.1161/HYPERTENSIONAHA.112.197152
   Hermida RC, 2011, J AM COLL CARDIOL, V58, P1165, DOI 10.1016/j.jacc.2011.04.043
   Kario K, 2003, CIRCULATION, V107, P1401, DOI 10.1161/01.CIR.0000056521.67546.AA
   Laukkanen JA, 2004, HYPERTENSION, V44, P820, DOI 10.1161/01.HYP.0000148460.95060.f2
   Verdecchia P, 2012, HYPERTENSION, V60, P34, DOI 10.1161/HYPERTENSIONAHA.112.191858
NR 5
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD SEP
PY 2012
VL 60
IS 3
BP E27
EP E27
DI 10.1161/HYPERTENSIONAHA.112.201079
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 994SM
UT WOS:000307951900009
PM 22824985
OA No
DA 2017-08-15
ER

PT J
AU Kyabayinze, DJ
   Achan, J
   Nakanjako, D
   Mpeka, B
   Mawejje, H
   Mugizi, R
   Kalyango, JN
   D'Alessandro, U
   Talisuna, A
   Van Geertruyden, JP
AF Kyabayinze, Daniel J.
   Achan, Jane
   Nakanjako, Damalie
   Mpeka, Betty
   Mawejje, Henry
   Mugizi, Rukaaka
   Kalyango, Joan N.
   D'Alessandro, Umberto
   Talisuna, Ambrose
   Van Geertruyden, Jean-Pierre
TI Parasite-based malaria diagnosis: Are Health Systems in Uganda equipped
   enough to implement the policy?
SO BMC PUBLIC HEALTH
LA English
DT Article
ID CASE-MANAGEMENT; TESTS; WORKERS; MICROSCOPY; TANZANIA; FACILITIES;
   COMMUNITY; COUNTRIES; CHILDREN; THERAPY
AB Background: Malaria case management is a key strategy for malaria control. Effective coverage of parasite-based malaria diagnosis (PMD) remains limited in malaria endemic countries. This study assessed the health system's capacity to absorb PMD at primary health care facilities in Uganda.
   Methods: In a cross sectional survey, using multi-stage cluster sampling, lower level health facilities (LLHF) in 11 districts in Uganda were assessed for 1) tools, 2) skills, 3) staff and infrastructure, and 4) structures, systems and roles necessary for the implementing of PMD.
   Results: Tools for PMD (microscopy and/or RDTs) were available at 30 (24%) of the 125 LLHF. All LLHF had patient registers and 15% had functional in-patient facilities. Three months' long stock-out periods were reported for oral and parenteral quinine at 39% and 47% of LLHF respectively. Out of 131 health workers interviewed, 86 (66%) were nursing assistants; 56 (43%) had received on-job training on malaria case management and 47 (36%) had adequate knowledge in malaria case management. Overall, only 18% (131/730) Ministry of Health approved staff positions were filled by qualified personnel and 12% were recruited or transferred within six months preceding the survey. Of 186 patients that received referrals from LLHF, 130(70%) had received pre-referral anti-malarial drugs, none received pre-referral rectal artesunate and 35% had been referred due to poor response to antimalarial drugs.
   Conclusion: Primary health care facilities had inadequate human and infrastructural capacity to effectively implement universal parasite-based malaria diagnosis. The priority capacity building needs identified were: 1) recruitment and retention of qualified staff, 2) comprehensive training of health workers in fever management, 3) malaria diagnosis quality control systems and 4) strengthening of supply chain, stock management and referral systems.
C1 [Kyabayinze, Daniel J.; Mpeka, Betty; Mawejje, Henry; Mugizi, Rukaaka] Malaria Consortium, Kampala, Uganda.
   [Kyabayinze, Daniel J.] Fdn Innovat New Diagnost, Kampala, Uganda.
   [Achan, Jane; Nakanjako, Damalie; Kalyango, Joan N.] Makerere Univ, Coll Hlth Sci, Kampala, Uganda.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Banjul, Gambia.
   [Talisuna, Ambrose] Makerere Univ, Sch Publ Hlth, Kampala, Uganda.
   [Talisuna, Ambrose] Univ Oxford, KEMRI, Wellcome Trust Res Programme, Oxford OX1 2JD, England.
   [Van Geertruyden, Jean-Pierre] Univ Antwerp, Fac Med, ESOC Dept, Unit Int Hlth, BE-2610 Antwerp, Belgium.
RP Kyabayinze, DJ (reprint author), Malaria Consortium, Upper Naguru E Rd,POB 8045, Kampala, Uganda.
EM drdjkyabayinze@yahoo.com
RI Van geertruyden, Jean-pierre/K-6425-2014; D'Alessandro,
   Umberto/D-3457-2015
OI Van geertruyden, Jean-pierre/0000-0001-5006-6364; D'Alessandro,
   Umberto/0000-0001-6341-5009
FU Malaria Consortium Regional program on Health Systems Strengthening;
   Other Communicable Disease Control
FX We would like to thank all the health workers, district health
   officials, patients and caregivers at the various health units visited
   for their cooperation and support. Our utmost appreciation goes to the
   survey team members for the tremendous amount of work done. We
   acknowledge financial support by the Irish Aid to conduct this study
   through Malaria Consortium Regional program on Health Systems
   Strengthening for Equitable Access to Malaria and Other Communicable
   Disease Control. The funding body had no role in study design, data
   collection, data analysis, data interpretation and decision to publish
   or preparation of the manuscript. The corresponding author had full
   access to study data and had final responsibility for submission for
   publication.
CR Abba K, 2011, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD008122PUB
   Achan J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017053
   Asiimwe C, 2011, AM J TROP MED HYG, V85, P26, DOI 10.4269/ajtmh.2011.10-0528
   Bell D, 2001, B WORLD HEALTH ORGAN, V79, P933
   BELL D, 2006, NAT REV MICROBIOL, V4, pS34, DOI DOI 10.1038/NRMICO1524
   Bell D, 2008, T ROY SOC TROP MED H, V102, P1064, DOI 10.1016/j.trstmh.2008.05.007
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Chandler CIR, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-95
   D'Acremont V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-240
   D'Acremont V, 2009, PLOS MED, V6, P4, DOI 10.1371/journal.pmed.0050252
   English M, 2009, PLOS MED, V6, P7, DOI 10.1371/journal.pmed.1000015
   Filmer D, 2000, WORLD BANK RES OBSER, V15, P199
   Fulton BD, 2011, HUM RESOUR HEALTH, V9, DOI 10.1186/1478-4491-9-1
   Hamer DH, 2007, JAMA-J AM MED ASSOC, V297, P2227, DOI 10.1001/jama.297.20.2227
   Hopkins H, 2008, J INFECT DIS, V197, P510, DOI 10.1086/526502
   Hopkins H, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2606
   Kyabayinze DJ, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-200
   Lehmann U, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-49
   Lubell Y, 2007, AM J TROP MED HYG, V77, P128
   Masanja MI, 2010, AM J TROP MED HYG, V83, P1238, DOI 10.4269/ajtmh.2010.10-0194
   Mukanga D, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-203
   Nankabirwa J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-66
   Pang T, 2007, T ROY SOC TROP MED H, V101, P856, DOI 10.1016/j.trstmh.2007.04.014
   Potter C, 2004, HEALTH POLICY PLANN, V19, P336, DOI 10.1093/heapol/czh038
   Reyburn H, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-4
   Reyburn H, 2007, BRIT MED J, V334, P403, DOI 10.1136/bmj.39073.496829.AE
   Ssekabira U, 2008, AM J TROP MED HYG, V79, P826
   [UNICEF UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases Centers for Disease Control (US)], 2009, MAL RAP DIAGN TEST P
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   World Health Organization, 2009, WORLD MAL REP 2009
   World Health Organization, 2010, GUID TREATM MAL
   World Health Organization (WHO), 2007, EV BUS STRENGTH HLTH
   Zurovac D, 2006, TROP MED INT HEALTH, V11, P432, DOI 10.1111/j.1365-3156.2006.01587.x
NR 33
TC 6
Z9 7
U1 1
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD AUG 24
PY 2012
VL 12
AR 695
DI 10.1186/1471-2458-12-695
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 037HT
UT WOS:000311093800001
PM 22920954
OA gold
DA 2017-08-15
ER

PT J
AU Odutola, AA
   Owolabi, OA
   Owiafe, PK
   McShane, H
   Ota, MOC
AF Odutola, A. A.
   Owolabi, O. A.
   Owiafe, P. K.
   McShane, H.
   Ota, M. O. C.
TI A new TB vaccine, MVA85A, induces durable antigen-specific responses 14
   months after vaccination in African infants
SO VACCINE
LA English
DT Article
DE MVA85A; TB vaccine, Durability of immunity; Tuberculin skin test; PPD-T;
   ESAT6/CFP10
ID TUBERCULOSIS VACCINE; MYCOBACTERIUM-TUBERCULOSIS; PROTECTIVE EFFICACY;
   VIRUS ANKARA; SOUTH-AFRICA; WEST-AFRICA; BCG; IMMUNOGENICITY; SAFETY;
   CHILDREN
AB This study aimed to evaluate the durability of the immunogenicity of MVA85A beyond infancy. Participants in an immunogenicity study of MVA85A administered at age of 4 months had additional evaluation 14 months after initial vaccination for IFN-gamma ELISPOT responses to Ag85A peptide and ESAT6/CFP-10 and tuberculin skin test (TST).
   112 children participated in this study. The anthropometry, biochemical and haematological safety profile were similar between the MVA85A recipients and controls. MVA85A recipients still had significantly higher immune responses to Ag85A compared to the controls. The majority of these children had negative responses to the TST as well as the ESAT6/CFP-10 antigens.
   In summary, MVA85A-vaccinated children had a persistently higher Ag85A immune response 14 months following vaccination than controls. All the children had negligible evidence of latent infection with M. tuberculosis (Mtb), suggesting that deploying a prophylactic vaccine against Mtb infection at this age could still be effective in this setting. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Odutola, A. A.; Owolabi, O. A.; Owiafe, P. K.; Ota, M. O. C.] MRC Unit, Banjul, Gambia.
   [McShane, H.] Univ Oxford, Jenner Inst, Oxford, England.
RP Odutola, AA (reprint author), MRC Unit, POB 273, Banjul, Gambia.
EM aaodutola@mrc.gm
OI Kwasi Owiafe, Patrick/0000-0002-4287-3577
FU Medical Research Council (UK); European Commission
FX The study was funded by the Medical Research Council (UK) and the
   European Commission. (EU 6th Framework; TBVAC). Neither funder had any
   role in the design of the study or the preparation of the manuscript.
   HMcS is a Wellcome Trust Senior Clinical Research Fellow.
CR Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x
   Brookes RH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002921
   Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
   Goonetilleke NP, 2003, J IMMUNOL, V171, P1602
   Hawkridge T, 2008, J INFECT DIS, V198, P544, DOI 10.1086/590185
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   Moyo S, 2011, INT J TUBERC LUNG D, V15, P1176, DOI 10.5588/ijtld.10.0770
   Ota MOC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002461
   Sander CR, 2009, AM J RESP CRIT CARE, V179, P724, DOI 10.1164/rccm.200809-1486OC
   Scriba TJ, 2010, EUR J IMMUNOL, V40, P279, DOI 10.1002/eji.200939754
   Sissolak D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-262
   Verreck FAW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005264
   Vordermeier HM, 2009, INFECT IMMUN, V77, P3364, DOI 10.1128/IAI.00287-09
   WHO, 2003, GLOB TUB CONTR SURV
   Williams A, 2005, INFECT IMMUN, V73, P3814, DOI 10.1128/IAI.73.6.3814-3816.2005
NR 15
TC 13
Z9 14
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD AUG 17
PY 2012
VL 30
IS 38
BP 5591
EP 5594
DI 10.1016/j.vaccine.2012.06.054
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 000JF
UT WOS:000308381900006
PM 22749600
OA No
DA 2017-08-15
ER

PT J
AU Ramutton, T
   Hendriksen, ICE
   Mwanga-Amumpaire, J
   Mtove, G
   Olaosebikan, R
   Tshefu, AK
   Onyamboko, MA
   Karema, C
   Maitland, K
   Gomes, E
   Gesase, S
   Reyburn, H
   Silamut, K
   Chotivanich, K
   Promnares, K
   Fanello, CI
   von Seidlein, L
   Day, NPJ
   White, NJ
   Dondorp, AM
   Imwong, M
   Woodrow, CJ
AF Ramutton, Thiranut
   Hendriksen, Ilse C. E.
   Mwanga-Amumpaire, Juliet
   Mtove, George
   Olaosebikan, Rasaq
   Tshefu, Antoinette K.
   Onyamboko, Marie A.
   Karema, Corine
   Maitland, Kathryn
   Gomes, Ermelinda
   Gesase, Samwel
   Reyburn, Hugh
   Silamut, Kamolrat
   Chotivanich, Kesinee
   Promnares, Kamoltip
   Fanello, Caterina I.
   von Seidlein, Lorenz
   Day, Nicholas P. J.
   White, Nicholas J.
   Dondorp, Arjen M.
   Imwong, Mallika
   Woodrow, Charles J.
TI Sequence variation does not confound the measurement of plasma PfHRP2
   concentration in African children presenting with severe malaria
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Falciparum; Severe; Africa; Histidine-rich protein; Tandem
   repeat
ID RAPID DIAGNOSTIC-TESTS; HISTIDINE-RICH PROTEIN-2; SEVERE
   FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES;
   LINKAGE GROUPS; GENETIC CROSS; PERFORMANCE; SENSITIVITY; DELETIONS
AB Background: Plasmodium falciparum histidine-rich protein PFHRP2 measurement is used widely for diagnosis, and more recently for severity assessment in falciparum malaria. The Pfhrp2 gene is highly polymorphic, with deletion of the entire gene reported in both laboratory and field isolates. These issues potentially confound the interpretation of PFHRP2 measurements.
   Methods: Studies designed to detect deletion of Pfhrp2 and its paralog Pfhrp3 were undertaken with samples from patients in seven countries contributing to the largest hospital-based severe malaria trial (AQUAMAT). The quantitative relationship between sequence polymorphism and PFHRP2 plasma concentration was examined in samples from selected sites in Mozambique and Tanzania.
   Results: There was no evidence for deletion of either Pfhrp2 or Pfhrp3 in the 77 samples with lowest PFHRP2 plasma concentrations across the seven countries. Pfhrp2 sequence diversity was very high with no haplotypes shared among 66 samples sequenced. There was no correlation between Pfhrp2 sequence length or repeat type and PFHRP2 plasma concentration.
   Conclusions: These findings indicate that sequence polymorphism is not a significant cause of variation in PFHRP2 concentration in plasma samples from African children. This justifies the further development of plasma PFHRP2 concentration as a method for assessing African children who may have severe falciparum malaria. The data also add to the existing evidence base supporting the use of rapid diagnostic tests based on PFHRP2 detection.
C1 [Hendriksen, Ilse C. E.; Silamut, Kamolrat; Chotivanich, Kesinee; Fanello, Caterina I.; Day, Nicholas P. J.; White, Nicholas J.; Dondorp, Arjen M.; Imwong, Mallika; Woodrow, Charles J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.
   [Ramutton, Thiranut] Mahidol Univ, Fac Trop Med, Dept Clin Trop Med, Bangkok, Thailand.
   [Hendriksen, Ilse C. E.; Fanello, Caterina I.; Day, Nicholas P. J.; White, Nicholas J.; Dondorp, Arjen M.; Woodrow, Charles J.] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Mwanga-Amumpaire, Juliet] Mbarara Univ Sci & Technol, Mbarara, Uganda.
   [Mwanga-Amumpaire, Juliet] Epictr Res Base, Mbarara, Uganda.
   [Mtove, George] Amani Ctr, Natl Inst Med Res, Tanga, Tanzania.
   [Olaosebikan, Rasaq] MRC Labs, Banjul, Gambia.
   [Tshefu, Antoinette K.; Onyamboko, Marie A.] Kingasani Res Ctr, Kinshasa Sch Publ Hlth, Kinshasa, Zaire.
   [Karema, Corine] Minist Hlth, Malaria Control Program, Kigali, Rwanda.
   [Maitland, Kathryn] Wellcome Trust Res Programme, Kenya Med Res Inst KEMRI, Kilifi, Kenya.
   [Gomes, Ermelinda] Hosp Cent Beira, Beira, Mozambique.
   [Gesase, Samwel] Korogwe Res Lab, Natl Inst Med Res, Tanga, Tanzania.
   [Reyburn, Hugh] London Sch Hyg & Trop Med, London WC1, England.
   [Promnares, Kamoltip] Prince Songkla Univ, Fac Sci, Dept Mol Biotechnol & Bioinformat, Hat Yai 90112, Songkhla, Thailand.
   [Promnares, Kamoltip] Prince Songkla Univ, Ctr Genom & Bioinformat Res, Fac Sci, Hat Yai 90112, Songkhla, Thailand.
   [von Seidlein, Lorenz] Menzies Sch Hlth Res, Casuarina, NT, Australia.
   [Imwong, Mallika] Mahidol Univ, Fac Trop Med, Dept Mol Trop Med & Genet, Bangkok, Thailand.
RP Imwong, M (reprint author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.
EM noi@tropmedres.ac; charlie@tropmedres.ac
OI Maitland, Kathryn/0000-0002-0007-0645
FU Wellcome Trust [076908, 082541]; Wellcome Trust of Great Britain
FX The study was supported by grants 076908 and 082541 from the Wellcome
   Trust, and was coordinated as part of the Wellcome Trust Mahidol
   University Oxford Tropical Medicine Research Programme funded by the
   Wellcome Trust of Great Britain.
CR Baker J, 2005, J INFECT DIS, V192, P870, DOI 10.1086/432010
   Baker J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022593
   Baker J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-129
   Beare NAV, 2006, AM J TROP MED HYG, V75, P790
   Bejon P, 2007, PLOS MED, V4, P1333, DOI 10.1371/journal.pmed.0040251
   Biswas S, 2005, ANN TROP MED PARASIT, V99, P553, DOI 10.1179/136485905X51463
   Desakorn V, 1997, T ROY SOC TROP MED H, V91, P479, DOI 10.1016/S0035-9203(97)90292-3
   Desakorn V, 2005, T ROY SOC TROP MED H, V99, P517, DOI 10.1016/j.trstmh.2004.11.014
   Dondorp AM, 2005, PLOS MED, V2, P788, DOI 10.1371/journal.pmed.0020204
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   Gamboa D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008091
   Hendriksen ICE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001297
   Houze S, 2011, J CLIN MICROBIOL, V49, P2694, DOI 10.1128/JCM.00281-11
   HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269
   KEMP DJ, 1987, P NATL ACAD SCI USA, V84, P7672, DOI 10.1073/pnas.84.21.7672
   Koita OA, 2012, AM J TROP MED HYG, V86, P194, DOI 10.4269/ajtmh.2012.10-0665
   Lee N, 2012, J CLIN MICROBIOL, V50, P1397, DOI 10.1128/JCM.06533-11
   Lee N, 2006, J CLIN MICROBIOL, V44, P2773, DOI 10.1128/JCM.02557-05
   LEECH JH, 1984, J CELL BIOL, V98, P1256, DOI 10.1083/jcb.98.4.1256
   Manning L, 2011, CLIN INFECT DIS, V52, P440, DOI 10.1093/cid/ciq105
   Mariette N, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-219
   Marquart L, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-74
   Noedl H, 2002, ANTIMICROB AGENTS CH, V46, P1658, DOI 10.1128/AAC.46.6.1658-1664.2002
   Ochola LB, 2005, PARASITOLOGY, V131, P449, DOI 10.1017/S0031182005008085
   Otto TD, 2010, MOL MICROBIOL, V76, P12, DOI 10.1111/j.1365-2958.2009.07026.x
   POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0
   ROCK EP, 1987, PARASITOLOGY, V95, P209
   SHIFF CJ, 1993, T ROY SOC TROP MED H, V87, P646, DOI 10.1016/0035-9203(93)90273-S
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219
   Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986
   WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T
   WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700
   WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3
   WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065
   Yeo TW, 2008, P NATL ACAD SCI USA, V105, P17097, DOI 10.1073/pnas.0805782105
NR 36
TC 11
Z9 12
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 16
PY 2012
VL 11
AR 276
DI 10.1186/1475-2875-11-276
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 025WU
UT WOS:000310228400001
PM 22898068
OA gold
DA 2017-08-15
ER

PT J
AU Ota, MOC
   Roca, A
   Bottomley, C
   Hill, PC
   Egere, U
   Greenwood, B
   Adegbola, RA
AF Ota, Martin O. C.
   Roca, Anna
   Bottomley, Christian
   Hill, Philip C.
   Egere, Uzochukwu
   Greenwood, Brian
   Adegbola, Richard A.
TI Pneumococcal Antibody Concentrations of Subjects in Communities Fully or
   Partially Vaccinated with a Seven-Valent Pneumococcal Conjugate Vaccine
SO PLOS ONE
LA English
DT Article
ID NASOPHARYNGEAL CARRIAGE; STREPTOCOCCUS-PNEUMONIAE; GAMBIAN CHILDREN;
   SUSCEPTIBILITY PATTERNS; SYSTEMATIC ANALYSIS; IMMUNOGENICITY; EFFICACY;
   SEROTYPE; DISEASE; REDUCTION
AB Background: A recent trial with PCV-7 in a rural Gambian community showed reduced vaccine-type pneumococcal carriage in fully vaccinated compared with control communities. We measured pneumococcal polysaccharide antibody concentrations in this trial to understand further the mechanisms underlying the observed changes.
   Methods: A single-blind, cluster-randomized (by village) trial was conducted in 21 Gambian villages. In 11 villages, all residents received PCV-7 (Vaccine group); in 10 control villages only children <30 months old or those born during the study received PCV-7. Subjects over the age of 30 months resident in vaccine villages received a single dose of PCV-7 whilst those in control villages received a single dose of a serogroup C meningococcal conjugate vaccine. Serum antibody concentrations against specific pneumococcal polysaccharides were measured in approximately 200 age-stratified subjects before, 4-6, 12 and 24 months following vaccination.
   Results: Baseline pneumococcal antibody concentrations were generally high and increased with age up to 10 years. One dose of PCV-7 increased geometric mean antibody concentrations (GMC) in vaccinated versus control villages for vaccine serotypes 6B and 18C, and 4 and 18C, in the young (under 5 years) and older age groups (5+ years) respectively. There were significantly higher proportions of subjects in the vaccinated than in the control communities with an antibody concentration believed to protect against carriage (>5.0 mu g/mL) for all but serotype 9V of the PCV-7 serotypes in the older group, but not in the younger age group.
   Conclusion: Higher antibodies in vaccinated communities provide an explanation for the lower pneumococcal carriage rates in fully vaccinated compared to control communities.
C1 [Ota, Martin O. C.; Roca, Anna; Hill, Philip C.; Egere, Uzochukwu; Adegbola, Richard A.] MRC Unit, Banjul, Gambia.
   [Roca, Anna] Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain.
   [Hill, Philip C.] Univ Otago, Sch Med, Ctr Int Hlth, Dunedin, New Zealand.
   [Adegbola, Richard A.] GlaxoSmithKline Biol, Wavre, Belgium.
   [Bottomley, Christian] London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, London WC1, England.
   [Greenwood, Brian] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
RP Ota, MOC (reprint author), MRC Unit, Banjul, Gambia.
EM mota@mrc.gm
FU United Kingdom Medical Research Council
FX The study was funded by the United Kingdom Medical Research Council.
   Study vaccines were donated by Wyeth Lederle Vaccines (Pfizer) and they
   played no role in the design of the study, writing or decision to
   publish this manuscript. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Cheung YB, 2008, TROP MED INT HEALTH, V13, P603, DOI 10.1111/j.1365-3156.2008.02050.x
   Cheung YB, 2009, PEDIATR INFECT DIS J, V28, P990, DOI 10.1097/INF.0b013e3181a78185
   Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525
   Dagan R, 1997, PEDIATR INFECT DIS J, V16, P1060, DOI 10.1097/00006454-199711000-00011
   Dagan R, 1996, J INFECT DIS, V174, P1271
   Deubzer HE, 2004, J INFECT DIS, V190, P1758, DOI 10.1086/424597
   Douglas RM, 1999, CLIN INFECT DIS, V28, P192, DOI 10.1086/515112
   Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524
   Hanquet G, 2010, EMERG INFECT DIS, V16, P1428, DOI 10.3201/eid1609.100102
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   Mulholland K, 1999, VACCINE, V17, pS79, DOI 10.1016/S0264-410X(99)00112-7
   Obaro SK, 2004, PEDIATR INFECT DIS J, V23, P1023, DOI 10.1097/01.inf.0000143651.54880.09
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   Palmer A, 1999, J TROP PEDIATRICS, V45, P51, DOI 10.1093/tropej/45.1.51
   Peltola H, 2003, LANCET, V361, P2170, DOI 10.1016/S0140-6736(03)13784-1
   Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9
   Rivera-Olivero IA, 2007, CLIN INFECT DIS, V45, P1427, DOI 10.1086/522984
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Russell FM, 2009, VACCINE, V27, P5685, DOI 10.1016/j.vaccine.2009.06.098
   Saaka M, 2008, VACCINE, V26, P3719, DOI 10.1016/j.vaccine.2008.04.066
   Shann F, 1999, LANCET S2, V354, pSII7
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   Usinger WR, 1999, INFECT IMMUN, V67, P2366
   Weinberger DM, 2008, J INFECT DIS, V197, P1511, DOI 10.1086/587941
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   [Anonymous], 2007, WKLY EPIDEMIOL REC, V82, P93
NR 32
TC 1
Z9 1
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2012
VL 7
IS 8
AR e42997
DI 10.1371/journal.pone.0042997
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 988OQ
UT WOS:000307500800036
PM 22916192
OA gold
DA 2017-08-15
ER

PT J
AU Bittaye, M
   Odukogbe, ATA
   Nyan, O
   Jallow, B
   Omigbodun, AO
AF Bittaye, Mustapha
   Odukogbe, Akin-Tunde Ademola
   Nyan, Ousman
   Jallow, Bintou
   Omigbodun, Akinyinka O.
TI Medical students' choices of specialty in The Gambia: the need for
   career counseling
SO BMC MEDICAL EDUCATION
LA English
DT Article
DE Medical students; Specialties; Choices; Careers
ID FAMILY MEDICINE; PREFERENCE
AB Background: Understanding preferences for specialties by medical students and the factors driving choices assists policy makers in ensuring optimal spread of personnel across disciplines.
   Methods: This cross-sectional survey using self-administered structured questionnaires was conducted on consenting students of the first medical school in The Gambia, established in 1999. Data collection was in June/July 2011. Questions were on sociodemographic characteristics of students, their parents, factors related to career preferences and opinions about counseling services. Data were analysed using JMP 8.0 software.
   Results: Respondents were 52.4% of 202 eligible students. Mean age was 24.1 +/- 5.0 years. Females constituted 54.7%. Muslims were 72.7% while Gambians formed 77.0%. Commonest specialties chosen by females were Obstetrics/Gynaecology, Paediatrics and Surgery in that order, while males preferred Internal Medicine, Surgery and Obstetrics/Gynaecology. Commonest factors influencing choices by females were 'focus on urgent care' (65.5%) and 'intellectual content of specialty' (56.9%). For males, these were 'intellectual content of specialty' (60.4%) and 'focus on urgent care'/'individual's competence' (50.0% each). More females (30.0%) than males (23.0%) had ever received career counseling, but all students desired it.
   Conclusions: Significant gender differences exist in specialty choices and factors influencing these choices amongst these students. All want career counseling.
C1 [Bittaye, Mustapha] KorleBu Univ Teaching Hosp, Dept Obstet & Gynaecol, Accra, Ghana.
   [Odukogbe, Akin-Tunde Ademola; Omigbodun, Akinyinka O.] Univ Ibadan, Coll Med, Dept Obstet & Gynaecol, Ibadan, Nigeria.
   [Nyan, Ousman] Univ Gambia, Sch Med & Allied Hlth Sci, Dept Med, Banjul, Gambia.
   [Jallow, Bintou] Royal Victoria Teaching Hosp, Dept Med, Banjul, Gambia.
RP Odukogbe, ATA (reprint author), Univ Ibadan, Coll Med, Dept Obstet & Gynaecol, Ibadan, Nigeria.
EM akin_tundeodukogbe@yahoo.com
FU African, Caribbean and Pacific Group of States (ACP Secretariat) at the
   European Union through the ACP-EU Cooperation Programme in Higher
   Education (EDULINK) [9 ACP RPR 12, 31]
FX The support of the African, Caribbean and Pacific Group of States (ACP
   Secretariat) at the European Union through the ACP-EU Cooperation
   Programme in Higher Education (EDULINK), which provided a grant [No. 9
   ACP RPR 12 # 31] to establish the Master of Science in Biomedical
   Education programme at the University of Ibadan, is gratefully
   acknowledged. MB was one of the sponsored pioneer students and the data
   in this paper were part of his dissertation.
CR Apker J, 2004, QUAL HEALTH RES, V14, P411, DOI 10.1177/1049732303260577
   Avgerinos ED, 2006, HEALTH POLICY, V79, P101, DOI 10.1016/j.healthpol.2005.12.007
   Colin S, 2005, POSTGRADUATE MED ED, P73
   COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606
   CRIMLISK HL, 1987, MED EDUC, V21, P464
   Dorsey ER, 2005, ACAD MED, V80, P791, DOI 10.1097/00001888-200509000-00002
   Edwards C, 1997, MED EDUC, V31, P237
   Feifel D, 1999, AM J PSYCHIAT, V156, P1397
   GORENFLO DW, 1994, J FAM PRACTICE, V39, P570
   Hutt R, 1981, Health Trends, V13, P17
   Lambert TW, 1998, MED EDUC, V32, P533, DOI 10.1046/j.1365-2923.1998.00244.x
   LINZER M, 1994, J GEN INTERN MED, V9, pS14, DOI 10.1007/BF02598114
   Makama JG, 2010, AFR HEALTH SCI, V10, P292
   Mariolis Anargiros, 2007, BMC Med Educ, V7, P15, DOI 10.1186/1472-6920-7-15
   McManus IC, 1996, PSYCHOL HEALTH MED, V1, P235, DOI 10.1080/13548509608402221
   Millan Luiz Roberto, 2005, Clinics (Sao Paulo), V60, P143, DOI 10.1590/S1807-59322005000200011
   Mwachaka P. M., 2010, Pan African Medical Journal, V5, P18
   PARIS J, 1983, CAN J PSYCHIAT, V28, P354
   PARKHOUSE J, 1990, MED EDUC, V24, P52
   Pawelczyk Agnieszka, 2007, Pol Merkur Lekarski, V22, P575
   Pugno PA, 2001, FAM MED, V33, P594
   Rabinowitz H K, 1999, Acad Med, V74, pS39, DOI 10.1097/00001888-199901000-00029
   REEVE PE, 1980, ANAESTHESIA, V35, P559, DOI 10.1111/j.1365-2044.1980.tb03852.x
   Saigal Priya, 2007, BMC Med Educ, V7, P31, DOI 10.1186/1472-6920-7-31
   Schwartz B, 2004, SCI AM, V290, P70
   Senf JH, 2003, J AM BOARD FAM PRACT, V16, P502
   WEIL PA, 1981, ANN INTERN MED, V94, P691
   Wright B, 2004, CAN MED ASSOC J, V170, P1920, DOI 10.1503/cmaj.1031111
   Yousef K, 2008, BMC MED EDUC, V8, P32
   Zarkovic Andrea, 2006, N Z Med J, V119, pU1851
   ZELDOW PB, 1992, MED EDUC, V26, P327
NR 31
TC 6
Z9 6
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6920
J9 BMC MED EDUC
JI BMC Med. Educ.
PD AUG 8
PY 2012
VL 12
AR 72
DI 10.1186/1472-6920-12-72
PG 9
WC Education & Educational Research; Education, Scientific Disciplines
SC Education & Educational Research
GA 092TZ
UT WOS:000315146900001
PM 22873698
OA gold
DA 2017-08-15
ER

PT J
AU Aaby, P
   Ravn, H
   Roth, A
   Rodrigues, A
   Lisse, IM
   Diness, BR
   Lausch, KR
   Lund, N
   Rasmussen, J
   Biering-Sorensen, S
   Whittle, H
   Benn, CS
AF Aaby, Peter
   Ravn, Henrik
   Roth, Adam
   Rodrigues, Amabelia
   Lisse, Ida Maria
   Diness, Birgitte Rode
   Lausch, Karen Rokkedal
   Lund, Najaaraq
   Rasmussen, Julie
   Biering-Sorensen, Sofie
   Whittle, Hilton
   Benn, Christine Stabell
TI Early diphtheria-tetanus-pertussis vaccination associated with higher
   female mortality and no difference in male mortality in a cohort of low
   birthweight children: an observational study within a randomised trial
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID VITAMIN-A SUPPLEMENTATION; TITER MEASLES-VACCINE; GUINEA-BISSAU; ROUTINE
   VACCINATIONS; CHILDHOOD SURVIVAL; COMMUNITY COHORT; PEDIATRIC WARD; BCG
   VACCINE; IMMUNIZATIONS; AGE
AB Background Studies from low-income countries have suggested that diphtheria-tetanus-pertussis (DTP) vaccine provided after Bacille Calmette-Guerin (BCG) vaccination may have a negative effect on female survival. The authors examined the effect of DTP in a cohort of low birthweight (LBW) infants.
   Methods 2320 LBW newborns were visited at 2, 6 and 12 months of age to assess nutritional and vaccination status. The authors examined survival until the 6-month visit for children who were DTP vaccinated and DTP unvaccinated at the 2-month visit.
   Results Two-thirds of the children had received DTP at 2 months and 50 deaths occurred between the 2-month and 6-month visits. DTP vaccinated children had a better anthropometric status for all indices than DTP unvaccinated children. Small mid-upper arm circumference (MUAC) was the strongest predictor of mortality. The death rate ratio (DRR) for DTP vaccinated versus DTP unvaccinated children differed significantly for girls (DRR 2.45; 95% CI 0.93 to 6.45) and boys (DRR 0.53; 95% CI 0.23 to 1.20) (p=0.018, homogeneity test). Adjusting for MUAC, the overall effect for DTP vaccinated children was 2.62 (95% CI 1.34 to 5.09); DRR was 5.68 (95% CI 1.83 to 17.7) for girls and 1.29 (95% CI 0.56 to 2.97) for boys (p=0.023, homogeneity test). While anthropometric indices were a strong predictor of mortality among boys, there was little or no association for girls.
   Conclusion Surprisingly, even though the children with the best nutritional status were vaccinated early, early DTP vaccination was associated with increased mortality for girls.
C1 [Ravn, Henrik; Roth, Adam; Benn, Christine Stabell] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen S, Denmark.
   [Aaby, Peter; Rodrigues, Amabelia; Diness, Birgitte Rode; Lausch, Karen Rokkedal; Lund, Najaaraq; Rasmussen, Julie; Biering-Sorensen, Sofie] Bandim Hlth Project, Bissau, Guinea Bissau.
   [Roth, Adam] Lund Univ, Dept Med Microbiol, Malmo, Sweden.
   [Lisse, Ida Maria] Herlev Univ Hosp, Dept Pathol, Copenhagen, Denmark.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Aaby, P (reprint author), Statens Serum Inst, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM p.aaby@bandim.org
FU EU [ICA4-CT-2002-10053]; March of Dimes; Danish National Research
   Foundation; DANIDA; Novo Nordisk Foundation
FX The study was funded by the EU (ICA4-CT-2002-10053), March of Dimes and
   the Danish National Research Foundation. The Bandim Health Project
   received support from DANIDA. PA holds a research professorship grant
   from the Novo Nordisk Foundation.
CR Aaby P, 2006, VACCINE, V24, P4701, DOI 10.1016/j.vaccine.2006.03.038
   Aaby P, 2006, VACCINE, V24, P2764, DOI 10.1016/j.vaccine.2006.01.004
   Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009
   Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   Aaby P, 2004, INT J EPIDEMIOL, V33, P367, DOI 10.1093/ije/dyh004
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   Aaby P, 2002, BMJ
   Aaby P, 2010, BRIT MED J, V341, pc6495
   Aaby P, 2007, VACCINE, V25, P1265, DOI 10.1016/j.vaccine.2006.10.007
   Aaby P, 2007, TROP MED INT HEALTH, V12, P15, DOI 10.1111/j.1365-3156.2006.01774.x
   Aaby P, 2006, PEDIATR INFECT DIS J, V25, P721, DOI 10.1097/01.inf.0000227829.64686.ae
   Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   Aaby P, 2010, PEDIATR INFECT DIS J, V29, P324, DOI 10.1097/INF.0b013e3181c15367
   Aaby P, 2009, LANCET, V373, P1428, DOI 10.1016/S0140-6736(09)60823-0
   Benn CS, 2009, AM J CLIN NUTR, V90, P629, DOI 10.3945/ajcn.2009.27477
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn CS, 2009, INT J EPIDEMIOL, V38, P304, DOI 10.1093/ije/dyn195
   Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208
   Benn CS, 2010, BRIT MED J, V340, pc1101
   Breiman RF, 2004, LANCET, V364, P2204, DOI 10.1016/S0140-6736(04)17593-4
   Diness BR, 2011, BRIT J NUTR, V105, P1819, DOI 10.1017/S0007114510005532
   Elguero E, 2005, TROP MED INT HEALTH, V10, P956, DOI 10.1111/j.1365-3156.2005.01479.x
   Farrington CP, 2009, TROP MED INT HEALTH, V14, P977, DOI 10.1111/j.1365-3156.2009.02302.x
   Fine PEM, 2007, TROP MED INT HEALTH, V12, P1, DOI 10.1111/j.1365-3156.2006.01794.x
   Fine PEM, 2009, TROP MED INT HEALTH, V14, P969, DOI 10.1111/j.1365-3156.2009.02301.x
   Fine PEM, 2004, BRIT MED J, V329, P1297, DOI 10.1136/bmj.329.7478.1297
   Fischer JE, 2000, J INFECT DIS, V182, P1029, DOI 10.1086/315806
   Fisker AB, 2007, AM J CLIN NUTR, V86, P1032
   HUBER SA, 1994, J VIROL, V68, P5126
   Jensen H, 2007, TROP MED INT HEALTH, V12, P5, DOI 10.1111/j.1365-3156.2006.01773.x
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Lehmann D, 2005, INT J EPIDEMIOL, V34, P138, DOI 10.1093/ije/dyh262
   MAHIEU JM, 1978, B WORLD HEALTH ORGAN, V56, P773
   Martins C, 2009, VACCINE, V27, P5220, DOI 10.1016/j.vaccine.2009.06.076
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   [Anonymous], 2008, WKLY EPIDEMIOL REC, V83, P287
   Moulton LH, 2005, TROP MED INT HEALTH, V10, P947, DOI 10.1111/j.1365-3156.2005.01434.x
   Nyarko P, 2001, POPULATION COUNCIL W, V147
   Rodrigues A, 2006, VACCINE, V24, P4737, DOI 10.1016/j.vaccine.2006.03.033
   Roth A, 2010, BRIT MED J, V340, pc671
   Shann F, 2011, J INFECT DIS, V204, P182, DOI 10.1093/infdis/jir244
   Shann F, 2010, ARCH DIS CHILD, V95, P662, DOI 10.1136/adc.2009.157537
   Shann F, 2010, PEDIATR INFECT DIS J, V29, P457, DOI 10.1097/INF.0b013e3181c91361
   Valentiner-Branth P, 2007, VACCINE, V25, P2733, DOI 10.1016/j.vaccine.2006.01.035
   Vaugelade J, 2004, BRIT MED J, V329, P1309, DOI 10.1136/bmj.38261.496366.82
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
NR 47
TC 33
Z9 33
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD AUG
PY 2012
VL 97
IS 8
BP 685
EP 691
DI 10.1136/archdischild-2011-300646
PG 7
WC Pediatrics
SC Pediatrics
GA 983DZ
UT WOS:000307100000003
PM 22331681
OA No
DA 2017-08-15
ER

PT J
AU Ahuja, SD
   Ashkin, D
   Avendano, M
   Banerjee, R
   Bauer, M
   Bayona, JN
   Becerra, MC
   Benedetti, A
   Burgos, M
   Centis, R
   Chan, ED
   Chiang, CY
   Cox, H
   D'Ambrosio, L
   DeRiemer, K
   Dung, NH
   Enarson, D
   Falzon, D
   Flanagan, K
   Flood, J
   Garcia-Garcia, ML
   Gandhi, N
   Granich, RM
   Hollm-Delgado, MG
   Holtz, TH
   Iseman, MD
   Jarlsberg, LG
   Keshavjee, S
   Kim, HR
   Koh, WJ
   Lancaster, J
   Lange, C
   de Lange, WCM
   Leimane, V
   Leung, CC
   Li, JH
   Menzies, D
   Migliori, GB
   Mishustin, SP
   Mitnick, CD
   Narita, M
   O'Riordan, P
   Pai, M
   Palmero, D
   Park, SK
   Pasvol, G
   Pena, J
   Perez-Guzman, C
   Quelapio, MID
   Ponce-de-Leon, A
   Riekstina, V
   Robert, J
   Royce, S
   Schaaf, HS
   Seung, KJ
   Shah, L
   Shim, TS
   Shin, SS
   Shiraishi, Y
   Sifuentes-Osornio, J
   Sotgiu, G
   Strand, MJ
   Tabarsi, P
   Tupasi, TE
   van Altena, R
   Van der Walt, M
   Van der Werf, TS
   Vargas, MH
   Viiklepp, P
   Westenhouse, J
   Yew, WW
   Yim, JJ
AF Ahuja, Shama D.
   Ashkin, David
   Avendano, Monika
   Banerjee, Rita
   Bauer, Melissa
   Bayona, Jamie N.
   Becerra, Mercedes C.
   Benedetti, Andrea
   Burgos, Marcos
   Centis, Rosella
   Chan, Eward D.
   Chiang, Chen-Yuan
   Cox, Helen
   D'Ambrosio, Lia
   DeRiemer, Kathy
   Nguyen Huy Dung
   Enarson, Donald
   Falzon, Dennis
   Flanagan, Katherine
   Flood, Jennifer
   Garcia-Garcia, Maria L.
   Gandhi, Neel
   Granich, Reuben M.
   Hollm-Delgado, Maria G.
   Holtz, Timothy H.
   Iseman, Michael D.
   Jarlsberg, Leah G.
   Keshavjee, Salmaan
   Kim, Hye-Ryoun
   Koh, Won-Jung
   Lancaster, Joey
   Lange, Christophe
   de lange, Wiel C. M.
   Leimane, Vaira
   Leung, Chi Chiu
   Li, Jiehui
   Menzies, Dick
   Migliori, Giovanni B.
   Mishustin, Sergey P.
   Mitnick, Carole D.
   Narita, Masa
   O'Riordan, Philly
   Pai, Madhukar
   Palmero, Domingo
   Park, Seung-kyu
   Pasvol, Geoffrey
   Pena, Jose
   Perez-Guzman, Carlos
   Quelapio, Maria I. D.
   Ponce-de-Leon, Alfredo
   Riekstina, Vija
   Robert, Jerome
   Royce, Sarah
   Schaaf, H. Simon
   Seung, Kwonjune J.
   Shah, Lena
   Shim, Tae Sun
   Shin, Sonya S.
   Shiraishi, Yuji
   Sifuentes-Osornio, Jose
   Sotgiu, Giovanni
   Strand, Matthew J.
   Tabarsi, Payam
   Tupasi, Thelma E.
   van Altena, Robert
   Van der Walt, Martie
   Van der Werf, Tjip S.
   Vargas, Mario H.
   Viiklepp, Pirett
   Westenhouse, Janice
   Yew, Wing Wai
   Yim, Jae-Joon
CA Collaborative Grp Meta-Anal
TI Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and
   Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153
   Patients
SO PLOS MEDICINE
LA English
DT Article
ID SHORT-COURSE CHEMOTHERAPY; STANDARDIZED REGIMENS; DRUG-RESISTANCE;
   DOTS-PLUS; FOLLOW-UP; TB; PROGRAM; COHORT; INTERVENTION; PHILIPPINES
AB Background: Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB.
   Methods and Findings: Three recent systematic reviews were used to identify studies reporting treatment outcomes of microbiologically confirmed MDR-TB. Study authors were contacted to solicit individual patient data including clinical characteristics, treatment given, and outcomes. Random effects multivariable logistic meta-regression was used to estimate adjusted odds of treatment success. Adequate treatment and outcome data were provided for 9,153 patients with MDR-TB from 32 observational studies. Treatment success, compared to failure/relapse, was associated with use of: later generation quinolones, (adjusted odds ratio [aOR]: 2.5 [95% CI 1.1-6.0]), ofloxacin (aOR: 2.5 [1.6-3.9]), ethionamide or prothionamide (aOR: 1.7 [1.3-2.3]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.3 [1.3-3.9]), and three or more likely effective drugs in the continuation phase (aOR: 2.7 [1.7-4.1]). Similar results were seen for the association of treatment success compared to failure/relapse or death: later generation quinolones, (aOR: 2.7 [1.7-4.3]), ofloxacin (aOR: 2.3 [1.3-3.8]), ethionamide or prothionamide (aOR: 1.7 [1.4-2.1]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.7 [1.9-3.9]), and three or more likely effective drugs in the continuation phase (aOR: 4.5 [3.4-6.0]).
   Conclusions: In this individual patient data meta-analysis of observational data, improved MDR-TB treatment success and survival were associated with use of certain fluoroquinolones, ethionamide, or prothionamide, and greater total number of effective drugs. However, randomized trials are urgently needed to optimize MDR-TB treatment.
C1 [Ahuja, Shama D.] Bur TB, New York, NY 11803 USA.
   [Ashkin, David] AG Holley Hosp, Lantana, FL USA.
   [Avendano, Monika] Univ Toronto, Toronto, ON, Canada.
   [Banerjee, Rita] Mayo Clin, Rochester, MN USA.
   [Bauer, Melissa; Benedetti, Andrea; Hollm-Delgado, Maria G.; Menzies, Dick; Pai, Madhukar; Shah, Lena] McGill Univ, Montreal Chest Inst, Montreal, PQ, Canada.
   [Bayona, Jamie N.] Dartmouth Ctr Hlth Care Delivery Sci, Hanover, NH USA.
   [Becerra, Mercedes C.; Keshavjee, Salmaan; Mitnick, Carole D.] Harvard Univ, Sch Med, Boston, MA USA.
   [Becerra, Mercedes C.] Partners Hlth, Boston, MA USA.
   [Burgos, Marcos] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA.
   [Centis, Rosella; D'Ambrosio, Lia; Migliori, Giovanni B.] Fdn S Maugeri, Care & Res Inst, WHO Collaborating Ctr TB & Lung Dis, Tradate, Italy.
   [Chan, Eward D.] Denver Vet Affair Med Ctr, Denver, CO USA.
   [Chiang, Chen-Yuan] Taipei Med Univ, Sch Med, Wan Fang Hosp, Taipei, Taiwan.
   [Cox, Helen] Med Sans Frontieres, Cape Town, South Africa.
   [DeRiemer, Kathy] UC Davis Sch Med, Davis, CA USA.
   [Nguyen Huy Dung] Natl TB Control Program, Hanoi, Vietnam.
   [Enarson, Donald] Int Union TB & Lung Dis, Paris, France.
   [Falzon, Dennis; Granich, Reuben M.] WHO, CH-1211 Geneva, Switzerland.
   [Flanagan, Katherine] MRC Labs, Banjul, Gambia.
   [Garcia-Garcia, Maria L.] Inst Nacl Salud Publ, Mexico City, DF, Mexico.
   [Gandhi, Neel] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Holtz, Timothy H.] Thailand MOPH & US CDC Collaborat, Bangkok, Thailand.
   [Iseman, Michael D.; Strand, Matthew J.] Natl Jewish Hlth, Denver, CO USA.
   [Jarlsberg, Leah G.; Royce, Sarah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Kim, Hye-Ryoun] Korea Canc Ctr Hosp, Seoul, South Korea.
   [Koh, Won-Jung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
   [Lancaster, Joey; Van der Walt, Martie] S African MRC, Pretoria, South Africa.
   [Lange, Christophe] TB Ctr Borstel, Med Clin, Borstel, Germany.
   [de lange, Wiel C. M.; van Altena, Robert; Van der Werf, Tjip S.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
   [Leimane, Vaira; Riekstina, Vija] Clin TB & Lung Dis, Riga, Latvia.
   [Leung, Chi Chiu] TB & Chest Serv, Hong Kong, Hong Kong, Peoples R China.
   [Li, Jiehui] New York City Hlth & Mental Hyg, New York, NY USA.
   [Mishustin, Sergey P.] Tomsk Oblast TB Dispensary, Tomsk, Russia.
   [Narita, Masa] Univ Washington, Seattle, WA 98195 USA.
   [O'Riordan, Philly] City Rd Med Ctr, London, England.
   [Palmero, Domingo] Hosp FJ Muniz, Buenos Aires, DF, Argentina.
   [Park, Seung-kyu] TB Ctr, Seoul, South Korea.
   [Pasvol, Geoffrey] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Pena, Jose] Univ Autonoma Madrid, Madrid, Spain.
   [Perez-Guzman, Carlos] Inst Salud Estado Aguascalientes, Mexico City, DF, Mexico.
   [Quelapio, Maria I. D.; Tupasi, Thelma E.] Trop Dis Fdn, Makati, Philippines.
   [Ponce-de-Leon, Alfredo; Sifuentes-Osornio, Jose] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Robert, Jerome] Bacteriol Hyg UPMC, Paris, France.
   [Schaaf, H. Simon] Univ Stellenbosch, ZA-7600 Stellenbosch, South Africa.
   [Seung, Kwonjune J.; Shin, Sonya S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Shim, Tae Sun] Univ Ulsan, Coll Med, Seoul, South Korea.
   [Shiraishi, Yuji] Fukujuji Hosp, Tokyo, Japan.
   [Tabarsi, Payam] Shaheed Beheshti Med Univ, Tehran, Iran.
   [Sotgiu, Giovanni] Univ Sassari, I-07100 Sassari, Italy.
   [Vargas, Mario H.] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico.
   [Viiklepp, Pirett] Natl Inst Hlth Dev, Tallinn, Estonia.
   [Westenhouse, Janice] Calif Dept Publ Hlth, Ctr Infect Dis, Sacramento, CA USA.
   [Yew, Wing Wai] Grantham Hosp, Hong Kong, Hong Kong, Peoples R China.
   [Yim, Jae-Joon] Seoul Natl Univ, Coll Med, Seoul, South Korea.
RP Ahuja, SD (reprint author), Bur TB, New York, NY 11803 USA.
EM Dick.Menzies@McGill.ca
RI Lange, Christoph/J-6289-2012; Yim, Jae Joon/J-2783-2012; Koh, Won
   Jung/C-9595-2011; ROBERT, Jerome/C-3993-2011
OI Hollm-Delgado, Maria-Graciela/0000-0003-1067-8520; Vargas, Mario
   H./0000-0002-8420-980X; SOTGIU, Giovanni/0000-0002-1600-4474; ROBERT,
   Jerome/0000-0002-9380-0570; Cox, Helen/0000-0002-6538-7192; DeRiemer,
   Kathryn/0000-0002-8375-7505; tabarsi, payam/0000-0002-8932-5420;
   Migliori, Giovanni Battista/0000-0002-2597-574X
FU USAID; US Centers for Disease Control Cooperative Agreement Funds;
   European Community's Seventh Framework Programme [FP7-223681]; Mexican
   Secretariat of Health; National Institutes of Health of the United
   States [A135969, K01TW000001]; Wellcome Trust [176W009]; Howard Hughes
   Medical Institute [55000632]; Mexican Council of Science and Technology
   [SEP 2004-C01-47499, FOSSIS 2005-2, FOSSIS 14475, FOSSIS 87332]; South
   African Medical Research Council; Fonds de Recherche en Sante de Quebec;
   CIHR (Canada Graduate Scholarship); Doris Duke Charitable Foundation
   Clinical Scientist Development Award; GlaxoSmithKline; Pfizer; Eli Lilly
   Foundation; Open Society Institute; Bill and Melinda Gates Foundation;
   NIH; Global Fund to fight AIDS, Tuberculosis and Malaria
FX Partial funding for the assembly of individual patient data and
   meta-analysis was provided from the Stop TB Department of the World
   Health Organization, through a grant from USAID. Funding for data
   gathering at participating centres came from the following sources: in
   the State of California from the US Centers for Disease Control
   Cooperative Agreement Funds; in Italy from the European Community's
   Seventh Framework Programme (FP7/2007-2013) under grant agreement
   FP7-223681; in Mexico (Veracruz) from the Mexican Secretariat of Health,
   the National Institutes of Health of the United States (A135969 and
   K01TW000001), the Wellcome Trust (176W009), the Howard Hughes Medical
   Institute (55000632), and the Mexican Council of Science and Technology:
   SEP 2004-C01-47499, FOSSIS 2005-2 (14475), (87332); in South Africa from
   the South African Medical Research Council funding. Funding was provided
   to the following investigators: M Bauer and D Menzies were supported by
   salary awards from the Fonds de Recherche en Sante de Quebec, L Shah was
   supported by CIHR (Canada Graduate Scholarship), Neel Gandhi received a
   Doris Duke Charitable Foundation Clinical Scientist Development Award.
   The funders had no role in study design, data collection and analysis,
   decisions to publish, or preparation of the manuscript.; JR is a
   Consultant for bioMerieux. WWY has been indirectly sponsored to
   participate in International Conferences by GlaxoSmithKline and Pfizer
   in the last 3 years. CDM is on the Scientific Advisory Board for Otsuka
   pharmaceuticals development of OPC67683 (Delaminid), a new anti-TB
   compound. SK received salary support from the Eli Lilly Foundation as
   part of funding for the activities of Partners In Health by the
   Foundation's MDR-TB Partnership. This funder was not involved in the
   study design; collection, analysis and interpretation of data; writing
   of the paper; and/or decision to submit for publication. The Partners In
   Health project in Tomsk received funding from Mr. Tom White, the Open
   Society Institute, the Bill and Melinda Gates Foundation, and the Global
   Fund to fight AIDS, Tuberculosis and Malaria. None of these funders were
   involved in the study design; collection, analysis and interpretation of
   data; writing of the paper; and/or decision to submit for publication.
   KD is an unpaid, volunteer member of the New Diagnostics Working Group
   (NDWG), formed of members of the Stop TB Partnership. The Secretariat of
   the NDWG is hosted by FIND (Foundation for New Innovative Diagnostics).
   JB was working as consultant for Otsuka Pharmaceutical for the
   implementation of clinical trial in Peru. JB was co PI of a NIH grant in
   Peru, Epidemiology of Tuberculosis. MP and GP are members of the
   Editorial Board of PLOS Medicine. All other authors have declared that
   no competing interests exist.
CR Akcakir Y., 2010, THESIS MCGILL U MONT
   Avendano M, 2000, Can Respir J, V7, P383
   Banerjee R, 2008, CLIN INFECT DIS, V47, P450, DOI 10.1086/590009
   Burgos M, 2005, CLIN INFECT DIS, V40, P968, DOI 10.1086/428582
   Caminero JA, 2010, LANCET INFECT DIS, V10, P621, DOI 10.1016/S1473-3099(10)70139-0
   Chan ED, 2004, AM J RESP CRIT CARE, V169, P1103, DOI 10.1164/rccm.200308-11590C
   Chiang CY, 2006, EUR RESPIR J, V28, P980, DOI 10.1183/09031936.06.00125705
   Cox HS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001126
   DeRiemer K, 2005, LANCET, V365, P1239, DOI 10.1016/S0140-6736(05)74812-1
   Escudero E, 2006, INT J TUBERC LUNG D, V10, P409
   Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537
   Geerligs WA, 2000, INT J TUBERC LUNG D, V4, P758
   Granich RM, 2005, JAMA-J AM MED ASSOC, V293, P2732, DOI 10.1001/jama.293.22.2732
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holtz TH, 2006, INT J TUBERC LUNG D, V10, P649
   Holtz TH, 2006, ANN INTERN MED, V144, P650
   ISEMAN MD, 1990, AM REV RESPIR DIS, V141, P623
   Johnston JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006914
   Kim DH, 2008, AM J RESP CRIT CARE, V178, P1075, DOI 10.1164/rccm.200801-132OC
   Kim HR, 2007, CLIN INFECT DIS, V45, P1290, DOI 10.1086/522537
   Kwon YS, 2008, CLIN INFECT DIS, V47, P496, DOI 10.1086/590005
   Laserson KF, 2005, INT J TUBERC LUNG D, V9, P640
   Leimane V, 2005, LANCET, V365, P318
   Li JH, 2004, CHEST, V126, P1770, DOI 10.1378/chest.126.6.1770
   Lockman S, 2001, CLIN INFECT DIS, V32, P373, DOI 10.1086/318489
   Masjedi MR, 2008, INT J TUBERC LUNG D, V12, P750
   Migliori GB, 2007, EUR RESPIR J, V30, P623, DOI 10.1183/09031936.00077307
   Migliori GB, 2002, INT J TUBERC LUNG D, V6, P858
   Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928
   Mitnick C, 2010, NEW ENGL J MED, V359, P563
   Mitnick CD, 2007, PLOS MED, V4, P1730, DOI 10.1371/journal.pmed.0040292
   Munsiff SS, 2006, INT J TUBERC LUNG D, V10, P639
   Narita M, 2001, CHEST, V120, P343, DOI 10.1378/chest.120.2.343
   O'Riordan P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003173
   Orenstein EW, 2009, LANCET INFECT DIS, V9, P153, DOI 10.1016/S1473-3099(09)70041-6
   Palmero DJ, 2004, INT J TUBERC LUNG D, V8, P778
   Park SK, 2004, INT J TUBERC LUNG D, V8, P361
   Perez-Guzman C, 2002, INT J TUBERC LUNG D, V6, P1102
   Pinheiro J. C., 1995, J COMPUTATIONAL GRAP, V4, P12, DOI [10.1080/10618600.1995.10474663, DOI 10.2307/1390625]
   Psaty BM, 2010, JAMA-J AM MED ASSOC, V304, P897, DOI 10.1001/jama.2010.1205
   Quy HT, 2006, INT J TUBERC LUNG D, V10, P45
   Riekstina V, 2007, INT J TUBERC LUNG D, V11, P585
   Schaaf HS, 2003, ARCH DIS CHILD, V88, P1106, DOI 10.1136/adc.88.12.1106
   Schabenberger O, 2011, INTRO GLIMMIX PROCED
   Shin SS, 2006, INT J TUBERC LUNG D, V10, P402
   Shiraishi Y, 2004, J THORAC CARDIOV SUR, V128, P523, DOI 10.1016/j.jtcvs.2004.06.012
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA, P548
   Thompson SG, 2001, STAT METHODS MED RES, V10, P375, DOI 10.1191/096228001682157616
   Tupasi TE, 2003, TUBERCULOSIS, V83, P52, DOI 10.1016/S1472-9792(02)00072-0
   Tupasi TE, 2006, PLOS MED, V3, P1587, DOI 10.1371/journal.pmed.0030352
   Turner RM, 2000, STAT MED, V19, P3417, DOI 10.1002/1097-0258(20001230)19:24<3417::AID-SIM614>3.3.CO;2-C
   Uffredi ML, 2007, INT J ANTIMICROB AG, V29, P434, DOI 10.1016/j.ijantimicag.2006.11.023
   Van Deun A, 2004, INT J TUBERC LUNG D, V8, P560
   Van Deun A, 2010, AM J RESP CRIT CARE, V182, P684, DOI 10.1164/rccm.201001-0077OC
   World Health Organization, 2011, GUID PROGR MAN DRUG
   World Health Organization, 2008, GUID PROGR MAN DRUG
   World Health Organization, 2006, WKLY EPIDEMIOL REC, V81, P430
   Yarandi HN, 2011, HANDLING MISSING DAT
   Yew WW, 2003, CHEST, V124, P1476, DOI 10.1378/chest.124.4.1476
   Yew WW, 2000, CHEST, V117, P744, DOI 10.1378/chest.117.3.744
NR 60
TC 212
Z9 218
U1 7
U2 34
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2012
VL 9
IS 8
AR e1001300
DI 10.1371/journal.pmed.1001300
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA 001XU
UT WOS:000308494600021
PM 22952439
OA gold
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Hendriksen, ICE
   Mwanga-Amumpaire, J
   von Seidlein, L
   Mtove, G
   White, LJ
   Olaosebikan, R
   Lee, SJ
   Tshefu, AK
   Woodrow, C
   Amos, B
   Karema, C
   Saiwaew, S
   Maitland, K
   Gomes, E
   Pan-Ngum, W
   Gesase, S
   Silamut, K
   Reyburn, H
   Joseph, S
   Chotivanich, K
   Fanello, CI
   Day, NPJ
   White, NJ
   Dondorp, AM
AF Hendriksen, Ilse C. E.
   Mwanga-Amumpaire, Juliet
   von Seidlein, Lorenz
   Mtove, George
   White, Lisa J.
   Olaosebikan, Rasaq
   Lee, Sue J.
   Tshefu, Antoinette K.
   Woodrow, Charles
   Amos, Ben
   Karema, Corine
   Saiwaew, Somporn
   Maitland, Kathryn
   Gomes, Ermelinda
   Pan-Ngum, Wirichada
   Gesase, Samwel
   Silamut, Kamolrat
   Reyburn, Hugh
   Joseph, Sarah
   Chotivanich, Kesinee
   Fanello, Caterina I.
   Day, Nicholas P. J.
   White, Nicholas J.
   Dondorp, Arjen M.
TI Diagnosing Severe Falciparum Malaria in Parasitaemic African Children: A
   Prospective Evaluation of Plasma PfHRP2 Measurement
SO PLOS MEDICINE
LA English
DT Article
ID HISTIDINE-RICH PROTEIN-2; PLASMODIUM-FALCIPARUM; CEREBRAL MALARIA;
   MULTIPLICATION RATE; GENETIC CROSS; RETINOPATHY; TESTS; BLOOD;
   SEQUESTRATION; PERFORMANCE
AB Background: In African children, distinguishing severe falciparum malaria from other severe febrile illnesses with coincidental Plasmodium falciparum parasitaemia is a major challenge. P. falciparum histidine-rich protein 2 (PfHRP2) is released by mature sequestered parasites and can be used to estimate the total parasite burden. We investigated the prognostic significance of plasma PfHRP2 and used it to estimate the malaria-attributable fraction in African children diagnosed with severe malaria.
   Methods and Findings: Admission plasma PfHRP2 was measured prospectively in African children (from Mozambique, The Gambia, Kenya, Tanzania, Uganda, Rwanda, and the Democratic Republic of the Congo) aged 1 month to 15 years with severe febrile illness and a positive P. falciparum lactate dehydrogenase (pLDH)-based rapid test in a clinical trial comparing parenteral artesunate versus quinine (the AQUAMAT trial, ISRCTN 50258054). In 3,826 severely ill children, Plasmadium falciparum PfHRP2 was higher in patients with coma (p = 0.0209), acidosis (p<0.0001), and severe anaemia (p<0.0001). Admission geometric mean (95%CI) plasma PfHRP2 was 1,611 (1,350-1,922) ng/mL in fatal cases (n = 381) versus 1,046 (9911,104) ng/mL in survivors (n = 3,445, p<0.0001), without differences in parasitaemia as assessed by microscopy. There was a U-shaped association between log(10) plasma PfHRP2 and risk of death. Mortality increased 20% per log(10) increase in PfHRP2 above 174 ng/mL (adjusted odds ratio [AOR] 1.21, 95% CI 1.05-1.39, p = 0.009). A mechanistic model assuming a PfHRP2-independent risk of death in non-malaria illness closely fitted the observed data and showed malaria-attributable mortality less than 50% with plasma PfHRP2 <= 174 ng/mL. The odds ratio (OR) for death in artesunate versus quinine-treated patients was 0.61 (95% CI 0.44-0.83, p = 0.0018) in the highest PfHRP2 tertile, whereas there was no difference in the lowest tertile (OR 1.05; 95% CI 0.69-1.61; p = 0.82). A limitation of the study is that some conclusions are drawn from a mechanistic model, which is inherently dependent on certain assumptions. However, a sensitivity analysis of the model indicated that the results were robust to a plausible range of parameter estimates. Further studies are needed to validate our findings.
   Conclusions: Plasma PfHRP2 has prognostic significance in African children with severe falciparum malaria and provides a tool to stratify the risk of "true'' severe malaria-attributable disease as opposed to other severe illnesses in parasitaemic African children.
C1 [Hendriksen, Ilse C. E.; White, Lisa J.; Lee, Sue J.; Woodrow, Charles; Saiwaew, Somporn; Pan-Ngum, Wirichada; Silamut, Kamolrat; Chotivanich, Kesinee; Fanello, Caterina I.; Day, Nicholas P. J.; White, Nicholas J.; Dondorp, Arjen M.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.
   [Hendriksen, Ilse C. E.; White, Lisa J.; Lee, Sue J.; Woodrow, Charles; Fanello, Caterina I.; Day, Nicholas P. J.; White, Nicholas J.; Dondorp, Arjen M.] Univ Oxford, Ctr Trop Med, Churchill Hosp, Oxford, England.
   [Mwanga-Amumpaire, Juliet] Mbarara Univ Sci & Technol, Mbarara, Uganda.
   [Mwanga-Amumpaire, Juliet] Epictr Res Base, Mbarara, Uganda.
   [von Seidlein, Lorenz] Menzies Sch Hlth Res, Casuarina, NT, Australia.
   [Mtove, George] Amani Ctr, Natl Inst Med Res, Tanga, Tanzania.
   [Olaosebikan, Rasaq] MRC Labs, Banjul, Gambia.
   [Tshefu, Antoinette K.] Kingasani Res Ctr, Kinshasa Sch Publ Hlth, Kinshasa, Zaire.
   [Amos, Ben] Hosp Teule, Muheza, Tanzania.
   [Karema, Corine] Minist Hlth, Malaria Control Program, Kigali, Rwanda.
   [Maitland, Kathryn] Kenya Med Res Inst KEMRI, Wellcome Trust Res Programme, Kilifi, Kenya.
   [Gomes, Ermelinda] Hosp Cent Beira, Beira, Mozambique.
   [Gesase, Samwel] Tanga Med Res Ctr, Natl Inst Med Res, Tanga, Tanzania.
   [Reyburn, Hugh] London Sch Trop Med & Hyg, London, England.
   [Joseph, Sarah] MRC, London, England.
RP Hendriksen, ICE (reprint author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.
EM arjen@tropmedres.ac
RI White, Nicholas/I-4629-2012
OI Amos, Benjamin/0000-0002-8569-1650; Maitland,
   Kathryn/0000-0002-0007-0645
FU Wellcome Trust [076908, 082541]; Wellcome Trust of Great Britain
FX This trial was supported by grants 076908 and 082541 from the Wellcome
   Trust, and was coordinated as part of the Wellcome Trust Mahidol
   University Oxford Tropical Medicine Research Programme funded by the
   Wellcome Trust of Great Britain (http://www.wellcome.ac.uk/). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abeku TA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-202
   Baker J, 2005, J INFECT DIS, V192, P870, DOI 10.1086/432010
   Baker J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022593
   Baker J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-129
   Beare NA, 2004, ARCH OPHTHALMOL-CHIC, V122, P1141, DOI 10.1001/archopht.122.8.1141
   Beare NAV, 2006, AM J TROP MED HYG, V75, P790
   Beare NAV, 2009, J INFECT DIS, V199, P263, DOI 10.1086/595735
   Bejon P, 2007, PLOS MED, V4, P1333, DOI 10.1371/journal.pmed.0040251
   Berkley J, 1999, T ROY SOC TROP MED H, V93, P283, DOI 10.1016/S0035-9203(99)90024-X
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299
   Biswas S, 2005, ANN TROP MED PARASIT, V99, P553, DOI 10.1179/136485905X51463
   Burton M, 2004, TROP DOCT, V34, P214
   Chotivanich K, 2000, J INFECT DIS, V181, P1206, DOI 10.1086/315353
   Deans AM, 2006, AM J TROP MED HYG, V74, P554
   Desakorn V, 2005, T ROY SOC TROP MED H, V99, P517, DOI 10.1016/j.trstmh.2004.11.014
   Dondorp A, 2005, J GERONTOL B-PSYCHOL, V366, P717
   Dondorp AM, 2008, J INFECT DIS, V197, P79, DOI 10.1086/523762
   Dondorp AM, 2005, PLOS MED, V2, P788, DOI 10.1371/journal.pmed.0020204
   Dondorp AM, 2004, ACTA TROP, V89, P309, DOI 10.1016/j.actatropica.2003.10.004
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   English M, 1996, T ROY SOC TROP MED H, V90, P658, DOI 10.1016/S0035-9203(96)90423-X
   Essuman VA, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-232
   Evans JA, 2004, QJM-INT J MED, V97, P591, DOI 10.1093/qjmed/hcho93
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Houze S, 2011, J CLIN MICROBIOL, V49, P2694, DOI 10.1128/JCM.00281-11
   HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269
   Jaffar S, 1997, AM J TROP MED HYG, V57, P20
   Kifude CM, 2008, CLIN VACCINE IMMUNOL, V15, P1012, DOI 10.1128/CVI.00385-07
   Koita OA, 2012, AM J TROP MED HYG, V86, P194, DOI 10.4269/ajtmh.2012.10-0665
   Le Scanf C, 2008, MICROBES INFECT, V10, P447, DOI 10.1016/j.micinf.2007.12.012
   MACPHERSON GG, 1985, AM J PATHOL, V119, P385
   Manning L, 2011, CLIN INFECT DIS, V52, P440, DOI 10.1093/cid/ciq105
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Martin SK, 2009, AM J TROP MED HYG, V80, P516
   PHU NH, 1995, T ROY SOC TROP MED H, V89, P200
   Planche T, 2001, AM J TROP MED HYG, V65, P599
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X
   SILAMUT K, 1993, T ROY SOC TROP MED H, V87, P436, DOI 10.1016/0035-9203(93)90028-O
   Simpson JA, 2002, PARASITOLOGY, V124, P247, DOI 10.1017/S0031182001001202
   StataCorp, 2007, STAT 10 BAS REF MAN
   Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986
   WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T
   WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3
   White VA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004317
   Yeo TW, 2008, P NATL ACAD SCI USA, V105, P17097, DOI 10.1073/pnas.0805782105
NR 47
TC 50
Z9 50
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2012
VL 9
IS 8
AR e1001297
DI 10.1371/journal.pmed.1001297
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 001XU
UT WOS:000308494600018
PM 22927801
OA gold
DA 2017-08-15
ER

PT J
AU Sandgren, A
   Cuevas, LE
   Dara, M
   Gie, RP
   Grzemska, M
   Hawkridge, A
   Hesseling, AC
   Kampmann, B
   Lienhardt, C
   Manissero, D
   Wingfield, C
   Graham, SM
AF Sandgren, Andreas
   Cuevas, Luis E.
   Dara, Masoud
   Gie, Robert P.
   Grzemska, Malgorzata
   Hawkridge, Anthony
   Hesseling, Anneke C.
   Kampmann, Beate
   Lienhardt, Christian
   Manissero, Davide
   Wingfield, Claire
   Graham, Stephen M.
TI Childhood tuberculosis: progress requires an advocacy strategy now
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
DE Control; infectious disease; Mycobacterium tuberculosis; public health
ID HIV; VACCINATION; INFANTS
AB Childhood tuberculosis (TB) is a preventable and curable infectious disease that remains overlooked by public health authorities, health policy makers and TB control programmes. Childhood TB contributes significantly to the burden of disease and represents the failure to control transmission in the community. Furthermore, the pool of infected children constitutes a reservoir of infection for the future burden of TB. It is time to prioritise childhood TB, advocate for addressing the challenges and grasp the opportunities in its prevention and control. Herein, we propose a scientifically informed advocacy agenda developed at the International Childhood TB meeting held in Stockholm, Sweden, from March 17 to 18, 2011, which calls for a renewed effort to improve the situation for children affected by Mycobacterium tuberculosis exposure, infection or disease. The challenges and needs in childhood TB are universal and apply to all settings and must be addressed more effectively by all stakeholders.
C1 [Sandgren, Andreas; Manissero, Davide] European Ctr Dis Prevent & Control, S-17183 Stockholm, Sweden.
   [Cuevas, Luis E.] World Bank, UNICEF, UNDP, WHO Special Programme Res & Training Trop Dis, Geneva, Switzerland.
   [Dara, Masoud] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark.
   [Gie, Robert P.; Hesseling, Anneke C.] Univ Stellenbosch, Fac Hlth Sci, Dept Paediat & Child Hlth, Desmond Tutu TB Ctr, ZA-7600 Stellenbosch, South Africa.
   [Grzemska, Malgorzata; Lienhardt, Christian] WHO, Stop TB Dept, Stop TB Partnership, CH-1211 Geneva, Switzerland.
   [Hawkridge, Anthony] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
   [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London, England.
   [Wingfield, Claire] Treatment Act Grp, New York, NY USA.
   [Kampmann, Beate] The Gambia, Med Res Council Unit, Banjul, Gambia.
   [Graham, Stephen M.] Univ Melbourne, Dept Paediat, Ctr Int Child Hlth, Melbourne, Vic, Australia.
   [Graham, Stephen M.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Graham, Stephen M.] Int Union TB & Lung Dis, Paris, France.
RP Sandgren, A (reprint author), European Ctr Dis Prevent & Control, Tomtebodavagen 11A, S-17183 Stockholm, Sweden.
EM andreas.sandgren@ecdc.europa.eu
OI Cuevas, Luis E./0000-0002-6581-0587; Kampmann, Beate/0000-0002-6546-4709
FU European Centre for Disease Prevention and Control (Stockholm, Sweden);
   Childhood TB subgroup
FX L. E. Cuevas, M. Grzemska and C. Lienhardt are staff of the World Health
   Organization. The authors of this paper alone are responsible for the
   views expressed in this publication which do not necessarily represent
   the decisions or policies of the World Health Organization. R. P. Gie,
   A. Hawkridge, A. C. Hesseling, B. Kampmann, C. Lienhardt, C. Wingfield
   and S. M. Graham received support from the European Centre for Disease
   Prevention and Control (Stockholm, Sweden) or the Childhood TB subgroup,
   Stop TB Partnership (Geneva, Switzerland) for travel and accommodation
   to attend the International Childhood TB meeting.
CR Burman WJ, 2008, PLOS MED, V5, P1168, DOI 10.1371/journal.pmed.0050176
   Frydenberg AR, 2009, TROP MED INT HEALTH, V14, P1329, DOI 10.1111/j.1365-3156.2009.02375.x
   Gupta A, 2007, CLIN INFECT DIS, V45, P241, DOI 10.1086/518974
   Gupta A, 2011, J INFECT DIS, V203, P358, DOI 10.1093/infdis/jiq064
   Harrington M, 2010, CLIN INFECT DIS, V50, pS260, DOI 10.1086/651500
   Hesseling AC, 2009, B WORLD HEALTH ORGAN, V87, P505, DOI 10.2471/BLT.08.055657
   Jones C, 2011, PAEDIATR RESPIR REV, V12, P3, DOI 10.1016/j.prrv.2010.09.006
   Kaufmann SHE, 2010, IMMUNITY, V33, P567, DOI 10.1016/j.immuni.2010.09.015
   Nelson LJ, 2004, INT J TUBERC LUNG D, V8, P636
   Stop TB Partnership, CALL ACT CHILDH TB
   Stop TB Partnership, CALL ACT CHILDH TB J
   Swaminathan S, 2010, CLIN INFECT DIS, V50, pS184, DOI 10.1086/651490
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
   World Health Organization, 2004, WKLY EPIDEMIOL REC, V79, P27
   World Health Organization, 2006, WHOHTMTB2006371
   World Health Organization, 2010, WHOHTMTB201013
   [Anonymous], 2007, WKLY EPIDEMIOL REC, V82, P193
   [Anonymous], 2011, US PRESIDENTS EMERGE
NR 18
TC 29
Z9 30
U1 0
U2 5
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
J9 EUR RESPIR J
JI Eur. Resp. J.
PD AUG
PY 2012
VL 40
IS 2
BP 294
EP 297
DI 10.1183/09031936.00187711
PG 4
WC Respiratory System
SC Respiratory System
GA 985SZ
UT WOS:000307291700005
PM 22337859
OA No
DA 2017-08-15
ER

PT J
AU Kattenberg, JH
   Tahita, CM
   Versteeg, IAJ
   Tinto, H
   Coulibaly, MT
   D'Alessandro, U
   Schallig, HDFH
   Mens, PF
AF Kattenberg, Johanna H.
   Tahita, Christian M.
   Versteeg, Inge A. J.
   Tinto, Halidou
   Coulibaly, Maminata Traore
   D'Alessandro, Umberto
   Schallig, Henk D. F. H.
   Mens, Petra F.
TI Evaluation of Antigen Detection Tests, Microscopy, and Polymerase Chain
   Reaction for Diagnosis of Malaria in Peripheral Blood in Asymptomatic
   Pregnant Women in Nanoro, Burkina Faso
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM; PCR
AB Rapid diagnostics tests (RDTs) detect malaria specific antigen(s) in the circulation, even when parasites are sequestered in the placenta and not visible by microscopy. However, research on their diagnostic accuracy during pregnancy is limited. Pregnant women (n = 418) were screened for malaria during routine antenatal care by using two RDTs that detect histidine-rich protein 2 (HRP2) or Plasmodium lactate dehydrogenase, and enzyme-linked immunosorbent assays with antibodies that detect dihydrofolate reductase-thymidylate synthase or heme-detoxification protein, and compared with real-time polymerase chain reaction (RT-PCR) and microscopy for evaluation of their diagnostic accuracy. Prevalence of malaria infection was high (53% by PCR). The RT-PCR and the HRP2 RDT detected most cases of malaria during pregnancy, whereas microscopy, the Plasmodium lactate dehydrogenase RDT, and enzyme-linked immunosorbent assays for dihydrofolate reductase-thymidylate synthase and heme-detoxification protein antibodies did not detect several low-density infections. Therefore, the HRP2 RDT could be a useful tool in high-transmission areas for diagnosis of malaria in asymptomatic pregnant women.
C1 Koninklijk Inst Tropen Biomed Res, Royal Trop Inst, Koninklijk Inst Tropen, Amsterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun, NL-1105 AZ Amsterdam, Netherlands.
   [Coulibaly, Maminata Traore] Inst Rech Sci Sante, Direct Reg Ouest, Ctr Muraz, Dept Mephatra Pharm, Bobo Dioulasso, Burkina Faso.
   [D'Alessandro, Umberto] MRC, Banjul, Gambia.
RP Kattenberg, JH (reprint author), Meibergdreef 39, NL-1105 AZ Amsterdam, Netherlands.
EM e.kattenberg@kit.nl; marctahita@yahoo.fr; I.Versteeg@KIT.nl;
   tintohalidou@yahoo.fr; traore_maminata@yahoo.fr; H.Schallig@KIT.nl;
   P.Mens@KIT.nl
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU European-Developing Countries Clinical Trials Programme; Belgian
   Cooperation; Sanofi S. A. (Paris, France)
FX The PREGACT-trial in Burkina Faso was supported by the
   European-Developing Countries Clinical Trials Programme, the Belgian
   Cooperation, and Sanofi S. A. (Paris, France). Johanna H. Kattenberg is
   supported by the Foundation for Innovative New Diagnostics in a
   collaborative effort for improvement of malaria diagnosis.
CR Arango Eliana, 2010, Rev Bras Epidemiol, V13, P373, DOI 10.1590/S1415-790X2010000300002
   Baker J, 2005, J INFECT DIS, V192, P870, DOI 10.1086/432010
   BANOO S, 2006, NAT REV MICROBIOL S, V4, pS20, DOI DOI 10.1038/NRMICRO1570
   Bell D, 2006, NAT REV MICROBIOL, V4, P682, DOI 10.1038/nrmicro1474
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hartman TK, 2010, ANN TROP PAEDIATR, V30, P271, DOI 10.1179/146532810X12858955921032
   Hermsen CC, 2001, MOL BIOCHEM PARASIT, V118, P247, DOI 10.1016/S0166-6851(01)00379-6
   Kattenberg JH, 2012, TROP MED INT HEALTH, V17, P550, DOI 10.1111/j.1365-3156.2012.02975.x
   Kattenberg JH, 2012, MABS-AUSTIN, V4, P120, DOI 10.4161/mabs.4.1.18529
   Kattenberg JH, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-321
   McGready R, 2004, AM J TROP MED HYG, V70, P398
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   Nosten F, 2004, TRENDS PARASITOL, V20, P425, DOI 10.1016/j.pt.2004.06.007
   Nosten F, 1999, LANCET, V354, P546, DOI 10.1016/S0140-6736(98)09247-2
   Perkins MD, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S5
   Rogerson SJ, 2007, LANCET INFECT DIS, V7, P105, DOI 10.1016/S1473-3099(07)70022-1
   Tagbor H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014425
   Uneke CJ, 2008, PARASITOL RES, V102, P333, DOI 10.1007/s00436-007-0782-6
   Wang CW, 2009, PARASITOL INT, V58, P478, DOI 10.1016/j.parint.2009.07.004
   WHO, 2008, MAL RAP DIAGN TEST P
   WHO, 2010, BAS MAL MICR 1
   WHO. World Health Organization, 2009, MAL RAP DIAGN TEST P
NR 24
TC 14
Z9 15
U1 0
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD AUG
PY 2012
VL 87
IS 2
BP 251
EP 256
DI 10.4269/ajtmh.2012.12-0125
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 984QA
UT WOS:000307204900010
PM 22859362
OA No
DA 2017-08-15
ER

PT J
AU Edwards, MD
   Morris, GAJ
   Burr, SE
   Walther, M
AF Edwards, Mathew D.
   Morris, Gerard A. J.
   Burr, Sarah E.
   Walther, Michael
TI Evaluating the frequency of bacterial co-infections in children
   recruited into a malaria pathogenesis study in The Gambia, West Africa
   using molecular methods
SO MOLECULAR AND CELLULAR PROBES
LA English
DT Article
DE Bacterial co-infection; Malaria; Pneumonia; Molecular diagnosis
ID POLYMERASE-CHAIN-REACTION; 16S RIBOSOMAL-RNA; REAL-TIME PCR;
   QUANTITATIVE DETECTION; GEL-ELECTROPHORESIS; FALCIPARUM-MALARIA; KENYAN
   CHILDREN; BACTEREMIA; DNA; BLOOD
AB Systemic bacteraemia has been reported in children with severe Plasmodium falciparum malaria in Sub Saharan Africa, making the identification or exclusion of concurrent infections a prerequisite for adequate treatment and studies of the immune responses to particular infections. Given the overlap in clinical signs in humans between malaria and, for example, pneumonia, the true cause of severe illness is sometimes difficult to establish. Traditional microbiological culture methods employed to detect systemic bactereamia are often time consuming and have modest sensitivity. Therefore, molecular methods have become increasingly used in the diagnosis of septicaemia. Here, we evaluated the usefulness of both broad-range 16S rRNA PCR, in conjunction with DNA sequencing and species-specific PCR targeting of Streptococcus pneumoniae and non-typhoidal Salmonella, to screen for bacterial co-infections in blood samples from children enrolled in a malaria pathogenesis study. PCR revealed no test-positive results for these pathogens and DNA sequencing of 16S rRNA amplicons identified the presence of bacterial genomic DNA (most probably from environmental bacterial sources) in a large proportion of samples. We demonstrate that the issue of potential mixed bacteraemic infection and/or background bacterial genomic DNA, which may relate to co-migration of PCR amplicons on agarose gels, can be overcome by using denaturing gradient gel electrophoresis (DGGE). PCR for Plasmodium spp. was also performed on genomic DNA from bloods from Gambian children with pneumonia, in order to estimate the prevalence of Plasmodium/pneumonia co-infections in the study population. While 12.2% of samples were test-positive, parasite density was very low and did not vary significantly between cases and controls. Published by Elsevier lid.
C1 [Edwards, Mathew D.; Morris, Gerard A. J.; Burr, Sarah E.; Walther, Michael] The Gambia, Med Res Council Unit, Banjul, Gambia.
   [Edwards, Mathew D.] Univ Manchester, Manchester M13 9PL, Lancs, England.
   [Burr, Sarah E.] Univ London London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 7HT, England.
RP Walther, M (reprint author), NIAID, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.
EM Michael.Walther@nih.gov
FU Medical Research Council Unit, The Gambia
FX The study was funded by the Medical Research Council Unit, The Gambia.
   We thank the clinical study teams of the MRC the Gambia Malaria Research
   Programme and the Bacterial Disease Programme for collecting and
   providing the samples, and Mr. Nuru Adams (MRC The Gambia) for the
   extraction of genomic DNAs.
CR Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X
   Bassat Q, 2009, TROP MED INT HEALTH, V14, P1011, DOI 10.1111/j.1365-3156.2009.02326.x
   Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299
   Brent AJ, 2006, PEDIATR INFECT DIS J, V25, P230, DOI 10.1097/01.inf.0000202066.02212.ff
   Bronzan RN, 2007, J INFECT DIS, V195, P895, DOI 10.1086/511437
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Ceesay SJ, 2010, PLOS ONE, V5
   Chakravorty S, 2007, J MICROBIOL METH, V69, P330, DOI 10.1016/j.mimet.2007.02.005
   Chan YR, 2007, CURR OPIN INFECT DIS, V20, P157, DOI 10.1097/QCO.0b013e32808255f1
   Cherkaoui A, 2009, J MICROBIOL METH, V79, P227, DOI 10.1016/j.mimet.2009.09.014
   FISCHER SG, 1979, CELL, V16, P191, DOI 10.1016/0092-8674(79)90200-9
   Fujimori M, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-53
   Goldenberger D, 1997, J CLIN MICROBIOL, V35, P2733
   Gomez-Escobar N, 2010, J INFECT DIS, V201, P444, DOI 10.1086/649902
   Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700
   IRALU JV, 1993, J CLIN MICROBIOL, V31, P1811
   Jayasooriya S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031142
   Kallander K, 2004, ACTA TROP, V90, P211, DOI 10.1016/j.actatropica.2003.11.013
   Laiakis EC, 2010, PLOS ONE, V5
   MacKenzie G, 2010, PLOS ONE, V5
   Malorny B, 2004, APPL ENVIRON MICROB, V70, P7046, DOI 10.1128/AEM.70.12.7046-7052.2004
   Matsuda K, 2007, APPL ENVIRON MICROB, V73, P32, DOI 10.1128/AEM.01224-06
   Metenou S, 2011, J IMMUNOL, V186, P4725, DOI 10.4049/jimmunol.1003778
   Millar BC, 2002, J CLIN MICROBIOL, V40, P1575, DOI 10.1128/JCM.40.5.1575-1580.2002
   Morris GAJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001773
   Muhl H, 2010, DIAGN MICR INFEC DIS, V66, P41, DOI 10.1016/j.diagmicrobio.2008.07.011
   MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695
   Nwakanma DC, 2009, J INFECT DIS, V199, P1567, DOI 10.1086/598856
   O'Meara WP, 2008, LANCET, V372, P1555, DOI 10.1016/S0140-6736(08)61655-4
   Okiro EA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-151
   Rayner MG, 1998, JAMA-J AM MED ASSOC, V279, P296, DOI 10.1001/jama.279.4.296
   Ritchie LMP, 2009, INT J TUBERC LUNG D, V13, P527
   Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004
   Satoguina J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-274
   Scott JAG, 2011, LANCET, V378, P1316, DOI 10.1016/S0140-6736(11)60888-X
   Shafazand S, 2002, CHEST, V122, P1727, DOI 10.1378/chest.122.5.1727
   SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232
   Smith-Vaughan H, 2006, BMC EAR NOSE THROAT, V6, DOI 10.1186/1472-6815-6-10
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   SONG JH, 1993, J CLIN MICROBIOL, V31, P1439
   Struik SS, 2005, NAT IMMUNOL, V6, P423, DOI 10.1038/ni0505-423
   Walther B, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-16
   Walther M, 2009, PLOS PATHOG, V5
   WEISBURG WG, 1991, J BACTERIOL, V173, P697
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
   Wintzingerode Friedrich V., 1997, FEMS Microbiology Reviews, V21, P213
NR 46
TC 3
Z9 3
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0890-8508
J9 MOL CELL PROBE
JI Mol. Cell. Probes
PD AUG
PY 2012
VL 26
IS 4
BP 151
EP 158
DI 10.1016/j.mcp.2012.04.003
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology; Cell Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Cell Biology
GA 963XQ
UT WOS:000305658700002
PM 22548974
OA No
DA 2017-08-15
ER

PT J
AU Noulin, F
   Borlon, C
   van den Eede, P
   Boel, L
   Verfaillie, CM
   D'Alessandro, U
   Erhart, A
AF Noulin, Florian
   Borlon, Celine
   van den Eede, Peter
   Boel, Luc
   Verfaillie, Catherine M.
   D'Alessandro, Umberto
   Erhart, Annette
TI Cryopreserved Reticulocytes Derived from Hematopoietic Stem Cells Can Be
   Invaded by Cryopreserved Plasmodium vivax Isolates
SO PLOS ONE
LA English
DT Article
ID RED-BLOOD-CELLS; FALCIPARUM; MALARIA; CHLOROQUINE; RESISTANCE;
   GENERATION; INVASION
AB The development of a system for the continuous culture of Plasmodium vivax in vitro would benefit from the use of reticulocytes derived from differentiated hematopoietic stem cells (HCS). At present, the need to use both fresh reticulocytes and fresh P. vivax isolates represents a major obstacle towards this goal, particularly for laboratories located in non-endemic countries. Here, we describe a new method for the cryopreservation of HSC-derived reticulocytes to be used for both P. falciparum and P. vivax invasion tests. Cryopreserved P. falciparum and P. vivax isolates could invade both fresh and cryopreserved HSC-derived reticulocytes with similar efficiency. This new technique allows the storage of HSC-derived reticulocytes which can be used for later invasion tests and represents an important step towards the establishment of a continuous P. vivax culture.
C1 [Noulin, Florian; Borlon, Celine; van den Eede, Peter; D'Alessandro, Umberto; Erhart, Annette] Inst Trop Med Antwerp, Unit Malariol, Antwerp, Belgium.
   [Boel, Luc] Inst Trop Med Antwerp, Immunol Unit, Antwerp, Belgium.
   [Noulin, Florian; Verfaillie, Catherine M.] Katholieke Univ Leuven, Stem Cells Inst, Louvain, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
RP Noulin, F (reprint author), Inst Trop Med Antwerp, Unit Malariol, Antwerp, Belgium.
EM fnoulin@itg.be
RI noulin, florian/J-3809-2013; D'Alessandro, Umberto/D-3457-2015
OI noulin, florian/0000-0001-7430-8073; Verfaillie,
   Catherine/0000-0001-7564-4079; D'Alessandro, Umberto/0000-0001-6341-5009
FU ITM Secondary Research Funding (SOFI-B) [755023]
FX Funding was provided by ITM Secondary Research Funding (SOFI-B),
   http://www.itg.be/itgtool_v2/Projecten/Project.asp?PNr=755023. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   DIGGS C, 1975, AM J TROP MED HYG, V24, P760
   Douay Luc, 2009, V482, P127, DOI 10.1007/978-1-59745-060-7_8
   Giarratana MC, 2005, NAT BIOTECHNOL, V23, P69, DOI 10.1038/nbt1047
   Giarratana MC, 2011, BLOOD
   GOLDMAN JM, 1978, BRIT J HAEMATOL, V40, P185, DOI 10.1111/j.1365-2141.1978.tb03656.x
   Golenda CF, 1997, P NATL ACAD SCI USA, V94, P6786, DOI 10.1073/pnas.94.13.6786
   Guerra CA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000774
   Laine J, 2007, CURR PROTOC STEM CEL, DOI [10.1002/9780470151808.sc02a02s1, DOI 10.1002/9780470151808.SC02A02S1]
   KLEIHAUER E, 1957, KLIN WOCHENSCHR, V35, P637, DOI 10.1007/BF01481043
   Kosaisavee V, 2006, EXP PARASITOL, V114, P34, DOI 10.1016/j.exppara.2006.02.006
   LAFOREST J, 1968, Revue Francaise de Transfusion, V11, P23, DOI 10.1016/S0035-2977(68)80078-1
   LORETZ LJ, 1989, XENOBIOTICA, V19, P489
   MECHETNER EB, 1991, AM J HEMATOL, V38, P61, DOI 10.1002/ajh.2830380110
   MONS B, 1990, BLOOD CELLS, V16, P299
   Nienhuis AW, 1979, METHODS CELL SCI, V1, P111
   Panichakul Tasanee, 2007, Int J Parasitol, V37, P1551, DOI 10.1016/j.ijpara.2007.05.009
   PASVOL G, 1982, LANCET, V2, P947
   Prajapati SK, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-102
   Price RN, 2009, CURR OPIN INFECT DIS, V22, P430, DOI 10.1097/QCO.0b013e32832f14c1
   Rayner JC, 2001, J EXP MED, V194, P1571, DOI 10.1084/jem.194.11.1571
   RIVADENEIRA EM, 1983, J PROTOZOOL, V30, P367, DOI 10.1111/j.1550-7408.1983.tb02932.x
   ROSSAN RN, 1985, AM J TROP MED HYG, V34, P207
   Russell B, 2011, BLOOD
   Sriprawat K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-115
   Tamez PA, 2009, BLOOD, V114, P3652, DOI 10.1182/blood-2009-07-231894
   Tjitra E, 2008, PLOS MED, V5, P890, DOI 10.1371/journal.pmed.0050128
   Tsiftsoglou AS, 2009, IUBMB LIFE, V61, P800, DOI 10.1002/iub.226
   Udomsangpetch R, 2007, PARASITOL INT, V56, P65, DOI 10.1016/j.parint.2006.12.005
   Yohannes AM, 2011, AM J TROP MED HYG, V84, P137, DOI 10.4269/ajtmh.2011.09-0723
NR 31
TC 12
Z9 12
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 23
PY 2012
VL 7
IS 7
AR e40798
DI 10.1371/journal.pone.0040798
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 977TM
UT WOS:000306687700018
PM 22844411
OA gold
DA 2017-08-15
ER

PT J
AU Manske, M
   Miotto, O
   Campino, S
   Auburn, S
   Almagro-Garcia, J
   Maslen, G
   O'Brien, J
   Djimde, A
   Doumbo, O
   Zongo, I
   Ouedraogo, JB
   Michon, P
   Mueller, I
   Siba, P
   Nzila, A
   Borrmann, S
   Kiara, SM
   Marsh, K
   Jiang, H
   Su, XZ
   Amaratunga, C
   Fairhurst, R
   Socheat, D
   Nosten, F
   Imwong, M
   White, NJ
   Sanders, M
   Anastasi, E
   Alcock, D
   Drury, E
   Oyola, S
   Quail, MA
   Turner, DJ
   Ruano-Rubio, V
   Jyothi, D
   Amenga-Etego, L
   Hubbart, C
   Jeffreys, A
   Rowlands, K
   Sutherland, C
   Roper, C
   Mangano, V
   Modiano, D
   Tan, JC
   Ferdig, MT
   Amambua-Ngwa, A
   Conway, DJ
   Takala-Harrison, S
   Plowe, CV
   Rayner, JC
   Rockett, KA
   Clark, TG
   Newbold, CI
   Berriman, M
   MacInnis, B
   Kwiatkowski, DP
AF Manske, Magnus
   Miotto, Olivo
   Campino, Susana
   Auburn, Sarah
   Almagro-Garcia, Jacob
   Maslen, Gareth
   O'Brien, Jack
   Djimde, Abdoulaye
   Doumbo, Ogobara
   Zongo, Issaka
   Ouedraogo, Jean-Bosco
   Michon, Pascal
   Mueller, Ivo
   Siba, Peter
   Nzila, Alexis
   Borrmann, Steffen
   Kiara, Steven M.
   Marsh, Kevin
   Jiang, Hongying
   Su, Xin-Zhuan
   Amaratunga, Chanaki
   Fairhurst, Rick
   Socheat, Duong
   Nosten, Francois
   Imwong, Mallika
   White, Nicholas J.
   Sanders, Mandy
   Anastasi, Elisa
   Alcock, Dan
   Drury, Eleanor
   Oyola, Samuel
   Quail, Michael A.
   Turner, Daniel J.
   Ruano-Rubio, Valentin
   Jyothi, Dushyanth
   Amenga-Etego, Lucas
   Hubbart, Christina
   Jeffreys, Anna
   Rowlands, Kate
   Sutherland, Colin
   Roper, Cally
   Mangano, Valentina
   Modiano, David
   Tan, John C.
   Ferdig, Michael T.
   Amambua-Ngwa, Alfred
   Conway, David J.
   Takala-Harrison, Shannon
   Plowe, Christopher V.
   Rayner, Julian C.
   Rockett, Kirk A.
   Clark, Taane G.
   Newbold, Chris I.
   Berriman, Matthew
   MacInnis, Bronwyn
   Kwiatkowski, Dominic P.
TI Analysis of Plasmodium falciparum diversity in natural infections by
   deep sequencing
SO NATURE
LA English
DT Article
ID PAPUA-NEW-GUINEA; MALARIA PARASITE; LIBRARY PREPARATION; GENOME;
   RESISTANCE; TRANSMISSION; POLYMORPHISM; EVOLUTION; SELECTION; PATTERNS
AB Malaria elimination strategies require surveillance of the parasite population for genetic changes that demand a public health response, such as new forms of drug resistance(1,2). Here we describe methods for the large-scale analysis of genetic variation in Plasmodium falciparum by deep sequencing of parasite DNA obtained from the blood of patients with malaria, either directly or after short-term culture. Analysis of 86,158 exonic single nucleotide polymorphisms that passed genotyping quality control in 227 samples from Africa, Asia and Oceania provides genome-wide estimates of allele frequency distribution, population structure and linkage disequilibrium. By comparing the genetic diversity of individual infections with that of the local parasite population, we derive a metric of within-host diversity that is related to the level of inbreeding in the population. An open-access web application has been established for the exploration of regional differences in allele frequency and of highly differentiated loci in the P. falciparum genome.
C1 [Manske, Magnus; Campino, Susana; Auburn, Sarah; Almagro-Garcia, Jacob; Maslen, Gareth; Sanders, Mandy; Anastasi, Elisa; Alcock, Dan; Drury, Eleanor; Oyola, Samuel; Quail, Michael A.; Turner, Daniel J.; Ruano-Rubio, Valentin; Jyothi, Dushyanth; Rayner, Julian C.; Rockett, Kirk A.; Clark, Taane G.; Newbold, Chris I.; Berriman, Matthew; MacInnis, Bronwyn; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
   [Manske, Magnus; Miotto, Olivo; Campino, Susana; Auburn, Sarah; Almagro-Garcia, Jacob; Maslen, Gareth; O'Brien, Jack; Ruano-Rubio, Valentin; Jyothi, Dushyanth; Amenga-Etego, Lucas; Rockett, Kirk A.; Clark, Taane G.; Newbold, Chris I.; MacInnis, Bronwyn; Kwiatkowski, Dominic P.] Univ Oxford, MRC Ctr Genom & Global Hlth, Oxford OX3 7BN, England.
   [Miotto, Olivo; Nosten, Francois; White, Nicholas J.] Mahidol Univ, Mahidol Oxford Trop Med Res Unit, Bangkok 10400, Thailand.
   [Auburn, Sarah] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0811, Australia.
   [Almagro-Garcia, Jacob; O'Brien, Jack; Ruano-Rubio, Valentin; Amenga-Etego, Lucas; Hubbart, Christina; Jeffreys, Anna; Rowlands, Kate; Rockett, Kirk A.; Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Djimde, Abdoulaye; Doumbo, Ogobara] Univ Bamako, Fac Med, Malaria Res & Training Ctr, Bamako, Mali.
   [Zongo, Issaka; Ouedraogo, Jean-Bosco] Inst Rech Sci Sante, Direct Reg Ouest, Bobo Dioulasso, Burkina Faso.
   [Michon, Pascal; Mueller, Ivo; Siba, Peter] Papua New Guinea Inst Med Res, Madang 511, Papua N Guinea.
   [Nzila, Alexis; Borrmann, Steffen; Kiara, Steven M.; Marsh, Kevin] KEMRI Wellcome Trust Res Program, Kilifi, Kenya.
   [Jiang, Hongying; Su, Xin-Zhuan; Amaratunga, Chanaki; Fairhurst, Rick] Nat Inst Allergy & Infect Dis, NIH, Rockville, MD 20892 USA.
   [Socheat, Duong] Cambodia Natl Malaria Ctr, Phnom Penh, Cambodia.
   [Nosten, Francois] Shoklo Malaria Res Unit, Mae Sot 63110, Tak, Thailand.
   [Nosten, Francois; White, Nicholas J.] Univ Oxford, Ctr Trop Med, Oxford OX3 7LJ, England.
   [Imwong, Mallika] Mahidol Univ, Fac Trop Med, Dept Mol Trop Med & Genet, Bangkok 10400, Thailand.
   [Amenga-Etego, Lucas] Navrongo Hlth Ctr, Navrongo, Ghana.
   [Sutherland, Colin; Roper, Cally; Conway, David J.; Clark, Taane G.] London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Mangano, Valentina; Modiano, David] Univ Roma La Sapienza, Dept Publ Hlth Sci, I-00185 Rome, Italy.
   [Tan, John C.; Ferdig, Michael T.] Univ Notre Dame, Eck Inst Global Hlth, Dept Biol Sci, Notre Dame, IN 46556 USA.
   [Amambua-Ngwa, Alfred; Conway, David J.] MRC Labs, Fajara, Gambia.
   [Takala-Harrison, Shannon; Plowe, Christopher V.] Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Newbold, Chris I.] Univ Oxford, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
RP Kwiatkowski, DP (reprint author), Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
EM dominic@sanger.ac.uk
RI ; mangano, valentina/I-2456-2012; White, Nicholas/I-4629-2012; Mueller,
   Ivo/C-7251-2013; Borrmann, Steffen/G-1838-2013; Roper,
   Cally/K-2989-2013; Ferdig, Michael/C-6627-2016; Jyothi,
   Dushyanth/H-9517-2014
OI Oyola, Samuel O./0000-0002-6425-7345; Rayner,
   Julian/0000-0002-9835-1014; Su, Xinzhuan/0000-0003-3246-3248;
   Kwiatkowski, Dominic/0000-0002-5023-0176; Manske,
   Magnus/0000-0001-5916-0947; Nosten, Francois/0000-0002-7951-0745;
   Auburn, Sarah/0000-0002-4638-536X; Conway, David/0000-0002-8711-3037;
   Mueller, Ivo/0000-0001-6554-6889; Borrmann, Steffen/0000-0001-9189-4393;
   Roper, Cally/0000-0002-6545-309X; Jyothi, Dushyanth/0000-0002-0448-5303;
   Mangano, Valentina D/0000-0002-2021-6162; Newbold,
   Chris/0000-0002-9274-3789; Miotto, Olivo/0000-0001-8060-6771
FU Wellcome Trust through Sanger Institute [077012/Z/05/Z, 098051,
   090770/Z/09/Z]; Medical Research Council (MRC) through the MRC Centre
   for Genomics and Global Health [G0600718]; MRC [G19/9]; Wellcome Trust
   [075491/Z/04, 090532/Z/09/Z]; Division of Intramural Research, National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health; Howard Hughes Medical Institute [55005502]
FX We thank G. Dougan and N. Day for support, and T. Anderson and M.
   Mackinnon for comments. The sequencing and analysis components of this
   study were supported by the Wellcome Trust through Sanger Institute core
   funding (077012/Z/05/Z; 098051) and a Strategic Award (090770/Z/09/Z);
   the Medical Research Council (MRC) through the MRC Centre for Genomics
   and Global Health (G0600718) and an MRC Professorship to D.P.K. (G19/9).
   Other parts of this study were partly supported by the Wellcome Trust
   including core support to the Wellcome Trust Centre for Human Genetics
   (075491/Z/04; 090532/Z/09/Z); the Division of Intramural Research,
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health; and a Howard Hughes Medical Institute
   International Scholarship (55005502) to A.D.
CR Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   Anthony TG, 2007, MOL BIOCHEM PARASIT, V156, P117, DOI 10.1016/j.moibiopara.2007.07.008
   Auburn S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032891
   Auburn S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022213
   Boisson B, 2011, MOL MICROBIOL, V81, P1343, DOI 10.1111/j.1365-2958.2011.07767.x
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Dye C, 1997, P ROY SOC B-BIOL SCI, V264, P61
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Hartl DL, 2007, PRINCIPLES POPULATIO
   HILL WG, 1995, GENET RES, V65, P53
   Jeffares DC, 2007, NAT GENET, V39, P120, DOI 10.1038/ng1931
   Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449
   Kozarewa I, 2009, NAT METHODS, V6, P291, DOI [10.1038/nmeth.1311, 10.1038/NMETH.1311]
   Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717
   Martin RE, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-3-r26
   Mehlotra RK, 2001, P NATL ACAD SCI USA, V98, P12689, DOI 10.1073/pnas.221440898
   Mu JB, 2007, NAT GENET, V39, P126, DOI 10.1038/ng1924
   Mu JB, 2010, NAT GENET, V42, P268, DOI 10.1038/ng.528
   Neafsey DE, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r171
   Oyola SO, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-1
   PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897
   Paul REL, 1999, T ROY SOC TROP MED H, V93, P587, DOI 10.1016/S0035-9203(99)90057-3
   Prugnolle F, 2010, P NATL ACAD SCI USA, V107, P1458, DOI 10.1073/pnas.0914440107
   Schultz L, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-336
   Smith DL, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1107
   Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351
   Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x
   van Dijk MR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000853
   Volkman SK, 2007, NAT GENET, V39, P113, DOI 10.1038/ng1930
   Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813
NR 30
TC 178
Z9 178
U1 0
U2 51
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD JUL 19
PY 2012
VL 487
IS 7407
BP 375
EP 379
DI 10.1038/nature11174
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 975JB
UT WOS:000306506500045
PM 22722859
OA No
DA 2017-08-15
ER

PT J
AU Merrick, CJ
   Huttenhower, C
   Buckee, C
   Amambua-Ngwa, A
   Gomez-Escobar, N
   Walther, M
   Conway, DJ
   Duraisingh, MT
AF Merrick, Catherine J.
   Huttenhower, Curtis
   Buckee, Caroline
   Amambua-Ngwa, Alfred
   Gomez-Escobar, Natalia
   Walther, Michael
   Conway, David J.
   Duraisingh, Manoj T.
TI Epigenetic Dysregulation of Virulence Gene Expression in Severe
   Plasmodium falciparum Malaria (vol 205, pg 1593, 2012)
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Correction
C1 [Merrick, Catherine J.; Duraisingh, Manoj T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Huttenhower, Curtis] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Buckee, Caroline] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Amambua-Ngwa, Alfred; Gomez-Escobar, Natalia; Walther, Michael; Conway, David J.] MRC Labs, Banjul, Gambia.
RP Merrick, CJ (reprint author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.
CR Merrick CJ, 2012, J INFECT DIS, V205, P1593, DOI 10.1093/infdis/jis239
NR 1
TC 0
Z9 0
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 15
PY 2012
VL 206
IS 2
BP 306
EP 306
DI 10.1093/infdis/jis370
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 963MX
UT WOS:000305626200022
OA No
DA 2017-08-15
ER

PT J
AU Dicks, MDJ
   Spencer, AJ
   Edwards, NJ
   Wadell, G
   Bojang, K
   Gilbert, SC
   Hill, AVS
   Cottingham, MG
AF Dicks, Matthew D. J.
   Spencer, Alexandra J.
   Edwards, Nick J.
   Wadell, Goran
   Bojang, Kalifa
   Gilbert, Sarah C.
   Hill, Adrian V. S.
   Cottingham, Matthew G.
TI A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence:
   Improved Systems for Vector Derivation and Comparative Immunogenicity
SO PLOS ONE
LA English
DT Article
ID PRIME-BOOST IMMUNIZATION; VACCINE VECTOR; CIRCUMSPOROZOITE PROTEIN;
   HOMOLOGOUS RECOMBINATION; NEUTRALIZING ANTIBODIES; PLASMODIUM-BERGHEI;
   HIV-1 VACCINE; T-CELLS; MALARIA; ANTIGEN
AB Recombinant adenoviruses are among the most promising tools for vaccine antigen delivery. Recently, the development of new vectors has focused on serotypes to which the human population is less exposed in order to circumvent preexisting anti vector immunity. This study describes the derivation of a new vaccine vector based on a chimpanzee adenovirus, Y25, together with a comparative assessment of its potential to elicit transgene product specific immune responses in mice. The vector was constructed in a bacterial artificial chromosome to facilitate genetic manipulation of genomic clones. In order to conduct a fair head-to-head immunological comparison of multiple adenoviral vectors, we optimised a method for accurate determination of infectious titre, since this parameter exhibits profound natural variability and can confound immunogenicity studies when doses are based on viral particle estimation. Cellular immunogenicity of recombinant E1 E3-deleted vector ChAdY25 was comparable to that of other species E derived chimpanzee adenovirus vectors including ChAd63, the first simian adenovirus vector to enter clinical trials in humans. Furthermore, the prevalence of virus neutralizing antibodies (titre >1:200) against ChAdY25 in serum samples collected from two human populations in the UK and Gambia was particularly low compared to published data for other chimpanzee adenoviruses. These findings support the continued development of new chimpanzee adenovirus vectors, including ChAdY25, for clinical use.
C1 [Dicks, Matthew D. J.; Spencer, Alexandra J.; Edwards, Nick J.; Gilbert, Sarah C.; Hill, Adrian V. S.; Cottingham, Matthew G.] Univ Oxford, Jenner Inst, Oxford, England.
   [Bojang, Kalifa] MRC Labs, Fajara, Gambia.
   [Wadell, Goran] Umea Univ, Dept Clin Microbiol, Umea, Sweden.
RP Dicks, MDJ (reprint author), Univ Oxford, Jenner Inst, Oxford, England.
EM matt.cottingham@ndm.ox.ac.uk
OI Dicks, Matthew/0000-0003-1909-7095; Gilbert, Sarah/0000-0002-6823-9750;
   Spencer, Alexandra/0000-0001-7958-6961; Edwards,
   Nick/0000-0002-7030-7839
FU Foundation for the National Institute of Health through the Grand
   Challenges in Global Health Initiative; Wellcome Trust; European Malaria
   Vaccine Development Association (EMVDA)
FX This work has been funded by grants from the Foundation for the National
   Institute of Health through the Grand Challenges in Global Health
   Initiative, with additional funding from the Wellcome Trust. MDJD
   received additional funding from the European Malaria Vaccine
   Development Association (EMVDA). MGC is a fellow of the Oxford Martin
   School Institute for Vaccine Design. SCG is a Jenner Investigator. AVSH
   is Director of the Jenner Institute and a Wellcome Trust Principal
   Research Fellow. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alcock R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000490
   Bewig B, 2000, BIOTECHNIQUES, V28, P870
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Capone S, 2010, VACCINE, V29, P256, DOI 10.1016/j.vaccine.2010.10.041
   Chartier C, 1996, J VIROL, V70, P4805
   Chen H, 2010, J VIROL, V84, P10522, DOI 10.1128/JVI.00450-10
   Colloca S, 2012, SCI TRANSL MED, V4, DOI DOI 10.1126/SCITRANSLMED.3002925
   Cottingham MG, 2012, BIOTECHNOL BIOENG, V109, P719, DOI 10.1002/bit.24342
   Draper SJ, 2010, J IMMUNOL, V185, P7583, DOI 10.4049/jimmunol.1001760
   Draper SJ, 2010, NAT REV MICROBIOL, V8, P62, DOI 10.1038/nrmicro2240
   Dudareva M, 2009, VACCINE, V27, P3501, DOI 10.1016/j.vaccine.2009.03.080
   Dunachie SJ, 2006, INFECT IMMUN, V74, P5933, DOI 10.1128/IAI.00590-06
   Ersching J, 2010, VIROLOGY, V407, P1, DOI 10.1016/j.virol.2010.07.043
   Fan ZC, 2008, J VIROL METHODS, V149, P309, DOI 10.1016/j.jviromet.2008.01.011
   Farina SF, 2001, J VIROL, V75, P11603, DOI 10.1128/JVI.75.23.11603-11613.2001
   Fitzgerald JC, 2003, J IMMUNOL, V170, P1416
   Goodman AL, 2010, INFECT IMMUN, V78, P4601, DOI 10.1128/IAI.00315-10
   Havenga M, 2006, J GEN VIROL, V87, P2135, DOI 10.1099/vir.0.81956-0
   HILLIS WD, 1969, J IMMUNOL, V103, P1089
   Kanopka A, 1998, NATURE, V393, P185
   Larsen KC, 2009, VACCINE, V27, P5589, DOI 10.1016/j.vaccine.2009.07.025
   Lin JP, 2010, VACCINE, V28, P5669, DOI 10.1016/j.vaccine.2010.06.053
   Louis N, 1997, VIROLOGY, V233, P423, DOI 10.1006/viro.1997.8597
   MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9
   Mannervik M, 1999, VIROLOGY, V256, P313, DOI 10.1006/viro.1999.9663
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   McShane H, 2002, INFECT IMMUN, V70, P1623, DOI 10.1128/IAI.70.3.1623-1626.2002
   O'Hara GA, 2012, J INFECT DIS, V205, P772, DOI 10.1093/infdis/jir850
   Pinto AR, 2003, J IMMUNOL, V171, P6774
   Rambaut A, 2009, FIGTREE V1 3 1 TREE
   Reyes-Sandoval A, 2008, EUR J IMMUNOL, V38, P732, DOI 10.1002/eji.200737672
   Reyes-Sandoval A, 2010, INFECT IMMUN, V78, P145, DOI 10.1128/IAI.00740-09
   ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0
   Roy S, 2004, VIROLOGY, V324, P361, DOI 10.1016/j.virol.2004.03.047
   Roy S, 2004, HUM GENE THER, V15, P519, DOI 10.1089/10430340460745838
   Roy S, 2011, J GENE MED, V13, P17, DOI 10.1002/jgm.1530
   Roy S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000503
   Sharan SK, 2009, NAT PROTOC, V4, P206, DOI 10.1038/nprot.2008.227
   Sheehy SH, 2011, MOL THER, V19, P2269, DOI 10.1038/mt.2011.176
   Sridhar S, 2008, J VIROL, V82, P3822, DOI 10.1128/JVI.02568-07
   Stanton RJ, 2008, BIOTECHNIQUES, V45, P659, DOI 10.2144/000112993
   Tatsis N, 2006, GENE THER, V13, P421, DOI 10.1038/sj.gt.3302675
   Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013
   Thomason LC, 2007, PLASMID, V58, P148, DOI 10.1016/j.plasmid.2007.03.001
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Warming S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni035
   WIGAND R, 1989, INTERVIROLOGY, V30, P1
   Wilson JM, 1996, NEW ENGL J MED, V334, P1185, DOI 10.1056/NEJM199605023341809
   Xiang ZQ, 2006, EMERG INFECT DIS, V12, P1596
   Yu D, 2011, J VIROL, V85, P13114, DOI 10.1128/JVI.05759-11
   Zhou DM, 2010, NAT PROTOC, V5, P1775, DOI 10.1038/nprot.2010.134
NR 51
TC 40
Z9 41
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 13
PY 2012
VL 7
IS 7
AR e40385
DI 10.1371/journal.pone.0040385
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 974CF
UT WOS:000306406700026
PM 22808149
OA gold
DA 2017-08-15
ER

PT J
AU Okomo, U
   Togun, T
   Oko, F
   Peterson, K
   Townend, J
   Peterson, I
   Jaye, A
AF Okomo, Uduak
   Togun, Toyin
   Oko, Francis
   Peterson, Kevin
   Townend, John
   Peterson, Ingrid
   Jaye, Assan
TI Treatment outcomes among HIV-1 and HIV-2 infected children initiating
   antiretroviral therapy in a concentrated low prevalence setting in West
   Africa
SO BMC PEDIATRICS
LA English
DT Article
ID FIXED-DOSE COMBINATION; COTE-DIVOIRE; DRUG-RESISTANCE; VIRAL LOAD;
   TRANSMISSION; ABIDJAN; GAMBIA; COHORT; AIDS; NEVIRAPINE
AB Background: There is little data on responses to combination antiretroviral therapy (cART) among HIV-infected children in the West African region. We describe treatment outcomes among HIV-1 and HIV-2 infected children initiating cART in a research clinic in The Gambia, West Africa.
   Methods: All treatment naive HIV-infected children who initiated cART according to the WHO ART guidelines for children between October 2004 and December 2009 were included in the analysis. Kaplan-Meir estimates and sign-rank test were used to investigate the responses to treatment.
   Results: 65 HIV-1 and five HIV-2 infected children aged < 15 years were initiated on cART over this time period. HIV-1 infected children were treated with a combination of Zidovudine or Stavudine + Lamivudine + Nevirapine or Efavirenz while children with HIV-2 were treated with Zidovudine + Lamivudine + ritonavir-boosted Lopinavir. HIV-1 infected children were followed-up for a median (IQR) duration of 20.1 months (6.9 - 34.3), with their median (IQR) age at treatment initiation, CD4% and plasma viral load at baseline found to be 4.9 years (2.1 - 9.1), 13.0% (7.0 - 16.0) and 5.4 log(10) copies/ml (4.4 - 6.0) respectively. The median age at treatment initiation of the five HIV-2 infected children was 12 years (range: 4.6 - 14.0) while their median baseline CD4(+) T cell count and HIV-2 viral load were 140 cells/mm(3) (Range: 40 - 570 cells/mm(3)) and 4.5 log(10)copies/mL (Range: 3.1 - 4.9 log(10)copies/mL) respectively. Among HIV-1 infected children < 5 years of age at ART initiation, the median (IQR) increases in CD4% from baseline to 12, 24 and 36 months were 14% (8 - 19; P = 0.0004), 21% (15 - 22; P = 0.005) and 15% (15 - 25; P = 0.0422) respectively, while the median (IQR) increase in absolute CD4 T cell count from baseline to 12, 24 and 36 months for those = 5 years at ART initiation were 470 cells/mm(3) (270 - 650; P = 0.0005), 230 cells/mm(3) (30 - 610; P = 0.0196) and 615 cells/mm(3) (250 - 1060; P = 0.0180) respectively. The proportions of children achieving undetectable HIV-1 viral load at 6-, 12-, 24- and 36 months of treatment were 24/38 (63.2%), 20/36 (55.6%), 8/22 (36.4%) and 7/12 (58.3%) respectively. The probability of survival among HIV-1 infected children after 12 months on ART was 89.9% (95% CI 78.8 - 95.3). CD4 T cell recovery was sub-optimal in all the HIV-2 infected children and none achieved virologic suppression. Two of the HIV-2 infected children died within 6 months of starting treatment while the remaining three were lost to follow-up.
   Conclusions: The beneficial effects of cART among HIV-1 infected children in our setting are sustained in the first 24 months of treatment with a significant improvement in survival experience up to 36 months; however the outcome was poor in the few HIV-2 infected children initiated on cART.
C1 [Okomo, Uduak; Togun, Toyin; Oko, Francis; Peterson, Kevin; Townend, John; Jaye, Assan] Med Res Council UK Labs, Banjul, Gambia.
   [Peterson, Kevin] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Peterson, Ingrid] Columbia Univ, Mailman Sch Publ Hlth, Int Ctr AIDS Care & Treatment Program ICAP Swazil, New York, NY USA.
   [Jaye, Assan] Univ Cheikh Anta Diop, Lab Bacteriol Virol, Hop A le Dantec, WAPHIR Network, Dakar, Senegal.
RP Okomo, U (reprint author), Med Res Council UK Labs, Atlantic Rd,Fajara273, Banjul, Gambia.
EM uokomo@mrc.gm
FU Elizabeth Glaser Pediatric AIDS Foundation [ILA 01-15]
FX We thank the field workers and nurses of the MRC HIV Clinic,
   particularly Mr. Saydiba Tamba. We acknowledge and appreciate the
   efforts of Gilleh Thomas and Mehedi Shams-Rony in acquisition of the
   data; Ramu Sarge-Njie, Samuel Nyamweya, Sheikh Jarju, Clayton Onyango
   and Mathew Cotten for their assistance with HIV diagnostics, CD4 and
   viral load measurements. This work was supported by the Elizabeth Glaser
   Pediatric AIDS Foundation [grant number: ILA # 01-15 to A.J]. Support
   for antiretroviral drugs and MRC HIV Clinic Staff was provided by the
   Global Fund for AIDS, TB and Malaria (GFATM)
CR Adje-Toure CA, 2003, AIDS, V17, pS49
   Adje-Toure C, 2008, AIDS RES HUM RETROV, V24, P911, DOI 10.1089/aid.2007.0264
   ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   ANDREASSON PA, 1993, AIDS, V7, P989
   Bolton-Moore C, 2007, JAMA-J AM MED ASSOC, V298, P1888, DOI 10.1001/jama.298.16.1888
   Burgard M, 2010, CLIN INFECT DIS, V51, P833, DOI 10.1086/656284
   Chokephaibulkit K, 2005, AIDS, V19, P1495, DOI 10.1097/01.aids.0000183625.97170.59
   CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903
   Damond F, 2008, J CLIN MICROBIOL, V46, P2088, DOI 10.1128/JCM.00126-08
   DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P1484, DOI 10.1001/jama.267.11.1484
   Department of State for Health, 2004, GAMB ANT THER MAN HL
   Diack MB, 2005, ARCH PEDIATR, V12, P404
   Elise A, 2005, JAIDS-J ACQ IMM DEF, V40, P498, DOI 10.1097/01.qai.0000168180.76405.5f
   Ellis JC, 2007, ANTIVIR THER, V12, P253
   Fassinou P, 2004, AIDS, V18, P1905, DOI 10.1097/00002030-200409240-00006
   Fenner L, 2010, JAIDS-J ACQ IMM DEF, V54, P524, DOI 10.1097/QAI.0b013e3181e0c4cf
   Gottlieb GS, 2008, AIDS, V22, P2069, DOI 10.1097/QAD.0b013e32830edd44
   Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Mocroft A, 1999, AIDS, V13, P943, DOI 10.1097/00002030-199905280-00010
   MORGAN G, 1990, AIDS, V4, P879, DOI 10.1097/00002030-199009000-00008
   National Sentinel Surveillance Working Group, 2008, NAT SENT SURV B 2008
   Nesheim SR, 2007, PEDIATRICS, V120, P100, DOI 10.1542/peds.2006-2052
   O'Brien DP, 2006, AIDS, V20, P1955, DOI 10.1097/01.aids.0000247117.66585.ce
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Ota MOC, 2000, AIDS, V14, P435, DOI 10.1097/00002030-200003100-00018
   Reddi A, 2007, S AFRICA BMC PEDIAT, V7, P13
   Resino S, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-10
   Sutcliffe CG, 2008, LANCET INFECT DIS, V8, P477, DOI 10.1016/S1473-3099(08)70180-4
   Tarwater PM, 2001, J ACQ IMMUN DEF SYND, V27, P168
   UNAIDS, 2000, PROV WHO UNAIDS SECR
   UNICEF, 2009, UN CHILDR UN AIDS CH
   van der Loeff MFS, 2003, AIDS, V17, P2389, DOI 10.1097/01.aids.0000076344.42412.05
   van der Loeff MFS, 2002, AIDS, V16, P1775
   Wamalwa DC, 2007, JAIDS-J ACQ IMM DEF, V45, P311
   WHO, 2010, PROGR REP 2010
   World Health Organization, 2006, ANT THER HIV INF INF
   World Health Organization (WHO), 2006, GUID COTR PROPH HIV
   World Health Organisation, 2004, SCAL ANT THER RES LT
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
NR 40
TC 10
Z9 12
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD JUL 8
PY 2012
VL 12
AR 95
DI 10.1186/1471-2431-12-95
PG 11
WC Pediatrics
SC Pediatrics
GA 981HY
UT WOS:000306958800001
PM 22770231
OA gold
DA 2017-08-15
ER

PT J
AU Moore, SE
   Richards, AA
   Goldblatt, D
   Ashton, L
   Szu, SC
   Prentice, AM
AF Moore, Sophie E.
   Richards, Anna A.
   Goldblatt, David
   Ashton, Lindsey
   Szu, Shousun Chen
   Prentice, Andrew M.
TI Early-life and contemporaneous nutritional and environmental predictors
   of antibody response to vaccination in young Gambian adults
SO VACCINE
LA English
DT Article
DE Vaccine responses; Immune programming; Birth weight; Infant growth;
   Gambia
ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; IMMUNE-RESPONSE;
   BIRTH SEASON; BREAST-MILK; VITAMIN-A; CHILDREN; INFANTS; MORTALITY;
   SUPPLEMENTATION
AB Recent research links nutritional exposures early in life with alterations in functional immunity that persist beyond childhood. Here we investigate predictors of antibody response to polysaccharide vaccines in a cohort of Gambian adults with detailed records from birth and early infancy available. 320 adults were given a single dose of a Vi polysaccharide vaccine for Salmonella typhi and a 23-valent capsular polysaccharide pneumococcal vaccine. Anti-Vi antibody levels and antibodies against 4 pneumococcal serotypes (1.5. 14 and 23F) were measured in serum samples collected at baseline and then 14 days following vaccination and compared to data available from birth and early infancy. Post-vaccination antibody titres to serotype 14 of the pneumococcal vaccine were negatively associated with rate of growth from birth to three months of age, infant weight at 12 months of age and season of birth, but no other associations were observed with early-life exposures. The strongest predictor of antibody levels was pre-vaccination antibody titres, with adult height and serum neopterin levels at time of vaccination also implicated. The current study does not support the hypothesis that nutritional exposures early in life consistently compromise antibody response to polysaccharide vaccines administered in young adulthood. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Moore, Sophie E.; Richards, Anna A.; Prentice, Andrew M.] MRC Keneba, MRC Labs, Fajara, Gambia.
   [Moore, Sophie E.; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
   [Goldblatt, David; Ashton, Lindsey] Inst Child Hlth, London, England.
   [Szu, Shousun Chen] NIH, Bethesda, MD 20892 USA.
RP Moore, SE (reprint author), MRC Keneba, MRC Unit Gambia, POB 273, Banjul, Gambia.
EM Sophie.Moore@lshtm.ac.uk
RI Goldblatt, David/C-5972-2008
OI Goldblatt, David/0000-0002-0769-5242
FU UK Medical Research Council
FX We are grateful to all the subjects who participated in this research
   project. We also thank the field staff from MRC Keneba for their
   assistance with this study. We acknowledge the role of the Nutritional
   Biochemistry Laboratory, MRC Human Nutrition Research, Cambridge in
   running the leptin and neopterin assays. This study was financed by the
   UK Medical Research Council. The vaccines were kindly donated by
   Sanofi-Pasteur, Lyon, France.
CR Abdullahi O, 2008, PEDIATR INFECT DIS J, V27, P59, DOI 10.1097/INF.0b013e31814da70c
   Baqui AH, 2002, BRIT MED J, V325, P1059, DOI 10.1136/bmj.325.7372.1059
   Benn CS, 2007, VACCINE, V25, P777, DOI 10.1016/j.vaccine.2006.09.044
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   Collinson AC, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-18
   Darboe MK, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-195
   Fewtrell MS, 2008, ARCH DIS CHILD, V93, P458, DOI 10.1136/adc.2007.127316
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-2
   Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762
   HUSSEY GD, 1993, J TROP PEDIATRICS, V39, P342
   Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   Moore SE, 2009, ACTA PAEDIATR, V98, P1168, DOI 10.1111/j.1651-2227.2009.01292.x
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moore SE, 2002, ARCH DIS CHILD, V87, P192, DOI 10.1136/adc.87.3.192
   Moore SE, 2008, VACCINE, V26, P158, DOI 10.1016/j.vaccine.2007.11.007
   Moore SE, 2006, P NUTR SOC, V65, P311, DOI 10.1079/PNS2006503
   Morgan G, 1997, LANCET, V349, P1693, DOI 10.1016/S0140-6736(96)12038-9
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P53
   Prentice Andrew, 1986, HUMAN LACTATION, P13
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   Rodgers GL, 2009, VACCINE, V27, P3802, DOI 10.1016/j.vaccine.2009.04.021
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Schaible UE, 2007, PLOS MED, V4, P806, DOI 10.1371/journal.pmed.0040115
   Scrimshaw NS, 1997, AM J CLIN NUTR, V66, P464
   Silfverdal SA, 2007, VACCINE, V25, P1497, DOI 10.1016/j.vaccine.2006.10.025
   Silfverdal SA, 2002, PEDIATR INFECT DIS J, V21, P816, DOI 10.1097/01.inf.0000027668.74570.96
   Singhal A, 2004, LANCET, V363, P1642, DOI 10.1016/S0140-6736(04)16210-7
   Wernette CM, 2003, CLIN DIAGN LAB IMMUN, V10, P514, DOI 10.1128/CDLI.10.4.514-519.2003
   WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624
NR 34
TC 4
Z9 4
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUL 6
PY 2012
VL 30
IS 32
BP 4842
EP 4848
DI 10.1016/j.vaccine.2012.05.009
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 978UJ
UT WOS:000306771000020
PM 22609011
OA No
DA 2017-08-15
ER

PT J
AU Mobegi, VA
   Loua, KM
   Ahouidi, AD
   Satoguina, J
   Nwakanma, DC
   Amambua-Ngwa, A
   Conway, DJ
AF Mobegi, Victor A.
   Loua, Kovana M.
   Ahouidi, Ambroise D.
   Satoguina, Judith
   Nwakanma, Davis C.
   Amambua-Ngwa, Alfred
   Conway, David J.
TI Population genetic structure of Plasmodium falciparum across a region of
   diverse endemicity in West Africa
SO MALARIA JOURNAL
LA English
DT Article
DE Plasmodium falciparum; Microsatellite; Population structure;
   Transmission intensity
ID PAPUA-NEW-GUINEA; MICROSATELLITE MARKERS; MALARIA PARASITES;
   TRANSMISSION; INFECTIONS; HERITABILITY; COMPLEXITY; MORTALITY; VILLAGE;
   REVEAL
AB Background: Malaria parasite population genetic structure varies among areas of differing endemicity, but this has not been systematically studied across Plasmodium falciparum populations in Africa where most infections occur.
   Methods: Ten polymorphic P. falciparum microsatellite loci were genotyped in 268 infections from eight locations in four West African countries (Republic of Guinea, Guinea Bissau, The Gambia and Senegal), spanning a highly endemic forested region in the south to a low endemic Sahelian region in the north. Analysis was performed on proportions of mixed genotype infections, genotypic diversity among isolates, multilocus standardized index of association, and inter-population differentiation.
   Results: Each location had similar levels of pairwise genotypic diversity among isolates, although there were many more mixed parasite genotype infections in the south. Apart from a few isolates that were virtually identical, the multilocus index of association was not significant in any population. Genetic differentiation between populations was low (most pairwise F-ST values < 0.03), and an overall test for isolation by distance was not significant.
   Conclusions: Although proportions of mixed genotype infections varied with endemicity as expected, population genetic structure was similar across the diverse sites. Very substantial reduction in transmission would be needed to cause fragmented or epidemic sub-structure in this region.
C1 [Mobegi, Victor A.; Conway, David J.] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London WC1E 7HT, England.
   [Mobegi, Victor A.; Satoguina, Judith; Nwakanma, Davis C.; Amambua-Ngwa, Alfred; Conway, David J.] MRC Unit, Fajara, Banjul, Gambia.
   [Loua, Kovana M.] Natl Inst Publ Hlth, Conakry, Guinea.
   [Ahouidi, Ambroise D.] Univ Cheikh Anta Diop, Dakar, Senegal.
RP Conway, DJ (reprint author), London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London WC1E 7HT, England.
EM david.conway@lshtm.ac.uk
OI Conway, David/0000-0002-8711-3037
FU UK Medical Research Council
FX This research was funded by the UK Medical Research Council.
CR Amodu OK, 2008, ANN TROP MED PARASIT, V102, P95, DOI 10.1179/136485908X252340
   Anderson TJC, 2010, P ROY SOC B-BIOL SCI, V277, P2531, DOI 10.1098/rspb.2010.0196
   Anderson TJC, 2010, J INFECT DIS, V201, P1326, DOI 10.1086/651562
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   Anderson TJC, 2000, GENET RES, V75, P285, DOI 10.1017/S0016672300004481
   Anderson TJC, 1999, PARASITOLOGY, V119, P113, DOI 10.1017/S0031182099004552
   Annan Z, 2007, P NATL ACAD SCI USA, V104, P7987, DOI 10.1073/pnas.0702715104
   Anthony TG, 2005, J INFECT DIS, V191, P1558, DOI 10.1086/429338
   BABIKER HA, 1994, PARASITOLOGY, V109, P413
   Beck HP, 1997, J INFECT DIS, V175, P921, DOI 10.1086/513991
   Bogreau H, 2006, AM J TROP MED HYG, V74, P953
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Chokejindachai W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005454
   CONWAY DJ, 1991, T ROY SOC TROP MED H, V85, P454, DOI 10.1016/0035-9203(91)90217-M
   Conway DJ, 2001, MOL BIOCHEM PARASIT, V115, P145, DOI 10.1016/S0166-6851(01)00278-X
   CONWAY DJ, 1991, PARASITOLOGY, V103, P7
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   Durand P, 2003, AM J TROP MED HYG, V68, P345
   ENGELBRECHT F, 1995, EXP PARASITOL, V81, P90, DOI 10.1006/expr.1995.1096
   Goudet J, 1995, J HERED, V86, P485
   Haubold B, 2000, BIOINFORMATICS, V16, P847, DOI 10.1093/bioinformatics/16.9.847
   Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3
   Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Iwagami M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-96
   Kyes S, 1997, AM J TROP MED HYG, V57, P205
   Lynch C, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001040
   Machado RLD, 2004, J INFECT DIS, V190, P1547, DOI 10.1086/424601
   Manske M, 2012, NATURE, V487, P375, DOI 10.1038/nature11174
   Maynard- Smith J, 1993, P NATIONAL ACADEMY S, V90, P4384
   Mu JB, 2005, PLOS BIOL, V3, P1734, DOI 10.1371/journal.pbio.0030335
   Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8
   Mzilahowa T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000613
   Nkhoma SC, 2012, P ROY SOC B-BIOL SCI, V279, P2589, DOI 10.1098/rspb.2012.0113
   O'Meara WP, 2010, LANCET INFECT DIS, V10, P545, DOI 10.1016/S1473-3099(10)70096-7
   PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897
   Pumpaibool T, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-155
   Razakandrainibe FG, 2005, P NATL ACAD SCI USA, V102, P17388, DOI 10.1073/pnas.0508871102
   Rebaudet S, 2010, EMERG INFECT DIS, V16, P1686, DOI 10.3201/eid1611.100694
   Roper C, 1998, PARASITOLOGY, V116, P501, DOI 10.1017/S0031182098002650
   Rousset F, 2008, MOL ECOL RESOUR, V8, P103, DOI 10.1111/j.1471-8286.2007.01931.x
   Satoguina J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-274
   Schultz L, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-336
   Singh B, 1999, AM J TROP MED HYG, V60, P687
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Su XZ, 1996, GENOMICS, V33, P430, DOI 10.1006/geno.1996.0218
   Trape JF, 2012, J INFECT DIS, V205, P672, DOI 10.1093/infdis/jir805
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   Zhong D, 2007, AM J TROP MED HYG, V77, P1043
   Zwetyenga J, 1998, AM J TROP MED HYG, V59, P726
NR 52
TC 32
Z9 33
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUL 3
PY 2012
VL 11
AR 223
DI 10.1186/1475-2875-11-223
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 993HS
UT WOS:000307849000001
PM 22759447
OA gold
DA 2017-08-15
ER

PT J
AU Hamill, M
   Ward, K
   Pettifor, J
   Norris, S
   Prentice, A
AF Hamill, Matthew
   Ward, Kate
   Pettifor, John
   Norris, Shane
   Prentice, Ann
TI BONE AND BODY COMPOSITION IN HIV-POSITIVE AND HIV-NEGATIVE BLACK, SOUTH
   AFRICAN WOMEN
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Meeting Abstract
CT Osteoporosis and Bone Conference
CY JUL 01-04, 2012
CL Manchester, ENGLAND
C1 [Hamill, Matthew; Ward, Kate; Prentice, Ann] MRC Human Nutr Res, ZA-2050 Cambridge, England.
   [Hamill, Matthew; Norris, Shane] Dev Pathways Hlth Res Unit, Johannesburg, South Africa.
   [Pettifor, John] Univ Witwatersrand, Dept Paediat, Fac Hlth Sci, Johannesburg, South Africa.
   [Prentice, Ann] MRC Keneba, Keneba, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUL
PY 2012
VL 23
SU 5
BP S550
EP S550
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 012UB
UT WOS:000309261000064
OA No
DA 2017-08-15
ER

PT J
AU Finney, OC
   Lawrence, E
   Gray, AP
   Njie, M
   Riley, EM
   Walther, M
AF Finney, Olivia C.
   Lawrence, Emma
   Gray, Alice P.
   Njie, Madi
   Riley, Eleanor M.
   Walther, Michael
TI Freeze-thaw lysates of Plasmodium falciparum-infected red blood cells
   induce differentiation of functionally competent regulatory T cells from
   memory T cells
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Malaria Immunology; Memory T cells; Treg cells; Treg-cell induction
ID HUMAN DENDRITIC CELLS; TGF-BETA; CUTTING EDGE; MALARIA PARASITES; FOXP3
   EXPRESSION; IN-VITRO; ANTIGEN; TOLERANCE; EFFECTOR; STIMULATION
AB In addition to naturally occurring regulatory T (nTreg) cells derived from the thymus, functionally competent Treg cells can be induced in vitro from peripheral blood lymphocytes in response to TCR stimulation with cytokine costimulation. Using these artificial stimulation conditions, both naive as well as memory CD4+ T cells can be converted into induced Treg (iTreg) cells, but the cellular origin of such iTreg cells in vivo or in response to more physiologic stimulation with pathogen-derived antigens is less clear. Here, we demonstrate that a freeze/thaw lysate of Plasmodium falciparum schizont extract (PfSE) can induce functionally competent Treg cells from peripheral lymphocytes in a time- and dose-dependent manner without the addition of exogenous costimulatory factors. The PfSE-mediated induction of Treg cells required the presence of nTreg cells in the starting culture. Further experiments mixing either memory or naive T cells with antigen presenting cells and CFSE-labeled Treg cells identified CD4+CD45RO+CD25- memory T cells rather than Treg cells as the primary source of PfSE-induced Treg cells. Taken together, these data suggest that in the presence of nTreg cells, PfSE induces memory T cells to convert into iTreg cells that subsequently expand alongside PfSE-induced effector T cells.
C1 [Walther, Michael] NIAID, NIH, Rockville, MD 20852 USA.
   [Finney, Olivia C.; Gray, Alice P.; Njie, Madi; Walther, Michael] MRC Labs, Malaria Programme, Banjul, Gambia.
   [Finney, Olivia C.; Riley, Eleanor M.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1, England.
   [Lawrence, Emma] Univ Manchester, Fac Life Sci, Manchester, Lancs, England.
RP Walther, M (reprint author), NIAID, NIH, 12441 Rockville, Rockville, MD 20852 USA.
EM Michael.Walther@nih.gov
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570
FU MRC (UK)
FX We would like to thank the participants who volunteered to donate blood
   for this study, Simon Correa for his help with PBMC separation and cell
   purification experiments, Idrissa Sambou for providing parasite
   material, and Professor David Conway for facilitating this work, which
   was funded by the MRC (UK).
CR Akbar AN, 2007, NAT REV IMMUNOL, V7, P231, DOI 10.1038/nri2037
   Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014
   Andersson J, 2008, J EXP MED, V205, P1975, DOI 10.1084/jem.20080308
   Banerjee DK, 2006, BLOOD, V108, P2655, DOI 10.1182/blood-2006-03-011353
   Belkaid Y, 2006, IMMUNOL REV, V212, P287, DOI 10.1111/j.0105-2896.2006.00409.x
   Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774
   Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032
   Brusko TM, 2008, IMMUNOL REV, V223, P371, DOI 10.1111/j.1600-065X.2008.00637.x
   Chaturvedi V, 2011, J IMMUNOL, V186, P6661, DOI 10.4049/jimmunol.1100315
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Clemente A, 2011, CELL MICROBIOL, V13, P1328, DOI 10.1111/j.1462-5822.2011.01622.x
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   Fantini MC, 2004, J IMMUNOL, V172, P5149
   Finney OC, 2010, TRENDS IMMUNOL, V31, P63, DOI 10.1016/j.it.2009.12.002
   Finney OC, 2010, EUR J IMMUNOL, V40, P47, DOI 10.1002/eji.200939708
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Fritzsching B, 2005, J IMMUNOL, V175, P32
   Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103
   Hansen DS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000771
   Hayashi Y, 2004, J IMMUNOL, V172, P5240
   Hisaeda H, 2008, J IMMUNOL, V180, P2496
   Horwitz DA, 2008, EUR J IMMUNOL, V38, P912, DOI 10.1002/eji.200738109
   Jonuleit H, 2002, J EXP MED, V196, P255, DOI 10.1084/jem.20020394
   Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213
   Kasow KA, 2004, J IMMUNOL, V172, P6123
   Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265
   Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485
   Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019
   Rouse BT, 2006, IMMUNOL REV, V212, P272, DOI 10.1111/j.0105-2896.2006.00412.x
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Scholzen A, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000543
   Selvaraj RK, 2007, J IMMUNOL, V178, P7667
   Stassen M, 2004, TRANSPLANTATION, V77, pS23, DOI 10.1097/00007890-200401151-00009
   Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P
   Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656
   Vukmanovic-Stejic M, 2008, J CLIN INVEST, V118, P3639, DOI 10.1172/JCI35834
   Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941
   Walker MR, 2005, P NATL ACAD SCI USA, V102, P4103, DOI 10.1073/pnas.0407691102
   Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1081/jem.20030422
   Zheng SG, 2004, J IMMUNOL, V172, P5213
NR 46
TC 6
Z9 6
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD JUL
PY 2012
VL 42
IS 7
BP 1767
EP 1777
DI 10.1002/eji.201142164
PG 11
WC Immunology
SC Immunology
GA 975FN
UT WOS:000306493100014
PM 22585585
OA No
DA 2017-08-15
ER

PT J
AU Satyanarayana, B
   Bhanderi, P
   Debry, M
   Maniatis, D
   Fore, F
   Badgie, D
   Jammeh, K
   Vanwing, T
   Farcy, C
   Koedam, N
   Dahdouh-Guebas, F
AF Satyanarayana, Behara
   Bhanderi, Preetika
   Debry, Melanie
   Maniatis, Danae
   Fore, Franka
   Badgie, Dawda
   Jammeh, Kawsu
   Vanwing, Tom
   Farcy, Christine
   Koedam, Nico
   Dahdouh-Guebas, Farid
TI A Socio-Ecological Assessment Aiming at Improved Forest Resource
   Management and Sustainable Ecotourism Development in the Mangroves of
   Tanbi Wetland National Park, The Gambia, West Africa
SO AMBIO
LA English
DT Article
DE Mangroves; Socio-ecology; Tanbi Wetland National Park; Resource
   utilization; Participatory methods; The Gambia
ID ESTUARY; SYSTEMS; ASSEMBLAGES; VARIABLES; CAMEROON; MALARIA; KENYA
AB Although mangroves dominated by Avicennia germinans and Rhizophora mangle are extending over 6000 ha in the Tanbi Wetland National Park (TWNP) (The Gambia), their importance for local populations (both peri-urban and urban) is not well documented. For the first time, this study evaluates the different mangrove resources in and around Banjul (i.e., timber, non-timber, edible, and ethnomedicinal products) and their utilization patterns, including the possibility of ecotourism development. The questionnaire-based results have indicated that more than 80% of peri-urban population rely on mangroves for timber and non-timber products and consider them as very important for their livelihoods. However, at the same time, urban households demonstrate limited knowledge on mangrove species and their ecological/economic benefits. Among others, fishing (including the oyster-Crassostrea cf. gasar collection) and tourism are the major income-generating activities found in the TWNP. The age-old practices of agriculture in some parts of the TWNP are due to scarcity of land available for agriculture, increased family size, and alternative sources of income. The recent focus on ecotourism (i.e., boardwalk construction inside the mangroves near Banjul city) received a positive response from the local stakeholders (i.e., users, government, and non-government organizations), with their appropriate roles in sharing the revenue, rights, and responsibilities of this project. Though the guidelines for conservation and management of the TWNP seem to be compatible, the harmony between local people and sustainable resource utilization should be ascertained.
C1 [Satyanarayana, Behara; Bhanderi, Preetika; Maniatis, Danae; Fore, Franka; Koedam, Nico; Dahdouh-Guebas, Farid] VUB, Mangrove Management Grp, Lab Plant Biol & Nat Management, B-1050 Brussels, Belgium.
   [Debry, Melanie; Farcy, Christine] UCL, Forest Nat & Soc Res Grp, Louvain, Belgium.
   [Jammeh, Kawsu] Dept Pk & Wildlife Management, Abuko, Gambia.
   [Badgie, Dawda] NEA, Banjul, Gambia.
   [Maniatis, Danae] Univ Oxford, Environm Change Inst, Sch Geog & Environm, Oxford OX1 3QY, England.
   [Bhanderi, Preetika] African Conservat Ctr, Nairobi, Kenya.
   [Satyanarayana, Behara] UMT, Inst Oceanog, Kuala 21030, Terengganu, Malaysia.
   [Satyanarayana, Behara; Dahdouh-Guebas, Farid] ULB, Fac Sci, Dept Biol Organismes, Lab Syst Ecol & Resource Management Complex & Dyn, B-1050 Brussels, Belgium.
RP Dahdouh-Guebas, F (reprint author), ULB, Fac Sci, Dept Biol Organismes, Lab Syst Ecol & Resource Management Complex & Dyn, Ave Franklin Roosevelt 50, B-1050 Brussels, Belgium.
EM satyam2149@gmail.com; preetika27@gmail.com; melaniedebry@hotmail.com;
   danae.maniatis@gmail.com; franka87@hotmail.com; badgiedawda@gmail.com;
   kjammehsopee@yahoo.com; tvwing@vub.ac.be; christine.farcy@uclouvain.be;
   nikoedam@vub.ac.be; fdahdouh@vub.ac.be
FU City Council of Oostende (Belgium)
FX This study was funded by the City Council of Oostende (Belgium). Special
   thanks are due to Tom Germonpre (Alderman in Ostend), Pa Sallah Jeng and
   Samba Fall (former and present Mayors of Banjul), Profs. Jonsyn-Ellis
   and Muhammadou M.O. Kah (former and present Vice-Chancellors of the
   University of The Gambia), Peter Vanslambrouck (Oostende-Banjul City
   Link Coordinator), Jacky Dereu and Mustapha for their courtesy and
   facilitation. Mr. Bah, Jatou, Kerai, Bakary, Dawda Badgie and Buba Carr
   Bah have helped us in both fieldwork and local language translation. Our
   earnest thanks to Abou and Ushman for their logistic support. Final
   thanks go to David Vande Wynckel, Mieke Vandaele and Prof. De
   Spiegeleire (KHBO, Oostende) for further engineering research on
   boardwalk construction in collaboration with the corresponding author.
   Authors are very grateful to the two unknown referees for their
   objective criticism and invaluable suggestions.
CR AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M
   Albaret JJ, 2004, AQUAT LIVING RESOUR, V17, P35, DOI 10.1051/alr:2004001
   Masso i Aleman S., 2010, PLANT ECOL EVOL, V143, P225, DOI DOI 10.5091/PLECEVO.2010.439
   Alongi DM, 2008, ESTUAR COAST SHELF S, V76, P1, DOI 10.1016/j.ecss.2007.08.024
   Atheull AN, 2009, J ETHNOBIOL ETHNOMED, V5, DOI 10.1186/1746-4269-5-35
   Avau J., 2011, J COASTAL RES, V64, P1277
   Bandaranayake W. M., 2002, Wetlands Ecology and Management, V10, P421, DOI 10.1023/A:1021397624349
   Bandaranayake W., 1998, MANGROVES SALT MARSH, V2, P133, DOI 10.1023/A:1009988607044
   Berger U, 2008, AQUAT BOT, V89, P260, DOI 10.1016/j.aquabot.2007.12.015
   Bosire JO, 2008, AQUAT BOT, V89, P251, DOI 10.1016/j.aquabot.2008.03.010
   Cannicci S, 2009, ESTUAR COAST SHELF S, V84, P305, DOI 10.1016/j.ecss.2009.04.021
   Chambers R., 2002, PART WORKSH SOURC 21
   Central Statistics Department (CSD), 2004, POP HOUS CENS GAMB P
   Dahdouh-Guebas F, 2008, AQUAT BOT, V89, P80, DOI 10.1016/j.aquabot.2008.03.012
   Dahdouh-Guebas F, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-24
   Dahdouh-Guebas F, 2006, SCIENCE, V311, P37, DOI 10.1126/science.311.5757.37
   Datta D, 2010, OCEAN COAST MANAGE, V53, P468, DOI 10.1016/j.ocecoaman.2010.06.007
   Debry M., 2009, THESIS U CATHOLIQUE
   Diop ES, 2002, ENVIRONM SCI, P63
   Department of Parks and Wildlife Management (DPWM), 2000, RAMS WETL STUD GAMB
   Department of Parks and Wildlife Management (DPWM), 2008, TANB WETL NAT PARK M
   Duke NC, 2007, SCIENCE, V317, P41
   Ecoutin JM, 2005, FISH RES, V72, P347, DOI 10.1016/j.fishres.2004.10.007
   Ellison AM, 2008, J SEA RES, V59, P2, DOI 10.1016/j.seares.2007.05.003
   FAO, 2004, 471 FAO
   FAO, 1994, 117 FAO
   Feka Njisuh Z., 2011, International Journal of Biodiversity Science Ecosystem Services & Management, V7, P108, DOI 10.1080/21513732.2011.606429
   Fore F., 2009, THESIS VRIJE U BRUSS
   Global Environment Facility (GEF), 2002, REG CONS AN 1 PHAS G
   Harpham T, 1996, HEALTH PLACE, V2, P45, DOI 10.1016/1353-8292(95)00041-0
   Hernandez-Cornejo R, 2005, ECOLOGY SOC, V10, P16
   Hirani P., 2005, THESIS VRIJE U BRUSS
   Jallow BP, 1996, CLIMATE RES, V6, P165, DOI 10.3354/cr006165
   Kairo JG, 2001, S AFR J BOT, V67, P383
   Kairo JG, 2002, AMBIO, V31, P562, DOI 10.1639/0044-7447(2002)031[0562:RSOMFI]2.0.CO;2
   Kinteh S. L., 2005, MANAGEMENT MANGROVE, V36
   Lae R, 2004, AQUAT LIVING RESOUR, V17, P75, DOI 10.1051/alr:2004010
   Lambin EF, 2005, GLOBAL ENVIRON CHANG, V15, P177, DOI 10.1016/j.gloenvcha.2005.06.002
   Lapegue S, 2002, BIOL BULL-US, V202, P232, DOI 10.2307/1543473
   Maniatis D., 2005, THESIS VRIJE U BRUSS
   Mayers J., 2005, 4 RS POWER TOOLS SER
   Mohamed MOS, 2009, WETL ECOL MANAG, V17, P243, DOI 10.1007/s11273-008-9104-8
   Mukherjee N, 2010, ENVIRON MANAGE, V46, P329, DOI 10.1007/s00267-010-9523-1
   Pattanaik C, 2008, INDIAN J TRADIT KNOW, V7, P598
   Pearce D., 1994, EC VALUE BIODIVERSIT
   Redman C. L., 1999, HUMAN IMPACT ANCIENT
   The Republic of The Gambia, 1996, GAMB INC VIS 2020 BL
   Satyanarayana B, 2011, MAR ECOL PROG SER, V443, P51, DOI 10.3354/meps09397
   Sharpley R, 1996, TOURISM MANAGE, V17, P1, DOI 10.1016/0261-5177(95)00094-1
   Shirley M. H., 2008, CROCODILE SPECIALIST, V27, P20
   Sillah J., 2002, ENV ACTION PLAN MANG
   Simier M, 2006, ESTUAR COAST SHELF S, V69, P615, DOI 10.1016/j.ecss.2006.05.028
   Spalding M., 2010, WORLD ATLAS MANGROVE
   Sukardjo S., 1995, 6FIDPINT91007 FAO
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   Tomlinson P. B., 1986, BOT MANGROVES
   United Nations Environment Programme (UNEP), 2002, UNEP GRID AR MAPS GR
   Vandaele M., 2011, THESIS KATHOLIEKE HO
   Varghese K, 2008, OCEAN COAST MANAGE, V51, P73, DOI 10.1016/j.ocecoaman.2007.03.002
   Walters BB, 2008, AQUAT BOT, V89, P220, DOI 10.1016/j.aquabot.2008.02.009
   Watts S., 1996, ESSENTIAL ENV SCI ME
NR 61
TC 12
Z9 13
U1 3
U2 109
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0044-7447
J9 AMBIO
JI Ambio
PD JUL
PY 2012
VL 41
IS 5
BP 513
EP 526
DI 10.1007/s13280-012-0248-7
PG 14
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 970II
UT WOS:000306121200009
PM 22351596
OA No
DA 2017-08-15
ER

PT J
AU Deitz, KC
   Reddy, VP
   Reddy, MR
   Satyanarayanah, N
   Lindsey, MW
   Overgaard, HJ
   Jawara, M
   Caccone, A
   Slotman, MA
AF Deitz, Kevin C.
   Reddy, Vamsi P.
   Reddy, Michael R.
   Satyanarayanah, Neha
   Lindsey, Michael W.
   Overgaard, Hans J.
   Jawara, Musa
   Caccone, Adalgisa
   Slotman, Michel A.
TI Limited Usefulness of Microsatellite Markers from the Malaria Vector
   Anopheles gambiae When Applied to the Closely Related Species Anopheles
   melas
SO JOURNAL OF HEREDITY
LA English
DT Article
DE Anopheles gambiae; Anopheles melas; cross-amplification; microsatellite
   markers; null alleles
ID ANTIMALARIAL IMMUNE GENES; MULTILOCUS GENOTYPE DATA; NULL ALLELES;
   POPULATION-STRUCTURE; EQUATORIAL-GUINEA; GENOME SEQUENCE; ARABIENSIS;
   COMPLEX; AMPLIFICATION; LOCI
AB Anopheles melas is a brackish water mosquito found in coastal West Africa where it is a dominant malaria vector locally. In order to facilitate genetic studies of this species, 45 microsatellite loci originally developed for Anopheles gambiae were sequenced in An. melas. Those that were suitable based on repeat number and flanking regions were examined in 2 natural populations from Equatorial Guinea. Only 15 loci were eventually deemed suitable as polymorphic markers in An. melas populations. These loci were screened in 4 populations from a wider geographic range. Heterozygosity estimates ranged from 0.18 to 0.79, and 2.5-15 average alleles were observed per locus, yielding 13 highly polymorphic markers and 2 loci with lower variability. To examine the usefulness of microsatellite markers when applied in a sibling species, the original An. gambiae specific markers were used to amplify 5 loci in An. melas. Null alleles were found for 1 An. gambiae marker. We discuss the pitfalls of using microsatellite loci across closely related species and conclude that in addition to the problem of null alleles associated with this practice, many loci may prove to be of very limited use as polymorphic markers even when used in a sibling species.
C1 [Deitz, Kevin C.; Reddy, Vamsi P.; Satyanarayanah, Neha; Lindsey, Michael W.; Slotman, Michel A.] Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA.
   [Reddy, Michael R.] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   [Overgaard, Hans J.] Norwegian Univ Life Sci, Dept Math Sci & Technol, As, Norway.
   [Jawara, Musa] MRC Labs, Fajara, Gambia.
   [Caccone, Adalgisa] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT USA.
RP Slotman, MA (reprint author), Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA.
EM maslotman@tamu.edu
FU Bioko Island Malaria Control Project (BIMCP); Texas Agrilife Research
   funds; Marathon Oil Corporation (Houston, TX); Government of Equatorial
   Guinea
FX Bioko Island Malaria Control Project (BIMCP) to M. A. S. and Texas
   Agrilife Research funds; BIMCP funded by a consortium led by Marathon
   Oil Corporation (Houston, TX) and the Government of Equatorial Guinea.
CR Athrey NRG, 2007, ENVIRON TOXICOL CHEM, V26, P1916, DOI 10.1897/06-589R.1
   Barbara T, 2007, MOL ECOL, V16, P3759, DOI 10.1111/j.1365-294X.2007.03439.x
   Besansky NJ, 2003, P NATL ACAD SCI USA, V100, P10818, DOI 10.1073/pnas.1434337100
   Brookfield JFY, 1996, MOL ECOL, V5, P453, DOI 10.1046/j.1365-294X.1996.00098.x
   Bryan J.H., 1987, Parassitologia (Rome), V29, P221
   BRYAN JH, 1983, ANN TROP MED PARASIT, V77, P1
   CALLEN DF, 1993, AM J HUM GENET, V52, P922
   Carreras-Carbonell J, 2008, CONSERV GENET, V9, P181, DOI 10.1007/s10592-007-9322-2
   CHAKRABORTY R, 1992, ANN HUM GENET, V56, P45, DOI 10.1111/j.1469-1809.1992.tb01128.x
   Chambers KE, 2004, AM J PRIMATOL, V64, P19, DOI 10.1002/ajp.20058
   Chandre F, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P319
   Chapuis MP, 2007, MOL BIOL EVOL, V24, P621, DOI 10.1093/molbev/msl191
   Coetzee M, 2004, AM J TROP MED HYG, V70, P103
   COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1
   Corander J, 2006, FISH B-NOAA, V104, P550
   Corander J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-539
   Dakin EE, 2004, HEREDITY, V93, P504, DOI 10.1038/sj.hdy.6800545
   Dawson DA, 2010, MOL ECOL RESOUR, V10, P475, DOI 10.1111/j.1755-0998.2009.02775.x
   dellaTorre A, 1997, GENETICS, V146, P239
   Donnelly MJ, 1999, HEREDITY, V83, P408, DOI 10.1038/sj.hdy.6885930
   Ekblom R, 2011, HEREDITY, V107, P1, DOI 10.1038/hdy.2010.152
   Excoffier L, 2010, MOL ECOL RESOUR, V10, P564, DOI 10.1111/j.1755-0998.2010.02847.x
   Falush D, 2003, GENETICS, V164, P1567
   Favia G, 1997, INSECT MOL BIOL, V6, P377, DOI 10.1046/j.1365-2583.1997.00189.x
   Guichoux E, 2011, MOL ECOL RESOUR, V11, P591, DOI 10.1111/j.1755-0998.2011.03014.x
   Hendrix R, 2010, MOL ECOL RESOUR, V10, P1038, DOI 10.1111/j.1755-0998.2010.02861.x
   Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181
   Hunt RH, 1998, T ROY SOC TROP MED H, V92, P231, DOI 10.1016/S0035-9203(98)90761-1
   Jarne P, 1996, TRENDS ECOL EVOL, V11, P424, DOI 10.1016/0169-5347(96)10049-5
   Kamau L, 1999, INSECT MOL BIOL, V8, P287, DOI 10.1046/j.1365-2583.1999.820287.x
   Kent RJ, 2007, AM J TROP MED HYG, V77, P316
   Kim KS, 2004, J HERED, V95, P521, DOI 10.1093/jhered/esh082
   Kleinschmidt I, 2009, AM J TROP MED HYG, V80, P882
   Lawson D, 2009, NUCLEIC ACIDS RES, V37, pD583, DOI 10.1093/nar/gkn857
   Miles LG, 2009, CONSERV GENET, V10, P935, DOI 10.1007/s10592-008-9601-6
   Obbard DJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-117
   Onyabe DY, 2001, MOL ECOL, V10, P2577, DOI 10.1046/j.0962-1083.2001.01387.x
   PAETKAU D, 1995, MOL ECOL, V4, P519, DOI 10.1111/j.1365-294X.1995.tb00248.x
   Panova M, 2008, J MOLLUS STUD, V74, P111, DOI 10.1093/mollus/eym052
   Parmakelis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008885
   Parmakelis A, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-79
   Pinto J, 2002, MOL ECOL, V11, P2183, DOI 10.1046/j.1365-294X.2002.01587.x
   Pompanon F, 2005, NAT REV GENET, V6, P847, DOI 10.1038/nrg1707
   Primmer CR, 2005, J AVIAN BIOL, V36, P348
   Pritchard JK, 2000, GENETICS, V155, P945
   QUELLER DC, 1993, TRENDS ECOL EVOL, V8, P285, DOI 10.1016/0169-5347(93)90256-O
   RAYMOND M, 1995, J HERED, V86, P248
   Reimer LJ, 2005, INSECT MOL BIOL, V14, P683, DOI 10.1111/j.1365-2583.2005.00599.x
   Rousset F, 2008, MOL ECOL RESOUR, V8, P103, DOI 10.1111/j.1471-8286.2007.01931.x
   Rozeu S., 2000, BIOINFORMATICS METHO, P365, DOI DOI 10.1385/1-59259-192-2:365
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Sharp BL, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-52
   Simard F, 2000, INSECT MOL BIOL, V9, P467, DOI 10.1046/j.1365-2583.2000.00210.x
   Sinka ME, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-117
   Slotman M, 2004, GENETICS, V167, P275, DOI 10.1534/genetics.167.1.275
   Slotman MA, 2005, AM J TROP MED HYG, V73, P326
   Slotman MA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000793
   Stinchcombe JR, 2008, HEREDITY, V100, P158, DOI 10.1038/sj.hdy.6800937
   Tabachnick WJ, 2003, J MED ENTOMOL, V40, P597, DOI 10.1603/0022-2585-40.5.597
   Thomas MA, 2004, TRENDS ECOL EVOL, V19, P439, DOI 10.1016/j.tree.2004.06.010
   Tripet F, 2005, GENETICS, V169, P313, DOI 10.1534/genetics.104.026534
   Van Oosterhout C, 2004, MOL ECOL NOTES, V4, P535, DOI 10.1111/j.1471-8286.2004.00684.x
   Wang-Sattler R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001249
   WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z
   Weill M, 2000, INSECT MOL BIOL, V9, P451, DOI 10.1046/j.1365-2583.2000.00206.x
   Wilson ACC, 2004, MOL ECOL NOTES, V4, P104, DOI 10.1046/j.1471-8286.2003.00584.x
   Wondji C, 2005, MOL ECOL, V14, P3683, DOI 10.1111/j.1365-294X.2005.02699.x
   Zheng LB, 1996, GENETICS, V143, P941
NR 68
TC 8
Z9 8
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1503
EI 1465-7333
J9 J HERED
JI J. Hered.
PD JUL
PY 2012
VL 103
IS 4
BP 585
EP 593
DI 10.1093/jhered/ess025
PG 9
WC Evolutionary Biology; Genetics & Heredity
SC Evolutionary Biology; Genetics & Heredity
GA 973NN
UT WOS:000306367000012
PM 22593601
OA No
DA 2017-08-15
ER

PT J
AU Zaidi, I
   Peterson, K
   Jeffries, D
   Whittle, H
   de Silva, T
   Rowland-Jones, S
   Jaye, A
   de Jong, BC
AF Zaidi, Irfan
   Peterson, Kevin
   Jeffries, David
   Whittle, Hilton
   de Silva, Thushan
   Rowland-Jones, Sarah
   Jaye, Assan
   de Jong, Bouke C.
TI Immune Reconstitution Inflammatory Syndrome and the Influence of T
   Regulatory Cells: A Cohort Study in the Gambia
SO PLOS ONE
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; RESTORATION DISEASE; RISK-FACTORS; INFECTED
   PATIENTS; TUBERCULOSIS; RESPONSES; PATHOGENESIS; BIOMARKERS; FOXP3
AB Objective: The factors associated with the development of immune reconstitution inflammatory syndrome in HIV patients commencing antiretroviral therapy have not been fully elucidated. Using a longitudinal study design, this study addressed whether alteration in the levels of T regulatory cells contributed to the development of IRIS in a West African cohort of HIV-1 and HIV-2 patients. Seventy-one HIV infected patients were prospectively recruited to the study and followed up for six months. The patients were categorized as IRIS or non-IRIS cases following published clinical guidelines. The levels of T regulatory cells were measured using flow cytometry at baseline and all follow-up visits. Baseline cytokine levels of IL-2, IL-6, IFN-gamma, TNF-alpha, MIP-1 beta, IL-1, IL-12, IL-13, and IL-10 were measured in all patients.
   Results: Twenty eight percent of patients (20/71) developed IRIS and were predominantly infected with HIV-1. Patients developing IRIS had lower nadir CD4 T cells at baseline (p = 0.03) and greater CD4 T cell reconstitution (p = 0.01) at six months post-ART. However, the development of IRIS was not influenced by the levels of T regulatory cells. Similarly, baseline cytokine levels did not predict the onset of IRIS.
   Conclusion: The development of IRIS was not associated with differences in levels of T regulatory cells or baseline pro-inflammatory cytokines.
C1 [Zaidi, Irfan; Peterson, Kevin; Jeffries, David; Whittle, Hilton; de Silva, Thushan; Jaye, Assan; de Jong, Bouke C.] Med Res Council UK Unit, Fajara, Gambia.
   [Peterson, Kevin; de Jong, Bouke C.] Inst Trop Med, B-2000 Antwerp, Belgium.
   [de Silva, Thushan; Rowland-Jones, Sarah] John Radcliffe Hosp, Human Immunol Unit, MRC, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [de Jong, Bouke C.] NYU, Div Infect Dis, New York, NY USA.
RP Zaidi, I (reprint author), Med Res Council UK Unit, Fajara, Gambia.
EM irfan.zaidi@gmail.com
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU MRC Unit in The Gambia
FX Funding for this study was provided by the MRC Unit in The Gambia. The
   study was approved by the scientific steering committee and the Gambia
   goverment ethics board. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Antonelli LRV, 2010, BLOOD, V116, P3818, DOI 10.1182/blood-2010-05-285080
   Barber DL, 2010, BLOOD, V116, P3485, DOI 10.1182/blood-2010-05-286336
   Berry N, 1998, J Hum Virol, V1, P457
   Bourgarit A, 2006, AIDS, V20, pF1, DOI 10.1097/01.aids.0000202648.18526.bf
   Bourgarit A, 2009, J IMMUNOL, V183, P3915, DOI 10.4049/jimmunol.0804020
   Elliott JH, 2009, J INFECT DIS, V200, P1736, DOI 10.1086/644784
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06
   Grant PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011416
   Haddow LJ, 2011, AIDS, V25, P1163, DOI 10.1097/QAD.0b013e3283477d67
   Haddow LJ, 2009, CLIN INFECT DIS, V49, P1424, DOI 10.1086/630208
   Hori S, 2004, MICROBES INFECT, V6, P745, DOI 10.1016/j.micinf.2004.02.020
   Jevtovic D, 2005, BIOMED PHARMACOTHER, V59, P446, DOI 10.1016/j.biopha.2005.07.006
   Kestens L, 2008, CURR OPIN HIV AIDS, V3, P419, DOI 10.1097/COH.0b013e328302ebbb
   Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909
   Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7
   Lawn SD, 2011, EXPERT REV ANTI-INFE, V9, P415, DOI [10.1586/eri.11.21, 10.1586/ERI.11.21]
   Lawn SD, 2009, AIDS, V23, P143, DOI 10.1097/QAD.0b013e32831d2a98
   Letang E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016946
   Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1
   Meintjes G, 2008, AM J RESP CRIT CARE, V178, P1083, DOI 10.1164/rccm.200806-858OC
   Montes M, 2011, J INFECT DIS, V203, P496, DOI 10.1093/infdis/jiq073
   Muller M, 2010, LANCET INFECT DIS, V10, P251, DOI 10.1016/S1473-3099(10)70026-8
   Murdoch DA, 2008, AIDS, V22, P601, DOI 10.1097/QAD.0b013e3282f4a607
   Murdoch David M, 2007, AIDS Res Ther, V4, P9, DOI 10.1186/1742-6405-4-9
   Ratnam I, 2006, CLIN INFECT DIS, V42, P418, DOI 10.1086/499356
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785
   Seddiki N, 2009, EUR J IMMUNOL, V39, P391, DOI 10.1002/eji.200838630
   Sereti I, 2010, CURR OPIN HIV AIDS, V5, P504, DOI 10.1097/COH.0b013e32833ed774
   Shelburne SA, 2005, CLIN INFECT DIS, V40, P1049
   Suffia IJ, 2006, J EXP MED, V203, P777, DOI 10.1084/jem.20052056
   Tan D, 2008, HIV MED, V9, P307, DOI 10.1111/j.1468-1293.2008.00565.x
   Valin N, 2010, AIDS, V24, P1519, DOI 10.1097/QAD.0b013e3283396007
NR 35
TC 8
Z9 9
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2012
VL 7
IS 6
AR e39213
DI 10.1371/journal.pone.0039213
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 964KK
UT WOS:000305693200048
PM 22745716
OA gold
DA 2017-08-15
ER

PT J
AU von Seidlein, L
   Ikonomidis, K
   Bruun, R
   Jawara, M
   Pinder, M
   Knols, BGJ
   Knudsen, JB
AF von Seidlein, Lorenz
   Ikonomidis, Konstantin
   Bruun, Rasmus
   Jawara, Musa
   Pinder, Margaret
   Knols, Bart G. J.
   Knudsen, Jakob B.
TI Airflow attenuation and bed net utilization: observations from Africa
   and Asia
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Bed nets; Africa; Tanzania; The Gambia; Asia; Thailand;
   Philippines; Airflow; Temperature; Humidity; Climate
AB Background/Methods: Qualitative studies suggest that bed nets affect the thermal comfort of users. To understand and reduce this discomfort the effect of bed nets on temperature, humidity, and airflow was measured in rural homes in Asia and Africa, as well as in an experimental wind tunnel. Two investigators with architectural training selected 60 houses in The Gambia, Tanzania, Philippines, and Thailand. Data-loggers were used to measure indoor temperatures in hourly intervals over a 12 months period. In a subgroup of 20 houses airflow, temperature and humidity were measured at five-minute intervals for one night from 21.00 to 6.00 hrs inside and outside of bed nets using sensors and omni-directional thermo-anemometers. An investigator set up a bed net with a mesh size of 220 holes per inch(2) in each study household and slept under the bed net to simulate a realistic environment. The attenuation of airflow caused by bed nets of different mesh sizes was also measured in an experimental wind tunnel.
   Results: The highest indoor temperatures (49.0 C) were measured in The Gambia. During the hottest months of the year the mean temperature at night (9 pm) was between 33.1 C (The Gambia) and 26.2 C (Thailand). The bed net attenuated the airflow from a minimum of 27% (Philippines) to a maximum of 71% (The Gambia). Overall the bed nets reduced airflow compared to un-attenuated airflow from 9 to 4 cm sec(-1) or 52% (p < 0.001). In all sites, no statistically significant difference in temperature or humidity was detected between the inside and outside of the bed net. Wind tunnel experiments with 11 different mesh-sized bed nets showed an overall reduction in airflow of 64% (range 55 - 71%) compared to un-attenuated airflow. As expected, airflow decreased with increasing net mesh size. Nets with a mesh of 136 holes inch(-2) reduced airflow by 55% (mean; range 51 - 73%). A denser net (200 holes inch-2) attenuated airflow by 59% (mean; range 56 - 74%).
   Discussion: Despite concerted efforts to increase the uptake of this intervention in many areas uptake remains poor. Bed nets reduce airflow, but have no influence on temperature and humidity. The discomfort associated with bed nets is likely to be most intolerable during the hottest and most humid period of the year, which frequently coincides with the peak of malaria vector densities and the force of pathogen transmission.
   Conclusions: These observations suggest thermal discomfort is a factor limiting bed net use and open a range of architectural possibilities to overcome this limitation.
C1 [von Seidlein, Lorenz] Menzies Sch Hlth Res, Casuarina, NT 0810, Australia.
   [Ikonomidis, Konstantin; Bruun, Rasmus; Knudsen, Jakob B.] Kongelige Danske Kunstakad, Skoler Arkitektur Design & Konservering, Arkitektskolen, Copenhagen, Denmark.
   [Jawara, Musa; Pinder, Margaret] MRC Labs, Fajara, Gambia.
   [Pinder, Margaret] London Sch Hyg & Trop Med, London WC1, England.
   [Knols, Bart G. J.] In2Care BV, Wageningen, Netherlands.
RP von Seidlein, L (reprint author), Menzies Sch Hlth Res, John Mathews Bldg,Bldg 58,POB 41096, Casuarina, NT 0810, Australia.
EM lseidlein@gmail.com
RI Knols, Bart/C-5765-2017
FU UBS Optimus Foundation
FX The project was dependent on the support of a large number of
   collaborators. We are grateful for the cooperation of the families who
   allowed us to collect data in their homes. In addition we wish the
   following individuals who helped and supported this work: Francois
   Nosten, Mondira Sarapark, Finn Andersen, Ramon Cabahug, Lamin Manneh,
   Alieu Comma, Tip, Aza, and Edna Mosha. This project has been funded by
   the UBS Optimus Foundation (www.ubs.com/optimus). The study sponsor had
   no role in the design of the study; the collection, analysis, or
   interpretation of the data; the writing of the manuscript; or the
   decision to submit the manuscript for publication.
CR Charlwood JD, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-45
   Fanger P.O., 1970, THERMAL COMFORT
   Koenigsberger O. H., 1974, MANUAL TROPICAL HO 1
   LENGELER C, 2004, COCHRANE DATABASE SY, DOI 10.1002/14651858.CD000363
   Owen SO, 2005, 2009 ASHRAE HDB FUND
   Pulford J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-83
   Thwing J, 2008, TROP MED INT HEALTH, V13, P827, DOI 10.1111/j.1365-3156.2008.02070.x
   Trape JF, 2011, LANCET INFECT DIS, V11, P925, DOI 10.1016/S1473-3099(11)70194-3
   World Health Organization, 2009, WORLD MAL REP 2009
NR 9
TC 13
Z9 13
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUN 15
PY 2012
VL 11
AR 200
DI 10.1186/1475-2875-11-200
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 008HZ
UT WOS:000308949300001
PM 22704585
OA gold
DA 2017-08-15
ER

PT J
AU Olausson, H
   Goldberg, GR
   Laskey, MA
   Schoenmakers, I
   Jarjou, LMA
   Prentice, A
AF Olausson, Hanna
   Goldberg, Gail R.
   Laskey, M. Ann
   Schoenmakers, Inez
   Jarjou, Landing M. A.
   Prentice, Ann
TI Calcium economy in human pregnancy and lactation
SO NUTRITION RESEARCH REVIEWS
LA English
DT Review
DE Calcium; Dual-energy X-ray absorptiometry; Pregnancy; Lactation;
   Metabolism; Vitamin D
ID BONE-MINERAL DENSITY; VITAMIN-D SUPPLEMENTATION; X-RAY ABSORPTIOMETRY;
   HORMONE-RELATED PEPTIDE; RURAL GAMBIAN WOMEN;
   OSTEOPROTEGERIN/OSTEOCLASTOGENESIS-INHIBITORY FACTOR; CALCANEAL
   QUANTITATIVE ULTRASOUND; NONLACTATING POSTPARTUM WOMEN; BREAST-FEEDING
   MOTHERS; POST-MENOPAUSAL WOMEN
AB Pregnancy and lactation are times of additional demand for Ca. Ca is transferred across the placenta for fetal skeletal mineralisation, and supplied to the mammary gland for secretion into breast milk. In theory, these additional maternal requirements could be met through mobilisation of Ca from the skeleton, increased intestinal Ca absorption efficiency, enhanced renal Ca retention or greater dietary Ca intake. The extent to which any or all of these apply, the underpinning biological mechanisms and the possible consequences for maternal and infant bone health in the short and long term are the focus of the present review. The complexities in the methodological aspects of interpreting the literature in this area are highlighted and the inter-individual variation in the response to pregnancy and lactation is reviewed. In summary, human pregnancy and lactation are associated with changes in Ca and bone metabolism that support the transfer of Ca between mother and child. The changes generally appear to be independent of maternal Ca supply in populations where Ca intakes are close to current recommendations. Evidence suggests that the processes are physiological in humans and that they provide sufficient Ca for fetal growth and breast-milk production, without relying on an increase in dietary Ca intake or compromising long-term maternal bone health. Further research is needed to determine the limitations of the maternal response to the Ca demands of pregnancy and lactation, especially among mothers with marginal and low dietary Ca intake, and to define vitamin D adequacy for reproductive women.
C1 [Olausson, Hanna; Goldberg, Gail R.; Laskey, M. Ann; Schoenmakers, Inez; Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Goldberg, Gail R.; Jarjou, Landing M. A.; Prentice, Ann] MRC Keneba, Keneba, Gambia.
RP Prentice, A (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
FU UK Medical Research Council [U105960371, U123261351]
FX The authors were supported by the UK Medical Research Council (unit
   programme no. U105960371 and U123261351). The present review received no
   specific grant from any funding agency in the public, commercial or
   not-for-profit sectors.
CR Abrams SA, 2011, J BONE MINER RES, V26, P2338, DOI 10.1002/jbmr.498
   Adams JE, 2004, PRACTICAL GUIDE BONE
   Affinito P, 1996, J CLIN ENDOCR METAB, V81, P2314, DOI 10.1210/jc.81.6.2314
   Aguado F, 1998, AM J OBSTET GYNECOL, V178, P1016, DOI 10.1016/S0002-9378(98)70541-1
   Akesson A, 2004, ACTA OBSTET GYN SCAN, V83, P1049, DOI 10.1111/j.0001-6349.2004.00428.x
   ALDERMAN BW, 1986, AM J EPIDEMIOL, V124, P262
   ALOIA JF, 1983, ARCH INTERN MED, V143, P1700, DOI 10.1001/archinte.143.9.1700
   American Society for Bone and Mineral Research, 2006, PRIM MET BON DIS DIS
   APTE SV, 1972, BRIT J NUTR, V27, P305, DOI 10.1079/BJN19720095
   Ardawi MSM, 1997, EUR J ENDOCRINOL, V137, P402, DOI 10.1530/eje.0.1370402
   Aspray TJ, 1996, J BONE MINER RES, V11, P1019
   Basile LA, 2006, BREASTFEED MED, V1, P27, DOI 10.1089/bfm.2006.1.27
   Bergel E, 2004, INT J EPIDEMIOL, V33, P1309, DOI 10.1093/ije/dyh362
   Bergel Eduardo, 2007, BMC Pediatr, V7, P15, DOI 10.1186/1471-2431-7-15
   Bilezikian JP, 2008, PRINCIPLES BONE BIOL
   Black AJ, 2000, J BONE MINER RES, V15, P557, DOI 10.1359/jbmr.2000.15.3.557
   Blake GM, 2006, BONE, V38, P935, DOI 10.1016/j.bone.2005.11.007
   Boushey CJ, 2006, NUTR HLTH, P39
   Brannon PM, 2008, AM J CLIN NUTR, V88, p483S
   Brannon PM, 2011, ANNU REV NUTR, V31, P89, DOI 10.1146/annurev.nutr.012809.104807
   BROOKE OG, 1981, BRIT MED J, V283, P1024
   BROOKE OG, 1980, BRIT MED J, V280, P751
   Butte NF, 2003, AM J OBSTET GYNECOL, V189, P1423, DOI 10.1067/S0002-9378(03)00596-9
   Caplan RH, 2004, J REPROD MED, V49, P214
   Carneiro RM, 2010, J CLIN ENDOCR METAB, V95, P1767, DOI 10.1210/jc.2009-1518
   Casanueva E, 2004, ADV EXP MED BIOL, V554, P341
   Chan GM, 2006, OBSTET GYNECOL, V108, P565, DOI 10.1097/01.AOG.0000231721.42823.9e
   CHAN GM, 1987, AM J CLIN NUTR, V46, P319
   Chan SM, 2005, EUR J CLIN NUTR, V59, P868, DOI 10.1038/sj.ejcn.1602148
   Chang SC, 2003, AM J CLIN NUTR, V77, P1248
   Chantry CJ, 2004, ARCH PEDIAT ADOL MED, V158, P650, DOI 10.1001/archpedi.158.7.650
   Chowdhury S, 2002, J HEALTH POPUL NUTR, V20, P26
   Clinical Trials, 2011, NCT00412074 EST VIT
   Clinical Trials, 2011, NCT01112891 VIT D PR
   COCKBURN F, 1980, BRIT MED J, V281, P11
   CONGDON P, 1983, BRIT MED J, V286, P1233
   Sawyer AJ, 2007, CURR CLIN PRACT, P1, DOI 10.1007/978-1-59745-211-3
   CROSS NA, 1995, J BONE MINER RES, V10, P1312
   CROSS NA, 1995, AM J CLIN NUTR, V61, P514
   CUMMING RG, 1993, INT J EPIDEMIOL, V22, P684, DOI 10.1093/ije/22.4.684
   Cure-Cure C, 2002, INT J GYNECOL OBSTET, V76, P285, DOI 10.1016/S0020-7292(01)00583-5
   Current Controlled Trials, 2011, ISRCTN82927713 MAT V
   DAHLMAN T, 1994, ACTA OBSTET GYN SCAN, V73, P393, DOI 10.3109/00016349409006250
   DEGRAZIA JA, 1965, J LAB CLIN MED, V66, P822
   DELVIN EE, 1986, J PEDIATR-US, V109, P328, DOI 10.1016/S0022-3476(86)80396-1
   Department of Health, 1998, NUTR BON HLTH PART R
   DeSantiago S, 2002, AM J CLIN NUTR, V76, P845
   DOBNIG H, 1995, J CLIN ENDOCR METAB, V80, P3699, DOI 10.1210/jc.80.12.3699
   DRINKWATER BL, 1991, BONE MINER, V14, P153, DOI 10.1016/0169-6009(91)90092-E
   Evans KN, 2004, J SOC GYNECOL INVEST, V11, P263, DOI 10.1016/j.jsgi.2004.02.002
   FAIRWEATHERTAIT S, 1995, AM J CLIN NUTR, V62, P1188
   FELDBLUM PJ, 1992, EPIDEMIOLOGY, V3, P527, DOI 10.1097/00001648-199211000-00012
   Fewtrell MS, 2003, ARCH DIS CHILD, V88, P795, DOI 10.1136/adc.88.9.795
   Fiore CE, 2003, HORM METAB RES, V35, P313
   Fomon SJ, 2002, ANNU REV NUTR, V22, P1, DOI 10.1146/annurev.nutr.22.111401.145049
   FORBES GB, 1976, PEDIATRICS, V57, P976
   GALLACHER SJ, 1994, EUR J ENDOCRINOL, V131, P369
   GAMBACCIANI M, 1995, AM J OBSTET GYNECOL, V173, P890, DOI 10.1016/0002-9378(95)90361-5
   Ganpule A, 2006, J CLIN ENDOCR METAB, V91, P2994, DOI 10.1210/jc.2005-2431
   GASSER A, 1979, CLIN CHIM ACTA, V95, P487, DOI 10.1016/0009-8981(79)90200-6
   GERTNER JM, 1986, AM J MED, V81, P451, DOI 10.1016/0002-9343(86)90298-6
   Godfrey K, 2001, J BONE MINER RES, V16, P1694, DOI 10.1359/jbmr.2001.16.9.1694
   Goldberg GR, 2003, NUTR ASPECTS BONE HL, P91, DOI 10.1039/9781847551559-00091
   Gordon MV, 2005, MED J AUSTRALIA, V182, P350
   GREER FR, 1984, J PEDIATR-US, V105, P431, DOI 10.1016/S0022-3476(84)80021-9
   GREER FR, 1984, J PEDIATR-US, V105, P61, DOI 10.1016/S0022-3476(84)80361-3
   GREER FR, 1984, AM J CLIN NUTR, V40, P562
   GREER FR, 1982, AM J CLIN NUTR, V36, P431
   GRILL V, 1992, CLIN ENDOCRINOL, V37, P405, DOI 10.1111/j.1365-2265.1992.tb02350.x
   GRUBER HE, 1984, METAB BONE DIS RELAT, V5, P159, DOI 10.1016/0221-8747(84)90023-7
   Halhali A, 2004, J STEROID BIOCHEM, V89-90, P553, DOI 10.1016/j.jsbmb.2004.03.069
   Hannon R, 2000, OSTEOPOROSIS INT, V11, P30
   Harvey NC, 2008, J CLIN ENDOCR METAB, V93, P1676, DOI 10.1210/jc.2007-0279
   Hawkesworth S, 2010, AM J CLIN NUTR, V92, P741, DOI 10.3945/ajcn.2010.29475
   HAYSLIP CC, 1989, OBSTET GYNECOL, V73, P588
   Heaney RP, 2008, AM J CLIN NUTR, V88, p541S
   HEANEY RP, 1971, J CLIN ENDOCR METAB, V33, P661
   Henderson PH, 2000, AM J OBSTET GYNECOL, V182, P1371, DOI 10.1067/mob.2000.107468
   Hillier TA, 2003, J BONE MINER RES, V18, P893, DOI 10.1359/jbmr.2003.18.5.893
   HILLMAN L, 1981, AM J OBSTET GYNECOL, V139, P471
   HOFFMAN S, 1993, OSTEOPOROSIS INT, V3, P171, DOI 10.1007/BF01623672
   Hofmeyr GJ, 2007, BJOG-INT J OBSTET GY, V114, P933, DOI 10.1111/j.1471-0528.2007.01389.x
   Hollis BW, 2011, J BONE MINER RES, V26, P2341, DOI 10.1002/jbmr.463
   Hollis BW, 2004, AM J CLIN NUTR, V80, p1752S
   HOLLIS BW, 1983, ANAL BIOCHEM, V131, P211, DOI 10.1016/0003-2697(83)90157-4
   Holmberg-Marttila D, 1999, OSTEOPOROSIS INT, V10, P41, DOI 10.1007/s001980050192
   Holmberg-Marttila D, 2000, OSTEOPOROSIS INT, V11, P570, DOI 10.1007/s001980070077
   Holmberg-Marttila D, 2003, OSTEOPOROSIS INT, V14, P103, DOI 10.1007/s00198-002-1320-0
   Holmberg-Marttila D, 2000, CALCIFIED TISSUE INT, V66, P184, DOI 10.1007/PL00005836
   Honda A, 1998, INT J GYNECOL OBSTET, V63, P253, DOI 10.1016/S0020-7292(98)00155-6
   Hopkinson JM, 2000, J NUTR, V130, P777
   HORSMAN A, 1989, ARCH DIS CHILD, V64, P1579
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Hosking DJ, 1996, CLIN ENDOCRINOL, V45, P1
   HOWIE PW, 1982, CLIN ENDOCRINOL, V17, P323, DOI 10.1111/j.1365-2265.1982.tb01597.x
   HRESHCHYSHYN MM, 1988, AM J OBSTET GYNECOL, V159, P318
   Hypponen E, 2010, BRIT J NUTR, V104, P309, DOI 10.1017/S0007114510002436
   Institute of Medicine, 2011, DIETARY REFERENCE IN
   [Institute of Medicine Food and Nutrition Board], 1997, DIET REF INT CALC PH
   Ilich JZ, 2000, J AM COLL NUTR, V19, P715
   Janakiraman V, 2003, AM J PREV MED, V24, P260, DOI 10.1016/S0749-3797(02)00641-4
   Jarjou LMA, 2012, EUR J CLIN NUTR, V66, P673, DOI 10.1038/ejcn.2012.7
   Jarjou LMA, 2010, AM J CLIN NUTR, V92, P450, DOI 10.3945/ajcn.2010.29217
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   Jarjou LMA, 2008, BREAST FEEDING EARLY, P376
   Jarjou LMA, 2004, THESIS OPEN U MILTON
   Javaid MK, 2005, J CLIN ENDOCR METAB, V90, P5182, DOI 10.1210/jc.2005-0195
   Javaid MK, 2006, LANCET, V367, P36, DOI 10.1016/S0140-6736(06)67922-1
   Johansen A, 1997, OSTEOPOROSIS INT, V7, P44, DOI 10.1007/BF01623459
   Jones D, 2003, THESIS U CAMBRIDGE C
   Jones D, 2008, BREAST FEEDING EARLY, P415
   Jones G, 2000, EUR J CLIN NUTR, V54, P749, DOI 10.1038/sj.ejcn.1601082
   KALENDER WA, 1992, OSTEOPOROSIS INT, V2, P82, DOI 10.1007/BF01623841
   Kalkwarf HJ, 1997, NEW ENGL J MED, V337, P523, DOI 10.1056/NEJM199708213370803
   Kalkwarf HJ, 1999, J CLIN ENDOCR METAB, V84, P464, DOI 10.1210/jc.84.2.464
   Kalkwarf HJ, 1999, J MAMMARY GLAND BIOL, V4, P319, DOI 10.1023/A:1018780425600
   KALKWARF HJ, 1995, OBSTET GYNECOL, V86, P26, DOI 10.1016/0029-7844(95)00083-4
   Kalkwarf HJ, 1996, AM J CLIN NUTR, V63, P526
   Karlsson C, 2001, OSTEOPOROSIS INT, V12, P828, DOI 10.1007/s001980170033
   Kaur M, 2003, ANN CLIN BIOCHEM, V40, P508, DOI 10.1258/000456303322326416
   Kaur M, 2003, BONE, V32, P449, DOI 10.1016/S8756-3282(03)00017-6
   KENT GN, 1990, J BONE MINER RES, V5, P361
   KENT GN, 1993, OSTEOPOROSIS INT, V3, pS44
   KENT GN, 1991, MINER ELECTROL METAB, V17, P1
   Kent Jacqueline C, 2009, Breastfeed Rev, V17, P5
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   KLEEREKOPER M, 1989, BONE MINER, V7, P171, DOI 10.1016/0169-6009(89)90074-3
   KLEIN CJ, 1995, AM J CLIN NUTR, V61, P779
   Kolthoff N, 1998, CLIN SCI, V94, P405
   Koo W, 2006, AM J CLIN NUTR, V84, P943
   KOO WWK, 1995, J BONE MINER RES, V10, P1111
   Koo WWK, 1998, J AM COLL NUTR, V17, P65
   Koo WWK, 2002, J NUTR, V132, P1380
   Koo WWK, 1999, OBSTET GYNECOL, V94, P577, DOI 10.1016/S0029-7844(99)00371-3
   Koo WWK, 1996, J BONE MINER RES, V11, P997
   Kovacs CS, 2008, AM J CLIN NUTR, V88, p520S
   Kovacs CS, 2005, J MAMMARY GLAND BIOL, V10, P105, DOI 10.1007/s10911-005-5394-0
   Kovacs CS, 2001, J CLIN ENDOCR METAB, V86, P2344, DOI 10.1210/jc.86.6.2344
   Kovacs CS, 1997, ENDOCR REV, V18, P832, DOI 10.1210/er.18.6.832
   Krebs NF, 1997, AM J CLIN NUTR, V65, P1738
   KREIGER N, 1982, AM J EPIDEMIOL, V116, P141
   KREIGER N, 1992, INT J EPIDEMIOL, V21, P953, DOI 10.1093/ije/21.5.953
   KRISHNAMACHARI KAVR, 1975, AM J CLIN NUTR, V28, P482
   KUMAR R, 1979, J CLIN INVEST, V63, P342, DOI 10.1172/JCI109308
   Laskey MA, 1996, NUTRITION, V12, P45, DOI 10.1016/0899-9007(95)00017-8
   LASKEY MA, 1990, ACTA PAEDIATR SCAND, V79, P507, DOI 10.1111/j.1651-2227.1990.tb11504.x
   Laskey MA, 2000, J BONE MINER RES, V15, P1232
   Laskey MA, 1998, AM J CLIN NUTR, V67, P685
   Laskey MA, 2004, J CLIN DENSITOM, V7, P296, DOI 10.1385/JCD:7:3:296
   Laskey MA, 2004, J CLIN DENSITOM, V7, P341, DOI 10.1385/JCD:7:3:341
   Laskey MA, 1997, LANCET, V349, P1518, DOI 10.1016/S0140-6736(05)62097-1
   Laskey MA, 1999, OBSTET GYNECOL, V94, P608, DOI 10.1016/S0029-7844(99)00369-5
   Lenora Janaka, 2009, BMC Womens Health, V9, P19, DOI 10.1186/1472-6874-9-19
   Lippuner K, 1996, J BONE MINER RES, V11, P1394
   LISSNER L, 1991, CALCIFIED TISSUE INT, V48, P319, DOI 10.1007/BF02556151
   Liu Z, 2011, ARCH GYNECOL OBSTET, V283, P205, DOI 10.1007/s00404-009-1345-0
   Lopez JM, 1996, OSTEOPOROSIS INT, V6, P153, DOI 10.1007/BF01623940
   MALLET E, 1986, OBSTET GYNECOL, V68, P300
   Mannion CA, 2006, CAN MED ASSOC J, V174, P1273, DOI 10.1503/cmaj.1041388
   Gomez JM, 2006, CURR PHARM BIOTECHNO, V7, P125
   Marks Jr S.C., 2002, PRINCIPLES BONE BIOL, P3, DOI 10.1016/B978-012098652-1.50103-7
   MARYA RK, 1988, INDIAN J MED RES, V88, P488
   MARYA RK, 1981, GYNECOL OBSTET INVES, V12, P155
   Mather KJ, 1999, J CLIN ENDOCR METAB, V84, P424, DOI 10.1210/jc.84.2.424
   McGrath JJ, 2005, EARLY HUM DEV, V81, P609, DOI 10.1016/j.earlhumdev.2005.03.013
   MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P76, DOI 10.1007/BF01623377
   Michaelsson K, 2001, AM J EPIDEMIOL, V153, P1166, DOI 10.1093/aje/153.12.1166
   Molgaard C, 1997, ARCH DIS CHILD, V76, P9
   More C, 2003, EUR J OBSTET GYN R B, V106, P209, DOI 10.1016/S0301-2115(02)00237-3
   More C, 2001, OSTEOPOROSIS INT, V12, P732, DOI 10.1007/s001980170048
   Morley R, 2006, J CLIN ENDOCR METAB, V91, P906, DOI 10.1210/jc.2005-1479
   MOSER PB, 1988, AM J CLIN NUTR, V47, P735
   NAMGUNG R, 1994, J PEDIATR GASTR NUTR, V19, P220, DOI 10.1097/00005176-199408000-00013
   Namgung R, 1998, J PEDIATR-US, V132, P421, DOI 10.1016/S0022-3476(98)70013-7
   Naylor KE, 2003, J CLIN ENDOCR METAB, V88, P5361, DOI 10.1210/jc.2003-030486
   Naylor KE, 2000, J BONE MINER RES, V15, P129, DOI 10.1359/jbmr.2000.15.1.129
   Njeh CF, 1999, APPL RADIAT ISOTOPES, V50, P215, DOI 10.1016/S0969-8043(98)00026-8
   Njeh CF, 2000, OSTEOPOROSIS INT, V11, P1051
   O'Brien KO, 2006, AM J CLIN NUTR, V83, P317
   O'Sullivan SM, 2006, OSTEOPOROSIS INT, V17, P1008, DOI 10.1007/s00198-006-0112-3
   Olausson H, 2007, J HUM LACT, V23, P98
   Olausson H, 2008, AM J CLIN NUTR, V88, P1032
   Ortega RM, 1998, BRIT J NUTR, V79, P501, DOI 10.1079/BJN19980088
   Orwoll ES, 2003, J BONE MINER RES, V18, P949, DOI 10.1359/jbmr.2003.18.6.949
   Paoletti AM, 2003, HORM RES, V59, P21, DOI 10.1159/000067935
   Paparella P., 1995, Clinical and Experimental Obstetrics and Gynecology, V22, P268
   Parsons TJ, 1996, J BONE MINER RES, V11, P264
   Paton LM, 2003, AM J CLIN NUTR, V77, P707
   Pawley N, 2004, AM J CLIN NUTR, V80, p1748S
   Pearson D, 2004, BONE, V34, P570, DOI 10.1016/j.bone.2003.11.005
   PITKIN RM, 1985, AM J OBSTET GYNECOL, V151, P99
   PITKIN RM, 1979, AM J OBSTET GYNECOL, V133, P781
   Pluskiewicz W, 2004, ULTRASOUND MED BIOL, V30, P1373, DOI 10.1016/j.ultrasmedbio.2004.08.013
   Polatti F, 1999, OBSTET GYNECOL, V94, P52, DOI 10.1016/S0029-7844(99)00236-7
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   Prentice A, 2007, P NUTR SOC, V66, p19A
   PRENTICE A, 1995, AM J CLIN NUTR, V62, P58
   PRENTICE A, 1991, BONE MINER, V12, P201, DOI 10.1016/0169-6009(91)90033-V
   Prentice A, 1997, ACTA PAEDIATR, V86, P1006, DOI 10.1111/j.1651-2227.1997.tb15189.x
   Prentice A, 2004, PUBLIC HEALTH NUTR, V7, P227, DOI 10.1079/PHN2003590
   Prentice A, 1998, J CLIN ENDOCR METAB, V83, P1059, DOI 10.1210/jc.83.4.1059
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   PRENTICE A, 1994, EUR J CLIN NUTR, V48, pS161
   PRENTICE A, 1994, LANCET, V344, P411, DOI 10.1016/S0140-6736(94)91440-0
   Prentice A, 2000, ANNU REV NUTR, V20, P249, DOI 10.1146/annurev.nutr.20.1.249
   Prentice A., 1999, NUTR BONE DEV, P127
   Prentice A., 2003, PEDIAT BONE BIOL DIS, P249, DOI 10.1016/B978-012286551-0/50012-9
   Prentice A., 2008, NUTR REV, V66, P153
   Prentice A, 2008, AM J CLIN NUTR, V88, p500S
   Prentice A, 2006, P NUTR SOC, V65, P348, DOI 10.1079/PNS2006519
   Prentice A, 2006, AM J CLIN NUTR, V84, P944
   Prentice Ann, 1995, V36, P1
   RAMAN L, 1978, AM J CLIN NUTR, V31, P466
   REITER EO, 1979, AM J OBSTET GYNECOL, V135, P227
   Riordan Jan, 1993, BREASTFEEDING HUMAN
   Ritchie LD, 1998, AM J CLIN NUTR, V67, P693
   RODIN A, 1989, J CLIN ENDOCR METAB, V68, P1123
   Rousiere M, 2001, JOINT BONE SPINE, V68, P71, DOI 10.1016/S1297-319X(01)00262-7
   Rutishauser I. H. E., 2002, Introduction to human nutrition, P225
   Schnatz PF, 2010, MENOPAUSE, V17, P1161, DOI 10.1097/gme.0b013e3181e0efb3
   Scientific Advisory Committee on Nutrition, 2007, UPD VIT D POS STAT S
   Scientific Advisory Committee on Nutrition, 2011, INFL MAT FET CHILD N
   Seki K, 1997, GYNECOL OBSTET INVES, V44, P102
   SMITH R, 1998, SCAND J RHEUMATOL S, V107, P66
   Sowers M, 1998, AM J CLIN NUTR, V67, P284
   SOWERS M, 1995, J CLIN ENDOCR METAB, V80, P2210, DOI 10.1210/jc.80.7.2210
   SOWERS M, 1995, OBSTET GYNECOL, V85, P285, DOI 10.1016/0029-7844(94)00351-D
   SOWERS M, 1993, JAMA-J AM MED ASSOC, V269, P3130, DOI 10.1001/jama.269.24.3130
   SOWERS M, 1991, OBSTET GYNECOL, V77, P841
   Sowers M, 1996, J BONE MINER RES, V11, P1052
   Sowers MF, 1996, JAMA-J AM MED ASSOC, V276, P549, DOI 10.1001/jama.276.7.549
   Sowers MF, 2000, OBSTET GYNECOL, V96, P189, DOI 10.1016/S0029-7844(00)00903-0
   Specker B, 2005, OSTEOPOROSIS INT, V16, P1969, DOI 10.1007/s00198-005-1978-1
   Specker B, 2004, AM J CLIN NUTR, V80, p1740S
   SPECKER BL, 1994, AM J CLIN NUTR, V59, P593
   SPECKER BL, 1992, J PEDIATR-US, V120, P733, DOI 10.1016/S0022-3476(05)80236-7
   SPECKER BL, 1994, AM J CLIN NUTR, V59, p484S
   SPECKER BL, 1991, OBSTET GYNECOL, V78, P56
   STEVENSON JC, 1979, LANCET, V2, P769
   Stewart A, 2000, BONE, V27, P139, DOI 10.1016/S8756-3282(00)00304-5
   To WWK, 2003, ACTA OBSTET GYN SCAN, V82, P820, DOI 10.1034/j.1600-0412.2003.00227.x
   Tranquilli AL, 2004, GYNECOL ENDOCRINOL, V18, P258, DOI 10.1080/09513590410001715216
   TURNER M, 1988, MINER ELECTROL METAB, V14, P246
   Uemura H, 1997, J ENDOCRINOL, V153, P445, DOI 10.1677/joe.0.1530445
   Uemura H, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740353
   Ulrich U., 2003, Archives of Gynecology and Obstetrics, V268, P309, DOI 10.1007/s00404-002-0410-8
   VAUGHAN LA, 1979, AM J CLIN NUTR, V32, P2301
   Veitch SW, 2004, J CLIN DENSITOM, V7, P209, DOI 10.1385/JCD:7:2:209
   Wagner CL, 2006, BREASTFEED MED, V1, P59, DOI 10.1089/bfm.2006.1.59
   WALKER ARP, 1972, AM J CLIN NUTR, V25, P518
   WALKER ARP, 1972, CLIN SCI, V42, P189
   WARDLAW GM, 1986, AM J CLIN NUTR, V44, P283
   Weaver CM, 2006, NUTR HLTH, P65
   Weaver CM, 2006, CURR OPIN CLIN NUTR, V9, P568, DOI 10.1097/01.mco.0000241666.46008.2c
   Weiler H, 2005, CAN MED ASSOC J, V172, P757, DOI 10.1503/cmaj.1040508
   Widdowson EM, 1964, MINER METABOL, P1
   Wisser J, 2005, ACTA OBSTET GYN SCAN, V84, P349, DOI 10.1111/j.0001-6349.2005.00766.x
   Wosje KS, 2004, AM J CLIN NUTR, V80, P423
   Wysolmerski JJ, 1998, ANNU REV PHYSIOL, V60, P431, DOI 10.1146/annurev.physiol.60.1.431
   Yamaga A, 1996, J CLIN ENDOCR METAB, V81, P752, DOI 10.1210/jc.81.2.752
   Yano K, 2001, BIOCHEM BIOPH RES CO, V288, P217, DOI 10.1006/bbrc.2001.5745
   Yasumizu T, 1998, ENDOCR J, V45, P679
   Yoon BK, 2000, J KOREAN MED SCI, V15, P189
   Zapata CLV, 2004, AM J CLIN NUTR, V80, P417
   Zeni S, 2003, CALCIFIED TISSUE INT, V73, P594, DOI 10.1007/s00223-002-1093-7
   Zeni SN, 2003, BONE, V33, P606, DOI 10.1016/S8956-3282(03)00203-5
   ZIEGLER EE, 1976, GROWTH, V40, P329
NR 267
TC 28
Z9 29
U1 0
U2 28
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0954-4224
EI 1475-2700
J9 NUTR RES REV
JI Nutr. Res. Rev.
PD JUN
PY 2012
VL 25
IS 1
BP 40
EP 67
DI 10.1017/S0954422411000187
PG 28
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 984FU
UT WOS:000307176300004
PM 22894942
OA No
DA 2017-08-15
ER

PT J
AU Salter, SJ
   Hinds, J
   Gould, KA
   Lambertsen, L
   Hanage, WP
   Antonio, M
   Turner, P
   Hermans, PWM
   Bootsma, HJ
   O'Brien, KL
   Bentley, SD
AF Salter, S. J.
   Hinds, J.
   Gould, K. A.
   Lambertsen, L.
   Hanage, W. P.
   Antonio, M.
   Turner, P.
   Hermans, P. W. M.
   Bootsma, H. J.
   O'Brien, K. L.
   Bentley, S. D.
TI Variation at the capsule locus, cps, of mistyped and non-typable
   Streptococcus pneumoniae isolates
SO MICROBIOLOGY-SGM
LA English
DT Article
ID COAGGREGATION RECEPTOR POLYSACCHARIDES; SEROTYPE 19A; SEQUENCE
   ALIGNMENT; INVASIVE DISEASE; UNITED-STATES; PNEUMOCOCCI; IDENTIFICATION;
   POPULATION; DYNAMICS; CHILDREN
AB The capsule polysaccharide locus (cps) is the site of the capsule biosynthesis gene cluster in encapsulated Streptococcus pneumoniae. A set of pneumococcal samples and non-pneumococcal streptococci from Denmark, the Gambia, the Netherlands, Thailand, the UK and the USA were sequenced at the cps locus to elucidate serologically mistyped or non-typable isolates. We identified a novel serotype 33B/33C mosaic capsule cluster and previously unseen serotype 22F capsule genes, disrupted and deleted cps clusters, the presence of aliB and nspA genes that are unrelated to capsule production, and similar genes in the non-pneumococcal samples. These data provide greater understanding of diversity at a locus which is crucial to the antigenic diversity of the pathogen and current vaccine strategies.
C1 [Salter, S. J.; Bentley, S. D.] Wellcome Trust Sanger Inst, Hinxton, England.
   [Hinds, J.; Gould, K. A.] Univ London, London WC1E 7HU, England.
   [Lambertsen, L.] Statens Serum Inst, DK-2300 Copenhagen, Denmark.
   [Hanage, W. P.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Antonio, M.] MRC Labs, Fajara, Gambia.
   [Turner, P.] Shoklo Malaria Res Unit, Mae Sot, Thailand.
   [Turner, P.] Univ Oxford, Ctr Trop Med, Oxford OX1 2JD, England.
   [Hermans, P. W. M.; Bootsma, H. J.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
   [O'Brien, K. L.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Salter, SJ (reprint author), Wellcome Trust Sanger Inst, Hinxton, England.
EM sb18@sanger.ac.uk
RI Hermans, Peter/F-4655-2010; Hermans, Peter/H-8042-2014
OI Salter, Susannah/0000-0003-3898-8504; Lambertsen,
   Lotte/0000-0001-6409-6337; Turner, Paul/0000-0002-1013-7815
FU Wellcome Trust [076964, 083735]; Royal Society; National Institute of
   General Medical Sciences [U54GM088558]; European Community
   [HEALTH-F3-2009-222983]
FX This work was supported by Wellcome Trust grant 076964. P. T. is
   supported by Wellcome Trust grant number 083735; W. P. H. has been
   supported by the Royal Society (University Research Fellowship) and
   National Institute of General Medical Sciences award number U54GM088558;
   H. J. B. is supported by European Community's Seventh Framework
   Programme FP7/2007-2013 under grant agreement number
   HEALTH-F3-2009-222983 (Pneumopath project). We would like to thank the
   Sanger core sequencing team and Christa van der Gaast-de Jongh for
   technical assistance, and Nicholas Croucher for his comments on this
   manuscript.
CR Aanensen DM, 2007, J BACTERIOL, V189, P7856, DOI 10.1128/JB.00837-07
   Ansaldi F, 2011, CLIN VACCINE IMMUNOL, V18, P343, DOI 10.1128/CVI.00383-10
   Beall BW, 2011, J INFECT DIS, V203, P1360, DOI 10.1093/infdis/jir052
   Bentley SD, 2006, PLOS GENET, V2, P262, DOI 10.1371/journal.pgen.0020031
   Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992
   Brueggemann AB, 2004, J INFECT DIS, V190, P1203, DOI 10.1086/423820
   Brueggemann AB, 2007, PLOS PATHOG, V3, P1628, DOI 10.1371/journal.ppat.0030168
   Brugger SD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011638
   Cole JR, 2007, NUCLEIC ACIDS RES, V35, pD169, DOI 10.1093/nar/gkl889
   Croucher NJ, 2011, SCIENCE, V331, P430, DOI 10.1126/science.1198545
   Dagan R, 2009, J INFECT DIS, V199, P776, DOI 10.1086/597044
   Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636
   Donati C, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r107
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Elm C, 2004, J BIOL CHEM, V279, P6296, DOI 10.1074/jbc.M310528200
   Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259
   Hammerschmidt S, 2005, INFECT IMMUN, V73, P4653, DOI 10.1128/IAI.73.8.4653-4667.2005
   Hanage WP, 2006, J CLIN MICROBIOL, V44, P743, DOI 10.1128/JCM.44.3.743-749.2006
   Hanage WP, 2005, INFECT IMMUN, V73, P431, DOI 10.1128/IAI.73.1.431-435.2005
   Hathaway LJ, 2004, J BACTERIOL, V186, P3721, DOI 10.1128/JB.186.12.3721-3729.2004
   Hathaway L. J., 2010, 7 INT S PNEUM PNEUM
   Hulo N, 2008, NUCLEIC ACIDS RES, V36, pD245, DOI 10.1093/nar/gkm977
   Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348
   Kerr AR, 2004, INFECT IMMUN, V72, P3902, DOI 10.1128/IAI.72.7.3902-3906.2004
   Kim JO, 1999, INFECT IMMUN, V67, P2327
   Kirkham LAS, 2006, J CLIN MICROBIOL, V44, P151, DOI 10.1128/JCM.44.1.151-159.2006
   Llull D, 1999, J EXP MED, V190, P241, DOI 10.1084/jem.190.2.241
   Marsh R, 2010, J CLIN MICROBIOL, V48, P831, DOI 10.1128/JCM.01701-09
   McMurray AA, 1998, GENOME RES, V8, P562
   Melin M, 2010, INFECT IMMUN, V78, P5262, DOI 10.1128/IAI.00740-10
   Moore MR, 2008, J INFECT DIS, V197, P1016, DOI 10.1086/528996
   Munoz R, 1997, MOL MICROBIOL, V25, P79, DOI 10.1046/j.1365-2958.1997.4341801.x
   Munoz-Almagro C, 2009, J INFECTION, V59, P75, DOI 10.1016/j.jinf.2009.05.012
   Nebenzahl YM, 2004, FEMS MICROBIOL LETT, V233, P147, DOI 10.1016/j.femsle.2004.02.003
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Oggioni MR, 1999, MICROBIOL-SGM, V145, P2647
   Paton J. C., 2007, MOL BIOL STREPTOCOCC, P119
   Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Siguier P, 2006, NUCLEIC ACIDS RES, V34, pD32, DOI 10.1093/nar/gkj014
   Temime L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003244
   Turner P, 2011, J CLIN MICROBIOL, V49, P1784, DOI 10.1128/JCM.00157-11
   van Selm S, 2003, INFECT IMMUN, V71, P6192, DOI 10.1128/IAI.71.11.6192-6198.2003
   Waite RD, 2003, MICROBIOL-SGM, V149, P497, DOI 10.1099/mic.0.26011-0
   Weinberger DM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000476
   Yang JH, 2009, J BACTERIOL, V191, P1891, DOI 10.1128/JB.01532-08
   Yoshida Y, 2006, J BACTERIOL, V188, P4125, DOI 10.1128/JB.01843-05
   Yu JG, 2011, CLIN VACCINE IMMUNOL, V18, P1900, DOI 10.1128/CVI.05312-11
NR 48
TC 28
Z9 31
U1 0
U2 2
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 1350-0872
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD JUN
PY 2012
VL 158
BP 1560
EP 1569
DI 10.1099/mic.0.056580-0
PN 6
PG 10
WC Microbiology
SC Microbiology
GA 975HG
UT WOS:000306500700018
PM 22403189
OA No
DA 2017-08-15
ER

PT J
AU van Tienen, C
   de Silva, TI
   Alcantara, LCJ
   Onyango, CO
   Jarju, S
   Goncalves, N
   Vincent, T
   Aaby, P
   Whittle, H
   van der Loeff, MS
   Cotten, M
AF van Tienen, Carla
   de Silva, Thushan I.
   Junior Alcantara, Luiz Carlos
   Onyango, Clayton O.
   Jarju, Sheikh
   Goncalves, Nato
   Vincent, Tim
   Aaby, Peter
   Whittle, Hilton
   van der Loeff, Maarten Schim
   Cotten, Matthew
TI Molecular Epidemiology of Endemic Human T-Lymphotropic Virus Type 1 in a
   Rural Community in Guinea-Bissau
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID WEST-AFRICAN POPULATION; RETROVIRUS INFECTIONS; RISK-FACTORS; STLV-I;
   HTLV-1; TRANSMISSION; PREVALENCE; HIV-2; INDIVIDUALS; SUBTYPES
AB Background: Human T-Lymphotropic Virus Type 1 (HTLV-1) infection causes lethal adult T-cell leukemia (ATL) and severely debilitating HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in up to 5% of infected adults. HTLV-1 is endemic in parts of Africa and the highest prevalence in West Africa (5%) has been reported in Caio, a rural area in the North-West of Guinea-Bissau. It is not known which HTLV-1 variants are present in this community. Sequence data can provide insights in the molecular epidemiology and help to understand the origin and spread of HTLV-1.
   Objective: To gain insight into the molecular diversity of HTLV-1 in West Africa.
   Methods: HTLV-1 infected individuals were identified in community surveys between 1990-2007. The complete Long Terminal Repeat (LTR) and p24 coding region of HTLV-1 was sequenced from infected subjects. Socio-demographic data were obtained from community census and from interviews performed by fieldworkers. Phylogenetic analyses were performed to characterize the relationship between the Caio HTLV-1 and HTLV-1 from other parts of the world.
   Results: LTR and p24 sequences were obtained from 72 individuals (36 LTR, 24 p24 only and 12 both). Consistent with the low evolutionary change of HTLV-1, many of the sequences from unrelated individuals showed 100% nucleotide identity. Most (45 of 46) of the LTR sequences clustered with the Cosmopolitan HTLV-1 subtype 1a, subgroup D (1aD). LTR and p24 sequences from two subjects were divergent and formed a significant cluster with HTLV-1 subtype 1g, and with the most divergent African Simian T-cell Lymphotropic Virus, Tan90.
   Conclusions: The Cosmopolitan HTLV-1 1aD predominates in this rural West African community. However, HTLV-1 subtype 1g is also present. This subtype has not been described before in West Africa and may be more widespread than previously thought. These data are in line with the hypothesis that multiple monkey-to-man zoonotic events are contributing to HTLV-1 diversity.
C1 [van Tienen, Carla; de Silva, Thushan I.; Onyango, Clayton O.; Jarju, Sheikh; Goncalves, Nato; Vincent, Tim; Whittle, Hilton; Cotten, Matthew] MRC, Fajara, Gambia.
   [van Tienen, Carla] Erasmus MC, Rotterdam, Netherlands.
   [de Silva, Thushan I.] UCL, UCL Ctr Med Mol Virol, Div Infect & Immun, London, England.
   [Junior Alcantara, Luiz Carlos] Fundacao Oswaldo Cruz, Publ Hlth Adv Lab, Goncalo Moniz Res Ctr, Salvador, BA, Brazil.
   [Junior Alcantara, Luiz Carlos] Bahia Sch Med & Publ Hlth Fdn Sci Dev, Salvador, BA, Brazil.
   [Onyango, Clayton O.] KEMRI Wellcome Trust Programme, Kilifi, Kenya.
   [Goncalves, Nato; Aaby, Peter] Indepth Network, Projecto Saude Bandim, Bissau, Guinea Bissau.
   [van der Loeff, Maarten Schim] Hlth Serv Amsterdam GGD, Amsterdam, Netherlands.
   [van der Loeff, Maarten Schim] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [Cotten, Matthew] Wellcome Trust Sanger Inst, Cambridge, England.
RP van Tienen, C (reprint author), MRC, Fajara, Gambia.
EM c.vantienen@erasmusmc.nl
RI van Tienen, Carla/A-1119-2012
FU Medical Research Council (UK/The Gambia)
FX This research was funded by the Medical Research Council (UK/The
   Gambia). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Alcantara LC, 2003, JAIDS-J ACQ IMM DEF, V33, P536
   Alcantara LCJ, 2006, AIDS, V20, P780, DOI 10.1097/01.aids.0000216383.14808.13
   Ariyoshi K, 2003, J INFECT DIS, V188, P1648, DOI 10.1086/379780
   Brucato N, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-314
   Buckner M, 2004, ENCY SEX GENDER MEN, P617
   Calattini S, 2011, VIROLOGY, V410, P48, DOI 10.1016/j.virol.2010.10.025
   Cooper S, 2009, J NEUROL NEUROSUR PS, V80, P66, DOI 10.1136/jnnp.2008.152819
   Diop S, 2006, J CLIN MICROBIOL, V44, P1550, DOI 10.1128/JCM.44.4.1550-1554.2006
   Etenna SLD, 2008, J CLIN MICROBIOL, V46, P3607, DOI 10.1128/JCM.01249-08
   Fouchard N, 1998, LEUKEMIA, V12, P578, DOI 10.1038/sj.leu.2400956
   Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Hlela C, 2009, AIDS REV, V11, P205
   Holmgren B, 1999, SCAND J INFECT DIS, V31, P459
   Iga M, 2002, J INFECT DIS, V185, P691, DOI 10.1086/339002
   Kakuda K, 2002, AM J TROP MED HYG, V66, P404
   Krook A, 1997, J ACQ IMMUN DEF SYND, V15, P381
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   MAHE A, 1994, ANN DERMATOL VENER, V121, P704
   Mahe A, 2004, BRIT J DERMATOL, V150, P958, DOI 10.1111/j.1365-2133.2003.05834.x
   Mauclere P, 2011, J INFECT DIS, V203, P1316, DOI 10.1093/infdis/jir031
   Melbye M, 1998, INT J CANCER, V76, P293, DOI 10.1002/(SICI)1097-0215(19980504)76:3<293::AID-IJC1>3.0.CO;2-Q
   Nicholas KB, 1997, EMBNET NEWS, P4
   Padua E, 2011, AIDS RES HUM RETROV, V27, P317, DOI 10.1089/aid.2010.0195
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   Pepin J, 2006, AIDS, V20, P1303
   Pepin J, 2010, CLIN INFECT DIS, V51, P777, DOI 10.1086/656232
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   SAKSENA NK, 1993, VIROLOGY, V192, P312, DOI 10.1006/viro.1993.1035
   Salemi M, 1998, VIROLOGY, V246, P277, DOI 10.1006/viro.1998.9215
   Slattery JP, 1999, GENOME RES, V9, P525
   Swofford DL, 2002, PAUP PHYLOGENETIC AN
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   Van Dooren S, 2005, J GEN VIROL, V86, P1953, DOI 10.1099/vir.0.80520-0
   Van Dooren S, 2004, MOL BIOL EVOL, V21, P603, DOI 10.1093/molbev/msh053
   Van Dooren S, 2001, MOL BIOL EVOL, V18, P661
   Van Dooren S, 1998, J GEN VIROL, V79, P2695
   Van Dooren S, 2007, INFECT GENET EVOL, V7, P374, DOI 10.1016/j.meegid.2006.06.003
   van Tienen C, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-50
   van Tienen C, 2010, JAIDS-J ACQ IMM DEF, V53, P640, DOI 10.1097/QAI.0b013e3181bf1a25
   Vandamme AM, 1998, TRENDS MICROBIOL, V6, P477, DOI 10.1016/S0966-842X(98)01406-1
   van Tienen C, 2011, AIDS RES HUM RETROVI
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   Vicente ACP, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001038
   WATTEL E, 1995, J VIROL, V69, P2863
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   Wolfe ND, 2005, P NATL ACAD SCI USA, V102, P7994, DOI 10.1073/pnas.0501734102
   Wolfe ND, 2004, LANCET, V363, P932, DOI 10.1016/S0140-6736(04)15787-5
   Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371
   Zehender G, 2008, JAIDS-J ACQ IMM DEF, V47, P269
NR 51
TC 7
Z9 7
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2012
VL 6
IS 6
AR e1690
DI 10.1371/journal.pntd.0001690
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 967YY
UT WOS:000305945300031
PM 22720106
OA gold
DA 2017-08-15
ER

PT J
AU Jarjou, LMA
   Goldberg, GR
   Coward, WA
   Prentice, A
AF Jarjou, L. M. A.
   Goldberg, G. R.
   Coward, W. A.
   Prentice, A.
TI Calcium intake of rural Gambian infants: a quantitative study of the
   relative contributions of breast milk and complementary foods at 3 and
   12 months of age
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE calcium intake; breast-milk intake; breast-milk calcium concentration;
   infant growth; dose-to-the-mother method; The Gambia
ID DEVELOPING-COUNTRIES; GROWTH; MOTHERS; LACTATION; CHILDREN; VOLUME;
   WOMEN; FAT
AB BACKGROUND/OBJECTIVES: There is a paucity of information from developing countries on total calcium intake during infancy, and potential consequences for growth and bone development.
   DESIGN: Observational longitudinal study of rural Gambian infants (13 males and 17 females) at 3 and 12 months of age.
   SUBJECTS/METHODS: Breast-milk intake and calcium concentration, weighed dietary intake, anthropometry, midshaft radius bone mineral content (BMC) and bone width (BW).
   RESULTS: At 3 and 12 months (mean +/- s.d.) calcium intake from breast milk was 179 +/- 53 and 117 +/- 38, and from other foods 12 +/- 38 and 73 +/- 105 mg/day. There was no difference in total calcium intake; 94% and 62% of calcium came from breast milk. At 3 and 12 months, weight s.d.-scores were -0.441 +/- 1.07 and -1.967 +/- 1.06; length s.d.-scores were -0.511 +/- 1.04 and -1.469 +/- 1.13. Breast-milk calcium intake positively predicted weight (P = 0.0002, P <= 0.0001) and length (P = 0.056, P = 0.001). These relationships were not independent of breast-milk intake, which positively predicted weight (P <= 0.002) and length (P = 0.06, P = 0.004). At 3, but not 12 months, weight and length correlated with total calcium intake. There were no relationships between total calcium intake and breast-milk intake with BW or BMC.
   CONCLUSION: The combination of low calcium intake from breast milk and complementary foods resulted in a low total calcium intake close to the estimated biological requirement for bone mineral accretion. Relationships between calcium intake and growth were largely accounted for by breast-milk intake, suggesting that low calcium intake per se was not the limiting factor in the poor growth. These findings have potential implications for deriving calcium requirements in developing countries.
C1 [Jarjou, L. M. A.; Goldberg, G. R.; Prentice, A.] MRC Keneba, Fajara, Gambia.
   [Goldberg, G. R.; Coward, W. A.; Prentice, A.] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
RP Jarjou, LMA (reprint author), MRC Keneba, POB 273, Fajara, Gambia.
EM ljarjou@mrc.gm
FU UK Medical Research Council [U105960371, U123261351]; European
   Commission [TS2*.0028.UK(JR)]
FX This work was supported by the UK Medical Research Council (Unit
   Programme numbers U105960371 and U123261351), and the European
   Commission under the Science and Technology Development Programme,
   TS2*.0028.UK(JR). We thank the mothers and infants from Keneba and
   Manduar for their participation. We also thank members of staff of MRC
   Keneba involved in the study; Mr Yankuba Sawo, Miss Sainabou Darboe, Dr
   Simon Hoare, Sister Frances Foord for assisting with recruiting mothers
   and their children; members of staff formerly at the MRC Dunn Nutrition
   Unit in Cambridge, Professor Andrew Prentice (now at MRC International
   Group, London School of Hygiene and Tropical Medicine, London) and
   Professor Roger Whitehead for facilitating LMAJ's training; Dorothy
   Stirling for assisting with the breast-milk calcium analysis; Professor
   Tim J Cole (now at MRC Centre For Paediatric Epidemiology and
   Biostatistics, Institute of Child Health, University College, London)
   for help with data analysis; members of staff at HNR, Mr Antony Wright
   (now at MRC Epidemiology Unit) for assisting with mass spectrometry, Mrs
   Sheila MV Levitt for data entry, Dr Les Bluck for isotope data
   interpretation.
CR BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   Branca F, 2002, ANN NUTR METAB, V46, P8, DOI 10.1159/000066397
   BROWN KH, 1986, PEDIATRICS, V78, P909
   BUTTE NF, 1992, AM J CLIN NUTR, V55, P1109
   COHEN RJ, 1994, LANCET, V344, P288, DOI 10.1016/S0140-6736(94)91337-4
   COWARD WA, 1982, HUM NUTR-CLIN NUTR, V36, P141
   COWARD WA, 1984, J PEDIATR GASTR NUTR, V3, P275, DOI 10.1097/00005176-198403000-00020
   Department of Health, 1998, 49 DEP HLTH STAT OFF
   DEWEY KG, 1992, AM J CLIN NUTR, V56, P1012
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Institute of Medicine Food and Nutrition Board, 2011, DIET REF INT CALC VI
   IAEA, 2010, HUM HLTH SER NUMB
   Jarjou L. M. A., 1993, Proceedings of the Nutrition Society, V52, p349A
   Jarjou LMA, 2006, AM J CLIN NUTR, V83, P675
   Kent JC, 2006, PEDIATRICS, V117, pE387, DOI 10.1542/peds.2005-1417
   Kent JC, 1999, EXP PHYSIOL, V84, P435, DOI 10.1111/j.1469-445X.1999.01808.x
   LASKEY MA, 1990, ACTA PAEDIATR SCAND, V79, P507, DOI 10.1111/j.1651-2227.1990.tb11504.x
   LASKEY MA, 1991, ANN CLIN BIOCHEM, V28, P49
   PRENTICE A, 1995, AM J CLIN NUTR, V62, P58
   Prentice A, 2003, J NUTR, V133, p1693S
   Prentice A, 1990, BREASTFEEDING NUTRIT, P87
   PRENTICE AM, 1994, EUR J CLIN NUTR, V48, pS78
   Prentice AM, 2000, AM J CLIN NUTR, V72, p1253S
   Prentice Andrew, 1986, HUMAN LACTATION, P13
   Prentice Ann, 1993, Nutrition Research Reviews, V6, P51, DOI 10.1079/NRR19930006
   Prynne CJ, 2002, J FOOD COMPOS ANAL, V15, P349, DOI 10.1006/jfca.2002.1074
   Raj S, 2008, INT BREASTFEED J, V3, DOI 10.1186/1746-4358-3-3
   WHITEHEAD RG, 1984, EARLY HUM DEV, V9, P187, DOI 10.1016/0378-3782(84)90031-8
   World Health Organization, 2001, GLOB STRAT INF YOUNG
   WHO, 2006, WHO CHILD GROWTH STA
NR 30
TC 5
Z9 5
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD JUN
PY 2012
VL 66
IS 6
BP 673
EP 677
DI 10.1038/ejcn.2012.7
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 956KF
UT WOS:000305087800004
PM 22333875
OA No
DA 2017-08-15
ER

PT J
AU Dibba, L
   Fialor, SC
   Diagne, A
   Nimoh, F
AF Dibba, Lamin
   Fialor, Simon C.
   Diagne, Aliou
   Nimoh, Fred
TI The impact of NERICA adoption on productivity and poverty of the
   small-scale rice farmers in the Gambia
SO FOOD SECURITY
LA English
DT Article
DE Heterogeneity; Impact; NERICA; Causal effects; Potential outcomes; The
   Gambia
ID AGRICULTURAL TECHNOLOGY; PROPENSITY-SCORE; WEST-AFRICA; MODELS
AB The study assessed the causal effects of NERICA adoption on rice yields and income, using country-wide data of 600 rice farmers in The Gambia. To control for differences in socio-demographic and environmental characteristics of adopters and non-adopters and enable a causal interpretation of NERICA adoption on the variables of interest, the study used the counterfactual outcome framework to control for such differences. The results, based on observed sample estimates, showed significant differences in rice yields and income between the NERICA adopters and non-adopters. Further, the results of the framework, based on the Local Average Treatment Effect (LATE) estimates, which allowed a causal interpretation, showed that NERICA adoption significantly increased average rice yields and annual income of small-scale rice farmers by 157 kg per hectare and $148, respectively.
C1 [Fialor, Simon C.; Nimoh, Fred] KNUST, Kumasi, Ghana.
   [Dibba, Lamin] NARI, Serekunda, Gambia.
   [Diagne, Aliou] Africa Rice Ctr AfricaRice, Cotonou, Benin.
RP Fialor, SC (reprint author), KNUST, Kumasi, Ghana.
EM dibbason@hotmail.com; simonfialor@yahoo.co.uk; A.Diagne@cgiar.org
CR Abadie A, 2003, J ECONOMETRICS, V113, P231, DOI 10.1016/S0304-4076(02)00201-4
   ADESINA AA, 1995, AGR ECON, V13, P1, DOI 10.1016/0169-5150(95)01142-8
   Dalton TJ, 2004, AGR ECON, V31, P149, DOI 10.1016/j.agecon.2004.09.003
   Datt G., 1996, WORLD BANK EC REVZ, V10, P1
   DfID, 2003, AGR POV RED UNL POT
   Diagne A., 2009, IMPACT AGR TECHNOLOG
   Diangne A., 2006, BRED WOMEN FARMERS I
   Fatty L., 2004, POVERTY MEASUREMENT
   Gridley H.-E., 2002, DEV NEW RICE AFRICA
   Heckman JJ, 2005, ECONOMETRICA, V73, P669, DOI 10.1111/j.1468-0262.2005.00594.x
   Imbens GW, 2004, REV ECON STAT, V86, P4, DOI 10.1162/003465304323023651
   IMBENS GW, 1994, ECONOMETRICA, V62, P467, DOI 10.2307/2951620
   Imbens GW, 1997, REV ECON STUD, V64, P555, DOI 10.2307/2971731
   Kijima Y., 2006, DEV ECON, V44, P232
   Lancon F., 2001, JIRCAS WORKSH EC AN
   Lee M., 2005, ADV TEXTS ECONOMETRI
   Matlon P., 1996, INT C IMP RIC RES BA
   Mendola M, 2007, FOOD POLICY, V32, P372, DOI 10.1016/j.foodpol.2006.07.003
   Rosenbaum P., 2001, OBSERVATIONAL STUDIE
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   RUBIN DB, 1974, J EDUC PSYCHOL, V66, P688, DOI 10.1037/h0037350
   Spencer D., 2006, EVALUATION ADOPTION
   Union Africaine, 2005, C MIN AGR UN AFR 31
   WARDA (West Africa Rice Development Association), 2002, WARDA ANN REP 2001 2
   West Africa Rice Development Association ( WARDA), 1996, WARDA ANN REP 1996
   [Anonymous], 1993, CENSUS NATL CENSUS G
NR 26
TC 2
Z9 2
U1 2
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1876-4517
J9 FOOD SECUR
JI Food Secur.
PD JUN
PY 2012
VL 4
IS 2
BP 253
EP 265
DI 10.1007/s12571-012-0180-5
PG 13
WC Food Science & Technology
SC Food Science & Technology
GA 958KA
UT WOS:000305234200008
OA No
DA 2017-08-15
ER

PT J
AU van Tienen, C
   McConkey, SJ
   de Silva, TI
   Cotten, M
   Kaye, S
   Sarge-Njie, R
   da Costa, C
   Goncalves, N
   Parker, J
   Vincent, T
   Jaye, A
   Aaby, P
   Whittle, H
   van der Loeff, MS
AF van Tienen, Carla
   McConkey, Samuel J.
   de Silva, Thushan I.
   Cotten, Matthew
   Kaye, Steve
   Sarge-Njie, Ramu
   da Costa, Carlos
   Goncalves, Nato
   Parker, Julia
   Vincent, Tim
   Jaye, Assan
   Aaby, Peter
   Whittle, Hilton
   van der Loeff, Maarten Schim
TI Maternal Proviral Load and Vertical Transmission of Human T Cell
   Lymphotropic Virus Type 1 in Guinea-Bissau
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID CHILD TRANSMISSION; HTLV-1 INFECTION; WEST-AFRICA; RISK; ASSOCIATION;
   PREVALENCE; POLYMORPHISMS; POPULATION; MOTHERS; JAMAICA
AB The relative importance of routes of transmission of human T cell lymphotropic virus type 1 (HTLV-1) in Guinea-Bissau is largely unknown; vertical transmission is thought to be important, but there are very few existing data. We aimed to examine factors associated with transmission in mothers and children in Guinea-Bissau, where HTLV-1 is endemic (prevalence of 5% in the adult population). A cross-sectional survey was performed among mothers and their children (aged <15 years) in a rural community in Guinea-Bissau. A questionnaire to identify risk factors for infection and a blood sample were obtained. HTLV-1 proviral load in peripheral blood was determined and PCR was performed to compare long terminal repeat (LTR) sequences in mother-child pairs. Fourteen out of 55 children (25%) of 31 HTLV-1-infected mothers were infected versus none of 70 children of 30 uninfected mothers. The only factor significantly associated with HTLV-1 infection in the child was the proviral load of the mother; the risk of infection increased significantly with the log(10) proviral load in the mother's peripheral blood (OR 5.5, 95% CI 2.1-14.6, per quartile), adjusted for weaning age and maternal income. HTLV-1 sequences of the LTR region obtained from mother-child pairs were identical within pairs but differed between the pairs. Vertical transmission plays an important role in HTLV-1 transmission in this community in Guinea-Bissau. The risk of transmission increases with the mother's proviral load in the peripheral blood. Identical sequences in mother-child pairs give additional support to the maternal source of the children's infection.
C1 [van Tienen, Carla; McConkey, Samuel J.; de Silva, Thushan I.; Cotten, Matthew; Kaye, Steve; Sarge-Njie, Ramu; da Costa, Carlos; Goncalves, Nato; Parker, Julia; Vincent, Tim; Jaye, Assan; Whittle, Hilton; van der Loeff, Maarten Schim] MRC, Viral Dis Program, Fajara, Gambia.
   [van Tienen, Carla] Erasmus MC, NL-3015 CE Rotterdam, Netherlands.
   [McConkey, Samuel J.] Royal Coll Surgeons Ireland, Dept Int Hlth & Trop Med, Dublin 2, Ireland.
   [de Silva, Thushan I.] UCL, Div Infect & Immun, UCL Ctr Med Mol Virol, London, England.
   [Cotten, Matthew] Wellcome Trust Sanger Inst, Cambridge, England.
   [Kaye, Steve] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England.
   [Aaby, Peter] Indepth Network, Projecto Saude Bandim, Bissau, Guinea Bissau.
   [Parker, Julia] NHS Hertfordshire, Welwyn Garden City, Herts, England.
   [van der Loeff, Maarten Schim] Hlth Serv Amsterdam GGD, Amsterdam, Netherlands.
   [van der Loeff, Maarten Schim] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
RP van Tienen, C (reprint author), MRC, Viral Dis Program, Atlantic Rd,POB 273, Fajara, Gambia.
EM c.vantienen@erasmusmc.nl
RI van Tienen, Carla/A-1119-2012
OI McConkey, Samuel/0000-0001-9085-7793
FU Medical Research Council [MC_U190081997]
CR BHAT NK, 1993, VIROLOGY, V196, P15, DOI 10.1006/viro.1993.1450
   Biggar RJ, 2006, J INFECT DIS, V193, P277, DOI 10.1086/498910
   da Silva ZJ, 2009, AIDS, V23, P637, DOI 10.1097/QAD.0b013e32832403e8
   Etenna SLD, 2008, J CLIN MICROBIOL, V46, P3607, DOI 10.1128/JCM.01249-08
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   HINO S, 1985, JPN J CANCER RES, V76, P474
   Hino S, 2011, P JPN ACAD B-PHYS, V87, P152, DOI 10.2183/pjab.87.152
   Hisada M, 2002, J INFECT DIS, V185, P1351, DOI 10.1086/340129
   Hisada M, 2002, CLIN INFECT DIS, V34, P1551, DOI 10.1086/340537
   Jakobsen MS, 2003, INT J EPIDEMIOL, V32, P92, DOI 10.1093/ije/dyg006
   Kakuda K, 2002, AM J TROP MED HYG, V66, P404
   Kamihira S, 2003, CLIN LAB HAEMATOL, V25, P111, DOI 10.1046/j.1365-2257.2003.00503.x
   Kashima S, 2009, J GEN VIROL, V90, P927, DOI 10.1099/vir.0.008367-0
   Krook A, 1997, J ACQ IMMUN DEF SYND, V15, P381
   Kwaan N, 2006, J INFECT DIS, V194, P1557, DOI 10.1086/508899
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Larsen O, 2000, J ACQ IMMUN DEF SYND, V25, P157, DOI 10.1097/00126334-200010010-00010
   Li HC, 2004, J INFECT DIS, V190, P1275, DOI 10.1086/423941
   Nyambi PN, 1996, J ACQ IMMUN DEF SYND, V12, P187
   Plancoulaine S, 2006, HUM MOL GENET, V15, P3306, DOI 10.1093/hmg/ddl406
   Ribeiro MA, 2010, REV PANAM SALUD PUBL, V27, P330
   Salemi M, 1998, VIROLOGY, V246, P277, DOI 10.1006/viro.1998.9215
   Silva MTT, 2007, CLIN INFECT DIS, V44, P689, DOI 10.1086/510679
   Takezaki Toshiro, 1997, Leukemia (Basingstoke), V11, P60
   Ureta-Vidal A, 1999, INT J CANCER, V82, P832, DOI 10.1002/(SICI)1097-0215(19990909)82:6<832::AID-IJC11>3.0.CO;2-P
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   Van Dooren S, 2004, MOL BIOL EVOL, V21, P603, DOI 10.1093/molbev/msh053
   van Tienen C, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-50
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   Alarcon Villaverde J, 2011, REV PERU MED EXP SAL, V28, P101
   Wiktor S Z, 1997, J Hum Virol, V1, P37
   Zehender G, 2008, JAIDS-J ACQ IMM DEF, V47, P269
NR 32
TC 1
Z9 1
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUN
PY 2012
VL 28
IS 6
BP 584
EP 590
DI 10.1089/aid.2011.0219
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 952GQ
UT WOS:000304780100009
PM 22066980
OA No
DA 2017-08-15
ER

PT J
AU Braithwaite, V
   Jarjou, LMA
   Goldberg, GR
   Prentice, A
AF Braithwaite, Vickie
   Jarjou, Landing M. A.
   Goldberg, Gail R.
   Prentice, Ann
TI Iron status and fibroblast growth factor-23 in Gambian children
SO BONE
LA English
DT Article
DE Iron deficiency; FGF23 metabolism; Gambian rickets
ID DOMINANT HYPOPHOSPHATEMIC RICKETS; FGF23
AB A relationship between iron and fibroblast growth factor-23 (FGF23) metabolic pathways has been proposed. Iron deficiency anaemia is prevalent in The Gambia and concentrations of fibroblast growth factor-23 FGF23 are elevated in a large percentage of Gambian children with rickets-like bone deformity.
   We speculate that low iron status may be involved in the aetiology of Gambian rickets. The aim of this study was to determine if there was a relationship between haemoglobin, as a marker of iron status, and FGF23 in samples from children with and without a history of rickets-like bone deformities in The Gambia. We conducted a retrospective analysis of studies carried out from 2006 to 2008 in children from a rural community in The Gambia where iron deficiency anaemia is endemic and where elevated circulating concentrations of FGF23 have been found. To investigate the relationship between circulating FGF23 and haemoglobin concentrations we used an age-adjusted linear regression model on data from children <18 y of age with a family or personal history of rickets-like bone deformity (BD) (n = 108) and from the local community (LC) (n = 382). We found that circulating concentration of FGF23 was inversely correlated with haemoglobin concentration. This effect was more pronounced in BD children compared with LC children (interaction: P <= 0.0001). Anaemia and elevated FGF23 were more prevalent in BD children compared to LC children (P = 0.0003 and P = 0.0001 respectively).
   In conclusion, there is a stronger relationship between FGF23 and haemoglobin in Gambian children with a history of rickets compared to local community children. This study provides support for the contention that iron may be involved in FGF23 metabolic pathways. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Braithwaite, Vickie] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Jarjou, Landing M. A.; Goldberg, Gail R.; Prentice, Ann] MRC Keneba, W Kiang, Gambia.
RP Braithwaite, V (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
EM Vickie.braithwaite@mrc-hnr.cam.ac.uk
OI Braithwaite, Vickie/0000-0002-3366-2903
FU UK Medical Research Council [U105960371, U123261351]
FX The work was performed at MRC Human Nutrition Research, Cambridge, UK
   and MRC Keneba, The Gambia and supported by the UK Medical Research
   Council [Unit Programme numbers U105960371 and U123261351]. We should
   like to thank Professor John Pettifor from the University of the
   Witwatersrand, Johannesburg, South Africa, and Dr Inez Schoenmakers from
   MRC HNR for helpful comments on early drafts of the manuscript; study
   participants; the clinical staff of MRC Keneba; the scientific, field
   staff and research assistants at MRC Keneba; the scientists and lab
   staff at MRC HNR, especially Ms Helen Jones, Dr Shailja Nigdikar, Mrs
   Janet Bennett and Mrs Ann Laidlaw.
CR Atkinson SH, 2006, PLOS MED, V3, P652, DOI 10.1371/journal.pmed.0030172
   Braithwaite V, 2012, BONE, V50, P218, DOI 10.1016/j.bone.2011.10.009
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Durham BH, 2007, ANN CLIN BIOCHEM, V44, P463, DOI 10.1258/000456307781646102
   Farrow EG, 2011, P NATL ACAD SCI USA, V108, pE1146, DOI 10.1073/pnas.1110905108
   Spiegel HE, 2001, ADV CLIN CHEM, P72, DOI 10.1016/S0065-2423(01)35015-1
   Hawkesworth S, 2010, AM J CLIN NUTR, V92, P741, DOI 10.3945/ajcn.2010.29475
   Imel EA, 2011, J CLIN ENDOCR METAB, V96, P3541, DOI 10.1210/jc.2011-1239
   Republic of The Gambia, 2001, NAT SURV PREV VIT A
   Payne RB, 1998, ANN CLIN BIOCHEM, V35, P201
   POWERS HJ, 1987, T ROY SOC TROP MED H, V81, P421, DOI 10.1016/0035-9203(87)90157-X
   Prentice A, 2008, AM J CLIN NUTR, V88, p500S
   Prentice A, 2008, BONE, V42, P788, DOI 10.1016/j.bone.2007.11.014
   Razzaque SM, 2009, NAT REV ENDOCRINOL, V5, P611
   Saitoh T, 2009, POPUL ECOL, V51, P1, DOI 10.1007/s10144-008-0129-x
   Schouten BJ, 2009, J CLIN ENDOCR METAB, V94, P2332, DOI 10.1210/jc.2008-2396
   Scientific Advisory Committee on Nutrition, 2010, IR HLTH
   Shimizu Y, 2009, BONE, V45, P814, DOI 10.1016/j.bone.2009.06.017
NR 18
TC 25
Z9 25
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD JUN
PY 2012
VL 50
IS 6
BP 1351
EP 1356
DI 10.1016/j.bone.2012.03.010
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 948LC
UT WOS:000304503700019
PM 22465847
OA No
DA 2017-08-15
ER

PT J
AU Yindom, LM
AF Yindom, L. -M.
TI Influence of HLA class I and HLA-KIR compound genotypes on HIV-2
   infection and markers of disease progression in a community in West
   Africa
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Yindom, L. -M.] Med Res Council MRC Labs, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2012
VL 17
SU 1
SI SI
BP 11
EP 11
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 945AB
UT WOS:000304244000030
OA No
DA 2017-08-15
ER

PT J
AU Gehre, F
AF Gehre, F.
TI Population structure of M. africanum and differences in ESAT-6
   immunogenicity between different lineages
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Gehre, F.] MRC, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2012
VL 17
SU 1
SI SI
BP 24
EP 24
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 945AB
UT WOS:000304244000075
OA No
DA 2017-08-15
ER

PT J
AU Ota, M
AF Ota, M.
TI Clinical trials with MVA85A, a candidate TB vaccine
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Ota, M.] MRC Unit, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2012
VL 17
SU 1
SI SI
BP 26
EP 26
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 945AB
UT WOS:000304244000082
OA No
DA 2017-08-15
ER

PT J
AU Sutherland, J
AF Sutherland, J.
TI Cellular and soluble biomarkers in the pleural fluid, absent from the
   peripheral blood, accurately diagnose pleural TB in a TB-endemic setting
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Sutherland, J.] MRC, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2012
VL 17
SU 1
SI SI
BP 26
EP 26
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 945AB
UT WOS:000304244000081
OA No
DA 2017-08-15
ER

PT J
AU Faal, TI
AF Faal, T. I.
TI M. tuberculosis complex within the tuberculosis case contact study in
   MRC Unit The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Faal, T. I.] MRC Unit, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2012
VL 17
SU 1
SI SI
BP 28
EP 28
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 945AB
UT WOS:000304244000089
OA No
DA 2017-08-15
ER

PT J
AU Out, JK
AF Out, J. K.
TI WANETAM TB capacity building in preparation of clinical trials in West
   Africa: case detection capacities training in MRC The Gambia Unit
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Out, J. K.] MRC Unit, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2012
VL 17
SU 1
SI SI
BP 31
EP 31
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 945AB
UT WOS:000304244000098
OA No
DA 2017-08-15
ER

PT J
AU Okoi, C
AF Okoi, C.
TI The kinetics of acid fast bacilli in smear-positive sputum samples
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Okoi, C.] MRC Unit, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2012
VL 17
SU 1
SI SI
BP 33
EP 33
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 945AB
UT WOS:000304244000106
OA No
DA 2017-08-15
ER

PT J
AU Mendy, F
AF Mendy, F.
TI Mycobacterial infections in an urban hospital in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Mendy, F.] Med Res Unit, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2012
VL 17
SU 1
SI SI
BP 35
EP 35
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 945AB
UT WOS:000304244000112
OA No
DA 2017-08-15
ER

PT J
AU Secka, O
AF Secka, O.
TI The use of spoligotyping to determine the molecular epidemiology of M.
   tuberculosis complex circulating in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Secka, O.] MRC Unit, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2012
VL 17
SU 1
SI SI
BP 36
EP 36
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 945AB
UT WOS:000304244000117
OA No
DA 2017-08-15
ER

PT J
AU Janha, R
AF Janha, R.
TI Pharmacogenetics determines treatment outcome of Lapdap in malaria
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Janha, R.] MRC, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2012
VL 17
SU 1
SI SI
BP 60
EP 60
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 945AB
UT WOS:000304244000196
OA No
DA 2017-08-15
ER

PT J
AU Roy, RB
   Whittaker, E
   Kampmann, B
AF Roy, Robindra Basu
   Whittaker, Elizabeth
   Kampmann, Beate
TI Current understanding of the immune response to tuberculosis in children
SO CURRENT OPINION IN INFECTIOUS DISEASES
LA English
DT Review
DE adaptive immunity; immunity; innate; paediatrics; tuberculosis
ID GAMMA RELEASE ASSAYS; CALMETTE-GUERIN VACCINATION; T-CELL RESPONSES;
   PRE-CHEMOTHERAPY ERA; MYCOBACTERIUM-TUBERCULOSIS; INTERFERON-GAMMA;
   ACTIVE TUBERCULOSIS; IFN-GAMMA; PULMONARY TUBERCULOSIS; CHILDHOOD
   TUBERCULOSIS
AB Purpose of review
   Even in the era of promising molecular diagnostics for tuberculosis, understanding of the immune response remains urgent and fundamental to combating paediatric tuberculosis, given its paucibacillary nature.
   Recent findings
   Significant advances have been made in unravelling the contributions of previously underappreciated components of the immune response to Mycobacterium tuberculosis. Research into the role of the 'innate' immune system such as neutrophils alongside 'adaptive' cells such as CD4(+), CD8(+), polyfunctional and regulatory T cells has highlighted the complexity of their interactions. Lessons from children with congenital or acquired susceptibility to mycobacterial disease, including HIV, continue to illuminate a broader understanding of the host immune response. The role of vitamin D is becoming apparent and highlights the importance of the environmental and clinical context of patients, especially in high prevalence areas. Several approaches show promise as diagnostic tests and in monitoring treatment response, although distinguishing latent from active disease remains a challenge.
   Summary
   Research into novel immunological biomarkers, and greater understanding of the complex network of interactions between the innate and adaptive immune systems, is key to understanding why following exposure some children are unaffected, others latently infected and yet another group succumb to disease.
C1 [Roy, Robindra Basu; Whittaker, Elizabeth; Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Paediat Allergy & Infect, London W2 1NY, England.
   [Kampmann, Beate] MRC, Banjul, Gambia.
RP Kampmann, B (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Paediat Allergy & Infect, Norfolk Pl, London W2 1NY, England.
EM b.kampmann@imperial.ac.uk
RI Basu Roy, Robin/L-2979-2016
OI Basu Roy, Robin/0000-0001-5648-3628; Whittaker,
   Elizabeth/0000-0002-7944-8793
FU Medical Research Council; National Institute of Health Research (NIHR)
FX B.K. is supported by grants from the Medical Research Council and the
   National Institute of Health Research (NIHR). E.W. is a Wellcome Trust
   Clinical Training Fellow. R.B. is an Academic Clinical Fellow, supported
   by NIHR.
CR Alsleben N, 2012, SCAND J INFECT DIS, V44, P256, DOI 10.3109/00365548.2011.632644
   Alvarez IB, 2010, J INFECT DIS, V202, P524, DOI 10.1086/654932
   Bamford ARJ, 2010, ARCH DIS CHILD, V95, P180, DOI 10.1136/adc.2009.169805
   Barber DL, 2011, J IMMUNOL, V186, P1598, DOI 10.4049/jimmunol.1003304
   Beetz S, 2008, IMMUNOBIOLOGY, V213, P173, DOI 10.1016/j.imbio.2007.10.006
   Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247
   Burl S, 2011, PLOS ONE, V6
   Bustamante J, 2011, NAT IMMUNOL, V12, P213, DOI 10.1038/ni.1992
   Caccamo N, 2006, J IMMUNOL, V177, P1780
   Caccamo N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005528
   Clark S, 2011, J ALLERGY CLIN IMMUN, V128, P838, DOI 10.1016/j.jaci.2011.05.025
   Commandeur S, 2011, EUR J IMMUNOL, V41, P2925, DOI 10.1002/eji.201141602
   Cottle LE, 2011, CLIN GENET, V79, P17, DOI 10.1111/j.1399-0004.2010.01510.x
   Day CL, 2011, J IMMUNOL, V187, P2222, DOI 10.4049/jimmunol.1101122
   de Almeida AS, 2012, CLIN VACCINE IMMUNOL, V19, P45, DOI 10.1128/CVI.05263-11
   Di Liberto D, 2007, TUBERCULOSIS, V87, P322, DOI 10.1016/j.tube.2007.01.003
   Diel R, 2011, EUR RESPIR J, V37, P88, DOI 10.1183/09031936.00115110
   Dieli F, 2002, J INFECT DIS, V186, P1835, DOI 10.1086/345766
   Elenga N, 2005, PEDIATR INFECT DIS J, V24, P1077, DOI 10.1097/01.inf.0000190008.91534.b7
   Fabri M, 2011, SCI TRANSL MED, V3, DOI [10.1126/scitranslmed.3003045, DOI 10.1126/SCITRANSLMED.3003045]
   Filias A, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-29
   Gallegos AM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002052
   Geldmacher C, 2010, J EXP MED, V207, P2869, DOI 10.1084/jem.20100090
   Gold MC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000957
   Heier I, 2008, THORAX, V63, P703, DOI 10.1136/thx.2007.082974
   Hoft DF, 1998, J IMMUNOL, V161, P1045
   Jones C, 2011, PAEDIATR RESPIR REV, V12, P3, DOI 10.1016/j.prrv.2010.09.006
   Jones CE, 2011, JAMA-J AM MED ASSOC, V305, P576, DOI 10.1001/jama.2011.100
   Kagina BMN, 2010, AM J RESP CRIT CARE, V182, P1073, DOI [10.1164/rccm.201003-0334OC, 10.1164/rrcm.201003-0334OC]
   Kampmann B, 2006, AIDS, V20, P1011, DOI 10.1097/01.aids.0000222073.45372.ce
   Kampmann B, 2006, LANCET, V368, P282, DOI 10.1016/S0140-6736(06)69064-8
   Khoo AL, 2011, CYTOKINE, V55, P294, DOI 10.1016/j.cyto.2011.04.016
   Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481
   Koyanagi A, 2011, PEDIATR INFECT DIS J, V30, P45, DOI 10.1097/INF.0b013e3181ecbf7e
   Kumar NP, 2011, CLIN VACCINE IMMUNOL, V18, P1856, DOI 10.1128/CVI.05366-11
   Lancioni C, 2012, AM J RESP CRIT CARE, V185, P206, DOI 10.1164/rccm.201107-1355OC
   Lewinsohn DA, 2004, INT J TUBERC LUNG D, V8, P658
   Ling DI, 2011, PAEDIATR RESPIR REV, V12, P9, DOI 10.1016/j.prrv.2010.09.009
   Lowe DM, 2012, TRENDS IMMUNOL, V33, P14, DOI 10.1016/j.it.2011.10.003
   Machingaidze S, 2011, PEDIATR INFECT DIS J, V30, P694, DOI 10.1097/INF.0b013e318214b915
   Maglione PJ, 2009, EUR J IMMUNOL, V39, P676, DOI 10.1002/eji.200839148
   Mandalakas AM, 2011, INT J TUBERC LUNG D, V15, P1018, DOI 10.5588/ijtld.10.0631
   Marais BJ, 2011, PAEDIATR RESPIR REV, V12, P39, DOI 10.1016/j.prrv.2010.09.002
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P278
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P392
   Martineau AR, 2007, J CLIN INVEST, V117, P1988, DOI 10.1172/JCI31097
   Martineau AR, 2007, J IMMUNOL, V178, P7190
   Martineau AR, 2011, LANCET, V377, P242, DOI 10.1016/S0140-6736(10)61889-2
   McNab FW, 2011, EUR J IMMUNOL, V41, P1941, DOI 10.1002/eji.201141421
   Mendez-Samperio P, 2008, PEPTIDES, V29, P1836, DOI 10.1016/j.peptides.2008.05.024
   Moretta A, 2002, NAT IMMUNOL, V3, P6, DOI 10.1038/ni0102-6
   Nicol MP, 2011, LANCET INFECT DIS, V11, P819, DOI 10.1016/S1473-3099(11)70167-0
   Nouailles G, 2011, EUR J IMMUNOL, V41, P981, DOI 10.1002/eji.201040608
   Qu HQ, 2011, INT J INFECT DIS, V15, pE305, DOI 10.1016/j.ijid.2011.01.004
   Quiroga MF, 2006, J IMMUNOL, V176, P5965
   Rangaka MX, 2012, LANCET INFECT DIS, V12, P45, DOI 10.1016/S1473-3099(11)70210-9
   Roy S, 2008, J IMMUNOL, V180, P1729
   Scriba TJ, 2008, J IMMUNOL, V180, P1962
   Scriba TJ, 2010, EUR J IMMUNOL, V40, P279, DOI 10.1002/eji.200939754
   Semple PL, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/438463
   Sepulveda RL, 1997, INT J TUBERC LUNG D, V1, P122
   Sester M, 2010, EUR RESPIR J, V36, P1242, DOI 10.1183/09031936.00040910
   Shey MS, 2012, J IMMUNOL METHODS, V376, P79, DOI 10.1016/j.jim.2011.11.011
   Soares AP, 2008, J IMMUNOL, V180, P3569
   Steingart KR, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001062
   Swaminathan S, 1999, CLIN INFECT DIS, V28, P1290, DOI 10.1086/514794
   Tena-Coki NG, 2010, AM J RESP CRIT CARE, V182, P120, DOI 10.1164/rccm.200912-1862OC
   Ulrichs T, 2004, J PATHOL, V204, P217, DOI 10.1002/path.1628
   Upham JW, 2006, INFECT IMMUN, V74, P1106, DOI 10.1128/IAI.74.2.1106-1112.2006
   Vankayalapati R, 2009, TUBERCULOSIS, V89, pS77, DOI 10.1016/S1472-9792(09)70018-6
   White GP, 2002, J IMMUNOL, V168, P2820
   Whittaker E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003901
   Williams B, 2008, PEDIATR INFECT DIS J, V27, P941, DOI 10.1097/INF.0b013e31817525df
   Yassin MA, 2011, PLOS ONE, V6
NR 74
TC 15
Z9 15
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0951-7375
J9 CURR OPIN INFECT DIS
JI Curr. Opin. Infect. Dis.
PD JUN
PY 2012
VL 25
IS 3
BP 250
EP 257
DI 10.1097/QCO.0b013e3283529af9
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 937NV
UT WOS:000303666100003
OA No
DA 2017-08-15
ER

PT J
AU Huang, HL
   Mackeen, MM
   Cook, M
   Oriero, E
   Locke, E
   Thezenas, ML
   Kessler, BM
   Nwakanma, D
   Casals-Pascual, C
AF Huang, Honglei
   Mackeen, Mukram M.
   Cook, Matthew
   Oriero, Eniyou
   Locke, Emily
   Thezenas, Marie L.
   Kessler, Benedikt M.
   Nwakanma, Davis
   Casals-Pascual, Climent
TI Proteomic identification of host and parasite biomarkers in saliva from
   patients with uncomplicated Plasmodium falciparum malaria
SO MALARIA JOURNAL
LA English
DT Article
ID LECTIN AFFINITY-CHROMATOGRAPHY; ALPHA-AMYLASE; ALBUMIN;
   OLIGOSACCHARIDES; GLYCOSYLATION; DEPLETION; PROTEINS; FLUIDS; SERUM; IGG
AB Background: Malaria cases attributed to Plasmodium falciparum account for approximately 600,000 deaths yearly, mainly in African children. The gold standard method to diagnose malaria requires the visualization of the parasite in blood. The role of non-invasive diagnostic methods to diagnose malaria remains unclear.
   Methods: A protocol was optimized to deplete highly abundant proteins from saliva to improve the dynamic range of the proteins identified and assess their suitability as candidate biomarkers of malaria infection. A starch-based amylase depletion strategy was used in combination with four different lectins to deplete glycoproteins (Concanavalin A and Aleuria aurantia for N-linked glycoproteins; jacalin and peanut agglutinin for O-linked glycoproteins). A proteomic analysis of depleted saliva samples was performed in 17 children with fever and a positive-malaria slide and compared with that of 17 malaria-negative children with fever.
   Results: The proteomic signature of malaria-positive patients revealed a strong up-regulation of erythrocyte-derived and inflammatory proteins. Three P. falciparum proteins, PFL0480w, PF08_0054 and PFI0875w, were identified in malaria patients and not in controls. Aleuria aurantia and jacalin showed the best results for parasite protein identification.
   Conclusions: This study shows that saliva is a suitable clinical specimen for biomarker discovery. Parasite proteins and several potential biomarkers were identified in patients with malaria but not in patients with other causes of fever. The diagnostic performance of these markers should be addressed prospectively.
C1 [Huang, Honglei; Mackeen, Mukram M.; Cook, Matthew; Thezenas, Marie L.; Kessler, Benedikt M.; Casals-Pascual, Climent] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Huang, Honglei; Mackeen, Mukram M.; Cook, Matthew; Thezenas, Marie L.; Kessler, Benedikt M.; Casals-Pascual, Climent] Ctr Cellular & Mol Physiol, Oxford OX3 7BN, England.
   [Oriero, Eniyou; Nwakanma, Davis] MRC Labs, Banjul, Gambia.
   [Locke, Emily] PATH Malaria Vaccine Initiat, Washington, DC 20001 USA.
RP Casals-Pascual, C (reprint author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM ccasals@well.ox.ac.uk
OI Kessler, Benedikt/0000-0002-8160-2446; Casals-Pascual,
   Climent/0000-0002-0867-8954
FU PATH Malaria Vaccine Initiative; Medical Research Council [G0701885];
   Biomedical Research Centre (NIHR), Oxford, UK
FX Financial support for the field trial, from which samples for proteomic
   analysis were generated, came from a "PATH Malaria Vaccine Initiative"
   project grant to DN. C.C-P is supported by the Medical Research Council
   (Clinician Scientist Fellowship: G0701885). B.M.K. is supported by the
   Biomedical Research Centre (NIHR), Oxford, UK.
CR Alonzi DS, 2008, BIOCHEM J, V409, P571, DOI 10.1042/BJ20070748
   Amado F, 2010, EXPERT REV PROTEOMIC, V7, P709, DOI [10.1586/epr.10.48, 10.1586/EPR.10.48]
   Deutsch O, 2008, ELECTROPHORESIS, V29, P4150, DOI 10.1002/elps.200800207
   Fu Q, 2005, PROTEOMICS, V5, P2656, DOI 10.1002/pmic.200402048
   GARLICK RL, 1983, J BIOL CHEM, V258, P6142
   Gowda DC, 1999, PARASITOL TODAY, V15, P147, DOI 10.1016/S0169-4758(99)01412-X
   Guile GR, 1998, EUR J BIOCHEM, V258, P623, DOI 10.1046/j.1432-1327.1998.2580623.x
   Hu S, 2008, CLIN CANCER RES, V14, P6246, DOI 10.1158/1078-0432.CCR-07-5037
   Krief G, 2011, ORAL DIS, V17, P45, DOI 10.1111/j.1601-0825.2010.01700.x
   Kullolli M, 2008, J SEP SCI, V31, P2733, DOI 10.1002/jssc.200800233
   Macedo Cristiana S de, 2010, Mem Inst Oswaldo Cruz, V105, P949
   Messana I, 2008, J SEP SCI, V31, P1948, DOI 10.1002/jssc.200800100
   MOORE RB, 1991, J BIOL CHEM, V266, P18964
   Nwakanma DC, 2009, J INFECT DIS, V199, P1567, DOI 10.1086/598856
   PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347
   Qiu RQ, 2005, ANAL CHEM, V77, P2802, DOI 10.1021/ac048751x
   ROQUEBARREIRA MC, 1985, J IMMUNOL, V134, P1740
   Scarano E, 2010, ACTA OTORHINOLARYNGO, V30, P125
   SCHENKELS LCPM, 1995, CRIT REV ORAL BIOL M, V6, P161
   Trudgian DC, 2010, BIOINFORMATICS, V26, P1131, DOI 10.1093/bioinformatics/btq081
   Trudgian DC, 2010, PROTEOMICS, V11, P2790
   von Itzstein M, 2008, TRENDS PARASITOL, V24, P210, DOI 10.1016/j.pt.2008.02.007
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
NR 23
TC 5
Z9 5
U1 0
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAY 28
PY 2012
VL 11
AR 178
DI 10.1186/1475-2875-11-178
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 982DB
UT WOS:000307020800001
PM 22640863
OA gold
DA 2017-08-15
ER

PT J
AU Merrick, CJ
   Huttenhower, C
   Buckee, C
   Amambua-Ngwa, A
   Gomez-Escobar, N
   Walther, M
   Conway, DJ
   Duraisingh, MT
AF Merrick, Catherine J.
   Huttenhower, Curtis
   Buckee, Caroline
   Amambua-Ngwa, Alfred
   Gomez-Escobar, Natalia
   Walther, Michael
   Conway, David J.
   Duraisingh, Manoj T.
TI Epigenetic Dysregulation of Virulence Gene Expression in Severe
   Plasmodium falciparum Malaria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID CHONDROITIN SULFATE-A; ANTIGENIC VARIATION; DIFFERENTIAL EXPRESSION;
   INFECTED ERYTHROCYTES; PARASITES; FAMILY; CYTOADHERENCE; TRANSCRIPTION;
   PATTERNS; RECEPTOR
AB Chronic infections with the human malaria parasite Plasmodium falciparum depend on antigenic variation. P. falciparum erythrocyte membrane protein 1 (PfEMP1), the major erythrocyte surface antigen mediating parasite sequestration in the microvasculature, is encoded in parasites by a highly diverse family of var genes. Antigenic switching is mediated by clonal variation in var expression, and recent in vitro studies have demonstrated a role for epigenetic processes in var regulation. Expression of particular PfEMP1 variants may result in parasite enrichment in different tissues, a factor in the development of severe disease. Here, we study in vivo human infections and provide evidence that infection-induced stress responses in the host can modify PfEMP1 expression via the perturbation of epigenetic mechanisms. Our work suggests that severe disease may not be the direct result of an adaptive virulence strategy to maximize parasite survival but that it may indicate a loss of control of the carefully regulated process of antigenic switching that maintains chronic infections.
C1 [Huttenhower, Curtis; Duraisingh, Manoj T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Merrick, Catherine J.; Duraisingh, Manoj T.] Keele Univ, Sch Life Sci, Keele ST5 5BG, Staffs, England.
   [Buckee, Caroline] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Amambua-Ngwa, Alfred; Gomez-Escobar, Natalia; Walther, Michael; Conway, David J.] MRC Labs, Banjul, Gambia.
RP Duraisingh, MT (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, 665 Huntington Ave,Bldg 1,Rm 715, Boston, MA 02115 USA.
EM mduraisi@hsph.harvard.edu
OI Huttenhower, Curtis/0000-0002-1110-0096; Conway,
   David/0000-0002-8711-3037
FU Burroughs Welcome Fund New Investigator in the Pathogenesis of
   Infectious Diseases Award; National Institutes of Health [R01AI057919];
   Medical Research Council of the United Kingdom for research at MRC
   Gambia; Charles H. Hood Foundation
FX This work was supported by a Burroughs Welcome Fund New Investigator in
   the Pathogenesis of Infectious Diseases Award (to M. T. D.), the
   National Institutes of Health (R01AI057919), the Medical Research
   Council of the United Kingdom for research at MRC Gambia, and a Charles
   H. Hood Foundation fellowship (to C. J. M.).
CR BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3
   CAMPBELL RB, 1995, MOL GEN GENET, V246, P291, DOI 10.1007/BF00288601
   Collins WE, 1999, AM J TROP MED HYG, V61, P44
   Daily JP, 2007, NATURE, V450, P1091, DOI 10.1038/nature06311
   Duraisingh MT, 2005, CELL, V121, P13, DOI 10.1016/j.cell.2005.01.036
   Dzikowski R, 2006, PLOS PATHOG, V2, P184, DOI 10.1371/journal.ppat.0020022
   Fang J, 2004, MOL BIOCHEM PARASIT, V133, P125, DOI 10.1016/j.molbiopara.2003.09.004
   Figueiredo LM, 2002, EMBO J, V21, P815, DOI 10.1093/emboj/21.4.815
   Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037
   Ganesan K, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000214
   Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274
   Kaestli M, 2006, J INFECT DIS, V193, P1567, DOI 10.1086/503776
   Kraemer SM, 2003, MOL MICROBIOL, V50, P1527, DOI 10.1046/j.1365-2958.2003.03814.x
   Kyriacou HM, 2006, MOL BIOCHEM PARASIT, V150, P211, DOI 10.1016/j.molbiopara.2006.08.005
   Lavstsen T, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-27
   Lopez-Rubio JJ, 2007, MOL MICROBIOL, V66, P1296, DOI 10.1111/j.1365-2958.2007.06009.x
   Lu SP, 2010, BBA-PROTEINS PROTEOM, V1804, P1567, DOI 10.1016/j.bbapap.2009.09.030
   Merrick CJ, 2010, INT J PARASITOL, V40, P35, DOI 10.1016/j.ijpara.2009.06.012
   Molineaux L, 2001, PARASITOLOGY, V122, P379, DOI 10.1017/S0031182001007533
   Nkrumah LJ, 2006, NAT METHODS, V3, P615, DOI 10.1038/NMETH904
   Oakley MSM, 2007, INFECT IMMUN, V75, P2012, DOI 10.1128/IAI.01236-06
   Rosenberg E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006991
   Rottmann M, 2006, INFECT IMMUN, V74, P3904, DOI 10.1128/IAI.02073-05
   Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x
   Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418
   SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X
   SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1
   Tonkin CJ, 2009, PLOS BIOL, V7, P771, DOI 10.1371/journal.pbio.1000084
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Udomsangpetch R, 2002, P NATL ACAD SCI USA, V99, P11825, DOI 10.1073/pnas.172398999
   Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Westerheide SD, 2009, SCIENCE, V323, P1063, DOI 10.1126/science.1165946
NR 33
TC 24
Z9 24
U1 0
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2012
VL 205
IS 10
BP 1593
EP 1600
DI 10.1093/infdis/jis239
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 932ZO
UT WOS:000303329200017
PM 22448008
OA No
DA 2017-08-15
ER

PT J
AU Cuevas, LE
   Browning, R
   Bossuyt, P
   Casenghi, M
   Cotton, MF
   Cruz, AT
   Dodd, LE
   Drobniewski, F
   Gale, M
   Graham, SM
   Grzemska, M
   Heinrich, N
   Hesseling, AC
   Huebner, R
   Jean-Philippe, P
   Kabra, SK
   Kampmann, B
   Lewinsohn, D
   Li, MJ
   Lienhardt, C
   Mandalakas, AM
   Marais, BJ
   Menzies, HJ
   Montepiedra, G
   Mwansambo, C
   Oberhelman, R
   Palumbo, P
   Russek-Cohen, E
   Shapiro, DE
   Smith, B
   Soto-Castellares, G
   Starke, JR
   Swaminathan, S
   Wingfield, C
   Worrell, C
AF Cuevas, Luis E.
   Browning, Renee
   Bossuyt, Patrick
   Casenghi, Martina
   Cotton, Mark F.
   Cruz, Andrea T.
   Dodd, Lori E.
   Drobniewski, Francis
   Gale, Marianne
   Graham, Stephen M.
   Grzemska, Malgosia
   Heinrich, Norbert
   Hesseling, Anneke C.
   Huebner, Robin
   Jean-Philippe, Patrick
   Kabra, Sushil Kumar
   Kampmann, Beate
   Lewinsohn, Deborah
   Li, Meijuan
   Lienhardt, Christian
   Mandalakas, Anna M.
   Marais, Ben J.
   Menzies, Heather J.
   Montepiedra, Grace
   Mwansambo, Charles
   Oberhelman, Richard
   Palumbo, Paul
   Russek-Cohen, Estelle
   Shapiro, David E.
   Smith, Betsy
   Soto-Castellares, Giselle
   Starke, Jeffrey R.
   Swaminathan, Soumya
   Wingfield, Claire
   Worrell, Carol
TI Evaluation of Tuberculosis Diagnostics in Children: 2. Methodological
   Issues for Conducting and Reporting Research Evaluations of Tuberculosis
   Diagnostics for Intrathoracic Tuberculosis in Children. Consensus From
   an Expert Panel(a)
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID DRUG-SUSCEPTIBILITY ASSAY; POLYMERASE-CHAIN-REACTION;
   MYCOBACTERIUM-TUBERCULOSIS; MICROSCOPIC-OBSERVATION; PULMONARY
   TUBERCULOSIS; ACCURACY; SPUTUM; TESTS
AB Confirming the diagnosis of childhood tuberculosis is a major challenge. However, research on childhood tuberculosis as it relates to better diagnostics is often neglected because of technical difficulties, such as the slow growth in culture, the difficulty of obtaining specimens, and the diverse and relatively nonspecific clinical presentation of tuberculosis in this age group. Researchers often use individually designed criteria for enrollment, diagnostic classifications, and reference standards, thereby hindering the interpretation and comparability of their findings. The development of standardized research approaches and definitions is therefore needed to strengthen the evaluation of new diagnostics for detection and confirmation of tuberculosis in children.
   In this article we present consensus statements on methodological issues for conducting research of Tuberculosis diagnostics among children, with a focus on intrathoracic tuberculosis. The statements are complementary to a clinical research case definition presented in an accompanying publication and suggest a phased approach to diagnostics evaluation; entry criteria for enrollment; methods for classification of disease certainty, including the rational use of culture within the case definition; age categories and comorbidities for reporting results; and the need to use standard operating procedures. Special consideration is given to the performance of microbiological culture in children and we also recommend for alternative methodological approaches to report findings in a standardized manner to overcome these limitations are made. This consensus statement is an important step toward ensuring greater rigor and comparability of pediatric tuberculosis diagnostic research, with the aim of realizing the full potential of better tests for children.
C1 [Cuevas, Luis E.] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England.
   [Browning, Renee; Jean-Philippe, Patrick] NIAID, Henry Jackson Fdn, HIV AIDS Sci & Operat Support HJF DAIDS, Bethesda, MD 20892 USA.
   [Bossuyt, Patrick] Univ Amsterdam, NL-1012 WX Amsterdam, Netherlands.
   [Casenghi, Martina] Med Sans Frontieres, Geneva, Switzerland.
   [Cotton, Mark F.] Univ Stellenbosch, Tygerberg Childrens Hosp, Childrens Infect Dis Clin Res Unit, Cape Town, South Africa.
   [Cruz, Andrea T.; Starke, Jeffrey R.] Baylor Sch Med, Houston, TX USA.
   [Dodd, Lori E.] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA.
   [Drobniewski, Francis] Barts & London Queen Marys Sch Med & Dent, Hlth Protect Agcy, Natl Mycobacterium Reference Lab, London, England.
   [Drobniewski, Francis] Barts & London Queen Marys Sch Med & Dent, Clin TB & HIV Grp, London, England.
   [Gale, Marianne] Med Sans Frontieres, Sydney, NSW, Australia.
   [Graham, Stephen M.] Univ Melbourne, Dept Paediat, Ctr Int Child Hlth, Melbourne, Vic 3010, Australia.
   [Graham, Stephen M.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Murdoch, WA, Australia.
   [Grzemska, Malgosia; Lienhardt, Christian] WHO, STOP TB Dept, CH-1211 Geneva, Switzerland.
   [Heinrich, Norbert] Univ Munich, Med Ctr, Div Infect Dis & Trop Med, D-80539 Munich, Germany.
   [Hesseling, Anneke C.] Univ Stellenbosch, Desmond Tutu TB Ctr, Cape Town, South Africa.
   [Huebner, Robin] NIAID, Epidemiol Branch, Div Aids, NIH, Bethesda, MD 20892 USA.
   [Kabra, Sushil Kumar] All India Inst Med Sci, New Delhi, India.
   [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London SW7 2AZ, England.
   [Kampmann, Beate] MRC, Banjul, Gambia.
   [Lewinsohn, Deborah] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA.
   [Li, Meijuan] US FDA, Div Biostat, Ctr Devices & Radiol Hlth, Silver Spring, MD USA.
   [Mandalakas, Anna M.] Texas Childrens Hosp, Baylor Coll Med, Ctr Global Hlth, Sect Retrovirol & Global Hlth, Houston, TX 77030 USA.
   [Marais, Ben J.] Univ Sydney, Childrens Hosp Westmead, Sydney, NSW 2006, Australia.
   [Menzies, Heather J.] Ctr Dis Control & Prevent, Int Res & Programs Branch, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
   [Montepiedra, Grace; Shapiro, David E.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Mwansambo, Charles] Minist Hlth, Lilongwe, Malawi.
   [Oberhelman, Richard] Tulane Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA USA.
   [Oberhelman, Richard] Tulane Sch Publ Hlth & Trop Med, Dept Pediat, New Orleans, LA USA.
   [Palumbo, Paul] Dartmouth Med Sch, Lebanon, NH USA.
   [Russek-Cohen, Estelle] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA.
   [Smith, Betsy] NIAID, Maternal Adolescent Pediat Res Branch, Div Aids, NIH, Bethesda, MD 20892 USA.
   [Soto-Castellares, Giselle] USN, Dept Emerging Infect Dis, Med Res Unit 6, Bellavista, Callao, Peru.
   [Swaminathan, Soumya] Natl Inst Res TB, Madras, Tamil Nadu, India.
   [Wingfield, Claire] Treatment Act Grp, New York, NY USA.
   [Worrell, Carol] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, Rockville, MD USA.
RP Cuevas, LE (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.
EM lcuevas@liv.ac.uk
RI Bossuyt, Patrick/B-4557-2016; Heinrich, Norbert/B-3750-2014
OI Bossuyt, Patrick/0000-0003-4427-0128; Cuevas, Luis
   E./0000-0002-6581-0587
FU National Institute of Allergy and Infectious Diseases; National
   Institutes of Health; National Institute of Child Health and Human
   Development; Centers for Disease Control and Prevention; Office of
   Global AIDS Coordinator; US Department of Department of Health and Human
   Services [HHSN272200800014C]; International Maternal Pediatric
   Adolescent AIDS Clinical Trials Group Statistical and Data Management
   Center [UM01 AI068616]; Thrasher Research Fund [02824-6]
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, National Institute
   of Child Health and Human Development, Centers for Disease Control and
   Prevention, and Office of Global AIDS Coordinator. Funding from these
   institutions was not associated with a research grant but supported
   directly the scientific workshop from which this work was generated. The
   project was also supported in part with US federal funds from the
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, and US Department of Department of Health and
   Human Services (contract HHSN272200800014C). D. S. and G. M. were
   supported by the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Group Statistical and Data Management Center grant
   (grant No UM01 AI068616). L. E. C. was supported by a Thrasher Research
   Fund grant (contract 02824-6).
CR Albert PS, 2004, BIOMETRICS, V60, P427, DOI 10.1111/j.0006-341X.2004.00187.x
   Arias M, 2007, CLIN INFECT DIS, V44, P674, DOI 10.1086/511639
   Bossuyt PM, 2003, BRIT MED J, V326, P41, DOI 10.1136/bmj.326.7379.41
   Caviedes L, 2000, J CLIN MICROBIOL, V38, P1203
   Cuevas LE, 2011, INDIAN J PEDIATR, V78, P449, DOI 10.1007/s12098-010-0354-0
   Dinnes J, 2007, HEALTH TECHNOL ASSES, V11, P1
   GOMEZPASTRANA D, 1999, PEDIATR PULM, V28, P344, DOI 10.1002/(SICI)1099-0496(199911)28:5<344::AID-PPUL6>3.0.CO;2-D
   Graham SM, 2012, J INFECT DIS, V205, pS199, DOI 10.1093/infdis/jis008
   Graham SM, 2010, LANCET INFECT DIS, V10, P581, DOI 10.1016/S1473-3099(10)70145-6
   Ha Dang Thi Minh, 2009, PLoS One, V4, pe8341, DOI 10.1371/journal.pone.0008341
   Hesseling AC, 2003, CLIN INFECT DIS, V37, P1226, DOI 10.1086/378298
   Mandalakas AM, 2011, INT J TUBERC LUNG D, V15, P1018, DOI 10.5588/ijtld.10.0631
   Mase SR, 2007, INT J TUBERC LUNG D, V11, P485
   Montenegro SH, 2003, CLIN INFECT DIS, V36, P16, DOI 10.1086/344900
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524
   Newton SM, 2008, LANCET INFECT DIS, V8, P498, DOI 10.1016/S1473-3099(08)70182-8
   Nicol MP, 2011, LANCET INFECT DIS, V11, P819, DOI 10.1016/S1473-3099(11)70167-0
   Oberhelman RA, 2010, LANCET INFECT DIS, V10, P612, DOI 10.1016/S1473-3099(10)70141-9
   Palme IB, 2004, ACTA PAEDIATR, V93, P311, DOI 10.1080/08035250410023566
   Pepe MS, 2004, STAT EVALUATION MED
   RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705
   Robledo JA, 2006, INT J TUBERC LUNG D, V10, P613
   Stockdale AJ, 2010, J TROP PEDIATRICS, V56, P291, DOI 10.1093/tropej/fmq081
   World Health Organization, 2009, PATHW BETT DIAGN TUB
   WHO, 2010, GLOB TUB CONTR
   Zar HJ, 2010, EXPERT REV ANTI-INFE, V8, P277, DOI [10.1586/eri.10.9, 10.1586/ERI.10.9]
NR 26
TC 38
Z9 38
U1 1
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2012
VL 205
SU 2
BP S209
EP S215
DI 10.1093/infdis/jir879
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 932ZT
UT WOS:000303329700008
PM 22476719
OA No
DA 2017-08-15
ER

PT J
AU Graham, SM
   Ahmed, T
   Amanullah, F
   Browning, R
   Cardenas, V
   Casenghi, M
   Cuevas, LE
   Gale, M
   Gie, RP
   Grzemska, M
   Handelsman, E
   Hatherill, M
   Hesseling, AC
   Jean-Philippe, P
   Kampmann, B
   Kabra, SK
   Lienhardt, C
   Lighter-Fisher, J
   Madhi, S
   Makhene, M
   Marais, BJ
   McNeeley, DF
   Menzies, H
   Mitchell, C
   Modi, S
   Mofenson, L
   Musoke, P
   Nachman, S
   Powell, C
   Rigaud, M
   Rouzier, V
   Starke, JR
   Swaminathan, S
   Wingfield, C
AF Graham, Stephen M.
   Ahmed, Tahmeed
   Amanullah, Farhana
   Browning, Renee
   Cardenas, Vicky
   Casenghi, Martina
   Cuevas, Luis E.
   Gale, Marianne
   Gie, Robert P.
   Grzemska, Malgosia
   Handelsman, Ed
   Hatherill, Mark
   Hesseling, Anneke C.
   Jean-Philippe, Patrick
   Kampmann, Beate
   Kabra, Sushil Kumar
   Lienhardt, Christian
   Lighter-Fisher, Jennifer
   Madhi, Shabir
   Makhene, Mamodikoe
   Marais, Ben J.
   McNeeley, David F.
   Menzies, Heather
   Mitchell, Charles
   Modi, Surbhi
   Mofenson, Lynne
   Musoke, Philippa
   Nachman, Sharon
   Powell, Clydette
   Rigaud, Mona
   Rouzier, Vanessa
   Starke, Jeffrey R.
   Swaminathan, Soumya
   Wingfield, Claire
TI Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed Clinical
   Case Definitions for Classification of Intrathoracic Tuberculosis
   Disease. Consensus From an Expert Panel
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HIV-INFECTED ADULTS; XPERT MTB/RIF TEST; CHILDHOOD TUBERCULOSIS;
   PULMONARY TUBERCULOSIS; SOUTH-AFRICA; PEDIATRIC TUBERCULOSIS; RESISTANT
   TUBERCULOSIS; ACCURACY
AB There is a critical need for improved diagnosis of tuberculosis in children, particularly in young children with intrathoracic disease as this represents the most common type of tuberculosis in children and the greatest diagnostic challenge. There is also a need for standardized clinical case definitions for the evaluation of diagnostics in prospective clinical research studies that include children in whom tuberculosis is suspected but not confirmed by culture of Mycobacterium tuberculosis. A panel representing a wide range of expertise and child tuberculosis research experience aimed to develop standardized clinical research case definitions for intrathoracic tuberculosis in children to enable harmonized evaluation of new tuberculosis diagnostic technologies in pediatric populations. Draft definitions and statements were proposed and circulated widely for feedback. An expert panel then considered each of the proposed definitions and statements relating to clinical definitions. Formal group consensus rules were established and consensus was reached for each statement. The definitions presented in this article are intended for use in clinical research to evaluate diagnostic assays and not for individual patient diagnosis or treatment decisions. A complementary article addresses methodological issues to consider for research of diagnostics in children with suspected tuberculosis.
C1 [Graham, Stephen M.] Univ Melbourne, Royal Childrens Hosp, Ctr Int Child Hlth, Dept Paediat & Murdoch Childrens,Res Inst, Parkville, Vic 3052, Australia.
   [Graham, Stephen M.] Int Union TB & Lung Dis, Paris, France.
   [Ahmed, Tahmeed] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Amanullah, Farhana] Indus Hosp, Karachi, Pakistan.
   [Browning, Renee; Jean-Philippe, Patrick] NIAID, Henry Jackson Fdn, Maternal Adolescent Pediat Res Branch, Div Aids,NIH, Bethesda, MD 20892 USA.
   [Cardenas, Vicky] Aeras, Rockville, MD USA.
   [Casenghi, Martina] Med Sans Frontieres, Geneva, Switzerland.
   [Cuevas, Luis E.] Univ Liverpool, Sch Trop Med, Liverpool L69 3BX, Merseyside, England.
   [Gale, Marianne] Med Sans Frontieres, Sydney, NSW, Australia.
   [Gie, Robert P.] Univ Stellenbosch, Dept Paediat & Child Hlth, Cape Town, South Africa.
   [Grzemska, Malgosia; Lienhardt, Christian] WHO, Stop TB Partnership, CH-1211 Geneva, Switzerland.
   [Handelsman, Ed] NIAID, Maternal Adolescent Pediat Res Branch, Div Aids, NIH, Bethesda, MD 20892 USA.
   [Hatherill, Mark] Univ Cape Town, Sch Child & Adolescent Hlth, S African TB Vaccine Initiat, ZA-7925 Cape Town, South Africa.
   [Hesseling, Anneke C.] Univ Stellenbosch, Desmond Tutu TB Ctr, Dept Paediat & Child Hlth, Cape Town, South Africa.
   [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London, England.
   [Kampmann, Beate] MRC Labs, Banjul, Gambia.
   [Kabra, Sushil Kumar] All India Inst Med Sci, New Delhi, India.
   [Lighter-Fisher, Jennifer; Rigaud, Mona] NYU, Sch Med, New York, NY USA.
   [Madhi, Shabir] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa.
   [Makhene, Mamodikoe] NIAID, Div Microbiol & Infect Dis, NIH, Bethesda, MD 20892 USA.
   [Marais, Ben J.] Univ Sydney, Childrens Hosp Westmead, Sydney, NSW 2006, Australia.
   [McNeeley, David F.] Med Serv Corp Int, Arlington, VA USA.
   [Menzies, Heather] Ctr Dis Control & Prevent, Int Res & Programs Branch, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
   [Mitchell, Charles] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Modi, Surbhi] Ctr Dis Control & Prevent, Maternal & Child Hlth Branch, Div Global HIV AIDS, Atlanta, GA USA.
   [Mofenson, Lynne] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, Rockville, MD USA.
   [Musoke, Philippa] Makerere Univ Johns Hopkins Univ Res Collaborat, Kampala, Uganda.
   [Nachman, Sharon] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA.
   [Powell, Clydette] US Agcy Int Dev, Div Infect Dis, Off Hlth Infect Dis & Nutr, Bur Global Hlth, Washington, DC 20523 USA.
   [Rouzier, Vanessa] GHESKIO Ctr, Port Au Prince, Haiti.
   [Starke, Jeffrey R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   [Swaminathan, Soumya] Natl Inst Res TB, Chennai, Tamil Nadu, India.
   [Wingfield, Claire] Treatment Act Grp, New York, NY USA.
RP Graham, SM (reprint author), Univ Melbourne, Royal Childrens Hosp, Ctr Int Child Hlth, Dept Paediat, Flemington Rd, Parkville, Vic 3052, Australia.
EM steve.graham@rch.org.au; jeanphilippep@niaid.nih.gov
OI Cuevas, Luis E./0000-0002-6581-0587; Mofenson,
   Lynne/0000-0002-2818-9808; Lighter, Jennifer/0000-0002-9313-2103;
   Kampmann, Beate/0000-0002-6546-4709
FU NIAID/NIH; Eunice Kennedy Shriver NICHD; CDC; OGAC; NIAID/NIH, US DHHS
   [HHSN272200800014C]
FX This work was supported by NIAID/NIH, Eunice Kennedy Shriver NICHD, CDC,
   and OGAC. This project has also been supported in part with federal
   funds from the NIAID/NIH, US DHHS, under contract no. HHSN272200800014C.
CR Barnes PF, 2001, AM J RESP CRIT CARE, V163, P807
   Boehme CC, 2011, LANCET, V377, P1495, DOI 10.1016/S0140-6736(11)60438-8
   Donald PR, 2004, INT J TUBERC LUNG D, V8, P627
   Fairlie L, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-28
   Graham SM, 2010, LANCET INFECT DIS, V10, P581, DOI 10.1016/S1473-3099(10)70145-6
   Harries AD, 2002, INT J TUBERC LUNG D, V6, P424
   Hatherill M, 2010, B WORLD HEALTH ORGAN, V88, P312, DOI 10.2471/BLT.09.062893
   Hesseling AC, 2002, INT J TUBERC LUNG D, V6, P1038
   Mandalakas AM, 2011, INT J TUBERC LUNG D, V15, P1018, DOI 10.5588/ijtld.10.0631
   Marais BJ, 2006, PEDIATRICS, V118, pE1350, DOI 10.1542/peds.2006-0519
   Marais BJ, 2006, INT J TUBERC LUNG D, V10, P259
   Marais BJ, 2005, ARCH DIS CHILD, V90, P1162, DOI 10.1136/adc.2004.070797
   Marais BJ, 2004, PEDIATR RADIOL, V34, P886, DOI 10.1007/s00247-004-1238-0
   Marais S, 2010, LANCET INFECT DIS, V10, P803, DOI 10.1016/S1473-3099(10)70138-9
   McNerney R, 2012, J INFECT DIS, V205, pS147, DOI 10.1093/infdis/jir860
   Nahid, 2012, J INFECT DIS S2, V205, pS159
   New Diagnostics Working Group of the Stop TB Partnership, 2009, PATHW BETT DIAGN TUB
   Newton SM, 2008, LANCET INFECT DIS, V8, P498, DOI 10.1016/S1473-3099(08)70182-8
   Nicol MP, 2011, LANCET INFECT DIS, V11, P819, DOI 10.1016/S1473-3099(11)70167-0
   Nicol MP, 2011, PAEDIATR RESPIR REV, V12, P16, DOI 10.1016/j.prrv.2010.09.008
   Oberhelman RA, 2010, LANCET INFECT DIS, V10, P612, DOI 10.1016/S1473-3099(10)70141-9
   Starke JR, 2002, INT J TUBERC LUNG D, V6, P373
   Swaminathan S, 2010, CLIN INFECT DIS, V50, pS184, DOI 10.1086/651490
   Swingler GH, 2005, ARCH DIS CHILD, V90, P1153, DOI 10.1136/adc.2004.062315
   Thomas TA, 2010, INT J TUBERC LUNG D, V14, P1244
   von Reyn CF, 2010, AIDS, V24, P675, DOI 10.1097/QAD.0b013e3283350f1b
   WHO, 2007, WHOHTMTB2007381
   Wilson D, 2006, INT J TUBERC LUNG D, V10, P31
   Wright CA, 2009, INT J TUBERC LUNG D, V13, P1467
   Zar HJ, 2007, PAEDIATR RESPIR REV, V8, P97, DOI 10.1016/j.prrv.2007.05.001
   Zumla A, 2012, J INFECT DIS, V205, pS228, DOI 10.1093/infdis/jir858
   [Anonymous], 2012, J INFECT DIS S2, V205, pS209
NR 32
TC 132
Z9 132
U1 0
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2012
VL 205
SU 2
BP S199
EP S208
DI 10.1093/infdis/jis008
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 932ZT
UT WOS:000303329700007
PM 22448023
OA No
DA 2017-08-15
ER

PT J
AU Manyando, C
   Kayentao, K
   D'Alessandro, U
   Okafor, HU
   Juma, E
   Hamed, K
AF Manyando, Christine
   Kayentao, Kassoum
   D'Alessandro, Umberto
   Okafor, Henrietta U.
   Juma, Elizabeth
   Hamed, Kamal
TI A systematic review of the safety and efficacy of
   artemether-lumefantrine against uncomplicated Plasmodium falciparum
   malaria during pregnancy
SO MALARIA JOURNAL
LA English
DT Review
DE Artemether-lumefantrine; Artemisinin-based combination therapy (ACT);
   Pregnancy; Malaria; Plasmodium falciparum
ID POPULATION PHARMACOKINETICS; DEVELOPMENTAL TOXICITY; RETICULOCYTE COUNT;
   INTERACTION TRIAL; WOMEN; ARTESUNATE; ARTEMISININS; ANTIMALARIALS;
   UGANDA; ARTEMETHER/LUMEFANTRINE
AB Malaria during pregnancy, particularly Plasmodium falciparum malaria, has been linked to increased morbidity and mortality, which must be reduced by both preventive measures and effective case management. The World Health Organization (WHO) recommends artemisinin-based combination therapy (ACT) to treat uncomplicated falciparum malaria during the second and third trimesters of pregnancy, and quinine plus clindamycin during the first trimester. However, the national policies of many African countries currently recommend quinine throughout pregnancy. Therefore, the aim of this article is to provide a summary of the available data on the safety and efficacy of artemether-lumefantrine (AL) in pregnancy. An English-language search identified 16 publications from 1989 to October 2011 with reports of artemether or AL exposure in pregnancy, including randomized clinical trials, observational studies and systematic reviews. Overall, there were 1,103 reports of AL use in pregnant women: 890 second/third trimester exposures; 212 first trimester exposures; and one case where the trimester of exposure was not reported. In the second and third trimesters, AL was not associated with increased adverse pregnancy outcomes as compared with quinine or sulphadoxine-pyrimethamine, showed improved tolerability relative to quinine, and its efficacy was non-inferior to quinine. There is evidence to suggest that the pharmacokinetics of antimalarial drugs may change in pregnancy, although the impact on efficacy and safety needs to be studied further, especially since the majority of studies report high cure rates and adequate tolerability. As there are fewer reports of AL safety in the first trimester, additional data are required to assess the potential to use AL in the first trimester. Though the available safety and efficacy data support the use of AL in the second and third trimesters, there is still a need for further information. These findings reinforce the WHO recommendation to treat uncomplicated falciparum malaria with quinine plus clindamycin in early pregnancy and ACT in later pregnancy.
C1 [Manyando, Christine] Trop Dis Res Ctr, Ndola, Zambia.
   [Kayentao, Kassoum] Malaria Res & Training Ctr, Bamako, Mali.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Okafor, Henrietta U.] Univ Nigeria, Dept Paediat, Coll Med, Enugu, Nigeria.
   [Juma, Elizabeth] Kenya Govt Med Res Ctr, Kisumu, Kenya.
   [Hamed, Kamal] Novartis Pharmaceut, E Hanover, NJ USA.
RP Manyando, C (reprint author), Trop Dis Res Ctr, Ndola, Zambia.
EM cmanyando@yahoo.com
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Hamed,
   Kamal/0000-0003-1896-9736
FU Novartis Pharma AG
FX The authors would like to thank Kirstin Stricker for her critical review
   of the manuscript. Dr Lisa Redrup of PreScript Communications provided
   editorial support sponsored by Novartis Pharma AG.
CR Adam I, 2004, T ROY SOC TROP MED H, V98, P509, DOI 10.1016/j.trstmh.2003.11.008
   Adam I, 2009, ANN TROP MED PARASIT, V103, P205, DOI 10.1179/136485909X398285
   Ashley EA, 2007, TROP MED INT HEALTH, V12, P201, DOI 10.1111/j.1365-3165.2006.01785.x
   Azairwe R., 2011, Southern Sudan Medical Journal, V4, P30
   Bardaji A, 2011, J INFECT DIS, V203, P691, DOI 10.1093/infdis/jiq049
   Birku Y, 2002, ETHIOPIAN MED J, V40, P17
   Byakika-Kibwika P, 2010, THER CLIN RISK MANAG, V6, P11
   Chi BH, 2011, INT J GYNECOL OBSTET, V113, P131, DOI [10.1016/j.ijgo.2010.11.013, 10.1016/j.ijgo.2010.11.1313]
   Clark RL, 2008, BIRTH DEFECTS RES B, V83, P397, DOI 10.1002/bdrb.20165
   Clark RL, 2012, BIRTH DEFECTS RES A, V94, P61, DOI 10.1002/bdra.22868
   Dellicour S, 2008, PLOS MED, V5, P1310, DOI 10.1371/journal.pmed.0050187
   Dellicour S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-15
   Dellicour S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000221
   Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X
   Djimde A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-S1-S4
   Ezzet F, 2000, ANTIMICROB AGENTS CH, V44, P697, DOI 10.1128/AAC.44.3.697-704.2000
   German P, 2009, JAIDS-J ACQ IMM DEF, V51, P424, DOI 10.1097/QAI.0b013e3181acb4ff
   Kaye DK, 2008, J INFECT DEV COUNTR, V2, P135, DOI 10.3855/T2.2.135
   Lefevre G, 2000, EUR J PHARM SCI, V10, P141, DOI 10.1016/S0928-0987(00)00060-9
   Lefevre G, 2002, J CLIN PHARMACOL, V42, P1147, DOI 10.1177/009127002237995
   Lefevre G, 2001, AM J TROP MED HYG, V64, P247
   Makanga M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-S1-S5
   Manyando C, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-249
   McGready R, 2012, LANCET INFECT DIS, V12, P388, DOI 10.1016/S1473-3099(11)70339-5
   McGready R, 2011, BJOG-INT J OBSTET GY, V118, P123, DOI 10.1111/j.1471-0528.2010.02810.x
   McGready R, 1999, ANN TROP MED PARASIT, V93, pS19, DOI 10.1080/00034989957709
   McGready R, 1998, T ROY SOC TROP MED H, V92, P430, DOI 10.1016/S0035-9203(98)91081-1
   McGready R, 2001, CLIN INFECT DIS, V33, P2009, DOI 10.1086/324349
   McGready R, 2008, PLOS MED, V5, P1699, DOI 10.1371/journal.pmed.0050253
   McGready R, 2006, EUR J CLIN PHARMACOL, V62, P1021, DOI 10.1007/s00228-006-0199-7
   Menendez C, 2008, PLOS MED, V5, P220, DOI 10.1371/journal.pmed.0050044
   Morris CA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-114
   Nosten F, 2007, LANCET INFECT DIS, V7, P118, DOI 10.1016/S1473-3099(07)70023-3
   Onyamboko MA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-49
   Orton LC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004912.pub3
   Piola P, 2005, LANCET, V365, P1467, DOI 10.1016/S0140-6736(05)66416-1
   Piola P, 2010, LANCET INFECT DIS, V10, P762, DOI 10.1016/S1473-3099(10)70202-4
   Poespoprodjo JR, 2011, AM J TROP MED HYG S6, V85
   President's Malaria Initiative, MAL OP PLAN MOP FY20
   Roll Back Malaria Partnership, 2005 THAIL COUNTR PR
   Roll Back Malaria Partnership, 2005 CHIN COUNTR PRO
   [Anonymous], 2010, GUID TREATM MAL S AF
   Sangare LR, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-152
   Sinclair D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007483.pub2
   Sowunmi A., 1998, Journal of Obstetrics and Gynaecology (Abingdon), V18, P322
   Tarning J, 2009, ANTIMICROB AGENTS CH, V53, P3837, DOI 10.1128/AAC.00195-09
   Ter Kuile FO, 2004, AM J TROP MED HYG, V71, P41
   Ugandan Malaria Control Programme, UG NAT POL MAL 2005
   Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35
   WANG T, 1989, Journal of Traditional Chinese Medicine, V9, P28
   White TEK, 2008, BIRTH DEFECTS RES B, V83, P407, DOI 10.1002/bdrb.20157
   Whitty CJM, 2005, BJOG-INT J OBSTET GY, V112, P1189, DOI 10.1111/j.1471-0528.2005.00714.x
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   WHO, COUNTR ANT DRUG POL
   [Anonymous], GLOB REP ANT DRUG EF
   World Health Organization, ASS SAF ART COMP PRE
   WHO, ANT CHLORPR DAPS LAP
   World Health Organization, 2010, GUID TREATM MAL
   Wilby KJ, 2011, CLIN PHARMACOKINET, V50, P705, DOI 10.2165/11594550-000000000-00000
   [Anonymous], PHARM STUD
NR 60
TC 27
Z9 27
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAY 1
PY 2012
VL 11
AR 141
DI 10.1186/1475-2875-11-141
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 982CU
UT WOS:000307020100001
PM 22548983
OA gold
DA 2017-08-15
ER

PT J
AU Dione, MM
   Geerts, S
   Antonio, M
AF Dione, Michel M.
   Geerts, Stanny
   Antonio, Martin
TI Characterisation of novel strains of multiply antibiotic-resistant
   Salmonella recovered from poultry in Southern Senegal
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE Salmonella; clones; antibiotic-resistant; Senegal
ID AMPLIFIED POLYMORPHIC DNA; ANTIMICROBIAL RESISTANCE; SUBSP ENTERICA;
   RISK-FACTORS; SEQUENCE; ENTERITIDIS; SEROVAR; DISCRIMINATION;
   EPIDEMIOLOGY; CARCASSES
AB Introduction: Non-typhoidal Salmonella (NTS) contamination in poultry and poultry products is a major cause of food-borne disease in humans. This study presents the molecular epidemiology of NTS isolated from poultry in Senegal.
   Methodology: A total of 261 NTS recovered from broiler farms, chicken carcasses and street vendors were characterized using random amplification of polymorphic DNA (RAPD) and multilocus sequence typing (MLST) techniques.
   Results: We observed 20 distinct RAPD profiles corresponding to 18 different serotypes. Strains from each of these 20 groups were further analysed using MLST. Consequently, 12 new MLST alleles and 17 new sequence types were discovered. Three sequence types (S. Kentucky ST198, S. Agona ST13 and S. Istanbul ST33) have previously been described in Senegal and other countries, suggesting that these clones are geographically widely distributed and are circulating in a wide range of hosts. Nine clones showed multi-resistance to the most commonly used antibiotics in both humans and animals. However, a novel multi-resistant clone of S. Kentucky ST832 was found.
   Conclusion: This study gives new insights into the genetic diversity of NTS in Senegal. Molecular tools remain essential to improve our understanding of the epidemiology of NTS by tracking the sources of infection and/or contamination.
C1 [Geerts, Stanny] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Dione, Michel M.; Antonio, Martin] MRC, Banjul, Gambia.
RP Antonio, M (reprint author), MRC Unit, Banjul, Gambia.
EM mantonio@mrc.gm
FU Flemish Interuniversity Council (VLIR-UOS, Brussels, Belgium); Medical
   Research Council, United Kingdom; Science Foundation of Ireland
   [05/FE1/B882]
FX This work was supported by the Flemish Interuniversity Council
   (VLIR-UOS, Brussels, Belgium) and the Medical Research Council, United
   Kingdom. We acknowledge Mark Achtman for the use of the Salmonella MLST
   database (http://mlst.ucc.ie/mlst/dbs/Senterica), which is hosted at the
   University College Cork and funded by the Science Foundation of Ireland
   (05/FE1/B882).
CR Aanensen DM, 2005, NUCLEIC ACIDS RES, V33, P728
   Alcaine SD, 2006, APPL ENVIRON MICROB, V72, P7575, DOI 10.1128/AEM.01174-06
   Bada-Alambedji R, 2006, BRAZ J MICROBIOL, V37, P510, DOI 10.1590/S1517-83822006000400020
   Betancor L, 2004, J CLIN MICROBIOL, V42, P1155, DOI 10.1128/JCM.42.3.1155-1162.2004
   Cardinale E., 2003, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V56, P13
   Cardinale E, 2005, INT J FOOD MICROBIOL, V103, P157, DOI 10.1016/j.ijfoodmicro.2004.12.023
   Cardinale E, 2004, PREV VET MED, V63, P151, DOI 10.1016/j.prevetmed.2004.03.002
   Chansiripornchai N, 2000, FEMS IMMUNOL MED MIC, V29, P221, DOI 10.1016/S0928-8244(00)00208-X
   Cooper JE, 2004, TRENDS MICROBIOL, V12, P373, DOI 10.1016/j.tim.2004.06.003
   Dione MM, 2009, J FOOD PROTECT, V72, P2423
   Grimont P., 2007, ANTIGENIC FORMULAE S
   Ikumapayi UN, 2007, J MED MICROBIOL, V56, P1479, DOI 10.1099/jmm.0.47416-0
   Kotetishvili M, 2002, J CLIN MICROBIOL, V40, P1626, DOI 10.1128/JCM.40.5.1626-1635.2002
   Lin AW, 1996, J CLIN MICROBIOL, V34, P870
   Maripandi A., 2007, Biotechnology, V6, P278
   Martinez ZL, 2002, CLIN MICROB REV, V15, P647
   [Anonymous], MULT SEQ TYP WEBS
   RAMPLING A, 1993, LANCET, V342, P317, DOI 10.1016/0140-6736(93)91466-Y
   Ross IL, 2005, J CLIN MICROBIOL, V43, P1604, DOI 10.1128/JCM.43.4.1604-1611.2005
   Sukhnanand S, 2005, J CLIN MICROBIOL, V43, P3688, DOI 10.1128/JCM.43.8.3688-3698.2005
   Tikoo A, 2001, CURR SCI INDIA, V80, P1049
   Torpdahl M, 2005, J MICROBIOL METH, V63, P173, DOI 10.1016/j.mimet.2005.03.006
   Urwin R, 2003, TRENDS MICROBIOL, V11, P479, DOI 10.1016/j.tim.2003.08.006
   Yaqoob E., 2007, Pakistan Veterinary Journal, V27, P102
NR 24
TC 8
Z9 8
U1 1
U2 7
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD MAY
PY 2012
VL 6
IS 5
BP 436
EP 442
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 967MG
UT WOS:000305911500010
PM 22610711
OA No
DA 2017-08-15
ER

PT J
AU Winrow, B
   Bile, K
   Hafeez, A
   Davies, H
   Brown, N
   Zafar, S
   Cham, M
   Phillips, B
   MacDonald, R
   Southall, DP
AF Winrow, Benjamin
   Bile, Khalif
   Hafeez, Assad
   Davies, Hugh
   Brown, Nick
   Zafar, Shamsa
   Cham, Mamady
   Phillips, Barbara
   MacDonald, Rhona
   Southall, David P.
TI A proposed new international convention supporting the rights of
   pregnant women and girls and their newborn infants
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Review
ID INTRAPARTUM-RELATED DEATHS; MATERNAL MORTALITY; POSTNATAL DEPRESSION;
   CHILD SURVIVAL; HEALTH; COUNTRIES; SETTINGS; CARE; INTERVENTIONS;
   OUTCOMES
AB For a multitude of eminently modifiable reasons, death rates for pregnant women and girls and their newborn infants in poorly resourced countries remain unacceptably high. The concomitant high morbidity rates compound the situation. The rights of these vulnerable individuals are incompletely protected by existing United Nations human rights conventions, which many countries have failed to implement. The authors propose a novel approach grounded on both human rights and robust evidence-based clinical guidelines to create a 'human rights convention specifically for pregnant women and girls and their newborn infants'. The approach targets the 'right to health' of these large, vulnerable and neglected populations. The proposed convention is designed so that it can be monitored, audited and evaluated objectively. It should also foster a sense of national ownership and accountability as it is designed to be relevant to local situations and to be incorporated into local clinical governance systems. It may be of particular value to those countries that are not yet on target to meet the Millennium Development Goals (MDGs), especially MDGs 4 and 5, which target child and maternal mortality, respectively. To foster a sense of international responsibility, two additional initiatives are integral to its philosophy: the promotion of twinning between well and poorly resourced regions and a raising of awareness of how some well-resourced countries can damage the health of mothers and babies, for example, through the recruitment of health workers trained by national governments and taken from the public health system.
C1 [Winrow, Benjamin; Phillips, Barbara; MacDonald, Rhona; Southall, David P.] MCAI, Nottingham NG1 5BB, England.
   [Bile, Khalif] WHO Pakistan, WHO, Stockholm, Sweden.
   [Hafeez, Assad] Hlth Serv Acad, Islamabad, Pakistan.
   [Davies, Hugh] Univ Oxford, Oxford, England.
   [Brown, Nick] Salisbury Dist Hosp, Dept Paediat, Salisbury, Wilts, England.
   [Zafar, Shamsa] RIPHAH Int Univ, Dept Obstet, Rawalpindi, Pakistan.
   [Cham, Mamady] Minist Hlth & Social Welf, Dept Hlth Serv, Banjul, Gambia.
RP Southall, DP (reprint author), MCAI, 83 Derby Rd, Nottingham NG1 5BB, England.
EM director@mcai.org.uk
CR Alam AY, 2011, J PAK MED ASSOC, V61, P1
   Almond P, 2009, PERSPECT PUBLIC HEAL, V129, P221, DOI 10.1177/1757913909343882
   Backman G, 2008, LANCET, V372, P2047, DOI 10.1016/S0140-6736(08)61781-X
   Barros FC, 2010, BMC PREGNANCY CHILDB, V10, DOI [10.1186/1471-2393-10-S1-S3, 10.1186/1471-2393-S1-S3]
   Bhutta ZA, 2005, PEDIATRICS, V115, P519, DOI 10.1542/peds.2004-1441
   Bhutta ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2
   Boesen JK, 2007, APPL RIGHTS BASED AP, P1
   Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1
   Chaudhury RH, 2008, UN EC SOC COMM AS PA
   Cole-Ceesay R, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-21
   Conde-Agudelo A, 2006, JAMA-J AM MED ASSOC, V295, P1809, DOI 10.1001/jama.295.15.1809
   Conde-Agudelo A, 2005, INT J GYNECOL OBSTET, V89, pS34, DOI 10.1016/j.ijgo.2004.08.003
   Costa AM, GLOBAL REPORT TRAFFI
   Costello A, 2004, BRIT MED J, V329, P1166, DOI 10.1136/bmj.329.7475.1166
   [Anonymous], 2002, BRING RIGHTS BEAR AD, P1
   Darmstadt GL, 2009, INT J GYNECOL OBSTET, V107, pS89, DOI 10.1016/j.ijgo.2009.07.010
   de Bernis L, 2003, BRIT MED BULL, V67, P39, DOI 10.1093/bmb/ldg017
   Dutta AK, 2009, INDIAN PEDIATR, V46, P835
   Easterly W, 2009, WORLD DEV, V37, P26, DOI 10.1016/j.worlddev.2008.02.009
   Editorial: Unsafe abortions: Eight maternal deaths every hour, 2009, LANCET, V374, P1301
   Espinoza H, 2005, REV PANAM SALUD PUBL, V17, P123, DOI 10.1590/S1020-49892005000200011
   Frisancho A, 2008, LANCET, V372, P2007, DOI 10.1016/S0140-6736(08)61785-7
   Hawkins K, 2005, DEV HUMAN RIGHTS BAS, P1
   Hesketh T, 2011, CAN MED ASSOC J, V183, P1374, DOI 10.1503/cmaj.101368
   Hill K, 2007, LANCET, V370, P1311, DOI 10.1016/S0140-6736(07)61572-4
   Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1
   Horton R, 2010, LANCET, V375, P1581, DOI 10.1016/S0140-6736(10)60547-8
   Hunt P, REDUCING MATERNAL MO
   Husain N, 2006, ARCH WOMEN MENT HLTH, V9, P197, DOI 10.1007/s00737-006-0129-9
   Kabali E, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-29
   Kowalewski M, 2000, Afr J Reprod Health, V4, P100, DOI 10.2307/3583247
   Lawn JE, 2009, BJOG-INT J OBSTET GY, V116, P49, DOI 10.1111/j.1471-0528.2009.02328.x
   Lawn JE, 2009, INT J GYNECOL OBSTET, V107, pS123, DOI 10.1016/j.ijgo.2009.07.021
   Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)71146-6
   Mostert S, 2010, ARCH DIS CHILD, V95, P20, DOI 10.1136/adc.2008.154138
   Osrin D, 2010, ARCH DIS CHILD, V95, P1039, DOI 10.1136/adc.2009.179366
   Raj A, 2010, ARCH DIS CHILD, V95, P931, DOI 10.1136/adc.2009.178707
   Salihu HM, 2006, J PEDIATR-US, V148, P522, DOI 10.1016/j.jpeds.2005.11.018
   Singh S, 2009, ABORTION WORLDWIDE D
   Southall D, 2011, EARLY HUM DEV, V87, P735, DOI 10.1016/j.earlhumdev.2011.08.020
   Southall D, 2010, LANCET, V376, P498, DOI 10.1016/S0140-6736(10)61157-9
   [Anonymous], 2008, 2008156 UN, P1
   UNICEF WHO UNESCO UNFPA UNDP UNAIDS WFP and World Bank, 2010, FACTS LIF, P1
   [Anonymous], 2008, PROGR CHILDR REP CAR, V7, P1
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
   World Health Organization, 2010, PREV INT PARTN SEX V
   WHO, 2007, UNS AB GLOB REG EST
NR 47
TC 3
Z9 3
U1 1
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD MAY
PY 2012
VL 97
IS 5
BP 447
EP 451
DI 10.1136/archdischild-2011-300684
PG 5
WC Pediatrics
SC Pediatrics
GA 932WQ
UT WOS:000303321600015
PM 22247245
OA No
DA 2017-08-15
ER

PT J
AU Lu, CX
   Holland, MJ
   Gong, SQ
   Peng, B
   Bailey, RL
   Mabey, DW
   Wu, YM
   Zhong, GM
AF Lu, Chunxue
   Holland, Martin J.
   Gong, Siqi
   Peng, Bo
   Bailey, Robin L.
   Mabey, David W.
   Wu, Yimou
   Zhong, Guangming
TI Genome-Wide Identification of Chlamydia trachomatis Antigens Associated
   with Trachomatous Trichiasis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HEAT-SHOCK-PROTEIN; HUMORAL IMMUNE-RESPONSE; T-CELL RESPONSE; TERM
   FOLLOW-UP; INCLUSION MEMBRANE; SCARRING TRACHOMA; INFECTED CELLS;
   BACTERIAL-INFECTION; PNEUMONIAE; VACCINE
AB PURPOSE. Chlamydia trachomatis is the leading infectious cause of blindness. The goal of the current study was to search for biomarkers associated with C. trachomatis-induced ocular pathologies.
   METHODS. We used a whole genome scale proteome array to systematically profile antigen specificities of antibody responses to C. trachomatis infection in individuals from trachoma-endemic communities with or without end-stage trachoma (trichiasis) in The Gambia.
   RESULTS. When 61 trichiasis patients were compared with their control counterparts for overall antibody reactivity with organisms of different chlamydial species, no statistically significant difference was found. Both groups developed significantly higher titers of antibodies against C. trachomatis ocular serovars A and B than ocular serovar C, genital serovar D, or Chlamydia psittaci, whereas the titers of anti-Chlamydia pneumoniae antibodies were the highest. When antisera from 33 trichiasis and 26 control patients (with relatively high titers of antibodies to C. trachomatis ocular serovars) were reacted with 908 C. trachomatis proteins, 447 antigens were recognized by at least 1 of the 59 antisera, and 10 antigens by 50% or more antisera, the latter being designated as immunodominant antigens. More importantly, four antigens were preferentially recognized by the trichiasis group, with antigens CT414, CT667, and CT706 collectively reacting with 30% of trichiasis antisera but none from the normal group, and antigen CT695 reacting with 61% of trichiasis but only 31% of normal antisera. On the other hand, eight antigens were preferentially recognized by the control group, with antigens CT019, CT117, CT301, CT553, CT556, CT571, and CT709 together reacting with 46% of normal antisera and none from the trichiasis group, whereas antigen CT442 reacted with 35% of normal and 19% of trichiasis antisera respectively.
   CONCLUSIONS. The current study, by mapping immunodominant C. trachomatis antigens and identifying antigens associated with both ocular pathology and protection, has provided important information for further understanding chlamydial pathogenesis and the development of subunit vaccines. (Invest Ophthalmol Vis Sci. 2012;53:2551-2559) DOI:10.1167/iovs.11-9212
C1 [Lu, Chunxue; Gong, Siqi; Peng, Bo; Zhong, Guangming] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
   [Lu, Chunxue; Peng, Bo; Wu, Yimou; Zhong, Guangming] Univ S China, Dept Microbiol, Hengyang, Hunan, Peoples R China.
   [Holland, Martin J.; Bailey, Robin L.; Mabey, David W.] London Sch Hyg & Trop Med, Dept Clin Res, London WC1E 7HT, England.
   [Holland, Martin J.] MRC Labs, Banjul, Gambia.
RP Zhong, GM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM Zhongg@UTHSCSA.EDU
OI Mabey, David/0000-0002-0031-8276
FU National Institutes of Health; Wellcome Trust [079246/Z/06/Z]; Medical
   Research Council Laboratories, UK, The Gambia
FX Supported by grants from the National Institutes of Health (GZ) and from
   the Wellcome Trust (079246/Z/06/Z). Additional support in The Gambia was
   provided by the Medical Research Council Laboratories, UK, The Gambia.
CR Abu el-Asrar AM, 2001, B SOC BELGE OPHTALMO, V280, P73
   Andreasen AA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000306
   Ausiello CM, 2006, MICROBES INFECT, V8, P714, DOI 10.1016/j.micinf.2005.09.007
   Ausiello CM, 2005, J BIOL REG HOMEOS AG, V19, P136
   Bannantine JP, 2000, CELL MICROBIOL, V2, P35
   Bannantine JP, 1998, MOL MICROBIOL, V28, P1017, DOI 10.1046/j.1365-2958.1998.00867.x
   Bulut Y, 2002, J IMMUNOL, V168, P1435
   Burton MJ, 2011, INFECT IMMUN, V79, P499, DOI 10.1128/IAI.00888-10
   Burton MJ, 2010, INVEST OPHTH VIS SCI, V51, P3583, DOI 10.1167/iovs.09-4550
   Caldwell HD, 2003, J CLIN INVEST, V111, P1757, DOI 10.1172/JCI200317993
   Cappello F, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000552
   Carlson JH, 2005, INFECT IMMUN, V73, P6407, DOI 10.1128/IAI.73.10.6407-6418.2005
   Carlson JH, 2004, INFECT IMMUN, V72, P7063, DOI 10.1128/IAI.72.12.7063-7072.2004
   CLEMENTS C, 1979, AM J OPHTHALMOL, V87, P350
   Clifton DR, 2004, P NATL ACAD SCI USA, V101, P10166, DOI 10.1073/pnas.0402829101
   Dean D, 2008, PLOS MED, V5, P57, DOI 10.1371/journal.pmed.0050014
   Domeika M, 1998, J INFECT DIS, V177, P714
   Engel J, 2004, P NATL ACAD SCI USA, V101, P9947, DOI 10.1073/pnas.0403633101
   Feise Ronald J, 2002, BMC Med Res Methodol, V2, P8, DOI 10.1186/1471-2288-2-8
   Fields KA, 2000, MOL MICROBIOL, V38, P1048, DOI 10.1046/j.1365-2958.2000.02212.x
   Gall A, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00010
   GAYDOS CA, 1993, INT J SYST BACTERIOL, V43, P610
   GRAYSTON JT, 1962, ANN NY ACAD SCI, V98, P352, DOI 10.1111/j.1749-6632.1962.tb30558.x
   Greene W, 2003, J INFECTION, V47, P45, DOI 10.1016/S0163-4453(03)00039-2
   Grinblat-Huse V, 2011, J BACTERIOL, V193, P4039, DOI 10.1128/JB.05277-11
   HAYES LJ, 1995, J INFECT DIS, V172, P268
   Hessel T, 2001, INFECT IMMUN, V69, P4996, DOI 10.1128/IAI.69.8.4996-5000.2001
   Holland MJ, 2010, INVEST OPHTH VIS SCI, V51, P3893, DOI 10.1167/iovs.09-5054
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   Hower S, 2009, MOL MICROBIOL, V72, P1423, DOI 10.1111/j.1365-2958.2009.06732.x
   Hu VH, 2012, INFECT IMMUN, V80, P121, DOI 10.1128/IAI.05965-11
   Hu VH, 2011, INVEST OPHTH VIS SCI, V52, P2181, DOI 10.1167/iovs.10-5829
   Hu VH, 2010, TROP MED INT HEALTH, V15, P673, DOI 10.1111/j.1365-3156.2010.02521.x
   Hudson L, 1989, PRACTICAL IMMUNOLOGY
   Kalman S, 1999, NAT GENET, V21, P385
   Kinnunen A, 2001, SCAND J IMMUNOL, V54, P76, DOI 10.1046/j.1365-3083.2001.00940.x
   Li ZY, 2008, INFECT IMMUN, V76, P3415, DOI 10.1128/IAI.01377-07
   Li ZY, 2008, INFECT IMMUN, V76, P2746, DOI 10.1128/IAI.00010-08
   Luo JH, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-38
   Lutter EI, 2010, INFECT IMMUN, V78, P3678, DOI 10.1128/IAI.00515-10
   Morrison R P, 1991, Semin Immunol, V3, P25
   Peeling RW, 1998, J INFECT DIS, V177, P256, DOI 10.1086/517367
   Pirbhai M, 2006, J BIOL CHEM, V281, P31495, DOI 10.1074/jbc.M602796200
   Rodgers AK, 2010, AM J OBSTET GYNECOL, V203
   Rodgers AK, 2011, FERTIL STERIL, V96, P715, DOI 10.1016/j.fertnstert.2011.06.021
   Roy PH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008842
   Sharma J, 2006, INFECT IMMUN, V74, P1490, DOI 10.1128/IAI.74.3.1490-1499.2006
   Skwor T, 2010, INVEST OPHTH VIS SCI, V51, P5128, DOI 10.1167/iovs.09-5113
   SOWA S, 1969, J HYG-CAMB, V67, P699
   Starnbach MN, 2008, NAT REV IMMUNOL, V8, P313, DOI 10.1038/nri2272
   Starnbach MN, 2003, J IMMUNOL, V171, P4742
   Stekel D, 2003, MICROARRAY BIOINFORM
   Stekel DJ, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni050
   TOYE B, 1993, J INFECT DIS, V168, P1236
   Wang J, 2010, J IMMUNOL, V185, P1670, DOI 10.4049/jimmunol.1001240
   Wang J, 2009, VACCINE, V27, P2967, DOI 10.1016/j.vaccine.2009.02.095
   WATKINS NG, 1986, P NATL ACAD SCI USA, V83, P7480, DOI 10.1073/pnas.83.19.7480
   WOOLRIDG.RL, 1967, AM J OPHTHALMOL, V63, P1650
   ZHANG YX, 1987, INFECT IMMUN, V55, P2570
   Zhong GM, 1999, J EXP MED, V189, P1931, DOI 10.1084/jem.189.12.1931
   Zhong GM, 2001, J EXP MED, V193, P935, DOI 10.1084/jem.193.8.935
   Zhong GM, 2000, J EXP MED, V191, P1525, DOI 10.1084/jem.191.9.1525
NR 62
TC 12
Z9 12
U1 1
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2012
VL 53
IS 6
BP 2551
EP 2559
DI 10.1167/iovs.11-9212
PG 9
WC Ophthalmology
SC Ophthalmology
GA 953JY
UT WOS:000304864600004
PM 22427578
OA No
DA 2017-08-15
ER

PT J
AU Gourlay, AJ
   van Tienen, C
   Dave, SS
   Vincent, T
   Rowland-Jones, SL
   Glynn, JR
   Whittle, HC
   van der Loeff, MFS
AF Gourlay, Annabelle J.
   van Tienen, Carla
   Dave, Sangeeta S.
   Vincent, Tim
   Rowland-Jones, Sarah L.
   Glynn, Judith R.
   Whittle, Hilton C.
   van der Loeff, Maarten F. Schim
TI Clinical predictors cannot replace biological predictors in HIV-2
   infection in a community setting in West Africa
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-2; Africa; Body mass index; Mortality; Cohort
ID PLASMA VIRAL LOAD; CD4 CELL PERCENTAGE; GUINEA-BISSAU; ANTIRETROVIRAL
   THERAPY; PROGNOSTIC VALUE; GAMBIAN PATIENTS; NORMAL SURVIVAL; RURAL
   UGANDA; MORTALITY; DISEASE
AB Objective: To identify clinical predictors of mortality in HIV-2-infected individuals that may be used in place of CD4 count or plasma viral load (PVL) to guide treatment management in resource-limited settings.
   Methods: A prospective community cohort study of HIV-infected and HIV-negative individuals in a rural area of Guinea-Bissau has been ongoing since 1989. In 2003 participants were invited for a clinical examination and blood tests. They were followed-up for vital status until 2010. Antiretroviral treatment (ART) became available in 2007. Cox regression was used to examine the association of clinical measures (World Health Organization (WHO) stage, body mass index (BMI), mid-upper arm circumference (MUAC), and WHO performance scale) measured in 2003 with subsequent mortality.
   Results: In 2003, 146 HIV-2-infected individuals (68% women; mean age 56 years) were examined. Over the next 7 years, 44 (30%) died. BMI < 18.5 kg/m(2) was associated with a crude mortality hazard ratio (HR) of 1.9 (95% confidence interval (CI) 1.0-3.9, p = 0.08); adjusted for age and sex, HR 1.8 (95% CI 0.9-3.8, p = 0.1). MUAC <230 mm in women and <240 mm in men was also associated with an elevated mortality HR, though statistical evidence was weak (crude HR 2.2, 95% CI 0.9-5.3, p = 0.1). WHO clinical stage and WHO performance scale were not associated with mortality (p = 0.6 and p = 0.2, respectively, for crude associations).
   Conclusions: Baseline BMI, MUAC, WHO stage, and WHO performance scale were not strong or statistically significant predictors of mortality among HIV-2-infected individuals. CD4 count and PVL are more reliable tools, when available, for the management of HIV-2-infected patients in the community setting. (C) 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Gourlay, Annabelle J.; Glynn, Judith R.; Whittle, Hilton C.] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [van Tienen, Carla] Erasmus MC, Rotterdam, Netherlands.
   [Dave, Sangeeta S.] UCL, Ctr Sexual Hlth & HIV Res, Res Dept Infect & Populat Hlth, London, England.
   [Vincent, Tim] MRC, Fajara, Gambia.
   [Rowland-Jones, Sarah L.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.
   [van der Loeff, Maarten F. Schim] Hlth Serv Amsterdam, Dept Infect Dis, Amsterdam, Netherlands.
   [van der Loeff, Maarten F. Schim] Univ Amsterdam, Acad Med Ctr,Ctr Infect & Immun Amsterdam CINIMA, Dept Internal Med, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands.
RP Gourlay, AJ (reprint author), Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM annabelle.gourlay@lshtm.ac.uk
RI van Tienen, Carla/A-1119-2012
FU Ministry of Health of Guinea-Bissau; Medical Research Council, UK
FX We thank the study participants and community of Caio, and all the staff
   at the field station. We also thank Peter Aaby, Ramu Sarge-Njie, Steve
   Kaye, and Pauline Kaye for help with logistics, laboratory analyses, and
   data management. We are grateful to the Ministry of Health of
   Guinea-Bissau for their continued support. Funding for this project was
   provided by the Medical Research Council, UK.
CR Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Ariyoshi K, 1998, J Hum Virol, V1, P193
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Castetbon K, 2001, AM J EPIDEMIOL, V154, P75, DOI 10.1093/aje/154.1.75
   Cooper M, 2010, TROP DOCT, V40, P181, DOI 10.1258/td.2010.090460
   Gustafson P, 2007, INFECTION, V35, P69, DOI 10.1007/s15010-007-6090-3
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Holmgren B, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-85
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   LINDAN CP, 1992, ANN INTERN MED, V116, P320
   Malamba SS, 1999, AIDS, V13, P2555, DOI 10.1097/00002030-199912240-00009
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Martinez-Steele E, 2007, AIDS, V21, P317, DOI 10.1097/QAD.0b013e328011d7ab
   Mekonnen Y, 2003, AIDS, V17, P815, DOI 10.1097/01.aids.0000050871.71999.df
   Morgan D, 1997, LANCET, V350, P245, DOI 10.1016/S0140-6736(97)01474-8
   Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   Sewankambo NK, 2000, AIDS, V14, P2391, DOI 10.1097/00002030-200010200-00021
   Tienen Carla van, 2010, J Acquir Immune Defic Syndr, V53, P640, DOI 10.1097/QAI.0b013e3181bf1a25
   Todd J, 2007, AIDS, V21, pS55, DOI 10.1097/01.aids.0000299411.75269.e8
   van der Loeff MFS, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-46
   van der Loeff MFS, 1999, AIDS, V13, pS69
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van der Sande MAB, 2004, JAIDS-J ACQ IMM DEF, V37, P1288, DOI 10.1097/01.qai.0000122708.59121.03
   Schim van der Loeff M., 2010, 18 INT AIDS C VIENN
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   WHO, 2007, WHO CAS DEF HIV SURV
   WHO Expert Committee, 1995, WHO TECHN REP SER, V854, P345
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 31
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAY
PY 2012
VL 16
IS 5
BP E337
EP E343
DI 10.1016/j.ijid.2012.01.001
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 925TI
UT WOS:000302784000004
PM 22387142
OA gold
DA 2017-08-15
ER

PT J
AU Khalid, M
   Yu, HX
   Sauter, D
   Usmani, SM
   Schmokel, J
   Feldman, J
   Gruters, RA
   van der Ende, ME
   Geyer, M
   Rowland-Jones, S
   Osterhaus, AD
   Kirchhoff, F
AF Khalid, Mohammad
   Yu, Hangxing
   Sauter, Daniel
   Usmani, Shariq M.
   Schmokel, Jan
   Feldman, Jerome
   Gruters, Rob A.
   van der Ende, Marchina E.
   Geyer, Matthias
   Rowland-Jones, Sarah
   Osterhaus, Albert D.
   Kirchhoff, Frank
TI Efficient Nef-Mediated Downmodulation of TCR-CD3 and CD28 Is Associated
   with High CD4(+) T Cell Counts in Viremic HIV-2 Infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SIMIAN IMMUNODEFICIENCY VIRUS; COMPLEX CLASS-I; SURFACE EXPRESSION;
   VIRAL REPLICATION; SOOTY MANGABEYS; RHESUS MACAQUES; PLASMA VIREMIA;
   TYPE-2; AIDS; INDUCTION
AB The role of the multifunctional accessory Nef protein in the immunopathogenesis of HIV-2 infection is currently poorly understood. Here, we performed comprehensive functional analyses of 50 nef genes from 21 viremic (plasma viral load, > 500 copies/ml) and 16 nonviremic (<500) HIV-2-infected individuals. On average, nef alleles from both groups were equally active in modulating CD4, TCR-CD3, CD28, MHC-I, and Ii cell surface expression and in enhancing virion infectivity. Thus, many HIV-2-infected individuals efficiently control the virus in spite of efficient Nef function. However, the potency of nef alleles in downmodulating TCR-CD3 and CD28 to suppress the activation and apoptosis of T cells correlated with high numbers of CD4(+) T cells in viremic patients. No such correlations were observed in HIV-2-infected individuals with undetectable viral load. Further functional analyses showed that the Nef-mediated downmodulation of TCR-CD3 suppressed the induction of Fas, Fas-L, PD-1, and CTLA-4 cell surface expression as well as the secretion of gamma interferon (IFN-gamma) by primary CD4(+) T cells. Moreover, we identified a single naturally occurring amino acid variation (I132T) in the core domain of HIV-2 Nef that selectively disrupts its ability to downmodulate TCR-CD3 and results in functional properties highly reminiscent of HIV-1 Nef proteins. Taken together, our data suggest that the efficient Nef-mediated downmodulation of TCR-CD3 and CD28 help viremic HIV-2-infected individuals to maintain normal CD4(+) T cell homeostasis by preventing T cell activation and by suppressing the induction of death receptors that may affect the functionality and survival of both virally infected and uninfected bystander cells.
C1 [Khalid, Mohammad; Yu, Hangxing; Sauter, Daniel; Usmani, Shariq M.; Schmokel, Jan; Kirchhoff, Frank] Univ Clin Ulm, Inst Mol Virol, Ulm, Germany.
   [Gruters, Rob A.; Osterhaus, Albert D.] Erasmus MC, Dept Virol, Rotterdam, Netherlands.
   [Feldman, Jerome] Inst Pasteur, Unite Virus & Immunite, Paris, France.
   [van der Ende, Marchina E.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Geyer, Matthias] Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44139 Dortmund, Germany.
   [Rowland-Jones, Sarah] MRC Labs, Fajara, Gambia.
   [Rowland-Jones, Sarah] John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DU, England.
RP Kirchhoff, F (reprint author), Univ Clin Ulm, Inst Mol Virol, Ulm, Germany.
EM frank.kirchhoff@uni-ulm.de
OI Osterhaus, Albert/0000-0002-6074-1172; Gruters, Rob/0000-0002-8486-5903
FU Deutsche Forschungsgemeinschaft (DFG) [GE 976/6-1]; Virgo FES
FX This work was supported by the Deutsche Forschungsgemeinschaft (DFG) to
   F.K. and M.G. (GE 976/6-1). R.A.G. is supported by Virgo FES.
CR Akari H, 2000, J VIROL, V74, P2907, DOI 10.1128/JVI.74.6.2907-2912.2000
   Arhel N, 2009, J CLIN INVEST, V119, P2965, DOI 10.1172/JCI38994
   Berry N, 1998, J Hum Virol, V1, P457
   Blaak H, 2005, J VIROL, V79, P1686, DOI 10.1128/JVI.79.3.1686-1700.2005
   Blaak H, 2004, JAIDS-J ACQ IMM DEF, V36, P777, DOI 10.1097/00126334-200407010-00003
   Brenchley JM, 2010, IMMUNITY, V32, P737, DOI 10.1016/j.immuni.2010.06.004
   CHOWERS MY, 1994, J VIROL, V68, P2906
   D'Souza M, 2007, J IMMUNOL, V179, P1979
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   de Silva TI, 2008, TRENDS MICROBIOL, V16, P588, DOI 10.1016/j.tim.2008.09.003
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   Estes JD, 2008, J IMMUNOL, V180, P6798
   Feldmann J, 2009, J VIROL, V83, P12968, DOI 10.1128/JVI.01252-09
   Fortin JF, 2004, J BIOL CHEM, V279, P39520, DOI 10.1074/jbc.M407477200
   GAO F, 1994, J VIROL, V68, P7433
   GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0
   Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141
   Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607
   Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   Kaufmann DE, 2009, J IMMUNOL, V182, P5891, DOI 10.4049/jimmunol.0803771
   Keele BF, 2009, NATURE, V460, P515, DOI 10.1038/nature08200
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I
   Kim WM, 2010, ACTA CRYSTALLOGR D, V66, P163, DOI 10.1107/S090744490904880X
   Kirchhoff F, 2008, CELL MOL LIFE SCI, V65, P2621, DOI 10.1007/s00018-008-8094-2
   KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405
   Kirchhoff F, 2009, NAT REV MICROBIOL, V7, P467, DOI 10.1038/nrmicro2111
   Lama J, 2003, CURR HIV RES, V1, P167, DOI 10.2174/1570162033485276
   Leonard JA, 2011, J VIROL, V85, P6867, DOI 10.1128/JVI.00229-11
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101
   Morner A, 1999, J VIROL, V73, P2343
   Munch J, 2007, J VIROL, V81, P13852, DOI 10.1128/JVI.00904-07
   Munch J, 2005, J VIROL, V79, P10547, DOI 10.1128/JVI.79.16.10547-10560.2005
   Munch J, 2001, J VIROL, V75, P10532, DOI 10.1128/JVI.75.21.10532-10536.2001
   Owen SM, 1998, J VIROL, V72, P5425
   Poonia B, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-91
   Rey-Cuille MA, 1998, J VIROL, V72, P3872
   Rowland-Jones SL, 2007, NAT IMMUNOL, V8, P329, DOI 10.1038/ni0407-329
   Schaefer TM, 2002, VIROLOGY, V302, P106, DOI 10.1006/viro.2002.1628
   Schindler M, 2005, J VIROL, V79, P5489, DOI 10.1128/JVI.79.9.5489-5498.2005
   Schindler M, 2003, J VIROL, V77, P10548, DOI 10.1128/JVI.77.19.10548-10556.2003
   Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033
   Schindler M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000107
   Shanmugam V, 2000, J ACQ IMMUN DEF SYND, V24, P257
   Sharp PM, 2010, PHILOS T R SOC B, V365, P2487, DOI 10.1098/rstb.2010.0031
   Silvestri G, 2005, J VIROL, V79, P4043, DOI 10.1128/JVI.79.7.4043-4054.2005
   Simone R, 2009, CURR HIV RES, V7, P266, DOI 10.2174/157016209788347949
   SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115
   Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498
   Swigut T, 2000, J VIROL, V74, P5691, DOI 10.1128/JVI.74.12.5691-5701.2000
   Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593
   Swigut T, 2003, J VIROL, V77, P8116, DOI 10.1128/JVI.77.14.8116-8126.2003
   Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482
   TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208
   van der Ende ME, 2000, J ACQ IMMUN DEF SYND, V25, P11, DOI 10.1097/00126334-200009010-00002
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 60
TC 10
Z9 11
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAY
PY 2012
VL 86
IS 9
BP 4906
EP 4920
DI 10.1128/JVI.06856-11
PG 15
WC Virology
SC Virology
GA 925RD
UT WOS:000302777800017
PM 22345473
OA No
DA 2017-08-15
ER

PT J
AU Mwangome, MK
   Fegan, G
   Mbunya, R
   Prentice, AM
   Berkley, JA
AF Mwangome, Martha K.
   Fegan, Greg
   Mbunya, Ronald
   Prentice, Andrew M.
   Berkley, James A.
TI Reliability and accuracy of anthropometry performed by community health
   workers among infants under 6 months in rural Kenya
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE community health workers; Mid Upper Arm Circumference; weight-for-length
   Z score; infants; malnutrition; Kenya; agents de sante communautaires;
   perimetre brachial; poids pour la taille; nourrissons; malnutrition;
   Kenya; Trabajadores sanitarios comunitarios; circunferencia en la parte
   superior del brazo; z-score; peso por talla; lactantes; desnutricion;
   Kenia
ID ARM CIRCUMFERENCE; GROWTH STANDARDS; SAMPLE-SIZE; UNDERNUTRITION;
   MALNUTRITION; PROGRAMS; WEIGHT; HEIGHT
AB Objective To assess the inter-observer variability and accuracy of Mid Upper Arm Circumference (MUAC) and weight-for-length Z score (WFLz) among infants aged <6 months performed by community health workers (CHWs) in Kilifi District, Kenya. methods A cross-sectional repeatability study estimated inter-observer variation and accuracy of measurements initially undertaken by an expert anthropometrist, nurses and public health technicians. Then, after training, 18 CHWs (three at each of six sites) repeatedly measured MUAC, weight and length of infants aged < 6 months. Intra-class correlations (ICCs) and the Pitman's statistic were calculated. results Among CHWs, ICCs pooled across the six sites (924 infants) were 0.96 (95% CI 0.95-0.96) for MUAC and 0.71 (95% CI 0.68-0.74) for WFLz. MUAC measures by CHWs differed little from their trainers: the mean difference in MUAC was 0.65 mm (95% CI 0.023-1.07), with no significant difference in variance (P = 0.075). conclusion Mid Upper Arm Circumference is more reliably measured by CHWs than WFLz among infants aged < 6 months. Further work is needed to define cut-off values based on MUAC's ability to predict mortality among younger infants.
C1 [Mwangome, Martha K.; Fegan, Greg; Berkley, James A.] KEMRI Wellcome Trust Res Programme, Kilifi 80108, Kenya.
   [Mbunya, Ronald] Kilifi Dist Hosp, Minist Health, Kilifi, Kenya.
   [Mwangome, Martha K.; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
   [Fegan, Greg; Berkley, James A.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Prentice, Andrew M.] MRC Keneba, Med Res Council Labs, Keneba, Gambia.
RP Mwangome, MK (reprint author), KEMRI Wellcome Trust Res Programme, POB 230, Kilifi 80108, Kenya.
EM mmwangome@kilifi.kemri-wellcome.org
OI Berkley, James/0000-0002-1236-849X; Fegan, Greg/0000-0002-2663-2765
FU Wellcome Trust; KEMRI; CGMR-Coast; Ministry of Health-Kenya
FX This work was supported by a strategic award and personal fellowship
   from the Wellcome Trust and is published with the permission of the
   Director, KEMRI. We acknowledge the expert anthropometrist Joyce Nduku
   of KEMRI, CPHR-Nairobi, the support from KEMRI, CGMR-Coast, the Ministry
   of Health-Kenya for permission to access health facilities and staff,
   the study participants and community for their co-operation.
CR Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0
   Bonett DG, 2002, STAT MED, V21, P1331, DOI 10.1002/sim.1108
   de Onis M, 2006, PUBLIC HEALTH NUTR, V9, P942, DOI 10.1017/PHS20062005
   Fernandez MAL, 2010, PEDIATRICS, V126, pE195, DOI 10.1542/peds.2009-2175
   Fjeld E, 2008, INT BREASTFEED J, V3, DOI 10.1186/1746-4358-3-26
   Kerac M, 2011, ARCH DIS CHILD, V96, P1008, DOI 10.1136/adc.2010.191882
   Kikafunda JK, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.4.e45
   Kirkwood BS, 2003, MED STAT
   KNBS NACC NASCOP NPHLS KEMRI NCAPD, 2009, KEN DEM HLTH SURV 20
   Lopriore C, 2007, PUBLIC HEALTH NUTR, V10, P79, DOI 10.1017/S1368980007219676
   Taking the Kenya Essential Package for Health to the Community, 2006, TAK KEN ESS PACK HLT
   Myatt M, 2006, FOOD NUTR BULL, V27, pS7
   Nwankwo BO, 2002, J TROP PEDIATRICS, V48, P109, DOI 10.1093/tropej/48.2.109
   Poustie VJ, 2000, ARCH DIS CHILD, V83, P183, DOI 10.1136/adc.83.2.183
   RAMAIYA C, 1994, TROP GEOGR MED, V46, P318
   Ulijaszek SJ, 1999, BRIT J NUTR, V82, P165
   United Nations, 1986, SUMM PROC WEIGH MEAS
   VELZEBOER MI, 1983, J TROP PEDIATRICS, V29, P159
   VOSS LD, 1990, ARCH DIS CHILD, V65, P1340
   Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.3.CO;2-5
   WHO, 2011, WHO ANTHR VERS 3 2 2
   WHO, 2010, WHO GROWTH STAND STA
   WHO, 2006, WHO CHILD GROWTH STA
   WHO, 2006, ACTA PAEDIATR, V95, P38
   World Bank, 2008, KEN POV IN ASS
NR 25
TC 14
Z9 15
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAY
PY 2012
VL 17
IS 5
BP 622
EP 629
DI 10.1111/j.1365-3156.2012.02959.x
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 928RU
UT WOS:000303001900011
PM 22364555
OA No
DA 2017-08-15
ER

PT J
AU Khulan, B
   Cooper, WN
   Skinner, BM
   Bauer, J
   Owens, S
   Prentice, AM
   Belteki, G
   Constancia, M
   Dunger, D
   Affara, NA
AF Khulan, Batbayar
   Cooper, Wendy N.
   Skinner, Benjamin M.
   Bauer, Julien
   Owens, Stephen
   Prentice, Andrew M.
   Belteki, Gusztav
   Constancia, Miguel
   Dunger, David
   Affara, Nabeel A.
TI Periconceptional maternal micronutrient supplementation is associated
   with widespread gender related changes in the epigenome: a study of a
   unique resource in the Gambia
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID ISCHEMIC-HEART-DISEASE; DNA METHYLATION; DEVELOPMENTAL ORIGINS; ADULT
   DISEASE; SEASONAL-VARIATIONS; GROWTH-RETARDATION; POSTNATAL-GROWTH;
   MORTALITY; LOCUS; BIRTH
AB In addition to the genetic constitution inherited by an organism, the developmental trajectory and resulting mature phenotype are also determined by mechanisms acting during critical windows in early life that influence and establish stable patterns of gene expression. This is the crux of the developmental origins of health and disease hypothesis that suggests undernutrition during gestation and infancy predisposes to ill health in later life. The hypothesis that periconceptional maternal micronutrient supplementation might affect fetal genome-wide methylation within gene promoters was explored in cord blood samples from offspring of Gambian women enrolled into a unique randomized, double blind controlled trial. Significant changes in the epigenome in cord blood DNA samples were further explored in a subset of offspring at 9 months. Gender-specific changes related to periconceptional nutritional supplementation were identified in cord blood DNA samples, some of which showed persistent changes in infant blood DNA samples. Significant effects of periconceptional micronutrient supplementation were also observed in postnatal samples which were not evident in cord blood. In this Gambian population, the increased death rate of individuals born in nutritionally poor seasons has been related to infection and it is of interest that we identified differential methylation at genes associated with defence against infection and immune response. Although the sample size was relatively small, these pilot data suggest that periconceptional nutrition in humans is an important determinant of newborn whole genome methylation patterns but may also influence postnatal developmental patterns of gene promoter methylation linking early with disease risk.
C1 [Khulan, Batbayar; Skinner, Benjamin M.; Bauer, Julien; Affara, Nabeel A.] Univ Cambridge, Dept Pathol, Mammalian Mol Genet Grp, Cambridge CB2 1QP, England.
   [Khulan, Batbayar; Cooper, Wendy N.; Constancia, Miguel] Univ Cambridge, Metab Res Labs, Dept Obstet & Gynaecol, Cambridge CB2 0SW, England.
   [Owens, Stephen; Prentice, Andrew M.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   [Owens, Stephen; Prentice, Andrew M.] MRC Keneba, Keneba, Gambia.
   [Belteki, Gusztav] Cambridge Univ Hosp NHS Fdn Trust, Neonatal Intens Care Unit, Cambridge CB2 0QQ, England.
   [Belteki, Gusztav; Dunger, David] Univ Cambridge, Dept Paediat, Cambridge CB2 0QQ, England.
   [Constancia, Miguel] Cambridge Biomed Res Ctr, Natl Inst Hlth Res, Cambridge CB2 0QQ, England.
   [Constancia, Miguel] Univ Cambridge, Ctr Trophoblast Res, Cambridge CB2 3EG, England.
RP Affara, NA (reprint author), Univ Cambridge, Dept Pathol, Mammalian Mol Genet Grp, Tennis Court Rd, Cambridge CB2 1QP, England.
EM na@mole.bio.cam.ac.uk
RI perumal, murugiah/D-1565-2012; Skinner, Benjamin/A-5265-2010;
   Constancia, Miguel/F-6654-2013; Belteki, Gusztav/B-8956-2008
OI Skinner, Benjamin/0000-0002-7152-1167; Dunger, Professor
   David/0000-0002-2566-9304
FU BBSRC [BB/F001355/1]
FX This work was supported by grant number BB/F001355/1 from the BBSRC.
CR Barker D J, 2001, Med Health Care Philos, V4, P31, DOI 10.1023/A:1009934412988
   BARKER DJP, 1989, LANCET, V2, P577
   BARKER DJP, 1986, LANCET, V1, P1077
   BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   BATES CJ, 1984, T ROY SOC TROP MED H, V78, P814, DOI 10.1016/0035-9203(84)90028-2
   Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725
   Bateson P, 2001, INT J EPIDEMIOL, V30, P928, DOI 10.1093/ije/30.5.928
   Bertram C, 2001, ENDOCRINOLOGY, V142, P2841, DOI 10.1210/endo.142.7.8238
   Bieswal F, 2006, OBESITY, V14, P1330, DOI 10.1038/oby.2006.151
   Bocker MT, 2011, BLOOD, V117, pE182, DOI 10.1182/blood-2011-01-331926
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Calvanese V, 2012, NUCLEIC ACIDS RES, V40, P116, DOI 10.1093/nar/gkr685
   Chen YA, 2011, GENOMICS, V97, P214, DOI 10.1016/j.ygeno.2010.12.004
   Desai M, 1996, BRIT J NUTR, V76, P591, DOI 10.1079/BJN19960065
   Drake AJ, 2007, CLIN SCI, V113, P219, DOI 10.1042/CS20070107
   Genevieve D, 2005, EUR J HUM GENET, V13, P1033, DOI 10.1038/sj.ejhg.5201448
   Gluckman PD, 2005, BIOL NEONATE, V87, P127, DOI 10.1159/000082311
   Gluckman PD, 2005, P ROY SOC B-BIOL SCI, V272, P671, DOI 10.1098/rspb.2004.3001
   Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292
   Gluckman PD, 2005, MATERN CHILD NUTR, V1, P130, DOI 10.1111/j.1740-8709.2005.00020.x
   Godfrey KM, 2011, DIABETES, V60, P1528, DOI 10.2337/db10-0979
   Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Ke X, 2006, PHYSIOL GENOMICS, V25, P16, DOI 10.1152/physiolgenomics.00093.2005
   Lillycrop KA, 2005, J NUTR, V135, P1382
   Martino DJ, 2011, EPIGENETICS-US, V6, P1085, DOI 10.4161/epi.6.9.16401
   Maupetit-Mehouas S, 2011, J MED GENET, V48, P55, DOI 10.1136/jmg.2010.081356
   McEwen KR, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-2
   McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Moore SE, 2006, P NUTR SOC, V65, P311, DOI 10.1079/PNS2006503
   Morris TJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007271
   Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   Sandovici I, 2011, P NATL ACAD SCI USA, V108, P5449, DOI 10.1073/pnas.1019007108
   Thompson RF, 2009, BIOINFORMATICS, V25, P2164, DOI 10.1093/bioinformatics/btp382
   Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353
   Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100
   Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83
   Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484
   Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252
   Woodall SM, 1996, J ENDOCRINOL, V150, P231, DOI 10.1677/joe.0.1500231
NR 43
TC 66
Z9 69
U1 1
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2012
VL 21
IS 9
BP 2086
EP 2101
DI 10.1093/hmg/dds026
PG 16
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 919DU
UT WOS:000302302800014
PM 22307237
OA No
DA 2017-08-15
ER

PT J
AU von Seidlein, L
   Olaosebikan, R
   Hendriksen, ICE
   Lee, SJ
   Adedoyin, OT
   Agbenyega, T
   Nguah, SB
   Bojang, K
   Deen, JL
   Evans, J
   Fanello, CI
   Gomes, E
   Pedro, AJ
   Kahabuka, C
   Karema, C
   Kivaya, E
   Maitland, K
   Mokuolu, OA
   Mtove, G
   Mwanga-Amumpaire, J
   Nadjm, B
   Nansumba, M
   Ngum, WP
   Onyamboko, MA
   Reyburn, H
   Sakulthaew, T
   Silamut, K
   Tshefu, AK
   Umulisa, N
   Gesase, S
   Day, NPJ
   White, NJ
   Dondorp, AM
AF von Seidlein, Lorenz
   Olaosebikan, Rasaq
   Hendriksen, Ilse C. E.
   Lee, Sue J.
   Adedoyin, Olanrewaju Timothy
   Agbenyega, Tsiri
   Nguah, Samuel Blay
   Bojang, Kalifa
   Deen, Jacqueline L.
   Evans, Jennifer
   Fanello, Caterina I.
   Gomes, Ermelinda
   Pedro, Alinia Jose
   Kahabuka, Catherine
   Karema, Corine
   Kivaya, Esther
   Maitland, Kathryn
   Mokuolu, Olugbenga A.
   Mtove, George
   Mwanga-Amumpaire, Juliet
   Nadjm, Behzad
   Nansumba, Margaret
   Ngum, Wirichada Pan
   Onyamboko, Marie A.
   Reyburn, Hugh
   Sakulthaew, Tharisara
   Silamut, Kamolrat
   Tshefu, Antoinette K.
   Umulisa, Noella
   Gesase, Samwel
   Day, Nicholas P. J.
   White, Nicholas J.
   Dondorp, Arjen M.
TI Predicting the Clinical Outcome of Severe Falciparum Malaria in African
   Children: Findings From a Large Randomized Trial
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID PEDIATRIC CEREBRAL MALARIA; TUMOR-NECROSIS-FACTOR; ACUTE-RENAL-FAILURE;
   PROGNOSTIC-SIGNIFICANCE; CHILDHOOD MALARIA; CAPILLARY REFILL;
   LACTIC-ACIDOSIS; FUNDUS CHANGES; SEVERE ADULT; CSF LACTATE
AB Background. Data from the largest randomized, controlled trial for the treatment of children hospitalized with severe malaria were used to identify such predictors of a poor outcome from severe malaria.
   Methods. African children (<15 years) with severe malaria participated in a randomized comparison of parenteral artesunate and parenteral quinine in 9 African countries. Detailed clinical assessment was performed on admission. Parasite densities were assessed in a reference laboratory. Predictors of death were examined using a multivariate logistic regression model.
   Results. Twenty indicators of disease severity were assessed, out of which 5 (base deficit, impaired consciousness, convulsions, elevated blood urea, and underlying chronic illness) were associated independently with death. Tachypnea, respiratory distress, deep breathing, shock, prostration, low pH, hyperparasitemia, severe anemia, and jaundice were statistically significant indicators of death in the univariate analysis but not in the multivariate model. Age, glucose levels, axillary temperature, parasite density, heart rate, blood pressure, and blackwater fever were not related to death in univariate models.
   Conclusions. Acidosis, cerebral involvement, renal impairment, and chronic illness are key independent predictors for a poor outcome in African children with severe malaria. Mortality is markedly increased in cerebral malaria combined with acidosis.
C1 [von Seidlein, Lorenz; Deen, Jacqueline L.] Menzies Sch Hlth Res, Dept Global Hlth, Casuarina, NT 0810, Australia.
   [Olaosebikan, Rasaq; Bojang, Kalifa] Royal Victoria Teaching Hosp, Banjul, Gambia.
   [Olaosebikan, Rasaq; Bojang, Kalifa] MRC Labs, Banjul, Gambia.
   [Hendriksen, Ilse C. E.; Lee, Sue J.; Fanello, Caterina I.; Ngum, Wirichada Pan; Sakulthaew, Tharisara; Silamut, Kamolrat; Day, Nicholas P. J.; White, Nicholas J.; Dondorp, Arjen M.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.
   [Adedoyin, Olanrewaju Timothy; Mokuolu, Olugbenga A.] Univ Ilorin, Teaching Hosp, Ilorin, Nigeria.
   [Agbenyega, Tsiri; Nguah, Samuel Blay; Evans, Jennifer] Komfo Anokye Teaching Hosp, Kumasi, Ghana.
   [Mtove, George] Teule Dist Hosp, Muheza, Tanzania.
   [Nadjm, Behzad; Reyburn, Hugh] London Sch Trop Med & Hyg, Dept Infect & Trop Dis, London, England.
   [Onyamboko, Marie A.; Tshefu, Antoinette K.] Kingasani Hlth Ctr, Kinshasa, Zaire.
RP von Seidlein, L (reprint author), Menzies Sch Hlth Res, Dept Global Hlth, John Mathews Bldg 58,POB 41096, Casuarina, NT 0810, Australia.
EM lseidlein@gmail.com
RI White, Nicholas/I-4629-2012
OI Nadjm, Behzad/0000-0002-7704-3629; Bojang, Kalifa/0000-0001-7506-0938;
   Maitland, Kathryn/0000-0002-0007-0645
FU Wellcome Trust [076908, 082541]; Wellcome Trust of Great Britain
FX This work was supported by the Wellcome Trust (grants 076908 and
   082541), and was coordinated as part of the Wellcome Trust Mahidol
   University-Oxford Tropical Medicine Research Programme funded by the
   Wellcome Trust of Great Britain.
CR Angyo IA, 1996, E AFR MED J, V73, P823
   Beare NA, 2004, ARCH OPHTHALMOL-CHIC, V122, P1141, DOI 10.1001/archopht.122.8.1141
   Bell DJ, 2007, EXPERT REV ANTI-INFE, V5, P141, DOI 10.1586/14787210.5-1-141
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299
   Bruneel F, 2003, AM J RESP CRIT CARE, V167, P684, DOI 10.1164/rccm.200206-631OC
   Central Intelligence Agency, 2005, CIA WORLD FACTB 2005
   Day NPJ, 2000, CRIT CARE MED, V28, P1833, DOI 10.1097/00003246-200006000-00025
   DELORON P, 1994, EUR CYTOKINE NETW, V5, P331
   Dondorp AM, 2004, CRIT CARE MED, V32, P1683, DOI 10.1097/01.CCM.0000132901.86681.CA
   Dondorp AM, 2008, CLIN INFECT DIS, V47, P151, DOI 10.1086/589287
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   Dzeing-Ella A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-1
   English M, 1996, T ROY SOC TROP MED H, V90, P658, DOI 10.1016/S0035-9203(96)90423-X
   English M, 1997, QJM-INT J MED, V90, P263, DOI 10.1093/qjmed/90.4.263
   English M, 2002, LANCET, V359, P494, DOI 10.1016/S0140-6736(02)07666-3
   ENGLISH M, 1995, ARCH DIS CHILD, V72, P334
   English M, 1996, AM J TROP MED HYG, V55, P521
   Essuman VA, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-232
   Evans JA, 2006, J PEDIATR-US, V149, P676, DOI 10.1016/j.peds.2006.07.040
   Genton B, 1997, INT J EPIDEMIOL, V26, P670, DOI 10.1093/ije/26.3.670
   Grau G E, 1992, Verh K Acad Geneeskd Belg, V54, P155
   Hanson J, 2010, CLIN INFECT DIS, V50, P679, DOI 10.1086/649928
   Harding SP, 2006, TROP DOCT, V36, P1, DOI 10.1258/004947506776315781
   Hargrove J, 2005, CRIT CARE, V9, P376, DOI 10.1186/cc3518
   Hirneiss C, 2005, KLIN MONATSBL AUGENH, V222, P704, DOI 10.1005/s-2005-858445
   Idro R, 2006, ANN TROP MED PARASIT, V100, P95, DOI 10.1179/136485906X91459
   Idro R, 2006, TROP MED INT HEALTH, V11, P115, DOI 10.1111/j.1365-3156.2005.01518.x
   Idro R, 2004, ANN TROP PAEDIATR, V24, P17, DOI 10.1179/027249304225013240
   Idro R, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-5
   Jaffar S, 1997, AM J TROP MED HYG, V57, P20
   Kochar D K, 2000, J Assoc Physicians India, V48, P473
   KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5
   KWIATKOWSKI D, 1990, IMMUNOL LETT, V25, P213, DOI 10.1016/0165-2478(90)90117-9
   Lewallen S, 1999, T ROY SOC TROP MED H, V93, P619, DOI 10.1016/S0035-9203(99)90071-8
   Lewallen S, 2008, T ROY SOC TROP MED H, V102, P1089, DOI 10.1016/j.trstmh.2008.06.014
   MABEZA GF, 1995, ANN TROP MED PARASIT, V89, P221
   Maitland K, 2005, CLIN INFECT DIS, V40, P538, DOI 10.1086/427505
   Maitland K, 2005, TRENDS PARASITOL, V21, P11, DOI 10.1016/j.pt.2004.10.010
   Malamba S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-143
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Miller R. G., 1981, SIMULTANEOUS STAT IN
   Mishra SK, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-24
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Murphy S, 1996, T ROY SOC TROP MED H, V90, P298, DOI 10.1016/S0035-9203(96)90260-6
   MYINT PT, 1987, LANCET, V1, P330
   Nadjm B, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1350
   Newton CRJC, 2005, CLIN INFECT DIS, V41, P948, DOI 10.1086/432941
   Newton CRJC, 1997, T ROY SOC TROP MED H, V91, P161, DOI 10.1016/S0035-9203(97)90207-8
   Newton CRJC, 2000, J NEUROL NEUROSUR PS, V69, P433, DOI 10.1136/jnnp.69.4.433
   Newton PN, 2003, CLIN INFECT DIS, V37, P7, DOI 10.1086/375059
   Nguyen T H, 1996, Lancet, V348, P917
   Oduro AR, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-96
   Oguche S, 2002, West Afr J Med, V21, P276
   Okubadejo N U, 2004, Niger Postgrad Med J, V11, P10
   Olliaro P, 2008, CLIN INFECT DIS, V47, P158, DOI 10.1086/589288
   Olowu WA, 2004, KIDNEY INT, V66, P1541, DOI 10.1111/j.1523-1755.2004.00918.x
   Olumese PE, 1997, E AFR MED J, V74, P285
   Pamba A, 2004, ARCH DIS CHILD, V89, P950, DOI 10.1136/adc.2003.032516
   Planche T, 2003, CLIN INFECT DIS, V37, P890, DOI 10.1086/377536
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   Royston P, 2005, METHOD INFORM MED, V44, P561
   Sadarangani M, 2008, LANCET NEUROL, V7, P145, DOI 10.1016/S1474-4422(07)70331-9
   SAISSY JM, 1994, PRESSE MED, V23, P1426
   Sattar M A, 2009, Bangladesh Med Res Counc Bull, V35, P15
   Schemann JF, 2002, AM J TROP MED HYG, V67, P61
   SHAFFER N, 1991, J INFECT DIS, V163, P96
   SILAMUT K, 1993, T ROY SOC TROP MED H, V87, P436, DOI 10.1016/0035-9203(93)90028-O
   Snow RW, 2000, TROP MED INT HEALTH, V5, P377, DOI 10.1046/j.1365-3156.2000.00568.x
   TAYLOR TE, 1993, Q J MED, V86, P99
   Taylor Walter R J, 2006, Treat Respir Med, V5, P419, DOI 10.2165/00151829-200605060-00007
   Thumasupapong S., 1995, Southeast Asian Journal of Tropical Medicine and Public Health, V26, P34
   Trampuz A, 2003, CRIT CARE, V7, P315, DOI 10.1186/cc2183
   Tran T H, 1996, N Engl J Med, V335, P76
   TRANG TTM, 1992, CLIN INFECT DIS, V15, P874
   vanHensbroek MB, 1997, J PEDIATR-US, V131, P125, DOI 10.1016/S0022-3476(97)70135-5
   Varandas L, 2000, ANN TROP PAEDIATR, V20, P265, DOI 10.1080/1465328002003852
   Vernon C, 2010, CRIT CARE CLIN, V26, P255, DOI 10.1016/j.ccc.2009.12.007
   WALLER D, 1995, CLIN INFECT DIS, V21, P577
   WATTANAGOON Y, 1994, T ROY SOC TROP MED H, V88, P426, DOI 10.1016/0035-9203(94)90415-4
   WHITE NJ, 1985, LANCET, V1, P776
   WHITE NJ, 1987, LANCET, V1, P1261
   [Anonymous], 2005, HOSP CAR CHILDR GUID
   WHO, 2000, T R SOC TROP MED S1, V94, P1
NR 84
TC 46
Z9 46
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 15
PY 2012
VL 54
IS 8
BP 1080
EP 1090
DI 10.1093/cid/cis034
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 915EW
UT WOS:000302007900011
PM 22412067
OA No
DA 2017-08-15
ER

PT J
AU Huang, CC
   Jatta, M
   Chuang, CC
AF Huang, C. -C.
   Jatta, M.
   Chuang, C. -C.
TI Dewatering of reservoir sediment slurry using woven geotextiles. Part
   II: Analytical results
SO GEOSYNTHETICS INTERNATIONAL
LA English
DT Article
DE Geosynthetics; Dewatering; Geotextile filter; Reservoir sediment; Soil
   cake; Hydraulic conductivity; Particle-settling velocity
ID SETTLING VELOCITY; FILTRATION; PERFORMANCE; SOIL
AB Geotextiles are increasingly being utilised in dewatering dredged reservoir sediment, as part of the sustainable management of reservoirs. To this end, analytical models for evaluating the effluent rate through geotextile dewatering systems have been developed. The proposed analytical model consists of Stokes' and Gibbs' particle-settling-velocity equations in evaluating the time-dependent soil cake formation upstream of the geotextile filter. Analytical results show good agreement of the predicted effluent rates with those observed in a series of laboratory falling-head dewatering column tests using two reservoir sediment slurries and four woven geotextile filters. Analytical results also show that the hydraulic conductivity of the soil cakes plays a key role, their compressibility plays a secondary role, and the permeability of the geotextile filters plays a minor role in accurately evaluating the effluent of a geotextile dewatering system. Stokes' particle-settling-velocity equation provides a better evaluation for the effluent rate, compared with that using Gibbs' equation. For Bai-Her sediment, which consists of relatively coarse particles, the advantage of the analytical model using Stokes' equation becomes more evident as the initial water height increases.
C1 [Huang, C. -C.; Jatta, M.; Chuang, C. -C.] Natl Cheng Kung Univ, Dept Civil Engn, Tainan 70101, Taiwan.
   [Jatta, M.] Univ Gambia, Div Phys & Nat Sci, Sch Arts & Sci, Serekunda, Gambia.
RP Huang, CC (reprint author), Natl Cheng Kung Univ, Dept Civil Engn, 1 Ta Hsueh Rd, Tainan 70101, Taiwan.
EM samhcc@mail.ncku.edu.tw; mjjatta@utg.edu.gm; yyjj121@yahoo.com.tw
CR [Anonymous], D422 ASTM
   Aydilek AH, 2002, GEOSYNTH INT, V9, P41
   Chuang C.-C., 2007, THESIS NATIONAL CHEN
   ELLIS JB, 1995, ENVIRON INT, V21, P177, DOI 10.1016/0160-4120(95)00007-0
   Fowler J., 2002, P 7 INT C GEOS FRANC, P1007
   GIBBS RJ, 1971, J SEDIMENT PETROL, V41, P7
   Giroud JP, 2005, GEOSYNTH INT, V12, P2, DOI 10.1680/gein.12.1.2.59422
   Holtz R. D., 1981, INTRO GEOTECHNICAL E, P283
   Huang CC, 2007, GEOSYNTH INT, V14, P253, DOI 10.1680/gein.2007.14.5.253
   Koerner GR, 2006, GEOTEXT GEOMEMBRANES, V24, P129, DOI 10.1016/j.geotexmem.2005.02.006
   Kutay ME, 2004, GEOSYNTH INT, V11, P100, DOI 10.1680/gein.11.2.100.46853
   Legret M, 1996, SCI TOTAL ENVIRON, V189, P335, DOI 10.1016/0048-9697(96)05228-X
   Loch RJ, 2001, COMPUT ELECTRON AGR, V31, P305, DOI 10.1016/S0168-1699(00)00189-7
   Lu WM, 1998, SEP PURIF TECHNOL, V13, P9, DOI 10.1016/S1383-5866(97)00052-X
   MATLAB, 2008, VERS 7 6 0 R 2008
   McLellan T. N., 2000, TRDOER5 ERDC US ARM
   Miki H., 1996, P 2 INT C ENV GEOT O, P385
   Moo-Young H, 1999, ENG GEOL, V53, P167, DOI 10.1016/S0013-7952(99)00030-7
   Mori H, 2002, GEOTEXT GEOMEMBRANES, V20, P281, DOI 10.1016/S0266-1144(02)00027-4
   Muthukumaran AE, 2006, GEOTEXT GEOMEMBRANES, V24, P210, DOI 10.1016/j.geotexmem.2006.03.002
   Rubey WW, 1933, AM J SCI, V25, P325
   Satyamurthy R, 2009, GEOSYNTH INT, V16, P83, DOI 10.1680/gein.2009.16.2.83
   Stokes G. G., 2009, T CAMBRIDGE PHILOS 2, V9, P8
   Tung KL, 2006, SEP PURIF TECHNOL, V48, P1, DOI 10.1016/j.seppur.2005.07.026
   U.S. Army Corps of Engineers, 1987, 111025027 US ARM COR
   Weggel J. R., 2010, GEOTEXT GEOMEMBRANES, V29, P65
   Yaman C, 2006, GEOSYNTH INT, V13, P87, DOI 10.1680/gein.2006.13.3.87
NR 27
TC 4
Z9 4
U1 3
U2 13
PU ICE PUBL
PI LONDON
PA 40 MARSH WALL, 2 FL, LONDON E14 9TP, ENGLAND
SN 1072-6349
J9 GEOSYNTH INT
JI Geosynth. Int.
PD APR
PY 2012
VL 19
IS 2
BP 93
EP 105
DI 10.1680/gein.2012.19.2.93
PG 13
WC Engineering, Geological; Geosciences, Multidisciplinary; Materials
   Science, Multidisciplinary
SC Engineering; Geology; Materials Science
GA 956KV
UT WOS:000305089400001
OA No
DA 2017-08-15
ER

PT J
AU Jones, KS
   Schoenmakers, I
   Bluck, LJC
   Ding, SJ
   Prentice, A
AF Jones, Kerry S.
   Schoenmakers, Inez
   Bluck, Les J. C.
   Ding, Shujing
   Prentice, Ann
TI Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin
   D-2 in healthy adults
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE 25-Hydroxyvitamin D; Absorption; Half life; Gambia
ID VITAMIN-D DEFICIENCY; INTESTINAL-ABSORPTION; PARATHYROID-HORMONE;
   CALCIUM-ABSORPTION; MASS-SPECTROMETRY; HALF-LIFE; METABOLISM;
   CHOLECALCIFEROL; SERUM; 25-HYDROXYCHOLECALCIFEROL
AB 25-Hydroxyvitamin D (25(OH)D) half-life is a potential biomarker for investigating vitamin D metabolism and requirements. We performed a pilot study to assess the approach and practical feasibility of measuring 25(OH)D half-life after an oral dose. A total of twelve healthy Gambian men aged 18-23 years were divided into two groups to investigate the rate and timing of (1) absorption and (2) plasma disappearance after an 80 nmol oral dose of 25(OH)D-2. Fasting blood samples were collected at baseline and, in the first group, every 2 h postdose for 12 h, at 24 h, 48 h and on day 15. In the second group, fasting blood samples were collected on days 3, 4, 5, 6, 9, 12, 15, 18 and 21. Urine was collected for 2 h after the first morning void at baseline and on day 15. 25(OH)D-2 plasma concentration was measured by ultra-performance liquid chromatography-tandem MS/MS and corrected for baseline. Biomarkers of vitamin D, Ca and P metabolism were measured at baseline and on day 15. The peak plasma concentration of 25(OH)D-2 was 9.6 (SD 0.9) nmol/l at 4.4 (SD 1.8) h. The terminal slope of 25(OH)D-2 disappearance was identified to commence from day 6. The terminal half-life of plasma 25(OH)D-2 was 13.4 (SD 2.7) d. There were no significant differences in plasma 25(OH)D-3, total 1,25(OH)(2)D, parathyroid hormone, P, Ca and ionised Ca and urinary Ca and P between baseline and day 15 and between the two groups. The present study provides data on the plasma response to oral 25(OH)D-2 that will underpin and contribute to the further development of studies to investigate 25(OH)D half-life.
C1 [Jones, Kerry S.; Prentice, Ann] MRC Keneba, MRC Unit, Banjul, Gambia.
   [Schoenmakers, Inez; Bluck, Les J. C.; Ding, Shujing; Prentice, Ann] Elsie Widdowson Lab, MRC Human Nutr Res, Cambridge CB1 9NL, England.
RP Jones, KS (reprint author), MRC Keneba, MRC Unit, POB 273, Banjul, Gambia.
EM kjones@mrc.gm
RI Jones, Kerry/D-2490-2014
OI Jones, Kerry/0000-0002-7380-9797
FU Medical Research Council (MRC), UK
FX This study was funded by the Medical Research Council (MRC), UK. We
   would like to acknowledge the field and support staff of MRC Keneba
   field station, in particular Mustapha Sise, Buba Sise and Fabakary Bajo.
   We also acknowledge Shailja Nigdikar, Janet Bennett and Ann Laidlaw who
   performed the biochemistry analyses. None of the authors had a personal
   or financial conflict of interest. K. S. J., I. S., L. J. C. B and A. P.
   designed the research; K. S. J. conducted the research; S. D. performed
   the MS; K. S. J., I. S. and L. J. C. B. analysed the data; K. S. J.
   wrote the manuscript; K. S. J., I. S. and A. P. had primary
   responsibility for the final content. All authors read and approved the
   final manuscript.
CR Abrams SA, 2005, J CLIN ENDOCR METAB, V90, P5576, DOI 10.1210/jc.2005-1021
   Armas LAG, 2004, J CLIN ENDOCR METAB, V89, P5387, DOI 10.1210/jc.2004-0360
   BATCHELOR AJ, 1982, GUT, V23, P1068, DOI 10.1136/gut.23.12.1068
   BATCHELOR AJ, 1983, BRIT J NUTR, V49, P213, DOI 10.1079/BJN19830027
   Biancuzzo RM, 2010, AM J CLIN NUTR, V91, P1621, DOI 10.3945/ajcn.2009.27972
   Binkley N, 2004, J CLIN ENDOCR METAB, V89, P3152, DOI 10.1210/jc.2003-031979
   Brannon PM, 2008, AM J CLIN NUTR, V88, p587S
   Brannon PM, 2008, AM J CLIN NUTR, V88, P483
   CLEMENTS MR, 1992, CLIN ENDOCRINOL, V37, P17, DOI 10.1111/j.1365-2265.1992.tb02278.x
   CLEMENTS MR, 1987, NATURE, V325, P62, DOI 10.1038/325062a0
   COMPSTON JE, 1981, CLIN SCI, V60, P241
   COMPSTON JE, 1977, GUT, V18, P171, DOI 10.1136/gut.18.3.171
   Davies AA, 2008, THESIS LONDON SCH HY
   Davies M, 1997, J CLIN ENDOCR METAB, V82, P209, DOI 10.1210/jc.82.1.209
   DAVIES M, 1980, GUT, V21, P287, DOI 10.1136/gut.21.4.287
   Ding SJ, 2010, ANAL BIOANAL CHEM, V398, P779, DOI 10.1007/s00216-010-3993-0
   DUELAND S, 1983, AM J PHYSIOL, V245, pE463
   Glendenning P, 2009, BONE, V45, P870, DOI 10.1016/j.bone.2009.07.015
   GRAY RW, 1974, J CLIN ENDOCR METAB, V39, P1045
   GRAY RW, 1978, J CLIN ENDOCR METAB, V46, P756
   HADDAD JG, 1993, J CLIN INVEST, V91, P2552, DOI 10.1172/JCI116492
   HADDAD JG, 1976, J CLIN ENDOCR METAB, V42, P284
   HALLORAN BP, 1989, BIOCHEMISTRY-US, V28, P1278, DOI 10.1021/bi00429a049
   Heaney RP, 2009, J AM COLL NUTR, V28, P252
   HIDIROGLOU M, 1987, J ANIM SCI, V65, P808
   HIDIROGLOU M, 1989, J ANIM SCI, V67, P794
   Holick MF, 2008, MOL ASPECTS MED, V29, P361, DOI 10.1016/j.mam.2008.08.008
   HOLLIS BW, 1984, J STEROID BIOCHEM, V21, P81, DOI 10.1016/0022-4731(84)90063-3
   HORST RL, 1984, ARCH BIOCHEM BIOPHYS, V231, P67, DOI 10.1016/0003-9861(84)90363-1
   Horst RL, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P15
   Jones G., 2009, 14 INT VIT D WORKSH
   Khazai NB, 2009, J CLIN ENDOCR METAB, V94, P2037, DOI 10.1210/jc.2008-2012
   KRABBE S, 1982, ARCH DIS CHILD, V57, P359
   KRAWITT EL, 1980, CALCIFIED TISSUE INT, V32, P183, DOI 10.1007/BF02408539
   Laing CJ, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P117
   LEICHTMANN GA, 1991, AM J CLIN NUTR, V54, P548
   Lo C. W., 1991, OSTEOPOROSIS 1990, P73
   MAISLOS M, 1981, GASTROENTEROLOGY, V80, P1528
   Mawer EB, 1998, J CLIN ENDOCR METAB, V83, P2156, DOI 10.1210/jc.83.6.2156
   MAWER EB, 1971, CLIN SCI, V40, P39
   MAWER EB, 1972, CLIN SCI, V43, P413
   NILSSON SF, 1972, BIOCHEM BIOPH RES CO, V46, P1380, DOI 10.1016/S0006-291X(72)80128-1
   Ovesen L, 2003, ANN NUTR METAB, V47, P107, DOI 10.1159/000070031
   Prentice A, 2010, DIET NUTR BONE
   Prentice A, 2008, NUTR REV, V66, pS153, DOI 10.1111/j.1753-4887.2008.00100.x
   Prentice A, 2008, AM J CLIN NUTR, V88, p500S
   Prentice Ann, 2009, Clin Rev Bone Miner Metab, V7, P94
   Rapuri PB, 2004, CALCIFIED TISSUE INT, V74, P150, DOI 10.1007/s00223-003-0083-8
   Romagnoli E, 2008, J CLIN ENDOCR METAB, V93, P3015, DOI 10.1210/jc.2008-0350
   Roth HJ, 2008, ANN CLIN BIOCHEM, V45, P153, DOI 10.1258/acb.2007.007091
   Schoenmakers I, 2010, J STEROID BIOCHEM, V121, P217, DOI 10.1016/j.jsbmb.2010.03.012
   SEAMANS KM, 2008, AM J CLIN NUTR, V89, P1997
   Shipley R. A., 1972, TRACER METHODS IN VI
   SITRIN MD, 1987, AM J CLIN NUTR, V46, P1011
   SITRIN MD, 1982, AM J PHYSIOL, V242, pG326
   SMITH JE, 1971, J CLIN INVEST, V50, P2159, DOI 10.1172/JCI106710
   Stamp TC, 1974, LANCET, V304, P121, DOI 10.1016/S0140-6736(74)91553-0
   TANAKA Y, 1982, ARCH BIOCHEM BIOPHYS, V213, P517, DOI 10.1016/0003-9861(82)90578-1
   Tang EKY, 2010, J STEROID BIOCHEM, V119, P171, DOI 10.1016/j.jsbmb.2010.02.022
   Thacher TD, 2009, J CLIN ENDOCR METAB, V94, P3314, DOI 10.1210/jc.2009-0018
   THOMPSON GR, 1966, J CLIN INVEST, V45, P94, DOI 10.1172/JCI105327
   Trang HM, 1998, AM J CLIN NUTR, V68, P854
   Urushino N, 2009, BIOCHEM BIOPH RES CO, V384, P144, DOI 10.1016/j.bbrc.2009.04.075
   VICCHIO D, 1993, BIOL MASS SPECTROM, V22, P53, DOI 10.1002/bms.1200220107
   Wejse C, 2007, AM J CLIN NUTR, V86, P1376
   Yan LY, 2009, BONE, V45, P238, DOI 10.1016/j.bone.2009.04.237
NR 66
TC 19
Z9 19
U1 1
U2 5
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD APR
PY 2012
VL 107
IS 8
BP 1128
EP 1137
DI 10.1017/S0007114511004132
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 944ZR
UT WOS:000304242800005
PM 21896243
OA No
DA 2017-08-15
ER

PT J
AU Ghumra, A
   Semblat, JP
   Ataide, R
   Kifude, C
   Adams, Y
   Claessens, A
   Anong, DN
   Bull, PC
   Fennell, C
   Arman, M
   Amambua-Ngwa, A
   Walther, M
   Conway, DJ
   Kassambara, L
   Doumbo, OK
   Raza, A
   Rowe, JA
AF Ghumra, Ashfaq
   Semblat, Jean-Philippe
   Ataide, Ricardo
   Kifude, Carolyne
   Adams, Yvonne
   Claessens, Antoine
   Anong, Damian N.
   Bull, Peter C.
   Fennell, Clare
   Arman, Monica
   Amambua-Ngwa, Alfred
   Walther, Michael
   Conway, David J.
   Kassambara, Lalla
   Doumbo, Ogobara K.
   Raza, Ahmed
   Rowe, J. Alexandra
TI Induction of Strain-Transcending Antibodies Against Group A PfEMP1
   Surface Antigens from Virulent Malaria Parasites
SO PLOS PATHOGENS
LA English
DT Article
ID FALCIPARUM-INFECTED ERYTHROCYTES; CHONDROITIN SULFATE-A;
   PREGNANCY-ASSOCIATED MALARIA; MEMBRANE PROTEIN-1 FAMILY; SEVERE
   CHILDHOOD MALARIA; VAR GENE-TRANSCRIPTION; RED-CELL SURFACE;
   PLASMODIUM-FALCIPARUM; ROSETTE FORMATION; UNCOMPLICATED MALARIA
AB Sequence diversity in pathogen antigens is an obstacle to the development of interventions against many infectious diseases. In malaria caused by Plasmodium falciparum, the PfEMP1 family of variant surface antigens encoded by var genes are adhesion molecules that play a pivotal role in malaria pathogenesis and clinical disease. PfEMP1 is a major target of protective immunity, however, development of drugs or vaccines based on PfEMP1 is problematic due to extensive sequence diversity within the PfEMP1 family. Here we identified the PfEMP1 variants transcribed by P. falciparum strains selected for a virulence-associated adhesion phenotype (IgM-positive rosetting). The parasites transcribed a subset of Group A PfEMP1 variants characterised by an unusual PfEMP1 architecture and a distinct N-terminal domain (either DBL alpha 1.5 or DBL alpha 1.8 type). Antibodies raised in rabbits against the N-terminal domains showed functional activity (surface reactivity with live infected erythrocytes (IEs), rosette inhibition and induction of phagocytosis of IEs) down to low concentrations (<10 mu g/ml of total IgG) against homologous parasites. Furthermore, the antibodies showed broad cross-reactivity against heterologous parasite strains with the same rosetting phenotype, including clinical isolates from four sub-Saharan African countries that showed surface reactivity with either DBL alpha 1.5 antibodies (variant HB3var6) or DBL alpha 1.8 antibodies (variant TM284var1). These data show that parasites with a virulence-associated adhesion phenotype share IE surface epitopes that can be targeted by strain-transcending antibodies to PfEMP1. The existence of shared surface epitopes amongst functionally similar disease-associated P. falciparum parasite isolates suggests that development of therapeutic interventions to prevent severe malaria is a realistic goal.
C1 [Ghumra, Ashfaq; Semblat, Jean-Philippe; Ataide, Ricardo; Kifude, Carolyne; Adams, Yvonne; Claessens, Antoine; Fennell, Clare; Arman, Monica; Raza, Ahmed; Rowe, J. Alexandra] Univ Edinburgh, Ctr Immun Infect & Evolut, Inst Immunol & Infect Res, Sch Biol Sci, Edinburgh, Midlothian, Scotland.
   [Kifude, Carolyne; Bull, Peter C.] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Kilifi, Kenya.
   [Anong, Damian N.] Univ Buea, Fac Sci, Biotechnol Unit, Buea, Cameroon.
   [Amambua-Ngwa, Alfred; Walther, Michael; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Kassambara, Lalla; Doumbo, Ogobara K.] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali.
RP Ghumra, A (reprint author), Univ Edinburgh, Ctr Immun Infect & Evolut, Inst Immunol & Infect Res, Sch Biol Sci, Edinburgh, Midlothian, Scotland.
EM Alex.Rowe@ed.ac.uk
OI Claessens, Antoine/0000-0002-4277-0914; Bull, Peter/0000-0002-7674-6752;
   Rowe, Alexandra/0000-0002-7702-1892; Conway, David/0000-0002-8711-3037
FU Wellcome Trust [084226, 084535]; UK Medical Research Council
FX This work was funded by the Wellcome Trust (Senior Research Fellowship
   in Basic Biomedical Science to JAR, grant no 084226). AA-N, MW and DJC
   were funded by the UK Medical Research Council. PCB is funded by the
   Wellcome Trust (Programme grant no. 084535). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Albrecht L, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-17
   Arman M, 2007, AM J TROP MED HYG, V77, P943
   Arman M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-243
   Avril M, 2008, INFECT IMMUN, V76, P1791, DOI 10.1128/IAI.01470-07
   Barfod L, 2011, P NATL ACAD SCI USA, V108, P12485, DOI 10.1073/pnas.1103708108
   Barfod L, 2010, J IMMUNOL, V185, P7553, DOI 10.4049/jimmunol.1002390
   Barragan A, 1998, INFECT IMMUN, V66, P4783
   Barry AE, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030034
   BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3
   Bull PC, 2000, J INFECT DIS, V182, P252, DOI 10.1086/315652
   Bull PC, 1999, INFECT IMMUN, V67, P733
   Bull PC, 2008, MOL MICROBIOL, V68, P1519, DOI 10.1111/j.1365-2958.2008.06248.x
   CARLSON J, 1992, J EXP MED, V176, P1311, DOI 10.1084/jem.176.5.1311
   CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N
   Chattopadhyay R, 2003, INFECT IMMUN, V71, P597, DOI 10.1128/IAI.71.2.597-604.2003
   Chen Donald S, 2011, PLoS One, V6, pe16629, DOI 10.1371/journal.pone.0016629
   Claessens A, 2012, JOVE-J VIS EXP, V59, pe3122, DOI DOI 10.3791/3122
   Claessens A, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-180
   Clough B, 1998, EXP PARASITOL, V89, P129, DOI 10.1006/expr.1998.4275
   Cockburn IA, 2004, P NATL ACAD SCI USA, V101, P272, DOI 10.1073/pnas.0305306101
   Corrigan RA, 2010, PARASITE IMMUNOL, V32, P512, DOI 10.1111/j.1365-3024.2010.01225.x
   Creasey AM, 2003, INFECT IMMUN, V71, P4767, DOI 10.1128/IAI.71.8.4767-4771.2003
   Czajkowsky DM, 2010, J IMMUNOL, V184, P4597, DOI 10.4049/jimmunol.1000203
   Deans AM, 2006, AM J TROP MED HYG, V74, P554
   Doumbo OK, 2009, AM J TROP MED HYG, V81, P987, DOI 10.4269/ajtmh.2009.09-0406
   Elliott SR, 2007, AM J TROP MED HYG, V76, P860
   Farnert A, 2001, T ROY SOC TROP MED H, V95, P225, DOI 10.1016/S0035-9203(01)90175-0
   Flick K, 2001, SCIENCE, V293, P2098, DOI 10.1126/science.1062891
   Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Fry AE, 2008, GENES IMMUN, V9, P462, DOI 10.1038/gene.2008.38
   Fry AE, 2008, HUM MOL GENET, V17, P567, DOI 10.1093/hmg/ddm331
   Ghumra A, 2008, J IMMUNOL, V181, P1988
   Ghumra A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016414
   Good MF, 2010, IMMUNITY, V33, P555, DOI 10.1016/j.immuni.2010.10.005
   Gupta S, 1999, NAT MED, V5, P340, DOI 10.1038/6560
   HANDUNNETTI SM, 1992, AM J TROP MED HYG, V46, P371
   Heddini A, 1998, AM J TROP MED HYG, V59, P663
   Horrocks P, 2004, P NATL ACAD SCI USA, V101, P11129, DOI 10.1073/pnas.0402347101
   Hviid L, 2010, HUM VACCINES, V6, P84
   Janes JH, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002032
   Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274
   KAUL DK, 1991, BLOOD, V78, P812
   Kirchgatter K, 2002, MOL MED, V8, P16
   Kraemer SM, 2003, MOL BIOCHEM PARASIT, V129, P91, DOI 10.1016/S0166-6851(03)00099-9
   Kraemer SM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-45
   Kraemer SM, 2006, CURR OPIN MICROBIOL, V9, P374, DOI 10.1016/j.mib.2006.06.006
   Krause DR, 2007, INFECT IMMUN, V75, P5967, DOI 10.1128/IAI.00327-07
   Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673
   Kyriacou HM, 2006, MOL BIOCHEM PARASIT, V150, P211, DOI 10.1016/j.molbiopara.2006.08.005
   Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205
   Le Scanf C, 2008, MICROBES INFECT, V10, P447, DOI 10.1016/j.micinf.2007.12.012
   LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567
   Magistrado P, 2008, J INFECT DIS, V198, P1071, DOI 10.1086/591502
   MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315
   Mayor A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019422
   Mu JB, 2005, PLOS BIOL, V3, P1734, DOI 10.1371/journal.pbio.0030335
   Newbold C, 1997, AM J TROP MED HYG, V57, P389
   NEWBOLD CI, 1992, EXP PARASITOL, V75, P281, DOI 10.1016/0014-4894(92)90213-T
   Nielsen MA, 2002, J IMMUNOL, V168, P3444
   Ochola LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014741
   Pain A, 2001, P NATL ACAD SCI USA, V98, P1805, DOI 10.1073/pnas.98.4.1805
   Peters JM, 2007, J INFECT DIS, V195, P748, DOI 10.1086/511436
   Pierce SK, 2009, J IMMUNOL, V182, P5171, DOI 10.4049/jimmunol.0804153
   Rappuoli R, 2011, NATURE, V473, P463, DOI 10.1038/nature10124
   Rask TS, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000933
   ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0
   Robinson BA, 2003, MOL MICROBIOL, V47, P1265, DOI 10.1046/j.1365-2958.2003.03378.x
   Rogerson SJ, 1999, AM J TROP MED HYG, V61, P467
   Rottmann M, 2006, INFECT IMMUN, V74, P3904, DOI 10.1128/IAI.02073-05
   ROWE A, 1995, INFECT IMMUN, V63, P2323
   Rowe JA, 2007, P NATL ACAD SCI USA, V104, P17471, DOI 10.1073/pnas.0705390104
   Rowe JA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001082
   Rowe JA, 2002, AM J TROP MED HYG, V66, P692
   Rowe JA, 2002, AM J TROP MED HYG, V66, P458
   Rowe JA, 1998, MOL BIOCHEM PARASIT, V92, P177, DOI 10.1016/S0166-6851(97)00237-5
   Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888
   Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579
   Scholander C, 1996, NAT MED, V2, P204, DOI 10.1038/nm0296-204
   Semblat JP, 2006, MOL BIOCHEM PARASIT, V146, P192, DOI 10.1016/j.molbiopara.2005.12.007
   Smith JD, 2000, MOL BIOCHEM PARASIT, V110, P293, DOI 10.1016/S0166-6851(00)00279-6
   Somner EA, 2000, BLOOD, V95, P674
   TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503
   Trimnell AR, 2006, MOL BIOCHEM PARASIT, V148, P169, DOI 10.1016/j.molbiopara.2006.03.012
   UDOMSANGPETCH R, 1989, J EXP MED, V169, P1835, DOI 10.1084/jem.169.5.1835
   Vigan-Womas I, 2008, INFECT IMMUN, V76, P5565, DOI 10.1128/IAI.00901-08
   Vigan-Womas I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016544
   Warimwe GM, 2009, P NATL ACAD SCI USA, V106, P21801, DOI 10.1073/pnas.0907590106
NR 88
TC 38
Z9 39
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2012
VL 8
IS 4
AR e1002665
DI 10.1371/journal.ppat.1002665
PG 18
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 934KY
UT WOS:000303444200053
PM 22532802
OA gold
DA 2017-08-15
ER

PT J
AU Levine, OS
   O'Brien, KL
   Deloria-Knoll, M
   Murdoch, DR
   Feikin, DR
   DeLuca, AN
   Driscoll, AJ
   Baggett, HC
   Brooks, WA
   Howie, SRC
   Kotloff, KL
   Madhi, SA
   Maloney, SA
   Sow, S
   Thea, DM
   Scott, JA
AF Levine, Orin S.
   O'Brien, Katherine L.
   Deloria-Knoll, Maria
   Murdoch, David R.
   Feikin, Daniel R.
   DeLuca, Andrea N.
   Driscoll, Amanda J.
   Baggett, Henry C.
   Brooks, W. Abdullah
   Howie, Stephen R. C.
   Kotloff, Karen L.
   Madhi, Shabir A.
   Maloney, Susan A.
   Sow, Samba
   Thea, Donald M.
   Scott, J. Anthony
TI The Pneumonia Etiology Research for Child Health Project: A 21st Century
   Childhood Pneumonia Etiology Study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID INFLUENZAE TYPE-B; PNEUMOCOCCAL CONJUGATE VACCINE; DEVELOPING-COUNTRIES;
   CONTROLLED-TRIAL; MORTALITY; INFANTS; DISEASE; EPIDEMIOLOGY; POPULATION;
   BANGLADESH
AB The Pneumonia Etiology Research for Child Health (PERCH) project is a 7-country, standardized, comprehensive evaluation of the etiologic agents causing severe pneumonia in children from developing countries. During previous etiology studies, between one-quarter and one-third of patients failed to yield an obvious etiology; PERCH will employ and evaluate previously unavailable innovative, more sensitive diagnostic techniques. Innovative and rigorous epidemiologic and analytic methods will be used to establish the causal association between presence of potential pathogens and pneumonia. By strategic selection of study sites that are broadly representative of regions with the greatest burden of childhood pneumonia, PERCH aims to provide data that reflect the epidemiologic situation in developing countries in 2015, using pneumococcal and Haemophilus influenzae type b vaccines. PERCH will also address differences in host, environmental, and/or geographic factors that might determine pneumonia etiology and, by preserving specimens, will generate a resource for future research and pathogen discovery.
C1 [Levine, Orin S.; O'Brien, Katherine L.; Deloria-Knoll, Maria; Feikin, Daniel R.; DeLuca, Andrea N.; Driscoll, Amanda J.; Brooks, W. Abdullah] Johns Hopkins Bloomberg Sch Hlth, Int Vaccine Access Ctr, Dept Int Hlth, Baltimore, MD 21205 USA.
   [Murdoch, David R.] Univ Otago, Dept Pathol, Christchurch, New Zealand.
   [Murdoch, David R.] Canterbury Hlth Labs, Christchurch, New Zealand.
   [Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
   [Baggett, Henry C.; Maloney, Susan A.] Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Int Emerging Infect Program, Nonthaburi, Thailand.
   [Howie, Stephen R. C.] Med Res Council Labs Gambia, Fajara, Gambia.
   [Kotloff, Karen L.; Sow, Samba] Univ Maryland, Sch Med, Dept Pediat, Div Infect Dis & Trop Pediat, Baltimore, MD 21201 USA.
   [Kotloff, Karen L.; Sow, Samba] Univ Maryland, Sch Med, Dept Med, Div Geog Med,Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Madhi, Shabir A.] Natl Inst Communicable Dis, Div Natl Hlth Lab Serv, Sandrigham, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, Dept Sci & Technol, Natl Res Fdn, ZA-2050 Johannesburg, South Africa.
   [Sow, Samba] Ctr Dev Vaccins, Bamako, Mali.
   [Thea, Donald M.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA.
   [Scott, J. Anthony] Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya.
   [Scott, J. Anthony] Univ Oxford, Nuffield Dept Clin Med, Oxford OX1 2JD, England.
RP Levine, OS (reprint author), Johns Hopkins Bloomberg Sch Hlth, Int Vaccine Access Ctr, Dept Int Hlth, Baltimore, MD 21205 USA.
EM olevine@jhsph.edu
RI kotloff, karen/E-7768-2012
OI kotloff, karen/0000-0003-1808-6431; Thea, Donald/0000-0002-6933-1030
FU The Bill & Melinda Gates Foundation
FX This article was published as part of a supplement entitled "Pneumonia
   Etiology Research for Child Health,'' sponsored by a grant from The Bill
   & Melinda Gates Foundation to the PERCH Project of Johns Hopkins
   Bloomberg School of Public Health, Baltimore, Maryland.
CR Berkley JA, 2010, JAMA-J AM MED ASSOC, V303, P2051, DOI 10.1001/jama.2010.675
   Brooks WA, 2005, LANCET, V366, P999, DOI 10.1016/S0140-6736(05)67109-7
   Bryce J, 2008, LANCET, V371, P1247
   Campbell James D, 2004, J Trop Pediatr, V50, P158, DOI 10.1093/tropej/50.3.158
   Cowgill KD, 2006, JAMA-J AM MED ASSOC, V296, P671, DOI 10.1001/jama.296.6.671
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Fry AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017780
   Gilani Z, 2012, CLIN INFECT DIS, V54, pS102, DOI 10.1093/cid/cir1053
   Islam MS, 2007, J APPL MICROBIOL, V103, P80, DOI 10.1111/j.1365-2672.2006.03234.x
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Levine OS, 1999, PEDIATR INFECT DIS J, V18, P1060, DOI 10.1097/00006454-199912000-00006
   Madhi SA, 2008, B WORLD HEALTH ORGAN, V86, P365, DOI 10.2471/BLT.07.044503
   Moisi JC, 2011, B WORLD HEALTH ORGAN, V89, P102, DOI 10.2471/BLT.10.080796
   Mulholland EK, 1998, PEDIATR INFECT DIS J, V17, pS123, DOI 10.1097/00006454-199809001-00006
   Olsen SJ, 2010, EPIDEMIOL INFECT, V138, P1811, DOI 10.1017/S0950268810000646
   Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0
   Scott JAG, 2008, B WORLD HEALTH ORGAN, V86, P494, DOI 10.2471/BLT.08.052753
   Scott JAG, 2008, J CLIN INVEST, V118, P1291, DOI 10.1172/JCI33947
   Scott JAG, 2011, LANCET, V378, P1316, DOI 10.1016/S0140-6736(11)60888-X
   SELWYN BJ, 1990, REV INFECT DIS, V12, pS870
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   SHANN F, 1995, PEDIATR INFECT DIS J, V14, P920
   Shann F, 1995, CLIN INFECT DIS, V21, pS218
   Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971
NR 24
TC 78
Z9 81
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 1
PY 2012
VL 54
SU 2
BP S93
EP S101
DI 10.1093/cid/cir1052
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 905TD
UT WOS:000301296500003
PM 22403238
OA No
DA 2017-08-15
ER

PT J
AU Njie-Jobe, J
   Nyamweya, S
   Miles, DJC
   van der Sande, M
   Zaman, S
   Touray, E
   Hossin, S
   Adetifa, J
   Palmero, M
   Burl, S
   Jeffries, D
   Rowland-Jones, S
   Flanagan, K
   Jaye, A
   Whittle, H
AF Njie-Jobe, Jainaba
   Nyamweya, Samuel
   Miles, David J. C.
   van der Sande, Marianne
   Zaman, Syed
   Touray, Ebrima
   Hossin, Safayet
   Adetifa, Jane
   Palmero, Melba
   Burl, Sarah
   Jeffries, David
   Rowland-Jones, Sarah
   Flanagan, Katie
   Jaye, Assan
   Whittle, Hilton
TI Immunological impact of an additional early measles vaccine in Gambian
   children: Responses to a boost at 3 years
SO VACCINE
LA English
DT Article
DE Measles vaccine; Two-dose schedule; Booster dose; Antibody; Cellular
   immunity
ID EDMONSTON-ZAGREB; CYTOMEGALOVIRUS-INFECTION; CYTOKINE PRODUCTION;
   IMMUNE-RESPONSES; DNA VACCINATION; GUINEA-BISSAU; UNITED-STATES; RURAL
   SENEGAL; T-CELLS; CLASS I
AB Background: Measles vaccine in early infancy followed by a dose at 9 months of age protects against measles and enhances child survival through non-specific effects. Little is known of immune responses in the short or long term after booster doses.
   Methods: Infants were randomized to receive measles vaccine at 9 months of age (group 1) or 4 and 9 months of age (group 2). Both groups received a boost at 36 months of age. T-cell effector and memory responses using IFN-gamma ELIspot and cytokine assays and antibody titres using a haemagglutination-inhibition assay were compared at various times.
   Results: Vaccination at 4 months of age elicited antibody and CD4T-cell mediated immune responses Two weeks after vaccination at 9 months of age group 2 had much higher antibody titres than group1 infants; cell-mediated effector responses were similar. At 36 months of age group 2 antibody titres exceeded protective levels but were 4-fold lower than group 1; effector and cytokine responses were similar. Re-vaccination resulted in similar rapid and high antibody titres in both groups (median 512); cellular immunity changed little. At 48 months of age group 2 antibody concentrations remained well above protective levels though 2-fold lower than group 1: T-cell memory was readily detectable and similar in both groups.
   Conclusions: An additional early measles vaccine given to children at 4 months of age induced a predominant CD4 T-cell response at 9 months and rapid development of high antibody concentrations after booster doses. However, antibody decayed faster in these children than in the group given primary vaccination at 9 months of age. Cellular responses after 9 months were generally insignificantly different. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Njie-Jobe, Jainaba; Nyamweya, Samuel; Miles, David J. C.; Touray, Ebrima; Hossin, Safayet; Adetifa, Jane; Jeffries, David; Flanagan, Katie; Jaye, Assan; Whittle, Hilton] MRC Labs, Banjul, Gambia.
   [van der Sande, Marianne] Ctr Infect Dis Control Netherlands, Natl Inst Hlth & Environm RIVM, Bilthoven, Netherlands.
   [van der Sande, Marianne] Univ Utrecht, Julius Ctr Hlth Sci, Med Ctr, Utrecht, Netherlands.
   [Zaman, Syed] Ctr Infect, Hlth Protect Agcy, London NW9 5EQ, England.
   [Palmero, Melba] Adventist Hlth Ministries, Adventist Community Serv, Anchorage, AK 99507 USA.
   [Burl, Sarah] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London W2 1PG, England.
   [Rowland-Jones, Sarah] Univ Oxford, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
RP Whittle, H (reprint author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Keppel St, London WC1 7HT, England.
EM hcwhittle@yahoo.co.uk
FU Medical Research Council (UK) [SCC 948]
FX This work was supported by the Medical Research Council (UK) as part of
   a 5 year program grant from 2007 to 2011. Grant number SCC 948.
CR Aaby P, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6495
   Dilraj A, 2000, LANCET, V355, P798, DOI 10.1016/S0140-6736(99)95140-1
   EPI, 1982, WKLY EPIDEMIOL REC, V57, P89
   Gans HA, 2004, J INFECT DIS, V190, P83, DOI 10.1086/421032
   Gans HA, 1999, J IMMUNOL, V162, P5569
   Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347
   Garly ML, 2001, VACCINE, V19, P1951, DOI 10.1016/S0264-410X(00)00431-X
   Helfand RF, 2008, J INFECT DIS, V198, P1457, DOI 10.1086/592756
   Heymann DL, 2010, LANCET, V376, P1719, DOI 10.1016/S0140-6736(10)61934-4
   Hutchins SS, 2001, AM J EPIDEMIOL, V154, P1064, DOI 10.1093/aje/154.11.1064
   Jaye A, 1998, J CLIN INVEST, V102, P1969, DOI 10.1172/JCI3290
   Jaye A, 1998, J INFECT DIS, V177, P1282
   Lievano FA, 2004, J INFECT DIS, V189, pS165, DOI 10.1086/377715
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   Miles DJC, 2008, IMMUNOLOGY, V124, P388, DOI 10.1111/j.1365-2567.2007.02787.x
   Otten M, 2005, LANCET, V366, P832, DOI 10.1016/S0140-6736(05)67216-9
   Ovsyannikova IG, 2003, VACCINE, V21, P3946, DOI 10.1016/S0264-410X(03)00272-X
   Papania M, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e59
   Permar SR, 2004, J INFECT DIS, V190, P998, DOI 10.1086/422846
   Premenko-Lanier M, 2003, VIROLOGY, V307, P67, DOI 10.1016/S0042-6822(02)00036-3
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   Samb B, 1997, AM J EPIDEMIOL, V145, P51
   Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705
   Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6
   Stittelaar KJ, 2002, VACCINE, V20, P2022
   Unger JP, 2003, INT J HEALTH PLAN M, V18, pS27, DOI 10.1002/hpm.723
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000492
   VANBINNENDIJK RS, 1990, J IMMUNOL, V144, P2394
   WARD BJ, 1993, CLIN IMMUNOL IMMUNOP, V67, P171, DOI 10.1006/clin.1993.1061
   Whelan KT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005934
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
   WHITTLE HC, 1990, LANCET, V336, P1046, DOI 10.1016/0140-6736(90)92501-8
   Yu XL, 2008, J IMMUNOL, V181, P7356
   [Anonymous], 2009, VACCINE, V27, P7219
NR 34
TC 10
Z9 11
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2012
VL 30
IS 15
BP 2543
EP 2550
DI 10.1016/j.vaccine.2012.01.083
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 926HT
UT WOS:000302822600006
PM 22314136
OA No
DA 2017-08-15
ER

PT J
AU Cook, J
   Speybroeck, N
   Sochanta, T
   Somony, H
   Sokny, M
   Claes, F
   Lemmens, K
   Theisen, M
   Soares, IS
   D'Alessandro, U
   Coosemans, M
   Erhart, A
AF Cook, Jackie
   Speybroeck, Nico
   Sochanta, Tho
   Somony, Heng
   Sokny, Mao
   Claes, Filip
   Lemmens, Kristel
   Theisen, Michael
   Soares, Irene S.
   D'Alessandro, Umberto
   Coosemans, Marc
   Erhart, Annette
TI Sero-epidemiological evaluation of changes in Plasmodium falciparum and
   Plasmodium vivax transmission patterns over the rainy season in Cambodia
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Serology; Classification and regression tree; Elimination;
   Cambodia
ID MALARIA TRANSMISSION; RISK-FACTORS; ANTIBODY-RESPONSES; CENTRAL VIETNAM;
   CIRCUMSPOROZOITE PROTEIN; FOREST MALARIA; ANTIGENS; INFECTION;
   ELIMINATION; LONGEVITY
AB Background: In Cambodia, malaria transmission is low and most cases occur in forested areas. Seroepidemiological techniques can be used to identify both areas of ongoing transmission and high-risk groups to be targeted by control interventions. This study utilizes repeated cross-sectional data to assess the risk of being malaria sero-positive at two consecutive time points during the rainy season and investigates who is most likely to sero-convert over the transmission season.
   Methods: In 2005, two cross-sectional surveys, one in the middle and the other at the end of the malaria transmission season, were carried out in two ecologically distinct regions in Cambodia. Parasitological and serological data were collected in four districts. Antibodies to Plasmodium falciparum Glutamate Rich Protein (GLURP) and Plasmodium vivax Merozoite Surface Protein-119 (MSP-119) were detected using Enzyme Linked Immunosorbent Assay (ELISA). The force of infection was estimated using a simple catalytic model fitted using maximum likelihood methods. Risks for sero-converting during the rainy season were analysed using the Classification and Regression Tree (CART) method.
   Results: A total of 804 individuals participating in both surveys were analysed. The overall parasite prevalence was low (4.6% and 2.0% for P. falciparum and 7.9% and 6.0% for P. vivax in August and November respectively). P. falciparum force of infection was higher in the eastern region and increased between August and November, whilst P. vivax force of infection was higher in the western region and remained similar in both surveys. In the western region, malaria transmission changed very little across the season (for both species). CART analysis for P. falciparum in the east highlighted age, ethnicity, village of residence and forest work as important predictors for malaria exposure during the rainy season. Adults were more likely to increase their antibody responses to P. falciparum during the transmission season than children, whilst members of the Charay ethnic group demonstrated the largest increases.
   Discussion: In areas of low transmission intensity, such as in Cambodia, the analysis of longitudinal serological data enables a sensitive evaluation of transmission dynamics. Consecutive serological surveys allow an insight into spatio-temporal patterns of malaria transmission. The use of CART enabled multiple interactions to be accounted for simultaneously and permitted risk factors for exposure to be clearly identified.
C1 [Cook, Jackie; Claes, Filip; Lemmens, Kristel; D'Alessandro, Umberto; Coosemans, Marc; Erhart, Annette] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Speybroeck, Nico] Catholic Univ Louvain, Ecole Sante Publ, B-1200 Brussels, Belgium.
   [Sochanta, Tho; Somony, Heng; Sokny, Mao] Natl Ctr Malaria Control Parasitol & Entomol, Phnom Penh, Cambodia.
   [Theisen, Michael] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Ctr Med Parasitol, Copenhagen, Denmark.
   [Soares, Irene S.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
RP Cook, J (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.
EM jcook@itg.be
RI Soares, Irene/C-5974-2012; Vacinas, Inct/J-9431-2013; D'Alessandro,
   Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU Institute of Tropical Medicine of Antwerp; National Center for Malaria
   Control, Parasitology and Entomology (CNM); Belgium Cooperation
   (Directorate-General for Development Co-operation)
FX We would like to thank the study population for all their support and
   contributions to the project. We are also grateful to Vincent Sluydts
   for designing the map in Figure 1. This study was funded by the
   Framework Agreement II (2003-2007) for capacity strengthening between
   the Institute of Tropical Medicine of Antwerp and the National Center
   for Malaria Control, Parasitology and Entomology (CNM) and supported by
   the Belgium Cooperation (Directorate-General for Development
   Co-operation).
CR Abe T, 2009, SE ASIAN J TROP MED, V40, P18
   Achtman AH, 2005, CURR TOP MICROBIOL, V297, P71
   Agak GW, 2008, VACCINE, V26, P1963, DOI 10.1016/j.vaccine.2008.02.020
   Ak Mucide, 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P685
   Bousema T, 2010, J INFECT DIS, V201, P1764, DOI 10.1086/652456
   Bousema T, 2010, EMERG INFECT DIS, V16, P392, DOI 10.3201/eid1603.090732
   BRUCECHWATT LJ, 1975, J TROP MED HYG, V78, P194
   BRUCECHWATT LJ, 1973, LANCET, V2, P547
   Chowell G, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-142
   Cook J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025137
   Corran P, 2007, TRENDS PARASITOL, V23, P575, DOI 10.1016/j.pt.2007.08.023
   Corran PH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-195
   DELGIUDICE G, 1990, B WORLD HEALTH ORGAN, V68, P191
   Drakeley C, 2009, ADV PARASIT, V69, P299, DOI 10.1016/S0065-308X(09)69005-9
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Durnez L, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-195
   Dysoley L, 2008, ACTA TROP, V106, P207, DOI 10.1016/j.actatropica.2007.01.007
   Erhart A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-58
   Incardona S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-37
   John CC, 2003, INFECT IMMUN, V71, P4320, DOI 10.1128/IAI.71.8.4320-4325.2003
   Kinyanjui SM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-82
   Maitland K, 1996, T ROY SOC TROP MED H, V90, P614, DOI 10.1016/S0035-9203(96)90406-X
   Maitland K, 1997, PARASITOL TODAY, V13, P227, DOI 10.1016/S0169-4758(97)01061-2
   Mehrizi AA, 2009, ACTA TROP, V112, P1, DOI 10.1016/j.actatropica.2009.05.016
   Mendis K, 2001, AM J TROP MED HYG, V64, P97
   Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X
   Okell LC, 2009, J INFECT DIS, V200, P1509, DOI 10.1086/644781
   Perraut R, 2000, AM J TROP MED HYG, V62, P746
   Protopopoff N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008022
   Snounou G, 2004, TRENDS PARASITOL, V20, P333, DOI 10.1016/j.pt.2004.05.004
   Soares IS, 1999, AM J TROP MED HYG, V60, P357
   Steenkeste N, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-108
   Taylor RR, 1996, INT IMMUNOL, V8, P905, DOI 10.1093/intimm/8.6.905
   Thang ND, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-28
   THEISEN M, 1995, CLIN DIAGN LAB IMMUN, V2, P30
   Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x
   Turner L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029025
   Van Bortel W, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-373
   Weiss GE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000912
NR 39
TC 25
Z9 25
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAR 25
PY 2012
VL 11
AR 86
DI 10.1186/1475-2875-11-86
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 951ZZ
UT WOS:000304760800001
PM 22443375
OA gold
DA 2017-08-15
ER

PT J
AU Dionisio, KL
   Howie, SRC
   Dominici, F
   Fornace, KM
   Spengler, JD
   Adegbola, RA
   Ezzati, M
AF Dionisio, Kathie L.
   Howie, Stephen R. C.
   Dominici, Francesca
   Fornace, Kimberly M.
   Spengler, John D.
   Adegbola, Richard A.
   Ezzati, Majid
TI Household Concentrations and Exposure of Children to Particulate Matter
   from Biomass Fuels in The Gambia
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article
ID INDOOR AIR-POLLUTION; ACUTE RESPIRATORY-INFECTIONS; CARBON-MONOXIDE;
   HIGHLAND GUATEMALA; COMBUSTION; CHINA; PATTERNS; KENYA; WOOD;
   METAANALYSIS
AB Particulate matter (PM) is an important metric for studying the health effects of household air pollution. There are limited data on PM exposure for children in homes that use biomass fuels, and no previous study has used direct measurement of personal exposure in children younger than 5 years of age. We estimated PM2.5 exposure for 1266 children in The Gambia by applying the cookhouse PM2.5-CO relationship to the child's CO exposure. Using this indirect method, mean PM2.5 exposure for all subjects was 135 +/- 38 mu g/m(3); 25% of children had exposures of 151 mu g/m(3) or higher. Indirectly estimated exposure was highest among children who lived in homes that used firewood (collected or purchased) as their main fuel (144 mu g/m(3)) compared to those who used charcoal (85 mu g/m(3)). To validate the indirect method, we also directly measured PM2.5 exposure on 31 children. Mean exposure for this validation data set was 65 +/- 41 mu g/m(3) using actual measurement and 125 +/- 54 mu g/m(3) using the indirect method based on simultaneously-measured CO exposure. The correlation coefficient between direct measurements and indirect estimates was 0.01. Children in The Gambia have relatively high PM2.5 exposure. There is a need for simple methods that can directly measure PM2.5 exposure in field studies.
C1 [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, London W2 1PG, England.
   [Dionisio, Kathie L.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
   [Dionisio, Kathie L.; Spengler, John D.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
   [Howie, Stephen R. C.; Adegbola, Richard A.] MRC, Gambia Unit, Fajara, Gambia.
   [Dominici, Francesca] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Fornace, Kimberly M.] Univ London Royal Vet Coll, Vet Epidemiol & Publ Hlth Grp, London, England.
   [Adegbola, Richard A.] GlaxoSmithKline Biol, Wavre, Belgium.
RP Ezzati, M (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, Norfolk Pl, London W2 1PG, England.
EM majid.ezzati@imperial.ac.uk
OI Fornace, Kimberly/0000-0002-5484-241X
FU National Institute of Environmental Health Sciences [1R21ES017855-01]
FX This work was supported by a grant from the National Institute of
   Environmental Health Sciences (1R21ES017855-01). We thank the households
   who participated in the study for their help and hospitality, our field
   workers and field supervisors for valuable assistance in data
   collection, the Biomedical Engineering Department at the MRC
   Laboratories for technical assistance throughout the study, Jose
   Vallarino for information on methods and instruments for personal
   exposure measurement, and Mariel Finucane for advice on presentation of
   statistical results. We also thank Grant Mackenzie for operational
   support and Nigel Bruce and Kirk Smith for advice on exposure
   measurement.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   ANDERSON HR, 1978, INT J EPIDEMIOL, V7, P63, DOI 10.1093/ije/7.1.63
   Balakrishnan K, 2002, ENVIRON HEALTH PERSP, V110, P1069
   Balakrishnan K, 2004, J EXPO ANAL ENV EPID, V14, pS14, DOI 10.1038/sj.jea.7500354
   Baumgartner J, 2011, INDOOR AIR, V21, P479, DOI 10.1111/j.1600-0668.2011.00730.x
   Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1
   Bruce N, 2004, J EXPO ANAL ENV EPID, V14, pS26, DOI 10.1038/sj.jea.7500355
   Dasgupta S, 2006, HEALTH POLICY PLANN, V21, P444, DOI 10.1093/heapol/czl027
   Dherani M, 2008, B WORLD HEALTH ORGAN, V86, P390, DOI 10.2471/BLT.07.044529
   Dionisio KL, 2008, INDOOR AIR, V18, P317, DOI 10.1111/j.1600-0668.2008.00533.x
   Dionisio KL, 2012, J EXPO SCI ENV EPID, V22, P173, DOI 10.1038/jes.2011.47
   Dionisio KL, 2010, ENVIRON SCI TECHNOL, V44, P2270, DOI 10.1021/es903276s
   Ezzati M, 2000, ENVIRON HEALTH PERSP, V108, P833, DOI 10.2307/3434990
   Ezzati M, 2000, ENVIRON SCI TECHNOL, V34, P578, DOI 10.1021/es9905795
   Ezzati M, 2001, LANCET, V358, P619, DOI 10.1016/S0140-6736(01)05777-4
   Ezzati M, 2001, ENVIRON HEALTH PERSP, V109, P481, DOI 10.2307/3454706
   Gelman A., 2007, DATA ANAL USING REGR
   Gupta P, 2006, ATMOS ENVIRON, V40, P5880, DOI 10.1016/j.atmosenv.2006.03.016
   He GL, 2005, ENVIRON SCI TECHNOL, V39, P991, DOI 10.1021/es049731f
   [Anonymous], 2001, AIRB PART HLTH HEI E
   Jin YL, 2005, ENVIRON SCI TECHNOL, V39, P9431, DOI 10.1021/es0507517
   Lewington S, 2002, LANCET, V360, P1903
   Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4
   McCracken JP, 2009, EPIDEMIOLOGY, V20, P127, DOI 10.1097/EDE.0b013e31818ef327
   Mestl HES, 2007, SCI TOTAL ENVIRON, V377, P12, DOI 10.1016/j.scitotenv.2007.01.087
   Naeher LP, 2000, INDOOR AIR, V10, P200
   Naeher LP, 2001, ENVIRON SCI TECHNOL, V35, P575, DOI 10.1021/es991225g
   Northcross A, 2010, J ENVIRON MONITOR, V12, P873, DOI 10.1039/b916068j
   Pope CA, 2006, J AIR WASTE MANAGE, V56, P709
   Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9
   Roehr B., 2011, BRIT MED J, P342
   SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136
   Smith K., 1987, BIOFUELS AIR POLLUTI
   Smith K.R., 2004, COMP QUANTIFICATION, P1435
   Smith K.R., 2009, J EXPO SCI ENV EPID, V20, P406
   World Health Organization- Regional Office for Europe, 2006, AIR QUAL GUID GLOB U
   Zheng M, 2005, ATMOS ENVIRON, V39, P3967, DOI 10.1016/j.atmosenv.2005.03.036
NR 37
TC 28
Z9 29
U1 1
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD MAR 20
PY 2012
VL 46
IS 6
BP 3519
EP 3527
DI 10.1021/es203047e
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 910IK
UT WOS:000301630200061
PM 22304223
OA No
DA 2017-08-15
ER

PT J
AU Ceesay, SJ
   Bojang, KA
   Nwakanma, D
   Conway, DJ
   Koita, OA
   Doumbia, SO
   Ndiaye, D
   Coulibaly, TF
   Diakite, M
   Traore, SF
   Coulibaly, M
   Ndiaye, JL
   Sarr, O
   Gaye, O
   Konate, L
   Sy, N
   Faye, B
   Faye, O
   Sogoba, N
   Jawara, M
   Dao, A
   Poudiougou, B
   Diawara, S
   Okebe, J
   Sangare, L
   Abubakar, I
   Sissako, A
   Diarra, A
   Keita, M
   Kandeh, B
   Long, CA
   Fairhurst, RM
   Duraisingh, M
   Perry, R
   Muskavitch, MAT
   Valim, C
   Volkman, SK
   Wirth, DF
   Krogstad, DJ
AF Ceesay, Serign J.
   Bojang, Kalifa A.
   Nwakanma, Davis
   Conway, David J.
   Koita, Ousmane A.
   Doumbia, Seydou O.
   Ndiaye, Daouda
   Coulibaly, Tinzana F.
   Diakite, Mahamadou
   Traore, Sekou F.
   Coulibaly, Mamadou
   Ndiaye, Jean-Louis
   Sarr, Ousmane
   Gaye, Oumar
   Konate, Lassana
   Sy, Ngayo
   Faye, Babacar
   Faye, Ousmane
   Sogoba, Nafomon
   Jawara, Musa
   Dao, Adama
   Poudiougou, Belco
   Diawara, Sory
   Okebe, Joseph
   Sangare, Lansana
   Abubakar, Ismaela
   Sissako, Aliou
   Diarra, Ayouba
   Keita, Moussa
   Kandeh, Balla
   Long, Carole A.
   Fairhurst, Rick M.
   Duraisingh, Manoj
   Perry, Robert
   Muskavitch, Marc A. T.
   Valim, Clarissa
   Volkman, Sarah K.
   Wirth, Dyann F.
   Krogstad, Donald J.
TI Sahel, savana, riverine and urban malaria in West Africa: Similar
   control policies with different outcomes
SO ACTA TROPICA
LA English
DT Article
DE Artemisinin Combination Therapies; Long-Lasting Insecticide Treated bed
   nets; Entomologic inoculation rate; Intermittent preventive treatment of
   malaria during pregnancy; Transmission intensity; Multiplicity of
   infection
ID PLASMODIUM-FALCIPARUM; ERADICATION; ELIMINATION; TRANSMISSION;
   FEASIBILITY; PROSPECTS; KENYA
AB The study sites for the West African ICEMR are in three countries (The Gambia, Senegal, Mali) and are located within 750 km of each other. In addition, the National Malaria Control Programmes of these countries have virtually identical policies: (1) Artemisinin Combination Therapies (ACTs) for the treatment of symptomatic Plasmodium falciparum infection, (2) Long-Lasting Insecticide-treated bed Nets (LLINs) to reduce the Entomololgic Inoculation Rate (EIR), and (3) sulfadoxine-pyrimethamine for the Intermittent Preventive Treatment of malaria during pregnancy (IPTp). However, the prevalence of P. falciparum malaria and the status of malaria control vary markedly across the four sites with differences in the duration of the transmission season (from 4-5 to 10-11 months), the intensity of transmission (with EIRs from unmeasurably low to 4-5 per person per month), multiplicity of infection (from a mean of 1.0 to means of 2-5) and the status of malaria control (from areas which have virtually no control to areas that are at the threshold of malaria elimination). The most important priority is the need to obtain comparable data on the population-based prevalence, incidence and transmission of malaria before new candidate interventions or combinations of interventions are introduced for malaria control. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Krogstad, Donald J.] Tulane Sch Publ Hlth & Trop Med, New Orleans, LA USA.
   [Ceesay, Serign J.; Bojang, Kalifa A.; Nwakanma, Davis; Conway, David J.; Jawara, Musa; Okebe, Joseph; Abubakar, Ismaela] MRC Labs, Int Ctr Excellence Malaria Res ICEMR W Africa, Fajara, Gambia.
   [Conway, David J.] London Sch Hyg & Trop Med, London WC1, England.
   [Koita, Ousmane A.; Doumbia, Seydou O.; Coulibaly, Tinzana F.; Diakite, Mahamadou; Traore, Sekou F.; Coulibaly, Mamadou; Sogoba, Nafomon; Dao, Adama; Poudiougou, Belco; Diawara, Sory; Sangare, Lansana; Sissako, Aliou; Diarra, Ayouba; Keita, Moussa] Uniivers Bamako, Bamako, Mali.
   [Ndiaye, Daouda; Ndiaye, Jean-Louis; Sarr, Ousmane; Gaye, Oumar; Konate, Lassana; Sy, Ngayo; Faye, Babacar; Faye, Ousmane] Uniivers Cheikh Anta Diop, Dakar, Senegal.
   [Long, Carole A.; Fairhurst, Rick M.] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
   [Duraisingh, Manoj; Valim, Clarissa; Volkman, Sarah K.; Wirth, Dyann F.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Muskavitch, Marc A. T.] Boston Coll, Chestnut Hill, MA 02167 USA.
RP Krogstad, DJ (reprint author), Tulane Sch Publ Hlth & Trop Med, New Orleans, LA USA.
EM krogstad@tulane.edu
OI Bojang, Kalifa/0000-0001-7506-0938; Conway, David/0000-0002-8711-3037
FU National Institutes of Allergy and Infectious Diseases (NIAID) [U19 AI
   089696]
FX The studies described here have been supported by a cooperative
   agreement from the National Institutes of Allergy and Infectious
   Diseases (NIAID U19 AI 089696) for an international center of excellence
   in malaria research (ICEMR) award to a consortium involving the
   University of Bamako in Mali, the University Cheikh Anta Diop in
   Senegal, the Medical Research Council (MRC) Laboratories in The Gambia,
   Harvard School of Public Health, Boston College, London School of
   Hygiene and Tropical Medicine and the Tulane School of Public Health and
   Tropical Medicine. We thank our many colleagues for administrative and
   financial support (Abdoulie Barry, Ron Cail, Salif Camara, Rosie Chavez,
   Abou Alassane Diallo, Khady Toure Diop, Ramona Gonski, Shannon Joyce,
   Dembo Kanteh, Glen McGugan, Carmen Mejia, Papa Alioune Ndao, Seybatou
   Magatte Ndaw, Peter Noble, Malla Rao, Brenda Rodriguez, Mamkumbah
   Sanneh, Moussa Dien Sarr, IP Singh, Paula Strickland, Don Van Noy, Joan
   Vivestomas, Tonu Wali, James Clint Welty, Kijuana Yarls), advice and
   mentoring (Tumani Corrah, Abarahmane Dia, Amadou Diallo, Souleymanne
   Mboup, Saliou Ndiaye, Omar Ndir), information technology and computing
   support (Christopher Whalen, Brian Moyer), public health and malaria
   control partnerships (Moussa Thior, Mrs. Adam Jagne Sonko, Claude-Emile
   Rwagacondo), and for generous access to their personal expertise
   (Jennifer Anderson, Thomas P. Eisele, Ivo Foppa, Nicholas Manoukis,
   Meredith McMorrow, David Parker, Robert Perry, Margaret Pinder, Jon Eric
   Tongren, Sixte Zigirumugabe).
CR Aguas R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001767
   ALLISON AC, 1954, T ROY SOC TROP MED H, V48, P312, DOI 10.1016/0035-9203(54)90101-7
   Beet E. A., 1946, EAST AFRICAN MED JOUR, V23, P75
   BROWN A W, 1958, Bull World Health Organ, V18, P309
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Chuma J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-243
   Cohen JM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-213
   Cortes A, 2003, TRENDS PARASITOL, V19, P246, DOI 10.1016/S1471-4922(03)00090-4
   Feachem R, 2008, LANCET, V371, P1633, DOI [10.1016/S0140-6736(08)60424-9, 10.1016/S1473-3099(08)70045-8]
   Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6
   Greenwood Brian, 2009, Trans R Soc Trop Med Hyg, V103 Suppl 1, pS2, DOI 10.1016/j.trstmh.2008.10.027
   Hay SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0
   Jongwutiwes S, 2010, VACCINE, V28, P3112, DOI 10.1016/j.vaccine.2010.02.062
   Keiser J, 2004, AM J TROP MED HYG, V71, P118
   Mccoy D, 2009, LANCET, V373, P1645, DOI 10.1016/S0140-6736(09)60571-7
   Mendis K, 2009, TROP MED INT HEALTH, V14, P802, DOI 10.1111/j.1365-3156.2009.02287.x
   Mills A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S11
   Moonen B, 2010, LANCET, V376, P1592, DOI 10.1016/S0140-6736(10)61269-X
   Nahlen BL, 2007, AM J TROP MED HYG, V77, P321
   Ndiaye D, 2010, AM J TROP MED HYG, V82, P228, DOI 10.4269/ajtmh.2010.09-0470
   O'Meara WP, 2010, LANCET INFECT DIS, V10, P545, DOI 10.1016/S1473-3099(10)70096-7
   Okech BA, 2004, ACTA TROP, V92, P99, DOI 10.1016/j.actatropica.2004.06.003
   Pampana E, 1969, TXB MALARIA ERADICAT, P1
   Roberts L, 2007, SCIENCE, V318, P1544, DOI 10.1126/science.318.5856.1544
   Sabot O, 2010, LANCET, V376, P1604, DOI 10.1016/S0140-6736(10)61355-4
   Shah SP, 2010, FRACTURE AND DAMAGE OF ADVANCED FIBRE-REINFORCED CEMENT-BASED MATERIALS, P1
   Sogoba N, 2007, ACTA TROP, V101, P232, DOI 10.1016/j.actatropica.2007.02.005
   TATEM AJ, 2010, P NATL ACAD SCI USA, V107, P1222, DOI DOI 10.1073/PNAS.1002971107
   Tatem AJ, 2010, LANCET, V376, P1579, DOI 10.1016/S0140-6736(10)61301-3
   Wellems TE, 2005, NAT GENET, V37, P1160, DOI 10.1038/ng1105-1160
   Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6
NR 31
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD MAR
PY 2012
VL 121
IS 3
SI SI
BP 166
EP 174
DI 10.1016/j.actatropica.2011.11.005
PG 9
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 924CN
UT WOS:000302668500003
PM 22119584
OA No
DA 2017-08-15
ER

PT J
AU Volkman, SK
   Ndiaye, D
   Diakite, M
   Koita, OA
   Nwakanma, D
   Daniels, RF
   Park, DJ
   Neafsey, DE
   Muskavitch, MAT
   Krogstad, DJ
   Sabeti, PC
   Hartl, DL
   Wirth, DF
AF Volkman, Sarah K.
   Ndiaye, Daouda
   Diakite, Mahamadou
   Koita, Ousmane A.
   Nwakanma, Davis
   Daniels, Rachel F.
   Park, Daniel J.
   Neafsey, Daniel E.
   Muskavitch, Marc A. T.
   Krogstad, Donald J.
   Sabeti, Pardis C.
   Hartl, Daniel L.
   Wirth, Dyann F.
TI Application of genomics to field investigations of malaria by the
   international centers of excellence for malaria research
SO ACTA TROPICA
LA English
DT Article
DE Malaria; Genomics; Population genetics; Plasmodium falciparum;
   Plasmodium vivax; International Centers of Excellence for Malaria
   Research
ID PARASITE PLASMODIUM-FALCIPARUM; POLYMERASE CHAIN-REACTION;
   PAPUA-NEW-GUINEA; NA+/H+ EXCHANGER; DRUG-RESISTANCE; LIFE-CYCLE; QUININE
   RESISTANCE; GENETIC DIVERSITY; ANOPHELES-GAMBIAE; CHLOROQUINE-RESISTANCE
AB Success of the global research agenda toward eradication of malaria will depend on development of new tools, including drugs, vaccines, insecticides and diagnostics. Genomic information, now available for the malaria parasites, their mosquito vectors, and human host, can be leveraged to both develop these tools and monitor their effectiveness. Although knowledge of genomic sequences for the malaria parasites, Plasmodium falciparum and Plasmodium vivax, have helped advance our understanding of malaria biology, simply knowing this sequence information has not yielded a plethora of new interventions to reduce the burden of malaria. Here we review and provide specific examples of how genomic information has increased our knowledge of parasite biology, focusing on P. falciparum malaria. We then discuss how population genetics can be applied toward the epidemiological and transmission-related goals outlined by the International Centers of Excellence for Malaria Research groups recently established by the National Institutes of Health. Finally, we propose genomics is a research area that can promote coordination and collaboration between various ICEMR groups, and that working together as a community can significantly advance the value of this information toward reduction of the global malaria burden. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Volkman, Sarah K.; Wirth, Dyann F.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Volkman, Sarah K.; Daniels, Rachel F.; Park, Daniel J.; Neafsey, Daniel E.; Sabeti, Pardis C.; Wirth, Dyann F.] 7 Cambridge Ctr, Broad Inst, Cambridge, MA USA.
   [Volkman, Sarah K.] Simmons Coll, Sch Nursing & Hlth Sci, Boston, MA 02115 USA.
   [Ndiaye, Daouda] Cheikh Anta Diop Univ, Fac Med & Pharm, Dakar, Senegal.
   [Diakite, Mahamadou; Koita, Ousmane A.] Univ Bamako, Fac Med & Pharm, Bamako, Mali.
   [Nwakanma, Davis] Med Res Council MRC Unit, Banjul, Gambia.
   [Daniels, Rachel F.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.
   [Muskavitch, Marc A. T.] Boston Coll, Chestnut Hill, MA 02467 USA.
   [Krogstad, Donald J.] Tulane Univ, New Orleans, LA 70112 USA.
   [Sabeti, Pardis C.] Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA.
RP Volkman, SK (reprint author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.
EM svolkman@hsph.harvard.edu
OI Daniels, Rachel/0000-0002-9712-4581
FU Medical Research Council [MC_UP_A900_1117]; NIAID NIH HHS [U19
   AI089696-01, U19 AI089696]
CR Adjalley S.H., 2011, P NATL ACAD SCI US
   Anderson T, 2011, PHARMACOGENOMICS, V12, P59, DOI [10.2217/pgs.10.165, 10.2217/PGS.10.165]
   Anderson TJC, 2010, P ROY SOC B-BIOL SCI, V277, P2531, DOI 10.1098/rspb.2010.0196
   Anderson TJC, 2010, J INFECT DIS, V201, P1326, DOI 10.1086/651562
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   Andriantsoanirina V, 2009, J MICROBIOL METH, V78, P165, DOI 10.1016/j.mimet.2009.05.013
   Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814
   Ayala HBR, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-577
   Bahl A, 2002, NUCLEIC ACIDS RES, V30, P87, DOI 10.1093/nar/30.1.87
   BAIRD JK, 1991, AM J TROP MED HYG, V44, P547
   Barry AE, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.008326
   Bass C, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-155
   Bass C, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-111
   Bei AK, 2010, J INFECT DIS, V202, P1722, DOI 10.1086/657157
   Bejon P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021711
   Bennett TN, 2007, MOL BIOCHEM PARASIT, V153, P48, DOI 10.1016/j.molbiopara.2007.01.018
   Besteiro S, 2010, PARASITOLOGY, V137, P1343, DOI 10.1017/S0031182009991934
   Bethke LL, 2006, MOL BIOCHEM PARASIT, V150, P10, DOI 10.1016/j.molbiopara.2006.06.004
   Bousema T, 2011, CLIN MICROBIOL REV, V24, P377, DOI 10.1128/CMR.00051-10
   Bousema T, 2010, J INFECT DIS, V201, P1764, DOI 10.1086/652456
   Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005
   Bright AT, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-50
   Briolant S, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-37
   Broadbent KM, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r56
   Burgoine KL, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-376
   Butler D, 2002, NATURE, V419, P426, DOI 10.1038/419426a
   Carlton J, 2005, CURR ISSUES MOL BIOL, V7, P23
   Carlton JM, 2008, NATURE, V455, P757, DOI 10.1038/nature07327
   Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099
   Carlton JMR, 1999, MOL BIOCHEM PARASIT, V101, P23, DOI 10.1016/S0166-6851(99)00045-6
   Carlton JMR, 1998, MOL BIOCHEM PARASIT, V93, P285, DOI 10.1016/S0166-6851(98)00043-7
   Conway DJ, 2007, CLIN MICROBIOL REV, V20, P188, DOI 10.1128/CMR.00021-06
   Cook J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025137
   COWMAN AF, 1988, P NATL ACAD SCI USA, V85, P9109, DOI 10.1073/pnas.85.23.9109
   Crompton PD, 2010, P NATL ACAD SCI USA, V107, P6958, DOI 10.1073/pnas.1001323107
   Daily JP, 2007, NATURE, V450, P1091, DOI 10.1038/nature06311
   Daniels R, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-223
   de Koning-Ward TF, 2008, MOL MICROBIOL, V67, P278, DOI 10.1111/j.1365-2958.2007.06039.x
   Dharia NV, 2010, P NATL ACAD SCI USA, V107, P20045, DOI 10.1073/pnas.1003776107
   Dharia NV, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-2-r21
   Djimde A, 2001, LANCET, V358, P890, DOI 10.1016/S0140-6736(01)06040-8
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Doolan DL, 2008, PROTEOMICS, V8, P4680, DOI 10.1002/pmic.200800194
   Drakeley C, 2009, ADV PARASIT, V69, P299, DOI 10.1016/S0065-308X(09)69005-9
   Duraisingh MT, 2005, CELL, V121, P13, DOI 10.1016/j.cell.2005.01.036
   Escalante AA, 2004, TRENDS PARASITOL, V20, P388, DOI 10.1016/j.pt.2004.06.002
   Ferdig MT, 2004, MOL MICROBIOL, V52, P985, DOI 10.1111/j.1365-2958.2004.04035.x
   Ferdig MT, 2000, PARASITOL TODAY, V16, P307, DOI 10.1016/S0169-4758(00)01676-8
   Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107
   FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9
   Foth BJ, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r177
   Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037
   Furuya T, 2005, P NATL ACAD SCI USA, V102, P16813, DOI 10.1073/pnas.0501858102
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Giarratana MC, 2005, NAT BIOTECHNOL, V23, P69, DOI 10.1038/nbt1047
   Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523
   Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717
   Harrington WE, 2009, P NATL ACAD SCI USA, V106, P9027, DOI 10.1073/pnas.0901415106
   Hayton K, 2008, CURR GENET, V54, P223, DOI 10.1007/s00294-008-0214-x
   Hayton K, 2008, CELL HOST MICROBE, V4, P40, DOI 10.1016/j.chom.2008.06.001
   Hedrick PW, 2011, HEREDITY, V107, P283, DOI 10.1038/hdy.2011.16
   Hemingway J, 2004, INSECT BIOCHEM MOLEC, V34, P653, DOI 10.1016/j.ibmb.2004.03.018
   Henry-Halldin CN, 2011, AM J TROP MED HYG, V84, P166, DOI 10.4269/ajtmh.2011.10-0438
   Hunt P, 2004, MOL BIOCHEM PARASIT, V136, P157, DOI 10.1016/j.molbiopara.2004.03.008
   Jeffares DC, 2007, NAT GENET, V39, P120, DOI 10.1038/ng1931
   Jiang HY, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-398
   Jiang HY, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r33
   Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573
   Karl S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020805
   Kazanidou A, 2009, AM J TROP MED HYG, V80, P236
   Khan SM, 2005, CELL, V121, P675, DOI 10.1016/j.cell.2005.03.027
   Kidgell Claire, 2006, PLoS Pathogens, V2, P562, DOI 10.1371/journal.ppat.0020057
   Kissinger JC, 2001, NUCLEIC ACIDS RES, V29, P66
   Kooij TWA, 2005, PLOS PATHOG, V1, P349, DOI 10.1371/journal.ppat.0010044
   Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111
   Lasonder E, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000195
   Laufer MK, 2006, NEW ENGL J MED, V355, P1959, DOI 10.1056/NEJMoa062032
   Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025
   Lemieux JE, 2009, P NATL ACAD SCI USA, V106, P7559, DOI 10.1073/pnas.0811829106
   Li J, 2011, P NATL ACAD SCI USA, V108, pE374, DOI 10.1073/pnas.1102261108
   Liu ZY, 2011, FUTURE MICROBIOL, V6, P1351, DOI [10.2217/fmb.11.108, 10.2217/FMB.11.108]
   Llinas M, 2008, TRENDS PARASITOL, V24, P551, DOI 10.1016/j.pt.2008.08.010
   Machado RLD, 2004, J INFECT DIS, V190, P1547, DOI 10.1086/424601
   Mackinnon MJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000644
   Maynard-Smith J, 1974, GENET RES, V23, P23, DOI 10.1017/S0016672300014634
   McNamara C, 2011, FUTURE MICROBIOL, V6, P693, DOI [10.2217/fmb.11.45, 10.2217/FMB.11.45]
   McNamara DT, 2006, AM J TROP MED HYG, V74, P413
   Melnikov A, 2011, GENOME BIOL, V12, DOI [10.1186/gb-2011-12-8-r73, 10.1186/gb-2011-12-8-R73]
   Menard D, 2010, P NATL ACAD SCI USA, V107, P5967, DOI 10.1073/pnas.0912496107
   Mu JB, 2005, PLOS BIOL, V3, P1734, DOI 10.1371/journal.pbio.0030335
   Mu JB, 2007, NAT GENET, V39, P126, DOI 10.1038/ng1924
   Mu JB, 2010, NAT GENET, V42, P268, DOI 10.1038/ng.528
   Nair S, 2003, MOL BIOL EVOL, V20, P1526, DOI 10.1093/molbev/msg162
   Nair S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000243
   Nam TG, 2011, ACS CHEM BIOL, V6, P1214, DOI 10.1021/cb200105d
   Neafsey DE, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r171
   Nkrumaha LJ, 2009, MOL BIOCHEM PARASIT, V165, P122, DOI 10.1016/j.molbiopara.2009.01.011
   Noedl H, 2008, NEW ENGL J MED, V359, P2619, DOI 10.1056/NEJMc0805011
   Nsobya SL, 2008, J INFECT DIS, V198, P1554, DOI 10.1086/592506
   Olszewski KL, 2010, NATURE, V466, P774, DOI 10.1038/nature09301
   Olszewski KL, 2009, CELL HOST MICROBE, V5, P191, DOI 10.1016/j.chom.2009.01.004
   Otto TD, 2010, MOL MICROBIOL, V76, P12, DOI 10.1111/j.1365-2958.2009.07026.x
   Pain A, 2008, NATURE, V455, P799, DOI 10.1038/nature07306
   Panichakul Tasanee, 2007, Int J Parasitol, V37, P1551, DOI 10.1016/j.ijpara.2007.05.009
   Patra KP, 2008, PROTEOMICS, V8, P2492, DOI 10.1002/pmic.200700727
   Pelleau S, 2011, ANTIMICROB AGENTS CH, V55, P5834, DOI 10.1128/AAC.00477-11
   PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114
   POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0
   Pumpaibool T, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-155
   Raabe CA, 2010, NUCLEIC ACIDS RES, V38, P608, DOI 10.1093/nar/gkp895
   Rao M., 2011, ACTA TROP
   Rosanas-Urgell A, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-361
   Rottmann M, 2010, SCIENCE, V329, P1175, DOI 10.1126/science.1193225
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Samarakoon U, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-457
   Sanchez CP, 2011, MOL MICROBIOL, V82, P865, DOI 10.1111/j.1365-2958.2011.07855.x
   Sinden RE, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-2-211
   Sinou V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-164
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8
   Su XZ, 2007, NAT REV GENET, V8, P497, DOI 10.1038/nrg2126
   Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351
   Tamez PA, 2009, BLOOD, V114, P3652, DOI 10.1182/blood-2009-07-231894
   Tan JC, 2009, GENOMICS, V93, P543, DOI 10.1016/j.ygeno.2009.02.007
   Tan XL, 2011, J INFECT DIS, V204, P1750, DOI 10.1093/infdis/jir638
   Teng RW, 2009, NMR BIOMED, V22, P292, DOI 10.1002/nbm.1323
   Thompson J, 2001, MOL BIOCHEM PARASIT, V118, P147, DOI 10.1016/S0166-6851(01)00377-2
   Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Triglia T, 1997, P NATL ACAD SCI USA, V94, P13944, DOI 10.1073/pnas.94.25.13944
   VAIDYA AB, 1995, MOL BIOCHEM PARASIT, V69, P65, DOI 10.1016/0166-6851(94)00199-W
   Van Tyne D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001383
   Volkman SK, 2007, NAT GENET, V39, P113, DOI 10.1038/ng1930
   WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382
   Westenberger SJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000653
   WILSON CM, 1993, MOL BIOCHEM PARASIT, V57, P151, DOI 10.1016/0166-6851(93)90252-S
   WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061
   Winzeler EA, 2008, NATURE, V455, P751, DOI 10.1038/nature07361
   Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813
   Wu T, 2011, J MED CHEM, V54, P5116, DOI 10.1021/jm2003359
   Wuchty S, 2009, PROTEOMICS, V9, P1841, DOI 10.1002/pmic.200800383
   Yeung BKS, 2010, J MED CHEM, V53, P5155, DOI 10.1021/jm100410f
   Yuan J, 2011, SCIENCE, V333, P724, DOI 10.1126/science.1205216
   [Anonymous], 2008, NATURE, V456, P732
NR 144
TC 14
Z9 14
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD MAR
PY 2012
VL 121
IS 3
SI SI
BP 324
EP 332
DI 10.1016/j.actatropica.2011.12.002
PG 9
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 924CN
UT WOS:000302668500021
PM 22182668
OA No
DA 2017-08-15
ER

PT J
AU Walther, M
   De Caul, A
   Aka, P
   Njie, M
   Amambua-Ngwa, A
   Walther, B
   Predazzi, IM
   Cunnington, A
   Deininger, S
   Takem, EN
   Ebonyi, A
   Weis, S
   Walton, R
   Rowland-Jones, S
   Sirugo, G
   Williams, SM
   Conway, DJ
AF Walther, Michael
   De Caul, Adam
   Aka, Peter
   Njie, Madi
   Amambua-Ngwa, Alfred
   Walther, Brigitte
   Predazzi, Irene M.
   Cunnington, Aubrey
   Deininger, Susanne
   Takem, Ebako N.
   Ebonyi, Augustine
   Weis, Sebastian
   Walton, Robert
   Rowland-Jones, Sarah
   Sirugo, Giorgio
   Williams, Scott M.
   Conway, David J.
TI HMOX1 Gene Promoter Alleles and High HO-1 Levels Are Associated with
   Severe Malaria in Gambian Children
SO PLOS PATHOGENS
LA English
DT Article
ID HEME OXYGENASE-1 GENE; PLASMODIUM-FALCIPARUM MALARIA; EXPERIMENTAL
   CEREBRAL MALARIA; RESPIRATORY-DISTRESS-SYNDROME; CRITICALLY-ILL
   PATIENTS; IRON CHELATION-THERAPY; MICROSATELLITE POLYMORPHISM;
   CARBON-MONOXIDE; OXIDATIVE STRESS; GLUCOSE-6-PHOSPHATE DEHYDROGENASE
AB Heme oxygenase 1 (HO-1) is an essential enzyme induced by heme and multiple stimuli associated with critical illness. In humans, polymorphisms in the HMOX1 gene promoter may influence the magnitude of HO-1 expression. In many diseases including murine malaria, HO-1 induction produces protective anti-inflammatory effects, but observations from patients suggest these may be limited to a narrow range of HO-1 induction, prompting us to investigate the role of HO-1 in malaria infection. In 307 Gambian children with either severe or uncomplicated P. falciparum malaria, we characterized the associations of HMOX1 promoter polymorphisms, HMOX1 mRNA inducibility, HO-1 protein levels in leucocytes (flow cytometry), and plasma (ELISA) with disease severity. The (GT)(n) repeat polymorphism in the HMOX1 promoter was associated with HMOX1 mRNA expression in white blood cells in vitro, and with severe disease and death, while high HO-1 levels were associated with severe disease. Neutrophils were the main HO-1-expressing cells in peripheral blood, and HMOX1 mRNA expression was upregulated by heme-moieties of lysed erythrocytes. We provide mechanistic evidence that induction of HMOX1 expression in neutrophils potentiates the respiratory burst, and propose this may be part of the causal pathway explaining the association between short (GT)(n) repeats and increased disease severity in malaria and other critical illnesses. Our findings suggest a genetic predisposition to higher levels of HO-1 is associated with severe illness, and enhances the neutrophil burst leading to oxidative damage of endothelial cells. These add important information to the discussion about possible therapeutic manipulation of HO-1 in critically ill patients.
C1 [Walther, Michael; De Caul, Adam; Aka, Peter; Njie, Madi; Amambua-Ngwa, Alfred; Walther, Brigitte; Cunnington, Aubrey; Deininger, Susanne; Takem, Ebako N.; Ebonyi, Augustine; Walton, Robert; Rowland-Jones, Sarah; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Walther, Michael] NIAID, NIH, Rockville, MD USA.
   [Predazzi, Irene M.; Williams, Scott M.] Vanderbilt Univ Sch Med, Div Human Genom, Nashville, TN USA.
   [Predazzi, Irene M.; Williams, Scott M.] Ctr Human Genet Res, Nashville, TN USA.
   [Cunnington, Aubrey; Conway, David J.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1, England.
   [Deininger, Susanne] Univ Clin Bonn, Inst Med Microbiol Immunol & Parasitol, Bonn, Germany.
   [Weis, Sebastian] Univ Leipzig, Dept Internal Med Neurol & Dermatol, Leipzig, Germany.
   [Walton, Robert] Queen Mary Univ, Barts & London Sch Med & Dent, Inst Hlth Sci Educ, London, England.
   [Rowland-Jones, Sarah] John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [Sirugo, Giorgio] Osped San Pietro FBF, Ctr Ric Sci, Ctr Genet, Rome, Italy.
RP Walther, M (reprint author), MRC Labs, Banjul, Gambia.
EM Michael.Walther@nih.gov
RI Williams, Scott/B-9491-2012; Weis, Sebastian/P-9016-2014
OI Weis, Sebastian/0000-0003-3201-2375; Cunnington,
   Aubrey/0000-0002-1305-3529; Walton, Robert/0000-0001-7700-1907; Conway,
   David/0000-0002-8711-3037
FU Medical Research Council (UK); NIH [2T32HL007751-16A2]
FX The work was funded by the Medical Research Council (UK). IMP was
   supported by NIH grant 2T32HL007751-16A2. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798
   Alam J, 2007, AM J RESP CELL MOL, V36, P166, DOI 10.1165/rcmb.2006-0340TR
   Alayash AI, 2004, NAT REV DRUG DISCOV, V3, P152, DOI 10.1038/nrd1307
   ALLISON AC, 1960, NATURE, V186, P531, DOI 10.1038/186531a0
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Bauer I, 2003, SHOCK, V20, P116, DOI 10.1097/01.shk.0000075568.93053.fa
   Bauer M, 2008, INTENS CARE MED, V34, P640, DOI 10.1007/s00134-008-1010-2
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   BEUTLER E, 1989, BLOOD, V74, P2550
   Bharucha AE, 2010, CLIN PHARMACOL THER, V87, P187, DOI 10.1038/clpt.2009.221
   BIENZLE U, 1972, LANCET, V1, P107
   Bilban M, 2008, J MOL MED, V86, P267, DOI 10.1007/s00109-007-0276-0
   Chen L, 2000, CLIN EXP IMMUNOL, V120, P125, DOI 10.1046/j.1365-2249.2000.01196.x
   Clark IA, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-41
   Clark TG, 2009, EUR J HUM GENET, V17, P1080, DOI 10.1038/ejhg.2009.8
   Cserti CM, 2007, BLOOD, V110, P2250, DOI 10.1182/blood-2007-03-077602
   Cunnington AJ, 2004, AM J TROP MED HYG, V71, P43
   daSilva JL, 1996, J LAB CLIN MED, V128, P290, DOI 10.1016/S0022-2143(96)90030-X
   De Araujo C, 2006, HAEMATOL-HEMATOL J, V91, P262
   Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937
   Dondorp AM, 2005, PLOS MED, V2, P788, DOI 10.1371/journal.pmed.0020204
   Epiphanio S, 2008, CELL HOST MICROBE, V3, P331, DOI 10.1016/j.chom.2008.04.003
   Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008
   Ferreira A, 2011, CELL, V145, P398, DOI 10.1016/j.cell.2011.03.049
   Fry AE, 2008, HUM MOL GENET, V17, P567, DOI 10.1093/hmg/ddm331
   Funke C, 2009, J NEURAL TRANSM, V116, P853, DOI 10.1007/s00702-009-0237-6
   Garcia-Santos D, 2010, MED HYPOTHESES, V74, P807, DOI 10.1016/j.mehy.2009.12.010
   GOLENSER J, 1992, FREE RADICAL RES COM, V17, P249, DOI 10.3109/10715769209079517
   GORDEUK V, 1992, NEW ENGL J MED, V327, P1473, DOI 10.1056/NEJM199211193272101
   GORDEUK VR, 1995, BLOOD, V85, P3297
   Greve B, 1999, J INFECT DIS, V179, P1584, DOI 10.1086/314780
   Griffiths MJ, 2005, J INFECT DIS, V191, P1599, DOI 10.1086/429297
   Guenegou A, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039743
   HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9
   Hirai H, 2003, BLOOD, V102, P1619, DOI 10.1182/blood-2002-12-3733
   Hunt NH, 2007, NAT MED, V13, P667, DOI 10.1038/nm0607-667
   HUNTER K, 1994, CELL MOL BIOL, V40, P507
   Hwang HW, 2009, J BIOL CHEM, V284, P22672, DOI 10.1074/jbc.M109.028001
   Joos C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009871
   KAPPAS A, 1988, PEDIATRICS, V81, P485
   KAPPAS A, 1986, J CLIN INVEST, V77, P335, DOI 10.1172/JCI112309
   Khan AA, 2011, BBA-MOL CELL RES, V1813, P668, DOI 10.1016/j.bbamcr.2011.01.008
   KHARAZMI A, 1984, CLIN EXP IMMUNOL, V57, P287
   KHARAZMI A, 1987, SCAND J IMMUNOL, V25, P335, DOI 10.1111/j.1365-3083.1987.tb02198.x
   Kikuchi A, 2005, HUM GENET, V116, P354, DOI 10.1007/s00439-004-1162-2
   Kimpara T, 1997, HUM GENET, V100, P145, DOI 10.1007/s004390050480
   Kitchin KT, 2001, J IMMUNOL METHODS, V247, P153, DOI 10.1016/S0022-1759(00)00325-2
   Kvam E, 2000, FREE RADICAL BIO MED, V28, P1191, DOI 10.1016/S0891-5849(00)00205-7
   Lamb NJ, 1999, BIOCHEM J, V344, P153, DOI 10.1042/0264-6021:3440153
   Lambert CA, 2010, AM J HUM GENET, V86, P34, DOI 10.1016/j.ajhg.2009.12.002
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240
   Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Melley DD, 2007, CRIT CARE MED, V35, P1882, DOI 10.1097/01.CCM.0000275268.94404.43
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   MITANI K, 1989, BIOCHEM BIOPH RES CO, V165, P437, DOI 10.1016/0006-291X(89)91089-9
   Mumby S, 2004, CRIT CARE MED, V32, P1130, DOI 10.1097/01.CCM.0000124869.86399.F2
   NNALUE NA, 1988, PARASITE IMMUNOL, V10, P47, DOI 10.1111/j.1365-3024.1988.tb00202.x
   Okinaga S, 1996, BLOOD, V87, P5074
   Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Pamplona A, 2009, INT J BIOCHEM CELL B, V41, P711, DOI 10.1016/j.biocel.2008.09.020
   Quinlan GJ, 2008, INTENS CARE MED, V34, P595, DOI 10.1007/s00134-008-1013-z
   Richardson MP, 1998, J IMMUNOL METHODS, V219, P187, DOI 10.1016/S0022-1759(98)00136-7
   Ross P, 1998, NAT BIOTECHNOL, V16, P1347, DOI 10.1038/4328
   ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605
   Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3
   Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   Sambo MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011141
   Saukkonen K, 2010, SHOCK, V34, P558, DOI 10.1097/SHK.0b013e3181e14de9
   SCHACTER BA, 1972, BIOCHIM BIOPHYS ACTA, V279, P221, DOI 10.1016/0304-4165(72)90259-0
   Schluesener HJ, 2001, ACTA NEUROPATHOL, V101, P65
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   SENALDI G, 1994, INFECT IMMUN, V62, P1144
   Sheu CC, 2009, INTENS CARE MED, V35, P1343, DOI 10.1007/s00134-009-1504-6
   Shibahara S, 2003, TOHOKU J EXP MED, V200, P167, DOI 10.1620/tjem.200.167
   SHIBAHARA S, 1989, EUR J BIOCHEM, V179, P557, DOI 10.1111/j.1432-1033.1989.tb14583.x
   SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889
   Suttner DM, 1999, FASEB J, V13, P1800
   Takaki S, 2010, INTENS CARE MED, V36, P42, DOI 10.1007/s00134-009-1575-4
   Takeda M, 2005, JPN J INFECT DIS, V58, P268
   TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748
   Thuma PE, 1998, T ROY SOC TROP MED H, V92, P214, DOI 10.1016/S0035-9203(98)90753-2
   Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573
   van der Woude FJ, 2004, J INVEST MED, V52, P323, DOI 10.1136/jim-52-05-32
   Volti GL, 2007, TRANSPL P, V39, P2986, DOI 10.1016/j.transproceed.2007.09.047
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x
   Weng YH, 2000, AM J PHYSIOL-LUNG C, V278, pL1273
   WHO, 2000, T R SOC TROP MED HYG, V94, pS1/1
   Williams TN, 2006, CURR OPIN MICROBIOL, V9, P388, DOI 10.1016/j.mib.2006.06.009
   Williams TN, 2005, J INFECT DIS, V192, P178, DOI 10.1086/430744
   Woollard KJ, 2009, J BIOL CHEM, V284, P13110, DOI 10.1074/jbc.M809095200
   Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165
   Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729
   Yasuda H, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.035824
   Yeo TW, 2007, J EXP MED, V204, P2693, DOI 10.1084/jem.20070819
   Yet SF, 1997, J BIOL CHEM, V272, P4295
NR 101
TC 36
Z9 38
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAR
PY 2012
VL 8
IS 3
AR e1002579
DI 10.1371/journal.ppat.1002579
PG 17
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 918CC
UT WOS:000302225600033
PM 22438807
OA gold
DA 2017-08-15
ER

PT J
AU Biering-Sorensen, S
   Aaby, P
   Napirna, BM
   Roth, A
   Ravn, H
   Rodrigues, A
   Whittle, H
   Benn, CS
AF Biering-Sorensen, Sofie
   Aaby, Peter
   Napirna, Bitiguida Mutna
   Roth, Adam
   Ravn, Henrik
   Rodrigues, Amabelia
   Whittle, Hilton
   Benn, Christine Stabell
TI SMALL RANDOMIZED TRIAL AMONG LOW-BIRTH-WEIGHT CHILDREN RECEIVING
   BACILLUS CALMETTE-GUERIN VACCINATION AT FIRST HEALTH CENTER CONTACT
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE BCG; infant mortality; neonatal mortality; nonspecific effects of
   vaccines
ID GUINEA-BISSAU
AB A total of 105 low-birth-weight children presenting for first vaccination were randomized to receive bacillus Calmette-Guerin (BCG) immediately or later (current practice). The mortality rate ratio for BCG was 0.17 (95% CI = 0.02-1.35) within 3 days of enrollment, 0.28 (0.06-1.37) in the first month, and 0.27 (0.07-0.98) after 2 months of age. The mortality rate ratio was 0.41 (0.14-1.18) (P = 0.098) in infancy. Administration of BCG vaccine at first contact may contribute to lower mortality.
C1 [Biering-Sorensen, Sofie; Aaby, Peter; Roth, Adam; Ravn, Henrik; Benn, Christine Stabell] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen S, Denmark.
   [Biering-Sorensen, Sofie; Aaby, Peter; Rodrigues, Amabelia; Benn, Christine Stabell] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Napirna, Bitiguida Mutna] Hosp Nacl Simao Mendes, Bissau, Guinea Bissau.
   [Roth, Adam] Lund Univ, Dept Med Microbiol, Malmo, Sweden.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Biering-Sorensen, S (reprint author), Statens Serum Inst, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM S.biering@bandim.org
FU EU [ICA4-CT-2002-10053]; March of Dimes; Danish National Research
   Foundation; European Research Council (ERC) [243149]; DANIDA; Novo
   Nordisk Foundation
FX The study was funded by the EU (ICA4-CT-2002-10053), the March of Dimes
   and the Danish National Research Foundation, and the European Research
   Council (ERC-2009-StG, grant agreement number 243149). The Bandim Health
   Project received support from DANIDA. P. A. holds a research
   professorship grant from the Novo Nordisk Foundation. Several of the
   authors are affiliated with the Statens Serum Institute (SSI) in
   Copenhagen, which administers their grants. SSI is a producer of BCG.
   However, SSI did not fund the vaccines, the study, or the researchers.
   The authors have no other funding or conflicts of interest to disclose.
CR Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Roth A, 2004, PEDIATR INFECT DIS J, V23, P544, DOI 10.1097/01.inf.0000129693.81082.a0
   Roth A, 2006, EXPERT REV VACCINES, V5, P277, DOI 10.1586/14760584-5.2.277
   Shann F, 2004, PEDIATR INFECT DIS J, V23, P555, DOI 10.1097/01.inf.0000130155.42392.04
NR 5
TC 73
Z9 73
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAR
PY 2012
VL 31
IS 3
BP 306
EP 308
DI 10.1097/INF.0b013e3182458289
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 898AH
UT WOS:000300706700021
PM 22189537
OA No
DA 2017-08-15
ER

PT J
AU Sabbah, S
   Jagne, YJ
   Zuo, JM
   de Silva, T
   Ahasan, MM
   Brander, C
   Rowland-Jones, S
   Flanagan, KL
   Hislop, AD
AF Sabbah, Shereen
   Jagne, Ya Jankey
   Zuo, Jianmin
   de Silva, Thushan
   Ahasan, Mohammad M.
   Brander, Christian
   Rowland-Jones, Sarah
   Flanagan, Katie L.
   Hislop, Andrew D.
TI T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of
   primary effusion lymphoma by LANA-specific CD4(+) T cells
SO BLOOD
LA English
DT Article
ID MULTICENTRIC CASTLEMANS-DISEASE; CLASS-II EXPRESSION; NUCLEAR-ANTIGEN;
   ANTIRETROVIRAL THERAPY; GENE-EXPRESSION; VIRAL PROTEIN; IN-VITRO; VIRUS;
   RESPONSES; HUMAN-HERPESVIRUS-8
AB T-cell immunity is important for controlling Kaposi sarcoma-associated herpesvirus (KSHV) diseases such as the endothelial cell malignancy Kaposi sarcoma, or the B-cell malignancy, primary effusion lymphoma (PEL). However, little is known about KSHV-specific T-cell immunity in healthy donors and immune control of disease. Using PBMCs from healthy KSHV-infected donors, we found weak ex vivo responses to the KSHV latent antigens LANA, vFLIP, vCyclin, and Kaposin, with LANA most frequently recognized. CD4(+) T-cell clones specific to LANA, a protein expressed in all KSHV-infected cells and malignancies, were established to determine whether they could recognize LANA-expressing cells. B-cell targets expressing or fed LANAprotein were consistently recognized by the clones; however, most PEL cell lines were not. PELs express the KSHV protein vIRF3 that inhibits promoter function of the HLA class II transactivator, decreasing expression of genes controlled by this transactivator. Re-expressing the class II transactivator in the PELs increased expression of downstream targets such as HLA class II and restored recognition but not killing by the LANA-specific clones. We suggest that PELs are poorly controlled in vivo because of inefficient recognition and killing by T cells. (Blood. 2012; 119(9): 2083-2092)
C1 [Sabbah, Shereen; Zuo, Jianmin; Ahasan, Mohammad M.; Hislop, Andrew D.] Univ Birmingham, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.
   [Sabbah, Shereen; Zuo, Jianmin; Ahasan, Mohammad M.; Hislop, Andrew D.] Univ Birmingham, MRC, Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England.
   [Jagne, Ya Jankey; de Silva, Thushan; Rowland-Jones, Sarah; Flanagan, Katie L.] MRC Labs, Fajara, Gambia.
   [Brander, Christian] Univ Autonoma Barcelona, IrsiCaixa AIDS Res Inst HIVACAT, Inst Catalana Recerca & Estudis Avancats, Dept Med, E-08193 Barcelona, Spain.
RP Hislop, AD (reprint author), Univ Birmingham, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.
EM a.d.hislop@bham.ac.uk
OI Brander, Christian/0000-0002-0548-5778
FU Medical Research Council United Kingdom [G0501074]; ICREA
FX A.D.H. and this work are funded by a New Investigator Award from the
   Medical Research Council United Kingdom (G0501074).
CR Adang LA, 2007, J VIROL, V81, P5079, DOI 10.1128/JVI.02738-06
   Amodio E, 2011, CANCER SCI, V102, P1769, DOI 10.1111/j.1349-7006.2011.02032.x
   Barozzi P, 2008, TRANSPLANTATION, V86, P738, DOI 10.1097/TP.0b013e318184112c
   Bihl F, 2007, AIDS, V21, P1245, DOI 10.1097/QAD.0b013e328182df03
   Bihl F, 2007, J VIROL, V81, P4904, DOI 10.1128/JVI.02509-06
   Blake N, 2000, J IMMUNOL, V165, P7078
   Bornkamm GW, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni137
   Boshoff C, 2001, EUR J CANCER, V37, P1202, DOI 10.1016/S0959-8049(01)00114-9
   Bourboulia D, 2004, AIDS, V18, P485, DOI 10.1097/01.aids.0000111409.02002.b8
   Bouvard V, 2009, LANCET ONCOL, V10, P321
   Brander C, 2000, J IMMUNOL, V165, P2077
   Chaux P, 1999, J EXP MED, V189, P767, DOI 10.1084/jem.189.5.767
   Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404
   Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025
   Draenert R, 2003, J IMMUNOL METHODS, V275, P19, DOI 10.1016/S0022-1759(02)00541-0
   Duman S, 2002, NEPHROL DIAL TRANSPL, V17, P892, DOI 10.1093/ndt/17.5.892
   Fogg MH, 2009, P NATL ACAD SCI USA, V106, P3318, DOI 10.1073/pnas.0813320106
   Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925
   Gudgeon NH, 2005, J VIROL, V79, P5477, DOI 10.1128/JVI.79.9.5477-5488.2005
   Guihot A, 2008, BLOOD, V111, P1387, DOI 10.1182/blood-2007-03-080648
   Guihot A, 2006, J INFECT DIS, V194, P1078, DOI 10.1086/507648
   Hislop AD, 2010, BLOOD, V116, P3249, DOI 10.1182/blood-2009-09-238832
   Kwun HJ, 2007, J VIROL, V81, P8225, DOI 10.1128/JVI.00411-07
   Lalvani A, 1997, J IMMUNOL METHODS, V210, P65, DOI 10.1016/S0022-1759(97)00177-4
   Lambert M, 2006, BLOOD, V108, P3871, DOI 10.1182/blood-2006-03-014225
   Ledergerber B, 1999, BRIT MED J, V319, P23
   Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980
   Lepone L, 2010, CLIN VACCINE IMMUNOL, V17, P1507, DOI 10.1128/CVI.00189-10
   Li D, 2009, J IMMUNOL, V182, P1799, DOI 10.4049/jimmunol.0802686
   Mackay LK, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000699
   Miller DM, 1998, J EXP MED, V187, P675, DOI 10.1084/jem.187.5.675
   Myoung J, 2011, J CLIN INVEST, V121, P1130, DOI 10.1172/JCI43755
   Njie R, 2009, J INFECT DIS, V199, P31, DOI 10.1086/594373
   Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904
   Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1
   Powles T, 2009, ANN ONCOL, V20, P775, DOI 10.1093/annonc/mdn697
   Pozharskaya VP, 2004, J GEN VIROL, V85, P2779, DOI 10.1099/vir.0.80214-0
   Pudney VA, 2005, J EXP MED, V201, P349, DOI 10.1084/jem.20041542
   Reith W, 2005, NAT REV IMMUNOL, V5, P793, DOI 10.1038/nri1708
   Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001
   Schmidt K, 2011, J VIROL, V85, P4530, DOI 10.1128/JVI.02123-10
   Shore AM, 2006, J VIROL, V80, P11191, DOI 10.1128/JVI.00983-06
   Suscovich TJ, 2004, LEUKEMIA LYMPHOMA, V45, P1223, DOI 10.1080/10428190310001643358
   Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895
   Wies E, 2008, BLOOD, V111, P320, DOI 10.1182/blood-2007-05-092288
   Wies E, 2009, J BIOL CHEM, V284, P8525, DOI 10.1074/jbc.M809252200
   Woodberry T, 2005, J INFECT DIS, V192, P622, DOI 10.1086/432103
   Yin Y, 2003, SCIENCE, V301, P1371, DOI 10.1126/science.1088902
   Zaldumbide A, 2007, MOL IMMUNOL, V44, P1352, DOI 10.1016/j.molimm.2006.05.012
NR 49
TC 17
Z9 17
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAR 1
PY 2012
VL 119
IS 9
BP 2083
EP 2092
DI 10.1182/blood-2011-07-366476
PG 10
WC Hematology
SC Hematology
GA 901GA
UT WOS:000300949500018
PM 22234686
OA No
DA 2017-08-15
ER

PT J
AU Thye, T
   Owusu-Dabo, E
   Vannberg, FO
   van Crevel, R
   Curtis, J
   Sahiratmadja, E
   Balabanova, Y
   Ehmen, C
   Muntau, B
   Ruge, G
   Sievertsen, J
   Gyapong, J
   Nikolayevskyy, V
   Hill, PC
   Sirugo, G
   Drobniewski, F
   van de Vosse, E
   Newport, M
   Alisjahbana, B
   Nejentsev, S
   Ottenhoff, THM
   Hill, AVS
   Horstmann, RD
   Meyer, CG
AF Thye, Thorsten
   Owusu-Dabo, Ellis
   Vannberg, Fredrik O.
   van Crevel, Reinout
   Curtis, James
   Sahiratmadja, Edhyana
   Balabanova, Yanina
   Ehmen, Christa
   Muntau, Birgit
   Ruge, Gerd
   Sievertsen, Juergen
   Gyapong, John
   Nikolayevskyy, Vladyslav
   Hill, Philip C.
   Sirugo, Giorgio
   Drobniewski, Francis
   van de Vosse, Esther
   Newport, Melanie
   Alisjahbana, Bachti
   Nejentsev, Sergey
   Ottenhoff, Tom H. M.
   Hill, Adrian V. S.
   Horstmann, Rolf D.
   Meyer, Christian G.
TI Common variants at 11p13 are associated with susceptibility to
   tuberculosis
SO NATURE GENETICS
LA English
DT Article
ID HUMAN GENETIC SUSCEPTIBILITY
AB After imputation of data from the 1000 Genomes Project into a genome-wide dataset of Ghanaian individuals with tuberculosis and controls, we identified a resistance locus on chromosome 11p13 downstream of the WT1 gene (encoding Wilms tumor 1). The strongest signal was obtained at the rs2057178 SNP (P = 2.63 x 10(-9)). Replication in Gambian, Indonesian and Russian tuberculosis case-control study cohorts increased the significance level for the association with this SNP to P = 2.57 x 10(-11).
C1 [Thye, Thorsten; Ehmen, Christa; Muntau, Birgit; Ruge, Gerd; Sievertsen, Juergen; Horstmann, Rolf D.; Meyer, Christian G.] Bernhard Nocht Inst Trop Med, Dept Mol Med, Hamburg, Germany.
   [Thye, Thorsten] Univ Hosp Schleswig Holstein, Inst Med Biometry & Stat, Lubeck, Germany.
   [Owusu-Dabo, Ellis] Kumasi Ctr Collaborat Res Trop Med, Kumasi, Ghana.
   [Owusu-Dabo, Ellis] Kwame Nkrumah Univ Sci & Technol, Coll Hlth Sci, Dept Community Hlth, Kumasi, Ghana.
   [Vannberg, Fredrik O.; Hill, Adrian V. S.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [van Crevel, Reinout] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands.
   [Curtis, James; Nejentsev, Sergey] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England.
   [Sahiratmadja, Edhyana] Padjadjaran State Univ, Fac Med, Hlth Res Unit, Bandung, Indonesia.
   [Balabanova, Yanina; Nikolayevskyy, Vladyslav; Drobniewski, Francis] Univ London, Barts & London Sch Med & Dent, Natl Mycobacterium Reference Lab, Clin TB & HIV Grp,Blizard Inst, London, England.
   [Balabanova, Yanina] Samara Oblast TB Dispensary, Samara, Samara, Russia.
   [Gyapong, John] Univ Ghana, Coll Hlth Sci, Sch Publ Hlth, Legon, Ghana.
   [Hill, Philip C.; Sirugo, Giorgio; Newport, Melanie] Med Res Council MRC Labs, Banjul, Gambia.
   [Sirugo, Giorgio] Osped San Pietro FBF, Ctr Ric, Rome, Italy.
   [van de Vosse, Esther; Ottenhoff, Tom H. M.] Leiden Univ Med Ctr, Dept Infect Dis, Leiden, Netherlands.
   [Newport, Melanie] Brighton & Sussex Med Sch, Brighton, E Sussex, England.
   [Alisjahbana, Bachti] Padjadjaran State Univ, Fac Med, Dept Internal Med, Div Trop & Infect Dis, Bandung, Indonesia.
RP Meyer, CG (reprint author), Bernhard Nocht Inst Trop Med, Dept Mol Med, Hamburg, Germany.
EM c.g.meyer@bnitm.de
RI van Crevel, reinout/A-6636-2010; van de Vosse, Esther/B-7285-2009
OI van de Vosse, Esther/0000-0001-5199-3426; Nikolayevskyy,
   Vladyslav/0000-0002-9502-0332
FU German Federal Ministry of Education and Research (BMBF); TB or not TB
   Project; German National Genome Research Network [NGFN1, 01GS0162,
   NGFN2, NIE-S17T20, NGFN-PLUS, 01GS0811]; European Union [201483]; BMBF
   Tuberculosis Research Network [01KI0780]; Gambian MRC Unit; MRC
   [G0000690]; Wellcome Trust [088838/Z/ 09/Z]; Royal Netherlands Academy
   of Arts and Sciences (KNAW) [KNAW99MED01]; Netherlands Organization for
   Scientific Research-Netherlands Foundation for the Advancement of
   Tropical Research (NWO-WOTRO); European Commission
   [QLK2-CT-2003-503367]; Royal Society [RG090638]; European Research
   Council (ERC) [260477]
FX Ghana. The participation of affected individuals and the volunteers who
   served as controls is gratefully acknowledged, as are the contributions
   of field workers, nurses and physicians involved in the recruitment of
   participants, the staff of the Kumasi Centre for Collaborative Research
   in Tropical Medicine (KCCR) and the excellent assistance of E.
   Abbeyquaye and L. Gankpala. The study protocol was approved by the
   Committee on Human Research, Publications and Ethics, School of Medical
   Sciences, Kwame Nkrumah University of Science and Technology, and the
   Ethics Committee of the Ghana Health Service. Consent was obtained from
   the enrolled individuals or from their parents or guardians by signature
   or by thumbprint in case of illiteracy. This work was supported by the
   German Federal Ministry of Education and Research (BMBF), the TB or not
   TB Project, the German National Genome Research Network (NGFN1,
   01GS0162; NGFN2, NIE-S17T20; and NGFN-PLUS, 01GS0811), the European
   Union Framework Programme 7 (201483; TB-EUROGEN) and the BMBF
   Tuberculosis Research Network (01KI0780).; The Gambia. We thank other
   members of the Wellcome Trust Case Control Consortium and collaborators
   for previous work on the Gambian sample sets. All samples were obtained
   with informed consent. Ethical approval for the study was granted by the
   Gambian MRC and the Gambian government joint ethical committee. Sample
   collection was supported by the Gambian MRC Unit funding, European
   Commission framework Programme awards, an MRC award (G0000690 to G. S.)
   and Wellcome Trust fellowship support (to A. V. S. H.). Laboratory work
   in Oxford was supported by the Wellcome Trust.; Indonesia. Written
   informed consent was obtained from all subjects, and the study was
   approved by the ethical committees of the Eijkman Institute of Molecular
   Biology and the Faculty of Medicine, Padjadjaran University, Hasan
   Sadikin Hospital. We gratefully acknowledge S. Marzuki, R. H. H. Nelwan
   and J. W. M. van der Meer for their continued support of the study. This
   study was supported by the Royal Netherlands Academy of Arts and
   Sciences (KNAW; KNAW99MED01), the Netherlands Organization for
   Scientific Research-Netherlands Foundation for the Advancement of
   Tropical Research (NWO-WOTRO) (Poverty Related Infection Oriented
   Research (PRIOR)-project) and the European Commission
   (QLK2-CT-2003-503367).; Russia. The participation of affected
   individuals and volunteer, control individuals is gratefully
   acknowledged. The study was approved by the Human Biology Research
   Ethics Committees of the University of Cambridge and Queen Mary College,
   and the local ethics committees in St. Petersburg and Samara, Russia.
   All participants provided written informed consent before being enrolled
   in the study. We thank O. Ignatyeva, I. Kontsevaya, S. Mironova, I.
   Fedorin and N. Malomanova for the recruitment of subjects and controls,
   as well as E. Stebbings, L. Kopanitsa and A. Speirs for DNA preparation.
   During the course of this study, S. N. was a Royal Society University
   Research Fellow and now holds the Wellcome Trust Senior Research
   Fellowship in Basic Biomedical Science. This study was supported by
   grants from the European Union Framework Programme 7 (201483;
   TB-EUROGEN), the Royal Society (RG090638), the Wellcome Trust (088838/Z/
   09/Z) and the European Research Council (ERC; starting grant 260477).
CR Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Huang L, 2009, AM J HUM GENET, V84, P235, DOI 10.1016/j.ajhg.2009.01.013
   Huff V, 2011, NAT REV CANCER, V11, P111, DOI 10.1038/nrc3002
   Intemann CD, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000577
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Maurer U, 2001, J BIOL CHEM, V276, P3727, DOI 10.1074/jbc.M005292200
   Moller M, 2010, TUBERCULOSIS, V90, P71, DOI 10.1016/j.tube.2010.02.002
   Ottenhoff THM, 2005, TUBERCULOSIS, V85, P53, DOI 10.1016/j.tube.2004.09.011
   Sciesielski LK, 2010, FEBS LETT, V584, P4665, DOI 10.1016/j.febslet.2010.10.045
   Thye T, 2010, NAT GENET, V42, P739, DOI 10.1038/ng.639
   Vannberg FO, 2011, IMMUNOL REV, V240, P105, DOI 10.1111/j.1600-065X.2010.00996.x
NR 11
TC 71
Z9 74
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD MAR
PY 2012
VL 44
IS 3
BP 257
EP 259
DI 10.1038/ng.1080
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA 899VC
UT WOS:000300843600009
PM 22306650
OA No
DA 2017-08-15
ER

PT J
AU Dionisio, KL
   Howie, SRC
   Dominici, F
   Fornace, KM
   Spengler, JD
   Donkor, S
   Chimah, O
   Oluwalana, C
   Ideh, RC
   Ebruke, B
   Adegbola, RA
   Ezzati, M
AF Dionisio, Kathie L.
   Howie, Stephen R. C.
   Dominici, Francesca
   Fornace, Kimberly M.
   Spengler, John D.
   Donkor, Simon
   Chimah, Osaretin
   Oluwalana, Claire
   Ideh, Readon C.
   Ebruke, Bernard
   Adegbola, Richard A.
   Ezzati, Majid
TI The exposure of infants and children to carbon monoxide from biomass
   fuels in The Gambia: a measurement and modeling study
SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY
LA English
DT Article
DE indoor air pollution; biomass fuels; global health; Africa; carbon
   monoxide; exposure assessment
ID INDOOR AIR-POLLUTION; RESPIRATORY-INFECTIONS; DEVELOPING-COUNTRIES;
   PARTICULATE MATTER; RISK-FACTORS; WEST-AFRICA; COMBUSTION; MORTALITY;
   HOUSEHOLDS; GUATEMALA
AB Smoke from biomass fuels is a risk factor for pneumonia, the leading cause of child death worldwide. Although particulate matter (PM) is the metric of choice for studying the health effects of biomass smoke, measuring children's PM exposure is difficult. Carbon monoxide (CO), which is easier to measure, can be used as a proxy for PM exposure. We measured the exposure of children <= 5 years of age in The Gambia to CO using small, passive, color stain diffusion tubes. We conducted multiple CO measurements on a subset of children to measure day-to-day exposure variability. Usual CO exposure was modeled using a mixed effects model, which also included individual and household level exposure predictors. Mean measured CO exposure for 1181 children (n = 2263 measurements) was 1.04 +/- 1.46 p.p.m., indicating that the Gambian children in this study on average have a relatively low CO exposure. However, 25% of children had exposures of 1.3 p.p.m. or higher. CO exposure was higher during the rainy months (1.33 +/- 1.62 p.p.m.). Burning insect coils, using charcoal, and measurement done in the rainy season were associated with higher exposure. A parsimonious model with fuel, season, and other PM sources as covariates explained 39% of between-child variation in exposure and helped remove within-child variability. Journal of Exposure Science and Environmental Epidemiology (2012) 22, 173-181; doi:10.1038/jes.2011.47; published online 14 December 2011
C1 [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, MRC HPA Ctr Environm & Hlth, Dept Epidemiol & Biostat, London W2 1PG, England.
   [Dionisio, Kathie L.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
   [Dionisio, Kathie L.; Spengler, John D.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
   [Howie, Stephen R. C.; Donkor, Simon; Chimah, Osaretin; Oluwalana, Claire; Ideh, Readon C.; Ebruke, Bernard; Adegbola, Richard A.] MRC, Gambia Unit, Fajara, Gambia.
   [Dominici, Francesca] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Fornace, Kimberly M.] Univ London Royal Vet Coll, Vet Epidemiol & Publ Hlth Grp, London, England.
   [Adegbola, Richard A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London W2 1PG, England.
RP Ezzati, M (reprint author), Univ London Imperial Coll Sci Technol & Med, MRC HPA Ctr Environm & Hlth, Dept Epidemiol & Biostat, Norfolk Pl, London W2 1PG, England.
EM majid.ezzati@imperial.ac.uk
OI Fornace, Kimberly/0000-0002-5484-241X
FU National Institute of Environmental Health Sciences [1R21ES017855-01]
FX This work was supported by a grant from the National Institute of
   Environmental Health Sciences (1R21ES017855-01). We thank the households
   who participated in the study for their help and hospitality, our field
   workers and field supervisors for valuable assistance in data
   collection, the Biomedical Engineering Department at the MRC for
   technical assistance throughout the study, Jose Vallarino for
   information on methods and instruments for personal exposure
   measurement, and Mariel Finucane for advice on presentation of
   statistical results. We also thank Grant Mackenzie for Operational
   support, Kim Mulholland, Philip Hill, Brian Greenwood, and Peter Smith
   for advice on case-control study design, and Nigel Bruce and Kirk Smith
   for advice on exposure measurement.
CR ARMSTRONG JRM, 1991, INT J EPIDEMIOL, V20, P424, DOI 10.1093/ije/20.2.424
   Balakrishnan K, 2002, ENVIRON HEALTH PERSP, V110, P1069
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Bruce N, 2004, J EXPO ANAL ENV EPID, V14, pS26, DOI 10.1038/sj.jea.7500355
   Dasgupta S, 2006, HEALTH POLICY PLANN, V21, P444, DOI 10.1093/heapol/czl027
   DEFRANCISCO A, 1993, INT J EPIDEMIOL, V22, P1174, DOI 10.1093/ije/22.6.1174
   Dherani M, 2008, B WORLD HEALTH ORGAN, V86, P390, DOI 10.2471/BLT.07.044529
   Dionisio KL, 2008, INDOOR AIR, V18, P317, DOI 10.1111/j.1600-0668.2008.00533.x
   Ezzati M, 2000, ENVIRON HEALTH PERSP, V108, P833, DOI 10.2307/3434990
   Ezzati M, 2001, LANCET, V358, P619, DOI 10.1016/S0140-6736(01)05777-4
   Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292
   Gelman A., 2007, DATA ANAL USING REGR
   Honaker J, AMELIA 2 PROGRAM MIS
   Honaker J, 2010, AM J POLIT SCI, V54, P561
   King G, 2001, AM POLIT SCI REV, V95, P49
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   McCracken JP, 2009, EPIDEMIOLOGY, V20, P127, DOI 10.1097/EDE.0b013e31818ef327
   Mestl HES, 2007, SCI TOTAL ENVIRON, V377, P12, DOI 10.1016/j.scitotenv.2007.01.087
   Naeher LP, 2001, ENVIRON SCI TECHNOL, V35, P575, DOI 10.1021/es991225g
   Northcross A, 2010, J ENVIRON MONITOR, V12, P873, DOI 10.1039/b916068j
   ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885
   SELWYN BJ, 1990, REV INFECT DIS, V12, pS870
   Smith K.R., 2004, COMP QUANTIFICATION, P1435
   Wagstaff A, 2000, B WORLD HEALTH ORGAN, V78, P19
   Xu RH, 2003, STAT MED, V22, P3527, DOI 10.1002/sim.1572
NR 26
TC 11
Z9 11
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1559-0631
J9 J EXPO SCI ENV EPID
JI J. Expo. Sci. Environ. Epidemiol.
PD MAR-APR
PY 2012
VL 22
IS 2
BP 173
EP 181
DI 10.1038/jes.2011.47
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 894WV
UT WOS:000300459100007
PM 22166810
OA No
DA 2017-08-15
ER

PT J
AU Oura, CAL
   Ivens, PAS
   Bachanek-Bankowska, K
   Bin-Tarif, A
   Jallow, DB
   Sailleau, C
   Maan, S
   Mertens, PC
   Batten, CA
AF Oura, C. A. L.
   Ivens, P. A. S.
   Bachanek-Bankowska, K.
   Bin-Tarif, A.
   Jallow, D. B.
   Sailleau, C.
   Maan, S.
   Mertens, P. C.
   Batten, C. A.
TI African horse sickness in The Gambia: circulation of a live-attenuated
   vaccine-derived strain
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Animal pathogens; asymptomatic viral infections; immunization
   (vaccination); veterinary epidemiology; veterinary virology
ID RT-PCR; VIRUS; CULICOIDES; IDENTIFICATION
AB African horse sickness virus serotype 9 (AHSV-9) has been known for some time to be circulating amongst equids in West Africa without causing any clinical disease in indigenous horse populations. Whether this is due to local breeds of horses being resistant to disease or whether the AHSV-9 strains circulating are avirulent is currently unknown. This study shows that the majority (96%) of horses and donkeys sampled across The Gambia were seropositive for AHS, despite most being unvaccinated and having no previous history of showing clinical signs of AHS. Most young horses (<3 years) were seropositive with neutralizing antibodies specific to AHSV-9. Eight young equids (<3 years) were positive for AHSV-9 by serotype-specific RT-PCR and live AHSV-9 was isolated from two of these horses. Sequence analysis revealed the presence of an AHSV-9 strain showing 100% identity to Seg-2 of the AHSV-9 reference strain, indicating that the virus circulating in The Gambia was highly likely to have been derived from a live-attenuated AHSV-9 vaccine strain.
C1 [Oura, C. A. L.; Bachanek-Bankowska, K.; Bin-Tarif, A.; Maan, S.; Mertens, P. C.; Batten, C. A.] Inst Anim Hlth, Woking GU24 0NF, Surrey, England.
   [Ivens, P. A. S.] Buckingham Equine Med Referrals, Overton Fields, Buckingham, Bucks, England.
   [Jallow, D. B.] Gambia Livestock Mkt Agcy, Abuko, Gambia.
RP Oura, CAL (reprint author), Inst Anim Hlth, Ash Rd, Woking GU24 0NF, Surrey, England.
EM chris.oura@bbsrc.ac.uk
RI Institute, Pirbright/K-4476-2014
OI Mertens, Peter/0000-0002-3438-3738
FU BEVA Trust
FX We thank the Department of Veterinary Services, The Gambia, and in
   particular Mr Borrie Jabang, Laboratory Technician at the Central
   Veterinary Laboratory, Abuko. We thank the entire local staff of The
   Gambia Horse and Donkey Trust, Sambel Kunda, and animal owners for
   providing their animals for sampling. We also thank the BEVA Trust for
   funding the field work in The Gambia.
CR Bourdin P., 1978, Equine infectious diseases IV,, P405
   Fernandez-Pinero J, 2009, RES VET SCI, V86, P353, DOI 10.1016/j.rvsc.2008.07.015
   Howell P., 1963, FAO AGR STUD, V61, P71
   KEMP GE, 1971, VET REC, V89, P127
   KEMP GE, 1974, VET REC, V95, P345
   MATTIOLI RC, 1992, TROP ANIM HEALTH PRO, V24, P207, DOI 10.1007/BF02356746
   MELLOR PS, 1993, BRIT VET J, V149, P5
   Diaz Montilla R, 1968, B OFF INT EPIZOOT, V70, P647
   Paweska JT, 2003, MED VET ENTOMOL, V17, P436, DOI 10.1111/j.1365-2915.2003.00467.x
   Rawlings P, 1998, MED VET ENTOMOL, V12, P155
   Sailleau C, 2000, J GEN VIROL, V81, P831
   Sailleau C, 2000, VET REC, V146, P107
   Sarr J, 1988, Rev Elev Med Vet Pays Trop, V41, P243
   Shah KV, 1963, B NATL I SCI INDIA, V24, P194
   STAEUBER N, 1993, J CLIN MICROBIOL, V31, P2241
   Venter GJ, 2007, MED VET ENTOMOL, V21, P377
NR 16
TC 5
Z9 5
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD MAR
PY 2012
VL 140
IS 3
BP 462
EP 465
DI 10.1017/S095026881100080X
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 886UB
UT WOS:000299878300011
PM 21733265
OA No
DA 2017-08-15
ER

PT J
AU Edwards, DRV
   Tacconelli, A
   Wejse, C
   Hill, PC
   Morris, GAJ
   Edwards, TL
   Gilbert, JR
   Myers, JL
   Park, YS
   Stryjewski, ME
   Abbate, E
   Estevan, R
   Rabna, P
   Novelli, G
   Hamilton, CD
   Adegbola, R
   Ostergaard, L
   Williams, SM
   Scott, WK
   Sirugo, G
AF Edwards, Digna R. Velez
   Tacconelli, Alessandra
   Wejse, Christian
   Hill, Philip C.
   Morris, Gerard A. J.
   Edwards, Todd L.
   Gilbert, John R.
   Myers, Jamie L.
   Park, Yo Son
   Stryjewski, Martin E.
   Abbate, Eduardo
   Estevan, Rosa
   Rabna, Paulo
   Novelli, Giuseppe
   Hamilton, Carol D.
   Adegbola, Richard
   Ostergaard, Lars
   Williams, Scott M.
   Scott, William K.
   Sirugo, Giorgio
TI MCP1 SNPs and Pulmonary Tuberculosis in Cohorts from West Africa, the
   USA and Argentina: Lack of Association or Epistasis with IL12B
   Polymorphisms
SO PLOS ONE
LA English
DT Article
ID HUMAN GENETIC SUSCEPTIBILITY; MYCOBACTERIUM-TUBERCULOSIS; PROMOTER
   POLYMORPHISM; RISK-FACTORS; GENOTYPE; PROTECTION; AMERICANS; GAMBIA;
   GENOME; FAMILY
AB The monocyte chemotactic protein-1 (MCP-1) is a chemokine that plays an important role in the recruitment of monocytes to M. tuberculosis infection sites, and previous studies have reported that genetic variants in MCP1 are associated with differential susceptibility to pulmonary tuberculosis (PTB). We examined eight MCP1 single nucleotide polymorphisms (SNPs) in a multi-ethnic, case-control design that included: 321 cases and 346 controls from Guinea-Bissau, 258 cases and 271 controls from The Gambia, 295 cases and 179 controls from the U. S. (African-Americans), and an additional set of 237 cases and 144 controls of European ancestry from the U. S. and Argentina. Two locus interactions were also examined for polymorphisms in MCP1 and interleukin 12B (IL12B), another gene implicated in PTB risk. Examination of previously associated MCP1 SNPs rs1024611 (-2581A/G), rs2857656 (-362G/C) and rs4586 (+900C/T) did not show evidence for association. One interaction between rs2857656 and IL12B SNP rs2288831 was observed among Africans but the effect was in the opposite direction in Guineans (OR = 1.90, p = 0.001) and Gambians (OR = 0.64, p = 0.024). Our data indicate that the effect of genetic variation within MCP1 is not clear cut and additional studies will be needed to elucidate its role in TB susceptibility.
C1 [Edwards, Digna R. Velez; Edwards, Todd L.; Gilbert, John R.; Myers, Jamie L.; Park, Yo Son; Scott, William K.] Univ Miami, Dr John T Macdonald Fdn Dept Human Genet, Miami, FL 33152 USA.
   [Edwards, Digna R. Velez; Edwards, Todd L.; Gilbert, John R.; Myers, Jamie L.; Park, Yo Son; Scott, William K.] Univ Miami, Miami Inst Human Genom, Miami, FL USA.
   [Edwards, Digna R. Velez; Williams, Scott M.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA.
   [Edwards, Digna R. Velez] Vanderbilt Univ, Med Ctr, Vanderbilt Epidemiol Ctr, Inst Med & Publ Hlth, Nashville, TN USA.
   [Edwards, Digna R. Velez] Vanderbilt Univ, Med Ctr, Dept Obstet & Gynecol, Nashville, TN 37232 USA.
   [Tacconelli, Alessandra; Novelli, Giuseppe; Sirugo, Giorgio] Osped San Pietro FBF, Ctr Ric Sci, Ctr Genet, Rome, Italy.
   [Wejse, Christian; Rabna, Paulo] Danish Epidemiol Sci Ctr, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Wejse, Christian; Rabna, Paulo] Statens Serum Inst, Bissau, Guinea Bissau.
   [Wejse, Christian; Ostergaard, Lars] Aarhus Univ, Dept Infect Dis, Skejby, Denmark.
   [Wejse, Christian] Aarhus Univ, Sch Publ Hlth, Ctr Global Hlth, Skejby, Denmark.
   [Hill, Philip C.; Morris, Gerard A. J.; Adegbola, Richard; Sirugo, Giorgio] MRC Labs, Fajara, Gambia.
   [Hill, Philip C.] Univ Otago, Sch Med, Ctr Int Hlth, Dunedin, New Zealand.
   [Edwards, Todd L.] Vanderbilt Univ, Sch Med, Vanderbilt Epidemiol Ctr, Dept Med,Div Epidemiol, Nashville, TN 37212 USA.
   [Stryjewski, Martin E.] Ctr Educ Med & Invest Clin Norberto Quirno CEMIC, Dept Med, Div Infect Dis, Buenos Aires, DF, Argentina.
   [Abbate, Eduardo; Estevan, Rosa] Hosp FJ Muniz, Dept Med, Buenos Aires, DF, Argentina.
   [Novelli, Giuseppe] Univ Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, Rome, Italy.
   [Hamilton, Carol D.] Family Hlth Int 360, Res Triangle Pk, NC USA.
   [Hamilton, Carol D.] Duke Univ, Med Ctr, Durham, NC USA.
   [Adegbola, Richard] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Edwards, DRV (reprint author), Univ Miami, Dr John T Macdonald Fdn Dept Human Genet, Miami, FL 33152 USA.
EM BScott@med.miami.edu; sirugo.giorgio@fbfrm.it
RI Williams, Scott/B-9491-2012; Velez Edwards, Digna/C-1090-2012; Wejse,
   Christian/C-8468-2014
OI Wejse, Christian/0000-0002-2534-2942; Novelli,
   Giuseppe/0000-0002-7781-602X
FU Medical Research Council UK (MRC) [G0000690]; MRC (UK) The Gambia Unit;
   Danish Medical Research Council; Danish Society of Respiratory Medicine;
   Danish Council of Development Research; United States National
   Institutes of Health [R01 HL68534]
FX This study was supported by the Medical Research Council UK (MRC) award
   G0000690 to GS; MRC (UK) The Gambia Unit core-funding to PCH and RA;
   grants from the Danish Medical Research Council, the Danish Society of
   Respiratory Medicine, the Danish Council of Development Research to CW
   and LO, and by the United States National Institutes of Health grant R01
   HL68534 to WKS. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   Arji N, 2012, J INFECT DEV COUNTR, V6, P73
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Ben-Selma W, 2011, MOL BIOL REP, V38, P5413, DOI 10.1007/s11033-011-0695-4
   Berrington WR, 2007, IMMUNOL REV, V219, P167, DOI 10.1111/j.1600-065X.2007.00545.x
   Blackwell JM, 1997, PHILOS T ROY SOC B, V352, P1331
   Buijtels PCAM, 2008, INT J TUBERC LUNG D, V12, P1485
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   Feng WX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014652
   Feng WX, 2011, INT J TUBERC LUNG DI
   Flores-Villanueva PO, 2005, J EXP MED, V202, P1649, DOI 10.1084/jem20050216
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Ganachari M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008881
   Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026
   Hancock DB, 2007, GENET EPIDEMIOL, V31, P883, DOI 10.1002/gepi.20249
   Hasan Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008459
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Intemann CD, 2011, BMC GENET, V12, DOI 10.1186/1471-2156-12-34
   Jensen LE, 2006, AM J MED GENET A, V140A, P1114, DOI 10.1002/ajmg.a.31212
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Modi WS, 2003, AIDS, V17, P2357, DOI 10.1097/01.aids.0000076359.20434.44
   Moller M, 2010, FEMS IMMUNOL MED MIC, V58, P3, DOI 10.1111/j.1574-695X.2009.00600.x
   Morris GAJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016656
   Olesen R, 2007, GENES IMMUN, V8, P456, DOI 10.1038/sj.gene.6364410
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Saunders BM, 2007, IMMUNOL CELL BIOL, V85, P103, DOI 10.1038/sj.icb.7100027
   Sirugo G, 2004, NAT GENET, V36, P785, DOI 10.1038/ng0804-785
   Sirugo G, 2008, HUM GENET, V123, P557, DOI 10.1007/s00439-008-0511-y
   Stein CM, 2010, MAMM GENOME, V22, P91
   Szalai C, 2001, ATHEROSCLEROSIS, V158, P233, DOI 10.1016/S0021-9150(01)00423-3
   Thye T, 2009, HUM MOL GENET, V18, P381, DOI 10.1093/hmg/ddn352
   Tishkoff SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/science.1172257
   Vannberg FO, 2011, IMMUNOL REV, V240, P105, DOI 10.1111/j.1600-065X.2010.00996.x
   Velez DR, 2009, INT J TUBERC LUNG D, V13, P1068
   WHO, 2010, GLOB TUB CONTR
NR 37
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2012
VL 7
IS 2
AR e32275
DI 10.1371/journal.pone.0032275
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 927OV
UT WOS:000302918500072
OA gold
DA 2017-08-15
ER

PT J
AU Rickard, IJ
   Prentice, AM
   Fulford, AJC
   Lummaa, V
AF Rickard, Ian J.
   Prentice, Andrew M.
   Fulford, Anthony J. C.
   Lummaa, Virpi
TI Twinning propensity and offspring in utero growth covary in rural
   African women
SO BIOLOGY LETTERS
LA English
DT Article
DE twins; twinning; birthweight; insulin-like growth factor I; insulin-like
   growth factor; life history
ID FETAL-GROWTH
AB In humans and other mammals, some females are more likely to experience twin pregnancies than others, but the reasons behind such individual variation are poorly understood. One hypothesis invokes variation in the dynamics of the insulin-like growth factor (IGF) system, which also regulates foetal growth. Using data from a rural African population living in a highly seasonal environment, we test a novel prediction generated by this hypothesis, that maternal twinning status predicts offspring birthweight. We found that among singleton offspring who experience a favourable in utero environment (born January-June), births before and after twins are, respectively, associated with a 134.07 g and 226.41 g increase in birthweight compared with those born to non-twinning mothers. These results were not mediated by maternal anthropometry. This is consistent with a role for the IGF system in individual variation in twinning propensity, a possibility with implications for understanding mechanisms of life-history variation in humans and other vertebrates.
C1 [Rickard, Ian J.; Lummaa, Virpi] Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.
   [Prentice, Andrew M.; Fulford, Anthony J. C.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Prentice, Andrew M.; Fulford, Anthony J. C.] MRC Labs, MRC Keneba, Banjul, Gambia.
RP Rickard, IJ (reprint author), Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.
EM i.rickard@sheffield.ac.uk
FU UK Medical Research Council; Wellcome Trust; MRC; ERC; Royal Society
FX Collection of the data used in this study was made possible by the
   efforts of many doctors, nurses, midwives and fieldworkers and funded by
   the UK Medical Research Council. Individual funding is by the Wellcome
   Trust (I.J.R.), MRC (A. M. P., A.J.C.F.), ERC (I.J.R., V. L.) and the
   Royal Society (V. L.). We thank the residents of West Kiang for their
   participation and support and two anonymous reviewers for their
   constructive suggestions.
CR Baker J, 1996, MOL ENDOCRINOL, V10, P903, DOI 10.1210/me.10.7.903
   Echternkamp SE, 2000, J ANIM SCI, V77, P1
   HARVEY PH, 1985, EVOLUTION, V39, P559, DOI 10.1111/j.1558-5646.1985.tb00395.x
   Hoekstra C, 2008, HUM REPROD UPDATE, V14, P37, DOI 10.1093/humupd/dmm036
   Khong TY, 2003, PLACENTA, V24, P348, DOI 10.1053/plac.2002.0922
   KROONSBERG C, 1989, J REPROD FERTIL, V87, P349
   Lackey BR, 2000, THERIOGENOLOGY, V53, P1147, DOI 10.1016/S0093-691X(00)00259-4
   Longo VD, 2002, CELL MOL LIFE SCI, V59, P903, DOI 10.1007/s00018-002-8477-8
   Murphy VE, 2006, ENDOCR REV, V27, P141, DOI 10.1210/er.2005-0011
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Sanchez-Luengo S, 2005, FERTIL STERIL, V83, P1064, DOI 10.1016/j.fertnstert.2004.12.003
   Sear R, 2001, J EVOLUTION BIOL, V14, P433, DOI 10.1046/j.1420-9101.2001.00287.x
   Silva JRV, 2009, THERIOGENOLOGY, V71, P1193, DOI 10.1016/j.theriogenology.2008.12.015
   Steinman Gary, 2009, J Reprod Med, V54, P609
   Yilmaz A, 2004, J ANIM SCI, V82, P2285
NR 15
TC 0
Z9 0
U1 0
U2 3
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1744-9561
J9 BIOL LETTERS
JI Biol. Lett.
PD FEB 23
PY 2012
VL 8
IS 1
BP 67
EP 70
DI 10.1098/rsbl.2011.0598
PG 4
WC Biology; Ecology; Evolutionary Biology
SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences &
   Ecology; Evolutionary Biology
GA 879IF
UT WOS:000299322200021
PM 21831878
OA No
DA 2017-08-15
ER

PT J
AU Akinsola, AK
   Ota, MOC
   Enwere, GC
   Okoko, BJ
   Zaman, SMA
   Saaka, M
   Nsekpong, ED
   Odutola, AA
   Greenwood, BM
   Cutts, FT
   Adegbola, RA
AF Akinsola, Adebayo K.
   Ota, Martin O. C.
   Enwere, Godwin C.
   Okoko, Brown J.
   Zaman, Syed M. A.
   Saaka, Mark
   Nsekpong, Ekpedeme D.
   Odutola, Aderonke A.
   Greenwood, Brian M.
   Cutts, Felicity T.
   Adegbola, Richard A.
TI Pneumococcal Antibody Concentrations and Carriage of Pneumococci more
   than 3 Years after Infant Immunization with a Pneumococcal Conjugate
   Vaccine
SO PLOS ONE
LA English
DT Article
ID INFLUENZAE TYPE-B; STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE;
   GAMBIAN INFANTS; INVASIVE-DISEASE; CHILDREN; IMMUNOGENICITY; SEROTYPE;
   TRIAL; EFFICACY
AB Background: A 9-valent pneumococcal conjugate vaccine (PCV-9), given in a 3-dose schedule, protected Gambian children against pneumococcal disease and reduced nasopharyngeal carriage of pneumococci of vaccine serotypes. We have studied the effect of a booster or delayed primary dose of 7-valent conjugate vaccine (PCV-7) on antibody and nasopharyngeal carriage of pneumococci 3-4 years after primary vaccination.
   Methodology/Principal Findings: We recruited a subsample of children who had received 3 doses of either PCV-9 or placebo (controls) into this follow-up study. Pre- and post-PCV-7 pneumococcal antibody concentrations to the 9 serotypes in PCV-9 and nasopharyngeal carriage of pneumococci were determined before and at intervals up to 18 months post-PCV7. We enrolled 282 children at a median age of 45 months (range, 38-52 months); 138 had received 3 doses of PCV-9 in infancy and 144 were controls. Before receiving PCV-7, a high proportion of children had antibody concentrations > 0.35 mu g/mL to most of the serotypes in PCV-9 (average of 75% in the PCV-9 and 66% in the control group respectively). The geometric mean antibody concentrations in the vaccinated group were significantly higher compared to controls for serotypes 6B, 14, and 23F. Antibody concentrations were significantly increased to serotypes in the PCV-7 vaccine both 6-8 weeks and 16-18 months after PCV-7. Antibodies to serotypes 6B, 9V and 23F were higher in the PCV-9 group than in the control group 6-8 weeks after PCV-7, but only the 6B difference was sustained at 16-18 months. There was no significant difference in nasopharyngeal carriage between the two groups.
   Conclusions/Significance: Pneumococcal antibody concentrations in Gambian children were high 34-48 months after a 3-dose primary infant vaccination series of PCV-9 for serotypes other than serotypes 1 and 18C, and were significantly higher than in control children for 3 of the 9 serotypes. Antibody concentrations increased after PCV-7 and remained raised for at least 18 months.
C1 [Akinsola, Adebayo K.; Ota, Martin O. C.; Enwere, Godwin C.; Okoko, Brown J.; Zaman, Syed M. A.; Saaka, Mark; Nsekpong, Ekpedeme D.; Odutola, Aderonke A.; Adegbola, Richard A.] MRC, Gambia Unit, Banjul, Gambia.
   [Greenwood, Brian M.; Cutts, Felicity T.] London Sch Hyg & Trop Med, London WC1, England.
RP Akinsola, AK (reprint author), MRC, Gambia Unit, Banjul, Gambia.
EM radegbola@hotmail.com
FU UK Medical Research Council
FX The study was funded by the UK Medical Research Council. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   Centers for Disease Control and Prevention, 2010, MMWR-MORBID MORTAL W, V59, P1
   Cheung YB, 2009, PEDIATR INFECT DIS J, V28, P990, DOI 10.1097/INF.0b013e3181a78185
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 2005, J INFECT DIS, V192, P367, DOI 10.1086/431679
   Goetghebuer T, 2000, TROP MED INT HEALTH, V5, P207, DOI 10.1046/j.1365-3156.2000.00535.x
   Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524
   Heath PT, 2002, ARCH DIS CHILD, V86, P396, DOI 10.1136/adc.86.6.396
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Madhi SA, 2007, VACCINE, V25, P2451, DOI 10.1016/j.vaccine.2006.09.019
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   Miernyk KM, 2000, CLIN INFECT DIS, V31, P34, DOI 10.1086/313907
   Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   Ota MO, 2011, VACCINE, V29, P2999, DOI 10.1016/j.vaccine.2011.01.098
   Palmer A, 1999, J TROP PEDIATRICS, V45, P51, DOI 10.1093/tropej/45.1.51
   Russel FM, 2010, CLIN VACCINE IMMUNOL, V12, P1970
   Saaka M, 2008, VACCINE, V26, P3719, DOI 10.1016/j.vaccine.2008.04.066
   Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119
   Trotter CL, 2008, VACCINE, V26, P4434, DOI 10.1016/j.vaccine.2008.05.073
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   Weinberger DM, 2008, J INFECT DIS, V197, P1511, DOI 10.1086/587941
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   World Health Organization, 2007, WKLY EPIDEMIOL REC, V82, P93
NR 32
TC 5
Z9 5
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2012
VL 7
IS 2
AR e31050
DI 10.1371/journal.pone.0031050
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 926YY
UT WOS:000302871500025
PM 22363544
OA gold
DA 2017-08-15
ER

PT J
AU Jayasooriya, S
   Hislop, A
   Peng, YC
   Croom-carter, D
   Jankey, Y
   Bell, A
   Dong, T
   Rowland-Jones, S
   Rickinson, A
   Walther, M
   Whittle, H
AF Jayasooriya, Shamanthi
   Hislop, Andrew
   Peng, Yanchun
   Croom-carter, Debbie
   Jankey, Ya
   Bell, Andrew
   Dong, Tao
   Rowland-Jones, Sarah
   Rickinson, Alan
   Walther, Michael
   Whittle, Hilton
TI Revisiting the Effect of Acute P. falciparum Malaria on Epstein-Barr
   Virus: Host Balance in the Setting of Reduced Malaria Endemicity
SO PLOS ONE
LA English
DT Article
ID T-CELL IMMUNITY; B-CELL; BURKITTS-LYMPHOMA; GAMBIAN CHILDREN; AFRICAN
   CHILDREN; IN-VIVO; DIFFERENTIATION; REACTIVATION; PARASITEMIA;
   PREVALENCE
AB Burkitt's lymphoma (BL), an EBV-associated tumour, occurs at high incidence in populations where malaria is holoendemic. Previous studies in one such population suggested that acute P. falciparum infection impairs EBV-specific T-cell surveillance, allowing expansion of EBV infected B-cells from which BL derives. We re-examined the situation in the same area, The Gambia, after a reduction in malaria endemicity. Cellular immune responses to EBV were measured in children with uncomplicated malaria before (day 0) and after treatment (day 28), comparing EBV genome loads in blood and EBV-specific CD8(+) T-cell numbers (assayed by MHC Class I tetramers and IFN gamma ELISPOTS) with those seen in age-and sex-matched healthy controls. No significant changes were seen in EBV genome loads, percentage of EBV-specific CD8(+) T-cells and IFN gamma producing T-cells in acute versus convalescent samples, nor any difference versus controls. Regression assays performed also no longer detected any impairment of EBV-specific T-cell surveillance. Acute uncomplicated malaria infection no longer alters EBV-specific immune responses in children in The Gambia. Given the recent decline in malaria incidence in that country, we hypothesise that gross disturbance of the EBV-host balance may be a specific effect of acute malaria only in children with a history of chronic/recurrent malaria challenge.
C1 [Jayasooriya, Shamanthi; Jankey, Ya; Walther, Michael; Whittle, Hilton] MRC Labs, Fajara, Gambia.
   [Jayasooriya, Shamanthi; Hislop, Andrew; Croom-carter, Debbie; Bell, Andrew; Rickinson, Alan] Univ Birmingham, Sch Canc Studies, Birmingham, W Midlands, England.
   [Peng, Yanchun; Dong, Tao; Rowland-Jones, Sarah] Univ Oxford, Weatherall Inst Mol Med, Oxford, England.
   [Walther, Michael] NIAID, Lab Malaria Immunol & Vaccinol, NIH, Rockville, MD USA.
   [Whittle, Hilton] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
RP Jayasooriya, S (reprint author), MRC Labs, Fajara, Gambia.
EM hcwhittle@yahoo.co.uk
OI Bell, Andrew/0000-0001-9520-4417
FU Medical Research Council (MRC), Gambia; MRC
FX This work was funded by the Medical Research Council (MRC), Gambia and
   Dr S Jayasooriya was a recipient of an MRC studentship. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2
   Bunce M., 1995, TISSUE ANTIGENS, V46, P355
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Corran PH, 2004, INFECT IMMUN, V72, P6185, DOI 10.1128/IAI.72.10.6185-6189.2004
   Donati D, 2006, J INFECT DIS, V193, P971, DOI 10.1086/500839
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Gudgeon NH, 2005, J VIROL, V79, P5477, DOI 10.1128/JVI.79.9.5477-5488.2005
   Junying Jia, 2003, Virology, V306, P236, DOI 10.1016/S0042-6822(02)00027-2
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   LISSE IM, 1994, T ROY SOC TROP MED H, V88, P709, DOI 10.1016/0035-9203(94)90242-9
   Mackenzie G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010568
   Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07
   Miyashita EM, 1997, J VIROL, V71, P4882
   Moormann AM, 2005, J INFECT DIS, V191, P1233, DOI 10.1086/428910
   Moormann AM, 2007, J INFECT DIS, V195, P799, DOI 10.1086/511984
   MOSS DJ, 1983, INT J CANCER, V31, P727, DOI 10.1002/ijc.2910310609
   Njie R, 2009, J INFECT DIS, V199, P31, DOI 10.1086/594373
   Nogaro SI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025582
   Obaro S, 2011, LANCET, V378, P1281, DOI 10.1016/S0140-6736(11)61146-X
   Rasti N, 2005, SCAND J IMMUNOL, V61, P461, DOI 10.1111/j.1365-3083.2005.01589.x
   Rezk SA, 2007, HUM PATHOL, V38, P1293, DOI 10.1016/j.humpath.2007.05.020
   Rickinson A, 2002, VIRUS RES, V82, P109
   Rochford R, 2005, NAT REV MICROBIOL, V3, P182, DOI 10.1038/nrmicro1089
   Satoguina J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-274
   Sauce D, 2007, AIDS, V21, P2005
   Shah KM, 2009, CLIN MICROBIOL INFEC, V15, P982, DOI 10.1111/j.1469-0691.2009.03033.x
   Shannon-Lowe CD, 2006, P NATL ACAD SCI USA, V103, P7065, DOI 10.1073/pnas.0510512103
   Snow RW, 2010, LANCET, V376, P137, DOI 10.1016/S0140-6736(10)60577-6
   Speck SH, 1997, TRENDS MICROBIOL, V5, P399, DOI 10.1016/S0966-842X(97)01129-3
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   WHITTLE HC, 1984, NATURE, V312, P449, DOI 10.1038/312449a0
   WHITTLE HC, 1990, CLIN EXP IMMUNOL, V80, P213
   Yone CLRP, 2006, T ROY SOC TROP MED H, V100, P669, DOI 10.1016/j.trstmh.2005.08.009
NR 36
TC 3
Z9 3
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 8
PY 2012
VL 7
IS 2
AR e31142
DI 10.1371/journal.pone.0031142
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 924ZP
UT WOS:000302730100046
PM 22347443
OA gold
DA 2017-08-15
ER

PT J
AU Borlon, C
   Russell, B
   Sriprawat, K
   Suwanarusk, R
   Erhart, A
   Renia, L
   Nosten, F
   D'Alessandro, U
AF Borlon, Celine
   Russell, Bruce
   Sriprawat, Kanlaya
   Suwanarusk, Rossarin
   Erhart, Annette
   Renia, Laurent
   Nosten, Francois
   D'Alessandro, Umberto
TI Cryopreserved Plasmodium vivax and cord blood reticulocytes can be used
   for invasion and short term culture
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE Malaria; Plasmodium vivax; Reticulocyte; Cord blood; Invasion;
   Cryopreservation
ID FETAL-HEMOGLOBIN; FALCIPARUM; MALARIA; CELLS; INVITRO; CHLOROQUINE;
   PROTEIN; GROWTH
AB The establishment of a Plasmodium vivax in vitro culture system is critical for the development of new vaccine, drugs and diagnostic tests. Although short-term cultures have been successfully set up, their reproducibility in laboratories without direct access to P. vivax-infected patients has been limited by the need for fresh parasite isolates. We explored the possibility of using parasite isolates and reticulocytes, both cryopreserved, to perform invasion and initiate short-term culture. Invasion results obtained with both cryopreserved isolates and reticulocytes were similar to those obtained with fresh samples. This method should be easily replicated in laboratories outside endemic areas and will substantially contribute to the development of a continuous P. vivax culture. In addition, this model could be used for testing vaccine candidates as well as for studying invasion-specific molecular mechanisms. (C) 2012 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Borlon, Celine; Erhart, Annette; D'Alessandro, Umberto] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium.
   [Russell, Bruce; Suwanarusk, Rossarin; Renia, Laurent] Biopolis, Lab Malaria Immunobiol, Singapore Immunol Network, Agcy Sci Technol & Res, Singapore, Singapore.
   [Sriprawat, Kanlaya; Nosten, Francois] Shoklo Malaria Res Unit, Mae Sot, Thailand.
   [Nosten, Francois] Mahidol Univ, Mahidol Oxford Res Unit, Fac Trop Med, Bangkok 10700, Thailand.
   [Nosten, Francois] Univ Oxford, Ctr Trop Med, Nuffield Dept Clin Med, Oxford OX3 7LJ, England.
   [D'Alessandro, Umberto] MRC, Fajara, Gambia.
RP Borlon, C (reprint author), Inst Trop Med, Dept Parasitol, 155 Natl Str, B-2000 Antwerp, Belgium.
EM cborlon@itg.be
RI Suwanarusk, Rossarin/E-2115-2013; D'Alessandro, Umberto/D-3457-2015;
   Russell, Bruce/A-9240-2011
OI Suwanarusk, Rossarin/0000-0002-7310-245X; D'Alessandro,
   Umberto/0000-0001-6341-5009; Russell, Bruce/0000-0003-2333-4348; Nosten,
   Francois/0000-0002-7951-0745
FU Wellcome Trust of Great Britain, as part of the Wellcome Trust-Mahidol
   University; Institute of Tropical Medicine (ITM), Antwerp (Belgium);
   Agency for Science Technology and Research (A*STAR) (Singapore);
   Wellcome Trust (UK)
FX We would like to thank all patients who agreed to donate their blood
   within the framework of the present study. In addition, we would like to
   thank all Shoklo Malaria Research Unit (Mae Sot, Thailand) staff for
   their valuable contributions in the completion of this study. SMRU is
   sponsored by The Wellcome Trust of Great Britain, as part of the Oxford
   Tropical Medicine Research Programme of the Wellcome Trust-Mahidol
   University. This study was funded by the Secondary Research Funding
   (SOFI-B) project from the Institute of Tropical Medicine (ITM), Antwerp
   (Belgium), and additional funds were provided by the Agency for Science
   Technology and Research (A*STAR) (Singapore) and The Wellcome Trust
   (UK).
CR Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011
   Blomqvist K., 2008, METHODS MALARIA RES, P15
   CHRISTOFINIS GJ, 1983, ANN TROP MED PARASIT, V77, P123
   DIGGS C, 1975, AM J TROP MED HYG, V24, P760
   Golenda CF, 1997, P NATL ACAD SCI USA, V94, P6786, DOI 10.1073/pnas.94.13.6786
   Grimberg BT, 2007, PLOS MED, V4, P1940, DOI 10.1371/journal.pmed.0040337
   Kitchen S, 1938, AM J TROP MED HYG  S, V1, P347
   Kosaisavee V, 2006, EXP PARASITOL, V114, P34, DOI 10.1016/j.exppara.2006.02.006
   Kwiatkowski DP, 2005, AM J HUM GENET, V77, P171, DOI 10.1086/432519
   LANNERS HN, 1992, PARASITOL RES, V78, P699, DOI 10.1007/BF00931524
   Lopez C, 2010, GENE, V467, P1, DOI 10.1016/j.gene.2010.07.008
   Mackinnon MJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000644
   MATHAI E, 1989, T ROY SOC TROP MED H, V83, P469, DOI 10.1016/0035-9203(89)90249-6
   MAZUR P, 1970, SCIENCE, V168, P939, DOI 10.1126/science.168.3934.939
   MONS B, 1988, EXP PARASITOL, V66, P183, DOI 10.1016/0014-4894(88)90089-6
   Panichakul Tasanee, 2007, Int J Parasitol, V37, P1551, DOI 10.1016/j.ijpara.2007.05.009
   PASVOL G, 1977, NATURE, V270, P171, DOI 10.1038/270171a0
   PASVOL G, 1976, LANCET, V1, P1269
   ROSSAN RN, 1985, AM J TROP MED HYG, V34, P207
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   Scott KL, 2005, TRANSFUS MED REV, V19, P127, DOI 10.1016/j.tmrv.2004.11.004
   Sharrock WW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-94
   Skadberg Oyvind, 2003, Lab Hematol, V9, P198
   Sriprawat K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-115
   Stewart VA, 2003, TRENDS PARASITOL, V19, P589, DOI 10.1016/j.pt.2003.10.008
   Thomas M J, 1995, Methods Mol Biol, V38, P235
   Udomsangpetch R, 2007, PARASITOL INT, V56, P65, DOI 10.1016/j.parint.2006.12.005
   WILSON RJM, 1977, B WORLD HEALTH ORGAN, V55, P179
NR 28
TC 19
Z9 19
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-7519
J9 INT J PARASITOL
JI Int. J. Parasit.
PD FEB
PY 2012
VL 42
IS 2
BP 155
EP 160
DI 10.1016/j.ijpara.2011.10.011
PG 6
WC Parasitology
SC Parasitology
GA 912SL
UT WOS:000301820000003
PM 22240310
OA No
DA 2017-08-15
ER

PT J
AU Bentley, SD
   Comas, I
   Bryant, JM
   Walker, D
   Smith, NH
   Harris, SR
   Thurston, S
   Gagneux, S
   Wood, J
   Antonio, M
   Quail, MA
   Gehre, F
   Adegbola, RA
   Parkhill, J
   de Jong, BC
AF Bentley, Stephen D.
   Comas, Inaki
   Bryant, Josephine M.
   Walker, Danielle
   Smith, Noel H.
   Harris, Simon R.
   Thurston, Scott
   Gagneux, Sebastien
   Wood, Jonathan
   Antonio, Martin
   Quail, Michael A.
   Gehre, Florian
   Adegbola, Richard A.
   Parkhill, Julian
   de Jong, Bouke C.
TI The Genome of Mycobacterium Africanum West African 2 Reveals a
   Lineage-Specific Locus and Genome Erosion Common to the M. tuberculosis
   Complex
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID EFFLUX PUMP; PULMONARY TUBERCULOSIS; CODING SEQUENCES; TUBERCLE-BACILLI;
   DRUG-RESISTANCE; BACTERIAL GENES; GUINEA-BISSAU; BOVIS BCG; VIRULENCE;
   EVOLUTION
AB Background: M. africanum West African 2 constitutes an ancient lineage of the M. tuberculosis complex that commonly causes human tuberculosis in West Africa and has an attenuated phenotype relative to M. tuberculosis.
   Methodology/Principal Findings: In search of candidate genes underlying these differences, the genome of M. africanum West African 2 was sequenced using classical capillary sequencing techniques. Our findings reveal a unique sequence, RD900, that was independently lost during the evolution of two important lineages within the complex: the "modern" M. tuberculosis group and the lineage leading to M. bovis. Closely related to M. bovis and other animal strains within the M. tuberculosis complex, M. africanum West African 2 shares an abundance of pseudogenes with M. bovis but also with M. africanum West African clade 1. Comparison with other strains of the M. tuberculosis complex revealed pseudogenes events in all the known lineages pointing toward ongoing genome erosion likely due to increased genetic drift and relaxed selection linked to serial transmission-bottlenecks and an intracellular lifestyle.
   Conclusions/Significance: The genomic differences identified between M. africanum West African 2 and the other strains of the Mycobacterium tuberculosis complex may explain its attenuated phenotype, and pave the way for targeted experiments to elucidate the phenotypic characteristic of M. africanum. Moreover, availability of the whole genome data allows for verification of conservation of targets used for the next generation of diagnostics and vaccines, in order to ensure similar efficacy in West Africa.
C1 [Bentley, Stephen D.; Bryant, Josephine M.; Walker, Danielle; Harris, Simon R.; Thurston, Scott; Wood, Jonathan; Quail, Michael A.; Parkhill, Julian] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
   [Comas, Inaki] Ctr Publ Hlth Res, Genom & Hlth Unit, Valencia, Spain.
   [Comas, Inaki] Natl Inst Med Res, MRC, Div Mycobacterial Res, London NW7 1AA, England.
   [Smith, Noel H.] VLA, TB Res Grp, Addlestone, Surrey, England.
   [Smith, Noel H.] Univ Sussex, Ctr Study Evolut, Brighton, E Sussex, England.
   [Gagneux, Sebastien] Swiss Trop & Publ Hlth Inst, Dept Med Parasitol & Infect Biol, Basel, Switzerland.
   [Gagneux, Sebastien] Univ Basel, Basel, Switzerland.
   [Antonio, Martin; Gehre, Florian; Adegbola, Richard A.; de Jong, Bouke C.] MRC Unit, Banjul, Gambia.
   [Gehre, Florian; de Jong, Bouke C.] Inst Trop Med, B-2000 Antwerp, Belgium.
   [de Jong, Bouke C.] NYU, New York, NY USA.
RP Bentley, SD (reprint author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton, Cambs, England.
EM bdejong@itg.be
RI Parkhill, Julian/G-4703-2011; Smith, Noel/C-6708-2011; Harris,
   Simon/K-1318-2013; APHA, Staff publications/E-6082-2010; de Jong,
   Bouke/A-3636-2013; Comas, Inaki/F-1185-2011
OI Parkhill, Julian/0000-0002-7069-5958; Harris, Simon/0000-0003-1512-6194;
   de Jong, Bouke/0000-0002-1017-4675; Comas, Inaki/0000-0001-5504-9408;
   Bryant, Josephine/0000-0002-0149-5768
FU Wellcome Trust through the Sanger Institute core budget
FX The genome sequencing of M. africanum strain GM041182 was funded by the
   Wellcome Trust through the Sanger Institute core budget. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Affolabi D, 2009, INT J TUBERC LUNG D, V13, P317
   Agarwal N, 2009, NATURE, V460, P98, DOI 10.1038/nature08123
   Alexander KA, 2010, EMERG INFECT DIS, V16, P1296, DOI 10.3201/eid1608.100314
   Balganesh M, ANTIMICROB AGENTS CH, V54, P5167
   Berriman Matt, 2003, Briefings in Bioinformatics, V4, P124, DOI 10.1093/bib/4.2.124
   BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1
   Bold TD, J INFECT DI IN PRESS
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299
   Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553
   Castets M, 1968, Rev Tuberc Pneumol (Paris), V32, P179
   Chain PSG, 2009, SCIENCE, V326, P236, DOI 10.1126/science.1180614
   Colangeli R, 2005, MOL MICROBIOL, V55, P1829, DOI 10.1111/j.1365-2958.2005.04510.x
   Comas I, 2010, NAT GENET, V42, P498, DOI 10.1038/ng.590
   Comas I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007815
   Coscolla Mireilla, 2010, Drug Discov Today Dis Mech, V7, pe43, DOI 10.1016/j.ddmec.2010.09.004
   Cubillos-Ruiz A, 2008, MC RES NOTES, V1, P110
   Dasgupta A, PLOS ONE, V5
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   de Jong BC, 2005, AIDS, V19, P1714, DOI 10.1097/01.aids.0000185991.54595.41
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   de Jong BC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000744
   de Jong BC, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-11
   De Smet KAL, 2000, MICROBIOL-UK, V146, P199
   Delcher AL, 2007, BIOINFORMATICS, V23, P673, DOI 10.1093/bioinformatics/btm009
   Deshayes C, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-78
   Desmond E, 2004, EMERG INFECT DIS, V10, P921
   Diop S, 1976, Bull Soc Med Afr Noire Lang Fr, V21, P50
   Domenech P, 2005, INFECT IMMUN, V73, P3492, DOI 10.1128/IAI.73.6.3492-3501.2005
   Durnez L, 2010, APPL ENVIRON MICROB, V76, P4574, DOI 10.1128/AEM.00199-10
   Fang Z, 1999, J BACTERIOL, V181, P1014
   Frothingham R, 1999, J CLIN MICROBIOL, V37, P1921
   Gao LY, 2004, MOL MICROBIOL, V53, P1677, DOI 10.1111/j.1365-2958.2004.04261.x
   Gioffre A, 2005, MICROBES INFECT, V7, P325, DOI 10.1016/j.micinf.2004.11.007
   Goossens B, 1998, VET REC, V142, P277
   Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x
   Hershberg R, 2008, PLOS BIOL, V6, P2658, DOI 10.1371/journal.pbio.0060311
   Honaker RW, 2008, INFECT IMMUN, V76, P2587, DOI 10.1128/IAI.01235-07
   Huard RC, 2006, J BACTERIOL, V188, P4271, DOI 10.1128/JB.01783-05
   Intemann CD, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000577
   Joshi SM, 2006, P NATL ACAD SCI USA, V103, P11760, DOI 10.1073/pnas.0603179103
   Kallenius G, 1999, J CLIN MICROBIOL, V37, P3872
   Kalscheuer R, 2010, P NATL ACAD SCI US
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   Karboul A, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-107
   Koivula T, 2004, MICROBES INFECT, V6, P272, DOI 10.1016/j.micinf.2003.12.006
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108
   Li XZ, 2004, ANTIMICROB AGENTS CH, V48, P2415, DOI 10.1128/AAC.48.7.2415-2423.2004
   Maurelli AT, 2007, FEMS MICROBIOL LETT, V267, P1, DOI 10.1111/j.1574-6968.2006.00526.x
   McLean KJ, 2008, J BIOL CHEM, V283, P33406, DOI 10.1074/jbc.M802115200
   Meyer CG, 2008, TUBERCULOSIS, V88, P482, DOI 10.1016/j.tube.2008.05.004
   Miller BH, 2000, INFECT IMMUN, V68, P387
   Mostowy S, 2004, J CLIN MICROBIOL, V42, P3594, DOI 10.1128/jcm.42.8.3594-3599.2004
   Mostowy S, 2002, J INFECT DIS, V186, P74, DOI 10.1086/341068
   Newton SM, 2006, P NATL ACAD SCI USA, V103, P15594, DOI 10.1073/pnas.0604283103
   Niemann S, 2004, J CLIN MICROBIOL, V42, P3958, DOI 10.1128/JCM.42.9.3958-3962.2004
   Niobe-Eyangoh SN, 2003, J CLIN MICROBIOL, V41, P2547, DOI 10.1128/JCM.41.6.2547-2553.2003
   Parsons S, 2008, TUBERCULOSIS, V88, P80, DOI 10.1016/j.tube.2007.08.012
   Pollock JM, 2003, J CLIN MICROBIOL, V41, P1856, DOI 10.1128/JCM.41.5.1856.1860.2003
   Raghavan S, 2008, NATURE, V454, P717, DOI 10.1038/nature07219
   Ramon-Garcia S, 2007, J ANTIMICROB CHEMOTH, V59, P544, DOI 10.1093/jac/dkl510
   Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x
   Smith NH, 2006, J THEOR BIOL, V239, P220, DOI 10.1016/j.jtbi.2005.08.036
   Sohaskey CD, 2003, J BACTERIOL, V185, P7247, DOI 10.1128/JB.185.24.7247-7256.2003
   Stinear TP, 2008, GENOME RES, V18, P729, DOI 10.1101/gr.075069.107
   Tamura K, 2011, MOL BIOL EVOL
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Thye T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020908
   Unger F, 2003, RISK ASS MYCOBACTERI, P1
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406
   Veyrier FJ, 2011, TRENDS MICROBIOL, V19, P156, DOI 10.1016/j.tim.2010.12.008
NR 73
TC 32
Z9 35
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD FEB
PY 2012
VL 6
IS 2
AR e1552
DI 10.1371/journal.pntd.0001552
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 901FX
UT WOS:000300949200051
PM 22389744
OA gold
DA 2017-08-15
ER

PT J
AU Dominguez-Salas, P
   Cox, SE
   Prentice, AM
   Hennig, BJ
   Moore, SE
AF Dominguez-Salas, Paula
   Cox, Sharon E.
   Prentice, Andrew M.
   Hennig, Branwen J.
   Moore, Sophie E.
TI Maternal nutritional status, C-1 metabolism and offspring DNA
   methylation: a review of current evidence in human subjects
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article
DE DNA methylation; C-1 metabolism; DOHaD; Methyl donors
ID NEURAL-TUBE DEFECTS; LINE TRANSGENERATIONAL RESPONSES; PLASMA TOTAL
   HOMOCYSTEINE; BIRTH-WEIGHT; NORMAL-PREGNANCY; DIETARY-INTAKE;
   MICRONUTRIENT SUPPLEMENTATION; METASTABLE EPIALLELES; PRENATAL
   ENVIRONMENT; INSULIN-RESISTANCE
AB Evidence is growing for the long-term effects of environmental factors during early-life on later disease susceptibility. It is believed that epigenetic mechanisms (changes in gene function not mediated by DNA sequence alteration), particularly DNA methylation, play a role in these processes. This paper reviews the current state of knowledge of the involvement of C-1 metabolism and methyl donors and cofactors in maternal diet-induced DNA methylation changes in utero as an epigenetic mechanism. Methyl groups for DNA methylation are mostly derived from the diet and supplied through C-1 metabolism by way of choline, betaine, methionine or folate, with involvement of riboflavin and vitamins B-6 and B-12 as cofactors. Mouse models have shown that epigenetic features, for example DNA methylation, can be altered by peri-conceptional nutritional interventions such as folate supplementation, thereby changing offspring phenotype. Evidence of early nutrient-induced epigenetic change in human subjects is scant, but it is known that during pregnancy C-1 metabolism has to cope with high fetal demands for folate and choline needed for neural tube closure and normal development. Retrospective studies investigating the effect of famine or season during pregnancy indicate that variation in early environmental exposure in utero leads to differences in DNA methylation of offspring. This may affect gene expression in the offspring. Further research is needed to examine the real impact of maternal nutrient availability on DNA methylation in the developing fetus.
C1 [Dominguez-Salas, Paula; Cox, Sharon E.; Prentice, Andrew M.; Hennig, Branwen J.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, EPH NPHIR, London WC1E 7HT, England.
   [Dominguez-Salas, Paula; Prentice, Andrew M.; Moore, Sophie E.] MRC Labs, MRC Keneba, Banjul, Gambia.
RP Dominguez-Salas, P (reprint author), Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, EPH NPHIR, Keppel St, London WC1E 7HT, England.
EM paula.dominguez-salas@lshtm.ac.uk
RI Hennig, Branwen/M-6444-2014
OI Cox, Sharon/0000-0002-9908-2936
FU Wellcome Trust [WT086369MA]
FX Paula Dominguez-Salas prepared the manuscript. Her PhD supervisors, Dr
   Hennig and Dr Moore, as well as Dr Cox and Professor Prentice, who are
   closely involved in her research, provided valuable input to this
   manuscript. All of the authors declare that there is no conflict of
   interests associated with this research. The present review was done in
   the framework of research supported by a Wellcome Trust project grant
   (ref. WT086369MA).
CR Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640
   Attig L, 2010, P NUTR SOC, V69, P221, DOI 10.1017/S002966511000008X
   BAKER H, 1981, AM J OBSTET GYNECOL, V141, P792
   Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235
   BARKER DJP, 1986, LANCET, V1, P1077
   Beaudin Anna E., 2007, Birth Defects Research, V81, P183, DOI 10.1002/bdrc.20100
   Bonnette RE, 1998, OBSTET GYNECOL, V92, P167, DOI 10.1016/S0029-7844(98)00154-9
   Brosnan JT, 2006, J NUTR, V136, p1636S
   BRUINSE HW, 1995, EUR J OBSTET GYN R B, V61, P31, DOI 10.1016/0028-2243(95)02150-Q
   Buiting K, 2003, AM J HUM GENET, V72, P571, DOI 10.1086/367926
   Burdge GC, 2007, BRIT J NUTR, V97, P435, DOI 10.1017/S0007114507352392
   Carmichael SL, 2010, BIRTH DEFECTS RES A, V88, P670, DOI 10.1002/bdra.20675
   Chang H, 2011, J NUTR BIOC IN PRESS
   Chen NC, 2010, FASEB J, V24, P2804, DOI 10.1096/fj.09-143651
   Chiuve SE, 2007, AM J CLIN NUTR, V86, P1073
   Chmurzynska A, 2010, NUTR REV, V68, P87, DOI 10.1111/j.1753-4887.2009.00265.x
   Christian P, 2003, BRIT MED J, V326, P571, DOI 10.1136/bmj.326.7389.571
   Clarke R, 2010, ARCH INTERN MED, V170, P1622, DOI 10.1001/archinternmed.2010.348
   Corwin Elizabeth J, 2004, Biol Res Nurs, V6, P11, DOI 10.1177/1099800404264779
   Craciunescu CN, 2004, J NUTR, V134, P162
   Craciunescu CN, 2003, J NUTR, V133, P3614
   Craig SAS, 2004, AM J CLIN NUTR, V80, P539
   da Costa KA, 2005, AM J CLIN NUTR, V81, P440
   da Costa KA, 2004, AM J CLIN NUTR, V80, P163
   DALERY K, 1995, AM J CARDIOL, V75, P1107, DOI 10.1016/S0002-9149(99)80739-5
   DANCIS J, 1988, AM J OBSTET GYNECOL, V158, P204
   DAVIES SEC, 1988, CLIN CHIM ACTA, V178, P241, DOI 10.1016/0009-8981(88)90232-X
   Dolinoy DC, 2007, PEDIATR RES, V61, p30R, DOI 10.1203/pdr.0b013e31804575f7
   DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59
   El-Maarri O, 2007, HUM GENET, V122, P505, DOI 10.1007/s00439-007-0430-3
   Fall C, 2009, INDIAN J MED RES, V130, P593
   Finkelstein JD, 2000, SEMIN THROMB HEMOST, V26, P219, DOI 10.1055/s-2000-8466
   FINKELSTEIN JD, 1988, J BIOL CHEM, V263, P11750
   Fischer LM, 2007, AM J CLIN NUTR, V85, P1275
   Fisher MC, 2002, FASEB J, V16, P619, DOI 10.1096/fj.01-0564fje
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Friesen RW, 2007, J NUTR, V137, P2641
   Gibson R., 2005, PRINCIPLES NUTR ASSE
   Gossell-Williams M, 2005, W INDIAN MED J, V54, P355
   Green R, 2011, AM J CLIN NUTR, V94, p666S, DOI 10.3945/ajcn.110.009613
   Hawkesworth S, 2009, P NUTR SOC, V68, P78, DOI 10.1017/S0029665108008781
   Heard E, 2005, CURR OPIN GENET DEV, V15, P482, DOI 10.1016/j.gde.2005.08.009
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Heijmans BT, 2009, EPIGENETICS, V4, P526
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/ge1068
   HOFFMAN DR, 1980, J BIOL CHEM, V255, P822
   *I MED NAT AC SCI, 1998, DIET REF INT FOL THI
   Jacob RA, 1999, J NUTR, V129, P712
   Jacques PF, 2001, AM J CLIN NUTR, V73, P613
   James SJ, 2002, J NUTR, V132, p2361S
   Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   KALNITSKY A, 1982, PEDIATR RES, V16, P628, DOI 10.1203/00006450-198208000-00008
   Killian JK, 2000, MOL CELL, V5, P707, DOI 10.1016/S1097-2765(00)80249-X
   Kim JK, 2009, CELL MOL LIFE SCI, V66, P596, DOI 10.1007/s00018-008-8432-4
   Kim KC, 2009, J NUTR BIOCHEM, V20, P917, DOI 10.1016/j.jnutbio.2009.06.008
   Kong A, 2009, NATURE, V462, P868, DOI 10.1038/nature08625
   Law CM, 1996, J HYPERTENS, V14, P935
   Lee NY, 2009, PLACENTA, V30, P368, DOI 10.1016/j.placenta.2009.01.011
   Lever M, 2010, CLIN BIOCHEM, V43, P732, DOI 10.1016/j.clinbiochem.2010.03.009
   Maier S., 2002, J NUTR SCI, V132, P2440
   Malinow MR, 1998, AM J OBSTET GYNECOL, V178, P228
   Maron BA, 2009, ANNU REV MED, V60, P39, DOI 10.1146/annurev.med.60.041807.123308
   Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1
   Michels KB, 2006, INT J CANCER, V119, P2007, DOI 10.1002/ijc.22004
   MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90040-W
   Morgan DK, 2009, NESTLE NUTR WORKS SE, V63, P109, DOI 10.1159/000209976
   Niculescu MD, 2002, J NUTR, V132, P2333
   Ozarda llcol Y., 2002, ARCH PHYSIOL BIOCHEM, V110, P393
   Pembrey ME, 2010, HUM FERTIL, V13, P268, DOI 10.3109/14647273.2010.524721
   Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5204538
   Persad VL, 2002, CAN MED ASSOC J, V167, P241
   Plass C, 2002, HUM MOL GENET, V11, P2479, DOI 10.1093/hmg/11.20.2479
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Rakyan VK, 2002, TRENDS GENET, V18, P348, DOI 10.1016/S0168-9525(02)02709-9
   Rao S, 2001, J NUTR, V131, P1217
   Refsum H, 2001, AM J CLIN NUTR, V74, P233
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Richards EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/nrg1834
   Richardson BC, 2002, J NUTR, V132, P2401
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001
   Schneider H, 2010, INT J DEV BIOL, V54, P367, DOI 10.1387/ijdb.082773hs
   SHANE B, 1975, AM J CLIN NUTR, V28, P739
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187
   Shaw GM, 1997, TERATOLOGY, V56, P295, DOI 10.1002/(SICI)1096-9926(199711)56:5<295::AID-TERA1>3.0.CO;2-X
   Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104
   Skinner MK, 2011, BIRTH DEFECTS RES C, V93, P51, DOI 10.1002/bdrc.20199
   Steegers-Theunissen RP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007845
   Steenge GR, 2003, J NUTR, V133, P1291
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102
   Tamura T, 2006, AM J CLIN NUTR, V83, P993
   Tobi EW, 2011, EPIGENETICS-US, V6, P171, DOI 10.4161/epi.6.2.13516
   Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353
   Tofail F, 2008, AM J CLIN NUTR, V87, P704
   Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100
   Vaidya A, 2008, LANCET, V371, P492, DOI 10.1016/S0140-6736(08)60172-5
   Velzing-Aarts FV, 2005, AM J CLIN NUTR, V81, P1383
   Vollset SE, 2000, AM J CLIN NUTR, V71, P962
   Walker MC, 1999, AM J OBSTET GYNECOL, V180, P660, DOI 10.1016/S0002-9378(99)70269-3
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Waterland RA, 2005, NESTLE NUTR WORKS SE, V56, P157, DOI 10.1159/000086298
   WATERLAND R.A., 2006, J NUTR, V136, P1706
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
   Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230
   Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252
   Weaver ICG, 2007, EPIGENETICS, V2, P22
   Weksberg R, 2010, EUR J HUM GENET, V18, P8, DOI 10.1038/ejhg.2009.106
   Whincup PH, 2008, JAMA-J AM MED ASSOC, V300, P2886, DOI 10.1001/jama.2008.886
   Whitelaw NC, 2006, HUM MOL GENET, V15, pR131, DOI 10.1093/hmg/ddl200
   Wolff GL, 1998, FASEB J, V12, P949
   Wong CCY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017873
   Xu F, 2010, CURR MED CHEM, V17, P4052
   Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y
   Youngson NA, 2008, ANNU REV GENOM HUM G, V9, P233, DOI 10.1146/annurev.genom.9.081307.164445
   Zeisel SH, 2005, AM J CLIN NUTR, V82, P719
   Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156
   Zeisel SH, 2009, NUTR REV, V67, P615, DOI 10.1111/j.1753-4887.2009.00246.x
   Zeisel SH, 2009, AM J CLIN NUTR, V89, p673S, DOI 10.3945/ajcn.2008.26811D
   Zeisel SH, 2009, AM J CLIN NUTR, V89, p685S, DOI 10.3945/ajcn.2008.26811F
   Zeisel SH, 2008, BRAIN RES, V1237, P5, DOI 10.1016/j.brainres.2008.08.059
   [Anonymous], 1991, LANCET, V338, P131
NR 124
TC 60
Z9 62
U1 0
U2 35
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0029-6651
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD FEB
PY 2012
VL 71
IS 1
BP 154
EP 165
DI 10.1017/S0029665111003338
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 886WI
UT WOS:000299884200018
PM 22124338
OA No
DA 2017-08-15
ER

PT J
AU Yindom, LM
   Forbes, R
   Aka, P
   Janha, O
   Jeffries, D
   Jallow, M
   Conway, DJ
   Walther, M
AF Yindom, L. -M.
   Forbes, R.
   Aka, P.
   Janha, O.
   Jeffries, D.
   Jallow, M.
   Conway, D. J.
   Walther, M.
TI Killer-cell immunoglobulin-like receptors and malaria caused by
   Plasmodium falciparum in The Gambia
SO TISSUE ANTIGENS
LA English
DT Article
DE Gambia; human leukocyte antigen; killer-cell immunoglobulin-like
   receptor; Malaria; Natural killer cells; Plasmodium falciparum
ID HUMAN NK CELLS; HLA CLASS-I; INHIBITORY RECEPTORS; INFECTED
   ERYTHROCYTES; ASSOCIATION ANALYSIS; DISEASE PROGRESSION;
   IMMUNE-RESPONSES; GENES INFLUENCE; WEST-AFRICA; KIR
AB The relevance of innate immune responses to Plasmodium falciparum infection, in particular the central role of natural killer (NK) cell-derived interferon gamma (IFN-?), is becoming increasingly recognised. Recently, it has been shown that IFN-? production in response to P. falciparum antigens is in part regulated by killer-cell immunoglobulin-like receptor (KIR) genes, and a study from malaria-exposed Melanesians suggested an association between KIR genotypes and susceptibility to infection. This prompted us to determine and compare the frequencies of 15 KIR genes in Gambian children presenting with either severe malaria (n = 133) or uncomplicated malaria (n = 188) and in cord-blood population control samples (n = 314) collected from the same area. While no significant differences were observed between severe and uncomplicated cases, proportions of individuals with KIR2DS2+C1 and KIR2DL2+C1 were significantly higher among malaria cases overall than in population control samples. In an exploratory analysis, activating KIR genes KIR2DS2, KIR3DS1 and KIR2DS5 were slightly higher in children in disease subgroups associated with the highest mortality. In addition, our data suggest that homozygosity for KIR genotype A might be associated with different malaria outcomes including protection from infection and higher blood parasitaemia levels in those that do get infected. These findings are consistent with a probable role of KIR genes in determining susceptibility to malaria, and further studies are warranted in different populations.
C1 [Yindom, L. -M.; Forbes, R.; Aka, P.; Janha, O.; Jeffries, D.; Jallow, M.; Conway, D. J.; Walther, M.] MRC Labs, Banjul, Gambia.
RP Yindom, LM (reprint author), MRC Labs, Banjul, Gambia.
EM louis-marie.yindom@ndm.ox.ac.uk
OI Conway, David/0000-0002-8711-3037
FU Medical Research Council of the United Kingdom
FX This work was funded by the Medical Research Council of the United
   Kingdom. We are very grateful to all study participants, and to all
   field and clinical staff at the government health facilities, MRC Fajara
   and field stations who contributed to this work. We appreciate the
   technical advice of Dr Mary Carrington at the National Cancer Institute,
   Frederick, MD, USA. LMY, RF, PA, OJ, DJ, MJ, DJC and MW made substantial
   contributions to the conception and design of the study, or acquisition,
   analysis and interpretation of data; LMY, PA, DJC and MW were involved
   in drafting the manuscript or critically revising its content.
CR Aguilar AMO, 2010, J IMMUNOL, V185, P4238, DOI 10.4049/jimmunol.1001494
   Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013
   Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x
   Artavanis-Tsakonas K, 2003, J IMMUNOL, V171, P5396
   Artavanis-Tsakonas K, 2002, J IMMUNOL, V169, P2956
   Carrington M, 2005, J EXP MED, V201, P1069, DOI 10.1081/jem.20042158
   Cooley S, 2007, BLOOD, V110, P578, DOI 10.1182/blood-2006-07-036228
   Cooley S, 2010, BLOOD, V116, P2411, DOI 10.1182/blood-2010-05-283051
   Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9
   Denis L, 2005, TISSUE ANTIGENS, V66, P267, DOI 10.1111/j.1399-0039.2005.00473.x
   Estefania E, 2007, TISSUE ANTIGENS, V70, P34, DOI 10.1111/j.1399-0039.2007.00844.x
   Gaudieri S, 2005, GENES IMMUN, V6, P683, DOI 10.1038/sj.gene.6364256
   Gomez-Escobar N, 2010, J INFECT DIS, V201, P444, DOI 10.1086/649902
   Gonzalez-Galarza FF, 2011, NUCLEIC ACIDS RES, V39, pD913, DOI 10.1093/nar/gkq1128
   Guinan KJ, 2010, GENES IMMUN, V11, P467, DOI 10.1038/gene.2010.9
   Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084/jem.20041214
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   Jacobs R, 2001, EUR J IMMUNOL, V31, P3121, DOI 10.1002/1521-4141(2001010)31:10<3121::AID-IMMU3121>3.0.CO;2-4
   Jallow M, 2009, NAT GENET, V41, P657, DOI 10.1038/ng.388
   Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847
   Korbel DS, 2009, J IMMUNOL, V182, P6426, DOI 10.4049/jimmunol.0804224
   Korbel DS, 2004, INT J PARASITOL, V34, P1517, DOI 10.1016/j.ijpara.2004.10.006
   Korbel DS, 2005, J IMMUNOL, V175, P7466
   Kwiatkowski DP, 2005, AM J HUM GENET, V77, P171, DOI 10.1086/432519
   Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205
   LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S
   Lodoen MB, 2006, CURR OPIN IMMUNOL, V18, P391, DOI 10.1016/j.coi.2006.05.002
   Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875
   Lyke KE, 2011, TISSUE ANTIGENS, V77, P562, DOI 10.1111/j.1399-0039.2011.01661.x
   Mackinnon MJ, 2005, PLOS MED, V2, P1253, DOI 10.1371/journa;.pmed.0020340
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Martin Maureen P., 2008, V415, P49, DOI 10.1007/978-1-59745-570-1_3
   Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934
   Martin MP, 2002, J IMMUNOL, V169, P2818
   Middleton D, 2009, TISSUE ANTIGENS, V73, P553, DOI 10.1111/j.1399-0039.2009.01235.x
   Mingari MC, 1996, P NATL ACAD SCI USA, V93, P12433, DOI 10.1073/pnas.93.22.12433
   Mohan K, 1997, J IMMUNOL, V159, P4990
   Newman KC, 2007, NAT REV IMMUNOL, V7, P279, DOI 10.1038/nri2057
   Newman KC, 2006, PLOS PATHOG, V2, P1120, DOI 10.1371/journal.ppat.0020118
   Norman PJ, 2007, NAT GENET, V39, P1092, DOI 10.1038/ng2111
   Parham P, 2008, SEMIN IMMUNOL, V20, P311, DOI 10.1016/j.smim.2008.10.002
   Pyo CW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015115
   Rajagopalan S, 2005, J EXP MED, V201, P1025, DOI 10.1081/jem.20050199
   Rauch A, 2007, TISSUE ANTIGENS, V69, P237, DOI 10.1111/j.1399-0039.2006.773_4.x
   Raulet DH, 2006, NAT REV IMMUNOL, V6, P520, DOI 10.1038/nri1863
   Single RM, 2007, NAT GENET, V39, P1114, DOI 10.1038/ng2077
   Single RM, 2008, IMMUNOGENETICS, V60, P711, DOI 10.1007/s00251-008-0331-1
   Smyth MJ, 2005, MOL IMMUNOL, V42, P501, DOI 10.1016/j.molimm.2004.07.034
   Taniguchi M, 2009, IMMUNOGENETICS, V61, P717, DOI 10.1007/s00251-009-0401-z
   van der Slik AR, 2003, DIABETES, V52, P2639, DOI 10.2337/diabetes.52.10.2639
   Walther M, 2006, J IMMUNOL, V177, P5736
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
   Yamazaki A, 2011, HUM IMMUNOL
   Yindom LM, 2010, J VIROL, V84, P8202, DOI 10.1128/JVI.00116-10
NR 56
TC 9
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD FEB
PY 2012
VL 79
IS 2
BP 104
EP 113
DI 10.1111/j.1399-0039.2011.01818.x
PG 10
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 873IB
UT WOS:000298873400004
PM 22220719
OA No
DA 2017-08-15
ER

PT J
AU Sutherland, JS
   Garba, D
   Fombah, AE
   Mendy-Gomez, A
   Mendy, FS
   Antonio, M
   Townend, J
   Ideh, RC
   Corrah, T
   Ota, MOC
AF Sutherland, Jayne S.
   Garba, Danlani
   Fombah, Augustin E.
   Mendy-Gomez, Awa
   Mendy, Francis S.
   Antonio, Martin
   Townend, John
   Ideh, Readon C.
   Corrah, Tumani
   Ota, Martin O. C.
TI Highly Accurate Diagnosis of Pleural Tuberculosis by Immunological
   Analysis of the Pleural Effusion
SO PLOS ONE
LA English
DT Article
ID INTERFERON-GAMMA; IFN-GAMMA; MYCOBACTERIUM-TUBERCULOSIS; T-LYMPHOCYTES;
   IP-10; INFECTION; UTILITY; RESPONSES; CYTOKINE; PROTEIN
AB Pleural TB is notoriously difficult to diagnose due to its paucibacillary nature yet it is the most common cause of pleural effusions in TB endemic countries such as The Gambia. We identified both cellular and soluble biomarkers in the pleural fluid that allowed highly accurate diagnosis of pleural TB compared to peripheral blood markers. Multi-plex cytokine analysis on unstimulated pleural fluid showed that IP-10 resulted in a positive likelihood ratio (LR) of 9.6 versus 2.8 for IFN-gamma; a combination of IP-10, IL-6 and IL-10 resulted in an AUC of 0.96 and positive LR of 10. A striking finding was the significantly higher proportion of PPD-specific IFN-gamma+TNF-alpha+ cell population (PPD-IGTA) in the pleural fluid compared to peripheral blood of TB subjects. Presence of this pleural PPD-IGTA population resulted in 95% correct classification of pleural TB disease with a sensitivity of 95% and specificity of 100%. These data suggest that analysis of the site of infection provides superior diagnostic accuracy compared to peripheral blood for pleural TB, likely due to the sequestration of effector cells at this acute stage of disease.
C1 [Sutherland, Jayne S.; Garba, Danlani; Fombah, Augustin E.; Mendy-Gomez, Awa; Mendy, Francis S.; Antonio, Martin; Townend, John; Ideh, Readon C.; Corrah, Tumani; Ota, Martin O. C.] MRC Unit, Fajara, Gambia.
RP Sutherland, JS (reprint author), MRC Unit, Atlantic Rd, Fajara, Gambia.
EM jsutherland@mrc.gm
OI Sutherland, Jayne/0000-0002-7083-4997
FU MRC Unit, The Gambia
FX This study was funded by the MRC Unit, The Gambia. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Baba K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002788
   Barry SM, 2003, J INFECT DIS, V187, P243, DOI 10.1086/346112
   Condos R, 1998, AM J RESP CRIT CARE, V157, P729
   Dheda K, 2009, EUR RESPIR J, V34, P1118, DOI 10.1183/09031936.00005309
   Dheda K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004689
   El Fenniri L, 2011, TUBERCULOSIS, V91, P224, DOI 10.1016/j.tube.2010.12.005
   Hirsch CS, 2001, J INFECT DIS, V183, P79
   Hodsdon WS, 2001, AIDS, V15, P467, DOI 10.1097/00002030-200103090-00005
   John SH, 2011, BIOMARKERS      1108
   Kalantri Y, 2011, INT J INFECT DIS, V15, pE226, DOI 10.1016/j.ijid.2010.11.011
   Kapina MA, 2007, J IMMUNOL, V178, P976
   Krenke R, 2010, CURR OPIN PULM MED, V16, P367, DOI 10.1097/MCP.0b013e32833a7154
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704
   Okamoto M, 2005, J LAB CLIN MED, V145, P88, DOI 10.1016/j.lab.2004.11.013
   Porcel JM, 2011, RESPIROLOGY, V16, P44, DOI 10.1111/j.1440-1843.2010.01794.x
   Porcel JM, 2010, EUR J INTERN MED, V21, P419, DOI 10.1016/j.ejim.2010.03.011
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Ruhwald M, 2011, TUBERCULOSIS, V91, P260, DOI 10.1016/j.tube.2011.01.001
   Supriya P, 2008, DIAGN MICR INFEC DIS, V62, P186, DOI 10.1016/j.diagmicrobio.2008.05.011
   Sutherland JS, TUBERCULOSIS, V89, P398
   Toossi Z, 2011, CLIN EXP IMMUNOL, V163, P333, DOI 10.1111/j.1365-2249.2010.04269.x
   Whittaker E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003901
   WHO, 2010, WHO 2010 2011 TB FAC
   WHO, WHO LAB BAS EV 19 CO
NR 24
TC 15
Z9 16
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 25
PY 2012
VL 7
IS 1
AR e30324
DI 10.1371/journal.pone.0030324
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 910ME
UT WOS:000301640600026
PM 22295081
OA gold
DA 2017-08-15
ER

PT J
AU Adetifa, IMO
   Antonio, M
   Okoromah, CAN
   Ebruke, C
   Inem, V
   Nsekpong, D
   Bojang, A
   Adegbola, RA
AF Adetifa, Ifedayo M. O.
   Antonio, Martin
   Okoromah, Christy A. N.
   Ebruke, Chinelo
   Inem, Victor
   Nsekpong, David
   Bojang, Abdoulie
   Adegbola, Richard A.
TI Pre-Vaccination Nasopharyngeal Pneumococcal Carriage in a Nigerian
   Population: Epidemiology and Population Biology
SO PLOS ONE
LA English
DT Article
ID RESISTANT STREPTOCOCCUS-PNEUMONIAE; ACUTE OTITIS-MEDIA; CONJUGATE
   VACCINE; RISK-FACTORS; SUSCEPTIBILITY PATTERNS; HAEMOPHILUS-INFLUENZAE;
   INVASIVE DISEASE; UNITED-STATES; MOLECULAR EPIDEMIOLOGY;
   ANTIBIOTIC-RESISTANCE
AB Background: Introduction of pneumococcal vaccines in Nigeria is a priority as part of the Accelerated Vaccine Introduction Initiative (AVI) of the Global Alliance for Vaccines and Immunisation (GAVI). However, country data on the burden of pneumococcal disease (IPD) is limited and coverage by available conjugate vaccines is unknown. This study was carried out to describe the pre vaccination epidemiology and population biology of pneumococcal carriage in Nigeria.
   Methods: This was a cross sectional survey. Nasopharyngeal swabs (NPS) were obtained from a population sample in 14 contiguous peri-urban Nigerian communities. Data on demographic characteristics and risk factor for carriage were obtained from all study participants. Pneumococci isolated from NPS were characterised by serotyping, antimicrobial susceptibility and Multi Locus Sequencing Typing (MLST).
   Results: The prevalence of pneumococcal carriage was 52.5%. Carriage was higher in children compared to adults (67.4% vs. 26%), highest (approximate to 90%) in infants aged <9 months and reduced significantly with increasing age (P<0.001). Serotypes 19F (18.6%) and 6A (14.4%) were most predominant. Potential vaccine coverage was 43.8%, 45.0% and 62% for PCV-7, PCV-10 and PCV-13 respectively. There were 16 novel alleles, 72 different sequence types (STs) from the isolates and 3 Sequence Types (280, 310 and 5543) were associated with isolates of more than one serotype indicative of serotype switching. Antimicrobial resistance was high for cotrimoxazole (93%) and tetracycline (84%), a third of isolates had intermediate resistance to penicillin. Young age was the only risk factor significantly associated with carriage.
   Conclusions: Pneumococcal carriage and serotype diversity is highly prevalent in Nigeria especially in infants. Based on the coverage of serotypes in this study, PCV-13 is the obvious choice to reduce disease burden and prevalence of drug resistant pneumococci. However, its use will require careful monitoring. Our findings provide sound baseline data for impact assessment following vaccine introduction in Nigeria.
C1 [Adetifa, Ifedayo M. O.; Antonio, Martin; Ebruke, Chinelo; Nsekpong, David; Bojang, Abdoulie; Adegbola, Richard A.] Med Res Council MRC Unit, Fajara, Gambia.
   [Okoromah, Christy A. N.] Univ Lagos, Coll Med, Dept Paediat & Child Hlth, Lagos, Nigeria.
   [Inem, Victor] Univ Lagos, Coll Med, Dept Community Hlth & Primary Care, Lagos, Nigeria.
RP Adetifa, IMO (reprint author), Med Res Council MRC Unit, Fajara, Gambia.
EM iadetifa@mrc.gm; radegbola@hotmail.com
FU International Society for Infectious Diseases (ISID); Medical Research
   Council (UK); European and Developing Countries Clinical Trials
   Partnership Career Development Fellowship [CG_ta_2005_40203_001]
FX This work was supported by an International Society for Infectious
   Diseases (ISID) Small Grant to IMOA (Spring 2008), a Medical Research
   Council (UK) Intramural funding to RAA and MA. IMOA also received
   support from a European and Developing Countries Clinical Trials
   Partnership Career Development Fellowship (grant number
   CG_ta_2005_40203_001). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Akanbi MO, 2009, AFRICAN J RESP MED, P10
   Antonio M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-81
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   BLOCK SL, 1995, PEDIATR INFECT DIS J, V14, P751, DOI 10.1097/00006454-199509000-00005
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Boken DJ, 1996, PEDIATR INFECT DIS J, V15, P667, DOI 10.1097/00006454-199608000-00006
   Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525
   Department of Infectious Disease Epidemiology IC, EBURSTV3
   Dheda K, 2007, J INFECTION, V55, P169, DOI 10.1016/j.jinf.2007.02.005
   Donkor ES, 2010, SCAND J INFECT DIS, V42, P254, DOI 10.3109/00365540903490000
   Faden H, 1997, J INFECT DIS, V175, P1440
   Falade AG, 2009, CLIN INFECT DIS, V48, pS190, DOI 10.1086/596500
   Farrell DJ, 2007, PEDIATR INFECT DIS J, V26, P123, DOI 10.1097/01.inf.0000253059.84602.c3
   Feikin DR, 2003, PEDIATR INFECT DIS J, V22, P564, DOI 10.1097/00006454-200306000-00016
   Gertz RE, 2003, J CLIN MICROBIOL, V41, P4194, DOI 10.1128/JCM.41.9.4194-4216.2003
   GRAY BM, 1980, J INFECT DIS, V142, P923
   Greenberg D, 2006, CLIN INFECT DIS, V42, P897, DOI 10.1086/500935
   Guillemot D, 1998, JAMA-J AM MED ASSOC, V279, P365, DOI 10.1001/jama.279.5.365
   Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Hill PC, 2010, CLIN INFECT DIS, V50, P1468, DOI 10.1086/652443
   Huang SS, 2005, PEDIATRICS, V116, pE408, DOI 10.1542/peds.2004-2338
   Jain A, 2005, TROP MED INT HEALTH, V10, P234, DOI 10.1111/j.1365-3156.2004.01379.x
   Johnson H.L., 2010, PLOS MED, V7
   Joloba ML, 2001, INT J ANTIMICROB AG, V17, P395, DOI 10.1016/S0924-8579(00)00345-9
   Kaplan SL, 2004, PEDIATRICS, V113, P443, DOI 10.1542/peds.113.3.443
   Leimkugel J, 2005, J INFECT DIS, V192, P192, DOI 10.1086/431151
   Lynch JP, 2010, CURR OPIN PULM MED, V16, P217, DOI 10.1097/MCP.0b013e3283385653
   Marchisio P, 2002, EMERG INFECT DIS, V8, P479
   Melnick N, 2010, J CLIN MICROBIOL, V48, P2311, DOI 10.1128/JCM.00410-10
   Mudhune S, 2009, CLIN INFECT DIS, V48, pS147, DOI 10.1086/596494
   Nwachukwu NC, 2008, AFRICAN J RESP M SEP
   O'Brien KL, 2001, J CLIN MICROBIOL, V39, P1021, DOI 10.1128/JCM.39.3.1021-1024.2001
   O'Brien K, 2003, PEDIATR INFECT DIS J, V22, P1
   ONYEMELUKWE GC, 1982, J INFECTION, V5, P157, DOI 10.1016/S0163-4453(82)91772-8
   OYEDEJI G A, 1985, Nigerian Journal of Paediatrics, V12, P111
   Principi N, 1999, PEDIATR INFECT DIS J, V18, P517, DOI 10.1097/00006454-199906000-00008
   Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9
   Rivera-Olivero IA, 2007, CLIN INFECT DIS, V45, P1427, DOI 10.1086/522984
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Russell FM, 2006, ANN TROP PAEDIATR, V26, P187, DOI 10.1179/146532806X120273
   Saha SK, 2003, J CLIN MICROBIOL, V41, P5582, DOI 10.1128/JCM.41.12.5582-5587.2003
   Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0
   SILVERMAN M, 1977, ARCH DIS CHILD, V52, P925
   Soewignjo S, 2001, CLIN INFECT DIS, V32, P1039, DOI 10.1086/319605
   Syrjanen RK, 2005, PEDIATR INFECT DIS J, V24, P801, DOI 10.1007/01.inf.0000178072.83531.4f
   [World Health Organization (WHO) The United Nations Childrens Fund (UNICEF)], 2006, PNEUM FORG KILL CHIL
   Ussery XT, 1996, PEDIATR INFECT DIS J, V15, P986, DOI 10.1097/00006454-199611000-00011
   World Health Organisation, 2007, WORLD HLTH STAT
   World Health Organization, 2008, INT MAN CHILDH ILLN
   Yaro S, 2006, CLIN INFECT DIS, V43, P693, DOI 10.1086/506940
NR 54
TC 35
Z9 36
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 24
PY 2012
VL 7
IS 1
AR e30548
DI 10.1371/journal.pone.0030548
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 910LV
UT WOS:000301639600032
PM 22291984
OA gold
DA 2017-08-15
ER

PT J
AU Walther, B
   Miles, DJC
   Waight, P
   Palmero, MS
   Ojuola, O
   Touray, ES
   Whittle, H
   van der Sande, M
   Crozier, S
   Flanagan, KL
AF Walther, Brigitte
   Miles, David J. C.
   Waight, Pauline
   Palmero, Melba S.
   Ojuola, Olubukola
   Touray, Ebrima S.
   Whittle, Hilton
   van der Sande, Marianne
   Crozier, Sarah
   Flanagan, Katie L.
TI Placental malaria is associated with attenuated CD4 T-cell responses to
   tuberculin PPD 12 months after BCG vaccination
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM INFECTION; INTERFERON-GAMMA-RECEPTOR;
   ANTIBODY-RESPONSE; IMMUNE-RESPONSES; IN-UTERO; MYCOBACTERIAL INFECTION;
   POSTNATAL ENVIRONMENTS; GAMBIAN CHILDREN; BIRTH COHORT; EARLY-LIFE
AB Background: Placental malaria (PM) is associated with prenatal malaise, but many PM+ infants are born without symptoms. As malaria has powerful immunomodulatory effects, we tested the hypothesis that PM predicts reduced T-cell responses to vaccine challenge.
   Methods: We recruited healthy PM+ and PM- infants at birth. At six and 12 months, we stimulated PBMCs with tuberculin purified protein derivative (PPD) and compared expression of CD154, IL-2 and IFN gamma by CD4 T-cells to a negative control using flow cytometry.
   We measured the length, weight and head circumference at birth and 12 months.
   Results: IL-2 and CD154 expression were low in both groups at both timepoints, without discernable differences. Expression of IFN gamma was similarly low at 6 months but by 12 months, the median response was higher in PM- than PM + infants (p = 0.026). The PM+ infants also had a lower weight (p = 0.032) and head circumference (p = 0.041) at 12 months, indicating lower growth rates.
   At birth, the size and weight of the PM+ and PM- infants were equivalent. By 12 months, the PM+ infants had a lower weight and head circumference than the PM- infants.
   Conclusions: Placental malaria was associated with reduced immune responses 12 months after immune challenge in infants apparently healthy at birth.
C1 [Walther, Brigitte; Miles, David J. C.; Waight, Pauline; Palmero, Melba S.; Ojuola, Olubukola; Touray, Ebrima S.; Whittle, Hilton; van der Sande, Marianne; Crozier, Sarah; Flanagan, Katie L.] MRC Labs Gambia, Banjul, Gambia.
   [Miles, David J. C.] Malawi Liverpool Wellcome Trust Clin Res Program, Blantyre 3, Malawi.
   [Waight, Pauline] Hlth Protect Agcy Ctr Infect, Immunisat Dept, London, England.
   [Ojuola, Olubukola] Bronx Lebanon Hosp Ctr, Dept Pediat, Bronx, NY 10456 USA.
   [van der Sande, Marianne] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Epidemiol & Surveillance Unit, NL-3720 BA Bilthoven, Netherlands.
   [van der Sande, Marianne] Univ Med Ctr Utrecht, Julius Ctr, Utrecht, Netherlands.
   [Crozier, Sarah] Univ Southampton, Southampton Gen Hosp, MRC Epidemiol Resource Ctr, Southampton, Hants, England.
RP Miles, DJC (reprint author), MRC Labs Gambia, POB 273, Banjul, Gambia.
EM d.miles@bham.ac.uk
OI Crozier, Sarah/0000-0002-9524-1127
FU Sukuta Government Hospital; Western Division Health Team; MRC (UK)
FX We thank the following staff involved in the care and follow up of the
   Sukuta birth cohort: Omar Badjie, Fatou Bah, Saihou Bobb, Janko Camara,
   Sulayman Colley, Isatou Drammeh, Mam Maram Drammeh, Baboucarr Jobe,
   Momodou Jobe, Albert Magnusen, John Mendy, Ngui Ndow, Faalou Njie, Bala
   Musa Sambou, Sarjo Sanneh, and Mamadi Sidibeh. Akram Zaman, Paul Snell,
   and David Jeffries helped with data handling. We are extremely grateful
   for the support of Sally Savage of the Sukuta Government Hospital and
   Abi Khan of the Western Division Health Team. We are also indebted to
   the study families and their children. The study was funded by MRC (UK).
CR Bisseye C, 2009, CLIN EXP IMMUNOL, V158, P287, DOI 10.1111/j.1365-2249.2009.04014.x
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   BRADLEYMOORE AM, 1985, ANN TROP MED PARASIT, V79, P563
   Broen K, 2007, MOL BIOCHEM PARASIT, V151, P1, DOI 10.1016/j.molbiopara.2006.10.001
   Brustoski K, 2006, J INFECT DIS, V193, P146, DOI 10.1086/498578
   Cunnington AJ, 2010, EXPERT REV VACCINES, V9, P409, DOI [10.1586/erv.10.16, 10.1586/ERV.10.16]
   Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901
   Elias D, 2008, VACCINE, V26, P3897, DOI 10.1016/j.vaccine.2008.04.083
   Flanagan K, 2010, EUR J IMMUNOL, V40, P1
   Garner P, 2003, COCHRANE DB SYST REV, V1
   Greenwood B, 1972, LANCET, V299, P169, DOI 10.1016/S0140-6736(72)90569-7
   HAYES K, 1987, J INFECT DIS, V156, P615
   HO M, 1988, J IMMUNOL, V141, P2755
   Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8
   Ismaili J, 2003, CLIN EXP IMMUNOL, V133, P414, DOI 10.1046/j.1365-2249.2003.02243.x
   Kampmann B, 2005, J CLIN INVEST, V115, P2480, DOI 10.1172/JCI19316
   Kaye S, 2008, J INFECT DIS, V197, P1307, DOI 10.1086/586715
   LaBeaud AD, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000442
   Lalor MK, 2009, J INFECT DIS, V199, P795, DOI 10.1086/597069
   le Cessie S., 2002, Archives of Disease in Childhood, V86, pF182, DOI 10.1136/fn.86.3.F182
   LeHesran JY, 1997, AM J EPIDEMIOL, V146, P826
   Luxemburger C, 2001, AM J EPIDEMIOL, V154, P459, DOI 10.1093/aje/154.5.459
   Malhotra I, 1999, J IMMUNOL, V162, P6843
   Malhotra I, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000116
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   McGREGOR IAN A., 1962, TRANS ROY SOC TROP MED AND HYG, V56, P364, DOI 10.1016/0035-9203(62)90005-6
   Miles DJC, 2008, CLIN VACCINE IMMUNOL, V15, P995, DOI 10.1128/CVI.00037-08
   Miles DJC, 2008, J INFECT DIS, V197, P658, DOI 10.1086/527418
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moormann AM, 2005, J INFECT DIS, V191, P1233, DOI 10.1086/428910
   Moormann AM, 2007, J INFECT DIS, V195, P799, DOI 10.1086/511984
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Njie R, 2009, J INFECT DIS, V199, P31, DOI 10.1086/594373
   PASS RF, 1985, J INFECT DIS, V152, P243
   Schwarz NG, 2008, CLIN INFECT DIS, V47, P1017, DOI 10.1086/591968
   Sullivan AD, 1999, J INFECT DIS, V179, P1580, DOI 10.1086/314752
   Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900
   Usen S, 2000, PEDIATR INFECT DIS J, V19, P444, DOI 10.1097/00006454-200005000-00010
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000492
   Walther B, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-16
   Wammes LJ, 2010, EUR J IMMUNOL, V40, P437, DOI 10.1002/eji.200939699
   Williamson W, 1978, LANCET, V311, P1328, DOI 10.1016/S0140-6736(78)92403-0
   WILSON ME, 1995, CLIN INFECT DIS, V20, P982
NR 44
TC 8
Z9 8
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JAN 14
PY 2012
VL 12
AR 6
DI 10.1186/1471-2334-12-6
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 889IN
UT WOS:000300067000002
PM 22243970
OA gold
DA 2017-08-15
ER

PT J
AU Grietens, KP
   Xuan, XN
   Ribera, JM
   Duc, TN
   van Bortel, W
   Ba, NT
   Van, KP
   Xuan, HL
   D'Alessandro, U
   Erhart, A
AF Grietens, Koen Peeters
   Xa Nguyen Xuan
   Ribera, Joan Muela
   Thang Ngo Duc
   van Bortel, Wim
   Nhat Truong Ba
   Ky Pham Van
   Xuan, Hung Le
   D'Alessandro, Umberto
   Erhart, Annette
TI Social Determinants of Long Lasting Insecticidal Hammock-Use Among the
   Ra-Glai Ethnic Minority in Vietnam: Implications for Forest Malaria
   Control
SO PLOS ONE
LA English
DT Article
ID TREATED HAMMOCK; TRANSMISSION; VECTORS; HEALTH; NETS; RISK
AB Background: Long-lasting insecticidal hammocks (LLIHs) are being evaluated as an additional malaria prevention tool in settings where standard control strategies have a limited impact. This is the case among the Ra-glai ethnic minority communities of Ninh Thuan, one of the forested and mountainous provinces of Central Vietnam where malaria morbidity persist due to the sylvatic nature of the main malaria vector An. dirus and the dependence of the population on the forest for subsistence - as is the case for many impoverished ethnic minorities in Southeast Asia.
   Methods: A social science study was carried out ancillary to a community-based cluster randomized trial on the effectiveness of LLIHs to control forest malaria. The social science research strategy consisted of a mixed methods study triangulating qualitative data from focused ethnography and quantitative data collected during a malariometric cross-sectional survey on a random sample of 2,045 study participants.
   Results: To meet work requirements during the labor intensive malaria transmission and rainy season, Ra-glai slash and burn farmers combine living in government supported villages along the road with a second home at their fields located in the forest. LLIH use was evaluated in both locations. During daytime, LLIH use at village level was reported by 69.3% of all respondents, and in forest fields this was 73.2%. In the evening, 54.1% used the LLIHs in the villages, while at the fields this was 20.7%. At night, LLIH use was minimal, regardless of the location (village 4.4%; forest 6.4%).
   Discussion: Despite the free distribution of insecticide-treated nets (ITNs) and LLIHs, around half the local population remains largely unprotected when sleeping in their forest plot huts. In order to tackle forest malaria more effectively, control policies should explicitly target forest fields where ethnic minority farmers are more vulnerable to malaria.
C1 [Grietens, Koen Peeters; van Bortel, Wim; D'Alessandro, Umberto] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.
   [Grietens, Koen Peeters; Ribera, Joan Muela] PASS Int, Tessenderlo, Belgium.
   [Xa Nguyen Xuan; Thang Ngo Duc; Xuan, Hung Le] Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam.
   [Nhat Truong Ba; Ky Pham Van] Prov Malaria Stn, Phan Rang, Vietnam.
   [D'Alessandro, Umberto] MRC Unit, Basse, Gambia.
   [Erhart, Annette] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium.
RP Grietens, KP (reprint author), Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.
EM kpeeters@itg.be
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009
FU UBS Optimus Foundation
FX The study was funded by the UBS Optimus Foundation. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR American Anthropological Association, AM ANTHR ASS STAT ET
   Bryant A., 2007, SAGE HDB GROUNDED TH
   Coosemans M, 2006, T PHNOM PHEN INT C R, P551
   Erhart A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-58
   Erhart A, 2004, AM J TROP MED HYG, V70, P110
   Erhart A, 2006, MALARIA CONTROL VIET
   Girod R, 2008, MEM I OSWALDO CRUZ, V103, P702, DOI 10.1590/S0074-02762008000700013
   Grietens KP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-23
   Hougard JM, 2007, J MED ENTOMOL, V44, P651, DOI 10.1603/0022-2585(2007)44[651:PFTOAL]2.0.CO;2
   ITM, 2007, ITM ANN C MAL MEK DE
   Kondrashin A. V., 1991, Forest malaria in southeast Asia: proceedings of an informal consultative meeting WHO/MRC, 18-22 February 1991., P1
   Langsang MA, 1997, ACTA TROP, V63, P257
   Magris M, 2007, TROP MED INT HEALTH, V12, P392, DOI 10.1111/j.1365-3156.2006.01801.x
   MAYS N, 1995, BRIT MED J, V311, P182
   NIMPE, 2003, ANN REP NAT MAL CONT
   NIMPE, 2004, ANN REP NAT MAL CONT
   NIMPE, 2005, ANN REP NAT MAL CONT
   POPE C, 1995, BRIT MED J, V311, P42
   Rahman W. A., 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P537
   ROZENDAAL JA, 1989, MED VET ENTOMOL, V3, P353, DOI 10.1111/j.1365-2915.1989.tb00242.x
   Seale C., 1999, QUALITY QUALITATIVE
   Singhasivanon Pratap, 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P399
   Sochantha T, 2010, TROP MED INT HEALTH, V15, P336, DOI 10.1111/j.1365-3156.2009.02457.x
   Somboon Pradya, 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P3
   Tashakkori A., 1998, APPL SOCIAL RES METH, V46
   Thang Ngo Duc, 2009, PLoS One, V4, pe7369, DOI 10.1371/journal.pone.0007369
   Thang ND, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-28
   Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x
   Trung HD, 2005, TROP MED INT HEALTH, p[10, 151]
   Van Bortel W, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-373
   Zimmerman RH, 1997, PAN AM J PUBLIC HLTH, V2, P18
NR 31
TC 12
Z9 12
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 12
PY 2012
VL 7
IS 1
AR e29991
DI 10.1371/journal.pone.0029991
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 906OY
UT WOS:000301357100035
PM 22253852
OA gold
DA 2017-08-15
ER

PT J
AU Battersby, AJ
   Kampmann, B
   Burl, S
AF Battersby, Anna Jane
   Kampmann, Beate
   Burl, Sarah
TI Vitamin D in Early Childhood and the Effect on Immunity to Mycobacterium
   tuberculosis
SO CLINICAL & DEVELOPMENTAL IMMUNOLOGY
LA English
DT Review
ID RESPIRATORY-TRACT INFECTION; RANDOMIZED CONTROLLED-TRIAL; D-RECEPTOR
   POLYMORPHISMS; D DEFICIENCY; PULMONARY-TUBERCULOSIS; INNATE IMMUNITY;
   HUMAN-MONOCYTES; DOUBLE-BLIND; CORD BLOOD; 1,25-DIHYDROXYVITAMIN D-3
AB A potential role for vitamin D as a therapeutic immunomodulator in tuberculosis (TB) has been recognised for over 150 years, but has only recently returned to the centre of the research arena due to the increasing awareness of the global vitamin D deficiency epidemic. As early as birth a child is often deficient in vitamin D, which may not only affect their bone metabolism but also modulate their immune function, contributing to the increased susceptibility to many infections seen early in life. Recent studies have begun to explain the mechanisms by which vitamin D affects immunity. Antimicrobial peptides are induced in conjunction with stimulation of innate pattern recognition receptors enhancing immunity to particular infections. In contrast the role of vitamin D within the adaptive immune response appears to be more regulatory in function, perhaps as a mechanism to reduce unwanted inflammation. In this paper we focus on the effect of vitamin D on immunity to TB. Where much of the attention has been paid by past reviews to the role of vitamin D in adult TB patients, this paper, where possible, focuses on research in paediatric populations.
C1 [Battersby, Anna Jane; Kampmann, Beate; Burl, Sarah] Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, London W2 1PG, England.
   [Kampmann, Beate] MRC Unit, Fajara, Gambia.
RP Battersby, AJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, St Marys Campus,Wright Fleming Bldg,Norfolk Pl, London W2 1PG, England.
EM a.battersby@imperial.ac.uk
FU NIHR; MRC; Biomedical Research Centre (BRC) at Imperial College
FX A. J. Battersby and B. Kampmann are funded by the NIHR. S. Burl and B.
   Kampmann are supported by the MRC. We acknowledge the support of the
   Biomedical Research Centre (BRC) at Imperial College for our work.
CR Adams JS, 2008, NAT CLIN PRACT ENDOC, V4, P80, DOI 10.1038/ncpendmet0716
   Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394
   Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013
   Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432
   Anand SP, 2009, CLIN IMMUNOL, V133, P126, DOI 10.1016/j.clim.2009.06.009
   Antal Attila S, 2011, Dermatoendocrinol, V3, P18, DOI 10.4161/derm.3.1.14616
   Belderbos ME, 2011, PEDIATRICS, V127, pE1513, DOI 10.1542/peds.2010-3054
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Boonstra A, 2001, J IMMUNOL, V167, P4974
   Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8
   Cantorna MT, 2008, MOL ASPECTS MED, V29, P369, DOI 10.1016/j.mam.2008.04.004
   Cantorna MT, 2000, ARCH BIOCHEM BIOPHYS, V377, P135, DOI 10.1006/abbi.2000.1765
   CHARPY J, 1945, Ann Dermatol Syphiligr (Paris), V5, P227
   Chen S, 2007, J IMMUNOL, V179, P1634
   Daniel C, 2008, J PHARMACOL EXP THER, V324, P23, DOI 10.1124/jpet.107.127209
   Davaasambuu G., 2010, ROLE VITAMIN D INNAT
   DENIS M, 1991, CLIN EXP IMMUNOL, V84, P200
   Di Rosa M, 2011, IMMUNOLOGY, V134, P123, DOI 10.1111/j.1365-2567.2011.03482.x
   Douglas AS, 1996, THORAX, V51, P944, DOI 10.1136/thx.51.9.944
   DOWLING GB, 1946, P ROY SOC MED, V39, P225
   Edfeldt K, 2010, P NATL ACAD SCI USA, V107, P22593, DOI 10.1073/pnas.1011624108
   Everett D, 1846, Prov Med Surg J, V10, P538
   Fabri M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003045
   Fabri M, 2009, CELL HOST MICROBE, V6, P201, DOI 10.1016/j.chom.2009.08.008
   Fares Auda, 2011, J Glob Infect Dis, V3, P46, DOI 10.4103/0974-777X.77296
   Fleet JC, 1996, ARCH BIOCHEM BIOPHYS, V329, P228, DOI 10.1006/abbi.1996.0213
   Gao L, 2010, INT J TUBERC LUNG D, V14, P15
   GAUMOND E, 1948, CAN MED ASSOC J, V59, P522
   Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560
   Goswami R., 2011, PULMONARY TUBERCULOS
   Greer FR, 2003, J PEDIATR-US, V143, P422, DOI 10.1067/S0022-3476(03)00465-7
   Griffin MD, 2003, ANNU REV NUTR, V23, P117, DOI 10.1146/annurev.nutr.23.011702.073114
   Harant H, 2000, J CELL BIOCHEM, V78, P112, DOI 10.1002/(SICI)1097-4644(20000701)78:1<112::AID-JCB10>3.3.CO;2-Z
   HART PD, 1946, BRIT MED J, V2, P805
   Hewison M, 2010, MOL CELL ENDOCRINOL, V321, P103, DOI 10.1016/j.mce.2010.02.013
   Holick MF, 2005, J NUTR, V135, P2739
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
   Holick MF, 2009, ANN EPIDEMIOL, V19, P73, DOI 10.1016/j.annepidem.2007.12.001
   Hollis BW, 2011, J BONE MINER RES, V26, P2341, DOI 10.1002/jbmr.463
   Imazeki I, 2006, BIOMED RES-TOKYO, V27, P1, DOI 10.2220/biomedres.27.1
   Inamo Y, 2011, PEDIATR INT, V53, P199, DOI 10.1111/j.1442-200X.2010.03224.x
   Jo EK, 2010, CELL MICROBIOL, V12, P1026, DOI 10.1111/j.1462-5822.2010.01491.x
   KREUTZ M, 1993, BLOOD, V82, P1300
   Kumar G. T., 2011, BRIT MED J, V342
   Laaksi I, 2007, AM J CLIN NUTR, V86, P714
   Lagishetty V, 2011, MOL CELL ENDOCRINOL, V347, P97, DOI 10.1016/j.mce.2011.04.015
   Lalor MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016709
   Lange NE, 2009, EXPERT REV CLIN IMMU, V5, P693, DOI 10.1586/ECI.09.53
   Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075
   Liu PT, 2008, CURR OPIN IMMUNOL, V20, P371, DOI 10.1016/j.coi.2008.05.014
   Liu PT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005810
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Lolong D. B., 2011, L ARGININE VITAMIN D
   Luxwolda M. F., BRIT J NUTR IN PRESS
   Mahon BD, 2003, J CELL BIOCHEM, V89, P922, DOI 10.1002/jcb.10580
   Manaseki-Holland S, 2010, TROP MED INT HEALTH, V15, P1148, DOI 10.1111/j.1365-3156.2010.02578.x
   Martineau AR, 2007, AM J RESP CRIT CARE, V176, P208, DOI 10.1164/rccm.200701-007OC
   Martineau AR, 2012, P NUTR SOC, V71, P84, DOI 10.1017/S0029665111003326
   Martineau AR, 2011, LANCET, V377, P242, DOI 10.1016/S0140-6736(10)61889-2
   Martineaua AR, 2011, P NATL ACAD SCI USA, V108, P19013, DOI 10.1073/pnas.1111825108
   Mathai D., CLIN TRIAL STUDY EFF
   McNally JD, 2009, PEDIATR PULM, V44, P981, DOI 10.1002/ppul.21089
   Messerlian S, 2000, J STEROID BIOCHEM, V72, P29, DOI 10.1016/S0960-0760(99)00148-X
   Mimouni FB, 2009, CURR OPIN CLIN NUTR, V12, P287, DOI 10.1097/MCO.0b013e32832a1329
   Molnar F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018124
   Moodley A., 2011, VITAMIN D SUPPLEMENT
   Morcos M M, 1998, Boll Chim Farm, V137, P157
   Moyo S, 2010, INT J TUBERC LUNG D, V14, P149
   Nelson CD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021674
   Newton SM, 2008, LANCET INFECT DIS, V8, P498, DOI 10.1016/S1473-3099(08)70182-8
   Nnoaham KE, 2008, INT J EPIDEMIOL, V37, P113, DOI 10.1093/ije/dym247
   Nursyam Elly Wijaya, 2006, Acta Med Indones, V38, P3
   OKAMURA WH, 1995, J STEROID BIOCHEM, V53, P603, DOI 10.1016/0960-0760(95)00107-B
   Pearce SHS, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5664
   Phelan J. J., 1947, LANCET, V249, P764, DOI 10.1016/S0140-6736(47)91513-4
   Prabhu Anand S, 2009, Cytokine, V45, P105, DOI 10.1016/j.cyto.2008.11.004
   PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748
   REICHEL H, 1987, P NATL ACAD SCI USA, V84, P3385, DOI 10.1073/pnas.84.10.3385
   Rider A A, 1970, J Nutr, V100, P1
   Rios M, 2000, EUR J EPIDEMIOL, V16, P483, DOI 10.1023/A:1007653329972
   ROOK GAW, 1986, IMMUNOLOGY, V57, P159
   Roth DE, 2010, ACTA PAEDIATR, V99, P389, DOI 10.1111/j.1651-2227.2009.01594.x
   Roth DE, 2009, EUR J CLIN NUTR, V63, P297, DOI 10.1038/sj.ejcn.1602946
   Roth DE, 2008, J INFECT DIS, V197, P676, DOI 10.1086/527488
   Salahuddin N., 2011, REPLACEMENT VITAMIN
   Schaaf HS, 1996, TUBERCLE LUNG DIS, V77, P43, DOI 10.1016/S0962-8479(96)90074-X
   Singh RJ, 2006, J CLIN ENDOCR METAB, V91, P3055, DOI 10.1210/jc.2006-0710
   STRACHAN DP, 1995, THORAX, V50, P175, DOI 10.1136/thx.50.2.175
   Strathmann FG, 2012, CLIN CHIM ACTA, V413, P203, DOI 10.1016/j.cca.2011.09.028
   Taylor CE, 2011, NUTR REV, V69, P259, DOI 10.1111/j.1753-4887.2011.00386.x
   Thorpe LE, 2004, NEW ENGL J MED, V350, P2105, DOI 10.1056/NEJM200405133502023
   Vidyarani M, 2007, CYTOKINE, V40, P128, DOI 10.1016/j.cyto.2007.08.005
   Vieth R, 2006, PROG BIOPHYS MOL BIO, V92, P26, DOI 10.1016/j.pbiomolbio.2006.02.003
   Vieth R, 2004, J STEROID BIOCHEM, V89-90, P575, DOI 10.1016/j.jsbmb.2004.03.038
   Vieth R, 2011, LANCET, V377, P189, DOI 10.1016/S0140-6736(10)62300-8
   Wagner CL, 2008, PEDIATRICS, V122, P1142, DOI 10.1542/peds.2008-1862
   Walker VP, 2011, J CLIN ENDOCR METAB, V96, P1835, DOI 10.1210/jc.2010-1559
   Walker VP, 2009, PEDIATR RES, V65, p106R, DOI 10.1203/PDR.0b013e31819dba91
   Watkins MLV, 2008, CLIN VACCINE IMMUNOL, V15, P1666, DOI 10.1128/CVI.00202-08
   Wayse V, 2004, EUR J CLIN NUTR, V58, P563, DOI 10.1038/sj.ejcn.1601845
   Wejse C, 2009, AM J RESP CRIT CARE, V179, P843, DOI 10.1164/rccm.200804-567OC
   White JH, 2012, REV ENDOCR METAB DIS, V13, P21, DOI 10.1007/s11154-011-9195-z
   Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6
   Williams B, 2008, PEDIATR INFECT DIS J, V27, P941, DOI 10.1097/INF.0b013e31817525df
   Williams CJB, 1849, LONDON J MED, V1, P1
   Yamshchikov AV, 2009, ENDOCR PRACT, V15, P438, DOI 10.4158/EP09101.ORR
   Yim J., 2011, IMPACT VITAMIN D TUB
   Yuk JM, 2009, CELL HOST MICROBE, V6, P231, DOI 10.1016/j.chom.2009.08.004
   Zhang R, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-65
   Ziegler T. R., 2011, IMPACT VITAMIN D SUP
   [Anonymous], 2011, INTRO SOLID FOODS GI
   [Anonymous], 1998, REPORTS HLTH SOCIAL, V49, P1
NR 113
TC 14
Z9 14
U1 0
U2 4
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1740-2522
J9 CLIN DEV IMMUNOL
JI Clin. Dev. Immunol.
PY 2012
AR 430972
DI 10.1155/2012/430972
PG 10
WC Immunology
SC Immunology
GA 989WN
UT WOS:000307591900001
OA gold
DA 2017-08-15
ER

PT J
AU Sesay, C
   Chien, LY
AF Sesay, Catherine
   Chien, Li-Yin
TI Analysis of factors associated with failure to return for an HIV-test
   result in The Gambia
SO AJAR-AFRICAN JOURNAL OF AIDS RESEARCH
LA English
DT Article
DE health behaviour; HIV/AIDS; nationality; prevention; qualitative
   research; voluntary testing and counselling; West Africa
ID HIGH-RISK; PREDICTORS; POPULATION; TANZANIA; TRENDS
AB Knowing one's HIV status is fundamental to the prevention and treatment of HIV and AIDS. However, HIV prevention is defeated if individuals who opt to be tested fail to return for their test result. Despite the burden of HIV and AIDS in sub-Saharan Africa, regional studies on failure to return (FTR) for an HIV-test result are lacking. We investigated the factors associated with FTR in The Gambia, West Africa. FTR was analysed for 1 755 persons who attended an outpatient clinic during 2000 to 2009. Overall, the proportion of FTR was 30%. Logistic regression showed that FTR was significantly higher among males, individuals whose nationality was not Gambian, individuals with a history of condom use, and individuals who resided in an urban area. Persons who were younger than age 18 years and persons who had received some formal education were more likely to not return for the HIV-test result than were persons aged 40 years or older and persons without formal schooling. The results provide evidence for the need for appropriate strategies to increase the receipt of HIV-test results among people in the general population and among certain group profiles.
C1 [Chien, Li-Yin] Natl Yang Ming Univ, Inst Clin & Community Hlth Nursing, Taipei 11221, Taiwan.
   [Sesay, Catherine] Univ Gambia, Dept Psychol, Sch Arts & Sci, Banjul, Gambia.
RP Chien, LY (reprint author), Natl Yang Ming Univ, Inst Clin & Community Hlth Nursing, 155 Li Nong St,Sect 2, Taipei 11221, Taiwan.
EM lychien@ym.edu.tw
FU Taiwan International Cooperation and Development Fund; Medical Research
   Council of The Gambia; Faculty of the National Yang-Ming University
   (Taiwan)
FX This study was funded by the Taiwan International Cooperation and
   Development Fund. The authors thank the Medical Research Council of The
   Gambia and the Faculty of the National Yang-Ming University (Taiwan) for
   their support and contribution to the study.
CR Central Intelligence Agency (CIA), 2011, WORLD FACT BOOK GAMB
   Fichtner RR, 1996, PSYCHOL HEALTH MED, V1, P83, DOI 10.1080/13548509608400008
   Grusky O., 2007, J INT ASS PHYS AIDS, V6, P46
   Hightow LB, 2003, AIDS EDUC PREV, V15, P282, DOI 10.1521/aeap.15.4.282.23826
   Hontelez J.A.C., 2009, SEXUALLY TRANSMITTED, V36, P1
   Kinsler JJ, 2007, SEX TRANSM DIS, V34, P397, DOI 10.1097/01.olq.0000249757.10209.b3
   Lazebnik R, 2001, SEX TRANSM DIS, V28, P401, DOI 10.1097/00007435-200107000-00007
   Mmbaga EJ, 2009, AIDS CARE, V21, P160, DOI 10.1080/09540120801982905
   Msuya SE, 2006, JAIDS-J ACQ IMM DEF, V43, P85, DOI 10.1097/01.qai.0000225016.50890.7e
   [National AIDS Secretariat (NAS) [The Gambia] UNAIDS], 2009, NAT AIDS SPEND ASS 2
   Stein JA, 2000, AIDS CARE, V12, P343, DOI 10.1080/09540120050043007
   Sullivan PS, 2004, JAIDS-J ACQ IMM DEF, V35, P511, DOI 10.1097/00126334-200404150-00009
   UNAIDS, 2008, FAST FACTS HIV TEST
   UNAIDS T.W.H. Organization, 2010, AIDS EP UPD 2010
   UNAIDS, 2009, FACT SHEET SUBS AFR
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   World Health Organization (WHO), 2000, MDG 6 COMB HIV AIDS
   World Health Organization (WHO), 2002, INCR ACC HIV TEST CO
   Wiley DJ, 1998, SEX TRANSM DIS, V25, P342, DOI 10.1097/00007435-199808000-00003
   Wolff B, 2005, HEALTH POLICY PLANN, V20, P109, DOI 10.1093/heapol/czi013
   Ziek K, 2000, J DRUG ISSUES, V30, P675
NR 21
TC 2
Z9 2
U1 1
U2 6
PU NATL INQUIRY SERVICES CENTRE PTY LTD
PI GRAHAMSTOWN
PA 19 WORCESTER STREET, PO BOX 377, GRAHAMSTOWN 6140, SOUTH AFRICA
SN 1608-5906
J9 AJAR-AFR J AIDS RES
JI AJAR-Afr. J. Aids Res.
PY 2012
VL 11
IS 2
BP 83
EP 89
DI 10.2989/16085906.2012.698053
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 963QW
UT WOS:000305639200002
PM 25859911
OA No
DA 2017-08-15
ER

PT J
AU Okomo, U
   Meremikwu, MM
AF Okomo, Uduak
   Meremikwu, Martin M.
TI Fluid replacement therapy for acute episodes of pain in people with
   sickle cell disease
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE *Fluid Therapy; *Pain Management; Anemia, Sickle Cell [*therapy]; Pain
   [etiology]; Humans
ID CRISIS; ANEMIA; MANAGEMENT; HYPOSTHENURIA; PREVENTION; KETOROLAC;
   EMERGENCY; CHILDREN
AB Background
   Treating vaso-occlusive painful crises in people with sickle cell disease is complex and requires multiple interventions. Extra fluids are routinely given as adjunct treatment, regardless of the individual's state of hydration with the aim of slowing or stopping the sickling process and thereby alleviating pain.
   Objectives
   To determine the optimal route, quantity and type of fluid replacement for people with sickle cell disease with acute painful crises.
   Search methods
   We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
   We also conducted searches of EMBASE (November 2007), LILACS and www.ClinicalTrials.gov (05 January 2010).
   Date of most recent search of the Group's Haemoglobinopathies Trials Register: 09 February 2012.
   Selection criteria
   Randomised and quasi-randomised controlled trials that compared the administration of supplemental fluids adjunctive to analgesics by any route in people with any type of sickle cell disease during an acute painful episode, under medical supervision (inpatient, day care or community).
   Data collection and analysis
   No relevant trials have yet been identified.
   Main results
   Sixteen trials were identified by the initial search. Of these, 15 were not suitable for inclusion in this review and one study is awaiting further assessment.
   Authors' conclusions
   Treating vaso-occlusive crises is complex and requires multiple interventions. Extra fluids, generally oral or intravenous, are routinely administered during acute painful episodes to people with sickle cell disease regardless of the individual's state of hydration. Reports of their use during these acute painful episodes do not state the efficacy of any single route, type or quantity of fluid compared to another. However, there are no randomised controlled trials that have assessed the safety and efficacy of different routes, types or quantities of fluid. This systematic review identifies the need for a multicentre randomised controlled trial assessing the efficacy and possible adverse effects of different routes, types and quantities of fluid administered to people with sickle cell disease during acute painful episodes.
C1 [Okomo, Uduak] Med Res Council UK, Viral Dis Programme, Fajara, Gambia.
   [Meremikwu, Martin M.] Univ Calabar, Teaching Hosp, Dept Paediat, Calabar, Nigeria.
RP Okomo, U (reprint author), Med Res Council UK, Viral Dis Programme, Atlantic Blvd,POB 273, Fajara, Gambia.
EM uokomo@mrc.gm
FU Institute of Tropical Diseases Research and Prevention, University of
   Calabar Teaching Hospital, Calabar, Nigeria; DFID, UK
FX Internal sources; Institute of Tropical Diseases Research and
   Prevention, University of Calabar Teaching Hospital, Calabar, Nigeria.;
   External sources; Effective Health Care Alliance Programme (supported by
   DFID), UK.
CR Adams S, 1996, Prof Care Mother Child, V6, P34
   Adekile AD, 1999, PAEDIAT CHILD HLTH T, P200
   ALLON M, 1990, ARCH INTERN MED, V150, P501, DOI 10.1001/archinte.150.3.501
   Alvim RC, 2005, ACTA HAEMATOL-BASEL, V113, P228, DOI 10.1159/000084675
   Ballas SK, 2005, HEMATOL ONCOL CLIN N, V19, P785, DOI 10.1016/j.hoc.2005.07.008
   Ballas SK, 2007, HEMATOL-AM SOC HEMAT, V1, P97
   Beiter JL, 2001, ARCH PEDIAT ADOL MED, V155, P496
   Brugnara C, 1995, Curr Opin Hematol, V2, P132
   CHARACHE S, 1983, AM J HEMATOL, V15, P315, DOI 10.1002/ajh.2830150402
   CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001
   CHARACHE S, 1981, BLOOD, V58, P892
   de Araujo J T, 1994, Rev Hosp Clin Fac Med Sao Paulo, V49, P13
   DECEULAER K, 1982, LANCET, V2, P229
   GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501
   GONZALEZ ER, 1991, ARCH INTERN MED, V151, P1373, DOI 10.1001/archinte.151.7.1373
   GONZALEZ ER, 1988, ANN EMERG MED, V17, P788, DOI 10.1016/S0196-0644(88)80554-7
   Guy R, 1971, CLIN RES, V21, P420
   GUY RB, 1973, AM J MED SCI, V266, P267, DOI 10.1097/00000441-197310000-00005
   Hardwick WE, 1999, PEDIATR EMERG CARE, V15, P179, DOI 10.1097/00006565-199906000-00004
   HATCH FE, 1965, ARCH INTERN MED, V116, P10
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Terry AL, DIPYRIDAMOLE MAGNESI
   KEITEL HG, 1956, J CLIN INVEST, V35, P998, DOI 10.1172/JCI103360
   KONTESSIS P, 1992, NEPHRON, V61, P10
   Lane PA, 2001, INPATIENT MANAGEMENT
   Lane PA, 2001, CURRENT PEDIAT DIAGN, P756
   Marti-Carvajal AJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006786.pub2
   NALBANDIAN RM, 1971, AM J MED SCI, V261, P309, DOI 10.1097/00000441-197106000-00002
   Okomo U, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005406.pub2
   Orringer EP, 2001, JAMA-J AM MED ASSOC, V286, P2099, DOI 10.1001/jama.286.17.2099
   OSKI FA, 1965, J AMER MED ASSOC, V191, P43
   PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103
   Rhodes RS, 1974, JAMA-J AM MED ASSOC, V228, P1129
   ROSA RM, 1980, NEW ENGL J MED, V303, P1138, DOI 10.1056/NEJM198011133032002
   Saborio P, 1999, J AM SOC NEPHROL, V10, P187
   Serjeant GR, 1992, SICKLE CELL DIS
   Sickle Cell Information Center, SICKL CELL INF CLIN
   Steinberg MH, 2006, TRENDS PHARMACOL SCI, V27, P204, DOI 10.1016/j.tips.2006.02.007
   Steinberg MH, 1999, NEW ENGL J MED, V340, P1021
   VANEPS LWS, 1967, CLIN CHIM ACTA, V17, P449, DOI 10.1016/0009-8981(67)90222-7
NR 40
TC 1
Z9 2
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2012
IS 6
AR CD005406
DI 10.1002/14651858.CD005406.pub3
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA 957VD
UT WOS:000305192500006
PM 22696351
OA No
DA 2017-08-15
ER

PT J
AU Kippler, M
   Hossain, MB
   Lindh, C
   Moore, SE
   Kabir, I
   Vahter, M
   Broberg, K
AF Kippler, Maria
   Hossain, Mohammad Bakhtiar
   Lindh, Christian
   Moore, Sophie E.
   Kabir, Iqbal
   Vahter, Marie
   Broberg, Karin
TI Early life low-level cadmium exposure is positively associated with
   increased oxidative stress
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE 8-oxodG; DNA damage; Infant; Cadmium; Breast-feeding
ID MODIFIED DNA LESIONS; BANGLADESHI WOMEN; ARSENIC EXPOSURE; IRON STATUS;
   CHILDRENS TOXICOLOGY; ANTIOXIDANT ENZYMES; DIETARY-CADMIUM; URINE;
   PREGNANCY; INFANTS
AB Environmental exposure to cadmium (Cd) is known to induce oxidative stress, a state of imbalance between the production of reactive oxygen species (ROS) and the ability to detoxify them, in adults. However, data are lacking on potential effects in early-life. We evaluated urinary concentrations of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), a recognized marker of oxidative DNA damage, in relation to Cd exposure in 96 predominantly breast-fed infants (11-17 weeks of age) in rural Bangladesh. Urinary 8-oxodG was measured using liquid chromatography tandem mass spectrometry and Cd in urine and breast milk by inductively coupled plasma mass spectrometry. Median concentration of 8-oxodG was 3.9 nmol/L, urinary Cd 0.30 mu g/L, and breast-milk Cd 0.13 mu g/L. In linear regression analyses, urinary 8-oxodG was positively associated with Cd in both urine (p=0.00067) and breast milk (p=0.0021), and negatively associated with body weight (kg: p=0.0041). Adjustment for age, body weight, socio-economic status, urinary arsenic, as well as magnesium, calcium, and copper in breast milk did not change the association between Cd exposure and urinary 8-oxodG. These findings suggest that early-life low-level exposure to Cd via breast milk induces oxidative stress. Further studies are warranted to elucidate whether this oxidative stress is associated with impaired child health and development. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Hossain, Mohammad Bakhtiar; Kabir, Iqbal; Broberg, Karin] Univ Lund Hosp, Sect Occupat & Environm Med, Dept Lab Med, SE-22185 Lund, Sweden.
   [Kippler, Maria; Vahter, Marie] Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden.
   [Hossain, Mohammad Bakhtiar; Lindh, Christian; Broberg, Karin] Int Ctr Diarrhoea Dis Res, Dhaka 1212, Bangladesh.
   [Moore, Sophie E.] MRC Labs, MRC Keneba, Banjul, Gambia.
RP Broberg, K (reprint author), Univ Lund Hosp, Sect Occupat & Environm Med, Dept Lab Med, SE-22185 Lund, Sweden.
EM karin.broberg_palmgren@med.lu.se
OI Lindh, Christian/0000-0001-7435-9890; Broberg, Karin/0000-0002-5862-468X
FU Swedish Research Council; Swedish Council for Working Life and Social
   Research; Karolinska Institute; AFA Foundation; European Union
   [FOOD-CT-2006-016253]; United Nations; Swedish International Development
   Agency; UK Medical Research Council; Swedish Research Council,
   Department for International Development; International Center for
   Diarrheal Disease Research, Bangladesh (ICDDR,B); Global Health Research
   Fund-japan; Child Health and Nutrition Research Initiative; Uppsala
   University; United States Agency for International Development
FX This work was supported by grants from the Swedish Research Council; the
   Swedish Council for Working Life and Social Research; the Karolinska
   Institute; the AFA Foundation and the European Union within the Sixth
   Framework Program for RTD ("PHIME" contract no FOOD-CT-2006-016253. This
   article reflects only the author's views. The Community is not liable
   for any use that may be made of the information contained herein). The
   MINIMat research study was funded by United Nations Children's Fund;
   Swedish International Development Agency; UK Medical Research Council;
   Swedish Research Council, Department for International Development;
   International Center for Diarrheal Disease Research, Bangladesh
   (ICDDR,B); Global Health Research Fund-japan; Child Health and Nutrition
   Research Initiative; Uppsala University and United States Agency for
   International Development.
CR Akesson A, 2002, AM J PUBLIC HEALTH, V92, P284, DOI 10.2105/AJPH.92.2.284
   Asikainen TM, 1998, AM J RESP CELL MOL, V19, P942
   Bergkvist C, 2010, ENVIRON RES, V110, P718, DOI 10.1016/j.envres.2010.07.004
   BERGLUND M, 1994, ENVIRON HEALTH PERSP, V102, P1058, DOI 10.2307/3431993
   Beyersmann D, 2008, ARCH TOXICOL, V82, P493, DOI 10.1007/s00204-008-0313-y
   Brzoska MM, 2011, TOXICOL APPL PHARM, V250, P327, DOI 10.1016/j.taap.2010.11.012
   Cooke MS, 2006, FREE RADICAL BIO MED, V41, P1829, DOI 10.1016/j.freeradbiomed.2006.09.009
   Cooke MS, 2008, CANCER EPIDEM BIOMAR, V17, P3, DOI 10.1158/1055-9965.EPI-07-0751
   Cooke MS, 2009, J CLIN BIOCHEM NUTR, V45, P255, DOI 10.3164/jcbn.SR09-41
   Crews HM, 2000, TOXICOL LETT, V112, P201, DOI 10.1016/S0378-4274(99)00284-2
   Cuypers A, 2010, BIOMETALS, V23, P927, DOI 10.1007/s10534-010-9329-x
   Domellof M, 2001, J PEDIATR-US, V138, P679, DOI 10.1067/mpd.2001.112895
   Engstrom KS, 2010, MUTAT RES-FUND MOL M, V683, P98, DOI 10.1016/j.mrfmmm.2009.10.014
   Engstrom KS, 2010, FREE RADICAL BIO MED, V48, P1211, DOI 10.1016/j.freeradbiomed.2010.02.004
   Fangstrom B, 2008, ENVIRON HEALTH PERSP, V116, P963, DOI 10.1289/ehp.11094
   Friel JK, 2011, PEDIATR RES, V69, P160, DOI 10.1203/PDR.0b013e3182042a07
   Garratt LW, 2010, FREE RADICAL BIO MED, V48, P1460, DOI 10.1016/j.freeradbiomed.2010.02.017
   Gobe G, 2010, TOXICOL LETT, V198, P49, DOI 10.1016/j.toxlet.2010.04.013
   Ikonomidou C, 2010, ANTIOXID REDOX SIGN, V14, P1535, DOI DOI 10.1089/ARS.2010.3581
   Jarup L, 2009, TOXICOL APPL PHARM, V238, P201, DOI 10.1016/j.taap.2009.04.020
   Joseph P, 2009, TOXICOL APPL PHARM, V238, P272, DOI 10.1016/j.taap.2009.01.011
   Kippler M, 2009, ENVIRON RES, V109, P914, DOI 10.1016/j.envres.2009.07.006
   Kippler M, 2007, TOXICOL APPL PHARM, V222, P221, DOI 10.1016/j.taap.2007.04.009
   Kippler M, 2010, TOXICOL LETT, V198, P20, DOI 10.1016/j.toxlet.2010.04.029
   Kippler M, 2010, TOXICOL LETT, V192, P162, DOI 10.1016/j.toxlet.2009.10.018
   Kippler M, 2009, TOXICOLOGY, V257, P64, DOI 10.1016/j.tox.2008.12.009
   Ledo A, 2009, AM J CLIN NUTR, V89, P210, DOI 10.3945/ajcn.2008.26845
   Lee DH, 2006, ENVIRON HEALTH PERSP, V114, P350, DOI 10.1289/ehp.8518
   Liu J, 2009, TOXICOL APPL PHARM, V238, P209, DOI 10.1016/j.taap.2009.01.029
   Ljung K., 2011, FOOD CHEM, P943
   Mao WP, 2011, HUM EXP TOXICOL, V30, P920, DOI 10.1177/0960327110384286
   Matsubasa T, 2002, FREE RADICAL RES, V36, P189, DOI 10.1080/10715760290006510
   Moore SE, 2007, AM J CLIN NUTR, V85, P1075
   Nassi N, 2009, PEDIATR INT, V51, P183, DOI 10.1111/j.1442-200X.2008.02662.x
   Nishijo M, 2002, OCCUP ENVIRON MED, V59, P394, DOI 10.1136/oem.59.6.394
   Ohrvik H, 2007, TOXICOLOGY, V240, P15, DOI 10.1016/j.tox.2007.07.012
   Olsson IM, 2002, ENVIRON HEALTH PERSP, V110, P1185
   Patra RC, 2008, SCI TOTAL ENVIRON, V404, P36, DOI 10.1016/j.scitotenv.2008.06.010
   Potts RJ, 2003, TOXICOLOGY, V184, P189, DOI 10.1016/S0300-483X(02)00579-6
   Rahman A, 2009, AM J EPIDEMIOL, V169, P304, DOI 10.1093/aje/kwn332
   Saha KK, 2008, AM J CLIN NUTR, V87, P1852
   Sekine T, 2009, J TOXICOL SCI, V34, pSP259
   Siomek A, 2006, CARCINOGENESIS, V27, P405, DOI 10.1093/carcin/bgi238
   Suzuki M, 2009, J TOXICOL SCI, V34, pSP267
   Szaflarska-Poplawska A, 2010, CANCER EPIDEM BIOMAR, V19, P1960, DOI 10.1158/1055-9965.EPI-10-0295
   Tofail F, 2008, AM J CLIN NUTR, V87, P704
   Vahter ME, 2006, J HEALTH POPUL NUTR, V24, P236
   Wang YD, 2004, FREE RADICAL BIO MED, V36, P1434, DOI 10.1016/j.freeradbiomed.2004.03.010
   World Health Organization, 2001, OPT DUR EXCL BREASTF
   WHO, 2006, WHO CILD GROWTH STAN
   Yao L, 2010, J PEDIATR GASTR NUTR, V50, P670, DOI 10.1097/MPG.0b013e3181bab2d3
NR 51
TC 21
Z9 22
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
J9 ENVIRON RES
JI Environ. Res.
PD JAN
PY 2012
VL 112
BP 164
EP 170
DI 10.1016/j.envres.2011.11.012
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 885TX
UT WOS:000299804800021
PM 22192840
OA No
DA 2017-08-15
ER

PT J
AU Mackenzie, GA
   Plumb, ID
   Sambou, S
   Saha, D
   Uchendu, U
   Akinsola, B
   Ikumapayi, UN
   Baldeh, I
   Usuf, E
   Touray, K
   Jasseh, M
   Howie, SRC
   Wattiaux, A
   Lee, E
   Knoll, MD
   Levine, OS
   Greenwood, BM
   Adegbola, RA
   Hill, PC
AF Mackenzie, Grant A.
   Plumb, Ian D.
   Sambou, Sana
   Saha, Debasish
   Uchendu, Uchendu
   Akinsola, Bolanle
   Ikumapayi, Usman N.
   Baldeh, Ignatius
   Usuf, Effua
   Touray, Kebba
   Jasseh, Momodou
   Howie, Stephen R. C.
   Wattiaux, Andre
   Lee, Ellen
   Knoll, Maria Deloria
   Levine, Orin S.
   Greenwood, Brian M.
   Adegbola, Richard A.
   Hill, Philip C.
TI Monitoring the Introduction of Pneumococcal Conjugate Vaccines into West
   Africa: Design and Implementation of a Population-Based Surveillance
   System
SO PLOS MEDICINE
LA English
DT Editorial Material
ID STREPTOCOCCUS-PNEUMONIAE; BLOOD CULTURE; DISEASE; CHILDREN; GAMBIA;
   BURDEN; TRIAL
C1 [Sambou, Sana; Usuf, Effua] Govt Gambia, Dept State Hlth, Dis Control Programme, Banjul, Gambia.
   [Lee, Ellen; Knoll, Maria Deloria; Levine, Orin S.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, PneumoADIP, Baltimore, MD USA.
   [Greenwood, Brian M.] London Sch Hyg & Trop Med, Infect & Trop Dis Dept, London WC1, England.
   [Adegbola, Richard A.] Bill & Melinda Gates Fdn, Div Infect Dis, Seattle, WA USA.
   [Hill, Philip C.] Univ Otago, Fac Med, Ctr Int Hlth, Dunedin, New Zealand.
EM gmackenzie@mrc.gm
FU Medical Research Council [MC_U190081970, MC_U190088478, MC_UP_A900_1124]
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Banya WAS, 1996, PEDIATR INFECT DIS J, V15, P292, DOI 10.1097/00006454-199604000-00003
   Benguigui Yehuda, 2006, Semin Pediatr Infect Dis, V17, P80, DOI 10.1053/j.spid.2006.04.006
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Duke T, 2002, B WORLD HEALTH ORGAN, V80, P16
   German R R, 2001, MMWR Recomm Rep, V50, P1
   German RR, 2001, MMWR RECOMM REP, V50
   Gordon SB, 2000, CLIN INFECT DIS, V31, P53, DOI 10.1086/313910
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Junge S, 2006, TROP MED INT HEALTH, V11, P367, DOI 10.1111/j.1365-3156.2006.01570.x
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Knoll MD, 2009, CLIN INFECT DIS, V48, pS37, DOI 10.1086/596480
   Lehmann D, 2010, CLIN INFECT DIS, V50, P1477, DOI 10.1086/652440
   Madhi SA, 2005, CLIN INFECT DIS, V40, P1511, DOI 10.1086/429828
   Madhi SA, 2007, VACCINE, V25, P2413, DOI 10.1016/j.vaccine.2006.09.010
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Saha S, 2011, J TROP PEDIATRICS, V57, P192, DOI 10.1093/tropej/fmq070
   Singleton RJ, 2007, JAMA-J AM MED ASSOC, V297, P1784, DOI 10.1001/jama.297.16.1784
   World Health Organization Department of Vaccines and Biologicals, 2001, WHOVB0135 DEP VACC B
   [Anonymous], 2010, WKLY EPIDEMIOL REC, V85, P434
NR 23
TC 16
Z9 16
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD JAN
PY 2012
VL 9
IS 1
AR e1001161
DI 10.1371/journal.pmed.1001161
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 894IE
UT WOS:000300419600009
PM 22272192
OA gold
DA 2017-08-15
ER

PT J
AU Joosten, SA
   Goeman, JJ
   Sutherland, JS
   Opmeer, L
   de Boer, KG
   Jacobsen, M
   Kaufmann, SHE
   Finos, L
   Magis-Escurra, C
   Ota, MOC
   Ottenhoff, THM
   Haks, MC
AF Joosten, S. A.
   Goeman, J. J.
   Sutherland, J. S.
   Opmeer, L.
   de Boer, K. G.
   Jacobsen, M.
   Kaufmann, S. H. E.
   Finos, L.
   Magis-Escurra, C.
   Ota, M. O. C.
   Ottenhoff, T. H. M.
   Haks, M. C.
TI Identification of biomarkers for tuberculosis disease using a novel
   dual-color RT-MLPA assay
SO GENES AND IMMUNITY
LA English
DT Article
DE dcRT-MLPA; host biomarkers; tuberculosis
ID DEPENDENT PROBE AMPLIFICATION; REGULATORY T-CELLS;
   MYCOBACTERIUM-TUBERCULOSIS; GENE-EXPRESSION; ACTIVE TUBERCULOSIS;
   IMMUNE-RESPONSES; INFECTION; LUNG; TH1
AB Owing to our lack of understanding of the factors that constitute protective immunity during natural infection with Mycobacterium tuberculosis (Mtb), there is an urgent need to identify host biomarkers that predict long-term outcome of infection in the absence of therapy. Moreover, the identification of host biomarkers that predict (in)adequate response to tuberculosis (TB) treatment would similarly be a major step forward. To identify/monitor multi-component host biomarker signatures at the transcriptomic level in large human cohort studies, we have developed and validated a dual-color reverse-transcriptase multiplex ligation-dependent probe amplification (dcRT-MLPA) method, permitting rapid and accurate expression profiling of as many as 60-80 transcripts in a single reaction. dcRT-MLPA is sensitive, highly reproducible, high-throughput, has an extensive dynamic range and is as quantitative as QPCR. We have used dcRT-MLPA to characterize the human immune response to Mtb in several cohort studies in two genetically and geographically diverse populations. A biomarker signature was identified that is strongly associated with active TB disease, and was profoundly distinct from that associated with treated TB disease, latent infection or uninfected controls, demonstrating the discriminating power of our biomarker signature. Identified biomarkers included apoptosis-related genes and T-cell/B-cell markers, suggesting important contributions of adaptive immunity to TB pathogenesis. Genes and Immunity (2012) 13, 71-82; doi:10.1038/gene.2011.64; published online 29 September 2011
C1 [Haks, M. C.] Leiden Univ, Dept Infect Dis, Med Ctr, Grp Immunol & Immunogenet Mycobacterial Infect Di, NL-2333 ZA Leiden, Netherlands.
   [Goeman, J. J.; Finos, L.] Leiden Univ, Dept Med Stat & Bioinformat, Med Ctr, NL-2333 ZA Leiden, Netherlands.
   [Sutherland, J. S.; Ota, M. O. C.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Jacobsen, M.; Kaufmann, S. H. E.] Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany.
RP Haks, MC (reprint author), Leiden Univ, Dept Infect Dis, Med Ctr, Grp Immunol & Immunogenet Mycobacterial Infect Di, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
EM m.c.haks@lumc.nl
RI Joosten, Simone/E-4731-2011; Goeman, Jelle/C-2260-2012; Joosten,
   Simone/F-1357-2011; Magis-Escurra Ibanez, C./L-4500-2015; Kaufmann,
   Stefan HE/I-5454-2014
OI Goeman, Jelle/0000-0003-4283-0259; Kaufmann, Stefan
   HE/0000-0001-9866-8268; Sutherland, Jayne/0000-0002-7083-4997
FU Bill and Melinda Gates Foundation [74]; TBVAC [LSHP-CT-2003-503367];
   NEWTBVAC [HEALTH-F3-2009-241745]; Netherlands Organization for
   Scientific Research (VENI) [916.86.115]; Gisela Thier foundation of the
   Leiden University Medical Center
FX We thank Dr SJ White for his technical support in designing a dual-color
   RT-MLPA, Dr EMS Leyten and Dr M van Westreenen for their contribution to
   the Paraguay cohort design and sample collection, and Dr A Geluk and Dr
   T van Hall for critically reviewing the manuscript. We gratefully
   acknowledge all the funding that made the work possible. We especially
   acknowledge the Bill and Melinda Gates Foundation (Grand Challenges in
   Global Health GC6#74), 6th framework programme TBVAC contract no.
   LSHP-CT-2003-503367, 7th framework programme NEWTBVAC contract no.
   HEALTH-F3-2009-241745 (the text represents the authors' views and does
   not necessarily represent a position of the Commission that will not be
   liable for the use made of such information), The Netherlands
   Organization for Scientific Research (VENI grant 916.86.115) and the
   Gisela Thier foundation of the Leiden University Medical Center. The
   funders had no role in study design, data collection and analysis,
   decision to publish or in preparation of the manuscript.
CR Abebe F, 2009, CLIN EXP IMMUNOL, V157, P235, DOI 10.1111/j.1365-2249.2009.03967.x
   Abebe M, 2010, EUR J IMMUNOL, V40, P291, DOI 10.1002/eji.200939856
   Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
   Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247
   Bonecini-Almeida MG, 2004, INFECT IMMUN, V72, P2628, DOI 10.1128/IAI.72.5.2628-2634.2004
   Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455
   Burl S, 2007, CLIN EXP IMMUNOL, V149, P117, DOI 10.1111/j.1365-2249.2007.03399.x
   Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703
   Demissie A, 2004, J IMMUNOL, V172, P6938
   Eldering E, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng153
   Goeman JJ, 2010, ANN STAT, V38, P3782, DOI 10.1214/10-AOS829
   Jacobsen M, 2007, J MOL MED-JMM, V85, P613, DOI 10.1007/s00109-007-0157-6
   Jenner RG, 2005, NAT REV MICROBIOL, V3, P281, DOI 10.1038/nrmicro1126
   Kaufmann SHE, 2010, IMMUNITY, V33, P567, DOI 10.1016/j.immuni.2010.09.015
   Knudsen TB, 2005, CLIN MICROBIOL INFEC, V11, P730, DOI 10.1111/j.1469-0691.2005.01229.x
   Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6
   Lonnroth K, 2010, LANCET, V375, P1814, DOI 10.1016/S0140-6736(10)60483-7
   Lund JM, 2008, SCIENCE, V320, P1220, DOI 10.1126/science.1155209
   Maertzdorf J, 2011, GENES IMMUN, V12, P15, DOI 10.1038/gene.2010.51
   Meinshausen N, 2008, BIOMETRIKA, V95, P265, DOI 10.1093/biomet/asn007
   Mistry R, 2007, J INFECT DIS, V195, P357, DOI 10.1086/510397
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Searle S. R., 1992, VARIANCE COMPONENTS
   Shafiani S, 2010, J EXP MED, V207, P1409, DOI 10.1084/jem.20091885
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267
   White SJ, 2004, HUM MUTAT, V24, P86, DOI 10.1002/humu.20054
   WHO, 2009, GLOB TUB CONTR EP ST
NR 27
TC 50
Z9 50
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JAN
PY 2012
VL 13
IS 1
BP 71
EP 82
DI 10.1038/gene.2011.64
PG 12
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 882XJ
UT WOS:000299596900009
PM 21956656
OA No
DA 2017-08-15
ER

PT J
AU de Silva, TI
   Aasa-Chapman, M
   Cotten, M
   Hue, S
   Robinson, J
   Bibollet-Ruche, F
   Sarge-Njie, R
   Berry, N
   Jaye, A
   Aaby, P
   Whittle, H
   Rowland-Jones, S
   Weiss, R
AF de Silva, Thushan I.
   Aasa-Chapman, Marlen
   Cotten, Matthew
   Hue, Stephane
   Robinson, James
   Bibollet-Ruche, Frederic
   Sarge-Njie, Ramu
   Berry, Neil
   Jaye, Assan
   Aaby, Peter
   Whittle, Hilton
   Rowland-Jones, Sarah
   Weiss, Robin
TI Potent Autologous and Heterologous Neutralizing Antibody Responses Occur
   in HIV-2 Infection across a Broad Range of Infection Outcomes
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-2 VIRAL LOAD; DUAL INFECTIONS; NORMAL
   SURVIVAL; VIREMIA CONTROL; GUINEA-BISSAU; C INFECTION; T-CELLS; IN-VIVO;
   ENVELOPE
AB Few studies have explored the role of neutralizing antibody (NAb) responses in controlling HIV-2 viremia and disease progression. Using a TZM-bl neutralization assay, we assessed heterologous and autologous NAb responses from a community cohort of HIV-2-infected individuals with a broad range of disease outcomes in rural Guinea-Bissau. All subjects (n = 40) displayed exceptionally high heterologous NAb titers (50% inhibitory plasma dilution or 50% inhibitory concentration [IC(50)], 1:7,000 to 1:1,000,000) against 5 novel primary HIV-2 envelopes and HIV-2 7312A, whereas ROD A and 3 primary envelopes were relatively resistant to neutralization. Most individuals also showed high autologous NAb against contemporaneous envelopes (78% of plasma-envelope combinations in 69 envelopes from 21 subjects), with IC(50)s above 1: 10,000. No association between heterologous or autologous NAb titer and greater control of HIV-2 was found. A subset of envelopes was found to be more resistant to neutralization (by plasma and HIV-2 monoclonal antibodies). These envelopes were isolated from individuals with greater intrapatient sequence diversity and were associated with changes in potential N-linked glycosylation sites but not CD4 independence or CXCR4 use. Plasma collected from up to 15 years previously was able to potently neutralize recent autologous envelopes, suggesting a lack of escape from NAb and the persistence of neutralization-sensitive variants over time, despite significant NAb pressure. We conclude that despite the presence of broad and potent NAb responses in HIV-2-infected individuals, these are not the primary forces behind the dichotomous outcomes observed but reveal a limited capacity for adaptive selection and escape from host immunity in HIV-2 infection.
C1 [de Silva, Thushan I.; Cotten, Matthew; Sarge-Njie, Ramu; Jaye, Assan; Whittle, Hilton] Med Res Council United Kingdom Labs, Fajara, Gambia.
   [de Silva, Thushan I.; Aasa-Chapman, Marlen; Hue, Stephane; Weiss, Robin] UCL, Div Infect & Immun, MRC UCL Ctr Med Mol Virol, London, England.
   [de Silva, Thushan I.; Rowland-Jones, Sarah] John Radcliffe Hosp, Nuffield Dept Med, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [Robinson, James] Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA.
   [Bibollet-Ruche, Frederic] Univ Penn, Perelman Sch Med, Dept Hematol Oncol, Philadelphia, PA 19104 USA.
   [Berry, Neil] Natl Inst Biol Stand & Control Hlth Protect Agcy, Div Retrovirol, Potters Bar, Herts, England.
   [Aaby, Peter] Indepth Network, Projecto Saude Bandim, Bissau, Guinea Bissau.
RP de Silva, TI (reprint author), Med Res Council United Kingdom Labs, Fajara, Gambia.
EM thushandesilva@hotmail.com
OI Hue, Stephane/0000-0002-8580-6905
FU Medical Research Council [G0701313]
FX T.I.D.S was supported by a Medical Research Council Clinical Research
   Training Fellowship (G0701313).
CR Aasa-Chapman MMI, 2006, VIROLOGY, V351, P489, DOI 10.1016/j.virol.2006.04.002
   Aasa-Chapman MMI, 2006, J VIROL, V80, P10884, DOI 10.1128/JVI.01030-06
   Aasa-Chapman MMI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023961
   Aasa-Chapman MMI, 2005, J VIROL, V79, P2823, DOI 10.1128/JVI.79.5.2823-2830-2005
   Abecasis AB, 2010, INFECT GENET EVOL, V10, P380, DOI 10.1016/j.meegid.2009.09.020
   Alter G, 2010, J INFECT DIS S2, V20, pS315
   Arien KK, 2005, J VIROL, V79, P8979, DOI 10.1128/JVI.79.14.8979-8990.2005
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Bailey JR, 2006, J VIROL, V80, P4758, DOI 10.1128/JVI.80.10.4758-4770.2006
   Barroso Helena, 2005, Infection Genetics and Evolution, V5, P239, DOI 10.1016/j.meegid.2004.07.008
   Barroso H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014548
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160
   Blaak H, 2006, VIROLOGY, V353, P144, DOI 10.1016/j.virol.2006.05.029
   Blish CA, 2007, CURR HIV RES, V5, P578, DOI 10.2174/157016207782418461
   Bunnik EM, 2008, J VIROL, V82, P7932, DOI 10.1128/JVI.00757-08
   Calado M, 2010, VIROLOGY, V408, P174, DOI 10.1016/j.virol.2010.09.020
   Carlson JM, 2008, MICROBES INFECT, V10, P455, DOI 10.1016/j.micinf.2008.01.013
   CLAPHAM PR, 1992, J VIROL, V66, P3531
   da Silva ZJ, 2008, AIDS, V22, P1195, DOI 10.1097/QAD.0b013e328300a33d
   Davis KL, 2009, J VIROL, V83, P1240, DOI 10.1128/JVI.01743-08
   de Silva TI, 2008, TRENDS MICROBIOL, V16, P588, DOI 10.1016/j.tim.2008.09.003
   Decker JM, 2005, J EXP MED, V201, P1407, DOI 10.1084/jem.20042510
   Deeks Steven G, 2006, J Virol, V80, P6155, DOI 10.1128/JVI.00093-06
   Delport W, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000885
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   Fenyo EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004505
   Frost SDW, 2005, P NATL ACAD SCI USA, V102, P18514, DOI 10.1073/pnas.0504658102
   GAO F, 1994, J VIROL, V68, P7433
   Gray ES, 2007, J VIROL, V81, P6187, DOI 10.1128/JVI.00239-07
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Hodges-Mameletzis I, 2011, EXPERT REV ANTI-INFE, V9, P195, DOI [10.1586/eri.10.176, 10.1586/ERI.10.176]
   Jordan MR, 2010, J VIROL METHODS, V168, P114, DOI 10.1016/j.jviromet.2010.04.030
   Kong R, 2009, 16 C RETR OPP INF MO
   Kong R, 2012, J VIROL, V86, P947, DOI 10.1128/JVI.06155-11
   KORBER BTM, 1994, J VIROL, V68, P7467
   Kosakovsky PSL, 2006, MOL BIOL EVOL, V23, P1891, DOI DOI 10.1093/MOLBEV/MSL051
   Pond SLK, 2006, PLOS COMPUT BIOL, V2, P530, DOI 10.1371/journal.pcbi.0020062
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Le Tortorec A, 2009, J VIROL, V83, P11966, DOI 10.1128/JVI.01515-09
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Leligdowicz A, 2010, EUR J IMMUNOL, V40, P1963, DOI 10.1002/eji.200940295
   Louder MK, 2005, VIROLOGY, V339, P226, DOI 10.1016/j.virol.2005.06.003
   MacNeil A, 2007, J INFECT DIS, V195, P726, DOI 10.1086/511308
   Mahalanabis M, 2009, J VIROL, V83, P662, DOI 10.1128/JVI.01328-08
   Marcelino JM, 2010, J VIROL, V84, P12429, DOI 10.1128/JVI.01102-10
   Martin N, 2010, J VIROL, V84, P3516, DOI 10.1128/JVI.02651-09
   McMichael AJ, 1997, ANNU REV IMMUNOL, V15, P271, DOI 10.1146/annurev.immunol.15.1.271
   MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687
   Montefiori DC, 2001, J VIROL, V75, P10200, DOI 10.1128/JVI.75.21.10200-10207.2001
   Moore PL, 2009, CURR OPIN HIV AIDS, V4, P358, DOI 10.1097/COH.0b013e32832ea7e8
   Moore PL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000598
   Onyango CO, 2010, VACCINE, V28, pB60, DOI 10.1016/j.vaccine.2009.08.060
   Piantadosi A, 2009, J VIROL, V83, P10269, DOI 10.1128/JVI.01149-09
   Pinter A, 2004, J VIROL, V78, P5205, DOI 10.1128/JVI.78.10.5205-5215.2004
   Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105
   Pond SLK, 2005, BIOINFORMATICS, V21, P2531, DOI 10.1093/bioinformatics/bti320
   Popper SJ, 2000, J VIROL, V74, P1554, DOI 10.1128/JVI.74.3.1554-1557.2000
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   Posada D, 2006, NUCLEIC ACIDS RES, V34, pW700, DOI 10.1093/nar/gkl042
   Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100
   Rodriguez SK, 2007, J VIROL, V81, P5331, DOI 10.1128/JVI.02789-06
   Rong R, 2007, J VIROL, V81, P1350, DOI 10.1128/JVI.01839-06
   Rong R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000594
   Sagar M, 2006, J VIROL, V80, P9586, DOI 10.1128/JVI.00141-06
   Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07
   Schramm B, 2000, J VIROL, V74, P9594, DOI 10.1128/JVI.74.20.9594-9600.2000
   Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09
   Shi Y, 2005, J GEN VIROL, V86, P3385, DOI 10.1099/vir.0.81259-0
   Skrabal K, 2005, J VIROL, V79, P11848, DOI 10.1128/JVI.79.18.11848-11857.2005
   Soda Y, 1999, BIOCHEM BIOPH RES CO, V258, P313, DOI 10.1006/bbrc.1999.0633
   Thomas ER, 2003, AIDS, V17, P291, DOI 10.1097/01.aids.0000050804.28043.58
   van der Kuyl AC, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-67
   van der Loeff MFS, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-46
   van Tienen C, 2010, JAIDS-J ACQ IMM DEF, V53, P640, DOI 10.1097/QAI.0b013e3181bf1a25
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Wren L, 2011, HUM VACCINES, V7, P467, DOI 10.4161/hv.7.4.14123
   Wu XL, 2006, J VIROL, V80, P835, DOI 10.1128/JVI.80.2.835-844.2006
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
NR 81
TC 27
Z9 27
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JAN
PY 2012
VL 86
IS 2
BP 930
EP 946
DI 10.1128/JVI.06126-11
PG 17
WC Virology
SC Virology
GA 870MW
UT WOS:000298674600026
PM 22072758
OA No
DA 2017-08-15
ER

PT J
AU Cunnington, AJ
   de Souza, JB
   Walther, M
   Riley, EM
AF Cunnington, Aubrey J.
   de Souza, J. Brian
   Walther, Michael
   Riley, Eleanor M.
TI Malaria impairs resistance to Salmonella through heme- and heme
   oxygenase-dependent dysfunctional granulocyte mobilization
SO NATURE MEDICINE
LA English
DT Article
ID CARBON-MONOXIDE; TYPHIMURIUM INFECTION; OXIDATIVE STRESS; CEREBRAL
   MALARIA; NADPH OXIDASE; IN-VIVO; SUSCEPTIBILITY; MICE; PROTOPORPHYRIN;
   INDUCTION
AB In sub-Saharan Africa, invasive nontyphoid Salmonella (NTS) infection is a common and often fatal complication of Plasmodium falciparum infection. Induction of heme oxygenase-1 (HO-1) mediates tolerance to the cytotoxic effects of heme during malarial hemolysis but might impair resistance to NTS by limiting production of bactericidal reactive oxygen species. We show that co-infection of mice with Plasmodium yoelii 17XNL (Py17XNL) and Salmonella enterica serovar Typhimurium 12023 (Salmonella typhimurium) causes acute, fatal bacteremia with high bacterial load, features reproduced by phenylhydrazine-induced hemolysis or hemin administration. S. typhimurium localized predominantly in granulocytes. Py17XNL, phenylhydrazine and hemin caused premature mobilization of granulocytes from bone marrow with a quantitative defect in the oxidative burst. Inhibition of HO by tin protoporphyrin abrogated the impairment of resistance to S. typhimurium by hemolysis. Thus, a mechanism of tolerance to one infection, malaria, impairs resistance to another, NTS. Furthermore, HO inhibitors may be useful adjunctive therapy for NTS infection in the context of hemolysis.
C1 [Cunnington, Aubrey J.; de Souza, J. Brian; Riley, Eleanor M.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1, England.
   [de Souza, J. Brian] UCL, Sch Med, Div Infect & Immun, London W1N 8AA, England.
   [Walther, Michael] MRC Labs, Banjul, Gambia.
RP Riley, EM (reprint author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1, England.
EM eleanor.riley@Ishtm.ac.uk
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570; Cunnington,
   Aubrey/0000-0002-1305-3529
FU UK Medical Research Council [G0701427]; European Society for Pediatric
   Infectious Diseases
FX This work was supported by a UK Medical Research Council Clinical
   Research Training Fellowship (G0701427) and a small grant award from the
   European Society for Pediatric Infectious Diseases awarded to A.J.C. We
   wish to thank D. Holden (Imperial College, London) for providing
   GFP-expressing S. typhimurium and R. Motterlini, S. Baines, H. Kaur, L.
   King, C. Stanley, R. Gregory, L. McCarthy, K. Couper, J. Hafalla, E.
   Findlay and D. Blount for technical advice and assistance.
CR Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599
   Ayres JS, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000150
   Belcher JD, 2006, J CLIN INVEST, V116, P808, DOI 10.1172/JCI26857
   Belyaev NN, 2010, NAT IMMUNOL, V11, P477, DOI 10.1038/ni.1869
   Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299
   Bilban M, 2008, J MOL MED, V86, P267, DOI 10.1007/s00109-007-0276-0
   Bronzan RN, 2007, J INFECT DIS, V195, P895, DOI 10.1086/511437
   Chauveau C, 2005, BLOOD, V106, P1694, DOI 10.1182/blood-2005-02-0494
   Datla SR, 2007, HYPERTENSION, V50, P636, DOI 10.1161/HYPERTENSIONAHA.107.092296
   DEHAAS M, 1994, BLOOD, V84, P3885
   DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986
   Epiphanio S, 2008, CELL HOST MICROBE, V3, P331, DOI 10.1016/j.chom.2008.04.003
   Ferreira A, 2011, CELL, V145, P398, DOI 10.1016/j.cell.2011.03.049
   GLASSER L, 1987, BLOOD, V69, P937
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   HESTDAL K, 1991, J IMMUNOL, V147, P22
   KAPPAS A, 1988, PEDIATRICS, V81, P485
   KAYE D, 1963, J IMMUNOL, V91, P65
   KAYE D, 1965, P SOC EXP BIOL MED, V120, P810
   KAYE D, 1963, J IMMUNOL, V91, P518
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   Li XL, 2008, J IMMUNOL, V180, P6933
   MABEY DCW, 1987, J INFECT DIS, V155, P1319
   MAINES MD, 1984, BIOCHEM J, V217, P409
   Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237
   Mastroeni P, 2009, NAT REV MICROBIOL, V7, P73, DOI 10.1038/nrmicro2034
   Morpeth SC, 2009, CLIN INFECT DIS, V49, P606, DOI 10.1086/603553
   MURPHY JR, 1981, INFECT IMMUN, V31, P396
   Nairz M, 2007, CELL MICROBIOL, V9, P2126, DOI 10.1111/j.1462-5822.2007.00942.x
   Otterbein LE, 2009, RESP CARE, V54, P925, DOI 10.4187/002013209793800394
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Pamplona A, 2009, INT J BIOCHEM CELL B, V41, P711, DOI 10.1016/j.biocel.2008.09.020
   Pham NK, 2005, INFECT IMMUN, V73, P8322, DOI 10.1128/IAI.73.12.8322-8333.2005
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925
   Read AF, 2008, PLOS BIOL, V6, P2638, DOI 10.1371/journal.pbio.1000004
   Richardson MP, 1998, J IMMUNOL METHODS, V219, P187, DOI 10.1016/S0022-1759(98)00136-7
   Roux CM, 2010, INFECT IMMUN, V78, P1520, DOI 10.1128/IAI.00887-09
   Roy MF, 2007, J EXP MED, V204, P2949, DOI 10.1084/jem.20062606
   Ryter SW, 2009, AM J RESP CELL MOL, V41, P251, DOI 10.1165/rcmb.2009-0170TR
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   Schneider DS, 2008, NAT REV IMMUNOL, V8, P889, DOI 10.1038/nri2432
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Shan Y, 2006, FASEB J, V20, P2651, DOI 10.1096/fj.06-6346fje
   Sheppard FR, 2005, J LEUKOCYTE BIOL, V78, P1025, DOI 10.1189/jlb.0804442
   Soares MP, 2009, TRENDS MOL MED, V15, P50, DOI 10.1016/j.molmed.2008.12.004
   Sponaas AM, 2009, BLOOD, V114, P5522, DOI 10.1182/blood-2009-04-217489
   Sun K, 2008, NAT MED, V14, P558, DOI 10.1038/nm1765
   TENHUNEN R, 1969, J BIOL CHEM, V244, P6388
   Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802
   Wright J, 1997, J PEDIATR-US, V130, P394, DOI 10.1016/S0022-3476(97)70201-4
   Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165
   Zaki MH, 2009, J IMMUNOL, V182, P3746, DOI 10.4049/jimmunol.0803363
NR 55
TC 85
Z9 87
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD JAN
PY 2012
VL 18
IS 1
BP 120
EP 127
DI 10.1038/nm.2601
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 875GO
UT WOS:000299018600037
OA No
DA 2017-08-15
ER

PT J
AU van Tienen, C
   van der Loeff, MS
   Peterson, I
   Cotten, M
   Andersson, S
   Holmgren, B
   Vincent, T
   de Silva, T
   Rowland-Jones, S
   Aaby, P
   Whittle, H
AF van Tienen, Carla
   van der Loeff, Maarten Schim
   Peterson, Ingrid
   Cotten, Matthew
   Andersson, Soren
   Holmgren, Birgitta
   Vincent, Tim
   de Silva, Thushan
   Rowland-Jones, Sarah
   Aaby, Peter
   Whittle, Hilton
TI HTLV-1 and HIV-2 Infection Are Associated with Increased Mortality in a
   Rural West African Community
SO PLOS ONE
LA English
DT Article
ID VIRUS TYPE-1 HTLV-1; PLASMA VIRAL LOAD; GUINEA-BISSAU; INCREASED
   PREVALENCE; DUAL INFECTIONS; NORMAL SURVIVAL; PROVIRUS LOAD;
   RISK-FACTORS; OLDER WOMEN; POPULATION
AB Background: Survival of people with HIV-2 and HTLV-1 infection is better than that of HIV-1 infected people, but long-term follow-up data are rare. We compared mortality rates of HIV-1, HIV-2, and HTLV-1 infected subjects with those of retrovirus-uninfected people in a rural community in Guinea-Bissau.
   Methods: In 1990, 1997 and 2007, adult residents (aged >= 15 years) were interviewed, a blood sample was drawn and retroviral status was determined. An annual census was used to ascertain the vital status of all subjects. Cox regression analysis was used to estimate mortality hazard ratios (HR), comparing retrovirus-infected versus uninfected people.
   Results: A total of 5376 subjects were included; 197 with HIV-1, 424 with HIV-2 and 325 with HTLV-1 infection. The median follow-up time was 10.9 years (range 0.0-20.3). The crude mortality rates were 9.6 per 100 person-years of observation (95% confidence interval 7.1-12.9) for HIV-1, 4.1 (3.4-5.0) for HIV-2, 3.6 (2.9-4.6) for HTLV-1, and 1.6 (1.5-1.8) for retrovirus-negative subjects. The HR comparing the mortality rate of infected to that of uninfected subjects varied significantly with age. The adjusted HR for HIV-1 infection varied from 4.0 in the oldest age group (>= 60 years) to 12.7 in the youngest (15-29 years). The HR for HIV-2 infection varied from 1.2 (oldest) to 9.1 (youngest), and for HTLV-1 infection from 1.2 (oldest) to 3.8 (youngest).
   Conclusions: HTLV-1 infection is associated with significantly increased mortality. The mortality rate of HIV-2 infection, although lower than that of HIV-1 infection, is also increased, especially among young people.
C1 [van Tienen, Carla; Peterson, Ingrid; Cotten, Matthew; Vincent, Tim; de Silva, Thushan; Whittle, Hilton] MRC, Fajara, Gambia.
   [van der Loeff, Maarten Schim] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [Andersson, Soren] Swedish Inst Infect Dis Control, Stockholm, Sweden.
   [Holmgren, Birgitta] Lund Univ, Lund, Sweden.
   [Holmgren, Birgitta] Dept Lab Med, Malmo, Sweden.
   [de Silva, Thushan] UCL, Ctr Med Mol Virol, Div Infect & Immun, London, England.
   [Rowland-Jones, Sarah] John Radcliffe Hosp, Weatherall Inst Mol Med, Human Immunol Unit, Oxford OX3 9DU, England.
   [Aaby, Peter] Indepth Network, Proj Saude Bandim, Bissau, Guinea Bissau.
   [van der Loeff, Maarten Schim] Municipal Hlth Serv, Amsterdam, Netherlands.
RP van Tienen, C (reprint author), MRC, Fajara, Gambia.
EM mschim@ggd.amsterdam.nl
RI van Tienen, Carla/A-1119-2012
FU Medical Research Council, United Kingdom
FX Funding provided by the Medical Research Council, United Kingdom. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aaby P, 1996, AIDS, V10, P1585
   Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Ariyoshi K, 2003, J INFECT DIS, V188, P1648, DOI 10.1086/379780
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Brinkhof MWG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000066
   Brites C, 2009, AIDS REV, V11, P8
   Cooke FJ, 2005, J MED VIROL, V76, P143, DOI 10.1002/jmv.20336
   Cooper S, 2009, J NEUROL NEUROSUR PS, V80, P66, DOI 10.1136/jnnp.2008.152819
   DASILVA ZJ, 2009, AIDS
   de Silva Thushan I., 2010, HIV Therapy, V4, P305, DOI 10.2217/HIV.10.26
   GABBAI AA, 1993, AM J TROP MED HYG, V49, P664
   GESKUS R, 2009, 13 INT WORKSH HIV OB
   Holmgren B, 1999, SCAND J INFECT DIS, V31, P459
   Holmgren B, 2003, AIDS, V17, P241, DOI 10.1097/01.aids.0000042947.95433.d9
   Holmgren B, 2002, J ACQ IMMUN DEF SYND, V30, P342, DOI 10.1097/01.QAI.0000013943.86473.3E
   Holmgren B, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-85
   IWATA K, 1994, JPN J CANCER RES, V85, P231
   Krook A, 1997, J ACQ IMMUN DEF SYND, V15, P381
   Larsen O, 2000, J ACQ IMMUN DEF SYND, V25, P157, DOI 10.1097/00126334-200010010-00010
   Marinho J, 2005, JAIDS-J ACQ IMM DEF, V40, P625, DOI 10.1097/01.qai.0000174252.73516.7a
   Melbye M, 1998, INT J CANCER, V76, P293, DOI 10.1002/(SICI)1097-0215(19980504)76:3<293::AID-IJC1>3.0.CO;2-Q
   NORRGREN H, 2010, INT J INFECT DIS
   Norrgren HR, 2008, JAIDS-J ACQ IMM DEF, V48, P607, DOI 10.1097/QAI.0b013e31817efb83
   Oliveira I, 2010, AIDS, V24, P783, DOI 10.1097/QAD.0b013e328335cead
   Orland Jennie R, 2004, Retrovirology, V1, P4, DOI 10.1186/1742-4690-1-4
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   Seng R, 2002, AIDS, V16, P1059, DOI 10.1097/00002030-200205030-00013
   Todd J, 1997, AIDS, V11, P801, DOI 10.1097/00002030-199706000-00013
   van der Loeff MFS, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-46
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   van Tienen C, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-50
   van Tienen C, 2010, JAIDS-J ACQ IMM DEF, V53, P640, DOI 10.1097/QAI.0b013e3181bf1a25
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   von Elm E, 2007, PLOS MED, V4, P1623, DOI 10.1371/journal.pmed.0040296
   Zehender G, 2004, J MED VIROL, V74, P207, DOI 10.1002/jmv.20165
NR 38
TC 7
Z9 7
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 14
PY 2011
VL 6
IS 12
AR e29026
DI 10.1371/journal.pone.0029026
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 866GS
UT WOS:000298369100143
PM 22194980
OA gold
DA 2017-08-15
ER

PT J
AU Nair, H
   Brooks, WA
   Katz, M
   Roca, A
   Berkley, JA
   Madhi, SA
   Simmerman, JM
   Gordon, A
   Sato, M
   Howie, S
   Krishnan, A
   Ope, M
   Lindblade, KA
   Carosone-Link, P
   Lucero, M
   Ochieng, W
   Kamimoto, L
   Dueger, E
   Bhat, N
   Vong, S
   Theodoratou, E
   Chittaganpitch, M
   Chimah, O
   Balmaseda, A
   Buchy, P
   Harris, E
   Evans, V
   Katayose, M
   Gaur, B
   O'Callaghan-Gordo, C
   Goswami, D
   Arvelo, W
   Venter, M
   Briese, T
   Tokarz, R
   Widdowson, MA
   Mounts, AW
   Breiman, RF
   Feikin, DR
   Klugman, KP
   Olsen, SJ
   Gessner, BD
   Wright, PF
   Rudan, I
   Broor, S
   Simoes, EAF
   Campbell, H
AF Nair, Harish
   Brooks, W. Abdullah
   Katz, Mark
   Roca, Anna
   Berkley, James A.
   Madhi, Shabir A.
   Simmerman, James Mark
   Gordon, Aubree
   Sato, Masatoki
   Howie, Stephen
   Krishnan, Anand
   Ope, Maurice
   Lindblade, Kim A.
   Carosone-Link, Phyllis
   Lucero, Marilla
   Ochieng, Walter
   Kamimoto, Laurie
   Dueger, Erica
   Bhat, Niranjan
   Vong, Sirenda
   Theodoratou, Evropi
   Chittaganpitch, Malinee
   Chimah, Osaretin
   Balmaseda, Angel
   Buchy, Philippe
   Harris, Eva
   Evans, Valerie
   Katayose, Masahiko
   Gaur, Bharti
   O'Callaghan-Gordo, Cristina
   Goswami, Doli
   Arvelo, Wences
   Venter, Marietjie
   Briese, Thomas
   Tokarz, Rafal
   Widdowson, Marc-Alain
   Mounts, Anthony W.
   Breiman, Robert F.
   Feikin, Daniel R.
   Klugman, Keith P.
   Olsen, Sonja J.
   Gessner, Bradford D.
   Wright, Peter F.
   Rudan, Igor
   Broor, Shobha
   Simoes, Eric A. F.
   Campbell, Harry
TI Global burden of respiratory infections due to seasonal influenza in
   young children: a systematic review and meta-analysis
SO LANCET
LA English
DT Review
ID COMMUNITY-ACQUIRED PNEUMONIA; HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIAL
   VIRUS; HUMAN METAPNEUMOVIRUS; TRACT INFECTIONS; VIRAL ETIOLOGY;
   UNITED-STATES; STREPTOCOCCUS-PNEUMONIAE; PNEUMOCOCCAL PNEUMONIA;
   CHILDHOOD PNEUMONIA
AB Background The global burden of disease attributable to seasonal influenza virus in children is unknown. We aimed to estimate the global incidence of and mortality from lower respiratory infections associated with influenza in children younger than 5 years.
   Methods We estimated the incidence of influenza episodes, influenza-associated acute lower respiratory infections (ALRI), and influenza-associated severe ALRI in children younger than 5 years, stratified by age, with data from a systematic review of studies published between Jan 1, 1995, and Oct 31, 2010, and 16 unpublished population-based studies. We applied these incidence estimates to global population estimates for 2008 to calculate estimates for that year. We estimated possible bounds for influenza-associated ALRI mortality by combining incidence estimates with case fatality ratios from hospital-based reports and identifying studies with population-based data for influenza seasonality and monthly ALRI mortality.
   Findings We identified 43 suitable studies, with data for around 8 million children. We estimated that, in 2008, 90 million (95% CI 49-162 million) new cases of influenza (data from nine studies), 20 million (13-32 million) cases of influenza-associated ALRI (13% of all cases of paediatric ALRI; data from six studies), and 1 million (1-2 million) cases of influenza-associated severe ALRI (7% of cases of all severe paediatric ALRI; data from 39 studies) occurred worldwide in children younger than 5 years. We estimated there were 28 000-111 500 deaths in children younger than 5 years attributable to influenza-associated ALRI in 2008, with 99% of these deaths occurring in developing countries. Incidence and mortality varied substantially from year to year in any one setting.
   Interpretation Influenza is a common pathogen identified in children with ALRI and results in a substantial burden on health services worldwide. Sufficient data to precisely estimate the role of influenza in childhood mortality from ALRI are not available.
C1 [Nair, Harish] Univ Edinburgh, Ctr Populat Hlth Sci, Sch Med, Global Hlth Acad, Edinburgh EH8 9AG, Midlothian, Scotland.
   [Nair, Harish] Publ Hlth Fdn India, New Delhi, India.
   [Brooks, W. Abdullah; Goswami, Doli] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Katz, Mark; Breiman, Robert F.; Feikin, Daniel R.] Kenya Govt Med Res Ctr, Nairobi, Kenya.
   [Katz, Mark; Breiman, Robert F.; Feikin, Daniel R.] Ctr Dis Control & Prevent Kenya, Nairobi, Kenya.
   [Roca, Anna; O'Callaghan-Gordo, Cristina] Univ Barcelona, Ctr Int Hlth Res CRESIB, Hosp Clin, IDIBAPS, Barcelona, Spain.
   [Berkley, James A.] Ctr Geog Med Res Coast, Kilin, Kenya.
   [Berkley, James A.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Madhi, Shabir A.] Univ Witwatersrand, Med Res Council, Resp & Meningeal Pathogens Res Unit, ZA-2050 Wits, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, ZA-2050 Wits, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, ZA-2050 Wits, South Africa.
   [Simmerman, James Mark; Olsen, Sonja J.] US Ctr Dis Control & Prevent Thailand, Div & Int Emerging Infect Program, MOPH Collaborat, Nonthaburi, Thailand.
   [Gordon, Aubree; Harris, Eva] Univ Calif Berkeley, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Gordon, Aubree] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
   [Sato, Masatoki] Fukushima Med Univ, Dept Paediat, Sch Med, Fukushima, Japan.
   [Howie, Stephen; Chimah, Osaretin] Med Res Council UK Labs, Banjul, Gambia.
   [Krishnan, Anand; Gaur, Bharti] All India Inst Med Sci, New Delhi, India.
   [Lindblade, Kim A.; Arvelo, Wences] Ctr Dis Control & Prevent, Global Dis Detect Program, Reg Off Cent Amer & Panama, Guatemala City, Guatemala.
   [Carosone-Link, Phyllis; Simoes, Eric A. F.] Univ Colorado, Denver, CO 80202 USA.
   [Lindblade, Kim A.; Simoes, Eric A. F.] Childrens Hosp, Denver, CO 80218 USA.
   [Ochieng, Walter] Kenya Govt Med Res Ctr, Ctr Virus Res, Nairobi, Kenya.
   [Kamimoto, Laurie; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Dueger, Erica] Global Dis Detect & Response Ctr, Naval Med Res Unit 3, Cairo, Egypt.
   [Bhat, Niranjan] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Amer Indian Hlth, Baltimore, MD USA.
   [Chittaganpitch, Malinee] Minist Publ Hlth, Natl Inst Hlth, Nonthaburi, Thailand.
   [Chimah, Osaretin] Med Ctr, Asaba, Delta State, Nigeria.
   [Katayose, Masahiko] Soma Gen Hosp, Dept Paediat, Soma, Japan.
   [Venter, Marietjie] Natl Inst Communicable Dis, Resp Virus Unit, Natl Inflenza Ctr, Natl Hlth Lab Serv, Johannesburg, South Africa.
   [Venter, Marietjie] Univ Pretoria, Resp & Zoonot Virus Programme, Dept Med Virol, ZA-0002 Pretoria, South Africa.
   [Briese, Thomas; Tokarz, Rafal] Columbia Univ, Ctr Infect & Immun, Mailman Sch Publ Hlth, New York, NY USA.
   [Mounts, Anthony W.] World Hlth Org, Global Influenza Program, Geneva, Switzerland.
   [Klugman, Keith P.] Emory Univ, Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Klugman, Keith P.] Emory Univ, Div Infect Dis, Sch Med, Atlanta, GA 30322 USA.
   [Gessner, Bradford D.] Agence Med Prevent, Paris, France.
   [Wright, Peter F.] Dartmouth Med Sch, Div Infect Dis & Int Hlth, Lebanon, NH USA.
   [Rudan, Igor] Univ Split, Croatian Ctr Global Hlth, Fac Med, Split, Croatia.
   [Simoes, Eric A. F.] Univ Padjadjaram, Bandung, Indonesia.
RP Nair, H (reprint author), Univ Edinburgh, Ctr Populat Hlth Sci, Sch Med, Global Hlth Acad, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.
EM harish.nair@ed.ac.uk; harry.campbell@ed.ac.uk
RI Nair, Harish/E-7431-2010; Krishnan, Anand/D-8537-2012; Rudan,
   Igor/I-1467-2012; Theodoratou, Evropi/C-3430-2014; Venter,
   Marietjie/P-9604-2016
OI Nair, Harish/0000-0002-9432-9100; Rudan, Igor/0000-0001-6993-6884;
   Theodoratou, Evropi/0000-0001-5887-9132; Venter,
   Marietjie/0000-0003-2696-824X; Widdowson,
   Marc-Alain/0000-0002-0682-6933; O'Callaghan-Gordo,
   Cristina/0000-0002-4229-2991; Gordon, Aubree/0000-0002-9352-7877;
   Berkley, James/0000-0002-1236-849X; Krishnan, Anand/0000-0002-9173-7811
FU WHO [HQGIP1002906]; Bill & Melinda Gates Foundation [51285]; Wyeth;
   Pfizer; GSK; Sanofi Pasteur; GlaxoSmithKline; Merck; MedImmune; Roche;
   Aventis Pasteur; Evans-Powderject; US Centers for Disease Control and
   Prevention (CDC); Indian Council of Medical Research
FX WHO; Bill & Melinda Gates Foundation.; SAM has received research funding
   from Wyeth for the Soweto study that contributed to the data. He has
   received consultancy from Pfizer, GSK, and Novartis and speaker fees
   from Pfizer and GSK. However, no honoraria were received for work
   included in this study. BDG has received consultancy from WHO and a
   travel grant from Sanofi Pasteur to attend a conference on influenza in
   2010. He is employed by Agence de Medecine Preventive, which has
   received funding from WHO, Pfizer, GlaxoSmithKline, and Merck. In 2010,
   the Agence de Medecine Preventive was hired by Sanofi Pasteur to
   organize a conference on influenza. However, no grants or honoraria were
   received for work included in this study. EAFS has received speaker fees
   and consultancy from MedImmune and research grants from Roche and
   MedImmune. However, no grants or honoraria were received for work
   included in this study. NB is employed by Johns Hopkins University which
   has received funding from Aventis Pasteur and Evans-Powderject. All
   other authors declare that they have no conflicts of interest.;
   Financial support for this work was provided by WHO Global Influenza
   Program (grant number HQGIP1002906) and the Bill & Melinda Gates
   Foundation (grant number 51285). The study in Ballabgarh, India,
   received financial support from US Centers for Disease Control and
   Prevention (CDC) and Indian Council of Medical Research. This work was
   done as part of the wider programme of the Child Health Epidemiology
   Working Group (CHERG) to establish the major causes of global childhood
   disease burden. Walter Ochieng sadly died suddenly and unexpectedly
   while this paper was being prepared for publication. We would like to
   acknowledge his important contribution to this study and his role in
   strengthening influenza surveillance in Kenya. We thank Johannes Forster
   (Department of Paediatrics, St Josefskrankenhaus Freiburg and University
   of Freiburg, Freiburg, Germany), Gabriele Ihorst (Clinical Trials
   Center, University Medical Centre Freiburg, Freiburg, Germany), Terho
   Heikkinen (Turku University Hospital, Turku, Finland), Alex Ezeh, Samuel
   Oti, and Catherine Kyobutungi (African Population and Health Research
   Centre, Nairobi, Kenya), and the Influenza Emerging Infections Program
   Network, USA for providing additional data from their published papers;
   Vivek Gupta and Sanjay K Rai (Comprehensive Rural Health Services
   Project, Ballabgarh and All India Institute of Medical Sciences, New
   Delhi, India); Samander Kaushik and Yashpal Singh (Department of
   Microbiology, All India Institute of Medical Sciences, New Delhi,
   India); National Institute of Virology, Pune, India; Wallace D Bulimo
   (National Influenza Centre, Nairobi, Kenya); Respiratory and Zoonosis
   group, Department of Medical Virology, University of Pretoria, South
   Africa; D James Nokes (KEMRI, Kilifi, Kenya); Locadiah Kuwanda (Chris
   Hani Baragwanath Hospital, Johannesburg, South Africa); Pedro L Alonso,
   Ll Quinto, Q Bassat (CRESIB, Hospital Clinic/IDIBAPS, Universitat de
   Barcelona, Barcelona, Spain and Centro de Investigacao em Saude da
   Manhica, Ministerio de Saude, Maputo, Mozambique); Jens Levy (Influenza
   Division and International Emerging Infections Program, US CDC-Thailand
   MOPH Collaboration, Nonthaburi, Thailand); Alejandra Estevez, Fabiola
   Moscoso, and Jennifer Gray (Centro de Estudios en Salud, Universidad del
   Valle de Guatemala); Lissette Reyes, Juan Carlos Moir (Ministerio de
   Salud Publica y Asistencia Social, Guatemala); Alicia M Fry (Influenza
   Division, CDC, Atlanta, USA); Hanna Nohynek, Taneli Puumalainen and
   Petri Ruutu (National Institute for Health and Welfare, Finland);
   Leilani Nillos (Research Institute for Tropical Medicine, Department of
   Health, Alabang, Muntinlupa, Philippines) and ARIVAC consortium; Ian
   Lipkin (University of Columbia, New York); Gerard Morris (University
   Witwatersrand, South Africa); Grant Mackenzie, Readon Ideh, Bernard
   Ebruke, Claire Oluwalana (MRC, Gambia) and the Gambia Severe Pneumonia
   Studies Group; Karen Fowler (University of Alabama at Birmingham,
   Birmingham, AL, USA); Katherine O'Brien (Center for American Indian
   Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
   USA) for their assistance; Jian Shayne F Zhang (Centre for Population
   Health Sciences, The University of Edinburgh, UK) for doing the
   literature search in Chinese language databases; Carolyn B Bridges
   (Influenza Division, National Center for Immunizations and Respiratory
   Disease, CDC, Atlanta, GA, USA) for critically reviewing the manuscript
   and providing helpful comments.; The findings and conclusions in this
   report are those of the authors and do not necessarily represent he
   views of the US CDC or WHO.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   *AIIMS, 53 AIIMS ANN REP 200
   Ajayi-Obe EK, 2008, EPIDEMIOL INFECT, V136, P1046, DOI 10.1017/S0950268807009557
   Ampofo K, 2006, PEDIATRICS, V118, P2409, DOI 10.1542/peds.2006-1475
   Berkley JA, 2010, JAMA-J AM MED ASSOC, V303, P2051, DOI 10.1001/jama.2010.675
   Bigogo G, 2010, INT J INFECT DIS, V14, pE967, DOI 10.1016/j.ijid.2010.05.016
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Bourgeois FT, 2006, PEDIATRICS, V118, pE1, DOI 10.1542/peds.2005-2248
   Brooks WA, 2010, PEDIATR INFECT DIS J, V29, P216, DOI 10.1097/INF.0b013e3181bc23fd
   Broor S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000491
   Brotherton J, 2004, COMMUN DIS INTELL S2, V28
   Bueving HJ, 2005, REV MED VIROL, V15, P383, DOI 10.1002/rmv.477
   Chiu SS, 2009, CLIN INFECT DIS, V49, P1016, DOI 10.1086/605570
   Coelho MC, 2007, BRAZ J INFECT DIS, V11, P220, DOI 10.1590/S1413-86702007000200010
   Coffin SE, 2007, PEDIATRICS, V119, P740, DOI 10.1542/peds.2006-2679
   D'Onise K, 2008, MED J AUSTRALIA, V188, P510
   Dawood FS, 2010, J PEDIATR-US, V157, P808, DOI 10.1016/j.jpeds.2010.05.012
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   ESPY MJ, 1986, J CLIN MICROBIOL, V24, P677
   Forster J, 2004, EUR J PEDIATR, V163, P709, DOI 10.1007/s00431-004-1523-9
   Foulongne V, 2006, PEDIATR INFECT DIS J, V25, P354, DOI 10.1097/01.inf.0000207480.55201.f6
   GRAHAM NMH, 1990, EPIDEMIOL REV, V12, P149
   Grijalva CG, 2007, EPIDEMIOL INFECT, V135, P951, DOI 10.1017/S095026880600762X
   Grijalva CG, 2007, PEDIATRICS, V119, pE6, DOI 10.1542/peds.2006-1694
   Grijalva CG, 2006, EMERG INFECT DIS, V12, P103
   Hamelin ME, 2004, CLIN INFECT DIS, V38, P983, DOI 10.1086/382536
   Hasan K, 2006, SCAND J INFECT DIS, V38, P690, DOI 10.1080/00365540600606473
   Heikkinen T, 2004, J INFECT DIS, V190, P1369, DOI 10.1086/424527
   Henrickson KJ, 2004, PEDIATR INFECT DIS J, V23, pS11, DOI 10.1097/01.inf.0000108188.37237.48
   *I HLTH METR EV, 2009, GLOB BURD D IN PRESS
   ISAACS D, 1989, PEDIATR INFECT DIS J, V8, P143
   Iskander M, 2007, CURR OPIN INFECT DIS, V20, P259, DOI 10.1097/QCO.0b013e3280ad4687
   Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758
   Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402
   Ji W, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-82
   Johnson AWBR, 2008, J NATL MED ASSOC, V100, P370
   Johnson BF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007671
   Karaivanova G M, 1995, Afr J Med Med Sci, V24, P1
   Klugman KP, 2009, VACCINE, V27, pC9, DOI 10.1016/j.vaccine.2009.06.007
   Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3
   Kwong KL, 2009, J PAEDIATR CHILD H, V45, P660, DOI 10.1111/j.1440-1754.2009.01591.x
   Lankinen KS, 1997, AM J TROP MED HYG, V56, P211
   Madhi SA, 2007, PEDIATR INFECT DIS J, V26, P693, DOI 10.1097/INF.0b013e3180621192
   McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05
   McCullers JA, 2010, J INFECT DIS, V202, P1287, DOI 10.1086/656333
   Milne Bronwyn G, 2004, Commun Dis Intell Q Rep, V28, P504
   Montes M, 2005, Vaccine, V23, P4302, DOI 10.1016/j.vaccine.2005.04.006
   Moore DL, 2006, PEDIATRICS, V118, pE610, DOI 10.1542/peds.2005-2744
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Nascimento-Carvalho CM, 2010, SCAND J INFECT DIS, V42, P839, DOI 10.3109/00365548.2010.498020
   Nelson Edmund A. S., 2007, Hong Kong Medical Journal, V13, P114
   Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363
   Nicholson KG, 2006, VACCINE, V24, P102, DOI 10.1016/j.vaccine.2005.02.004
   Nokes DJ, 2008, CLIN INFECT DIS, V46, P50, DOI 10.1086/524019
   Nokes DJ, 2009, CLIN INFECT DIS, V49, P1341, DOI 10.1086/606055
   Nongkynrih Baridalyne, 2003, Indian Pediatr, V40, P766
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   O'Brien KL, 2000, CLIN INFECT DIS, V30, P784, DOI 10.1086/313772
   O'Callaghan-Gordo C, 2011, PEDIATR INFECT DIS J, V30, P39, DOI 10.1097/INF.0b013e3181f232fe
   Ortiz JR, 2009, EMERG INFECT DIS, V15, P1271, DOI 10.3201/eid1508.081422
   Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869
   Rawlinson WD, 2004, J MED VIROL, V74, P127, DOI 10.1002/jmv.20155
   Regamey N, 2008, PEDIATR INFECT DIS J, V27, P100, DOI 10.1097/INF.0b013e31815922c8
   Rojo JC, 2006, PEDIATR INFECT DIS J, V25, P596, DOI 10.1097/01.inf.0000220208.59965.95
   Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Sam IC, 2010, INT J INFECT DIS, V14, pE36, DOI 10.1016/j.ijid.2009.10.005
   Schrag SJ, 2006, PEDIATR INFECT DIS J, V25, P395, DOI 10.1097/01.inf.0000214988.81379.71
   Simmerman JM, 2008, INFLUENZA OTHER RESP, V2, P81, DOI 10.1111/j.1750-2659.2008.00045.x
   Singeton RJ, 2010, J MED VIROL, V82, P1282, DOI 10.1002/jmv.21790
   Stockton J, 1998, J CLIN MICROBIOL, V36, P2990
   Straliotto SM, 2004, MEM I OSWALDO CRUZ, V99, P883, DOI 10.1590/S0074-02762004000800017
   Sutanto A, 2002, AM J TROP MED HYG, V66, P175
   SUTMOLLER F, 1995, CLIN INFECT DIS, V20, P854
   Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   *UNICEF, 2009, STAT WORLDS CHIDR SP
   Watt JP, 2009, LANCET, V374, P903, DOI 10.1016/S0140-6736(09)61203-4
   Weber MW, 2002, B WORLD HEALTH ORGAN, V80, P562
   Weigl JAI, 2005, KLIN PADIATR, V217, P259, DOI 10.1055/s-2004-820352
   World Health Organization, 1985, CAS MAN AC RESP INF
   World Health Organization, 2008, GLOB BURD DIS 2004 U
   World Health Organization, 1991, TECHN BAS WHO REC MA
   Wolf DG, 2006, PEDIATR INFECT DIS J, V25, P320, DOI 10.1097/01.inf.0000207395.80657.cf
   Ye Y, 2009, AM J TROP MED HYG, V81, P770, DOI 10.4269/ajtmh.2009.09-0070
   Yoo Y, 2007, CLIN VACCINE IMMUNOL, V14, P1050, DOI 10.1128/CVI.00465-06
   Yoshida LM, 2010, PEDIATR INFECT DIS J, V29, P75, DOI 10.1097/INF.0b013e3181af61e9
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
NR 89
TC 242
Z9 250
U1 5
U2 47
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD DEC 3
PY 2011
VL 378
IS 9807
BP 1917
EP 1930
DI 10.1016/S0140-6736(11)61051-9
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 863AW
UT WOS:000298136200026
PM 22078723
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Hegedus, A
   Nyamweya, S
   Govind, S
   Aspinall, R
   Jansen, V
   Jaye, A
   Macallan, D
   Flanagan, K
AF Hegedus, A.
   Nyamweya, S.
   Govind, S.
   Aspinall, R.
   Jansen, V.
   Jaye, A.
   Macallan, D.
   Flanagan, K.
TI A comparison of the effects of HIV-1 and HIV-2 infection on T-lymphocyte
   turnover and their relationship to immune activation
SO IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Congress of the British-Society-for-Immunology
CY DEC 05-08, 2011
CL Liverpool, ENGLAND
SP British Soc Immunol
C1 [Hegedus, A.; Macallan, D.] St Georges Univ London, Res Ctr Infect & Immun, London, England.
   [Nyamweya, S.; Jaye, A.] MRC Unit Gambia, Fajara, Gambia.
   [Govind, S.; Aspinall, R.] Cranfield Univ, Cranfield Hlth, Cranfield MK43 0AL, Beds, England.
   [Jansen, V.] Univ London, Egham, Surrey, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD DEC
PY 2011
VL 135
SU 1
SI SI
BP 36
EP 36
PG 1
WC Immunology
SC Immunology
GA 854PQ
UT WOS:000297507100093
OA No
DA 2017-08-15
ER

PT J
AU Konteh, FN
   Adetifa, J
   Lee, MT
   Barker, F
   Cox, M
   Drammeh, A
   Nyamweya, S
   Kampmann, B
   van der Sande, M
   van der Klis, F
   Rowland-Jones, S
   Whittle, H
   Thorsten, F
   Dickinson, P
   Ghazal, P
   Flanagan, KL
AF Konteh, F. N.
   Adetifa, J.
   Lee, M. T.
   Barker, F.
   Cox, M.
   Drammeh, A.
   Nyamweya, S.
   Kampmann, B.
   van der Sande, M.
   van der Klis, F.
   Rowland-Jones, S.
   Whittle, H.
   Thorsten, F.
   Dickinson, P.
   Ghazal, P.
   Flanagan, K. L.
TI The immunological effects of co-administering diphtheria, tetanus,
   pertussis combined vaccine with measles vaccine to 9 month old Gambian
   infants
SO IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Congress of the British-Society-for-Immunology
CY DEC 05-08, 2011
CL Liverpool, ENGLAND
SP British Soc Immunol
C1 [Konteh, F. N.; Adetifa, J.; Lee, M. T.; Barker, F.; Cox, M.; Drammeh, A.; Nyamweya, S.; Kampmann, B.; Rowland-Jones, S.; Whittle, H.; Flanagan, K. L.] MRC Labs, Banjul, Gambia.
   [van der Sande, M.; van der Klis, F.] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
   [Thorsten, F.; Dickinson, P.; Ghazal, P.] Univ Edinburgh, Div Pathway Med, Edinburgh, Midlothian, Scotland.
RI Dickinson, Paul/B-7598-2014
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD DEC
PY 2011
VL 135
SU 1
SI SI
BP 62
EP 62
PG 1
WC Immunology
SC Immunology
GA 854PQ
UT WOS:000297507100165
OA No
DA 2017-08-15
ER

PT J
AU Hawkesworth, S
   Walker, CG
   Sawo, Y
   Fulford, AJC
   Jarjou, LMA
   Goldberg, GR
   Prentice, A
   Prentice, AM
   Moore, SE
AF Hawkesworth, Sophie
   Walker, Celia G.
   Sawo, Yankuba
   Fulford, Anthony J. C.
   Jarjou, Landing M. A.
   Goldberg, Gail R.
   Prentice, Ann
   Prentice, Andrew M.
   Moore, Sophie E.
TI Nutritional supplementation during pregnancy and offspring
   cardiovascular disease risk in The Gambia
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article; Proceedings Paper
CT International Conference on The Power of Programming - Developmental
   Origins of Health and Disease
CY MAY 06-08, 2010
CL Univ Munich Med Ctr, Munich, GERMANY
SP Early Nutr Acad, European Early Nutr Programming Project, Dev Origins Hlth & Dis Soc, Abbott Nutr Hlth Inst/Abbott Nutr, Danone Baby Nutr/Danone Res, Nestle Nutr Inst, Ferrero MSC GmbH & Co KG, S.A. Beneo Orafti, Biovitrum AB, DSM Nutrit Prod Ltd, Fresenius Kabi Deutschland GmbH, Labs Ordesa SL, Life Measurement Inc, Martek Corp
HO Univ Munich Med Ctr
ID RANDOMIZED CONTROLLED-TRIAL; MATERNAL CALCIUM SUPPLEMENTATION;
   ADOLESCENT BLOOD-PRESSURE; REDUCED FETAL-GROWTH; FOLLOW-UP; DIETARY
   SUPPLEMENTATION; METABOLIC SYNDROME; MICRONUTRIENT SUPPLEMENTATION;
   BODY-COMPOSITION; GESTATIONAL AGE
AB Background: Maternal nutritional intake during pregnancy may have important consequences for long-term health in offspring.
   Objective: The objective was to follow up the offspring in 2 randomized trials of nutrient supplementation during pregnancy to investigate the effect on cardiovascular disease (CVD) risk in offspring.
   Design: We recruited offspring born during 2 trials in The Gambia, West Africa. One trial provided protein-energy-dense food supplements (1015 kcal and 22 g protein/d) to pregnant (intervention, from 20 wk gestation until delivery) or lactating (control, for 20 wk from birth) women and was randomized at the village level. The second was a double-blind, individually randomized, placebo-controlled trial of calcium supplementation (1.5 g/d), which was also provided from 20 wk gestation until delivery.
   Results: Sixty-two percent (n = 1267) of children (aged 11-17 y) born during the protein-energy trial were recruited and included in the analysis, and 64% (n = 350) of children (aged 5-10 y) born during the calcium trial were recruited and included in the analysis. Fasted plasma glucose was marginally lower in children born to mothers receiving protein-energy supplements during pregnancy than in those children of the lactating group (adjusted mean difference: 20.05 mmol/L; 95% CI: -0.10, -0.001 mmol/L). There were no other differences in CVD risk factors, including blood pressure, body composition, and cholesterol, between children born to intervention and control women from the protein-energy trial. Maternal calcium supplementation during pregnancy was unrelated to offspring blood pressure.
   Conclusion: These data suggest that providing supplements to pregnant women in the second half of pregnancy may have little effect on the CVD risk of their offspring, at least in this setting and at the ages studied here. This trial was registered at www.controlled-trials.com as ISRCTN96502494 Am J Clin Nutr 2011;94(suppl):1853S-60S.
C1 [Hawkesworth, Sophie] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Nutr & Publ Hlth Intervent Res Unit, MRC Int Nutr Grp, London WC1E 7HT, England.
   [Walker, Celia G.; Goldberg, Gail R.; Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
   [Sawo, Yankuba; Jarjou, Landing M. A.; Goldberg, Gail R.; Prentice, Ann; Prentice, Andrew M.; Moore, Sophie E.] MRC Keneba, MRC Labs, Fajara, Gambia.
RP Hawkesworth, S (reprint author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Nutr & Publ Hlth Intervent Res Unit, MRC Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM sophie.hawkesworth@lshtm.ac.uk
OI Hawkesworth, Sophie/0000-0002-3554-242X
FU Medical Research Council [, MC_U105960371, MC_U123292699, MC_U123292701]
CR Adair L, 2005, ANNU REV NUTR, V25, P407, DOI 10.1146/annurev.nutr.25.050304.092538
   Adair LS, 2001, CIRCULATION, V104, P1034, DOI 10.1161/hc3401.095037
   BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095
   Barker DJP, 1998, MOTHERS BABIES HLTH
   Belizan JM, 1997, BRIT MED J, V315, P281
   Brion MJA, 2008, PEDIATR RES, V63, P593, DOI 10.1203/PDR.0b013e31816fdbd3
   Campbell DM, 1996, BRIT J OBSTET GYNAEC, V103, P273, DOI 10.1111/j.1471-0528.1996.tb09718.x
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Conlisk AJ, 2004, J NUTR, V134, P890
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Falkner B, 1996, PEDIATRICS, V98, P649
   Fernandez-Twinn DS, 2006, PHYSIOL BEHAV, V88, P234, DOI 10.1016/j.physbeh.2006.05.039
   Fewtrell MS, 2008, ARCH DIS CHILD, V93, P458, DOI 10.1136/adc.2007.127316
   Fulford AJC, 2006, PAEDIATR PERINAT EP, V20, P251, DOI 10.1111/j.1365-3016.2006.00714.x
   Gambling L, 2003, J PHYSIOL-LONDON, V552, P603, DOI 10.1113/jphysiol.2003.051383
   Gillman MW, 2004, CIRCULATION, V110, P1990, DOI 10.1161/01.CIR.0000143199.93495.96
   Gluckman PD, 2004, TRENDS ENDOCRIN MET, V15, P183, DOI 10.1016/j.tem.2004.03.002
   Harding JE, 2001, INT J EPIDEMIOL, V30, P15, DOI 10.1093/ije/30.1.15
   Hatton DC, 2003, AM J HYPERTENS, V16, P801, DOI 10.1016/S0895-7061(03)01027-6
   Hawkesworth S, 2009, INT J EPIDEMIOL, V38, P119, DOI 10.1093/ije/dyn156
   Hawkesworth S, 2008, J NUTR, V138, P2468, DOI 10.3945/jn.108.098665
   Hawkesworth S, 2010, AM J CLIN NUTR, V92, P741, DOI 10.3945/ajcn.2010.29475
   Hawkesworth S, 2009, P NUTR SOC, V68, P78, DOI 10.1017/S0029665108008781
   Hiller JE, 2007, AUST NZ J OBSTET GYN, V47, P115, DOI 10.1111/j.1479-828X.2007.00696.x
   Huh SY, 2005, INT J EPIDEMIOL, V34, P378, DOI 10.1093/ije/dyh373
   Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   Kajantie E, 2005, INT J EPIDEMIOL, V34, P655
   Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402
   Kinra S, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a605
   Langley-Evans SC, 2006, P NUTR SOC, V65, P97, DOI 10.1079/PNS2005478
   Langley-Evans SC, 1999, LIFE SCI, V64, P965, DOI 10.1016/S0024-3205(99)00022-3
   Leary SD, 2005, ARCH DIS CHILD, V90, P492, DOI 10.1136/adc.2004.070698
   Leon DA, 1998, BRIT MED J, V317, P241
   MARTORELL R, 1995, J NUTR, V125, pS1027
   MARTORELL R, 1995, J NUTR, V125, pS1127
   McArdle HJ, 2006, PLACENTA, V27, pS56, DOI 10.1016/j.placenta.2006.01.014
   MCGARVEY ST, 1991, HYPERTENSION, V17, P218
   Morley R, 2004, INT J EPIDEMIOL, V33, P1304, DOI 10.1093/ije/dyh284
   PARKIN JM, 1976, ARCH DIS CHILD, V51, P259
   PRENTICE A, 1994, ADV EXP MED BIOL, V352, P243
   Prentice A, 2000, AM J CLIN NUTR, V71, p1312S
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P65
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P53
   Prins M, 2008, EUR J CLIN NUTR, V62, P1065, DOI 10.1038/sj.ejcn.1602830
   RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701
   RIVERA JA, 1995, J NUTR, V125, pS1068
   Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001
   Simmons RA, 2001, DIABETES, V50, P2279, DOI 10.2337/diabetes.50.10.2279
   Stein AD, 2006, EUR J EPIDEMIOL, V21, P759, DOI 10.1007/s10654-006-9065-2
   Stein AD, 2006, AM J EPIDEMIOL, V164, P1160, DOI 10.1093/aje/kwj328
   Stewart CP, 2009, J NUTR, V139, P1575, DOI 10.3945/jn.109.106666
   Vaidya A, 2008, LANCET, V371, P492, DOI 10.1016/S0140-6736(08)60172-5
   Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83
   Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487
   Wells JCK, 2002, INT J OBESITY, V26, P947, DOI 10.1038/sj.ijo.0802027
   Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zimmet P, 2007, PEDIATR DIABETES, V8, P299, DOI 10.1111/j.1399-5448.2007.00271.x
NR 60
TC 17
Z9 18
U1 0
U2 9
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD DEC
PY 2011
VL 94
IS 6
BP 1853S
EP 1860S
DI 10.3945/ajcn.110.000877
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 852PA
UT WOS:000297368700070
PM 21677054
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Ramadhani, A
   Weiss, HA
   Hu, V
   Massae, P
   Burr, SE
   Shangali, W
   Holland, MJ
   Mabey, DCW
   Bailey, RL
AF Burton, Matthew J.
   Ramadhani, Athumani
   Weiss, Helen A.
   Hu, Victor
   Massae, Patrick
   Burr, Sarah E.
   Shangali, Wahida
   Holland, Martin J.
   Mabey, David C. W.
   Bailey, Robin L.
TI Active Trachoma Is Associated with Increased Conjunctival Expression of
   IL17A and Profibrotic Cytokines
SO INFECTION AND IMMUNITY
LA English
DT Article
ID TISSUE GROWTH-FACTOR; CHLAMYDIAL GENITAL-INFECTION; PROINFLAMMATORY
   CYTOKINES; PULMONARY-FIBROSIS; SYSTEMIC-SCLEROSIS; PROTEIN PSORIASIN;
   ESCHERICHIA-COLI; GENE-EXPRESSION; ONCOSTATIN-M; CELLS
AB The immunological basis of scarring trachoma is not well understood. It is unclear whether it is driven primarily through cell-mediated adaptive or epithelial-cell-derived innate responses. The purpose of this study was to investigate the expression of the inflammatory and fibrogenic mediators which may be involved. We conducted a cross-sectional survey of children living in an untreated trachoma-endemic community in Tanzania. The children were examined for signs of trachoma, and swabs were collected for bacteriological culture and RNA and DNA isolation. Chlamydia trachomatis was detected by the Amplicor PCR test. The expression of the following genes was measured by quantitative reverse transcription-PCR (RT-PCR): S100A7, IL1B, IL17A, IL23A, CXCL5, CCL18, TLR2, NLRP3, KLRD1, CTGF, and MMP9. Four hundred seventy children under the age of 10 years were included. Follicular trachoma (TF) was detected in 65 children (14%), C. trachomatis was detected in 25 (5%), and bacterial pathogens were cultured in 161 (34%). TF was associated with significantly increased expression of S100A7, IL17A, CCL18, CXCL5, and CTGF. Expression was increased further in the presence of papillary inflammation. Nonchlamydial bacterial infection was associated with increased expression of IL17A, CXCL5, CCL18, and KLRD1. IL17A expression was associated with increased expression of S100A7, CXCL5, CCL18, KLRD1, and CTGF. These data are consistent with a role for IL-17A in orchestrating the proinflammatory response in trachoma. Its activity may be promoted either as part of the cell-mediated response or through innate pathways. It may drive a range of proinflammatory factors leading to excessive tissue damage and repair involving fibrosis.
C1 [Burton, Matthew J.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Burton, Matthew J.; Ramadhani, Athumani; Hu, Victor; Massae, Patrick] Kilimanjaro Christian Med Ctr, Moshi, Tanzania.
   [Burr, Sarah E.] MRC Labs, Fajara, Gambia.
   [Shangali, Wahida] Kilimanjaro Reg Eye Care Programme, Moshi, Tanzania.
RP Burton, MJ (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU Wellcome Trust [080741/Z/06/Z]
FX This work was supported by a grant to M.J.B. from The Wellcome Trust
   (080741/Z/06/Z).
CR Abraham D, 2008, RHEUMATOLOGY, V47, pV8, DOI 10.1093/rheumatology/ken278
   Abtin A, 2008, FASEB J, V22, P2168, DOI 10.1096/fj.07-104117
   Abu El-Asrar AM, 2006, EYE, V20, P362, DOI 10.1038/sj.eye.6701884
   BAILEY RL, 1993, EPIDEMIOL INFECT, V111, P315
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   Bobo L, 1996, INFECT IMMUN, V64, P3273
   Burton MJ, 2011, INVEST OPHTH VIS SCI, V52, P6012, DOI 10.1167/iovs.11-7326
   Burton MJ, 2011, INFECT IMMUN, V79, P499, DOI 10.1128/IAI.00888-10
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P1282, DOI 10.1136/bjo.2004.062489
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Chang Y, 2010, FASEB J, V24, P5063, DOI 10.1096/fj.10-162560
   Chen Xin-Ming, 2009, Front Biosci (Schol Ed), V1, P132, DOI 10.2741/s13
   Darville T, 2010, J INFECT DIS, V201, pS114, DOI 10.1086/652397
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Dawson CR, 1990, CHLAMYDIAL INFECT, P271
   Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x
   Garreis F, 2011, INVEST OPHTH VIS SCI, V52, P4914, DOI 10.1167/iovs.10-6598
   GhaemMaghami S, 1997, INFECT IMMUN, V65, P4958
   Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142
   Gressner OA, 2008, LIVER INT, V28, P1065, DOI 10.1111/j.1478-3231.2008.01826.x
   Guilloteau K, 2010, J IMMUNOL, V184, P5263, DOI 10.4049/jimmunol.0902464
   Holland MJ, 2010, INVEST OPHTH VIS SCI, V51, P3893, DOI 10.1167/iovs.09-5054
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   Hu VH, 2011, INVEST OPHTH VIS SCI, V52, P2181, DOI 10.1167/iovs.10-5829
   Jeyaseelan S, 2005, AM J RESP CELL MOL, V32, P531, DOI 10.1165/rcmb.2005-0063OC
   Jinquan Tan, 1996, Journal of Investigative Dermatology, V107, P5, DOI 10.1111/1523-1747.ep12294284
   Keenan JD, 2010, AM J TROP MED HYG, V82, P482, DOI 10.4269/ajtmh.2010.09-0315
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041
   Mathai SK, 2010, LAB INVEST, V90, P812, DOI 10.1038/labinvest.2010.73
   Meyer-Hoffert U, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016433
   Michalek M, 2009, DEV COMP IMMUNOL, V33, P740, DOI 10.1016/j.dci.2008.12.005
   Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K
   Natividad A, 2010, INFECT IMMUN, V78, P4895, DOI 10.1128/IAI.00844-10
   Nedeau AE, 2008, EXP CELL RES, V314, P2176, DOI 10.1016/j.yexcr.2008.04.007
   Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x
   Phanish MK, 2010, NEPHRON EXP NEPHROL, V114, pE83, DOI 10.1159/000262316
   Prasse A, 2006, AM J RESP CRIT CARE, V173, P781, DOI 10.1164/rccm.200509-1518OC
   Prasse A, 2007, ARTHRITIS RHEUM, V56, P1685, DOI 10.1002/art.22559
   Prassel A, 2009, AM J RESP CRIT CARE, V179, P717, DOI 10.1164/rccm.200808-1201OC
   Prokop S, 2011, AM J PATHOL, V178, P1279, DOI 10.1016/j.ajpath.2010.11.065
   RAMSEY KH, 1991, INFECT IMMUN, V59, P925
   Rank RG, 2010, J INFECT DIS, V201, pS168, DOI 10.1086/652399
   Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136
   Reynolds JM, 2010, CYTOKINE GROWTH F R, V21, P413, DOI 10.1016/j.cytogfr.2010.10.002
   Saw VPJ, 2009, AM J PATHOL, V175, P2406, DOI 10.2353/ajpath.2009.090579
   Skwor TA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000264
   Stephens RS, 2003, TRENDS MICROBIOL, V11, P44, DOI 10.1016/S0966-842X(02)00011-2
   TAYLOR HR, 1987, J IMMUNOL, V138, P3023
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   Torrado E, 2010, CYTOKINE GROWTH F R, V21, P455, DOI 10.1016/j.cytogfr.2010.10.004
   VanVoorhis WC, 1997, INFECT IMMUN, V65, P2175
   Verdoni AM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002701
   Wang Qingjian, 2011, Fibrogenesis Tissue Repair, V4, P4, DOI 10.1186/1755-1536-4-4
   West NR, 2010, ONCOGENE, V29, P2083, DOI 10.1038/onc.2009.488
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
   Wolf R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001108
   Wolle MA, 2009, OPHTHALMOLOGY, V116, P243, DOI 10.1016/j.ophtha.2008.09.011
   Wright HR, 2005, LANCET INFECT DIS, V5, P313, DOI 10.1016/S1473-3099(05)70116-X
   Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412
   Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354
   Wyrick PB, 1999, J INFECT DIS, V179, P954, DOI 10.1086/314676
   Zheng Y, 2008, IMMUNOLOGY, V124, P357, DOI 10.1111/j.1365-2567.2007.02782.x
NR 64
TC 20
Z9 21
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 2011
VL 79
IS 12
BP 4977
EP 4983
DI 10.1128/IAI.05718-11
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 846RL
UT WOS:000296920800023
PM 21911461
OA No
DA 2017-08-15
ER

PT J
AU Bisseye, C
   Yindom, LM
   Simpore, J
   Morgan, WD
   Holder, AA
   Ismaili, J
AF Bisseye, C.
   Yindom, L. M.
   Simpore, J.
   Morgan, W. D.
   Holder, A. A.
   Ismaili, J.
TI An engineered Plasmodium falciparum C-terminal 19-kilodalton merozoite
   surface protein 1 vaccine candidate induces high levels of
   interferon-gamma production associated with cellular immune responses to
   specific peptide sequences in Gambian adults naturally exposed to
   malaria
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE IFN-gamma; malaria; MSP1(19); Th1/Th2
ID LIVER-STAGE ANTIGEN-1; T-CELL; ANTIBODY-RESPONSE; DISULFIDE BONDS;
   EPITOPES; PROTECTION; CHILDREN
AB The 19-kDa C-terminal region of merozoite surface protein 1 (MSP1(19)), a major blood stage malaria vaccine candidate, is the target of cellular and humoral immune responses in humans naturally infected with Plasmodium falciparum. We have previously described engineered variants of this protein, designed to be better vaccine candidates, but the human immune response to these proteins has not been characterized fully. Here we have investigated the antigenicity of one such variant compared to wild-type MSP1(19)-derived protein and peptides. Gambian adults produced both high T helper type 1 (Th1) [interferon (IFN)-gamma] and Th0/Th2 [interleukin (IL)-13 and sCD30] responses to the wild-type MSP119 and the modified protein as wells as to peptides derived from both forms. Response to the modified MSP119 (with three amino acid substitutions: Glu27Tyr, Leu31Arg and Glu43Leu) relative to the wild-type, included higher IFN-gamma production. Interestingly, some peptides evoked different patterns of cytokine responses. Modified peptides induced higher IL-13 production than the wild-type, while the conserved peptides P16 and P19 induced the highest IFN-gamma and IL-13 and/or sCD30 release, respectively. We identified P16 as the immunodominant peptide that was recognized by cells from 63% of the study population, and not restricted to any particular human leucocyte antigen D-related (HLA-DR) type. These findings provide new and very useful information for future vaccine development and formulation as well as potential Th1/Th2 immunmodulation using either wild-type or modified protein in combination with their peptides.
C1 [Bisseye, C.; Yindom, L. M.; Ismaili, J.] MRC Labs, Banjul, Gambia.
   [Morgan, W. D.; Holder, A. A.] MRC Natl Inst Med Res, Div Parasitol, London, England.
   [Simpore, J.] Ctr Rech Biomol Pietro Annigoni, Ouagadougou, Burkina Faso.
RP Ismaili, J (reprint author), Inst Pasteur, IBL, 1 Rue Prof Calmette,BP 447, F-59021 Lille, France.
EM jamila.ismaili@ibl.fr
RI Holder, Anthony/A-7554-2013
OI Holder, Anthony/0000-0002-8490-6058
FU UK Medical Research Council [U117532067]; European Commission through
   the EUROMALVAC Consortium [QLK2-CT-1999-01293]
FX We thank Saikou Keita for technical assistance during experiments and
   all participants of this study from Brefet Village. The work was
   supported in part by the UK Medical Research Council (U117532067) and
   the European Commission through the EUROMALVAC Consortium, contract
   QLK2-CT-1999-01293.
CR BECK HP, 1995, AM J TROP MED HYG, V53, P284
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Egan A, 1997, INFECT IMMUN, V65, P3024
   Gerold P, 1996, MOL BIOCHEM PARASIT, V75, P131, DOI 10.1016/0166-6851(95)02518-9
   Hensmann M, 2004, EUR J IMMUNOL, V34, P639, DOI 10.1002/eji.200324514
   Hirunpetcharat C, 1999, J IMMUNOL, V162, P7309
   Holder AA, 2009, PARASITOLOGY, V136, P1445, DOI 10.1017/S0031182009990515
   HOLDER AA, 1994, PARASITOL TODAY, V10, P182, DOI 10.1016/0169-4758(94)90025-6
   John CC, 2004, INFECT IMMUN, V72, P5135, DOI 10.1128/IAI.72.9.5135-5142.2004
   Lee EAM, 2002, INFECT IMMUN, V70, P1417, DOI 10.1128/IAI.70.3.1417-1421.2002
   Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689
   May J, 2001, J INFECT DIS, V183, P168, DOI 10.1086/317642
   MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F
   Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753
   Nwuba RI, 2002, INFECT IMMUN, V70, P5328, DOI 10.1128/IAI.70.9.5328-5331.2002
   Ogutu BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004708
   Okafor CMF, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-263
   Osafo-Addo AD, 2008, AM J TROP MED HYG, V78, P251
   Patino Jose A. Guevara, 1997, Journal of Experimental Medicine, V186, P1689
   Quin SJ, 2001, INFECT IMMUN, V69, P2245, DOI 10.1128/IAI.69.4.2245-2251.2001
   SOKAL RR, 1995, ANAL PROPORTION
   UDHAYAKUMAR V, 1995, J IMMUNOL, V154, P6022
   Uthaipibull C, 2001, J MOL BIOL, V307, P1381, DOI 10.1006/jmbi.2001.4574
NR 23
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD DEC
PY 2011
VL 166
IS 3
BP 366
EP 373
DI 10.1111/j.1365-2249.2011.04467.x
PG 8
WC Immunology
SC Immunology
GA 846OF
UT WOS:000296912400009
PM 22059995
OA No
DA 2017-08-15
ER

PT J
AU Secka, O
   Antonio, M
   Berg, DE
   Tapgun, M
   Bottomley, C
   Thomas, V
   Walton, R
   Corrah, T
   Thomas, JE
   Adegbola, RA
AF Secka, Ousman
   Antonio, Martin
   Berg, Douglas E.
   Tapgun, Mary
   Bottomley, Christian
   Thomas, Vivat
   Walton, Robert
   Corrah, Tumani
   Thomas, Julian E.
   Adegbola, Richard A.
TI Mixed Infection with cagA Positive and cagA Negative Strains of
   Helicobacter pylori Lowers Disease Burden in The Gambia
SO PLOS ONE
LA English
DT Article
ID HIGH PREVALENCE; AFRICAN ENIGMA; MULTIPLE STRAINS; BIOPSY SPECIMENS;
   GASTRIC-CANCER; ICEA GENOTYPES; VACA; ASSOCIATION; DIVERSITY; HOST
AB Background: The prevalence of Helicobacter pylori including strains with putatively virulent genotypes is high, whereas the H. pylori-associated disease burden is low, in Africa compared to developed countries. In this study, we investigated the prevalence of virulence-related H. pylori genotypes and their association with gastroduodenal diseases in The Gambia.
   Methods and Findings: DNA extracted from biopsies and H. pylori cultures from 169 subjects with abdominal pain, dyspepsia or other gastroduodenal diseases were tested by PCR for H. pylori. The H. pylori positive samples were further tested for the cagA oncogene and vacA toxin gene. One hundred and twenty one subjects (71.6%) were H. pylori positive. The cagA gene and more toxigenic s1 and m1 alleles of the vacA gene were found in 61.2%, 76.9% and 45.5% respectively of Gambian patients harbouring H. pylori. There was a high prevalence of cagA positive strains in patients with overt gastric diseases than those with non-ulcerative dyspepsia (NUD) (p = 0.05); however, mixed infection by cagA positive and cagA negative strains was more common in patients with NUD compared to patients with gastric disease (24.5% versus 0%; p = 0.002).
   Conclusion: This study shows that the prevalence of H. pylori is high in dyspeptic patients in The Gambia and that many strains are of the putatively more virulent cagA(+), vacAs1 and vacAm1 genotypes. This study has also shown significantly lower disease burden in Gambians infected with a mixture of cag-positive and cag-negative strains, relative to those containing only cag-positive or only cag-negative strains, which suggests that harbouring both cag-positive and cag-negative strains is protective.
C1 [Secka, Ousman; Antonio, Martin; Tapgun, Mary; Thomas, Vivat; Walton, Robert; Corrah, Tumani; Adegbola, Richard A.] MRC Unit, Fajara, Gambia.
   [Thomas, Julian E.] Newcastle Univ, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Berg, Douglas E.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Bottomley, Christian] London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, London WC1, England.
RP Secka, O (reprint author), MRC Unit, Fajara, Gambia.
EM osecka@mrc.gm
OI Walton, Robert/0000-0001-7700-1907
FU US National Institutes of Health [RO3-AI061308]; Medical Research
   Council Unit, The Gambia
FX This work was supported by grant RO3-AI061308 from the US National
   Institutes of Health and The Medical Research Council Unit, The Gambia.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agha A, 2005, SCAND J GASTROENTERO, V40, P523, DOI 10.1080/00365520510012280
   Ahmed Niyaz, 2005, Ann Clin Microbiol Antimicrob, V4, P1, DOI 10.1186/1476-0711-4-1
   Akada JK, 2003, MICROBIOL-SGM, V149, P1901, DOI 10.1099/mic.0.26129-0
   Alam SI, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-194
   Berg S, 2006, SCAND J INFECT DIS, V38, P427, DOI 10.1080/00365540500532852
   Blaser MJ, 2001, J CLIN INVEST, V107, P767, DOI 10.1172/JCI12672
   Boyanova L, 2009, DIAGN MICR INFEC DIS, V64, P374, DOI 10.1016/j.diagmicrobio.2009.04.005
   Campbell DI, 2001, HELICOBACTER, V6, P263, DOI 10.1046/j.1083-4389.2001.00047.x
   Chen XJ, 2005, CHINESE MED J-PEKING, V118, P460
   Figueiredo C, 2001, SCAND J GASTROENTERO, V36, P128, DOI 10.1080/003655201750065861
   Graham DY, 2009, J DIG DIS, V10, P77, DOI 10.1111/j.1751-2980.2009.00368.x
   HOLCOMBE C, 1992, GUT, V33, P429, DOI 10.1136/gut.33.4.429
   Jemilohun Abiodun Christopher, 2010, Pan Afr Med J, V6, P18
   Kim YS, 2009, EUR J GASTROEN HEPAT, V21, P522, DOI 10.1097/MEG.0b013e3283196af0
   Kumar S, 2010, J MED MICROBIOL, V59, P32, DOI 10.1099/jmm.0.013763-0
   Linz B, 2007, NATURE, V445, P915, DOI 10.1038/nature05562
   Matteo MJ, 2007, J MED MICROBIOL, V56, P664, DOI 10.1099/jmm.0.46885-0
   Miernyk K, 2011, J CLIN MICROBIOL, V49, P3114, DOI 10.1128/JCM.00469-11
   Momynaliev K, 2003, EUR J CLIN MICROBIOL, V22, P573, DOI 10.1007/s10096-003-0987-2
   Mukhopadhyay AK, 2000, J BACTERIOL, V182, P3219, DOI 10.1128/JB.182.11.3219-3227.2000
   Nguyen LT, 2008, J MED MICROBIOL, V57, P1445, DOI 10.1099/jmm.0.2008/003160-0
   OWEN RJ, 1994, FEMS IMMUNOL MED MIC, V9, P307
   Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540
   Pan ZJ, 1998, J INFECT DIS, V178, P220
   Panangala VS, 2009, AQUAC RES, V40, P915, DOI 10.1111/j.1365-2109.2009.02185.x
   Park CY, 2003, J CLIN MICROBIOL, V41, P3336, DOI 10.1128/JCM.41.7.3336-3338.2003
   Rieder G, 2005, CURR OPIN MICROBIOL, V8, P67, DOI 10.1016/j.mib.2004.12.004
   Secka O, 2011, GUT PATHOG, V3, DOI 10.1186/1757-4749-3-5
   Segal I, 2001, QJM-MON J ASSOC PHYS, V94, P561, DOI 10.1093/qjmed/94.10.561
   Serge B, 2002, VET RES, V33, P55
   Smith SI, 2002, J MED MICROBIOL, V51, P851
   Soto G, 2003, J INFECT DIS, V188, P1263, DOI 10.1086/379046
   Sugimoto M, 2009, CLIN MICROBIOL INFEC, V15, P835, DOI 10.1111/j.1469-0691.2009.02769.x
   Tanih NF, 2010, ACTA TROP, V116, P68, DOI 10.1016/j.actatropica.2010.05.011
   TAYLOR NS, 1995, J CLIN MICROBIOL, V33, P918
   Tegtmeyer N, 2009, CELL MICROBIOL, V11, P488, DOI 10.1111/j.1462-5822.2008.01269.x
   Thomas JE, 1999, PEDIATR RES, V45, P218, DOI 10.1203/00006450-199902000-00010
   van Doorn LJ, 1998, GASTROENTEROLOGY, V115, P58, DOI 10.1016/S0016-5085(98)70365-8
   Yamaoka Y, 1999, J CLIN MICROBIOL, V37, P2274
   Yamaoka Y, 2008, INTERNAL MED, V47, P1077, DOI 10.2169/internalmedicine.47.0975
NR 40
TC 13
Z9 13
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 29
PY 2011
VL 6
IS 11
AR e27954
DI 10.1371/journal.pone.0027954
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 863LT
UT WOS:000298166300018
PM 22140492
OA gold
DA 2017-08-15
ER

PT J
AU Peterson, I
   Togun, O
   de Silva, T
   Oko, F
   Rowland-Jones, S
   Jaye, A
   Peterson, K
AF Peterson, Ingrid
   Togun, Oluwatoyin
   de Silva, Thushan
   Oko, Francis
   Rowland-Jones, Sarah
   Jaye, Assan
   Peterson, Kevin
TI Mortality and immunovirological outcomes on antiretroviral therapy in
   HIV-1 and HIV-2-infected individuals in the Gambia
SO AIDS
LA English
DT Article
DE Africa; antiretroviral therapy; HIV-2; mortality; risk factors
ID IMMUNODEFICIENCY-VIRUS TYPE-2; PLASMA VIRAL LOAD; CD4 CELL PERCENTAGE;
   SUB-SAHARAN AFRICA; DRUG-RESISTANCE; SOUTH-AFRICA; INFECTED-PATIENTS;
   IMMUNOLOGICAL RESPONSE; INCOME COUNTRIES; COTE-DIVOIRE
AB Objectives: This study's objective was to assess outcomes in HIV-1 and HIV-2 infected antiretroviral therapy (ART)-naive patients starting ART in the Gambia, West Africa.
   Design: A cohort design was used to estimate survival in ART patients and determine whether survival and time to virologic failure varied across patient subgroups.
   Methods: Mortality, virologic failures and CD4(+) cell recovery were assessed in a clinical cohort of patients from the Genito-Urinary Medicine (GUM) clinic of the MRC Laboratories in the Gambia. Kaplan-Meier estimates of survival were determined for mortality and virologic failure. A Cox proportional hazards model was used to identify baseline demographic, clinical, immunologic and virologic factors associated with increased risk of death.
   Results: The overall Kaplan-Meier estimate of survival to 36 months was 73.4% (66.5, 80.3). Survival was marginally higher in HIV-2-infected patients compared to HIV-1-infected patients; it was significantly higher in patients with a baseline CD4(+) lymphocyte cell count of greater than 50 cells/mu l compared to those with a baseline CD4(+) count of less than 50 cells/mu l. CD4(+) cell recovery was faster in HIV-1-infected individuals compared to HIV-2-infected patients up to 24 months, although this did not result higher mortality in the latter group. No differences in virologic failure were observed by HIV type.
   Conclusion: HIV-1 and HIV-2-infected patients receiving ART in a clinical setting in the Gambia had good survival to 36 months. HIV-2-infected patients did as well as HIV-1-infected patients in terms of long-term immunological and virological responses and overall survival. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Peterson, Ingrid; de Silva, Thushan] Columbia Univ, ICAP, Mbabane, Swaziland.
   [Togun, Oluwatoyin; Oko, Francis; Jaye, Assan; Peterson, Kevin] Med Res Council UK, Gambia Unit, Fajara, Gambia.
   [de Silva, Thushan] UCL, Div Infect & Immun, UCL Ctr Med Mol Virol, London, England.
   [de Silva, Thushan; Rowland-Jones, Sarah] John Radcliffe Hosp, Weatherall Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DU, England.
   [Jaye, Assan] Univ Cheick Anta Diop, W Africa Platform HIV Intervent Res WAPHIR Networ, Bacteriol Lab, Hop A, Dakar, Senegal.
   [Peterson, Kevin] Inst Trop Med, B-2000 Antwerp, Belgium.
RP Peterson, I (reprint author), ICAP Columbia Univ, Swaziland HIV Incidence Measurement Survey, Mbabane, Hhohho, Swaziland.
EM idpet2@gmail.com
FU GUM Clinic; Global Fund for AIDS, TB and Malaria
FX We thank RamuSarge-Njie and Mathew Cotten for their assistance with HIV
   diagnostics and viral load measurement; the clinical and field staff of
   the GUM Clinic, study participants, and the Global Fund for AIDS, TB and
   Malaria for their financial support.
CR Adje-Toure CA, 2003, AIDS, V17, pS49
   Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Bartlett JA, 2009, LANCET INFECT DIS, V9, P637, DOI 10.1016/S1473-3099(09)70227-0
   Bassett IV, 2009, JAIDS-J ACQ IMM DEF, V51, P135, DOI 10.1097/QAI.0b013e3181a44ef2
   Benard A, 2009, AIDS, V23, P1171, DOI 10.1097/QAD.0b013e32832949f0
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   Braitstein P, 2006, LANCET, V367, P817
   Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/01.aids.0000125925.87797.38
   Cornell M, 2009, TROP MED INT HEALTH, V14, P722, DOI 10.1111/j.1365-3156.2009.02290.x
   Damond F, 2008, J CLIN MICROBIOL, V46, P2088, DOI 10.1128/JCM.00126-08
   de Silva TI, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-82
   Desbois D, 2008, ANTIMICROB AGENTS CH, V52, P1545, DOI 10.1128/AAC.01284-07
   Drylewicz J, 2008, AIDS, V22, P457, DOI 10.1097/QAD.0b013e3282f4ddfc
   Drylewicz J, 2010, AIDS, V24, P1043, DOI 10.1097/QAD.0b013e3283377a06
   Easterbrook PJ, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-4
   Fielding KL, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-93
   Geretti AM, 2009, CLIN INFECT DIS, V48, P1296, DOI 10.1086/598502
   Gottlieb GS, 2009, CLIN INFECT DIS, V48, P476, DOI 10.1086/596504
   Hammond R, 2008, INT J STD AIDS, V19, P291, DOI 10.1258/ijsa.2007.007248
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Harries K, 2010, T ROY SOC TROP MED H, V104, P154, DOI 10.1016/j.trstmh.2009.08.012
   Hawkins C, 2011, AIDS, V25, P1189, DOI 10.1097/QAD.0b013e3283471deb
   Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786
   Jallow S, 2006, AIDS, V20, P1455, DOI 10.1097/01.aids.0000233582.64467.8e
   Jallow S, 2009, J CLIN MICROBIOL, V47, P2200, DOI 10.1128/JCM.01654-08
   JOHANNESSEN A, 2008, BMC INFECT DIS, P8
   Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd
   MacPherson P, 2009, T ROY SOC TROP MED H, V103, P588, DOI 10.1016/j.trstmh.2008.10.001
   Marazzi MC, 2008, AIDS RES HUM RETROV, V24, P555, DOI 10.1089/aid.2007.0217
   Martinez-Cajas JL, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-11
   Matheron S, 2006, AIDS, V20, P459, DOI 10.1097/01.aids.0000199829.57112.2f
   Matheron S, 2003, AIDS, V17, P2593, DOI 10.1097/01.aids.0000096907.73209.b9
   Mullins C, 2004, CLIN INFECT DIS, V38, P1771, DOI 10.1086/421390
   Ntemgwa ML, 2009, ANTIMICROB AGENTS CH, V53, P3611, DOI 10.1128/AAC.00154-09
   RHAMADANI HO, 2007, CLIN INFECT DIS, V45, P1492
   Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298
   Sarfo FS, 2009, J ANTIMICROB CHEMOTH, V64, P667, DOI 10.1093/jac/dkp216
   *SURV UWWGOGHAAS, 2008, EP FACT SHEET HIV AI
   Toure S, 2008, AIDS, V22, P873, DOI 10.1097/QAD.0b013e3282f768f8
   *UNAIDS, 2008, GLOB REP AIDS
   van der Loeff MFS, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-46
   van der Loeff MFS, 2002, AIDS, V16, P1775
   *WHO, 2008, UN ACC SCAL PRIOR HL
   WHO, 2006, ANT THER HIV INF AD
   Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0
NR 46
TC 20
Z9 21
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD NOV 13
PY 2011
VL 25
IS 17
BP 2167
EP 2175
DI 10.1097/QAD.0b013e32834c4adb
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 841QG
UT WOS:000296526900014
PM 21881480
OA No
DA 2017-08-15
ER

PT J
AU Oduro, AR
   Bojang, KA
   Conway, DJ
   Corrah, T
   Greenwood, BM
   Schellenberg, D
AF Oduro, Abraham R.
   Bojang, Kalifa A.
   Conway, David J.
   Corrah, Tumani
   Greenwood, Brian M.
   Schellenberg, David
TI Health Centre Surveys as a Potential Tool for Monitoring Malaria
   Epidemiology by Area and over Time
SO PLOS ONE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM INFECTION; FACILITY-BASED DATA; TREATED BED NETS;
   WEST-AFRICA; TARGETED CHEMOPROPHYLAXIS; CASE DEFINITIONS; RURAL AREA;
   GAMBIA; TRANSMISSION; CHILDREN
AB Background: Presently, many malaria control programmes use health facility data to evaluate the impact of their interventions. Facility-based malaria data, although useful, have problems with completeness, validity and representativeness and reliance on routinely collected health facility data might undermine demonstration of the magnitude of the impact of the recent scaleups of malaria interventions. To determine whether carefully conducted health centre surveys can be reliable means of monitoring area specific malaria epidemiology, we have compared malaria specific indices obtained from surveys in health centres with indices obtained from cross-sectional surveys conducted in their catchment communities.
   Methods: A series of age stratified, seasonal, cross-sectional surveys were conducted during the peak malaria transmission season in 2008 and during the following dry season in 2009 in six ecologically diverse areas in The Gambia. Participants were patients who attended the health centres plus a representative sample from the catchment villages of these health facilities. Parasitaemia, anaemia, attributable proportion of fever and anti-MSP1-(19) antibody seroprevalence were compared in the health facility attendees and community participants.
   Results: A total of 16,230 subjects completed the study; approximately half participated in the health centre surveys and half in the wet season surveys. Data from both the health centre and community surveys showed that malaria endemicity in The Gambia is now low, heterogeneous and seasonal. In the wet season, parasitaemia, seroprevalence and fever prevalence were higher in subjects seen in the health centres than in the community surveys. Age patterns of parasitaemia, attributable proportions of fever and seroprevalence rates were similar in subjects who participated in the community and health centre surveys.
   Conclusion: Health centre surveys have potential as a surveillance tool for evaluating area specific malaria control activities and for monitoring changes in local malaria epidemiology over time.
C1 [Oduro, Abraham R.; Bojang, Kalifa A.; Conway, David J.; Corrah, Tumani] MRC Labs, Banjul, Gambia.
   [Oduro, Abraham R.; Conway, David J.; Greenwood, Brian M.; Schellenberg, David] London Sch Hyg & Trop Med, London WC1, England.
RP Oduro, AR (reprint author), MRC Labs, Banjul, Gambia.
EM aroduro@yahoo.com
OI Bojang, Kalifa/0000-0001-7506-0938; Conway, David/0000-0002-8711-3037
FU Medical Research Council (UK)
FX This work was sponsored by a Medical Research Council (UK) PhD
   studentship and supported by core funding to the Malaria Programme at
   the Medical Research Council Laboratories in The Gambia. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bousema T, 2010, J INFECT DIS, V201, P1764, DOI 10.1086/652456
   Carneiro I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008988
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Central Intelligence Agency, 2010, WORLD FACTB
   Cibulskis RE, 2007, AM J TROP MED HYG, V77, P133
   Corran PH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-195
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Gambia Bureau of Statistics (GBOS), 2003, GAMB BUR STAT GBOS C
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   GREENWOOD BM, 1987, ANN TROP MED PARASIT, V81, P345
   Greenwood BM, 2008, J CLIN INVEST, V118, P1266, DOI 10.1172/JCI33996
   Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000290
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L
   MCGREGOR IA, 1952, T ROY SOC TROP MED H, V46, P403, DOI 10.1016/0035-9203(52)90058-8
   O'Meara WP, 2010, LANCET INFECT DIS, V10, P545, DOI 10.1016/S1473-3099(10)70096-7
   Okiro EA, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-99
   Omosun YO, 2005, ACTA TROP, V95, P233, DOI 10.1016/j.actatropica.2005.06.019
   Rogers WO, 2006, J INFECT DIS, V193, P467, DOI 10.1086/499314
   Rowe AK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-209
   Skarbinski J, 2008, TROP MED INT HEALTH, V13, P396, DOI 10.1111/j.1365-3156.2008.02014.x
   Smith DL, 2005, NATURE, V438, P492, DOI 10.1038/nature04024
   SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206
   Thomson M, 1996, SOC SCI MED, V43, P101, DOI 10.1016/0277-9536(95)00346-0
   UNICEF, 2010, MULT IND CLUST SURV
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   World Health Organization, 2010, GUID TREATM MAL
   Roll Back Malaria MEASURE Evaluation World Health Organization UNICEF, 2006, GUID COR POP COV IND
NR 27
TC 8
Z9 8
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2011
VL 6
IS 11
AR e26305
DI 10.1371/journal.pone.0026305
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 850MH
UT WOS:000297198200007
PM 22073155
OA gold
DA 2017-08-15
ER

PT J
AU Dione, MM
   Ikumapayi, U
   Saha, D
   Mohammed, NI
   Adegbola, RA
   Geerts, S
   Ieven, M
   Antonio, M
AF Dione, Michel M.
   Ikumapayi, Usman
   Saha, Debasish
   Mohammed, Nuredin Ibrahim
   Adegbola, Richard A.
   Geerts, Stanny
   Ieven, Margareta
   Antonio, Martin
TI Antimicrobial resistance and virulence genes of non-typhoidal Salmonella
   isolates in The Gambia and Senegal
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE non-typhoidal Salmonella; virulence genes; children; animals; West
   Africa
ID CHLORAMPHENICOL THERAPY; PNEUMOCOCCAL MENINGITIS; PATHOGENICITY ISLANDS;
   ESCHERICHIA-COLI; RISK-FACTORS; IDENTIFICATION; EVOLUTION; CHILDREN;
   DAKAR
AB Introduction: The prevalence of virulence genes in non-typhoidal Salmonella (NTS) and its association with commonly used antibiotics in West Africa is unknown.
   Methodology: We tested 185 NTS isolates from children, animals, and food products for the presence of twelve virulence genes by PCR. Ten of the virulence genes tested belonged to the five Salmonella pathogenicity islands implicated in its pathogenesis.
   Results: Ten of twelve virulence genes except sopE and pefA were present in at least 70% of the isolates tested; sopE and pefA were observed in 33% and 44% of the isolates, respectively. The most prevalent gene was invA (99.5%), which is an invasion gene conserved within the Salmonella enterica. pipD and sopB genes, which were associated with serovar Enteritidis, were detected in 92.4% and 94.1% of isolates respectively. S. Istanbul and S. Javiana, which were isolated from chicken-serving restaurants, carried all the virulence genes of the five pathogenicity islands. There was significant association between sopB, sitC, orfLC, pipD and pefA virulence genes and resistance to commonly used antibiotics in Senegal and The Gambia, namely amoxicillin, ticarcillin, trimethoprim plus sulfamethoxazole, tetracycline, trimethoprim, spectinomycin, streptomycin, sulfonamides and nitrofurantoin.
   Conclusions: This study shows that virulence genes are present in NTS strains isolated from various sources. The significant association between some virulence genes and antibiotic resistance may have important implications with regard to the spread and persistence of resistance and virulence genes in Salmonella and to the prudent use of antimicrobial agents in humans and animals in West Africa.
C1 [Dione, Michel M.; Ikumapayi, Usman; Saha, Debasish; Mohammed, Nuredin Ibrahim; Adegbola, Richard A.; Antonio, Martin] MRC Unit, Banjul, Gambia.
   [Dione, Michel M.; Geerts, Stanny] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Dione, Michel M.; Ieven, Margareta] Univ Antwerp, Dept Microbiol, B-2020 Antwerp, Belgium.
   [Adegbola, Richard A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Antonio, M (reprint author), MRC Unit, Banjul, Gambia.
EM mantonio@mrc.gm
FU Flemish Interuniversity Council (VLIR-UOS, Brussels, Belgium); Medical
   Research Council, United Kingdom
FX This work was supported by the Flemish Interuniversity Council
   (VLIR-UOS, Brussels, Belgium) and the Medical Research Council, United
   Kingdom. We thank the study participants, the field staff who obtained
   the samples, the laboratory staff at the MRC who processed the samples,
   and the data management team.
CR Azoulay-Dupuis E, 2000, ANTIMICROB AGENTS CH, V44, P1575, DOI 10.1128/AAC.44.6.1575-1577.2000
   Blazquez R, 1999, EUR J CLIN MICROBIOL, V18, P503, DOI 10.1007/s100960050332
   BLOT M, 1994, MOL GEN GENET, V242, P595, DOI 10.1007/BF00285283
   Blum GM, 1994, INFECT IMMUN, V62, P189
   Carattoli Alessandra, 2003, Current Issues in Molecular Biology, V5, P113
   Cardinale E., 2003, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V56, P13
   Cardinale E, 2005, INT J FOOD MICROBIOL, V103, P157, DOI 10.1016/j.ijfoodmicro.2004.12.023
   Cardinale E, 2004, PREV VET MED, V63, P151, DOI 10.1016/j.prevetmed.2004.03.002
   Chiu CH, 1996, J CLIN MICROBIOL, V34, P2619
   Darwin KH, 1999, CLIN MICROBIOL REV, V12, P405
   de Oliveira SD, 2003, BRAZ J MICROBIOL, V34, P123, DOI 10.1590/S1517-83822003000500042
   Dione MM, 2009, J FOOD PROTECT, V72, P2423
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   FRIEDLAND IR, 1992, LANCET, V339, P405, DOI 10.1016/0140-6736(92)90087-J
   FRIEDLAND IR, 1991, PEDIATR INFECT DIS J, V10, P705, DOI 10.1097/00006454-199109000-00018
   GRATTEN M, 1991, PAPUA NEW GUINEA MED, V34, P185
   Grimont P., 2007, ANTIGENIC FORMULAE S
   Groisman EA, 1997, TRENDS MICROBIOL, V5, P343, DOI 10.1016/S0966-842X(97)01099-8
   Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6
   Hacker J, 1997, MOL MICROBIOL, V23, P1089, DOI 10.1046/j.1365-2958.1997.3101672.x
   Hughes LA, 2008, BMC VET RES, V4, DOI 10.1186/1746-6148-4-4
   JENIKOVA, 2000, INT MICROBIOL, V3, P225
   Martinez ZL, 2002, CLIN MICROB REV, V15, P647
   Mirold S, 1999, P NATL ACAD SCI USA, V96, P9845, DOI 10.1073/pnas.96.17.9845
   Saheli TZ, 2005, INT J POULT SCI, V4, P557
   Seydi M, 2008, MED MALADIES INFECT, V38, P25, DOI 10.1016/j.medmal.2007.10.007
   Seydi M, 2005, MED MALADIES INFECT, V35, P23, DOI 10.1016/j.medmal.2004.09.002
   Wood MW, 1998, MOL MICROBIOL, V29, P883, DOI 10.1046/j.1365-2958.1998.00984.x
NR 28
TC 21
Z9 23
U1 1
U2 5
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD NOV
PY 2011
VL 5
IS 11
BP 765
EP 775
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 905JW
UT WOS:000301269500003
PM 22112729
OA No
DA 2017-08-15
ER

PT J
AU Donkor, ES
   Bishop, CJ
   Gould, KA
   Hinds, J
   Antonio, M
   Wren, B
   Hanage, WP
AF Donkor, E. S.
   Bishop, C. J.
   Gould, K. A.
   Hinds, J.
   Antonio, M.
   Wren, B.
   Hanage, W. P.
TI High Levels of Recombination among Streptococcus pneumoniae Isolates
   from the Gambia (vol 2, e00040, 2011)
SO MBIO
LA English
DT Correction
C1 [Donkor, E. S.; Wren, B.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   [Bishop, C. J.; Hanage, W. P.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England.
   [Gould, K. A.; Hinds, J.] Univ London, Bacterial Microarray Grp, Div Clin Sci, London, England.
   [Antonio, M.] Med Res Council Labs United Kingdom, Bacterial Dis Programme, Fajara, Gambia.
RP Donkor, ES (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
CR Donkor ES, 2011, MBIO, V2, DOI 10.1128/mBio.00040-11
NR 1
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD NOV-DEC
PY 2011
VL 2
IS 6
AR e00222-11
DI 10.1128/mBio.00222-11
PG 1
WC Microbiology
SC Microbiology
GA 888GV
UT WOS:000299992700007
OA gold
DA 2017-08-15
ER

PT J
AU Prentice, AM
AF Prentice, Andrew M.
TI Hepcidin and iron-mediated resistance to malaria
SO EMBO MOLECULAR MEDICINE
LA English
DT Editorial Material
DE Hepcidin; inter-kingdom signalling; iron; malaria; super-infection
C1 [Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   [Prentice, Andrew M.] MRC Keneba, Keneba, Gambia.
RP Prentice, AM (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
EM andrew.prentice@lshtm.ac.uk
CR Albuquerque SS, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-270
   Armitage AE, 2009, BRIT J HAEMATOL, V147, P769, DOI 10.1111/j.1365-2141.2009.07880.x
   Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467
   Portugal S, 2011, NAT MED, V17, P732, DOI 10.1038/nm.2368
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
NR 5
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1757-4676
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD NOV
PY 2011
VL 3
IS 11
BP 620
EP 622
DI 10.1002/emmm.201100170
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 877GC
UT WOS:000299164300002
PM 21882342
OA gold
DA 2017-08-15
ER

PT J
AU Villar, S
   Le Roux-Goglin, E
   Gouas, DA
   Plymoth, A
   Ferro, G
   Boniol, M
   Lereau, M
   Bah, E
   Hall, AJ
   Wild, CP
   Mendy, M
   Norder, H
   van der Sande, M
   Whittle, H
   Friesen, MD
   Groopman, JD
   Hainaut, P
AF Villar, Stephanie
   Le Roux-Goglin, Emilie
   Gouas, Doriane A.
   Plymoth, Amelie
   Ferro, Gilles
   Boniol, Mathieu
   Lereau, Myriam
   Bah, Ebrima
   Hall, Andrew J.
   Wild, Christopher P.
   Mendy, Maimuna
   Norder, Helene
   van der Sande, Marianne
   Whittle, Hilton
   Friesen, Marlin D.
   Groopman, John D.
   Hainaut, Pierre
TI Seasonal Variation in TP53 R249S-Mutated Serum DNA with Aflatoxin
   Exposure and Hepatitis B Virus Infection
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
DE 1762(T)/1764(A); circulating DNA; mycotoxin; seasonality; TP53 mutation
ID HEPATOCELLULAR-CARCINOMA PATIENTS; BASAL CORE PROMOTER; PLASMA DNA;
   WEST-AFRICA; 1762(T)/1764(A) MUTATIONS; GAMBIAN CHILDREN; P53 MUTATIONS;
   LIVER-CANCER; EPIDEMIOLOGY; GENOTYPES
AB BACKGROUND: Chronic hepatitis B virus (HBV) infection and dietary aflatoxin B(1) (AFB(1)) exposure are etiological factors for hepato-cellular carcinoma (HCC) in countries with hot, humid climates. HCC often harbors a TP53 (tumor protein p53) mutation at codon 249 (R249S). In chronic carriers, 1762(T)/1764(A) mutations in the HBV X gene are associated with increased HCC risk. Both mutations have been detected in circulating cell-free DNA (CFDNA) from asymptomatic HBV carriers.
   OBJECTIVE: We evaluated seasonal variation in R249S and HBV in relation to AFB(1) exposure.
   METHODS: R249S was quantitated by mass spectrometry in CFDNA in a cross-sectional survey of 473 asymptomatic subjects (237 HBV carriers and 236 non-carriers) recruited in three villages in the Gambia over a 10-month period. 1762(T)/1764(A) HBV mutations were detected by quantitative polymerase chain reaction. In addition, the HBV S gene was sequenced in 99 subjects positive for HBV surface antigen (HBsAg).
   RESULTS: We observed a seasonal variation of serum R249S levels. Positivity for R249S and average concentration were significantly higher in HBsAg-positive subjects surveyed during April-July (61%; 5,690 +/- 11,300 R249S copies/mL serum) than in those surveyed October-March [32% and 480 +/- 1,030 copies/mL serum (odds ratio = 3.59; 95% confidence interval: 2.05, 6.30; p < 0.001)]. Positivity for HBV e antigen (HBeAg) (a marker of HBV replication) and viral DNA load also varied seasonally, with 15-30% of subjects surveyed between April and June HBeAg positive, compared with < 10% surveyed during other months. We detected 1762(T)/1764(A) mutations in 8% of carriers, half of whom were positive for R249S. We found HBV genotype E in 95 of 99 HBsAg-positive subjects.
   CONCLUSION: R249S is detectable in CFDNA of asymptomatic subjects. Evidence of temporal and quantitative variations suggests an interaction among AFB(1) exposure, HBV positivity, and replication on TP53 mutation formation or persistence.
C1 [Hainaut, Pierre] Int Agcy Res Canc, Mech Carcinogenesis Sect, Mol Carcinogenesis Grp, F-69372 Lyon 08, France.
   [Bah, Ebrima; Whittle, Hilton] Gambia Hepatitis Intervent Study, Labs Fajara, Banjul, Gambia.
   [Hall, Andrew J.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England.
   [Mendy, Maimuna] MRC, Labs Fajara, Banjul, Gambia.
   [Norder, Helene] Swedish Inst Infect Dis Control, Solna, Sweden.
   [van der Sande, Marianne] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
   [Friesen, Marlin D.; Groopman, John D.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Hainaut, P (reprint author), Int Agcy Res Canc, Mech Carcinogenesis Sect, Mol Carcinogenesis Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
EM hainaut@iarc.fr
RI Friesen, Marlin/D-7328-2012; Hainaut, Pierre /B-6018-2012; Boniol,
   Mathieu/F-9623-2011
OI Hainaut, Pierre /0000-0002-1303-1610; Boniol,
   Mathieu/0000-0003-1052-5604; Norder, Helene/0000-0002-7528-3872
FU French National Cancer Institute [PL06-028]; U.S. National Institutes of
   Health [P01 ES006052]; National Institute of Environmental Health
   Sciences [ES 06052]; Universite Claude Bernard Lyon 1
FX This work was supported by project CirBioCancer from the French National
   Cancer Institute (PL06-028), by the U.S. National Institutes of Health
   (P01 ES006052), and by the National Institute of Environmental Health
   Sciences (ES 06052 to C.P.W.). E.G.-R. participated in this work as part
   of her Ph.D. research, and was supported by Universite Claude Bernard
   Lyon 1.
CR Arbuthnot P, 2001, INT J EXP PATHOL, V82, P77, DOI 10.1046/j.1365-2613.2001.00178.x
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336
   Besaratinia A, 2009, GASTROENTEROLOGY, V137, P1127, DOI 10.1053/j.gastro.2009.06.002
   Chan KCA, 2008, CLIN CANCER RES, V14, P4141, DOI 10.1158/1078-0432.CCR-08-0182
   Department of Agricultural Services the Gambia, 2008, PROF ACH 1994 2001
   Gormally E, 2007, MUTAT RES-REV MUTAT, V635, P105, DOI 10.1016/j.mrrev.2006.11.002
   Gormally E, 2006, CANCER RES, V66, P6871, DOI 10.1158/0008-5472.CAN-05-4556
   Gouas D, 2009, CANCER LETT, V286, P29, DOI 10.1016/j.canlet.2009.02.057
   Hagiwara N, 2006, CANCER RES, V66, P8309, DOI 10.1158/0008-5472.CAN-06-0991
   Hou JL, 1999, LIVER, V19, P411, DOI 10.1111/j.1478-3231.1999.tb00070.x
   Hussain M, 2003, J CLIN MICROBIOL, V41, P3699, DOI 10.1128/JCM.41.8.3699-3705.2003
   IARC, 1994, IARC MON EV CARC RIS, V59, P1
   IARC, 2002, IARC MONOGR EVAL CAR, V82, P1
   Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101
   Kew MC, 2003, LIVER INT, V23, P405, DOI 10.1111/j.1478-3231.2003.00869.x
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kirk GD, 2006, CARCINOGENESIS, V27, P2070, DOI 10.1093/carcin/bgl060
   Kramvis A, 2005, VACCINE, V23, P2409, DOI 10.1016/j.vaccine.2004.10.045
   Kuang SY, 2005, CANCER EPIDEM BIOMAR, V14, P380, DOI 10.1158/1055-9965.EPI-04-0380
   Kuang SY, 2004, P NATL ACAD SCI USA, V101, P3575, DOI 10.1073/pnas.0308232100
   Lleonart ME, 2005, CANCER EPIDEM BIOMAR, V14, P2956, DOI 10.1158/1055-9965.EPI-05-0612
   Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205
   McGlynn KA, 2005, BEST PRACT RES CL GA, V19, P3, DOI 10.1016/j.bpg.2004.10.004
   Mendy ME, 2008, J CLIN MICROBIOL, V46, P2723, DOI 10.1128/JCM.01622-07
   Mendy ME, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-23
   NORDER H, 1992, J GEN VIROL, V73, P3141, DOI 10.1099/0022-1317-73-12-3141
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   NORDER H, 1993, J GEN VIROL, V74, P1341, DOI 10.1099/0022-1317-74-7-1341
   Sherman M, 2005, SEMIN LIVER DIS, V25, P143, DOI 10.1055/s-2005-871194
   Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103
   Szymanska K, 2009, CANCER EPIDEM BIOMAR, V18, P1638, DOI 10.1158/1055-9965.EPI-08-1102
   Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x
   van der Sande MAB, 2006, J INFECT DIS, V193, P1528
   Whittle H, 2002, BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2
   Yuan JM, 2009, CANCER EPIDEM BIOMAR, V18, P590, DOI 10.1158/1055-9965.EPI-08-0966
   Zhang SJ, 2006, J GASTROENTEROL, V41, P1107, DOI 10.1007/s00535-006-1903-1
NR 40
TC 14
Z9 14
U1 0
U2 14
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 2011
VL 119
IS 11
BP 1635
EP 1640
DI 10.1289/ehp.1103539
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 844XL
UT WOS:000296785900033
PM 21768053
OA gold
DA 2017-08-15
ER

PT J
AU Greenwood, B
   Bojang, K
   Tagbor, H
   Pagnoni, F
AF Greenwood, Brian
   Bojang, Kalifa
   Tagbor, Harry
   Pagnoni, Franco
TI Combining community case management and intermittent preventive
   treatment for malaria
SO TRENDS IN PARASITOLOGY
LA English
DT Review
ID SENEGALESE CHILDREN; RANDOMIZED-TRIAL; HOME; PROGRAM; CARE
AB Employment of members of the community to treat malaria is a promising approach to the management of this infection in areas where access to treatment is difficult. Intermittent preventive treatment (IPT) of malaria has recently been shown to be a highly effective way of reducing morbidity from malaria in children living in areas of seasonal malaria transmission, and it can be delivered efficiently by community volunteers. Therefore, we suggest that in areas where malaria transmission is seasonal, and IPT an appropriate malaria intervention in children, community volunteers could be employed to deliver IPT during the peak malaria-transmission season and also to provide community case management during this period and during the rest of the year when occasional cases of malaria continue to occur.
C1 [Greenwood, Brian] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England.
   [Bojang, Kalifa] Med Res Council MRC Unit, Banjul, Gambia.
   [Tagbor, Harry] Kwame Nkrumah Univ Sci & Technol, Dept Community Hlth, Kumasi, Ghana.
   [Pagnoni, Franco] WHO, United Nations Childrens Fund UNICEF, UNDP, World Bank,Special Programme Res & Training Trop, CH-1211 Geneva, Switzerland.
RP Greenwood, B (reprint author), Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM brian.greenwood@lshtm.ac.uk
OI Bojang, Kalifa/0000-0001-7506-0938
FU Medical Research Council [MC_UP_A900_1118]
CR AHORLU CK, 2011, MALARIA J, V10, pE127
   AHORLU CK, 2009, MALARIA J, V8, pE292
   Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7
   Bojang K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011225
   Bojang KA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000409
   Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   Delacollette C, 1996, B WORLD HEALTH ORGAN, V74, P423
   DICKO A, 2011, PLOS MED, V8
   DICKO A, 2008, MALARIA J, V7, pE123
   Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6
   Garner P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000169.pub2
   GREENWOOD BM, 1988, LANCET, V1, P1121
   Gyapong M, 2007, LESSONS LEARNED HOME
   HARVEY SA, 2008, MALARIA J, V7, pE160
   HOPKINS H, 2007, MALARIA J, V6, pE134
   Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0
   KONATE AT, 2011, PLOS MED, V8
   Kweku M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007256
   Kweku M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004000
   Pagnoni F, 1997, T ROY SOC TROP MED H, V91, P512, DOI 10.1016/S0035-9203(97)90006-7
   Pagnoni F, 2009, TRENDS PARASITOL, V25, P115, DOI 10.1016/j.pt.2008.12.003
   SESAY S, 2011, MALARIA J, V10, pE2
   Sirima SB, 2003, TROP MED INT HEALTH, V8, P133, DOI 10.1046/j.1365-3156.2003.00997.x
   Sokhna C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001471
   SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P36
   Staedke SG, 2009, LANCET, V373, P1623, DOI 10.1016/S0140-6736(09)60328-7
   Tagbor H, 2011, TROP MED INT HEALTH, V16, P280, DOI 10.1111/j.1365-3156.2010.02699.x
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   Wilson AL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016976
NR 29
TC 7
Z9 9
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4922
J9 TRENDS PARASITOL
JI Trends Parasitol.
PD NOV
PY 2011
VL 27
IS 11
BP 477
EP 480
DI 10.1016/j.pt.2011.06.005
PG 4
WC Parasitology
SC Parasitology
GA 853RP
UT WOS:000297443700001
PM 21802363
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, E
AF Onyekwelu, E.
TI COMPATIBLE CONGENITAL ADRENAL HYPERPLASIA (CAH) PRESENTING COVERTLY AS
   CHRONIC PERSISTENT GASTROENTERITIS/FAILURE TO THRIVE (FTT) IN FEMALE
   INFANTS WITH CLINICIAN IDENTIFIED AMBIGUOUS GENITALIA IMPLIES EVALUATING
   DIFFICULT CASES METICULOUSLY
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Onyekwelu, E.] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD NOV
PY 2011
VL 37
SU 2
MA 210
BP S390
EP S390
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA V34JO
UT WOS:000209082900210
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, EU
AF Onyekwelu, E. U.
CA Acute Paediatrics Neurology
TI A MODIFIABLE DESCRIPTIVE CLASSIFICATION SYSTEM FOR
   ENCEPHALOPATHIC/NEUROTOXIC ACUTE CHILDHOOD POISONINGS WITH REMARKS FOR
   COMMONLY OCCURRING CONTEMPORANEOUS CONFOUNDING FACTORS
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Onyekwelu, E. U.] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD NOV
PY 2011
VL 37
SU 2
MA 189
BP S382
EP S383
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA V34JO
UT WOS:000209082900189
OA No
DA 2017-08-15
ER

PT J
AU Erskine, J
AF Erskine, Jamie
TI Single-disease health campaigns: the case of cervical cancer
SO LANCET
LA English
DT Letter
C1 Sibanor Hlth Ctr, Banjul, Gambia.
RP Erskine, J (reprint author), Sibanor Hlth Ctr, POB 86, Banjul, Gambia.
EM jamieerskine@doctors.org.uk
CR Burns A, 2011, LANCET, V377, P1318, DOI 10.1016/S0140-6736(11)60541-2
NR 1
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD OCT 15
PY 2011
VL 378
IS 9800
BP 1378
EP 1378
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 838EM
UT WOS:000296269600022
PM 22000134
OA No
DA 2017-08-15
ER

PT J
AU Porter, DW
   Thompson, FM
   Berthoud, TK
   Hutchings, CL
   Andrews, L
   Biswas, S
   Poulton, I
   Prieur, E
   Correa, S
   Rowland, R
   Lang, T
   Williams, J
   Gilbert, SC
   Sinden, RE
   Todryk, S
   Hill, AVS
AF Porter, David W.
   Thompson, Fiona M.
   Berthoud, Tamara K.
   Hutchings, Claire L.
   Andrews, Laura
   Biswas, Sumi
   Poulton, Ian
   Prieur, Eric
   Correa, Simon
   Rowland, Rosalind
   Lang, Trudie
   Williams, Jackie
   Gilbert, Sarah C.
   Sinden, Robert E.
   Todryk, Stephen
   Hill, Adrian V. S.
TI A human Phase I/IIa malaria challenge trial of a polyprotein malaria
   vaccine
SO VACCINE
LA English
DT Article
DE Malaria; Vaccine; Heterologous prime-boost
ID PLASMODIUM-FALCIPARUM MALARIA; POLYMERASE-CHAIN-REACTION; VIRUS ANKARA;
   VIRAL VECTORS; GAMBIAN MEN; ANTIGEN; IMMUNOGENICITY; SPOROZOITES;
   EFFICACY; PARASITE
AB We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum.
   Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-gamma ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Porter, David W.; Thompson, Fiona M.; Poulton, Ian; Rowland, Rosalind; Lang, Trudie; Hill, Adrian V. S.] Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England.
   [Berthoud, Tamara K.; Hutchings, Claire L.; Andrews, Laura; Biswas, Sumi; Prieur, Eric; Gilbert, Sarah C.; Todryk, Stephen; Hill, Adrian V. S.] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England.
   [Correa, Simon] Med Res Council MRC Labs, Fajara, Gambia.
   [Williams, Jackie] Walter Reed Army Inst Res, Div Entomol, Silver Spring, MD 20910 USA.
   [Sinden, Robert E.] Univ London Imperial Coll Sci Technol & Med, Infect & Immun Sect, Dept Biol, London SW7 2AZ, England.
RP Porter, DW (reprint author), Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Old Rd, Oxford OX3 7LJ, England.
EM david.porter@paediatrics.ox.ac.uk
OI Gilbert, Sarah/0000-0002-6823-9750
FU European Vaccine Initiative (EVI)
FX This study was principally funded by the European Malaria Vaccine
   Initiative (EMVI) now European Vaccine Initiative (EVI). The authors
   would like to thank Odile Leroy and Egeruan Imoukhuede for advice and
   support. Additional support from the Wellcome Trust and the NIHR Oxford
   Biomedical Research Centre is gratefully acknowledged. SG is a Jenner
   Institute Investigator and AVSH is a Wellcome Trust Principal Research
   Fellow.
CR Andrews L, 2005, AM J TROP MED HYG, V73, P191
   BARNES DA, 1995, EXP PARASITOL, V81, P79, DOI 10.1006/expr.1995.1095
   Bejon P, 2005, J INFECT DIS, V191, P619, DOI 10.1086/427243
   CHULAY JD, 1986, AM J TROP MED HYG, V35, P66
   Daubersies P, 2000, NAT MED, V6, P1258
   FERREIRA A, 1986, SCIENCE, V232, P881, DOI 10.1126/science.3085218
   FIDOCK DA, 1994, MOL BIOCHEM PARASIT, V64, P219, DOI 10.1016/0166-6851(94)00012-3
   Gasteiger G, 2007, J VIROL, V81, P11925, DOI 10.1128/JVI.00903-07
   GUERINMARCHAND C, 1987, NATURE, V329, P164, DOI 10.1038/329164a0
   Hermsen CC, 2004, AM J TROP MED HYG, V71, P196
   Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409
   HOPE IA, 1984, NATURE, V308, P191, DOI 10.1038/308191a0
   Imoukhuede EB, 2006, VACCINE, V24, P6526, DOI 10.1016/j.vaccine.2006.06.022
   Kumar KA, 2006, NATURE, V444, P937, DOI 10.1038/nature05361
   Li SQ, 2007, VACCINE, V25, P2567, DOI 10.1016/j.vaccine.2006.07.035
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V45, P193, DOI 10.1016/0166-6851(91)90086-L
   MOELANS IIMD, 1995, MOL BIOCHEM PARASIT, V72, P179, DOI 10.1016/0166-6851(95)00072-9
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515
   Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331
   Prieur E, 2004, P NATL ACAD SCI USA, V101, P290, DOI 10.1073/pnas.0307158101
   ROBSON KJH, 1990, P ROY SOC B-BIOL SCI, V242, P205, DOI 10.1098/rspb.1990.0126
   Sanderson F, 2008, AM J TROP MED HYG, V78, P878
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   STICKL H, 1974, DEUT MED WOCHENSCHR, V99, P2386
   Vuola JM, 2005, J IMMUNOL, V174, P449
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
   World Health Organization (WHO), 2008, WORLD MAL REP
NR 30
TC 30
Z9 30
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD OCT 6
PY 2011
VL 29
IS 43
BP 7514
EP 7522
DI 10.1016/j.vaccine.2011.03.083
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 838SC
UT WOS:000296311500028
PM 21501642
OA No
DA 2017-08-15
ER

PT J
AU Nogaro, SI
   Hafalla, JC
   Walther, B
   Remarque, EJ
   Tetteh, KKA
   Conway, DJ
   Riley, EM
   Walther, M
AF Nogaro, Sarah I.
   Hafalla, Julius C.
   Walther, Brigitte
   Remarque, Edmond J.
   Tetteh, Kevin K. A.
   Conway, David J.
   Riley, Eleanor M.
   Walther, Michael
TI The Breadth, but Not the Magnitude, of Circulating Memory B Cell
   Responses to P. falciparum Increases with Age/Exposure in an Area of Low
   Transmission
SO PLOS ONE
LA English
DT Article
ID MEROZOITE SURFACE PROTEIN-1; APICAL MEMBRANE ANTIGEN-1; MALARIA-ENDEMIC
   AREA; PLASMODIUM-FALCIPARUM; SERUM ANTIBODIES; ACQUIRED-IMMUNITY;
   NATURAL-SELECTION; GAMBIAN CHILDREN; INDIVIDUALS; RECOGNITION
AB Background: Malaria caused by Plasmodium falciparum remains a major cause of death in sub-Saharan Africa. Immunity against symptoms of malaria requires repeated exposure, suggesting either that the parasite is poorly immunogenic or that the development of effective immune responses to malaria may be impaired.
   Methods: We carried out two age-stratified cross-sectional surveys of anti-malarial humoral immune responses in a Gambian village where P. falciparum malaria transmission is low and sporadic. Circulating antibodies and memory B cells (MBC) to four malarial antigens were measured using ELISA and cultured B cell ELISpot.
   Findings and Conclusions: The proportion of individuals with malaria-specific MBC and antibodies, and the average number of antigens recognised by each individual, increased with age but the magnitude of these responses did not. Malaria-specific antibody levels did not correlate with either the prevalence or median number of MBC, indicating that these two assays are measuring different aspects of the humoral immune response. Among those with immunological evidence of malaria exposure (defined as a positive response to at least one malarial antigen either by ELISA or ELISPOT), the median number of malaria-specific MBC was similar to median numbers of diphtheria-specific MBC, suggesting that the circulating memory cell pool for malaria antigens is of similar size to that for other antigens.
C1 [Nogaro, Sarah I.; Walther, Brigitte; Conway, David J.; Walther, Michael] MRC Labs, Banjul, Gambia.
   [Nogaro, Sarah I.; Hafalla, Julius C.; Riley, Eleanor M.] London Sch Hyg & Trop Med, Dept Immunol & Infect, Fac Infect & Trop Dis, London WC1, England.
   [Remarque, Edmond J.] Biomed Primate Res Ctr, Dept Parasitol, Gj Rijswijk, Netherlands.
   [Tetteh, Kevin K. A.; Conway, David J.] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, Fac Infect & Trop Dis, London WC1, England.
RP Nogaro, SI (reprint author), MRC Labs, Banjul, Gambia.
EM Michael.Walther@nih.gov
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570; Conway, David/0000-0002-8711-3037
FU Medical Research Council (UK), The Gambia; Wellcome Trust [079920];
   Royal Society (UK)
FX This work was funded by the Medical Research Council (UK), The Gambia.
   J.C.H. was a recipient of a Wellcome Trust Visiting Fellowship (grant
   reference number 079920) and is currently supported by a University
   Research Fellowship from The Royal Society (UK). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Achtman AH, 2005, CURR TOP MICROBIOL, V297, P71
   Akpogheneta OJ, 2008, INFECT IMMUN, V76, P1748, DOI 10.1128/IAI.01333-07
   Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358
   BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V67, P343, DOI 10.1016/0166-6851(94)90026-4
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Chelimo K, 2005, PEDIATR INFECT DIS J, V24, P680, DOI 10.1097/01.inf.0000172151.28851.fd
   Clarke SE, 2002, T ROY SOC TROP MED H, V96, P499, DOI 10.1016/S0035-9203(02)90419-0
   Cockburn IA, 2007, CURR OPIN IMMUNOL, V19, P424, DOI 10.1016/j.coi.2007.05.008
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6
   Crompton PD, 2009, J IMMUNOL, V182, P3318, DOI 10.4049/jimmunol.0803596
   Crotty S, 2003, J IMMUNOL, V171, P4969
   Crotty S, 2004, SEMIN IMMUNOL, V16, P197, DOI 10.1016/j.smim.2004.02.008
   Crotty S, 2004, J IMMUNOL METHODS, V286, P111, DOI 10.1016/j.jim.2003.12.015
   Donati D, 2004, INFECT IMMUN, V72, P5412, DOI 10.1128/IAI.72.9.5412-5418.2004
   Dorfman JR, 2005, J INFECT DIS, V191, P1623, DOI 10.1086/429671
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Egan A, 1997, INFECT IMMUN, V65, P3024
   EGAN AF, 1995, INFECT IMMUN, V63, P456
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Fowkes FJI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000218
   Gomez-Escobar N, 2010, J INFECT DIS, V201, P444, DOI 10.1086/649902
   GREENWOOD BM, 1974, LANCET, V1, P435
   GREENWOOD BM, 1975, NATURE, V257, P592, DOI 10.1038/257592a0
   Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001
   Kinyanjui SM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-82
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683
   Okech BA, 2004, INFECT IMMUN, V72, P1557, DOI 10.1128/IAI.72.3.1557-1567.2004
   OSIER FH, 2011, INFECT IMMU IN PRESS, P1
   Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030
   Polley SD, 2007, J INFECT DIS, V195, P279, DOI 10.1086/509806
   RAMASAMY R, 1994, AM J TROP MED HYG, V50, P537
   Remarque EJ, 2008, INFECT IMMUN, V76, P2660, DOI 10.1128/IAI.00170-08
   SABCHAREON A, 1991, AM J TROP MED HYG, V45, P297
   Satoguina J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-274
   Schofield L, 2006, CURR MOL MED, V6, P205, DOI 10.2174/156652406776055221
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   Struik SS, 2004, IMMUNOL REV, V201, P268, DOI 10.1111/j.0105-2896.2004.00181.x
   Taylor RR, 1996, INT IMMUNOL, V8, P905, DOI 10.1093/intimm/8.6.905
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   Traore B, 2009, VACCINE, V27, P7299, DOI 10.1016/j.vaccine.2009.08.023
   Udhayakumar V, 2001, AM J TROP MED HYG, V65, P100
   UNICEF, 2011, INF COUNTR
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Weiss GE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015983
   Weiss GE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000912
   Weiss GE, 2009, J IMMUNOL, V183, P2176, DOI 10.4049/jimmunol.0901297
   WHITTLE HC, 1990, CLIN EXP IMMUNOL, V80, P213
   World Health Organization/UNICEF, 2009, REV NAT IMM COV 1980
   Wipasa J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000770
NR 53
TC 30
Z9 30
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 4
PY 2011
VL 6
IS 10
AR e25582
DI 10.1371/journal.pone.0025582
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 834MB
UT WOS:000295963300013
PM 21991321
OA gold
DA 2017-08-15
ER

PT J
AU Afolabi, MO
   Ndure, J
   Mueller, J
   Thomas, V
   Shams-Rony, M
   Borthwick, N
   Bridgeman, A
   Black, A
   Reilly, M
   Jaoko, W
   John-Stewart, G
   Ambler, G
   Lohman-Payne, B
   Hanke, T
   Flanagan, KL
AF Afolabi, M. O.
   Ndure, J.
   Mueller, J.
   Thomas, V.
   Shams-Rony, M.
   Borthwick, N.
   Bridgeman, A.
   Black, A.
   Reilly, M.
   Jaoko, W.
   John-Stewart, G.
   Ambler, G.
   Lohman-Payne, B.
   Hanke, T.
   Flanagan, K. L.
TI PedVacc001:Safety and Immunogenicity of a Candidate HIV-1 Vaccine,
   MVA.HIVA, Administered to Healthy Gambian Infants Born to
   HIV-1/2-Uninfected Mothers
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY SEP 12-15, 2011
CL Bangkok, THAILAND
C1 [Afolabi, M. O.; Ndure, J.; Mueller, J.; Thomas, V.; Shams-Rony, M.; Flanagan, K. L.] The Gambia, Med Res Council Labs, Banjul, Gambia.
   [Borthwick, N.; Bridgeman, A.; Black, A.; Hanke, T.] Univ Oxford, Jenner Inst, Oxford, England.
   [Reilly, M.] Karolinska Inst, Stockholm, Sweden.
   [Jaoko, W.] Univ Nairobi, Kenya AIDS Vaccine Initiat, Nairobi, Kenya.
   [John-Stewart, G.; Ambler, G.; Lohman-Payne, B.] Univ Washington, Dept Med, Seattle, WA USA.
   [John-Stewart, G.; Ambler, G.; Lohman-Payne, B.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2011
VL 27
IS 10
BP A22
EP A22
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 832GD
UT WOS:000295790500054
OA No
DA 2017-08-15
ER

PT J
AU Jasseh, M
   Webb, EL
   Jaffar, S
   Howie, S
   Townend, J
   Smith, PG
   Greenwood, BM
   Corrah, T
AF Jasseh, M.
   Webb, E. L.
   Jaffar, S.
   Howie, S.
   Townend, J.
   Smith, P. G.
   Greenwood, B. M.
   Corrah, T.
TI Reaching millennium development goal 4-the Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Jasseh, M.; Howie, S.; Townend, J.; Corrah, T.] MRC Labs, Fajara, Gambia.
   [Webb, E. L.; Jaffar, S.; Smith, P. G.; Greenwood, B. M.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD OCT
PY 2011
VL 16
SU 1
SI SI
BP 44
EP 44
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 828RC
UT WOS:000295519100120
OA No
DA 2017-08-15
ER

PT J
AU Damond, F
   Benard, A
   Balotta, C
   Boni, J
   Cotten, M
   Duque, V
   Ferns, B
   Garson, J
   Gomes, P
   Goncalves, F
   Gottlieb, G
   Kupfer, B
   Ruelle, J
   Rodes, B
   Soriano, V
   Wainberg, M
   Taieb, A
   Matheron, S
   Chene, G
   Brun-Vezinet, F
AF Damond, F.
   Benard, A.
   Balotta, Claudia
   Boeni, Juerg
   Cotten, Matthew
   Duque, Vitor
   Ferns, Bridget
   Garson, Jeremy
   Gomes, Perpetua
   Goncalves, Fatima
   Gottlieb, Geoffrey
   Kupfer, Bernd
   Ruelle, Jean
   Rodes, Berta
   Soriano, Vicente
   Wainberg, Mark
   Taieb, Audrey
   Matheron, Sophie
   Chene, Genevieve
   Brun-Vezinet, Francoise
CA ACHIEV2E Study Grp
TI An International Collaboration To Standardize HIV-2 Viral Load Assays:
   Results from the 2009 ACHI(E)V(2E) Quality Control Study
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-2; ANTIRETROVIRAL THERAPY; DRUG-RESISTANCE;
   COBAS AMPLICOR; GUINEA-BISSAU; TAQMAN HIV-1; WEST-AFRICA; PLASMA;
   QUANTIFICATION; SUBTYPES
AB Accurate HIV-2 plasma viral load quantification is crucial for adequate HIV-2 patient management and for the proper conduct of clinical trials and international cohort collaborations. This study compared the homogeneity of HIV-2 RNA quantification when using HIV-2 assays from ACHI(E)V(2E) study sites and either in-house PCR calibration standards or common viral load standards supplied to all collaborators. Each of the 12 participating laboratories quantified blinded HIV-2 samples, using its own HIV-2 viral load assay and standard as well as centrally validated and distributed common HIV-2 group A and B standards (http://www.hiv.lanl.gov/content/sequence/HelpDocs/subtypes-more.html). Aliquots of HIV-2 group A and B strains, each at 2 theoretical concentrations (2.7 and 3.7 log(10) copies/ml), were tested. Intralaboratory, interlaboratory, and overall variances of quantification results obtained with both standards were compared using F tests. For HIV-2 group A quantifications, overall and interlaboratory and/or intralaboratory variances were significantly lower when using the common standard than when using in-house standards at the concentration levels of 2.7 log(10) copies/ml and 3.7 log(10) copies/ml, respectively. For HIV-2 group B, a high heterogeneity was observed and the variances did not differ according to the type of standard used. In this international collaboration, the use of a common standard improved the homogeneity of HIV-2 group A RNA quantification only. The diversity of HIV-2 group B, particularly in PCR primer-binding regions, may explain the heterogeneity in quantification of this strain. Development of a validated HIV-2 viral load assay that accurately quantifies distinct circulating strains is needed.
C1 [Damond, F.; Brun-Vezinet, Francoise] Hop Bichat Claude Bernard, APHP, Virol Lab, F-75018 Paris, France.
   [Benard, A.; Taieb, Audrey; Chene, Genevieve] Univ Victor Segalen, INSERM, ISPED, U593, Bordeaux, France.
   [Balotta, Claudia] Univ Milan, Lab Dept Clin Sci, Infect Dis Sect, Milan, Italy.
   [Balotta, Claudia] Univ Milan, Immunopathol L Sacco Hosp, Milan, Italy.
   [Boeni, Juerg] Univ Zurich, Inst Med Virol, Natl Ctr Retroviruses, Zurich, Switzerland.
   [Cotten, Matthew] MRC Labs, Fajara, Gambia.
   [Duque, Vitor] Hosp Univ Coimbra, Virol Lab, Dept Doencas Infecciosas, Coimbra, Portugal.
   [Ferns, Bridget; Garson, Jeremy] UCL Med Sch, Ctr Virol, Res Dept Infect, London, England.
   [Gomes, Perpetua; Goncalves, Fatima] CHLO Hosp Egas Moniz, Mol Biol Lab, Lisbon, Portugal.
   [Gomes, Perpetua] Inst Super Saude Egas Moniz, Monte De Caparica, Portugal.
   [Gottlieb, Geoffrey] Univ Washington, Sch Med, Div Allergy & Infect Dis, Seattle, WA USA.
   [Ruelle, Jean] Catholic Univ Louvain, AIDS Reference Lab, B-1348 Louvain, Belgium.
   [Kupfer, Bernd] Inst Virol, Bonn, Germany.
   [Rodes, Berta; Soriano, Vicente] Hosp Carlos III, Dept Infect Dis, Madrid, Spain.
   [Wainberg, Mark] McGill Univ, Jewish Gen Hosp, McGill Univ AIDS Ctr, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
   [Matheron, Sophie] Hop Bichat Claude Bernard, APHP, Serv Malad Infect & Trop, F-75018 Paris, France.
   [Matheron, Sophie; Brun-Vezinet, Francoise] Univ Paris 07, Fac Med Denis Diderot, Paris, France.
RP Damond, F (reprint author), Hop Bichat Claude Bernard, APHP, Virol Lab, F-75018 Paris, France.
EM florence.damond@bch.aphp.fr
RI Gomes, Perpetua/I-5652-2012; chene, genevieve/H-8665-2014; Benard,
   Antoine/N-4738-2015
OI Gomes, Perpetua/0000-0003-3271-8255; Benard,
   Antoine/0000-0003-2289-8096; Cavaco Silva, Perpetua/0000-0001-8429-1316;
   Matheron, Sophie/0000-0001-7879-6553
FU Agence Nationale de Recherche sur le SIDA et les Hepatites Virales
   (ANRS); Swiss National Science Foundation
FX This work was supported by the Agence Nationale de Recherche sur le SIDA
   et les Hepatites Virales (ANRS). The Swiss HIV Cohort Study is supported
   by the Swiss National Science Foundation.
CR Arien KK, 2005, J VIROL, V79, P8979, DOI 10.1128/JVI.79.14.8979-8990.2005
   Benard A, 2011, CLIN INFECT DIS, V52, P1257, DOI 10.1093/cid/cir123
   Borget MY, 2009, J CLIN VIROL, V45, P72, DOI 10.1016/j.jcv.2009.03.011
   Chen ZW, 1997, J VIROL, V71, P3953
   Damond F, 2007, J CLIN MICROBIOL, V45, P3436, DOI 10.1128/JCM.00973-07
   Damond F, 2005, J CLIN MICROBIOL, V43, P4234, DOI 10.1128/JCM.43.8.4234-4236.2005
   Damond F, 1999, AIDS, V13, P286, DOI 10.1097/00002030-199902040-00023
   Damond F, 2001, VIROLOGY, V280, P19, DOI 10.1006/viro.2000.0685
   DAMOND F, 2001, J CLIN MICROBIOL, V48, P1413
   Damond F, 2008, J CLIN MICROBIOL, V46, P2088, DOI 10.1128/JCM.00126-08
   Ferns RB, 2006, J VIROL METHODS, V135, P102, DOI 10.1016/j.jviromet.2006.02.005
   FULTZ PN, 1988, AIDS, V2, P129, DOI 10.1097/00002030-198804000-00010
   GAO F, 1994, J VIROL, V68, P7433
   GAO F, 1993, AIDS RES HUM RETROV, V9, P703, DOI 10.1089/aid.1993.9.703
   Gao Feng, 2005, Methods Mol Biol, V304, P191
   Gottlieb GS, 2008, AIDS, V22, P2069, DOI 10.1097/QAD.0b013e32830edd44
   Gottlieb GS, 2009, CLIN INFECT DIS, V48, P476, DOI 10.1086/596504
   Heredia A, 1998, AIDS RES HUM RETROV, V14, P471, DOI 10.1089/aid.1998.14.471
   Jallow S, 2009, J CLIN MICROBIOL, V47, P2200, DOI 10.1128/JCM.01654-08
   Matheron S, 2003, AIDS, V17, P2593, DOI 10.1097/01.aids.0000096907.73209.b9
   Muyldermans G, 2000, CLIN MICROBIOL INFEC, V6, P213, DOI 10.1046/j.1469-0691.2000.00048.x
   NAUCLER A, 1989, J ACQ IMMUN DEF SYND, V2, P88
   Ntemgwa ML, 2009, ANTIMICROB AGENTS CH, V53, P708, DOI 10.1128/AAC.01109-08
   Rodes B, 2007, J CLIN MICROBIOL, V45, P88, DOI 10.1128/JCM.01613-06
   Ruelle J, 2004, J VIROL METHODS, V117, P67, DOI 10.1016/j.jviromet.2003.12.006
   Sarfo FS, 2009, J ANTIMICROB CHEMOTH, V64, P667, DOI 10.1093/jac/dkp216
   Scott LE, 2009, J CLIN MICROBIOL, V47, P2209, DOI 10.1128/JCM.01761-08
   SMALLMANRAYNOR M, 1991, INT J EPIDEMIOL, V20, P480, DOI 10.1093/ije/20.2.480
   Soriano V, 2000, J MED VIROL, V61, P111, DOI 10.1002/(SICI)1096-9071(200005)61:1<111::AID-JMV18>3.0.CO;2-W
   Toro Carlos, 2002, HIV Clin Trials, V3, P397
   Valadas E, 2009, CLIN INFECT DIS, V48, P1166, DOI 10.1086/597504
   Wirden M, 2009, J CLIN MICROBIOL, V47, P1543, DOI 10.1128/JCM.02134-08
NR 32
TC 13
Z9 13
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD OCT
PY 2011
VL 49
IS 10
BP 3491
EP 3497
DI 10.1128/JCM.02389-10
PG 7
WC Microbiology
SC Microbiology
GA 826NK
UT WOS:000295360700008
PM 21813718
OA No
DA 2017-08-15
ER

PT J
AU Jasseh, M
   Webb, EL
   Jaffar, S
   Howie, S
   Townend, J
   Smith, PG
   Greenwood, BM
   Corrah, T
AF Jasseh, Momodou
   Webb, Emily L.
   Jaffar, Shabbar
   Howie, Stephen
   Townend, John
   Smith, Peter G.
   Greenwood, Brian M.
   Corrah, Tumani
TI Reaching Millennium Development Goal 4-The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE child mortality; The Gambia; Millennium Development Goals; malaria
ID PRIMARY-HEALTH-CARE; CHILD-MORTALITY; VERBAL AUTOPSY; RURAL SENEGAL;
   WEST-AFRICA; MALARIA; MORBIDITY; DECLINE; TRENDS; SURVIVAL
AB OBJECTIVE To describe how, through a DSS in a rural area of The Gambia, it has been possible to measure substantial reductions in child mortality rates and how we investigated whether the decline paralleled the registered fall in malaria incidence in the country.
   METHODS Demographic surveillance data spanning 19.5 years (1 April 1989-30 September 2008) from 42 villages around the town of Farafenni, The Gambia, were used to estimate childhood mortality rates for neonatal, infant, child (1-4 years) and under-5 age groups. Data were presented in five a priori defined time periods, and annual rates per 1000 live births were derived from Kaplan-Meier survival probabilities.
   RESULTS From 1989-1992 to 2004-2008, under-5 mortality declined by 56% (95% CI: 48-63%), from 165 (95% CI: 151-181) per 1000 live births to 74 (95% CI: 65-84) per 1000 live births. In 1- to 4-year-olds, mortality during the period 2004-2008 was 69% (95% CI: 60-76%) less than in 1989-1992. The corresponding mortality decline in infants was 39% (95% CI: 23-52%); in neonates, it was 38% (95% CI: 13-66%). The derived annual under-5 mortality rates declined from 159 per 1000 live births in 1990 to 45 per 1000 live births in 2008, thus implying an attainment of MDG4 seven years in advance of the target year of 2015.
   CONCLUSION Achieving MDG4 is possible in poor, rural areas of Africa through widespread deployment of relatively simple measures that improve child survival, such as immunisation and effective malaria control.
C1 [Jasseh, Momodou; Howie, Stephen; Townend, John; Corrah, Tumani] MRC Labs, Fajara, Gambia.
   [Webb, Emily L.; Jaffar, Shabbar; Smith, Peter G.; Greenwood, Brian M.] London Sch Hyg & Trop Med, London WC1, England.
RP Jasseh, M (reprint author), MRC Labs, Fajara, Gambia.
EM mjasseh@mrc.gm
OI Webb, Emily/0000-0002-4019-7456
FU UK Medical Research Council (MRC)
FX Financial support for the research was provided by the UK Medical
   Research Council (MRC). We thank the current and former residents of the
   Farafenni Demographic Surveillance Area for participating in the DSS
   activities; Olumuyiwa Owolabi, Ogochukuwu Ofordile, Claire Oluwalana,
   Adewumi Durodola, Danlami Garba, Ifedayo Adetifa, Augustin Fombah,
   Bernard Ebruke, Chukwugoziem Ideh Readon, David Ameh and Uduak Okomo for
   reviewing the verbal autopsies; and Paul Snell, Ruhul Amin, Paul
   Milligan, Maimuna Sowe, Amy Ratcliffe, Allan Hill and former Heads of
   the MRC Farafenni Field Station for their significant contributions
   towards the maintenance of the Farafenni DSS. We also acknowledge the
   assistance over the years of the FDSS Data and Field staff led by Pierre
   Gomez and Louie Loppy, respectively; and the INDEPTH Network.
CR BLACKER JG, 1985, INT POP C 1985 FLOR
   BRADLEY AK, 1986, LANCET, V2, P204
   CANTRELLE P, 1971, POP STUD-J DEMOG, V25, P505, DOI 10.1080/00324728.1971.10405821
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   Delaunay V, 2001, INT J EPIDEMIOL, V30, P1286, DOI 10.1093/ije/30.6.1286
   FREDERIKSEN H, 1961, PUBLIC HEALTH REP, V76, P659, DOI 10.2307/4591240
   Gambia Bureau of Statistics, 2007, GAMB MULT IND CLUST
   Garenne M, 2006, B WORLD HEALTH ORGAN, V84, P470, DOI 10.2471/BLT.05.029231
   Government of The Gambia UNICEF, 2002, GAMB MULT IND CLUST
   GREENWOOD BM, 1988, LANCET, V1, P1121
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   GREENWOOD BM, 1990, J TROP MED HYG, V93, P87
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   Haines A, 2004, BRIT MED J, V329, P394, DOI 10.1136/bmj.329.7462.394
   Hill AG, 1998, LANCET, V352, P1909, DOI 10.1016/S0140-6736(05)60400-X
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   HILL K, 1995, POPULATION B UN, V39, P112
   *INDEPTH NETW, 2006, INDEPTH RES KIT DEM
   INDEPTH Network, 2002, POP HLTH DEV COUNTR, V1
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Kleinschmidt I, 2009, AM J TROP MED HYG, V80, P882
   Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1
   Lawn JE, 2007, ARCH DIS CHILD, V92, P551, DOI 10.1136/adc.2006.099291
   Loaiza E, 2008, LANCET, V372, P874, DOI 10.1016/S0140-6736(08)61378-1
   MABEY DCW, 1987, J INFECT DIS, V155, P1319
   Mackenzie G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010568
   MACLEOD B, 1991, 2 ANN C ADV COMP INF
   MACLEOD WB, 1998, DESCRIPTION FARAFENN
   Masanja H, 2008, LANCET, V371, P1276, DOI 10.1016/S0140-6736(08)60562-0
   Ntab B, 2007, AM J TROP MED HYG, V77, P411
   PISON G, 1993, INT J EPIDEMIOL, V22, P72, DOI 10.1093/ije/22.1.72
   SEIDLEIN L, 2003, T ROY SOC TROP MED H, V97, P217, DOI 10.1016/S0035-9203(03)90125-8
   Soleman N, 2006, B WORLD HEALTH ORGAN, V84, P239, DOI 10.2471/BLT.05.027003
   Timaeus IM, 2001, INT J EPIDEMIOL, V30, P1294, DOI 10.1093/ije/30.6.1294
   Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0
   United Nations Development Programme, 2003, HUM DEV REP 2003 MIL
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   World Bank, 2004, MILL DEV GOALS HLTH
NR 40
TC 25
Z9 25
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD OCT
PY 2011
VL 16
IS 10
BP 1314
EP 1325
DI 10.1111/j.1365-3156.2011.02809.x
PG 12
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 822MN
UT WOS:000295052000014
PM 21707875
OA No
DA 2017-08-15
ER

PT J
AU Sutherland, JS
   Hill, PC
   Adetifa, IM
   de Jong, BC
   Donkor, S
   Joosten, SA
   Opmeer, L
   Haks, MC
   Ottenhoff, THM
   Adegbola, RA
   Ota, MOC
AF Sutherland, Jayne S.
   Hill, Philip C.
   Adetifa, Ifedayo M.
   de Jong, Bouke C.
   Donkor, Simon
   Joosten, Simone A.
   Opmeer, Lizet
   Haks, Marielle C.
   Ottenhoff, Tom H. M.
   Adegbola, Richard A.
   Ota, Martin O. C.
TI Identification of Probable Early-Onset Biomarkers for Tuberculosis
   Disease Progression
SO PLOS ONE
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS; PREDICTIVE-VALUE; INFECTION; EXPRESSION;
   ASSAY
AB Determining what constitutes protective immunity to TB is critical for the development of improved diagnostics and vaccines. The comparison of the immune system between contacts of TB patients, who later develop TB disease (progressors), versus contacts who remain healthy (non-progressors), allows for identification of predictive markers of TB disease. This study provides the first comprehensive analysis of the immune system of progressors and non-progressors using a well-characterised TB case-contact (TBCC) platform in The Gambia, West Africa. 22 progressors and 31 non-progressors were analysed at recruitment, 3 months and 18 months (time to progression: median[IQR] of 507[187-714] days). Immunophenotyping of PBMC, plasma cytokine levels and RT-MLPA analysis of whole blood-derived RNA was performed to capture key immune system parameters. At recruitment, progressors had lower PBMC proportions of CD4+ T cells, NKT cells and B cells relative to non-progressors. Analysis of the plasma showed higher levels of IL-18 in progressors compared to non-progressors and analysis of the RNA showed significantly lower gene expression of Bcl2 but higher CCR7 in progressors compared to non-progressors. This study shows several markers that may predict the onset of active TB at a very early stage after infection. Once these markers have been validated in larger studies, they provide avenues to prospectively identify people at risk of developing TB, a key issue in the testing of new TB vaccines.
C1 [Sutherland, Jayne S.; Hill, Philip C.; Adetifa, Ifedayo M.; de Jong, Bouke C.; Donkor, Simon; Adegbola, Richard A.; Ota, Martin O. C.] MRC Unit, Vaccinol Theme Grp, Fajara, Gambia.
   [Joosten, Simone A.; Opmeer, Lizet; Haks, Marielle C.; Ottenhoff, Tom H. M.] Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands.
RP Sutherland, JS (reprint author), MRC Unit, Vaccinol Theme Grp, Fajara, Gambia.
EM jsutherland@mrc.gm
RI Joosten, Simone/E-4731-2011; Joosten, Simone/F-1357-2011; de Jong,
   Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; Sutherland,
   Jayne/0000-0002-7083-4997
FU MRC Unit, The Gambia
FX This work was funded by the MRC Unit, The Gambia. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Abebe M, 2010, EUR J IMMUNOL, V40, P291, DOI 10.1002/eji.200939856
   Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247
   Diel R, 2011, AM J RESP CRIT CARE, V183, P88, DOI 10.1164/rccm.201006-0974OC
   Doherty M, 2009, CURR OPIN PULM MED, V15, P181, DOI 10.1097/MCP.0b013e328326f42c
   Eldering E, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng153
   Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594
   Hill PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001379
   Hill PC, 2010, LANCET INFECT DIS, V10, P723, DOI 10.1016/S1473-3099(10)70164-X
   Hoogerwerf JJ, 2010, J INNATE IMMUN, V2, P461, DOI 10.1159/000317035
   Jacobsen M, 2007, J MOL MED-JMM, V85, P613, DOI 10.1007/s00109-007-0157-6
   Joosten SA, 2011, GENES IMMUN IN PRESS
   Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810
   Kaufmann SHE, 2008, CELL HOST MICROBE, V4, P219, DOI 10.1016/j.chom.2008.08.002
   Kaufmann SHE, 2011, LANCET INFECT DIS, V11, P633, DOI 10.1016/S1473-3099(11)70146-3
   Lienhardt C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010508
   Maertzdorf J, 2011, GENES IMMUN, V12, P15, DOI 10.1038/gene.2010.51
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704
   Parida SK, 2010, DRUG DISCOV TODAY, V15, P148, DOI 10.1016/j.drudis.2009.10.005
   Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210
   Rios-Barrera Victor Adolfo, 2006, Eur J Immunol, V36, P345, DOI 10.1002/eji.200535202
   Sada-Ovalle I, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000239
   Schultz H, 2007, CLIN CHIM ACTA, V384, P12, DOI 10.1016/j.cca.2007.07.005
   Stenger S, 2005, ANN RHEUM DIS, V64, P24, DOI 10.1136/ard.2005.042531
   Stop TB Partnership, GLOB PLAN STOP TB 20
   Sutherland JS, 2009, TUBERCULOSIS, V89, P398, DOI 10.1016/j.tube.2009.07.004
   Sutherland JS, 2009, EUR J IMMUNOL, V39, P723, DOI 10.1002/eji.200838693
   Wallis RS, 2009, LANCET INFECT DIS, V9, P162, DOI 10.1016/S1473-3099(09)70042-8
   White SJ, 2004, HUM MUTAT, V24, P86, DOI 10.1002/humu.20054
   Yamada G, 2000, AM J RESP CRIT CARE, V161, P1786
NR 29
TC 21
Z9 21
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 23
PY 2011
VL 6
IS 9
AR e25230
DI 10.1371/journal.pone.0025230
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 825IZ
UT WOS:000295267100031
PM 21966464
OA gold
DA 2017-08-15
ER

PT J
AU Walther, B
   Hossin, S
   Townend, J
   Abernethy, N
   Parker, D
   Jeffries, D
AF Walther, Brigitte
   Hossin, Safayet
   Townend, John
   Abernethy, Neil
   Parker, David
   Jeffries, David
TI Comparison of Electronic Data Capture (EDC) with the Standard Data
   Capture Method for Clinical Trial Data
SO PLOS ONE
LA English
DT Article
ID HAND-HELD COMPUTERS; SKILL; ENTRY; AGE
AB Background: Traditionally, clinical research studies rely on collecting data with case report forms, which are subsequently entered into a database to create electronic records. Although well established, this method is time-consuming and error-prone. This study compares four electronic data capture (EDC) methods with the conventional approach with respect to duration of data capture and accuracy. It was performed in a West African setting, where clinical trials involve data collection from urban, rural and often remote locations.
   Methodology/Principal Findings: Three types of commonly available EDC tools were assessed in face-to-face interviews; netbook, PDA, and tablet PC. EDC performance during telephone interviews via mobile phone was evaluated as a fourth method. The Graeco Latin square study design allowed comparison of all four methods to standard paper-based recording followed by data double entry while controlling simultaneously for possible confounding factors such as interview order, interviewer and interviewee. Over a study period of three weeks the error rates decreased considerably for all EDC methods. In the last week of the study the data accuracy for the netbook (5.1%, CI95%: 3.5-7.2%) and the tablet PC (5.2%, CI95%: 3.7-7.4%) was not significantly different from the accuracy of the conventional paper-based method (3.6%, CI95%: 2.2-5.5%), but error rates for the PDA (7.9%, CI95%: 6.0-10.5%) and telephone (6.3%, CI95% 4.6-8.6%) remained significantly higher. While EDC-interviews take slightly longer, data become readily available after download, making EDC more time effective. Free text and date fields were associated with higher error rates than numerical, single select and skip fields.
   Conclusions: EDC solutions have the potential to produce similar data accuracy compared to paper-based methods. Given the considerable reduction in the time from data collection to database lock, EDC holds the promise to reduce research-associated costs. However, the successful implementation of EDC requires adjustment of work processes and reallocation of resources.
C1 [Walther, Brigitte; Hossin, Safayet; Townend, John; Parker, David; Jeffries, David] MRC, Stat & Data Management Dept, Fajara, Gambia.
   [Abernethy, Neil] Univ Washington, Dept Bioinformat, Seattle, WA 98195 USA.
   [Jeffries, David] Populat Serv Int, Washington, DC USA.
RP Walther, B (reprint author), MRC, Stat & Data Management Dept, Fajara, Gambia.
EM waltherbrigitte@t-online.de
FU Medical Research Council (UK), The Gambia
FX The study was funded by the Medical Research Council (UK), The Gambia.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR *AK, 2011, OPENCLINICA 3 1
   BOSMAN EA, 1993, PSYCHOL AGING, V8, P87, DOI 10.1037//0882-7974.8.1.87
   Bosman E. A., 1996, PERSPECTIVES COGNITI, P428
   FRANKLIN JD, 2011, J BIOMED INFORM, DOI DOI 10.1016/JJBI201105008
   *GAMT, 2009, GAMT CREAT BRIGHT FU
   Garritty C, 2006, J MED INTERNET RES, V8, DOI 10.2196/jmir.8.2.e7
   *HLTH DEC, 2009, SMARTPEN ADV EDC SYS
   International Committee of the Red Cross, 2009, INT TEL UN MEAS INF, P33
   KAYIWA D, 2010, MOBILE DATA ENTRY US
   Lane Shannon J, 2006, BMC Med Inform Decis Mak, V6, P23, DOI 10.1186/1472-6947-6-23
   MEASURE DHS, 2010, DEM HLTH SURV
   MEUNIER PNS, 2002, P 11 IEEE INT WORKSH
   OCRAN CQ, 2007, GENERIC ADJUDICATED, P9
   *OPENCLINICA, 2003, AK RES
   *QUANTUMNET, 2008, QUANTUMNET GROUP SET
   SALTHOUSE TA, 1984, J EXP PSYCHOL GEN, V113, P345, DOI 10.1037//0096-3445.113.3.345
   SEARS A, 1993, BEHAV INFORM TECHNOL, V12, P17
   Seebregts CJ, 2009, INT J MED INFORM, V78, P721, DOI 10.1016/j.ijmedinf.2008.10.006
   Shelby-James TM, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-5
   SMITH CC, 1982, BYTE, V7, P242
   *SNAP SURV, 2010, SNAP SURV SOFTW
   Tesler L., 1981, BYTE, V6, P90
   Tomlinson M, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-51
   UNICEF, 2010, MULT IND CLUST SURV
   US Department of Health and Human Services, 1996, HLTH INS PORT ACC AC
   *US DEP HHS, 2005, PAT SAF QUAL IMPR AC
   US Food and Drug Administration, 2007, GUID IND COMP SYST U
   Vanden Eng Jodi L, 2007, Am J Trop Med Hyg, V77, P393
   WHO, 2002, WORLD HLTH SURV 2002
   Wright P, 2000, ERGONOMICS, V43, P702, DOI 10.1080/001401300404689
   2008, NETPAGE TECHNOLOGY S
NR 31
TC 31
Z9 32
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 23
PY 2011
VL 6
IS 9
AR e25348
DI 10.1371/journal.pone.0025348
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 825IZ
UT WOS:000295267100047
PM 21966505
OA gold
DA 2017-08-15
ER

PT J
AU Fullen, MA
   Subedi, M
   Booth, CA
   Sarsby, RW
   Davies, K
   Bhattacharyya, R
   Kugan, R
   Luckhurst, DA
   Chan, K
   Black, AW
   Townrow, D
   James, T
   Poesen, J
   Smets, T
   Kertesz, A
   Toth, A
   Szalai, Z
   Jakab, G
   Jankauskas, B
   Jankauskiene, G
   Buhmann, C
   Paterson, G
   Mulibana, E
   Nell, JP
   van der Merwe, GME
   Guerra, AJT
   Mendonca, JKS
   Guerra, TT
   Sathler, R
   Bezerra, JFR
   Peres, SM
   Yi, Z
   Li, YM
   Li, T
   Panomtaranichagul, M
   Peukrai, S
   Thu, DC
   Cuong, TH
   Toan, TT
   Jonsyn-Ellis, F
   Sylva, JZ
   Cole, A
   Mulholland, B
   Dearlove, M
   Corkill, C
   Tomlinson, P
AF Fullen, M. A.
   Subedi, M.
   Booth, C. A.
   Sarsby, R. W.
   Davies, K.
   Bhattacharyya, R.
   Kugan, R.
   Luckhurst, D. A.
   Chan, K.
   Black, A. W.
   Townrow, D.
   James, T.
   Poesen, J.
   Smets, T.
   Kertesz, A.
   Toth, A.
   Szalai, Z.
   Jakab, G.
   Jankauskas, B.
   Jankauskiene, G.
   Buehmann, C.
   Paterson, G.
   Mulibana, E.
   Nell, J. P.
   van Der Merwe, G. M. E.
   Guerra, A. J. T.
   Mendonca, J. K. S.
   Guerra, T. T.
   Sathler, R.
   Bezerra, J. F. R.
   Peres, S. M.
   Yi, Zheng
   Li Yongmei
   Li, Tang
   Panomtaranichagul, M.
   Peukrai, S.
   Thu, D. C.
   Cuong, T. H.
   Toan, T. T.
   Jonsyn-Ellis, F.
   Sylva, J. Z.
   Cole, A.
   Mulholland, B.
   Dearlove, M.
   Corkill, C.
   Tomlinson, P.
TI UTILISING BIOLOGICAL GEOTEXTILES: INTRODUCTION TO THE BORASSUS PROJECT
   AND GLOBAL PERSPECTIVES
SO LAND DEGRADATION & DEVELOPMENT
LA English
DT Article
DE soil and water conservation; bioengineering technology; socio-economic
   development; BORASSUS; biological geotextiles
ID YUNNAN PROVINCE; PALM; CHINA; LAND
AB Field and laboratory studies indicate that utilisation of biological geotextiles constructed from palm-leaves and other selected organic materials are an effective, sustainable and economically viable soil conservation technique. The three-year plus (1 July 2005-28 February 2009) EU-funded BORASSUS Project (contract no. INCO-CT-2005-510745) evaluated the long-term effectiveness of biological geotextiles in controlling soil erosion and assessing their sustainability and economic viability. These studies progressed in ten countries, both in the 'industrial north' (in Europe) and in the 'developing south' (Africa, South America and South East Asia). The studied countries in the 'developing south' included Brazil, China, The Gambia, South Africa, Thailand and Vietnam. The 'industrial north' countries included Belgium, Hungary, Lithuania and the UK. The main findings of these studies are summarised in this paper and thematic information is presented in the other four papers in this Special Issue.
   Biological geotextiles offer potentially novel bioengineering solutions to environmental problems, including technologies for soil conservation, sustainable plant production and use of indigenous plants, improved ecosystem management by decreasing deforestation, improving agroforestry and cost-effective biogeotextile applications in diverse environments. Biogeotextiles may provide socio-economic platforms for sustainable development and the benefits for developing countries may include poverty alleviation, engagement of local people as stakeholders, employment for disadvantaged groups, small and medium enterprise (SME) development, earning hard currency, environmental education and local community involvement in land reclamation and environmental education programmes. These benefits are achieved through: (i) promotion of sustainable and environmentally friendly palm-agriculture to discourage deforestation, promoting both reforestation and agroforestry; (ii) construction of biogeotextiles enabling development of a rural labour-intensive industry, particularly encouraging employment of socially disadvantaged groups and (iii) export of biogeotextiles to industrialised countries could earn hard currency for developing economies, based on the principles of fair trade. Research and development activities of the BORASSUS Project have improved our knowledge on the effect of biogeotextile mats on the micro-and macro-soil environments and at larger scales through controlled laboratory and field experiments in diverse environments. Copyright (C) 2011 John Wiley & Sons, Ltd.
C1 [Fullen, M. A.; Subedi, M.; Booth, C. A.; Sarsby, R. W.; Davies, K.; Bhattacharyya, R.; Kugan, R.; Luckhurst, D. A.; Chan, K.; Black, A. W.; Townrow, D.; James, T.] Wolverhampton Univ, Wolverhampton WV1 1LY, W Midlands, England.
   [Poesen, J.; Smets, T.] Catholic Univ Louvain, B-3000 Louvain, Belgium.
   [Kertesz, A.; Toth, A.; Szalai, Z.; Jakab, G.] Geog Res Inst, H-1112 Budapest, Hungary.
   [Jankauskas, B.; Jankauskiene, G.] Lithuanian Inst Agr, Kaltinenai Res Stn, LT-5926 Traku Voke, Lithuania.
   [Buehmann, C.; Paterson, G.; Mulibana, E.; Nell, J. P.; van Der Merwe, G. M. E.] Agr Res Council, Pretoria, South Africa.
   [Guerra, A. J. T.; Mendonca, J. K. S.; Guerra, T. T.; Sathler, R.; Bezerra, J. F. R.; Peres, S. M.] Univ Fed Rio de Janeiro, BR-21940590 Rio De Janeiro, Brazil.
   [Yi, Zheng; Li Yongmei; Li, Tang] Yunnan Agr Univ, Kunming 650201, Peoples R China.
   [Panomtaranichagul, M.; Peukrai, S.] Chiang Mai Univ, Chiang Mai 50200, Thailand.
   [Thu, D. C.; Cuong, T. H.; Toan, T. T.] Hanoi Agr Univ, Hanoi, Vietnam.
   [Jonsyn-Ellis, F.; Sylva, J. Z.; Cole, A.] Catholic Dev Org CaDO, Caritas, Gambia.
   [Mulholland, B.; Dearlove, M.] Duchy Agr Coll, Camborne, Cornwall, England.
   [Corkill, C.; Tomlinson, P.] Univ Liverpool, Ctr Manx Studies, Douglas, Man, England.
RP Fullen, MA (reprint author), Wolverhampton Univ, Wolverhampton WV1 1LY, W Midlands, England.
EM m.fullen@wlv.ac.uk
OI Jakab, Gergely/0000-0001-5424-1983; Szalai, Zoltan/0000-0001-5267-411X
FU European Commission [INCO-CT-2005-510745]
FX This work is dedicated to the memory of Dr. Kathy Davies, who initiated
   and inspired the concept of developing palm-leaf biological geotextiles.
   We also gratefully thank all technical and support staff involved with
   this Project. All authors acknowledge and thank the European Commission
   for the financial support of the BORASSUS Project (contract number
   INCO-CT-2005-510745) and Dr. Michele Genovese (of the European
   Commission) for his advice and support.
CR Bhattacharyya R, 2009, AGR ECOSYST ENVIRON, V130, P50, DOI 10.1016/j.agee.2008.11.015
   BOOTH CA, 2005, ECOSYSTEMS SUSTAINAB, V5, P649
   BOOTH CA, 2007, SUSTAINABLE DEV PLAN, V3, P601
   Davies K, 2006, EARTH SURF PROC LAND, V31, P561, DOI 10.1002/esp.1349
   FULLEN MA, 2007, SUSTAIN DEV, V6, P123
   Garforth C, 2003, LAND USE POLICY, V20, P323, DOI 10.1016/S0264-8377(03)00035-8
   JANKAUSKAS B, 2010, TILTAI BRIDGES J KLA, V1, P119
   MAGLINAO AR, 1996, SOIL CONSERVATION EX
   Rickson R.J., 2000, ASPECTS APPL BIOL, V58, P107
   Santos LMP, 2005, ECOL FOOD NUTR, V44, P345, DOI 10.1080/03670240500253369
   Smets T, 2007, SOIL USE MANAGE, V23, P306, DOI 10.1111/j.1475-2743.2007.00098.x
   SMETS T, 2009, THESIS U LEUVEN LEUV, P287
   SMITH R, 2001, P SEM ROM
   Subedi M, 2009, PEDOSPHERE, V19, P344, DOI 10.1016/S1002-0160(09)60125-9
   Subedi M, 2009, AGRIC SCI CHINA, V8, P188, DOI [10.1016/S1671-2927(08)60200-X, 10.1016/S1671-2927(09)60027-4]
NR 15
TC 9
Z9 9
U1 3
U2 39
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1085-3278
J9 LAND DEGRAD DEV
JI Land Degrad. Dev.
PD SEP-OCT
PY 2011
VL 22
IS 5
SI SI
BP 453
EP 462
DI 10.1002/ldr.1105
PG 10
WC Environmental Sciences; Soil Science
SC Environmental Sciences & Ecology; Agriculture
GA 824TW
UT WOS:000295226100001
OA No
DA 2017-08-15
ER

PT J
AU Secka, O
   Thomas, JE
   Berg, DE
   Antonio, M
   Tapgun, M
   Thomas, V
   Walton, R
   Corrah, T
   Bottomley, C
   Adegbola, RA
AF Secka, O.
   Thomas, J. E.
   Berg, D. E.
   Antonio, M.
   Tapgun, M.
   Thomas, V.
   Walton, R.
   Corrah, T.
   Bottomley, C.
   Adegbola, R. A.
TI PREVALENCE OF CAGA AND VACA GENES IN HELICOBACTER PYLORI FROM THE GAMBIA
   IN RELATION TO DISEASE PHENOTYPE
SO HELICOBACTER
LA English
DT Meeting Abstract
CT 24th International Workshop on Helicobacter and Related Bacteria in
   Chronic Digestive Inflammation and Gastric Cancer
CY SEP 11-13, 2011
CL Dublin, IRELAND
C1 [Secka, O.; Antonio, M.; Tapgun, M.; Thomas, V.; Walton, R.; Corrah, T.] MRC Labs, Fajara, Gambia.
   [Thomas, J. E.] Univ Newcastle, Newcastle Upon Tyne, Tyne & Wear, England.
   [Berg, D. E.] Washington Univ, St Louis, MO USA.
   [Bottomley, C.] London Sch Hyg & Trop Med, London WC1, England.
   [Adegbola, R. A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1083-4389
J9 HELICOBACTER
JI Helicobacter
PD SEP
PY 2011
VL 16
SU 1
SI SI
BP 102
EP 102
PG 1
WC Gastroenterology & Hepatology; Microbiology
SC Gastroenterology & Hepatology; Microbiology
GA 820ZF
UT WOS:000294943900092
OA No
DA 2017-08-15
ER

PT J
AU Nyan, O
   Mendy, AM
   Moraru, D
   Berger, C
   Thome, J
AF Nyan, Ousman
   Mendy, Ann Marie
   Moraru, Diana
   Berger, Christoph
   Thome, Johannes
TI Diagnostic characteristics of inpatients in a Western African
   psychiatric hospital
SO WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Africa; BPRS; developing countries; epidemiology; MINI; psychiatric
   services; transcultural psychiatry
ID GENDER
AB Little is known about psychiatric patients and psychiatric service delivery in non-Western developing countries. Therefore, this naturalistic pilot study aimed at analysing and describing the patient population treated in the Tanka Tanka Psychiatric Hospital, the mental health inpatient facility of The Gambia. Most patients were male and exhibited a wide age range of over 40 years. There were also indicators that the hospital population consisted of two distinguished groups: a large group of chronically ill patients and a smaller group of psychiatric patients with very acute symptoms. Psychotic/mood disorders and substance dependence/abuse were the most common diagnoses. In many patients problematic cannabis use was prevalent. Such research can contribute to better understand the needs of psychiatric patients, and help to develop continuously improved service delivery and optimise therapeutic options.
C1 [Berger, Christoph; Thome, Johannes] Univ Rostock, Clin & Policlin Psychiat & Psychotherapy, D-18147 Rostock, Germany.
   [Nyan, Ousman; Mendy, Ann Marie] Univ Gambia, TankaTanka Psychiat Hosp, Banjul, Gambia.
   [Nyan, Ousman; Mendy, Ann Marie] Univ Gambia, Sch Med, Royal Victoria Teaching Hosp, Banjul, Gambia.
   [Moraru, Diana] Univ Swansea, Coll Med, Swansea, W Glam, Wales.
RP Thome, J (reprint author), Univ Rostock, Clin & Policlin Psychiat & Psychotherapy, Gehlsheimerstr 20, D-18147 Rostock, Germany.
EM johannes.thome@med.uni-rostock.de
FU AstraZeneca; Bristol-Myers Squibb; Janssen-Cilag; Lilly; Lundbeck;
   MEDICE; Merz; Novartis; Pfizer; Servier; Shire
FX JT has received financial support (including paritially for this paper)
   from the following pharmaceutical companies: AstraZeneca, Bristol-Myers
   Squibb, Janssen-Cilag, Lilly, Lundbeck, MEDICE, Merz, Novartis, Pfizer,
   Servier, Shire.
CR Magadi MA, 2011, SOCIOL HEALTH ILL, V33, P522, DOI 10.1111/j.1467-9566.2010.01304.x
   Makanjuola V, 2011, AFR J PSYCHIATRY, V14, P89
   OVERALL JE, 1962, PSYCHOL REP, V10, P799
   SEDERER LI, 1995, PSYCHIAT QUART, V66, P263, DOI 10.1007/BF02265675
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Timms D, 1998, SOC SCI MED, V46, P1235, DOI 10.1016/S0277-9536(97)10052-1
   Weich L, 2009, AFR J PSYCHIATRY, V12, P213
NR 7
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1562-2975
EI 1814-1412
J9 WORLD J BIOL PSYCHIA
JI World J. Biol. Psychiatry
PD SEP
PY 2011
VL 12
SU 1
BP 85
EP 88
DI 10.3109/15622975.2011.601926
PG 4
WC Psychiatry
SC Psychiatry
GA 819YO
UT WOS:000294871700018
PM 21906002
OA No
DA 2017-08-15
ER

PT J
AU Thome, J
   Marenah, E
   Moraru, D
   Hoppner, J
   Nyan, O
AF Thome, Johannes
   Marenah, Essa
   Moraru, Diana
   Hoeppner, Jacqueline
   Nyan, Ousman
TI Availability of psychiatric medication in an urban area of The
   Gambia/West Africa
SO WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE ADHD; Africa; antidepressants; antipsychotics; developing countries;
   medication; mood stabilisers; pharmacology; psychiatry;
   psychopharmacology; tranquilisers
AB The use of a wide and differentiated arsenal of psychopharmacological substances is integral part of modern psychiatric treatment in addition to non-pharmacological interventions (e. g., psychotherapy). However, worldwide the access to such medication can vary considerably. In this study, access to a wide range of psychiatric medication including antidepressants, antipsychotics, tranquilisers, mood stabilisers and ADHD medication was analysed for the Western African country of The Gambia by surveying private pharmacies within the urban and sub-urban areas of Banjul, the country's capital. The results show that most of these pharmacies tend to keep a very limited range of psychiatric drugs in stock. In many instances only a tricyclic antidepressant (e. g., amitriptyline), the neuroleptic haloperidol and the benzodiazepine diazepam were readily available. None of the pharmacies kept ADHD medication in stock, and only very few had mood stabilisers. However, several pharmacies reported to be able to obtain at request most of the drugs from international sources, including atypical antipsychotics, SSRIs, and dual-acting antidepressants. Therefore, it can be concluded that in rapidly growing urban centres of developing countries exemplified by Banjul, the infrastructure for modern psychopharmacotherapy is well established, and that the lack of immediate access to modern psychopharmacological compounds represents not so much a genuine lack of availability, but rather a lack of demand which may be associated with the considerable cost-implications of such treatment and the absence of prescribers (i.e. psychiatrists and other doctors with an expertise in modern psychopharmcotherapy). To our knowledge this is the first such study for The Gambia and results might be representative for the wider Western African region. It also exemplifies the challenges psychiatry is facing in developing countries worldwide. It is essential that government-sponsored so-called "essential medication lists" are continuously updated in order to reflect the progress in medical research including psychopharmacology. Further research into how to facilitate psychopharmacotherapy is urgently needed in order to further improve psychiatric services.
C1 [Thome, Johannes; Hoeppner, Jacqueline] Univ Rostock, Clin & Policlin Psychiat & Psychotherapy, D-18147 Rostock, Germany.
   [Marenah, Essa; Nyan, Ousman] Univ Gambia, Royal Victoria Teaching Hosp, Sch Med, Banjul, Gambia.
   [Moraru, Diana] Swansea Univ, Coll Med, Swansea, W Glam, Wales.
RP Thome, J (reprint author), Univ Rostock, Clin & Policlin Psychiat & Psychotherapy, Gehlsheimerstr 20, D-18147 Rostock, Germany.
EM johannes.thome@med.uni-rostock.de
RI Hoppner, Jacqueline/B-6389-2015
FU AstraZeneca; Bristol-Myers Squibb; Janssen-Cilag; Lilly; Lundbeck;
   MEDICE; Merz; Novartis; Pfizer; Servier; Shire
FX The authors would like to thank the Final Year Medical Students, Class
   of 2010, at the University of The Gambia for their excellent and
   enthusiastic support with this research: Chimeka Anyta-Coker, Yorro Bah,
   Kajali Camara, David M. Ellis, M. Yarkpalo Harris, Lamin F. Jarju,
   Miriam Joof, Sabina Kangakan, Abdulhamid Kanteh, Aji-Binta Njie, Momodou
   A. I. Tekayi, Uchenna Usanakpo, Momodou Lamin Waggeh, Joy Williams.; JT
   has received financial support (including paritially for this paper)
   from the following pharmaceutical companies: AstraZeneca, Bristol-Myers
   Squibb, Janssen-Cilag, Lilly, Lundbeck, MEDICE, Merz, Novartis, Pfizer,
   Servier, Shire.
CR Adeponle A B, 2008, West Afr J Med, V27, P106
   Eaton J, 2008, Afr J Psychiatry (Johannesbg), V11, P179
   Liberman RP, 2001, PSYCHIATR SERV, V52, P1331, DOI 10.1176/appi.ps.52.10.1331
   Peen J, 2010, ACTA PSYCHIAT SCAND, V121, P84, DOI 10.1111/j.1600-0447.2009.01438.x
   Schuklenk U, 2002, J MED PHILOS, V27, P179, DOI 10.1076/jmep.27.2.179.2989
   Westermeyer J, 1988, Acta Psychiatr Scand Suppl, V344, P23
   Whyte L, 2001, J Psychosoc Nurs Ment Health Serv, V39, P26
NR 7
TC 2
Z9 2
U1 1
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1562-2975
J9 WORLD J BIOL PSYCHIA
JI World J. Biol. Psychiatry
PD SEP
PY 2011
VL 12
SU 1
BP 114
EP 117
DI 10.3109/15622975.2011.601925
PG 4
WC Psychiatry
SC Psychiatry
GA 819YO
UT WOS:000294871700024
PM 21906008
OA No
DA 2017-08-15
ER

PT J
AU Findlow, H
   Sow, S
   Borrow, R
   Tapia, M
   Haidara, FC
   Akinsola, AK
   Idoko, OT
   Diallo, F
   Adegbola, R
   Tang, YX
   Parulekar, V
   Chadha, H
   Mabey, L
   Holme, D
   Townsend, K
   Chaumont, J
   LaForce, FM
   Kulkarni, PS
   Marchetti, E
   Viviani, S
   Hassan-King, M
   Preziosi, MP
AF Findlow, Helen
   Sow, Samba
   Borrow, Ray
   Tapia, Milagritos
   Haidara, Fadima Cheick
   Akinsola, Adebayo K.
   Idoko, Olubukola T.
   Diallo, Fatoumata
   Adegbola, Richard
   Tang, Yuxiao
   Parulekar, Varsha
   Chadha, Helen
   Mabey, Lesley
   Holme, Daniel
   Townsend, Kelly
   Chaumont, Julie
   LaForce, F. Marc
   Kulkarni, Prasad S.
   Marchetti, Elisa
   Viviani, Simonetta
   Hassan-King, Musa
   Preziosi, Marie-Pierre
TI Meningococcal Group C and W135 Immunological Hyporesponsiveness in
   African Toddlers
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID TOXOID CONJUGATE VACCINE; SEROGROUP-C; POLYSACCHARIDE VACCINATION;
   IMMUNE MEMORY; GROUP-A; IMMUNOGENICITY; SAFETY; CHILDREN; RESPONSES;
   INFANTS
AB A phase II clinical study was conducted in African toddlers (aged 12 to 23 months), with subjects receiving either investigational meningococcal group A conjugate (PsA-TT), meningococcal ACWY polysaccharide (PsACWY), or Haemophilus influenzae type b (Hib-TT) vaccine. Ten months following vaccination, the 3 study groups were further randomized to receive a dose of PsA-TT, a 1/5 dose of PsACWY, or a dose of Hib-TT vaccine. Group A serum bactericidal antibody (SBA) results have been reported previously, with PsA-TT demonstrating superior immunogenicity versus PsACWY vaccine. Immunogenicity for serogroups W135 and C was assessed by SBA assay to investigate the impact of multiple doses in this age group. Blood samples were taken prior to vaccination, 28 days and 40 weeks post-primary vaccination, and 7 and 28 days post-booster vaccination with a 1/5 dose of PsACWY. Subjects who had previously received a full dose of PsACWY had W135 SBA geometric mean titers (GMTs) of 26.1 and 4.4 at 7 and 28 days post-booster vaccination with a 1/5 PsACWY dose, respectively, whereas the W135 SBA GMTs of naive subjects at these time points following vaccination with a 1/5 dose of PsACWY were 861.1 and 14.6, respectively. Similar differences were observed for serogroup C, with SBA GMTs of 99 and 5.9 at 7 and 28 days post-booster vaccination with a 1/5 dose of PsACWY, respectively, for naive subjects, compared to 4.1 and 3.2 for previously vaccinated subjects. Immunologic hyporesponsiveness for groups C and W135 was observed following a full dose of PsACWY vaccine at 12 to 23 months of age and a 1/5 dose of PsACWY 10 months later compared to the case for PsACWY-naive subjects receiving a 1/5 dose of PsACWY vaccine.
C1 [Findlow, Helen; Borrow, Ray; Chadha, Helen; Mabey, Lesley; Holme, Daniel; Townsend, Kelly] Manchester Royal Infirm, Vaccine Evaluat Unit, Hlth Protect Agcy NW, Manchester M13 9WZ, Lancs, England.
   [Sow, Samba; Tapia, Milagritos; Haidara, Fadima Cheick; Diallo, Fatoumata] Ctr Dev Vaccins CVD Mali, Bamako, Mali.
   [Borrow, Ray] Univ Manchester, Inflammat Sci Res Grp, Sch Translat Med, Manchester M13 9PL, Lancs, England.
   [Akinsola, Adebayo K.; Idoko, Olubukola T.; Adegbola, Richard] MRC Labs, Basse, Gambia.
   [Tang, Yuxiao; Chaumont, Julie; LaForce, F. Marc; Marchetti, Elisa; Viviani, Simonetta; Hassan-King, Musa] PATH, MVP, Ferney Voltaire, France.
   [Parulekar, Varsha] DiagnoSearch Life Sci Pvt Ltd, Bombay, Maharashtra, India.
   [Kulkarni, Prasad S.] Serum Inst India Ltd, Pune, Maharashtra, India.
   [Preziosi, Marie-Pierre] WHO, MVP, Initiat Vaccine Res, CH-1211 Geneva, Switzerland.
RP Findlow, H (reprint author), Manchester Royal Infirm, Vaccine Evaluat Unit, Hlth Protect Agcy NW, POB 209,Clin Sci Bldg, Manchester M13 9WZ, Lancs, England.
EM helen.findlow@hpa.org.uk
FU Malian and Gambian Ministries of Health; Meningitis Vaccine Project;
   Bill & Melinda Gates Foundation
FX We thank the study participants and their families and communities. We
   thank the core teams at CVD Mali and MRC Basse, the Fajara MRC
   leadership, Jenny Mueller, MVP, HPA, CDC, SIIL, and the Malian and
   Gambian Ministries of Health for their support; the WHO country offices
   in Mali and The Gambia for their constant advice and support throughout
   the study; the study monitors at Agence Africaine de Recherche en Sante
   Humaine, under the leadership of Veronique Mazarin-Diop; Manisha Ginde
   and Gandhali Paranjape at DiagnoSearch Life Science for
   pharmacovigilance; Poornima Desai, Prajakti Diwadkar, and their team for
   data management; Prathamesh Athavale and Reshma Sawant for support of
   the statistical analyses; Katharina Hartmann for guidance at all stages
   of this research; M. Teresa Aguado, Marie-Paule Kieny, and Myron M.
   Levine for their support; and the MVP Project Advisory Group (chaired by
   Francis Nkrumah) and the MVP Expert Panel (in particular Brian
   Greenwood) for invaluable guidance.; This study was funded by the
   Meningitis Vaccine Project, a partnership between PATH and the World
   Health Organization (http://www.meningvax.org/) supported by a grant
   from the Bill & Melinda Gates Foundation.
CR AlMazrou Y, 2005, INFECT IMMUN, V73, P2932, DOI 10.1128/IAI.73.5.2932-2939.2005
   Andrews N, 2003, CLIN DIAGN LAB IMMUN, V10, P780, DOI 10.1128/CDLI.10.5.780-786.2003
   Borrow R, 2009, TRAVEL MED INFECT DI, V7, P219, DOI 10.1016/j.tmaid.2009.05.003
   GOLD R, 1975, J CLIN INVEST, V56, P1536, DOI 10.1172/JCI108235
   Jokhdar H, 2004, CLIN DIAGN LAB IMMUN, V11, P83, DOI 10.1128/CDLI.11.1.83-88.2004
   Keyserling H, 2005, ARCH PEDIAT ADOL MED, V159, P907, DOI 10.1001/archpedi.159.10.907
   Kshirsagar N, 2007, VACCINE, V25, pA101, DOI 10.1016/j.vaccine.2007.04.050
   MacDonald NE, 1998, JAMA-J AM MED ASSOC, V280, P1685, DOI 10.1001/jama.280.19.1685
   Maslanka SE, 1997, CLIN DIAGN LAB IMMUN, V4, P156
   NAESS LM, 2009, 10 EUR MEN DIS SOC E, P46
   PELTOLA H, 1985, PEDIATRICS, V76, P91
   Pichichero M, 2006, PEDIATR INFECT DIS J, V25, P995, DOI 10.1097/01.inf.0000243215.46312.4a
   RICHMOND P, 1998, J INFECT DIS, V178, P870
   Southern J, 2004, CLIN DIAGN LAB IMMUN, V11, P1100, DOI 10.1128/CDLI.11.6.1100-1104.2004
   Sow SO, 2011, NEW ENGL J MED, V364, P2293, DOI 10.1056/NEJMoa1003812
   TIMENS W, 1989, J IMMUNOL, V143, P3200
NR 16
TC 11
Z9 11
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD SEP
PY 2011
VL 18
IS 9
BP 1492
EP 1496
DI 10.1128/CVI.05020-11
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 814LA
UT WOS:000294452800016
PM 21752951
OA No
DA 2017-08-15
ER

PT J
AU Sawyer, A
   Ayers, S
   Smith, H
   Sidibeh, L
   Nyan, O
   Dale, J
AF Sawyer, Alexandra
   Ayers, Susan
   Smith, Helen
   Sidibeh, Lamin
   Nyan, Ousman
   Dale, John
TI Women's experiences of pregnancy, childbirth, and the postnatal period
   in The Gambia: A qualitative study
SO BRITISH JOURNAL OF HEALTH PSYCHOLOGY
LA English
DT Article
ID SUB-SAHARAN AFRICA; WEST-AFRICA; POSTPARTUM DEPRESSION; INFERTILITY;
   MOTHERHOOD; PREVALENCE; GROWTH; HEALTH; IMPACT
AB Objective. In sub-Saharan African countries, there are unique cultural factors and adverse physical conditions that contribute to women's experiences of pregnancy and birth. The objective of this study was to qualitatively explore women's experiences of pregnancy, childbirth, the postnatal period, and maternal psychological distress in The Gambia.
   Design and methods. Semi-structured interviews were carried out with 55 women who had given birth within the previous year.
   Results. Thematic analysis identified five themes: ( I) transition to adulthood, (2) physical difficulties, (3) value of children in relation to others, (4) children as a strain, and (5) going through it alone. The results suggest that having a child is a defining point in women's lives associated with happiness and joy. However, women also described situations which could lead to unhappiness and distress in the perinatal period. A child conceived out of wedlock or a baby girl can be sources of distress because of negative cultural perceptions. The strain of having a child, particularly the additional financial burden, and minimal support from men were also a concern for women. Finally, women recognized the danger associated with delivery and expressed recurrent worries of complications during childbirth which could result in the death of them or the baby.
   Conclusions. Further research is needed to identify women vulnerable to psychological distress so that health services and target interventions can be developed accordingly.
C1 [Sawyer, Alexandra] Univ Sussex, Sch Psychol, Dept Psychol, Brighton BN1 9QH, E Sussex, England.
   [Smith, Helen; Dale, John] Brighton & Sussex Med Sch, Brighton, E Sussex, England.
   [Sidibeh, Lamin] Univ Gambia, Dept Social Sci, Kanifing, Gambia.
   [Nyan, Ousman] Univ Gambia, Sch Med, Kanifing, Gambia.
RP Sawyer, A (reprint author), Univ Sussex, Sch Psychol, Dept Psychol, Brighton BN1 9QH, E Sussex, England.
EM a.e.sawyer@sussex.ac.uk
RI Smith, Helen/M-2449-2016
OI Smith, Helen/0000-0003-1883-6124
CR Adewuya AO, 2008, J AFFECT DISORDERS, V108, P191, DOI 10.1016/j.jad.2007.09.013
   Adewuya AO, 2007, DEPRESS ANXIETY, V24, P15, DOI 10.1002/da.20221
   Adewuya Abiodun O, 2005, J Psychiatr Pract, V11, P353, DOI 10.1097/00131746-200509000-00009
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   ANYA SE, 2008, PREGNANCY CHILDBIRTH, V8, P9, DOI DOI 10.1186/1471-2393-8-9
   Beck CT, 2001, NURS RES, V50, P275, DOI 10.1097/00006199-200109000-00004
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP063OA
   Cham M, 2005, REPROD HLTH, V2, P3, DOI DOI 10.1186/1742-4755-2-3
   Coleman R, 2006, SOC PSYCH PSYCH EPID, V41, P720, DOI 10.1007/s00127-006-0085-8
   Donkor ES, 2007, SOC SCI MED, V65, P1683, DOI 10.1016/j.socscimed.2007.06.003
   Dyer SJ, 2002, HUM REPROD, V17, P1663, DOI 10.1093/humrep/17.6.1663
   FORTES M, 1978, J DEV STUD, V14, P121, DOI 10.1080/00220387808421692
   *GAMB BUR STAT, 2003, GAMB POP HOUS CENS 2
   Geller PA, 2004, CNS SPECTRUMS, V9, P188
   Halbreich U, 2006, J AFFECT DISORDERS, V91, P97, DOI 10.1016/j.jad.2005.12.051
   Halbreich U, 2007, J AFFECT DISORDERS, V102, P159, DOI 10.1016/j.jad.2006.09.033
   Hanlon C, 2010, ARCH WOMEN MENT HLTH, V13, P385, DOI 10.1007/s00737-010-0149-3
   Hanlon C, 2009, SOC SCI MED, V69, P1211, DOI 10.1016/j.socscimed.2009.07.043
   Hollos M, 2008, CULT HEALTH SEX, V10, P159, DOI 10.1080/13691050701656789
   Inhorn Marcia, 2002, INFERTILITY GLOBE NE
   Nakku Juliet E M, 2006, Afr Health Sci, V6, P207
   Oates MR, 2004, BR J PSYCHIAT S46, V46, P10, DOI DOI 10.1192/BJP.184.46.S10
   Obi SN, 2009, INT J GYNECOL OBSTET, V105, P60, DOI 10.1016/j.ijgo.2008.11.036
   Oladokun A, 2009, INT J OBSTET ANESTH, V18, P38, DOI 10.1016/j.ijoa.2008.07.011
   Pestvenidze E, 2007, Glob Public Health, V2, P169, DOI 10.1080/17441690601054330
   Prual A, 2000, B WORLD HEALTH ORGAN, V78, P593
   Rodrigues M, 2003, SOC SCI MED, V57, P1797, DOI 10.1016/S0277-9536(03)00062-5
   Sawyer A, 2010, J AFFECT DISORDERS, V123, P17, DOI 10.1016/j.jad.2009.06.027
   Stewart RC, 2008, MATERN CHILD NUTR, V4, P209, DOI 10.1111/j.1740-8709.2008.00147.x
   Sundby J, 1997, PATIENT EDUC COUNS, V31, P29, DOI 10.1016/S0738-3991(97)01006-9
   Tomlinson M, 2007, J AFFECT DISORDERS, V102, P191, DOI 10.1016/j.jad.2006.09.029
   World Health Organization, 1992, INT CLASS DIS 10 REV
   World Health Organization, 2004, MAT MORT 2000 EST DE
NR 33
TC 8
Z9 8
U1 0
U2 14
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1359-107X
J9 BRIT J HEALTH PSYCH
JI Br. J. Health Psychol.
PD SEP
PY 2011
VL 16
BP 528
EP 541
DI 10.1348/135910710X528710
PN 3
PG 14
WC Psychology, Clinical
SC Psychology
GA 797DT
UT WOS:000293105400005
PM 21722274
OA No
DA 2017-08-15
ER

PT J
AU Bale, C
   Garly, ML
   Martins, C
   Nielsen, J
   Whittle, H
   Aaby, P
AF Bale, Carlito
   Garly, May-Lill
   Martins, Cesario
   Nielsen, Jens
   Whittle, Hilton
   Aaby, Peter
TI Risk Factors for Measles in Young Infants in an Urban African Area With
   High Measles Vaccination Coverage
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE Africa; age at infection; age at vaccination; high coverage; maternal
   measles antibodies; measles infection; measles vaccination
ID GUINEA-BISSAU; MORTALITY; ANTIBODIES; INFECTION; PREVALENCE; TUBERCULIN;
   INTENSITY; RESPONSES; EXPOSURE; CHILDREN
AB Background: We examined risk factors for measles infection before measles vaccination at 9 months of age in Guinea-Bissau.
   Methods: Among 1524 children enrolled in a trial of early measles vaccination at 4.5 months of age, we assessed the relative risk (RR) of measles before enrollment and the incidence rate ratio between 4.5 and 9 months of age for different groups.
   Results: The incidence was high, with 4% having measles before 4.5 months and 10% having measles between 4.5 and 9 months of age. The main risk factor was the age of the mother; children of young mothers (age, 15-24 years) had lower antibody titers and higher risk of measles than children of older mothers both before 4.5 months (RR = 1.74 [1.02-2.96]) and between 4.5 and 9 months of age (incidence rate ratio = 1.59 [1.05-2.41]). Having no Bacillus Calmette-Guerin scar was associated with a higher risk of measles before 4.5 months of age (RR = 2.61 [1.54-4.45]). Children who were not breast-fed and had fever or respiratory infection at enrollment had a 2- to 4-fold higher risk of measles between 4.5 and 9 months of age.
   Interpretation: Young mothers transmit lower titers of antibodies to their children and an increasing proportion of infants become susceptible to measles before the age of measles vaccination.
C1 [Bale, Carlito; Martins, Cesario; Aaby, Peter] INDEPTH Network, Projecto Saude Bandim, Bissau, Guinea Bissau.
   [Garly, May-Lill; Nielsen, Jens] Statens Serum Inst, Danish Epidemiol Sci Ctr, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Bale, C (reprint author), INDEPTH Network, Projecto Saude Bandim, Apartado 861, Bissau, Guinea Bissau.
EM c.bale@bandim.org
FU DANIDA; Danish National Research Foundation; Fonden til
   Laegevidenskabens Fremme; Novo Nordisk Foundation
FX Supported by DANIDA and the Danish National Research Foundation. The
   project also received support from Fonden til Laegevidenskabens Fremme
   and Novo Nordisk Foundation. The BHP received support from DANIDA.
   Supported by Novo Nordisk Foundation a research professorship grant (to
   P.A.).
CR AABY P, 1986, J PEDIATR-US, V109, P40, DOI 10.1016/S0022-3476(86)80569-8
   AABY P, 1983, LANCET, V2, P690
   AABY P, 1990, J INFECT DIS, V162, P1043
   AABY P, 1984, AM J EPIDEMIOL, V120, P49
   Aaby P, 2010, BRIT MED J, V341, pc6495
   Aaby P, 2010, PEDIATR INFECT DIS J, V29, P324, DOI 10.1097/INF.0b013e3181c15367
   Barreto ML, 2000, J INFECT DIS, V182, P1800, DOI 10.1086/317627
   Cisse B, 2001, THESIS LONDON SCH HY
   da Silva ZJ, 2008, AIDS, V22, P1195, DOI 10.1097/QAD.0b013e328300a33d
   deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224
   Duke T, 2003, LANCET, V361, P763, DOI 10.1016/S0140-6736(03)12661-X
   EMBREE JE, 1992, J INFECT DIS, V165, P262
   Gagneur A, 2008, CLIN VACCINE IMMUNOL, V15, P1845, DOI 10.1128/CVI.00229-08
   Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347
   Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
   Garly ML, 2001, VACCINE, V20, P468, DOI 10.1016/S0264-410X(01)00339-5
   JENSEN TG, 1994, VACCINE, V12, P1026, DOI 10.1016/0264-410X(94)90340-9
   Leuridan E, 2010, BMJ-BRIT MED J, V340, pc1626
   MALDONADO YA, 1995, PEDIATRICS, V96, P447
   Martins C, 2009, VACCINE, V27, P5220, DOI 10.1016/j.vaccine.2009.06.076
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   MARTINS CL, 2002, NIVEIS ANTICORPOS SA
   MORLEY D, 1969, BRIT MED J, V1, P297
   Moss WJ, 2002, CLIN INFECT DIS, V35, P189, DOI 10.1086/341248
   NARAIN JP, 1989, INT J EPIDEMIOL, V18, P952, DOI 10.1093/ije/18.4.952
   Otten M, 2005, LANCET, V366, P832, DOI 10.1016/S0140-6736(05)67216-9
   Scott S, 2005, J INFECT DIS, V191, P1854, DOI 10.1086/429963
   Slifka MK, 2003, J CLIN INVEST, V111, P805, DOI 10.1172/JCI200313603
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
   WHITTLE HC, 2004, PRINCIPLES MED AFRIC, P640
   [Anonymous], 2006, WKLY EPIDEMIOL REC, V81, P190
   2002, WKLY EPIDEMIOL REC, V77, P50
   2007, WEEKLY EPIDEMIOL REC, V82, P1
   2002, WKLY EPIDEMIOL REC, V77, P58
NR 34
TC 4
Z9 4
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD AUG 11
PY 2011
VL 30
IS 8
BP 689
EP 693
DI 10.1097/INF.0b013e31821786a4
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 796PN
UT WOS:000293064200015
PM 21753261
OA No
DA 2017-08-15
ER

PT J
AU Harding-Esch, EM
   Holland, MJ
   Schemann, JF
   Molina, S
   Sarr, I
   Andreasen, AA
   Roberts, CH
   Sillah, A
   Sarr, B
   Harding, EF
   Edwards, T
   Bailey, RL
   Mabey, DCW
AF Harding-Esch, Emma M.
   Holland, Martin J.
   Schemann, Jean-Francois
   Molina, Sandra
   Sarr, Isatou
   Andreasen, Aura A.
   Roberts, Chrissy H.
   Sillah, Ansumana
   Sarr, Boubacar
   Harding, Edward F.
   Edwards, Tansy
   Bailey, Robin L.
   Mabey, David C. W.
TI Diagnostic Accuracy of a Prototype Point-of-Care Test for Ocular
   Chlamydia trachomatis under Field Conditions in The Gambia and Senegal
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; ACTIVE TRACHOMA; REACTION ASSAY;
   AMPLIFICATION METHODS; INFECTIOUS TRACHOMA; SPECIMENS; PCR;
   CONJUNCTIVAL; PREVALENCE; COMMUNITY
AB Background: The clinical signs of active trachoma are often present in the absence of ocular Chlamydia trachomatis infection in low prevalence and mass treated settings. Treatment decisions are currently based on the prevalence of clinical signs, and this may result in the unnecessary distribution of mass antibiotic treatment. We aimed to evaluate the diagnostic accuracy of a prototype point-of-care (POC) test, developed for field diagnosis of ocular C. trachomatis, in low prevalence settings of The Gambia and Senegal.
   Methodology/Principal Findings: Three studies were conducted, two in The Gambia and one in Senegal. Children under the age of 10 years were screened for the clinical signs of trachoma. Two ocular swabs were taken from the right eye. The first swab was tested by the POC test in the field and the result independently graded by two readers. The second swab was tested for the presence of C. trachomatis by Amplicor Polymerase Chain Reaction. In Senegal, measurements of humidity and temperature in the field were taken. A total of 3734 children were screened, 950 in the first and 1171 in the second Gambian study, and 1613 in Senegal. The sensitivity of the prototype POC test ranged between 33.3-67.9%, the specificity between 92.4-99.0%, the positive predictive value between 4.3-21.0%, and the negative predictive value between 98.0-99.8%. The rate of false-positives increased markedly at temperatures above 31.4 degrees C and relative humidities below 11.4%.
   Conclusions/Significance: In its present format, this prototype POC test is not suitable for field diagnosis of ocular C. trachomatis as its specificity decreases in hot and dry conditions: the environment in which trachoma is predominantly found. In the absence of a suitable test for infection, trachoma diagnosis remains dependent on clinical signs. Under current WHO recommendations, this is likely resulting in the continued mass treatment of non-infected communities.
C1 [Harding-Esch, Emma M.; Holland, Martin J.; Molina, Sandra; Andreasen, Aura A.; Roberts, Chrissy H.; Edwards, Tansy; Bailey, Robin L.; Mabey, David C. W.] London Sch Hyg & Trop Med, London WC1, England.
   [Holland, Martin J.; Sarr, Isatou] MRC Labs, Banjul, Gambia.
   [Schemann, Jean-Francois] IRD, Dakar, Senegal.
   [Sillah, Ansumana] Minist Hlth, Natl Eye Care Programme, Banjul, Gambia.
   [Sarr, Boubacar] Minist Sante, Programme Natl Lutte Cecite, Dakar, Senegal.
RP Harding-Esch, EM (reprint author), London Sch Hyg & Trop Med, London WC1, England.
EM david.mabey@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Roberts, Chrissy
   h./0000-0003-1064-5980
FU Wellcome Trust [078460/Z/05/Z]
FX The authors are grateful to the Wellcome Trust for funding this study
   (grant number 078460/Z/05/Z). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Andreasen AA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000306
   Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   Bossuyt PM, 2003, CLIN CHEM, V49, P7, DOI 10.1373/49.1.7
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Castriciano S, 2002, J CLIN MICROBIOL, V40, P2632, DOI 10.1128/JCM.40.7.2632-2634.2002
   Chanteau S, 2003, LANCET, V361, P211, DOI 10.1016/S0140-6736(03)12270-2
   Chidambaram JD, 2006, JAMA-J AM MED ASSOC, V295, P1142, DOI 10.1001/jama.295.10.1142
   Culler EE, 2003, J CLIN MICROBIOL, V41, P3911, DOI 10.1128/JCM.41.8.3911-3914.2003
   de Barbeyrac B, 2007, CLIN MICROBIOL INFEC, V13, P689, DOI 10.1111/j.1469-0691.2007.01741.x
   Garcia-Lerma JG, 2009, J ANTIMICROB CHEMOTH, V64, P33, DOI 10.1093/jac/dkp150
   Goldschmidt P, 2006, BRIT J OPHTHALMOL, V90, P1425, DOI 10.1136/bjo.2006.096420
   Hammerschlag MR, 1997, PEDIATR INFECT DIS J, V16, P293, DOI 10.1097/00006454-199703000-00008
   Harding-Esch EM, 2008, T ROY SOC TROP MED H, V102, P1255, DOI 10.1016/j.trstmh.2008.04.022
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142
   KESSLER HH, 1994, SEX TRANSM DIS, V21, P191, DOI 10.1097/00007435-199407000-00002
   KOWALSKI RP, 1995, OPHTHALMOLOGY, V102, P1016
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Mahilum-Tapay L, 2007, BRIT MED J, V335, P1190, DOI 10.1136/bmj.39402.463854.AE
   Michel CEC, 2006, LANCET, V367, P1585, DOI 10.1016/S0140-6736(06)68695-9
   Miller K, 2004, OPHTHAL EPIDEMIOL, V11, P255, DOI 10.1080/09286580490514577
   MIYASHITA N, 1994, MICROBIOL IMMUNOL, V38, P81
   Mulcahy GM, 1998, CLIN CHEM, V44, P1575
   Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07
   Nato F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000361
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Saison F, 2007, J CLIN MICROBIOL, V45, P4011, DOI 10.1128/JCM.01343-07
   Schachter J, 2006, J CLIN MICROBIOL, V44, P2512, DOI 10.1128/JCM.02620-05
   Schemann JF, 2007, T ROY SOC TROP MED H, V101, P996, DOI 10.1016/j.trstmh.2007.05.015
   Shattock RM, 1998, SEX TRANSM INFECT, V74, P289
   Solomon AW, 2008, NEW ENGL J MED, V358, P1870, DOI 10.1056/NEJMc0706263
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   Verkooyen RP, 2003, J CLIN MICROBIOL, V41, P3013, DOI 10.1128/JCM.41.7.3013-3016.2003
   Gower EW, 2006, INVEST OPHTH VIS SCI, V47, P4767, DOI 10.1167/iovs.05-1599
   West SK, 2005, LANCET, V366, P1296, DOI 10.1016/S0140-6736(05)67529-0
   World Health Organization, 2004, 8 M WHO ALL GLOB EL
NR 37
TC 9
Z9 9
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2011
VL 5
IS 8
AR e1234
DI 10.1371/journal.pntd.0001234
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 814TJ
UT WOS:000294479800006
PM 21829735
OA gold
DA 2017-08-15
ER

PT J
AU Secka, A
   Grimm, F
   Marcotty, T
   Geysen, D
   Niang, AM
   Ngale, V
   Boutche, L
   Van Marck, E
   Geerts, S
AF Secka, Arss
   Grimm, Felix
   Marcotty, Tanguy
   Geysen, Dirk
   Niang, Alassane M.
   Ngale, Victoire
   Boutche, Laurent
   Van Marck, Eric
   Geerts, Stanny
TI Old focus of cysticercosis in a senegalese village revisited after half
   a century
SO ACTA TROPICA
LA English
DT Article
DE Neurocysticercosis; Taenia solium; Ag-ELISA; EITB; CT-scan; Senegal
ID TAENIA-SOLIUM TAENIASIS; SEROPREVALENCE; ASSAY; ANTIGENS; SAGINATA;
   MEXICO; ELISA
AB The objective of this epidemiological study was to determine whether cysticercosis and especially neurocysticercosis is endemic in Soutou village about half a century after the 1962 outbreak. This study was carried out from September 2009 to February 2010. It involved a questionnaire administration, serology, treatment, coproscopy and neuro-imaging. Four hundred and three serum samples were collected from the village people, which covered 94% of the village population. By using a parallel combination of the antigen-detection ELISA and the enzyme-linked immunoelectrotransfer blot (EITB) a cysticercosis seroprevalence of 11.9% (95% Cl: 8.9-15.4%) was found. Cerebral CT-scans showed that 23.3% (10/43) of the seropositives were affected by neurocysticercosis. Four out of these 43 (9.3%) were tapeworm carriers. Seropositivity was significantly associated to older age groups (41-60 years old; p = 0.001 and 61-91 years old: p = 0.028) and absence of a household toilet (p = 0.001). It can be concluded that Soutou village is an active focus of Taenia solium cysticercosis about 50 years after the first reported epidemic outbreak. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Marcotty, Tanguy; Geysen, Dirk; Geerts, Stanny] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium.
   [Secka, Arss] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Grimm, Felix] Univ Zurich, Inst Parasitol, CH-8057 Zurich, Switzerland.
   [Marcotty, Tanguy] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0002 Pretoria, South Africa.
   [Van Marck, Eric] Univ Antwerp, Pathol Lab, B-2020 Antwerp, Belgium.
   [Niang, Alassane M.] Bignona Hosp, Bignona, Senegal.
   [Ngale, Victoire; Boutche, Laurent] Ziguinchor Reg Hosp, Ziguinchor, Senegal.
RP Geerts, S (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.
EM geerts.demedts@gmail.com
FU Flemish Interuniversity Council (VLIR, Brussels); Epidemiology and
   Control of Zoonotic Infections in The Gambia and Senegal implemented in
   collaboration with the International Trypanotolerance Centre (ITC) in
   The Gambia
FX This study was financed by the Flemish Interuniversity Council (VLIR,
   Brussels) within the framework of a project entitled Epidemiology and
   Control of Zoonotic Infections in The Gambia and Senegal implemented in
   collaboration with the International Trypanotolerance Centre (ITC) in
   The Gambia. Contributions from the technical and administrative staff of
   ITC, the medical personnel of Soutou Health Centre, the administrative
   staff of Bignona hospital, radiologists and laboratory staff of
   Ziguinchor hospital are greatly appreciated. We would also like to thank
   all the inhabitants of Soutou village, especially the village chief and
   the village committee.
CR BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E
   COLLOMB H, 1964, B MEMOIRE FACULTE MI, V12, P148
   Dorny P, 2004, TRENDS PARASITOL, V20, P259, DOI 10.1016/j.pt.2004.04.001
   DUMAS M, 1989, Acta Leidensia, V57, P191
   Dumas M, 1976, Bull Soc Med Afr Noire Lang Fr, V21, P203
   Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7
   Garcia HH, 2001, AM J TROP MED HYG, V65, P31
   GarciaNoval J, 1996, AM J TROP MED HYG, V55, P282
   Geerts S., 2004, SE ASIAN J TROP MED, V35, P262
   Houinato D, 1998, T ROY SOC TROP MED H, V92, P621, DOI 10.1016/S0035-9203(98)90785-4
   ILAE, 1989, EPILEPSIA, V30, P389
   Nguekam JP, 2003, TROP MED INT HEALTH, V8, P144, DOI 10.1046/j.1365-3156.2003.01000.x
   Prado-Jean A, 2007, TROP MED INT HEALTH, V12, P895, DOI 10.1111/j.1365-3156.2007.01860.x
   RITCHIE LAWRENCE S., 1948, BULL U S ARMY MED DEPT, V8, P326
   Rodriguez-Hidalgo R, 2002, J PARASITOL, V88, P1007, DOI 10.1645/0022-3395(2002)088[1007:COCTTD]2.0.CO;2
   SARTI E, 1992, AM J TROP MED HYG, V46, P677
   SARTI E, 1994, T ROY SOC TROP MED H, V88, P49, DOI 10.1016/0035-9203(94)90493-6
   Secka A., 2010, Journal of Parasitology Research, V2010, P823892, DOI 10.1155/2010/823892
   Sokol R.R., 1981, BIOMETRY
   TSANG VCW, 1989, J INFECT DIS, V159, P50
   Vanderick F X, 1972, Ann Soc Belg Med Trop, V52, P153
NR 21
TC 10
Z9 10
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
J9 ACTA TROP
JI Acta Trop.
PD AUG
PY 2011
VL 119
IS 2-3
BP 199
EP 202
DI 10.1016/j.actatropica.2011.05.003
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 805HJ
UT WOS:000293717200022
PM 21605539
OA No
DA 2017-08-15
ER

PT J
AU Iddriss, A
   Shivute, N
   Bickler, S
   Cole-Ceesay, R
   Jargo, B
   Abdullah, F
   Cherian, M
AF Iddriss, Adam
   Shivute, Nestor
   Bickler, Stephen
   Cole-Ceesay, Ramou
   Jargo, Bakary
   Abdullah, Fizan
   Cherian, Meena
TI Emergency, anaesthetic and essential surgical capacity in the Gambia
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID DEVELOPING-COUNTRIES; INTENSIVE-CARE; HEALTH-CARE; SURGERY; EXPERIENCE;
   MORTALITY; WORKFORCE
AB Objective To assess the resources for essential and emergency surgical care in the Gambia.
   Methods The World Health Organization's Tool for Situation Analysis to Assess Emergency and Essential Surgical Care was distributed to health-care managers in facilities throughout the country. The survey was completed by 65 health facilities one tertiary referral hospital, 7 district/general hospitals, 46 health centres and 11 private health facilities and included 110 questions divided into four sections: (i) infrastructure, type of facility, population served and material resources; (ii) human resources; (iii) management of emergency and other surgical interventions; (iv) emergency equipment and supplies for resuscitation. Questionnaire data were complemented by interviews with health facility staff, Ministry of Health officials and representatives of nongovernmental organizations.
   Findings Important deficits were identified in infrastructure, human resources, availability of essential supplies and ability to perform trauma, obstetric and general surgical procedures. Of the 18 facilities expected to perform surgical procedures, 50.0% had interruptions in water supply and 55.6% in electricity. Only 38.9% of facilities had a surgeon and only 16.7% had a physician anaesthetist. All facilities had limited ability to perform basic trauma and general surgical procedures. Of public facilities, 54.5% could not perform laparotomy and 58.3% could not repair a hernia. Only 25.0% of them could manage an open fracture and 41.7% could perform an emergency procedure for an obstructed airway.
   Conclusion The present survey of health-care facilities in the Gambia suggests that major gaps exist in the physical and human resources needed to carry out basic life-saving surgical interventions.
C1 [Iddriss, Adam; Abdullah, Fizan] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA.
   [Shivute, Nestor] World Hlth Org, Country Off, Kanifang, Gambia.
   [Bickler, Stephen] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.
   [Cole-Ceesay, Ramou] Minist Hlth, Banjul, Gambia.
   [Jargo, Bakary] Royal Victoria Teaching Hosp, Banjul, Gambia.
   [Cherian, Meena] World Hlth Org, Dept Essential Hlth Technol, Geneva, Switzerland.
RP Iddriss, A (reprint author), Johns Hopkins Univ, Sch Med, Dept Surg, Harvey 319,600 Wolfe St, Baltimore, MD 21205 USA.
EM iddriss@jhmi.edu
FU Johns Hopkins Center for Global Health from the Fogarty International
   Center at the National Institutes of Health [5R25TW007506]
FX This work was supported by the Johns Hopkins Center for Global Health
   (grant number 5R25TW007506) from the Fogarty International Center at the
   National Institutes of Health.
CR AGGARWAL SK, 1993, INVEST RADIOL, V28, pS32, DOI 10.1097/00004424-199308003-00017
   Bastos PG, 1996, INTENS CARE MED, V22, P664, DOI 10.1007/BF01709743
   Bickler SW, 2010, WORLD J SURG, V34, P386, DOI 10.1007/s00268-009-0273-2
   Blanchard RJW, 2001, J AM COLL SURGEONS, V193, P417, DOI 10.1016/S1072-7515(01)01037-7
   Cherian M, 2010, B WORLD HEALTH ORGAN, V88, P637, DOI 10.2471/BLT.09.072371
   Chianakwana GU, 2005, WORLD J SURG, V29, P804, DOI 10.1007/s00268-005-7670-y
   Choo S, 2010, TROP MED INT HEALTH, V15, P1109, DOI 10.1111/j.1365-3156.2010.02589.x
   Cole-Ceesay R, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-21
   Contini S, 2010, WORLD J SURG, V34, P473, DOI 10.1007/s00268-010-0406-7
   De Brouwere V, 1998, TROP MED INT HEALTH, V3, P771, DOI 10.1046/j.1365-3156.1998.00310.x
   Debas HT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1245
   Dovlo D, 2004, HUM RESOUR HEALTH, V2, P7, DOI DOI 10.1186/1478-4491-2-7
   Dubowitz G, 2010, WORLD J SURG, V34, P438, DOI 10.1007/s00268-009-0229-6
   Dunser MW, 2006, CRIT CARE MED, V34, P1234, DOI 10.1097/01.CCM.0000208360.70835.87
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Hodges SC, 2007, ANAESTHESIA, V62, P26, DOI 10.1111/j.1365-2044.2007.05294.x
   Kingham TP, 2009, ARCH SURG-CHICAGO, V144, P122, DOI 10.1001/archsurg.2008.540
   Kamara TB, 2009, ARCH SURG-CHICAGO, V144, P128, DOI [10.1001/archsurg.2008.540, DOI 10.1001/ARCHSURG.2008.540]
   Meo G, 2006, WORLD J SURG, V30, P495, DOI 10.1007/s00268-005-0093-y
   Mullan F, 2005, NEW ENGL J MED, V353, P1810, DOI 10.1056/NEJMsa050004
   Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139
   Osen H, 2011, WORLD J SURG, V35, P500, DOI 10.1007/s00268-010-0918-1
   Ozgediz D, 2008, WORLD J SURG, V32, P1208, DOI 10.1007/s00268-008-9473-4
   Ozgediz Doruk, 2009, Bull Am Coll Surg, V94, P14
   Pemberton J, 2010, MUMJ, V7, P5
   Pereira C, 2007, BJOG-INT J OBSTET GY, V114, P1530, DOI 10.1111/j.1471-0528.2007.01489.x
   Stilwell B, 2004, B WORLD HEALTH ORGAN, V82, P595
   United Nations Development Programme, 2010, HUM DEV REP 2010 20
   Vaz F, 1999, B WORLD HEALTH ORGAN, V77, P688
   WHITE SM, 1987, LANCET, V2, P612
   *WHO, 2011, WHO TOOL SIT AN ASS
   World Health Organization, 2011, COUNTR COOP STRAT WH
   *WHO, 2010, GLOB HLTH OBS 2010
   Williams BG, 2006, PLOS MED, V3, P1032, DOI 10.1371/journal.pmed.0030262
NR 34
TC 47
Z9 47
U1 1
U2 11
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD AUG
PY 2011
VL 89
IS 8
BP 565
EP 572
DI 10.2471/BLT.11.086892
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 804TC
UT WOS:000293675900008
PM 21836755
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Roth, A
   Ravn, H
   Napirna, BM
   Rodrigues, A
   Lisse, IM
   Stensballe, L
   Diness, BR
   Lausch, KR
   Lund, N
   Biering-Sorensen, S
   Whittle, H
   Benn, CS
AF Aaby, Peter
   Roth, Adam
   Ravn, Henrik
   Napirna, Bitiguida Mutna
   Rodrigues, Amabelia
   Lisse, Ida Maria
   Stensballe, Lone
   Diness, Birgitte Rode
   Lausch, Karen Rokkedal
   Lund, Najaaraq
   Biering-Sorensen, Sofie
   Whittle, Hilton
   Benn, Christine Stabell
TI Randomized Trial of BCG Vaccination at Birth to Low-Birth-Weight
   Children: Beneficial Nonspecific Effects in the Neonatal Period?
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID DIPHTHERIA-TETANUS-PERTUSSIS; BACILLUS-CALMETTE-GUERIN; FEMALE-MALE
   MORTALITY; VITAMIN-A SUPPLEMENTATION; GUINEA-BISSAU; ROUTINE
   VACCINATIONS; CHILDHOOD MORTALITY; TUBERCULIN REACTION; DENDRITIC CELLS;
   MEASLES-VACCINE
AB Background. Observational studies have suggested that BCG may have nonspecific beneficial effects on survival. Low-birth-weight (LBW) children are not given BCG at birth in Guinea-Bissau; we conducted a randomized trial of BCG at birth (early BCG) vs delayed BCG.
   Methods. In the period 2004-2008 we recruited 2320 LBW children in Bissau. The children were visited at home at 2, 6, and 12 months of age. With a pretrial infant mortality of 250 per 1000, we hypothesized a 25% reduction in infant mortality for LBW children.
   Results. Infant mortality was only 101 per 1000 during the trial. In the primary analysis, infant mortality was reduced insignificantly by 17% (mortality rate ratio [MRR] = .83 [.63-1.08]). In secondary analyses, early BCG vaccine was safe with an MRR of .49 (.21-1.15) after 3 days and .55 (.34-.89) after 4 weeks. The reduction in neonatal mortality was mainly due to fewer cases of neonatal sepsis, respiratory infection, and fever. The impact of early BCG on infant mortality was marked for children weighing <1.5 kg (MRR = .43 [.21-.85]) who had lower coverage for diphtheria-tetanus-pertussis vaccinations.
   Conclusions. Though early BCG did not reduce infant mortality significantly, it may have a beneficial effect in the neonatal period. This could be important for public health because BCG is often delayed in low-income countries.
C1 [Aaby, Peter; Roth, Adam; Ravn, Henrik; Stensballe, Lone; Benn, Christine Stabell] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen S, Denmark.
   [Aaby, Peter; Rodrigues, Amabelia; Diness, Birgitte Rode; Lausch, Karen Rokkedal; Lund, Najaaraq; Biering-Sorensen, Sofie; Benn, Christine Stabell] Hosp Nacl Simao Mendes, Bandim Hlth Project, Indepth Network, Bissau, Guinea Bissau.
   [Lisse, Ida Maria] Herlev Univ Hosp, Dept Pathol, Herlev, Denmark.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
   [Roth, Adam] Lund Univ, Dept Med Microbiol, Malmo, Sweden.
RP Aaby, P (reprint author), Statens Serum Inst, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM P.aaby@bandim.org
RI Rivet, Catherine/M-7978-2014
FU European Union [ICA4-CT-2002-10053]; March of Dimes; Danish National
   Research Foundation; DANIDA; Novo Nordisk Foundation
FX The study was funded by the European Union (ICA4-CT-2002-10053), the
   March of Dimes, and the Danish National Research Foundation. The Bandim
   Health Project received support from DANIDA. P. A. holds a research
   professorship grant from the Novo Nordisk Foundation.
CR Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   Aaby P, 2004, INT J EPIDEMIOL, V33, P367, DOI 10.1093/ije/dyh004
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   Aaby P, 2009, INT J EPIDEMIOL, V38, P320, DOI 10.1093/ije/dyn005
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   Aaby P, 2006, PEDIATR INFECT DIS J, V25, P721, DOI 10.1097/01.inf.0000227829.64686.ae
   Aaby P, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6495
   ARONSON JD, 1948, AM REV TUBERC PULM, V58, P255
   Benn CS, 2009, AM J CLIN NUTR, V90, P629, DOI 10.3945/ajcn.2009.27477
   Benn CS, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1101
   Breiman RF, 2004, LANCET, V364, P2204, DOI 10.1016/S0140-6736(04)17593-4
   CLARK IA, 1976, NATURE, V259, P309, DOI 10.1038/259309a0
   Elguero E, 2005, TROP MED INT HEALTH, V10, P956, DOI 10.1111/j.1365-3156.2005.01479.x
   FERGUSON R. G., 1949, TUBERCLE, V30, P5, DOI 10.1016/S0041-3879(49)80055-9
   Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
   GOMES V, 2009, THESIS U COPENHAGEN
   Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026
   HOSKINS EW, 1993, THESIS U OXFORD
   Jason J, 2002, INFECT IMMUN, V70, P6188, DOI 10.1128/IAI.70.11.6188-6195.2002
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Lalor MK, 2009, J INFECT DIS, V199, P795, DOI 10.1086/597069
   Larsen JM, 2007, IMMUNOLOGY, V121, P276, DOI 10.1111/j.1365-2567.2007.02575.x
   LEVINE MI, 1946, AM REV TUBERC PULM, V53, P517
   Mak TK, 2008, LANCET, V372, P786, DOI 10.1016/S0140-6736(08)61318-5
   Mathurin KS, 2009, J VIROL, V83, P3528, DOI 10.1128/JVI.02393-08
   *MRC, 1959, BRIT MED J, V2, P369
   Ota MOC, 2002, J IMMUNOL, V168, P919
   ROSENTHAL S, 1961, AM REV RESPIR DIS, V84, P690
   Roth A, 2005, INT J EPIDEMIOL, V34, P540, DOI 10.1093/ije/dyh393
   Roth A, 2004, PEDIATR INFECT DIS J, V23, P544, DOI 10.1097/01.inf.0000129693.81082.a0
   Roth AE, 2006, TUBERCULOSIS, V86, P397, DOI 10.1016/j.tube.2006.02.001
   Roth A, 2006, EXPERT REV VACCINES, V5, P277, DOI 10.1586/14760584-5.2.277
   Roth A, 2006, EPIDEMIOLOGY, V17, P562, DOI 10.1097/01.ede.0000231546.14749.ab
   Roth AE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c671
   Shann F, 2010, PEDIATR INFECT DIS J, V29, P457, DOI 10.1097/INF.0b013e3181c91361
   Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
   VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474
   WHO, 2007, WKLY EPIDEMIOL REC, V82, P193
   WHO, 2007, WKLY EPIDEMIOL REC, V82, P181
   Wynn JL, 2009, J PERINATOL, V29, P79, DOI 10.1038/jp.2008.132
   Wynn JL, 2008, BLOOD, V112, P1750, DOI 10.1182/blood-2008-01-130500
NR 44
TC 144
Z9 145
U1 3
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 15
PY 2011
VL 204
IS 2
BP 245
EP 252
DI 10.1093/infdis/jir240
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 790AZ
UT WOS:000292562200013
PM 21673035
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Hu, VH
   Massae, P
   Burr, SE
   Chevallier, C
   Afwamba, IA
   Courtright, P
   Weiss, HA
   Mabey, DCW
   Bailey, RL
AF Burton, Matthew J.
   Hu, Victor H.
   Massae, Patrick
   Burr, Sarah E.
   Chevallier, Caroline
   Afwamba, Isaac A.
   Courtright, Paul
   Weiss, Helen A.
   Mabey, David C. W.
   Bailey, Robin L.
TI What Is Causing Active Trachoma? The Role of Nonchlamydial Bacterial
   Pathogens in a Low Prevalence Setting
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SEVERE ENDEMIC TRACHOMA; CHLAMYDIA-TRACHOMATIS; INFECTION; AZITHROMYCIN;
   TRICHIASIS; GAMBIA; CONJUNCTIVITIS; POPULATION; COMMUNITY; SURGERY
AB PURPOSE. In low prevalence settings, clinically active follicular trachoma (TF) is often found in the absence of detectable Chlamydia trachomatis. The reasons for this persistent follicular phenotype are not well understood; one possible explanation is that other bacterial species are provoking the inflammatory response. This study investigated the relationship between TF, C. trachomatis, and nonchlamydial bacterial infection.
   METHODS. A cross-sectional survey was conducted in a trachoma endemic village in Tanzania. All available children were examined for trachoma and swabs were collected for microbiologic culture (blood and chocolate agar) and C. trachomatis PCR (Amplicor).
   RESULTS. Four hundred seventy-three children under 10 years of age were recruited for this study. The prevalences of TF and C. trachomatis were 13.7% and 5.3%, respectively, and were not associated. Bacteria were cultured from 305 (64.5%) swab samples; 162 (34.3%) grew a pathogen (with or without a commensal organism) and 143 (30.2%) grew commensal bacteria only. The most common pathogens were Streptococcus pneumoniae and Haemophilus influenzae (type B and non-type B). The presence of bacterial pathogens was associated with TF (odds ratio, 4.68; 95% confidence interval, 2.31-9.50; P < 0.001).
   CONCLUSIONS. In regions with low levels of endemic trachoma, it is possible that much of the TF that is observed is attributable to nonchlamydial bacterial pathogens. It is plausible that individuals who have previously developed a follicular conjunctivitis in response to C. trachomatis may more readily reform conjunctival follicles when challenged with certain other bacterial species. (Invest Ophthalmol Vis Sci. 2011;52:6012-6017) DOI:10.1167/iovs.11-7326
C1 [Burton, Matthew J.] Univ London London Sch Hyg & Trop Med, Dept Clin Sci, Int Ctr Eye Hlth, London WC1E 7HT, England.
   [Weiss, Helen A.] Univ London London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1E 7HT, England.
   [Burton, Matthew J.; Hu, Victor H.; Massae, Patrick; Courtright, Paul] Kilimanjaro Ctr Community Ophthalmol, Moshi, Tanzania.
   [Chevallier, Caroline; Afwamba, Isaac A.] Kilimanjaro Christian Med Ctr, Biotechnol Lab, Moshi, Tanzania.
   [Burr, Sarah E.] MRC Labs, Fajara, Gambia.
RP Burton, MJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Clin Sci, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU Wellcome Trust [080741/Z/06/Z]
FX Supported by The Wellcome Trust Grant 080741/Z/06/Z.
CR Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   Burton MJ, 2007, INVEST OPHTH VIS SCI, V48, P4440, DOI 10.1167/iovs.07-0315
   Burton MJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000835
   Burton MJ, 2010, INVEST OPHTH VIS SCI, V51, P3583, DOI 10.1167/iovs.09-4550
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P1282, DOI 10.1136/bjo.2004.062489
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Capriotti J. A., 2009, International Ophthalmology, V29, P81, DOI 10.1007/s10792-008-9196-4
   Chern KC, 1999, BRIT J OPHTHALMOL, V83, P1332, DOI 10.1136/bjo.83.12.1332
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Grassly NC, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000341
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Holland MJ, 2010, INVEST OPHTH VIS SCI, V51, P3893, DOI 10.1167/iovs.09-5054
   Hu VH, 2011, INVEST OPHTH VIS SCI, V52, P2181, DOI 10.1167/iovs.10-5829
   Keenan JD, 2010, AM J TROP MED HYG, V82, P482, DOI 10.4269/ajtmh.2010.09-0315
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   Michel CEC, 2006, LANCET, V367, P1585, DOI 10.1016/S0140-6736(06)68695-9
   REINHARD.J, 1968, B WORLD HEALTH ORGAN, V39, P497
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Solomon AW, 2008, NEW ENGL J MED, V358, P1870, DOI 10.1056/NEJMc0706263
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   VASTINE DW, 1974, BRIT J OPHTHALMOL, V58, P833, DOI 10.1136/bjo.58.10.833
   World Health Organization, 2004, 2 GLOB SCI M TRACH
   WOOD TR, 1967, AM J OPHTHALMOL, V63, P1298
   WOOLRIDGE RL, 1962, B WORLD HEALTH ORGAN, V26, P789
   Wright HR, 2005, LANCET INFECT DIS, V5, P313, DOI 10.1016/S1473-3099(05)70116-X
   YONEDA C, 1975, BRIT J OPHTHALMOL, V59, P116, DOI 10.1136/bjo.59.3.116
NR 26
TC 32
Z9 32
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2011
VL 52
IS 8
BP 6012
EP 6017
DI 10.1167/iovs.11-7326
PG 6
WC Ophthalmology
SC Ophthalmology
GA 800QC
UT WOS:000293377400128
PM 21693601
OA No
DA 2017-08-15
ER

PT J
AU Lubell, Y
   Riewpaiboon, A
   Dondorp, AM
   von Seidlein, L
   Mokuolu, OA
   Nansumba, M
   Gesase, S
   Kent, A
   Mtove, G
   Olaosebikan, R
   Ngum, WP
   Fanello, CI
   Hendriksen, I
   Day, NPJ
   White, NJ
   Yeung, S
AF Lubell, Yoel
   Riewpaiboon, Arthorn
   Dondorp, Arjen M.
   von Seidlein, Lorenz
   Mokuolu, Olugbenga A.
   Nansumba, Margaret
   Gesase, Samwel
   Kent, Alison
   Mtove, George
   Olaosebikan, Rasaq
   Ngum, Wirichada Pan
   Fanello, Caterina I.
   Hendriksen, Ilse
   Day, Nicholas P. J.
   White, Nicholas J.
   Yeung, Shunmay
TI Cost-effectiveness of parenteral artesunate for treating children with
   severe malaria in sub-Saharan Africa
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID SEVERE FALCIPARUM-MALARIA; RANDOMIZED-TRIAL; QUININE
AB Objective To explore the cost-effectiveness of parenteral artesunate for the treatment of severe malaria in children and its potential impact on hospital budgets:
   Methods The costs of inpatient care of children with severe malaria were assessed in four of the 11 sites included in the African Quinine Artesunate Malaria Treatment trial, conducted with over 5400 children. The drugs, laboratory tests and intravenous fluids provided to 2300 patients from admission to discharge were recorded, as was the length of inpatient stay, to calculate the cost of inpatient care. The data were matched with pooled clinical outcomes and entered into a decision model to calculate the cost per disability-adjusted life year (DALY) averted and the cost per death averted.
   Findings The mean cost of treating severe malaria patients was similar in the two study groups: 63.5 United States dollars (US$) (95% confidence interval. CI: 61.7-65.2) in the quinine arm and US$ 66.5 (95% CI: 63.7-69.2) in the artesunate arm. Children treated with artesunate had 22.5% lower mortality than those treated with quinine and the same rate of neurological sequelae: (artesunate arm: 2.3 DALYs per patient; quinine arm: 3.0 DALYs per patient). Compared with quinine as a baseline, artesunate showed an incremental cost per DALY averted and an incremental cost per death averted of US$ 3.8 and US$ 123, respectively.
   Conclusion Artesunate is a highly cost-effective and affordable alternative to quinine for treating children with severe malaria, The budgetary implications of adopting artesunate for routine use in hospital-based care are negligible.
C1 [Lubell, Yoel; Dondorp, Arjen M.; Ngum, Wirichada Pan; Fanello, Caterina I.; Hendriksen, Ilse; Day, Nicholas P. J.; White, Nicholas J.] Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand.
   [Riewpaiboon, Arthorn] Mahidol Univ, Fac Pharm, Bangkok 10400, Thailand.
   [von Seidlein, Lorenz] Menzies Sch Hlth Research, Casuarina, Australia.
   [Mokuolu, Olugbenga A.] Univ Ilorin, Dept Paediat & Child Hlth, Ilorin, Nigeria.
   [Nansumba, Margaret] Epictr Mbarara Res Base, Mbarara, Uganda.
   [Gesase, Samwel] Tanga Res Ctr, Natl Inst Med Res, Tanga, Tanzania.
   [Kent, Alison] Joint Malaria Program, Moshi, Tanzania.
   [Mtove, George] Natl Inst Med Res, Amani Ctr, Tanga, Tanzania.
   [Olaosebikan, Rasaq] MRC Labs, Malaria Programme, Fajara, Gambia.
   [Yeung, Shunmay] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London WC1, England.
RP Lubell, Y (reprint author), Mahidol Univ, Fac Trop Med, 420-6 Ratchawithi Rd, Bangkok 10400, Thailand.
EM yoel@tropmedres.ac
RI White, Nicholas/I-4629-2012
OI Lubell, Yoel/0000-0002-0237-1070
FU Wellcome Trust [076908, 082541]; Wellcome Trust of Great Britain
FX This trial was supported by grants 076908 and 082541 from the Wellcome
   Trust and was coordinated as part of the Wellcome Trust Mahidol
   University Oxford Tropical Medicine Research Programme funded by the
   Wellcome Trust of Great Britain.
CR Arnesen T, 2004, HEALTH POLICY, V70, P137, DOI 10.1016/j.healthpol.2003.08.004
   Ayieko Philip, 2009, Cost Eff Resour Alloc, V7, P3, DOI 10.1186/1478-7547-7-3
   Crawley J, 2010, LANCET, V375, P1468, DOI 10.1016/S0140-6736(10)60447-3
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   Drummond MF, 2005, METHODS EC EVALUATIO
   Faiz MA, 2005, LANCET, V366, P717
   Fox-Rushby J. A., 2002, DISABILITY ADJUSTED
   Gosling RD, 2008, PMID, V7, P132, DOI 10.1186/1475-2875-7-132
   Lubell Y, 2009, TROP MED INT HEALTH, V14, P332, DOI 10.1111/j.1365-3156.2009.02227.x
   Lubell Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012439
   Lyttkens CH, 2003, J HLTH EC, V4, P195, DOI [10.1007/s10198 003-0169-2, DOI 10.1007/S10198003-0169-2]
   Morris S, 2007, EC ANAL HLTH CARE
   Mulligan J., 2005, COST EFFECTIVENESS M
   Nadjm B, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1350
   Okell LC, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-125
   Pongtavornpinyo W, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-229
   [Anonymous], RES PIP INT
   [Anonymous], 2010, CONS PRIC IND 2006 2
   White LJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-212
   WHO, 2004, GLOB BURD DIS 2004 U
   World Health Organization, 2009, WORLD MAL REP 2009
   WHO, 1996, INV HLTH RES DEV REP
   [Anonymous], 2008, CHOOS INT COST EFF C
   World Health Organization, 2010, WORLD HLTH STAT
   World Bank, 1993, WORLD DEV REP
   [Anonymous], 2010, OFF AV PER EXCH RAT
   YEN LM, 1994, LANCET, V344, P786, DOI 10.1016/S0140-6736(94)92342-6
   [Anonymous], 2009, INT DRUG PRICE INDIC
NR 28
TC 24
Z9 24
U1 0
U2 5
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD JUL
PY 2011
VL 89
IS 7
BP 504
EP 512
DI 10.2471/BLT.11.085878
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 791MG
UT WOS:000292668700019
PM 21734764
OA No
DA 2017-08-15
ER

PT J
AU Vanderwal, L
   Rautiainen, R
   Kuye, R
   Peek-Asa, C
   Cook, T
   Ramirez, M
   Culp, K
   Donham, K
AF Vanderwal, Londa
   Rautiainen, Risto
   Kuye, Rex
   Peek-Asa, Corinne
   Cook, Thomas
   Ramirez, Marizen
   Culp, Kennith
   Donham, Kelley
TI Evaluation of long- and short-handled hand hoes for land preparation,
   developed in a participatory manner among women vegetable farmers in The
   Gambia
SO APPLIED ERGONOMICS
LA English
DT Article
DE Agriculture; Vegetable farming; Women; Safety; Hand tools; Africa
ID DEVELOPING-COUNTRIES; CROP PRODUCTION; HEALTH; INTERVENTIONS;
   AGRICULTURE; ERGONOMICS; OUTCOMES; STATE
AB Objective: This study evaluated land preparation interventions (new short- and long-handled hoes), developed in a participatory manner with women vegetable farmers in West Africa, and identified indicators of long-term adoption of these interventions.
   Methods: Subjects (n = 48) engaged in timed trials, alternating between using an intervention tool and their traditional hand hoe to till specified plots of land. Heart rates were measured and subjects reported the relative ergonomic comfort and safeness of the tool after each trial. Follow-up interviews and focus groups were held one, two, and three months after the trials.
   Results: Compared to the traditional hoe, the new long-handled hoe required 22% less time (p = 0.01), while the new short hoe took 20% more time (p = 0.05) to till the standard plots in this study. Two months after the initial trials, 94% of subjects preferred the new hoes over the traditional hoe. Most subjects (75%) preferred the new short hoe over the new long hoe and thought it was faster (81%), despite measurements to the contrary.
   Conclusions: While the new long-handled hoe performed better in the timed trials in this study, most subjects preferred the new short-handled hoe. Subjects should be sensitized on the benefits of the long-handled hoe. (C) 2010 Elsevier Ltd and The Ergonomics Society. All rights reserved.
C1 [Vanderwal, Londa; Rautiainen, Risto; Peek-Asa, Corinne; Cook, Thomas; Ramirez, Marizen; Culp, Kennith; Donham, Kelley] Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Hlth, Iowa City, IA USA.
   [Kuye, Rex] Univ Gambia, Sch Publ Hlth, Brikama, Gambia.
RP Rautiainen, R (reprint author), Univ Nebraska Med Ctr, Swanson Hall 3058, Omaha, NE 68198 USA.
EM rrautiainen@unmc.edu
RI Culp, Kennith/C-5798-2013
OI Culp, Kennith/0000-0002-7197-385X
FU University of Iowa Heartland Center for Occupational Health and Safety
   [T42OH008491-04]; University of Iowa Injury Prevention Research Center
   [1R49CE001167-03]; University of Iowa; Great Plains Center for
   Agricultural Safety and Health [1U500H009001-01]
FX Funding for this study was provided by the University of Iowa Heartland
   Center for Occupational Health and Safety (Grant number: T42OH008491-04)
   pilot grant and traineeship programs, the University of Iowa Injury
   Prevention Research Center (Grant number: 1R49CE001167-03), a Sigma
   Delta Epsilon/Graduate Women in Science fellowship, a University of Iowa
   T. Anne Cleary International Dissertation Research Fellowship and a
   Stanley Graduate Award for International Research, and a University of
   Iowa Executive Council of Graduate and Professional Students Research
   Grant. Dr. Rautiainen's contribution was funded by the Great Plains
   Center for Agricultural Safety and Health (Grant number:
   1U500H009001-01). We wish to express our sincere gratitude to all these
   organizations for their financial support. We would also like to
   sincerely thank the staff of The Gambia College, the Trust Agency for
   Rural Development (TARUD, local NGO supervising the garden where the
   research was conducted), and the student research assistants from The
   Gambia College for all their support and assistance in this study.
CR Baron S, 2001, DHHS NIOSH PUBLICATI, V2001-111
   Carney J. A., 1998, Agriculture and Human Values, V15, P325, DOI 10.1023/A:1007580801416
   Chatizawa I, 1997, PROC BRIGHTON CROP, P203
   Chhaya Badiger, 2006, Karnataka Journal of Agricultural Sciences, V19, P182
   Creswell J.W., 2003, HDB MIXED METHODS SO, P209
   Culp Kennith, 2007, Clin Nurs Res, V16, P170, DOI 10.1177/1054773807302399
   Earle-Richardson G, 2005, APPL ERGON, V36, P327, DOI 10.1016/j.apergo.2004.12.003
   Egharevba RK, 2004, J SUSTAIN AGR, V24, P39, DOI 10.1300/J064v24n01_05
   Fathallah F A, 2008, J Agric Saf Health, V14, P221
   Faucett J, 2007, APPL ERGON, V38, P219, DOI 10.1016/j.apergo.2006.02.003
   Glaser B., 1967, DISCOVERY GROUNDED T
   JANOWITZ I, 2000, P HUM FACT ERG SOC A, P628
   Kaul R. N., 1993, Proceedings, XXV CIOSTA-CIGR V Congress: farm planning, labour and labour conditions, computers in agricultural management, held in Wageningen, Netherlands, 10-13 May 1993., P20
   Kaul R. N., 1992, Journal for Farming Systems Research-Extension, V3, P35
   Kuye R, 2006, ANN AGR ENV MED, V13, P1
   Nag PK, 2004, IND HEALTH, V42, P149, DOI 10.2486/indhealth.42.149
   NWUBA EIU, 1986, J AGR ENG RES, V33, P179
   O'Neill DH, 2000, APPL ERGON, V31, P631, DOI 10.1016/S0003-6870(00)00033-8
   Peterson R., 2000, CONSTRUCTING EFFECTI
   RAMAHI A, 2006, P HUM FACT ERG SOC 5, P1421
   RAMANA C, 2002, INDIAN J DRYLAND AGR, V17, P28
   Rivilis I, 2008, APPL ERGON, V39, P342, DOI 10.1016/j.apergo.2007.08.006
   ROGAN A, 1993, APPL ERGON, V24, P371, DOI 10.1016/0003-6870(93)90169-A
   Rogers EM, 2003, DIFFUSION INNOVATION
   *SAS I INC, 2008, GEN EST EQ
   *SAS I INC, 2009, GENMOD PROC
   TEWARI VK, 1991, APPL ERGON, V22, P111, DOI 10.1016/0003-6870(91)90309-6
   *UN FAO IFAD, 1998, AGR IMPL US WOM FARM
   VANDERWAL LS, 2009, THESIS U IOWA IOWA C
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 30
TC 4
Z9 4
U1 2
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0003-6870
J9 APPL ERGON
JI Appl. Ergon.
PD JUL
PY 2011
VL 42
IS 5
BP 749
EP 756
DI 10.1016/j.apergo.2010.12.002
PG 8
WC Engineering, Industrial; Ergonomics; Psychology, Applied
SC Engineering; Psychology
GA 758VJ
UT WOS:000290194900015
PM 21236415
OA No
DA 2017-08-15
ER

PT J
AU Ekouevi, DK
   Azondekon, A
   Dicko, F
   Malateste, K
   Toure, P
   Eboua, FT
   Kouadio, K
   Renner, L
   Peterson, K
   Dabis, F
   Sy, HS
   Leroy, V
AF Ekouevi, Didier K.
   Azondekon, Alain
   Dicko, Fatoumata
   Malateste, Karen
   Toure, Pety
   Eboua, Francois T.
   Kouadio, Kouakou
   Renner, Lorna
   Peterson, Kevin
   Dabis, Francois
   Sy, Haby Signate
   Leroy, Valeriane
CA IeDEA Pediat W Africa Working Grp
TI 12-month mortality and loss-to-program in antiretroviral-treated
   children: The IeDEA pediatric West African Database to evaluate AIDS
   (pWADA), 2000-2008
SO BMC PUBLIC HEALTH
LA English
DT Article
ID HEALTH-CARE FACILITIES; COTE-DIVOIRE; HIV-1-INFECTED CHILDREN;
   FOLLOW-UP; THERAPY; OUTCOMES; INFANTS; TRANSMISSION; DIAGNOSIS; SURVIVAL
AB Background: The IeDEA West Africa Pediatric Working Group (pWADA) was established in January 2007 to study the care and treatment of HIV-infected children in this region. We describe here the characteristics at antiretroviral treatment (ART) initiation and study the 12-month mortality and loss-to-program of HIV-infected children followed in ART programs in West Africa.
   Methods: Standardized data from HIV-infected children followed-up in ART programs were included. Nine clinical centers from six countries contributed to the dataset (Benin, Cote d'Ivoire, Gambia, Ghana, Mali and Senegal). Inclusion criteria were the followings: age 0-15 years and initiated triple antiretroviral drug regimens. Baseline time was the date of ART initiation. WHO criteria was used to define severe immunosuppression based on CD4 count by age or CD4 percent < 15%. We estimated the 12-month Kaplan-Meier probabilities of mortality and loss-to-program (death or loss to follow-up > 6 months) after ART initiation and factors associated with these two outcomes.
   Results: Between June 2000 and December 2007, 2170 children were included. Characteristics at ART initiation were the following: median age of 5 years (Interquartile range (IQR: 2-9) and median CD4 percentage of 13% (IQR: 7-19). The most frequent drug regimen consisted of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitors (62%). During the first 12 months, 169 (7.8%) children died and 461 (21.2%) were lost-to-program. Overall, in HIV-infected children on ART, the 12-month probability of death was 8.3% (95% Confidence Interval (CI): 7.2-9.6%), and of loss-to-program was 23.1% (95% CI: 21.3-25.0%). Both mortality and loss-to program were associated with advanced clinical stage, CD4 percentage < 15% at ART initiation and year (> 2005) of ART initiation.
   Conclusion: Innovative and sustainable approaches are needed to better document causes of death and increase retention in HIV pediatric clinics in West Africa.
C1 [Ekouevi, Didier K.; Malateste, Karen; Dabis, Francois; Leroy, Valeriane] Univ Bordeaux 2, INSERM, U89, F-33076 Bordeaux, France.
   [Ekouevi, Didier K.; Malateste, Karen; Dabis, Francois; Leroy, Valeriane] Univ Bordeaux 2, ISPED, F-33076 Bordeaux, France.
   [Ekouevi, Didier K.] CHU Treichville, Programme PAC CI, Abidjan, Cote Ivoire.
   [Azondekon, Alain] Hop Instruct Armees St Anne, Cotonou, Benin.
   [Dicko, Fatoumata] Hop Gabriel Toure, Serv Pediat Bamako, Bamako, Mali.
   [Toure, Pety] ACONDA, MTCT Plus Initiat, Abidjan, Cote Ivoire.
   [Toure, Pety] ACONDA, CePReF, Abidjan, Cote Ivoire.
   [Eboua, Francois T.] CHU Yopougon, Serv Pediat, Abidjan, Cote Ivoire.
   [Kouadio, Kouakou] CIRBA, Abidjan, Cote Ivoire.
   [Renner, Lorna] Korlebu Hosp, Pediat Ward, Accra, Ghana.
   [Peterson, Kevin] MRC, Banjul, Gambia.
   [Sy, Haby Signate] Hop Enfants Albert Royer, Dakar, Senegal.
RP Ekouevi, DK (reprint author), Univ Bordeaux 2, INSERM, U89, F-33076 Bordeaux, France.
EM didier.ekouevi@gmail.com
RI EKOUEVI, Didier/E-7960-2014; Leroy, Valeriane/F-8129-2013
OI Leroy, Valeriane/0000-0003-3542-8616
FU National Institute of Allergy and Infectious Diseases (NIAID) of the U.
   S. National Institutes of Health (NIH) as part of the International
   Epidemiologic Databases to Evaluate AIDS (IeDEA) [5U01AI069919-01,
   5U01AI069919-02, 5U01AI069919-03, 5U01AI069919-04, 5U01AI069919-05]
FX The International epidemiological Database to Evaluate AIDS in West
   Africa (IeDEA West Africa) is supported by the National Institute of
   Allergy and Infectious Diseases (NIAID) of the U. S. National Institutes
   of Health (NIH) as part of the International Epidemiologic Databases to
   Evaluate AIDS (IeDEA) (grant no. 5U01AI069919-01 to 05). The content of
   this publication is solely the responsibility of the authors and does
   not necessarily represent the official views of any of the institutions
   mentioned above.
CR Anaky MF, 2010, B WORLD HEALTH ORGAN, V88, P490, DOI 10.2471/BLT.09.068015
   Bolton-Moore C, 2007, JAMA-J AM MED ASSOC, V298, P1888, DOI 10.1001/jama.298.16.1888
   Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248
   Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790
   Creek T, 2008, PEDIATR INFECT DIS J, V27, P22, DOI 10.1097/INF.0b013e3181469050
   Davies MA, 2009, SAMJ S AFR MED J, V99, P730
   EKOUEVI DK, 2011, TROP MED INT HLTH S1, V15, P34
   Fassinou P, 2004, AIDS, V18, P1905, DOI 10.1097/00002030-200409240-00006
   FOX MP, 2011, TROP MED INT HLTH S1, V15, P1
   HARRIES AD, TROP MED INT HLTH S1, V15, P70
   HUONG NNG, 2008, J ACQ IMMUN DEF SYND, V49, P465
   Kiboneka A, 2008, AIDS, V22, P2493, DOI 10.1097/QAD.0b013e328318f148
   KIDS ART LINC, 2008, J ACQ IMMUN DEF SYND, V49, P523, DOI DOI 10.1097/QAI.0B013E31818AADCE
   Kjaer J, 2004, ANTIVIR THER, V9, P631
   Lofgren SM, 2009, AIDS, V23, P2459, DOI 10.1097/QAD.0b013e328331f702
   Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7
   Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298
   Rouet F, 2006, AIDS, V20, P2315, DOI 10.1097/QAD.0b013e328010943b
   SAUVAGEOT D, PEDIATRICS, V125, pE1039
   Tonwe-Gold B, 2009, TROP MED INT HEALTH, V14, P204, DOI 10.1111/j.1365-3156.2008.02182.x
   Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO), AIDS EP UPD 2009
   Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971
   World Health Organization, 2006, ANT THER HIV INF INF
   WHO, 2008, WHO TECHN REF GROUP
   *WHO, 2004, CAR TREATM SUPP WOM
   World Health Organization, 2006, WHO HIV PREV TREATM
   World Health Organization (WHO) Joint United Nations Programme on HIV/ AIDS (UNAIDS) The United Nations Children's Fund (UNICEF), 2010, UN ACC SCAL PRIOR HI
   Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739
NR 28
TC 25
Z9 25
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD JUN 30
PY 2011
VL 11
AR 519
DI 10.1186/1471-2458-11-519
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 796BT
UT WOS:000293025900002
PM 21718505
OA gold
DA 2017-08-15
ER

PT J
AU Aspinall, R
   Prentice, AM
   Ngom, PT
AF Aspinall, Richard
   Prentice, Andrew M.
   Ngom, Pa Tamba
TI Interleukin 7 from Maternal Milk Crosses the Intestinal Barrier and
   Modulates T-Cell Development in Offspring
SO PLOS ONE
LA English
DT Article
ID BREAST-FED INFANTS; THYMUS SIZE; PNEUMOCOCCAL VACCINE; IL-7; MORTALITY;
   WOMEN; BIRTH; IMMUNIZATION; LYMPHOCYTES; EXPRESSION
AB Background: Breastfeeding protects against illnesses and death in hazardous environments, an effect partly mediated by improved immune function. One hypothesis suggests that factors within milk supplement the inadequate immune response of the offspring, but this has not been able to account for a series of observations showing that factors within maternally derived milk may supplement the development of the immune system through a direct effect on the primary lymphoid organs. In a previous human study we reported evidence suggesting a link between IL-7 in breast milk and the thymic output of infants. Here we report evidence in mice of direct action of maternally-derived IL-7 on T cell development in the offspring.
   Methods and Findings: We have used recombinant IL-7 labelled with a fluorescent dye to trace the movement in live mice of IL-7 from the stomach across the gut and into the lymphoid tissues. To validate the functional ability of maternally derived IL-7 we cross fostered IL-7 knock-out mice onto normal wild type mothers. Subsets of thymocytes and populations of peripheral T cells were significantly higher than those found in knock-out mice receiving milk from IL-7 knock-out mothers.
   Conclusions/Significance: Our study provides direct evidence that interleukin 7, a factor which is critical in the development of T lymphocytes, when maternally derived can transfer across the intestine of the offspring, increase T cell production in the thymus and support the survival of T cells in the peripheral secondary lymphoid tissue.
C1 [Aspinall, Richard; Ngom, Pa Tamba] Univ London Imperial Coll Sci Technol & Med, Dept Immunol, London, England.
   [Prentice, Andrew M.; Ngom, Pa Tamba] MRC Labs, Nutr Programme, Serrekunda, Gambia.
   [Prentice, Andrew M.] London Sch Hyg & Trop Med, Med Res Council Int Nutr Grp, London WC1, England.
   [Aspinall, Richard] Cranfield Univ, Cranfield MK43 0AL, Beds, England.
RP Aspinall, R (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Immunol, London, England.
EM r.aspinall@cranfield.ac.uk
RI Aspinall, Richard/E-4924-2013
OI Aspinall, Richard/0000-0002-1648-1887
FU Medical Research Council International Nutrition Group; Islamic
   Development Bank; Westminster Medical School Research Trust
FX This work was supported by the Medical Research Council International
   Nutrition Group, the Islamic Development Bank and the Westminster
   Medical School Research Trust. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aaby P, 2002, ACTA PAEDIATR, V91, P698, DOI 10.1080/080352502760069142
   Andrew D, 2001, J IMMUNOL, V166, P1524
   Aspinall R, 2001, CELL IMMUNOL, V212, P150, DOI 10.1006/cimm.2001.1848
   Bains I, 2009, J IMMUNOL, V183, P4329, DOI 10.4049/jimmunol.0900743
   Bains I, 2009, BLOOD, V113, P5480, DOI 10.1182/blood-2008-10-184184
   BEISEL WR, 1992, J NUTR, V122, P591
   Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0
   Brandtzaeg P, 2003, VACCINE, V21, P3382, DOI 10.1016/S0264-410X(03)00338-4
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   Danneman PJ, 1997, LAB ANIM SCI, V47, P386
   DEREN JS, 1971, AM J CLIN NUTR, V24, P144
   Deubzer HE, 2004, J INFECT DIS, V190, P1758, DOI 10.1086/424597
   El Kassar N, 2004, BLOOD, V104, P1419, DOI 10.1182/blood-2004-01-0201
   Finn A, 2002, J INFECT DIS, V186, P1422, DOI 10.1086/344356
   Fry TJ, 2005, J IMMUNOL, V174, P6571
   Garly ML, 2008, J PEDIATR, V153, P683, DOI 10.1016/j.jpeds.2008.04.069
   Hasselbalch H, 1996, ACTA PAEDIATR, V85, P1029, DOI 10.1111/j.1651-2227.1996.tb14211.x
   Hasselbalch H, 1999, EUR J PEDIATR, V158, P964, DOI 10.1007/s004310051258
   JEFFRY UV, 1995, J EXP MED, V181, P1519
   Jeppesen DL, 2004, PEDIATR ALLERGY IMMU, V15, P127, DOI 10.1111/j.1399-3038.2004.00032.x
   Kim K, 1998, J IMMUNOL, V160, P5735
   KOLDOVSKY O, 1989, J NUTR, V119, P1543
   Lawrence Robert M, 2007, Curr Probl Pediatr Adolesc Health Care, V37, P7, DOI 10.1016/j.cppeds.2006.10.002
   Lima K, 2010, CLIN EXP IMMUNOL, V161, P98, DOI 10.1111/j.1365-2249.2010.04152.x
   LOSONSKY GA, 1982, J INFECT DIS, V145, P654
   MASCARTLEMONE F, 1988, SCAND J IMMUNOL, V28, P443, DOI 10.1111/j.1365-3083.1988.tb01474.x
   Mazzucchelli R, 2007, NAT REV IMMUNOL, V7, P144, DOI 10.1038/nri2023
   Min BK, 2003, IMMUNITY, V18, P131, DOI 10.1016/S1074-7613(02)00508-3
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   MOSINGER B, 1959, NATURE, V184, P1245, DOI 10.1038/1841245a0
   Munoz FM, 2003, VACCINE, V21, P3465, DOI 10.1016/S0264-410X(03)00352-9
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   Obaro SK, 2004, PEDIATR INFECT DIS J, V23, P1023, DOI 10.1097/01.inf.0000143651.54880.09
   Prentice AM, 2000, ACTA PAEDIATR, V89, P8, DOI 10.1080/080352500750028979
   SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2
   Takahata Y, 2001, PEDIATR RES, V50, P268, DOI 10.1203/00006450-200108000-00017
   Vivien L, 2001, INT IMMUNOL, V13, P763, DOI 10.1093/intimm/13.6.763
   Walter J, 2007, JAIDS-J ACQ IMM DEF, V46, P200, DOI 10.1097/QAI.0b013e318141f942
   World Health Organization, 2001, GLOB STRAT INF YOUNG
   Wilks AB, 2010, J IMMUNOL, V185, P7097, DOI 10.4049/jimmunol.1002751
   Wu L, 2006, CURR OPIN IMMUNOL, V18, P121, DOI 10.1016/j.coi.2006.01.006
   WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0
   Yuan X, 1998, AM J PHYSIOL-GASTR L, V274, pG342
NR 44
TC 14
Z9 15
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 30
PY 2011
VL 6
IS 6
AR e20812
DI 10.1371/journal.pone.0020812
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 786GP
UT WOS:000292291800004
PM 21738587
OA gold
DA 2017-08-15
ER

PT J
AU Ota, MOC
   Odutola, AA
   Owiafe, PK
   Donkor, S
   Owolabi, OA
   Brittain, NJ
   Williams, N
   Rowland-Jones, S
   Hill, AVS
   Adegbola, RA
   McShane, H
AF Ota, Martin O. C.
   Odutola, Aderonke A.
   Owiafe, Patrick K.
   Donkor, Simon
   Owolabi, Olumuyiwa A.
   Brittain, Nathaniel J.
   Williams, Nicola
   Rowland-Jones, Sarah
   Hill, Adrian V. S.
   Adegbola, Richard A.
   McShane, Helen
TI Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by
   Coadministration with EPI Vaccines in a Randomized Controlled Trial in
   Gambian Infants
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS; INTERFERON-GAMMA; WEST-AFRICA; SAFETY; BCG;
   PROTECTION; INFECTION; RESPONSES; EFFICACY; ANTIBODY
AB New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vaccines administered in infancy, we randomized healthy 4-month-old infants who had received Bacille Calmette-Guerin at birth to receive Expanded Program on Immunization (EPI) vaccines alone, EPI and MVA85A simultaneously, or MVA85A alone. Adverse events were monitored throughout. Blood samples obtained before vaccination and at 1, 4, and 20 weeks after vaccination were used to assess safety and immunogenicity. The safety profile of both low and standard doses was comparable, but the standard dose was more immunogenic and therefore was selected for the second stage of the study. In total, 72 (first stage) and 142 (second stage) infants were enrolled. MVA85A was safe and well tolerated and induced a potent cellular immune response. Coadministration of MVA85A with EPI vaccines was associated with a significant reduction in MVA85A immunogenicity, but did not affect humoral responses to the EPI vaccines. These results provide important information regarding timing of immunizations, which is required for the design of infant efficacy trials with MVA85A, and suggest that modifications to the standard EPI schedule may be required to incorporate a new generation of T cell-inducing vaccines.
C1 [Ota, Martin O. C.; Odutola, Aderonke A.; Owiafe, Patrick K.; Donkor, Simon; Owolabi, Olumuyiwa A.; Rowland-Jones, Sarah] MRC, Bacterial Dis Programme, Banjul, Gambia.
   [Brittain, Nathaniel J.; Hill, Adrian V. S.; McShane, Helen] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England.
   [Williams, Nicola] Univ Oxford Wolfson Coll, Ctr Stat Med, Oxford OX2, England.
   [Adegbola, Richard A.] Bill & Melinda Gates Fdn, Seattle, WA 98102 USA.
RP Ota, MOC (reprint author), MRC, Bacterial Dis Programme, Banjul, Gambia.
EM mota@mrc.gm
OI Kwasi Owiafe, Patrick/0000-0002-4287-3577
FU Medical Research Council (UK); European Commission
FX Funding: The study was funded by the Medical Research Council (UK) and
   the European Commission (EU 6th Framework; TBVAC). Neither funder had
   any role in the design of the study or the preparation of the
   manuscript. H.M. is a Wellcome Trust Senior Clinical Research Fellow,
   and A.V.S.H. is a Wellcome Trust Principal Research Fellow.
CR Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773
   Brookes RH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002921
   Bungener L, 2008, VACCINE, V26, P2350, DOI 10.1016/j.vaccine.2008.02.063
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   D'Souza S, 2003, INFECT IMMUN, V71, P483, DOI 10.1128/IAI.71.1.483-493.2003
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
   Hawkridge T, 2008, J INFECT DIS, V198, P544, DOI 10.1086/590185
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Scriba TJ, 2010, EUR J IMMUNOL, V40, P279, DOI 10.1002/eji.200939754
   Spazierer D, 2009, CLIN EXP ALLERGY, V39, P999, DOI 10.1111/j.1365-2222.2008.03177.x
   Vordermeier HM, 2009, INFECT IMMUN, V77, P3364, DOI 10.1128/IAI.00287-09
   Walther M, 2006, INFECT IMMUN, V74, P2706, DOI 10.1128/IAI.74.5.2706-2716.2006
   WATSON B, 1992, PEDIATR INFECT DIS J, V11, P930
   Zepp F, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e58
   Zodpey Sanjoy P, 2007, Indian J Public Health, V51, P184
NR 21
TC 21
Z9 21
U1 0
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUN 22
PY 2011
VL 3
IS 88
AR 88ra56
DI 10.1126/scitranslmed.3002461
PG 6
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 795NV
UT WOS:000292981800005
PM 21697532
OA No
DA 2017-08-15
ER

PT J
AU Kwambana, BA
   Barer, MR
   Bottomley, C
   Adegbola, RA
   Antonio, M
AF Kwambana, Brenda A.
   Barer, Michael R.
   Bottomley, Christian
   Adegbola, Richard A.
   Antonio, Martin
TI Early acquisition and high nasopharyngeal co-colonisation by
   Streptococcus pneumoniae and three respiratory pathogens amongst Gambian
   new-borns and infants
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Nasopharyngeal; PCR; respiratory pathogens
ID INFLUENZAE-TYPE-B; PNEUMOCOCCAL CONJUGATE VACCINE; DETERMINING CAPSULAR
   SEROTYPES; HAEMOPHILUS-INFLUENZAE; STAPHYLOCOCCUS-AUREUS;
   BACTERIAL-COLONIZATION; MORAXELLA-CATARRHALIS; SYSTEMATIC ANALYSIS;
   NASAL COLONIZATION; OTITIS-MEDIA
AB Background: Although Haemophilus influenzae type b (Hib), Staphylococcus aureus and Moraxella catarrhalis are important causes of invasive and mucosal bacterial disease among children, co-carriage with Streptococcus pneumoniae during infancy has not been determined in West Africa.
   Methods: Species specific PCR was applied to detect each microbe using purified genomic DNA from 498 nasopharyngeal (NP) swabs collected from 30 Gambian neonates every two weeks from 0 to 6 months and bimonthly up to 12 months.
   Results: All infants carried S. pneumoniae, H. influenzae and M. catarrhalis at several time points during infancy. S. pneumoniae co-colonized the infant nasopharynx with at least one other pathogen nine out of ten times. There was early colonization of the newborns and neonates, the average times to first detection were 5, 7, 3 and 14 weeks for S. pneumoniae, H. influenzae, M. catarrhalis and S. aureus respectively. The prevalence of S. pneumoniae, H. influenzae and M. catarrhalis increased among the neonates and exceeded 80% by 13, 15 and 23 weeks respectively. In contrast, the prevalence of S. aureus decreased from 50% among the newborns to 20% amongst nine-week old neonates. S. pneumoniae appeared to have a strong positive association with H. influenzae (OR 5.03; 95% Cl 3.02, 8.39; p < 0.01) and M. catarrhalis (OR 2.20; 95% Cl 1.29; p < 0.01) but it was negatively associated with S. aureus (OR 0.53; 95% Cl 0.30, 0.94; p = 0.03).
   Conclusion: This study shows early acquisition and high co-carriage of three important respiratory pathogens with S. pneumoniae in the nasopharyngeal mucosa among Gambian neonates and infants. This has important potential implications for the aetiology of respiratory polymicrobial infections, biofilm formation and vaccine strategies.
C1 [Kwambana, Brenda A.; Adegbola, Richard A.; Antonio, Martin] Med Res Council Labs UK, Bacterial Dis Programme, Banjul, Gambia.
   [Kwambana, Brenda A.; Barer, Michael R.] Dept Infect Immun & Inflammat, Leicester LE1 9HN, Leics, England.
   [Bottomley, Christian] Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England.
   [Adegbola, Richard A.] Bill & Melinda Gates Fdn, Global Hlth Program, Seattle, WA 98102 USA.
RP Antonio, M (reprint author), Med Res Council Labs UK, Bacterial Dis Programme, Atlantic Blvd,POB 273, Banjul, Gambia.
EM mantonio@mrc.gm
FU Medical Research Council, United Kingdom
FX This work was funded by the Medical Research Council, United Kingdom. We
   would like to thank the study participants and their parents, the field
   team and laboratory support group.
CR Adegbola RA, 1998, J INFECT DIS, V177, P1758, DOI 10.1086/517440
   Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X
   Antonio M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-81
   Beisswenger C, 2009, INFECT IMMUN, V77, P2212, DOI 10.1128/IAI.01224-08
   BERMAL N, 2010, PEDIAT INFECT DIS J
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Bogaert D, 2004, LANCET, V363, P1871, DOI 10.1016/S0140-6736(04)16357-5
   Carvalho BTC, 1999, CLIN DIAGN LAB IMMUN, V6, P50
   Carvalho MD, 2010, J CLIN MICROBIOL, V48, P1611, DOI 10.1128/JCM.02243-09
   *CDCP, 2010, PCR DED PNEUM SER
   Dagan R, 2009, VACCINE, V27, pC22, DOI 10.1016/j.vaccine.2009.06.004
   Daher M, 1998, J Med Liban, V46, P212
   Dworkin MS, 2007, CLIN INFECT DIS, V44, P810, DOI 10.1086/511861
   Garcia-Rodriguez JA, 2002, J ANTIMICROB CHEMOTH, V50, P59, DOI 10.1093/jac/dkf506
   Granat SM, 2007, PEDIATR INFECT DIS J, V26, P319, DOI 10.1097/01.inf.0000257425.24492.11
   GRAY BM, 1980, J INFECT DIS, V142, P923
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-2
   Hill PC, 2010, CLIN INFECT DIS, V50, P1468, DOI 10.1086/652443
   Howie SRC, 2007, VACCINE, V25, P6305, DOI 10.1016/j.vaccine.2007.06.023
   Kelly DF, 2004, IMMUNOLOGY, V113, P163, DOI 10.1111/j.1365-2567.2004.01971.x
   Krishnamurthy A, 2009, MICROBES INFECT, V11, P545, DOI 10.1016/j.micinf.2009.03.001
   Kwambana BA, 2011, BMC CLIN PATHOL, V11, DOI 10.1186/1472-6890-11-2
   LEACH AJ, 1994, PEDIATR INFECT DIS J, V13, P983, DOI 10.1097/00006454-199411000-00009
   Maaroufi Y, 2007, J CLIN MICROBIOL, V45, P2305, DOI 10.1128/JCM.00102-07
   Madhi SA, 2007, J INFECT DIS, V196, P1662, DOI 10.1086/522164
   Margolis E, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-59
   MONTGOMERY JM, 1990, REV INFECT DIS, V12, pS1006
   Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007
   Murphy TF, 2009, CLIN INFECT DIS, V49, P124, DOI 10.1086/599375
   Nizet V, 1996, J INFECT DIS, V173, P180
   Nohynek H, 2009, PEDIATR INFECT DIS J, V28, pS127, DOI 10.1097/INF.0b013e3181b6d800
   Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006
   Pletz MW, 2008, INT J ANTIMICROB AG, V32, P199, DOI 10.1016/j.ijantimicag.2008.01.021
   Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9
   Reddy MS, 1996, INFECT IMMUN, V64, P1477
   Regev-Yochay G, 2006, J BACTERIOL, V188, P4996, DOI 10.1128/JB.00317-06
   Scott JAG, 2008, PLOS MED, V5, P548, DOI 10.1371/journal.pmed.0050086
   Selva L, 2009, P NATL ACAD SCI USA, V106, P1234, DOI 10.1073/pnas.0809600106
   Sethi S, 1997, INFECT IMMUN, V65, P3666
   Stuhlmeier R, 2003, J CLIN PATHOL, V56, P782, DOI 10.1136/jcp.56.10.782
   Syrjanen RK, 2001, J INFECT DIS, V184, P451, DOI 10.1086/322048
   Ulanova M, 2009, INFECT GENET EVOL, V9, P594, DOI 10.1016/j.meegid.2009.03.001
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   Watson K, 2006, PEDIATR INFECT DIS J, V25, P782, DOI 10.1097/01.inf.0000232705.49634.68
   Zucol F, 2006, J CLIN MICROBIOL, V44, P2750, DOI 10.1128/JCM.00112-06
   2003, CARING, V22, P6
   2003, CARING, V22, P12
NR 50
TC 43
Z9 46
U1 2
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUN 20
PY 2011
VL 11
AR 175
DI 10.1186/1471-2334-11-175
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 787KM
UT WOS:000292375000001
PM 21689403
OA gold
DA 2017-08-15
ER

PT J
AU Sow, SO
   Okoko, BJ
   Diallo, A
   Viviani, S
   Borrow, R
   Carlone, G
   Tapia, M
   Akinsola, AK
   Arduin, P
   Findlow, H
   Elie, C
   Haidara, FC
   Adegbola, RA
   Diop, D
   Parulekar, V
   Chaumont, J
   Martellet, L
   Diallo, F
   Idoko, OT
   Tang, YX
   Plikaytis, BD
   Kulkarni, PS
   Marchetti, E
   LaForce, FM
   Preziosi, MP
AF Sow, Samba O.
   Okoko, Brown J.
   Diallo, Aldiouma
   Viviani, Simonetta
   Borrow, Ray
   Carlone, George
   Tapia, Milagritos
   Akinsola, Adebayo K.
   Arduin, Pascal
   Findlow, Helen
   Elie, Cheryl
   Haidara, Fadima Cheick
   Adegbola, Richard A.
   Diop, Doudou
   Parulekar, Varsha
   Chaumont, Julie
   Martellet, Lionel
   Diallo, Fatoumata
   Idoko, Olubukola T.
   Tang, Yuxiao
   Plikaytis, Brian D.
   Kulkarni, Prasad S.
   Marchetti, Elisa
   LaForce, F. Marc
   Preziosi, Marie-Pierre
TI Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in
   Africans
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID NEISSERIA-MENINGITIDIS GROUP; POLYSACCHARIDE VACCINE; EPIDEMIC
   MENINGITIS; SEROGROUP-A; ANTIBODY; MEMORY; TRIAL; BELT; RISK;
   QUADRIVALENT
AB Background
   Group A meningococci are the source of major epidemics of meningitis in Africa. An affordable, highly immunogenic meningococcal A conjugate vaccine is needed.
   Methods
   We conducted two studies in Africa to evaluate a new MenA conjugate vaccine (PsA-TT). In study A, 601 children, 12 to 23 months of age, were randomly assigned to receive PsA-TT, a quadrivalent polysaccharide reference vaccine (PsACWY), or a control vaccine (Haemophilus influenzae type b conjugate vaccine [Hib-TT]). Ten months later, these children underwent another round of randomization within each group to receive a full dose of PsA-TT, a one-fifth dose of PsACWY, or a full dose of Hib-TT, with 589 of the original participants receiving a booster dose. In study B, 900 subjects between 2 and 29 years of age were randomly assigned to receive PsA-TT or PsACWY. Safety and reactogenicity were evaluated, and immunogenicity was assessed by measuring the activity of group A serum bactericidal antibody (SBA) with rabbit complement and performing an IgG group A-specific enzyme-linked immunosorbent assay.
   Results
   In study A, 96.0% of the subjects in the PsA-TT group and 63.7% of those in the PsACWY group had SBA titers that were at least four times as high as those at baseline; in study B, 78.2% of the subjects in the PsA-TT group and 46.2% of those in the PsACWY group had SBA titers that were at least four times as high as those at baseline. The geometric mean SBA titers in the PsA-TT groups in studies A and B were greater by factors of 16 and 3, respectively, than they were in the PsACWY groups (P<0.001). In study A, the PsA-TT group had higher antibody titers at week 40 than the PsACWY group and had obvious immunologic memory after receiving a polysaccharide booster vaccine. Safety profiles were similar across vaccine groups, although PsA-TT recipients were more likely than PsACWY recipients to have tenderness and induration at the vaccination site. Adverse events were consistent with age-specific morbidity in the study areas; no serious vaccine-related adverse events were reported.
   Conclusions
   The PsA-TT vaccine elicited a stronger response to group A antibody than the PsACWY vaccine. (Funded by the Meningitis Vaccine Project through a grant from the Bill and Melinda Gates Foundation; Controlled-Trials.com numbers, ISRCTN78147026 and ISRCTN87739946.)
C1 [Sow, Samba O.; Tapia, Milagritos; Haidara, Fadima Cheick; Diallo, Fatoumata] Ctr Dev Vaccins, Bamako, Mali.
   [Okoko, Brown J.; Akinsola, Adebayo K.; Adegbola, Richard A.; Idoko, Olubukola T.] MRC Labs, Basse, Gambia.
   [Diallo, Aldiouma; Arduin, Pascal; Diop, Doudou] Inst Rech Dev, Dakar, Senegal.
   [Viviani, Simonetta; Chaumont, Julie; Martellet, Lionel; Tang, Yuxiao; Marchetti, Elisa; LaForce, F. Marc] Program Appropriate Technol Hlth, Meningitis Vaccine Project, Ferney Voltaire, France.
   [Borrow, Ray; Findlow, Helen] Hlth Protect Agcy NW, Vaccine Evaluat Unit, Manchester, Lancs, England.
   [Carlone, George; Elie, Cheryl; Plikaytis, Brian D.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Parulekar, Varsha] DiagnoSearch Life Sci, Bombay, Maharashtra, India.
   [Kulkarni, Prasad S.] Serum Inst India, Pune, Maharashtra, India.
   [Preziosi, Marie-Pierre] WHO, Initiat Vaccine Res, Meningitis Vaccine Project, CH-1211 Geneva 27, Switzerland.
RP Preziosi, MP (reprint author), WHO, Initiat Vaccine Res, Meningitis Vaccine Project, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
EM preziosim@who.int
FU Bill and Melinda Gates Foundation
FX Supported by the Meningitis Vaccine Project (MVP) through a grant from
   the Bill and Melinda Gates Foundation.
CR Andrews N, 2003, CLIN DIAGN LAB IMMUN, V10, P780, DOI 10.1128/CDLI.10.5.780-786.2003
   Auckland C, 2006, J INFECT DIS, V194, P1745, DOI 10.1086/509619
   Baxendale HE, 2010, VACCINE, V28, P4763, DOI 10.1016/j.vaccine.2010.04.103
   Black S, 2010, VACCINE, V28, P657, DOI 10.1016/j.vaccine.2009.10.104
   Borrow R, 2005, VACCINE, V23, P2222, DOI 10.1016/j.vaccine.2005.01.051
   Borrow R, 2000, VACCINE, V19, P1129, DOI 10.1016/S0264-410X(00)00317-0
   Campagne G, 1999, B WORLD HEALTH ORGAN, V77, P499
   CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154
   EMEA (The European Agency for the Evaluation of Medicinal Products), 2000, CPMPEWP48299 EMEA
   ERWA HH, 1973, B WORLD HEALTH ORGAN, V49, P301
   FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208
   *FOOD DRUG ADM, 2011, VACC MENV VACC BLOOD
   *FOOD DRUG ADM, 2009, MEN VACC BLOOD BIOL
   Frasch CE, 2009, VACCINE, V27, pB112, DOI 10.1016/j.vaccine.2009.04.065
   Greenwood B, 2006, TROP MED INT HEALTH, V11, P773, DOI 10.1111/j.1365-3156.2006.01639.x
   Guerin PJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000342
   HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8
   Jodar L, 2003, LANCET, V361, P1902, DOI 10.1016/S0140-6736(03)13494-0
   Keyserling H, 2005, ARCH PEDIAT ADOL MED, V159, P907, DOI 10.1001/archpedi.159.10.907
   Knuf M, 2010, VACCINE, V28, P744, DOI 10.1016/j.vaccine.2009.10.064
   Kshirsagar N, 2007, VACCINE, V25, pA101, DOI 10.1016/j.vaccine.2007.04.050
   LaForce FM, 2007, VACCINE, V25, pA97, DOI 10.1016/j.vaccine.2007.04.049
   LaForce FM, 2009, VACCINE, V27, pB13, DOI 10.1016/j.vaccine.2009.04.062
   LAPEYSSONNIE L, 1963, Bull World Health Organ, V28 Suppl, P1
   Maslanka SE, 1997, CLIN DIAGN LAB IMMUN, V4, P156
   MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211
   Molesworth AM, 2002, T ROY SOC TROP MED H, V96, P242, DOI 10.1016/S0035-9203(02)90089-1
   Pichichero M, 2005, PEDIATR INFECT DIS J, V24, P57, DOI 10.1097/01.inf.0000148928.10057.86
   Richmond P, 2001, J INFECT DIS, V183, P160, DOI 10.1086/317646
   Ruben FL, 2001, CLIN INFECT DIS, V32, P170, DOI 10.1086/317553
   Saliou P, 1978, Dev Biol Stand, V41, P97
   Teyssou R, 2007, VACCINE, V25, pA3, DOI 10.1016/j.vaccine.2007.04.032
   Trotter CL, 2007, LANCET INFECT DIS, V7, P797, DOI 10.1016/S1473-3099(07)70288-8
   WAHDAN MH, 1973, B WORLD HEALTH ORGAN, V48, P667
   World Health Organization, 1998, WHOEMCBAC983
   2009, WKLY EPIDEMIOL REC, V84, P117
   [Anonymous], 2005, WKLY EPIDEMIOL REC, V80, P313
NR 37
TC 102
Z9 102
U1 0
U2 8
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 16
PY 2011
VL 364
IS 24
BP 2293
EP 2304
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 777RZ
UT WOS:000291643800007
PM 21675889
OA No
DA 2017-08-15
ER

PT J
AU Ngom, PT
   Solon, J
   Moore, SE
   Morgan, G
   Prentice, AM
   Aspinall, R
AF Ngom, Pa T.
   Solon, Juan
   Moore, Sophie E.
   Morgan, Gareth
   Prentice, Andrew M.
   Aspinall, Richard
TI Thymic function and T cell parameters in a natural human experimental
   model of seasonal infectious diseases and nutritional burden
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
ID B-VIRUS-INFECTION; HEPATITIS-B; PLASMODIUM-FALCIPARUM;
   CYTOMEGALOVIRUS-INFECTION; PERIPHERAL-BLOOD; GAMBIAN MOTHERS;
   GUINEA-BISSAU; HIV-INFECTION; WEST-AFRICA; BREAST-MILK
AB Background: The study exploits a natural human experimental model of subsistence farmers experiencing chronic and seasonally modified food shortages and infectious burden. Two seasons existed, one of increased deprivation and infections (Jul-Dec), another of abundance and low infections (Jan-Jun); referred to as the hungry/high infection and harvest/low infection seasons respectively. Prior analysis showed a 10-fold excess in infectious disease associated mortality in young adults born in the hungry/high infection versus harvest/low infection season, and reduced thymic output and T cell counts in infancy. Here we report findings on the role of early life stressors as contributors to the onset of T cell immunological defects in later life.
   Methods: We hypothesised that season of birth effects on thymic function and T cell immunity would be detectable in young adults since Kaplan-Meier survival curves indicated this to be the time of greatest mortality divergence. T cell subset analyses by flow-cytometry, sjTRECs, TCRV beta repertoire and telomere length by PCR, were performed on samples from 60 males (18-23 y) selected to represent births in the hungry/high infection and harvest/low infection
   Results: Total lymphocyte counts were normal and did not differ by birth season. CD3(+) and CD4(+) but not CD8(+) counts were lower for those born during the hungry/high infection season. CD8(+) telomere length also tended to be shorter. Overall, CD8(+) TCRV beta repertoire skewing was observed with 'public' expressions and deletions seen in TCRV beta 12/22 and TCRV beta 24, respectively but no apparent effect of birth season.
   Conclusions: We conclude that, although thymic function was unchanged, the CD4(+) and CD3(+) counts, and CD8(+) telomere length results suggested that aspects of adult T cell immunity were under the influence of early life stressors. The endemicity of CMV and HBV suggested that chronic infections may modulate immunity through T cell repertoire development. The overall implications being that, this population is at an elevated risk of premature immunosenescence possibly driven by a combination of nutritional and infectious burden.
C1 [Ngom, Pa T.; Solon, Juan; Moore, Sophie E.; Morgan, Gareth; Prentice, Andrew M.] MRC Labs, Nutr Programme, Banjul, Gambia.
   [Prentice, Andrew M.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   [Aspinall, Richard] Cranfield Hlth, Translat Med, Cranfield, Beds, England.
RP Ngom, PT (reprint author), MRC Labs, Nutr Programme, Banjul, Gambia.
EM tngom@mrc.gm
RI Aspinall, Richard/E-4924-2013
OI Aspinall, Richard/0000-0002-1648-1887
FU MRC; IDB
FX We are grateful to the subjects who donated blood samples and to the
   Nutrition Program staff at Keneba. We thank the MRC and IDB for funding.
   This work was supported by the MRC and IDB Merit scholarship award.
CR Aaby P, 2002, ACTA PAEDIATR, V91, P698, DOI 10.1080/080352502760069142
   ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306
   ANDRADE CF, 2008, CELL IMMUNOL
   AREF GH, 1982, J TROP MED HYG, V85, P109
   Baum MK, 1997, J ACQ IMMUN DEF SYND, V15, P370
   BELLO C, 1991, J CLIN PATHOL, V44, P366, DOI 10.1136/jcp.44.5.366
   Beverley PCL, 2000, PHILOS T R SOC B, V355, P401
   Blattman JN, 2002, J EXP MED, V195, P657, DOI 10.1084/jem.20001021
   Blotta MH, 1996, J IMMUNOL, V156, P3133
   Bodey B, 1998, IN VIVO, V12, P599
   Brooks WA, 2004, LANCET, V363, P1683, DOI 10.1016/S0140-6736(04)16252-1
   Burns JB, 2000, EUR J IMMUNOL, V30, P1894, DOI 10.1002/1521-4141(200007)30:7<1894::AID-IMMU1894>3.0.CO;2-N
   Casanueva FF, 1999, FRONT NEUROENDOCRIN, V20, P317, DOI 10.1006/frne.1999.0187
   Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47
   Cermelli C, 2002, J TRACE ELEM MED BIO, V16, P41, DOI 10.1016/S0946-672X(02)80007-4
   Chevalier P, 2002, J ACQ IMMUN DEF SYND, V29, P427
   CHOTARD J, 1992, J INFECT DIS, V166, P764
   Currier JR, 1999, HUM IMMUNOL, V60, P209, DOI 10.1016/S0198-8859(98)00109-8
   Douek DC, 1998, NATURE, V396, P690
   Drakeley CJ, 2000, T ROY SOC TROP MED H, V94, P472, DOI 10.1016/S0035-9203(00)90056-7
   EVEN J, 1995, RES IMMUNOL, V146, P65, DOI 10.1016/0923-2494(96)80240-9
   Fillol F, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-116
   Foster HD, 2008, MED HYPOTHESES, V70, P21, DOI 10.1016/j.mehy.2007.05.008
   Garderet L, 1998, BLOOD, V91, P340
   Garly ML, 2008, J PEDIATR, V153, P683, DOI 10.1016/j.jpeds.2008.04.069
   Ginde AA, 2009, CURR ALLERGY ASTHM R, V9, P81, DOI 10.1007/s11882-009-0012-7
   Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0
   Hazenberg MD, 2000, NAT MED, V6, P1036
   HINGORANI R, 1993, J IMMUNOL, V151, P5762
   Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762
   Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357
   KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kou ZC, 2000, CLIN DIAGN LAB IMMUN, V7, P953, DOI 10.1128/CDLI.7.6.953-959.2000
   Lewin SR, 2002, J IMMUNOL, V169, P4657
   LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013
   LISSE IM, 1994, T ROY SOC TROP MED H, V88, P709, DOI 10.1016/0035-9203(94)90242-9
   Lisse IM, 1997, SCAND J IMMUNOL, V45, P637, DOI 10.1046/j.1365-3083.1997.d01-440.x
   LISSE IM, 1990, J IMMUNOL METHODS, V129, P49, DOI 10.1016/0022-1759(90)90419-V
   Maini MK, 2000, J EXP MED, V191, P1269, DOI 10.1084/jem.191.8.1269
   Maini MK, 2000, EUR J IMMUNOL, V30, P3067, DOI 10.1002/1521-4141(200011)30:11<3067::AID-IMMU3067>3.0.CO;2-L
   MARTINEZ D, 1975, J NATL CANCER I, V55, P935
   McFarland RD, 2000, P NATL ACAD SCI USA, V97, P4215, DOI 10.1073/pnas.070061597
   McMurray D N, 1990, Prog Clin Biol Res, V325, P403
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Mueller SN, 2006, J IMMUNOL, V176, P7379
   MULHOLLAND K, 1995, LANCET, V346, P1554, DOI 10.1016/S0140-6736(95)92082-X
   Najera O, 2007, CLIN EXP IMMUNOL, V148, P501, DOI 10.1111/j.1365-2249.2007.03369.x
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   Ogunro P S, 2006, Niger Postgrad Med J, V13, P1
   Poskitt EM, 1999, ARCH DIS CHILD, V80, P119, DOI DOI 10.1136/ADC.80.2.115
   Poskitt EME, 1999, ARCH DIS CHILD, V80, P115
   PRENTICE A, 1984, ACTA PAEDIATR SCAND, V73, P803, DOI 10.1111/j.1651-2227.1984.tb17779.x
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   PRENTICE AM, 1994, P NUTR SOC, V53, P509, DOI 10.1079/PNS19940061
   Rowland M G, 1986, Dialogue Diarrhoea, P3
   Sazawal S, 1997, Indian Pediatr, V34, P589
   SLATER AFG, 1986, PARASITOLOGY, V93, P177
   Son NH, 2000, J IMMUNOL, V165, P1191
   Staszewski S, 1999, AIDS, V13, P951, DOI 10.1097/00002030-199905280-00011
   Talvensarri K, 2002, BLOOD, V99, P1458, DOI 10.1182/blood.V99.4.1458
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000492
   van der Sande MAB, 2007, PLOS ONE, V2, pe753
   Weng NP, 2008, MECH AGEING DEV, V129, P60, DOI 10.1016/j.mad.2007.11.005
   Worku S, 1997, CLIN EXP IMMUNOL, V108, P34, DOI 10.1046/j.1365-2249.1997.d01-981.x
   Yao XS, 2007, CELL MOL IMMUNOL, V4, P215
   Yarilin AA, 2004, CURR MED CHEM, V11, P447, DOI 10.2174/0929867043455972
NR 70
TC 7
Z9 9
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1021-7770
EI 1423-0127
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD JUN 15
PY 2011
VL 18
AR 41
DI 10.1186/1423-0127-18-41
PG 11
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 786OB
UT WOS:000292316700001
PM 21676219
OA gold
DA 2017-08-15
ER

PT J
AU Pinder, M
   Jawara, M
   Jarju, LBS
   Kandeh, B
   Jeffries, D
   Lluberas, MF
   Mueller, J
   Parker, D
   Bojang, K
   Conway, DJ
   Lindsay, SW
AF Pinder, Margaret
   Jawara, Musa
   Jarju, Lamin B. S.
   Kandeh, Ballah
   Jeffries, David
   Lluberas, Manuel F.
   Mueller, Jenny
   Parker, David
   Bojang, Kalifa
   Conway, David J.
   Lindsay, Steve W.
TI To assess whether indoor residual spraying can provide additional
   protection against clinical malaria over current best practice of
   long-lasting insecticidal mosquito nets in The Gambia: study protocol
   for a two-armed cluster-randomised trial
SO TRIALS
LA English
DT Article
ID TREATED BED NETS; WEST-AFRICA; RURAL AREA; TARGETED CHEMOPROPHYLAXIS;
   UNTREATED BEDNETS; CHILDREN; MORTALITY; MORBIDITY; TANZANIA; COMPLEX
AB Background: Recently, there has been mounting interest in scaling-up vector control against malaria in Africa. It needs to be determined if indoor residual spraying (IRS with DDT) will provide significant marginal protection against malaria over current best practice of long-lasting insecticidal nets (LLINs) and prompt treatment in a controlled trial, given that DDT is currently the most persistent insecticide for IRS.
   Methods: A 2 armed cluster-randomised controlled trial will be conducted to assess whether DDT IRS and LLINs combined provide better protection against clinical malaria in children than LLINs alone in rural Gambia. Each cluster will be a village, or a group of small adjacent villages; all clusters will receive LLINs and half will receive IRS in addition. Study children, aged 6 months to 13 years, will be enrolled from all clusters and followed for clinical malaria using passive case detection to estimate malaria incidence for 2 malaria transmission seasons in 2010 and 2011. This will be the primary endpoint. Exposure to malaria parasites will be assessed using light and exit traps followed by detection of Anopheles gambiae species and sporozoite infection. Study children will be surveyed at the end of each transmission season to estimate the prevalence of Plasmodium falciparum infection and the prevalence of anaemia.
   Discussion: Practical issues concerning intervention implementation, as well as the potential benefits and risks of the study, are discussed.
C1 [Pinder, Margaret; Conway, David J.; Lindsay, Steve W.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Jawara, Musa; Jeffries, David; Mueller, Jenny; Parker, David; Bojang, Kalifa; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Jarju, Lamin B. S.; Kandeh, Ballah] Natl Malaria Control Programme, Banjul, Gambia.
   [Lluberas, Manuel F.] HD Hudson Mfg Co, Chicago, IL 60611 USA.
RP Lindsay, SW (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM Steve.Lindsay@lshtm.ac.uk
OI Bojang, Kalifa/0000-0001-7506-0938; Conway, David/0000-0002-8711-3037
FU Medical Research Council, UK; Malaria Centre at the London School of
   Hygiene and Tropical Medicine; Science and Technology Directory,
   Department of Homeland Security; Fogarty International Center, National
   Institutes of Health
FX The study was supported by the Medical Research Council, UK, the Malaria
   Centre at the London School of Hygiene and Tropical Medicine, the
   Research and Policy for Infectious Disease Dynamics (RAPIDD) Program of
   the Science and Technology Directory, Department of Homeland Security,
   and Fogarty International Center, National Institutes of Health.
   Research Ethics Committee reference Number: The Gambian Government/MRC
   Laboratories Joint Ethics Committee L2010.19; LSHTM 5592 Grant Reference
   Number: MRC GO900220
CR ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P13, DOI 10.1016/0035-9203(93)90170-U
   Bennett S, 2002, INT J EPIDEMIOL, V31, P839, DOI 10.1093/ije/31.4.839
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   Dunn J. C., 1973, Journal of Cybernetics, V3, P32
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319
   Howard SC, 2000, T ROY SOC TROP MED H, V94, P357, DOI 10.1016/S0035-9203(00)90103-2
   Jowett M, 2005, INT J HEALTH PLAN M, V20, P67, DOI 10.1002/hpm.796
   Kelly AH, 2010, SOC SCI MED, V70, P1912, DOI 10.1016/j.socscimed.2010.02.012
   Kirby MJ, 2010, AM J TROP MED HYG, V83, P965, DOI [10.4269/ajtmh.2010.10-0311, 10.4269/ajtmh.2010.10.0311]
   Kirby MJ, 2008, PARASITE VECTOR, V1, DOI 10.1186/1756-3305-1-41
   Kouznetsov R L, 1977, Trop Doct, V7, P81
   Lengeler C, 2009, COCHRANE REV
   Lengeler C., 2003, REDUCING MALARIAS BU, P17
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P45, DOI 10.1016/0035-9203(93)90175-P
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P253, DOI 10.1111/j.1365-2915.1989.tb00225.x
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P263, DOI 10.1111/j.1365-2915.1989.tb00226.x
   MAGESA SM, 1991, ACTA TROP, V49, P97, DOI 10.1016/0001-706X(91)90057-Q
   MANLY BFJ, 1997, RANDOMIZATION BOOTST, P2
   Moorthy Vasee, 2007, Vaccine, V25, P5115, DOI 10.1016/j.vaccine.2007.01.085
   O'Meara W, 2010, LANCET INFECT DIS, V10, P505
   Pluess B, 2010, COCHRANE REV
   Quinones ML, 1998, T ROY SOC TROP MED H, V92, P373, DOI 10.1016/S0035-9203(98)91053-7
   Rabe-Hesketh S., 2008, MULTILEVEL LONGITUDI
   Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a
   SATOGUINA J, 2009, MALARIA J, V8
   Schellenberg DM, 2003, T ROY SOC TROP MED H, V97, P647, DOI 10.1016/S0035-9203(03)80096-2
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   SMITH A, 1969, B ENTOMOL RES, V59, P33
   Smith PG, 1996, FIELD TRIALS HLTH IN
   SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6
   von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X
   WHO, 2000, M FUT DIR ROT VACC R, P1
   World Health Organization (WHO), 2007, US DDT MAL VECT CONT
   World Health Organization, 2006, INN WORK DOC, P1
   WHO, 2008, WORLD MAL REP 2008, P190
   *WHO, 2006, PEST THEIR APPL CONT, P6
   WIRTZ RA, 1989, B WORLD HEALTH ORGAN, V67, P535
   Xu BZ, 1998, T ROY SOC TROP MED H, V92, P135
NR 43
TC 9
Z9 9
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD JUN 10
PY 2011
VL 12
AR 147
DI 10.1186/1745-6215-12-147
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 782HG
UT WOS:000291998500001
PM 21663656
OA gold
DA 2017-08-15
ER

PT J
AU Dunyo, S
   Sirugo, G
   Sesay, S
   Bisseye, C
   Njie, F
   Adiamoh, M
   Nwakanma, D
   Diatta, M
   Janha, R
   Joof, FS
   Temple, B
   Snell, P
   Conway, D
   Walton, R
   Cheung, YB
   Milligan, P
AF Dunyo, Samuel
   Sirugo, Giorgio
   Sesay, Sanie
   Bisseye, Cyrille
   Njie, Fanta
   Adiamoh, Majidah
   Nwakanma, Davis
   Diatta, Mathurin
   Janha, Ramatoulie
   Joof, Fatou Sisay
   Temple, Beth
   Snell, Paul
   Conway, David
   Walton, Robert
   Cheung, Yin Bun
   Milligan, Paul
TI Randomized Trial of Safety and Effectiveness of Chlorproguanil-Dapsone
   and Lumefantrine-Artemether for Uncomplicated Malaria in Children in The
   Gambia
SO PLOS ONE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE
   DEFICIENCY; SULFADOXINE-PYRIMETHAMINE; ANTIMALARIAL-DRUGS; AFRICAN
   CHILDREN; BLIND; G6PD; ARTESUNATE; POLYMORPHISM; POPULATION
AB Background: Chlorproguanil-dapsone (Lapdap), developed as a low-cost antimalarial, was withdrawn in 2008 after concerns about safety in G6PD deficient patients. This trial was conducted in 2004 to evaluate the safety and effectiveness of CD and comparison with artemether-lumefantrine (AL) under conditions of routine use in G6PD normal and G6PD deficient patients with uncomplicated malaria in The Gambia. We also examined the effects of a common genetic variant that affects chlorproguanil metabolism on risk of treatment failure.
   Methods: 1238 children aged 6 months to 10 years with uncomplicated malaria were randomized to receive CD or artemether-lumefantrine (AL) and followed for 28 days. The first dose was supervised, subsequent doses given unsupervised at home. G6PD genotype was determined to assess the interaction between treatment and G6PD status in their effects on anaemia. The main endpoints were clinical treatment failure by day 28, incidence of severe anaemia (Hb<5 g/dL), and haemoglobin concentration on day 3.
   Findings: One third of patients treated with AL, and 6% of patients treated with CD, did not complete their course of medication. 18% (109/595) of children treated with CD and 6.1% (36/587) with AL required rescue medication within 4 weeks, risk difference 12% (95% CI 8.9%-16%). 23 children developed severe anaemia (17 (2.9%) treated with CD and 6 (1.0%) with AL, risk difference 1.8%, 95% CI 0.3%-3.4%, P = 0.02). Haemoglobin concentration on day 3 was lower among children treated with CD than AL (difference 0.43 g/dL, 95% CI 0.24 to 0.62), and within the CD group was lower among those children who had higher parasite density at enrolment. Only 17 out of 1069 children who were typed were G6PD A-deficient, of these 2/9 treated with CD and 1/8 treated with AL developed severe anaemia. 5/9 treated with CD had a fall of 2 g/dL or more in haemoglobin concentration by day 3.
   Interpretation: AL was well tolerated and highly effective and when given under operational conditions despite poor adherence to the six-dose regimen. There were more cases of severe malaria and anaemia after CD treatment although G6PD deficiency was uncommon.
C1 [Dunyo, Samuel; Sirugo, Giorgio; Sesay, Sanie; Bisseye, Cyrille; Njie, Fanta; Adiamoh, Majidah; Nwakanma, Davis; Diatta, Mathurin; Janha, Ramatoulie; Joof, Fatou Sisay; Snell, Paul; Conway, David; Walton, Robert] MRC Labs, Banjul, Gambia.
   [Temple, Beth; Cheung, Yin Bun; Milligan, Paul] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England.
RP Dunyo, S (reprint author), MRC Labs, Banjul, Gambia.
EM paul.milligan@lshtm.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Walton, Robert/0000-0001-7700-1907;
   Conway, David/0000-0002-8711-3037
FU Medical Research Council
FX The study was funded by the Medical Research Council. CD was supplied by
   GSK pharmaceuticals. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abdulla S, 2008, LANCET, V372, P1819, DOI 10.1016/S0140-6736(08)61492-0
   Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2
   Amin AA, 2004, TROP MED INT HEALTH, V9, P967, DOI 10.1111/j.1365-3156.2004.01291.x
   Amukoye E, 1997, ANTIMICROB AGENTS CH, V41, P2261
   Beutler E, 2007, AM J TROP MED HYG, V77, P779
   Boxtel C. J. van, 2005, International Journal of Risk & Safety in Medicine, V17, P169
   Clark TG, 2009, EUR J HUM GENET, V17, P1080, DOI 10.1038/ejhg.2009.8
   De Araujo C, 2006, HAEMATOL-HEMATOL J, V91, P262
   DEGOWIN RL, 1966, B WORLD HEALTH ORGAN, V35, P165
   DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
   DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014
   Duraisingh MT, 1998, EXP PARASITOL, V89, P1, DOI 10.1006/expr.1998.4274
   Fanello CI, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004031
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Guindo A, 2007, PLOS MED, V4, P516, DOI 10.1371/journal.pmed.0040066
   Krattiger A, 2007, EXECUTIVE GUIDE INTE
   Lang T, 2006, LANCET INFECT DIS, V6, P46, DOI 10.1016/S1473-3099(05)70326-1
   Lang T, 2003, LANCET INFECT DIS, V3, P162, DOI 10.1016/S1473-3099(03)00547-4
   LUZZATTO L, 1998, OXFORD TXB MED, P3537
   Luzzatto L, 2010, LANCET, V376, P739, DOI 10.1016/S0140-6736(10)60396-0
   May J, 2000, TROP MED INT HEALTH, V5, P119, DOI 10.1046/j.1365-3156.2000.00529.x
   Mockenhaupt FP, 2005, TROP MED INT HEALTH, V10, P512, DOI 10.1111/j.1365-3156.2005.01427.x
   Premji Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006682
   ROGERS L, 2005, SUNDAY TIMES    0612
   Schoepflin S, 2010, AM J TROP MED HYG, V82, P529, DOI 10.4269/ajtmh.2010.09-0334
   Sirugo G, 2004, AM J MED GENET A, V128A, P104, DOI 10.1002/ajmg.a.30080
   Sulo J, 2002, LANCET, V360, P1136, DOI 10.1016/S0140-6736(02)11198-6
   VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90080-N
   Walton R, 2005, NAT GENET, V37, P915, DOI 10.1038/ng0905-915
   *WHO, 2008, QSMMCIEA117 WHO
   *WHO, 2004, REV SAF CHLORPR TREA
   Winstanley P, 1997, T ROY SOC TROP MED H, V91, P322, DOI 10.1016/S0035-9203(97)90093-6
   Winstanley P, 2001, TROP MED INT HEALTH, V6, P952, DOI 10.1046/j.1365-3156.2001.00751.x
   Yeung S, 2005, TROP MED INT HEALTH, V10, P121, DOI 10.1111/j.1365-3156.2004.01364.x
NR 35
TC 14
Z9 14
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 7
PY 2011
VL 6
IS 6
AR e17371
DI 10.1371/journal.pone.0017371
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 777HR
UT WOS:000291607000002
PM 21666744
OA gold
DA 2017-08-15
ER

PT J
AU Ideh, RC
   Howie, SRC
   Ebruke, B
   Secka, O
   Greenwood, BM
   Adegbola, RA
   Corrah, T
AF Ideh, R. C.
   Howie, S. R. C.
   Ebruke, B.
   Secka, O.
   Greenwood, B. M.
   Adegbola, R. A.
   Corrah, T.
TI Transthoracic lung aspiration for the aetiological diagnosis of
   pneumonia: 25 years of experience from The Gambia
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Review
DE lung aspiration; pneumonia; Gambia; Africa; children
ID LOWER-RESPIRATORY-TRACT; COMMUNITY-ACQUIRED PNEUMONIA; SPUTUM INDUCTION;
   BRONCHOALVEOLAR LAVAGE; BLOOD CULTURES; YOUNG-CHILDREN; TRANSTRACHEAL
   ASPIRATION; EMERGENCY-DEPARTMENT; LOBAR PNEUMONIA; ADULT PATIENTS
AB Pneumonia remains the leading cause of death in young children worldwide. Global pneumonia control depends on a good understanding of the aetiology of pneumonia. Percutaneous transthoracic aspiration culture is much more sensitive than blood culture in identifying the aetiological agents of pneumonia. However, the procedure is not widely practised because of lack of familiarity with it and concerns about potential adverse events. We review the diagnostic usefulness and safety of this procedure over 25 years of its use in research and routine practice at the UK Medical Research Council (MRC), The Gambia, and give a detailed description of the procedure itself. Published materials were identified from the MRC's publication database and systematic searches using the PubMed/Medline and Google search engines. Data from a current pneumonia aetiology study in the unit are included together with clinical experience of SUMMARY staff practising at the unit over the period covered in this review. A minimum of 500 lung aspirates were performed over the period of review. Lung aspiration produces a greater yield of diagnostic bacterial isolates than blood culture. It is especially valuable clinically when pathogens not covered by standard empirical antibiotic treatment, such as Mycobacterium tuberculosis and Staphylococcus aureus, are identified. There have been no deaths following the procedure in our setting and a low rate of other complications, all transient. Lung aspiration is currently the most sensitive method for diagnosing pneumonia in children. With appropriate training and precautions it can be safely used for routine diagnosis in suitable referral hospitals.
C1 [Ideh, R. C.; Corrah, T.] MRC Labs, Clin Serv Dept, Banjul, Gambia.
   [Howie, S. R. C.; Ebruke, B.; Secka, O.; Adegbola, R. A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Greenwood, B. M.] London Sch Hyg & Trop Med, London WC1, England.
   [Adegbola, R. A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Ideh, RC (reprint author), MRC Labs, Clin Serv Dept, POB 273, Banjul, Gambia.
EM rideh@mrc.gm
FU Medical Research Council [MC_UP_A900_1124, MC_U190088478]
CR ABRAMSON O, 1995, ARCH PEDIAT ADOL MED, V149, P1237
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   BATES JH, 1992, CHEST, V101, P1005, DOI 10.1378/chest.101.4.1005
   BERMAN SZ, 1975, J ALLERGY CLIN IMMUN, V56, P206, DOI 10.1016/0091-6749(75)90091-3
   Bullowa J, 1937, MANAGEMENT PNEUMONIA
   Campbell SG, 2003, EMERG MED J, V20, P521, DOI 10.1136/emj.20.6.521
   Campbell SG, 2003, CHEST, V123, P1142, DOI 10.1378/chest.123.4.1142
   Cham G, 2009, ANN ACAD MED SINGAP, V38, P508
   CUNANAN GD, 1979, PHILIPP J PEDIATR, V28, P169
   DONATELLA D, 2002, AIDS, V16, P105
   Eren S, 2004, PEDIATR INT, V46, P580, DOI 10.1111/j.1442-200x.2004.01957.x
   Falade AG, 1997, ANN TROP PAEDIATR, V17, P315
   FOOT ABM, 1992, J INFECTION, V24, P49, DOI 10.1016/0163-4453(92)90954-5
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   FRANKEL L, 1988, PEDIATRICS, V81, P765
   *GAMB CENTR STAT D, 2003, 2003 CENS
   Gomes JCP, 2000, CHEST, V118, P1739
   HENDERSON AJW, 1994, ARCH DIS CHILD, V70, P167
   Jones PD, 2001, AM J RESP CRIT CARE, V164, P1146
   KAHN FW, 1987, J INFECT DIS, V155, P862
   KALINSKE RW, 1967, NEW ENGL J MED, V276, P604, DOI 10.1056/NEJM196703162761103
   LAURENZI GA, 1961, NEW ENGL J MED, V265, P1273, DOI 10.1056/NEJM196112282652601
   LEES AW, 1959, LANCET, V2, P1112
   Lyon AB, 1922, AM J DIS CHILD, V23, P72
   MIMICA I, 1971, AM J DIS CHILD, V122, P278
   MOSER KM, 1982, AM REV RESPIR DIS, V125, P436
   Obaro SK, 2006, LANCET INFECT DIS, V6, P150, DOI 10.1016/S1473-3099(06)70411-X
   PECORA DV, 1958, NEW ENGL J MED, V258, P71, DOI 10.1056/NEJM195801092580204
   Qazi S, 2008, GLOB ACT PLAN PREV C
   SCHUSTER A, 1968, Pediatrics, V42, P647
   Scott JAG, 2008, PLOS MED, V5, P548, DOI 10.1371/journal.pmed.0050086
   Scott JAG, 1999, CHEST, V116, P1716, DOI 10.1378/chest.116.6.1716
   Scott JAG, 2003, J CLIN MICROBIOL, V41, P2554, DOI 10.1128/JCM.41.6.2554-2559.2003
   Scott JAG, 2000, LANCET, V355, P1225, DOI 10.1016/S0140-6736(00)02089-4
   SHANN F, 1984, LANCET, V2, P537
   SPRINGMEYER SC, 1986, J INFECT DIS, V154, P604
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   WESLEY A G, 1971, South African Medical Journal, V45, P1402
   *WHO, 2003, WHOFCHCAH039
   *WHO, 2004, GLOB BURD DIS REP 2
   ZALACAIN R, 1993, MED CLIN-BARCELONA, V100, P567
   Zar HJ, 2000, ARCH DIS CHILD, V82, P305, DOI 10.1136/adc.82.4.305
   Zar HJ, 2003, PEDIATR PULM, V36, P58, DOI 10.1002/ppul.10302
NR 44
TC 11
Z9 11
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD JUN
PY 2011
VL 15
IS 6
BP 729
EP 735
DI 10.5588/ijtld.10.0468
PG 7
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 805KH
UT WOS:000293724800005
PM 21477423
OA No
DA 2017-08-15
ER

PT J
AU Faye, B
   Bucheton, B
   Banuls, AL
   Senghor, MW
   Niang, AA
   Diedhiou, S
   Konate, O
   Dione, MM
   Hide, M
   Mellul, S
   Knecht, R
   Delaunay, P
   Marty, P
   Gaye, O
AF Faye, Babacar
   Bucheton, Bruno
   Banuls, Anne Laure
   Senghor, Massila Wague
   Niang, Abdoul Aziz
   Diedhiou, Souleymane
   Konate, Oumar
   Dione, Michel Mainack
   Hide, Mallorie
   Mellul, Sandra
   Knecht, Romy
   Delaunay, Pascal
   Marty, Pierre
   Gaye, Oumar
TI Seroprevalence of Leishmania infantum in a rural area of Senegal:
   analysis of risk factors involved in transmission to humans
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE Leishmaniasis; Leishmania infantum; Serology; Epidemiology; Risk
   factors; Senegal
ID WESTERN-BLOT-ANALYSIS; VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS;
   INFECTION; DONORS; HIV; COINFECTION; DIAGNOSIS; ANTIGENS; CHAGASI
AB Whereas Leishmania infantum, the agent of visceral leishmaniasis (VL), is well known in North Africa, very limited data exist on its spread in West Africa, where mainly cutaneous leishmaniasis has been widely reported. Nevertheless, dogs infected with L. infantum were recently found in the Mont Rolland District in Senegal. To provide a better understanding of L. infantum epidemiology in this area, clinical and serological surveys were carried out to determine the seroprevalence of L. infantum-specific antibodies in the human population. In parallel, an analysis of environmental and individual factors associated with Leishmania antigen seropositivity was conducted to identify potential risk factors for exposure. Although no cases of VL were detected within this study, a large part of the population (73/315; 23%) was exposed to infection, with a strong age effect (being >40 years old increased the risk of being seropositive). Moreover, the presence of Nebedaye trees (Moringa oleifera) and infected dogs in the household were factors increasing the risk of exposure in household members. These results may provide important information to identify the still unknown sandfly species involved in transmission. (C) 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 [Faye, Babacar; Diedhiou, Souleymane; Konate, Oumar; Gaye, Oumar] Univ Cheikh Anta Diop, Fac Med & Pharm, Serv Parasitol & Mycol, Dakar, Senegal.
   [Bucheton, Bruno] IRD CIRAD, UMR 177, Bobo Dioulasso, Burkina Faso.
   [Banuls, Anne Laure; Hide, Mallorie] IRD CNRS UM1, UMR 2724, F-34394 Montpellier, France.
   [Senghor, Massila Wague; Niang, Abdoul Aziz] Univ Cheikh Anta Diop, IFAN, Dakar, Senegal.
   [Dione, Michel Mainack] ITC, Banjul, Gambia.
   [Mellul, Sandra; Knecht, Romy; Delaunay, Pascal; Marty, Pierre] CHU Nice, Hop Archet 2, Lab Parasitol Mycol, Nice, France.
RP Faye, B (reprint author), Univ Cheikh Anta Diop, Fac Med & Pharm, Serv Parasitol & Mycol, BP 5005 Dakar Fann, Dakar, Senegal.
EM bfaye67@yahoo.fr
OI Banuls, Anne-Laure/0000-0002-2106-8667
FU Agence Universitaire de la Francophonie (AUF), Paris, France; Centre
   National de la Recherche Scientifique (CNRS), Paris, France; Institut de
   Recherche pour le Developpement (IRD), Marseille, France; Agence
   Nationale de la Recherche (ANR), Paris, France
FX Agence Universitaire de la Francophonie (AUF), Paris, France; Centre
   National de la Recherche Scientifique (CNRS), Paris, France; Institut de
   Recherche pour le Developpement (IRD), Marseille, France; and Agence
   Nationale de la Recherche (ANR), Paris, France
CR Ajdary S, 2000, INFECT IMMUN, V68, P1760, DOI 10.1128/IAI.68.4.1760-1764.2000
   Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07
   Ba Y., 1998, Parasite, V5, P143
   Badaro R, 1996, J INFECT DIS, V173, P758
   Braz RFS, 2002, AM J TROP MED HYG, V67, P344
   CHANCE ML, 1981, BRIT MED J, V6301, P1245
   *CONS NAT LUTT SID, 2007, PLAN STRAT LUTT SID
   Dereure J, 2003, MICROBES INFECT, V5, P1103, DOI 10.1016/j.micinf.2003.07.003
   DESJEUX P, 1982, T ROY SOC TROP MED H, V76, P132, DOI 10.1016/0035-9203(82)90041-4
   Develoux M, 1996, T ROY SOC TROP MED H, V90, P396, DOI 10.1016/S0035-9203(96)90520-9
   EHOLIE SP, 2008, B SOC PATHOL EXOT, V1, P60
   Faye B, 2010, MICROBES INFECT, V12, P1219, DOI 10.1016/j.micinf.2010.09.003
   Guiguemde RT, 2003, T ROY SOC TROP MED H, V97, P168, DOI 10.1016/S0035-9203(03)90109-X
   Hartzell JD, 2008, AM J TROP MED HYG, V79, P843
   Kubar J, 1997, NAT MED, V3, P368, DOI 10.1038/nm0497-368
   le Fichoux Y, 1999, J CLIN MICROBIOL, V37, P1953
   MARTY P, 1994, T ROY SOC TROP MED H, V88, P658, DOI 10.1016/0035-9203(94)90214-3
   Marty P, 1995, T ROY SOC TROP MED H, V89, P690, DOI 10.1016/0035-9203(95)90447-6
   MARY C, 1992, AM J TROP MED HYG, V47, P764
   Ndongo S, 2004, Dakar Med, V49, P207
   NIAMBA P, 2006, ANN DERMATOL VENER, V6, P537
   Ranque P, 1970, Bull Acad Natl Med, V154, P510
   Ranque P, 1974, Bull Soc Pathol Exot Filiales, V67, P167
   Riera C, 2004, T ROY SOC TROP MED H, V98, P102, DOI 10.1016/S0035-9203(03)00015-4
   RIERA C, 2008, TRANSFUSION, V7, P1383
   Rosenthal E, 2000, CLIN INFECT DIS, V31, P1093, DOI 10.1086/318135
   Rosenthal E, 2000, ANN TROP MED PARASIT, V94, P37, DOI 10.1080/00034980057590
   Sacks D L, 1988, Mem Inst Oswaldo Cruz, V83 Suppl 1, P506
   SUFFIA JF, 1995, INFECT IMMUN, V63, P3765
   Traore KS, 2001, B SOC PATHOL EXOT, V94, P52
   VALCARCEL Y, 2008, ENFERM INFEC MICR CL, V5, P278
   WALTERS JH, 1949, T ROY SOC TROP MED H, V43, P287, DOI 10.1016/0035-9203(49)90005-X
NR 32
TC 11
Z9 11
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUN
PY 2011
VL 105
IS 6
BP 333
EP 340
DI 10.1016/j.trstmh.2011.02.009
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 780IS
UT WOS:000291848500006
PM 21543098
OA No
DA 2017-08-15
ER

PT J
AU Diness, BR
   Martins, CL
   Bale, C
   Garly, ML
   Ravn, H
   Rodrigues, A
   Whittle, H
   Aaby, P
   Benn, CS
AF Diness, Birgitte R.
   Martins, Cesario L.
   Bale, Carlitos
   Garly, May-Lill
   Ravn, Henrik
   Rodrigues, Amabelia
   Whittle, Hilton
   Aaby, Peter
   Benn, Christine S.
TI The effect of high-dose vitamin A supplementation at birth on measles
   incidence during the first 12 months of life in boys and girls: an
   unplanned study within a randomised trial
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Vitamin A; Sex differences; Measles; Infant mortality
ID GUINEA-BISSAU; BCG VACCINE; MORTALITY; CHILDREN; INFANTS; AGE
AB Vitamin A treatment reduces mortality during acute measles infection, and vitamin A supplementation (VAS) to children above 6 months of age may reduce the incidence of measles infection. The effect of VAS at birth on measles incidence is unknown. In a randomised placebo-controlled trial in Guinea-Bissau, normal-birth-weight newborns were randomised to 50 000 IU (15 mg) VAS or placebo. During the trial, a measles epidemic occurred. We linked data from the trial with data from the measles infection surveillance and studied the effect of VAS on the measles incidence before 12 months of age in both sexes. A total of 165 measles cases were identified among the 4183 children followed from 28 d of age. Up to 6 months of age, the incidence rate ratio of measles for VAS compared with placebo was 0.54 (95% CI 0.25, 1.15) among boys and 1.57 (95% CI 0.80, 3.08) among girls (test of interaction, P=0.04). The corresponding figures at 12 months were 0.67 (95% CI 0.43, 1.05) and 1.17 (95% CI 0.76, 1.79) (test of interaction, P=0.08). VAS compared with placebo tended to be associated with less measles hospitalisation or death during the first 6 months of life in boys (P=0.06), but not in girls. VAS at birth may affect the susceptibility to measles infection during the first 6 months of life in a sex-differential manner.
C1 [Diness, Birgitte R.; Martins, Cesario L.; Bale, Carlitos; Garly, May-Lill; Ravn, Henrik; Rodrigues, Amabelia; Aaby, Peter; Benn, Christine S.] INDEPTH Network, Bandim Hlth Project, Fajara, Gambia.
   [Diness, Birgitte R.; Martins, Cesario L.; Bale, Carlitos; Garly, May-Lill; Ravn, Henrik; Rodrigues, Amabelia; Aaby, Peter; Benn, Christine S.] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   [Whittle, Hilton] MRC, Fajara, Gambia.
RP Benn, CS (reprint author), INDEPTH Network, Bandim Hlth Project, Fajara, Gambia.
EM cb@ssi.dk
FU March of Dimes; European Commission [ICA4-CT-2002-10053]; Danish Medical
   Research Council; University of Copenhagen; Novo Nordisk Foundation;
   Ville Heise Foundation; DANIDA; Danish National Research Foundation
FX C. S. B., H. W., A. R. and P. A. designed the VAS study and obtained
   funding. C. S. B. and P. A. initiated enrolment in the randomised trial.
   M.-L. G., C. L. M., H. W. and P. A. planned the measles studies. C. L.
   M., C. B. and P. A. H. conducted the investigation of suspected measles
   cases. H. W. analysed the serological samples. B. R. D. supervised the
   follow-up visits. H. R. provided the statistical support. B. R. D. wrote
   the first draft of the manuscript. All authors contributed to the final
   version. The study was supported by March of Dimes, the European
   Commission, Specific International Scientific Cooperation Activities
   (INCO) programme (contract no. ICA4-CT-2002-10053), the Danish Medical
   Research Council, University of Copenhagen, the Novo Nordisk Foundation
   and the Ville Heise Foundation. The BHP received support from DANIDA and
   the Danish National Research Foundation. P. A. holds a research
   professorship grant from the Novo Nordisk Foundation. None of the
   authors has conflicts of interest.
CR Beaton G., 1993, EFFECTIVENESS VITAMI
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn CS, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1101
   Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5
   BENN CS, 2006, J INFECT DIS, V194, P721, DOI 10.1086/506457
   Dollimore N, 1997, AM J EPIDEMIOL, V146, P646
   FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898
   Fisker AB, 2007, AM J CLIN NUTR, V86, P1032
   HUSSEY GD, 1993, J TROP PEDIATRICS, V39, P342
   Martins C, 2009, VACCINE, V27, P5220, DOI 10.1016/j.vaccine.2009.06.076
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
NR 11
TC 8
Z9 8
U1 0
U2 5
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD JUN
PY 2011
VL 105
IS 12
BP 1819
EP 1822
DI 10.1017/S0007114510005532
PG 4
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 782CH
UT WOS:000291984700015
PM 21294931
OA No
DA 2017-08-15
ER

PT J
AU Wille, E
   Scholze, J
   Alegria, E
   Ferri, C
   Langham, S
   Stevens, W
   Jeffries, D
   Uhl-Hochgraeber, K
AF Wille, Eberhard
   Scholze, Juergen
   Alegria, Eduardo
   Ferri, Claudio
   Langham, Sue
   Stevens, Warren
   Jeffries, David
   Uhl-Hochgraeber, Kerstin
TI Modelling the costs of care of hypertension in patients with metabolic
   syndrome and its consequences, in Germany, Spain and Italy
SO EUROPEAN JOURNAL OF HEALTH ECONOMICS
LA English
DT Article
DE Cost of illness; Health care costs; Prevalence; Metabolic syndrome;
   Hypertension
ID BLOOD-PRESSURE CONTROL; CARDIOVASCULAR-DISEASE; EUROPEAN-SOCIETY;
   LIFE-EXPECTANCY; HEART-DISEASE; RISK PROFILE; TASK-FORCE; PREVALENCE;
   POPULATION; STROKE
AB The presence of metabolic syndrome in patients with hypertension significantly increases the risk of cardiovascular disease, type 2 diabetes and mortality. Our aim is to estimate the economic burden to the health service of metabolic syndrome (MetS) in patients with hypertension and its consequences, in three European countries in 2008, and to forecast future economic burden in 2020 using projected demographic estimates and assumptions around the growth of MetS. An age-, sex- and risk group-structured prevalence-based cost of illness model was developed using the United States Adult Treatment Panel III of the National Cholesterol Education Program criteria to define MetS. Data sources included published information and public use databases on disease prevalence, incidence of cardiovascular events, prevalence of type 2 diabetes, treatment patterns and cost of management in Germany, Spain and Italy. The economic burden to the health service of MetS in patients with hypertension has been estimated at 24,427 a,not sign, 1,900 a,not sign and 4,877 a,not sign million in Germany, Spain and Italy, and is forecast to rise by 59, 179 and 157%, respectively, by 2020. The largest components of costs included the management of prevalent type 2 diabetes and incident cardiovascular events. Mean annual costs per hypertensive patient were around three-fold higher in subjects with MetS compared to those without and rose incrementally with the additional number of MetS components present. In conclusion, the presence of MetS in patients with hypertension significantly inflates economic burden, and costs are likely to increase in the future due to an aging population and an increase in the prevalence of components of MetS.
C1 [Wille, Eberhard] Fak Volkswirtschaftslehre, D-68131 Mannheim, Germany.
   [Scholze, Juergen] Charite, CCM, Dept Med, Outpatient Clin, D-10117 Berlin, Germany.
   [Alegria, Eduardo] Policlin Gipuzkoa, Serv Cardiol, San Sebastian, Spain.
   [Ferri, Claudio] Univ LAquila, San Salvatore Hosp, Dept Internal Med & Publ Hlth, Hypertens & Cardiovasc Prevent Ctr,Div Internal M, Laquila, Italy.
   [Langham, Sue] Independent Hlth Economist, Manchester, Lancs, England.
   [Stevens, Warren] Independent Hlth Economist, Boston, MA USA.
   [Jeffries, David] MRC Trop Dis Res Unit, Banjul, Gambia.
   [Uhl-Hochgraeber, Kerstin] Bayer Schering Pharma AG, Global Hlth Econ & Outcomes Res, Berlin, Germany.
RP Wille, E (reprint author), Fak Volkswirtschaftslehre, L 7,3-5,2 OG,Raum 21, D-68131 Mannheim, Germany.
EM wille@uni-mannheim.de; sue.langham@btinternet.com
OI Ferri, Claudio/0000-0002-3594-2503
CR Andreadis EA, 2007, AM J HYPERTENS, V20, P558, DOI 10.1016/j.amjhyper.2006.12.001
   Barrios Vivencio, 2007, J Cardiometab Syndr, V2, P9, DOI 10.1111/j.1559-4564.2007.06313.x
   Berghofer A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-200
   Boudreau DM, 2009, METAB SYNDR RELAT D, V7, P305, DOI 10.1089/met.2008.0070
   Breekveldt-Postma NS, 2008, CURR MED RES OPIN, V24, P121, DOI 10.1185/030079907X253843
   Caro JJ, 1999, CAN MED ASSOC J, V160, P31
   Cordero A, 2006, AM J HYPERTENS, V19, P189, DOI 10.1016/j.amjhyper.2005.08.018
   Cordero A, 2008, AM J CARDIOL, V102, P424, DOI 10.1016/j.amjcard.2008.03.079
   Corrao G, 2008, J HYPERTENS, V26, P819, DOI 10.1097/HJH.0b013e3282f4edd7
   Curtis LH, 2007, DIABETES CARE, V30, P2553, DOI 10.2337/dc07-0460
   *DAT, 2004, STAK INS MET SYNDR
   de la Sierra A, 2006, MED CLIN-BARCELONA, V126, P406, DOI 10.1157/13086123
   Dunbar-Jacob J, 2000, Annu Rev Nurs Res, V18, P48
   Eckel RH, 2004, CIRCULATION, V110, P2968, DOI 10.1161/01.CIR.0000140086.88453.9A
   Elliott WJ, 2007, LANCET, V369, P201, DOI 10.1016/S0140-6736(07)60108-1
   Esposti LD, 2004, J CLIN HYPERTENS GRE, V6, P76, DOI 10.1111/j.1524-6175.2004.03044.x
   Ferrara LA, 2007, J HUM HYPERTENS, V21, P795, DOI 10.1038/sj.jhh.1002232
   Ford ES, 2005, DIABETES CARE, V28, P1769, DOI 10.2337/diacare.28.7.1769
   Frericks H, 1998, STROKE, V29, P244
   Gabriel R, 2008, REV ESP CARDIOL, V61, P1030
   Galassi A, 2006, AM J MED, V119, P812, DOI 10.1016/j.amjmed.2006.02.031
   Gami AS, 2007, J AM COLL CARDIOL, V49, P403, DOI 10.1016/j.jacc.2006.09.032
   Gandjour A, 2007, HEALTH POLICY, V83, P257, DOI 10.1016/j.healthpol.2007.01.003
   Grundy SM, 2002, CIRCULATION, V106, P3143
   Hansson L, 2002, BLOOD PRESSURE, V11, P35, DOI 10.1080/080370502753543945
   *INT ASS STUD OB, 2009, AD OV OB EU 27
   Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683
   Jonsson B, 2002, DIABETOLOGIA, V45, pS5, DOI 10.1007/s00125-002-0858-x
   Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289
   Kiiskinen U, 1998, J HYPERTENS, V16, P1103, DOI 10.1097/00004872-199816080-00004
   Kjeldsen SE, 2008, J HYPERTENS, V26, P2064, DOI 10.1097/HJH.0b013e32830c45c3
   Kurtz TW, 2006, AM J MED, V119, p24S, DOI 10.1016/j.amjmed.2006.01.011
   Lonati C, 2008, J HYPERTENS, V26, P1801, DOI 10.1097/HJH.0b013e328307a07f
   Luders S, 2005, INT J CLIN PRACT, V59, P632, DOI 10.1111/j.1368-5031.2005.00518.x
   Maetzel A, 2004, ANN RHEUM DIS, V63, P395, DOI 10.1136/ard.2003.006031
   Mancia G, 2004, J HYPERTENS, V22, P51, DOI 10.1097/01.hjh.0000098194.36890.0e
   Mancia G, 2006, J HYPERTENS, V24, P837, DOI 10.1097/01.hjh.0000222752.67572.61
   Mancia G, 2007, EUR HEART J, V28, P1462, DOI 10.1093/eurheartj/ehm236
   Mancia G, 2007, HYPERTENSION, V49, P40, DOI 10.1161/01.HYP.0000251933.22091.24
   Mancia G, 2009, BLOOD PRESSURE, V18, P308, DOI 10.3109/08037050903450468
   Mar J, 2001, J HYPERTENS, V19, P149, DOI 10.1097/00004872-200101000-00020
   Mathes J, 2008, VALUE HEALTH, V11, pA415, DOI 10.1016/S1098-3015(10)66406-6
   Mazzaglia G, 2005, J HYPERTENS, V23, P2093, DOI 10.1097/01.hjh.0000186832.41125.8a
   Mullins CD, 2004, PHARMACOECONOMICS, V22, P1001, DOI 10.2165/00019053-200422150-00004
   *NAT I HLTH CLIN E, 2006, CG34 HYP NICE CLIN G
   Navarro J, 2007, BLOOD PRESSURE, V16, P20, DOI 10.1080/08037050701217817
   Neuhauser H, 2008, J PUBLIC HEALTH-HEID, V16, P221, DOI 10.1007/s10389-007-0168-3
   Noto D, 2008, ATHEROSCLEROSIS, V197, P147, DOI 10.1016/j.atherosclerosis.2007.03.005
   Organization for Economic Cooperation and Development (OECD), 2007, OECD HLTH DAT 2007 S
   Perez-Fernandez R, 2007, J HUM HYPERTENS, V21, P366, DOI 10.1038/sj.jhh.1002158
   Pierdomenico SD, 2007, AM J HYPERTENS, V20, P1291, DOI 10.1016/j.amjhyper.2007.06.011
   *R KOCH I, 2000, PUBL US FIL BGS98 GE
   Redon J, 2008, J HYPERTENS, V26, P1891, DOI 10.1097/HJH.0b013e328302ca38
   Rodriguez-Colon SM, 2009, STROKE, V40, P200, DOI 10.1161/STROKEAHA.108.523035
   Romero R, 2007, BLOOD PRESSURE, V16, P347, DOI 10.1080/08037050701715117
   Roux L, 2004, OBES RES, V12, P173, DOI 10.1038/oby.2004.23
   ROVIRA J, 1992, J HUM HYPERTENS, V6, P481
   Sattar N, 2003, CIRCULATION, V108, P414, DOI 10.1161/01.CIR.0000080897.52664.94
   Schillaci G, 2004, J AM COLL CARDIOL, V43, P1817, DOI 10.1016/j.jacc.2003.12.049
   Segura Julian, 2007, J Clin Hypertens (Greenwich), V9, P595, DOI 10.1111/j.1524-6175.2007.06522.x
   Steckelings UM, 2004, BLOOD PRESSURE, V13, P80, DOI 10.1080/08037050310030982
   Taylor MJ, 2007, CURR MED RES OPIN, V23, P495, DOI 10.1185/030079906X167462
   Volpe M, 2007, J HYPERTENS, V25, P1491, DOI 10.1097/HJH.0b013e3280fa83a6
   Wolf-Maier K, 2003, JAMA-J AM MED ASSOC, V289, P2363, DOI 10.1001/jama.289.18.2363
NR 64
TC 7
Z9 8
U1 7
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1618-7598
EI 1618-7601
J9 EUR J HEALTH ECON
JI Eur. J. Health Econ.
PD JUN
PY 2011
VL 12
IS 3
BP 205
EP 218
DI 10.1007/s10198-010-0223-9
PG 14
WC Economics; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 750VH
UT WOS:000289575600003
PM 20405160
OA No
DA 2017-08-15
ER

PT J
AU Jawara, M
   Awolola, TS
   Pinder, M
   Jeffries, D
   Smallegange, RC
   Takken, W
   Conway, DJ
AF Jawara, Musa
   Awolola, Taiwo S.
   Pinder, Margaret
   Jeffries, David
   Smallegange, Renate C.
   Takken, Willem
   Conway, David J.
TI Field Testing of Different Chemical Combinations as Odour Baits for
   Trapping Wild Mosquitoes in The Gambia
SO PLOS ONE
LA English
DT Article
ID VECTOR ANOPHELES-GAMBIAE; MALARIA MOSQUITO; CARBON-DIOXIDE;
   SENSU-STRICTO; CULICIDAE; DIPTERA; RESPONSES; BEHAVIOR; YEAST
AB Odour baited traps have potential use in population surveillance of insect vectors of disease, and in some cases for vector population reduction. Established attractants for human host-seeking mosquitoes include a combination of CO(2) with L-lactic acid and ammonia, on top of which additional candidate compounds are being tested. In this field study in rural Gambia, using Latin square experiments with thorough randomization and replication, we tested nine different leading candidate combinations of chemical odorants for attractiveness to wild mosquitoes including anthropophilic malaria vectors, using modified Mosquito Magnet-X (MM-X) counterflow traps outside experimental huts containing male human sleepers. Highest catches of female mosquitoes, particularly of An. gambiae s.l. and Mansonia species, were obtained by incorporation of tetradecanoic acid. As additional carboxylic acids did not increase the trap catches further, this 'reference blend' (tetradecanoic acid with L-lactic acid, ammonia and CO(2)) was used in subsequent experiments. MM-X traps with this blend caught similar numbers of An. gambiae s.l. and slightly more Mansonia and Culex mosquitoes than a standard CDC light trap, and these numbers were not significantly affected by the presence or absence of human sleepers in the huts. Experiments with CO(2) produced from overnight yeast cultures showed that this organic source was effective in enabling trap attractiveness for all mosquito species, although at a slightly lower efficiency than obtained with use of CO(2) gas cylinders. Although further studies are needed to discover additional chemicals that increase attractiveness, as well as to optimise trap design and CO(2) source for broader practical use, the odour-baited traps described here are safe and effective for sampling host-seeking mosquitoes outdoors and can be incorporated into studies of malaria vector ecology.
C1 [Jawara, Musa; Awolola, Taiwo S.; Pinder, Margaret; Jeffries, David; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Awolola, Taiwo S.] Nigerian Inst Med Res, Lagos, Nigeria.
   [Smallegange, Renate C.; Takken, Willem] Wageningen Univ, Entomol Lab, Wageningen, Netherlands.
   [Conway, David J.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Jawara, M (reprint author), MRC Labs, Banjul, Gambia.
EM david.conway@lshtm.ac.uk
OI Conway, David/0000-0002-8711-3037
FU Foundation for the National Institutes of Health; Bill and Melinda Gates
   Foundation through the Grand Challenges in Global Health Initiative
   (GCGH) [121]; Medical Research Council of the United Kingdom
FX This work was funded by the Foundation for the National Institutes of
   Health and the Bill and Melinda Gates Foundation, through the Grand
   Challenges in Global Health Initiative (GCGH# 121 grant co-ordinated by
   Dr. Larry Zwiebel), and by the Medical Research Council of the United
   Kingdom. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Caputo B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-182
   Carey AF, 2010, NATURE, V464, P66, DOI 10.1038/nature08834
   Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242
   Costantini C, 1996, MED VET ENTOMOL, V10, P220, DOI 10.1111/j.1365-2915.1996.tb00734.x
   Costantini C, 2001, MED VET ENTOMOL, V15, P259, DOI 10.1046/j.0269-283x.2001.00297.x
   GILLIES MT, 1980, B ENTOMOL RES, V70, P525
   Jawara M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008167
   Kline DL, 2007, J AM MOSQUITO CONTR, V23, P241, DOI 10.2987/8756-971X(2007)23[241:STAMTT]2.0.CO;2
   Krockel U, 2006, J AM MOSQUITO CONTR, V22, P229, DOI 10.2987/8756-971X(2006)22[229:NTFSOA]2.0.CO;2
   LINDSAY SW, 1993, J MED ENTOMOL, V30, P368
   Mukabana Wolfgang R, 2002, Malar J, V1, P17, DOI 10.1186/1475-2875-1-17
   Okumu FO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008951
   Oli K., 2005, Tropical Biomedicine, V22, P249
   Pickett JA, 2010, J CHEM ECOL, V36, P113, DOI 10.1007/s10886-010-9739-9
   QIU YT, 2010, MED VET ENTOMOL
   Qiu YT, 2006, CHEM SENSES, V31, P845, DOI 10.1093/chemse/bjl027
   Saitoh Y, 2004, J AM MOSQUITO CONTR, V20, P261
   Schmied WH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-230
   Smallegange RC, 2005, CHEM SENSES, V30, P145, DOI 10.1093/chemse/bji010
   Smallegange RC, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-292
   Smallegange RC, 2010, J MED ENTOMOL, V47, P338, DOI 10.1603/ME09015
   Smallegange RC, 2009, J CHEM ECOL, V35, P933, DOI 10.1007/s10886-009-9668-7
NR 22
TC 21
Z9 22
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 26
PY 2011
VL 6
IS 5
AR e19676
DI 10.1371/journal.pone.0019676
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 769XS
UT WOS:000291052200012
PM 21637337
OA gold
DA 2017-08-15
ER

PT J
AU Obaro, S
   Lawson, L
   Essen, U
   Ibrahim, K
   Brooks, K
   Otuneye, A
   Shetima, D
   Ahmed, P
   Ajose, T
   Olugbile, M
   Idiong, D
   Ogundeji, D
   Ochigbo, C
   Olanipekun, G
   Khalife, W
   Adegbola, R
AF Obaro, Stephen
   Lawson, Lovett
   Essen, Uduak
   Ibrahim, Khalid
   Brooks, Kevin
   Otuneye, Adekunle
   Shetima, Denis
   Ahmed, Patience
   Ajose, Theresa
   Olugbile, Michael
   Idiong, David
   Ogundeji, Damola
   Ochigbo, Comfort
   Olanipekun, Grace
   Khalife, Walid
   Adegbola, Richard
TI Community Acquired Bacteremia in Young Children from Central Nigeria- A
   Pilot Study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; DEVELOPING-COUNTRIES; DISEASE; GAMBIA;
   IMMUNIZATION; TRIAL
AB Background: Reports of the etiology of bacteremia in children from Nigeria are sparse and have been confounded by wide spread non-prescription antibiotic use and suboptimal laboratory culture techniques. We aimed to determine causative agents and underlying predisposing conditions of bacteremia in Nigerian children using data arising during the introduction of an automated blood culture system accessed by 7 hospitals and clinics in the Abuja area.
   Methods: Between September 2008 and November 2009, we enrolled children with clinically suspected bacteremia at rural and urban clinical facilities in Abuja or within the Federal Capital Territory of Nigeria. Blood was cultured using an automated system with antibiotic removing device. We documented clinical features in all children and tested for prior antibiotic use in a random sample of sera from children from each site.
   Results: 969 children aged 2 months-5 years were evaluated. Mean age was 21 +/- 15.2 months. All children were not systematically screened but there were 59 (6%) children with established diagnosis of sickle cell disease and 42 (4.3%) with HIV infection. Overall, 212 (20.7%) had a positive blood culture but in only 105 (10.8%) were these considered to be clinically significant. Three agents, Staphylococcus aureus (20.9%), Salmonella typhi (20.9%) and Acinetobacter (12.3%) accounted for over half of the positive cultures. Streptococcus pneumoniae and non-typhi Salmonellae each accounted for 7.6%. Although not the leading cause of bacteremia, Streptococcus pneumoniae was the single leading cause of all deaths that occurred during hospitalization and after hospital discharge.
   Conclusion: S. typhi is a significant cause of vaccine-preventable morbidity while S. pneumoniae may be a leading cause of mortality in this setting. This observation contrasts with reports from most other African countries where non-typhi Salmonellae are predominant in young children. Expanded surveillance is required to confirm the preliminary observations from this pilot study to inform implementation of appropriate public health control measures.
C1 [Obaro, Stephen; Ibrahim, Khalid; Brooks, Kevin; Khalife, Walid] Michigan State Univ, E Lansing, MI 48824 USA.
   [Lawson, Lovett; Essen, Uduak; Ajose, Theresa; Olugbile, Michael; Idiong, David; Ochigbo, Comfort; Olanipekun, Grace] Zankli Med Ctr, Abuja, Nigeria.
   [Adegbola, Richard] MRC Labs, Fajara, Gambia.
RP Obaro, S (reprint author), Michigan State Univ, E Lansing, MI 48824 USA.
EM Stephen.obaro@hc.msu.edu
OI Lawson, Lovett/0000-0001-9019-7537
FU Michigan State University Department of Pediatrics and Human Development
FX Zankli Medical Center graciously permitted the use of their Bactec
   incubator for this study and also provided office space and utilities
   that supported this study. This is much appreciated. We are grateful to
   Becton Dickinson for the generous donation of a Bactec incubator and
   supplies that supported the commencement of this study. We are also
   grateful to Dr. Maria Carvalho of the CDC for her initial supervisory
   visit and donation of control bacterial isolates. We are grateful to the
   physicians (Dr. Chinatu Ohiaeri, Dr. Augustine Madukwe, Dr. Eyinade
   Olateju, Dr. Anthony Adetola, Dr. Nnenna Ihebuzor, Dr. Uduak Offiong,
   Dr. Adebanke Adebisi) for their support in patient enrolment. We are
   also grateful to the administration of Zankli Medical Center for
   providing the logistic support for the commencement of this study and
   the National Primary Health Care Development Agency for facilitating
   access to the health care facilities and Michigan State University
   Department of Pediatrics and Human Development for funding support.
   Finally, we are indebted to the parents and guardians of all
   participants.
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Daza P, 2006, VACCINE, V24, P6232, DOI 10.1016/j.vaccine.2006.05.076
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   Evans JA, 2004, QJM-INT J MED, V97, P591, DOI 10.1093/qjmed/hcho93
   Falade AG, 2009, CLIN INFECT DIS, V48, pS190, DOI 10.1086/596500
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Obaro S, 2009, EXPERT REV VACCINES, V8, P1051, DOI [10.1586/erv.09.66, 10.1586/ERV.09.66]
   Ochiai RL, 2008, B WORLD HEALTH ORGAN, V86, P260, DOI 10.2471/BLT.06.039818
   Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9
   Russell FM, 2006, J CLIN MICROBIOL, V44, P3346, DOI 10.1128/JCM.02631-05
   Sigauque B, 2009, PEDIATR INFECT DIS J, V28, P108, DOI 10.1097/INF.0b013e318187a87d
   Walsh AL, 2000, PEDIATR INFECT DIS J, V19, P312, DOI 10.1097/00006454-200004000-00010
   2008, STATE WORLD CHILDREN
NR 15
TC 23
Z9 23
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAY 19
PY 2011
VL 11
AR 137
DI 10.1186/1471-2334-11-137
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA 775AT
UT WOS:000291429400001
PM 21595963
OA gold
DA 2017-08-15
ER

PT J
AU Donkor, ES
   Bishop, CJ
   Antonio, M
   Wren, B
   Hanage, WP
AF Donkor, E. S.
   Bishop, C. J.
   Antonio, M.
   Wren, B.
   Hanage, W. P.
TI High Levels of Recombination among Streptococcus pneumoniae Isolates
   from the Gambia
SO MBIO
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; INVASIVE-DISEASE; NASOPHARYNGEAL
   CARRIAGE; ANTIBIOTIC-RESISTANCE; POPULATION-STRUCTURE;
   BAYESIAN-ANALYSIS; SEROTYPES; CHILDREN; DIVERSITY; CLONES
AB We carried out multilocus sequence typing (MLST) on 148 pneumococcal carriage isolates collected from children < 24 months old in the Upper River Division, the Gambia. MLST revealed a diverse population. Seventy-six different sequence types (STs) were found, the most common of which were 802 and 919, associated with 23F and 6A serotypes, respectively. Comparison with the MLST database showed that only 11 of the STs found in the present sample had been reported outside Africa. Six STs showed evidence of capsular switching (172, 802, 847, 1730, 1736, and 1737). Serotype switches were confirmed by microarrays that detected capsule genes. Of isolates analyzed by using microarrays, 40/69 (58%) harbored the tetM resistance determinant. A statistical genetic analysis to detect recombination found that 49/144 (34%) isolates showed significant (P < 0.05) evidence of admixture, which is greater than that observed in similar samples from the United Kingdom (5%) and Finland (2%). We hypothesize that large amounts of admixture could reflect the high prevalence of multiple carriage in this region, leading to more opportunities for homologous recombination between strains. This could have consequences for the population response to conjugate vaccination.
   IMPORTANCE The population structure of the pneumococcus in sub-Saharan Africa has barely been studied despite the high levels of morbidity and mortality due to pneumococcal disease in this region. We report the largest sample to date from carriage in sub-Saharan Africa to be typed by sequencing (multilocus sequence typing [ MLST]) and microarray analysis. The results clearly show that the population is highly distinct and divergent from others studied in the United States and Europe. Moreover, in contrast with samples from developed countries, the population contains a high proportion of isolates showing a history of homologous recombination, which shuffles genetic information into new combinations and can generate drug-resistant and vaccine escape strains. This is likely to have important consequences for the evolutionary response of the pneumococcal population to conjugate vaccination targeting a subset of pneumococcal serotypes, which is under way in the Gambia and other countries.
C1 [Donkor, E. S.; Wren, B.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   [Bishop, C. J.; Hanage, W. P.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England.
   [Antonio, M.] Med Res Council Labs United Kingdom, Bacterial Dis Programme, Fajara, Gambia.
RP Hanage, WP (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
EM whanage@hsph.harvard.edu
FU Royal Society; Ghanaian Education Trust; Medical Research Council UK;
   Wellcome Trust
FX This work was funded by the award of a Royal Society University Research
   Fellowship to W. P. H., by a Ghanaian Education Trust Fund scholarship
   to E. S. D., and by the Medical Research Council UK (M. A.) and the
   Wellcome Trust (C.J.B.).
CR Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Antonio M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-81
   Antonio M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-198
   Brouwer MC, 2009, LANCET INFECT DIS, V9, P31, DOI 10.1016/S1473-3099(08)70261-5
   Brueggemann AB, 2004, J INFECT DIS, V190, P1203, DOI 10.1086/423820
   Brueggemann AB, 2003, J CLIN MICROBIOL, V41, P4966, DOI 10.1128/JCM.41.11.4966-4970.2003
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   Brueggemann AB, 2007, PLOS PATHOG, V3, P1628, DOI 10.1371/journal.ppat.0030168
   Brugger SD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011638
   Coffey TJ, 1998, MOL MICROBIOL, V27, P73, DOI 10.1046/j.1365-2958.1998.00658.x
   Corander J, 2004, BIOINFORMATICS, V20, P2363, DOI 10.1093/bioinformatics/bth250
   Corander J, 2003, GENETICS, V163, P367
   Corander J, 2007, MATH BIOSCI, V205, P19, DOI 10.1016/j.mbs.2006.09.015
   Crook DW, 2004, PNEUMOCCOCUS, P136
   Croucher NJ, 2011, SCIENCE, V331, P430, DOI 10.1126/science.1198545
   Donkor ES, 2010, SCAND J INFECT DIS, V42, P254, DOI 10.3109/00365540903490000
   Enright MC, 1998, MICROBIOL-UK, V144, P3049
   Feil EJ, 2004, J BACTERIOL, V186, P1518, DOI 10.1128/JB.186.5.1518-1530.2004
   Hakenbeck R, 1998, ELECTROPHORESIS, V19, P597, DOI 10.1002/elps.1150190423
   Hanage WP, 2007, J INFECT DIS, V195, P347, DOI 10.1086/510249
   Hanage WP, 2009, SCIENCE, V324, P1454, DOI 10.1126/science.1171908
   Hanage WP, 2005, INFECT IMMUN, V73, P431, DOI 10.1128/IAI.73.1.431-435.2005
   Hanage WP, 2004, INFECT IMMUN, V72, P76, DOI 10.1128/IAI.72.1.76-81.2004
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Hill PC, 2010, CLIN INFECT DIS, V50, P1468, DOI 10.1086/652443
   Hinds J, 2010, P 7 INT S PNEUM PNEU
   Marchisio P, 2002, EMERG INFECT DIS, V8, P479
   Meats E, 2003, J CLIN MICROBIOL, V41, P386, DOI 10.1128/JCM.41.1.386-392.2003
   Moore MR, 2008, J INFECT DIS, V197, P1016, DOI 10.1086/528996
   Mothibeli KM, 2009, J CLIN MICROBIOL, V48, P184
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Obaro S, 2001, LANCET, V357, P1800, DOI 10.1016/S0140-6736(00)04915-1
   Obaro SK, 2004, PEDIATR INFECT DIS J, V23, P1023, DOI 10.1097/01.inf.0000143651.54880.09
   Pelton SI, 2007, PEDIATR INFECT DIS J, V26, P468, DOI 10.1097/TNF.0b013e31803df9ca
   Spratt BG, 2004, PNEUMOCCOCUS, P119
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
NR 37
TC 20
Z9 20
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD MAY-JUN
PY 2011
VL 2
IS 3
AR e00040-11
DI 10.1128/mBio.00040-11
PG 8
WC Microbiology
SC Microbiology
GA 845SW
UT WOS:000296843900003
PM 21693638
OA gold
DA 2017-08-15
ER

PT J
AU Dione, MM
   Ikumapayi, UN
   Saha, D
   Mohammed, NI
   Geerts, S
   Ieven, M
   Adegbola, RA
   Antonio, M
AF Dione, Michel M.
   Ikumapayi, Usman N.
   Saha, Debasish
   Mohammed, Nuredin I.
   Geerts, Stanny
   Ieven, Margareta
   Adegbola, Richard A.
   Antonio, Martin
TI Clonal Differences between Non-Typhoidal Salmonella (NTS) Recovered from
   Children and Animals Living in Close Contact in The Gambia
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID AGED 2-29 MONTHS; TYPHIMURIUM INFECTION; ENTERITIDIS; SEROVAR; AFRICA;
   BACTEREMIA; CHICKENS; STRAIN; SHEEP; DAKAR
AB Background: Non-Typhoidal Salmonella (NTS) is an important cause of invasive bacterial disease and associated with mortality in Africa. However, little is known about the environmental reservoirs and predominant modes of transmission. Our study aimed to study the role of domestic animals in the transmission of NTS to humans in rural area of The Gambia.
   Methodology: Human NTS isolates were obtained through an active population-based case-control surveillance study designated to determine the aetiology and epidemiology of enteric infections covering 27,567 Gambian children less than five years of age in the surveillance area. Fourteen children infected with NTS were traced back to their family compounds and anal swabs collected from 210 domestic animals present in their households. Identified NTSs were serotyped and genotyped by multi-locus sequencing typing.
   Principal Findings: NTS was identified from 21/210 animal sources in the households of the 14 infected children. Chickens carried NTS more frequently than sheep and goats; 66.6%, 28.6% and 4.8% respectively. The most common NTS serovars were S. Colindale in humans (21.42%) and S. Poona in animals (14.28%). MLST on the 35 NTS revealed four new alleles and 24 sequence types (ST) of which 18 (75%) STs were novel. There was no overlap in serovars or genotypes of NTS recovered from humans or animal sources in the same household.
   Conclusion: Our results do not support the hypothesis that humans and animals in close contact in the same household carry genotypically similar Salmonella serovars. These findings form an important baseline for future studies of transmission of NTS in humans and animals in Africa.
C1 [Dione, Michel M.] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Ikumapayi, Usman N.; Saha, Debasish; Mohammed, Nuredin I.; Adegbola, Richard A.; Antonio, Martin] Med Res Council UK Labs, Banjul, Gambia.
   [Dione, Michel M.; Geerts, Stanny] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Dione, Michel M.; Ieven, Margareta] Univ Antwerp, B-2020 Antwerp, Belgium.
RP Dione, MM (reprint author), Int Trypanotolerance Ctr, Banjul, Gambia.
EM mantonio@mrc.gm
FU Flemish Interuniversity Council (VLIR-UOS, Brussels, Belgium); Medical
   Research Council, United Kingdom; Science Foundation of Ireland
   [05/FE1/B882]
FX This work was supported by the Flemish Interuniversity Council
   (VLIR-UOS, Brussels, Belgium) and the Medical Research Council, United
   Kingdom. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.; We
   acknowledge Kebba Touray for technical assistance with GIS and Mark
   Achtman for the use of the Salmonella MLST database [30], which is
   hosted at the University College Cork and funded by the Science
   Foundation of Ireland (05/FE1/B882).
CR Aanensen DM, 2005, NUCLEIC ACIDS RES, V33, pW728, DOI 10.1093/nar/gki415
   Alvseike O, 2002, PREV VET MED, V52, P277, DOI 10.1016/S0167-5877(01)00252-5
   BARROW PA, 1987, RES VET SCI, V42, P194
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Braden CR, 2006, CLIN INFECT DIS, V43, P512, DOI 10.1086/505973
   Cardinale E, 2005, INT J FOOD MICROBIOL, V103, P157, DOI 10.1016/j.ijfoodmicro.2004.12.023
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   Gordon MA, 2008, CLIN INFECT DIS, V46, P963, DOI 10.1086/529146
   Graham SM, 2000, PEDIATR INFECT DIS J, V19, P1189, DOI 10.1097/00006454-200012000-00016
   Grimont P., 2007, ANTIGENIC FORMULAE S
   Hill PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-2
   Ikumapayi UN, 2007, J MED MICROBIOL, V56, P1479, DOI 10.1099/jmm.0.47416-0
   Kariuki S, 2002, FEMS IMMUNOL MED MIC, V33, P165, DOI 10.1016/S0928-8244(02)00309-7
   Kotetishvili M, 2002, J CLIN MICROBIOL, V40, P1626, DOI 10.1128/JCM.40.5.1626-1635.2002
   Mandomando I, 2009, TROP MED INT HEALTH, V14, P1467, DOI 10.1111/j.1365-3156.2009.02399.x
   Morpeth SC, 2009, CLIN INFECT DIS, V49, P606, DOI 10.1086/603553
   Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007
   Sadeyen JR, 2004, MICROBES INFECT, V6, P1278, DOI 10.1016/j.micinf.2004.07.005
   Sow AI, 2000, MED MALADIES INFECT, V30, P657, DOI 10.1016/S0399-077X(00)80037-2
   Spratt Brian G, 2004, Methods Mol Biol, V266, P323
   Suerbaum S, 2004, INT J MED MICROBIOL, V294, P133, DOI 10.1016/j.ijmm.2004.06.014
   Torpdahl M, 2005, J MICROBIOL METH, V63, P173, DOI 10.1016/j.mimet.2005.03.006
   Uzzau S, 2001, INFECT IMMUN, V69, P3092, DOI 10.1128/IAI.69.5.3092-3099.2001
   Van Immerseel F, 2002, DEV COMP IMMUNOL, V26, P355, DOI 10.1016/S0145-305X(01)00084-2
   Wall PG, 1996, LANCET, V348, P471, DOI 10.1016/S0140-6736(96)24033-4
NR 25
TC 14
Z9 14
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2011
VL 5
IS 5
AR e1148
DI 10.1371/journal.pntd.0001148
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 770OZ
UT WOS:000291099100026
PM 21655353
OA gold
DA 2017-08-15
ER

PT J
AU Douglas, AD
   Andrews, L
   Draper, SJ
   Bojang, K
   Milligan, P
   Gilbert, SC
   Imoukhuede, EB
   Hill, AVS
AF Douglas, A. D.
   Andrews, L.
   Draper, S. J.
   Bojang, K.
   Milligan, P.
   Gilbert, S. C.
   Imoukhuede, E. B.
   Hill, A. V. S.
TI Substantially Reduced Pre-patent Parasite Multiplication Rates Are
   Associated With Naturally Acquired Immunity to Plasmodium falciparum
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; TROPHOZOITE-INDUCED INFECTIONS; RETROSPECTIVE
   EXAMINATION; CLINICAL IMMUNITY; MALARIA VACCINES; EFFICACY; TRIALS
AB Naturally acquired immunity to Plasmodium falciparum's asexual blood stage reduces parasite multiplication at microscopically detectable densities. The effect of natural immunity on initial prepatent parasite multiplication during the period following a new infection has been uncertain, contributing to doubt regarding the utility of experimental challenge models for blood-stage vaccine trials. Here we present data revealing that parasite multiplication rates during the initial prepatent period in semi-immune Gambian adults are substantially lower than in malaria-naive participants. This supports the view that a blood-stage vaccine capable of emulating the disease-reducing effect of natural immunity could achieve a detectable effect during the prepatent period.
C1 [Douglas, A. D.; Andrews, L.; Draper, S. J.; Gilbert, S. C.; Hill, A. V. S.] Univ Oxford, Nuffield Dept Med, Jenner Inst, Oxford OX1 2JD, England.
   [Bojang, K.; Milligan, P.; Imoukhuede, E. B.] MRC Labs, Banjul, Gambia.
RP Douglas, AD (reprint author), Jenner Inst Labs, Old Rd Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.
EM sandy.douglas@ndm.ox.ac.uk
RI Draper, Simon/F-1758-2011; Douglas, Alexander/E-7040-2012; Milligan,
   Paul/D-8985-2017
OI Draper, Simon/0000-0002-9415-1357; Douglas,
   Alexander/0000-0002-5410-7562; Milligan, Paul/0000-0003-3430-3395;
   Imoukhuede, Egeruan Babatunde/0000-0001-6679-0904; Gilbert,
   Sarah/0000-0002-6823-9750
FU Gates Malaria Partnership; London School of Hygiene; Tropical Medicine;
   Wellcome Trust
FX The Gambian clinical trial was funded by the Gates Malaria Partnership,
   London School of Hygiene and Tropical Medicine, which receives support
   from the Bill and Melinda Gates Foundation, the University of Oxford,
   and the Wellcome Trust. A.D.D. is supported by the Wellcome Trust.
CR Andrews L, 2005, AM J TROP MED HYG, V73, P191
   Bejon P, 2005, J INFECT DIS, V191, P619, DOI 10.1086/427243
   Bottius E, 1996, T ROY SOC TROP MED H, V90, P15, DOI 10.1016/S0035-9203(96)90463-0
   Collins WE, 1999, AM J TROP MED HYG, V61, P4
   Collins WE, 1999, AM J TROP MED HYG, V61, P20
   Druilhe P, 1997, PARASITOL TODAY, V13, P353, DOI 10.1016/S0169-4758(97)01095-8
   Edstein MD, 2005, ANTIMICROB AGENTS CH, V49, P4421, DOI 10.1128/AAC.49.10.4421-4422.2005
   Ellis RD, 2010, HUM VACCINES, V6, P627, DOI 10.4161/hv.6.8.11446
   Hill AVS, 2010, HUM VACCINES, V6, P78
   Imoukhuede EB, 2007, AM J TROP MED HYG, V76, P486
   Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205
   Sanderson F, 2008, AM J TROP MED HYG, V78, P878
NR 12
TC 20
Z9 20
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 1
PY 2011
VL 203
IS 9
BP 1337
EP 1340
DI 10.1093/infdis/jir033
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 747FQ
UT WOS:000289306100019
PM 21459819
OA No
DA 2017-08-15
ER

PT J
AU Hamdi, L
   Creidy, R
   Rince, P
   Abbed, K
   Clavel, J
   Raphael, M
   Landman-Parker, J
   Besson, C
AF Hamdi, Leila
   Creidy, Rita
   Rince, Patricia
   Abbed, Karim
   Clavel, Jacqueline
   Raphael, Martine, Sr.
   Landman-Parker, Judith
   Besson, Caroline
TI A STUDY OF IMMUNE DEFICIENCY AS RISK FACTOR FOR HODGKIN LYMPHOMA IN
   CHILDREN
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Hamdi, Leila] INSERM U802, Le Kremlin Bicetre, France.
   [Rince, Patricia] Univ Paris 11, Le Kremlin Bicetre, Gambia.
   [Abbed, Karim] CHU Bicetre, Le Kremlin Bicetre, France.
   [Clavel, Jacqueline] INSERM, F-94275 Le Kremlin Bicetre, France.
   [Raphael, Martine, Sr.] Univ Paris 11, Le Kremlin Bicetre, France.
   [Landman-Parker, Judith] UPMC Paris 6, Hop Trousseau, Dept Hem Onc Pediat, Paris, France.
   [Besson, Caroline] Hop Bicetre, Paris, France.
RI Clavel, Jacqueline/Q-2750-2016
OI Clavel, Jacqueline/0000-0002-3616-7676
NR 0
TC 0
Z9 0
U1 1
U2 3
PU WILEY PERIODICALS, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD MAY
PY 2011
VL 56
IS 5
MA II-1
BP 877
EP 877
PG 1
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 731TK
UT WOS:000288132100043
OA No
DA 2017-08-15
ER

PT J
AU Estevez, PT
   Satoguina, J
   Nwakanma, DC
   West, S
   Conway, DJ
   Drakeley, CJ
AF Estevez, Patricia Tabernero
   Satoguina, Judith
   Nwakanma, Davis C.
   West, Sheila
   Conway, David J.
   Drakeley, Chris J.
TI Human saliva as a source of anti-malarial antibodies to examine
   population exposure to Plasmodium falciparum
SO MALARIA JOURNAL
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; FLUID COLLECTION DEVICES; ORAL-FLUID;
   MALARIA TRANSMISSION; SEROLOGICAL MARKERS; CHILDREN; INFECTION;
   DIAGNOSIS; TANZANIA; SAMPLES
AB Background: Antibody responses to malaria antigens reflect exposure to parasites, and seroprevalence correlates with malaria transmission intensity. Antibodies are routinely measured in sera or on dried blood spots but a non-invasive method would provide extra utility in sampling general populations. Saliva is already in use in the detection of plasma-derived IgM and IgG to viral infections. In this study, antibodies to Plasmodium falciparum merozoite antigens were compared between blood and saliva samples from the same individuals in unlinked surveys conducted in Tanzania and The Gambia.
   Methods: In Tanzania, 53 individuals provided paired fingerprick blood and saliva sample using two commercially available sampling devices. In the Gambia, archived plasma and saliva samples collected from 200 children in the Farafenni area in a cross-sectional survey were analyzed.
   IgG antibodies against P. falciparum antigens, Merozoite Surface Protein-1 (MSP-1(19)) and Apical membrane Antigen (AMA-1) were measured by ELISA in paired saliva and blood samples from both sites. Antibody levels were compared as continuous optical density (OD) values and by sero-positivity.
   Results: Significant correlations between saliva and plasma antibody levels were seen in Tanzania for both antigens, AMA-1(r(2) range 0.93 to 0.89, p < 0.001) and MSP-1(19) (r(2) range 0.93 to 0.75, p < 0.001), with a weaker correlation for results from The Gambia (r(2)range 0.64 to 0.63, p < 0.01). When assessed as seropositivity and compared with plasma, sensitivity and specificity were good with saliva antibody levels to both AMA-1 and MSP-1(19) (sensitivity range 64-77% and specificity range 91-100% & 47-67% and 90-97% respectively) over the different sample sets.
   Conclusions: These data demonstrate anti-malarial antibodies can be detected in saliva and correlate strongly with levels in plasma. This non-invasive relatively simple collection method will be potentially useful for general population surveys, and particularly in migratory populations or those with infrequent contact with health services or opposed to blood withdrawal. Further studies will be needed to optimize collection methods, standardize volumes and content and develop controls.
C1 [Estevez, Patricia Tabernero; Conway, David J.; Drakeley, Chris J.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
   [Satoguina, Judith; Nwakanma, Davis C.; Conway, David J.] Med Res Council Labs UK, Fajara, Gambia.
   [Satoguina, Judith] Univ Abomey Calavi, LBBM, Cotonou, Benin.
   [West, Sheila] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
RP Drakeley, CJ (reprint author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
EM chris.drakeley@lshtm.ac.uk
OI Conway, David/0000-0002-8711-3037
FU PATH-Malaria Vaccine Initiative; Wellcome Trust [078925]; Bill & Melinda
   Gates Foundation
FX We wish to thank the participants and staff of the KTP & MRC (UK) The
   Gambia. We thank Ed Remarque and Bart Faber for the provision of the
   AMA-1 protein, Tedson Lukindo for help in the laboratory in Moshi,
   Eniyou Oriero in Fajara and Patrick Corran and Jackie Cook for help and
   advice in London. The Gambia sampling and assays were supported by a
   project grant to DCN from PATH-Malaria Vaccine Initiative and Tanzania
   studies through a grant to from the Wellcome Trust to CD (078925) and a
   Grant from Bill & Melinda Gates Foundation to SW.
CR A-Elgayoum SME, 2010, J MOL MICROB BIOTECH, V18, P148, DOI 10.1159/000308516
   BOUSEMA JT, 2010, EMERG INFECT DIS, V16, P392
   Bousema T, 2010, J INFECT DIS, V201, P1764, DOI 10.1086/652456
   Brandtzaeg P, 2007, ANN NY ACAD SCI, V1098, P288, DOI 10.1196/annals.1384.012
   Corran P, 2007, TRENDS PARASITOL, V23, P575, DOI 10.1016/j.pt.2007.08.023
   Drakeley CJ, 2005, J INFECT DIS, V191, P1589, DOI 10.1086/429669
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Duah NO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007381
   Greenwood BM, 2008, TRENDS PARASITOL, V24, P449, DOI 10.1016/j.pt.2008.07.002
   Hofman LF, 2001, J NUTR, V131, p1621S
   Langel K, 2008, J ANAL TOXICOL, V32, P393
   Lejon V, 2006, TROP MED INT HEALTH, V11, P620, DOI 10.1111/j.1365-3156.2006.01620.x
   Litt DJ, 2006, J MED MICROBIOL, V55, P1223, DOI 10.1099/jmm.0.46543-0
   Luzza F, 1997, J CLIN MICROBIOL, V35, P3358
   Mharakurwa S, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-103
   Nokes DJ, 1998, T ROY SOC TROP MED H, V92, P679, DOI 10.1016/S0035-9203(98)90811-2
   Nurkka A, 2000, VACCINE, V19, P547, DOI 10.1016/S0264-410X(00)00180-8
   Nwakanma DC, 2009, J INFECT DIS, V199, P1567, DOI 10.1086/598856
   Oesterholt MJAM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-98
   Okiro EA, 2008, J CLIN MICROBIOL, V46, P1659, DOI 10.1128/JCM.02190-07
   Piwowar-Manning Estelle M, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P170, DOI 10.1177/1545109710368151
   Razakandrainibe R, 2009, ACTA TROP, V111, P160, DOI 10.1016/j.actatropica.2009.04.007
   Schellenberg D, 2004, TROP MED INT HEALTH, V9, P68, DOI 10.1046/j.1365-3156.2003.01161.x
   Sheppard C, 2001, J VIROL METHODS, V93, P157, DOI 10.1016/S0166-0934(01)00264-6
   Stewart L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006083
   Tapia MD, 2006, PEDIATR INFECT DIS J, V25, P819, DOI 10.1097/01.inf.0000232629.72160.bb
   Vyse AJ, 2001, PUBLIC HEALTH, V115, P201, DOI 10.1038/sj.ph.1900751
   WEBSTER HK, 1992, AM J TROP MED HYG, V47, P489
   Williams GS, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-168
   Wilson NO, 2008, AM J TROP MED HYG, V78, P733
   Wilson SD, 2000, J MED VIROL, V61, P81, DOI 10.1002/(SICI)1096-9071(200005)61:1<81::AID-JMV13>3.0.CO;2-O
NR 31
TC 12
Z9 12
U1 2
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD APR 29
PY 2011
VL 10
AR 104
DI 10.1186/1475-2875-10-104
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 777EF
UT WOS:000291597700001
PM 21527045
OA gold
DA 2017-08-15
ER

PT J
AU Jones, CE
   Kampmann, B
AF Jones, C. E.
   Kampmann, B.
TI Children and multidrug-resistant tuberculosis
SO LANCET
LA English
DT Letter
ID CHILDHOOD TUBERCULOSIS
C1 [Jones, C. E.; Kampmann, B.] Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, Paediat Infect & Immun Res Grp, London W2 1PG, England.
   [Kampmann, B.] MRC, Banjul, Gambia.
RP Jones, CE (reprint author), Univ London Imperial Coll Sci Technol & Med, Acad Dept Paediat, Paediat Infect & Immun Res Grp, London W2 1PG, England.
EM christine.jones@imperial.ac.uk
FU Department of Health [SRF-2009-02-07]
CR Becerra MC, 2011, LANCET, V377, P147, DOI 10.1016/S0140-6736(10)61972-1
   Brent AJ, 2008, T ROY SOC TROP MED H, V102, P217, DOI 10.1016/j.trstmh.2007.09.011
   Nelson LJ, 2004, INT J TUBERC LUNG D, V8, P636
   Newton SM, 2008, LANCET INFECT DIS, V8, P498, DOI 10.1016/S1473-3099(08)70182-8
   Schaaf HS, 2011, PAEDIATR RESPIR REV, V12, P31, DOI 10.1016/j.prrv.2010.09.010
NR 5
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 23
PY 2011
VL 377
IS 9775
BP 1404
EP 1405
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 755UF
UT WOS:000289963000020
PM 21515155
OA No
DA 2017-08-15
ER

PT J
AU Secka, O
   Antonio, M
   Tapgun, M
   Berg, DE
   Bottomley, C
   Thomas, V
   Walton, R
   Corrah, T
   Adegbola, RA
   Thomas, JE
AF Secka, Ousman
   Antonio, Martin
   Tapgun, Mary
   Berg, Douglas E.
   Bottomley, Christian
   Thomas, Vivat
   Walton, Robert
   Corrah, Tumani
   Adegbola, Richard A.
   Thomas, Julian E.
TI PCR-based genotyping of Helicobacter pylori of Gambian children and
   adults directly from biopsy specimens and bacterial cultures
SO GUT PATHOGENS
LA English
DT Article
DE Genotyping Helicobacter pylori; biopsy specimens; bacterial cultures
ID AFRICAN ENIGMA; STRAINS; COLONIZATION; INFECTION; SINGLE; GENE; DNA
AB Background: Helicobacter pylori is an important agent of gastroduodenal disease in Africa and throughout the world. We sought to determine an optimum method for genotyping H. pylori strains from children and adults in The Gambia, West Africa.
   Results: Virulence genes were amplified in 127 of 190 cases tested (121 adults and 6 children); each of 60 bacterial cultures, and 116 from DNA extracted directly from biopsies. The proportion of biopsies that were cagA+, the ratio of vacAs1/s2, and vacAm1/m2, and the proportion of mixed strain populations in individual subjects changed with age. Strains lacking virulence cagA and vacA genes and with apparently homogeneous (one predominant strain) infections were more common among infants than adults.
   Conclusions: In order to detect the range of bacterial genotypes harbored by individual patients, direct PCR proved slightly superior to isolation of H. pylori by biopsy culture, but the techniques were complementary, and the combination of both culture and direct PCR produced the most complete picture. The seemingly higher virulence of strains from adult than infant infections in The Gambia merits further analysis.
C1 [Secka, Ousman; Antonio, Martin; Tapgun, Mary; Thomas, Vivat; Walton, Robert; Corrah, Tumani; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Thomas, Julian E.] Newcastle Univ, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Berg, Douglas E.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Bottomley, Christian] London Sch Hyg & Trop Med, London WC1, England.
   [Adegbola, Richard A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Secka, O (reprint author), MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
EM osecka@mrc.gm
OI Walton, Robert/0000-0001-7700-1907
FU US National Institutes of Health [RO3-AI061308]; Medical Research
   Council Laboratories, The Gambia
FX This work was supported in part by grant RO3-AI061308 from the US
   National Institutes of Health and The Medical Research Council
   Laboratories, The Gambia.
CR Akada JK, 2003, MICROBIOL-SGM, V149, P1901, DOI 10.1099/mic.0.26129-0
   Akcam M, 2010, INDIAN PEDIATR, V47, P119
   Campbell DI, 2001, HELICOBACTER, V6, P263, DOI 10.1046/j.1083-4389.2001.00047.x
   Chattopadhyay Santanu, 2004, J CLIN MICROBIOL, V42, P2821
   Danon SJ, 1998, HELICOBACTER, V3, P254, DOI 10.1046/j.1523-5378.1998.08010.x
   Fernandez-Banares F, 2010, INDIAN PEDIATR, V47, P119
   Goodman KJ, 1996, AM J EPIDEMIOL, V144, P290
   HO SA, 1991, J CLIN MICROBIOL, V29, P2543
   HOLCOMBE C, 1992, GUT, V33, P429, DOI 10.1136/gut.33.4.429
   Hua JS, 1999, HELICOBACTER, V4, P28, DOI 10.1046/j.1523-5378.1999.09043.x
   Lim CY, 2003, J CLIN MICROBIOL, V41, P3387, DOI 10.1128/JCM.41.7.3387-3391.2003
   Mbulaiteye SM, 2009, FRONT BIOSCI, V14, P1490, DOI 10.2741/3320
   Mukhopadhyay AK, 2000, J BACTERIOL, V182, P3219, DOI 10.1128/JB.182.11.3219-3227.2000
   Park CY, 2003, J CLIN MICROBIOL, V41, P3336, DOI 10.1128/JCM.41.7.3336-3338.2003
   Smith SI, 2004, WORLD J GASTROENTERO, V10, P1958
   TAYLOR NS, 1995, J CLIN MICROBIOL, V33, P918
   Thomas JE, 1999, PEDIATR RES, V45, P218, DOI 10.1203/00006450-199902000-00010
   Thoreson ACE, 1999, FEMS IMMUNOL MED MIC, V24, P201, DOI 10.1111/j.1574-695X.1999.tb01283.x
   WEAVER LT, 1995, T ROY SOC TROP MED H, V89, P347, DOI 10.1016/0035-9203(95)90002-0
   Wu IC, 2009, WORLD J GASTROENTERO, V15, P5465, DOI 10.3748/wjg.15.5465
NR 20
TC 11
Z9 11
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757-4749
J9 GUT PATHOG
JI Gut Pathogens
PD APR 20
PY 2011
VL 3
AR 5
DI 10.1186/1757-4749-3-5
PG 7
WC Gastroenterology & Hepatology; Microbiology
SC Gastroenterology & Hepatology; Microbiology
GA 879OB
UT WOS:000299338800001
PM 21507253
OA gold
DA 2017-08-15
ER

PT J
AU Sighoko, D
   Curado, MP
   Bourgeois, D
   Mendy, M
   Hainaut, P
   Bah, E
AF Sighoko, Dominique
   Curado, Maria Paula
   Bourgeois, Denis
   Mendy, Maimuna
   Hainaut, Pierre
   Bah, Ebrima
TI Increase in Female Liver Cancer in The Gambia, West Africa: Evidence
   from 19 Years of Population-Based Cancer Registration (1988-2006)
SO PLOS ONE
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; HEPATITIS-B; TOBACCO USE; INFECTION;
   AFLATOXIN; OBESITY; METAANALYSIS; CHILDREN; ENZYMES; COUNTRY
AB Background: Hepatocellular Carcinoma (HCC) is a common malignancy worldwide with a high burden in West Africa. Male to female ratios show consistent bias toward males, the biological bases and variations of which are not well understood. We have used data from the Gambian National Cancer Registry to compare trends in incidence of HCC in both genders.
   Methods and Findings: Two periods were compared, 1988-1997 (early) and 1998-2006 (recent). In addition, the regression program joinpoint was used to assess trends over 19 years. Differences with self-reported ethnicity were assessed for the recent period using population data from 2003 census. Male to female ratio showed a significant decrease between the two periods from 3.28:1 (95% CI, [2.93-3.65]) to 2.2:1 (95% CI, [1.99-2.43]). Although rates in males were relatively stable (38.36 and 32.84 for, respectively, early and recent periods), they increased from 11.71 to 14.9 in females with a significant Annual Percentage Change of 3.01 [0.3-5.8] over 19 years and an increase in number of cases of 80.28% (compared to 26% in males). Significant variations in HCC risk, but not in gender ratio were observed in relation with ethnicity.
   Conclusion: This analysis of the only national, population-based cancer registry in West Africa shows a significant increase in HCC in females over recent years. This increase may be the consequence of major changes in lifestyle or viral risk factors, in particular obesity and hepatitis C, which have both been documented to increase in West Africa during recent years.
C1 [Sighoko, Dominique; Curado, Maria Paula; Hainaut, Pierre; Bah, Ebrima] Int Agcy Res Canc, F-69372 Lyon, France.
   [Sighoko, Dominique; Bourgeois, Denis] Fac Odontol, Lyon, France.
   [Mendy, Maimuna] MRC, Fajara, Gambia.
   [Bah, Ebrima] Gambia Hepatitis Intervent Study, Fajara, Gambia.
RP Sighoko, D (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.
EM hainaut@iarc.fr
RI Curado, Maria Paula/M-6200-2013
OI Curado, Maria Paula/0000-0001-8172-2483; Hainaut, Pierre
   /0000-0002-1303-1610
FU International Agency for Research on Cancer
FX This work was supported by the International Agency for Research on
   Cancer. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abubakari AR, 2008, OBES REV, V9, P297, DOI 10.1111/j.1467-789X.2007.00462.x
   Abubakari AR, 2009, PUBLIC HEALTH, V123, P602, DOI 10.1016/j.puhe.2009.07.009
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Coleman M P, 1991, IARC Sci Publ, P267
   Curado MP, 2008, CANC INCIDENCE 5 CON, VIX
   Souza PSD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-246
   Jallow M, 2009, NAT GENET
   JEANSELLIER, 2003, ATLAS PEUPLES AFRIQ, P115
   JENSEN OM, 1996, ENREGISTREMENT CANCE, P142
   Jie X, 2007, ONCOGENE, V26, P5741, DOI 10.1038/sj.onc.1210362
   Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Larsson SC, 2007, BRIT J CANCER, V97, P1005
   Ocama P, 2009, BRIT J CANCER, V100, P799, DOI 10.1038/sj.bjc.6604893
   Pampel F, 2008, SOC SCI MED, V66, P1772, DOI 10.1016/j.socscimed.2007.12.003
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74
   Siervo M, 2006, EUR J CLIN NUTR, V60, P455, DOI 10.1038/sj.ejcn.1602337
   Sighoko D, 2010, INT J CANCER, V127, P2248, DOI 10.1002/ijc.25244
   SILVA ID, 1999, EPIDEMIOLOGIE CANC P, P334
   Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103
   Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x
   Umoh NJ, 2011, LIVER INT, V31, P215, DOI 10.1111/j.1478-3231.2010.02418.x
   Viviani S, 2008, CANCER EPIDEM BIOMAR, V17, P3216, DOI 10.1158/1055-9965.EPI-08-0303
   *WHO, 2009, GLOB STAT REP ALC 20
   WILD CP, 1993, CANCER EPIDEM BIOMAR, V2, P555
   Yach D, 2002, TOB CONTROL, V11, P252
   [Anonymous], 2006, CANC EPIDEMIOLOGY PR
NR 27
TC 8
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 7
PY 2011
VL 6
IS 4
AR e18415
DI 10.1371/journal.pone.0018415
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 746IN
UT WOS:000289238700013
PM 21490972
OA gold
DA 2017-08-15
ER

PT J
AU Ota, MO
   Akinsola, A
   Townend, J
   Antonio, M
   Enwere, G
   Nsekpong, D
   Bojang, A
   Saaka, M
   Burton, RL
   Zaman, A
   Goldblatt, D
   Adegbola, RA
AF Ota, Martin O.
   Akinsola, Adebayo
   Townend, John
   Antonio, Martin
   Enwere, Godwin
   Nsekpong, David
   Bojang, Abdoulie
   Saaka, Mark
   Burton, R. L.
   Zaman, Akram
   Goldblatt, David
   Adegbola, Richard A.
TI The immunogenicity and impact on nasopharyngeal carriage of fewer doses
   of conjugate pneumococcal vaccine immunization schedule
SO VACCINE
LA English
DT Article
DE Alternative; Pneumococcus; Conjugate; Vaccine; Schedule; Antibodies;
   Opsonophagocytic assay
ID RANDOMIZED-CONTROLLED-TRIAL; POLYSACCHARIDE VACCINE; ANTIBODY-RESPONSES;
   ACQUIRED-IMMUNITY; STREPTOCOCCUS-PNEUMONIAE; OTITIS-MEDIA; RURAL AREA;
   CHILDREN; INFANTS; COLONIZATION
AB The immunogenicity and impact on carriage of fewer doses of pneumococcal conjugate vaccine (PCV7) followed by booster with pneumococcal polysaccharide vaccine (PPV) were investigated. 684 infants were assigned randomly to one of the three groups that received one (A), two (B) or three (C) doses of PCV7 between 2 and 4 months of age, plus PPV at 10 months. Following primary vaccination protective antibody titers of > 0.35 mu/ml against the PCV7 serotypes combined increased significantly with the number of PCV7 doses, 44% vs. 77% vs. 94% (p < 0.001), and correlated positively with the opsonophagocytic indices, but negatively with nasopharyngeal carriage of pneumococcus. The differences in antibody responses and pneumococcal carriage between the groups diminished following booster with PPV, implying that administration of one or two doses of PCV7, with a booster dose of PPV might lower the cost of protection against IPD in young children in resource poor countries. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Ota, Martin O.; Akinsola, Adebayo; Townend, John; Antonio, Martin; Enwere, Godwin; Nsekpong, David; Bojang, Abdoulie; Saaka, Mark; Zaman, Akram; Adegbola, Richard A.] Med Res Council MRC Labs, Banjul, Gambia.
   [Enwere, Godwin] London Sch Hyg & Trop Med, London WC1, England.
   [Goldblatt, David] UCL, Inst Child Hlth, London, England.
   [Burton, R. L.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
   [Adegbola, Richard A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Ota, MO (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM mota@mrc.gm
RI Goldblatt, David/C-5972-2008
OI Goldblatt, David/0000-0002-0769-5242
FU NIH [N01 AI-30021]; WHO; UK Medical Research Council
FX We thank the Gambian government, and the staff of Expanded Programme on
   Immunisation and the Divisional Health Team of the Upper and Central
   River Regions of The Gambia for their kind assistance in the conduct of
   this study. We appreciate the great input of the field workers for the
   excellent field work. We thank Professor Felicity Cutts for her
   participation in study design and for critically reviewing this
   manuscript. We thankfully acknowledge Professor Moon H. Nahm of
   University of Alabama at Birmingham and Dr. Farukh M. Khambaty of NIH,
   Bethesda, USA for facilitating the OPA experiments through their NIH
   contract (N01 AI-30021). We are particularly grateful to the parents and
   guardians that allowed their infants to participate in this study.
   Funding for this study was provided by WHO and UK Medical Research
   Council.
CR Arifeen SE, 2009, LANCET, V374, P393, DOI 10.1016/S0140-6736(09)60828-X
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   BROWN EJ, 1983, REV INFECT DIS, V5, pS797
   Burton RL, 2006, CLIN VACCINE IMMUNOL, V13, P1004, DOI 10.1128/CVI.00112-06
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 1996, J INFECT DIS, V174, P1352
   Dagan R, 2005, J INFECT DIS, V192, P367, DOI 10.1086/431679
   Douglas RM, 1999, CLIN INFECT DIS, V28, P192, DOI 10.1086/515112
   Ekstrom N, 2005, INFECT IMMUN, V73, P369, DOI 10.1128/IAI.73.1.369-377.2005
   Givon-Lavi N, 2010, PEDIATR INFECT DIS J, V29, P756, DOI 10.1097/INF.0b013e3181d99345
   Goldblatt D, 2006, PEDIATR INFECT DIS J, V25, P312, DOI 10.1097/01.inf.0000207483.60267.e7
   Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524
   GRANOFF DM, 1994, JAMA-J AM MED ASSOC, V272, P1116, DOI 10.1001/jama.272.14.1116
   Guimaraes Thais, 2002, International Journal of Infectious Diseases, V6, P113, DOI 10.1016/S1201-9712(02)90071-8
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Huebner RE, 2002, PEDIATR INFECT DIS J, V21, P1004, DOI 10.1097/01.inf.0000036012.37665.fe
   King WJ, 1996, J PEDIATR-US, V128, P196, DOI 10.1016/S0022-3476(96)70389-X
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Lu YJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000159
   Malley R, 2005, P NATL ACAD SCI USA, V102, P4848, DOI 10.1073/pnas.0501254102
   Marchant A, 2006, J INFECT DIS, V193, P1598, DOI 10.1086/503775
   Matsuzaki G, 2007, MICROBIOL IMMUNOL, V51, P1139
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   Millar EV, 2007, CLIN INFECT DIS, V44, P1173, DOI 10.1086/513199
   Nurkka A, 2001, VACCINE, V20, P194, DOI 10.1016/S0264-410X(01)00250-X
   Obaro SK, 2004, PEDIATR INFECT DIS J, V23, P1023, DOI 10.1097/01.inf.0000143651.54880.09
   Obaro SK, 1997, PEDIATR INFECT DIS J, V16, P1135, DOI 10.1097/00006454-199712000-00007
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   Obaro SK, 2000, ACTA TROP, V75, P141, DOI 10.1016/S0001-706X(99)00094-7
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   Peltola H, 2003, LANCET, V361, P2170, DOI 10.1016/S0140-6736(03)13784-1
   Russell FM, 2010, VACCINE, V28, P3341, DOI 10.1016/j.vaccine.2010.02.087
   Russell FM, 2009, VACCINE, V27, P5685, DOI 10.1016/j.vaccine.2009.06.098
   Saaka M, 2008, VACCINE, V26, P3719, DOI 10.1016/j.vaccine.2008.04.066
   Shann F, 1999, LANCET S2, V354, P7
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   Weinberger DM, 2008, J INFECT DIS, V197, P1511, DOI 10.1086/587941
NR 37
TC 19
Z9 20
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 5
PY 2011
VL 29
IS 16
BP 2999
EP 3007
DI 10.1016/j.vaccine.2011.01.098
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 757CU
UT WOS:000290062700025
PM 21320549
OA No
DA 2017-08-15
ER

PT J
AU Choi, Y
   Townend, J
   Vincent, T
   Zaidi, I
   Sarge-Njie, R
   Jaye, A
   Clifford, DB
AF Choi, Youngjee
   Townend, John
   Vincent, Tim
   Zaidi, Irfan
   Sarge-Njie, Ramu
   Jaye, Assan
   Clifford, David B.
TI Neurologic manifestations of human immunodeficiency virus-2: dementia,
   myelopathy, and neuropathy in West Africa
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Article
DE HIV; Neurology; Polyneuropathy; HIV-associated neurocognitive disorder;
   HAND
ID DISTAL SENSORY POLYNEUROPATHY; INTERNATIONAL HIV DEMENTIA; RISK-FACTORS;
   CLINICAL-FEATURES; NEUROCOGNITIVE DISORDERS; ANTIRETROVIRAL THERAPY;
   PERIPHERAL NEUROPATHY; VIRAL LOAD; INFECTION; DISEASE
AB While well documented in human immunodeficiency virus (HIV)-1, neurologic sequelae have not been systematically evaluated in HIV-2. After excluding for confounding comorbidities, 67 individuals from a rural cohort in Guinea-Bissau (22 HIV-2 participants, 45 seronegative controls) were evaluated. HIV + individuals were divided into CD4 < 350 and CD4 a parts per thousand yenaEuro parts per thousand 350 for analysis. HIV-associated neurocognitive disorders (HAND), assessed by the International HIV Dementia Scale (IHDS), distal sensory polyneuropathy (DSPN), and myelopathy were the main outcome variables. In univariate analysis, there was no difference in IHDS scores among groups. When analyzed by primary education attainment, IHDS scores were nonsignificantly higher (p = 0.06) with more education. There was no significant difference in DSPN prevalence among groups; overall, 45% of participants had DSPN. There were no cases of myelopathy. In multivariate linear regression, higher IHDS scores were significantly correlated with older age (coefficient = -0.11, p < 0.001). Logistic regression analysis showed that older age (odds ratio (OR) 95% CI 1.04-1.20), lower CD4 count (OR 95% CI 0.996-0.999), and higher BMI (OR 95% CI 1.02-1.43) significantly predicted the presence of DSPN. While a significant increase in cognitive impairment was not observed in HIV-2-infected individuals, the study suggests the IHDS may be a less effective screening tool for HAND in settings of lower educational attainment as encountered in rural Guinea-Bissau. Similar to HIV-1, DSPN seems to occur with lower CD4 counts in HIV-2. Further study of the viral-host interactions in HIV-2 and its consequent neurological diseases may provide an avenue for understanding the epidemic problems of HIV-1.
C1 [Clifford, David B.] Washington Univ, Sch Med, St Louis, MO 63110 USA.
   [Townend, John; Vincent, Tim; Zaidi, Irfan; Sarge-Njie, Ramu] MRC, Banjul, Gambia.
   [Jaye, Assan] Univ Cheikh Anta Diop, Dakar, Senegal.
RP Clifford, DB (reprint author), Washington Univ, Sch Med, POB 8111,660 S Euclid, St Louis, MO 63110 USA.
EM cliffordd@neuro.wustl.edu
FU Medical Research Council [MC_UP_A900_1121, MC_UP_A900_1125]; NIMH NIH
   HHS [R21 MH083489]
CR Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b
   Arvidson N, 2004, AIDS RES HUM RETROV, V20, P711, DOI 10.1089/0889222041524625
   BACELLAR H, 1994, NEUROLOGY, V44, P1892
   Beghi E, 1998, J CLIN EPIDEMIOL, V51, P697, DOI 10.1016/S0895-4356(98)00039-0
   Boisse L, 2008, NEUROL CLIN, V26, P799, DOI 10.1016/j.ncl.2008.04.002
   Childs EA, 1999, NEUROLOGY, V52, P607
   Ellis RJ, 2010, ARCH NEUROL-CHICAGO, V67, P552, DOI 10.1001/archneurol.2010.76
   England JD, 2005, MUSCLE NERVE, V31, P113, DOI 10.1002/mus.20233
   KARNOFSKY DA, 1948, CANCER, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
   KLEMM E, 1988, J NEUROL, V235, P304, DOI 10.1007/BF00314179
   Letendre Scott L, 2009, Top HIV Med, V17, P46
   Lichtenstein KA, 2005, CLIN INFECT DIS, V40, P148, DOI 10.1086/426076
   LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005
   MABEY DCW, 1988, BRIT MED J, V296, P83
   Maritz J, 2010, MUSCLE NERVE, V41, P599, DOI 10.1002/mus.21535
   Martinez-Steele E, 2007, AIDS, V21, P317, DOI 10.1097/QAD.0b013e328011d7ab
   McArthur JC, 2004, J NEUROIMMUNOL, V157, P3, DOI 10.1016/j.jneuroim.2004.08.042
   McArthur JC, 2005, LANCET NEUROL, V4, P543, DOI 10.1016/S1474-4422(05)70165-4
   McArthur JC, 2010, ANN NEUROL, V67, P699, DOI 10.1002/ana.22053
   Mold JW, 2004, J AM BOARD FAM PRACT, V17, P309
   MONFORTE R, 1995, ARCH NEUROL-CHICAGO, V52, P45
   Morgello S, 2004, ARCH NEUROL-CHICAGO, V61, P546, DOI 10.1001/archneur.61.4.546
   Moulignier A, 2006, CLIN INFECT DIS, V42, pE89, DOI 10.1086/503909
   Njamnshi AK, 2008, JAIDS-J ACQ IMM DEF, V49, P393, DOI 10.1097/QAI.0b013e318183a9df
   Novella SP, 2001, MUSCLE NERVE, V24, P1229, DOI 10.1002/mus.1137
   Pardo CA, 2001, J PERIPHER NERV SYST, V6, P21, DOI 10.1046/j.1529-8027.2001.006001021.x
   PRICE RW, 1988, J INFECT DIS, V158, P1079
   RAMIANDRISOA H, 1991, J TROP GEOGR NEUROL, V1, P39
   Riedel D, 2006, J NEUROVIROL, V12, P34, DOI 10.1080/13550280500516500
   Robertson K, 2009, NEUROPSYCHOL REV, V19, P232, DOI 10.1007/s11065-009-9096-z
   Rowland-Jones SL, 2007, NAT IMMUNOL, V8, P329, DOI 10.1038/ni0407-329
   Sacktor NC, 2005, AIDS, V19, P1367
   Schifitto G, 2002, NEUROLOGY, V58, P1764
   Simioni S, 2010, AIDS, V24, P1243, DOI 10.1097/QAD.0b013e3283354a7b
   Simpson DM, 2006, NEUROLOGY, V66, P1679, DOI 10.1212/01.wnl.0000218211.85675.18
   Sithinamsuwan P, 2008, JAIDS-J ACQ IMM DEF, V49, P456, DOI 10.1097/QAI.0b013e318186eb03
   SO YT, 1988, ARCH NEUROL-CHICAGO, V45, P945
   Tagliati M, 1999, ARCH NEUROL-CHICAGO, V56, P84, DOI 10.1001/archneur.56.1.84
   Teunissen LL, 2002, J NEUROL NEUROSUR PS, V72, P590, DOI 10.1136/jnnp.72.5.590
   Tienen Carla van, 2010, J Acquir Immune Defic Syndr, V53, P640, DOI 10.1097/QAI.0b013e3181bf1a25
   Valcour VG, 2007, NEUROLOGY, V68, P525, DOI 10.1212/01.wnl.0000253196.78193.c7
   Waldrop-Valverde D, 2010, J NEUROVIROL, V16, P264, DOI 10.3109/13550284.2010.497808
   Watters MR, 2004, NEUROLOGY, V62, P1378
NR 43
TC 15
Z9 15
U1 2
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD APR
PY 2011
VL 17
IS 2
BP 166
EP 175
DI 10.1007/s13365-011-0022-9
PG 10
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 750RV
UT WOS:000289566600005
PM 21424866
OA No
DA 2017-08-15
ER

PT J
AU Ota, MOC
   Oluwalana, C
   Howie, SRC
   Gomez, M
   Ogunniyi, AD
   Mendy-Gomez, AL
   Owolabi, O
   Mureithi, MW
   Townend, J
   Secka, O
   Antonio, M
   Sutherland, JS
   Adegbola, RA
AF Ota, M. O. C.
   Oluwalana, C.
   Howie, S. R. C.
   Gomez, M.
   Ogunniyi, A. D.
   Mendy-Gomez, A. L.
   Owolabi, O.
   Mureithi, M. W.
   Townend, J.
   Secka, O.
   Antonio, M.
   Sutherland, J. S.
   Adegbola, R. A.
TI Antibody and T-cell responses during acute and convalescent stages of
   invasive pneumococcal disease
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Pneumococcal proteins; Antibodies; T-cells; Invasive pneumococcal
   disease; Immune responses; Humans
ID SURFACE PROTEIN-A; STREPTOCOCCUS-PNEUMONIAE; GAMMA-INTERFERON;
   OTITIS-MEDIA; NASOPHARYNGEAL COLONIZATION; CONJUGATE VACCINES; MUCOSAL
   ANTIBODY; CARRIAGE; CHILDREN; ANTIGENS
AB Objective: To understand the pattern of immune responses to pneumococcal proteins during invasive disease as a guide to their development as vaccine candidates.
   Methods: The antibody concentration and avidity, as well as frequency of interferon-gamma (IFN-gamma)-, interleukin-10 (IL-10)-, and tumor necrosis factor-alpha (TNF-alpha)-containing CD4+ T-lymphocytes in response to pneumolysin, pneumococcal surface protein A (PspA), and choline-binding protein A (CbpA), during and after invasive pneumococcal disease (IPD) in 20 children were compared to those of 20 healthy matched controls.
   Results: During the acute phase of IPD, the concentrations of antibodies against these three pneumococcal proteins were lower, whereas the frequencies of IL-10-and TNF-alpha-producing CD4+ T-cells were higher, compared to values obtained during convalescence and in healthy controls (p < 0.01). In addition, the concentrations of antibodies against the capsular polysaccharides for the serotypes isolated from these patients, were all below the detection level of the assay during both the acute and convalescent phases of IPD.
   Conclusion: These data indicate that the recognition of these antigens by the immune system occurs in variable proportions according to the stage of infection, implying the important role of these in the pathogenesis of IPD, and support their usefulness in vaccine development. (C) 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Ota, M. O. C.; Oluwalana, C.; Howie, S. R. C.; Gomez, M.; Mendy-Gomez, A. L.; Owolabi, O.; Mureithi, M. W.; Townend, J.; Secka, O.; Antonio, M.; Sutherland, J. S.; Adegbola, R. A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Ogunniyi, A. D.] Univ Adelaide, Sch Mol & Biochem Sci, Res Ctr Infect Dis, Adelaide, SA 5005, Australia.
   [Mureithi, M. W.] Harvard Univ, Sch Med, Boston, MA USA.
   [Adegbola, R. A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Ota, MOC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM mota@mrc.gm
OI Sutherland, Jayne/0000-0002-7083-4997
FU UK Medical Research Council; Hib Initiative
FX This study was made possible through funding from the UK Medical
   Research Council and the Hib Initiative.
CR ANIANSSON G, 1992, J INFECT DIS, V165, pS38
   Bernatoniene J, 2005, DRUGS, V65, P229, DOI 10.2165/00003495-200565020-00005
   BROWN EJ, 1982, J CLIN INVEST, V69, P85, DOI 10.1172/JCI110444
   BROWN EJ, 1983, REV INFECT DIS, V5, pS797
   Choo S, 2001, ARCH DIS CHILD, V84, P289, DOI 10.1136/adc.84.4.289
   Ekstrom N, 2005, INFECT IMMUN, V73, P369, DOI 10.1128/IAI.73.1.369-377.2005
   Faden H, 1997, J INFECT DIS, V175, P1440
   GRAY BM, 1980, J INFECT DIS, V142, P923
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Kadioglu A, 2004, INFECT IMMUN, V72, P2689, DOI 10.1128/IAI.72.5.2689-2697.2004
   Khan AQ, 2002, INFECT IMMUN, V70, P749, DOI 10.1128/IAI.70.2.749-761.2002
   Kyaw MH, 2005, J INFECT DIS, V192, P377, DOI 10.1086/431521
   Morrison KE, 2000, J CLIN MICROBIOL, V38, P434
   Mulholland EK, 2005, NEW ENGL J MED, V352, P75, DOI 10.1056/NEJMe048306
   Mulholland K, 1999, LANCET, V354, P590, DOI 10.1016/S0140-6736(98)10238-6
   Mureithi MW, 2009, J INFECT DIS, V200, P783, DOI 10.1086/605023
   Musher DM, 2001, J INFECT DIS, V183, P827, DOI 10.1086/318833
   O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097
   Obaro S, 2002, J MED MICROBIOL, V51, P98
   Ota MOC, 2004, VACCINE, V22, P511, DOI 10.1016/j.vaccine.2003.07.020
   Paton JC, 1998, TRENDS MICROBIOL, V6, P85, DOI 10.1016/S0966-842X(98)01220-7
   PATON JC, 1998, TRENDS MICROBIOL, V6, P87
   Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x
   Rubins JB, 1997, INFECT IMMUN, V65, P2975
   Saaka M, 2008, VACCINE, V26, P3719, DOI 10.1016/j.vaccine.2008.04.066
   SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278
   Simell B, 2001, J INFECT DIS, V183, P887, DOI 10.1086/319246
   Sun K, 2007, INFECT IMMUN, V75, P1196, DOI 10.1128/IAI.01403-06
   Sutherland JS, 2010, J IMMUNOL, V184, P6537, DOI 10.4049/jimmunol.1000399
   Usinger WR, 1999, INFECT IMMUN, V67, P2366
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   Virolainen A, 2000, PEDIATR INFECT DIS J, V19, P134, DOI 10.1097/00006454-200002000-00011
   Zhang QB, 2006, EUR J IMMUNOL, V36, P46, DOI 10.1002/eji.200535101
   Zhang QB, 2006, INFECT IMMUN, V74, P4735, DOI 10.1128/IAI.00165-06
   Zhang QB, 2010, J INFECT DIS, V201, P1753, DOI 10.1086/652495
NR 36
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD APR
PY 2011
VL 15
IS 4
BP E282
EP E288
DI 10.1016/j.ijid.2010.12.011
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 736OL
UT WOS:000288503900011
PM 21330177
OA gold
DA 2017-08-15
ER

PT J
AU Ngom, PT
   Solon, J
   Moore, S
   Morgan, G
   Prentice, A
   Aspinall, R
AF Ngom, Pa Tamba
   Solon, Juan
   Moore, Sophie
   Morgan, Gareth
   Prentice, Andrew
   Aspinall, Richard
TI Early life nutritional influences on thymic activity and T cell
   parameters in adults
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting 2011
CY APR 09-13, 2011
CL Washington, DC
SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET)
C1 [Ngom, Pa Tamba; Solon, Juan; Moore, Sophie; Prentice, Andrew] British Med Res Council MRC, Dept Nutr, Banjul, Gambia.
   [Morgan, Gareth] Univ Coll Swansea, Dept Pediat Immunol, Swansea, W Glam, Wales.
   [Aspinall, Richard] Cranfield Univ, Cranfield MK43 0AL, Beds, England.
RI Aspinall, Richard/E-4924-2013
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2011
VL 25
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 032IE
UT WOS:000310708405214
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
   van der Merwe, L
AF Prentice, Andrew M.
   van der Merwe, Liandre
TI Impact of fatty acid status on immune function of children in low-income
   countries
SO MATERNAL AND CHILD NUTRITION
LA English
DT Review
DE immunity; fatty acid; PUFA; low-income countries; children; enteropathy;
   growth
ID INTESTINAL PERMEABILITY; MEMBRANE MICRODOMAINS; ANTIGEN PRESENTATION;
   INFANT GROWTH; LIPID RAFTS; SUPPLEMENTATION; INFLAMMATION; MODULATION;
   MECHANISMS; RESPONSES
AB In vitro and animal studies point to numerous mechanisms by which fatty acids, especially long-chain polyunsaturated fatty acids (LCPUFA), can modulate the innate and adaptive arms of the immune system. These data strongly suggest that improving the fatty acid supply of young children in low-income countries might have immune benefits. Unfortunately, there have been virtually no studies of fatty acid/immune interactions in such settings. Clinical trial registers list over 150 randomized controlled trials (RCTs) involving PUFAs, only one in a low-income setting (the Gambia). We summarize those results here. There was evidence for improved growth and nutritional status, but the primary end point of chronic environmental enteropathy showed no benefit, possibly because the infants were still substantially breastfed. In high-income settings, there have been RCTs with fatty acids (usually LCPUFAs) in relation to 18 disease end points, for some of which there have been numerous trials (asthma, inflammatory bowel disease and rheumatoid arthritis). For these diseases, the evidence is judged reasonable for risk reduction for childhood asthma (but not in adults), as yielding possible benefit in Crohn's disease (insufficient evidence in ulcerative colitis) and for convincing evidence for rheumatoid arthritis at sufficient dose levels, though formal meta-analyses are not yet available. This analysis suggests that fatty acid interventions could yield immune benefits in children in poor settings, especially in non-breastfed children and in relation to inflammatory conditions such as persistent enteropathy. Benefits might include improved responses to enteric vaccines, which frequently perform poorly in low-income settings, and these questions merit randomized trials.
C1 [Prentice, Andrew M.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   MRC Keneba, Keneba, Gambia.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM Andrew.Prentice@lshtm.ac.uk
CR Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0
   Calder P. C., 2006, AM J CLIN NUTR, V83, p1505S
   Calder PC, 2010, J PEDIATR-US, V156, P869, DOI 10.1016/j.jpeds.2010.03.024
   Calder PC, 2009, INT REV IMMUNOL, V28, P506, DOI 10.3109/08830180903197480
   Calder PC, 2009, BRIT J NUTR, V101, P1, DOI 10.1017/S0007114508076228
   Calder PC, 2008, PROSTAG LEUKOTR ESS, V79, P101, DOI 10.1016/j.plefa.2008.09.016
   Campbell DI, 2004, J PEDIATR GASTR NUTR, V39, P153, DOI 10.1097/00005176-200408000-00005
   Campbell DI, 2003, PEDIATR RES, V54, P306, DOI 10.1203/01.PDR.0000076666.16021.5E
   Fan YY, 2003, J NUTR, V133, P1913
   FAO, 1994, 57 FAO
   Galli C, 2009, ANN NUTR METAB, V55, P123, DOI 10.1159/000228999
   Ganapathy S, 2009, INDIAN PEDIATR, V46, P785
   German JB, 2011, MATERN CHILD NUTR, V7, P2, DOI 10.1111/j.1740-8709.2011.00300.x
   Glaser C, 2011, MATERN CHILD NUTR, V7, P27, DOI 10.1111/j.1740-8709.2011.00319.x
   Goto R, 2009, BRIT J NUTR, V101, P1509, DOI 10.1017/S0007114508083554
   Gottrand F, 2008, J NUTR, V138, p1807S
   Grimble RF, 2001, P NUTR SOC, V60, P389, DOI 10.1079/PNS2001102
   Harbige LS, 2003, LIPIDS, V38, P323, DOI 10.1007/s11745-003-1067-z
   Harbige LS, 2001, P NUTR SOC, V60, P449, DOI 10.1079/PNS2001123
   Horejsi V, 2003, IMMUNOL REV, V191, P148, DOI 10.1034/j.1600-065X.2003.00001.x
   Horvath A, 2007, BRIT J NUTR, V98, P253, DOI 10.1017/S0007114507709078
   Hughes DA, 1996, AM J CLIN NUTR, V63, P267
   Katagiri YU, 2001, MICROBIOL IMMUNOL, V45, P1
   Lauritzen L, 2011, MATERN CHILD NUTR, V7, P41, DOI 10.1111/j.1740-8709.2011.00303.x
   Leite MS, 2005, SHOCK, V23, P173, DOI 10.1097/01.shk.0000148072.12094.77
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   Makrides M, 2005, AM J CLIN NUTR, V81, P1094
   Makrides M, 2011, MATERN CHILD NUTR, V7, P80, DOI 10.1111/j.1740-8709.2011.00304.x
   Mattacks Christine A, 2004, Lymphat Res Biol, V2, P107, DOI 10.1089/1539685042564363
   Michaelsen KF, 2011, MATERN CHILD NUTR, V7, P124, DOI 10.1111/j.1740-8709.2011.00302.x
   Pond CM, 2005, PROSTAG LEUKOTR ESS, V73, P17, DOI 10.1016/j.plefa.2005.04.005
   Prentice AM, 2000, AM J CLIN NUTR, V72, p1253S
   Raviv S, 2010, CURR OPIN PULM MED, V16, P71, DOI 10.1097/MCP.0b013e3283323b73
   Razzaq TM, 2004, IMMUNOLOGY, V113, P413, DOI 10.1111/j.1365-2567.2004.01998.x
   Roig-Perez S, 2010, J NUTR, V140, P1557, DOI 10.3945/jn.109.120469
   Rosenfeld E, 2009, ACTA PAEDIATR, V98, P91, DOI 10.1111/j.1651-2227.2008.00988.x
   Sanderson P, 1997, J LEUKOCYTE BIOL, V62, P771
   Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7
   Shaikh SR, 2007, J LIPID RES, V48, P127, DOI 10.1194/jlr.M600365-JLR200
   Simmer K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000376.pub2
   Simmer K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000375.pub3
   Smit EN, 2004, PROSTAG LEUKOTR ESS, V71, P241, DOI 10.1016/j.plefa.2004.03.019
   Smit EN, 2000, ARCH DIS CHILD, V82, P366, DOI 10.1136/adc.82.5.366
   Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637
   Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200
   Sullivan PB, 2002, J PEDIATR GASTR NUTR, V34, pS11, DOI 10.1097/01.MPG.0000017289.92960.F2
   Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI13416
   Vachier I, 2002, BIOCHEM BIOPH RES CO, V290, P219, DOI 10.1006/bbrc.2001.6155
   VANDERMERWE L, 2009, THESIS U LONDON
   Weatherill AR, 2005, J IMMUNOL, V174, P5390
   Yaqoob P, 2007, BRIT J NUTR, V98, pS41, DOI 10.1017/S0007114507832995
NR 51
TC 6
Z9 6
U1 2
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1740-8695
J9 MATERN CHILD NUTR
JI Matern. Child Nutr.
PD APR
PY 2011
VL 7
SU 2
BP 89
EP 98
DI 10.1111/j.1740-8709.2011.00313.x
PG 10
WC Nutrition & Dietetics; Pediatrics
SC Nutrition & Dietetics; Pediatrics
GA 729DH
UT WOS:000287928100008
PM 21366869
OA No
DA 2017-08-15
ER

PT J
AU Flanagan, KL
   Klein, SL
   Skakkebaek, NE
   Marriott, I
   Marchant, A
   Selin, L
   Fish, EN
   Prentice, AM
   Whittle, H
   Benn, CS
   Aaby, P
AF Flanagan, Katie L.
   Klein, Sabra L.
   Skakkebaek, Niels E.
   Marriott, Ian
   Marchant, Arnaud
   Selin, Liisa
   Fish, Eleanor N.
   Prentice, Andrew M.
   Whittle, Hilton
   Benn, Christine Stabell
   Aaby, Peter
CA Optimize Immunization Network Op
TI Sex differences in the vaccine-specific and non-targeted effects of
   vaccines
SO VACCINE
LA English
DT Article
DE Vaccines; Non-specific effects; Non-targeted effects; Sex differences;
   Innate immunity; Adaptive immunity; Sex hormones; X-linked genes;
   Vitamin A; Reactogenicity; Heterologous immunity
ID FEMALE-MALE MORTALITY; DIPHTHERIA-TETANUS-PERTUSSIS; TITER
   MEASLES-VACCINE; INNATE IMMUNITY; GUINEA-BISSAU; ROUTINE VACCINATIONS;
   HETEROLOGOUS IMMUNITY; CHILDHOOD MORTALITY; CYTOKINE PRODUCTION; GUERIN
   VACCINATION
AB Vaccines have non-specific effects (NSE) on subsequent morbidity and mortality from non-vaccine related infectious diseases. Thus NSE refers to any effect that cannot be accounted for by the induction of immunity against the vaccine-targeted disease. These effects are sex-differential, generally being more pronounced in females than males. Furthermore, the NSE are substantial causing greater than fifty percent changes in all cause mortality in certain settings, yet have never been systematically tested despite the fact that millions of children receive vaccines each year. As we strive to eliminate infectious diseases through vaccination programmes, the relative impact of NSE of vaccines on mortality is likely to increase, raising important questions regarding the future of certain vaccine schedules. A diverse group of scientists met in Copenhagen to discuss non-specific and sex-differential effects of vaccination, and explore plausible biological explanations. Herein we describe the contents of the meeting and the establishment of the 'Optimmunize' network aimed at raising awareness of this important issue among the wider scientific community.
C1 [Flanagan, Katie L.; Whittle, Hilton] MRC Labs, Fajara, Gambia.
   [Klein, Sabra L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA.
   [Skakkebaek, Niels E.] Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark.
   [Marriott, Ian] Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA.
   [Marchant, Arnaud] Univ Libre Bruxelles, Inst Med Immunol, Brussels, Belgium.
   [Selin, Liisa] Univ Massachusetts, Sch Med, Worcester, MA USA.
   [Fish, Eleanor N.] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada.
   [Fish, Eleanor N.] Univ Toronto, Dept Immunol, Toronto, ON, Canada.
   [Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
   [Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC Int Nutr Grp, Keneba, Gambia.
   [Benn, Christine Stabell; Aaby, Peter] State Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   [Benn, Christine Stabell; Aaby, Peter] Indepth Network, Bandim Hlth Project, Bissau Codex 1004, Guinea Bissau.
RP Flanagan, KL (reprint author), MRC Labs, POB 273, Fajara, Gambia.
EM kflanagan@mrc.gm; saklein@jhsph.edu; niels.erik.skakkebaek@rh.hosp.dk;
   imarriot@uncc.edu; arnaud.marchant@ulb.ac.be; Liisa.Selin@umassmed.edu;
   en.fish@utoronto.ca; Andrew.Prentice@lshtm.ac.uk; hcwhittle@yahoo.co.uk;
   cb@ssi.dk; p.aaby@bandim.org
FU Novo Nordisk Foundation
FX The authors wish to thank the Novo Nordisk Foundation for sponsoring the
   workshop held in Copenhagen in January 2010. The following people also
   participated in the workshop (those that gave talks are indicated by an
   asterisk). Gert Almind*, Novo Nordisk Foundation, Copenhagen, Denmark;
   Jacobus Boomsma, University of Copenhagen; Mogens Claesson*, University
   of Copenhagen; Hazel Dockrell, LSHTM, UK; Kosuke Kawai*, Harvard School
   of Public Health, USA; Henrik Leffers*; University of Copenhagen;
   Jennifer Moisi, Centre for Geographic Medicine, Kilifi, Kenya; Anita Van
   Den Biggela, University of Western Australia; Maria Yazdan-bakhsh*,
   Leiden University Medical Centre, The Netherlands.
CR Aaby P, 2006, VACCINE, V24, P4701, DOI 10.1016/j.vaccine.2006.03.038
   Aaby P, 2006, VACCINE, V24, P2764, DOI 10.1016/j.vaccine.2006.01.004
   AABY P, 1993, AM J EPIDEMIOL, V138, P746
   Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   Aaby P, 2004, INT J EPIDEMIOL, V33, P367, DOI 10.1093/ije/dyh004
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2003, INT J EPIDEMIOL, V32, P106, DOI 10.1093/ije/dyg005
   AABY P, 1993, J PEDIATR-US, V122, P904
   Aaby P, 2006, PEDIATR INFECT DIS J, V25, P721, DOI 10.1097/01.inf.0000227829.64686.ae
   Aaby P, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6495
   Alexandroff AB, 1999, LANCET, V353, P1689, DOI 10.1016/S0140-6736(98)07422-4
   Andersson AM, 1998, J CLIN ENDOCR METAB, V83, P675, DOI 10.1210/jc.83.2.675
   Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P1227, DOI 10.1067/mai.2003.1483
   Benn CS, 2009, AM J CLIN NUTR, V90, P629, DOI 10.3945/ajcn.2009.27477
   Benn CS, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1101
   Benn CS, 2009, VACCINE, V27, P2891, DOI 10.1016/j.vaccine.2009.02.080
   Burl S, 2010, J IMMUNOL, V185, P2620, DOI 10.4049/jimmunol.1000552
   Chen HD, 2003, AM J PATHOL, V163, P1341, DOI 10.1016/S0002-9440(10)63493-1
   Farrington CP, 2009, TROP MED INT HEALTH, V14, P977, DOI 10.1111/j.1365-3156.2009.02302.x
   Fine PEM, 2009, TROP MED INT HEALTH, V14, P969, DOI 10.1111/j.1365-3156.2009.02301.x
   Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
   Garly ML, 2004, PEDIATR INFECT DIS J, V23, P1086, DOI 10.1097/01.inf.0000145700.77286.94
   Goriely S, 2001, J IMMUNOL, V166, P2141
   HOLT EA, 1993, J INFECT DIS, V168, P1087
   Kahlke V, 2002, SHOCK, V18, P24, DOI 10.1097/00024382-200207000-00005
   Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589
   Kawai K, 2010, BRIT J NUTR, V103, P1784, DOI 10.1017/S0007114509993862
   Kim AM, 2010, NATURE, V465, P688, DOI 10.1038/465688a
   Klein Sabra, 2005, Gend Med, V2, P197, DOI 10.1016/S1550-8579(05)80050-6
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Klein SL, 2000, NEUROSCI BIOBEHAV R, V24, P627, DOI 10.1016/S0149-7634(00)00027-0
   Klein SL, 2010, SEX GENDER INFLUENZA
   Krampera M, 2000, HAEMATOLOGICA, V85, P675
   Levy O, 2004, J IMMUNOL, V173, P4627
   Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   Marriott I, 2006, J REPROD IMMUNOL, V71, P12, DOI 10.1016/j.jri.2006.01.004
   Mckee AS, 2007, IMMUNITY, V27, P687, DOI 10.1016/j.immuni.2007.11.003
   Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164
   Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004
   Merkel SM, 2001, INFECT IMMUN, V69, P6119, DOI 10.1128/IAI.69.10.6119-6122.2001
   Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105
   Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740
   Ovsyannikova IG, 2003, VACCINE, V21, P3946, DOI 10.1016/S0264-410X(03)00272-X
   Page KR, 2006, CELL MICROBIOL, V8, P185, DOI 10.1111/j.1462-5822.2005.00653.x
   Pittman PR, 2002, VACCINE, V20, pS48, DOI 10.1016/S0264-410X(02)00172-X
   Reif DM, 2009, GENES IMMUN, V10, P112, DOI 10.1038/gene.2008.80
   Rettew JA, 2008, BIOL REPROD, V78, P432, DOI 10.1095/biolreprod.107.063545
   Rettew JA, 2009, ENDOCRINOLOGY, V150, P3877, DOI 10.1210/en.2009-0098
   Rodrigues A, 2006, VACCINE, V24, P4737, DOI 10.1016/j.vaccine.2006.03.033
   Savy M, 2009, J NUTR, V139, p2154S, DOI 10.3945/jn.109.105312
   Shann F, 2010, PEDIATR INFECT DIS J, V29, P457, DOI 10.1097/INF.0b013e3181c91361
   Smart JM, 2001, PEDIATR ALLERGY IMMU, V12, P181, DOI 10.1034/j.1399-3038.2001.012004181.x
   Stensballe LG, 2005, VACCINE, V23, P1251, DOI 10.1016/j.vaccine.2004.09.006
   Valentiner-Branth P, 2007, VACCINE, V25, P2733, DOI 10.1016/j.vaccine.2006.01.035
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474
   Villumsen M, 2009, VACCINE, V27, P6950, DOI 10.1016/j.vaccine.2009.08.103
   Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x
   WINTER JSD, 1976, J CLIN ENDOCR METAB, V42, P679
   Yan SR, 2004, INFECT IMMUN, V72, P1223, DOI 10.1128/IAI.72.3.1233-1229.2004
   2010, NATURE, V465, P7299
NR 62
TC 22
Z9 22
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAR 16
PY 2011
VL 29
IS 13
BP 2349
EP 2354
DI 10.1016/j.vaccine.2011.01.071
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 745CC
UT WOS:000289140500001
PM 21300095
OA No
DA 2017-08-15
ER

PT J
AU Ceesay, M
AF Ceesay, Mustapha
TI An opportunity for increasing factor productivity for rice cultivation
   in The Gambia through SRI
SO PADDY AND WATER ENVIRONMENT
LA English
DT Article
DE Rice profitability; Rice yield; System of Rice Intensification; Water
   productivity
ID ZINC-DEFICIENCY; NITROGEN; SOILS; MINERALIZATION; INTENSIFICATION;
   AMMONIUM; SYSTEMS; MATTER; YIELDS
AB Promising results from an increasing number of field evaluations of the System of Rice Intensification (SRI) conducted in Asia and Africa indicate that African farmers could increase their rice production while lowering costs of operation and reducing the need for water by utilizing its principles and practices. This system relies not on external inputs to raise productivity but on alternative methods for managing rice plants and the soil and water resources devoted to their cultivation. Farmers in sub-Saharan Africa increasingly have to cope with the impacts of adverse climate effects because water shortages and long dry spells during the cropping season are becoming common, even in lowland rice agroecosystems. SRI management practices create both larger rice root systems that make their plants more resistant to biotic and abiotic stresses and more conducive environments for beneficial soil microflora and fauna to flourish. Better plant growth and development result from promoting plant-soil synergies. Controlled fertilizer management experiments conducted with SRI practices in The Gambia have showed that grain production can be significantly increased without higher application of inorganic fertilizer and with less requirement for water. SRI management practices with fertilizer application at the national recommended dose produced a grain yield of 7.6 t ha(-1). Water productivity was greatly increased, with 0.76 g of grain produced per kg total water input, compared to 0.10 g of grain per kg of water when the crop was continuously flooded. Recent hikes in fuel prices and consequent rises in input costs are making domestic rice production less attractive and importation even more attractive. Computation of production costs showed that SRI production, not needing heavy applications of fertilizer, is economically cost-effective. Achieving yield increases through ever-higher fertilizer applications is not economically or environmentally viable. SRI management with recommended fertilizer applications produced a net return of $853 ha(-1) compared to $37 when using farmers' present low-productivity practices.
C1 Natl Agr Res Inst, Brikama, Gambia.
RP Ceesay, M (reprint author), Natl Agr Res Inst, Brikama, Gambia.
EM musceesay@yahoo.com
CR BIRCH H. F., 1958, Plant and Soil, V10, P9, DOI 10.1007/BF01343734
   CABRERA ML, 1993, SOIL SCI SOC AM J, V57, P63
   Ceesay M., 2006, International Journal of Agricultural Sustainability, V4, P5
   DOBERMANN A, 2000, RICE NUTRIENT DISORD
   ELLIOTT ET, 1986, SOIL SCI SOC AM J, V50, P627
   FORNO DA, 1975, PLANT SOIL, V42, P537, DOI 10.1007/BF00009941
   HAYGARTH PM, 2001, NATURE, V411, P258
   INUBUSHI K, 1987, SOIL SCI PLANT NUTR, V33, P567
   Kar S, 1974, IL RISO, V23, P173
   KHUSH GS, 1996, RICE GENETICS 3, P57, DOI 10.1142/9789812814289_0005
   Kronzucker HJ, 1999, PLANT PHYSIOL, V119, P1041, DOI 10.1104/pp.119.3.1041
   MOORE PA, 1988, AGRON J, V80, P882
   Schneiders M, 1998, EUR J AGRON, V8, P181, DOI 10.1016/S1161-0301(97)00055-5
   SENEVIRATNE R, 1985, PLANT SOIL, V84, P175, DOI 10.1007/BF02143181
   Sheehy JE, 2004, FIELD CROP RES, V88, P1, DOI 10.1016/j.fcr.2003.12.006
   Stoop WA, 2002, AGR SYST, V71, P249, DOI 10.1016/S0308-521X(01)00070-1
   Uphoff N., 2002, Agroecological innovations: increasing food production with participatory development, P145
   Uphoff N., 2002, WATER WISE RICE PROD, P71
   Uphoff N., 2004, RICE TODAY, V3, P42
   VLEK PLG, 1979, SOIL SCI SOC AM J, V43, P352
   YAMAH A, 2002, ASSESSMENTS SYSTEM R, P103
   Ying JF, 1998, FIELD CROP RES, V57, P71, DOI 10.1016/S0378-4290(98)00077-X
NR 22
TC 2
Z9 2
U1 1
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1611-2490
J9 PADDY WATER ENVIRON
JI Paddy Water Environ.
PD MAR
PY 2011
VL 9
IS 1
SI SI
BP 129
EP 135
DI 10.1007/s10333-010-0235-1
PG 7
WC Agricultural Engineering; Agronomy
SC Agriculture
GA 732HR
UT WOS:000288176100015
OA No
DA 2017-08-15
ER

PT J
AU Oduwole, OA
   Ejezie, GC
   Odey, FA
   Oringanje, CM
   Nwakanma, D
   Bello, S
   Oriero, E
   Okebe, J
   Alaribe, AA
   Etuk, S
   Meremikwu, M
AF Oduwole, Olabisi A.
   Ejezie, G. C.
   Odey, Friday A.
   Oringanje, Chioma M.
   Nwakanma, Davis
   Bello, Segun
   Oriero, Eniyou
   Okebe, Joseph
   Alaribe, Anyawu A.
   Etuk, Saturday
   Meremikwu, Martin
TI Congenital Malaria in Calabar, Nigeria: The Molecular Perspective
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID HEMOGLOBIN; PREVALENCE
AB Polymerase chain reaction (PCR) has been shown to be more sensitive in detecting low-level parasitemia than conventional blood film microscopy. We estimated the prevalence of congenital malaria using nested PCR amplification of the small subunit 18S RNA gene to detect low-level parasitemia and identify Plasmodium species in 204 mother-neonate pairs. Cord-blood parasitemia was detected in four babies by PCR, giving a prevalence of 2.0%. The newborns of primidgravidae were more susceptible to congenital malaria than those of multigravidae (P < 0.0001). There was a strong correlation between placental malaria and congenital malaria (odds ratio = 10.1, 95% confidence interval = 1.3-76.1, P = 0.0487). We conclude that the prevalence of congenital malaria in Calabar detected by PCR is lower than has been reported in this environment through microscopy.
C1 [Oduwole, Olabisi A.; Ejezie, G. C.; Odey, Friday A.; Oringanje, Chioma M.; Bello, Segun; Alaribe, Anyawu A.; Etuk, Saturday; Meremikwu, Martin] Univ Calabar, Teaching Hosp, Inst Trop Dis Res & Prevent, Calabar 540001, Cross River, Nigeria.
   [Nwakanma, Davis; Oriero, Eniyou; Okebe, Joseph] United Kingdom Med Res Council Labs, Malaria Programme, Fajara, Gambia.
RP Oduwole, OA (reprint author), Univ Calabar, Teaching Hosp, Inst Trop Dis Res & Prevent, GPO Box 3134, Calabar 540001, Cross River, Nigeria.
EM olabisioduwole@yahoo.co.uk; gcejezie@netscape.net; awhobe@yahoo.com;
   chyoma@yahoo.com; dnwakanma@mrc.gm; drsegunbello@yahoo.com;
   eoriero@mrc.gm; jokebe@mrc.gm; anyanwualaribe@yahoo.com;
   imaetuks345@yahoo.com; mmeremiku@yahoo.co.uk
FU United Kingdom Medical Research Laboratory; Gambia; Institute of
   Tropical Diseases Research and Prevention (ITDR&P), University of
   Calabar Teaching Hospital (UCTH)
FX The authors wish to acknowledge the support of the United Kingdom
   Medical Research Laboratory (Malaria Programme), The Gambia, and the
   Institute of Tropical Diseases Research and Prevention (ITDR&P),
   University of Calabar Teaching Hospital (UCTH) for supporting this work.
   We also wish to acknowledge the contributions of Vivian Asiegbu and Umoh
   Ita Umoh for conducting the microscopy method. The American Society of
   Tropical Medicine and Hygiene (ASTMH) assisted with publication
   expenses.; The laboratory work for this project was supported by the
   Institute of Tropical Diseases Research and Prevention, University of
   Calabar Teaching Hospital, Calabar, and the United Kingdom Medical
   Research Council Laboratory, The Gambia.
CR Ahmed A, 1998, AM J PERINAT, V15, P19, DOI 10.1055/s-2007-993892
   Bassey A. E., 2005, Mary Slessor Journal of Medicine, V5, P37
   Berry A, 2005, Med Trop (Mars), V65, P176
   DISANTI SM, 2004, REV INST MED TROP SP, V46, P185
   Dorman E., 2000, CURR OBSTET GYNAECOL, V10, P183, DOI 10.1054/cuog.2000.0129
   Durrheim DN, 1997, S AFR MED J, V87, P609
   Egwunyenga O. A., 1997, Southeast Asian Journal of Tropical Medicine and Public Health, V28, P741
   EZEOKE ACJ, 1985, CENT AFR J MED, V31, P241
   Falade C, 2007, TROP MED INT HEALTH, V12, P1279, DOI 10.1111/j.1365-3156.2007.01931.x
   Falade CO, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-88
   Fischer PR, 2003, J TROP PEDIATRICS, V49, P132, DOI 10.1093/tropej/49.3.132
   Gamble C.L., 2006, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003755.PUB2
   Gies S, 2009, TROP MED INT HEALTH, V14, P174, DOI 10.1111/j.1365-3156.2008.02215.x
   Lesko CR, 2007, ARCH PEDIAT ADOL MED, V161, P1062, DOI 10.1001/archpedi.161.11.1062
   Mukhtar MY, 2006, J TROP PEDIATRICS, V52, P19, DOI 10.1093/tropej/fmi044
   Mwangoka GW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-117
   Obiajunwa PO, 2005, J TROP PEDIATRICS, V51, P219, DOI 10.1093/tropej/fmi003
   PASVOL G, 1976, LANCET, V1, P1269
   Remington JS, 1995, INFECTIOUS DIS FETUS, p765 
   Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004
   RUNSEWEABIODUN IA, 2006, BIOMED CENTRAL PEDIA
   SANTHANAKRISHNAN B R, 1985, Indian Journal of Pediatrics, V52, P249, DOI 10.1007/BF02754851
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8
   Steketee RW, 2001, AM J TROP MED HYG, V64, P28
   Uneke Chigozie J, 2007, Yale J Biol Med, V80, P39
   World Health Organization (WHO), 2003, AFR MAL REP 2003
   Wilson WR, 2001, CURRENT DIAGNOSIS TR
NR 27
TC 5
Z9 5
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAR
PY 2011
VL 84
IS 3
BP 386
EP 389
DI 10.4269/ajtmh.2011.10-0253
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 730AK
UT WOS:000287995600005
PM 21363974
OA No
DA 2017-08-15
ER

PT J
AU Caputo, B
   Santolamazza, F
   Vicente, JL
   Nwakanma, DC
   Jawara, M
   Palsson, K
   Jaenson, T
   White, BJ
   Mancini, E
   Petrarca, V
   Conway, DJ
   Besansky, NJ
   Pinto, J
   della Torre, A
AF Caputo, Beniamino
   Santolamazza, Federica
   Vicente, Jose L.
   Nwakanma, Davis C.
   Jawara, Musa
   Palsson, Katinka
   Jaenson, Thomas
   White, Bradley J.
   Mancini, Emiliano
   Petrarca, Vincenzo
   Conway, David J.
   Besansky, Nora J.
   Pinto, Joao
   della Torre, Alessandra
TI The "Far-West'' of Anopheles gambiae Molecular Forms
SO PLOS ONE
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; GENOMIC DIVERGENCE; GENE-FLOW; COMPLEX;
   SPECIATION; DIFFERENTIATION; IDENTIFICATION; HYBRIDIZATION; CULICIDAE;
   SELECTION
AB The main Afrotropical malaria vector, Anopheles gambiae sensu stricto, is undergoing a process of sympatric ecological diversification leading to at least two incipient species (the M and S molecular forms) showing heterogeneous levels of divergence across the genome. The physically unlinked centromeric regions on all three chromosomes of these closely related taxa contain fixed nucleotide differences which have been found in nearly complete linkage disequilibrium in geographic areas of no or low M-S hybridization. Assays diagnostic for SNP and structural differences between M and S forms in the three centromeric regions were applied in samples from the western extreme of their range of sympatry, the only area where high frequencies of putative M/S hybrids have been reported. The results reveal a level of admixture not observed in the rest of the range. In particular, we found: i) heterozygous genotypes at each marker, although at frequencies lower than expected under panmixia; ii) virtually all possible genotypic combinations between markers on different chromosomes, although genetic association was nevertheless detected; iii) discordant M and S genotypes at two X-linked markers near the centromere, suggestive of introgression and inter-locus recombination. These results could be indicative either of a secondary contact zone between M and S, or of the maintenance of ancestral polymorphisms. This issue and the perspectives opened by these results in the study of the M and S incipient speciation process are discussed.
C1 [Caputo, Beniamino; Santolamazza, Federica; Mancini, Emiliano; della Torre, Alessandra] Univ Roma La Sapienza, Dipartimento Sanita Pubbl & Malattie Infett, Ist Pasteur, Fdn Cenci Bolognetti, Rome, Italy.
   [Vicente, Jose L.; Pinto, Joao] Univ Nova Lisboa, Inst Higiene & Med Trop, UEI Malaria & UEI Entomol Med, Ctr Malaria & Outras Doencas Trop, P-1200 Lisbon, Portugal.
   [Nwakanma, Davis C.; Jawara, Musa; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Palsson, Katinka; Jaenson, Thomas] Uppsala Univ, Dept Systemat Biol, Med Entomol Unit, Uppsala, Sweden.
   [White, Bradley J.; Besansky, Nora J.] Univ Notre Dame, Dept Biol Sci, Eck Inst Global Hlth, Notre Dame, IN 46556 USA.
   [Petrarca, Vincenzo] Univ Roma La Sapienza, Dipartimento Biol & Biotecnol Charles Darwin, Ist Pasteur, Fdn Cenci Bolognetti, Rome, Italy.
RP Caputo, B (reprint author), Univ Roma La Sapienza, Dipartimento Sanita Pubbl & Malattie Infett, Ist Pasteur, Fdn Cenci Bolognetti, Rome, Italy.
EM ale.dellatorre@uniroma1.it
RI Mancini, Emiliano/G-4771-2012; Vicente, Jose/I-2126-2012; Caputo,
   Beniamino/I-2880-2015; Pinto, Joao/C-2208-2012; santos,
   sofia/I-1637-2012
OI Caputo, Beniamino/0000-0002-5650-8773; Pinto, Joao/0000-0001-8572-7708;
   Conway, David/0000-0002-8711-3037
FU Medical Research Council of the UK; UNICEF/UNDP/World Bank/WHO [A50239];
   I Faculty of Medicine of Universita "La Sapienza"; Universita "La
   Sapienza"; National Institutes of Health [R01-AI063508]
FX Field collections and laboratory analysis in The Gambia was supported by
   the Medical Research Council of the UK, with helpful facilitation from
   the Gambian National Malaria Control Programme. Laboratory analysis of
   Guinean samples received financial support from the UNICEF/UNDP/World
   Bank/WHO Special Programme for Research and Training in Tropical
   Diseases (TDR, A50239). BC was partially supported by I Faculty of
   Medicine of Universita "La Sapienza". The work was supported by
   Universita "La Sapienza" (Progetti di Ricerca Universitari - 2009) and
   by R01-AI063508 grant to NJB from the National Institutes of Health. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Calzetta M, 2008, AM J TROP MED HYG, V78, P169
   Caputo B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-182
   Carr IM, 2009, BIOINFORMATICS, V25, P3244, DOI 10.1093/bioinformatics/btp583
   Costantini Carlo, 2009, BMC Ecology, V9, P16, DOI 10.1186/1472-6785-9-16
   della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x
   della Torre A, 2002, SCIENCE, V298, P115, DOI 10.1126/science.1078170
   della Torre A, 2005, INSECT BIOCHEM MOLEC, V35, P755, DOI 10.1016/j.ibmb.2005.02.006
   Diabate A, 2006, J MED ENTOMOL, V43, P480, DOI 10.1603/0022-2585(2006)43[480:MSOTMM]2.0.CO;2
   Diabate A, 2007, J MED ENTOMOL, V44, P60, DOI 10.1603/0022-2585(2007)44[60:ETEOPI]2.0.CO;2
   Diabate A, 2009, P R SOC B, V276, P4215, DOI 10.1098/rspb.2009.1167
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Gentile G, 2001, INSECT MOL BIOL, V10, P25, DOI 10.1046/j.1365-2583.2001.00237.x
   Lawniczak MKN, 2010, SCIENCE, V330, P512, DOI 10.1126/science.1195755
   Lehmann T, 2008, INFECT GENET EVOL, V8, P737, DOI 10.1016/j.meegid.2008.06.003
   Ndiath MO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-136
   Neafsey DE, 2010, SCIENCE, V330, P514, DOI 10.1126/science.1193036
   Nosil P, 2009, MOL ECOL, V18, P375, DOI 10.1111/j.1365-294X.2008.03946.x
   Oliveira E, 2008, J MED ENTOMOL, V45, P1057, DOI 10.1603/0022-2585(2008)45[1057:HLOHBM]2.0.CO;2
   Pennetier C, 2010, CURR BIOL, V20, P131, DOI 10.1016/j.cub.2009.11.040
   Pombi M, 2006, AM J TROP MED HYG, V75, P901
   Rauscher JT, 2002, MOL ECOL, V11, P2691, DOI 10.1046/j.1365-294X.2002.01640.x
   RAYMOND M, 1995, J HERED, V86, P248
   Rundle HD, 2005, ECOL LETT, V8, P336, DOI 10.1111/j.1461-0248.2004.00715.x
   Santolamazza F, 2004, AM J TROP MED HYG, V70, P604
   Santolamazza F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-163
   Santolamazza F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-74
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Simard Frederic, 2009, BMC Ecology, V9, P17, DOI 10.1186/1472-6785-9-17
   Slatkin M, 1996, HEREDITY, V76, P377, DOI 10.1038/hdy.1996.55
   Stump AD, 2005, P NATL ACAD SCI USA, V102, P15930, DOI 10.1073/pnas.0508161102
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Toure Y. T., 1998, Parassitologia (Rome), V40, P477
   Tripet F, 2001, MOL ECOL, V10, P1725, DOI 10.1046/j.0962-1083.2001.01301.x
   Turner TL, 2007, MOL BIOL EVOL, V24, P2132, DOI 10.1093/molbev/msm143
   Turner TL, 2005, PLOS BIOL, V3, P1572, DOI 10.1371/journal.pbio.0030285
   WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x
   White BJ, 2010, MOL ECOL, V19, P925, DOI 10.1111/j.1365-294X.2010.04531.x
   Wondji C, 2005, J MED ENTOMOL, V42, P998, DOI 10.1603/0022-2585(2005)042[0998:SAPOTA]2.0.CO;2
NR 39
TC 39
Z9 39
U1 0
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 15
PY 2011
VL 6
IS 2
AR e16415
DI 10.1371/journal.pone.0016415
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 721QH
UT WOS:000287369200003
PM 21347223
OA gold
DA 2017-08-15
ER

PT J
AU Cavenaugh, JS
   Awi, D
   Mendy, M
   Hill, AVS
   Whittle, H
   McConkey, SJ
AF Cavenaugh, James S.
   Awi, Dorka
   Mendy, Maimuna
   Hill, Adrian V. S.
   Whittle, Hilton
   McConkey, Samuel J.
TI Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic
   Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV
   Infection
SO PLOS ONE
LA English
DT Article
ID REGULATORY T-CELLS; BOOST IMMUNIZATION STRATEGIES;
   HEPATOCELLULAR-CARCINOMA; ENHANCED IMMUNOGENICITY; PROTECTIVE EFFICACY;
   LAMIVUDINE TREATMENT; VACCINATION REGIMEN; LYMPHOCYTE RESPONSE;
   VIRAL-HEPATITIS; IMMUNE-RESPONSE
AB Background: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secondary goal was to characterize the immune responses.
   Methods: Firstly 32 HBV e antigen negative (eAg(-)) participants were randomly assigned to one of four groups: to receive vaccines alone, lamivudine (3TC) alone, both, or neither. Later 16 eAg(+) volunteers in two groups received either 3TC alone or both 3TC and vaccines. Finally, 12 eAg(-) and 12 eAg+ subjects were enrolled into higher-dose treatment groups. Healthy but chronically HBV-infected males between the ages of 15-25 who lived in the western part of The Gambia were eligible. Participants in some groups received 1 mg or 2 mg of pSG2.HBs intramuscularly twice followed by 5x10(7) pfu or 1.5x10(8) pfu of MVA.HBs intradermally at 3-weekly intervals with or without concomitant 3TC for 11-14 weeks. Intradermal rabies vaccine was administered to a negative control group. Safety was assessed clinically and biochemically. The primary measure of efficacy was a quantitative PCR assay of plasma HBV. Immunity was assessed by IFN-gamma ELISpot and intracellular cytokine staining.
   Results: Mild local and systemic adverse events were observed following the vaccines. A small shiny scar was observed in some cases after MVA.HBs. There were no significant changes in AST or ALT.HBeAg was lost in one participant in the higher-dose group. As expected, the 3TC therapy reduced viraemia levels during therapy, but the prime-boost vaccine regimen did not reduce the viraemia. The immune responses were variable. The majority of IFN-gamma was made by antigen non-specific CD16(+) cells (both CD3(+) and CD3(-)).
   Conclusions: The vaccines were well tolerated but did not control HBV infection.
C1 [Cavenaugh, James S.; Awi, Dorka; Mendy, Maimuna; Whittle, Hilton; McConkey, Samuel J.] MRC Labs, Banjul, Gambia.
   [Cavenaugh, James S.; Hill, Adrian V. S.; McConkey, Samuel J.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Cavenaugh, James S.] Univ Rochester, Sch Med & Dent, David H Smith Ctr Vaccine Biol & Immunol, Rochester, NY USA.
   [Awi, Dorka] Univ Port Harcourt, Inst Maternal & Child Hlth, Post Harcourt, Nigeria.
   [Mendy, Maimuna] Int Agcy Res Canc, F-69372 Lyon, France.
   [Hill, Adrian V. S.] Wellcome Trust Ctr Human Genet, Oxford, England.
   [McConkey, Samuel J.] Royal Coll Surgeons Ireland, Dept Int Hlth & Trop Med, Dublin 2, Ireland.
RP Cavenaugh, JS (reprint author), Royal Coll Surgeons Ireland, Dept Int Hlth & Trop Med, Dublin 2, Ireland.
EM smcconkey@rcsi.ie
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
FU Wellcome Trust, United Kingdom [060288]; National Institutes of Health
   [2T32 ES007271]
FX Financial support was provided by the Wellcome Trust, United Kingdom,
   Project Grant Award Number 060288. Medical Research Council
   Laboratories, The Gambia, contributed to the costs of the project
   including equipment and infrastructure. Oxxon Therapeutics (Oxford, UK
   and Boston, USA) provided the vaccines, lamivudine and some reagents and
   paid for external monitoring and auditing. Oxxon Therapeutics did not
   influence the composition of this paper. James Cavenaugh was further
   supported by National Institutes of Health Training Grant 2T32 ES007271
   during subsequent write-up. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Barboza L, 2007, VIROLOGY, V368, P41, DOI 10.1016/j.virol.2007.06.030
   Bejon P, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010029
   BERTOLETTI A, 1991, P NATL ACAD SCI USA, V88, P10445, DOI 10.1073/pnas.88.23.10445
   Bertoletti A, 2003, HEPATOLOGY, V38, P4, DOI 10.1053/jhep.2003.50310
   Bertoletti A, 2000, CURR OPIN IMMUNOL, V12, P403, DOI 10.1016/S0952-7915(00)00108-4
   Boni C, 2004, J HEPATOL, V40, P1053, DOI 10.1016/j.jhep.2004.04.011
   Boni C, 2001, HEPATOLOGY, V33, P963, DOI 10.1053/jhep.2001.23045
   Boni C, 1998, J CLIN INVEST, V102, P968, DOI 10.1172/JCI3731
   Boni C, 2003, J HEPATOL, V39, P595, DOI 10.1016/S0168-8278(03)00292-7
   CAVEN TH, 2006, IGE PRODUCTION REGUL
   Cavenaugh JS, 2007, CYTOM PART B-CLIN CY, V72B, P49, DOI 10.1002/cyto.b.20146
   Cavenaugh JS, 2003, PHARMACEUT RES, V20, P591, DOI 10.1023/A:1023242631413
   CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29
   Chisari FV, 2000, AM J PATHOL, V156, P1117, DOI 10.1016/S0002-9440(10)64980-2
   Chisari FV, 1997, J CLIN INVEST, V99, P1472, DOI 10.1172/JCI119308
   Couillin I, 1999, J INFECT DIS, V180, P15, DOI 10.1086/314828
   Dahmen A, 2002, J MED VIROL, V66, P452, DOI 10.1002/jmv.2165
   Depla E, 2008, J VIROL, V82, P435, DOI 10.1128/JVI.01505-07
   Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617
   Dumpis U, 2001, J HEPATOL, V35, P99, DOI 10.1016/S0168-8278(01)00064-2
   Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   Franzese O, 2005, J VIROL, V79, P3322, DOI 10.1128/JVI.79.6.3322-3328.2005
   Gilbert SC, 1999, BIOL CHEM, V380, P299, DOI 10.1515/BC.1999.041
   Goonetilleke NP, 2003, J IMMUNOL, V171, P1602
   Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825
   Hanke T, 1999, J VIROL, V73, P7524
   Hill AVS, 2006, NAT REV IMMUNOL, V6, P21, DOI 10.1038/nri1746
   Hilleman MR, 2003, VACCINE, V21, P4626, DOI 10.1016/S0264-410X(03)00529-2
   Horiike N, 2005, J CLIN VIROL, V32, P156, DOI 10.1016/j.jcv.2004.07.004
   Jung MC, 2002, VACCINE, V20, P3598, DOI 10.1016/S0264-410X(02)00309-2
   Jung MC, 2002, LANCET INFECT DIS, V2, P43, DOI 10.1016/S1473-3099(01)00172-4
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   Maini MK, 2000, J EXP MED, V191, P1269, DOI 10.1084/jem.191.8.1269
   Mancini-Bourgine M, 2004, HEPATOLOGY, V40, P874, DOI 10.1002/hep.20408
   Mancini-Bourgine M, 2006, VACCINE, V24, P4482, DOI 10.1016/j.vaccine.2005.08.013
   MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375
   McClary H, 2000, J VIROL, V74, P2255, DOI 10.1128/JVI.74.5.2255-2264.2000
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   McShane H, 2005, MICROBES INFECT, V7, P962, DOI 10.1016/j.micinf.2005.03.009
   McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001
   Mendy ME, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-23
   Mendy ME, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-49
   MILICH DR, 1986, SCIENCE, V234, P1398, DOI 10.1126/science.3491425
   Mommeja-Marin H, 2003, HEPATOLOGY, V37, P1309, DOI 10.1053/jhep.2003.50208
   Montalto G, 2002, ANN NY ACAD SCI, V963, P13
   Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515
   Murray JM, 2005, P NATL ACAD SCI USA, V102, P17780, DOI 10.1073/pnas.0508913102
   Nakajima A, 2005, JPN J INFECT DIS, V58, P244
   Nassal M, 1999, INTERVIROLOGY, V42, P100, DOI 10.1159/000024970
   Pan CQ, 2005, INT J MED SCI, V2, P36
   Pancholi P, 2001, HEPATOLOGY, V33, P448, DOI 10.1053/jhep.2001.21594
   Pol S, 2001, J HEPATOL, V34, P917, DOI 10.1016/S0168-8278(01)00028-9
   Rapicetta M, 2002, J MED VIROL, V67, P454, DOI 10.1002/jmv.10096
   REHERMANN B, 1995, J EXP MED, V181, P1047, DOI 10.1084/jem.181.3.1047
   Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573
   Robek MD, 2005, J VIROL, V79, P3851, DOI 10.1128/JVI.79.6.3851-3854.2005
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Schneider J, 1999, IMMUNOL REV, V170, P29, DOI 10.1111/j.1600-065X.1999.tb01326.x
   Smith KA, 2007, PLOS CLIN TRIALS, V2, DOI 10.1371/journal.pctr.0020005
   Srivastava IK, 2003, ANN INTERN MED, V138, P550
   Stoop JN, 2005, HEPATOLOGY, V41, P771, DOI 10.1002/hep.20649
   van der Sande MAB, 2006, J INFECT DIS, V193, P1528
   Vandepapeliere P, 2007, VACCINE, V25, P8585, DOI 10.1016/j.vaccine.2007.09.072
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   Webster GJM, 2004, J VIROL, V78, P5707, DOI 10.1128/JVI.78.11.5707-5719.2004
   Webster GJM, 2000, HEPATOLOGY, V32, P1117, DOI 10.1053/jhep.2000.19324
   WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6
   Wieland SF, 2005, P NATL ACAD SCI USA, V102, P9913, DOI 10.1073/pnas.0504273102
   Wieland SF, 2000, J VIROL, V74, P4165, DOI 10.1128/JVI.74.9.4165-4173.2000
   Wieland SF, 2004, P NATL ACAD SCI USA, V101, P2129, DOI 10.1073/pnas.0308478100
   Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2
   Woodland DL, 2004, TRENDS IMMUNOL, V25, P98, DOI 10.1016/j.it.2003.11.009
   Yalcin K, 2003, J CLIN GASTROENTEROL, V37, P330, DOI 10.1097/00004836-200310000-00012
   YOSHIHIRO F, 2005, WORLD J GASTROENTERO, V11, P3772
   2002, BD FASTIMMUNE CFC HD
NR 78
TC 31
Z9 34
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 15
PY 2011
VL 6
IS 2
AR e14626
DI 10.1371/journal.pone.0014626
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 721QH
UT WOS:000287369200001
PM 21347224
OA gold
DA 2017-08-15
ER

PT J
AU Morris, GAJ
   Edwards, DRV
   Hill, PC
   Wejse, C
   Bisseye, C
   Olesen, R
   Edwards, TL
   Gilbert, JR
   Myers, JL
   Stryjewski, ME
   Abbate, E
   Estevan, R
   Hamilton, CD
   Tacconelli, A
   Novelli, G
   Brunetti, E
   Aaby, P
   Sodemann, M
   Ostergaard, L
   Adegbola, R
   Williams, SM
   Scott, WK
   Sirugo, G
AF Morris, Gerard A. J.
   Edwards, Digna R. Velez
   Hill, Philip C.
   Wejse, Christian
   Bisseye, Cyrille
   Olesen, Rikke
   Edwards, Todd L.
   Gilbert, John R.
   Myers, Jamie L.
   Stryjewski, Martin E.
   Abbate, Eduardo
   Estevan, Rosa
   Hamilton, Carol D.
   Tacconelli, Alessandra
   Novelli, Giuseppe
   Brunetti, Ercole
   Aaby, Peter
   Sodemann, Morten
   Ostergaard, Lars
   Adegbola, Richard
   Williams, Scott M.
   Scott, William K.
   Sirugo, Giorgio
TI Interleukin 12B (IL12B) Genetic Variation and Pulmonary Tuberculosis: A
   Study of Cohorts from The Gambia, Guinea-Bissau, United States and
   Argentina
SO PLOS ONE
LA English
DT Article
ID D-RECEPTOR POLYMORPHISMS; IFN-GAMMA; LINKAGE DISEQUILIBRIUM;
   WEST-AFRICA; SUSCEPTIBILITY; ASSOCIATION; DEFICIENCY; POPULATION;
   INFECTION; VARIANTS
AB We examined whether polymorphisms in interleukin-12B (IL12B) associate with susceptibility to pulmonary tuberculosis (PTB) in two West African populations (from The Gambia and Guinea-Bissau) and in two independent populations from North and South America. Nine polymorphisms (seven SNPs, one insertion/deletion, one microsatellite) were analyzed in 321 PTB cases and 346 controls from Guinea-Bissau and 280 PTB cases and 286 controls from The Gambia. For replication we studied 281 case and 179 control African-American samples and 221 cases and 144 controls of European ancestry from the US and Argentina. First-stage single locus analyses revealed signals of association at IL12B 3' UTR SNP rs3212227 (unadjusted allelic p = 0.04; additive genotypic p = 0.05, OR = 0.78, 95% CI [0.61-0.99]) in Guinea-Bissau and rs11574790 (unadjusted allelic p = 0.05; additive genotypic p = 0.05, OR = 0.76, 95% CI [0.58-1.00]) in The Gambia. Association of rs3212227 was then replicated in African-Americans (rs3212227 allelic p = 0.002; additive genotypic p = 0.05, OR = 0.78, 95% CI [0.61-1.00]); most importantly, in the African-American cohort, multiple significant signals of association (seven of the nine polymorphisms tested) were detected throughout the gene. These data suggest that genetic variation in IL12B, a highly relevant candidate gene, is a risk factor for PTB in populations of African ancestry, although further studies will be required to confirm this association and identify the precise mechanism underlying it.
C1 [Morris, Gerard A. J.; Hill, Philip C.; Bisseye, Cyrille; Adegbola, Richard] MRC Labs, Fajara, Gambia.
   [Edwards, Digna R. Velez; Edwards, Todd L.; Tacconelli, Alessandra; Brunetti, Ercole; Sirugo, Giorgio] Osped San Pietro FBF, Unita Genet Med, Rome, Italy.
   [Edwards, Digna R. Velez; Edwards, Todd L.; Gilbert, John R.; Myers, Jamie L.; Scott, William K.] Univ Miami, Dr John T Macdonald Fdn Dept Human Genet, Coral Gables, FL 33124 USA.
   [Edwards, Digna R. Velez; Edwards, Todd L.; Gilbert, John R.; Myers, Jamie L.; Scott, William K.] Univ Miami, Hussman Inst Human Gen, Coral Gables, FL 33124 USA.
   [Hill, Philip C.] Univ Otago, Sch Med, Ctr Int Hlth, Christchurch, New Zealand.
   [Wejse, Christian; Olesen, Rikke; Ostergaard, Lars] Aarhus Univ Hosp, Dept Infect Dis, Skejby, Denmark.
   [Wejse, Christian; Aaby, Peter] Danish Epidemiol Sci Ctr, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Wejse, Christian; Aaby, Peter] Statens Serum Inst, Bissau, Guinea Bissau.
   [Stryjewski, Martin E.] Ctr Educ Med & Invest Clin Norberto Quirno CEMIC, Div Infect Dis, Dept Med, Buenos Aires, DF, Argentina.
   [Abbate, Eduardo; Estevan, Rosa] Hosp FJ Muniz, Dept Med, Buenos Aires, DF, Argentina.
   [Hamilton, Carol D.] Family Hlth Int, Res Triangle Pk, NC 27709 USA.
   [Hamilton, Carol D.] Duke Univ, Med Ctr, Durham, NC USA.
   [Novelli, Giuseppe] Univ Roma Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, Rome, Italy.
   [Sodemann, Morten] Univ So Denmark, Odense, Denmark.
   [Williams, Scott M.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA.
RP Morris, GAJ (reprint author), MRC Labs, Fajara, Gambia.
EM BScott@med.miami.edu; sirugo.giorgio@fbfrm.it
RI Williams, Scott/B-9491-2012; Edwards, Todd/B-9750-2012; Velez Edwards,
   Digna/C-1090-2012; Wejse, Christian/C-8468-2014
OI Wejse, Christian/0000-0002-2534-2942; Novelli,
   Giuseppe/0000-0002-7781-602X; Olesen, Rikke/0000-0002-5157-080X
FU Medical Research Council [G0000690]; Danish Medical Research Council;
   Danish Society of Respiratory Medicine; Danish Council of Development
   Research; U.S. National Institutes of Health [HL068534]
FX This work was supported by the Medical Research Council award G0000690
   to GS, by Grants from the Danish Medical Research Council, the Danish
   Society of Respiratory Medicine, the Danish Council of Development
   Research to RO, CW, MS and LO and by the U.S. National Institutes of
   Health grant HL068534 to WKS. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bergholdt R, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.010454
   Bornman L, 2004, J INFECT DIS, V190, P1631, DOI 10.1086/424462
   Campbell MC, 2008, ANNU REV GENOM HUM G, V9, P403, DOI 10.1146/annurev.genom.9.081307.164258
   Cooke GS, 2006, AM J RESP CRIT CARE, V174, P339, DOI 10.1164/rccm.200601-088OC
   Cooper AM, 2007, CURR OPIN IMMUNOL, V19, P441, DOI 10.1016/j.coi.2007.07.004
   DEVLIN B, 1995, GENOMICS, V29, P311
   Flores-Villanueva PO, 2005, J EXP MED, V202, P1649, DOI 10.1084/jem20050216
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Frazer KA, 2004, NUCLEIC ACIDS RES, V32, pW273, DOI 10.1093/nar/gkh458
   Freidin MB, 2006, INT J IMMUNOGENET, V33, P231, DOI 10.1111/j.1744-313X.2006.00591.x
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4
   Frucht DM, 1996, J IMMUNOL, V157, P411
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Greene CS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005639
   Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026
   Ha SJ, 2006, INFECT IMMUN, V74, P4954, DOI 10.1128/IAI.01781-05
   Hancock DB, 2007, GENET EPIDEMIOL, V31, P883, DOI 10.1002/gepi.20249
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Holland SM, 1998, J INFECT DIS, V178, P1095, DOI 10.1086/515670
   Kaufmann SHE, 2000, NAT MED, V6, P955, DOI 10.1038/79631
   Khader SA, 2005, J IMMUNOL, V175, P788
   LEWONTIN RC, 1964, GENETICS, V49, P49
   Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282
   Ma X, 2003, J INFECT DIS, V188, P1116, DOI 10.1086/378674
   Marquet S, 2008, HUM MOL GENET, V17, P2190, DOI 10.1093/hmg/ddn118
   Martin ER, 2003, AM J HUM GENET, V73, P1016, DOI 10.1086/378779
   Martineau AR, 2007, J IMMUNOL, V178, P7190
   Moller M, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-154
   Morahan G, 2007, TISSUE ANTIGENS, V69, P234, DOI 10.1111/j.1399-0039.2006.773_3.x
   Morahan G, 2001, NAT GENET, V27, P218, DOI 10.1038/84872
   Olesen R, 2007, GENES IMMUN, V8, P456, DOI 10.1038/sj.gene.6364410
   Picard C, 2002, AM J HUM GENET, V70, P336, DOI 10.1086/338625
   Prabhu Anand S, 2007, INDIAN J MED RES, V126, P135
   Raymond M, 1995, EVOLUTION, V49, P1280, DOI 10.1111/j.1558-5646.1995.tb04456.x
   Sahiratmadja E, 2007, TUBERCULOSIS, V87, P303, DOI 10.1016/j.tube.2007.02.001
   Seegers D, 2002, GENES IMMUN, V3, P419, DOI 10.1038/sj.gene.6363919
   Selvaraj P, 2003, CURR SCI INDIA, V84, P1564
   Sirugo G, 2004, NAT GENET, V36, P785, DOI 10.1038/ng0804-785
   Sirugo G, 2008, HUM GENET, V123, P557, DOI 10.1007/s00439-008-0511-y
   Tso HW, 2004, J INFECT DIS, V190, P913, DOI 10.1086/422693
   Velez D., 2010, INT J TUBERC LUNG D, V13, P1068
   WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x
   Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6
   Wright G W, 1969, J Air Pollut Control Assoc, V19, P681
   Wu B, 2007, J IMMUNOL, V178, P3688
   Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986
   Zhang SY, 2008, IMMUNOL REV, V226, P29, DOI 10.1111/j.1600-065X.2008.00698.x
NR 49
TC 22
Z9 23
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 9
PY 2011
VL 6
IS 2
AR e16656
DI 10.1371/journal.pone.0016656
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 721NN
UT WOS:000287361700024
PM 21339808
OA gold
DA 2017-08-15
ER

PT J
AU Jones, CE
   Naidoo, S
   De Beer, C
   Esser, M
   Kampmann, B
   Hesseling, AC
AF Jones, Christine E.
   Naidoo, Shalena
   De Beer, Corena
   Esser, Monika
   Kampmann, Beate
   Hesseling, Anneke C.
TI Maternal HIV Infection and Antibody Responses Against
   Vaccine-Preventable Diseases in Uninfected Infants
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID INFLUENZAE TYPE-B; PNEUMOCOCCAL CONJUGATE VACCINE; ACTIVE ANTIRETROVIRAL
   THERAPY; PLACENTAL MALARIA; MEASLES-VIRUS; PERTUSSIS ANTIBODIES; AFRICAN
   CHILDREN; IMMUNIZATION; MORTALITY; SERUM
AB Context Altered immune responses might contribute to the high morbidity and mortality observed in human immunodeficiency virus (HIV)-exposed uninfected infants.
   Objective To study the association of maternal HIV infection with maternal-and infant-specific antibody levels to Haemophilus influenzae type b (Hib), pneumococcus, Bordetella pertussis antigens, tetanus toxoid, and hepatitis B surface antigen.
   Design, Setting, and Participants A community-based cohort study in Khayelitsha, Western Cape Province, South Africa, between March 3, 2009, and April 28, 2010, of 109 HIV-infected and uninfected women and their infants. Serum samples from 104 women and 100 infants were collected at birth and samples from 93 infants were collected at 16 weeks.
   Main Outcome Measure Level of specific antibody in mother-infant pairs at delivery and in infants at 16 weeks, determined by enzyme-linked immunosorbent assays.
   Results At birth, HIV-exposed uninfected infants (n=46) had lower levels of specific antibodies than unexposed infants (n=54) did to Hib (0.37 [interquartile range {IQR}, 0.22-0.67] mg/L vs 1.02 [IQR, 0.34-3.79] mg/L; P<.001), pertussis (16.07 [IQR, 8.87-30.43] Food and Drug Administration [FDA] U/mL vs 36.11 [IQR, 20.41-76.28] FDA U/mL; P<.001), pneumococcus (17.24 [IQR, 11.33-40.25] mg/L vs 31.97 [IQR, 18.58-61.80] mg/L; P=.02), and tetanus (0.08 [IQR, 0.03-0.39] IU/mL vs 0.24 [IQR, 0.08-0.92] IU/mL; P=.006). Compared with HIV-uninfected women (n=58), HIV-infected women (n=46) had lower specific antibody levels to Hib (0.67 [IQR, 0.16-1.54] mg/L vs 1.34 [IQR, 0.15-4.82] mg/L; P=.009) and pneumococcus (33.47 [IQR, 4.03-69.43] mg/L vs 50.84 [IQR, 7.40-118.00] mg/L; P=.03); however, no differences were observed for antipertussis or antitetanus antibodies. HIV-exposed uninfected infants (n=38) compared with HIV-unexposed infants (n=55) had robust antibody responses following vaccination, with higher antibody responses to pertussis (270.1 [IQR, 84.4-355.0] FDA U/mL vs 91.7 [IQR, 27.9-168.4] FDA U/mL; P=.006) and pneumoccocus (47.32 [IQR, 32.56-77.80] mg/L vs 14.77 [IQR, 11.06-41.08] mg/L; P=.001).
   Conclusion Among South African infants, antenatal HIV exposure was associated with lower specific antibody responses in exposed uninfected infants compared with unexposed infants at birth, but with robust responses following routine vaccination. JAMA. 2011; 305(6): 576-584
C1 [Jones, Christine E.; Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Acad Dept Pediat, London W2 1PG, England.
   [Jones, Christine E.; Kampmann, Beate] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
   [Kampmann, Beate] Med Res Council UK Gambia, Fajara, Gambia.
   [Naidoo, Shalena; De Beer, Corena; Esser, Monika] Univ Stellenbosch, Dept Pathol, Cape Town, South Africa.
   [De Beer, Corena; Esser, Monika] Tygerberg Hosp, Natl Hlth Lab Serv, Cape Town, South Africa.
   [Hesseling, Anneke C.] Univ Stellenbosch, Dept Pediat & Child Hlth, Desmond Tutu TB Ctr, Cape Town, South Africa.
RP Jones, CE (reprint author), Univ London Imperial Coll Sci Technol & Med, Acad Dept Pediat, St Marys Campus,Norfolk Pl, London W2 1PG, England.
EM christine.jones@imperial.ac.uk
FU European Society for Pediatric Infectious Diseases; Thrasher Research
   Foundation; Wellcome Trust; National Institute for Health Research,
   England; Elizabeth Glaser Pediatric AIDS Foundation
FX This work was supported by the European Society for Pediatric Infectious
   Diseases (Dr Jones), the Thrasher Research Foundation (Dr Jones), the
   Wellcome Trust (Dr Kampmann), National Institute for Health Research,
   England (Dr Kampmann), and Elizabeth Glaser Pediatric AIDS Foundation
   (Dr Hesseling).
CR AGBARAKWE AE, 1995, J CLIN PATHOL, V48, P206, DOI 10.1136/jcp.48.3.206
   ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4
   Bisgard KM, 2004, PEDIATR INFECT DIS J, V23, P985, DOI 10.1097/01.inf.0000145263.37198.2b
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Caceres VM, 2000, CLIN INFECT DIS, V31, P110, DOI 10.1086/313926
   Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P1050
   Centers for Disease Control and Prevention. Pertussis-United States, 2005, MMWR-MORBID MORTAL W, V54, P1283
   Cumberland P, 2007, J INFECT DIS, V196, P550, DOI 10.1086/519845
   de Moraes-Pinto MI, 1998, ARCH DIS CHILD, V79, pF202
   DUCLOS P, 2009, J AM COLL CARDIOL, V9, pS2
   Dworkin MS, 2001, CLIN INFECT DIS, V32, P794, DOI 10.1086/319218
   ENGLUND JA, 1995, PEDIATRICS, V96, P580
   Farquhar C, 2005, JAIDS-J ACQ IMM DEF, V40, P494, DOI 10.1097/01.qai.0000168179.68781.95
   Healy CM, 2006, CURR OPIN INFECT DIS, V19, P271, DOI 10.1097/01.qco.0000224822.65599.5b
   Healy CM, 2004, J INFECT DIS, V190, P335, DOI 10.1086/421033
   Hesseling AC, 2009, B WORLD HEALTH ORGAN, V87, P505, DOI 10.2471/BLT.08.055657
   Joint United Nations Programme on HIV/AIDS, 2011, GLOB REP UNAIDS REP
   KNUF M, 2008, J PEDIAT, V152, pE1
   KNUF M, 2008, J PEDIAT, V152, P660
   Knuf M, 2008, J PEDIATR, V152, P655, DOI 10.1016/j.jpeds.2007.09.034
   Koyanagi A, 2011, PEDIATR INFECT DIS J, V30, P45, DOI 10.1097/INF.0b013e3181ecbf7e
   Kuhn L, 2005, CLIN INFECT DIS, V41, P1654, DOI 10.1086/498029
   Kurikka S, 1996, PEDIATR INFECT DIS J, V15, P530, DOI 10.1097/00006454-199606000-00011
   Madhi SA, 2005, VACCINE, V23, P5517, DOI 10.1016/j.vaccine.2005.07.038
   Madhi SA, 2005, PEDIATR INFECT DIS J, V24, P410, DOI 10.1097/01.inf.0000160942.84169.14
   Madhi SA, 2010, J INFECT DIS, V202, P355, DOI 10.1086/653704
   Marinda E, 2007, PEDIATR INFECT DIS J, V26, P519, DOI 10.1097/01.inf.0000264527.69954.4c
   McNally LM, 2007, LANCET, V369, P1440, DOI 10.1016/S0140-6736(07)60670-9
   MUSHER DM, 1990, J INFECT DIS, V161, P728
   Nair N, 2009, J INFECT DIS, V200, P1031, DOI 10.1086/605648
   Ned RM, 2008, J INFECT DIS, V198, P1609, DOI 10.1086/593066
   Nuttall JJ, 2008, INT J INFECT DIS, V12, pE99, DOI 10.1016/j.ijid.2008.06.014
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862
   SARVAS H, 1992, J INFECT DIS, V165, P977
   Scott S, 2005, J INFECT DIS, V191, P1854, DOI 10.1086/429963
   Scott S, 2007, CLIN INFECT DIS, V45, P1417, DOI 10.1086/522989
   Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6
   *U CAP TOWN CTR IN, COMPR TB HIV SERV PR
   *U CAP TOWN CTR IN, PROV HIV TB CAR PRIM
   World Health Organization, 2006, WKLY EPIDEMIOL REC, V81, P198
   WHO, 2007, WKLY EPIDEMIOL REC, V82, P193
   [Anonymous], 2005, WKLY EPIDEMIOL REC, V80, P279
NR 43
TC 103
Z9 104
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 9
PY 2011
VL 305
IS 6
BP 576
EP 584
DI 10.1001/jama.2011.100
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 717XI
UT WOS:000287080500022
PM 21304083
OA No
DA 2017-08-15
ER

PT J
AU Stare, D
   Harding-Esch, E
   Munoz, B
   Bailey, R
   Mabey, D
   Holland, M
   Gaydos, C
   West, S
AF Stare, Dianne
   Harding-Esch, Emma
   Munoz, Beatriz
   Bailey, Robin
   Mabey, David
   Holland, Martin
   Gaydos, Charlotte
   West, Sheila
CA PRET Study Grp
TI Design and Baseline Data of a Randomized Trial to Evaluate Coverage and
   Frequency of Mass Treatment with Azithromycin: The Partnership for Rapid
   Elimination of Trachoma (PRET) in Tanzania and The Gambia
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
ID CHLAMYDIA-TRACHOMATIS; INFECTION; COMMUNITY; EYE
AB Methods: The Partnership for the Rapid Elimination of Trachoma supervises 2 randomized, community-based clinical trials in Tanzania and The Gambia. Although each trial is a stand-alone effort, protocols, data collection, and analytic approaches have been harmonized to permit generalizations. Communities in each site were randomized using a 2X2 factorial design to standard (80%--90.0%) versus high (over 90.0%) treatment coverage; communities were further randomized to annual treatment for 3 years versus a ""graduation"" rule where evidence indicates an absence of follicular trachoma or infection and annual treatment is halted.
   Results: Average prevalence of follicular trachoma in children age less than 5 years was 32.2% in Tanzania and 5.96% in The Gambia. Randomization appeared to be effective, as prevalence was not statistically different between the arms within each country.
   Conclusions: There are challenges in harmonizing 2, large trials in Africa. Study outcomes will provide critical data to national trachoma control programs on treatment methodology and resource allocation toward elimination of the disease.
C1 [Stare, Dianne] Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA.
   [Harding-Esch, Emma; Bailey, Robin; Mabey, David; Holland, Martin] London Sch Hyg & Trop Med, Clin Res Unit, Dept Trop & Infect Dis, London WC1, England.
   [Holland, Martin] MRC Labs, Banjul, Gambia.
   [Gaydos, Charlotte] Johns Hopkins Univ, Dept Infect Dis, Baltimore, MD 21287 USA.
RP Stare, D (reprint author), Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, 600 N Wolfe St,Room 117A, Baltimore, MD 21287 USA.
EM dstare1@jhmi.edu
OI Mabey, David/0000-0002-0031-8276
FU Bill and Melinda Gates Foundation; Research to Prevent Blindness
FX The PRET study received operational support from Trachoma Control
   Programs in Tanzania and The Gambia. The study was funded by the Bill
   and Melinda Gates Foundation. Dr. West is the recipient of a Senior
   Scientific Investigator award from Research to Prevent Blindness.
CR Bailey R, 2007, BRIT J OPHTHALMOL, V91, P271, DOI 10.1136/bjo.2006.105270
   Baltussen RMRM, 2005, OPHTHAL EPIDEMIOL, V12, P91, DOI 10.1080/09286580490932761
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Chaudhary MA, 2006, COMPUT METH PROG BIO, V83, P205, DOI 10.1016/j.cmpb.2006.04.011
   Chidambaram JD, 2006, JAMA-J AM MED ASSOC, V295, P1142, DOI 10.1001/jama.295.10.1142
   Chow S, 2003, SAMPLE SIZE CALCULAT
   DALESIO NV, 2004, J CLIN MICROBIOL, P3300
   Diamant J, 2001, Ophthalmic Epidemiol, V8, P109, DOI 10.1076/opep.8.2.109.4156
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Faal H, 2000, BRIT J OPHTHALMOL, V84, P948, DOI 10.1136/bjo.84.9.948
   Frick KD, 2003, OPHTHALMIC EPIDEMIOL, V10, P121, DOI 10.1076/opep.10.2.121.13899
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Jansen E, 2007, OPHTHAL EPIDEMIOL, V14, P278, DOI 10.1080/092S6580701299403
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   Mathew AA, 2009, DRUGS, V69, P953, DOI 10.2165/00003495-200969080-00002
   Melese M, 2004, JAMA-J AM MED ASSOC, V292, P721, DOI 10.1001/jama.292.6.721
   Mkocha H, 2009, Tanzan J Health Res, V11, P103
   Solomon AW, 2008, NEW ENGL J MED, V358, P1870, DOI 10.1056/NEJMc0706263
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   SOLOMON AW, 2003, LANCET, V362, P181
   Solomon AW, 2006, TRACHOMA CONTROL GUI
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   West SK, 2005, LANCET, V366, P1296, DOI 10.1016/S0140-6736(05)67529-0
   World Health Organization, 2004, 8 M WHO ALL GLOB EL
NR 24
TC 46
Z9 46
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD FEB
PY 2011
VL 18
IS 1
BP 20
EP 29
DI 10.3109/09286586.2010.545500
PG 10
WC Ophthalmology
SC Ophthalmology
GA 715XM
UT WOS:000286928600002
PM 21275593
OA No
DA 2017-08-15
ER

PT J
AU Tappe, D
   Meyer, M
   Oesterlein, A
   Jaye, A
   Frosch, M
   Schoen, C
   Pantchev, N
AF Tappe, Dennis
   Meyer, Michael
   Oesterlein, Anett
   Jaye, Assan
   Frosch, Matthias
   Schoen, Christoph
   Pantchev, Nikola
TI Transmission of Armillifer armillatus Ova at Snake Farm, The Gambia,
   West Africa
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID PENTASTOMIASIS
AB Visceral pentastomiasis caused by Armillifer armillatus larvae was diagnosed in 2 dogs in The Gambia. Parasites were subjected to PCR; phylogenetic analysis confirmed relatedness with branchiurans/crustaceans. Our investigation highlights transmission of infective A. armillatus ova to dogs and, by serologic evidence, also to 1 human, demonstrating a public health concern.
C1 [Tappe, Dennis; Oesterlein, Anett; Frosch, Matthias; Schoen, Christoph] Univ Wurzburg, Inst Hyg & Microbiol, D-97080 Wurzburg, Germany.
   [Meyer, Michael] Touray & Meyer Vet Clin, Bijilo, Gambia.
   [Jaye, Assan] MRC Labs, Fajara, Gambia.
   [Pantchev, Nikola] Vet Med Lab, Ludwigsburg, Germany.
RP Tappe, D (reprint author), Univ Wurzburg, Inst Hyg & Microbiol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.
EM dtappe@hygiene.uni-wuerzburg.de
RI Schoen, Christoph/G-9837-2013; Frosch, Matthias/H-2411-2013
OI Schoen, Christoph/0000-0003-2222-1085; 
FU Robert Koch Institute, Federal Ministry of Health, Germany [1369-378]
FX This study was supported in part by the Robert Koch Institute, Federal
   Ministry of Health, Germany (fund 1369-378).
CR Brookins MD, 2009, VET PATHOL, V46, P460, DOI 10.1354/vp.07-VP-0246-R-BC
   Chen SH, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000647
   Dakubo J C B, 2006, West Afr J Med, V25, P166
   Dakubo Jcb, 2008, Ghana Med J, V42, P165
   Ette HY, 2003, FORENSIC SCI INT, V137, P52, DOI 10.1016/S0379-0738(03)00281-0
   Lavarde V, 1999, CLIN INFECT DIS, V29, P1346, DOI 10.1086/313460
   Lavrov DV, 2004, P ROY SOC B-BIOL SCI, V271, P537, DOI 10.1098/rspb.2003.2631
   Ma KC, 2002, TROP MED INT HEALTH, V7, P166, DOI 10.1046/j.1365-3156.2002.00839.x
   Magnino S, 2009, INT J FOOD MICROBIOL, V134, P163, DOI 10.1016/j.ijfoodmicro.2009.07.001
   Nozais J P, 1982, Med Trop (Mars), V42, P497
   Nzeh D. A., 1996, Central African Journal of Medicine, V42, P29
   PRATHAP K, 1969, AM J TROP MED HYG, V18, P20
   Reiter-Owona I, 2009, CLIN LAB, V55, P41
   Tappe D, 2006, EMERG INFECT DIS, V12, P1034
   Tappe D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000320
NR 15
TC 15
Z9 18
U1 1
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD FEB
PY 2011
VL 17
IS 2
BP 251
EP 254
DI 10.3201/eid1702.101118
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 722MM
UT WOS:000287436400015
PM 21291598
OA gold
DA 2017-08-15
ER

PT J
AU Umoh, NJ
   Lesi, OA
   Mendy, M
   Bah, E
   Akano, A
   Whittle, H
   Hainaut, P
   Kirk, GD
AF Umoh, Nsikak J.
   Lesi, Olufunmilayo A.
   Mendy, Maimuna
   Bah, Ebrima
   Akano, Aliu
   Whittle, Hilton
   Hainaut, Pierre
   Kirk, Gregory D.
TI Aetiological differences in demographical, clinical and pathological
   characteristics of hepatocellular carcinoma in The Gambia
SO LIVER INTERNATIONAL
LA English
DT Article
DE aflatoxin; hepatitis B virus; hepatitis C virus; hepatocellular
   carcinoma
ID AFLATOXIN-ALBUMIN ADDUCTS; PRIMARY LIVER-CANCER; HEPATITIS-B-VIRUS;
   WEST-AFRICA; ALPHA-FETOPROTEIN; CIRRHOSIS; RISK; EXPOSURE; INFECTION;
   INTERVENTION
AB Background
   Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with a high burden in West Africa. Data evaluating aetiological differences in HCC presentation from this region are limited.
   Aims
   The aim of this study was to describe the demographical, clinical and pathological characteristics of HCC by aetiology (hepatitis B or C infection, aflatoxin associated).
   Methods
   One hundred and ninty-three cases of HCC diagnosed between 1997 and 2001 in The Gambia were analysed. Characteristics were compared by aetiology using chi 2-tests, student t-test and Wilcoxon's rank sum tests as appropriate.
   Results
   The prevalence of hepatitis B surface antigen, hepatitis C antibody and aflatoxin-associated 249serTP53 mutations among HCC patients was 60, 20 and 38% respectively. The typical HCC patient was a 49-year-old male positive for hepatitis B surface antigen presenting with hepatomegaly (93%), abdominal pain (94%) and weight loss (95%) 8 weeks after symptom onset. Most patients had multifocal lesions with background cirrhosis. The median largest tumour was 10.3 cm and the median alpha-fetoprotein level was 500 ng/ml. Eighty-four per cent of patients had advanced HCC (patients not meeting the Milan criteria) at presentation.
   Conclusions
   Irrespective of aetiological agent, HCC among West Africans presents at very advanced stages. Few clinical or pathological differences exist by aetiology. More studies are needed to understand the mechanisms of hepatocarcinogenesis among these patients as well as identify high-risk populations in which early detection through screening will be beneficial.
C1 [Umoh, Nsikak J.] Geisinger Med Ctr, Dept Surg, Danville, PA 17822 USA.
   [Lesi, Olufunmilayo A.; Mendy, Maimuna; Bah, Ebrima; Whittle, Hilton; Hainaut, Pierre; Kirk, Gregory D.] Gambia Hepatitis Intervent Study, Banjul, Gambia.
   [Lesi, Olufunmilayo A.] Univ Lagos, Teaching Hosp, Dept Med, Lagos, Nigeria.
   [Mendy, Maimuna; Whittle, Hilton] MRC Labs, Banjul, Gambia.
   [Akano, Aliu] Natl Hosp, Dept Radiodiag, Abuja, Nigeria.
   [Hainaut, Pierre] Int Agcy Res Canc, F-69372 Lyon, France.
   [Kirk, Gregory D.] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA.
   [Kirk, Gregory D.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP Umoh, NJ (reprint author), Geisinger Med Ctr, Dept Surg, Danville, PA 17822 USA.
EM nsykumoh@yahoo.com
RI Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
CR ANTHONY PP, 1973, J PATHOL, V110, P37, DOI 10.1002/path.1711100105
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Besaratinia A, 2009, GASTROENTEROLOGY, V137, P1127, DOI 10.1053/j.gastro.2009.06.002
   Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011
   Boucher E, 2009, LIVER INT, V29, P148, DOI 10.1111/j.1478-3231.2008.01929.x
   Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep20933
   Colombo M, 2009, LIVER INT, V29, P143, DOI 10.1111/j.1478-3231.2008.01938.x
   Colombo Massimo, 2005, Cancer Imaging, V5, P85, DOI 10.1102/1470-7330.2005.0014
   Daniele B, 2004, GASTROENTEROLOGY, V127, pS108, DOI 10.1053/j.gastro.2004.09.023
   Hung CH, 2003, J GASTROENTEROL, V38, P153, DOI 10.1007/s005350300025
   IARC, 1993, IARC MON EV CARC RIS, V56, P245
   KEW MC, 1989, GASTROENTEROLOGY, V97, P136
   Kew MC, 2003, LIVER INT, V23, P405, DOI 10.1111/j.1478-3231.2003.00869.x
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2006, CARCINOGENESIS, V27, P2070, DOI 10.1093/carcin/bgl060
   Klich MA, 2007, MOL PLANT PATHOL, V8, P713, DOI [10.1111/j.1364-3703.2007.00436.x, 10.1111/J.1364-3703.2007.00436.X]
   Kuniholm MH, 2008, ENVIRON HEALTH PERSP, V116, P1553, DOI 10.1289/ehp.11661
   Lerose R, 2001, EUR J CANCER, V37, P239, DOI 10.1016/S0959-8049(00)00354-3
   LIN DY, 1993, J CLIN ULTRASOUND, V21, P303, DOI 10.1002/jcu.1870210502
   Mandishona E, 1998, HEPATOLOGY, V27, P1563, DOI 10.1002/hep.510270614
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   Montesano R, 2002, J MED VIROL, V67, P444, DOI 10.1002/jmv.10093
   N'Gbesso RD, 1998, J RADIOL, V79, P409
   Ocama P, 2009, BRIT J CANCER, V100, P799, DOI 10.1038/sj.bjc.6604893
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74
   ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G
   Seeff LB, 2004, GASTROENTEROLOGY, V127, pS1, DOI 10.1016/j.gastro.2004.09.010
   TAKETA K, 1990, HEPATOLOGY, V12, P1420, DOI 10.1002/hep.1840120625
   THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604
   Trevisani F, 2008, CARCINOGENESIS, V29, P1299, DOI 10.1093/carcin/bgn113
   Turner PC, 2005, LANCET, V365, P1950, DOI 10.1016/S0140-6736(05)66661-5
   Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x
   Villa E, 1998, HEPATOLOGY, V27, P983, DOI 10.1002/hep.510270413
   Wang LY, 1996, INT J CANCER, V67, P620, DOI 10.1002/(SICI)1097-0215(19960904)67:5<620::AID-IJC5>3.3.CO;2-V
   WANG T L, 1991, Annals Academy of Medicine Singapore, V20, P215
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   Wojnowski L, 2004, PHARMACOGENETICS, V14, P691, DOI 10.1097/00008571-200410000-00007
   Zhang BH, 2004, J CANCER RES CLIN, V130, P417, DOI 10.1007/s00432-004-0552-0
NR 39
TC 19
Z9 19
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1478-3223
J9 LIVER INT
JI Liver Int.
PD FEB
PY 2011
VL 31
IS 2
BP 215
EP 221
DI 10.1111/j.1478-3231.2010.02418.x
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 702FF
UT WOS:000285879300009
PM 21143369
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
   Akor, F
   Conteh, L
   Webb, E
   Bittaye, O
   Conway, DJ
   Jasseh, M
   Wiseman, V
   Milligan, PJ
   Greenwood, B
AF Bojang, Kalifa A.
   Akor, Francis
   Conteh, Lesong
   Webb, Emily
   Bittaye, Ousman
   Conway, David J.
   Jasseh, Momodou
   Wiseman, Virginia
   Milligan, Paul J.
   Greenwood, Brian
TI Two Strategies for the Delivery of IPTc in an Area of Seasonal Malaria
   Transmission in The Gambia: A Randomised Controlled Trial
SO PLOS MEDICINE
LA English
DT Article
ID INTERMITTENT SULFADOXINE-PYRIMETHAMINE; PLACEBO-CONTROLLED TRIAL;
   TREATED BED NETS; CHILDHOOD MORTALITY; COST-EFFECTIVENESS;
   HEALTH-WORKERS; SEVERE ANEMIA; RURAL AREA; CHILDREN; CHEMOPROPHYLAXIS
AB Background: The Expanded Programme on Immunisation (EPI) provides an effective way of delivering intermittent preventive treatment for malaria (IPT) to infants. However, it is uncertain how IPT can be delivered most effectively to older children. Therefore, we have compared two approaches to the delivery of IPT to Gambian children: distribution by village health workers (VHWs) or through reproductive and child health (RCH) trekking teams. In rural areas, RCH trekking teams provide most of the health care to children under the age of 5 years in the Infant Welfare Clinic, and provide antenatal care for pregnant women.
   Methods and Findings: During the 2006 malaria transmission season, the catchment populations of 26 RCH trekking clinics in The Gambia, each with 400-500 children 6 years of age and under, were randomly allocated to receive IPT from an RCH trekking team or from a VHW. Treatment with a single dose of sulfadoxine pyrimethamine (SP) plus three doses of amodiaquine (AQ) were given at monthly intervals during the malaria transmission season. Morbidity from malaria was monitored passively throughout the malaria transmission season in all children, and a random sample of study children from each cluster was examined at the end of the malaria transmission season. The primary study endpoint was the incidence of malaria. Secondary endpoints included coverage of IPTc, mean haemoglobin (Hb) concentration, and the prevalence of asexual malaria parasitaemia at the end of malaria transmission period. Financial and economic costs associated with the two delivery strategies were collected and incremental cost and effects were compared. A nested case-control study was used to estimate efficacy of IPT treatment courses. Treatment with SP plus AQ was safe and well tolerated. There were 49 cases of malaria with parasitaemia above 5,000/mu l in the areas where IPT was delivered through RCH clinics and 21 cases in the areas where IPT was delivered by VHWs, (incidence rates 2.8 and 1.2 per 1,000 child months, respectively, rate difference 1.6 [95% confidence interval (CI) -0.24 to 3.5]). Delivery through VHWs achieved a substantially higher coverage level of three courses of IPT than delivery by RCH trekking teams (74% versus 48%, a difference of 27% [95% CI 16%-38%]). For both methods of delivery, coverage was unrelated to indices of wealth, with similar coverage being achieved in the poorest and wealthiest groups. The prevalence of anaemia was low in both arms of the trial at the end of the transmission season. Efficacy of IPTc against malaria during the month after each treatment course was 87% (95% CI 54%-96%). Delivery of IPTc by VHWs was less costly in both economic and financial terms than delivery through RCH trekking teams, resulting in incremental savings of US$872 and US$1,244 respectively. The annual economic cost of delivering at least the first dose of each course of IPTc was US$3.47 and US$1.63 per child using trekking team and VHWs respectively.
   Conclusions: In this setting in The Gambia, delivery of IPTc to children 6 years of age and under by VHWs is more effective and less costly than delivery through RCH trekking clinics.
C1 [Bojang, Kalifa A.; Akor, Francis; Bittaye, Ousman; Conway, David J.; Jasseh, Momodou] MRC Labs, Banjul, Gambia.
   [Conteh, Lesong] Univ London Imperial Coll Sci Technol & Med, Inst Global Hlth Innovat, London, England.
   [Webb, Emily; Wiseman, Virginia; Milligan, Paul J.; Greenwood, Brian] London Sch Hyg & Trop Med, London WC1, England.
RP Bojang, KA (reprint author), MRC Labs, Banjul, Gambia.
EM kbojang@mrc.gm
RI Agyemang, Samuel/H-8377-2014; Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Akor, Francis/0000-0002-5181-8609;
   Webb, Emily/0000-0002-4019-7456; Conway, David/0000-0002-8711-3037
FU Gates Malaria Partnership; Bill & Melinda Gates Foundation; Medical
   Research Council, UK
FX This study was funded by the Gates Malaria Partnership, which receives
   financial support from the Bill & Melinda Gates Foundation and by the
   Medical Research Council, UK. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ALLEN SJ, 1990, J TROP MED HYG, V93, P313
   ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7
   Bennett S, 2002, INT J EPIDEMIOL, V31, P839, DOI 10.1093/ije/31.4.839
   Bojang K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011225
   BRADLEYMOORE AM, 1985, ANN TROP MED PARASIT, V79, P549
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   Cisse B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007164
   Conteh L, 2004, TROP MED INT HEALTH, V9, P125, DOI 10.1046/j.1365-3156.2003.01150.x
   Conteh L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012223
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   Dicko A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000407
   Dicko A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-123
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014
   Etard JF, 2004, INT J EPIDEMIOL, V33, P1286, DOI 10.1093/ije/dyh259
   *GAMB BUR STAT MIC, 2007, GAMB MULT IND CLUST
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   GREENWOOD BM, 1988, LANCET, V1, P1121
   Greenwood B, 2007, CLIN INFECT DIS, V45, P26, DOI 10.1086/518574
   Haines A, 2007, LANCET, V369, P2121, DOI 10.1016/S0140-6736(07)60325-0
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Johns B, 2003, COST EFF RESOUR ALLO, V1, P1, DOI 10.1186/1478-7547-1-1
   Kish L., 1965, SURVEY SAMPLING
   Kolaczinski J, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-37
   Konate AT, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000408
   Kweku M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007256
   Kweku M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004000
   LAING ABG, 1984, B WORLD HEALTH ORGAN, V62, P41
   Lehmann U., 2007, COMMUNITY HLTH WORKE
   Manzi F, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-165
   Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3
   MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L
   PRINGLE G, 1966, B WORLD HEALTH ORGAN, V34, P269
   Rogerson SJ, 2000, T ROY SOC TROP MED H, V94, P549, DOI 10.1016/S0035-9203(00)90083-X
   SANIESESAY, 2010, MAL J IN PRESS
   SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   Smith PG, 1996, FIELD TRIALS HLTH IN
   Sokhna C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001471
   Tan-Torres T, 2003, MAKING CHOICES HLTH
   Temperley M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-196
NR 43
TC 25
Z9 25
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD FEB
PY 2011
VL 8
IS 2
AR e1000409
DI 10.1371/journal.pmed.1000409
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 725PK
UT WOS:000287657600004
PM 21304921
OA gold
DA 2017-08-15
ER

PT J
AU Nweneka, CV
   Prentice, AM
AF Nweneka, Chidi V.
   Prentice, Andrew M.
TI Helicobacter pylori infection and circulating ghrelin levels - A
   systematic review
SO BMC GASTROENTEROLOGY
LA English
DT Review
ID PEPTIC-ULCER DISEASE; CHRONIC ATROPHIC GASTRITIS; MORBIDLY
   OBESE-PATIENTS; BODY-MASS INDEX; PLASMA GHRELIN; FUNCTIONAL DYSPEPSIA;
   LEPTIN CONCENTRATIONS; SERUM GHRELIN; GASTROINTESTINAL SYMPTOMS;
   PREPUBERTAL CHILDREN
AB Background: The nature of the association between ghrelin, an orexigenic hormone produced mainly in the stomach, and Helicobacter pylori (H pylori), a bacterium that colonises the stomach, is still controversial. We examined available evidence to determine whether an association exists between the two; and if one exists, in what direction.
   Methods: We reviewed original English language studies on humans reporting circulating ghrelin levels in H pylori infected and un-infected participants; and circulating ghrelin levels before and after H pylori eradication. Meta-analyses were conducted for eligible studies by combining study specific estimates using the inverse variance method with weighted average for continuous outcomes in a random effects model.
   Results: Seventeen out of 27 papers that reported ghrelin levels in H pylori positive and negative subjects found lower circulating ghrelin levels in H pylori positive subjects; while 10 found no difference. A meta-analysis of 19 studies with a total of 1801 participants showed a significantly higher circulating ghrelin concentration in H pylori negative participants than in H pylori positive participants (Effect estimate (95%CI) = -0.48 (-0.60, -0.36)). However, eradicating H pylori did not have any significant effect on circulating ghrelin levels (Effect estimate (95%CI) = 0.08 (-0.33, 0.16); Test for overall effect: Z = 0.67 (P = 0.5)).
   Conclusions: We conclude that circulating ghrelin levels are lower in H pylori infected people compared to those not infected; but the relationship between circulating ghrelin and eradication of H pylori is more complex.
C1 [Nweneka, Chidi V.; Prentice, Andrew M.] MRC Labs, Nutr Programme, Banjul, Gambia.
   [Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
RP Nweneka, CV (reprint author), MRC Labs, Nutr Programme, POB 273, Banjul, Gambia.
EM cnweneka@mrc.gm
FU UK Medical Research Council
FX The authors declare that they have no competing interests. Funding for
   this study was provided by the UK Medical Research Council.
CR Abiko Y, 2005, WORLD J GASTROENTERO, V11, P4148
   Alonso N, 2007, EUR J ENDOCRINOL, V157, P763, DOI 10.1530/EJE-07-0300
   Anania C, 2007, HELICOBACTER, V12, P393
   Ando T, 2006, ALIMENT PHARM THERAP, V24, P58, DOI 10.1111/j.1365-2036.2006.00026.x
   Ates Y, 2008, DIGEST DIS SCI, V53, P2215, DOI 10.1007/s10620-007-0113-x
   Bercik P, 2009, AM J PHYSIOL-REG I, V296, pR587, DOI 10.1152/ajpregu.90752.2008
   Campana D, 2007, CLIN ENDOCRINOL, V67, P761, DOI 10.1111/j.1365-2265.2007.02959.x
   Checchi S, 2007, J CLIN ENDOCR METAB, V92, P4346, DOI 10.1210/jc.2007-0988
   Cherian S, 2009, ACTA PAEDIATR, V98, P860, DOI 10.1111/j.1651-2227.2009.01221.x
   Choe YH, 2007, GUT LIVER, V1, P132, DOI 10.5009/gnl.2007.1.2.132
   Choi Jeong Young, 2006, Korean J Gastroenterol, V48, P75
   Chuang CH, 2009, HELICOBACTER, V14, P54, DOI 10.1111/j.1523-5378.2009.00653.x
   Cindoruk M, 2007, WORLD J GASTROENTERO, V13, P1595
   Czesnikiewicz-Guzik M, 2005, J Physiol Pharmacol, V56 Suppl 6, P77
   Czesnikiewicz-Guzik M, 2007, J CLIN GASTROENTEROL, V41, P145, DOI 10.1097/01.mcg.0000225654.85060.3d
   D'Onghia V, 2007, BIOMED PHARMACOTHER, V61, P137, DOI 10.1016/j.biopha.2006.08.007
   de Martel C, 2007, AM J GASTROENTEROL, V102, P1166, DOI 10.1111/j.1572-0241.2007.01116.x
   Doki Y, 2006, SURGERY, V139, P797, DOI 10.1016/j.surg.2005.11.015
   Dutta SK, 2009, DIGEST DIS SCI, V54, P1243, DOI 10.1007/s10620-008-0485-6
   Gao XY, 2008, PEPTIDES, V29, P1749, DOI 10.1016/j.peptides.2008.05.027
   Gao XY, 2009, NUTRITION, V25, P506, DOI 10.1016/j.nut.2008.11.002
   Gen R, 2010, SOUTH MED J, V103, P190, DOI 10.1097/SMJ.0b013e3181cf373f
   Gokcel A, 2003, EUR J ENDOCRINOL, V148, P423, DOI 10.1530/eje.0.1480423
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Huang Q, 2007, DIGEST DIS SCI, V52, P803, DOI 10.1007/s10620-006-9508-3
   Hussein NR, 2008, J CLIN MICROBIOL, V46, P1774, DOI 10.1128/JCM.01737-07
   Isomoto H, 2005, AM J GASTROENTEROL, V100, P1711, DOI 10.1111/j.1572-0241.2005.41492.x
   Isomoto H, 2005, AM J GASTROENTEROL, V100, P1425, DOI 10.1111/j.1572-0241.2005.41929_7.x
   Isomoto H, 2004, AM J MED, V117, P429, DOI 10.1016/j.amjmed.2004.01.030
   Isomoto H, 2005, WORLD J GASTROENTERO, V11, P1644
   Jang EJ, 2008, J GASTROEN HEPATOL, V23, pS278, DOI 10.1111/j.1440-1746.2008.05415.x
   Jun DW, 2007, DIGEST DIS SCI, V52, P2866, DOI 10.1007/s10620-006-9651-x
   Kawashima J, 2009, J GASTROENTEROL, V44, P1046, DOI 10.1007/s00535-009-0120-0
   Kebapcilar L, 2009, INTERNAL MED, V48, P2055, DOI 10.2169/internalmedicine.48.2562
   Kempa A, 2007, J ENDOCRINOL INVEST, V30, P659
   Konturek PC, 2006, J PHYSIOL PHARMACOL, V57, P67
   Lee ES, 2010, J KOREAN MED SCI, V25, P265, DOI 10.3346/jkms.2010.25.2.265
   Liew PL, 2006, OBES SURG, V16, P612, DOI 10.1381/096089206776945002
   Masaoka T, 2005, HEPATO-GASTROENTEROL, V52, P1
   Mendez-Sanchez Nahum, 2007, Rev Gastroenterol Mex, V72, P359
   Nishizawa T, 2006, ALIMENT PHARM THER, V24, P104, DOI 10.1111/j.1365-2036.2006.00032.x
   Nunes FA, 2006, HELICOBACTER, V11, P368
   Nwokolo CU, 2003, GUT, V52, P637, DOI 10.1136/gut.52.5.637
   Osawa H, 2005, J CLIN ENDOCR METAB, V90, P10, DOI 10.1210/jc.2004-1330
   Osawa H, 2008, WORLD J GASTROENTERO, V14, P6327, DOI 10.3748/wjg.14.6327
   Osawa H, 2006, J GASTROENTEROL, V41, P954, DOI 10.1007/s00535-006-1880-4
   Pacifico L, 2008, EUR J ENDOCRINOL, V158, P323, DOI 10.1530/EJE-07-0438
   Plonka M, 2006, ALIMENT PHARM THERAP, V24, P160, DOI 10.1111/j.1365-2036.2006.00040.x
   Plonka M, 2006, DIGEST LIVER DIS, V38, P91, DOI 10.1016/j.dld.2005.10.013
   Roper J, 2008, J CLIN ENDOCR METAB, V93, P2350, DOI 10.1210/jc.2007-2057
   Salles N, 2006, J GERONTOL A-BIOL, V61, P1144
   Shak JR, 2008, OBES SURG, V18, P1089, DOI 10.1007/s11695-008-9454-6
   Shindo T, 2009, DIGESTION, V79, P65, DOI 10.1159/000205740
   Shinomiya T, 2005, SCAND J GASTROENTERO, V40, P648, DOI 10.1080/00365520510015403
   Shiotani A, 2005, HELICOBACTER, V10, P373, DOI 10.1111/j.1523-5378.2005.00343.x
   Stec-Michalska K, 2009, WORLD J GASTROENTERO, V15, P5409, DOI 10.3748/wjg.15.5409
   Sundbom M, 2007, OBES SURG, V17, P304, DOI 10.1007/s11695-007-9056-8
   Suzuki H, 2006, ALIMENT PHARM THERAP, V24, P120, DOI 10.1111/j.1365-2036.2006.00034.x
   Suzuki H, 2005, J GASTROEN HEPATOL, V20, P1652, DOI 10.1111/j.1440-1746.2005.04039.x
   Suzuki H, 2004, HEPATO-GASTROENTEROL, V51, P1249
   Suzuki H, 2004, GUT, V53, P187, DOI 10.1136/gut.2003.021568
   Suzuki Hidekazu, 2005, Nihon Saikingaku Zasshi, V60, P453
   Taniaka-Shintani M, 2005, J GASTROENTEROL, V40, P345, DOI 10.1007/s00535-004-155-03
   Tatsuguchi A, 2004, AM J GASTROENTEROL, V99, P2121, DOI 10.1111/j.1572-0241-2004.30291.x
   Uzzan B, 2007, OBES SURG, V17, P1159, DOI 10.1007/s11695-007-9197-9
   Wang HH, 2006, OBES SURG, V16, P297, DOI 10.1381/096089206776116417
   Weigt J, 2009, CURR OPIN CLIN NUTR, V12, P522, DOI 10.1097/MCO.0b013e32832eb56e
   Wu MS, 2005, ARCH INTERN MED, V165, P1552, DOI 10.1001/archinte.165.13.1552
   Zub-Pokrowiecka A, 2010, MED SCI MONITOR, V16, pCR493
NR 70
TC 30
Z9 33
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD JAN 26
PY 2011
VL 11
AR 7
DI 10.1186/1471-230X-11-7
PG 18
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 719UG
UT WOS:000287235200001
PM 21269467
OA gold
DA 2017-08-15
ER

PT J
AU Agergaard, J
   Nante, E
   Poulstrup, G
   Nielsen, J
   Flanagan, KL
   Ostergaard, L
   Benn, CS
   Aaby, P
AF Agergaard, J.
   Nante, E.
   Poulstrup, G.
   Nielsen, J.
   Flanagan, K. L.
   Ostergaard, L.
   Benn, C. S.
   Aaby, P.
TI Diphtheria-tetanus-pertussis vaccine administered simultaneously with
   measles vaccine is associated with increased morbidity and poor growth
   in girls. A randomised trial from Guinea-Bissau
SO VACCINE
LA English
DT Article
DE Diphtheria-tetanus-pertussis; Sex; Morbidity
ID FEMALE-MALE MORTALITY; ROUTINE VACCINATIONS; IMMUNE-RESPONSES; COMMUNITY
   COHORT; SEX-DIFFERENCES; CHILD SURVIVAL; IMMUNIZATION; INFECTION;
   AFRICA; GENDER
AB Background: Combined vaccination with diphtheria-tetanus-pertussis (DTP) and measles vaccine (MV) has been associated with increased mortality in observational studies. Among children missing MV and a dose of DTP and oral polio vaccine (OPV), we conducted a randomised trial of providing MV + DTP + OPV simultaneously, as currently recommended, or MV + OPV only, and examined the effect on morbidity and growth. We hypothesised that the MV + OPV group would experience less morbidity and grow better. Due to previous observations of sex differences in the non-specific effects of vaccinations, we analysed all data stratified by sex.
   Methods: At the Bandim Health Project in Guinea-Bissau. 568 children who were due to receive MV and who were missing either DTP3 or DTP booster were enrolled in the study. A subgroup of 332 children was followed intensively to register adverse events and infections in the first month after vaccination. A subgroup of 276 children was followed every third month for a year to monitor growth. All children were followed for one year for infectious diseases, consultations, and hospitalisations.
   Results: As expected, adverse events were more common in the MV + DTP + OPV group; diarrhoea and use of medication were increased among girls but not among boys (both p = 0.02, test of interaction between DTP and sex). Febrile disease with vesicular rash, as well as consultations and hospitalisations tended to be more common in the MV + DTP + OPV group than in the MV + OPV group; the hazard ratio (HR) for febrile disease with vesicular rash was 1.86 (1.00; 3.47). The strongest tendencies for more febrile diseases and hospitalisations in the MV + DTP + OPV group were found in girls. Overall, growth did not differ by randomisation group. However, results differed by sex. Girls in the MV + DTP + OPV group had a consistent pattern of worse z-scores for weight, height, and mid-upper-arm-circumference (MUAC) than girls in the MV + OPV group. The effect was opposite for boys, with boys in the MV + OPV group faring worse than those in the MV + DTP + OPV group, the interaction test for sex and DTP being significant for weight at 6 and 9 months, for MUAC at 12 months and for weight-for-height at 3 and 9 months after randomisation.
   Conclusion: This is the first randomised trial of the non-specific effects of DTP and supports that these effects may be sex-differential and of clinical and anthropometric importance. Combined vaccination with DTP + MV + OPV may be detrimental for girls. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Agergaard, J.; Ostergaard, L.] Aarhus Univ Hosp, Dept Infect Dis, Skejby Sygehus, DK-8200 Aarhus N, Denmark.
   [Agergaard, J.; Nante, E.; Poulstrup, G.; Aaby, P.] Indepth Network, Bandim Hlth Project, Bissau 1004, Guinea Bissau.
   [Poulstrup, G.; Nielsen, J.; Benn, C. S.; Aaby, P.] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen S, Denmark.
   [Flanagan, K. L.] MRC Labs, Banjul, Gambia.
RP Agergaard, J (reprint author), Aarhus Univ Hosp Skejby, Dept Infect Dis, Brenstrupgaardsvej 100, DK-8200 Aarhus N, Denmark.
EM heja@dadlnet.dk
FU Danish Medical Research Council; Lundbeck Foundation; Danish National
   Research Foundation; Graduate School of International Health; Clinical
   Institute Aarhus University Hospital Skejby; DANIDA; Aarhus University
   Hospitals Research Initiative; Danish Pasteur Society; Aase and Ejnar
   Danielsens' Foundation; Scandinavian Society for Antimicrobial
   Chemotherapy; Danish Medical Associations; Novo Nordisk Foundation;
   Medical Research Council UK
FX The main financial support for the present study came from The Danish
   Medical Research Council, The Lundbeck Foundation, The Danish National
   Research Foundation, The Graduate School of International Health and
   Clinical Institute Aarhus University Hospital Skejby. The Bandim Health
   project is supported by DANIDA. The study received financial support
   also from Aarhus University Hospitals Research Initiative, The Danish
   Pasteur Society, Aase and Ejnar Danielsens' Foundation, Scandinavian
   Society for Antimicrobial Chemotherapy and Danish Medical Associations.
   PA holds a research professorship grant from the Novo Nordisk
   Foundation. KF is funded by the Medical Research Council UK.
CR Aaby P, 2006, VACCINE, V24, P4701, DOI 10.1016/j.vaccine.2006.03.038
   Aaby P, 2006, VACCINE, V24, P2764, DOI 10.1016/j.vaccine.2006.01.004
   Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   Aaby P, 2004, INT J EPIDEMIOL, V33, P367, DOI 10.1093/ije/dyh004
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   Aaby P, 2007, VACCINE, V25, P1265, DOI 10.1016/j.vaccine.2006.10.007
   Aaby P, 2006, PEDIATR INFECT DIS J, V25, P721, DOI 10.1097/01.inf.0000227829.64686.ae
   Aaby P, 2009, LANCET, V373, P1428, DOI 10.1016/S0140-6736(09)60823-0
   Benn CS, 2009, AM J CLIN NUTR, V90, P629, DOI 10.3945/ajcn.2009.27477
   Benn CS, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1101
   Benn Christine Stabell, 2008, PLoS One, V3, pe4056, DOI 10.1371/journal.pone.0004056
   Bland RM, 2004, TROP MED INT HEALTH, V9, P118, DOI 10.1046/j.1365-3156.2003.01148.x
   Casimir GJA, 2010, SHOCK, V33, P258, DOI 10.1097/SHK.0b013e3181b2b36b
   Deressa W, 2003, B WORLD HEALTH ORGAN, V81, P261
   Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
   FISHMAN S, 2004, WHO, V1, P39
   Klein Sabra, 2005, Gend Med, V2, P197, DOI 10.1016/S1550-8579(05)80050-6
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Klein SL, 2004, PARASITE IMMUNOL, V26, P247, DOI 10.1111/j.0141-9838.2004.00710.x
   Klein SL, 2000, NEUROSCI BIOBEHAV R, V24, P627, DOI 10.1016/S0149-7634(00)00027-0
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Lapidus N, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000039
   Lim SS, 2008, LANCET, V372, P2031, DOI 10.1016/S0140-6736(08)61869-3
   Marriott I, 2006, IMMUNOL RES, V34, P177, DOI 10.1385/IR:34:3:177
   Nielsen A M, 1991, Ugeskr Laeger, V153, P1482
   Pasetti M, 1997, INFECTION, V25, P339, DOI 10.1007/BF01740813
   Poulsen A, 2002, J INFECTION, V45, P237, DOI 10.1053/jinf.2002.1049
   Rodrigues A, 2006, VACCINE, V24, P4737, DOI 10.1016/j.vaccine.2006.03.033
   *RXLIST, 2008, INT DRUG IND
   Simondon F, 1996, EUR J CLIN MICROBIOL, V15, P927, DOI 10.1007/BF01690510
   Valentiner-Branth P, 2007, VACCINE, V25, P2733, DOI 10.1016/j.vaccine.2006.01.035
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
   Veirum JE, 2007, ACTA PAEDIATR, V96, P1526, DOI 10.1111/j.1651-2227.2007.00467.x
   WINTER JSD, 1976, J CLIN ENDOCR METAB, V42, P679
NR 36
TC 10
Z9 10
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2011
VL 29
IS 3
BP 487
EP 500
DI 10.1016/j.vaccine.2010.10.071
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 715AQ
UT WOS:000286853200018
PM 21093496
OA No
DA 2017-08-15
ER

PT J
AU Sesay, S
   Milligan, P
   Touray, E
   Sowe, M
   Webb, EL
   Greenwood, BM
   Bojang, KA
AF Sesay, Sanie
   Milligan, Paul
   Touray, Ensa
   Sowe, Maimuna
   Webb, Emily L.
   Greenwood, Brian M.
   Bojang, Kalifa A.
TI A trial of intermittent preventive treatment and home-based management
   of malaria in a rural area of The Gambia
SO MALARIA JOURNAL
LA English
DT Article
ID SULFADOXINE-PYRIMETHAMINE; CHILDHOOD MORTALITY; PREGNANCY; MORBIDITY
AB Background: Individual malaria interventions provide only partial protection in most epidemiological situations. Thus, there is a need to investigate whether combining interventions provides added benefit in reducing mortality and morbidity from malaria. The potential benefits of combining IPT in children (IPTc) with home management of malaria (HMM) was investigated.
   Methods: During the 2008 malaria transmission season, 1,277 children under five years of age resident in villages within the rural Farafenni demographic surveillance system (DSS) in North Bank Region, The Gambia were randomized to receive monthly IPTc with a single dose of sulphadoxine/pyrimethamine (SP) plus three doses of amodiaquine (AQ) or SP and AQ placebos given by village health workers (VHWs) on three occasions during the months of September, October and November, in a double-blind trial. Children in all study villages who developed an acute febrile illness suggestive of malaria were treated by VHWs who had been taught how to manage malaria with artemether-lumefantrine (Coartem (TM)). The primary aims of the project were to determine whether IPTc added significant benefit to HMM and whether VHWs could effectively combine the delivery of both interventions.
   Results: The incidence of clinical attacks of malaria was very low in both study groups. The incidence rate of malaria in children who received IPTc was 0.44 clinical attacks per 1,000 child months at risk while that for control children was 1.32 per 1,000 child months at risk, a protective efficacy of 66% (95% Cl -23% to 96%; p = 0.35). The mean (standard deviation) haemoglobin concentration at the end of the malaria transmission season was similar in the two treatment groups: 10.2 (1.6) g/dL in the IPTc group compared to 10.3 (1.5) g/dL in the placebo group. Coverage with IPTc was high, with 94% of children receiving all three treatments during the study period.
   Conclusion: Due to the very low incidence of malaria, no firm conclusion can be drawn on the added benefit of IPTc in preventing clinical episodes of malaria among children who had access to HMM in The Gambia. However, the study showed that VHWs can successfully combine provision of HMM with provision of IPTc.
C1 [Sesay, Sanie; Touray, Ensa; Sowe, Maimuna; Bojang, Kalifa A.] MRC Labs, Banjul, Gambia.
   [Milligan, Paul; Webb, Emily L.; Greenwood, Brian M.] London Sch Hyg & Trop Med, London WC1, England.
RP Bojang, KA (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM kbojang@mrc.gm
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Webb, Emily/0000-0002-4019-7456
FU Bill and Melinda Gates Foundation; Medical Research Council, UK
FX We are indebted to the children, their parents, field workers, nurses
   and data entry who participated in the study. We also thank the DSMB
   members (Chair, Prof. Chris Whitty) and the local safety monitor (Prof.
   Ousman Nyang). The study was funded by the Gates Malaria Partnership,
   which received financial support from the Bill and Melinda Gates
   Foundation and Medical Research Council, UK
CR Ahorlu CK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-292
   Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   DICKO A, PLOS MED
   Dicko A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-123
   Etard JF, 2004, INT J EPIDEMIOL, V33, P1286, DOI 10.1093/ije/dyh259
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   Greenwood BM, 2008, TRENDS PARASITOL, V24, P449, DOI 10.1016/j.pt.2008.07.002
   Hopkins H, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-134
   *IND NETW, 2002, POP HLTH DEV COUNTR, V1
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0
   KONATE AT, PLOS MED
   Kweku M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004000
   Nsabagasani X, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-11
   O'Meara WP, 2010, LANCET INFECT DIS, V10, P545, DOI 10.1016/S1473-3099(10)70096-7
   Rogerson SJ, 2000, T ROY SOC TROP MED H, V94, P549, DOI 10.1016/S0035-9203(00)90083-X
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   Sirima SB, 2003, TROP MED INT HEALTH, V8, P133, DOI 10.1046/j.1365-3156.2003.00997.x
   *WHO, 2009, TECHN CONS INT PREV
   WHO, 2004, SCAL HOM BAS MAN MAL
   *WORLD HLTH ORG, 2005, ROLL BACK MAL STRAT, P1101
NR 23
TC 10
Z9 10
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JAN 7
PY 2011
VL 10
AR 2
DI 10.1186/1475-2875-10-2
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 740QK
UT WOS:000288809300002
PM 21214940
OA gold
DA 2017-08-15
ER

PT J
AU Okebe, JU
   Yahav, D
   Shbita, R
   Paul, M
AF Okebe, Joseph U.
   Yahav, Dafna
   Shbita, Rana
   Paul, Mical
TI Oral iron supplements for children in malaria-endemic areas
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Endemic Diseases; Anemia, Iron-Deficiency [etiology; prevention &
   control]; Antimalarials [administration & dosage]; Dietary Supplements
   [adverse effects]; Iron [adverse effects; therapeutic use]; Malaria
   [chemically induced; complications]; Parasitemia [chemically induced;
   complications]; Randomized Controlled Trials as Topic; Child; Child,
   Preschool; Humans
ID PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; FOLIC-ACID
   SUPPLEMENTATION; CELL-MEDIATED-IMMUNITY; BIRTH-WEIGHT INFANTS;
   BREAST-FED INFANTS; PAPUA-NEW-GUINEA; VITAMIN-A STATUS; ROUTINE
   PROPHYLACTIC SUPPLEMENTATION; WEEKLY MICRONUTRIENT SUPPLEMENTATION
AB Background
   Iron-deficiency anaemia is common during childhood. Iron supplementation has been claimed to increase the risk of malaria.
   Objectives
   To assess the effect of iron on malaria and deaths.
   Search strategy
   We searched The Cochrane Library, PUBMED, MEDLINE, LILACS; and trial registry databases, all up to June 2011. We scanned references of included trials.
   Selection criteria
   Individually and cluster randomized controlled trials conducted in hypoendemic to holoendemic malaria regions and including children below 18 years of age. We included trials comparing orally administered iron, iron with antimalarial treatment, or iron with folic acid versus placebo or no treatment. Iron fortification was excluded. Antihelminthics could be administered to either group. Additional micronutrients had to be administered equally to both groups.
   Data collection and analysis
   The primary outcomes were clinical (symptomatic) malaria, severe malaria, and death. Two authors independently selected the studies and extracted the data. We assessed heterogeneity and conducted subgroup analyses by the presence of anaemia at baseline, age, and malaria endemicity. We assessed risk of bias using domain-based evaluation. We performed a fixed-effect meta-analysis for all outcomes and random-effects meta-analysis for hematological outcomes. We adjusted analyses for cluster randomized trials.
   Main results
   Seventy-one trials (45,353 children) were included. For clinical malaria, no significant difference between iron alone and placebo was detected, (risk ratio (RR) 0.99, 95% confidence intervals (CI) 0.90 to 1.09, 13 trials). The results were similar in the subgroups of non-anaemic children and children below 2 years of age. There was no significant difference in deaths in hyper- and holoendemic areas, risk difference +1.93 per 1000 children (95% CI -1.78 to 5.64, 13 trials, 17,898 children). Iron administered for treatment of anaemia resulted in a larger increase in haemoglobin than iron given for prevention, and the benefit was similar in hyper- or holoendemic and lower endemicity settings. Iron and folic acid supplementation resulted in mixed results for severe malaria. Overall, the risk for clinical malaria was higher with iron or with iron plus folic acid in trials where services did not provide for malaria surveillance and treatment. Iron with antimalarial treatment significantly reduced malaria. Iron supplementation during an acute attack of malaria did not increase the risk for parasitological failure, (RR 0.96, 95% CI 0.74 to 1.24, three trials) or deaths.
   Authors' conclusions
   Iron alone or with antimalaria treatment does not increase the risk of clinical malaria or death when regular malaria surveillance and treatment services are provided. There is no need to screen for anaemia prior to iron supplementation.
C1 [Paul, Mical] Tel Aviv Univ, Infect Dis Unit, Sackler Fac Med, IL-49100 Petah Tiqwa, Israel.
   [Okebe, Joseph U.] MRC Unit, Banjul, Gambia.
   [Yahav, Dafna; Shbita, Rana] Beilinson Med Ctr, Rabin Med Ctr, Dept Med E, Petah Tiqwa, Israel.
RP Paul, M (reprint author), Tel Aviv Univ, Infect Dis Unit, Sackler Fac Med, IL-49100 Petah Tiqwa, Israel.
EM paulm@post.tau.ac.il
RI Gough, Ethan/B-8633-2012
FU UK Department for International Development (DFID), UK; UK Department
   for International Development (DFID); Nuffield Foundation, Afghanistan;
   Nuffield Foundation; Micronutrients Unit, Department of Nutrition for
   Health and Development, World Health Organization, Switzerland
FX Internal sources; UK Department for International Development (DFID),
   UK.; The editorial base for the Cochrane Infectious Diseases Group is
   funded by the UK Department for International Development (DFID) for the
   benefit of developing countries. Dafna Yahav received funding from the
   editorial base.; External sources; The Nuffield Foundation,
   Afghanistan.; Dr Juliana U Ojukwu was awarded a Reviews for Africa
   Programme Fellowship (www.mrc.ac.za/cochrane/rap.htm), funded by a grant
   from the Nuffield Commonwealth Programme, through The Nuffield
   Foundation.; Micronutrients Unit, Department of Nutrition for Health and
   Development, World Health Organization, Switzerland. Grant to support
   the 2011 update
CR Abdelrazik N, 2007, INDIAN J PEDIATR, V74, P739, DOI 10.1007/s12098-007-0130-y
   Adam C, 1997, THESIS LONDON SCH TR
   Adu-Afarwuah S, 2008, AM J CLIN NUTR, V87, P929
   Agarwal K N, 2003, Indian Pediatr, V40, P296
   Aggarwal D, 2005, ARCH DIS CHILD, V90, P26, DOI 10.1136/adc.2003.040410
   Aggarwal D, 2002, BRIT MED J, V325, P1142
   Aguayo VM, 2000, EUR J NUTR, V39, P263, DOI 10.1007/s003940070005
   Ahmed F, 2001, AM J CLIN NUTR, V74, P108
   AKENZUA GI, 1985, J TROP PEDIATRICS, V31, P59
   Allen LH, 2000, AM J CLIN NUTR, V71, P1485
   Anand K, 2007, INDIAN PEDIATR, V44, P823
   ANGELES IT, 1993, AM J CLIN NUTR, V58, P339
   AngelesAgdeppa I, 1997, AM J CLIN NUTR, V66, P177
   Arcanjo FPN, 2008, J TROP PEDIATRICS, V54, P243, DOI 10.1093/tropej/fmm113
   Asibey-Berko E, 2007, East Afr Med J, V84, P473
   Atukorala S, 2001, INT NUTR AN CONS GRO
   AUKETT MA, 1986, ARCH DIS CHILD, V61, P849
   Ayoya MA, 2009, J NUTR, V139, P1972, DOI 10.3945/jn.109.106625
   Baird JK, 1997, LANCET, V350, P1855, DOI 10.1016/S0140-6736(05)63676-8
   Baqui AH, 2005, J NUTR, V135, P2187
   Baqui AH, 2003, J NUTR, V133, P4150
   BARCLAY SM, 1991, PEDIATR RES, V29, P297, DOI 10.1203/00006450-199103000-00015
   BATES CJ, 1987, T ROY SOC TROP MED H, V81, P286, DOI 10.1016/0035-9203(87)90244-6
   BATES CJ, 1994, BRIT J NUTR, V72, P601, DOI 10.1079/BJN19940062
   Beard JL, 2001, J NUTR, V131, P568
   Beasley NMR, 2000, TROP MED INT HEALTH, V5, P794, DOI 10.1046/j.1365-3156.2000.00641.x
   Beck HP, 1999, LANCET, V93, P41
   BENDERGOTZE C, 1980, FORTSCHR MED, V98, P590
   Berger J, 1997, EUR J CLIN NUTR, V51, P381, DOI 10.1038/sj.ejcn.1600418
   Berger J, 2006, EUR J CLIN NUTR, V60, P443, DOI 10.1038/sj.ejcn.1602336
   BERGER J, 1992, NUTR RES, V12, P39, DOI 10.1016/S0271-5317(05)80408-7
   Berger J, 2000, EUR J CLIN NUTR, V54, P29, DOI 10.1038/sj.ejcn.1600888
   Bhandari N, 2001, BRIT J NUTR, V85, pS131
   Bhatia D, 1993, Indian Pediatr, V30, P195
   Black MM, 2004, AM J CLIN NUTR, V80, P903
   Bloland PB, 1999, AM J TROP MED HYG, V60, P635
   BOIVIN MJ, 1993, J PEDIATR PSYCHOL, V18, P249, DOI 10.1093/jpepsy/18.2.249
   Bojang KA, 1997, T ROY SOC TROP MED H, V91, P557, DOI 10.1016/S0035-9203(97)90025-0
   BRADFIELD RB, 1968, AM J CLIN NUTR, V21, P57
   BRADFIELD RB, 1968, AM J CLIN NUTR, V21, P68
   Breman JG, 2001, AM J TROP MED HYG, V64, P1
   Browne E, 2005, 4 MIM MAL C YAOUND C
   Bruner AB, 1996, LANCET, V348, P992, DOI 10.1016/S0140-6736(96)02341-0
   BRUNSER O, 1993, EUR J CLIN NUTR, V47, P317
   Carneiro I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008988
   Carter JY, 2005, AM J TROP MED HYG, V73, P166
   Chandramohan D, 2005, BRIT MED J, V331, P727, DOI 10.1136/bmj.331.7519.727
   CHAROENLARP P, 1973, Southeast Asian Journal of Tropical Medicine and Public Health, V4, P588
   CHIPPAUX JP, 1991, B SOC PATHOL EXOT, V84, P54
   CHWANG LC, 1988, AM J CLIN NUTR, V47, P496
   Chilenje Infant Growth Nutrition and Infection (CIGNIS) Study Team, 2010, PLOS ONE, V5
   Cusick SE, 2005, AM J CLIN NUTR, V82, P406
   Darboe MK, 2007, LANCET, V369, P2088, DOI 10.1016/S0140-6736(07)60981-7
   de Silva A, 2003, AM J CLIN NUTR, V77, P234
   Deeksha Kapur, 2002, Indian Pediatrics, V39, P136
   DEINARD AS, 1986, J PEDIATR-US, V108, P681, DOI 10.1016/S0022-3476(86)81041-1
   Desai MR, 2004, J NUTR, V134, P1167
   Desai MR, 2003, J INFECT DIS, V187, P658, DOI 10.1086/367986
   Devaki PB, 2007, ARZNEIMITTEL-FORSCH, V57, P417
   Dewey KG, 2002, J NUTR, V132, P3249
   Dijkhuizen MA, 2001, J NUTR, V131, P2860
   Diouf S, 2002, ARCH PEDIATRIE, V9, P102, DOI 10.1016/S0929-693X(01)00704-7
   Domellof M, 2001, J PEDIATR-US, V138, P679, DOI 10.1067/mpd.2001.112895
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   Dossa RAM, 2001, J NUTR, V131, P2874
   Dossa RAM, 2001, EUR J CLIN NUTR, V55, P223, DOI 10.1038/sj.ejcn.1601126
   Ekvall H, 2000, TROP MED INT HEALTH, V5, P696, DOI 10.1046/j.1365-3156.2000.00626.x
   Ekvall H, 2003, CURR OPIN HEMATOL, V10, P108, DOI 10.1097/00062752-200303000-00002
   Engstrom Elyne Montenegro, 2008, Rev Saude Publica, V42, P786, DOI [10.1590/S0034-89102008005000043, 10.1590/s0034-89102008000500002]
   Fahmida U, 2007, ASIA PAC J CLIN NUTR, V16, P301
   FAO/WHO, 2005, VIT MIN REQ HUM NUTR, P246
   Februhartanty J, 2002, ASIA PAC J CLIN NUTR, V11, P36, DOI 10.1046/j.1440-6047.2002.00264.x
   Assuncao MCF, 2007, REV SAUDE PUBL, V41, P539, DOI 10.1590/s0034-89102006005000031
   FUERTH JH, 1972, J PEDIATR-US, V80, P974, DOI 10.1016/S0022-3476(72)80010-6
   Gara SN, 2010, AM J TROP MED HYG, V83, P843, DOI 10.4269/ajtmh.2010.10-0170
   Gebreselassie H., 1996, THESIS MCGILL U MONT
   Gera T, 2002, BRIT MED J, V325, P1142, DOI 10.1136/bmj.325.7373.1142
   Gera T, 2007, J PEDIATR GASTR NUTR, V44, P468, DOI 10.1097/01.mpg.0000243440.85452.38
   Gewa CA, 2009, BRIT J NUTR, V101, P1
   Giovannini M, 2006, J PEDIATR GASTR NUTR, V42, P306, DOI 10.1097/01.mpg.0000189363.07040.4b
   Gomber S, 1998, INDIAN J MED RES, V107, P269
   GOPALDAS T, 1985, Indian Pediatrics, V22, P745
   GOPALDAS T, 1985, Indian Pediatrics, V22, P731
   GOPALDAS T, 1985, Indian Pediatrics, V22, P737
   GOPALDAS T, 1983, NUTR RES, V3, P831, DOI 10.1016/S0271-5317(83)80036-0
   Grantham-McGregor S, 2001, J NUTR, V131, P649
   GREISEN G, 1986, ACTA PAEDIATR SCAND, V75, P662, DOI 10.1111/j.1651-2227.1986.tb10268.x
   Gulliford MC, 1999, AM J EPIDEMIOL, V149, P876
   Hall A, 2002, PUBLIC HEALTH NUTR, V5, P413, DOI 10.1079/PHN2001327
   HARVEY PWJ, 1989, AM J TROP MED HYG, V40, P12
   HATHIRAT P, 1992, BRIT J NUTR, V68, P245, DOI 10.1079/BJN19920081
   Hay SI, 2004, REPORT AGREEMENT PER
   Hess SY, 2002, AM J CLIN NUTR, V75, P743
   Hettiarachchi M, 2008, EUR J CLIN NUTR, V62, P856, DOI 10.1038/sj.ejcn.1602791
   HEYWOOD A, 1989, AM J CLIN NUTR, V50, P630
   Higgins Jpt GS, 2011, COCHRANE HDB SYSTEMA
   Hirve S, 2007, INDIAN PEDIATR, V44, P91
   Honig AS, 1978, INFANT BEHAV DEV, V1, P168, DOI 10.1016/S0163-6383(78)80027-7
   Hop LT, 2005, J NUTR, V135, p660S
   Hussen MA, 1985, 13 INT C NUTR BRIGNT
   Hyder SMZ, 2007, J NUTR, V137, P2147
   Iannotti LL, 2006, AM J CLIN NUTR, V84, P1261
   IDJRADINATA P, 1993, LANCET, V341, P1, DOI 10.1016/0140-6736(93)92477-B
   IDJRADINATA P, 1994, LANCET, V343, P1252, DOI 10.1016/S0140-6736(94)92151-2
   International Nutritional Anemia Consultative Group (INACG), INACG CONS STAT SAF
   Ip H, 2009, EUR J CLIN NUTR, V63, P165, DOI 10.1038/sj.ejcn.1602917
   Isager H, 1974, Scand J Haematol Suppl, V21, P1
   JACOBI H, 1972, Medizinische Welt, V23, P228
   Kaiser R, 2006, DISASTERS, V30, P199, DOI 10.1111/j.0361-3666.2006.00315.x
   Kanani SJ, 2000, J NUTR, V130, p452S
   Kapur D, 2005, INDIAN PEDIATR, V42, P351
   Kapur D, 2003, Indian Pediatr, V40, P1131
   KASHYAP P, 1987, NUTR RES, V7, P1127, DOI 10.1016/S0271-5317(87)80038-6
   Kazembe PN, 1995, AM J TROPICAL MED S2, V53, P91
   Kianfar H, 2000, INT J VITAM NUTR RES, V70, P172, DOI 10.1024/0300-9831.70.4.172
   Kleinschmidt H, 1985, MUNCHEN MED WOCHEN, V107, P1835
   Kochan I, 1973, Curr Top Microbiol Immunol, V60, P1
   Kordas K, 2005, J PEDIATR-US, V147, P632, DOI 10.1016/j.jpeds.2005.06.037
   Kurz KM, 1985, THESIS CORNELL U ITH
   LATHAM MC, 1990, NUTRITION, V6, P159
   LAWLESS JW, 1994, J NUTR, V124, P645
   le Cessie S., 2002, Archives of Disease in Childhood, V86, pF182, DOI 10.1136/fn.86.3.F182
   Le Huong Thi, 2007, Br J Nutr, V97, P955
   Leenstra T, 2009, EUR J CLIN NUTR, V63, P173, DOI 10.1038/sj.ejcn.1602919
   Lefebvre C, COCHRANE HDB SYSTEMA
   LENGELER C, 2004, COCHRANE DATABASE SY, DOI 10.1002/14651858.CD000363
   Lima Ana C V M S, 2006, J Pediatr (Rio J), V82, P452, DOI 10.1590/S0021-75572006000800010
   Lind T, 2004, AM J CLIN NUTR, V80, P729
   Lind T, 2003, AM J CLIN NUTR, V77, P883
   Lind T, 2008, ACTA PAEDIATR, V97, P770, DOI 10.1111/j.1651-2227.2008.00773.x
   Liu X N, 1996, Biomed Environ Sci, V9, P341
   Liu Xu-Nian, 1995, Food and Nutrition Bulletin, V16, P139
   Maldonado Lozano J., 2007, AN PEDIATR, V66, P591, DOI 10.1157/13107394
   Lozoff B, 2003, PEDIATRICS, V112, P846
   LOZOFF B, 1987, PEDIATRICS, V79, P981
   Lozoff B, 1996, J PEDIATR-US, V129, P382, DOI 10.1016/S0022-3476(96)70070-7
   LOZOFF B, 1982, J PEDIATR-US, V100, P351, DOI 10.1016/S0022-3476(82)80428-9
   Lutter CK, 2008, J NUTR, V138, P379, DOI 10.3945/jn.108.095406
   Lynch S, 2011, AM J CLIN NUTR, V93, P1188, DOI 10.3945/ajcn.111.015214
   Majumdar I, 2003, J TROP PEDIATRICS, V49, P84, DOI 10.1093/tropej/49.2.84
   Mamiro P R, 2001, Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet, V66, P291
   Martin S, 2001, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001444
   Massaga JJ, 2003, LANCET, V361, P1853, DOI 10.1016/S0140-6736(03)13504-0
   Mburu ASW, 2008, J NUTR, V138, P613
   Mebrahtu T, 2004, J NUTR, V134, P3037
   Mei ZG, 2005, J NUTR, V135, P1974
   MEJIA LA, 1988, AM J CLIN NUTR, V48, P595
   Menendez C, 2000, PARASITOL TODAY, V16, P469, DOI 10.1016/S0169-4758(00)01774-9
   Menendez C, 2004, AM J TROP MED HYG, V71, P434
   Menendez C, 2002, PEDIATR INFECT DIS J, V21, P249, DOI 10.1097/00006454-200203000-00016
   Meremikwu MM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003756.pub2
   Metz J, 2007, FOOD NUTR BULL, V28, pS540
   Migasena P, 1972, Southeast Asian J Trop Med Public Health, V3, P255
   Mitra AK, 1997, J NUTR, V127, P1451
   Morales J, 2008, J FOOD SCI, V73, pS1, DOI 10.1111/j.1750-3841.2007.00581.x
   Morley R, 1999, ARCH DIS CHILD, V81, P247
   Mozaffari-Khosravi H, 2010, BIOL TRACE ELEM RES, V135, P22, DOI 10.1007/s12011-009-8480-0
   Mulenga M, 2006, AM J TROP MED HYG, V74, P980
   Munoz EC, 2000, AM J CLIN NUTR, V71, P789
   MURRAY MJ, 1978, BRIT MED J, V2, P1113
   Mwanakasale V, 2009, MALAWI MED J, V21, P12
   Mwanri L, 2000, J NUTR, V130, P2691
   Naghii MR, 2007, BIOFACTORS, V30, P19
   Nagpal J, 2004, J HEALTH POPUL NUTR, V22, P203
   Nagpal J, 2000, BRIT MED J, V325, P1142
   Nchito M, 2004, T ROY SOC TROP MED H, V98, P218, DOI 10.1016/S0035-9203(03)00045-2
   Ngnie-Teta I, 2008, FOOD NUTR BULL, V28, P76
   Nguyen Xuan Ninh, 2002, Sante, V12, P31
   Arcanjo FPN, 2011, J TROP PEDIATRICS, V57, P433, DOI 10.1093/tropej/fmq119
   Review Manager (RevMan), 2011, REV MAN REVMAN COMP
   Nwanyanwu OC, 1996, ANN TROP MED PARASIT, V90, P589
   Nyakeriga AM, 2004, J INFECT DIS, V190, P439, DOI 10.1086/422331
   Olney DK, 2006, J NUTR, V136, P2427
   Olsen A, 2006, ANN TROP MED PARASIT, V100, P251, DOI 10.1179/136485906X91486
   OPPENHEIMER SJ, 1987, T ROY SOC TROP MED H, V81, P322, DOI 10.1016/0035-9203(87)90253-7
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P603, DOI 10.1016/0035-9203(86)90154-9
   OPPENHEIMER SJ, 1984, LANCET, V1, P389
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P596, DOI 10.1016/0035-9203(86)90153-7
   Oppenheimer SJ, 2001, J NUTR, V131, p616S
   OSKI FA, 1983, PEDIATRICS, V71, P877
   OSKI FA, 1978, J PEDIATR-US, V92, P21, DOI 10.1016/S0022-3476(78)80063-8
   Ouedraogo HZ, 2010, PUBLIC HEALTH NUTR, V13, P1923, DOI 10.1017/S1368980010000911
   Palupi L, 1997, AM J CLIN NUTR, V65, P1057
   PARKS YA, 1989, ARCH DIS CHILD, V64, P400
   PEREIRA SM, 1978, BRIT J NUTR, V39, P493, DOI 10.1079/BJN19780065
   Perrone L, 1999, J TRACE ELEM MED BIO, V13, P51
   Pollitt E, 1993, ANNU REV NUTR, V13, P521
   POLLITT E, 1989, AM J CLIN NUTR, V50, P687
   POWERS HJ, 1983, HUM NUTR-CLIN NUTR, V37, P413
   Rahimy MC, 2007, PEDIATR BLOOD CANCER, V48, P544, DOI 10.1002/pbc.21103
   Rahman MM, 1999, J NUTR, V129, P1319
   Rajaratnam JK, 2010, LANCET, V375, P1988
   Ramakrishnan U, 2004, J NUTR, V134, P2592
   Rice AL, 2002, BRIT MED J, V325, P1142
   Richard SA, 2006, AM J TROP MED HYG, V75, P126
   Rico JA, 2006, PEDIATRICS, V117, pE518, DOI 10.1542/peds.2005-1172
   Rohner F, 2010, J NUTR, V140, P635, DOI 10.3945/jn.109.114256
   Rosado JL, 1997, AM J CLIN NUTR, V65, P13
   Roschnik N, 2004, TROP MED INT HEALTH, V9, P904, DOI 10.1111/j.1365-3156.2004.01279.x
   Roschnik N., 2003, IMPACT WEEKLY SCH BA
   Roth DE, 2010, EVID BASED CHILD HLT, V5, P1186, DOI DOI 10.1002/EBCH.505
   Sachdev HPS, 2006, PUBLIC HEALTH NUTR, V9, P904, DOI 10.1017/PHN2005918
   Sachdev HPS, 2005, PUBLIC HEALTH NUTR, V8, P117, DOI 10.1079/PHN2004677
   Salinas-Pielago JE, 1998, REV NEUROLOGIA, V27, P400
   Sankar MJ, 2009, ACTA PAEDIATR, V98, P953, DOI 10.1111/j.1651-2227.2009.01267.x
   Sarker SA, 2008, GASTROENTEROLOGY, V135, P1534, DOI 10.1053/j.gastro.2008.07.030
   Sarma KVR, 2006, NUTRITION, V22, pS8, DOI 10.1016/j.nut.2005.07.011
   SARMA KVR, 1977, INDIAN J MED RES, V65, P839
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Schellenberg D, 2004, AM J TROP MED HYG, V71, P428
   Schellenberg D, 2001, LANCET, V357, P1471
   Schneider D, 1995, Bull Soc Pathol Exot, V88, P260
   Schumann K, 2009, EUR J CLIN NUTR, V63, P355, DOI 10.1038/sj.ejcn.1602930
   SCHULTINK W, 1995, AM J CLIN NUTR, V61, P111
   SESHADRI S, 1984, Indian Pediatrics, V21, P529
   SESHADRI S, 1984, INDIAN J MED RES, V80, P164
   SESHADRI S, 1989, AM J CLIN NUTR, V50, P675
   SESHADRI S, 1982, BRIT J NUTR, V48, P233, DOI 10.1079/BJN19820109
   Shah BK, 2002, ARCH PEDIAT ADOL MED, V156, P131
   Sharma A, 2000, Indian Pediatr, V37, P261
   Siegel E, 2004, THESIS J HOPKINS U
   SINGLA PN, 1982, J TROP PEDIATRICS, V28, P77
   SMITH AW, 1989, ANN TROP PAEDIATR, V9, P17
   SMITH AW, 1989, ANN TROP PAEDIATR, V9, P6
   Smuts CM, 2005, J NUTR, V135, p631S
   Soekarjo DD, 2004, EUR J CLIN NUTR, V58, P927, DOI 10.1038/sj.ejcn.1601914
   SOEMANTRI AG, 1989, AM J CLIN NUTR, V50, P698
   SOEMANTRI AG, 1985, AM J CLIN NUTR, V42, P1221
   SOEWONDO S, 1989, AM J CLIN NUTR, V50, P667
   Stoltzfus Rebecca, 2010, Int J Epidemiol, V39, P34, DOI 10.1093/ije/dyp368
   Stoltzfus RJ, 2011, J NUTR, V141, p756S, DOI 10.3945/jn.110.128793
   Stoltzfus RJ, 2004, J NUTR, V134, P348
   Stoltzfus RJ, 2001, BRIT MED J, V323, P1389, DOI 10.1136/bmj.323.7326.1389
   Stoltzfus RJ, 1998, GUIDELINES USE IRON
   Stoltzfus RJ, 1997, NUTR REV, V55, P223
   Suchdev PS, 2010, J NUTR, V140, P875, DOI 10.3945/jn.109.118638
   Sungthong R, 2002, J NUTR, V132, P418
   Taylor M, 2001, T ROY SOC TROP MED H, V95, P211, DOI 10.1016/S0035-9203(01)90171-3
   Tee ES, 1999, AM J CLIN NUTR, V69, P1249
   Terlouw DJ, 2004, AM J CLIN NUTR, V79, P466
   THIBAULT H, 1993, EUR J PEDIATR, V152, P120, DOI 10.1007/BF02072487
   Thu BD, 1999, AM J CLIN NUTR, V69, P80
   Thurnham DI, 2010, AM J CLIN NUTR, V92, P546, DOI 10.3945/ajcn.2010.29284
   Tielsch JM, 2006, LANCET, V367, P144, DOI 10.1016/S0140-6736(06)67963-4
   Tomashek KM, 2001, AM J TROP MED HYG, V64, P164
   Troesch B, 2011, J NUTR, V141, P237, DOI 10.3945/jn.110.129247
   *UN, 2011, MILL DEV GOALS
   UNICEF, 1998, STAT WORLDS CHIDR 19, P78
   Untoro J, 2005, J NUTR, V135, p639S
   vandenHombergh J, 1996, J TROP PEDIATRICS, V42, P220, DOI 10.1093/tropej/42.4.220
   vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7
   van Stuijvenberg ME, 2008, J NUTR, V138, P782
   VAUGHAN JP, 1977, TROP GEOGR MED, V29, P369
   Verhoef H, 2002, BLOOD, V100, P3489, DOI 10.1182/blood-2001-12-0228
   Verhoef H, 2002, LANCET, V360, P908, DOI 10.1016/S0140-6736(02)11027-0
   Walker CLF, 2009, EUR J CLIN NUTR, V63, P87, DOI 10.1038/sj.ejcn.1602905
   WALTER T, 1986, AM J CLIN NUTR, V44, P877
   WALTER T, 1989, PEDIATRICS, V84, P7
   WALTER T, 1989, AM J CLIN NUTR, V50, P655
   Walter T, 1989, AM J CLIN NUTR S, V50
   Wasantwisut E, 2006, J NUTR, V136, P2405
   Wegmuller R, 2006, J NUTR, V136, P1814
   WHO, 2011, HAEM CONC DIAGN AN A
   [Anonymous], 2004, COMP QUANT HLTH RISK, V1
   WHO, 2007, FOOD NUTR BULL, V28, pS621
   World Health Organization, 2008, WORLDW PREV AN REP 1
   World Health Organization, 2011, SER FERR CONC ASS IR
   World Health Organisation, WORLD MAL REP 2010
   World Health Organisation/Centers for Disease Control and Prevention, 2004, ASS IR STAT POP
   World Health Organization (WHO), 2008, WORLD MAL REP
   WORLD HEALTH ORGANIZATION, GUID TREATM MAL
   World Health Organization (WHO), 2003, AFR MAL REP 2003
   Wijaya-Erhardt M, 2007, AM J CLIN NUTR, V86, P1680
   Williams J, 1999, BRIT MED J, V318, P693
   Yalcin SS, 2000, PEDIATR INT, V42, P625, DOI 10.1046/j.1442-200x.2000.01299.x
   Yang Qingjun, 2004, Wei Sheng Yan Jiu, V33, P205
   Zavaleta N, 2000, J NUTR, V130, p462S
   Zavaleta N, 1997, 16 INT C NUTR CAN, VPW5, P62
   Zimmermann MB, 2005, AM J CLIN NUTR, V81, P615
   Zimmermann MB, 2010, AM J CLIN NUTR, V92, P1406, DOI 10.3945/ajcn.110.004564
   Zlotkin S, 2003, B WORLD HEALTH ORGAN, V81, P108
   [Anonymous], 2006, PRESCRIRE INT, V15, P233
   [Anonymous], NCT00213161 USING IR
   [Anonymous], ISRCTN21782274 IRON
   [Anonymous], ISRCTN88523834 PREVE
   [Anonymous], ISRCTN85737357 INTER
   [Anonymous], NCT00301054 PREVENTI
NR 287
TC 31
Z9 31
U1 1
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2011
IS 10
AR CD006589
DI 10.1002/14651858.CD006589.pub3
PG 205
WC Medicine, General & Internal
SC General & Internal Medicine
GA 830RM
UT WOS:000295674300025
PM 21975754
OA No
DA 2017-08-15
ER

PT J
AU Okebe, JU
   Skoetz, N
   Meremikwu, MM
   Richards, S
AF Okebe, Joseph U.
   Skoetz, Nicole
   Meremikwu, Martin M.
   Richards, Sue
TI Therapeutic interventions for Burkitt lymphoma in children
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Adolescent; Burkitt Lymphoma [therapy]; Randomized Controlled Trials as
   Topic; Remission Induction; Adult; Child; Humans
ID NON-HODGKINS-LYMPHOMA; PEDIATRIC-ONCOLOGY-GROUP; B-CELL LYMPHOMAS;
   IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; HIV-ASSOCIATED LYMPHOMA;
   HIGH-DOSE METHOTREXATE; RANDOMIZED PHASE-II; EPSTEIN-BARR-VIRUS;
   CLINICAL-TRIAL; AGGRESSIVE LYMPHOMAS
AB Background
   Burkitt lymphoma (BL) is an important cancer found mostly in children but uncertainty remains as to the most effective form of management. In endemic areas, late-stage presentation as a result of delayed access to treatment compounds the situation.
   Objectives
   To assess the evidence for chemotherapy, surgery, radiotherapy and immunotherapy in the treatment of children with endemic BL.
   Search strategy
   We updated and re-ran the searches in the following electronic databases from the time of the first publication; the Cochrane Controlled Trials Register (CENTRAL) (Issue 1, 2011); MEDLINE (January 2011); EMBASE (January 2011); and the clinical trials registry (up to January 2011) to identify relevant trials. In addition, we also updated the search of the US clinical trials register for on-going and completed trials up to January 2011. We also updated the search terms and used the Cochrane filter for identifying randomised trials in MEDLINE.
   Selection criteria
   We included randomised controlled trials (RCTs) of any duration. We included studies conducted in children with a confirmed diagnosis of BL. We did not restrict studies by geographical location or by language of publication. We considered any therapeutic intervention. The primary outcome was overall survival.
   Data collection and analysis
   Two review authors assessed studies for relevance. We assessed studies that met the entry criteria for study quality. We independently extracted data and entered the data into Review Manager (RevMan). In this update, two review authors independently assessed citations from the updated search and reviewed abstracts for relevance.
   Main results
   We included one new study in this update. In total, 13 trials involving 1824 participants met the inclusion criteria for this review however, data in usable format were only available in 10 trials (732 participants). Inadequate reporting of study methodology was a common feature of the trials preventing thorough assessment of study quality. We were unable to pool data for any of the outcomes due to the differences between the interventions assessed in the studies. Eight studies aimed to induce remission; overall survival did not differ significantly between treatment groups. Five studies aimed to maintain remission. In two out of three studies reporting survival, this was substantial but the difference was not statistically significant between treatment groups. Less aggressive treatment schedules appear to produce similar effects with less adverse event profiles.
   Authors' conclusions
   This review notes a preference in more recent studies for less aggressive care options for treatment of BL. However, the evidence for the relative effectiveness of interventions to treat BL is not strong as studies were small, underpowered and prone to both systematic and random error. We included one additional trial without change of conclusions.
C1 [Okebe, Joseph U.] MRC Unit, Banjul, Gambia.
   [Skoetz, Nicole] Univ Hosp Cologne, Cochrane Haematol Malignancies Grp, Dept Internal Med 1, Cologne, Germany.
   [Meremikwu, Martin M.] Univ Calabar, Teaching Hosp, Dept Paediat, Calabar, Nigeria.
   [Richards, Sue] Univ Oxford, Clin Trials Serv Unit, Oxford, England.
RP Okebe, JU (reprint author), MRC Unit, POB 273, Banjul, Gambia.
EM j_okebs@yahoo.com
RI Skoetz, Nicole/J-9509-2014
OI Skoetz, Nicole/0000-0003-4744-6192
FU German Ministry of Education and Research (BMBF), Germany [FKZ :
   01GH0501]
FX External sources; Jim Milan Memorial Award, UK.; The Editorial Base of
   CHMG is funded by the German Ministry of Education and Research (BMBF)
   FKZ : 01GH0501, Germany.
CR Adde M, 1998, SEMIN ONCOL, V25, P33
   Akbayram S, 2010, TARGET ONCOL, V5, P291, DOI 10.1007/s11523-010-0161-6
   Amengual JE, 2008, BLOOD, V112, P4359, DOI 10.1182/blood-2008-06-162289
   ANDERSON JR, 1983, NEW ENGL J MED, V308, P559, DOI 10.1056/NEJM198303103081003
   Aviles A, 1996, Eur J Cancer B Oral Oncol, V32B, P420, DOI 10.1016/S0964-1955(96)00031-0
   Baldissera RC, 2006, ACTA HAEMATOL-BASEL, V115, P15, DOI 10.1159/000089460
   BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X
   Blum KA, 2004, BLOOD, V104, P3009, DOI 10.1182/blood-2004-02-0405
   Blum KA, 2006, CANCER, V107, P2817, DOI 10.1002/cncr.22344
   Boue F, 2006, J CLIN ONCOL, V24, P4123, DOI 10.1200/JCO.2005.05.4684
   Brecher ML, 1997, MED PEDIATR ONCOL, V29, P526, DOI 10.1002/(SICI)1096-911X(199712)29:6<526::AID-MPO2>3.0.CO;2-M
   Burkitt, 1958, BRIT J SURG, V46, P218
   Cairo MS, 2007, BLOOD, V109, P2736, DOI 10.1182/blood-2006-07-036665
   Cairo MS, 2003, BRIT J HAEMATOL, V120, P660, DOI 10.1046/j.1365-2141.2003.04134.x
   CAIRO MS, 2003, P AN M AM SOC CLIN, V22, P796
   COIFFIER B, 1990, ANN ONCOL, V1, P45
   Economopoulos T, 2007, CANCER J, V13, P327, DOI 10.1097/PPO.0b013e3181570170
   Eldar AH, 2009, J PEDIAT HEMATOL ONC, V31, P428, DOI 10.1097/MPH.0b013e31819a5d58
   Federico M, 2006, EUR J HAEMATOL, V76, P217, DOI 10.1111/j.1600-0609.2005.00609.x
   Goldstein JA, 1990, J TROPICAL PAEDIAT, V30, P114
   Grogg KL, 2007, J CLIN PATHOL, V60, P1365, DOI 10.1136/jcp.2007.051953
   Gururangan S, 2000, J CLIN ONCOL, V18, P2017
   Hagenbeek A, 2006, J CLIN ONCOL, V24, P1590, DOI 10.1200/JCO.2005.03.7952
   Hainsworth JD, 2005, J CLIN ONCOL, V23, P1088, DOI 10.1200/JCO.2005.12.191
   Haioun C, 1993, 5 INT C MAL LYMPH, p85a
   Harris NL, 2000, MODERN PATHOL, V13, P193, DOI 10.1038/modpathol.3880035
   Hesseling P, 2009, ANN TROP PAEDIATR, V29, P29, DOI 10.1179/146532809X402006
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA
   Hsu FJ, 1997, BLOOD, V89, P3129
   KAPLAN LD, 1991, J CLIN ONCOL, V9, P929
   Kasamon YL, 2004, CURR OPIN ONCOL, V16, P429, DOI 10.1097/00001622-200409000-00003
   Kimby E, 1993, 5 INT C MAL LYMPH
   Knowles DM, 2003, HEMATOL ONCOL CLIN N, V17, P785, DOI 10.1016/S0889-8588(03)00050-9
   Laver JH, 2005, J CLIN ONCOL, V23, P541, DOI 10.1200/JCO.2005.11.075
   Lefebre C, 2008, COCHRANE HDB SYSTEMA
   LEVINE AM, 1991, JAMA-J AM MED ASSOC, V266, P84, DOI 10.1001/jama.266.1.84
   Magrath I T, 1987, Hematol Oncol Clin North Am, V1, P577
   Magrath I T, 1989, Oncology (Williston Park), V3, P41
   Magrath I, 2009, CURR OPIN ONCOL, V21, P462, DOI 10.1097/CCO.0b013e32832f3dcd
   MAGRATH IT, 1973, P AM ASSOC CANC RES, V14, P67
   MAGRATH IT, 1974, BRIT MED J, V2, P308
   MAGRATH IT, 1976, BRIT MED J, V1, P615
   Magrath IT, 1974, RECENT RESULTS CANC, V47, P461
   Maloney DG, 1997, J CLIN ONCOL, V15, P3266
   MALONEY DG, 1994, BLOOD, V84, P2457
   Martinez-Maza O, 2002, CURR OPIN ONCOL, V14, P528, DOI 10.1097/01.CCO.0000027015.90629.6B
   Meremikwu MM, 2005, TROPICAL ME IN PRESS
   NEEQUAYE J, 1990, ANTICANCER RES, V10, P1183
   Norlin T, 1971, ACTA RADIOL, V10, P545
   Oguonu T, 2002, ANN TROP PAEDIATR, V22, P369, DOI 10.1179/027249302125002038
   Okebe JU, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005198.pub2, DOI 10.1002/14651858.CD005198.PUB2]
   Olweny C L, 1971, East Afr Med J, V48, P585
   OLWENY CLM, 1976, INT J CANCER, V17, P436, DOI 10.1002/ijc.2910170404
   OLWENY CLM, 1980, INT J CANCER, V26, P261, DOI 10.1002/ijc.2910260302
   OLWENY CLM, 1977, ACTA RADIOL THER PHY, V16, P225
   Oriol A, 2005, HAEMATOL-HEMATOL J, V90, P990
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   PATTE C, 1991, J CLIN ONCOL, V9, P123
   Patte C, 2007, BLOOD, V109, P2773, DOI 10.1182/blood-2006-07-036673
   Pfreundschuh M, 2008, ANN ONCOL, V19, P545, DOI 10.1093/annonc/mdm514
   Pfreundschuh M, 2004, BLOOD, V104, P626, DOI 10.1182/blood-2003-06-2094
   REITER A, 1994, KLIN PADIATR, V206, P222, DOI 10.1055/s-2008-1046608
   Reiter A, 1994, KLIN PADIATR, V204, P242
   Smeland S, 2004, ANN ONCOL, V15, P1072, DOI 10.1093/annonc/mdh262
   Sparano JA, 2007, CURR OPIN ONCOL, V19, P458, DOI 10.1097/CCO.0b013e3282c8c835
   Spina M, 2005, CURR OPIN ONCOL, V17, P462, DOI 10.1097/01.cco.0000172824.78318.b9
   Sugimoto M, 2004, CANCER RES, V64, P3361, DOI 10.1158/0008-5472.CAN-04-0079
   SULLIVAN MP, 1991, AM J PEDIAT HEMATOL, V13, P288
   Sun XF, 2006, EUR J HAEMATOL, V77, P365, DOI 10.1111/j.1600-0609.2006.00735.x
   Tilly H, 2000, J CLIN ONCOL, V18, P1309
   Tsurumi H, 2004, J CANCER RES CLIN, V130, P107, DOI 10.1007/s00432-003-0508-9
   TURA S, 1991, LEUKEMIA, V5, P74
   Verdonck LF, 2007, BLOOD, V109, P2759, DOI 10.1182/blood-2006-07-035709
   Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076
   Witzig TE, 2000, SEMIN ONCOL, V27, P74
   Wood C, 2005, CELL RES, V15, P947, DOI 10.1038/sj.cr.7290372
   Ziegler J L, 1973, Natl Cancer Inst Monogr, V39, P199
   ZIEGLER JL, 1972, INT J CANCER, V10, P254, DOI 10.1002/ijc.2910100205
   ZIEGLER JL, 1972, CANCER, V30, P1534, DOI 10.1002/1097-0142(197212)30:6<1534::AID-CNCR2820300619>3.0.CO;2-6
   ZIEGLER JL, 1981, NEW ENGL J MED, V305, P735, DOI 10.1056/NEJM198109243051305
   ZIEGLER JL, 1971, BRIT MED J, V3, P508
   ZIEGLER JL, 1972, P AM ASSOC CANC RES, V13, P38
   Ziegler JL, 1974, PATHOLOGY ANN
NR 83
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2011
IS 7
AR CD005198
DI 10.1002/14651858.CD005198.pub3
PG 39
WC Medicine, General & Internal
SC General & Internal Medicine
GA 789YB
UT WOS:000292554306006
PM 21735399
OA No
DA 2017-08-15
ER

PT J
AU Dionisio, K
   Howie, S
   Dominici, F
   Fornace, K
   Adegbola, R
   Spengler, J
   Ezzati, M
AF Dionisio, Kathie
   Howie, Stephen
   Dominici, Francesca
   Fornace, Kimberly
   Adegbola, Richard
   Spengler, John
   Ezzati, Majid
TI Measuring the Exposure of Infants and Children to Indoor Air Pollution
   From Biomass Fuels in the Gambia
SO EPIDEMIOLOGY
LA English
DT Meeting Abstract
CT Joint Conference of
   International-Society-of-Exposure-Science/International-Society-for-Envi
   ronmental-Epidemiology
CY AUG 28-SEP 01, 2010
CL Seoul, SOUTH KOREA
SP Int Soc Exposure Sci, Int Soc Environm Epidemiol
C1 [Dionisio, Kathie; Dominici, Francesca; Fornace, Kimberly; Spengler, John; Ezzati, Majid] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Howie, Stephen; Adegbola, Richard] MRC Labs, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1044-3983
EI 1531-5487
J9 EPIDEMIOLOGY
JI Epidemiology
PD JAN
PY 2011
VL 22
IS 1
SU S
BP S117
EP S118
DI 10.1097/01.ede.0000392029.80000.89
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 695VN
UT WOS:000285400800337
OA No
DA 2017-08-15
ER

PT J
AU Klis, S
   Velding, K
   Gidron, Y
   Peterson, K
AF Klis, Sandor
   Velding, Kristien
   Gidron, Yori
   Peterson, Kevin
TI Posttraumatic stress and depressive symptoms among people living with
   HIV in the Gambia
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE HIV; the Gambia; PTSD; depression; CD4; illness perception
ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; PICTORIAL REPRESENTATION;
   DISEASE PROGRESSION; NORTHERN UGANDA; SOUTH-AFRICA; SELF MEASURE;
   ILLNESS; DISORDER; IMPACT
AB This study aimed to assess the prevalence and clinical and psychosocial correlates of psychiatric symptoms in a sample of HIV patients in the Gambia. Data from 44 HIV-positive outpatients were collected at a Genito-Urinary Medicine clinic in Fajara, the Gambia. Translated versions of the Impact of Event Scale Revised and the Centre for Epidemiologic Studies Short Depression Scale were used to assess posttraumatic stress disorder (PTSD) symptoms and depressive symptoms, respectively. The Pictorial Representation of Illness and Self Measure revised was used to assess illness perception (IP). All other data (e. g., CD4 counts) were retrieved from medical charts or through standardised questions.
   The prevalence of PTSD symptoms (43.2%) and depressive symptoms (40.9%) was high. Not having an independent income and having a CD4 count under 200 cells/mu l were independent correlates of depressive symptoms. Only IP was an independent correlate of PTSD symptoms. Finally, IP tended to moderate the relationship between CD4 cell counts and depressive symptoms.
   These findings indicate that routine screening for psychiatric symptoms is both necessary and feasible among HIV patients in the Gambia. In addition, any intervention targeting these symptoms should take IP into account.
C1 [Klis, Sandor; Velding, Kristien; Gidron, Yori] Tilburg Univ, Dept Psychol & Hlth, NL-5000 LE Tilburg, Netherlands.
   [Peterson, Kevin] Med Res Council UK, Fajara, Gambia.
RP Klis, S (reprint author), Tilburg Univ, Dept Psychol & Hlth, NL-5000 LE Tilburg, Netherlands.
EM s.klis@student.rug.nl
CR ALCIATI A, 2007, PSYCHOPHARMACOLOGY, V22, P40
   American Psychiatric Association, 2000, DIAGN CRIT DSM 4 TR
   Amberbir A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-265
   Ammassari A, 2002, JAIDS, V31, pS123
   Amone-P'Olak K, 2007, J ADOLESCENCE, V30, P655, DOI 10.1016/j.adolescence.2006.05.004
   ANDRESEN EM, 1994, AM J PREV MED, V10, P77
   Antelman G, 2007, JAIDS-J ACQ IMM DEF, V44, P470, DOI 10.1097/QAI.0b013e31802f1318
   Asch SM, 2003, J GEN INTERN MED, V18, P450, DOI 10.1046/j.1525-1497.2003.20938.x
   Atkinson JH, 2008, J AFFECT DISORDERS, V108, P225, DOI 10.1016/j.jad.2007.10.017
   Atwoli L, 2006, East Afr Med J, V83, P352
   Bass J, 2006, BRIT J PSYCHIAT, V188, P567, DOI 10.1192/bjp.188.6.567
   Boarts JM, 2006, AIDS BEHAV, V10, P253, DOI 10.1007/s10461-006-9069-7
   Bolton P, 2007, JAMA-J AM MED ASSOC, V298, P519, DOI 10.1001/jama.298.5.519
   Buchi S, 1998, PSYCHOTHER PSYCHOSOM, V67, P222, DOI 10.1159/000012284
   Buchi S, 2002, PSYCHOTHER PSYCHOSOM, V71, P333, DOI 10.1159/000065994
   CAMPOS LN, 2010, AIDS BEHAV, V14, P289, DOI DOI 10.1007/s10461-008-9435-8
   CASTRO KG, 1993, CLIN INFECT DIS, V17, P802
   Cheng ST, 2005, INT J GERIATR PSYCH, V20, P465, DOI 10.1002/gps.1314
   Collins PY, 2006, AIDS, V20, P1571, DOI 10.1097/01.aids.0000238402.70379.d4
   Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010
   Cruess DG, 2003, BIOL PSYCHIAT, V54, P307, DOI 10.1016/S0006-3223(03)00318-4
   DUNCAN E, 2005, AUSTR J DISASTER TRA, V1
   Eller LS, 2006, NURS CLIN N AM, V41, P437, DOI 10.1016/j.cnur.2006.04.001
   GLATTACKER M, 2009, BRIT J HEALTH PSYCH, V15, P367
   Hartzell JD, 2008, J ANTIMICROB CHEMOTH, V62, P246, DOI 10.1093/jac/dkn193
   Hyde JS, 2008, PSYCHOL REV, V115, P291, DOI 10.1037/0033-295X.115.2.291
   Israelski DM, 2007, AIDS CARE, V19, P220, DOI 10.1080/09540120600774230
   Ivanova S A, 2007, Neurosci Behav Physiol, V37, P527, DOI 10.1007/s11055-007-0047-y
   John Prashantham Baddam, 2007, Clin Pract Epidemiol Ment Health, V3, P4, DOI 10.1186/1745-0179-3-4
   Judd FK, 1996, AUST NZ J PSYCHIAT, V30, P104, DOI 10.3109/00048679609076077
   Kaharuza FM, 2006, AIDS BEHAV, V10, pS105, DOI 10.1007/s10461-006-9142-2
   Klis S, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-104
   Leserman J, 2008, PSYCHOSOM MED, V70, P539, DOI 10.1097/PSY.0b013e3181777a5f
   LEVINE J, 1987, PSYCHOSOM MED, V49, P109
   Martin L., 2008, AIDS BEHAV
   Martinez A, 2002, AIDS PATIENT CARE ST, V16, P283, DOI 10.1089/10872910260066714
   Monahan PO, 2009, J GEN INTERN MED, V24, P189, DOI 10.1007/s11606-008-0846-z
   Musisi S, 2009, East Afr Med J, V86, P16
   Myer L, 2008, AIDS PATIENT CARE ST, V22, P147, DOI 10.1089/apc.2007.0102
   MYERS JK, 1980, AM J PSYCHIAT, V137, P1081
   Neuner F, 2008, J CONSULT CLIN PSYCH, V76, P686, DOI 10.1037/0022-006X.76.4.686
   ODELL MW, 1995, J ACQ IMMUN DEF SYND, V10, P350
   Olley BO, 2006, J PSYCHOSOM RES, V61, P479, DOI 10.1016/j.jpsychores.2006.03.010
   Paschalides C, 2004, J PSYCHOSOM RES, V57, P557, DOI 10.1016/j.jpsychores.2004.03.006
   Poupard M, 2007, HIV MED, V8, P92, DOI 10.1111/j.1468-1293.2007.00435.x
   Radloff R. L., 1977, APPL PSYCH MEAS, V1, P385
   Rahman A, 2008, LANCET, V372, P902, DOI 10.1016/S0140-6736(08)61400-2
   Reimus JLM, 2007, INT J DERMATOL, V46, P1042, DOI 10.1111/j.1365-4632.2007.03191.x
   Roberts B, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-38
   Sheldrick R, 2006, BRIT J HEALTH PSYCH, V11, P387, DOI 10.1348/135910705X71434
   Sledjeski EM, 2005, AIDS PATIENT CARE ST, V19, P728, DOI 10.1089/apc.2005.19.728
   Tedstone JE, 2003, CLIN PSYCHOL REV, V23, P409, DOI 10.1016/S0272-7358(03)00031-X
   Villes V, 2007, ANTIVIR THER, V12, P1067
   Wanke C, 2004, JAIDS-J ACQ IMM DEF, V37, pS277, DOI 10.1097/01.qai.0000144382.47468.34
   Weiss Daniel S., 1997, P399
   WHO, 2008, EP FACT SHEETS HIV A
   Wouters EJM, 2008, BEHAV MED, V34, P65, DOI 10.3200/BMED.34.2.65-78
NR 57
TC 8
Z9 9
U1 4
U2 10
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PY 2011
VL 23
IS 4
BP 426
EP 434
DI 10.1080/09540121.2010.507756
PG 9
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychology, Multidisciplinary; Respiratory System; Social Sciences,
   Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychology; Respiratory System; Biomedical Social Sciences
GA 731OK
UT WOS:000288118800005
PM 21271395
OA No
DA 2017-08-15
ER

PT J
AU Togun, T
   Peterson, I
   Jaffar, S
   Oko, F
   Okomo, U
   Peterson, K
   Jaye, A
AF Togun, Toyin
   Peterson, Ingrid
   Jaffar, Shabbar
   Oko, Francis
   Okomo, Uduak
   Peterson, Kevin
   Jaye, Assan
TI Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and
   HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy
   in The Gambia, West Africa
SO AIDS RESEARCH AND THERAPY
LA English
DT Article
AB Background: High early mortality rate among HIV infected patients following initiation of antiretroviral therapy (ART) in resource limited settings may indicate high pre-treatment mortality among ART-eligible patients. There is dearth of data on pre-treatment mortality in ART programmes in sub-Sahara Africa. This study aims to determine pre-treatment mortality rate and predictors of pre-treatment mortality among ART-eligible adult patients in a West Africa clinic-based cohort.
   Methods: All HIV-infected patients aged 15 years or older eligible for ART between June 2004 and September 2009 were included in the analysis. Assessment for eligibility was based on the Gambia ART guideline. Survival following ART-eligibility was determined by Kaplan-Meier estimates and predictors of pre-treatment mortality determined by Cox proportional hazard models.
   Result: Overall, 790 patients were assessed as eligible for ART based on their clinical and/or immunological status among whom 510 (64.6%) started treatment, 26 (3.3%) requested transfer to another health facility, 136 (17.2%) and 118 (14.9%) were lost to follow-up and died respectively without starting ART. ART-eligible patients who died or were lost to follow-up were more likely to be male or to have a CD4 T-cell count < 100 cells/mu L, while patients in WHO clinical stage 3 or 4 were more likely to die without starting treatment. The overall pretreatment mortality rate was 21.9 deaths per 100 person-years (95% CI 18.3-26.2) and the rate for the composite end point of death or loss to follow-up was 47.1 per 100 person-years (95% CI 41.6-53.2). Independent predictors of pre-treatment mortality were CD4 T-cell count < 100 cells/mu L (adjusted Hazard ratio [AHR] 3.71; 95% CI 2.54-5.41) and WHO stage 3 or 4 disease (AHR 1.91; 95% CI 1.12-3.23). Forty percent of ART-eligible patients lost to follow-up seen alive at field visit cited difficulty with the requirement of disclosing their HIV status as reason for not starting ART.
   Conclusion: Approximately one third of ART-eligible patients did not start ART and pre-treatment mortality rate was found high among HIV infected patients in our cohort. CD4 T-cell count < 100 cells/mu L is the strongest independent predictor of pre-treatment mortality. The requirement to disclose HIV status as part of ART preparation counselling constitutes a huge barrier for eligible patients to access treatment.
C1 [Togun, Toyin; Oko, Francis; Okomo, Uduak; Peterson, Kevin; Jaye, Assan] MRC, Gambia Unit, Fajara, Gambia.
   [Jaffar, Shabbar] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Peterson, Kevin] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Jaye, Assan] Univ Cheick Anta Diop, WAPHIR Network, Lab Bacteriol Virol, Dakar, Senegal.
RP Togun, T (reprint author), MRC, Gambia Unit, POB 273 Banjul, Fajara, Gambia.
EM ttogun@mrc.gm
FU Global Fund for AIDS, Tuberculosis and Malaria (GFATM)
FX We thank the field workers and nurses of the MRC HIV clinic. We also
   acknowledge and appreciate the efforts of Gilleh Thomas in acquisition
   of the data and John Townend for his advice in the statistical analysis.
   Support for the MRC HIV clinic staff was provided by the Global Fund for
   AIDS, Tuberculosis and Malaria (GFATM).
CR Amuron B, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-290
   Bassett IV, 2009, JAIDS-J ACQ IMM DEF, V51, P135, DOI 10.1097/QAI.0b013e3181a44ef2
   Bemelmans M, 2010, TROP MED INT HEALTH, V15, P1413, DOI 10.1111/j.1365-3156.2010.02649.x
   Bizuwork T, 2007, Malawi Med J, V19, P104
   Braitstein P, 2006, LANCET, V367, P817
   Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248
   Dalal RP, 2008, JAIDS-J ACQ IMM DEF, V47, P101
   Department of State for Health, 2004, GAMB ANT THER MAN HL
   Department of State for Health (DoSH), 2008, NAT SENT SURV B
   Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01
   Jaffar Shabbar, 2008, AIDS Res Ther, V5, P4, DOI 10.1186/1742-6405-5-4
   Kagaayi J, 2007, AIDS, V21, P1208, DOI 10.1097/QAD.0b013e32810c8dce
   Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1
   Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd
   Marazzi MC, 2008, AIDS RES HUM RETROV, V24, P555, DOI 10.1089/aid.2007.0217
   McGrath N, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-601
   Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298
   Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X
   UNAIDS/WHO, 2010, UNAIDS REP GLOB AIDS
   van der Loeff MFS, 2002, AIDS, V16, P1775
   World Health Organization, 2009, RAP ADV ANT THER HIV
NR 21
TC 19
Z9 19
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-6405
J9 AIDS RES THER
JI Aids Res. Ther.
PY 2011
VL 8
AR 24
DI 10.1186/1742-6405-8-24
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA V27LK
UT WOS:000208614500024
PM 21774813
OA gold
DA 2017-08-15
ER

PT J
AU Howie, SRC
AF Howie, Stephen R. C.
TI Blood sample volumes in child health research: review of safe limits
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID TRANSFUSION; DEFICIENCY; INFANTS; IMPACT
AB Objective To determine paediatric blood sample volume limits that are consistent with physiological "minimal risk."
   Methods A literature review was performed to search for evidence concerning the adverse effects of blood sampling in children and for guidelines on sampling volume in paediatric research. The search included Medline, EMBASE, other web-based and non-web-based sources and the bibliographies of the sources identified. Experts were also consulted.
   Findings Five studies and nine guidelines were identified. Existing guidelines specify paediatric blood sample volume limits ranging from 1% to 5% of total blood volume (TBV) over 24 hours and up to 10% of TBV over 8 weeks. The evidence available is limited and includes findings from non-randomized studies showing a minimal risk with one-off sampling of up to 5% of TBV.
   Conclusion The evidence available is consistent with the conclusion that all identified guidelines are within the limits of "minimal risk." However, more and better evidence is required to draw firmer conclusions. Researchers and institutional review boards need to take into account the total sampling volume needed for both clinical care and research rather than for each alone. The child's general state of health should be considered and extra caution should be observed particularly with children whose illness can deplete blood volume or haemoglobin or hinder their replenishment. Local policies must also address the appropriateness and local acceptability of collection procedures and of the blood volumes drawn.
C1 Med Res Council UK Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Howie, SRC (reprint author), Med Res Council UK Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM showie@mrc.gm
FU UK Medical Research Council
FX The UK Medical Research Council funded this study.
CR *AM AC PED, AM AC PED POL
   Behrman R.E., 2000, NELSON TXB PEDIAT
   *BLOODMED, GLOB SOURC HEM ED PR
   *BMJ GROUP, CLIN EV
   Broder-Fingert S, 2009, J PEDIATR-US, V154, P578, DOI 10.1016/j.jpeds.2008.10.007
   Cable R, 2007, PRACTICE GUIDELINES
   [Anonymous], 2006, EMEACHMPEWP147013200
   Cole M, 2006, PEDIATR BLOOD CANCER, V46, P723, DOI 10.1002/pbc.20463
   [Anonymous], 2010, CPMPEWPQWP140198
   *DUK U, 2008, BLOOD DRAW HUM SUBJ
   *GAMB GOV MED RES, 2000, GUID SCI
   Gibson BES, 2004, BRIT J HAEMATOL, V124, P433, DOI 10.1111/j.1365-2141.2004.04815.x
   *GOOGL INC, GOOGL SEARCH ENG
   Hack K E A, 2008, Ned Tijdschr Geneeskd, V152, P1419
   *HOSP SICK CHILDR, 2004, BLOOD SAMPL GUID
   Kauffman R E, 2000, Paediatr Drugs, V2, P411, DOI 10.2165/00128072-200002060-00001
   Madsen LP, 2000, SCAND J CLIN LAB INV, V60, P125, DOI 10.1080/00365510050184949
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Nuffield Council on Bioethics, 2002, ETH RES REL HEALTHC
   *PARTN HUM RES COM, BLOOD SAMPL GUID
   PEARSON H, 2003, RUDOLPHS PEDIAT, P1521
   *ROYAL COLL PEAD C, ROYAL COLL PEAD CHIL
   Rudolph CD, 2003, RUDOLPHS PEDIAT
   SANCHEZMEDAL L, 1969, BRIT J HAEMATOL, V17, P343, DOI 10.1111/j.1365-2141.1969.tb01380.x
   SCHWARTZ E, 2000, NELSON TXB PEDIAT, P1471
   SEGEL G, 2000, NELSON TXB PEDIAT, P1472
   SWAN HT, 1959, BRIT MED J, V2, P782
   Testa M, 2006, Minerva Pediatr, V58, P263
   *U CAL, 2006, CMRC IRB MAX ALL TOT
   *UK COCHR CTR, COCHR LIBR
   US Department of Health and Human Services; Office for Human Research Protections (OHRP), CAT RES MAY BE REV I
   *USC LA CHILDR HOS, NEW STUD APPL SMART
   *WAYN STAT U HUM I, 2008, RES STUD INV COLL BL
   World Medical Association, 1964, DECL HELS ETH PRINC
NR 34
TC 35
Z9 35
U1 0
U2 5
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD JAN
PY 2011
VL 89
IS 1
BP 46
EP 53
DI 10.2471/BLT.10.080010
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 712WO
UT WOS:000286697200010
PM 21346890
OA No
DA 2017-08-15
ER

PT J
AU Gall, A
   Horowitz, A
   Joof, H
   Natividad, A
   Tetteh, K
   Riley, E
   Bailey, RL
   Mabey, DCW
   Holland, MJ
AF Gall, Alevtina
   Horowitz, Amir
   Joof, Hassan
   Natividad, Angels
   Tetteh, Kevin
   Riley, Eleanor
   Bailey, Robin L.
   Mabey, David C. W.
   Holland, Martin J.
TI Systemic effector and regulatory immune responses to chlamydial antigens
   in trachomatous trichiasis
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE Chlamydia trachomatis; trachoma; immune response; Tregs; NK cells;
   interferon-gamma
AB Trachomatous trichiasis (TT) caused by repeated or chronic ocular infection with Chlamydia trachomatis is the result of a pro-fibrotic ocular immune response. At the conjunctiva, the increased expression of both inflammatory (IL1B, TNF) and regulatory cytokines (IL10) have been associated with adverse clinical outcomes. We measured in vitro immune responses of peripheral blood to a number of chlamydial antigens. Peripheral blood effector cells (CD4, CD69, IFN gamma, IL-10) and regulatory cells (CD4, CD25, FOXP3, CTLA4/GITR) were readily stimulated by C. trachomatis antigens but neither the magnitude (frequency or stimulation index) or the breadth and amount of cytokines produced in vitro [IL-5, IL-10, IL-12 (p70), IL-13, IFN gamma, and TNF alpha] were significantly different between TT cases and their non-diseased controls. Interestingly we observed that CD4+T cells account for <50% of the IFN gamma positive cells induced following stimulation. Further investigation in individuals selected from communities where exposure to ocular infection with C. trachomatis is endemic indicated that CD3-CD56+ (classical natural killer cells) were a major early source of IFN gamma production in response to C. trachomatis elementary body stimulation and that the magnitude of this response increased with age. Future efforts to unravel the contribution of the adaptive immune response to conjunctival fibrosis should focus on the early events following infection and the interaction with innate immune mediated mechanisms of inflammation in the conjunctiva.
C1 [Gall, Alevtina; Joof, Hassan; Holland, Martin J.] MRC Labs, Viral Dis Programme, Banjul, Gambia.
   [Horowitz, Amir; Riley, Eleanor] London Sch Hyg & Trop Med, Dept Immunol & Infect, London WC1E 7HT, England.
   [Natividad, Angels; Bailey, Robin L.; Mabey, David C. W.; Holland, Martin J.] London Sch Hyg & Trop Med, Dept Clin Res, London WC1E 7HT, England.
   [Tetteh, Kevin] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London WC1E 7HT, England.
RP Holland, MJ (reprint author), London Sch Hyg & Trop Med, Dept Clin Res, London WC1E 7HT, England.
EM martin.holland@lshtm.ac.uk
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570; Mabey, David/0000-0002-0031-8276
FU Wellcome Trust [079246/Z/06/Z]; Medical Research Council, UK in The
   Gambia
FX The authors thank the ophthalmic nurses of the Gambian National Eye Care
   Programme and the field staff from the Medical Research Council
   Laboratories for their hard work and dedication. This study was funded
   by a grant from the Wellcome Trust (079246/Z/06/Z) with additional
   support from the Medical Research Council, UK in The Gambia.
CR Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886
   Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   Barker CJ, 2008, VACCINE, V26, P1285, DOI 10.1016/j.vaccine.2007.12.048
   Belkaid Y, 2009, ANNU REV IMMUNOL, V27, P551, DOI 10.1146/annurev.immunol.021908.132723
   BENNETT S, 1992, J IMMUNOL METHODS, V146, P229, DOI 10.1016/0022-1759(92)90232-I
   Burl S, 2010, J IMMUNOL, V185, P2620, DOI 10.4049/jimmunol.1000552
   Burton MJ, 2007, INVEST OPHTH VIS SCI, V48, P4440, DOI 10.1167/iovs.07-0315
   Burton MJ, 2011, INFECT IMMUN, V79, P499, DOI 10.1128/IAI.00888-10
   Burton MJ, 2010, INVEST OPHTH VIS SCI, V51, P3583, DOI 10.1167/iovs.09-4550
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903
   Cohen CR, 2005, J INFECT DIS, V192, P591, DOI 10.1086/432070
   Coler RN, 2009, FEMS IMMUNOL MED MIC, V55, P258, DOI 10.1111/j.1574-695X.2008.00527.x
   COTTER TW, 1995, INFECT IMMUN, V63, P4704
   Crane DD, 2006, P NATL ACAD SCI USA, V103, P1894, DOI 10.1073/pnas.0508983103
   Faal N, 2006, PLOS MED, V3, P1292, DOI 10.1371/journal.pmed.0030266
   Felton M., 2002, THESIS U LONDON LOND
   Finney OC, 2010, EUR J IMMUNOL, V40, P47, DOI 10.1002/eji.200939708
   Follmann F, 2008, J INFECT DIS, V197, P897, DOI 10.1086/528378
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   Gervassi AL, 2004, J IMMUNOL, V173, P6905
   Gondek DC, 2009, J IMMUNOL, V183, P1313, DOI 10.4049/jimmunol.0900295
   Goodall JC, 2001, CLIN EXP IMMUNOL, V126, P488, DOI 10.1046/j.1365-2249.2001.01709.x
   Goodall JC, 2001, EUR J IMMUNOL, V31, P1513, DOI 10.1002/1521-4141(200105)31:5<1513::AID-IMMU1513>3.0.CO;2-U
   Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Holland MJ, 2010, INVEST OPHTH VIS SCI, V51, P3893, DOI 10.1167/iovs.09-5054
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Horowitz A, 2010, J IMMUNOL, V185, P2808, DOI 10.4049/jimmunol.1000844
   Horowitz A, 2010, J IMMUNOL, V184, P6043, DOI 10.4049/jimmunol.1000106
   Horowitz A, 2010, METHODS MOL BIOL, V612, P429, DOI 10.1007/978-1-60761-362-6_29
   Igietseme JU, 2009, J INFECT DIS, V200, P926, DOI 10.1086/605411
   Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175
   Jiang H, 2004, J CLIN INVEST, V114, P1198, DOI 10.1172/JCI200423411
   Kari L, 2009, J IMMUNOL, V182, P8063, DOI 10.4049/jimmunol.0804375
   Kelly-Rogers J, 2006, HUM IMMUNOL, V67, P863, DOI 10.1016/j.humimm.2006.08.292
   Kim SK, 2001, CURR OPIN IMMUNOL, V13, P429, DOI 10.1016/S0952-7915(00)00237-5
   KNIGHT SC, 1995, IMMUNOLOGY, V85, P8
   Li W, 2009, J INFECT DIS, V200, P590, DOI 10.1086/600123
   Linn YC, 2009, IMMUNOLOGY, V126, P423, DOI 10.1111/j.1365-2567.2008.02910.x
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   McCall MBB, 2010, EUR J IMMUNOL, V40, P3472, DOI 10.1002/eji.201040587
   McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288
   Meier UC, 2005, J VIROL, V79, P12365, DOI 10.1128/JVI.79.19.12365-12374.2005
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   Natividad A, 2008, HUM MOL GENET, V17, P323, DOI 10.1093/hmg/ddm310
   Natividad A, 2010, INFECT IMMUN, V78, P4895, DOI 10.1128/IAI.00844-10
   Nesburn AB, 2007, J VIROL, V81, P7647, DOI 10.1128/JVI.00294-07
   Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818
   Nunes A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013171
   Olsen AW, 2007, J INFECT DIS, V196, P1546, DOI 10.1086/522524
   Olsen AW, 2006, J INFECT DIS, V194, P1258, DOI 10.1086/508203
   Olsen AW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010768
   Rockey DD, 2009, EXPERT REV VACCINES, V8, P1365, DOI [10.1586/erv.09.98, 10.1586/ERV.09.98]
   Skwor T, 2010, INVEST OPHTH VIS SCI, V51, P5128, DOI 10.1167/iovs.09-5113
   Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122
   Suvas S, 2004, J IMMUNOL, V172, P4123
   Thorpe C, 2007, VACCINE, V25, P2252, DOI 10.1016/j.vaccine.2006.12.003
   Titanji K, 2008, IMMUNOLOGY, V123, P164, DOI 10.1111/j.1365-2567.2007.02657.x
   Vieira PL, 2004, J IMMUNOL, V172, P5986
   Wang CB, 2005, J INFECT DIS, V191, P1084, DOI 10.1086/428592
   Wang J, 2010, J IMMUNOL, V185, P1670, DOI 10.4049/jimmunol.1001240
   Wang J, 2009, VACCINE, V27, P2967, DOI 10.1016/j.vaccine.2009.02.095
   Wang SH, 1999, EUR J IMMUNOL, V29, P3782, DOI 10.1002/(SICI)1521-4141(199911)29:11<3782::AID-IMMU3782>3.0.CO;2-B
   WHO, 2007, SEX TRANSM DIS CHLAM
   Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412
   Yang X, 1999, J IMMUNOL, V162, P1010
   Yang X, 2003, CURR PHARM DESIGN, V9, P67, DOI 10.2174/1381612033392486
   Zhang DJ, 1997, J INFECT DIS, V176, P1035
   Zheng XC, 2004, J IMMUNOL, V173, P2253
NR 75
TC 13
Z9 13
U1 0
U2 2
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PY 2011
VL 2
AR 10
DI 10.3389/fmicb.2011.00010
PG 13
WC Microbiology
SC Microbiology
GA V31DE
UT WOS:000208863500020
PM 21747780
OA gold
DA 2017-08-15
ER

PT J
AU Vanderwal, L
   Rautiainen, R
   Kuye, R
   Peek-Asa, C
   Cook, T
   Ramirez, M
   Culp, K
   Donham, K
AF Vanderwal, Londa
   Rautiainen, Risto
   Kuye, Rex
   Peek-Asa, Corinne
   Cook, Thomas
   Ramirez, Marizen
   Culp, Kennith
   Donham, Kelley
TI Effectiveness, Safety, and Sustainability of a Hand Water Pump Among
   Women Vegetable Farmers in the Gambia
SO JOURNAL OF SUSTAINABLE AGRICULTURE
LA English
DT Article
DE hand water pump; Africa; vegetable farming; women; worker health
ID HEALTH
AB Women vegetable farmers (n = 48) in West Africa engaged in timed trials with a hand water pump and traditional water lifting methods. Use of the water pump increased the mean time required to lift water by 14% (p 0.01), compared to traditional lifting. Average and maximum heart rates increased by 7% and 6%, respectively (each p 0.01), compared to traditional water lifting. Discomfort and injury indicators were consistently better for the pump. Two months later, most subjects reported that the water pump was safer (65%), faster (77%), and was preferred (77%). Manual water pumps should be comprehensively evaluated for efficiency and long-term sustainability.
C1 [Vanderwal, Londa; Peek-Asa, Corinne; Cook, Thomas; Ramirez, Marizen; Donham, Kelley] Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Hlth, Iowa City, IA USA.
   [Rautiainen, Risto] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Environm Agr & Occupat Hlth, Omaha, NE 68198 USA.
   [Kuye, Rex] Univ Gambia, Sch Publ Hlth, Brikama, Gambia.
   [Culp, Kennith] Univ Iowa, Coll Nursing, Occupat Hlth Nursing Program, Iowa City, IA 52242 USA.
RP Rautiainen, R (reprint author), Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Environm Agr & Occupat Hlth, Swanson Hall 3058, Omaha, NE 68198 USA.
EM rrautiainen@unmc.edu
RI Culp, Kennith/C-5798-2013
OI Culp, Kennith/0000-0002-7197-385X
FU University of Iowa Heartland Center for Occupational Health and Safety
   [T42OH008491-04]; University of Iowa Injury Prevention Research Center
   [1R49CE001167-03]; Sigma Delta Epsilon/Graduate Women in Science
   fellowship; University of Iowa; University of Iowa Executive Council of
   Graduate and Professional Students; Great Plains Center for Agricultural
   Safety and Health [1U50OH009001-01, 1KO1OH008300]
FX Funding for this study was provided by the University of Iowa Heartland
   Center for Occupational Health and Safety (Grant number: T42OH008491-04)
   pilot grant and traineeship programs, the University of Iowa Injury
   Prevention Research Center (Grant number: 1R49CE001167-03)), a Sigma
   Delta Epsilon/Graduate Women in Science fellowship, a University of Iowa
   T. Anne Cleary International Dissertation Research Fellowship and a
   Stanley Graduate Award for International Research, and a University of
   Iowa Executive Council of Graduate and Professional Students Research
   Grant. Dr. Rautiainen's contribution was funded by the Great Plains
   Center for Agricultural Safety and Health (Grant number:
   1U50OH009001-01) and his research career award (Grant number:
   1KO1OH008300). We wish to express our sincere gratitude to all these
   organizations for their financial support. We would also like to
   sincerely thank the staff of the Gambia College, the Trust Agency for
   Rural Development (TARUD, local NGO supervising the garden where the
   research was conducted), and the student research assistants from the
   Gambia College for all their support and assistance in this study.
CR Aubel J, 1996, World Health Forum, V17, P52
   Carney J. A., 1998, Agriculture and Human Values, V15, P325, DOI 10.1023/A:1007580801416
   Creswell J.W., 2003, HDB MIXED METHODS SO, P209
   Egharevba RK, 2004, J SUSTAIN AGR, V24, P39, DOI 10.1300/J064v24n01_05
   *FAO UN, 2004, APPR WAT LIFT TECHN
   *FAO UN IFAD, 1998, AGR IMPL WOM FARM AF
   Fathallah F A, 2008, J Agric Saf Health, V14, P221
   Faucett J, 2007, APPL ERGON, V38, P219, DOI 10.1016/j.apergo.2006.02.003
   Glaser B., 1967, DISCOVERY GROUNDED T
   Kaul R. N., 1993, Proceedings, XXV CIOSTA-CIGR V Congress: farm planning, labour and labour conditions, computers in agricultural management, held in Wageningen, Netherlands, 10-13 May 1993., P20
   Kuye R, 2006, ANN AGR ENV MED, V13, P1
   *NAWFA, 2007, 5 YEAR PROGR STRAT J
   Rogers EM, 2003, DIFFUSION INNOVATION
   *SAS I INC, 2008, GEN EST EQ
   *SAS I INC, 2009, GENMOD PROC
   VANDERWAL LS, 2009, THESIS U IOWA IOWA
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 17
TC 0
Z9 0
U1 1
U2 13
PU HAWORTH PRESS INC
PI BINGHAMTON
PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA
SN 1044-0046
J9 J SUSTAIN AGR
JI J. Sustain. Agric.
PY 2011
VL 35
IS 4
BP 394
EP 407
AR PII 935845271
DI 10.1080/10440046.2011.562053
PG 14
WC Agriculture, Multidisciplinary
SC Agriculture
GA 746OF
UT WOS:000289255900004
OA No
DA 2017-08-15
ER

PT J
AU Zolfo, M
   Bateganya, MH
   Adetifa, IM
   Colebunders, R
   Lynen, L
AF Zolfo, Maria
   Bateganya, Moses H.
   Adetifa, Ifedayo M.
   Colebunders, Robert
   Lynen, Lutgarde
TI A telemedicine service for HIV/AIDS physicians working in developing
   countries
SO JOURNAL OF TELEMEDICINE AND TELECARE
LA English
DT Article
ID DEVELOPING-WORLD; INTERNET; SYSTEM; AFRICA; CONSULTATIONS; EDUCATION;
   MEDICINE; CAMBODIA; HEALTH; EMAIL
AB In 2003, the Institute of Tropical Medicine (ITM) in Antwerp set up an Internet-based decision support service to assist health-care workers in the management of difficult HIV/AIDS cases. This service is available to physicians working in resource-limited settings. Between April 2003 and December 2009, the telemedicine service received 1058 queries, from more than 40 countries, mostly resource-constrained. In the first six years there were 952 queries, of which 459 (49%) were posted on the web-based telemedicine discussion forum and the rest sent by email. All queries were handled by a co-ordinator who forwarded them to a network of specialists, based at the ITM and at other institutions. The average time to provide a first reply was 24 hours. Almost half of the queries received in the first six years (n = 466) were related to the use of antiretroviral medications. The response rate to a user questionnaire was 19% (73 questionnaires returned out of 387 delivered): half of those (n = 37) came from active users and the remainder (n = 36) from clinicians who had never used the system. The user survey showed that telemedicine advice was valuable in the management of specific cases, and significantly influenced the way that clinicians managed other similar cases subsequently. Nonetheless, there was a declining trend in the rate of use of the service.
C1 [Zolfo, Maria; Colebunders, Robert; Lynen, Lutgarde] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Bateganya, Moses H.] Univ Washington, Dept Global Hlth, Washington, DC USA.
   [Adetifa, Ifedayo M.] MRC Labs, Banjul, Gambia.
RP Zolfo, M (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.
EM mzolfo@itg.be
RI Lynen, Lutgarde/A-1212-2014
OI Lynen, Lutgarde/0000-0001-7183-4895
FU Belgian Directory General of Development Cooperation
FX This project was supported by the Belgian Directory General of
   Development Cooperation. We are grateful to the ITM telemedicine
   international experts' network: A De Weggheleire, J van Griensven, M
   Vekemans, K Fransen, E Van den Enden, J Van den Ende, N Lorent, T
   Vandendriessche, A Van de Velde, D Van der Linden (Belgium); JM Schapiro
   (Israel); C van Hees, B Naafs, J G Bollemeijer, C Boucher (Netherlands).
CR Bagayoko CO, 2006, COMPUT MED IMAG GRAP, V30, P407, DOI 10.1016/j.compmedimag.2006.09.014
   Brauchli K, 2004, J TELEMED TELECARE, V10, pS14
   Callahan CW, 2005, ARCH PEDIAT ADOL MED, V159, P389, DOI 10.1001/archpedi.159.4.389
   Clevenbergh P, 2006, HIV CLIN TRIALS, V7, P255, DOI 10.1310/hct0705-255
   Fraser HSF, 2001, ST HEAL T, V84, P815
   Geissbuhler A, 2007, INT J MED INFORM, V76, P351, DOI 10.1016/j.ijmedinf.2007.01.012
   Graham LE, 2003, TROP DOCT, V33, P36
   Heinzelmann PJ, 2005, J TELEMED TELECARE, V11, P44, DOI 10.1258/135763305775124858
   *ITM, TEL ONL SUPP HIV AID
   Kuntalp M, 2004, COMPUT METH PROG BIO, V75, P117, DOI 10.1016/j.cmpb.2003.11.004
   Kvedar J, 2006, ANN ONCOL, V17, P37, DOI 10.1093/annonc.mdl986
   Latifi R, 2008, STUD HEALTH TECHNOL, V131, P39
   Rao B, 2009, J DRUGS DERMATOL, V8, P371
   Swinfen R, 2002, J TELEMED TELECARE, V8, P63, DOI 10.1258/13576330260440899
   World Health Organization, 2010, UN ACC SCAL PRIOR HI
   Wootton R, 2005, J TELEMED TELECARE, V11, P100, DOI 10.1258/135763305775124966
   Wootton R., 2009, TELEHEALTH DEV WORLD
   Wootton R, 2008, J TELEMED TELECARE, V14, P109, DOI 10.1258/jtt.2008.003001
   ZOLFO M, 2006, P 11 C INT SOC TEL 2
   Zolfo M, 2006, INT J MED INFORM, V75, P633, DOI 10.1016/j.ijmedinf.2006.03.002
NR 20
TC 7
Z9 7
U1 1
U2 4
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 1357-633X
J9 J TELEMED TELECARE
JI J. Telemed. Telecare
PY 2011
VL 17
IS 2
BP 65
EP 70
DI 10.1258/jtt.2010.100308
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 757WP
UT WOS:000290119500002
PM 21078680
OA No
DA 2017-08-15
ER

PT J
AU Kaplan, A
   Hechavarria, S
   Martin, M
   Bonhoure, I
AF Kaplan, Adriana
   Hechavarria, Suiberto
   Martin, Miguel
   Bonhoure, Isabelle
TI Health consequences of female genital mutilation/cutting in the Gambia,
   evidence into action
SO REPRODUCTIVE HEALTH
LA English
DT Article
DE Female Genital Mutilation/Cutting; Gambia; Sexual and Reproductive
   Health; Africa
AB Background: Female Genital Mutilation/Cutting (FGM/C) is a harmful traditional practice with severe health complications, deeply rooted in many Sub-Saharan African countries. In The Gambia, the prevalence of FGM/C is 78.3% in women aged between 15 and 49 years. The objective of this study is to perform a first evaluation of the magnitude of the health consequences of FGM/C in The Gambia.
   Methods: Data were collected on types of FGM/C and health consequences of each type of FGM/C from 871 female patients who consulted for any problem requiring a medical gynaecologic examination and who had undergone FGM/C in The Gambia.
   Results: The prevalence of patients with different types of FGM/C were: type I, 66.2%; type II, 26.3%; and type III, 7.5%. Complications due to FGM/C were found in 299 of the 871 patients (34.3%). Even type I, the form of FGM/C of least anatomical extent, presented complications in 1 of 5 girls and women examined.
   Conclusion: This study shows that FGM/C is still practiced in all the six regions of The Gambia, the most common form being type I, followed by type II. All forms of FGM/C, including type I, produce significantly high percentages of complications, especially infections.
C1 [Kaplan, Adriana] Univ Autonoma Barcelona, Catedra Transferencia Conocimiento, UAB Santander, Dept Antropol Social & Cultural, E-08193 Barcelona, Spain.
   [Kaplan, Adriana; Bonhoure, Isabelle] Univ Autonoma Barcelona, Grp Interdisciplinar Prevenc & El Estudio Pract T, Fac Letras & Psicol, Dept Antropol Social & Cultural, E-08193 Barcelona, Spain.
   [Kaplan, Adriana] NGO Wassu Gambia Kafo, Fajara Sect F, Banjul, Gambia.
   [Hechavarria, Suiberto] Cuban Med Mission Gambia, Banjul, Gambia.
   [Hechavarria, Suiberto] Minist Hlth & Social Welf, Community Based Med Program, Banjul, Gambia.
   [Hechavarria, Suiberto] Univ Med la Habana, Fac Ciencias Med Manuel Fajardo, Havana, Cuba.
   [Martin, Miguel] Univ Autonoma Barcelona, Fac Med, GRAAL, Unitat Bioestadist, E-08193 Barcelona, Spain.
RP Kaplan, A (reprint author), Univ Autonoma Barcelona, Catedra Transferencia Conocimiento, UAB Santander, Dept Antropol Social & Cultural, Parc Recerca, E-08193 Barcelona, Spain.
EM adriana.kaplan@uab.cat
RI Hechavarria Toledo, Suiberto/G-8706-2016
OI Hechavarria Toledo, Suiberto/0000-0002-3470-8352; Bonhoure,
   Isabelle/0000-0002-2971-3069
FU Fundacio "La Caixa"; NGO Wassu Gambia Kafo
FX We are grateful to the Fundacio "La Caixa" that sponsored the project
   and to the NGO Wassu Gambia Kafo, for its support.
CR Adam T, 2010, B WORLD HEALTH ORGAN, V88, P281, DOI 10.2471/BLT.09.064808
   Ahmadu F., 2000, FEMALE CIRCUMCISION
   Almroth L, 2005, LANCET, V366, P385, DOI 10.1016/S0140-6736(05)67023-7
   Almroth Lars, 2005, Afr J Reprod Health, V9, P118
   Alsibiani SA, 2010, FERTIL STERIL, V93, P722, DOI 10.1016/j.fertnstert.2008.10.035
   Banks E, 2006, LANCET, V367, P1835
   Behrendt A, 2005, AM J PSYCHIAT, V162, P1000, DOI 10.1176/appi.ajp.162.5.1000
   Cham M, 2005, REPROD HLTH, V2, P3, DOI DOI 10.1186/1742-4755-2-3
   Cole-Ceesay R, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-21
   Cottingham J, 2009, INT J GYNECOL OBSTET, V106, P128, DOI 10.1016/j.ijgo.2009.03.024
   Dare F. O., 2004, INT J GYNECOL OBSTET, V24, P281
   Elmusharaf S, 2006, BJOG-INT J OBSTET GY, V113, P469, DOI 10.1111/j.1471-0528.2006.00896.x
   Elmusharaf S, 2006, BRIT MED J, V333, P124, DOI 10.1136/bmj.38873.649074.55
   Gage AJ, 2006, INT J GYNECOL OBSTET, V92, P92, DOI 10.1016/j.ijgo.2005.09.019
   GBoS, 2007, GAMB MULT IND CLUST
   Hernlund Y, 2000, FEMALE CIRCUMCISION
   Kaplan A, 1998, SENEGAMBIA CATALONIA
   Kaplan A, 1999, STRATEGIES ED FAMILL
   Kaplan-Marcusan A, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-193
   Kaplan-Marcusan A, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-11
   Morison L, 2001, TROP MED INT HEALTH, V6, P643, DOI 10.1046/j.1365-3156.2001.00749.x
   Obi SN, 2004, INT J GYNECOL OBSTET, V84, P183, DOI 10.1016/j.ijgo.2003.08.014
   Oduro Ar, 2006, Ghana Med J, V40, P87
   United Nations Children's Found, 2010, DYN SOC CHANG AB FEM
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   World Health Organization, 2008, EL FEM GEN MUT INT S
   Organization WH, 1995, FEM GEN MUT REP WHO
NR 27
TC 17
Z9 17
U1 0
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4755
J9 REPROD HEALTH
JI Reprod. Health
PY 2011
VL 8
AR 26
DI 10.1186/1742-4755-8-26
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V27IX
UT WOS:000208608000026
PM 21967670
OA gold
DA 2017-08-15
ER

PT J
AU Bankole, AA
   Secka, A
   Ly, C
AF Bankole, Anani Adeniran
   Secka, Arss
   Ly, Cheikh
TI Risk behaviours for milk-borne diseases transmission along the milk
   chain in The Gambia and Senegal
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
DE Milk chain actors; Milk-borne diseases; Milk consumption;
   Pasteurisation; Risk
ID BRUCELLA-ABORTUS; MANAGEMENT-PRACTICES; DAIRY-PRODUCTS; SURVIVAL;
   SYSTEMS; HEALTH; KENYA; FARMS; HERDS
AB The objective of this study was the characterisation of the traditional milk chain in Western Region (The Gambia) and Kolda (Southern Senegal); and the analysis of milk chain actors' risk behaviours for milk-borne diseases transmission. For this purpose, cattle herds involved in milk production, milk collectors, milk vendors and small-scale milk processing units were surveyed in the two study sites. A similar general milk chain organisation was found in the two sites with some particularities in farm management, compliance with hygienic measures at different levels, treatment of milk and milk consumption patterns. This results in a variable degree of risk of consumers' exposure to milk-borne diseases. Although the quality of the milk has been improved with the development of small-scale milk processing units, serious efforts are still needed with respect to pasteurisation procedure and to change the mindset of consumers who prefer in their majority drinking raw milk, fresh or soured, without any prior treatment.
C1 [Bankole, Anani Adeniran; Secka, Arss] Int Trypanotolerance Ctr ITC, Banjul, Gambia.
   [Ly, Cheikh] Interstates Sch Vet Sci & Med EISMV, Dept Biol Sci & Anim Prod, Dakar, Senegal.
RP Bankole, AA (reprint author), Int Trypanotolerance Ctr ITC, PMB 14, Banjul, Gambia.
EM hbankole@gmail.com
FU Vlaamse Interuniversitaire Raad-University Development Cooperation
   (VLIR-UOS)
FX This study was conducted within the framework of Ph.D. research
   activities financially supported by the Vlaamse Interuniversitaire
   Raad-University Development Cooperation (VLIR-UOS). The author thanks
   the staff of the Livestock Services in The Gambia and Senegal for their
   full cooperation, and International Trypanotolerance Centre (ITC) for
   the logistic and technical support.
CR Abraha S, 2009, TROP ANIM HEALTH PRO, V41, P1597, DOI 10.1007/s11250-009-9352-5
   Arimi SM, 2005, ACTA TROP, V96, P1, DOI 10.1016/j.actatropica.2005.05.012
   Bishop J. R., 2006, Food Protection Trends, V26, P714
   Broutin C., 2000, Paysage des Entreprises et Environnement de la Filiere Lait au Senegal
   Carpenter CM, 1928, AM J PUBLIC HEALTH N, V18, P743, DOI 10.2105/AJPH.18.6.743
   DIEYE PN, 2003, THESIS CIHEAM MONTPE
   ELDAHER N, 1990, ANN TROP MED PARASIT, V84, P523
   FAYE B, 2000, GESTION SECURITE ALI
   Harouna A, 2009, TROP ANIM HEALTH PRO, V41, P705, DOI 10.1007/s11250-008-9257-8
   HOLLOWAY G, 2000, MAKE MILK MARKET CAS, P28
   HUDSON A, 2003, PASTEURISATION DAIRY
   Jaitner J, 2003, TROP ANIM HEALTH PRO, V35, P179, DOI 10.1023/A:1022881703918
   Mapekula M, 2009, TROP ANIM HEALTH PRO, V41, P1475, DOI 10.1007/s11250-009-9336-5
   Mekonnen HM, 2006, PREV VET MED, V74, P99, DOI 10.1016/j.prevetmed.2005.10.004
   METZGER R, 1995, PRODUCTION SANTE ANI, V124
   Musalia LM, 2007, TROP ANIM HEALTH PRO, V39, P199, DOI 10.1007/s11250-007-9011-7
   Ndambi OA, 2007, LIVESTOCK RES RURAL, V19
   NDAMBI OA, 2008, LIVESTOCK RES RURAL, V20
   Nkya R, 2007, TROP ANIM HEALTH PRO, V39, P627, DOI 10.1007/s11250-007-9059-4
   PLOMMET M, 1988, LAIT, V68, P115, DOI 10.1051/lait:198828
   Saegerman C., 2010, INFECT PARASITIC DIS, P971
   Sidibe M, 2004, TROP ANIM HEALTH PRO, V36, P95, DOI 10.1023/B:TROP.0000009525.23669.c2
   Somda J, 2005, AGR SYST, V85, P42, DOI 10.1016/j.agsy.2004.07.011
   SOMDA J, 2004, 2 ITC
   Srairi MT, 2009, TROP ANIM HEALTH PRO, V41, P259, DOI 10.1007/s11250-008-9183-9
   Unger F., 2003, 2 ITC, V37, P3
   ZUNIGA EA, 2005, REV LATINOARM MICROB, V47, P88
NR 27
TC 1
Z9 1
U1 1
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0049-4747
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD JAN
PY 2011
VL 43
IS 1
BP 103
EP 109
DI 10.1007/s11250-010-9660-9
PG 7
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA 688WD
UT WOS:000284884800017
PM 20676765
OA No
DA 2017-08-15
ER

PT J
AU Southall, D
   Cham, M
AF Southall, David
   Cham, Mamady
TI International health organisations and recruitment of health workers
   Reply
SO LANCET
LA English
DT Letter
C1 [Southall, David] Maternal & Childhealth Advocacy Int, Conway Chambers, Nottingham NG1 5BB, England.
   [Cham, Mamady] Minist Hlth & Social Welf, Banjul, Gambia.
RP Southall, D (reprint author), Maternal & Childhealth Advocacy Int, Conway Chambers, Nottingham NG1 5BB, England.
EM director@mcai.org.uk
CR Cole-Ceesay R, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-21
   Hafeez Assad, 2009, JPMA Journal of the Pakistan Medical Association, V59, P243
NR 2
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD DEC 4
PY 2010
VL 376
IS 9756
BP 1899
EP 1900
DI 10.1016/S0140-6736(10)62211-8
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 696KH
UT WOS:000285439800022
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
   Cox, SE
   Nweneka, CV
AF Prentice, Andrew M.
   Cox, Sharon E.
   Nweneka, Chidi V.
TI Asymptomatic malaria in the etiology of iron deficiency anemia a
   nutritionist's viewpoint
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Editorial Material
ID PLASMODIUM-FALCIPARUM MALARIA; CHILDREN; HEPCIDIN
C1 [Prentice, Andrew M.; Cox, Sharon E.; Nweneka, Chidi V.] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   [Prentice, Andrew M.; Cox, Sharon E.; Nweneka, Chidi V.] MRC Keneba, Keneba, Gambia.
   [Cox, Sharon E.] Muhimbili Univ Hlth & Allied Sci, Dept Haematol & Blood Transfus, Dar Es Salaam, Tanzania.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, Keppel St, London WC1E 7HT, England.
OI Cox, Sharon/0000-0002-9908-2936
FU Medical Research Council; Wellcome Trust
CR Andrews NC, 2007, ANNU REV PHYSIOL, V69, P69, DOI 10.1146/annurev.physiol.69.031905.164337
   Atkinson SH, 2008, BLOOD, V112, P4276, DOI 10.1182/blood-2008-06-162008
   Cercamondi CI, 2010, AM J CLIN NUTR, V92, P1385, DOI 10.3945/ajcn.2010.30051
   Doherty CP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002133
   Howard CT, 2007, AM J TROP MED HYG, V77, P623
   Iyer JK, 2003, MOL MED, V9, P175
   Laftah AH, 2006, BIOCHEM J, V397, P61, DOI 10.1042/BJ20060215
   MABEY DCW, 1987, J INFECT DIS, V155, P1319
   Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303
   Nweneka CV, 2009, T R SOC TROP MED HYG, V104, P175
   Prentice AM, 2007, J NUTR, V137, P1334
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Verhoef H, 2010, AM J CLIN NUTR, V92, P1285, DOI 10.3945/ajcn.110.006700
NR 13
TC 8
Z9 8
U1 0
U2 4
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD DEC
PY 2010
VL 92
IS 6
BP 1283
EP 1284
DI 10.3945/ajcn.110.004465
PG 2
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 690HM
UT WOS:000284993600001
PM 21068349
OA No
DA 2017-08-15
ER

EF